Studie 015

(CTN015-FCE20124)

Studienbericht

Pharmacia Document 9550082

Reboxetine CLINICAL STUDY 015 18 December 1995

Multicentre, Multinational Double-Blind Study of the Activity and Tolerability of Reboxetine *vs* Imipramine and Placebo in Patients Suffering from Major Depressive Episodes

(Phase III)

Final report of study
CTN015-FCE20124

Authors: Ban TA, Dubini A, Vanoni G, Petroccione A, Aguglia E, Burrows GD, Castiglioni RA, Ohayon M, Priest RG, Vorbach EU

Pharmacia Document 9550082

STUDY CO-ORDINATION, MANAGEMENT AND REPORTING

Steering Committee Member

Prof. Thomas A. Ban MD
Professor of Psychiatry Emeritus
Vanderbilt University
Nashville, Tennessee USA

Thomas A. Ban January 5, 1996
signature date

Study Director

Adriana Dubini Pharm.D
Pharmacia, CNS R&D
Milan Italy

Adriana Dubini 18.12.95
signature date

Medical Research Associate

Giuliana Vanoni Biol.D
Pharmacia, CNS R&D
Milan Italy

Giuliana Vanoni 18 12. 1995
signature date

Statistics

Anna Petroccione MD
Pharmacia, Oncology R&D
Biometrics and Data Management
Milan Italy

Anna Petroccione 18.12.1995
signature date

Pharmacia Document 9550082

Clinical Investigator

Prof. Eugenio Aguglia
Department of Psychiatry
University of Trieste
Italy

10.1.96 Aguglia
date signature

Pharmacia Document 9550082

Clinical Investigator

Prof. Graham D. Burrows
Department of Psychiatry
University of Melbourne
Austin Hospital
Heidelberg, Australia

4-3-96
date signature

Pharmacia Document 9550082

Clinical Investigator

Dr. René A. Castiglioni
Hôpital Saint Marguerite
Service de Psychiatrie
Marseille France

10-01-96
date signature

Pharmacia Document 9550082

Clinical Investigator and Steering Committee Member

Prof. Maurice Ohayon
Louis H. LaFontaine Hospital
Montreal Canada

12.02.96 M. Ohayon
date signature

Pharmacia Document 9550082

Clinical Investigator

Prof. Robert G. Priest
Academic Department of Psychiatry
St. Mary's Hospital
London UK

3/2/96 Robert G Priest
date signature

Pharmacia Document 9550082

Clinical Investigator

Prof. Ernst U. Vorbach
Psychiatrische Klinik,
Elisabethenstift
Darmstadt, Germany

Dr. med. E. U. VORBACH
Arzt für Neurologie und Psychiatrie
Landgraf-Georg-Str. 100
64287 Darmstadt
Tel. 06151 / 403423

6/2/96
date

signature

TABLE OF CONTENTS

TABLE OF CONTENTS (continued)

TABLE OF CONTENTS (continued)

LIST OF ABBREVIATIONS AND TERMS

ANOVA	analysis of variance
AUC	area under the curve
b.i.d.	twice daily
BUN	blood urea nitrogen
CGI	clinical global impression
C.I.	confidence interval
CRF	case record form
DMI	desipramine
DSM-III-R	diagnostic and statistical manual - third edition - revised
ECG	electrocardiogram
ECT	electroconvulsive therapy
EI	efficacy index
gamma GT	gamma glutamyl transpeptidase
GCP	Good Clinical Practice
HAMD	Hamilton depression rating scale
IRB	Institutional Review Board
MADRS	Montgomery and Asberg depression rating scale
MMS	mini mental state
o.d.	once daily
REM	rapid eye movement
RDRS	relational depression rating scale
SD	standard deviation
SGOT	serum glutamic-oxaloacetic transaminase
SGPT	serum glutamic-pyruvic transaminase
T4	thyroxin
TSH	thyroid-stimulating hormone

REBOXETINE - PROTOCOL 20124/015
SYNOPSIS

Name of Company: Pharmacia Spa **Name of finished product:** **Name of active ingredient(s):** Reboxetine	**Individual study table referring to part IV of the dossier** **Ref.:** **Vol.:** **Page:**	**(For national authority use only)**
Title of study: Multicentre, multinational double-blind study of the activity and tolerability of reboxetine *vs* imipramine and placebo in patients suffering from Major Depressive Episodes (protocol 20124/015, Report n° 9550082).		
Investigators: Dr R Gupta, Prof J Pellet, Dr JL Terra, Dr Scharbach, Dr G Leibovici, Dr RA Castiglioni, Dr Houri, Dr M Costes, Dr JP Chabannes, Dr M Goudemand, Dr Briole, Dr JC Haxaire, Dr G Campa, Dr C Blanchard, Dr R Pagot, Prof JM Leger, Dr M Bouchard, Dr JF Charbonnier, Prof S Brion, Dr PY Cullerre, Dr B Baranowski, Dr EU Vorbach, Prof M Hummel, Prof HJ Schierle, Prof T Schmitt, Prof P Mayr, Prof J Schimek, Prof E Aguglia, Prof E Smeraldi, Prof RG Priest, Prof M Ohayon, Prof GD Burrows, Prof J Tiller, Dr T George.		
Study centres: Phillip Health Centre, Woden, Canberra, Australia; Hôpital Bellevue, St. Etienne, France; Centre Hôpitalier Spécialisé, Le Vinatier, Lyon, France; CHU Service Médico-Psycholog., Nantes, France; Avenue de la Serane, Marseille, France; Hôpital Sainte Marguerite, Service de Psychiatrie, Marseille, France; Clinique Psychiatrique du Parc, Nantes, France; Centre Hôpitalier Spécialisé, Saint Egréve, France; Centre Hôpitalier Spécialisé de Bassens, Chambéry, France; Unité de Soins Normalisés, Lille, France; Hôpital d'Instruction des Armées du Val-de-Grace, Paris, France; Bd Joffre, Nancy, France; Rue Nestor Cornier, Grenoble, France; CH, St Nazaire, France; Centre Hôpitalier Spécialisé, Saint-Ave, France; CHU - Service de Psychiatrie, Limoges, France; Centre Hôpitalier Spécialisé Gerard Marchant, Toulouse, France; Hôpital St Jacques, Clermont-Ferrand, France; Hôpital Richaud, Service de Psychiatrie, Versailles, France; Rue Colonel Jean Muller, Lorient, France; Rue de Nemours, Rennes, France; Psychiatrische Klinik, Elisabethenstift, Darmstadt, Germany; Psychiatrische Univ. Klinik, Marburg/Lahn, Germany; Puiseaux Platz, Rodgau, Germany; General Hospital, Waldbrunn-Hintermeilingen, Germany; Mozartstr, Stokach, Germany; Münchener Str., Frankfurt, Germany; Dpt. of Psychiatry, Università di Trieste, Trieste, Italy; Associazione Croce al Vallone, Biancavilla CT, Italy; Ospedale S Raffaele - Villa Turro, Milano, Italy; Academic Dpt. of Psychiatry, St Mary's Hospital, London, UK; Centre of Research, Hôpital Louis La Fontaine, Montreal, Canada; Dpt. of Psychiatry, University of Melbourne, Austin Hospital, Heidelberg, Australia; The Royal Hospital, Melbourne, Australia; The Prince Charles Hospital, Chermside, Brisbane, Australia.		
Publication (reference): None		
Study period: January 1991 - November 1992	**Clinical Phase:** III	
Objectives: To assess the activity and tolerability of reboxetine in comparison with placebo and imipramine in patients suffering from Major Depressive Episodes.		
Methodology: In this prospective, double-blind, randomised, controlled, parallel group, multicentre and multinational trial, patients underwent an initial wash-out period of 4-14 days (≥3 weeks in the case of fluoxetine administration), after which they received reboxetine 4 mg b.i.d., imipramine 50 mg b.i.d. (Days 1-3) then imipramine 150 mg/daily (50 mg in the morning and 100 mg in the evening) (Days 4-42) or placebo b.i.d. for six weeks. At the end of the initial 3 weeks of treatment, patients could be switched to an higher dose regimen, corresponding to 10 mg/day reboxetine and 200 mg/day imipramine.		

Name of Company: Pharmacia Spa **Name of finished product:** **Name of active ingredient(s):** Reboxetine	**Individual study table referring to part IV of the dossier** **Ref.:** **Vol.:** **Page:**	**(For national authority use only)**

For ethical reasons, patients willing to continue after completion of 6 weeks' treatment were provided with study medication and maintained on the same medication until the last patient recruited had completed the study and all the CRFs had been collected. The response to treatment was assessed by the investigators using the Hamilton Depression Scale (HAMD), Clinical Global Impression (CGI), the Montgomery and Asberg Depression Rating Scale (MADRS), and the Relational Depression Rating Scale (RDRS) and by the patients using the Patient Global Impression (PGI) and the Cognitive Evaluation. The results of the PGI and the Cognitive Evaluation were not evaluated due to the very low number of patients completing the assessments.

Safety and tolerability were assessed by the reporting of any adverse events and assessment of vital signs (supine and standing blood pressure and heart rate), laboratory tests, and ECG.

Number of subjects (planned and analysed): Three hundred and thirty patients were to be recruited in the study. Three hundred and thirty-nine patients (201 females and 138 males) from 34 centres were recruited to the study and treated with either reboxetine (112), imipramine (115) or placebo (112).

Diagnosis and main criteria for inclusion: Patients were diagnosed according to the DSM-III-R classification. The severity of depression was evaluated using the HAMD and CGI scales. Criteria for inclusion were as follows: (1) Patients of either sex, of any race, aged 18 to 65 years, with a diagnosis of acute of Major Depressive Episodes, not accompanied by psychotic features (DSM-III-R) with the current episode having been present for 1-4 months; (2) Initial (pre-treatment) total score for the 21-item HAMD had to be $\geq$22.

Test product: capsules containing RBX methanesulphonate tablets

Unit dose: 4 mg (two 2 mg tablets) or 6 mg (three 2 mg tablets) of reboxetine (free base)

Mode of administration: by oral route, b.i.d.

Batch no.: 4 mg: SF1131, SF1264; 6 mg: SF1132, SF1291

Duration of treatment: Double-blind phase : 6 weeks

Reference therapy: Imipramine 50 mg (25 mg x 2 tablets) and 100 mg (25 mg x 4 tablets) in capsules. Placebo tablets (excipients alone) in indistinguishable capsules

Unit Dose: 50 mg or 100 mg imipramine

Mode of administration: by oral route b.i.d. (both imipramine and placebo)

Batch no.: SF1130, SF1265 (imipramine 50 mg); SF1129, SF1151, SF1263 (imipramine 100 mg); SF1133, SF1247 (placebo 4 mg); SF1134, SF1306 (placebo 6 mg)

Criteria for evaluation:

Efficacy

Study end-point: difference of HAMD total score at last assessment *vs* baseline.

Response: HAMD total score decrease equal to or greater than 50% compared to the baseline value (Visit 0).

Remission: HAMD total score lower than or equal to 10 (absolute value).

Time to response: no. of days at onset of response confirmed at all subsequent available assessments.

HAMD total scores and factor scores, MADRS total scores, CGI classification, RDRS total scores.

Name of Company: Pharmacia Spa **Name of finished product:** **Name of active ingredient(s):** Reboxetine	**Individual study table referring to part IV of the dossier** **Ref.:** **Vol.:** **Page:**	**(For national authority use only)**

Safety

Reporting of adverse events, measurements of vital signs (supine and standing blood pressure and heart rate), laboratory tests, and ECG. Clinically relevant modifications of blood pressure (BP) and heart rate (HR) (≥20% *vs* baseline), or such modifications associated with critical values (≥160 or ≤100 mmHg for systolic BP; ≥100 or ≤70 mmHg for diastolic BP; ≥100 or ≤50 beats/min for HR). Orthostatic hypotension (decrease of systolic BP ≥30 mmHg from lying to standing). Clinically relevant changes of laboratory tests and abnormal ECG findings according to standardised criteria.

Statistical Method:

Efficacy

Mean decreases of HAMD total score at last valid observation were analysed by one-way ANOVA, testing differences between each of the active treatments (reboxetine and imipramine) and placebo by one-tailed Dunett's-test (overall type I error of 0.05). Secondary efficacy variables, including HAMD ,MADRS and RDRS total scores and CGI, were summarised by descriptive statistics at each visit and at the last valid observation. Homogeneity of baseline HAMD total scores across treatment groups was tested by ANOVA. Homogeneity of variances was tested by Bartlett's test. Ninety-five per cent confidence intervals (two tails) of the mean difference of each treatment were computed.

The same sets of analyses were carried out on the subset of severe (CGI-Severity of illness, markedly to extremely ill at baseline) and melancholic patients (DSM IV criteria).

Independent Chi square tests was applied in order to compare frequency of response/remission in the three treatment groups. The cumulative probability of the onset of response (time to response) was computed adopting the Kaplan-Meier method and pairwaise comparisons between each of the active treatments and placebo were carried out by log-rank test.

Safety

For all the laboratory tests frequency of patients shifted from values below, within or above the normal range at baseline to values below, within or above the normal range at each visit were computed. The Stuart Maxwell test was applied to test the changes in the distribution across categories at each visit *vs* baseline.

Continuous values of laboratory tests were standardised according to method proposed by Chuang-Stein and Wilcoxon Rank Signed test for paired data was applied in order to compare the values during treatment with those recorded at baseline.

The cumulative risk of developing the first adverse event, as well as individual adverse event and adverse event clusters (newly emerged in 5% or more of patients in at least one treatment group) was estimated by Kaplan-Meier method and the difference between treatments was tested by the log-rank test.

Results

Three hundred and thirty-nine patients (201 females and 138 males) were admitted to the study. A total of 252 patients (74.3%) completed the study and 87 (25.7%) withdrew (3 of them, 2 in the imipramine and 1 in the placebo group, having the last assessment at Day 42 visit): 23 (20.5%) in the reboxetine group, 38 (33.0%) in the imipramine group and 26 (23.2%) in the placebo group. Newly emerged adverse events were the main reason for treatment discontinuation in 11 (9.8%), 15 (13.0%) and 7 (6.3%) patients in the reboxetine, imipramine and placebo groups. One patient from the imipramine group died by suicide.

Name of Company: Pharmacia Spa Name of finished product: Name of active ingredient(s): Reboxetine	Individual study table referring to part IV of the dossier Ref.: Vol.: Page:	(For national authority use only)

Results (continued)

Deterioration was the main reason for withdrawal in 5 (4.5%), 11 (9.6%) and 11 (9.8%) patients in the three groups, respectively. Remaining cases included mainly lost to follow up and uncooperative patients (reboxetine 5, imipramine 10 and placebo 7).

Efficacy

In the 110 patients randomised to reboxetine who had at least one assessment in addition to baseline, the mean HAMD total score was reduced from 27.5 at Day 0 to 14.0 at last assessment, and to 11.3 at Day 42 in the 89 patients assessed at Day 42. In the 111 patients randomised to imipramine with at least one assessment in addition to baseline, the mean HAMD total score was reduced from 26.9 at Day 0 to 13.2 at last assessment, and to 9.4 at Day 42 (79 patients). Mean HAMD total score in the 111 patients randomised to placebo was reduced from 27.1 at Day 0 to 15.8 at last assessment, and to 13.1 at Day 42 (87 patients). The between treatment difference in the decrease of HAMD total score at last assessment was not statistically significant ($p>0.025$,one-tailed test) for both the reboxetine *vs* placebo and the imipramine *vs* placebo comparisons.

At last assessment, 59.1% of the 110 reboxetine-treated patients, 62.2% of the 111 imipramine-treated patients and 52.3% of the 111 placebo-treated patients were classified as responders, while 42.7%, 50.5% and 36.0%, respectively, were seen to be in remission. There were no statistically significant differences between active treatments and placebo for response and remission. Patients on imipramine showed a cumulative probability of response (Kaplan-Meier method) significantly higher ($p = 0.0055$) than patients on placebo, while was not the case for the patients on reboxetine ($p=0.081$).

With regard to the mean decrease of the HAMD total score at last assessment in patients classified as markedly to extremely ill at admission in the three treatment groups (77 reboxetine, 80 imipramine and 69 placebo), the improvement on both active treatments is maximal and is minimal on placebo; the mean difference between active treatments was almost nihil (0.12 points, 95% C.I.: -3.2 ÷3.4), but the difference between active treatments and placebo reached statistically significance ($p < 0.025$) only for imipramine. For the mean decrease at last assessment of the HAMD total score in those patients which could be classified as melancholic at admission in the three treatment groups (melancholic/non-melancholic: 51/46 reboxetine, 44/53 imipramine, 41/60 placebo), the difference between active treatments and placebo reached statistical significance in the case of reboxetine, but not of imipramine. The mean difference between active treatments was in fact in favour of reboxetine with a value of 3.9 points (95% C.I.: -0.5 ÷ 8.3).

As for the frequency distribution of CGI scores at last assessment, the clearest difference between treatments was related to the percentage of patients who were 'very much improved'; this was higher in the reboxetine group (29.1%) and the imipramine group (28.8%) compared with the placebo group (17.1%). In addition, the percentage of patients judged unchanged was higher in the placebo group (17.1%) than in the reboxetine group (9.1%) and imipramine group (10.8%). A similar pattern was observed at Day 42 in the patients who completed the study: 34.8% of the 89 reboxetine- and 39.2% of the 79 imipramine- *vs* 20.7% of the 87 placebo-treated patients were judged very much improved.

The mean total MADRS score was reduced from 16.4 at Day 0 to 8.4 at last assessment in the 110 reboxetine group patients with at least one assessment in addition to baseline, and to 6.6 at Day 42 in the 89 reboxetine patients assessed. In patients randomised to imipramine, values changed from 16.7 at Day 0 to 8.2 at last assessment (111 patients), and to 5.8 at Day 42 (79 patients). The corresponding reductions in placebo group patients were from 16.3 at Day 0 to 9.8 at last assessment (111 patients) and to 7.7 at Day 42 (87 patients).

Name of Company: Pharmacia Spa **Name of finished product:** **Name of active ingredient(s):** Reboxetine	**Individual study table referring to part IV of the dossier** **Ref.:** **Vol.:** **Page:**	**(For national authority use only)**

Efficacy (continued)

The mean total RDRS score was reduced from 18.8 at Day 0 to 9.6 at last assessment in the 109 reboxetine group patients with at least one assessment in addition to baseline, and to 7.6 at Day 42 (88 patients). In patients randomised to imipramine, values changed from 18.6 at Day 0 to 9.1 at last assessment (111 patients), and to 6.5 at Day 42 (79 patients). The corresponding reductions in placebo group patients were from 18.0 at Day 0 to 11.1 at last assessment (111 patients) and to 9.4 at Day 42 (87 patients).

Safety

All the 339 patients who received study treatment were included in the safety analysis (112 reboxetine, 115 imipramine, 112 placebo). For clinical and laboratory tests were analysed only patients with at least one assessment in addition to baseline.

During the study, the occurrence of newly reported adverse events was higher in the imipramine group than in the reboxetine or placebo groups; 71/112 (63%) reboxetine group patients reported 211 adverse events compared with 81/115 (70%) imipramine patients who reported 288 adverse events and 58/112 placebo group (52%) patients who reported 141 adverse events. Compared to placebo the cumulative risk of occurrence of adverse events (Kaplan Meier) was significantly higher on imipramine ($p = 0.001$) and approaches significance for reboxetine ($p = 0.051$).

Most frequently reported were: dry mouth (25.0% reboxetine, 42.6% imipramine and 12.5% placebo); constipation (15.2%, 15.7%, 5.4%) and increased sweating (12.5%, 19.1%, 2.7%). In addition, events reported with different frequencies in the three groups were: insomnia (11% on reboxetine, 7% on imipramine, 4% on placebo), vertigo (5% and 6% on reboxetine and imipramine, 0% on placebo), tremor (5% on reboxetine and placebo, 17% on imipramine), hypotension and related symptoms (9% on reboxetine, 17% on imipramine, 5% on placebo) blurred vision (9% on imipramine, 5% on reboxetine, 3% on placebo). The majority of adverse events were moderate in all treatment groups. Adverse events were reported with a similar frequency by women and men in all treatment groups. As for individual events or clusters the most relevant between-gender differences were noticed in all treatment groups and were related to the frequency of dry mouth, constipation, increased sweating, and nausea and related symptoms, complained of mainly by female patients.

As for individual events or clusters, the cumulative risk was significantly higher on reboxetine than on placebo for insomnia, increased sweating, dry mouth, vertigo and constipation. Similarly, the cumulative risk was significantly higher on imipramine than on placebo for dry mouth, constipation, increased sweating, vertigo, hypotension and related symptoms, tremor and blurred vision. The direct comparison between reboxetine and imipramine is in favour of reboxetine for dry mouth, hypotension and related symptoms and tremor.

There were one death (suicide) in the imipramine group and 5 cases of serious adverse events, all occurred in the imipramine- and placebo-treated patients: 2 cases of attempted suicide occurred in the placebo group, while 1 case of attempted suicide, 1 case of postural hypotension, dizziness and syncope and 1 case of attention seeking autolesionistic behaviour in the imipramine group.

There was no indication of modifications in laboratory tests that were of clinical significance.

Vital signs were not modified to any significant extent with the exception of heart rate, which more frequently increased to clinically significant values in the reboxetine (up to 12% of the patients) and imipramine (up to 8% of the patients) groups compared to placebo (up to 2% of the patients)

No indication of effect on cardiac function emerged from ECG recordings.

Pharmacia Document 9550082

Name of Company: Pharmacia Spa **Name of finished product:** **Name of active ingredient(s):** Reboxetine	**Individual study table referring to part IV of the dossier** **Ref.:** **Vol.:** **Page:**	**(For national authority use only)**

Conclusions:

The results of the statistical analysis of the study end-point do not allow the refusal of the null hypothesis of no difference between both active treatments and placebo. However, indications on the higher efficacy of active treatments compared to placebo derive from the analysis of the cumulative rate of response in the total population, particularly in the case of imipramine, and from the sub-population analyses in severe and melancholic patients, for both reboxetine and imipramine.

The safety profiles of reboxetine and imipramine, compared to placebo, were similar with regard to vital signs, haematology and blood chemistry tests and ECG examinations. The cumulative risk of adverse events according to the Kaplan-Meier method and log-rank test was significantly higher on imipramine compared to placebo and approached significance on reboxetine compared with placebo. As for individual events, the cumulative risk was higher on reboxetine (as well as on imipramine) than on placebo for dry mouth, increased sweating, constipation and vertigo, while it was higher on reboxetine (but not on imipramine) than on placebo for insomnia. The direct comparison between reboxetine and imipramine in terms of increased risk of adverse events indicated significant differences always in favour of reboxetine (dry mouth, hypotension and related symptoms and tremor).

1. INTRODUCTION

Reboxetine (FCE 20124 or (2RS, αRS)-2-[α-(2-ethoxy-phenoxy) benzyl] morpholine) is a new chemical compound which is highly potent in the pharmacological and biochemical tests predictive of antidepressant efficacy such as reserpine antagonism, norepinephrine reuptake inhibition and REM sleep latency increase [1]. Reboxetine also demonstrates the ability to prevent the effects of clonidine after a single oral dose in an animal model, where tricyclic antidepressants were active only upon repeated administration [1]. Therefore, reboxetine was hypothesised to exert antidepressant efficacy of faster onset than the antidepressants currently available in depressed patients. In addition, comparison with imipramine 75 mg in healthy volunteers [2, 3] revealed that reboxetine does not possess the marked sedative activity of imipramine, but rather psychostimulating properties.

Pharmacokinetic studies in healthy volunteers [4], showed that average peak reboxetine levels were observed at 2 hours after oral administration, with remarkably stable levels 1-6 hours after administration; its plasma half-life was estimated as 13.2 hours and 73% of the AUC following an oral dose was accounted for by unchanged reboxetine.

An early phase II, 4-week, multicentre study in 98 patients in which reboxetine was administered at fixed changing doses, with maximum doses of 4 and 12 mg, showed that it was well tolerated at doses of up to 10 mg/day [5].

A double-blind, parallel groups, multicentre study in 258 patients hospitalised due to a major depressive episode compared maximum doses of 8 mg reboxetine with 200 mg of desipramine and placebo over a period of 4 weeks [6]. Reboxetine was found to be more effective than placebo with decreases of ≥50% in Hamilton Depression Rating Scale (HAMD) at the end of treatment in 63% of patients compared with 36% for placebo and 46% for desipramine. These decreases were present after 14 days of treatment in 31% of reboxetine patients and 22% of desipramine patients. More reboxetine patients complained of headache and urinary retention, whereas more desipramine patients experienced dry mouth, sweating and blurred vision. Cardiovascular adverse events were relatively rare, but appeared with slightly higher frequency in the desipramine group (hypotension and tachycardia).

Phase II results obtained in controlled conditions in patients suffering from major depressive disorders indicate that reboxetine is an effective antidepressant agent with a favourable therapeutic index with respect to desipramine. The present study was designed to extend information obtained from other placebo-controlled studies and to collect comparative evidence of reboxetine's safety and efficacy *vs* a tricyclic antidepressant [7]. A comparison of reboxetine with imipramine was expected to provide a proper appraisal of the activity and tolerability of reboxetine.

2. STUDY OBJECTIVES

To assess the activity and tolerability of reboxetine in comparison with placebo and imipramine in patients suffering from major depressive episodes.

3. INVESTIGATIONAL PLAN

3.1 Study Design and Plan - Description and Rationale

3.1.1 OVERVIEW AND JUSTIFICATION

This phase III study was designed as a prospective, double-blind, randomised, controlled, parallel-group, multicentre trial. Its aim was to compare the efficacy and tolerability of reboxetine with that of imipramine and of placebo, administered orally for 6 weeks, in adult patients with major depressive episodes. The design of the study is shown overleaf.

A total of 330 patients with major depressive episodes was to be recruited in accordance with the inclusion and exclusion criteria, and an informed consent obtained from each patient prior to screening.

At screening, a full medical history and physical examination (including chest X-ray and electrocardiogram (ECG)) were carried out and vital signs and laboratory values were measured. Patients were classified according to the DSM-III-R classification and the severity of depression was evaluated using the Hamilton Depression Rating Scale (HAMD) and Mini Mental State (MMS) examination.

After an initial wash-out period of 4-14 days (14 days in the case of monoamine oxidase inhibitors administration and 3-4 weeks in the case of fluoxetine treatment), patients received one of 3 treatments: oral reboxetine 4 mg b.i.d., oral imipramine 50 mg b.i.d. (Days 1-3) then 50 mg in the morning and 100 mg in the evening (Days 4-42), or placebo b.i.d. for 6 weeks. In the case of inefficacy or unsatisfactory response, combined with good tolerability, after 3 weeks of treatment, the total daily dose was allowed to be increased to 10 mg for reboxetine (4 mg in the morning and 6 mg in the evening) and 200 mg (100 mg b.i.d.) for imipramine for the remaining 3 weeks of the study.

The primary study end-point was defined as the HAMD total score difference *vs* Day 0 at last assessment. Response (a decrease of at least 50% in the total HAMD score) and remission (a total HAMD score of 10 or less) were considered to be additional study end-points and their rates at last assessments were also to be compared statistically between treatment groups.

Other variables used for evaluating efficacy were the Clinical Global Impression (CGI), the Montgomery and Asberg Depression Rating Scale (MADRS), Patient Global Impression (PGI) Scale, the Relational Depression Rating Scale (RDRS) and cognitive evaluation.

Safety and tolerability were assessed by the reporting of any adverse events and measurements of vital signs (blood pressure and heart rate (supine and standing)), ECG and laboratory tests.

For ethical reasons, patients willing to continue receiving the test treatment after completion of the 6 weeks' treatment period were provided with study medication and maintained on the same medication under blind conditions until the completion of the last patient in the study and collection of the Case Record Forms (CRFs).

A follow-up visit was to be carried out for each patient one month after treatment discontinuation, in order to monitor possible withdrawal reactions and collect information on any events since treatment discontinuation.

A copy of the final protocol can be found in Appendix 12.1.1. A modified protocol used in the Canadian centre is also included.



3.1.2 PROTOCOL AMENDMENTS

There were three protocol amendments. The first one extended the wash-out period to 3-4 weeks in case of previous fluoxetine administration. The second ones were requested by different countries' ethical committees (France, Australia, Germany and Canada) In the French country the amendment specified that the patient and the investigator should sign the consent form. If the patient was not able to give his or her consent, the signature of the next of kin was to testify that full information was given to the patient; in the Australian

country it replaced chloral hydrate with short acting benzodiazepines (e.g. temazepam 10 mg) as a permitted sleep inducer at bed-time and in the German and Canadian countries it specified that the exclusion criteria "High risk of suicide" had to be correspond to a score "3" or "4" in the HAMD scale item 3 "Suicide".

A modified version of the protocol was used in the Canadian centre: here in fact, only the patients with a total score of 22 or above in the first 17 items of the 21-HAMD were to be included in the study, while all the patients in whom the use of any psychotropic agent could not be removed during the entire experimental study were to be excluded, as well as the patients with a clinical improvement at the end of the wash-out period (decrease of the HAMD of at least 1 point).

3.2 Ethics

3.2.1 ETHICS COMMITTEE

Approval from the Ethics Committees or Institutional Review Boards (IRBs) of the participating centres, in accordance with the regulations and requirements of individual countries, had to be obtained before the study could be undertaken. It was the responsibility of each of the investigators to submit the study protocol with its attachments to the Ethics Committee/IRB. A central approval allowing the clinical evaluation of the product was required and obtained in Italy, Australia and UK, and local approvals were required and obtained in France, Germany, Italy, UK and Australia.

The Central/IRB notifications of approval are kept in the trial master file.

The written approval of the Ethics Committee or IRB had to include the names and professions of all its members. In accordance with local requirements, the investigators were responsible for informing the Ethics Committees of any emergent problems, serious adverse events or protocol amendments.

3.2.2 PATIENT INFORMATION

Before entering the study, an explanation of the nature, duration, purpose of the study and action of the compound had to be given to each patient, in such a manner that he/she was made aware of the potential risks, inconveniences or adverse events that could occur, and could express his/her informed consent to participation. The proposed consent form is enclosed (Enclosure 3 of Appendix 12.1.1). The translations in the national languages and the individual centres forms containing the possible changes requested by the Ethics Committees, if any, are kept in the study master file. The forms were signed by the patient or the next of kin, and/or the investigator. In the latter case, the signature of a witness was required to testify that full information was given to the patient.

All unpublished documentation including the protocol, the CRF and the Investigator's Brochure was confidential. These documents could not be disclosed to a third party without the written consent of the Sponsor. The submission of these documents to the Ethics Committee was expressly permitted. The investigators agreed that the Sponsor maintained the right to utilise the results of this study, in their original form and/or in a global report, for submission to the governmental and regulatory authorities of any country.

3.3 Study Population

Adult patients who were under in-patient care or attending out-patient or day-hospital clinics of the participating centres were selected in accordance with the following inclusion and exclusion criteria.

3.3.1 INCLUSION CRITERIA

The criteria for participation in this study were as follows:

- Patients of either sex, of any race, aged 18 to 65 years
- A diagnosis of acute major depressive episodes, not accompanied by psychotic features (DSM-III-R) [8]; the current episode was to have been present for at least one month but no more than 4 months
- The initial (pre-treatment) total score for the 21-item HAMD [9] had to be $\geq$22. In the Canadian centre, a total score of $\geq$22 in the first 17 items of the 21-item HAMD was required
- Informed consent was obtained from the patient or next of kin, and/or the investigator (see Section 3.2.2)

3.3.2 EXCLUSION CRITERIA

Exclusion criteria for patients recruited to this study were as follows:

- Dysthymia/cyclothymia
- History of major depressive disorder associated with endocrine disorders: hypo- or hyperthyroidism (defined as values at least 10% outside normal tests for TSH and T_4), adrenal insufficiency, etc.
- Pregnancy (excluded by a pregnancy test at the end of the wash-out period)

- Refusal by female patients of childbearing age to use effective contraception during the study period
- Past history of drug hypersensitivity
- Participation in a clinical study with an investigational compound in the 4 weeks preceding the study
- Evidence of Substance Use Disorder (DSM-III-R), currently or within the past 6 months
- Chronic respiratory insufficiency (excluded by physical examination and X-ray)
- History or presence of gastrointestinal, hepatic or renal disease, or other conditions known to interfere with the absorption, distribution, metabolism and excretion of drugs
- History of seizures or brain injury; current evidence of clinically important haematopoietic or cardiovascular diseases; current evidence of urinary retention or glaucoma
- Symptoms of any other important clinical illness in the 4 weeks preceding the study
- Clinically relevant abnormal findings in the physical examination, laboratory tests and ECG at admission
- MMS score <22 (Enclosures 4 and 6 of Appendix 12.1.1)
- Electroconvulsive therapy (ECT) in the previous 3 months
- High risk of suicide

In the Canadian centre, the final exclusion criterion was modified to "risk of suicide" and there were two additional exclusion criteria:

- Use of any psychotropic agent which cannot be removed during the entire experimental study
- Clinical improvement at the end of the wash-out period (decrease of the HAMD of at least one point)

3.3.3 WITHDRAWAL CRITERIA

Patients could be withdrawn from the study at any time for the following reasons:

- Voluntary withdrawal by the patient
- Unacceptable toxicity, defined as the occurrence of serious adverse events (see Section 3.6.2.1)
- Lack of efficacy, defined as patients who showed worsening of the global clinical picture (CGI - see Section 3.6.1.2) after at least 2 weeks of treatment
- Shift to mania

In the case of treatment discontinuation, the final set of tests was carried out wherever possible.

3.3.4 SAMPLE SIZE - NUMBER OF PATIENTS PLANNED

Each of the planned centres participating in the study were to recruit, within a period of one year, a sample of 24-42 patients, so that a total of 330 patients was to be recruited overall.

In fact, several of the centres which initially agreed to participate in the study never did so for logistical reasons, and were replaced with other centres. As shown in the Clinical Investigators List (Appendix 12.1.4), 34 centres located in 6 countries (Australia, France, Germany, Italy, UK, and Canada) participated in the study. In 33 of these centres the number of patients admitted was lower than twenty-four. Recruitment was stopped after randomisation of 339 patients.

Patients who dropped out of the study for any reason were not substituted. For those patients selected for the study who dropped out at any time, even before entrance to the treatment period, documentation was provided.

3.4 Treatments

3.4.1 TREATMENTS TO BE COMPARED

After an initial wash-out period of 4-7 days (14 days in the case of monoamine oxidase inhibitors administration and 3-4 weeks in the case of previous fluoxetine treatment) patients received one of 3 possible treatments for 6 weeks: oral reboxetine 4 mg b.i.d., oral imipramine 50 mg b.i.d. (Days 1-3) then 50 mg in the morning and 100 mg in the evening (Days 4-42), or placebo b.i.d.. In the case of inefficacy or unsatisfactory response, combined with good tolerability, after 3 weeks of treatment, the total daily dose was increased to 10 mg for reboxetine (4 mg in the morning and 6 mg in the evening) and 200 mg (100 mg b.i.d.) for imipramine for the remaining 3 weeks of the study.

3.4.2 IDENTITY OF TEST TREATMENTS

Indistinguishable capsules containing either reboxetine 4 mg (2 x 2 mg tablets) or 6 mg (3 x 2 mg tablets) (Batch No: 4 mg: SF1131, SF1264; 6 mg: SF1132, SF1291) or imipramine 50 mg (2 x 25 mg tablets) or 100 mg (4 x 25 mg tablets) (Batch No: 50 mg: SF1130, SF1265; 100 mg: SF1129, SF1151, SF1263) plus excipients or excipients only (placebo, Batch No: 4 mg: SF1133, SF1246; 6 mg: SF1134, SF1306) were supplied by the Sponsor. Copies of certificates of analysis for the test treatments are presented in Appendix 12.1.5.

3.4.3 DOSE SELECTION AND TIMING

All patients recruited for the study received either one capsule of reboxetine 4 mg b.i.d. (morning and evening), one capsule of imipramine 50 mg b.i.d. (morning and evening) on Days 1-3 then one capsule of imipramine 50 mg o.d. (morning) and one of 100 mg o.d. (evening) on Days 4-42, or placebo b.i.d. (morning and evening) for 6 weeks. For patients who showed an ineffective or unsatisfactory response (worsening, no change or minimal improvement in the CGI; see Section 3.6.1.2) with good tolerability (especially non-symptomatic hypotension) after 3 weeks of treatment, the dose of reboxetine was increased to 10 mg daily (4 mg in the morning and 6 mg in the evening) and the daily dose of imipramine increased to 200 mg (100 mg b.i.d.), for the remaining 3 weeks of the study. In those patients who then displayed poor tolerance at this increased dose, the dose was reduced to the previously well-tolerated level.

The treatment was administered at least 2 hours before or after meals.

The daily dose of reboxetine was chosen on the basis of the results of the previously mentioned open-dose finding study [5], in which daily doses of 8 to 10 mg were found to be associated with the best therapeutic index, and of the controlled phase II study *vs* Desipramine (DMI) and placebo [6], where the 8 mg/day dose regimen was proved to possess antidepressant efficacy. The daily dose of imipramine was selected on the basis of published evidence from controlled studies [7].

3.4.4 METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUPS

A randomisation list balanced within each centre and every 6 assignments was originally generated for patient allocation to either reboxetine, imipramine or placebo. In this list, in order to make the patient unequivocally identified across centres by his assignment number, a progressive number from 1 to 582 was generated. The randomisation list was prepared by Biometrics and Data Management Dept. Milano by SAS proc plan, version 5.18-6.06 and kept in a safe place until the conclusion of data clean up procedure. The test treatments were labelled according to the randomisation sequence number. Each randomised patient

was then identified by the corresponding treatment number. In spite of the anticipated break down by centre of such a sequential list, in order to minimise the waste of drug supply, the latter was shipped to the centres by full blocks of six treatments each.

Patient allocation to treatment was done by the principal investigator at the end of the wash-out period, on the basis of the patient's time of entry into the study and on the available treatment blocks.

3.4.5 TREATMENT SUPPLY AND BLINDING

To ensure the double-blind nature of the study, indistinguishable test treatment in identical cartons was to be identified using double labels indicating the protocol number, patient number, treatment period, batch number and expiry date (Enclosure 5 of Appendix 12.1.1). The detachable half of the label was to be included in the appropriate place in the CRF.

Six cartons showing the patient number and the appropriate week of treatment (Week 1-6) were prepared for each patient. Each carton contained the medication necessary for 1 week of treatment (i.e. 16 capsules, one capsule b.i.d. and 2 additional capsules for possible losses). Additional 3 cartons showing the patient number, the appropriate week of treatment (Week 4-6) and the level of dosage (dose 2) were prepared for each patient in case of possible dosage increases during the last 3 weeks of the study.

3.5 Treatment Procedures

The investigators were given individual sealed envelopes containing the information on patient's treatment, and these were to be opened only in case of emergency necessitating treatment identification. In the event of an emergency, the investigators were to notify the study monitor immediately (within 24 hours), and were to report a full description of the reasons for opening the code on the adverse event form in the CRF. The sealed individual codes were to be returned to the Sponsor at the end of the study.

3.5.1 CONCOMITANT THERAPY

With the exception of hypnotics used for sleep induction on an 'as required' basis, no concomitant medication was allowed on entry to the study. In the case of events arising during the course of the study, non-psychotropic medications which were considered necessary for the patient's welfare could be administered and were not considered protocol violations. The medication, dosage and frequency of administration was recorded on the CRF. Chloral hydrate (0.5-1 g) (or Temazepam 10 mg in the Canadian centre) was permitted at bed-time as a sleep inducer on an 'as required' basis.

3.5.2 TREATMENT ACCOUNTABILITY AND COMPLIANCE

All drug supplies were handled under the direct responsibility of the investigators and held by the Hospital Pharmacy. The study monitors checked drug storage conditions during site visits.

The investigators were responsible for drug accountability and kept a record of the test compounds received from the Sponsor, as well as the drugs dispensed to each patient on the occasion of each visit. The upper label from each of the weekly cartons dispensed to each patient was detached and fixed in the appropriate space in the CRF. On the same occasion, cartons of the previous supply were returned by the patient. These used cartons were returned to the study monitors during site visits. All unused medication was to be returned to the Sponsor at the end of the study.

3.6 Efficacy and Safety Variables

At screening, a full medical history and physical examination (including chest X-ray and ECG) were carried out and vital signs and laboratory values were measured. Patients were classified according to the DSM-III-R classification and the severity of depression was evaluated using the HAMD scale and MMS.

3.6.1 EFFICACY

Every randomised patient with at least one assessment in addition to baseline was evaluable for efficacy analysis.

Patients were seen at regular intervals throughout the study and the following efficacy assessments carried out at the specified intervals. All psychiatric evaluations and ratings were to be carried out by the same observer for a given patient and in the same setting and at the same time of day if possible.

3.6.1.1 Hamilton Depression Rating Scale

The severity of depression was evaluated using the HAMD at screening, and on Days 0, 7, 14, 21, 28, 35 and 42.

The HAMD scale [9] contained 21 items, each of which was scored (0-2, 0-3 or 0-4) to reflect whether the symptom was absent, trivial, mild, moderate or severe. Some of the items were more heavily weighted than others. The scores for all the symptoms were added together to give a global judgement of the severity of the depression.

A decrease of at least 50% in the total HAMD score compared with Day 0 was considered to be an **index of response**, whereas a total HAMD score of 10 or less was considered an **index of remission**.

The 21-item list of the HAMD used in this study is as follows:

	Item	Score range	Factor
1.	Depressed mood	(0-4)	V
2.	Feelings of guilt	(0-4)	III
3.	Suicide	(0-4)	III
4.	Insomnia early	(0-2)	VI
5.	Insomnia middle	(0-2)	VI
6.	Insomnia late	(0-2)	VI
7.	Work and activities	(0-4)	V
8.	Retardation	(0-4)	V
9.	Agitation	(0-4)	III
10.	Anxiety (psychic)	(0-4)	I
11.	Anxiety (somatic)	(0-4)	I
12.	Somatic symptoms gastrointestinal	(0-2)	I
13.	Somatic symptoms general	(0-2)	I
14.	Genital symptoms	(0-2)	V
15.	Hypochondriasis	(0-4)	I
16.	Loss of weight	(0-3)	II
17.	Insight	(0-2)	I
18.	Diurnal variation	(0-2)	IV
19.	Depersonalisation and derealisation	(0-4)	III
20.	Paranoid symptoms	(0-3)	III
21.	Obsessional symptoms	(0-2)	III

More detailed definitions of the items included in the scale can be found in Enclosure 7 of Appendix 12.1.1.

Factorialisation was carried out according to the ECDEU manual [10], to yield 6 factors: Anxiety/somatisation (I), Weight (II), Cognitive Disturbances (III), Diurnal Variation (IV), Retardation (V), Sleep Disturbances (VI).

3.6.1.2 Clinical Global Impression

Severity of illness was assessed by the investigator, using the CGI [10], on Days 0, 7, 14, 21, 28, 35 and 42. The following scale was used:

1. = normal, not at all ill
2. = borderline mentally ill
3. = mildly ill
4. = moderately ill
5. = markedly ill
6. = severely ill
7. = amongst the most extremely ill patients

The investigator also evaluated the effect of treatment at each visit, with reference to the patients' condition at the start of the study, according to the following scale:

1. = very much improved
2. = much improved
3. = minimally improved
4. = no change
5. = minimally worse
6. = much worse
7. = very much worse

An Efficacy Index was then assessed by the investigators described in [10], as the ratio between the objective evaluation of improvement, scored from 1 (unchanged or worsened) to 4 (marked improvement) and the subjective evaluation of tolerability, scored from 1 (no side-effects) to 4 (side-effects outweigh therapeutic effect). The Efficacy Index score

ranges from 0.25 (no global benefit) to 4 (maximal global benefit). Details of the Efficacy Index can be found in Enclosure 8 of Appendix 12.1.1.

3.6.1.3 Montgomery and Asberg Depression Rating Scale

The MADRS [11] was measured on Days 0, 7, 14, 21, 28, 35 and 42.

This scale consists of ten items relating to depression, selected from the 67 items in the Comprehensive Psychiatric Rating Scale [12]. The items contained in the MADRS were selected on the grounds that they were sensitive to change. The 10 items were as follows:

1. Reported sadness
2. Inner tension
3. Apparent sadness
4. Suicidal thoughts
5. Inertia
6. Inability to feel
7. Pessimistic thoughts
8. Concentration difficulties
9. Reduced sleep
10. Reduced appetite

The scale requires a structured interview for completion. A score of 0 to 3 for each item was used as in reference 12. In a proportion of cases (approximately 29.6% of the total sample) a score of 0 to 6 was used, as in reference 11. Data have been pooled by dividing by two item scores of the latter sample.

More detailed definitions of the items included in the scale can be found in Enclosure 9 of Appendix 12.1.1.

3.6.1.4 Patient Global Impression Scale

Each patient had to complete a visual analogue scale, indicating his or her general condition on Days 7, 14, 21, 28, 35 and 42. The results collected were not evaluated due to the very low number of patients completing the assessments.

3.6.1.5 Relational Depression Rating Scale

The relational aspects of depression were explored using the RDRS on Days 0, 7, 14, 21, 28, 35 and 42 (Enclosure 11 of Appendix 12.1.1). The investigators used their judgement to propose one or two additional items of relevance for each patient. The consistency of their suggestions was evaluated and an international scale was in development.

3.6.1.6 Cognitive Function Evaluation

Cognitive function was evaluated on Days 0, 14 and 42. Details of the cognitive function tests are provided in Appendix No 1 of Appendix 12.1.1. The results collected were not evaluated due to the very low number of patients completing the assessments.

3.6.2 SAFETY

Every patient who received one dose of test treatment was included in the safety evaluation. For clinical and laboratory tests, only patients with at least one assessment in addition to baseline were analysed.

3.6.2.1 Adverse Events

Spontaneously reported

Patients were notified of any possible adverse events they might experience and were instructed to report any such adverse event to the investigators immediately.

The occurrence of adverse events was recorded on Days 0, 7, 14, 21, 28, 35 and 42.

Any newly observed sign or symptom (including clinically relevant laboratory abnormalities), noticed by the investigators or reported by the patients were reported, regardless of presumed relationship to the study medication, in the appropriate section of the CRF (Adverse Event Report Form - Enclosure 14 of Appendix 12.1.1).

For each adverse event, the following information was entered in the CRF: description, date of onset, date of stopping, severity, drug cause-effect relationship, outcome, effect of withdrawal of treatment and rechallenge. The investigators also had to note if the double-

blind code had been broken, the action taken regarding the test drug (none, dose reduced or discontinued) and any treatment given as a result of the adverse event.

Severity was coded as follows:

1. = mild - awareness of sign or symptom, but easily tolerated
2. = moderate - discomfort enough to cause interference with usual activity
3. = severe - incapacitating with inability to work or do usual activity
4. = unknown

Relationship to test drug was coded as definite, probable, possible, doubtful, unknown or not related, according to Karch and Lasagna modified criteria [13], as shown also in Enclosure 13 of Appendix 12.1.1.

All serious* and/or unexpected** adverse events had to be reported to study monitors immediately (within 24 hours), and the details recorded on an Adverse Event Report Form. **Serious adverse event** was defined as any experience that was (potentially) fatal or life-threatening, disabling, incapacitating, requiring inpatient hospitalisation, causing a congenital anomaly or cancer, or due to an overdose. **Unexpected adverse event** was defined as any adverse experience that was not identified in nature, severity or frequency in the current Investigator's Brochure for the study.

The same procedure applied for all patients who died during the course of the study or within 30 days of completion, irrespective of whether the event was judged as related to treatment. If an autopsy was performed, a copy of the pathological report was to be sent to the Sponsor.

Adverse events reported through a check-list

The presence or absence of selected adverse events was noted through a check-list especially designed for the notification of events frequently reported in patients on antidepressant medication. The check-list is shown in Enclosure 12 of Appendix 12.1.1. These events could be either reported by the patient or observed by the investigator.

---

* Code of Federal Regulation, Vol. 21, Part 312. Revised as of April 1 1987, page 75.

** Bem JL, Breckenridge AM, Mann RD, Rawlins MD: Review of yellow cards (1986): report to the Committee on the Safety of Medicines. Br J Clin Pharmac 1988; 26: 679-689.

For each adverse event, the same procedure as for spontaneously reported adverse events was followed in terms of recording of information in the CRF (Adverse Event Report Form) and reporting of the 'serious' or 'unexpected' adverse event to the Sponsor.

3.6.2.2 Clinical and Laboratory Tests

Vital signs

Body weight and temperature, as well as blood pressure and heart rate (supine and standing) were measured at screening, and on Days 0, 7, 14, 21, 28, 35 and 42.

Supine blood pressure and heart rate were measured in the morning after 5 minutes in the supine position and standing blood pressure and heart rate were measured 1 to 2 minutes after standing up.

ECG

An ECG was recorded at screening, on Days 21 and 42.

Laboratory tests

Laboratory tests were recorded at screening, on Days 21 and 42.

The laboratory tests comprised the following: full blood count, serum electrolytes, liver enzymes, urinalysis, blood sugar, serum alkaline phosphatase, blood urea nitrogen (BUN), serum creatinine, uric acid, total and direct bilirubin, total serum protein and electrophoresis, serum cholesterol and triglycerides, and at screening only, TSH and T_4.

For patients who withdrew prematurely for any reason, all the assessments, including vital signs, ECG and laboratory tests, were to be performed.

3.7 Study Procedures and Flow Chart

3.7.1 SCHEDULE OF ASSESSMENTS

Assessment	Pre-Treatment Screening	Treatment Day 0	7	14	21	28	35	42
Diagnosis: DSM-III-R	x							
Medical history	x							
Physical examination	x							
MMS	x							
Chest X-ray	x							
ECG	x				x			x
Laboratory tests	x				x			x
Vital signs	x	x	x	x	x	x	x	x
21-item HAMD	x	x	x	x	x	x	x	x
CGI		x	x	x	x	x	x	x
MADRS		x	x	x	x	x	x	x
PGI			x	x	x	x	x	x
RDRS		x	x	x	x	x	x	x
Cognitive evaluation		x		x				x
Compliance check			x	x	x	x	x	x
Dispensing medication		x	x	x	x	x	x	
Adverse events		x	x	x	x	x	x	x

3.7.2 PROCEDURES AT EACH VISIT

At screening, a full medical history and physical examination (including chest X-ray and ECG) were carried out and vital signs and laboratory values were measured. Patients were classified according to DSM-III-R and the severity of depression was evaluated using the HAMD scale and MMS.

One month after treatment discontinuation, a follow-up visit was carried out for each patient, in order to monitor possible withdrawal reactions and to collect information on any adverse events that had occurred during this period. For ethical reasons, patients willing to continue receiving study drug after completion of the 6-week treatment period were provided with study medication and maintained on the same medication in blind conditions until the study was completed in the last patient and all the CRFs were collected. Efficacy was assessed by HAMD and CGI at monthly visits. Adverse events were also recorded at monthly intervals and ECG and laboratory values at 3-monthly intervals. The medications were prepared as described for the initial double-blind phase, but in monthly, instead of weekly, units (see Section 3.4.5). Following completion in the last patient of the study and collection of all the CRFs, follow-up was performed under open conditions. The follow-up results will be reported separately in an Addendum to the present report

3.8 GCP Compliance, Data Quality Assurance

The study was initiated before the formal adoption of GCPs by European Regulatory Authorities and in the absence of Company Standard Operating Procedures. However, operating procedures for study monitoring and co-ordination were defined and are described in Attachment A of Appendix 12.1.1.

The study was conducted in accordance with the Declaration of Helsinki, adopted by the 18th World Medical Assembly, Helsinki, June 1964, and amended by the 41st World Medical Assembly, Hong Kong, 1989. A copy of declaration of Helsinki can be found in Enclosure 15 of Appendix 12.1.1. Inter-rater reliability sessions with training purpose on the instrument used for the assessment of change, and particularly on the HAMD, were carried out during the investigators meetings organised by country and/or the monitoring visits by employing 4 videotaped interviews.

During the Study monitoring visits, made at regular intervals, the monitor validated the content of the CRF against source documents, on the basis of the agreed procedures.

Site, trial master file and report audits were carried out by the Company Quality Assurance Unit.

3.9 Statistical Analysis

3.9.1 DETERMINATION OF SAMPLE SIZE

The main evaluation of reboxetine effectiveness was based on the comparison with placebo of the difference between the HAMD score as measured at the last valid assessment and the same score as above as measured at the study entry.

In agreement with this goal the following system of hypotheses was set up:

$$H_o : \delta_{RBX} \leq \delta_{PLC}$$

$$H_a : \delta_{RBX} > \delta_{PLC}$$

where δ_{RBX} and δ_{PLC} are the true mean differences of HAMD scores in reboxetine and placebo arm, respectively. Imipramine arm was included in order to ensure the sensitivity of the experimental setting.

In order to take into consideration the multiple comparisons carried out, the overall 0.05 Type I error was halved in the computation of the sample size.

From the Phase II experience [6] and from the literature [7] it seemed reasonable to assume that the treatments groups would have shown a variability (expressed as standard deviation) of 9 points.

Considering of clinical relevance a difference between either reboxetine or imipramine and placebo of at least 4 points, 80 patients in each treatment group were necessary to provide the test with a power ≥ 0.80 if the alternative hypothesis was true with an α level 0.025 for each of the two tests.

The number of required patients was increased to the actual number recruited, in order to take into consideration that drop-outs might have increased variability.

3.9.2 ANALYSES CARRIED OUT

3.9.2.1 Baseline Comparability of Treatments Groups

Baseline characteristics (e.g. age, diagnosis, age at onset, number of previous episodes) which might have influenced the main end-point of the study were summarised considering all the patients entered into the study and subsequently randomised either to reboxetine or to imipramine or to placebo arm.

3.9.2.2 Efficacy Analyses

Definitions

The following definitions apply to the set of data analysed:

HAMD decrease	The difference between the end of treatment and baseline measurements of HAMD total score. Either the last per-protocol assessment, when the patient regularly completed the study, or the last assessment before dropping out was taken as the end of treatment.
Remission	HAMD total score lower than or equal to 10 (absolute value).
Response	HAMD total score decrease equal to or greater than 50% of the pre-treatment value (Baseline: visit 0). According to this definition and based on the inclusion criterion which required a HAMD total score at entry at least greater than 22, all patients who achieved a remission (as defined above) were included into the broader category of response (22*0.5=11).
Time to response	Number of days elapsing between the first visit date (Baseline) and the date when first the patient achieved the response (according to the above definition), which was afterwards maintained until the end of the study or earlier termination. This definition excludes patients who achieved occasional response, but were not classified as such at the last observation.
Severe patients	Patients scored 5 to 7 (markedly to extremely ill) on CGI-Severity of Illness scale [10] at entry.
Melancholic patients	On the basis of applicable DSM IV criteria [14]: presence of item 2, i.e. loss of pleasure in all or almost all daily activities in the DSM-III-R classification at entry, and of at least three of the following items in the day 0 HAMD scale: late insomnia (item 6) of maximal severity; agitation (item 9) or retardation (item 6) of at least moderate severity; definite loss of weight (item 16) or loss of appetite (item 12) of maximal severity; diurnal variation with worsening in the morning (item 18); excessive or inappropriate guilt (score 2 or 3 of item 2).

Methods

The data set analysed included all the patients entered, with the only exception of those patients who did not have at least one post-baseline evaluation.

Efficacy variables, including HAMD and MADRS total score, as well as CGI, were summarised by descriptive statistics (mean, standard deviation -SD-, minimum, maximum, or distribution of frequency of scores) as calculated both at each visit and considering the last valid observation, in the three treatment groups. In particular, in order to describe the time pattern of last valid observation values, one table reports descriptive statistics visit by visit only for those patients who drop the study at that particular time.
The frequency of patients improved, unchanged or deteriorated as for the CGI-Severity of Illness at last assessment compared to baseline was also presented.

The primary end-point for efficacy analysis was HAMD decrease. Treatment mean decreases were analysed by one-way ANOVA [15] and each of the active treatments (reboxetine and imipramine) mean decrease was compared with the one of placebo treatment by one-tailed Dunett's t-test [16]. This test ensures an overall Type I error of 0.05 for the two comparisons carried out. Moreover the 95% C.I. of the difference between the HAMD decrease in the two active treatments was calculated.

Although not strictly necessary to the analysis of differences from baseline, homogeneity of baseline HAMD total scores across treatment groups was tested by ANOVA, in order to assess the comparability of the disease severity within each assignment group. No transformation of the original variable was deemed necessary being the outcome variable the difference between two random variates and as such known to tend to be normally distributed; homogeneity of variances was tested by Bartlett's test [17].
Ninety-five percent confidence intervals (two-tails) of the mean difference of each treatment were computed using in the computation the standard error (SE) obtained by the ANOVA.
No baseline characteristics among the one initially tested (i.e. sex and diagnosis, namely first episode *vs* recurrence) were included into the final model analysed, since they didn't increase the variability explained by the model and there was no significant interaction between each of them and the treatment.

The same sets of analyses were carried out on the subset of severe and melancholic patients as defined above.

Complementary to the quantitative analysis of HAMD total score, the qualitative analysis classifying the patients according to the above definition as either responder or failure at last valid assessment was carried out. Independent Chi square tests [18] were applied, in order to compare either reboxetine or imipramine with placebo.

No hypothesis was anticipated in the protocol for these comparisons, since this analysis was intended as simply confirmatory of the analysis of the main end-point, i.e. the quantitative evaluation of HAMD. However, a *post-hoc* calculation of the power of the test carried out indicated that a trial of such a size, aiming at identifying a treatment difference as big as 20%, would have had a power greater than 85% in the extreme case of a two tailed test at an α-level 0.025, allowing for protection for multiple comparisons.
The cumulative probability of the onset of response (time to response) was computed adopting the Kaplan-Meier method and pairwise comparisons between each of the active treatments and placebo were carried out by the log-rank test [19].

3.9.2.3 Safety Analyses

Vital signs as measured at each assessment time were summarised by descriptive statistics. Patients with orthostatic hypotension (a decrease ≥30 mmHg of systolic blood pressure from lying to standing) were described. Moreover, the frequency of patients showing clinically relevant (20% or more *vs* baseline) or such a modification accompanied by absolute critical values (≥ 160 or ≤ 100 mmHg for systolic blood pressure; ≥ 100 or ≤ 70 mmHg for diastolic blood pressure; ≥ 100 or ≤ 50 beats/min for heart rate) at each evaluation time were tabulated.

ECG have been summarised in frequency tables, showing normal/abnormal findings at each visit. Changes from baseline (i.e. normal to abnormal and viceversa) have been displayed.

For all the laboratory examinations and within each of the three treatments, the following analyses have been provided:

- frequency and percentage of patients whose values were below, equal or above the normal range at baseline and shifted to values below, within or above the normal range at each visit. Either MacNemar test or Stuart Maxwell test [20] has been applied, in order to test if the distribution across categories at baseline differs from the distribution at each visit.

- continuous values of laboratory tests were standardised according to a method proposed by Chuang-Stein [21] , using as reference values mainly the one reported in Cecil Textbook of Medicine [22] (see Appendix 12.1.8); the Wilcoxon Rank Signed test for paired data [23] was applied, in order to compare the values during treatment with those recorded at baseline.

The usage of statistical tests in this framework aimed mainly at providing screening tools for selecting the relevant changes within each single examination, to this purpose the tests were considered as statistically significant if $p < 0.01$.

Moreover, abnormal values of laboratory tests defined as clinically relevant were specially considered and their frequencies at each visit computed. The criteria used to define the observed modifications of laboratory values with respect to baseline as clinically relevant are reported in Appendix 12.1.8.

In the analysis of the adverse events, the attention has been focused on treatment emergent signs and symptoms, i.e. events that were not present at baseline and appeared during treatment or, if present at baseline, became more severe during treatment. The analyses were essentially descriptive and for each treatment group, they were performed in terms of both patients complaining of adverse events and events.
The analyses were performed taking into account the occurrence of at least one sign or symptom, the occurrence of at least one event for each body system or selected aggregation of symptoms (cluster) likely to share the same underlying mechanism or described with synonyms and, in detail, the occurrence of each type of sign or symptom. The events occurred during the study that were grouped in clusters are described in Appendix 12.1.9. When severity of the events was considered, the worst reported degree was selected. In order to explore possible differences, patients were also classified by sex and age.

The cumulative risk of developing the first adverse event, as well as individual adverse event and adverse event clusters (newly emerged in 5% or more of patients in at least one treatment group) was estimated by Kaplan-Meier method. Furthermore, the weekly frequency of patients experiencing adverse events (either because of the onset of new events or because of the persistence of those previously developed) was assessed.

The events have been described by frequency tables according to duration, onset time, symptomatic treatment, relationship to study medication, study drug adjustment, dechallenge/rechallenge after action on study drug and outcome. The duration of any event was computed as the number of days from its onset up to its recovery or, in the absence of recovery date, up to the last reporting date (approximate duration).

3.9.2.4 Changes in the Conduct of the Study or Planned Analysis

No deviation of the main end-point was introduced into the final analysis. In general, analyses carried out were consistent with the ones anticipated in the protocol with a few exceptions:

a) subset analyses of severe and melancholic patients was introduced.

b) safety was presented in a more articulated fashion than that anticipated into the protocol.

Both the deviations were introduced to give a better picture of the product profile and no extra claim is being done on the results obtained.

3.10 Data Management

Data management was carried out in the Biometrics and Data Management Department of Pharmacia, Milan.
CRFs data were entered into a IBM 3090 computer (according to the arrival flow) through data entry masks generated by SAS FSP release 6.06 and 6.07.
Subsequently, data were scrubbed by an electronic procedure set up to this purpose, which generated listings of discrepancies between the actual value entered and predefined algorithms. Computer programs generated to this purpose are archived in Biometrics and Data Management Department. These listings were reviewed by clinical personnel and editing of CRFs were requested at the Investigator site, whenever appropriate.
Corrections were entered iterating the loop until the files were completely cleaned.

ECG tracings were classified and subsequently grouped according to the codes reported in Appendix 12.1.10. Previous and concomitant diseases were coded according to ICD9 dictionary [24]; concomitant drugs according to the Drug Reference List [25]; adverse events according to the WHO-ART dictionary [26]. In the absence of an adequate WHO-ART dictionary code, blurred vision was coded under the preferred term of vision abnormal and urinary hesitancy under the preferred term of micturition disorder. In addition is to be noticed that the dictionary subsumes under the preferred term of suicide: attempt suicide, suicide attempt and suicidal tendency.

Reporting, as well as statistical analyses, were carried out with SAS PROCs (version 6.07), apart from Stuart-Maxwell test and confidence interval calculation. The programs relevant to the latter ones are appended in Appendix 12.1.11. A selection of statistical analyses outputs is shown in Appendix 12.1.12.

4. STUDY PATIENTS

4.1 Disposition of Patients

Randomisation list is given in Appendix 12.1.7.

Three hundred and thirty-nine patients (201 females and 138 males) were admitted to the study from January 1991 to October 1992 and randomised to treatment by investigators at 34 centres, as shown in Table 1.

As shown in Table 2, a total of 252 patients (74.3%) completed the study and 87 (25.7%) withdrew; 23 (20.5%) in the reboxetine group, 38 (33.0%) in the imipramine group, and 26 (23.2%) in the placebo group. Frequency and timing of withdrawal are shown by the primary reason for withdrawal in Table 3.

Adverse events or intercurrent illnesses were the main reason for withdrawal in 12, 15 and 8 patients of the reboxetine, imipramine and placebo groups, respectively. The discontinuation for newly emerged adverse events occurred in 11 (9.8%), 15 (13.0%) and 7 (6.3%) on reboxetine, imipramine and placebo respectively. In fact, two patients dropped out the study due to intercurrent medical problems without having a newly emerged adverse event form filled in the CRF: one patient (No 416 from the reboxetine group) dropped out due to the discovery of hypothyroidism which was present before the start of treatment, and a second patient (No 138 from the placebo group) due to bad hepatic function. Adverse events associated with discontinuation in individual cases are discussed in the Adverse Event Section (Section 8.2.3.2). Deterioration was the reported reason for withdrawal in 5, 11 and 11 patients of the reboxetine, imipramine and placebo groups, respectively, i.e. it was given as the reason for withdrawal approximately twice as often by imipramine and placebo group patients compared with reboxetine group patients. Five, eight and six patients were withdrawn due to the non-compliance in the reboxetine, imipramine and placebo group, respectively, while two patients on imipramine and one on placebo were lost to follow up. One patient on imipramine stopped the experimental treatment due to improvement. In the reboxetine group, one patient interrupted the study because of a protocol violation (significant irregularities in drug compliance), and in the imipramine group one patient died (committed suicide) and one discontinued for other reasons (decision of the Principal Investigator at the centre).

The disposition of patients is shown in the following figure and in Table 2.

Disposition of patients



4.2 Protocol Deviations

Compliance with entry criteria

The frequency of non-compliance with inclusion/exclusion criteria of relevance for inferential purpose is given in Table 4. The most frequent reason (4.5%, 10.4% and 5.4% in the reboxetine, imipramine and placebo group patients, respectively) for possible non-compliance with one of the exclusion criteria was related to abnormalities of thyroid function tests, possibly suggestive of an underlying, undiagnosed endocrine disorder. Concomitant medications not allowed according to the protocol during the wash-out period were administered to 5.4% of the reboxetine group patients, 2.6% of the imipramine group patients and 0.9% of the placebo group patients.

Randomisation

Distribution and use of study medication were to be done, as previously mentioned, in blocks of 6 treatments, used in sequence from the smallest to the highest number, according to patient temporal entry into the study. In order to provide a discrepancy log with respect to the randomisation sequence, patients were listed according to their study entry date and the treatment foreseen to be assigned, according to the random sequence of the blocks available at the centre, was matched by a sequential criterion. Mismatching between the foreseen treatment and the treatment actually received was identified as a randomisation error.

As reported in Table 5, errors in randomisation procedures led to administration of non-randomised treatment to a few patients, at a similar frequency in all three treatment groups. Of the 111 patients randomised to reboxetine, 16 received imipramine and 15 received placebo treatment; of the 114 randomised to imipramine, 19 received reboxetine and 6 received placebo, and of 112 patients randomised to placebo, 12 received reboxetine and 9 received imipramine. For 2 patients (1 on reboxetine and 1 on imipramine) was not possible to identify the treatment which had to be assigned and they were considered out of randomization. All the patients were analysed according to the treatment received.

Assessment intervals

The summary statistics of the efficacy and safety assessment intervals in days from treatment start are shown in Table 6. There were few deviations from scheduled times and these were mainly related to screen and last laboratory tests and ECG evaluations. The deviation rate was similar in the three treatment groups.

Concomitant medications

The frequency of administration of non-protocolled concomitant medications (because of their psychotropic properties) is given by active principle in Table 7, and by class in Table 8. Non-protocolled drugs were administered to only two patients on imipramine (1 long-acting benzodiazepines and 1 antiepileptics) and to five patients on placebo (1 phenothiazines and 4 long-acting benzodiazepines). There were no withdrawals classified as protocol deviation in either of the three groups.

4.3 Demographic Data

Summary statistics of demographic data are given by treatment group in Table 9 (sex, age, weight, height) and Table 10 (race), and summarised below.

Summary of Demographic Data

		Reboxetine		Imipramine		Placebo	
		n	(%)	n	(%)	n	(%)
Sex	Female	70	62.5	77	67.0	54	48.2
	Male	42	37.5	38	33.0	58	51.8
	Total	112	100	115	100	112	100
Race	Caucasian	111	99.1	114	99.1	108	96.4
	Asian	0	0.0	0	0.0	2	1.8
	Other	1	0.9	1	0.9	2	1.8
	Total	112	100	115	100	112	100
		mean	SD*	mean	SD*	mean	SD*
Age (years)		45.9	12.7	43.5	11.1	43.3	11.7
Height (cm)		166.1	9.3	165.7	8.9	167.8	8.4
Weight (kg)		68.6	15.3	67.4	13.1	69.7	14.1

*SD standard deviation

The majority of patients, in the reboxetine and imipramine groups, were female, but the percentage of females and males was about the same in the placebo group. The vast majority of patients were Caucasian and only 2 patients were Asian. Of the 4 patients with unspecified race, the investigators reported in CRF their nationality (2 patients from Iran, one in both the reboxetine and imipramine groups, and 2 patients, from Madagascar and Sri Lanka respectively, in the placebo group). All treatment groups were well matched for age, height, weight and race.

4.3.1 DIAGNOSIS AND HISTORY OF THE DEPRESSIVE DISORDER

The frequency of the DSM-III-R diagnostic classifications, the summary statistics of the history of the depressive disorder, and the characteristics of the index episode are given by treatment, and sex, in Tables 11 and 12. Recurrent Major Depressive Disorder (DSM-III-R No 296.3) was diagnosed for the majority of patients in each treatment group (67.9% reboxetine, 69.6% imipramine, and 73.2% placebo). A Major Depression First Episode (DSM-III-R No 296.2) was diagnosed in almost all remaining cases, except for 2 patients (1 reboxetine and 1 imipramine) who were diagnosed as Bipolar Disorder, Depressed, unspecified (DSM-III-R No 296.5).

The age of onset, the median number of previous episodes of depression, the median duration of the last episode and the median duration of the present episode of the patients at entry into the study are shown below.

Previous History of Depression

	Reboxetine			Imipramine			Placebo		
	n	median	range (min-max)	n	median	range (min-max)	n	median	range (min-max)
Age at onset (years)	97	39	13-72	98	37	14-59	99	36	14-59
Number of previous episodes	72	2.0	1-20	76	2.5	1-40	76	2.0	1-11
Duration of the last episode (weeks)	76	12	4-52	76	12	2-156	80	12	1-364
Duration of the present episode (weeks)	112	8	3-16	115	8	3-20	112	8	3-24

The treatment groups were well matched with regard to all the tests characterising the history of mental disorders, as well as for the MMS total scores (Table 12.1).

As shown in Table 12, the onset of the index episode was acute or subacute in the majority of the patients in each treatment group (71.4% of the reboxetine group patients, 85.2% of the imipramine group patients, and 75.9% of the placebo group patients). A precipitating external stress was absent in a similar proportion of patients in each treatment group (39.3%, 40.9%, 39.3% in the reboxetine, imipramine and placebo groups, respectively).

4.3.2 SEVERITY OF DEPRESSION

The severity of the depression, according to the HAMD, MADRS, CGI and RDRS scales, at the various assessment intervals during the study is displayed in terms of summary statistics in Tables 19 to 41 and summarised below at Day 0 for those patients with at least one assessment in addition to baseline. There was no significant difference between the treatment groups at Day 0 with regard to the mean HAMD total scores. Similarly, there were no significant group differences for the initial CGI, RDRS and MADRS scores.

Severity of Depression at Day 0

	Reboxetine			Imipramine			Placebo		
	n	mean	SD*	n	mean	SD*	n	mean	SD*
HAMD	110	27.5	5.1	111	26.9	4.7	111	27.1	5.3
MADRS	110	16.4	3.9	111	16.7	3.4	111	16.3	3.5
RDRS	109	18.8	7.0	111	18.6	6.2	111	18.0	7.0
	n	(%)		n	(%)		n	(%)	
CGI Severity									
Normal	0	0.0		0	0.0		0	0.0	
Borderline mentally ill	0	0.0		0	0.0		0	0.0	
Mildly ill	1	0.9		2	1.8		4	3.6	
Moderately ill	33	29.7		29	26.1		38	34.2	
Markedly ill	54	48.6		64	57.7		51	45.9	
Severely ill	22	19.8		15	13.5		18	16.2	
Extremely ill	1	0.9		1	0.9		0	0.0	

*SD standard deviation

On the whole, there were no major imbalances between the three treatment groups in terms of demography, psychiatric medical history and characteristics of the index episode.

4.3.3 PREVIOUS ANTIDEPRESSANT TREATMENTS

Frequency of treatment of previous or index episode with different antidepressant drugs is given by active principle in Table 13. As expected, tricyclic antidepressants were the most frequently prescribed drugs; selective serotonin reuptake inhibitors (with the exception of fluoxetine and fluvoxamine) and monoamine oxidase inhibitors were infrequently mentioned. Active principles are similarly represented in the three treatment groups.

4.3.4 MEDICAL HISTORY

The medical history and medical examination findings at entry to the study are summarised by single disease entity in Table 14, and by affected body system in Table 15. A minority of

the patients had history or presence of diseases other than the affective disorder at admission. No imbalances among the three treatment groups are apparent.

5. STUDY MEDICATION AND COMPLIANCE

The frequency of administration of different doses of each experimental treatment on each study day is given by treatment in Table 16. The per protocol dose was administered to the vast majority of the patients. On Day 1, 20/112 (17.9%) of the reboxetine group patients, 17/115 (14.8%) of the imipramine group patients and 22/112 (19.6%) of the placebo group patients received half of the protocolled number of daily capsules, because they started their treatment in the afternoon. This resulted in a Day 1 dose of 4 mg of reboxetine, 50 mg of imipramine and 1 capsule of excipients, respectively. Over the next few days a maximum of 3 patients per day in the reboxetine group, 7 patients per day in the imipramine group and 5 patients per day in the placebo group had their number of daily capsules decreased (for the reasons indicated in the individual data listing for the experimental treatment). These were mainly missed intake, lost medication or emergence of signs/symptoms of intolerance.

At the end of the initial 3 weeks of treatment (Table 16.1), 21 patients of the reboxetine group (18.8% of patients treated), 18 of the imipramine group (15.7% of patients treated), and 39 of the placebo group (34.8% of patients treated) had the daily dose increased according to the protocol provisions to a dose corresponding to 10 mg of reboxetine and 200 mg of imipramine (level 2 dose). In the following days, 5 additional patients in the reboxetine group, 3 patients in the imipramine group and 5 patients in the placebo group were changed to level 2 dose. Over the following period, a maximum of 3 patients in both the reboxetine and imipramine groups, and a maximum of 2 patients in the placebo group, had their number of daily capsules decreased (for the reasons indicated in the individual data listing for the experimental treatment). These were mainly missed intake, lost medication or emergence of signs/symptoms of intolerance. During this period, on several treatment days, 3 reboxetine patients, 2 imipramine patients and 3 placebo patients mistakenly took both level 1 and 2 doses, corresponding to 18 mg/day of reboxetine, 350 mg/day of imipramine and 4 capsules per day of placebo (Table 16).

Comparison of the daily dose administered (as reported in the compliance section of the CRF) with the expected dose (as indicated in the Experimental Treatment Section of the CRF) allowed calculation of the compliance with the treatment regimen. Full compliance was defined where there was full agreement between the dose prescribed (the per protocol dose, or a lower dose, mainly in case of adverse events) and the dose reported to have been taken. The total compliance over the treatment period was calculated for each patient and the patients were classified accordingly (Table 17). One hundred per cent compliance was reported in 68.8% of the reboxetine group patients, 70.4% of the imipramine group patients, and 75.0% of the placebo group patients. Only in a few cases the reported

compliance was lower than 80% (3 imipramine group patients and 2 placebo group patients) or between 80% and 89% (5 reboxetine group patients, 2 imipramine group patients and 1 placebo group patient). The remaining patients reported a total compliance between 90% to 99% (26.8% of reboxetine, 25.2% of imipramine and 22.4% of placebo patients).

6. CONCOMITANT MEDICATIONS

The absolute and per cent frequencies during the treatment period, of those patients who received concomitant medications, either as a continuation of baseline therapy or as a newly introduced medication for treatment emergent events, is shown in Table 18. In addition to those non-protocolled psychotropic medications discussed previously in Section 4.2, other drugs were occasionally administered, generally following the emergence of adverse events, at similar frequency in the three treatment groups.

7. EFFICACY RESULTS

Every randomised patient with at least one assessment in addition to baseline was considered as evaluable for efficacy analysis.
Eighty-nine out of the 110 evaluable patients on reboxetine, 77 out of the 111 evaluable patients on imipramine and 86 out of the 111 evaluable patients on placebo completed the study, while 89 patients on reboxetine, 79 on imipramine and 87 on placebo had the last assessment at the Day 42 visit, in spite of the fact that three of them (2 in the imipramine and 1 in the placebo group) withdrew from the study during the last week of the treatment (in comparison with the Table 2 and related figure at page 53).

7.1 Hamilton Depression Rating Scale

Summary statistics of HAMD assessment at each visit in the observed cases are shown in Table 19 (total scores), Table 20 (factors) and Table 21 (individual items). Summary statistics of the last assessment are given in Table 22 (total scores), Table 23 (factors) and Table 24 (individual items). The mean HAMD total score was reduced from 27.5 at Day 0 to 14.0 at last assessment (mean decrease 13.5, 95% C.I.: 11.6 ÷ 15.4), in the 110 patients randomised to reboxetine who had at least one assessment in addition to baseline (2 patients had only baseline data), and to 11.3 at Day 42 in the 89 patients who completed the study. In the 111 patients randomised to imipramine with at least one assessment in addition to baseline (4 patients had only baseline data), the mean HAMD total score was reduced from 26.9 at Day 0 to 13.2 at last assessment (mean decrease 13.8, 95% C.I.: 11.9 ÷ 15.7), and to 9.4 at Day 42 in the 79 patients still on treatment. Mean HAMD total scores in the 111 patients randomised to placebo were reduced from 27.1 at Day 0 to 15.8 at last assessment (mean decrease 11.3, 95% C.I.: 9.4 ÷ 13.2), and to 13.1 at Day 42 in the 87 patients still on

treatment. In order to give a better insight of the estimated mean decrease, the two-tailed 95% confidence interval for each arm is shown in Figure 1.

The between treatment difference in HAMD total score at last assessment (study end-point) is not statistically significant (p>0.025, one-tailed test) for both the reboxetine *vs* placebo and the imipramine *vs* placebo comparisons.

The pattern of improvement of HAMD factors was similar in the reboxetine-treated and imipramine-treated patients. At the last assessment, the most clear placebo-active treatment differences were seen in: Factor V (Retardation), the most severely affected at baseline, (median difference *vs* Day 0 of 1.00 [reboxetine group] and 1.00 [imipramine group] and *vs* 0.75 [placebo group]); Factor I (Anxiety-Somatisation) (median difference *vs* Day 0 of 0.67 [reboxetine group] and 0.67 [imipramine group] *vs* 0.50 [placebo group]; and Factor III (Cognitive Disturbances) (median difference *vs* Day 0 of 0.50 [reboxetine group] and 0.50 [imipramine group] *vs* 0.33 [placebo group]).

Absolute and per cent frequency of patients who achieved response or remission is shown (with 95% confidence intervals) by treatment group over time in Table 25 and at last assessment in Table 26. The percentage of responders at each visit is higher in the reboxetine group (20.0%) in comparison with the placebo group (9.7%) from Day 14 onwards, and in the imipramine group is higher in comparison with the placebo group from Day 7 onwards (7.2% *vs* 4.5%, respectively). The percentage of responders is somewhat higher in the imipramine group compared to reboxetine group in the intermediate assessments up to Day 42, except for Day 35 (64.6% *vs* 65.6%, respectively). In comparison with placebo, the percentage of patients in remission was higher in the reboxetine group from Day 14 onwards (11.4% *vs* 4.9%) and in the imipramine group from Day 7 onwards (7.2% *vs* 0.9%). The percentage of remissions was higher in the imipramine group compared with the reboxetine group in the intermediate assessments up to Day 42, except for Day 14 (8.9% *vs* 11.4%, respectively).

At last assessment (Table 26) 59.1% of the 110 reboxetine-treated patients, 62.2% of the 111 imipramine-treated patients and 52.3% of the 111 placebo-treated patients were classified as responders, while 42.7%, 50.5% and 36.0%, respectively, were seen to be in remission. The between treatment difference in the proportion of remissions and responders both for imipramine and reboxetine compared with placebo did not reach the statistical significance (p > 0.025).

The cumulative probability of response (confirmed at all available subsequent assessments) is plotted according to the Kaplan-Meier method in Figure 2. Patients on imipramine had a cumulative probability of response significantly higher (p = 0.0055) from patients on placebo, while patients on reboxetine had a probability of response whose difference from placebo didn't reach statistical significance (p=0.081). The time to response appears to be

somewhat quicker on imipramine than on reboxetine: the between treatment difference was, however, far from significant.

Additional analyses were carried out on the sub-populations of patients classified as markedly to extremely ill at admission (according to the CGI-Severity of Illness scale) and on those characterised as melancholic (DSM IV criteria) at admission (possible for 295 of the 339 patients admitted (Appendix 12.1.12), in view of the missing information on time frame of diurnal variation, scored as present at the relevant HAMD item).

The mean decrease at last assessment of the HAMD total score in patients classified as markedly to extremely ill at admission in the three treatment groups (77 reboxetine, 80 imipramine and 69 placebo) is shown, together with the 95% confidence interval, in Figure 3. With respect to the total population (Figure 1), the improvement on both active treatments was maximal and on placebo it was minimal. The mean decrease in the two active treatments was very similar, the mean difference between imipramine and reboxetine being of 0.12 points (95% C.I.: -3.2 ÷3.4). However the difference between active treatments compared to placebo was statistically significant ($p<0.025$) only for imipramine.

The mean decrease at last assessment of the HAMD total score in those patients which could be classified as melancholic at admission in the three treatment groups (melancholic/non-melancholic: 51/46 reboxetine, 44/53 imipramine, 41/60 placebo (Appendix 12.1.12)), is shown, together with the 95% confidence interval, in Figure 4. The difference between active treatments and placebo was statistically significant for reboxetine, but not for imipramine. The mean difference between active treatments was in favour of reboxetine, with a value of 3.9 points (95% C.I.: -0.5÷ 8.3).

7.2 Clinical Global Impression

7.2.1 SEVERITY OF ILLNESS

The distribution of the CGI severity scores at each visit in the observed cases is presented by treatment group in Table 27, while the distribution of the scores at the last assessment during the study are provided in Table 28. The distribution pattern is clearly different in the three treatment groups, the most important difference being seen in the proportion of normal or borderline cases in the two active treatment groups compared to placebo. This corresponds, at last assessment, to 43.6% of the cases on reboxetine, 44.1% of the cases on imipramine and 29.7% of the cases on placebo. Only two patients (1 on imipramine and 1 on placebo group) were extremely ill at last assessment.

A shift table of the last record *vs* Day 0 (Table 29) showed that the CGI severity of illness had decreased in 77.3% and 77.5% of the reboxetine- and imipramine-treated patients, respectively, compared with 65.8% of the placebo-treated patients, increased in 5.5% and

4.5% of the reboxetine- and imipramine-treated patients, respectively, compared with 8.1% of the placebo-treated patients, and had remained the same in the 17.3% and 18.0% of reboxetine- and imipramine-treated patients compared with 26.1% of the placebo-treated patients.

7.2.2 GLOBAL IMPROVEMENT

The distribution of Global Improvement scores in CGI at each visit is shown by treatment group in Table 30. The distribution of last assessment scores is shown in Table 31.

The clearest difference between treatments is related to the percentage of patients who were 'very much improved' at last assessment; this was higher in the reboxetine group (29.1%) and the imipramine group (28.8%) compared with the placebo group (17.1%). The same difference was observed at Day 42 in the patients who completed the study: 34.8% of the 89 reboxetine patients and 39.2% of the 79 imipramine patients compared with 20.7% of the 87 placebo patients. In addition, the percentage of patients at last assessment with 'no change' was higher in the placebo group (17.1%) than in the reboxetine group (9.1%) and imipramine group (10.8%).

7.2.3 EFFICACY INDEX

The CGI efficacy index, which was assessed in order to relate therapeutic efficacy and tolerability, is shown by treatment group at each visit in Table 32. The distribution of last assessment values is shown in Table 33. At last assessment side-effects were judged to outweigh efficacy in 15.3% of the reboxetine patient group, 16.2% of the imipramine patient group and 13.5% of the placebo patient group. The most relevant placebo-active treatment group differences are seen either in the proportion of cases where no advantage in terms of efficacy *vs* side-effects was identified (index = 1), i.e. 21.6% of the placebo-treated cases compared with 13.5% of the reboxetine-treated and 13.5% of the imipramine-treated cases, and in the proportion of cases where efficacy outweighed side-effects (index = 4), i.e. 22.5% of the placebo-treated cases, compared with 28.8% of the reboxetine-treated cases and only 14.4% of the imipramine-treated cases. A clear benefit from therapy (EI ≥2) was observed in approximately 62.2% of reboxetine patients compared with 59.5% of both imipramine and placebo patients.

7.3 Montgomery and Asberg Depression Rating Scale

Summary statistics of MADRS assessment at each visit in the observed cases are shown in Table 34 (total scores) and Table 35 (individual items). Summary statistics of the last assessment are given in Table 36 (total scores) and Table 37 (individual items).

The mean total MADRS score was reduced from 16.4 at Day 0 to 8.4 (mean difference *vs* Day 0 of 7.9) at last assessment in the 110 reboxetine group patients with at least one assessment in addition to baseline, and to 6.6 at Day 42 in the 89 reboxetine patients who completed the study. In patients randomised to imipramine, values changed from 16.7 at Day 0 to 8.2 (mean difference *vs* Day 0 of 8.6) at last assessment (111 patients), and to 5.8 at Day 42 (79 assessed patients). The corresponding reductions in placebo group patients were from 16.3 at Day 0 to 9.8 (mean difference *vs* Day 0 of 6.5) at last assessment (111 patients) and to 7.7 at Day 42 (87 assessed patients).

7.4 Relational Depression Rating Scale

Summary statistics of RDRS assessment at each visit in the observed cases are shown in Table 38 (total scores) and Table 39 (individual items). Summary statistics of the last assessment are given in Table 40 (total scores) and Table 41 (individual items).

The mean total RDRS score was reduced from 18.8 at Day 0 to 9.6 (mean difference *vs* Day 0 of 9.2) at last assessment in the 109 reboxetine patients with at least one assessment in addition to baseline, and to 7.6 at Day 42 in the 88 reboxetine patients who completed the study. In patients randomised to imipramine, values changed from 18.6 at Day 0 to 9.1 (mean difference *vs* Day 0 of 9.5) at last assessment (111 patients), and to 6.5 at Day 42 (79 assessed patients). The corresponding reductions in placebo group patients were from 18.0 at Day 0 to 11.1 (mean difference *vs* Day 0 of 6.9) at last assessment (111 patients) and to 9.4 at Day 42 (86 assessed patients).

7.5 Efficacy Conclusion

In the 110 patients randomised to reboxetine who had at least one assessment in addition to baseline, the mean HAMD total score was reduced from 27.5 at Day 0 to 14.0 at last assessment, and to 11.3 at Day 42 in the 89 patients assessed at Day 42. In the 111 patients randomised to imipramine with at least one assessment in addition to baseline, the mean HAMD total score was reduced from 26.9 at Day 0 to 13.2 at last assessment, and to 9.4 at Day 42 (79 patients). Mean HAMD total score in the 111 patients randomised to placebo was reduced from 27.1 at Day 0 to 15.8 at last assessment, and to 13.1 at Day 42 (87 patients). The results of the planned analysis of the study end-point indicate slightly higher improvement on both reboxetine and imipramine, compared to placebo, though the differences do not reach statistical significance ($p>0.025$,one-tailed test).

At last assessment, 59.1% of the reboxetine-treated patients, 62.2% of the imipramine-treated patients and 52.3% of the placebo-treated patients were classified as responders, while 42.7%, 50.5% and 36.0%, respectively, were seen to be in remission. The between treatment difference in the proportion of remissions and responders both for imipramine and reboxetine compared with placebo did not reach the statistical significance ($p > 0.025$).

Patients on imipramine had a rate of response (Kaplan-Meier method) significantly higher ($p = 0.0055$) than patients on placebo, while patients on reboxetine had a rate of response whose difference from placebo didn't reach significance ($p = 0.081$).

Additional analyses were carried out in the sub-populations of severe (CGI- Severity of Illness: marked to extreme severity at the admission) and melancholic (DSM IV criteria) patients. In severe patients, with respect to the total population, the improvement on both active treatments was maximal and on placebo it was minimal. The mean decrease in the two active treatments was very similar, the mean difference between imipramine and reboxetine being of 0.12 points (95% C.I.: -3.2 ÷3.4). However, the difference between active treatments compared to placebo was statistically significant ($p<0.025$) only for imipramine. In melancholic patients the difference between placebo and active treatments was significantly superior for reboxetine, but not for imipramine. The mean difference between active treatments was in favour of reboxetine with a value of 3.9 points (95% C.I.: -0.5 ÷ 8.3).

The CGI severity of illness had decreased in 77.3% and 77.5% of the reboxetine and imipramine patients, respectively, compared with 65.8% of the placebo patients, increased in 5.5% and 4.5% of the reboxetine and imipramine patients, respectively, compared with 8.1% of the placebo patients, and had remained the same in the 17.3% and 18.1% of reboxetine and imipramine patients, respectively, compared with 26.1% of the placebo patients.

The clearest difference between treatments is related to the percentage of patients who were 'very much improved' at last assessment. This was higher in the reboxetine group (29.1%) and the imipramine group (28.8%) compared with the placebo group (17.1%). In addition, the percentage of patients with 'no change' was higher in the placebo group (17.1%) than in the reboxetine group (9.1%) and the imipramine group (10.8%).

At last assessment, side-effects were judged to outweigh efficacy in 15.3% of the reboxetine patients, 16.2% of the imipramine patients and 13.5% of the placebo patients. The most relevant placebo-active treatment group differences in the Efficacy Index are seen in the proportion of cases where no advantage in terms of efficacy *vs* side-effects was identified (index = 1) (21.6% of the placebo patients *vs* 13.5% of the reboxetine patients and 13.5% of the imipramine patients), and in the proportion of cases where efficacy outweighed side-effects (index = 4) (22.5% of the placebo patients *vs* 28.8% of the reboxetine patients and only 14.4% of the imipramine patients). A clear benefit from therapy (EI ≥2) was observed in approximately 62.2% of reboxetine patients compared with 59.5% of both imipramine and placebo patients.

The mean total MADRS score was reduced from 16.4 at Day 0 to 8.4 (mean difference *vs* Day 0 of 7.9) at last assessment in the 110 reboxetine group patients with at least one

assessment in addition to baseline, and to 6.6 at Day 42 in the 89 reboxetine patients who completed the study. In patients randomised to imipramine, values changed from 16.7 at Day 0 to 8.2 (mean difference *vs* Day 0 of 8.6) at last assessment (111 patients), and to 5.8 at Day 42 (79 assessed patients). The corresponding reductions in placebo group patients were from 16.3 at Day 0 to 9.8 (mean difference *vs* Day 0 of 6.5) at last assessment (111 patients) and to 7.7 at Day 42 (87 assessed patients).

8. SAFETY RESULTS

8.1 Safety Population and Extent of Exposure

8.1.1 NUMBER OF PATIENTS IN SAFETY ANALYSIS

All the patients who received study treatment were included in the safety analysis, i.e. 112 reboxetine patients, 115 imipramine patients and 112 placebo patients.

8.1.2 TOTAL DRUG EXPOSURE

As shown in Table 16, of the 112, 115 and 112 patients exposed to reboxetine, imipramine and placebo, 96, 88 and 96, respectively, were treated at least for 3 weeks, while 89, 77 and 86 were treated at least for 6 weeks.

8.2 Adverse Events

8.2.1 ANALYSIS OF ADVERSE EVENTS

The number of patients with adverse events and the number of adverse events during the study are grouped by sex in Table 42, by age classes in Table 43 and by DSM III-R diagnosis in Table 44; 63.4% of the reboxetine patients, 70.4% of the imipramine patients and 51.8% of the placebo patients exposed to treatment had at least one, and an average of 3, 4 and 2 adverse events, respectively. Females and males suffered from adverse events to a similar extent on reboxetine (62.9% *vs* 64.3%), on imipramine (70.1% *vs* 71.1%) and on placebo (53.7% *vs* 50.0%). Patients aged over 45 years old had adverse events less frequently than those who were 18 to 30 years or 31 to 45 years old on reboxetine (56.1%, 71.4%, 70.7%, respectively) and on placebo (46.8%, 53.3%, 56.0%). On imipramine, the pattern of adverse events was similar in the three age groups (70.4%, 70.6%, 70.5%, respectively).

Patients with no history of previous depressive illness, diagnosed as Major Depressive Episodes (296.2) complained of adverse events less frequently than recurrent cases (296.3) on reboxetine (57.1% *vs* 67.1%) and placebo (40.0% *vs* 56.1%) but not on imipramine (70.6% *vs* 70.0%).

8.2.1.1 Absolute and Per Cent Frequency

The absolute and per cent frequency of patients suffering from adverse events is grouped by event and sex in Tables 45 (all events) and 47 (grouped by body system, with relevant events grouped in clusters) and by body system and sex in Table 46. Among the most frequently reported adverse events (≥5% of exposed patients in at least one group) more frequently reported on reboxetine than on placebo were dry mouth (25.0% *vs* 12.5%), constipation (15.2% *vs* 5.4%), increased sweating (12.5% *vs* 2.7%), headache/migraine (13.4% *vs* 8.0%), vertigo (4.5% *vs* 0%), insomnia (10.7% *vs* 3.6%), hypotension and related symptoms (8.9% *vs* 5.4%), blurred vision (5.4% *vs* 2.7%) and urinary hesitancy/retention (5.4% *vs* 1.8%).

More frequently reported on imipramine than on placebo were dry mouth (42.6% *vs* 12.5%), constipation (15.7% *vs* 5.4%), increased sweating (19.1% *vs* 2.7%), nausea and related symptoms (14.8% *vs* 8.9%), tremor (17.4% *vs* 4.5%), vertigo (6.1% *vs* 0%), paraesthesia (5.2% *vs* 1.8%), insomnia (7.0% *vs* 3.6%), hypotension and related symptoms (17.4% *vs* 5.4%) and blurred vision (7.8% *vs* 2.7%).

The most relevant between-gender differences were noticed in all treatment groups and were related to the frequency of dry mouth, constipation, increased sweating, and nausea, complained of mainly by female patients (27.1%, 45.5%, 18.5% dry mouth; 17.1%, 18.2%, 9.3% constipation; 15.7%, 20.8%, 3.7% increased sweating; 10%, 16.9%, 16.7% nausea and related symptoms) on reboxetine, imipramine and placebo, respectively. The corresponding figures for male patients were 21.4%, 36.8%, 6.9% dry mouth; 11.9%, 10.5%, 1.7% constipation; 7.1%, 15.8%, 1.7% increased sweating; 7.1%, 10.5%, 1.7% nausea and related symptoms, on reboxetine, imipramine and placebo, respectively. Tremor was complained of by more female than male patients (20.8% *vs* 10.5%) on imipramine, but not on placebo (3.7% of female patients *vs* 5.2% of male patients) and on reboxetine (5.7% *vs* 4.8% of female and male patients, respectively). Conversely, urinary hesitancy/retention was complained of by more male than female patients on reboxetine (14.3% *vs* 0%, respectively), but not by patients on imipramine and placebo (0% and 1.7% *vs* 1.3% and 1.9% of male and female patients, respectively).

Disorders more frequently complained of by reboxetine and imipramine patients than by placebo patients were disorders of the autonomic nervous system (35.7% and 48.7% *vs* 15.2%, respectively), gastrointestinal (GI) system disorders (23.2% and 31.3% *vs* 16.1%, respectively), central and peripheral nervous system disorders (24.1% and 31.3% *vs* 14.3%, respectively), cardiovascular disorders (14.3% and 24.3% *vs* 8.9%, respectively). Urinary system disorders were complained of by more reboxetine patients (10.7%) than by imipramine (1.7%) and placebo patients (3.6%).

8.2.1.2 Occurrence

The occurrence of adverse events is grouped by week of onset and event or body system in Tables 48, 49 and 50, respectively. The majority of events on reboxetine, imipramine and placebo emerged initially during treatment, within the first week (autonomic NS disorders, 55.6%, 60.8%, 55.6%, GI disorders, 44.4%, 36.0%, 38.7%, respectively; psychiatric disorders, 42.9%, 66.7%, 38.7%; central and peripheral NS disorders, 61.8%, 42.9%, 45.0%; cardiovascular disorders, 38.1%, 43.6%, 20.0%).

8.2.1.3 Overall Risk

The cumulative risk of developing the first adverse event, as well as adverse event clusters or individual events reported in at least 5% of exposed patients in at least one treatment group is described according to the Kaplan-Meier method and analysed by the log-rank test in Figures 5 to 20. As shown in Figure 5, the risk of developing at least one adverse event is significantly higher in the imipramine group compared to placebo ($p = 0.001$) and approaches significance in the reboxetine group ($p = 0.051$). As for individual events or clusters, the cumulative risk is significantly higher on reboxetine than on placebo for insomnia ($p = 0.041$), increased sweating ($p = 0.006$), dry mouth ($p = 0.017$), vertigo ($p = 0.024$) and constipation ($p = 0.016$). Similarly, the cumulative risk is significantly higher on imipramine than on placebo for dry mouth ($p = 0.0001$), constipation ($p = 0.007$), increased sweating ($p = 0.0001$), vertigo ($p = 0.008$), hypotension and related symptoms ($p = 0.003$), blurred vision ($p = 0.042$) and tremor ($p = 0.001$).

The log-rank tests on the direct comparison between reboxetine and imipramine in terms of increased risk of adverse events indicate significant differences in favour of reboxetine for dry mouth ($p = 0.003$), hypotension and related symptoms ($p = 0.041$) and tremor ($p = 0.003$). A slighter difference in favour of reboxetine, but not a significant one, was also noticed for nausea and related symptoms, somnolence and increased sweating, while the difference was in favour of imipramine, but not significantly so, for headache/migraine and urinary hesitancy/retention.

8.2.1.4 Dose-relationship

The absolute frequency of adverse events is grouped by maximal severity and by dose taken on the onset day and in the three preceding days in Table 51. For none of the events and treatments there is any indication of increased frequency or severity in patients (see Table 16) switched according to the protocol to the higher dose level, corresponding to 10 mg/day for reboxetine and to 200 mg/day for imipramine.

8.2.1.5 Maximal Severity

The maximal severity of adverse events is grouped by sex age and DSM III-R classification in Table 52 and by event or body system in Tables 53 and 54, respectively. Events were most frequently moderate on imipramine, placebo and reboxetine (50.6%, 51.7% and 39.4%, respectively), while severe events were being reported by 32.4%, 30.9% and 19.0% of reboxetine, imipramine and placebo patients For two patients (one in the imipramine group died committing suicide and one in the placebo group had a rhinitis) the investigator did not fill in the severity of the event. The major between-gender differences were in the imipramine and reboxetine groups. In the reboxetine group, the events of mild severity were more frequent in male than in female patients (40.7% *vs* 20.5%), while the events of moderate severity were more frequent in female than in male patients (47.7% *vs* 25.9%). In the imipramine group, the events of mild severity were more frequent in male than in female patients (33.3% *vs* 9.3%), while the severe events were more frequent in female than in male patients (38.9% *vs* 14.8%). Moderateness characterised the severity of events for the majority of the affected body systems: 47.5%, 57.1%, 52.9% of the patients on reboxetine, imipramine and placebo, respectively, for autonomic NS disorders, 65.4%, 55.6%, 66.7% for GI disorders and 48.1%, 61.1%, 62.5% for central and peripheral NS disorders.

8.2.1.6 Duration

Summary statistics of the duration of adverse events are described in Table 55. The median duration was 10 days for reboxetine, 13 days for imipramine and 8 days for placebo. Among the most frequent events, the median duration was higher in both active treatment groups than in placebo group for dry mouth (26 days, 20 days, 15 days on reboxetine, imipramine and placebo, respectively) and tremor (11 days, 20 days, 3 days on reboxetine, imipramine and placebo, respectively); the median duration was similar in the reboxetine and imipramine groups, but lower than that in the placebo group for increased sweating (15 days, 14 days and 35 days, respectively). For constipation, the median duration was lower on reboxetine than on imipramine and placebo (13 days, 23 days, 20 days, respectively), while the median duration for nausea on reboxetine was higher than on both imipramine and placebo (18 days, 6 days, 6 days, respectively).

8.2.1.7 Symptomatic Treatment

As shown in Table 56, 19.0%, 10.4%, and 16.3% of the events on reboxetine, imipramine and placebo, respectively, required symptomatic treatment in 33.8%, 27.2% and 25.9% of the affected patients. Headache and insomnia were the most frequent events leading to symptomatic treatment.

8.2.1.8 Modification of Study Medication and Patient Outcome

As shown in Table 57, no change in study medication was required for 85.8%, 81.6% and 88.7% of the events, for patients on reboxetine, imipramine and placebo, respectively, while the daily dose was reduced in 1.9%, 2.1% and 0% of the occurrences, respectively, or the treatment temporarily interrupted in 0%, 1.7% and 1.4%. According to the Adverse Event outcome reported by the investigators, 9.5%, 10.4% and 8.5% of the cases in the reboxetine, imipramine and placebo groups, respectively caused or contributed to treatment withdrawal. This was most frequently seen for increased sweating, nausea and related symptoms and hypotension and related symptoms in the imipramine group, hypotension and related symptoms and anxiety/agitation/nervousness in the reboxetine group and anxiety/agitation/nervousness in the cases from the placebo group. Suicide attempts (one successful) caused withdrawal in 2 cases in the imipramine group and 2 cases in the placebo group. Suicidal ideas caused withdrawal in 1 case in each of the imipramine and the reboxetine groups (the latter classified as discontinuation due to deterioration). The individual cases of patients withdrawn due to adverse events are described in Section 8.2.3.2.

As shown in Table 58, of the 24, 41 and 14 events requiring modification of the study medication in the reboxetine, imipramine and placebo groups, the majority in the reboxetine and imipramine groups (50.0%, 43.9%, respectively) disappeared following the modification of the regimen, while the majority in the placebo group did not (78.6%). The patient outcome (grouped by event and action taken on study medication in Table 59) corresponds to full recovery in 29.2%, 36.6% and 64.3% (7, 15 and 9 events, respectively) of the cases in the reboxetine, imipramine and placebo groups following modification of the treatment regimen. The event was still present at last assessment in 70.8%, 61.0% and 28.6% (17, 25 and 4 events, respectively) of the cases in reboxetine, imipramine and placebo groups, respectively; in 1 case on placebo, the patient had incompletely recovered (recovered with sequelae). In the cases of unchanged study medication, the event was still present at last assessment in 37.4%, 46.6% and 33.9% while was fully recovered in 55.6%, 47.0% and 63.0% of the reboxetine, imipramine and placebo groups, respectively. One patient died in the imipramine group.

8.2.1.9 Prevalence

The prevalence of adverse events is grouped by week of treatment and event, event cluster or body system in Tables 60, 61 and 62. Among the most frequent events, in keeping with the selection of the most tolerant population over the treatment period, the proportion of affected patients tended to decrease during treatment, particularly during the last two weeks, in all treatment groups, with the exception of dry mouth, constipation, urinary

hesitancy and dizziness and related disorders in the reboxetine group and of dry mouth, constipation, tremor and blurred vision in the imipramine group.

The overall prevalence of adverse events in the three treatment groups is shown in Figure 21. The proportion of patients affected by at least one adverse event during the different weeks of treatment was higher on both imipramine and reboxetine than on placebo during the whole treatment period. In addition, the proportion of patients was always slightly higher on imipramine than reboxetine, particularly during the fourth and the sixth week.

8.2.1.10 Relationship Between Adverse Events and Study Medication

The relationship between adverse events and study medication, as judged by the investigators on the basis of Karch and Lasagna modified criteria (Enclosure 13 of Appendix 12.1.1) is described in Table 63. The majority of events on reboxetine, imipramine and placebo (48.8%, 53.1%, 36.9%, respectively) were judged possibly related, while 11.4%, 22.2% and 15.6%, respectively, were judged probably related and 2.4%, 2.1% and 4.3%, respectively, were judged definitely related. Among the most frequent events, the maximal frequency of definite/probable relationship was present for dry mouth (27.6%, 35.9%, 40.0%) and increased sweating (26.7%, 38.5%, 66.7%) for reboxetine, imipramine and placebo, respectively.

8.2.2 ADVERSE EVENT SUMMARY

Of the 112 reboxetine patients, 115 imipramine patients and 112 placebo patients who received study medication, 71 (63.4%), 81 (70.4%), and 58 (51.8%) patients reported a total of 211, 288, 141 adverse events, respectively (3, 4, 2 per patient) (Table 42). The cumulative risk of occurrence of adverse events was significantly higher in the imipramine group compared to the placebo group ($p = 0.001$) and approached significance in the reboxetine group ($p = 0.051$), while the risk of developing at least one adverse event was similar in the reboxetine and the imipramine groups (Figure 5). The prevalence of adverse events during the study indicated a higher proportion of patients with adverse events in both imipramine and reboxetine groups than in the placebo group during the whole treatment period. In addition the proportion was always slightly higher on imipramine than on reboxetine, particularly during the fourth and the sixth week (Figure 21).

8.2.2.1 Severity of Adverse Events

The maximum severity of adverse events is presented in Tables 52-54 and summarised as follows:

Severity of Adverse Events

No. of patients								
Reboxetine			Imipramine			Placebo		
Mild	Moderate	Severe	Mild	Moderate	Severe	Mild	Moderate	Severe
20	28	23	14	41	25	16	30	11

For two patients (one in the imipramine group died committing suicide and one in the placebo group had a rhinitis) the investigator did not fill in the severity of the event.

Adverse events were more frequently moderate or severe in the reboxetine and imipramine treatment groups, and more frequently mild or moderate in the placebo treatment group.

8.2.2.2 Age- and Gender-Related Effects

Females and males suffered from adverse events to a similar extent on reboxetine (62.9% *vs* 64.3%), on imipramine (70.1% *vs* 71.1%) and on placebo (53.7% *vs* 50.0%) (Table 42). Patients aged over 45 years old had adverse events less frequently than those who were 18 to 30 years or 31 to 45 years old on reboxetine (56.1%, 71.4%, 70.7%, respectively) and on placebo (46.8%, 53.3%, 56.0%). On imipramine, the pattern of adverse events was similar in the three age categories (70.4%, 70.6%, 70.5%) (Table 43). The most relevant between-gender differences were related to the frequency of dry mouth, constipation, increased sweating, and nausea, complained of mainly by female patients (27.1%, 45.5%, 18.5% dry mouth; 17.1%, 18.2%, 9.3% constipation; 15.7%, 20.8%, 3.7% increased sweating; 10.0%, 16.9%, 16.7% nausea and related symptoms) on reboxetine, imipramine and placebo, respectively. The corresponding figures for male patients were 21.4%, 36.8%, 6.9% dry mouth; 11.9%, 10.5%, 1.7% constipation; 7.1%, 15.8%, 1.7% increased sweating; 7.1%, 10.5%, 1.7% nausea and related symptoms on reboxetine, imipramine and placebo, respectively. Tremor was complained of by more female than male patients (20.8% *vs* 10.5%) on imipramine but not on placebo (3.7% of female patients *vs* 5.2% of male patients) and on reboxetine (5.7% *vs* 4.8% of female and male patients, respectively). Conversely, urinary hesitancy/retention was complained of by more male than female patients on reboxetine (14.3% *vs* 0%, respectively), but not by patients on imipramine and placebo (0% and 1.7% *vs* 1.3% and 1.9% of male and female patients, respectively) (Table 46).

8.2.2.3 Frequently Reported Adverse Events

Adverse events which occurred in 5% or more of the patients in at least one treatment group are presented by body system in the following table:

Adverse Events Occurring in 5% or More of Patients in at Least One Group

		Reboxetine (n=112)		Imipramine (n=115)		Placebo (n=112)	
Body system	**Adverse event**	**No. of patients with event**	**% of patients exposed**	**No. of patients with event**	**% of patients exposed**	**No. of patients with event**	**% of patients exposed**
Autonomic NS disorders	Dry mouth	28	25	49	43	14	13
	Increased sweating	14	13	22	19	3	3
GI disorders	Constipation	17	15	18	16	6	5
	Nausea and related symptoms	10	9	17	15	10	9
Central and peripheral NS disorders	Headache / migraine	15	13	9	8	9	8
	Tremor	6	5	20	17	5	5
	Vertigo	5	5	7	6	0	
	Paraesthesia	2	2	6	5	2	2
Psychiatric disorders	Agitation / anxiety / nervousness	11	10	5	4	10	9
	Insomnia	12	11	8	7	4	4
	Somnolence	1	1	6	5	9	8

Adverse Events Occurring in 5% or More of Patients Continued

		Reboxetine (n=112)		Imipramine (n=115)		Placebo (n=112)	
Body system	**Adverse event**	**No. of patients with event**	**% of patients exposed**	**No. of patients with event**	**% of patients exposed**	**No. of patients with event**	**% of patients exposed**
General cardiovascular disorders	Hypotension and related symptoms	10	9	20	17	6	5
Vision disorders	Abnormal vision / accommodation abnormal	6	5	10	9	3	3
Body as a whole - general disorders	Asthenia / fatigue	4	4	6	5	4	4
Urinary system disorders	Urinary hesitancy / retention	6	5	1	1	2	2

The estimate of the cumulative risk of adverse events according to the Kaplan-Meier method and log-rank test is significantly higher in the imipramine group compared to placebo ($p = 0.001$) and approaches significance in the reboxetine group compared with placebo ($p = 0.051$). As for individual events or clusters, the cumulative risk is significantly higher on reboxetine than on placebo for insomnia, increased sweating, dry mouth, vertigo and constipation. Similarly, the cumulative risk is significantly higher on imipramine than on placebo for dry mouth, constipation, increased sweating, vertigo, hypotension and related symptoms, tremor and blurred vision.

The log-rank tests on the direct comparison between reboxetine and imipramine in terms of increased risk of adverse events indicate significant differences in favour of reboxetine for dry mouth, hypotension and related symptoms and tremor. A difference in favour of reboxetine, but not a significant one, was also reported of nausea and related symptoms, somnolence and increased sweating, while the difference was in favour for imipramine, but not significantly so, for headache/migraine and urinary hesitancy/retention.

8.2.3 SERIOUS ADVERSE EVENTS, DEATHS AND ADVERSE EVENTS ASSOCIATED WITH WITHDRAWAL

8.2.3.1 Serious Adverse Events and Deaths

There were one death (one patient committed suicide in the imipramine group) and 5 serious adverse events, all occurred in the imipramine-and placebo-treated patients: 2 cases of attempted suicide occurred in the placebo group and 1 case of attempted suicide, 1 case of postural hypotension, dizziness and syncope, 1 case of attention seeking autolesionistic behaviour in the imipramine group. Case histories for these patients are provided in Appendix 12.2.1.

8.2.3.2 Adverse Events Associated with Withdrawal

Thirty-three patients (11 on reboxetine, 9.8%; 15 on imipramine, 13.0% and 7 on placebo, 6.3%) withdrew from the study because of newly emerged adverse events (Table 64). The nature of the adverse events is summarised as follows:

Adverse Events Associated with Withdrawal

Treatment	Patient no.	Adverse event	Relationship to study drug
Reboxetine	460, 255, 252, 161	Dry mouth	Probable, Possible, Possible, Possible
	255, 253, 252	Agitation	Possible, Possible, Possible
	334, 143	Increased sweating	Probable, Probable
	510, 163	Vertigo	Possible, Possible
	143	Dyspnoea	Possible
	451	Constipation	Definite
	451	Thrombosed haemorrhoids	None
	460	Confusion	Probable
	161	Urinary tract infection	None
	163	Anxiety	Possible
	163	Tachycardia	Possible
	510	Hypotension	Probable
	510	Insomnia	Possible
	185	Impotence	Definite
	185	Increased gamma-GT	Doubtful
	185	Urinary retention	Definite
	252	Involuntary muscle contractions	Possible
	252	Tremor	Possible
	255	Mydriasis	Doubtful
	255	Pyuria	None
	334	Chest pain	Probable
	334	Dizziness	Probable
	334	Paraesthesia	Probable

Treatment	Patient no.	Adverse event	Relationship to study drug
Imipramine	461, 456, 371, 254, 151	Dry mouth	Possible, Probable, Possible, Possible, Possible
	456, 183, 151, 100, 16	Increased sweating	Probable, Possible, Possible, Possible, Probable
	461, 116, 100, 16	Nausea	Possible, Possible, Possible, Possible
	461, 80, 11	Dizziness	Possible, Possible, Definite
	254, 183, 100	Tremor	Possible, Unknown, Possible
	375, 213, 191	Suicide attempt/ideation	Possible, None, None
	151, 11	Postural hypotension	Possible, Definite
	375, 80	Abnormal vision	Doubtful, Possible
	462, 254	Insomnia	Possible, Possible
	116, 100	Vertigo	Possible, Possible
	456	Constipation	Probable
	456	Precordial chest pain	Possible
	456	Syncope	Possible
	456	Tachycardia	Probable
	462	Depersonalisation	Possible
	462	Hyperkinesia	Possible
	116	Headache	Possible
	151	Asthenia	Possible
	183	Abdominal pain	None
	183	Agitation	Unknown
	183	Colitis	Unknown
	183	Dysphagia	Unknown
	183	Paraesthesia	Unknown
	183	Rigors	Unknown
	183	Tinnitus	Definite
	16	Hot flushes	Probable

Treatment	Patient no.	Adverse event	Relationship to study drug
Placebo	241, 83	Agitation	Possible, Possible
	99, 83	Diarrhoea	Possible, Possible
	179, 176	Suicide attempt	Unknown, None
	6	Abdominal pain	Possible
	6	Arthralgia	Doubtful
	6	Constipation	Probable
	6	Dry mouth	Definite
	6	Flatulence	Doubtful
	6	Micturition disorder	Definite
	6	Nausea	Possible
	6	Paroniria	Unknown
	6	Rash	Possible
	6	Taste perversion	Unknown
	83	Insomnia	Possible
	83	Tremor	Possible
	99	Dyspepsia	Possible
	176	Aggravated depression	None
	241	Hyperkinesia	Possible
	246	Bradycardia	Probable

Patient No 213 from the imipramine group died by suicide.

In addition, two patients dropped out the study due to intercurrent medical problems without having a newly emerged adverse event form filled in the CRF: one patient (No 416 from the reboxetine group) dropped out due to the discovery of hypothyroidism which was present before the start of treatment, and a second patient (No 138 from the placebo group) due to bad hepatic function.

8.3 Laboratory Tests

8.3.1 SUMMARY STATISTICS OF LABORATORY VALUES

As shown in Table 65, in the reboxetine group, compared to baseline, there was a significant ($p<0.01$) decrease after 6 weeks of treatment in total cholesterol (median difference −10.88 mg/dl). After 3 weeks of treatment, there were no such significant differences.

Similarly, in the imipramine group, compared to baseline, there was a significant decrease after 3 weeks of treatment in lymphocytes (median difference −1.00 %) and chloride (median difference −0.89 mEq/l), whilst there was a significant increase in creatinine after 3 weeks of treatment (median difference 0.03 mg/dl) and in alkaline phosphatase after 6 weeks of treatment (median difference 7.92 U/l). In the placebo group, compared to baseline, there was a significant decrease in gamma GT after 3 weeks of treatment (median difference −1.91 U/l) and in total cholesterol after 6 weeks of treatment (median difference −10.00 mg/dl).

8.3.2 URINALYSIS

Frequency of abnormal findings at baseline and during the treatment period or at last assessment, are shown in Table 66 and 67, respectively. No indication of increased frequencies of abnormal findings as compared to baseline emerges. In fact, there is no indication of increased proportions of patients shifted from absence to presence of albumin, sugar, WBC and RBC as compared to baseline both at the various assessment intervals (Table 68) and at the last available assessment (Table 69). The same considerations hold for specific gravity (Tables 70 and 71).

8.3.3 ABNORMAL LABORATORY VALUES

The number and percentage of patients shifted from values within, below or above the normal range to values within, below or above the latter are given by period in Table 72. In the imipramine group, a statistically significant shift in the distribution of the frequencies toward lower values was found for eosinophils and calcium after 3 weeks of treatment, and higher values for SGPT after 6 weeks of treatment ($p<0.01$; Maxwell's test). In the reboxetine group, a statistically significant shift in the distribution of the frequencies toward lower values was found for total cholesterol after 6 weeks of treatment ($p<0.01$; Maxwell's test). There were no statistically significant shifts ($p<0.01$) in the distribution of the frequencies (either towards the higher or lower values) in the placebo group.

8.3.4 ABNORMAL LABORATORY VALUES OF CLINICAL RELEVANCE

The distribution pattern of patients with clinically relevant abnormal values is given by variable and period of treatment in Table 73. Frequency of clinically relevant abnormal values was similarly low in the three treatment groups over the study period; no significantly increased frequency over baseline was present for any of the variables measured in the reboxetine, imipramine and placebo patient groups.

8.4 Vital Signs

8.4.1 BLOOD PRESSURE AND HEART RATE

Summary statistics of blood pressure and heart rate values and changes *vs* baseline at each visit during the study are presented in Tables 74 to 78. There were no important trends apparent in mean and median blood pressure and heart rate values and changes during the study.

The absolute and per cent frequency of patients at each visit showing a modification of 20% or more *vs* baseline is given in Table 75, while the absolute frequency of patients showing such a modification accompanied by absolute critical values (≥160 or ≤100 mmHg for systolic blood pressure; ≥100 or ≤70 mmHg for diastolic blood pressure; ≥100 or ≤50 beats/min for heart rate) are given in Table 76, together with their frequency (once, twice or more times) during the study (Table 77).

The proportion of patients showing an increase and a decrease of possible clinical relevance for the systolic and diastolic blood pressure in lying and standing position was similar in all groups. As for the lying and standing heart rate, a slightly higher proportion of patients with at least 20% increased values *vs* baseline, as well as such increases associated with values ≥100 beats/min was observed during the whole treatment period in both active treatment groups compared with placebo treatment group. The same results were observed in patients who had clinically relevant increase at least once during the treatment period. A total of 11 and 13 patients in the two positions, respectively, in the reboxetine group (10.4% of 106 evaluated patients [lying position] and 12.4% of 105 evaluated patients [standing position]) and a total of 5 and 8 patients in the two positions, respectively, in the imipramine group (5.0% of 100 evaluated patients [lying position] and 8.1% of 99 evaluated patients [standing position]) had relevant increased values compared with a total of 1 and 2 patients in the two positions, respectively, in the placebo group (1.0% of 104 evaluated patients [lying] and 1.9% of 105 evaluated patients [standing]) (Table 77).

The number and percentage of patients with orthostatic hypotension at each visit is presented in Table 78. At baseline the event was present in 3 patients of the reboxetine group, while it was absent in the imipramine and placebo groups. Subsequently, the event had a low frequency at all visits, affecting a maximum of 4.6% of the reboxetine patients on Day 42, 3.6% of the imipramine patients on Day 7 and 2.0% of the placebo patients on Day 14.

8.4.2 BODY WEIGHT

Summary statistics of the body weight values (Kg) during the study are given in Tables 79 and 80, respectively. No trends toward modification and no difference between the reboxetine, imipramine and placebo groups were apparent.

8.4.3 BODY TEMPERATURE

Individual data are reported in Appendix 12.2.2, Listing 20.0. No modifications of note were evident.

8.5 Electrocardiogram

As shown in Table 81, 277 patients had their ECG recorded at baseline. Of these patients, 16.5% on reboxetine, 15.4% on imipramine and 10.5% on placebo showed at least one ECG abnormality. During the study, 252 patients had their ECG recorded after 3 weeks of treatment, and 236 after 6 weeks of treatment. Of these patients, in the reboxetine group, 15.1% (after 3 weeks) and 12.7% (after 6 weeks) had at least one ECG abnormality recorded during treatment. The equivalent proportions in the imipramine group were 27.5% (after 3 weeks) and 18.7% (after 6 weeks) and in the placebo group 14.0% (after 3 weeks) and 11.0% (after 6 weeks). As shown in Table 82, during the study, the frequency of normalisation of ECG recordings in patients with at least one abnormality at entry was always similar to or higher than the frequency of at least one newly emerged abnormality in patients with normal tracing at baseline in all the treatment groups. At last assessment of the study (Table 83), of the 39 patients (15 reboxetine, 14 imipramine and 10 placebo) who had had at least one abnormality at baseline, 33.3% of reboxetine, 28.6% of imipramine and 40.0% of placebo patients were reported as normal. Among the 238 patients (76 reboxetine, 77 imipramine and 85 placebo) with normal tracings at baseline, 2.6% of reboxetine, 14.3% of imipramine and 5.9% of placebo patients showed at least one abnormality during the study.

The frequency of individual abnormalities at admission and during the study is shown by treatment group in Table 84. At screening, among the individual abnormalities, the most frequent was sinus bradycardia with a maximum of 5.5% of the 91 evaluated cases of the reboxetine group, 4.4% of the 91 evaluated cases in the imipramine group, and 3.2% of the 95 evaluated cases in the placebo group. During treatment, the frequencies of all observed abnormalities were not modified to any significant extent in either treatment group. As shown in Table 85, at last assessment, for all abnormalities and treatment groups, the proportion of newly observed cases among normal baseline cases is similar or lower than the proportion of normalised cases among abnormal baseline cases. Newly emerged abnormalities never reported at baseline occurred in rare cases and with a higher frequency in the imipramine group than in the reboxetine and placebo groups (13 of 91 evaluated *vs* 7

of 95 and 3 of 91 evaluated newly cases on imipramine, placebo and reboxetine, respectively). The between treatment group difference was due especially to sinus tachycardia, which occurred more in imipramine (7 new cases) than in reboxetine (2 new cases) and in placebo (0 cases) patients.

The frequencies of randomised patients with at least one abnormality by abnormality group during the study is shown in Table 86. At screening, from 1.1% (conduction disorders) to 8.8% (rhythm disorders) of the evaluated patients in the reboxetine group, 1.1% (other disorders) to 7.7% (rhythm disorders) in the imipramine group and 1.1% (other disorders) to 4.2% (rhythm disorders) in the placebo group showed at least one abnormality of the indicated groups. During treatment, the frequencies were not modified to any significant extent in any of the treatment groups, except for conduction disorders, which from 4.4% at screen increased to 8.8% after 3 weeks of treatment and to 6.7% after 6 weeks of treatment in the imipramine group, as well as for rhythm disorders, which, from 7.7% at screen, increased to 12.5% after 3 weeks of treatment and 10.7% after 6 weeks of treatment in the imipramine group and, from 4.2% at screen, to 9.3% and 8.5% after 3 and 6 weeks of treatment in the placebo group. As shown in Table 87, at last assessment, the proportion of newly emerged cases was similar in all treatment groups, and in all groups was far lower than the proportion of normalised cases, except for abnormalities of rhythm and conduction disorders. In the first case, the abnormalities occurred slightly more frequently in the imipramine- (8 new cases of 91 evaluated) than in the reboxetine-(3 new cases of 91 evaluated) and placebo-treated patients (5 new cases of 95 evaluated), while in the second case the abnormalities occurred only in the imipramine-treated patients (3 new cases of the 91 evaluated).

8.6 Safety Conclusions

All the 339 patients who received study treatment were included in the safety analysis (112 reboxetine, 115 imipramine, 112 placebo).

The occurrence of newly reported adverse events was higher in the imipramine group than in the reboxetine or placebo groups during the study; 71/112 reboxetine group patients reported 211 adverse events compared with 81/115 imipramine patients who reported 288 adverse events and 58/112 placebo group patients who reported 141 adverse events. The cumulative risk of occurrence of adverse events was significantly higher in the imipramine group compared to placebo ($p = 0.001$) and approached significance in the reboxetine group ($p = 0.051$), while the risk of developing at least one adverse event was similar in the reboxetine and the imipramine groups.

The prevalence of adverse events during the study indicated a higher proportion of patients with adverse events in both imipramine and reboxetine groups than in placebo group during

the whole treatment period. In addition, the proportion was always slightly higher on imipramine than on reboxetine, particularly during the fourth and the sixth week.

Thirty-three patients (11 on reboxetine, 9.8%; 15 on imipramine, 13.0% and 7 on placebo, 6.3%) withdrew from the study because of adverse events. One patient of the imipramine group died by suicide. In addition, two patients dropped out of the study due to intercurrent medical problems without having a newly emerged adverse event form filled in the CRF: one patient (No 416 from the reboxetine group) dropped out due to the discovery of hypothyroidism which was present before the start of treatment, and a second one (No 138 from the placebo group) due to bad hepatic function.

Most frequently reported adverse events were: dry mouth (25.0% reboxetine, 42.6% imipramine and 12.5% placebo); constipation (15.2%, 15.7%, 5.4%, respectively) and increased sweating (12.5%, 19.1%, 2.7%, respectively). The majority of adverse events were moderate in all treatment groups. Adverse events were reported with a similar frequency by women and men in all treatment groups.

The most relevant between-gender differences were related to the frequency of dry mouth, constipation, increased sweating, and nausea, complained of mainly by female patients (27%, 46%, 19% dry mouth; 17%, 18%, 9% constipation; 16%, 21%, 4% increased sweating; 10%, 17%, 17% nausea and related symptoms) on reboxetine, imipramine and placebo, respectively. The corresponding figures for male patients were 21%, 37%, 7% dry mouth; 12%, 11%, 2% constipation; 7%, 16%, 2% increased sweating; 7%, 11%, 2% nausea and related symptoms on reboxetine, imipramine and placebo, respectively. Tremor was complained of by more female than male patients (21% *vs* 11%) on imipramine but not on placebo (4% of female patients *vs* 5% of male patients) and on reboxetine (6% *vs* 5% of female and male patients, respectively). Conversely, urinary hesitancy/retention was complained of by more male than female patients on reboxetine (14% *vs* 0%, respectively), but not by patients on imipramine and placebo (0% and 2% *vs* 1% and 2% of male and female patients, respectively).

The estimate of the cumulative risk of adverse events according to the Kaplan-Meier method and log-rank test is significantly higher in the imipramine group compared to placebo ($p = 0.001$) and approaches significance in the reboxetine group compared with placebo ($p = 0.051$). As for individual events or clusters, the cumulative risk is significantly higher on reboxetine than on placebo for insomnia, increased sweating, dry mouth, vertigo and constipation. Similarly, the cumulative risk is significantly higher on imipramine than on placebo for dry mouth, constipation, increased sweating, vertigo, hypotension and related symptoms, tremor and blurred vision.

The log-rank tests on the direct comparison between reboxetine and imipramine in terms of increased risk of adverse events indicate significant differences in favour of reboxetine for

dry mouth, hypotension and related symptoms and tremor. A difference in favour of reboxetine, but not a significant one, was also reported for nausea and related symptoms, somnolence and increased sweating, while the difference was in favour of imipramine, but not significantly so, for headache/migraine and urinary hesitancy/retention.

In addition to the mentioned death (suicide) in the imipramine group, 5 serious adverse events, all occurred in the imipramine- and placebo-treated patients were reported: 2 cases of attempted suicide occurred in the placebo group and 1 case of attempted suicide , 1 case of postural hypotension, dizziness and syncope and 1 case of attention seeking autolesionistic behaviour in the imipramine group.

There was no indication of modifications in laboratory tests that were of clinical significance.

Vital signs were not modified to any significant extent. The proportion of patients showing an increase and a decrease of possible clinical relevance for the systolic and diastolic blood pressure in lying and standing position was similar in all groups. As for the lying and standing heart rate, a slightly higher proportion of patients with at least 20% increased values *vs* baseline, as well as such increases associated with values ≥100 beats/min was observed during the whole treatment period in both active treatment groups compared with the placebo treatment group. The same results were observed in patients who had clinically relevant increase at least once during the treatment period. A total of 11 and 13 patients in the two positions, respectively, in the reboxetine group (10.4% of 106 evaluated patients [lying position] and 12.4% of 105 evaluated patients [standing position]) and a total of 5 and 8 patients in the two positions, respectively, in the imipramine group (5.0% of 100 evaluated patients [lying position] and 8.1% of 99 evaluated patients [standing position]) had relevant increased values compared with a total of 1 and 2 patients in the two positions, respectively, in the placebo group (1.0% of 104 evaluated patients [lying] and 1.9% of 105 evaluated patients [standing]).

No indication of effect on cardiac function emerged from ECG recordings. Newly emerged abnormalities never reported at baseline occurred in rare cases and with a higher frequency in the imipramine group than in the reboxetine and placebo groups (13 of 91 evaluated *vs* 7 of 95 and 3 of 91 evaluated newly cases on imipramine, placebo and reboxetine, respectively). The between treatment group difference was due especially to sinus tachycardia, which occurred more in imipramine (7 new cases) than in reboxetine (2 new cases) and in placebo (0 cases) patients. During treatment, the frequencies were not modified to any significant extent in any of the treatment groups, except for conduction disorders, which from 4% at screen increased to 9% after 3 weeks of treatment and to 7% after 6 weeks of treatment in the imipramine group, as well as for rhythm disorders, which, from 8% at screen, increased to 13% after 3 weeks of treatment and 11% after 6 weeks of

treatment in the imipramine group and, from 4% at screen, to 9% both after 3 and 6 weeks of treatment in the placebo group. At last assessment, the proportion of newly emerged cases was similar in all treatment groups, and in all groups was far lower than the proportion of normalised cases, except for abnormalities of rhythm and conduction disorders. In the first case, the abnormalities occurred slightly more frequently in the imipramine- (8 new cases of 91 evaluated) than in the reboxetine-(3 new cases of 91 evaluated) and placebo-treated patients (5 new cases of 95 evaluated), while in the second case the abnormalities occurred only in the imipramine-treated patients (3 new cases of the 91 evaluated).

9. DISCUSSION

Three hundred and thirty-nine patients were admitted to the study from January 1991 to October 1992 and randomised to treatment by investigators at 34 centres. A total of 252 patients (74.3%) completed the study and 87 (25.7%) withdrew (3 of them, 2 in the imipramine and 1 in the placebo group, having the last assessment at Day 42 visit); 23 (20.5%) in the reboxetine group, 38 (33.0%) in the imipramine groups, and 26 (23.2%) in the placebo group.

Newly emerged adverse events or intercurrent illnesses were the main reasons for withdrawal in 11, 15 and 7 patients of the reboxetine, imipramine and placebo groups, respectively. One patient from the imipramine group died by suicide.

The majority of patients, in the reboxetine and imipramine groups, were female, and the proportion of females and males was similar in the placebo group. The vast majority of patients were Caucasian. All treatment groups were well matched for age, height, weight and race. Recurrent Major Depressive Disorder (DSM-III-R No 296.3) was diagnosed for the majority of patients in each treatment group (68% reboxetine, 70% imipramine, and 73% placebo). A Major Depression First Episode (DSM-III-R No 296.2) was diagnosed in almost all remaining cases, except for 2 patients (1 reboxetine and 1 imipramine) who were diagnosed as Bipolar Disorder, Depressed, unspecified (DSM-III-R No 296.5). The treatment groups were well matched with regard to all the tests characterising the history of mental disorders.

In the 110 patients randomised to reboxetine who had at least one assessment in addition to baseline, the mean HAMD total score was reduced from 27.5 at Day 0 to 14.0 at last assessment, and to 11.3 at Day 42 in the 89 patients assessed at Day 42. In the 111 patients randomised to imipramine with at least one assessment in addition to baseline, the mean HAMD total score was reduced from 26.9 at Day 0 to 13.2 at last assessment, and to 9.4 at Day 42 (79 patients). Mean HAMD total score in the 111 patients randomised to placebo was reduced from 27.1 at Day 0 to 15.8 at last assessment, and to 13.1 at Day 42 (87 patients). The results of the planned analysis of the study end-point indicate slightly higher

improvement on both reboxetine and imipramine, compared to placebo, though the differences do not reach statistical significance (p>0.025,one-tailed test).

The results of the planned analysis of the study end-point, i.e. the difference *vs* baseline of the HAMD total score at last assessment, do not allow the refusal of the null hypothesis of no difference between reboxetine and placebo. Though the positive control, imipramine, resulted similarly not different from placebo in terms of extent of the induced clinical improvement.

This finding is not surprising. Reviews of placebo-controlled studies carried out with tricyclic antidepressants, including imipramine, have shown that the variability of placebo associated response is very high. In view of this, a not irrelevant proportion of the controlled studies comparing imipramine to placebo failed to detect statistically significant differences [27]. However, as in our case for both reboxetine and imipramine, the direction of the difference of outcome is almost always in favour of the active treatments [28].

At last assessment, 59.1% of the reboxetine-treated patients, 62.2% of the imipramine-treated patients and 52.3% of the placebo-treated patients were classified as responders, while 42.7%, 50.5% and 36.0%, respectively, were seen to be in remission. The between treatment difference in the proportion of remissions and responders both for imipramine and reboxetine compared with placebo did not reach the statistical significance ($p > 0.025$). Patients on imipramine had showed a cumulative response over time (Kaplan-Meier method) significantly higher ($p = 0.0055$) than patients on placebo while patients on reboxetine had a rate of response whose difference from placebo didn't reach significance ($p=0.081$).

Additional analyses were carried out in the sub-populations of melancholic (DSM IV criteria) and severe (CGI- Severity of Illness: marked to extreme ill at the admission) patients. In the former case, with respect to the total population, the improvement on both active treatments was maximal and on placebo it was minimal. The mean decrease in the two active treatment groups was very similar, the mean difference between imipramine and reboxetine being of 0.12 points (95% C.I.: -3.2 ÷ 3.4). However, the difference between active treatments and placebo was statistically significant ($p<0.025$) only for imipramine. In melancholic patients the difference between placebo and active treatments was significantly superior for reboxetine, but not for imipramine. In fact, the mean difference between active treatments was in favour of reboxetine with a value of 3.9 points (95% C.I.: -0.5 ÷ 8.3).

The CGI severity of illness had decreased in 77.3% and 77.5% of the reboxetine and imipramine patients, respectively, compared with 65.8% of the placebo patients, increased in 5.5% and 4.5% of the reboxetine and imipramine patients, respectively, compared with 8.1% of the placebo patients, and had remained the same in the 17.3% and 18.1% of

reboxetine and imipramine patients, respectively, compared with 26.1% of the placebo patients. The clearest difference between treatments is related to the percentage of patients who were 'very much improved' at last assessment. This was higher in the reboxetine group (29.1%) and the imipramine group (28.8%) compared with the placebo group (17.1%). In addition, the percentage of patients with 'no change' was higher in the placebo group (17.1%) than in the reboxetine group (9.1%) and the imipramine group (10.8%).

At last assessment, side-effects were judged to outweigh efficacy in 15.3% of the reboxetine patients, 16.2% of the imipramine patients and in 13.5% of the placebo patients. The most relevant placebo-active treatment group differences in the Efficacy Index are seen in the proportion of cases where no advantage in terms of efficacy *vs* side-effects was identified (index = 1): 21.6% of the placebo-treated cases compared with 13.5% of the reboxetine-treated and 13.5% of the imipramine-treated cases. It was also seen in the proportion of cases where efficacy outweighed side-effects (index = 4): 22.5% of the placebo-treated cases compared with 28.8% of the reboxetine-treated cases and only 14.4% of the imipramine-treated cases.

The mean total MADRS score was reduced from 16.4 at Day 0 to 8.4 at last assessment in the 110 reboxetine group patients with at least one assessment in addition to baseline, and to 6.6 at Day 42 in the 89 reboxetine patients who completed the study. In patients randomised to imipramine, values changed from 16.7 at Day 0 to 8.2 at last assessment (111 patients), and to 5.8 at Day 42 (79 assessed patients). The corresponding reductions in placebo group patients were from 16.3 at Day 0 to 9.8 at last assessment (111 patients) and to 7.7 at Day 42 (87 assessed patients).

All the 339 patients who received study treatment were included in the safety analysis (112 reboxetine, 115 imipramine, 112 placebo).

Safety and tolerability were assessed by the reporting of any adverse event and assessment of vital signs (supine and standing blood pressure and heart rate), laboratory tests, and ECG. For clinical and laboratory tests were analysed only patients with at least one assessment in addition to baseline.

The occurrence of newly reported adverse events was higher in the imipramine group than in the reboxetine or placebo groups during the study; 71/112 reboxetine group patients reported 211 adverse events compared with 81/115 imipramine patients who reported 288 adverse events and 58/112 placebo group patients who reported 141 adverse events.

The prevalence of adverse events during the study indicated a higher proportion of patients with adverse events in the both imipramine and reboxetine groups than in the placebo group during the whole treatment period. In addition, the proportion was always slightly higher on imipramine than on reboxetine, particularly during the fourth and the sixth week.

Most frequently reported were: dry mouth (25.0% reboxetine, 42.6% imipramine and 12.5% placebo); constipation (15.2%, 15.7%, 5.4%) and increased sweating (12.5%, 19.1%, 2.7%). In addition, events reported with different frequencies in the three groups were: insomnia (11% on reboxetine, 7% on imipramine, 4% on placebo), vertigo (5% and 6% on reboxetine and imipramine, 0% on placebo), tremor (5% on reboxetine and placebo, 17% on imipramine), hypotension and related symptoms (9% on reboxetine, 17% on imipramine, 5% on placebo) blurred vision (9% on imipramine, 5% on reboxetine, 3% on placebo). The majority of adverse events were moderate in all treatment groups. Adverse events were reported with a similar frequency by women and men in all treatment groups. The most significant between-gender differences were related to the frequency of dry mouth, constipation, increased sweating, and nausea and related symptoms, complained of mainly by female patients.

The estimate of the cumulative risk of adverse events according to the Kaplan-Meier method and log-rank test was significantly higher in the imipramine group compared to placebo ($p = 0.001$) and approached significance in the reboxetine group compared with placebo ($p = 0.051$). As for individual events, the cumulative risk was higher on reboxetine (as well as imipramine) than on placebo for dry mouth, increased sweating, constipation and vertigo, while it was higher on reboxetine (but not on imipramine) than on placebo for insomnia and it was higher on imipramine (but not reboxetine) than on placebo for hypotension and related symptoms, tremor and blurred vision.

The log-rank tests on the direct comparison between reboxetine and imipramine in terms of increased risk of adverse events indicate significant differences in favour of reboxetine for dry mouth, hypotension and related symptoms and tremor. A difference in favour of reboxetine, although not a significant one, was also reported for nausea and related symptoms, somnolence and increased sweating, while the difference was in favour of imipramine, but not significantly so, for headache/migraine and urinary hesitancy/retention.

In addition to the mentioned death (suicide) in the imipramine group, 5 serious adverse events , all occurred in the imipramine-and placebo-treated patients were reported: 2 cases of attempted suicide occurred in the placebo group and 1 case of attempted suicide, 1 case of postural hypotension, dizziness and syncope and 1 case of attention seeking autolesionistic behaviour in the imipramine group.

There was no indication of modifications in laboratory tests that were of clinical significance.

Vital signs were not modified to any significant extent, with the exception of the lying and standing heart rate, for which a slightly higher proportion of patients with at least 20% increased values *vs* baseline as well as such increases associated with values ≥100 beats/min, was observed during the whole treatment period in both active treatment groups compared

with the placebo treatment group. The same results were observed in patients who had clinically relevant increased at least once during the treatment period. The proportions of patients showing an increase and a decrease of possible clinical relevance for the systolic and diastolic blood pressure in lying and standing position was similar in all groups.

No indication of effect on cardiac function emerged from ECG recordings. The proportion of newly emerged abnormal ECG recordings was lower than the frequency of normalisation of readings classified as abnormal at baseline in all groups. Newly emerged abnormalities never reported at baseline occurred in rare cases and with a higher frequency in the imipramine group than in the reboxetine and placebo groups (13 of 91 evaluated *vs* 7 of 95 and 3 of 91 evaluated newly cases on imipramine, placebo and reboxetine, respectively). The between treatment group difference was due especially to sinus tachycardia, which occurred more in imipramine (7 new cases) than in reboxetine (2 new cases) and in placebo (0 cases) patients. During treatment, the frequencies were not modified to any significant extent in any of the treatment groups, except for conduction disorders, which from 4% at screen increased to 9% after 3 weeks of treatment and to 7% after 6 weeks of treatment in the imipramine group, as well as for rhythm disorders, which, from 8% at screen, increased to 13% after 3 weeks of treatment and 11% after 6 weeks of treatment in the imipramine group and, from 4% at screen, to 9% both after 3 and 6 weeks of treatment in the placebo group. At last assessment, the proportion of newly emerged cases was similar in all treatment groups, and in all groups was far lower than the proportion of normalised cases, except for abnormalities of rhythm and conduction disorders. In the first case, the abnormalities occurred slightly more frequently in the imipramine- (8 new cases of 91 evaluated) than in the reboxetine-(3 new cases of 91 evaluated) and placebo-treated patients (5 new cases of 95 evaluated), while in the second case the abnormalities occurred only in the imipramine-treated patients (3 new cases of the 91 evaluated).

10. CONCLUSION

The results of the statistical analysis of the study end-point do not allow the refusal of the null hypothesis of no difference between both active treatments and placebo. However, indications on the higher efficacy of the active treatments compared to placebo derive from the analysis of the cumulative rate of response in according to the Kaplan-Meier method in the total population, particularly in the case of imipramine, and from the sub-population analyses in severe and melancholic patients, for both reboxetine and imipramine.

The safety profiles of reboxetine and imipramine compared to placebo were similar with regard to vital signs, haematology and blood chemistry tests and ECG examinations. The cumulative risk of adverse events was significantly higher on imipramine compared to placebo and approached significance on reboxetine compared with placebo. As for individual events, the cumulative risk was higher on reboxetine (as well as imipramine) than on placebo for dry mouth, increased sweating, constipation and vertigo, while it was higher on reboxetine (but not on imipramine) than on placebo for insomnia. The direct comparison between reboxetine and imipramine in terms of increased risk of adverse events indicated significant differences always in favour of reboxetine (dry mouth, hypotension and related symptoms and tremor).

11. REFERENCES

1. Reboxetine Investigator Brochure, Farmitalia Carlo Erba, CNS Line, 1988.

2. Herrman WM, Schneider J, Boden S, Wagner W, Rohmel J, Grunmach J. Safety and tolerance of reboxetine in healthy male volunteers - A single rising dose tolerance study. Pharmacia Internal Report FCE 20124/602i, June 1984.

3. Herrman WM, Schneider J, Irrgang U, Rosener B, Willman J, Rohmel J, et al. Reboxetine - Quantitative pharmaco-EEG and pharmaco-psychological study. Pharmacia Internal Report FCE 20124/603i, January 1985.

4. Dubini A, Goldaniga GC, Montesanti L, Savoia L, Tamassia V, Vicario GP. Disposition and fate of ^{14}C-reboxetine administered orally to healthy volunteers. Pharmacia Internal Report FCE 20124/604I, March 1985.

5. Dubini A, Ban T. Open dose range finding study in patients hospitalised for Major Depressive Disorders. Pharmacia Internal Report FCE 20124/701i, April 1989.

6. Dubini A, Ban T, Morey LC. Phase II controlled study of the activity and tolerability of reboxetine in comparison with placebo and desipramine in patients hospitalised for Major Depressive Disorders. Pharmacia Internal Report FCE 20124/702i, February 1991.

7. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine *vs* imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985; 46: 53-58.

8. American Psychiatric Association. Mood disorders. In: Williams JBW (Ed). Diagnostic and Statistical Manual of Mental Disorder. Third edition revised, American Psychiatric Association, Washington DC, 1987.

9. Hamilton M. A rating scale for depression. J Neurosurg Psychiatry 1960; 23: 56-62.

10. Guy W. ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and mental health Administration. Rockville, Maryland: 1976.

11. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.

12. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological psychiatric rating scale (CPRS). Acta Psychiatr Scand 1978; 271 (Suppl): 5-27.

13. Karch FE, Lasagna L. Adverse drug reactions - a critical review. JAMA 1975; 234: 1236-1241.

14. American Psychiatric Association. Mood disorders. In: Diagnostic and Statistical Manual of Mental Disorders: Fourth edition. American Psychiatric Association, Washington DC, 1994.

15. Gill JL. Design and Analyses of Experiments in the Animal and Medical Sciences. Ames, Iowa, USA: The Iowa State University Press, 1978: 135-150.

16. Dunnett CW. A Multiple Comparison Procedure for Comparing Several Treatments with a Control. Journal of American Statistical Association 1955; 50: 1096-1121.

17. Gill JL. Design and Analysis of Experiments in the Animal and Medical Sciences. Ames, Iowa, USA: The Iowa State University Press, 1978: 156-159.

18. Snedecor GW. Statistical Methods. Ames, Iowa, USA: The Iowa State University Press, 1964: 1-34, 217-219.

19. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, 1980: 16-19.

20. Fleiss JL. Statistical Methods for Rates and Proportions. New York: John Wiley & Sons, 1973: 72-80.

21. Chuang-Stein C. Summarizing laboratory data with different reference ranges in multicenter clinical trials. Drug Information Journal 1992; 26: 77-84.

22. Wyngaarden JB, Smith LH, Bennett JC, Editors. Cecil Textbook of Medicine. Philadelphia: Saunders, 1988.

23. Hollander M, Wolfe DA: Nonparametric Statistical Methods. New York: John Wiley & Sons, 1973: 26-38.

24. Collaborating Centre for International Drug Monitoring. Manual of the international statistical classification of diseases, injuries, and causes of death. Geneva: World Health Organization, 1977.

25. Collaborating Centre for International Drug Monitoring. Drug Reference List. Geneva: World Health Organization, 1989.

26. Collaborating Centre for International Drug Monitoring. Adverse Reactions Terminology. International monitoring of adverse reactions to drugs. Geneva: World Health Organization, 1989.

27. Brotman AW, Falk WE, Gelenberg AJ. Pharmacological Treatment of Acute Depressive Subtypes. In: Herbert Y Meltzer, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987:1031-1040 .

28. Maxwell C. Placebos and trials, overviews and depression - a polemic based on early meta-analysis. J Pharm Med 1993; 3: 33-44.

TABLES

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 1

NUMBER OF PATIENTS BY CENTRE, VISIT AND TREATMENT

Centre/Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	Imipramine	8	8	8	7	6	6	6	6
	Placebo	5	5	5	5	5	5	5	5
	Reboxetine	6	6	6	6	5	4	4	4
2/1	Imipramine	1	1	1	1	1	1	1	1
	Placebo	1	1	1	1	1	1	1	1
	Reboxetine	1	1	1	1	1	1	1	1
2/2	Imipramine	2	2	2	2	2	2	2	1
	Placebo	2	2	2	2	2	2	1	1
	Reboxetine	2	2	2	2	2	2	2	2
2/3	Imipramine	3	3	3	3	3	3	3	3
	Placebo	2	2	2	2	2	2	2	2
	Reboxetine	2	2	2	2	2	2	2	2
2/4	Imipramine	2	2	2	2	2	2	2	2
	Placebo	2	2	2	2	2	2	2	2
	Reboxetine	2	2	2	2	2	2	2	2
2/5	Imipramine	2	2	2	2	2	2	2	2
	Placebo	2	2	2	2	2	2	2	2
	Reboxetine	2	2	2	2	2	2	2	1
2/6	Imipramine	2	2	2	2	2	2	2	2
	Placebo	2	2	2	2	2	2	1	1
	Reboxetine	2	2	2	2	2	2	2	2
3/1	Imipramine	6	6	6	6	4	3	3	2
	Placebo	6	6	6	6	6	6	6	6
	Reboxetine	6	6	6	6	5	5	5	4

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 1

NUMBER OF PATIENTS BY CENTRE, VISIT AND TREATMENT

Centre/Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/2	Reboxetine	1	1	1	1	1	1	1	1
3/3	Imipramine	2	2	2	2	2	2	2	2
	Placebo	2	2	2	2	2	2	2	2
	Reboxetine	2	2	2	2	2	2	2	2
3/4	Imipramine	6	6	6	5	4	3	3	3
	Placebo	6	6	6	5	5	4	4	4
	Reboxetine	6	6	6	5	4	4	4	4
4/1	Imipramine	6	6	6	5	5	5	5	5
	Placebo	6	6	5	5	5	5	5	5
	Reboxetine	6	6	6	6	6	6	6	6
4/2	Placebo	2	2	2	2	2	2	2	2
	Reboxetine	1	1	1	1	1	1	1	1
4/3	Imipramine	2	2	2	2	2	1	1	1
	Placebo	2	2	2	2	1	1	1	1
	Reboxetine	1	1	1	1	1	1	1	
4/4	Imipramine	4	4	4	4	4	3	3	3
	Placebo	4	4	4	4	4	3	2	2
	Reboxetine	4	4	4	4	4	4	4	4
5/1	Imipramine	2	2	2	2	2	2	2	2
	Placebo	2	2	2	2	2	2	2	2
	Reboxetine	2	2	2	2	2	2	2	2
5/2	Imipramine	1	1	1	1	1	1	1	1
	Reboxetine	1	1	1	1	1	1	1	1
5/3	Imipramine	2	2	2	2	2	2	2	2

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 1

NUMBER OF PATIENTS BY CENTRE, VISIT AND TREATMENT

Centre/Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
5/3	Placebo	2	2	2	1				
	Reboxetine	2	2	2	2	2	2	2	2
6/1	Imipramine	2	2	2					
	Placebo	2	2	2	2	2	2	1	1
	Reboxetine	2	2	2	2	2	2	2	2
6/2	Imipramine	4	4	4	4	4	3	3	3
	Placebo	4	4	4	3	2	2	2	2
	Reboxetine	4	4	4	4	4	4	3	3
6/3	Imipramine	6	6	6	6	5	5	5	4
	Placebo	5	5	5	4	4	4	4	3
	Reboxetine	4	4	4	2	1	1	1	1
7/02	Imipramine	2	2	2	2	2	1	1	1
	Placebo	3	3	3	3	3	3	3	3
	Reboxetine	3	3	3	3	3	3	2	2
7/03	Imipramine	4	4	4	4	4	4	4	3
	Placebo	4	4	4	4	4	4	4	4
	Reboxetine	4	4	4	4	4	4	4	4
7/04	Imipramine	4	4	4	4	4	4	4	4
	Placebo	4	4	4	4	4	4	4	4
	Reboxetine	4	4	4	4	4	4	4	4
7/05	Imipramine	4	4	4	4	4	4	4	4
	Placebo	4	4	4	4	4	4	4	4
	Reboxetine	4	4	4	4	4	4	4	4
7/07	Imipramine	2	2	2	2	2	1	1	1

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 1

NUMBER OF PATIENTS BY CENTRE, VISIT AND TREATMENT

Centre/Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/07	Placebo	2	2	2	2	2	2	2	2
	Reboxetine	2	2	2	2	2	2	2	2
8	Imipramine	8	8	8	6	6	6	6	6
	Placebo	8	8	8	8	8	7	7	7
	Reboxetine	8	8	8	8	7	7	7	7
8/A	Imipramine	3	3	3	3	3	3	3	3
	Placebo	3	3	3	3	3	3	3	3
	Reboxetine	4	4	4	4	4	4	4	4
9	Imipramine	6	6	6	6	5	5	2	2
	Placebo	6	6	6	5	2	2		
	Reboxetine	6	6	6	4	3	1		
11	Imipramine	7	7	7	3	3	3	3	3
	Placebo	6	6	6	6	6	6	6	6
	Reboxetine	7	7	7	6	6	6	6	6
12	Imipramine	3	3	3	1	1			
	Placebo	3	3	3	3	3	3	1	1
	Reboxetine	3	3	3	3	3	3	3	3
13	Imipramine	3	3	3	3	3	3	3	3
	Placebo	4	4	4	4	4	4	4	4
	Reboxetine	3	3	3	3	3	3	3	3
14	Imipramine	2	2	2	2	2	2	2	1
	Reboxetine	1	1	1	1	1	1		
15	Imipramine	4	4	4	4	4	4	4	4
	Placebo	6	6	6	6	6	5	5	5

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 1

NUMBER OF PATIENTS BY CENTRE, VISIT AND TREATMENT

Centre/Assigned treatment		Visit								
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	Reboxetine	4	4	4	4	4	4	3	3
Total	Imipramine	115	115	115	102	96	88	85	80
	Placebo	112	112	111	106	100	96	88	87
	Reboxetine	112	112	112	106	100	97	92	89
	Total	339	339	338	314	296	281	265	256

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 2

PATIENT DISPOSITION

	Treatment assigned						Total	
	Imipramine		Placebo		Reboxetine			
	No.	%	No.	%	No.	%	No.	%
Screened	115	100.00	112	100.00	112	100.00	339	100.00
Exposed	115	100.00	112	100.00	112	100.00	339	100.00
Completed	77	66.96	86	76.79	89	79.46	252	74.34
Dropped	38	33.04	26	23.21	23	20.54	87	25.66

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 3

END OF STUDY: REASONS FOR DISCONTINUATION AND VISIT AT WHICH DISCONTINUATION OCCURED, BY ASSIGNED TREATMENT

Assigned treatment / Reasons		Total		Last visit													
				Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	ADVERSE EVENT (*)	14	100			6	42.9	3	21.4	3	21.4					2	14.3
	DEATH	1	100			1	100										
	LOST TO FOLLOW UP	2	100			2	100										
	DETERIORATION	11	100			1	9.1	3	27.3	3	27.3	1	9.1	2	18.2	1	9.1
	IMPROVEMENT	1	100											1	100		
	PATIENT UNCOOPERATIVE	8	100			3	37.5			2	25.0	1	12.5	2	25.0		
	OTHER	1	100									1	100				
	Total	38	100			13	34.2	6	15.8	8	21.1	3	7.9	5	13.2	3	7.9
Placebo	ADVERSE EVENT (*)	8	100			2	25.0	2	25.0	1	12.5	2	25.0			1	12.5
	LOST TO FOLLOW UP	1	100	1	100												
	DETERIORATION	11	100					3	27.3	2	18.2	5	45.5	1	9.1		
	PATIENT UNCOOPERATIVE	6	100			3	50.0	1	16.7	1	16.7	1	16.7				
	Total	26	100	1	3.8	5	19.2	6	23.1	4	15.4	8	30.8	1	3.8	1	3.8
Reboxetine	ADVERSE EVENT (*)	12	100			4	33.3	3	25.0	1	8.3	3	25.0	1	8.3		
	PROTOCOL VIOLATION	1	100					1	100								
	DETERIORATION	5	100			1	20.0	1	20.0	1	20.0	2	40.0				
	PATIENT UNCOOPERATIVE	5	100			1	20.0	1	20.0	1	20.0			2	40.0		
	Total	23	100			6	26.1	6	26.1	3	13.0	5	21.7	3	13.0		

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/015

TABLE No.: 4
PROTOCOL VIOLATION AT ADMISSION

	Imipramine		Placebo		Reboxetine	
	No.	%	No.	%	No.	%
Patients exposed	115	100.00	112	100.00	112	100.00
Age > 65 years					1	0.89
Pregnancy						
Thyroid function tests abnormal*	12	10.43	6	5.36	5	4.46
Thyroid function tests missing	16	13.91	11	9.82	11	9.82
Evidence of Substance Use Disorder						
Associated endocrine disorder						
Not allowed concomitant medication during wash-out	3	2.61	1	0.89	6	5.36
Index episode < 4 weeks	1	0.87	2	1.79		
Index episode > 4 months	4	3.48	2	1.79	3	2.68
Index episode duration: unknown						
Clinical relevant associated pathology						

* > 10% deviation from normal range limits

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Table No.: 5

RANDOMIZATION: ASSIGNED TREATMENT vs RANDOMIZED TREATMENT

Assigned treatment	Randomized treatment				Total
	Imipramine	Placebo	Reboxetine	Out of Random.	
Imipramine	89	9	16	1	115
Reboxetine	19	12	80	1	112
Placebo	6	91	15		112
Total	114	112	111	2	339

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 6

COMPLIANCE TO SCHEDULE TIME AS PER PROTOCOL

Assigned treatment: Reboxetine

		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Assessment time	No.	112	112	106	100	97	92	89	89
	Min	-25	-3	7	13	20	27	34	41
	Max	1	1	8	16	25	31	42	62
	Median	-4	1	8	15	22	29	36	43
	95th percentile	1	1	8	15	23	30	37	44
Laboratory test	No.	110				94			86
	Min	-46				14			35
	Max	4				30			74
	Median	-3				22			43
	95th percentile	1				24			48
E.C.G.	No.	111				96			89
	Min	-45				13			35
	Max	9				29			74
	Median	-4				22			43
	95th percentile	2				25			52

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 6

COMPLIANCE TO SCHEDULE TIME AS PER PROTOCOL

Assigned treatment: Imipramine

		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Assessment time	No.	115	115	102	96	88	85	80	77
	Min	-24	-1	6	13	20	26	34	41
	Max	1	1	14	18	28	35	43	47
	Median	-4	1	8	15	22	29	36	43
	95th percentile	1	1	8	16	24	31	38	45
Laboratory test	No.	111				85			75
	Min	-35				16			33
	Max	7				31			57
	Median	-3				22			43
	95th percentile	1				25			48
E.C.G.	No.	115				84			77
	Min	-104				20			36
	Max	5				36			78
	Median	-3				22			43
	95th percentile	1				25			57

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 6

COMPLIANCE TO SCHEDULE TIME AS PER PROTOCOL

Assigned treatment: Placebo

		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Assessment time	No.	112	112	106	100	96	88	87	86
	Min	-27	0	7	12	19	26	34	40
	Max	1	2	9	22	24	36	40	48
	Median	-4	1	8	15	22	29	36	43
	95th percentile	1	1	8	15	22	30	37	45
Laboratory test	No.	109				94			81
	Min	-56				15			36
	Max	8				31			66
	Median	-3				22			43
	95th percentile	1				25			48
E.C.G.	No.	111				95			85
	Min	-48				19			29
	Max	8				32			75
	Median	-3				22			43
	95th percentile	2				28			54

PHARMACIA CNS R2D

REBOXETINE - PROTOCOL 20124/015
Table No.: 7

CONCOMITANT DRUGS NOT ALLOWED BY PROTOCOL GROUPED BY ACTIVE PRINCIPLE
NUMBER OF PATIENTS

Class / Active principle		Assigned treatment	
		Placebo	Imipramine
BDZ long acting	DIAZEPAM	2	
	NITRAZEPAM	1	
	FLURAZEPAM		1
	LORAZEPAM	1	
	Total	4	1
Neuroleptics	CHLORMEZANONE	1	
	Total	1	
Antiepileptics	CLONAZEPAM		1
	Total		1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Table No.: 8

CONCOMITANT DRUGS NOT ALLOWED BY PROTOCOL GROUPED BY CLASS
NUMBER OF PATIENTS

	Assigned treatment	
	Imipramine	Placebo
At least one	1	5
Antiepileptics	1	
BD2 long acting	1	4
Neuroleptics		1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Table No.: 9

DEMOGRAPHY BY ASSIGNED TREATMENT - AGE, WEIGHT, HEIGHT

Assigned treatment		Age			Weight			Height		
		Sex			Sex			Sex		
		Female	Male	Total	Female	Male	Total	Female	Male	Total
Imipramine	No	77	38	115	77	38	115	77	38	115
	Mean	43.57	43.32	43.49	62.96	76.46	67.42	161.58	174.00	165.69
	S.D.	11.38	10.54	11.06	11.88	10.54	13.07	6.61	6.89	8.88
	Min	20.00	22.00	20.00	40.00	55.00	40.00	140.00	158.00	140.00
	Max	62.00	65.00	65.00	99.00	99.00	99.00	179.00	185.00	185.00
Placebo	No	54	58	112	53	58	111	54	57	111
	Mean	45.11	41.67	43.33	63.24	75.52	69.66	161.81	173.39	167.76
	S.D.	12.19	11.06	11.69	11.55	13.72	14.09	4.86	7.00	8.37
	Min	23.00	18.00	18.00	41.00	48.50	41.00	150.00	155.00	150.00
	Max	65.00	63.00	65.00	91.00	133.00	133.00	174.00	193.00	193.00
Reboxetine	No	70	42	112	69	42	111	70	42	112
	Mean	45.43	46.74	45.92	63.83	76.41	68.59	161.20	174.31	166.12
	S.D.	13.54	11.23	12.68	14.45	13.41	15.29	6.58	6.97	9.25
	Min	19.00	23.00	19.00	38.00	61.00	38.00	147.00	154.00	147.00
	Max	72.00	64.00	72.00	116.00	141.00	141.00	176.00	188.00	188.00
Total	No	201	138	339	199	138	337	201	137	338
	Mean	44.63	43.67	44.24	63.34	76.05	68.54	161.51	173.84	166.51
	S.D.	12.35	11.10	11.85	12.69	12.74	14.15	6.15	6.92	8.86
	Min	19.00	18.00	18.00	38.00	48.50	38.00	140.00	154.00	140.00
	Max	72.00	65.00	72.00	116.00	141.00	141.00	179.00	193.00	193.00

weight and height at screening visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Table No.: 10

DEMOGRAPHY BY ASSIGNED TREATMENT - RACE

Assigned treatment / Sex		Race						Total	
		Caucasian		Asian		Other			
		No.	%	No.	%	No.	%	No.	%
Imipramine	Female	77	100.00					77	100.00
	Male	37	97.37			1	2.63	38	100.00
	Total	114	99.13			1	0.87	115	100.00
Placebo	Female	52	96.30	2	3.70			54	100.00
	Male	56	96.55			2	3.45	58	100.00
	Total	108	96.43	2	1.79	2	1.79	112	100.00
Reboxetine	Female	69	98.57			1	1.43	70	100.00
	Male	42	100.00					42	100.00
	Total	111	99.11			1	0.89	112	100.00
Total	Female	198	98.51	2	1.00	1	0.50	201	100.00
	Male	135	97.83			3	2.17	138	100.00
	Total	333	98.23	2	0.59	4	1.18	339	100.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 11

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS BY SEX AND ASSIGNED TREATMENT

		Sex											
		Female				Male				Total			
		Imipramine	Placebo	Reboxetine	Total	Imipramine	Placebo	Reboxetine	Total	Imipramine	Placebo	Reboxetine	Total
DSM-III-R diagnosis	296.2 No.	20	9	19	48	14	21	16	51	34	30	35	99
	296.3 No.	56	45	50	151	24	37	26	87	80	82	76	238
	296.5 No.	1		1	2					1		1	2
Age of onset (years)	No.	65	48	63	176	33	51	34	118	98	99	97	294
	Mean	36.40	35.90	38.79	37.12	38.39	36.24	41.24	38.28	37.07	36.07	39.65	37.59
	STD	10.92	11.67	13.32	12.03	9.66	11.24	12.63	11.35	10.50	11.39	13.07	11.75
	Median	37.00	33.50	38.00	37.00	41.00	37.00	40.50	40.00	37.00	36.00	39.00	38.00
	Min	14	14	13	13	17	16	15	15	14	14	13	13
	Max	59	59	72	72	56	57	63	63	59	59	72	72
	unknown	12	6	7	25	5	7	8	20	17	13	15	45
Number of previous episodes	No.	53	44	49	146	23	32	23	78	76	76	72	224
	Mean	4.21	2.73	3.16	3.41	2.30	2.34	2.78	2.46	3.63	2.57	3.04	3.08
	STD	6.11	2.42	3.22	4.35	1.55	1.56	2.26	1.78	5.23	2.10	2.94	3.69
	Median	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.50	2.00	2.00	2.00
	Min	1	1	1	1	1	1	1	1	1	1	1	1
	Max	40	11	20	40	6	7	10	10	40	11	20	40

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 11

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS BY SEX AND ASSIGNED TREATMENT

		Sex											
		Female				Male				Total			
		Imipramine	Placebo	Reboxetine	Total	Imipramine	Placebo	Reboxetine	Total	Imipramine	Placebo	Reboxetine	Total
Duration of last episode (weeks)	No.	52	43	51	146	24	37	25	86	76	80	76	232
	Mean	17.96	17.09	12.94	15.95	14.17	30.00	13.96	20.92	16.76	23.06	13.28	17.79
	STD	22.26	12.44	7.37	15.58	20.05	62.39	10.51	43.03	21.52	43.56	8.47	28.97
	Median	12.00	12.00	12.00	12.00	10.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00
	Min	3	1	4	1	2	3	4	2	2	1	4	1
	Max	156	52	39	156	104	364	52	364	156	364	52	364
Duration of present episode (weeks)	No.	77	54	70	201	38	58	42	138	115	112	112	339
	Mean	8.01	8.21	8.84	8.35	8.28	9.06	8.71	8.74	8.10	8.65	8.79	8.51
	STD	3.93	3.77	3.89	3.87	3.74	4.30	3.65	3.94	3.86	4.05	3.78	3.90
	Median	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00
	Min	3	3	3	3	3	3	3	3	3	3	3	3
	Max	20	16	16	20	16	24	16	24	20	24	16	24

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 12

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS BY SEX AND ASSIGNED TREATMENT

All patients

		Imipramine		Placebo		Reboxetine		Total	
		No	%	No	%	No	%	No	%
Charact. of present episode	Exacerbation of chronic cond.	9	7.83	12	10.71	11	9.82	32	9.44
	Recurrence of similar prev. cond.	65	56.52	63	56.25	65	58.04	193	56.93
	Different from any prev. cond.	9	7.83	8	7.14	7	6.25	24	7.08
	First occurence	32	27.83	29	25.89	29	25.89	90	26.55
	Total	115	100.00	112	100.00	112	100.00	339	100.00
Onset of present episode	Acute (< 2 weeks)	16	13.91	9	8.04	16	14.29	41	12.09
	Subacute (>= 2 & < 12 weeks)	82	71.30	76	67.86	64	57.14	222	65.49
	Insidious (>= 3 months)	17	14.78	26	23.21	32	28.57	75	22.12
	Unknown			1	0.89			1	0.29
	Total	115	100.00	112	100.00	112	100.00	339	100.00
Precipit. external stress	Absent	47	40.87	44	39.29	44	39.29	135	39.82
	Probably present	48	41.74	54	48.21	47	41.96	149	43.95
	Definitely present	19	16.52	14	12.50	21	18.75	54	15.93
	Unknown	1	0.87					1	0.29
	Total	115	100.00	112	100.00	112	100.00	339	100.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 12

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS BY SEX AND ASSIGNED TREATMENT

Sex: Female

		Imipramine		Placebo		Reboxetine		Total	
		No	%	No	%	No	%	No	%
Charact. of present episode	Exacerbation of chronic cond.	6	7.79	6	11.11	5	7.14	17	8.46
	Recurrence of similar prev. cond.	45	58.44	35	64.81	45	64.29	125	62.19
	Different from any prev. cond.	7	9.09	4	7.41	5	7.14	16	7.96
	First occurence	19	24.68	9	16.67	15	21.43	43	21.39
	Total	77	100.00	54	100.00	70	100.00	201	100.00
Onset of present episode	Acute (< 2 weeks)	11	14.29	4	7.41	10	14.29	25	12.44
	Subacute (>= 2 & < 12 weeks)	56	72.73	38	70.37	42	60.00	136	67.66
	Insidious (>= 3 months)	10	12.99	11	20.37	18	25.71	39	19.40
	Unknown			1	1.85			1	0.50
	Total	77	100.00	54	100.00	70	100.00	201	100.00
Precipit. external stress	Absent	32	41.56	23	42.59	28	40.00	83	41.29
	Probably present	33	42.86	24	44.44	30	42.86	87	43.28
	Definitely present	12	15.58	7	12.96	12	17.14	31	15.42
	Total	77	100.00	54	100.00	70	100.00	201	100.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 12

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS BY SEX AND ASSIGNED TREATMENT

Sex: Male

		Imipramine		Placebo		Reboxetine		Total	
		No	%	No	%	No	%	No	%
Charact. of present episode	Exacerbation of chronic cond.	3	7.89	6	10.34	6	14.29	15	10.87
	Recurrence of similar prev. cond.	20	52.63	28	48.28	20	47.62	68	49.28
	Different from any prev. cond.	2	5.26	4	6.90	2	4.76	8	5.80
	First occurence	13	34.21	20	34.48	14	33.33	47	34.06
	Total	38	100.00	58	100.00	42	100.00	138	100.00
Onset of present episode	Acute (< 2 weeks)	5	13.16	5	8.62	6	14.29	16	11.59
	Subacute (>= 2 & < 12 weeks)	26	68.42	38	65.52	22	52.38	86	62.32
	Insidious (>= 3 months)	7	18.42	15	25.86	14	33.33	36	26.09
	Total	38	100.00	58	100.00	42	100.00	138	100.00
Precipit. external stress	Absent	15	39.47	21	36.21	16	38.10	52	37.68
	Probably present	15	39.47	30	51.72	17	40.48	62	44.93
	Definitely present	7	18.42	7	12.07	9	21.43	23	16.67
	Unknown	1	2.63					1	0.72
	Total	38	100.00	58	100.00	42	100.00	138	100.00

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 12.1

MINI MENTAL STATE - TOTAL SCORE

	Imipramine	Placebo	Reboxetine
No.	115	112	112
Mean	27.90	28.06	27.91
STD	2.12	2.09	1.98
Median	28.00	29.00	28.00
Min	20	20	20
Max	30	30	30

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 13

PREVIOUS ANTIDEPRESSIVE TREATMENT BY ACTIVE PRINCIPLE

	Assigned treatment						Total	
	Placebo		Imipramine		Reboxetine			
	No	%	No	%	No	%	No	%
Screened patient	112	100.0	115	100.0	112	100.0	339	100.0
CLOMIPRAMINE	13	11.6	11	9.6	14	12.5	38	11.2
FLUOXETINE	9	8.0	11	9.6	12	10.7	32	9.4
AMITRIPTYLINE	7	6.3	3	2.6	11	9.8	21	6.2
DOSULEPIN	10	8.9	1	0.9	5	4.5	16	4.7
TRIMIPRAMINE	6	5.4	5	4.3	3	2.7	14	4.1
FLUVOXAMINE	4	3.6	4	3.5	5	4.5	13	3.8
MIANSERIN	6	5.4	4	3.5	2	1.8	12	3.5
LITHIUM	3	2.7	3	2.6	2	1.8	8	2.4
IMIPRAMINE	4	3.6	3	2.6	1	0.9	8	2.4
DOXEPIN	3	2.7	2	1.7	3	2.7	8	2.4
TIANEPTINE	2	1.8	4	3.5	2	1.8	8	2.4
MAPROTILINE	1	0.9	3	2.6	2	1.8	6	1.8
LOFEPRAMINE	1	0.9	2	1.7	2	1.8	5	1.5
TRANYLCYPROMINE	2	1.8	2	1.7	1	0.9	5	1.5
VILOXAZINE	2	1.8	1	0.9	2	1.8	5	1.5
VENLAFAXINE	1	0.9	2	1.7	1	0.9	4	1.2
NORTRIPTYLINE			2	1.7	1	0.9	3	0.9
AMINEPTINE	1	0.9			2	1.8	3	0.9
DESIPRAMINE	2	1.8	1	0.9			3	0.9
MEDIFOXAMINE	1	0.9			2	1.8	3	0.9
TRAZODONE	1	0.9	1	0.9			2	0.6
MOCLOBEMIDE			2	1.7			2	0.6

(CONTINUED)

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 13

PREVIOUS ANTIDEPRESSIVE TREATMENT BY ACTIVE PRINCIPLE

	Assigned treatment						Total	
	Placebo		Imipramine		Reboxetine			
	No	%	No	%	No	%	No	%
DIBENZEPIN	1	0.9	1	0.9			2	0.6
PHENELZINE	1	0.9					1	0.3
PAROXETINE	1	0.9					1	0.3
AMOXAPINE			1	0.9			1	0.3
TOLOXATONE			1	0.9			1	0.3
METAPRAMINE			1	0.9			1	0.3
QUINUPRAMINE			1	0.9			1	0.3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 14

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY SEX AND ASSIGNED TREATMENT

Previous diseases	Female								Male								Total							
	Imipramine		Reboxetine		Placebo		Total		Imipramine		Reboxetine		Placebo		Total		Imipramine		Reboxetine		Placebo		Total	
	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.
Screened patients	77	100	70	100	54	100	201	100	38	100	42	100	58	100	138	100	115	100	112	100	112	100	339	100
HYPERTENSION NOS	4	5.2	3	4.3	3	5.6	10	5.0	1	2.6	2	4.8	1	1.7	4	2.9	5	4.3	5	4.5	4	3.6	14	4.1
URIN TRACT INFECTION NOS	2	2.6	4	5.7			6	3.0					1	1.7	1	0.7	2	1.7	4	3.6	1	0.9	7	2.1
DIABETES MELLITUS UNCOMP	2	2.6					2	1.0			3	7.1			3	2.2	2	1.7	3	2.7			5	1.5
MALIGN NEOPL BREAST NOS	2	2.6	1	1.4			3	1.5									2	1.7	1	0.9			3	0.9
OTHER GU NEOPLASM NOS	2	2.6	1	1.4	2	3.7	5	2.5									2	1.7	1	0.9	2	1.8	5	1.5
GOITER NOS	2	2.6					2	1.0	1	2.6					1	0.7	3	2.6					3	0.9
OBESITY	2	2.6	1	1.4	1	1.9	4	2.0			1	2.4	1	1.7	2	1.4	2	1.7	2	1.8	2	1.8	6	1.8
PNEUMONIA, ORGANISM NOS	2	2.6					2	1.0					1	1.7	1	0.7	2	1.7			1	0.9	3	0.9
APPENDICITIS NOS	2	2.6					2	1.0									2	1.7					2	0.6
HEADACHE	2	2.6					2	1.0									2	1.7					2	0.6
TACHYCARDIA NOS	2	2.6					2	1.0									2	1.7					2	0.6
ASTHMA NOS					2	3.7	2	1.0													2	1.8	2	0.6
ALCOHOL DEPENDENCE SYNDR	1	1.3	2	2.9			3	1.5	2	5.3					2	1.4	3	2.6	2	1.8			5	1.5
CIRCULATORY DISEASE NOS			2	2.9	1	1.9	3	1.5	1	2.6					1	0.7	1	0.9	2	1.8	1	0.9	4	1.2
PURE HYPERCHOLESTEROLEM	1	1.3			1	1.9	2	1.0	1	2.6			2	3.4	3	2.2	2	1.7			3	2.7	5	1.5
DIARRHEA OF INFECT ORIG	1	1.3					1	0.5									1	0.9					1	0.3
PULMONARY TB NOS	1	1.3					1	0.5									1	0.9					1	0.3
THYROTOXICOSIS NOS	1	1.3					1	0.5									1	0.9					1	0.3
HYPOTHYROIDISM NOS	1	1.3	1	1.4			2	1.0									1	0.9	1	0.9			2	0.6
HYPERLIPIDEMIA NEC/NOS	1	1.3	1	1.4			2	1.0	1	2.6			1	1.7	2	1.4	2	1.7	1	0.9	1	0.9	4	1.2
HYPOPOTASSEMIA	1	1.3					1	0.5									1	0.9					1	0.3

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 14

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY SEX AND ASSIGNED TREATMENT

Previous diseases	Female								Male								Total							
	Imipramine		Reboxetine		Placebo		Total		Imipramine		Reboxetine		Placebo		Total		Imipramine		Reboxetine		Placebo		Total	
	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.
CHR ISCHEMIC HRT DIS NEC	1	1.3					1	0.5									1	0.9					1	0.3
PREMATURE BEATS	1	1.3					1	0.5									1	0.9					1	0.3
CARDIAC DYSRHYTHMIAS NEC	1	1.3					1	0.5									1	0.9					1	0.3
THROMBOPHLEBITIS LEG NOS	1	1.3					1	0.5									1	0.9					1	0.3
HYPOTENSION NOS	1	1.3			1	1.9	2	1.0									1	0.9			1	0.9	2	0.6
FLU W RESP MANIFEST NEC	1	1.3					1	0.5									1	0.9					1	0.3
BRONCHITIS NOS	1	1.3					1	0.5									1	0.9					1	0.3
DUODENAL ULCER NOS	1	1.3					1	0.5					1	1.7	1	0.7	1	0.9			1	0.9	2	0.6
PEPTIC ULCER NOS	1	1.3					1	0.5									1	0.9					1	0.3
GASTRITIS/DUODENITIS NOS	1	1.3	1	1.4			2	1.0									1	0.9	1	0.9			2	0.6
ACUTE APPENDICITIS NOS	1	1.3			1	1.9	2	1.0									1	0.9			1	0.9	2	0.6
ALCOHOL LIVER DAMAGE NOS	1	1.3					1	0.5									1	0.9					1	0.3
CALCULUS OF KIDNEY	1	1.3					1	0.5									1	0.9					1	0.3
INFERTILITY-TUBAL ORIGIN	1	1.3					1	0.5									1	0.9					1	0.3
CERVICAL SPONDYLOSIS	1	1.3					1	0.5									1	0.9					1	0.3
PANNICULITIS OF NECK	1	1.3					1	0.5									1	0.9					1	0.3
BACKACHE NOS	1	1.3					1	0.5			1	2.4			1	0.7	1	0.9	1	0.9			2	0.6
CONGENITAL ANOMALIES NEC	1	1.3					1	0.5									1	0.9					1	0.3
PALPITATIONS	1	1.3					1	0.5									1	0.9					1	0.3
FX TARSL/METATARS NEC-CL	1	1.3					1	0.5									1	0.9					1	0.3
FRACTURE NOS	1	1.3					1	0.5									1	0.9					1	0.3
ALLERGY, UNSPECIFIED	1	1.3					1	0.5									1	0.9					1	0.3

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 14

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY SEX AND ASSIGNED TREATMENT

Previous diseases	Female								Male								Total							
	Imipramine		Reboxetine		Placebo		Total		Imipramine		Reboxetine		Placebo		Total		Imipramine		Reboxetine		Placebo		Total	
	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.
HEPATITIS A W/O COMA					1	1.9	1	0.5													1	0.9	1	0.3
BENIGN NEOPLASM SKIN NOS					1	1.9	1	0.5													1	0.9	1	0.3
BENIGN NEOPLASM BREAST					1	1.9	1	0.5													1	0.9	1	0.3
BENIGN NEO UTERUS NOS					1	1.9	1	0.5													1	0.9	1	0.3
EMOTIONAL DIS CHILD NOS					1	1.9	1	0.5													1	0.9	1	0.3
MIGRAINE NOS					1	1.9	1	0.5													1	0.9	1	0.3
VARICOSE VEIN OF LEG NOS					1	1.9	1	0.5					1	1.7	1	0.7					2	1.8	2	0.6
DIAPHRAGMATIC HERNIA					1	1.9	1	0.5													1	0.9	1	0.3
HEPATITIS NOS					1	1.9	1	0.5													1	0.9	1	0.3
CHOLELITH W CHOLECYS NEC					1	1.9	1	0.5													1	0.9	1	0.3
INTEST MALABSORPTION NEC					1	1.9	1	0.5													1	0.9	1	0.3
CERVICITIS					1	1.9	1	0.5													1	0.9	1	0.3
METRORRHAGIA					1	1.9	1	0.5													1	0.9	1	0.3
PARAPSORIASIS					1	1.9	1	0.5													1	0.9	1	0.3
SPONDYLOSIS NOS					1	1.9	1	0.5	1	2.6					1	0.7	1	0.9			1	0.9	2	0.6
CERVICALGIA					1	1.9	1	0.5													1	0.9	1	0.3
SCIATICA					1	1.9	1	0.5													1	0.9	1	0.3
OSTEITIS DEFORMANS NOS					1	1.9	1	0.5													1	0.9	1	0.3
OSTEOPOROSIS			1	1.4	1	1.9	2	1.0											1	0.9	1	0.9	2	0.6
BONE/CARTIL DIS NEC/NOS			1	1.4	1	1.9	2	1.0											1	0.9	1	0.9	2	0.6
FLAT FOOT					1	1.9	1	0.5													1	0.9	1	0.3
OTHER SKIN ANOMALIES					1	1.9	1	0.5													1	0.9	1	0.3

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 14

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY SEX AND ASSIGNED TREATMENT

Previous diseases	Female								Male								Total							
	Imipramine		Reboxetine		Placebo		Total		Imipramine		Reboxetine		Placebo		Total		Imipramine		Reboxetine		Placebo		Total	
	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.
ABN LIVER FUNCTION STUDY					1	1.9	1	0.5					1	1.7	1	0.7					2	1.8	2	0.6
BRAIN INJURY NEC					1	1.9	1	0.5													1	0.9	1	0.3
SPINAL CORD INJURY NOS					1	1.9	1	0.5													1	0.9	1	0.3
TRUNK INJURY NOS					1	1.9	1	0.5													1	0.9	1	0.3
SARCOIDOSIS			1	1.4			1	0.5											1	0.9			1	0.3
DIS IRON METABOLISM			1	1.4			1	0.5											1	0.9			1	0.3
ANEMIA NOS			1	1.4			1	0.5											1	0.9			1	0.3
STAMMERING STUTTERING			1	1.4			1	0.5											1	0.9			1	0.3
ANOREXIA NERVOSA			1	1.4			1	0.5											1	0.9			1	0.3
HEARING LOSS NOS			1	1.4			1	0.5											1	0.9			1	0.3
ALLERGIC RHINITIS NOS			1	1.4			1	0.5											1	0.9			1	0.3
DIVERTICULA OF COLON			1	1.4			1	0.5											1	0.9			1	0.3
PREMENSTRUAL TENSION			1	1.4			1	0.5											1	0.9			1	0.3
UNSPECIFIED ABORTION			1	1.4			1	0.5											1	0.9			1	0.3
PRURITIC DISORDER NOS			1	1.4			1	0.5											1	0.9			1	0.3
DISC DISPLACEMENT NOS			1	1.4			1	0.5	1	2.6					1	0.7	1	0.9	1	0.9			2	0.6
MYALGIA AND MYOSITIS NOS			1	1.4			1	0.5											1	0.9			1	0.3
PAIN IN LIMB			1	1.4			1	0.5											1	0.9			1	0.3
CHONDRODYSTROPHY			1	1.4			1	0.5											1	0.9			1	0.3
ABN URINE FINDINGS NEC			1	1.4			1	0.5											1	0.9			1	0.3
FX BIMALLEOLAR-CLOSED			1	1.4			1	0.5											1	0.9			1	0.3
DIGESTIVE NEOPLASM NOS									1	2.6					1	0.7	1	0.9					1	0.3

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 14

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY SEX AND ASSIGNED TREATMENT

Previous diseases	Female								Male								Total							
	Imipramine		Reboxetine		Placebo		Total		Imipramine		Reboxetine		Placebo		Total		Imipramine		Reboxetine		Placebo		Total	
	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.
PURE HYPERGLYCERIDEMIA									1	2.6					1	0.7	1	0.9					1	0.3
AC INFECT POLYNEURITIS									1	2.6					1	0.7	1	0.9					1	0.3
AC PERICARDITIS NEC/NOS									1	2.6					1	0.7	1	0.9					1	0.3
STOMACH ULCER NOS									1	2.6	1	2.4			2	1.4	1	0.9	1	0.9			2	0.6
INGUIN HERNIA W OBSTRUCT									1	2.6					1	0.7	1	0.9					1	0.3
OTHER PSORIASIS									1	2.6					1	0.7	1	0.9					1	0.3
ARTHROPATHY NOS									1	2.6					1	0.7	1	0.9					1	0.3
VERTEBRAL FX NOS-CLOSED									1	2.6					1	0.7	1	0.9					1	0.3
LOWER LEG INJURY NOS									1	2.6					1	0.7	1	0.9					1	0.3
ACUTE POLIOMYELITIS NOS											1	2.4	1	1.7	2	1.4			1	0.9	1	0.9	2	0.6
ACUTE BRONCHITIS													1	1.7	1	0.7					1	0.9	1	0.3
OBSTRUCT CHR BRONCHITIS													1	1.7	1	0.7					1	0.9	1	0.3
PNEUMOTHORAX													1	1.7	1	0.7					1	0.9	1	0.3
ANKYLOSING SPONDYLITIS													1	1.7	1	0.7					1	0.9	1	0.3
THORAC/LUMB DISC DISPLAC													1	1.7	1	0.7					1	0.9	1	0.3
ABN BLOOD CHEMISTRY NEC													1	1.7	1	0.7					1	0.9	1	0.3
RETINAL DETACHMENT NOS											1	2.4			1	0.7			1	0.9			1	0.3
SENILE CATARACT											1	2.4			1	0.7			1	0.9			1	0.3
ATRIAL FIBRILL/FLUTTER											1	2.4			1	0.7			1	0.9			1	0.3
ARTERITIS NOS											1	2.4			1	0.7			1	0.9			1	0.3
HEMORRHOIDS NOS											1	2.4			1	0.7			1	0.9			1	0.3
CHRONIC LIVER DIS NEC											1	2.4			1	0.7			1	0.9			1	0.3

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/045
TABLE No.: 14

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY SEX AND ASSIGNED TREATMENT

Previous diseases	Female								Male								Total							
	Imipramine		Reboxetine		Placebo		Total		Imipramine		Reboxetine		Placebo		Total		Imipramine		Reboxetine		Placebo		Total	
	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.
CERVICOBRACHIAL SYNDROME											1	2.4			1	0.7			1	0.9			1	0.3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 15

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY BODY SYSTEM, SEX AND ASSIGNED TREATMENT

Previous diseases (body system)	Female								Male								Total							
	Imipramine		Reboxetine		Placebo		Total		Imipramine		Reboxetine		Placebo		Total		Imipramine		Reboxetine		Placebo		Total	
	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.
Screened Patients	77	100	70	100	54	100	201	100	38	100	42	100	58	100	138	100	115	100	112	100	112	100	339	100
CIRCULATORY SYSTEM	7	9.1	5	7.1	5	9.3	17	8.5	3	7.9	5	11.9	2	3.4	10	7.2	10	8.7	10	8.9	7	6.3	27	8.0
GENITOURINARY SYSTEM	4	5.2	5	7.1	2	3.7	11	5.5					1	1.7	1	0.7	4	3.5	5	4.5	3	2.7	12	3.5
ENDOCR., NUTRIT. AND METAB. DISEASES	9	11.7	4	5.7	2	3.7	15	7.5	4	10.5	4	9.5	4	6.9	12	8.7	13	11.3	8	7.1	6	5.4	27	8.0
NEOPLASM	3	3.9	1	1.4	5	9.3	9	4.5	1	2.6					1	0.7	4	3.5	1	0.9	5	4.5	10	2.9
RESPIRATORY SYSTEM	3	3.9	1	1.4	2	3.7	6	3.0					3	5.2	3	2.2	3	2.6	1	0.9	5	4.5	9	2.7
DIGESTIVE SYSTEM	5	6.5	2	2.9	5	9.3	12	6.0	2	5.3	2	4.8	1	1.7	5	3.6	7	6.1	4	3.6	6	5.4	17	5.0
SYMPTOMS, SIGNS AND ILL DEFINED CONDITIONS	4	5.2	1	1.4	1	1.9	6	3.0					2	3.4	2	1.4	4	3.5	1	0.9	3	2.7	8	2.4
MENTAL DISORDERS	1	1.3	3	4.3	1	1.9	5	2.5	2	5.3					2	1.4	3	2.6	3	2.7	1	0.9	7	2.1
INFECTIOUS AND PARASTITIC DISEASE	2	2.6	1	1.4	1	1.9	4	2.0			1	2.4	1	1.7	2	1.4	2	1.7	2	1.8	2	1.8	6	1.8
MUSCOLOSKELETAL SYS. AND CONNETIVE TISSUE	3	3.9	4	5.7	6	11.1	13	6.5	3	7.9	2	4.8	2	3.4	7	5.1	6	5.2	6	5.4	8	7.1	20	5.9
CONGENITAL ANOMALIES	1	1.3	1	1.4	1	1.9	3	1.5									1	0.9	1	0.9	1	0.9	3	0.9
INJURY AND POISONING	3	3.9	1	1.4	3	5.6	7	3.5	2	5.3					2	1.4	5	4.3	1	0.9	3	2.7	9	2.7
NERVOUS SYSTEM AND SENSE ORGANS			1	1.4	1	1.9	2	1.0	1	2.6	1	2.4			2	1.4	1	0.9	2	1.8	1	0.9	4	1.2
SKIN AND SUBCUTANEOUS TISSUE			1	1.4	1	1.9	2	1.0	1	2.6					1	0.7	1	0.9	1	0.9	1	0.9	3	0.9
BLOOD AND BLOOD-FORMING ORGANS			1	1.4			1	0.5											1	0.9			1	0.3
PREGNANCY,CHILDBIRTH AND PUERPERIUM			1	1.4			1	0.5											1	0.9			1	0.3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 16

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

days of treatment		Dose (mg/day)												Total	
		0		4		8		10		12		18			
		No	%	No	%	No	%	No	%	No	%	No	%	No	%
Day 0	1			20	17.9	92	82.1							112	100
	2					112	100							112	100
	3			2	1.8	109	98.2							111	100
	4	1	0.9	1	0.9	108	98.2							110	100
	5					108	100							108	100
	6					107	100							107	100
	7			2	2.0	98	98.0							100	100
	8					1	100							1	100
Day 7	1					105	99.1			1	0.9			106	100
	2					106	100							106	100
	3					106	100							106	100
	4			2	1.9	103	97.2			1	0.9			106	100
	5	1	0.9			104	98.1			1	0.9			106	100
	6	1	1.0	2	1.9	101	97.1							104	100
	7	1	1.0	1	1.0	97	98.0							99	100
	8			2	50.0	2	50.0							4	100
Day 14	1			2	2.0	98	98.0							100	100
	2			1	1.0	99	99.0							100	100
	3			1	1.0	99	99.0							100	100
	4			1	1.0	99	99.0							100	100
	5			1	1.0	99	99.0							100	100
	6					99	100							99	100
	7					96	100							96	100
	8			2	25.0	6	75.0							8	100
	9					1	100							1	100
Day 21	1					77	79.4	18	18.6			2	2.1	97	100
	2					77	79.4	18	18.6			2	2.1	97	100
	3			3	3.1	74	76.3	18	18.6			2	2.1	97	100
	4			2	2.1	76	78.4	17	17.5			2	2.1	97	100
	5			1	1.0	74	77.1	19	19.8			2	2.1	96	100
	6					74	78.7	18	19.1			2	2.1	94	100
	7			2	2.2	71	77.2	17	18.5			2	2.2	92	100
	8	1	14.3	1	14.3	5	71.4							7	100
	9					1	100							1	100
Day 28	1	1	1.1			67	72.8	21	22.8			3	3.3	92	100
	2	1	1.1			67	72.8	21	22.8			3	3.3	92	100
	3	1	1.1	1	1.1	66	71.7	22	23.9			2	2.2	92	100
	4	2	2.2			66	71.7	22	23.9			2	2.2	92	100
	5	1	1.1			67	72.8	22	23.9			2	2.2	92	100
	6	1	1.1	1	1.1	66	72.5	21	23.1			2	2.2	91	100
	7	1	1.1	1	1.1	64	72.7	20	22.7			2	2.3	88	100
	8			1	50.0			1	50.0					2	100
Day 35	1			1	1.1	64	71.9	22	24.7			2	2.2	89	100
	2					64	71.9	23	25.8			2	2.2	89	100
	3					64	71.9	23	25.8			2	2.2	89	100
	4			1	1.1	64	71.9	22	24.7			2	2.2	89	100
	5			1	1.1	64	71.9	22	24.7			2	2.2	89	100
	6			1	1.1	64	72.7	21	23.9			2	2.3	88	100
	7			3	3.5	60	69.8	21	24.4			2	2.3	86	100
	8			11	64.7	4	23.5	2	11.8					17	100
	9			2	66.7	1	33.3							3	100

PHARMACIA CNS R&D 550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 16

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

days of treatment		Dose (mg/day)														Total	
		0		50		100		150		200		300		350			
		No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Day 0	1	3	2.6	17	14.8	95	82.6									115	100
	2	3	2.6	1	0.9	111	96.5									115	100
	3	2	1.8			111	97.4			1	0.9					114	100
	4	3	2.7					109	96.5			1	0.9			113	100
	5	3	2.7					109	97.3							112	100
	6	4	3.6	1	0.9			107	95.5							112	100
	7	3	2.9	4	3.9	2	1.9	94	91.3							103	100
	8	2	15.4	4	30.8			7	53.8							13	100
	9	1	100													1	100
Day 7	1	2	2.0	1	1.0			99	97.1							102	100
	2	2	2.0					99	98.0							101	100
	3	2	2.0	2	2.0			96	96.0							100	100
	4	2	2.1	2	2.1			93	95.9							97	100
	5	1	1.0	1	1.0			95	97.9							97	100
	6	1	1.0	1	1.0	1	1.0	94	96.9							97	100
	7	1	1.1	1	1.1			91	97.8							93	100
	8	1	14.3	1	14.3			5	71.4							7	100
Day 14	1	2	2.1	1	1.1			92	96.8							95	100
	2	2	2.1	2	2.1			91	95.8							95	100
	3	2	2.1	1	1.1	1	1.1	91	95.8							95	100
	4	1	1.1	1	1.1			92	97.9							94	100
	5	1	1.1	3	3.2			90	95.7							94	100
	6	1	1.1	2	2.2			90	96.8							93	100
	7	1	1.1	2	2.3			85	96.6							88	100
	8							4	100							4	100
	9	1	100													1	100
Day 21	1			1	1.1	3	3.4	71	80.7	11	12.5			2	2.3	88	100
	2					3	3.4	68	77.3	15	17.0			2	2.3	88	100
	3			2	2.3	1	1.1	67	77.0	15	17.2			2	2.3	87	100
	4					1	1.2	68	79.1	15	17.4			2	2.3	86	100
	5			1	1.2	1	1.2	66	77.6	15	17.6			2	2.4	85	100
	6			1	1.2	2	2.4	66	77.6	14	16.5			2	2.4	85	100
	7			3	3.8	2	2.5	60	75.0	13	16.2			2	2.5	80	100
	8	1	20.0	1	20.0			1	20.0	2	40.0					5	100
Day 28	1			1	1.2			68	80.0	14	16.5			2	2.4	85	100
	2			1	1.2			66	77.6	16	18.8			2	2.4	85	100
	3	1	1.2	1	1.2			65	76.5	16	18.8			2	2.4	85	100
	4			1	1.2	1	1.2	64	76.2	16	19.0			2	2.4	84	100
	5			2	2.4			64	76.2	16	19.0			2	2.4	84	100
	6			2	2.4			64	76.2	16	19.0			2	2.4	84	100
	7			2	2.4	1	1.2	64	76.2	15	17.9			2	2.4	84	100
	8	1	11.1			1	11.1	4	44.4	3	33.3					9	100
	9							1	100							1	100
Day 35	1			2	2.5			60	75.0	16	20.0			2	2.5	80	100
	2			1	1.2			61	76.3	16	20.0			2	2.5	80	100
	3			1	1.2			61	76.3	16	20.0			2	2.5	80	100
	4			2	2.5	1	1.2	60	75.0	15	18.8			2	2.5	80	100
	5			1	1.3			59	75.6	16	20.5			2	2.6	78	100
	6			1	1.3			59	75.6	16	20.5			2	2.6	78	100
	7			3	4.0	1	1.3	55	73.3	14	18.7			2	2.7	75	100
	8			5	38.5	2	15.4	6	46.2							13	100
	9			2	100											2	100

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 16
EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO CAPSULES TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY ASSIGNED TREATMENT

Assigned treatment: Placebo

days of treatment		Daily caps										Total	
		0		1		2		3		4			
		No	%	No	%	No	%	No	%	No	%	No	%
Day 0	1	1	0.9	22	19.6	89	79.5					112	100
	2			1	0.9	109	99.1					110	100
	3					109	100					109	100
	4			1	0.9	108	99.1					109	100
	5			1	0.9	107	99.1					108	100
	6					107	99.1			1	0.9	108	100
	7			1	1.0	100	98.0	1	1.0			102	100
	8			1	12.5	7	87.5					8	100
Day 7	1	1	0.9	1	0.9	103	97.2	1	0.9			106	100
	2			1	0.9	105	99.1					106	100
	3			1	1.0	104	99.0					105	100
	4					104	100					104	100
	5					103	100					103	100
	6					102	100					102	100
	7			2	2.0	97	98.0					99	100
	8					9	100					9	100
Day 14	1	1	1.0	1	1.0	98	98.0					100	100
	2	1	1.0	1	1.0	98	98.0					100	100
	3	1	1.0	1	1.0	98	98.0					100	100
	4	1	1.0	2	2.0	97	97.0					100	100
	5	1	1.0	3	3.0	96	96.0					100	100
	6	1	1.0	2	2.0	96	97.0					99	100
	7			5	5.2	91	94.8					96	100
	8			2	40.0	3	60.0					5	100
	9			1	100							1	100
Day 21	1			2	2.1	91	94.8			3	3.1	96	100
	2					92	96.8			3	3.2	95	100
	3					92	96.8			3	3.2	95	100
	4					91	96.8			3	3.2	94	100
	5			1	1.1	90	95.7			3	3.2	94	100
	6					90	96.8			3	3.2	93	100
	7			2	2.2	86	94.5			3	3.3	91	100
	8			1	25.0	3	75.0					4	100
	9			2	100							2	100
Day 28	1			1	1.1	85	96.6			2	2.3	88	100
	2					86	97.7			2	2.3	88	100
	3			1	1.1	85	96.6			2	2.3	88	100
	4					86	97.7			2	2.3	88	100
	5			1	1.1	85	96.6			2	2.3	88	100
	6					86	97.7			2	2.3	88	100
	7					83	97.6			2	2.4	85	100
	8			1	16.7	5	83.3					6	100
Day 35	1					85	97.7			2	2.3	87	100
	2	1	1.1			84	96.6			2	2.3	87	100
	3					85	97.7			2	2.3	87	100
	4					85	97.7			2	2.3	87	100
	5					84	97.7			2	2.3	86	100
	6			1	1.2	83	96.5			2	2.3	86	100
	7			4	4.7	79	92.9			2	2.4	85	100
	8			13	61.9	8	38.1					21	100
	9			2	100							2	100

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 16.1

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS WHO SWITCHED FROM LOW TO HIGH DOSE BY ASSIGNED TREATMENT

		Total		visit of first change in dose			
		No	%	Day 0	Day 21	Day 28	Day 35
Imipramine	always low dose	93	80.87	93			
	at least one high dose	22	19.13	1	18	2	1
	Total	115	100.00	94	18	2	1
Placebo	always low dose	67	60.36	67			
	at least one high dose	44	39.64		39	4	1
	Total	111	100.00	67	39	4	1
Reboxetine	always low dose	86	76.79	86			
	at least one high dose	26	23.21		21	4	1
	Total	112	100.00	86	21	4	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015

TABLE No.: 17

EXPERIMENTAL TREATMENT: DISTRIBUTION OF PATIENTS ACCORDING TO CAPSULES TAKEN BY ASSIGNED TREATMENT

	Compliance										Total	
	< 80 %		80 - 89 %		90 - 95 %		95 - 99 %		100 %			
	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	3	2.6	2	1.7	15	13.0	14	12.2	81	70.4	115	100.0
Placebo	2	1.8	1	0.9	7	6.3	18	16.1	84	75.0	112	100.0
Reboxetine			5	4.5	5	4.5	25	22.3	77	68.8	112	100.0
Total	5	1.5	8	2.4	27	8.0	57	16.8	242	71.4	339	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 18

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
BY ASSIGNED TREATMENT AND INITIAL PERIOD OF ADMINISTRATION

Concomitant drugs	Before treatment			During treatment			Total		
	Imipramine	Placebo	Reboxetine	Imipramine	Placebo	Reboxetine	Imipramine	Placebo	Reboxetine
	No.	No.	No.	No.	No.	No.	No.	No.	No.
CHLORAL HYDRATE	20	20	18	10	9	8	30	29	26
TEMAZEPAM	2	3	3	3	4	5	5	7	8
PARACETAMOL	1			1	6	5	2	6	5
ACETYLSALICYLIC ACID	2			3	4		5	4	
LACTULOSE	1			3		1	4		1
HEPTAMINOL	1	1	1			2	1	1	3
MAALOX				3	1		3	1	
SENNA	1			1	1	1	2	1	1
AMOXICILLIN					2	2		2	2
EUGYNON		1		1		1	1	1	1
METOCLOPRAMIDE						3			3
ANETHOLE				1	1	1	1	1	1
THEOPHYLLINE		2						2	
DIAZEPAM					2			2	
DIHYDROERGOTAMINE				1		1	1		1
PROPRANOLOL	2						2		
POTASSIUM			1	1			1		1
ESTRADIOL	1	1					1	1	
IBUPROFEN	1		1				1		1
SALBUTAMOL	1					1	1		1
NAFTIDROFURYL		1	1					1	1
NIFEDIPINE		1				1		1	1

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 18

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
BY ASSIGNED TREATMENT AND INITIAL PERIOD OF ADMINISTRATION

Concomitant drugs	Before treatment			During treatment			Total		
	Imipramine	Placebo	Reboxetine	Imipramine	Placebo	Reboxetine	Imipramine	Placebo	Reboxetine
	No.	No.	No.	No.	No.	No.	No.	No.	No.
CALCITONIN		1	1					1	1
CAPTOPRIL		2						2	
RANITIDINE		1		1			1	1	
AUGMENTIN						2			2
ENALAPRIL	2						2		
METHYLDOPA	1						1		
ANOVLAR		1						1	
BENZYLPENICILLIN				1			1		
METRONIDAZOLE				1			1		
COLCHICINE					1			1	
DIGOXIN			1						1
DIMENHYDRINATE						1			1
ERYTHROMYCIN	1						1		
ETHINYLESTRADIOL			1						1
ISPAGHULA				1			1		
INSULIN	1						1		
FUROSEMIDE			1						1
MYLANTA				1			1		
LEVOMEPROMAZINE				1			1		
NORETHISTERONE	1						1		
IMMUNOGLOBULIN HUMAN ANTI-TETANUS				1			1		
SULFAMETHIZOLE						1			1

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 18

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
BY ASSIGNED TREATMENT AND INITIAL PERIOD OF ADMINISTRATION

Concomitant drugs	Before treatment			During treatment			Total		
	Imipramine	Placebo	Reboxetine	Imipramine	Placebo	Reboxetine	Imipramine	Placebo	Reboxetine
	No.	No.	No.	No.	No.	No.	No.	No.	No.
TETANUS TOXOID				1			1		
CHLORMEZANONE					1			1	
DOXYCYCLINE					1			1	
ALKA-SELTZER						1			1
HYDROXYZINE				1			1		
CALCIUM GLUCONATE		1						1	
CARBACHOL						1			1
DIETHYLSTILBESTROL	1						1		
DYDROGESTERONE		1						1	
LEVOTHYROXINE	1						1		
ESTROGENS CONJUGATED	1						1		
PSEUDOEPHEDRINE				1			1		
DYAZIDE			1						1
HISTAMINE						1			1
IODINE	1						1		
ACETYLCYSTEINE						1			1
ISOSORBIDE DINITRATE	1						1		
ETILEFRINE				1			1		
AGAROL	1						1		
MEDROXYPROGESTERONE	1						1		
MULTIVITAMINS		1						1	
TIEMONIUM				1			1		

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 18

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
BY ASSIGNED TREATMENT AND INITIAL PERIOD OF ADMINISTRATION

Concomitant drugs	Before treatment			During treatment			Total		
	Imipramine	Placebo	Reboxetine	Imipramine	Placebo	Reboxetine	Imipramine	Placebo	Reboxetine
	No.	No.	No.	No.	No.	No.	No.	No.	No.
ARGININE				1			1		
HYDROXYCARBAMIDE	1						1		
MEBEVERINE					1			1	
GLIBENCLAMIDE			1						1
TRIMETHOPRIM			1						1
DIMETICONE						1			1
NORGESTREL			1						1
PHENOBARBITAL SALT WITH QUINIDINE	1						1		
NEUROBION FOR INJECTION			1						1
FERROGRAD C				1			1		
CLOTRIMAZOLE	1						1		
BECLOMETASONE		1						1	
APOREX				1			1		
NIFLUMIC ACID						1			1
KAOLIN						1			1
GAVISCON		1						1	
FLUCLOXACILLIN				1			1		
FLURAZEPAM				1			1		
NAPROXEN					1			1	
CITROSAN						1			1
LORAZEPAM					1			1	
CLONAZEPAM				1			1		

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 18

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
BY ASSIGNED TREATMENT AND INITIAL PERIOD OF ADMINISTRATION

Concomitant drugs	Before treatment			During treatment			Total		
	Imipramine	Placebo	Reboxetine	Imipramine	Placebo	Reboxetine	Imipramine	Placebo	Reboxetine
	No.	No.	No.	No.	No.	No.	No.	No.	No.
MICROLAX						1			1
CALCIUM LACTATE		1						1	
KETOPROFEN				1			1		
LOPERAMIDE						1			1
URAL					1			1	
ACEBUTOLOL						1			1
HISTADESTAL			1						1
GLICLAZIDE	1						1		
ATENOLOL	1						1		
CEFUROXIME				1			1		
NIFUROXAZIDE						1			1
TRASITENSIN			1						1
SUGUAN			1						1
DILTIAZEM	1						1		
DOMPERIDONE						1			1
FENOFIBRATE	1						1		
NICARDIPINE	1						1		
NORFLOXACIN	1						1		
TRITOQUALINE			1						1
CAPOZIDE		1						1	
CYAMEMAZINE					1			1	
CIPROFIBRATE		1						1	

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 18

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
BY ASSIGNED TREATMENT AND INITIAL PERIOD OF ADMINISTRATION

Concomitant drugs	Before treatment			During treatment			Total		
	Imipramine	Placebo	Reboxetine	Imipramine	Placebo	Reboxetine	Imipramine	Placebo	Reboxetine
	No.	No.	No.	No.	No.	No.	No.	No.	No.
HEPTAMINOL ADENOSINE PHOSPHATE			1						1
QUINAPRIL			1						1
FUMARIA EXTRACT				1			1		
AGAR						1			1
DEXFENFLURAMINE						1			1
EUPHYTOSE						1			1
GELATIN						1			1
NU-LAX	1						1		
ETHINYL ESTRADIOL W/NORGESTREL			1						1
DEFIBROTIDE			1						1
AMLODIPINE			1						1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 19

HAMILTON DEPRESSION RATING SCALE: SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Mean	27.21	26.93	22.41	18.90	14.95	12.47	11.13	9.44
	Median	26	26	23	18	13	12	9	9
	STD	5.10	4.67	7.12	7.86	8.35	6.26	6.36	6.65
	Min	22	19	2	1	0	0	0	0
	Max	51	51	52	53	58	28	28	28
	Mean diff. vs day0 (*)			4.52	8.24	12.29	14.60	16.07	17.70
Placebo	No	111	111	111	103	100	93	87	87
	Mean	27.37	27.12	23.96	21.62	18.10	15.90	14.10	13.08
	Median	26	26	24	21	17	14	14	11
	STD	5.15	5.30	6.51	7.75	7.73	8.75	7.78	8.06
	Min	22	20	9	6	2	1	1	1
	Max	54	54	53	51	39	43	34	35
	Mean diff. vs day0 (*)			3.15	5.30	8.86	11.17	13.00	13.95
Reboxetine	No	110	110	110	105	98	97	90	89
	Mean	27.73	27.53	23.55	19.90	16.61	14.46	12.07	11.26
	Median	26	26	24	19	17	14	11	10
	STD	5.21	5.07	6.51	7.87	8.09	7.73	7.55	7.17
	Min	22	22	6	0	0	0	0	0
	Max	48	49	45	43	39	39	38	38
	Mean diff. vs day0 (*)			3.97	7.68	11.15	13.22	15.72	16.62

Mean (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 20

FACTORIALISATION HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: ANXIETY/SOMATIZATION

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	1.33	1.33	1.17	1.00	0.83	0.67	0.50	0.50
	Min	0.50	0.50	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.33	2.33	2.33	2.50	2.67	1.67	1.67	2.00
	Median diff. vs day0 (*)			0.17	0.33	0.50	0.67	0.67	0.83
Placebo	No	111	111	111	103	100	93	87	87
	Median	1.33	1.33	1.33	1.17	0.83	0.83	0.67	0.67
	Min	0.67	0.67	0.33	0.17	0.00	0.00	0.00	0.00
	Max	3.00	3.00	3.00	3.00	2.50	2.17	2.00	2.00
	Median diff. vs day0 (*)			0.00	0.17	0.42	0.50	0.67	0.67
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	1.33	1.33	1.17	1.00	0.83	0.67	0.67	0.50
	Min	0.83	0.67	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.83	2.83	2.33	2.33	1.83	1.67	1.83	1.83
	Median diff. vs day0 (*)			0.17	0.33	0.50	0.67	0.67	0.67

Median (*): median of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 20

FACTORIALISATION HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: COGNITIVE DISTURBANCE

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	0.83	0.83	0.67	0.33	0.33	0.33	0.17	0.17
	Min	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.83	2.83	3.00	2.50	3.00	1.33	1.17	1.17
	Median diff. vs day0 (*)			0.00	0.33	0.50	0.50	0.50	0.67
Placebo	No	111	111	111	103	100	93	87	87
	Median	0.83	0.67	0.67	0.50	0.50	0.33	0.33	0.33
	Min	0.17	0.17	0.17	0.00	0.00	0.00	0.00	0.00
	Max	3.00	3.00	2.83	2.83	2.00	2.00	1.50	1.50
	Median diff. vs day0 (*)			0.17	0.17	0.33	0.33	0.33	0.50
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	0.83	0.83	0.67	0.50	0.33	0.33	0.17	0.17
	Min	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.50	2.50	2.50	2.33	1.83	1.83	1.67	1.83
	Median diff. vs day0 (*)			0.00	0.17	0.33	0.50	0.50	0.50

Median (*): median of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 20

FACTORIALISATION HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: RETARDATION

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	2.00	2.00	1.75	1.50	1.25	1.00	1.00	0.50
	Min	1.00	1.00	0.00	0.25	0.00	0.00	0.00	0.00
	Max	3.25	3.25	3.00	3.25	3.25	2.50	2.00	2.00
	Median diff. vs day0 (*)			0.25	0.50	0.75	1.00	1.25	1.25
Placebo	No	111	111	111	103	100	93	87	87
	Median	2.00	2.00	1.75	1.75	1.50	1.25	1.25	1.00
	Min	1.25	1.25	0.50	0.50	0.00	0.00	0.00	0.00
	Max	3.00	3.25	3.25	3.25	3.25	3.25	2.75	2.75
	Median diff. vs day0 (*)			0.00	0.25	0.50	0.75	0.75	1.00
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	2.25	2.13	2.00	1.50	1.25	1.00	1.00	0.75
	Min	0.75	0.75	0.50	0.00	0.00	0.00	0.00	0.00
	Max	3.25	3.25	3.00	3.00	3.00	3.00	2.75	2.50
	Median diff. vs day0 (*)			0.25	0.50	0.75	1.00	1.25	1.25

Median (*): median of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 20

FACTORIALISATION HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: SLEEP DISTURBANCE

Assigned treatment		Visit							
		Screen	Day -0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	1.33	1.33	1.00	1.00	0.67	0.67	0.33	0.33
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median diff. vs day0 (*)			0.00	0.33	0.67	0.67	0.67	1.00
Placebo	No	111	111	111	103	100	93	87	87
	Median	1.33	1.33	1.00	1.00	0.67	0.67	0.67	0.33
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median diff. vs day0 (*)			0.00	0.33	0.67	0.67	0.67	0.67
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	1.33	1.33	1.33	1.00	1.00	0.67	0.67	0.67
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median diff. vs day0 (*)			0.00	0.33	0.33	0.67	0.67	1.00

Median (*): median of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: DEPRESSED MOOD

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	3	3	2	2	2	1	1	1
	Min	1	1	0	0	0	0	0	0
	Max	4	4	4	4	4	3	3	3
Placebo	No	111	111	111	103	100	93	87	87
	Median	3	3	3	2	2	1	2	1
	Min	1	1	0	0	0	0	0	0
	Max	4	4	4	4	4	4	4	4
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	3	3	2	2	2	1	1	1
	Min	1	1	1	0	0	0	0	0
	Max	4	4	4	4	4	4	4	4

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: GUILT

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	2	2	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	4	4	4	4	4	3	3	3
Placebo	No	111	111	111	103	100	93	87	87
	Median	2	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	4	4	3	3	3	3	3	3
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	2	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: SUICIDE

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	1	1	1	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	4	4	4	3	4	3	3	2
Placebo	No	111	111	111	103	100	93	87	87
	Median	1	1	1	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	4	3	3	3	4	4	3	3
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	1	1	1	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: INSOMNIA EARLY

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	2	2	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Placebo	No	111	111	111	103	100	93	87	87
	Median	2	2	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	2	2	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: INSOMNIA MIDDLE

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	1	1	1	1	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Placebo	No	111	111	111	103	100	93	87	87
	Median	1	1	1	1	1	1	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	1	1	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: INSOMNIA LATE

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	1	2	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Placebo	No	111	111	111	103	100	93	87	87
	Median	1	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	2	2	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: WORK AND ACTIVITIES

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	3	3	2	2	1	1	1	1
	Min	1	1	0	0	0	0	0	0
	Max	4	4	4	4	4	4	3	3
Placebo	No	111	111	111	103	100	93	87	87
	Median	3	3	2	2	2	2	1	1
	Min	1	1	1	0	0	0	0	0
	Max	4	4	4	4	4	4	4	4
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	3	3	2	2	2	1	1	1
	Min	0	1	0	0	0	0	0	0
	Max	4	4	4	4	4	4	3	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: RETARDATION

Assigned treatment		Visit								
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	2	2	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	3	2	2	2
Placebo	No	111	111	111	103	100	93	87	87
	Median	2	2	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3	3
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	2	2	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: AGITATION

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	1	1	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	4	4	4	3	4	2	2	2
Placebo	No	111	111	111	103	100	93	87	87
	Median	1	1	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	4	4	4	3	3	3	2	3
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	1	1	1	1	1	1	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	4	4	4	2	2

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: ANXIETY PSYCHIC

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	2	2	2	2	1	1	1	1
	Min	1	1	0	0	0	0	0	0
	Max	4	4	4	4	4	3	3	3
Placebo	No	111	111	111	103	100	93	87	87
	Median	2	2	2	2	2	1	1	1
	Min	1	1	0	0	0	0	0	0
	Max	4	4	4	4	4	4	3	3
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	2	2	2	2	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	4	4	4	4	4	4	3	3

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: ANXIETY SOMATIC

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	2	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	3	4	4	4	4	2	3	2
Placebo	No	111	111	111	103	100	93	87	87
	Median	2	2	2	2	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	4	4	4	4	3	3	3	3
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	2	2	2	1	1	1	1	1
	Min	0	1	0	0	0	0	0	0
	Max	4	4	4	4	4	3	3	2

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: SOMATIC GASTROINTESTINAL

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	1	1	1	1	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Placebo	No	111	111	111	103	100	93	87	87
	Median	1	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	1	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: SOMATIC GENERAL

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	1	1	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Placebo	No	111	111	111	103	100	93	87	87
	Median	1	1	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	2	2	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: GENITAL SYMPTOMS

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	1	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Placebo	No	111	111	111	103	100	93	87	87
	Median	1	1	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	1	1	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: HYPOCHONDRIASIS

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	1	1	1	1	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	4	4	3	3	3	3	3	3
Placebo	No	111	111	111	103	100	93	87	87
	Median	1	1	1	1	1	1	0	0
	Min	0	0	0	0	0	0	0	0
	Max	4	4	4	4	3	3	3	3
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	1	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	4	4	3	3	3	3	3	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: LOSS OF WEIGHT

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	3	2	2	2
Placebo	No	111	111	111	103	100	93	87	87
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	3	2	2	2
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	2	1	1	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: INSIGHT

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Placebo	No	111	111	111	103	100	93	87	87
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015

TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:

SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: DIURNAL VARIATION

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	1	1	1	1	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Placebo	No	111	111	111	103	100	93	87	87
	Median	1	1	1	1	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	1	1	1	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: DEPERSONALIZATION

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	3	2	1	2
Placebo	No	111	111	111	103	100	93	87	87
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	4	4	4	4	3	3	2	2
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: PARANOID

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	2	1	1	1
Placebo	No	111	111	111	103	100	93	87	87
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	2	2	1	1
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: OBSESSIONAL/COMPULSIVE

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	111	101	93	87	82	79
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Placebo	No	111	111	111	103	100	93	87	87
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	110	110	110	105	98	97	90	89
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 22

HAMILTON DEPRESSION RATING SCALE: SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT BY ASSIGNED TREATMENT

		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Mean	20.60	27.43	28.14	12.50	15.67	9.44	13.15
	Median	23	25	28	13	18	9	10
	STD	6.83	6.05	15.85	12.02	8.59	6.65	9.91
	Min	9	19	10	4	4	0	0
	Max	30	36	58	21	24	28	58
	Mean diff. vs day0 (*)	4.20	-1.29	0.86	13.50	10.83	17.70	13.77
Placebo	No	6	5	5	7	1	87	111
	Mean	25.67	33.40	25.40	20.71	26.00	13.08	15.83
	Median	27	33	28	24	26	11	13
	STD	5.54	2.61	8.32	9.52		8.06	9.58
	Min	16	30	11	4	26	1	1
	Max	31	36	31	30	26	35	36
	Mean diff. vs day0 (*)	5.00	-7.40	0.20	6.14	2.00	13.95	11.29
Reboxetine	No	4	6	3	5	3	89	110
	Mean	28.75	27.50	29.00	25.80	15.33	11.26	14.04
	Median	29	28	29	23	11	10	12
	STD	5.06	5.65	4.00	5.76	13.05	7.17	9.22
	Min	23	18	25	21	5	0	0
	Max	35	33	33	33	30	38	38
	Mean diff. vs day0 (*)	-1.75	-2.17	-1.33	-0.20	10.00	16.62	13.49

Mean (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 23

FACTORIALISATION HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: ANXIETY/SOMATIZATION

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1.33	1.50	1.50	0.50	1.00	0.50	0.67
	Min	0.33	1.17	0.33	0.17	0.17	0.00	0.00
	Max	1.67	2.00	2.67	0.83	1.50	2.00	2.67
	Median diff. vs day0 (*)	0.00	-0.17	-0.33	0.33	0.50	0.83	0.67
Placebo	No	6	5	5	7	1	87	111
	Median	1.50	1.83	1.33	1.00	1.67	0.67	0.67
	Min	0.50	1.50	0.50	0.17	1.67	0.00	0.00
	Max	1.67	2.17	1.50	1.83	1.67	2.00	2.17
	Median diff. vs day0 (*)	0.00	-0.67	0.00	0.33	-0.17	0.67	0.50
Reboxetine	No	4	6	3	5	3	89	110
	Median	1.75	1.67	1.50	1.00	0.83	0.50	0.83
	Min	1.67	1.17	0.83	0.83	0.00	0.00	0.00
	Max	2.00	2.33	1.83	1.67	1.83	1.83	2.33
	Median diff. vs day0 (*)	0.00	-0.08	-0.17	0.17	0.33	0.67	0.67

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 23

FACTORIALISATION HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: COGNITIVE DISTURBANCE

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	0.50	0.50	0.83	0.33	0.42	0.17	0.17
	Min	0.00	0.17	0.17	0.17	0.00	0.00	0.00
	Max	1.00	1.67	3.00	0.50	1.17	1.17	3.00
	Median diff. vs day0 (*)	0.00	0.17	0.00	0.42	0.50	0.67	0.50
Placebo	No	6	5	5	7	1	87	111
	Median	0.75	0.83	0.83	0.67	0.83	0.33	0.33
	Min	0.50	0.83	0.17	0.17	0.83	0.00	0.00
	Max	1.17	1.33	1.50	1.00	0.83	1.50	1.50
	Median diff. vs day0 (*)	0.00	-0.33	-0.17	0.00	0.00	0.50	0.33
Reboxetine	No	4	6	3	5	3	89	110
	Median	0.83	0.67	1.00	1.00	0.33	0.17	0.33
	Min	0.33	0.33	0.83	0.67	0.17	0.00	0.00
	Max	1.17	1.17	1.00	1.50	0.83	1.83	1.83
	Median diff. vs day0 (*)	-0.17	0.00	-0.17	-0.17	0.67	0.50	0.50

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 23

FACTORIALISATION HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: RETARDATION

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1.50	2.00	2.00	1.25	1.50	0.50	1.00
	Min	0.75	1.75	0.75	0.25	0.25	0.00	0.00
	Max	2.75	3.00	3.25	2.25	1.75	2.00	3.25
	Median diff. vs day0 (*)	0.13	0.25	0.00	1.50	0.50	1.25	1.00
Placebo	No	6	5	5	7	1	87	111
	Median	2.00	2.25	2.25	2.00	2.25	1.00	1.25
	Min	1.00	2.00	1.50	0.25	2.25	0.00	0.00
	Max	2.00	2.75	3.00	3.25	2.25	2.75	3.25
	Median diff. vs day0 (*)	0.00	0.00	0.00	0.50	0.25	1.00	0.75
Reboxetine	No	4	6	3	5	3	89	110
	Median	2.13	2.38	2.00	1.75	0.75	0.75	1.00
	Min	1.25	1.25	2.00	1.25	0.50	0.00	0.00
	Max	2.75	2.75	2.25	2.75	2.00	2.50	2.75
	Median diff. vs day0 (*)	0.13	-0.25	0.00	0.00	1.50	1.25	1.00

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 23

FACTORIALISATION HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: SLEEP DISTURBANCE

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1.33	2.00	1.33	0.67	0.67	0.33	0.67
	Min	0.33	0.00	0.67	0.33	0.00	0.00	0.00
	Max	2.00	2.00	2.00	1.00	1.00	2.00	2.00
	Median diff. vs day0 (*)	0.17	0.00	0.33	0.33	0.83	1.00	0.67
Placebo	No	6	5	5	7	1	87	111
	Median	1.17	2.00	1.33	1.00	0.67	0.33	0.67
	Min	0.67	1.33	0.33	0.33	0.67	0.00	0.00
	Max	1.67	2.00	1.67	1.67	0.67	2.00	2.00
	Median diff. vs day0 (*)	0.00	-0.33	0.33	0.33	0.00	0.67	0.67
Reboxetine	No	4	6	3	5	3	89	110
	Median	1.50	1.50	2.00	1.67	0.33	0.67	0.67
	Min	0.00	1.00	1.67	1.00	0.33	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median diff. vs day0 (*)	0.00	-0.33	0.00	0.00	0.00	1.00	0.67

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: DEPRESSED MOOD

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	2	2	2	2	3	1	1
	Min	1	2	1	0	0	0	0
	Max	4	4	4	3	3	3	4
Placebo	No	6	5	5	7	1	87	111
	Median	2	3	3	2	2	1	2
	Min	2	3	3	0	2	0	0
	Max	3	4	3	4	2	4	4
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	3	3	2	1	1	1
	Min	1	2	2	1	1	0	0
	Max	3	4	4	4	3	4	4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: GUILT

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	1	2	1	1	0	1
	Min	0	0	0	1	0	0	0
	Max	2	3	4	1	2	3	4
Placebo	No	6	5	5	7	1	87	111
	Median	2	2	2	1	2	1	1
	Min	1	1	1	0	2	0	0
	Max	2	3	3	2	2	3	3
Reboxetine	No	4	6	3	5	3	89	110
	Median	0	2	1	1	1	1	1
	Min	0	0	1	1	1	0	0
	Max	1	2	2	2	2	3	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: SUICIDE

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	0	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	2	3	4	1	3	2	4
Placebo	No	6	5	5	7	1	87	111
	Median	1	2	2	1	2	0	0
	Min	0	1	0	0	2	0	0
	Max	2	3	4	4	2	3	4
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	1	2	1	0	0	0
	Min	0	0	1	0	0	0	0
	Max	3	3	2	3	1	3	3

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015

TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:

SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: INSOMNIA EARLY

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	2	2	1	1	1	0	1
	Min	0	0	1	0	0	0	0
	Max	2	2	2	1	1	2	2
Placebo	No	6	5	5	7	1	87	111
	Median	1	2	1	1	2	1	1
	Min	1	1	1	0	2	0	0
	Max	2	2	2	2	2	2	2
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	2	2	2	1	1	1
	Min	0	1	1	0	0	0	0
	Max	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015

TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:

SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: INSOMNIA MIDDLE

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	2	1	1	1	0	0
	Min	0	0	0	0	0	0	0
	Max	2	2	2	1	1	2	2
Placebo	No	6	5	5	7	1	87	111
	Median	1	2	1	1	0	0	0
	Min	0	1	0	0	0	0	0
	Max	2	2	1	2	0	2	2
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	2	2	2	1	0	1
	Min	0	1	2	1	0	0	0
	Max	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: INSOMNIA LATE

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	2	1	1	1	0	0
	Min	0	0	1	1	0	0	0
	Max	2	2	2	1	1	2	2
Placebo	No	6	5	5	7	1	87	111
	Median	2	2	1	1	0	0	0
	Min	0	2	0	0	0	0	0
	Max	2	2	2	2	0	2	2
Reboxetine	No	4	6	3	5	3	89	110
	Median	1	2	2	1	0	1	1
	Min	0	0	2	1	0	0	0
	Max	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: WORK AND ACTIVITIES

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	2	3	4	2	2	1	1
	Min	1	2	1	1	0	0	0
	Max	4	4	4	3	3	3	4
Placebo	No	6	5	5	7	1	87	111
	Median	2	3	3	3	3	1	2
	Min	1	3	2	0	3	0	0
	Max	4	4	4	4	3	4	4
Reboxetine	No	4	6	3	5	3	89	110
	Median	4	3	3	2	1	1	1
	Min	2	2	2	2	1	0	0
	Max	4	4	3	4	2	3	4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015

TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:

SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: RETARDATION

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	2	1	1	1	0	0
	Min	0	1	0	0	1	0	0
	Max	2	3	3	1	1	2	3
Placebo	No	6	5	5	7	1	87	111
	Median	1	1	1	1	2	1	1
	Min	0	0	0	0	2	0	0
	Max	2	3	3	3	2	3	3
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	1	1	1	0	0	1
	Min	0	0	0	0	0	0	0
	Max	3	3	1	3	2	3	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: AGITATION

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	1	1	0	1	0	1
	Min	0	0	0	0	0	0	0
	Max	2	3	4	0	2	2	4
Placebo	No	6	5	5	7	1	87	111
	Median	2	2	0	1	0	1	1
	Min	0	1	0	0	0	0	0
	Max	2	3	1	3	0	3	3
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	2	2	2	1	0	1
	Min	2	0	2	1	0	0	0
	Max	2	4	4	4	2	2	4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: ANXIETY PSYCHIC

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	2	2	3	0	2	1	1
	Min	1	1	1	0	0	0	0
	Max	3	4	4	0	3	3	4
Placebo	No	6	5	5	7	1	87	111
	Median	2	3	2	2	3	1	1
	Min	1	3	1	0	3	0	0
	Max	3	3	3	4	3	3	4
Reboxetine	No	4	6	3	5	3	89	110
	Median	3	3	2	2	1	1	1
	Min	2	2	2	1	0	0	0
	Max	4	4	4	4	2	3	4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: ANXIETY SOMATIC

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	2	3	2	2	1	1	1
	Min	0	1	1	1	0	0	0
	Max	3	4	4	2	2	2	4
Placebo	No	6	5	5	7	1	87	111
	Median	2	3	2	1	2	1	1
	Min	1	2	0	0	2	0	0
	Max	3	4	2	2	2	3	4
Reboxetine	No	4	6	3	5	3	89	110
	Median	3	2	3	2	2	1	1
	Min	2	2	0	0	0	0	0
	Max	3	4	4	3	2	2	4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: SOMATIC GASTROINTESTINAL

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	1	2	2	2	1	2	2
Placebo	No	6	5	5	7	1	87	111
	Median	1	1	1	1	1	0	0
	Min	0	1	0	0	1	0	0
	Max	1	2	2	2	1	2	2
Reboxetine	No	4	6	3	5	3	89	110
	Median	1	2	1	1	1	0	0
	Min	1	0	1	0	0	0	0
	Max	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: SOMATIC GENERAL

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	2	2	2	1	1	1	1
	Min	0	1	0	0	0	0	0
	Max	2	2	2	1	2	2	2
Placebo	No	6	5	5	7	1	87	111
	Median	2	2	1	1	1	1	1
	Min	1	2	1	0	1	0	0
	Max	2	2	2	2	1	2	2
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	2	2	1	1	1	1
	Min	1	1	1	0	0	0	0
	Max	2	2	2	1	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: GENITAL SYMPTOMS

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	1	1	1	1	0	1
	Min	0	0	0	0	0	0	0
	Max	2	2	2	2	1	2	2
Placebo	No	6	5	5	7	1	87	111
	Median	2	2	2	2	2	0	1
	Min	0	0	0	0	2	0	0
	Max	2	2	2	2	2	2	2
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	2	2	1	1	0	1
	Min	1	1	2	0	0	0	0
	Max	2	2	2	2	1	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: HYPOCHONDRIASIS

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	0	1	1	0	2	0	0
	Min	0	0	0	0	0	0	0
	Max	2	3	3	0	3	3	3
Placebo	No	6	5	5	7	1	87	111
	Median	2	2	1	0	3	0	1
	Min	0	1	0	0	3	0	0
	Max	2	3	2	2	3	3	3
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	2	0	1	0	0	0
	Min	1	0	0	0	0	0	0
	Max	3	3	1	2	3	3	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: LOSS OF WEIGHT

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	0	2	3	0	0	2	3
Placebo	No	6	5	5	7	1	87	111
	Median	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	2	1	1	0	0	2	2
Reboxetine	No	4	6	3	5	3	89	110
	Median	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	0	0	1	0	0	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: INSIGHT

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	1	0	1	0	0	2	2
Placebo	No	6	5	5	7	1	87	111
	Median	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	0	1	1	2	0	2	2
Reboxetine	No	4	6	3	5	3	89	110
	Median	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	1	0	0	1	0	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: DIURNAL VARIATION

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	0	1	1	1	0	0
	Min	0	0	0	0	0	0	0
	Max	2	2	2	1	1	2	2
Placebo	No	6	5	5	7	1	87	111
	Median	2	1	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	2	2	2	1	0	2	2
Reboxetine	No	4	6	3	5	3	89	110
	Median	1	0	1	1	0	0	0
	Min	1	0	0	0	0	0	0
	Max	2	1	1	2	1	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: DEPERSONALIZATION

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	0	0	0	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	1	0	3	1	0	2	3
Placebo	No	6	5	5	7	1	87	111
	Median	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	1	0	1	1	0	2	2
Reboxetine	No	4	6	3	5	3	89	110
	Median	0	0	0	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	0	0	0	1	0	2	2

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: PARANOID

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	1	1	2	0	0	1	2
Placebo	No	6	5	5	7	1	87	111
	Median	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	1	0	2	1	0	1	2
Reboxetine	No	4	6	3	5	3	89	110
	Median	0	0	0	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	0	0	0	1	0	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: OBSESSIONAL/COMPULSIVE

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	1	1	2	0	1	2	2
Placebo	No	6	5	5	7	1	87	111
	Median	0	0	0	0	1	0	0
	Min	0	0	0	0	1	0	0
	Max	1	1	1	1	1	2	2
Reboxetine	No	4	6	3	5	3	89	110
	Median	1	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	2	0	0	0	0	2	2

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 25

EFFICACY: CLASSIFICATION OF PATIENTS ACCORDING TO PROTOCOL CRITERIA ON TOTAL SCORE OF HAMILTON DEPRESSION RATING SCALE OVER TIME BY ASSIGNED TREATMENT

Assigned treatment		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	Patients No.	111	101	93	87	82	79
	Responders No.	8	23	45	52	53	62
	Responders %	7.2	22.8	48.4	59.8	64.6	78.5
	95% L.L.	3.2	15.0	37.9	48.7	53.3	67.8
	95% U.L.	13.7	32.2	59.0	70.1	74.9	86.9
	Remissions No.	8	9	29	40	46	50
	Remissions %	7.2	8.9	31.2	46.0	56.1	63.3
	95% L.L.	3.2	4.2	22.0	35.2	44.7	51.7
	95% U.L.	13.7	16.2	41.6	57.0	67.0	73.9
Placebo	Patients No.	111	103	100	93	87	87
	Responders No.	5	10	33	42	45	54
	Responders %	4.5	9.7	33.0	45.2	51.7	62.1
	95% L.L.	1.5	4.8	23.9	34.8	40.8	51.0
	95% U.L.	10.2	17.1	43.1	55.8	62.6	72.3
	Remissions No.	1	5	14	27	32	39
	Remissions %	0.9	4.9	14.0	29.0	36.8	44.8
	95% L.L.	0.0	1.6	7.9	20.1	26.7	34.1
	95% U.L.	4.9	11.0	22.4	39.4	47.8	55.9
Reboxetine	Patients No.	110	105	98	97	90	89
	Responders No.	5	21	38	46	59	63
	Responders %	4.5	20.0	38.8	47.4	65.6	70.8
	95% L.L.	1.5	12.8	29.1	37.2	54.8	60.2
	95% U.L.	10.3	28.9	49.2	57.8	75.3	79.9
	Remissions No.	1	12	27	32	40	46
	Remissions %	0.9	11.4	27.6	33.0	44.4	51.7
	95% L.L.	0.0	6.0	19.0	23.8	34.0	40.8
	95% U.L.	5.0	19.1	37.5	43.3	55.3	62.4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 26

EFFICACY: CLASSIFICATION OF PATIENTS ACCORDING TO PROTOCOL CRITERIA ON TOTAL SCORE OF HAMILTON DEPRESSION RATING SCALE AT LAST ASSESSMENT VERSUS DAY 0 BY ASSIGNED TREATMENT

	Assigned treatment		
	Imipramine	Placebo	Reboxetine
Patients No.	111	111	110
Responders No.	69	58	65
Responders %	62.2	52.3	59.1
95% L.L.	52.5	42.6	49.3
95% U.L.	71.2	61.8	68.4
Remissions No.	56	40	47
Remissions %	50.5	36.0	42.7
95% L.L.	40.8	27.1	33.3
95% U.L.	60.1	45.7	52.5

COMPARISON BETWEEN TREATMENTS

RESPONSE : Reboxetine vs Placebo Adj. Chi-square = 0.788 Prob. = 0.375
Imipramine vs Placebo Adj. Chi-square = 1.840 Prob. = 0.175

REMISSION: Reboxetine vs Placebo Adj. Chi-square = 0.775 Prob. = 0.379
Imipramine vs Placebo Adj. Chi-square = 4.129 Prob. = 0.042

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 27

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment/Severity of illness		Visit													
		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	NORMAL			2	1.8	2	2.0	6	6.4	7	8.0	11	13.1	20	25.3
	BORDERLINE MENTALLY ILL			4	3.6	4	4.0	13	13.8	22	25.3	27	32.1	25	31.6
	MILDLY ILL	2	1.8	10	9.0	21	20.8	38	40.4	35	40.2	28	33.3	24	30.4
	MODERATELY ILL	29	26.1	43	38.7	47	46.5	24	25.5	18	20.7	14	16.7	8	10.1
	MARKEDLY ILL	64	57.7	45	40.5	23	22.8	8	8.5	5	5.7	4	4.8	2	2.5
	SEVERELY ILL	15	13.5	7	6.3	4	4.0	4	4.3						
	EXTREMELY ILL	1	0.9					1	1.1						
	Total	111	100.0	111	100.0	101	100.0	94	100.0	87	100.0	84	100.0	79	100.0
Placebo	NORMAL							2	2.0	6	6.4	8	9.2	13	14.9
	BORDERLINE MENTALLY ILL			1	0.9	4	3.8	8	8.1	17	18.1	18	20.7	20	23.0
	MILDLY ILL	4	3.6	10	9.0	17	16.3	30	30.3	26	27.7	28	32.2	22	25.3
	MODERATELY ILL	38	34.2	47	42.3	44	42.3	36	36.4	24	25.5	24	27.6	24	27.6
	MARKEDLY ILL	51	45.9	43	38.7	30	28.8	16	16.2	12	12.8	6	6.9	6	6.9
	SEVERELY ILL	18	16.2	10	9.0	9	8.7	7	7.1	8	8.5	3	3.4	2	2.3
	EXTREMELY ILL									1	1.1				
	Total	111	100.0	111	100.0	104	100.0	99	100.0	94	100.0	87	100.0	87	100.0
Reboxetine	NORMAL					1	1.0	5	5.1	8	8.2	13	14.4	15	16.9
	BORDERLINE MENTALLY ILL			3	2.7	8	7.6	18	18.4	27	27.8	28	31.1	32	36.0
	MILDLY ILL	1	0.9	9	8.2	26	24.8	28	28.6	22	22.7	24	26.7	20	22.5
	MODERATELY ILL	33	29.7	46	41.8	36	34.3	29	29.6	27	27.8	18	20.0	16	18.0
	MARKEDLY ILL	54	48.6	37	33.6	26	24.8	15	15.3	10	10.3	5	5.6	4	4.5
	SEVERELY ILL	22	19.8	15	13.6	8	7.6	3	3.1	3	3.1	2	2.2	2	2.2
	EXTREMELY ILL	1	0.9												

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015

TABLE No.: 27

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment/Severity of illness		Visit																	
		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42					
		No	%	No	%	No	%	No	%	No	%	No	%	No	%				
Reboxetine	Total	111	100.0	110	100.0	105	100.0	98	100.0	97	100.0	90	100.0	89	100.0				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 28

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Assigned treatment/Severity of illness		Total		Last Visit											
				Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	NORMAL	21	18.9							1	50.0			20	25.3
	BORDERLINE MENTALLY ILL	28	25.2	1	10.0							2	33.3	25	31.6
	MILDLY ILL	26	23.4	1	10.0			1	12.5					24	30.4
	MODERATELY ILL	18	16.2	4	40.0	1	16.7	3	37.5			2	33.3	8	10.1
	MARKEDLY ILL	14	12.6	4	40.0	4	66.7	1	12.5	1	50.0	2	33.3	2	2.5
	SEVERELY ILL	3	2.7			1	16.7	2	25.0						
	EXTREMELY ILL	1	0.9					1	12.5						
	Total	111	100.0	10	100.0	6	100.0	8	100.0	2	100.0	6	100.0	79	100.0
Placebo	NORMAL	13	11.7											13	14.9
	BORDERLINE MENTALLY ILL	20	18.0											20	23.0
	MILDLY ILL	25	22.5	1	16.7			1	25.0	1	12.5			22	25.3
	MODERATELY ILL	30	27.0	3	50.0	1	20.0	1	25.0	1	12.5			24	27.6
	MARKEDLY ILL	11	9.9	2	33.3	1	20.0			2	25.0			6	6.9
	SEVERELY ILL	11	9.9			3	60.0	2	50.0	3	37.5	1	100.0	2	2.3
	EXTREMELY ILL	1	0.9							1	12.5				
	Total	111	100.0	6	100.0	5	100.0	4	100.0	8	100.0	1	100.0	87	100.0
Reboxetine	NORMAL	15	13.6											15	16.9
	BORDERLINE MENTALLY ILL	33	30.0									1	33.3	32	36.0
	MILDLY ILL	23	20.9			1	16.7			1	20.0	1	33.3	20	22.5
	MODERATELY ILL	21	19.1			1	16.7	2	66.7	2	40.0			16	18.0
	MARKEDLY ILL	11	10.0	2	50.0	2	33.3	1	33.3	1	20.0	1	33.3	4	4.5
	SEVERELY ILL	7	6.4	2	50.0	2	33.3			1	20.0			2	2.2
	Total	110	100.0	4	100.0	6	100.0	3	100.0	5	100.0	3	100.0	89	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 29

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS SHIFT TABLE (LAST VALUE VS DAY 0) BY ASSIGNED TREATMENT

Assigned treatment/Shift severity		Total		Last visit											
				Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	DECREASED	86	77.5	4	40.0			3	37.5	1	50.0	4	66.7	74	93.7
	NO CHANGE	20	18.0	6	60.0	5	83.3	3	37.5	1	50.0	1	16.7	4	5.1
	INCREASED	5	4.5			1	16.7	2	25.0			1	16.7	1	1.3
	Total	111	100.0	10	100.0	6	100.0	8	100.0	2	100.0	6	100.0	79	100.0
Placebo	DECREASED	73	65.8	1	16.7					2	25.0			70	80.5
	NO CHANGE	29	26.1	4	66.7	2	40.0	2	50.0	5	62.5	1	100.0	15	17.2
	INCREASED	9	8.1	1	16.7	3	60.0	2	50.0	1	12.5			2	2.3
	Total	111	100.0	6	100.0	5	100.0	4	100.0	8	100.0	1	100.0	87	100.0
Reboxetine	DECREASED	85	77.3			2	33.3	1	33.3	1	20.0	2	66.7	79	88.8
	NO CHANGE	19	17.3	3	75.0			2	66.7	4	80.0			10	11.2
	INCREASED	6	5.5	1	25.0	4	66.7					1	33.3		
	Total	110	100.0	4	100.0	6	100.0	3	100.0	5	100.0	3	100.0	89	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 30

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment/Global improvement		Visit											
		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	VERY MUCH IMPROVED	2	1.8	2	2.0	12	12.8	15	17.2	20	23.8	31	39.2
	MUCH IMPROVED	12	10.8	32	31.7	43	45.7	44	50.6	40	47.6	34	43.0
	MINIMALLY IMPROVED	44	39.6	40	39.6	21	22.3	19	21.8	14	16.7	8	10.1
	NO CHANGE	44	39.6	20	19.8	11	11.7	5	5.7	9	10.7	3	3.8
	MINIMALLY WORSE	7	6.3	5	5.0	2	2.1	2	2.3			2	2.5
	MUCH WORSE	2	1.8	2	2.0	4	4.3	2	2.3	1	1.2	1	1.3
	VERY MUCH WORSE					1	1.1						
	Total	111	100.0	101	100.0	94	100.0	87	100.0	84	100.0	79	100.0
Placebo	VERY MUCH IMPROVED	1	0.9	1	1.0	4	4.0	10	10.6	13	14.9	18	20.7
	MUCH IMPROVED	8	7.2	20	19.2	29	29.3	34	36.2	35	40.2	36	41.4
	MINIMALLY IMPROVED	32	28.8	38	36.5	34	34.3	27	28.7	26	29.9	20	23.0
	NO CHANGE	58	52.3	36	34.6	24	24.2	15	16.0	9	10.3	9	10.3
	MINIMALLY WORSE	11	9.9	3	2.9	6	6.1	2	2.1	2	2.3	1	1.1
	MUCH WORSE	1	0.9	6	5.8	2	2.0	5	5.3	2	2.3	3	3.4
	VERY MUCH WORSE							1	1.1				
	Total	111	100.0	104	100.0	99	100.0	94	100.0	87	100.0	87	100.0
Reboxetine	VERY MUCH IMPROVED	3	2.7	6	5.7	17	17.3	22	22.7	25	27.8	31	34.8
	MUCH IMPROVED	7	6.4	27	25.7	30	30.6	37	38.1	42	46.7	34	38.2
	MINIMALLY IMPROVED	43	39.1	43	41.0	31	31.6	22	22.7	13	14.4	15	16.9
	NO CHANGE	45	40.9	21	20.0	14	14.3	9	9.3	5	5.6	5	5.6
	MINIMALLY WORSE	10	9.1	4	3.8	6	6.1	6	6.2	4	4.4	4	4.5
	MUCH WORSE	2	1.8	4	3.8			1	1.0	1	1.1		
	Total	110	100.0	105	100.0	98	100.0	97	100.0	90	100.0	89	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 31

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Assigned treatment/Global improvement		Total		Last visit											
				Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	VERY MUCH IMPROVED	32	28.8							1	50.0			31	39.2
	MUCH IMPROVED	38	34.2	2	20.0			1	12.5			1	16.7	34	43.0
	MINIMALLY IMPROVED	18	16.2	5	50.0	2	33.3	2	25.0			1	16.7	8	10.1
	NO CHANGE	12	10.8	2	20.0	2	33.3	1	12.5	1	50.0	3	50.0	3	3.8
	MINIMALLY WORSE	4	3.6	1	10.0	1	16.7							2	2.5
	MUCH WORSE	6	5.4			1	16.7	3	37.5			1	16.7	1	1.3
	VERY MUCH WORSE	1	0.9					1	12.5						
	Total	111	100.0	10	100.0	6	100.0	8	100.0	2	100.0	6	100.0	79	100.0
Placebo	VERY MUCH IMPROVED	19	17.1	1	16.7									18	20.7
	MUCH IMPROVED	38	34.2					1	25.0	1	12.5			36	41.4
	MINIMALLY IMPROVED	21	18.9							1	12.5			20	23.0
	NO CHANGE	19	17.1	4	66.7	1	20.0	1	25.0	4	50.0			9	10.3
	MINIMALLY WORSE	2	1.8					1	25.0					1	1.1
	MUCH WORSE	11	9.9	1	16.7	4	80.0	1	25.0	1	12.5	1	100.0	3	3.4
	VERY MUCH WORSE	1	0.9							1	12.5				
	Total	111	100.0	6	100.0	5	100.0	4	100.0	8	100.0	1	100.0	87	100.0
Reboxetine	VERY MUCH IMPROVED	32	29.1									1	33.3	31	34.8
	MUCH IMPROVED	35	31.8									1	33.3	34	38.2
	MINIMALLY IMPROVED	18	16.4			2	33.3			1	20.0			15	16.9
	NO CHANGE	10	9.1	2	50.0			1	33.3	2	40.0			5	5.6
	MINIMALLY WORSE	7	6.4					2	66.7	1	20.0			4	4.5
	MUCH WORSE	8	7.3	2	50.0	4	66.7			1	20.0	1	33.3		
	Total	110	100.0	4	100.0	6	100.0	3	100.0	5	100.0	3	100.0	89	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 32

CLINICAL GLOBAL IMPRESSION: EFFICACY INDEX
ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment / Efficacy index (*)		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	< 1	28	25.2	12	11.9	10	10.6	7	8.0	5	6.0	4	5.1
	1	50	45.0	34	33.7	17	18.1	8	9.2	6	7.1	4	5.1
	1.33 - 1.5	8	7.2	17	16.8	20	21.3	16	18.4	12	14.3	10	12.7
	2	17	15.3	23	22.8	23	24.5	31	35.6	31	36.9	29	36.7
	3	6	5.4	12	11.9	18	19.1	16	18.4	17	20.2	16	20.3
	4	2	1.8	3	3.0	6	6.4	9	10.3	13	15.5	16	20.3
	Total	111	100	101	100	94	100	87	100	84	100	79	100
Placebo	< 1	18	16.2	13	12.5	11	11.1	10	10.6	3	3.4	2	2.3
	1	61	55.0	43	41.3	28	28.3	19	20.2	17	19.5	17	19.5
	1.33 - 1.5	6	5.4	9	8.7	8	8.1	7	7.4	13	14.9	6	6.9
	2	20	18.0	22	21.2	24	24.2	24	25.5	19	21.8	19	21.8
	3	5	4.5	15	14.4	21	21.2	18	19.1	14	16.1	20	23.0
	4	1	0.9	2	1.9	7	7.1	16	17.0	21	24.1	23	26.4
	Total	111	100	104	100	99	100	94	100	87	100	87	100
Reboxetine	< 1	26	23.4	16	15.2	9	9.2	7	7.2	4	4.4	3	3.4
	1	51	45.9	32	30.5	22	22.4	16	16.5	11	12.2	10	11.2
	1.33 - 1.5	4	3.6	11	10.5	10	10.2	11	11.3	6	6.7	8	9.0
	2	21	18.9	25	23.8	26	26.5	27	27.8	23	25.6	19	21.3
	3	8	7.2	17	16.2	21	21.4	22	22.7	24	26.7	17	19.1
	4	1	0.9	4	3.8	10	10.2	14	14.4	22	24.4	32	36.0
	Total	111	100	105	100	98	100	97	100	90	100	89	100

EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 33

CLINICAL GLOBAL IMPRESSION: EFFICACY INDEX
AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Assigned treatment / Efficacy index (*)		total		Last Assessment											
				Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	< 1	18	16.22	5	50.00	4	66.67	3	37.50			2	33.33	4	5.06
	1	15	13.51	2	20.00	1	16.67	5	62.50	1	50.00	2	33.33	4	5.06
	1.33 - 1.5	12	10.81	2	20.00									10	12.66
	2	33	29.73	1	10.00	1	16.67			1	50.00	1	16.67	29	36.71
	3	17	15.32									1	16.67	16	20.25
	4	16	14.41											16	20.25
	Total	111	100.0	10	100.0	6	100.0	8	100.0	2	100.0	6	100.0	79	100.0
Placebo	< 1	15	13.51	2	33.33	4	80.00	2	50.00	4	50.00	1	100.0	2	2.30
	1	24	21.62	3	50.00	1	20.00	1	25.00	2	25.00			17	19.54
	1.33 - 1.5	6	5.41											6	6.90
	2	20	18.02							1	12.50			19	21.84
	3	21	18.92					1	25.00					20	22.99
	4	25	22.52	1	16.67					1	12.50			23	26.44
	Total	111	100.0	6	100.0	5	100.0	4	100.0	8	100.0	1	100.0	87	100.0
Reboxetine	< 1	17	15.32	5	100.0	4	66.67	2	66.67	3	60.00			3	3.37
	1	15	13.51			2	33.33	1	33.33	1	20.00	1	33.33	10	11.24
	1.33 - 1.5	10	9.01							1	20.00	1	33.33	8	8.99
	2	20	18.02									1	33.33	19	21.35
	3	17	15.32											17	19.10
	4	32	28.83											32	35.96
	Total	111	100.0	5	100.0	6	100.0	3	100.0	5	100.0	3	100.0	89	100.0

EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R#550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 34

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	84	79
	Mean	16.74	14.36	11.96	9.60	7.79	6.81	5.84
	Median	16	14	12	9	7	6	5
	STD	3.41	4.52	4.97	5.18	4.00	3.87	4.00
	Min	8	1	0	0	0	0	0
	Max	26	25	26	28	21	19	20
	Mean diff. vs day0 (*)		2.38	4.87	7.21	8.89	9.79	10.95
Placebo	No	111	111	103	100	92	87	87
	Mean	16.28	14.77	13.57	11.31	9.91	8.30	7.73
	Median	16	15	14	11	9	8	7
	STD	3.45	4.07	4.77	4.98	5.71	4.98	4.91
	Min	8	5	3	2	0	0	0
	Max	25	25	25	26	25	21	21
	Mean diff. vs day0 (*)		1.51	2.63	4.90	6.35	7.74	8.17
Reboxetine	No	110	110	105	98	97	90	89
	Mean	16.38	14.55	12.39	9.96	8.75	7.14	6.62
	Median	16	15	13	10	9	7	6
	STD	3.92	4.33	5.10	5.23	5.07	4.76	4.73
	Min	7	3	0	0	0	0	0
	Max	26	25	25	25	25	25	25
	Mean diff. vs day0 (*)		1.82	4.07	6.60	7.77	9.49	9.87

Mean (*): mean of differences vs day0

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: REPORTED SADNESS

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	84	79
	Median	2	2	2	1	1	1	1
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	3	2	3
Placebo	No	111	111	103	100	92	87	87
	Median	2	2	2	1	1	1	1
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3
Reboxetine	No	110	110	105	98	97	90	89
	Median	2	2	2	1	1	1	1
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3

PHARMACIA CNS R9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: INNER TENSION

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	84	79
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	2	2
Placebo	No	111	111	103	100	92	87	87
	Median	2	2	2	1	1	1	1
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3
Reboxetine	No	110	110	105	98	97	90	89
	Median	2	2	1	1	1	1	1
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	3	3	2

PHARMACIA CNS R9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: APPARENT SADNESS

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	84	79
	Median	2	2	1	1	1	1	1
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	3	2	2
Placebo	No	111	111	103	100	92	87	87
	Median	2	2	2	1	1	1	1
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3
Reboxetine	No	110	110	105	98	97	90	89
	Median	2	2	1	1	1	1	1
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3

PHARMACIA CNS R95550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: SUICIDAL THOUGHTS

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	84	79
	Median	1	1	1	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	2	2	2
Placebo	No	111	111	103	100	92	87	87
	Median	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3
Reboxetine	No	110	110	105	98	97	90	89
	Median	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	2	2

PHARMACIA CNS R9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: INNER TENSION

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	84	79
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	2	2
Placebo	No	111	111	103	100	92	87	87
	Median	2	2	2	1	1	1	1
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3
Reboxetine	No	110	110	105	98	97	90	89
	Median	2	2	1	1	1	1	1
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	3	3	2

PHARMACIA CNS R[illegible]550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: INERTIA

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	84	79
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	2	2
Placebo	No	111	111	103	100	92	87	87
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3
Reboxetine	No	110	110	105	98	97	90	89
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3

PHARMACIA CNS R9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: INABILITY TO FEEL

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	84	79
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3
Placebo	No	111	111	103	100	92	87	87
	Median	2	2	2	1	1	1	1
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	3	2	2
Reboxetine	No	110	110	105	98	97	90	89
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3

PHARMACIA CNS R95550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: PESSIMISTIC THOUGHTS

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	84	79
	Median	2	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	2	2	2
Placebo	No	111	111	103	100	92	87	87
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	2
Reboxetine	No	110	110	105	98	97	90	89
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	2	2	2

PHARMACIA CNS 95550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: CONCENTRATIONS DIFFICULTIES

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	84	79
	Median	2	2	1	1	1	1	1
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	2	2	2
Placebo	No	111	111	103	100	92	87	87
	Median	2	2	2	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	2
Reboxetine	No	110	110	105	98	97	90	89
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3

PHARMACIA CNS R9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: REDUCED SLEEP

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	84	79
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	2	2	2
Placebo	No	111	111	103	100	92	87	87
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	2	3	2	2
Reboxetine	No	110	110	105	98	97	90	89
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	2	3

PHARMACIA CNS R[illegible]550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: REDUCED APPETITE

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	84	79
	Median	1	1	1	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	2	2	3
Placebo	No	111	111	103	100	92	87	87
	Median	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	2	2	3	2	2	2	2
Reboxetine	No	110	110	105	98	97	90	89
	Median	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	3	3	2	2	2	2	2

PHARMACIA CNS R0550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 36

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Mean	13.50	17.00	17.50	11.00	7.58	5.84	8.15
	Median	14	19	20	11	7	5	7
	STD	3.96	5.07	8.04	12.73	5.42	4.00	6.12
	Min	8	11	6	2	2	0	0
	Max	20	24	28	20	15	20	28
	Mean diff. vs day0 (*)	2.40	0.21	0.86	8.50	6.67	10.95	8.59
Placebo	No	6	5	5	7	1	87	111
	Mean	14.33	21.60	17.70	16.29	21.00	7.73	9.82
	Median	16	21	19	18	21	7	8
	STD	4.59	2.41	7.03	8.32		4.91	6.57
	Min	6	19	7	3	21	0	0
	Max	18	25	26	25	21	21	26
	Mean diff. vs day0 (*)	2.67	-4.80	-0.40	2.43	-1.00	8.17	6.46
Reboxetine	No	4	6	3	5	3	89	110
	Mean	16.75	18.00	17.33	16.10	10.33	6.62	8.44
	Median	17	20	17	16	7	6	7
	STD	4.03	3.74	2.52	5.27	9.45	4.73	6.09
	Min	12	12	15	11	3	0	0
	Max	21	22	20	23	21	25	25
	Mean diff. vs day0 (*)	-2.00	-2.17	-2.33	0.40	7.00	9.87	7.94

Mean (*): mean of differences vs day0

PHARMACIA CNS R[illegible]550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: REPORTED SADNESS

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	2	2	2	2	1	1	1
	Min	1	1	1	0	0	0	0
	Max	3	3	3	3	2	3	3
Placebo	No	6	5	5	7	1	87	111
	Median	2	3	3	2	3	1	1
	Min	1	2	1	0	3	0	0
	Max	2	3	3	3	3	3	3
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	2	2	2	1	1	1
	Min	1	2	2	1	1	0	0
	Max	3	3	3	3	3	3	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: INNER TENSION

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	2	2	2	1	1	1	1
	Min	1	2	1	0	0	0	0
	Max	3	3	3	1	2	2	3
Placebo	No	6	5	5	7	1	87	111
	Median	2	3	2	2	2	1	1
	Min	1	2	1	1	2	0	0
	Max	3	3	3	3	2	3	3
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	2	2	2	1	1	1
	Min	1	2	2	2	1	0	0
	Max	3	3	3	3	3	2	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: APPARENT SADNESS

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	2	2	2	1	1	1	1
	Min	1	2	1	0	0	0	0
	Max	2	3	3	2	2	2	3
Placebo	No	6	5	5	7	1	87	111
	Median	2	3	2	2	3	1	1
	Min	1	2	1	0	3	0	0
	Max	2	3	3	3	3	3	3
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	2	2	2	0	1	1
	Min	1	2	2	1	0	0	0
	Max	2	2	3	2	3	3	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: SUICIDAL THOUGHTS

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	2	2	1	1	0	0
	Min	0	0	0	0	0	0	0
	Max	2	3	3	1	2	2	3
Placebo	No	6	5	5	7	1	87	111
	Median	1	1	2	1	2	0	1
	Min	0	1	0	0	2	0	0
	Max	2	2	3	3	2	3	3
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	2	1	3	0	0	0
	Min	0	0	1	1	0	0	0
	Max	3	2	2	3	1	2	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: INERTIA

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	2	2	2	0	1	1
	Min	0	1	0	1	0	0	0
	Max	2	3	3	2	1	2	3
Placebo	No	6	5	5	7	1	87	111
	Median	2	2	2	2	2	1	1
	Min	1	2	1	0	2	0	0
	Max	2	3	3	3	2	3	3
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	2	1	2	1	1	1
	Min	1	0	1	1	1	0	0
	Max	2	3	2	3	2	3	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: INABILITY TO FEEL

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	2	1	2	2	1	1	1
	Min	1	1	1	0	0	0	0
	Max	2	2	3	3	2	3	3
Placebo	No	6	5	5	7	1	87	111
	Median	2	2	2	2	1	1	1
	Min	0	1	1	0	1	0	0
	Max	2	2	2	3	1	2	3
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	2	2	1	0	1	1
	Min	1	1	1	1	0	0	0
	Max	3	2	2	3	2	3	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: PESSIMISTIC THOUGHTS

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	2	2	1	1	1	1
	Min	1	1	0	0	0	0	0
	Max	2	3	3	2	2	2	3
Placebo	No	6	5	5	7	1	87	111
	Median	2	2	2	2	2	1	1
	Min	0	1	1	0	2	0	0
	Max	2	2	3	3	2	2	3
Reboxetine	No	4	6	3	5	3	89	110
	Median	1	2	1	1	1	1	1
	Min	0	1	1	1	0	0	0
	Max	2	2	2	2	2	2	2

PHARMACIA CNS R9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: CONCENTRATIONS DIFFICULTIES

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	1	2	1	1	1	1
	Min	1	1	0	0	1	0	0
	Max	2	2	3	2	2	2	3
Placebo	No	6	5	5	7	1	87	111
	Median	2	2	2	2	3	1	1
	Min	1	2	1	1	3	0	0
	Max	3	3	2	3	3	2	3
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	2	1	2	1	1	1
	Min	2	1	1	1	0	0	0
	Max	2	3	2	3	2	3	3

PHARMACIA CNS R95550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: REDUCED SLEEP

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	2	2	2	2	1	1	1
	Min	1	0	1	1	0	0	0
	Max	3	3	2	2	1	2	3
Placebo	No	6	5	5	7	1	87	111
	Median	2	3	2	2	2	1	1
	Min	1	2	0	1	2	0	0
	Max	2	3	2	3	2	2	3
Reboxetine	No	4	6	3	5	3	89	110
	Median	2	2	2	2	1	1	1
	Min	0	1	2	1	0	0	0
	Max	3	3	3	3	2	3	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: REDUCED APPETITE

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	1	2	1	0	0	0
	Min	1	0	0	0	0	0	0
	Max	2	2	3	2	1	3	3
Placebo	No	6	5	5	7	1	87	111
	Median	1	2	2	1	1	0	0
	Min	0	0	0	0	1	0	0
	Max	2	3	2	2	1	2	3
Reboxetine	No	4	6	3	5	3	89	110
	Median	1	2	1	1	1	0	0
	Min	0	0	1	0	0	0	0
	Max	3	2	1	1	1	2	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 38

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	82	79
	Mean	18.59	16.02	13.61	11.27	8.93	8.02	6.46
	Median	18	17	13	11	8	8	6
	STD	6.18	6.74	6.67	6.96	6.05	5.73	5.32
	Min	4	0	0	0	0	0	0
	Max	40	37	33	36	29	22	22
	Mean diff. vs day0 (*)		2.58	5.13	7.70	10.07	11.02	12.67
Placebo	No	111	111	103	100	93	87	86
	Mean	18.00	16.05	14.99	12.60	11.75	9.98	9.43
	Median	18	15	14	12	10	10	8
	STD	7.04	7.12	7.44	7.71	8.16	7.48	7.47
	Min	2	0	0	0	0	0	0
	Max	44	43	41	33	31	32	33
	Mean diff. vs day0 (*)		1.95	3.11	5.55	6.72	8.36	8.79
Reboxetine	No	109	109	103	97	96	89	88
	Mean	18.80	16.08	13.88	10.77	9.97	8.07	7.59
	Median	18	16	13	11	10	7	7
	STD	6.96	7.60	7.57	7.52	7.50	6.63	6.87
	Min	1	0	0	0	0	0	0
	Max	40	39	38	36	35	32	34
	Mean diff. vs day0 (*)		2.72	5.10	8.38	9.26	11.24	11.66

Mean (*): mean of differences vs day0

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 39

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: FACIAL EXPRESSION

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	82	79
	Median	2	2	1	1	1	1	0
	Min	0	0	0	0	0	0	0
	Max	4	3	3	3	3	3	2
Placebo	No	111	111	103	100	93	87	86
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	4	4	4	3	4	4	4
Reboxetine	No	109	109	103	97	96	89	88
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	4	4	4	3	4	4	4

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 39

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: BODY GESTURES

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	82	79
	Median	2	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0
	Max	3	4	3	3	3	3	2
Placebo	No	111	111	103	100	93	87	86
	Median	2	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	4	4	3	3	3	3	3
Reboxetine	No	109	109	103	97	96	89	88
	Median	2	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3

PHARMACIA CNS R[illegible]550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 39

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: LOOK

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	82	79
	Median	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	2	2
Placebo	No	111	111	103	100	93	87	86
	Median	1	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0
	Max	4	4	4	3	3	3	3
Reboxetine	No	109	109	103	97	96	89	88
	Median	1	1	1	1	1	0	0
	Min	0	0	0	0	0	0	0
	Max	4	4	4	3	4	3	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 39

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: OUTWARD APPEARANCE

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	82	79
	Median	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	4	4	3	3	3	2	2
Placebo	No	111	111	103	100	93	87	86
	Median	1	1	1	1	1	0	0
	Min	0	0	0	0	0	0	0
	Max	4	4	4	3	3	2	2
Reboxetine	No	109	109	103	97	96	89	88
	Median	1	1	1	1	1	0	0
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 39

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: SPEECH

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	82	79
	Median	2	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	2	2
Placebo	No	111	111	103	100	93	87	86
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	4	4	3	3	3	3	3
Reboxetine	No	109	109	103	97	96	89	88
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	4	4	3	3	3	3	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 39

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: VOICE

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	82	79
	Median	1	1	1	1	1	0	0
	Min	0	0	0	0	0	0	0
	Max	4	4	3	3	2	2	2
Placebo	No	111	111	103	100	93	87	86
	Median	1	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	4	4	4	3	3	3	3
Reboxetine	No	109	109	103	97	96	89	88
	Median	1	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0
	Max	4	4	4	3	3	2	2

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 39

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: ADAPTABILITY, SUGGESTIBILITY

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	82	79
	Median	2	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0
	Max	4	3	3	3	2	3	2
Placebo	No	111	111	103	100	93	87	86
	Median	2	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	4	3	3	3	3	3	4
Reboxetine	No	109	109	103	97	96	89	88
	Median	2	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 39

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: CONTACTS, AFFECTIVE NEED

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	82	79
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	4	4	3	3	3	3	3
Placebo	No	111	111	103	100	93	87	86
	Median	2	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	4	4
Reboxetine	No	109	109	103	97	96	89	88
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	4	4	3	3	3	3	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 39

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: ANGUISH, ANXIETY

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	82	79
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	4	4	4	3	3	3	3
Placebo	No	111	111	103	100	93	87	86
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	4	4	4	4	4	3	3
Reboxetine	No	109	109	103	97	96	89	88
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	4	4	4	3	3	3	3

PHARMACIA CNS R9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 39

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: AGGRESSION, IRRITABILITY

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	82	79
	Median	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	3	3	4	3	2	2	3
Placebo	No	111	111	103	100	93	87	86
	Median	1	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	4	4	4	3	3	2	2
Reboxetine	No	109	109	103	97	96	89	88
	Median	1	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	4	4	3	3	3	2	2

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 39

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: SELF-AGGRESSION

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	82	79
	Median	1	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	2
Placebo	No	111	111	103	100	93	87	86
	Median	1	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	4	3	2
Reboxetine	No	109	109	103	97	96	89	88
	Median	1	1	1	1	1	0	0
	Min	0	0	0	0	0	0	0
	Max	4	4	4	3	3	3	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 39

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: GLOBAL EVALUATION

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	111	111	101	93	87	82	79
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	2
Placebo	No	111	111	103	100	93	87	86
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3
Reboxetine	No	109	109	103	97	96	89	88
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 41

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: BODY GESTURES

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	2	1	1	2	0	1
	Min	0	1	1	0	0	0	0
	Max	2	3	3	1	2	2	3
Placebo	No	6	5	5	7	2	86	111
	Median	2	2	1	2	1	1	1
	Min	1	0	0	0	0	0	0
	Max	2	3	2	2	2	3	3
Reboxetine	No	4	6	3	5	3	88	109
	Median	2	2	1	2	1	1	1
	Min	1	1	1	1	0	0	0
	Max	3	3	1	3	2	3	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 40

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Mean	13.50	19.29	19.14	7.50	14.17	6.46	9.14
	Median	14	18	19	8	19	6	8
	STD	6.75	6.50	8.97	9.19	7.96	5.32	7.44
	Min	2	12	8	1	3	0	0
	Max	24	32	36	14	21	22	36
	Mean diff. vs day0 (*)	3.60	-3.43	-0.71	12.00	3.00	12.67	9.46
Placebo	No	6	5	5	7	2	86	111
	Mean	14.00	19.00	16.20	17.29	18.00	9.43	11.06
	Median	15	22	14	20	18	8	10
	STD	6.23	5.20	8.04	7.93	14.14	7.47	7.96
	Min	6	10	5	3	8	0	0
	Max	21	22	25	25	28	33	33
	Mean diff. vs day0 (*)	4.33	-4.40	-1.00	1.86	1.00	8.79	6.94
Reboxetine	No	4	6	3	5	3	88	109
	Mean	21.00	19.00	15.00	20.40	10.67	7.59	9.59
	Median	22	20	15	20	6	7	8
	STD	7.07	5.48	1.00	8.99	11.72	6.87	8.10
	Min	12	11	14	8	2	0	0
	Max	29	24	16	30	24	34	34
	Mean diff. vs day0 (*)	-3.50	-2.83	-3.00	-0.20	6.33	11.66	9.21

Mean (*): mean of differences vs day0

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 41

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: LOOK

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	1	2	1	1	0	0
	Min	0	1	0	0	0	0	0
	Max	2	2	3	1	1	2	3
Placebo	No	6	5	5	7	2	86	111
	Median	1	1	1	2	1	0	1
	Min	0	0	0	0	0	0	0
	Max	1	2	2	2	2	3	3
Reboxetine	No	4	6	3	5	3	88	109
	Median	1	1	1	2	1	0	1
	Min	0	1	1	0	0	0	0
	Max	1	2	1	4	2	3	4

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 41

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: OUTWARD APPEARANCE

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	1	1	1	0	0	0
	Min	0	1	0	0	0	0	0
	Max	2	3	3	1	1	2	3
Placebo	No	6	5	5	7	2	86	111
	Median	1	1	1	1	1	0	1
	Min	0	1	0	0	0	0	0
	Max	1	2	2	2	2	2	2
Reboxetine	No	4	6	3	5	3	88	109
	Median	1	2	0	1	1	0	0
	Min	0	1	0	0	0	0	0
	Max	1	3	2	3	2	3	3

PHARMACIA CNS R95550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 41

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: SPEECH

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	2	2	1	2	2	1	1
	Min	0	1	1	0	0	0	0
	Max	2	3	3	3	2	2	3
Placebo	No	6	5	5	7	2	86	111
	Median	2	2	2	2	2	1	1
	Min	0	1	1	0	1	0	0
	Max	2	3	3	3	3	3	3
Reboxetine	No	4	6	3	5	3	88	109
	Median	2	2	2	2	0	1	1
	Min	2	1	2	1	0	0	0
	Max	3	3	2	3	2	3	3

PHARMACIA CNS R9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 41

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: VOICE

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	2	1	1	2	0	1
	Min	0	1	1	0	1	0	0
	Max	2	2	3	1	2	2	3
Placebo	No	6	5	5	7	2	86	111
	Median	1	1	1	2	2	1	1
	Min	0	0	1	0	1	0	0
	Max	2	2	2	2	2	3	3
Reboxetine	No	4	6	3	5	3	88	109
	Median	2	2	1	2	0	0	1
	Min	0	0	0	0	0	0	0
	Max	2	2	2	3	2	2	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 41

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: ADAPTABILITY, SUGGESTIBILITY

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	1	1	1	2	0	1
	Min	0	1	0	0	0	0	0
	Max	2	3	3	2	2	2	3
Placebo	No	6	5	5	7	2	86	111
	Median	1	1	2	2	1	1	1
	Min	1	0	0	0	0	0	0
	Max	2	2	2	2	2	4	4
Reboxetine	No	4	6	3	5	3	88	109
	Median	2	2	1	1	1	1	1
	Min	2	1	0	1	0	0	0
	Max	3	2	2	3	2	3	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 41

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: CONTACTS, AFFECTIVE NEED

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	2	1	1	2	1	1
	Min	0	1	1	0	0	0	0
	Max	3	3	3	1	3	3	3
Placebo	No	6	5	5	7	2	86	111
	Median	2	2	1	2	2	1	1
	Min	0	0	1	0	0	0	0
	Max	2	2	3	3	3	4	4
Reboxetine	No	4	6	3	5	3	88	109
	Median	3	2	1	2	1	1	1
	Min	2	0	1	1	1	0	0
	Max	3	3	1	3	2	3	3

PHARMACIA CNS R9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 41

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: ANGUISH, ANXIETY

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	2	2	1	1	1	1
	Min	0	1	1	1	0	0	0
	Max	3	3	3	1	3	3	3
Placebo	No	6	5	5	7	2	86	111
	Median	2	3	2	2	2	1	1
	Min	1	2	0	1	1	0	0
	Max	3	4	3	4	3	3	4
Reboxetine	No	4	6	3	5	3	88	109
	Median	3	2	2	2	1	1	1
	Min	2	2	2	0	0	0	0
	Max	3	4	3	3	2	3	4

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 41

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: GLOBAL EVALUATION

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	1	2	1	1	1	1
	Min	0	1	1	0	0	0	0
	Max	2	2	3	1	3	2	3
Placebo	No	6	5	5	7	2	86	111
	Median	2	2	0	2	2	1	1
	Min	0	1	0	0	1	0	0
	Max	2	2	3	2	2	3	3
Reboxetine	No	4	6	3	5	3	88	109
	Median	2	2	1	2	1	1	1
	Min	1	0	1	1	0	0	0
	Max	2	2	2	3	2	3	3

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 41

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: SELF-AGGRESSION

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	1	1	0	1	0	1
	Min	1	0	1	0	0	0	0
	Max	2	2	3	0	3	2	3
Placebo	No	6	5	5	7	2	86	111
	Median	1	1	2	1	2	1	1
	Min	0	0	1	1	1	0	0
	Max	2	3	3	4	3	2	4
Reboxetine	No	4	6	3	5	3	88	109
	Median	2	1	1	1	0	0	1
	Min	1	0	1	1	0	0	0
	Max	3	3	1	3	2	3	3

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 41

RELATIONAL DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: GLOBAL EVALUATION

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	10	7	7	2	6	79	111
	Median	1	1	2	1	1	1	1
	Min	0	1	1	0	0	0	0
	Max	2	2	3	1	3	2	3
Placebo	No	6	5	5	7	2	86	111
	Median	2	2	0	2	2	1	1
	Min	0	1	0	0	1	0	0
	Max	2	2	3	2	2	3	3
Reboxetine	No	4	6	3	5	3	88	109
	Median	2	2	1	2	1	1	1
	Min	1	0	1	1	0	0	0
	Max	2	2	2	3	2	3	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 42

ADVERSE EVENTS: FREQUENCY (95% C.I.) OF PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENT DURING THERAPY BY SEX AND ASSIGNED TREATMENT

	Assigned treatment								
	Imipramine			Placebo			Reboxetine		
	Female	Male	Total	Female	Male	Total	Female	Male	Total
Pt exposed	77	38	115	54	58	112	70	42	112
Pt with adverse events	54	27	81	29	29	58	44	27	71
% on exposed	70.12	71.05	70.43	53.70	50.00	51.78	62.85	64.28	63.39
95% L.L.	58.62	54.10	61.21	39.61	36.58	42.15	50.48	48.03	53.76
95% U.L.	80.03	84.58	78.58	67.38	63.42	61.33	74.11	78.45	72.29
No. of adverse events	218	70	288	78	63	141	136	75	211
Ratio A.E. on Pt with A.E.	4.03	2.59	3.55	2.68	2.17	2.43	3.09	2.77	2.97

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 43

ADVERSE EVENTS: FREQUENCY (95% C.I.) OF PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENT DURING THERAPY
BY AGE AND ASSIGNED TREATMENT

	Assigned treatment											
	Imipramine				Placebo				Reboxetine			
	Total	18 - 30	31 - 45	> 45	Total	18 - 30	31 - 45	> 45	Total	18 - 30	31 - 45	> 45
Pt exposed	115	17	44	54	112	15	50	47	112	14	41	57
Pt with adverse events	81	12	31	38	58	8	28	22	71	10	29	32
% on exposed	70.43	70.58	70.45	70.37	51.78	53.33	56.00	46.80	63.39	71.42	70.73	56.14
95% L.L.	61.21	44.04	54.80	56.39	42.15	26.59	41.25	32.11	53.76	41.90	54.46	42.36
95% U.L.	78.58	89.69	83.24	82.02	61.33	78.73	70.01	61.92	72.29	91.61	83.87	69.26
No. of adverse events	288	44	123	121	141	20	74	47	211	32	83	96
Ratio A.E. on Pt with A.E.	3.55	3.66	3.96	3.18	2.43	2.50	2.64	2.13	2.97	3.20	2.86	3.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 44

ADVERSE EVENTS: FREQUENCY (95% C.I.) OF PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENT DURING THERAPY
BY DSM III CLASSIFICATION AND ASSIGNED TREATMENT

	Assigned treatment											
	Inipramine				Placebo				Reboxetine			
	Total	296.2	296.3	296.5	Total	296.2	296.3		Total	296.2	296.3	296.5
Pt exposed	115	34	80	1	112	30	82		112	35	76	1
Pt with adverse events	81	24	56	1	58	12	46		71	20	51	0
% on exposed	70.43	70.58	70.00	100.00	51.78	40.00	56.09		63.39	57.14	67.10	0.00
95% L.L.	61.21	52.52	58.72	5.00	42.15	22.66	44.70		53.76	39.35	55.37	0.00
95% U.L.	78.58	84.90	79.74	100.00	61.33	59.40	67.05		72.29	73.68	77.46	95.00
No. of adverse events	288	82	204	2	141	19	122		211	53	158	0
Ratio A.E. on Pt with A.E.	3.55	3.41	3.64	2.00	2.43	1.58	2.65		2.97	2.65	3.09	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 45

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
Pt exposed	Imipramine	77	100.0				38	100.0				115	100.0			
	Placebo	54	100.0				58	100.0				112	100.0			
	Reboxetine	70	100.0				42	100.0				112	100.0			
Pt with a.e.	Imipramine	54	70.1	100.0	218	4.03	27	71.1	100.0	70	2.59	81	70.4	100.0	288	3.55
	Placebo	29	53.7	100.0	78	2.68	29	50.0	100.0	63	2.17	58	51.8	100.0	141	2.43
	Reboxetine	44	62.9	100.0	136	3.09	27	64.3	100.0	75	2.77	71	63.4	100.0	211	2.97
MOUTH DRY	Imipramine	35	45.5	64.8	38	1.08	14	36.8	51.8	15	1.07	49	42.6	60.4	53	1.08
	Placebo	10	18.5	34.4	10	1.00	4	6.9	13.7	5	1.25	14	12.5	24.1	15	1.07
	Reboxetine	19	27.1	43.1	20	1.05	9	21.4	33.3	9	1.00	28	25.0	39.4	29	1.03
CONSTIPATION	Imipramine	14	18.2	25.9	14	1.00	4	10.5	14.8	4	1.00	18	15.7	22.2	18	1.00
	Placebo	5	9.3	17.2	5	1.00	1	1.7	3.4	1	1.00	6	5.4	10.3	6	1.00
	Reboxetine	12	17.1	27.2	14	1.16	5	11.9	18.5	6	1.20	17	15.2	23.9	20	1.17
SWEATING INCREASED	Imipramine	16	20.8	29.6	20	1.25	6	15.8	22.2	6	1.00	22	19.1	27.1	26	1.18
	Placebo	2	3.7	6.8	2	1.00	1	1.7	3.4	1	1.00	3	2.7	5.1	3	1.00
	Reboxetine	11	15.7	25.0	12	1.09	3	7.1	11.1	3	1.00	14	12.5	19.7	15	1.07
HEADACHE	Imipramine	7	9.1	12.9	7	1.00	2	5.3	7.4	2	1.00	9	7.8	11.1	9	1.00
	Placebo	3	5.6	10.3	4	1.33	6	10.3	20.6	6	1.00	9	8.0	15.5	10	1.11
	Reboxetine	10	14.3	22.7	14	1.40	4	9.5	14.8	4	1.00	14	12.5	19.7	18	1.28
TREMOR	Imipramine	16	20.8	29.6	16	1.00	4	10.5	14.8	4	1.00	20	17.4	24.6	20	1.00
	Placebo	2	3.7	6.8	2	1.00	3	5.2	10.3	3	1.00	5	4.5	8.6	5	1.00
	Reboxetine	4	5.7	9.0	4	1.00	2	4.8	7.4	2	1.00	6	5.4	8.4	6	1.00
NAUSEA	Imipramine	11	14.3	20.3	13	1.18	2	5.3	7.4	3	1.50	13	11.3	16.0	16	1.23

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 45

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
NAUSEA	Placebo	8	14.8	27.5	10	1.25	1	1.7	3.4	1	1.00	9	8.0	15.5	11	1.22
	Reboxetine	6	8.6	13.6	6	1.00	3	7.1	11.1	3	1.00	9	8.0	12.6	9	1.00
DIZZINESS	Imipramine	10	13.0	18.5	12	1.20	4	10.5	14.8	4	1.00	14	12.2	17.2	16	1.14
	Placebo						4	6.9	13.7	4	1.00	4	3.6	6.8	4	1.00
	Reboxetine	3	4.3	6.8	4	1.33	3	7.1	11.1	4	1.33	6	5.4	8.4	8	1.33
INSOMNIA	Imipramine	6	7.8	11.1	6	1.00	2	5.3	7.4	2	1.00	8	7.0	9.8	8	1.00
	Placebo	2	3.7	6.8	2	1.00	2	3.4	6.8	2	1.00	4	3.6	6.8	4	1.00
	Reboxetine	7	10.0	15.9	7	1.00	5	11.9	18.5	5	1.00	12	10.7	16.9	12	1.00
AGITATION	Imipramine	2	2.6	3.7	2	1.00	2	5.3	7.4	2	1.00	4	3.5	4.9	4	1.00
	Placebo	1	1.9	3.4	1	1.00	6	10.3	20.6	6	1.00	7	6.3	12.0	7	1.00
	Reboxetine	4	5.7	9.0	4	1.00	3	7.1	11.1	4	1.33	7	6.3	9.8	8	1.14
VISION ABNORMAL	Imipramine	6	7.8	11.1	7	1.16	3	7.9	11.1	3	1.00	9	7.8	11.1	10	1.11
	Placebo						3	5.2	10.3	3	1.00	3	2.7	5.1	3	1.00
	Reboxetine	3	4.3	6.8	3	1.00	3	7.1	11.1	4	1.33	6	5.4	8.4	7	1.16
SOMNOLENCE	Imipramine	4	5.2	7.4	4	1.00	2	5.3	7.4	2	1.00	6	5.2	7.4	6	1.00
	Placebo	4	7.4	13.7	5	1.25	5	8.6	17.2	5	1.00	9	8.0	15.5	10	1.11
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
VERTIGO	Imipramine	7	9.1	12.9	8	1.14						7	6.1	8.6	8	1.14
	Reboxetine	4	5.7	9.0	4	1.00	1	2.4	3.7	1	1.00	5	4.5	7.0	5	1.00
FATIGUE	Imipramine	3	3.9	5.5	3	1.00	1	2.6	3.7	1	1.00	4	3.5	4.9	4	1.00
	Placebo	1	1.9	3.4	1	1.00	3	5.2	10.3	3	1.00	4	3.6	6.8	4	1.00
	Reboxetine	1	1.4	2.2	1	1.00	2	4.8	7.4	2	1.00	3	2.7	4.2	3	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 45

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
PARAESTHESIA	Imipramine	5	6.5	9.2	5	1.00	1	2.6	3.7	1	1.00	6	5.2	7.4	6	1.00
	Placebo	1	1.9	3.4	1	1.00	1	1.7	3.4	1	1.00	2	1.8	3.4	2	1.00
	Reboxetine	1	1.4	2.2	1	1.00	1	2.4	3.7	1	1.00	2	1.8	2.8	2	1.00
SUICIDE ATTEMPT	Imipramine	2	2.6	3.7	2	1.00	2	5.3	7.4	2	1.00	4	3.5	4.9	4	1.00
	Placebo	3	5.6	10.3	3	1.00	1	1.7	3.4	1	1.00	4	3.6	6.8	4	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
HYPOTENSION POSTURAL	Imipramine	5	6.5	9.2	5	1.00	1	2.6	3.7	1	1.00	6	5.2	7.4	6	1.00
	Reboxetine	2	2.9	4.5	2	1.00						2	1.8	2.8	2	1.00
ABDOMINAL PAIN	Imipramine	3	3.9	5.5	4	1.33	1	2.6	3.7	1	1.00	4	3.5	4.9	5	1.25
	Placebo	2	3.7	6.8	2	1.00	1	1.7	3.4	1	1.00	3	2.7	5.1	3	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
TACHYCARDIA	Imipramine	4	5.2	7.4	4	1.00						4	3.5	4.9	4	1.00
	Reboxetine	2	2.9	4.5	2	1.00	1	2.4	3.7	1	1.00	3	2.7	4.2	3	1.00
RHINITIS	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
	Placebo						4	6.9	13.7	4	1.00	4	3.6	6.8	4	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
VOMITING	Imipramine						1	2.6	3.7	1	1.00	1	0.9	1.2	1	1.00
	Placebo	4	7.4	13.7	4	1.00						4	3.6	6.8	4	1.00
	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
DYSPEPSIA	Imipramine	4	5.2	7.4	4	1.00	1	2.6	3.7	1	1.00	5	4.3	6.1	5	1.00
	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
HOT FLUSHES	Imipramine	2	2.6	3.7	2	1.00	1	2.6	3.7	2	2.00	3	2.6	3.7	4	1.33

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 45

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
HOT FLUSHES	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
	Reboxetine	1	1.4	2.2	1	1.00	1	2.4	3.7	1	1.00	2	1.8	2.8	2	1.00
HYPOTENSION	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Placebo	1	1.9	3.4	1	1.00	1	1.7	3.4	1	1.00	2	1.8	3.4	2	1.00
	Reboxetine	1	1.4	2.2	1	1.00	1	2.4	3.7	1	1.00	2	1.8	2.8	2	1.00
ANXIETY	Imipramine						1	2.6	3.7	1	1.00	1	0.9	1.2	1	1.00
	Placebo	2	3.7	6.8	2	1.00	1	1.7	3.4	1	1.00	3	2.7	5.1	3	1.00
	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
NERVOUSNESS	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
	Reboxetine	3	4.3	6.8	3	1.00	1	2.4	3.7	1	1.00	4	3.6	5.6	4	1.00
DYSPNOEA	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
	Reboxetine	3	4.3	6.8	5	1.66						3	2.7	4.2	5	1.66
MICTURITION DISORDER	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
	Reboxetine						3	7.1	11.1	3	1.00	3	2.7	4.2	3	1.00
URINARY TRACT INFECTION	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
	Reboxetine	4	5.7	9.0	4	1.00						4	3.6	5.6	4	1.00
URINARY RETENTION	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
	Reboxetine						3	7.1	11.1	3	1.00	3	2.7	4.2	3	1.00
PALPITATION	Imipramine	1	1.3	1.8	1	1.00	1	2.6	3.7	1	1.00	2	1.7	2.4	2	1.00
	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 45

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
ASTHENIA	Imipramine	1	1.3	1.8	1	1.00	2	5.3	7.4	2	1.00	3	2.6	3.7	3	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
RASH	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Placebo	2	3.7	6.8	2	1.00						2	1.8	3.4	2	1.00
MYALGIA	Imipramine						1	2.6	3.7	1	1.00	1	0.9	1.2	1	1.00
	Placebo						2	3.4	6.8	2	1.00	2	1.8	3.4	2	1.00
CONFUSION	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
HYPERKINESIA	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Placebo	1	1.9	3.4	1	1.00	1	1.7	3.4	1	1.00	2	1.8	3.4	2	1.00
MUSCLE CONTRACTIONS INVOLUNTARY	Imipramine						2	5.3	7.4	2	1.00	2	1.7	2.4	2	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
DIARRHOEA	Placebo	1	1.9	3.4	1	1.00	2	3.4	6.8	2	1.00	3	2.7	5.1	3	1.00
APPETITE INCREASED	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
WEIGHT INCREASE	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
SINUSITIS	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
	Reboxetine	2	2.9	4.5	2	1.00						2	1.8	2.8	2	1.00
DYSURIA	Imipramine						1	2.6	3.7	1	1.00	1	0.9	1.2	1	1.00
	Reboxetine						2	4.8	7.4	2	1.00	2	1.8	2.8	2	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 45

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
CHEST PAIN PRECORDIAL	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
INFLUENZA-LIKE SYMPTOMS	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
ARTHRALGIA	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
BACK PAIN	Placebo	2	3.7	6.8	2	1.00						2	1.8	3.4	2	1.00
HYPERTENSION	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
MYDRIASIS	Reboxetine	1	1.4	2.2	1	1.00	1	2.4	3.7	1	1.00	2	1.8	2.8	2	1.00
CONJUNCTIVITIS	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
TINNITUS	Imipramine	1	1.3	1.8	1	1.00	1	2.6	3.7	1	1.00	2	1.7	2.4	2	1.00
FLATULENCE	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
GAMMA-GT INCREASED	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
WEIGHT DECREASE	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
SYNCOPE	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
CHEST PAIN	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 45

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
RASH ERYTHEMATOUS	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
RHAGADES	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
COLD URTICARIA	Imipramine						1	2.6	3.7	1	1.00	1	0.9	1.2	1	1.00
HYPERTONIA	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
MIGRAINE	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
SPEECH DISORDER	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
ANOREXIA	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
ACCOMMODATION ABNORMAL	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
FLUSHING	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
BRADYCARDIA	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
SALIVA INCREASED	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
CHROMATOPSIA	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
EYE ABNORMALITY	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
TASTE LOSS	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
TASTE PERVERSION	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
AUTOLESIONIST BEHAVIOUR	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
DEPERSONALIZATION	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
LIBIDO DECREASED	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
PARONIRIA	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
SLEEP DISORDER	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 45

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
DEPRESSION AGGRAVATED	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
CONCENTRATION IMPAIRED	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
COLITIS	Imipramine						1	2.6	3.7	1	1.00	1	0.9	1.2	1	1.00
DUODENAL ULCER REACTIVATED	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
DYSPHAGIA	Imipramine						1	2.6	3.7	1	1.00	1	0.9	1.2	1	1.00
GASTRITIS	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
GASTROENTERITIS	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
TONGUE ULCERATION	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
TOOTH DISORDER	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
HYPERURICAEMIA	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
HYPOKALAEMIA	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
PHOSPHATASE ALKALINE INCREASED	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
HYPERTRIGLYCERIDA-EMIA	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
EXTRASYSTOLES	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
HAEMORRHOIDS THROMBOSED	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
BRONCHITIS	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
ANAEMIA HYPOCHROMIC	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
EOSINOPHILIA	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 45

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
MICTURITION FREQUENCY	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
PYURIA	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
IMPOTENCE	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
PERINEAL PAIN MALE	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
EPIDIDYMITIS	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
MALAISE	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
RIGORS	Imipramine						1	2.6	3.7	1	1.00	1	0.9	1.2	1	1.00
HYPERPYREXIA	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
PHARYNGITIS	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
HERPES SIMPLEX	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: AUTONOMIC NERVOUS SYSTEM DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
MOUTH DRY	Imipramine	35	45.5	64.8	38	1.08	14	36.8	51.8	15	1.07	49	42.6	60.4	53	1.08
	Placebo	10	18.5	34.4	10	1.00	4	6.9	13.7	5	1.25	14	12.5	24.1	15	1.07
	Reboxetine	19	27.1	43.1	20	1.05	9	21.4	33.3	9	1.00	28	25.0	39.4	29	1.03
SWEATING INCREASED	Imipramine	16	20.8	29.6	20	1.25	6	15.8	22.2	6	1.00	22	19.1	27.1	26	1.18
	Placebo	2	3.7	6.8	2	1.00	1	1.7	3.4	1	1.00	3	2.7	5.1	3	1.00
	Reboxetine	11	15.7	25.0	12	1.09	3	7.1	11.1	3	1.00	14	12.5	19.7	15	1.07
SALIVA INCREASED	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: BODY AS A WHOLE-GENERAL DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
ASTHENIA / FATIGUE	Imipramine	3	3.9	5.5	4	1.33	3	7.9	11.1	3	1.00	6	5.2	7.4	7	1.16
	Placebo	1	1.9	3.4	1	1.00	3	5.2	10.3	3	1.00	4	3.6	6.8	4	1.00
	Reboxetine	2	2.9	4.5	2	1.00	2	4.8	7.4	2	1.00	4	3.6	5.6	4	1.00
INFLUENZA-LIKE SYMPTOMS	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
CHEST PAIN	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
HYPERPYREXIA	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
MALAISE	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
RIGORS	Imipramine						1	2.6	3.7	1	1.00	1	0.9	1.2	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: CARDIOVASCULAR DISORDERS, GENERAL

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
HYPOTENSION AND RELATED SYMPTOMS	Imipramine	15	19.5	27.7	20	1.33	5	13.2	18.5	5	1.00	20	17.4	24.6	25	1.25
	Placebo	1	1.9	3.4	1	1.00	5	8.6	17.2	5	1.00	6	5.4	10.3	6	1.00
	Reboxetine	6	8.6	13.6	7	1.16	4	9.5	14.8	5	1.25	10	8.9	14.0	12	1.20
FLUSHING / HOT FLUSHES	Imipramine	2	2.6	3.7	2	1.00	1	2.6	3.7	2	2.00	3	2.6	3.7	4	1.33
	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
	Reboxetine	2	2.9	4.5	2	1.00	1	2.4	3.7	1	1.00	3	2.7	4.2	3	1.00
TACHYCARDIA	Imipramine	4	5.2	7.4	4	1.00						4	3.5	4.9	4	1.00
	Reboxetine	2	2.9	4.5	2	1.00	1	2.4	3.7	1	1.00	3	2.7	4.2	3	1.00
PALPITATION	Imipramine	1	1.3	1.8	1	1.00	1	2.6	3.7	1	1.00	2	1.7	2.4	2	1.00
	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
CARDIAC ISCHEMIA AND RELATED SYMPTOMS	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
HYPERTENSION	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
BRADYCARDIA	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
EXTRASYSTOLES	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
HAEMORRHOIDS THROMBOSED	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
HEADACHE / MIGRAINE	Imipramine	7	9.1	12.9	7	1.00	2	5.3	7.4	2	1.00	9	7.8	11.1	9	1.00
	Placebo	3	5.6	10.3	4	1.33	6	10.3	20.6	6	1.00	9	8.0	15.5	10	1.11
	Reboxetine	10	14.3	22.7	14	1.40	5	11.9	18.5	5	1.00	15	13.4	21.1	19	1.26
TREMOR	Imipramine	16	20.8	29.6	16	1.00	4	10.5	14.8	4	1.00	20	17.4	24.6	20	1.00
	Placebo	2	3.7	6.8	2	1.00	3	5.2	10.3	3	1.00	5	4.5	8.6	5	1.00
	Reboxetine	4	5.7	9.0	4	1.00	2	4.8	7.4	2	1.00	6	5.4	8.4	6	1.00
VERTIGO	Imipramine	7	9.1	12.9	8	1.14						7	6.1	8.6	8	1.14
	Reboxetine	4	5.7	9.0	4	1.00	1	2.4	3.7	1	1.00	5	4.5	7.0	5	1.00
PARAESTHESIA	Imipramine	5	6.5	9.2	5	1.00	1	2.6	3.7	1	1.00	6	5.2	7.4	6	1.00
	Placebo	1	1.9	3.4	1	1.00	1	1.7	3.4	1	1.00	2	1.8	3.4	2	1.00
	Reboxetine	1	1.4	2.2	1	1.00	1	2.4	3.7	1	1.00	2	1.8	2.8	2	1.00
CONFUSION	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
HYPERKINESIA	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Placebo	1	1.9	3.4	1	1.00	1	1.7	3.4	1	1.00	2	1.8	3.4	2	1.00
MUSCLE CONTRACTIONS INVOLUNTARY	Imipramine						2	5.3	7.4	2	1.00	2	1.7	2.4	2	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
HYPERTONIA	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
SPEECH DISORDER	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: GASTRO-INTESTINAL SYSTEM DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
CONSTIPATION	Imipramine	14	18.2	25.9	14	1.00	4	10.5	14.8	4	1.00	18	15.7	22.2	18	1.00
	Placebo	5	9.3	17.2	5	1.00	1	1.7	3.4	1	1.00	6	5.4	10.3	6	1.00
	Reboxetine	12	17.1	27.2	14	1.16	5	11.9	18.5	6	1.20	17	15.2	23.9	20	1.17
NAUSEA AND RELATED SYMPTOMS	Imipramine	13	16.9	24.0	17	1.30	4	10.5	14.8	5	1.25	17	14.8	20.9	22	1.29
	Placebo	9	16.7	31.0	15	1.66	1	1.7	3.4	1	1.00	10	8.9	17.2	16	1.60
	Reboxetine	7	10.0	15.9	7	1.00	3	7.1	11.1	4	1.33	10	8.9	14.0	11	1.10
ABDOMINAL PAIN	Imipramine	3	3.9	5.5	4	1.33	1	2.6	3.7	1	1.00	4	3.5	4.9	5	1.25
	Placebo	2	3.7	6.8	2	1.00	1	1.7	3.4	1	1.00	3	2.7	5.1	3	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
APPETITE INCREASED	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
DIARRHOEA	Placebo	1	1.9	3.4	1	1.00	2	3.4	6.8	2	1.00	3	2.7	5.1	3	1.00
FLATULENCE	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
ANOREXIA	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
COLITIS	Imipramine						1	2.6	3.7	1	1.00	1	0.9	1.2	1	1.00
DUODENAL ULCER REACTIVATED	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
DYSPHAGIA	Imipramine						1	2.6	3.7	1	1.00	1	0.9	1.2	1	1.00
GASTROENTERITIS	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
TONGUE ULCERATION	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: GASTRO-INTESTINAL SYSTEM DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
TOOTH DISORDER	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: HEARING AND VESTIBULAR DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
TINNITUS	Imipramine	1	1.3	1.8	1	1.00	1	2.6	3.7	1	1.00	2	1.7	2.4	2	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: HEMATOLOGY DISORDERS

Adverse events/Assigned treatment		Female					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
ANEMIA	Imipramine	1	1.3	1.8	1	1.00	1	0.9	1.2	1	1.00
EOSINOPHILIA	Imipramine	1	1.3	1.8	1	1.00	1	0.9	1.2	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: LIVER AND BILIAR SYSTEM DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
INCREASED LIVER ENZYMES	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: METABOLIC AND NUTRITIONAL DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
WEIGHT INCREASE	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
WEIGHT DECREASE	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
HYPERTRIGLYCERIDA-EMIA	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
HYPERURICAEMIA	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
HYPOKALAEMIA	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
PHOSPHATASE ALKALINE INCREASED	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: MUSCOLO-SKELETAL SYSTEM DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
MYALGIA	Imipramine						1	2.6	3.7	1	1.00	1	0.9	1.2	1	1.00
	Placebo						2	3.4	6.8	2	1.00	2	1.8	3.4	2	1.00
ARTHRALGIA	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
BACK PAIN	Placebo	2	3.7	6.8	2	1.00						2	1.8	3.4	2	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: PSYCHIATRIC DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
AGITATION / ANXIETY / NERVOUSNESS	Imipramine	2	2.6	3.7	2	1.00	3	7.9	11.1	3	1.00	5	4.3	6.1	5	1.00
	Placebo	4	7.4	13.7	4	1.00	6	10.3	20.6	7	1.16	10	8.9	17.2	11	1.10
	Reboxetine	7	10.0	15.9	7	1.00	4	9.5	14.8	6	1.50	11	9.8	15.4	13	1.18
INSOMNIA	Imipramine	6	7.8	11.1	6	1.00	2	5.3	7.4	2	1.00	8	7.0	9.8	8	1.00
	Placebo	2	3.7	6.8	2	1.00	2	3.4	6.8	2	1.00	4	3.6	6.8	4	1.00
	Reboxetine	7	10.0	15.9	7	1.00	5	11.9	18.5	5	1.00	12	10.7	16.9	12	1.00
SOMNOLENCE	Imipramine	4	5.2	7.4	4	1.00	2	5.3	7.4	2	1.00	6	5.2	7.4	6	1.00
	Placebo	4	7.4	13.7	5	1.25	5	8.6	17.2	5	1.00	9	8.0	15.5	10	1.11
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
SUICIDE ATTEMPT	Imipramine	2	2.6	3.7	2	1.00	2	5.3	7.4	2	1.00	4	3.5	4.9	4	1.00
	Placebo	3	5.6	10.3	3	1.00	1	1.7	3.4	1	1.00	4	3.6	6.8	4	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
AUTOLESIONIST BEHAVIOUR	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
CONCENTRATION IMPAIRED	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
DEPERSONALIZATION	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
DEPRESSION AGGRAVATED	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
LIBIDO DECREASED	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
PARONIRIA	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
SLEEP DISORDER	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: REPRODUCTIVE DISORDERS, MALE

Adverse events/Assigned treatment		Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
EPIDIDYMITIS	Reboxetine	1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
IMPOTENCE	Reboxetine	1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
PERINEAL PAIN MALE	Reboxetine	1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: RESISTANCE MECHANISM DISORDERS

Adverse events/Assigned treatment		Female					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
HERPES SIMPLEX	Placebo	1	1.9	3.4	1	1.00	1	0.9	1.7	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: RESPIRATORY SYSTEM DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
RHINITIS	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
	Placebo						4	6.9	13.7	4	1.00	4	3.6	6.8	4	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
DYSPNOEA	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
	Reboxetine	3	4.3	6.8	5	1.66						3	2.7	4.2	5	1.66
SINUSITIS	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
	Reboxetine	2	2.9	4.5	2	1.00						2	1.8	2.8	2	1.00
BRONCHITIS	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
PHARYNGITIS	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: SKIN AND APPENDAGES DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
ERYTHEMA / RASH	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Placebo	2	3.7	6.8	2	1.00						2	1.8	3.4	2	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
COLD URTICARIA	Imipramine						1	2.6	3.7	1	1.00	1	0.9	1.2	1	1.00
RHAGADES	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: SPECIAL SENSES OTHER, DISORDERS

Adverse events/Assigned treatment		Female					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
TASTE LOSS	Imipramine	1	1.3	1.8	1	1.00	1	0.9	1.2	1	1.00
TASTE PERVERSION	Placebo	1	1.9	3.4	1	1.00	1	0.9	1.7	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: URINARY SYSTEM DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
URINARY HESITANCY / RETENTION	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Placebo	1	1.9	3.4	1	1.00	1	1.7	3.4	1	1.00	2	1.8	3.4	2	1.00
	Reboxetine						6	14.3	22.2	6	1.00	6	5.4	8.4	6	1.00
URINARY TRACT INFECTION	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
	Reboxetine	4	5.7	9.0	4	1.00						4	3.6	5.6	4	1.00
DYSURIA	Imipramine						1	2.6	3.7	1	1.00	1	0.9	1.2	1	1.00
	Reboxetine						2	4.8	7.4	2	1.00	2	1.8	2.8	2	1.00
MICTURITION FREQUENCY	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
PYURIA	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: VISION DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
BLURRED VISION	Imipramine	7	9.1	12.9	8	1.14	3	7.9	11.1	3	1.00	10	8.7	12.3	11	1.10
	Placebo						3	5.2	10.3	3	1.00	3	2.7	5.1	3	1.00
	Reboxetine	3	4.3	6.8	3	1.00	3	7.1	11.1	4	1.33	6	5.4	8.4	7	1.16
CONJUNCTIVITIS	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
MYDRIASIS	Reboxetine	1	1.4	2.2	1	1.00	1	2.4	3.7	1	1.00	2	1.8	2.8	2	1.00
CHROMATOPSIA	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
EYE ABNORMALITY	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT AND SEX, GROUPED BY BODY SYSTEM

Body system/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
Pt exposed	Imipramine	77	100.0				38	100.0				115	100.0			
	Placebo	54	100.0				58	100.0				112	100.0			
	Reboxetine	70	100.0				42	100.0				112	100.0			
Pt with a.e.	Imipramine	54	70.1	100.0	218	4.03	27	71.1	100.0	70	2.59	81	70.4	100.0	288	3.55
	Placebo	29	53.7	100.0	78	2.68	29	50.0	100.0	63	2.17	58	51.8	100.0	141	2.43
	Reboxetine	44	62.9	100.0	136	3.09	27	64.3	100.0	75	2.77	71	63.4	100.0	211	2.97
AUTONOMIC NERVOUS SYSTEM DISORDERS	Imipramine	39	50.6	72.2	58	1.48	17	44.7	62.9	21	1.23	56	48.7	69.1	79	1.41
	Placebo	12	22.2	41.3	12	1.00	5	8.6	17.2	6	1.20	17	15.2	29.3	18	1.05
	Reboxetine	27	38.6	61.3	32	1.18	13	31.0	48.1	13	1.00	40	35.7	56.3	45	1.12
GASTRO-INTESTINAL SYSTEM DISORDERS	Imipramine	28	36.4	51.8	38	1.35	8	21.1	29.6	12	1.50	36	31.3	44.4	50	1.38
	Placebo	13	24.1	44.8	25	1.92	5	8.6	17.2	6	1.20	18	16.1	31.0	31	1.72
	Reboxetine	19	27.1	43.1	26	1.36	7	16.7	25.9	10	1.42	26	23.2	36.6	36	1.38
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Imipramine	30	39.0	55.5	40	1.33	6	15.8	22.2	9	1.50	36	31.3	44.4	49	1.36
	Placebo	7	13.0	24.1	9	1.28	9	15.5	31.0	11	1.22	16	14.3	27.5	20	1.25
	Reboxetine	18	25.7	40.9	24	1.33	9	21.4	33.3	10	1.11	27	24.1	38.0	34	1.25
PSYCHIATRIC DISORDERS	Imipramine	16	20.8	29.6	18	1.12	9	23.7	33.3	9	1.00	25	21.7	30.8	27	1.08
	Placebo	13	24.1	44.8	16	1.23	11	19.0	37.9	15	1.36	24	21.4	41.3	31	1.29
	Reboxetine	12	17.1	27.2	16	1.33	8	19.0	29.6	12	1.50	20	17.9	28.1	28	1.40
CARDIOVASCULAR DISORDERS, GENERAL	Imipramine	21	27.3	38.8	31	1.47	7	18.4	25.9	8	1.14	28	24.3	34.5	39	1.39
	Placebo	4	7.4	13.7	4	1.00	6	10.3	20.6	6	1.00	10	8.9	17.2	10	1.00
	Reboxetine	9	12.9	20.4	13	1.44	7	16.7	25.9	8	1.14	16	14.3	22.5	21	1.31
VISION DISORDERS	Imipramine	9	11.7	16.6	10	1.11	3	7.9	11.1	3	1.00	12	10.4	14.8	13	1.08

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT AND SEX, GROUPED BY BODY SYSTEM

Body system/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
VISION DISORDERS	Placebo	1	1.9	3.4	1	1.00	3	5.2	10.3	3	1.00	4	3.6	6.8	4	1.00
	Reboxetine	5	7.1	11.3	5	1.00	4	9.5	14.8	5	1.25	9	8.0	12.6	10	1.11
BODY AS A WHOLE-GENERAL DISORDERS	Imipramine	5	6.5	9.2	6	1.20	4	10.5	14.8	4	1.00	9	7.8	11.1	10	1.11
	Placebo	1	1.9	3.4	1	1.00	5	8.6	17.2	5	1.00	6	5.4	10.3	6	1.00
	Reboxetine	4	5.7	9.0	4	1.00	3	7.1	11.1	3	1.00	7	6.3	9.8	7	1.00
URINARY SYSTEM DISORDERS	Imipramine	1	1.3	1.8	1	1.00	1	2.6	3.7	1	1.00	2	1.7	2.4	2	1.00
	Placebo	2	3.7	6.8	2	1.00	2	3.4	6.8	2	1.00	4	3.6	6.8	4	1.00
	Reboxetine	5	7.1	11.3	5	1.00	7	16.7	25.9	8	1.14	12	10.7	16.9	13	1.08
RESPIRATORY SYSTEM DISORDERS	Imipramine	4	5.2	7.4	4	1.00						4	3.5	4.9	4	1.00
	Placebo	1	1.9	3.4	1	1.00	6	10.3	20.6	6	1.00	7	6.3	12.0	7	1.00
	Reboxetine	4	5.7	9.0	8	2.00						4	3.6	5.6	8	2.00
METABOLIC AND NUTRITIONAL DISORDERS	Imipramine	5	6.5	9.2	5	1.00						5	4.3	6.1	5	1.00
	Placebo						1	1.7	3.4	1	1.00	1	0.9	1.7	1	1.00
	Reboxetine	1	1.4	2.2	2	2.00	1	2.4	3.7	1	1.00	2	1.8	2.8	3	1.50
MUSCOLO-SKELETAL SYSTEM DISORDERS	Imipramine						1	2.6	3.7	1	1.00	1	0.9	1.2	1	1.00
	Placebo	3	5.6	10.3	3	1.00	2	3.4	6.8	2	1.00	5	4.5	8.6	5	1.00
	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
SKIN AND APPENDAGES DISORDERS	Imipramine	2	2.6	3.7	2	1.00	1	2.6	3.7	1	1.00	3	2.6	3.7	3	1.00
	Placebo	2	3.7	6.8	2	1.00						2	1.8	3.4	2	1.00
	Reboxetine	1	1.4	2.2	1	1.00						1	0.9	1.4	1	1.00
HEARING AND VESTIBULAR DISORDERS	Imipramine	1	1.3	1.8	1	1.00	1	2.6	3.7	1	1.00	2	1.7	2.4	2	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT AND SEX, GROUPED BY BODY SYSTEM

Body system/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
HEMATOLOGY DISORDERS	Imipramine	2	2.6	3.7	2	1.00						2	1.7	2.4	2	1.00
LIVER AND BILIAR SYSTEM DISORDERS	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Reboxetine						1	2.4	3.7	1	1.00	1	0.9	1.4	1	1.00
REPRODUCTIVE DISORDERS, MALE	Reboxetine						2	4.8	7.4	3	1.50	2	1.8	2.8	3	1.50
SPECIAL SENSES OTHER, DISORDERS	Imipramine	1	1.3	1.8	1	1.00						1	0.9	1.2	1	1.00
	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00
RESISTANCE MECHANISM DISORDERS	Placebo	1	1.9	3.4	1	1.00						1	0.9	1.7	1	1.00

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 48

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Adverse events	Assigned treatment																
MOUTH DRY	Imipramine	53	100	33	62.3	8	15.1	6	11.3	4	7.5	2	3.8				
	Placebo	15	100	8	53.3	2	13.3	2	13.3	3	20.0						
	Reboxetine	29	100	17	58.6	9	31.0	2	6.9					1	3.4		
CONSTIPATION	Imipramine	18	100	5	27.8	7	38.9	3	16.7			2	11.1	1	5.6		
	Placebo	6	100	1	16.7	3	50.0	1	16.7			1	16.7				
	Reboxetine	20	100	7	35.0	8	40.0	1	5.0	3	15.0	1	5.0				
SWEATING INCREASED	Imipramine	26	100	15	57.7	3	11.5	1	3.8	4	15.4	1	3.8	1	3.8	1	3.8
	Placebo	3	100	2	66.7	1	33.3										
	Reboxetine	15	100	7	46.7	6	40.0	1	6.7	1	6.7						
TREMOR	Imipramine	20	100	6	30.0	6	30.0	5	25.0	1	5.0	2	10.0				
	Placebo	5	100	4	80.0							1	20.0				
	Reboxetine	6	100	4	66.7	1	16.7			1	16.7						
HEADACHE	Imipramine	9	100	4	44.4	1	11.1	2	22.2	2	22.2						
	Placebo	10	100	3	30.0	2	20.0	3	30.0	1	10.0	1	10.0				
	Reboxetine	18	100	10	55.6	3	16.7			3	16.7	1	5.6	1	5.6		
NAUSEA	Imipramine	16	100	6	37.5	3	18.8	4	25.0					2	12.5	1	6.3
	Placebo	11	100	3	27.3	3	27.3	2	18.2	1	9.1	2	18.2				
	Reboxetine	9	100	6	66.7			2	22.2	1	11.1						
INSOMNIA	Imipramine	8	100	4	50.0	1	12.5	1	12.5			2	25.0				
	Placebo	4	100	2	50.0			1	25.0	1	25.0						
	Reboxetine	12	100	6	50.0	2	16.7	3	25.0					1	8.3		
VISION ABNORMAL	Imipramine	10	100	3	30.0	4	40.0	1	10.0			2	20.0				

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 48

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Adverse events	Assigned treatment																
VISION ABNORMAL	Placebo	3	100			3	100										
	Reboxetine	7	100	3	42.9	1	14.3	1	14.3	2	28.6						
DIZZINESS	Imipramine	16	100	6	37.5	4	25.0	2	12.5	1	6.3	1	6.3	2	12.5		
	Placebo	4	100	1	25.0			2	50.0			1	25.0				
	Reboxetine	8	100	2	25.0	2	25.0			2	25.0	2	25.0				
SOMNOLENCE	Imipramine	6	100	6	100												
	Placebo	10	100	3	30.0	1	10.0			3	30.0	2	20.0	1	10.0		
	Reboxetine	1	100					1	100								
AGITATION	Imipramine	4	100	3	75.0	1	25.0										
	Placebo	7	100	4	57.1	2	28.6			1	14.3						
	Reboxetine	8	100	2	25.0	3	37.5	2	25.0					1	12.5		
FATIGUE	Imipramine	4	100					1	25.0	1	25.0	2	50.0				
	Placebo	4	100			3	75.0	1	25.0								
	Reboxetine	3	100	1	33.3	1	33.3	1	33.3								
VERTIGO	Imipramine	8	100	5	62.5			1	12.5	2	25.0						
	Reboxetine	5	100	3	60.0	2	40.0										
ABDOMINAL PAIN	Imipramine	5	100	2	40.0	2	40.0	1	20.0								
	Placebo	3	100	1	33.3	2	66.7										
	Reboxetine	1	100					1	100								
MICTURITION DISORDER	Imipramine	1	100	1	100												
	Placebo	1	100	1	100												
	Reboxetine	3	100	1	33.3			1	33.3	1	33.3						

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 48

ADVERSE EVENTS; OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Adverse events	Assigned treatment																
HOT FLUSHES	Imipramine	4	100	1	25.0	1	25.0	1	25.0			1	25.0				
	Placebo	1	100									1	100				
	Reboxetine	2	100			1	50.0	1	50.0								
PARAESTHESIA	Imipramine	6	100	4	66.7	1	16.7			1	16.7						
	Placebo	2	100	1	50.0			1	50.0								
	Reboxetine	2	100	2	100												
RHINITIS	Imipramine	2	100	1	50.0			1	50.0								
	Placebo	4	100	1	25.0	1	25.0	2	50.0								
	Reboxetine	1	100	1	100												
HYPOTENSION POSTURAL	Imipramine	6	100	4	66.7					1	16.7			1	16.7		
	Reboxetine	2	100	1	50.0					1	50.0						
WEIGHT INCREASE	Imipramine	2	100	1	50.0					1	50.0						
	Reboxetine	1	100	1	100												
APPETITE INCREASED	Imipramine	2	100	2	100												
	Placebo	1	100	1	100												
DYSPEPSIA	Imipramine	5	100	1	20.0	1	20.0	2	40.0					1	20.0		
	Placebo	1	100	1	100												
URINARY RETENTION	Placebo	1	100	1	100												
	Reboxetine	3	100	3	100												
NERVOUSNESS	Placebo	1	100			1	100										
	Reboxetine	4	100	2	50.0	2	50.0										
ASTHENIA	Imipramine	3	100	2	66.7			1	33.3								

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 48

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Adverse events	Assigned treatment																
ASTHENIA	Reboxetine	1	100	1	100												
TACHYCARDIA	Imipramine	4	100	2	50.0	1	25.0	1	25.0								
	Reboxetine	3	100	2	66.7			1	33.3								
URINARY TRACT INFECTION	Placebo	1	100											1	100		
	Reboxetine	4	100					3	75.0					1	25.0		
PALPITATION	Imipramine	2	100	1	50.0			1	50.0								
	Placebo	1	100					1	100								
	Reboxetine	1	100	1	100												
SUICIDE ATTEMPT	Imipramine	4	100	2	50.0							1	25.0	1	25.0		
	Placebo	4	100					1	25.0	2	50.0	1	25.0				
	Reboxetine	1	100	1	100												
HYPOTENSION	Imipramine	1	100			1	100										
	Placebo	2	100	1	50.0					1	50.0						
	Reboxetine	2	100	1	50.0					1	50.0						
DYSPNOEA	Imipramine	2	100	2	100												
	Reboxetine	5	100							2	40.0	2	40.0	1	20.0		
FLATULENCE	Placebo	1	100			1	100										
	Reboxetine	1	100			1	100										
HYPERKINESIA	Imipramine	1	100	1	100												
	Placebo	2	100	1	50.0	1	50.0										
HYPERTENSION	Imipramine	1	100	1	100												
	Reboxetine	1	100	1	100												

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 48

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Adverse events	Assigned treatment																
VOMITING	Imipramine	1	100	1	100												
	Placebo	4	100	2	50.0	1	25.0	1	25.0								
	Reboxetine	1	100	1	100												
SLEEP DISORDER	Imipramine	1	100	1	100												
WEIGHT DECREASE	Placebo	1	100					1	100								
	Reboxetine	1	100	1	100												
SINUSITIS	Placebo	1	100			1	100										
	Reboxetine	2	100			1	50.0	1	50.0								
MUSCLE CONTRACTIONS INVOLUNTARY	Imipramine	2	100					1	50.0	1	50.0						
	Reboxetine	1	100					1	100								
RASH	Imipramine	1	100									1	100				
	Placebo	2	100											2	100		
ANXIETY	Imipramine	1	100							1	100						
	Placebo	3	100	3	100												
	Reboxetine	1	100	1	100												
PERINEAL PAIN MALE	Reboxetine	1	100	1	100												
MYALGIA	Imipramine	1	100	1	100												
	Placebo	2	100	2	100												
CONFUSION	Imipramine	2	100	1	50.0	1	50.0										
	Reboxetine	1	100	1	100												
CONJUNCTIVITIS	Imipramine	2	100	1	50.0	1	50.0										
CHEST PAIN PRECORDIAL	Imipramine	2	100	1	50.0	1	50.0										

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 48

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

		Total		Days of treatment															
				0-7		8-14		15-21		22-28		29-35		36-42		> 42			
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%		
Adverse events	Assigned treatment																		
CHEST PAIN PRECORDIAL	Placebo	1	100			1	100												
DIARRHOEA	Placebo	3	100	3	100														
IMPOTENCE	Reboxetine	1	100	1	100														
EPIDIDYMITIS	Reboxetine	1	100	1	100														
BACK PAIN	Placebo	2	100					1	50.0	1	50.0								
TINNITUS	Imipramine	2	100	1	50.0	1	50.0												
TASTE LOSS	Imipramine	1	100	1	100														
DYSURIA	Imipramine	1	100	1	100														
	Reboxetine	2	100	2	100														
ARTHRALGIA	Placebo	1	100	1	100														
	Reboxetine	1	100									1	100						
ANOREXIA	Reboxetine	1	100	1	100														
MYDRIASIS	Reboxetine	2	100	1	50.0	1	50.0												
RHAGADES	Imipramine	1	100					1	100										
CONCENTRATION IMPAIRED	Imipramine	1	100							1	100								
INFLUENZA-LIKE SYMPTOMS	Imipramine	1	100							1	100								
	Placebo	1	100							1	100								
	Reboxetine	1	100									1	100						
HYPERURICAEMIA	Reboxetine	1	100							1	100								
DYSPHAGIA	Imipramine	1	100	1	100														
SALIVA INCREASED	Reboxetine	1	100	1	100														

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 48

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Adverse events	Assigned treatment																
DUODENAL ULCER REACTIVATED	Imipramine	1	100			1	100										
GAMMA-GT INCREASED	Imipramine	1	100											1	100		
	Reboxetine	1	100					1	100								
SPEECH DISORDER	Imipramine	1	100							1	100						
HYPERTONIA	Placebo	1	100							1	100						
DEPERSONALIZATION	Imipramine	1	100	1	100												
SYNCOPE	Imipramine	2	100	1	50.0	1	50.0										
CHEST PAIN	Imipramine	1	100	1	100												
	Reboxetine	1	100	1	100												
MICTURITION FREQUENCY	Placebo	1	100	1	100												
EYE ABNORMALITY	Reboxetine	1	100	1	100												
TOOTH DISORDER	Reboxetine	1	100	1	100												
COLD URTICARIA	Imipramine	1	100			1	100										
RIGORS	Imipramine	1	100			1	100										
PHARYNGITIS	Placebo	1	100			1	100										
FLUSHING	Reboxetine	1	100			1	100										
HAEMORRHOIDS THROMBOSED	Reboxetine	1	100			1	100										
TONGUE ULCERATION	Placebo	1	100					1	100								
LIBIDO DECREASED	Reboxetine	1	100					1	100								
TASTE PERVERSION	Placebo	1	100							1	100						
PARONIRIA	Placebo	1	100							1	100						

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 48

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Adverse events	Assigned treatment																
ACCOMMODATION ABNORMAL	Imipramine	1	100									1	100				
AUTOLESIONIST BEHAVIOUR	Imipramine	1	100	1	100												
MIGRAINE	Reboxetine	1	100	1	100												
HYPERPYREXIA	Reboxetine	1	100	1	100												
COLITIS	Imipramine	1	100					1	100								
EXTRASYSTOLES	Imipramine	1	100					1	100								
BRADYCARDIA	Placebo	1	100					1	100								
CHROMATOPSIA	Placebo	1	100					1	100								
MALAISE	Placebo	1	100					1	100								
HYPOKALAEMIA	Imipramine	1	100							1	100						
DEPRESSION AGGRAVATED	Placebo	1	100							1	100						
GASTRITIS	Reboxetine	1	100							1	100						
PYURIA	Reboxetine	1	100							1	100						
GASTROENTERITIS	Reboxetine	1	100									1	100				
PHOSPHATASE ALKALINE INCREASED	Imipramine	1	100											1	100		
ANAEMIA HYPOCHROMIC	Imipramine	1	100											1	100		
EOSINOPHILIA	Imipramine	1	100											1	100		
BRONCHITIS	Placebo	1	100											1	100		
HERPES SIMPLEX	Placebo	1	100											1	100		
RASH ERYTHEMATOUS	Reboxetine	1	100											1	100		
HYPERTRIGLYCERIDAEMIA	Imipramine	1	100													1	100

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: AUTONOMIC NERVOUS SYSTEM DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
MOUTH DRY	Imipramine	53	100	33	62.3	8	15.1	6	11.3	4	7.5	2	3.8				
	Placebo	15	100	8	53.3	2	13.3	2	13.3	3	20.0						
	Reboxetine	29	100	17	58.6	9	31.0	2	6.9					1	3.4		
SWEATING INCREASED	Imipramine	26	100	15	57.7	3	11.5	1	3.8	4	15.4	1	3.8	1	3.8	1	3.8
	Placebo	3	100	2	66.7	1	33.3										
	Reboxetine	15	100	7	46.7	6	40.0	1	6.7	1	6.7						
SALIVA INCREASED	Reboxetine	1	100	1	100												

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: BODY AS A WHOLE-GENERAL DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment															
				0-7		8-14		15-21		22-28		29-35		36-42		> 42			
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%		
ASTHENIA / FATIGUE	Imipramine	7	100	2	28.6			2	28.6	1	14.3	2	28.6						
	Placebo	4	100			3	75.0	1	25.0										
	Reboxetine	4	100	2	50.0	1	25.0	1	25.0										
INFLUENZA-LIKE SYMPTOMS	Imipramine	1	100							1	100								
	Placebo	1	100							1	100								
	Reboxetine	1	100									1	100						
CHEST PAIN	Imipramine	1	100	1	100														
	Reboxetine	1	100	1	100														
RIGORS	Imipramine	1	100			1	100												
HYPERPYREXIA	Reboxetine	1	100	1	100														
MALAISE	Placebo	1	100					1	100										

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: CARDIOVASCULAR DISORDERS, GENERAL

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
HYPOTENSION AND RELATED SYMPTOMS	Imipramine	25	100	11	44.0	6	24.0	2	8.0	2	8.0	1	4.0	3	12.0		
	Placebo	6	100	2	33.3			2	33.3	1	16.7	1	16.7				
	Reboxetine	12	100	4	33.3	2	16.7			4	33.3	2	16.7				
FLUSHING / HOT FLUSHES	Imipramine	4	100	1	25.0	1	25.0	1	25.0			1	25.0				
	Placebo	1	100									1	100				
	Reboxetine	3	100			2	66.7	1	33.3								
TACHYCARDIA	Imipramine	4	100	2	50.0	1	25.0	1	25.0								
	Reboxetine	3	100	2	66.7			1	33.3								
PALPITATION	Imipramine	2	100	1	50.0			1	50.0								
	Placebo	1	100					1	100								
	Reboxetine	1	100	1	100												
HYPERTENSION	Imipramine	1	100	1	100												
	Reboxetine	1	100	1	100												
CARDIAC ISCHEMIA AND RELATED SYMPTOMS	Imipramine	2	100	1	50.0	1	50.0										
	Placebo	1	100			1	100										
HAEMORRHOIDS THROMBOSED	Reboxetine	1	100			1	100										
EXTRASYSTOLES	Imipramine	1	100					1	100								
BRADYCARDIA	Placebo	1	100					1	100								

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
TREMOR	Imipramine	20	100	6	30.0	6	30.0	5	25.0	1	5.0	2	10.0				
	Placebo	5	100	4	80.0							1	20.0				
	Reboxetine	6	100	4	66.7	1	16.7			1	16.7						
HEADACHE / MIGRAINE	Imipramine	9	100	4	44.4	1	11.1	2	22.2	2	22.2						
	Placebo	10	100	3	30.0	2	20.0	3	30.0	1	10.0	1	10.0				
	Reboxetine	19	100	11	57.9	3	15.8			3	15.8	1	5.3	1	5.3		
VERTIGO	Imipramine	8	100	5	62.5			1	12.5	2	25.0						
	Reboxetine	5	100	3	60.0	2	40.0										
PARAESTHESIA	Imipramine	6	100	4	66.7	1	16.7			1	16.7						
	Placebo	2	100	1	50.0			1	50.0								
	Reboxetine	2	100	2	100												
HYPERKINESIA	Imipramine	1	100	1	100												
	Placebo	2	100	1	50.0	1	50.0										
MUSCLE CONTRACTIONS INVOLUNTARY	Imipramine	2	100					1	50.0	1	50.0						
	Reboxetine	1	100					1	100								
CONFUSION	Imipramine	2	100	1	50.0	1	50.0										
	Reboxetine	1	100	1	100												
SPEECH DISORDER	Imipramine	1	100							1	100						
HYPERTONIA	Placebo	1	100							1	100						

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: GASTRO-INTESTINAL SYSTEM DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment															
				0-7		8-14		15-21		22-28		29-35		36-42		> 42			
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%		
CONSTIPATION	Imipramine	18	100	5	27.8	7	38.9	3	16.7			2	11.1	1	5.6				
	Placebo	6	100	1	16.7	3	50.0	1	16.7			1	16.7						
	Reboxetine	20	100	7	35.0	8	40.0	1	5.0	3	15.0	1	5.0						
NAUSEA AND RELATED SYMPTOMS	Imipramine	22	100	8	36.4	4	18.2	6	27.3					3	13.6	1	4.5		
	Placebo	16	100	6	37.5	4	25.0	3	18.8	1	6.3	2	12.5						
	Reboxetine	11	100	7	63.6			2	18.2	2	18.2								
ABDOMINAL PAIN	Imipramine	5	100	2	40.0	2	40.0	1	20.0										
	Placebo	3	100	1	33.3	2	66.7												
	Reboxetine	1	100					1	100										
APPETITE INCREASED	Imipramine	2	100	2	100														
	Placebo	1	100	1	100														
FLATULENCE	Placebo	1	100			1	100												
	Reboxetine	1	100			1	100												
DIARRHOEA	Placebo	3	100	3	100														
ANOREXIA	Reboxetine	1	100	1	100														
DYSPHAGIA	Imipramine	1	100	1	100														
DUODENAL ULCER REACTIVATED	Imipramine	1	100			1	100												
TOOTH DISORDER	Reboxetine	1	100	1	100														
TONGUE ULCERATION	Placebo	1	100					1	100										
COLITIS	Imipramine	1	100					1	100										
GASTROENTERITIS	Reboxetine	1	100									1	100						

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: HEARING AND VESTIBULAR DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
TINNITUS	Imipramine	2	100	1	50.0	1	50.0										

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: HEMATOLOGY DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
ANEMIA	Imipramine	1	100											1	100		
EOSINOPHILIA	Imipramine	1	100											1	100		

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: LIVER AND BILIAR SYSTEM DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment															
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
INCREASED LIVER ENZYMES	Imipramine	1	100											1	100		
	Reboxetine	1	100					1	100								

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: METABOLIC AND NUTRITIONAL DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
WEIGHT INCREASE	Imipramine	2	100	1	50.0					1	50.0						
	Reboxetine	1	100	1	100												
WEIGHT DECREASE	Placebo	1	100					1	100								
	Reboxetine	1	100	1	100												
HYPERURICAEMIA	Reboxetine	1	100							1	100						
HYPOKALAEMIA	Imipramine	1	100							1	100						
PHOSPHATASE ALKALINE INCREASED	Imipramine	1	100											1	100		
HYPERTRIGLYCERIDAEMIA	Imipramine	1	100													1	100

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: MUSCOLO-SKELETAL SYSTEM DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
MYALGIA	Imipramine	1	100	1	100												
	Placebo	2	100	2	100												
BACK PAIN	Placebo	2	100					1	50.0	1	50.0						
ARTHRALGIA	Placebo	1	100	1	100												
	Reboxetine	1	100									1	100				

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: PSYCHIATRIC DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
INSOMNIA	Imipramine	8	100	4	50.0	1	12.5	1	12.5			2	25.0				
	Placebo	4	100	2	50.0			1	25.0	1	25.0						
	Reboxetine	12	100	6	50.0	2	16.7	3	25.0					1	8.3		
AGITATION / ANXIETY / NERVOUSNESS	Imipramine	5	100	3	60.0	1	20.0			1	20.0						
	Placebo	11	100	7	63.6	3	27.3			1	9.1						
	Reboxetine	13	100	5	38.5	5	38.5	2	15.4					1	7.7		
SOMNOLENCE	Imipramine	6	100	6	100												
	Placebo	10	100	3	30.0	1	10.0			3	30.0	2	20.0	1	10.0		
	Reboxetine	1	100					1	100								
SUICIDE ATTEMPT	Imipramine	4	100	2	50.0							1	25.0	1	25.0		
	Placebo	4	100					1	25.0	2	50.0	1	25.0				
	Reboxetine	1	100	1	100												
SLEEP DISORDER	Imipramine	1	100	1	100												
CONCENTRATION IMPAIRED	Imipramine	1	100							1	100						
DEPERSONALIZATION	Imipramine	1	100	1	100												
LIBIDO DECREASED	Reboxetine	1	100					1	100								
PARONIRIA	Placebo	1	100							1	100						
AUTOLESIONIST BEHAVIOUR	Imipramine	1	100	1	100												
DEPRESSION AGGRAVATED	Placebo	1	100							1	100						

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: REPRODUCTIVE DISORDERS, MALE

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
PERINEAL PAIN MALE	Reboxetine	1	100	1	100												
EPIDIDYMITIS	Reboxetine	1	100	1	100												
IMPOTENCE	Reboxetine	1	100	1	100												

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: RESISTANCE MECHANISM DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment															
				0-7		8-14		15-21		22-28		29-35		36-42		> 42			
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%		
HERPES SIMPLEX	Placebo	1	100											1	100				

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: RESPIRATORY SYSTEM DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
RHINITIS	Imipramine	2	100	1	50.0			1	50.0								
	Placebo	4	100	1	25.0	1	25.0	2	50.0								
	Reboxetine	1	100	1	100												
DYSPNOEA	Imipramine	2	100	2	100												
	Reboxetine	5	100							2	40.0	2	40.0	1	20.0		
SINUSITIS	Placebo	1	100			1	100										
	Reboxetine	2	100			1	50.0	1	50.0								
PHARYNGITIS	Placebo	1	100			1	100										
BRONCHITIS	Placebo	1	100											1	100		

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: SKIN AND APPENDAGES DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
ERYTHEMA / RASH	Imipramine	1	100									1	100				
	Placebo	2	100											2	100		
	Reboxetine	1	100											1	100		
RHAGADES	Imipramine	1	100					1	100								
COLD URTICARIA	Imipramine	1	100			1	100										

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: SPECIAL SENSES OTHER, DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
TASTE LOSS	Imipramine	1	100	1	100												
TASTE PERVERSION	Placebo	1	100							1	100						

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: URINARY SYSTEM DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
URINARY HESITANCY / RETENTION	Imipramine	1	100	1	100												
	Placebo	2	100	2	100												
	Reboxetine	6	100	4	66.7			1	16.7	1	16.7						
URINARY TRACT INFECTION	Placebo	1	100											1	100		
	Reboxetine	4	100					3	75.0					1	25.0		
DYSURIA	Imipramine	1	100	1	100												
	Reboxetine	2	100	2	100												
MICTURITION FREQUENCY	Placebo	1	100	1	100												
PYURIA	Reboxetine	1	100							1	100						

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 49

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: VISION DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
BLURRED VISION	Imipramine	11	100	3	27.3	4	36.4	1	9.1			3	27.3				
	Placebo	3	100			3	100										
	Reboxetine	7	100	3	42.9	1	14.3	1	14.3	2	28.6						
CONJUNCTIVITIS	Imipramine	2	100	1	50.0	1	50.0										
MYDRIASIS	Reboxetine	2	100	1	50.0	1	50.0										
EYE ABNORMALITY	Reboxetine	1	100	1	100												
CHROMATOPSIA	Placebo	1	100					1	100								

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 50

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Body system	Assigned treatment																
AUTONOMIC NERVOUS SYSTEM DISORDERS	Imipramine	79	100	48	60.8	11	13.9	7	8.9	8	10.1	3	3.8	1	1.3	1	1.3
	Placebo	18	100	10	55.6	3	16.7	2	11.1	3	16.7						
	Reboxetine	45	100	25	55.6	15	33.3	3	6.7	1	2.2			1	2.2		
GASTRO-INTESTINAL SYSTEM DISORDERS	Imipramine	50	100	18	36.0	14	28.0	11	22.0			2	4.0	4	8.0	1	2.0
	Placebo	31	100	12	38.7	10	32.3	5	16.1	1	3.2	3	9.7				
	Reboxetine	36	100	16	44.4	9	25.0	4	11.1	5	13.9	2	5.6				
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Imipramine	49	100	21	42.9	9	18.4	9	18.4	8	16.3	2	4.1				
	Placebo	20	100	9	45.0	3	15.0	4	20.0	2	10.0	2	10.0				
	Reboxetine	34	100	21	61.8	6	17.6	1	2.9	4	11.8	1	2.9	1	2.9		
PSYCHIATRIC DISORDERS	Imipramine	27	100	18	66.7	2	7.4	1	3.7	2	7.4	3	11.1	1	3.7		
	Placebo	31	100	12	38.7	4	12.9	2	6.5	9	29.0	3	9.7	1	3.2		
	Reboxetine	28	100	12	42.9	7	25.0	7	25.0					2	7.1		
CARDIOVASCULAR DISORDERS, GENERAL	Imipramine	39	100	17	43.6	9	23.1	6	15.4	2	5.1	2	5.1	3	7.7		
	Placebo	10	100	2	20.0	1	10.0	4	40.0	1	10.0	2	20.0				
	Reboxetine	21	100	8	38.1	5	23.8	2	9.5	4	19.0	2	9.5				
VISION DISORDERS	Imipramine	13	100	4	30.8	5	38.5	1	7.7			3	23.1				
	Placebo	4	100			3	75.0	1	25.0								
	Reboxetine	10	100	5	50.0	2	20.0	1	10.0	2	20.0						
BODY AS A WHOLE-GENERAL DISORDERS	Imipramine	10	100	3	30.0	1	10.0	2	20.0	2	20.0	2	20.0				
	Placebo	6	100			3	50.0	2	33.3	1	16.7						
	Reboxetine	7	100	4	57.1	1	14.3	1	14.3			1	14.3				

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 50

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Body system	Assigned treatment																
URINARY SYSTEM DISORDERS	Imipramine	2	100	2	100												
	Placebo	4	100	3	75.0									1	25.0		
	Reboxetine	13	100	6	46.2			4	30.8	2	15.4			1	7.7		
RESPIRATORY SYSTEM DISORDERS	Imipramine	4	100	3	75.0			1	25.0								
	Placebo	7	100	1	14.3	3	42.9	2	28.6					1	14.3		
	Reboxetine	8	100	1	12.5	1	12.5	1	12.5	2	25.0	2	25.0	1	12.5		
METABOLIC AND NUTRITIONAL DISORDERS	Imipramine	5	100	1	20.0					2	40.0			1	20.0	1	20.0
	Placebo	1	100					1	100								
	Reboxetine	3	100	2	66.7					1	33.3						
REPRODUCTIVE DISORDERS, MALE	Reboxetine	3	100	3	100												
MUSCOLO-SKELETAL SYSTEM DISORDERS	Imipramine	1	100	1	100												
	Placebo	5	100	3	60.0			1	20.0	1	20.0						
	Reboxetine	1	100									1	100				
SKIN AND APPENDAGES DISORDERS	Imipramine	3	100			1	33.3	1	33.3			1	33.3				
	Placebo	2	100											2	100		
	Reboxetine	1	100											1	100		
SPECIAL SENSES OTHER, DISORDERS	Imipramine	1	100	1	100												
	Placebo	1	100							1	100						
HEARING AND VESTIBULAR DISORDERS	Imipramine	2	100	1	50.0	1	50.0										

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 50

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Body system	Assigned treatment																
LIVER AND BILIAR SYSTEM DISORDERS	Imipramine	1	100											1	100		
	Reboxetine	1	100					1	100								
HEMATOLOGY DISORDERS	Imipramine	2	100											2	100		
RESISTANCE MECHANISM DISORDERS	Placebo	1	100											1	100		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
All adverse events	Mild	62	55	7		60	2	
	Moderate	105	102	3		102	3	
	Severe	33	31	2		33		
	Unknown	11	9	2		10	1	
	Total	211	197	14		205	6	
MOUTH DRY	Mild	14	13	1		13	1	
	Moderate	12	12			12		
	Severe	3	3			3		
	Total	29	28	1		28	1	
SWEATING INCREASED	Mild	6	6			6		
	Moderate	8	8			8		
	Unknown	1	1			1		
	Total	15	15			15		
TREMOR	Mild	4	4			4		
	Moderate	1	1			1		
	Severe	1	1			1		
	Total	6	6			6		
CONSTIPATION	Mild	4	3	1		3	1	
	Moderate	14	14			14		
	Severe	2	2			2		
	Total	20	19	1		19	1	

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
DIZZINESS	Mild	3	1	2		3		
	Moderate	3	3			3		
	Unknown	2	2			2		
	Total	8	6	2		8		
NAUSEA	Mild	1	1			1		
	Moderate	7	7			7		
	Severe	1	1			1		
	Total	9	9			9		
VISION ABNORMAL	Mild	4	3	1		4		
	Moderate	1	1			1		
	Unknown	2	2			2		
	Total	7	6	1		7		
HEADACHE	Mild	4	4			4		
	Moderate	13	13			13		
	Severe	1	1			1		
	Total	18	18			18		
VERTIGO	Mild	2	2			2		
	Moderate	1	1			1		
	Severe	2	2			2		
	Total	5	5			5		
INSOMNIA	Moderate	6	6			6		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
INSOMNIA	Severe	4	4			4		
	Unknown	2	1	1		2		
	Total	12	11	1		12		
PARAESTHESIA	Moderate	2	2			2		
	Total	2	2			2		
SOMNOLENCE	Moderate	1	1			1		
	Total	1	1			1		
HYPOTENSION POSTURAL	Moderate	1	1			1		
	Severe	1		1		1		
	Total	2	1	1		2		
ABDOMINAL PAIN	Moderate	1	1			1		
	Total	1	1			1		
TACHYCARDIA	Moderate	2	2			2		
	Severe	1	1			1		
	Total	3	3			3		
HOT FLUSHES	Moderate	2	2			2		
	Total	2	2			2		
AGITATION	Mild	2	1	1		2		
	Moderate	2	1	1		1	1	
	Severe	4	4			4		
	Total	8	6	2		7	1	

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
SUICIDE ATTEMPT	Severe	1	1			1		
	Total	1	1			1		
FATIGUE	Mild	1	1			1		
	Severe	1	1			1		
	Unknown	1	1			1		
	Total	3	3			3		
ASTHENIA	Moderate	1	1			1		
	Total	1	1			1		
PALPITATION	Moderate	1	1			1		
	Total	1	1			1		
DYSPNOEA	Mild	1		1		1		
	Moderate	4	4			4		
	Total	5	4	1		5		
CONFUSION	Severe	1	1			1		
	Total	1	1			1		
MUSCLE CONTRACTIONS INVOLUNTARY	Moderate	1	1			1		
	Total	1	1			1		
WEIGHT INCREASE	Moderate	1	1			1		
	Total	1	1			1		
RHINITIS	Moderate	1	1			1		
	Total	1	1			1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*).	High dose	Overdose
HYPOTENSION	Moderate	2	2			2		
	Total	2	2			2		
VOMITING	Severe	1	1			1		
	Total	1	1			1		
DYSURIA	Mild	1	1			1		
	Moderate	1	1			1		
	Total	2	2			2		
CHEST PAIN	Severe	1	1			1		
	Total	1	1			1		
HYPERTENSION	Moderate	1	1			1		
	Total	1	1			1		
ANXIETY	Severe	1	1			1		
	Total	1	1			1		
GAMMA-GT INCREASED	Moderate	1	1			1		
	Total	1	1			1		
MICTURITION DISORDER	Mild	3	3			3		
	Total	3	3			3		
INFLUENZA-LIKE SYMPTOMS	Unknown	1		1			1	
	Total	1		1			1	
NERVOUSNESS	Mild	1	1			1		
	Moderate	3	3			3		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
NERVOUSNESS	Total	4	4			4		
URINARY TRACT INFECTION	Mild	2	2			2		
	Moderate	2	2			2		
	Total	4	4			4		
URINARY RETENTION	Mild	2	2			2		
	Severe	1	1			1		
	Total	3	3			3		
MYDRIASIS	Mild	2	2			2		
	Total	2	2			2		
SINUSITIS	Moderate	2	2			2		
	Total	2	2			2		
ARTHRALGIA	Mild	1	1			1		
	Total	1	1			1		
EYE ABNORMALITY	Mild	1	1			1		
	Total	1	1			1		
PYURIA	Mild	1	1			1		
	Total	1	1			1		
PERINEAL PAIN MALE	Mild	1	1			1		
	Total	1	1			1		
HYPERPYREXIA	Mild	1	1			1		
	Total	1	1			1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
ANOREXIA	Moderate	1	1			1		
	Total	1	1			1		
SALIVA INCREASED	Moderate	1	1			1		
	Total	1	1			1		
GASTRITIS	Moderate	1		1			1	
	Total	1		1			1	
GASTROENTERITIS	Moderate	1		1			1	
	Total	1		1			1	
WEIGHT DECREASE	Moderate	1	1			1		
	Total	1	1			1		
HAEMORRHOIDS THROMBOSED	Moderate	1	1			1		
	Total	1	1			1		
EPIDIDYMITIS	Moderate	1	1			1		
	Total	1	1			1		
RASH ERYTHEMATOUS	Severe	1	1			1		
	Total	1	1			1		
MIGRAINE	Severe	1	1			1		
	Total	1	1			1		
FLUSHING	Severe	1	1			1		
	Total	1	1			1		
FLATULENCE	Severe	1	1			1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
FLATULENCE	Total	1	1			1		
HYPERURICAEMIA	Severe	1		1		1		
	Total	1		1		1		
IMPOTENCE	Severe	1	1			1		
	Total	1	1			1		
LIBIDO DECREASED	Unknown	1	1			1		
	Total	1	1			1		
TOOTH DISORDER	Unknown	1	1			1		
	Total	1	1			1		

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
All adverse events	Mild	75	74	1		75		
	Moderate	158	151	5	2	149	7	2
	Severe	44	43	1		43	1	
	Unknown	11	10	1		11		
	Total	288	278	8	2	278	8	2
MOUTH DRY	Mild	19	18	1		19		
	Moderate	29	28	1		28	1	
	Severe	4	4			4		
	Unknown	1	1			1		
	Total	53	51	2		52	1	
SWEATING INCREASED	Mild	4	4			4		
	Moderate	15	15			15		
	Severe	6	6			6		
	Unknown	1	1			1		
	Total	26	26			26		
TREMOR	Mild	5	5			5		
	Moderate	12	11	1		11	1	
	Severe	3	3			3		
	Total	20	19	1		19	1	
CONSTIPATION	Mild	5	5			5		
	Moderate	10	10			10		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
CONSTIPATION	Severe	2	2			2		
	Unknown	1	1			1		
	Total	18	18			18		
DIZZINESS	Mild	4	4			4		
	Moderate	10	8		2	8		2
	Severe	2	2			2		
	Total	16	14		2	14		2
NAUSEA	Mild	4	4			4		
	Moderate	8	8			8		
	Severe	3	2	1		2	1	
	Unknown	1	1			1		
	Total	16	15	1		15	1	
VISION ABNORMAL	Mild	3	3			3		
	Moderate	7	6	1		6	1	
	Total	10	9	1		9	1	
HEADACHE	Mild	3	3			3		
	Moderate	4	3	1		4		
	Severe	2	2			2		
	Total	9	8	1		9		
VERTIGO	Mild	1	1			1		
	Moderate	6	6			6		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
VERTIGO	Severe	1	1			1		
	Total	8	8			8		
INSOMNIA	Moderate	1	1			1		
	Severe	5	5			5		
	Unknown	2	1	1		2		
	Total	8	7	1		8		
PARAESTHESIA	Mild	1	1			1		
	Moderate	3	3			3		
	Severe	1	1			1		
	Unknown	1	1			1		
	Total	6	6			6		
SOMNOLENCE	Mild	2	2			2		
	Moderate	4	4			4		
	Total	6	6			6		
HYPOTENSION POSTURAL	Moderate	3	3			3		
	Severe	3	3			3		
	Total	6	6			6		
ABDOMINAL PAIN	Mild	2	2			2		
	Moderate	3	3			3		
	Total	5	5			5		
DYSPEPSIA	Mild	2	2			2		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
DYSPEPSIA	Moderate	1	1			1		
	Severe	2	2			2		
	Total	5	5			5		
TACHYCARDIA	Mild	2	2			2		
	Severe	1	1			1		
	Unknown	1	1			1		
	Total	4	4			4		
HOT FLUSHES	Mild	1	1			1		
	Moderate	2	2			2		
	Severe	1	1			1		
	Total	4	4			4		
AGITATION	Moderate	4	4			4		
	Total	4	4			4		
SUICIDE ATTEMPT	Moderate	2	2			2		
	Severe	1	1			1		
	Unknown	1	1			1		
	Total	4	4			4		
FATIGUE	Moderate	3	3			3		
	Severe	1	1			1		
	Total	4	4			4		
ASTHENIA	Moderate	2	2			2		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
ASTHENIA	Severe	1	1			1		
	Total	3	3			3		
PALPITATION	Mild	2	2			2		
	Total	2	2			2		
CONJUNCTIVITIS	Mild	2	2			2		
	Total	2	2			2		
TINNITUS	Mild	1	1			1		
	Moderate	1	1			1		
	Total	2	2			2		
DYSPNOEA	Mild	1	1			1		
	Moderate	1	1			1		
	Total	2	2			2		
CHEST PAIN PRECORDIAL	Mild	1	1			1		
	Severe	1	1			1		
	Total	2	2			2		
CONFUSION	Moderate	1	1			1		
	Unknown	1	1			1		
	Total	2	2			2		
MUSCLE CONTRACTIONS INVOLUNTARY	Moderate	2	2			2		
	Total	2	2			2		
APPETITE INCREASED	Moderate	2	2			2		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
APPETITE INCREASED	Total	2	2			2		
WEIGHT INCREASE	Moderate	2	2			2		
	Total	2	2			2		
RHINITIS	Moderate	2	2			2		
	Total	2	2			2		
SYNCOPE	Severe	2	2			2		
	Total	2	2			2		
SPEECH DISORDER	Mild	1	1			1		
	Total	1	1			1		
HYPOTENSION	Mild	1	1			1		
	Total	1	1			1		
VOMITING	Mild	1	1			1		
	Total	1	1			1		
AUTOLESIONIST BEHAVIOUR	Mild	1	1			1		
	Total	1	1			1		
SLEEP DISORDER	Mild	1	1			1		
	Total	1	1			1		
HYPOKALAEMIA	Mild	1	1			1		
	Total	1	1			1		
HYPERTRIGLYCERIDAEMIA	Mild	1	1			1		
	Total	1	1			1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
ANAEMIA HYPOCHROMIC	Mild	1	1			1		
	Total	1	1			1		
DYSURIA	Mild	1	1			1		
	Total	1	1			1		
CHEST PAIN	Mild	1	1			1		
	Total	1	1			1		
RHAGADES	Moderate	1	1			1		
	Total	1	1			1		
COLD URTICARIA	Moderate	1	1			1		
	Total	1	1			1		
MYALGIA	Moderate	1	1			1		
	Total	1	1			1		
HYPERKINESIA	Moderate	1	1			1		
	Total	1	1			1		
ACCOMMODATION ABNORMAL	Moderate	1	1			1		
	Total	1	1			1		
HYPERTENSION	Moderate	1	1			1		
	Total	1	1			1		
TASTE LOSS	Moderate	1	1			1		
	Total	1	1			1		
ANXIETY	Moderate	1	1			1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
ANXIETY	Total	1	1			1		
CONCENTRATION IMPAIRED	Moderate	1		1			1	
	Total	1		1			1	
COLITIS	Moderate	1	1			1		
	Total	1	1			1		
DUODENAL ULCER REACTIVATED	Moderate	1	1			1		
	Total	1	1			1		
DYSPHAGIA	Moderate	1	1			1		
	Total	1	1			1		
GAMMA-GT INCREASED	Moderate	1	1				1	
	Total	1	1				1	
PHOSPHATASE ALKALINE INCREASED	Moderate	1	1				1	
	Total	1	1				1	
EXTRASYSTOLES	Moderate	1	1			1		
	Total	1	1			1		
EOSINOPHILIA	Moderate	1	1				1	
	Total	1	1				1	
MICTURITION DISORDER	Moderate	1	1			1		
	Total	1	1			1		
RIGORS	Moderate	1	1			1		
	Total	1	1			1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 51

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
RASH	Severe	1	1			1		
	Total	1	1			1		
DEPERSONALIZATION	Severe	1	1			1		
	Total	1	1			1		
INFLUENZA-LIKE SYMPTOMS	Unknown	1	1			1		
	Total	1	1			1		

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 52

ADVERSE EVENTS: NUMBER OF PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENT
BY MAXIMAL SEVERITY LEVEL, SEX, AGE, DSMIII

Assigned treatment / Severity level		Sex						Age						DSM III					
		Total		Female		Male		18 - 30		31 - 45		> 45		296.2		296.3		296.5	
		No. Pt	%	No. Pt	%	No. Pt	%	No. Pt	%	No. Pt	%	No. Pt	%	No. Pt	%	No. Pt	%	No. Pt	%
Imipramine	Missing	1	1.2			1	3.7					1	2.6			1	1.8		
	Mild	14	17.3	5	9.3	9	33.3	1	8.3	5	16.1	8	21.1	6	25.0	8	14.3		
	Moderate	41	50.6	28	51.9	13	48.1	9	75.0	11	35.5	21	55.3	9	37.5	31	55.4	1	100.0
	Severe	25	30.9	21	38.9	4	14.8	2	16.7	15	48.4	8	21.1	9	37.5	16	28.6		
	Total	81	100.0	54	100.0	27	100.0	12	100.0	31	100.0	38	100.0	24	100.0	56	100.0	1	100.0
Placebo	Missing	1	1.7			1	3.4					1	4.5			1	2.2		
	Mild	16	27.6	8	27.6	8	27.6	1	12.5	9	32.1	6	27.3	8	66.7	8	17.4		
	Moderate	30	51.7	15	51.7	15	51.7	5	62.5	13	46.4	12	54.5	4	33.3	26	56.5		
	Severe	11	19.0	6	20.7	5	17.2	2	25.0	6	21.4	3	13.6			11	23.9		
	Total	58	100.0	29	100.0	29	100.0	8	100.0	28	100.0	22	100.0	12	100.0	46	100.0		
Reboxetine	Mild	20	28.2	9	20.5	11	40.7	3	30.0	6	20.7	11	34.4	7	35.0	13	25.5		
	Moderate	28	39.4	21	47.7	7	25.9	4	40.0	13	44.8	11	34.4	6	30.0	22	43.1		
	Severe	23	32.4	14	31.8	9	33.3	3	30.0	10	34.5	10	31.3	7	35.0	16	31.4		
	Total	71	100.0	44	100.0	27	100.0	10	100.0	29	100.0	32	100.0	20	100.0	51	100.0		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 53

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
All adverse events	Mild	5	9.3	9.3	9	34.6	33.3	14	17.5	17.3	8	27.6	27.6	8	28.6	27.6	16	28.1	27.6	9	20.5	20.5	11	40.7	40.7	20	28.2	28.2
	Moderate	28	51.9	51.9	13	50.0	48.1	41	51.3	50.6	15	51.7	51.7	15	53.6	51.7	30	52.6	51.7	21	47.7	47.7	7	25.9	25.9	28	39.4	39.4
	Severe	21	38.9	38.9	4	15.4	14.8	25	31.3	30.9	6	20.7	20.7	5	17.9	17.2	11	19.3	19.0	14	31.8	31.8	9	33.3	33.3	23	32.4	32.4
	Total	54	100	100	26	100	96.3	80	100	98.8	29	100	100	28	100	96.6	57	100	98.3	44	100	100	27	100	100	71	100	100
MOUTH DRY	Mild	8	22.9	14.8	9	64.3	33.3	17	34.7	21.0	5	50.0	17.2	2	50.0	6.9	7	50.0	12.1	7	36.8	15.9	7	77.8	25.9	14	50.0	19.7
	Moderate	23	65.7	42.6	4	28.6	14.8	27	55.1	33.3	4	40.0	13.8	2	50.0	6.9	6	42.9	10.3	9	47.4	20.5	2	22.2	7.4	11	39.3	15.5
	Severe	3	8.6	5.6	1	7.1	3.7	4	8.2	4.9	1	10.0	3.4				1	7.1	1.7	3	15.8	6.8				3	10.7	4.2
	Missing	1	2.9	1.9				1	2.0	1.2																		
	Total	35	100	64.8	14	100	51.9	49	100	60.5	10	100	34.5	4	100	13.8	14	100	24.1	19	100	43.2	9	100	33.3	28	100	39.4
CONSTIPATION	Mild	2	14.3	3.7	3	75.0	11.1	5	27.8	6.2	1	20.0	3.4	1	100	3.4	2	33.3	3.4				3	60.0	11.1	3	17.6	4.2
	Moderate	9	64.3	16.7	1	25.0	3.7	10	55.6	12.3	4	80.0	13.8				4	66.7	6.9	11	91.7	25.0	1	20.0	3.7	12	70.6	16.9
	Severe	2	14.3	3.7				2	11.1	2.5										1	8.3	2.3	1	20.0	3.7	2	11.8	2.8
	Missing	1	7.1	1.9				1	5.6	1.2																		
	Total	14	100	25.9	4	100	14.8	18	100	22.2	5	100	17.2	1	100	3.4	6	100	10.3	12	100	27.3	5	100	18.5	17	100	23.9
SWEATING INCREASED	Mild	2	12.5	3.7	1	16.7	3.7	3	13.6	3.7										4	36.4	9.1	1	33.3	3.7	5	35.7	7.0
	Moderate	10	62.5	18.5	3	50.0	11.1	13	59.1	16.0	2	100	6.9	1	100	3.4	3	100	5.2	6	54.5	13.6	2	66.7	7.4	8	57.1	11.3
	Severe	3	18.8	5.6	2	33.3	7.4	5	22.7	6.2																		
	Missing	1	6.3	1.9				1	4.5	1.2										1	9.1	2.3				1	7.1	1.4
	Total	16	100	29.6	6	100	22.2	22	100	27.2	2	100	6.9	1	100	3.4	3	100	5.2	11	100	25.0	3	100	11.1	14	100	19.7
HEADACHE	Mild	2	28.6	3.7	1	50.0	3.7	3	33.3	3.7	1	33.3	3.4	2	33.3	6.9	3	33.3	5.2	4	40.0	9.1				4	28.6	5.6

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 53

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
HEADACHE	Moderate	3	42.9	5.6	1	50.0	3.7	4	44.4	4.9	2	66.7	6.9	4	66.7	13.8	6	66.7	10.3	6	60.0	13.6	3	75.0	11.1	9	64.3	12.7
	Severe	2	28.6	3.7				2	22.2	2.5													1	25.0	3.7	1	7.1	1.4
	Total	7	100	13.0	2	100	7.4	9	100	11.1	3	100	10.3	6	100	20.7	9	100	15.5	10	100	22.7	4	100	14.8	14	100	19.7
TREMOR	Mild	4	25.0	7.4	1	25.0	3.7	5	25.0	6.2				1	33.3	3.4	1	20.0	1.7	3	75.0	6.8	1	50.0	3.7	4	66.7	5.6
	Moderate	9	56.3	16.7	3	75.0	11.1	12	60.0	14.8	2	100	6.9	1	33.3	3.4	3	60.0	5.2				1	50.0	3.7	1	16.7	1.4
	Severe	3	18.8	5.6				3	15.0	3.7				1	33.3	3.4	1	20.0	1.7	1	25.0	2.3				1	16.7	1.4
	Total	16	100	29.6	4	100	14.8	20	100	24.7	2	100	6.9	3	100	10.3	5	100	8.6	4	100	9.1	2	100	7.4	6	100	8.5
NAUSEA	Mild	2	18.2	3.7	1	50.0	3.7	3	23.1	3.7	3	37.5	10.3	1	100	3.4	4	44.4	6.9	1	16.7	2.3				1	11.1	1.4
	Moderate	6	54.5	11.1				6	46.2	7.4	5	62.5	17.2				5	55.6	8.6	5	83.3	11.4	2	66.7	7.4	7	77.8	9.9
	Severe	2	18.2	3.7	1	50.0	3.7	3	23.1	3.7													1	33.3	3.7	1	11.1	1.4
	Missing	1	9.1	1.9				1	7.7	1.2																		
	Total	11	100	20.4	2	100	7.4	13	100	16.0	8	100	27.6	1	100	3.4	9	100	15.5	6	100	13.6	3	100	11.1	9	100	12.7
DIZZINESS	Mild	3	30.0	5.6	1	25.0	3.7	4	28.6	4.9				2	50.0	6.9	2	50.0	3.4				3	100	11.1	3	50.0	4.2
	Moderate	5	50.0	9.3	3	75.0	11.1	8	57.1	9.9				2	50.0	6.9	2	50.0	3.4	3	100	6.8				3	50.0	4.2
	Severe	2	20.0	3.7				2	14.3	2.5																		
	Total	10	100	18.5	4	100	14.8	14	100	17.3				4	100	13.8	4	100	6.9	3	100	6.8	3	100	11.1	6	100	8.5
INSOMNIA	Moderate				1	50.0	3.7	1	12.5	1.2	1	50.0	3.4	1	50.0	3.4	2	50.0	3.4	3	42.9	6.8	3	60.0	11.1	6	50.0	8.5
	Severe	5	83.3	9.3				5	62.5	6.2				1	50.0	3.4	1	25.0	1.7	3	42.9	6.8	1	20.0	3.7	4	33.3	5.6
	Missing	1	16.7	1.9	1	50.0	3.7	2	25.0	2.5	1	50.0	3.4				1	25.0	1.7	1	14.3	2.3	1	20.0	3.7	2	16.7	2.8
	Total	6	100	11.1	2	100	7.4	8	100	9.9	2	100	6.9	2	100	6.9	4	100	6.9	7	100	15.9	5	100	18.5	12	100	16.9

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 53

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
AGITATION	Mild													2	33.3	6.9	2	28.6	3.4				2	66.7	7.4	2	28.6	2.8
	Moderate	2	100	3.7	2	100	7.4	4	100	4.9				1	16.7	3.4	1	14.3	1.7				1	33.3	3.7	1	14.3	1.4
	Severe										1	100	3.4	3	50.0	10.3	4	57.1	6.9	4	100	9.1				4	57.1	5.6
	Total	2	100	3.7	2	100	7.4	4	100	4.9	1	100	3.4	6	100	20.7	7	100	12.1	4	100	9.1	3	100	11.1	7	100	9.9
VISION ABNORMAL	Mild	2	33.3	3.7	1	33.3	3.7	3	33.3	3.7				1	33.3	3.4	1	33.3	1.7	2	66.7	4.5	1	33.3	3.7	3	50.0	4.2
	Moderate	4	66.7	7.4	2	66.7	7.4	6	66.7	7.4				2	66.7	6.9	2	66.7	3.4				1	33.3	3.7	1	16.7	1.4
	Missing																			1	33.3	2.3	1	33.3	3.7	2	33.3	2.8
	Total	6	100	11.1	3	100	11.1	9	100	11.1				3	100	10.3	3	100	5.2	3	100	6.8	3	100	11.1	6	100	8.5
SOMNOLENCE	Mild	1	25.0	1.9	1	50.0	3.7	2	33.3	2.5	1	25.0	3.4	3	60.0	10.3	4	44.4	6.9									
	Moderate	3	75.0	5.6	1	50.0	3.7	4	66.7	4.9	3	75.0	10.3	2	40.0	6.9	5	55.6	8.6	1	100	2.3				1	100	1.4
	Total	4	100	7.4	2	100	7.4	6	100	7.4	4	100	13.8	5	100	17.2	9	100	15.5	1	100	2.3				1	100	1.4
VERTIGO	Mild	1	14.3	1.9				1	14.3	1.2										2	50.0	4.5				2	40.0	2.8
	Moderate	5	71.4	9.3				5	71.4	6.2										1	25.0	2.3				1	20.0	1.4
	Severe	1	14.3	1.9				1	14.3	1.2										1	25.0	2.3	1	100	3.7	2	40.0	2.8
	Total	7	100	13.0				7	100	8.6										4	100	9.1	1	100	3.7	5	100	7.0
FATIGUE	Mild																						1	50.0	3.7	1	33.3	1.4
	Moderate	2	66.7	3.7	1	100	3.7	3	75.0	3.7	1	100	3.4	3	100	10.3	4	100	6.9									
	Severe	1	33.3	1.9				1	25.0	1.2										1	100	2.3				1	33.3	1.4
	Missing																						1	50.0	3.7	1	33.3	1.4
	Total	3	100	5.6	1	100	3.7	4	100	4.9	1	100	3.4	3	100	10.3	4	100	6.9	1	100	2.3	2	100	7.4	3	100	4.2

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 53

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
PARAESTHESIA	Mild	1	20.0	1.9				1	16.7	1.2	1	100	3.4				1	50.0	1.7									
	Moderate	3	60.0	5.6				3	50.0	3.7				1	100	3.4	1	50.0	1.7	1	100	2.3	1	100	3.7	2	100	2.8
	Severe				1	100	3.7	1	16.7	1.2																		
	Missing	1	20.0	1.9				1	16.7	1.2																		
	Total	5	100	9.3	1	100	3.7	6	100	7.4	1	100	3.4	1	100	3.4	2	100	3.4	1	100	2.3	1	100	3.7	2	100	2.8
SUICIDE ATTEMPT	Mild										1	33.3	3.4				1	25.0	1.7									
	Moderate	1	50.0	1.9	1	50.0	3.7	2	50.0	2.5	1	33.3	3.4				1	25.0	1.7									
	Severe	1	50.0	1.9				1	25.0	1.2	1	33.3	3.4	1	100	3.4	2	50.0	3.4	1	100	2.3				1	100	1.4
	Missing				1	50.0	3.7	1	25.0	1.2																		
	Total	2	100	3.7	2	100	7.4	4	100	4.9	3	100	10.3	1	100	3.4	4	100	6.9	1	100	2.3				1	100	1.4
HYPOTENSION POSTURAL	Moderate	3	60.0	5.6				3	50.0	3.7										1	50.0	2.3				1	50.0	1.4
	Severe	2	40.0	3.7	1	100	3.7	3	50.0	3.7										1	50.0	2.3				1	50.0	1.4
	Total	5	100	9.3	1	100	3.7	6	100	7.4										2	100	4.5				2	100	2.8
ABDOMINAL PAIN	Mild	1	33.3	1.9				1	25.0	1.2																		
	Moderate	2	66.7	3.7	1	100	3.7	3	75.0	3.7	2	100	6.9	1	100	3.4	3	100	5.2	1	100	2.3				1	100	1.4
	Total	3	100	5.6	1	100	3.7	4	100	4.9	2	100	6.9	1	100	3.4	3	100	5.2	1	100	2.3				1	100	1.4
TACHYCARDIA	Mild	2	50.0	3.7				2	50.0	2.5																		
	Moderate																			2	100	4.5				2	66.7	2.8
	Severe	1	25.0	1.9				1	25.0	1.2													1	100	3.7	1	33.3	1.4
	Missing	1	25.0	1.9				1	25.0	1.2																		

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 53

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
TACHYCARDIA	Total	4	100	7.4				4	100	4.9										2	100	4.5	1	100	3.7	3	100	4.2
RHINITIS	Mild													3	75.0	10.3	3	75.0	5.2									
	Moderate	2	100	3.7				2	100	2.5										1	100	2.3				1	100	1.4
	Missing													1	25.0	3.4	1	25.0	1.7									
	Total	2	100	3.7				2	100	2.5				4	100	13.8	4	100	6.9	1	100	2.3				1	100	1.4
VOMITING	Mild				1	100	3.7	1	100	1.2																		
	Moderate										3	75.0	10.3				3	75.0	5.2									
	Severe										1	25.0	3.4				1	25.0	1.7				1	100	3.7	1	100	1.4
	Total				1	100	3.7	1	100	1.2	4	100	13.8				4	100	6.9				1	100	3.7	1	100	1.4
DYSPEPSIA	Mild	2	50.0	3.7				2	40.0	2.5																		
	Moderate	1	25.0	1.9				1	20.0	1.2	1	100	3.4				1	100	1.7									
	Severe	1	25.0	1.9	1	100	3.7	2	40.0	2.5																		
	Total	4	100	7.4	1	100	3.7	5	100	6.2	1	100	3.4				1	100	1.7									
HOT FLUSHES	Mild	1	50.0	1.9				1	33.3	1.2	1	100	3.4				1	100	1.7									
	Moderate	1	50.0	1.9				1	33.3	1.2										1	100	2.3	1	100	3.7	2	100	2.8
	Severe				1	100	3.7	1	33.3	1.2																		
	Total	2	100	3.7	1	100	3.7	3	100	3.7	1	100	3.4				1	100	1.7	1	100	2.3	1	100	3.7	2	100	2.8
HYPOTENSION	Mild	1	100	1.9				1	100	1.2	1	100	3.4				1	50.0	1.7									
	Moderate													1	100	3.4	1	50.0	1.7	1	100	2.3	1	100	3.7	2	100	2.8
	Total	1	100	1.9				1	100	1.2	1	100	3.4	1	100	3.4	2	100	3.4	1	100	2.3	1	100	3.7	2	100	2.8

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 53

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
ANXIETY	Mild										1	50.0	3.4				1	33.3	1.7									
	Moderate				1	100	3.7	1	100	1.2																		
	Severe										1	50.0	3.4	1	100	3.4	2	66.7	3.4				1	100	3.7	1	100	1.4
	Total				1	100	3.7	1	100	1.2	2	100	6.9	1	100	3.4	3	100	5.2				1	100	3.7	1	100	1.4
NERVOUSNESS	Mild																						1	100	3.7	1	25.0	1.4
	Moderate										1	100	3.4				1	100	1.7	3	100	6.8				3	75.0	4.2
	Total										1	100	3.4				1	100	1.7	3	100	6.8	1	100	3.7	4	100	5.6
DYSPNOEA	Mild	1	50.0	1.9				1	50.0	1.2										1	33.3	2.3				1	33.3	1.4
	Moderate	1	50.0	1.9				1	50.0	1.2										2	66.7	4.5				2	66.7	2.8
	Total	2	100	3.7				2	100	2.5										3	100	6.8				3	100	4.2
MICTURITION DISORDER	Mild																						3	100	11.1	3	100	4.2
	Moderate	1	100	1.9				1	100	1.2	1	100	3.4				1	100	1.7									
	Total	1	100	1.9				1	100	1.2	1	100	3.4				1	100	1.7				3	100	11.1	3	100	4.2
URINARY TRACT INFECTION	Mild																			2	50.0	4.5				2	50.0	2.8
	Moderate										1	100	3.4				1	100	1.7	2	50.0	4.5				2	50.0	2.8
	Total										1	100	3.4				1	100	1.7	4	100	9.1				4	100	5.6
URINARY RETENTION	Mild													1	100	3.4	1	100	1.7				2	66.7	7.4	2	66.7	2.8
	Severe																						1	33.3	3.7	1	33.3	1.4
	Total													1	100	3.4	1	100	1.7				3	100	11.1	3	100	4.2
PALPITATION	Mild	1	100	1.9	1	100	3.7	2	100	2.5				1	100	3.4	1	100	1.7									

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 53

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
PALPITATION	Moderate																			1	100	2.3				1	100	1.4
	Total	1	100	1.9	1	100	3.7	2	100	2.5				1	100	3.4	1	100	1.7	1	100	2.3				1	100	1.4
ASTHENIA	Moderate	1	100	1.9	1	50.0	3.7	2	66.7	2.5										1	100	2.3				1	100	1.4
	Severe				1	50.0	3.7	1	33.3	1.2																		
	Total	1	100	1.9	2	100	7.4	3	100	3.7										1	100	2.3				1	100	1.4
RASH	Mild										1	50.0	3.4				1	50.0	1.7									
	Moderate										1	50.0	3.4				1	50.0	1.7									
	Severe	1	100	1.9				1	100	1.2																		
	Total	1	100	1.9				1	100	1.2	2	100	6.9				2	100	3.4									
MYALGIA	Mild													2	100	6.9	2	100	3.4									
	Moderate				1	100	3.7	1	100	1.2																		
	Total				1	100	3.7	1	100	1.2				2	100	6.9	2	100	3.4									
CONFUSION	Moderate	1	50.0	1.9				1	50.0	1.2																		
	Severe																						1	100	3.7	1	100	1.4
	Missing	1	50.0	1.9				1	50.0	1.2																		
	Total	2	100	3.7				2	100	2.5													1	100	3.7	1	100	1.4
HYPERKINESIA	Moderate	1	100	1.9				1	100	1.2				1	100	3.4	1	50.0	1.7									
	Severe										1	100	3.4				1	50.0	1.7									
	Total	1	100	1.9				1	100	1.2	1	100	3.4	1	100	3.4	2	100	3.4									

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 53

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
MUSCLE CONTRACTIONS INVOLUNTARY	Moderate				2	100	7.4	2	100	2.5										1	100	2.3				1	100	1.4
	Total				2	100	7.4	2	100	2.5										1	100	2.3				1	100	1.4
DIARRHOEA	Moderate										1	100	3.4	2	100	6.9	3	100	5.2									
	Total										1	100	3.4	2	100	6.9	3	100	5.2									
APPETITE INCREASED	Moderate	2	100	3.7				2	100	2.5	1	100	3.4				1	100	1.7									
	Total	2	100	3.7				2	100	2.5	1	100	3.4				1	100	1.7									
WEIGHT INCREASE	Moderate	2	100	3.7				2	100	2.5										1	100	2.3				1	100	1.4
	Total	2	100	3.7				2	100	2.5										1	100	2.3				1	100	1.4
SINUSITIS	Moderate																			2	100	4.5				2	100	2.8
	Severe													1	100	3.4	1	100	1.7									
	Total													1	100	3.4	1	100	1.7	2	100	4.5				2	100	2.8
DYSURIA	Mild				1	100	3.7	1	100	1.2													1	50.0	3.7	1	50.0	1.4
	Moderate																						1	50.0	3.7	1	50.0	1.4
	Total				1	100	3.7	1	100	1.2													2	100	7.4	2	100	2.8
CHEST PAIN PRECORDIAL	Mild	1	50.0	1.9				1	50.0	1.2	1	100	3.4				1	100	1.7									
	Severe	1	50.0	1.9				1	50.0	1.2																		
	Total	2	100	3.7				2	100	2.5	1	100	3.4				1	100	1.7									
INFLUENZA-LIKE SYMPTOMS	Missing	1	100	1.9				1	100	1.2				1	100	3.4	1	100	1.7				1	100	3.7	1	100	1.4
	Total	1	100	1.9				1	100	1.2				1	100	3.4	1	100	1.7				1	100	3.7	1	100	1.4

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 53

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
ARTHRALGIA	Mild																						1	100	3.7	1	100	1.4
	Moderate										1	100	3.4				1	100	1.7									
	Total										1	100	3.4				1	100	1.7				1	100	3.7	1	100	1.4
BACK PAIN	Moderate										2	100	6.9				2	100	3.4									
	Total										2	100	6.9				2	100	3.4									
HYPERTENSION	Moderate	1	100	1.9				1	100	1.2													1	100	3.7	1	100	1.4
	Total	1	100	1.9				1	100	1.2													1	100	3.7	1	100	1.4
MYDRIASIS	Mild																			1	100	2.3	1	100	3.7	2	100	2.8
	Total																			1	100	2.3	1	100	3.7	2	100	2.8
CONJUNCTIVITIS	Mild	2	100	3.7				2	100	2.5																		
	Total	2	100	3.7				2	100	2.5																		
TINNITUS	Mild	1	100	1.9				1	50.0	1.2																		
	Moderate				1	100	3.7	1	50.0	1.2																		
	Total	1	100	1.9	1	100	3.7	2	100	2.5																		
FLATULENCE	Moderate										1	100	3.4				1	100	1.7									
	Severe																			1	100	2.3				1	100	1.4
	Total										1	100	3.4				1	100	1.7	1	100	2.3				1	100	1.4
GAMMA-GT INCREASED	Moderate	1	100	1.9				1	100	1.2													1	100	3.7	1	100	1.4
	Total	1	100	1.9				1	100	1.2													1	100	3.7	1	100	1.4
WEIGHT DECREASE	Moderate													1	100	3.4	1	100	1.7	1	100	2.3				1	100	1.4

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 53

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
WEIGHT DECREASE	Total													1	100	3.4	1	100	1.7	1	100	2.3				1	100	1.4
SYNCOPE	Severe	2	100	3.7				2	100	2.5																		
	Total	2	100	3.7				2	100	2.5																		
CHEST PAIN	Mild	1	100	1.9				1	100	1.2																		
	Severe																			1	100	2.3				1	100	1.4
	Total	1	100	1.9				1	100	1.2										1	100	2.3				1	100	1.4
RASH ERYTHEMAT-OUS	Severe																			1	100	2.3				1	100	1.4
	Total																			1	100	2.3				1	100	1.4
RHAGADES	Moderate	1	100	1.9				1	100	1.2																		
	Total	1	100	1.9				1	100	1.2																		
COLD URTICARIA	Moderate				1	100	3.7	1	100	1.2																		
	Total				1	100	3.7	1	100	1.2																		
HYPERTONIA	Moderate										1	100	3.4				1	100	1.7									
	Total										1	100	3.4				1	100	1.7									
MIGRAINE	Severe																						1	100	3.7	1	100	1.4
	Total																						1	100	3.7	1	100	1.4
SPEECH DISORDER	Mild	1	100	1.9				1	100	1.2																		
	Total	1	100	1.9				1	100	1.2																		
ANOREXIA	Moderate																			1	100	2.3				1	100	1.4
	Total																			1	100	2.3				1	100	1.4

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 53

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
ACCOMMODATION ABNORMAL	Moderate	1	100	1.9				1	100	1.2																			
	Total	1	100	1.9				1	100	1.2													-						
FLUSHING	Severe																			1	100	2.3				1	100	1.4	
	Total																			1	100	2.3				1	100	1.4	
BRADYCARDIA	Severe										1	100	3.4				1	100	1.7										
	Total										1	100	3.4				1	100	1.7										
SALIVA INCREASED	Moderate																						1	100	3.7	1	100	1.4	
	Total																						1	100	3.7	1	100	1.4	
CHROMATOPSIA	Mild										1	100	3.4				1	100	1.7										
	Total										1	100	3.4				1	100	1.7										
EYE ABNORMALITY	Mild																			1	100	2.3				1	100	1.4	
	Total																			1	100	2.3				1	100	1.4	
TASTE LOSS	Moderate	1	100	1.9				1	100	1.2																			
	Total	1	100	1.9				1	100	1.2																			
TASTE PERVERSION	Moderate										1	100	3.4				1	100	1.7										
	Total										1	100	3.4				1	100	1.7										
AUTOLESIONIST BEHAVIOUR	Mild	1	100	1.9				1	100	1.2																			
	Total	1	100	1.9				1	100	1.2																			
DEPERSONALIZATION	Severe	1	100	1.9				1	100	1.2																			
	Total	1	100	1.9				1	100	1.2																			

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 53

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
LIBIDO DECREASED	Missing																						1	100	3.7	1	100	1.4
	Total																						1	100	3.7	1	100	1.4
PARONIRIA	Moderate										1	100	3.4				1	100	1.7									-
	Total										1	100	3.4				1	100	1.7									
SLEEP DISORDER	Mild	1	100	1.9				1	100	1.2																		
	Total	1	100	1.9				1	100	1.2																		
DEPRESSION AGGRAVATED	Severe										1	100	3.4				1	100	1.7									
	Total										1	100	3.4				1	100	1.7									
CONCENTRATION IMPAIRED	Moderate	1	100	1.9				1	100	1.2																		
	Total	1	100	1.9				1	100	1.2																		
COLITIS	Moderate				1	100	3.7	1	100	1.2																		
	Total				1	100	3.7	1	100	1.2																		
DUODENAL ULCER REACTIVATED	Moderate	1	100	1.9				1	100	1.2																		
	Total	1	100	1.9				1	100	1.2																		
DYSPHAGIA	Moderate				1	100	3.7	1	100	1.2																		
	Total				1	100	3.7	1	100	1.2																		
GASTRITIS	Moderate																			1	100	2.3				1	100	1.4
	Total																			1	100	2.3				1	100	1.4
GASTROENTERITIS	Moderate																			1	100	2.3				1	100	1.4
	Total																			1	100	2.3				1	100	1.4

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 53

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
TONGUE ULCERATION	Moderate													1	100	3.4	1	100	1.7									
	Total													1	100	3.4	1	100	1.7									
TOOTH DISORDER	Missing																			1	100	2.3				1	100	1.4
	Total																			1	100	2.3				1	100	1.4
HYPERURIC-AEMIA	Severe																						1	100	3.7	1	100	1.4
	Total																						1	100	3.7	1	100	1.4
HYPOKALAE-MIA	Mild	1	100	1.9				1	100	1.2																		
	Total	1	100	1.9				1	100	1.2																		
PHOSPHATA-SE ALKALINE INCREASED	Moderate	1	100	1.9				1	100	1.2																		
	Total	1	100	1.9				1	100	1.2																		
HYPERTRIG-LYCERIDAE-MIA	Mild	1	100	1.9				1	100	1.2																		
	Total	1	100	1.9				1	100	1.2																		
EXTRASYST-OLES	Moderate	1	100	1.9				1	100	1.2																		
	Total	1	100	1.9				1	100	1.2																		
HAEMORRHO-IDS THROMBOSED	Moderate																			1	100	2.3				1	100	1.4
	Total																			1	100	2.3				1	100	1.4
BRONCHITIS	Mild										1	100	3.4				1	100	1.7									
	Total										1	100	3.4				1	100	1.7									
ANAEMIA HYPOCHROM-IC	Mild	1	100	1.9				1	100	1.2																		
	Total	1	100	1.9				1	100	1.2																		

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 53

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																								
		Imipramine									Placebo								Reboxetine							
		Female			Male			Total			Female			Male			Total		Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
EOSINOPHILIA	Moderate	1	100	1.9				1	100	1.2																	
	Total	1	100	1.9				1	100	1.2																	
MICTURITION FREQUENCY	Mild													1	100	3.4	1	100	1.7								
	Total													1	100	3.4	1	100	1.7								
PYURIA	Mild																			1	100	2.3				1	100	1.4
	Total																			1	100	2.3				1	100	1.4
IMPOTENCE	Severe																						1	100	3.7	1	100	1.4
	Total																						1	100	3.7	1	100	1.4
PERINEAL PAIN MALE	Mild																						1	100	3.7	1	100	1.4
	Total																						1	100	3.7	1	100	1.4
EPIDIDYMITIS	Moderate																						1	100	3.7	1	100	1.4
	Total																						1	100	3.7	1	100	1.4
MALAISE	Moderate													1	100	3.4	1	100	1.7								
	Total													1	100	3.4	1	100	1.7								
RIGORS	Moderate				1	100	3.7	1	100	1.2																	
	Total				1	100	3.7	1	100	1.2																	
HYPERPYREXIA	Mild																			1	100	2.3				1	100	1.4
	Total																			1	100	2.3				1	100	1.4
PHARYNGITIS	Mild													1	100	3.4	1	100	1.7								
	Total													1	100	3.4	1	100	1.7								

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 53

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
HERPES SIMPLEX	Mild										1	100	3.4				1	100	1.7									
	Total										1	100	3.4				1	100	1.7									

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 54

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Body system / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
All adverse events	Mild	5	9.3	9.3	9	34.6	33.3	14	17.5	17.3	8	27.6	27.6	8	28.6	27.6	16	28.1	27.6	9	20.5	20.5	11	40.7	40.7	20	28.2	28.2
	Moderate	28	51.9	51.9	13	50.0	48.1	41	51.3	50.6	15	51.7	51.7	15	53.6	51.7	30	52.6	51.7	21	47.7	47.7	7	25.9	25.9	28	39.4	39.4
	Severe	21	38.9	38.9	4	15.4	14.8	25	31.3	30.9	6	20.7	20.7	5	17.9	17.2	11	19.3	19.0	14	31.8	31.8	9	33.3	33.3	23	32.4	32.4
	Total	54	100	100	26	100	96.3	80	100	98.8	29	100	100	28	100	96.6	57	100	98.3	44	100	100	27	100	100	71	100	100
AUTONOMIC NERVOUS SYSTEM DISORDERS	Mild	7	17.9	13.0	8	47.1	29.6	15	26.8	18.5	5	41.7	17.2	2	40.0	6.9	7	41.2	12.1	10	37.0	22.7	8	61.5	29.6	18	45.0	25.4
	Moderate	25	64.1	46.3	7	41.2	25.9	32	57.1	39.5	6	50.0	20.7	3	60.0	10.3	9	52.9	15.5	14	51.9	31.8	5	38.5	18.5	19	47.5	26.8
	Severe	6	15.4	11.1	2	11.8	7.4	8	14.3	9.9	1	8.3	3.4				1	5.9	1.7	3	11.1	6.8				3	7.5	4.2
	Missing	1	2.6	1.9				1	1.8	1.2																		
	Total	39	100	72.2	17	100	63.0	56	100	69.1	12	100	41.4	5	100	17.2	17	100	29.3	27	100	61.4	13	100	48.1	40	100	56.3
GASTRO-INTESTINAL SYSTEM DISORDERS	Mild	5	17.9	9.3	4	50.0	14.8	9	25.0	11.1	3	23.1	10.3	2	40.0	6.9	5	27.8	8.6	1	5.3	2.3	2	28.6	7.4	3	11.5	4.2
	Moderate	18	64.3	33.3	2	25.0	7.4	20	55.6	24.7	9	69.2	31.0	3	60.0	10.3	12	66.7	20.7	15	78.9	34.1	2	28.6	7.4	17	65.4	23.9
	Severe	5	17.9	9.3	2	25.0	7.4	7	19.4	8.6	1	7.7	3.4				1	5.6	1.7	2	10.5	4.5	3	42.9	11.1	5	19.2	7.0
	Missing																			1	5.3	2.3				1	3.8	1.4
	Total	28	100	51.9	8	100	29.6	36	100	44.4	13	100	44.8	5	100	17.2	18	100	31.0	19	100	43.2	7	100	25.9	26	100	36.6
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Mild	6	20.0	11.1	1	16.7	3.7	7	19.4	8.6	2	28.6	6.9	2	22.2	6.9	4	25.0	6.9	8	44.4	18.2				8	29.6	11.3
	Moderate	18	60.0	33.3	4	66.7	14.8	22	61.1	27.2	4	57.1	13.8	6	66.7	20.7	10	62.5	17.2	8	44.4	18.2	5	55.6	18.5	13	48.1	18.3
	Severe	5	16.7	9.3	1	16.7	3.7	6	16.7	7.4	1	14.3	3.4	1	11.1	3.4	2	12.5	3.4	2	11.1	4.5	4	44.4	14.8	6	22.2	8.5
	Missing	1	3.3	1.9				1	2.8	1.2																		
	Total	30	100	55.6	6	100	22.2	36	100	44.4	7	100	24.1	9	100	31.0	16	100	27.6	18	100	40.9	9	100	33.3	27	100	38.0

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 54

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Body system / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
PSYCHIATRIC DISORDERS	Mild	3	18.8	5.6	1	11.1	3.7	4	16.0	4.9	3	23.1	10.3	5	45.5	17.2	8	33.3	13.8				2	25.0	7.4	2	10.0	2.8
	Moderate	6	37.5	11.1	6	66.7	22.2	12	48.0	14.8	6	46.2	20.7	2	18.2	6.9	8	33.3	13.8	4	33.3	9.1	4	50.0	14.8	8	40.0	11.3
	Severe	6	37.5	11.1				6	24.0	7.4	3	23.1	10.3	4	36.4	13.8	7	29.2	12.1	7	58.3	15.9	2	25.0	7.4	9	45.0	12.7
	Missing	1	6.3	1.9	2	22.2	7.4	3	12.0	3.7	1	7.7	3.4				1	4.2	1.7	1	8.3	2.3				1	5.0	1.4
	Total	16	100	29.6	9	100	33.3	25	100	30.9	13	100	44.8	11	100	37.9	24	100	41.4	12	100	27.3	8	100	29.6	20	100	28.2
CARDIOVASCULAR DISORDERS, GENERAL	Mild	6	28.6	11.1	2	28.6	7.4	8	28.6	9.9	3	75.0	10.3	3	50.0	10.3	6	60.0	10.3				3	42.9	11.1	3	18.8	4.2
	Moderate	10	47.6	18.5	3	42.9	11.1	13	46.4	16.0				3	50.0	10.3	3	30.0	5.2	7	77.8	15.9	3	42.9	11.1	10	62.5	14.1
	Severe	4	19.0	7.4	2	28.6	7.4	6	21.4	7.4	1	25.0	3.4				1	10.0	1.7	2	22.2	4.5	1	14.3	3.7	3	18.8	4.2
	Missing	1	4.8	1.9				1	3.6	1.2																	
	Total	21	100	38.9	7	100	25.9	28	100	34.6	4	100	13.8	6	100	20.7	10	100	17.2	9	100	20.5	7	100	25.9	16	100	22.5
VISION DISORDERS	Mild	4	44.4	7.4	1	33.3	3.7	5	41.7	6.2	1	100	3.4	1	33.3	3.4	2	50.0	3.4	4	80.0	9.1	2	50.0	7.4	6	66.7	8.5
	Moderate	5	55.6	9.3	2	66.7	7.4	7	58.3	8.6				2	66.7	6.9	2	50.0	3.4				1	25.0	3.7	1	11.1	1.4
	Missing																			1	20.0	2.3	1	25.0	3.7	2	22.2	2.8
	Total	9	100	16.7	3	100	11.1	12	100	14.8	1	100	3.4	3	100	10.3	4	100	6.9	5	100	11.4	4	100	14.8	9	100	12.7
BODY AS A WHOLE-GENERAL DISORDERS	Mild	1	20.0	1.9				1	11.1	1.2										1	25.0	2.3	1	33.3	3.7	2	28.6	2.8
	Moderate	2	40.0	3.7	3	75.0	11.1	5	55.6	6.2	1	100	3.4	4	80.0	13.8	5	83.3	8.6	1	25.0	2.3				1	14.3	1.4
	Severe	1	20.0	1.9	1	25.0	3.7	2	22.2	2.5										2	50.0	4.5				2	28.6	2.8
	Missing	1	20.0	1.9				1	11.1	1.2				1	20.0	3.4	1	16.7	1.7				2	66.7	7.4	2	28.6	2.8
	Total	5	100	9.3	4	100	14.8	9	100	11.1	1	100	3.4	5	100	17.2	6	100	10.3	4	100	9.1	3	100	11.1	7	100	9.9

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 54

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Body system / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
URINARY SYSTEM DISORDERS	Mild				1	100	3.7	1	50.0	1.2				2	100	6.9	2	50.0	3.4	3	60.0	6.8	5	71.4	18.5	8	66.7	11.3
	Moderate	1	100	1.9				1	50.0	1.2	2	100	6.9				2	50.0	3.4	2	40.0	4.5	1	14.3	3.7	3	25.0	4.2
	Severe																						1	14.3	3.7	1	8.3	1.4
	Total	1	100	1.9	1	100	3.7	2	100	2.5	2	100	6.9	2	100	6.9	4	100	6.9	5	100	11.4	7	100	25.9	12	100	16.9
RESPIRATORY SYSTEM DISORDERS	Mild	1	25.0	1.9				1	25.0	1.2	1	100	3.4	4	66.7	13.8	5	71.4	8.6									
	Moderate	3	75.0	5.6				3	75.0	3.7										4	100	9.1				4	100	5.6
	Severe													1	16.7	3.4	1	14.3	1.7									
	Missing													1	16.7	3.4	1	14.3	1.7									
	Total	4	100	7.4				4	100	4.9	1	100	3.4	6	100	20.7	7	100	12.1	4	100	9.1				4	100	5.6
METABOLIC AND NUTRITIONAL DISORDERS	Mild	2	40.0	3.7				2	40.0	2.5																		
	Moderate	3	60.0	5.6				3	60.0	3.7				1	100	3.4	1	100	1.7	1	100	2.3				1	50.0	1.4
	Severe																						1	100	3.7	1	50.0	1.4
	Total	5	100	9.3				5	100	6.2				1	100	3.4	1	100	1.7	1	100	2.3	1	100	3.7	2	100	2.8
MUSCOLOSKELETAL SYSTEM DISORDERS	Mild													2	100	6.9	2	40.0	3.4				1	100	3.7	1	100	1.4
	Moderate				1	100	3.7	1	100	1.2	3	100	10.3				3	60.0	5.2									
	Total				1	100	3.7	1	100	1.2	3	100	10.3	2	100	6.9	5	100	8.6				1	100	3.7	1	100	1.4
SKIN AND APPENDAGES DISORDERS	Mild										1	50.0	3.4				1	50.0	1.7									
	Moderate	1	50.0	1.9	1	100	3.7	2	66.7	2.5	1	50.0	3.4				1	50.0	1.7									
	Severe	1	50.0	1.9				1	33.3	1.2										1	100	2.3				1	100	1.4
	Total	2	100	3.7	1	100	3.7	3	100	3.7	2	100	6.9				2	100	3.4	1	100	2.3				1	100	1.4

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 54

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Body system / Severity		Assigned treatment																											
		Imipramine									Placebo									Reboxetine									
		Female			Male			Total			Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
HEARING AND VESTIBULAR DISORDERS	Mild	1	100	1.9				1	50.0	1.2																			
	Moderate				1	100	3.7	1	50.0	1.2																			
	Total	1	100	1.9	1	100	3.7	2	100	2.5																			
HEMATOLOGY DISORDERS	Mild	1	50.0	1.9				1	50.0	1.2																			
	Moderate	1	50.0	1.9				1	50.0	1.2																			
	Total	2	100	3.7				2	100	2.5																			
LIVER AND BILIAR SYSTEM DISORDERS	Moderate	1	100	1.9				1	100	1.2													1	100	3.7	1	100	1.4
	Total	1	100	1.9				1	100	1.2													1	100	3.7	1	100	1.4
REPRODUCTIVE DISORDERS, MALE	Mild																						1	50.0	3.7	1	50.0	1.4
	Severe																						1	50.0	3.7	1	50.0	1.4
	Total																						2	100	7.4	2	100	2.8
SPECIAL SENSES OTHER, DISORDERS	Moderate	1	100	1.9				1	100	1.2	1	100	3.4				1	100	1.7									
	Total	1	100	1.9				1	100	1.2	1	100	3.4				1	100	1.7									
RESISTANCE MECHANISM DISORDERS	Mild										1	100	3.4				1	100	1.7									
	Total										1	100	3.4				1	100	1.7									

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 55

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		No of Episodes	Duration of episodes (days)			
			Min	50%	90%	Max
All adverse events	Imipramine	288	1	13	40	67
	Placebo	141	1	8	28	46
	Reboxetine	211	1	10	35	43
MOUTH DRY	Imipramine	53	1	20	41	44
	Placebo	15	2	15	44	46
	Reboxetine	29	1	26	41	42
SWEATING INCREASED	Imipramine	26	1	14	39	43
	Placebo	3	1	35	38	38
	Reboxetine	15	2	15	35	43
CONSTIPATION	Imipramine	18	7	23	40	41
	Placebo	6	3	20	40	40
	Reboxetine	20	3	13	38	41
HEADACHE	Imipramine	9	1	7	41	41
	Placebo	10	1	7	35	41
	Reboxetine	18	1	6	40	43
NAUSEA	Imipramine	16	1	6	21	42
	Placebo	11	1	6	12	13
	Reboxetine	9	2	18	24	24
TREMOR	Imipramine	20	7	20	37	41
	Placebo	5	1	3	8	8
	Reboxetine	6	4	11	14	14
DIZZINESS	Imipramine	16	1	8	19	31

(CONTINUED)

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 55

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		No of Episodes	Duration of episodes (days)			
			Min	50%	90%	Max
DIZZINESS	Placebo	4	1	3	25	25
	Reboxetine	8	1	6	29	29
INSOMNIA	Imipramine	8	6	8	42	42
	Placebo	4	8	17	28	28
	Reboxetine	12	1	6	29	40
VISION ABNORMAL	Imipramine	10	3	15	39	42
	Placebo	3	33	34	36	36
	Reboxetine	7	1	12	15	15
AGITATION	Imipramine	4	1	21	36	36
	Placebo	7	2	7	28	28
	Reboxetine	8	1	9	22	22
SOMNOLENCE	Imipramine	6	4	26	42	42
	Placebo	10	7	13	21	21
	Reboxetine	1	27	27	27	27
VERTIGO	Imipramine	8	3	5	21	21
	Reboxetine	5	1	6	43	43
FATIGUE	Imipramine	4	12	15	29	29
	Placebo	4	7	15	35	35
	Reboxetine	3	1	5	35	35
PARAESTHESIA	Imipramine	6	3	11	36	36
	Placebo	2	5	5	5	5
	Reboxetine	2	2	3	4	4

(CONTINUED)

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 55

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		No of Episodes	Duration of episodes (days)			
			Min	50%	90%	Max
SUICIDE ATTEMPT	Imipramine	4	1	3	67	67
	Placebo	4	1	4	7	7
	Reboxetine	1	2	2	2	2
ABDOMINAL PAIN	Imipramine	5	4	10	35	35
	Placebo	3	6	9	12	12
	Reboxetine	1	20	20	20	20
HYPOTENSION POSTURAL	Imipramine	6	3	5	10	10
	Reboxetine	2	8	15	22	22
TACHYCARDIA	Imipramine	4	1	3	15	15
	Reboxetine	3	3	8	16	16
DYSPNOEA	Imipramine	2	2	3	4	4
	Reboxetine	5	1	1	7	7
RHINITIS	Imipramine	2	15	28	41	41
	Placebo	4	2	7	13	13
	Reboxetine	1	15	15	15	15
HOT FLUSHES	Imipramine	4	8	15	27	27
	Placebo	1	10	10	10	10
	Reboxetine	2	15	21	27	27
VOMITING	Imipramine	1	2	2	2	2
	Placebo	4	1	4	4	4
	Reboxetine	1	2	2	2	2
DYSPEPSIA	Imipramine	5	1	8	30	30

(CONTINUED)

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 55

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		No of Episodes	Duration of episodes (days)			
			Min	50%	90%	Max
DYSPEPSIA	Placebo	1	12	12	12	12
HYPOTENSION	Imipramine	1	1	1	1	1
	Placebo	2	10	12	13	13
	Reboxetine	2	8	9	10	10
ANXIETY	Imipramine	1	4	4	4	4
	Placebo	3	1	4	8	8
	Reboxetine	1	3	3	3	3
NERVOUSNESS	Placebo	1	10	10	10	10
	Reboxetine	4	1	11	43	43
MICTURITION DISORDER	Imipramine	1	43	43	43	43
	Placebo	1	7	7	7	7
	Reboxetine	3	19	22	34	34
URINARY TRACT INFECTION	Placebo	1	5	5	5	5
	Reboxetine	4	8	12	14	14
URINARY RETENTION	Placebo	1	1	1	1	1
	Reboxetine	3	6	32	37	37
PALPITATION	Imipramine	2	5	24	43	43
	Placebo	1	1	1	1	1
	Reboxetine	1	5	5	5	5
ASTHENIA	Imipramine	3	3	29	31	31
	Reboxetine	1	3	3	3	3
RASH	Imipramine	1	14	14	14	14

(CONTINUED)

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 55

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		No of Episodes	Duration of episodes (days)			
			Min	50%	90%	Max
RASH	Placebo	2	4	5	5	5
MYALGIA	Imipramine	1	9	9	9	9
	Placebo	2	1	4	7	7
CONFUSION	Imipramine	2	3	9	15	15
	Reboxetine	1	4	4	4	4
HYPERKINESIA	Imipramine	1	7	7	7	7
	Placebo	2	7	13	19	19
MUSCLE CONTRACTIONS INVOLUNTARY	Imipramine	2	14	19	23	23
	Reboxetine	1	5	5	5	5
DIARRHOEA	Placebo	3	4	6	12	12
APPETITE INCREASED	Imipramine	2	40	41	41	41
	Placebo	1	10	10	10	10
WEIGHT INCREASE	Imipramine	2	20	30	40	40
	Reboxetine	1	41	41	41	41
SINUSITIS	Placebo	1	27	27	27	27
	Reboxetine	2	5	7	8	8
DYSURIA	Imipramine	1	3	3	3	3
	Reboxetine	2	1	5	8	8
CHEST PAIN PRECORDIAL	Imipramine	2	1	10	18	18
	Placebo	1	2	2	2	2
INFLUENZA-LIKE SYMPTOMS	Imipramine	1	3	3	3	3
	Placebo	1	1	1	1	1

(CONTINUED)

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 55

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		No of Episodes	Duration of episodes (days)			
			Min	50%	90%	Max
INFLUENZA-LIKE SYMPTOMS	Reboxetine	1	5	5	5	5
ARTHRALGIA	Placebo	1	3	3	3	3
	Reboxetine	1	6	6	6	6
BACK PAIN	Placebo	2	5	12	19	19
HYPERTENSION	Imipramine	1	2	2	2	2
	Reboxetine	1	42	42	42	42
MYDRIASIS	Reboxetine	2	5	10	14	14
CONJUNCTIVITIS	Imipramine	2	13	14	14	14
TINNITUS	Imipramine	2	7	10	13	13
FLATULENCE	Placebo	1	40	40	40	40
	Reboxetine	1	12	12	12	12
GAMMA-GT INCREASED	Imipramine	1	1	1	1	1
	Reboxetine	1	8	8	8	8
WEIGHT DECREASE	Placebo	1	14	14	14	14
	Reboxetine	1	19	19	19	19
SYNCOPE	Imipramine	2	1	1	1	1
CHEST PAIN	Imipramine	1	3	3	3	3
	Reboxetine	1	4	4	4	4
RASH ERYTHEMATOUS	Reboxetine	1	6	6	6	6
RHAGADES	Imipramine	1	21	21	21	21
COLD URTICARIA	Imipramine	1	4	4	4	4
HYPERTONIA	Placebo	1	18	18	18	18

(CONTINUED)

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 55

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		No of Episodes	Duration of episodes (days)			
			Min	50%	90%	Max
MIGRAINE	Reboxetine	1	2	2	2	2
SPEECH DISORDER	Imipramine	1	18	18	18	18
ANOREXIA	Reboxetine	1	19	19	19	19
ACCOMMODATION ABNORMAL	Imipramine	1	14	14	14	14
FLUSHING	Reboxetine	1	11	11	11	11
BRADYCARDIA	Placebo	1	5	5	5	5
SALIVA INCREASED	Reboxetine	1	20	20	20	20
CHROMATOPSIA	Placebo	1	1	1	1	1
EYE ABNORMALITY	Reboxetine	1	12	12	12	12
TASTE LOSS	Imipramine	1	22	22	22	22
TASTE PERVERSION	Placebo	1	5	5	5	5
AUTOLESIONIST BEHAVIOUR	Imipramine	1	1	1	1	1
DEPERSONALIZATION	Imipramine	1	8	8	8	8
LIBIDO DECREASED	Reboxetine	1	7	7	7	7
PARONIRIA	Placebo	1	5	5	5	5
SLEEP DISORDER	Imipramine	1	45	45	45	45
DEPRESSION AGGRAVATED	Placebo	1	2	2	2	2
CONCENTRATION IMPAIRED	Imipramine	1	20	20	20	20
COLITIS	Imipramine	1	5	5	5	5
DUODENAL ULCER REACTIVATED	Imipramine	1	15	15	15	15
DYSPHAGIA	Imipramine	1	19	19	19	19
GASTRITIS	Reboxetine	1	2	2	2	2

(CONTINUED)

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 55

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		No of Episodes	Duration of episodes (days)			
			Min	50%	90%	Max
GASTROENTERITIS	Reboxetine	1	6	6	6	6
TONGUE ULCERATION	Placebo	1	8	8	8	8
TOOTH DISORDER	Reboxetine	1	8	8	8	8
HYPERURICAEMIA	Reboxetine	1	22	22	22	22
HYPOKALAEMIA	Imipramine	1	5	5	5	5
PHOSPHATASE ALKALINE INCREASED	Imipramine	1	1	1	1	1
HYPERTRIGLYCERIDAEMIA	Imipramine	1	30	30	30	30
EXTRASYSTOLES	Imipramine	1	3	3	3	3
HAEMORRHOIDS THROMBOSED	Reboxetine	1	6	6	6	6
BRONCHITIS	Placebo	1	6	6	6	6
ANAEMIA HYPOCHROMIC	Imipramine	1	2	2	2	2
EOSINOPHILIA	Imipramine	1	1	1	1	1
MICTURITION FREQUENCY	Placebo	1	7	7	7	7
PYURIA	Reboxetine	1	4	4	4	4
IMPOTENCE	Reboxetine	1	32	32	32	32
PERINEAL PAIN MALE	Reboxetine	1	35	35	35	35
EPIDIDYMITIS	Reboxetine	1	32	32	32	32
MALAISE	Placebo	1	1	1	1	1
RIGORS	Imipramine	1	13	13	13	13
HYPERPYREXIA	Reboxetine	1	2	2	2	2
PHARYNGITIS	Placebo	1	8	8	8	8
HERPES SIMPLEX	Placebo	1	6	6	6	6

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: S6

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment																	
	Imipramine						Placebo						Reboxetine					
	Symptomatic treatment						Symptomatic treatment						Symptomatic treatment					
	YES		NO		Total		YES		NO		Total		YES		NO		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
No. of pt. with A.E.	22	27.2	59	72.8	81	100.0	15	25.9	43	74.1	58	100.0	24	33.8	47	66.2	71	100.0
No. of adverse events	30	10.4	258	89.6	288	100.0	23	16.3	118	83.7	141	100.0	40	19.0	171	81.0	211	100.0
MOUTH DRY	2	3.8	51	96.2	53	100.0	1	6.7	14	93.3	15	100.0	1	3.4	28	96.6	29	100.0
SWEATING INCREASED			26	100.0	26	100.0			3	100.0	3	100.0			15	100.0	15	100.0
CONSTIPATION	7	38.9	11	61.1	18	100.0	2	33.3	4	66.7	6	100.0	2	10.0	18	90.0	20	100.0
HEADACHE	5	55.6	4	44.4	9	100.0	2	20.0	8	80.0	10	100.0	6	33.3	12	66.7	18	100.0
NAUSEA	1	6.3	15	93.8	16	100.0			11	100.0	11	100.0	4	44.4	5	55.6	9	100.0
TREMOR			20	100.0	20	100.0			5	100.0	5	100.0			6	100.0	6	100.0
DIZZINESS			16	100.0	16	100.0			4	100.0	4	100.0			8	100.0	8	100.0
INSOMNIA	3	37.5	5	62.5	8	100.0	3	75.0	1	25.0	4	100.0	6	50.0	6	50.0	12	100.0
VISION ABNORMAL			10	100.0	10	100.0			3	100.0	3	100.0			7	100.0	7	100.0
AGITATION			4	100.0	4	100.0	1	14.3	6	85.7	7	100.0			8	100.0	8	100.0
SOMNOLENCE			6	100.0	6	100.0			10	100.0	10	100.0			1	100.0	1	100.0
VERTIGO			8	100.0	8	100.0							2	40.0	3	60.0	5	100.0
FATIGUE			4	100.0	4	100.0			4	100.0	4	100.0			3	100.0	3	100.0
PARAESTHESIA			6	100.0	6	100.0	1	50.0	1	50.0	2	100.0			2	100.0	2	100.0
SUICIDE ATTEMPT			4	100.0	4	100.0	2	50.0	2	50.0	4	100.0			1	100.0	1	100.0
ABDOMINAL PAIN	1	20.0	4	80.0	5	100.0			3	100.0	3	100.0			1	100.0	1	100.0
HYPOTENSION POSTURAL	2	33.3	4	66.7	6	100.0									2	100.0	2	100.0
TACHYCARDIA			4	100.0	4	100.0									3	100.0	3	100.0
DYSPNOEA			2	100.0	2	100.0							3	60.0	2	40.0	5	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 56

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment																	
	Imipramine						Placebo						Reboxetine					
	Symptomatic treatment						Symptomatic treatment						Symptomatic treatment					
	YES		NO		Total		YES		NO		Total		YES		NO		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
RHINITIS	1	50.0	1	50.0	2	100.0	1	25.0	3	75.0	4	100.0			1	100.0	1	100.0
HOT FLUSHES			4	100.0	4	100.0			1	100.0	1	100.0			2	100.0	2	100.0
VOMITING			1	100.0	1	100.0			4	100.0	4	100.0			1	100.0	1	100.0
DYSPEPSIA	2	40.0	3	60.0	5	100.0	1	100.0			1	100.0						
HYPOTENSION			1	100.0	1	100.0			2	100.0	2	100.0	1	50.0	1	50.0	2	100.0
ANXIETY	1	100.0			1	100.0			3	100.0	3	100.0			1	100.0	1	100.0
NERVOUSNESS									1	100.0	1	100.0			4	100.0	4	100.0
MICTURITION DISORDER			1	100.0	1	100.0			1	100.0	1	100.0			3	100.0	3	100.0
URINARY TRACT INFECTION							1	100.0			1	100.0	2	50.0	2	50.0	4	100.0
PALPITATION			2	100.0	2	100.0			1	100.0	1	100.0			1	100.0	1	100.0
ASTHENIA			3	100.0	3	100.0									1	100.0	1	100.0
URINARY RETENTION									1	100.0	1	100.0	1	33.3	2	66.7	3	100.0
RASH	1	100.0			1	100.0			2	100.0	2	100.0						
CONFUSION			2	100.0	2	100.0									1	100.0	1	100.0
HYPERKINESIA			1	100.0	1	100.0			2	100.0	2	100.0						
MUSCLE CONTRACTIONS INVOLUNTARY			2	100.0	2	100.0									1	100.0	1	100.0
DIARRHOEA									3	100.0	3	100.0						
APPETITE INCREASED			2	100.0	2	100.0			1	100.0	1	100.0						
WEIGHT INCREASE			2	100.0	2	100.0									1	100.0	1	100.0
SINUSITIS							1	100.0			1	100.0	1	50.0	1	50.0	2	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 56

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment																	
	Imipramine						Placebo						Reboxetine					
	Symptomatic treatment						Symptomatic treatment						Symptomatic treatment					
	YES		NO		Total		YES		NO		Total		YES		NO		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
CHEST PAIN PRECORDIAL			2	100.0	2	100.0	1	100.0			1	100.0						
INFLUENZA-LIKE SYMPTOMS	1	100.0			1	100.0	1	100.0			1	100.0	1	100.0			1	100.0
MYALGIA			1	100.0	1	100.0			2	100.0	2	100.0						
DYSURIA			1	100.0	1	100.0									2	100.0	2	100.0
ARTHRALGIA							1	100.0			1	100.0	1	100.0			1	100.0
BACK PAIN							2	100.0			2	100.0						
HYPERTENSION			1	100.0	1	100.0							1	100.0			1	100.0
MYDRIASIS															2	100.0	2	100.0
CONJUNCTIVITIS			2	100.0	2	100.0												
TINNITUS			2	100.0	2	100.0												
FLATULENCE									1	100.0	1	100.0	1	100.0			1	100.0
GAMMA-GT INCREASED			1	100.0	1	100.0									1	100.0	1	100.0
WEIGHT DECREASE									1	100.0	1	100.0			1	100.0	1	100.0
SYNCOPE			2	100.0	2	100.0												
CHEST PAIN			1	100.0	1	100.0									1	100.0	1	100.0
RASH ERYTHEMATOUS															1	100.0	1	100.0
RHAGADES	1	100.0			1	100.0												
HYPERTONIA							1	100.0			1	100.0						
SPEECH DISORDER			1	100.0	1	100.0												
ANOREXIA													1	100.0			1	100.0
ACCOMMODATION ABNORMAL			1	100.0	1	100.0												

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 56

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment																	
	Imipramine						Placebo						Reboxetine					
	Symptomatic treatment						Symptomatic treatment						Symptomatic treatment					
	YES		NO		Total		YES		NO		Total		YES		NO		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
FLUSHING															1	100.0	1	100.0
BRADYCARDIA									1	100.0	1	100.0						
CHROMATOPSIA									1	100.0	1	100.0						
EYE ABNORMALITY															1	100.0	1	100.0
TASTE LOSS			1	100.0	1	100.0												
TASTE PERVERSION									1	100.0	1	100.0						
AUTOLESIONIST BEHAVIOUR			1	100.0	1	100.0												
DEPERSONALIZATION			1	100.0	1	100.0												
PARONIRIA							1	100.0			1	100.0						
SLEEP DISORDER			1	100.0	1	100.0												
DEPRESSION AGGRAVATED									1	100.0	1	100.0						
CONCENTRATION IMPAIRED			1	100.0	1	100.0												
DUODENAL ULCER REACTIVATED	1	100.0			1	100.0												
GASTRITIS													1	100.0			1	100.0
GASTROENTERITIS													1	100.0			1	100.0
TOOTH DISORDER													1	100.0			1	100.0
HYPOKALAEMIA			1	100.0	1	100.0												
PHOSPHATASE ALKALINE INCREASED			1	100.0	1	100.0												
HYPERTRIGLYCERIDAEMIA			1	100.0	1	100.0												
EXTRASYSTOLES			1	100.0	1	100.0												

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 56

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment																	
	Imipramine						Placebo						Reboxetine					
	Symptomatic treatment						Symptomatic treatment						Symptomatic treatment					
	YES		NO		Total		YES		NO		Total		YES		NO		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
HAEMORRHOIDS THROMBOSED													1	100.0			1	100.0
BRONCHITIS									1	100.0	1	100.0						
ANAEMIA HYPOCHROMIC	1	100.0			1	100.0												
EOSINOPHILIA			1	100.0	1	100.0												
PYURIA															1	100.0	1	100.0
HYPERPYREXIA													1	100.0			1	100.0
HERPES SIMPLEX									1	100.0	1	100.0						
COLD URTICARIA			1	100.0	1	100.0												
MIGRAINE													1	100.0			1	100.0
SALIVA INCREASED															1	100.0	1	100.0
LIBIDO DECREASED															1	100.0	1	100.0
COLITIS			1	100.0	1	100.0												
DYSPHAGIA			1	100.0	1	100.0												
TONGUE ULCERATION									1	100.0	1	100.0						
HYPERURICAEMIA															1	100.0	1	100.0
MICTURITION FREQUENCY									1	100.0	1	100.0						
IMPOTENCE															1	100.0	1	100.0
PERINEAL PAIN MALE															1	100.0	1	100.0
EPIDIDYMITIS															1	100.0	1	100.0
MALAISE									1	100.0	1	100.0						
RIGORS			1	100.0	1	100.0												

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 56

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment																	
	Imipramine						Placebo						Reboxetine					
	Symptomatic treatment						Symptomatic treatment						Symptomatic treatment					
	YES		NO		Total		YES		NO		Total		YES		NO		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
PHARYNGITIS									1	100.0	1	100.0						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 57

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Study drug											
		No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
All adverse events	Imipramine	235	81.6	6	2.1	5	1.7	30	10.4	12	4.2	288	100.0
	Placebo	125	88.7			2	1.4	12	8.5	2	1.4	141	100.0
	Reboxetine	181	85.8	4	1.9			20	9.5	6	2.8	211	100.0
MOUTH DRY	Imipramine	49	92.5	1	1.9			2	3.8	1	1.9	53	100.0
	Placebo	13	86.7			1	6.7	1	6.7			15	100.0
	Reboxetine	27	93.1	1	3.4			1	3.4			29	100.0
NAUSEA AND RELATED SYMPTOMS	Imipramine	15	68.2	1	4.5	1	4.5	3	13.6	2	9.1	22	100.0
	Placebo	15	93.8					1	6.3			16	100.0
	Reboxetine	11	100.0									11	100.0
SWEATING INCREASED	Imipramine	21	80.8					4	15.4	1	3.8	26	100.0
	Placebo	3	100.0									3	100.0
	Reboxetine	13	86.7					1	6.7	1	6.7	15	100.0
CONSTIPATION	Imipramine	16	88.9	1	5.6					1	5.6	18	100.0
	Placebo	6	100.0									6	100.0
	Reboxetine	19	95.0					1	5.0			20	100.0
HYPOTENSION AND RELATED SYMPTOMS	Imipramine	20	80.0	1	4.0	1	4.0	3	12.0			25	100.0
	Placebo	6	100.0									6	100.0
	Reboxetine	9	75.0					2	16.7	1	8.3	12	100.0
HEADACHE / MIGRAINE	Imipramine	7	77.8					1	11.1	1	11.1	9	100.0
	Placebo	10	100.0									10	100.0
	Reboxetine	19	100.0									19	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 57

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Study drug											
		No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
TREMOR	Imipramine	17	85.0	1	5.0			2	10.0			20	100.0
	Placebo	5	100.0									5	100.0
	Reboxetine	5	83.3	1	16.7							6	100.0
AGITATION / ANXIETY / NERVOUSNESS	Imipramine	4	80.0			1	20.0					5	100.0
	Placebo	7	63.6			1	9.1	3	27.3			11	100.0
	Reboxetine	10	76.9	1	7.7			2	15.4			13	100.0
INSOMNIA	Imipramine	4	50.0	1	12.5			1	12.5	2	25.0	8	100.0
	Placebo	3	75.0							1	25.0	4	100.0
	Reboxetine	9	75.0					2	16.7	1	8.3	12	100.0
BLURRED VISION	Imipramine	9	81.8					2	18.2			11	100.0
	Placebo	3	100.0									3	100.0
	Reboxetine	6	85.7							1	14.3	7	100.0
SOMNOLENCE	Imipramine	6	100.0									6	100.0
	Placebo	10	100.0									10	100.0
	Reboxetine	1	100.0									1	100.0
ASTHENIA / FATIGUE	Imipramine	7	100.0									7	100.0
	Placebo	4	100.0									4	100.0
	Reboxetine	4	100.0									4	100.0
VERTIGO	Imipramine	6	75.0					2	25.0			8	100.0
	Reboxetine	3	60.0					2	40.0			5	100.0
PARAESTHESIA	Imipramine	5	83.3							1	16.7	6	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 57

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Study drug											
		No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
PARAESTHESIA	Placebo	2	100.0									2	100.0
	Reboxetine	1	50.0					1	50.0			2	100.0
ABDOMINAL PAIN	Imipramine	4	80.0					1	20.0			5	100.0
	Placebo	3	100.0									3	100.0
	Reboxetine	1	100.0									1	100.0
SUICIDE ATTEMPT	Imipramine	1	25.0					3	75.0			4	100.0
	Placebo	2	50.0					2	50.0			4	100.0
	Reboxetine							1	100.0			1	100.0
URINARY HESITANCY / RETENTION	Imipramine	1	100.0									1	100.0
	Placebo	2	100.0									2	100.0
	Reboxetine	5	83.3					1	16.7			6	100.0
FLUSHING / HOT FLUSHES	Imipramine	2	50.0			1	25.0	1	25.0			4	100.0
	Placebo	1	100.0									1	100.0
	Reboxetine	3	100.0									3	100.0
TACHYCARDIA	Imipramine	2	50.0					1	25.0	1	25.0	4	100.0
	Reboxetine	2	66.7					1	33.3			3	100.0
DYSPNOEA	Imipramine	2	100.0									2	100.0
	Reboxetine	5	100.0									5	100.0
RHINITIS	Imipramine	2	100.0									2	100.0
	Placebo	4	100.0									4	100.0
	Reboxetine	1	100.0									1	100.0

(CONTINUED)

(some adverse events are grouped in clustor)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 57

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Study drug											
		No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
URINARY TRACT INFECTION	Placebo	1	100.0									1	100.0
	Reboxetine	3	75.0					1	25.0			4	100.0
PALPITATION	Imipramine	2	100.0									2	100.0
	Placebo	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
ERYTHEMA / RASH	Imipramine	1	100.0									1	100.0
	Placebo	1	50.0					1	50.0			2	100.0
	Reboxetine	1	100.0									1	100.0
CARDIAC ISCHEMIA AND RELATED SYMPTOMS	Imipramine	1	50.0					1	50.0			2	100.0
	Placebo	1	100.0									1	100.0
CONFUSION	Imipramine	1	50.0							1	50.0	2	100.0
	Reboxetine							1	100.0			1	100.0
HYPERKINESIA	Imipramine	1	100.0									1	100.0
	Placebo	1	50.0					1	50.0			2	100.0
MUSCLE CONTRACTIONS INVOLUNTARY	Imipramine	2	100.0									2	100.0
	Reboxetine			1	100.0							1	100.0
APPETITE INCREASED	Imipramine	2	100.0									2	100.0
	Placebo	1	100.0									1	100.0
DIARRHOEA	Placebo	2	66.7					1	33.3			3	100.0
WEIGHT INCREASE	Imipramine	2	100.0									2	100.0
	Reboxetine	1	100.0									1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 57

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Study drug											
		No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
MYALGIA	Imipramine	1	100.0									1	100.0
	Placebo	2	100.0									2	100.0
SINUSITIS	Placebo	1	100.0									1	100.0
	Reboxetine	2	100.0									2	100.0
DYSURIA	Imipramine	1	100.0									1	100.0
	Reboxetine	2	100.0									2	100.0
INFLUENZA-LIKE SYMPTOMS	Imipramine									1	100.0	1	100.0
	Placebo									1	100.0	1	100.0
	Reboxetine									1	100.0	1	100.0
CHEST PAIN	Imipramine	1	100.0									1	100.0
	Reboxetine							1	100.0			1	100.0
HYPERTENSION	Imipramine	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
FLATULENCE	Placebo	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
TINNITUS	Imipramine	1	50.0					1	50.0			2	100.0
INCREASED LIVER ENZYMES	Imipramine	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
WEIGHT DECREASE	Placebo	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
ARTHRALGIA	Placebo	1	100.0									1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 57

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Study drug											
		No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
ARTHRALGIA	Reboxetine	1	100.0									1	100.0
BACK PAIN	Placebo	2	100.0									2	100.0
CONJUNCTIVITIS	Imipramine	2	100.0									2	100.0
MYDRIASIS	Reboxetine	2	100.0									2	100.0
SALIVA INCREASED	Reboxetine	1	100.0									1	100.0
HYPERPYREXIA	Reboxetine	1	100.0									1	100.0
MALAISE	Placebo	1	100.0									1	100.0
RIGORS	Imipramine	1	100.0									1	100.0
EXTRASYSTOLES	Imipramine	1	100.0									1	100.0
HYPERTONIA	Placebo	1	100.0									1	100.0
SPEECH DISORDER	Imipramine	1	100.0									1	100.0
ANOREXIA	Reboxetine	1	100.0									1	100.0
DUODENAL ULCER REACTIVATED	Imipramine	1	100.0									1	100.0
GASTROENTERITIS	Reboxetine	1	100.0									1	100.0
TONGUE ULCERATION	Placebo	1	100.0									1	100.0
ANEMIA	Imipramine	1	100.0									1	100.0
EOSINOPHILIA	Imipramine	1	100.0									1	100.0
HYPERTRIGLYCERIDAEMIA	Imipramine	1	100.0									1	100.0
HYPERURICAEMIA	Reboxetine	1	100.0									1	100.0
HYPOKALAEMIA	Imipramine	1	100.0									1	100.0
PHOSPHATASE ALKALINE INCREASED	Imipramine	1	100.0									1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 57

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Study drug											
		No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
CONCENTRATION IMPAIRED	Imipramine	1	100.0									1	100.0
DEPERSONALIZATION	Imipramine	1	100.0									1	100.0
LIBIDO DECREASED	Reboxetine	1	100.0									1	100.0
PARONIRIA	Placebo	1	100.0									1	100.0
SLEEP DISORDER	Imipramine	1	100.0									1	100.0
EPIDIDYMITIS	Reboxetine	1	100.0									1	100.0
PERINEAL PAIN MALE	Reboxetine	1	100.0									1	100.0
HERPES SIMPLEX	Placebo	1	100.0									1	100.0
BRONCHITIS	Placebo	1	100.0									1	100.0
PHARYNGITIS	Placebo	1	100.0									1	100.0
COLD URTICARIA	Imipramine	1	100.0									1	100.0
RHAGADES	Imipramine	1	100.0									1	100.0
TASTE LOSS	Imipramine	1	100.0									1	100.0
TASTE PERVERSION	Placebo	1	100.0									1	100.0
MICTURITION FREQUENCY	Placebo	1	100.0									1	100.0
PYURIA	Reboxetine	1	100.0									1	100.0
CHROMATOPSIA	Placebo	1	100.0									1	100.0
EYE ABNORMALITY	Reboxetine	1	100.0									1	100.0
AUTOLESIONIST BEHAVIOUR	Imipramine					1	100.0					1	100.0
BRADYCARDIA	Placebo							1	100.0			1	100.0
HAEMORRHOIDS THROMBOSED	Reboxetine							1	100.0			1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 57

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Study drug											
		No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
COLITIS	Imipramine							1	100.0			1	100.0
DYSPHAGIA	Imipramine							1	100.0			1	100.0
DEPRESSION AGGRAVATED	Placebo							1	100.0			1	100.0
IMPOTENCE	Reboxetine							1	100.0			1	100.0
TOOTH DISORDER	Reboxetine									1	100.0	1	100.0

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 58

ADVERSE EVENTS: DISAPPEARED AFTER ACTION ON STUDY DRUG AND REAPPEARED ON RESUMING TREATMENT
BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug								Temporarily interrupted							
		Disappeared								Riappeared							
		YES		NO		Not applicable		Total		YES		NO		Not applicable		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
All adverse events	Placebo	1	7.1	11	78.6	2	14.3	14	100.0					2	100.0	2	100.0
	Reboxetine	12	50.0	12	50.0			24	100.0								
	Imipramine	18	43.9	12	29.3	11	26.8	41	100.0					5	100.0	5	100.0
AGITATION / ANXIETY / NERVOUSNESS	Placebo			3	75.0	1	25.0	4	100.0					1	100.0	1	100.0
	Reboxetine	1	33.3	2	66.7			3	100.0								
	Imipramine					1	100.0	1	100.0					1	100.0	1	100.0
MOUTH DRY	Placebo			2	100.0			2	100.0					1	100.0	1	100.0
	Reboxetine	1	50.0	1	50.0			2	100.0								
	Imipramine	2	66.7			1	33.3	3	100.0								
HYPOTENSION AND RELATED SYMPTOMS	Reboxetine	1	50.0	1	50.0			2	100.0								
	Imipramine	1	20.0	3	60.0	1	20.0	5	100.0					1	100.0	1	100.0
NAUSEA AND RELATED SYMPTOMS	Placebo			1	100.0			1	100.0								
	Imipramine	2	40.0	1	20.0	2	40.0	5	100.0					1	100.0	1	100.0
SUICIDE ATTEMPT	Placebo			2	100.0			2	100.0								
	Reboxetine	1	100.0					1	100.0								
	Imipramine	2	66.7	1	33.3			3	100.0								
SWEATING INCREASED	Reboxetine			1	100.0			1	100.0								
	Imipramine	1	25.0	3	75.0			4	100.0								
TREMOR	Reboxetine	1	100.0					1	100.0								
	Imipramine			1	33.3	2	66.7	3	100.0								

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 58

ADVERSE EVENTS: DISAPPEARED AFTER ACTION ON STUDY DRUG AND REAPPEARED ON RESUMING TREATMENT
BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug								Temporarily interrupted							
		Disappeared								Riappeared							
		YES		NO		Not applicable		Total		YES		NO		Not applicable		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
VERTIGO	Reboxetine	1	50.0	1	50.0			2	100.0								
	Imipramine	1	50.0	1	50.0			2	100.0								
INSOMNIA	Reboxetine	2	100.0					2	100.0								
	Imipramine	1	50.0			1	50.0	2	100.0								
FLUSHING / HOT FLUSHES	Imipramine	1	50.0			1	50.0	2	100.0					1	100.0	1	100.0
TACHYCARDIA	Reboxetine			1	100.0			1	100.0								
	Imipramine			1	100.0			1	100.0								
CONSTIPATION	Reboxetine	1	100.0					1	100.0								
	Imipramine	1	100.0					1	100.0								
BLURRED VISION	Imipramine	1	50.0	1	50.0			2	100.0								
CHEST PAIN	Reboxetine			1	100.0			1	100.0								
BRADYCARDIA	Placebo			1	100.0			1	100.0								
CARDIAC ISCHEMIA AND RELATED SYMPTOMS	Imipramine					1	100.0	1	100.0								
HAEMORRHOIDS THROMBOSED	Reboxetine	1	100.0					1	100.0								
CONFUSION	Reboxetine			1	100.0			1	100.0								
HEADACHE / MIGRAINE	Imipramine	1	100.0					1	100.0								
HYPERKINESIA	Placebo					1	100.0	1	100.0								
MUSCLE CONTRACTIONS INVOLUNTARY	Reboxetine	1	100.0					1	100.0								
PARAESTHESIA	Reboxetine			1	100.0			1	100.0								

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/015
TABLE No.: 58

ADVERSE EVENTS: DISAPPEARED AFTER ACTION ON STUDY DRUG AND REAPPEARED ON RESUMING TREATMENT
BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug								Temporarily interrupted							
		Disappeared								Riappeared							
		YES		NO		Not applicable		Total		YES		NO		Not applicable		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
ABDOMINAL PAIN	Imipramine	1	100.0					1	100.0								
COLITIS	Imipramine	1	100.0					1	100.0								
DIARRHOEA	Placebo			1	100.0			1	100.0								
DYSPHAGIA	Imipramine	1	100.0					1	100.0								
TINNITUS	Imipramine	1	100.0					1	100.0								
AUTOLESIONIST BEHAVIOUR	Imipramine					1	100.0	1	100.0					1	100.0	1	100.0
DEPRESSION AGGRAVATED	Placebo	1	100.0					1	100.0								
IMPOTENCE	Reboxetine			1	100.0			1	100.0								
ERYTHEMA / RASH	Placebo			1	100.0			1	100.0								
URINARY HESITANCY / RETENTION	Reboxetine			1	100.0			1	100.0								
URINARY TRACT INFECTION	Reboxetine	1	100.0					1	100.0								

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

3.4.1

Adverse events/Assigned treatment		Modified study drug												Unchanged study drug or Missing									
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
All adverse events	Placebo	9	64.3	1	7.1	4	28.6					14	100	80	63.0			43	33.9			4	3.1	127	100
	Reboxetine	7	29.2			17	70.8					24	100	104	55.6			70	37.4			13	7.0	187	100
	Imipramine	15	36.6			25	61.0			1	2.4	41	100	116	47.0			115	46.6	1	0.4	15	6.1	247	100
MOUTH DRY	Placebo	2	100									2	100	8	61.5			4	30.8			1	7.7	13	100
	Reboxetine	1	50.0			1	50.0					2	100	7	25.9			19	70.4			1	3.7	27	100
	Imipramine					3	100					3	100	17	34.0			31	62.0			2	4.0	50	100
NAUSEA AND RELATED SYMPTOMS	Placebo	1	100									1	100	14	93.3			1	6.7					15	100
	Reboxetine													9	81.8			2	18.2					11	100
	Imipramine	2	40.0			3	60.0					5	100	12	70.6			4	23.5			1	5.9	17	100
SWEATING INCREASED	Placebo													1	33.3			2	66.7					3	100
	Reboxetine					1	100					1	100	8	57.1			3	21.4			3	21.4	14	100
	Imipramine	3	75.0			1	25.0					4	100	13	59.1			8	36.4			1	4.5	22	100
CONSTIPATION	Placebo													2	33.3			4	66.7					6	100
	Reboxetine					1	100					1	100	7	36.8			12	63.2					19	100
	Imipramine					1	100					1	100	5	29.4			11	64.7			1	5.9	17	100
HYPOTENSION AND RELATED SYMPTOMS	Placebo													5	83.3			1	16.7					6	100
	Reboxetine					2	100					2	100	6	60.0			2	20.0			2	20.0	10	100
	Imipramine	1	20.0			4	80.0					5	100	14	70.0			5	25.0			1	5.0	20	100
HEADACHE / MIGRAINE	Placebo													8	80.0			2	20.0					10	100
	Reboxetine													15	78.9			4	21.1					19	100

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug												Unchanged study drug or Missing											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
HEADACHE / MIGRAINE	Imipramine					1	100					1	100	3	37.5			5	62.5					8	100
TREMOR	Placebo													4	80.0			1	20.0					5	100
	Reboxetine					1	100					1	100	5	100									5	100
	Imipramine	1	33.3			2	66.7					3	100	8	47.1			8	47.1			1	5.9	17	100
AGITATION / ANXIETY / NERVOUSNESS	Placebo	2	50.0			2	50.0					4	100	5	71.4			2	28.6					7	100
	Reboxetine	1	33.3			2	66.7					3	100	4	40.0			6	60.0					10	100
	Imipramine	1	100									1	100	2	50.0			2	50.0					4	100
INSOMNIA	Placebo													1	25.0			2	50.0			1	25.0	4	100
	Reboxetine					2	100					2	100	4	40.0			4	40.0			2	20.0	10	100
	Imipramine					2	100					2	100					4	66.7			2	33.3	6	100
BLURRED VISION	Placebo																	3	100					3	100
	Reboxetine													4	57.1			2	28.6			1	14.3	7	100
	Imipramine	1	50.0			1	50.0					2	100	5	55.6			3	33.3			1	11.1	9	100
SOMNOLENCE	Placebo													4	40.0			6	60.0					10	100
	Reboxetine																	1	100					1	100
	Imipramine													4	66.7			1	16.7			1	16.7	6	100
ASTHENIA / FATIGUE	Placebo													2	50.0			2	50.0					4	100
	Reboxetine													2	50.0			2	50.0					4	100
	Imipramine													1	14.3			6	85.7					7	100
VERTIGO	Reboxetine	1	50.0			1	50.0					2	100	2	66.7			1	33.3					3	100

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug												Unchanged study drug or Missing									
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
VERTIGO	Imipramine	1	50.0			1	50.0					2	100	6	100									6	100
PARAESTHESIA	Placebo													2	100									2	100
	Reboxetine					1	100					1	100	1	100									1	100
	Imipramine													3	50.0			2	33.3			1	16.7	6	100
ABDOMINAL PAIN	Placebo													2	66.7			1	33.3					3	100
	Reboxetine													1	100									1	100
	Imipramine					1	100					1	100	3	75.0			1	25.0					4	100
SUICIDE ATTEMPT	Placebo	1	50.0	1	50.0							2	100	1	50.0			1	50.0					2	100
	Reboxetine					1	100					1	100												
	Imipramine	1	33.3			1	33.3			1	33.3	3	100							1	100			1	100
URINARY HESITANCY / RETENTION	Placebo													1	50.0			1	50.0					2	100
	Reboxetine	1	100									1	100	3	60.0			2	40.0					5	100
	Imipramine																	1	100					1	100
FLUSHING / HOT FLUSHES	Placebo													1	100									1	100
	Reboxetine													2	66.7			1	33.3					3	100
	Imipramine	1	50.0			1	50.0					2	100	2	100									2	100
TACHYCARDIA	Reboxetine	1	100									1	100	1	50.0							1	50.0	2	100
	Imipramine	1	100									1	100	2	66.7							1	33.3	3	100
DYSPNOEA	Reboxetine													4	80.0			1	20.0					5	100
	Imipramine													2	100									2	100

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug												Unchanged study drug or Missing											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
RHINITIS	Placebo													3	75.0							1	25.0	4	100
	Reboxetine													1	100									1	100
	Imipramine																	2	100					2	100
URINARY TRACT INFECTION	Placebo																	1	100					1	100
	Reboxetine					1	100					1	100	2	66.7			1	33.3					3	100
PALPITATION	Placebo													1	100									1	100
	Reboxetine													1	100									1	100
	Imipramine													1	50.0			1	50.0					2	100
ERYTHEMA / RASH	Placebo	1	100									1	100	1	100									1	100
	Reboxetine																	1	100					1	100
	Imipramine																	1	100					1	100
INFLUENZA-LIKE SYMPTOMS	Placebo																					1	100	1	100
	Reboxetine																					1	100	1	100
	Imipramine																					1	100	1	100
CARDIAC ISCHEMIA AND RELATED SYMPTOMS	Placebo													1	100									1	100
	Imipramine	1	100									1	100	1	100									1	100
CONFUSION	Reboxetine	1	100									1	100												
	Imipramine													1	50.0							1	50.0	2	100
HYPERKINESIA	Placebo					1	100					1	100					1	100					1	100
	Imipramine																	1	100					1	100

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug												Unchanged study drug or Missing									
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
MUSCLE CONTRACTIONS INVOLUNTARY	Reboxetine					1	100					1	100												
	Imipramine													1	50.0			1	50.0					2	100
APPETITE INCREASED	Placebo													1	100									1	100
	Imipramine																	2	100					2	100
DIARRHOEA	Placebo	1	100									1	100	1	50.0			1	50.0					2	100
WEIGHT INCREASE	Reboxetine																	1	100					1	100
	Imipramine																	2	100					2	100
MYALGIA	Placebo													1	50.0			1	50.0					2	100
	Imipramine													1	100									1	100
SINUSITIS	Placebo													1	100									1	100
	Reboxetine													2	100									2	100
DYSURIA	Reboxetine													2	100									2	100
	Imipramine													1	100									1	100
CHEST PAIN	Reboxetine					1	100					1	100												
	Imipramine													1	100									1	100
HYPERTENSION	Reboxetine																	1	100					1	100
	Imipramine													1	100									1	100
FLATULENCE	Placebo																	1	100					1	100
	Reboxetine																	1	100					1	100
TINNITUS	Imipramine					1	100					1	100	1	100									1	100

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug												Unchanged study drug or Missing									
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
INCREASED LIVER ENZYMES	Reboxetine																	1	100					1	100
	Imipramine																	1	100					1	100
WEIGHT DECREASE	Placebo													1	100									1	100
	Reboxetine													1	100									1	100
ARTHRALGIA	Placebo																	1	100					1	100
	Reboxetine													1	100									1	100
BACK PAIN	Placebo													1	50.0			1	50.0					2	100
CONJUNCTIVITIS	Imipramine													2	100									2	100
MYDRIASIS	Reboxetine													1	50.0			1	50.0					2	100
SALIVA INCREASED	Reboxetine													1	100									1	100
HYPERPYREXIA	Reboxetine													1	100									1	100
MALAISE	Placebo													1	100									1	100
RIGORS	Imipramine																	1	100					1	100
BRADYCARDIA	Placebo	1	100									1	100												
EXTRASYSTOLES	Imipramine																	1	100					1	100
HAEMORRHOIDS THROMBOSED	Reboxetine					1	100					1	100												
HYPERTONIA	Placebo													1	100									1	100
SPEECH DISORDER	Imipramine																	1	100					1	100
ANOREXIA	Reboxetine													1	100									1	100
COLITIS	Imipramine					1	100					1	100												

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug												Unchanged study drug or Missing											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
DUODENAL ULCER REACTIVATED	Imipramine																	1	100					1	100
DYSPHAGIA	Imipramine					1	100					1	100												
GASTROENTERITIS	Reboxetine													1	100									1	100
TONGUE ULCERATION	Placebo													1	100									1	100
TOOTH DISORDER	Reboxetine																					1	100	1	100
ANEMIA	Imipramine																	1	100					1	100
EOSINOPHILIA	Imipramine																	1	100					1	100
HYPERTRIGLYCERID-AEMIA	Imipramine																	1	100					1	100
HYPERURICAEMIA	Reboxetine													1	100									1	100
HYPOKALAEMIA	Imipramine													1	100									1	100
PHOSPHATASE ALKALINE INCREASED	Imipramine																	1	100					1	100
AUTOLESIONIST BEHAVIOUR	Imipramine	1	100									1	100												
CONCENTRATION IMPAIRED	Imipramine																	1	100					1	100
DEPERSONALIZATION	Imipramine																	1	100					1	100
DEPRESSION AGGRAVATED	Placebo					1	100					1	100												
LIBIDO DECREASED	Reboxetine																					1	100	1	100
PARONIRIA	Placebo																	1	100					1	100

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug												Unchanged study drug or Missing											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
SLEEP DISORDER	Imipramine																	1	100					1	100
EPIDIDYMITIS	Reboxetine													1	100									1	100
IMPOTENCE	Reboxetine	1	100									1	100												
PERINEAL PAIN MALE	Reboxetine													1	100									1	100
HERPES SIMPLEX	Placebo													1	100									1	100
BRONCHITIS	Placebo													1	100									1	100
PHARYNGITIS	Placebo													1	100									1	100
COLD URTICARIA	Imipramine																	1	100					1	100
RHAGADES	Imipramine													1	100									1	100
TASTE LOSS	Imipramine													1	100									1	100
TASTE PERVERSION	Placebo																	1	100					1	100
MICTURITION FREQUENCY	Placebo																	1	100					1	100
PYURIA	Reboxetine																	1	100					1	100
CHROMATOPSIA	Placebo													1	100									1	100
EYE ABNORMALITY	Reboxetine													1	100									1	100

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		All adverse events											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
All adverse events	Placebo	89	63.1	1	0.7	47	33.3			4	2.8	141	100.0
	Reboxetine	111	52.6			87	41.2			13	6.2	211	100.0
	Imipramine	131	45.5			140	48.6	1	0.3	16	5.6	288	100.0
MOUTH DRY	Placebo	10	66.7			4	26.7			1	6.7	15	100.0
	Reboxetine	8	27.6			20	69.0			1	3.4	29	100.0
	Imipramine	17	32.1			34	64.2			2	3.8	53	100.0
NAUSEA AND RELATED SYMPTOMS	Placebo	15	93.8			1	6.3					16	100.0
	Reboxetine	9	81.8			2	18.2					11	100.0
	Imipramine	14	63.6			7	31.8			1	4.5	22	100.0
SWEATING INCREASED	Placebo	1	33.3			2	66.7					3	100.0
	Reboxetine	8	53.3			4	26.7			3	20.0	15	100.0
	Imipramine	16	61.5			9	34.6			1	3.8	26	100.0
CONSTIPATION	Placebo	2	33.3			4	66.7					6	100.0
	Reboxetine	7	35.0			13	65.0					20	100.0
	Imipramine	5	27.8			12	66.7			1	5.6	18	100.0
HYPOTENSION AND RELATED SYMPTOMS	Placebo	5	83.3			1	16.7					6	100.0
	Reboxetine	6	50.0			4	33.3			2	16.7	12	100.0
	Imipramine	15	60.0			9	36.0			1	4.0	25	100.0
HEADACHE / MIGRAINE	Placebo	8	80.0			2	20.0					10	100.0
	Reboxetine	15	78.9			4	21.1					19	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		All adverse events											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
HEADACHE / MIGRAINE	Imipramine	3	33.3			6	66.7					9	100.0
TREMOR	Placebo	4	80.0			1	20.0					5	100.0
	Reboxetine	5	83.3			1	16.7					6	100.0
	Imipramine	9	45.0			10	50.0			1	5.0	20	100.0
AGITATION / ANXIETY / NERVOUSNESS	Placebo	7	63.6			4	36.4					11	100.0
	Reboxetine	5	38.5			8	61.5					13	100.0
	Imipramine	3	60.0			2	40.0					5	100.0
INSOMNIA	Placebo	1	25.0			2	50.0			1	25.0	4	100.0
	Reboxetine	4	33.3			6	50.0			2	16.7	12	100.0
	Imipramine					6	75.0			2	25.0	8	100.0
BLURRED VISION	Placebo					3	100.0					3	100.0
	Reboxetine	4	57.1			2	28.6			1	14.3	7	100.0
	Imipramine	6	54.5			4	36.4			1	9.1	11	100.0
SOMNOLENCE	Placebo	4	40.0			6	60.0					10	100.0
	Reboxetine					1	100.0					1	100.0
	Imipramine	4	66.7			1	16.7			1	16.7	6	100.0
ASTHENIA / FATIGUE	Placebo	2	50.0			2	50.0					4	100.0
	Reboxetine	2	50.0			2	50.0					4	100.0
	Imipramine	1	14.3			6	85.7					7	100.0
VERTIGO	Reboxetine	3	60.0			2	40.0					5	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		All adverse events											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
VERTIGO	Imipramine	7	87.5			1	12.5					8	100.0
PARAESTHESIA	Placebo	2	100.0									2	100.0
	Reboxetine	1	50.0			1	50.0					2	100.0
	Imipramine	3	50.0			2	33.3			1	16.7	6	100.0
ABDOMINAL PAIN	Placebo	2	66.7			1	33.3					3	100.0
	Reboxetine	1	100.0									1	100.0
	Imipramine	3	60.0			2	40.0					5	100.0
SUICIDE ATTEMPT	Placebo	2	50.0	1	25.0	1	25.0					4	100.0
	Reboxetine					1	100.0					1	100.0
	Imipramine	1	25.0			1	25.0	1	25.0	1	25.0	4	100.0
URINARY HESITANCY / RETENTION	Placebo	1	50.0			1	50.0					2	100.0
	Reboxetine	4	66.7			2	33.3					6	100.0
	Imipramine					1	100.0					1	100.0
FLUSHING / HOT FLUSHES	Placebo	1	100.0									1	100.0
	Reboxetine	2	66.7			1	33.3					3	100.0
	Imipramine	3	75.0			1	25.0					4	100.0
TACHYCARDIA	Reboxetine	2	66.7							1	33.3	3	100.0
	Imipramine	3	75.0							1	25.0	4	100.0
DYSPNOEA	Reboxetine	4	80.0			1	20.0					5	100.0
	Imipramine	2	100.0									2	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		All adverse events											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
RHINITIS	Placebo	3	75.0							1	25.0	4	100.0
	Reboxetine	1	100.0									1	100.0
	Imipramine					2	100.0					2	100.0
URINARY TRACT INFECTION	Placebo					1	100.0					1	100.0
	Reboxetine	2	50.0			2	50.0					4	100.0
PALPITATION	Placebo	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
	Imipramine	1	50.0			1	50.0					2	100.0
ERYTHEMA / RASH	Placebo	2	100.0									2	100.0
	Reboxetine					1	100.0					1	100.0
	Imipramine					1	100.0					1	100.0
INFLUENZA-LIKE SYMPTOMS	Placebo									1	100.0	1	100.0
	Reboxetine									1	100.0	1	100.0
	Imipramine									1	100.0	1	100.0
CARDIAC ISCHEMIA AND RELATED SYMPTOMS	Placebo	1	100.0									1	100.0
	Imipramine	2	100.0									2	100.0
CONFUSION	Reboxetine	1	100.0									1	100.0
	Imipramine	1	50.0							1	50.0	2	100.0
HYPERKINESIA	Placebo					2	100.0					2	100.0
	Imipramine					1	100.0					1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		All adverse events											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
MUSCLE CONTRACTIONS INVOLUNTARY	Reboxetine					1	100.0					1	100.0
	Imipramine	1	50.0			1	50.0					2	100.0
APPETITE INCREASED	Placebo	1	100.0									1	100.0
	Imipramine					2	100.0					2	100.0
DIARRHOEA	Placebo	2	66.7			1	33.3					3	100.0
WEIGHT INCREASE	Reboxetine					1	100.0					1	100.0
	Imipramine					2	100.0					2	100.0
MYALGIA	Placebo	1	50.0			1	50.0					2	100.0
	Imipramine	1	100.0									1	100.0
SINUSITIS	Placebo	1	100.0									1	100.0
	Reboxetine	2	100.0									2	100.0
DYSURIA	Reboxetine	2	100.0									2	100.0
	Imipramine	1	100.0									1	100.0
CHEST PAIN	Reboxetine					1	100.0					1	100.0
	Imipramine	1	100.0									1	100.0
HYPERTENSION	Reboxetine					1	100.0					1	100.0
	Imipramine	1	100.0									1	100.0
FLATULENCE	Placebo					1	100.0					1	100.0
	Reboxetine					1	100.0					1	100.0
TINNITUS	Imipramine	1	50.0			1	50.0					2	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		All adverse events											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
INCREASED LIVER ENZYMES	Reboxetine					1	100.0					1	100.0
	Imipramine					1	100.0					1	100.0
WEIGHT DECREASE	Placebo	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
ARTHRALGIA	Placebo					1	100.0					1	100.0
	Reboxetine	1	100.0									1	100.0
BACK PAIN	Placebo	1	50.0			1	50.0					2	100.0
CONJUNCTIVITIS	Imipramine	2	100.0									2	100.0
MYDRIASIS	Reboxetine	1	50.0			1	50.0					2	100.0
SALIVA INCREASED	Reboxetine	1	100.0									1	100.0
HYPERPYREXIA	Reboxetine	1	100.0									1	100.0
MALAISE	Placebo	1	100.0									1	100.0
RIGORS	Imipramine					1	100.0					1	100.0
BRADYCARDIA	Placebo	1	100.0									1	100.0
EXTRASYSTOLES	Imipramine					1	100.0					1	100.0
HAEMORRHOIDS THROMBOSED	Reboxetine					1	100.0					1	100.0
HYPERTONIA	Placebo	1	100.0									1	100.0
SPEECH DISORDER	Imipramine					1	100.0					1	100.0
ANOREXIA	Reboxetine	1	100.0									1	100.0
COLITIS	Imipramine					1	100.0					1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		All adverse events											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
DUODENAL ULCER REACTIVATED	Imipramine					1	100.0					1	100.0
DYSPHAGIA	Imipramine					1	100.0					1	100.0
GASTROENTERITIS	Reboxetine	1	100.0									1	100.0
TONGUE ULCERATION	Placebo	1	100.0									1	100.0
TOOTH DISORDER	Reboxetine									1	100.0	1	100.0
ANEMIA	Imipramine					1	100.0					1	100.0
EOSINOPHILIA	Imipramine					1	100.0					1	100.0
HYPERTRIGLYCERIDAEMIA	Imipramine					1	100.0					1	100.0
HYPERURICAEMIA	Reboxetine	1	100.0									1	100.0
HYPOKALAEMIA	Imipramine	1	100.0									1	100.0
PHOSPHATASE ALKALINE INCREASED	Imipramine					1	100.0					1	100.0
AUTOLESIONIST BEHAVIOUR	Imipramine	1	100.0									1	100.0
CONCENTRATION IMPAIRED	Imipramine					1	100.0					1	100.0
DEPERSONALIZATION	Imipramine					1	100.0					1	100.0
DEPRESSION AGGRAVATED	Placebo					1	100.0					1	100.0
LIBIDO DECREASED	Reboxetine									1	100.0	1	100.0
PARONIRIA	Placebo					1	100.0					1	100.0
SLEEP DISORDER	Imipramine					1	100.0					1	100.0
EPIDIDYMITIS	Reboxetine	1	100.0									1	100.0
IMPOTENCE	Reboxetine	1	100.0									1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 59

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		All adverse events											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
PERINEAL PAIN MALE	Reboxetine	1	100.0									1	100.0
HERPES SIMPLEX	Placebo	1	100.0									1	100.0
BRONCHITIS	Placebo	1	100.0									1	100.0
PHARYNGITIS	Placebo	1	100.0									1	100.0
COLD URTICARIA	Imipramine					1	100.0					1	100.0
RHAGADES	Imipramine	1	100.0									1	100.0
TASTE LOSS	Imipramine	1	100.0									1	100.0
TASTE PERVERSION	Placebo					1	100.0					1	100.0
MICTURITION FREQUENCY	Placebo					1	100.0					1	100.0
PYURIA	Reboxetine					1	100.0					1	100.0
CHROMATOPSIA	Placebo	1	100.0									1	100.0
EYE ABNORMALITY	Reboxetine	1	100.0									1	100.0

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 60

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																						
Pt exposed	Imipramine	115	100	2.33	107	100	2.70	96	100	2.73	89	100	2.45	85	100	2.46	81	100	2.46	17	100	2.42
	Placebo	112	100	1.62	107	100	1.68	102	100	1.67	97	100	1.75	89	100	1.92	87	100	1.78	23	100	1.81
	Reboxetine	112	100	2.10	106	100	2.24	102	100	2.22	98	100	2.19	93	100	1.97	90	100	1.84	14	100	1.47
MOUTH DRY	Imipramine	33	28.7	1.00	37	34.6	1.00	33	34.4	1.00	32	36.0	1.00	27	31.8	1.00	26	32.1	1.00	14	82.4	1.00
	Placebo	8	7.1	1.00	7	6.5	1.00	9	8.8	1.00	10	10.3	1.00	8	9.0	1.00	5	5.7	1.00	3	13.0	1.00
	Reboxetine	17	15.2	1.00	22	20.8	1.04	22	21.6	1.04	19	19.4	1.05	16	17.2	1.00	14	15.6	1.00	8	57.1	1.00
CONSTIPATION	Imipramine	5	4.3	1.00	12	11.2	1.00	14	14.6	1.00	12	13.5	1.00	12	14.1	1.00	12	14.8	1.00	9	52.9	1.00
	Placebo	1	0.9	1.00	4	3.7	1.00	3	2.9	1.00	3	3.1	1.00	4	4.5	1.00	4	4.6	1.00	2	8.7	1.00
	Reboxetine	7	6.3	1.00	14	13.2	1.00	13	12.7	1.00	12	12.2	1.00	10	10.8	1.00	9	10.0	1.00	4	28.6	1.00
SWEATING INCREASED	Imipramine	15	13.0	1.00	17	15.9	1.00	9	9.4	1.00	11	12.4	1.00	9	10.6	1.00	9	11.1	1.00	4	23.5	1.25
	Placebo	2	1.8	1.00	2	1.9	1.00	2	2.0	1.00	2	2.1	1.00	2	2.2	1.00	2	2.3	1.00	2	8.7	1.00
	Reboxetine	7	6.3	1.00	11	10.4	1.00	9	8.8	1.11	9	9.2	1.00	5	5.4	1.00	4	4.4	1.00	1	7.1	1.00
TREMOR	Imipramine	6	5.2	1.00	12	11.2	1.00	16	16.7	1.00	13	14.6	1.00	11	12.9	1.00	8	9.9	1.00	4	23.5	1.00
	Placebo	4	3.6	1.00	3	2.8	1.00							1	1.1	1.00						
	Reboxetine	4	3.6	1.00	3	2.8	1.00	3	2.9	1.00	1	1.0	1.00	1	1.1	1.00						
HEADACHE	Imipramine	4	3.5	1.00	5	4.7	1.00	3	3.1	1.00	4	4.5	1.00	2	2.4	1.00	2	2.5	1.00	1	5.9	1.00
	Placebo	3	2.7	1.00	4	3.7	1.00	5	4.9	1.00	4	4.1	1.00	4	4.5	1.00	3	3.4	1.00	1	4.3	1.00
	Reboxetine	10	8.9	1.00	8	7.5	1.12	5	4.9	1.00	6	6.1	1.00	4	4.3	1.00	3	3.3	1.00	2	14.3	1.00
NAUSEA	Imipramine	6	5.2	1.00	8	7.5	1.00	7	7.3	1.00	5	5.6	1.00	1	1.2	1.00	3	3.7	1.00	2	11.8	1.00
	Placebo	3	2.7	1.00	4	3.7	1.00	3	2.9	1.00	4	4.1	1.00	3	3.4	1.00	1	1.1	1.00			

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 60

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																						
NAUSEA	Reboxetine	6	5.4	1.00	3	2.8	1.00	5	4.9	1.00	4	4.1	1.00	3	3.2	1.00	2	2.2	1.00	1	7.1	1.00
INSOMNIA	Imipramine	4	3.5	1.00	5	4.7	1.00	4	4.2	1.00	3	3.4	1.00	4	4.7	1.00	3	3.7	1.00	2	11.8	1.00
	Placebo	2	1.8	1.00	2	1.9	1.00	1	1.0	1.00	2	2.1	1.00	2	2.2	1.00	2	2.3	1.00	1	4.3	1.00
	Reboxetine	6	5.4	1.00	5	4.7	1.00	6	5.9	1.00	4	4.1	1.00	4	4.3	1.00	5	5.6	1.00	1	7.1	1.00
VISION ABNORMAL	Imipramine	3	2.6	1.00	6	5.6	1.00	5	5.2	1.00	5	5.6	1.00	6	7.1	1.00	5	6.2	1.00	4	23.5	1.00
	Placebo				3	2.8	1.00	3	2.9	1.00	3	3.1	1.00	3	3.4	1.00	3	3.4	1.00	2	8.7	1.00
	Reboxetine	3	2.7	1.00	3	2.8	1.00	3	2.9	1.00	3	3.1	1.00	3	3.2	1.00	1	1.1	1.00			
DIZZINESS	Imipramine	6	5.2	1.00	9	8.4	1.00	7	7.3	1.00	6	6.7	1.00	3	3.5	1.00	3	3.7	1.00	2	11.8	1.00
	Placebo	1	0.9	1.00	1	0.9	1.00	3	2.9	1.00	2	2.1	1.00	1	1.1	1.00						
	Reboxetine	2	1.8	1.00	3	2.8	1.00	2	2.0	1.00	2	2.0	1.50	3	3.2	1.33	1	1.1	1.00			
SOMNOLENCE	Imipramine	6	5.2	1.00	5	4.7	1.00	4	4.2	1.00	4	4.5	1.00	3	3.5	1.00	2	2.5	1.00	1	5.9	1.00
	Placebo	3	2.7	1.00	4	3.7	1.00	2	2.0	1.00	5	5.2	1.00	5	5.6	1.00	4	4.6	1.00	3	13.0	1.00
	Reboxetine							1	1.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00
AGITATION	Imipramine	3	2.6	1.00	3	2.8	1.00	3	3.1	1.00	2	2.2	1.00	1	1.2	1.00	1	1.2	1.00			
	Placebo	4	3.6	1.00	5	4.7	1.00	2	2.0	1.00	2	2.1	1.00	1	1.1	1.00						
	Reboxetine	2	1.8	1.00	4	3.8	1.00	5	4.9	1.00	3	3.1	1.00	1	1.1	1.00	2	2.2	1.00	1	7.1	1.00
FATIGUE	Imipramine							1	1.0	1.00	2	2.2	1.00	4	4.7	1.00	4	4.9	1.00	3	17.6	1.00
	Placebo				3	2.8	1.00	4	3.9	1.00	2	2.1	1.00	2	2.2	1.00	1	1.1	1.00	1	4.3	1.00
	Reboxetine	1	0.9	1.00	1	0.9	1.00	2	2.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00
VERTIGO	Imipramine	5	4.3	1.00	2	1.9	1.00	2	2.1	1.00	3	3.4	1.00	1	1.2	1.00	1	1.2	1.00			

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 60

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																						
VERTIGO	Reboxetine	3	2.7	1.00	4	3.8	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00
ABDOMINAL PAIN	Imipramine	2	1.7	1.00	3	2.8	1.00	4	4.2	1.00	1	1.1	1.00	1	1.2	1.00	1	1.2	1.00			
	Placebo	1	0.9	1.00	3	2.8	1.00	2	2.0	1.00	1	1.0	1.00									
	Reboxetine							1	1.0	1.00	1	1.0	1.00	1	1.1	1.00						
MICTURITION DISORDER	Imipramine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
	Placebo	1	0.9	1.00	1	0.9	1.00															
	Reboxetine	1	0.9	1.00	1	0.9	1.00	2	2.0	1.00	3	3.1	1.00	3	3.2	1.00	3	3.3	1.00			
HOT FLUSHES	Imipramine	1	0.9	1.00	2	1.9	1.00	3	3.1	1.00	2	2.2	1.00	1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
	Placebo													1	1.1	1.00	1	1.1	1.00			
	Reboxetine				1	0.9	1.00	2	2.0	1.00	2	2.0	1.00	1	1.1	1.00	1	1.1	1.00			
PARAESTHESIA	Imipramine	4	3.5	1.00	4	3.7	1.00	2	2.1	1.00	2	2.2	1.00	2	2.4	1.00	1	1.2	1.00			
	Placebo	1	0.9	1.00				1	1.0	1.00												
	Reboxetine	2	1.8	1.00																		
RHINITIS	Imipramine	1	0.9	1.00	1	0.9	1.00	2	2.1	1.00	2	2.2	1.00	2	2.4	1.00	1	1.2	1.00			
	Placebo	1	0.9	1.00	1	0.9	1.00	2	2.0	1.00	1	1.0	1.00	1	1.1	1.00						
	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00												
HYPOTENSION POSTURAL	Imipramine	4	3.5	1.00	3	2.8	1.00				1	1.1	1.00	1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	2	2.0	1.00	1	1.1	1.00						
WEIGHT INCREASE	Imipramine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	2	2.2	1.00	2	2.4	1.00	2	2.5	1.00	1	5.9	1.00
	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 60

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																						
APPETITE INCREASED	Imipramine	2	1.7	1.00	2	1.9	1.00	2	2.1	1.00	2	2.2	1.00	2	2.4	1.00	2	2.5	1.00	2	11.8	1.00
	Placebo	1	0.9	1.00	1	0.9	1.00															
DYSPEPSIA	Imipramine	1	0.9	1.00	1	0.9	1.00	3	3.1	1.00	2	2.2	1.00	2	2.4	1.00	3	3.7	1.00	2	11.8	1.00
	Placebo	1	0.9	1.00	1	0.9	1.00															
URINARY RETENTION	Placebo	1	0.9	1.00																		
	Reboxetine	3	2.7	1.00	3	2.8	1.00	2	2.0	1.00	2	2.0	1.00	2	2.2	1.00	1	1.1	1.00			
NERVOUSNESS	Placebo				1	0.9	1.00	1	1.0	1.00												
	Reboxetine	2	1.8	1.00	4	3.8	1.00	2	2.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00
ASTHENIA	Imipramine	2	1.7	1.00	2	1.9	1.00	2	2.1	1.00	2	2.2	1.00	2	2.4	1.00	1	1.2	1.00	1	5.9	1.00
	Reboxetine	1	0.9	1.00																		
TACHYCARDIA	Imipramine	2	1.7	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.2	1.00						
	Reboxetine	2	1.8	1.00	1	0.9	1.00	2	2.0	1.00	1	1.0	1.00									
URINARY TRACT INFECTION	Placebo																1	1.1	1.00	1	4.3	1.00
	Reboxetine							3	2.9	1.00	3	3.1	1.00	2	2.2	1.00	1	1.1	1.00	1	7.1	1.00
PALPITATION	Imipramine	1	0.9	1.00	1	0.9	1.00	2	2.1	1.00	2	2.2	1.00	1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
	Placebo							1	1.0	1.00												
	Reboxetine	1	0.9	1.00																		
SUICIDE ATTEMPT	Imipramine	2	1.7	1.00										1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
	Placebo							1	1.0	1.00	2	2.1	1.00	2	2.2	1.00						
	Reboxetine	1	0.9	1.00																		

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 60

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																						
HYPOTENSION	Imipramine				1	0.9	1.00																
	Placebo	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00						
	Reboxetine	1	0.9	1.00	1	0.9	1.00				1	1.0	1.00	1	1.1	1.00						
DYSPNOEA	Imipramine	2	1.7	1.00	1	0.9	1.00																
	Reboxetine										2	2.0	1.00	2	2.2	1.00	2	2.2	1.00			
FLATULENCE	Placebo				1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	4.3	1.00
	Reboxetine				1	0.9	1.00	1	1.0	1.00	1	1.0	1.00									
HYPERKINESIA	Imipramine	1	0.9	1.00	1	0.9	1.00															
	Placebo	1	0.9	1.00	2	1.9	1.00	1	1.0	1.00	1	1.0	1.00									
HYPERTENSION	Imipramine	1	0.9	1.00																		
	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00			
VOMITING	Imipramine	1	0.9	1.00																		
	Placebo	2	1.8	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00									
	Reboxetine	1	0.9	1.00																		
SLEEP DISORDER	Imipramine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
WEIGHT DECREASE	Placebo							1	1.0	1.00	1	1.0	1.00	1	1.1	1.00						
	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00									
SINUSITIS	Placebo				1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00						
	Reboxetine				1	0.9	1.00	1	1.0	1.00	1	1.0	1.00									

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 60

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																					
MUSCLE CONTRACTIONS INVOLUNTARY	Imipramine							1	1.0	1.00	2	2.2	1.00	1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
	Reboxetine							1	1.0	1.00												
RASH	Imipramine													1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
	Placebo																2	2.3	1.00	2	8.7	1.00
ANXIETY	Imipramine										1	1.1	1.00									
	Placebo	3	2.7	1.00	1	0.9	1.00															
	Reboxetine	1	0.9	1.00																		
PERINEAL PAIN MALE	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00			
MYALGIA	Imipramine	1	0.9	1.00	1	0.9	1.00															
	Placebo	2	1.8	1.00	1	0.9	1.00															
CONFUSION	Imipramine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00									
	Reboxetine	1	0.9	1.00																		
CONJUNCTIVITIS	Imipramine	1	0.9	1.00	2	1.9	1.00	1	1.0	1.00	1	1.1	1.00									
CHEST PAIN PRECORDIAL	Imipramine	1	0.9	1.00	2	1.9	1.00	1	1.0	1.00												
	Placebo				1	0.9	1.00															
DIARRHOEA	Placebo	3	2.7	1.00	2	1.9	1.00															
IMPOTENCE	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00						
EPIDIDYMITIS	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00						
BACK PAIN	Placebo							1	1.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	4.3	1.00

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 60

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																						
TINNITUS	Imipramine	1	0.9	1.00	2	1.9	1.00	1	1.0	1.00													
TASTE LOSS	Imipramine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00										
DYSURIA	Imipramine	1	0.9	1.00																			
	Reboxetine	2	1.8	1.00	1	0.9	1.00																
ARTHRALGIA	Placebo	1	0.9	1.00	1	0.9	1.00																
	Reboxetine													1	1.1	1.00	1	1.1	1.00				
ANOREXIA	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00										
MYDRIASIS	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00										
RHAGADES	Imipramine							1	1.0	1.00	1	1.1	1.00	1	1.2	1.00	1	1.2	1.00				
CONCENTRATION IMPAIRED	Imipramine										1	1.1	1.00	1	1.2	1.00	1	1.2	1.00	1	5.9	1.00	
INFLUENZA-LIKE SYMPTOMS	Imipramine										1	1.1	1.00	1	1.2	1.00							
	Placebo										1	1.0	1.00										
	Reboxetine													1	1.1	1.00							
HYPERURICAEMIA	Reboxetine										1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00	
DYSPHAGIA	Imipramine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00													
SALIVA INCREASED	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00													
DUODENAL ULCER REACTIVATED	Imipramine				1	0.9	1.00	1	1.0	1.00	1	1.1	1.00										

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 60

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																				
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																					
GAMMA-GT INCREASED	Imipramine																1	1.2	1.00			
	Reboxetine							1	1.0	1.00	1	1.0	1.00									
SPEECH DISORDER	Imipramine										1	1.1	1.00	1	1.2	1.00	1	1.2	1.00			
HYPERTONIA	Placebo										1	1.0	1.00	1	1.1	1.00	1	1.1	1.00			
DEPERSONALIZ-ATION	Imipramine	1	0.9	1.00	1	0.9	1.00															
SYNCOPE	Imipramine	1	0.9	1.00	1	0.9	1.00															
CHEST PAIN	Imipramine	1	0.9	1.00																		
	Reboxetine	1	0.9	1.00																		
MICTURITION FREQUENCY	Placebo	1	0.9	1.00	1	0.9	1.00															
EYE ABNORMALITY	Reboxetine	1	0.9	1.00	1	0.9	1.00															
TOOTH DISORDER	Reboxetine	1	0.9	1.00	1	0.9	1.00															
COLD URTICARIA	Imipramine				1	0.9	1.00	1	1.0	1.00												
RIGORS	Imipramine				1	0.9	1.00	1	1.0	1.00												
PHARYNGITIS	Placebo				1	0.9	1.00	1	1.0	1.00												
FLUSHING	Reboxetine				1	0.9	1.00	1	1.0	1.00												
HAEMORRHOIDS THROMBOSED	Reboxetine				1	0.9	1.00	1	1.0	1.00												

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 60

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																						
TONGUE ULCERATION	Placebo							1	1.0	1.00	1	1.0	1.00										
LIBIDO DECREASED	Reboxetine							1	1.0	1.00	1	1.0	1.00										
TASTE PERVERSION	Placebo										1	1.0	1.00	1	1.1	1.00							
PARONIRIA	Placebo										1	1.0	1.00	1	1.1	1.00							
ACCOMMODATION ABNORMAL	Imipramine													1	1.2	1.00	1	1.2	1.00				
AUTOLESIONIST BEHAVIOUR	Imipramine	1	0.9	1.00																			
MIGRAINE	Reboxetine	1	0.9	1.00																			
HYPERPYREXIA	Reboxetine	1	0.9	1.00																			
COLITIS	Imipramine							1	1.0	1.00													
EXTRASYSTOLES	Imipramine							1	1.0	1.00													
BRADYCARDIA	Placebo							1	1.0	1.00													
CHROMATOPSIA	Placebo							1	1.0	1.00													
MALAISE	Placebo							1	1.0	1.00													
HYPOKALAEMIA	Imipramine										1	1.1	1.00										
DEPRESSION AGGRAVATED	Placebo										1	1.0	1.00										
GASTRITIS	Reboxetine										1	1.0	1.00										
PYURIA	Reboxetine										1	1.0	1.00										

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 60

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																						
GASTROENTERITIS	Reboxetine													1	1.1	1.00							
PHOSPHATASE ALKALINE INCREASED	Imipramine																1	1.2	1.00				
ANAEMIA HYPOCHROMIC	Imipramine																1	1.2	1.00				
EOSINOPHILIA	Imipramine																1	1.2	1.00				
BRONCHITIS	Placebo																1	1.1	1.00				
HERPES SIMPLEX	Placebo																1	1.1	1.00				
RASH ERYTHEMATOUS	Reboxetine																1	1.1	1.00				
HYPERTRIGLYCERIDAEMIA	Imipramine																			1	5.9	1.00	

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: AUTONOMIC NERVOUS SYSTEM DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
MOUTH DRY	Imipramine	33	28.7	1.00	37	34.6	1.00	33	34.4	1.00	32	36.0	1.00	27	31.8	1.00	26	32.1	1.00	14	82.4	1.00
	Placebo	8	7.1	1.00	7	6.5	1.00	9	8.8	1.00	10	10.3	1.00	8	9.0	1.00	5	5.7	1.00	3	13.0	1.00
	Reboxetine	17	15.2	1.00	22	20.8	1.04	22	21.6	1.04	19	19.4	1.05	16	17.2	1.00	14	15.6	1.00	8	57.1	1.00
SWEATING INCREASED	Imipramine	15	13.0	1.00	17	15.9	1.00	9	9.4	1.00	11	12.4	1.00	9	10.6	1.00	9	11.1	1.00	4	23.5	1.25
	Placebo	2	1.8	1.00	2	1.9	1.00	2	2.0	1.00	2	2.1	1.00	2	2.2	1.00	2	2.3	1.00	2	8.7	1.00
	Reboxetine	7	6.3	1.00	11	10.4	1.00	9	8.8	1.11	9	9.2	1.00	5	5.4	1.00	4	4.4	1.00	1	7.1	1.00
SALIVA INCREASED	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00												

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: BODY AS A WHOLE-GENERAL DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
ASTHENIA / FATIGUE	Imipramine	2	1.7	1.00	2	1.9	1.00	2	2.1	1.50	3	3.4	1.33	5	5.9	1.20	4	4.9	1.25	3	17.6	1.33
	Placebo				3	2.8	1.00	4	3.9	1.00	2	2.1	1.00	2	2.2	1.00	1	1.1	1.00	1	4.3	1.00
	Reboxetine	2	1.8	1.00	1	0.9	1.00	2	2.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00
INFLUENZA-LIKE SYMPTOMS	Imipramine										1	1.1	1.00	1	1.2	1.00						
	Placebo										1	1.0	1.00									
	Reboxetine													1	1.1	1.00						
CHEST PAIN	Imipramine	1	0.9	1.00																		
	Reboxetine	1	0.9	1.00																		
RIGORS	Imipramine				1	0.9	1.00	1	1.0	1.00												
HYPERPYREXIA	Reboxetine	1	0.9	1.00																		
MALAISE	Placebo							1	1.0	1.00												

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: CARDIOVASCULAR DISORDERS, GENERAL

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
HYPOTENSION AND RELATED SYMPTOMS	Imipramine	9	7.8	1.22	14	13.1	1.00	7	7.3	1.00	7	7.9	1.00	4	4.7	1.00	4	4.9	1.00	3	17.6	1.00
	Placebo	2	1.8	1.00	2	1.9	1.00	4	3.9	1.00	3	3.1	1.00	2	2.2	1.00						
	Reboxetine	4	3.6	1.00	5	4.7	1.00	3	2.9	1.00	5	5.1	1.20	5	5.4	1.20	1	1.1	1.00			
FLUSHING / HOT FLUSHES	Imipramine	1	0.9	1.00	2	1.9	1.00	3	3.1	1.00	2	2.2	1.00	1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
	Placebo													1	1.1	1.00	1	1.1	1.00			
	Reboxetine				2	1.9	1.00	3	2.9	1.00	2	2.0	1.00	1	1.1	1.00	1	1.1	1.00			
TACHYCARDIA	Imipramine	2	1.7	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.2	1.00						
	Reboxetine	2	1.8	1.00	1	0.9	1.00	2	2.0	1.00	1	1.0	1.00									
PALPITATION	Imipramine	1	0.9	1.00	1	0.9	1.00	2	2.1	1.00	2	2.2	1.00	1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
	Placebo							1	1.0	1.00												
	Reboxetine	1	0.9	1.00																		
HYPERTENSION	Imipramine	1	0.9	1.00																		
	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00			
CARDIAC ISCHEMIA AND RELATED SYMPTOMS	Imipramine	1	0.9	1.00	2	1.9	1.00	1	1.0	1.00												
	Placebo				1	0.9	1.00															
HAEMORRHOIDS THROMBOSED	Reboxetine				1	0.9	1.00	1	1.0	1.00												
EXTRASYSTOLES	Imipramine							1	1.0	1.00												
BRADYCARDIA	Placebo							1	1.0	1.00												

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
TREMOR	Imipramine	6	5.2	1.00	12	11.2	1.00	16	16.7	1.00	13	14.6	1.00	11	12.9	1.00	8	9.9	1.00	4	23.5	1.00
	Placebo	4	3.6	1.00	3	2.8	1.00							1	1.1	1.00						
	Reboxetine	4	3.6	1.00	3	2.8	1.00	3	2.9	1.00	1	1.0	1.00	1	1.1	1.00						
HEADACHE / MIGRAINE	Imipramine	4	3.5	1.00	5	4.7	1.00	3	3.1	1.00	4	4.5	1.00	2	2.4	1.00	2	2.5	1.00	1	5.9	1.00
	Placebo	3	2.7	1.00	4	3.7	1.00	5	4.9	1.00	4	4.1	1.00	4	4.5	1.00	3	3.4	1.00	1	4.3	1.00
	Reboxetine	11	9.8	1.00	8	7.5	1.12	5	4.9	1.00	6	6.1	1.00	4	4.3	1.00	3	3.3	1.00	2	14.3	1.00
VERTIGO	Imipramine	5	4.3	1.00	2	1.9	1.00	2	2.1	1.00	3	3.4	1.00	1	1.2	1.00	1	1.2	1.00			
	Reboxetine	3	2.7	1.00	4	3.8	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00
PARAESTHESIA	Imipramine	4	3.5	1.00	4	3.7	1.00	2	2.1	1.00	2	2.2	1.00	2	2.4	1.00	1	1.2	1.00			
	Placebo	1	0.9	1.00				1	1.0	1.00												
	Reboxetine	2	1.8	1.00																		
HYPERKINESIA	Imipramine	1	0.9	1.00	1	0.9	1.00															
	Placebo	1	0.9	1.00	2	1.9	1.00	1	1.0	1.00	1	1.0	1.00									
MUSCLE CONTRACTIONS INVOLUNTARY	Imipramine							1	1.0	1.00	2	2.2	1.00	1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
	Reboxetine							1	1.0	1.00												
CONFUSION	Imipramine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00									
	Reboxetine	1	0.9	1.00																		
SPEECH DISORDER	Imipramine										1	1.1	1.00	1	1.2	1.00	1	1.2	1.00			
HYPERTONIA	Placebo										1	1.0	1.00	1	1.1	1.00	1	1.1	1.00			

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: GASTRO-INTESTINAL SYSTEM DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
CONSTIPATION	Imipramine	5	4.3	1.00	12	11.2	1.00	14	14.6	1.00	12	13.5	1.00	12	14.1	1.00	12	14.8	1.00	9	52.9	1.00
	Placebo	1	0.9	1.00	4	3.7	1.00	3	2.9	1.00	3	3.1	1.00	4	4.5	1.00	4	4.6	1.00	2	8.7	1.00
	Reboxetine	7	6.3	1.00	14	13.2	1.00	13	12.7	1.00	12	12.2	1.00	10	10.8	1.00	9	10.0	1.00	4	28.6	1.00
NAUSEA AND RELATED SYMPTOMS	Imipramine	8	7.0	1.00	8	7.5	1.12	9	9.4	1.11	7	7.9	1.00	3	3.5	1.00	6	7.4	1.00	4	23.5	1.00
	Placebo	4	3.6	1.50	5	4.7	1.20	3	2.9	1.33	4	4.1	1.25	3	3.4	1.00	1	1.1	1.00			
	Reboxetine	6	5.4	1.16	3	2.8	1.00	5	4.9	1.00	5	5.1	1.00	3	3.2	1.00	2	2.2	1.00	1	7.1	1.00
ABDOMINAL PAIN	Imipramine	2	1.7	1.00	3	2.8	1.00	4	4.2	1.00	1	1.1	1.00	1	1.2	1.00	1	1.2	1.00			
	Placebo	1	0.9	1.00	3	2.8	1.00	2	2.0	1.00	1	1.0	1.00									
	Reboxetine							1	1.0	1.00	1	1.0	1.00	1	1.1	1.00						
APPETITE INCREASED	Imipramine	2	1.7	1.00	2	1.9	1.00	2	2.1	1.00	2	2.2	1.00	2	2.4	1.00	2	2.5	1.00	2	11.8	1.00
	Placebo	1	0.9	1.00	1	0.9	1.00															
FLATULENCE	Placebo				1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	4.3	1.00
	Reboxetine				1	0.9	1.00	1	1.0	1.00	1	1.0	1.00									
DIARRHOEA	Placebo	3	2.7	1.00	2	1.9	1.00															
ANOREXIA	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00									
DYSPHAGIA	Imipramine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00												
DUODENAL ULCER REACTIVATED	Imipramine				1	0.9	1.00	1	1.0	1.00	1	1.1	1.00									
TOOTH DISORDER	Reboxetine	1	0.9	1.00	1	0.9	1.00															

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: GASTRO-INTESTINAL SYSTEM DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
TONGUE ULCERATION	Placebo							1	1.0	1.00	1	1.0	1.00									
COLITIS	Imipramine							1	1.0	1.00												
GASTROENTERI-TIS	Reboxetine													1	1.1	1.00						

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: HEARING AND VESTIBULAR DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
TINNITUS	Imipramine	1	0.9	1.00	2	1.9	1.00	1	1.0	1.00												

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: HEMATOLOGY DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
ANEMIA	Imipramine																1	1.2	1.00			
EOSINOPHILIA	Imipramine																1	1.2	1.00			

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: LIVER AND BILIAR SYSTEM DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
INCREASED LIVER ENZYMES	Imipramine																1	1.2	1.00			
	Reboxetine							1	1.0	1.00	1	1.0	1.00									

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: METABOLIC AND NUTRITIONAL DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
WEIGHT INCREASE	Imipramine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	2	2.2	1.00	2	2.4	1.00	2	2.5	1.00	1	5.9	1.00
	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00
WEIGHT DECREASE	Placebo							1	1.0	1.00	1	1.0	1.00	1	1.1	1.00						
	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00									
HYPERURICAEMIA	Reboxetine										1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00
HYPOKALAEMIA	Imipramine										1	1.1	1.00									
PHOSPHATASE ALKALINE INCREASED	Imipramine																1	1.2	1.00			
HYPERTRIGLYCERIDAEMIA	Imipramine																			1	5.9	1.00

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: MUSCOLO-SKELETAL SYSTEM DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
MYALGIA	Imipramine	1	0.9	1.00	1	0.9	1.00															
	Placebo	2	1.8	1.00	1	0.9	1.00															
BACK PAIN	Placebo							1	1.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	4.3	1.00
ARTHRALGIA	Placebo	1	0.9	1.00	1	0.9	1.00															
	Reboxetine													1	1.1	1.00	1	1.1	1.00			

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: PSYCHIATRIC DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
INSOMNIA	Imipramine	4	3.5	1.00	5	4.7	1.00	4	4.2	1.00	3	3.4	1.00	4	4.7	1.00	3	3.7	1.00	2	11.8	1.00
	Placebo	2	1.8	1.00	2	1.9	1.00	1	1.0	1.00	2	2.1	1.00	2	2.2	1.00	2	2.3	1.00	1	4.3	1.00
	Reboxetine	6	5.4	1.00	5	4.7	1.00	6	5.9	1.00	4	4.1	1.00	4	4.3	1.00	5	5.6	1.00	1	7.1	1.00
AGITATION / ANXIETY / NERVOUSNESS	Imipramine	3	2.6	1.00	3	2.8	1.00	3	3.1	1.00	3	3.4	1.00	1	1.2	1.00	1	1.2	1.00			
	Placebo	7	6.3	1.00	7	6.5	1.00	3	2.9	1.00	2	2.1	1.00	1	1.1	1.00						
	Reboxetine	5	4.5	1.00	7	6.6	1.14	7	6.9	1.00	4	4.1	1.00	2	2.2	1.00	3	3.3	1.00	2	14.3	1.00
SOMNOLENCE	Imipramine	6	5.2	1.00	5	4.7	1.00	4	4.2	1.00	4	4.5	1.00	3	3.5	1.00	2	2.5	1.00	1	5.9	1.00
	Placebo	3	2.7	1.00	4	3.7	1.00	2	2.0	1.00	5	5.2	1.00	5	5.6	1.00	4	4.6	1.00	3	13.0	1.00
	Reboxetine							1	1.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00
SUICIDE ATTEMPT	Imipramine	2	1.7	1.00										1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
	Placebo							1	1.0	1.00	2	2.1	1.00	2	2.2	1.00						
	Reboxetine	1	0.9	1.00																		
SLEEP DISORDER	Imipramine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
CONCENTRATION IMPAIRED	Imipramine										1	1.1	1.00	1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
DEPERSONALIZ-ATION	Imipramine	1	0.9	1.00	1	0.9	1.00															
LIBIDO DECREASED	Reboxetine							1	1.0	1.00	1	1.0	1.00									
PARONIRIA	Placebo										1	1.0	1.00	1	1.1	1.00						
AUTOLESIONIST BEHAVIOUR	Imipramine	1	0.9	1.00																		

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: PSYCHIATRIC DISORDERS

Adverse events/Assigned treatment		Days of treatment																			
		0-7			8-14			15-21			22-28			29-35			36-42			> 42	
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp. (*)
DEPRESSION AGGRAVATED	Placebo										1	1.0	1.00								

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: REPRODUCTIVE DISORDERS, MALE

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
PERINEAL PAIN MALE	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00			
EPIDIDYMITIS	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00						
IMPOTENCE	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00						

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: RESISTANCE MECHANISM DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
HERPES SIMPLEX	Placebo																1	1.1	1.00			

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEN

Body system: RESPIRATORY SYSTEM DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
RHINITIS	Imipramine	1	0.9	1.00	1	0.9	1.00	2	2.1	1.00	2	2.2	1.00	2	2.4	1.00	1	1.2	1.00			
	Placebo	1	0.9	1.00	1	0.9	1.00	2	2.0	1.00	1	1.0	1.00	1	1.1	1.00						
	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00												
DYSPNOEA	Imipramine	2	1.7	1.00	1	0.9	1.00															
	Reboxetine										2	2.0	1.00	2	2.2	1.00	2	2.2	1.00			
SINUSITIS	Placebo				1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00						
	Reboxetine				1	0.9	1.00	1	1.0	1.00	1	1.0	1.00									
PHARYNGITIS	Placebo				1	0.9	1.00	1	1.0	1.00												
BRONCHITIS	Placebo																1	1.1	1.00			

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: SKIN AND APPENDAGES DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
ERYTHEMA / RASH	Imipramine													1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
	Placebo																2	2.3	1.00	2	8.7	1.00
	Reboxetine																1	1.1	1.00			
RHAGADES	Imipramine							1	1.0	1.00	1	1.1	1.00	1	1.2	1.00	1	1.2	1.00			
COLD URTICARIA	Imipramine				1	0.9	1.00	1	1.0	1.00												

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: SPECIAL SENSES OTHER, DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
TASTE LOSS	Imipramine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00									
TASTE PERVERSION	Placebo										1	1.0	1.00	1	1.1	1.00						

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: URINARY SYSTEM DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
URINARY HESITANCY / RETENTION	Imipramine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
	Placebo	2	1.8	1.00	1	0.9	1.00															
	Reboxetine	4	3.6	1.00	4	3.8	1.00	4	3.9	1.00	5	5.1	1.00	5	5.4	1.00	4	4.4	1.00			
URINARY TRACT INFECTION	Placebo																1	1.1	1.00	1	4.3	1.00
	Reboxetine							3	2.9	1.00	3	3.1	1.00	2	2.2	1.00	1	1.1	1.00	1	7.1	1.00
DYSURIA	Imipramine	1	0.9	1.00																		
	Reboxetine	2	1.8	1.00	1	0.9	1.00															
MICTURITION FREQUENCY	Placebo	1	0.9	1.00	1	0.9	1.00															
PYURIA	Reboxetine										1	1.0	1.00									

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 61

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: VISION DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
BLURRED VISION	Imipramine	3	2.6	1.00	6	5.6	1.00	5	5.2	1.00	5	5.6	1.00	7	8.2	1.00	6	7.4	1.00	4	23.5	1.00
	Placebo				3	2.8	1.00	3	2.9	1.00	3	3.1	1.00	3	3.4	1.00	3	3.4	1.00	2	8.7	1.00
	Reboxetine	3	2.7	1.00	3	2.8	1.00	3	2.9	1.00	3	3.1	1.00	3	3.2	1.00	1	1.1	1.00			
CONJUNCTIVITIS	Imipramine	1	0.9	1.00	2	1.9	1.00	1	1.0	1.00	1	1.1	1.00									
MYDRIASIS	Reboxetine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00									
EYE ABNORMALITY	Reboxetine	1	0.9	1.00	1	0.9	1.00															
CHROMATOPSIA	Placebo							1	1.0	1.00												

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 62

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)
Body system	Assigned treatment																						
Pt exposed	Imipramine	115	100	2.33	107	100	2.70	96	100	2.73	89	100	2.45	85	100	2.46	81	100	2.46	17	100	2.42
	Placebo	112	100	1.62	107	100	1.68	102	100	1.67	97	100	1.75	89	100	1.92	87	100	1.78	23	100	1.81
	Reboxetine	112	100	2.10	106	100	2.24	102	100	2.22	98	100	2.19	93	100	1.97	90	100	1.84	14	100	1.47
AUTONOMIC NERVOUS SYSTEM DISORDERS	Imipramine	38	33.0	1.26	44	41.1	1.22	37	38.5	1.13	37	41.6	1.16	31	36.5	1.16	29	35.8	1.20	16	94.1	1.18
	Placebo	10	8.9	1.00	9	8.4	1.00	11	10.8	1.00	12	12.4	1.00	10	11.2	1.00	7	8.0	1.00	5	21.7	1.00
	Reboxetine	24	21.4	1.04	33	31.1	1.06	31	30.4	1.09	27	27.6	1.07	20	21.5	1.05	17	18.9	1.05	9	64.3	1.00
GASTRO-INTESTINAL SYSTEM DISORDERS	Imipramine	17	14.8	1.05	24	22.4	1.16	26	27.1	1.26	20	22.5	1.15	18	21.2	1.00	19	23.5	1.10	14	82.4	1.07
	Placebo	8	7.1	1.50	12	11.2	1.41	7	6.9	1.57	8	8.2	1.37	6	6.7	1.33	5	5.7	1.20	2	8.7	1.50
	Reboxetine	14	12.5	1.14	19	17.9	1.05	18	17.6	1.16	18	18.4	1.11	14	15.1	1.07	11	12.2	1.00	5	35.7	1.00
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Imipramine	19	16.5	1.10	20	18.7	1.25	20	20.8	1.25	22	24.7	1.18	16	18.8	1.12	13	16.0	1.07	6	35.3	1.00
	Placebo	8	7.1	1.12	9	8.4	1.00	7	6.9	1.00	6	6.2	1.00	6	6.7	1.00	4	4.6	1.00	1	4.3	1.00
	Reboxetine	21	18.8	1.00	15	14.2	1.06	9	8.8	1.11	8	8.2	1.00	6	6.5	1.00	4	4.4	1.00	3	21.4	1.00
PSYCHIATRIC DISORDERS	Imipramine	16	13.9	1.12	14	13.1	1.07	12	12.5	1.00	12	13.5	1.00	11	12.9	1.00	9	11.1	1.00	6	35.3	1.00
	Placebo	11	9.8	1.09	12	11.2	1.08	7	6.9	1.00	11	11.3	1.18	9	10.1	1.22	6	6.9	1.00	4	17.4	1.00
	Reboxetine	10	8.9	1.20	10	9.4	1.30	12	11.8	1.25	10	10.2	1.00	7	7.5	1.00	9	10.0	1.00	4	28.6	1.00
CARDIOVASCULAR DISORDERS, GENERAL	Imipramine	14	12.2	1.21	18	16.8	1.11	14	14.6	1.07	11	12.4	1.09	7	8.2	1.00	6	7.4	1.00	5	29.4	1.00
	Placebo	2	1.8	1.00	3	2.8	1.00	6	5.9	1.00	3	3.1	1.00	3	3.4	1.00	1	1.1	1.00			
	Reboxetine	7	6.3	1.14	9	8.5	1.11	9	8.8	1.11	9	9.2	1.11	7	7.5	1.14	3	3.3	1.00			
VISION DISORDERS	Imipramine	4	3.5	1.00	8	7.5	1.00	6	6.3	1.00	6	6.7	1.00	7	8.2	1.00	6	7.4	1.00	4	23.5	1.00

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 62

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)
Body system	Assigned treatment																					
VISION DISORDERS	Placebo				3	2.8	1.00	4	3.9	1.00	3	3.1	1.00	3	3.4	1.00	3	3.4	1.00	2	8.7	1.00
	Reboxetine	5	4.5	1.00	5	4.7	1.00	4	3.9	1.00	4	4.1	1.00	3	3.2	1.00	1	1.1	1.00			
BODY AS A WHOLE-GENERAL DISORDERS	Imipramine	3	2.6	1.00	3	2.8	1.00	3	3.1	1.33	4	4.5	1.25	6	7.1	1.16	4	4.9	1.25	3	17.6	1.33
	Placebo				3	2.8	1.00	5	4.9	1.00	3	3.1	1.00	2	2.2	1.00	1	1.1	1.00	1	4.3	1.00
	Reboxetine	4	3.6	1.00	1	0.9	1.00	2	2.0	1.00	1	1.0	1.00	2	2.2	1.00	1	1.1	1.00	1	7.1	1.00
URINARY SYSTEM DISORDERS	Imipramine	2	1.7	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.2	1.00	1	1.2	1.00	1	5.9	1.00
	Placebo	3	2.7	1.00	2	1.9	1.00										1	1.1	1.00	1	4.3	1.00
	Reboxetine	6	5.4	1.00	5	4.7	1.00	7	6.9	1.00	9	9.2	1.00	7	7.5	1.00	5	5.6	1.00	1	7.1	1.00
RESPIRATORY SYSTEM DISORDERS	Imipramine	3	2.6	1.00	2	1.9	1.00	2	2.1	1.00	2	2.2	1.00	2	2.4	1.00	1	1.2	1.00			
	Placebo	1	0.9	1.00	3	2.8	1.00	4	3.9	1.00	2	2.1	1.00	2	2.2	1.00	1	1.1	1.00			
	Reboxetine	1	0.9	1.00	2	1.9	1.00	1	1.0	2.00	2	2.0	1.50	2	2.2	1.00	2	2.2	1.00			
METABOLIC AND NUTRITIONAL DISORDERS	Imipramine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	3	3.4	1.00	2	2.4	1.00	3	3.7	1.00	2	11.8	1.00
	Placebo							1	1.0	1.00	1	1.0	1.00	1	1.1	1.00						
	Reboxetine	1	0.9	2.00	1	0.9	2.00	1	1.0	2.00	2	2.0	1.50	2	2.2	1.00	2	2.2	1.00	2	14.3	1.00
REPRODUCTIVE DISORDERS, MALE	Reboxetine	2	1.8	1.50	2	1.9	1.50	2	2.0	1.50	2	2.0	1.50	2	2.2	1.50	1	1.1	1.00			
MUSCOLO-SKELETAL SYSTEM DISORDERS	Imipramine	1	0.9	1.00	1	0.9	1.00															
	Placebo	3	2.7	1.00	2	1.9	1.00	1	1.0	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	4.3	1.00
	Reboxetine													1	1.1	1.00	1	1.1	1.00			

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 62

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)
Body system	Assigned treatment																						
SKIN AND APPENDAGES DISORDERS	Imipramine				1	0.9	1.00	2	2.1	1.00	1	1.1	1.00	2	2.4	1.00	2	2.5	1.00	1	5.9	1.00
	Placebo																2	2.3	1.00	2	8.7	1.00
	Reboxetine																1	1.1	1.00			
SPECIAL SENSES OTHER, DISORDERS	Imipramine	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00									
	Placebo										1	1.0	1.00	1	1.1	1.00						
HEARING AND VESTIBULAR DISORDERS	Imipramine	1	0.9	1.00	2	1.9	1.00	1	1.0	1.00												
LIVER AND BILIAR SYSTEM DISORDERS	Imipramine																1	1.2	1.00			
	Reboxetine							1	1.0	1.00	1	1.0	1.00									
HEMATOLOGY DISORDERS	Imipramine																2	2.5	1.00			
RESISTANCE MECHANISM DISORDERS	Placebo																1	1.1	1.00			

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 63

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Relationship															
		Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Total adverse events	Placebo	6	4.3	22	15.6	52	36.9	26	18.4	17	12.1	15	10.6	3	2.1	141	100.0
	Reboxetine	5	2.4	24	11.4	103	48.8	41	19.4	23	10.9	8	3.8	7	3.3	211	100.0
	Imipramine	6	2.1	64	22.2	153	53.1	26	9.0	9	3.1	20	6.9	10	3.5	288	100.0
MOUTH DRY	Placebo	3	20.0	3	20.0	8	53.3	1	6.7							15	100.0
	Reboxetine	1	3.4	7	24.1	18	62.1	2	6.9			1	3.4			29	100.0
	Imipramine	1	1.9	18	34.0	31	58.5	1	1.9			1	1.9	1	1.9	53	100.0
NAUSEA AND RELATED SYMPTOMS	Placebo			4	25.0	8	50.0	4	25.0							16	100.0
	Reboxetine			1	9.1	7	63.6	1	9.1	2	18.2					11	100.0
	Imipramine			3	13.6	13	59.1	2	9.1			3	13.6	1	4.5	22	100.0
SWEATING INCREASED	Placebo	1	33.3	1	33.3			1	33.3							3	100.0
	Reboxetine			4	26.7	7	46.7	2	13.3			1	6.7	1	6.7	15	100.0
	Imipramine	1	3.8	9	34.6	11	42.3	2	7.7	2	7.7			1	3.8	26	100.0
CONSTIPATION	Placebo			3	50.0	2	33.3			1	16.7					6	100.0
	Reboxetine	1	5.0	3	15.0	8	40.0	8	40.0							20	100.0
	Imipramine			6	33.3	9	50.0	2	11.1					1	5.6	18	100.0
HYPOTENSION AND RELATED SYMPTOMS	Placebo					5	83.3					1	16.7			6	100.0
	Reboxetine			2	16.7	6	50.0	2	16.7			1	8.3	1	8.3	12	100.0
	Imipramine	3	12.0	4	16.0	16	64.0	1	4.0			1	4.0			25	100.0
HEADACHE / MIGRAINE	Placebo					2	20.0	6	60.0	2	20.0					10	100.0
	Reboxetine					7	36.8	8	42.1	3	15.8	1	5.3			19	100.0
	Imipramine					3	33.3	5	55.6	1	11.1					9	100.0
TREMOR	Placebo			1	20.0	1	20.0	1	20.0			2	40.0			5	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 63

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Relationship															
		Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
TREMOR	Reboxetine					5	83.3	1	16.7							6	100.0
	Imipramine			6	30.0	11	55.0	2	10.0			1	5.0			20	100.0
AGITATION / ANXIETY / NERVOUSNESS	Placebo			2	18.2	5	45.5	3	27.3			1	9.1			11	100.0
	Reboxetine					11	84.6	2	15.4							13	100.0
	Imipramine			1	20.0	2	40.0			1	20.0	1	20.0			5	100.0
INSOMNIA	Placebo					1	25.0	1	25.0			1	25.0	1	25.0	4	100.0
	Reboxetine					6	50.0	4	33.3			1	8.3	1	8.3	12	100.0
	Imipramine					6	75.0							2	25.0	8	100.0
BLURRED VISION	Placebo	1	33.3	2	66.7											3	100.0
	Reboxetine			1	14.3	3	42.9	1	14.3					2	28.6	7	100.0
	Imipramine			4	36.4	4	36.4	3	27.3							11	100.0
SOMNOLENCE	Placebo			4	40.0	5	50.0	1	10.0							10	100.0
	Reboxetine					1	100.0									1	100.0
	Imipramine			4	66.7	2	33.3									6	100.0
ASTHENIA / FATIGUE	Placebo					3	75.0	1	25.0							4	100.0
	Reboxetine			1	25.0	2	50.0	1	25.0							4	100.0
	Imipramine					7	100.0									7	100.0
VERTIGO	Reboxetine					4	80.0	1	20.0							5	100.0
	Imipramine			1	12.5	6	75.0					1	12.5			8	100.0
PARAESTHESIA	Placebo					1	50.0			1	50.0					2	100.0
	Reboxetine			1	50.0	1	50.0									2	100.0
	Imipramine					3	50.0	1	16.7			1	16.7	1	16.7	6	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 63

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Relationship															
		Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
URINARY HESITANCY / RETENTION	Placebo	1	50.0									1	50.0			2	100.0
	Reboxetine	2	33.3	1	16.7	2	33.3	1	16.7							6	100.0
	Imipramine					1	100.0									1	100.0
ABDOMINAL PAIN	Placebo					2	66.7	1	33.3							3	100.0
	Reboxetine					1	100.0									1	100.0
	Imipramine			1	20.0	2	40.0	1	20.0	1	20.0					5	100.0
SUICIDE ATTEMPT	Placebo									1	25.0	3	75.0			4	100.0
	Reboxetine											1	100.0			1	100.0
	Imipramine					1	25.0	1	25.0	2	50.0					4	100.0
FLUSHING / HOT FLUSHES	Placebo					1	100.0									1	100.0
	Reboxetine			1	33.3	1	33.3					1	33.3			3	100.0
	Imipramine			1	25.0	2	50.0					1	25.0			4	100.0
TACHYCARDIA	Reboxetine					3	100.0									3	100.0
	Imipramine			1	25.0	2	50.0							1	25.0	4	100.0
DYSPNOEA	Reboxetine					1	20.0	1	20.0	3	60.0					5	100.0
	Imipramine					2	100.0									2	100.0
RHINITIS	Placebo							1	25.0	2	50.0			1	25.0	4	100.0
	Reboxetine					1	100.0									1	100.0
	Imipramine					1	50.0	1	50.0							2	100.0
URINARY TRACT INFECTION	Placebo									1	100.0					1	100.0
	Reboxetine									4	100.0					4	100.0
PALPITATION	Placebo									1	100.0					1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 63

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Relationship															
		Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
PALPITATION	Reboxetine					1	100.0									1	100.0
	Imipramine					2	100.0									2	100.0
ERYTHEMA / RASH	Placebo					1	50.0	1	50.0							2	100.0
	Reboxetine					1	100.0									1	100.0
	Imipramine											1	100.0			1	100.0
CARDIAC ISCHEMIA AND RELATED SYMPTOMS	Placebo							1	100.0							1	100.0
	Imipramine			1	50.0	1	50.0									2	100.0
CONFUSION	Reboxetine			1	100.0											1	100.0
	Imipramine							1	50.0					1	50.0	2	100.0
APPETITE INCREASED	Placebo			1	100.0											1	100.0
	Imipramine					1	50.0					1	50.0			2	100.0
WEIGHT INCREASE	Reboxetine					1	100.0									1	100.0
	Imipramine			1	50.0	1	50.0									2	100.0
HYPERKINESIA	Placebo					2	100.0									2	100.0
	Imipramine					1	100.0									1	100.0
MUSCLE CONTRACTIONS INVOLUNTARY	Reboxetine					1	100.0									1	100.0
	Imipramine					1	50.0	1	50.0							2	100.0
DIARRHOEA	Placebo					2	66.7	1	33.3							3	100.0
MYALGIA	Placebo					1	50.0					1	50.0			2	100.0
	Imipramine							1	100.0							1	100.0
DYSURIA	Reboxetine					1	50.0	1	50.0							2	100.0
	Imipramine					1	100.0									1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 63

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Relationship															
		Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
SINUSITIS	Placebo											1	100.0			1	100.0
	Reboxetine									2	100.0					2	100.0
INFLUENZA-LIKE SYMPTOMS	Placebo													1	100.0	1	100.0
	Reboxetine													1	100.0	1	100.0
	Imipramine													1	100.0	1	100.0
TINNITUS	Imipramine	1	50.0			1	50.0									2	100.0
CHEST PAIN	Reboxetine			1	100.0											1	100.0
	Imipramine			1	100.0											1	100.0
CONJUNCTIVITIS	Imipramine			1	50.0							1	50.0			2	100.0
HYPERTENSION	Reboxetine									1	100.0					1	100.0
	Imipramine					1	100.0									1	100.0
INCREASED LIVER ENZYMES	Reboxetine							1	100.0							1	100.0
	Imipramine					1	100.0									1	100.0
WEIGHT DECREASE	Placebo					1	100.0									1	100.0
	Reboxetine									1	100.0					1	100.0
MYDRIASIS	Reboxetine					1	50.0	1	50.0							2	100.0
FLATULENCE	Placebo							1	100.0							1	100.0
	Reboxetine							1	100.0							1	100.0
ARTHRALGIA	Placebo							1	100.0							1	100.0
	Reboxetine									1	100.0					1	100.0
BACK PAIN	Placebo									2	100.0					2	100.0
IMPOTENCE	Reboxetine	1	100.0													1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 63

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Relationship															
		Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
BRADYCARDIA	Placebo			1	100.0											1	100.0
TASTE LOSS	Imipramine			1	100.0											1	100.0
SALIVA INCREASED	Reboxetine					1	100.0									1	100.0
EXTRASYSTOLES	Imipramine					1	100.0									1	100.0
SPEECH DISORDER	Imipramine					1	100.0									1	100.0
EOSINOPHILIA	Imipramine					1	100.0									1	100.0
HYPERURICAEMIA	Reboxetine					1	100.0									1	100.0
PHOSPHATASE ALKALINE INCREASED	Imipramine					1	100.0									1	100.0
CONCENTRATION IMPAIRED	Imipramine					1	100.0									1	100.0
DEPERSONALIZATION	Imipramine					1	100.0									1	100.0
SLEEP DISORDER	Imipramine					1	100.0									1	100.0
MICTURITION FREQUENCY	Placebo					1	100.0									1	100.0
ANEMIA	Imipramine							1	100.0							1	100.0
LIBIDO DECREASED	Reboxetine							1	100.0							1	100.0
PERINEAL PAIN MALE	Reboxetine							1	100.0							1	100.0
HYPERPYREXIA	Reboxetine									1	100.0					1	100.0
HAEMORRHOIDS THROMBOSED	Reboxetine									1	100.0					1	100.0
ANOREXIA	Reboxetine									1	100.0					1	100.0
GASTROENTERITIS	Reboxetine									1	100.0					1	100.0
TONGUE ULCERATION	Placebo									1	100.0					1	100.0
AUTOLESIONIST BEHAVIOUR	Imipramine									1	100.0					1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 63

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Relationship															
		Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
DEPRESSION AGGRAVATED	Placebo									1	100.0					1	100.0
EPIDIDYMITIS	Reboxetine									1	100.0					1	100.0
HERPES SIMPLEX	Placebo									1	100.0					1	100.0
BRONCHITIS	Placebo									1	100.0					1	100.0
PHARYNGITIS	Placebo									1	100.0					1	100.0
RHAGADES	Imipramine									1	100.0					1	100.0
PYURIA	Reboxetine									1	100.0					1	100.0
CHROMATOPSIA	Placebo									1	100.0					1	100.0
MALAISE	Placebo											1	100.0			1	100.0
RIGORS	Imipramine											1	100.0			1	100.0
HYPERTONIA	Placebo											1	100.0			1	100.0
COLITIS	Imipramine											1	100.0			1	100.0
DUODENAL ULCER REACTIVATED	Imipramine											1	100.0			1	100.0
DYSPHAGIA	Imipramine											1	100.0			1	100.0
HYPERTRIGLYCERIDAEMIA	Imipramine											1	100.0			1	100.0
HYPOKALAEMIA	Imipramine											1	100.0			1	100.0
PARONIRIA	Placebo											1	100.0			1	100.0
COLD URTICARIA	Imipramine											1	100.0			1	100.0
TASTE PERVERSION	Placebo											1	100.0			1	100.0
EYE ABNORMALITY	Reboxetine											1	100.0			1	100.0
TOOTH DISORDER	Reboxetine													1	100.0	1	100.0

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 64

ADVERSE EVENTS(*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

				Relationship							Total
				Possible	Doubtful	Probable	Definite	Unknown	None	Missing	
All adverse events		Ass. treatment									
		Placebo		11	2	2	2	3	2		22
		Imipramine		28	1	6	3	6	3		47
		Reboxetine		15	2	8	3		3		31
Centre - Patient	Days of Treatment	Adverse events	Ass. treatment								
1 - 6 (Female)	44	RASH	Placebo	1							1
		ARTHRALGIA	Placebo		1						1
		CONSTIPATION	Placebo			1					1
		MOUTH DRY	Placebo				1				1
		TASTE PERVERSION	Placebo					1			1
		PARONIRIA	Placebo					1			1
		ABDOMINAL PAIN	Placebo	1							1
		FLATULENCE	Placebo		1						1
		NAUSEA	Placebo	1							1
		MICTURITION DISORDER	Placebo				1				1
1 - 11 (Female)	4	DIZZINESS	Imipramine				1				1
		HYPOTENSION POSTURAL	Imipramine				1				1
3/1 - 143 (Female)	36	SWEATING INCREASED	Reboxetine			1					1
		DYSPNOEA	Reboxetine	1							1
3/1 - 451 (Female)	13	CONSTIPATION	Reboxetine				1				1
		HAEMORRHOIDS THROMBOSED	Reboxetine						1		1

(CONTINUED)

(*) Only adverse events complained on the last day of treatment and still present or resulting in withdrawal

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 64

ADVERSE EVENTS(*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

				Relationship							Total
				Possible	Doubtful	Probable	Definite	Unknown	None	Missing	
Centre - Patient	Days of Treatment	Adverse events	Ass. treatment								
3/1 - 456 (Female)	10	CONSTIPATION	Imipramine			1					1
		MOUTH DRY	Imipramine			1					1
		SWEATING INCREASED	Imipramine			1					1
		TACHYCARDIA	Imipramine			1					1
		SYNCOPE	Imipramine	1							1
		CHEST PAIN PRECORDIAL	Imipramine	1							1
3/4 - 80 (Male)	24	DIZZINESS	Imipramine	1							1
		VISION ABNORMAL	Imipramine	1							1
3/4 - 83 (Male)	8	TREMOR	Placebo	1							1
		AGITATION	Placebo	1							1
		DIARRHOEA	Placebo	1							1
		INSOMNIA	Placebo	1							1
3/4 - 460 (Male)	2	MOUTH DRY	Reboxetine			1					1
		CONFUSION	Reboxetine			1					1
3/4 - 461 (Female)	8	MOUTH DRY	Imipramine	1							1
		NAUSEA	Imipramine	1							1
		DIZZINESS	Imipramine	1							1
3/4 - 462 (Female)	10	INSOMNIA	Imipramine	1							1
		HYPERKINESIA	Imipramine	1							1
		DEPERSONALIZATION	Imipramine	1							1
4/1 - 116 (Female)	7	NAUSEA	Imipramine	1							1

(CONTINUED)

(*) Only adverse events complained on the last day of treatment and still present or resulting in withdrawal

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 64

ADVERSE EVENTS(*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

				Relationship							Total
				Possible	Doubtful	Probable	Definite	Unknown	None	Missing	
Centre - Patient	Days of Treatment	Adverse events	Ass. treatment								
4/1 - 116 (Female)	7	HEADACHE	Imipramine	1							1
		VERTIGO	Imipramine	1							1
4/3 - 99 (Female)	8	DIARRHOEA	Placebo	1							1
		DYSPEPSIA	Placebo	1							1
4/3 - 100 (Female)	21	NAUSEA	Imipramine	1							1
		SWEATING INCREASED	Imipramine	1							1
		TREMOR	Imipramine	1							1
		VERTIGO	Imipramine	1							1
4/4 - 176 (Female)	26	SUICIDE ATTEMPT	Placebo						1		1
		DEPRESSION AGGRAVATED	Placebo						1		1
4/4 - 179 (Female)	19	SUICIDE ATTEMPT	Placebo					1			1
6/1 - 151 (Male)	8	MOUTH DRY	Imipramine	1							1
		HYPOTENSION POSTURAL	Imipramine	1							1
		SWEATING INCREASED	Imipramine	1							1
		ASTHENIA	Imipramine	1							1
6/2 - 161 (Female)	28	MOUTH DRY	Reboxetine	1							1
		URINARY TRACT INFECTION	Reboxetine						1		1
6/3 - 163 (Male)	3	TACHYCARDIA	Reboxetine	1							1
		VERTIGO	Reboxetine	1							1
		ANXIETY	Reboxetine	1							1

(CONTINUED)

(*) Only adverse events complained on the last day of treatment and still present or resulting in withdrawal

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 64

ADVERSE EVENTS(*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

				Relationship							Total
				Possible	Doubtful	Probable	Definite	Unknown	None	Missing	
Centre - Patient	Days of Treatment	Adverse events	Ass. treatment								
6/3 - 510 (Female)	13	INSOMNIA	Reboxetine	1							1
		VERTIGO	Reboxetine	1							1
		HYPOTENSION	Reboxetine			1					1
7/02 - 183 (Male)	17	ABDOMINAL PAIN	Imipramine						1		1
		SWEATING INCREASED	Imipramine	1							1
		TREMOR	Imipramine					1			1
		AGITATION	Imipramine					1			1
		PARAESTHESIA	Imipramine					1			1
		TINNITUS	Imipramine				1				1
		COLITIS	Imipramine					1			1
		DYSPHAGIA	Imipramine					1			1
		RIGORS	Imipramine					1			1
7/02 - 185 (Male)	26	URINARY RETENTION	Reboxetine				1				1
		GAMMA-GT INCREASED	Reboxetine		1						1
		IMPOTENCE	Reboxetine				1				1
7/03 - 191 (Female)	39	SUICIDE ATTEMPT	Imipramine						1		1
8 - 213 (Male)	3	SUICIDE ATTEMPT	Imipramine						1		1
9 - 241 (Female)	11	AGITATION	Placebo	1							1
		HYPERKINESIA	Placebo	1							1
9 - 246 (Female)	24	BRADYCARDIA	Placebo			1					1
9 - 252 (Female)	19	MOUTH DRY	Reboxetine	1							1

(CONTINUED)

(*) Only adverse events complained on the last day of treatment and still present or resulting in withdrawal

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 64

ADVERSE EVENTS(*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

				Relationship							Total
				Possible	Doubtful	Probable	Definite	Unknown	None	Missing	
Centre - Patient	Days of Treatment	Adverse events	Ass. treatment								
9 - 252 (Female)	19	TREMOR	Reboxetine	1							1
		AGITATION	Reboxetine	1							1
		MUSCLE CONTRACTIONS INVOLUNTARY	Reboxetine	1							1
9 - 253 (Female)	7	AGITATION	Reboxetine	1							1
9 - 254 (Female)	8	MOUTH DRY	Imipramine	1							1
		TREMOR	Imipramine	1							1
		INSOMNIA	Imipramine	1							1
9 - 255 (Female)	25	MOUTH DRY	Reboxetine	2							2
		AGITATION	Reboxetine	1							1
		MYDRIASIS	Reboxetine		1						1
		PYURIA	Reboxetine						1		1
11 - 334 (Female)	3	DIZZINESS	Reboxetine			1					1
		SWEATING INCREASED	Reboxetine			1					1
		PARAESTHESIA	Reboxetine			1					1
		CHEST PAIN	Reboxetine			1					1
12 - 371 (Female)	6	MOUTH DRY	Imipramine	1							1
12 - 375 (Male)	2	VISION ABNORMAL	Imipramine		1						1
		SUICIDE ATTEMPT	Imipramine	1							1
13 - 16 (Male)	45	NAUSEA	Imipramine	1							1
		SWEATING INCREASED	Imipramine			1					1

(CONTINUED)

(*) Only adverse events complained on the last day of treatment and still present or resulting in withdrawal

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 64

ADVERSE EVENTS(*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

				Relationship							
				Possible	Doubtful	Probable	Definite	Unknown	None	Missing	Total
Centre - Patient	Days of Treatment	Adverse events	Ass. treatment								
13 - 16 (Male)	45	HOT FLUSHES	Imipramine			1					1

(*) Only adverse events complained on the last day of treatment and still present or resulting in withdrawal

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
HB	Evaluated	87	78	70	98	92	81	92	86	79
	Mean	14.13	14.15	13.98	14.62	14.47	14.47	14.15	14.22	14.33
	STD	1.74	2.00	1.83	1.55	1.43	1.72	1.68	1.39	1.55
	Min	10.63	10.21	10.42	12.00	12.00	11.42	9.40	11.07	11.07
	Max	23.39	25.06	23.61	22.28	20.83	22.72	19.50	18.03	19.10
	Median	14.00	14.00	13.68	14.58	14.34	14.10	13.99	14.30	14.20
	Median diff.		0.16	-0.09		-0.07	-0.29		0.00	0.07
	P value		0.2894	0.7270		0.1157	0.1240		0.6914	0.5953
HT	Evaluated	84	73	67	89	83	72	83	78	70
	Mean	41.16	40.91	40.89	42.68	42.59	42.25	41.99	42.17	42.23
	STD	5.21	4.84	4.96	4.47	4.28	4.64	4.61	4.24	4.29
	Min	31.89	31.33	30.90	32.10	34.80	32.59	31.90	34.00	32.00
	Max	54.92	53.00	57.56	51.71	54.54	52.50	53.00	51.29	50.26
	Median	40.00	40.59	40.00	42.41	41.84	41.28	40.75	42.05	41.78
	Median diff.		0.53	0.25		-0.08	0.00		0.11	-0.41
	P value		0.0731	0.9899		0.6430	0.3024		0.7196	0.3306
RBC	Evaluated	87	77	69	98	92	81	93	87	80
	Mean	4.60	4.63	4.57	4.82	4.81	4.83	4.67	4.71	4.71
	STD	0.59	0.57	0.51	0.59	0.59	0.78	0.65	0.59	0.56
	Min	2.89	3.50	3.38	3.89	3.71	2.88	2.38	3.40	3.56
	Max	5.93	6.12	5.86	6.90	6.54	8.33	6.73	6.68	6.40

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015

TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment									
		Imipramine			Placebo			Reboxetine			
		Days of treatment			Days of treatment			Days of treatment			
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
RBC	Median	4.55	4.56	4.53	4.79	4.70	4.70	4.63	4.70	4.73
	Median diff.		0.06	0.02		0.01	-0.02		0.00	-0.00
	P value		0.1507	0.9882		0.4240	0.6181		0.4517	0.9094
PLATELETS	Evaluated	83	73	66	93	89	74	88	79	75
	Mean	272.00	274.27	281.18	259.35	253.86	258.74	255.33	262.11	254.50
	STD	71.57	68.15	69.74	72.15	68.04	79.19	70.68	70.35	79.44
	Min	20.00	75.00	92.50	-97.50	-90.00	-82.50	50.00	107.50	43.75
	Max	504.00	468.75	470.00	409.00	438.33	486.21	403.00	405.56	490.00
	Median	267.65	274.00	287.83	260.00	250.83	252.89	257.00	271.00	254.00
	Median diff.		-5.00	5.92		-5.00	-0.96		2.78	0.00
	P value		0.6748	0.1615		0.2145	0.6553		0.6130	0.6202

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
WBC	Evaluated	87	78	70	98	92	81	93	87	80
	Mean	7.26	7.22	7.07	7.97	7.55	7.78	7.25	7.50	7.40
	STD	2.09	2.16	2.25	2.49	2.20	2.19	2.27	2.59	2.09
	Min	-0.07	1.66	1.41	3.33	3.30	3.31	2.44	4.50	3.09
	Max	11.14	13.06	15.23	17.40	16.49	13.92	13.97	20.86	13.48
	Median	6.99	7.17	7.00	7.58	7.43	7.75	6.84	7.01	7.10
	Median diff.		-0.17	-0.11		-0.28	-0.37		0.35	0.52
	P value		0.6517	0.6809		0.0904	0.1361		0.0928	0.0389
WBC: N	Evaluated	81	71	67	93	85	78	88	79	79
	Mean	61.26	62.43	61.80	61.79	61.52	61.79	61.35	61.57	62.42
	STD	5.24	5.13	4.12	3.75	4.09	3.71	7.12	5.72	5.02
	Min	44.14	44.14	51.00	52.71	48.43	54.65	29.86	31.29	38.43
	Max	82.71	79.86	69.55	75.57	70.25	74.14	94.14	79.00	78.43
	Median	61.84	62.78	62.41	62.00	61.33	61.96	61.57	62.00	62.65
	Median diff.		0.00	0.06		-0.20	-0.50		0.00	0.50
	P value		0.1283	0.1294		0.6640	0.2204		0.4349	0.1113
WBC: E	Evaluated	80	70	65	92	84	77	87	77	78
	Mean	1.65	1.75	1.82	1.94	1.68	1.76	1.62	1.89	1.76
	STD	0.97	1.34	1.26	1.48	1.11	1.07	1.15	1.35	1.20
	Min	0.00	0.00	0.00	-1.00	-1.00	0.00	-1.00	-1.00	-1.00
	Max	7.00	8.56	7.92	9.71	6.00	5.29	7.00	7.00	7.00

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
WBC: E	Median	1.46	1.59	1.50	1.67	1.50	1.55	1.50	1.60	1.57
	Median diff.		0.00	0.00		0.00	0.00		0.00	0.00
	P value		0.9875	0.7205		0.0357	0.5127		0.0569	0.1107
WBC: B	Evaluated	78	67	64	90	82	73	86	77	77
	Mean	0.28	0.25	0.31	0.26	0.19	0.27	0.20	0.26	0.28
	STD	0.34	0.32	0.34	0.30	0.26	0.40	0.27	0.37	0.36
	Min	0.00	-0.38	-0.08	-0.02	-0.08	-0.03	-0.08	-0.08	0.00
	Max	2.06	1.50	1.72	1.50	1.13	2.25	0.75	1.50	1.50
	Median	0.25	0.19	0.25	0.19	0.00	0.00	0.00	0.00	0.08
	Median diff.		0.00	0.00		0.00	0.00		0.00	0.00
	P value		0.9882	0.4144		0.0926	0.4861		0.5995	0.1019
WBC: L	Evaluated	87	76	70	98	91	81	91	82	79
	Mean	28.43	26.99	27.67	28.37	28.63	28.25	28.80	28.21	28.11
	STD	5.24	5.21	4.97	4.74	4.96	4.53	5.79	4.47	4.60
	Min	17.67	15.75	18.55	19.80	15.33	17.80	14.33	17.10	18.60
	Max	40.50	43.00	40.17	47.00	49.29	43.00	45.67	43.67	43.00
	Median	27.80	26.58	26.47	28.35	28.53	27.40	28.33	27.70	27.83
	Median diff.		-1.00	-0.44		0.71	0.00		-0.14	-0.40
	P value		0.0008	0.0824		0.2852	0.8801		0.2796	0.2519
WBC: M	Evaluated	87	75	70	98	91	81	91	81	79
	Mean	4.24	4.24	4.36	4.74	4.52	4.63	4.47	4.67	4.77

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
WBC: M	STD	2.08	1.86	2.01	2.00	1.46	1.73	2.00	2.11	2.30
	Min	-3.60	-1.20	-2.20	0.00	1.27	0.00	0.00	2.00	0.00
	Max	10.50	11.00	10.54	13.00	8.14	9.29	11.00	15.00	15.00
	Median	4.21	4.30	4.29	4.39	4.33	4.47	4.21	4.26	4.47
	Median diff.		0.00	0.00		0.00	0.00		0.20	0.00
	P value		0.9892	0.7517		0.4819	0.8810		0.2049	0.2120

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
CREATININE	Evaluated	92	84	75	97	91	77	94	88	84
	Mean	0.85	0.88	0.86	0.90	0.89	0.86	0.86	0.85	0.86
	STD	0.20	0.24	0.20	0.22	0.22	0.20	0.22	0.23	0.23
	Min	0.35	0.40	0.37	0.10	0.40	0.50	0.26	0.24	0.40
	Max	1.40	1.79	1.54	1.41	1.42	1.30	1.64	1.69	1.57
	Median	0.82	0.84	0.86	0.90	0.88	0.81	0.85	0.82	0.86
	Median diff.		0.03	0.00		0.00	-0.01		0.00	-0.01
	P value		0.0064	0.6598		0.4993	0.2075		0.3067	0.2133
UREA	Evaluated	54	48	44	56	50	41	56	51	49
	Mean	24.62	23.77	24.96	26.07	26.36	24.03	22.05	23.27	22.56
	STD	6.01	6.63	6.60	5.52	6.07	6.35	7.63	5.21	5.99
	Min	10.30	12.31	10.86	16.13	14.57	9.59	7.00	13.86	9.86
	Max	39.40	43.00	43.00	38.91	41.09	37.61	41.00	35.40	40.22
	Median	24.20	23.23	24.35	26.87	26.32	24.33	21.53	23.11	21.80
	Median diff.		-1.20	-0.75		-0.83	-1.20		1.51	-0.30
	P value		0.3545	0.6377		0.5955	0.0883		0.1904	0.8065
BUN	Evaluated	32	31	24	35	35	29	37	36	29
	Mean	11.90	13.10	12.88	12.93	12.98	13.37	13.47	13.44	14.01
	STD	2.14	3.10	2.63	3.92	3.21	2.61	3.16	3.26	4.65
	Min	7.00	6.18	7.70	7.70	6.73	8.22	7.58	7.70	8.10
	Max	15.80	21.03	16.90	28.44	22.13	18.83	22.13	21.85	30.83

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
BUN	Median	11.72	13.21	12.64	13.08	12.50	13.49	13.08	13.33	13.68
	Median diff.		0.55	1.24		0.58	0.83		0.27	0.00
	P value		0.0331	0.0490		0.3797	0.0897		0.5201	0.7310
URIC ACID	Evaluated	80	72	65	90	85	76	86	79	79
	Mean	4.58	4.59	4.90	5.02	5.15	5.06	4.86	5.05	5.00
	STD	1.62	1.55	1.72	1.46	1.61	1.64	1.36	1.72	1.54
	Min	0.24	0.33	0.24	1.50	2.25	2.43	1.42	0.56	1.60
	Max	8.64	8.27	9.89	8.57	9.44	11.57	7.83	10.42	9.63
	Median	4.36	4.58	4.68	4.91	5.10	4.90	4.88	4.98	4.88
	Median diff.		0.11	0.00		0.15	-0.06		0.10	0.00
	P value		0.1222	0.3169		0.1935	0.8561		0.4934	0.3415

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
TOT. PROTEINS	Evaluated	88	81	70	92	88	73	92	87	81
	Mean	7.40	7.41	7.52	7.36	7.31	7.36	7.38	7.41	7.37
	STD	0.62	0.59	0.64	0.59	0.58	0.58	0.64	0.68	0.58
	Min	5.62	5.26	5.77	5.77	6.02	6.06	5.95	4.63	4.88
	Max	8.71	8.93	9.09	8.68	8.84	8.64	9.65	9.41	8.78
	Median	7.45	7.35	7.43	7.38	7.30	7.31	7.35	7.40	7.41
	Median diff.		0.07	0.00		-0.09	0.00		0.08	0.07
	P value		0.4259	0.2741		0.3756	0.7078		0.3321	0.2976
ALBUMINE	Evaluated	87	81	67	93	88	73	89	81	79
	Mean	4.61	4.60	4.62	4.53	4.59	4.61	4.44	4.43	4.24
	STD	1.14	0.94	0.95	0.96	0.94	1.03	0.74	0.88	1.02
	Min	1.08	3.14	1.42	1.63	1.66	0.91	2.53	1.51	0.61
	Max	8.78	8.33	8.00	8.42	7.67	7.91	6.50	7.67	6.50
	Median	4.42	4.49	4.58	4.40	4.54	4.50	4.34	4.42	4.31
	Median diff.		-0.06	0.00		0.00	-0.05		-0.10	-0.01
	P value		0.3498	0.5926		0.5119	0.8449		0.1869	0.0535
TOT BILIRUBIN	Evaluated	88	81	72	95	91	73	93	89	82
	Mean	0.58	0.51	0.55	0.59	0.60	0.54	0.63	0.58	0.57
	STD	0.26	0.25	0.25	0.25	0.26	0.22	0.25	0.28	0.21
	Min	0.20	0.15	0.09	0.10	0.15	0.20	0.20	0.20	0.20
	Max	1.48	1.57	1.17	1.47	1.79	1.51	1.70	2.30	1.18

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
TOT BILIRUBIN	Median	0.54	0.45	0.52	0.57	0.57	0.52	0.60	0.55	0.54
	Median diff.		-0.04	-0.02		0.00	0.00		0.00	-0.01
	P value		0.0147	0.1509		0.8177	0.3603		0.1234	0.0789
DIR BILIRUBIN	Evaluated	34	31	26	39	38	31	39	36	31
	Mean	0.08	0.08	0.07	0.10	0.12	0.11	0.13	0.09	0.09
	STD	0.07	0.07	0.07	0.17	0.22	0.14	0.14	0.05	0.04
	Min	0.00	0.00	-0.10	0.00	0.00	0.00	0.00	0.00	0.00
	Max	0.36	0.32	0.24	1.09	1.41	0.85	0.84	0.24	0.17
	Median	0.07	0.07	0.07	0.08	0.08	0.08	0.11	0.08	0.09
	Median diff.		0.00	-0.00		0.00	0.00		-0.03	0.00
	P value		0.4150	0.0616		0.4978	0.3889		0.0324	0.0338

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
SGOT	Evaluated	90	80	74	95	88	76	94	88	84
	Mean	21.20	20.94	22.62	27.35	19.19	19.49	21.13	18.71	19.96
	STD	15.96	13.34	12.93	72.73	6.36	6.45	10.16	4.89	6.68
	Min	8.00	10.00	9.00	9.00	10.00	9.00	9.00	10.00	10.53
	Max	142.00	124.00	100.00	725.00	53.33	50.00	80.00	34.42	54.32
	Median	17.40	18.30	19.28	18.18	18.57	18.00	18.82	18.17	18.75
	Median diff.		0.00	1.07		-0.60	-0.93		-0.56	0.00
	P value *		0.4365	0.1199		0.3022	0.1130		0.1654	0.5011
SGPT	Evaluated	84	75	68	88	81	69	89	84	79
	Mean	16.87	17.86	20.82	22.51	17.56	15.68	16.37	14.92	16.15
	STD	14.18	15.25	14.55	56.10	14.88	10.49	12.75	7.35	10.36
	Min	1.43	2.50	5.00	5.00	0.83	3.33	2.50	2.50	3.33
	Max	96.94	90.83	74.64	532.78	100.97	73.00	92.50	45.44	66.90
	Median	14.20	13.57	17.11	13.06	14.38	13.00	13.13	14.19	13.82
	Median diff.		0.00	2.57		-0.64	-1.39		0.00	0.50
	P value		0.3134	0.0125		0.3337	0.0228		0.3351	0.8373
GAMMA GT	Evaluated	82	75	62	95	88	72	88	82	76
	Mean	64.21	58.42	79.23	34.08	28.08	29.56	40.85	30.02	29.37
	STD	204.06	212.31	205.93	33.58	19.31	17.82	69.43	27.09	21.12
	Min	5.54	5.44	8.00	10.00	8.00	10.74	8.00	3.53	8.00
	Max	1800.00	1846.77	1514.46	279.30	107.70	97.83	568.00	206.55	131.64

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
GAMMA GT	Median	23.02	23.54	29.67	23.91	22.20	22.41	22.74	23.88	23.34
	Median diff.		0.00	2.46		-1.91	-1.50		-1.71	-0.86
	P value		0.9729	0.0558		0.0018	0.0224		0.0159	0.0919
LDH	Evaluated	76	68	54	82	76	64	80	72	68
	Mean	287.90	306.99	320.38	284.91	278.61	277.58	286.72	300.82	320.15
	STD	107.60	125.18	108.99	149.42	138.62	119.19	128.69	137.54	131.08
	Min	-90.00	-6.00	42.00	-99.00	-90.00	-150.00	-129.00	-48.00	-24.00
	Max	539.00	667.75	688.33	1148.00	695.33	521.64	550.20	737.52	812.00
	Median	301.03	303.37	320.92	291.39	281.81	292.08	298.59	297.65	298.67
	Median diff.		6.50	16.99		-15.94	-13.22		9.23	12.21
	P value		0.3600	0.0574		0.1219	0.5838		0.5512	0.1184
ALK. PHOSPH.	Evaluated	88	79	73	97	91	77	94	87	84
	Mean	104.38	104.73	116.80	123.44	124.26	123.33	108.19	106.81	105.56
	STD	44.44	40.78	52.10	151.82	148.88	162.27	40.87	40.78	38.07
	Min	1.55	1.55	-8.35	46.10	41.15	46.10	39.20	36.35	35.13
	Max	277.76	222.50	335.68	1561.94	1487.69	1497.21	246.58	231.73	229.25
	Median	92.97	98.61	108.80	107.60	109.41	105.70	102.94	98.30	99.78
	Median diff.		3.60	7.92		-3.26	-3.76		0.00	0.38
	P value		0.4275	0.0046		0.0772	0.0302		0.9758	0.6046

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
GLOBULINS ALPHA 1	Evaluated	67	59	49	71	67	54	67	59	60
	Mean	0.20	0.19	0.20	0.20	0.18	0.21	0.18	0.20	0.19
	STD	0.07	0.08	0.07	0.10	0.06	0.07	0.07	0.07	0.07
	Min	0.06	0.06	0.07	0.03	0.05	0.06	-0.03	0.10	0.03
	Max	0.36	0.46	0.40	0.64	0.32	0.37	0.32	0.40	0.33
	Median	0.19	0.18	0.20	0.18	0.19	0.20	0.19	0.18	0.17
	Median diff.		0.00	0.01		0.00	0.00		0.00	0.00
	P value		0.4154	0.1923		0.8289	0.3122		0.2572	0.4776
GLOBULINS ALPHA 2	Evaluated	67	59	49	71	67	54	67	59	60
	Mean	0.82	0.82	0.84	0.80	0.78	0.83	0.82	0.84	0.83
	STD	0.17	0.17	0.20	0.14	0.15	0.14	0.19	0.18	0.19
	Min	0.51	0.47	0.38	0.55	0.50	0.59	0.53	0.57	0.52
	Max	1.27	1.32	1.24	1.23	1.45	1.27	1.88	1.68	1.58
	Median	0.79	0.81	0.80	0.77	0.76	0.80	0.78	0.83	0.82
	Median diff.		-0.01	0.00		-0.01	0.00		0.01	0.00
	P value		0.5843	0.4902		0.5110	0.3613		0.4283	0.5906
GLOBULINS BETA	Evaluated	67	59	49	71	67	54	67	59	60
	Mean	0.96	0.95	0.95	0.95	0.95	0.94	0.95	0.94	0.91
	STD	0.15	0.17	0.17	0.18	0.17	0.14	0.20	0.20	0.15
	Min	0.74	0.59	0.59	0.53	0.56	0.70	0.56	0.26	0.53
	Max	1.55	1.43	1.28	1.40	1.57	1.38	1.60	1.54	1.21

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
GLOBULINS BETA	Median	0.94	0.94	0.95	0.94	0.90	0.93	0.92	0.94	0.92
	Median diff.		0.00	0.02		0.00	0.00		0.00	-0.01
	P value		0.7471	0.9460		0.7462	0.4376		0.9930	0.6117
GLOBULINS GAMMA	Evaluated	67	59	49	71	67	54	67	59	60
	Mean	1.11	1.14	1.14	1.08	1.16	1.15	1.14	1.15	1.13
	STD	0.31	0.39	0.29	0.35	0.40	0.41	0.40	0.35	0.38
	Min	0.00	-0.13	0.27	0.45	0.53	0.45	0.13	0.11	-0.13
	Max	1.94	2.32	1.73	2.27	2.60	2.30	2.50	2.25	2.39
	Median	1.07	1.08	1.16	1.06	1.08	1.13	1.10	1.12	1.10
	Median diff.		0.00	0.01		0.07	0.09		0.05	-0.01
	P value		0.3039	0.4475		0.0414	0.0415		0.3309	0.8365

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
TOT. CHOLEST.	Evaluated	87	78	68	94	87	74	90	84	78
	Mean	254.95	260.75	263.68	261.14	248.63	250.56	250.12	243.30	237.99
	STD	74.68	71.87	75.76	66.95	61.29	65.28	66.84	60.81	67.71
	Min	115.04	101.86	145.37	87.20	75.40	102.37	85.25	101.86	88.12
	Max	515.47	455.08	540.46	458.06	450.70	479.70	444.32	395.18	421.12
	Median	238.42	252.15	247.41	254.19	235.38	245.11	250.34	238.07	228.93
	Median diff.		7.60	5.12		-4.72	-10.00		-4.54	-10.88
	P value		0.4190	0.0817		0.1012	0.0094		0.1021	0.0080
TRIGLYCERIDES	Evaluated	86	77	66	93	87	72	89	83	77
	Mean	174.35	166.52	148.99	197.19	183.48	194.78	166.06	171.74	162.10
	STD	129.67	138.23	98.71	176.27	136.16	188.95	115.19	169.21	119.71
	Min	20.38	28.00	36.94	27.07	0.31	-22.98	-6.36	-8.65	-6.36
	Max	754.00	892.86	584.80	1266.73	714.83	1352.18	546.77	1330.82	583.09
	Median	129.50	128.70	125.07	150.24	139.87	143.37	142.00	132.45	133.21
	Median diff.		1.81	-9.32		0.00	-0.39		-14.08	-2.22
	P value		0.8288	0.0172		0.6172	0.6493		0.1066	0.3636
GLUCOSE	Evaluated	90	81	73	97	90	77	95	89	81
	Mean	91.84	86.61	87.27	89.16	89.69	88.63	90.73	89.73	90.99
	STD	24.05	13.99	12.30	10.94	12.48	14.82	15.10	14.96	17.24
	Min	42.00	7.00	56.00	65.80	63.70	60.90	65.33	63.00	61.25
	Max	282.33	117.73	119.70	117.89	136.82	154.88	148.24	147.21	142.33

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
GLUCOSE	Median	90.24	85.75	86.00	87.50	89.59	86.80	87.50	88.38	85.75
	Median diff.		-1.84	-3.89		1.48	0.00		1.56	-1.84
	P value		0.0408	0.0208		0.4123	0.8742		0.6543	0.6321

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
NA+	Evaluated	90	82	73	96	90	77	96	90	84
	Mean	140.54	139.61	140.09	141.17	140.65	140.60	140.78	140.46	140.95
	STD	2.55	3.11	2.50	2.73	2.44	2.54	3.20	2.50	2.72
	Min	134.46	124.89	134.00	134.00	134.00	135.00	131.00	134.00	136.00
	Max	146.00	144.75	146.00	151.56	148.50	146.00	151.56	149.00	146.00
	Median	140.71	140.00	140.00	141.00	141.00	141.00	141.00	140.44	141.00
	Median diff.		-1.00	-1.00		0.00	0.00		0.00	0.00
	P value		0.0534	0.0711		0.3120	0.5510		0.1699	0.9910
CL-	Evaluated	81	73	63	85	79	67	86	81	73
	Mean	102.20	101.25	101.76	102.51	102.83	102.76	102.32	102.16	102.60
	STD	2.51	2.79	2.75	3.22	2.80	2.61	3.52	2.50	2.65
	Min	94.00	95.09	91.60	90.67	94.36	98.00	88.55	92.91	91.45
	Max	107.78	107.78	108.67	109.64	108.40	109.20	110.00	108.67	109.20
	Median	102.00	101.20	101.64	102.57	102.80	102.36	102.80	102.00	102.80
	Median diff.		-0.89	-0.78		0.00	0.00		-0.73	0.00
	P value		0.0032	0.0571		0.6694	0.4484		0.3096	0.7246
K+	Evaluated	91	82	74	95	88	76	95	88	82
	Mean	4.11	4.17	4.22	4.35	4.20	4.24	4.19	4.31	4.25
	STD	0.51	0.53	0.55	0.72	0.52	0.59	0.51	0.59	0.72
	Min	2.52	2.70	2.96	3.26	2.86	2.54	3.18	3.05	2.28
	Max	5.58	5.31	6.66	8.36	5.63	6.46	5.90	6.70	7.85

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 65

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment								
		Imipramine			Placebo			Reboxetine		
		Days of treatment			Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42	Screen	1-21	22-42
K+	Median	4.11	4.14	4.20	4.25	4.25	4.25	4.14	4.23	4.16
	Median diff.		0.02	0.08		-0.10	-0.11		0.09	0.03
	P value		0.6763	0.1237		0.0875	0.1038		0.0750	0.7753
Ca++	Evaluated	83	75	67	89	86	73	87	83	78
	Mean	4.93	4.92	4.87	4.96	4.90	4.96	4.95	4.98	4.89
	STD	0.27	0.38	0.39	0.29	0.32	0.32	0.30	0.32	0.30
	Min	4.10	3.70	3.65	4.25	3.70	4.25	3.85	4.00	4.10
	Max	5.45	5.62	5.55	5.54	5.74	5.66	5.60	5.88	5.60
	Median	4.96	4.99	4.93	5.00	4.90	4.92	5.00	5.00	4.92
	Median diff.		0.00	-0.04		-0.06	-0.04		0.00	-0.05
	P value		0.9538	0.4169		0.0380	0.4648		0.7097	0.1684
PO4--	Evaluated	76	69	64	89	85	73	86	81	73
	Mean	1.24	1.30	1.26	1.33	1.27	1.31	1.25	1.26	1.26
	STD	0.16	0.26	0.16	0.41	0.21	0.18	0.19	0.17	0.35
	Min	0.62	0.79	0.77	0.86	0.85	0.88	0.86	0.67	0.65
	Max	1.63	2.54	1.67	4.84	2.42	1.92	1.89	1.74	3.90
	Median	1.24	1.29	1.26	1.28	1.26	1.28	1.23	1.26	1.21
	Median diff.		0.05	0.02		-0.03	-0.02		0.02	0.00
	P value		0.1199	0.1554		0.1199	0.7076		0.1579	0.4300

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 66

URINALYSIS: NUMBER AND PERCENTAGE OF PATIENTS ACCORDING TO TIME INTERVAL, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Reboxetine

Urinalysis		Days of treatment																	
		Screening						1-21 days						22-42 days					
		Female		Male		Total		Female		Male		Total		Female		Male		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
SPECIFIC GRAVITY	Normal	30	100.0	19	100.0	49	100.0	29	96.7	19	100.0	48	98.0	23	95.8	17	94.4	40	95.2
	Not done							1	3.3			1	2.0	1	4.2	1	5.6	2	4.8
	Total	30	100.0	19	100.0	49	100.0	30	100.0	19	100.0	49	100.0	24	100.0	18	100.0	42	100.0
ALBUMIN	Absent	43	93.5	34	100.0	77	96.3	41	91.1	32	94.1	73	92.4	33	84.6	31	93.9	64	88.9
	Present	3	6.5			3	3.8	2	4.4	2	5.9	4	5.1	5	12.8	2	6.1	7	9.7
	Not done							2	4.4			2	2.5	1	2.6			1	1.4
	Total	46	100.0	34	100.0	80	100.0	45	100.0	34	100.0	79	100.0	39	100.0	33	100.0	72	100.0
SUGAR	Absent	48	98.0	33	97.1	81	97.6	46	95.8	33	97.1	79	96.3	40	97.6	32	97.0	72	97.3
	Present	1	2.0	1	2.9	2	2.4			1	2.9	1	1.2			1	3.0	1	1.4
	Not done							2	4.2			2	2.4	1	2.4			1	1.4
	Total	49	100.0	34	100.0	83	100.0	48	100.0	34	100.0	82	100.0	41	100.0	33	100.0	74	100.0
RBC	Absent	32	69.6	20	71.4	52	70.3	34	75.6	23	82.1	57	78.1	26	68.4	22	81.5	48	73.8
	Present	14	30.4	8	28.6	22	29.7	10	22.2	4	14.3	14	19.2	11	28.9	5	18.5	16	24.6
	Not done							1	2.2	1	3.6	2	2.7	1	2.6			1	1.5
	Total	46	100.0	28	100.0	74	100.0	45	100.0	28	100.0	73	100.0	38	100.0	27	100.0	65	100.0
WBC	Absent	26	61.9	11	47.8	37	56.9	24	58.5	15	65.2	39	60.9	18	52.9	15	68.2	33	58.9
	Present	16	38.1	12	52.2	28	43.1	16	39.0	8	34.8	24	37.5	15	44.1	7	31.8	22	39.3
	Not done							1	2.4			1	1.6	1	2.9			1	1.8
	Total	42	100.0	23	100.0	65	100.0	41	100.0	23	100.0	64	100.0	34	100.0	22	100.0	56	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 66

URINALYSIS: NUMBER AND PERCENTAGE OF PATIENTS ACCORDING TO TIME INTERVAL, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Imipramine

Urinalysis		Days of treatment																	
		Screening						1-21 days						22-42 days					
		Female		Male		Total		Female		Male		Total		Female		Male		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
SPECIFIC GRAVITY	Normal	33	100.0	18	100.0	51	100.0	30	90.9	14	82.4	44	88.0	24	100.0	15	88.2	39	95.1
	Not done							3	9.1	3	17.6	6	12.0			2	11.8	2	4.9
	Total	33	100.0	18	100.0	51	100.0	33	100.0	17	100.0	50	100.0	24	100.0	17	100.0	41	100.0
ALBUMIN	Absent	44	91.7	27	93.1	71	92.2	41	85.4	24	85.7	65	85.5	29	78.4	22	84.6	51	81.0
	Present	4	8.3	2	6.9	6	7.8	5	10.4	1	3.6	6	7.9	6	16.2	1	3.8	7	11.1
	Not done							2	4.2	3	10.7	5	6.6	2	5.4	3	11.5	5	7.9
	Total	48	100.0	29	100.0	77	100.0	48	100.0	28	100.0	76	100.0	37	100.0	26	100.0	63	100.0
SUGAR	Absent	47	95.9	29	96.7	76	96.2	47	95.9	26	89.7	73	93.6	36	94.7	23	85.2	59	90.8
	Present	2	4.1	1	3.3	3	3.8									2	7.4	2	3.1
	Not done							2	4.1	3	10.3	5	6.4	2	5.3	2	7.4	4	6.2
	Total	49	100.0	30	100.0	79	100.0	49	100.0	29	100.0	78	100.0	38	100.0	27	100.0	65	100.0
RBC	Absent	36	76.6	21	75.0	57	76.0	32	68.1	16	59.3	48	64.9	24	66.7	17	68.0	41	67.2
	Present	11	23.4	7	25.0	18	24.0	11	23.4	8	29.6	19	25.7	10	27.8	5	20.0	15	24.6
	Not done							4	8.5	3	11.1	7	9.5	2	5.6	3	12.0	5	8.2
	Total	47	100.0	28	100.0	75	100.0	47	100.0	27	100.0	74	100.0	36	100.0	25	100.0	61	100.0
WBC	Absent	24	54.5	16	66.7	40	58.8	22	50.0	11	47.8	33	49.3	19	57.6	13	61.9	32	59.3
	Present	20	45.5	8	33.3	28	41.2	19	43.2	9	39.1	28	41.8	12	36.4	5	23.8	17	31.5
	Not done							3	6.8	3	13.0	6	9.0	2	6.1	3	14.3	5	9.3
	Total	44	100.0	24	100.0	68	100.0	44	100.0	23	100.0	67	100.0	33	100.0	21	100.0	54	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 66

URINALYSIS: NUMBER AND PERCENTAGE OF PATIENTS ACCORDING TO TIME INTERVAL, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Placebo

Urinalysis		Days of treatment																			
		Screening						1-21 days						22-42 days							
		Female		Male		Total		Female		Male		Total		Female		Male		Total			
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%		
SPECIFIC GRAVITY	Normal	30	100.0	25	100.0	55	100.0	29	96.7	21	84.0	50	90.9	24	92.3	18	81.8	42	87.5		
	Not done							1	3.3	4	16.0	5	9.1	2	7.7	4	18.2	6	12.5		
	Total	30	100.0	25	100.0	55	100.0	30	100.0	25	100.0	55	100.0	26	100.0	22	100.0	48	100.0		
ALBUMIN	Absent	35	94.6	39	90.7	74	92.5	35	97.2	36	83.7	71	89.9	31	96.9	31	81.6	62	88.6		
	Present	2	5.4	4	9.3	6	7.5	1	2.8	4	9.3	5	6.3			2	5.3	2	2.9		
	Not done									3	7.0	3	3.8	1	3.1	5	13.2	6	8.6		
	Total	37	100.0	43	100.0	80	100.0	36	100.0	43	100.0	79	100.0	32	100.0	38	100.0	70	100.0		
SUGAR	Absent	40	100.0	45	100.0	85	100.0	38	97.4	41	91.1	79	94.0	33	94.3	34	85.0	67	89.3		
	Present							1	2.6	1	2.2	2	2.4			1	2.5	1	1.3		
	Not done									3	6.7	3	3.6	2	5.7	5	12.5	7	9.3		
	Total	40	100.0	45	100.0	85	100.0	39	100.0	45	100.0	84	100.0	35	100.0	40	100.0	75	100.0		
RBC	Absent	26	74.3	25	61.0	51	67.1	24	70.6	22	53.7	46	61.3	27	84.4	22	59.5	49	71.0		
	Present	9	25.7	16	39.0	25	32.9	7	20.6	15	36.6	22	29.3	5	15.6	11	29.7	16	23.2		
	Not done							3	8.8	4	9.8	7	9.3			4	10.8	4	5.8		
	Total	35	100.0	41	100.0	76	100.0	34	100.0	41	100.0	75	100.0	32	100.0	37	100.0	69	100.0		
WBC	Absent	21	63.6	19	55.9	40	59.7	19	59.4	14	41.2	33	50.0	21	70.0	15	48.4	36	59.0		
	Present	12	36.4	15	44.1	27	40.3	10	31.3	16	47.1	26	39.4	9	30.0	11	35.5	20	32.8		
	Not done							3	9.4	4	11.8	7	10.6			5	16.1	5	8.2		
	Total	33	100.0	34	100.0	67	100.0	32	100.0	34	100.0	66	100.0	30	100.0	31	100.0	61	100.0		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 67
URINALYSIS: NUMBER AND PERCENTAGE OF PATIENTS AT BASELINE AND LAST ASSESSMENT, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Reboxetine

Urinalysis		Baseline						Last assessment					
		Female		Male		Total		Female		Male		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
SPECIFIC GRAVITY	Normal	30	100.0	19	100.0	49	100.0	29	96.7	18	94.7	47	95.9
	Not done							1	3.3	1	5.3	2	4.1
	Total	30	100.0	19	100.0	49	100.0	30	100.0	19	100.0	49	100.0
ALBUMIN	Absent	43	93.5	34	100.0	77	96.3	39	84.8	32	94.1	71	88.8
	Present	3	6.5			3	3.8	6	13.0	2	5.9	8	10.0
	Not done							1	2.2			1	1.2
	Total	46	100.0	34	100.0	80	100.0	46	100.0	34	100.0	80	100.0
SUGAR	Absent	48	98.0	33	97.1	81	97.6	48	98.0	32	94.1	80	96.4
	Present	1	2.0	1	2.9	2	2.4			2	5.9	2	2.4
	Not done							1	2.0			1	1.2
	Total	49	100.0	34	100.0	83	100.0	49	100.0	34	100.0	83	100.0
RBC	Absent	32	69.6	20	71.4	52	70.3	31	67.4	22	78.6	53	71.6
	Present	14	30.4	8	28.6	22	29.7	14	30.4	6	21.4	20	27.0
	Not done							1	2.2			1	1.4
	Total	46	100.0	28	100.0	74	100.0	46	100.0	28	100.0	74	100.0
WBC	Absent	26	61.9	11	47.8	37	56.9	21	50.0	15	65.2	36	55.4
	Present	16	38.1	12	52.2	28	43.1	20	47.6	8	34.8	28	43.1
	Not done							1	2.4			1	1.5
	Total	42	100.0	23	100.0	65	100.0	42	100.0	23	100.0	65	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015

TABLE No.: 67

URINALYSIS: NUMBER AND PERCENTAGE OF PATIENTS AT BASELINE AND LAST ASSESSMENT, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Imipramine

Urinalysis		Baseline						Last assessment					
		Female		Male		Total		Female		Male		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
SPECIFIC GRAVITY	Normal	33	100.0	18	100.0	51	100.0	33	100.0	16	88.9	49	96.1
	Not done									2	11.1	2	3.9
	Total	33	100.0	18	100.0	51	100.0	33	100.0	18	100.0	51	100.0
ALBUMIN	Absent	44	91.7	27	93.1	71	92.2	39	81.3	25	86.2	64	83.1
	Present	4	8.3	2	6.9	6	7.8	7	14.6	1	3.4	8	10.4
	Not done							2	4.2	3	10.3	5	6.5
	Total	48	100.0	29	100.0	77	100.0	48	100.0	29	100.0	77	100.0
SUGAR	Absent	47	95.9	29	96.7	76	96.2	47	95.9	26	86.7	73	92.4
	Present	2	4.1	1	3.3	3	3.8			2	6.7	2	2.5
	Not done							2	4.1	2	6.7	4	5.1
	Total	49	100.0	30	100.0	79	100.0	49	100.0	30	100.0	79	100.0
RBC	Absent	36	76.6	21	75.0	57	76.0	31	66.0	18	64.3	49	65.3
	Present	11	23.4	7	25.0	18	24.0	14	29.8	7	25.0	21	28.0
	Not done							2	4.3	3	10.7	5	6.7
	Total	47	100.0	28	100.0	75	100.0	47	100.0	28	100.0	75	100.0
WBC	Absent	24	54.5	16	66.7	40	58.8	22	50.0	14	58.3	36	52.9
	Present	20	45.5	8	33.3	28	41.2	20	45.5	7	29.2	27	39.7
	Not done							2	4.5	3	12.5	5	7.4
	Total	44	100.0	24	100.0	68	100.0	44	100.0	24	100.0	68	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 67
URINALYSIS: NUMBER AND PERCENTAGE OF PATIENTS AT BASELINE AND LAST ASSESSMENT, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Placebo

Urinalysis		Baseline						Last assessment					
		Female		Male		Total		Female		Male		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
SPECIFIC GRAVITY	Normal	30	100.0	25	100.0	55	100.0	28	93.3	21	84.0	49	89.1
	Not done							2	6.7	4	16.0	6	10.9
	Total	30	100.0	25	100.0	55	100.0	30	100.0	25	100.0	55	100.0
ALBUMIN	Absent	35	94.6	39	90.7	74	92.5	35	94.6	36	83.7	71	88.8
	Present	2	5.4	4	9.3	6	7.5	1	2.7	2	4.7	3	3.8
	Not done							1	2.7	5	11.6	6	7.5
	Total	37	100.0	43	100.0	80	100.0	37	100.0	43	100.0	80	100.0
SUGAR	Absent	40	100.0	45	100.0	85	100.0	37	92.5	39	86.7	76	89.4
	Present							1	2.5	1	2.2	2	2.4
	Not done							2	5.0	5	11.1	7	8.2
	Total	40	100.0	45	100.0	85	100.0	40	100.0	45	100.0	85	100.0
RBC	Absent	26	74.3	25	61.0	51	67.1	30	85.7	24	58.5	54	71.1
	Present	9	25.7	16	39.0	25	32.9	5	14.3	13	31.7	18	23.7
	Not done									4	9.8	4	5.3
	Total	35	100.0	41	100.0	76	100.0	35	100.0	41	100.0	76	100.0
WBC	Absent	21	63.6	19	55.9	40	59.7	23	69.7	16	47.1	39	58.2
	Present	12	36.4	15	44.1	27	40.3	10	30.3	13	38.2	23	34.3
	Not done									5	14.7	5	7.5
	Total	33	100.0	34	100.0	67	100.0	33	100.0	34	100.0	67	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 68

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT URINALYSIS VALUE AT EACH EVALUATION TIME AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Urinalysis test at baseline		Days of treatment							
		1-21 days				22-42 days			
		Absent	Present	Not done	Total	Absent	Present	Not done	Total
ALBUMIN	Absent	72	3	1	76	64	4	1	69
	Present	1	1	1	3		3		3
	Total	73	4	2	79	64	7	1	72
SUGAR	Absent	78		2	80	71	1	1	73
	Present	1	1		2	1			1
	Total	79	1	2	82	72	1	1	74
RBC	Absent	46	3	2	51	41	6	1	48
	Present	11	11		22	7	10		17
	Total	57	14	2	73	48	16	1	65
WBC	Absent	34	1	1	36	28	4	1	33
	Present	5	23		28	5	18		23
	Total	39	24	1	64	33	22	1	56

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 68

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT URINALYSIS VALUE AT EACH EVALUATION TIME AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Urinalysis test at baseline		Days of treatment							
		1-21 days				22-42 days			
		Absent	Present	Not done	Total	Absent	Present	Not done	Total
ALBUMIN	Absent	61	4	5	70	50	5	4	59
	Present	4	2		6	1	2	1	4
	Total	65	6	5	76	51	7	5	63
SUGAR	Absent	71		4	75	57	1	4	62
	Present	2		1	3	2	1		3
	Total	73		5	78	59	2	4	65
RBC	Absent	44	7	5	56	38	7	3	48
	Present	4	12	2	18	3	8	2	13
	Total	48	19	7	74	41	15	5	61
WBC	Absent	28	7	4	39	29	4	2	35
	Present	5	21	2	28	3	13	3	19
	Total	33	28	6	67	32	17	5	54

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 68

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT URINALYSIS VALUE AT EACH EVALUATION TIME AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Placebo

Urinalysis test at baseline		Days of treatment								
		1-21 days				22-42 days				
		Absent	Present	Not done	Total	Absent	Present	Not done	Total
ALBUMIN	Absent	69	2	2	73	60		6	66
	Present	2	3	1	6	2	2		4
	Total	71	5	3	79	62	2	6	70
SUGAR	Absent	79	2	3	84	67	1	7	75
	Total	79	2	3	84	67	1	7	75
RBC	Absent	42	4	4	50	43	3	2	48
	Present	4	18	3	25	6	13	2	21
	Total	46	22	7	75	49	16	4	69
WBC	Absent	30	5	4	39	32	4	2	38
	Present	3	21	3	27	4	16	3	23
	Total	33	26	7	66	36	20	5	61

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 69

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT URINALYSIS VALUE AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Urinalysis test at baseline		Total				Last assessment									
						1-21 days				22-42 days					
		Absent	Present	Not done	Total	Absent	Present	Total		Absent	Present	Not done	Total		
ALBUMIN	Absent	71	5	1	77	7	1	8		64	4	1	69		
	Present		3		3						3		3		
	Total	71	8	1	80	7	1	8		64	7	1	72		
SUGAR	Absent	79	1	1	81	8		8		71	1	1	73		
	Present	1	1		2		1	1		1			1		
	Total	80	2	1	83	8	1	9		72	1	1	74		
RBC	Absent	45	6	1	52	4		4		41	6	1	48		
	Present	8	14		22	1	4	5		7	10		17		
	Total	53	20	1	74	5	4	9		48	16	1	65		
WBC	Absent	31	5	1	37	3	1	4		28	4	1	33		
	Present	5	23		28		5	5		5	18		23		
	Total	36	28	1	65	3	6	9		33	22	1	56		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 69

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT URINALYSIS VALUE AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Urinalysis test at baseline		Total				Last assessment						
						1-21 days			22-42 days			
		Absent	Present	Not done	Total	Absent	Present	Total	Absent	Present	Not done	Total
ALBUMIN	Absent	62	5	4	71	12		12	50	5	4	59
	Present	2	3	1	6	1	1	2	1	2	1	4
	Total	64	8	5	77	13	1	14	51	7	5	63
SUGAR	Absent	71	1	4	76	14		14	57	1	4	62
	Present	2	1		3				2	1		3
	Total	73	2	4	79	14		14	59	2	4	65
RBC	Absent	46	8	3	57	8	1	9	38	7	3	48
	Present	3	13	2	18		5	5	3	8	2	13
	Total	49	21	5	75	8	6	14	41	15	5	61
WBC	Absent	33	5	2	40	4	1	5	29	4	2	35
	Present	3	22	3	28		9	9	3	13	3	19
	Total	36	27	5	68	4	10	14	32	17	5	54

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 69

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT URINALYSIS VALUE AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Placebo

Urinalysis test at baseline		Total				Last assessment							
						1-21 days			22-42 days				
		Absent	Present	Not done	Total	Absent	Present	Total	Absent	Present	Not done	Total
ALBUMIN	Absent	68		6	74	8		8	60		6	66
	Present	3	3		6	1	1	2	2	2		4
	Total	71	3	6	80	9	1	10	62	2	6	70
SUGAR	Absent	76	2	7	85	9	1	10	67	1	7	75
	Total	76	2	7	85	9	1	10	67	1	7	75
RBC	Absent	46	3	2	51	3		3	43	3	2	48
	Present	8	15	2	25	2	2	4	6	13	2	21
	Total	54	18	4	76	5	2	7	49	16	4	69
WBC	Absent	34	4	2	40	2		2	32	4	2	38
	Present	5	19	3	27	1	3	4	4	16	3	23
	Total	39	23	5	67	3	3	6	36	20	5	61

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 70

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT EACH EVALUATION TIME AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT (SPECIFIC GRAVITY)

Assigned treatment: Reboxetine

Urinalysis test at baseline		Days of treatment					
		1-21 days			22-42 days		
		Normal	Not done	Total	Normal	Not done	Total
SPECIFIC GRAVITY	Normal	48	1	49	40	2	42
	Total	48	1	49	40	2	42

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 70

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT EACH EVALUATION TIME AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT (SPECIFIC GRAVITY)

Assigned treatment: Imipramine

Urinalysis test at baseline		Days of treatment					
		1-21 days			22-42 days		
		Normal	Not done	Total	Normal	Not done	Total
SPECIFIC GRAVITY	Normal	44	6	50	39	2	41
	Total	44	6	50	39	2	41

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 70

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT EACH EVALUATION TIME AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT (SPECIFIC GRAVITY)

Assigned treatment: Placebo

Urinalysis test at baseline		Days of treatment					
		1-21 days			22-42 days		
		Normal	Not done	Total	Normal	Not done	Total
SPECIFIC GRAVITY	Normal	50	5	55	42	6	48
	Total	50	5	55	42	6	48

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015

TABLE No.: 71

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT (SPECIFIC GRAVITY)

Assigned treatment: Reboxetine

Urinalysis test at baseline		Total			Last assessment					
					1-21 days			22-42 days		
		Normal	Not done	Total	Normal	Total	Normal	Not done	Total
SPECIFIC GRAVITY	Normal	47	2	49	7	7	40	2	42
	Total	47	2	49	7	7	40	2	42

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 71

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT (SPECIFIC GRAVITY)

Assigned treatment: Imipramine

Urinalysis test at baseline		Total			Last assessment					
					1-21 days			22-42 days		
		Normal	Not done	Total	Normal	Total	Normal	Not done	Total
SPECIFIC GRAVITY	Normal	49	2	51	10	10	39	2	41
	Total	49	2	51	10	10	39	2	41

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 71

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT (SPECIFIC GRAVITY)

Assigned treatment: Placebo

Urinalysis test at baseline		Total			Last assessment					
					1-21 days			22-42 days		
		Normal	Not done	Total	Normal	Total	Normal	Not done	Total
SPECIFIC GRAVITY	Normal	49	6	55	7	7	42	6	48
	Total	49	6	55	7	7	42	6	48

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 72

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment																					
		Imipramine								Placebo								Reboxetine					
		Days of treatment								Days of treatment								Days of treatment					
		1-21				22-42				1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
HB	LOW	3	3			4	2											6	4			4	3		
	NORMAL	3	67			2	61			1	89			4	74	1		1	72			1	66	2	
	HIGH			2	1.000			1	1.000			2	1.000			2	0.082		2	1	0.150		2	1	0.607
HT	LOW	8	3			7	4			1	4			2	2			5	4			5	2		
	NORMAL	4	58			1	53			5	72	1		7	61			5	61	1		2	59	1	
	HIGH				1.000		1	1	0.247				0.574				0.180		2		0.801		1		1.000
RBC	LOW	10	4			7	6			2	2			4	1			11	3			11	1		
	NORMAL	2	56	2		3	51			8	71	5		3	64	5		2	66			3	60	1	
	HIGH		2	1	0.717		1	1	0.368		1	3	0.044		1	3	0.160		1	4	0.549		1	3	0.607
PLATELETS	LOW	2				3				1				1				4				3	1		
	NORMAL		66	3			60	1			85	1		1	69	1		1	71	2		4	64	3	
	HIGH		2		1.000		1	1	1.000		2		1.000		2		0.513		1		0.513				0.091

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 72

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment																							
		Imipramine								Placebo								Reboxetine							
		Days of treatment								Days of treatment								Days of treatment							
		1-21				22-42				1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
WBC	LOW	4	3			4	3			2	2			2					6			2	4		
	NORMAL	1	66	3		4	56	2		2	80	2		1	69	4			73	3		2	62	4	
	HIGH			1	0.135			1	0.343		3	1	0.905		2	3	0.435		3	2	0.050		4	2	0.717
WBC: N	LOW	5	2	1		6	2			6	3			4	2			6	6			5	8		
	NORMAL	1	51	5		1	50	4		3	61	7		3	60	5		3	51	5		2	47	8	
	HIGH		3	3	0.424		2	2	0.607		5		0.846		3	1	0.705		5	3	0.607		5	4	0.117
WBC: E	LOW	3		1		1	3	1		5	1	1		6	2			3	8			6	5		
	NORMAL	10	51	2		3	51	2		6	60	3		5	52	4		1	57	5		2	57	5	
	HIGH		1	2	0.009		1	3	0.595		5	3	0.363		3	5	0.490		2	1	0.035		1	2	0.139
WBC: B	LOW									1				1				2					2		
	NORMAL	2	60	2			58	3		1	75	3			69	3		2	70	3			72	3	
	HIGH	1	2		0.223	1	1	1	0.368		2		0.549				0.250				0.082				0.082
WBC: L	LOW	8	4			4	5			3	4			2	4			4	6			6	4		
	NORMAL	3	43	2		6	37	4		3	65	5		4	58	5		3	50	6		2	51	3	
	HIGH	1	7	8	0.162		7	7	0.635		5	6	0.931		4	4	0.946		10	3	0.368		9	4	0.160
WBC: M	LOW	5	11			7	4			2	8			2	6			2	10	1		6	7		
	NORMAL	3	49	1		5	47	2		5	63	3		5	56	3		3	56	3		5	51	4	
	HIGH		3	3	0.062	1	1	3	0.815		8	2	0.227	1	4	4	0.777	1	4	1	0.158		4	2	0.846

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 72

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment																							
		Imipramine								Placebo								Reboxetine							
		Days of treatment								Days of treatment								Days of treatment							
		1-21				22-42				1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
CREATININE	LOW	3				2					2				2			2	2			3	1		
	NORMAL		73	4		2	66			3	74	4			67	3		2	75	3		1	73	2	
	HIGH		2	2	0.688		2	3	0.135		5	3	0.856		4	1	0.343		1	3	0.607		2	2	1.000
UREA	LOW	1				1												1	6			2	5		
	NORMAL	3	39	3		1	37	3		2	43	3		3	35	3		1	39	1		3	35	1	
	HIGH		2		0.202		1	1	0.368		2		0.333				0.050		3		0.102		2	1	0.659
BUN	LOW																								
	NORMAL	1	29	1			24			1	31	2			28	1			32	1			24	2	
	HIGH				0.368				1.000		1		0.513				1.000			3	1.000		2	1	1.000
URIC ACID	LOW	4	3			4	2			1	4			1	2			2	2			2	2		
	NORMAL	2	56	3			50	4		3	63	6		4	59	2		5	56	7		2	61	6	
	HIGH		1	3	0.549		2	3	0.264		4	4	0.762		4	4	0.513		4	3	0.349		2	4	0.368

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 72

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment																							
		Imipramine								Placebo								Reboxetine							
		Days of treatment								Days of treatment								Days of treatment							
		1-21				22-42				1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
TOT. PROTEINS	LOW	1	2			1	2			2	1				3			2	3			1	4		
	NORMAL	1	74	1		1	59	3		4	76	1		4	59	4		2	73	2		1	69	1	
	HIGH			2	0.513		1	3	0.513		2	2	0.344		3		0.867	1	2	2	0.902	1	4		0.143
ALBUMINE	LOW	1	2	1		1	2			2	1			1	1			2	2	1		4	1	1	
	NORMAL	3	56	3		1	45	7		4	63	4		3	52	4		3	52	5		5	50	3	
	HIGH		5	10	0.945		4	7	0.562		2	12	0.291		1	11	0.247		6	10	1.000	1	5	9	0.349
TOT BILIRUBIN	LOW										1				1										
	NORMAL	1	75	1		3	63	1		1	81	3			68	1			83				76	1	
	HIGH		2	2	0.513		3	2	0.135		3	2	1.000		2	1	0.513		4	2	0.125		4	1	0.375
DIR BILIRUBIN	LOW																								
	NORMAL		28	1		2	22				37				30				33				29		
	HIGH		1	1	1.000		1	1	0.223			1	1.000			1	1.000		2	1	0.500		2		0.500

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 72

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment																					
		Imipramine								Placebo								Reboxetine					
		Days of treatment								Days of treatment								Days of treatment					
		1-21				22-42				1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
SGOT	LOW		1			1					1								1				1		
	NORMAL		70	3			62	6			79	1		1	65	2			79	1			69	5	
	HIGH		5	1	0.472		3	2	0.508		4	3	0.247		6	2	0.223		6	1	0.102		8	1	0.429
SGPT	LOW	1	3				5											1	3			1	3		
	NORMAL	1	62	4			49	9		2	68	4		2	58	2		2	69				63	3	
	HIGH		2	2	0.435		2	3	0.009		5	2	0.348		5	2	0.193		6	3	0.045		6	3	0.135
GAMMA GT	LOW	2					1																		
	NORMAL	1	54	3			43	5			71	3			55	2		2	65	1			60	4	
	HIGH	1	3	11	0.368		2	11	0.319		7	7	0.344		5	10	0.453		5	9	0.097		7	5	0.549
LDH	LOW	6	3			4	1	1		10	4			8	4			10	1			5	3		
	NORMAL	3	47	6		2	40	4		5	49	3		2	42	2		1	51	3			47	6	
	HIGH		1	2	0.168		1	1	0.249			5	0.211		3	3	0.648		2	4	0.905		1	6	0.037
ALK. PHOSPH.	LOW	3	2			1	4		-	2	5			1	4			4	3			3	4		
	NORMAL	2	64	2		2	56	4		1	74	2		3	63			2	68	3		3	65	2	
	HIGH		1	5	0.846		1	5	0.291		2	5	0.264		2	4	0.343		3	4	0.905		3	4	0.842

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 72

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment																							
		Imipramine								Placebo								Reboxetine							
		Days of treatment								Days of treatment								Days of treatment							
		1-21				22-42				1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
GLOBULINS ALPHA 1	LOW	2	1			1	3			1	3				2				4	1		1	2		
	NORMAL	1	47	3		2	37	2		2	58	1		1	46	3			48	3		1	50	3	
	HIGH		4	1	0.931		3	1	0.819		2		0.766		2		0.766		3		0.082		2	1	0.766
GLOBULINS ALPHA 2	LOW	2	1			2	3				2				1				2			1	2		
	NORMAL	2	42	2		1	30	6		3	54	3		1	45	2		2	47	3		3	43	7	
	HIGH		6	4	0.311		3	4	0.368		3	2	0.905		4	1	0.717		3	2	1.000	1	1	2	0.143
GLOBULINS BETA	LOW									2	2				2				2			3	1		
	NORMAL	4	40	6		4	33	4		1	45	5			41	2		1	42	5		2	43	4	
	HIGH		4	5	0.111		3	5	0.126		5	7	0.846		5	4	0.193	1	4	4	1.000		5	2	0.801
GLOBULINS GAMMA	LOW	3	5			1	3			7	5			8	5			3	6			3	6		
	NORMAL	1	44	3		1	42	1		2	44	4		3	31	3		4	38	2		4	38	1	
	HIGH		1	2	0.160		1		0.607		1	4	0.214		1	3	0.472	1	4	1	0.479		5	3	0.216

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 72

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment																							
		Imipramine								Placebo								Reboxetine							
		Days of treatment								Days of treatment								Days of treatment							
		1-21				22-42				1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
TOT. CHOLEST.	LOW	1	1	1			3			2	1			2	1			2				1	1		
	NORMAL	1	41	9		1	36	7		2	46	4		2	38	2		2	46	5		4	46	1	
	HIGH		6	18	0.551		6	15	0.584		12	20	0.115		10	19	0.059		12	17	0.087	1	10	14	0.007
TRIGLYCERIDES	LOW		2				1				1							2	2			2	3		
	NORMAL	1	49	8		1	45	3		4	52	11		3	47	7		3	51	6		2	46	6	
	HIGH		5	12	0.599		6	10	0.607	1	3	15	0.036		5	10	0.189	1	9	9	0.469		9	9	0.670
GLUCOSE	LOW	1	3			2	2				2			1	1				4				4		
	NORMAL	1	66	2		2	52	5		3	75	6		4	62	5		7	60	6		2	57	7	
	HIGH	1	5	2	0.292		7	3	0.846		2	2	0.333		2	2	0.214		8	4	0.576		4	7	0.476

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 72

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment																							
		Inipramine								Placebo								Reboxetine							
		Days of treatment								Days of treatment								Days of treatment							
		1-21				22-42				1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
NA+	LOW		2				1				1								6				5		
	NORMAL	4	76			2	70			3	80	1		2	72			1	79	1			76		
	HIGH				0.688				1.000		4	1	0.247		3		0.082		2	1	0.142		3		0.018
CL-	LOW	1	2			1				1	4	1			5			1	5			1	4		
	NORMAL	7	57	2		1	57			2	55	10			51	6			64	1		1	56	2	
	HIGH		3	1	0.226		3	1	0.135		4	2	0.123		4	1	0.067		6	4	0.014		5	4	0.214
K+	LOW	2	3			2	3			2				3				1	4			1	4		
	NORMAL	3	66	5		2	62	3		4	75	4		2	66	1		3	71	6		4	65	5	
	HIGH		3		0.779		2		0.819		3		0.126		2	2	0.311		1	2	0.156		1	2	0.264
Ca++	LOW	2				3					3			2	2			2	2			2	3		
	NORMAL	9	62	2		5	57	2		6	75	1		3	64	1			75	3		2	69	1	
	HIGH				0.004				0.030		1		0.607		1		0.905		1		0.223		1		0.905
PO4--	LOW	2				2	1			1	2			1	2				3	1			2		
	NORMAL	3	58	3			56	3		2	68	3			59	4		3	67	3		3	58	3	
	HIGH		1	2	0.135		1	1	0.368		8	1	0.321		5	2	0.348		3	1	0.882		6	1	0.549

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 73

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment			Days of treatment					
			Screen		1-21		22-42	
			No	%	No	%	No	%
HT	Placebo	Eval.	89	100.0	84	100.0	72	100.0
		down					1	1.4
	Reboxetine	Eval.	83	100.0	78	100.0	70	100.0
		down	1	1.2				
RBC	Imipramine	Eval.	87	100.0	77	100.0	70	100.0
		down	1	1.1				
	Placebo	Eval.	98	100.0	93	100.0	81	100.0
		down					1	1.2
	Reboxetine	Eval.	93	100.0	87	100.0	80	100.0
		down	2	2.2	1	1.1		
PLATELETS	Imipramine	Eval.	83	100.0	73	100.0	67	100.0
		down	1	1.2				
	Placebo	Eval.	93	100.0	89	100.0	74	100.0
		down	1	1.1	1	1.1	1	1.4
	Reboxetine	Eval.	88	100.0	79	100.0	75	100.0
		down	1	1.1			2	2.7
WBC	Imipramine	Eval.	87	100.0	78	100.0	71	100.0
		down	1	1.1	1	1.3	1	1.4
		up					1	1.4
	Placebo	Eval.	98	100.0	93	100.0	81	100.0
		up	2	2.0	1	1.1		
	Reboxetine	Eval.	93	100.0	87	100.0	80	100.0
		down	1	1.1			1	1.2

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 73

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment			Days of treatment					
			Screen		1-21		22-42	
			No	%	No	%	No	%
WBC	Reboxetine	up			2	2.3		
WBC: N	Imipramine	Eval.	81	100.0	71	100.0	68	100.0
		down	1	1.2				
	Placebo	Eval.	93	100.0	86	100.0	78	100.0
		down	1	1.1	1	1.2	1	1.3
	Reboxetine	Eval.	88	100.0	79	100.0	79	100.0
		down	2	2.3				
		up	1	1.1	1	1.3	1	1.3
WBC: E	Imipramine	Eval.	80	100.0	70	100.0	66	100.0
		up	2	2.5	5	7.1	5	7.6
	Placebo	Eval.	92	100.0	85	100.0	77	100.0
		up	7	7.6	3	3.5	6	7.8
	Reboxetine	Eval.	87	100.0	77	100.0	78	100.0
		up	3	3.4	4	5.2	5	6.4
WBC: B	Imipramine	Eval.	78	100.0	67	100.0	65	100.0
		up	1	1.3	1	1.5	2	3.1
	Placebo	Eval.	90	100.0	83	100.0	73	100.0
		up	1	1.1	1	1.2	3	4.1
	Reboxetine	Eval.	86	100.0	77	100.0	77	100.0
		up			3	3.9	2	2.6
WBC: L	Imipramine	Eval.	87	100.0	76	100.0	71	100.0
		down	1	1.1	6	7.9	2	2.8
		up	2	2.3	2	2.6	2	2.8

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 73

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment			Days of treatment					
			Screen		1-21		22-42	
			No	%	No	%	No	%
WBC: L	Placebo	Eval.	98	100.0	92	100.0	81	100.0
		down	1	1.0	2	2.2	1	1.2
		up	2	2.0	2	2.2	2	2.5
	Reboxetine	Eval.	91	100.0	82	100.0	79	100.0
		down	4	4.4	2	2.4	4	5.1
		up	4	4.4	1	1.2	2	2.5
WBC: M	Imipramine	Eval.	87	100.0	75	100.0	71	100.0
		up	4	4.6	1	1.3	2	2.8
	Placebo	Eval.	98	100.0	92	100.0	81	100.0
		up	4	4.1			1	1.2
	Reboxetine	Eval.	91	100.0	81	100.0	79	100.0
		up	4	4.4	2	2.5	4	5.1
CREATININE	Imipramine	Eval.	92	100.0	84	100.0	76	100.0
		up			1	1.2		
BUN	Placebo	Eval.	35	100.0	35	100.0	29	100.0
		up	1	2.9				
	Reboxetine	Eval.	37	100.0	36	100.0	29	100.0
		up					1	3.4
URIC ACID	Imipramine	Eval.	80	100.0	72	100.0	66	100.0
		up	1	1.2	1	1.4	2	3.0
	Placebo	Eval.	90	100.0	85	100.0	76	100.0
		up			2	2.4	1	1.3
	Reboxetine	Eval.	86	100.0	79	100.0	79	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 73

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment			Days of treatment					
			Screen		1-21		22-42	
			No	%	No	%	No	%
URIC ACID	Reboxetine	up			2	2.5	1	1.3
ALBUMINE	Placebo	Eval.	93	100.0	88	100.0	73	100.0
		up					1	1.4
TOT BILIRUBIN	Reboxetine	Eval.	93	100.0	89	100.0	82	100.0
		up			1	1.1		
DIR BILIRUBIN	Placebo	Eval.	39	100.0	38	100.0	31	100.0
		up	1	2.6	1	2.6	1	3.2
	Reboxetine	Eval.	39	100.0	36	100.0	31	100.0
		up	1	2.6				
SGOT	Imipramine	Eval.	90	100.0	80	100.0	75	100.0
		up	2	2.2	1	1.2	3	4.0
	Placebo	Eval.	95	100.0	88	100.0	76	100.0
		up	2	2.1				
	Reboxetine	Eval.	94	100.0	88	100.0	84	100.0
		up	2	2.1			1	1.2
SGPT	Imipramine	Eval.	84	100.0	75	100.0	69	100.0
		up	2	2.4	3	4.0	2	2.9
	Placebo	Eval.	88	100.0	81	100.0	69	100.0
		up	2	2.3	3	3.7	1	1.4
	Reboxetine	Eval.	89	100.0	84	100.0	79	100.0
		up	1	1.1			1	1.3
GAMMA GT	Imipramine	Eval.	82	100.0	75	100.0	62	100.0
		up	9	11.0	6	8.0	9	14.5

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 73

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment			Days of treatment					
			Screen		1-21		22-42	
			No	%	No	%	No	%
GAMMA GT	Placebo	Eval.	95	100.0	88	100.0	72	100.0
		up	4	4.2	2	2.3		
	Reboxetine	Eval.	88	100.0	82	100.0	76	100.0
		up	5	5.7	3	3.7	3	3.9
LDH	Placebo	Eval.	82	100.0	76	100.0	64	100.0
		up	1	1.2				
ALK. PHOSPH.	Imipramine	Eval.	88	100.0	79	100.0	74	100.0
		up					1	1.4
	Placebo	Eval.	97	100.0	91	100.0	77	100.0
		up	1	1.0	1	1.1	1	1.3
GLOBULINS ALPHA 1	Imipramine	Eval.	67	100.0	59	100.0	49	100.0
		up			1	1.7		
	Placebo	Eval.	71	100.0	67	100.0	54	100.0
		down	3	4.2				
		up	2	2.8				
	Reboxetine	Eval.	67	100.0	59	100.0	60	100.0
		down	1	1.5			1	1.7
GLOBULINS ALPHA 2	Imipramine	Eval.	67	100.0	59	100.0	49	100.0
		down					1	2.0
		up			1	1.7		
	Placebo	Eval.	71	100.0	67	100.0	54	100.0
		up			1	1.5	1	1.9
	Reboxetine	Eval.	67	100.0	59	100.0	60	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 73

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment			Days of treatment					
			Screen		1-21		22-42	
			No	%	No	%	No	%
GLOBULINS ALPHA 2	Reboxetine	up	1	1.5	1	1.7	2	3.3
GLOBULINS BETA	Imipramine	Eval.	67	100.0	59	100.0	49	100.0
		up	1	1.5	1	1.7		
	Placebo	Eval.	71	100.0	67	100.0	54	100.0
		up			1	1.5		
	Reboxetine	Eval.	67	100.0	59	100.0	60	100.0
		up	2	3.0	2	3.4		
GLOBULINS GAMMA	Imipramine	Eval.	67	100.0	59	100.0	49	100.0
		down					1	2.0
	Placebo	Eval.	71	100.0	67	100.0	54	100.0
		up			1	1.5	1	1.9
	Reboxetine	Eval.	67	100.0	59	100.0	60	100.0
		up	1	1.5			1	1.7
TOT. CHOLEST.	Imipramine	Eval.	87	100.0	78	100.0	69	100.0
		up	7	8.0	7	9.0	6	8.7
	Placebo	Eval.	94	100.0	87	100.0	74	100.0
		up	6	6.4	2	2.3	2	2.7
	Reboxetine	Eval.	90	100.0	84	100.0	78	100.0
		up	7	7.8	4	4.8	4	5.1
TRIGLYCERIDES	Imipramine	Eval.	86	100.0	77	100.0	67	100.0
		up	10	11.6	9	11.7	4	6.0
	Placebo	Eval.	93	100.0	87	100.0	72	100.0
		up	11	11.8	15	17.2	8	11.1

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 73

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment			Days of treatment					
			Screen		1-21		22-42	
			No	%	No	%	No	%
TRIGLYCERIDES	Reboxetine	Eval.	89	100.0	83	100.0	77	100.0
		up	9	10.1	10	12.0	9	11.7
GLUCOSE	Imipramine	Eval.	90	100.0	81	100.0	74	100.0
		up	1	1.1				
	Placebo	Eval.	97	100.0	90	100.0	77	100.0
		up			1	1.1	1	1.3
	Reboxetine	Eval.	95	100.0	89	100.0	81	100.0
		up	2	2.1	3	3.4	2	2.5
CL-	Placebo	Eval.	85	100.0	79	100.0	67	100.0
		down	1	1.2				
	Reboxetine	Eval.	86	100.0	81	100.0	73	100.0
		down	1	1.2				
K+	Imipramine	Eval.	91	100.0	82	100.0	75	100.0
		down	1	1.1	1	1.2	1	1.3
		up					1	1.3
	Placebo	Eval.	95	100.0	88	100.0	76	100.0
		down			1	1.1	1	1.3
		up	3	3.2			2	2.6
	Reboxetine	Eval.	95	100.0	88	100.0	82	100.0
		down					1	1.2
		up			1	1.1	1	1.2
PO4--	Imipramine	Eval.	76	100.0	69	100.0	65	100.0
		down	1	1.3	3	4.3		

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 73

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment			Days of treatment					
			Screen		1-21		22-42	
			No	%	No	%	No	%
P04--	Imipramine	up			3	4.3	1	1.5
	Placebo	Eval.	89	100.0	85	100.0	73	100.0
		down	1	1.1	1	1.2	1	1.4
		up	3	3.4	2	2.4	3	4.1
	Reboxetine	Eval.	86	100.0	81	100.0	73	100.0
		down	1	1.2	2	2.5	1	1.4
		up	4	4.7	2	2.5	2	2.7

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 74

BLOOD PRESSURE AND HEART RATE: SUMMARY STATISTICS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Vital signs		LYING							STANDING						
		time interval							time interval						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
S.B.P.	Evaluated	111	111	105	98	96	90	87	111	111	105	98	96	89	87
	Mean	126.5	125.2	126.9	125.3	125.7	125.5	126.7	123.9	121.9	122.9	121.7	122.4	122.9	121.5
	STD	14.5	14.3	14.2	13.8	13.4	13.0	15.5	14.4	16.6	17.1	14.5	14.6	15.2	15.2
	Median	125.0	125.0	130.0	125.0	125.0	125.0	125.0	120.0	120.0	125.0	120.0	120.0	120.0	120.0
	Min	95.0	95.0	98.0	100.0	90.0	100.0	95.0	90.0	70.0	70.0	85.0	90.0	80.0	80.0
	Max	160.0	160.0	170.0	160.0	150.0	170.0	186.0	160.0	165.0	170.0	160.0	155.0	155.0	150.0
D.B.P.	Evaluated	111	111	105	98	96	90	87	111	111	105	97	96	89	87
	Mean	79.1	77.9	78.0	77.0	78.8	79.2	78.9	78.1	77.1	77.2	76.8	78.7	78.7	77.4
	STD	9.3	9.7	10.3	9.5	10.9	10.3	10.8	10.1	11.0	11.3	10.2	10.3	10.4	10.3
	Median	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0
	Min	60.0	50.0	50.0	50.0	50.0	60.0	60.0	50.0	40.0	50.0	50.0	50.0	60.0	50.0
	Max	110.0	102.0	120.0	100.0	120.0	112.0	114.0	105.0	105.0	100.0	100.0	110.0	110.0	102.0
Heart Rate	Evaluated	107	106	102	90	88	86	82	106	105	101	90	88	87	82
	Mean	75.5	76.9	78.4	76.2	77.3	76.7	76.7	78.7	81.1	82.5	80.8	80.4	81.1	80.3
	STD	8.4	9.7	9.5	8.8	8.0	9.6	9.9	9.3	11.8	11.4	11.9	9.0	10.5	10.8
	Median	74.0	76.0	78.0	75.0	76.0	76.0	76.0	78.0	80.0	80.0	80.0	80.0	80.0	80.0
	Min	60.0	52.0	54.0	60.0	60.0	60.0	60.0	58.0	60.0	60.0	61.0	62.0	60.0	60.0
	Max	110.0	105.0	100.0	104.0	100.0	100.0	100.0	118.0	140.0	120.0	120.0	113.0	116.0	125.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 74

BLOOD PRESSURE AND HEART RATE: SUMMARY STATISTICS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Vital signs		LYING							STANDING						
		time interval							time interval						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
S.B.P.	Evaluated	111	111	101	90	87	81	76	110	110	100	90	86	81	75
	Mean	126.4	123.5	124.0	125.0	122.7	123.7	125.1	124.0	120.3	119.9	121.0	120.2	119.7	120.2
	STD	13.1	12.8	12.7	13.5	11.7	12.9	14.9	12.6	14.3	13.9	13.9	14.0	12.6	15.2
	Median	130.0	120.0	120.0	125.0	125.0	125.0	126.5	125.0	120.0	120.0	120.0	120.0	120.0	120.0
	Min	100.0	95.0	95.0	95.0	92.0	90.0	90.0	90.0	80.0	80.0	90.0	70.0	80.0	80.0
	Max	160.0	160.0	170.0	165.0	150.0	160.0	160.0	165.0	150.0	160.0	165.0	160.0	150.0	160.0
D.B.P.	Evaluated	111	111	101	90	87	81	76	110	110	100	90	86	81	75
	Mean	78.5	77.6	77.7	78.4	77.4	76.6	78.0	78.8	76.7	76.8	77.2	77.2	76.2	77.0
	STD	9.4	8.5	8.9	9.9	9.3	10.2	10.7	8.9	8.1	9.3	9.6	10.7	9.9	9.5
	Median	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0
	Min	50.0	60.0	60.0	50.0	60.0	50.0	60.0	60.0	60.0	50.0	50.0	50.0	50.0	50.0
	Max	100.0	100.0	95.0	105.0	110.0	100.0	100.0	105.0	95.0	100.0	105.0	120.0	100.0	100.0
Heart Rate	Evaluated	104	100	93	86	82	76	71	99	96	90	83	77	69	67
	Mean	77.2	77.6	76.3	78.3	78.6	78.3	79.1	79.6	80.4	80.3	81.5	81.3	79.4	82.0
	STD	10.0	9.2	8.7	10.7	9.0	9.0	11.0	11.1	11.5	10.2	11.9	11.9	10.2	11.4
	Median	76.0	78.0	76.0	78.0	78.0	80.0	78.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0
	Min	56.0	60.0	56.0	60.0	60.0	60.0	55.0	58.0	60.0	60.0	60.0	60.0	64.0	55.0
	Max	112.0	100.0	107.0	110.0	100.0	112.0	110.0	128.0	134.0	112.0	112.0	124.0	132.0	111.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 74

BLOOD PRESSURE AND HEART RATE: SUMMARY STATISTICS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Placebo

Vital signs		LYING							STANDING						
		time interval							time interval						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
S.B.P.	Evaluated	110	108	103	100	94	87	86	109	107	101	98	92	86	85
	Mean	123.3	124.7	124.3	124.9	125.4	123.6	122.5	122.0	123.7	122.5	122.1	123.6	122.0	122.5
	STD	13.7	12.9	12.5	15.4	12.7	13.7	14.1	14.0	14.4	15.1	14.5	13.6	15.3	13.5
	Median	120.0	128.0	125.0	123.0	130.0	125.0	120.0	120.0	125.0	120.0	120.0	125.0	120.0	120.0
	Min	100.0	100.0	95.0	90.0	95.0	94.0	92.0	95.0	95.0	90.0	90.0	95.0	90.0	95.0
	Max	160.0	160.0	158.0	180.0	160.0	160.0	190.0	160.0	160.0	180.0	185.0	165.0	170.0	180.0
D.B.P.	Evaluated	110	107	103	100	94	87	86	109	106	101	98	92	86	85
	Mean	76.7	77.6	76.2	77.1	78.5	76.6	75.8	77.1	78.0	76.9	76.7	78.6	77.6	76.3
	STD	9.2	9.0	8.6	10.4	9.1	8.8	9.8	10.0	9.9	9.8	10.8	10.3	9.4	9.6
	Median	80.0	80.0	76.0	80.0	80.0	80.0	76.5	80.0	80.0	79.0	77.5	80.0	80.0	76.0
	Min	60.0	50.0	60.0	50.0	60.0	60.0	60.0	60.0	55.0	60.0	55.0	50.0	50.0	55.0
	Max	105.0	100.0	100.0	110.0	105.0	100.0	100.0	110.0	110.0	115.0	120.0	115.0	105.0	105.0
Heart Rate	Evaluated	105	104	96	94	84	79	78	104	101	96	93	83	78	76
	Mean	74.7	75.5	75.0	73.8	73.7	73.9	71.5	77.2	78.0	77.2	77.1	76.4	76.7	74.3
	STD	9.2	7.5	7.5	8.1	8.4	7.5	7.5	10.0	8.1	8.3	9.7	8.5	7.9	8.3
	Median	76.0	76.0	76.0	72.0	72.0	72.0	72.0	76.0	78.0	76.0	78.0	76.0	76.0	74.0
	Min	56.0	58.0	56.0	58.0	56.0	60.0	50.0	48.0	56.0	56.0	58.0	58.0	58.0	50.0
	Max	100.0	96.0	96.0	100.0	98.0	92.0	86.0	120.0	104.0	98.0	120.0	104.0	100.0	92.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 75

BLOOD PRESSURE AND HEART RATE: SUMMARY STATISTICS ON CHANGES FROM BASELINE OBSERVED DURING TREATMENT ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Vital signs		LYING						STANDING					
		Time interval						Time interval					
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
S.B.P.	Evaluated	111	105	98	96	90	87	111	105	98	96	89	87
	Mean	-1.4	-0.1	-2.0	-1.4	-1.2	-0.1	-2.1	-1.5	-3.2	-2.4	-1.9	-3.2
	STD	10.3	11.6	12.0	11.5	11.5	11.2	10.1	12.7	10.9	12.2	13.0	11.2
	Median	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0
	Min	-34.0	-40.0	-40.0	-38.0	-26.0	-32.0	-44.0	-34.0	-30.0	-44.0	-60.0	-36.0
	Max	32.0	30.0	20.0	30.0	25.0	36.0	35.0	40.0	20.0	30.0	25.0	30.0
D.B.P.	Evaluated	111	105	98	96	90	87	111	105	97	96	89	87
	Mean	-1.2	-1.4	-2.5	-0.8	-0.0	-0.4	-1.1	-1.1	-1.7	0.3	0.5	-0.9
	STD	6.5	8.3	8.9	9.5	9.2	9.4	7.2	7.7	8.0	8.4	9.5	8.8
	Median	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	Min	-20.0	-30.0	-30.0	-34.0	-30.0	-30.0	-26.0	-20.0	-30.0	-24.0	-40.0	-32.0
	Max	20.0	20.0	25.0	30.0	20.0	30.0	20.0	20.0	20.0	30.0	30.0	20.0
Heart Rate	Evaluated	106	102	90	88	86	82	105	101	90	88	87	82
	Mean	1.6	2.7	0.3	1.4	1.0	1.4	2.4	3.6	1.8	1.2	2.1	1.1
	STD	7.7	8.6	9.3	8.4	9.6	10.4	9.6	10.4	10.3	8.7	10.3	10.2
	Median	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.5	0.0	0.0
	Min	-20.0	-14.0	-26.0	-20.0	-26.0	-22.0	-19.0	-15.0	-24.0	-20.0	-34.0	-34.0
	Max	32.0	28.0	36.0	20.0	30.0	30.0	36.0	47.0	40.0	20.0	30.0	25.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 75

BLOOD PRESSURE AND HEART RATE: SUMMARY STATISTICS ON CHANGES FROM BASELINE OBSERVED DURING TREATMENT ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Vital signs		LYING						STANDING					
		Time interval						Time interval					
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
S.B.P.	Evaluated	111	101	90	87	81	76	110	100	90	86	81	75
	Mean	-2.9	-2.7	-2.1	-4.1	-2.4	-1.9	-3.7	-4.3	-3.1	-4.1	-3.8	-3.6
	STD	8.8	12.6	11.5	11.5	12.7	14.6	12.3	13.6	12.9	13.2	14.5	16.6
	Median	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.0	-1.0	-5.0	-3.0
	Min	-38.0	-60.0	-40.0	-50.0	-40.0	-41.0	-55.0	-70.0	-65.0	-45.0	-55.0	-55.0
	Max	20.0	30.0	30.0	20.0	30.0	40.0	35.0	20.0	25.0	30.0	30.0	40.0
D.B.P.	Evaluated	111	101	90	87	81	76	110	100	90	86	81	75
	Mean	-0.9	-1.1	-0.5	-1.1	-1.6	-0.4	-2.1	-2.4	-2.1	-2.1	-2.8	-2.0
	STD	8.7	9.9	9.5	8.5	9.8	8.9	8.4	8.9	8.3	9.8	9.7	9.9
	Median	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	Min	-30.0	-30.0	-24.0	-20.0	-20.0	-20.0	-30.0	-30.0	-30.0	-20.0	-30.0	-30.0
	Max	20.0	30.0	26.0	20.0	20.0	20.0	30.0	20.0	20.0	30.0	20.0	20.0
Heart Rate	Evaluated	100	93	86	82	76	71	96	90	83	77	69	67
	Mean	0.1	-0.9	0.5	1.3	1.3	1.6	0.5	0.4	1.0	1.2	-0.2	1.7
	STD	6.6	9.1	11.1	8.4	10.3	11.8	9.0	9.7	11.2	9.2	9.4	11.0
	Median	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0
	Min	-24.0	-28.0	-31.0	-21.0	-24.0	-28.0	-28.0	-27.0	-34.0	-21.0	-30.0	-24.0
	Max	24.0	30.0	40.0	20.0	42.0	50.0	30.0	30.0	30.0	26.0	28.0	40.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 75

BLOOD PRESSURE AND HEART RATE: SUMMARY STATISTICS ON CHANGES FROM BASELINE OBSERVED DURING TREATMENT ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Placebo

Vital signs		LYING						STANDING					
		Time interval						Time interval					
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
S.B.P.	Evaluated	108	103	100	94	87	86	107	101	98	92	86	85
	Mean	1.4	1.4	1.8	1.9	0.2	-0.9	1.6	0.5	0.6	1.8	-0.3	-0.1
	STD	10.7	11.9	12.6	12.5	12.4	12.4	11.0	12.7	13.0	12.9	13.3	12.2
	Median	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	Min	-30.0	-40.0	-30.0	-40.0	-35.0	-40.0	-30.0	-50.0	-35.0	-30.0	-35.0	-30.0
	Max	40.0	40.0	36.0	40.0	30.0	30.0	40.0	55.0	35.0	50.0	50.0	30.0
D.B.P.	Evaluated	107	103	100	94	87	86	106	101	98	92	86	85
	Mean	0.8	-0.2	0.6	2.0	0.2	-0.8	0.7	-0.2	-0.4	1.8	1.0	-0.8
	STD	7.7	8.0	9.0	9.1	9.2	9.9	8.4	7.8	10.9	9.8	9.0	8.4
	Median	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	Min	-30.0	-30.0	-30.0	-30.0	-30.0	-40.0	-30.0	-25.0	-40.0	-30.0	-30.0	-30.0
	Max	20.0	20.0	30.0	20.0	20.0	20.0	20.0	20.0	30.0	25.0	20.0	20.0
Heart Rate	Evaluated	104	96	94	84	79	78	101	96	93	83	78	76
	Mean	0.8	0.5	-0.2	-0.0	0.5	-1.6	0.7	0.2	0.2	0.1	0.3	-1.8
	STD	7.1	7.5	9.0	8.3	8.2	8.6	7.6	8.8	10.2	9.1	9.3	10.2
	Median	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.5
	Min	-20.0	-20.0	-30.0	-26.0	-24.0	-32.0	-30.0	-36.0	-30.0	-26.0	-30.0	-36.0
	Max	30.0	30.0	36.0	28.0	24.0	22.0	24.0	35.0	35.0	29.0	23.0	24.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 76

BLOOD PRESSURE AND HEART RATE: NUMBER AND PERCENTAGE OF PATIENTS WITH DECREASE OR INCREASE *vs* BASELINE OF CLINICAL RELEVANCE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Vital signs			LYING						STANDING					
			time intervals						time intervals					
			Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
S.B.P.	Evaluated	No	111	105	98	96	90	87	111	105	98	96	89	87
	Decrease (1)	No	1		3			1		4	1	1		1
		%	0.9		3.1			1.1		3.8	1.0	1.0		1.1
	Increase (2)	No	1				1	1		1			1	1
		%	0.9				1.1	1.1		1.0			1.1	1.1
D.B.P.	Evaluated	No	111	105	98	96	90	87	111	105	97	96	89	87
	Decrease (1)	No	2	4	5	1	3	2		1	2	1	1	2
		%	1.8	3.8	5.1	1.0	3.3	2.3		1.0	2.1	1.0	1.1	2.3
	Increase (2)	No		2	1	4	4	4	1	1	2	4	5	3
		%		1.9	1.0	4.2	4.4	4.6	0.9	1.0	2.1	4.2	5.6	3.4
Both	Evaluated	No	111	105	98	96	90	87	111	105	97	96	89	87
	Decrease (1)	No		1	1	1			2	3		1	2	1
		%		1.0	1.0	1.0			1.8	2.9		1.0	2.2	1.1
	Increase (2)	No	1	1		1			1	2		1		
		%	0.9	1.0		1.0			0.9	1.9		1.0		
Heart rate	Evaluated	No	106	102	90	88	86	82	105	101	90	88	87	82
	Decrease (1)	No	3	1	4		2	2	1		1	1	2	2
		%	2.8	1.0	4.4		2.3	2.4	1.0		1.1	1.1	2.3	2.4
	Increase (2)	No	5	11	7	8	8	11	8	11	8	6	8	9
		%	4.7	10.8	7.8	9.1	9.3	13.4	7.6	10.9	8.9	6.8	9.2	11.0

(1) decrease => 20 % of baseline value
(2) increase => 20 % of baseline value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 76

BLOOD PRESSURE AND HEART RATE: NUMBER AND PERCENTAGE OF PATIENTS WITH DECREASE OR INCREASE vs BASELINE OF CLINICAL RELEVANCE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Vital signs			LYING						STANDING					
			time intervals						time intervals					
			Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
S.B.P.	Evaluated	No	111	101	90	87	81	76	110	100	90	86	81	75
	Decrease (1)	No	1	3	2	3	2	6	4	5	2	3		3
		%	0.9	3.0	2.2	3.4	2.5	7.9	3.6	5.0	2.2	3.5		4.0
	Increase (2)	No			1		2		1			2	2	2
		%			1.1		2.5		0.9			2.3	2.5	2.7
D.B.P.	Evaluated	No	111	101	90	87	81	76	110	100	90	86	81	75
	Decrease (1)	No	4	6	3	3	6	2	4	7	1	2	4	3
		%	3.6	5.9	3.3	3.4	7.4	2.6	3.6	7.0	1.1	2.3	4.9	4.0
	Increase (2)	No	5	3	3	2	2	1		1	1	2	2	1
		%	4.5	3.0	3.3	2.3	2.5	1.3		1.0	1.1	2.3	2.5	1.3
Both	Evaluated	No	111	101	90	87	81	76	110	100	90	86	81	75
	Decrease (1)	No	1	1	1	1			2	1	2	4	4	2
		%	0.9	1.0	1.1	1.1			1.8	1.0	2.2	4.7	4.9	2.7
	Increase (2)	No		1			1	1	1			1		2
		%		1.0			1.2	1.3	0.9			1.2		2.7
Heart rate	Evaluated	No	100	93	86	82	76	71	96	90	83	77	69	67
	Decrease (1)	No	1	4	3	1	2	3	2	4	4		2	2
		%	1.0	4.3	3.5	1.2	2.6	4.2	2.1	4.4	4.8		2.9	3.0
	Increase (2)	No	3	4	6	7	6	8	6	4	7	4	2	7
		%	3.0	4.3	7.0	8.5	7.9	11.3	6.3	4.4	8.4	5.2	2.9	10.4

(1) decrease => 20 % of baseline value
(2) increase => 20 % of baseline value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 76

BLOOD PRESSURE AND HEART RATE: NUMBER AND PERCENTAGE OF PATIENTS WITH DECREASE OR INCREASE vs BASELINE OF CLINICAL RELEVANCE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Placebo

Vital signs			LYING						STANDING					
			time intervals						time intervals					
			Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
S.B.P.	Evaluated	No	108	103	100	94	87	86	107	101	98	92	86	85
	Decrease (1)	No	1	1	1	2	3	1	1		2	1	2	1
		%	0.9	1.0	1.0	2.1	3.4	1.2	0.9		2.0	1.1	2.3	1.2
	Increase (2)	No	2		3	1	2	2	2	1	2	3	2	2
		%	1.9		3.0	1.1	2.3	2.3	1.9	1.0	2.0	3.3	2.3	2.4
D.B.P.	Evaluated	No	107	103	100	94	87	86	106	101	98	92	86	85
	Decrease (1)	No	2	3	3	1	4	2	5	3	5	2	1	1
		%	1.9	2.9	3.0	1.1	4.6	2.3	4.7	3.0	5.1	2.2	1.2	1.2
	Increase (2)	No	5	2	4	5	4	5	5	2	6	6	5	2
		%	4.7	1.9	4.0	5.3	4.6	5.8	4.7	2.0	6.1	6.5	5.8	2.4
Both	Evaluated	No	107	103	100	94	87	86	106	101	98	92	86	85
	Decrease (1)	No		1		1		1		1	2	2	1	1
		%		1.0		1.1		1.2		1.0	2.0	2.2	1.2	1.2
	Increase (2)	No		3	1	1	1		1	1		1	1	1
		%		2.9	1.0	1.1	1.1		0.9	1.0		1.1	1.2	1.2
Heart rate	Evaluated	No	104	96	94	84	79	78	101	96	93	83	78	76
	Decrease (1)	No	1	1	3	1	2	4	2	2	3	1	3	6
		%	1.0	1.0	3.2	1.2	2.5	5.1	2.0	2.1	3.2	1.2	3.8	7.9
	Increase (2)	No	6	7	4	5	6	3	5	5	6	6	7	3
		%	5.8	7.3	4.3	6.0	7.6	3.8	5.0	5.2	6.5	7.2	9.0	3.9

(1) decrease => 20 % of baseline value
(2) increase => 20 % of baseline value

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 77

BLOOD PRESSURE AND HEART RATE: ABSOLUTE NUMBER OF PATIENTS SHOWING CLINICALLY RELEVANT CHANGES, COMPARED TO BASELINE, ONCE, TWICE OR MORE TIMES DURING THE THERAPY

Assigned treatment / Vital signs			LYING			STANDING		
			1 time	2 times	3 times or more	1 time	2 times	3 times or more
Imipramine	S.B.P. (1)	Decrease	4		1	5	1	
	D.B.P. (2)	Decrease	6	3	4	8	5	1
		Increase	3	1		2		
	BOTH (1 & 2)	Decrease				6		1
	HEART RATE (3)	Increase	3	2		4	3	1
Placebo	S.B.P. (1)	Decrease	1		1		2	1
		Increase	3			3	1	
	D.B.P. (2)	Decrease	5	2	2	5	3	2
		Increase	3					
	BOTH (1 & 2)	Decrease				4		
	HEART RATE (3)	Decrease	1			1		
		Increase	1			2		
Reboxetine	S.B.P. (1)	Decrease				3	1	
		Increase	1					
	D.B.P. (2)	Decrease	5	2	2	3	2	
		Increase	8			2	1	
	BOTH (1 & 2)	Decrease	1			3	1	1
		Increase	1			2		
	HEART RATE (3)	Increase	9	1	1	8	4	1

(1) decrease => 20 % vs baseline value and systolic value <= 100 mmHg
increase => 20 % vs baseline value and systolic value >= 160 mmHg
(2) decrease => 20 % vs baseline value and diastolic value <= 70 mmHg
increase => 20 % vs baseline value and diastolic value >= 100 mmHg
(3) decrease => 20 % vs baseline value and heart rate value <= 50 beats/min
increase => 20 % vs baseline value and heart rate value >= 100 beats/min

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 78

BLOOD PRESSURE: NUMBER AND PERCENTAGE OF PATIENTS WITH ORTHOSTATIC HYPOTENSION (*) BEFORE AND DURING THE STUDY ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment / Vital signs		According to time interval							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	Eval.	108	110	110	100	90	86	81	75
	No.	2		4	3	2	1	2	1
	%	1.9		3.6	3.0	2.2	1.2	2.5	1.3
	Mean	55.0		37.5	43.3	30.0	30.0	35.0	40.0
	Max.	60.0		55.0	60.0	30.0	30.0	40.0	40.0
Placebo	Eval.	107	109	107	101	98	92	86	85
	No.				2	1	1		
	%				2.0	1.0	1.1		
	Mean				30.0	58.0	36.0		
	Max.				30.0	58.0	36.0		
Reboxetine	Eval.	110	111	111	105	98	96	89	87
	No.	2	3	3	4	2	3	2	4
	%	1.8	2.7	2.7	3.8	2.0	3.1	2.2	4.6
	Mean	42.5	38.3	33.7	39.0	35.0	40.0	55.0	48.0
	Max.	45.0	45.0	35.0	50.0	40.0	50.0	60.0	60.0

(*) orthostatic hypotension = decrease of systolic blood pressure in standing position => 30 mm hg as compared to lying position

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 79

BODY WEIGHT: SUMMARY STATISTICS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Reboxetine

Sex		Time interval						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Female	Evaluated	68	68	65	59	56	52	49
	Mean	64.3	64.2	64.5	64.2	63.4	63.0	63.4
	STD	14.5	14.3	14.3	14.6	13.5	13.2	13.3
	Median	64.0	63.0	64.0	62.8	62.5	61.8	63.0
	Min	38.0	40.0	41.0	40.0	38.0	38.0	39.0
	Max	116.0	116.0	115.0	115.0	97.0	97.0	97.0
Male	Evaluated	42	42	40	38	40	38	38
	Mean	76.5	76.2	76.8	77.1	76.9	77.2	76.7
	STD	13.3	13.0	12.6	12.7	12.2	12.3	12.2
	Median	75.5	75.0	75.6	76.0	75.7	76.0	75.8
	Min	62.0	61.0	60.0	60.0	60.0	61.0	62.0
	Max	141.0	138.0	136.0	135.0	133.0	132.0	130.0
Total	Evaluated	110	110	105	97	96	90	87
	Mean	68.9	68.8	69.2	69.3	69.0	69.0	69.2
	STD	15.2	14.9	14.9	15.2	14.5	14.5	14.4
	Median	67.5	67.3	68.0	68.0	69.0	69.0	68.0
	Min	38.0	40.0	41.0	40.0	38.0	38.0	39.0
	Max	141.0	138.0	136.0	135.0	133.0	132.0	130.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 79

BODY WEIGHT: SUMMARY STATISTICS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Imipramine

Sex		Time interval						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Female	Evaluated	75	74	69	59	58	54	49
	Mean	63.4	63.5	62.5	62.3	63.5	63.7	63.4
	STD	12.1	12.0	11.3	11.6	11.6	11.8	11.8
	Median	61.0	61.1	61.0	60.0	61.0	61.1	61.5
	Min	40.0	41.0	41.0	41.5	41.5	42.0	40.0
	Max	99.5	99.0	86.5	87.7	88.0	91.5	91.0
Male	Evaluated	36	36	32	29	29	27	26
	Mean	76.4	76.2	77.4	78.4	77.9	78.3	78.4
	STD	10.9	10.8	10.4	10.0	9.6	9.6	10.2
	Median	76.5	75.3	76.5	77.0	77.0	77.0	76.5
	Min	55.0	55.0	61.0	63.5	63.5	63.5	61.0
	Max	99.0	99.0	99.0	99.0	99.0	99.0	99.0
Total	Evaluated	111	110	101	88	87	81	75
	Mean	67.6	67.6	67.2	67.6	68.3	68.5	68.6
	STD	13.1	13.0	13.0	13.4	12.9	13.1	13.3
	Median	67.0	66.0	66.0	66.3	68.0	68.0	70.0
	Min	40.0	41.0	41.0	41.5	41.5	42.0	40.0
	Max	99.5	99.0	99.0	99.0	99.0	99.0	99.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 79

BODY WEIGHT: SUMMARY STATISTICS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Placebo

Sex		Time interval						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Female	Evaluated	51	51	48	47	43	41	40
	Mean	63.9	63.7	64.2	64.3	64.4	65.1	64.7
	STD	12.4	12.4	12.3	12.6	12.3	13.2	12.9
	Median	61.0	61.0	61.0	61.0	61.5	61.5	61.5
	Min	41.0	41.0	41.0	40.5	41.0	41.0	41.5
	Max	96.2	96.0	96.0	96.3	98.0	98.0	96.5
Male	Evaluated	58	56	53	51	48	46	46
	Mean	75.4	75.6	75.4	76.0	75.7	75.4	75.6
	STD	13.8	14.0	14.3	13.8	14.0	14.2	14.2
	Median	74.5	75.0	75.0	74.3	74.7	74.1	74.1
	Min	48.5	48.3	48.2	52.0	53.0	53.0	53.0
	Max	133.0	133.0	133.0	133.0	133.0	133.0	133.0
Total	Evaluated	109	107	101	98	91	87	86
	Mean	70.0	70.0	70.1	70.4	70.3	70.5	70.5
	STD	14.3	14.5	14.5	14.4	14.4	14.6	14.6
	Median	68.0	69.0	69.0	68.5	69.0	69.0	69.0
	Min	41.0	41.0	41.0	40.5	41.0	41.0	41.5
	Max	133.0	133.0	133.0	133.0	133.0	133.0	133.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 80

BODY WEIGHT: NUMBER AND PERCENTAGE OF PATIENTS WITH VALUES LOWER OR HIGHER (*) THAN PRE-TREATMENT AT EACH EVALUATION TIME, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Reboxetine

Sex		Time interval											
		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%
Female	Lower	1	1.5	2	3.1	2	3.4	2	3.6	5	9.6	7	14.3
	Same	65	95.6	61	93.8	55	93.2	48	85.7	43	82.7	38	77.6
	Higher	2	2.9	2	3.1	2	3.4	6	10.7	4	7.7	4	8.2
	Total	68	100.0	65	100.0	59	100.0	56	100.0	52	100.0	49	100.0
Male	Lower					1	2.6	3	7.5	2	5.3		
	Same	41	97.6	38	95.0	36	94.7	36	90.0	35	92.1	35	92.1
	Higher	1	2.4	2	5.0	1	2.6	1	2.5	1	2.6	3	7.9
	Total	42	100.0	40	100.0	38	100.0	40	100.0	38	100.0	38	100.0
Total	Lower	1	0.9	2	1.9	3	3.1	5	5.2	7	7.8	7	8.0
	Same	106	96.4	99	94.3	91	93.8	84	87.5	78	86.7	73	83.9
	Higher	3	2.7	4	3.8	3	3.1	7	7.3	5	5.6	7	8.0
	Total	110	100.0	105	100.0	97	100.0	96	100.0	90	100.0	87	100.0

(*) LOWER: decrease > 2.5 Kg.
HIGHER: increase > 2.5 Kg.

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 80

BODY WEIGHT: NUMBER AND PERCENTAGE OF PATIENTS WITH VALUES LOWER OR HIGHER (*) THAN PRE-TREATMENT AT EACH EVALUATION TIME, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Imipramine

Sex		Time interval											
		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%
Female	Lower					3	5.1	4	6.9	6	11.1	11	22.4
	Same	73	98.6	66	95.7	53	89.8	51	87.9	44	81.5	36	73.5
	Higher	1	1.4	3	4.3	3	5.1	3	5.2	4	7.4	2	4.1
	Total	74	100.0	69	100.0	59	100.0	58	100.0	54	100.0	49	100.0
Male	Lower					2	6.9	1	3.4	1	3.7	2	7.7
	Same	35	97.2	31	96.9	26	89.7	27	93.1	23	85.2	22	84.6
	Higher	1	2.8	1	3.1	1	3.4	1	3.4	3	11.1	2	7.7
	Total	36	100.0	32	100.0	29	100.0	29	100.0	27	100.0	26	100.0
Total	Lower					5	5.7	5	5.7	7	8.6	13	17.3
	Same	108	98.2	97	96.0	79	89.8	78	89.7	67	82.7	58	77.3
	Higher	2	1.8	4	4.0	4	4.5	4	4.6	7	8.6	4	5.3
	Total	110	100.0	101	100.0	88	100.0	87	100.0	81	100.0	75	100.0

(*) LOWER: decrease > 2.5 Kg.
HIGHER: increase > 2.5 Kg.

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 80

BODY WEIGHT: NUMBER AND PERCENTAGE OF PATIENTS WITH VALUES LOWER OR HIGHER (*) THAN PRE-TREATMENT AT EACH EVALUATION TIME, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Placebo

Sex		Time interval											
		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%
Female	Lower	1	2.0	1	2.1	2	4.3	1	2.3	3	7.3	3	7.5
	Same	48	94.1	45	93.8	44	93.6	41	95.3	38	92.7	36	90.0
	Higher	2	3.9	2	4.2	1	2.1	1	2.3			1	2.5
	Total	51	100.0	48	100.0	47	100.0	43	100.0	41	100.0	40	100.0
Male	Lower					2	3.9	1	2.1	2	4.3	1	2.2
	Same	56	100.0	51	96.2	47	92.2	44	91.7	42	91.3	43	93.5
	Higher			2	3.8	2	3.9	3	6.3	2	4.3	2	4.3
	Total	56	100.0	53	100.0	51	100.0	48	100.0	46	100.0	46	100.0
Total	Lower	1	0.9	1	1.0	4	4.1	2	2.2	5	5.7	4	4.7
	Same	104	97.2	96	95.0	91	92.9	85	93.4	80	92.0	79	91.9
	Higher	2	1.9	4	4.0	3	3.1	4	4.4	2	2.3	3	3.5
	Total	107	100.0	101	100.0	98	100.0	91	100.0	87	100.0	86	100.0

(*) LOWER: decrease > 2.5 Kg.
HIGHER: increase > 2.5 Kg.

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 81

E.C.G.: NUMBER AND PERCENTAGE OF PATIENTS WITH ABNORMAL E.C.G. ACCORDING TO TIME INTERVALS, BY ASSIGNED TREATMENT AND SEX

Assigned treatment/Sex			Female			Male			Total		
			Screening	1-21 days	22-42 days	Screening	1-21 days	22-42 days	Screening	1-21 days	22-42 days
Imipramine	Eval.	No.	63	54	50	28	26	25	91	80	75
	Normal	No.	53	37	39	24	21	22	77	58	61
		%	84.13	68.52	78.00	85.71	80.77	88.00	84.62	72.50	81.33
	Abnormal	No.	10	17	11	4	5	3	14	22	14
		%	15.87	31.48	22.00	14.29	19.23	12.00	15.38	27.50	18.67
Placebo	Eval.	No.	44	38	37	51	48	45	95	86	82
	Normal	No.	39	34	33	46	40	40	85	74	73
		%	88.64	89.47	89.19	90.20	83.33	88.89	89.47	86.05	89.02
	Abnormal	No.	5	4	4	5	8	5	10	12	9
		%	11.36	10.53	10.81	9.80	16.67	11.11	10.53	13.95	10.98
Reboxetine	Eval.	No.	54	50	45	37	36	34	91	86	79
	Normal	No.	43	43	39	33	30	30	76	73	69
		%	79.63	86.00	86.67	89.19	83.33	88.24	83.52	84.88	87.34
	Abnormal	No.	11	7	6	4	6	4	15	13	10
		%	20.37	14.00	13.33	10.81	16.67	11.76	16.48	15.12	12.66

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 82

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH NORMAL OR ABNORMAL E.C.G. VALUE AT EACH EVALUATION TIME AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment/E.C.G. at Baseline			Time interval			
			1-21 days		22-42 days	
			Abnormal	Normal	Abnormal	Normal
Imipramine	Abnormal	No.	11	2	6	3
		%	84.6	15.4	66.7	33.3
	Normal	No.	11	56	8	58
		%	16.4	83.6	12.1	87.9
	Total	No.	22	58	14	61
		%	27.5	72.5	18.7	81.3
Placebo	Abnormal	No.	7	2	4	4
		%	77.8	22.2	50.0	50.0
	Normal	No.	5	72	5	69
		%	6.5	93.5	6.8	93.2
	Total	No.	12	74	9	73
		%	14.0	86.0	11.0	89.0
Reboxetine	Abnormal	No.	7	6	9	3
		%	53.8	46.2	75.0	25.0
	Normal	No.	6	67	1	66
		%	8.2	91.8	1.5	98.5
	Total	No.	13	73	10	69
		%	15.1	84.9	12.7	87.3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 83

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH NORMAL OR ABNORMAL E.C.G. VALUE AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment/E.C.G. at Baseline		Last assessment				Total	
		Abnormal		Normal			
		No.	%	No.	%	No.	%
Imipramine	Abnormal	10	71.4	4	28.6	14	100.0
	Normal	11	14.3	66	85.7	77	100.0
	Total	21	23.1	70	76.9	91	100.0
Placebo	Abnormal	6	60.0	4	40.0	10	100.0
	Normal	5	5.9	80	94.1	85	100.0
	Total	11	11.6	84	88.4	95	100.0
Reboxetine	Abnormal	10	66.7	5	33.3	15	100.0
	Normal	2	2.6	74	97.4	76	100.0
	Total	12	13.2	79	86.8	91	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 84

E.C.G.: NUMBER AND PERCENTAGE OF E.C.G. ABNORMALITIES OBSERVED DURING THE STUDY, BY ASSIGNED TREATMENT

E.C.G. abnormality type	Imipramine						Placebo						Reboxetine					
	Screening		1-21 days		22-42 days		Screening		1-21 days		22-42 days		Screening		1-21 days		22-42 days	
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Evaluated Pt	91	100.0	80	100.0	75	100.0	95	100.0	86	100.0	82	100.0	91	100.0	86	100.0	79	100.0
ATRIAL ECTOPIC BEATS - OCCASIONAL	1	1.1	2	2.5							1	1.2	1	1.1	1	1.2	1	1.3
ATRIAL FIBRILLATION / FLUTTER													1	1.1	1	1.2	1	1.3
CONDUCTION DISORDER							1	1.1					1	1.1	1	1.2		
LEFT ANTERIOR HEMIBLOCK	1	1.1	1	1.2	1	1.3			1	1.2								
LEFT AXIAL DEVIATION	1	1.1	2	2.5	1	1.3	1	1.1	1	1.2	1	1.2						
LEFT BUNDLE BRANCH BLOCK	1	1.1	1	1.2	1	1.3												
LEFT VENTRICULAR HYPERTROPHY			1	1.2			1	1.1					2	2.2	2	2.3	2	2.5
MYOCARDIAL ISCHEMIA	3	3.3	2	2.5	2	2.7	1	1.1	1	1.2								
NON SPECIFIC ST-T WAVE CHANGES	1	1.1							1	1.2			3	3.3	1	1.2	2	2.5
OTHER	1	1.1	2	2.5														
PREVIOUS MYOCARDIAL INFARCTION			1	1.2									1	1.1	1	1.2	1	1.3
RIGHT BUNDLE BRANCH BLOCK	1	1.1	4	5.0	3	4.0	1	1.1			1	1.2						
RIGHT INCOMPLETE BUNDLE BRANCH BLOCK	1	1.1							1	1.2					1	1.2		
RIPOLARIZATION DISTURBANCES							2	2.1	1	1.2			2	2.2	1	1.2	1	1.3
SINUS BRADYCARDIA (< 60)	4	4.4	1	1.2	2	2.7	3	3.2	6	7.0	5	6.1	5	5.5	1	1.2	1	1.3
SINUS TACHYCARDIA (> 100)	3	3.3	7	8.8	6	8.0	1	1.1	1	1.2			2	2.2	3	3.5	2	2.5
VENTRICULAR ECTOPIC BEATS - OCCASIONAL	1	1.1	2	2.5					1	1.2	1	1.2						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 85

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

		Last assessment				Total	
		Absent		Present			
		No	%	No	%	No	%
E.C.G. Abnormality	Baseline						
ATRIAL ECTOPIC BEATS - OCCASIONAL	Absent	89	98.9	1	1.1	90	100.0
	Present	1	100.0			1	100.0
	Total	90	98.9	1	1.1	91	100.0
ATRIAL FIBRILLATION / FLUTTER	Baseline						
	Absent	90	100.0			90	100.0
	Present			1	100.0	1	100.0
	Total	90	98.9	1	1.1	91	100.0
CONDUCTION DISORDER	Baseline						
	Absent	90	100.0			90	100.0
	Present			1	100.0	1	100.0
	Total	90	98.9	1	1.1	91	100.0
LEFT ANTERIOR HEMIBLOCK	Baseline						
	Absent	91	100.0			91	100.0
	Total	91	100.0			91	100.0
LEFT AXIAL DEVIATION	Baseline						
	Absent	91	100.0			91	100.0
	Total	91	100.0			91	100.0
LEFT BUNDLE BRANCH BLOCK	Baseline						
	Absent	91	100.0			91	100.0
	Total	91	100.0			91	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 85

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

		Last assessment				Total	
		Absent		Present			
		No	%	No	%	No	%
E.C.G. Abnormality	Baseline						
LEFT VENTRICULAR HYPERTROPHY	Absent	89	100.0			89	100.0
	Present			2	100.0	2	100.0
	Total	89	97.8	2	2.2	91	100.0
MYOCARDIAL ISCHEMIA	Baseline						
	Absent	91	100.0			91	100.0
	Total	91	100.0			91	100.0
NON SPECIFIC ST-T WAVE CHANGES	Baseline						
	Absent	88	100.0			88	100.0
	Present	1	33.3	2	66.7	3	100.0
	Total	89	97.8	2	2.2	91	100.0
OTHER	Baseline						
	Absent	91	100.0			91	100.0
	Total	91	100.0			91	100.0
PREVIOUS MYOCARDIAL INFARCTION	Baseline						
	Absent	90	100.0			90	100.0
	Present			1	100.0	1	100.0
	Total	90	98.9	1	1.1	91	100.0
RIGHT BUNDLE BRANCH BLOCK	Baseline						
	Absent	91	100.0			91	100.0
	Total	91	100.0			91	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 85

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

		Last assessment				Total	
		Absent		Present			
		No	%	No	%	No	%
E.C.G. Abnormality	Baseline						
RIGHT INCOMPLETE BUNDLE BRANCH BLOCK	Absent	91	100.0			91	100.0
	Total	91	100.0			91	100.0
RIPOLARIZATION DISTURBANCES	Baseline						
	Absent	89	100.0			89	100.0
	Present	1	50.0	1	50.0	2	100.0
	Total	90	98.9	1	1.1	91	100.0
SINUS BRADYCARDIA (< 60)	Baseline						
	Absent	86	100.0			86	100.0
	Present	4	80.0	1	20.0	5	100.0
	Total	90	98.9	1	1.1	91	100.0
SINUS TACHYCARDIA (> 100)	Baseline						
	Absent	87	97.8	2	2.2	89	100.0
	Present	1	50.0	1	50.0	2	100.0
	Total	88	96.7	3	3.3	91	100.0
VENTRICULAR ECTOPIC BEATS - OCCASIONAL	Baseline						
	Absent	91	100.0			91	100.0
	Total	91	100.0			91	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 85

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

		Last assessment				Total	
		Absent		Present			
		No	%	No	%	No	%
E.C.G. Abnormality	Baseline						
ATRIAL ECTOPIC BEATS - OCCASIONAL	Absent	90	100.0			90	100.0
	Present	1	100.0			1	100.0
	Total	91	100.0			91	100.0
ATRIAL FIBRILLATION / FLUTTER	Baseline						
	Absent	91	100.0			91	100.0
	Total	91	100.0			91	100.0
CONDUCTION DISORDER	Baseline						
	Absent	91	100.0			91	100.0
	Total	91	100.0			91	100.0
LEFT ANTERIOR HEMIBLOCK	Baseline						
	Absent	90	100.0			90	100.0
	Present			1	100.0	1	100.0
	Total	90	98.9	1	1.1	91	100.0
LEFT AXIAL DEVIATION	Baseline						
	Absent	89	98.9	1	1.1	90	100.0
	Present			1	100.0	1	100.0
	Total	89	97.8	2	2.2	91	100.0
LEFT BUNDLE BRANCH BLOCK	Baseline						
	Absent	90	100.0			90	100.0
	Present			1	100.0	1	100.0
	Total	90	98.9	1	1.1	91	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 85

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

		Last assessment				Total	
		Absent		Present			
		No	%	No	%	No	%
E.C.G. Abnormality	Baseline						
LEFT VENTRICULAR HYPERTROPHY	Absent	90	98.9	1	1.1	91	100.0
	Present						
	Total	90	98.9	1	1.1	91	100.0
MYOCARDIAL ISCHEMIA	Baseline						
	Absent	88	100.0			88	100.0
	Present			3	100.0	3	100.0
	Total	88	96.7	3	3.3	91	100.0
NON SPECIFIC ST-T WAVE CHANGES	Baseline						
	Absent	90	100.0			90	100.0
	Present	1	100.0			1	100.0
	Total	91	100.0			91	100.0
OTHER	Baseline						
	Absent	90	100.0			90	100.0
	Present			1	100.0	1	100.0
	Total	90	98.9	1	1.1	91	100.0
PREVIOUS MYOCARDIAL INFARCTION	Baseline						
	Absent	91	100.0			91	100.0
	Total	91	100.0			91	100.0
RIGHT BUNDLE BRANCH BLOCK	Baseline						
	Absent	87	96.7	3	3.3	90	100.0
	Present			1	100.0	1	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 85

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Inipramine

		Last assessment				Total	
		Absent		Present			
		No	%	No	%	No	%
E.C.G. Abnormality	Total						
RIGHT BUNDLE BRANCH BLOCK		87	95.6	4	4.4	91	100.0
RIGHT INCOMPLETE BUNDLE BRANCH BLOCK	Baseline						
	Absent	90	100.0			90	100.0
	Present	1	100.0			1	100.0
	Total	91	100.0			91	100.0
RIPOLARIZATION DISTURBANCES	Baseline						
	Absent	91	100.0			91	100.0
	Total	91	100.0			91	100.0
SINUS BRADYCARDIA (< 60)	Baseline						
	Absent	86	98.9	1	1.1	87	100.0
	Present	3	75.0	1	25.0	4	100.0
	Total	89	97.8	2	2.2	91	100.0
SINUS TACHYCARDIA (> 100)	Baseline						
	Absent	81	92.0	7	8.0	88	100.0
	Present	1	33.3	2	66.7	3	100.0
	Total	82	90.1	9	9.9	91	100.0
VENTRICULAR ECTOPIC BEATS - OCCASIONAL	Baseline						
	Absent	90	100.0			90	100.0
	Present	1	100.0			1	100.0
	Total	91	100.0			91	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 85

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Placebo

		Last assessment				Total	
		Absent		Present			
		No	%	No	%	No	%
E.C.G. Abnormality	Baseline						
ATRIAL ECTOPIC BEATS - OCCASIONAL	Absent	94	98.9	1	1.1	95	100.0
	Present						
	Total	94	98.9	1	1.1	95	100.0
ATRIAL FIBRILLATION / FLUTTER	Baseline						
	Absent	95	100.0			95	100.0
	Total	95	100.0			95	100.0
CONDUCTION DISORDER	Baseline						
	Absent	94	100.0			94	100.0
	Present	1	100.0			1	100.0
	Total	95	100.0			95	100.0
LEFT ANTERIOR HEMIBLOCK	Baseline						
	Absent	94	98.9	1	1.1	95	100.0
	Present						
	Total	94	98.9	1	1.1	95	100.0
LEFT AXIAL DEVIATION	Baseline						
	Absent	94	100.0			94	100.0
	Present			1	100.0	1	100.0
	Total	94	98.9	1	1.1	95	100.0
LEFT BUNDLE BRANCH BLOCK	Baseline						
	Absent	95	100.0			95	100.0
	Total	95	100.0			95	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 85

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Placebo

		Last assessment					
		Absent		Present		Total	
		No	%	No	%	No	%
E.C.G. Abnormality	Baseline						
LEFT VENTRICULAR HYPERTROPHY	Absent	94	100.0			94	100.0
	Present	1	100.0			1	100.0
	Total	95	100.0			95	100.0
MYOCARDIAL ISCHEMIA	Baseline						
	Absent	94	100.0			94	100.0
	Present	1	100.0			1	100.0
	Total	95	100.0			95	100.0
NON SPECIFIC ST-T WAVE CHANGES	Baseline						
	Absent	94	98.9	1	1.1	95	100.0
	Present						
	Total	94	98.9	1	1.1	95	100.0
OTHER	Baseline						
	Absent	95	100.0			95	100.0
	Total	95	100.0			95	100.0
PREVIOUS MYOCARDIAL INFARCTION	Baseline						
	Absent	95	100.0			95	100.0
	Total	95	100.0			95	100.0
RIGHT BUNDLE BRANCH BLOCK	Baseline						
	Absent	94	100.0			94	100.0
	Present			1	100.0	1	100.0
	Total	94	98.9	1	1.1	95	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 85

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Placebo

		Last assessment				Total	
		Absent		Present			
		No	%	No	%	No	%
E.C.G. Abnormality	Baseline						
RIGHT INCOMPLETE BUNDLE BRANCH BLOCK	Absent	95	100.0			95	100.0
	Total	95	100.0			95	100.0
RIPOLARIZATION DISTURBANCES	Baseline						
	Absent	93	100.0			93	100.0
	Present	1	50.0	1	50.0	2	100.0
	Total	94	98.9	1	1.1	95	100.0
SINUS BRADYCARDIA (< 60)	Baseline						
	Absent	89	96.7	3	3.3	92	100.0
	Present	1	33.3	2	66.7	3	100.0
	Total	90	94.7	5	5.3	95	100.0
SINUS TACHYCARDIA (> 100)	Baseline						
	Absent	94	100.0			94	100.0
	Present	1	100.0			1	100.0
	Total	95	100.0			95	100.0
VENTRICULAR ECTOPIC BEATS - OCCASIONAL	Baseline						
	Absent	94	98.9	1	1.1	95	100.0
	Present						
	Total	94	98.9	1	1.1	95	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 86

E.C.G.: NUMBER AND PERCENTAGE OF E.C.G. ABNORMALITIES, BY ABNORMALITY GROUP, OBSERVED DURING THE STUDY
BY ASSIGNED TREATMENT

Group of abnormalities	Imipramine						Placebo						Reboxetine					
	Screening		1-21 days		22-42 days		Screening		1-21 days		22-42 days		Screening		1-21 days		22-42 days	
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Evaluated Pt.	91	100.0	80	100.0	75	100.0	95	100.0	86	100.0	82	100.0	91	100.0	86	100.0	79	100.0
Rhythm disorders	7	7.7	10	12.5	8	10.7	4	4.2	8	9.3	7	8.5	8	8.8	6	7.0	5	6.3
Conduction disorders	4	4.4	7	8.8	5	6.7	3	3.2	3	3.5	2	2.4	1	1.1	2	2.3		
Ischemic signs	4	4.4	2	2.5	2	2.7	3	3.2	3	3.5			5	5.5	2	2.3	3	3.8
Other disorders	1	1.1	3	3.8			1	1.1					3	3.3	3	3.5	3	3.8

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
TABLE No.: 87

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES, BY ABNORMALITY GROUP, AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION, BY ASSIGNED TREATMENT

E.C.G. Abnormality / Baseline		Last assessment																	
		Imipramine						Placebo						Reboxetine					
		Absent		Present		Total		Absent		Present		Total		Absent		Present		Total	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Rhythm disorders	Absent	76	90.5	8	9.5	84	100	86	94.5	5	5.5	91	100	80	96.4	3	3.6	83	100
	Present	4	57.1	3	42.9	7	100	2	50.0	2	50.0	4	100	5	62.5	3	37.5	8	100
	Total	80	87.9	11	12.1	91	100	88	92.6	7	7.4	95	100	85	93.4	6	6.6	91	100
Conduction disorders	Absent	84	96.6	3	3.4	87	100	92	100			92	100	90	100			90	100
	Present			4	100	4	100			3	100	3	100			1	100	1	100
	Total	84	92.3	7	7.7	91	100	92	96.8	3	3.2	95	100	90	98.9	1	1.1	91	100
Ischemic signs	Absent	87	100			87	100	91	98.9	1	1.1	92	100	86	100			86	100
	Present	1	25.0	3	75.0	4	100	2	66.7	1	33.3	3	100	2	40.0	3	60.0	5	100
	Total	88	96.7	3	3.3	91	100	93	97.9	2	2.1	95	100	88	96.7	3	3.3	91	100
Other disorders	Absent	90	100			90	100	94	100			94	100	88	100			88	100
	Present			1	100	1	100	1	100			1	100			3	100	3	100
	Total	90	98.9	1	1.1	91	100	95	100			95	100	88	96.7	3	3.3	91	100

FIGURES

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

MEAN DECREASES OF HAMILTON TOTAL SCORE AT LAST ASSESSMENT
POINT ESTIMATES AND CONFIDENCE INTERVALS
Figure No.: 1





PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

SEVERE PATIENTS JUDGED BY CGI SEVERITY AT BASELINE

MEAN DECREASES OF HAMILTON TOTAL SCORE AT LAST ASSESSMENT

POINT ESTIMATES AND 95% CONFIDENCE INTERVALS

Figure No.: 3

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

MELANCHOLIC PATIENTS MEAN DECREASES OF HAMILTON TOTAL SCORE AT LAST ASSESSMENT

POINT ESTIMATES AND 95% CONFIDENCE INTERVALS

Figure No.: 4

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 2012A/015

CUMULATIVE RISK OF DEVELOPING THE FIRST ADVERSE EVENT DURING TREATMENT

Figure No.: 5



PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

CUMULATIVE RISK OF DEVELOPING AGITATION / ANXIETY / NERVOUSNESS

Figure No.: 6



Log–Rank Test RBX vs IMI: (1 df) = 2.2547 P = 0.1332

Log–Rank Test RBX vs PLC: (1 df) = 0.0360 P = 0.8496

Log–Rank Test IMI vs PLC: (1 df) = 1.8003 P = 0.1797

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

CUMULATIVE RISK OF DEVELOPING ASTHENIA / FATIGUE

Figure No.: 7



Log–Rank Test RBX vs IMI: (1 df) = 0.4422 P = 0.5061

Log–Rank Test RBX vs PLC: (1 df) = 0.0001 P = 0.9932

Log–Rank Test IMI vs PLC: (1 df) = 0.4591 P = 0.4980

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

CUMULATIVE RISK OF DEVELOPING BLURRED VISION

Figure No.: 8



Log – Rank Test RBX vs IMI: (1 df) = 1.1657 P = 0.2803

Log – Rank Test RBX vs PLC: (1 df) = 1.0249 P = 0.3114

Log – Rank Test IMI vs PLC: (1 df) = 4.1156 P = 0.0425

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

CUMULATIVE RISK OF DEVELOPING CONSTIPATION

Figure No.: 9



Log–Rank Test RBX vs IMI: (1 df) = 0.0529 P = 0.8182

Log–Rank Test RBX vs PLC: (1 df) = 5.8558 P = 0.0155

Log–Rank Test IMI vs PLC: (1 df) = 7.2476 P = 0.0071

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

CUMULATIVE RISK OF DEVELOPING HEADACHE / MIGRAINE

Figure No.: 10



Log–Rank Test RBX vs IMI: (1 df) = 1.7542 P = 0.1853
Log–Rank Test RBX vs PLC: (1 df) = 1.7892 P = 0.1810
Log–Rank Test IMI vs PLC: (1 df) = 0.0023 P = 0.9619

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

CUMULATIVE RISK OF DEVELOPING HYPOTENSION AND RELATED SYMPTOMS

Figure No.: 11



Log – Rank Test RBX vs IMI: (1 df) = 4.1630 P = 0.0413

Log – Rank Test RBX vs PLC: (1 df) = 1.0066 P = 0.3157

Log – Rank Test IMI vs PLC: (1 df) = 8.9049 P = 0.0028

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

CUMULATIVE RISK OF DEVELOPING INSOMNIA

Figure No.: 12



Log–Rank Test RBX vs IMI: (1 df) = 0.7933 P = 0.3731

Log–Rank Test RBX vs PLC: (1 df) = 4.1602 P = 0.0414

Log–Rank Test IMI vs PLC: (1 df) = 1.4072 P = 0.2355

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

CUMULATIVE RISK OF DEVELOPING MOUTH DRY

Figure No.: 13



Log – Rank Test RBX vs IMI: (1 df) = 9.0046 P = 0.0027

Log – Rank Test RBX vs PLC: (1 df) = 5.6707 P = 0.0173

Log – Rank Test IMI vs PLC: (1 df) = 27.5434 P = 0.0001

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 2012/015

CUMULATIVE RISK OF DEVELOPING NAUSEA AND RELATED SYMPTOMS

Figure No.: 14



Log–Rank Test RBX vs IMI: (1 df) = 2.0986 P = 0.1474

Log–Rank Test RBX vs PLC: (1 df) = 0.0000 P = 0.9963

Log–Rank Test IMI vs PLC: (1 df) = 2.1983 P = 0.1382

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 2012/015

CUMULATIVE RISK OF DEVELOPING PARAESTHESIA

Figure No.: 15



Log–Rank Test RBX vs IMI: (1 df) = 2.0112 P = 0.1561

Log–Rank Test RBX vs PLC: (1 df) = 0.0000 P = 0.9945

Log–Rank Test IMI vs PLC: (1 df) = 2.0573 P = 0.1515

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

CUMULATIVE RISK OF DEVELOPING SOMNOLENCE

Figure No.: 16



Log – Rank Test RBX vs IMI: (1 df) = 3.6284 P = 0.0568

Log – Rank Test RBX vs PLC: (1 df) = 6.8579 P = 0.0088

Log – Rank Test IMI vs PLC: (1 df) = 0.5682 P = 0.4510

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

CUMULATIVE RISK OF DEVELOPING SWEATING INCREASED

Figure No.: 17



Log–Rank Test RBX vs IMI: (1 df) = 2.1584 P = 0.1418

Log–Rank Test RBX vs PLC: (1 df) = 7.4965 P = 0.0062

Log–Rank Test IMI vs PLC: (1 df) = 15.9829 P = 0.0001

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

CUMULATIVE RISK OF DEVELOPING TREMOR

Figure No.: 18



Log–Rank Test RBX vs IMI: (1 df) = 8.6796 P = 0.0032

Log–Rank Test RBX vs PLC: (1 df) = 0.0863 P = 0.7690

Log–Rank Test IMI vs PLC: (1 df) = 10.2165 P = 0.0014

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

CUMULATIVE RISK OF DEVELOPING URINARY HESITANCY / RETENTION

Figure No.: 19



Log – Rank Test RBX vs IMI: (1 df) = 3.6499 P = 0.0561
Log – Rank Test RBX vs PLC: (1 df) = 1.9920 P = 0.1581
Log – Rank Test IMI vs PLC: (1 df) = 0.3831 P = 0.5360

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 2012/015

CUMULATIVE RISK OF DEVELOPING VERTIGO

Figure No.: 20



Log – Rank Test RBX vs IMI: (1 df) = 0.3223 P = 0.5702

Log – Rank Test RBX vs PLC: (1 df) = 5.0571 P = 0.0245

Log – Rank Test IMI vs PLC: (1 df) = 7.1125 P = 0.0077

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/015

PERCENTAGE OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT ON EXPOSED ACCORDING TO TIME INTERVAL

Figure No: 21



12. APPENDICES

12.1 Study Information

Pharmacia Document 9550082

12.1.1 PROTOCOLS* AND PROTOCOL AMENDMENTS

*Copy of the final protocol, as well as the modified protocol used in the Canadian centre.

9550082

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

AMENDMENT 1 to the
REBOXETINE PROTOCOL 20124/015

The paragraph 9.1 will be as follow:

9.1. Pre-treatment period

Patients will be checked for eligibility according to the inclusion and exclusion criteria. A washout period of 4-7 days (14 days in case of MAOI administration, and 3-4 weeks in case of previous fluoxetine treatment) will then be undertaken, during which only chloral hydrate (0.5 - 1.0 g) as sleep inducer on p.r.n. basis will be allowed. Informed consent will be obtained from each patient and/or next of kin.

Eligible patients will be then randomized to one of the three treatment groups and will undergo baseline assessments.

Information on patients screened for the study and found not to be eligible will be collected in the appropriate form (screening form, enclosure 5).

Signatures:

Investigator _____

Study Monitor _____

Product Leader _____

Line Medical Head _____

Biostatisticians _____

1400X

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

AMENDMENT 2 to the
REBOXETINE PROTOCOL 20124/015
AUSTRALIA

The paragraph 9.1 will be as follow:

Patients will be checked for eligibility according to the inclusion and exclusion criteria. A washout period of 4-7 days (14 days in case of MAOI administration and 3 - 4 weeks in case of previous fluoxetine treatment) will then be undertaken, during which only sleep inducer (see 9.2.5) will be allowed. Informed consent will be obtained from each patient and/or next of kin. Eligible patients will be then randomized to one of the three treatment groups and will undergo baseline assessments. Information on patients screened for the study and found not to be eligible will be collected in the appropriate screening form.

The paragraph 9.2.5 will be as follow:

No concomitant medications other than hypnotic on p.r.n. basis are allowed at entry into the study. Concomitant medication should be avoided throughout the study. In case of events arising during the course of the study nonpsychotropic medications which are considered necessary for the patient´s welfare may be administered and will not be considered violation to the protocol. The drugs, dosage and frequency of administration will be recorded. Short acting benzodiazepines (for instance temazepam 10mg tablet) as sleep inducer on p.r.n. basis at bed-time are allowed.

Signatures:

Investigator_____

Study Monitor_____

Product Leader_____

Line Medical Head_____

9550082

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

AMENDMENT 2 to the
REBOXETINE PROTOCOL 20124/015
FRANCE

1) The paragraph 15.2 will be as follows :

Before entering the study each patient will receive an explanation of the nature, duration and purpose of the study and the action of the compound in such a manner that the patient is aware of the pontential risks, inconveniances or adverse effects that may occured and can express his/her informed consent to participate.

Tne consent form (enclosure 3) will be signed by the patient and by the investigator. If the patient is not able to give his/her consent, the signature by the next of kin will testify that full informations was given to the patient.

2) Consent Form
(to see the next page)

Signatures:

Investigator _____

Study Monitor _____

Product Leader _____

Line Medical Head _____

Biostatisticians _____

9550082

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

AMENDMENT 2 to the
REBOXETINE PROTOCOL 20124/015
GERMANY and CANADA

The statement "High risk of suicide" in the paragraph 6.3 Exclusion criteria **will be as follows:**

- High risk of suicide defined as a score "3" or "4" in the Hamilton Depression Rating Scale item # 3 "Suicide".

Signatures:

Investigator_____

Study Monitor_____

Product Leader_____

Line Medical Head_____

Biostatistician_____

FARMITALIA CARLO ERBA
R&D - C.N.S. LINE

COMPOUND:		REBOXETINE
PROTOCOL No.	:	20124/015
VERSION	:	Final: 19.09.1990
PHASE	:	III
TITLE	:	**Multicenter, multinational double-blind study of the activity and tolerability of reboxetine vs imipramine and placebo in patients suffering from Major Depressive Episodes.**
INVESTIGATORS	:	See enclosure 1
PRODUCT LEADER	:	Marek Jarema Farmitalia Carlo Erba R&D, CNS Dpt Via Carlo Imbonati, 24 20159 Milano Phone: 039-2-69952749
STUDY MONITOR	:	See enclosure 16
DATA MANAGEMENT CENTER	:	Biostatistics and Data Management FICE Milan

TABLE OF CONTENTS

1.0 PROTOCOL SUMMARY

The study, aimed at the evaluation of the efficacy and tolerability of reboxetine in comparison with imipramine and placebo in patients suffering from Major Depressive Episodes, will be carried out on a multinational basis, according to a double-blind parallel group design, in 330 patients. After an initial washout period of 1-2 weeks, patients will receive either reboxetine or imipramine or placebo, administered according to a fixed-flexible dose regimen, for 6 weeks. Efficacy (Clinical Global Impression, Hamilton Depression Rating Scale, Montgomery -Asberg Depression Rating Scale, Patient Global Impression), and tolerability (newly observed signs and symptoms, lab tests and ECG) will be assessed every 1-2 weeks. At the end of the 6-week treatment period a long-term follow-up may be undertaken.

2.0 INTRODUCTION

Reboxetine (FCE 20124 or RS, RS 2-[α-(2-ethoxy-phenoxy) benzyl] morpholine methanesulphonate) is a chemically new compound highly potent in pharmacological and biochemical tests predictive of antidepressant effectiveness: reserpine antagonism, norepinephrine reuptake inhibition, REM sleep latency increase. In addition reboxetine has been found to be able to prevent clonidine effects in rodents after single oral administration, in contrast with what observed following tricyclic monoamine uptake inhibitors, which were found to be active only upon repeated doses: these results indicate that the compound is able to decrease the sensitivity of α2 noradrenergic receptors, one of the biochemical correlates of chronic antidepressant treatment, after single oral dose: therefore it may be expected to exert antidepressant effectiveness of faster onset with respect to available antidepressants in patients (1).

In phase I studies (2, 3) single doses of 0.5 - 5 mg of compound, were administered orally to healthy volunteers. After 5 mg orthostatic hypotension, accompanied by tachycardia and by subjective symptomatology consistent with the disturbed circulatory regulation was observed.

In these studies single doses of 1 & 3 mg of the compound showed dose-dependent CNS effects with EEG modifications (decreased power of theta and fast-beta waves in the fronto-central derivative), performance improvement (peg-board test) and growth hormone increase, the latter reportedly sensitive to hypothalamic noradrenergic stimulation by norepinephrine reuptake inhibitors.

The comparison with the positive control, imipramine 75 mg, associated to similar EEG modifications in the fronto-central derivative, to modifications indicative of sedative activity in the occipito-temporal derivative and to deterioration of the Pauli performance test, in the absence of growth hormone modifications, indicate that reboxetine does not possess the marked sedative activity of imipramine, but rather psychostimulating properties. After all treatment standing heart rate increase and salivation decrease was apparent. No other modifications of tolerability parameters were observed.

The pharmacokinetics of the compound were evaluated in the above mentioned studies as well as after administration of 2 mg 14C-FCE 20124 to 3 healthy volunteers (4). Most of the radioactivity circulating in plasma (73% in terms of AUC) was accounted for by unchanged reboxetine; the average peak levels were observed at 2 h, with remarkably stable levels 1-6 hours after administration; its plasma half-life was estimated as 13.2 h, slightly lower than that of total radioactivity.

In addition the autonomic effects of the compound have been evaluated in a study carried out in 16 healthy volunteers according to a double-blind, latin square experimental design. Single doses of reboxetine 1, 2 & 4 mg, desipramine 25, 50 and 100 mg and placebo were administered at weekly intervals. Both reboxetine and desipramine were found to be similarly active in reducing salivation and antagonizing carbachol-evoked sweating, activities consistent with anticholinergic properties, and in increasing heart rate (consistent with muscarinic receptor blockade and/or noradrenergic stimulation); reboxetine, but not desipramine, was found to increase resting pupil diameter (consistent with muscarinic receptor blockade and/or α-stimulation) and to antagonize light evoked-miosis (consistent with anticholinergic activity).

Neither reboxetine nor desipramine were found to modify phenylephrine evoked sweating (no evidence of α-adrenoceptor blockade); following reboxetine a reduction of phenylephrine-evoked mydriasis was apparent, possibly due to a "ceiling effect" (due to the mydriatic effect of reboxetine) rather than α-adrenoceptor blockade. No evidence of noradrenaline-uptake blockade could be observed, since noradrenaline failed to evoke measurable pupillary response.

On the basis of the results of the phase I studies, a 6-center early phase II study was carried out aimed at assessing tolerability and activity of progressively increased doses of reboxetine, administered over a 4-week period to hospitalized patients suffering from Major Depressive Disorders (5).

Ninety-eight patients were admitted to the study to be treated with maximum reboxetine daily doses of 4 mg (29 pts), 6 mg (27 pts), 8 mg (18 pts), 10 mg (12 pts) and 12 mg (12 pts). Treatment was discontinued in 4 patients in the 4 mg group due to deterioration of the clinical picture (with a manic syndrome in one case); in 2 patients of the 6 mg group due to the development of a manic episode; in one patient of the 6 mg group due to a convulsive episode, under associated treatment with levomepromazine. Dosage decrease was almost only present in the 12 mg group where in 5/12 cases, due to hypotension and tachycardia, the daily dose was decreased to 10 mg until completion of the treatment period.

The rating scales applied showed dose related improvement of the clinical picture both as average changes vs basal conditions as well as frequencies of relevant modifications (defined as 50% decrease of HAMD) up to the 10 mg/day dose, whereas slight deterioration, concomitant to the intolerance signs/symptoms, was observed in the highest dose group.

The compound was well tolerated when administered at doses up to 10 mg/day, as shown by newly observed signs and symptoms, mainly of mild to moderate severity and transient, and by vital signs and lab tests assessments, ECG included.

A double blind parallel group study was subsequently carried out in 10 centers (Hungary, Italy, France and Latin America) in 258 patients hospitalized due to a Major DepressiveEpisode. The experimental treatment had to be administered for 4 weeks, with maximum doses of 8 mg reboxetine(RBX) or 200 mg desipramine(DMI). The experimental treatment was discontinued in 26 patients (10%): in 18 cases (5, 6 e 7 of the RBX, DMI and P group respectively) for inefficacy; in 3 cases for adverse events (2 of the RBX group due to deterioration of ventricular extrasystoles present before study start and hypertensive episodes respectively and 1 of the placebo group due to a cutaneous rash); in 5 cases (2, 1 and 2 in the RBX, DMI and P group respectively) for reasons unrelated to the experimental treatment.

Of the 80, 82 and 81 cases evaluable for efficacy in the RBX, DMI and P group (after exclusion of protocol violations, mainly related to associated treatments) 63%, 46% and 36% respectively showed a decrease >50% of the HAMD total score at the end of treatment; in 31%, 22% and 21% of these patients respectively the decrease was present within the 14th day of treatment. As to within-center results, the highest frequency of response was observed in the RBX group in all but 3 of the participating centers. After 2 and 4 weeks of treatment an average decrease of 23% and 34% of the HAMD was present in

the P group; the corresponding figures were 34% and 49% in the DMI group and 39% e 57% in the RBX group.
As to signs/symptoms, more frequent in the RBX group were headache, complained of by 33% of the patients (20% and 21% in the DMI e P group respectively), and urinary hesitancy/retention, present in 12% vs 4% vs 1% of the cases, RBX vs DMI vs P. More frequent in the DMI group were dry mouth (45% vs 26% vs 21%, DMI vs RBX vs P), sweating (28% vs 18% vs 22%), blurred vision (17% vs 4% in both RBX and P groups). Cardiovascular signs/symptoms were relatively rare, and appeared with slightly higher frequency in the DMI group: hypotension 13%, vs 6% in the RBX and 8% in the P group and tachycardia 19% vs 12% and 8% in the RBX and P group respectively.

3.0 RATIONALE

Phase II results obtained in controlled conditions in patients suffering from Major Depressive Disorders indicate that reboxetine is an effective antidepressant agent, with a favourable therapeutic index with respect to desipramine. Consistent information from further placebo-controlled studies is needed in order to properly document the activity and tolerability of the compound. In addition comparative evidence vs another tricyclic antidepressant is expected to allow a proper appraisal of the usefulness of the new molecule.

4.0 OBJECTIVES

To assess activity and tolerability of reboxetine in comparison with placebo and imipramine in patients suffering from Major Depressive Episodes.

5.0 DESIGN

5.1 Description

This phase III study will be carried out according to a double blind parallel group design, controlled vs imipramine and placebo, with random allocation of patients to one of the three treatments. The study will be organized on a multicentre, multinational basis.

5.2 Number of subjects proposed

Each center will recruit 24-42 patients, within a period of 12 months, for a total of 330 patients overall.

5.3 Logistics

The centers participating in the study are listed in enclosure 1.

6.0 STUDY POPULATION

6.1 Source of subjects

- Adult patients selected from the population under in-patient care or attending out-patient or day-hospital clinics of the participating centers will be studied. These latter can be hospitalised for the study.

6.2 Inclusion criteria

- Patients affected by acute episodes of Major Depressive Episodes (DSM III R) (enclosure 2) not accompanied by psychotic features, with presence of episode for at least one month and not more than four.

- Patients of either sex, of any race, aged 18 to 65 years.

- A total score of 22 or above in the 21-HAMD.

- Patient's consent: informed written consent will be obtained - see 15.2 (proposed form: enclosure 3).

6.3 Exclusion criteria

- Dysthymia, Cyclothymia

- History of Major Depressive Episodes associated with Endocrine Disorders: hypo and hyper-thyroidism tested by TSH and T4 at screening and defined as at least 10% abnormal values of the laboratory norms; adrenal insufficiency, etc.

- Pregnancy (tested by pregnancy test at the end of the wash-out period).

- Refusal by female patients in potential child bearing age of efficient contraceptive use during the study period.

- Past history of any drug hypersensitivity.

- Participation in a clinical study with an investigational compound in the 4 weeks preceding the study.

- Evidence of Substance Use Disorder (DSM-III-R) within past 6 months or currently.

- Chronic respiratory insufficiency in the physical examination and in X-ray.

- Progressive illnes or systemic disease of the digestive system, liver, or kidneys, or other conditions known to interfere with the absorption, distribution, metabolism and excretion of drugs.

- History of seizures or brain injury; current evidence of clinically important hematopoietic or cardiovascular diseases. Current evidence of urinary retention, or glaucoma.

- Symptoms of any other important clinical illness in the 4 weeks preceding the study.

- Clinically relevant abnormal findings in the physical examination, laboratory tests and ECG at admission.

- ECT in the previous 3 months.

- MMS (mini mental State) < 22 (enclosure 4).

- High risk of suicide.

6.4 Identification of subjects

Patients will be identified by their initials and by the number in the trial.

7.0 RANDOMIZATION PROCEDURES

A randomization list balanced within center will be prepared for patient allocation to one of the 3 possible treatments (reboxetine, imipramine or placebo). On this basis the experimental treatments will be prepared and labelled with the corresponding patient number.

Patient allocation to treatment will be done at the end of the pre-treatment period by the main Investigator on the basis of the patient's temporal entry into the study.

8.0 EXPERIMENTAL TREATMENTS

8.1 Test preparation

Indistinguishable capsules containing reboxetine 4 mg (2 tabl of 2 mg, batch no..) or 6 mg (3 tabl of 2 mg, batch no.....) or imipramine 50 mg (2 tabl of 25 mg, batch no.....) or 100 mg (4 tabl of 25 mg, batch no.....) or excipients only (placebo, batch no....) will be used. The experimental treatments will be administered according to fixed-flexible dose schedules as indicated under Study Conduct . Test preparations will consist of:

	morning	evening
-reboxetine	1 cps 4 mg	1 cps 4 mg
-reboxetine DOSE 2 (last 3 weeks)	as above	1 cps 6 mg
-imipramine day 1-3	1 cps 50 mg	1 cps 50 mg
day 4-42	1 cps 50 mg	1 cps 100 mg
-imipramine DOSE 2 (last 3 weeks)	1 cps 100 mg	1 cps 100 mg
-placebo	1 cps	1 cps
-placebo DOSE 2 (last 3 weeks)	as above	as above

8.2 Labelling

The experimental treatment will be labelled by using the labels in enclosure 5. Double labels will be used.

8.3 Packaging

For each patient 6 cartons labelled with the patient number and the indication "week 1" to "week 6" will be prepared. Each carton will contain the medication necessary for 1 week plus 2 cps for possible losses, prepared according to the b.i.d. regimen with 1 cps for the "morning" and 1 cps for the "evening" dose. In addition for each patient 3 cartons labelled with the patient number and the indication "week 4-dose 2", "week 5-dose 2" and "week 6-dose 2" will be provided, for the possible dosage increase during the last 3 weeks of treatment (see Study Conduct).

8.4 Drug supplies storage

Drug supplies will be stored at room temperature. All drug supplies will be handled under the direct responsibility of the Investigator and held by the Hospital Pharmacy. The study Monitor will check drug storage conditions during site visits.

The Investigator will be also responsible for drug accountability and will keep a record of the test compounds received from the Sponsor as well as of the dispensed drug.

8.5 Dispensing, use and disposition of test drugs during and at the end of the study

Medication will be dispensed to the patient on the occasion of each visit; the Investigator will detach the upper label from each of the weekly cartons he is dispensing to the patient and will attach them in the appropriate space in the Case Record Form. On the same occasion cartons of the possible previous supply will be returned by the patient.

Used cartons will be returned to the study Monitor during site visits.

All unused medication has to be returned to Farmitalia Carlo Erba at the end of the study.

9.0 STUDY CONDUCT

9.1 Pre-treatment period

Patients will be checked for eligibility according to the inclusion and exclusion criteria. A washout period of 4-7 days (14 days in case of MAOI administration) will then be undertaken, during which only chloral hydrate (0,5 - 1 g) as sleep inducer on p.r.n. basis will be allowed. Informed consent will be obtained from each patient.

Eligible patients will be then randomized to one of the three treatment groups and will undergo baseline assessments.

Information on patients screened for the study and found not to be eligible will be collected in the appropriate form (screening form, enclosure 6).

9.2 Treatment period

9.2.1 Dose/route of administration/treatment schedule

Treatments will be administered under close monitoring (hospital or day hospital for the first two weeks at least) to reduce suicidal risk to a minimum.

Patients will receive 1 capsule b.i.d. from day 1 to day 42. In case of inefficacy or unsatisfactory response (slight worsening or no change or minimal improvement at the CGI, see assessments), the dose will be increased to "dose 2" (see 8.0 Experimental Treatments) from day 22 to day 42, i.e. up to the end of treatment. In case of intolerance the dose will be reduced to the previously well tolerated lower dosage level.

The treatments will be administered in the morning and in the evening, at least 2 hours before or after meals.

9.2.2 Duration of treatment

The experimental treatment will be administered for 6 weeks.

9.2.3 Indications for early termination of test therapy

Termination of test therapy prior to completion of the 6 weeks treatment period may be considered under the following circumstances:

- Patient's request

- Switch to mania

- Unacceptable toxicity: this is defined as the occurrence of serious (see Adverse Events) adverse events (see 12.0)

- Lack of efficacy: this will apply to patients who will show unacceptable deterioration after at least 2 weeks of treatment (worsening in CGI)

In case of treatment discontinuation the complete final battery of assessments will be carried out.

9.2.4 Dropouts/replacement of subjects

Patients who drop out of the study for any reason will not be substituted.

For those patients who have been selected for the study who drop out at any time, even if it is before entrance to the treatment period, documentation will be provided.

9.2.5 Concomitant therapy

No concomitant medications other than hypnotic on p.r.n. basis are allowed at entry into the study. Concomitant medication should be avoided throughout the study. In case the events arising during the course of the study nonpsychotropic medications which are considered necessary for the patient's welfare may be administered and will not be considered violation to the protocol. The drugs, dosage and frequency of administration will be recorded. Chloral hydrate(0.5-1g/night) as sleep inducer on p.r.n. basis at bed-time is allowed.

9.2.6 Indications for opening the code

The Investigator will be given individual sealed envelopes containing the information on patient's treatment. These latter may be opened only in case of emergency necessitating treatment identification; the Investigator will immediately (within 24 hours) inform the study Monitor at FICE Subsidiaries and will report full description of reasons for opening the code in the CRF (Adverse Event Form).

The sealed individual codes will be returned to Farmitalia Carlo Erba at the end of the study.

9.3 Follow-up

A follow-up visit will be carried out for each patient one month after treatment discontinuation, in order to monitor possible withdrawal reactions and collect information on interval events.

Patients willing to continue receiving the experimental treatment after completion of the 6 weeks treatment period will be maintained under the same medication in blind conditions until completion of the last patient of the center. Monthly visits will be carried out for efficacy and safety assessment and drug dispensing. The medications will be prepared as described for the initial double-blind treatment period, but in monthly units.

Afterwards, patients will be followed-up in open conditions. Reboxetine tablets will be provided by Farmitalia Carlo Erba while, for those patients who were receiving imipramine, Tofranil will be prescribed.

9.4 Study timetable

Foreseen start date: September-October 90
Duration of accrual: 12 months
Foreseen end date (date of the last visit of the last patient, excluding follow up)): November-December 91.

10.0 EFFICACY ASSESSMENTS

10.1 Variables to be measured for efficacy assessment

On days 0, 7, 14, 21, 28, 35, 42 :

- Hamilton Depression Rating Scale (21 items HAMD, enclosure 7); as above plus at screening for entry and monthly during the follow-up period.

- Clinical Global Impression (Enclosure 8), as above plus monthly during the follow-up period.

- Montgomery-Asberg Depression Rating Scale (Enclosure 9)

- Patient Global Impression (Enclosure 10)-excluding day 0

- Relational rating scales (Enclosure 11)

The latter is adopted in order to explore relational aspects of the Depressive Disorders ; Investigators are expected to propose 1-2 additional items of relevance for each patient in their opinion.Consistency of suggestions will be evaluated and on this basis an International Scale developed.

All psychiatric evaluations and ratings will be carried out by the same observer for a given patient, preferably in the same setting and at the same time of the day.

10.2 Efficacy definition

Decreases of at least 50 % in the total HAMD score vs day 0 will be considered index of response whereas total HAMD score of 10 or less will be considered index of remission.

10.3 Cognitive function evaluation

Cognitive function will be evaluated on the day 0, day 14, and at the end of the study according to the model tests described in Attachment C.

10.4 Criteria for subject evaluability

Every randomized patient will be included in the analysis.

11.0 SAFETY ASSESSMENT

11.1 Variables to be measured for safety assessment

- Standard medical history: at screening

- Standard clinical examination: full physical examination: at screening

- Blood pressure and pulse will be measured in the lying (after 5 minutes lying) and in the standing position (1 -2 minutes after standing up) in the morning: at screening and at each visit.

- ECG: at screening, day 21, day 42 and every three months during follow-up.

- Chest X-ray: at screening

- Laboratory: TSH and T4 at screening; full blood count, sodium, potassium, chlorine, BUN, creatinine, glucose, bilirubin, calcium, phosphorus, SGOT, SGPT, gamma GT, alkaline phosphatase, LDH, total proteins, albumin, cholesterol, uric acid, triglycerides, globulins - α_1, α_2, ß, gamma -, urinanalysis: at screening, day 21, day 42 and every three months during follow-up.

- Adverse events: a check-list will be administered at each visit (Enclosure 12).

11.2 Criteria for subject evaluability

Every patient who has received at least one dose of the experimental treatment will be included in the safety evaluation.

12.0 ADVERSE EVENTS

Patients will be notified of possible adverse events they could experience and instructed to immediately report them to the Investigator.

Any newly observed sign or symptom, noticed by the Investigator or complained of by the patient, including clinically relevant lab abnormalities, will be recorded in the appropriate section of the CRF, regardless of presumed relationship to study medication.

For each event, the following information will be entered in the CRF: description, onset date, disappearance date, severity (1 = mild, awareness of sign or symptom, but easily tolerated; 2 = moderate, discomfort enough to cause interference with usual activity; 3 = severe, incapacitating with inability to work or do usual activity; 4 = unknown), drug cause-effect relationship (according to Karch and Lasagna modified criteria; see enclosure 13), outcome, dechallenge (what happened to the adverse event when the drug was stopped or the dose decreased?) rechallenge (what happened when the drug was restarted after the adverse event had disappeared ?). The Investigator will also note if the double-blind code has been opened, the action taken regarding the test drug (none, discontinued, dosage reduced) and any treatment applied because of the adverse reactions.

All serious* ("any experience that is (potentially) fatal or life-threatening, disabling, incapacitating, requires inpatient hospitalization, or causes a congenital anomaly or cancer or is due to overdose") and/or unexpected* ("any adverse experience that is not identified in nature, severity or frequency in the current investigator's brochure for the study") adverse events must be immediately (within 24 hours) reported by telephone to FICE Subsidiaries Monitors (see Section 17.0) and the Adverse Event Report Form (enclosure 14) must be filled in immediately. FICE will notify the Regulatory Authority in accordance with statutory requirements. The same applies to all patients who die, irrespective of whether the event was judged as related to treatment, during the course of the study or within 30 days of completion of treatment.

In case of death, if an autopsy is performed, a copy of the pathological report should be sent to the FICE subsidiary monitor.

13.0 EVALUATION SCHEDULE

Is reported in table 1.

14.0 STATISTICAL CONSIDERATIONS

14.1 Sample size

The main evaluation of treatment effectiveness will be based on the comparison with respect to placebo of the total score of the HAMD. The comparison will be performed on the difference between baseline and the last postbaseline score for each patient regardless of length of time in the study. Thus, this analysis, requiring at least one visit after baseline, takes into account differential dropout rates among treatment groups.

Either imipramine and reboxetine will be compared to placebo. The first comparison is set up in order to establish the sensitivity of the trial, while the second one will allow the evaluation of the new compound (reboxetine).

---

* Code of Federal Regulation, Vol 21 Part 312. Revised as of April 1, 1987, pg. 75.
* J.L.Bem et al.: Review of yellow cards (1986): report to the Committe on the Safety of Medicines. Br.J. Clin. Pharmac. (1988), **26**, 679-689.

Therefore the following hypothesis systems set up:

Ho: $\delta t \geq \delta p$ i.e. $\delta t - \delta p \geq 0$

Ha: $\delta t < \delta p$ $\delta t - \delta p < 0$

where δt and δp represent respectively the true mean of the distribution of the difference from baseline of total score of the HAMD for reboxetine (or imipramine) and placebo.

In order to take into account the multiplicity of the comparisons, the criterion of Bonferroni is applied. Consequently the α level for the simultaneous inference is fixed at 0.025 for each comparison (overall α level = 0.05) (this is equivalent to the Dunnett procedure which would lead to an α level of 0.024 for each comparison).

From the phase II trial and from the literature (6) it seems reasonable to assume that treatment groups will show a variability (expressed as standard deviation) of 9 points. Considering of clinical relevance a difference between reboxetine, or imipramine, and placebo of at least 4 points, 80 patients per group are necessary in order to provide a power ≥ 0.80 if the alternative hypothesis is true, with the α level fixed at 0.025, for each of the two tests. Taking into account the possibility of dropouts before the first postbaseline visit and nonevaluable patients according to protocol criteria, 100 patients per group should be recruited.

14.2 Statistical analysis

The main analysis of treatment effectiveness will be carried out on the variable 'total score of HAMD' considering the difference between baseline and the last postbaseline score for each patient regardless of length of time in study. Both reboxetine and imipramine will be compared to placebo. Consistently with the method used for the sample size calculation a multiple t test procedure will be adopted to test the null hypothesis. Analysis of variance will produce the appropriate estimate of residual variability.

Evident unbalances among baseline values in the three groups will be taken into account by means of analysis of covariance.

As secondary aim reboxetine will be compared to imipramine in respect to HAMD total score considering the difference between baseline and the last postbaseline score for each patient. In this case a two tail test will be applied. Confidence interval of the difference between treatment mean decrements vs baseline will also be computed.

In order to have a more complete picture of reboxetine effectiveness results obtained from the other administered scales (Montgomery-Asberg, CGI, PGI) as well as response/remission rates will be considered. Response/remission rate is defined as the proportion of randomized patients experiencing response/remission (see 10.2) at a fixed time.

All the efficacy variables will be analysed taking into account both the values obtained at the last postbaseline visit and values obtained at each week. Explorative comparisons among the three groups will be performed.

Time course of the score of the administered rating scales will be described for all the three groups. Time trend analysis will be performed on patients completing the six weeks treatment period. If judged to be informative, weekly analysis, including only those patients remaining in the study at a particular week, will be carried out.

Dropouts will be classified by reasons for study termination and proportions of patients dropped out compared among groups.

Frequencies of patients showing maximum decrease ≥ 20 mmHg in the standing systolic blood pressure will be compared among groups.

Adverse events will be presented by patient-by-patient listing and tabulated by treatment both on a patient basis and on an event basis. If clinically significant differences arise, they will be submitted to non parametric test of the differences among treatment groups.

Deccriptive statistics (mean, median, etc.) for laboratory data will be provided as well as frequency of abnormal values, with respect to normal range, after treatment in each group.

15.0 ETHICAL ASPECTS

The study will be carried out according to the Helsinki Declaration (Venice revision, Enclosure 15)

15.1 Ethical Committee

This study will not be undertaken until approval is obtained from the Ethical Committee Institutional Review Board (IRB) of the participating centres. It is responsibility of the Investigator to submit the study protocol with its attachments to the Ethical Committee.

The written approval of the Ethical Committee or IRB will report the name and profession of all its members and a copy of it will be sent to the Sponsor before the study begins.

The Investigator is committed, in compliance with local requirements, to inform the Ethical Committee of any emergent problems, serious adverse reactions or protocol amendments.

15.2 Informed consent

Before entering the study each patient will be receive an explanation of the nature, duration, and purpose of the study and the action of the compounds in such a manner that the patient is aware of the potential risks, inconveniences or adverse effects that may occur and can express his/her informed consent to participate. The consent form (enclosure 3) will be signed by the patient or by the next of kin and/or by the Investigator. In the latter case, the signature of a witness will testify that full information was given to the patient.

16.0 PROTOCOL AMENDMENTS

After the protocol has been signed, no changes will be made without the agreement of both the Investigator, the Steering Committee and the Sponsor. Any change will be recorded on a written agreement which will be signed and dated by both parties and attached to the original protocol. No protocol change will be implemented without Regulatory approval, where required.

17.0 STUDY MONITORING

The monitors of the study are listed in enclosure 16.

A pre-study visit will be made by the monitor to the Investigator in order to discuss problems, if any, and the obligations of both the Sponsor and the Investigator. During the trial monitoring visits will be paid to the site by the study monitor every four weeks. During the visits the monitor will assess the progress of the study, review the compliance with the study protocol, discuss any problem, check the CRFs for legibility, accuracy and completeness, validate CRFs content against source documents, assess the status of drug storage dispensing and retrieval.

Operating procedures for training on assessment instruments, study monitoring and coordination are described in attachment A.

18.0 DRUG SUPPLY AND INVENTORY

Test preparation will be supplied by Farmitalia Carlo Erba in the form described in 8.1. Records will be kept by the Investigator as to the disposition of study drug for each patient. A disposition form accounting for all study supplies will be signed by the Investigator (enclosure 17).

19.0 ADMINISTRATIVE ASPECTS

19.1 **Insurance policy** (enclosure 18)

Farmitalia Carlo Erba Company declares to have a group insurance cover (policy N0. 4W8102 - Italia Assicurazioni) which provides indemnity to the Investigator, to the co-Investigators and to the subjects participating in the trial.

19.2 **Curriculum vitae**

The Investigator will provide the Sponsor with signed copies of his/her and his/her co- Investigators CVs.

19.3 **Data collection in the Case Record Form**

All study data will be recorded in the CRF supplied by the Sponsor (Attachment B). A black ink ball point pen should be used for entering the data to ensure the good quality of the reproduced CRFs copies.

Only the Principal Investigator and the duly authorized co-Investigators can make entries in the CRF.

In case of errors corrections must be made by crossing out the incorrect entry (that must remain legible) and entering the correction followed by the Investigator's initials and the date of the correction.

On the occasion of the monitoring visits the monitor will take away the original and one copy of each page, while the Investigator will retain a copy for his files, together with the drug disposition records, for ten years after the discontinuation of the investigation.

19.4 Use and publication of the date obtained from the study

All unpublished documentation including the protocol, the CRF and the Investigator's Brochure, given to the Investigator is confidential. These documents cannot be disclosed to a third party without the written consent of FICE R&D. The submission of these documents to the Ethical Committee is expressely permitted.

The Investigator agrees that FICE R&D maintains the right to utilize the results of this study, in their original form and/or in a global report, for submission to the governmental and regulatory authorities of any country.

20.0 STUDY REPORT

20.1 Clinical Study Final Report

The final Medical Study Report will be written by the Product Leader and will be submitted to the Investigator for approval and signature.

20.2 Use and publication of Study Results

The Investigators, whilst free to use the data resulting from this study, are asked to discuss any paper with Farmitalia Carlo Erba prior to publication; to this purpose copy of manuscript/abstract as to be available for FICE R&D Approval Procedure 30 days prior to publication. The results of the study may be submitted for a common publication, agreed upon between the Investigator and FICE R&D.

21.0 END OF THE STUDY

The Investigator or FICE R&D could terminate this study at any time for well documented reasons. In this event the other party will be immediately notified.

22.0 STUDY COORDINATION

A Steering Committee in charge of the coordination of the study will be formed, as described in Attachment A.

23.0 REFERENCES

1. Reboxetine Investigator Brochure, FICE, CNS Line, June 1988

2. /602i - Herrmann W.M. et al. (AFB - Berlin)
Safety and tolerance of reboxetine in healthy male volunteers - A single rising dose tolerance study.
June 15 1984.

3. /603i - Herrmann W.M. (AFB - Berlin)
Reboxetine - Quantitative pharmaco EEG and pharmaco-psychological study.
January 1985.

4. /604i - Dubini A. et al.
Disposition and fate of ^{14}C-reboxetine administered orally to healthy volunteers.
March 1985.

5. /701 - A. Dubini, T. Ban
Reboxetine: Open Dose Range Finding study in patients hospitalized for major depressive disorders
February 89

6. Stark P., Hardison D.
J. Clin. Psychiatry, 46:53-58, 1985

24.0 SIGNATURES

Signatures of the:

Investigator _____

Study Monitor _____

Product Leader _____

Line Medical Head Adriano Dubini

Biostatisticians _____

TABLE 1 — **EVALUATION SCHEDULE**

DAY	SCREEN	0	4	7	14	21	28	35	42
TREATMENT RBX mg		8-->				10-->			
TREATMENT IMI mg		100-150-->				200-->			
TREATMENT PLACEBO									
DIAGNOSIS : DSM III R	■								
MEDICAL HISTORY	■								
PHYSICAL EXAMINATION	■								
MMS	■								
VITAL SIGNS	■	■		■	■	■	■	■	■
ECG	■					■			■
X-RAY	■								
LABORATORY	■					■			■
21-ITEM HAMD	■	■		■	■	■	■	■	■
CGI		■		■	■	■	■	■	■
MADRS		■		■	■	■	■	■	■
PATIENT GLOBAL IMPR.				■	■	■	■	■	■
RELATIONAL RATING SCALE		■		■	■	■	■	■	■
COGNITIVE EVALUATION		■			■				■
ADVERSE EVENTS		■		■	■	■	■	■	■

LIST OF ENCLOSURES

1) LIST OF CENTERS

2) DSM-III-R CRITERIA

3) CONSENT FORM

4) MMS: MINI MENTAL STATE

5) EXPERIMENTAL TREATMENT LABELLING

6) SCREENING FORM

7) HAMD: HAMILTON DEPRESSION RATING SCALE

8) CGI: CLINICAL GLOBAL IMPRESSION

9) MADRS: MONTGOMERY ASBERG DEPRESSION RATING SCALE

10) PATIENT GLOBAL IMPRESSION

11) RDRS: RELATIONAL RATING SCALE

12) ADVERSE EVENTS: CHECK LIST

13) KARCH AND LASAGNA MODIFIED CRITERIA

14) ADVERSE EVENTS REPORT

15) DECLARATION OF HELSINKI

16) LIST OF MONITORS

17) DRUG ACCOUNTABILITY FORM

18) INSURANCE POLICY

ATTACHMENT A

PROTOCOL 20124/015: OPERATING PROCEDURES FOR TRAINING ON ASSESSMENT INSTRUMENTS, STUDY MONITORING AND COORDINATION

ATTACHMENT B

CASE RECORD FORM

ATTACHMENT C

COGNITIVE FUNCTION EVALUATION

Appendix 1 : Manual for COGNITIVE EVALUATION
Appendix 2 : Manual for MEMORY ASSESSMENT

Enclosure 1

LIST OF PARTICIPATING CENTERS

No.	Country	Principal Investigator (Institution, Address)	Number of patients
1.	Australia	Dr. Ramesh Gupta Phillip Health Centre Woden, Canberra	18
2.	France	Prof. Pellet Hopital Bellevue Boulevard Pasteur Service de Psychiatrie 42043 Saint Etienne Cedex	24
3.	France	Dr. Chabannes Clinique du Nivolet Service de Psychiatrie B.P. 126 73011 Chambery Cedex	24
4.	France	Dr. Haxaire Cabinet Médical 15 bd Joffre A 54000 Nancy	24
5.	France	Prof. Leger Centre Hospitalier Spécialisé "Esquirol" 15 rue du Docteur-Marcland 87025 Limoges Cedex	24
6.	France	Dr. Cullerre Cabinet Médical 189 rue Colonel Jean Muller 56000 Lorient	24
7.	Germany	Dr. E.U. Vorbach Psychiatrische Klinik Elisabethenstift Landgraf-Georg Str. 100 6100 Darmstadt	24

8. Italy	Prof. E. Aguglia Department of Psychiatry University of Trieste via s. Cilino 16 34126 Trieste phone:040/671077	24
9. Italy	Prof. E.Smeraldi Ospedale San Raffaele Villa Turro via Prinetti 29 20127 Milano phone: 02/28043229	24
10. Sweden	Dr. B. Wistedt Danderyd's Hospital Stockholm	24
11. United Kingdom	Prof. R.G.Priest Academic Department of Psychiatry St. Marys Hospital Pread Street London W2 1NY phone: 0717251648	42
12. Canada	Prof. M. Ohayon Center of Research Hopital Loui Lafontaine 7401 Rue Hochelaga Montreal, Que H1N 3M5 phone: 514/2514015	36
13. Australia	Prof. G.D.Burrows Department of Psychiatry University of Melbourne Austin Hospital, Heidelberg, Vic. 3084 phone: 450-5111	18
14. "	Prof. J. Tiller Royal Hospital Melbourne	12
15. "	Dr. T. George Prince Charles Hospital Brisbane	12

Enclosure 2

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1

Centre No. | | | | |

Pat. Initials 9550082

Visit/cycle S C R E E

Date D M Y

DSM-III-R: DIAGNOSTIC CRITERIA FOR THE *MAJOR DEPRESSIVE EPISODE*

Note: all A, B, C and D must be marked as "present"

Mark "X" if present

A. At least five of the following symptoms have been present during the same two-week period and represent a change from previous functioning; at least one of the symptoms is either 1) depressed mood or 2) loss of interest or pleasure.

1) depressed mood most of the day, nearly every day, as indicated by subjective account or observation by others ☐
2) markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated either by subjective account or observation by others of apathy most of the time) ☐
3) significant weight loss or weight gain when not dieting (e.g. more than 5% of body weight in a month), or decrease or increase in appetite nearly every day ☐
4) insomnia or hipersomnia nearly every day ☐
5) psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down) ☐
6) fatigue or loss of energy nearly every day ☐
7) feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick) ☐
8) diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or as observed by others) ☐
9) recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide ☐

"A" present..... ☐

B. 1) It cannot be established that an organic factor initiated and maintained the disturbance ☐

2) The disturbance is not a normal reaction to the death of a loved one ☐

"B" present..... ☐

C. At no time during the disturbance have there been delusions or hallucinations for as long as two weeks in the absence of prominent mood symptoms (i.e., before the mood symptoms developed or after they have remitted)

"C" present..... ☐

D. Not superimposed on Schizophrenia, Schizophreniform, Disorder, Delusional Disorder, or Psychotic Disorder NOS.

"D" present..... ☐

Investigator's signature _____

ENCLOSURE No. 3

9550082

REBOXETINE PROTOCOL 20124/015

Multicenter, multinational double blind study of the activity and tolerability of reboxetine vs imipramine and placebo in patients suffering from Major Depressive Disorders.

CONSENT FORM

Principal Investigator: .....

EXPLANATION

Purpose of the study

Reboxetine, a new potential antidepressant agent, has effects in animals which suggest that it may exert therapeutic efficacy of faster onset, in comparison with established antidepressant drugs, in patients suffering from depressive disorders. The trial is proposed in order to learn about the antidepressant effectiveness of the compound and its tolerability.

Plan of the study

After an initial drug free wash out period of at least one week, patients will receive either reboxetine or imipramine, an antidepressant of established efficacy, available on the market in most countries or a harmless inactive treatment (placebo). Neither patients nor doctors will know which treatment will be administered in individual cases untill after the study is completed. The identity of the treatments can anyhow be determined immediately if any medical problem will develop and it will become important to learn which of the two possible treatments is being given.

Treatment will be administered for six weeks. It will be discontinued in case of deterioration of psychiatric symptomatology or in case of significant side-effects. In addition patients participating in the study may withdraw their consent at any time without prejudice to their continued medical treatment.

During treatment, physical and psychiatric examinations will be done on frequent occasions, in order to determine

possible side-effects and benefits of treatments. Blood tests, urinalysis, ECG will be undertaken be-weekly. Blood pressure and pulse will be taken every week, on the occasion of each visit.

Possible discomforts and risks

Antidepressant drugs can cause dry mouth, blurred vision, dizziness, mild difficulty in voiding urine, postural hypotension and electrocardiographic changes.

Reboxetine has been so far administered for 28 days to about 180 patients and was well tolerated up to the dose of 5 mg twice daily. In the dose range of 3-5 mg twice daily clinically relevant improvement of depressive condition was present in the majority of patients; symptoms complained off by patients were mainly mild and transient and included most frequently headache, sweating, lassitude, nasal congestion, constipation and urinary hesitancy. At higher doses orthostatic hypotension, tachycardia, dizziness, blurred vision and nausea were reported.

Patients participating in the study will be carefully monitored to detect early signs of such side-effects.

Possible benefits

Other drugs are available for treatment of depressive disorders but none has been of proven value in all cases. This study will allow the evaluation of the antidepressant activity of reboxetine in comparison with placebo (associated to a response rate of 30-40% in acute depressive episodes) and imipramine, a compound of established efficacy. The evaluation of patient response under placebo could be useful in deciding the most appropriate treatment approach in individual cases.

Alternative treatment

Patients would receive alternative pharmacological therapy with an antidepressant drug chosen on the basis of response during previous episodes, if any. Risks and benefits of receiving treatment with any of the available antidepressant drugs can be explained by .....

Confidentiality

Participation in the study will be kept confidential to the extent permitted by law.

Problems and questions

Should any problem or question arise with regard to the study, patients can contact the Principal Investigator:

.....
or the other staff members also involved in the study:

.....

.....

.....

In addition any problem or question can be discussed with a member of the Institutional Review Board (.....
.....), the Committee which has evaluated the potential risks and possible benefits of the study.

Payments and policy regarding research-related injuries.

Patients will not be paid for the participation in the study. The Clinical Center will provide short-term medical care for any physical injury resulting from participation in the study. No long-term medical care or financial compensation for such injuries will be provided except as it may be through whatever remedies are normally available under law. Insurance coverage is granted through the Sponsor Company.

PATIENTS CONSENT

I have read the explanation about this study and I have been given the opportunity to discuss it and to ask questions. I hereby consent to take part in this study.

_____ _____

Patient Signature date

I have explained all the above indicated aspects of the study to the patient, who expressed his/her consent to the participation.

_____ _____

Investigator Signature date

_____ _____

Wittness Signature date

Enclosure 4

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**
9550082

Protocol No. 2|0|1|2|4|0|1

Centre No. | | | | |

Pat. Initials | | |

Visit/cycle S|C|R|E|E

Date | | | | | | |
D M Y

THE MINI-MENTAL STATE EXAMINATION

		Score	Point
Orientation			
1. What is the	Year?	-	1
	Season?	-	1
	Date?	-	1
	Day?	-	1
	Month?	-	1
2. Where are we?	State?	-	1
	County?	-	1
	Town or city?	-	1
	Hospital?	-	1
	Floor?	-	1
Registration			
3. Name three objects, taking one second to say each. Then ask the patient all three after you have said them. Give one point for each correct answer. Repeat the answers until the patient learns all three.		-	3
Attention and calculation			
4. Serial sevens. Give one point for each correct answer. Stop after five answers. ALTERNATE: Spell WORLD backwards.		-	5
Recall			
5. Ask for names of three objects learned in Question 3. Give one point for each correct answer.		-	3
Language			
6. Point to a pencil and a watch. Have the patient name them as you point.		-	2
7. Have the patient repeat "No ifs, ands, or buts."		-	1
8. Have the patient follow a three-stage command: "Take the paper in your right hand. Fold the paper in half. Put the paper on the floor".		-	3
9. Have the patient read and obey the following: "CLOSE YOUR EYES". (Write it in large letters.)		-	1
10. Have the patient write a sentence of his or her own choice. (The sentence should contain a subject and an object and should make sense. Ignore spelling errors when scoring.)		-	1
11. Enlarge the design printed below to 1-5 cm per side and have the patient copy it. (Give one point if all sides and angles are preserved and if the intersecting sides form a quadrangle.)		-	1



____ = Total 30

Investigator's signature _____

Enclosure 5

9550082

REBOXETINE PROTOCOL 20124/015

EXPERIMENTAL TREATMENT LABELLING

TREATMENT PHASE:

reboxetine protocol 20124/015
patient No.....
week 1 - 6
batch No.....
expiry.....
drug for ivestigational use

DOSE 2 TREATMEN PHASE:

reboxetine protocol 20124/015
patient No.....
week 4 - 6
batch No.....
expiry.....
drug for investigational use

Enclosure 6

FARMITALIA CARLO ERBA

CNS LINE

Patient initials ⌊_⌊_⌊_⌋

Hospital File/Out Patient Reg. N° ⌊_⌊_⌊_⌊_⌊_⌊_⌋

Phase III

Multicenter, multinational double-blind study of the activity and tolerability of reboxetine vs imipramine and placebo in patients suffering from major depressive episodes

PROTOCOL 20124/015

SCREENING FORM

Investigator's signature _____

577

ERBAMONT GROUP

Cont.'d enclosure 6

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2|0|1|2|4|0|1|

Centre No. ____ Pat. Initials 9550082 Visit/cycle S|C|R|E|E|

Investigator's name _____ Monitor's name _____ Date ___ ___ ___ (D M Y)

PATIENT IDENTIFICATION

Hospital File/Out Pat. Register N° _____

Initials ____ Sex M F Age (years) ___ Weight (kg) ___ Height (cm) ___

Birth date ___ ___ ___ (D M Y)

Ethnic group: Caucasian ☐ Black ☐ Asian ☐ Other ☐, specify _____

Out-patient ☐ In patient ☐, hospitalized on ___ ___ ___ (D M Y)

DIAGNOSIS

– DSM-III-R AXIS I _____

HISTORY OF THE MENTAL DISORDER: Unknown ☐ if known:

– Age of onset of disease years ___

– Number of previous episodes ___

– Approximate duration of last episode weeks ___ months ___ years ___

PRESENT EPISODE

– Approximate duration at the time of admission to the study days ___ weeks ___ months ___ years ___

THE PRESENT EPISODE IS BEST CHARACTERIZED AS:

– Exacerbation of chronic condition 1

– Recurrence of similar previous conditions 2

– Significantly different from any previous conditions 3

– First occurrence, no previous psychiatric diagnosis 4

ONSET OF PRESENT EPISODE WAS:

– Acute (<2 weeks) 1

– Subacute (≥ 2 weeks) 2

– Insidious (≥ 3 months) 3

PRECIPITATING EXTERNAL STRESS WAS:

– Absent 1

– Probably present 2

– Definitely present 3

578

1-scree

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2|0|1|2|4|0|1|

Centre No. | | | |

Pat. Initials 9550082

Visit/cycle S|C|R|E|E|

Date | | | | | | | | |
D M Y

DSM-III-R: DIAGNOSTIC CRITERIA FOR THE *MAJOR DEPRESSIVE EPISODE*

Note: all A, B, C and D must be marked as "present"

Mark "X" if present

A. At least five of the following symptoms have been present during the same two-week period and represent a change from previous functioning; at least one of the symptoms is either 1) depressed mood or 2) loss of interest or pleasure.

1) depressed mood most of the day, nearly every day, as indicated by subjective account or observation by others ☐
2) markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated either by subjective account or observation by others of apathy most of the time) ☐
3) significant weight loss or weight gain when not dieting (e.g. more than 5% of body weight in a month), or decrease or increase in appetite nearly every day ☐
4) insomnia or hipersomnia nearly every day ☐
5) psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down) ☐
6) fatigue or loss of energy nearly every day ☐
7) feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick) ☐
8) diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or as observed by others) ☐
9) recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide ☐

"A" present..... ☐

B. 1) It cannot be established that an organic factor initiated and maintained the disturbance ☐
2) The disturbance is not a normal reaction to the death of a loved one ☐

"B" present..... ☐

C. At no time during the disturbance have there been delusions or hallucinations for as long as two weeks in the absence of prominent mood symptoms (i.e., before the mood symptoms developed or after they have remitted)

"C" present..... ☐

D. Not superimposed on Schizophrenia, Schizophreniform, Disorder, Delusional Disorder, or Psychotic Disorder NOS.

"D" present..... ☐

2-scree

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound REBOXETINE

Cont. 'd enclosure
Protocol No. 2 0 1 2 4 0 1

Centre No. | | | |

Pat. Initials 9550082

Visit/cycle S C R E E

Date D M Y

THE MINI-MENTAL STATE EXAMINATION

		Score	Points
Orientation			
1. What is the	Year?	-	1
	Season?	-	1
	Date?	-	1
	Day?	-	1
	Month?	-	1
2. Where are we?	State?	-	1
	County?	-	1
	Town or city?	-	1
	Hospital?	-	1
	Floor?	-	1
Registration			
3. Name three objects, taking one second to say each. Then ask the patient all three after you have said them. Give one point for each correct answer. Repeat the answers until the patient learns all three.		-	3
Attention and calculation			
4. Serial sevens. Give one point for each correct answer. Stop after five answers. ALTERNATE: Spell WORLD backwards.		-	5
Recall			
5. Ask for names of three objects learned in Question 3. Give one point for each correct answer.		-	3
Language			
6. Point to a pencil and a watch. Have the patient name them as you point.		-	2
7. Have the patient repeat "No ifs, ands, or buts."		-	1
8. Have the patient follow a three-stage command: "Take the paper in your right hand. Fold the paper in half. Put the paper on the floor".		-	3
9. Have the patient read and obey the following: "CLOSE YOUR EYES". (Write it in large letters.)		-	1
10. Have the patient write a sentence of his or her own choice. (The sentence should contain a subject and an object and should make sense. Ignore spelling errors when scoring.)		-	1
11. Enlarge the design printed below to 1-5 cm per side and have the patient copy it. (Give one point if all sides and angles are preserved and if the intersecting sides form a quadrangle.)		-	1



_____ = Total 30

580

3-scree

Investigator's signature _____

Cont.'d enclosure 6

[illegible]MITALIA CARLO ERBA Erbamont Group | Compound **REBOXETINE** | Protocol No. 2 0 1 2 4 0 1

Centre No. | Pat. Initials 9550082 | Visit/cycle S C R E E N

Date D M Y

HAMD: HAMILTON DEPRESSION RATING SCALE

1. Depressed mood ***(Sadness, hopeless, helpless, worthless)***

[0] Absent
[1] These feeling states indicated only on questioning
[2] These feeling states spontaneously reported verbally
[3] Communicates feeling states non-verbally - i.e., through facial expression, posture, voice, and tendency to wee
[4] Patient reports VIRTUALLY ONLY these feeling states in his spontaneous verbal and non-verbal communication

2. Feelings of guilt

[0] Absent
[1] Self reproach, feels he has let people down
[2] Ideas of guilt or rumination over past errors or sinful deeds
[3] Present illness is a punishment. Delusions of guilt
[4] Hears accusatory or denunciatory voices and/or experiences threatening visual hallucinations

3. Suicide

[0] Absent
[1] Feels life is not worth living
[2] Wishes he were dead or any throughts of possible death to self
[3] Suicide ideas or gesture
[4] Attempts at suicide *(any serious attempt rates 4)*

4. Insomnia early

[0] No difficulty falling asleep
[1] Complains of occasional difficulty falling asleep - i.e., more than ½ hour
[2] Complains of nightly difficulty falling asleep

5. Insomnia middle

[0] No difficulty
[1] Patient complains of being restless and disturbed during the night
[2] Waking during the night - any getting out of bed rates 2 *(except for purposes of voiding)*

6. Insomnia late

[0] No difficulty
[1] Waking in early hours of the morning but goes back to slepp
[2] Unable to fall asleep again if he gets out of bed

7. Work and activities

[0] No difficulty
[1] Thoughts and feelings of incapacity, fatigue or weakness related to activities; work or hobbies
[2] Loss of interest in activity; hobbies or work - either directly reported by patient, or indirect in listlessness, indecision and vacillation *(feels he has to push self to work or activities)*
[3] Decrease in actual time spent in activities or decrease in productivity. In hospital, rate 3 if patient does not spend at least three hours a day in activities *(hospital job or hobbies)* exclusive of ward chores
[4] Stopped working because of present illness. In hospital, rate 4 if patient engages in no activities except ward chores, or if patient fails to perform ward chores unassisted

4-scree 581 Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound REBOXETINE

Protocol No. 2|0|1|2|4|0|1|5

Centre No. | | | | |

P... initials 9550082

Visit/cycle S|C|R|E|E|N

Date | | | | | |
D M Y

8. Retardation ***(Slowness of thought and speech; impaired ability to concentrate; decreased motor activity)***

[0] Normal speech and thought
[1] Slight retardation at interview
[2] Obvious retardation at interview
[3] Interview difficult
[4] Complete stupor

9. Agitation

[0] None [1] Fidgetiness [2] Playing with hands, hair, etc.
[3] Moving about, can't sit still [4] Hand wringing, nail biting, hair-pulling, biting of lips

10. Anxiety psychic

[0] No difficulty [1] Subjective tension and irritability
[2] Worrying about mirror matters [3] Apprehensive attitude apparent in face or speech
[4] Fears expressed without questioning

11. Anxiety somatic

Physiological concomitants of anxiety, such as: Gastro-intestinal *(dry mouth, wind, indigestion, diarrhea, cramps, belching)*; Cardio-vascular *(palpitations, headaches)*; Respiratory *(hyperventilation, sighing)*; Urinary frequency; Sweating

[0] Absent [1] Mild [2] Moderate
[3] Severe [4] Incapacitating

12. Somatic symptoms gastrointestinal

[0] None
[1] Loss of appetite but eating without staff encouragement. Heavy feeelings in abdomen
[2] Difficulty eating without staff urging. Requests or requires laxatives or medication for bowels or medication for G.I. symptoms

13. Somatic symptoms general

[0] None
[1] Heaviness in limbs, back or head. Backaches, headache, muscle aches. Loss of energy and fatigability
[2] Any clear-cut symptoms rates 2

14. Genital symptoms (Such as: *Loss of libido; Menstrual disturbances)*

[0] Absent [1] Mild [2] Severe

15. Hypochondriasis

[0] Not present [1] Self-absorption (bodily)
[2] Preoccupation with health [3] Frequent complaints, requests for help, etc.
[4] Hypocondriacal delusions

 Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2|0|1|2|4|0|1|

Centre No. | | | | |

Pat. Initials 9550082

Visit/cycle S|C|R|E|E|N

Date D M Y

16. Loss of weight ***Rate either A or B***

A. When Rating By History:

0 No weight loss
1 Probable weight loss associated with present illness
2 Definite (according to patient) weight loss
3 Not assessed

B. On Weakly Ratings By Ward Psychiatrist, When Actual Weight Changes Are Measured:

0 Less than 1 lb. weight loss in week
1 Greater than 1 lb. weight loss in week
2 Greater than 2 lb. weight loss in week
3 Not assessed

17. Insight

0 Acknowledges being depressed and ill
1 Acknowledges illness but attributes cause to bad food, climate, overwork, virus, need for rest, etc.
2 Denies being ill at all

18. Diurnal variation

A. Note Whether Symptoms Are Worse In Morning Or Evening. If NO Diurnal Variation, Mark "none":

0 No variation 1 Worse in A.M. 2 Worse in P.M.

B. When Present, Mark The Severity Of The Variation. Mark "None" If NO Variation:

0 None 1 Mild 2 Severe

19. Depersonalization and derealization (Such as: *Feelings of unreality, Nihilistic ideas)*

0 Absent 1 Mild 2 Moderate
3 Severe 4 Incapacitating

20. Paranoid symptoms

0 None
1 Suspicious
2 Ideas of reference
3 Delusions of reference and persecution

21. Obsessional and compulsive symptoms

0 Absent 1 Mild 2 Severe

Total score | |

6-scree

Investigator's signature _____

Cont. d enclosure 6

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1

Centre No. ____

Pat. Initials 9550082

Visit/cycle SCREEN

Date ____ (D M Y)

ADMISSION EXAMINATION

CHEST X-RAY taken on ____ (D M Y) normal ☐ abnormal ☐

If abnormal, detail _____

VITAL SIGNS

– Body temperature (°C)		___		
– Respiratory rate (breaths/min)		___		
– 3 min lying arterial blood pressure (mmHg)	systolic	___	diastolic	___
– 5 min lying heart rate (beats/min)		___		
– 2 min standing arterial blood pressure (mmHg)	systolic	___	diastolic	___
– 2 min standing heart rate (beats/min)		___		

MEDICAL HISTORY

– Important previous diseases _____

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1

Centre No. _____

Pat. Initials 9550082

Visit/cycle S C R E E

Date _____ D M Y

ECG

HEART RATE _____

- Normal .....
- Abnormal .....

if abnormal check one or more boxes as appropriate:

1 Sinus bradycardia (<60) .....
2 Sinus tachycardia (>100) .....
3 Sick Sinus Syndrome .....

- Atrial ectopic beats:
  - Occasional .....
  - Frequent (>6/mm) .....
  - Couplets .....
  - Supraventricular Tachycardia .....
- Ventricular ectopic beats:
  - Occasional .....
  - Frequent (>6/mm) .....
  - Polymorphic .....
  - Couplets .....
  - Ventricular Tachycardia .....
- Atrial fibrillation/flutter .....
- A-V Block 1st degree .....
  - 2nd degree - Mobitz 1 .....
  - Mobitz 2 .....
  - Complete .....
- Left ventricular hypertrophy .....
- Right ventricular hypertrophy .....
- Myocardial ischemia .....
- Previous Myocardial infarction .....
- Acute Myocardial infarction .....
- Right bundle branch block .....
- Left bundle branch block .....
- Left anterior hemiblock .....
- Left posterior hemiblock .....
- Bifascicular Block (specify) .....
- Trifascicular Block (specify) .....
- Other .....

(specify) _____

8-scree

Investigator's signature _____

Cont. 'd enclosure 6

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1

Centre No. | | | |

Pat. Initials 9550082

Visit/cycle S C R E E

Date D M Y

CONT' ECG

Please, add here the ORIGINAL TRACING AND MEDICAL REPORT

9-scree

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Cont. 'd enclosure 6
Protocol No. 2 0 1 2 4 0 1

Centre No. ____

Pat. Initials 9550082

Visit/cycle S C R E E

Date ____ D M Y

LABORATORY TESTS

Tests	Value	Clinically Significant abnormality**	Tests		Value*	Clinically Significant abnormality
BLOOD TESTS			BUN			
HB			Creatinine			
HCT			Uric acid			
RBC			Total bilirubin			
WBC			Direct bilirubin			
Neutrophils			Total protein			
Lymphocytes			Blood albumin			
Eosinophils			Cholesterol*			
Monocytes			Triglycerides*			
Basophils			Globulins:	α 1		
Platelets				α 2		
Na^+				β		
K^+				γ		
CL^-			TSH			
Ca^{++}						
PO_4			T_4			
SGOT			**URINALYSIS**			
SGPT			Specific gravity			
γ-GT			Albumin			
LDH			Sugar			
Alkaline phosphatase			RBC			
Blood sugar*			WBC			

* Fasting blood sample is required
** Cross in case of clinically significant abnormality

Observation: ____

10-scree

Investigator's signature ____

Cont. 'd enclosure 6

FARMITALIA CARLO ERBA
Erbamont Group

Compound REBOXET[illegible]

Protocol No. 2 0 1 2 4 0 1

Centre No. | | | | |

Pat. Initials 9550082

Visit/cycle S C R E E

Date | | | | | | (D M Y)

PREVIOUS TREATMENTS

NAME*	EFFICACY (Very poor, Poor, Fair, Good, Very good)	SIDE EFFECTS (if any)
	VP P F G VG	
	VP P F G VG	
	VP P F G VG	
	VP P F G VG	
	VP P F G VG	

Last treatment taken: name* _____ Last day of treatment | | | | | | (D M Y)

Drug free. Wash-Out Period: from | | | | | | (D M Y) to | | | | | | (D M Y)

CONCOMITANT DRUGS (during the drug free. wash-out period)

NAME*	Daily Dose (mg)	Started on (date)			Discontinued on (date)			Reason for the administration
		D	M	Y	D	M	Y	

* Whenever possible use non-proprietary name instead of trade name

Observations: _____

588

11-scree

Investigator's signature _____

Cont.'d enclosure 6

,,MITALIA CARLO ERBA Erbamont Group | Compound **REBOXETINE** | Protocol No. 2|0|1|2|4|0|1|E

Centre No. | | | | | | Pat. Initials 9550082 | Visit/cycle S|C|R|E|E|N

Date | | | | | | D M Y

PRE-STUDY CHECKLIST

IN THE PATIENT:

ARE THE FOLLOWING CONDITIONS PRESENT?	YES	NO
– Aged between 18 and 65 years inclusive?	☐	☐
– Affected by acute episodes of Major Depressive Episodes (DSM-III-R), *not accompanied by psycothic features with presence of episode for at least* one month and not for more than four?	☐	☐
– With a total score of 22 or above in the 21-HAMD?	☐	☐
– Able and willing (he/she or the next of kin) to give Informed Consent?	☐	☐
ARE THE FOLLOWING CONDITIONS ABSENT?		
– Dysthymia?	☐	☐
– History of Major Depressive Episodes, associated to Endocrine Disorders?	☐	☐
– Pregnancy? *(if applicable)*	☐	☐
– Refusal of contraceptive use during the study period? (if applicable)	☐	☐
– Clinically significant hematopoietic abnormality?	☐	☐
– Clinically significant lab values abnormality?	☐	☐
– Current evidence of urinary retention?	☐	☐
– Current evidence of glaucoma?	☐	☐
– Clinically significant physical abnormality?	☐	☐

If NO, please cross and detail:

– Hepatic function ☐: _____

_____

_____

– Renal function ☐: _____

_____

_____

– Gastrointestinal function ☐: _____

_____

_____

– Cardiovascular function ☐: _____

_____

_____

12-scree 589 Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 5

Centre No. | | | | |

Pat. Initials | | | 9550082

Visit/cycle S C R E E N

Date | | | | | | D M Y

(CONT'D)

ARE THE FOLLOWING CONDITIONS ABSENT?	YES	NO
- Participation in a clinical trial with an investigational compound in the 4 weeks preceding the study?	☐	☐
- Evidence of substance use disorder within past 6 months or currently?	☐	☐
- Chronic respiratory insufficienty?	☐	☐
- History of drug hypersensitivity?	☐	☐
- Any history of seizures or brain injury?	☐	☐
- Any other important clinical illness in the 4 weeks preceding the study?	☐	☐
- ECT in the previous 3 months?	☐	☐
- MMS < 22?	☐	☐
- High risk of suicide?	☐	☐

If the answer to any of the above questions is NO the patient is unsuitable for entry into the study and should no proceed further.

CONCLUSION

I, dr. _____ confirm that the available informations on the patient agree with exclusion and inclusion criteria and that the patient is suitable to be included in this study and will receive the following patient number | | | .

590

13-scree

Investigator's signature _____

Enclosure 7

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 5

Centre No. | | |

Patient No. | | |

Initials 9550082

Visit/cycle D A Y | |

Date | | | | | | D M Y

HAMD: HAMILTON DEPRESSION RATING SCALE

1. Depressed mood ***(Sadness, hopeless, helpless, worthless)***

[0] Absent
[1] These feeling states indicated only on questioning
[2] These feeling states spontaneously reported verbally
[3] Communicates feeling states non-verbally - i.e., through facial expression, posture, voice, and tendency to weep
[4] Patient reports VIRTUALLY ONLY these feeling states in his spontaneous verbal and non-verbal communication

2. Feelings of guilt

0 Absent
1 Self reproach, feels he has let people down
2 Ideas of guilt or rumination over past errors or sinful deeds
3 Present illness is a punishment. Delusions of guilt
4 Hears accusatory or denunciatory voices and/or experiences threatening visual hallucinations

3. Suicide

0 Absent
1 Feels life is not worth living
2 Wishes he were dead or any throughts of possible death to self
3 Suicide ideas or gesture
4 Attempts at suicide *(any serious attempt rates 4)*

4. Insomnia early

0 No difficulty falling asleep
1 Complains of occasional difficulty falling asleep - i.e., more than ½ hour
2 Complains of nightly difficulty falling asleep

5. Insomnia middle

0 No difficulty
1 Patient complains of being restless and disturbed during the night
2 Waking during the night - any getting out of bed rates 2 *(except for purposes of voiding)*

6. Insomnia late

0 No difficulty
1 Waking in early hours of the morning but goes back to slepp
2 Unable to fall asleep again if he gets out of bed

7. Work and activities

[0] No difficulty
[1] Thoughts and feelings of incapacity, fatigue or weakness related to activities; work or hobbies
[2] Loss of interest in activity; hobbies or work - either directly reported by patient, or indirect in listlessness, indecision and vacillation *(feels he has to push self to work or activities)*
[3] Decrease in actual time spent in activities or decrease in productivity. In hospital, rate 3 if patient does not spend at least three hours a day in activities *(hospital job or hobbies)* exclusive of ward chores
[4] Stopped working because of present illness. In hospital, rate 4 if patient engages in no activities except ward chores, or if patient fails to perform ward chores unassisted

 Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2|0|1|2|4|0|1|5

Centre No. | | | | |

Patient No. | | |

Initials 9550082

Visit/cycle D|A|Y | |

Date | | | | | | |
D M Y

8. Retardation ***(Slowness of thought and speech; impaired ability to concentrate; decreased motor activity)***

[0] Normal speech and thought
[1] Slight retardation at interview
[2] Obvious retardation at interview
[3] Interview difficult
[4] Complete stupor

9. Agitation

[0] None
[1] Fidgetiness
[2] Playing with hands, hair, etc.
[3] Moving about, can't sit still
[4] Hand wringing, nail biting, hair-pulling, biting of lips

10. Anxiety psychic

[0] No difficulty
[1] Subjective tension and irritability
[2] Worrying about mirror matters
[3] Apprehensive attitude apparent in face or speech
[4] Fears expressed without questioning

11. Anxiety somatic

Physiological concomitants of anxiety, such as: Gastro-intestinal *(dry mouth, wind, indigestion, diarrhea, cramps, belching)*; Cardio-vascular *(palpitations, headaches)*; Respiratory *(hyperventilation, sighing)*; Urinary frequency; Sweating

[0] Absent
[1] Mild
[2] Moderate
[3] Severe
[4] Incapacitating

12. Somatic symptoms gastrointestinal

[0] None
[1] Loss of appetite but eating without staff encouragement. Heavy feeelings in abdomen
[2] Difficulty eating without staff urging. Requests or requires laxatives or medication for bowels or medication for G.I. symptoms

13. Somatic symptoms general

[0] None
[1] Heaviness in limbs, back or head. Backaches, headache, muscle aches. Loss of energy and fatigability
[2] Any clear-cut symptoms rates 2

14. Genital symptoms (Such as: *Loss of libido; Menstrual disturbances)*

[0] Absent
[1] Mild
[2] Severe

15. Hypochondriasis

[0] Not present
[1] Self-absorption (bodily)
[2] Preoccupation with health
[3] Frequent complaints, requests for help, etc.
[4] Hypocondriacal delusions

 Investigator's signature _____

Cont. 'd Enclosure 7

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 5

Centre No. | | | |

Patient No. | | |

Initials | | |

9550082

Visit cycle D A Y | |

Date | | | | | |
D M Y

16. Loss of weight ***Rate either A or B***

A. When Rating By History:

0 No weight loss

1 Probable weight loss associated with present illness

2 Definite (according to patient) weight loss

3 Not assessed

B. On Weakly Ratings By Ward Psychiatrist. When Actual Weight Changes Are Measured:

0 Less than 1 lb. weight loss in week

1 Greater than 1 lb. weight loss in week

2 Greater than 2 lb. weight loss in week

3 Not assessed

17. Insight

0 Acknowledges being depressed and ill

1 Acknowledges illness but attributes cause to bad food, climate, overwork, virus, need for rest, etc.

2 Denies being ill at all

18. Diurnal variation

A. Note Whether Symptoms Are Worse In Morning Or Evening. If NO Diurnal Variation, Mark "none":

0 No variation 1 Worse in A.M. 2 Worse in P.M.

B. When Present, Mark The Severity Of The Variation. Mark "None" If NO Variation:

0 None 1 Mild 2 Severe

19. Depersonalization and derealization (Such as: *Feelings of unreality, Nihilistic ideas)*

0 Absent 1 Mild 2 Moderate

3 Severe 4 Incapacitating

20. Paranoid symptoms

0 None

1 Suspicious

2 Ideas of reference

3 Delusions of reference and persecution

21. Obsessional and compulsive symptoms

0 Absent 1 Mild 2 Severe

Total score | |

Investigator's signature _____

Enclosure 8

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 5

Centre No. | | | | |

Patient No. | | |

9550082
Initials | | |

Visit/cycle D A Y | |

Date | | | | | | |
D M Y

CLINICAL GLOBAL IMPRESSION (CGI)

A. SEVERITY OF ILLNESS

Considering your clinical experience with this particular population, how mentally ill is the patient at this time?

[1] Normal, not at all ill
[2] Borderline mentally ill
[3] Mildly ill
[4] Moderately ill
[5] Markedly ill
[7] Severily ill
[8] Among the most extremely ill patients

B. GLOBAL IMPROVEMENT (rate total improvement whether or not, in your judgement, it is due entirely to drug treatment)
Compared to this condition at admission to the study, how much has he changed?

[1] Very much improved
[2] Much improved
[3] Minimally improved
[4] No change
[5] Minimally worse
[6] Much worse
[7] Very much worse

C. EFFICACY INDEX (rate this item on the basis of drug effect only)

	Tolerability: side effects			
Activity	None	Do not significantly Interfere with patient's functioning	Significantly inter-fere with patient's functioning	Outweigh therapeutic effect
MARKED Vast improvememt, complete or nearly complete remission of all symptoms	1	2	3	4
MODERATE Decided improvement, partial remission of symptoms	5	6	7	8
MINIMAL Slight improvement which does not alter status of care of patient	9	10	11	12
UNCHANGED OR WORSE	13	14	15	16

Investigator's signature _____

Enclosure 9

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 5

Centre No. | | | |

Patient No. | | | |

Initials 9550082

Visit/cycle D A Y | |

Date | | | | | | | | |
D M Y

MADRS: MONTGOMERY ASBERG DEPRESSION RATING SCALE

1. Reported sadness
- Representing subjectively experienced mood, regardless of whether it is reflected in appearance or not. Includes depressed mood, low spirits, despondency, and the feeling of being beyond help and without hope.
- Rate according to intensity, duration and the extent to which the mood is influenced by events.
- Elated mood is scored zero on this item.

Occasional sadness may occur in the circumstances [0]; Predominant feelings of sadness, but brighter moments occur [1]; Pervasive feelings of sadness or gloominess, the mood is hardly influenced by external circumstances [2]; Continuous experience of misery or extreme despondency [3]. [ ]

2. Inner tension
- Representing feelings of ill-defined discomfort, edginess, inner turmoil, mental tension mounting to panic, dread and anguish.
- Rate according to intensity, frequency, duration and the extent of reassurance called for.
- Distinguish from sadness, worrying and muscular tension.

Placid, only fleeting inner tension [0]; Occasional feelings of edginess and ill-defined discomfort [1]; Continuous feelings of inner tension, or intermittent panic which the patient can only master with some difficulty [2]; Unrelenting dread or anguish, overwhelming panic [3]. [ ]

3. Apparent sadness
- Representing despondency, gloom and despair (more than just ordinary transient low spirits) reflected in speech, facial expression, and posture, rate by depth and inability to brighten up.

No sadness [0]; Looks dispirited but brightens up occasionally [1]; Appears sad and unhappy all of the time [2]; Extreme and continuous gloom and despondency [3]. [ ]

4. Suicidal thoughts
- Representing the feeling that life is not worth living, that a natural death would be welcome, suicidal thoughts, and preparations for suicide.
- Suicidal attempts should not in themselves influence the rating.

Enjoys life or takes it as it comes [0]; Weary of life, only fleeting suicidal thoughts [1]; Much better off dead. Suicidal thoughts are common, and suicide is considered as a possible solution, but without specific plans or intention [2]; Explicit plans for suicide when there is an opportunity, active preparation for suicide [3]. [ ]

5. Inertia
- Representing a difficulty getting started or slowness initiating and performing everyday activities
- Distinguish from indecision and fatiguability.

No difficulty in getting started. No sluggishness [0]; Difficulties in starting new activities [1]; Difficulties in starting very simple routine activities, which are carried out only with effort [2]; Complete inertia, unable to start any activity without help [3]. [ ]

6. Inability to feel
- Representing the subjective experience of reduced interest in the surroundings, or activities that normally give pleasure. The ability to react with adequate emotion to circumstances or people is produced.
- Distinguish from inertia

Normal interest in the surroundings and in other people [0]; Reduced ability to enjoy usual interests. Reduced ability to feel anger [1]; loss of interest in the surroundings. Loss of feelings for friends and acquaintances [2]; The experience of being emotionally paralyzed, inability to feel anger or grief, and a complete or even painful failure to feel for close relatives and friends [3]. [ ]

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2|0|1|2|4|0|1|5|

Centre No. | | | | | Patient No. | | | Initials 9550082 Visit/cycle D|A|Y| | |

Date | | | | | | | | |
D M Y

7. Pessimistic thoughts
– Representing thoughts of guilt, inferiority, self-reproach, sinfulness, remorse and ruin.

No pessimistic thoughts [0]; fluctuating ideas of failure, self-reproach or self-depreciation [1]; Persistent self-accusations, or definite but still rational ideas of guilt or sin. Increasingly pessimistic about the future [2]; Delusions of ruin, remorse and unredeemable sin. Absurd self-accusations [3]. | |

8. Concentration difficulties
– Representing difficulties in collecting one's thoughts mounting to incapacitating lack of concentration.
– Rate according to intensity, frequency, and degree of incapacity recorded.
– Distinguish from failing memory and disrupted thought.

No difficulties in concentrating [0]; Occasional difficulties in collecting one's thoughts [1]; Difficulties in concentrating and sustaining thoughts which interfere with reading or conversation [2]; Incapacitating lack of concentration [3]. | |

9. Reduced sleep
– Representing a subjective experience of reduced duration or depth of sleep compared to the subject's own fitful sleep.

Sleep as usual [0]; Slight difficulty dropping off to sleep or slightly reduced, light or fitful sleep [1]; sleep reduced or broken by at least 2 hours [2]; Less than two or three hours sleep [3]. | |

10. Reduced appetite
– Representing the feeling of a loss of appetite compared with when well.

Normal or increased appetite [0]; Slightly reduced appetite [1]; No appetite. Food is tastless. Need to force oneself to eat [2]; Must be forced to eat. Food refusal [3]. | |

Total score | |

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamount group
R & D, CNS Line

9550082

Enclosure 10

PATIENT GLOBAL IMPRESSION

FROM STUDY START MY GENERAL CONDITIONS ARE:



By using this visual-analogue scale, please write the number corresponding to your actual situation.....

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Enclosure 11
Protocol No. 2 0 1 2 4 0 1 5

Centre No. | | | | | Patient No. | | | | Initials 9550082 | | | Visit/cycle D A Y | |

Date | | | | | | |
D M Y

R.D.R.S.: RELATIONAL DEPRESSION RATING SCALE

Maurice OHAYON, 1985

SCORING INSTRUCTIONS

The scoring should be based upon the clinical interview as a whole, resorting to subjective observations rather than to specific questioning and/or medical history.
The clinician should spot the clues indicating the patient's social withdrawal and loss of interest in other people, a characteristic feature of the depressive condition, through the impairment of the clinician/patient relationship.

The relational viewpoint in non-verbal communications: the patient's outward appearance (clothes, grooming, body gestures) allows the evaluation of the relational dynamics, apart from the patient's verbal complaints.

I. Facial expression

0 - The mimics fits in well with the speech, emphasizing emotions. The subjects smiles at the clinician or clearly expresses his feelings.
1 - The subject appears sometimes absent-minded, but quickly regains attention as soon as the clinician enlivens the interview. He smiles easily when stimulated.
2 - The patient does not smile. The mimics is poor, stereotyped. The patient gets lively only if stimulated.
3 - The patient's face hardly lits up, and this only under strong stimulation.
4 - The patient is completely unconcerned. The face is motionless, set, expressionless.

II. Body gestures

0 - Patient's bearing and movements are in keeping with speech. The posture is lithe, the patient makes himself comfortable in the chair.
1 - The patient exhibits some awkwardness, slightly shrinking or stooping. He/She sits ont he chair's edge. The patient gets progressively livelier in the course of the interview.
2 - The patient has a set expression, his movements involve the limbs only and not the rest of the body and are not harmonized with the speech. These features poorly improve during the interview.
3 - Heavily reduced motion, involving hands only. Movements and speech are not, or badly, in tune. Gestures are mechanical, stereotyped.
4 - Complete inertia. The posture is frozen, the back bent; the patient may fold up on the couch. He/She hardly speaks and is completely motionless.

III. Look

0 - The patient has keen, mobile eyes, exploring the room and making the eye-contact with the clinician. His/Her look is harmonized with speech and emotions.
1 - The patient looks around quite slowly, stares at the clinician and, from to time in the course of the interview, at unimportant objects.
2 - Patient's eyes are shifty, avoiding the clinician's eyes. At times, be stares into space.
3 - The patient hardly looks at the clinician unless stimulated.
4 - The patient has a dull, absent look, be stares into space and eyes are half- of fully closed.

IV. Outward appearance

0 - The patient is well groomed. His clothes reflect his desire to please, even some stylishness. He has proper clothes, hairdo and makeup.
1 - The patient's bearing betrays some carelessness, he seems unconcerned with his physical condition or, on the contrary, excessively stylish.
2 - The patient is disheveled and slovenly dressed; he rather keeps on his night clothes.
3 - The patient neither washes nor combs his hair or gets properly dressed, unless stimulated.
4 - The patient is absolutely unable to get dressed without help. He is completely unconcerned.

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2|0|1|2|4|0|1|5|

Centre No. ____ Patient No. ____ Initials 9550082 Visit/cycle D|A|Y| |.|

Date ___ D M Y

The relational viewpoint in verbal communications. Throughout the interview, the clinician should pay attention to the "relational" features of patient's speech: voice, flexibility, variety of topics should reflect the patient's ability to establish social relations.

V. Speech

0 - The patient has a broad and rich choice of topics, with covers family life, work, hobbies, friends, etc. The patient is interested in both the interview and the clinician.
1 - The patient's variety of topics is poorer. He is only concerned with his family, job, somatic complaints or his current illness.
2 - The subjects is interested only in few topics.
3 - The patient is wholly unconcerned about his surroundings. His choice of topics is poor, limited and repetitive.
4 - The patient is completely unconcerned with the outside world.

VI. Voice

0 - Voice's level and modulation are normal. Speech is fluent. Voice and speech are well harmonized.
1 - The voice is somewhat monotonous: speech slackens.
2 - The voice is monochord, low-pitched, speech is slow and interrupted by long breaks.
4 - The patient's speech is scarcely audible or monosyllabic.

VII. Adaptability, suggestibility

0 - The patient's answers, his whole behavior are matching to the situation. He/She reacts quickly when stimulated and follows the suggestions.
1 - The subject exhibits a slight sluggishness during the interview: he/she reacts a bit slowly, switching from one subject to the next quite reluctantly.
2 - The subject's thinking process is definitely sluggish: dulled ability to feel, to experience emotions. Reactions are slow and poorly improved by stimulations from the clinician. Fears and avoids the new experiences.
3 - Severe emotional withdrawal, reflexted by the patient's lack of interest in the present situation, the future, treatment, etc.
4 - Patient's adjustement to reality is nil. He/She fells quite cut off from the outside world and makes no attempts at communicating.

The relational viewpoint in affects: during the interview, depressive patients usually exhibit anxious and/or aggressive feelings. The rating should take them into account insofar as they impair the relations with the others or even hinder any self-expression. Guilt and self-aggression should be considered insofar as they allow or prevent the patient from calling on others for help.

VIII. Contacts, affective need

0 - The patient/clinician relationship is easily established, the patient is effusive, outgoing or even pushy.
1 - The patient exhibits a slight reserve, by no means pathological.
2 - The patient is reserved, aloof, shy, but gets progressively livelier in the course of the interview.
3 - The patient is withdrawn, self-concerned, avoids contact.
4 - No patient/clinician relationship can possibly be established.

IX. Anguish, anxiety

0 - The patient shows little or no anxiety during the interview. Anxiety arises in response to specific situations and is freely expressed through speech, voice and movements.
1 - The patient is plainly anxious during the interview and shows it through speech, posture and mimics.
2 - The patient actually complains of fear and anxiety: he seeks help and comfort. Somatic symptoms are more or less severe.
3 - The patient manifests strong anxiety throughout the interview, though he might express it badly. His complaints are vague, indefinite.
4 - The patient suffers from extremely severe anxiety, manifested by restlessness or nearly complete motionlessness. He/She is unable to verbalize his/her anxiety.

 Investigator's signature _____

Cont. 'd Enclosure 11

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 5

Centre No. ____ Patient No. ____ In 9550082

Visit/cycle D A Y __ .

Date __ __ __ (D M Y)

X. Aggression, irritability

0 - The patient exhibits no aggression in his social relationships or aggressivity arising in response to peculiar conditions.
1 - The patient is irritable at times; he/she cannot easily endure minor everyday conflicts and will ascribe this to overtiredness.
2 - The patient is obviously irritable and hostile. He/She tends to reject the others. He/She ascribes his irritability to other people's aggressiveness or unreasonable demands.
3 - The patient is definitely aggressive. He sees the interview as intrusive and distressing, maintains a stubborn silence or utters aggressive claims. Contacts with close relations are felt as unduly distressing.
4 - The patient perceives human relations as distressing, intrusive, unbearable; he refuses to speak and to communicate.

XI. Self-aggression

0 - The patient easily communicates with other people, is able to endure minor aggressions and to react appropriately.
1 - Occasional awkwardness and anxiety, when the patient should be aggressive or authoritarian. He will try and avoid such situation and would rather bottle up his anger.
2 - Agressions cause the patient anguish and intense guilt. Somatic symptoms are present.
3 - Severe self-aggression; suicidal ideas or plans, severe somatic symptoms or overwhelming unjustified guilty feelings.
4 - Delusional shamefulness or guilt, suicidal plans or acts.

The relational viewpoint in the patient/clinician relationship.
The scoring should take into account the clinician's subjective evaluation of the patient/clinician relationship and of the patient's relational skills in the course of the interview.

XII. Global evaluation

0 - Relationship are easily and freely established, in keeping with the situation.
1 - Slight aloofness, hardly perceptible.
2 - Obvious withdrawal; the relationship is eventually established after an initial phase of mistrust and reserve.
3 - Severe withdrawal, difficult relationship. The patient refuses contact.
4 - The patient/clinician relationship can hardly be established.

Could you suggest one or two items which are missing in the Relational Scale according to you.

ITEM No. 1: Title:

0 -

1 -

2 -

3 -

4 -

ITEM No. 2: Title:

0 -

1 -

2 -

3 -

4 -

Investigator's signature ____________

Enclosure 12

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 5

Centre No. | | | |

Patient No. | | | |

9550082

Visit/cycle D A Y | |

Date | | | | | | D M Y

NEWLY ADVERSE EVENTS: CHECK-LIST

1. AUTONOMIC

- Dry mouth
- Nasal congestion
- Blurred vision
- Constipation
- Urinary hesitancy
- Urinary retention
- Increased salivation
- Sweating
- Vomiting
- Diarrhoea
- Sexual disturbances
- Nausea

2. BEHAVIORAL TOXICITY

- Confusional reaction
- Excitement/agitation
- Increased motor activity
- Decreased motor activity
- Insomnia
- Drowsiness
- Lassitude

3. CARDIOVASCULAR

- Hypotension
- Dizziness
- Circulatory collapse
- Tachycardia
- Hypertension
- Precordial pain

4. NEUROLOGICAL

- Rigidity
- Tremor
- Akathisia
- Dystonia
- Paresthesias
- Seizures
- Myoclonus
- Muscular pain

5. OTHER

- Skin-rash
- Urticaria
- Decreased appetite
- Headache
- Dyspnea

Farmitalia Carlo Erba
Erbamont Group
Corporate Medical Coordination

ENCLOSURE 13

9550082

ADVERSE DRUG REACTION - A CRITICAL REVIEW

CAUSE-EFFECT RELATIONSHIP

F.E.KARCH, L.LASAGNA
(JAMA Dec. 22, 1975-Vol.234)

1. DEFINITE (or CERTAIN)
A reaction that follows a reasonable temporal sequence from administration of the drug or in which the drug level has been established in body fluids or tissues; that follows a known response pattern to the suspected drug; and that is confirmed by improvement on stopping the drug (dechallenge), and reappearance of the reaction on repeated exposure (rechallenge).

2. PROBABLE
A reaction that follows a reasonable temporal sequence from administration of the drug; that follows a known response pattern to the suspected drug; that is confirmed by dechallenge; and that could not be reasonably explained by the known characteristics of the patient's clinical state.

3. POSSIBLE
A reaction that follows a reasonable temporal sequence from administration of the drug; that follows a known response pattern to the suspected drug; but that could have been produced by the patient's clinical state or other modes of therapy administered to the patient.

4. DOUBTFUL
Any reaction that does not meet the criteria above.

5. UNKNOWN
Relationship for which no evaluation can be made.

6.NOT RELATED
A reaction for which sufficient information exists to indicate tha the aetiology is unrelated to the study drug.

Enclosure 14

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 5

Centre No. ____ Patient No. ____ Initials 9550082 Visit cycle D A Y

Date ____ D M Y

ADVERSE EVENT REPORT FORM*

1. DESCRIPTION/DURATION

WHO CODE

Adverse event (verbatim): _____

Report 1:	Onset date:	Still present:	End date:
1 ☐ spontaneously	D M Y	1 ☐ no 2 ☐ yes	D M Y
2 ☐ non-leading question			
3 ☐ check list	single episodes duration d ____ or hr ____ or min ____		

case of multiple episodes, give mean duration d ____ or hr ____ or min ____

2. CHARACTERIZATION

Severity:	Source:	Frequency:	History:
1 ☐ mild	1 ☐ physician	1 ☐ single episode	1 ☐ observed before the current treatment
2 ☐ moderate	2 ☐ patients	2 ☐ continuous	2 ☐ not observed before
3 ☐ severe	3 ☐ other specify	3 ☐ multiple episodes,	3 ☐ unknown
4 ☐ unknown	_____	specify No. of episodes: ____	

3. ACTION TAKEN

Hospitalization:	Study drug:	Other actions:
1 ☐ required	1 ☐ no change	1 ☐ discontinuation of other medication (if yes, fill in the form about medication at page 1)
2 ☐ not required	2 ☐ dose reduced	2 ☐ Symptomatic treatment (if yes, fill in the form about medication at page 1)
3 ☐ not applicable	3 ☐ definitively withdrawn	3 ☐ other action: _____
	4 ☐ temporarily interrupted, specify No. of days ____	

Code opened:

1 ☐ no 2 ☐ yes

* **FILL IN ONE FORM BY SINGLE EVENT** (if serious or unexpected promptly inform the Study Monitor)

603 Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 5

Centre No. [ ] [ ] [ ]

Patient No. [ ] [ ]

Initials 9550082

Visit/cycle D A Y

Date [ ] [ ] [ ] [ ] [ ] [ ]
D M Y

4. DECHALLANGE/RECHALLANGE

Did the adverse event disappear after treatment withdrawal or dose reduction?

1 ☐ no
2 ☐ yes
3 ☐ not applicable

Did the adverse event reappear on resuming treatment?

1 ☐ no
2 ☐ yes
3 ☐ not applicable

5. PREDISPOSING OR CONTRIBUTING CONDITIONS

1 ☐ no 2 ☐ yes, specify: _____

6. RELATIONSHIP TO STUDY MEDICATION (according to modified Karch and Lasagna criteria, see protocol)

1 ☐ definite
2 ☐ probable
3 ☐ possible
4 ☐ doubtful
5 ☐ unknown
6 ☐ none

7. OUTCOME OF EVENT TO DATE (If patient died, fill in the Death Report Form)

1 ☐ recovered
2 ☐ recovered with sequelae
3 ☐ still present
4 ☐ death

8. DESCRIPTIVE SUMMARY/OTHER RELEVANT MEDICAL DATA

_____
_____
_____
_____
_____
_____
_____
_____

Investigator's signature _____

Enclosure 15

9550082

Appendix 5
Declaration of Helsinki IV (Hong Kong - September 1989)

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI

Recommendations guiding physicians
in biomedical research involving human subjects

Adopted by the 18th World Medical Assembly,
Helsinki, Finland, June 1964,

and amended by the
29th World Medical Assembly,
Tokyo, Japan, October 1975,
35th World Medical Assembly,
Venice, Italy, October 1983
and the
41st World Medical Assembly
Hong Kong, September 1989

INTRODUCTION

It is the mission of the physician to safeguard the healthy of the people. His or her knowledge and conscience are dedicated to the fulfillment of this mission.

The Declaration of Geneva of the World Medical Association binds the physician with the words, "The health of my patient will be my first consideration," and the International Code of Medical Ethics declares that, "A physician shall act only in the patient's interest when providing medical care which might have the effect of weakening the physical and mental condition of the patient." The purpose of biomedical research involving human subjects must be to improve diagnostic, therapeutic and prophylactic procedures and the understanding of the aetiology and pathogenesis of disease.
In current medical practice most diagnostic, therapeutic or prophylactic procedures involve hazards. This applies especially to biomedical research.

Medical progress is based on research which ultimately must rest in part on experimentation involving human subjects.

In the field of biomedical research a fundamental distinction must be recognized between medica research in which the aim is essentially diagnostic or therapeutic for a patient, and medica research, the essential object of which is purely scientific and without implying direct diagnostic or therapeutic value to the person subjected to the research.

Special caution must be exercised in the conduct of research which may affect the environment and the welfare of animals used for research must be respected.

Because it is essential that the results of laboratory experiments be applied to human beings tc further scientific knowledge and to help suffering humanity, the World Medical Association has prepared the following recommendations as a guide to every physician in biomedical research involving human subjects. They should be kept under review in the future. It must be stressed tha the standards as drafted are only a guide to physicians all over the world. Physicians are no relieved from criminal, civil and ethical responsibilities under the laws of their own countries.

I. BASIC PRINCIPLES

1. Biomedical research involving human subjects must conform to generally accepted scientific principles and should be based on adequately performed laboratory and animal experimentation and on a thorough knowledge of the scientific literature.
2. The design and performance of each experimental procedure involving human subjects should be clearly formulated in an experimental protocol which should be transmitted for consideration, comment and guidance to a specially appointed committee independent of the investigator and the sponsor provided that this independent committee is in conformity with the laws and regulations of the country in which the research experiment is performed.
3. Biomedical research involving human subjects should be conducted only by scientifically qualified persons and under the supervision of a clinically competent medical person. The responsibility for the human subject must always rest with a medically qualified person and never rest on the subject of the research , even though the subject has given his or her consent.
4. Biomedical research involving human subjects cannot legitimately be carried out unless the importance of the objective is in proportion to the inherent risk to the subject.
5. Every biomedical research project involving human subjects should be preceded by careful assessment of predictable risks in comparison with foreseable benefits to the subject or to others. Concern for the interests of the subject must always prevail over the interests of science and society.
6. The right of the research subject to safeguard his or her integrity must always be respected. Every precaution should be taken to respect the privacy of the subject and to minimize the impact of the study on the subject's physical and mental integrity and on the personality of the subject.
7. Physicians should abstain from engaging in research projects involving human subject unless they are satisfied that the hazard involved are believed to be predictable. Physicians should cease any investigation if the hazards are found to outweigh the potential benefits.
8. In publication of the results of his or her research, the physician is obliged to preserve the accuracy of the results. Reports of experimentation not in accordance with the principles laid down in this Declaration should not be accepted for publication.
9. In any research on human beings, each potential subject must be adequately informed of the aims, methods, anticipated benefits and potential hazard of the study and the discomfort it may entail. He or she should be informed that he or she is at liberty to abstain from participation in the study and that he or she is free to withdraw his or her consent to participation at any time. The physician should then obtain the subject's freely-given informed consent, preferably in writing.
10. When obtaining informed consent for the research project the physician should be particularly cautious if the subject is in a dependent relationship to him or her or may consent under duress. In that case the informed consent should be obtained by a physician who is not engaged in the investigation and who is completely independent of this official relationship.
11. In case of legal incompetence, informed consent should be obtained from the legal guardian in accordance with national legislation. Where physical or mental incapacity makes it impossible to obtain informed consent, or when the subject is a minor, permission from the responsible relative replaces that of the subject in accordance with national legislation. Whenever the minor child is in fact able to give a consent, the minor's consent must be obtained in addition to the consent of the minor's legal guardian.
12. The research protocol should always contain a statement of the ethical considerations involved and should indicate that the principles enunciated in the present Declaration are complied with.

II. MEDICAL RESEARCH COMBINED WITH PROFESSIONAL CARE
(Clinical research)

1. In the treatment of the sick person, the physician must be free to use a new diagnostic and therapeutic measure, if in his or her judgement it offers hope of saving life, reestablishing health or alleviating suffering.

2. The potential benefits, hazards and discomfort of a new method should be weighed against the advantages of the best current diagnostic and therapeutic methods.

3. In any medical study, every patient - including those of a control group, if any - should be assured of the best proven diagnostic and therapeutic method.

4. The refusal of the patient of participate in a study must never interfere with the physician-patient relationship.

5. If the physician considers it essential not to obtain informed consent, the specific reasons for this proposal should be stated in the experimental protocol for transmission to the independent committee (1, 2).

6. The physician can combine medical research with professional care, the objective being the acquisition of new medical knowledge, only to the extent that medical research is justified by its potential diagnostic or therapeutic value for the patient.

III. NON-THERAPEUTIC BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (Non-clinical biomedical research)

1. In the purely scientific application of medical research carried out on a human being, it is the duty of the physician to remain the protector of the life and health of that person on whom biomedical research is being carried out.

2. The subjects should be volunteers - either healthy persons or patients for whom the experimental design is not related to the patient's illness.

3. The investigator or the investigating team should discontinue the research if in his/her or their judgement it may, if continued, be harmful to the individual.

4. In research on man, the interest of science and society should never take precedence over considerations related to the wellbeing of the subject.

9550082

Enclosure 16

LIST OF MONITORS

No.	Country	Monitor (Address)
1.	Australia	Dr. R. Degaris 765 Glenferie Road Hawthorn, Vic. 3122 phone: (61-3) 8192900 fax: (61-3) 8192469
2-6.	France	Dr. M. Bosc 100, Av. Albert 1er, B.P.203 92502 Ruel Malmaison Cedex phone: (31-1) 47142200 fax: (31-1) 47496658
7.	Germany	Dr. I. Götz-Lee Merzhauser Str. 112 Postfach 480 7800 Freiburg in Breisgan phone: (49-761) 4013125 fax: (49-761) 4013199
8-9.	Italy	Dr. S. Tazzari via C.Imbonati 24 20159 Milano phone: (39-2) 69952749 fax: (39-2) 69952249
10.	Sweden	Dr. G. Wedin Alvägen 5, Box 3511 183 03 TÄBY phone: (46-8) 7567085 fax: (46-8) 7568247
11.	United Kingdom	Dr. J. Powell Italia House 23 Grosvenor Road St. Alban's, Herts. AL1 3AW phone: (44) 72740290 fax: (44) 72740290
12.	Canada	Dr. S. Gupta Adria Laboratories 5476 Gorvan Drive, Mississauga Ont. L4W 3E8 phone: (416) 6254552, fax: (416) 6256801

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

Enclosure 17

9550082

DRUG ACCOUNTABILITY

Compound: **REBOXETINE** Protocol N°: **20124/015**

Title: Multicenter, multinational double-blind study of the activity and tolerability of Reboxetine vs Imipramine vs Placebo in patients suffering from Major Depressive Episodes

Centre N°/City__________________ Investigator:__________________________

Treatment received: |__|__|__| (d m y) for patient N°____ to patient N°___ Receipt N°__________

Bottles per patient received: 14 + 6 (dose 2)

Pat N°	Pat. Init.	Date Start	Weekly treatment given	N° of remaining bottles per pat.	N° of remaining caps. per pat.
			1___ 2___ 3___ 4___ 5___ 6___ **Dose 2:** 4___ 5___ 6___	└─┘ + └─┘ **(dose 2)**	└┴┘ + └┴┘ **(dose 2)**
			1___ 2___ 3___ 4___ 5___ 6___ **Dose 2:** 4___ 5___ 6___	└─┘ + └─┘ **(dose 2)**	└┴┘ + └┴┘ **(dose 2)**
			1___ 2___ 3___ 4___ 5___ 6___ **Dose 2:** 4___ 5___ 6___	└─┘ + └─┘ **(dose 2)**	└┴┘ + └┴┘ **(dose 2)**
			1___ 2___ 3___ 4___ 5___ 6___ **Dose 2:** 4___ 5___ 6___	└─┘ + └─┘ **(dose 2)**	└┴┘ + └┴┘ **(dose 2)**
			1___ 2___ 3___ 4___ 5___ 6___ **Dose 2:** 4___ 5___ 6___	└─┘ + └─┘ **(dose 2)**	└┴┘ + └┴┘ **(dose 2)**
			1___ 2___ 3___ 4___ 5___ 6___ **Dose 2:** 4___ 5___ 6___	└─┘ + └─┘ **(dose 2)**	└┴┘ + └┴┘ **(dose 2)**

N° of total caps. to be returned: ________

N° of total bottles to be returned: _______

Date:__________ Investigator's signature __________________

- The present form, duly filled out, should be kept as record by the investigator, together with his/her copy of CRFs.
- A photocopy of the present form should be given to the monitor of Farmitalia Carlo Erba, together with the unused drug at the end of the study.

ITALIA ASSICURAZIONI Enclosure 18

9550082

Milano 11/01/90/GF

Spett.Le
FARMITALIA CARLO
ERBA S.R.L.
Via C. Imbonati 24

20159 MILANO

D I C H I A R A Z I O N E
D E C L A R A T I O N
To whom it may concern

La sottoscritta ITALIA Assicurazioni S.p.A. con sede in Genova -Via Fieschi 9 -
THE UNDERSIGNED ITALIA Assicurazioni S.p.A., with head office in Genoa,Via Fieschi 9,

dichiara a tutti gli effetti che la Spett.le FARMITALIA CARLO ERBA SRL .
hereby declares to all intents and purposes that the firma FARMITALIA CARLO ERBA SRL

con sede in Milano - Via C. Imbonati 24 e' assicurata contro la
with head office in Milan - Via C. Imbonati 24, is insured against

responsabilita' civile verso terzi per danni derivanti dalla sua attivita' (ivi compresa "produzione"
third party liability for damage deriving from their activities (including "production".

e "smercio") e dalle sue proprieta' con polizza n.4W8102, scadente il 31.12.1990
and "sales") and its properties, under policy No.4W8102, expiring on 31.12.90

e tacitamente rinnovabile di anno in anno, per il massimale unico
di L. 10.000.000.000.=(diecimiliardi) per sinistro
automatically renewable for one year at a time, to cover up
to L.10.000.000.000 (ten thausand million Lire) as a single anyone claim,

nei termini tutti di cui alla polizza stessa.
in all terms concerning the policy itself.

La garanzia e'valida per il mondo intero e prevede, tra l'altro, anche l'estensione della copertura ai seguenti:
This coverage is applicable through out the world, and includes the following:

- danni causati da specialita' medicinali e prodotti medicinali che secondo la
- damage arising from medicinal specialities and products which, according to

comune prassi, prima della loro registrazione sanitaria e della loro
normal practice, before they are officially registered and

immissione in commercio, vengono consegnati a cliniche, ospedali,
put on the market, are giving to clinics, hospitals

case di cura ed esercenti professioni sanitarie per sperimentazioni e
nursing homes and professional healt workers for clinical trials and

Mod. 90/182 P - 7/86 - CRESTA-GENOVA

Italia assicurazioni spa sede legale 16121 Genova via Fieschi 9 capitale sociale L. 30.000.000.000 trib. Genova 101 cciaa 30488
autorizzata all'esercizio delle assicurazioni (art. 65 r.d.l. 966/29-4-23) c.f. 00432690105

ITALIA ASSICURAZIONI 9550082 Enclosure 18 cont'd

prove cliniche, nonche'ai danni causati a seguito di somministrazione
tests and damage arising following administration for pharmacological tests

per ricerche di farmacologia ed esperimenti con farmaci e preparazioni gia' registrate in Italia
experiments of drugs or preparations already registered in Italy

e/o all'estero, ma con posologie diverse da quelle
and/or in other countries but using dosages different from these

indicate dalle case produttrici e con nuovi farmaci in fase di studio;
indicated by the manufacturer and of new drugs in the study stage;

comprese tutte le attivita' inerenti e connesse alle sperimentazioni stesse,
including all activities connected with and inherent to tests and trials

quali la tecnica di somministrazione dei farmaci ed il prelievo dei
such as the methods of administering drugs and withdrawing

sangue dai soggetti per studio; il tutto con prodotti
blood samples from subjects under study; all with products

sia ad uso umano che non, propri e/o di terzi:
for human use or not, own and/or of the third party.

- connessi a responsabilita' civile che possa derivare personalmente
- damage relating to third party liability which may result personally

agli esperimentatori sia nel paese dell'Assicurata che all'estero
to the experimenters both in the country of Insured and/or in other countries

in ragione degli esperimenti effettuati su richiesta e/o per conto dell'Assicurata stessa.
because of the experiments effected at request and/or for account of the Insured.

La presente viene rilasciata a richiesta della Spett.le FARMITALIA CARLO ERBA SRL
This declaration is issued in response to a request by FARMITALIA CARLO ERBA SRL

Relativamente alla presente dichiarazione redatta sia in lingua italiana che in
Relatively to the present declaration drawn up both in italian language and

lingua inglese, viene convenuto che, in caso di divergenza tra i due testi,
English language, it is agreed that, in case of divergence between the two texts,

Mod. 66/183 EP - 7/88 - ERETA-GENOVA

611

2

ITALIA ASSICURAZIONI 9550082 Enclosure 18 cont'd

prevarra', ai fini interpretativi, il testo in lingua italiana.
the one in Italian language will prevail for the purpose of interpretation.

In fede

ITALIA Assicurazioni S.p.A.
UPD Grandi Rischi

Mod. 99/182 P - 7/86 - CRESTA-GENOVA

3

9550082

Attachment A

REBOXETINE PROTOCOL 20124/015: OPERATING PROCEDURES FOR TRAINING ON ASSESSMENT INSTRUMENTS, STUDY MONITORING AND COORDINATION.

Aim

The purpose of these procedures is to provide standardization of the study conduct in the different clinical centers and to assure data uniformity and compatibility by appropriate interventions during data gathering.

Inter-rater reliability

During the clinical trial:

- inter-rater agreement for the instruments used in the assessment of change (HAMD, RDRS) will be tested on the occasion of the first Investigator Meeting (2 videotaped interviews) and of the monitoring visits (2 videotaped interviews).

Study monitoring

During the course of the study (14-months) monthly monitoring visits will be conducted by Study Monitors from Farmitalia Carlo Erba.

The start-up visit will take place after approval of the protocol by the Institutional Review Board (IRB) or Ethical Committee. On this visit the following documents will be collected:

- copy of the protocol signed by the Principal Investigator;
- CV of Principal Investigator and Co-Investigators;
- the written approval of the study (typed on the Institute's letter head) by the Hospital or University Center Review Board and the IRB members list;

- an IRB approved blank copy of the consent form;
- the list of the laboratory normal values or ranges of the lab. tests.

These documents will be sent to FICE-Milan. On the occasion of this visit the monitor will also check that the CRFs and the drug supply have been delivered to the Clinical Investigator and the accompanying letter, signed by the Clinical Investigator, will be collected. In addition the Monitor will identify the staff members who will be involved in the study conduct and the monitoring visits schedule will be agreed.

Following the start-up visit the form A (enclosed) will be filled in. Copy of it will be sent to FICE in Milan.

The first monitoring visit will be done immediately after the recruitment of the first two, three patients.

The periodic monitoring visits are carried out in order to:

1 verify protocol adherence: patient eligibility (page 1 of the CRF), times of assessments, completeness of data, pill count;

2 verify data consistency looking for inconsistencies or errors in the data recorded on the CRF;

3 verify the accuracy of data collection in CRFs against the original clinic or hospital records for:

- pt initials and hospital record no
- signed informed consent
- study medication administration and concomitant medications
- physician notes on adverse events
- 20% of data for laboratory tests, patient history and vital signs; in case of an error rate > 15% all data need to be monitored;
- total Hamilton score reported in the hospital record.

Source-verified data can be initialled by the study monitor in the CRF.

4 review all adverse events including laboratory abnormalities, occurred since the previous visit. Should the information of a serious, or unexpected adverse event newly emerge, the local study Monitor

must immediately (within two working days) inform the Product Leader in Milan;

5 evaluate patient recruitment rate and treatment discontinuations;

6 verify study medication storage and accountability and collect bottles of completed treatments;

7 ensure continued acceptability of the facilities and of the staff.

CRFs will be completed in black ink and corrections, if needed, made only by the Clinical Investigator with a single line throughout; the corrections will be initialled by Clinical Investigator and dated. Each page of each completed CRF will be signed by Clinical Investigator.

After review for accuracy and completeness, the original and first copy of each page of the CRF will be removed (leaving the second copy with the Investigator). The first copy will be sent to Milan by Special Delivery Service for review and data processing while the original will be retained by the Monitor in the subsidiary until completion of the whole treatment period of the individual patient.

After each monitoring visit the periodic site visit report and the patients progress report form (form B and C enclosed) will be filled in. Copy of them will be sent to FICE Milan.

The study termination visit will be performed upon Investigator's completion of all CRFs of treated patients. During this visit:

1 the monitor will check and collect the remaining completed CRFs and will perform a final data review;

2 a final check and review of drug accounting, inventorying of remaining drug supplies and arrangement to send them to FICE will be done;

3 a time frame for study reporting will be discussed;

4 appropriate follow-up of patients under long-term treatment will be assured and monitoring and collection of data from these patients discussed and agreed

The study termination visit from (form D) will be filled in and copy of it sent to FICE Milan.

Study coordination

In order to obtain uniformity and standardization in the carrying out of the study a Steering Committee is established. All questions arising during the conduct of the study will be submitted to the Committee for advice and action taking.

In particular the Committee will take care of:

- queries about patients acceptability
- possible need of protocol amendments
- possible need of premature termination of the study
- acceptability of particular cases of protocol violations
- evaluation of clinically relevant adverse events and their scientific and ethical consequences in terms of issues raised or study discontinuation.

Members of the Committee will be: Prof. T. Ban and Prof. M. Ohayon

Any problem or issue arising during the conduct of the study will be submitted to the Committee in writing by the Clinical Investigators or by the study Monitors. "Ad hoc" meetings of the Committee will be organized when needed. File note of the meeting with conclusions about action taking will be circulated to Clinical Investigators and study Monitors.

ATTACHMENT C: ASSESSMENT OF COGNITIVE FUNCTION

BACKGROUND

Difficulties in concentration, slowing down of thought processes and indecisiveness are common during the depressive state (1); these cognitive symptoms are well defined on a clinical basis. Other cognitive aspect of depression refer to psychological constructs suggested by different psychological theories of depression (2); these aspects will not be considered in the present study.

In order to evaluate the cognitive deficit associated with depressive illness and the effect of treatment on it, a test is proposed based on the analogic model of the cognitive process (3), focused on the deficit of the processing of information.

The tests are aimed at stimulating the analogic power ability of the patient for the cration of the new rule of production of information.

ASSESSMENT INSTRUMENTS

Tests consist of a series of visual elements and the patient is asked to image the last element of the series, from previous elements information. The prosed model for the analysis of cognitive disorders is as follow:

1) If A .....> B

2) Then C .....?.....> D

3) What's the patient's opinion about the quality of his (her) reply, of his (her) degree of satisfaction with it?

The comprehension of the relation between A and B is related to the level of vigilance. Vigilance increases with low levels of anxiety, but decreases when the intensity of anxiety overshoots a threshold. In addition attention and vigilance are known to be disturbed in drepessive disorders.

When the relation between C and D is obtained (in case of relation established, two alternatives are possible) the analysis of the reply of the patient allows the estimation of the severity of the depressive disorder and of patient adaptation reasoning ability.

The analysis of the patient opinion about the quality of the reply allows the evaluatin of judgement ability of the patient.

It can be hypothesized that in basal conditions and under placebo patients would poorly understand the relation between A and B. Imipramine is expected to have a negative effect on the learning process, whereas reboxetine is expected to improve the learning ability of the patient.

Moreover the correlation between presence of anticholinergic type side-effects and learning ability will be estimated, in order to test the hypothesis that anticholinergic properties are associated with modification of cognitive or memory performance.

The evaluation of cognitive disorder will be done manual at [illegible] 0, D 14, D-end. For each evaluation, a manual (Appendix 1) will be used in which several series of visual elements have been assembled. The patient will complete the empty rectangle and will reply to the questions.

Presence of dementia will be excluded at admission (score lower than 22 on MMS scale).

Presence of melancolia with inhibition is expected to prevent testing in extreme conditions. In this case the patient will be included in the study and the cognitive test will be administered again after the first week of treatment.

If the patient is not able to fill in the form, or refuse to fill it in, this has to be specified in the appropriate space, with a comment to justify his (or her) attitude.

In addition in order to assess the correspondence between the new model and a more classic approach for the evaluation of cognitive function memorization ability will be evaluated according to Signoret (4-8) (evocation and recognition of figures) and vigilance explored according to Mesulam (7-9). For the Signoret test the score corresponds to the number of figures recognized (recognition) and memorized (evocation), while for the Mesulam test the score is represented by the number of recognized letters. Data will be collected in the appended exercise booklet (Appendix 2).

STATISTICAL CONSIDERATIONS

All randomized patients will be included in the analysis of cognitive function assessment.

This analysis will consider several aspects.

- Evaluation of relation between memory and cognitive disorders at D 0, D 14, D end.

- Study of C_____D relation of cognitive process with rankin of the 2 possible responses and evaluation of the treatment effect on their frequencies.

- Study of judgement quality, evaluation of treatment influence according to treatment duration.

- Search for a correlation between judgement quality and depression rating scales scores.

The comparison between these qualitative data will be done by arm and by assessment interval by means of chi-square test. Correspondence analysis will be used for the evaluation of the possible correlation between cognitive function and depression raiting scales and between cognitive function and anticholinergic-type side effects.

REFERENCE

1) American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Third Edition.
Washington, D.C.: APA. 1980.

2) RUSH, A.J.
Measurement of the Cognitive Aspects of Depression..
In: The Measurement of Depression, Marsella A.J., Hirschfeld R.M.A. and Katz M.M. Eds.
Guildford Press, USA 1987.

3) OHAYON M.
Analyse et modélisation cognitive du processus analogique dans la psychose.
Ann. Med Psychol., 146: 52. 1988.

4) SIGNORET J.L.
Mémoire et age. Les déficits mnésiques liés à l'âge.
Med Hyg., 44 (1673): 2682-2688, 1986.

5) SIGNORET J.L. HARDY M.C., GIBELLO B. et GIBELLO M.L.
Quelques nouvelles approches de l'organisation de la pensée et de ses troubles.
Entretiens de Bichat (Thérapeutique). 275-278, 1988.

6) SIGNORET J.L.
Evaluation neuropsychologique (Alzheimer).
Rev. Prat. (Paris) 39 (6): 483-485, 1989.

7) WEINTRAUB S. et MESULAM M.M.
Developmental learning disabilities of the right hemisphere.
Emotional, interpersonal, and cognitive components.
Arch. Neurol (Chicago) 40 (8): 463-468, 1983.

COMPOUND :REBOXETINE Prot.N°20124/015

APPENDIX N°1

9550082

MANUAL FOR

COGNITIVE EVALUATION

Protocol n°

Center n°

Patient initial |_|_|_| n° |_|_|

Day of assessment D |_|_|_|

9550082

EXPLANATIONS
(to be re d attentively):

We have just given you an exercise-book, in which you have to reply to a set of simple questions.

Each page is composed of one or two pictures.
Each picture comprises 4 rectangles.
In the first three rectangles (n° 1,2,3) you can see a figure, while the rectangle n° 4 is empty.

You have to find and write the figure in the rectangle n°4, which results from the rectangle n° 3 in using between the rectangle n° 3 and n° 4 the same relation which links the rectangle n° 1 and n° 2.

Below the picture, you have to tell if your reply seems correct or not, in expressing your opinion by crossing one of the 4 drawed squares after the question "Do you consider your answer to be :"

This exercice is not a test to evaluate your efficiency or your judgment capacity; there are several possible replies for each question, and all the answers are valid.

M.M.S. score only at Do: ⌊__⌋⌊__⌋

621

9550082

EXEMPLE

(to fill only at Do, helping the patient)

If figure 1 becomes figure 2, what does figure 3 become ?

N A



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

9550082

Jo

☐ the patient gave the reply without help.

☐ the patient gave the reply with help.

- ☐ important help
- ☐ moderate help
- ☐ minimal help

☐ the patient didn't give a reply

The patient filled the test Yes ☐

No ☐

If NO, comments: _____

9550082

You don't must come back to the prior page.
(Use a ball-point pen and no a pencil; you can do deletions.

If figure 1 becomes figure 2, what does figure 3 become ?

N B



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

624

9550082

If figure 1 becomes figure 2, what does figure 3 become ?

N C



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

9550082

If figure 1 becomes figure 2, what does figure 3 become ? N 1



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

626

9550082

If figure 1 becomes figure 2, what does figure 3 become ? N 1



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

If the result (figure 4) becomes figure 6, what does figure 7 become ?



627

Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

9550082

If figure 1 becomes figure 2, what does figure 3 become ? N 3



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

If the result (figure 4) becomes figure 6, what does figure 7 become ?



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

628

9550082

If figure 1 becomes figure 2, what does figure 3 become ? N 3



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

9550082

If figure 1 becomes figure 2, what does figure 3 become ? N 4



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

9550082

If figure 1 becomes figure 2, what does figure 3 become ? N 4



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

f the result (figure 4) becomes figure 6, what does figure 7 become ?



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

631

9550082

If figure 1 becomes figure 2, what does figure 3 become ? N_5



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

If the result (figure 4) becomes figure 6, what does figure 7 become ?



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

632

9550082

If figure 1 becomes figure 2, what does figure 3 become ? N 6



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

9550082

If figure 1 becomes figure 2, what does figure 3 become ? N 6



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

If the result (figure 4) becomes figure 6, what does figure 7 become ?



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

635

9550082

If figure 1 becomes figure 2, what does figure 3 become ? N 6



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

9550082

If figure 1 becomes figure 2, what does figure 3 become ? N 10



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

f the result (figure 4) becomes figure 6, what does figure 7 become ?



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

637

9550082

If figure 1 becomes figure 2, what does figure 3 become ? N 10



Do you consider your answer to be : VERY GOOD ☐ GOOD ☐ Medium ☐ POOR ☐

9550082

COMPOUND :REBOXETINE Prot.N°20124/015

APPENDIX N°2

MANUAL FOR

MEMORY ASSESSMENT

Center n°

Patient initial └┴┴┘ n° └┴┘

Day of assessment D └┴┴┘

9550082

MEMORY TEST
(According to Signoret)

EVOCATION

-The six pictures have to be memorized.
-Showing duration : 30 secondes.
-To inform the patient, he has to find in 5 minutes.

Maximum Score = 5

Score: ⌊___⌋

9550082



641

9550082

MEMORY TEST
(According to Signoret)

RECOGNITION

Whatever the prior performance, the patient is invited to recognise the 6 pictures among the 24 represented pictures; there is a good picture by row; you have to inform the patient and to get him proceeded row by row.

Maximum Score = 6

EVOCATION + RECOGNITION

Maximum Score = 5 + 6

Score < 9 = memory disorder

642

9550082

RECOGNITION

Can you show me which pictures I saw you, at the beginning of the test.



Score: ___

643

9550082

ATTENTION / VIGILANCE TEST
(According to Mesulam)

To cross out the A in 2 minutes.

Quotation: A crossed out = +1
Other letter crossed out = -1

Maximum Score = 30

Score < 20 = Attention/Vigilance Disorders

9550082

ATTENTION / VIGILANCE TEST

Let cross out the A; you have got 2 minutes.

E	A	P	W	B	V	A	Q	H	R	Y	A	K	O	G	M	A
Z	R	U	A	T	I	L	S	C	X	E	P	W	B	A	Q	V
O	G	A	V	K	Y	D	U	A	A	B	Z	T	F	J	A	L
L	P	K	R	A	J	E	I	O	Z	H	V	X	A	Q	F	W
S	A	F	M	Z	V	A	K	L	E	U	A	R	I	H	P	A
R	E	W	C	A	H	P	Y	Q	M	J	S	D	A	Z	V	K
I	Z	X	A	O	B	L	F	T	G	P	Y	C	W	A	E	R
A	J	P	S	R	K	I	A	B	N	A	F	X	U	M	Q	D
Q	D	C	M	H	W	G	E	V	R	S	B	I	L	Z	T	Y
A	U	T	I	G	F	S	A	J	O	A	D	P	H	N	R	M
W	H	R	A	L	T	B	M	D	V	I	G	O	S	A	K	U
P	Y	N	K	A	S	W	L	U	C	Q	E	H	A	F	B	J

645

Score: ____

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

FARMITALIA CARLO ERBA
R&D - C.N.S. LINE

COMPOUND:		REBOXETINE
PROTOCOL No.	:	20124/015
VERSION	:	Final: 26.02.1991
PHASE	:	III
TITLE	:	**Multicenter, multinational double-blind study of the activity and tolerability of reboxetine vs imipramine and placebo in patients suffering from Major Depressive Episodes.**
INVESTIGATOR	:	Prof. Maurice Ohayon Center of Research, Hopital L. Lafontaine 7401 Rue Hochelaga, Montreal, Que. H1N 3M5 Canada, phone: +514/2514015, fax: 2512617
PRODUCT LEADER	:	Dr. Marek Jarema Farmitalia Carlo Erba, R&D, CNS Dpt Via Carlo Imbonati 24, 20159 Milano Phone: +392/69959081, fax: 69952249
STUDY MONITOR	:	Dr. Sunil Gupta, Adria Laboratories 5476 orvan Drive, Mississauga, Ont. L4W3E8 Canada, phone: +416/6254552, fax: 6256801
DATA MANAGEMENT CENTER	:	Biostatistics and Data Management FICE Milan

TABLE OF CONTENTS

1.0 PROTOCOL SUMMARY

The study, aimed at the evaluation of the efficacy and tolerability of reboxetine in comparison with imipramine and placebo in patients suffering from Major Depressive Episodes, will be carried out on a multinational basis, according to a double-blind parallel group design, in 330 patients. After an initial washout period of 1-2 weeks, patients will receive either reboxetine or imipramine or placebo, administered according to a fixed-flexible dose regimen, for 6 weeks. Efficacy (Clinical Global Impression, Hamilton Depression Rating Scale, Montgomery-Asberg Depression Rating Scale, Patient Global Impression), and tolerability (newly observed signs and symptoms, lab tests and ECG) will be assessed every 1-2 weeks. At the end of the 6-week treatment period a long-term follow-up may be undertaken.

2.0 INTRODUCTION

Reboxetine (FCE 20124 or RS, RS 2-[α-(2-ethoxy-phenoxy) benzyl] morpholine methanesulphonate) is a chemically new compound highly potent in pharmacological and biochemical tests predictive of antidepressant effectiveness: reserpine antagonism, norepinephrine reuptake inhibition, REM sleep latency increase. In addition reboxetine has been found to be able to prevent clonidine effects in rodents after single oral administration, in contrast with what observed following tricyclic monoamine uptake inhibitors, which were found to be active only upon repeated doses: these results indicate that the compound is able to decrease the sensitivity of α2 noradrenergic receptors, one of the biochemical correlates of chronic antidepressant treatment, after single oral dose: therefore it may be expected to exert antidepressant effectiveness of faster onset with respect to available antidepressants in patients (1).

In phase I studies (2, 3) single doses of 0.5 - 5 mg of compound, were administered orally to healthy volunteers. After 5 mg orthostatic hypotension, accompanied by tachycardia and by subjective symptomatology consistent with the disturbed circulatory regulation was observed.

In these studies single doses of 1 & 3 mg of the compound showed dose-dependent CNS effects with EEG modifications (decreased power of theta and fast-beta

waves in the fronto-central derivative), performance improvement (peg-board test) and growth hormone increase, the latter reportedly sensitive to hypothalamic noradrenergic stimulation by norepinephrine reuptake inhibitors.

The comparison with the positive control, imipramine 75 mg, associated to similar EEG modifications in the fronto-central derivative, to modifications indicative of sedative activity in the occipito-temporal derivative and to deterioration of the Pauli performance test, in the absence of growth hormone modifications, indicate that reboxetine does not possess the marked sedative activity of imipramine, but rather psychostimulating properties. After all treatment standing heart rate increase and salivation decrease was apparent. No other modifications of tolerability parameters were observed.

The pharmacokinetics of the compound were evaluated in the above mentioned studies as well as after administration of 2 mg 14C-FCE 20124 to 3 healthy volunteers (4). Most of the radioactivity circulating in plasma (73% in terms of AUC) was accounted for by unchanged reboxetine; the average peak levels were observed at 2 h, with remarkably stable levels 1-6 hours after administration; its plasma half-life was estimated as 13.2 h, slightly lower than that of total radioactivity.

In addition the autonomic effects of the compound have been evaluated in a study carried out in 16 healthy volunteers according to a double-blind, latin square experimental design. Single doses of reboxetine 1, 2 & 4 mg, desipramine 25, 50 and 100 mg and placebo were administered at weekly intervals. Both reboxetine and desipramine were found to be similarly active in reducing salivation and antagonizing carbachol-evoked sweating, activities consistent with anticholinergic properties, and in increasing heart rate (consistent with muscarinic receptor blockade and/or noradrenergic stimulation); reboxetine, but not desipramine, was found to increase resting pupil diameter (consistent with muscarinic receptor blockade and/or α-stimulation)
and to antagonize light evoked-miosis (consistent with anticholinergic activity).

Neither reboxetine nor desipramine were found to modify phenylephrine evoked sweating (no evidence of α-adrenoceptor blockade); following reboxetine a

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

reduction of phenylephrine-evoked mydriasis was apparent, possibly due to a "ceiling effect" (due to the mydriatic effect of reboxetine) rather than α-adrenoceptor blockade. No evidence of noradrenaline-uptake blockade could be observed, since noradrenaline failed to evoke measurable pupillary response.

On the basis of the results of the phase I studies, a 6-center early phase II study was carried out aimed at assessing tolerability and activity of progressively increased doses of reboxetine, administered over a 4-week period to hospitalized patients suffering from Major Depressive Disorders (5).

Ninety-eight patients were admitted to the study to be treated with maximum reboxetine daily doses of 4 mg (29 pts), 6 mg (27 pts), 8 mg (18 pts), 10 mg (12 pts) and 12 mg (12 pts). Treatment was discontinued in 4 patients in the 4 mg group due to deterioration of the clinical picture (with a manic syndrome in one case); in 2 patients of the 6 mg group due to the development of a manic episode; in one patient of the 6 mg group due to a convulsive episode, under associated treatment with levomepromazine. Dosage decrease was almost only present in the 12 mg group where in 5/12 cases, due to hypotension and tachycardia, the daily dose was decreased to 10 mg until completion of the treatment period.

The rating scales applied showed dose related improvement of the clinical picture both as average changes vs basal conditions as well as frequencies of relevant modifications (defined as 50% decrease of HAMD) up to the 10 mg/day dose, whereas slight deterioration, concomitant to the intolerance signs/symptoms, was observed in the highest dose group.

The compound was well tolerated when administered at doses up to 10 mg/day, as shown by newly observed signs and symptoms, mainly of mild to moderate severity and transient, and by vital signs and lab tests assessments, ECG included.

A double blind parallel group study was subsequently carried out in 10 centers (Hungary, Italy, France and Latin America) in 258 patients hospitalized due to a Major DepressiveEpisode. The experimental treatment had to be administered for 4 weeks, with maximum doses of 8 mg reboxetine(RBX) or 200 mg desipramine(DMI). The experimental treatment was discontinued in 26 patients (10%): in 18 cases (5, 6 e 7 of the RBX, DMI

and P group respectively) for inefficacy; in 3 cases for adverse events (2 of the RBX group due to deterioration of ventricular extrasystoles present before study start and hypertensive episodes respectively and 1 of the placebo group due to a cutaneous rash); in 5 cases (2, 1 and 2 in the RBX, DMI and P group respectively) for reasons unrelated to the experimental treatment.

Of the 80, 82 and 81 cases evaluable for efficacy in the RBX, DMI and P group (after exclusion of protocol violations, mainly related to associated treatments) 63%, 46% and 36% respectively showed a decrease >50% of the HAMD total score at the end of treatment; in 31%, 22% and 21% of these patients respectively the decrease was present within the 14th day of treatment. As to within-center results, the highest frequency of response was observed in the RBX group in all but 3 of the participating centers. After 2 and 4 weeks of treatment an average decrease of 23% and 34% of the HAMD was present in the P group; the corresponding figures were 34% and 49% in the DMI group and 39% e 57% in the RBX group.

As to signs/symptoms, more frequent in the RBX group were headache, complained of by 33% of the patients (20% and 21% in the DMI e P group respectively), and urinary hesitancy/retention, present in 12% vs 4% vs 1% of the cases, RBX vs DMI vs P. More

frequent in the DMI group were dry mouth (45% vs 26% vs 21%, DMI vs RBX vs P), sweating (28% vs 18% vs 22%), blurred vision (17% vs 4% in both RBX and P groups). Cardiovascular signs/symptoms were relatively rare, and appeared with slightly higher frequency in the DMI group: hypotension 13%, vs 6% in the RBX and 8% in the P group and tachycardia 19% vs 12% and 8% in the RBX and P group respectively.

3.0 RATIONALE

Phase II results obtained in controlled conditions in patients suffering from Major Depressive Disorders indicate that reboxetine is an effective antidepressant agent, with a favourable therapeutic index with respect to desipramine. Consistent information from further placebo-controlled studies is needed in order to properly document the activity and tolerability of the compound. In addition comparative evidence vs another tricyclic antidepressant is expected to allow a proper appraisal of the usefulness of the new molecule.

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

4.0 OBJECTIVES

To assess activity and tolerability of reboxetine in comparison with placebo and imipramine in patients suffering from Major Depressive Episodes.

5.0 DESIGN

5.1 Description

This phase III study will be carried out according to a double blind parallel group design, controlled vs imipramine and placebo, with random allocation of patients to one of the three treatments. The study will be organized on a multicentre, multinational basis.

5.2 Number of subjects proposed

Each center will recruit 24-42 patients, within a period of 12 months, for a total of 300 patients overall.

5.3 Logistics

The centers participating in the study are listed in enclosure 1.

6.0 STUDY POPULATION

6.1 Source of subjects

Adult patients selected from the population under in-patient care or attending out-patient or day-hospital clinics of the participating centers will be studied. These latter can be hospitalised for the study.

6.2 Inclusion criteria

- Patients affected by acute episodes of Major Depressive Disorders (DSM III R) (enclosure 2) not accompanied by psychotic features, with presence of illness for at least one month and not more than four.

- Patients of either sex, of any race, aged 18 to 65 years.

- A total score of 22 or above in the first 17 items of the 21-HAMD.

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

- Patient's consent: informed written consent will be obtained - see 15.2 (proposed form: enclosure 3).

6.3 Exclusion criteria

- Dysthymia, Cyclothymia.

- History of Major Depressive Disorders associated with Endocrine Disorders: hypo and hyper-thyroidism tested by TSH and T4 at admission and defined as at least 10% abnormal values of the laboratory norms; adrenal insufficiency, etc.

- Pregnancy (tested by pregnancy test at the end of the wash-out period).

- Refusal of the use of efficient contraceptive methods by female patients in child bearing age during the study period.

- Past history of any drug hypersensitivity.

- Participation in any clinical study with an investigational compound in the 4 weeks preceding the study.

- Evidence of Substance Use Disorder (DSM-III-R) within past 6 months or currently.

- Chronic respiratory insufficiency in the physical examination and X-ray.

- Progressive illness or systematic disease of the digestive system, liver, or kidney or other conditions known to interfere with the absorption, distribution, metabolism and excretion of drugs.

- History of seizures or brain injury; current evidence of clinically important hematopoietic or cardiovascular diseases. Current evidence of urinary retention, or glaucoma.

- Symptoms of any other important clinical illness in the 4 weeks preceding the study.

- Clinically relevant abnormal findings in the physical examination, laboratory tests and ECG at admission.

- ECT in the previous 3 months.

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

- MMS (Mini Mental State) < 22 (enclosure 4).

- Risk of suicide.

- The use of any psychotropic agent which cannot be removed during the entire experimental study.

- Clinical improvement at the end of the washout period (decrease of the HAMD of at least 1 point).

6.4 Identification of subjects

Patients will be identified by their initials and by the number in the trial.

7.0 RANDOMIZATION PROCEDURES

A randomization list balanced within center will be prepared for patient allocation to one of the 3 possible treatments (reboxetine, imipramine or placebo). On this basis the experimental treatments will be prepared and labelled with the corresponding patient number. Patient allocation to treatment will be done at the end of the pre-treatment period by the main Investigator on the basis of the patient's temporal entry into the study.

8.0 EXPERIMENTAL TREATMENTS

8.1 Test preparation

Indistinguishable capsules containing reboxetine 4 mg (2 tabl of 2mg, batch no.....) or 6 mg (3 tabl of 2mg, batch no..) or imipramine 50 mg (2 tabl of 25mg, batch no.....) or 100mg (4 tabl of 25mg, batch no.....) or excipients only (placebo, batch no...) will be used. The experimental treatments will be administered according to fixed-flexible dose schedules as indicated under Study Conduct. Test preparations will consist of:

		morning	evening
-reboxetine		1 cps 4 mg	1 cps 4 mg
-reboxetine DOSE 2 (last 3 weeks)		as above	1 cps 6 mg
-imipramine	day 1-3	1 cps 50 mg	1 cps 50 mg
	day 4-42	1 cps 50 mg	1 cps 100 mg
-imipramine DOSE 2 (last 3 weeks)		1 cps 100 mg	1 cps 100 mg
-placebo		1 cps	1 cps
-placebo DOSE 2 (last 3 weeks)		as above	as above

8.2 Labelling

The experimental treatment will be labelled by using the labels in enclosure 5. Double labels will be used.

8.3 Packaging

For each patient 6 cartons labelled with the patient number and the indication "week 1" to "week 6" will be prepared. Each carton will contain the medication necessary for 1 week plus 2 cps for possible losses, prepared according to the b.i.d. regimen with 1 cps for the "morning" and 1 cps for the "evening" dose. In addition for each patient 3 cartons labelled with the patient number and the indication "week 4-dose 2", "week 5-dose 2" and "week 6-dose 2" will be provided, for the possible dosage increase during the last 3 weeks of treatment (see Study Conduct).

8.4 Drug supplies storage

Drug supplies will be stored at room temperature. All drug supplies will be handled under the direct responsibility of the Investigator and held by the Hospital Pharmacy. The study Monitor will check drug storage conditions during site visits.

The Investigator will be also responsible for drug accountability and will keep a record of the test compounds received from the Sponsor as well as of the dispensed drug.

8.5 Dispensing, use and disposition of test drugs during and at the end of the study

Medication will be dispensed to the patient on the occasion of each visit; the Investigator will detach the upper label from each of the weekly cartons he is dispensing to the patient and will attach them in the appropriate space in the Case Record Form. On the same occasion cartons of the possible previous supply will be returned by the patient.

Used cartons will be returned to the study Monitor during site visits.

All unused medication has to be returned to Farmitalia Carlo Erba at the end of the study.

9.0 STUDY CONDUCT

9.1 Pre-treatment period

Patients will be checked for eligibility according to the inclusion and exclusion criteria. A washout period of 4-7 days (14 days in case of MAOI administration and 3 - 4 weeks in the case of previous fluoxetine treatment) will then be undertaken, during which only chloral hydrate (0.5 - 1g) as sleep inducer on p.r.n. basis will be allowed. Informed consent will be obtained from each patient.

Eligible patients will be then randomized to one of the three treatment groups and will undergo baseline assessments.

Information on patients screened for the study and found not to be eligible will be collected in the appropriate form (screening form, enclosure 6).

9.2 Treatment period

9.2.1 Dose/route of administration/treatment schedule

Treatments will be administered under close monitoring (hospital or day hospital for the first two weeks at least) to reduce suicidal risk to a minimum.

Patients will receive 1 capsule b.i.d. from day 1 to day 42. In case of inefficacy or unsatisfactory response (slight worsening or no change or minimal improvement at the CGI, see assessments), the dose will be increased to "dose 2" (see 8.0 Experimental Treatments) from day 22 to day 42, i.e. up to the end of treatment. In case of intolerance the dose will be reduced to the previously well tolerated lower dosage level.

The treatments will be administered in the morning and in the evening, at least 2 hours before or after meals.

9.2.2 Duration of treatment

The experimental treatment will be administered for 6 weeks.

9.2.3 Indications for early termination of test therapy

Termination of test therapy prior to completion of the 6 weeks treatment period may be considered under the following circumstances:

- Patient's request

- Switch to mania

- Unacceptable toxicity: this is defined as the occurrence of serious (see Adverse Events) adverse events (see 12.0)

- Lack of efficacy: this will apply to patients who will show unacceptable deterioration after 2 weeks of treatment (worsening in CGI)

In case of treatment discontinuation the complete final battery of assessments will be carried out.

9.2.4 Dropouts/replacement of subjects

Patients who drop out of the study for any reason will not be substituted.

For those patients who have been selected for the study who drop out at any time, even if it is before entrance to the treatment period, documentation will be provided.

9.2.5 Concomitant therapy

No concomitant medications other than hypnotic on p.r.n. basis are allowed at entry into the study. Concomitant medication should be avoided throughout the study. In case the events arising during the course of the study nonpsychotropic medications which are considered necessary for the patient's welfare may be administered and will not be considered violation to the protocol. The drugs, dosage and frequency of administration will be recorded. Chloral hydrate(0.5-1g/night) as sleep inducer on p.r.n. basis at bed-time is allowed.

9.2.6 Indications for opening the code

The Investigator will be given individual sealed envelopes containing the information on patient's treatment. These latter may be opened only in case of emergency necessitating treatment identification; the Investigator will immediately (within 24 hours) inform the study Monitor at FICE Subsidiaries and will report full description of reasons for opening the code in the CRF (Adverse Event Form).

The sealed individual codes will be returned to Farmitalia Carlo Erba at the end of the study.

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

9.3 Follow-up

A follow-up visit will be carried out for each patient one month after treatment discontinuation, in order to monitor possible withdrawal reactions and collect information on interval events.

Patients willing to continue receiving the experimental treatment after completion of the 6 weeks treatment period will be maintained under the same medication in blind conditions until completion of the last patient of the center. Monthly visits will be carried out for efficacy and safety assessment and drug dispensing. The medications will be prepared as described for the initial double-blind treatment period, but in monthly units.

Afterwards, patients will be followed-up in open conditions. Reboxetine tablets will be provided by Farmitalia Carlo Erba while, for those patiehts who were receiving imipramine, Tofranil will be prescribed.

9.4 Study timetable

Foreseen start date: March 91
Duration of accrual: 12 months
Foreseen end date (date of the last visit of the last patient, excluding follow up)): April - May 92

10.0 EFFICACY ASSESSMENTS

10.1 Variables to be measured for efficacy assessment

On days 0, 7, 14, 21, 28, 35, 42 :

- Hamilton Depression Rating Scale (21 items HAMD, enclosure 7); as above plus at screening for entry and monthly during the follow-up period.

- Clinical Global Impression (Enclosure 8), as above plus monthly during the follow-up period.

- Montgomery-Asberg Depression Rating Scale (Enclosure 9)

- Patient Global Impression (Enclosure 10)- excluding day 0

- Relational rating scales (Enclosure 11)

The latter is adopted in order to explore relational aspects of the Depressive Disorders ; Investigators are expected to propose 1-2 additional items of relevance for each patient in their opinion. Consistency of suggestions will be evaluated and on this basis an International Scale developed.

All psychiatric evaluations and ratings will be carried out by the same observer for a given patient, preferably in the same setting and at the same time of the day.

10.2 Efficacy definition

Decreases of at least 50% in the total HAMD score vs day 0 will be considered index of response whereas total HAMD score of 10 or less will be considered index of remission.

10.3 Cognitive function evaluation

Cognitive function will be evaluated on the day 0, day 14, and at the end of the study according to the model tests described in Attachment C.

10.4 Criteria for subject evaluability

Every randomized patient (see 7.0) will be included in the analysis.

11.0 SAFETY ASSESSMENT

11.1 Variables to be measured for safety assessment

- Standard medical history: at screening

- Standard clinical examination: full physical examination: at screening

- Blood pressure and pulse will be measured in the lying (after 5 minutes lying) and in the standing position (1 -2 minutes after standing up) in the morning: at screening and at each visit.

- ECG: at screening, day 21, day 42 and every three months during follow-up.

- Chest X-ray: at screening

- Laboratory: TSH and T4 at screening; full blood count, sodium, potassium, chlorine, BUN, creatinine, glucose, bilirubin, calcium, phosphorus, SGOT, SGPT, gamma GT, alkaline phosphatase, LDH, total proteins, albumin, cholesterol, uric acid, triglycerides, globulins - α_1, α_2, β, gamma -, urinanalysis: at screening, day 21, day 42 and every three months during follow-up.

- Adverse events: a check-list will be administered at each visit (Enclosure 12).

11.2 Criteria for subject evaluability

Every patient who has received at least one dose of the experimental treatment will be included in the safety evaluation.

12.0 ADVERSE EVENTS

Patients will be notified of possible adverse events they could experience and instructed to immediately report them to the Investigator.

Any newly observed sign or symptom, noticed by the Investigator or complained of by the patient, including clinically relevant lab abnormalities, will be recorded in the appropriate section of the CRF, regardless of presumed relationship to study medication.

For each event, the following information will be entered in the CRF: description, onset date, disappearance date, severity (1 = mild, awareness of sign or symptom, but easily tolerated; 2 = moderate, discomfort enough to cause interference with usual activity; 3 = severe, incapacitating with inability to work or do usual activity; 4 = unknown), drug cause-effect relationship (according to Karch and Lasagna modified criteria; see enclosure 13), outcome, dechallenge (what happened to the adverse event when the drug was stopped or the dose decreased?) rechallenge (what happened when the drug was restarted after the adverse event had disappeared ?). The Investigator will also note if the double-blind code has been opened, the action taken regarding the test drug (none, discontinued, dosage reduced) and any treatment applied because of the adverse reactions.

All serious* ("any experience that is (potentially) fatal or life-threatening, disabling, incapacitating, requires inpatient hospitalization, or causes a congenital anomaly or cancer or is due to overdose") and/or unexpected* ("any adverse experience that is not identified in nature, severity or frequency in the current investigator's brochure for the study") adverse events must be immediately (within 24 hours) reported by telephone to FICE Subsidiaries Monitors (see Section 17.0) and the Adverse Event Report Form (enclosure 14) must be filled in immediately. FICE will notify the Regualtory Authority in accordance with statutory requirements. The same applies to all patients who die, irrespective of whether the event was judged as related to treatment, during the course of the study or within 30 days of completion of treatment.

In case of death, if an autopsy is performed, a copy of the pathological report should be sent to the FICE subsidiary monitor.

13.0 EVALUATION SCHEDULE

Is reported in table 1.

14.0 STATISTICAL CONSIDERATIONS

14.1 Sample size

The main evaluation of treatment effectiveness will be based on the comparison with respect to placebo of the total score of the HAMD. The study shall be sized to evidentiate the difference between baseline and the last postbaseline score for each patient regardless of length of time in the study. Thus, this analysis, requiring at least one visit after baseline, takes into account differential dropout rates among treatment groups.

Either imipramine and reboxetine will be compared to placebo. The first comparison is set up in order to establish the sensitivity of the trial, while the second one will allow the evaluation of the new compound (reboxetine).

---

* Code of Federal Regulation, Vol 21 Part 312. Revised as of April 1, 1987, pg. 75.
* J.L.Bem et al.: Review of yellow cards (1986): report to the Committe on the Safety of Medicines. Br.J. Clin. Pharmac. (1988), **26**, 679-689.

Therefore the following hypothesis systems set up:

Ho: $\delta t \geq \delta p$ i.e. $\delta t - \delta p \geq 0$

Ha: $\delta t < \delta p$ $\delta t - \delta p < 0$

where δt and δp represent respectively the true mean of the distribution of the difference from baseline of total score of the HAMD for reboxetine (or imipramine) and placebo.

In order to take into account the multiplicity of the comparisons, the criterion of Bonferroni is applied. Consequently the α level for the simultaneous inference is fixed at 0.025 for each comparison (overall α level = 0.05) (this is equivalent to the Dunnett procedure which would lead to an α level of 0.024 for each comparison).

From the phase II trial and from the literature (6) it seems reasonable to assume that treatment groups will show a variability (expressed as standard deviation) of 9 points. Considering of clinical relevance a difference between reboxetine, or imipramine, and placebo of at least 4 points, 80 patients per group are necessary in order to provide a power ≥ 0.80 if the alternative hypothesis is true, with the α level fixed at 0.025, for each of the two tests. Taking into account the possibility of dropouts before the first postbaseline visit and nonevaluable patients according to protocol criteria, 100 patients per group should be recruited.

14.2 Statistical analysis

The main analysis of treatment effectiveness will be carried out on the variable 'total score of HAMD' considering the difference between baseline and the last postbaseline score for each patient regardless of length of time in study. Both reboxetine and imipramine will be compared to placebo. Consistently with the method used for the sample size calculation a multiple t test procedure will be adopted to test the null hypothesis. Analysis of variance will produce the appropriate estimate of residual variability.

Evident unbalances among baseline values in the three groups will be taken into account by means of analysis of covariance. As secondary aim reboxetine will be compared to imipramine in respect to HAMD total score considering the difference between baseline and the last postbaseline score for each patient. In this case a two tail test will be applied. Confidence interval

of the difference between treatment mean decrements vs baseline will also be computed.

In order to have a more complete picture of reboxetine effectiveness results obtained from the other administered scales (Montgomery-Asberg, CGI, PGI) as well as response/remission rates will be considered. Response/remission rate is defined as the proportion of randomized patients experiencing response/remission (see 10.2) at a fixed time.

All the efficacy variables will be analysed taking into account both the values obtained at the last postbaseline visit and values obtained at each week. Explorative comparisons among the three groups will be performed.

Time course of the score of the administered rating scales will be described for all the three groups. Time trend analysis will be performed on patients completing the six weeks treatment period. If judged to be informative, weekly analysis, including only those patients remaining in the study at a particular week, will be carried out.

Dropouts will be classified by reasons for study termination and proportions of patients dropped out compared among groups.

Frequencies of patients showing maximum decrease ≥ 20 mmHg in the standing systolic blood pressure will be compared among groups.

Adverse events will be presented by patient-by-patient listing and tabulated by treatment both on a patient basis and on an event basis. If clinically significant differences arise, they will be submitted to non parametric test of the differences among treatment groups.

Decriptive statistics (mean, median, etc.) for laboratory data will be provided as well as frequency of abnormal values, with respect to normal range, after treatment in each group.

15.0 ETHICAL ASPECTS

The study will be carried out according to the Helsinki Declaration (Venice revision, Enclosure 15)

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

15.1 Ethical Committee

This study will not be undertaken until approval is obtained from the Ethical Committee Institutional Review Board (IRB) of the participating centres. It is responsibility of the Investigator to submit the study protocol with its attachments to the Ethical Committee.

The written approval of the Ethical Committee or IRB will report the name and profession of all its members and a copy of it will be sent to the Sponsor before the study begins.

The Investigator is committed, in compliance with local requirements, to inform the Ethical Committee of any emergent problems, serious adverse reactions or protocol amendments.

15.2 Informed consent

Before entering the study each patient will be receive an explanation of the nature, duration, and purpose of the study and the action of the compounds in such a manner that the patient is aware of the potential risks, inconveniences or adverse effects that may occur and can express his/her informed consent to participate. The consent form (enclosure 1) will be signed by the patient or by the Investigator. In the latter case, the signature of a witness will testify that full information was given to the patient.

16.0 PROTOCOL AMENDMENTS

After the protocol has been signed, no changes will be made without the agreement of both the Investigator, the Steering Committee and the Sponsor. Any change will be recorded on a written agreement which will be signed and dated by both parties and attached to the original protocol. No protocol change will be implemented without Regulatory approval, where required.

17.0 STUDY MONITORING

The monitors of the study are listed in enclosure 16.

A pre-study visit will be made by the monitor to the Investigator in order to discuss problems, if any, and

the obligations of both the Sponsor and the Investigator. During the trial monitoring visits will be paid to the site by the study monitor every four weeks. During the visits the monitor will assess the progress of the study, review the compliance with the study protocol, discuss any problem, check the CRFs for legibility, accuracy and completeness, validate CRFs content against source documents, assess the status of drug storage dispensing and retrieval.

Operating procedures for training on assessment instruments, study monitoring and coordination are described in attachment A.

18.0 DRUG SUPPLY AND INVENTORY

Test preparation will be supplied by Farmitalia Carlo Erba in the form described in 8.1. Records will be kept by the Investigator as to the disposition of study drug for each patient. A disposition form accounting for all study supplies will be signed by the Investigator (enclosure 17).

19.0 ADMINISTRATIVE ASPECTS

19.1 Insurance policy (enclosure 18)

Farmitalia Carlo Erba Company declares to have a group insurance cover (policy NO. 4W8102 - Italia Assicurazioni) which provides indemnity to the Investigator, to the co-Investigators and to the subjects participating in the trial.

19.2 Curriculum vitae

The Investigator will provide the Sponsor with signed copies of his/her and his/her co- Investigators CVs.

19.3 Data collection in the Case Record Form

All study data will be recorded in the CRF supplied by the Sponsor (Attachment B). A black ink ball point pen should be used for entering the data to ensure the good quality of the reproduced CRFs copies.

Only the Principal Investigator and the duly authorized co-Investigators can make entries in the CRF.

In case of errors corrections must be made by crossing out the incorrect entry (that must remain legible) and entering the correction followed by the Investigator's initials and the date of the correction.

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

On the occasion of the monitoring visits the monitor will take away the original and one copy of each page, while the Investigator will retain a copy for his files, together with the drug disposition records, for ten years after the discontinuation of the investigation.

19.4 Use and publication of the date obtained from the study

All unpublished documentation including the protocol, the CRF and the Investigator's Brochure, given to the Investi-gator is confidential. These documents cannot be disclosed to a third party without the written consent of FICE R&D. The submission of these documents to the Ethical Committee is expressely permitted.

The Investigator agrees that FICE R&D maintains the right to utilize the results of this study, in their original form and/or in a global report, for submission to the governmental and regulatory authorities of any country.

20.0 STUDY REPORT

20.1 Clinical Study Final Report

The final Medical Study Report will be written by the Product Leader and will be submitted to the Investigator for approval and signature.

20.2 Use and publication of Study Results

The Investigators, whilst free to use the data resulting from this study, are asked to discuss any paper with Farmitalia Carlo Erba prior to publication; to this purpose copy of manuscript/abstract as to be available for FICE R&D Approval Procedure 30 days prior to publication.
The results of the study may be submitted for a common publication, agreed upon between the Investigator and FICE R&D.

21.0 END OF THE STUDY

The Investigator or FICE R&D could terminate this study at any time for well documented reasons. In this event the other party will be immediately notified.

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

22.0 STUDY COORDINATION

A Steering Committee in charge of the coordination of the study will be formed, as described in Attachment A.

23.0 REFERENCES

1. Reboxetine Investigator Brochure, FICE, CNS Line, June 1988

2. /602i - Herrmann W.M. et al. (AFB - Berlin)
Safety and tolerance of reboxetine in healthy male volunteers - A single rising dose tolerance study.
June 15 1984.

3. /603i - Herrmann W.M. (AFB - Berlin)
Reboxetine - Quantitative pharmaco EEG and pharmaco-psychological study.
January 1985.

4. /604i - Dubini A. et al.
Disposition and fate of ^{14}C-reboxetine administered orally to healthy volunteers.
March 1985.

5. /701 - A. Dubini, T. Ban
Reboxetine: Open Dose Range Finding study in patients hospitalized for major depressive disorders February 89

6. Stark P., Hardison D.
J. Clin. Psychiatry, 46:53-58, 1985

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

24.0 SIGNATURES

Signatures of the:

Investigator _____

Study Monitor _____

Product Leader _____

Line Medical Head _____

Biostatisticians _____

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

LIST OF ENCLOSURES

1) LIST OF CENTERS

2) DSM-III-R CRITERIA

3) CONSENT FORM

4) MMS: MINI MENTAL STATE

5) EXPERIMENTAL TREATMENT LABELLING

6) SCREENING FORM

7) HAMD: HAMILTON DEPRESSION RATING SCALE

8) CGI: CLINICAL GLOBAL IMPRESSION

9) MADRS: MONTGOMERY ASBERG DEPRESSION RATING SCALE

10) PATIENT GLOBAL IMPRESSION

11) RDRS: RELATIONAL RATING SCALE

12) ADVERSE EVENTS: CHECK LIST

13) KARCH AND LASAGNA MODIFIED CRITERIA

14) ADVERSE EVENTS REPORT

15) DECLARATION OF HELSINKI

16) LIST OF MONITORS

17) DRUG ACCOUNTABILITY FORM

18) INSURANCE POLICY

ATTACHMENT A

PROTOCOL 20124/015: OPERATING PROCEDURES FOR TRAINING ON ASSESSMENT INSTRUMENTS, STUDY MONITORING AND COOPDINATION

ATTACHMENT B

CASE RECORD FORM

ATTACHMENT C

COGNITIVE FUNCTION EVALUATION
Appendix 1 : Manual for COGNITIVE EVALUATION
Appendix 2 : Manual for MFMORY ASSESSMENT

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

TABLE 1 **EVALUATION SCHEDULE**

DAY		SCREEN	0	4	7	14	21	28	35	42
TREATMENT	REX mg		8----------							---->
	IMI mg		100-150----------				10----------			---->
	PLACEBO						200----------			---->
DIAGNOSIS : DSM III R		■								
MEDICAL HISTORY		■								
PHYSICAL EXAMINATION		■								
MMS		■								
VITAL SIGNS		■	■		■	■	■	■	■	■
ECG		■					■			■
X-RAY		■								
LABORATORY		■					■			■
21-ITEM HAMD		■	■		■	■	■	■	■	■
CGI			■		■	■	■	■	■	■
MADRS			■		■	■	■	■	■	■
PATIENT GLOBAL IMPR.					■	■	■	■	■	■
RELATIONAL RATING SCALE			■		■	■	■	■	■	■
COGNITIVE EVALUATION			■			■				■
ADVERSE EVENTS			■		■	■	■	■	■	■

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

Enclosure 1

LIST OF PARTICIPATING CENTERS

No.	Country	Principal Investigator (Institution, Address)	Number of patients
1.	Australia	Prof. G.D.Burrows Department of Psychiatry University of Melbourne, Austin Hospital, Heidelberg, Vic. 3084 phone: +613/4505111	24
2.	France	Prof. Pellet Hopital Bellevue, Boulevard Pasteur Service de Psychiatrie 42043 Saint Etienne Cedex	24
3.	France	Dr. Chabannes Clinique du Nivolet Service de Psychiatrie, B.P. 126 73011 Chambery Cedex	24
4.	France	Dr. Haxaire Cabinet Médical, 15 bd Joffre A 54000 Nancy	24
5.	France	Prof. Leger Centre Hospitalier Spécialisé "Esquirol" 15 rue du Docteur-Marcland 87025 Limoges Cedex	24
6.	France	Dr. Cullerre Cabinet Médical 189 rue Colonel Jean Muller 56000 Lorient	24
7.	Germany	Dr. Benkert University of Meinz	24

Pharmacia Document 9550082

12.1.2 CRF SAMPLE

A complete CRF is filed in the Study Master File.

12.1.3 ETHICS COMMITTEES OR INVESTIGATIONAL REVIEW BOARDS: APPROVALS, LIST OF MEMBERS, PATIENT INFORMATION AND CONSENT FORMS

Investigational Review Boards and Ethics Committees approvals were obtained according to local regulations and laws: copy of the approval documents and, in case of Ethics Committees, list of members are filed in the Study Master File.

The proposed consent form is enclosed (Enclosure 3 of Appendix 12.1.1). Copy of forms approved by Ethics Committees and local translations are filed in the Study Master File.

12.1.4 CLINICAL INVESTIGATORS LIST, SIGNATURES AND CURRICULA VITAE

Centre 1: Dr R Gupta (principal investigator)
Phillip Health Centre, Woden, Canberra, Australia

Centre 2/1: Prof J Pellet (principal investigator)
Dr MLJ Pichon (co-investigator)
Hôpital Bellevue, St. Etienne, France

Centre 2/2: Dr JL Terra (principal investigator)
Dr C Bourdet, Dr S Besançon, Dr JL Salinas (co-investigators)
Centre Hôpitalier Spécialisé, Le Vinatier - Secteur G10, Lyon, France

Centre 2/3: Dr H Scharbach (principal investigator)
Dr J Guilloux (co-investigator)
CHU Service Médico-Psycholog., Nantes, France

Centre 2/4: Dr G Leibovici (principal investigator)
Avenue de la Serane, Marseille, France,

Centre 2/5: Dr RA Castiglioni (principal investigator)
Hôpital Sainte Marguerite, Service de Psychiatrie, Marseille, France

Centre 2/6: Dr Z Houri (principal investigator)
Clinique Psychiatrique du Parc, Nantes, France

Centre 3/1: Dr M Costes (principal investigator)
Dr L Gujadhur (co-investigator)
Centre Hôpitalier Spécialisé, Saint Egréve, France

Centre 3/2: Dr JP Chabannes (principal investigator)
Dr P Sechier (co-investigator)
Centre Hôpitalier Spécialisé de Bassens, Chambéry, France

Centre 3/3: Prof M Goudemand (principal investigator)
Dr P Thomas (co-investigator)
Unité de Soins Normalisés, Lille, France

Centre 3/4: Prof G Briole (principal investigator)
Dr A Payen, Dr D Vallet, Dr P Clervoy, Dr A Suner-Churlaud (co-investigators)
Hôpital d'Instruction des Armées du Val-de-Grace, Paris, France

Centre 4/1: Dr JC Haxaire (principal investigator)
Dr F Nicolas, Dr N Bertoni (co-investigators)
Bd Joffre, Nancy, France

Centre 4/2: Dr G Campa (principal investigator)
Rue Nestor Cornier, Grenoble, France

Centre 4/3: Dr C Blanchard (principal investigator)
CH, St Nazaire, France

Centre 4/4: Dr R Pagot (principal investigator)
Centre Hôpitalier Spécialisé, Saint-Ave, France

Centre 5/1: Prof JM Leger (principal investigator)
Dr JF Therme, Dr S Altuzarra, Dr C Franceschi (co-investigators)
CHU - Service de Psychiatrie, Limoges, France

Centre 5/2: Dr JM Bouchard (principal investigator)
Dr E Pezé (co-investigator)
Centre Hôpitalier Spécialisé Gerard Marchant, Toulouse, France

Centre 5/3: Dr JF Charbonnier (principal investigator)
Hôpital St Jacques, Clermont-Ferrand, France

Centre 6/1: Prof S Brion (principal investigator)
Dr A Fallet, Dr J Gailledreau, Dr V Mahe (co-investigators)
Hôpital Richaud, Service de Psychiatrie, Versailles, France

Centre 6/2: Dr PYH Cullerre (principal investigator)
Dr Le Brenn (co-investigator)
Rue Colonel Jean Muller, Lorient, France

Centre 6/3: Dr B Baranowski (principal investigator)
Rue de Nemours, Rennes, France

Centre 7/1: Dr EU Vorbach (principal investigator)
Psychiatrische Klinik, Elisabethenstift, Darmstadt, Germany

Centre 7/2: Prof M Hummel (principal investigator)
Dr T Reüster, Dr B Wennhold (co-investigators)
Psychiatrische Univ. Klinik, Marburg/Lahn, Germany

Centre 7/3: Prof HJ Schierle (principal investigator)
Puiseaux Platz, Rodgau, Germany

Centre 7/4: Prof T Schmitt (principal investigator)
General Hospital, Waldbrunn-Hintermeilingen, Germany

Centre 7/5: Prof P Mayr (principal investigator)
Mozartstr, Stockach, Germany

Centre 7/7: Prof J. Schimek (principal investigator)
Münchener Str., Frankfurt, Germany

Centre 8: Prof E Aguglia (principal investigator)
Dr G Quarantotto, Dr P Duse (co-investigators)
Dept. of Psychiatry, Università di Trieste, Trieste, Italy

Centre 8a: Prof E Aguglia (principal investigator)
Dr M Santagati, Dr G Barbagallo, Dr C Caprino Campana (co-investigators)
Associazione Croce al Vallone, Biancavilla CT, Italy

Centre 9: Prof E Smeraldi (principal investigator)
Dr P Della Maggiore, Dr L Bellini, Dr V Brancato (co-investigators)
Ospedale S Raffaele - Villa Turro, Milano, Italy

Centre 11: Prof RG Priest (principal investigator)
Dr J Steinert, Dr RC Gimbrett, Dr MC Roberts (co-investigators)
Academic Dept of Psychiatry, St Mary's Hospital, London, UK

Centre 12: Prof M Ohayon (principal investigator)
Dr E Stip, Dr JY Roy (co-investigators)
Centre of Research, Louis La Fontaine Hospital, Montreal, Canada

Centre 13: Prof GD Burrows (principal investigator)
Dr S Gyorki (co-investigator)
Department of Psychiatry, University of Melbourne, Austin Hospital, Heidelberg, Australia

Centre 14: Prof JWG Tiller (principal investigator)
Dr V Tuckwell, Dr KP Maguire, Dr ACN Holmes, Dr AM Keogh (co-investigators)
The Royal Hospital, Melbourne, Australia

Centre 15: Dr T George (principal investigator)
The Prince Charles Hospital, Chermside, Brisbane, Australia

Investigators' signatures and Curricula Vitae are filed in the Study Master File.

Pharmacia Document 9550082

12.1.5 CERTIFICATES OF ANALYSIS

CENTRO RICERCHE
VIA GIOVANNI XXIII, 23
20014 NERVIANO

TELEFONO (0331) 587250
TELEGRAMMI FARMITALIA CARLO ERBA NERVIANO
CASELLA POSTALE 7
TELEX 310379 MONTED PER FARMITALIA NERVIANO

9550082

FARMITALIA CARLO ERBA

DATA December 9th, 1992

CERTIFICATE OF ANALYSIS

REBOXETINE 4 mg capsules

Batch SF 1131

Manufacturing date	: September, 1990
Expiry date	: June, 1993
Appearance	: red-brown, hard-gelatin capsule, snap-fit, size No. 0, containing two 2 mg Reboxetine white, round, convex, 6 mm diameter tablets, marked S.F. on one surface (batch No. SF 1105)
Identification	: positive
Average weight	: mg 202.01
Uniformity of content	: within the limits, according to Ph. Eur. 2nd Ed., Section V.5.2.2
Assay	: mg 3.998 of Reboxetine/capsule
Related substances	: 1.04%
Disintegration	: 6 minutes
Microbial contamination	: total viabl aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent
Reanalysis date	: December 9th, 1992

Note : this certificate replaces the previous one, edited on March 11th, 1992, owing to the extension of the shelf-life

Approved by : V. Busnelli

9550082

Pharmacia
Farmitalia Carlo Erba

Data January 24th, 1994
Vs. Rif.
Ns. Rif.
Tel. Diretto

CERTIFICATE OF ANALYSIS No. PC/267

REBOXETINE 4 mg capsules

Batch SF 1264

Manufacturing date	: October, 1991
Expiry date	: September, 1994
Appearance	: red-brown, hard-gelatin capsule, snap-fit, size No. 0, containing two 2 mg Reboxetine white, round, convex, 6 mm diameter tablets, marked S.F. on one surface (batch No. SF 1249)
Identification	: positive
Average weight	: mg 201.10
Uniformity of content	: within the limits, according to Ph. Eur. 2nd Ed., Section V.5.2.2
Assay	: mg 3.95 of Reboxetine/capsule
Dissolution	: 93.9% of the L.A. after 15 minutes
Disintegration	: 6 minutes
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent

Note : this certificate replaces the previous one edited on May 14th, 1992, vis-a-vis the extension of shelf-life

Approved by : V. Busnelli

681

Centro Ricerche
Farmitalia Carlo Erba srl
Via Giovanni XXIII, 23
20014 Nerviano (Mi) Italy

Telef. (0331) 58.3111 (Centralino)
Casella Postale 2

Sede Legale Milano
Capit. L. 528.732.127.000 I.V.
Trib. Milano R.S. N. 238246
Vol. 6366 - Fasc. 46

C.C.I.A.A. N. 1171077
Cod. Fisc. e Part. IVA
N. 07608290156

9550082

CENTRO RICERCHE
VIA GIOVANNI XXIII, 23
20014 NERVIANO
TELEFONO (0331) 587250
TELEGRAMMI FARMITALIA CARLO ERBA NERVIANO
CASELLA POSTALE 2
TELEX 310679 MONTED PER FARMITALIA NERVIANO

FARMITALIA CARLO ERBA

DATA December 9th, 1992

CERTIFICATE OF ANALYSIS

REBOXETINE 6 mg capsules

Batch SF 1132

Manufacturing date	: September, 1990
Expiry date	: June, 1993
Appearance	: red-brown, hard-gelatin capsule, snap-fit, size No. 0, containing three 2 mg Reboxetine white, round, convex, 6 mm diameter tablets, marked S.F. on one surface (batch No. SF 1105)
Identification	: positive
Average weight	: mg 302.97
Uniformity of content	: within the limits, according to Ph. Eur. 2nd Ed., Section V.5.2.2
Assay	: mg 5.993 of Reboxetine/capsule
Related substances	: 0.74%
Disintegration	: 6 minutes
Microbial contamination	: total viabl aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent
Reanalysis date	: December 9th, 1992

Note : this certificate replaces the previous one, edited on March 11th, 1992, owing to the extension of the shelf-life

Approved by : V. Busnelli

682

GRUPPO ERBAMONT

9550082

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 6095.1 (CENTRALINO)
TELEGRAMMI ERBACAR-MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBA-I-

FARMITALIA CARLO ERBA

DATA May 7th, 1992

VS. RIF.

NS. RIF.

TEL. DIRETTO

CERTIFICATE OF ANALYSIS

REBOXETINE 6 mg capsules

Batch SF 1291

Manufacturing date	: March, 1992
Expiry date	: September, 1994
Appearance	: red-brown, hard-gelatin capsule, snap-fit, size No. 0, containing three 2 mg Reboxetine white, round, convex, 6 mm diameter tablets, marked S.F. on one surface (batch No. SF 1249)
Identification	: positive
Average weight	: mg 303.66
Uniformity of content	: within the limits, according to Ph. Eur. 2nd Ed., Section V.5.2.2
Assay	: mg 6.08 of Reboxetine/capsule
Related substances	: 0.19%
Disintegration	: 6 minutes
Microbial contamination	: total viable aerobic counts < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent
Approved by	: V. Busnelli

683

GRUPPO ERBAMONT

9550082

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO 02/ 6995.1 (CENTRALINO)
TELEGRAMMI ERBACAR MILANO
CASELLA POSTALE 10510
C.C. POSTALE 619205
TELEX 330371 ERBA I

FARMITALIA CARLO ERBA

DATA October 22, 1990

VS. RIF

NS. RIF

TEL. DIRETTO

CERTIFICATE OF ANALYSIS

PLACEBO for Reboxetine 4 mg capsules

Batch SF 1133

Manufacturing date	: September 1990
Description	: hard-gelatin capsule, opaque red-brown, size No. 0, containing two white, round, convex, 6 mm diameter placebo tablets for reboxetine 2 mg, marked S.F. on one surface
Average weight	: 203.63 mg
Uniformity of mass	: complies, according to Eur. Ph., 2nd Ed., requirements
Identification	: negative
Disintegration time	: 6 minutes
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonella : absent

Approved by 68/4 Virginio Busnelli

9550082

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 6995.1 (CENTRALINO)
TELEGRAMMI ERBACAR-MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBA-I-

FARMITALIA CARLO ERBA

DATA September 17, 1990

VS. RIF.

NS. RIF.

TEL. DIRETTO

CERTIFICATE OF ANALYSIS

PLACEBO for Reboxetine 6 mg capsules

Batch SF 1134

Manufacturing date	: September 1990
Description	: hard-gelatin capsule, opaque red-brown, size No. 0, containing three white, round, convex, 6 mm diameter placebo tablets for reboxetine 2 mg, marked S.F. on one surface
Average weight	: 303.64 mg
Uniformity of mass	: complies, according to Eur. Ph., 2nd Ed., requirements
Identification	: negative
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonella : absent
Approved by	: Virginio Busnelli

685

S.R.L. SEDE LEGALE IN MILANO
CAPITALE L. 533.742.617.000 I.V.
TRIBUNALE DI MILANO R.S. N. 298246
VOL. 6366 - FASC. 46 C.C.I.A.A. N. 1171077
COD. FISC. E PART. IVA N. 07608290156

GRUPPO ERBAMONT
MONTEDISON CURA DELLA SALUTE

9550082

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 6905.1 (CENTRALINO)
TELEGRAMMI ERBACAR MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBA-I-

FARMITALIA CARLO ERBA

DATA December 11th, 1991

VS. RIF.

NS. RIF.

TEL. DIRETTO

CERTIFICATE OF ANALYSIS

PLACEBO for Reboxetine capsules

Batch SF 1247

Manufacturing date	: October, 1991
Appearance	: red-brown, hard-gelatin capsule, snap-fit, size No. 0, containing two round, convex, 6 mm diameter, white tablets, marked S.F. on a side (batch SF 1205)
Identification	: negative
Average weight	: mg 199.76
Uniformity of weight	: within the limits, according to Ph. Eur. 2nd Ed., Section V.5.2.1
Disintegration	: 10 minutes
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent
Approved by	: Virginio Busnelli

686

GRUPPO ERBAMONT

9550082

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 6995.1 (CENTRALINO)
TELEGRAMMI ERBACAR-MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBA-I-

FARMITALIA CARLO ERBA

DATA May 20th, 1992

VS. RIF.

NS. RIF.

TEL DIRETTO

CERTIFICATE OF ANALYSIS

PLACEBO for Reboxetine capsules

Batch SF 1306

Manufacturing date	: April, 1992
Appearance	: red-brown, hard-gelatin capsule, snap-fit, size No. 0, containing three round, convex, 6 mm diameter, white tablets, marked S.F. on a side (batch SF 1205)
Identification	: negative
Average weight	: mg 298.27
Uniformity of weight	: within the limits, according to Ph. Eur. 2nd Ed., Section V.5.2.1
Disintegration	: 8 minutes
Microbial contamination	: total viable aerobic counts < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent
Approved by	: Virginio Busnelli

687

GRUPPO ERBAMONT

9550082

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 6995.1 (CENTRALINO)
TELEGRAMMI ERBACAR-MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBA I

FARMITALIA CARLO ERBA

DATA October 19, 1990

VS. RIF

NS. RIF.

TEL. DIRETTO

CERTIFICATE OF ANALYSIS

Imipramine hydrochloride 50 mg capsules

Batch SF 1130

Manufacturing date	: September 1990
Expiry date	: October 1994
Description	: hard-gelatin capsule, opaque red-brown, size No. 0, containing two 25 mg TOFRANIL sugar coated, dark pink orange, tablets (GEIGY, batch No.153)
Average weight	: mg 149.443
Uniformity of mass	: complies, according to Eur. Ph., 2nd Ed., requirements
Disintegration time	: 13 minutes
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonella : absent
Approved by	: Virginio Busnelli

688

9550082

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 6995.1 (CENTRALINO)
TELEGRAMMI ERBACAR-MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBA-I-

FARMITALIA CARLO ERBA

DATA March 24th, 1992

VS. RIF.

NS. RIF.

TEL DIRETTO

CERTIFICATE OF ANALYSIS

Imipramine hydrochloride 50 mg capsules

Batch SF 1265

Manufacturing date	: December 1990
Expiry date	: December 1995
Description	: hard-gelatin capsule, opaque red-brown, size No.0, containing two 25 mg TOFRANIL sugar coated, dark pink orange, tablets (GEIGY, batch No. 178)
Average weight	: mg 151.49
Uniformity of mass	: complies, according to Eur. Ph., 2nd Ed., requirements
Disintegration time	: 12 minutes
Identification	: positive, according to B.P. 1988 monograph texts A, B and C, page 956
Assay	: 48.41 mg/capsule (B.P. 1988 monograph, page 956)
Related substances	: within the limits, according to B.P.1988 monograph, page 956
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent
Approved by 689	: V. Busnelli

GRUPPO ERBAMONT

9550082

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 6995 1 (CENTRALINO)
TELEGRAMMI ERBACAR-MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBA-I-

FARMITALIA CARLO ERBA

DATA October 22, 1990

VS. RIF.

NS. RIF.

TEL. DIRETTO

CERTIFICATE OF ANALYSIS

Imipramine hydrochloride 100 mg capsules

Batch SF 1129

Manufacturing date	: September 1990
Expiry date	: October 1994
Description	: hard-gelatin capsule, opaque red-brown, size No. 0, containing four 25 mg TOFRANIL sugar coated, dark pink orange, tablets (GEIGY, batch No.156)
Average weight	: mg 301.251
Uniformity of mass	: complies, according to Eur. Ph., 2nd Ed., requirements
Disintegration time	: 12 minutes
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonella : absent
Approved by	: Virginio Busnelli

690

9550082

VIA CARLO IMBONATI 24
20159 MILANO

TELEFONO (02) 6995.1 (CENTRALINO)
TELEGRAMMI ERBACAR MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBAM

FARMITALIA CARLO ERBA

DATA October 25, 1990

VS. RIF

NS. RIF

TEL. DIRETTO

ANALISYS CERTIFICATE

Imipramine hydrochloride 100 mg capsules

Batch SF 1151

Manufacturing date	: October 1990
Expiry date	: October 1994
Description	: hard-gelatin capsule, opaque red-brown, size No.0, containing four 25 mg TOFRANIL sugar coated, dark pink orange, tablets (GEIGY, batch No. 153)
Average weight	: mg 300.63
Uniformity of mass	: complies, according to Eur. Ph., 2nd Ed., requirements
Disintegration time	: 12 minutes
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. coli and Salmonella : absent
APPROVED BY	: Virginio Busnelli

691

9550082

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 6995.1 (CENTRALINO)
TELEGRAMMI ERBACAR-MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBA-I-

FARMITALIA CARLO ERBA

DATA March 24th, 1992

VS. RIF.

NS. RIF.

TEL. DIRETTO

CERTIFICATE OF ANALYSIS

Imipramine hydrochloride 100 mg capsules

Batch SF 1263

Manufacturing date	: December 1990
Expiry date	: December 1995
Description	: hard-gelatin capsule, opaque red-brown, size No.0, containing four 25 mg TOFRANIL sugar coated, dark pink orange, tablets (GEIGY, batch No. 178)
Average weight	: mg 299.87
Uniformity of mass	: complies, according to Eur. Ph., 2nd Ed., requirements
Disintegration time	: 12 minutes
Identification	: positive, according to B.P. 1988 monograph texts A, B and C, page 956
Assay	: 95.43 mg/capsule (B.P. 1988 monograph, page 956)
Related substances	: within the limits, according to B.P.1988 monograph, page 956
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent
Approved by	: V. Busnelli

692

GRUPPO ERBAMONT

12.1.6 AUDIT CERTIFICATE

9550082

Pharmacia & Upjohn
PPC Italy / GCP-Quality Assurance

R&D/Q.A. AUDIT CERTIFICATE

Product **REBOXETINE**

Protocol N°: **FCE 20124/015** N° GCP: **44**

Study title: Multicenter, multinational double-blind study of the activity and tolerability of Reboxetine vs Imipramine and placebo in patients suffering from Major Depressive Episodes.

Type of Audit	Site	Audit date(s)	Reporting date
Draft Protocol	FICE - Milan	04.05.1990	21.05.1990
Final Protocol	FICE - Milan	08.1990	28.08.1990
Study Master File	Pharmacia - Milan	11.02.1992	24.02.1992
Audit at CRO-ACRS	Germany	07.05.1992	20.05.1992
Study Master File	Pharmacia - Milan	04-05.05.1993	20.05.1993
Investigator Site	Centre N°9 (Italy)	28.06.1993	05.07.1993
Investigator Site	Centre N°8 (Italy)	30.09.1993	15.10.1993
Study Master File	Pharmacia - Milan	08-15.02.1995	16.02.1995
Draft Final Report	Pharmacia - Milan	05-19.12.1995	08.01.1996
Final Report	Pharmacia - Milan	13.03.1996	13.03.1996

Signature of the Head of PPC Italy/GCP-Q.A. ---

Date: March 13th, 1996

694

12.1.7 RANDOMISATION LIST

REBOXETINE - PROT. 015 9550082
RANDOMIZATION LIST
8:46 Friday, September 14, 1990

---------- CENTRE=1 AUSTRALIA ----------

PTS N.	TREATMENT
1	imipramine
2	reboxetine
3	imipramine
4	placebo
5	reboxetine
6	placebo
7	reboxetine
8	placebo
9	reboxetine
10	placebo
11	imipramine
12	imipramine
13	placebo
14	placebo
15	imipramine
16	imipramine
17	reboxetine
18	reboxetine
19	reboxetine
20	imipramine
21	imipramine
22	placebo
23	reboxetine
24	placebo
25	reboxetine
26	placebo
27	imipramine
28	reboxetine
29	placebo
30	imipramine

REBOXETINE - PROT 015
RANDOMIZATION LIST
9550082
8:46 Friday, September 14, 1990

CENTRE=2 FRANCE

PTS N.	TREATMENT
31	placebo
32	reboxetine
33	imipramine
34	placebo
35	reboxetine
36	imipramine
37	reboxetine
38	placebo
39	imipramine
40	reboxetine
41	placebo
42	imipramine
43	imipramine
44	imipramine
45	reboxetine
46	placebo
47	placebo
48	reboxetine
49	placebo
50	reboxetine
51	imipramine
52	imipramine
53	placebo
54	reboxetine
55	reboxetine
56	reboxetine
57	imipramine
58	placebo
59	placebo
60	imipramine

REBOXETINE - PROT. 015
RANDOMIZATION LIST
8:46 Friday, September 14, 1990

---------- CENTRE=3 FRANCE ----------

PTS N.	TREATMENT
61	imipramine
62	imipramine
63	placebo
64	placebo
65	reboxetine
66	reboxetine
67	placebo
68	reboxetine
69	placebo
70	imipramine
71	imipramine
72	reboxetine
73	placebo
74	reboxetine
75	imipramine
76	imipramine
77	placebo
78	reboxetine
79	imipramine
80	imipramine
81	reboxetine
82	placebo
83	placebo
84	reboxetine
85	imipramine
86	imipramine
87	placebo
88	placebo
89	reboxetine
90	reboxetine

REBOXETINE - PROT. 015 9550082
RANDOMIZATION LIST
8:46 Friday, September 14, 1990

---------- CENTRE=4 FRANCE ----------

PTS N.	TREATMENT
91	imipramine
92	reboxetine
93	placebo
94	placebo
95	imipramine
96	reboxetine
97	placebo
98	reboxetine
99	placebo
100	imipramine
101	imipramine
102	reboxetine
103	imipramine
104	reboxetine
105	placebo
106	imipramine
107	placebo
108	reboxetine
109	reboxetine
110	imipramine
111	imipramine
112	placebo
113	reboxetine
114	placebo
115	reboxetine
116	imipramine
117	imipramine
118	reboxetine
119	placebo
120	placebo

REBOXETINE - PROT. 015
RANDOMIZATION LIST 9550082
8:46 Friday, September 14, 1990

---------- CENTRE=5 FRANCE ----------

PTS N.	TREATMENT
121	imipramine
122	placebo
123	imipramine
124	placebo
125	reboxetine
126	reboxetine
127	reboxetine
128	reboxetine
129	placebo
130	placebo
131	imipramine
132	imipramine
133	placebo
134	reboxetine
135	imipramine
136	imipramine
137	reboxetine
138	placebo
139	imipramine
140	placebo
141	placebo
142	imipramine
143	reboxetine
144	reboxetine
145	imipramine
146	placebo
147	reboxetine
148	imipramine
149	reboxetine
150	placebo

REBOXETINE - PROT. 015 9550082
RANDOMIZATION LIST
8:46 Friday, September 14, 1990

---------- CENTRE=6 FRANCE ----------

PTS N.	TREATMENT
151	imipramine
152	reboxetine
153	reboxetine
154	imipramine
155	placebo
156	placebo
157	reboxetine
158	imipramine
159	imipramine
160	placebo
161	reboxetine
162	placebo
163	reboxetine
164	imipramine
165	imipramine
166	reboxetine
167	placebo
168	placebo
169	imipramine
170	placebo
171	imipramine
172	reboxetine
173	placebo
174	reboxetine
175	imipramine
176	placebo
177	imipramine
178	reboxetine
179	placebo
180	reboxetine

REBOXETINE - PROT. Q15
RANDOMIZATION LIST 9550082
8:46 Friday, September 14, 1990

---------- CENTRE=7 GERMANY ----------

PTS N.	TREATMENT
181	reboxetine
182	placebo
183	imipramine
184	imipramine
185	reboxetine
186	placebo
187	imipramine
188	placebo
189	placebo
190	reboxetine
191	imipramine
192	reboxetine
193	placebo
194	reboxetine
195	placebo
196	reboxetine
197	imipramine
198	imipramine
199	imipramine
200	placebo
201	reboxetine
202	reboxetine
203	placebo
204	imipramine
205	placebo
206	imipramine
207	imipramine
208	reboxetine
209	placebo
210	reboxetine

REBOXETINE - PROT. 015
RANDOMIZATION LIST 9550082
8:46 Friday, September 14, 1990

---------- CENTRE=8 ITALY ----------

PTS N.	TREATMENT
211	reboxetine
212	placebo
213	imipramine
214	reboxetine
215	placebo
216	imipramine
217	reboxetine
218	reboxetine
219	placebo
220	imipramine
221	imipramine
222	placebo
223	imipramine
224	placebo
225	placebo
226	reboxetine
227	reboxetine
228	imipramine
229	imipramine
230	reboxetine
231	imipramine
232	reboxetine
233	placebo
234	placebo
235	placebo
236	placebo
237	reboxetine
238	reboxetine
239	imipramine
240	imipramine

REBOXETINE - PROT. 015
RANDOMIZATION LIST 9550082
8:46 Friday, September 14, 1990

---------- CENTRE=9 ITALY ----------

PTS N.	TREATMENT
241	placebo
242	reboxetine
243	reboxetine
244	imipramine
245	imipramine
246	placebo
247	placebo
248	placebo
249	reboxetine
250	imipramine
251	imipramine
252	reboxetine
253	reboxetine
254	imipramine
255	reboxetine
256	imipramine
257	placebo
258	placebo
259	reboxetine
260	imipramine
261	placebo
262	reboxetine
263	imipramine
264	placebo
265	imipramine
266	reboxetine
267	placebo
268	reboxetine
269	imipramine
270	placebo
271	reboxetine
272	placebo
273	imipramine
274	reboxetine
275	placebo
276	imipramine
277	placebo
278	imipramine
279	reboxetine
280	reboxetine
281	imipramine
282	placebo
283	reboxetine
284	placebo
285	imipramine
286	placebo
287	reboxetine
288	imipramine

REBOXETINE - PROT. Q15
RANDOMIZATION LIST 9550082
8:46 Friday, September 14, 1990

---------- CENTRE=10 SWEDEN ----------

PTS N.	TREATMENT
289	placebo
290	placebo
291	imipramine
292	reboxetine
293	imipramine
294	reboxetine
295	placebo
296	reboxetine
297	imipramine
298	reboxetine
299	imipramine
300	placebo
301	reboxetine
302	reboxetine
303	placebo
304	imipramine
305	imipramine
306	placebo
307	reboxetine
308	imipramine
309	reboxetine
310	placebo
311	imipramine
312	placebo
313	reboxetine
314	imipramine
315	placebo
316	placebo
317	imipramine
318	reboxetine

REBOXETINE - PROT. 015 9550082
RANDOMIZATION LIST
8:46 Friday, September 14, 1990

---------- CENTRE=11 U.K. ----------

PTS N.	TREATMENT
319	placebo
320	imipramine
321	placebo
322	reboxetine
323	reboxetine
324	imipramine
325	reboxetine
326	placebo
327	imipramine
328	imipramine
329	placebo
330	reboxetine
331	imipramine
332	reboxetine
333	placebo
334	reboxetine
335	placebo
336	imipramine
337	reboxetine
338	imipramine
339	imipramine
340	reboxetine
341	placebo
342	placebo
343	imipramine
344	placebo
345	reboxetine
346	imipramine
347	reboxetine
348	placebo
349	imipramine
350	imipramine
351	reboxetine
352	placebo
353	placebo
354	reboxetine
355	imipramine
356	reboxetine
357	placebo
358	imipramine
359	reboxetine
360	placebo
361	imipramine
362	reboxetine
363	imipramine
364	placebo
365	reboxetine
366	placebo

REBOXETINE - PROT. 015
RANDOMIZATION LIS**9550082**
12:38 Tuesday, September 18, 1990

CENTRE=12 CANADA

PTS N.	TREATMENT
367	reboxetine
368	placebo
369	imipramine
370	placebo
371	imipramine
372	reboxetine
373	reboxetine
374	placebo
375	imipramine
376	reboxetine
377	imipramine
378	placebo
379	imipramine
380	reboxetine
381	imipramine
382	reboxetine
383	placebo
384	placebo
385	placebo
386	imipramine
387	reboxetine
388	placebo
389	imipramine
390	reboxetine
391	imipramine
392	imipramine
393	placebo
394	placebo
395	reboxetine
396	reboxetine
397	reboxetine
398	imipramine
399	placebo
400	placebo
401	imipramine
402	reboxetine

REBOXETINE - PROT. 015
RANDOMIZATION LIST

---------- CENTRE=1 b AUSTRALIA ----------

PTS N.	TREATMENT
403	imipramine
404	reboxetine
405	placebo
406	imipramine
407	reboxetine
408	placebo
409	reboxetine
410	placebo
411	imipramine
412	reboxetine
413	placebo
414	imipramine
415	imipramine
416	reboxetine
417	imipramine
418	placebo
419	placebo
420	reboxetine
421	imipramine
422	imipramine
423	placebo
424	reboxetine
425	placebo
426	reboxetine
427	imipramine
428	reboxetine
429	placebo
430	reboxetine
431	imipramine
432	placebo

REBOXETINE - PROT. 015
RANDOMIZATION LIST 9550082 Tuesday, May 14, 1991

---------- CENTRE=2 FRANCE BIS ----------

PTS N.	TREATMENT
433	reboxetine
434	reboxetine
435	placebo
436	imipramine
437	placebo
438	imipramine
439	placebo
440	reboxetine
441	imipramine
442	reboxetine
443	imipramine
444	placebo
445	placebo
446	reboxetine
447	reboxetine
448	imipramine
449	imipramine
450	placebo

REBOXETINE - PROT. 015
RANDOMIZATION LIST 9550082 Tuesday, May 14, 1991

---------- CENTRE=3 FRANCE BIS ----------

PTS N.	TREATMENT
451	reboxetine
452	placebo
453	imipramine
454	reboxetine
455	placebo
456	imipramine
457	placebo
458	reboxetine
459	placebo
460	reboxetine
461	imipramine
462	imipramine
463	reboxetine
464	imipramine
465	imipramine
466	reboxetine
467	placebo
468	placebo

REBOXETINE - PROT. 015
RANDOMIZATION LIST 9550082 Tuesday, May 14, 1991

---------- CENTRE=4 FRANCE BIS ----------

PTS N.	TREATMENT
469	imipramine
470	reboxetine
471	placebo
472	reboxetine
473	placebo
474	imipramine
475	reboxetine
476	placebo
477	imipramine
478	imipramine
479	reboxetine
480	placebo
481	placebo
482	imipramine
483	imipramine
484	reboxetine
485	reboxetine
486	placebo

REBOXETINE - PROT. 015 9550082
RANDOMIZATION LIST 9:46 Tuesday, May 14, 1991

CENTRE=5 FRANCE BIS

PTS N.	TREATMENT
487	imipramine
488	reboxetine
489	imipramine
490	placebo
491	placebo
492	reboxetine
493	reboxetine
494	placebo
495	imipramine
496	placebo
497	reboxetine
498	imipramine
499	reboxetine
500	imipramine
501	imipramine
502	placebo
503	reboxetine
504	placebo

REBOXETINE - PROT. 015
RANDOMIZATION LIST 9550082 Tuesday, May 14, 1991

---------- CENTRE=6 FRANCE BIS ----------

PTS N.	TREATMENT
505	imipramine
506	placebo
507	imipramine
508	reboxetine
509	placebo
510	reboxetine
511	imipramine
512	placebo
513	imipramine
514	reboxetine
515	placebo
516	reboxetine
517	reboxetine
518	reboxetine
519	placebo
520	imipramine
521	imipramine
522	placebo

9550082
REBOXETINE - PROT. 015
RANDOMIZATION LIST

---------- CENTRE=7 GERMANY BIS ----------

PTS N.	TREATMENT
523	reboxetine
524	placebo
525	placebo
526	reboxetine
527	imipramine
528	imipramine
529	placebo
530	imipramine
531	reboxetine
532	imipramine
533	reboxetine
534	placebo
535	placebo
536	reboxetine
537	imipramine
538	reboxetine
539	imipramine
540	placebo
541	reboxetine
542	imipramine
543	imipramine
544	placebo
545	placebo
546	reboxetine
547	placebo
548	placebo
549	reboxetine
550	reboxetine
551	imipramine
552	imipramine

REBOXETINE - PROT. 015 9550082
RANDOMIZATION LIST

---------- CENTRE=8 ITALY BIS ----------

PTS N.	TREATMENT
553	placebo
554	reboxetine
555	reboxetine
556	imipramine
557	placebo
558	imipramine
559	reboxetine
560	imipramine
561	placebo
562	placebo
563	imipramine
564	reboxetine
565	placebo
566	reboxetine
567	imipramine
568	reboxetine
569	imipramine
570	placebo
571	placebo
572	imipramine
573	reboxetine
574	imipramine
575	reboxetine
576	placebo
577	reboxetine
578	imipramine
579	imipramine
580	placebo
581	reboxetine
582	placebo

12.1.8 CRITERIA USED TO JUDGE LABORATORY ABNORMALITIES AS CLINICALLY RELEVANT AND REFERENCE VALUES FOR LABORATORY TESTS

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.8

CRITERIA USED TO JUDGE LABORATORY ABNORMALITIES AS CLINICALLY RELEVANT

Laboratory test	Percent variation above or below normal range (*)
HB	- 15
HT	- 15
RBC	- 15
PLATELETS	-+ 30
WBC	-+ 30
WBC: N	-+ 30
WBC: E	+ 30
WBC: B	+ 30
WBC: L	-+ 30
WBC: M	+ 30
CREATININE	+ 50
UREA	+ 50
BUN	+ 50
URIC ACID	+ 30
TOT. PROTEINS	-+ 30
ALBUMINE	-+ 30
TOT BILIRUBIN	+ 100
DIR BILIRUBIN	+ 100
SGOT	+ 100
SGPT	+ 100
GAMMA GT	+ 100
LDH	+ 100
ALK. PHOSPH.	+ 100
GLOBULINS ALPHA 1	-+ 30
GLOBULINS ALPHA 2	-+ 30
GLOBULINS BETA	-+ 30
GLOBULINS GAMMA	-+ 30
TOT. CHOLEST.	+ 30
HDL	- 20
TRIGLYCERIDES	+ 30
GLUCOSE	-+ 30
NA+	-+ 10
CL-	-+ 10
K+	-+ 15
Ca++	-+ 15
PO4--	-+ 15
RT3	not defined
T3	not defined
T4	-+ 10
TSH	-+ 10
ESR/SEDIMENT. RATE	not defined

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

PHARMACIA CNS R&D 9550082

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.8

LABORATORY REFERENCE VALUES

		Range values			
		Female		Male	
		Min	Max	Min	Max
Laboratory test	Units				
HB	g/dl	12.00	16.00	13.50	17.50
HT	%	36.00	46.00	41.00	53.00
RBC	10-6/mm-3	4.00	5.20	4.50	5.90
PLATELETS	10-3/mm-3	150.00	400.00	150.00	400.00
ESR/SEDIMENT. RATE 1st h	mm	0.00	10.00	0.00	10.00
ESR/SEDIMENT. RATE 2nd h	mm	0.00	20.00	0.00	20.00
WBC	10-3/mm-3	4.50	11.00	4.50	11.00
WBC: N	%	57.00	67.00	57.00	67.00
WBC: E	%	1.00	3.00	1.00	3.00
WBC: B	%	0.00	0.75	0.00	0.75
WBC: L	%	23.00	33.00	23.00	33.00
WBC: M	%	3.00	7.00	3.00	7.00
CREATININE	mg/dl	0.50	1.10	0.60	1.20
CREATININE CLEARANCE	ml/min	88.00	128.00	97.00	137.00
UREA	mg/dl	15.00	35.00	15.00	35.00
BUN	mg/dl	7.00	18.00	7.00	18.00
URIC ACID	mg/dl	2.60	6.00	3.50	7.20
TOT. PROTEINS	g/dl	6.40	8.30	6.40	8.30
ALBUMINE	g/dl	3.50	5.00	3.50	5.00
TOT BILIRUBIN	mg/dl	0.20	1.00	0.20	1.00
DIR BILIRUBIN	mg/dl	0.00	0.20	0.00	0.20
SGOT	U/l	10.00	30.00	10.00	30.00
SGPT	U/l	5.00	30.00	5.00	30.00
GAMMA GT	U/l	8.00	40.00	9.00	50.00
LDH	U/l	210.00	420.00	210.00	420.00
ALK. PHOSPH.	U/l	56.00	155.00	62.00	176.00
GLOBULINS ALPHA 1	g/dl	0.10	0.30	0.10	0.30
GLOBULINS ALPHA 2	g/dl	0.60	1.00	0.60	1.00
GLOBULINS BETA	g/dl	0.70	1.10	0.70	1.10
GLOBULINS GAMMA	g/dl	0.80	1.60	0.80	1.60
SEDIMENT.	mm/h	0.00	20.00	0.00	15.00
TOT. CHOLEST.	mg/dl	152.00	268.00	158.00	276.00
HDL	mg/dl	35.00	65.00	29.00	60.00
TRIGLYCERIDES	mg/dl	38.00	160.00	49.00	284.00
GLUCOSE	mg/dl	70.00	105.00	70.00	105.00
NA+	mEq/l	136.00	146.00	136.00	146.00
CL-	mEq/l	98.00	106.00	98.00	106.00
K+	mEq/l	3.50	5.10	3.50	5.10
Ca++	mEq/l	4.50	5.50	4.50	5.50
PO4--	mEq/l	1.00	1.50	1.00	1.50
T4	ug/dl	5.00	12.00	5.00	12.00
TSH	mU/l	2.00	10.00	2.00	10.00

Pharmacia Document 9550082

12.1.9 ADVERSE EVENTS GROUPED IN CLUSTERS

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Appendix No.: 12.1.9

ADVERSE EVENTS GROUPED IN CLUSTERS

Body System	Cluster	Adverse event	Treatment	No of AE	No of Pt with AE
BODY AS A WHOLE-GENERAL DISORDERS	ASTHENIA / FATIGUE	ASTHENIA	Imipramine	3	3
		ASTHENIA	Reboxetine	1	1
		FATIGUE	Imipramine	4	4
		FATIGUE	Placebo	4	4
		FATIGUE	Reboxetine	3	3
CARDIOVASCULAR DISORDERS, GENERAL	CARDIAC ISCHEMIA AND RELATED SYMPTOMS	CHEST PAIN PRECORDIAL	Imipramine	2	2
		CHEST PAIN PRECORDIAL	Placebo	1	1
	FLUSHING / HOT FLASHING	FLUSHING	Reboxetine	1	1
		HOT FLUSHES	Imipramine	4	3
		HOT FLUSHES	Placebo	1	1
		HOT FLUSHES	Reboxetine	2	2
	HYPOTENSION AND RELATED SYMPTOMS	DIZZINESS	Imipramine	16	14
		DIZZINESS	Placebo	4	4
		DIZZINESS	Reboxetine	8	6
		HYPOTENSION	Imipramine	1	1
		HYPOTENSION	Placebo	2	2
		HYPOTENSION	Reboxetine	2	2
		HYPOTENSION POSTURAL	Imipramine	6	6
		HYPOTENSION POSTURAL	Reboxetine	2	2
		SYNCOPE	Imipramine	2	2
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	HEADACHE / MIGRAINE	HEADACHE	Imipramine	9	9
		HEADACHE	Placebo	10	9
		HEADACHE	Reboxetine	18	14
		MIGRAINE	Reboxetine	1	1
GASTRO-INTESTINAL SYSTEM DISORDERS	NAUSEA AND RELATED SYMPTOMS	VOMITING	Imipramine	1	1
		VOMITING	Placebo	4	4
		VOMITING	Reboxetine	1	1
		DYSPEPSIA	Imipramine	5	5
		DYSPEPSIA	Placebo	1	1
		GASTRITIS	Reboxetine	1	1
		NAUSEA	Imipramine	16	13
		NAUSEA	Placebo	11	9
		NAUSEA	Reboxetine	9	9
HEMATOLOGY DISORDERS	ANEMIA	ANAEMIA HYPOCHROMIC	Imipramine	1	1
LIVER AND BILIAR SYSTEM DISORDERS	INCREASED LIVER ENZYMES	GAMMA-GT INCREASED	Imipramine	1	1
		GAMMA-GT INCREASED	Reboxetine	1	1
PSYCHIATRIC DISORDERS	AGITATION / ANXIETY / NERVOUSNESS	AGITATION	Imipramine	4	4
		AGITATION	Placebo	7	7
		AGITATION	Reboxetine	8	7

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Appendix No.: 12.1.9

ADVERSE EVENTS GROUPED IN CLUSTERS

Body System	Cluster	Adverse event	Treatment	No of AE	No of Pt with AE
PSYCHIATRIC DISORDERS	AGITATION / ANXIETY / NERVOUSNESS	ANXIETY	Imipramine	1	1
		ANXIETY	Placebo	3	3
		ANXIETY	Reboxetine	1	1
		NERVOUSNESS	Placebo	1	1
		NERVOUSNESS	Reboxetine	4	4
SKIN AND APPENDAGES DISORDERS	ERYTHEMA / RASH	RASH	Imipramine	1	1
		RASH	Placebo	2	2
		RASH ERYTHEMATOUS	Reboxetine	1	1
URINARY SYSTEM DISORDERS	URINARY HESITANCY / RETENTION	URINARY RETENTION	Placebo	1	1
		URINARY RETENTION	Reboxetine	3	3
		MICTURITION DISORDER	Imipramine	1	1
		MICTURITION DISORDER	Placebo	1	1
		MICTURITION DISORDER	Reboxetine	3	3
VISION DISORDERS	BLURRED VISION	ACCOMMODATION ABNORMAL	Imipramine	1	1
		VISION ABNORMAL	Imipramine	10	9
		VISION ABNORMAL	Placebo	3	3
		VISION ABNORMAL	Reboxetine	7	6

Pharmacia Document 9550082

12.1.10 ECG CODES

APPENDIX No.: 12.1.10

ECG CODES

0 Normal

1 Rhythm disorders

10 Sinus bradycardia (<60)

20 Sinus tachycardia (>100)

30 Sick Sinus Syndrome

40 • Atrial ectopic beats:
- 41 - Occasional
- 42 - Frequent (>6/mm)
- 43 - Couplets
- 44 - Supraventricular Tachycardia

50 • Ventricular ectopic beats:
- 51 - Occasional
- 52 - Frequent (>6/mm)
- 53 - Polymorphic
- 54 - Couplets
- 55 - Ventricular Tachycardia

60 • Atrial fibrillation/flutter

105 • Vagotonia

108 • Atrial-ventricular dissociation

2 Conduction disorders

70 • A-V Block 1st degree
- 71 - 2nd degree - Mobitz 1
- 72 - - Mobitz 2
- 73 - Complete

85 • Right bundle branch block

86 • Left bundle branch block

87 • Left anterior hemiblock

88 • Left posterior hemiblock

89 • Bifascicular Block (specify)

90 • Trifascicular Block (specify)

91 • Conduction disorders

103 • Left axial deviation

106 • Right incomplete bundle branch block

3 Ischemic signs

102 • Ripolarization disturbances

107 • Non specific ST-T changes

82 • Myocardial ischemia

84 • Acute Myocardial infarction

4 Other

80 • Left ventricular hypertrophy

81 • Right ventricular hypertrophy

83 • Previous Myocardial infarction

93 • Other (specify)_____

104 • Right axial deviation

12.1.11 STATISTICAL ANALYSIS PROGRAMS LISTINGS

```
*                                                                  ;
*                      PHARMACIA CNS R&D                           ;
                                                9550082
*                      APPENDIX No.: 12.1.11                       ;
*                                                                  ;

 *-------------------------------------------------------------*
 *                                                             *
 *  PGM NAME: LAB003                                           *
 *  CREATED:  07.12.93                                         *
 *  AIM    :  Stuart-Maxwell test                              *
 *                                                             *
 *                                                             *
 *  BY CORTESI - PANSID MI                                     *
 *-------------------------------------------------------------*;

%macro labstat(var= );

proc sort data = labst;
 by centre patient lab_par day;

data stat(keep = lab_par  day  lab_ind  lab_dif  &var
                 cod_trt  bas  nr_paz   nvis     num_ord)

     shift(keep = lab_par  day      &var  cod_trt   num_ord
                  lab_bas  lab_now  k     up  down  same  nvis)

     maxw  (keep = lab_par  day     &var   cod_trt
                   indice   k       nvis   num_ord);

 set labst;
 by centre patient lab_par day ;
 retain bas lab_bas 0;

 if first.patient then nr_paz = 1;
 else nr_paz = 0;

 if first.lab_par then do;
                   bas = lab_ind;
                   lab_bas = lab_uid;
                   lab_dif = .;
                 end;
 else do;
        k = 1;
        lab_now = lab_uid;
        lab_dif =lab_ind - bas;
        up = 0;
        down = 0;
        same = 0;
        if lab_dif > 0 then up = 1;
        else if lab_dif < 0 then down = 1;
        else same = 1;
        output shift;
        indice = (lab_bas-1) * 3 + (lab_now);
        output maxw;
      end;
 output stat;

               * proc univariate * ;

proc sort data = stat;
 by &var cod_trt lab_par day;

proc univariate data = stat noprint;
 by &var cod_trt lab_par  day;
 var lab_ind lab_dif bas;
 id num_ord;
 output out    =stat (drop=x2-x8 y1-y5)
        mean   =lab_mean x2        bas_mean
        median=lab_medi dif_medi  bas_medi
        std    =lab_std  x3        bas_std
        min    =lab_min  x4        y1
        max    =lab_max  x5        y2
        n      =lab_frq  x6        y3
        probt =x7       t_prob    y4
        probs =x8       s_prob    y5;

proc sort data = shift ;
 by &var cod_trt lab_par day lab_bas lab_now;

proc means data = shift noprint;
 by  &var cod_trt lab_par day;
 var up down same;
 id num_ord;
 output out=shifts
        sum=up down same;
```

```
data stat  ;
 merge stat (in=a) shifts(in=b);
 by  &var cod_trt lab_par day;                          9550082
 if a = 1 or b = 1;
 if b=1 then do;
        if up = down then p_value = 1;
        else p_value = 2. * (probbnml(.5,sum(up,down),min(up,down)));
 end;

 p_test = s_prob;


          *--------------------------------------*
          * MAXWELL TEST                         *
          *--------------------------------------*;

proc sort data = maxw  ;
 by  &var cod_trt lab_par  day indice;

proc means data = maxw noprint;
 by  &var cod_trt lab_par  day indice;
 var k;
 id num_ord;
 output out=maxw
        sum=k;

 data maxw(keep = &var cod_trt lab_par  day  p_maxw num_ord);
  set maxw;
 by  &var cod_trt lab_par  day indice;
  retain  a11 a12 a13 a21 a22 a23 a31 a32 a33;
  array _a_ (9) a11 a12 a13 a21 a22 a23 a31 a32 a33;

  if first.day then do i=1 to 9; _a_(i) = 0 ; end;

  _a_(indice)=k;
  if last.day then do;
       n12=(a12+a21)/2;
       n13=(a13+a31)/2;
       n23=(a23+a32)/2;

       d1=a12+a13-a21-a31;
       d2=a21+a23-a12-a32;
       d3=a31+a32-a13-a23;

       d1=d1*d1;
       d2=d2*d2;
       d3=d3*d3;

       numx2=n23*d1+n13*d2+n12*d3;
       denx2=(n12*(n13+n23)+n13*n23)*2;
       if denx2 > 0 then do;
                          x2=numx2/denx2;
                          p_maxw = 1 - probchi(x2,2);
                         end;
        else do;
              if a32 > 0 or a23 > 0 then do;
                    if a32 = a23 then p_maxw = 1;
                         else do;
                               denx2=a32+a23;
                               numx2=min(a32,a23);
                               p_maxw = 2. * probbnml(0.5,denx2,numx2);
                              end;
                   end; * if a32 > 0 ..... ;
              else if a21 > 0 or a12 > 0 then do;
                    if a21 = a12 then p_maxw = 1;
                         else do;
                               denx2=a21+a12;
                               numx2=min(a21,a12);
                               p_maxw = 2. * probbnml(0.5,denx2,numx2);
                              end;
                   end; * if a21 > 0 ..... ;
              else if a31 > 0 or a13 > 0 then do;
                    if a31 = a13 then p_maxw = 1;
                         else do;
                               denx2=a31+a13;
                               numx2=min(a31,a13);
                               p_maxw = 2. * probbnml(0.5,denx2,numx2);
                              end;
                    end; * if a31 > 0 ..... ;
              else p_maxw = 1;  * tutti gli elementi no su diag.;
        end; * if denx2 <= 0 ..... ;
        output;
        end; * if last day ..... ;

proc means data = shift noprint;
 by &var cod_trt lab_par day lab_bas lab_now;
 var k ;
 id num_ord;
 output out=shift
        sum=k;
```

```
data maxw (keep = &var cod_trt lab_par  day  p_maxw maxw_p  num_ord
                  dw sm up k lab_bas);;
 merge shift(in=a) maxw(in=b);                          9550082
 by &var cod_trt lab_par day ;
 retain maxw_p;
 if first.day then maxw_p = .;
 dw = .; sm = .; up = . ;
 array now (3) dw sm up;
 now(lab_now) = k;
 output;
 if last.day then do;
    * generazione di tutti i possibili incroci (con valori a zero);
    dw = .; sm = .; up = . ; k = .;
    lab_bas = 1; output;
    lab_bas = 2; output;
    lab_bas = 3;
    maxw_p = p_maxw;
    output;
 end;
run;

 %mend labstat;
```

```
                PHARMACIA CNS R&D                          9550082
             APPENDIX NO. : 12.1.11
  *-------------------------------------------------------------------*
  *                                                                   *
  *  PGM NAME: tav50var                                               *
  *  CREATED:  16.05.95                                               *
  *  AIM     :  MEAN DECREASE OF HAMILTON TOTAL SCORE                 *
  *             AT LAST ASSESSMENT WITH RESPECT TO BASELINE           *
  *             AND 95% CONFIDENCE INTERVAL                           *
  *             USING OUTPUT OF ANOVA                                 *
  *                                                                   *
  *                                                                   *
  *  BY CORTESI - PANSID MI                                           *
  *-------------------------------------------------------------------*;

  options pageno=1;

  options pageno=1;
  proc glm data=last outstat=sta noprint;
 TITLE7 'ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE'
        ' AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE';
  class cod_trt;
  model diffn=cod_trt;
  lsmeans cod_trt /out=med;
  run;


data sta;
 set sta;
where _source_='ERROR';
tt=abs(tinv(0.025,df));

proc sort data=sta;
 by _name_;

proc sort data=med;
 by _name_;

data tot;
  merge sta med;
 by _name_;

limi=lsmean-tt*stderr;
lims=lsmean+tt*stderr;

 proc print data = tot;
 var cod_trt lsmean tt limi lims;

 proc sort data=tot;
  by cod_trt;

%let gmaxlev = 0.5;
%let gmaxval= 5;
%let gminval= 25;
%let gbyval =  5;

data graf(keep=cod_trt level value);
 set tot end=fine;
  by cod_trt;
retain level 0 maxv_ minv_ difval_;
array dati (3) limi lsmean lims;

 if limi < minv_ or minv_ = . then minv_ = limi;
 if lims > maxv_ then maxv_ = lims;
 x_ = lims - limi;
 if x_ > difval_ then difval_ = x_;

 level=level + 0.1;
 do _i_ = 1 to 3;
      value = dati(_i_);
      output;
 end;
 if fine then do;
              difval_ =abs(difval_)+1;
              minv_ = minv_ - difval_ ;
              if minv_ < 0 then minv_ = 0;
              maxv_ = maxv_ + difval_ ;
              gby_ = abs((maxv_ - minv_)* 0.1);
       *      if gby_ < 1 then gby_ = 1;
              call symput('gmaxlev',put(level+0.1,4.1));
              call symput('gminval',put(minv_,4.));
              call symput('gmaxval',put(maxv_,4.));
              call symput('gbyval',put(gby_,4.));
             end;

proc sort data = graf;
  by level;
RUN;

goptions reset=global gunit=pct  /*rotate=landscape */
```

```
        rotate=portrait
        device=gddmfam4 gddmtoken=fine240 gddmnickname=p3820
        vsize=      hsize= 7  in    hpos=   vpos=
        vorigin=1.25 in horigin=2.25 in
        ftext=swiss  htitle=3 htext=2 display;
RUN;


%include pgmgen(gtitle);
%include pgmgen(gsymb4);

title5 f=swiss  h=2.5
       'MEAN DECREASES OF HAMILTON TOTAL SCORE AT LAST ASSESSMENT';
TITLE6 F=SWISS  H=2.5  'POINT ESTIMATES AND CONFIDENCE INTERVALS';
title7 ' ' ;

data b;
 set graf;
 format function $8. text $8. x y 8.4 ;
   function='label';
   position='3';
   size=3  ;
   style='swiss';
   hsys = '1';
   xsys ='2';
   ysys = '2' ;
   when= 'a';

   x=value;
   y=level;
   text=put(value,4.1);
RUN;

axis1 label =(a=90 '          ')
      style=0
      offset=(2  )
      order=0 to &gmaxlev by 0.1
      value=none
      minor=none
      major=none;

axis2 label =(f=swiss h=1.8 '   ')
      value=(f=swiss h=1.5)
      minor=none
      order=&gminval to &gmaxval by &gbyval;

legend1 label =none
        frame
        value=(f=swiss h=2.0)
        position=(bottom center outside);

* legend1 label =(position=top  f=swiss h=1.8 'Treatments:')
        down=5
        value=(f=swiss h=2.0);

proc gplot data=graf;
plot level*value=cod_trt /
    annotate=b
    vaxis=axis1
    haxis=axis2
    legend=legend1;
format cod_trt $ftrt.;
run;


proc sort data = med;
 by descending cod_trt;

data med1(keep=trt_con dif ls li er);
 set med end=fine;
 retain m1-m10 st1-st10 i 0 ;
 format trt1-trt10 $8. trt_con $30.;
 retain trt1-trt10;
 array tmean (10) m1-m10;
 array tstd (10) st1-st10;
 array ttrt (10) trt1-trt10;
 i = i + 1;
 file print;
 if i > 10 then
    put 'MORE THAN 10 TREATMENTS  '
        ' delle array ' i= trt1= trt2= trt3= trt4= trt5= trt6=
         trt7= trt8= trt9= trt10=;

 else do;
       ttrt(i) = cod_trt;
       tmean(i) = lsmean;
       tstd(i) = stderr;
      end;
 if fine=1 then do;
    da = 0;
    DO K = 1 TO I - 1; *        MAX NUMBER OF TREATMENTS     ;
```

```
      do da = k + 1 to i;                                    9550082
         trt_con = trim(put(ttrt(k),$ftrt.))||' - '||
                   trim(put(ttrt(da),$ftrt.));
         dif = tmean(k) - tmean(da);
         er=sqrt(tstd(k)**2+tstd(da)**2);
         ls=dif+1.96*er;
         li=dif-1.96*er;
         output;
      end;
   end;
end;
label trt_con='Treatments'
      dif='means difference'
       li='lower confidence limit'
       ls='upper confidence limit';
```

```
*                                                                     ;
*                       PHARMACIA CNS R&D              9550082        ;
*                      APPENDIX No.: 12.1.11                          ;
*                                                                     ;

 *-----------------------------------------------------------------*
 *  PGM NAME: perul95                                              *
 *  CREATED:  15.02.94                                             *
 *  AIM    :  95% exact confidence interval for a proportion       *
 *-----------------------------------------------------------------*
   *-------------------------------------------------------------*
   *  INPUT  :                                                   *
   *                                                             *
   *  _pop_  -> total number of patients                         *
   *  _nr_   -> number of events                                 *
   *            % : pct=(_nr_/_pop_)*100                         *
   *                                                             *
   *  OUTPUT  :                                                  *
   *  l95 -> % LOWER LIMIT                                       *
   *  u95 -> % UPPER LIMIT                                       *
   *-------------------------------------------------------------*;

   if pct = 0 then do;
                    l95=0;
                    u95 = (1-exp(log(0.05)/_pop_)) * 100;
                  end;
   else
   if pct = 100 then do;
                    u95=100;
                    l95 = exp(log(0.05)/_pop_) * 100;
                  end;
   else if pct ne . then do;

    li=pct/100;  * lower limit     ;
    ls=1;    * upper limit      ;

    do k =1 to 100;
      z =((ls - li) / 2) + li;
      a = probbnml(z,_pop_,_nr_);
      if .02501 > a > .02499 then leave;
      else
      if a > .02501 then li = z;
      else ls=z;
    end;
    u95 = z * 100;
    if k > 100 then put '**1** convergence was not attained in 100 '
                        'iterations ' k= z= pct= ls= li= ;


    ls=pct/100;  * limite superiore;
    li=0;    * limite inferiore ;

    do k =1 to 100;
      z=((ls - li) / 2) + li;
      a =1 - probbnml((1 - z),_pop_,(_pop_ - _nr_));
     if .97501 > a > .97499 then leave;
     else
     if a > .97501 then li = z;
     else ls=z;
   end;
   l95 = z * 100;
   if k > 100 then put '**1** convergence was not attained in 100 '
                       'iterations ' k= z= pct= ls= li= ;
 end;
```

```
*                                                      9550082       ;
*                        PHARMACIA CNS R&D                           ;

*                      APPENDIX No.: 12.1.11                         ;
*                                                                    ;

 *-------------------------------------------------------------------*
 *  PGM NAME: bartlett                                               *
 *  CREATED:  18.10.95                                               *
 *  AIM    :  Bartlett's test for the equality of variances          *
 *                                                                   *
 *-------------------------------------------------------------------*;

proc sort data=last out=lbart;
 by cod_trt;

proc means data=lbart noprint;
 by cod_trt;  * compute the within-group sample variance;
 var diffn;
 format cod_trt $ftrt.;
 output out=bart1 n=num var=var;
run;

data _null_;
 set bart1 end=fine;
 retain sumdf suminvdf sumlvadf sumdfvar n 0;

 * compute the pooled variance;
 n=_N_;
 df=num-1;

 logvar=log10(var);
 logvardf=df*logvar;
 sumlvadf=sumlvadf+logvardf;

 sumdf=sumdf+df;

 invdf=1/df;
 suminvdf=suminvdf+invdf;

 dfvar=df*var;
 sumdfvar=sumdfvar+dfvar;

 logs=log10(sumdfvar/sumdf);      * log(base10) (var. totale);

 if fine then do;
    m=log(10)*(sumdf*logs-sumlvadf);
    chidf=n-1;
    c=1+(1/(3*chidf))*(suminvdf-(1/sumdf));
    chi=m/c;
    output;
 end;
 p=1-probchi(chi,chidf);

 file print;
 if fine
    then put /// '    '
             /// @69 "BARTLETT'S TEST RESULTS"
             /// '    '
             / @45 'CHI SQUARE = ' chi '    WITH   ' chidf
                    'DEGREES OF FREEDOM  p= ' p;
run;
```

12.1.12 SELECTION OF STATISTICAL ANALYSIS OUTPUTS

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/015

Appendix No.: 12.1.12

SELECTION OF STATISTICAL ANALYSIS OUTPUTS

Efficacy analyses

Study end point : HAMD decrease

- ANOVA on baseline values for comparison between treatments

- ANOVA on decreases at last assessment according to the models:
  HAMD decrease = treatment + sex + sex * treatment
  HAMD decrease = treatment + diagnosis + treatment * diagnosis

The following analyses have been carried out on three sets of patients: all patients, severe and melancholic patients.
- Tables showing descriptive statistics (n, mean, standard deviation S.D.)
- Bartlett test for testing homogeneity of variances
- ANOVA according to the model : HAMD decrease = treatment
- one-side Dunnett's test for comparison between each active treatment and placebo

Response : 50% HAMD decrease

- Chi square test for the comparison of the frequency of responders in each active treatment Vs placebo group.
- Log-rank test on time to response (pairwise comparisons between each of the active treatments and placebo)

Remission : HAMD total score lower than or equal to 10

- Chi square test for the comparison of the number of remission cases in each active treatment and in placebo group

Analysis of Adverse events

- Log-rank test on the time to the first occurrence of either any event and selected signs-symptoms (pairwise comparisons between each of the active treatment and placebo)

9550082

1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON AT BASELINE

General Linear Models Procedure
Class Level Information

Class	Levels	Values
COD_TRT	3	IMI PLC RBX

Number of observations in data set = 332

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON AT BASELINE

General Linear Models Procedure

Dependent Variable: HAM0

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	20.72609800	10.36304900	0.41	0.6631
Error	329	8288.31908272	25.19245922		
Corrected Total	331	8309.04518072			

R-Square	C.V.	Root MSE	HAM0 Mean
0.002494	18.45992	5.01920902	27.18975904

Source	DF	Type I SS	Mean Square	F Value	Pr > F
COD_TRT	2	20.72609800	10.36304900	0.41	0.6631

Source	DF	Type III SS	Mean Square	F Value	Pr > F
COD_TRT	2	20.72609800	10.36304900	0.41	0.6631

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure
Class Level Information

Class	Levels	Values
COD_TRT	3	IMI PLC RBX
SEX	2	F M

Number of observations in data set = 332

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure

Dependent Variable: DIFFN

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	5	836.37894136	167.27578827	1.65	0.1464
Error	326	33056.09093815	101.39905196		
Corrected Total	331	33892.46987952			

R-Square	C.V.	Root MSE	DIFFN Mean
0.024677	78.36717	10.06970963	12.84939759

Source	DF	Type I SS	Mean Square	F Value	Pr > F
COD_TRT	2	410.83482628	205.41741314	2.03	0.1335
SEX	1	0.58760159	0.58760159	0.01	0.9394
COD_TRT*SEX	2	424.95651349	212.47825675	2.10	0.1247

Source	DF	Type III SS	Mean Square	F Value	Pr > F
COD_TRT	2	406.14884366	203.07442183	2.00	0.1366
SEX	1	0.41871360	0.41871360	0.00	0.9488
COD_TRT*SEX	2	424.95651349	212.47825675	2.10	0.1247

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/045
APPENDIX No.: 12.1.12

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure
Class Level Information

Class	Levels	Values
COD_TRT	3	IMI PLC RBX
DSMIII	2	296.2 296.3

Number of observations in data set = 331

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure

Dependent Variable: DIFFN

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	5	590.33749693	118.06749939	1.15	0.3313
Error	325	33223.58395322	102.22641216		
Corrected Total	330	33813.92145015			

R-Square	C.V.	Root MSE	DIFFN Mean
0.017458	78.52286	10.11070780	12.87613293

Source	DF	Type I SS	Mean Square	F Value	Pr > F
COD_TRT	2	428.70122083	214.35061042	2.10	0.1245
DSMIII	1	51.10710833	51.10710833	0.50	0.4800
COD_TRT*DSMIII	2	110.52916777	55.26458388	0.54	0.5829

Source	DF	Type III SS	Mean Square	F Value	Pr > F
COD_TRT	2	317.48636835	158.74318418	1.55	0.2132
DSMIII	1	50.42113892	50.42113892	0.49	0.4830
COD_TRT*DSMIII	2	110.52916777	55.26458388	0.54	0.5829

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

TABLE OF COD_TRT BY RESP

COD_TRT(treatment code)

RESP	0	1	Total
PLC	53	58	111
Frequency			
Expected	49.222	61.778	
Percent	23.98	26.24	50.23
Row Pct	47.75	52.25	
Col Pct	54.08	47.15	
RBX	45	65	110
Frequency			
Expected	48.778	61.222	
Percent	20.36	29.41	49.77
Row Pct	40.91	59.09	
Col Pct	45.92	52.85	
Total	98	123	221
	44.34	55.66	100.00

STATISTICS FOR TABLE OF COD_TRT BY RESP

Statistic	DF	Value	Prob
Chi-Square	1	1.047	0.306
Likelihood Ratio Chi-Square	1	1.048	0.306
Continuity Adj. Chi-Square	1	0.788	0.375
Mantel-Haenszel Chi-Square	1	1.042	0.307
Fisher's Exact Test (Left)			0.877
(Right)			0.187
(2-Tail)			0.344
Phi Coefficient		0.069	
Contingency Coefficient		0.069	
Cramer's V		0.069	

Sample Size = 221

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

TABLE OF COD_TRT BY RESP

COD_TRT(treatment code)

RESP			
Frequency Expected Percent Row Pct Col Pct	0	1	Total
IMI	42 47.5 18.92 37.84 44.21	69 63.5 31.08 62.16 54.33	111 50.00
PLC	53 47.5 23.87 47.75 55.79	58 63.5 26.13 52.25 45.67	111 50.00
Total	95 42.79	127 57.21	222 100.00

STATISTICS FOR TABLE OF COD_TRT BY RESP

Statistic	DF	Value	Prob
Chi-Square	1	2.226	0.136
Likelihood Ratio Chi-Square	1	2.230	0.135
Continuity Adj. Chi-Square	1	1.840	0.175
Mantel-Haenszel Chi-Square	1	2.216	0.137
Fisher's Exact Test (Left)			0.087
(Right)			0.948
(2-Tail)			0.175
Phi Coefficient		-0.100	
Contingency Coefficient		0.100	
Cramer's V		-0.100	

Sample Size = 222

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

TABLE OF COD_TRT BY REM

COD_TRT(treatment code)

REM			
Frequency / Expected / Percent / Row Pct / Col Pct	0	1	Total
PLC	71	40	111
	67.303	43.697	
	32.13	18.10	50.23
	63.96	36.04	
	52.99	45.98	
RBX	63	47	110
	66.697	43.303	
	28.51	21.27	49.77
	57.27	42.73	
	47.01	54.02	
Total	134	87	221
	60.63	39.37	100.00

STATISTICS FOR TABLE OF COD_TRT BY REM

Statistic	DF	Value	Prob
Chi-Square	1	1.036	0.309
Likelihood Ratio Chi-Square	1	1.037	0.308
Continuity Adj. Chi-Square	1	0.775	0.379
Mantel-Haenszel Chi-Square	1	1.032	0.310
Fisher's Exact Test (Left)			0.876
(Right)			0.189
(2-Tail)			0.337
Phi Coefficient		0.068	
Contingency Coefficient		0.068	
Cramer's V		0.068	

Sample Size = 221

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

TABLE OF COD_TRT BY REM

COD_TRT(treatment code)

Frequency / Expected / Percent / Row Pct / Col Pct	REM 0	REM 1	Total
IMI	55	56	111
	63	48	
	24.77	25.23	50.00
	49.55	50.45	
	43.65	58.33	
PLC	71	40	111
	63	48	
	31.98	18.02	50.00
	63.96	36.04	
	56.35	41.67	
Total	126	96	222
	56.76	43.24	100.00

STATISTICS FOR TABLE OF COD_TRT BY REM

Statistic	DF	Value	Prob
Chi-Square	1	4.698	0.030
Likelihood Ratio Chi-Square	1	4.716	0.030
Continuity Adj. Chi-Square	1	4.129	0.042
Mantel-Haenszel Chi-Square	1	4.677	0.031
Fisher's Exact Test (Left)			0.021
(Right)			0.989
(2-Tail)			0.042
Phi Coefficient		-0.145	
Contingency Coefficient		0.144	
Cramer's V		-0.145	

Sample Size = 222

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

EFFICACY: KAPLAN / MEIER ANALYSIS - TIME TO ONSET OF RESPONSE (50 % HAMILTON DECREASE)
FAILURE DISTRIBUTION FUNCTION

Treatment	Days of treatment	Events	Withdrawals (t-1 -- t)	At risk (t -- t+1)	FDF C.I. lower 95%	FDF estimate	FDF C.I. upper 95%
Imipramine	0			111	0.00000	0.00000	0.00000
	7	1	3	107	0.00000	0.00909	0.02683
	8	3	6	98	0.00141	0.03687	0.07234
	14	5	4	89	0.03280	0.08756	0.14233
	15	7	1	81	0.08757	0.15933	0.23109
	16	1	0	80	0.09680	0.16971	0.24341
	21	8	6	66	0.16826	0.25487	0.34147
	22	13	0	53	0.30189	0.40163	0.50137
	23	1	1	51	0.31264	0.41292	0.51321
	25	1	0	50	0.32361	0.42444	0.52526
	26	1	0	49	0.33465	0.43595	0.53725
	28	4	1	44	0.37940	0.48199	0.58458
	29	7	0	37	0.46156	0.56440	0.66724
	31	1	0	36	0.47356	0.57618	0.67879
	35	1	2	33	0.48589	0.58828	0.69068
	36	5	1	27	0.55024	0.65067	0.75109
	41	1	1	25	0.56415	0.66410	0.76405
	42	4	15	6	0.62100	0.71785	0.81469
	43	3	0	3	0.73609	0.85892	0.98175
	44	1	0	2	0.79473	0.90595	1.00000
	45	1	1	0	0.86730	0.95297	1.00000
Placebo	0			111	0.00000	0.00000	0.00000
	8	2	6	103	0.00000	0.01869	0.04435
	12	1	2	100	0.00000	0.02841	0.06010
	14	2	1	97	0.00691	0.04784	0.08877
	15	5	1	91	0.03980	0.09692	0.15404
	21	3	2	86	0.06244	0.12702	0.19160
	22	11	2	73	0.15520	0.23868	0.32216
	23	1	0	72	0.16431	0.24911	0.33391
	28	6	4	62	0.22162	0.31347	0.40532
	29	7	0	55	0.29319	0.39098	0.48878
	31	1	1	53	0.30381	0.40226	0.50071
	35	2	1	50	0.32524	0.42482	0.52439
	36	4	0	46	0.36953	0.47083	0.57214
	37	2	0	44	0.39205	0.49384	0.59564
	42	4	26	14	0.43868	0.54092	0.64317
	43	6	6	2	0.60510	0.73767	0.87024
	45	1	1	0	1.00000	1.00000	1.00000
Reboxetine	0			110	0.00000	0.00000	0.00000
	8	3	4	103	0.00000	0.02830	0.05987
	13	1	3	99	0.00146	0.03783	0.07419
	14	7	1	91	0.04668	0.10586	0.16504
	15	6	2	83	0.09316	0.16481	0.23647
	21	4	2	77	0.12706	0.20556	0.28405
	22	12	1	64	0.23699	0.32937	0.42174
	28	3	4	57	0.26727	0.36235	0.45742

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

EFFICACY: KAPLAN / MEIER ANALYSIS - TIME TO ONSET OF RESPONSE (50 % HAMILTON DECREASE)
FAILURE DISTRIBUTION FUNCTION

Treatment	Days of treatment	Events	Withdrawals (t-1 -- t)	At risk (t -- t+1)	FDF C.I. lower 95%	FDF estimate	FDF C.I. upper 95%
Reboxetine	29	7	1	49	0.34112	0.44066	0.54019
	34	3	1	45	0.37475	0.47561	0.57648
	35	5	0	40	0.43211	0.53388	0.63565
	36	7	0	33	0.51514	0.61545	0.71576
	42	4	23	6	0.56406	0.66206	0.76006
	43	2	3	1	0.63147	0.77471	0.91794
	44	1	0	0	1.00000	1.00000	1.00000

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

EFFICACY: KAPLAN / MEIER ANALYSIS - TIME TO ONSET OF RESPONSE (50 % HAMILTON DECREASE)

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	111	69	42	37.8378
RBX	110	65	45	40.9091
Total	221	134	87	39.3665

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	5.5996	806.00
RBX	-5.5996	-806.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	29.2737	-29.2737
RBX	-29.2737	29.2737

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	572340	-572340
RBX	-572340	572340

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	1.0711	1	0.3007
Wilcoxon	1.1351	1	0.2867
-2Log(LR)	0.7101	1	0.3994

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

EFFICACY: KAPLAN / MEIER ANALYSIS - TIME TO ONSET OF RESPONSE (50 % HAMILTON DECREASE)

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	111	58	53	47.7477
RBX	110	65	45	40.9091
Total	221	123	98	44.3439

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-9.0868	-1292.0
RBX	9.0868	1292.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	27.1537	-27.1537
RBX	-27.1537	27.1537

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	578912	-578912
RBX	-578912	578912

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	3.0408	1	0.0812
Wilcoxon	2.8835	1	0.0895
-2Log(LR)	1.0819	1	0.2983

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

EFFICACY: KAPLAN / MEIER ANALYSIS - TIME TO ONSET OF RESPONSE (50 % HAMILTON DECREASE)

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	111	69	42	37.8378
PLC	111	58	53	47.7477
Total	222	127	95	42.7928

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	14.488	2094.0
PLC	-14.488	-2094.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	27.2814	-27.2814
PLC	-27.2814	27.2814

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	549491	-549491
PLC	-549491	549491

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	7.6935	1	0.0055
Wilcoxon	7.9798	1	0.0047
-2Log(LR)	3.5183	1	0.0607

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX NO.:12.1.12

HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS AT LAST ASSESSMENT

HAMILTON TOTAL SCORE		BASELINE	LAST ASSESSMENT	DECREASE
TREATMENT				
Imipramine	N	111	111	111
	MEAN	26.93	13.15	13.77
	S.D.	4.67	9.91	10.23
Placebo	N	111	111	111
	MEAN	27.12	15.83	11.29
	S.D.	5.30	9.58	10.06
Reboxetine	N	110	110	110
	MEAN	27.53	14.04	13.49
	S.D.	5.07	9.22	9.97

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

BARTLETT'S TEST RESULTS

CHI SQUARE = 0.07524902524 WITH 2 DEGREES OF FREEDOM p= 0.9630787198

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure
Class Level Information

Class	Levels	Values
COD_TRT	3	IMI PLC R&X

Number of observations in data set = 332

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure

Dependent Variable: DIFFN

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	410.83482628	205.41741314	2.02	0.1345
Error	329	33481.63505324	101.76788770		
Corrected Total	331	33892.46987952			

R-Square	C.V.	Root MSE	DIFFN Mean
0.012122	78.50957	10.08800712	12.84939759

Source	DF	Type I SS	Mean Square	F Value	Pr > F
COD_TRT	2	410.83482628	205.41741314	2.02	0.1345

Source	DF	Type III SS	Mean Square	F Value	Pr > F
COD_TRT	2	410.83482628	205.41741314	2.02	0.1345

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure

Dunnett's One-tailed T tests for variable: DIFFN

NOTE: This tests controls the type I experimentwise error for comparisons of all treatments against a control.

Alpha= 0.05 Confidence= 0.95 df= 329 MSE= 101.7679
Critical Value of Dunnett's T= 1.923

Comparisons significant at the 0.05 level are indicated by '***'.

COD_TRT Comparison	Simultaneous Lower Confidence Limit	Difference Between Means	Simultaneous Upper Confidence Limit
IMI - PLC	-0.117	2.486	5.090
RBX - PLC	-0.407	2.203	4.812

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX NO.: 12.1.12
HAMILTON DEPRESSION RATING SCALE
DESCRIPTIVE STATISTICS ON LAST ASSESSMENT
SEVERE PATIENTS JUDGED BY CGI SEVERITY AT BASELINE

TOTAL SCORE HAMILTON			BASELINE	LAST ASSESS.	DECREASE
SEVERE	TREATMENT				
NO	Imipramine	N	31	31	31
		MEAN	23.97	12.84	11.13
		S.D.	1.91	8.20	7.98
	Placebo	N	42	42	42
		MEAN	24.86	13.79	11.07
		S.D.	2.47	8.39	8.62
	Reboxetine	N	33	33	33
		MEAN	25.00	14.27	10.73
		S.D.	2.61	8.86	9.69
YES	Imipramine	N	80	80	80
		MEAN	28.08	13.28	14.80
		S.D.	4.92	10.54	10.85
	Placebo	N	69	69	69
		MEAN	28.49	17.07	11.42
		S.D.	6.06	10.10	10.89
	Reboxetine	N	77	77	77
		MEAN	28.61	13.94	14.68
		S.D.	5.48	9.43	9.92

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

SEVERE PATIENTS JUDGED BY CGI SEVERITY AT BASELINE
ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

BARTLETT'S TEST RESULTS

CHI SQUARE = 0.8228624414 WITH 2 DEGREES OF FREEDOM p= 0.6627010995

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

SEVERE PATIENTS JUDGED BY CGI SEVERITY AT BASELINE
ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure
Class Level Information

Class	Levels	Values
COD_TRT	3	IMI PLC RBX

Number of observations in data set = 227

NOTE: Due to missing values, only 226 observations can be used in this analysis.

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

SEVERE PATIENTS JUDGED BY CGI SEVERITY AT BASELINE
ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure

Dependent Variable: DIFFN

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	528.49643936	264.24821968	2.37	0.0957
Error	223	24852.49471109	111.44616462		
Corrected Total	225	25380.99115044			

R-Square	C.V.	Root MSE	DIFFN Mean
0.020823	76.91290	10.55680655	13.72566372

Source	DF	Type I SS	Mean Square	F Value	Pr > F
COD_TRT	2	528.49643936	264.24821968	2.37	0.0957

Source	DF	Type III SS	Mean Square	F Value	Pr > F
COD_TRT	2	528.49643936	264.24821968	2.37	0.0957

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

SEVERE PATIENTS JUDGED BY CGI SEVERITY AT BASELINE
ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure

Dunnett's One-tailed T tests for variable: DIFFN

NOTE: This tests controls the type I experimentwise error for comparisons of all treatments against a control.

Alpha= 0.05 Confidence= 0.95 df= 223 MSE= 111.4462
Critical Value of Dunnett's T= 1.921

Comparisons significant at the 0.05 level are indicated by '***'.

COD_TRT Comparison	Simultaneous Lower Confidence Limit	Difference Between Means	Simultaneous Upper Confidence Limit	
IMI - PLC	0.048	3.380	6.711	***
RBX - PLC	-0.107	3.255	6.617	

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX NO.: 12.1.12
HAMILTON DEPRESSION RATING SCALE
DESCRIPTIVE STATISTICS ON LAST ASSESSMENT
MELANCHOLIC PATIENTS

TOTAL SCORE HAMILTON			BASELINE	LAST ASSESS.	DECREASE
MELANCH-OLIC	TREATME-NT				
NO	Imipram-ine	N	53	53	53
		MEAN	25.45	12.75	12.70
		S.D.	2.86	8.25	8.63
	Placebo	N	60	60	60
		MEAN	26.15	14.32	11.83
		S.D.	5.37	9.20	9.90
	Reboxet-ine	N	46	46	46
		MEAN	24.98	16.33	8.65
		S.D.	2.78	9.60	9.30
YES	Imipram-ine	N	44	44	44
		MEAN	28.98	15.23	13.75
		S.D.	6.08	11.88	12.41
	Placebo	N	41	41	41
		MEAN	28.85	18.76	10.10
		S.D.	5.34	10.12	10.99
	Reboxet-ine	N	51	51	51
		MEAN	29.78	12.14	17.65
		S.D.	5.81	8.81	9.21

4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12
MELANCHOLIC PATIENTS

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENTN WITH RESPECT TO BASELINE VALUE

BARTLETT'S TEST RESULTS

CHI SQUARE = 4.0885015361 WITH 2 DEGREES OF FREEDOM p= 0.1294771621

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12
MELANCHOLIC PATIENTS

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENTN WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure
Class Level Information

Class	Levels	Values
COD_TRT	3	IMI PLC RBX

Number of observations in data set = 140

NOTE: Due to missing values, only 136 observations can be used in this analysis.

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 29124/015
APPENDIX No.: 12.1.12

MELANCHOLIC PATIENTS

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENTN WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure

Dependent Variable: DIFFN

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	1303.83877331	651.91938666	5.52	0.0050
Error	133	15693.50681492	117.99629184		
Corrected Total	135	16997.34558824			

R-Square	C.V.	Root MSE	DIFFN Mean
0.076708	76.98358	10.86260981	14.11029412

Source	DF	Type I SS	Mean Square	F Value	Pr > F
COD_TRT	2	1303.83877331	651.91938666	5.52	0.0050

Source	DF	Type III SS	Mean Square	F Value	Pr > F
COD_TRT	2	1303.83877331	651.91938666	5.52	0.0050

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

MELANCHOLIC PATIENTS

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENTN WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure

Dunnett's One-tailed T tests for variable: DIFFN

NOTE: This tests controls the type I experimentwise error for comparisons of all treatments against a control.

Alpha= 0.05 Confidence= 0.95 df= 133 MSE= 117.9963
Critical Value of Dunnett's T= 1.927

Comparisons significant at the 0.05 level are indicated by '***'.

COD_TRT Comparison	Simultaneous Lower Confidence Limit	Difference Between Means	Simultaneous Upper Confidence Limit	
RBX - PLC	3.159	7.549	11.940	***
IMI - PLC	-0.891	3.652	8.196	

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/15

APPENDIX N0. 12.1.12
HAMILTON DECREASE AT LAST ASSESSMENT

BETWEEN TREATMENT DIFFERENCE AND 95% CONFIDENCE INTERVAL

POPULATION	MEAN REBOXETINE	MEAN IMIPRAMINE	DIFFERENCE CAMPION-STANDARD	LOWER LIMIT	UPPER LIMIT
TOTAL	13.49	13.77	-0.28	-2.94991	2.38991
ONLY MELANCHOLIC	17.65	13.75	3.90	-0.52088	8.32088
ONLY SEVERE	14.68	14.80	-0.12	-3.44132	3.20132

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING THE FIRST ADVERSE EVENT DURING TREATMENT

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	81	34	29.5652
RBX	112	71	41	36.6071
Total	227	152	75	33.0396

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	7.1329	867.00
RBX	-7.1329	-867.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	34.4317	-34.4317
RBX	-34.4317	34.4317

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	922000	-922000
RBX	-922000	922000

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	1.4777	1	0.2241
Wilcoxon	0.8153	1	0.3666
-2Log(LR)	4.2204	1	0.0399

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING THE FIRST ADVERSE EVENT DURING TREATMENT

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	58	54	48.2143
RBX	112	71	41	36.6071
Total	224	129	95	42.4107

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-10.748	-2100.0
RBX	10.748	2100.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	30.2177	-30.2177
RBX	-30.2177	30.2177

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	833970	-833970
RBX	-833970	833970

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	3.8228	1	0.0506
Wilcoxon	5.2880	1	0.0215
-2Log(LR)	4.2412	1	0.0395

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING THE FIRST ADVERSE EVENT DURING TREATMENT

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	81	34	29.5652
PLC	112	58	54	48.2143
Total	227	139	88	38.7665

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	18.534	3209.0
PLC	-18.534	-3209.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	31.7491	-31.7491
PLC	-31.7491	31.7491

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	874020	-874020
PLC	-874020	874020

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	10.8192	1	0.0010
Wilcoxon	11.7820	1	0.0006
-2Log(LR)	16.7170	1	0.0001

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING AGITATION / ANXIETY / NERVOUSNESS

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	5	110	95.6522
RBX	112	11	101	90.1786
Total	227	16	211	92.9515

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	-2.9943	-619.00
RBX	2.9943	619.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	3.97647	-3.97647
RBX	-3.97647	3.97647

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	172461	-172461
RBX	-172461	172461

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	2.2547	1	0.1332
Wilcoxon	2.2217	1	0.1361
-2Log(LR)	2.0745	1	0.1498

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING AGITATION / ANXIETY / NERVOUSNESS

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	10	102	91.0714
RBX	112	11	101	90.1786
Total	224	21	203	90.6250

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-0.43291	-62.000
RBX	0.43291	62.000

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	5.21181	-5.21181
RBX	-5.21181	5.21181

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	227727	-227727
RBX	-227727	227727

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.0360	1	0.8496
Wilcoxon	0.0169	1	0.8966
-2Log(LR)	0.0420	1	0.8377

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING AGITATION / ANXIETY / NERVOUSNESS

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	5	110	95.6522
PLC	112	10	102	91.0714
Total	227	15	212	93.3921

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	-2.5921	-569.00
PLC	2.5921	569.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	3.73221	-3.73221
PLC	-3.73221	3.73221

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	167625	-167625
PLC	-167625	167625

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	1.8003	1	0.1797
Wilcoxon	1.9315	1	0.1646
-2Log(LR)	1.5345	1	0.2154

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING ASTHENIA / FATIGUE

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	6	109	94.7826
RBX	112	4	108	96.4286
Total	227	10	217	95.5947

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	1.0510	158.00
RBX	-1.0510	-158.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	2.49813	-2.49813
RBX	-2.49813	2.49813

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	99457.0	-99457.0
RBX	-99457.0	99457.0

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.4422	1	0.5061
Wilcoxon	0.2510	1	0.6164
-2Log(LR)	0.5101	1	0.4751

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING ASTHENIA / FATIGUE

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	4	108	96.4286
RBX	112	4	108	96.4286
Total	224	8	216	96.4286

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-0.01200	-14.000
RBX	0.01200	14.000

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	1.99269	-1.99269
RBX	-1.99269	1.99269

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	86299.5	-86299.5
RBX	-86299.5	86299.5

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.0001	1	0.9932
Wilcoxon	0.0023	1	0.9620
-2Log(LR)	0.0002	1	0.9898

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING ASTHENIA / FATIGUE

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	6	109	94.7826
PLC	112	4	108	96.4286
Total	227	10	217	95.5947

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	1.0706	177.00
PLC	-1.0706	-177.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	2.49639	-2.49639
PLC	-2.49639	2.49639

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	95294.1	-95294.1
PLC	-95294.1	95294.1

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.4591	1	0.4980
Wilcoxon	0.3288	1	0.5664
-2Log(LR)	0.4900	1	0.4839

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING BLURRED VISION

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	10	105	91.3043
RBX	112	6	106	94.6429
Total	227	16	211	92.9515

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	2.1554	400.00
RBX	-2.1554	-400.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	3.98514	-3.98514
RBX	-3.98514	3.98514

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	159695	-159695
RBX	-159695	159695

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	1.1657	1	0.2803
Wilcoxon	1.0019	1	0.3168
-2Log(LR)	1.3236	1	0.2500

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING BLURRED VISION

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	3	109	97.3214
RBX	112	6	106	94.6429
Total	224	9	215	95.9821

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-1.5169	-310.00
RBX	1.5169	310.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	2.24505	-2.24505
RBX	-2.24505	2.24505

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	96243.0	-96243.0
RBX	-96243.0	96243.0

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	1.0249	1	0.3114
Wilcoxon	0.9985	1	0.3177
-2Log(LR)	1.0520	1	0.3050

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING BLURRED VISION

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	10	105	91.3043
PLC	112	3	109	97.3214
Total	227	13	214	94.2731

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	3.6482	704.00
PLC	-3.6482	-704.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	3.23396	-3.23396
PLC	-3.23396	3.23396

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	128703	-128703
PLC	-128703	128703

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	4.1156	1	0.0425
Wilcoxon	3.8509	1	0.0497
-2Log(LR)	4.5851	1	0.0323

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING CONSTIPATION

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	18	97	84.3478
RBX	112	17	95	84.8214
Total	227	35	192	84.5815

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	0.67680	12.000
RBX	-0.67680	-12.000

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	8.66579	-8.66579
RBX	-8.66579	8.66579

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	325343	-325343
RBX	-325343	325343

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.0529	1	0.8182
Wilcoxon	0.0004	1	0.9832
-2Log(LR)	0.1362	1	0.7121

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING CONSTIPATION

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	6	106	94.6429
RBX	112	17	95	84.8214
Total	224	23	201	89.7321

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-5.7862	-1202.0
RBX	5.7862	1202.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	5.71740	-5.71740
RBX	-5.71740	5.71740

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	231472	-231472
RBX	-231472	231472

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	5.8558	1	0.0155
Wilcoxon	6.2418	1	0.0125
-2Log(LR)	6.3040	1	0.0120

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING CONSTIPATION

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	18	97	84.3478
PLC	112	6	106	94.6429
Total	227	24	203	89.4273

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	6.5712	1259.0
PLC	-6.5712	-1259.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	5.95786	-5.95786
PLC	-5.95786	5.95786

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	221931	-221931
PLC	-221931	221931

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	7.2476	1	0.0071
Wilcoxon	7.1422	1	0.0075
-2Log(LR)	8.0710	1	0.0045

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING HEADACHE / MIGRAINE

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	9	106	92.1739
RBX	112	15	97	86.6071
Total	227	24	203	89.4273

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	-3.2290	-742.00
RBX	3.2290	742.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	5.94381	-5.94381
RBX	-5.94381	5.94381

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	250240	-250240
RBX	-250240	250240

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	1.7542	1	0.1853
Wilcoxon	2.2001	1	0.1380
-2Log(LR)	1.5160	1	0.2182

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING HEADACHE / MIGRAINE

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	9	103	91.9643
RBX	112	15	97	86.6071
Total	224	24	200	89.2857

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-3.2596	-731.00
RBX	3.2596	731.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	5.93844	-5.93844
RBX	-5.93844	5.93844

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	246895	-246895
RBX	-246895	246895

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	1.7892	1	0.1810
Wilcoxon	2.1643	1	0.1412
-2Log(LR)	1.8208	1	0.1772

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING HEADACHE / MIGRAINE

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	9	106	92.1739
PLC	112	9	103	91.9643
Total	227	18	209	92.0705

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	0.10095	22.000
PLC	-0.10095	-22.000

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	4.46200	-4.46200
PLC	-4.46200	4.46200

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	178720	-178720
PLC	-178720	178720

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.0023	1	0.9619
Wilcoxon	0.0027	1	0.9585
-2Log(LR)	0.0106	1	0.9181

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING HYPOTENSION AND RELATED SYMPTOMS

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	20	95	82.6087
RBX	112	10	102	91.0714
Total	227	30	197	86.7841

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	5.5611	1111.0
RBX	-5.5611	-1111.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	7.42875	-7.42875
RBX	-7.42875	7.42875

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	291279	-291279
RBX	-291279	291279

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	4.1630	1	0.0413
Wilcoxon	4.2376	1	0.0395
-2Log(LR)	4.8504	1	0.0276

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING HYPOTENSION AND RELATED SYMPTOMS

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	6	106	94.6429
RBX	112	10	102	91.0714
Total	224	16	208	92.8571

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-2.0059	-418.00
RBX	2.0059	418.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	3.99752	-3.99752
RBX	-3.99752	3.99752

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	158295	-158295
RBX	-158295	158295

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	1.0066	1	0.3157
Wilcoxon	1.1038	1	0.2934
-2Log(LR)	1.0607	1	0.3031

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING HYPOTENSION AND RELATED SYMPTOMS

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	20	95	82.6087
PLC	112	6	106	94.6429
Total	227	26	201	88.5463

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	7.5732	1536.0
PLC	-7.5732	-1536.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	6.44061	-6.44061
PLC	-6.44061	6.44061

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	250363	-250363
PLC	-250363	250363

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	8.9049	1	0.0028
Wilcoxon	9.4235	1	0.0021
-2Log(LR)	10.1118	1	0.0015

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING INSOMNIA

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	8	107	93.0435
RBX	112	12	100	89.2857
Total	227	20	207	91.1894

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	-1.9857	-410.00
RBX	1.9857	410.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	4.97007	-4.97007
RBX	-4.97007	4.97007

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	204710	-204710
RBX	-204710	204710

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.7933	1	0.3731
Wilcoxon	0.8212	1	0.3648
-2Log(LR)	0.6973	1	0.4037

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING INSOMNIA

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	4	108	96.4286
RBX	112	12	100	89.2857
Total	224	16	208	92.8571

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-4.0739	-829.00
RBX	4.0739	829.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	3.98941	-3.98941
RBX	-3.98941	3.98941

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	166779	-166779
RBX	-166779	166779

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	4.1602	1	0.0414
Wilcoxon	4.1207	1	0.0424
-2Log(LR)	4.4791	1	0.0343

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING INSOMNIA

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	8	107	93.0435
PLC	112	4	108	96.4286
Total	227	12	215	94.7137

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	2.0504	407.00
PLC	-2.0504	-407.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	2.98753	-2.98753
PLC	-2.98753	2.98753

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	124378	-124378
PLC	-124378	124378

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	1.4072	1	0.2355
Wilcoxon	1.3318	1	0.2485
-2Log(LR)	1.6274	1	0.2021

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING MOUTH DRY

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	49	66	57.3913
RBX	112	28	84	75.0000
Total	227	77	150	66.0793

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	12.896	2335.0
RBX	-12.896	-2335.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	18.4688	-18.4688
RBX	-18.4688	18.4688

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	642568	-642568
RBX	-642568	642568

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	9.0046	1	0.0027
Wilcoxon	8.4851	1	0.0036
-2Log(LR)	13.8606	1	0.0002

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING MOUTH DRY

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	14	98	87.5000
RBX	112	28	84	75.0000
Total	224	42	182	81.2500

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-7.6558	-1534.0
RBX	7.6558	1534.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	10.3357	-10.3357
RBX	-10.3357	10.3357

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	400308	-400308
RBX	-400308	400308

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	5.6707	1	0.0173
Wilcoxon	5.8784	1	0.0153
-2Log(LR)	6.2222	1	0.0126

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING MOUTH DRY

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	49	66	57.3913
PLC	112	14	98	87.5000
Total	227	63	164	72.2467

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	20.396	3828.0
PLC	-20.396	-3828.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	15.1032	-15.1032
PLC	-15.1032	15.1032

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	545229	-545229
PLC	-545229	545229

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	27.5434	1	0.0001
Wilcoxon	26.8760	1	0.0001
-2Log(LR)	37.0287	1	0.0001

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING NAUSEA AND RELATED SYMPTOMS

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	17	98	85.2174
RBX	112	10	102	91.0714
Total	227	27	200	88.1057

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	3.7482	709.00
RBX	-3.7482	-709.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	6.69458	-6.69458
RBX	-6.69458	6.69458

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	267469	-267469
RBX	-267469	267469

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	2.0986	1	0.1474
Wilcoxon	1.8794	1	0.1704
-2Log(LR)	2.5167	1	0.1126

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING NAUSEA AND RELATED SYMPTOMS

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	10	102	91.0714
RBX	112	10	102	91.0714
Total	224	20	204	91.0714

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-0.01046	-37.000
RBX	0.01046	37.000

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	4.97236	-4.97236
RBX	-4.97236	4.97236

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	201385	-201385
RBX	-201385	201385

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.0000	1	0.9963
Wilcoxon	0.0068	1	0.9343
-2Log(LR)	0.0000	1	0.9977

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING NAUSEA AND RELATED SYMPTOMS

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	17	98	85.2174
PLC	112	10	102	91.0714
Total	227	27	200	88.1057

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	3.8406	779.00
PLC	-3.8406	-779.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	6.70973	-6.70973
PLC	-6.70973	6.70973

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	260328	-260328
PLC	-260328	260328

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	2.1983	1	0.1382
Wilcoxon	2.3311	1	0.1268
-2Log(LR)	2.5273	1	0.1119

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING PARAESTHESIA

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	6	109	94.7826
RBX	112	2	110	98.2143
Total	227	8	219	96.4758

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	2.0017	412.00
RBX	-2.0017	-412.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	1.99221	-1.99221
RBX	-1.99221	1.99221

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	92923.1	-92923.1
RBX	-92923.1	92923.1

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	2.0112	1	0.1561
Wilcoxon	1.8267	1	0.1765
-2Log(LR)	2.5049	1	0.1135

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING PARAESTHESIA

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	2	110	98.2143
RBX	112	2	110	98.2143
Total	224	4	220	98.2143

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	0.00685	-10.000
RBX	-0.00685	10.000

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	0.999974	-.999974
RBX	-.999974	0.999974

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	46435.0	-46435.0
RBX	-46435.0	46435.0

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.0000	1	0.9945
Wilcoxon	0.0022	1	0.9630
-2Log(LR)	0.0003	1	0.9859

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING PARAESTHESIA

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	6	109	94.7826
PLC	112	2	110	98.2143
Total	227	8	219	96.4758

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	2.0267	435.00
PLC	-2.0267	-435.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	1.99649	-1.99649
PLC	-1.99649	1.99649

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	89246.0	-89246.0
PLC	-89246.0	89246.0

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	2.0573	1	0.1515
Wilcoxon	2.1203	1	0.1454
-2Log(LR)	2.4280	1	0.1192

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING SOMNOLENCE

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	6	109	94.7826
RBX	112	1	111	99.1071
Total	227	7	220	96.9163

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	2.5159	578.00
RBX	-2.5159	-578.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	1.74458	-1.74458
RBX	-1.74458	1.74458

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	83505.0	-83505.0
RBX	-83505.0	83505.0

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	3.6284	1	0.0568
Wilcoxon	4.0008	1	0.0455
-2Log(LR)	4.5473	1	0.0330

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING SOMNOLENCE

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	9	103	91.9643
RBX	112	1	111	99.1071
Total	224	10	214	95.5357

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	4.1343	816.00
RBX	-4.1343	-816.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	2.49240	-2.49240
RBX	-2.49240	2.49240

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	97918.0	-97918.0
RBX	-97918.0	97918.0

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	6.8579	1	0.0088
Wilcoxon	6.8001	1	0.0091
-2Log(LR)	7.8786	1	0.0050

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING SOMNOLENCE

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	6	109	94.7826
PLC	112	9	103	91.9643
Total	227	15	212	93.3921

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	-1.4550	-183.00
PLC	1.4550	183.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	3.72606	-3.72606
PLC	-3.72606	3.72606

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	154057	-154057
PLC	-154057	154057

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.5682	1	0.4510
Wilcoxon	0.2174	1	0.6410
-2Log(LR)	0.4657	1	0.4950

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING SWEATING INCREASED

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	22	93	80.8696
RBX	112	14	98	87.5000
Total	227	36	191	84.1410

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	4.3832	845.00
RBX	-4.3832	-845.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	8.90132	-8.90132
RBX	-8.90132	8.90132

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	356121	-356121
RBX	-356121	356121

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	2.1584	1	0.1418
Wilcoxon	2.0050	1	0.1568
-2Log(LR)	2.7566	1	0.0969

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING SWEATING INCREASED

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	3	109	97.3214
RBX	112	14	98	87.5000
Total	224	17	207	92.4107

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-5.6256	-1164.0
RBX	5.6256	1164.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	4.22166	-4.22166
RBX	-4.22166	4.22166

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	183570	-183570
RBX	-183570	183570

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	7.4965	1	0.0062
Wilcoxon	7.3808	1	0.0066
-2Log(LR)	8.4722	1	0.0036

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING SWEATING INCREASED

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	22	93	80.8696
PLC	112	3	109	97.3214
Total	227	25	202	88.9868

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	9.9524	1990.0
PLC	-9.9524	-1990.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	6.19730	-6.19730
PLC	-6.19730	6.19730

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	256040	-256040
PLC	-256040	256040

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	15.9829	1	0.0001
Wilcoxon	15.4667	1	0.0001
-2Log(LR)	19.8038	1	0.0001

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING TACHYCARDIA

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	4	111	96.5217
RBX	112	3	109	97.3214
Total	227	7	220	96.9163

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	0.51767	100.00
RBX	-0.51767	-100.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	1.74871	-1.74871
RBX	-1.74871	1.74871

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	78840.0	-78840.0
RBX	-78840.0	78840.0

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.1532	1	0.6955
Wilcoxon	0.1268	1	0.7217
-2Log(LR)	0.2150	1	0.6429

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING TACHYCARDIA

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	0	112	100.0000
RBX	112	3	109	97.3214
Total	224	3	221	98.6607

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-1.5003	-322.00
RBX	1.5003	322.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	0.749989	-.749989
RBX	-.749989	0.749989

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	34654.0	-34654.0
RBX	-34654.0	34654.0

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	3.0010	1	0.0832
Wilcoxon	2.9920	1	0.0837
-2Log(LR)*	4.1735	1	0.0411

* some strata had no events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING TACHYCARDIA

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	4	111	96.5217
PLC	112	0	112	100.0000
Total	227	4	223	98.2379

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	2.0196	424.00
PLC	-2.0196	-424.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	0.999114	-.999114
PLC	-.999114	0.999114

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	44292.0	-44292.0
PLC	-44292.0	44292.0

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	4.0824	1	0.0433
Wilcoxon	4.0589	1	0.0439
-2Log(LR)*	5.8269	1	0.0158

* some strata had no events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING TREMOR

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	20	95	82.6087
RBX	112	6	106	94.6429
Total	227	26	201	88.5463

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	7.4724	1397.0
RBX	-7.4724	-1397.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	6.43315	-6.43315
RBX	-6.43315	6.43315

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	252826	-252826
RBX	-252826	252826

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	8.6796	1	0.0032
Wilcoxon	7.7192	1	0.0055
-2Log(LR)	10.1769	1	0.0014

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING TREMOR

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	5	107	95.5357
RBX	112	6	106	94.6429
Total	224	11	213	95.0893

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-0.48628	-103.00
RBX	0.48628	103.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	2.74085	-2.74085
RBX	-2.74085	2.74085

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	120685	-120685
RBX	-120685	120685

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.0863	1	0.7690
Wilcoxon	0.0879	1	0.7669
-2Log(LR)	0.0966	1	0.7559

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING TREMOR

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	20	95	82.6087
PLC	112	5	107	95.5357
Total	227	25	202	88.9868

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	7.9547	1497.0
PLC	-7.9547	-1497.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	6.19357	-6.19357
PLC	-6.19357	6.19357

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	242835	-242835
PLC	-242835	242835

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	10.2165	1	0.0014
Wilcoxon	9.2285	1	0.0024
-2Log(LR)	12.0972	1	0.0005

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING URINARY HESITANCY / RETENTION

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	1	114	99.1304
RBX	112	6	106	94.6429
Total	227	7	220	96.9163

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	-2.5235	-516.00
RBX	2.5235	516.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	1.74478	-1.74478
RBX	-1.74478	1.74478

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	77460.6	-77460.6
RBX	-77460.6	77460.6

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	3.6499	1	0.0561
Wilcoxon	3.4373	1	0.0637
-2Log(LR)	3.8314	1	0.0503

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING URINARY HESITANCY / RETENTION

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	2	110	98.2143
RBX	112	6	106	94.6429
Total	224	8	216	96.4286

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-1.9947	-394.00
RBX	1.9947	394.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	1.99744	-1.99744
RBX	-1.99744	1.99744

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	88520.0	-88520.0
RBX	-88520.0	88520.0

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	1.9920	1	0.1581
Wilcoxon	1.7537	1	0.1854
-2Log(LR)	2.1572	1	0.1419

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING URINARY HESITANCY / RETENTION

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	1	114	99.1304
PLC	112	2	110	98.2143
Total	227	3	224	98.6784

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	-0.53584	-123.00
PLC	0.53584	123.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	0.749526	-.749526
PLC	-.749526	0.749526

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	37613.0	-37613.0
PLC	-37613.0	37613.0

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.3831	1	0.5360
Wilcoxon	0.4022	1	0.5259
-2Log(LR)	0.2988	1	0.5847

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING VERTIGO

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	7	108	93.9130
RBX	112	5	107	95.5357
Total	227	12	215	94.7137

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	0.98121	187.00
RBX	-0.98121	-187.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	2.98684	-2.98684
RBX	-2.98684	2.98684

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	136524	-136524
RBX	-136524	136524

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.3223	1	0.5702
Wilcoxon	0.2561	1	0.6128
-2Log(LR)	0.4965	1	0.4810

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING VERTIGO

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
PLC	112	0	112	100.0000
RBX	112	5	107	95.5357
Total	224	5	219	97.7679

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
PLC	-2.5119	-546.00
RBX	2.5119	546.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	PLC	RBX
PLC	1.24768	-1.24768
RBX	-1.24768	1.24768

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	PLC	RBX
PLC	59018.5	-59018.5
RBX	-59018.5	59018.5

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	5.0571	1	0.0245
Wilcoxon	5.0512	1	0.0246
-2Log(LR)*	6.9990	1	0.0082

* some strata had no events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING VERTIGO

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	115	7	108	93.9130
PLC	112	0	112	100.0000
Total	227	7	220	96.9163

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	3.5194	745.00
PLC	-3.5194	-745.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	PLC
IMI	1.74145	-1.74145
PLC	-1.74145	1.74145

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	PLC
IMI	78760.5	-78760.5
PLC	-78760.5	78760.5

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	7.1125	1	0.0077
Wilcoxon	7.0470	1	0.0079
-2Log(LR)*	10.3214	1	0.0013

* some strata had no events

12.2 Patient Information

Pharmacia Document 9550082

12.2.1 SERIOUS ADVERSE EVENTS - CASE HISTORIES

Case summaries of serious adverse events reported on reference treatments.

Pharmacia Document 9550082

CLINICAL REPORT

CASE SUMMARY OF EVENT	AU 0055
PROTOCOL N°	20124/015
PT. N°	11
SEX	F
AGE AT ENTRY	30
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	100 mg
TREATMENT PERIOD	10 October 1991 - 13 October 1991
AFTER DAYS	2
ADE (DATE OF THE EVENT)	POSTURAL HYPOTENSION, DIZZINESS AND FALLING UNCONSCIOUS (11 October 1991)
DISCONTINUED	Yes
COURSE	RECOVERED WITH SEQUELAE
RELEVANT HISTORY	SEE BASELINE CONDITIONS
RELEVANT BASELINE CONDIT.	MAJOR DEPRESSIVE DISORDER, MARFAN'S SYNDROME
PREVIOUS ANTIDEPRESSIVE TREATMENTS	TRIMIPRAMINE, FLUOXETINE
RELEVANT EVENTS	NO
CONCOMITANT MEDICATIONS	TEMAZEPAM

CLINICAL REPORT (continued)

CASE SUMMARY OF EVENT	AU 0101
PROTOCOL N°	20124/015
PT. N°	20
SEX	F
AGE AT ENTRY	59
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	100 mg
TREATMENT PERIOD	29 April 1992 - 09 June 1992
AFTER DAYS	1
ADE (DATE OF THE EVENT)	ATTENTION SEEKING OVERDOSE OF OXAZAPAM AND LACERATION OF WRIST (30 April 92)
DISCONTINUED	No
COURSE	RECOVERED
RELEVANT HISTORY	SEE BASELINE CONDITIONS
RELEVANT BASELINE CONDIT.	MAJOR DEPRESSIVE DISORDER
PREVIOUS ANTIDEPRESSIVE TREATMENTS	VENLAFAXINE
RELEVANT EVENTS	NO
CONCOMITANT MEDICATIONS	NONE

CLINICAL REPORT (continued)

CASE SUMMARY OF EVENT	IT
PROTOCOL N°	20124/015
PT. N°	213
SEX	M
AGE AT ENTRY	59
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	100 mg
TREATMENT PERIOD	22 November 1991 - 24 November 1991
AFTER DAYS	3
ADE (DATE OF THE EVENT)	SUICIDE (25 November 1991)
DISCONTINUED	
COURSE	
RELEVANT HISTORY	SEE BASELINE CONDITIONS
RELEVANT BASELINE CONDIT.	MAJOR DEPRESSIVE DISORDER
PREVIOUS ANTIDEPRESSIVE TREATMENTS	CLOMIPRAMINE
RELEVANT EVENTS	NO
CONCOMITANT MEDICATIONS	NONE

CLINICAL REPORT (continued)

CASE SUMMARY OF EVENT	CA
PROTOCOL N°	20124/015
PT. N°	375
SEX	M
AGE AT ENTRY	47
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	100 mg
TREATMENT PERIOD	17 June 1992 - 18 June 1992
AFTER DAYS	2
ADE (DATE OF THE EVENT)	ATTEMPTED SUICIDE (18 June 1992)
DISCONTINUED	Yes
COURSE	UNDER TREATMENT
RELEVANT HISTORY	CANCER OF COLON (OPERATED), VIRAL PERICARDITIS
RELEVANT BASELINE CONDIT.	MAJOR DEPRESSIVE DISORDER
PREVIOUS ANTIDEPRESSIVE TREATMENTS	IMIPRAMINE
RELEVANT EVENTS	NO
CONCOMITANT MEDICATIONS	CHLORAL HYDRATE, ACETAMINOPHEN, CLONAZEPAM, FLURAZEPAM

CLINICAL REPORT (continued)

CASE SUMMARY OF EVENT	FR 0093
PROTOCOL N°	20124/015
PT. N°	176
SEX	F
AGE AT ENTRY	31
EXPERIMENTAL TREATMENT	Placebo
DAILY DOSE	0
TREATMENT PERIOD	14 March 1993 - 08 April 1992
AFTER DAYS	26
ADE (DATE OF THE EVENT)	ATTEMPTED SUICIDE (08 April 1992)
DISCONTINUED	Yes
COURSE	UNDER TREATMENT
RELEVANT HISTORY	SEE BASELINE CONDITIONS
RELEVANT BASELINE CONDIT.	MAJOR DEPRESSIVE DISORDER
PREVIOUS ANTIDEPRESSIVE TREATMENTS	NO
RELEVANT EVENTS	NO
CONCOMITANT MEDICATIONS	CHLORAL HYDRATE

CLINICAL REPORT (continued)

CASE SUMMARY OF EVENT	FR 0123
PROTOCOL N°	20124/015
PT. N°	179
SEX	F
AGE AT ENTRY	43
EXPERIMENTAL TREATMENT	Placebo
DAILY DOSE	0
TREATMENT PERIOD	11 September 1992 - 29 September 1992
AFTER DAYS	19
ADE (DATE OF THE EVENT)	ATTEMPTED SUICIDE (29 September 1992)
DISCONTINUED	Yes
COURSE	RECOVERED
RELEVANT HISTORY	SEE BASELINE CONDITIONS
RELEVANT BASELINE CONDIT.	MAJOR DEPRESSIVE DISORDER
PREVIOUS ANTIDEPRESSIVE TREATMENTS	FLUOXETINE
RELEVANT EVENTS	NO
CONCOMITANT MEDICATIONS	CHLORAL HYDRATE

Pharmacia Document 9550082

12.2.2 INDIVIDUAL DATA LISTINGS

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status In-out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)
1	1	Imipramine	MJS	OUT		Female	35	54.0	165.0	Caucasian	296.3	22.0
	2	Reboxetine	MK	OUT		Male	49	75.0	170.0	Caucasian	296.3	20.0
	3	Imipramine	MP	OUT		Male	41	77.0	172.0	Caucasian	296.3	22.0
	4	Placebo	KJ	IN	02/06/91	Male	35	93.0	190.0	Caucasian	296.2	24.0
	5	Reboxetine	BC	OUT		Female	57	67.0	160.0	Caucasian	296.3	24.0
	6	Placebo	NL	OUT		Female	36	54.0	166.0	Caucasian	296.3	29.0
	7	Reboxetine	TS	OUT		Female	19	46.0	158.0	Caucasian	296.2	28.0
	8	Placebo	AT	OUT		Male	49	64.0	174.0	Caucasian	296.3	28.0
	9	Reboxetine	MF	OUT		Female	38	64.0	166.0	Caucasian	296.3	29.0
	10	Placebo	JB	OUT		Male	32	77.0		Caucasian	296.3	28.0
	11	Imipramine	NK	OUT		Female	39	58.0	160.0	Caucasian	296.3	29.0
	12	Imipramine	JF	OUT		Female	30	62.0	173.0	Caucasian	296.3	28.0
	412	Reboxetine	PG	OUT		Male	41	76.0	173.0	Caucasian	296.3	30.0
	413	Placebo	RJ	OUT		Male	51	72.0	181.0	Caucasian	296.3	29.0
	414	Imipramine	JC	IN	17/01/92	Female	47	67.7	148.0	Caucasian	296.3	24.0
	415	Imipramine	TM	OUT		Male	40	67.0	170.0	Caucasian	296.3	28.0
	416	Reboxetine	TH	OUT	17/01/92	Female	41	66.0	148.0	Caucasian	296.3	26.0
	421	Imipramine	EK	OUT		Male	57	77.0	168.0	Caucasian	296.3	25.0
	422	Imipramine	MJ	OUT		Male	44	61.0	161.0	Caucasian	296.2	28.0
2/1	49	Placebo	PIN	IN	13/05/91	Female	53	60.0	151.0	Caucasian	296.3	22.0
	50	Reboxetine	MAG	IN	21/12/91	Female	43	50.0	152.0	Caucasian	296.3	29.0
	51	Imipramine	CES	IN	24/01/92	Female	38	68.0	168.0	Caucasian	296.2	25.0
2/2	43	Imipramine	VAL	OUT		Female	26	61.0	175.0	Caucasian	296.3	30.0
	44	Imipramine	STE	OUT		Female	20	62.0	165.0	Caucasian	296.3	30.0
	45	Reboxetine	BER	OUT		Female	26	59.6	160.0	Caucasian	296.3	30.0
	46	Placebo	GEO	OUT		Female	43	63.0	165.0	Caucasian	296.3	30.0
	47	Placebo	FA	OUT		Female	35	53.0	164.0	Caucasian	296.3	30.0
	48	Reboxetine	FAY	OUT		Female	31	64.0	158.0	Caucasian	296.2	30.0
2/3	36/A	Imipramine	ROU	OUT		Male	53	99.0	170.0	Caucasian	296.3	29.0
	37	Reboxetine	DMF	OUT		Female	46	43.0	161.0	Caucasian	296.3	25.0
	38	Placebo	PEJ	OUT		Male	45	94.0	174.0	Caucasian	296.2	26.0
	39	Imipramine	PMT	OUT		Female	52	60.0	162.0	Caucasian	296.3	28.0
	40	Reboxetine	SG	IN	17/10/91	Female	59	38.0	162.0	Caucasian	296.3	27.0
	41	Placebo	MD	OUT		Male	25	63.0	169.0	Caucasian	296.3	30.0
	42	Imipramine	JD	IN	04/05/92	Female	40	78.0	155.0	Caucasian	296.3	25.0
2/4	31	Placebo	CHA	OUT		Male	35	75.0	170.0	Caucasian	296.2	26.0
	32	Reboxetine	MAL	OUT		Male	59	80.0	175.0	Caucasian	296.2	30.0

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status In-out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)
2/4	33	Imipramine	LDM	OUT		Male	38	80.0	180.0	Caucasian	296.2	25.0
	34	Placebo	BES	OUT		Female	55	42.0	155.0	Caucasian	296.3	20.0
	35	Reboxetine	LAB	OUT		Female	64	65.0	160.0	Caucasian	296.2	26.0
	36	Imipramine	XIB	OUT		Female	57	45.0	140.0	Caucasian	296.3	20.0
2/5	73	Placebo	DUD	IN	27/01/92	Male	48	73.0	173.0	Caucasian	296.3	26.0
	74	Reboxetine	GAU	IN	15/06/92	Male	52	65.0	154.0	Caucasian	296.2	28.0
	75	Imipramine	THO	IN	03/09/92	Male	50	71.0	181.0	Caucasian	296.3	29.0
	76	Imipramine	REV	IN	09/09/92	Female	32	45.0	178.0	Caucasian	296.2	30.0
	77	Placebo	BRE	IN	03/06/92	Male	38	77.0	178.0	Caucasian	296.3	28.0
	78	Reboxetine	ASS	IN	29/09/92	Female	51	57.0	161.0	Caucasian	296.3	27.0
2/6	55	Reboxetine	THE	IN	12/06/92	Female	57	55.0	162.0	Caucasian	296.2	30.0
	56	Reboxetine	DEG	IN	12/06/92	Female	59	64.0	157.0	Caucasian	296.2	29.0
	57	Imipramine	CON	OUT		Female	57	60.0	155.0	Caucasian	296.3	29.0
	58	Placebo	BOU	IN	17/05/92	Female	59	55.0	158.0	Caucasian	296.3	29.0
	59	Placebo	FOU	IN	26/05/92	Male	33	70.0	175.0	Caucasian	296.2	30.0
	60	Imipramine	MAR	IN	11/05/92	Female	38	47.0	155.0	Caucasian	296.3	29.0
3/1	61	Imipramine	THI	OUT		Male	22	79.0	173.0	Caucasian	296.2	28.0
	62	Imipramine	TOU	IN	12/04/91	Female	24	60.0	165.0	Caucasian	296.3	30.0
	63	Placebo	SAC	IN	10/03/91	Male	43	70.0	165.0	Caucasian	296.2	30.0
	64	Placebo	PF	OUT		Female	57	63.0	163.0	Caucasian	296.3	27.0
	65	Reboxetine	AMA	IN	11/09/91	Male	62	70.0	168.0	Caucasian	296.2	29.0
	66	Reboxetine	RF	OUT		Male	50	90.0	170.0	Caucasian	296.3	30.0
	139	Imipramine	M B	OUT		Male	31	61.0	168.0	Caucasian	296.3	30.0
	140	Placebo	BH	OUT		Male	56	67.0	182.0	Caucasian	296.3	30.0
	141	Placebo	M M	OUT		Female	40	56.0	162.0	Caucasian	296.3	30.0
	142	Imipramine	KAR	IN	14/11/91	Female	20	50.0	152.0	Caucasian	296.2	30.0
	143	Reboxetine	R H	OUT		Female	44	48.0	152.0	Caucasian	296.3	27.0
	144	Reboxetine	HD	OUT		Female	26	42.0	169.0	Caucasian	296.2	29.0
	451	Reboxetine	G D	OUT		Female	57	76.0	163.0	Caucasian	296.3	29.0
	452	Placebo	DT	OUT		Male	44	70.0	170.0	Caucasian	296.2	29.0
	453	Imipramine	T L	OUT		Female	55	72.0	155.0	Caucasian	296.3	26.0
	454	Reboxetine	BG	OUT		Male	56	77.0	172.0	Caucasian	296.3	29.0
	455	Placebo	M M	OUT		Female	47	58.0	164.0	Caucasian	296.3	28.0
	456	Imipramine	GM	OUT		Female	39	48.0	159.0	Caucasian	296.2	28.0
3/2	65/A	Reboxetine	REN	IN	23/01/91	Female	21	56.0	169.0	Caucasian	296.3	30.0

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status In-out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)
3/3	67	Placebo	JMD	IN	12/07/91	Male	38	61.0	168.0	Caucasian	296.3	25.0
	68	Reboxetine	MMO	IN	10/01/92	Male	45	80.0	180.0	Caucasian	296.3	25.0
	69	Placebo	AMA	IN	29/01/92	Male	34	60.0	173.0	Caucasian	296.3	26.0
	70	Imipramine	MDE	IN	08/04/92	Male	40	77.0	178.0	Caucasian	296.2	26.0
	71	Imipramine	SDU	IN	10/04/92	Female	26	57.0	170.0	Caucasian	296.3	30.0
	72	Reboxetine	PDU	IN	20/07/92	Male	31	65.0	179.0	Caucasian	296.2	28.0
3/4	79	Imipramine	BLA	IN	01/05/91	Female	45	50.0	157.0	Caucasian	296.3	22.0
	80	Imipramine	DUH	IN	31/08/91	Male	46	68.0	176.0	Caucasian	296.2	27.0
	81	Reboxetine	SIA	IN	14/05/91	Female	35	55.0	164.0	Caucasian	296.2	26.0
	82	Placebo	PER	IN	14/06/91	Male	49	71.0	162.0	Caucasian	296.2	29.0
	83	Placebo	POU	OUT		Male	49	75.0	174.0	Caucasian	296.3	30.0
	84	Reboxetine	MOU	IN	07/10/91	Female	27	60.0	158.0	Caucasian	296.2	25.0
	85	Imipramine	NAR	IN	25/10/91	Female	45	54.0	160.0	Caucasian	296.3	30.0
	86	Imipramine	COU	OUT		Male	34	63.0	174.0	Caucasian	296.2	26.0
	87	Placebo	HAI	IN	05/12/91	Female	33	61.0	162.0	Caucasian	296.3	30.0
	88	Placebo	WOI	OUT		Male	53	76.0	168.0	Caucasian	296.2	28.0
	89	Reboxetine	ANN	OUT		Female	49	51.0	163.0	Caucasian	296.3	28.0
	90	Reboxetine	COR	OUT		Male	47	72.0	174.0	Caucasian	296.2	30.0
	457	Placebo	PRO	IN	18/05/92	Female	48	63.0	167.0	Caucasian	296.3	30.0
	458	Reboxetine	LAU	OUT		Female	43	79.0	167.0	Caucasian	296.3	30.0
	459	Placebo	NGU	OUT		Female	57	41.0	158.0	Asian	296.3	30.0
	460	Reboxetine	CHA	OUT		Male	38	62.0	174.0	Caucasian	296.2	30.0
	461	Imipramine	BRA	OUT		Female	45	79.0	167.0	Caucasian	296.2	28.0
	462	Imipramine	VOU	OUT		Female	39	68.0	166.0	Caucasian	296.2	28.0
4/1	91	Imipramine	MAT	OUT		Female	36	67.0	165.0	Caucasian	296.2	29.0
	92	Reboxetine	ADE	OUT		Female	28	41.0	160.0	Caucasian	296.3	30.0
	93	Placebo	AUB	OUT		Male	18	71.0	179.0	Caucasian	296.2	30.0
	94	Placebo	MAI	OUT		Female	59	60.0	157.0	Caucasian	296.3	28.0
	95	Imipramine	CHA	OUT		Female	42	77.0	154.0	Caucasian	296.3	27.0
	96	Reboxetine	ABR	OUT		Female	52	79.0	157.0	Caucasian	296.3	29.0
	115	Reboxetine	CED	OUT		Female	55	76.0	148.0	Caucasian	296.3	30.0
	116	Imipramine	EST	OUT		Female	41	56.0	163.0	Caucasian	296.3	30.0
	117	Imipramine	EMA	OUT		Female	59	64.0	160.0	Caucasian	296.3	29.0
	118	Reboxetine	BAR	OUT		Female	43	84.0	161.0	Caucasian	296.2	29.0
	119	Placebo	BAV	OUT		Female	46	54.0	168.0	Caucasian	296.3	29.0
	120	Placebo	ZEI	OUT		Female	35	56.0	164.0	Caucasian	296.3	29.0
	145	Imipramine	LON	OUT		Female	47	62.0	163.0	Caucasian	296.3	29.0
	146	Placebo	BLU	OUT		Female	55	59.0	165.0	Caucasian	296.2	29.0
	147	Reboxetine	DEC	OUT		Female	65	96.0	156.0	Caucasian	296.3	29.0
	148	Imipramine	AIG	OUT		Female	59	77.0	164.0	Caucasian	296.3	29.0
	149	Reboxetine	LHU	OUT		Male	56	74.0	170.0	Caucasian	296.2	30.0

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status: In-out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)
4/1	150	Placebo	GIL	OUT		Male	52	82.0	169.0	Caucasian	296.3	29.0
4/2	93/A	Placebo	GRA	OUT		Male	48	100.0	178.0	Caucasian	296.3	23.0
	99/A	Placebo	GUE	OUT		Male	48	83.0	176.0	Caucasian	296.3	24.0
	104	Reboxetine	DUP	OUT		Male	57	82.0	178.0	Caucasian	296.3	24.0
4/3	97	Placebo	DEL	OUT		Male	42	62.0	173.0	Caucasian	296.3	28.0
	98	Reboxetine	PER	OUT		Female	58	53.0	159.0	Caucasian	296.3	28.0
	99	Placebo	LEH	OUT		Female	59	60.0	150.0	Caucasian	296.3	28.0
	100	Imipramine	BRA	OUT		Female	24	44.0	165.0	Caucasian	296.3	25.0
	101	Imipramine	PEL	OUT		Male	55	74.0	180.0	Caucasian	296.3	27.0
4/4	109	Reboxetine	DUC	OUT		Female	28	59.0	151.0	Caucasian	296.3	25.0
	110	Imipramine	DUP	IN	06/06/91	Male	64	66.5	158.0	Caucasian	296.3	28.0
	111	Imipramine	ROU	OUT		Male	65	66.0	169.0	Caucasian	296.3	30.0
	112	Placebo	BOT	IN	05/07/91	Male	23	65.0	174.0	Caucasian	296.3	30.0
	113	Reboxetine	NIC	IN	25/08/91	Male	23	96.6	184.0	Caucasian	296.3	29.0
	114	Placebo	BOT	OUT		Female	62	61.0	155.0	Caucasian	296.3	27.0
	175	Imipramine	DAN	IN	10/02/92	Female	48	50.0	157.0	Caucasian	296.3	29.0
	176	Placebo	MOR	IN	11/03/92	Female	31	50.0	160.0	Caucasian	296.3	27.0
	177	Imipramine	HEL	OUT		Female	55	59.0	155.0	Caucasian	296.3	25.0
	178	Reboxetine	JEF	IN	18/04/92	Female	35	71.0	171.0	Caucasian	296.3	26.0
	179	Placebo	JEG	IN	07/09/92	Female	43	65.5	158.0	Caucasian	296.3	30.0
	180	Reboxetine	BOU	IN	16/09/92	Male	40	69.0	173.0	Caucasian	296.3	30.0
5/1	127	Reboxetine	SUZ	IN	28/05/91	Male	34	84.0	179.0	Caucasian	296.3	30.0
	128	Reboxetine	FRO	IN	08/06/91	Female	33	54.0	159.0	Caucasian	296.3	29.0
	129	Placebo	BEA	IN	16/12/91	Male	19	55.0	163.0	Caucasian	296.3	30.0
	130	Placebo	THE	IN	24/02/92	Male	30	58.0	176.0	Caucasian	296.3	29.0
	131	Imipramine	GUI	IN	18/03/92	Female	43	81.0	155.0	Caucasian	296.3	27.0
	132	Imipramine	DE	IN	18/06/92	Male	38	83.0	170.0	Caucasian	296.2	30.0
5/2	121	Imipramine	ROU	OUT	19/12/91	Female	20	45.0	162.0	Caucasian	296.3	27.0
	125	Reboxetine	ROL	IN	24/01/91	Male	48	72.0	169.0	Caucasian	296.3	28.0
5/3	133	Placebo	MAR	IN	23/11/91	Male	55	72.0	172.0	Caucasian	296.3	30.0
	134	Reboxetine	MOL	IN	29/11/91	Female	31	47.0	167.0	Caucasian	296.3	26.0
	135	Imipramine	SOU	IN	05/01/92	Female	48	76.0	162.0	Caucasian	296.3	30.0
	136	Imipramine	POM	IN	18/02/92	Female	47	73.0	150.0	Caucasian	296.3	27.0

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status In-out patient	Patient status Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)
5/3	137	Reboxetine	MAG	IN	04/05/92	Female	32	46.0	151.0	Caucasian	296.3	28.0
	138	Placebo	PLU	IN	10/05/92	Female	31	59.0	158.0	Caucasian	296.2	28.0
6/1	151	Imipramine	LEC	OUT		Male	43	55.0	172.0	Caucasian	296.2	29.0
	152	Reboxetine	BRA	OUT		Female	56	67.0	157.0	Caucasian	296.3	29.0
	153	Reboxetine	RHE	OUT		Male	50	75.0	173.0	Caucasian	296.3	25.0
	154	Imipramine	BEQ	OUT		Female	26	52.0	163.0	Caucasian	296.2	30.0
	155	Placebo	CHA	OUT		Male	63	76.0	171.0	Caucasian	296.3	30.0
	156	Placebo	VON	OUT		Female	41	72.0	156.0	Caucasian	296.3	27.0
6/2	157	Reboxetine	MAZ	OUT		Male	43	61.0	176.0	Caucasian	296.3	29.0
	158	Imipramine	KER	OUT		Female	37	52.0	163.0	Caucasian	296.3	30.0
	159	Imipramine	JEG	IN	20/06/91	Male	46	89.0	178.0	Caucasian	296.3	29.0
	160	Placebo	MEN	IN	20/11/91	Male	35	89.0	179.0	Caucasian	296.2	30.0
	161	Reboxetine	BRE	OUT		Female	20	56.0	160.0	Caucasian	296.2	30.0
	162	Placebo	MAR	IN	01/06/91	Male	47	70.0	172.0	Caucasian	296.2	30.0
	169	Imipramine	BUR	OUT		Female	53	52.0	161.0	Caucasian	296.3	28.0
	170	Placebo	LD	OUT		Male	45	88.0	180.0	Caucasian	296.3	24.0
	171	Imipramine	PAG	OUT		Female	54	52.0	161.0	Caucasian	296.2	27.0
	172	Reboxetine	PAJ	OUT		Female	72	52.0	147.0	Caucasian	296.2	27.0
	173	Placebo	RAO	OUT		Male	44	75.0	181.0	Caucasian	296.2	27.0
	174	Reboxetine	COL	OUT		Male	55	77.0	175.0	Caucasian	296.3	28.0
6/3	163	Reboxetine	FEV	OUT		Male	37	63.0	178.0	Caucasian	296.3	24.0
	164	Imipramine	BRO	OUT		Male	29	74.0	178.0	Caucasian	296.3	28.0
	165	Imipramine	BAS	OUT		Female	54	49.0	159.0	Caucasian	296.3	29.0
	166	Reboxetine	CLE	OUT		Female	40	60.0	167.0	Caucasian	296.3	26.0
	167	Placebo	JUS	OUT		Female	33	55.0	162.0	Caucasian	296.3	30.0
	168	Placebo	DUC	OUT		Female	34	80.0	161.0	Caucasian	296.3	26.0
	505	Imipramine	CHA	OUT		Female	41	56.0	158.0	Caucasian	296.3	26.0
	506	Placebo	MEI	OUT		Female	48	89.0	174.0	Caucasian	296.3	26.0
	507	Imipramine	NOU	OUT		Female	34	57.0	160.0	Caucasian	296.3	30.0
	508	Reboxetine	GRE	OUT		Female	52	60.0	150.0	Caucasian	296.3	26.0
	509	Placebo	RAZ	OUT		Male	27	52.0	164.0	MADAGASCAR	296.3	30.0
	510	Reboxetine	LAU	OUT		Female	20	55.0	157.0	Caucasian	296.2	26.0
	511	Imipramine	LEB	OUT		Female	21	68.0	167.0	Caucasian	296.2	29.0
	512	Placebo	BAD	OUT		Female	23	45.0	159.0	Asian	296.3	26.0
	513	Imipramine	LAR	OUT		Female	41	55.0	158.0	Caucasian	296.3	26.0
7/02	181	Reboxetine	VH	OUT		Male	36	85.0	182.0	Caucasian	296.2	29.0
	182	Placebo	HLE	OUT		Male	57	64.0	176.0	Caucasian	296.3	29.0

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status In-out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)
7/02	183	Imipramine	HHE	OUT		Male	51	93.0	183.0	Caucasian	296.2	30.0
	184	Imipramine	HT	OUT		Female	43	60.0	160.0	Caucasian	296.2	27.0
	185	Reboxetine	YE	OUT		Male	59	73.0	172.0	Caucasian	296.2	30.0
	186	Placebo	HJS	OUT		Male	36	67.0	170.0	Caucasian	296.2	30.0
	535	Placebo	GT	OUT		Male	40	85.0	182.0	Caucasian	296.3	30.0
	536	Reboxetine	KR	OUT		Female	32	80.0	172.0	Caucasian	296.2	27.0
7/03	187	Imipramine	HK	OUT		Female	49	77.0	165.0	Caucasian	296.2	26.0
	188	Placebo	GH	OUT		Male	38	71.0	175.0	Caucasian	296.2	26.0
	189	Placebo	HM	OUT		Male	50	86.0	174.0	Caucasian	296.3	27.0
	190	Reboxetine	JS	OUT		Male	43	80.0	178.0	Caucasian	296.2	29.0
	191	Imipramine	AM	OUT		Female	48	82.0	158.0	Caucasian	296.2	27.0
	192	Reboxetine	CK	OUT		Female	63		176.0	Caucasian	296.3	27.0
	523	Reboxetine	DG	OUT		Female	35	52.0	160.0	Caucasian	296.3	26.0
	524	Placebo	DB	OUT		Female	26	52.0	156.0	Caucasian	296.2	25.0
	525	Placebo	GM	OUT		Female	35	91.0	160.0	Caucasian	296.3	25.0
	526	Reboxetine	MG	OUT		Female	57	97.0	171.0	Caucasian	296.3	25.0
	527	Imipramine	RE	OUT		Female	36	60.0	168.0	Caucasian	296.2	25.0
	528	Imipramine	CR	OUT		Female	35	64.0	160.0	Caucasian	296.2	26.0
7/04	193	Placebo	SM	OUT		Female	64	61.0	163.0	Caucasian	296.2	29.0
	194	Reboxetine	SC	OUT		Male	28	78.0	180.0	Caucasian	296.2	29.0
	195	Placebo	MM	OUT		Female	60	67.0	162.0	Caucasian	296.2	28.0
	196	Reboxetine	FH	OUT		Female	50	67.0	164.0	Caucasian	296.2	28.0
	197	Imipramine	HJ	OUT		Male	30	79.0	180.0	Caucasian	296.2	28.0
	198	Imipramine	KN	OUT		Female	55	61.0	164.0	Caucasian	296.2	28.0
	199	Imipramine	LD	OUT		Male	55	78.0	180.0	Caucasian	296.2	27.0
	200	Placebo	FB	OUT		Male	40	89.0	184.0	Caucasian	296.2	25.0
	201	Reboxetine	OH	OUT		Female	59	79.0	163.0	Caucasian	296.2	25.0
	202	Reboxetine	KH	OUT		Male	38	96.0	179.0	Caucasian	296.2	26.0
	203	Placebo	FM	OUT		Female	41	67.0	167.0	Caucasian	296.2	26.0
	204	Imipramine	ZC	OUT		Female	58	82.0	165.0	Caucasian	296.2	26.0
7/05	205	Placebo	HS	OUT		Male	61	74.0	169.0	Caucasian	296.3	27.0
	206	Imipramine	UR	OUT		Female	52	72.0	155.0	Caucasian	296.3	26.0
	207	Imipramine	EH	OUT		Female	62	72.0	158.0	Caucasian	296.2	27.0
	208	Reboxetine	FW	OUT		Male	42	75.0	174.0	Caucasian	296.3	28.0
	209	Placebo	AM	OUT		Male	53	86.0	177.0	Caucasian	296.2	26.0
	210	Reboxetine	OK	OUT		Male	64	76.0	170.0	Caucasian	296.2	25.0
	541	Reboxetine	HH	OUT		Female	59	74.0	168.0	Caucasian	296.3	25.0
	542	Imipramine	JW	OUT		Male	47	83.0	172.0	Caucasian	296.3	25.0
	543	Imipramine	UF	OUT		Male	50	98.0	185.0	Caucasian	296.3	28.0

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status In-out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)
7/05	544	Placebo	JT	OUT		Female	56	72.0	170.0	Caucasian	296.3	26.0
	545	Placebo	WR	OUT		Male	55	74.0	168.0	Caucasian	296.3	26.0
	546	Reboxetine	GS	OUT		Female	61	73.0	165.0	Caucasian	296.2	26.0
7/07	529	Placebo	MD	OUT		Female	57	75.0	170.0	Caucasian	296.3	27.0
	530	Imipramine	KM	OUT		Female	53	73.0	163.0	Caucasian	296.3	29.0
	531	Reboxetine	KR	OUT		Female	58	84.0	160.0	Caucasian	296.3	28.0
	532	Imipramine	BI	OUT		Female	50	58.0	158.0	Caucasian	296.3	29.0
	533	Reboxetine	JS	OUT		Male	40	85.0	170.0	Caucasian	296.3	30.0
	534	Placebo	PN	OUT		Female	45	66.0	159.0	Caucasian	296.2	29.0
8	211	Reboxetine	DUN	IN	07/05/91	Female	41	65.0	168.0	Caucasian	296.3	28.0
	212	Placebo	GRL	IN	10/09/91	Female	65	76.5	162.0	Caucasian	296.3	26.0
	213	Imipramine	DS	OUT	21/11/91	Male	59	79.0	173.0	Caucasian	296.3	27.0
	214	Reboxetine	BUB	IN	19/11/91	Female	54	72.0	160.0	Caucasian	296.3	26.0
	215	Placebo	RIM	IN	14/02/92	Female	46	43.0	166.0	Caucasian	296.3	30.0
	216	Imipramine	LEP	OUT	26/03/92	Male	46	92.0	180.0	Caucasian	296.3	29.0
	217	Reboxetine	LEO	IN	23/03/92	Female	41	62.8	167.0	Caucasian	296.3	29.0
	218	Reboxetine	SKS	OUT		Female	53	66.0	170.0	Caucasian	296.3	29.0
	219	Placebo	DID	OUT		Female	23	52.0	162.0	Caucasian	296.3	30.0
	220	Imipramine	CLA	IN	21/04/92	Female	38	56.5	163.0	Caucasian	296.3	30.0
	221	Imipramine	CEL	IN	24/04/92	Male	41	77.0	170.0	Caucasian	296.3	30.0
	222	Placebo	ROL	IN	20/04/92	Female	64	66.0	162.0	Caucasian	296.3	28.0
	223	Imipramine	MAA	IN	04/05/92	Female	57	54.0	166.0	Caucasian	296.3	30.0
	224	Placebo	VEB	OUT		Female	25	56.0	164.0	Caucasian	296.3	30.0
	225	Placebo	BED	OUT		Male	20	68.0	170.0	Caucasian	296.3	29.0
	226	Reboxetine	GIC	OUT		Male	58	62.0	162.0	Caucasian	296.3	28.0
	227	Reboxetine	PEM	OUT		Male	64	70.0	172.0	Caucasian	296.3	30.0
	228	Imipramine	SAR	OUT		Male	31	74.0	172.0	Caucasian	296.3	29.0
	229	Imipramine	COE	OUT		Female	55	66.0	162.0	Caucasian	296.3	28.0
	230	Reboxetine	MAG	OUT		Female	43	56.0	160.0	Caucasian	296.3	29.0
	231	Imipramine	STE	OUT		Male	46	88.0	180.0	Caucasian	296.3	30.0
	232	Reboxetine	SPA	OUT		Male	29	76.0	186.0	Caucasian	296.3	30.0
	233	Placebo	ZOG	OUT		Female	52	70.0	164.0	Caucasian	296.3	30.0
	234	Placebo	FRM	OUT		Female	65	62.0	163.0	Caucasian	296.3	27.0
8/A	235	Placebo	BM	OUT		Female	62	75.0	155.0	Caucasian	296.3	27.0
	236	Placebo	DN	OUT		Female	44	85.0	165.0	Caucasian	296.3	24.0
	237	Reboxetine	PC	OUT		Female	57	62.0	153.0	Caucasian	296.3	27.0
	238	Reboxetine	GR	OUT		Female	52	60.0	158.0	Caucasian	296.3	24.0
	239	Imipramine	GG	OUT		Female	62	62.0	161.0	Caucasian	296.3	27.0
	240	Imipramine	LL	OUT		Female	46	68.0	153.0	Caucasian	296.3	26.0

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status In-out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)
8/A	553	Placebo	LM	OUT		Female	36	68.0	164.0	Caucasian	296.3	25.0
	554	Reboxetine	PF	OUT		Male	60	64.0	160.0	Caucasian	296.3	27.0
	555	Reboxetine	SC	OUT		Female	64	57.0	153.0	Caucasian	296.3	25.0
	556	Imipramine	PG	OUT		Male	43	64.0	164.0	Caucasian	296.3	25.0
9	241	Placebo	MG	IN	24/01/91	Female	43	58.0	163.0	Caucasian	296.3	30.0
	242	Reboxetine	AF	IN	07/02/91	Female	58	50.0	164.0	Caucasian	296.3	26.0
	243	Reboxetine	RF	IN	23/01/91	Female	54	67.5	165.0	Caucasian	296.3	27.0
	244	Imipramine	MC	IN	06/02/91	Female	56	69.0	158.0	Caucasian	296.3	30.0
	245	Imipramine	MG	IN	12/02/91	Female	44	61.5	170.0	Caucasian	296.3	29.0
	246	Placebo	MC	IN	12/02/91	Female	41	69.0	160.0	Caucasian	296.3	28.0
	247	Placebo	VM	IN	29/01/91	Female	33		169.0	Caucasian	296.3	29.0
	248	Placebo	TG	IN	22/02/91	Male	37	81.5	175.0	Caucasian	296.3	27.0
	249	Reboxetine	ME	IN	01/03/91	Female	42	72.0	164.0	Caucasian	296.5	30.0
	250	Imipramine	BF	IN	07/03/91	Female	51	52.0	158.0	Caucasian	296.5	27.0
	251	Imipramine	LRS	IN	13/03/91	Female	22	61.0	173.0	Caucasian	296.2	28.0
	252	Reboxetine	DGF	IN	26/03/91	Female	61	116.0	160.0	Caucasian	296.3	27.0
	253	Reboxetine	PM	IN	14/03/91	Female	32	67.5	168.0	Caucasian	296.3	30.0
	254	Imipramine	PL	IN	03/04/91	Female	54	71.5	160.0	Caucasian	296.3	26.0
	255	Reboxetine	BM	IN	08/05/91	Female	24	76.0	158.0	Caucasian	296.2	26.0
	256	Imipramine	BA	IN	21/05/91	Female	51	54.0	165.0	Caucasian	296.3	30.0
	257	Placebo	TS	IN	18/06/91	Male	25	64.0	155.0	Caucasian	296.2	29.0
	258	Placebo	AG	IN	25/06/91	Male	29	48.5	160.0	Caucasian	296.2	30.0
11	319	Placebo	PA	OUT		Male	45	74.0	175.0	Caucasian	296.2	30.0
	320	Imipramine	RZ	OUT	03/09/91	Male	34	74.0	163.0	IRANIAN	296.3	30.0
	321	Placebo	EK	OUT		Male	45	65.0	165.0	Caucasian	296.3	29.0
	322	Reboxetine	JN	OUT		Female	57	73.0	170.0	Caucasian	296.3	28.0
	323	Reboxetine	LB	OUT		Male	36	65.0	178.0	Caucasian	296.2	30.0
	324	Imipramine	MC	OUT		Male	31	76.0	173.0	Caucasian	296.2	28.0
	325	Reboxetine	JFC	OUT		Male	58	83.0	185.0	Caucasian	296.2	29.0
	326	Placebo	CM	OUT		Male	55	75.0	168.0	Caucasian	296.3	30.0
	327	Imipramine	NA	OUT		Male	33	64.0	183.0	Caucasian	296.3	30.0
	328	Imipramine	SW	OUT		Female	29	60.0	168.0	Caucasian	296.3	29.0
	329	Placebo	LG	OUT		Female	40	86.0	160.0	Caucasian	296.3	30.0
	330	Reboxetine	JL	OUT		Male	36	69.0	160.0	Caucasian	296.2	29.0
	331	Imipramine	JK	OUT		Male	54	74.0	163.0	Caucasian	296.3	30.0
	332	Reboxetine	RC	OUT		Male	64	79.0	180.0	Caucasian	296.3	28.0
	333	Placebo	AL	OUT		Male	33	133.0	183.0	Caucasian	296.2	30.0
	334	Reboxetine	PT	OUT		Female	36	43.0	160.0	IRANIAN	296.2	29.0
	335	Placebo	AH	OUT		Male	33	103.0	193.0	Caucasian	296.3	30.0
	336	Imipramine	EM	OUT		Female	42	99.0	173.0	Caucasian	296.3	29.0
	337	Reboxetine	EM	OUT		Female	25	64.0	165.0	Caucasian	296.3	30.0

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status: In-out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)
11	338	Imipramine	GT	OUT		Male	29	75.0	183.0	Caucasian	296.2	30.0
12	367	Reboxetine	DSP	IN	11/12/91	Female	62	51.5	152.0	Caucasian	296.3	27.0
	368	Placebo	RJD	IN	16/12/91	Female	40	77.2	161.0	Caucasian	296.2	29.0
	369	Imipramine	SDD	IN	14/04/92	Female	50	70.4	165.0	Caucasian	296.3	29.0
	370	Placebo	MJB	IN	13/04/92	Male	60	89.0	170.0	Caucasian	296.3	25.0
	371	Imipramine	DSV	IN	15/04/92	Female	50	70.8	164.0	Caucasian	296.3	26.0
	372	Reboxetine	DBM	OUT	01/06/92	Male	36	141.0	188.0	Caucasian	296.3	30.0
	373	Reboxetine	RJP	IN	04/06/92	Male	52	71.3	172.0	Caucasian	296.3	30.0
	374	Placebo	MCT	IN	08/02/92	Female	34	71.0	165.0	Caucasian	296.3	28.0
	375	Imipramine	SLC	IN	05/06/92	Male	47	78.1	172.0	Caucasian	296.3	30.0
13	13	Placebo	EP	IN	03/04/91	Male	44	80.0	178.0	Caucasian	296.3	27.0
	14	Placebo	SMF	OUT		Male	28	78.0	180.0	SRILANKA	296.3	29.0
	15	Imipramine	CLB	IN	01/07/91	Female	29	80.7	164.0	Caucasian	296.3	29.0
	16	Imipramine	RD	OUT		Male	52	95.0	175.0	Caucasian	296.3	30.0
	17	Reboxetine	SC	OUT		Male	35	65.0	177.0	Caucasian	296.3	29.0
	18	Reboxetine	IZ	OUT		Male	51	82.5	175.0	Caucasian	296.3	28.0
	409	Reboxetine	BC	OUT		Male	61	68.0	177.0	Caucasian	296.3	30.0
	410	Placebo	JMT	OUT		Male	45	65.0	169.0	Caucasian	296.3	27.0
	411	Imipramine	DCR	IN	18/03/92	Female	40	47.0	158.0	Caucasian	296.3	27.0
	423	Placebo	JJC	OUT		Male	52	87.2	179.0	Caucasian	296.3	30.0
14	19	Reboxetine	VB	IN	02/04/92	Female	52	89.0	161.0	Caucasian	296.3	26.0
	20	Imipramine	MR	IN	24/04/92	Female	59	85.0	179.0	Caucasian	296.3	30.0
	21	Imipramine	MD	IN	15/07/92	Female	59	83.0	160.0	Caucasian	296.3	23.0
15	25	Reboxetine	NN	OUT		Female	60	65.0	153.0	Caucasian	296.3	29.0
	26	Placebo	VJ	OUT		Male	36	80.0	165.0	Caucasian	296.3	30.0
	27	Imipramine	EB	OUT		Female	53	40.0	151.0	Caucasian	296.3	30.0
	28	Reboxetine	JB	OUT		Female	43	82.0	175.0	Caucasian	296.3	30.0
	29	Placebo	DG	IN	28/08/91	Male	47	87.0	170.0	Caucasian	296.2	28.0
	30	Imipramine	HM	OUT		Female	44	85.0	167.0	Caucasian	296.3	30.0
	403	Imipramine	JMB	IN	02/10/91	Female	44	61.0	155.0	Caucasian	296.2	30.0
	404	Reboxetine	MV	OUT		Female	42	67.0	162.0	Caucasian	296.2	30.0
	405	Placebo	RP	OUT		Female	49	56.5	163.0	Caucasian	296.2	30.0
	406	Imipramine	DS	OUT		Male	31	77.0	185.0	Caucasian	296.2	30.0
	407	Reboxetine	EC	IN	29/11/91	Female	40	52.5	171.0	Caucasian	296.3	30.0
	408	Placebo	BC	IN	08/01/92	Female	34	80.0	165.0	Caucasian	296.3	30.0
	418	Placebo	LM	OUT		Female	63	58.5	151.0	Caucasian	296.3	30.0
	419	Placebo	JM	OUT		Female	30	56.5	165.0	Caucasian	296.3	30.0

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 2.0

HISTORY OF MENTAL DISORDER AND PRESENT EPISODE

		History of mental disorder				Present episode			
Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Onset was	External stress
1	1			1	10 weeks	2 months and 5 days	Similar prev. cond.	Acute (< 2 weeks)	Absent
	2		44	4	12 weeks	3 months	Similar prev. cond.	Acute (< 2 weeks)	Probably present
	3		35	4	2 weeks	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	4		35	0		3 months	First occurence	Insidious (>= 3 months)	Probably present
	5		50	1	5 months	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	6		30	7	8 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	7	Yes	19	0		4 months	First occurence	Insidious (>= 3 months)	Absent
	8		46	1	4 months	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	9		37	1	12 weeks	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	10		27		3 years	6 months	Chronic condition	Insidious (>= 3 months)	Absent
	11		36	3	20 weeks	20 days	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	12		30	1	3 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	412		35	1	5 months	10 weeks	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	413		44		7 years	6 weeks	Chronic condition	Subacute (>= 2 weeks)	Absent
	414		44	4	3 years	3 months	Chronic condition	Insidious (>= 3 months)	Probably present
	415		33	1	8 weeks	10 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	416		33	1	6 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	421		52	1	3 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	422		44			3 months	First occurence	Subacute (>= 2 weeks)	Definitely present
2/1	49		20	1		8 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	50		42	1	3 months	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	51		27			1 month	Different prev. cond.	Subacute (>= 2 weeks)	Probably present
2/2	43		15	2	6 months	3 months	Different prev. cond.	Subacute (>= 2 weeks)	Absent
	44		17	3		3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	45		20	10	2 months	4 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	46		19	2	3 months	1 month	Different prev. cond.	Subacute (>= 2 weeks)	Probably present
	47		30	2	6 months	3 months	Chronic condition	Insidious (>= 3 months)	Probably present
	48	Yes				2 months	Chronic condition	Insidious (>= 3 months)	Probably present
2/3	36/A		17	5	10 weeks	10 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	37		43	2	16 weeks	5 weeks	Chronic condition	Insidious (>= 3 months)	Probably present
	38		45	0		1 month and 21 days	First occurence	Insidious (>= 3 months)	Probably present
	39		51	3	3 months	2 months	Chronic condition	Subacute (>= 2 weeks)	Definitely present
	40		55	4	2 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	41		23	2	4 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	42		35	4	1 month	1 month and 15 days	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
2/4	31	Yes				2 months	Chronic condition	Subacute (>= 2 weeks)	Absent
	32	Yes				1 month	Chronic condition	Insidious (>= 3 months)	Absent
	33	Yes				1 month	Chronic condition	Insidious (>= 3 months)	Absent
	34	Yes				4 weeks	Chronic condition	Subacute (>= 2 weeks)	Absent
	35		64			5 weeks	First occurence	Acute (< 2 weeks)	Absent
	36	Yes				1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Absent

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 2.0

HISTORY OF MENTAL DISORDER AND PRESENT EPISODE

		History of mental disorder				Present episode			
Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Onset was	External stress
2/5	73		44	3	2 months	3 weeks	Chronic condition	Subacute (>= 2 weeks)	Absent
	74		52	0		2 months	Different prev. cond.	Subacute (>= 2 weeks)	Definitely present
	75		47	3	1 month	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	76		32	0		1 month	First occurence	Subacute (>= 2 weeks)	Probably present
	77		22	3	1 year	4 months	Similar prev. cond.	Acute (< 2 weeks)	Probably present
	78		37	20	3 months	1 month	Chronic condition	Acute (< 2 weeks)	Definitely present
2/6	55		57	0		3 months	First occurence	Insidious (>= 3 months)	Probably present
	56		59	0		3 months	First occurence	Insidious (>= 3 months)	Probably present
	57		50	1	3 months	2 months	Different prev. cond.	Insidious (>= 3 months)	Probably present
	58		59	1	3 months	3 months	Different prev. cond.	Insidious (>= 3 months)	Probably present
	59		33	0		1 month	First occurence	Insidious (>= 3 months)	Probably present
	60		34	1	2 months	2 months	Different prev. cond.	Subacute (>= 2 weeks)	Probably present
3/1	61		22	0		1 month	First occurence	Subacute (>= 2 weeks)	Probably present
	62	Yes				5 weeks and 5 days	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	63	Yes				4 weeks and 10 days	First occurence	Acute (< 2 weeks)	Probably present
	64		44	3	6 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	65	Yes				4 weeks	First occurence	Subacute (>= 2 weeks)	Absent
	66		40	2	4 months	8 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	139		27	2	3 months	6 weeks	Similar prev. cond.	Acute (< 2 weeks)	Probably present
	140		53	2	3 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	141		37	1	6 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	142	Yes				1 month and 2 weeks	First occurence	Acute (< 2 weeks)	Absent
	143		39	3	5 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	144	Yes				2 months	Different prev. cond.	Subacute (>= 2 weeks)	Definitely present
	451		51	2	4 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	452		44	0		3 months	First occurence	Subacute (>= 2 weeks)	Definitely present
	453		50	3	4 months	6 weeks	Different prev. cond.	Acute (< 2 weeks)	Definitely present
	454		55	1	6 months	2 months	Similar prev. cond.	Acute (< 2 weeks)	Probably present
	455		40	1	6 months	1 month and 2 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	456		28	0		3 months	First occurence	Subacute (>= 2 weeks)	Definitely present
3/2	65/A		19	1	2 months	2 months and 2 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
3/3	67		34	6	3 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	68		38	2	1 month	1 month and 2 weeks	Similar prev. cond.	Acute (< 2 weeks)	Definitely present
	69		24	3	4 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	70		40			2 months	First occurence	Subacute (>= 2 weeks)	Definitely present
	71		23	1	4 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	72		31			1 month and 2 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
3/4	79		42	1	4 months	2 months and 15 days	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 2.0

HISTORY OF MENTAL DISORDER AND PRESENT EPISODE

		History of mental disorder				Present episode			
Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Onset was	External stress
3/4	80		46	0		1 month and 3 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
	81		35	0		4 months	First occurence	Insidious (>= 3 months)	Definitely present
	82		49	0		10 weeks	First occurence	Acute (< 2 weeks)	Probably present
	83		32	1	1 year	4 months	Different prev. cond.	Insidious (>= 3 months)	Probably present
	84		27	0		5 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
	85		39	1	4 months	1 month and 2 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	86		34	0		3 months and 1 week	First occurence	Insidious (>= 3 months)	
	87		26	1	2 months and 2 weeks	2 months and 3 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	88		53	0		4 months and 1 week	First occurence	Insidious (>= 3 months)	Probably present
	89		46	3	2 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	90		47	0		3 months	First occurence	Insidious (>= 3 months)	Probably present
	457		43	2	6 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	458		30	4	4 months	2 months	Chronic condition	Insidious (>= 3 months)	Probably present
	459		47	3	6 months	1 month	Chronic condition	Subacute (>= 2 weeks)	Probably present
	460		38	0		3 months	First occurence	Insidious (>= 3 months)	Probably present
	461		45	0		2 months and 3 weeks	First occurence	Insidious (>= 3 months)	Definitely present
	462		39	0		2 months	First occurence	Subacute (>= 2 weeks)	Definitely present
4/1	91		36			4 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	92		13	6	4 months	3 months	Similar prev. cond.	Acute (< 2 weeks)	Probably present
	93	Yes				2 months	First occurence	Insidious (>= 3 months)	Probably present
	94		44	3	1 year	3 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	95		37	2	3 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	96		40	10	3 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	115		51	4	4 months	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	116		39	1	2 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	117		36	5	4 months	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	118		22			3 months	First occurence	Subacute (>= 2 weeks)	Definitely present
	119		44	1	3 months	4 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	120		31	1	6 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	145		40	1	3 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	146		55	0		3 months	First occurence	Subacute (>= 2 weeks)	Absent
	147		34	3	3 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	148		42	6	3 months	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	149		56	0		3 months	First occurence	Insidious (>= 3 months)	Probably present
	150		40	5	2 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
4/2	93/A		45	3	3 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	99/A		42	5	1 month	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	104		46	6	6 months	3 months	Chronic condition	Insidious (>= 3 months)	Absent
4/3	97		41	1	10 months	7 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	98		58	2	9 months and 3 weeks	3 months and 2 weeks	Similar prev. cond.	Insidious (>= 3 months)	Absent
	99		55	8	2 months	2 months	Chronic condition	Subacute (>= 2 weeks)	Absent
	100		19	5	3 months and 2 weeks	5 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	101		43	1	6 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 2.0

HISTORY OF MENTAL DISORDER AND PRESENT EPISODE

		History of mental disorder			Present episode			
Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Onset was	External stress
4/4	109		27	1	6 weeks	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	110		53	3	4 weeks	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	111		49	6	3 months	2 months	Chronic condition	Insidious (>= 3 months)	Absent
	112		22	1	6 weeks	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	113		22	2	4 weeks	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	114		32	8	2 months	1 month and 2 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	175		40	3	2 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	176		14	3	2 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	177		52	3	2 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	178		30	2	2 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
8	179		28	1	2 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
3	180		39	1	6 weeks	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
8									
5/1	127		20	4	3 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	128		30	3	2 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	129		18	1	3 weeks	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	130		18	1	3 weeks	2 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	131		25	20	4 weeks	2 months	Chronic condition	Subacute (>= 2 weeks)	Probably present
	132	Yes				4 months	First occurence	Insidious (>= 3 months)	Probably present
5/2	121		17	3	2 months and 2 weeks	3 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	125		39	5	2 months	11 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
5/3	133		51	2	8 weeks	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	134		20	4	7 weeks	7 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	135		42	3	5 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	136		37	7	10 weeks	8 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	137		18	5	2 months	2 months	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	138		31	0		1 month and 3 weeks	First occurence		Definitely present
6/1	151		43			3 months	First occurence	Subacute (>= 2 weeks)	Probably present
	152		40	2	6 months	1 month	Different prev. cond.	Subacute (>= 2 weeks)	Probably present
	153		43	4	5 weeks	7 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	154		26			2 months	First occurence	Subacute (>= 2 weeks)	Probably present
	155		26	2	4 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	156		33	1	6 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
6/2	157		25	10	4 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	158		32	5	6 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	159		44	1	2 years	4 weeks	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	160		34			6 weeks	First occurence	Insidious (>= 3 months)	Definitely present
	161	Yes				3 months	First occurence	Subacute (>= 2 weeks)	Probably present
	162		47			3 months	First occurence	Insidious (>= 3 months)	Definitely present

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 2.0

HISTORY OF MENTAL DISORDER AND PRESENT EPISODE

		History of mental disorder				Present episode			
Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Onset was	External stress
6/2	169		20	40	3 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	170		37	2	2 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	171		54	0		3 months and 3 weeks	First occurence	Insidious (>= 3 months)	Absent
	172		72	0		3 months	First occurence	Insidious (>= 3 months)	Absent
	173		44	0		1 month	First occurence	Subacute (>= 2 weeks)	Probably present
	174		53	2	2 months	30 days	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
6/3	163		33	1	1 year	3 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	164		24	1	6 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	165		52	2	6 months	2 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	166		37	1	6 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	167		30	2	3 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	168		15	5	1 year	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	505		31	3	1 year	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	506		25	5	6 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	507		32	2	6 months	4 weeks	Different prev. cond.	Subacute (>= 2 weeks)	Probably present
	508		30	4	8 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	509		24	2	6 months	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	510		18			4 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	511		21	0		4 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	512		21	1	4 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	513		30	2	6 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
7/02	181	Yes				1 month and 2 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	182		45	7	3 months	1 month and 2 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	183	Yes				2 months	First occurence	Subacute (>= 2 weeks)	Probably present
	184	Yes				2 months	First occurence	Subacute (>= 2 weeks)	Probably present
	185	Yes				3 months	First occurence	Subacute (>= 2 weeks)	Absent
	186	Yes				4 months	First occurence	Subacute (>= 2 weeks)	Probably present
	535		36	2	3 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	536	Yes				4 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
7/03	187		49	0		4 weeks	First occurence	Subacute (>= 2 weeks)	Absent
	188		38	0		8 weeks	First occurence	Subacute (>= 2 weeks)	Absent
	189		44	1	8 weeks	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	190		43	0		8 weeks	First occurence	Subacute (>= 2 weeks)	Absent
	191		48	0		3 weeks and 4 days	First occurence	Acute (< 2 weeks)	Probably present
	192		55	2	12 weeks	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	523		33	1	3 months and 1 week	28 days	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	524	Yes		0		28 days	First occurence	Subacute (>= 2 weeks)	Probably present
	525		33	1	3 months	4 months	Chronic condition	Subacute (>= 2 weeks)	Absent
	526		54	1	3 months	24 days	Chronic condition	Subacute (>= 2 weeks)	Absent
	527	Yes				5 weeks	First occurence	Subacute (>= 2 weeks)	Absent
	528	Yes				6 weeks	First occurence	Subacute (>= 2 weeks)	Absent
7/04	193	Yes				3 months	First occurence	Insidious (>= 3 months)	Absent

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 2.0

HISTORY OF MENTAL DISORDER AND PRESENT EPISODE

		History of mental disorder				Present episode			
Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Onset was	External stress
7/04	194	Yes				3 months	First occurence	Insidious (>= 3 months)	Absent
	195	Yes				2 months	First occurence	Insidious (>= 3 months)	Absent
	196	Yes				3 months	First occurence	Insidious (>= 3 months)	Absent
	197	Yes				2 months	First occurence	Subacute (>= 2 weeks)	Absent
	198	Yes				3 months	First occurence	Insidious (>= 3 months)	Absent
	199	Yes				2 months	First occurence	Subacute (>= 2 weeks)	Absent
	200	Yes				2 months and 2 weeks	First occurence	Subacute (>= 2 weeks)	Absent
	201	Yes				2 months	First occurence	Subacute (>= 2 weeks)	Absent
	202	Yes				3 months	First occurence	Insidious (>= 3 months)	Definitely present
	203	Yes				1 month	First occurence	Subacute (>= 2 weeks)	Absent
	204	Yes				2 months	First occurence	Subacute (>= 2 weeks)	Absent
7/05	205		57	2	2 months	6 weeks	Different prev. cond.	Subacute (>= 2 weeks)	Absent
	206		48	3	3 months	7 weeks	Different prev. cond.	Subacute (>= 2 weeks)	Absent
	207	Yes				2 months	First occurence	Subacute (>= 2 weeks)	Absent
	208		41	1	2 months and 2 weeks	6 weeks	Different prev. cond.	Subacute (>= 2 weeks)	Absent
	209	Yes				6 weeks	First occurence	Subacute (>= 2 weeks)	Absent
	210	Yes				7 weeks	First occurence	Subacute (>= 2 weeks)	Absent
	541		56	4	4 weeks	4 weeks	Different prev. cond.	Subacute (>= 2 weeks)	Absent
	542		42	3	3 months	3 months	Different prev. cond.	Subacute (>= 2 weeks)	Absent
	543		49	2	3 months	3 months	Different prev. cond.	Subacute (>= 2 weeks)	Absent
	544		51	3	4 months	3 months	Different prev. cond.	Subacute (>= 2 weeks)	Absent
	545		52	2	4 months	5 weeks	Different prev. cond.	Subacute (>= 2 weeks)	Absent
	546	Yes				3 months	Different prev. cond.	Subacute (>= 2 weeks)	Absent
7/07	529		47	3	3 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	530		41	6	4 weeks	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	531		56	1	2 months	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	532	Yes				4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	533	Yes				4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	534	Yes				5 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
8	211		26	4	4 weeks	45 days	Similar prev. cond.	Acute (< 2 weeks)	Absent
	212		50	3	1 week	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	213		56	4	2 months	40 days	Similar prev. cond.	Acute (< 2 weeks)	Absent
	214		40	4	1 month	45 days	Similar prev. cond.	Acute (< 2 weeks)	Absent
	215		43	1	4 weeks	35 days	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	216		41	4	4 weeks	30 days	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	217		26	1	1 month	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	218		49	1	2 months	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	219		22	1	2 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	220		35	2	1 month	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	221		39	2	4 weeks	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	222		40	2	1 month	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	223		25	3	3 months	28 days	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	224		22	1	2 months	35 days	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	225		19	1	6 weeks	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 2.0

HISTORY OF MENTAL DISORDER AND PRESENT EPISODE

		History of mental disorder				Present episode			
Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Onset was	External stress
8	226		48	2	3 months	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	227		62	1	2 months	35 days	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	228		29	1	6 weeks	35 days	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	229		52	2	2 months	40 days	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	230		41	3	5 weeks	35 days	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	231		44	1	2 months	40 days	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	232		26	1	1 month	40 days	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	233		49	1	2 months	45 days	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	234		36	2	6 months	40 days	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
8/A	235		52	7	3 months	2 months	Similar prev. cond.	Acute (< 2 weeks)	Absent
	236		37	7	2 months	3 weeks	Similar prev. cond.	Acute (< 2 weeks)	Absent
	237		33	5	3 months	1 month	Similar prev. cond.	Acute (< 2 weeks)	Absent
	238		50	3	1 month	3 weeks	Similar prev. cond.	Acute (< 2 weeks)	Absent
	239		59	2	3 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	240		40	6	1 month	3 weeks	Similar prev. cond.	Acute (< 2 weeks)	Absent
	553		34	1	2 months	1 month and 2 weeks	Different prev. cond.	Subacute (>= 2 weeks)	Absent
	554		59	3	1 month	3 weeks	Chronic condition	Acute (< 2 weeks)	Absent
	555		60	2	3 months	2 months	Similar prev. cond.	Acute (< 2 weeks)	Absent
	556		41	4	10 weeks	3 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
9	241		42	2	3 months	4 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	242		38		4 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	243		51	4	3 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	244		39	13	2 months	4 weeks	Similar prev. cond.	Acute (< 2 weeks)	Absent
	245		34	2	8 months	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	246		27	11	1 month	4 weeks	Similar prev. cond.	Acute (< 2 weeks)	Absent
	247		30	4	5 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	248		26	1	6 months	2 months	Similar prev. cond.	Acute (< 2 weeks)	Absent
	249		36		3 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	250		45	3	6 months	4 weeks	Similar prev. cond.	Acute (< 2 weeks)	Absent
	251		22			3 months	First occurence	Acute (< 2 weeks)	Definitely present
	252		46	4	5 months	1 month	Similar prev. cond.	Acute (< 2 weeks)	Absent
	253		28	2	2 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	254		25	15	3 months	3 months	Similar prev. cond.	Acute (< 2 weeks)	Absent
	255		24			2 months	Different prev. cond.	Acute (< 2 weeks)	Definitely present
	256		27	2	3 months	2 months	Similar prev. cond.	Acute (< 2 weeks)	Absent
	257		25			3 months	First occurence	Subacute (>= 2 weeks)	Probably present
	258		29			2 months	First occurence	Subacute (>= 2 weeks)	Probably present
11	319					3 months	First occurence	Subacute (>= 2 weeks)	Probably present
	320		33	1	5 months	1 month	Similar prev. cond.	Acute (< 2 weeks)	Definitely present
	321		44	1	6 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	322		45	1	2 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	323		36	0		4 months	First occurence	Insidious (>= 3 months)	Absent
	324		31	0		3 months	First occurence	Subacute (>= 2 weeks)	Absent
	325		58	0		3 months	First occurence	Subacute (>= 2 weeks)	Definitely present

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 2.0

HISTORY OF MENTAL DISORDER AND PRESENT EPISODE

		History of mental disorder				Present episode			
Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Onset was	External stress
11	326		47	3	1 year	4 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	327		23	1	3 months	4 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	328			1	6 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	329		30	2	1 year	4 months	Chronic condition	Subacute (>= 2 weeks)	Definitely present
	330		36	0		3 months	First occurence	Acute (< 2 weeks)	Definitely present
	331		44	1	2 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	332		63	1	3 months	2 months	Similar prev. cond.	Acute (< 2 weeks)	Definitely present
	333		33	0		2 months	First occurence	Acute (< 2 weeks)	Definitely present
	334		36	0		4 months	First occurence	Insidious (>= 3 months)	Definitely present
	335		31	1	3 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	336		37	2		4 months	Chronic condition	Insidious (>= 3 months)	Definitely present
	337		24	1	6 months	4 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	338		29	0		2 months	First occurence	Acute (< 2 weeks)	Definitely present
12	367		47	1	3 months	3 months and 12 days	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	368		40	0		2 months	First occurence	Subacute (>= 2 weeks)	Absent
	369		33	2	3 weeks	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	370		51	2	2 months	8 weeks	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	371		48	3	5 weeks	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	372		19	2	3 months	9 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	373		46	2	6 months	15 weeks	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	374		20	1	8 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	375		45	1	4 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
13	13		42	2	6 months	3 months	Different prev. cond.	Insidious (>= 3 months)	Definitely present
	14		16		2 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	15		14		10 months	3 months	Chronic condition	Subacute (>= 2 weeks)	Absent
	16		37		1 month	2 months	Chronic condition	Subacute (>= 2 weeks)	Absent
	17		15		6 months	3 months	Chronic condition	Insidious (>= 3 months)	Absent
	18		40	6	5 months	4 months	Chronic condition	Insidious (>= 3 months)	Absent
	409		54		2 months	6 weeks	Chronic condition	Subacute (>= 2 weeks)	Absent
	410		29		2 months	8 weeks	Chronic condition	Insidious (>= 3 months)	Absent
	411		27	4	6 months	2 months	Chronic condition	Subacute (>= 2 weeks)	Probably present
	423		16		10 months	3 months	Chronic condition	Subacute (>= 2 weeks)	Absent
14	19		38	1	2 months	4 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	20		56	1	3 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	21		35	4	1 month	4 months	Similar prev. cond.	Acute (< 2 weeks)	Definitely present
15	25		49	2	3 months	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	26		26	4	3 months	10 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	27		49	3	10 weeks	9 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	28		35	6	10 weeks	14 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	29		45			2 months	First occurence	Insidious (>= 3 months)	Probably present
	30		37	2	1 year	2 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	403		44			16 weeks	First occurence	Subacute (>= 2 weeks)	Probably present

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 2.0

HISTORY OF MENTAL DISORDER AND PRESENT EPISODE

		History of mental disorder				Present episode			
Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Onset was	External stress
15	404		42			12 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	405		49			14 weeks	First occurence	Insidious (>= 3 months)	Definitely present
	406		31			8 weeks	First occurence	Acute (< 2 weeks)	Definitely present
	407		23	1	6 months	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	408		32	1	2 months	2 months	Similar prev. cond.	Acute (< 2 weeks)	Absent
	418		57	2	3 months	8 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	419		27	1	3 months	10 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 3.0
DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

A. At least five of the following symptoms have been present during the same two-week period and represent a change from previous functioning: at least one of the symptoms is either 1) depressed mood or 2) loss of interest or pleasure.

1) depressed mood most of day, nearly every day, as indicated by subjective account or observation by others

2) markedly diminished interest or pleasure in all, or almost all, activites most of day, nearly every day (as indicated either by subjective account or observation by others of apathy most of the time

3) significant weight loss or weight gain when not dieting (e.g. more than 5% of body weight in a month), or decrease or increase in appetite nearly every day

4) insomnia or hypersomnia nearly every day

5) psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down)

6) fatigue or loss of energy nearly every day

7) feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick)

8) diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or as observed by others)

9) recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide

B. 1) it cannot be established that an organic factor initiated and maintained the disturbance

2) the disturbance is not a normal reaction to the death of a loved one

C. At no time during the disturbance have there been delusions or hallucinations for as long as two weeks in the absence of prominent mood symptoms (i.e., before the mood symptoms developed or after they have remitted)

D. Not superimposed on Schizophrenia, Schizophreniform, Disorder, Delusional Disorder, or Psychotic Disorder NOS.

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

					A										B			C	D
						items										items			
Centre	Patient	Sex	Age	DSM-III-R	Present	1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	1)	2)	Present	Present
1	1	Female	35	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	2	Male	49	296.3	x	x	x		x	x	x	x	x	x	x	x	x	x	x
	3	Male	41	296.3	x	x	x		x	x	x		x		x	x	x	x	x
	4	Male	35	296.2	x	x	x		x	x	x	x	x	x	x	x	x	x	x
	5	Female	57	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
	6	Female	36	296.3	x	x	x		x	x	x	x	x	x	x	x	x	x	x
	7	Female	19	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	8	Male	49	296.3	x	x	x	x	x	x	x	x	x		x	x	x	x	x
	9	Female	38	296.3	x	x	x		x	x	x	x	x	x	x	x	x	x	x
	10	Male	32	296.3	x	x	x		x	x	x	x	x	x	x	x	x	x	x
	11	Female	39	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	12	Female	30	296.3	x	x	x		x	x	x	x	x	x	x	x	x	x	x
	412	Male	41	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	413	Male	51	296.3	x	x	x		x	x	x	x	x	x	x	x	x	x	x
	414	Female	47	296.3	x	x	x	x	x	x	x		x		x	x	x	x	x
	415	Male	40	296.3	x	x	x		x	x	x	x	x	x	x	x	x	x	x
	416	Female	41	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	421	Male	57	296.3	x	x	x		x	x	x	x	x	x	x	x	x	x	x
	422	Male	44	296.2	x	x	x		x		x	x	x	x	x	x	x	x	x
2/1	49	Female	53	296.3	x	x	x			x	x		x	x	x	x	x	x	x
	50	Female	43	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
	51	Female	38	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
2/2	43	Female	26	296.3	x	x	x		x		x		x		x	x	x	x	x
	44	Female	20	296.3	x	x		x	x	x	x	x			x	x	x	x	x
	45	Female	26	296.3	x	x	x	x	x		x	x	x		x	x	x	x	x
	46	Female	43	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	47	Female	35	296.3	x	x	x		x	x	x		x		x	x	x	x	x
	48	Female	31	296.2	x	x	x	x	x	x	x	x	x		x	x	x	x	x
2/3	36/A	Male	53	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	37	Female	46	296.3	x	x	x		x		x		x		x	x	x	x	x
	38	Male	45	296.2	x	x	x				x	x	x		x	x	x	x	x
	39	Female	52	296.3	x	x			x		x	x	x		x	x	x	x	x
	40	Female	59	296.3	x	x	x	x	x		x		x		x	x	x	x	x
	41	Male	25	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
	42	Female	40	296.3	x	x		x	x		x		x		x	x	x	x	x
2/4	31	Male	35	296.2	x	x	x			x	x		x		x	x	x	x	x
	32	Male	59	296.2	x	x	x		x		x		x	x	x	x	x	x	x
	33	Male	38	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	34	Female	55	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	35	Female	64	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	36	Female	57	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

					A										B			C	D
						items										items			
Centre	Patient	Sex	Age	DSM-III-R	Present	1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	1)	2)	Present	Present
2/5	73	Male	48	296.3	X	X	X		X	X	X		X	X	X	X	X	X	X
	74	Male	52	296.2	X	X	X		X	X	X		X		X	X	X	X	X
	75	Male	50	296.3	X	X	X	X		X	X	X	X		X	X	X	X	X
	76	Female	32	296.2	X	X	X	X	X	X	X		X		X	X	X	X	X
	77	Male	38	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	78	Female	51	296.3	X	X	X			X	X			X	X	X	X	X	X
2/6	55	Female	57	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	56	Female	59	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	57	Female	57	296.3	X	X	X	X	X	X	X		X	X	X	X	X	X	X
	58	Female	59	296.3	X	X	X	X	X	X	X		X	X	X	X	X	X	X
	59	Male	33	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	60	Female	38	296.3	X	X	X		X	X	X		X	X	X	X	X	X	X
3/1	61	Male	22	296.2	X	X	X			X	X	X	X		X	X	X	X	X
	62	Female	24	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	63	Male	43	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	64	Female	57	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	65	Male	62	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	66	Male	50	296.3	X	X	X	X	X	X	X		X		X	X	X	X	X
	139	Male	31	296.3	X	X	X		X	X	X	X	X	X	X	X	X	X	X
	140	Male	56	296.3	X	X	X	X	X	X	X		X	X	X	X	X	X	X
	141	Female	40	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	142	Female	20	296.2	X	X	X		X		X	X	X	X	X	X	X	X	X
	143	Female	44	296.3	X	X	X		X	X	X	X	X	X	X	X	X	X	X
	144	Female	26	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	451	Female	57	296.3	X	X	X		X	X	X	X	X	X	X	X	X	X	X
	452	Male	44	296.2	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	453	Female	55	296.3	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	454	Male	56	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	455	Female	47	296.3	X	X	X			X	X	X	X	X	X	X	X	X	X
	456	Female	39	296.2	X	X	X	X	X	X	X	X	X		X	X	X	X	X
3/2	65/A	Female	21	296.3	X	X	X		X		X	X		X	X	X	X	X	X
3/3	67	Male	38	296.3	X	X	X		X	X	X	X	X	X	X	X	X	X	X
	68	Male	45	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	69	Male	34	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	70	Male	40	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	71	Female	26	296.3	X	X	X				X	X	X	X	X	X	X	X	X
	72	Male	31	296.2	X	X	X	X	X		X	X	X	X	X	X	X	X	X
3/4	79	Female	45	296.3	X	X	X	X	X	X	X		X		X	X	X	X	X

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

					A										B			C	D
						items										items			
Centre	Patient	Sex	Age	DSM-III-R	Present	1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	1)	2)	Present	Present
3/4	80	Male	46	296.2	X	X	X	X	X	X	X		X	X	X	X	X	X	X
	81	Female	35	296.2	X	X	X	X	X	X		X	X	X	X	X	X	X	X
	82	Male	49	296.2	X	X	X		X			X	X	X	X	X	X	X	X
	83	Male	49	296.3	X	X	X	X	X		X		X	X	X	X	X	X	X
	84	Female	27	296.2	X	X	X	X	X	X	X		X		X	X	X	X	X
	85	Female	45	296.3	X	X	X	X	X		X		X	X	X	X	X	X	X
	86	Male	34	296.2	X	X	X		X	X	X		X	X	X	X	X	X	X
	87	Female	33	296.3	X	X	X		X		X		X	X	X	X	X	X	X
	88	Male	53	296.2	X	X	X		X	X	X		X		X	X	X	X	X
	89	Female	49	296.3	X	X	X		X	X	X		X		X	X	X	X	X
	90	Male	47	296.2	X	X	X		X		X	X	X		X	X	X	X	X
	457	Female	48	296.3	X	X	X		X	X	X		X	X	X	X	X	X	X
	458	Female	43	296.3	X	X	X			X	X	X	X		X	X	X	X	X
	459	Female	57	296.3	X	X	X		X	X	X	X	X	X	X	X	X	X	X
	460	Male	38	296.2	X		X	X	X	X	X		X		X	X	X	X	X
	461	Female	45	296.2	X	X	X	X	X	X	X		X		X	X	X	X	X
	462	Female	39	296.2	X	X	X	X	X		X		X		X	X	X	X	X
4/1	91	Female	36	296.2	X	X	X	X	X	X	X		X	X	X	X	X	X	X
	92	Female	28	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	93	Male	18	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	94	Female	59	296.3	X	X	X	X	X	X	X		X		X	X	X	X	X
	95	Female	42	296.3	X	X	X	X	X	X	X		X		X	X	X	X	X
	96	Female	52	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	115	Female	55	296.3	X	X	X		X	X	X	X	X	X	X	X	X	X	X
	116	Female	41	296.3	X	X	X		X	X	X	X	X	X	X	X	X	X	X
	117	Female	59	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	118	Female	43	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	119	Female	46	296.3	X	X	X		X	X	X		X		X	X	X	X	X
	120	Female	35	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	145	Female	47	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	146	Female	55	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	147	Female	65	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	148	Female	59	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	149	Male	56	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	150	Male	52	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
4/2	93/A	Male	48	296.3	X	X		X	X		X		X	X	X	X	X	X	X
	99/A	Male	48	296.3	X	X	X	X	X		X		X	X	X	X	X	X	X
	104	Male	57	296.3	X	X		X	X		X	X	X	X	X	X	X	X	X
4/3	97	Male	42	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	98	Female	58	296.3	X	X	X		X		X	X	X		X	X	X	X	X
	99	Female	59	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	100	Female	24	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	101	Male	55	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

Centre	Patient	Sex	Age	DSM-III-R	A items Present	A items 1)	A items 2)	A items 3)	A items 4)	A items 5)	A items 6)	A items 7)	A items 8)	A items 9)	B items Present	B items 1)	B items 2)	C Present	D Present
4/4	109	Female	28	296.3	x	x	x	x	x	x	x	x	x		x	x	x	x	x
	110	Male	64	296.3	x	x	x	x	x	x	x		x		x	x	x	x	x
	111	Male	65	296.3	x	x	x	x	x	x	x	x	x		x	x	x	x	x
	112	Male	23	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	113	Male	23	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	114	Female	62	296.3	x	x	x	x	x	x	x	x	x		x	x	x	x	x
	175	Female	48	296.3	x	x	x	x	x	x	x	x	x		x	x	x	x	x
	176	Female	31	296.3	x	x	x	x	x	x	x	x	x		x	x	x	x	x
	177	Female	55	296.3	x	x	x	x	x	x	x	x	x		x	x	x	x	x
	178	Female	35	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	179	Female	43	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	180	Male	40	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
5/1	127	Male	34	296.3	x	x	x	x	x	x	x	x	x		x	x	x	x	x
	128	Female	33	296.3	x	x	x	x	x	x	x	x	x		x	x	x	x	x
	129	Male	19	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	130	Male	30	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	131	Female	43	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	132	Male	38	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
5/2	121	Female	20	296.3	x	x	x	x	x	x	x		x		x	x	x	x	x
	125	Male	48	296.3	x	x	x	x	x	x	x		x		x	x	x	x	x
5/3	133	Male	55	296.3		x	x	x	x		x	x	x		x	x	x	x	x
	134	Female	31	296.3	x	x	x	x	x		x	x	x		x	x	x	x	x
	135	Female	48	296.3	x	x	x	x	x		x		x		x	x	x	x	x
	136	Female	47	296.3	x	x	x	x	x		x		x		x	x	x	x	x
	137	Female	32	296.3	x	x	x	x	x	x	x		x		x	x	x	x	x
	138	Female	31	296.2	x	x	x	x	x		x		x		x	x	x	x	x
6/1	151	Male	43	296.2	x	x	x	x	x		x		x		x	x	x	x	x
	152	Female	56	296.3	x	x	x	x	x		x		x		x	x	x	x	x
	153	Male	50	296.3	x	x	x	x	x		x		x	x	x	x	x	x	x
	154	Female	26	296.2	x	x	x	x	x				x		x	x	x	x	x
	155	Male	63	296.3	x	x	x	x	x	x	x		x		x	x	x	x	x
	156	Female	41	296.3	x	x	x	x	x		x		x		x	x	x	x	x
6/2	157	Male	43	296.3	x	x	x		x		x		x		x	x	x	x	x
	158	Female	37	296.3	x	x	x		x		x	x	x		x	x	x	x	x
	159	Male	46	296.3	x	x	x	x	x		x		x		x	x	x	x	x
	160	Male	35	296.2	x	x	x	x	x		x		x		x	x	x	x	x
	161	Female	20	296.2	x	x	x	x	x		x		x		x	x	x	x	x
	162	Male	47	296.2	x	x	x	x	x		x		x		x	x	x	x	x

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

					A										B			C	D
						items										items			
Centre	Patient	Sex	Age	DSM-III-R	Present	1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	1)	2)	Present	Present
6/2	169	Female	53	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	170	Male	45	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	171	Female	54	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	172	Female	72	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	173	Male	44	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	174	Male	55	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
6/3	163	Male	37	296.3	X	X	X			X	X		X		X	X	X	X	X
	164	Male	29	296.3	X	X	X			X	X	X	X		X	X	X	X	X
	165	Female	54	296.3	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	166	Female	40	296.3	X	X	X			X	X	X	X		X	X	X	X	X
	167	Female	33	296.3	X	X	X	X		X	X	X	X		X	X	X	X	X
	168	Female	34	296.3	X	X	X	X		X	X	X	X		X	X	X	X	X
	505	Female	41	296.3	X	X	X	X		X	X	X			X	X	X	X	X
	506	Female	48	296.3	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	507	Female	34	296.3	X	X	X	X	X	X	X		X		X	X	X	X	X
	508	Female	52	296.3	X	X	X	X	X	X	X		X		X	X	X	X	X
	509	Male	27	296.3	X	X	X		X	X	X		X		X	X	X	X	X
	510	Female	20	296.2	X	X	X		X	X	X		X		X	X	X	X	X
	511	Female	21	296.2	X	X	X	X		X	X		X		X	X	X	X	X
	512	Female	23	296.3	X	X	X		X	X	X		X		X	X	X	X	X
	513	Female	41	296.3	X	X	X		X	X			X		X	X	X	X	X
7/02	181	Male	36	296.2	X	X			X	X	X		X		X	X	X	X	X
	182	Male	57	296.3	X	X	X	X		X	X		X		X	X	X	X	X
	183	Male	51	296.2	X	X	X	X	X		X		X		X	X	X	X	X
	184	Female	43	296.2	X	X	X		X		X		X		X	X	X	X	X
	185	Male	59	296.2	X		X		X	X	X	X			X	X	X	X	X
	186	Male	36	296.2	X	X	X		X		X	X		X	X	X	X	X	X
	535	Male	40	296.3	X		X		X	X	X		X		X	X	X	X	X
	536	Female	32	296.2	X	X	X	X	X	X	X	X			X	X	X	X	X
7/03	187	Female	49	296.2	X	X	X		X	X	X	X	X		X	X	X	X	X
	188	Male	38	296.2	X	X	X		X	X	X	X	X		X	X	X	X	X
	189	Male	50	296.3	X	X	X		X	X	X		X		X	X	X	X	X
	190	Male	43	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	191	Female	48	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	192	Female	63	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	523	Female	35	296.3	X	X	X		X		X		X	X	X	X	X	X	X
	524	Female	26	296.2	X	X	X		X	X	X	X	X		X	X	X	X	X
	525	Female	35	296.3	X	X	X		X	X	X		X		X	X	X	X	X
	526	Female	57	296.3	X	X	X		X	X		X	X		X	X	X	X	X
	527	Female	36	296.2	X	X	X		X		X	X	X		X	X	X	X	X
	528	Female	35	296.2	X	X	X	X	X		X	X			X	X	X	X	X
7/04	193	Female	64	296.2	X	X	X		X	X	X	X	X		X	X	X	X	X

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

					A									B			C	D
						items									items			
Centre	Patient	Sex	Age	DSM-III-R	Present	1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	1)	2)	Present	Present
7/04	194	Male	28	296.2	X	X	X		X	X	X	X		X	X	X	X	X	X
	195	Female	60	296.2	X	X	X		X	X	X	X	X		X	X	X	X	X
	196	Female	50	296.2	X	X	X		X	X	X	X	X		X	X	X	X	X
	197	Male	30	296.2	X	X	X		X	X	X	X	X		X	X	X	X	X
	198	Female	55	296.2	X	X	X		X	X	X	X	X		X	X	X	X	X
	199	Male	55	296.2	X	X	X		X	X	X	X	X		X	X	X	X	X
	200	Male	40	296.2	X	X	X		X	X	X	X	X		X	X	X	X	X
	201	Female	59	296.2	X	X	X		X	X	X	X	X		X	X	X	X	X
	202	Male	38	296.2	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	203	Female	41	296.2	X	X	X		X	X	X	X	X		X	X	X	X	X
	204	Female	58	296.2	X	X	X	X	X	X	X	X	X		X	X	X	X	X
7/05	205	Male	61	296.3	X	X	X		X		X	X	X		X	X	X	X	X
	206	Female	52	296.3	X	X	X	X	X		X	X	X		X	X	X	X	X
	207	Female	62	296.2	X	X	X				X	X	X		X	X	X	X	X
	208	Male	42	296.3	X	X	X		X		X	X	X		X	X	X	X	X
	209	Male	53	296.2	X	X	X		X		X	X	X		X	X	X	X	X
	210	Male	64	296.2	X	X	X		X		X	X	X		X	X	X	X	X
	541	Female	59	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	542	Male	47	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	543	Male	50	296.3	X	X	X		X	X	X	X	X	X	X	X	X	X	X
	544	Female	56	296.3	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	545	Male	55	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	546	Female	61	296.2	X	X	X		X	X	X	X	X	X	X	X	X	X	X
7/07	529	Female	57	296.3	X	X	X		X	X	X	X	X	X	X	X	X	X	X
	530	Female	53	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	531	Female	58	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	532	Female	50	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	533	Male	40	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	534	Female	45	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
8	211	Female	41	296.3	X	X	X		X		X		X		X	X	X	X	X
	212	Female	65	296.3	X	X	X	X	X		X	X	X		X	X	X	X	X
	213	Male	59	296.3		X	X		X		X		X		X	X	X	X	X
	214	Female	54	296.3	X	X	X		X		X		X		X	X	X	X	X
	215	Female	46	296.3	X	X	X	X			X		X		X	X	X	X	X
	216	Male	46	296.3	X	X	X		X		X		X		X	X	X	X	X
	217	Female	41	296.3	X	X	X		X		X		X		X	X	X	X	X
	218	Female	53	296.3	X	X	X				X	X	X		X	X	X	X	X
	219	Female	23	296.3	X	X	X				X	X	X		X	X	X	X	X
	220	Female	38	296.3	X	X	X		X		X	X	X		X	X	X	X	X
	221	Male	41	296.3	X	X	X		X		X	X	X		X	X	X	X	X
	222	Female	64	296.3		X	X		X		X		X		X	X	X	X	X
	223	Female	57	296.3	X	X	X				X	X	X		X	X	X	X	X
	224	Female	25	296.3	X	X	X		X		X		X		X	X	X	X	X
	225	Male	20	296.3	X	X	X	X	X		X		X		X	X	X	X	X

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

					A										B			C	D
						items										items			
Centre	Patient	Sex	Age	DSM-III-R	Present	1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	1)	2)	Present	Present
8	226	Male	58	296.3	X	X	X	X	X		X		X		X	X	X	X	X
	227	Male	64	296.3	X	X	X		X		X		X		X	X	X	X	X
	228	Male	31	296.3	X	X	X	X	X		X		X		X	X	X	X	X
	229	Female	55	296.3	X	X	X		X		X	X	X		X	X	X	X	X
	230	Female	43	296.3	X	X	X	X	X		X		X		X	X	X	X	X
	231	Male	46	296.3	X	X	X		X		X		X		X	X	X	X	X
	232	Male	29	296.3	X	X	X	X	X		X		X		X	X	X	X	X
	233	Female	52	296.3	X	X	X		X		X		X		X	X	X	X	X
	234	Female	65	296.3	X	X	X		X		X		X		X	X	X	X	X
8/A	235	Female	62	296.3	X	X	X				X	X		X	X	X	X	X	X
	236	Female	44	296.3	X	X	X				X		X	X	X	X	X	X	X
	237	Female	57	296.3	X	X	X		X			X	X		X	X	X	X	X
	238	Female	52	296.3	X	X	X	X	X		X		X		X	X	X	X	X
	239	Female	62	296.3	X	X	X		X		X		X		X	X	X	X	X
	240	Female	46	296.3	X	X	X		X		X		X		X	X	X	X	X
	553	Female	36	296.3	X		X		X	X	X		X		X	X	X	X	X
	554	Male	60	296.3	X	X	X		X		X	X	X		X	X	X	X	X
	555	Female	64	296.3	X	X	X		X		X			X	X	X	X	X	X
	556	Male	43	296.3	X	X	X	X	X		X		X		X	X	X	X	X
9	241	Female	43	296.3	X	X	X	X	X		X	X	X		X	X	X	X	X
	242	Female	58	296.3	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	243	Female	54	296.3	X	X	X	X	X		X		X	X	X	X	X	X	X
	244	Female	56	296.3	X	X	X	X	X		X		X	X	X	X	X	X	X
	245	Female	44	296.3	X	X	X	X	X		X	X	X		X	X	X	X	X
	246	Female	41	296.3		X	X	X	X	X		X	X		X	X	X	X	X
	247	Female	33	296.3	X	X	X		X		X	X	X		X	X	X	X	X
	248	Male	37	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	249	Female	42	296.5	X	X	X		X		X	X	X		X	X	X	X	X
	250	Female	51	296.5	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	251	Female	22	296.2	X	X	X	X	X	X		X	X	X	X	X	X	X	X
	252	Female	61	296.3	X	X	X		X		X	X	X		X	X	X	X	X
	253	Female	32	296.3	X	X	X	X	X		X	X	X	X	X	X	X	X	X
	254	Female	54	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	255	Female	24	296.2	X	X	X			X	X	X	X	X	X	X	X	X	X
	256	Female	51	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	257	Male	25	296.2	X	X	X	X	X		X	X	X		X	X	X	X	X
	258	Male	29	296.2	X	X	X		X		X	X	X		X	X	X	X	X
11	319	Male	45	296.2	X	X	X	X	X		X		X	X	X	X	X	X	X
	320	Male	34	296.3	X	X			X	X	X	X	X		X	X	X	X	X
	321	Male	45	296.3	X	X	X		X		X		X		X	X	X	X	X
	322	Female	57	296.3	X	X		X	X		X		X		X	X	X	X	X
	323	Male	36	296.2	X	X	X	X	X		X	X	X		X	X	X	X	X
	324	Male	31	296.2	X	X	X	X	X				X		X	X	X	X	X
	325	Male	58	296.2	X	X	X	X	X		X		X		X	X	X	X	X

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

					A										B			C	D
						items										items			
Centre	Patient	Sex	Age	DSM-III-R	Present	1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	1)	2)	Present	Present
11	326	Male	55	296.3	X	X	X		X		X	X	X	X	X	X	X	X	X
	327	Male	33	296.3	X	X	X		X			X	X		X	X	X	X	X
	328	Female	29	296.3	X	X	X		X			X	X	X	X	X	X	X	X
	329	Female	40	296.3	X	X	X		X		X		X		X	X	X	X	X
	330	Male	36	296.2	X	X	X	X	X		X		X		X	X	X	X	X
	331	Male	54	296.3	X	X	X		X		X	X	X		X	X	X	X	X
	332	Male	64	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	333	Male	33	296.2	X	X	X	X	X		X	X	X		X	X	X	X	X
	334	Female	36	296.2	X	X	X	X	X		X	X	X		X	X	X	X	X
	335	Male	33	296.3	X	X	X	X			X	X	X		X	X	X	X	X
	336	Female	42	296.3	X	X	X			X	X	X	X		X	X	X	X	X
	337	Female	25	296.3	X	X	X		X		X		X		X	X	X	X	X
	338	Male	29	296.2	X	X	X	X	X		X	X	X		X	X	X	X	X
12	367	Female	62	296.3	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	368	Female	40	296.2	X	X	X		X	X	X	X	X		X	X	X	X	X
	369	Female	50	296.3	X	X	X		X		X	X	X	X	X	X	X	X	X
	370	Male	60	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	371	Female	50	296.3	X	X	X	X	X		X	X			X	X	X	X	X
	372	Male	36	296.3	X	X	X	X	X	X	X		X	X	X	X	X	X	X
	373	Male	52	296.3	X	X	X	X	X	X		X	X	X	X	X	X	X	X
	374	Female	34	296.3	X	X	X				X	X	X	X	X	X	X	X	X
	375	Male	47	296.3	X	X	X			X	X	X	X	X	X	X	X	X	X
13	13	Male	44	296.3	X	X	X		X			X		X	X	X	X	X	X
	14	Male	28	296.3	X	X	X		X	X	X	X	X	X	X	X	X	X	X
	15	Female	29	296.3	X	X	X		X	X	X	X	X	X	X	X	X	X	X
	16	Male	52	296.3	X	X	X	X	X	X	X				X	X	X	X	X
	17	Male	35	296.3	X	X	X				X	X	X	X	X	X	X	X	X
	18	Male	51	296.3	X	X	X		X	X	X		X		X	X	X	X	X
	409	Male	61	296.3	X	X			X	X	X		X		X	X	X	X	X
	410	Male	45	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	411	Female	40	296.3	X	X	X		X	X	X		X	X	X	X	X	X	X
	423	Male	52	296.3	X	X	X		X		X	X	X		X	X	X	X	X
14	19	Female	52	296.3	X	X	X		X	X	X		X		X	X	X	X	X
	20	Female	59	296.3	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	21	Female	59	296.3	X	X	X		X	X	X	X	X	X	X	X	X	X	X
15	25	Female	60	296.3	X	X	X	X	X	X	X		X	X	X	X	X	X	X
	26	Male	36	296.3	X	X	X		X		X	X	X		X	X	X	X	X
	27	Female	53	296.3	X	X	X		X		X	X	X		X	X	X	X	X
	28	Female	43	296.3	X	X	X		X		X	X	X		X	X	X	X	X
	29	Male	47	296.2	X	X	X		X	X	X	X	X		X	X	X	X	X
	30	Female	44	296.3	X	X	X			X	X	X	X		X	X	X	X	X
	403	Female	44	296.2	X	X	X	X	X		X		X		X	X	X	X	X

10

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

						A items									B items		C	D
Centre	Patient	Sex	Age	DSM-III-R	Present	1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	1) 2)	Present	Present
15	404	Female	42	296.2	x	x	x		x	x	x	x			x	x x	x	x
	405	Female	49	296.2	x	x	x		x	x	x	x	x		x	x x	x	x
	406	Male	31	296.2	x	x	x	x			x	x	x		x	x x	x	x
	407	Female	40	296.3	x	x	x	x	x	x	x		x		x	x x	x	x
	408	Female	34	296.3	x	x	x		x	x	x	x		x	x	x x	x	x
	418	Female	63	296.3	x	x	x		x	x	x	x			x	x x	x	x
	419	Female	30	296.3	x	x	x		x		x	x	x	x	x	x x	x	x

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
1	6	Female	36	OTHER GU NEOPLASM NOS	
	11	Female	39	FLU W RESP MANIFEST NEC	CONGENITAL ANOMALIES NEC
	413	Male	51	ANKYLOSING SPONDYLITIS PURE HYPERCHOLESTEROLEM	
	416	Female	41	GASTRITIS/DUODENITIS NOS	ANEMIA NOS HYPOTHYROIDISM NOS
	421	Male	57		PURE HYPERGLYCERIDEMIA
	422	Male	44	ARTHROPATHY NOS	PURE HYPERCHOLESTEROLEM
2/1	49	Female	53	SPONDYLOSIS NOS OTHER GU NEOPLASM NOS OTHER GU NEOPLASM NOS	
2/2	45	Female	26	PRURITIC DISORDER NOS ALLERGIC RHINITIS NOS	
	47	Female	35	BRAIN INJURY NEC CHOLELITH W CHOLECYS NEC BENIGN NEOPLASM BREAST	
	48	Female	31	UNSPECIFIED ABORTION	
2/3	36/A	Male	53	AC INFECT POLYNEURITIS	
	39	Female	52	DIARRHEA OF INFECT ORIG ALLERGY, UNSPECIFIED	
	40	Female	59	ALCOHOL DEPENDENCE SYNDR ANOREXIA NERVOSA URIN TRACT INFECTION NOS	URIN TRACT INFECTION NOS
	41	Male	25		ABN LIVER FUNCTION STUDY

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
2/3	42	Female	40	FX TARSL/METATARS NEC-CL URIN TRACT INFECTION NOS OBESITY	ALCOHOL LIVER DAMAGE NOS URIN TRACT INFECTION NOS ALCOHOL DEPENDENCE SYNDR
2/4	32	Male	59	BACKACHE NOS ATRIAL FIBRILL/FLUTTER	ATRIAL FIBRILL/FLUTTER
	33	Male	38		ALCOHOL DEPENDENCE SYNDR
	34	Female	55	HYPOTENSION NOS CIRCULATORY DISEASE NOS	
	35	Female	64	PAIN IN LIMB	
	36	Female	57	HYPERTENSION NOS DIABETES MELLITUS UNCOMP	HYPOPOTASSEMIA
2/5	74	Male	52	ARTERITIS NOS	
3/1	453	Female	55	DIABETES MELLITUS UNCOMP PURE HYPERCHOLESTEROLEM HYPERTENSION NOS	
	454	Male	56	SENILE CATARACT RETINAL DETACHMENT NOS DIABETES MELLITUS UNCOMP	
	456	Female	39	PANNICULITIS OF NECK TACHYCARDIA NOS PREMATURE BEATS THROMBOPHLEBITIS LEG NOS	PALPITATIONS HYPOTENSION NOS
3/3	69	Male	34	ACUTE POLIOMYELITIS NOS	
	70	Male	40	SPONDYLOSIS NOS	
	71	Female	26	HEADACHE	URIN TRACT INFECTION NOS
3/4	83	Male	49	OBSTRUCT CHR BRONCHITIS	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
3/4	87	Female	33	ASTHMA NOS	
	457	Female	48	BENIGN NEO UTERUS NOS METRORRHAGIA	
	459	Female	57	HEPATITIS A W/O COMA DIAPHRAGMATIC HERNIA CERVICALGIA SCIATICA	
	461	Female	45	PULMONARY TB NOS FRACTURE NOS	
	462	Female	39	INFERTILITY-TUBAL ORIGIN	
4/1	92	Female	28		URIN TRACT INFECTION NOS
	117	Female	59	HYPOTHYROIDISM NOS	
	146	Female	55		HYPERTENSION NOS
	147	Female	65		URIN TRACT INFECTION NOS
	148	Female	59	TACHYCARDIA NOS	
4/4	110	Male	64	LOWER LEG INJURY NOS	
	112	Male	23		URIN TRACT INFECTION NOS
	178	Female	35	DIS IRON METABOLISM FX BIMALLEOLAR-CLOSED	DIS IRON METABOLISM
5/1	132	Male	38	ALCOHOL DEPENDENCE SYNDR	
5/3	138	Female	31		ABN LIVER FUNCTION STUDY

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
6/1	152	Female	56	ALCOHOL DEPENDENCE SYNDR	
	155	Male	63	PURE HYPERCHOLESTEROLEM	
	156	Female	41	HEPATITIS NOS HYPERTENSION NOS	
6/2	160	Male	35	PNEUMONIA, ORGANISM NOS	
	161	Female	20	HEARING LOSS NOS	URIN TRACT INFECTION NOS
	169	Female	53	HYPERTENSION NOS MALIGN NEOPL BREAST NOS	
7/02	182	Male	57	DUODENAL ULCER NOS	
	183	Male	51	GOITER NOS HYPERTENSION NOS	
	185	Male	59	DIABETES MELLITUS UNCOMP	
7/03	187	Female	49	GOITER NOS	GOITER NOS
	191	Female	48	OBESITY CARDIAC DYSRHYTHMIAS NEC	
	523	Female	35	STAMMERING STUTTERING PREMENSTRUAL TENSION	
	524	Female	26	EMOTIONAL DIS CHILD NOS	
	525	Female	35	OBESITY	
	526	Female	57	MYALGIA AND MYOSITIS NOS DISC DISPLACEMENT NOS OBESITY	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
7/03	527	Female	36	HEADACHE	
7/04	193	Female	64	PURE HYPERCHOLESTEROLEM	
	194	Male	28	CHRONIC LIVER DIS NEC	
	198	Female	55	HYPERLIPIDEMIA NEC/NOS	
7/05	205	Male	61	VARICOSE VEIN OF LEG NOS	
	206	Female	52	CALCULUS OF KIDNEY GOITER NOS APPENDICITIS NOS	
	207	Female	62	BACKACHE NOS APPENDICITIS NOS GASTRITIS/DUODENITIS NOS	
	210	Male	64	HEMORRHOIDS NOS CERVICOBRACHIAL SYNDROME	
	541	Female	59	CIRCULATORY DISEASE NOS	
	542	Male	47	DISC DISPLACEMENT NOS VERTEBRAL FX NOS-CLOSED STOMACH ULCER NOS	
	543	Male	50	HYPERLIPIDEMIA NEC/NOS CIRCULATORY DISEASE NOS INGUIN HERNIA W OBSTRUCT	
	544	Female	56	SPINAL CORD INJURY NOS BENIGN NEOPLASM SKIN NOS FLAT FOOT	
	545	Male	55	HYPERLIPIDEMIA NEC/NOS ABN BLOOD CHEMISTRY NEC	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
7/05	546	Female	61	HYPERLIPIDEMIA NEC/NOS BONE/CARTIL DIS NEC/NOS CIRCULATORY DISEASE NOS	
8	215	Female	46	INTEST MALABSORPTION NEC	
	218	Female	53	MALIGN NEOPL BREAST NOS OTHER GU NEOPLASM NOS	
	219	Female	23	OTHER SKIN ANOMALIES	
8/A	235	Female	62	OSTEOPOROSIS	
	238	Female	52	OSTEOPOROSIS	
	239	Female	62	CHR ISCHEMIC HRT DIS NEC	
	554	Male	60	DIABETES MELLITUS UNCOMP HYPERTENSION NOS	
	555	Female	64	HYPERTENSION NOS	
9	241	Female	43	VARICOSE VEIN OF LEG NOS CERVICITIS ACUTE APPENDICITIS NOS	
	244	Female	56	DUODENAL ULCER NOS	
	249	Female	42		ABN URINE FINDINGS NEC
	250	Female	51	HYPERTENSION NOS	
	252	Female	61	HYPERTENSION NOS	
11	325	Male	58	ACUTE POLIOMYELITIS NOS	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
11	329	Female	40	HYPERTENSION NOS	
	332	Male	64	HYPERTENSION NOS	
	333	Male	33	OBESITY	
	336	Female	42	OTHER GU NEOPLASM NOS PNEUMONIA, ORGANISM NOS	
12	367	Female	62	HYPERTENSION NOS	
	370	Male	60	HYPERTENSION NOS	
	372	Male	36	OBESITY	
	373	Male	52	STOMACH ULCER NOS	
	374	Female	34	MIGRAINE NOS	
	375	Male	47	DIGESTIVE NEOPLASM NOS AC PERICARDITIS NEC/NOS	
13	13	Male	44	PNEUMOTHORAX ACUTE BRONCHITIS	
	15	Female	29	BRONCHITIS NOS PNEUMONIA, ORGANISM NOS	
	16	Male	52	OTHER PSORIASIS	
14	21	Female	59	THYROTOXICOSIS NOS	
15	25	Female	60	SARCOIDOSIS DIVERTICULA OF COLON	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
15	27	Female	53	OTHER GU NEOPLASM NOS MALIGN NEOPL BREAST NOS ACUTE APPENDICITIS NOS PEPTIC ULCER NOS	
	29	Male	47	THORAC/LUMB DISC DISPLAC	
	403	Female	44	CERVICAL SPONDYLOSIS	
	404	Female	42	CHONDRODYSTROPHY	
	405	Female	49	PARAPSORIASIS	
	418	Female	63	OSTEITIS DEFORMANS NOS	
	419	Female	30	TRUNK INJURY NOS BONE/CARTIL DIS NEC/NOS ASTHMA NOS	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
1	1	Female	Screen		Not done	
	2	Male	Screen		Not done	
	3	Male	Screen	02/05/91	Normal	
	4	Male	Screen	04/06/91	Normal	
	5	Female	Screen	12/06/91	Normal	
	6	Female	Screen	24/05/91	Normal	
	7	Female	Screen	28/08/91	Normal	
	8	Male	Screen	06/09/91	Normal	
	9	Female	Screen	28/11/91	Normal	
	10	Male	Screen	25/09/91	Normal	
	11	Female	Screen	10/10/91	Normal	
	12	Female	Screen	25/10/91	Normal	
	412	Male	Screen	12/11/91	Normal	
	413	Male	Screen	03/12/91	Normal	
	414	Female	Screen	20/01/92	Normal	
	415	Male	Screen	14/01/92	Normal	
	416	Female	Screen	20/01/92	Normal	

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
1	421	Male	Screen	27/02/92	Normal	
	422	Male	Screen	05/08/92	Normal	
2/1	49	Female	Screen	16/05/91	Normal	
	50	Female	Screen	24/12/91	Normal	
	51	Female	Screen	28/01/92	Normal	
2/2	43	Female	Screen		Not done	
	44	Female	Screen		Not done	
	45	Female	Screen		Not done	
	46	Female	Screen		Not done	
	47	Female	Screen	13/03/92	Normal	
	48	Female	Screen	03/04/92	Normal	
2/3	36/A	Male	Screen	06/03/91	Normal	
	37	Female	Screen	23/03/91	Normal	
	38	Male	Screen	23/05/91	Normal	
	39	Female	Screen	06/08/91	Normal	
	40	Female	Screen	22/10/91	Normal	
	41	Male	Screen	10/10/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
2/3	42	Female	Screen	07/05/92	Normal	
2/4	31	Male	Screen		Not done	
	32	Male	Screen		Not done	
	33	Male	Screen		Not done	
	34	Female	Screen		Not done	
	35	Female	Screen		Normal	
	36	Female	Screen		Not done	
2/5	73	Male	Screen	28/01/92	Normal	
	74	Male	Screen	16/06/92	Normal	
	75	Male	Screen	03/09/92	Normal	
	76	Female	Screen	29/09/92	Normal	
	77	Male	Screen	15/09/92	Normal	
	78	Female	Screen	29/09/92	Normal	
2/6	55	Female	Screen		Not done	
	56	Female	Screen		Not done	
	57	Female	Screen		Not done	
	58	Female	Screen		Not done	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function Assessment	Date	Value	Abnormality
2/6	59	Male	Screen		Not done	
	60	Female	Screen		Not done	
3/1	61	Male	Screen		Not done	
	62	Female	Screen	12/04/91	Normal	
	63	Male	Screen	10/05/91	Normal	
	64	Female	Screen		Not done	
	65	Male	Screen	11/09/91	Normal	
	66	Male	Screen		Not done	
	139	Male	Screen		Not done	
	140	Male	Screen		Not done	
	141	Female	Screen		Not done	
	142	Female	Screen		Not done	
	143	Female	Screen		Not done	
	144	Female	Screen		Not done	
	451	Female	Screen		Not done	
	452	Male	Screen		Not done	
	453	Female	Screen		Not done	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Pulmonary Function Value	Abnormality
3/1	454	Male	Screen		Not done	
	455	Female	Screen		Not done	
	456	Female	Screen		Not done	
3/2	65/A	Female	Screen	28/01/91	Normal	
3/3	67	Male	Screen	16/07/91	Normal	
	68	Male	Screen	13/01/92	Normal	
	69	Male	Screen	30/01/92	Normal	
	70	Male	Screen	10/04/92	Normal	
	71	Female	Screen	14/04/92	Normal	
	72	Male	Screen	19/07/92	Normal	
3/4	79	Female	Screen	13/05/91	Normal	
	80	Male	Screen	91	Normal	
	81	Female	Screen	14/05/91	Normal	
	82	Male	Screen	18/06/91	Normal	
	83	Male	Screen	17/10/90	Normal	
	84	Female	Screen	08/10/91	Normal	
	85	Female	Screen	29/10/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
3/4	86	Male	Screen	03/12/91	Normal	
	87	Female	Screen	06/12/91	Normal	
	88	Male	Screen		Not done	
	89	Female	Screen		Normal	
	90	Male	Screen	91	Normal	
	457	Female	Screen	19/05/92	Normal	
	458	Female	Screen	28/01/92	Normal	
	459	Female	Screen	01/06/92	Normal	
	460	Male	Screen		Not done	
	461	Female	Screen		Normal	
	462	Female	Screen		Normal	
4/1	91	Female	Screen	01/01/91	Normal	
	92	Female	Screen	05/08/91	Normal	
	93	Male	Screen	29/06/91	Normal	
	94	Female	Screen	29/06/91	Normal	
	95	Female	Screen	06/06/91	Normal	
	96	Female	Screen	30/08/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
4/1	115	Female	Screen	04/05/92	Abnormal	PULMON CIRCULAT DIS NOS
	116	Female	Screen	07/05/92	Normal	
	117	Female	Screen	02/09/91	Normal	
	118	Female	Screen	19/05/92	Normal	
	119	Female	Screen		Not done	
	120	Female	Screen		Normal	
	145	Female	Screen	30/09/92	Normal	
	146	Female	Screen	31/07/92	Normal	
	147	Female	Screen	15/07/92	Normal	
	148	Female	Screen	10/09/92	Normal	
	149	Male	Screen	22/09/92	Normal	
	150	Male	Screen	23/09/92	Normal	
4/2	93/A	Male	Screen	22/02/91	Normal	
	99/A	Male	Screen	09/04/91	Normal	
	104	Male	Screen	11/06/91	Normal	
4/3	97	Male	Screen	15/04/91	Normal	
	98	Female	Screen	18/06/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function Assessment	Date	Value	Abnormality
4/3	99	Female	Screen	07/08/91	Abnormal	ENLARGEMENT LYMPH NODES
	100	Female	Screen	20/11/91	Normal	
	101	Male	Screen	16/03/92	Normal	
4/4	109	Female	Screen	05/06/91	Normal	
	110	Male	Screen	04/06/91	Normal	
	111	Male	Screen	10/05/91	Normal	
	112	Male	Screen	09/07/91	Normal	
	113	Male	Screen	06/09/91	Normal	
	114	Female	Screen	07/11/91	Normal	
	175	Female	Screen	05/02/91	Normal	
	176	Female	Screen	13/03/92	Normal	
	177	Female	Screen	24/04/92	Normal	
	178	Female	Screen	21/04/92	Normal	
	179	Female	Screen	09/09/92	Normal	
	180	Male	Screen	19/09/92	Normal	
5/1	127	Male	Screen	31/05/91	Normal	
	128	Female	Screen	13/06/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Chest X-Ray - Pulmonary Function Date	Value	Abnormality
5/1	129	Male	Screen	23/12/91	Normal	
	130	Male	Screen	02/03/92	Normal	
	131	Female	Screen	24/03/92	Normal	
	132	Male	Screen	04/06/92	Normal	
5/2	121	Female	Screen		Not done	
	125	Male	Screen		Not done	
5/3	133	Male	Screen	26/11/91	Normal	
	134	Female	Screen	04/12/91	Normal	
	135	Female	Screen	08/01/92	Normal	
	136	Female	Screen		Not done	
	137	Female	Screen	13/05/92	Normal	
	138	Female	Screen	14/05/92	Normal	
6/1	151	Male	Screen	15/01/91	Abnormal	CHRONIC BRONCHITIS NOS
	152	Female	Screen	14/07/92	Abnormal	FX RIB/STERN/LARYN/TRACH
	153	Male	Screen	07/03/91	Normal	
	154	Female	Screen	18/03/92	Normal	
	155	Male	Screen		Not done	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
6/1	156	Female	Screen		Not done	
6/2	157	Male	Screen	23/04/91	Abnormal	LUNG DISEASE NEC
	158	Female	Screen	21/11/91	Normal	
	159	Male	Screen	11/07/91	Normal	
	160	Male	Screen	22/11/91	Normal	
	161	Female	Screen	06/02/92	Normal	
	162	Male	Screen	05/07/91	Normal	
	169	Female	Screen	22/10/91	Normal	
	170	Male	Screen	28/10/91	Normal	
	171	Female	Screen	18/07/92	Normal	
	172	Female	Screen		Not done	
	173	Male	Screen		Normal	
	174	Male	Screen	05/05/92	Normal	
6/3	163	Male	Screen		Not done	
	164	Male	Screen		Not done	
	165	Female	Screen	08/10/91	Normal	
	166	Female	Screen		Not done	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Pulmonary Function Value	Abnormality
6/3	167	Female	Screen	91	Normal	
	168	Female	Screen	25/11/92	Normal	
	505	Female	Screen	91	Normal	
	506	Female	Screen	06/01/92	Normal	
	507	Female	Screen	07/01/92	Normal	
	508	Female	Screen	01/02/92	Normal	
	509	Male	Screen		Not done	
	510	Female	Screen		Not done	
	511	Female	Screen		Not done	
	512	Female	Screen		Not done	
	513	Female	Screen		Not done	
7/02	181	Male	Screen		Not done	
	182	Male	Screen		Not done	
	183	Male	Screen		Not done	
	184	Female	Screen		Not done	
	185	Male	Screen		Not done	
	186	Male	Screen		Not done	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Chest X-Ray - Pulmonary Function Date	Value	Abnormality
7/02	535	Male	Screen		Not done	
	536	Female	Screen		Not done	
7/03	187	Female	Screen		Not done	
	188	Male	Screen		Normal	
	189	Male	Screen	10/02/92	Normal	
	190	Male	Screen	21/01/92	Normal	
	191	Female	Screen		Normal	
	192	Female	Screen		Not done	
	523	Female	Screen	28/04/92	Normal	
	524	Female	Screen		Normal	
	525	Female	Screen		Normal	
	526	Female	Screen		Normal	
	527	Female	Screen		Normal	
	528	Female	Screen		Normal	
7/04	193	Female	Screen		Not done	
	194	Male	Screen		Not done	
	195	Female	Screen		Not done	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Chest X-Ray - Pulmonary Function Date	Value	Abnormality
7/04	196	Female	Screen		Not done	
	197	Male	Screen		Not done	
	198	Female	Screen		Not done	
	199	Male	Screen		Not done	
	200	Male	Screen		Not done	
	201	Female	Screen		Not done	
	202	Male	Screen		Not done	
	203	Female	Screen		Not done	
	204	Female	Screen		Not done	
7/05	205	Male	Screen	30/12/91	Normal	
	206	Female	Screen	14/01/92	Normal	
	207	Female	Screen	21/01/92	Normal	
	208	Male	Screen	24/01/92	Normal	
	209	Male	Screen	29/01/92	Normal	
	210	Male	Screen	03/02/92	Normal	
	541	Female	Screen	02/03/92	Normal	
	542	Male	Screen	02/03/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Chest X-Ray - Pulmonary Function Abnormality Date	Value
7/05	543	Male	Screen	03/03/92	Normal
	544	Female	Screen	04/03/92	Normal
	545	Male	Screen	09/03/92	Normal
	546	Female	Screen	10/03/92	Normal
7/07	529	Female	Screen		Not done
	530	Female	Screen		Not done
	531	Female	Screen		Not done
	532	Female	Screen		Not done
	533	Male	Screen		Not done
	534	Female	Screen		Normal
8	211	Female	Screen		Not done
	212	Female	Screen		Not done
	213	Male	Screen		Not done
	214	Female	Screen		Not done
	215	Female	Screen		Not done
	216	Male	Screen		Not done
	217	Female	Screen		Not done

15

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
8	218	Female	Screen		Not done	
	219	Female	Screen		Not done	
	220	Female	Screen		Not done	
	221	Male	Screen		Not done	
	222	Female	Screen		Not done	
	223	Female	Screen		Not done	
	224	Female	Screen		Not done	
	225	Male	Screen		Not done	
	226	Male	Screen		Not done	
	227	Male	Screen		Not done	
	228	Male	Screen		Not done	
	229	Female	Screen		Not done	
	230	Female	Screen		Not done	
	231	Male	Screen		Not done	
	232	Male	Screen		Not done	
	233	Female	Screen		Not done	
	234	Female	Screen		Not done	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Chest X-Ray - Pulmonary Function Date	Value	Abnormality
8/A	235	Female	Screen		Not done	
	236	Female	Screen		Not done	
	237	Female	Screen		Not done	
	238	Female	Screen		Not done	
	239	Female	Screen		Not done	
	240	Female	Screen		Not done	
	553	Female	Screen		Not done	
	554	Male	Screen		Not done	
	555	Female	Screen		Not done	
	556	Male	Screen		Not done	
9	241	Female	Screen	12/02/91	Normal	
	242	Female	Screen		Not done	
	243	Female	Screen		Not done	
	244	Female	Screen		Not done	
	245	Female	Screen	18/02/91	Normal	
	246	Female	Screen		Not done	
	247	Female	Screen		Not done	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
9	248	Male	Screen	21/03/91	Abnormal	CHRONIC BRONCHITIS NOS
	249	Female	Screen		Not done	
	250	Female	Screen	12/03/91	Normal	
	251	Female	Screen	21/03/91	Normal	
	252	Female	Screen		Not done	
	253	Female	Screen	02/04/91	Normal	
	254	Female	Screen	04/04/91	Normal	
	255	Female	Screen	14/05/91	Normal	
	256	Female	Screen		Not done	
	257	Male	Screen	23/06/91	Normal	
	258	Male	Screen	28/06/91	Normal	
11	319	Male	Screen	25/07/91	Normal	
	320	Male	Screen	08/08/91	Normal	
	321	Male	Screen	23/08/91	Normal	
	322	Female	Screen	19/09/91	Normal	
	323	Male	Screen	07/11/91	Normal	
	324	Male	Screen	02/12/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
11	325	Male	Screen	09/12/91	Normal	
	326	Male	Screen	15/01/92	Normal	
	327	Male	Screen	24/01/92	Normal	
	328	Female	Screen	29/01/92	Not done	
	329	Female	Screen	01/04/92	Normal	
	330	Male	Screen	07/04/92	Normal	
	331	Male	Screen	13/04/92	Normal	
	332	Male	Screen	13/05/92	Normal	
	333	Male	Screen	19/05/92	Normal	
	334	Female	Screen	21/05/92	Normal	
	335	Male	Screen	22/05/92	Normal	
	336	Female	Screen	16/06/92	Normal	
	337	Female	Screen	25/06/92	Normal	
	338	Male	Screen	15/07/92	Normal	
12	367	Female	Screen	16/12/91	Normal	
	368	Female	Screen	07/01/92	Normal	
	369	Female	Screen	22/04/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Chest X-Ray - Pulmonary Function Abnormality Date	Value
12	370	Male	Screen	17/04/92	Normal
	371	Female	Screen	21/04/92	Normal
	372	Male	Screen	01/06/92	Normal
	373	Male	Screen	05/04/92	Normal
	374	Female	Screen		Normal
	375	Male	Screen	08/06/92	Normal
13	13	Male	Screen	12/04/91	Normal
	14	Male	Screen		Not done
	15	Female	Screen	01/07/91	Normal
	16	Male	Screen		Not done
	17	Male	Screen		Not done
	18	Male	Screen		Not done
	409	Male	Screen		Normal
	410	Male	Screen		Not done
	411	Female	Screen	01/04/92	Normal
	423	Male	Screen		Not done
14	19	Female	Screen	06/04/92	Normal

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
14	20	Female	Screen	27/04/92	Normal	
	21	Female	Screen	16/07/92	Normal	
15	25	Female	Screen	17/06/91	Abnormal	ENLARGEMENT LYMPH NODES
	26	Male	Screen	17/06/91	Normal	
	27	Female	Screen	27/06/91	Normal	
	28	Female	Screen	06/08/91	Normal	
	29	Male	Screen	29/08/91	Normal	
	30	Female	Screen	03/09/91	Normal	
	403	Female	Screen	04/10/91	Normal	
	404	Female	Screen	10/09/91	Abnormal	ASTHMA NOS
	405	Female	Screen	11/11/91	Normal	
	406	Male	Screen	27/11/91	Normal	
	407	Female	Screen	02/12/91	Normal	
	408	Female	Screen	15/01/92	Normal	
	418	Female	Screen	30/01/92	Normal	
	419	Female	Screen	27/04/92	Abnormal	TRACHEA/BRONCHUS DIS NEC

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Previous antidepressive treatment Name	Efficacy	Side effects	Last taken	Last day of treat.
1	1	Female	35	ANAFRANIL	Good	Y	***	25/12/90
	2	Male	49	AMITRIPTYLINE	Good	Y	***	11/04/91
	3	Male	41	LITHIUM TRYPTANOL	Fair Fair		***	29/04/91
	5	Female	57	ANAFRANIL SURMONTIL	Good Good		***	08/10/90
	6	Female	36	PROZAC TRYPTANOL	Good Good	Y Y	***	03/91
	8	Male	49	SINEQUAN	Good		***	88
	9	Female	38	TRYPTANOL	Good		***	11/90
	10	Male	32	NARDIL PROTHIADEN	Poor Poor		***	15/09/91
	11	Female	39	SURMONTIL FLUOXETINE	Fair Good	Y	***	07/06/91
	12	Female	30	TRIMIPRAMINE	Good		***	28/09/91
	412	Male	41	SINEQUAN	Poor		***	12/11/91
	413	Male	51	SINEQUAN TOLVON SURMONTIL	Good Poor Good		***	05/12/88
	414	Female	47	SURMONTIL TOLVON	Good Good		***	16/01/92
	415	Male	40	PROTHIADEN	Good		***	24/12/91

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Previous antidepressive treatment Name	Efficacy	Side effects	Last taken	Last day of treat.
1	421	Male	57	TRIMIPRAMINE	Good		***	06/86
2/1	49	Female	53	ANAFRANIL	Very poor		***	11/05/91
2/2	47	Female	35	CHLORIMIPRAMINE	Poor		***	13/03/92
	48	Female	31	DOSULEPIN	Poor		***	03/04/92
2/3	36/A	Male	53	MACLAMINE			***	26/02/91
	39	Female	52	CLOMIPRAMINE	Fair		***	31/07/91
	41	Male	25	FLUVOXAMINE	Fair		***	20/09/91
2/4	36	Female	57	MACLAMINE	Good		***	04/02/91
2/5	75	Male	50	TRIMIPRAMINE CLOMIPRAMINE MIANSERIN	Fair Good Poor		***	02/09/92
	77	Male	38	INIPRAMINE FLUOXETINE TRIMIPRAMINE	Poor Good Good		***	14/09/92
	78	Female	51	CLOMIPRAMINE	Very poor		***	28/09/92
3/1	64	Female	57	SURMONTIL CLEDIAL	Very poor Poor	Y	***	26/02/91
	139	Male	31	LUDIOMIL	Very poor		***	27/08/91
	140	Male	56	FLOXYFRAL	Fair		***	15/04/91
	141	Female	40	PROTHIADEN PROZAC	Poor Poor		***	25/09/91

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

				Previous antidepressive treatment				
Centre	Patient	Sex	Age	Name	Efficacy	Side effects	Last taken	Last day of treat.
3/1	143	Female	44	LUDIOMIL	Poor			
	451	Female	57	SURMONTIL	Poor		***	15/01/92
	452	Male	44	LUDIOMIL	Poor		***	16/01/92
	453	Female	55	VIVALAN STABLON	Good Fair		***	91
	454	Male	56	LAROXYL	Poor		***	14/02/92
	455	Female	47	STABLON	Poor		***	04/03/92
3/2	65/A	Female	21	PROZAC SURMONTIL	Poor Poor		***	22/01/91
3/3	67	Male	38	CLOMIPRAMINE IMIPRAMINE	Fair Good		***	04/91
	68	Male	45	PROTHIADEN	Good		***	84
	69	Male	34	TRIMIPRAMINE	Fair		***	29/01/92
	70	Male	40	MIANSERIN	Poor			
	71	Female	26	AMOXAPINE	Poor		***	09/04/92
3/4	79	Female	45	HUMORYL	Poor		***	15/02/90
	81	Female	35	CLOMIPRAMINE	Poor		***	14/05/91
	83	Male	49	VILOXAZINE	Poor		***	23/04/91

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

				Previous antidepressive treatment				
Centre	Patient	Sex	Age	Name	Efficacy	Side effects	Last taken	Last day of treat.
3/4	89	Female	49	PROZAC	Poor		***	08/03/92
	90	Male	47	LAROXYL	Poor	Y	***	22/04/92
	457	Female	48	CLOMIPRAMINE	Very good	Y	***	08/91
	458	Female	43	TIANEPTINE FLUOXETINE	Fair Good		***	15/04/92
	461	Female	45	STABLON	Poor		***	31/08/92
4/1	93	Male	18	PRAGMAREL	Fair		***	02/06/91
	95	Female	42	TIMAXEL	Good		***	04/87
	119	Female	46	STABLON				
	147	Female	65	VIVALAN ANAFRANIL PROTHIADEN	Very poor Poor Good		***	09/91
4/2	93/A	Male	48	ANAFRANIL LITHIUM	Fair		*** ***	01/10/90
	104	Male	57	LAROXYL	Fair		***	30/11/90
4/3	97	Male	42	SURVECTOR	Poor		***	10/04/91
	98	Female	58	ANAFRANIL - SLOW RELEASE	Fair		***	15/06/91
	100	Female	24	FLOXYFRAL	Poor		***	10/09/91
	101	Male	55	PROZAC	Very poor		***	25/11/91
4/4	110	Male	64	LUDIOMIL	Poor			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Previous antidepressive treatment Name	Efficacy	Side effects	Last taken	Last day of treat.
4/4	111	Male	65	CLOMIPRAMINE	Poor		***	26/06/91
	112	Male	23	MIANSERIN	Very poor		***	04/07/91
	114	Female	62	PROTHIADEN	Poor		***	13/11/91
	179	Female	43	PROZAC	Very poor		***	06/09/92
	180	Male	40	ATHYMIL STABLON	Poor Poor		***	29/09/92
5/1	127	Male	34	FLOXYFRAL	Poor		***	28/05/91
	128	Female	33	PROZAC	Poor			
	131	Female	43	FLUVOXAMINE	Poor		***	09/03/92
5/2	125	Male	48	AMINEPTINE FLUVOXAMINE	Poor Poor		***	20/01/91
5/3	134	Female	31	PROZAC	Fair		***	23/11/91
6/1	152	Female	56	CLOMIPRAMINE	Very poor	Y	***	17/02/92
	153	Male	50	CLEDIAL FLUOXETINE IMIPRAMINE	Poor Good Good	Y	***	18/02/91
	155	Male	63	CLOMIPRAMINE	Poor	Y	***	01/07/92
	156	Female	41	CLOMIPRAMINE	Fair		***	89
6/2	157	Male	43	VIVALAN	Poor		***	10/04/91

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Previous antidepressive treatment Name	Efficacy	Side effects	Last taken	Last day of treat.
6/2	158	Female	37	QUITAXON PERTOFRAN	Poor Poor		***	10/11/91
	169	Female	53	FLUOXETINE	Very good		***	06/91
	170	Male	45	VIVALAN	Fair		***	02/90
6/3	163	Male	37	PROZAC	Poor		***	15/05/91
	164	Male	29	STABLON	Poor		***	07/10/91
	165	Female	54	PROZAC	Poor		***	01/10/91
	166	Female	40	MAPROTILINE	Poor		***	16/10/91
	167	Female	33	FLUOXETINE CLOMIPRAMINE	Fair Poor		***	01/06/91
	168	Female	34	DOSULEPIN	Poor		***	25/11/91
	505	Female	41	PROZAC	Poor		***	19/11/91
	506	Female	48	PROZAC	Poor		***	16/12/91
	507	Female	34	STABLON FLOXYFRAL	Poor Poor		***	06/01/92
	508	Female	52	MEDIFOXAMINE PROZAC	Poor Good		***	28/01/92
	509	Male	27	ANAFRANIL	Fair			
	512	Female	23	ANAFRANIL	Good		***	01/12/90

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

				Previous antidepressive treatment				
Centre	Patient	Sex	Age	Name	Efficacy	Side effects	Last taken	Last day of treat.
6/3	513	Female	41	KINUPRIL	Poor		***	28/04/92
7/02	181	Male	36	SAROTEN RETARD	Fair	Y	***	17/01/92
	182	Male	57	AMITRIPTYLINE APONAL	Fair Poor		***	10/11/91
	183	Male	51	FLUOXETINE	Very poor	Y	***	30/11/91
	184	Female	43	DOXEPIN	Poor	Y	***	17/01/92
7/05	205	Male	61	FLUOXETINE	Fair		***	29/12/91
	541	Female	59	FLUOXETINE	Good		***	23/07/91
	542	Male	47	FLUOXETINE			***	02/12/91
	543	Male	50	NOVERIL - SLOW RELEASE	Good		***	17/05/91
	544	Female	56	NOVERIL - SLOW RELEASE	Fair			
	545	Male	55	STANGYL	Fair		***	11/02/92
7/07	530	Female	53	LUDIOMIL	Poor		***	16/02/92
	533	Male	40	DOXEPIN	Poor		***	27/04/92
8	211	Female	41	CLOMIPRAMINE	Good		***	01/02/91
	213	Male	59	CLOMIPRAMINE	Good		***	01/08/91
	214	Female	54	CLOMIPRAMINE	Good		***	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

				Previous antidepressive treatment				
Centre	Patient	Sex	Age	Name	Efficacy	Side effects	Last taken	Last day of treat.
8	215	Female	46	AMITRIPTYLINE	Good		***	12/91
	216	Male	46	CLOMIPRAMINE	Good		***	89
	219	Female	23	FLUVOXAMINE	Poor		***	02/92
	220	Female	38	CLOMIPRAMINE	Fair		***	12/90
	224	Female	25	FLUOXETINE	Good		***	90
	226	Male	58	CLOMIPRAMINE	Good		***	
	227	Male	64	AMITRIPTYLINE	Fair		***	91
	229	Female	55	MIANSERIN CLOMIPRAMINE	Good Fair		***	91
	230	Female	43	MIANSERIN CLOMIPRAMINE	Fair Good		***	02/92
	231	Male	46	FLUOXETINE	Good		***	91
	233	Female	52	MIANSERIN	Good		***	
	234	Female	65	MIANSERIN	Good		***	91
8/A	236	Female	44	FEVARIN	Fair		***	18/09/92
	238	Female	52	FLUVOXAMINE	Fair		***	18/09/92
	239	Female	62	FEVARIN	Good		***	22/09/92
	240	Female	46	CLOMIPRAMINE HYDROCHLORIDE	Good	Y	***	22/09/92

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

				Previous antidepressive treatment				
Centre	Patient	Sex	Age	Name	Efficacy	Side effects	Last taken	Last day of treat.
8/A	554	Male	60	CLOMIPRAMINE HYDROCHLORIDE	Fair	Y	***	22/08/92
	555	Female	64	AMITRIPTYLINE HYDROCHLORIDE	Good	Y	***	22/09/92
	556	Male	43	FLUOXETINE	Fair		***	22/09/92
9	241	Female	43	AMITRIPTYLINE	Poor			
	242	Female	58	LITHIUM	Poor		***	12/01/91
	243	Female	54	FLUVOXAMINE	Poor		***	15/02/91
	244	Female	56	LITHIUM CHLORIMIPRAMINE AMITRIPTYLINE	Poor Good Good		***	11/02/91
	246	Female	41	CARBOLITHIUM AMITRIPTYLINE	Poor Good		***	13/02/91
	247	Female	33	CHLORIMIPRAMINE IMIPRAMINE	Good Good			
	248	Male	37	CHLORIMIPRAMINE	Good			
	249	Female	42	CHLORIMIPRAMINE	Good			
	250	Female	51	AMITRIPTYLINE FLUOXETINE NORTRIPTYLINE	Good Very poor Good		***	07/03/91
	252	Female	61	NORTRIPTYLINE	Poor			
	253	Female	32	FLUVOXAMINE AMITRIPTYLINE AMINEPTINE	Poor Fair Poor		***	28/03/91

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Previous antidepressive treatment Name	Efficacy	Side effects	Last taken	Last day of treat.
9	255	Female	24	CLOMIPRAMINE	Poor		***	18/04/91
	256	Female	51	NORTRIPTYLINE	Very poor		***	10/05/91
11	320	Male	34	TRAZODONE	Good	Y	***	05/91
	321	Male	45	PROTHIADEN	Fair		***	05/91
	322	Female	57	DOXEPIN	Poor		***	08/91
	326	Male	55	LOFEPRAMINE AMITRIPTYLINE NIANSERIN TRIMIPRAMINE	Very poor Poor Poor Good	 Y 	***	10/91
	329	Female	40	PROTHIADEN PAROXETINE	Poor Poor	 Y	***	31/03/92
	331	Male	54	LOFEPRAMINE	Poor		***	07/04/92
	332	Male	64	LOFEPRAMINE FLUOXETINE	Very poor Good		***	07/05/92
	334	Female	36	FLUOXETINE	Poor	Y	***	17/05/92
	335	Male	33	FLUOXETINE	Poor		***	06/05/92
	336	Female	42	IMIPRAMINE LOFEPRAMINE	Poor Poor		***	89
	337	Female	25	FLUOXETINE PROTHIADEN LOFEPRAMINE	Very poor Very poor Very poor	 Y 	***	16/06/92
12	369	Female	50	CHLORIMIPRAMINE	Fair		***	14/04/92

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

				Previous antidepressive treatment				
Centre	Patient	Sex	Age	Name	Efficacy	Side effects	Last taken	Last day of treat.
12	370	Male	60	DESIPRAMINE	Poor		***	23/04/92
	371	Female	50	FLUOXETINE	Fair		***	17/04/92
	375	Male	47	IMIPRAMINE	Poor		***	09/06/92
13	13	Male	44	PROTHIADEN	Poor			
	14	Male	28	TOLVON	Fair		***	05/91
				TOFRANIL	Poor	Y		
				PARNATE	Poor			
				LITHIUM	Poor			
				PROTHIADEN	Poor			
	15	Female	29	TOFRANIL	Fair		***	16/06/91
				LITHIUM	Poor			
	16	Male	52	PARNATE	Fair	Y	***	16/11/91
	17	Male	35	LITHIUM	Fair			
	18	Male	51	ANAFRANIL	Fair	Y	***	15/06/92
	409	Male	61	AMITRIPTYLINE	Fair		***	11/91
	410	Male	45	AMITRIPTYLINE	Good	Y	***	07/02/92
				PARNATE	Fair			
	411	Female	40	PARNATE	Fair	Y	***	17/03/92
	423	Male	52	PROTHIADEN	Fair	Y	***	04/92
14	19	Female	52	TRANYLCYPROMINE	Very poor		***	01/04/92
				AMITRIPTYLINE	Very poor			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

				Previous antidepressive treatment				
Centre	Patient	Sex	Age	Name	Efficacy	Side effects	Last taken	Last day of treat.
14	20	Female	59	VENLAFAXINE	Very good		***	15/02/90
15	25	Female	60	DOTHIEPIN	Fair	Y	***	24/03/91
	26	Male	36	VENLAFAXINE	Very good	Y	***	02/08/90
	27	Female	53	VENLAFAXINE	Very good			
	28	Female	43	VENLAFAXINE	Very good		***	02/08/90
	29	Male	47	DESIPRAMINE	Poor	Y	***	22/08/91
				DOTHIEPIN	Poor	Y		
	408	Female	34	CLOMIPRAMINE	Poor	Y	***	10/01/92

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
1	1	25/12/90	26/12/90	09/04/91	106	10/04/91	Imipramine
	2	11/04/91	12/04/91	14/04/91	4	15/04/91	Reboxetine
	3	29/04/91	30/04/91	05/05/91	7	06/05/91	Imipramine
	4		28/05/91	03/06/91	7	04/06/91	Placebo
	5	08/10/90	20/05/91	11/06/91	23	12/06/91	Reboxetine
	6	03/91	01/04/91	22/05/91	52	23/05/91	Placebo
	7			26/08/91		27/08/91	Reboxetine
	8	88	02/01/88	04/09/91	1343	05/09/91	Placebo
	9	11/90	27/11/90	26/11/91	365	27/11/91	Reboxetine
	10	15/09/91	16/09/91	23/09/91	8	24/09/91	Placebo
	11	07/06/91	04/10/91	09/10/91	6	10/10/91	Imipramine
	12	28/09/91	29/09/91	17/10/91	20	18/10/91	Imipramine
	412	12/11/91	13/11/91	12/11/91	0	13/11/91	Reboxetine
	413	05/12/88	03/12/91	08/12/91	6	09/12/91	Placebo
	414	16/01/92	17/01/92	21/01/92	5	22/01/92	Imipramine
	415	24/12/91	25/12/91	13/01/92	21	14/01/92	Imipramine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (a)	Days	Start date	Randomized
1	416		14/01/92	16/01/92	3	17/01/92	Reboxetine
	421	06/86	02/06/86	26/02/92	2097	27/02/92	Imipramine
	422		23/07/92	04/08/92	13	05/08/92	Imipramine
2/1	49	11/05/91	12/05/91	17/05/91	6	18/05/91	Placebo
	50		23/12/91	26/12/91	4	27/12/91	Reboxetine
	51		29/01/92	01/02/92	4	02/02/92	Imipramine
2/2	43			17/04/91		18/04/91	Imipramine
	44		30/06/91	18/07/91	19	19/07/91	Imipramine
	45		90	07/09/91	615	08/09/91	Reboxetine
	46		16/09/91	25/09/91	10	26/09/91	Placebo
	47	13/03/92	14/03/92	23/03/92	11	24/03/92	Placebo
	48	03/04/92	04/04/92	06/04/92	4	07/04/92	Reboxetine
2/3	36/A	26/02/91	27/02/91	06/03/91	9	07/03/91	Imipramine
	37		09/02/91	26/03/91	46	27/03/91	Reboxetine
	38			13/08/91		14/08/91	Placebo
	39	31/07/91	01/08/91	09/08/91	9	10/08/91	Imipramine

(*) if missing date = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
2/3	40		17/10/91	23/10/91	7	24/10/91	Reboxetine
	41	20/09/91	21/09/91	02/10/91	13	03/10/91	Placebo
	42		06/05/92	18/05/92	13	19/05/92	Imipramine
2/4	31		18/03/91	25/03/91	8	26/03/91	Placebo
	32		18/10/91	25/10/91	8	26/10/91	Reboxetine
	33		22/05/91	28/05/91	7	29/05/91	Imipramine
	34			16/04/92		17/04/92	Placebo
	35			14/09/92		15/09/92	Reboxetine
	36	04/02/91	05/02/91	11/02/92	372	12/02/92	Imipramine
2/5	73		28/01/92	06/02/92	10	07/02/92	Placebo
	74		30/04/92	20/06/92	52	21/06/92	Reboxetine
	75	02/09/92	03/09/92	10/09/92	8	11/09/92	Imipramine
	76			14/09/92		15/09/92	Imipramine
	77	14/09/92	15/09/92	21/09/92	7	22/09/92	Placebo
	78	28/09/92	01/10/92	09/10/92	9	10/10/92	Reboxetine
2/6	55			11/06/92		12/06/92	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
2/6	56			11/06/92		12/06/92	Reboxetine
	57			04/05/92		05/05/92	Imipramine
	58			17/05/92		18/05/92	Placebo
	59			26/05/92		27/05/92	Placebo
	60		07/05/92	11/05/92	5	12/05/92	Imipramine
3/1	61			04/03/91		05/03/91	Imipramine
	62			15/04/91		16/04/91	Imipramine
	63			12/05/91		13/05/91	Placebo
	64	26/02/91	27/02/91	13/03/91	16	14/03/91	Placebo
	65			15/09/91		16/09/91	Reboxetine
	66			09/06/91		10/06/91	Reboxetine
	139	27/08/91	28/08/91	02/09/91	6	03/09/91	Imipramine
	140	15/04/91	04/09/91	11/09/91	8	12/09/91	Placebo
	141	25/09/91	26/09/91	02/10/91	7	03/10/91	Placebo
	142			17/11/91		18/11/91	Imipramine
	143		08/04/92	14/04/92	7	15/04/92	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
3/1	144			08/06/92		09/06/92	Reboxetine
	451	15/01/92	16/01/92	19/01/92	5	20/01/92	Reboxetine
	452	16/01/92	17/01/92	21/01/92	6	22/01/92	Placebo
	453	91	02/01/91	28/01/92	393	29/01/92	Imipramine
	454	14/02/92	15/02/92	16/02/92	3	17/02/92	Reboxetine
	455	04/03/92	05/03/92	10/03/92	7	11/03/92	Placebo
	456			24/03/92		25/03/92	Imipramine
3/2	65/A	22/01/91	23/01/91	28/01/91	6	29/01/91	Reboxetine
3/3	67	04/91	12/07/91	17/07/91	6	18/07/91	Placebo
	68	84	10/01/92	20/01/92	11	21/01/92	Reboxetine
	69	29/01/92	30/01/92	03/02/92	6	04/02/92	Placebo
	70		08/04/92	14/04/92	7	15/04/92	Imipramine
	71	09/04/92	10/04/92	15/04/92	6	16/04/92	Imipramine
	72		20/07/92	24/07/92	5	25/07/92	Reboxetine
3/4	79	15/02/90	16/02/90	03/05/91	442	04/05/91	Imipramine
	80			31/08/91		01/09/91	Imipramine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
3/4	81	14/05/91	15/05/91	16/05/91	3	17/05/91	Reboxetine
	82			16/06/91		17/06/91	Placebo
	83	23/04/91	14/06/91	16/06/91	3	17/06/91	Placebo
	84			08/10/91		09/10/91	Reboxetine
	85		25/10/91	28/10/91	4	29/10/91	Imipramine
	86			02/12/91		03/12/91	Imipramine
	87		06/12/91	08/12/91	3	09/12/91	Placebo
	88			22/03/92		23/03/92	Placebo
	89	08/03/92	09/03/92	25/03/92	17	26/03/92	Reboxetine
	90	22/04/92	23/04/92	27/04/92	5	28/04/92	Reboxetine
	457	08/91	18/05/92	21/05/92	4	22/05/92	Placebo
	458	15/04/92	25/04/92	25/05/92	31	26/05/92	Reboxetine
	459		29/05/92	01/06/92	4	02/06/92	Placebo
	460		14/08/92	18/08/92	5	19/08/92	Reboxetine
	461	31/08/92	01/09/92	16/09/92	16	17/09/92	Imipramine
	462			28/09/92		29/09/92	Imipramine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (a)	Days	Start date	Randomized
4/1	91			11/10/91		12/10/91	Imipramine
	92			06/08/91		07/08/91	Reboxetine
	93	02/06/91	03/06/91	02/07/91	30	03/07/91	Placebo
	94			04/07/91		05/07/91	Placebo
	95	04/87	02/04/87	02/06/91	1524	03/06/91	Imipramine
	96			03/09/91		04/09/91	Reboxetine
	115			05/05/92		06/05/92	Reboxetine
	116			15/05/92		16/05/92	Imipramine
	117			02/09/91		03/09/91	Imipramine
	118			22/05/92		23/05/92	Reboxetine
	119		10/03/92				Placebo
	120			30/07/92		31/07/92	Placebo
	145			29/09/92		30/09/92	Imipramine
	146			15/09/92		16/09/92	Placebo
	147	09/91	02/09/91	31/08/92	366	01/09/92	Reboxetine
	148			25/09/92		26/09/92	Imipramine

(*) if missing date = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
4/1	149			29/09/92		30/09/92	Reboxetine
	150			29/09/92		30/09/92	Placebo
4/2	93/A	01/10/90	02/10/90	21/02/91	143	22/02/91	Placebo
	99/A			26/03/91		27/03/91	Placebo
	104	30/11/90	01/12/90	21/05/91	172	22/05/91	Reboxetine
4/3	97	10/04/91	11/04/91	16/04/91	6	17/04/91	Placebo
	98	15/06/91	16/06/91	19/06/91	4	20/06/91	Reboxetine
	99			07/08/91		08/08/91	Placebo
	100	10/09/91	11/09/91	26/11/91	78	27/11/91	Imipramine
	101	25/11/91	26/11/91	16/03/92	112	17/03/92	Imipramine
4/4	109		04/06/91	07/06/91	4	08/06/91	Reboxetine
	110		11/06/91	14/06/91	4	15/06/91	Imipramine
	111	26/06/91	27/06/91	03/07/91	7	04/07/91	Imipramine
	112	04/07/91	05/07/91	09/07/91	5	10/07/91	Placebo
	113			30/08/91		31/08/91	Reboxetine
	114	13/11/91	14/11/91	19/11/91	7	20/11/91	Placebo

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (a)	Days	Start date	Randomized
4/4	175		05/02/92	12/02/92	8	13/02/92	Imipramine
	176		10/03/92	13/03/92	4	14/03/92	Placebo
	177		23/04/92	27/04/92	5	28/04/92	Imipramine
	178		01/04/92	27/04/92	27	28/04/92	Reboxetine
	179	06/09/92	07/09/92	10/09/92	4	11/09/92	Placebo
	180	29/09/92	30/09/92	06/10/92	7	07/10/92	Reboxetine
5/1	127	28/05/91	29/05/91	05/06/91	9	06/06/91	Reboxetine
	128		06/06/91	13/06/91	8	14/06/91	Reboxetine
	129		15/12/91	23/12/91	9	24/12/91	Placebo
	130		25/02/92	04/03/92	9	05/03/92	Placebo
	131	09/03/92	10/03/92	20/03/92	11	21/03/92	Imipramine
	132		23/06/92	24/06/92	2	25/06/92	Imipramine
5/2	121		13/12/91	19/12/91	7	20/12/91	Imipramine
	125	20/01/91	21/01/91	27/01/91	8	28/01/91	Reboxetine
5/3	133			28/11/91		29/11/91	Placebo
	134	23/11/91	28/11/91	05/12/91	8	06/12/91	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
5/3	135		30/12/91	09/01/92	11	10/01/92	Imipramine
	136		27/02/92	01/03/92	4	02/03/92	Imipramine
	137			14/05/92		15/05/92	Reboxetine
	138			14/05/92		15/05/92	Placebo
6/1	151			20/01/92		21/01/92	Imipramine
	152	17/02/92	18/02/92	23/02/92	7	24/02/92	Reboxetine
	153	18/02/91	19/02/91	17/03/91	28	18/03/91	Reboxetine
	154		25/03/92	29/03/92	5	30/03/92	Imipramine
	155	01/07/92	02/07/92	07/07/92	7	08/07/92	Placebo
	156	89	01/09/92	07/09/92	7	08/09/92	Placebo
6/2	157	10/04/91	11/04/91	29/04/91	19	30/04/91	Reboxetine
	158	10/11/91	11/11/91	23/11/91	13	24/11/91	Imipramine
	159		05/07/91	13/07/91	9	14/07/91	Imipramine
	160			23/11/91		24/11/91	Placebo
	161			19/02/92		20/02/92	Reboxetine
	162			09/07/91		10/07/91	Placebo

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (a)	Days	Start date	Randomized
6/2	169	06/91	09/12/91	25/12/91	17	26/12/91	Imipramine
	170	02/90	17/10/91	31/10/91	15	01/11/91	Placebo
	171			21/07/92		22/07/92	Imipramine
	172			06/07/92		07/07/92	Reboxetine
	173			04/07/92		05/07/92	Placebo
	174			10/05/92		11/05/92	Reboxetine
6/3	163	15/05/91	16/05/91	05/06/91	22	06/06/91	Reboxetine
	164	07/10/91	08/10/91	10/10/91	4	11/10/91	Imipramine
	165	01/10/91	02/10/91	15/10/91	15	16/10/91	Imipramine
	166	16/10/91	17/10/91	24/10/91	9	25/10/91	Reboxetine
	167	01/06/91	02/06/91	17/11/91	170	18/11/91	Placebo
	168	25/11/91	26/11/91	02/12/91	7	03/12/91	Placebo
	505	19/11/91	20/11/91	02/12/91	14	03/12/91	Imipramine
	506	16/12/91	17/12/91	07/01/92	23	08/01/92	Placebo
	507	06/01/92	07/01/92	13/01/92	8	14/01/92	Imipramine
	508	28/01/92	29/01/92	04/02/92	7	05/02/92	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
6/3	509		18/02/92	23/02/92	6	24/02/92	Placebo
	510		14/02/92	26/02/92	13	27/02/92	Reboxetine
	511			18/03/92		19/03/92	Imipramine
	512	01/12/90	02/12/90	31/03/92	487	01/04/92	Placebo
	513	28/04/92	29/04/92	12/05/92	15	13/05/92	Imipramine
7/02	181	17/01/92	18/01/92	26/01/92	9	27/01/92	Reboxetine
	182	10/11/91	11/11/91	22/11/91	13	23/11/91	Placebo
	183	30/11/91	01/12/91	01/01/92	32	02/01/92	Imipramine
	184	17/01/92	18/01/92	26/01/92	9	27/01/92	Imipramine
	185			09/04/92		10/04/92	Reboxetine
	186			15/04/92		16/04/92	Placebo
	535			14/04/92		15/04/92	Placebo
	536			07/05/92		08/05/92	Reboxetine
7/03	187			17/02/92		18/02/92	Imipramine
	188			24/02/92		25/02/92	Placebo
	189			24/02/92		25/02/92	Placebo

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
7/03	190			27/02/92		28/02/92	Reboxetine
	191			02/03/92		03/03/92	Imipramine
	192			09/03/92		10/03/92	Reboxetine
	523			05/05/92		06/05/92	Reboxetine
	524			05/05/92		06/05/92	Placebo
	525			05/05/92		06/05/92	Placebo
	526			05/05/92		06/05/92	Reboxetine
	527			18/05/92		19/05/92	Imipramine
	528			18/05/92		19/05/92	Imipramine
7/04	193			24/01/92		25/01/92	Placebo
	194			24/01/92		25/01/92	Reboxetine
	195			24/01/92		25/01/92	Placebo
	196			31/01/92		01/02/92	Reboxetine
	197			31/01/92		01/02/92	Imipramine
	198			31/01/92		01/02/92	Imipramine
	199			27/03/92		28/03/92	Imipramine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
7/04	200			27/03/92		28/03/92	Placebo
	201			27/03/92		28/03/92	Reboxetine
	202			03/04/92		04/04/92	Reboxetine
	203			03/04/92		04/04/92	Placebo
	204			03/04/92		04/04/92	Imipramine
7/05	205	29/12/91	30/12/91	26/01/92	28	27/01/92	Placebo
	206		06/01/92	27/01/92	22	28/01/92	Imipramine
	207			27/01/92		28/01/92	Imipramine
	208			29/01/92		30/01/92	Reboxetine
	209			04/02/92		05/02/92	Placebo
	210			06/02/92		07/02/92	Reboxetine
	541	23/07/91	02/03/92	16/03/92	15	17/03/92	Reboxetine
	542	02/12/91	03/12/91	16/03/92	105	17/03/92	Imipramine
	543	17/05/91	18/05/91	17/03/92	306	18/03/92	Imipramine
	544		03/12/91	23/03/92	112	24/03/92	Placebo
	545	11/02/92	12/02/92	24/03/92	43	25/03/92	Placebo

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (a)	Days	Start date	Randomized
7/05	546			24/03/92		25/03/92	Reboxetine
7/07	529		10/02/92	17/02/92	8	18/02/92	Placebo
	530	16/02/92	17/02/92	19/02/92	3	20/02/92	Imipramine
	531		17/02/92	23/02/92	7	24/02/92	Reboxetine
	532		21/04/92	26/04/92	6	27/04/92	Imipramine
	533	27/04/92	28/04/92	03/05/92	7	04/05/92	Reboxetine
	534		12/05/92	14/05/92	3	15/05/92	Placebo
8	211	01/02/91	07/05/91	12/05/91	6	13/05/91	Reboxetine
	212		10/09/91	13/09/91	4	14/09/91	Placebo
	213	01/08/91	18/11/91	21/11/91	4	22/11/91	Imipramine
	214		19/11/91	22/11/91	4	23/11/91	Reboxetine
	215	12/91	14/02/92	17/02/92	4	18/02/92	Placebo
	216	89	23/03/92	26/03/92	4	27/03/92	Imipramine
	217		23/03/92	29/03/92	7	30/03/92	Reboxetine
	218		01/04/92	08/04/92	8	09/04/92	Reboxetine
	219	02/92	03/04/92	10/04/92	8	11/04/92	Placebo

(*) if missing date = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
8	220	12/90	21/04/92	26/04/92	6	27/04/92	Imipramine
	221		24/04/92	27/04/92	4	28/04/92	Imipramine
	222		20/04/92	27/04/92	8	28/04/92	Placebo
	223		04/05/92	10/05/92	7	11/05/92	Imipramine
	224	90	27/08/92	06/09/92	11	07/09/92	Placebo
	225		05/09/92	10/09/92	6	11/09/92	Placebo
	226		15/09/92	22/09/92	8	23/09/92	Reboxetine
	227	91	18/09/92	24/09/92	7	25/09/92	Reboxetine
	228		18/09/92	25/09/92	8	26/09/92	Imipramine
	229	91	24/09/92	29/09/92	6	30/09/92	Imipramine
	230	02/92	24/09/92	27/09/92	4	28/09/92	Reboxetine
	231	91	25/09/92	29/09/92	5	30/09/92	Imipramine
	232		25/09/92	01/10/92	7	02/10/92	Reboxetine
	233		28/09/92	06/10/92	9	07/10/92	Placebo
	234	91	30/09/92	06/10/92	7	07/10/92	Placebo
B/A	235			13/10/92		14/10/92	Placebo

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
8/A	236	18/09/92	19/09/92	13/10/92	26	14/10/92	Placebo
	237			13/10/92		14/10/92	Reboxetine
	238	18/09/92	19/09/92	13/10/92	26	14/10/92	Reboxetine
	239	22/09/92	23/09/92	15/10/92	24	16/10/92	Imipramine
	240	22/09/92	23/09/92	15/10/92	24	16/10/92	Imipramine
	553			15/10/92		16/10/92	Placebo
	554	22/08/92	23/08/92	15/10/92	55	16/10/92	Reboxetine
	555	22/09/92	23/09/92	15/10/92	24	16/10/92	Reboxetine
	556	22/09/92	23/09/92	15/10/92	24	16/10/92	Imipramine
9	241		04/02/91	06/02/91	3	07/02/91	Placebo
	242	12/01/91	13/02/91	17/02/91	5	18/02/91	Reboxetine
	243	15/02/91	16/02/91	19/02/91	4	20/02/91	Reboxetine
	244	11/02/91	12/02/91	18/02/91	8	19/02/91	Imipramine
	245		17/02/91	21/02/91	5	22/02/91	Imipramine
	246	13/02/91	18/02/91	21/02/91	4	22/02/91	Placebo
	247		21/02/91	24/02/91	4	25/02/91	Placebo

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (a)	Days	Start date	Randomized
9	248		04/03/91	06/03/91	3	07/03/91	Placebo
	249		04/03/91	07/03/91	4	08/03/91	Reboxetine
	250	07/03/91	08/03/91	11/03/91	5	12/03/91	Imipramine
	251		13/03/91	19/03/91	7	20/03/91	Imipramine
	252		28/03/91	01/04/91	5	02/04/91	Reboxetine
	253	28/03/91	29/03/91	01/04/91	4	02/04/91	Reboxetine
	254		05/04/91	08/04/91	4	09/04/91	Imipramine
	255	18/04/91	19/04/91	12/05/91	24	13/05/91	Reboxetine
	256	10/05/91	11/05/91	26/05/91	17	27/05/91	Imipramine
	257		21/06/91	24/06/91	4	25/06/91	Placebo
	258		25/06/91	30/06/91	6	01/07/91	Placebo
11	319			01/08/91		02/08/91	Placebo
	320	05/91	02/05/91	16/08/91	108	17/08/91	Imipramine
	321	05/91	02/05/91	05/09/91	128	06/09/91	Placebo
	322	08/91	02/08/91	26/09/91	57	27/09/91	Reboxetine
	323			14/11/91		15/11/91	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
11	324			05/12/91		06/12/91	Imipramine
	325			12/12/91		13/12/91	Reboxetine
	326	10/91	02/10/91	15/01/92	107	16/01/92	Placebo
	327			29/01/92		30/01/92	Imipramine
	328			30/01/92		31/01/92	Imipramine
	329	31/03/92	01/04/92	09/04/92	9	10/04/92	Placebo
	330			08/04/92		09/04/92	Reboxetine
	331	07/04/92	08/04/92	16/04/92	9	17/04/92	Imipramine
	332	07/05/92	08/05/92	18/05/92	11	19/05/92	Reboxetine
	333			26/05/92		27/05/92	Placebo
	334	17/05/92	18/05/92	28/05/92	12	29/05/92	Reboxetine
	335	06/05/92	07/05/92	02/06/92	27	03/06/92	Placebo
	336	89	02/01/89	17/06/92	1264	18/06/92	Imipramine
	337	16/06/92	17/06/92	01/07/92	16	02/07/92	Reboxetine
	338			22/07/92		23/07/92	Imipramine
12	367		15/12/91	19/12/91	5	20/12/91	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
12	368		19/12/91	23/12/91	5	24/12/91	Placebo
	369	14/04/92	17/04/92	22/04/92	6	23/04/92	Imipramine
	370	23/04/92	24/04/92	28/04/92	6	29/04/92	Placebo
	371	17/04/92	18/04/92	30/04/92	14	01/05/92	Imipramine
	372		28/05/92	01/06/92	5	02/06/92	Reboxetine
	373		03/06/92	04/06/92	2	05/06/92	Reboxetine
	374		03/06/92	08/06/92	6	09/06/92	Placebo
	375	09/06/92	12/06/92	16/06/92	5	17/06/92	Imipramine
13	13		03/04/91	12/04/91	10	13/04/91	Placebo
	14	05/91	02/05/91	01/07/91	62	02/07/91	Placebo
	15	16/06/91	01/07/91	04/07/91	4	05/07/91	Imipramine
	16	16/11/91	17/11/91	02/12/91	16	03/12/91	Imipramine
	17		20/04/92	20/05/92	31	21/05/92	Reboxetine
	18	15/06/92	16/06/92	23/06/92	9	24/06/92	Reboxetine
	409	11/91	23/11/91	09/12/91	17	10/12/91	Reboxetine
	410	07/02/92	08/02/92	13/02/92	7	14/02/92	Placebo

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
13	411	17/03/92	18/03/92	27/03/92	11	28/03/92	Imipramine
	423	04/92	02/04/92	13/09/92	166	14/09/92	Placebo
14	19	01/04/92	02/04/92	09/04/92	9	10/04/92	Reboxetine
	20	15/02/90	16/02/90	28/04/92	804	29/04/92	Imipramine
	21		15/07/92	19/07/92	5	20/07/92	Imipramine
15	25	24/03/91	25/03/91	17/06/91	85	18/06/91	Reboxetine
	26	02/08/90	03/08/90	19/06/91	321	20/06/91	Placebo
	27		28/11/90	01/07/91	216	02/07/91	Imipramine
	28	02/08/90	03/08/90	07/08/91	370	08/08/91	Reboxetine
	29	22/08/91	23/08/91	28/08/91	7	29/08/91	Placebo
	30			02/09/91		03/09/91	Imipramine
	403			03/10/91		04/10/91	Imipramine
	404			07/10/91		08/10/91	Reboxetine
	405			10/11/91		11/11/91	Placebo
	406			26/11/91		27/11/91	Imipramine
	407			02/12/91		03/12/91	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
15	408	10/01/92	11/01/92	19/01/92	9	20/01/92	Placebo
	418			29/01/92		30/01/92	Placebo
	419			27/04/92		28/04/92	Placebo

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R[illegible]550082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 1

	Patient												
	1	2	3	4	5	6	7	8	9	10	11	12	412
	Fem.	Male	Male	Male	Fem.	Fem.	Fem.	Male	Fem.	Male	Fem.	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA CNS R95 50082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 1

	Patient					
	413	414	415	416	421	422
	Male	Fem.	Male	Fem.	Male	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?						
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?						
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES

PHARMACIA CNS9850082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 2/1

	Patient		
	49	50	51
	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?			
Aged between 18 and 65 years inclusive	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?			
Dysthymia, Cyclothymia	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES
Pregnancy	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES
MMST < 22	YES	YES	YES
High risk of suicide	YES	YES	YES

PHARMACIA CNS00000082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 2/2

	Patient					
	43	44	45	46	47	48
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?						
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?						
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 96050082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 2/3

	Patient						
	36/A	37	38	39	40	41	42
	Male	Fem.	Male	Fem.	Fem.	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?							
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?							
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	N/A	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	N/A	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 95[illegible]0082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 2/4

	Patient					
	31	32	33	34	35	36
	Male	Male	Male	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?						
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?						
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 00082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 2/5

	Patient					
	73	74	75	76	77	78
	Male	Male	Male	Fem.	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?						
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?						
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES

PHARMACIA CN9600082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 2/6

	Patient					
	55	56	57	58	59	60
	Fem.	Fem.	Fem.	Fem.	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?						
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?						
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 00082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 3/1

	Patient												
	61	62	63	64	65	66	139	140	141	142	143	144	451
	Male	Fem.	Male	Fem.	Male	Male	Male	Male	Fem.	Fem.	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA CN95[illegible]0082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 3/1

	Patient				
	452	453	454	455	456
	Male	Fem.	Male	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?					
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?					
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES

PHARMACIA CN9560082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 3/2

	Patient
	65/A
	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?	
Aged between 18 and 65 years inclusive	YES
Affected by acute episodes of DSM-III-R.	YES
With a total score of 22 of above 21HAMD	YES
Able and willing to give Informed Cons..	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?	
Dysthymia, Cyclothymia	YES
History of DSM-III-R, associated to	YES
Pregnancy	YES
Refusal of contraceptive use during	YES
Clinically significant hematopoietic ...	YES
Clinically significant lab values abnor.	YES
Current evidence of urinary retention	YES
Current evidence of glaucoma	YES
Clinically significant physical abnorma.	YES
Participation in a clinical trial with .	YES
Evidence of substance use disorder	YES
Chronic respiratory insufficienty	YES
History of drug hypersensitivity	YES
Any history of seizures of brain injury	YES
Any other important clinical illness ...	YES
ECT in the previous 6 months	YES
MMST < 22	YES
High risk of suicide	YES

PHARMACIA CNS 95000082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 3/3

	Patient					
	67	68	69	70	71	72
	Male	Male	Male	Male	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?						
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?						
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 00082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 3/4

	Patient												
	79	80	81	82	83	84	85	86	87	88	89	90	457
	Fem.	Male	Fem.	Male	Male	Fem.	Fem.	Male	Fem.	Male	Fem.	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA CNS 98[illegible]0082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 3/4

	Patient				
	458	459	460	461	462
	Fem.	Fem.	Male	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?					
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?					
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES

PHARMACIA CNS 9650082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 4/1

	Patient												
	91	92	93	94	95	96	115	116	117	118	119	120	145
	Fem.	Fem.	Male	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA CNS 95 0082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 4/1

	Patient				
	146	147	148	149	150
	Fem.	Fem.	Fem.	Male	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?					
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?					
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES

PHARMACIA CNS 00082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 4/2

	Patient		
	93/A	99/A	104
	Male	Male	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?			
Aged between 18 and 65 years inclusive	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?			
Dysthymia, Cyclothymia	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES
Pregnancy	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES
MMST < 22	YES	YES	YES
High risk of suicide	YES	YES	YES

PHARMACIA CNS 9550082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 4/3

	Patient				
	97	98	99	100	101
	Male	Fem.	Fem.	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?					
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?					
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES

PHARMACIA CNS 00082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 4/4

	Patient											
	109	110	111	112	113	114	175	176	177	178	179	180
	Fem.	Male	Male	Male	Male	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?												
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?												
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficionty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 9550082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 5/1

	Patient					
	127	128	129	130	131	132
	Male	Fem.	Male	Male	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?						
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?						
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES

PHARMACIA CNS98000082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 5/2

	Patient	
	121	125
	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?		
Aged between 18 and 65 years inclusive	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES
With a total score of 22 of above 21HAMD	YES	YES
Able and willing to give Informed Cons..	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?		
Dysthymia, Cyclothymia	YES	YES
History of DSM-III-R, associated to	YES	YES
Pregnancy	YES	YES
Refusal of contraceptive use during	YES	YES
Clinically significant hematopoietic ...	YES	YES
Clinically significant lab values abnor.	YES	YES
Current evidence of urinary retention	YES	YES
Current evidence of glaucoma	YES	YES
Clinically significant physical abnorma.	YES	YES
Participation in a clinical trial with .	YES	YES
Evidence of substance use disorder	YES	YES
Chronic respiratory insufficienty	YES	YES
History of drug hypersensitivity	YES	YES
Any history of seizures of brain injury	YES	YES
Any other important clinical illness ...	YES	YES
ECT in the previous 6 months	YES	YES
MMST < 22	YES	YES
High risk of suicide	YES	YES

PHARMACIA CNS 95000082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 5/3

	Patient					
	133	134	135	136	137	138
	Male	Fem.	Fem.	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?						
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?						
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	NO
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 95E00082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 6/1

	Patient					
	151	152	153	154	155	156
	Male	Fem.	Male	Fem.	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?						
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?						
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 00050082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 6/2

	Patient											
	157	158	159	160	161	162	169	170	171	172	173	174
	Male	Fem.	Male	Male	Fem.	Male	Fem.	Male	Fem.	Fem.	Male	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?												
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	NO	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?												
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 96 50082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 6/3

	Patient												
	163	164	165	166	167	168	505	506	507	508	509	510	511
	Male	Male	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA CNS 95000082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 6/3

	Patient	
	512	513
	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?		
Aged between 18 and 65 years inclusive	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES
With a total score of 22 of above 21HAMD	YES	YES
Able and willing to give Informed Cons..	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?		
Dysthymia, Cyclothymia	YES	YES
History of DSM-III-R, associated to	YES	YES
Pregnancy	YES	YES
Refusal of contraceptive use during	YES	YES
Clinically significant hematopoietic ...	YES	YES
Clinically significant lab values abnor.	YES	YES
Current evidence of urinary retention	YES	YES
Current evidence of glaucoma	YES	YES
Clinically significant physical abnorma.	YES	YES
Participation in a clinical trial with .	YES	YES
Evidence of substance use disorder	YES	YES
Chronic respiratory insufficienty	YES	YES
History of drug hypersensitivity	YES	YES
Any history of seizures of brain injury	YES	YES
Any other important clinical illness ...	YES	YES
ECT in the previous 6 months	YES	YES
MMST < 22	YES	YES
High risk of suicide	YES	YES

PHARMACIA CNS 95[illegible]0082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 7/02

	Patient							
	181	182	183	184	185	186	535	536
	Male	Male	Male	Fem.	Male	Male	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?								
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?								
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 95000082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 7/03

	Patient											
	187	188	189	190	191	192	523	524	525	526	527	528
	Fem.	Male	Male	Male	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?												
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?												
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 9650082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 7/04

	Patient											
	193	194	195	196	197	198	199	200	201	202	203	204
	Fem.	Male	Fem.	Fem.	Male	Fem.	Male	Male	Fem.	Male	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?												
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?												
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 9990082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 7/05

	Patient											
	205	206	207	208	209	210	541	542	543	544	545	546
	Male	Fem.	Fem.	Male	Male	Male	Fem.	Male	Male	Fem.	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?												
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?												
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 9560082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 7/07

	Patient					
	529	530	531	532	533	534
	Fem.	Fem.	Fem.	Fem.	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?						
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?						
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES

PHARMACIA CNS98000082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 8

	Patient												
	211	212	213	214	215	216	217	218	219	220	221	222	223
	Fem.	Fem.	Male	Fem.	Fem.	Male	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA CNS 0550082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 8

	Patient										
	224	225	226	227	228	229	230	231	232	233	234
	Fem.	Male	Male	Male	Male	Fem.	Fem.	Male	Male	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?											
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?											
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 95000082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 8/A

	Patient									
	235	236	237	238	239	240	553	554	555	556
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?										
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?										
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA CNS9850082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 9

	Patient												
	241	242	243	244	245	246	247	248	249	250	251	252	253
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Fem.	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	N/A	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	N/A	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA CNS 9550082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 9

	Patient				
	254	255	256	257	258
	Fem.	Fem.	Fem.	Male	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?					
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?					
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES

PHARMACIA CN 95 0082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 11

	Patient												
	319	320	321	322	323	324	325	326	327	328	329	330	331
	Male	Male	Male	Fem.	Male	Male	Male	Male	Male	Fem.	Fem.	Male	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA CNS 9550082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 11

	Patient						
	332	333	334	335	336	337	338
	Male	Male	Fem.	Male	Fem.	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?							
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?							
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 9[illegible]0082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 12

	Patient								
	367	368	369	370	371	372	373	374	375
	Fem.	Fem.	Fem.	Male	Fem.	Male	Male	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?									
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?									
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	N/A	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	N/A	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 9550082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 13

	Patient									
	13	14	15	16	17	18	409	410	411	423
	Male	Male	Fem.	Male	Male	Male	Male	Male	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?										
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?										
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 14

	Patient		
	19	20	21
	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?			
Aged between 18 and 65 years inclusive	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?			
Dysthymia, Cyclothymia	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES
Pregnancy	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES
MMST < 22	YES	YES	YES
High risk of suicide	YES	YES	YES

PHARMACIA CNS 9550082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 15

	Patient												
	25	26	27	28	29	30	403	404	405	406	407	408	418
	Fem.	Male	Fem.	Fem.	Male	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
MMST < 22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA CNS 9550082

REBOXETINE - PROTOCOL 20124/015
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 15

	Patient
	419
	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?	
Aged between 18 and 65 years inclusive	YES
Affected by acute episodes of DSM-III-R.	YES
With a total score of 22 of above 21HAMD	YES
Able and willing to give Informed Cons..	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?	
Dysthymia, Cyclothymia	YES
History of DSM-III-R, associated to	YES
Pregnancy	YES
Refusal of contraceptive use during	YES
Clinically significant hematopoietic ...	YES
Clinically significant lab values abnor.	YES
Current evidence of urinary retention	YES
Current evidence of glaucoma	YES
Clinically significant physical abnorma.	YES
Participation in a clinical trial with .	YES
Evidence of substance use disorder	YES
Chronic respiratory insufficienty	YES
History of drug hypersensitivity	YES
Any history of seizures of brain injury	YES
Any other important clinical illness ...	YES
ECT in the previous 6 months	YES
MMST < 22	YES
High risk of suicide	YES

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
1	1	Female	Imipramine	YES	MYLANTA	17/04/91	Day 42	22/05/91(*)	Day 42
					NORMISON	10/04/91	Screen	24/04/91	Day 21
	2	Male	Reboxetine	YES	NORMISON	15/04/91	Day 21	23/05/91	Day 42
	4	Male	Placebo	YES	MOGADON	02/06/91	Screen	04/06/91	Screen
					NORMISON	04/06/91	Screen	06/06/91	Day 7
	5	Female	Reboxetine	NO	AMOXIL	19/06/91	Day 14	26/06/91	Day 14
					NORMISON	12/06/91	Screen	02/07/91(*)	Day 21
	6	Female	Placebo	NO	NORMISON	23/05/91	Screen	05/07/91(*)	Day 28
					PANADOL	28/05/91	Day 7	05/07/91(*)	Day 7
	7	Female	Reboxetine	YES	NORMISON	27/08/91	Day 7	20/09/91	Day 21
	8	Male	Placebo	YES	ASPIRINE	20/09/91	Day 21	21/09/91	Day 21
					NORMISON	05/09/91	Screen	19/10/91(*)	Day 42
	9	Female	Reboxetine	YES	NORMISON	27/11/91	Screen	06/01/92(*)	Day 42
	10	Male	Placebo	YES	ASPRO	21/10/91	Day 28	21/10/91	Day 28
					VALIUM	15/10/91	Day 21	15/10/91	Day 21
	11	Female	Imipramine	NO	NORMISON	09/91	Day 7	10/10/91	Screen

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
1	12	Female	Imipramine	YES	ASPIRIN 'BAYER'	14/11/91	Day 28	14/11/91	Day 28
	412	Male	Reboxetine	YES	NORMISON	12/11/91	Screen	14/12/91	Day 42
	413	Male	Placebo	YES	NAPROSYN	06/89 24/12/91	Screen Day 21	03/12/91 20/01/92(*)	Screen Day 42
					NICOTINIC ACID	03/12/91($)	Screen	03/12/91	Screen
	414	Female	Imipramine	NO	NORMISON	21/01/92	Day 7	29/01/92(*)	Day 14
	415	Male	Imipramine	YES	NORMISON	21/01/92	Day 7	29/01/92	Day 21
					SENNA	19/02/92	Day 35	19/02/92	Day 35
	416	Female	Reboxetine	NO	NORMISON	24/01/92	Day 7	30/01/92	Day 14
	421	Male	Imipramine	YES	ASPIRINE	26/02/92($)	Screen	09/04/92(*)	Day 42
					SENOKOT	26/02/92($)	Day 42	09/04/92(*)	Day 42
					TEMAZEPAM	27/02/92	Screen	09/04/92(*)	Day 35
	422	Male	Imipramine	YES	ORUDIS	04/08/92($)	Screen	04/08/92	Screen
2/1	49	Female	Placebo	YES	NOCTEC	14/05/91	Screen	28/06/91(*)	Day 42
	50	Female	Reboxetine	YES	EFFERALGAN	29/12/91	Day 7	31/12/91	Day 7
					NOCTEC	23/12/91	Screen	05/02/92	Day 42
					VENTOLINE	22/01/92 27/01/92	Day 28 Day 35	22/01/92 27/01/92	Day 28 Day 35

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
2/1	50	Female	Reboxetine	YES	VENTOLINE	03/02/92	Day 42	03/02/92	Day 42
	51	Female	Imipramine	YES	DI-ANTALVIC	21/02/92	Day 21	04/03/92	Day 35
					NOCTEC	28/01/92	Screen	15/03/92(*)	Day 42
					SPAGULAX	21/02/92	Day 21	29/02/92	Day 28
2/2	43	Female	Imipramine	NO	ASPRO	02/05/91	Day 28	02/05/91	Day 28
					NOCTEC	01/05/91	Day 14	01/05/91	Day 14
						12/05/91	Day 28	13/05/91	Day 28
						15/05/91	Day 35	15/05/91	Day 35
					VISCERALGINE	02/05/91	Day 28	02/05/91	Day 28
961	44	Female	Imipramine	YES	ADEPAL	19/07/91	Day 7	29/08/91(*)	Day 42
					ARGININE	20/07/91	Day 7	25/07/91	Day 7
					DIANE	08/90	Screen	19/07/91	Screen
					EFFERALGAN	01/90	Screen	19/07/91	Screen
					FERROGRAD C	26/08/91	Day 42	29/08/91(*)	Day 42
					NOCTEC	07/07/91	Day 21	07/07/91	Day 21
						25/07/91	Day 14	25/07/91	Day 14
						11/08/91	Day 28	11/08/91	Day 28
						22/08/91	Day 42	22/08/91	Day 42
						25/08/91	Day 42	25/08/91	Day 42
	45	Female	Reboxetine	YES	ADEPAL	10/09/91	Day 7	20/10/91(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
2/2	45	Female	Reboxetine	YES	AGAR	04/10/91	Day 28	04/10/91	Day 28
					ALKA-SELTZER	16/09/91	Day 14	16/09/91	Day 14
						24/09/91	Day 21	24/09/91	Day 21
					EUPHYTOSE	05/10/91	Day 28	05/10/91	Day 28
					GELATIN	04/10/91	Day 28	04/10/91	Day 28
					HISTAGLOBINE	19/08/91	Screen	04/10/91	Screen
					HISTAMINE	01/10/91	Day 28	01/10/91	Day 28
						05/10/91	Day 28	05/10/91	Day 28
					HYPOSTAMINE	09/08/91	Screen	09/10/91	Screen
					KAOLIN	04/10/91	Day 28	04/10/91	Day 28
					NOCTEC	09/09/91	Day 7	09/09/91	Day 7
						11/09/91	Day 7	11/09/91	Day 7
						23/09/91	Day 21	26/09/91	Day 21
						01/10/91	Day 28	01/10/91	Day 28
						09/10/91	Day 35	09/10/91	Day 35
						15/10/91	Day 42	16/10/91	Day 42
	46	Female	Placebo	NO	NOCTEC	26/09/91	Day 7	15/10/91	Day 21
						17/10/91	Day 28	23/10/91	Day 28
	47	Female	Placebo	YES	NOCTEC	13/03/92	Screen	17/04/92	Day 28
	48	Female	Reboxetine	YES	NOCTEC	03/04/92	Screen	28/04/92	Day 28
2/3	36/A	Male	Imipramine	YES	ODDIBIL	23/03/91	Day 21	17/04/91(*)	Day 42
	37	Female	Reboxetine	YES	NOCTEC	18/03/91	Screen	07/05/91(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
2/3	39	Female	Imipramine	YES	NOCTEC	01/08/91	Screen	20/09/91	Day 42
	40	Female	Reboxetine	YES	DIHYDROERGOTAMIN	31/10/91	Day 14	04/12/91(*)	Day 42
					VITAMIN B 1-6-12	17/10/91	Screen	04/12/91(*)	Day 42
	42	Female	Imipramine	YES	ASPIRINE	17/06/92	Day 35	20/06/92	Day 42
					CEFUROXIME	17/06/92	Day 35	30/06/92(*)	Day 42
					CIFLOX	04/05/92	Screen	11/05/92	Screen
					NOROXIN	15/05/92	Screen	15/06/92	Day 28
2/4	31	Male	Placebo	YES	NOCTEC	25/03/91	Day 7	05/05/91(*)	Day 42
	32	Male	Reboxetine	YES	DIGOXINE	87	Screen	06/12/91(*)	Day 42
					IBUPROFEN	87	Screen	06/12/91(*)	Day 42
					LASILIX	87	Screen	06/12/91(*)	Day 42
					NOCTEC	18/10/91	Screen	06/12/91(*)	Day 42
					POTASSIUM	87	Screen	06/12/91(*)	Day 42
	33	Male	Imipramine	YES	NOCTEC	22/05/91	Screen	10/07/91(*)	Day 42
	34	Female	Placebo	YES	HEPT-A-MYL	10/04/92($)	Screen	28/05/92(*)	Day 42
					NOCTEC	17/04/92	Day 7	28/05/92(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
2/4	34	Female	Placebo	YES	PRAXILENE	04/88	Screen	28/05/92(*)	Day 42
	35	Female	Reboxetine	YES	AMPECYCLAL	07/92	Screen	26/10/92(*)	Day 42
	36	Female	Imipramine	YES	CHLORAL HYDRATE	12/02/92	Day 7	17/03/92	Day 35
					DIFFU K	12/02/92 28/02/92	Day 35 Day 21	17/02/92 24/03/92(*)	Day 35 Day 42
					INSULIN MONOTARD	87	Screen	24/03/92(*)	Day 42
					LOXEN	90	Screen	24/03/92(*)	Day 42
2/5	73	Male	Placebo	YES	ATARAX	27/01/92	Screen	03/02/92	Screen
					CHLORAL HYDRATE	07/02/92	Day 7	20/03/92(*)	Day 42
	74	Male	Reboxetine	YES	NAFTIDROFURYL OXALATE	89	Screen	01/08/92(*)	Day 42
	75	Male	Imipramine	YES	CHLORAL HYDRATE	03/09/92	Day 7	02/10/92	Day 28
					HYDROXYZINE	03/10/92	Day 28	06/10/92	Day 28
					LEVOMEPROMAZINE	03/10/92	Day 28	06/10/92	Day 28
	76	Female	Imipramine	YES	CHLORAL HYDRATE	19/09/92	Day 21	26/10/92(*)	Day 42
					DIHYDROERGOTAMIN	24/09/92	Day 14	28/09/92	Day 14
	77	Male	Placebo	YES	LEVOMEPROMAZINE	23/06/92	Screen	17/09/92	Screen

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
2/6	55	Female	Reboxetine	YES	CHLORAL HYDRATE	12/06/92	Screen	23/07/92(*)	Day 42
	56	Female	Reboxetine	YES	CHLORAL HYDRATE	12/06/92	Screen	23/07/92(*)	Day 42
	57	Female	Imipramine	YES	CHLORAL HYDRATE	05/05/92	Screen	15/06/92(*)	Day 42
	58	Female	Placebo	YES	CHLORAL HYDRATE	18/05/92	Screen	29/06/92(*)	Day 42
	59	Male	Placebo	NO	CHLORAL HYDRATE	27/05/92	Screen	23/06/92(*)	Day 28
	60	Female	Imipramine	YES	CHLORAL HYDRATE	07/04/92	Screen	22/06/92(*)	Day 42
3/1	144	Female	Reboxetine	YES	HEPT-A-MYL	15/06/92	Day 14	22/07/92(*)	Day 42
	451	Female	Reboxetine	NO	DUPHALAC	28/01/92	Day 7	01/02/92(*)	Day 14
					MICROLAX	29/01/92	Day 14	29/01/92	Day 14
	453	Female	Imipramine	YES	ALDOMET	88	Screen	10/03/92(*)	Day 42
					DIAMICRON	22/01/92($)	Screen	10/03/92(*)	Day 42
					DUPHALAC	31/01/92	Day 14	10/03/92(*)	Day 42
					LIPANTHYL	88	Screen	10/03/92(*)	Day 42
	456	Female	Imipramine	NO	DUPHALAC	01/04/92	Day 7	03/04/92	Day 14
					HEPT-A-MYL	02/92	Screen	03/04/92(*)	Day 14
					NATISEDINE	02/92	Screen	03/04/92(*)	Day 14

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
3/2	65/A	Female	Reboxetine	YES	NOCTEC	29/01/91	Day 7	11/03/91(*)	Day 42
3/3	67	Male	Placebo	YES	CHLORAL HYDRATE	12/07/91	Screen	24/07/91	Day 7
					NOCTEC	19/08/91	Day 35	28/08/91(*)	Day 42
	69	Male	Placebo	YES	NOCTEC	29/01/92	Screen	16/03/92(*)	Day 42
					TERCIAN	29/02/92	Day 28	02/03/92	Day 28
	70	Male	Imipramine	YES	INDOMETACIN	08/04/92	Screen	15/04/92	Day 7
					KETOPROFEN	15/04/92	Day 7	26/05/92(*)	Day 42
					NOCTEC	08/04/92	Screen	26/05/92(*)	Day 42
	71	Female	Imipramine	YES	PROPRANOLOL	10/02/92	Screen	27/05/92(*)	Day 42
	72	Male	Reboxetine	YES	CHLORAL HYDRATE	21/07/92	Screen	01/08/92	Day 14
3/4	79	Female	Imipramine	YES	CHLORAL HYDRATE	04/05/91	Day 7	11/05/91	Day 7
	81	Female	Reboxetine	YES	CHLORAL HYDRATE	14/05/91	Day 7	22/05/91	Day 7
					ETHINYL ESTRADIOL W/NORGE	14/05/91($)	Screen	27/06/91(*)	Day 42
	82	Male	Placebo	YES	CHLORAL HYDRATE	14/06/91	Screen	01/07/91	Day 21
	83	Male	Placebo	NO	BECLOMETASONE	90	Screen	24/06/91(*)	Day 7
					THEOPHYLLINE	90	Screen	24/06/91(*)	Day 7

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
3/4	84	Female	Reboxetine	YES	ETHINYLESTRADIOL	86	Screen	23/11/91(*)	Day 42
					NORGESTREL	86	Screen	23/11/91(*)	Day 42
	85	Female	Imipramine	YES	CHLORAL HYDRATE	25/10/91	Screen	06/12/91	Day 42
	87	Female	Placebo	YES	ALINAM	06/01/92	Day 35	18/01/92	Day 42
					CHLORAL HYDRATE	06/12/91	Screen	17/12/91	Day 14
					MINIPHASE	06/12/91	Screen	19/01/92(*)	Day 42
					THEOSTAT	09/91	Screen	19/01/92(*)	Day 42
	89	Female	Reboxetine	YES	CHLORAL HYDRATE	02/04/92	Day 14	06/05/92(*)	Day 42
	457	Female	Placebo	NO	CHLORAL HYDRATE	29/05/92	Day 14	11/06/92(*)	Day 21
	458	Female	Reboxetine	NO	PARACETAMOL	04/06/92	Day 14	08/06/92	Day 14
					PRIMPERAN	02/06/92	Day 14	09/06/92(*)	Day 14
	459	Female	Placebo	YES	COLCHICINE	24/06/92	Day 28	13/07/92(*)	Day 42
					DAFALGAN	24/06/92	Day 28	05/07/92	Day 35
					DUSPATALIN	24/06/92	Day 28	13/07/92(*)	Day 42
					DYDROGESTERONE	29/05/92($)	Screen	13/07/92(*)	Day 42
					GAVISCON	91	Screen	13/07/92(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
3/4	459	Female	Placebo	YES	OESTRADIOL	91	Day 42	13/07/92(*)	Screen
					PARACETAMOL	18/06/92	Day 21	22/06/92	Day 21
					SULFARLEM	10/06/92	Day 14	13/07/92(*)	Day 42
4/1	92	Female	Reboxetine	YES	CLAMOXYL	13/09/91	Day 42	23/09/91	Day 42
	96	Female	Reboxetine	YES	ISOMERIDE	10/09/91	Day 21	25/09/91	Day 21
	117	Female	Imipramine	YES	LEVOTHYROX	58	Screen	14/10/91(*)	Day 42
	146	Female	Placebo	YES	LOPRIL	91	Screen	27/10/92(*)	Day 42
	148	Female	Imipramine	YES	AVLOCARDYL	87	Screen	06/11/92(*)	Day 42
4/3	99	Female	Placebo	NO	MAALOX	14/08/91	Day 14	15/08/91(*)	Day 14
4/4	109	Female	Reboxetine	YES	CHLORAL HYDRATE	03/06/91	Screen	19/07/91(*)	Day 42
	110	Male	Imipramine	YES	CHLORAL HYDRATE	03/06/91	Screen	26/07/91(*)	Day 42
	111	Male	Imipramine	YES	CHLORAL HYDRATE	27/06/91	Screen	14/08/91(*)	Day 42
	112	Male	Placebo	YES	CHLORAL HYDRATE	05/07/91	Screen	20/08/91(*)	Day 42
	113	Male	Reboxetine	YES	CHLORAL HYDRATE	26/08/91	Screen	11/10/91(*)	Day 42
					NIFLURIL	30/09/91	Day 35	04/10/91	Day 35
	114	Female	Placebo	YES	CHLORAL HYDRATE	13/11/91	Screen	31/12/91(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
4/4	175	Female	Imipramine	YES	CHLORAL HYDRATE	11/02/92	Day 7	25/03/92(*)	Day 42
					SULFARLEM	14/02/92	Day 7	25/03/92(*)	Day 42
	176	Female	Placebo	NO	CHLORAL HYDRATE	11/03/92	Screen	10/04/92	Day 28
	178	Female	Reboxetine	YES	SULFARLEM	18/05/92	Day 21	08/06/92(*)	Day 42
	179	Female	Placebo	NO	CHLORAL HYDRATE	07/09/92	Screen	29/09/92	Day 21
					TRINORDIOL	07/09/92	Screen	29/09/92(*)	Day 21
	180	Male	Reboxetine	YES	CHLORAL HYDRATE	30/09/92	Screen	17/11/92(*)	Day 42
					HEPT-A-MYL	03/11/92	Day 28	17/11/92(*)	Day 42
5/1	127	Male	Reboxetine	YES	CHLORAL HYDRATE	28/05/91	Screen	26/06/91	Day 21
	128	Female	Reboxetine	YES	CHLORAL HYDRATE	09/06/91	Screen	13/06/91	Day 7
	130	Male	Placebo	YES	AMOXICILLIN	12/03/92	Day 14	20/03/92	Day 21
					ASPIRINE	12/03/92	Day 14	20/03/92	Day 21
					DOXYCYCLINE	25/03/92	Day 21	07/04/92	Day 35
	132	Male	Imipramine	YES	CHLORAL HYDRATE	23/06/92	Screen	30/07/92	Day 42
					METRONIDAZOLE	08/07/92	Day 14	06/08/92(*)	Day 42
					TIAPRIDAL	18/06/92	Screen	22/06/92	Screen

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
5/2	121	Female	Imipramine	NO	CHLORAL HYDRATE	26/12/91	Day 7	27/12/91	Day 7
	125	Male	Reboxetine	YES	METOCLOPRAMIDE	18/02/91	Day 21	20/02/91	Day 21
5/3	133	Male	Placebo	NO	CHLORAL HYDRATE	04/12/91	Day 7	12/12/91(*)	Day 14
6/1	151	Male	Imipramine	NO	CHLORAL HYDRATE	13/01/92	Screen	15/01/92	Screen
	152	Female	Reboxetine	YES	ACETYLCYSTEINE	04/03/92	Day 14	08/03/92	Day 14
					AMOXICILINA + CLAVULANICO	04/03/92	Day 14	08/03/92	Day 14
					CHLORAL HYDRATE	17/02/92	Screen	07/04/92(*)	Day 42
					ERCEFURYL	29/03/92	Day 35	03/04/92	Day 42
					IMODIUM	29/03/92	Day 35	03/04/92	Day 42
					MOTILIUM	29/03/92	Day 35	03/04/92	Day 42
					PRIMPERAN	29/03/92	Day 35	03/04/92	Day 42
	153	Male	Reboxetine	YES	CHLORAL HYDRATE	18/02/91	Screen	18/03/91	Screen
	154	Female	Imipramine	NO	NOCTEC	25/03/92	Screen	06/04/92(*)	Screen
	155	Male	Placebo	NO	CHLORAL HYDRATE	01/07/92	Screen	04/08/92(*)	Day 28
					LIPANOR	25/03/92	Screen	04/08/92(*)	Day 28
	156	Female	Placebo	YES	CAPTEA	10/91	Screen	19/10/92(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
6/2	159	Male	Imipramine	YES	CHLORAL HYDRATE	13/07/91	Day 7	24/08/91(*)	Day 42
	160	Male	Placebo	YES	CHLORAL HYDRATE	23/11/91	Day 7	04/01/92(*)	Day 42
	161	Female	Reboxetine	NO	RUFOL	06/03/92	Day 21	18/03/92(*)	Day 28
	169	Female	Imipramine	NO	RENITEC	09/12/91($)	Screen	15/01/92(*)	Day 21
	171	Female	Imipramine	YES	MAALOX	04/08/92	Day 14	11/08/92	Day 21
6/3	166	Female	Reboxetine	NO	HEPT-A-MYL	01/06/91	Screen	29/10/91(*)	Day 7
	168	Female	Placebo	NO	CHLORAL HYDRATE	21/11/91	Screen	02/12/91	Day 7
7/02	182	Male	Placebo	YES	SOSTRIL	08/91	Screen	03/01/92(*)	Day 42
	183	Male	Imipramine	NO	IODINE	88	Screen	18/01/92(*)	Day 21
					TAFIL	30/12/91($)	Screen	30/12/91	Screen
					TENORMIN	91	Screen	18/01/92(*)	Day 21
	185	Male	Reboxetine	NO	DORYL	12/04/92	Day 7	05/05/92(*)	Day 28
					EUGLUCON N	88	Screen	05/05/92(*)	Day 28
8/A	235	Female	Placebo	YES	CALCITONIN	20/09/92	Screen	24/11/92(*)	Day 42
	238	Female	Reboxetine	YES	CALCITONIN	90	Screen	24/11/92(*)	Day 42
	239	Female	Imipramine	YES	DILZENE	88	Screen	26/11/92(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
8/A	239	Female	Imipramine	YES	ISMO	88	Screen	26/11/92(*)	Day 42
	554	Male	Reboxetine	YES	AMLODIPINE	89	Screen	26/11/92(*)	Day 42
					NORAVID	91	Screen	26/11/92(*)	Day 42
					SUGUAN	90	Screen	26/11/92(*)	Day 42
	555	Female	Reboxetine	YES	QUINAPRIL	89	Screen	26/11/92(*)	Day 42
9	241	Female	Placebo	NO	CHLORAL HYDRATE	24/01/91	Screen	18/02/91	Day 14
	242	Female	Reboxetine	NO	CHLORAL HYDRATE	13/02/91	Screen	11/03/91	Day 21
					SIMETHICONE	04/03/91	Day 14	11/03/91(*)	Day 21
	243	Female	Reboxetine	NO	CHLORAL HYDRATE	16/02/91	Screen	06/03/91(*)	Day 14
	244	Female	Imipramine	NO	CHLORAL HYDRATE	14/02/91	Day 7	13/03/91	Day 28
					RANITIDINE	27/02/91	Day 14	13/03/91(*)	Day 28
	245	Female	Imipramine	YES	CHLORAL HYDRATE	18/02/91	Screen	04/04/91	Day 42
	246	Female	Placebo	NO	CHLORAL HYDRATE	18/02/91	Screen	17/03/91	Day 28
	247	Female	Placebo	NO	CHLORAL HYDRATE	21/02/91	Screen	26/03/91(*)	Day 28
	248	Male	Placebo	NO	CHLORAL HYDRATE	04/03/91	Screen	21/03/91	Day 14
	249	Female	Reboxetine	NO	CHLORAL HYDRATE	04/03/91	Screen	11/03/91(*)	Day 7

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
9	250	Female	Imipramine	NO	CHLORAL HYDRATE	07/03/91	Day 7	07/04/91	Day 28
					ENALAPRIL MALEATE	89	Screen	08/04/91(*)	Day 28
					LAEVOLAC	11/03/91	Day 7	08/04/91(*)	Day 28
					MAALOX	02/04/91	Day 28	08/04/91(*)	Day 28
	252	Female	Reboxetine	NO	CHLORAL HYDRATE	28/03/91	Screen	20/04/91	Day 21
					TRASITENSIN	90	Screen	20/04/91(*)	Day 21
	253	Female	Reboxetine	NO	CHLORAL HYDRATE	29/03/91	Screen	08/04/91	Day 7
	254	Female	Imipramine	NO	CHLORAL HYDRATE	05/04/91	Screen	17/04/91	Day 14
	255	Female	Reboxetine	NO	CHLORAL HYDRATE	08/05/91	Screen	06/06/91	Day 28
	256	Female	Imipramine	YES	CHLORAL HYDRATE	23/05/91	Day 7	08/07/91	Day 42
					EFFORTIL	01/07/91	Day 35	08/07/91(*)	Day 42
					LAEVOLAC	01/07/91	Day 35	08/07/91(*)	Day 42
					MAALOX	01/07/91	Day 35	08/07/91(*)	Day 42
	257	Male	Placebo	NO	CHLORAL HYDRATE	21/06/91	Screen	01/07/91	Day 7
	258	Male	Placebo	NO	CHLORAL HYDRATE	25/06/91	Screen	10/07/91	Day 14
11	319	Male	Placebo	YES	CHLORAL HYDRATE	23/08/91 30/08/91	Day 28 Day 35	24/08/91 12/09/91	Day 28 Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
11	320	Male	Imipramine	YES	CHLORAL HYDRATE	22/08/91	Day 14	26/09/91(*)	Day 42
	322	Female	Reboxetine	YES	CHLORAL HYDRATE	01/11/91	Day 42	04/11/91	Day 42
	324	Male	Imipramine	YES	CHLORAL HYDRATE	03/01/92	Day 35	15/01/92	Day 42
	326	Male	Placebo	YES	DIAZEPAM	25/01/92	Day 14	29/01/92	Day 14
	329	Female	Placebo	YES	CAPTOPRIL	91	Screen	21/05/92(*)	Day 42
	336	Female	Imipramine	NO	BRUFEN	15/06/92($)	Screen	25/06/92(*)	Day 7
					PREMARIN	15/06/92($)	Screen	25/06/92(*)	Day 7
	337	Female	Reboxetine	YES	CHLORAL HYDRATE	30/07/92	Day 35	13/08/92(*)	Day 42
12	367	Female	Reboxetine	YES	CHLORAL HYDRATE	15/12/91 24/01/92	Screen Day 42	22/01/92 31/01/92	Day 35 Day 42
					HYDROCHLOROTHIAZIDE WITH	15/12/91	Screen	06/01/92	Day 21
	368	Female	Placebo	YES	ACETAMINOPHEN	05/01/92	Day 14	05/01/92	Day 14
					CHLORAL HYDRATE	26/12/91 01/01/92 13/01/92 25/01/92 01/02/92	Day 7 Day 14 Day 21 Day 35 Day 42	26/12/91 07/01/92 13/01/92 25/01/92 03/02/92	Day 7 Day 14 Day 21 Day 35 Day 42
	369	Female	Imipramine	NO	CHLORAL HYDRATE	18/04/92 11/05/92	Screen Day 21	22/04/92 11/05/92	Screen Day 21
					CLONAZEPAM	17/04/92	Screen	21/04/92	Screen

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
12	369	Female	Imipramine	NO	MEDROXYPROGESTERONE ACETA	14/04/92	Screen	13/05/92(*)	Day 21
					OESTROGEN-HOLZINGER	14/04/92	Screen	13/05/92(*)	Day 21
	370	Male	Placebo	NO	CHLORAL HYDRATE	22/04/92	Screen	19/05/92	Day 21
					LORAZEPAM	15/05/92	Day 21	15/05/92	Day 21
					NIFEDIPINE	13/04/92	Screen	20/05/92(*)	Day 28
					NITRAZEPAM	22/04/92	Screen	24/04/92	Screen
					PIMOZIDE	23/04/92	Screen	27/04/92	Screen
					PROCYCLIDINE HYDROCHLORID	23/04/92	Screen	27/04/92	Screen
	371	Female	Imipramine	NO	ACETAMINOPHEN	17/04/92	Screen	28/04/92	Screen
					BACITRACIN	16/04/92	Screen	22/04/92	Screen
					CHLORAL HYDRATE	24/04/92	Screen	07/05/92	Day 7
					PSEUDOEPHEDRINE HYDROCHLO	22/04/92	Screen	27/04/92	Screen
					TEMAZEPAM	15/04/92	Screen	21/04/92	Screen
	372	Male	Reboxetine	YES	ACEBUTOLOL HYDROCHLORIDE	11/06/92	Day 14	13/07/92(*)	Day 42
					ACETAMINOPHEN	02/06/92	Day 7	04/06/92	Day 7
					CHLORAL HYDRATE	02/06/92	Day 7	13/07/92	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
12	372	Male	Reboxetine	YES	DIMENHYDRINATE	03/06/92	Day 7	03/06/92	Day 7
					NIFEDIPINE	03/06/92	Day 7	03/06/92	Day 7
	374	Female	Placebo	NO	CHLORAL HYDRATE	08/06/92	Screen	09/06/92	Day 7
	375	Male	Imipramine	NO	ACETAMINOPHEN	13/06/92 15/06/92	Screen Screen	13/06/92 15/06/92	Screen Screen
					CHLORAL HYDRATE	11/06/92	Screen	18/06/92	Day 7
					CLONAZEPAM	18/06/92	Day 7	18/06/92	Day 7
					FLURAZEPAM	18/06/92	Day 7	18/06/92	Day 7
13	13	Male	Placebo	YES	TEMAZEPAM	03/04/91	Screen	24/05/91(*)	Day 42
	15	Female	Imipramine	YES	CANESTEN	01/07/91	Day 14	15/08/91(*)	Day 42
					ERYTHROMYCIN	30/06/91	Day 7	10/07/91	Day 7
					PANADOL	01/07/91	Day 7	15/08/91(*)	Day 42
					VENTOLIN	01/07/91	Day 7	15/08/91(*)	Day 42
	16	Male	Imipramine	NO	HYDROXYUREA	18/11/91 30/11/91	Screen Screen	24/11/91 16/01/92(*)	Screen Day 42
	18	Male	Reboxetine	YES	PANADOL	22/07/92	Day 35	26/07/92	Day 35
	410	Male	Placebo	YES	PANADOL	14/02/92	Day 7	20/02/92	Day 7

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
13	411	Female	Imipramine	YES	AGAROL	91	Screen	04/04/92	Day 7
					ASPIRINE	25/03/92	Screen	08/05/92(*)	Day 42
					DIAZEPAM	18/03/92	Screen	23/03/92	Screen
					NU-LAX	18/03/92	Day 14	08/05/92(*)	Day 42
					PANADOL	18/04/92	Day 28	08/05/92(*)	Day 42
					SUDAFED	02/04/92 22/04/92	Day 7 Day 28	04/04/92 29/04/92	Day 7 Day 35
					TEMAZEPAM	18/03/92	Day 14	23/03/92	Day 14
14	19	Female	Reboxetine	NO	TRIMETHOPRIM	06/04/92	Day 7	15/04/92	Day 7
	20	Female	Imipramine	YES	FLUCLOXACILLIN	30/04/92	Day 7	02/05/92	Day 7
					PENICILLIN G	30/04/92	Day 7	02/05/92	Day 7
					TETANUS IMMUNOGLOBULIN	30/04/92	Day 7	30/04/92	Day 7
					TETANUS TOXOID	30/04/92	Day 7	30/04/92	Day 7
	21	Female	Imipramine	NO	CHLORAL HYDRATE	15/07/92	Screen	19/07/92	Screen
15	25	Female	Reboxetine	YES	PARACETAMOL	20/06/91 20/07/91	Day 7 Day 35	23/06/91 22/07/91	Day 7 Day 35
					TEMAZEPAM	02/04/91	Screen	29/07/91(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
15	27	Female	Imipramine	YES	NORETHISTERONE	06/85	Screen	13/08/91(*)	Day 42
					OESTRADIOL	06/85	Screen	13/08/91(*)	Day 42
	28	Female	Reboxetine	YES	AUGMENTIN	03/09/91	Day 28	07/09/91	Day 35
					SENOKOT	31/08/91	Day 28	02/09/91	Day 28
						06/09/91	Day 35	10/09/91	Day 35
						15/09/91	Day 42	18/09/91	Day 42
					TEMAZEPAM	21/05/91	Screen	11/09/91	Day 35
	29	Male	Placebo	NO	TEMAZEPAM	22/08/91	Screen	08/09/91	Day 14
						17/09/91	Day 21	18/09/91	Day 21
	403	Female	Imipramine	YES	TEMAZEPAM	02/10/91	Day 7	14/11/91(*)	Day 42
	405	Female	Placebo	YES	MULTIVITAMINS	06/91	Screen	23/12/91(*)	Day 42
	407	Female	Reboxetine	YES	PARACETAMOL	21/12/91	Day 21	22/12/91	Day 21
						10/01/92	Day 42	13/01/92	Day 42
	408	Female	Placebo	YES	PARACETAMOL	03/02/92	Day 14	04/02/92	Day 21
					TEMAZEPAM	11/02/92	Day 35	04/03/92(*)	Day 42
	418	Female	Placebo	YES	CALCIUM GLUCONATE	71	Screen	12/03/92(*)	Day 42
					CALCIUM LACTATE	71	Screen	12/03/92(*)	Day 42
					SENOKOT	06/03/92	Day 42	12/03/92(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
15	418	Female	Placebo	YES	TEMAZEPAM	16/10/89	Screen	12/03/92(*)	Day 42
	419	Female	Placebo	YES	AMOXICILLIN	06/06/92	Day 42	09/06/92(*)	Day 42
					ASPIRINE	01/06/92	Day 35	03/06/92	Day 42
					PARACETAMOL	11/05/92	Day 14	11/05/92	Day 14
						22/05/92	Day 28	24/05/92	Day 28
					URAL	06/06/92	Day 42	09/06/92(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
1	1	Imipramine	10/04/91	10/04/91	1	100	50	100.0	100.0	9m		50	
			11/04/91	12/04/91	2	100	100	100.0	100.0		50	50	
			13/04/91	28/04/91	16	150	150	100.0	100.0		50	100	
			29/04/91	29/04/91	1	150	50	33.3	96.7	1e	50		
			30/04/91	09/05/91	10	150	150	100.0	97.8		50	100	
			10/05/91	10/05/91	1	150		0.0	94.6	10m 10e			
			11/05/91	11/05/91	1	150	150	100.0	94.8		50	100	
			12/05/91	13/05/91	2	150	50	33.3	91.2	10e	50		
			14/05/91	21/05/91	8	150	150	100.0	92.9		50	100	
			22/05/91	22/05/91	1	150	50	100.0	93.0	9e	50		
					43								
	2	Reboxetine	15/04/91	15/04/91	1	8	4	100.0	100.0	9m		4	
			16/04/91	12/05/91	27	8	8	100.0	100.0		4	4	
			13/05/91	26/05/91	14	10	10	100.0	100.0		4	6	
			27/05/91	27/05/91	1	10	4	100.0	100.0	9e	4		
					43								
	3	Imipramine	06/05/91	06/05/91	1	100	50	100.0	100.0	9m		50	
			07/05/91	08/05/91	2	100	100	100.0	100.0		50	50	
			09/05/91	02/06/91	25	150	150	100.0	100.0		50	100	
			03/06/91	03/06/91	1	200	150	100.0	100.0		50	100	
			04/06/91	16/06/91	13	200	200	100.0	100.0		100	100	
					42								
	4	Placebo	04/06/91	04/06/91	1	0	0	100.0	100.0	9m		0	
			05/06/91	15/07/91	41	0	0	100.0	100.0		0	0	
			16/07/91	16/07/91	1	0	0	100.0	100.0	9e	0		
					43								
	5	Reboxetine	12/06/91	12/06/91	1	8	4	100.0	100.0	9m		4	
			13/06/91	01/07/91	19	8	8	100.0	100.0		4	4	
			02/07/91	02/07/91	1	8	4	100.0	100.0	6e	4		
					21								
	6	Placebo	23/05/91	23/05/91	1	0	0	100.0	100.0	9m		0	
			24/05/91	05/07/91	43	0	0	100.0	100.0		0	0	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(xx) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					44								
1	7	Reboxetine	27/08/91	27/08/91	1	8	4	100.0	100.0	9m		4	
			28/08/91	05/09/91	9	8	8	100.0	100.0		4	4	
			06/09/91	06/09/91	1	8	4	50.0	95.5	1e	4		
			07/09/91	07/10/91	31	8	8	100.0	98.8		4	4	
			08/10/91	08/10/91	1	8	4	100.0	98.8	9e	4		
					43								
	8	Placebo	05/09/91	18/09/91	14	0	0	100.0	100.0		0	0	
			19/09/91	20/09/91	2	0	0	100.0	100.0	10e	0		
			21/09/91	24/09/91	4	0	0	100.0	100.0		0	0	
			25/09/91	25/09/91	1	0	0	100.0	100.0	1m		0	
			26/09/91	27/09/91	2	0	0	100.0	100.0	4e	0		
			28/09/91	18/10/91	21	0	0	100.0	100.0		0	0	
			19/10/91	19/10/91	1	0	0	100.0	100.0	9e	0		
					45								
	9	Reboxetine	27/11/91	27/11/91	1	8	4	100.0	100.0	9m		4	
			28/11/91	17/12/91	20	8	8	100.0	100.0		4	4	
			18/12/91	05/01/92	19	10	10	100.0	100.0		4	6	
			06/01/92	06/01/92	1	10	4	100.0	100.0	9e	4		
					41								
	10	Placebo	24/09/91	24/09/91	1	0	0	100.0	100.0	9m		0	
			25/09/91	13/10/91	19	0	0	100.0	100.0		0	0	
			14/10/91	14/10/91	1	0	0	100.0	100.0	10e	0		
			15/10/91	03/11/91	20	0	0	100.0	100.0		0	0	
			04/11/91	04/11/91	1	0	0	100.0	100.0	9e	0		
					42								
	11	Imipramine	10/10/91	12/10/91	3	100	100	100.0	100.0		50	50	
			13/10/91	13/10/91	1	150	150	100.0	100.0		50	100	
					4								
	12	Imipramine	18/10/91	20/10/91	3	100	100	100.0	100.0		50	50	
			21/10/91	29/11/91	40	150	150	100.0	100.0		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
1	12	Imipramine	30/11/91	30/11/91	1	150	50	100.0	100.0	9e	50		
					44								
	412	Reboxetine	13/11/91	13/11/91	1	8	4	100.0	100.0	9m		4	
			14/11/91	03/12/91	20	8	8	100.0	100.0		4	4	
			04/12/91	22/12/91	19	10	10	100.0	100.0		4	6	
			23/12/91	23/12/91	1	10	4	100.0	100.0	6e	4		
					41								
	413	Placebo	09/12/91	19/01/92	42	0	0	100.0	100.0		0	0	
			20/01/92	20/01/92	1	0	0	100.0	100.0	9e	0		
					43								
	414	Imipramine	22/01/92	24/01/92	3	100	100	100.0	100.0		50	50	
			25/01/92	29/01/92	5	150	150	100.0	100.0		50	100	
					8								
	415	Imipramine	14/01/92	14/01/92	1	100	50	100.0	100.0	9m		50	
			15/01/92	16/01/92	2	100	100	100.0	100.0		50	50	
			17/01/92	27/01/92	11	150	150	100.0	100.0		50	100	
			28/01/92	28/01/92	1	150	50	33.3	95.6	10e	50		
			29/01/92	05/02/92	8	150	150	100.0	97.1		50	100	
			06/02/92	06/02/92	1	150		0.0	93.1	10m 10e			
			07/02/92	27/02/92	21	150	150	100.0	96.3		50	100	
					45								
	416	Reboxetine	17/01/92	17/01/92	1	8	4	100.0	100.0	9m		4	
			18/01/92	23/01/92	6	8	8	100.0	100.0		4	4	
			24/01/92	24/01/92	1	8	12	100.0	100.0	9e	8	4	yes
			25/01/92	28/01/92	4	8	8	100.0	100.0		4	4	
					12								
	421	Imipramine	27/02/92	27/02/92	1	100	50	100.0	100.0	9m		50	
			28/02/92	29/02/92	2	100	100	100.0	100.0		50	50	
			01/03/92	09/04/92	40	150	150	100.0	100.0		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient,
5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening,
10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose,
C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					43								
1	422	Imipramine	05/08/92	07/08/92	3	100	100	100.0	100.0		50	50	
			08/08/92	14/08/92	7	150	150	100.0	100.0		50	100	
			15/08/92	15/08/92	1	150	50	33.3	93.9	1e	50		
			16/08/92	19/08/92	4	150	150	100.0	95.6		50	100	
			20/08/92	20/08/92	1	150	50	33.3	91.7	1e	50		
			21/08/92	25/08/92	5	150	150	100.0	93.7		50	100	
			26/08/92	26/08/92	1	150	50	33.3	90.9	1e	50		
			27/08/92	27/08/92	1	150	100	66.7	89.9	1m		100	
			28/08/92	01/09/92	5	150	150	100.0	91.7		50	100	
			02/09/92	02/09/92	1	150		0.0	88.5	10m 10e			
			03/09/92	09/09/92	7	150	150	100.0	90.7		50	100	
			10/09/92	10/09/92	1	150		0.0	88.3	1m 1e			
			11/09/92	17/09/92	7	150	150	100.0	90.2		50	100	
					44								
2/1	49	Placebo	18/05/91	28/06/91	42	0	0	100.0	100.0		0	0	
					42								
	50	Reboxetine	27/12/91	05/02/92	41	8	8	100.0	100.0		4	4	
			06/02/92	06/02/92	1	8	4	100.0	100.0	6e	4		
					42								
	51	Imipramine	02/02/92	04/02/92	3	100	100	100.0	100.0		50	50	
			05/02/92	15/03/92	40	150	150	100.0	100.0		50	100	
					43								
2/2	43	Imipramine	18/04/91	18/04/91	1	100	50	100.0	100.0	9m		50	
			19/04/91	20/04/91	2	100	100	100.0	100.0		50	50	
			21/04/91	23/04/91	3	150	150	100.0	100.0		50	100	
			24/04/91	24/04/91	1	150	50	100.0	100.0	3e	50		
			25/04/91	02/05/91	8	150		100.0	100.0	3m 3e			
			03/05/91	16/05/91	14	150	150	100.0	100.0		50	100	
					29								
	44	Imipramine	19/07/91	19/07/91	1	100		0.0	0.0	9m 1e			

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
2/2	44	Imipramine	20/07/91	21/07/91	2	100	100	100.0	66.7		50	50	
			22/07/91	29/08/91	39	150	150	100.0	97.6		50	100	
					42								
	45	Reboxetine	08/09/91	29/09/91	22	8	8	100.0	100.0		4	4	
			30/09/91	20/10/91	21	10	10	100.0	100.0		4	6	
					43								
	46	Placebo	26/09/91	26/09/91	1	0	0	100.0	100.0	9m		0	
			27/09/91	10/10/91	14	0	0	100.0	100.0		0	0	
			11/10/91	16/10/91	6	0		100.0	100.0	3m 3e			
			17/10/91	17/10/91	1	0	0	100.0	100.0	3m		0	
			18/10/91	22/10/91	5	0	0	100.0	100.0		0	0	
			23/10/91	23/10/91	1	0	0	100.0	100.0	9e	0		
					28								
	47	Placebo	24/03/92	05/04/92	13	0	0	100.0	100.0		0	0	
			06/04/92	06/04/92	1	0	0	100.0	100.0	1e	0		
			07/04/92	02/05/92	26	0	0	100.0	100.0		0	0	
			03/05/92	03/05/92	1	0	0	100.0	100.0	1m		0	
			04/05/92	04/05/92	1	0	0	100.0	100.0		0	0	
					42								
	48	Reboxetine	07/04/92	04/05/92	28	8	8	100.0	100.0		4	4	
			05/05/92	05/05/92	1	8		0.0	96.6	1m 1e			
			06/05/92	19/05/92	14	8	8	100.0	97.7		4	4	
					43								
2/3	36/A	Imipramine	07/03/91	09/03/91	3	100	100	100.0	100.0		50	50	
			10/03/91	17/04/91	39	150	150	100.0	100.0		50	100	
					42								
	37	Reboxetine	27/03/91	07/05/91	42	8	8	100.0	100.0		4	4	
					42								
	38	Placebo	14/08/91	25/09/91	43	0	0	100.0	100.0		0	0	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					43								
2/3	39	Imipramine	10/08/91	12/08/91	3	100	100	100.0	100.0		50	50	
			13/08/91	20/09/91	39	150	150	100.0	100.0		50	100	
					42								
	40	Reboxetine	24/10/91	04/12/91	42	8	8	100.0	100.0		4	4	
					42								
	41	Placebo	03/10/91	13/11/91	42	0	0	100.0	100.0		0	0	
					42								
	42	Imipramine	19/05/92	21/05/92	3	100	100	100.0	100.0		50	50	
			22/05/92	30/06/92	40	150	150	100.0	100.0		50	100	
					43								
2/4	31	Placebo	26/03/91	05/05/91	41	0	0	100.0	100.0		0	0	
					41								
	32	Reboxetine	26/10/91	06/12/91	42	8	8	100.0	100.0		4	4	
					42								
	33	Imipramine	29/05/91	29/05/91	1	100	50	100.0	100.0	9m		50	
			30/05/91	31/05/91	2	100	100	100.0	100.0		50	50	
			01/06/91	09/07/91	39	150	150	100.0	100.0		50	100	
			10/07/91	10/07/91	1	150	50	100.0	100.0	9e	50		
					43								
	34	Placebo	17/04/92	28/05/92	42	0	0	100.0	100.0		0	0	
					42								
	35	Reboxetine	15/09/92	26/10/92	42	8	8	100.0	100.0		4	4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
2/4	36	Imipramine	12/02/92	14/02/92	3	100	100	100.0	100.0		50	50	
			15/02/92	24/03/92	39	150	150	100.0	100.0		50	100	
					42								
2/5	73	Placebo	07/02/92	20/03/92	43	0	0	100.0	100.0		0	0	
					43								
	74	Reboxetine	21/06/92	01/08/92	42	8	8	100.0	100.0		4	4	
					42								
	75	Imipramine	11/09/92	13/09/92	3	100	100	100.0	100.0		50	50	
			14/09/92	22/10/92	39	150	150	100.0	100.0		50	100	
					42								
	76	Imipramine	15/09/92	17/09/92	3	100	100	100.0	100.0		50	50	
			18/09/92	26/10/92	39	150	150	100.0	100.0		50	100	
					42								
	77	Placebo	22/09/92	02/11/92	42	0	0	100.0	100.0		0	0	
					42								
	78	Reboxetine	10/10/92	13/11/92	35	8	8	100.0	100.0		4	4	
					35								
2/6	55	Reboxetine	12/06/92	02/07/92	21	8	8	100.0	100.0		4	4	
			03/07/92	23/07/92	21	8	18	100.0	100.0		8	10	(3 - m) (3 - e)
					42								
	56	Reboxetine	12/06/92	02/07/92	21	8	8	100.0	100.0		4	4	
			03/07/92	23/07/92	21	8	18	100.0	100.0		8	10	(3 - m) (3 - e)

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
2/6	57	Imipramine	05/05/92	07/05/92	3	100	100	100.0	100.0		50	50	
			08/05/92	25/05/92	18	150	150	100.0	100.0		50	100	
			26/05/92	15/06/92	21	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
					42								
	58	Placebo	18/05/92	08/06/92	22	0	0	100.0	100.0		0	0	
			09/06/92	29/06/92	21	0	0	100.0	100.0		0	0	(3 - m) (3 - e)
					43								
	59	Placebo	27/05/92	16/06/92	21	0	0	100.0	100.0		0	0	
			17/06/92	23/06/92	7	0	0	100.0	100.0		0	0	(3 - m) (3 - e)
					28								
4	60	Imipramine	12/05/92	14/05/92	3	100	100	100.0	100.0		50	50	
			15/05/92	01/06/92	18	150	150	100.0	100.0		50	100	
			02/06/92	22/06/92	21	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
					42								
3/1	61	Imipramine	05/03/91	07/03/91	3	100	100	100.0	100.0		50	50	
			08/03/91	20/03/91	13	150	150	100.0	100.0		50	100	
			21/03/91	21/03/91	1	150	100	66.7	98.0	1m		100	
			22/03/91	22/03/91	1	150	150	100.0	98.1		50	100	
			23/03/91	23/03/91	1	150	50	33.3	94.7	1e	50		
			24/03/91	31/03/91	8	150	150	100.0	96.3		50	100	
			01/04/91	01/04/91	1	150	50	33.3	94.0	1e	50		
			02/04/91	07/04/91	6	150	150	100.0	95.1		50	100	
			08/04/91	08/04/91	1	150	50	33.3	93.3	1e	50		
					35								
	62	Imipramine	16/04/91	18/04/91	3	100	100	100.0	100.0		50	50	
			19/04/91	26/05/91	38	150	150	100.0	100.0		50	100	
					41								
	63	Placebo	13/05/91	23/06/91	42	0	0	100.0	100.0		0	0	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
3/1	64	Placebo	14/03/91	01/04/91	19	0	0	100.0	100.0		0	0	
			02/04/91	02/04/91	1	0	0	100.0	100.0	1e	0		
			03/04/91	24/04/91	22	0	0	100.0	100.0		0	0	
					42								
	65	Reboxetine	16/09/91	27/10/91	42	8	8	100.0	100.0		4	4	
					42								
	66	Reboxetine	10/06/91	21/07/91	42	8	8	100.0	100.0		4	4	
					42								
	139	Imipramine	03/09/91	05/09/91	3	100	100	100.0	100.0		50	50	
			06/09/91	12/09/91	7	150	150	100.0	100.0		50	100	
					10								
	140	Placebo	12/09/91	23/10/91	42	0	0	100.0	100.0		0	0	
					42								
	141	Placebo	03/10/91	14/11/91	43	0	0	100.0	100.0		0	0	
					43								
	142	Imipramine	18/11/91	20/11/91	3	100	100	100.0	100.0		50	50	
			21/11/91	08/12/91	18	150	150	100.0	100.0		50	100	
					21								
	143	Reboxetine	15/04/92	15/04/92	1	8	4	100.0	100.0	9m		4	
			16/04/92	19/05/92	34	8	8	100.0	100.0		4	4	
			20/05/92	20/05/92	1	8	4	100.0	100.0	6e	4		
					36								
	144	Reboxetine	09/06/92	09/06/92	1	8	4	100.0	100.0	9m		4	
			10/06/92	22/07/92	43	8	8	100.0	100.0		4	4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
					44								
3/1	451	Reboxetine	20/01/92	20/01/92	1	8	4	100.0	100.0	9m		4	
			21/01/92	31/01/92	11	8	8	100.0	100.0		4	4	
			01/02/92	01/02/92	1	8	4	100.0	100.0	6e	4		
					13								
	452	Placebo	22/01/92	22/01/92	1	0	0	100.0	100.0	9m		0	
			23/01/92	03/03/92	41	0	0	100.0	100.0		0	0	
			04/03/92	04/03/92	1	0	0	100.0	100.0	9e	0		
					43								
	453	Imipramine	29/01/92	29/01/92	1	100	50	100.0	100.0	9m		50	
			30/01/92	31/01/92	2	100	100	100.0	100.0		50	50	
			01/02/92	10/03/92	39	150	150	100.0	100.0		50	100	
					42								
	454	Reboxetine	17/02/92	17/02/92	1	8	4	100.0	100.0	9m		4	
			18/02/92	31/03/92	43	8	8	100.0	100.0		4	4	
			01/04/92	01/04/92	1	8	4	100.0	100.0	9e	4		
					45								
	455	Placebo	11/03/92	11/03/92	1	0	0	100.0	100.0	9m		0	
			12/03/92	22/04/92	42	0	0	100.0	100.0		0	0	
					43								
	456	Imipramine	25/03/92	25/03/92	1	100	50	100.0	100.0	9m		50	
			26/03/92	27/03/92	2	100	100	100.0	100.0		50	50	
			28/03/92	02/04/92	6	150	150	100.0	100.0		50	100	
			03/04/92	03/04/92	1	150	50	100.0	100.0	3e	50		
					10								
3/2	65/A	Reboxetine	29/01/91	25/02/91	28	8	8	100.0	100.0		4	4	
			26/02/91	27/02/91	2	8	18	100.0	100.0		8	10	(3 - m) (3 - e)
			28/02/91	04/03/91	5	8	10	100.0	100.0		4	6	
			05/03/91	11/03/91	7	10	10	100.0	100.0		4	6	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
3/3	67	Placebo	18/07/91	28/08/91	42	0	0	100.0	100.0		0	0	
					42								
	68	Reboxetine	21/01/92	02/03/92	42	8	8	100.0	100.0		4	4	
					42								
	69	Placebo	04/02/92	16/03/92	42	0	0	100.0	100.0		0	0	
					42								
	70	Imipramine	15/04/92	17/04/92	3	100	100	100.0	100.0		50	50	
			18/04/92	26/05/92	39	150	150	100.0	100.0		50	100	
					42								
	71	Imipramine	16/04/92	18/04/92	3	100	100	100.0	100.0		50	50	
			19/04/92	27/05/92	39	150	150	100.0	100.0		50	100	
					42								
	72	Reboxetine	25/07/92	04/09/92	42	8	8	100.0	100.0		4	4	
					42								
3/4	79	Imipramine	04/05/91	05/05/91	2	100	100	100.0	100.0		50	50	
			06/05/91	06/05/91	1	100	200	100.0	100.0		100	100	(B - m)
			07/05/91	07/05/91	1	150	300	100.0	100.0		100	200	(B - m) (B - e)
			08/05/91	03/06/91	27	150	150	100.0	100.0		50	100	
			04/06/91	04/06/91	1	150	100	66.7	99.0	10m		100	
			05/06/91	15/06/91	11	150	150	100.0	99.2		50	100	
					43								
	80	Imipramine	01/09/91	03/09/91	3	100	100	100.0	100.0		50	50	
			04/09/91	24/09/91	21	150	150	100.0	100.0		50	100	
					24								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

990

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
3/4	81	Reboxetine	17/05/91	27/06/91	42	8	8	100.0	100.0		4	4	
					42								
	82	Placebo	17/06/91	28/07/91	42	0	0	100.0	100.0		0	0	
					42								
	83	Placebo	17/06/91	17/06/91	1	0	0	100.0	100.0	9m		0	
			18/06/91	23/06/91	6	0	0	100.0	100.0		0	0	
			24/06/91	24/06/91	1	0	0	100.0	100.0	6e	0		
					8								
	84	Reboxetine	09/10/91	22/11/91	45	8	8	100.0	100.0		4	4	
			23/11/91	23/11/91	1	8	4	100.0	100.0	9e	4		
					46								
	85	Imipramine	29/10/91	31/10/91	3	100	100	100.0	100.0		50	50	
			01/11/91	08/12/91	38	150	150	100.0	100.0		50	100	
					41								
	86	Imipramine	03/12/91	05/12/91	3	100	100	100.0	100.0		50	50	
			06/12/91	14/01/92	40	150	150	100.0	100.0		50	100	
			15/01/92	15/01/92	1	150	50	100.0	100.0	9e	50		
					44								
	87	Placebo	09/12/91	19/01/92	42	0	0	100.0	100.0		0	0	
					42								
	88	Placebo	23/03/92	23/03/92	1	0	0	100.0	100.0	9m		0	
			24/03/92	27/03/92	4	0	0	100.0	100.0		0	0	
			28/03/92	28/03/92	1	0	0	100.0	100.0		0	0	(B - m) (B - e)
			29/03/92	29/03/92	1	0	0	100.0	100.0		0	0	(B - e)
			30/03/92	30/03/92	1	0	0	100.0	100.0		0	0	(B - m)
			31/03/92	19/04/92	20	0	0	100.0	100.0		0	0	
			20/04/92	21/04/92	2	0	0	100.0	100.0	4e	0		
			22/04/92	22/04/92	1	0	0	100.0	100.0	4m		0	
			23/04/92	07/05/92	15	0	0	100.0	100.0		0	0	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
3/4	88	Placebo	08/05/92	08/05/92	1	0	0	100.0	100.0	9e	0		
					47								
	89	Reboxetine	26/03/92	05/05/92	41	8	8	100.0	100.0		4	4	
			06/05/92	06/05/92	1	8	4	100.0	100.0	9e	4		
					42								
	90	Reboxetine	28/04/92	08/06/92	42	8	8	100.0	100.0		4	4	
					42								
	457	Placebo	22/05/92	11/06/92	21	0	0	100.0	100.0		0	0	
					21								
	458	Reboxetine	26/05/92	26/05/92	1	8	4	100.0	100.0	9m		4	
			27/05/92	08/06/92	13	8	8	100.0	100.0		4	4	
			09/06/92	09/06/92	1	8	4	100.0	100.0	6e	4		
					15								
	459	Placebo	02/06/92	18/06/92	17	0	0	100.0	100.0		0	0	
			19/06/92	20/06/92	2	0	0	100.0	100.0	10e	0		
			21/06/92	13/07/92	23	0	0	100.0	100.0		0	0	
					42								
	460	Reboxetine	19/08/92	20/08/92	2	8	8	100.0	100.0		4	4	
					2								
	461	Imipramine	17/09/92	17/09/92	1	100	50	100.0	100.0	9m		50	
			18/09/92	19/09/92	2	100	100	100.0	100.0		50	50	
			20/09/92	23/09/92	4	150	150	100.0	100.0		50	100	
			24/09/92	24/09/92	1	150	50	100.0	100.0	6e	50		
					8								
	462	Imipramine	29/09/92	29/09/92	1	100	50	100.0	100.0	9m		50	
			30/09/92	01/10/92	2	100	100	100.0	100.0		50	50	
			02/10/92	07/10/92	6	150	150	100.0	100.0		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
3/4	462	Imipramine	08/10/92	08/10/92	1	150	50	100.0	100.0	6e	50		
					10								
4/1	91	Imipramine	12/10/91	14/10/91	3	100	100	100.0	100.0		50	50	
			15/10/91	22/11/91	39	150	150	100.0	100.0		50	100	
					42								
	92	Reboxetine	07/08/91	10/09/91	35	8	8	100.0	100.0		4	4	
			11/09/91	17/09/91	7	10	10	100.0	100.0		4	6	
					42								
	93	Placebo	03/07/91	15/08/91	44	0	0	100.0	100.0		0	0	
			16/08/91	16/08/91	1	0	0	100.0	100.0	9e	0		
					45								
	94	Placebo	05/07/91	19/07/91	15	0	0	100.0	100.0		0	0	
			20/07/91	23/07/91	4	0	0	100.0	100.0	4e	0		
			24/07/91	13/08/91	21	0	0	100.0	100.0		0	0	
					40								
	95	Imipramine	03/06/91	05/06/91	3	100	100	100.0	100.0		50	50	
			06/06/91	16/07/91	41	150	150	100.0	100.0		50	100	
					44								
	96	Reboxetine	04/09/91	16/10/91	43	8	8	100.0	100.0		4	4	
					43								
	115	Reboxetine	06/05/92	16/06/92	42	8	8	100.0	100.0		4	4	
					42								
	116	Imipramine	16/05/92	18/05/92	3	100	100	100.0	100.0		50	50	
			19/05/92	21/05/92	3	150	150	100.0	100.0		50	100	
			22/05/92	22/05/92	1	150	50	100.0	100.0	6e	50		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					7								
4/1	117	Imipramine	03/09/91	05/09/91	3	100	100	100.0	100.0		50	50	
			06/09/91	14/10/91	39	150	150	100.0	100.0		50	100	
					42								
	118	Reboxetine	23/05/92	03/07/92	42	8	8	100.0	100.0		4	4	
					42								
	120	Placebo	31/07/92	31/07/92	1	0	0	100.0	100.0	9m		0	
			01/08/92	11/09/92	42	0	0	100.0	100.0		0	0	
					43								
	145	Imipramine	30/09/92	02/10/92	3	100	100	100.0	100.0		50	50	
			03/10/92	05/10/92	3	150	150	100.0	100.0		50	100	
			06/10/92	06/10/92	1	150	100	66.7	95.2	10m		100	
			07/10/92	10/11/92	35	150	150	100.0	99.2		50	100	
					42								
	146	Placebo	16/09/92	26/10/92	41	0	0	100.0	100.0		0	0	
			27/10/92	27/10/92	1	0	0	100.0	100.0	9e	0		
					42								
	147	Reboxetine	01/09/92	02/09/92	2	8	8	100.0	100.0		4	4	
			03/09/92	03/09/92	1	8	4	50.0	83.3	10e	4		
			04/09/92	12/10/92	39	8	8	100.0	98.8		4	4	
					42								
	148	Imipramine	26/09/92	28/09/92	3	100	100	100.0	100.0		50	50	
			29/09/92	06/11/92	39	150	150	100.0	100.0		50	100	
					42								
	149	Reboxetine	30/09/92	10/11/92	42	8	8	100.0	100.0		4	4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
4/1	150	Placebo	30/09/92	10/11/92	42	0	0	100.0	100.0		0	0	
					42								
4/2	93/A	Placebo	22/02/91	04/04/91	42	0	0	100.0	100.0		0	0	
					42								
	99/A	Placebo	27/03/91	07/05/91	42	0	0	100.0	100.0		0	0	
					42								
	104	Reboxetine	22/05/91	02/07/91	42	8	8	100.0	100.0		4	4	
					42								
4/3	97	Placebo	17/04/91	29/04/91	13	0	0	100.0	100.0		0	0	
			30/04/91	30/04/91	1	0	0	100.0	100.0	10e	0		
			01/05/91	28/05/91	28	0	0	100.0	100.0		0	0	
					42								
	98	Reboxetine	20/06/91	11/07/91	22	8	8	100.0	100.0		4	4	
			12/07/91	12/07/91	1	8	4	50.0	97.8	1e	4		
			13/07/91	16/07/91	4	8	8	100.0	98.1		4	4	
			17/07/91	21/07/91	5	10	10	100.0	98.4		4	6	
					32								
	99	Placebo	08/08/91	14/08/91	7	0	0	100.0	100.0		0	0	
			15/08/91	15/08/91	1	0	0	100.0	100.0	6e	0		
					8								
	100	Imipramine	27/11/91	27/11/91	1	100	50	100.0	100.0	9m		50	
			28/11/91	29/11/91	2	100	100	100.0	100.0		50	50	
			30/11/91	17/12/91	18	150	150	100.0	100.0		50	100	
					21								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
4/3	101	Imipramine	17/03/92	19/03/92	3	100	100	100.0	100.0		50	50	
			20/03/92	27/04/92	39	150	150	100.0	100.0		50	100	
					42								
4/4	109	Reboxetine	08/06/91	19/07/91	42	8	8	100.0	100.0		4	4	
					42								
	110	Imipramine	15/06/91	17/06/91	3	100	100	100.0	100.0		50	50	
			18/06/91	26/07/91	39	150	150	100.0	100.0		50	100	
					42								
	111	Imipramine	04/07/91	06/07/91	3	100	100	100.0	100.0		50	50	
			07/07/91	14/08/91	39	150	150	100.0	100.0		50	100	
					42								
	112	Placebo	10/07/91	20/08/91	42	0	0	100.0	100.0		0	0	
					42								
	113	Reboxetine	31/08/91	11/10/91	42	8	8	100.0	100.0		4	4	
					42								
	114	Placebo	20/11/91	31/12/91	42	0	0	100.0	100.0		0	0	
					42								
	175	Imipramine	13/02/92	15/02/92	3	100	100	100.0	100.0		50	50	
			16/02/92	25/03/92	39	150	150	100.0	100.0		50	100	
					42								
	176	Placebo	14/03/92	07/04/92	25	0	0	100.0	100.0		0	0	
			08/04/92	08/04/92	1	0	0	100.0	100.0	6e	0		
					26								
	177	Imipramine	28/04/92	30/04/92	3	100	100	100.0	100.0		50	50	
			01/05/92	11/05/92	11	150	150	100.0	100.0		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					14								
4/4	178	Reboxetine	28/04/92	08/06/92	42	8	8	100.0	100.0		4	4	
					42								
	179	Placebo	11/09/92	28/09/92	18	0	0	100.0	100.0		0	0	
			29/09/92	29/09/92	1	0	0	100.0	100.0	6e	0		
					19								
	180	Reboxetine	07/10/92	17/11/92	42	8	8	100.0	100.0		4	4	
					42								
5/1	127	Reboxetine	06/06/91	26/06/91	21	8	8	100.0	100.0		4	4	
			27/06/91	17/07/91	21	10	10	100.0	100.0		4	6	
					42								
	128	Reboxetine	14/06/91	25/07/91	42	8	8	100.0	100.0		4	4	
					42								
	129	Placebo	24/12/91	03/02/92	42	0	0	100.0	100.0		0	0	
					42								
	130	Placebo	05/03/92	14/04/92	41	0	0	100.0	100.0		0	0	
			15/04/92	15/04/92	1	0	0	100.0	100.0	5e	0		
					42								
	131	Imipramine	21/03/92	23/03/92	3	100	100	100.0	100.0		50	50	
			24/03/92	30/04/92	38	150	150	100.0	100.0		50	100	
					41								
	132	Imipramine	25/06/92	27/06/92	3	100	100	100.0	100.0		50	50	
			28/06/92	06/08/92	40	150	150	100.0	100.0		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					43								
5/2	121	Imipramine	20/12/91	22/12/91	3	100	100	100.0	100.0		50	50	
			23/12/91	26/01/92	35	150	150	100.0	100.0		50	100	
			27/01/92	27/01/92	1	150	50	100.0	100.0	6e	50		
					39								
	125	Reboxetine	28/01/91	23/02/91	27	8	8	100.0	100.0		4	4	
			24/02/91	24/02/91	1	8	4	50.0	98.2	1e	4		
			25/02/91	09/03/91	13	8	8	100.0	98.8		4	4	
			10/03/91	10/03/91	1	8	4	50.0	97.6	1e	4		
					42								
5/3	133	Placebo	29/11/91	12/12/91	14	0	0	100.0	100.0		0	0	
					14								
	134	Reboxetine	06/12/91	16/01/92	42	8	8	100.0	100.0		4	4	
					42								
	135	Imipramine	10/01/92	12/01/92	3	100	100	100.0	100.0		50	50	
			13/01/92	20/02/92	39	150	150	100.0	100.0		50	100	
					42								
	136	Imipramine	02/03/92	04/03/92	3	100	100	100.0	100.0		50	50	
			05/03/92	07/03/92	3	150	150	100.0	100.0		50	100	
			08/03/92	08/03/92	1	150	50	33.3	90.5	10e	50		
			09/03/92	12/04/92	35	150	150	100.0	98.4		50	100	
					42								
	137	Reboxetine	15/05/92	25/06/92	42	8	8	100.0	100.0		4	4	
					42								
	138	Placebo	15/05/92	15/05/92	1	0	0	100.0	100.0		0	0	
			16/05/92	16/05/92	1	0	0	100.0	100.0	6e	0		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

998

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					2								
6/1	151	Imipramine	21/01/92	21/01/92	1	100	50	100.0	100.0	9m		50	
			22/01/92	23/01/92	2	100	100	100.0	100.0		50	50	
			24/01/92	27/01/92	4	150	150	100.0	100.0		50	100	
			28/01/92	28/01/92	1	150	50	100.0	100.0	6e	50		
					8								
	152	Reboxetine	24/02/92	15/03/92	21	8	8	100.0	100.0		4	4	
			16/03/92	07/04/92	23	10	10	100.0	100.0		4	6	
					44								
	153	Reboxetine	18/03/91	18/03/91	1	8	4	100.0	100.0	9m		4	
			19/03/91	28/04/91	41	8	8	100.0	100.0		4	4	
			29/04/91	29/04/91	1	8	4	100.0	100.0	9e	4		
					43								
	154	Imipramine	30/03/92	01/04/92	3	100		0.0	0.0				
			02/04/92	06/04/92	5	150		0.0	0.0				
					8								
	155	Placebo	08/07/92	04/08/92	28	0	0	100.0	100.0		0	0	
					28								
	156	Placebo	08/09/92	19/10/92	42	0	0	100.0	100.0		0	0	
					42								
6/2	157	Reboxetine	30/04/91	26/05/91	27	8	8	100.0	100.0		4	4	
			27/05/91	27/05/91	1	8	4	50.0	98.2	1e	4		
			28/05/91	10/06/91	14	8	8	100.0	98.8		4	4	
					42								
	158	Imipramine	24/11/91	26/11/91	3	100	100	100.0	100.0		50	50	
			27/11/91	05/01/92	40	150	150	100.0	100.0		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					43								
6/2	159	Imipramine	14/07/91	16/07/91	3	100	100	100.0	100.0		50	50	
			17/07/91	24/08/91	39	150	150	100.0	100.0		50	100	
					42								
	160	Placebo	24/11/91	04/01/92	42	0	0	100.0	100.0		0	0	
					42								
	161	Reboxetine	20/02/92	18/03/92	28	8	8	100.0	100.0		4	4	
					28								
	162	Placebo	10/07/91	12/07/91	3	0	0	100.0	100.0		0	0	
			13/07/91	13/07/91	1	0	0	100.0	100.0	6e	0		
					4								
1000	169	Imipramine	26/12/91	28/12/91	3	100	100	100.0	100.0		50	50	
			29/12/91	15/01/92	18	150	150	100.0	100.0		50	100	
					21								
	170	Placebo	01/11/91	15/11/91	15	0	0	100.0	100.0		0	0	
					15								
	171	Imipramine	22/07/92	24/07/92	3	100	100	100.0	100.0		50	50	
			25/07/92	01/09/92	39	150	150	100.0	100.0		50	100	
					42								
	172	Reboxetine	07/07/92	17/08/92	42	8	8	100.0	100.0		4	4	
					42								
	173	Placebo	05/07/92	15/08/92	42	0	0	100.0	100.0		0	0	
					42								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
6/2	174	Reboxetine	11/05/92	21/06/92	42	8	8	100.0	100.0		4	4	
					42								
6/3	163	Reboxetine	06/06/91	07/06/91	2	8	8	100.0	100.0		4	4	
			08/06/91	08/06/91	1	8	4	100.0	100.0	6e	4		
					3								
	164	Imipramine	11/10/91	13/10/91	3	100	100	100.0	100.0		50	50	
			14/10/91	30/10/91	17	150	150	100.0	100.0		50	100	
			31/10/91	21/11/91	22	200	200	100.0	100.0		100	100	
					42								
	165	Imipramine	16/10/91	18/10/91	3	100	100	100.0	100.0		50	50	
			19/10/91	05/11/91	18	150	150	100.0	100.0		50	100	
			06/11/91	25/11/91	20	200	200	100.0	100.0		100	100	
			26/11/91	26/11/91	1	200	100	100.0	100.0	5e	100		
					42								
	166	Reboxetine	25/10/91	29/10/91	5	8	8	100.0	100.0		4	4	
					5								
	167	Placebo	18/11/91	18/11/91	1	0	0	100.0	100.0	9m		0	
			19/11/91	08/12/91	20	0	0	100.0	100.0		0	0	
			09/12/91	09/12/91	1	0	0	100.0	100.0	10e	0		
			10/12/91	27/12/91	18	0	0	100.0	100.0		0	0	
					40								
	168	Placebo	03/12/91	05/01/92	34	0	0	100.0	100.0		0	0	
			06/01/92	06/01/92	1	0	0	100.0	100.0	9e	0		
					35								
	505	Imipramine	03/12/91	05/12/91	3	100	100	100.0	100.0		50	50	
			06/12/91	17/12/91	12	150	150	100.0	100.0		50	100	
					15								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

1001

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
6/3	506	Placebo	08/01/92	08/01/92	1	0	0	100.0	100.0	9m		0	
			09/01/92	19/02/92	42	0	0	100.0	100.0		0	0	
					43								
	507	Imipramine	14/01/92	16/01/92	3	100	100	100.0	100.0		50	50	
			17/01/92	24/02/92	39	150	150	100.0	100.0		50	100	
					42								
	508	Reboxetine	05/02/92	04/03/92	29	8	8	100.0	100.0		4	4	
			05/03/92	17/03/92	13	10	10	100.0	100.0		4	6	
					42								
	509	Placebo	24/02/92	24/02/92	1	0	0	100.0	100.0	9m		0	
			25/02/92	06/04/92	42	0	0	100.0	100.0		0	0	
					43								
	510	Reboxetine	27/02/92	09/03/92	12	8	8	100.0	100.0		4	4	
			10/03/92	10/03/92	1	8	4	100.0	100.0	6e	4		
					13								
	511	Imipramine	19/03/92	21/03/92	3	100	100	100.0	100.0		50	50	
			22/03/92	21/04/92	31	150	150	100.0	100.0		50	100	
					34								
	512	Placebo	01/04/92	01/04/92	1	0	0	100.0	100.0	3e	0		
					1								
	513	Imipramine	13/05/92	15/05/92	3	100	100	100.0	100.0		50	50	
			16/05/92	23/06/92	39	150	150	100.0	100.0		50	100	
					42								
7/02	181	Reboxetine	27/01/92	16/02/92	21	8	8	100.0	100.0		4	4	
			17/02/92	08/03/92	21	10	10	100.0	100.0		4	6	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient,
5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening,
10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose,
C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

1002

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
7/02	182	Placebo	23/11/91	03/01/92	42	0	0	100.0	100.0		0	0	
					42								
	183	Imipramine	02/01/92	04/01/92	3	100	100	100.0	100.0		50	50	
			05/01/92	15/01/92	11	150	150	100.0	100.0		50	100	
			16/01/92	18/01/92	3	150		0.0	82.4				
					17								
	184	Imipramine	27/01/92	29/01/92	3	100	100	100.0	100.0		50	50	
			30/01/92	08/03/92	39	150	150	100.0	100.0		50	100	
					42								
1003	185	Reboxetine	10/04/92	04/05/92	25	8	8	100.0	100.0		4	4	
			05/05/92	05/05/92	1	8	4	100.0	100.0	6e	4		
					26								
	186	Placebo	16/04/92	27/05/92	42	0	0	100.0	100.0		0	0	
					42								
	535	Placebo	15/04/92	26/05/92	42	0	0	100.0	100.0		0	0	
					42								
	536	Reboxetine	08/05/92	28/05/92	21	8	8	100.0	100.0		4	4	
			29/05/92	18/06/92	21	10	10	100.0	100.0		4	6	
					42								
7/03	187	Imipramine	18/02/92	20/02/92	3	100	100	100.0	100.0		50	50	
			21/02/92	30/03/92	39	150	150	100.0	100.0		50	100	
					42								
	188	Placebo	25/02/92	06/04/92	42	0	0	100.0	100.0		0	0	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
7/03	189	Placebo	25/02/92	06/04/92	42	0	0	100.0	100.0		0	0	
					42								
	190	Reboxetine	28/02/92	09/04/92	42	8	8	100.0	100.0		4	4	
					42								
	191	Imipramine	03/03/92	05/03/92	3	100	100	100.0	100.0		50	50	
			06/03/92	10/04/92	36	150	150	100.0	100.0		50	100	
					39								
	192	Reboxetine	10/03/92	20/04/92	42	8	8	100.0	100.0		4	4	
					42								
	523	Reboxetine	06/05/92	16/06/92	42	8	8	100.0	100.0		4	4	
					42								
	524	Placebo	06/05/92	16/06/92	42	0	0	100.0	100.0		0	0	
					42								
	525	Placebo	06/05/92	16/06/92	42	0	0	100.0	100.0		0	0	
					42								
	526	Reboxetine	06/05/92	16/06/92	42	8	8	100.0	100.0		4	4	
					42								
	527	Imipramine	19/05/92	21/05/92	3	100	100	100.0	100.0		50	50	
			22/05/92	08/06/92	18	150	150	100.0	100.0		50	100	
			09/06/92	15/06/92	7	150	100	66.7	91.7	4m		100	
			16/06/92	29/06/92	14	150	150	100.0	94.4		50	100	
					42								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
7/03	528	Imipramine	19/05/92	21/05/92	3	100		0.0	0.0				
			22/05/92	25/05/92	4	150		0.0	0.0				
			26/05/92	22/06/92	28	150	150	100.0	80.0		50	100	
					35								
7/04	193	Placebo	25/01/92	06/03/92	42	0	0	100.0	100.0		0	0	
					42								
	194	Reboxetine	25/01/92	06/03/92	42	8	8	100.0	100.0		4	4	
					42								
	195	Placebo	25/01/92	06/03/92	42	0	0	100.0	100.0		0	0	
					42								
	196	Reboxetine	01/02/92	21/02/92	21	8	8	100.0	100.0		4	4	
			22/02/92	28/02/92	7	8	8	100.0	100.0	4m		8	(D - e)
			29/02/92	05/03/92	6	8	8	100.0	100.0		4	4	
			06/03/92	06/03/92	1	8	4	50.0	98.6	10e	4		
			07/03/92	13/03/92	7	8	8	100.0	98.8		4	4	
					42								
	197	Imipramine	01/02/92	03/02/92	3	100	100	100.0	100.0		50	50	
			04/02/92	21/02/92	18	150	150	100.0	100.0		50	100	
			22/02/92	13/03/92	21	200	200	100.0	100.0		100	100	
					42								
	198	Imipramine	01/02/92	03/02/92	3	100	100	100.0	100.0		50	50	
			04/02/92	13/03/92	39	150	150	100.0	100.0		50	100	
					42								
	199	Imipramine	28/03/92	30/03/92	3	100	100	100.0	100.0		50	50	
			31/03/92	17/04/92	18	150	150	100.0	100.0		50	100	
			18/04/92	04/05/92	17	200	200	100.0	100.0		100	100	
			05/05/92	05/05/92	1	200	100	50.0	98.7	1m		100	
			06/05/92	08/05/92	3	200	200	100.0	98.8		100	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
7/04	200	Placebo	28/03/92	08/05/92	42	0	0	100.0	100.0		0	0	
					42								
	201	Reboxetine	28/03/92	27/04/92	31	8	8	100.0	100.0		4	4	
			28/04/92	28/04/92	1	8		0.0	96.9	1m 1e			
			29/04/92	08/05/92	10	8	8	100.0	97.6		4	4	
					42								
	202	Reboxetine	04/04/92	24/04/92	21	8	8	100.0	100.0		4	4	
			25/04/92	27/04/92	3	10	10	100.0	100.0		4	6	
			28/04/92	28/04/92	1	10	4	40.0	97.6	1e	4		
			29/04/92	15/05/92	17	10	10	100.0	98.6		4	6	
					42								
	203	Placebo	04/04/92	21/04/92	18	0	0	100.0	100.0		0	0	
			22/04/92	22/04/92	1	0	0	100.0	100.0	1m		0	
			23/04/92	15/05/92	23	0	0	100.0	100.0		0	0	
					42								
	204	Imipramine	04/04/92	06/04/92	3	100	100	100.0	100.0		50	50	
			07/04/92	24/04/92	18	150	150	100.0	100.0		50	100	
			25/04/92	29/04/92	5	200	200	100.0	100.0		100	100	
			30/04/92	30/04/92	1	200	100	50.0	98.1	1m		100	
			01/05/92	15/05/92	15	200	200	100.0	98.8		100	100	
					42								
7/05	205	Placebo	27/01/92	16/02/92	21	0	0	100.0	100.0		0	0	
			17/02/92	08/03/92	21	0	0	100.0	100.0		0	0	(3 - m) (3 - e)
					42								
	206	Imipramine	28/01/92	30/01/92	3	100	100	100.0	100.0		50	50	
			31/01/92	09/03/92	39	150	150	100.0	100.0		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient,
5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening,
10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose,
C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
7/05	207	Imipramine	28/01/92	30/01/92	3	100	100	100.0	100.0		50	50	
			31/01/92	09/03/92	39	150	150	100.0	100.0		50	100	
					42								
	208	Reboxetine	30/01/92	11/03/92	42	8	8	100.0	100.0		4	4	
					42								
	209	Placebo	05/02/92	17/03/92	42	0	0	100.0	100.0		0	0	
					42								
	210	Reboxetine	07/02/92	19/03/92	42	8	8	100.0	100.0		4	4	
					42								
	541	Reboxetine	17/03/92	27/04/92	42	8	8	100.0	100.0		4	4	
					42								
	542	Imipramine	17/03/92	19/03/92	3	100	100	100.0	100.0		50	50	
			20/03/92	27/04/92	39	150	150	100.0	100.0		50	100	
					42								
	543	Imipramine	18/03/92	20/03/92	3	100	100	100.0	100.0		50	50	
			21/03/92	28/04/92	39	150	150	100.0	100.0		50	100	
					42								
	544	Placebo	24/03/92	04/05/92	42	0	0	100.0	100.0		0	0	
					42								
	545	Placebo	25/03/92	05/05/92	42	0	0	100.0	100.0		0	0	
					42								
	546	Reboxetine	25/03/92	05/05/92	42	8	8	100.0	100.0		4	4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
7/07	529	Placebo	18/02/92	30/03/92	42	0	0	100.0	100.0		0	0	
					42								
	530	Imipramine	20/02/92	22/02/92	3	100	100	100.0	100.0		50	50	
			23/02/92	04/03/92	11	150	150	100.0	100.0		50	100	
			05/03/92	11/03/92	7	150		0.0	66.7				
					21								
	531	Reboxetine	24/02/92	24/03/92	30	8	8	100.0	100.0		4	4	
			25/03/92	25/03/92	1	8	4	50.0	98.4	1m		4	
			26/03/92	05/04/92	11	8	8	100.0	98.8		4	4	
					42								
	532	Imipramine	27/04/92	29/04/92	3	100	100	100.0	100.0		50	50	
			30/04/92	07/06/92	39	150	150	100.0	100.0		50	100	
					42								
	533	Reboxetine	04/05/92	24/05/92	21	8	8	100.0	100.0		4	4	
			25/05/92	14/06/92	21	10	10	100.0	100.0		4	6	
					42								
	534	Placebo	15/05/92	25/06/92	42	0	0	100.0	100.0		0	0	
					42								
8	211	Reboxetine	13/05/91	26/05/91	14	8	8	100.0	100.0		4	4	
					14								
	212	Placebo	14/09/91	25/10/91	42	0	0	100.0	100.0		0	0	
					42								
	213	Imipramine	22/11/91	24/11/91	3	100	100	100.0	100.0		50	50	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					3								
8	214	Reboxetine	23/11/91	03/01/92	42	8	8	100.0	100.0		4	4	
					42								
	215	Placebo	18/02/92	30/03/92	42	0	0	100.0	100.0		0	0	
					42								
	216	Imipramine	27/03/92	29/03/92	3	100	100	100.0	100.0		50	50	
			30/03/92	16/04/92	18	150	150	100.0	100.0		50	100	
			17/04/92	07/05/92	21	200	200	100.0	100.0		100	100	
					42								
	217	Reboxetine	30/03/92	10/05/92	42	8	8	100.0	100.0		4	4	
					42								
	218	Reboxetine	09/04/92	20/05/92	42	8	8	100.0	100.0		4	4	
					42								
	219	Placebo	11/04/92	01/05/92	21	0	0	100.0	100.0		0	0	
					21								
	220	Imipramine	27/04/92	29/04/92	3	100	100	100.0	100.0		50	50	
			30/04/92	07/06/92	39	150	150	100.0	100.0		50	100	
					42								
	221	Imipramine	28/04/92	30/04/92	3	100	100	100.0	100.0		50	50	
			01/05/92	08/06/92	39	150	150	100.0	100.0		50	100	
					42								
	222	Placebo	28/04/92	08/06/92	42	0	0	100.0	100.0		0	0	
					42								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

1009

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
8	223	Imipramine	11/05/92	13/05/92	3	100	100	100.0	100.0		50	50	
			14/05/92	21/06/92	39	150	150	100.0	100.0		50	100	
					42								
	224	Placebo	07/09/92	18/10/92	42	0	0	100.0	100.0		0	0	
					42								
	225	Placebo	11/09/92	22/10/92	42	0	0	100.0	100.0		0	0	
					42								
	226	Reboxetine	23/09/92	13/10/92	21	8	8	100.0	100.0		4	4	
			14/10/92	03/11/92	21	10	10	100.0	100.0		4	6	
					42								
	227	Reboxetine	25/09/92	15/10/92	21	8	8	100.0	100.0		4	4	
			16/10/92	05/11/92	21	10	10	100.0	100.0		4	6	
					42								
	228	Imipramine	26/09/92	28/09/92	3	100	100	100.0	100.0		50	50	
			29/09/92	02/10/92	4	150	150	100.0	100.0		50	100	
					7								
	229	Imipramine	30/09/92	02/10/92	3	100	100	100.0	100.0		50	50	
			03/10/92	20/10/92	18	150	150	100.0	100.0		50	100	
			21/10/92	10/11/92	21	200	200	100.0	100.0		100	100	
					42								
	230	Reboxetine	28/09/92	18/10/92	21	8	8	100.0	100.0		4	4	
			19/10/92	08/11/92	21	10	10	100.0	100.0		4	6	
					42								
	231	Imipramine	30/09/92	02/10/92	3	100	100	100.0	100.0		50	50	
			03/10/92	20/10/92	18	150	150	100.0	100.0		50	100	
			21/10/92	10/11/92	21	200	200	100.0	100.0		100	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient,
5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening,
10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose,
C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
8	232	Reboxetine	02/10/92	22/10/92	21	8	8	100.0	100.0		4	4	
			23/10/92	12/11/92	21	10	10	100.0	100.0		4	6	
					42								
	233	Placebo	07/10/92	17/11/92	42	0	0	100.0	100.0		0	0	
					42								
	234	Placebo	07/10/92	17/11/92	42	0	0	100.0	100.0		0	0	
					42								
8/A	235	Placebo	14/10/92	24/11/92	42	0	0	100.0	100.0		0	0	
					42								
	236	Placebo	14/10/92	24/11/92	42	0	0	100.0	100.0		0	0	
					42								
	237	Reboxetine	14/10/92	24/11/92	42	8	8	100.0	100.0		4	4	
					42								
	238	Reboxetine	14/10/92	24/11/92	42	8	8	100.0	100.0		4	4	
					42								
	239	Imipramine	16/10/92	18/10/92	3	100	100	100.0	100.0		50	50	
			19/10/92	05/11/92	18	150	150	100.0	100.0		50	100	
			06/11/92	26/11/92	21	200	200	100.0	100.0		100	100	
					42								
	240	Imipramine	16/10/92	18/10/92	3	100	100	100.0	100.0		50	50	
			19/10/92	05/11/92	18	150	150	100.0	100.0		50	100	
			06/11/92	26/11/92	21	200	200	100.0	100.0		100	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient,
5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening,
10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose,
C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
8/A	553	Placebo	16/10/92	26/11/92	42	0	0	100.0	100.0		0	0	
					42								
	554	Reboxetine	16/10/92	26/11/92	42	8	8	100.0	100.0		4	4	
					42								
	555	Reboxetine	16/10/92	26/11/92	42	8	8	100.0	100.0		4	4	
					42								
	556	Imipramine	16/10/92	18/10/92	3	100	100	100.0	100.0		50	50	
			19/10/92	26/11/92	39	150	150	100.0	100.0		50	100	
					42								
9	241	Placebo	07/02/91	17/02/91	11	0	0	100.0	100.0		0	0	
					11								
	242	Reboxetine	18/02/91	10/03/91	21	8	8	100.0	100.0		4	4	
			11/03/91	11/03/91	1	8	4	100.0	100.0	6e	4		
					22								
	243	Reboxetine	20/02/91	01/03/91	10	8	8	100.0	100.0		4	4	
			02/03/91	03/03/91	2	8	12	100.0	100.0		8	4	(B - m)
			04/03/91	05/03/91	2	8	8	100.0	100.0		4	4	
			06/03/91	06/03/91	1	8	4	100.0	100.0	6e	4		
					15								
	244	Imipramine	19/02/91	21/02/91	3	100	100	100.0	100.0		50	50	
			22/02/91	11/03/91	18	150	150	100.0	100.0		50	100	
			12/03/91	12/03/91	1	200	150	100.0	100.0		50	100	
			13/03/91	13/03/91	1	200	100	100.0	100.0	6e	100		
					23								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
9	245	Imipramine	22/02/91	24/02/91	3	100	100	100.0	100.0		50	50	
			25/02/91	04/04/91	39	150	150	100.0	100.0		50	100	
					42								
	246	Placebo	22/02/91	17/03/91	24	0	0	100.0	100.0		0	0	
					24								
	247	Placebo	25/02/91	25/03/91	29	0	0	100.0	100.0		0	0	
			26/03/91	26/03/91	1	0	0	100.0	100.0	6e	0		
					30								
	248	Placebo	07/03/91	07/03/91	1	0	0	100.0	100.0	9m		0	
			08/03/91	21/03/91	14	0	0	100.0	100.0		0	0	
					15								
	249	Reboxetine	08/03/91	10/03/91	3	8	8	100.0	100.0		4	4	
			11/03/91	11/03/91	1	8	4	100.0	100.0	6e	4		
					4								
	250	Imipramine	12/03/91	14/03/91	3	100	100	100.0	100.0		50	50	
			15/03/91	01/04/91	18	150	150	100.0	100.0		50	100	
			02/04/91	02/04/91	1	200	150	100.0	100.0		50	100	
			03/04/91	07/04/91	5	200	200	100.0	100.0		100	100	
			08/04/91	08/04/91	1	200	100	100.0	100.0	6e	100		
					28								
	251	Imipramine	20/03/91	22/03/91	3	100	100	100.0	100.0		50	50	
			23/03/91	11/04/91	20	150	150	100.0	100.0		50	100	
			12/04/91	12/04/91	1	150	50	100.0	100.0	6e	50		
					24								
	252	Reboxetine	02/04/91	17/04/91	16	8	8	100.0	100.0		4	4	
			18/04/91	20/04/91	3	8	4	100.0	100.0	3e	4		
					19								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

1013

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
9	253	Reboxetine	02/04/91	07/04/91	6	8	8	100.0	100.0		4	4	
			08/04/91	08/04/91	1	8	4	100.0	100.0	6e	4		
					7								
	254	Imipramine	09/04/91	11/04/91	3	100	100	100.0	100.0		50	50	
			12/04/91	15/04/91	4	150	150	100.0	100.0		50	100	
			16/04/91	16/04/91	1	150	50	100.0	100.0	6e	50		
					8								
	255	Reboxetine	13/05/91	05/06/91	24	8	8	100.0	100.0		4	4	
			06/06/91	06/06/91	1	8	4	100.0	100.0	6e	4		
					25								
	256	Imipramine	27/05/91	29/05/91	3	100	100	100.0	100.0		50	50	
			30/05/91	05/06/91	7	150	150	100.0	100.0		50	100	
			06/06/91	09/06/91	4	150	50	100.0	100.0	3e	50		
			10/06/91	10/06/91	1	150	50	100.0	100.0	3e	50		
			11/06/91	16/06/91	6	150	50	100.0	100.0	3e	50		
			17/06/91	20/06/91	4	150	150	100.0	100.0		50	100	
			21/06/91	08/07/91	18	150	50	100.0	100.0	3e	50		
					43								
	257	Placebo	25/06/91	30/06/91	6	0	0	100.0	100.0		0	0	
			01/07/91	01/07/91	1	0	0	100.0	100.0	6e	0		
					7								
	258	Placebo	01/07/91	09/07/91	9	0	0	100.0	100.0		0	0	
			10/07/91	10/07/91	1	0	0	100.0	100.0	6e	0		
					10								
11	319	Placebo	02/08/91	12/09/91	42	0	0	100.0	100.0		0	0	
					42								
	320	Imipramine	17/08/91	19/08/91	3	100	100	100.0	100.0		50	50	
			20/08/91	27/08/91	8	150	150	100.0	100.0		50	100	
			28/08/91	28/08/91	1	150	100	66.7	97.2	1m		100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
11	320	Imipramine	29/08/91	01/09/91	4	150	150	100.0	97.9		50	100	
			02/09/91	02/09/91	1	150	50	33.3	94.1	4e	50		
			03/09/91	03/09/91	1	200	100	50.0	91.7	4m		100	
			04/09/91	25/09/91	22	200	200	100.0	96.3		100	100	
			26/09/91	26/09/91	1	200	100	100.0	96.3	9e	100		
					41								
	321	Placebo	06/09/91	16/10/91	41	0	0	100.0	100.0		0	0	
			17/10/91	17/10/91	1	0	0	100.0	100.0	9e	0		
					42								
	322	Reboxetine	27/09/91	16/10/91	20	8	8	100.0	100.0		4	4	
			17/10/91	06/11/91	21	10	10	100.0	100.0		4	6	
			07/11/91	07/11/91	1	10	4	100.0	100.0	9e	4		
					42								
	323	Reboxetine	15/11/91	25/12/91	41	8	8	100.0	100.0		4	4	
			26/12/91	26/12/91	1	8	4	100.0	100.0	9e	4		
					42								
	324	Imipramine	06/12/91	08/12/91	3	100	100	100.0	100.0		50	50	
			09/12/91	26/12/91	18	150	150	100.0	100.0		50	100	
			27/12/91	27/12/91	1	200	150	100.0	100.0		50	100	
			28/12/91	15/01/92	19	200	200	100.0	100.0		100	100	
			16/01/92	16/01/92	1	200	100	100.0	100.0	9e	100		
					42								
	325	Reboxetine	13/12/91	18/12/91	6	8	8	100.0	100.0		4	4	
			19/12/91	19/12/91	1	8	4	50.0	92.9	10e	4		
			20/12/91	26/12/91	7	8	8	100.0	96.4		4	4	
			27/12/91	27/12/91	1	8	4	50.0	93.3	1e	4		
			28/12/91	22/01/92	26	8	8	100.0	97.6		4	4	
			23/01/92	23/01/92	1	8	4	100.0	97.6	9e	4		
					42								
	326	Placebo	16/01/92	16/01/92	1	0	0	100.0	100.0	9m		0	
			17/01/92	20/02/92	35	0	0	100.0	100.0		0	0	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
11	326	Placebo	21/02/92	21/02/92	1	0		100.0	100.0	10m 10e			
			22/02/92	26/02/92	5	0	0	100.0	100.0		0	0	
			27/02/92	27/02/92	1	0	0	100.0	100.0	9e	0		
					43								
	327	Imipramine	30/01/92	01/02/92	3	100	100	100.0	100.0		50	50	
			02/02/92	04/02/92	3	150	150	100.0	100.0		50	100	
			05/02/92	05/02/92	1	150	50	100.0	100.0	6e	50		
					7								
	328	Imipramine	31/01/92	02/02/92	3	100	100	100.0	100.0		50	50	
			03/02/92	04/02/92	2	150	150	100.0	100.0		50	100	
			05/02/92	05/02/92	1	150		100.0	100.0	3m 6e			
					6								
	329	Placebo	10/04/92	20/05/92	41	0	0	100.0	100.0		0	0	
			21/05/92	21/05/92	1	0	0	100.0	100.0	9e	0		
					42								
	330	Reboxetine	09/04/92	09/04/92	1	8	4	100.0	100.0	9m		4	
			10/04/92	29/04/92	20	8	8	100.0	100.0		4	4	
			30/04/92	13/05/92	14	10	10	100.0	100.0		4	6	
			14/05/92	14/05/92	1	10	4	50.0	98.6	1e	4		
			15/05/92	16/05/92	2	10	10	100.0	98.7		4	6	
			17/05/92	17/05/92	1	10	4	40.0	97.2	1e	4		
			18/05/92	20/05/92	3	10	10	100.0	97.4		4	6	
			21/05/92	21/05/92	1	10	4	100.0	97.4	9e	4		
					43								
	331	Imipramine	17/04/92	19/04/92	3	100	100	100.0	100.0		50	50	
			20/04/92	27/05/92	38	150	150	100.0	100.0		50	100	
			28/05/92	28/05/92	1	150	50	100.0	100.0	9e	50		
					42								
	332	Reboxetine	19/05/92	28/06/92	41	8	8	100.0	100.0		4	4	
			29/06/92	29/06/92	1	8	4	100.0	100.0	9e	4		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(xx) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
11	333	Placebo	27/05/92	06/07/92	41	0	0	100.0	100.0		0	0	
			07/07/92	07/07/92	1	0	0	100.0	100.0	9e	0		
					42								
	334	Reboxetine	29/05/92	31/05/92	3	8	8	100.0	100.0		4	4	
			01/06/92	01/06/92	1	8		100.0	100.0	3m 6e			
					4								
	335	Placebo	03/06/92	13/07/92	41	0	0	100.0	100.0		0	0	
			14/07/92	14/07/92	1	0	0	100.0	100.0	9e	0		
					42								
	336	Imipramine	18/06/92	18/06/92	1	100	50	100.0	100.0	9m		50	
			19/06/92	20/06/92	2	100	100	100.0	100.0		50	50	
			21/06/92	24/06/92	4	150	150	100.0	100.0		50	100	
			25/06/92	25/06/92	1	150	50	100.0	100.0	6e	50		
					8								
	337	Reboxetine	02/07/92	02/07/92	1	8	4	100.0	100.0	9m		4	
			03/07/92	15/07/92	13	8	8	100.0	100.0		4	4	
			16/07/92	16/07/92	1	8	4	50.0	96.7	1m		4	
			17/07/92	22/07/92	6	8	8	100.0	97.6		4	4	
			23/07/92	12/08/92	21	10	10	100.0	98.8		4	6	
			13/08/92	13/08/92	1	10	4	100.0	98.8	9e	4		
					43								
	338	Imipramine	23/07/92	23/07/92	1	100	50	100.0	100.0	9m		50	
			24/07/92	25/07/92	2	100	100	100.0	100.0		50	50	
			26/07/92	29/07/92	4	150	150	100.0	100.0		50	100	
			30/07/92	30/07/92	1	150	50	100.0	100.0	6e	50		
					8								
12	367	Reboxetine	20/12/91	20/12/91	1	8	4	100.0	100.0	9m		4	
			21/12/91	30/01/92	41	8	8	100.0	100.0		4	4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
					42								
12	368	Placebo	24/12/91	24/12/91	1	0	0	100.0	100.0	9m		0	
			25/12/91	03/02/92	41	0	0	100.0	100.0		0	0	
					42								
	369	Imipramine	23/04/92	25/04/92	3	100	100	100.0	100.0		50	50	
			26/04/92	12/05/92	17	150	150	100.0	100.0		50	100	
			13/05/92	13/05/92	1	150	50	100.0	100.0	6e	50		
					21								
	370	Placebo	29/04/92	19/05/92	21	0	0	100.0	100.0		0	0	
			20/05/92	20/05/92	1	0	0	100.0	100.0	6e	0		
					22								
	371	Imipramine	01/05/92	03/05/92	3	100	100	100.0	100.0		50	50	
			04/05/92	06/05/92	3	150	150	100.0	100.0		50	100	
					6								
	372	Reboxetine	02/06/92	02/06/92	1	8	4	100.0	100.0	9m		4	
			03/06/92	13/07/92	41	8	8	100.0	100.0		4	4	
					42								
	373	Reboxetine	05/06/92	05/06/92	1	8	4	100.0	100.0	9m		4	
			06/06/92	29/06/92	24	8	8	100.0	100.0		4	4	
			30/06/92	02/07/92	3	8	10	100.0	100.0		4	6	
			03/07/92	13/07/92	11	10	10	100.0	100.0		4	6	
			14/07/92	14/07/92	1	10	4	100.0	100.0	6e	4		
					40								
	374	Placebo	09/06/92	05/07/92	27	0	0	100.0	100.0		0	0	
			06/07/92	06/07/92	1	0	0	100.0	100.0	6e	0		
					28								
	375	Imipramine	17/06/92	17/06/92	1	100	100	100.0	100.0		50	50	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
12	375	Imipramine	18/06/92	18/06/92	1	100	50	100.0	100.0	6e	50		
					2								
13	13	Placebo	13/04/91	24/05/91	42	0	0	100.0	100.0		0	0	
					42								
	14	Placebo	02/07/91	22/07/91	21	0	0	100.0	100.0		0	0	
			23/07/91	23/07/91	1	0	0	100.0	100.0	1e	0		
			24/07/91	13/08/91	21	0	0	100.0	100.0		0	0	
					43								
	15	Imipramine	05/07/91	07/07/91	3	100	100	100.0	100.0		50	50	
			08/07/91	31/07/91	24	150	150	100.0	100.0		50	100	
			01/08/91	01/08/91	1	200	150	100.0	100.0		50	100	
			02/08/91	15/08/91	14	200	200	100.0	100.0		100	100	
					42								
	16	Imipramine	03/12/91	05/12/91	3	100	100	100.0	100.0		50	50	
			06/12/91	15/12/91	10	150		100.0	100.0	3m 3e			
			16/12/91	09/01/92	25	150	150	100.0	100.0		50	100	
			10/01/92	16/01/92	7	200	200	100.0	100.0		100	100	
					45								
	17	Reboxetine	21/05/92	01/06/92	12	8	8	100.0	100.0		4	4	
			02/06/92	02/06/92	1	8	4	50.0	96.2	10e	4		
			03/06/92	10/06/92	8	8	8	100.0	97.6		4	4	
			11/06/92	16/06/92	6	10	10	100.0	98.1		4	6	
			17/06/92	23/06/92	7	10		0.0	77.9				
			24/06/92	01/07/92	8	10	10	100.0	82.1		4	6	
					42								
	18	Reboxetine	24/06/92	12/07/92	19	8	8	100.0	100.0		4	4	
			13/07/92	02/08/92	21	10	10	100.0	100.0		4	6	
					40								
	409	Reboxetine	10/12/91	20/12/91	11	8	8	100.0	100.0		4	4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
13	409	Reboxetine	21/12/91	23/12/91	3	8		0.0	78.6	4m 4e			
			24/12/91	20/01/92	28	8	8	100.0	92.9		4	4	
					42								
	410	Placebo	14/02/92	20/02/92	7	0	0	100.0	100.0		0	0	
			21/02/92	21/02/92	1	0		100.0	100.0	10m 10e			
			22/02/92	26/03/92	34	0	0	100.0	100.0		0	0	
					42								
	411	Imipramine	28/03/92	30/03/92	3	100	100	100.0	100.0		50	50	
			31/03/92	17/04/92	18	150	150	100.0	100.0		50	100	
			18/04/92	08/05/92	21	200	200	100.0	100.0		100	100	
					42								
	423	Placebo	14/09/92	27/10/92	44	0	0	100.0	100.0		0	0	
					44								
14	19	Reboxetine	10/04/92	06/05/92	27	8	8	100.0	100.0		4	4	
					27								
	20	Imipramine	29/04/92	29/04/92	1	100	100	100.0	100.0		50	50	
			30/04/92	30/04/92	1	100		100.0	100.0	3m 3e			
			01/05/92	01/05/92	1	100	100	100.0	100.0		50	50	
			02/05/92	09/06/92	39	150	150	100.0	100.0		50	100	
					42								
	21	Imipramine	20/07/92	20/07/92	1	100	50	100.0	100.0	9m		50	
			21/07/92	22/07/92	2	100	100	100.0	100.0		50	50	
			23/07/92	10/08/92	19	150	150	100.0	100.0		50	100	
			11/08/92	16/08/92	6	150	200	100.0	100.0		100	100	
			17/08/92	22/08/92	6	200	200	100.0	100.0		100	100	
			23/08/92	23/08/92	1	200	100	50.0	98.6	4m		100	
			24/08/92	24/08/92	1	200	100	100.0	98.6	6e	100		
					36								
15	25	Reboxetine	18/06/91	18/06/91	1	8	4	100.0	100.0	9m		4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
15	25	Reboxetine	19/06/91	29/07/91	41	8	8	100.0	100.0		4	4	
					42								
	26	Placebo	20/06/91	20/06/91	1	0	0	100.0	100.0	9m		0	
			21/06/91	26/06/91	6	0	0	100.0	100.0		0	0	
			27/06/91	27/06/91	1	0	0	100.0	100.0	1m		0	
			28/06/91	31/07/91	34	0	0	100.0	100.0		0	0	
			01/08/91	01/08/91	1	0	0	100.0	100.0	9e	0		
					43								
	27	Imipramine	02/07/91	04/07/91	3	100	100	100.0	100.0		50	50	
			05/07/91	29/07/91	25	150	150	100.0	100.0		50	100	
			30/07/91	30/07/91	1	150	50	33.3	97.7	1e	50		
			31/07/91	12/08/91	13	150	150	100.0	98.4		50	100	
			13/08/91	13/08/91	1	150	50	100.0	98.4	9e	50		
					43								
	28	Reboxetine	08/08/91	09/09/91	33	8	8	100.0	100.0		4	4	
			10/09/91	10/09/91	1	8	4	50.0	98.5	1m		4	
			11/09/91	19/09/91	9	8	8	100.0	98.8		4	4	
					43								
	29	Placebo	29/08/91	29/08/91	1	0	0	100.0	100.0	9m		0	
			30/08/91	18/09/91	20	0	0	100.0	100.0		0	0	
			19/09/91	19/09/91	1	0	0	100.0	100.0	6e	0		
					22								
	30	Imipramine	03/09/91	05/09/91	3	100	100	100.0	100.0		50	50	
			06/09/91	07/09/91	2	150	150	100.0	100.0		50	100	
			08/09/91	08/09/91	1	150	50	33.3	88.9	10e	50		
			09/09/91	09/09/91	1	150	100	66.7	85.7	10m		100	
			10/09/91	23/09/91	14	150	150	100.0	95.2		50	100	
			24/09/91	24/09/91	1	150	100	66.7	93.9	10m		100	
			25/09/91	25/09/91	1	150	150	100.0	94.2		50	100	
			26/09/91	26/09/91	1	150	50	33.3	91.7	10e	50		
			27/09/91	07/10/91	11	150	150	100.0	94.3		50	100	
			08/10/91	08/10/91	1	150	50	33.3	92.6	1e	50		
			09/10/91	14/10/91	6	150	150	100.0	93.7		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
15	30	Imipramine	15/10/91	15/10/91	1	150	50	100.0	93.8	9e	50		
					43								
	403	Imipramine	04/10/91	04/10/91	1	100	50	100.0	100.0	9m		50	
			05/10/91	06/10/91	2	100	100	100.0	100.0		50	50	
			07/10/91	13/11/91	38	150	150	100.0	100.0		50	100	
			14/11/91	14/11/91	1	150	50	100.0	100.0	9e	50		
					42								
	404	Reboxetine	08/10/91	08/10/91	1	8	4	100.0	100.0	9m		4	
			09/10/91	17/10/91	9	8	8	100.0	100.0		4	4	
			18/10/91	18/10/91	1	8	4	50.0	95.5	10e	4		
			19/10/91	22/10/91	4	8	8	100.0	96.7		4	4	
			23/10/91	23/10/91	1	8	4	50.0	93.8	10e	4		
			24/10/91	30/10/91	7	8	8	100.0	95.7		4	4	
			31/10/91	31/10/91	1	8	4	50.0	93.8	10e	4		
			01/11/91	04/11/91	4	8	8	100.0	94.6		4	4	
			05/11/91	05/11/91	1	8	4	100.0	94.8	6e	4		
					29								
	405	Placebo	11/11/91	11/11/91	1	0	0	100.0	100.0	9m		0	
			12/11/91	22/12/91	41	0	0	100.0	100.0		0	0	
			23/12/91	23/12/91	1	0	0	100.0	100.0	9e	0		
					43								
	406	Imipramine	27/11/91	27/11/91	1	100	50	100.0	100.0	9m		50	
			28/11/91	29/11/91	2	100	100	100.0	100.0		50	50	
			30/11/91	06/01/92	38	150	150	100.0	100.0		50	100	
			07/01/92	07/01/92	1	150	50	100.0	100.0	9e	50		
					42								
	407	Reboxetine	03/12/91	03/12/91	1	8	4	100.0	100.0	9m		4	
			04/12/91	25/12/91	22	8	8	100.0	100.0		4	4	
			26/12/91	26/12/91	1	8	4	50.0	97.9	10m		4	
			27/12/91	10/01/92	15	8	8	100.0	98.7		4	4	
			11/01/92	11/01/92	1	8	8	100.0	98.8	1m		8	(B - e)
			12/01/92	13/01/92	2	8	8	100.0	98.8		4	4	
			14/01/92	14/01/92	1	8	4	100.0	98.8	9e	4		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					43								
15	408	Placebo	20/01/92	20/01/92	1	0	0	100.0	100.0	9m		0	
			21/01/92	03/03/92	43	0	0	100.0	100.0		0	0	
			04/03/92	04/03/92	1	0	0	100.0	100.0	9e	0		
					45								
	418	Placebo	30/01/92	30/01/92	1	0	0	100.0	100.0	9m		0	
			31/01/92	11/03/92	41	0	0	100.0	100.0		0	0	
			12/03/92	12/03/92	1	0	0	100.0	100.0	9e	0		
					43								
	419	Placebo	28/04/92	28/04/92	1	0	0	100.0	100.0	9m		0	
			29/04/92	01/05/92	3	0	0	100.0	100.0		0	0	
			02/05/92	02/05/92	1	0	0	100.0	100.0	1e	0		
			03/05/92	27/05/92	25	0	0	100.0	100.0		0	0	
			28/05/92	28/05/92	1	0	0	100.0	100.0	1m		0	
			29/05/92	29/05/92	1	0	0	100.0	100.0		0	0	
			30/05/92	30/05/92	1	0	0	100.0	100.0	1e	0		
			31/05/92	08/06/92	9	0	0	100.0	100.0		0	0	
			09/06/92	09/06/92	1	0	0	100.0	100.0	9e	0		
					43								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
1	1	Imipramine	10/04/91	10/04/91	1	2	1	100.0	100.0	0	1	9m	
			11/04/91	28/04/91	18	2	2	100.0	100.0	1	1		
			29/04/91	29/04/91	1	2	1	50.0	97.5	1		1e	
			30/04/91	09/05/91	10	2	2	100.0	98.3	1	1		
			10/05/91	10/05/91	1	2		0.0	95.2			10m 10e	
			11/05/91	11/05/91	1	2	2	100.0	95.3	1	1		
			12/05/91	13/05/91	2	2	1	50.0	92.6	1		10e	
			14/05/91	21/05/91	8	2	2	100.0	94.0	1	1		
			22/05/91	22/05/91	1	2	1	100.0	94.2	1	0	9e	
					43								
	2	Reboxetine	15/04/91	15/04/91	1	2	1	100.0	100.0	0	1	9m	
			16/04/91	26/05/91	41	2	2	100.0	100.0	1	1		
			27/05/91	27/05/91	1	2	1	100.0	100.0	1	0	9e	
					43								
	3	Imipramine	06/05/91	06/05/91	1	2	1	100.0	100.0	0	1	9m	
			07/05/91	16/06/91	41	2	2	100.0	100.0	1	1		
					42								
	4	Placebo	04/06/91	04/06/91	1	2	1	100.0	100.0	0	1	9m	
			05/06/91	15/07/91	41	2	2	100.0	100.0	1	1		
			16/07/91	16/07/91	1	2	1	100.0	100.0	1	0	9e	
					43								
	5	Reboxetine	12/06/91	12/06/91	1	2	1	100.0	100.0	0	1	9m	
			13/06/91	01/07/91	19	2	2	100.0	100.0	1	1		
			02/07/91	02/07/91	1	2	1	50.0	97.6	1		6e	
					21								
	6	Placebo	23/05/91	23/05/91	1	2	1	100.0	100.0	0	1	9m	
			24/05/91	05/07/91	43	2	2	100.0	100.0	1	1		
					44								
	7	Reboxetine	27/08/91	27/08/91	1	2	1	100.0	100.0	0	1	9m	
			28/08/91	05/09/91	9	2	2	100.0	100.0	1	1		
			06/09/91	06/09/91	1	2	1	50.0	95.5	1		1e	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
1	7	Reboxetine	07/09/91	07/10/91	31	2	2	100.0	98.8	1	1		
			08/10/91	08/10/91	1	2	1	100.0	98.8	1	0	9e	
					43								
	8	Placebo	05/09/91	18/09/91	14	2	2	100.0	100.0	1	1		
			19/09/91	20/09/91	2	2	1	50.0	93.8	1		10e	
			21/09/91	24/09/91	4	2	2	100.0	95.0	1	1		
			25/09/91	25/09/91	1	2	1	50.0	92.9		1	1m	
			26/09/91	27/09/91	2	2	1	50.0	89.1	1		4e	
			28/09/91	18/10/91	21	2	2	100.0	94.8	1	1		
			19/10/91	19/10/91	1	2	1	100.0	94.4	1	0	9e	
					45								
	9	Reboxetine	27/11/91	27/11/91	1	2	1	100.0	100.0	0	1	9m	
			28/11/91	05/01/92	39	2	2	100.0	100.0	1	1		
			06/01/92	06/01/92	1	2	1	100.0	100.0	1	0	9e	
					41								
	10	Placebo	24/09/91	24/09/91	1	2	1	100.0	100.0	0	1	9m	
			25/09/91	13/10/91	19	2	2	100.0	100.0	1	1		
			14/10/91	14/10/91	1	2	1	50.0	97.6	1		10e	
			15/10/91	03/11/91	20	2	2	100.0	98.8	1	1		
			04/11/91	04/11/91	1	2	1	100.0	98.8	1	0	9e	
					42								
	11	Imipramine	10/10/91	13/10/91	4	2	2	100.0	100.0	1	1		
					4								
	12	Imipramine	18/10/91	29/11/91	43	2	2	100.0	100.0	1	1		
			30/11/91	30/11/91	1	2	1	100.0	100.0	1	0	9e	
					44								
	412	Reboxetine	13/11/91	13/11/91	1	2	1	100.0	100.0	0	1	9m	
			14/11/91	22/12/91	39	2	2	100.0	100.0	1	1		
			23/12/91	23/12/91	1	2	1	50.0	98.8	1		6e	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					41								
1	413	Placebo	09/12/91	19/01/92	42	2	2	100.0	100.0	1	1		
			20/01/92	20/01/92	1	2	1	100.0	100.0	1	0	9e	
					43								
	414	Imipramine	22/01/92	29/01/92	8	2	2	100.0	100.0	1	1		
					8								
	415	Imipramine	14/01/92	14/01/92	1	2	1	100.0	100.0	0	1	9m	
			15/01/92	27/01/92	13	2	2	100.0	100.0	1	1		
			28/01/92	28/01/92	1	2	1	50.0	96.7	1		10e	
			29/01/92	05/02/92	8	2	2	100.0	97.8	1	1		
			06/02/92	06/02/92	1	2		0.0	93.8			10m 10e	
			07/02/92	27/02/92	21	2	2	100.0	96.7	1	1		
					45								
	416	Reboxetine	17/01/92	17/01/92	1	2	1	100.0	100.0	0	1	9m	
			18/01/92	23/01/92	6	2	2	100.0	100.0	1	1		
			24/01/92	24/01/92	1	2	3	0.0	87.5	2	1	9e	yes
			25/01/92	28/01/92	4	2	2	100.0	91.7	1	1		
					12								
	421	Imipramine	27/02/92	27/02/92	1	2	1	100.0	100.0	0	1	9m	
			28/02/92	09/04/92	42	2	2	100.0	100.0	1	1		
					43								
	422	Imipramine	05/08/92	14/08/92	10	2	2	100.0	100.0	1	1		
			15/08/92	15/08/92	1	2	1	50.0	95.5	1		1e	
			16/08/92	19/08/92	4	2	2	100.0	96.7	1	1		
			20/08/92	20/08/92	1	2	1	50.0	93.8	1		1e	
			21/08/92	25/08/92	5	2	2	100.0	95.2	1	1		
			26/08/92	26/08/92	1	2	1	50.0	93.2	1		1e	
			27/08/92	27/08/92	1	2	1	50.0	91.3		1	1m	
			28/08/92	01/09/92	5	2	2	100.0	92.9	1	1		
			02/09/92	02/09/92	1	2		0.0	89.7			10m 10e	
			03/09/92	09/09/92	7	2	2	100.0	91.7	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
1	422	Imipramine	10/09/92	10/09/92	1	2		0.0	89.2			1m 1e	
			11/09/92	17/09/92	7	2	2	100.0	90.9	1	1		
					44								
2/1	49	Placebo	18/05/91	28/06/91	42	2	2	100.0	100.0	1	1		
					42								
	50	Reboxetine	27/12/91	05/02/92	41	2	2	100.0	100.0	1	1		
			06/02/92	06/02/92	1	2	1	50.0	98.8	1		6e	
					42								
	51	Imipramine	02/02/92	15/03/92	43	2	2	100.0	100.0	1	1		
					43								
2/2	43	Imipramine	18/04/91	18/04/91	1	2	1	100.0	100.0	0	1	9m	
			19/04/91	23/04/91	5	2	2	100.0	100.0	1	1		
			24/04/91	24/04/91	1	2	1	100.0	100.0	1		3e	
			25/04/91	02/05/91	8	2		100.0	100.0			3m 3e	
			03/05/91	16/05/91	14	2	2	100.0	100.0	1	1		
					29								
	44	Imipramine	19/07/91	19/07/91	1	2	0	50.0	50.0	0		9m 1e	
			20/07/91	29/08/91	41	2	2	100.0	98.8	1	1		
					42								
	45	Reboxetine	08/09/91	20/10/91	43	2	2	100.0	100.0	1	1		
					43								
	46	Placebo	26/09/91	26/09/91	1	2	1	100.0	100.0	0	1	9m	
			27/09/91	10/10/91	14	2	2	100.0	100.0	1	1		
			11/10/91	16/10/91	6	2		100.0	100.0			3m 3e	
			17/10/91	17/10/91	1	2	1	100.0	100.0		1	3m	
			18/10/91	22/10/91	5	2	2	100.0	100.0	1	1		
			23/10/91	23/10/91	1	2	1	100.0	100.0	1	0	9e	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					28								
2/2	47	Placebo	24/03/92	05/04/92	13	2	2	100.0	100.0	1	1		
			06/04/92	06/04/92	1	2	1	50.0	96.4	1		1e	
			07/04/92	02/05/92	26	2	2	100.0	98.8	1	1		
			03/05/92	03/05/92	1	2	1	50.0	97.6		1	1m	
			04/05/92	04/05/92	1	2	2	100.0	97.6	1	1		
					42								
	48	Reboxetine	07/04/92	04/05/92	28	2	2	100.0	100.0	1	1		
			05/05/92	05/05/92	1	2		0.0	96.6			1m 1e	
			06/05/92	19/05/92	14	2	2	100.0	97.7	1	1		
					43								
2/3	36/A	Imipramine	07/03/91	17/04/91	42	2	2	100.0	100.0	1	1		
					42								
	37	Reboxetine	27/03/91	07/05/91	42	2	2	100.0	100.0	1	1		
					42								
	38	Placebo	14/08/91	25/09/91	43	2	2	100.0	100.0	1	1		
					43								
	39	Imipramine	10/08/91	20/09/91	42	2	2	100.0	100.0	1	1		
					42								
	40	Reboxetine	24/10/91	04/12/91	42	2	2	100.0	100.0	1	1		
					42								
	41	Placebo	03/10/91	13/11/91	42	2	2	100.0	100.0	1	1		
					42								
	42	Imipramine	19/05/92	30/06/92	43	2	2	100.0	100.0	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					43								
2/4	31	Placebo	26/03/91	05/05/91	41	2	2	100.0	100.0	1	1		
					41								
	32	Reboxetine	26/10/91	06/12/91	42	2	2	100.0	100.0	1	1		
					42								
	33	Imipramine	29/05/91	29/05/91	1	2	1	100.0	100.0	0	1	9m	
			30/05/91	09/07/91	41	2	2	100.0	100.0	1	1		
			10/07/91	10/07/91	1	2	1	100.0	100.0	1	0	9e	
					43								
	34	Placebo	17/04/92	28/05/92	42	2	2	100.0	100.0	1	1		
					42								
	35	Reboxetine	15/09/92	26/10/92	42	2	2	100.0	100.0	1	1		
					42								
	36	Imipramine	12/02/92	24/03/92	42	2	2	100.0	100.0	1	1		
					42								
2/5	73	Placebo	07/02/92	20/03/92	43	2	2	100.0	100.0	1	1		
					43								
	74	Reboxetine	21/06/92	01/08/92	42	2	2	100.0	100.0	1	1		
					42								
	75	Imipramine	11/09/92	22/10/92	42	2	2	100.0	100.0	1	1		
					42								
	76	Imipramine	15/09/92	26/10/92	42	2	2	100.0	100.0	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient,
5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening,
10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose,
C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					42								
2/5	77	Placebo	22/09/92	02/11/92	42	2	2	100.0	100.0	1	1		
					42								
	78	Reboxetine	10/10/92	13/11/92	35	2	2	100.0	100.0	1	1		
					35								
2/6	55	Reboxetine	12/06/92	02/07/92	21	2	2	100.0	100.0	1	1		
			03/07/92	23/07/92	21	2	4	100.0	100.0	2	2		(3 - m) (3 - e)
					42								
	56	Reboxetine	12/06/92	02/07/92	21	2	2	100.0	100.0	1	1		
			03/07/92	23/07/92	21	2	4	100.0	100.0	2	2		(3 - m) (3 - e)
					42								
	57	Imipramine	05/05/92	25/05/92	21	2	2	100.0	100.0	1	1		
			26/05/92	15/06/92	21	2	4	100.0	100.0	2	2		(3 - m) (3 - e)
					42								
	58	Placebo	18/05/92	08/06/92	22	2	2	100.0	100.0	1	1		
			09/06/92	29/06/92	21	2	4	100.0	100.0	2	2		(3 - m) (3 - e)
					43								
	59	Placebo	27/05/92	16/06/92	21	2	2	100.0	100.0	1	1		
			17/06/92	23/06/92	7	2	4	100.0	100.0	2	2		(3 - m) (3 - e)
					28								
	60	Imipramine	12/05/92	01/06/92	21	2	2	100.0	100.0	1	1		
			02/06/92	22/06/92	21	2	4	100.0	100.0	2	2		(3 - m) (3 - e)
					42								
3/1	61	Imipramine	05/03/91	20/03/91	16	2	2	100.0	100.0	1	1		
			21/03/91	21/03/91	1	2	1	50.0	97.1		1	1m	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
3/1	61	Imipramine	22/03/91	22/03/91	1	2	2	100.0	97.2	1	1		
			23/03/91	23/03/91	1	2	1	50.0	94.7	1		1e	
			24/03/91	31/03/91	8	2	2	100.0	96.3	1	1		
			01/04/91	01/04/91	1	2	1	50.0	94.6	1		1e	
			02/04/91	07/04/91	6	2	2	100.0	95.6	1	1		
			08/04/91	08/04/91	1	2	1	50.0	94.3	1		1e	
					35								
	62	Imipramine	16/04/91	26/05/91	41	2	2	100.0	100.0	1	1		
					41								
	63	Placebo	13/05/91	23/06/91	42	2	2	100.0	100.0	1	1		
					42								
	64	Placebo	14/03/91	01/04/91	19	2	2	100.0	100.0	1	1		
			02/04/91	02/04/91	1	2	1	50.0	97.5	1		1e	
			03/04/91	24/04/91	22	2	2	100.0	98.8	1	1		
					42								
	65	Reboxetine	16/09/91	27/10/91	42	2	2	100.0	100.0	1	1		
					42								
	66	Reboxetine	10/06/91	21/07/91	42	2	2	100.0	100.0	1	1		
					42								
	139	Imipramine	03/09/91	12/09/91	10	2	2	100.0	100.0	1	1		
					10								
	140	Placebo	12/09/91	23/10/91	42	2	2	100.0	100.0	1	1		
					42								
	141	Placebo	03/10/91	14/11/91	43	2	2	100.0	100.0	1	1		
					43								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
3/1	142	Imipramine	18/11/91	08/12/91	21	2	2	100.0	100.0	1	1		
					21								
	143	Reboxetine	15/04/92	15/04/92	1	2	1	100.0	100.0	0	1	9m	
			16/04/92	19/05/92	34	2	2	100.0	100.0	1	1		
			20/05/92	20/05/92	1	2	1	50.0	98.6	1		6e	
					36								
	144	Reboxetine	09/06/92	09/06/92	1	2	1	100.0	100.0	0	1	9m	
			10/06/92	22/07/92	43	2	2	100.0	100.0	1	1		
					44								
	451	Reboxetine	20/01/92	20/01/92	1	2	1	100.0	100.0	0	1	9m	
			21/01/92	31/01/92	11	2	2	100.0	100.0	1	1		
			01/02/92	01/02/92	1	2	1	50.0	96.2	1		6e	
					13								
	452	Placebo	22/01/92	22/01/92	1	2	1	100.0	100.0	0	1	9m	
			23/01/92	03/03/92	41	2	2	100.0	100.0	1	1		
			04/03/92	04/03/92	1	2	1	100.0	100.0	1	0	9e	
					43								
	453	Imipramine	29/01/92	29/01/92	1	2	1	100.0	100.0	0	1	9m	
			30/01/92	10/03/92	41	2	2	100.0	100.0	1	1		
					42								
	454	Reboxetine	17/02/92	17/02/92	1	2	1	100.0	100.0	0	1	9m	
			18/02/92	31/03/92	43	2	2	100.0	100.0	1	1		
			01/04/92	01/04/92	1	2	1	100.0	100.0	1	0	9e	
					45								
	455	Placebo	11/03/92	11/03/92	1	2	1	100.0	100.0	0	1	9m	
			12/03/92	22/04/92	42	2	2	100.0	100.0	1	1		
					43								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
3/1	456	Imipramine	25/03/92	25/03/92	1	2	1	100.0	100.0	0	1	9m	
			26/03/92	02/04/92	8	2	2	100.0	100.0	1	1		
			03/04/92	03/04/92	1	2	1	100.0	100.0	1		3e	
					10								
3/2	65/A	Reboxetine	29/01/91	25/02/91	28	2	2	100.0	100.0	1	1		
			26/02/91	27/02/91	2	2	4	100.0	100.0	2	2		(3 - m) (3 - e)
			28/02/91	11/03/91	12	2	2	100.0	100.0	1	1		
					42								
3/3	67	Placebo	18/07/91	28/08/91	42	2	2	100.0	100.0	1	1		
					42								
	68	Reboxetine	21/01/92	02/03/92	42	2	2	100.0	100.0	1	1		
					42								
	69	Placebo	04/02/92	16/03/92	42	2	2	100.0	100.0	1	1		
					42								
	70	Imipramine	15/04/92	26/05/92	42	2	2	100.0	100.0	1	1		
					42								
	71	Imipramine	16/04/92	27/05/92	42	2	2	100.0	100.0	1	1		
					42								
	72	Reboxetine	25/07/92	04/09/92	42	2	2	100.0	100.0	1	1		
					42								
3/4	79	Imipramine	04/05/91	05/05/91	2	2	2	100.0	100.0	1	1		
			06/05/91	06/05/91	1	2	3	50.0	83.3	2	1		(B - m)
			07/05/91	07/05/91	1	2	4	0.0	62.5	2	2		(B - m) (B - e)
			08/05/91	03/06/91	27	2	2	100.0	95.2	1	1		
			04/06/91	04/06/91	1	2	1	50.0	93.8		1	10m	
			05/06/91	15/06/91	11	2	2	100.0	95.3	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					43								
3/4	80	Imipramine	01/09/91	24/09/91	24	2	2	100.0	100.0	1	1		
					24								
	81	Reboxetine	17/05/91	27/06/91	42	2	2	100.0	100.0	1	1		
					42								
	82	Placebo	17/06/91	28/07/91	42	2	2	100.0	100.0	1	1		
					42								
	83	Placebo	17/06/91	17/06/91	1	2	1	100.0	100.0	0	1	9m	
			18/06/91	23/06/91	6	2	2	100.0	100.0	1	1		
			24/06/91	24/06/91	1	2	1	50.0	93.8	1		6e	
					8								
	84	Reboxetine	09/10/91	22/11/91	45	2	2	100.0	100.0	1	1		
			23/11/91	23/11/91	1	2	1	100.0	100.0	1	0	9e	
					46								
	85	Imipramine	29/10/91	08/12/91	41	2	2	100.0	100.0	1	1		
					41								
	86	Imipramine	03/12/91	14/01/92	43	2	2	100.0	100.0	1	1		
			15/01/92	15/01/92	1	2	1	100.0	100.0	1	0	9e	
					44								
	87	Placebo	09/12/91	19/01/92	42	2	2	100.0	100.0	1	1		
					42								
	88	Placebo	23/03/92	23/03/92	1	2	1	100.0	100.0	0	1	9m	
			24/03/92	27/03/92	4	2	2	100.0	100.0	1	1		
			28/03/92	28/03/92	1	2	4	0.0	83.3	2	2		(B - m) (B - e)
			29/03/92	29/03/92	1	2	3	50.0	78.6	1	2		(B - e)

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUNULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
3/4	88	Placebo	30/03/92	30/03/92	1	2	3	75.0	78.1	2	1		(B - m)
			31/03/92	19/04/92	20	2	2	100.0	93.8	1	1		
			20/04/92	21/04/92	2	2	1	50.0	90.8	1		4e	
			22/04/92	22/04/92	1	2	1	50.0	89.5		1	4m	
			23/04/92	07/05/92	15	2	2	100.0	92.9	1	1		
			08/05/92	08/05/92	1	2	1	100.0	93.1	1	0	9e	
					47								
	89	Reboxetine	26/03/92	05/05/92	41	2	2	100.0	100.0	1	1		
			06/05/92	06/05/92	1	2	1	100.0	100.0	1	0	9e	
					42								
	90	Reboxetine	28/04/92	08/06/92	42	2	2	100.0	100.0	1	1		
					42								
	457	Placebo	22/05/92	11/06/92	21	2	2	100.0	100.0	1	1		
					21								
	458	Reboxetine	26/05/92	26/05/92	1	2	1	100.0	100.0	0	1	9m	
			27/05/92	08/06/92	13	2	2	100.0	100.0	1	1		
			09/06/92	09/06/92	1	2	1	50.0	96.7	1		6e	
					15								
	459	Placebo	02/06/92	18/06/92	17	2	2	100.0	100.0	1	1		
			19/06/92	20/06/92	2	2	1	50.0	94.7	1		10e	
			21/06/92	13/07/92	23	2	2	100.0	97.6	1	1		
					42								
	460	Reboxetine	19/08/92	20/08/92	2	2	2	100.0	100.0	1	1		
					2								
	461	Imipramine	17/09/92	17/09/92	1	2	1	100.0	100.0	0	1	9m	
			18/09/92	23/09/92	6	2	2	100.0	100.0	1	1		
			24/09/92	24/09/92	1	2	1	50.0	93.8	1		6e	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					8								
3/4	462	Imipramine	29/09/92	29/09/92	1	2	1	100.0	100.0	0	1	9m	
			30/09/92	07/10/92	8	2	2	100.0	100.0	1	1		
			08/10/92	08/10/92	1	2	1	50.0	95.0	1		6e	
					10								
3/1	91	Imipramine	12/10/91	22/11/91	42	2	2	100.0	100.0	1	1		
					42								
	92	Reboxetine	07/08/91	17/09/91	42	2	2	100.0	100.0	1	1		
					42								
	93	Placebo	03/07/91	15/08/91	44	2	2	100.0	100.0	1	1		
			16/08/91	16/08/91	1	2	1	100.0	100.0	1	0	9e	
					45								
	94	Placebo	05/07/91	19/07/91	15	2	2	100.0	100.0	1	1		
			20/07/91	23/07/91	4	2	1	50.0	89.5	1		4e	
			24/07/91	13/08/91	21	2	2	100.0	95.0	1	1		
					40								
	95	Imipramine	03/06/91	16/07/91	44	2	2	100.0	100.0	1	1		
					44								
	96	Reboxetine	04/09/91	16/10/91	43	2	2	100.0	100.0	1	1		
					43								
	115	Reboxetine	06/05/92	16/06/92	42	2	2	100.0	100.0	1	1		
					42								
	116	Imipramine	16/05/92	21/05/92	6	2	2	100.0	100.0	1	1		
			22/05/92	22/05/92	1	2	1	50.0	92.9	1		6e	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					7								
4/1	117	Imipramine	03/09/91	14/10/91	42	2	2	100.0	100.0	1	1		
					42								
	118	Reboxetine	23/05/92	03/07/92	42	2	2	100.0	100.0	1	1		
					42								
	120	Placebo	31/07/92	31/07/92	1	2	1	100.0	100.0	0	1	9m	
			01/08/92	11/09/92	42	2	2	100.0	100.0	1	1		
					43								
	145	Imipramine	30/09/92	05/10/92	6	2	2	100.0	100.0	1	1		
			06/10/92	06/10/92	1	2	1	50.0	92.9		1	10m	
			07/10/92	10/11/92	35	2	2	100.0	98.8	1	1		
					42								
	146	Placebo	16/09/92	26/10/92	41	2	2	100.0	100.0	1	1		
			27/10/92	27/10/92	1	2	1	100.0	100.0	1	0	9e	
					42								
	147	Reboxetine	01/09/92	02/09/92	2	2	2	100.0	100.0	1	1		
			03/09/92	03/09/92	1	2	1	50.0	83.3	1		10e	
			04/09/92	12/10/92	39	2	2	100.0	98.8	1	1		
					42								
	148	Imipramine	26/09/92	06/11/92	42	2	2	100.0	100.0	1	1		
					42								
	149	Reboxetine	30/09/92	10/11/92	42	2	2	100.0	100.0	1	1		
					42								
	150	Placebo	30/09/92	10/11/92	42	2	2	100.0	100.0	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					42								
4/2	93/A	Placebo	22/02/91	04/04/91	42	2	2	100.0	100.0	1	1		
					42								
	99/A	Placebo	27/03/91	07/05/91	42	2	2	100.0	100.0	1	1		
					42								
	104	Reboxetine	22/05/91	02/07/91	42	2	2	100.0	100.0	1	1		
					42								
4/3	97	Placebo	17/04/91	29/04/91	13	2	2	100.0	100.0	1	1		
			30/04/91	30/04/91	1	2	1	50.0	96.4	1		10e	
			01/05/91	28/05/91	28	2	2	100.0	98.8	1	1		
					42								
	98	Reboxetine	20/06/91	11/07/91	22	2	2	100.0	100.0	1	1		
			12/07/91	12/07/91	1	2	1	50.0	97.8	1		1e	
			13/07/91	21/07/91	9	2	2	100.0	98.4	1	1		
					32								
	99	Placebo	08/08/91	14/08/91	7	2	2	100.0	100.0	1	1		
			15/08/91	15/08/91	1	2	1	50.0	93.8	1		6e	
					8								
	100	Imipramine	27/11/91	27/11/91	1	2	1	100.0	100.0	0	1	9m	
			28/11/91	17/12/91	20	2	2	100.0	100.0	1	1		
					21								
	101	Imipramine	17/03/92	27/04/92	42	2	2	100.0	100.0	1	1		
					42								
4/4	109	Reboxetine	08/06/91	19/07/91	42	2	2	100.0	100.0	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					42								
4/4	110	Imipramine	15/06/91	26/07/91	42	2	2	100.0	100.0	1	1		
					42								
	111	Imipramine	04/07/91	14/08/91	42	2	2	100.0	100.0	1	1		
					42								
	112	Placebo	10/07/91	20/08/91	42	2	2	100.0	100.0	1	1		
					42								
	113	Reboxetine	31/08/91	11/10/91	42	2	2	100.0	100.0	1	1		
					42								
	114	Placebo	20/11/91	31/12/91	42	2	2	100.0	100.0	1	1		
					42								
	175	Imipramine	13/02/92	25/03/92	42	2	2	100.0	100.0	1	1		
					42								
	176	Placebo	14/03/92	07/04/92	25	2	2	100.0	100.0	1	1		
			08/04/92	08/04/92	1	2	1	50.0	98.1	1		6e	
					26								
	177	Imipramine	28/04/92	11/05/92	14	2	2	100.0	100.0	1	1		
					14								
	178	Reboxetine	28/04/92	08/06/92	42	2	2	100.0	100.0	1	1		
					42								
	179	Placebo	11/09/92	28/09/92	18	2	2	100.0	100.0	1	1		
			29/09/92	29/09/92	1	2	1	50.0	97.4	1		6e	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					19								
4/4	180	Reboxetine	07/10/92	17/11/92	42	2	2	100.0	100.0	1	1		
					42								
5/1	127	Reboxetine	06/06/91	17/07/91	42	2	2	100.0	100.0	1	1		
					42								
	128	Reboxetine	14/06/91	25/07/91	42	2	2	100.0	100.0	1	1		
					42								
	129	Placebo	24/12/91	03/02/92	42	2	2	100.0	100.0	1	1		
					42								
	130	Placebo	05/03/92	14/04/92	41	2	2	100.0	100.0	1	1		
			15/04/92	15/04/92	1	2	1	100.0	100.0	1		5e	
					42								
	131	Imipramine	21/03/92	30/04/92	41	2	2	100.0	100.0	1	1		
					41								
	132	Imipramine	25/06/92	06/08/92	43	2	2	100.0	100.0	1	1		
					43								
5/2	121	Imipramine	20/12/91	26/01/92	38	2	2	100.0	100.0	1	1		
			27/01/92	27/01/92	1	2	1	50.0	98.7	1		6e	
					39								
	125	Reboxetine	28/01/91	23/02/91	27	2	2	100.0	100.0	1	1		
			24/02/91	24/02/91	1	2	1	50.0	98.2	1		1e	
			25/02/91	09/03/91	13	2	2	100.0	98.8	1	1		
			10/03/91	10/03/91	1	2	1	50.0	97.6	1		1e	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient,
5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening,
10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose,
C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					42								
5/3	133	Placebo	29/11/91	12/12/91	14	2	2	100.0	100.0	1	1		
					14								
	134	Reboxetine	06/12/91	16/01/92	42	2	2	100.0	100.0	1	1		
					42								
	135	Imipramine	10/01/92	20/02/92	42	2	2	100.0	100.0	1	1		
					42								
	136	Imipramine	02/03/92	07/03/92	6	2	2	100.0	100.0	1	1		
			08/03/92	08/03/92	1	2	1	50.0	92.9	1		10e	
			09/03/92	12/04/92	35	2	2	100.0	98.8	1	1		
					42								
	137	Reboxetine	15/05/92	25/06/92	42	2	2	100.0	100.0	1	1		
					42								
	138	Placebo	15/05/92	15/05/92	1	2	2	100.0	100.0	1	1		
			16/05/92	16/05/92	1	2	1	50.0	75.0	1		6e	
					2								
6/1	151	Imipramine	21/01/92	21/01/92	1	2	1	100.0	100.0	0	1	9m	
			22/01/92	27/01/92	6	2	2	100.0	100.0	1	1		
			28/01/92	28/01/92	1	2	1	50.0	93.8	1		6e	
					8								
	152	Reboxetine	24/02/92	07/04/92	44	2	2	100.0	100.0	1	1		
					44								
	153	Reboxetine	18/03/91	18/03/91	1	2	1	100.0	100.0	0	1	9m	
			19/03/91	28/04/91	41	2	2	100.0	100.0	1	1		
			29/04/91	29/04/91	1	2	1	100.0	100.0	1	0	9e	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					43								
6/1	154	Imipramine	30/03/92	06/04/92	8	2		0.0	0.0				
					8								
	155	Placebo	08/07/92	04/08/92	28	2	2	100.0	100.0	1	1		
					28								
	156	Placebo	08/09/92	19/10/92	42	2	2	100.0	100.0	1	1		
					42								
6/2	157	Reboxetine	30/04/91	26/05/91	27	2	2	100.0	100.0	1	1		
			27/05/91	27/05/91	1	2	1	50.0	98.2	1		1e	
			28/05/91	10/06/91	14	2	2	100.0	98.8	1	1		
					42								
	158	Imipramine	24/11/91	05/01/92	43	2	2	100.0	100.0	1	1		
					43								
	159	Imipramine	14/07/91	24/08/91	42	2	2	100.0	100.0	1	1		
					42								
	160	Placebo	24/11/91	04/01/92	42	2	2	100.0	100.0	1	1		
					42								
	161	Reboxetine	20/02/92	18/03/92	28	2	2	100.0	100.0	1	1		
					28								
	162	Placebo	10/07/91	12/07/91	3	2	2	100.0	100.0	1	1		
			13/07/91	13/07/91	1	2	1	50.0	87.5	1		6e	
					4								
	169	Imipramine	26/12/91	15/01/92	21	2	2	100.0	100.0	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					21								
6/2	170	Placebo	01/11/91	15/11/91	15	2	2	100.0	100.0	1	1		
					15								
	171	Imipramine	22/07/92	01/09/92	42	2	2	100.0	100.0	1	1		
					42								
	172	Reboxetine	07/07/92	17/08/92	42	2	2	100.0	100.0	1	1		
					42								
	173	Placebo	05/07/92	15/08/92	42	2	2	100.0	100.0	1	1		
					42								
	174	Reboxetine	11/05/92	21/06/92	42	2	2	100.0	100.0	1	1		
					42								
6/3	163	Reboxetine	06/06/91	07/06/91	2	2	2	100.0	100.0	1	1		
			08/06/91	08/06/91	1	2	1	50.0	83.3	1		6e	
					3								
	164	Imipramine	11/10/91	21/11/91	42	2	2	100.0	100.0	1	1		
					42								
	165	Imipramine	16/10/91	25/11/91	41	2	2	100.0	100.0	1	1		
			26/11/91	26/11/91	1	2	1	100.0	100.0	1		5e	
					42								
	166	Reboxetine	25/10/91	29/10/91	5	2	2	100.0	100.0	1	1		
					5								
	167	Placebo	18/11/91	18/11/91	1	2	1	100.0	100.0	0	1	9m	
			19/11/91	08/12/91	20	2	2	100.0	100.0	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
6/3	167	Placebo	09/12/91	09/12/91	1	2	1	50.0	97.7	1		10e	
			10/12/91	27/12/91	18	2	2	100.0	98.8	1	1		
					40								
	168	Placebo	03/12/91	05/01/92	34	2	2	100.0	100.0	1	1		
			06/01/92	06/01/92	1	2	1	100.0	100.0	1	0	9e	
					35								
	505	Imipramine	03/12/91	17/12/91	15	2	2	100.0	100.0	1	1		
					15								
	506	Placebo	08/01/92	08/01/92	1	2	1	100.0	100.0	0	1	9m	
			09/01/92	19/02/92	42	2	2	100.0	100.0	1	1		
					43								
	507	Imipramine	14/01/92	24/02/92	42	2	2	100.0	100.0	1	1		
					42								
	508	Reboxetine	05/02/92	17/03/92	42	2	2	100.0	100.0	1	1		
					42								
	509	Placebo	24/02/92	24/02/92	1	2	1	100.0	100.0	0	1	9m	
			25/02/92	06/04/92	42	2	2	100.0	100.0	1	1		
					43								
	510	Reboxetine	27/02/92	09/03/92	12	2	2	100.0	100.0	1	1		
			10/03/92	10/03/92	1	2	1	50.0	96.2	1		6e	
					13								
	511	Imipramine	19/03/92	21/04/92	34	2	2	100.0	100.0	1	1		
					34								
	512	Placebo	01/04/92	01/04/92	1	2	1	100.0	100.0	1		3e	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					1								
6/3	513	Imipramine	13/05/92	23/06/92	42	2	2	100.0	100.0	1	1		
					42								
7/02	181	Reboxetine	27/01/92	08/03/92	42	2	2	100.0	100.0	1	1		
					42								
	182	Placebo	23/11/91	03/01/92	42	2	2	100.0	100.0	1	1		
					42								
	183	Imipramine	02/01/92	15/01/92	14	2	2	100.0	100.0	1	1		
			16/01/92	18/01/92	3	2		0.0	82.4				
					17								
	184	Imipramine	27/01/92	08/03/92	42	2	2	100.0	100.0	1	1		
					42								
	185	Reboxetine	10/04/92	04/05/92	25	2	2	100.0	100.0	1	1		
			05/05/92	05/05/92	1	2	1	50.0	98.1	1		6	e
					26								
	186	Placebo	16/04/92	27/05/92	42	2	2	100.0	100.0	1	1		
					42								
	535	Placebo	15/04/92	26/05/92	42	2	2	100.0	100.0	1	1		
					42								
	536	Reboxetine	08/05/92	18/06/92	42	2	2	100.0	100.0	1	1		
					42								
7/03	187	Imipramine	18/02/92	30/03/92	42	2	2	100.0	100.0	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					42								
7/03	188	Placebo	25/02/92	06/04/92	42	2	2	100.0	100.0	1	1		
					42								
	189	Placebo	25/02/92	06/04/92	42	2	2	100.0	100.0	1	1		
					42								
	190	Reboxetine	28/02/92	09/04/92	42	2	2	100.0	100.0	1	1		
					42								
	191	Imipramine	03/03/92	10/04/92	39	2	2	100.0	100.0	1	1		
					39								
	192	Reboxetine	10/03/92	20/04/92	42	2	2	100.0	100.0	1	1		
					42								
	523	Reboxetine	06/05/92	16/06/92	42	2	2	100.0	100.0	1	1		
					42								
	524	Placebo	06/05/92	16/06/92	42	2	2	100.0	100.0	1	1		
					42								
	525	Placebo	06/05/92	16/06/92	42	2	2	100.0	100.0	1	1		
					42								
	526	Reboxetine	06/05/92	16/06/92	42	2	2	100.0	100.0	1	1		
					42								
	527	Imipramine	19/05/92	08/06/92	21	2	2	100.0	100.0	1	1		
			09/06/92	15/06/92	7	2	1	50.0	87.5		1	4m	
			16/06/92	29/06/92	14	2	2	100.0	91.7	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					42								
7/03	528	Imipramine	19/05/92	25/05/92	7	2		0.0	0.0				
			26/05/92	22/06/92	28	2	2	100.0	80.0	1	1		
					35								
7/04	193	Placebo	25/01/92	06/03/92	42	2	2	100.0	100.0	1	1		
					42								
	194	Reboxetine	25/01/92	06/03/92	42	2	2	100.0	100.0	1	1		
					42								
	195	Placebo	25/01/92	06/03/92	42	2	2	100.0	100.0	1	1		
					42								
	196	Reboxetine	01/02/92	21/02/92	21	2	2	100.0	100.0	1	1		
			22/02/92	28/02/92	7	2	2	0.0	75.0		2	4m	(D - e)
			29/02/92	05/03/92	6	2	2	100.0	79.4	1	1		
			06/03/92	06/03/92	1	2	1	50.0	78.6	1		10e	
			07/03/92	13/03/92	7	2	2	100.0	82.1	1	1		
					42								
	197	Imipramine	01/02/92	13/03/92	42	2	2	100.0	100.0	1	1		
					42								
	198	Imipramine	01/02/92	13/03/92	42	2	2	100.0	100.0	1	1		
					42								
	199	Imipramine	28/03/92	04/05/92	38	2	2	100.0	100.0	1	1		
			05/05/92	05/05/92	1	2	1	50.0	98.7		1	1m	
			06/05/92	08/05/92	3	2	2	100.0	98.8	1	1		
					42								
	200	Placebo	28/03/92	08/05/92	42	2	2	100.0	100.0	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					42								
7/04	201	Reboxetine	28/03/92	27/04/92	31	2	2	100.0	100.0	1	1		
			28/04/92	28/04/92	1	2		0.0	96.9			1m 1e	
			29/04/92	08/05/92	10	2	2	100.0	97.6	1	1		
					42								
	202	Reboxetine	04/04/92	27/04/92	24	2	2	100.0	100.0	1	1		
			28/04/92	28/04/92	1	2	1	50.0	98.0	1		1e	
			29/04/92	15/05/92	17	2	2	100.0	98.8	1	1		
					42								
	203	Placebo	04/04/92	21/04/92	18	2	2	100.0	100.0	1	1		
			22/04/92	22/04/92	1	2	1	50.0	97.4		1	1m	
			23/04/92	15/05/92	23	2	2	100.0	98.8	1	1		
					42								
	204	Imipramine	04/04/92	29/04/92	26	2	2	100.0	100.0	1	1		
			30/04/92	30/04/92	1	2	1	50.0	98.1		1	1m	
			01/05/92	15/05/92	15	2	2	100.0	98.8	1	1		
					42								
7/05	205	Placebo	27/01/92	16/02/92	21	2	2	100.0	100.0	1	1		
			17/02/92	08/03/92	21	2	4	100.0	100.0	2	2		(3 - m) (3 - e)
					42								
	206	Imipramine	28/01/92	09/03/92	42	2	2	100.0	100.0	1	1		
					42								
	207	Imipramine	28/01/92	09/03/92	42	2	2	100.0	100.0	1	1		
					42								
	208	Reboxetine	30/01/92	11/03/92	42	2	2	100.0	100.0	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					42								
7/05	209	Placebo	05/02/92	17/03/92	42	2	2	100.0	100.0	1	1		
					42								
	210	Reboxetine	07/02/92	19/03/92	42	2	2	100.0	100.0	1	1		
					42								
	541	Reboxetine	17/03/92	27/04/92	42	2	2	100.0	100.0	1	1		
					42								
	542	Imipramine	17/03/92	27/04/92	42	2	2	100.0	100.0	1	1		
					42								
	543	Imipramine	18/03/92	28/04/92	42	2	2	100.0	100.0	1	1		
					42								
	544	Placebo	24/03/92	04/05/92	42	2	2	100.0	100.0	1	1		
					42								
	545	Placebo	25/03/92	05/05/92	42	2	2	100.0	100.0	1	1		
					42								
	546	Reboxetine	25/03/92	05/05/92	42	2	2	100.0	100.0	1	1		
					42								
7/07	529	Placebo	18/02/92	30/03/92	42	2	2	100.0	100.0	1	1		
					42								
	530	Imipramine	20/02/92	04/03/92	14	2	2	100.0	100.0	1	1		
			05/03/92	11/03/92	7	2		0.0	66.7				

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					21								
7/07	531	Reboxetine	24/02/92	24/03/92	30	2	2	100.0	100.0	1	1		
			25/03/92	25/03/92	1	2	1	50.0	98.4		1	1m	
			26/03/92	05/04/92	11	2	2	100.0	98.8	1	1		
					42								
	532	Imipramine	27/04/92	07/06/92	42	2	2	100.0	100.0	1	1		
					42								
	533	Reboxetine	04/05/92	14/06/92	42	2	2	100.0	100.0	1	1		
					42								
	534	Placebo	15/05/92	25/06/92	42	2	2	100.0	100.0	1	1		
					42								
8	211	Reboxetine	13/05/91	26/05/91	14	2	2	100.0	100.0	1	1		
					14								
	212	Placebo	14/09/91	25/10/91	42	2	2	100.0	100.0	1	1		
					42								
	213	Imipramine	22/11/91	24/11/91	3	2	2	100.0	100.0	1	1		
					3								
	214	Reboxetine	23/11/91	03/01/92	42	2	2	100.0	100.0	1	1		
					42								
	215	Placebo	18/02/92	30/03/92	42	2	2	100.0	100.0	1	1		
					42								
	216	Imipramine	27/03/92	07/05/92	42	2	2	100.0	100.0	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient,
5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening,
10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose,
C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					42								
8	217	Reboxetine	30/03/92	10/05/92	42	2	2	100.0	100.0	1	1		
					42								
	218	Reboxetine	09/04/92	20/05/92	42	2	2	100.0	100.0	1	1		
					42								
	219	Placebo	11/04/92	01/05/92	21	2	2	100.0	100.0	1	1		
					21								
	220	Imipramine	27/04/92	07/06/92	42	2	2	100.0	100.0	1	1		
					42								
	221	Imipramine	28/04/92	08/06/92	42	2	2	100.0	100.0	1	1		
					42								
	222	Placebo	28/04/92	08/06/92	42	2	2	100.0	100.0	1	1		
					42								
	223	Imipramine	11/05/92	21/06/92	42	2	2	100.0	100.0	1	1		
					42								
	224	Placebo	07/09/92	18/10/92	42	2	2	100.0	100.0	1	1		
					42								
	225	Placebo	11/09/92	22/10/92	42	2	2	100.0	100.0	1	1		
					42								
	226	Reboxetine	23/09/92	03/11/92	42	2	2	100.0	100.0	1	1		
					42								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
8	227	Reboxetine	25/09/92	05/11/92	42	2	2	100.0	100.0	1	1		
					42								
	228	Imipramine	26/09/92	02/10/92	7	2	2	100.0	100.0	1	1		
					7								
	229	Imipramine	30/09/92	10/11/92	42	2	2	100.0	100.0	1	1		
					42								
	230	Reboxetine	28/09/92	08/11/92	42	2	2	100.0	100.0	1	1		
					42								
	231	Imipramine	30/09/92	10/11/92	42	2	2	100.0	100.0	1	1		
					42								
	232	Reboxetine	02/10/92	12/11/92	42	2	2	100.0	100.0	1	1		
					42								
	233	Placebo	07/10/92	17/11/92	42	2	2	100.0	100.0	1	1		
					42								
	234	Placebo	07/10/92	17/11/92	42	2	2	100.0	100.0	1	1		
					42								
8/A	235	Placebo	14/10/92	24/11/92	42	2	2	100.0	100.0	1	1		
					42								
	236	Placebo	14/10/92	24/11/92	42	2	2	100.0	100.0	1	1		
					42								
	237	Reboxetine	14/10/92	24/11/92	42	2	2	100.0	100.0	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					42								
8/A	238	Reboxetine	14/10/92	24/11/92	42	2	2	100.0	100.0	1	1		
					42								
	239	Imipramine	16/10/92	26/11/92	42	2	2	100.0	100.0	1	1		
					42								
	240	Imipramine	16/10/92	26/11/92	42	2	2	100.0	100.0	1	1		
					42								
	553	Placebo	16/10/92	26/11/92	42	2	2	100.0	100.0	1	1		
					42								
	554	Reboxetine	16/10/92	26/11/92	42	2	2	100.0	100.0	1	1		
					42								
	555	Reboxetine	16/10/92	26/11/92	42	2	2	100.0	100.0	1	1		
					42								
	556	Imipramine	16/10/92	26/11/92	42	2	2	100.0	100.0	1	1		
					42								
9	241	Placebo	07/02/91	17/02/91	11	2	2	100.0	100.0	1	1		
					11								
	242	Reboxetine	18/02/91	10/03/91	21	2	2	100.0	100.0	1	1		
			11/03/91	11/03/91	1	2	1	50.0	97.7	1		6e	
					22								
	243	Reboxetine	20/02/91	01/03/91	10	2	2	100.0	100.0	1	1		
			02/03/91	03/03/91	2	2	3	50.0	91.7	2	1		(B - m)
			04/03/91	05/03/91	2	2	2	100.0	92.9	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
9	243	Reboxetine	06/03/91	06/03/91	1	2	1	50.0	90.0	1		6e	
					15								
	244	Imipramine	19/02/91	12/03/91	22	2	2	100.0	100.0	1	1		
			13/03/91	13/03/91	1	2	1	50.0	97.8	1		6e	
					23								
	245	Imipramine	22/02/91	04/04/91	42	2	2	100.0	100.0	1	1		
					42								
	246	Placebo	22/02/91	17/03/91	24	2	2	100.0	100.0	1	1		
					24								
	247	Placebo	25/02/91	25/03/91	29	2	2	100.0	100.0	1	1		
			26/03/91	26/03/91	1	2	1	50.0	98.3	1		6e	
					30								
	248	Placebo	07/03/91	07/03/91	1	2	1	100.0	100.0	0	1	9m	
			08/03/91	21/03/91	14	2	2	100.0	100.0	1	1		
					15								
	249	Reboxetine	08/03/91	10/03/91	3	2	2	100.0	100.0	1	1		
			11/03/91	11/03/91	1	2	1	50.0	87.5	1		6e	
					4								
	250	Imipramine	12/03/91	07/04/91	27	2	2	100.0	100.0	1	1		
			08/04/91	08/04/91	1	2	1	50.0	98.2	1		6e	
					28								
	251	Imipramine	20/03/91	11/04/91	23	2	2	100.0	100.0	1	1		
			12/04/91	12/04/91	1	2	1	50.0	97.9	1		6e	
					24								
	252	Reboxetine	02/04/91	17/04/91	16	2	2	100.0	100.0	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
9	252	Reboxetine	18/04/91	20/04/91	3	2	1	100.0	100.0	1		3e	
					19								
	253	Reboxetine	02/04/91	07/04/91	6	2	2	100.0	100.0	1	1		
			08/04/91	08/04/91	1	2	1	50.0	92.9	1		6e	
					7								
	254	Imipramine	09/04/91	15/04/91	7	2	2	100.0	100.0	1	1		
			16/04/91	16/04/91	1	2	1	50.0	93.8	1		6e	
					8								
	255	Reboxetine	13/05/91	05/06/91	24	2	2	100.0	100.0	1	1		
			06/06/91	06/06/91	1	2	1	50.0	98.0	1		6e	
					25								
	256	Imipramine	27/05/91	05/06/91	10	2	2	100.0	100.0	1	1		
			06/06/91	09/06/91	4	2	1	100.0	100.0	1		3e	
			10/06/91	10/06/91	1	2	1	100.0	100.0	1	0		3
			11/06/91	16/06/91	6	2	1	100.0	100.0	1		3e	
			17/06/91	20/06/91	4	2	2	100.0	100.0	1	1		
			21/06/91	08/07/91	18	2	1	100.0	100.0	1		3e	
					43								
	257	Placebo	25/06/91	30/06/91	6	2	2	100.0	100.0	1	1		
			01/07/91	01/07/91	1	2	1	50.0	92.9	1		6e	
					7								
	258	Placebo	01/07/91	09/07/91	9	2	2	100.0	100.0	1	1		
			10/07/91	10/07/91	1	2	1	50.0	95.0	1		6e	
					10								
11	319	Placebo	02/08/91	12/09/91	42	2	2	100.0	100.0	1	1		
					42								
	320	Imipramine	17/08/91	27/08/91	11	2	2	100.0	100.0	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
11	320	Imipramine	28/08/91	28/08/91	1	2	1	50.0	95.8		1	1m	
			29/08/91	01/09/91	4	2	2	100.0	96.9	1	1		
			02/09/91	02/09/91	1	2	1	50.0	94.1	1		4e	
			03/09/91	03/09/91	1	2	1	50.0	91.7		1	4m	
			04/09/91	25/09/91	22	2	2	100.0	96.3	1	1		
			26/09/91	26/09/91	1	2	1	100.0	96.3	1	0	9e	
					41								
	321	Placebo	06/09/91	16/10/91	41	2	2	100.0	100.0	1	1		
			17/10/91	17/10/91	1	2	1	100.0	100.0	1	0	9e	
					42								
	322	Reboxetine	27/09/91	06/11/91	41	2	2	100.0	100.0	1	1		
			07/11/91	07/11/91	1	2	1	100.0	100.0	1	0	9e	
					42								
	323	Reboxetine	15/11/91	25/12/91	41	2	2	100.0	100.0	1	1		
			26/12/91	26/12/91	1	2	1	100.0	100.0	1	0	9e	
					42								
	324	Imipramine	06/12/91	15/01/92	41	2	2	100.0	100.0	1	1		
			16/01/92	16/01/92	1	2	1	100.0	100.0	1	0	9e	
					42								
	325	Reboxetine	13/12/91	18/12/91	6	2	2	100.0	100.0	1	1		
			19/12/91	19/12/91	1	2	1	50.0	92.9	1		10e	
			20/12/91	26/12/91	7	2	2	100.0	96.4	1	1		
			27/12/91	27/12/91	1	2	1	75.0	95.0	1	0	1	
			28/12/91	22/01/92	26	2	2	100.0	98.2	1	1		
			23/01/92	23/01/92	1	2	1	100.0	98.2	1	0	9e	
					42								
	326	Placebo	16/01/92	16/01/92	1	2	1	100.0	100.0	0	1	9m	
			17/01/92	20/02/92	35	2	2	100.0	100.0	1	1		
			21/02/92	21/02/92	1	2		0.0	97.3			10m 10e	
			22/02/92	26/02/92	5	2	2	100.0	97.6	1	1		
			27/02/92	27/02/92	1	2	1	100.0	97.7	1	0	9e	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					43								
11	327	Imipramine	30/01/92	04/02/92	6	2	2	100.0	100.0	1	1		
			05/02/92	05/02/92	1	2	1	50.0	92.9	1		6e	
					7								
	328	Imipramine	31/01/92	04/02/92	5	2	2	100.0	100.0	1	1		
			05/02/92	05/02/92	1	2		50.0	91.7			3m 6e	
					6								
	329	Placebo	10/04/92	20/05/92	41	2	2	100.0	100.0	1	1		
			21/05/92	21/05/92	1	2	1	100.0	100.0	1	0	9e	
					42								
	330	Reboxetine	09/04/92	09/04/92	1	2	1	100.0	100.0	0	1	9m	
			10/04/92	13/05/92	34	2	2	100.0	100.0	1	1		
			14/05/92	14/05/92	1	2	1	75.0	99.3	1	0		1
			15/05/92	16/05/92	2	2	2	100.0	99.3	1	1		
			17/05/92	17/05/92	1	2	1	50.0	98.1	1		1e	
			18/05/92	20/05/92	3	2	2	100.0	98.2	1	1		
			21/05/92	21/05/92	1	2	1	100.0	98.3	1	0	9e	
					43								
	331	Imipramine	17/04/92	27/05/92	41	2	2	100.0	100.0	1	1		
			28/05/92	28/05/92	1	2	1	100.0	100.0	1	0	9e	
					42								
	332	Reboxetine	19/05/92	28/06/92	41	2	2	100.0	100.0	1	1		
			29/06/92	29/06/92	1	2	1	100.0	100.0	1	0	9e	
					42								
	333	Placebo	27/05/92	06/07/92	41	2	2	100.0	100.0	1	1		
			07/07/92	07/07/92	1	2	1	100.0	100.0	1	0	9e	
					42								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
11	334	Reboxetine	29/05/92	31/05/92	3	2	2	100.0	100.0	1	1		
			01/06/92	01/06/92	1	2		50.0	87.5			3m 6e	
					4								
	335	Placebo	03/06/92	13/07/92	41	2	2	100.0	100.0	1	1		
			14/07/92	14/07/92	1	2	1	100.0	100.0	1	0	9e	
					42								
	336	Imipramine	18/06/92	18/06/92	1	2	1	100.0	100.0	0	1	9m	
			19/06/92	24/06/92	6	2	2	100.0	100.0	1	1		
			25/06/92	25/06/92	1	2	1	50.0	93.8	1		6e	
					8								
	337	Reboxetine	02/07/92	02/07/92	1	2	1	100.0	100.0	0	1	9m	
			03/07/92	15/07/92	13	2	2	100.0	100.0	1	1		
			16/07/92	16/07/92	1	2	1	75.0	98.3	0	1	1	
			17/07/92	12/08/92	27	2	2	100.0	99.4	1	1		
			13/08/92	13/08/92	1	2	1	100.0	99.4	1	0	9e	
					43								
	338	Imipramine	23/07/92	23/07/92	1	2	1	100.0	100.0	0	1	9m	
			24/07/92	29/07/92	6	2	2	100.0	100.0	1	1		
			30/07/92	30/07/92	1	2	1	50.0	93.8	1		6e	
					8								
12	367	Reboxetine	20/12/91	20/12/91	1	2	1	100.0	100.0	0	1	9m	
			21/12/91	30/01/92	41	2	2	100.0	100.0	1	1		
					42								
	368	Placebo	24/12/91	24/12/91	1	2	1	100.0	100.0	0	1	9m	
			25/12/91	03/02/92	41	2	2	100.0	100.0	1	1		
					42								
	369	Imipramine	23/04/92	12/05/92	20	2	2	100.0	100.0	1	1		
			13/05/92	13/05/92	1	2	1	50.0	97.6	1		6e	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient,
5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening,
10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose,
C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					21								
12	370	Placebo	29/04/92	19/05/92	21	2	2	100.0	100.0	1	1		
			20/05/92	20/05/92	1	2	1	50.0	97.7	1		6e	
					22								
	371	Imipramine	01/05/92	06/05/92	6	2	2	100.0	100.0	1	1		
					6								
	372	Reboxetine	02/06/92	02/06/92	1	2	1	100.0	100.0	0	1	9m	
			03/06/92	13/07/92	41	2	2	100.0	100.0	1	1		
					42								
	373	Reboxetine	05/06/92	05/06/92	1	2	1	100.0	100.0	0	1	9m	
			06/06/92	13/07/92	38	2	2	100.0	100.0	1	1		
			14/07/92	14/07/92	1	2	1	50.0	98.8	1		6e	
					40								
	374	Placebo	09/06/92	05/07/92	27	2	2	100.0	100.0	1	1		
			06/07/92	06/07/92	1	2	1	50.0	98.2	1		6e	
					28								
	375	Imipramine	17/06/92	17/06/92	1	2	2	100.0	100.0	1	1		
			18/06/92	18/06/92	1	2	1	50.0	75.0	1		6e	
					2								
13	13	Placebo	13/04/91	24/05/91	42	2	2	100.0	100.0	1	1		
					42								
	14	Placebo	02/07/91	22/07/91	21	2	2	100.0	100.0	1	1		
			23/07/91	23/07/91	1	2	1	50.0	97.7	1		1e	
			24/07/91	13/08/91	21	2	2	100.0	98.8	1	1		
					43								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

1059

9550082

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
13	15	Imipramine	05/07/91	15/08/91	42	2	2	100.0	100.0	1	1		
					42								
	16	Imipramine	03/12/91	05/12/91	3	2	2	100.0	100.0	1	1		
			06/12/91	15/12/91	10	2		100.0	100.0			3m 3e	
			16/12/91	16/01/92	32	2	2	100.0	100.0	1	1		
					45								
	17	Reboxetine	21/05/92	01/06/92	12	2	2	100.0	100.0	1	1		
			02/06/92	02/06/92	1	2	1	50.0	96.2	1		10e	
			03/06/92	16/06/92	14	2	2	100.0	98.1	1	1		
			17/06/92	23/06/92	7	2		0.0	77.9				
			24/06/92	01/07/92	8	2	2	100.0	82.1	1	1		
					42								
	18	Reboxetine	24/06/92	02/08/92	40	2	2	100.0	100.0	1	1		
					40								
	409	Reboxetine	10/12/91	20/12/91	11	2	2	100.0	100.0	1	1		
			21/12/91	23/12/91	3	2		0.0	78.6			4m 4e	
			24/12/91	20/01/92	28	2	2	100.0	92.9	1	1		
					42								
	410	Placebo	14/02/92	20/02/92	7	2	2	100.0	100.0	1	1		
			21/02/92	21/02/92	1	2		0.0	87.5			10m 10e	
			22/02/92	26/03/92	34	2	2	100.0	97.6	1	1		
					42								
	411	Imipramine	28/03/92	08/05/92	42	2	2	100.0	100.0	1	1		
					42								
	423	Placebo	14/09/92	27/10/92	44	2	2	100.0	100.0	1	1		
					44								
14	19	Reboxetine	10/04/92	06/05/92	27	2	2	100.0	100.0	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
					27								
14	20	Imipramine	29/04/92	29/04/92	1	2	2	100.0	100.0	1	1		
			30/04/92	30/04/92	1	2		100.0	100.0			3m 3e	
			01/05/92	09/06/92	40	2	2	100.0	100.0	1	1		
					42								
	21	Imipramine	20/07/92	20/07/92	1	2	1	100.0	100.0	0	1	9m	
			21/07/92	22/08/92	33	2	2	100.0	100.0	1	1		
			23/08/92	23/08/92	1	2	1	50.0	98.6		1	4m	
			24/08/92	24/08/92	1	2	1	50.0	97.2	1		6e	
					36								
15	25	Reboxetine	18/06/91	18/06/91	1	2	1	100.0	100.0	0	1	9m	
			19/06/91	29/07/91	41	2	2	100.0	100.0	1	1		
					42								
	26	Placebo	20/06/91	20/06/91	1	2	1	100.0	100.0	0	1	9m	
			21/06/91	26/06/91	6	2	2	100.0	100.0	1	1		
			27/06/91	27/06/91	1	2	1	50.0	93.8		1	1m	
			28/06/91	31/07/91	34	2	2	100.0	98.8	1	1		
			01/08/91	01/08/91	1	2	1	100.0	98.8	1	0	9e	
					43								
	27	Imipramine	02/07/91	29/07/91	28	2	2	100.0	100.0	1	1		
			30/07/91	30/07/91	1	2	1	50.0	98.3	1		1e	
			31/07/91	12/08/91	13	2	2	100.0	98.8	1	1		
			13/08/91	13/08/91	1	2	1	100.0	98.8	1	0	9e	
					43								
	28	Reboxetine	08/08/91	09/09/91	33	2	2	100.0	100.0	1	1		
			10/09/91	10/09/91	1	2	1	50.0	98.5		1	1m	
			11/09/91	19/09/91	9	2	2	100.0	98.8	1	1		
					43								
	29	Placebo	29/08/91	29/08/91	1	2	1	100.0	100.0	0	1	9m	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
15	29	Placebo	30/08/91	18/09/91	20	2	2	100.0	100.0	1	1		
			19/09/91	19/09/91	1	2	1	50.0	97.7	1		6e	
					22								
	30	Imipramine	03/09/91	07/09/91	5	2	2	100.0	100.0	1	1		
			08/09/91	08/09/91	1	2	1	50.0	91.7	1		10e	
			09/09/91	09/09/91	1	2	1	50.0	85.7		1	10m	
			10/09/91	23/09/91	14	2	2	100.0	95.2	1	1		
			24/09/91	24/09/91	1	2	1	50.0	93.2		1	10m	
			25/09/91	25/09/91	1	2	2	100.0	93.5	1	1		
			26/09/91	26/09/91	1	2	1	50.0	91.7	1		10e	
			27/09/91	07/10/91	11	2	2	100.0	94.3	1	1		
			08/10/91	08/10/91	1	2	1	50.0	93.1	1		1e	
			09/10/91	14/10/91	6	2	2	100.0	94.0	1	1		
			15/10/91	15/10/91	1	2	1	100.0	94.2	1	0	9e	
					43								
	403	Imipramine	04/10/91	04/10/91	1	2	1	100.0	100.0	0	1	9m	
			05/10/91	13/11/91	40	2	2	100.0	100.0	1	1		
			14/11/91	14/11/91	1	2	1	100.0	100.0	1	0	9e	
					42								
	404	Reboxetine	08/10/91	08/10/91	1	2	1	100.0	100.0	0	1	9m	
			09/10/91	17/10/91	9	2	2	100.0	100.0	1	1		
			18/10/91	18/10/91	1	2	1	50.0	95.5	1		10e	
			19/10/91	22/10/91	4	2	2	100.0	96.7	1	1		
			23/10/91	23/10/91	1	2	1	50.0	93.8	1		10e	
			24/10/91	30/10/91	7	2	2	100.0	95.7	1	1		
			31/10/91	31/10/91	1	2	1	50.0	93.8	1		10e	
			01/11/91	04/11/91	4	2	2	100.0	94.6	1	1		
			05/11/91	05/11/91	1	2	1	50.0	93.1	1		6e	
					29								
	405	Placebo	11/11/91	11/11/91	1	2	1	100.0	100.0	0	1	9m	
			12/11/91	22/12/91	41	2	2	100.0	100.0	1	1		
			23/12/91	23/12/91	1	2	1	100.0	100.0	1	0	9e	
					43								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Afternoon Cps	Reason (*)	Overdose (**)
15	406	Imipramine	27/11/91	27/11/91	1	2	1	100.0	100.0	0	1	9m	
			28/11/91	06/01/92	40	2	2	100.0	100.0	1	1		
			07/01/92	07/01/92	1	2	1	100.0	100.0	1	0	9e	
					42								
	407	Reboxetine	03/12/91	03/12/91	1	2	1	100.0	100.0	0	1	9m	
			04/12/91	25/12/91	22	2	2	100.0	100.0	1	1		
			26/12/91	26/12/91	1	2	1	50.0	97.9		1	10m	
			27/12/91	10/01/92	15	2	2	100.0	98.7	1	1		
			11/01/92	11/01/92	1	2	2	0.0	96.3		2	1m	(B - e)
			12/01/92	13/01/92	2	2	2	100.0	96.4	1	1		
			14/01/92	14/01/92	1	2	1	100.0	96.5	1	0	9e	
					43								
	408	Placebo	20/01/92	20/01/92	1	2	1	100.0	100.0	0	1	9m	
			21/01/92	03/03/92	43	2	2	100.0	100.0	1	1		
			04/03/92	04/03/92	1	2	1	100.0	100.0	1	0	9e	
					45								
	418	Placebo	30/01/92	30/01/92	1	2	1	100.0	100.0	0	1	9m	
			31/01/92	11/03/92	41	2	2	100.0	100.0	1	1		
			12/03/92	12/03/92	1	2	1	100.0	100.0	1	0	9e	
					43								
	419	Placebo	28/04/92	28/04/92	1	2	1	100.0	100.0	0	1	9m	
			29/04/92	01/05/92	3	2	2	100.0	100.0	1	1		
			02/05/92	02/05/92	1	2	1	50.0	90.0	1		1e	
			03/05/92	27/05/92	25	2	2	100.0	98.3	1	1		
			28/05/92	28/05/92	1	2	1	50.0	96.8		1	1m	
			29/05/92	29/05/92	1	2	2	100.0	96.9	1	1		
			30/05/92	30/05/92	1	2	1	50.0	95.5	1		1e	
			31/05/92	08/06/92	9	2	2	100.0	96.4	1	1		
			09/06/92	09/06/92	1	2	1	100.0	96.5	1	0	9e	
					43								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Given				Randomized			Error (*)
	Sequen. block	Treatment	Start treat. date	Patient	Patient	Treatment	Sequen. block	
1	1	Imipramine	10/04/91	1	1	Imipramine	1	
	1	Reboxetine	15/04/91	2	2	Reboxetine	1	
	1	Imipramine	06/05/91	3	3	Imipramine	1	
	1	Placebo	23/05/91	6	4	Placebo	1	
	1	Placebo	04/06/91	4	5	Reboxetine	1	*
	1	Reboxetine	12/06/91	5	6	Placebo	1	*
	2	Reboxetine	27/08/91	7	7	Reboxetine	2	
	2	Placebo	05/09/91	8	8	Placebo	2	
	2	Placebo	24/09/91	10	9	Reboxetine	2	*
	2	Imipramine	10/10/91	11	10	Placebo	2	*
	2	Imipramine	18/10/91	12	11	Imipramine	2	
	3	Reboxetine	13/11/91	412	12	Imipramine	2	*
	2	Reboxetine	27/11/91	9	412	Reboxetine	3	
	3	Placebo	09/12/91	413	413	Placebo	3	
	4	Imipramine	14/01/92	415	414	Imipramine	3	
	4	Reboxetine	17/01/92	416	415	Imipramine	4	*
	3	Imipramine	22/01/92	414	416	Reboxetine	4	*
	5	Imipramine	27/02/92	421	417	Imipramine	4	
	5	Imipramine	05/08/92	422	418	Placebo	4	*
2/1	1	Placebo	18/05/91	49	49	Placebo	1	
	1	Reboxetine	27/12/91	50	50	Reboxetine	1	
	1	Imipramine	02/02/92	51	51	Imipramine	1	
2/2	1	Imipramine	18/04/91	43	43	Imipramine	1	
	1	Imipramine	19/07/91	44	44	Imipramine	1	
	1	Reboxetine	08/09/91	45	45	Reboxetine	1	
	1	Placebo	26/09/91	46	46	Placebo	1	
	1	Placebo	24/03/92	47	47	Placebo	1	
	1	Reboxetine	07/04/92	48	48	Reboxetine	1	
2/3	1	Imipramine	07/03/91	36/A	37	Reboxetine	2	*
	2	Reboxetine	27/03/91	37	38	Placebo	2	*
	2	Imipramine	10/08/91	39	39	Imipramine	2	
	2	Placebo	14/08/91	38	40	Reboxetine	2	*
	2	Placebo	03/10/91	41	41	Placebo	2	
	2	Reboxetine	24/10/91	40	42	Imipramine	2	*
	2	Imipramine	19/05/92	42		Out of Rando		*
2/4	1	Placebo	26/03/91	31	31	Placebo	1	
	1	Imipramine	29/05/91	33	32	Reboxetine	1	*
	1	Reboxetine	26/10/91	32	33	Imipramine	1	*

(*) - (1) Start new block not with first patient of block
- (2) Start new block without ending previuos block
- (3) Sequence error
- (4) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Given: Sequen. block	Given: Treatment	Given: Start treat. date	Given: Patient	Randomized: Patient	Randomized: Treatment	Randomized: Sequen. block	Error (*)
2/4	1	Imipramine	12/02/92	36	34	Placebo	1	*
	1	Placebo	17/04/92	34	35	Reboxetine	1	*
	1	Reboxetine	15/09/92	35	36	Imipramine	1	*
2/5	1	Placebo	07/02/92	73	73	Placebo	1	
	1	Reboxetine	21/06/92	74	74	Reboxetine	1	
	1	Imipramine	11/09/92	75	75	Imipramine	1	
	1	Imipramine	15/09/92	76	76	Imipramine	1	
	1	Placebo	22/09/92	77	77	Placebo	1	
	1	Reboxetine	10/10/92	78	78	Reboxetine	1	
2/6	1	Imipramine	05/05/92	57	55	Reboxetine	1	*
	1	Imipramine	12/05/92	60	56	Reboxetine	1	*
	1	Placebo	18/05/92	58	57	Imipramine	1	*
	1	Placebo	27/05/92	59	58	Placebo	1	
	1	Reboxetine	12/06/92	55	59	Placebo	1	*
	1	Reboxetine	12/06/92	56	60	Imipramine	1	*
3/1	1	Imipramine	05/03/91	61	61	Imipramine	1	
	1	Placebo	14/03/91	64	62	Imipramine	1	*
	1	Imipramine	16/04/91	62	63	Placebo	1	*
	1	Placebo	13/05/91	63	64	Placebo	1	
	1	Reboxetine	10/06/91	66	65	Reboxetine	1	
	2	Imipramine	03/09/91	139	66	Reboxetine	1	*
	2	Placebo	12/09/91	140	139	Imipramine	2	*
	1	Reboxetine	16/09/91	65	140	Placebo	2	*
	2	Placebo	03/10/91	141	141	Placebo	2	
	2	Imipramine	18/11/91	142	142	Imipramine	2	
	3	Reboxetine	20/01/92	451	143	Reboxetine	2	
	3	Placebo	22/01/92	452	144	Reboxetine	2	*
	3	Imipramine	29/01/92	453	451	Reboxetine	3	*
	3	Reboxetine	17/02/92	454	452	Placebo	3	*
	3	Placebo	11/03/92	455	453	Imipramine	3	*
	3	Imipramine	25/03/92	456	454	Reboxetine	3	*
	2	Reboxetine	15/04/92	143	455	Placebo	3	*
	2	Reboxetine	09/06/92	144	456	Imipramine	3	*
3/2	1	Reboxetine	29/01/91	65/A		Out of Rando		*
3/3	1	Placebo	18/07/91	67	67	Placebo	1	
	1	Reboxetine	21/01/92	68	68	Reboxetine	1	

(*) - (1) Start new block not with first patient of block
- (2) Start new block without ending previuos block
- (3) Sequence error
- (4) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

	Given				Randomized			Error
Centre	Sequen. block	Treatment	Start treat. date	Patient	Patient	Treatment	Sequen. block	(*)
3/3	1	Placebo	04/02/92	69	69	Placebo	1	
	1	Imipramine	15/04/92	70	70	Imipramine	1	
	1	Imipramine	16/04/92	71	71	Imipramine	1	
	1	Reboxetine	25/07/92	72	72	Reboxetine	1	
3/4	1	Imipramine	04/05/91	79	79	Imipramine	1	
	1	Reboxetine	17/05/91	81	80	Imipramine	1	*
	1	Placebo	17/06/91	82	81	Reboxetine	1	*
	1	Placebo	17/06/91	83	82	Placebo	1	
	1	Imipramine	01/09/91	80	83	Placebo	1	*
	1	Reboxetine	09/10/91	84	84	Reboxetine	1	
	2	Imipramine	29/10/91	85	85	Imipramine	2	
	2	Imipramine	03/12/91	86	86	Imipramine	2	
	2	Placebo	09/12/91	87	87	Placebo	2	
	2	Placebo	23/03/92	88	88	Placebo	2	
	2	Reboxetine	26/03/92	89	89	Reboxetine	2	
	2	Reboxetine	28/04/92	90	90	Reboxetine	2	
	3	Placebo	22/05/92	457	457	Placebo	3	
	3	Reboxetine	26/05/92	458	458	Reboxetine	3	
	3	Placebo	02/06/92	459	459	Placebo	3	
	3	Reboxetine	19/08/92	460	460	Reboxetine	3	
	3	Imipramine	17/09/92	461	461	Imipramine	3	
	3	Imipramine	29/09/92	462	462	Imipramine	3	
4/1	1	Placebo		119	115	Reboxetine	1	*
	2	Imipramine	03/06/91	95	116	Imipramine	1	
	2	Placebo	03/07/91	93	117	Imipramine	1	*
	2	Placebo	05/07/91	94	118	Reboxetine	1	*
	2	Reboxetine	07/08/91	92	119	Placebo	1	*
	1	Imipramine	03/09/91	117	120	Placebo	1	*
	2	Reboxetine	04/09/91	96	91	Imipramine	2	*
	2	Imipramine	12/10/91	91	92	Reboxetine	2	*
	1	Reboxetine	06/05/92	115	93	Placebo	2	*
	1	Imipramine	16/05/92	116	94	Placebo	2	*
	1	Reboxetine	23/05/92	118	95	Imipramine	2	*
	1	Placebo	31/07/92	120	96	Reboxetine	2	*
	3	Reboxetine	01/09/92	147	145	Imipramine	3	*
	3	Placebo	16/09/92	146	146	Placebo	3	
	3	Imipramine	26/09/92	148	147	Reboxetine	3	*
	3	Imipramine	30/09/92	145	148	Imipramine	3	
	3	Reboxetine	30/09/92	149	149	Reboxetine	3	
	3	Placebo	30/09/92	150	150	Placebo	3	

(*) - (1) Start new block not with first patient of block
- (2) Start new block without ending previuos block
- (3) Sequence error
- (4) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Given: Sequen. block	Given: Treatment	Given: Start treat. date	Given: Patient	Randomized: Patient	Randomized: Treatment	Randomized: Sequen. block	Error (*)
4/2	1	Placebo	22/02/91	93/A	104	Reboxetine	2	*
	1	Placebo	27/03/91	99/A	105	Placebo	2	
	2	Reboxetine	22/05/91	104	106	Imipramine	2	*
4/3	1	Placebo	17/04/91	97	97	Placebo	1	
	1	Reboxetine	20/06/91	98	98	Reboxetine	1	
	1	Placebo	08/08/91	99	99	Placebo	1	
	1	Imipramine	27/11/91	100	100	Imipramine	1	
	1	Imipramine	17/03/92	101	101	Imipramine	1	
4/4	1	Reboxetine	08/06/91	109	109	Reboxetine	1	
	1	Imipramine	15/06/91	110	110	Imipramine	1	
	1	Imipramine	04/07/91	111	111	Imipramine	1	
	1	Placebo	10/07/91	112	112	Placebo	1	
	1	Reboxetine	31/08/91	113	113	Reboxetine	1	
	1	Placebo	20/11/91	114	114	Placebo	1	
	2	Imipramine	13/02/92	175	175	Imipramine	2	
	2	Placebo	14/03/92	176	176	Placebo	2	
	2	Imipramine	28/04/92	177	177	Imipramine	2	
	2	Reboxetine	28/04/92	178	178	Reboxetine	2	
	2	Placebo	11/09/92	179	179	Placebo	2	
	2	Reboxetine	07/10/92	180	180	Reboxetine	2	
5/1	1	Reboxetine	06/06/91	127	127	Reboxetine	1	
	1	Reboxetine	14/06/91	128	128	Reboxetine	1	
	1	Placebo	24/12/91	129	129	Placebo	1	
	1	Placebo	05/03/92	130	130	Placebo	1	
	1	Imipramine	21/03/92	131	131	Imipramine	1	
	1	Imipramine	25/06/92	132	132	Imipramine	1	
5/2	1	Reboxetine	28/01/91	125	121	Imipramine	1	*
	1	Imipramine	20/12/91	121	122	Placebo	1	*
5/3	1	Placebo	29/11/91	133	133	Placebo	1	
	1	Reboxetine	06/12/91	134	134	Reboxetine	1	
	1	Imipramine	10/01/92	135	135	Imipramine	1	
	1	Imipramine	02/03/92	136	136	Imipramine	1	
	1	Reboxetine	15/05/92	137	137	Reboxetine	1	
	1	Placebo	15/05/92	138	138	Placebo	1	

(*) - (1) Start new block not with first patient of block
- (2) Start new block without ending previuos block
- (3) Sequence error
- (4) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Given: Sequen. block	Given: Treatment	Given: Start treat. date	Given: Patient	Randomized: Patient	Randomized: Treatment	Randomized: Sequen. block	Error (*)
6/1	1	Reboxetine	18/03/91	153	151	Imipramine	1	*
	1	Imipramine	21/01/92	151	152	Reboxetine	1	*
	1	Reboxetine	24/02/92	152	153	Reboxetine	1	
	1	Imipramine	30/03/92	154	154	Imipramine	1	
	1	Placebo	08/07/92	155	155	Placebo	1	
	1	Placebo	08/09/92	156	156	Placebo	1	
6/2	1	Reboxetine	30/04/91	157	157	Reboxetine	1	
	1	Placebo	10/07/91	162	158	Imipramine	1	*
	1	Imipramine	14/07/91	159	159	Imipramine	1	
	2	Placebo	01/11/91	170	160	Placebo	1	
	1	Imipramine	24/11/91	158	161	Reboxetine	1	*
	1	Placebo	24/11/91	160	162	Placebo	1	
	2	Imipramine	26/12/91	169	169	Imipramine	2	
	1	Reboxetine	20/02/92	161	170	Placebo	2	*
	2	Reboxetine	11/05/92	174	171	Imipramine	2	*
	2	Placebo	05/07/92	173	172	Reboxetine	2	*
	2	Reboxetine	07/07/92	172	173	Placebo	2	*
	2	Imipramine	22/07/92	171	174	Reboxetine	2	*
6/3	1	Reboxetine	06/06/91	163	163	Reboxetine	1	
	1	Imipramine	11/10/91	164	164	Imipramine	1	
	1	Imipramine	16/10/91	165	165	Imipramine	1	
	1	Reboxetine	25/10/91	166	166	Reboxetine	1	
	1	Placebo	18/11/91	167	167	Placebo	1	
	1	Placebo	03/12/91	168	168	Placebo	1	
	2	Imipramine	03/12/91	505	505	Imipramine	2	
	2	Placebo	08/01/92	506	506	Placebo	2	
	2	Imipramine	14/01/92	507	507	Imipramine	2	
	2	Reboxetine	05/02/92	508	508	Reboxetine	2	
	2	Placebo	24/02/92	509	509	Placebo	2	
	2	Reboxetine	27/02/92	510	510	Reboxetine	2	
	3	Imipramine	19/03/92	511	511	Imipramine	3	
	3	Placebo	01/04/92	512	512	Placebo	3	
	3	Imipramine	13/05/92	513	513	Imipramine	3	
7/02	1	Placebo	23/11/91	182	181	Reboxetine	1	*
	1	Imipramine	02/01/92	183	182	Placebo	1	*
	1	Reboxetine	27/01/92	181	183	Imipramine	1	*
	1	Imipramine	27/01/92	184	184	Imipramine	1	
	1	Reboxetine	10/04/92	185	185	Reboxetine	1	
	2	Placebo	15/04/92	535	186	Placebo	1	
	1	Placebo	16/04/92	186	535	Placebo	2	

(*) - (1) Start new block not with first patient of block
- (2) Start new block without ending previuos block
- (3) Sequence error
- (4) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Given: Sequen. block	Given: Treatment	Given: Start treat. date	Given: Patient	Randomized: Patient	Randomized: Treatment	Randomized: Sequen. block	Error (*)
7/02	2	Reboxetine	08/05/92	536	536	Reboxetine	2	
7/03	1	Imipramine	18/02/92	187	187	Imipramine	1	
	1	Placebo	25/02/92	188	188	Placebo	1	
	1	Placebo	25/02/92	189	189	Placebo	1	
	1	Reboxetine	28/02/92	190	190	Reboxetine	1	
	1	Imipramine	03/03/92	191	191	Imipramine	1	
	1	Reboxetine	10/03/92	192	192	Reboxetine	1	
	2	Reboxetine	06/05/92	523	523	Reboxetine	2	
	2	Placebo	06/05/92	524	524	Placebo	2	
	2	Placebo	06/05/92	525	525	Placebo	2	
	2	Reboxetine	06/05/92	526	526	Reboxetine	2	
	2	Imipramine	19/05/92	527	527	Imipramine	2	
	2	Imipramine	19/05/92	528	528	Imipramine	2	
7/04	1	Placebo	25/01/92	193	193	Placebo	1	
	1	Reboxetine	25/01/92	194	194	Reboxetine	1	
	1	Placebo	25/01/92	195	195	Placebo	1	
	1	Reboxetine	01/02/92	196	196	Reboxetine	1	
	1	Imipramine	01/02/92	197	197	Imipramine	1	
	1	Imipramine	01/02/92	198	198	Imipramine	1	
	2	Imipramine	28/03/92	199	199	Imipramine	2	
	2	Placebo	28/03/92	200	200	Placebo	2	
	2	Reboxetine	28/03/92	201	201	Reboxetine	2	
	2	Reboxetine	04/04/92	202	202	Reboxetine	2	
	2	Placebo	04/04/92	203	203	Placebo	2	
	2	Imipramine	04/04/92	204	204	Imipramine	2	
7/05	1	Placebo	27/01/92	205	205	Placebo	1	
	1	Imipramine	28/01/92	206	206	Imipramine	1	
	1	Imipramine	28/01/92	207	207	Imipramine	1	
	1	Reboxetine	30/01/92	208	208	Reboxetine	1	
	1	Placebo	05/02/92	209	209	Placebo	1	
	1	Reboxetine	07/02/92	210	210	Reboxetine	1	
	2	Reboxetine	17/03/92	541	541	Reboxetine	2	
	2	Imipramine	17/03/92	542	542	Imipramine	2	
	2	Imipramine	18/03/92	543	543	Imipramine	2	
	2	Placebo	24/03/92	544	544	Placebo	2	
	2	Placebo	25/03/92	545	545	Placebo	2	
	2	Reboxetine	25/03/92	546	546	Reboxetine	2	
7/07	1	Placebo	18/02/92	529	529	Placebo	1	

(*) - (1) Start new block not with first patient of block
- (2) Start new block without ending previuos block
- (3) Sequence error
- (4) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Given: Sequen. block	Given: Treatment	Given: Start treat. date	Given: Patient	Randomized: Patient	Randomized: Treatment	Randomized: Sequen. block	Error (*)
7/07	1	Imipramine	20/02/92	530	530	Imipramine	1	
	1	Reboxetine	24/02/92	531	531	Reboxetine	1	
	1	Imipramine	27/04/92	532	532	Imipramine	1	
	1	Reboxetine	04/05/92	533	533	Reboxetine	1	
	1	Placebo	15/05/92	534	534	Placebo	1	
8	1	Reboxetine	13/05/91	211	211	Reboxetine	1	
	1	Placebo	14/09/91	212	212	Placebo	1	
	1	Imipramine	22/11/91	213	213	Imipramine	1	
	1	Reboxetine	23/11/91	214	214	Reboxetine	1	
	1	Placebo	18/02/92	215	215	Placebo	1	
	1	Imipramine	27/03/92	216	216	Imipramine	1	
	2	Reboxetine	30/03/92	217	217	Reboxetine	2	
	2	Reboxetine	09/04/92	218	218	Reboxetine	2	
	2	Placebo	11/04/92	219	219	Placebo	2	
	2	Imipramine	27/04/92	220	220	Imipramine	2	
	2	Imipramine	28/04/92	221	221	Imipramine	2	
	2	Placebo	28/04/92	222	222	Placebo	2	
	3	Imipramine	11/05/92	223	223	Imipramine	3	
	3	Placebo	07/09/92	224	224	Placebo	3	
	3	Placebo	11/09/92	225	225	Placebo	3	
	3	Reboxetine	23/09/92	226	226	Reboxetine	3	
	3	Reboxetine	25/09/92	227	227	Reboxetine	3	
	3	Imipramine	26/09/92	228	228	Imipramine	3	
	4	Reboxetine	28/09/92	230	229	Imipramine	4	*
	4	Imipramine	30/09/92	229	230	Reboxetine	4	*
	4	Imipramine	30/09/92	231	231	Imipramine	4	
	4	Reboxetine	02/10/92	232	232	Reboxetine	4	
	4	Placebo	07/10/92	233	233	Placebo	4	
	4	Placebo	07/10/92	234	234	Placebo	4	
8/A	1	Placebo	14/10/92	235	235	Placebo	1	
	1	Placebo	14/10/92	236	236	Placebo	1	
	1	Reboxetine	14/10/92	237	237	Reboxetine	1	
	1	Reboxetine	14/10/92	238	238	Reboxetine	1	
	1	Imipramine	16/10/92	239	239	Imipramine	1	
	1	Imipramine	16/10/92	240	240	Imipramine	1	
	2	Placebo	16/10/92	553	553	Placebo	2	
	2	Reboxetine	16/10/92	554	554	Reboxetine	2	
	2	Reboxetine	16/10/92	555	555	Reboxetine	2	
	2	Imipramine	16/10/92	556	556	Imipramine	2	
9	1	Placebo	07/02/91	241	241	Placebo	1	

(*) - (1) Start new block not with first patient of block
- (2) Start new block without ending previuos block
- (3) Sequence error
- (4) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

	Given				Randomized			Error
Centre	Sequen. block	Treatment	Start treat. date	Patient	Patient	Treatment	Sequen. block	(*)
9	1	Reboxetine	18/02/91	242	242	Reboxetine	1	
	1	Imipramine	19/02/91	244	243	Reboxetine	1	*
	1	Reboxetine	20/02/91	243	244	Imipramine	1	*
	1	Imipramine	22/02/91	245	245	Imipramine	1	
	1	Placebo	22/02/91	246	246	Placebo	1	
	2	Placebo	25/02/91	247	247	Placebo	2	
	2	Placebo	07/03/91	248	248	Placebo	2	
	2	Reboxetine	08/03/91	249	249	Reboxetine	2	
	2	Imipramine	12/03/91	250	250	Imipramine	2	
	2	Imipramine	20/03/91	251	251	Imipramine	2	
	2	Reboxetine	02/04/91	252	252	Reboxetine	2	
	3	Reboxetine	02/04/91	253	253	Reboxetine	3	
	3	Imipramine	09/04/91	254	254	Imipramine	3	
	3	Reboxetine	13/05/91	255	255	Reboxetine	3	
	3	Imipramine	27/05/91	256	256	Imipramine	3	
	3	Placebo	25/06/91	257	257	Placebo	3	
	3	Placebo	01/07/91	258	258	Placebo	3	
11	1	Placebo	02/08/91	319	319	Placebo	1	
	1	Imipramine	17/08/91	320	320	Imipramine	1	
	1	Placebo	06/09/91	321	321	Placebo	1	
	1	Reboxetine	27/09/91	322	322	Reboxetine	1	
	1	Reboxetine	15/11/91	323	323	Reboxetine	1	
	1	Imipramine	06/12/91	324	324	Imipramine	1	
	2	Reboxetine	13/12/91	325	325	Reboxetine	2	
	2	Placebo	16/01/92	326	326	Placebo	2	
	2	Imipramine	30/01/92	327	327	Imipramine	2	
	2	Imipramine	31/01/92	328	328	Imipramine	2	
	2	Reboxetine	09/04/92	330	329	Placebo	2	*
	2	Placebo	10/04/92	329	330	Reboxetine	2	*
	3	Imipramine	17/04/92	331	331	Imipramine	3	
	3	Reboxetine	19/05/92	332	332	Reboxetine	3	
	3	Placebo	27/05/92	333	333	Placebo	3	
	3	Reboxetine	29/05/92	334	334	Reboxetine	3	
	3	Placebo	03/06/92	335	335	Placebo	3	
	3	Imipramine	18/06/92	336	336	Imipramine	3	
	4	Reboxetine	02/07/92	337	337	Reboxetine	4	
	4	Imipramine	23/07/92	338	338	Imipramine	4	
12	1	Reboxetine	20/12/91	367	367	Reboxetine	1	
	1	Placebo	24/12/91	368	368	Placebo	1	
	1	Imipramine	23/04/92	369	369	Imipramine	1	
	1	Placebo	29/04/92	370	370	Placebo	1	
	1	Imipramine	01/05/92	371	371	Imipramine	1	

(*) - (1) Start new block not with first patient of block
- (2) Start new block without ending previuos block
- (3) Sequence error
- (4) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Given: Sequen. block	Given: Treatment	Given: Start treat. date	Given: Patient	Randomized: Patient	Randomized: Treatment	Randomized: Sequen. block	Error (*)
12	1	Reboxetine	02/06/92	372	372	Reboxetine	1	
	2	Reboxetine	05/06/92	373	373	Reboxetine	2	
	2	Placebo	09/06/92	374	374	Placebo	2	
	2	Imipramine	17/06/92	375	375	Imipramine	2	
13	1	Placebo	13/04/91	13	13	Placebo	1	
	1	Placebo	02/07/91	14	14	Placebo	1	
	1	Imipramine	05/07/91	15	15	Imipramine	1	
	1	Imipramine	03/12/91	16	16	Imipramine	1	
	2	Reboxetine	10/12/91	409	17	Reboxetine	1	
	2	Placebo	14/02/92	410	18	Reboxetine	1	*
	2	Imipramine	28/03/92	411	409	Reboxetine	2	*
	1	Reboxetine	21/05/92	17	410	Placebo	2	*
	1	Reboxetine	24/06/92	18	411	Imipramine	2	*
	3	Placebo	14/09/92	423	412	Reboxetine	2	*
14	1	Reboxetine	10/04/92	19	19	Reboxetine	1	
	1	Imipramine	29/04/92	20	20	Imipramine	1	
	1	Imipramine	20/07/92	21	21	Imipramine	1	
15	1	Reboxetine	18/06/91	25	25	Reboxetine	1	
	1	Placebo	20/06/91	26	26	Placebo	1	
	1	Imipramine	02/07/91	27	27	Imipramine	1	
	1	Reboxetine	08/08/91	28	28	Reboxetine	1	
	1	Placebo	29/08/91	29	29	Placebo	1	
	1	Imipramine	03/09/91	30	30	Imipramine	1	
	2	Imipramine	04/10/91	403	403	Imipramine	2	
	2	Reboxetine	08/10/91	404	404	Reboxetine	2	
	2	Placebo	11/11/91	405	405	Placebo	2	
	2	Imipramine	27/11/91	406	406	Imipramine	2	
	2	Reboxetine	03/12/91	407	407	Reboxetine	2	
	2	Placebo	20/01/92	408	408	Placebo	2	
	3	Placebo	30/01/92	418	418	Placebo	3	
	3	Placebo	28/04/92	419	419	Placebo	3	

(*) - (1) Start new block not with first patient of block
- (2) Start new block without ending previous block
- (3) Sequence error
- (4) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
1	1	Female	Day 42	22/05/91	YES			As prescribed
	2	Male	Day 42	27/05/91	YES			As prescribed
	3	Male	Day 42	16/06/91	YES			As prescribed
	4	Male	Day 42	16/07/91	YES			As prescribed
	5	Female	Day 21	02/07/91	NO	Deterioration	Patient	As prescribed
	6	Female	Day 42	05/07/91	NO	Adverse event	Patient	As prescribed
	7	Female	Day 42	08/10/91	YES			As prescribed
	8	Male	Day 42	19/10/91	YES			As prescribed
	9	Female	Day 42	06/01/92	YES			As prescribed
	10	Male	Day 42	04/11/91	YES			As prescribed
	11	Female	Day 7	13/10/91	NO	Adverse event	Physician Patient Others	As prescribed
	12	Female	Day 42	30/11/91	YES			As prescribed
	412	Male	Day 42	23/12/91	YES			As prescribed
	413	Male	Day 42	20/01/92	YES			As prescribed
	414	Female	Day 14	29/01/92	NO	Deterioration	Physician	As prescribed
	415	Male	Day 42	27/02/92	YES			As prescribed
	416	Female	Day 14	28/01/92	NO	Protocol violation	Physician	As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
1	416	Female	Day 14	28/01/92	NO	Intercurrent medical problem		
	421	Male	Day 42	09/04/92	YES			As prescribed
	422	Male	Day 42	17/09/92	YES			As prescribed
2/1	49	Female	Day 42	28/06/91	YES			As prescribed
	50	Female	Day 42	06/02/92	YES			As prescribed
	51	Female	Day 42	15/03/92	YES			As prescribed
2/2	43	Female	Day 35	16/05/91	NO	Protocol violation Improvement Patient uncooperative	Patient	Confirmed irregularities
	44	Female	Day 42	29/08/91	YES			Unknown
	45	Female	Day 42	20/10/91	YES			As prescribed
	46	Female	Day 28	23/10/91	NO	Protocol violation Patient uncooperative	Physician	Confirmed irregularities
	47	Female	Day 42	04/05/92	YES			As prescribed
	48	Female	Day 42	19/05/92	YES			As prescribed
2/3	36/A	Male	Day 42	17/04/91	YES			As prescribed
	37	Female	Day 42	07/05/91	YES			As prescribed
	38	Male	Day 42	25/09/91	YES			As prescribed
	39	Female	Day 42	20/09/91	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
2/3	40	Female	Day 42	04/12/91	YES			As prescribed
	41	Male	Day 42	13/11/91	YES			As prescribed
	42	Female	Day 42	30/06/92	YES			As prescribed
2/4	31	Male	Day 42	05/05/91	YES			As prescribed
	32	Male	Day 42	06/12/91	YES			As prescribed
	33	Male	Day 42	10/07/91	YES			As prescribed
	34	Female	Day 42	28/05/92	YES			As prescribed
	35	Female	Day 42	26/10/92	YES			As prescribed
	36	Female	Day 42	24/03/92	YES			As prescribed
2/5	73	Male	Day 42	20/03/92	YES			As prescribed
	74	Male	Day 42	01/08/92	YES			As prescribed
	75	Male	Day 42	22/10/92	YES			As prescribed
	76	Female	Day 42	26/10/92	YES			As prescribed
	77	Male	Day 42	02/11/92	YES			As prescribed
	78	Female	Day 35	13/11/92	NO	Lost to follow up Patient uncooperative	Others	As prescribed
2/6	55	Female	Day 42	23/07/92	YES			As prescribed
	56	Female	Day 42	23/07/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
2/6	57	Female	Day 42	15/06/92	YES			As prescribed
	58	Female	Day 42	29/06/92	YES			As prescribed
	59	Male	Day 28	23/06/92	NO	Deterioration	Physician	As prescribed
	60	Female	Day 42	22/06/92	YES			As prescribed
3/1	61	Male	Day 35	08/04/91	NO	Patient uncooperative	Physician Patient	Suspected irregularities
	62	Female	Day 42	26/05/91	YES			As prescribed
	63	Male	Day 42	23/06/91	YES			As prescribed
	64	Female	Day 42	24/04/91	YES			As prescribed
	65	Male	Day 42	27/10/91	YES			As prescribed
	66	Male	Day 42	21/07/91	YES			As prescribed
	139	Male	Day 14	12/09/91	NO	Deterioration	Physician	As prescribed
	140	Male	Day 42	23/10/91	YES			As prescribed
	141	Female	Day 42	14/11/91	YES			As prescribed
	142	Female	Day 21	08/12/91	NO	Patient uncooperative	Patient	As prescribed
	143	Female	Day 35	20/05/92	NO	Adverse event Deterioration	Patient	As prescribed
	144	Female	Day 42	22/07/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
3/1	451	Female	Day 14	01/02/92	NO	Adverse event Lost to follow up	Patient	As prescribed
	452	Male	Day 42	04/03/92	YES			As prescribed
	453	Female	Day 42	10/03/92	YES			As prescribed
	454	Male	Day 42	01/04/92	YES			As prescribed
	455	Female	Day 42	22/04/92	YES			As prescribed
	456	Female	Day 14	03/04/92	NO	Adverse event	Physician Patient	As prescribed
3/2	65/A	Female	Day 42	11/03/91	YES			As prescribed
3/3	67	Male	Day 42	28/08/91	YES			As prescribed
	68	Male	Day 42	02/03/92	YES			As prescribed
	69	Male	Day 42	16/03/92	YES			As prescribed
	70	Male	Day 42	26/05/92	YES			As prescribed
	71	Female	Day 42	27/05/92	YES			As prescribed
	72	Male	Day 42	04/09/92	YES			As prescribed
3/4	79	Female	Day 42	15/06/91	YES			As prescribed
	80	Male	Day 21	24/09/91	NO	Adverse event	Patient	As prescribed
	81	Female	Day 42	27/06/91	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
3/4	82	Male	Day 42	28/07/91	YES			As prescribed
	83	Male	Day 7	24/06/91	NO	Adverse event Deterioration	Physician	As prescribed
	84	Female	Day 42	23/11/91	YES			As prescribed
	85	Female	Day 42	08/12/91	YES			As prescribed
	86	Male	Day 42	15/01/92	YES			As prescribed
	87	Female	Day 42	19/01/92	YES			As prescribed
	88	Male	Day 42	08/05/92	YES			As prescribed
	89	Female	Day 42	06/05/92	YES			As prescribed
	90	Male	Day 42	08/06/92	YES			As prescribed
	457	Female	Day 21	11/06/92	NO	Deterioration	Physician	As prescribed
	458	Female	Day 14	09/06/92	NO	Deterioration Patient uncooperative	Patient	As prescribed
	459	Female	Day 42	13/07/92	YES			As prescribed
	460	Male	Day 7	20/08/92	NO	Adverse event	Physician Patient	As prescribed
	461	Female	Day 7	24/09/92	NO	Adverse event	Patient	As prescribed
	462	Female	Day 14	08/10/92	NO	Adverse event	Patient	As prescribed
4/1	91	Female	Day 42	22/11/91	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
4/1	92	Female	Day 42	17/09/91	YES			As prescribed
	93	Male	Day 42	16/08/91	YES			As prescribed
	94	Female	Day 42	13/08/91	YES			As prescribed
	95	Female	Day 42	16/07/91	YES			As prescribed
	96	Female	Day 42	16/10/91	YES			As prescribed
	115	Female	Day 42	16/06/92	YES			As prescribed
	116	Female	Day 7	22/05/92	NO	Adverse event	Patient	As prescribed
	117	Female	Day 42	14/10/91	YES			As prescribed
	118	Female	Day 42	03/07/92	YES			As prescribed
	120	Female	Day 42	11/09/92	YES			As prescribed
	145	Female	Day 42	10/11/92	YES			As prescribed
	146	Female	Day 42	27/10/92	YES			As prescribed
	147	Female	Day 42	12/10/92	YES			As prescribed
	148	Female	Day 42	06/11/92	YES			As prescribed
	149	Male	Day 42	10/11/92	YES			As prescribed
	150	Male	Day 42	10/11/92	YES			As prescribed
4/2	93/A	Male	Day 42	04/04/91	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
4/2	99/A	Male	Day 42	07/05/91	YES			As prescribed
	104	Male	Day 42	02/07/91	YES			As prescribed
4/3	97	Male	Day 42	28/05/91	YES			As prescribed
	98	Female	Day 35	21/07/91	NO	Patient uncooperative	Patient	Suspected irregularities
	99	Female	Day 14	15/08/91	NO	Adverse event	Physician Patient	As prescribed
	100	Female	Day 21	17/12/91	NO	Adverse event Deterioration	Physician Patient	As prescribed
	101	Male	Day 42	27/04/92	YES			As prescribed
4/4	109	Female	Day 42	19/07/91	YES			As prescribed
	110	Male	Day 42	26/07/91	YES			As prescribed
	111	Male	Day 42	14/08/91	YES			As prescribed
	112	Male	Day 42	20/08/91	YES			As prescribed
	113	Male	Day 42	11/10/91	YES			As prescribed
	114	Female	Day 42	31/12/91	YES			As prescribed
	175	Female	Day 42	25/03/92	YES			As prescribed
	176	Female	Day 28	08/04/92	NO	Adverse event Deterioration	Physician	As prescribed
	177	Female	Day 21	11/05/92	NO	Deterioration	Physician	As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
4/4	177	Female	Day 21	11/05/92	NO		Patient	
	178	Female	Day 42	08/06/92	YES			As prescribed
	179	Female	Day 21	29/09/92	NO	Adverse event Deterioration	Physician	As prescribed
	180	Male	Day 42	17/11/92	YES			As prescribed
5/1	127	Male	Day 42	17/07/91	YES			As prescribed
	128	Female	Day 42	25/07/91	YES			As prescribed
	129	Male	Day 42	03/02/92	YES			Suspected irregularities
	130	Male	Day 42	15/04/92	YES			As prescribed
	131	Female	Day 42	30/04/92	YES			As prescribed
	132	Male	Day 42	06/08/92	YES			As prescribed
5/2	121	Female	Day 42	27/01/92	NO	Deterioration	Physician	As prescribed
	125	Male	Day 42	10/03/91	YES			As prescribed
5/3	133	Male	Day 14	12/12/91	NO	Deterioration	Physician	As prescribed
	134	Female	Day 42	16/01/92	YES			As prescribed
	135	Female	Day 42	20/02/92	YES			As prescribed
	136	Female	Day 42	12/04/92	YES			As prescribed
	137	Female	Day 42	25/06/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
5/3	138	Female	Day 7	16/05/92	NO	Intercurrent medical problem	Physician	As prescribed
6/1	151	Male	Day 7	28/01/92	NO	Adverse event	Physician	As prescribed
	152	Female	Day 42	07/04/92	YES			As prescribed
	153	Male	Day 42	29/04/91	YES			As prescribed
	155	Male	Day 28	04/08/92	NO	Deterioration Other	Physician	As prescribed
	156	Female	Day 42	19/10/92	YES			As prescribed
6/2	157	Male	Day 42	10/06/91	YES			As prescribed
	158	Female	Day 42	05/01/92	YES			As prescribed
	159	Male	Day 42	24/08/91	YES			As prescribed
	160	Male	Day 42	04/01/92	YES			As prescribed
	161	Female	Day 28	18/03/92	NO	Intercurrent medical problem	Patient	As prescribed
	162	Male	Day 7	13/07/91	NO	Patient uncooperative	Patient	Suspected irregularities
	169	Female	Day 21	15/01/92	NO	Deterioration	Physician Patient	As prescribed
	170	Male	Day 14	15/11/91	NO	Deterioration	Patient	As prescribed
	171	Female	Day 42	01/09/92	YES			As prescribed
	172	Female	Day 42	17/08/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
6/2	173	Male	Day 42	15/08/92	YES			As prescribed
	174	Male	Day 42	21/06/92	YES			As prescribed
6/3	163	Male	Day 7	08/06/91	NO	Adverse event	Physician Patient	As prescribed
	164	Male	Day 42	21/11/91	YES			As prescribed
	165	Female	Day 42	26/11/91	YES			As prescribed
	166	Female	Day 7	29/10/91	NO	Deterioration	Physician	As prescribed
	167	Female	Day 42	27/12/91	YES			As prescribed
	168	Female	Day 35	06/01/92	NO	Deterioration	Physician	As prescribed
	505	Female	Day 14	17/12/91	NO	Deterioration	Physician Patient	As prescribed
	506	Female	Day 42	19/02/92	YES			Suspected irregularities
	507	Female	Day 42	24/02/92	YES			As prescribed
	508	Female	Day 42	17/03/92	YES			As prescribed
	509	Male	Day 42	06/04/92	YES			As prescribed
	510	Female	Day 14	10/03/92	NO	Adverse event	Physician Patient	As prescribed
	511	Female	Day 35	21/04/92	NO	Deterioration	Physician	As prescribed
	512	Female	Day 7	01/04/92	NO	Patient uncooperative	Patient	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
6/3	513	Female	Day 42	23/06/92	YES			As prescribed
7/02	181	Male	Day 42	08/03/92	YES			As prescribed
	182	Male	Day 42	03/01/92	YES			As prescribed
	183	Male	Day 21	18/01/92	NO	Adverse event Patient uncooperative	Physician Patient	Confirmed irregularities
	184	Female	Day 42	08/03/92	YES			As prescribed
	185	Male	Day 28	05/05/92	NO	Adverse event	Physician Patient	As prescribed
	186	Male	Day 42	27/05/92	YES			As prescribed
	535	Male	Day 42	26/05/92	YES			As prescribed
	536	Female	Day 42	18/06/92	YES			As prescribed
7/03	187	Female	Day 42	30/03/92	YES			As prescribed
	188	Male	Day 42	06/04/92	YES			As prescribed
	189	Male	Day 42	06/04/92	YES			As prescribed
	190	Male	Day 42	09/04/92	YES			As prescribed
	191	Female	Day 42	10/04/92	NO	Adverse event	Physician	As prescribed
	192	Female	Day 42	20/04/92	YES			As prescribed
	523	Female	Day 42	16/06/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
7/03	524	Female	Day 42	16/06/92	YES			As prescribed
	525	Female	Day 42	16/06/92	YES			As prescribed
	526	Female	Day 42	16/06/92	YES			Suspected irregularities
	527	Female	Day 42	29/06/92	YES			Confirmed irregularities
	528	Female	Day 35	22/06/92	NO	Patient uncooperative	Physician Patient	Suspected irregularities
7/04	193	Female	Day 42	06/03/92	YES			As prescribed
	194	Male	Day 42	06/03/92	YES			As prescribed
	195	Female	Day 42	06/03/92	YES			As prescribed
	196	Female	Day 42	13/03/92	YES			As prescribed
	197	Male	Day 42	13/03/92	YES			As prescribed
	198	Female	Day 42	13/03/92	YES			As prescribed
	199	Male	Day 42	08/05/92	YES			As prescribed
	200	Male	Day 42	08/05/92	YES			As prescribed
	201	Female	Day 42	08/05/92	YES			As prescribed
	202	Male	Day 42	15/05/92	YES			As prescribed
	203	Female	Day 42	15/05/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
7/04	204	Female	Day 42	15/05/92	YES			As prescribed
7/05	205	Male	Day 42	08/03/92	YES			As prescribed
	206	Female	Day 42	09/03/92	YES			As prescribed
	207	Female	Day 42	09/03/92	YES			As prescribed
	208	Male	Day 42	11/03/92	YES			As prescribed
	209	Male	Day 42	17/03/92	YES			As prescribed
	210	Male	Day 42	19/03/92	YES			As prescribed
	541	Female	Day 42	27/04/92	YES			As prescribed
	542	Male	Day 42	27/04/92	YES			As prescribed
	543	Male	Day 42	28/04/92	YES			As prescribed
	544	Female	Day 42	04/05/92	YES			As prescribed
	545	Male	Day 42	05/05/92	YES			As prescribed
	546	Female	Day 42	05/05/92	YES			As prescribed
7/07	529	Female	Day 42	30/03/92	YES			As prescribed
	530	Female	Day 21	09/03/92	NO	Patient uncooperative	Patient	Unknown
	531	Female	Day 42	05/04/92	YES			As prescribed
	532	Female	Day 42	07/06/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
7/07	533	Male	Day 42	14/06/92	YES			As prescribed
	534	Female	Day 42	25/06/92	YES			As prescribed
8	211	Female	Day 14	26/05/91	NO	Patient uncooperative	Patient	As prescribed
	212	Female	Day 42	25/10/91	YES			As prescribed
	213	Male	Day 7	24/11/91	NO	Death		
	214	Female	Day 42	03/01/92	YES			As prescribed
	215	Female	Day 42	30/03/92	YES			As prescribed
	216	Male	Day 42	07/05/92	YES			As prescribed
	217	Female	Day 42	10/05/92	YES			As prescribed
	218	Female	Day 42	20/05/92	YES			As prescribed
	219	Female	Day 21	01/05/92	NO	Patient uncooperative	Patient	Suspected irregularities
	220	Female	Day 42	07/06/92	YES			As prescribed
	221	Male	Day 42	08/06/92	YES			As prescribed
	222	Female	Day 42	08/06/92	YES			As prescribed
	223	Female	Day 42	21/06/92	YES			As prescribed
	224	Female	Day 42	18/10/92	YES			As prescribed
	225	Male	Day 42	22/10/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
8	226	Male	Day 42	03/11/92	YES			As prescribed
	227	Male	Day 42	05/11/92	YES			As prescribed
	228	Male	Day 7	02/10/92	NO	Deterioration Patient uncooperative	Physician Patient	As prescribed
	229	Female	Day 42	10/11/92	YES			As prescribed
	230	Female	Day 42	08/11/92	YES			As prescribed
	231	Male	Day 42	10/11/92	YES			As prescribed
	232	Male	Day 42	12/11/92	YES			As prescribed
	233	Female	Day 42	17/11/92	YES			As prescribed
	234	Female	Day 42	17/11/92	YES			As prescribed
8/A	235	Female	Day 42	24/11/92	YES			As prescribed
	236	Female	Day 42	24/11/92	YES			As prescribed
	237	Female	Day 42	24/11/92	YES			As prescribed
	238	Female	Day 42	24/11/92	YES			As prescribed
	239	Female	Day 42	26/11/92	YES			As prescribed
	240	Female	Day 42	26/11/92	YES			As prescribed
	553	Female	Day 42	26/11/92	YES			As prescribed
	554	Male	Day 42	26/11/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
8/A	555	Female	Day 42	26/11/92	YES			As prescribed
	556	Male	Day 42	26/11/92	YES			As prescribed
9	241	Female	Day 14	17/02/91	NO	Adverse event Deterioration	Physician Patient	As prescribed
	242	Female	Day 21	11/03/91	NO	Patient uncooperative	Patient	As prescribed
	243	Female	Day 14	06/03/91	NO	Protocol violation	Physician	Confirmed irregularities
	244	Female	Day 28	13/03/91	NO	Patient uncooperative	Patient	As prescribed
	245	Female	Day 42	04/04/91	YES			As prescribed
	246	Female	Day 28	17/03/91	NO	Adverse event	Physician	As prescribed
	247	Female	Day 28	26/03/91	NO	Deterioration	Physician	As prescribed
	248	Male	Day 14	21/03/91	NO	Deterioration	Physician	As prescribed
	249	Female	Day 7	11/03/91	NO	Patient uncooperative	Patient	As prescribed
	250	Female	Day 28	08/04/91	NO	Deterioration	Physician Patient	As prescribed
	251	Female	Day 28	12/04/91	NO	Other	Others	As prescribed
	252	Female	Day 21	20/04/91	NO	Adverse event Patient uncooperative	Patient	As prescribed
	253	Female	Day 7	08/04/91	NO	Adverse event Deterioration Patient uncooperative	Physician Patient	As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
9	254	Female	Day 14	16/04/91	NO	Adverse event Patient uncooperative	Patient	As prescribed
	255	Female	Day 28	06/06/91	NO	Adverse event Deterioration	Physician	As prescribed
	256	Female	Day 42	08/07/91	YES			As prescribed
	257	Male	Day 7	01/07/91	NO	Patient uncooperative	Patient	As prescribed
	258	Male	Day 14	10/07/91	NO	Patient uncooperative	Patient	As prescribed
11	319	Male	Day 42	12/09/91	YES			As prescribed
	320	Male	Day 42	26/09/91	YES			As prescribed
	321	Male	Day 42	17/10/91	YES			As prescribed
	322	Female	Day 42	07/11/91	YES			As prescribed
	323	Male	Day 42	26/12/91	YES			As prescribed
	324	Male	Day 42	16/01/92	YES			As prescribed
	325	Male	Day 42	23/01/92	YES			As prescribed
	326	Male	Day 42	27/02/92	YES			As prescribed
	327	Male	Day 7	05/02/92	NO	Patient uncooperative	Patient	Unknown
	328	Female	Day 7	04/02/92	NO	Patient uncooperative	Patient	Unknown
	329	Female	Day 42	21/05/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
11	330	Male	Day 42	21/05/92	YES			As prescribed
	331	Male	Day 42	28/05/92	YES			As prescribed
	332	Male	Day 42	29/06/92	YES			As prescribed
	333	Male	Day 42	07/07/92	YES			As prescribed
	334	Female	Day 7	31/05/92	NO	Adverse event	Patient	
	335	Male	Day 42	14/07/92	YES			As prescribed
	336	Female	Day 7	25/06/92	NO	Patient uncooperative	Patient	Confirmed irregularities
	337	Female	Day 42	13/08/92	YES			As prescribed
	338	Male	Day 7	30/07/92	NO	Lost to follow up	Patient	Unknown
12	367	Female	Day 42	30/01/92	YES			As prescribed
	368	Female	Day 42	03/02/92	YES			As prescribed
	369	Female	Day 21	13/05/92	NO	Deterioration	Physician	As prescribed
	370	Male	Day 28	20/05/92	NO	Deterioration	Physician	As prescribed
	371	Female	Day 7	06/05/92	NO	Intercurrent medical problem	Physician	As prescribed
	372	Male	Day 42	13/07/92	YES			As prescribed
	373	Male	Day 42	14/07/92	YES			As prescribed
	374	Female	Day 28	05/07/92	NO	Deterioration	Physician	As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
12	374	Female	Day 28	05/07/92	NO		Patient	
	375	Male	Day 7	18/06/92	NO	Adverse event Deterioration	Physician Patient	As prescribed
13	13	Male	Day 42	24/05/91	YES			As prescribed
	14	Male	Day 42	13/08/91	YES			As prescribed
	15	Female	Day 42	15/08/91	YES			As prescribed
	16	Male	Day 42	16/01/92	NO	Adverse event Deterioration	Patient	Confirmed irregularities
	17	Male	Day 42	01/07/92	YES			Suspected irregularities
	18	Male	Day 42	02/08/92	YES			As prescribed
	409	Male	Day 42	20/01/92	YES			As prescribed
	410	Male	Day 42	26/03/92	YES			As prescribed
	411	Female	Day 42	08/05/92	YES			As prescribed
	423	Male	Day 42	27/10/92	YES			As prescribed
14	19	Female	Day 28	06/05/92	NO	Deterioration	Physician Patient	As prescribed
	20	Female	Day 42	09/06/92	YES			As prescribed
	21	Female	Day 35	24/08/92	NO	Deterioration	Physician Patient	As prescribed
15	25	Female	Day 42	29/07/91	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
15	26	Male	Day 42	01/08/91	YES			As prescribed
	27	Female	Day 42	13/08/91	YES			As prescribed
	28	Female	Day 42	19/09/91	YES			As prescribed
	29	Male	Day 21	19/09/91	NO	Deterioration	Physician	As prescribed
	30	Female	Day 42	15/10/91	YES			As prescribed
	403	Female	Day 42	14/11/91	YES			As prescribed
	404	Female	Day 28	05/11/91	NO	Deterioration	Patient	As prescribed
	405	Female	Day 42	23/12/91	YES			As prescribed
	406	Male	Day 42	07/01/92	YES			As prescribed
	407	Female	Day 42	14/01/92	YES			As prescribed
	408	Female	Day 42	04/03/92	YES			As prescribed
	418	Female	Day 42	12/03/92	YES			As prescribed
	419	Female	Day 42	09/06/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	1	Imipramine	Female	01.DEPRESSED MOOD	4	4	4	1	2	1	1	0
				02.GUILT	2	2	3	3	2	1	1	1
				03.SUICIDE	2	2	3	1	0	1	1	0
				04.INSOMNIA EARLY	2	2	1	2	2	0	0	0
				05.INSOMNIA MIDDLE	2	2	1	1	2	0	0	0
				06.INSOMNIA LATE	2	2	1	2	2	2	0	1
				07.WORK AND ACTIVITIES	3	3	4	1	1	2	0	0
				08.RETARDATION	2	2	1	1	0	1	1	0
				09.AGITATION	1	1	4	2	2	0	0	1
				10.ANXIETY PSYCHIC	3	3	4	2	2	2	1	1
				11.ANXIETY SOMATIC	3	3	2	1	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	2	1	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	2	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	2	0	0	0	0	0
				17.INSIGHT	1	1	2	2	2	1	1	1
				18.DIURNAL VARIATION	2	2	2	0	0	1	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	1	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	1	0
				22.Total score	37	37	42	22	19	14	8	6
	2	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	2	2	2	2	2
				02.GUILT	3	3	3	2	2	2	0	1
				03.SUICIDE	3	3	2	2	2	2	1	1
				04.INSOMNIA EARLY	2	2	2	2	2	2	1	1
				05.INSOMNIA MIDDLE	2	2	2	1	2	2	1	1
				06.INSOMNIA LATE	2	2	1	1	2	2	1	1
				07.WORK AND ACTIVITIES	4	3	3	2	2	2	2	1
				08.RETARDATION	3	2	2	1	1	2	0	0
				09.AGITATION	3	2	0	0	0	0	2	1
				10.ANXIETY PSYCHIC	2	2	3	2	2	2	2	1
				11.ANXIETY SOMATIC	0	2	1	1	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	1	1	1	0
				13.SOMATIC GENERAL	2	2	2	1	2	2	2	1
				14.GENITAL SYMPTOMS	2	1	2	2	1	2	1	1
				15.HYPOCHONDRIASIS	1	2	2	0	1	0	1	0
				16.LOSS OF WEIGHT	0	0	2	0	0	0	0	0
				17.INSIGHT	0	0	1	0	0	0	0	0
				18.DIURNAL VARIATION	0	1	0	1	1	1	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	0	0	1	1	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	0	0	0	0	0	0	0
				22.Total score	36	34	33	22	25	24	18	12
	3	Imipramine	Male	01.DEPRESSED MOOD	2	2	2	2	2	1	1	1
				02.GUILT	1	1	2	1	1	1	1	1
				03.SUICIDE	2	1	1	0	1	1	1	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	3	Imipramine	Male	05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	0	1
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	0
				08.RETARDATION	2	2	1	2	1	2	2	0
				09.AGITATION	0	2	1	0	0	0	0	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	0	1
				11.ANXIETY SOMATIC	2	3	1	2	2	0	1	1
				12.SOMATIC GASTROINTESTINAL	0	1	2	2	1	1	1	0
				13.SOMATIC GENERAL	2	1	2	2	1	1	1	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	2	1	0	0	1	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	0	0	0	0	0	0	0
				22.Total score	22	23	23	21	17	14	13	9
	4	Placebo	Male	01.DEPRESSED MOOD	3	3	2	0	0	0	0	0
				02.GUILT	3	3	2	0	0	0	0	0
				03.SUICIDE	2	2	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	1	2	2	1	1	1
				06.INSOMNIA LATE	1	1	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	3	3	2	1	1	0	0	0
				09.AGITATION	1	1	2	1	1	0	0	0
				10.ANXIETY PSYCHIC	2	2	0	2	2	2	2	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	2	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	19	12	10	6	5	4
	5	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	2			
				02.GUILT	2	2	2	2	2			
				03.SUICIDE	1	1	1	1	2			
				04.INSOMNIA EARLY	2	2	1	1	1			
				05.INSOMNIA MIDDLE	2	2	2	2	2			
				06.INSOMNIA LATE	2	2	2	2	2			
				07.WORK AND ACTIVITIES	2	2	3	3	3			
				08.RETARDATION	2	2	1	1	1			

1095

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	5	Reboxetine	Female	09.AGITATION	2	2	2	2	2			
				10.ANXIETY PSYCHIC	2	2	2	2	2			
				11.ANXIETY SOMATIC	2	2	1	0	0			
				12.SOMATIC GASTROINTESTINAL	2	2	1	1	1			
				13.SOMATIC GENERAL	2	2	2	2	2			
				14.GENITAL SYMPTOMS	1	1	2	2	2			
				15.HYPOCHONDRIASIS	0	0	0	0	0			
				16.LOSS OF WEIGHT	2	2	0	0	0			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	2	2	1	1	1			
				19.DEPERSONALIZATION	0	0	0	0	0			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	31	31	25	24	25			
	6	Placebo	Female	01.DEPRESSED MOOD	3	3	2	2	2	2	2	2
				02.GUILT	2	2	2	2	2	2	3	3
				03.SUICIDE	2	2	1	1	1	0	1	1
				04.INSOMNIA EARLY	0	0	1	2	2	1	2	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	1	1	1
				07.WORK AND ACTIVITIES	3	3	2	2	2	2	1	1
				08.RETARDATION	2	2	0	0	0	0	1	1
				09.AGITATION	2	2	1	0	2	1	1	1
				10.ANXIETY PSYCHIC	2	2	3	2	2	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	0	1	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	1	1
				13.SOMATIC GENERAL	2	2	1	2	2	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	1	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	1	1
				22.Total score	31	31	21	20	23	13	20	19
	7	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	1	1	0	0
				02.GUILT	2	2	2	2	1	0	0	0
				03.SUICIDE	2	2	0	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	0	1	0	1
				05.INSOMNIA MIDDLE	2	2	2	1	1	0	0	0
				06.INSOMNIA LATE	2	2	2	1	1	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	0	0	0
				08.RETARDATION	2	2	2	2	1	1	0	0
				09.AGITATION	2	2	2	2	1	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	2	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	2	2	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	7	Reboxetine	Female	13.SOMATIC GENERAL	2	2	2	1	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	1	0	0	0	0	0
				22.Total score	33	33	25	20	11	5	2	2
	8	Placebo	Male	01.DEPRESSED MOOD	2	2	2	2	1	1	1	1
				02.GUILT	2	2	1	1	1	1	1	1
				03.SUICIDE	0	0	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	2	1	0	1
				05.INSOMNIA MIDDLE	2	2	2	1	1	1	1	0
				06.INSOMNIA LATE	2	2	1	1	1	2	2	0
				07.WORK AND ACTIVITIES	2	2	1	1	1	1	1	0
				08.RETARDATION	1	1	2	0	1	0	0	0
				09.AGITATION	1	1	1	2	1	1	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	2	1	1	1
				11.ANXIETY SOMATIC	2	2	1	0	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	0	1	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	0
				22.Total score	27	27	20	14	14	12	9	5
	9	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	3	2	2	1
				02.GUILT	2	2	2	2	2	2	1	1
				03.SUICIDE	2	2	2	2	3	2	1	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	1	0
				06.INSOMNIA LATE	2	2	2	2	2	1	2	1
				07.WORK AND ACTIVITIES	3	3	2	3	3	2	1	1
				08.RETARDATION	2	2	2	2	2	1	1	1
				09.AGITATION	3	3	2	2	3	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	3	1	2	1
				11.ANXIETY SOMATIC	2	2	2	1	2	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	2	1	1	1	0
				13.SOMATIC GENERAL	2	2	1	2	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	0
				15.HYPOCHONDRIASIS	0	0	1	2	1	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0

1097

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	9	Reboxetine	Female	17.INSIGHT	1	1	0	0	1	0	0	0
				18.DIURNAL VARIATION	2	2	2	0	2	1	1	1
				19.DEPERSONALIZATION	3	3	2	0	0	0	0	0
				20.PARANOID	0	0	0	0	1	0	0	0
				21.OBSESSIONAL/COMPULSIVE	2	2	2	0	0	1	1	1
				22.Total score	39	39	33	30	36	21	19	11
	10	Placebo	Male	01.DEPRESSED MOOD	2	2	2	2	2	2	1	2
				02.GUILT	2	2	2	1	1	2	1	1
				03.SUICIDE	2	2	1	1	0	0	1	0
				04.INSOMNIA EARLY	2	2	2	1	1	0	0	0
				05.INSOMNIA MIDDLE	2	2	1	0	0	0	0	0
				06.INSOMNIA LATE	2	2	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	1	2	1	2	1
				08.RETARDATION	2	2	2	1	1	1	1	1
				09.AGITATION	1	1	1	1	0	1	0	1
				10.ANXIETY PSYCHIC	3	2	0	0	1	2	1	1
				11.ANXIETY SOMATIC	2	3	0	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	1	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	2	1	2	2	2	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	1	0	1	0
				22.Total score	28	28	20	12	13	13	12	11
	11	Imipramine	Female	01.DEPRESSED MOOD	2	2						
				02.GUILT	1	1						
				03.SUICIDE	2	2						
				04.INSOMNIA EARLY	2	2						
				05.INSOMNIA MIDDLE	2	2						
				06.INSOMNIA LATE	2	2						
				07.WORK AND ACTIVITIES	3	3						
				08.RETARDATION	2	2						
				09.AGITATION	0	0						
				10.ANXIETY PSYCHIC	2	2						
				11.ANXIETY SOMATIC	2	2						
				12.SOMATIC GASTROINTESTINAL	2	2						
				13.SOMATIC GENERAL	2	2						
				14.GENITAL SYMPTOMS	0	0						
				15.HYPOCHONDRIASIS	0	0						
				16.LOSS OF WEIGHT	1	1						
				17.INSIGHT	0	0						
				18.DIURNAL VARIATION	1	1						
				19.DEPERSONALIZATION	0	0						
				20.PARANOID	0	0						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	11	Imipramine	Female	21.OBSESSIONAL/COMPULSIVE	0	0						
				22.Total score	26	26						
	12	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	1	1	1	0	0
				02.GUILT	2	2	2	1	0	1	0	0
				03.SUICIDE	2	2	1	0	0	1	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	1	0	0
				05.INSOMNIA MIDDLE	0	0	0	1	0	1	1	1
				06.INSOMNIA LATE	0	0	0	1	0	0	1	0
				07.WORK AND ACTIVITIES	3	3	2	1	1	0	1	1
				08.RETARDATION	2	2	1	0	1	1	0	0
				09.AGITATION	2	2	1	1	1	1	0	1
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	1	1	2	2	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	0	0	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	0	2	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	0	1	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	2	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	23	23	20	12	8	11	6	5
	412	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	2	2	2	1	1
				02.GUILT	2	2	2	2	2	1	0	0
				03.SUICIDE	2	2	1	1	1	0	0	0
				04.INSOMNIA EARLY	2	2	1	2	1	0	1	0
				05.INSOMNIA MIDDLE	1	1	1	2	1	1	1	0
				06.INSOMNIA LATE	1	1	1	2	1	1	1	0
				07.WORK AND ACTIVITIES	3	3	2	2	3	3	1	1
				08.RETARDATION	2	2	1	1	1	1	0	0
				09.AGITATION	0	0	1	1	1	0	0	0
				10.ANXIETY PSYCHIC	3	3	1	2	2	1	0	1
				11.ANXIETY SOMATIC	2	2	0	0	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	2	1	0	1	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	1	1
				14.GENITAL SYMPTOMS	1	1	2	1	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	1	0	0
				16.LOSS OF WEIGHT	1	1	1	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	0	0
				22.Total score	29	29	21	21	18	15	6	4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	413	Placebo	Male	01.DEPRESSED MOOD	2	3	3		1		2	2
				02.GUILT	2	2	2		1		2	1
				03.SUICIDE	2	2	1		1		2	1
				04.INSOMNIA EARLY	2	2	2		1		0	0
				05.INSOMNIA MIDDLE	1	2	0		0		0	0
				06.INSOMNIA LATE	0	2	0		0		0	0
				07.WORK AND ACTIVITIES	2	2	3		1		2	2
				08.RETARDATION	0	2	1		0		1	0
				09.AGITATION	2	2	2		2		2	1
				10.ANXIETY PSYCHIC	2	1	2		1		2	1
				11.ANXIETY SOMATIC	1	1	2		2		1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1		0		0	0
				13.SOMATIC GENERAL	1	1	0		2		1	1
				14.GENITAL SYMPTOMS	1	1	1		1		1	0
				15.HYPOCHONDRIASIS	2	2	0		0		0	0
				16.LOSS OF WEIGHT	0	0	0		0		0	0
				17.INSIGHT	0	0	0		0		0	0
				18.DIURNAL VARIATION	1	1	1		0		0	0
				19.DEPERSONALIZATION	0	0	0		0		0	0
				20.PARANOID	0	0	0		0		0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1		1		0	0
				22.Total score	23	28	22		14		16	10
	414	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2				
				02.GUILT	2	0	0	0				
				03.SUICIDE	1	0	1	1				
				04.INSOMNIA EARLY	2	2	2	2				
				05.INSOMNIA MIDDLE	2	2	2	2				
				06.INSOMNIA LATE	2	2	2	2				
				07.WORK AND ACTIVITIES	3	3	3	3				
				08.RETARDATION	2	2	2	2				
				09.AGITATION	3	1	0	2				
				10.ANXIETY PSYCHIC	2	1	2	1				
				11.ANXIETY SOMATIC	2	2	2	2				
				12.SOMATIC GASTROINTESTINAL	1	1	1	2				
				13.SOMATIC GENERAL	2	2	2	2				
				14.GENITAL SYMPTOMS	1	2	1	0				
				15.HYPOCHONDRIASIS	0	0	0	0				
				16.LOSS OF WEIGHT	0	2	0	2				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	2	0	0	0				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	1	1	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	30	25	22	25				
	415	Imipramine	Male	01.DEPRESSED MOOD	2	2	1	2	1	1	0	0
				02.GUILT	1	1	1	1	1	0	0	0
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	2	2	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	415	Imipramine	Male	05.INSOMNIA MIDDLE	2	2	2	1	1	1	2	2
				06.INSOMNIA LATE	1	1	2	1	1	0	0	1
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	0	0
				08.RETARDATION	1	1	0	1	0	0	0	0
				09.AGITATION	2	2	2	1	0	0	1	0
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	0
				11.ANXIETY SOMATIC	2	2	2	2	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	0	0	0	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	1	0	1	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	0	0
				22.Total score	22	22	22	15	12	8	8	7
1101	416	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	2				
				02.GUILT	2	2	1	1				
				03.SUICIDE	2	2	1	1				
				04.INSOMNIA EARLY	2	2	2	2				
				05.INSOMNIA MIDDLE	1	1	2	2				
				06.INSOMNIA LATE	2	2	2	2				
				07.WORK AND ACTIVITIES	2	2	2	2				
				08.RETARDATION	0	0	1	0				
				09.AGITATION	2	2	2	2				
				10.ANXIETY PSYCHIC	3	2	2	2				
				11.ANXIETY SOMATIC	3	2	3	2				
				12.SOMATIC GASTROINTESTINAL	1	1	1	1				
				13.SOMATIC GENERAL	1	1	1	2				
				14.GENITAL SYMPTOMS	1	1	1	1				
				15.HYPOCHONDRIASIS	3	2	2	2				
				16.LOSS OF WEIGHT	1	1	1	0				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	1	1	0	1				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	29	26	26	25				
	421	Imipramine	Male	01.DEPRESSED MOOD	2	2	2	1	1	1	1	0
				02.GUILT	1	1	1	1	0	0	0	0
				03.SUICIDE	3	3	3	1	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	1	0	1	1	1
				06.INSOMNIA LATE	2	2	1	1	1	0	0	1
				07.WORK AND ACTIVITIES	3	3	3	2	1	1	1	1
				08.RETARDATION	2	2	2	1	1	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	421	Imipramine	Male	09.AGITATION	0	0	0	0	1	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	1	0	1	1
				11.ANXIETY SOMATIC	2	2	1	1	0	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	0	2	2
				14.GENITAL SYMPTOMS	2	2	1	1	1	0	1	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	1	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	25	22	15	10	5	9	6
	422	Imipramine	Male	01.DEPRESSED MOOD	2	2	2	2	1	1	1	0
				02.GUILT	1	1	1	1	0	0	0	0
				03.SUICIDE	1	1	1	0	1	1	0	0
				04.INSOMNIA EARLY	2	2	1	0	1	0	0	1
				05.INSOMNIA MIDDLE	2	2	2	0	1	1	0	1
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	1	1	1	0	0
				08.RETARDATION	0	0	0	0	1	0	0	0
				09.AGITATION	2	2	0	0	0	1	0	1
				10.ANXIETY PSYCHIC	2	2	1	1	0	1	0	1
				11.ANXIETY SOMATIC	2	2	1	1	1	1	0	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	1	0	1
				13.SOMATIC GENERAL	1	1	1	0	1	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	2	1	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	1	0	0	0	0
				16.LOSS OF WEIGHT	1	1	1	1	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	1	0	0	0	0	0
				20.PARANOID	1	1	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	19	12	9	8	4	5
2/1	49	Placebo	Female	01.DEPRESSED MOOD	4	4	3	1	0	0	0	0
				02.GUILT	1	1	1	0	0	0	0	0
				03.SUICIDE	4	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	2	2	2	2	2	1	1
				06.INSOMNIA LATE	0	1	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	1	0	0	0	0
				08.RETARDATION	3	3	2	0	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	1	0	0	0	0
				11.ANXIETY SOMATIC	1	1	2	1	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	2	2	1	0	0	0

1102

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/1	49	Placebo	Female	13.SOMATIC GENERAL	2	2	1	0	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	1	0	0	0	0	0
				17.INSIGHT	1	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	22	22	9	5	3	2	1
	50	Reboxetine	Female	01.DEPRESSED MOOD	3	3	1	0	0	0	0	0
				02.GUILT	2	2	1	1	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	1	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	3	1	0	0	0	0	0
				08.RETARDATION	1	1	1	1	0	0	0	0
				09.AGITATION	1	1	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	1	1	2	1	1	1
				11.ANXIETY SOMATIC	2	2	3	3	3	2	1	1
				12.SOMATIC GASTROINTESTINAL	1	0	0	0	0	1	1	1
				13.SOMATIC GENERAL	2	1	1	0	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	2	2	2
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	22	14	11	9	8	7	7
	51	Imipramine	Female	01.DEPRESSED MOOD	4	3	2	1	1	0	0	0
				02.GUILT	3	3	1	1	1	0	0	0
				03.SUICIDE	2	2	1	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	0	0	0	0	0
				06.INSOMNIA LATE	2	2	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	0	0	0	0
				08.RETARDATION	2	1	1	1	0	0	0	0
				09.AGITATION	2	2	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	2	1	2	2	2
				11.ANXIETY SOMATIC	2	2	3	3	1	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	0	2	1	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	2	0	0	0	2	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/1	51	Imipramine	Female	17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	1	1	2	2	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	32	30	27	20	12	11	13	11
2/2	43	Imipramine	Female	01.DEPRESSED MOOD	2	2	0	3		0	0	
				02.GUILT	2	2	0	0		0	0	
				03.SUICIDE	1	2	0	0		0	0	
				04.INSOMNIA EARLY	2	2	1	2		1	0	
				05.INSOMNIA MIDDLE	1	1	1	1		0	0	
				06.INSOMNIA LATE	0	0	0	0		1	0	
				07.WORK AND ACTIVITIES	3	3	0	1		0	0	
				08.RETARDATION	2	1	0	1		1	1	
				09.AGITATION	2	2	3	1		0	1	
				10.ANXIETY PSYCHIC	1	1	0	2		1	0	
				11.ANXIETY SOMATIC	2	2	0	0		0	0	
				12.SOMATIC GASTROINTESTINAL	0	1	0	0		0	0	
				13.SOMATIC GENERAL	1	1	0	0		0	1	
				14.GENITAL SYMPTOMS	0	0	0	0		0	0	
				15.HYPOCHONDRIASIS	2	2	0	0		0	0	
				16.LOSS OF WEIGHT	0	0	0	0		0	0	
				17.INSIGHT	1	1	0	2		0	0	
				18.DIURNAL VARIATION	1	1	1	2		0	1	
				19.DEPERSONALIZATION	1	1	0	0		0	0	
				20.PARANOID	0	0	0	0		0	0	
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0		0	0	
				22.Total score	24	25	6	15		4	4	
	44	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	1	1	1	0	0
				02.GUILT	2	2	1	2	1	1	2	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	1	0	2	2	0	0	2	0
				07.WORK AND ACTIVITIES	1	1	1	0	2	0	1	0
				08.RETARDATION	0	1	0	0	0	0	0	0
				09.AGITATION	2	2	3	1	1	2	2	2
				10.ANXIETY PSYCHIC	2	1	1	2	2	0	2	0
				11.ANXIETY SOMATIC	2	2	2	0	0	1	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	2	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	2	0	2	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	1	2	1	1	2	1	1
				16.LOSS OF WEIGHT	2	0	2	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	2	1	1	2	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	0	1	0	0	1	0

1104

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/2	44	Imipramine	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	22	25	14	14	10	16	7
	45	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3	3	2	1	3
				02.GUILT	3	3	1	2	1	1	1	0
				03.SUICIDE	2	2	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	1	0	0	0	0	1	1
				05.INSOMNIA MIDDLE	0	0	1	1	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	1	0	1	1
				07.WORK AND ACTIVITIES	2	1	2	0	2	0	0	0
				08.RETARDATION	0	1	1	0	0	0	0	1
				09.AGITATION	0	2	0	1	0	2	1	0
				10.ANXIETY PSYCHIC	2	1	1	1	2	2	2	1
				11.ANXIETY SOMATIC	1	1	1	1	0	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	0	0	0	1	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	3	2	2	1	2	2	2	2
				16.LOSS OF WEIGHT	0	0	2	0	0	0	0	1
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	2	0	0	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	1	0	1	1	1	1	0
				21.OBSESSIONAL/COMPULSIVE	2	1	0	0	0	0	1	1
				22.Total score	25	23	17	12	14	11	13	13
	46	Placebo	Female	01.DEPRESSED MOOD	3	2	3		1	0		
				02.GUILT	1	1	1		1	0		
				03.SUICIDE	2	2	0		0	0		
				04.INSOMNIA EARLY	2	2	0		1	0		
				05.INSOMNIA MIDDLE	2	2	0		0	0		
				06.INSOMNIA LATE	1	1	0		0	1		
				07.WORK AND ACTIVITIES	3	2	1		1	0		
				08.RETARDATION	0	1	0		1	1		
				09.AGITATION	2	2	1		1	0		
				10.ANXIETY PSYCHIC	2	2	0		1	0		
				11.ANXIETY SOMATIC	2	2	0		0	0		
				12.SOMATIC GASTROINTESTINAL	1	0	0		0	0		
				13.SOMATIC GENERAL	2	2	1		2	0		
				14.GENITAL SYMPTOMS	0	0	0		0	0		
				15.HYPOCHONDRIASIS	0	1	2		2	1		
				16.LOSS OF WEIGHT	0	0	0		0	0		
				17.INSIGHT	0	0	0		0	0		
				18.DIURNAL VARIATION	0	2	0		0	0		
				19.DEPERSONALIZATION	0	0	0		0	0		
				20.PARANOID	1	1	0		1	1		
				21.OBSESSIONAL/COMPULSIVE	1	0	0		0	0		
				22.Total score	25	25	9		12	4		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/2	47	Placebo	Female	01.DEPRESSED MOOD	4	3	3	2	2	3	3	2
				02.GUILT	2	1	1	1	1	1	1	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	2	2	1	0	1	1	0
				05.INSOMNIA MIDDLE	1	2	2	0	0	0	1	0
				06.INSOMNIA LATE	1	1	1	0	1	0	0	0
				07.WORK AND ACTIVITIES	4	3	4	3	2	4	4	2
				08.RETARDATION	1	2	1	0	0	1	1	1
				09.AGITATION	1	1	1	0	0	2	1	2
				10.ANXIETY PSYCHIC	3	1	2	1	1	1	1	2
				11.ANXIETY SOMATIC	2	3	2	2	2	2	2	1
				12.SOMATIC GASTROINTESTINAL	1	2	1	1	0	2	2	1
				13.SOMATIC GENERAL	0	2	2	2	1	1	0	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	0	2	1	0	0	0	0	0
				16.LOSS OF WEIGHT	0	1	1	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	1	1	1	1	1	1	2
				19.DEPERSONALIZATION	0	1	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	31	27	16	13	21	20	16
	48	Reboxetine	Female	01.DEPRESSED MOOD	4	4	3	3	1	2	0	1
				02.GUILT	2	2	1	0	0	1	0	0
				03.SUICIDE	0	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	2
				05.INSOMNIA MIDDLE	2	2	0	0	0	0	0	0
				06.INSOMNIA LATE	1	1	2	1	0	2	1	1
				07.WORK AND ACTIVITIES	4	4	4	4	2	0	0	0
				08.RETARDATION	2	2	2	1	1	0	0	1
				09.AGITATION	1	2	1	2	0	1	2	1
				10.ANXIETY PSYCHIC	1	3	1	3	1	1	0	0
				11.ANXIETY SOMATIC	2	2	2	3	1	0	0	1
				12.SOMATIC GASTROINTESTINAL	0	0	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	0	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	2	0	2	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	0	0	0	0	0	0	0
				22.Total score	26	28	21	19	10	8	3	8
2/3	36/A	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	1	1	1	1	1
				02.GUILT	1	2	2	0	0	0	0	0
				03.SUICIDE	1	2	2	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/3	36/A	Imipramine	Male	05.INSOMNIA MIDDLE	2	1	1	0	0	0	0	0
				06.INSOMNIA LATE	2	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	1	1	1	1	1
				08.RETARDATION	1	2	2	0	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	1	1	1	1
				13.SOMATIC GENERAL	2	1	1	1	1	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	0	0	0
				15.HYPOCHONDRIASIS	1	2	2	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	2	2	0	1	1	1	1
				22.Total score	27	27	27	10	11	10	10	10
	37	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3	2	2	2	1
				02.GUILT	1	1	1	1	1	0	0	0
				03.SUICIDE	1	1	1	1	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	1
				06.INSOMNIA LATE	2	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	0	3	2	2	2	1
				08.RETARDATION	2	2	2	1	0	0	0	0
				09.AGITATION	0	0	1	1	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	3	3	3	3	3	1
				11.ANXIETY SOMATIC	2	2	3	3	3	3	3	1
				12.SOMATIC GASTROINTESTINAL	1	1	2	2	2	2	2	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	2	2	2	2	2	1
				15.HYPOCHONDRIASIS	0	0	1	1	1	1	1	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	26	28	23	21	21	10
	38	Placebo	Male	01.DEPRESSED MOOD	2	2	2	2	2	2	1	1
				02.GUILT	2	2	1	1	1	1	1	1
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	1	1	1	2	1	1
				06.INSOMNIA LATE	2	2	1	1	1	0	0	1
				07.WORK AND ACTIVITIES	2	3	2	2	2	1	1	1
				08.RETARDATION	3	3	2	2	0	0	0	0

1107

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/3	38	Placebo	Male	09.AGITATION	0	0	0	0	0	1	1	1
				10.ANXIETY PSYCHIC	3	3	2	2	2	0	0	0
				11.ANXIETY SOMATIC	3	3	2	2	2	2	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	2	2	1	1
				13.SOMATIC GENERAL	1	1	1	1	2	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	1	1	1
				22.Total score	31	32	25	25	21	19	13	14
	39	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	2	1	1	0
				02.GUILT	2	2	2	1	0	0	0	0
				03.SUICIDE	1	2	2	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	1	0	0	0	0
				06.INSOMNIA LATE	2	2	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	1	1	0	0
				08.RETARDATION	3	1	0	1	1	0	0	0
				09.AGITATION	0	0	0	0	0	1	0	0
				10.ANXIETY PSYCHIC	3	3	3	2	2	1	1	1
				11.ANXIETY SOMATIC	3	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	0	0	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	0	1	0
				14.GENITAL SYMPTOMS	1	2	2	1	1	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	2	0	0	0
				16.LOSS OF WEIGHT	1	2	0	0	0	2	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	0	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	1	0	0	0	0
				22.Total score	32	33	29	20	12	8	5	3
	40	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	0	0	0	0
				02.GUILT	1	1	2	1	1	1	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	2	2	0
				05.INSOMNIA MIDDLE	2	2	0	0	0	1	1	0
				06.INSOMNIA LATE	1	1	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	4	4	3	1	0	2
				08.RETARDATION	0	0	0	0	0	1	1	1
				09.AGITATION	0	0	0	0	0	2	0	0
				10.ANXIETY PSYCHIC	3	3	3	3	2	1	1	1
				11.ANXIETY SOMATIC	1	1	1	0	0	1	1	0
				12.SOMATIC GASTROINTESTINAL	2	2	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/3	40	Reboxetine	Female	13.SOMATIC GENERAL	0	0	0	0	0	1	1	0
				14.GENITAL SYMPTOMS	1	1	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	2	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	2	2	1	0	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	1	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	2	2	2	0	0	1
				22.Total score	23	23	19	15	10	14	8	6
	41	Placebo	Male	01.DEPRESSED MOOD	3	3	2	2	3	3	2	2
				02.GUILT	2	2	1	2	1	0	0	0
				03.SUICIDE	1	1	0	1	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	0	0	0	0
				06.INSOMNIA LATE	1	1	2	2	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	4	4	4	4	4	4
				08.RETARDATION	1	1	2	2	2	2	2	2
				09.AGITATION	2	2	1	2	1	0	2	0
				10.ANXIETY PSYCHIC	2	2	3	2	3	0	0	2
				11.ANXIETY SOMATIC	1	1	1	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	0	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	2
				15.HYPOCHONDRIASIS	2	2	2	0	0	2	2	2
				16.LOSS OF WEIGHT	0	0	0	0	0	1	0	0
				17.INSIGHT	1	1	0	1	0	1	1	1
				18.DIURNAL VARIATION	1	1	2	1	2	2	2	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	1	1	2	1
				22.Total score	26	27	26	22	19	18	18	18
	42	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	1	0	0	2
				02.GUILT	2	2	1	1	0	1	1	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	2	2	0	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	0	1	0	1	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	1	2	2	0
				08.RETARDATION	3	3	2	2	1	2	1	2
				09.AGITATION	2	0	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	2	2	2	2	1	0	1
				11.ANXIETY SOMATIC	2	2	1	1	1	0	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	1	0	0
				13.SOMATIC GENERAL	2	1	1	2	1	0	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	2	2	2
				15.HYPOCHONDRIASIS	2	3	2	2	2	2	2	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/3	42	Imipramine	Female	17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	0	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	2	0	0	0	0
				20.PARANOID	0	1	1	2	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	28	20	25	15	15	14	14
2/4	31	Placebo	Male	01.DEPRESSED MOOD	3	3	3	3	3	3	2	2
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	3	3	3	2	2	2	2	2
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	2	2
				08.RETARDATION	2	3	3	3	3	3	2	2
				09.AGITATION	4	4	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	3	3	3	3	3	3	2	2
				11.ANXIETY SOMATIC	3	3	3	3	3	3	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	2	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	3	3	3	3	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	1	1
				19.DEPERSONALIZATION	3	3	3	3	3	3	2	2
				20.PARANOID	2	2	2	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	44	45	44	39	36	36	29	29
	32	Reboxetine	Male	01.DEPRESSED MOOD	4	4	4	4	3	1	1	1
				02.GUILT	3	3	3	3	3	1	1	1
				03.SUICIDE	2	1	1	1	1	1	1	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	1	1	1	0
				06.INSOMNIA LATE	2	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	4	4	4	4	4	1	1	1
				08.RETARDATION	3	3	3	3	2	2	1	1
				09.AGITATION	3	3	3	3	2	1	1	0
				10.ANXIETY PSYCHIC	4	4	4	4	3	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	0	0	0
				15.HYPOCHONDRIASIS	4	4	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	2	2	1	1	1	1
				19.DEPERSONALIZATION	3	3	3	3	2	1	1	1
				20.PARANOID	2	2	2	2	1	1	1	1

1110

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/4	32	Reboxetine	Male	21.OBSESSIONAL/COMPULSIVE	2	2	2	2	2	1	1	1
				22.Total score	48	46	43	43	33	19	18	15
	33	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3	2	1	1	1
				02.GUILT	4	4	4	4	3	1	0	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	2	0	0	0
				06.INSOMNIA LATE	2	2	2	2	1	0	0	0
				07.WORK AND ACTIVITIES	1	1	1	1	1	1	1	1
				08.RETARDATION	1	1	1	1	1	1	0	0
				09.AGITATION	2	2	2	2	2	1	1	1
				10.ANXIETY PSYCHIC	3	3	3	3	2	1	1	1
				11.ANXIETY SOMATIC	0	0	0	0	0	1	1	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	0	0	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	1	1	0	0
				19.DEPERSONALIZATION	2	2	2	2	1	1	1	1
				20.PARANOID	2	2	2	2	1	1	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	29	29	29	29	20	12	7	7
	34	Placebo	Female	01.DEPRESSED MOOD	4	4	4	3	2	1	0	0
				02.GUILT	4	4	3	3	2	1	1	1
				03.SUICIDE	2	2	2	2	2	1	1	1
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	4	4	4	3	2	2	2	1
				08.RETARDATION	3	3	3	3	2	1	1	1
				09.AGITATION	3	3	3	3	2	1	1	1
				10.ANXIETY PSYCHIC	4	4	4	4	3	2	1	1
				11.ANXIETY SOMATIC	4	4	4	4	3	2	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	4	4	4	4	3	2	2	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	2	2	2	1	1	1
				18.DIURNAL VARIATION	2	2	2	2	1	2	1	1
				19.DEPERSONALIZATION	4	4	4	4	3	2	1	1
				20.PARANOID	3	3	3	3	2	1	1	1
				21.OBSESSIONAL/COMPULSIVE	2	2	2	2	1	1	1	0
				22.Total score	54	54	53	51	39	24	19	16

1111

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/4	35	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3	2	1	1	1
				02.GUILT	3	3	3	2	2	1	1	1
				03.SUICIDE	3	3	3	3	2	1	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	0	0
				05.INSOMNIA MIDDLE	2	2	2	1	1	1	1	0
				06.INSOMNIA LATE	2	2	2	2	2	1	1	0
				07.WORK AND ACTIVITIES	3	3	3	3	2	1	1	1
				08.RETARDATION	3	3	3	2	2	2	1	1
				09.AGITATION	3	3	3	3	2	1	1	0
				10.ANXIETY PSYCHIC	4	4	3	3	2	1	1	1
				11.ANXIETY SOMATIC	3	3	2	2	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	4	4	3	3	2	2	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	2	2	1	1	1	1
				18.DIURNAL VARIATION	1	2	2	2	1	1	0	0
				19.DEPERSONALIZATION	3	3	3	2	1	1	1	1
				20.PARANOID	2	2	2	1	1	1	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	48	49	45	40	29	20	14	11
	36	Imipramine	Female	01.DEPRESSED MOOD	4	4	4	3	2	1	0	0
				02.GUILT	3	3	3	3	2	1	1	0
				03.SUICIDE	2	2	3	1	1	1	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	2	0	0	0
				06.INSOMNIA LATE	2	2	2	2	2	0	0	0
				07.WORK AND ACTIVITIES	4	4	4	3	2	2	1	1
				08.RETARDATION	3	3	3	3	2	2	1	1
				09.AGITATION	4	4	4	3	2	1	1	0
				10.ANXIETY PSYCHIC	4	4	4	3	2	1	1	1
				11.ANXIETY SOMATIC	3	3	3	3	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	1	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	0	0	0
				15.HYPOCHONDRIASIS	3	3	3	3	1	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	2	2	2	1	0	0
				18.DIURNAL VARIATION	2	2	2	2	1	1	1	1
				19.DEPERSONALIZATION	3	3	3	3	2	1	1	0
				20.PARANOID	3	3	3	3	1	1	0	0
				21.OBSESSIONAL/COMPULSIVE	2	2	2	2	1	1	0	0
				22.Total score	51	51	52	46	32	18	9	6
2/5	73	Placebo	Male	01.DEPRESSED MOOD	2	2	1	1	1	3	3	3
				02.GUILT	2	2	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	1	1	2
				04.INSOMNIA EARLY	1	1	1	1	1	2	1	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/5	73	Placebo	Male	05.INSOMNIA MIDDLE	1	1	1	1	0	1	1	1
				06.INSOMNIA LATE	1	1	1	1	0	0	0	1
				07.WORK AND ACTIVITIES	4	4	3	3	2	2	2	3
				08.RETARDATION	2	2	1	1	1	1	1	2
				09.AGITATION	0	0	0	0	0	2	2	2
				10.ANXIETY PSYCHIC	2	2	2	1	1	2	2	2
				11.ANXIETY SOMATIC	2	2	1	1	1	2	1	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	0	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	1	1	1	1
				15.HYPOCHONDRIASIS	3	3	3	3	2	2	2	3
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	19	18	11	22	20	26
	74	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	1	1	1	0	0
				02.GUILT	3	3	1	1	1	0	1	0
				03.SUICIDE	0	0	0	1	0	0	0	0
				04.INSOMNIA EARLY	1	2	1	1	1	1	0	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	0
				06.INSOMNIA LATE	1	1	1	1	1	1	1	0
				07.WORK AND ACTIVITIES	2	3	2	1	1	1	0	2
				08.RETARDATION	2	2	1	0	0	0	1	0
				09.AGITATION	1	1	1	1	0	0	0	0
				10.ANXIETY PSYCHIC	3	1	1	1	0	0	0	1
				11.ANXIETY SOMATIC	2	1	1	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	0	1	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	2	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	16	12	7	5	4	4
	75	Imipramine	Male	01.DEPRESSED MOOD	3	3	2	1	1	0	0	0
				02.GUILT	2	2	2	2	0	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	2	1	1	0	0
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	1	1
				06.INSOMNIA LATE	1	2	1	0	1	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	1	1	1	0	0
				08.RETARDATION	2	2	2	0	0	0	0	0

1113

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/5	75	Imipramine	Male	09.AGITATION	3	2	2	1	2	2	0	0
				10.ANXIETY PSYCHIC	3	2	2	1	2	1	0	0
				11.ANXIETY SOMATIC	1	1	2	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	0	0	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	0	0	0	1	0
				15.HYPOCHONDRIASIS	1	2	1	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	19	11	9	6	2	1
	76	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	1	3	1	1	0
				02.GUILT	3	2	2	1	2	2	1	0
				03.SUICIDE	0	1	1	0	1	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	0	0	1	0
				05.INSOMNIA MIDDLE	2	1	1	1	0	1	0	0
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	1	3	2	1	1
				08.RETARDATION	0	2	2	0	1	0	0	0
				09.AGITATION	4	2	2	1	0	0	1	0
				10.ANXIETY PSYCHIC	3	2	2	1	2	1	0	0
				11.ANXIETY SOMATIC	3	1	1	0	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	1	0	0	0	0	1
				13.SOMATIC GENERAL	2	1	1	0	2	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	0	0
				15.HYPOCHONDRIASIS	1	3	2	1	2	0	0	0
				16.LOSS OF WEIGHT	1	0	0	0	0	0	0	0
				17.INSIGHT	0	0	1	0	0	0	0	0
				18.DIURNAL VARIATION	0	1	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	26	25	11	19	9	5	2
	77	Placebo	Male	01.DEPRESSED MOOD	4	3	1	2	1	0	0	0
				02.GUILT	3	3	1	1	1	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	1	0	1	0	1	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	0	1	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	1	1	1	1	0
				08.RETARDATION	3	2	1	1	1	1	0	0
				09.AGITATION	2	2	2	1	0	0	0	0
				10.ANXIETY PSYCHIC	3	2	1	1	0	1	1	1
				11.ANXIETY SOMATIC	2	2	1	0	0	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/5	77	Placebo	Male	13.SOMATIC GENERAL	1	1	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	1	0	1	0	0	0
				15.HYPOCHONDRIASIS	3	2	2	1	2	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	24	13	10	8	5	2	1
	78	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	2	1	1	
				02.GUILT	2	2	3	2	0	1	1	
				03.SUICIDE	0	0	0	0	0	0	0	
				04.INSOMNIA EARLY	0	1	1	1	1	1	1	
				05.INSOMNIA MIDDLE	0	0	1	1	1	1	0	
				06.INSOMNIA LATE	2	1	1	1	1	0	0	
				07.WORK AND ACTIVITIES	3	3	3	2	0	2	1	
				08.RETARDATION	3	1	2	2	1	0	0	
				09.AGITATION	3	2	1	1	1	1	1	
				10.ANXIETY PSYCHIC	2	2	1	2	1	2	0	
				11.ANXIETY SOMATIC	2	2	2	1	0	0	0	
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	
				13.SOMATIC GENERAL	1	1	1	0	0	0	0	
				14.GENITAL SYMPTOMS	2	2	1	1	0	0	0	
				15.HYPOCHONDRIASIS	3	2	0	0	0	0	0	
				16.LOSS OF WEIGHT	0	0	0	0	0	1	0	
				17.INSIGHT	1	2	0	0	0	0	0	
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	
				20.PARANOID	0	0	0	0	0	0	0	
				21.OBSESSIONAL/COMPULSIVE	1	2	0	0	0	0	0	
				22.Total score	29	27	20	16	8	10	5	
2/6	55	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	1	0	0	0
				02.GUILT	1	1	1	0	0	0	0	0
				03.SUICIDE	2	2	2	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	0
				06.INSOMNIA LATE	2	2	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	1	1	1	1
				08.RETARDATION	2	2	2	1	1	0	0	0
				09.AGITATION	2	2	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	1	1	1	0	0	0
				11.ANXIETY SOMATIC	3	3	3	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	1	0	0
				15.HYPOCHONDRIASIS	3	3	3	2	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0

1115

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/6	55	Reboxetine	Female	17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	32	32	27	17	9	4	3	3
	56	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	2	2	2	3
				02.GUILT	2	2	2	2	2	2	1	1
				03.SUICIDE	3	3	3	2	2	1	1	2
				04.INSOMNIA EARLY	1	1	0	0	0	0	0	1
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	1	1	0	0	0	0	0	1
				07.WORK AND ACTIVITIES	3	3	3	3	3	2	3	3
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	1	1	1	1	1	1	1	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	2
				11.ANXIETY SOMATIC	3	3	3	3	3	1	1	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	2	2	1
				14.GENITAL SYMPTOMS	0	0	0	1	1	1	1	0
				15.HYPOCHONDRIASIS	3	3	3	3	3	2	1	2
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	1
				22.Total score	29	29	25	24	24	19	18	23
	57	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	0	0	0	0
				02.GUILT	1	1	0	0	0	0	0	0
				03.SUICIDE	2	2	2	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	0	0	1	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	2	2	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	1	1	0	1
				08.RETARDATION	2	2	2	1	1	0	0	0
				09.AGITATION	2	2	2	1	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	1	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	2	1	1	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/6	57	Imipramine	Female	21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	30	30	25	15	5	4	1	2
	58	Placebo	Female	01.DEPRESSED MOOD	3	3	3	2	0	0	0	0
				02.GUILT	1	1	1	1	0	0	0	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	2	1	1	1
				08.RETARDATION	2	2	1	1	1	0	0	0
				09.AGITATION	0	0	0	1	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	0	0	0	0
				11.ANXIETY SOMATIC	3	3	3	3	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	1	0	0	0
				15.HYPOCHONDRIASIS	3	3	3	3	1	0	0	0
				16.LOSS OF WEIGHT	2	2	2	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	25	22	6	1	1	1
	59	Placebo	Male	01.DEPRESSED MOOD	3	3	3	3	3	2		
				02.GUILT	1	1	1	1	1	1		
				03.SUICIDE	3	3	3	3	2	3		
				04.INSOMNIA EARLY	2	2	1	0	0	1		
				05.INSOMNIA MIDDLE	1	1	1	1	0	1		
				06.INSOMNIA LATE	1	1	0	0	0	0		
				07.WORK AND ACTIVITIES	3	3	3	3	3	3		
				08.RETARDATION	2	2	2	2	2	1		
				09.AGITATION	0	0	0	0	0	1		
				10.ANXIETY PSYCHIC	3	3	2	2	2	1		
				11.ANXIETY SOMATIC	1	1	1	1	2	1		
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1		
				13.SOMATIC GENERAL	1	1	1	1	1	1		
				14.GENITAL SYMPTOMS	2	2	2	2	2	2		
				15.HYPOCHONDRIASIS	2	2	2	2	1	2		
				16.LOSS OF WEIGHT	1	1	0	0	0	0		
				17.INSIGHT	1	1	1	1	1	1		
				18.DIURNAL VARIATION	1	1	1	1	2	1		
				19.DEPERSONALIZATION	0	0	0	0	0	0		
				20.PARANOID	0	0	0	0	0	0		
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1		
				22.Total score	30	30	26	25	24	24		

1117

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/6	60	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	1	0	0	0	0
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	1	1	1	1	1	1
				08.RETARDATION	2	2	2	1	0	0	0	0
				09.AGITATION	2	2	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	1	0	0	0	0
				11.ANXIETY SOMATIC	1	1	2	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	1
				15.HYPOCHONDRIASIS	2	2	2	1	1	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	1	1	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	0	0
				22.Total score	28	28	26	13	4	3	2	2
3/1	61	Imipramine	Male	01.DEPRESSED MOOD	2	2	2	2	1	1	1	
				02.GUILT	2	2	2	1	0	0	0	
				03.SUICIDE	2	2	2	1	0	0	0	
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	
				05.INSOMNIA MIDDLE	1	1	1	1	0	0	0	
				06.INSOMNIA LATE	0	0	0	0	0	0	0	
				07.WORK AND ACTIVITIES	3	3	4	4	2	1	1	
				08.RETARDATION	2	2	2	1	1	1	1	
				09.AGITATION	0	0	0	0	0	0	0	
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	
				11.ANXIETY SOMATIC	2	2	2	2	1	0	0	
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	
				15.HYPOCHONDRIASIS	1	1	2	2	1	1	1	
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	
				17.INSIGHT	0	0	0	0	0	0	0	
				18.DIURNAL VARIATION	1	1	1	1	1	0	0	
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	
				20.PARANOID	0	0	0	0	0	0	0	
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	
				22.Total score	24	24	24	20	11	7	7	
	62	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	1	1	1	1	1
				02.GUILT	2	2	1	1	1	1	0	0
				03.SUICIDE	2	2	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/1	62	Imipramine	Female	05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	1	1	0	1	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	3	2	1	1	0	0
				08.RETARDATION	1	1	1	1	1	1	0	0
				09.AGITATION	2	2	0	1	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	1	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	1	0	0	0	1	1
				13.SOMATIC GENERAL	1	1	1	0	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	1	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	16	12	8	7	5	5
	63	Placebo	Male	01.DEPRESSED MOOD	3	3	3	2	2	1	1	1
				02.GUILT	2	2	2	2	2	1	1	1
				03.SUICIDE	3	2	2	1	1	1	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	1	1
				05.INSOMNIA MIDDLE	1	2	2	1	1	0	0	1
				06.INSOMNIA LATE	1	1	1	1	1	1	0	0
				07.WORK AND ACTIVITIES	4	4	4	3	3	1	1	0
				08.RETARDATION	2	1	1	1	1	1	1	1
				09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	2	1	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	1	1	1	1	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	26	26	21	21	13	10	10
	64	Placebo	Female	01.DEPRESSED MOOD	3	3	2	3	3	3	3	3
				02.GUILT	2	2	2	2	2	2	2	2
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	0	0	0	1	1
				05.INSOMNIA MIDDLE	1	2	1	0	0	0	0	0
				06.INSOMNIA LATE	0	1	1	0	0	0	1	0
				07.WORK AND ACTIVITIES	3	3	3	4	4	4	4	4
				08.RETARDATION	1	1	1	2	2	2	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/1	64	Placebo	Female	09.AGITATION	2	2	2	1	1	1	1	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	1	1	1	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	1	1	1	3	3	3	2	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	28	24	26	26	26	26	24
	65	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	2	1	1	1	1
				02.GUILT	2	2	2	1	1	1	0	0
				03.SUICIDE	3	3	2	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	0	0	0
				06.INSOMNIA LATE	1	1	0	1	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	2	2	1	1	1	1
				08.RETARDATION	2	2	1	1	1	1	1	1
				09.AGITATION	1	1	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	2	2	2	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	2	1	1	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	0	0
				14.GENITAL SYMPTOMS	2	1	1	1	0	1	1	1
				15.HYPOCHONDRIASIS	2	2	1	2	1	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	31	31	21	19	12	11	8	8
	66	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	1	1	1	1	1
				02.GUILT	2	2	2	1	1	1	1	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	0	1	1
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	2	2	2	2
				08.RETARDATION	2	2	2	1	1	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	2	2	2	1	0	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	1	1	1	0	1	1

1120

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/1	66	Reboxetine	Male	13.SOMATIC GENERAL	2	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	27	23	15	14	9	11	10
	139	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3				
				02.GUILT	2	2	2	3				
				03.SUICIDE	2	2	3	3				
				04.INSOMNIA EARLY	1	1	1	2				
				05.INSOMNIA MIDDLE	0	0	0	2				
				06.INSOMNIA LATE	1	2	2	2				
				07.WORK AND ACTIVITIES	2	2	2	4				
				08.RETARDATION	2	2	2	3				
				09.AGITATION	0	0	1	3				
				10.ANXIETY PSYCHIC	3	3	3	3				
				11.ANXIETY SOMATIC	1	1	1	1				
				12.SOMATIC GASTROINTESTINAL	1	1	1	1				
				13.SOMATIC GENERAL	1	1	1	1				
				14.GENITAL SYMPTOMS	1	1	1	2				
				15.HYPOCHONDRIASIS	1	1	1	1				
				16.LOSS OF WEIGHT	0	0	0	0				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	2	2	2	0				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	1				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	23	24	26	35				
	140	Placebo	Male	01.DEPRESSED MOOD	2	2	2	1	1	1	1	1
				02.GUILT	1	1	1	1	1	1	1	0
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	1	0	0	0	0
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	1	1	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	1	1
				13.SOMATIC GENERAL	2	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	0
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	1	1
				16.LOSS OF WEIGHT	2	2	1	0	0	0	0	0

1121

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/1	140	Placebo	Male	17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	25	15	11	10	9	6
	141	Placebo	Female	01.DEPRESSED MOOD	2	2	2	1	1	1	1	1
				02.GUILT	2	2	2	1	1	1	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	0	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	0	0	0	1
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	2	2	2	1	0	1	1	0
				09.AGITATION	2	2	3	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	2	2	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	1	1	0
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	0	1
				16.LOSS OF WEIGHT	0	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	25	24	17	9	12	9	9
	142	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2	2			
				02.GUILT	2	2	2	2	2			
				03.SUICIDE	2	2	2	2	2			
				04.INSOMNIA EARLY	2	2	2	2	2			
				05.INSOMNIA MIDDLE	2	2	2	2	2			
				06.INSOMNIA LATE	2	2	2	2	2			
				07.WORK AND ACTIVITIES	4	4	4	4	4			
				08.RETARDATION	2	2	2	2	2			
				09.AGITATION	2	2	2	2	2			
				10.ANXIETY PSYCHIC	3	3	3	3	3			
				11.ANXIETY SOMATIC	2	2	2	2	2			
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1			
				13.SOMATIC GENERAL	1	1	1	1	1			
				14.GENITAL SYMPTOMS	1	1	1	1	1			
				15.HYPOCHONDRIASIS	2	2	1	1	1			
				16.LOSS OF WEIGHT	1	0	0	0	0			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	0	0	0	0	0			
				19.DEPERSONALIZATION	0	0	0	0	0			
				20.PARANOID	0	0	0	0	0			

1122

9550082

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/1	142	Imipramine	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	31	30	29	29	29			
	143	Reboxetine	Female	01.DEPRESSED MOOD	3	3	1		1	1	1	
				02.GUILT	1	2	2		1	1	1	
				03.SUICIDE	3	3	1		0	0	0	
				04.INSOMNIA EARLY	0	0	0		0	0	0	
				05.INSOMNIA MIDDLE	1	1	1		1	1	1	
				06.INSOMNIA LATE	0	0	0		0	0	0	
				07.WORK AND ACTIVITIES	3	3	2		1	1	1	
				08.RETARDATION	1	1	0		0	0	0	
				09.AGITATION	1	1	1		1	1	0	
				10.ANXIETY PSYCHIC	2	2	2		1	1	1	
				11.ANXIETY SOMATIC	1	1	1		1	1	2	
				12.SOMATIC GASTROINTESTINAL	1	1	1		1	1	1	
				13.SOMATIC GENERAL	2	2	2		1	1	1	
				14.GENITAL SYMPTOMS	2	2	1		1	1	1	
				15.HYPOCHONDRIASIS	1	1	1		0	0	0	
				16.LOSS OF WEIGHT	0	0	0		0	0	0	
				17.INSIGHT	0	0	0		0	0	0	
				18.DIURNAL VARIATION	1	1	1		1	1	1	
				19.DEPERSONALIZATION	0	0	0		0	0	0	
				20.PARANOID	0	0	0		0	0	0	
				21.OBSESSIONAL/COMPULSIVE	0	0	0		0	0	0	
				22.Total score	23	24	17		11	11	11	
	144	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	1		0	0	0
				02.GUILT	2	2	2	1		1	1	1
				03.SUICIDE	2	2	2	0		0	0	0
				04.INSOMNIA EARLY	2	2	2	2		1	1	0
				05.INSOMNIA MIDDLE	2	2	2	0		0	0	0
				06.INSOMNIA LATE	1	0	2	0		0	0	0
				07.WORK AND ACTIVITIES	2	2	2	1		1	0	0
				08.RETARDATION	2	2	2	1		1	1	1
				09.AGITATION	0	0	1	1		1	1	1
				10.ANXIETY PSYCHIC	3	3	3	3		2	1	1
				11.ANXIETY SOMATIC	1	1	1	1		2	2	2
				12.SOMATIC GASTROINTESTINAL	0	0	0	0		0	0	0
				13.SOMATIC GENERAL	1	1	1	1		1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1		1	1	1
				15.HYPOCHONDRIASIS	0	0	2	1		2	1	1
				16.LOSS OF WEIGHT	2	2	0	0		0	0	0
				17.INSIGHT	0	0	0	0		0	0	0
				18.DIURNAL VARIATION	0	0	0	0		0	0	0
				19.DEPERSONALIZATION	0	0	0	0		0	0	0
				20.PARANOID	0	0	0	0		0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0		0	0	0
				22.Total score	24	23	26	14		13	10	9

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/1	451	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3				
				02.GUILT	2	2	2	2				
				03.SUICIDE	1	1	0	0				
				04.INSOMNIA EARLY	1	1	1	1				
				05.INSOMNIA MIDDLE	1	2	2	2				
				06.INSOMNIA LATE	2	2	2	2				
				07.WORK AND ACTIVITIES	3	3	2	3				
				08.RETARDATION	2	2	2	3				
				09.AGITATION	0	0	0	0				
				10.ANXIETY PSYCHIC	2	2	2	2				
				11.ANXIETY SOMATIC	2	2	2	2				
				12.SOMATIC GASTROINTESTINAL	1	1	1	2				
				13.SOMATIC GENERAL	2	2	2	2				
				14.GENITAL SYMPTOMS	2	2	2	2				
				15.HYPOCHONDRIASIS	1	1	1	1				
				16.LOSS OF WEIGHT	0	0	0	0				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	0	0	0	0				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	25	26	24	27				
	452	Placebo	Male	01.DEPRESSED MOOD	3	3	3	1	0	0	1	1
				02.GUILT	1	1	1	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	2	0	0	0	1	0
				08.RETARDATION	2	2	1	1	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	1	1
				10.ANXIETY PSYCHIC	2	2	2	1	0	0	2	1
				11.ANXIETY SOMATIC	2	1	1	0	0	0	2	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	1	0
				13.SOMATIC GENERAL	2	2	1	0	0	0	1	1
				14.GENITAL SYMPTOMS	2	2	1	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	0	0	1	1
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	25	15	6	2	1	11	6
	453	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	2	1	1		1
				02.GUILT	2	1	0	0	0	0		0
				03.SUICIDE	0	0	0	0	0	0		0
				04.INSOMNIA EARLY	1	1	1	1	1	1		1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/1	453	Imipramine	Female	05.INSOMNIA MIDDLE	1	1	1	0	0	0		0
				06.INSOMNIA LATE	1	1	1	1	0	0		0
				07.WORK AND ACTIVITIES	3	3	2	2	1	1		1
				08.RETARDATION	2	2	1	1	0	0		0
				09.AGITATION	0	0	0	0	0	0		0
				10.ANXIETY PSYCHIC	3	3	2	2	1	0		1
				11.ANXIETY SOMATIC	2	2	1	1	0	0		0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1		1
				13.SOMATIC GENERAL	2	2	1	1	1	1		1
				14.GENITAL SYMPTOMS	1	2	2	2	2	2		2
				15.HYPOCHONDRIASIS	1	1	1	1	1	1		1
				16.LOSS OF WEIGHT	0	0	0	0	0	0		0
				17.INSIGHT	0	0	0	0	0	0		0
				18.DIURNAL VARIATION	1	1	1	1	1	1		1
				19.DEPERSONALIZATION	0	0	0	0	0	0		0
				20.PARANOID	0	0	0	0	0	0		0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		0
				22.Total score	24	24	17	16	10	9		10
	454	Reboxetine	Male	01.DEPRESSED MOOD	2	2	1	1	0	0	1	0
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	1	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	2	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	0	0	0	1
				07.WORK AND ACTIVITIES	3	3	2	2	1	1	1	0
				08.RETARDATION	2	2	1	1	0	0	0	0
				09.AGITATION	1	1	1	1	1	0	0	0
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	0	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	0	0	0	0	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	2	2	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	24	13	12	8	7	9	8
	455	Placebo	Female	01.DEPRESSED MOOD	3	3	3	2	2	2	2	2
				02.GUILT	2	1	2	2	1	1	1	1
				03.SUICIDE	2	2	2	1	1	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	0	0	0	0	1	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	4	4	3	3	3	2
				08.RETARDATION	3	3	2	2	1	2	2	1

1125

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/1	455	Placebo	Female	09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	2	2	3	2	2
				11.ANXIETY SOMATIC	0	0	0	0	0	2	3	3
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	1
				15.HYPOCHONDRIASIS	1	1	1	1	0	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	24	24	21	17	18	18	15
	456	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	2				
				02.GUILT	2	2	1	1				
				03.SUICIDE	1	1	0	0				
				04.INSOMNIA EARLY	2	2	1	0				
				05.INSOMNIA MIDDLE	1	1	1	0				
				06.INSOMNIA LATE	1	1	1	0				
				07.WORK AND ACTIVITIES	4	4	3	3				
				08.RETARDATION	2	2	2	2				
				09.AGITATION	0	0	1	1				
				10.ANXIETY PSYCHIC	2	2	2	2				
				11.ANXIETY SOMATIC	2	2	1	4				
				12.SOMATIC GASTROINTESTINAL	0	0	0	0				
				13.SOMATIC GENERAL	1	1	1	2				
				14.GENITAL SYMPTOMS	2	2	2	2				
				15.HYPOCHONDRIASIS	0	1	0	0				
				16.LOSS OF WEIGHT	1	0	0	0				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	0	0	0	0				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	24	24	18	19				
3/2	65/A	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	2	2	3	2	2
				02.GUILT	3	2	2	2	2	2	2	2
				03.SUICIDE	3	3	2	1	2	2	2	2
				04.INSOMNIA EARLY	2	1	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	0	2	2	1	1	1	1
				06.INSOMNIA LATE	1	0	1	1	0	0	1	1
				07.WORK AND ACTIVITIES	2	2	2	1	2	2	2	2
				08.RETARDATION	1	2	1	1	2	2	1	1
				09.AGITATION	2	1	2	1	1	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	2	3	1	2	2
				11.ANXIETY SOMATIC	3	2	2	1	1	1	0	1
				12.SOMATIC GASTROINTESTINAL	0	0	1	0	0	0	1	0

1126

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/2	65/A	Reboxetine	Female	13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	2	1
				15.HYPOCHONDRIASIS	2	3	2	1	0	0	1	1
				16.LOSS OF WEIGHT	0	0	2	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	2	1	0	1	1	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	25	27	17	19	17	19	18
3/3	67	Placebo	Male	01.DEPRESSED MOOD	3	3	3	3	1	2	2	2
				02.GUILT	1	1	1	1	1	0	0	1
				03.SUICIDE	3	2	1	3	0	0	0	0
				04.INSOMNIA EARLY	2	2	0	2	2	2	2	2
				05.INSOMNIA MIDDLE	1	1	0	1	0	0	0	0
				06.INSOMNIA LATE	0	1	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	4	4	4	2	2	1
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	2	3	3	2	1	0	2
				11.ANXIETY SOMATIC	2	2	1	1	0	1	0	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	0	1	0	0
				16.LOSS OF WEIGHT	1	0	1	0	0	2	0	0
				17.INSIGHT	1	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	2	1	0	0	1
				19.DEPERSONALIZATION	1	1	0	1	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	25	19	25	13	13	7	11
	68	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	1	0	0	0	0
				02.GUILT	3	3	2	2	0	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	4	3	1	1	0	0	0
				08.RETARDATION	3	3	2	2	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	1	2	1	1	0	0	0	0
				11.ANXIETY SOMATIC	2	2	2	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	0	0	1	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0

1127

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/3	68	Reboxetine	Male	17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	15	9	3	1	0	0
	69	Placebo	Male	01.DEPRESSED MOOD	4	3	3	2	1	4	2	2
				02.GUILT	2	2	3	3	2	3	2	2
				03.SUICIDE	2	1	2	1	0	2	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	2	1	1
				05.INSOMNIA MIDDLE	1	0	1	1	0	1	0	0
				06.INSOMNIA LATE	1	0	0	0	0	1	0	0
				07.WORK AND ACTIVITIES	4	4	4	2	1	4	1	1
				08.RETARDATION	2	2	3	2	1	2	2	2
				09.AGITATION	2	2	4	2	1	3	2	1
				10.ANXIETY PSYCHIC	3	3	3	1	1	3	1	1
				11.ANXIETY SOMATIC	3	3	3	2	2	2	1	1
				12.SOMATIC GASTROINTESTINAL	1	0	0	1	1	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	1	2	0	0	1	0	0
				16.LOSS OF WEIGHT	1	0	0	1	0	0	0	0
				17.INSIGHT	0	0	0	1	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	0	2	0	0	1	0	0
				20.PARANOID	0	0	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	33	25	34	21	12	31	12	11
	70	Imipramine	Male	01.DEPRESSED MOOD	4	3	3	2	1	1	1	1
				02.GUILT	2	2	2	2	1	1	0	0
				03.SUICIDE	2	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	0	0	0	1	0	0
				05.INSOMNIA MIDDLE	2	2	1	0	0	0	0	0
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	3	2	1	1	0	0	0	0
				08.RETARDATION	2	2	1	1	0	1	1	1
				09.AGITATION	2	2	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	2	1	1	1	2	1	1
				11.ANXIETY SOMATIC	3	3	2	1	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	1	1	0	0	1	1
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	3	2	1	1	1	1	0	0
				16.LOSS OF WEIGHT	1	2	1	0	1	0	0	0
				17.INSIGHT	1	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

1128

9550082

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/3	70	Imipramine	Male	21.OBSESSIONAL/COMPULSIVE	1	1	1	1	0	1	0	0
				22.Total score	36	31	21	15	10	13	8	8
	71	Imipramine	Female	01.DEPRESSED MOOD	4	3	2	1	1	1	1	1
				02.GUILT	3	3	2	2	2	2	2	1
				03.SUICIDE	2	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	1	1	0	0
				08.RETARDATION	2	2	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	0	0	0	0
				10.ANXIETY PSYCHIC	3	2	2	1	1	1	0	0
				11.ANXIETY SOMATIC	2	2	2	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	26	23	17	12	8	7	5	4
	72	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	1	1	1	1	1
				02.GUILT	3	2	2	2	2	2	1	1
				03.SUICIDE	2	1	1	0	0	0	0	1
				04.INSOMNIA EARLY	2	2	1	0	0	1	0	1
				05.INSOMNIA MIDDLE	1	0	0	0	0	0	0	1
				06.INSOMNIA LATE	1	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	1	0	0	0	0	1
				08.RETARDATION	1	1	1	1	1	1	1	0
				09.AGITATION	2	1	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	1	2	1	1	1	2	1	1
				11.ANXIETY SOMATIC	2	1	0	1	1	0	0	1
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	0	0	0	0	0	1
				14.GENITAL SYMPTOMS	2	1	0	1	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	0	1	1	0	0	0
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	2
				17.INSIGHT	1	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	1	0	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	0	0	0	0
				22.Total score	31	22	13	10	7	8	5	12

1129

9550082

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/4	79	Imipramine	Female	01.DEPRESSED MOOD	4	4	2	2	1	0	0	0
				02.GUILT	1	1	1	1	1	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	2	1	0	0	0
				08.RETARDATION	2	2	2	1	1	0	0	0
				09.AGITATION	1	1	0	0	1	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	2	2	1	0	0
				11.ANXIETY SOMATIC	2	2	2	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	1	1
				16.LOSS OF WEIGHT	2	2	3	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	24	20	13	4	3	3
	80	Imipramine	Male	01.DEPRESSED MOOD	2	2	2	2	1			
				02.GUILT	1	1	1	1	1			
				03.SUICIDE	3	3	3	0	0			
				04.INSOMNIA EARLY	1	1	1	1	1			
				05.INSOMNIA MIDDLE	1	1	0	0	0			
				06.INSOMNIA LATE	1	1	1	1	1			
				07.WORK AND ACTIVITIES	2	2	2	1	1			
				08.RETARDATION	2	2	2	1	1			
				09.AGITATION	0	0	0	0	0			
				10.ANXIETY PSYCHIC	3	3	3	2	1			
				11.ANXIETY SOMATIC	2	2	2	2	1			
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0			
				13.SOMATIC GENERAL	1	1	1	1	1			
				14.GENITAL SYMPTOMS	0	0	0	0	0			
				15.HYPOCHONDRIASIS	1	1	0	0	1			
				16.LOSS OF WEIGHT	0	1	0	0	0			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	1	2	2	2	0			
				19.DEPERSONALIZATION	0	0	0	0	0			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	22	24	21	14	10			
	81	Reboxetine	Female	01.DEPRESSED MOOD	3	3	1	1	1	1	1	1
				02.GUILT	2	2	1	0	0	1	1	1
				03.SUICIDE	3	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	0

1130

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/4	81	Reboxetine	Female	05.INSOMNIA MIDDLE	1	2	0	0	0	0	0	0
				06.INSOMNIA LATE	2	2	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	2	1	0	1	1	0
				08.RETARDATION	2	2	1	0	0	1	1	0
				09.AGITATION	0	1	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	0	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	11	4	2	5	5	3
1131	82	Placebo	Male	01.DEPRESSED MOOD	2	2	2	1	1	1	1	1
				02.GUILT	2	2	2	2	1	1	1	1
				03.SUICIDE	2	2	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	0	0	1	1
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	1	1	1	1	1	1	1	1
				08.RETARDATION	2	2	1	1	1	1	1	1
				09.AGITATION	2	2	2	1	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	1	1	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	19	13	9	8	9	9
	83	Placebo	Male	01.DEPRESSED MOOD	3	3	3					
				02.GUILT	2	2	2					
				03.SUICIDE	1	1	2					
				04.INSOMNIA EARLY	0	0	1					
				05.INSOMNIA MIDDLE	1	1	2					
				06.INSOMNIA LATE	2	2	2					
				07.WORK AND ACTIVITIES	2	2	2					
				[illegible]	1	1	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/4	83	Placebo	Male	09.AGITATION	2	2	2					
				10.ANXIETY PSYCHIC	2	2	2					
				11.ANXIETY SOMATIC	2	2	3					
				12.SOMATIC GASTROINTESTINAL	0	0	1					
				13.SOMATIC GENERAL	1	1	2					
				14.GENITAL SYMPTOMS	1	1	1					
				15.HYPOCHONDRIASIS	2	2	2					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	1	1	2					
				19.DEPERSONALIZATION	0	0	1					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	23	23	31					
	84	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	1	1	1	1	1
				02.GUILT	1	1	1	1	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	1	1	1	1	0	0
				08.RETARDATION	2	2	2	1	0	0	0	0
				09.AGITATION	1	1	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	0	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	1	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	15	7	3	3	2	2
	85	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	2	2	2	1	1
				02.GUILT	2	2	2	2	1	1	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	0	0	2	1	0
				05.INSOMNIA MIDDLE	1	1	1	0	0	1	1	0
				06.INSOMNIA LATE	1	1	1	0	0	1	0	0
				07.WORK AND ACTIVITIES	4	4	3	2	1	1	1	1
				08.RETARDATION	1	1	1	1	1	1	1	0
				09.AGITATION	2	2	1	0	0	2	1	0
				10.ANXIETY PSYCHIC	3	3	2	1	1	2	1	1
				11.ANXIETY SOMATIC	1	1	1	1	2	2	1	0
				12.SOMATIC GASTROINTESTINAL	2	2	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/4	85	Imipramine	Female	13.SOMATIC GENERAL	2	2	2	1	1	1	1	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	27	20	11	10	17	10	4
	86	Imipramine	Male	01.DEPRESSED MOOD	4	4	2	1	1	1	1	1
				02.GUILT	1	1	1	1	0	0	0	0
				03.SUICIDE	3	3	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	1	1	0	0	0
				08.RETARDATION	2	2	2	1	1	1	1	1
				09.AGITATION	1	1	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	0	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	28	28	19	9	6	4	5	5
	87	Placebo	Female	01.DEPRESSED MOOD	3	3	3	2	2	3	2	2
				02.GUILT	2	2	2	2	2	2	2	1
				03.SUICIDE	3	3	2	1	1	3	1	0
				04.INSOMNIA EARLY	1	1	1	1	0	2	1	0
				05.INSOMNIA MIDDLE	2	2	1	0	0	1	0	0
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	1	1	1	3	1	1
				08.RETARDATION	1	1	1	1	0	1	1	1
				09.AGITATION	1	1	1	1	1	2	1	1
				10.ANXIETY PSYCHIC	3	3	3	2	2	3	2	2
				11.ANXIETY SOMATIC	1	1	1	1	1	2	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	2	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	1	1	0

1133

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/4	87	Placebo	Female	17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	21	15	12	27	16	12
	88	Placebo	Male	01.DEPRESSED MOOD	2	2	1	1	1	1	1	1
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	1	1	1	1	1	1
				08.RETARDATION	2	2	2	1	1	0	0	0
				09.AGITATION	1	1	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	0	0
				15.HYPOCHONDRIASIS	3	3	3	2	2	2	2	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	2	2	2	2	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	0	0	0	0
				22.Total score	25	26	19	14	11	8	7	6
	89	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	2	2	1	1
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	0	0	2	2	2	1
				06.INSOMNIA LATE	2	2	2	2	2	2	1	1
				07.WORK AND ACTIVITIES	0	3	2	2	1	1	1	1
				08.RETARDATION	2	2	2	2	1	1	1	0
				09.AGITATION	1	1	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	2	2	2	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	2	2	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	2	2	1	0	1	1	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

1134

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/4	89	Reboxetine	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	28	22	20	19	18	12	10
	90	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	3	3	2	1	1
				02.GUILT	2	2	2	2	2	1	0	0
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	0	1	1	1
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	0	0
				08.RETARDATION	1	1	1	1	1	0	0	0
				09.AGITATION	2	2	2	2	1	1	0	0
				10.ANXIETY PSYCHIC	3	3	3	2	2	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	1	1	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	0	0
				22.Total score	24	24	24	16	13	9	3	3
	457	Placebo	Female	01.DEPRESSED MOOD	3	2	3	3	3			
				02.GUILT	1	1	2	1	2			
				03.SUICIDE	2	2	2	2	2			
				04.INSOMNIA EARLY	2	2	2	2	2			
				05.INSOMNIA MIDDLE	1	1	1	1	1			
				06.INSOMNIA LATE	2	2	2	2	2			
				07.WORK AND ACTIVITIES	4	4	4	3	3			
				08.RETARDATION	2	2	2	2	2			
				09.AGITATION	1	1	1	1	1			
				10.ANXIETY PSYCHIC	2	2	2	2	2			
				11.ANXIETY SOMATIC	2	2	2	2	2			
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1			
				13.SOMATIC GENERAL	1	1	1	1	1			
				14.GENITAL SYMPTOMS	2	2	2	2	2			
				15.HYPOCHONDRIASIS	2	2	2	2	2			
				16.LOSS OF WEIGHT	0	0	1	0	0			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	0	0	0	0	0			
				19.DEPERSONALIZATION	0	0	0	0	0			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	28	27	30	27	28			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/4	458	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	3				
				02.GUILT	2	2	2	2				
				03.SUICIDE	1	1	1	3				
				04.INSOMNIA EARLY	1	1	1	1				
				05.INSOMNIA MIDDLE	0	0	1	1				
				06.INSOMNIA LATE	1	1	1	1				
				07.WORK AND ACTIVITIES	3	2	3	3				
				08.RETARDATION	1	1	1	1				
				09.AGITATION	1	1	1	2				
				10.ANXIETY PSYCHIC	3	3	3	3				
				11.ANXIETY SOMATIC	4	4	4	4				
				12.SOMATIC GASTROINTESTINAL	1	1	2	2				
				13.SOMATIC GENERAL	2	2	2	2				
				14.GENITAL SYMPTOMS	2	2	2	2				
				15.HYPOCHONDRIASIS	3	3	3	3				
				16.LOSS OF WEIGHT	0	0	0	0				
				17.INSIGHT	1	1	0	0				
				18.DIURNAL VARIATION	0	0	0	0				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	28	27	29	33				
	459	Placebo	Female	01.DEPRESSED MOOD	3	3	2	2	1	1	1	1
				02.GUILT	1	1	1	1	1	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	0	0	1	0	0	0
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	1	1
				08.RETARDATION	2	2	1	1	1	1	1	0
				09.AGITATION	2	2	2	2	2	1	1	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	1	1
				11.ANXIETY SOMATIC	3	3	2	2	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	1
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	19	18	16	11	11	8
	460	Reboxetine	Male	01.DEPRESSED MOOD	1	1	1					
				02.GUILT	0	0	0					
				03.SUICIDE	0	0	0					
				04.INSOMNIA EARLY	2	2	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/4	460	Reboxetine	Male	05.INSOMNIA MIDDLE	2	2	2					
				06.INSOMNIA LATE	2	2	2					
				07.WORK AND ACTIVITIES	2	2	2					
				08.RETARDATION	2	2	1					
				09.AGITATION	2	2	2					
				10.ANXIETY PSYCHIC	2	2	2					
				11.ANXIETY SOMATIC	3	3	3					
				12.SOMATIC GASTROINTESTINAL	2	2	2					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	1	1	1					
				15.HYPOCHONDRIASIS	1	1	1					
				16.LOSS OF WEIGHT	2	2	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	1	1	1					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	27	27	23					
1137	461	Imipramine	Female	01.DEPRESSED MOOD	3	3	2					
				02.GUILT	1	1	1					
				03.SUICIDE	0	0	0					
				04.INSOMNIA EARLY	2	2	2					
				05.INSOMNIA MIDDLE	1	1	1					
				06.INSOMNIA LATE	2	2	2					
				07.WORK AND ACTIVITIES	2	2	1					
				08.RETARDATION	1	1	1					
				09.AGITATION	1	1	1					
				10.ANXIETY PSYCHIC	2	2	2					
				11.ANXIETY SOMATIC	1	1	3					
				12.SOMATIC GASTROINTESTINAL	1	1	1					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	2	2	2					
				15.HYPOCHONDRIASIS	2	2	1					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	1	1	1					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	24	24	23					
	462	Imipramine	Female	01.DEPRESSED MOOD	3	3	2					
				02.GUILT	1	1	0					
				03.SUICIDE	0	0	0					
				04.INSOMNIA EARLY	1	1	2					
				05.INSOMNIA MIDDLE	1	1	1					
				06.INSOMNIA LATE	2	2	1					
				07.WORK AND ACTIVITIES	2	2	1					
				08.RETARDATION	2	2	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/4	462	Imipramine	Female	09.AGITATION	1	1	1					
				10.ANXIETY PSYCHIC	3	3	2					
				11.ANXIETY SOMATIC	1	1	1					
				12.SOMATIC GASTROINTESTINAL	1	1	1					
				13.SOMATIC GENERAL	1	1	2					
				14.GENITAL SYMPTOMS	1	1	0					
				15.HYPOCHONDRIASIS	0	0	0					
				16.LOSS OF WEIGHT	1	1	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	1	1	1					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	22	22	16					
4/1	91	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	1	1	1	1
				02.GUILT	1	1	2	1	1	1	1	1
				03.SUICIDE	2	2	2	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	1
				06.INSOMNIA LATE	2	2	0	1	2	2	2	1
				07.WORK AND ACTIVITIES	3	3	3	1	1	1	1	1
				08.RETARDATION	1	1	2	1	0	0	0	0
				09.AGITATION	0	0	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	2	1	1	1	1
				11.ANXIETY SOMATIC	3	2	2	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	1	2	1	1	1	0
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	1	1	1	0	0	0
				17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	27	25	16	12	10	10	7
	92	Reboxetine	Female	01.DEPRESSED MOOD	2	2	3	3	3	2	2	2
				02.GUILT	3	3	3	3	3	3	3	3
				03.SUICIDE	2	2	2	2	2	2	2	3
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	4	4	4	3	4	4	3	3
				08.RETARDATION	3	3	3	3	3	3	3	3
				09.AGITATION	2	2	2	2	2	3	2	2
				10.ANXIETY PSYCHIC	3	3	3	3	3	3	3	3
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/1	92	Reboxetine	Female	13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	2	2	2	2	2	3	3	3
				16.LOSS OF WEIGHT	1	1	0	0	0	1	1	1
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	1	0	0	0
				19.DEPERSONALIZATION	2	2	2	2	2	2	2	2
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	37	37	37	36	38	39	37	38
	93	Placebo	Male	01.DEPRESSED MOOD	3	3	3	3	2	1	1	0
				02.GUILT	2	2	2	3	2	1	1	0
				03.SUICIDE	2	2	1	3	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	0
				05.INSOMNIA MIDDLE	2	2	1	2	1	0	0	0
				06.INSOMNIA LATE	1	1	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	4	2	1	1	1
				08.RETARDATION	2	2	2	2	2	1	1	0
				09.AGITATION	2	2	2	2	1	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	3	2	1	1	0
				11.ANXIETY SOMATIC	2	2	2	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	2	1	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	2	1	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	2	2	2	0	0	0
				19.DEPERSONALIZATION	1	1	1	2	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	26	36	21	6	6	1
	94	Placebo	Female	01.DEPRESSED MOOD	3	3	3	2	2	0	0	0
				02.GUILT	2	2	2	0	0	0	0	0
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	0	0	0	0
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	1	1	1	0	0
				08.RETARDATION	2	2	2	1	1	0	0	0
				09.AGITATION	2	2	2	1	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	1	1	1	1	1
				11.ANXIETY SOMATIC	3	3	3	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	0	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	1	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	2	1	1	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/1	94	Placebo	Female	17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	0	0	1	1	0	0	0	0
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	32	32	32	14	7	4	3	3
	95	Imipramine	Female	01.DEPRESSED MOOD	3	3	1	1	1	1	1	0
				02.GUILT	2	2	1	1	1	1	1	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	0
				05.INSOMNIA MIDDLE	2	2	0	0	0	0	0	0
				06.INSOMNIA LATE	1	1	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	1	0	0	0	1	0
				08.RETARDATION	2	2	1	1	1	1	1	0
				09.AGITATION	2	2	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	1	0	0	0	1	0
				11.ANXIETY SOMATIC	2	2	0	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	6	4	4	4	6	0
	96	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	1	1	1	1
				02.GUILT	3	3	2	2	1	1	1	1
				03.SUICIDE	2	2	2	2	1	1	1	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	2	2	1	1	1	1
				08.RETARDATION	3	3	2	2	1	1	1	1
				09.AGITATION	2	2	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	2	2	2	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	0	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	0

1140

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/1	96	Reboxetine	Female	21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	36	36	27	24	17	15	16	15
	115	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	2	2	1	1
				02.GUILT	2	2	1	1	1	1	1	1
				03.SUICIDE	2	2	1	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	0	0
				06.INSOMNIA LATE	2	2	2	1	1	1	1	1
				07.WORK AND ACTIVITIES	4	4	3	3	2	2	2	2
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	2	2	1	1	1	1
				11.ANXIETY SOMATIC	3	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	1	1	1	1	0
				16.LOSS OF WEIGHT	0	0	0	0	1	1	1	1
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	34	33	27	22	20	19	17	15
	116	Imipramine	Female	01.DEPRESSED MOOD	3	3	3					
				02.GUILT	2	2	2					
				03.SUICIDE	2	2	2					
				04.INSOMNIA EARLY	1	1	1					
				05.INSOMNIA MIDDLE	1	0	1					
				06.INSOMNIA LATE	1	1	1					
				07.WORK AND ACTIVITIES	4	4	4					
				08.RETARDATION	2	2	2					
				09.AGITATION	1	1	1					
				10.ANXIETY PSYCHIC	3	3	3					
				11.ANXIETY SOMATIC	2	1	2					
				12.SOMATIC GASTROINTESTINAL	1	1	1					
				13.SOMATIC GENERAL	1	1	1					
				14.GENITAL SYMPTOMS	2	2	2					
				15.HYPOCHONDRIASIS	2	1	2					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	1	1	1					
				18.DIURNAL VARIATION	0	0	0					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	1	1	1					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	30	27	30					

1141

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/1	117	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	2	1	1	1	1
				02.GUILT	3	3	2	1	1	1	1	1
				03.SUICIDE	3	3	2	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	0	0	0	0	0
				06.INSOMNIA LATE	2	2	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	3	2	2	0	0	0
				08.RETARDATION	3	3	2	1	0	0	0	0
				09.AGITATION	3	3	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	2	1	0	0	0	0
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	1	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	0	0	0	0
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	0	0
				22.Total score	41	41	26	16	10	8	8	9
	118	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	2	1	1	1	1
				02.GUILT	2	2	2	2	1	1	1	1
				03.SUICIDE	1	2	2	2	1	0	0	0
				04.INSOMNIA EARLY	1	2	2	1	1	1	1	0
				05.INSOMNIA MIDDLE	1	1	1	1	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	2	1	1	1
				08.RETARDATION	2	1	1	1	1	1	1	1
				09.AGITATION	1	1	1	1	1	0	0	0
				10.ANXIETY PSYCHIC	3	2	2	2	2	1	1	1
				11.ANXIETY SOMATIC	2	2	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	1	1	0	0	0	0	0
				16.LOSS OF WEIGHT	0	1	1	1	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	2	2	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	28	27	20	13	9	9	9
	119	Placebo	Female	01.DEPRESSED MOOD	2	2						
				02.GUILT	2	2						
				03.SUICIDE	0	0						
				04.INSOMNIA EARLY	1	1						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/1	119	Placebo	Female	05.INSOMNIA MIDDLE	1	1						
				06.INSOMNIA LATE	2	2						
				07.WORK AND ACTIVITIES	3	3						
				08.RETARDATION	1	1						
				09.AGITATION	2	2						
				10.ANXIETY PSYCHIC	3	3						
				11.ANXIETY SOMATIC	3	3						
				12.SOMATIC GASTROINTESTINAL	2	2						
				13.SOMATIC GENERAL	1	1						
				14.GENITAL SYMPTOMS	1	1						
				15.HYPOCHONDRIASIS	2	2						
				16.LOSS OF WEIGHT	1	1						
				17.INSIGHT	0	0						
				18.DIURNAL VARIATION	1	1						
				19.DEPERSONALIZATION	0	0						
				20.PARANOID	0	0						
				21.OBSESSIONAL/COMPULSIVE	0	0						
				22.Total score	28	28						
	120	Placebo	Female	01.DEPRESSED MOOD	2	2	2	1	1	1	1	1
				02.GUILT	2	1	1	1	1	1	1	1
				03.SUICIDE	1	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	0
				05.INSOMNIA MIDDLE	1	1	0	0	0	1	1	0
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	1	1	1	1	1	1	1	1
				08.RETARDATION	2	2	2	1	1	1	1	1
				09.AGITATION	2	2	2	1	0	0	0	0
				10.ANXIETY PSYCHIC	3	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	3	1	1	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	0	0	0
				16.LOSS OF WEIGHT	0	0	1	1	1	1	1	1
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	22	20	16	14	12	11	9
	145	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	2	2	2	1	1
				02.GUILT	3	3	2	1	1	1	1	1
				03.SUICIDE	2	2	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	1	1	1	1	1	1	0
				05.INSOMNIA MIDDLE	2	2	1	0	0	0	0	0
				06.INSOMNIA LATE	2	2	1	1	1	1	1	0
				07.WORK AND ACTIVITIES	3	3	2	1	1	1	1	1
				08.RETARDATION	3	3	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/1	145	Imipramine	Female	09.AGITATION	2	2	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	1	1	1	1
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	35	34	22	15	15	15	14	12
	146	Placebo	Female	01.DEPRESSED MOOD	2	2	2	2	1	1	1	1
				02.GUILT	2	2	2	1	1	1	1	1
				03.SUICIDE	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	0
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	2	2	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	2	1	1
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	2	2	2	2	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	1	1	1	0	0	0
				16.LOSS OF WEIGHT	1	1	1	1	1	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	22	19	15	13	12	10
	147	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	2	1	1	1
				02.GUILT	2	2	2	2	1	1	1	1
				03.SUICIDE	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	2	2	2	1	1
				07.WORK AND ACTIVITIES	3	3	2	2	2	2	1	1
				08.RETARDATION	2	2	2	2	2	2	2	1
				09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	3	3	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	1	1	2	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/1	147	Reboxetine	Female	13.SOMATIC GENERAL	2	2	2	2	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	1	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	0	0	0	0
				22.Total score	32	31	28	28	22	20	19	17
	148	Imipramine	Female	01.DEPRESSED MOOD	3	3	1	1	1	1	1	1
				02.GUILT	3	3	2	2	2	2	1	1
				03.SUICIDE	2	2	2	1	1	1	1	1
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	0	0
				07.WORK AND ACTIVITIES	3	3	2	1	1	1	1	1
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	2	2	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	1
				11.ANXIETY SOMATIC	2	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	1	1	1	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	1	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	26	22	20	17	17	14	12
	149	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	2	1	1	1	1
				02.GUILT	3	3	2	2	1	1	1	1
				03.SUICIDE	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	0	0	0
				06.INSOMNIA LATE	1	1	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	2	1	1	1
				08.RETARDATION	2	2	2	2	2	1	1	1
				09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	2	1	2	1	1	1
				13.SOMATIC GENERAL	2	2	2	1	2	1	1	1
				14.GENITAL SYMPTOMS	1	1	2	2	2	2	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0

1145

95500822

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/1	149	Reboxetine	Male	17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	26	20	20	14	13	13
	150	Placebo	Male	01.DEPRESSED MOOD	3	3	2	2	1	1	1	1
				02.GUILT	2	2	2	1	1	1	1	1
				03.SUICIDE	2	2	2	1	1	1	1	1
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	2	2	2	1	1	1	1	1
				09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	2	2	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	26	26	21	17	14	14	14	13
4/2	93/A	Placebo	Male	01.DEPRESSED MOOD	3	3	3	3	1	0	0	0
				02.GUILT	2	2	2	2	1	0	0	0
				03.SUICIDE	2	2	2	2	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	1	0	0	0
				06.INSOMNIA LATE	2	2	2	2	1	0	0	0
				07.WORK AND ACTIVITIES	4	4	4	4	2	1	1	0
				08.RETARDATION	2	2	2	2	1	1	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	4	3	2	1	0	0
				11.ANXIETY SOMATIC	2	2	2	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	1	1	0
				15.HYPOCHONDRIASIS	2	2	2	2	2	0	0	0
				16.LOSS OF WEIGHT	1	1	1	1	0	0	0	0
				17.INSIGHT	0	0	0	0	0	2	2	2
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/2	93/A	Placebo	Male	21.OBSESSIONAL/COMPULSIVE	1	1	1	0	1	0	0	0
				22.Total score	33	33	34	32	20	6	4	2
	99/A	Placebo	Male	01.DEPRESSED MOOD	3	3	3	2	2	1	0	0
				02.GUILT	2	2	2	1	1	1	0	0
				03.SUICIDE	3	3	3	2	2	1	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	0	0
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	1	1	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	2	1	0	0
				08.RETARDATION	2	2	2	1	1	1	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	2	2	1	1	0
				11.ANXIETY SOMATIC	2	2	2	1	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	0
				13.SOMATIC GENERAL	2	2	2	1	1	1	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	1	1	0
				15.HYPOCHONDRIASIS	2	2	2	2	2	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	2	2
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	30	30	19	19	13	4	2
	104	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	2	2	2	2	2
				02.GUILT	3	3	3	2	2	2	2	2
				03.SUICIDE	3	3	3	2	2	2	2	2
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	3	3	3	3	2	2	2	2
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	3	3	3	3	2	2	2	2
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	2	2	3	3	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	35	35	36	32	26	26	26	26

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/3	97	Placebo	Male	01.DEPRESSED MOOD	2	2	2	2	2	3	3	3
				02.GUILT	2	2	2	2	2	2	2	2
				03.SUICIDE	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	1	1
				06.INSOMNIA LATE	1	1	2	2	2	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	0	0	0	0	0	1	1	1
				10.ANXIETY PSYCHIC	1	4	3	3	3	3	3	3
				11.ANXIETY SOMATIC	3	2	2	2	2	3	3	3
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	2	2	2
				14.GENITAL SYMPTOMS	1	2	2	2	2	1	1	1
				15.HYPOCHONDRIASIS	3	3	2	2	2	3	3	3
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	24	27	25	25	25	27	27	27
	98	Reboxetine	Female	01.DEPRESSED MOOD	2	2	3	3	2	2	3	
				02.GUILT	2	2	2	2	2	2	2	
				03.SUICIDE	1	1	1	1	1	1	1	
				04.INSOMNIA EARLY	1	1	2	2	1	1	2	
				05.INSOMNIA MIDDLE	1	1	2	2	1	1	2	
				06.INSOMNIA LATE	1	1	2	2	1	1	2	
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	
				08.RETARDATION	1	1	2	2	1	1	2	
				09.AGITATION	1	1	1	1	1	1	2	
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	2	
				11.ANXIETY SOMATIC	2	2	2	2	1	1	2	
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	2	
				13.SOMATIC GENERAL	1	1	1	1	1	1	2	
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	
				15.HYPOCHONDRIASIS	3	3	2	2	2	2	3	
				16.LOSS OF WEIGHT	0	0	0	3	0	0	0	
				17.INSIGHT	1	1	0	1	1	1	0	
				18.DIURNAL VARIATION	1	1	1	1	1	1	0	
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	
				20.PARANOID	0	0	0	0	0	0	0	
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	0	
				22.Total score	25	25	28	32	22	22	30	
	99	Placebo	Female	01.DEPRESSED MOOD	3	3	3	3				
				02.GUILT	3	3	3	3				
				03.SUICIDE	1	1	1	1				
				04.INSOMNIA EARLY	2	2	2	2				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/3	99	Placebo	Female	05.INSOMNIA MIDDLE	2	2	2	2				
				06.INSOMNIA LATE	2	2	2	2				
				07.WORK AND ACTIVITIES	3	3	3	3				
				08.RETARDATION	2	2	2	2				
				09.AGITATION	0	0	0	1				
				10.ANXIETY PSYCHIC	3	3	3	3				
				11.ANXIETY SOMATIC	1	1	1	3				
				12.SOMATIC GASTROINTESTINAL	1	1	1	2				
				13.SOMATIC GENERAL	2	2	2	2				
				14.GENITAL SYMPTOMS	0	0	0	0				
				15.HYPOCHONDRIASIS	2	2	2	3				
				16.LOSS OF WEIGHT	0	0	0	0				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	1	1	1	1				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	28	28	28	33				
	100	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2	2			
				02.GUILT	2	2	1	2	2			
				03.SUICIDE	1	1	0	1	1			
				04.INSOMNIA EARLY	2	2	2	2	2			
				05.INSOMNIA MIDDLE	2	1	1	1	1			
				06.INSOMNIA LATE	1	1	1	1	1			
				07.WORK AND ACTIVITIES	2	2	1	1	1			
				08.RETARDATION	1	2	2	2	2			
				09.AGITATION	1	1	1	1	1			
				10.ANXIETY PSYCHIC	1	2	2	2	2			
				11.ANXIETY SOMATIC	2	1	1	2	2			
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2			
				13.SOMATIC GENERAL	1	1	1	2	2			
				14.GENITAL SYMPTOMS	1	2	2	2	2			
				15.HYPOCHONDRIASIS	1	2	2	2	2			
				16.LOSS OF WEIGHT	2	2	1	1	1			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	1	1	0	0	0			
				19.DEPERSONALIZATION	0	0	0	0	0			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1			
				22.Total score	26	28	23	27	27			
	101	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	2	1	1	1	1
				02.GUILT	3	3	3	2	1	1	1	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	0	1	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	2	2	2	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/3	101	Imipramine	Male	09.AGITATION	0	0	1	1	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	2	1	1	1	0
				11.ANXIETY SOMATIC	2	2	2	2	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	1	1	2	1	1	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	2	1	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	1	0
				18.DIURNAL VARIATION	2	2	2	1	0	1	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	0	0	0
				22.Total score	27	27	29	23	11	9	6	3
4/4	109	Reboxetine	Female	01.DEPRESSED MOOD	2	2	1	1	0	0	0	0
				02.GUILT	2	2	2	1	1	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	1	1	1	1	1	1	0
				05.INSOMNIA MIDDLE	2	1	1	0	0	0	0	0
				06.INSOMNIA LATE	2	2	1	1	0	1	0	0
				07.WORK AND ACTIVITIES	4	4	3	3	2	2	1	0
				08.RETARDATION	2	2	2	1	1	0	0	0
				09.AGITATION	1	2	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	2	1	1	1	1	1	0
				11.ANXIETY SOMATIC	2	2	1	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	2	2	2	2	1	0	0
				13.SOMATIC GENERAL	1	1	2	1	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	1	1	0	0	0	0	0
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	25	18	13	8	6	3	1
	110	Imipramine	Male	01.DEPRESSED MOOD	2	3	2	2	1	1	1	1
				02.GUILT	1	2	1	1	1	1	1	1
				03.SUICIDE	0	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	2	1	0	0	1
				05.INSOMNIA MIDDLE	2	1	1	1	0	0	0	0
				06.INSOMNIA LATE	2	2	2	1	1	0	1	0
				07.WORK AND ACTIVITIES	4	4	3	3	2	2	2	2
				08.RETARDATION	2	3	2	2	2	1	1	1
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	2	2	2	1	1	0	1
				11.ANXIETY SOMATIC	2	2	1	2	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	1	1	1	1	1	1

1150

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/4	110	Imipramine	Male	13.SOMATIC GENERAL	2	1	1	2	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	27	18	20	12	9	8	9
	111	Imipramine	Male	01.DEPRESSED MOOD	2	2	2	1	1	1	1	1
				02.GUILT	2	2	2	1	1	0	0	0
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	0	0
				05.INSOMNIA MIDDLE	1	2	1	1	0	0	0	0
				06.INSOMNIA LATE	2	2	2	1	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	4	3	2	2	2	0
				08.RETARDATION	3	3	3	2	2	1	1	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	2	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	1	1	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	1	1	1	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	25	23	14	10	8	6	3
	112	Placebo	Male	01.DEPRESSED MOOD	2	2	2	2	1	1	2	1
				02.GUILT	0	1	1	1	1	0	1	1
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	0	0	1	1	0
				06.INSOMNIA LATE	2	2	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	4	4	3	2	2	2	2	2
				08.RETARDATION	1	1	1	1	1	1	2	1
				09.AGITATION	1	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	2	1
				11.ANXIETY SOMATIC	2	2	2	1	1	0	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	0	1	1	1	2	2
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	0	0	0	0	0	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/4	112	Placebo	Male	17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	22	15	13	11	9	16	11
	113	Reboxetine	Male	01.DEPRESSED MOOD	3	2	2	2	1	1	1	0
				02.GUILT	2	2	1	1	1	1	0	0
				03.SUICIDE	2	2	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	1	1	1	0	0
				06.INSOMNIA LATE	2	2	2	2	1	1	0	0
				07.WORK AND ACTIVITIES	4	4	4	4	3	2	1	1
				08.RETARDATION	2	2	2	1	1	1	1	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	1	2	2	1	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	2	1	1	1
				13.SOMATIC GENERAL	1	1	2	1	1	1	1	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	0	2	0	2	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	25	25	18	16	12	7	4
	114	Placebo	Female	01.DEPRESSED MOOD	3	3	2	2	1	1	1	1
				02.GUILT	2	2	2	1	1	0	0	0
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	0	1	0	0	0	0	0
				06.INSOMNIA LATE	1	2	2	1	1	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	3	2	2	1	1
				08.RETARDATION	2	2	2	1	1	1	1	1
				09.AGITATION	0	1	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	3	2	2	2	2	1	1
				11.ANXIETY SOMATIC	3	3	3	2	1	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	1	1	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	0	0	1	1
				16.LOSS OF WEIGHT	1	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

1152

9550082

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/4	114	Placebo	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	29	25	17	13	11	9	9
	175	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	1	1	1	0	0
				02.GUILT	2	1	1	1	0	0	1	0
				03.SUICIDE	1	2	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	0	0	0	0
				06.INSOMNIA LATE	1	2	2	1	1	0	0	0
				07.WORK AND ACTIVITIES	3	4	4	3	2	2	1	0
				08.RETARDATION	2	2	2	1	1	1	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	1	1
				11.ANXIETY SOMATIC	2	1	2	2	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	2	1	2	1	1	1	1
				13.SOMATIC GENERAL	2	2	1	1	1	1	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	0	0	0	1	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	26	21	18	13	10	6	3
	176	Placebo	Female	01.DEPRESSED MOOD	3	3	2	2	2	3		
				02.GUILT	2	2	2	1	1	2		
				03.SUICIDE	1	1	1	0	0	4		
				04.INSOMNIA EARLY	2	1	0	0	0	1		
				05.INSOMNIA MIDDLE	1	1	1	1	1	1		
				06.INSOMNIA LATE	2	2	2	2	1	1		
				07.WORK AND ACTIVITIES	4	4	3	2	2	4		
				08.RETARDATION	1	1	1	1	1	1		
				09.AGITATION	0	0	0	0	0	0		
				10.ANXIETY PSYCHIC	2	2	2	2	3	3		
				11.ANXIETY SOMATIC	1	1	1	1	0	2		
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2		
				13.SOMATIC GENERAL	1	1	1	1	1	1		
				14.GENITAL SYMPTOMS	0	0	1	1	1	2		
				15.HYPOCHONDRIASIS	0	0	0	0	0	0		
				16.LOSS OF WEIGHT	1	0	0	0	1	0		
				17.INSIGHT	0	0	0	0	0	0		
				18.DIURNAL VARIATION	1	1	1	0	0	0		
				19.DEPERSONALIZATION	0	0	0	0	0	0		
				20.PARANOID	0	0	0	0	0	0		
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		
				22.Total score	24	22	20	16	16	27		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/4	177	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2				
				02.GUILT	1	1	1	0				
				03.SUICIDE	1	1	1	1				
				04.INSOMNIA EARLY	2	1	1	1				
				05.INSOMNIA MIDDLE	1	1	0	1				
				06.INSOMNIA LATE	2	2	1	2				
				07.WORK AND ACTIVITIES	3	3	3	3				
				08.RETARDATION	1	2	2	2				
				09.AGITATION	0	0	0	0				
				10.ANXIETY PSYCHIC	2	3	2	2				
				11.ANXIETY SOMATIC	3	3	3	3				
				12.SOMATIC GASTROINTESTINAL	2	2	2	2				
				13.SOMATIC GENERAL	2	2	2	2				
				14.GENITAL SYMPTOMS	0	0	0	0				
				15.HYPOCHONDRIASIS	3	3	3	3				
				16.LOSS OF WEIGHT	2	0	0	1				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	0	0	0	0				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	27	26	23	25				
	178	Reboxetine	Female	01.DEPRESSED MOOD	2	2	1	1	1	0	0	0
				02.GUILT	2	2	1	1	0	0	0	0
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	1	1	1	1	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	1
				06.INSOMNIA LATE	2	2	1	0	0	1	1	1
				07.WORK AND ACTIVITIES	4	4	3	2	2	1	1	1
				08.RETARDATION	2	2	2	1	1	1	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	1	1	1	1	0
				11.ANXIETY SOMATIC	2	2	2	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	0	0	0	1	0	1	1
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	24	17	10	8	5	5	5
	179	Placebo	Female	01.DEPRESSED MOOD	3	2	2	2	3			
				02.GUILT	2	2	2	1	3			
				03.SUICIDE	3	1	1	1	4			
				04.INSOMNIA EARLY	2	2	1	1	1			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/4	179	Placebo	Female	05.INSOMNIA MIDDLE	1	2	1	1	1			
				06.INSOMNIA LATE	2	2	2	1	2			
				07.WORK AND ACTIVITIES	4	4	3	2	4			
				08.RETARDATION	2	1	1	1	3			
				09.AGITATION	0	0	0	0	0			
				10.ANXIETY PSYCHIC	2	2	2	1	3			
				11.ANXIETY SOMATIC	1	1	1	1	0			
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2			
				13.SOMATIC GENERAL	2	2	2	2	2			
				14.GENITAL SYMPTOMS	1	1	1	1	2			
				15.HYPOCHONDRIASIS	0	0	0	0	0			
				16.LOSS OF WEIGHT	1	0	1	0	1			
				17.INSIGHT	1	0	0	0	0			
				18.DIURNAL VARIATION	1	1	1	1	0			
				19.DEPERSONALIZATION	0	0	0	0	0			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	30	25	23	18	31			
	180	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	1	1	1	0	0
				02.GUILT	2	2	1	1	0	0	0	0
				03.SUICIDE	2	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	0	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	2	2	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	4	4	3	2	2	1	1	1
				08.RETARDATION	1	2	2	1	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	0	1
				11.ANXIETY SOMATIC	1	1	1	1	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	1	1	0	0
				13.SOMATIC GENERAL	2	2	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	0	0	0	1	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	20	13	10	6	3	4
5/1	127	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	2	1	3	1	1
				02.GUILT	1	2	1	1	2	2	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	2	0	1	1	2	0	1
				05.INSOMNIA MIDDLE	1	1	2	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	0	1	1
				07.WORK AND ACTIVITIES	4	4	3	2	2	3	2	3
				08.RETARDATION	3	3	2	2	2	2	2	1

1155

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
5/1	127	Reboxetine	Male	09.AGITATION	1	0	0	1	2	0	1	2
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	1	2
				11.ANXIETY SOMATIC	2	2	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	1	1	1	0	1	1
				13.SOMATIC GENERAL	2	2	1	1	1	0	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	1
				15.HYPOCHONDRIASIS	2	2	1	1	1	2	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	1	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	0	1	1
				22.Total score	30	31	21	21	21	20	18	20
	128	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	1	1	1	1	1
				02.GUILT	2	2	2	1	2	1	1	1
				03.SUICIDE	2	2	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	0	0	0	1	0	0
				06.INSOMNIA LATE	2	1	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	2	1	2	1	1	1
				08.RETARDATION	2	1	1	0	0	0	0	0
				09.AGITATION	2	2	1	2	1	2	2	2
				10.ANXIETY PSYCHIC	3	3	1	2	2	2	2	2
				11.ANXIETY SOMATIC	3	3	1	1	1	1	1	2
				12.SOMATIC GASTROINTESTINAL	2	2	0	1	1	0	1	1
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	2
				14.GENITAL SYMPTOMS	1	1	0	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	1	1	1	1	1	1
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	2	1	2	1	1	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	1	1
				22.Total score	36	33	13	14	14	13	13	15
	129	Placebo	Male	01.DEPRESSED MOOD	2	2	3	1	1	1	2	2
				02.GUILT	0	0	2	1	2	1	1	2
				03.SUICIDE	3	3	3	1	0	0	0	1
				04.INSOMNIA EARLY	2	2	0	0	0	0	1	1
				05.INSOMNIA MIDDLE	2	2	0	0	0	0	0	1
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	4	2	1	1	0	2
				08.RETARDATION	2	2	1	0	1	0	0	1
				09.AGITATION	1	1	2	2	1	0	1	0
				10.ANXIETY PSYCHIC	2	2	2	3	1	2	3	2
				11.ANXIETY SOMATIC	2	2	1	1	2	0	0	2
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
5/1	129	Placebo	Male	13.SOMATIC GENERAL	0	0	0	0	0	0	0	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	2	2	0	0	0	1
				17.INSIGHT	0	0	0	0	0	0	0	1
				18.DIURNAL VARIATION	1	1	0	0	0	0	1	0
				19.DEPERSONALIZATION	1	1	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	0	1
				22.Total score	25	25	23	14	10	6	9	19
	130	Placebo	Male	01.DEPRESSED MOOD	3	3	2	2	3	1	1	2
				02.GUILT	1	1	1	1	2	1	0	1
				03.SUICIDE	3	3	2	1	3	0	0	0
				04.INSOMNIA EARLY	1	1	0	1	1	1	1	0
				05.INSOMNIA MIDDLE	0	0	0	1	0	2	1	0
				06.INSOMNIA LATE	1	1	0	0	0	2	1	0
				07.WORK AND ACTIVITIES	4	4	3	1	2	1	1	1
				08.RETARDATION	3	3	2	1	2	1	1	1
				09.AGITATION	3	3	1	0	1	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	2	2	0	0	2
				11.ANXIETY SOMATIC	3	3	3	2	2	0	0	2
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	3	2	2	0	0	2
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	0	0	1	0	0	1	0	0
				18.DIURNAL VARIATION	2	2	1	1	1	1	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	33	33	22	16	22	11	6	12
	131	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	1	2	1	0	0
				02.GUILT	2	2	3	2	1	1	1	0
				03.SUICIDE	2	2	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	1	1	1	2	1	0
				06.INSOMNIA LATE	2	2	1	1	1	2	1	0
				07.WORK AND ACTIVITIES	2	2	2	2	3	0	0	0
				08.RETARDATION	3	3	2	1	2	1	1	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	0	2
				11.ANXIETY SOMATIC	1	1	0	1	2	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	1	0	0	0
				13.SOMATIC GENERAL	1	1	0	1	1	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	1
				15.HYPOCHONDRIASIS	2	2	1	1	2	0	0	0
				16.LOSS OF WEIGHT	0	0	0	2	0	0	0	0

1157

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
5/1	131	Imipramine	Female	17.INSIGHT	0	0	1	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	2	1	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	2	1	1	0
				22.Total score	26	26	19	18	22	10	6	3
	132	Imipramine	Male	01.DEPRESSED MOOD	3	3	0	0	0	0		0
				02.GUILT	1	1	0	0	0	0		0
				03.SUICIDE	3	3	0	0	0	0		0
				04.INSOMNIA EARLY	2	2	0	0	0	0		0
				05.INSOMNIA MIDDLE	1	1	1	0	0	0		0
				06.INSOMNIA LATE	1	1	1	0	0	0		0
				07.WORK AND ACTIVITIES	2	2	0	0	0	0		0
				08.RETARDATION	2	2	0	0	0	0		0
				09.AGITATION	1	1	0	0	0	0		0
				10.ANXIETY PSYCHIC	3	3	0	0	0	0		0
				11.ANXIETY SOMATIC	2	2	0	0	0	0		0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0		0
				13.SOMATIC GENERAL	0	0	0	0	0	0		0
				14.GENITAL SYMPTOMS	2	2	0	1	0	0		0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0		0
				16.LOSS OF WEIGHT	0	0	0	0	0	0		0
				17.INSIGHT	0	0	0	0	0	0		0
				18.DIURNAL VARIATION	1	1	0	0	0	0		0
				19.DEPERSONALIZATION	0	0	0	0	0	0		0
				20.PARANOID	0	0	0	0	0	0		0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		0
				22.Total score	24	24	2	1	0	0		0
5/2	121	Imipramine	Female	01.DEPRESSED MOOD	4	4	3	4	2	1	2	3
				02.GUILT	3	3	2	2	0	1	1	1
				03.SUICIDE	3	3	3	2	0	0	1	2
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	1
				05.INSOMNIA MIDDLE	0	0	1	0	0	0	0	0
				06.INSOMNIA LATE	2	2	1	2	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	3	4	2	3	3	3
				08.RETARDATION	2	2	2	2	2	1	1	2
				09.AGITATION	2	2	2	2	2	1	1	2
				10.ANXIETY PSYCHIC	4	2	3	3	2	2	2	3
				11.ANXIETY SOMATIC	2	2	2	2	1	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	1	1	2	1	0	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	3	3	2	2	2	3
				16.LOSS OF WEIGHT	2	0	1	1	0	2	0	2
				17.INSIGHT	0	0	0	0	0	0	1	1
				18.DIURNAL VARIATION	1	1	0	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
5/2	121	Imipramine	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	37	34	33	34	16	19	20	28
	125	Reboxetine	Male	01.DEPRESSED MOOD	3	2	3	0	0	0	0	0
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	0	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	0	1	0	1	0	1	1	2
				05.INSOMNIA MIDDLE	0	0	0	0	1	1	0	1
				06.INSOMNIA LATE	0	1	2	1	1	0	0	1
				07.WORK AND ACTIVITIES	4	4	4	1	1	1	1	1
				08.RETARDATION	3	2	1	1	0	0	0	0
				09.AGITATION	0	1	3	0	0	0	1	0
				10.ANXIETY PSYCHIC	2	2	3	0	1	1	1	1
				11.ANXIETY SOMATIC	2	1	2	0	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	2	0	2	1	0	1
				13.SOMATIC GENERAL	2	2	2	1	1	0	1	1
				14.GENITAL SYMPTOMS	2	1	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	3	1	0	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	23	24	27	7	8	6	5	8
5/3	133	Placebo	Male	01.DEPRESSED MOOD	3	3	3	3				
				02.GUILT	2	2	2	3				
				03.SUICIDE	1	1	1	2				
				04.INSOMNIA EARLY	2	1	1	2				
				05.INSOMNIA MIDDLE	2	2	2	2				
				06.INSOMNIA LATE	2	2	2	2				
				07.WORK AND ACTIVITIES	3	3	3	3				
				08.RETARDATION	2	2	2	3				
				09.AGITATION	0	0	2	2				
				10.ANXIETY PSYCHIC	3	3	3	3				
				11.ANXIETY SOMATIC	2	2	2	2				
				12.SOMATIC GASTROINTESTINAL	2	2	1	1				
				13.SOMATIC GENERAL	1	1	1	2				
				14.GENITAL SYMPTOMS	1	1	1	2				
				15.HYPOCHONDRIASIS	1	1	1	1				
				16.LOSS OF WEIGHT	2	0	0	0				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	2	2	2	2				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	1	0				
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1				
				22.Total score	32	29	31	36				

1159

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
5/3	134	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	1	2	0		0
				02.GUILT	2	2	1	0	2	0		0
				03.SUICIDE	2	1	1	0	1	0		0
				04.INSOMNIA EARLY	2	2	2	2	2	2		0
				05.INSOMNIA MIDDLE	2	2	2	2	2	2		1
				06.INSOMNIA LATE	2	2	2	2	2	2		0
				07.WORK AND ACTIVITIES	2	2	2	1	2	0		0
				08.RETARDATION	2	2	2	0	1	0		0
				09.AGITATION	2	2	2	1	2	0		0
				10.ANXIETY PSYCHIC	3	3	3	1	2	0		1
				11.ANXIETY SOMATIC	2	2	2	0	0	0		0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0		0
				13.SOMATIC GENERAL	2	2	2	0	0	0		0
				14.GENITAL SYMPTOMS	2	2	1	0	0	0		0
				15.HYPOCHONDRIASIS	2	2	1	0	0	0		0
				16.LOSS OF WEIGHT	0	0	0	0	2	0		0
				17.INSIGHT	0	0	0	0	0	0		0
				18.DIURNAL VARIATION	2	2	1	0	0	0		0
				19.DEPERSONALIZATION	0	0	0	0	0	0		0
				20.PARANOID	0	0	0	0	0	0		0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		0
				22.Total score	33	32	28	10	20	6		2
	135	Imipramine	Female	01.DEPRESSED MOOD	3	3	1	0	0	0	2	3
				02.GUILT	2	1	0	0	0	0	1	2
				03.SUICIDE	0	0	0	0	0	0	0	1
				04.INSOMNIA EARLY	1	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	0	0	0	2	2
				06.INSOMNIA LATE	1	2	1	0	0	0	0	1
				07.WORK AND ACTIVITIES	2	2	1	1	1	2	3	3
				08.RETARDATION	1	1	0	0	0	1	1	1
				09.AGITATION	0	1	0	0	0	0	1	0
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	2	2
				11.ANXIETY SOMATIC	2	1	0	0	0	0	0	2
				12.SOMATIC GASTROINTESTINAL	2	2	0	1	1	1	0	2
				13.SOMATIC GENERAL	2	1	1	0	0	2	2	2
				14.GENITAL SYMPTOMS	2	2	1	0	0	0	0	1
				15.HYPOCHONDRIASIS	1	1	0	0	0	0	0	2
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	1	0	0	0	0	0	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	24	8	4	4	8	14	26
	136	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	0	0	0	0	0
				02.GUILT	2	2	1	0	0	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	1	0

1160

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
5/3	136	Imipramine	Female	05.INSOMNIA MIDDLE	1	2	2	0	1	1	2	1
				06.INSOMNIA LATE	2	2	2	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	1	0	1	0	0
				08.RETARDATION	2	1	1	0	0	0	0	0
				09.AGITATION	0	1	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	0	1	0	0
				11.ANXIETY SOMATIC	2	3	3	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	2	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	0	1	0	0
				14.GENITAL SYMPTOMS	1	2	2	0	0	0	0	0
				15.HYPOCHONDRIASIS	3	2	2	0	0	0	0	0
				16.LOSS OF WEIGHT	1	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	30	26	6	3	6	3	1
	137	Reboxetine	Female	01.DEPRESSED MOOD	3	3	1	0	0	0	0	0
				02.GUILT	2	2	1	0	0	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	1	1
				05.INSOMNIA MIDDLE	2	1	1	2	2	2	0	0
				06.INSOMNIA LATE	2	2	2	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	2	1	0	0	0	0
				08.RETARDATION	3	3	1	1	0	0	0	0
				09.AGITATION	0	2	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	0	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	2	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	31	21	9	7	7	4	4
	138	Placebo	Female	01.DEPRESSED MOOD	3	3	3					
				02.GUILT	2	2	2					
				03.SUICIDE	1	0	0					
				04.INSOMNIA EARLY	2	1	1					
				05.INSOMNIA MIDDLE	1	1	1					
				06.INSOMNIA LATE	2	2	2					
				07.WORK AND ACTIVITIES	3	3	3					
				08.RETARDATION	1	1	1					

1161

9550082

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
5/3	138	Placebo	Female	09.AGITATION	2	1	1					
				10.ANXIETY PSYCHIC	2	2	2					
				11.ANXIETY SOMATIC	1	2	2					
				12.SOMATIC GASTROINTESTINAL	1	1	1					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	1	1	1					
				15.HYPOCHONDRIASIS	2	2	2					
				16.LOSS OF WEIGHT	2	2	2					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	2	2	2					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	30	28	28					
6/1	151	Imipramine	Male	01.DEPRESSED MOOD	3	3	3					
				02.GUILT	0	0	0					
				03.SUICIDE	1	1	0					
				04.INSOMNIA EARLY	2	2	2					
				05.INSOMNIA MIDDLE	2	2	2					
				06.INSOMNIA LATE	1	2	1					
				07.WORK AND ACTIVITIES	3	3	3					
				08.RETARDATION	1	1	1					
				09.AGITATION	2	2	1					
				10.ANXIETY PSYCHIC	3	3	2					
				11.ANXIETY SOMATIC	1	3	3					
				12.SOMATIC GASTROINTESTINAL	2	1	1					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	0	0	0					
				15.HYPOCHONDRIASIS	0	0	0					
				16.LOSS OF WEIGHT	2	0	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	1	1	1					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	26	26	22					
	152	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3	3	2	2	1
				02.GUILT	1	1	0	0	0	0	0	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	1	1
				05.INSOMNIA MIDDLE	1	2	2	2	2	1	1	1
				06.INSOMNIA LATE	1	1	2	2	0	2	2	1
				07.WORK AND ACTIVITIES	4	3	2	1	1	1	1	0
				08.RETARDATION	2	2	1	1	1	1	1	0
				09.AGITATION	1	1	1	1	0	1	0	1
				10.ANXIETY PSYCHIC	1	2	2	1	0	1	1	0
				11.ANXIETY SOMATIC	2	2	1	2	2	2	1	0
				12.SOMATIC GASTROINTESTINAL	2	1	1	1	1	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/1	152	Reboxetine	Female	13.SOMATIC GENERAL	2	2	2	2	2	2	2	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	2	1	1	2	1	1	0
				16.LOSS OF WEIGHT	2	0	0	0	1	1	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	21	20	17	18	14	6
	153	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	2	1	1	1	1
				02.GUILT	1	1	1	1	0	1	1	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	1	1	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	2	2	2	2
				08.RETARDATION	1	0	0	0	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	1	1	2	2	2	2
				11.ANXIETY SOMATIC	3	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	1	1	1	1	1
				15.HYPOCHONDRIASIS	3	2	2	1	2	1	1	1
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	23	21	16	15	14	14	13
	154	Imipramine	Female	01.DEPRESSED MOOD	3	3						
				02.GUILT	0	0						
				03.SUICIDE	1	0						
				04.INSOMNIA EARLY	2	2						
				05.INSOMNIA MIDDLE	1	1						
				06.INSOMNIA LATE	2	2						
				07.WORK AND ACTIVITIES	3	3						
				08.RETARDATION	1	1						
				09.AGITATION	2	2						
				10.ANXIETY PSYCHIC	3	2						
				11.ANXIETY SOMATIC	1	1						
				12.SOMATIC GASTROINTESTINAL	1	1						
				13.SOMATIC GENERAL	1	1						
				14.GENITAL SYMPTOMS	2	2						
				15.HYPOCHONDRIASIS	0	2						
				16.LOSS OF WEIGHT	0	0						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/1	154	Imipramine	Female	17.INSIGHT	0	0						
				18.DIURNAL VARIATION	0	0						
				19.DEPERSONALIZATION	0	0						
				20.PARANOID	0	0						
				21.OBSESSIONAL/COMPULSIVE	0	0						
				22.Total score	23	23						
	155	Placebo	Male	01.DEPRESSED MOOD	4	4	4	4	3	3		
				02.GUILT	1	1	0	1	1	2		
				03.SUICIDE	1	1	1	1	1	2		
				04.INSOMNIA EARLY	2	2	2	1	1	1		
				05.INSOMNIA MIDDLE	2	2	2	2	2	2		
				06.INSOMNIA LATE	2	2	1	2	1	2		
				07.WORK AND ACTIVITIES	3	3	3	3	3	3		
				08.RETARDATION	2	2	2	2	2	2		
				09.AGITATION	2	2	2	2	1	1		
				10.ANXIETY PSYCHIC	2	3	2	2	2	2		
				11.ANXIETY SOMATIC	2	2	2	2	1	1		
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1		
				13.SOMATIC GENERAL	2	2	2	2	2	2		
				14.GENITAL SYMPTOMS	2	2	2	1	1	1		
				15.HYPOCHONDRIASIS	0	0	0	0	0	0		
				16.LOSS OF WEIGHT	1	0	0	0	0	0		
				17.INSIGHT	0	0	0	0	0	0		
				18.DIURNAL VARIATION	1	1	1	1	1	1		
				19.DEPERSONALIZATION	0	0	0	0	0	0		
				20.PARANOID	0	0	0	0	0	0		
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		
				22.Total score	30	30	27	27	23	26		
	156	Placebo	Female	01.DEPRESSED MOOD	2	3	3	1	1	1	1	1
				02.GUILT	1	1	1	0	0	0	0	0
				03.SUICIDE	0	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	2	1	1	1
				08.RETARDATION	2	2	2	2	1	0	1	1
				09.AGITATION	1	1	1	1	1	0	0	0
				10.ANXIETY PSYCHIC	2	1	2	1	1	1	1	2
				11.ANXIETY SOMATIC	2	1	1	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	1	1	1	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	1	1	2	1	1	0	1	1
				15.HYPOCHONDRIASIS	2	2	2	0	1	1	1	2
				16.LOSS OF WEIGHT	2	2	1	0	0	0	0	0
				17.INSIGHT	0	1	0	0	0	1	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

1164

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/1	156	Placebo	Female	21.OBSESSIONAL/COMPULSIVE	1	1	1	1	0	0	0	1
				22.Total score	23	24	22	14	12	8	7	10
6/2	157	Reboxetine	Male	01.DEPRESSED MOOD	3	2	2	1	1	1	1	1
				02.GUILT	2	2	2	2	2	2	1	1
				03.SUICIDE	1	1	1	0	0	1	1	1
				04.INSOMNIA EARLY	1	1	2	2	1	0	0	0
				05.INSOMNIA MIDDLE	0	2	2	0	0	0	0	0
				06.INSOMNIA LATE	1	1	2	1	1	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	2	2	2	1
				08.RETARDATION	2	2	2	1	1	1	1	1
				09.AGITATION	2	2	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	1	1	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	1	1	2	2	1	1	1
				13.SOMATIC GENERAL	1	1	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	0	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	3	2	1	2	2	2	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	2	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	29	29	27	19	18	17	16	14
	158	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	2	1		1
				02.GUILT	2	2	2	2	1	1		0
				03.SUICIDE	1	1	1	1	1	1		0
				04.INSOMNIA EARLY	2	2	2	0	0	0		0
				05.INSOMNIA MIDDLE	1	1	1	0	0	0		0
				06.INSOMNIA LATE	1	1	1	0	0	0		0
				07.WORK AND ACTIVITIES	3	3	3	3	2	2		1
				08.RETARDATION	1	1	1	1	1	1		0
				09.AGITATION	1	1	1	1	1	0		1
				10.ANXIETY PSYCHIC	3	3	2	2	2	2		1
				11.ANXIETY SOMATIC	1	1	1	1	1	1		0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	1		0
				13.SOMATIC GENERAL	0	0	0	0	1	1		0
				14.GENITAL SYMPTOMS	0	0	0	0	1	1		0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0		0
				16.LOSS OF WEIGHT	2	2	2	2	0	0		0
				17.INSIGHT	0	0	0	0	0	0		0
				18.DIURNAL VARIATION	2	2	1	1	1	1		0
				19.DEPERSONALIZATION	0	0	0	0	0	0		0
				20.PARANOID	0	0	0	0	0	0		0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		0
				22.Total score	24	24	22	17	14	13		4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/2	159	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3	2	2	2	2
				02.GUILT	2	2	2	2	1	2	2	2
				03.SUICIDE	1	1	1	1	0	1	1	1
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	2	2	2	1	2	0	0	1
				09.AGITATION	3	3	3	3	1	0	0	2
				10.ANXIETY PSYCHIC	3	2	2	3	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	0	0	1	1	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	1	1	0
				13.SOMATIC GENERAL	2	1	1	1	1	0	0	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	1	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	1	1	1
				19.DEPERSONALIZATION	0	0	2	0	2	2	0	2
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	25	25	22	17	16	14	20
	160	Placebo	Male	01.DEPRESSED MOOD	3	3	0	0	0	2	2	3
				02.GUILT	1	1	2	2	1	1	1	2
				03.SUICIDE	2	2	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	0	0	1	0	0	0
				05.INSOMNIA MIDDLE	1	1	2	2	1	2	2	1
				06.INSOMNIA LATE	1	1	0	0	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	1	1	2	1	1	2
				08.RETARDATION	1	2	1	1	1	1	1	2
				09.AGITATION	1	1	1	1	2	2	2	3
				10.ANXIETY PSYCHIC	1	1	2	2	1	2	2	3
				11.ANXIETY SOMATIC	2	2	2	2	1	0	0	3
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	1
				13.SOMATIC GENERAL	1	1	0	0	0	0	0	1
				14.GENITAL SYMPTOMS	2	2	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	0	0	0	1	1	2
				19.DEPERSONALIZATION	2	2	0	0	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	2	2	1	1	1	1	1	1
				22.Total score	31	32	13	13	16	15	15	26
	161	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	1	1	1		
				02.GUILT	2	2	2	2	2	2		
				03.SUICIDE	2	1	1	1	1	1		
				04.INSOMNIA EARLY	2	2	2	1	1	1		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/2	161	Reboxetine	Female	05.INSOMNIA MIDDLE	1	1	1	1	1	1		
				06.INSOMNIA LATE	1	1	1	1	1	1		
				07.WORK AND ACTIVITIES	3	3	3	2	2	2		
				08.RETARDATION	2	2	3	2	2	2		
				09.AGITATION	1	1	1	2	2	2		
				10.ANXIETY PSYCHIC	2	2	2	2	2	2		
				11.ANXIETY SOMATIC	2	2	2	2	2	2		
				12.SOMATIC GASTROINTESTINAL	0	0	2	0	2	2		
				13.SOMATIC GENERAL	0	0	1	1	1	1		
				14.GENITAL SYMPTOMS	0	0	0	0	0	0		
				15.HYPOCHONDRIASIS	0	0	0	0	0	0		
				16.LOSS OF WEIGHT	1	1	0	0	0	0		
				17.INSIGHT	1	1	1	1	1	1		
				18.DIURNAL VARIATION	1	1	0	0	0	0		
				19.DEPERSONALIZATION	0	0	0	0	0	0		
				20.PARANOID	0	0	0	0	0	0		
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		
				22.Total score	24	23	24	19	21	21		
	162	Placebo	Male	01.DEPRESSED MOOD	2	2	2					
				02.GUILT	2	2	2					
				03.SUICIDE	1	1	1					
				04.INSOMNIA EARLY	2	2	2					
				05.INSOMNIA MIDDLE	1	1	1					
				06.INSOMNIA LATE	2	2	2					
				07.WORK AND ACTIVITIES	2	2	2					
				08.RETARDATION	2	2	2					
				09.AGITATION	2	2	2					
				10.ANXIETY PSYCHIC	3	3	3					
				11.ANXIETY SOMATIC	2	2	2					
				12.SOMATIC GASTROINTESTINAL	1	1	1					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	2	2	2					
				15.HYPOCHONDRIASIS	2	2	2					
				16.LOSS OF WEIGHT	2	2	2					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	0	0	0					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	30	30	30					
	169	Imipramine	Female	01.DEPRESSED MOOD	4	4	0	4	4			
				02.GUILT	3	3	0	4	4			
				03.SUICIDE	2	1	0	2	4			
				04.INSOMNIA EARLY	2	2	0	2	2			
				05.INSOMNIA MIDDLE	2	2	0	2	2			
				06.INSOMNIA LATE	2	2	1	2	2			
				07.WORK AND ACTIVITIES	4	4	0	4	4			
				08.RETARDATION	3	3	0	3	3			

1167

9550082

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/2	169	Imipramine	Female	09.AGITATION	2	2	1	3	3			
				10.ANXIETY PSYCHIC	4	4	0	4	4			
				11.ANXIETY SOMATIC	3	3	1	4	4			
				12.SOMATIC GASTROINTESTINAL	2	2	1	2	2			
				13.SOMATIC GENERAL	2	2	1	2	2			
				14.GENITAL SYMPTOMS	2	2	0	2	2			
				15.HYPOCHONDRIASIS	2	3	0	3	3			
				16.LOSS OF WEIGHT	3	3	0	3	3			
				17.INSIGHT	0	0	0	0	1			
				18.DIURNAL VARIATION	1	1	0	1	2			
				19.DEPERSONALIZATION	1	1	0	3	3			
				20.PARANOID	1	1	0	1	2			
				21.OBSESSIONAL/COMPULSIVE	2	2	0	2	2			
				22.Total score	47	47	5	53	58			
	170	Placebo	Male	01.DEPRESSED MOOD	4	4	2					
				02.GUILT	4	4	2					
				03.SUICIDE	2	2	1					
				04.INSOMNIA EARLY	2	2	1					
				05.INSOMNIA MIDDLE	2	2	1					
				06.INSOMNIA LATE	2	2	0					
				07.WORK AND ACTIVITIES	3	4	1					
				08.RETARDATION	3	3	1					
				09.AGITATION	2	2	1					
				10.ANXIETY PSYCHIC	3	4	1					
				11.ANXIETY SOMATIC	4	4	1					
				12.SOMATIC GASTROINTESTINAL	2	2	0					
				13.SOMATIC GENERAL	2	2	1					
				14.GENITAL SYMPTOMS	2	2	0					
				15.HYPOCHONDRIASIS	3	3	0					
				16.LOSS OF WEIGHT	3	3	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	2	2	1					
				19.DEPERSONALIZATION	3	3	1					
				20.PARANOID	2	2	1					
				21.OBSESSIONAL/COMPULSIVE	2	2	0					
				22.Total score	52	54	16					
	171	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	1	0	0	0	0
				02.GUILT	2	2	2	1	0	0	0	0
				03.SUICIDE	3	2	2	0	0	0	0	0
				04.INSOMNIA EARLY	1	0	0	1	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	1	0	0	0	0
				06.INSOMNIA LATE	1	2	2	1	0	0	0	0
				07.WORK AND ACTIVITIES	4	2	2	1	0	0	0	0
				08.RETARDATION	3	2	2	1	0	0	0	0
				09.AGITATION	3	3	2	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	2	2	1	1	0	0	0
				11.ANXIETY SOMATIC	3	2	2	1	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/2	171	Imipramine	Female	13.SOMATIC GENERAL	2	2	2	1	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	3	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	2	1	1	0	0	0	0	0
				20.PARANOID	2	2	2	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	2	2	2	1	0	0	0	0
				22.Total score	43	35	34	16	2	0	0	0
	172	Reboxetine	Female	01.DEPRESSED MOOD	4	4	4	4	4	4	3	3
				02.GUILT	2	2	2	2	2	2	2	2
				03.SUICIDE	2	2	3	3	3	3	3	3
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	2
				08.RETARDATION	3	3	3	3	3	3	3	3
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	3	3	3	2	2	2	2	2
				16.LOSS OF WEIGHT	3	3	3	3	1	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	1	1	1	1	1	1	2	2
				20.PARANOID	0	0	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	1	1	1	2	2	2	2	2
				22.Total score	39	39	41	41	39	38	38	38
	173	Placebo	Male	01.DEPRESSED MOOD	2	2	2	2	2	3	2	2
				02.GUILT	2	2	2	3	3	2	2	2
				03.SUICIDE	3	3	3	1	1	3	1	1
				04.INSOMNIA EARLY	1	1	1	2	2	2	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	0	0
				06.INSOMNIA LATE	2	2	2	2	2	2	0	0
				07.WORK AND ACTIVITIES	4	4	3	3	3	3	2	2
				08.RETARDATION	2	2	2	2	2	3	2	2
				09.AGITATION	2	2	2	2	2	1	1	1
				10.ANXIETY PSYCHIC	3	3	3	3	3	4	2	3
				11.ANXIETY SOMATIC	2	2	2	2	2	3	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	2
				15.HYPOCHONDRIASIS	3	3	3	3	3	2	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/2	173	Placebo	Male	17.INSIGHT	1	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	2	1	1
				19.DEPERSONALIZATION	1	1	1	1	1	2	1	1
				20.PARANOID	2	2	2	2	2	2	1	1
				21.OBSESSIONAL/COMPULSIVE	2	2	1	2	2	2	2	2
				22.Total score	41	40	38	39	39	43	25	27
	174	Reboxetine	Male	01.DEPRESSED MOOD	4	4	1	0	0	0	0	2
				02.GUILT	2	2	0	0	0	0	0	2
				03.SUICIDE	3	3	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	0	0	0	0	0	0
				06.INSOMNIA LATE	2	2	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	0	0	0	0	0	2
				08.RETARDATION	3	3	1	0	0	0	0	1
				09.AGITATION	2	1	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	4	4	1	0	0	0	0	2
				11.ANXIETY SOMATIC	3	2	1	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	0	0	0	0	1
				14.GENITAL SYMPTOMS	2	2	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	0	0	0	0	0	2
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	2	2	0	0	0	0	0	0
				20.PARANOID	2	2	0	0	0	0	0	1
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	1
				22.Total score	46	44	6	0	0	0	0	14
6/3	163	Reboxetine	Male	01.DEPRESSED MOOD	2	3	2					
				02.GUILT	0	0	0					
				03.SUICIDE	1	1	1					
				04.INSOMNIA EARLY	0	0	0					
				05.INSOMNIA MIDDLE	0	0	0					
				06.INSOMNIA LATE	0	0	0					
				07.WORK AND ACTIVITIES	4	3	4					
				08.RETARDATION	2	2	2					
				09.AGITATION	2	2	2					
				10.ANXIETY PSYCHIC	3	3	3					
				11.ANXIETY SOMATIC	3	3	3					
				12.SOMATIC GASTROINTESTINAL	1	1	1					
				13.SOMATIC GENERAL	1	1	1					
				14.GENITAL SYMPTOMS	1	1	1					
				15.HYPOCHONDRIASIS	3	3	3					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	1	1	1					
				18.DIURNAL VARIATION	1	1	1					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
673	163	Reboxetine	Male	21.OBSESSIONAL/COMPULSIVE	2	2	2					
				22.Total score	27	27	27					
	164	Imipramine	Male	01.DEPRESSED MOOD	2	2	2	2	2	2	2	2
				02.GUILT	0	0	1	1	1	1	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	2	2	2	1
				08.RETARDATION	2	2	2	1	2	2	2	1
				09.AGITATION	1	1	2	1	2	1	1	1
				10.ANXIETY PSYCHIC	3	3	2	2	3	3	2	2
				11.ANXIETY SOMATIC	3	3	3	2	1	0	0	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	2	0	0	0	1	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	3	3	3	2	2	2	2	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	2	2	2	2	2	2	2	2
				22.Total score	26	26	27	19	20	17	16	14
	165	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2	2	2	2	1
				02.GUILT	2	2	0	0	0	1	2	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	1	0	0	0	0	0	0
				06.INSOMNIA LATE	2	2	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	1	2	1	2	2	1	1	0
				09.AGITATION	2	2	2	2	2	2	1	2
				10.ANXIETY PSYCHIC	2	3	2	2	1	2	2	2
				11.ANXIETY SOMATIC	3	3	3	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	0	0	0	1	0	1	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	1	2	2
				15.HYPOCHONDRIASIS	2	2	2	1	2	2	2	1
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	2	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	2	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	27	30	22	22	21	19	19	15

1171

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/3	166	Reboxetine	Female	01.DEPRESSED MOOD	2	3	2					
				02.GUILT	1	1	1					
				03.SUICIDE	0	0	3					
				04.INSOMNIA EARLY	0	0	2					
				05.INSOMNIA MIDDLE	0	0	2					
				06.INSOMNIA LATE	0	0	0					
				07.WORK AND ACTIVITIES	3	4	4					
				08.RETARDATION	2	2	3					
				09.AGITATION	2	2	2					
				10.ANXIETY PSYCHIC	3	3	3					
				11.ANXIETY SOMATIC	2	2	2					
				12.SOMATIC GASTROINTESTINAL	1	1	1					
				13.SOMATIC GENERAL	1	2	2					
				14.GENITAL SYMPTOMS	2	2	2					
				15.HYPOCHONDRIASIS	2	3	3					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	2	2	2					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	1	1	1					
				22.Total score	24	28	35					
	167	Placebo	Female	01.DEPRESSED MOOD	2	2	2	2	2	1	1	1
				02.GUILT	2	2	1	1	1	1	1	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	1	2	1	1	1
				08.RETARDATION	1	0	2	1	2	1	0	1
				09.AGITATION	2	2	1	1	2	1	0	0
				10.ANXIETY PSYCHIC	3	3	3	3	1	2	2	2
				11.ANXIETY SOMATIC	1	2	0	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	0	0	0	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	1	0	1
				19.DEPERSONALIZATION	2	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	2	2	1	2	1	1	1	1
				22.Total score	25	23	19	17	17	12	9	11
	168	Placebo	Female	01.DEPRESSED MOOD	2	3	2	2	2	2	2	
				02.GUILT	2	2	0	0	1	2	2	
				03.SUICIDE	0	0	0	0	0	0	2	
				04.INSOMNIA EARLY	2	0	1	0	1	1	2	

1172

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/3	168	Placebo	Female	05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	
				06.INSOMNIA LATE	0	2	1	0	1	1	0	
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	
				08.RETARDATION	2	2	2	2	2	2	2	
				09.AGITATION	1	1	2	2	1	0	0	
				10.ANXIETY PSYCHIC	3	3	3	3	2	3	3	
				11.ANXIETY SOMATIC	3	3	1	1	2	2	2	
				12.SOMATIC GASTROINTESTINAL	0	0	0	1	0	1	1	
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	
				15.HYPOCHONDRIASIS	2	2	2	2	2	3	3	
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	
				17.INSIGHT	0	0	0	0	0	0	0	
				18.DIURNAL VARIATION	0	2	2	1	0	0	0	
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	
				20.PARANOID	0	0	0	0	0	0	0	
				21.OBSESSIONAL/COMPULSIVE	2	2	2	1	1	1	1	
				22.Total score	27	28	24	21	21	24	26	
	505	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2				
				02.GUILT	1	1	1	1				
				03.SUICIDE	0	0	0	0				
				04.INSOMNIA EARLY	0	0	1	2				
				05.INSOMNIA MIDDLE	0	0	0	0				
				06.INSOMNIA LATE	0	0	1	2				
				07.WORK AND ACTIVITIES	3	3	3	2				
				08.RETARDATION	2	2	2	2				
				09.AGITATION	1	1	1	1				
				10.ANXIETY PSYCHIC	3	3	3	3				
				11.ANXIETY SOMATIC	3	4	1	3				
				12.SOMATIC GASTROINTESTINAL	0	0	1	1				
				13.SOMATIC GENERAL	2	2	1	1				
				14.GENITAL SYMPTOMS	2	2	2	2				
				15.HYPOCHONDRIASIS	2	2	2	2				
				16.LOSS OF WEIGHT	0	0	0	0				
				17.INSIGHT	1	1	0	0				
				18.DIURNAL VARIATION	1	2	0	0				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	1	2	2	1				
				22.Total score	24	27	23	25				
	506	Placebo	Female	01.DEPRESSED MOOD	2	2	2	2	2	1	1	2
				02.GUILT	1	1	1	1	2	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	1	1	1	2	2	0	2
				05.INSOMNIA MIDDLE	1	1	1	1	2	0	0	1
				06.INSOMNIA LATE	1	1	1	1	2	1	2	1
				07.WORK AND ACTIVITIES	2	2	1	2	2	1	2	2
				08.RETARDATION	2	2	2	2	2	2	1	1

1173

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/3	506	Placebo	Female	09.AGITATION	0	0	1	2	1	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	2	2	1	2	2
				11.ANXIETY SOMATIC	2	2	3	2	2	2	3	2
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	1	2	1	2
				15.HYPOCHONDRIASIS	2	2	3	2	2	1	1	2
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	0	2	0	1	0
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	0	1	1	1
				22.Total score	26	25	23	22	25	16	17	20
	507	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2	2	1	1	1
				02.GUILT	2	2	0	1	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	1	0	0	0	0	0
				06.INSOMNIA LATE	1	1	0	0	0	0	1	0
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	0	0
				08.RETARDATION	1	1	1	1	1	1	0	0
				09.AGITATION	2	2	1	2	0	1	0	0
				10.ANXIETY PSYCHIC	3	3	2	3	2	1	1	0
				11.ANXIETY SOMATIC	2	2	3	2	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	1	1	1	0	1
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	1	0	1	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	23	23	20	18	11	10	6	4
	508	Reboxetine	Female	01.DEPRESSED MOOD	2	2	1	2	2	2	1	1
				02.GUILT	1	1	1	0	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	2	0	1	0	1	1
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	1	1	0	0	1	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	2	1	1	1
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	1	1	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	1
				11.ANXIETY SOMATIC	1	2	0	0	0	1	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	1	0	0

1174

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/3	508	Reboxetine	Female	13.SOMATIC GENERAL	0	1	0	1	0	1	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	1	2	1	1
				15.HYPOCHONDRIASIS	2	2	1	3	2	2	1	1
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	1	2	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	0	0
				22.Total score	22	24	17	17	16	16	11	9
	509	Placebo	Male	01.DEPRESSED MOOD	2	2	1	1	2	1	2	2
				02.GUILT	1	2	1	1	1	1	1	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	2	0	1	0	0	1
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	1
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	1	2	1	2	1	1
				08.RETARDATION	1	2	1	1	1	1	1	1
				09.AGITATION	1	1	1	2	0	1	1	1
				10.ANXIETY PSYCHIC	2	3	2	1	2	2	1	1
				11.ANXIETY SOMATIC	3	2	2	1	2	1	0	0
				12.SOMATIC GASTROINTESTINAL	0	1	0	1	1	0	1	1
				13.SOMATIC GENERAL	1	1	0	0	1	0	1	0
				14.GENITAL SYMPTOMS	2	2	2	1	2	1	1	1
				15.HYPOCHONDRIASIS	3	2	1	2	2	2	2	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	1	0	0	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	0	1	1
				22.Total score	22	23	15	14	18	13	14	13
	510	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	2				
				02.GUILT	1	1	1	0				
				03.SUICIDE	0	0	0	0				
				04.INSOMNIA EARLY	2	2	1	2				
				05.INSOMNIA MIDDLE	0	0	2	2				
				06.INSOMNIA LATE	0	0	0	0				
				07.WORK AND ACTIVITIES	2	2	2	2				
				08.RETARDATION	2	2	2	0				
				09.AGITATION	2	2	0	2				
				10.ANXIETY PSYCHIC	2	2	2	2				
				11.ANXIETY SOMATIC	2	2	1	2				
				12.SOMATIC GASTROINTESTINAL	0	0	0	0				
				13.SOMATIC GENERAL	1	1	1	1				
				14.GENITAL SYMPTOMS	2	2	1	1				
				15.HYPOCHONDRIASIS	3	3	2	2				
				16.LOSS OF WEIGHT	0	0	0	0				

1175

9550082

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/3	510	Reboxetine	Female	17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	2	2	0	0				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0				
				22.Total score	24	24	18	18				
	511	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2	2	2	3	
				02.GUILT	1	1	1	0	1	1	1	
				03.SUICIDE	0	0	0	0	0	0	3	
				04.INSOMNIA EARLY	0	2	0	0	0	1	1	
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	
				06.INSOMNIA LATE	0	0	0	1	1	1	1	
				07.WORK AND ACTIVITIES	2	2	2	2	1	2	2	
				08.RETARDATION	2	2	1	1	1	0	1	
				09.AGITATION	2	2	2	1	2	2	2	
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	2	
				11.ANXIETY SOMATIC	2	2	1	1	2	1	1	
				12.SOMATIC GASTROINTESTINAL	0	1	1	1	1	0	0	
				13.SOMATIC GENERAL	1	1	0	0	0	1	1	
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	
				15.HYPOCHONDRIASIS	2	3	1	1	1	1	3	
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	
				17.INSIGHT	0	0	0	0	0	0	0	
				18.DIURNAL VARIATION	2	2	1	0	1	1	1	
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	
				20.PARANOID	0	0	0	0	0	0	0	
				21.OBSESSIONAL/COMPULSIVE	2	2	1	1	1	1	1	
				22.Total score	23	27	15	13	16	16	24	
	512	Placebo	Female	01.DEPRESSED MOOD	2	2	2					
				02.GUILT	1	1	1					
				03.SUICIDE	0	0	0					
				04.INSOMNIA EARLY	1	2	2					
				05.INSOMNIA MIDDLE	0	0	0					
				06.INSOMNIA LATE	1	1	1					
				07.WORK AND ACTIVITIES	2	2	2					
				08.RETARDATION	2	2	2					
				09.AGITATION	2	2	2					
				10.ANXIETY PSYCHIC	2	2	3					
				11.ANXIETY SOMATIC	2	2	3					
				12.SOMATIC GASTROINTESTINAL	0	0	0					
				13.SOMATIC GENERAL	1	1	1					
				14.GENITAL SYMPTOMS	2	2	2					
				15.HYPOCHONDRIASIS	2	2	2					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	2	2	2					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					

1176

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/3	512	Placebo	Female	21.OBSESSIONAL/COMPULSIVE	1	1	1					
				22.Total score	23	24	26					
	513	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2	2	1	1	1
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	1	1	0	1	0	0
				06.INSOMNIA LATE	1	1	1	0	0	0	1	0
				07.WORK AND ACTIVITIES	2	2	1	1	1	0	0	1
				08.RETARDATION	2	2	1	1	1	0	0	0
				09.AGITATION	2	2	2	1	2	2	1	1
				10.ANXIETY PSYCHIC	3	3	2	1	1	2	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	0	1	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	2	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	1	1	1	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	25	25	19	13	12	10	9	7
7/02	181	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	4	3	2	2	2
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	1
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	1	1	1	1	1	1	0	0
				09.AGITATION	2	2	2	2	1	2	2	2
				10.ANXIETY PSYCHIC	4	4	4	4	3	3	3	3
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	23	24	20	19	17	17

1177

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/02	182	Placebo	Male	01.DEPRESSED MOOD	3	3	2	1	1	1	1	1
				02.GUILT	0	0	0	1	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	0	0	1	1
				05.INSOMNIA MIDDLE	2	2	2	0	0	0	0	0
				06.INSOMNIA LATE	1	1	2	0	1	1	1	1
				07.WORK AND ACTIVITIES	1	1	1	2	2	2	2	2
				08.RETARDATION	0	0	0	1	0	0	0	0
				09.AGITATION	2	2	1	0	0	1	0	1
				10.ANXIETY PSYCHIC	3	3	3	1	1	1	1	1
				11.ANXIETY SOMATIC	3	3	3	1	3	3	3	3
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	2	2	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	0	1	2	2	2	2
				15.HYPOCHONDRIASIS	0	0	0	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	2	1	1	1	1	1
				19.DEPERSONALIZATION	1	1	0	0	0	1	0	0
				20.PARANOID	0	0	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	23	23	22	14	13	15	14	15
	183	Imipramine	Male	01.DEPRESSED MOOD	1	1	1	1	2			
				02.GUILT	1	1	1	1	1			
				03.SUICIDE	0	0	0	0	1			
				04.INSOMNIA EARLY	2	2	1	1	1			
				05.INSOMNIA MIDDLE	2	2	2	2	2			
				06.INSOMNIA LATE	2	2	2	2	2			
				07.WORK AND ACTIVITIES	2	2	2	2	4			
				08.RETARDATION	1	1	0	1	0			
				09.AGITATION	0	0	1	1	1			
				10.ANXIETY PSYCHIC	2	2	1	2	3			
				11.ANXIETY SOMATIC	2	2	2	2	3			
				12.SOMATIC GASTROINTESTINAL	1	1	2	2	2			
				13.SOMATIC GENERAL	2	2	2	2	2			
				14.GENITAL SYMPTOMS	1	1	1	1	2			
				15.HYPOCHONDRIASIS	1	1	1	1	1			
				16.LOSS OF WEIGHT	1	1	0	0	0			
				17.INSIGHT	1	1	0	0	0			
				18.DIURNAL VARIATION	1	1	1	1	1			
				19.DEPERSONALIZATION	1	1	0	0	0			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	24	24	20	22	28			
	184	Imipramine	Female	01.DEPRESSED MOOD	4	4	4	3	2	2	1	1
				02.GUILT	2	2	2	2	1	1	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/02	184	Imipramine	Female	05.INSOMNIA MIDDLE	1	1	1	1	1	1	0	0
				06.INSOMNIA LATE	2	2	2	1	1	1	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	1	1	1	0
				08.RETARDATION	1	1	1	1	0	0	0	0
				09.AGITATION	1	1	1	2	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	2	1	1	0	0
				11.ANXIETY SOMATIC	1	1	1	1	2	2	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	1	1	1	1
				15.HYPOCHONDRIASIS	0	1	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	0	1	1	1	1	1	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	26	22	12	12	6	3
	185	Reboxetine	Male	01.DEPRESSED MOOD	1	1	2	2	1	2		
				02.GUILT	2	2	2	1	1	1		
				03.SUICIDE	0	0	0	0	0	0		
				04.INSOMNIA EARLY	2	2	2	2	2	2		
				05.INSOMNIA MIDDLE	2	2	2	2	2	2		
				06.INSOMNIA LATE	1	1	1	1	1	1		
				07.WORK AND ACTIVITIES	1	1	2	1	1	2		
				08.RETARDATION	0	0	0	0	1	1		
				09.AGITATION	1	1	1	1	1	1		
				10.ANXIETY PSYCHIC	2	2	2	2	2	1		
				11.ANXIETY SOMATIC	3	3	3	3	3	1		
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1		
				13.SOMATIC GENERAL	2	2	2	2	2	1		
				14.GENITAL SYMPTOMS	1	1	2	2	2	2		
				15.HYPOCHONDRIASIS	1	1	1	1	1	1		
				16.LOSS OF WEIGHT	0	0	0	0	0	0		
				17.INSIGHT	1	1	1	0	0	0		
				18.DIURNAL VARIATION	0	0	0	0	0	0		
				19.DEPERSONALIZATION	1	1	1	1	1	1		
				20.PARANOID	1	1	1	1	1	1		
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		
				22.Total score	23	23	26	23	23	21		
	186	Placebo	Male	01.DEPRESSED MOOD	2	2	1	1	1	1	1	0
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	2	2	2	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	1	0
				06.INSOMNIA LATE	2	2	2	2	2	2	2	0
				07.WORK AND ACTIVITIES	1	1	1	1	1	1	0	0
				08.RETARDATION	1	1	1	1	1	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/02	186	Placebo	Male	09.AGITATION	1	1	1	1	1	0	0	1
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	1	0
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	2	1	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	21	19	16	15	14	7
	535	Placebo	Male	01.DEPRESSED MOOD	1	1	1	2	2	2	2	2
				02.GUILT	2	2	2	2	2	2	2	2
				03.SUICIDE	0	0	1	1	1	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	0	0
				06.INSOMNIA LATE	0	0	0	0	0	2	0	0
				07.WORK AND ACTIVITIES	3	3	3	3	2	2	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	3	3	3	3	3	2	1	1
				10.ANXIETY PSYCHIC	2	2	3	3	3	2	2	2
				11.ANXIETY SOMATIC	3	3	3	3	3	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	3	3	3	3	3	3	3	3
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	2	2	2	2	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	27	29	30	29	27	20	20
	536	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	2	2	2	2	2
				02.GUILT	2	2	2	2	1	1	1	1
				03.SUICIDE	1	1	1	1	1	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	2	2	2	1	1	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	3	2	2	2	2
				08.RETARDATION	1	1	1	0	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/02	536	Reboxetine	Female	13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	2	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	23	19	17	15	14	14
7/03	187	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2	2	2	1	1
				02.GUILT	2	2	2	2	2	2	1	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	0
				06.INSOMNIA LATE	1	1	1	1	1	1	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	1	1
				08.RETARDATION	2	2	2	2	2	2	0	0
				09.AGITATION	0	0	0	0	0	0	1	1
				10.ANXIETY PSYCHIC	3	3	3	3	3	3	1	0
				11.ANXIETY SOMATIC	2	2	2	2	2	2	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	1	0
				19.DEPERSONALIZATION	1	1	1	1	1	1	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	23	23	23	23	10	5
	188	Placebo	Male	01.DEPRESSED MOOD	3	3	3	3	1	2	2	2
				02.GUILT	2	2	2	2	0	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	0	0	0
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	2	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	0	0	0	0	0	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	0	1	1	1
				11.ANXIETY SOMATIC	2	3	3	3	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	2	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	0	1	1	1
				16.LOSS OF WEIGHT	1	1	1	1	0	0	0	0

1181

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/03	188	Placebo	Male	17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	1	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	0	1	1	1
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	23	23	10	14	14	14
	189	Placebo	Male	01.DEPRESSED MOOD	3	3	3	2	1	1	1	1
				02.GUILT	1	1	1	1	0	0	1	1
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	0	0	1	0
				05.INSOMNIA MIDDLE	2	2	2	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	1	0
				08.RETARDATION	3	3	3	1	0	0	0	0
				09.AGITATION	0	1	1	0	1	1	1	1
				10.ANXIETY PSYCHIC	2	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	0	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	0	0	0	1	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	1	1	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	25	26	13	6	6	8	8
	190	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	2	2	2	2	2
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	0	0	0
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	3	3	1	1	1	1
				08.RETARDATION	1	1	2	2	0	1	1	1
				09.AGITATION	0	0	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	1	1	1	1	1	0	0	0
				11.ANXIETY SOMATIC	1	1	1	1	0	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	1	0	0	0	0	0	0
				17.INSIGHT	0	0	1	1	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	1	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/03	190	Reboxetine	Male	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	23	21	21	12	11	11	11
	191	Imipramine	Female	01.DEPRESSED MOOD	3	4	2	2	2	2	2	
				02.GUILT	2	2	0	0	1	1	1	
				03.SUICIDE	1	1	1	1	0	0	0	
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	
				05.INSOMNIA MIDDLE	2	2	1	1	0	1	1	
				06.INSOMNIA LATE	1	2	1	1	0	0	0	
				07.WORK AND ACTIVITIES	2	3	2	2	1	2	2	
				08.RETARDATION	2	2	1	1	1	1	1	
				09.AGITATION	1	2	0	0	1	1	1	
				10.ANXIETY PSYCHIC	1	2	1	1	1	1	1	
				11.ANXIETY SOMATIC	2	2	1	1	0	1	1	
				12.SOMATIC GASTROINTESTINAL	2	1	0	0	0	1	1	
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	
				14.GENITAL SYMPTOMS	1	1	1	1	0	0	0	
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	
				17.INSIGHT	1	1	0	0	0	0	0	
				18.DIURNAL VARIATION	1	1	1	1	0	1	1	
				19.DEPERSONALIZATION	1	1	1	1	0	0	0	
				20.PARANOID	0	0	0	0	0	0	0	
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	
				22.Total score	27	31	16	16	10	15	15	
	192	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	2	1	1	1
				02.GUILT	2	2	2	1	1	1	1	1
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	0	0	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	2	2	2	2	2
				08.RETARDATION	1	1	1	0	0	1	1	1
				09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	1	1	0	0	0
				16.LOSS OF WEIGHT	1	1	1	0	0	0	0	0
				17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	0	0	0
				19.DEPERSONALIZATION	1	1	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	23	14	14	12	12	12

1183

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/03	523	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3	2	1	1	1
				02.GUILT	3	3	3	3	0	0	0	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	3	2	2	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	1	3	3	3	1	1	1	1
				10.ANXIETY PSYCHIC	2	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	29	29	29	17	16	16	16
	524	Placebo	Female	01.DEPRESSED MOOD	3	3	3	3	2	1	1	1
				02.GUILT	2	2	2	1	1	1	1	1
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	1	0	0	0
				06.INSOMNIA LATE	2	2	2	2	1	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	2	1	1	1
				08.RETARDATION	1	1	1	1	1	0	0	0
				09.AGITATION	2	2	2	2	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	2	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	0	0	0
				15.HYPOCHONDRIASIS	3	3	3	3	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	0	0	0	0
				20.PARANOID	0	0	1	1	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	30	26	16	8	8	8
	525	Placebo	Female	01.DEPRESSED MOOD	3	3	3	2	1	1	1	1
				02.GUILT	3	3	3	1	1	0	0	0
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/03	525	Placebo	Female	05.INSOMNIA MIDDLE	2	2	2	1	1	0	0	0
				06.INSOMNIA LATE	2	2	2	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	1	1	1	1
				08.RETARDATION	2	2	2	2	1	0	0	0
				09.AGITATION	1	1	1	1	1	1	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	28	19	14	5	4	4
	526	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	2	2	1	1
				02.GUILT	3	3	3	2	2	2	0	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	1	0
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	1	0
				06.INSOMNIA LATE	2	2	2	2	2	2	1	0
				07.WORK AND ACTIVITIES	3	3	3	2	2	2	1	0
				08.RETARDATION	3	3	3	3	3	3	1	0
				09.AGITATION	1	1	1	1	1	1	1	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	0
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	26	23	23	23	12	4
	527	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	2	2	2	2
				02.GUILT	2	2	2	2	1	1	1	1
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	3	2	2	2	2
				08.RETARDATION	1	1	1	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/03	527	Imipramine	Female	09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	3	3	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	1	1	1	1	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	27	27	27	16	16	16	16
	528	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	2	2	2	3	
				02.GUILT	2	2	1	1	1	1	2	
				03.SUICIDE	1	1	0	0	0	0	0	
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	
				06.INSOMNIA LATE	2	1	0	0	0	0	1	
				07.WORK AND ACTIVITIES	3	2	2	2	2	2	2	
				08.RETARDATION	1	1	1	1	1	1	1	
				09.AGITATION	1	1	1	1	1	1	1	
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	2	
				11.ANXIETY SOMATIC	2	2	2	2	2	2	1	
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	2	
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	
				17.INSIGHT	0	0	0	0	0	0	0	
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	
				19.DEPERSONALIZATION	1	1	1	1	1	1	0	
				20.PARANOID	0	0	0	0	0	0	0	
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	
				22.Total score	25	23	17	17	17	17	20	
7/04	193	Placebo	Female	01.DEPRESSED MOOD	3	3	3	3	1	1	0	0
				02.GUILT	2	2	2	2	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	1	1	0	0
				06.INSOMNIA LATE	2	2	2	2	1	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	0	0	0
				08.RETARDATION	2	2	2	2	1	1	0	0
				09.AGITATION	2	2	2	2	1	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	3	2	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/04	193	Placebo	Female	13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	2	2	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	28	28	17	8	5	5
	194	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	3	2	1	1	1
				02.GUILT	3	3	3	3	2	1	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	1	1	1	0
				06.INSOMNIA LATE	2	2	2	2	2	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	0	0
				08.RETARDATION	3	3	3	3	2	1	1	1
				09.AGITATION	2	2	2	2	1	1	1	1
				10.ANXIETY PSYCHIC	0	0	0	0	0	0	0	0
				11.ANXIETY SOMATIC	2	2	2	2	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	1
				14.GENITAL SYMPTOMS	0	2	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	3	3	3	3	2	0	0	0
				17.INSIGHT	2	2	2	2	1	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	1	1
				19.DEPERSONALIZATION	2	0	2	2	1	1	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	32	32	32	32	20	12	8	7
	195	Placebo	Female	01.DEPRESSED MOOD	3	3	3	3	1	1	1	1
				02.GUILT	3	3	3	3	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	1	0
				06.INSOMNIA LATE	2	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	1	0	0	1
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	2	2	2	2	2	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	1	0	0	0
				11.ANXIETY SOMATIC	2	2	2	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/04	195	Placebo	Female	17.INSIGHT	2	2	2	2	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	28	28	16	8	8	7
	196	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3	2	1	1	1
				02.GUILT	3	3	3	3	2	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	0	0
				06.INSOMNIA LATE	2	2	2	2	1	1	1	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	0	0
				08.RETARDATION	2	2	2	2	2	1	1	1
				09.AGITATION	2	2	2	2	1	1	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	1	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	2	2	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	26	26	19	14	7	6
	197	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3
				02.GUILT	3	3	3	3	3	3	3	3
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	1	1	2	2	2	2	2	1
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	2	2	2	2	2	2	2	2
				09.AGITATION	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	2	2	2	2	2	2	2	2
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/04	197	Imipramine	Male	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	27	28	28	28	28	28	27
	198	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	2	2	2	1
				02.GUILT	2	2	2	2	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	1	0	0	0
				06.INSOMNIA LATE	2	2	2	2	1	1	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	2	1	1	0
				08.RETARDATION	2	2	2	2	2	2	2	1
				09.AGITATION	2	2	2	2	2	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	2	2	1	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	27	27	27	14	10	9	5
	199	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3	3	2	2	2
				02.GUILT	3	3	3	3	3	2	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	3	3	3	3	3	2	1	1
				09.AGITATION	2	2	2	2	2	1	1	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	1	0	0	0	0	0
				17.INSIGHT	2	2	2	2	2	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	29	28	27	19	16	15

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/04	200	Placebo	Male	01.DEPRESSED MOOD	2	2	2	2	2	2	2	2
				02.GUILT	3	3	3	3	2	2	2	2
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	0	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	3	3	3	3	3	2	2	2
				09.AGITATION	3	3	3	3	3	3	2	2
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	2	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	2	2	2	2	2	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	28	27	25	23	22	22
	201	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3	3	3	2	2
				02.GUILT	2	2	2	2	2	2	2	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	1
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	3	3	3	3	1	1	1	1
				08.RETARDATION	3	3	3	3	2	2	2	1
				09.AGITATION	2	2	2	2	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	3	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	2	2	2	2	2	2
				18.DIURNAL VARIATION	2	2	2	2	2	1	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	28	29	22	21	17	13
	202	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	3	3	3	2	2
				02.GUILT	3	3	3	3	3	3	2	2
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/04	202	Reboxetine	Male	05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	2	2
				08.RETARDATION	3	3	3	3	2	2	2	2
				09.AGITATION	2	2	2	2	2	2	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	1	1	0	0	0	0
				17.INSIGHT	2	2	2	2	2	2	2	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	29	29	25	25	19	17
	203	Placebo	Female	01.DEPRESSED MOOD	3	3	3	3	3	3	3	2
				02.GUILT	2	2	2	2	2	2	2	2
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	3	3	3	3	3	2	2	2
				09.AGITATION	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	2	2	2	2	0	0
				17.INSIGHT	2	2	2	2	2	2	2	2
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	27	28	28	27	24	21	19
	204	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2	2	2	2	1
				02.GUILT	2	2	2	2	2	2	2	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	2	2	2	2	2	2	2	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/04	204	Imipramine	Female	09.AGITATION	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	1	1	1	1	0	0
				17.INSIGHT	2	2	2	2	2	2	2	2
				18.DIURNAL VARIATION	2	2	2	2	2	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	26	26	26	24	23	19
7/05	205	Placebo	Male	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3
				02.GUILT	2	2	2	2	2	2	2	2
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3
				08.RETARDATION	2	3	3	3	3	3	3	3
				09.AGITATION	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	3	3	3	3	3	2	3	3
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	2	2	2	2	2	2	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	1	1	1	1	1	1	1	1
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	2	2	2	2	2	2
				19.DEPERSONALIZATION	1	1	1	1	1	1	1	1
				20.PARANOID	0	0	0	0	0	1	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	33	34	34	34	34	34	33
	206	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	2	2	1	1
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/05	206	Imipramine	Female	13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	1	1	1	1	1	1
				16.LOSS OF WEIGHT	3	3	2	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	30	26	21	16	16	15	15
	207	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2	2	2	2	2
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	2	2	2	2	2	1	1	1
				09.AGITATION	2	2	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	1
				19.DEPERSONALIZATION	1	1	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	24	20	16	14	14	15
	208	Reboxetine	Male	01.DEPRESSED MOOD	2	2	2	2	2	1	1	1
				02.GUILT	2	2	2	1	1	1	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	1	1
				08.RETARDATION	2	2	1	1	1	1	1	1
				09.AGITATION	2	2	2	2	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	0	0
				11.ANXIETY SOMATIC	2	2	2	1	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	2	1	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/05	208	Reboxetine	Male	17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	2	1	0	0	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	29	23	19	13	11	9	9
	209	Placebo	Male	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3
				02.GUILT	2	2	3	3	3	3	3	3
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	2	2	2	2
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	2	2	2	2	2	2	2	2
				09.AGITATION	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	1	1	1	1	1	2	3	3
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	2	2	2	2	2	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	2	2	2	2	2	2
				19.DEPERSONALIZATION	1	1	1	1	1	1	1	1
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	28	28	29	30	31	31
	210	Reboxetine	Male	01.DEPRESSED MOOD	2	2	2	1	1	1	1	1
				02.GUILT	1	1	1	1	1	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	1	1
				08.RETARDATION	2	2	1	1	1	1	1	1
				09.AGITATION	2	2	2	2	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	2	2	1	0	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	1	0	0	0	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/05	210	Reboxetine	Male	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	20	13	11	8	9	8
	541	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	1	1	1	1	1
				02.GUILT	2	2	2	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	1	1	0	0	0	0
				06.INSOMNIA LATE	2	2	2	1	1	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	1	1	1	1	1
				08.RETARDATION	3	3	2	1	1	1	1	1
				09.AGITATION	2	2	2	2	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	1	1	0	0	0
				11.ANXIETY SOMATIC	2	2	2	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	2	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	1	0	0	0	0	0
				17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	0	0	1	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	30	24	15	10	7	7	6
	542	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3	3	3	2	2
				02.GUILT	2	2	2	2	2	2	2	2
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	1	1	1	1	1
				07.WORK AND ACTIVITIES	4	4	3	2	2	2	2	2
				08.RETARDATION	3	3	3	2	2	2	2	2
				09.AGITATION	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	4	4	3	3	2	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	3	3	3	3	2	2	2	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	1	2	1	0	2	2	0
				19.DEPERSONALIZATION	1	1	1	1	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	0	0	0	0
				22.Total score	38	37	35	29	24	24	23	21

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.8

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/05	543	Imipramine	Male	01.DEPRESSED MOOD	3	3	2	1	1	1	1	1
				02.GUILT	2	2	2	1	1	1	1	1
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	1	0	0	0
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	2	2	2	2	2	1	1	1
				09.AGITATION	2	2	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	0	0	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	1	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	23	23	19	14	12	9	9	9
	544	Placebo	Female	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3
				02.GUILT	3	3	3	3	3	3	3	3
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	2	2	2
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3
				08.RETARDATION	2	2	2	2	2	2	2	2
				09.AGITATION	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	2
				11.ANXIETY SOMATIC	1	1	1	2	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	2	2	0	1	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	2	2	2	2
				19.DEPERSONALIZATION	1	1	1	1	1	1	1	1
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	33	33	31	32	32	32	32	33
	545	Placebo	Male	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3
				02.GUILT	3	3	3	3	3	3	3	3
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/05	545	Placebo	Male	05.INSOMNIA MIDDLE	2	2	2	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3
				08.RETARDATION	2	2	2	2	2	2	2	2
				09.AGITATION	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	3	3	3	3	3	3	3	3
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	2	1	1	1	1	2
				19.DEPERSONALIZATION	2	2	2	2	2	2	2	2
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	36	36	36	34	34	34	34	35
	546	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	1	1	1	1
				02.GUILT	2	2	2	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	2	1	1	1	1
				08.RETARDATION	2	2	2	2	2	1	1	1
				09.AGITATION	2	2	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	1	1	1	0	0	0
				18.DIURNAL VARIATION	0	1	1	1	1	0	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	27	24	19	15	12	13	12
7/07	529	Placebo	Female	01.DEPRESSED MOOD	4	3	3	3	2	2	2	2
				02.GUILT	1	2	1	1	1	1	1	1
				03.SUICIDE	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	1	2	2	2	2	2	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	1	1	1	0	0	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/07	529	Placebo	Female	09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	3	2	3	3	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	0	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	1	1	1	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	0	1	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	2	2	2	1	1	1
				19.DEPERSONALIZATION	1	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	24	27	22	20	20	20	19
	530	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3				
				02.GUILT	2	2	1	2				
				03.SUICIDE	1	1	1	1				
				04.INSOMNIA EARLY	2	2	2	2				
				05.INSOMNIA MIDDLE	2	2	2	2				
				06.INSOMNIA LATE	1	2	2	2				
				07.WORK AND ACTIVITIES	3	3	2	2				
				08.RETARDATION	0	1	1	1				
				09.AGITATION	2	2	1	1				
				10.ANXIETY PSYCHIC	2	2	2	2				
				11.ANXIETY SOMATIC	2	2	3	2				
				12.SOMATIC GASTROINTESTINAL	0	1	1	1				
				13.SOMATIC GENERAL	2	2	2	2				
				14.GENITAL SYMPTOMS	2	1	1	1				
				15.HYPOCHONDRIASIS	1	0	0	2				
				16.LOSS OF WEIGHT	0	0	0	0				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	1	1	1	1				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	26	27	25	27				
	531	Reboxetine	Female	01.DEPRESSED MOOD	3	2	3	2	2	3	2	1
				02.GUILT	2	3	3	2	1	2	0	1
				03.SUICIDE	2	2	2	2	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	1	1	2	2	2
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	1	1
				08.RETARDATION	0	1	1	1	1	1	1	1
				09.AGITATION	2	1	2	1	1	2	1	2
				10.ANXIETY PSYCHIC	2	2	2	1	1	2	1	2
				11.ANXIETY SOMATIC	2	2	2	2	1	2	2	1
				12.SOMATIC GASTROINTESTINAL	1	0	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/07	531	Reboxetine	Female	13.SOMATIC GENERAL	2	2	2	2	2	2	1	2
				14.GENITAL SYMPTOMS	1	1	1	0	1	2	1	0
				15.HYPOCHONDRIASIS	0	0	0	0	1	1	0	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	0	0	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	25	28	21	20	25	18	20
	532	Imipramine	Female	01.DEPRESSED MOOD	2	3	3	2	2	2	2	2
				02.GUILT	1	1	1	2	2	1	1	1
				03.SUICIDE	1	1	1	1	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	1
				05.INSOMNIA MIDDLE	2	2	2	1	2	1	2	1
				06.INSOMNIA LATE	2	2	2	1	2	1	1	1
				07.WORK AND ACTIVITIES	2	3	2	2	2	2	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	2	2	1	2	1	1	1	0
				10.ANXIETY PSYCHIC	2	2	2	3	2	2	1	1
				11.ANXIETY SOMATIC	2	3	3	2	2	2	2	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	2	2	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	1	2	2	1	1	0	0	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	30	28	26	26	22	21	16
	533	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	3	3	3	2	3
				02.GUILT	2	2	2	2	2	1	1	1
				03.SUICIDE	1	2	2	2	2	1	1	1
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	1	1	1	1	1	1	1	0
				09.AGITATION	2	2	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	2	2	2	2	2	1
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	2	2	1	1	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	2	2	1	1	0	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/07	533	Reboxetine	Male	17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	1	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	30	28	29	28	25	24	21
	534	Placebo	Female	01.DEPRESSED MOOD	3	2	3	3	3	2	3	2
				02.GUILT	2	2	2	2	2	1	1	1
				03.SUICIDE	2	1	1	0	0	1	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	2	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	1
				06.INSOMNIA LATE	2	2	2	1	1	2	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	1	2	2	2
				08.RETARDATION	1	1	1	1	1	1	0	1
				09.AGITATION	1	2	2	2	1	1	1	1
				10.ANXIETY PSYCHIC	3	2	2	2	2	2	1	2
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	1
				13.SOMATIC GENERAL	2	2	2	2	1	2	2	2
				14.GENITAL SYMPTOMS	2	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	1	1	1	1	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	1	1	1	1	1	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	27	28	26	23	24	20	18
8	211	Reboxetine	Female	01.DEPRESSED MOOD	4	4	4	4				
				02.GUILT	2	2	2	2				
				03.SUICIDE	0	0	0	1				
				04.INSOMNIA EARLY	1	1	1	1				
				05.INSOMNIA MIDDLE	1	1	1	1				
				06.INSOMNIA LATE	2	2	2	2				
				07.WORK AND ACTIVITIES	4	4	4	4				
				08.RETARDATION	0	0	1	1				
				09.AGITATION	1	1	1	1				
				10.ANXIETY PSYCHIC	4	4	4	4				
				11.ANXIETY SOMATIC	2	2	2	2				
				12.SOMATIC GASTROINTESTINAL	1	1	1	1				
				13.SOMATIC GENERAL	1	1	1	1				
				14.GENITAL SYMPTOMS	1	1	1	1				
				15.HYPOCHONDRIASIS	3	3	3	3				
				16.LOSS OF WEIGHT	0	0	0	0				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	0	0	0	0				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				

1200

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	211	Reboxetine	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	27	27	28	29				
	212	Placebo	Female	01.DEPRESSED MOOD	4	4	4	4	3	4	4	4
				02.GUILT	2	2	2	2	2	2	2	2
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	0	0	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	3	3	3	3	3	3
				11.ANXIETY SOMATIC	2	2	2	2	1	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	24	23	21	24	24	24
	213	Imipramine	Male	01.DEPRESSED MOOD	4	4						
				02.GUILT	2	2						
				03.SUICIDE	1	1						
				04.INSOMNIA EARLY	1	1						
				05.INSOMNIA MIDDLE	1	1						
				06.INSOMNIA LATE	2	2						
				07.WORK AND ACTIVITIES	3	3						
				08.RETARDATION	0	0						
				09.AGITATION	2	2						
				10.ANXIETY PSYCHIC	3	3						
				11.ANXIETY SOMATIC	1	1						
				12.SOMATIC GASTROINTESTINAL	1	1						
				13.SOMATIC GENERAL	1	1						
				14.GENITAL SYMPTOMS	1	1						
				15.HYPOCHONDRIASIS	3	3						
				16.LOSS OF WEIGHT	0	0						
				17.INSIGHT	0	0						
				18.DIURNAL VARIATION	0	0						
				19.DEPERSONALIZATION	0	0						
				20.PARANOID	0	0						
				21.OBSESSIONAL/COMPULSIVE	1	1						
				22.Total score	27	27						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	214	Reboxetine	Female	01.DEPRESSED MOOD	4	4	4	4	4	4	4	4
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	4	4	4	3	3	3	3	3
				08.RETARDATION	1	1	1	1	1	1	0	0
				09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	3	2	2	2	2	2
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	23	22	22	22	21	21
	215	Placebo	Female	01.DEPRESSED MOOD	3	3	2	2	1	1	1	1
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	0
				06.INSOMNIA LATE	1	1	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	4	4	3	2	1	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	2	2	1	1	1	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	0	0
				11.ANXIETY SOMATIC	1	1	1	1	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	1	1	1	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	22	15	15	10	9	5	4
	216	Imipramine	Male	01.DEPRESSED MOOD	4	4	4	4	3	3	3	2
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	216	Imipramine	Male	05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	2	2	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	4	4	4	4	4	4	3	3
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	1	1	1	1	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	22	21	20	18	16	14	13
	217	Reboxetine	Female	01.DEPRESSED MOOD	4	4	4	3	2	2	2	2
				02.GUILT	1	1	1	1	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	4	4	3	3	2	1	1	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	1	1	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	0	0	0	0
				11.ANXIETY SOMATIC	1	1	1	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	0	0	0	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	22	18	14	8	6	4	5
	218	Reboxetine	Female	01.DEPRESSED MOOD	4	4	4	4	4	3	3	3
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	2	2	2	1	1	1	0	0
				07.WORK AND ACTIVITIES	3	3	3	3	3	2	2	2
				08.RETARDATION	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	218	Reboxetine	Female	09.AGITATION	2	2	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	2	2	2	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	2	2	2	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	23	24	22	21	19	14	11	11
	219	Placebo	Female	01.DEPRESSED MOOD	4	4	4	3	3			
				02.GUILT	1	1	1	1	1			
				03.SUICIDE	0	0	0	0	0			
				04.INSOMNIA EARLY	1	1	1	1	1			
				05.INSOMNIA MIDDLE	1	1	0	0	0			
				06.INSOMNIA LATE	1	1	1	0	0			
				07.WORK AND ACTIVITIES	3	3	3	3	2			
				08.RETARDATION	0	0	0	0	0			
				09.AGITATION	1	1	1	1	0			
				10.ANXIETY PSYCHIC	2	2	2	2	1			
				11.ANXIETY SOMATIC	1	1	1	0	0			
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0			
				13.SOMATIC GENERAL	1	1	1	1	1			
				14.GENITAL SYMPTOMS	1	1	1	1	1			
				15.HYPOCHONDRIASIS	1	1	1	1	1			
				16.LOSS OF WEIGHT	1	1	0	0	0			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	1	1	1	1	0			
				19.DEPERSONALIZATION	0	0	0	0	0			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0			
				22.Total score	22	22	20	15	11			
	220	Imipramine	Female	01.DEPRESSED MOOD	4	4	4	4	3	2	2	1
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	4	4	4	4	3	3	3	2
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	2	1	1	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	0

1204

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	220	Imipramine	Female	13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	0	0
				22.Total score	22	22	22	20	15	13	13	10
	221	Imipramine	Male	01.DEPRESSED MOOD	4	4	4	4	3	2	1	1
				02.GUILT	1	1	1	1	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	0	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	4	4	4	4	3	3	2	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	1	1	1	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	0	0	0	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	1	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	22	22	21	19	12	11	8	5
	222	Placebo	Female	01.DEPRESSED MOOD	4	4	2	2	1	1	2	2
				02.GUILT	1	1	1	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	0	0	0	0	1	1
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	0	0	0	1	1
				07.WORK AND ACTIVITIES	4	4	3	3	2	0	0	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	1	0	0	0	0	0
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	0	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	222	Placebo	Female	17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	22	13	9	5	3	6	6
	223	Imipramine	Female	01.DEPRESSED MOOD	4	4	4	3	3	2	2	2
				02.GUILT	2	2	2	1	1	1	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	4	4	4	4	3	3	2	2
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	1	2	1	0	0	0	0
				10.ANXIETY PSYCHIC	1	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	1	1
				16.LOSS OF WEIGHT	1	1	1	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	25	18	14	12	9	9
	224	Placebo	Female	01.DEPRESSED MOOD	4	4	4	3	3	3	2	2
				02.GUILT	1	1	1	1	1	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	1	1	0	0
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	2	2
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	0
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	224	Placebo	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	23	20	17	16	15	12	10
	225	Placebo	Male	01.DEPRESSED MOOD	3	3	3	3	3	3	3	2
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	0	0
				06.INSOMNIA LATE	2	2	2	1	1	1	1	0
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	2	2
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	2	2	2	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	2	2	2	2	2	1	1
				16.LOSS OF WEIGHT	1	1	1	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	0	0	0
				18.DIURNAL VARIATION	0	0	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	24	25	23	23	20	15	12
	226	Reboxetine	Male	01.DEPRESSED MOOD	4	4	4	4	4	4	4	4
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	3	3	3	2	2	2	2	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	25	25	25	23	23	22	22	22

1207

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	227	Reboxetine	Male	01.DEPRESSED MOOD	4	4	4	3	3	3	3	3
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	0	0	0
				06.INSOMNIA LATE	1	2	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	0	0
				22.Total score	24	25	23	22	21	19	18	17
	228	Imipramine	Male	01.DEPRESSED MOOD	3	4	4					
				02.GUILT	1	1	1					
				03.SUICIDE	0	0	0					
				04.INSOMNIA EARLY	1	1	1					
				05.INSOMNIA MIDDLE	1	1	1					
				06.INSOMNIA LATE	1	2	2					
				07.WORK AND ACTIVITIES	3	3	3					
				08.RETARDATION	0	0	0					
				09.AGITATION	1	1	2					
				10.ANXIETY PSYCHIC	1	2	2					
				11.ANXIETY SOMATIC	1	1	1					
				12.SOMATIC GASTROINTESTINAL	1	1	1					
				13.SOMATIC GENERAL	1	1	1					
				14.GENITAL SYMPTOMS	1	1	1					
				15.HYPOCHONDRIASIS	2	2	2					
				16.LOSS OF WEIGHT	1	0	0					
				17.INSIGHT	1	1	1					
				18.DIURNAL VARIATION	1	1	1					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	1	1	1					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	22	24	25					
	229	Imipramine	Female	01.DEPRESSED MOOD	4	4	4	4	3	3	3	2
				02.GUILT	2	2	2	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	229	Imipramine	Female	05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	2
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	25	25	20	19	18	18	15
	230	Reboxetine	Female	01.DEPRESSED MOOD	4	4	4	4	3	3	3	2
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	1	1	1
				07.WORK AND ACTIVITIES	4	4	4	4	4	4	3	3
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	2	2	2	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	1	2	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	1	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	25	24	22	20	19	18
	231	Imipramine	Male	01.DEPRESSED MOOD	4	4	4	3	3	2	2	2
				02.GUILT	1	1	1	1	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	0	0	0	0
				06.INSOMNIA LATE	2	2	2	1	1	1	1	0
				07.WORK AND ACTIVITIES	3	3	3	3	3	2	2	2
				08.RETARDATION	0	0	0	0	0	0	0	0

1209

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	231	Imipramine	Male	09.AGITATION	1	1	1	1	1	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	22	19	16	13	12	11
	232	Reboxetine	Male	01.DEPRESSED MOOD	4	4	4	3	3	3	2	2
				02.GUILT	1	1	1	1	1	1	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	0	0	0
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	2	2
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	1	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	1	1	1	1	1
				16.LOSS OF WEIGHT	1	1	1	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	0	0	0	0
				22.Total score	24	24	23	19	18	15	12	10
	233	Placebo	Female	01.DEPRESSED MOOD	4	4	4	4	4	3	3	2
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	0	0	0
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	2
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	2	2	1	1	1	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	233	Placebo	Female	13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	0	0	0
				22.Total score	25	25	25	25	22	17	16	12
	234	Placebo	Female	01.DEPRESSED MOOD	4	4	4	4	4	4	3	3
				02.GUILT	1	1	1	1	1	1	1	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	0	0
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	24	24	23	22	20	20	18	17
8/A	235	Placebo	Female	01.DEPRESSED MOOD	3	2	2	2	2	2	2	2
				02.GUILT	2	2	1	1	1	1	1	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	1	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	1	1	1	1	0	1	0	0
				06.INSOMNIA LATE	2	2	2	1	1	1	0	1
				07.WORK AND ACTIVITIES	3	3	2	2	2	2	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	2	2	1	1	1	1	1	0
				10.ANXIETY PSYCHIC	2	3	2	1	1	0	1	1
				11.ANXIETY SOMATIC	2	2	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	2	2	2	1	0	1	1
				14.GENITAL SYMPTOMS	1	2	1	1	1	1	1	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0

1211

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8/A	235	Placebo	Female	17.INSIGHT	2	2	2	2	1	1	1	1
				18.DIURNAL VARIATION	1	2	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	30	33	25	22	18	17	17	16
	236	Placebo	Female	01.DEPRESSED MOOD	3	3	2	2	2	2	1	1
				02.GUILT	1	1	1	1	1	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	0	0	1	1	0	0	1	0
				06.INSOMNIA LATE	1	2	2	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	2	2	1	1	1	1
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	2	2	1	1	1	1	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	3	3	2	1	0	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	0	1
				14.GENITAL SYMPTOMS	1	1	2	1	1	0	1	0
				15.HYPOCHONDRIASIS	2	2	1	1	0	0	0	0
				16.LOSS OF WEIGHT	2	1	1	0	0	0	0	0
				17.INSIGHT	2	2	1	0	1	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	0	0
				22.Total score	30	30	24	16	13	11	9	8
	237	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	2	1	1	1
				02.GUILT	3	2	2	1	1	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	2	2	2	1	2	1	1
				05.INSOMNIA MIDDLE	1	1	0	1	1	1	1	0
				06.INSOMNIA LATE	2	2	2	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	2	2	1	1	1	1
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	2	2	1	1	0	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	0	0
				11.ANXIETY SOMATIC	3	3	2	1	0	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	2	2	1	1	1	1	0
				13.SOMATIC GENERAL	1	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	1	1	1	0	1	0	0
				15.HYPOCHONDRIASIS	2	2	1	1	1	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	2	1	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	0	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8/A	237	Reboxetine	Female	21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	0	1	1
				22.Total score	32	35	26	20	13	13	10	8
	238	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	2	1	1	1
				02.GUILT	2	2	2	1	0	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	1
				05.INSOMNIA MIDDLE	0	0	1	0	1	1	0	0
				06.INSOMNIA LATE	2	2	2	1	1	0	1	0
				07.WORK AND ACTIVITIES	3	3	2	1	1	1	1	1
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	1	1	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	1	2	1	1	1	0	0	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	2	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	0	1	1	2	1
				15.HYPOCHONDRIASIS	1	1	1	1	0	0	0	0
				16.LOSS OF WEIGHT	1	1	1	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	27	29	23	16	13	10	11	10
	239	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	2	2	1	1	1
				02.GUILT	2	2	2	1	1	1	0	0
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	0
				06.INSOMNIA LATE	1	2	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	2	2	1	1	1	1
				08.RETARDATION	1	1	1	1	2	2	2	2
				09.AGITATION	1	1	1	1	1	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	2	1	1	0	0
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	2	1	1	1
				13.SOMATIC GENERAL	1	2	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	1	1	1	1	0	1
				15.HYPOCHONDRIASIS	1	1	1	1	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	0	0
				18.DIURNAL VARIATION	1	2	1	0	0	0	0	0
				19.DEPERSONALIZATION	1	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	28	30	21	18	16	13	9	10

1213

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8/A	240	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	2	2	2	2	2
				02.GUILT	2	2	2	1	1	1	1	0
				03.SUICIDE	2	2	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	0	1	1	0	1	0	1	0
				06.INSOMNIA LATE	1	1	2	2	1	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	2	2	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	1	1	1	1	1	0	0	1
				10.ANXIETY PSYCHIC	1	2	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	1	2	1	1	1	0
				15.HYPOCHONDRIASIS	1	1	1	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	2	2	1	1	1	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	27	29	26	21	19	16	16	14
	553	Placebo	Female	01.DEPRESSED MOOD	3	3	2	2	2	2	2	2
				02.GUILT	3	3	2	2	1	1	1	1
				03.SUICIDE	1	1	1	1	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	2	2
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	2	1	1	1	1	1
				07.WORK AND ACTIVITIES	4	3	2	2	2	2	2	1
				08.RETARDATION	2	2	3	2	2	2	2	2
				09.AGITATION	1	1	1	0	1	0	1	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	0	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	1	1	1	1	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	1	1	1	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	29	29	27	23	21	18	20	17
	554	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	2	2	2	1	1
				02.GUILT	3	2	2	1	1	0	0	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8/A	554	Reboxetine	Male	05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	0
				06.INSOMNIA LATE	2	2	2	1	1	1	1	0
				07.WORK AND ACTIVITIES	4	4	3	2	2	1	1	1
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	1	1	1	1	0	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	0	0	0	0
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	0	1	1	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	27	26	22	17	14	12	10	9
	555	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	2	2	2	2
				02.GUILT	2	2	2	1	1	1	0	0
				03.SUICIDE	1	1	1	1	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	2	1
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	0
				06.INSOMNIA LATE	1	2	2	2	1	1	0	1
				07.WORK AND ACTIVITIES	3	3	3	2	2	2	2	1
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	2	1	0	0	1	0	1	0
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	1	1	1	1
				13.SOMATIC GENERAL	1	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	1	1	2	1	2	1	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	2	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	23	19	18	17	16	13
	556	Imipramine	Male	01.DEPRESSED MOOD	3	3	2	2	1	1	1	1
				02.GUILT	2	2	2	1	1	1	1	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	2	1
				05.INSOMNIA MIDDLE	1	0	0	0	1	1	0	0
				06.INSOMNIA LATE	2	2	1	0	0	0	0	1
				07.WORK AND ACTIVITIES	4	4	3	2	2	1	1	1
				08.RETARDATION	1	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8/A	556	Imipramine	Male	09.AGITATION	1	1	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	0	0	0	0
				11.ANXIETY SOMATIC	2	2	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	1	1	1	1	1	0
				13.SOMATIC GENERAL	1	1	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	1	1	1	1	0	1	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	2	1	1	1	1	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	1	1	1	1	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	31	28	23	18	16	12	12	9
9	241	Placebo	Female	01.DEPRESSED MOOD	3	4	4	4				
				02.GUILT	1	1	1	1				
				03.SUICIDE	1	2	2	1				
				04.INSOMNIA EARLY	2	1	1	2				
				05.INSOMNIA MIDDLE	2	1	1	2				
				06.INSOMNIA LATE	2	1	1	2				
				07.WORK AND ACTIVITIES	3	3	3	3				
				08.RETARDATION	1	2	2	1				
				09.AGITATION	3	0	2	3				
				10.ANXIETY PSYCHIC	3	2	2	3				
				11.ANXIETY SOMATIC	2	0	2	3				
				12.SOMATIC GASTROINTESTINAL	1	2	2	1				
				13.SOMATIC GENERAL	1	2	1	2				
				14.GENITAL SYMPTOMS	2	2	2	2				
				15.HYPOCHONDRIASIS	0	0	1	1				
				16.LOSS OF WEIGHT	2	1	1	1				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	0	0	0	0				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	29	24	28	32				
	242	Reboxetine	Female	01.DEPRESSED MOOD	3	3	1	3	3			
				02.GUILT	2	2	1	2	1			
				03.SUICIDE	1	1	1	1	2			
				04.INSOMNIA EARLY	2	2	1	1	2			
				05.INSOMNIA MIDDLE	2	2	1	1	2			
				06.INSOMNIA LATE	2	2	2	1	2			
				07.WORK AND ACTIVITIES	3	3	2	2	2			
				08.RETARDATION	1	1	0	1	1			
				09.AGITATION	2	2	0	1	2			
				10.ANXIETY PSYCHIC	3	3	1	2	2			
				11.ANXIETY SOMATIC	2	2	2	2	3			
				12.SOMATIC GASTROINTESTINAL	1	1	0	2	2			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	242	Reboxetine	Female	13.SOMATIC GENERAL	1	1	1	1	1			
				14.GENITAL SYMPTOMS	2	2	2	2	2			
				15.HYPOCHONDRIASIS	1	1	1	2	1			
				16.LOSS OF WEIGHT	2	0	0	0	0			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	1	0	1	0	1			
				19.DEPERSONALIZATION	0	0	0	1	0			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	31	28	17	25	29			
	243	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3				
				02.GUILT	1	1	1	1				
				03.SUICIDE	1	1	1	1				
				04.INSOMNIA EARLY	1	1	2	2				
				05.INSOMNIA MIDDLE	1	1	2	2				
				06.INSOMNIA LATE	1	1	1	2				
				07.WORK AND ACTIVITIES	3	3	3	4				
				08.RETARDATION	1	1	1	1				
				09.AGITATION	1	1	3	4				
				10.ANXIETY PSYCHIC	2	2	3	4				
				11.ANXIETY SOMATIC	2	2	2	4				
				12.SOMATIC GASTROINTESTINAL	1	1	1	2				
				13.SOMATIC GENERAL	1	1	1	1				
				14.GENITAL SYMPTOMS	2	2	2	2				
				15.HYPOCHONDRIASIS	0	0	0	0				
				16.LOSS OF WEIGHT	1	1	0	0				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	0	0	0	0				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	22	22	26	33				
	244	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	2	2			
				02.GUILT	0	0	0	0	0			
				03.SUICIDE	2	2	0	0	0			
				04.INSOMNIA EARLY	2	2	1	1	1			
				05.INSOMNIA MIDDLE	2	2	2	1	1			
				06.INSOMNIA LATE	2	2	2	1	1			
				07.WORK AND ACTIVITIES	3	3	2	2	2			
				08.RETARDATION	0	0	0	0	0			
				09.AGITATION	2	2	1	1	1			
				10.ANXIETY PSYCHIC	1	2	1	1	1			
				11.ANXIETY SOMATIC	1	1	1	1	1			
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0			
				13.SOMATIC GENERAL	1	1	0	0	0			
				14.GENITAL SYMPTOMS	1	1	1	1	1			
				15.HYPOCHONDRIASIS	0	0	0	0	0			
				16.LOSS OF WEIGHT	1	0	0	0	0			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	244	Imipramine	Female	17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	1	1	1	1	1			
				19.DEPERSONALIZATION	0	0	0	0	0			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	23	23	14	12	12			
	245	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	0	0	0	0
				02.GUILT	2	2	2	1	0	0	0	0
				03.SUICIDE	2	2	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	4	4	3	1	0	0	1	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	0	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	1	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	24	20	13	6	4	6	5
	246	Placebo	Female	01.DEPRESSED MOOD	4	4	4	4	4	4		
				02.GUILT	1	1	1	1	1	1		
				03.SUICIDE	1	1	0	0	0	0		
				04.INSOMNIA EARLY	2	2	2	2	2	2		
				05.INSOMNIA MIDDLE	2	2	0	0	0	0		
				06.INSOMNIA LATE	2	2	0	0	0	0		
				07.WORK AND ACTIVITIES	4	4	4	4	4	4		
				08.RETARDATION	1	1	3	3	3	3		
				09.AGITATION	3	3	3	3	3	3		
				10.ANXIETY PSYCHIC	4	4	4	4	4	4		
				11.ANXIETY SOMATIC	1	1	2	2	2	2		
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2		
				13.SOMATIC GENERAL	1	1	1	1	1	1		
				14.GENITAL SYMPTOMS	2	2	2	2	2	2		
				15.HYPOCHONDRIASIS	0	0	0	0	0	0		
				16.LOSS OF WEIGHT	2	0	2	2	0	0		
				17.INSIGHT	0	0	2	2	2	2		
				18.DIURNAL VARIATION	0	0	0	0	0	0		
				19.DEPERSONALIZATION	0	0	0	0	0	0		
				20.PARANOID	1	1	0	0	0	0		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	246	Placebo	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		
				22.Total score	33	31	32	32	30	30		
	247	Placebo	Female	01.DEPRESSED MOOD	3	3	3	2	2	2		
				02.GUILT	2	2	1	1	1	1		
				03.SUICIDE	1	1	1	1	1	1		
				04.INSOMNIA EARLY	1	1	1	1	2	2		
				05.INSOMNIA MIDDLE	1	1	2	2	2	1		
				06.INSOMNIA LATE	1	1	1	1	1	2		
				07.WORK AND ACTIVITIES	4	4	3	2	3	3		
				08.RETARDATION	0	0	0	0	0	0		
				09.AGITATION	0	0	0	0	1	1		
				10.ANXIETY PSYCHIC	2	2	2	1	2	2		
				11.ANXIETY SOMATIC	3	3	3	2	2	2		
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0		
				13.SOMATIC GENERAL	1	1	1	1	1	1		
				14.GENITAL SYMPTOMS	2	2	2	2	2	2		
				15.HYPOCHONDRIASIS	1	1	0	1	1	1		
				16.LOSS OF WEIGHT	0	0	0	0	0	0		
				17.INSIGHT	0	0	0	0	0	0		
				18.DIURNAL VARIATION	1	1	1	1	1	1		
				19.DEPERSONALIZATION	1	1	1	1	1	1		
				20.PARANOID	0	0	0	0	0	0		
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		
				22.Total score	25	25	23	20	24	23		
	248	Placebo	Male	01.DEPRESSED MOOD	3	3	3	3				
				02.GUILT	2	2	2	2				
				03.SUICIDE	1	2	2	3				
				04.INSOMNIA EARLY	1	1	1	2				
				05.INSOMNIA MIDDLE	1	1	2	2				
				06.INSOMNIA LATE	1	1	1	2				
				07.WORK AND ACTIVITIES	4	4	4	4				
				08.RETARDATION	1	1	1	0				
				09.AGITATION	0	0	1	3				
				10.ANXIETY PSYCHIC	1	1	2	3				
				11.ANXIETY SOMATIC	1	1	1	4				
				12.SOMATIC GASTROINTESTINAL	1	1	1	2				
				13.SOMATIC GENERAL	2	2	2	2				
				14.GENITAL SYMPTOMS	2	2	2	2				
				15.HYPOCHONDRIASIS	0	0	0	2				
				16.LOSS OF WEIGHT	0	0	0	0				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	1	1	1	0				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	22	23	26	36				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	249	Reboxetine	Female	01.DEPRESSED MOOD	3	3						
				02.GUILT	2	2						
				03.SUICIDE	2	2						
				04.INSOMNIA EARLY	2	2						
				05.INSOMNIA MIDDLE	1	1						
				06.INSOMNIA LATE	2	0						
				07.WORK AND ACTIVITIES	3	3						
				08.RETARDATION	2	2						
				09.AGITATION	0	1						
				10.ANXIETY PSYCHIC	2	2						
				11.ANXIETY SOMATIC	1	0						
				12.SOMATIC GASTROINTESTINAL	1	1						
				13.SOMATIC GENERAL	1	1						
				14.GENITAL SYMPTOMS	2	2						
				15.HYPOCHONDRIASIS	0	0						
				16.LOSS OF WEIGHT	3	3						
				17.INSIGHT	0	0						
				18.DIURNAL VARIATION	0	0						
				19.DEPERSONALIZATION	0	0						
				20.PARANOID	0	0						
				21.OBSESSIONAL/COMPULSIVE	0	0						
				22.Total score	27	25						
	250	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	3	3		
				02.GUILT	1	1	1	1	1	1		
				03.SUICIDE	2	2	2	1	1	1		
				04.INSOMNIA EARLY	2	2	2	1	1	1		
				05.INSOMNIA MIDDLE	2	1	1	1	1	1		
				06.INSOMNIA LATE	1	2	2	1	1	1		
				07.WORK AND ACTIVITIES	3	3	3	3	3	3		
				08.RETARDATION	2	2	2	2	1	1		
				09.AGITATION	0	0	0	0	0	0		
				10.ANXIETY PSYCHIC	1	1	1	0	0	0		
				11.ANXIETY SOMATIC	0	0	0	1	2	2		
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	2	2		
				13.SOMATIC GENERAL	2	2	2	2	1	1		
				14.GENITAL SYMPTOMS	2	2	2	0	2	2		
				15.HYPOCHONDRIASIS	0	0	0	0	0	0		
				16.LOSS OF WEIGHT	0	2	0	0	0	0		
				17.INSIGHT	0	0	0	0	0	0		
				18.DIURNAL VARIATION	1	1	1	1	1	1		
				19.DEPERSONALIZATION	0	0	0	0	0	1		
				20.PARANOID	0	0	0	0	0	0		
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		
				22.Total score	23	25	23	18	20	21		
	251	Imipramine	Female	01.DEPRESSED MOOD	4	4	1	3	1	0		
				02.GUILT	2	2	2	2	1	1		
				03.SUICIDE	3	3	1	3	0	0		
				04.INSOMNIA EARLY	1	1	1	1	0	0		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	251	Imipramine	Female	05.INSOMNIA MIDDLE	0	0	1	1	0	0		
				06.INSOMNIA LATE	0	0	1	1	1	1		
				07.WORK AND ACTIVITIES	4	4	3	3	1	1		
				08.RETARDATION	2	2	1	0	0	0		
				09.AGITATION	1	1	0	0	0	0		
				10.ANXIETY PSYCHIC	2	2	1	2	0	0		
				11.ANXIETY SOMATIC	1	1	1	2	1	1		
				12.SOMATIC GASTROINTESTINAL	1	1	0	1	0	0		
				13.SOMATIC GENERAL	0	0	1	2	0	0		
				14.GENITAL SYMPTOMS	2	2	2	2	0	0		
				15.HYPOCHONDRIASIS	0	0	0	0	0	0		
				16.LOSS OF WEIGHT	2	2	0	0	0	0		
				17.INSIGHT	2	2	2	1	0	0		
				18.DIURNAL VARIATION	0	0	1	1	0	0		
				19.DEPERSONALIZATION	0	0	0	0	0	0		
				20.PARANOID	0	0	0	0	0	0		
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		
				22.Total score	27	27	19	25	5	4		
	252	Reboxetine	Female	01.DEPRESSED MOOD	3	3	4	4	4			
				02.GUILT	1	1	1	1	1			
				03.SUICIDE	1	1	1	1	1			
				04.INSOMNIA EARLY	2	2	2	2	2			
				05.INSOMNIA MIDDLE	2	2	2	2	2			
				06.INSOMNIA LATE	1	1	2	2	2			
				07.WORK AND ACTIVITIES	3	3	3	3	3			
				08.RETARDATION	0	1	1	0	0			
				09.AGITATION	1	1	2	3	4			
				10.ANXIETY PSYCHIC	2	2	2	3	4			
				11.ANXIETY SOMATIC	2	2	2	3	4			
				12.SOMATIC GASTROINTESTINAL	0	1	1	1	1			
				13.SOMATIC GENERAL	2	2	2	2	2			
				14.GENITAL SYMPTOMS	2	2	2	2	2			
				15.HYPOCHONDRIASIS	0	0	0	0	0			
				16.LOSS OF WEIGHT	0	0	0	1	1			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	0	0	0	0	0			
				19.DEPERSONALIZATION	0	0	0	0	0			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	22	24	27	30	33			
	253	Reboxetine	Female	01.DEPRESSED MOOD	4	4	3					
				02.GUILT	1	1	0					
				03.SUICIDE	2	2	3					
				04.INSOMNIA EARLY	2	2	2					
				05.INSOMNIA MIDDLE	2	2	2					
				06.INSOMNIA LATE	2	2	2					
				07.WORK AND ACTIVITIES	3	3	3					
				08.RETARDATION	2	2	0					

1221

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	253	Reboxetine	Female	09.AGITATION	0	0	2					
				10.ANXIETY PSYCHIC	1	1	4					
				11.ANXIETY SOMATIC	2	2	2					
				12.SOMATIC GASTROINTESTINAL	0	0	1					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	2	2	2					
				15.HYPOCHONDRIASIS	1	1	1					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	0	0	1					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	26	26	30					
	254	Imipramine	Female	01.DEPRESSED MOOD	4	4	4	4				
				02.GUILT	1	1	1	1				
				03.SUICIDE	2	2	2	2				
				04.INSOMNIA EARLY	0	0	2	2				
				05.INSOMNIA MIDDLE	2	2	2	2				
				06.INSOMNIA LATE	2	2	2	2				
				07.WORK AND ACTIVITIES	3	3	4	4				
				08.RETARDATION	1	1	1	1				
				09.AGITATION	2	2	3	3				
				10.ANXIETY PSYCHIC	3	3	4	4				
				11.ANXIETY SOMATIC	3	3	4	4				
				12.SOMATIC GASTROINTESTINAL	1	1	1	1				
				13.SOMATIC GENERAL	2	2	2	2				
				14.GENITAL SYMPTOMS	1	1	1	1				
				15.HYPOCHONDRIASIS	1	1	1	1				
				16.LOSS OF WEIGHT	2	0	0	0				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	2	2	2	2				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	32	30	36	36				
	255	Reboxetine	Female	01.DEPRESSED MOOD	1	1	1	1	1	2		
				02.GUILT	1	1	1	1	1	1		
				03.SUICIDE	2	2	2	2	2	3		
				04.INSOMNIA EARLY	1	1	1	2	2	2		
				05.INSOMNIA MIDDLE	1	1	1	2	2	2		
				06.INSOMNIA LATE	0	1	1	2	2	2		
				07.WORK AND ACTIVITIES	3	3	3	3	3	3		
				08.RETARDATION	2	2	2	1	1	1		
				09.AGITATION	1	1	1	2	2	4		
				10.ANXIETY PSYCHIC	2	2	2	4	4	4		
				11.ANXIETY SOMATIC	2	2	2	2	2	3		
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	255	Reboxetine	Female	13.SOMATIC GENERAL	1	1	1	1	1	1		
				14.GENITAL SYMPTOMS	2	2	2	2	2	1		
				15.HYPOCHONDRIASIS	0	0	0	2	2	2		
				16.LOSS OF WEIGHT	0	0	0	0	0	0		
				17.INSIGHT	1	1	1	0	0	0		
				18.DIURNAL VARIATION	1	1	1	1	1	1		
				19.DEPERSONALIZATION	1	1	1	1	1	1		
				20.PARANOID	0	0	0	0	0	0		
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		
				22.Total score	22	23	23	29	29	33		
	256	Imipramine	Female	01.DEPRESSED MOOD	4	4	4	1	1	3	1	1
				02.GUILT	2	2	2	0	0	1	0	0
				03.SUICIDE	4	4	4	0	0	2	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	1	1
				06.INSOMNIA LATE	2	2	2	1	1	2	1	1
				07.WORK AND ACTIVITIES	4	4	4	1	1	3	2	2
				08.RETARDATION	1	1	1	0	0	2	0	0
				09.AGITATION	0	0	0	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	0	0	2	2	2
				11.ANXIETY SOMATIC	0	0	0	0	0	2	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	0	0	2	1	1
				15.HYPOCHONDRIASIS	3	3	3	0	0	0	1	1
				16.LOSS OF WEIGHT	2	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	33	32	32	10	10	26	15	15
	257	Placebo	Male	01.DEPRESSED MOOD	2	2	2					
				02.GUILT	2	2	2					
				03.SUICIDE	2	2	2					
				04.INSOMNIA EARLY	1	1	1					
				05.INSOMNIA MIDDLE	1	1	1					
				06.INSOMNIA LATE	1	1	1					
				07.WORK AND ACTIVITIES	4	4	4					
				08.RETARDATION	0	0	0					
				09.AGITATION	0	0	0					
				10.ANXIETY PSYCHIC	2	2	2					
				11.ANXIETY SOMATIC	1	1	1					
				12.SOMATIC GASTROINTESTINAL	1	1	1					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	2	2	2					
				15.HYPOCHONDRIASIS	1	1	1					
				16.LOSS OF WEIGHT	2	2	0					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	257	Placebo	Male	17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	1	1	1					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	25	25	23					
	258	Placebo	Male	01.DEPRESSED MOOD	3	3	3	3				
				02.GUILT	2	2	2	2				
				03.SUICIDE	1	1	2	2				
				04.INSOMNIA EARLY	1	1	1	1				
				05.INSOMNIA MIDDLE	1	1	1	1				
				06.INSOMNIA LATE	1	1	2	2				
				07.WORK AND ACTIVITIES	4	4	4	4				
				08.RETARDATION	0	0	0	0				
				09.AGITATION	1	1	1	1				
				10.ANXIETY PSYCHIC	2	2	3	3				
				11.ANXIETY SOMATIC	1	1	2	2				
				12.SOMATIC GASTROINTESTINAL	1	1	1	1				
				13.SOMATIC GENERAL	2	2	2	2				
				14.GENITAL SYMPTOMS	2	2	2	2				
				15.HYPOCHONDRIASIS	1	1	2	2				
				16.LOSS OF WEIGHT	1	1	0	0				
				17.INSIGHT	1	1	1	1				
				18.DIURNAL VARIATION	1	1	1	1				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	26	26	30	30				
11	319	Placebo	Male	01.DEPRESSED MOOD	3	3	3	3	3	3	3	2
				02.GUILT	2	2	2	2	2	2	2	1
				03.SUICIDE	3	3	2	2	2	2	2	1
				04.INSOMNIA EARLY	2	2	1	2	2	2	1	2
				05.INSOMNIA MIDDLE	1	1	0	0	1	1	0	1
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	2	2	2	2	2	2	1	1
				10.ANXIETY PSYCHIC	3	3	3	3	3	3	3	2
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	2	2
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	0	0	0	2	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	2	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	319	Placebo	Male	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	27	24	25	28	26	24	22
	320	Imipramine	Male	01.DEPRESSED MOOD	3	3	4	2	4	2	3	2
				02.GUILT	1	1	2	1	2	2	1	1
				03.SUICIDE	2	2	2	1	2	1	1	1
				04.INSOMNIA EARLY	2	2	2	1	2	1	1	0
				05.INSOMNIA MIDDLE	2	2	2	1	1	0	0	0
				06.INSOMNIA LATE	2	2	2	2	1	2	2	2
				07.WORK AND ACTIVITIES	2	2	3	2	2	2	2	1
				08.RETARDATION	1	1	1	1	1	0	0	0
				09.AGITATION	2	2	2	1	2	1	1	1
				10.ANXIETY PSYCHIC	4	4	4	3	4	3	3	2
				11.ANXIETY SOMATIC	3	3	3	1	2	1	3	2
				12.SOMATIC GASTROINTESTINAL	1	0	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	2	1	2	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	0	0	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	2	0	0	1
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	30	32	17	27	17	20	15
	321	Placebo	Male	01.DEPRESSED MOOD	3	3	3	2	2	1	1	1
				02.GUILT	2	2	1	2	1	1	1	0
				03.SUICIDE	2	2	2	1	1	0	0	0
				04.INSOMNIA EARLY	0	1	1	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	0	0	1	1	0	0
				06.INSOMNIA LATE	1	1	1	0	1	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	2	1	0	0
				08.RETARDATION	1	1	2	1	0	0	0	0
				09.AGITATION	1	1	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	4	3	2	2	2	1
				11.ANXIETY SOMATIC	1	1	2	2	1	1	0	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	1	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	2	2	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	23	23	16	14	7	4	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	322	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	2	2	2	2	2
				02.GUILT	2	2	2	2	2	2	2	2
				03.SUICIDE	2	3	1	1	1	1	1	2
				04.INSOMNIA EARLY	2	2	1	2	2	2	2	0
				05.INSOMNIA MIDDLE	0	0	2	1	1	1	2	1
				06.INSOMNIA LATE	0	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	1	1	1	2	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	1
				13.SOMATIC GENERAL	2	2	2	1	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	2	2	2	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	1	1	2	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	28	24	19	20	20	23	21
	323	Reboxetine	Male	01.DEPRESSED MOOD	2	2	1	1	1	0	0	1
				02.GUILT	2	2	2	1	1	1	0	0
				03.SUICIDE	2	2	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	1	0	0	0	0
				06.INSOMNIA LATE	2	2	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	2	2	1	1	1	1	1	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	0	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	0	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	0	0	0	1	1
				14.GENITAL SYMPTOMS	1	1	1	2	2	2	1	1
				15.HYPOCHONDRIASIS	0	0	1	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	2	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	25	17	10	8	5	5	6
	324	Imipramine	Male	01.DEPRESSED MOOD	2	2	2	2	2	2	2	2
				02.GUILT	1	2	2	2	1	2	2	2
				03.SUICIDE	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	1	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	324	Imipramine	Male	05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	0	1	1	1	1	1	1	1
				09.AGITATION	1	0	0	0	0	1	1	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	3	3	2
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	2	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	1	0	0	0	0	0
				16.LOSS OF WEIGHT	2	1	2	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	2	2	2	2	2	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	27	22	20	24	24	22
	325	Reboxetine	Male	01.DEPRESSED MOOD	2	2	1	1	0	0	0	0
				02.GUILT	2	2	1	0	0	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	2	2	2	1	1	0	1	1
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	1	1
				08.RETARDATION	1	1	1	0	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	1	1	0	1	1	1
				11.ANXIETY SOMATIC	1	2	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	22	14	7	3	3	4	4
	326	Placebo	Male	01.DEPRESSED MOOD	3	3	3	4	3	4	4	4
				02.GUILT	1	1	0	0	0	0	0	0
				03.SUICIDE	2	2	2	2	2	3	3	3
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	2	2	2	3	3	3
				08.RETARDATION	2	2	2	2	2	2	2	2

1227

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	326	Placebo	Male	09.AGITATION	1	0	0	2	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	4	3	3	1	1	1
				11.ANXIETY SOMATIC	0	0	0	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	2	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	2	2	2
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	1	2	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	22	23	24	21	24	25	23
	327	Imipramine	Male	01.DEPRESSED MOOD	2	2	1					
				02.GUILT	2	2	0					
				03.SUICIDE	2	2	0					
				04.INSOMNIA EARLY	2	2	1					
				05.INSOMNIA MIDDLE	2	2	0					
				06.INSOMNIA LATE	2	2	0					
				07.WORK AND ACTIVITIES	1	1	2					
				08.RETARDATION	1	1	1					
				09.AGITATION	0	0	0					
				10.ANXIETY PSYCHIC	2	2	1					
				11.ANXIETY SOMATIC	1	1	1					
				12.SOMATIC GASTROINTESTINAL	1	1	0					
				13.SOMATIC GENERAL	1	1	0					
				14.GENITAL SYMPTOMS	2	2	2					
				15.HYPOCHONDRIASIS	0	0	0					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	2	2	0					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	23	23	9					
	328	Imipramine	Female	01.DEPRESSED MOOD	4	2	2					
				02.GUILT	2	2	2					
				03.SUICIDE	2	2	1					
				04.INSOMNIA EARLY	2	2	0					
				05.INSOMNIA MIDDLE	2	2	1					
				06.INSOMNIA LATE	1	0	2					
				07.WORK AND ACTIVITIES	2	2	2					
				08.RETARDATION	2	2	1					
				09.AGITATION	2	1	1					
				10.ANXIETY PSYCHIC	4	3	2					
				11.ANXIETY SOMATIC	3	2	2					
				12.SOMATIC GASTROINTESTINAL	2	1	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	328	Imipramine	Female	13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	0	0	0					
				15.HYPOCHONDRIASIS	0	0	0					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	2	2	2					
				19.DEPERSONALIZATION	2	2	1					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	34	27	22					
	329	Placebo	Female	01.DEPRESSED MOOD	2	2	2	2	2	0	0	0
				02.GUILT	1	1	1	1	1	0	0	0
				03.SUICIDE	1	1	1	1	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	1	0	1	1
				06.INSOMNIA LATE	1	2	2	2	1	0	0	0
				07.WORK AND ACTIVITIES	3	2	2	2	2	1	0	1
				08.RETARDATION	1	1	1	1	1	1	0	0
				09.AGITATION	0	0	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	3	3	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	2	1	1	2
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	1	2	2
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	1	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	22	23	22	16	8	6	8
	330	Reboxetine	Male	01.DEPRESSED MOOD	2	2	2	2	1	2	1	0
				02.GUILT	2	2	2	1	1	1	1	0
				03.SUICIDE	1	1	2	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	2	1	2	1
				05.INSOMNIA MIDDLE	2	2	2	1	2	2	1	2
				06.INSOMNIA LATE	2	2	2	2	1	2	0	1
				07.WORK AND ACTIVITIES	2	2	2	1	0	1	0	0
				08.RETARDATION	0	0	1	0	0	0	0	0
				09.AGITATION	0	0	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	3	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	2	1	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	330	Reboxetine	Male	17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	24	26	17	15	14	9	8
	331	Imipramine	Male	01.DEPRESSED MOOD	2	2	2	2	1	2	2	2
				02.GUILT	2	2	2	1	0	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	1	0	0	0	0	0	0
				06.INSOMNIA LATE	2	1	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	1	1
				08.RETARDATION	1	1	0	0	0	1	1	1
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	1	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	2
				12.SOMATIC GASTROINTESTINAL	1	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	0	1	2	2
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	1	2	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	22	19	13	10	4	10	12	13
	332	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	1	0	0	0	0
				02.GUILT	2	2	2	1	0	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	0	1	0	0	0
				05.INSOMNIA MIDDLE	2	2	1	1	2	0	0	0
				06.INSOMNIA LATE	2	2	2	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	2	2	1	1	0	2	1
				08.RETARDATION	2	2	1	0	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	2	2	1	0	2
				11.ANXIETY SOMATIC	2	2	2	2	1	1	0	2
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	2	1
				13.SOMATIC GENERAL	2	2	2	2	1	2	1	2
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	2	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

1230

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	332	Reboxetine	Male	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	25	18	10	8	4	7	6
	333	Placebo	Male	01.DEPRESSED MOOD	2	2	2	2	1	1	1	1
				02.GUILT	2	2	2	1	1	1	1	1
				03.SUICIDE	2	2	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	0	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	1	1	0	0	0	0
				08.RETARDATION	1	1	1	1	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	0	2	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	24	22	20	12	9	9	9
	334	Reboxetine	Female	01.DEPRESSED MOOD	3	3						
				02.GUILT	2	2						
				03.SUICIDE	1	1						
				04.INSOMNIA EARLY	2	2						
				05.INSOMNIA MIDDLE	2	2						
				06.INSOMNIA LATE	2	2						
				07.WORK AND ACTIVITIES	2	2						
				08.RETARDATION	1	1						
				09.AGITATION	1	0						
				10.ANXIETY PSYCHIC	3	3						
				11.ANXIETY SOMATIC	3	3						
				12.SOMATIC GASTROINTESTINAL	1	1						
				13.SOMATIC GENERAL	2	2						
				14.GENITAL SYMPTOMS	0	0						
				15.HYPOCHONDRIASIS	0	0						
				16.LOSS OF WEIGHT	1	0						
				17.INSIGHT	0	0						
				18.DIURNAL VARIATION	2	2						
				19.DEPERSONALIZATION	0	0						
				20.PARANOID	0	0						
				21.OBSESSIONAL/COMPULSIVE	0	0						
				22.Total score	28	26						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	335	Placebo	Male	01.DEPRESSED MOOD	2	2	2	2	2	2	2	1
				02.GUILT	2	2	2	2	2	2	2	2
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	1	1
				05.INSOMNIA MIDDLE	1	1	1	2	2	2	2	2
				06.INSOMNIA LATE	0	0	0	1	2	2	2	1
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	1	1	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	2	2	2	2	2
				11.ANXIETY SOMATIC	3	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	1
				14.GENITAL SYMPTOMS	1	1	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	1	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	1	0	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	20	15	16	15	15	17	14
	336	Imipramine	Female	01.DEPRESSED MOOD	3	3	3					
				02.GUILT	1	1	1					
				03.SUICIDE	2	2	2					
				04.INSOMNIA EARLY	2	2	2					
				05.INSOMNIA MIDDLE	1	1	2					
				06.INSOMNIA LATE	2	2	2					
				07.WORK AND ACTIVITIES	3	3	3					
				08.RETARDATION	2	2	2					
				09.AGITATION	0	0	0					
				10.ANXIETY PSYCHIC	2	2	2					
				11.ANXIETY SOMATIC	3	3	3					
				12.SOMATIC GASTROINTESTINAL	1	1	1					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	0	0	0					
				15.HYPOCHONDRIASIS	1	1	1					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	0	0	0					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	25	25	26					
	337	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	2	2	2	2	2
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	1	1	1	1	1	2	2	2
				04.INSOMNIA EARLY	2	2	2	1	0	0	0	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	337	Reboxetine	Female	05.INSOMNIA MIDDLE	2	1	2	2	2	2	0	1
				06.INSOMNIA LATE	2	2	2	2	2	2	2	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	1	1	1	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	1	1	1	1	1	1	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	1	1	2	2	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	2	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	24	22	19	21	19	18
	338	Imipramine	Male	01.DEPRESSED MOOD	2	3	2					
				02.GUILT	2	2	2					
				03.SUICIDE	2	2	2					
				04.INSOMNIA EARLY	2	2	2					
				05.INSOMNIA MIDDLE	2	2	1					
				06.INSOMNIA LATE	1	2	1					
				07.WORK AND ACTIVITIES	2	2	2					
				08.RETARDATION	0	1	1					
				09.AGITATION	0	0	0					
				10.ANXIETY PSYCHIC	3	3	3					
				11.ANXIETY SOMATIC	1	1	2					
				12.SOMATIC GASTROINTESTINAL	1	1	1					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	0	0	0					
				15.HYPOCHONDRIASIS	0	0	0					
				16.LOSS OF WEIGHT	2	0	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	1	2	2					
				19.DEPERSONALIZATION	1	0	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	24	25	23					
12	367	Reboxetine	Female	01.DEPRESSED MOOD	3	3	1	0	0	0	0	0
				02.GUILT	3	2	1	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	2	1	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	0	1	1	1	1
				06.INSOMNIA LATE	2	2	1	1	0	0	0	1
				07.WORK AND ACTIVITIES	4	3	1	3	0	0	0	0
				08.RETARDATION	3	3	1	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
12	367	Reboxetine	Female	09.AGITATION	3	2	2	2	0	1	0	1
				10.ANXIETY PSYCHIC	2	0	1	2	1	0	0	0
				11.ANXIETY SOMATIC	1	2	1	2	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	0	0	0	1	0	0
				15.HYPOCHONDRIASIS	2	0	0	0	2	0	0	0
				16.LOSS OF WEIGHT	2	2	0	2	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	1	0	0	0
				22.Total score	32	27	13	17	6	3	1	3
	368	Placebo	Female	01.DEPRESSED MOOD	3	3	1	3	1	1	2	1
				02.GUILT	1	1	1	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	1	1	0	0	0	0	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3
				08.RETARDATION	2	2	2	3	2	1	1	1
				09.AGITATION	1	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	1	1	2	1	0
				11.ANXIETY SOMATIC	1	1	1	2	0	0	1	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	0	1	1	1	1	0	1	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	2	0	0	0	0
				16.LOSS OF WEIGHT	1	2	0	0	0	0	0	2
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	0	0	0	0	0	0	0
				22.Total score	25	24	19	18	11	9	11	10
	369	Imipramine	Female	01.DEPRESSED MOOD	3	3	0	2	4			
				02.GUILT	2	1	0	1	2			
				03.SUICIDE	4	4	0	0	3			
				04.INSOMNIA EARLY	1	1	1	0	1			
				05.INSOMNIA MIDDLE	2	2	0	1	1			
				06.INSOMNIA LATE	1	1	0	0	1			
				07.WORK AND ACTIVITIES	3	3	1	1	4			
				08.RETARDATION	1	1	0	0	0			
				09.AGITATION	1	2	2	1	4			
				10.ANXIETY PSYCHIC	3	2	1	2	3			
				11.ANXIETY SOMATIC	2	1	1	2	3			
				12.SOMATIC GASTROINTESTINAL	1	0	0	0	1			

1234

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
12	369	Imipramine	Female	13.SOMATIC GENERAL	1	1	0	0	2			
				14.GENITAL SYMPTOMS	1	1	0	0	1			
				15.HYPOCHONDRIASIS	0	2	0	0	0			
				16.LOSS OF WEIGHT	0	0	0	0	0			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	1	1	0	0	1			
				19.DEPERSONALIZATION	2	0	0	0	2			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	0			
				22.Total score	30	27	7	11	33			
	370	Placebo	Male	01.DEPRESSED MOOD	3	3	2	3	3			
				02.GUILT	2	1	0	2	3			
				03.SUICIDE	4	2	1	1	3			
				04.INSOMNIA EARLY	2	2	2	1	2			
				05.INSOMNIA MIDDLE	2	2	1	1	1			
				06.INSOMNIA LATE	1	1	0	1	1			
				07.WORK AND ACTIVITIES	3	3	2	3	3			
				08.RETARDATION	1	2	0	2	1			
				09.AGITATION	1	0	0	0	0			
				10.ANXIETY PSYCHIC	2	1	1	2	2			
				11.ANXIETY SOMATIC	1	2	1	2	2			
				12.SOMATIC GASTROINTESTINAL	1	2	1	1	2			
				13.SOMATIC GENERAL	1	1	1	2	1			
				14.GENITAL SYMPTOMS	0	0	0	0	0			
				15.HYPOCHONDRIASIS	0	2	0	2	2			
				16.LOSS OF WEIGHT	2	0	0	0	1			
				17.INSIGHT	1	0	0	0	0			
				18.DIURNAL VARIATION	1	1	0	1	1			
				19.DEPERSONALIZATION	0	0	0	1	1			
				20.PARANOID	0	1	1	1	2			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	28	26	13	26	31			
	371	Imipramine	Female	01.DEPRESSED MOOD	2	2	1					
				02.GUILT	2	2	1					
				03.SUICIDE	0	0	0					
				04.INSOMNIA EARLY	2	2	1					
				05.INSOMNIA MIDDLE	1	1	0					
				06.INSOMNIA LATE	2	1	0					
				07.WORK AND ACTIVITIES	3	3	1					
				08.RETARDATION	1	1	0					
				09.AGITATION	2	0	1					
				10.ANXIETY PSYCHIC	4	3	1					
				11.ANXIETY SOMATIC	2	2	0					
				12.SOMATIC GASTROINTESTINAL	2	2	0					
				13.SOMATIC GENERAL	1	1	1					
				14.GENITAL SYMPTOMS	1	1	1					
				15.HYPOCHONDRIASIS	3	2	0					
				16.LOSS OF WEIGHT	0	0	0					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
12	371	Imipramine	Female	17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	1	1	1					
				19.DEPERSONALIZATION	2	1	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	1	0	1					
				22.Total score	32	25	10					
	372	Reboxetine	Male	01.DEPRESSED MOOD	3	4	3	1	1	0	0	3
				02.GUILT	2	2	2	1	0	1	0	2
				03.SUICIDE	2	3	2	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	0	0	0	1	0
				05.INSOMNIA MIDDLE	2	2	0	0	1	0	0	0
				06.INSOMNIA LATE	1	2	0	1	0	0	0	1
				07.WORK AND ACTIVITIES	3	3	1	1	0	0	0	1
				08.RETARDATION	2	2	1	1	1	0	0	1
				09.AGITATION	2	2	1	1	0	1	0	1
				10.ANXIETY PSYCHIC	3	2	3	1	1	3	1	3
				11.ANXIETY SOMATIC	2	3	2	1	1	1	0	1
				12.SOMATIC GASTROINTESTINAL	1	0	1	2	0	0	0	1
				13.SOMATIC GENERAL	1	2	1	1	0	0	0	1
				14.GENITAL SYMPTOMS	2	2	1	1	1	0	0	0
				15.HYPOCHONDRIASIS	0	1	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	0	2	2	2	0	0	1
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	0	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	1	1	1	0	1	0	1
				22.Total score	32	34	24	15	8	7	2	19
	373	Reboxetine	Male	01.DEPRESSED MOOD	3	3	1	2	0	1	1	0
				02.GUILT	2	2	2	2	2	2	2	0
				03.SUICIDE	3	3	2	3	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	2	2	2	1
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	1
				06.INSOMNIA LATE	2	1	0	2	0	2	1	1
				07.WORK AND ACTIVITIES	3	3	1	3	2	2	0	0
				08.RETARDATION	0	1	0	0	0	0	0	0
				09.AGITATION	2	2	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	0	3	0	1	0	0
				11.ANXIETY SOMATIC	2	2	0	0	0	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	1	0	0	0	0
				13.SOMATIC GENERAL	0	1	0	2	0	2	0	0
				14.GENITAL SYMPTOMS	1	1	2	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	0	0	0	0	1	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	2	1	2	2	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
12	373	Reboxetine	Male	21.OBSESSIONAL/COMPULSIVE	1	0	0	0	2	1	1	0
				22.Total score	32	30	11	21	10	17	9	3
	374	Placebo	Female	01.DEPRESSED MOOD	3	3	2	2	2	1		
				02.GUILT	2	2	2	1	0	1		
				03.SUICIDE	3	2	0	0	0	0		
				04.INSOMNIA EARLY	0	0	0	0	0	1		
				05.INSOMNIA MIDDLE	1	0	0	0	0	0		
				06.INSOMNIA LATE	0	0	0	0	0	2		
				07.WORK AND ACTIVITIES	2	2	2	1	2	1		
				08.RETARDATION	2	2	1	0	2	1		
				09.AGITATION	2	2	1	0	1	0		
				10.ANXIETY PSYCHIC	3	4	3	2	2	1		
				11.ANXIETY SOMATIC	2	2	2	0	1	1		
				12.SOMATIC GASTROINTESTINAL	0	1	1	0	0	0		
				13.SOMATIC GENERAL	1	1	1	1	0	0		
				14.GENITAL SYMPTOMS	2	2	1	1	1	1		
				15.HYPOCHONDRIASIS	1	0	0	0	0	0		
				16.LOSS OF WEIGHT	0	0	0	0	0	0		
				17.INSIGHT	0	0	0	0	0	0		
				18.DIURNAL VARIATION	1	1	1	0	0	0		
				19.DEPERSONALIZATION	0	0	0	0	0	0		
				20.PARANOID	0	0	0	0	0	0		
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	1	1		
				22.Total score	26	25	18	8	12	11		
	375	Imipramine	Male	01.DEPRESSED MOOD	3	3						
				02.GUILT	3	3						
				03.SUICIDE	2	2						
				04.INSOMNIA EARLY	2	2						
				05.INSOMNIA MIDDLE	1	1						
				06.INSOMNIA LATE	1	1						
				07.WORK AND ACTIVITIES	2	2						
				08.RETARDATION	2	2						
				09.AGITATION	1	1						
				10.ANXIETY PSYCHIC	1	1						
				11.ANXIETY SOMATIC	1	2						
				12.SOMATIC GASTROINTESTINAL	1	1						
				13.SOMATIC GENERAL	0	1						
				14.GENITAL SYMPTOMS	0	1						
				15.HYPOCHONDRIASIS	0	0						
				16.LOSS OF WEIGHT	2	0						
				17.INSIGHT	0	0						
				18.DIURNAL VARIATION	0	1						
				19.DEPERSONALIZATION	0	1						
				20.PARANOID	1	1						
				21.OBSESSIONAL/COMPULSIVE	1	0						
				22.Total score	24	26						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
13	13	Placebo	Male	01.DEPRESSED MOOD	2	2	2	1	2	2	2	3
				02.GUILT	3	3	2	2	2	2	2	2
				03.SUICIDE	3	3	0	0	1	0	1	2
				04.INSOMNIA EARLY	0	0	1	2	2	2	2	2
				05.INSOMNIA MIDDLE	1	1	1	1	1	0	1	1
				06.INSOMNIA LATE	2	2	1	0	1	1	0	0
				07.WORK AND ACTIVITIES	3	3	1	2	2	1	2	2
				08.RETARDATION	1	1	1	1	0	1	1	2
				09.AGITATION	2	2	1	0	1	1	0	0
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	0	0	0	1
				12.SOMATIC GASTROINTESTINAL	0	0	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	0	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	1	1	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	1	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	16	14	17	14	16	19
	14	Placebo	Male	01.DEPRESSED MOOD	3	3	1	3	3	0	2	1
				02.GUILT	2	2	0	3	1	0	1	1
				03.SUICIDE	2	2	0	0	1	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	2	1	0
				05.INSOMNIA MIDDLE	0	0	0	1	0	0	1	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	1
				07.WORK AND ACTIVITIES	2	2	1	2	2	1	1	1
				08.RETARDATION	2	2	0	2	1	0	1	1
				09.AGITATION	1	1	2	1	2	2	2	2
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	0	2	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	1
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	1	1	0	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	0	1	1	0	0	1
				16.LOSS OF WEIGHT	1	1	0	1	1	1	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	1	2	1
				19.DEPERSONALIZATION	0	0	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	1	0	1	1
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	1	0	0
				22.Total score	25	25	12	23	21	12	15	13
	15	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	1	1	3	3	3
				02.GUILT	2	2	1	1	1	1	1	1
				03.SUICIDE	4	4	1	0	0	1	1	2
				04.INSOMNIA EARLY	2	2	1	1	2	2	2	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
13	15	Imipramine	Female	05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	0	0	1	0	1
				07.WORK AND ACTIVITIES	2	2	2	1	1	3	2	2
				08.RETARDATION	2	2	1	1	1	1	1	1
				09.AGITATION	1	1	1	0	1	2	1	1
				10.ANXIETY PSYCHIC	1	1	1	0	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	1	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	0	0	1	1	1	0	1	1
				13.SOMATIC GENERAL	1	1	1	1	0	1	1	1
				14.GENITAL SYMPTOMS	2	2	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	2	0
				19.DEPERSONALIZATION	0	0	0	0	0	1	0	1
				20.PARANOID	1	1	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	1	1	1
				22.Total score	28	28	19	13	16	24	21	21
	16	Imipramine	Male	01.DEPRESSED MOOD	2	2	3	2	1	1	1	1
				02.GUILT	2	2	2	2	0	1	1	1
				03.SUICIDE	0	0	1	1	0	0	0	0
				04.INSOMNIA EARLY	1	2	2	1	1	1	0	2
				05.INSOMNIA MIDDLE	2	2	1	1	0	1	2	2
				06.INSOMNIA LATE	2	2	2	1	1	1	1	2
				07.WORK AND ACTIVITIES	2	1	2	1	1	1	1	1
				08.RETARDATION	1	1	2	1	0	1	1	1
				09.AGITATION	2	2	2	2	1	2	2	2
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	1	1	2	2	1	1	1	2
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	1	1	0	0	0	1
				15.HYPOCHONDRIASIS	1	1	2	2	1	1	1	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	2	2	0	2	2	2
				19.DEPERSONALIZATION	1	1	1	1	0	0	0	1
				20.PARANOID	0	0	0	0	0	1	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	1	1
				22.Total score	22	22	28	23	9	16	16	24
	17	Reboxetine	Male	01.DEPRESSED MOOD	2	2	2	1	1	1	1	1
				02.GUILT	2	2	2	1	0	0	0	0
				03.SUICIDE	2	2	1	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	1	1	1	1	2	1
				08.RETARDATION	1	1	1	1	0	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
13	17	Reboxetine	Male	09.AGITATION	2	2	2	1	2	0	0	2
				10.ANXIETY PSYCHIC	2	2	1	2	2	2	2	1
				11.ANXIETY SOMATIC	2	2	1	2	1	1	0	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	1	0	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	0	0	0	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	1	1	1	1
				19.DEPERSONALIZATION	2	2	0	0	0	0	0	0
				20.PARANOID	1	1	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	15	13	11	10	10	11
	18	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	2	1	2	1	1
				02.GUILT	1	1	0	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	2	1	1	2	1	1
				06.INSOMNIA LATE	0	0	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	1	1	1	1	1	1
				08.RETARDATION	1	1	1	1	0	1	1	0
				09.AGITATION	2	2	2	2	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	0	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	1	1	1	1	2	2
				15.HYPOCHONDRIASIS	1	1	0	0	0	2	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	0	0	1	0	0
				20.PARANOID	1	1	0	1	1	0	1	1
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	22	14	13	9	14	11	10
	409	Reboxetine	Male	01.DEPRESSED MOOD	2	2	2	1		2		1
				02.GUILT	1	1	1	1		1		1
				03.SUICIDE	1	1	1	0		0		0
				04.INSOMNIA EARLY	2	2	2	2		2		1
				05.INSOMNIA MIDDLE	1	1	1	1		1		1
				06.INSOMNIA LATE	2	2	2	2		1		0
				07.WORK AND ACTIVITIES	1	1	1	1		1		1
				08.RETARDATION	1	1	1	1		1		1
				09.AGITATION	2	2	2	2		2		0
				10.ANXIETY PSYCHIC	2	2	2	1		1		1
				11.ANXIETY SOMATIC	3	3	3	2		1		2
				12.SOMATIC GASTROINTESTINAL	0	0	0	0		1		1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
13	409	Reboxetine	Male	13.SOMATIC GENERAL	2	2	1	1		1		0
				14.GENITAL SYMPTOMS	1	1	0	1		0		0
				15.HYPOCHONDRIASIS	1	1	2	1		2		1
				16.LOSS OF WEIGHT	0	0	0	0		0		1
				17.INSIGHT	0	0	0	0		0		0
				18.DIURNAL VARIATION	2	2	2	2		2		2
				19.DEPERSONALIZATION	0	0	1	0		0		0
				20.PARANOID	0	0	0	0		0		0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0		0		0
				22.Total score	24	24	24	19		19		14
	410	Placebo	Male	01.DEPRESSED MOOD	2	2	2	3	3	2	2	2
				02.GUILT	1	2	1	2	1	0	1	0
				03.SUICIDE	2	1	1	1	1	0	1	0
				04.INSOMNIA EARLY	1	2	1	2	2	0	2	1
				05.INSOMNIA MIDDLE	0	1	1	1	0	0	1	1
				06.INSOMNIA LATE	0	0	0	1	1	0	2	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	1	2	1	1	1	1	1	1
				09.AGITATION	2	1	2	2	1	2	2	1
				10.ANXIETY PSYCHIC	3	1	2	2	2	1	1	1
				11.ANXIETY SOMATIC	3	2	2	2	2	2	2	3
				12.SOMATIC GASTROINTESTINAL	0	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	0	1	0
				15.HYPOCHONDRIASIS	2	2	2	2	2	1	2	1
				16.LOSS OF WEIGHT	0	0	1	1	0	0	1	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	2	2	2	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	0	0	0	0
				20.PARANOID	0	1	0	1	0	1	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	0	1	1	0
				22.Total score	23	24	25	30	23	15	24	16
	411	Imipramine	Female	01.DEPRESSED MOOD	3	3	1	0	3	3	2	1
				02.GUILT	0	0	0	0	0	2	2	1
				03.SUICIDE	2	2	0	0	0	1	1	0
				04.INSOMNIA EARLY	2	2	1	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	0	0	0	1	0
				07.WORK AND ACTIVITIES	2	2	1	1	2	2	2	1
				08.RETARDATION	1	1	1	1	2	2	1	1
				09.AGITATION	1	1	1	1	0	2	2	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	2	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	1	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	2	2	1
				14.GENITAL SYMPTOMS	0	0	0	0	1	1	1	1
				15.HYPOCHONDRIASIS	4	4	1	0	2	3	2	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
13	411	Imipramine	Female	17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	2	0	1	0	0	0
				19.DEPERSONALIZATION	0	0	1	0	0	2	1	0
				20.PARANOID	0	0	0	1	1	1	0	1
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	0	0	0
				22.Total score	23	23	15	9	18	26	20	9
	423	Placebo	Male	01.DEPRESSED MOOD	2	2	2	2	2			0
				02.GUILT	2	2	1	1	2			0
				03.SUICIDE	1	1	1	0	1			1
				04.INSOMNIA EARLY	1	1	1	1	1			1
				05.INSOMNIA MIDDLE	1	1	1	1	1			0
				06.INSOMNIA LATE	2	2	0	1	1			1
				07.WORK AND ACTIVITIES	2	2	2	2	2			1
				08.RETARDATION	1	1	1	1	2			0
				09.AGITATION	2	2	0	1	2			0
				10.ANXIETY PSYCHIC	2	2	1	1	1			1
				11.ANXIETY SOMATIC	1	1	0	0	0			0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0			0
				13.SOMATIC GENERAL	2	2	1	0	1			1
				14.GENITAL SYMPTOMS	0	0	0	1	1			0
				15.HYPOCHONDRIASIS	0	0	0	0	0			0
				16.LOSS OF WEIGHT	0	0	0	0	0			0
				17.INSIGHT	0	0	0	0	0			0
				18.DIURNAL VARIATION	2	2	0	0	1			0
				19.DEPERSONALIZATION	0	0	2	1	1			0
				20.PARANOID	0	0	0	1	0			0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	1	1			1
				22.Total score	22	22	13	15	20			7
14	19	Reboxetine	Female	01.DEPRESSED MOOD	4	4	4	4	3	4		
				02.GUILT	1	1	1	0	1	1		
				03.SUICIDE	1	2	1	1	2	2		
				04.INSOMNIA EARLY	2	2	2	2	2	2		
				05.INSOMNIA MIDDLE	2	2	2	2	2	2		
				06.INSOMNIA LATE	2	2	2	0	2	2		
				07.WORK AND ACTIVITIES	4	4	4	2	3	4		
				08.RETARDATION	3	3	3	1	2	3		
				09.AGITATION	3	3	3	1	1	1		
				10.ANXIETY PSYCHIC	3	3	3	1	3	3		
				11.ANXIETY SOMATIC	3	2	2	0	1	0		
				12.SOMATIC GASTROINTESTINAL	0	1	1	0	1	2		
				13.SOMATIC GENERAL	2	1	1	0	1	0		
				14.GENITAL SYMPTOMS	0	0	0	0	0	0		
				15.HYPOCHONDRIASIS	3	1	3	0	1	1		
				16.LOSS OF WEIGHT	0	1	2	0	0	0		
				17.INSIGHT	0	0	0	0	0	0		
				18.DIURNAL VARIATION	0	1	0	0	2	2		
				19.DEPERSONALIZATION	3	2	2	0	1	1		
				20.PARANOID	0	1	0	0	1	1		

1242

9550082

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14	19	Reboxetine	Female	21.OBSESSIONAL/COMPULSIVE	1	0	0	0	0	0		
				22.Total score	37	36	36	14	29	31		
	20	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	1	1	0	0
				02.GUILT	2	2	2	1	1	1	0	1
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	1	1	0	0
				06.INSOMNIA LATE	2	2	2	2	1	1	0	0
				07.WORK AND ACTIVITIES	3	3	3	1	1	0	0	1
				08.RETARDATION	1	1	1	1	0	0	0	0
				09.AGITATION	2	2	2	1	1	1	0	0
				10.ANXIETY PSYCHIC	3	3	3	3	1	1	0	0
				11.ANXIETY SOMATIC	1	1	2	1	0	0	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	1	0	0	0	0	0
				16.LOSS OF WEIGHT	3	3	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	2	2	1	1	1	1
				19.DEPERSONALIZATION	0	0	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	27	18	9	7	2	3
	21	Imipramine	Female	01.DEPRESSED MOOD	4	3	3	2	3	3	3	
				02.GUILT	2	0	0	1	1	1	1	
				03.SUICIDE	3	1	0	0	3	3	1	
				04.INSOMNIA EARLY	1	2	1	1	1	1	1	
				05.INSOMNIA MIDDLE	1	2	1	1	1	1	1	
				06.INSOMNIA LATE	0	2	2	1	1	1	1	
				07.WORK AND ACTIVITIES	3	3	2	2	3	2	3	
				08.RETARDATION	1	1	1	0	1	1	1	
				09.AGITATION	2	1	2	2	3	2	2	
				10.ANXIETY PSYCHIC	3	3	3	1	3	2	3	
				11.ANXIETY SOMATIC	0	3	2	1	1	0	2	
				12.SOMATIC GASTROINTESTINAL	1	1	2	0	2	0	0	
				13.SOMATIC GENERAL	0	2	2	0	1	1	2	
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	
				15.HYPOCHONDRIASIS	1	3	3	3	2	2	2	
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	
				17.INSIGHT	0	0	0	0	0	0	0	
				18.DIURNAL VARIATION	2	1	1	1	2	1	1	
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	
				20.PARANOID	0	0	0	0	0	0	0	
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	
				22.Total score	25	29	25	16	28	21	24	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	25	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	2	2	2	2
				02.GUILT	2	2	2	2	1	2	2	1
				03.SUICIDE	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	1	1	2	2	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	2	1	2	2	2	2
				06.INSOMNIA LATE	1	1	1	2	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	2	2	2	2	2
				08.RETARDATION	2	2	1	0	1	0	0	1
				09.AGITATION	1	1	1	2	1	1	2	1
				10.ANXIETY PSYCHIC	2	2	2	3	2	1	2	2
				11.ANXIETY SOMATIC	1	1	1	2	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	1	1
				13.SOMATIC GENERAL	2	2	2	1	2	1	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	1	1	0	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	1	1
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	1	1	1	0	0
				22.Total score	27	27	26	27	24	20	22	21
	26	Placebo	Male	01.DEPRESSED MOOD	3	3	2	1	2	2	1	1
				02.GUILT	2	2	2	1	1	1	1	1
				03.SUICIDE	2	2	1	1	0	1	1	0
				04.INSOMNIA EARLY	2	2	2	1	1	2	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	0	1
				06.INSOMNIA LATE	1	1	0	2	1	1	0	0
				07.WORK AND ACTIVITIES	2	2	1	2	1	2	2	2
				08.RETARDATION	1	1	1	0	1	1	0	0
				09.AGITATION	2	2	1	1	1	0	1	1
				10.ANXIETY PSYCHIC	2	2	2	1	1	2	2	1
				11.ANXIETY SOMATIC	2	2	2	1	2	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	2	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	1	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	1	1	1	1	1	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	21	18	15	19	14	10
	27	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	2	1	1	1	0
				02.GUILT	2	2	2	1	1	1	0	1
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	0	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	27	Imipramine	Female	05.INSOMNIA MIDDLE	1	1	1	1	1	1	0	1
				06.INSOMNIA LATE	2	2	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	0	0
				08.RETARDATION	1	1	1	0	1	0	0	0
				09.AGITATION	1	1	1	1	0	1	1	0
				10.ANXIETY PSYCHIC	3	3	2	2	2	1	1	1
				11.ANXIETY SOMATIC	2	2	1	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	0	1	1	1
				14.GENITAL SYMPTOMS	2	2	1	2	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	1	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	1	0	0	0	0
				22.Total score	27	27	18	20	11	8	6	6
	28	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	1	1	1	1	0
				02.GUILT	1	1	2	1	1	1	1	1
				03.SUICIDE	1	1	1	1	1	1	1	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	0
				05.INSOMNIA MIDDLE	2	2	2	1	0	0	1	0
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	2	1	1
				08.RETARDATION	0	0	0	0	1	0	0	0
				09.AGITATION	1	1	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	2	1
				11.ANXIETY SOMATIC	2	2	1	1	0	0	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	0	0	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	1	1	1	1	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	0
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	24	24	19	12	10	10	12	5
	29	Placebo	Male	01.DEPRESSED MOOD	3	3	3	2	3			
				02.GUILT	2	2	2	2	2			
				03.SUICIDE	1	1	1	1	0			
				04.INSOMNIA EARLY	0	0	0	0	1			
				05.INSOMNIA MIDDLE	1	1	1	1	1			
				06.INSOMNIA LATE	2	2	1	1	1			
				07.WORK AND ACTIVITIES	3	3	3	3	3			
				08.RETARDATION	1	1	1	1	1			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	29	Placebo	Male	09.AGITATION	0	0	0	1	1			
				10.ANXIETY PSYCHIC	3	3	3	3	3			
				11.ANXIETY SOMATIC	2	2	2	2	2			
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0			
				13.SOMATIC GENERAL	2	2	2	2	1			
				14.GENITAL SYMPTOMS	2	2	2	2	2			
				15.HYPOCHONDRIASIS	2	2	2	1	1			
				16.LOSS OF WEIGHT	0	0	0	0	0			
				17.INSIGHT	1	1	1	1	1			
				18.DIURNAL VARIATION	1	1	2	2	2			
				19.DEPERSONALIZATION	0	0	0	0	0			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1			
				22.Total score	28	28	28	27	26			
	30	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	2	1	2	1	1
				02.GUILT	2	2	2	2	1	2	1	1
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	1	1	0	0	0	1	0	0
				05.INSOMNIA MIDDLE	2	2	1	1	1	0	1	1
				06.INSOMNIA LATE	0	0	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	2	1	1
				08.RETARDATION	1	1	1	1	0	0	0	0
				09.AGITATION	1	1	1	1	0	1	0	0
				10.ANXIETY PSYCHIC	3	3	2	2	2	2	1	2
				11.ANXIETY SOMATIC	1	1	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	0	0	1	1	0	0	0	0
				13.SOMATIC GENERAL	1	1	2	2	0	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	1	0	1	0	0
				19.DEPERSONALIZATION	1	1	1	1	1	0	0	1
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	0	1	0	0
				22.Total score	24	24	24	21	10	16	9	11
	408	Imipramine	Female	01.DEPRESSED MOOD	3	3	1	2	1	1	0	0
				02.GUILT	2	2	1	1	1	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	0	1	1
				06.INSOMNIA LATE	1	1	1	0	0	1	0	0
				07.WORK AND ACTIVITIES	3	3	2	2	2	1	1	1
				08.RETARDATION	1	1	0	0	0	0	0	0
				09.AGITATION	1	1	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	2	2
				11.ANXIETY SOMATIC	1	1	0	1	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	403	Imipramine	Female	13.SOMATIC GENERAL	2	2	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	1	1	1	0	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	1	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	0	0
				22.Total score	27	27	14	12	12	7	8	7
	404	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	2	3		
				02.GUILT	2	2	2	2	2	2		
				03.SUICIDE	1	1	1	1	1	1		
				04.INSOMNIA EARLY	2	2	2	1	0	0		
				05.INSOMNIA MIDDLE	1	1	1	2	2	2		
				06.INSOMNIA LATE	1	1	1	1	1	1		
				07.WORK AND ACTIVITIES	2	2	2	2	2	2		
				08.RETARDATION	0	0	0	0	0	0		
				09.AGITATION	1	1	2	2	2	2		
				10.ANXIETY PSYCHIC	2	2	2	2	1	2		
				11.ANXIETY SOMATIC	2	2	2	2	2	2		
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0		
				13.SOMATIC GENERAL	1	1	2	2	2	1		
				14.GENITAL SYMPTOMS	0	0	1	1	2	2		
				15.HYPOCHONDRIASIS	0	0	0	0	0	0		
				16.LOSS OF WEIGHT	1	1	0	0	0	0		
				17.INSIGHT	1	1	1	1	1	1		
				18.DIURNAL VARIATION	1	1	1	1	1	1		
				19.DEPERSONALIZATION	0	0	0	0	0	0		
				20.PARANOID	1	1	1	1	1	1		
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		
				22.Total score	23	23	24	23	22	23		
	405	Placebo	Female	01.DEPRESSED MOOD	3	3	2	3	1	1	1	0
				02.GUILT	1	1	1	1	1	0	0	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	0	1
				05.INSOMNIA MIDDLE	1	1	2	1	0	1	1	0
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	2	2	2	1	1
				08.RETARDATION	1	1	0	0	0	0	0	0
				09.AGITATION	2	2	2	1	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	1
				11.ANXIETY SOMATIC	2	2	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	1	0	1
				14.GENITAL SYMPTOMS	1	1	2	2	1	1	1	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	405	Placebo	Female	17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	25	25	21	20	10	10	7	5
	406	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	1	1	1	1	1
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	2	1	1	1	1
				05.INSOMNIA MIDDLE	0	0	1	1	0	0	0	1
				06.INSOMNIA LATE	1	1	0	1	1	1	0	0
				07.WORK AND ACTIVITIES	3	3	2	2	1	0	0	1
				08.RETARDATION	1	1	0	0	0	0	0	0
				09.AGITATION	1	1	0	0	1	1	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	2
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	1	0	0	1
				14.GENITAL SYMPTOMS	2	2	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	1	0	1
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	16	15	10	9	6	11
	407	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	2	2	1	1
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	2	2	1	1	1	1	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	0
				06.INSOMNIA LATE	0	0	1	0	0	1	0	1
				07.WORK AND ACTIVITIES	3	3	3	3	2	2	1	1
				08.RETARDATION	1	1	1	1	0	0	0	0
				09.AGITATION	2	2	2	2	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	2	2	1	1	1	0	0	1
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	407	Reboxetine	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	23	22	17	17	13	14
	408	Placebo	Female	01.DEPRESSED MOOD	3	3	3	3	2	1	1	1
				02.GUILT	2	2	2	2	1	1	1	1
				03.SUICIDE	1	1	1	2	1	1	0	0
				04.INSOMNIA EARLY	1	1	1	1	2	2	1	1
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	1	1
				06.INSOMNIA LATE	2	2	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	4	4	2	2	2	1
				08.RETARDATION	2	2	2	2	1	1	0	0
				09.AGITATION	0	0	0	0	0	1	1	1
				10.ANXIETY PSYCHIC	3	3	3	3	2	2	1	2
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	1	1	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	1	1	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	0	1	0
				19.DEPERSONALIZATION	1	1	1	1	1	1	0	1
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	28	28	17	16	13	13
	418	Placebo	Female	01.DEPRESSED MOOD	3	3	3	3	2	2	1	1
				02.GUILT	2	2	2	2	2	1	1	0
				03.SUICIDE	1	1	1	1	0	1	0	0
				04.INSOMNIA EARLY	2	2	1	2	2	2	2	2
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	0	0
				06.INSOMNIA LATE	2	2	2	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	3	3	2	1	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	2	1	1	1	0	0
				10.ANXIETY PSYCHIC	3	3	2	2	2	2	2	1
				11.ANXIETY SOMATIC	2	2	2	1	1	2	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	1	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	0	0
				22.Total score	28	28	25	23	20	20	11	7

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	419	Placebo	Female	01.DEPRESSED MOOD	3	3	2	2	2	1	2	2
				02.GUILT	2	2	1	2	1	0	1	1
				03.SUICIDE	1	1	0	1	1	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	0	0
				05.INSOMNIA MIDDLE	2	2	1	2	1	1	1	1
				06.INSOMNIA LATE	1	1	0	1	1	1	0	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	0	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	1
				11.ANXIETY SOMATIC	1	1	1	1	2	1	2	1
				12.SOMATIC GASTROINTESTINAL	1	1	0	1	1	0	0	0
				13.SOMATIC GENERAL	2	2	0	2	2	2	2	0
				14.GENITAL SYMPTOMS	1	1	1	2	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	1	1	2	1	1	1
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	0	1	0	0
				19.DEPERSONALIZATION	0	0	1	0	0	0	0	1
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	25	14	21	20	15	15	12

1250

9550082

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	1	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	2.17	1.17	1.00	0.67	0.50	0.50
				2.WEIGHT	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.83	1.00	0.67	0.50	0.50	0.33
				4.DIURNAL VARIATION	2.00	2.00	2.00	0.00	0.00	1.00	0.00	0.00
				5.RETARDATION	2.50	2.50	2.75	1.00	0.75	1.00	0.50	0.00
				6.SLEEP DISTURBANCE	2.00	2.00	1.00	1.67	2.00	0.67	0.00	0.33
				7.Total score	11.33	11.33	11.75	4.83	4.42	3.83	1.50	1.17
	2	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.67	1.83	0.83	1.17	0.83	1.00	0.33
				2.WEIGHT	0.00	0.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.83	1.33	0.83	0.83	0.83	0.67	0.50	0.50
				4.DIURNAL VARIATION	0.00	1.00	0.00	1.00	1.00	1.00	1.00	0.00
				5.RETARDATION	3.00	2.25	2.50	1.75	1.50	2.00	1.25	1.00
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.33	2.00	2.00	1.00	1.00
				7.Total score	8.00	8.25	8.83	5.75	6.50	6.50	4.75	2.83
	3	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.00	1.17	1.17	1.33	1.00	0.50	0.50	0.33
				2.WEIGHT	1.00	1.00	2.00	1.00	0.00	0.00	1.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.17	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.75	2.00	1.50	1.50	1.25	0.50
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	0.67	1.00
				7.Total score	5.67	5.83	6.58	5.50	3.83	3.33	3.75	2.17
	4	Placebo	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	0.67	0.83	0.67	0.67	0.50	0.33
				2.WEIGHT	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.67	0.17	0.17	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.50	0.75	0.50	0.25	0.25	0.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.00	0.67	0.67	0.33	0.33	0.33
				7.Total score	8.08	8.08	5.83	3.42	3.00	1.25	1.08	0.92
	5	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.00	0.83	0.83			
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	1.00			
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00			
				5.RETARDATION	2.00	2.00	2.00	2.00	2.00			
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.67	1.67			
				7.Total score	10.17	10.17	6.50	6.33	6.50			
	6	Placebo	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.00	1.00	1.00	0.33	0.67	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.33	0.67	0.50	0.83	0.50	1.00	1.00
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	1.00	1.00
				5.RETARDATION	2.50	2.50	1.50	1.25	1.25	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	1.33	1.33	1.67	2.00	2.00	1.00	1.33	1.00
				7.Total score	7.50	7.50	4.83	4.75	6.08	3.08	5.25	4.92

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	7	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.00	0.83	0.50	0.33	0.33	0.17
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.83	0.83	0.33	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.75	1.75	0.75	0.50	0.00	0.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.00	0.67	0.33	0.00	0.33
				7.Total score	8.92	8.92	6.58	4.42	3.25	1.17	0.33	0.50
	8	Placebo	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	0.83	0.50	0.67	0.50	0.33	0.33
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.50	0.50	0.33	0.17
				4.DIURNAL VARIATION	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.25	1.00	0.75	0.50	0.50	0.25
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.00	1.33	1.33	1.00	0.33
				7.Total score	8.50	8.50	5.42	3.17	3.25	2.83	2.17	1.08
	9	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	1.50	1.50	0.67	0.83	0.33
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	2.00	2.00	1.67	1.00	1.50	1.00	0.67	0.50
				4.DIURNAL VARIATION	2.00	2.00	2.00	0.00	2.00	1.00	1.00	1.00
				5.RETARDATION	2.50	2.50	2.00	2.25	2.50	1.75	1.25	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	1.00	1.33	0.67
				7.Total score	10.83	10.83	8.83	6.75	9.50	5.42	5.08	3.25
	10	Placebo	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	0.67	0.50	0.83	1.00	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.67	0.50	0.33	0.50	0.50	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.75	1.00	1.25	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	2.00	2.00	1.33	0.67	0.33	0.00	0.00	0.00
				7.Total score	7.00	7.00	5.42	2.67	2.75	2.50	2.33	2.17
	11	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33						
				2.WEIGHT	1.00	1.00						
				3.COGNITIVE DISTURBANCE	0.50	0.50						
				4.DIURNAL VARIATION	1.00	1.00						
				5.RETARDATION	1.75	1.75						
				6.SLEEP DISTURBANCE	2.00	2.00						
				7.Total score	7.58	7.58						
	12	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.83	0.83	1.17	0.67	0.67	0.50	0.50	0.33
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.67	0.33	0.17	0.50	0.00	0.17
				4.DIURNAL VARIATION	1.00	1.00	2.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.75	1.00	0.75	0.75	0.25	0.25

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	12	Imipramine	Female	6.SLEEP DISTURBANCE	0.00	0.00	0.00	0.67	0.00	0.67	0.67	0.33
				7.Total score	6.25	6.25	5.58	2.67	1.58	2.42	1.42	1.08
	412	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	0.83	0.83	0.83	1.00	0.17	0.33
				2.WEIGHT	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.83	0.67	0.67	0.17	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.75	1.50	1.50	1.50	0.50	0.50
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	2.00	1.00	0.67	1.00	0.00
				7.Total score	7.92	7.92	5.42	5.00	4.00	3.33	1.67	0.83
	413	Placebo	Male	1.ANXIETY/SOMATIZATION	1.17	1.00	0.83		0.83		0.67	0.50
				2.WEIGHT	0.00	0.00	0.00		0.00		0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.00		0.83		1.00	0.50
				4.DIURNAL VARIATION	1.00	1.00	1.00		0.00		0.00	0.00
				5.RETARDATION	1.25	2.00	2.00		0.75		1.50	1.00
				6.SLEEP DISTURBANCE	1.00	2.00	0.67		0.33		0.00	0.00
				7.Total score	5.58	7.17	5.50		2.75		3.17	2.00
	414	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.00	1.17	1.17				
				2.WEIGHT	0.00	2.00	0.00	2.00				
				3.COGNITIVE DISTURBANCE	1.17	0.33	0.17	0.50				
				4.DIURNAL VARIATION	2.00	0.00	0.00	0.00				
				5.RETARDATION	2.00	2.25	2.00	1.75				
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00				
				7.Total score	8.33	7.58	5.33	7.42				
	415	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	0.67	0.50	0.33	0.50	0.33
				2.WEIGHT	0.00	0.00	1.00	0.00	1.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.33	0.17	0.00	0.17	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.00	1.25	0.75	0.75	0.25	0.25
				6.SLEEP DISTURBANCE	1.67	1.67	2.00	1.00	1.33	1.00	1.00	1.33
				7.Total score	5.00	5.00	5.83	4.25	3.75	2.08	1.92	1.92
	416	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.33	1.50	1.50				
				2.WEIGHT	1.00	1.00	1.00	0.00				
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.67	0.67				
				4.DIURNAL VARIATION	1.00	1.00	0.00	1.00				
				5.RETARDATION	1.25	1.25	1.50	1.25				
				6.SLEEP DISTURBANCE	1.67	1.67	2.00	2.00				
				7.Total score	7.75	7.25	6.67	6.42				
	421	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.00	1.00	0.83	0.83	0.50	0.17	0.67	0.50
				2.WEIGHT	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.33	0.17	0.00	0.00	0.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	421	Imipramine	Male	4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.00	1.25	1.00	0.75	1.00	0.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.00	0.67	0.33	0.33	0.67
				7.Total score	6.58	6.58	5.83	3.42	2.33	1.25	2.00	1.42
	422	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.00	1.00	0.67	0.67	0.33	0.50	0.17	0.33
				2.WEIGHT	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.17	0.17	0.33	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.25	1.25	1.00	0.50	0.25	0.00
				6.SLEEP DISTURBANCE	1.67	1.67	1.33	0.00	0.67	0.33	0.33	0.67
				7.Total score	7.00	7.00	5.92	4.08	2.17	1.67	0.92	1.17
2/1	49	Placebo	Female	1.ANXIETY/SOMATIZATION	1.33	1.17	1.33	0.67	0.33	0.17	0.17	0.00
				2.WEIGHT	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.33	0.33	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	2.00	0.50	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	0.00	1.00	1.00	1.00	1.00	0.67	0.33	0.33
				7.Total score	4.67	5.00	5.67	2.17	1.33	0.83	0.50	0.33
	50	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.17	1.00	0.83	1.00	1.00	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.17	0.17	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	1.75	0.75	0.25	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.00	0.67	0.67	0.67
				7.Total score	6.33	5.75	3.25	2.58	2.00	1.67	1.50	1.50
	51	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.50	1.67	0.83	0.83	0.83	0.83
				2.WEIGHT	0.00	0.00	2.00	0.00	0.00	0.00	2.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.50	0.17	0.17	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	1.00	1.00	2.00	2.00	2.00
				5.RETARDATION	2.75	2.25	2.00	1.50	0.75	0.50	0.50	0.50
				6.SLEEP DISTURBANCE	1.33	1.33	1.67	0.67	0.67	0.67	0.67	0.67
				7.Total score	6.92	6.42	7.67	5.00	3.42	4.00	6.00	4.00
2/2	43	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	0.00	0.67		0.17	0.17	
				2.WEIGHT	0.00	0.00	0.00	0.00		0.00	0.00	
				3.COGNITIVE DISTURBANCE	1.00	1.17	0.50	0.17		0.00	0.17	
				4.DIURNAL VARIATION	1.00	1.00	1.00	2.00		0.00	1.00	
				5.RETARDATION	1.75	1.50	0.00	1.25		0.25	0.25	
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	1.00		0.67	0.00	
				7.Total score	5.92	6.00	2.17	5.08		1.08	1.58	
	44	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.50	0.67	0.83	0.50	0.83	0.17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/2	44	Imipramine	Female	2.WEIGHT	2.00	0.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.67	0.33	0.50	0.83	0.50
				4.DIURNAL VARIATION	1.00	2.00	1.00	1.00	2.00	1.00	1.00	1.00
				5.RETARDATION	1.00	1.25	1.00	0.25	0.75	0.25	0.25	0.00
				6.SLEEP DISTURBANCE	1.33	1.00	1.67	1.33	0.67	0.67	1.33	0.67
				7.Total score	7.33	6.25	7.83	3.92	4.58	2.92	4.25	2.33
	45	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.00	0.83	0.50	0.67	0.83	1.00	0.67
				2.WEIGHT	0.00	0.00	2.00	0.00	0.00	0.00	0.00	1.00
				3.COGNITIVE DISTURBANCE	1.17	1.50	0.33	0.67	0.33	0.67	0.67	0.17
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	2.00	0.00	0.00	1.00
				5.RETARDATION	1.25	1.25	1.50	0.75	1.25	0.50	0.25	1.00
				6.SLEEP DISTURBANCE	1.00	0.67	0.67	0.67	0.33	0.00	0.67	0.67
				7.Total score	5.92	5.42	5.33	2.58	4.58	2.00	2.58	4.50
	46	Placebo	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	0.50		0.83	0.17		
				2.WEIGHT	0.00	0.00	0.00		0.00	0.00		
				3.COGNITIVE DISTURBANCE	1.17	1.00	0.33		0.50	0.17		
				4.DIURNAL VARIATION	0.00	2.00	0.00		0.00	0.00		
				5.RETARDATION	1.50	1.25	1.00		0.75	0.25		
				6.SLEEP DISTURBANCE	1.67	1.67	0.00		0.33	0.33		
				7.Total score	5.50	7.08	1.83		2.42	0.92		
	47	Placebo	Female	1.ANXIETY/SOMATIZATION	1.00	1.67	1.33	1.00	0.67	1.00	0.83	0.83
				2.WEIGHT	0.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.17	0.17	0.50	0.33	0.33
				4.DIURNAL VARIATION	0.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00
				5.RETARDATION	2.75	2.50	2.50	1.75	1.50	2.50	2.50	1.75
				6.SLEEP DISTURBANCE	0.67	1.67	1.67	0.33	0.33	0.33	0.67	0.00
				7.Total score	5.08	8.50	7.83	4.25	3.67	5.33	5.33	4.92
	48	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.83	1.00	0.83	1.17	0.50	0.17	0.00	0.17
				2.WEIGHT	0.00	0.00	2.00	0.00	2.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.83	0.33	0.33	0.00	0.33	0.33	0.17
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.75	2.50	2.25	1.25	0.75	0.00	0.75
				6.SLEEP DISTURBANCE	1.67	1.67	0.67	0.33	0.00	0.67	0.33	1.00
				7.Total score	6.92	7.25	6.33	4.08	3.75	1.92	0.67	2.08
2/3	36/A	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	1.17	1.17	0.67	0.67	0.83	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	1.00	1.00	0.00	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.50	2.50	1.00	1.00	0.50	0.50	0.50
				6.SLEEP DISTURBANCE	2.00	1.33	1.33	0.67	0.67	0.67	0.67	0.67
				7.Total score	6.25	6.00	6.00	2.33	2.50	2.17	2.17	2.17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/3	37	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.67	1.67	1.67	1.67	1.67	0.50
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.50	0.50	0.33	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.75	2.25	1.50	1.50	1.50	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	1.67	1.67	1.67	1.33
				7.Total score	6.58	6.58	5.92	6.42	5.17	4.83	4.83	2.58
	38	Placebo	Male	1.ANXIETY/SOMATIZATION	1.83	1.83	1.50	1.50	1.67	1.17	0.67	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.50	0.17	0.50	0.50	0.50
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.50	2.00	2.00	1.50	1.25	0.75	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	1.33	1.33	1.33	1.33	1.00	1.33
				7.Total score	7.75	8.00	6.33	6.33	4.67	4.25	2.92	3.25
	39	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.00	1.83	1.83	1.17	1.17	0.50	0.67	0.50
				2.WEIGHT	1.00	2.00	0.00	0.00	0.00	2.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.67	0.67	0.50	0.00	0.17	0.00	0.00
				4.DIURNAL VARIATION	0.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.25	2.00	1.50	1.25	0.50	0.25	0.00
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.00	0.00	0.00	0.00	0.00
				7.Total score	8.00	9.75	7.17	5.17	2.42	3.17	0.92	0.50
	40	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.17	0.83	0.50	0.83	0.67	0.33
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.67	0.50	0.50	0.50	0.00	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.50	1.50	0.75	0.50	0.25	0.75
				6.SLEEP DISTURBANCE	1.67	1.67	0.67	0.33	0.33	1.00	1.00	0.00
				7.Total score	6.92	6.92	4.00	3.17	2.08	3.83	1.92	1.25
	41	Placebo	Male	1.ANXIETY/SOMATIZATION	1.17	1.33	1.33	0.50	0.50	0.50	0.50	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.50	0.83	0.50	0.17	0.67	0.17
				4.DIURNAL VARIATION	1.00	1.00	2.00	1.00	2.00	2.00	2.00	2.00
				5.RETARDATION	2.50	2.50	2.50	2.50	2.75	2.75	2.25	2.50
				6.SLEEP DISTURBANCE	0.67	0.67	1.00	1.00	0.00	0.00	0.00	0.00
				7.Total score	6.33	6.50	7.33	5.83	5.75	6.42	5.42	5.50
	42	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.67	1.17	1.33	1.17	0.83	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.50	0.50	0.83	0.17	0.33	0.33	0.17
				4.DIURNAL VARIATION	2.00	2.00	0.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.00	1.75	0.75	1.50	1.25	1.50

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/3	42	Imipramine	Female	6.SLEEP DISTURBANCE	1.33	1.33	0.67	1.33	1.00	0.67	0.67	0.67
				7.Total score	8.08	7.75	4.33	6.25	4.08	3.33	3.08	3.17
2/4	31	Placebo	Male	1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.83	1.83	1.83	1.50	1.50
				2.WEIGHT	3.00	3.00	3.00	3.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	2.33	2.33	2.00	1.67	1.67	1.67	1.50	1.50
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00
				5.RETARDATION	2.25	2.50	2.75	2.25	2.25	2.25	1.50	1.50
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.33	1.33	1.33	1.33	1.33
				7.Total score	13.08	13.33	13.25	12.08	9.08	9.08	6.83	6.83
	32	Reboxetine	Male	1.ANXIETY/SOMATIZATION	2.17	2.00	1.50	1.50	1.33	0.83	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	2.50	2.33	2.33	2.33	1.83	1.00	1.00	0.67
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
				5.RETARDATION	3.00	3.00	3.00	3.00	2.50	1.00	0.75	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	1.00	1.00	1.00	0.67
				7.Total score	11.67	11.33	10.83	10.83	7.67	4.83	4.58	3.92
	33	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.50	0.50	0.50	0.50	0.33	0.50	0.33	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	2.00	2.00	2.00	2.00	1.33	0.83	0.50	0.50
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	1.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.50	1.50	1.25	0.75	0.50	0.50
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	1.33	0.00	0.00	0.00
				7.Total score	8.00	8.00	8.00	8.00	5.25	3.08	1.33	1.33
	34	Placebo	Female	1.ANXIETY/SOMATIZATION	3.00	3.00	3.00	3.00	2.50	1.33	1.00	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	3.00	3.00	2.83	2.83	2.00	1.17	1.00	0.83
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	2.00	1.00	1.00
				5.RETARDATION	2.75	2.75	2.75	2.25	1.50	1.00	0.75	0.50
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.00	1.00	1.00
				7.Total score	12.42	12.42	12.25	11.75	8.67	6.50	4.75	4.17
	35	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.83	2.83	2.17	2.17	1.33	1.00	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	2.50	2.50	2.50	2.00	1.50	1.00	0.67	0.50
				4.DIURNAL VARIATION	1.00	2.00	2.00	2.00	1.00	1.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	2.00	1.50	1.00	0.75	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.67	1.00	0.67	0.00
				7.Total score	10.58	11.58	10.92	9.83	7.00	5.00	2.92	2.08
	36	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.33	2.33	2.33	2.17	1.50	1.00	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	2.83	2.83	3.00	2.50	1.50	1.00	0.50	0.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/4	36	Imipramine	Female	4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
				5.RETARDATION	3.00	3.00	3.00	2.50	1.75	1.25	0.50	0.50
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	0.00	0.00	0.00
				7.Total score	12.17	12.17	12.33	11.17	7.75	4.25	2.50	2.00
2/5	73	Placebo	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.17	0.67	1.17	1.00	1.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.17	0.17	0.17	0.67	0.67	0.83
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00
				5.RETARDATION	2.50	2.50	1.75	1.75	1.25	1.75	1.75	2.25
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	0.33	1.00	0.67	1.33
				7.Total score	5.33	5.33	4.25	4.08	2.42	5.58	5.08	6.58
	74	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.83	1.33	0.83	0.50	0.17	0.00	0.00	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.50	0.17	0.00	0.17	0.00
				4.DIURNAL VARIATION	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.25	1.50	0.75	0.50	0.50	0.25	0.50
				6.SLEEP DISTURBANCE	1.00	1.33	1.00	1.00	1.00	1.00	0.67	0.33
				7.Total score	5.50	6.58	3.67	2.75	1.83	1.50	1.08	1.00
	75	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.83	0.83	0.83	0.50	0.33	0.17	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	0.83	0.67	0.50	0.33	0.33	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.75	0.50	0.50	0.25	0.25	0.00
				6.SLEEP DISTURBANCE	1.33	1.67	1.00	1.00	1.00	0.67	0.33	0.33
				7.Total score	5.42	5.58	4.25	2.50	2.17	1.42	0.58	0.33
	76	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.17	1.33	0.33	1.17	0.17	0.00	0.17
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	0.83	0.83	0.33	0.50	0.33	0.33	0.00
				4.DIURNAL VARIATION	0.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.50	2.00	1.00	2.25	1.25	0.50	0.25
				6.SLEEP DISTURBANCE	1.33	1.00	1.00	1.00	0.00	0.33	0.33	0.00
				7.Total score	7.00	6.50	6.17	2.67	3.92	2.08	1.17	0.42
	77	Placebo	Male	1.ANXIETY/SOMATIZATION	1.83	1.17	0.67	0.33	0.33	0.33	0.17	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.50	0.33	0.17	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	3.00	2.50	1.25	1.00	1.00	0.50	0.25	0.00
				6.SLEEP DISTURBANCE	0.00	0.67	0.33	0.67	0.33	0.33	0.00	0.00
				7.Total score	5.67	5.17	2.75	2.33	1.83	1.17	0.42	0.17
	78	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	0.83	0.50	0.17	0.33	0.00	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/5	78	Reboxetine	Female	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	1.00	0.00	
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.67	0.50	0.17	0.33	0.33	
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5.RETARDATION	2.75	2.25	2.00	1.75	0.75	0.75	0.50	
				6.SLEEP DISTURBANCE	0.67	0.67	1.00	1.00	1.00	0.67	0.33	
				7.Total score	6.08	5.58	4.50	3.75	2.08	3.08	1.17	
2/6	55	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.67	1.17	0.67	0.33	0.33	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.17	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	2.50	1.75	1.25	0.50	0.25	0.25
				6.SLEEP DISTURBANCE	1.67	1.67	0.67	0.33	0.00	0.00	0.00	0.00
				7.Total score	7.83	7.83	6.50	4.42	1.92	0.83	0.58	0.58
	56	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.83	1.83	1.33	1.17	1.50
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	0.83	0.83	0.67	0.50	0.67
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.75	1.75	1.50	1.75	1.75	1.50	1.75	1.75
				6.SLEEP DISTURBANCE	1.00	1.00	0.33	0.00	0.00	0.00	0.00	0.67
				7.Total score	7.58	7.58	5.67	5.42	5.42	4.50	4.42	5.58
	57	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.00	0.50	0.33	0.17	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.67	0.33	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	2.50	1.50	0.50	0.25	0.00	0.25
				6.SLEEP DISTURBANCE	1.33	1.33	0.67	0.00	0.00	0.33	0.00	0.00
				7.Total score	7.33	7.33	6.17	3.83	1.00	0.92	0.17	0.42
	58	Placebo	Female	1.ANXIETY/SOMATIZATION	2.00	2.00	2.00	2.00	0.33	0.00	0.00	0.00
				2.WEIGHT	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.50	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	2.25	1.75	1.00	0.25	0.25	0.25
				6.SLEEP DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	6.83	6.83	6.58	4.25	1.33	0.25	0.25	0.25
	59	Placebo	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.33	1.33	1.17		
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.67	1.00		
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	2.00	1.00		
				5.RETARDATION	2.50	2.50	2.50	2.50	2.50	2.00		
				6.SLEEP DISTURBANCE	1.33	1.33	0.67	0.33	0.00	0.67		
				7.Total score	8.17	8.17	6.33	6.00	6.50	5.83		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2/6	60	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	0.50	0.17	0.00	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.33	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.00	1.25	0.75	0.75	0.50	0.50
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	0.67	0.00	0.00	0.00	0.00
				7.Total score	6.92	6.92	6.50	3.75	0.92	0.75	0.50	0.50
3/1	61	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.33	1.17	0.67	0.33	0.33	
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.33	0.00	0.00	0.00	
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	0.00	0.00	
				5.RETARDATION	2.00	2.00	2.25	2.00	1.25	1.00	1.00	
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.67	0.33	0.33	0.33	
				7.Total score	6.83	6.83	5.92	5.17	3.25	1.67	1.67	
	62	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	0.83	0.50	0.33	0.17	0.33	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.33	0.33	0.17	0.17	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	1.75	1.25	1.00	1.00	0.50	0.50
				6.SLEEP DISTURBANCE	1.33	1.33	0.67	0.67	0.33	0.33	0.33	0.33
				7.Total score	6.33	6.33	3.58	2.75	1.83	1.67	1.17	1.17
	63	Placebo	Male	1.ANXIETY/SOMATIZATION	1.50	1.00	1.17	1.00	1.00	0.50	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	0.83	0.83	0.67	0.67	0.50	0.33	0.33
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.50	2.25	1.75	1.75	1.00	1.00	0.75
				6.SLEEP DISTURBANCE	1.33	1.67	1.67	1.33	1.33	1.00	0.33	0.67
				7.Total score	6.58	6.00	5.92	4.75	4.75	3.00	2.17	2.25
	64	Placebo	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	1.33	1.83	1.83	1.83	1.67	1.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.50	0.50	0.50	0.50	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.25	2.25	2.00	2.75	2.75	2.75	2.50	2.50
				6.SLEEP DISTURBANCE	1.00	1.67	1.00	0.00	0.00	0.00	0.67	0.33
				7.Total score	6.25	7.08	6.00	6.08	6.08	6.08	6.33	5.83
	65	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.67	1.17	1.17	0.83	0.67	0.33	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	0.50	0.33	0.33	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.50	1.50	1.50	0.75	1.00	1.00	1.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/1	65	Reboxetine	Male	6.SLEEP DISTURBANCE	1.67	1.67	0.67	1.00	0.67	0.33	0.33	0.33
				7.Total score	6.92	6.83	4.33	4.17	2.58	2.33	1.83	1.83
	66	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.67	1.50	1.33	1.00	0.83	0.33	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.33	0.17	0.17	0.17	0.17	0.00
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.50	2.50	2.25	1.50	1.50	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.33	0.33	0.00	0.33	0.33
				7.Total score	7.67	7.50	5.92	4.00	3.83	2.75	3.25	3.08
	139	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.17				
				2.WEIGHT	0.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.67	0.67	1.00	1.67				
				4.DIURNAL VARIATION	2.00	2.00	2.00	0.00				
				5.RETARDATION	2.00	2.00	2.00	3.00				
				6.SLEEP DISTURBANCE	0.67	1.00	1.00	2.00				
				7.Total score	6.50	6.83	7.17	7.83				
	140	Placebo	Male	1.ANXIETY/SOMATIZATION	1.83	1.83	1.67	1.33	1.00	1.00	0.83	0.67
				2.WEIGHT	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.33	0.17	0.17	0.17	0.17	0.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.25	0.75	0.75	0.75	0.50
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.33	0.33	0.00	0.00	0.00
				7.Total score	9.08	9.08	7.75	3.08	2.25	1.92	1.75	1.17
	141	Placebo	Female	1.ANXIETY/SOMATIZATION	1.50	1.67	1.67	1.33	0.83	0.83	0.50	0.67
				2.WEIGHT	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.33	0.33	0.33	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.50	1.00	0.50	1.00	1.00	0.50
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	0.00	0.33	0.33	0.67
				7.Total score	4.83	6.00	5.00	3.67	1.67	2.50	2.00	2.00
	142	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.33	1.33			
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	1.00			
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00			
				5.RETARDATION	2.25	2.25	2.25	2.25	2.25			
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00			
				7.Total score	7.75	6.75	6.58	6.58	6.58			
	143	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17		0.67	0.67	0.83	
				2.WEIGHT	0.00	0.00	0.00		0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.83	1.00	0.67		0.33	0.33	0.17	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/1	143	Reboxetine	Female	4.DIURNAL VARIATION	1.00	1.00	1.00		1.00	1.00	1.00	
				5.RETARDATION	2.25	2.25	1.00		0.75	0.75	0.75	
				6.SLEEP DISTURBANCE	0.33	0.33	0.33		0.33	0.33	0.33	
				7.Total score	5.58	5.75	4.17		3.08	3.08	3.08	
	144	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.83	0.83	1.17	1.00		1.17	0.83	0.83
				2.WEIGHT	2.00	2.00	0.00	0.00		0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.83	0.33		0.33	0.33	0.33
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00		0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	1.00		0.75	0.50	0.50
				6.SLEEP DISTURBANCE	1.67	1.33	2.00	0.67		0.33	0.33	0.00
				7.Total score	7.17	6.83	6.00	3.00		2.58	2.00	1.67
	451	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.50				
				2.WEIGHT	0.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.33	0.33				
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00				
				5.RETARDATION	2.50	2.50	2.25	2.75				
				6.SLEEP DISTURBANCE	1.33	1.67	1.67	1.67				
				7.Total score	5.67	6.00	5.58	6.25				
	452	Placebo	Male	1.ANXIETY/SOMATIZATION	1.33	1.17	0.83	0.33	0.00	0.00	1.17	0.50
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.17	0.17	0.17	0.00	0.00	0.00	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.75	1.75	0.50	0.00	0.00	0.50	0.25
				6.SLEEP DISTURBANCE	1.33	1.33	0.67	0.67	0.67	0.33	0.33	0.33
				7.Total score	7.58	7.42	3.42	1.50	0.67	0.33	2.17	1.25
	453	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.00	1.00	0.67	0.50		0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00		0.00
				3.COGNITIVE DISTURBANCE	0.33	0.17	0.00	0.00	0.00	0.00		0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00		1.00
				5.RETARDATION	2.25	2.50	1.75	1.75	1.00	1.00		1.00
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.67	0.33	0.33		0.33
				7.Total score	6.08	6.17	4.75	4.42	3.00	2.83		3.00
	454	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	0.33	0.33	0.33	0.33	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.17	0.17	0.17	0.17	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.50	1.50	0.75	0.75	1.00	0.50
				6.SLEEP DISTURBANCE	1.00	1.00	1.33	1.00	0.67	0.67	0.67	1.00
				7.Total score	7.08	6.92	3.33	3.00	1.92	1.75	2.17	2.00
	455	Placebo	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	0.83	0.67	1.17	1.17	1.17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/1	455	Placebo	Female	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.50	0.67	0.50	0.33	0.17	0.17	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00
				5.RETARDATION	3.00	3.00	2.75	2.50	2.00	2.25	2.25	1.50
				6.SLEEP DISTURBANCE	0.33	0.33	0.33	0.33	0.67	0.33	0.33	0.33
				7.Total score	7.00	6.83	6.75	6.17	4.67	3.92	3.92	3.17
	456	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.83	1.00	0.67	1.33				
				2.WEIGHT	1.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.33	0.33				
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00				
				5.RETARDATION	2.75	2.75	2.25	2.25				
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	0.00				
				7.Total score	6.42	5.58	4.25	3.92				
3/2	65/A	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	0.83	0.83	0.50	0.83	0.83
				2.WEIGHT	0.00	0.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.17	1.00	0.67	0.83	0.67	0.67	0.67
				4.DIURNAL VARIATION	0.00	2.00	1.00	0.00	1.00	1.00	0.00	0.00
				5.RETARDATION	1.25	1.50	1.25	1.00	1.50	1.75	1.75	1.50
				6.SLEEP DISTURBANCE	1.67	0.33	1.67	1.33	0.67	0.67	1.00	1.00
				7.Total score	5.75	6.50	8.25	3.83	4.83	4.58	4.25	4.00
3/3	67	Placebo	Male	1.ANXIETY/SOMATIZATION	1.33	1.00	1.00	1.00	0.50	0.67	0.00	0.50
				2.WEIGHT	1.00	0.00	1.00	0.00	0.00	2.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.67	0.33	0.83	0.17	0.00	0.00	0.17
				4.DIURNAL VARIATION	2.00	2.00	1.00	2.00	1.00	0.00	0.00	1.00
				5.RETARDATION	2.25	2.25	2.25	2.25	1.50	1.25	1.25	1.00
				6.SLEEP DISTURBANCE	1.00	1.33	0.00	1.00	0.67	0.67	0.67	0.67
				7.Total score	8.42	7.25	5.58	7.08	3.83	4.58	1.92	3.33
	68	Reboxetine	Male	1.ANXIETY/SOMATIZATION	0.83	1.00	0.67	0.33	0.17	0.00	0.00	0.00
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.33	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.50	1.75	1.00	0.25	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.33	0.33	0.33	0.00	0.00
				7.Total score	6.75	5.17	3.42	2.00	0.75	0.33	0.00	0.00
	69	Placebo	Male	1.ANXIETY/SOMATIZATION	1.67	1.33	1.50	1.00	0.83	1.33	0.33	0.33
				2.WEIGHT	1.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.00	2.00	1.00	0.50	1.50	0.67	0.50
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.25	2.50	1.50	0.75	2.50	1.25	1.25
				6.SLEEP DISTURBANCE	1.33	0.67	1.00	0.67	0.33	1.33	0.33	0.33
				7.Total score	7.83	5.25	7.00	5.17	2.42	6.67	2.58	2.42

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/3	70	Imipramine	Male	1.ANXIETY/SOMATIZATION	2.33	1.83	1.00	0.83	0.67	0.83	0.50	0.50
				2.WEIGHT	1.00	2.00	1.00	0.00	1.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.00	1.00	0.67	0.33	0.50	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	1.75	1.25	1.00	0.25	0.50	0.50	0.50
				6.SLEEP DISTURBANCE	1.67	1.67	1.00	0.67	0.67	1.00	0.67	0.67
				7.Total score	8.42	8.25	5.25	3.17	2.92	2.83	1.83	1.83
	71	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.50	1.33	0.83	0.50	0.33	0.17	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.00	0.67	0.67	0.50	0.50	0.50	0.33
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.00	1.25	0.75	0.50	0.50	0.25	0.25
				6.SLEEP DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	5.08	4.50	3.25	2.25	1.50	1.33	0.92	0.75
	72	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.00	0.17	0.50	0.50	0.33	0.17	0.50
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	2.00
				3.COGNITIVE DISTURBANCE	1.33	0.83	0.83	0.50	0.33	0.33	0.17	0.33
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	0.00	1.00	1.00	1.00
				5.RETARDATION	2.00	1.75	1.00	0.75	0.50	0.50	0.50	0.50
				6.SLEEP DISTURBANCE	1.33	0.67	0.33	0.00	0.00	0.33	0.00	0.67
				7.Total score	9.83	6.25	4.33	2.75	1.33	2.50	1.83	5.00
3/4	79	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.50	1.50	1.00	0.50	0.33	0.33
				2.WEIGHT	2.00	2.00	3.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.17	0.17	0.33	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	1.75	1.50	0.75	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	1.00	0.33	0.33	0.33	0.33
				7.Total score	8.83	8.83	8.42	5.17	3.42	0.83	0.67	0.67
	80	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	0.83	0.67			
				2.WEIGHT	0.00	1.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.17	0.17			
				4.DIURNAL VARIATION	1.00	2.00	2.00	2.00	0.00			
				5.RETARDATION	1.50	1.50	1.50	1.00	0.75			
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.67	0.67			
				7.Total score	5.50	7.50	6.00	4.67	2.25			
	81	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	0.83	0.33	0.17	0.17	0.17	0.17
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.67	0.17	0.00	0.00	0.17	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	1.25	0.50	0.25	0.75	0.75	0.25

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/4	81	Reboxetine	Female	6.SLEEP DISTURBANCE	1.67	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	8.17	8.33	2.25	0.83	0.42	1.08	1.08	0.58
	82	Placebo	Male	1.ANXIETY/SOMATIZATION	1.00	1.00	0.83	0.50	0.50	0.50	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	1.00	1.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.83	0.50	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.25	0.75	0.75	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	1.00	0.33	0.33	0.67	0.67
				7.Total score	5.83	5.83	4.92	3.75	2.75	1.75	2.08	2.08
	83	Placebo	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.67					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.83	0.83	1.17					
				4.DIURNAL VARIATION	1.00	1.00	2.00					
				5.RETARDATION	1.75	1.75	1.75					
				6.SLEEP DISTURBANCE	1.00	1.00	1.67					
				7.Total score	5.75	5.75	8.25					
	84	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	0.83	0.33	0.17	0.17	0.17	0.17
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.17	0.17	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.25	0.75	0.50	0.50	0.25	0.25
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	0.33	0.00	0.00	0.00	0.00
				7.Total score	6.92	6.92	4.25	1.58	0.67	0.67	0.42	0.42
	85	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.00	0.50	0.67	0.83	0.50	0.17
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.50	0.33	0.17	0.50	0.17	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.75	1.50	1.25	1.25	1.00	0.75
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	0.00	0.00	1.33	0.67	0.00
				7.Total score	7.75	6.75	5.25	2.33	2.08	3.92	2.33	0.92
	86	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.00	0.67	0.50	0.33	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.33	0.17	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.50	0.75	0.75	0.50	0.50	0.50
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.33	0.00	0.00	0.00	0.00
				7.Total score	7.58	7.58	5.83	1.92	1.25	0.83	1.00	1.00
	87	Placebo	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	0.83	0.67	1.33	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	1.00	1.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.83	0.67	0.67	1.17	0.67	0.33

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/4	87	Placebo	Female	4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.50	1.25	1.00	2.00	1.25	1.25
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	0.33	0.00	1.00	0.33	0.00
				7.Total score	6.08	6.08	5.33	3.08	2.33	6.50	4.08	2.42
	88	Placebo	Male	1.ANXIETY/SOMATIZATION	1.83	1.83	1.50	1.17	0.83	0.83	0.83	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.17	0.17	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	2.00	2.00	2.00	2.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.25	1.00	1.00	0.75	0.50	0.50
				6.SLEEP DISTURBANCE	1.33	1.33	0.67	0.00	0.00	0.00	0.00	0.00
				7.Total score	6.25	7.25	5.58	4.33	3.83	1.58	1.33	1.17
	89	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	1.00	1.17	1.00	0.67	0.67
				2.WEIGHT	2.00	2.00	1.00	0.00	1.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.17	0.17	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00
				5.RETARDATION	1.75	2.50	2.00	2.00	1.25	1.25	1.00	0.75
				6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.33	1.33	1.33	1.00	0.67
				7.Total score	8.08	8.83	6.67	5.50	5.92	5.75	2.83	2.25
	90	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	0.67	0.67	0.50	0.17	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	0.67	0.50	0.33	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.50	1.50	0.75	0.25	0.25
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.33	0.00	0.33	0.33	0.33
				7.Total score	5.92	5.92	5.92	4.17	2.67	1.92	0.75	0.75
	457	Placebo	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	1.33			
				2.WEIGHT	0.00	0.00	1.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.83	0.67	0.83			
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00			
				5.RETARDATION	2.75	2.50	2.75	2.50	2.50			
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67			
				7.Total score	6.42	6.17	7.58	6.17	6.33			
	458	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.33	2.33	2.33	2.33				
				2.WEIGHT	0.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	1.17				
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00				
				5.RETARDATION	2.00	1.75	2.00	2.25				
				6.SLEEP DISTURBANCE	0.67	0.67	1.00	1.00				
				7.Total score	5.67	5.42	6.00	6.75				
	459	Placebo	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.33	1.33	1.33	1.00	1.00	0.83

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3/4	459	Placebo	Female	2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.50	0.50	0.17	0.17	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.50	1.25	1.00	1.00	1.00	0.75
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.67	0.33	0.00	0.00	0.00
				7.Total score	6.33	6.33	4.00	3.75	3.17	2.17	2.17	1.58
	460	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67					
				2.WEIGHT	2.00	2.00	0.00					
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33					
				4.DIURNAL VARIATION	1.00	1.00	1.00					
				5.RETARDATION	1.50	1.50	1.25					
				6.SLEEP DISTURBANCE	2.00	2.00	1.67					
				7.Total score	8.50	8.50	5.92					
	461	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.50					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33					
				4.DIURNAL VARIATION	1.00	1.00	1.00					
				5.RETARDATION	2.00	2.00	1.50					
				6.SLEEP DISTURBANCE	1.67	1.67	1.67					
				7.Total score	6.33	6.33	6.00					
	462	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00					
				2.WEIGHT	1.00	1.00	0.00					
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.17					
				4.DIURNAL VARIATION	1.00	1.00	1.00					
				5.RETARDATION	2.00	2.00	1.00					
				6.SLEEP DISTURBANCE	1.33	1.33	1.33					
				7.Total score	6.67	6.67	4.50					
4/1	91	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.67	1.33	1.00	0.50	0.50	0.50	0.17
				2.WEIGHT	0.00	0.00	1.00	1.00	1.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.83	0.17	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	2.00	1.00	0.50	0.50	0.50	0.50
				6.SLEEP DISTURBANCE	2.00	2.00	0.67	1.00	1.33	1.33	1.33	1.00
				7.Total score	7.08	6.92	6.83	5.17	4.50	2.50	2.50	1.83
	92	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	1.50	1.67	1.67	1.67
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	1.00	1.00	1.00
				3.COGNITIVE DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.83	1.67	1.83
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.75	3.00	2.75	3.00	2.75	2.50	2.50
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				7.Total score	8.92	8.92	8.17	7.92	9.17	9.25	8.83	9.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/1	93	Placebo	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	1.67	1.00	0.17	0.17	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.00	1.67	0.67	0.17	0.17	0.00
				4.DIURNAL VARIATION	1.00	1.00	2.00	2.00	2.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.75	2.25	1.50	0.75	0.75	0.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.67	1.00	0.33	0.33	0.00
				7.Total score	7.17	7.17	7.25	9.25	6.17	1.42	1.42	0.25
	94	Placebo	Female	1.ANXIETY/SOMATIZATION	2.17	2.17	2.00	0.83	0.33	0.17	0.17	0.17
				2.WEIGHT	1.00	1.00	2.00	1.00	1.00	2.00	2.00	2.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.83	0.17	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	1.00	1.00	0.25	0.00	0.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	0.67	0.00	0.00	0.00	0.00
				7.Total score	7.50	7.50	9.17	4.67	2.33	2.42	2.17	2.17
	95	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	0.17	0.00	0.00	0.00	0.17	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.17	0.17	0.17	0.17	0.17	0.00
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	0.75	0.50	0.50	0.50	0.75	0.00
				6.SLEEP DISTURBANCE	1.33	1.33	0.33	0.33	0.33	0.33	0.33	0.00
				7.Total score	6.17	6.17	1.42	1.00	1.00	1.00	1.42	0.00
	96	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.17	1.00	0.67	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.67	1.67	1.33	1.17	0.67	0.67	0.67	0.50
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.75	2.00	1.75	1.00	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				7.Total score	7.92	7.92	5.67	5.08	3.67	3.33	3.50	3.33
	115	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.67	1.50	1.17	1.00	1.00	1.00	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.50	0.50	0.50	0.50	0.50	0.50
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.75	2.50	2.25	1.75	1.50	1.25	1.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.00	1.00	1.00	0.67	0.67
				7.Total score	7.42	7.25	6.17	4.92	5.25	5.00	4.42	4.08
	116	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.33	1.67					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00					
				4.DIURNAL VARIATION	0.00	0.00	0.00					
				5.RETARDATION	2.75	2.75	2.75					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/1	116	Imipramine	Female	6.SLEEP DISTURBANCE	1.00	0.67	1.00					
				7.Total score	6.42	5.75	6.42					
	117	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.17	0.83	0.50	0.50	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	2.00	2.00	1.17	0.50	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	3.00	3.00	2.00	1.50	1.00	0.50	0.50	0.50
				6.SLEEP DISTURBANCE	2.00	2.00	1.00	0.33	0.33	0.33	0.33	0.67
				7.Total score	10.50	10.50	6.33	4.17	2.17	1.67	1.67	2.00
	118	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.33	1.17	0.83	0.67	0.50	0.50	0.50
				2.WEIGHT	0.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.83	0.83	0.83	0.50	0.17	0.17	0.17
				4.DIURNAL VARIATION	0.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.00	2.00	1.50	1.25	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	1.00	1.33	1.33	1.00	0.33	0.33	0.33	0.33
				7.Total score	5.58	8.50	8.33	5.17	2.75	2.00	2.00	2.00
	119	Placebo	Female	1.ANXIETY/SOMATIZATION	1.83	1.83						
				2.WEIGHT	1.00	1.00						
				3.COGNITIVE DISTURBANCE	0.67	0.67						
				4.DIURNAL VARIATION	1.00	1.00						
				5.RETARDATION	1.75	1.75						
				6.SLEEP DISTURBANCE	1.33	1.33						
				7.Total score	7.58	7.58						
	120	Placebo	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.17	1.17	1.00	0.50	0.50	0.50
				2.WEIGHT	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00
				3.COGNITIVE DISTURBANCE	0.83	0.50	0.50	0.33	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.25	1.25	1.25	1.00	1.00
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.33	0.33	0.67	0.67	0.00
				7.Total score	5.08	4.75	5.08	4.08	3.75	3.58	3.33	2.67
	145	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.17	0.83	0.83	0.83	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.67	1.67	0.83	0.50	0.50	0.50	0.50	0.50
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	1.75	1.25	1.25	1.25	1.00	1.00
				6.SLEEP DISTURBANCE	2.00	1.67	1.00	0.67	0.67	0.67	0.67	0.00
				7.Total score	7.67	7.33	4.75	3.25	3.25	3.25	3.00	2.33
	146	Placebo	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.00	1.00	1.00	0.67	0.67	0.50
				2.WEIGHT	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.50	0.50	0.50	0.50

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/1	146	Placebo	Female	4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.00	1.00	1.25	1.00	1.00
				6.SLEEP DISTURBANCE	1.67	1.67	1.00	0.33	0.33	0.33	0.33	0.00
				7.Total score	7.00	7.00	5.67	4.83	3.83	2.75	2.50	2.00
	147	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.67	1.50	1.00	1.00	1.17	1.00
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.50	0.50	0.50	0.50
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.50	2.50	2.00	2.00	1.75	1.50	1.25	1.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.67	1.67	1.33	1.00	1.00
				7.Total score	8.50	7.50	6.83	7.00	5.92	5.33	4.92	4.50
	148	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.17	1.33	1.33	1.00	1.00	0.83	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.83	0.67	0.67	0.67	0.50	0.50
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.50	1.25	1.00	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	0.67	0.67
				7.Total score	5.75	5.58	4.67	4.25	3.67	3.67	3.00	2.67
	149	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.67	1.00	1.33	0.83	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.67	0.50	0.50	0.50	0.50
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.50	2.00	1.75	1.25	1.00	1.00
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.67	0.67	0.33	0.33	0.33
				7.Total score	5.58	5.58	5.50	4.33	4.25	2.92	2.67	2.67
	150	Placebo	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.00	0.83	0.67	0.67	0.67	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.00	0.67	0.67	0.67	0.67	0.67
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.75	1.50	1.00	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67
				7.Total score	5.42	5.42	4.42	3.67	3.00	3.00	3.00	2.83
4/2	93/A	Placebo	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	1.83	1.67	1.33	0.50	0.33	0.33
				2.WEIGHT	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.67	0.50	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.75	2.75	2.75	1.50	0.75	0.50	0.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00
				7.Total score	8.25	8.25	8.42	8.08	4.33	1.25	0.83	0.33
	99/A	Placebo	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.17	1.17	0.83	0.50	0.33

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/2	99/A	Placebo	Male	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.50	0.50	0.33	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	1.75	1.75	1.00	0.25	0.00
				6.SLEEP DISTURBANCE	1.33	1.33	0.67	0.67	0.67	0.00	0.00
				7.Total score	6.50	6.50	4.08	4.08	2.83	0.75	0.33
	104	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.33	1.33	1.33	1.33
				2.WEIGHT	2.00	2.00	3.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.50	1.50	1.00	1.00	1.00	1.00	1.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	2.25	1.75	1.75	1.75	1.75
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67
				7.Total score	9.17	9.17	10.17	9.42	5.75	5.75	5.75
4/3	97	Placebo	Male	1.ANXIETY/SOMATIZATION	1.50	1.83	1.50	1.50	1.50	2.00	2.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.50	0.50	0.67	0.67
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	2.00	2.00	2.00	2.00	2.00	2.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.67	1.67	1.67	1.00	1.00
				7.Total score	5.25	5.83	5.67	5.67	5.67	5.67	5.67
	98	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.33	1.50	1.17	1.17	1.83
				2.WEIGHT	0.00	0.00	0.00	3.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.83	0.83	0.83
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	0.00
				5.RETARDATION	1.50	1.50	2.00	2.00	1.50	1.50	2.00
				6.SLEEP DISTURBANCE	1.00	1.00	2.00	2.00	1.00	1.00	2.00
				7.Total score	6.00	6.00	7.17	10.33	5.50	5.50	6.67
	99	Placebo	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	2.17			
				2.WEIGHT	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.83			
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00			
				5.RETARDATION	2.00	2.00	2.00	2.00			
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00			
				7.Total score	7.17	7.17	7.17	8.00			
	100	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	1.33	1.67	1.67		
				2.WEIGHT	2.00	2.00	1.00	1.00	1.00		
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.50	0.83	0.83		
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00		
				5.RETARDATION	1.50	2.00	1.75	1.75	1.75		
				6.SLEEP DISTURBANCE	1.67	1.33	1.33	1.33	1.33		
				7.Total score	8.17	8.50	5.92	6.58	6.58		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/3	101	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.33	0.83	0.50	0.33	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	1.00	0.83	0.33	0.17	0.17	0.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	0.00	1.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.25	1.50	1.00	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	0.00	0.33	0.00	0.00
				7.Total score	7.33	7.33	7.75	5.67	2.17	2.75	1.25	0.75
4/4	109	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	1.17	0.83	0.50	0.33	0.17	0.17
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.83	0.33	0.17	0.17	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.50	1.25	0.75	0.50	0.25	0.00
				6.SLEEP DISTURBANCE	2.00	1.33	1.00	0.67	0.33	0.67	0.33	0.00
				7.Total score	7.83	5.50	4.00	2.92	1.75	1.50	0.75	0.17
	110	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	1.17	0.83	1.17	0.67	0.67	0.33	0.50
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.17	0.50	0.33	0.33	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.50	1.75	1.75	1.25	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	2.00	1.67	1.33	1.33	0.67	0.00	0.33	0.33
				7.Total score	7.67	7.83	4.25	4.58	2.75	1.83	1.83	2.00
	111	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	1.17	1.00	0.67	0.50	0.50	0.33	0.33
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.17	0.17	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	1.50	1.25	1.00	1.00	0.25
				6.SLEEP DISTURBANCE	1.67	2.00	1.67	1.00	0.33	0.33	0.00	0.00
				7.Total score	7.92	5.92	5.42	3.33	2.25	1.83	1.33	0.58
	112	Placebo	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	0.83	0.83	0.67	0.50	1.00	0.83
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.17	0.17	0.17	0.00	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.50	1.25	1.00	1.00	1.50	1.00
				6.SLEEP DISTURBANCE	2.00	1.67	1.00	0.67	0.67	0.67	0.67	0.33
				7.Total score	7.42	5.08	3.50	2.92	2.50	2.17	4.33	2.33
	113	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.00	1.17	1.33	0.83	0.83	0.67	0.50	0.33
				2.WEIGHT	1.00	0.00	2.00	0.00	2.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.33	0.17	0.17	0.00	0.00
				4.DIURNAL VARIATION	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.00	2.00	1.75	1.25	1.00	0.75	0.25

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/4	113	Reboxetine	Male	6.SLEEP DISTURBANCE	2.00	1.67	1.67	1.33	1.00	1.00	0.33	0.33
				7.Total score	6.92	6.50	7.33	4.25	5.25	2.83	1.58	0.92
	114	Placebo	Female	1.ANXIETY/SOMATIZATION	1.67	1.83	1.67	1.33	1.00	1.00	0.83	0.83
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.67	0.50	0.17	0.17	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.00	1.50	1.00	1.00	0.75	0.75
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	0.67	0.67	0.33	0.33	0.33
				7.Total score	7.75	7.08	5.50	3.67	2.83	2.33	1.92	1.92
	175	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.00	1.17	0.83	0.67	0.33	0.33
				2.WEIGHT	1.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.33	0.33	0.00	0.00	0.17	0.00
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.50	2.25	1.50	1.25	1.25	0.50	0.00
				6.SLEEP DISTURBANCE	1.33	1.67	1.33	1.00	0.67	0.33	0.33	0.33
				7.Total score	7.25	6.83	4.92	4.00	3.75	2.25	1.33	0.67
	176	Placebo	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	1.00	1.00	1.33		
				2.WEIGHT	1.00	0.00	0.00	0.00	1.00	0.00		
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.17	0.17	1.00		
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00		
				5.RETARDATION	2.00	2.00	1.75	1.50	1.50	2.50		
				6.SLEEP DISTURBANCE	1.67	1.33	1.00	1.00	0.67	1.00		
				7.Total score	7.17	5.83	5.25	3.67	4.33	5.83		
	177	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.00	2.17	2.00	2.00				
				2.WEIGHT	2.00	0.00	0.00	1.00				
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.17				
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00				
				5.RETARDATION	1.50	1.75	1.75	1.75				
				6.SLEEP DISTURBANCE	1.67	1.33	0.67	1.33				
				7.Total score	7.50	5.58	4.75	6.25				
	178	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.00	0.67	0.33	0.33	0.33	0.17
				2.WEIGHT	1.00	0.00	0.00	0.00	1.00	0.00	1.00	1.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.33	0.17	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.50	1.00	1.00	0.50	0.25	0.25
				6.SLEEP DISTURBANCE	1.67	1.33	1.00	0.33	0.33	0.33	0.33	0.67
				7.Total score	6.67	5.33	3.83	2.17	2.67	1.17	1.92	2.08
	179	Placebo	Female	1.ANXIETY/SOMATIZATION	1.33	1.17	1.17	1.00	1.17			
				2.WEIGHT	1.00	0.00	1.00	0.00	1.00			
				3.COGNITIVE DISTURBANCE	0.83	0.50	0.50	0.33	1.17			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4/4	179	Placebo	Female	4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00			
				5.RETARDATION	2.50	2.00	1.75	1.50	3.00			
				6.SLEEP DISTURBANCE	1.67	2.00	1.33	1.00	1.33			
				7.Total score	8.33	6.67	6.75	4.83	7.67			
	180	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.00	0.67	0.67	0.33	0.00	0.17
				2.WEIGHT	1.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.50	0.33	0.33	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.50	2.00	1.25	1.00	0.75	0.50	0.50
				6.SLEEP DISTURBANCE	1.67	1.67	1.33	0.67	0.33	0.33	0.33	0.33
				7.Total score	6.75	6.83	4.67	2.92	3.00	1.42	0.83	1.00
5/1	127	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.83	1.83	1.00	1.00	1.00	0.67	0.83	1.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.33	0.50	0.83	0.33	0.50	0.67
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	1.00	1.00
				5.RETARDATION	3.00	3.00	2.25	2.00	1.75	2.50	1.75	1.50
				6.SLEEP DISTURBANCE	1.00	1.33	1.00	1.00	1.00	1.00	0.67	1.00
				7.Total score	7.33	7.67	5.58	5.50	4.58	5.50	4.75	5.17
	128	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.00	2.00	0.67	1.00	1.00	0.83	1.00	1.33
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.50	0.50	0.50	0.50	0.67	0.67
				4.DIURNAL VARIATION	1.00	2.00	1.00	2.00	1.00	1.00	0.00	0.00
				5.RETARDATION	2.25	2.00	1.25	0.75	1.00	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	2.00	1.67	0.00	0.00	0.00	0.33	0.00	0.00
				7.Total score	10.25	8.67	3.42	4.25	3.50	3.42	2.42	2.75
	129	Placebo	Male	1.ANXIETY/SOMATIZATION	0.67	0.67	0.50	0.67	0.50	0.33	0.50	1.17
				2.WEIGHT	2.00	2.00	2.00	2.00	0.00	0.00	0.00	1.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.50	0.83	0.67	0.33	0.33	0.67
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	1.00	0.00
				5.RETARDATION	1.75	1.75	2.00	0.75	0.75	0.50	0.50	1.25
				6.SLEEP DISTURBANCE	1.67	1.67	0.33	0.00	0.00	0.00	0.33	0.67
				7.Total score	8.08	8.08	6.33	4.25	1.92	1.17	2.67	4.75
	130	Placebo	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.17	1.17	0.17	0.00	1.17
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.33	0.67	0.33	1.00	0.17	0.00	0.17
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00
				5.RETARDATION	2.50	2.50	1.75	1.00	1.75	0.75	0.75	1.00
				6.SLEEP DISTURBANCE	0.67	0.67	0.00	0.67	0.33	1.67	1.00	0.00
				7.Total score	9.17	9.17	5.08	4.17	5.25	3.75	1.75	2.33
	131	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	0.67	0.83	1.33	0.17	0.00	0.33

1274

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
5/1	131	Imipramine	Female	2.WEIGHT	0.00	0.00	0.00	2.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.50	0.50	0.33	0.33	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	2.00	1.00	1.00	0.00
				5.RETARDATION	2.00	2.00	1.50	1.00	1.75	0.50	0.25	0.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.00	1.00	0.67	1.33	0.67	0.00
				7.Total score	6.67	6.67	5.00	6.33	6.25	3.33	2.25	0.58
	132	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.83	0.83	0.00	0.00	0.00	0.00		0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00		0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.00	0.00	0.00	0.00		0.00
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00		0.00
				5.RETARDATION	2.25	2.25	0.00	0.25	0.00	0.00		0.00
				6.SLEEP DISTURBANCE	1.33	1.33	0.67	0.00	0.00	0.00		0.00
				7.Total score	6.25	6.25	0.67	0.25	0.00	0.00		0.00
5/2	121	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.67	2.00	1.83	1.17	1.50	1.67	2.00
				2.WEIGHT	2.00	0.00	1.00	1.00	0.00	2.00	0.00	2.00
				3.COGNITIVE DISTURBANCE	1.33	1.33	1.17	1.00	0.33	0.33	0.50	0.83
				4.DIURNAL VARIATION	1.00	1.00	0.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.75	2.25	2.75	1.50	1.25	1.50	2.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	0.33	0.33	0.33	0.33
				7.Total score	10.25	8.08	7.75	8.92	3.33	5.42	4.00	7.17
	125	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	2.00	0.33	0.83	0.50	0.33	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.17	0.50	0.67	0.00	0.00	0.00	0.17	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	3.00	2.25	2.25	0.75	0.25	0.25	0.25	0.25
				6.SLEEP DISTURBANCE	0.00	0.67	0.67	0.67	0.67	0.67	0.33	1.33
				7.Total score	4.83	5.08	5.58	1.75	1.75	1.42	1.08	2.08
5/3	133	Placebo	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.50				
				2.WEIGHT	2.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.67	0.67	1.17	1.33				
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00				
				5.RETARDATION	2.25	2.25	2.25	2.75				
				6.SLEEP DISTURBANCE	2.00	1.67	1.67	2.00				
				7.Total score	10.42	8.08	8.42	9.58				
	134	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.50	0.17	0.33	0.00		0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	2.00	0.00		0.00
				3.COGNITIVE DISTURBANCE	1.00	0.83	0.67	0.17	0.83	0.00		0.00
				4.DIURNAL VARIATION	2.00	2.00	1.00	0.00	0.00	0.00		0.00
				5.RETARDATION	2.25	2.25	2.00	0.50	1.25	0.00		0.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00		0.33
				7.Total score	8.92	8.75	7.17	2.83	6.42	2.00		0.50

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
5/3	135	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.17	0.33	0.33	0.33	0.67	0.67	1.67
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.00	0.00	0.00	0.00	0.17	0.50
				4.DIURNAL VARIATION	0.00	1.00	0.00	0.00	0.00	0.00	0.00	1.00
				5.RETARDATION	2.00	2.00	0.75	0.25	0.25	0.75	1.50	2.00
				6.SLEEP DISTURBANCE	1.33	2.00	1.00	0.33	0.33	0.33	1.00	1.33
				7.Total score	7.17	6.50	2.08	0.92	0.92	1.75	3.33	6.50
	136	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	0.50	0.00	0.33	0.00	0.00
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.67	0.33	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.75	0.25	0.00	0.25	0.00	0.00
				6.SLEEP DISTURBANCE	1.67	2.00	2.00	0.67	1.00	1.00	1.00	0.33
				7.Total score	7.25	6.75	5.92	1.42	1.00	1.58	1.00	0.33
	137	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.00	0.17	0.17	0.17	0.17	0.17
				2.WEIGHT	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.83	0.33	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.75	1.50	0.75	0.25	0.25	0.25	0.25
				6.SLEEP DISTURBANCE	2.00	1.67	1.67	1.67	1.67	1.67	0.67	0.67
				7.Total score	8.58	8.58	6.50	2.58	2.08	2.08	1.08	1.08
	138	Placebo	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.50					
				2.WEIGHT	2.00	2.00	2.00					
				3.COGNITIVE DISTURBANCE	0.83	0.50	0.50					
				4.DIURNAL VARIATION	2.00	2.00	2.00					
				5.RETARDATION	2.00	2.00	2.00					
				6.SLEEP DISTURBANCE	1.67	1.33	1.33					
				7.Total score	9.83	9.33	9.33					
6/1	151	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.33	1.50	1.33					
				2.WEIGHT	2.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.17					
				4.DIURNAL VARIATION	1.00	1.00	1.00					
				5.RETARDATION	1.75	1.75	1.75					
				6.SLEEP DISTURBANCE	1.67	2.00	1.67					
				7.Total score	8.25	6.75	5.92					
	152	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.50	1.17	1.17	1.17	1.17	1.00	0.17
				2.WEIGHT	2.00	0.00	0.00	0.00	1.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.33	0.33	0.00	0.17	0.00	0.17
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.00	1.50	1.25	1.25	1.00	1.00	0.25

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/1	152	Reboxetine	Female	6.SLEEP DISTURBANCE	1.33	1.67	2.00	2.00	1.33	1.67	1.33	1.00
				7.Total score	8.25	6.67	5.00	4.75	4.75	5.00	3.33	1.58
	153	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.67	1.33	1.17	1.00	1.33	1.17	1.17	1.17
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.00	0.17	0.17	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.00	2.00	1.25	1.00	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	1.00	0.67	0.67	0.67
				7.Total score	6.58	6.00	4.83	3.58	3.33	3.00	3.00	2.83
	154	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.17						
				2.WEIGHT	0.00	0.00						
				3.COGNITIVE DISTURBANCE	0.50	0.33						
				4.DIURNAL VARIATION	0.00	0.00						
				5.RETARDATION	2.25	2.25						
				6.SLEEP DISTURBANCE	1.67	1.67						
				7.Total score	5.42	5.42						
	155	Placebo	Male	1.ANXIETY/SOMATIZATION	1.17	1.33	1.17	1.17	1.00	1.00		
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.67	0.50	0.83		
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00		
				5.RETARDATION	2.75	2.75	2.75	2.50	2.25	2.25		
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.67	1.33	1.67		
				7.Total score	8.58	7.75	7.08	7.00	6.08	6.75		
	156	Placebo	Female	1.ANXIETY/SOMATIZATION	1.50	1.33	1.17	0.83	0.83	0.83	0.50	0.83
				2.WEIGHT	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.67	0.50	0.33	0.17	0.00	0.00	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.25	2.50	1.50	1.25	0.50	1.00	1.00
				6.SLEEP DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.33	0.00	0.00
				7.Total score	6.33	6.58	5.50	3.00	2.58	1.67	1.50	2.00
6/2	157	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	1.17	1.17	1.17	1.17	1.17	1.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.00	0.83	0.50	0.50	0.67	0.50	0.50
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.00	2.00	2.00	1.25	1.25	1.25	1.25	1.00
				6.SLEEP DISTURBANCE	0.67	1.33	2.00	1.00	0.67	0.00	0.00	0.00
				7.Total score	6.67	7.00	7.00	4.92	4.58	4.08	3.92	3.50
	158	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.83	0.83	0.67	0.67	0.67	0.83		0.17
				2.WEIGHT	2.00	2.00	2.00	2.00	0.00	0.00		0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.50	0.33		0.17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/2	158	Imipramine	Female	4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00		0.00
				5.RETARDATION	1.75	1.75	1.75	1.50	1.50	1.25		0.50
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	0.00	0.00	0.00		0.00
				7.Total score	8.58	8.58	7.42	5.83	3.67	3.42		0.83
	159	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.33	1.00	1.00	1.00	0.50	0.67	0.67	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.33	1.00	0.67	0.83	0.50	1.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00
				5.RETARDATION	2.25	2.25	2.25	2.00	2.00	1.50	1.50	1.75
				6.SLEEP DISTURBANCE	0.67	0.67	0.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	7.25	6.92	6.58	6.00	5.17	4.00	3.67	4.75
	160	Placebo	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	0.67	0.67	0.33	0.33	0.33	1.33
				2.WEIGHT	0.00	0.00	0.00	0.00	3.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.50	1.50	0.67	0.67	0.67	0.67	0.67	1.00
				4.DIURNAL VARIATION	2.00	2.00	0.00	0.00	0.00	1.00	1.00	2.00
				5.RETARDATION	2.25	2.50	0.75	0.75	1.00	1.25	1.25	2.00
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.67	1.00	1.00	1.00	0.67
				7.Total score	8.08	8.33	2.75	2.75	6.00	4.25	4.25	7.00
	161	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.83	0.83	1.33	1.00	1.33	1.33		
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.83	0.67	0.67	0.83	0.83	0.83		
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00		
				5.RETARDATION	2.00	2.00	2.00	1.25	1.25	1.25		
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	1.00	1.00		
				7.Total score	7.00	6.83	5.33	4.08	4.42	4.42		
	162	Placebo	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67					
				2.WEIGHT	2.00	2.00	2.00					
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83					
				4.DIURNAL VARIATION	0.00	0.00	0.00					
				5.RETARDATION	2.00	2.00	2.00					
				6.SLEEP DISTURBANCE	1.67	1.67	1.67					
				7.Total score	8.17	8.17	8.17					
	169	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.17	2.33	0.50	2.50	2.67			
				2.WEIGHT	3.00	3.00	0.00	3.00	3.00			
				3.COGNITIVE DISTURBANCE	1.83	1.67	0.17	2.50	3.00			
				4.DIURNAL VARIATION	1.00	1.00	0.00	1.00	2.00			
				5.RETARDATION	3.25	3.25	0.00	3.25	3.25			
				6.SLEEP DISTURBANCE	2.00	2.00	0.33	2.00	2.00			
				7.Total score	13.25	13.25	1.00	14.25	15.92			
	170	Placebo	Male	1.ANXIETY/SOMATIZATION	2.33	2.50	0.50					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/2	170	Placebo	Male	2.WEIGHT	3.00	3.00	0.00					
				3.COGNITIVE DISTURBANCE	2.50	2.50	1.00					
				4.DIURNAL VARIATION	2.00	2.00	1.00					
				5.RETARDATION	3.00	3.25	1.00					
				6.SLEEP DISTURBANCE	2.00	2.00	0.67					
				7.Total score	14.83	15.25	4.17					
	171	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.17	1.83	1.83	1.00	0.33	0.00	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	2.33	2.00	1.83	0.33	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.00	2.00	1.25	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	0.00	0.00	0.00	0.00
				7.Total score	9.58	7.17	7.00	3.58	0.33	0.00	0.00	0.00
	172	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.67	1.67	1.67	1.67	1.83
				2.WEIGHT	3.00	3.00	3.00	3.00	1.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.33	1.50	1.50	1.50	1.67	1.67
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	3.00	3.00	3.00	3.00	3.00	3.00	2.75	2.50
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				7.Total score	11.83	11.83	12.17	12.17	10.17	9.17	9.08	9.00
	173	Placebo	Male	1.ANXIETY/SOMATIZATION	2.17	2.00	2.00	2.00	2.00	2.17	1.17	1.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00
				3.COGNITIVE DISTURBANCE	2.00	2.00	1.83	1.83	1.83	2.00	1.33	1.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	2.00	1.00	1.00
				5.RETARDATION	2.50	2.50	2.25	2.25	2.25	2.75	1.75	2.00
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	2.00	2.00	1.67	0.33	0.33
				7.Total score	9.33	9.17	8.75	9.08	9.08	10.58	6.58	7.00
	174	Reboxetine	Male	1.ANXIETY/SOMATIZATION	2.17	2.00	0.67	0.00	0.00	0.00	0.00	0.83
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	2.00	1.83	0.00	0.00	0.00	0.00	0.00	0.67
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	3.25	3.25	0.50	0.00	0.00	0.00	0.00	1.25
				6.SLEEP DISTURBANCE	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	11.42	11.08	1.17	0.00	0.00	0.00	0.00	2.75
6/3	163	Reboxetine	Male	1.ANXIETY/SOMATIZATION	2.00	2.00	2.00					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83					
				4.DIURNAL VARIATION	1.00	1.00	1.00					
				5.RETARDATION	2.25	2.25	2.25					
				6.SLEEP DISTURBANCE	0.00	0.00	0.00					
				7.Total score	6.08	6.08	6.08					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/3	164	Imipramine	Male	1.ANXIETY/SOMATIZATION	2.00	2.00	1.83	1.00	1.00	0.83	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.83	0.67	0.83	0.67	0.50	0.50
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	1.75	2.00	2.00	2.00	1.50
				6.SLEEP DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	6.75	6.75	6.92	5.42	4.83	3.50	3.33	2.83
	165	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.67	1.50	1.33	1.17	1.17	1.00	0.83
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.50	0.50	0.50	0.67	0.67	0.67
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00
				5.RETARDATION	1.75	2.00	1.75	2.00	2.00	1.50	1.75	1.25
				6.SLEEP DISTURBANCE	0.67	1.00	0.33	0.33	0.33	0.00	0.00	0.00
				7.Total score	8.75	9.50	6.08	6.17	6.00	5.33	5.42	3.75
	166	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.83	1.83					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.67	0.67	1.17					
				4.DIURNAL VARIATION	2.00	2.00	2.00					
				5.RETARDATION	2.25	2.75	2.75					
				6.SLEEP DISTURBANCE	0.00	0.00	1.33					
				7.Total score	6.42	7.25	9.08					
	167	Placebo	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.00	0.83	0.50	0.50	0.67	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.00	0.50	0.67	0.67	0.50	0.33	0.33
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	1.00	0.00	1.00
				5.RETARDATION	1.75	1.50	2.00	1.50	2.00	1.25	0.75	1.00
				6.SLEEP DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	6.42	6.00	5.50	5.00	5.17	3.25	1.75	3.00
	168	Placebo	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.17	1.33	1.17	1.67	1.67	
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.50	0.50	0.50	0.83	
				4.DIURNAL VARIATION	0.00	2.00	2.00	1.00	0.00	0.00	0.00	
				5.RETARDATION	2.25	2.50	2.25	2.25	2.25	2.25	2.25	
				6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.00	0.67	0.67	0.67	
				7.Total score	7.25	7.50	6.75	5.08	4.58	5.08	5.42	
	505	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	2.00	1.33	1.67				
				2.WEIGHT	0.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.50	0.67	0.67	0.50				
				4.DIURNAL VARIATION	1.00	2.00	0.00	0.00				
				5.RETARDATION	2.25	2.25	2.25	2.00				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/3	505	Imipramine	Female	6.SLEEP DISTURBANCE	0.00	0.00	0.67	1.33				
				7.Total score	5.58	6.92	4.92	5.50				
	506	Placebo	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.17	1.17	0.83	1.17	1.17
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.67	0.50	0.33	0.33	0.33
				4.DIURNAL VARIATION	2.00	2.00	1.00	0.00	2.00	0.00	1.00	0.00
				5.RETARDATION	2.00	2.00	1.75	2.00	1.75	1.50	1.25	1.75
				6.SLEEP DISTURBANCE	0.67	1.00	1.00	1.00	2.00	1.00	0.67	1.33
				7.Total score	8.67	7.00	5.75	4.83	7.42	3.67	4.42	4.58
	507	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	0.83	0.50	0.50	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.33	0.67	0.17	0.33	0.17	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	0.00	1.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.25	1.25	1.00	0.25	0.50
				6.SLEEP DISTURBANCE	0.33	0.33	0.33	0.00	0.00	0.00	0.33	0.00
				7.Total score	6.25	6.25	5.75	4.25	2.25	2.83	1.25	0.83
	508	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.83	1.17	0.50	1.00	0.67	1.17	0.50	0.33
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.17	0.33	0.33	0.17	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	1.00	2.00	1.00
				5.RETARDATION	2.00	2.00	1.75	2.00	1.50	1.50	1.00	1.00
				6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.00	0.67	0.00	0.33	0.33
				7.Total score	8.00	8.33	5.42	5.17	5.17	4.00	4.00	2.83
	509	Placebo	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	0.83	0.83	1.33	0.83	0.83	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.67	0.50	0.67	0.33	0.33	0.50	0.33
				4.DIURNAL VARIATION	2.00	1.00	0.00	0.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.75	2.00	1.25	1.25	1.50	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	0.33	0.33	0.67	0.00	0.33	0.00	0.00	0.67
				7.Total score	6.08	5.50	3.25	2.75	4.50	3.42	3.58	3.75
	510	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.00	1.17				
				2.WEIGHT	0.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.33				
				4.DIURNAL VARIATION	2.00	2.00	0.00	0.00				
				5.RETARDATION	2.00	2.00	1.75	1.25				
				6.SLEEP DISTURBANCE	0.67	0.67	1.00	1.33				
				7.Total score	6.67	6.67	4.08	4.08				
	511	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.50	0.67	0.67	0.83	0.67	1.17	
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.33	0.67	0.67	1.17	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6/3	511	Imipramine	Female	4.DIURNAL VARIATION	2.00	2.00	1.00	0.00	1.00	1.00	1.00	
				5.RETARDATION	1.75	1.75	1.50	1.50	1.25	1.25	1.75	
				6.SLEEP DISTURBANCE	0.00	0.67	0.00	0.33	0.33	0.67	0.67	
				7.Total score	7.75	8.75	3.83	2.83	4.08	4.25	5.75	
	512	Placebo	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.50					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67					
				4.DIURNAL VARIATION	2.00	2.00	2.00					
				5.RETARDATION	2.00	2.00	2.00					
				6.SLEEP DISTURBANCE	0.67	1.00	1.00					
				7.Total score	6.50	6.83	7.17					
	513	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.00	0.50	0.50	0.50	0.50	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.67	0.67	0.50	0.50
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	1.00	1.00	1.00	0.00
				5.RETARDATION	1.75	1.75	1.25	1.25	1.00	0.25	0.25	0.50
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.33	0.00	0.33	0.33	0.00
				7.Total score	6.92	6.92	5.58	3.58	3.17	2.75	2.58	1.33
7/02	181	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	1.33	1.33	1.17	1.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.33	0.50	0.50	0.50
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.25	2.00	1.75	1.50	1.50
				6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.67	0.33	0.33	0.33	0.33
				7.Total score	5.67	5.67	5.67	5.92	5.00	3.92	3.50	3.50
	182	Placebo	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.50	1.00	1.00	1.00	1.00	1.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.17	0.00	0.33	0.00	0.17
				4.DIURNAL VARIATION	1.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.25	1.25	0.75	1.25	1.25	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	1.67	1.67	2.00	0.33	0.33	0.33	0.67	0.67
				7.Total score	5.92	5.92	6.58	3.75	3.58	3.92	3.92	4.08
	183	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.50	1.83			
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.50			
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00			
				5.RETARDATION	1.25	1.25	1.00	1.25	2.00			
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.67	1.67			
				7.Total score	7.08	7.08	5.33	5.75	7.00			
	184	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.00	0.83	0.83	0.50	0.17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/02	184	Imipramine	Female	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.67	0.17	0.17	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	2.50	2.00	1.00	1.00	0.75	0.50
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.00	0.67	0.67	0.00	0.00
				7.Total score	6.83	6.83	6.83	5.67	2.67	2.67	1.25	0.67
	185	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.50	1.50	0.83		
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.67	0.67	0.67		
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00		
				5.RETARDATION	0.75	0.75	1.50	1.25	1.25	1.75		
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67		
				7.Total score	4.92	4.92	5.67	5.08	5.08	4.92		
	186	Placebo	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	0.83	0.83	0.83	0.83	0.83	0.50
				2.WEIGHT	0.00	0.00	2.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.33	0.17	0.17	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.25	1.25	1.00	1.00	1.00	1.00	0.75	0.00
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.67	1.33	1.33	1.33	0.33
				7.Total score	6.08	6.08	7.17	6.00	4.50	4.33	4.08	2.17
	535	Placebo	Male	1.ANXIETY/SOMATIZATION	2.17	2.17	2.33	2.33	2.33	2.00	1.67	1.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	1.00	1.00	1.00	0.67	0.50	0.50
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	2.00	1.75	1.75	1.75	1.75
				6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.67	0.67	1.33	0.00	0.00
				7.Total score	5.42	5.42	5.75	6.00	5.75	5.75	3.92	3.92
	536	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.33	1.33	1.33	1.33	1.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.33	0.17	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	1.75	1.50	1.50	1.25	1.25
				6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.33	0.33	0.00	0.00	0.00
				7.Total score	4.83	4.83	4.83	3.92	3.50	3.00	2.75	2.75
7/03	187	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.17	1.17	1.17	0.33	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.50	0.50	0.33	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	1.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.75	1.75	1.75	0.75	0.50
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.33	0.67	0.33
				7.Total score	6.75	6.75	6.75	6.75	6.75	6.75	3.08	1.17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/03	188	Placebo	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	0.50	0.67	0.67	0.67
				2.WEIGHT	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.00	0.50	0.50	0.50
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.75	1.00	1.50	1.50	1.50
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	0.67	0.33	0.33	0.33
				7.Total score	5.92	5.92	5.92	5.92	3.17	3.00	3.00	3.00
	189	Placebo	Male	1.ANXIETY/SOMATIZATION	1.17	1.00	1.17	0.83	0.50	0.50	0.33	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.67	0.67	0.17	0.17	0.17	0.33	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	1.00	0.50	0.50	0.75	0.75
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	0.67	0.00	0.00	0.33	0.33
				7.Total score	6.58	6.58	6.75	3.67	1.17	1.17	1.75	1.75
	190	Reboxetine	Male	1.ANXIETY/SOMATIZATION	0.83	0.83	0.83	0.83	0.50	0.50	0.50	0.50
				2.WEIGHT	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.67	0.67	0.50	0.33	0.33	0.33
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	2.00	2.00	1.00	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.00	1.00	0.67	0.33	0.33	0.33
				7.Total score	6.75	7.75	5.50	5.50	2.67	2.42	2.42	2.42
	191	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	0.67	0.67	0.50	0.83	0.83	
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.83	1.00	0.33	0.33	0.33	0.33	0.33	
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	1.00	1.00	
				5.RETARDATION	2.00	2.50	1.50	1.50	1.00	1.25	1.25	
				6.SLEEP DISTURBANCE	1.33	1.67	1.00	1.00	0.33	0.67	0.67	
				7.Total score	7.50	8.50	4.50	4.50	2.17	4.08	4.08	
	192	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	0.83	0.83	0.50	0.50	0.50
				2.WEIGHT	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.33	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.00	1.00	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.67	0.67	1.00	1.00	1.00
				7.Total score	6.58	6.58	6.58	3.83	3.83	2.83	2.83	2.83
	523	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.17	1.17	1.17	1.17	1.17	1.17	1.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.33	1.33	1.33	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.00	1.50	1.25	1.25	1.25

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/03	523	Reboxetine	Female	6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
				7.Total score	6.33	6.50	6.50	6.50	3.83	3.58	3.58	3.58
	524	Placebo	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.33	0.83	0.67	0.67	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.17	0.83	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	1.75	1.50	0.50	0.50	0.50
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.00	0.00	0.00	0.00
				7.Total score	7.17	7.17	7.33	6.58	3.67	1.50	1.50	1.50
	525	Placebo	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	1.00	0.17	0.17	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.33	0.33	0.17	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	1.75	1.00	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	0.67	0.67	0.00	0.00	0.00
				7.Total score	6.42	6.42	6.42	4.08	3.00	1.08	0.92	0.92
	526	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	1.00	1.00	1.00	0.67	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.50	0.50	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	2.50	2.00	2.00	2.00	1.00	0.25
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	1.00	0.00
				7.Total score	6.17	6.17	6.17	5.50	5.50	5.50	2.83	0.75
	527	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	1.00	1.00	1.00	1.00
				2.WEIGHT	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.00	1.25	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				7.Total score	7.33	7.33	7.33	7.33	3.58	3.58	3.58	3.58
	528	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.00	1.00	1.00	1.00	1.17	
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.50	0.50	0.50	0.50	0.50	
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	
				5.RETARDATION	2.00	1.75	1.50	1.50	1.50	1.50	1.75	
				6.SLEEP DISTURBANCE	1.33	1.00	0.67	0.67	0.67	0.67	1.00	
				7.Total score	6.33	5.75	3.67	3.67	3.67	3.67	4.42	
7/04	193	Placebo	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.67	1.17	0.50	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.33	0.17	0.17	0.17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/04	193	Placebo	Female	4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.75	0.75	0.50	0.00	0.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	1.33	0.67	0.33	0.33
				7.Total score	7.08	7.08	7.08	7.08	4.58	1.83	1.00	1.00
	194	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	0.83	0.50	0.33	0.33
				2.WEIGHT	3.00	3.00	3.00	3.00	2.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	0.83	1.17	1.17	0.67	0.50	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00
				5.RETARDATION	2.00	2.50	2.00	2.00	1.25	0.75	0.50	0.50
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	1.33	1.00	0.67	0.33
				7.Total score	9.50	9.67	9.50	9.50	6.08	2.75	2.67	2.33
	195	Placebo	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	0.83	0.33	0.33	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.50	0.33	0.33	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.75	0.75	0.50	0.50	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	1.33	0.67	0.67	0.33
				7.Total score	7.08	7.08	7.08	7.08	4.42	1.83	1.83	1.58
	196	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	1.17	1.00	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.50	0.33	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.75	1.25	0.75	0.50	0.50
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.00	1.00	0.33	0.00
				7.Total score	6.42	6.42	6.42	6.42	4.92	3.08	1.50	1.17
	197	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75
				6.SLEEP DISTURBANCE	1.33	1.33	2.00	2.00	2.00	2.00	2.00	1.67
				7.Total score	7.42	7.42	7.08	7.08	7.08	7.08	7.08	6.75
	198	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	0.50	0.33	0.33	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.50	0.33	0.33	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.75	1.50	1.25	1.25	0.50
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	0.67	0.33	0.00	0.00
				7.Total score	6.92	6.92	6.92	6.92	3.17	2.25	1.92	1.00
	199	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	1.50	1.00	1.00	1.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/04	199	Imipramine	Male	2.WEIGHT	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.83	0.50	0.33	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.00	2.00	2.00	2.00	1.75	1.25	1.00	1.00
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.33	1.00	1.00
				7.Total score	8.00	8.00	8.00	7.00	6.75	5.08	4.33	4.17
	200	Placebo	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.17	1.17	1.17	1.00	1.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	0.83	0.83	0.67	0.67
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				5.RETARDATION	1.75	1.75	1.75	1.75	1.50	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.33	1.67	1.67
				7.Total score	7.75	7.75	7.75	7.58	7.17	6.58	6.58	6.58
	201	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.50	1.00	1.00	0.67	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.50	0.50	0.50	0.33
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	1.00	1.00	0.00
				5.RETARDATION	2.25	2.25	2.25	2.25	1.50	1.50	1.25	1.00
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.33	1.00
				7.Total score	7.92	7.92	7.92	8.08	6.67	5.67	4.75	3.00
	202	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	1.17	1.17	1.00	0.83
				2.WEIGHT	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.83	0.83	0.50	0.50
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.50	2.50	2.50	2.50	2.00	2.00	1.50	1.50
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.33	1.00	0.67
				7.Total score	8.00	8.00	8.00	8.00	6.33	6.33	5.00	4.50
	203	Placebo	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.17	1.00	1.00	0.83	0.67
				2.WEIGHT	1.00	1.00	2.00	2.00	2.00	2.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.00	2.00	2.00	2.00	2.00	1.75	1.75	1.50
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	1.33	1.33	1.33
				7.Total score	7.83	7.83	8.83	8.83	8.67	7.75	5.58	5.17
	204	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	1.33	1.17	1.17	1.17
				2.WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.50
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00
				5.RETARDATION	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.00
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.33
				7.Total score	8.17	8.17	8.17	8.17	8.17	7.00	6.00	5.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/05	205	Placebo	Male	1.ANXIETY/SOMATIZATION	1.50	1.67	1.67	1.67	1.67	1.50	1.67	1.50
				2.WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.83	1.00	0.83	0.83
				4.DIURNAL VARIATION	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00
				5.RETARDATION	2.00	2.50	2.50	2.50	2.50	2.50	2.50	2.50
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				7.Total score	8.33	9.00	10.00	10.00	10.00	10.00	10.00	9.83
	206	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.33	1.00	1.00	1.00	1.00	1.00
				2.WEIGHT	3.00	3.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.50	0.50	0.50	0.50
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.00	1.25	1.25	1.00	1.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	1.00	0.67	0.67	0.67	0.67
				7.Total score	9.67	9.67	8.00	5.50	3.42	3.42	3.17	3.17
	207	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.17	1.00	0.83	0.83	0.83
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.33	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	1.00
				5.RETARDATION	1.75	1.75	1.75	1.75	1.25	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.00	1.00	1.00	1.00	1.00
				7.Total score	7.42	7.42	6.08	5.25	3.58	3.17	3.17	4.17
	208	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.67	1.33	1.17	0.67	0.50	0.17	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.33	0.33	0.17	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	0.00	0.00	1.00	1.00
				5.RETARDATION	1.75	1.75	1.50	1.25	1.00	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				7.Total score	7.92	8.08	6.50	4.92	3.00	2.58	3.08	3.08
	209	Placebo	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.33	1.33	1.33	1.50	1.67	1.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	1.00	1.00	1.00	1.00	1.00	1.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				5.RETARDATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.67	1.67	1.67	1.67
				7.Total score	7.33	7.33	7.67	7.67	8.00	8.17	8.33	8.33
	210	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.17	0.83	0.67	0.33	0.33	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.33	0.17	0.17	0.17
				4.DIURNAL VARIATION	2.00	2.00	1.00	0.00	0.00	0.00	1.00	0.00
				5.RETARDATION	1.75	1.75	1.50	0.75	0.75	0.75	0.75	0.75

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/05	210	Reboxetine	Male	6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.67	0.67	0.67	0.67	0.67
				7.Total score	6.75	6.75	5.17	2.75	2.42	1.92	2.92	1.92
	541	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.67	1.33	1.00	0.67	0.17	0.17	0.17
				2.WEIGHT	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	2.00	2.00	1.00	0.00	0.00	1.00	1.00	0.00
				5.RETARDATION	2.25	2.25	1.50	0.75	0.75	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.00	0.33	0.00	0.00	0.00
				7.Total score	8.08	8.25	6.83	3.25	2.08	2.25	2.25	1.25
	542	Imipramine	Male	1.ANXIETY/SOMATIZATION	2.17	2.17	2.00	1.83	1.50	1.17	1.17	1.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	0.67	0.67	0.67	0.67
				4.DIURNAL VARIATION	2.00	1.00	2.00	1.00	0.00	2.00	2.00	0.00
				5.RETARDATION	2.75	2.75	2.50	2.00	2.00	2.00	1.75	1.75
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.00	1.00	1.00	1.00	1.00
				7.Total score	9.92	8.92	9.17	6.83	5.17	6.83	6.58	4.58
	543	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.67	0.67	0.67	0.67	0.50	0.50	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.83	0.33	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.50	1.25	1.00	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	0.33	0.33	0.33
				7.Total score	6.58	6.58	5.00	3.25	2.83	1.92	1.92	1.92
	544	Placebo	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.67	1.67	1.50	1.50	1.67
				2.WEIGHT	2.00	2.00	0.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00
				5.RETARDATION	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.67	1.67	1.67
				7.Total score	9.42	9.42	7.42	8.42	8.42	8.58	8.58	8.75
	545	Placebo	Male	1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.83	1.83	1.83	1.83	1.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	1.00	1.00	1.00	2.00
				5.RETARDATION	2.50	2.50	2.50	2.50	2.50	2.50	2.50	2.50
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.67	1.67	1.67	1.67
				7.Total score	9.50	9.50	9.50	8.17	8.17	8.17	8.17	9.17
	546	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.17	0.83	0.67	0.67	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.33	0.33	0.33	0.33	0.33

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/05	546	Reboxetine	Female	4.DIURNAL VARIATION	0.00	1.00	1.00	1.00	1.00	0.00	1.00	0.00
				5.RETARDATION	2.25	2.25	2.00	1.50	1.00	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	1.00	1.00	1.00	1.00	1.00
				7.Total score	5.75	6.75	6.00	5.00	4.17	2.75	3.75	2.75
7/07	529	Placebo	Female	1.ANXIETY/SOMATIZATION	1.50	1.17	1.50	1.00	0.83	0.83	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.50	0.50	0.50	0.50	0.50
				4.DIURNAL VARIATION	1.00	1.00	2.00	2.00	2.00	1.00	1.00	1.00
				5.RETARDATION	2.00	1.75	1.75	1.25	1.00	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	2.00	1.67	2.00	2.00	2.00	2.00	2.00	1.67
				7.Total score	7.17	6.25	7.75	6.75	6.33	5.58	5.58	5.25
	530	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.33	1.50				
				2.WEIGHT	0.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.50	0.67				
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00				
				5.RETARDATION	2.00	2.00	1.75	1.75				
				6.SLEEP DISTURBANCE	1.67	2.00	2.00	2.00				
				7.Total score	6.67	7.00	6.58	6.92				
	531	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.00	1.17	1.00	1.00	1.33	0.83	1.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.17	0.83	0.50	0.67	0.17	0.50
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	1.00	1.00
				5.RETARDATION	1.50	1.50	1.75	1.25	1.50	2.00	1.25	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.67	1.67	2.00	2.00
				7.Total score	6.67	6.50	7.08	4.75	4.67	5.67	5.25	5.42
	532	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.67	1.67	1.50	1.33	1.33	1.17	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.83	0.67	0.33	0.33	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00
				5.RETARDATION	1.75	2.25	2.00	1.75	1.75	1.75	1.75	1.75
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.33	2.00	1.33	1.67	1.00
				7.Total score	6.75	7.58	7.17	6.42	6.75	5.75	4.92	3.75
	533	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	1.33	1.50	1.33	1.33	1.33	1.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	1.00	0.83	0.83	0.83	0.50	0.50	0.50
				4.DIURNAL VARIATION	0.00	0.00	1.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.00	2.00	2.00	1.75	1.75
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.67
				7.Total score	6.50	6.67	7.17	7.33	7.17	5.83	5.58	4.92
	534	Placebo	Female	1.ANXIETY/SOMATIZATION	1.83	1.50	1.50	1.50	1.33	1.50	1.17	1.17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7/07	534	Placebo	Female	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.67	0.50	0.50	0.33	0.33
				4.DIURNAL VARIATION	0.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00
				5.RETARDATION	2.00	1.50	1.75	1.75	1.50	1.50	1.50	1.50
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.67	1.67	1.67	1.00
				7.Total score	6.67	6.83	7.08	6.58	6.00	6.17	4.67	4.00
8	211	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.83				
				2.WEIGHT	0.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.67				
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00				
				5.RETARDATION	2.25	2.25	2.50	2.50				
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33				
				7.Total score	5.92	5.92	6.17	6.33				
	212	Placebo	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	1.33	1.50	1.50	1.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.00	1.75	2.00	2.00	2.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	1.00	1.33	1.33	1.33
				7.Total score	5.33	5.33	5.33	5.00	4.58	5.33	5.33	5.33
	213	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50						
				2.WEIGHT	0.00	0.00						
				3.COGNITIVE DISTURBANCE	1.00	1.00						
				4.DIURNAL VARIATION	0.00	0.00						
				5.RETARDATION	2.00	2.00						
				6.SLEEP DISTURBANCE	1.33	1.33						
				7.Total score	5.83	5.83						
	214	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.17	1.17	1.17	1.17	1.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.50	2.50	2.50	2.25	2.25	2.25	2.00	2.00
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				7.Total score	5.17	5.17	5.17	5.75	5.75	5.75	5.50	5.50
	215	Placebo	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	0.83	0.83	0.83	0.83	0.33	0.33
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.17	0.17	0.17	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.75	1.75	1.00	0.75	0.50	0.50
				6.SLEEP DISTURBANCE	1.33	1.33	0.33	0.33	0.00	0.00	0.00	0.00
				7.Total score	6.67	6.67	3.25	3.25	2.00	1.75	1.00	0.83

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	216	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.17	1.00	1.00	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	2.25	2.00	2.00	1.75	1.50
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	0.67	0.67	0.00	0.00	0.00
				7.Total score	5.08	5.08	4.75	4.42	4.00	3.33	2.92	2.67
	217	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.00	0.67	0.17	0.17	0.00	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.17	0.17	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.00	1.75	1.25	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	1.00	1.00	0.33	0.33	0.33	0.00	0.00	0.00
				7.Total score	5.75	5.75	4.67	3.08	1.92	1.33	1.00	1.17
	218	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	1.17	1.17	0.83	0.50	0.33	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.50	0.50	0.50	0.50	0.50
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.00	2.00	1.50	1.50	1.50
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.67	0.67	0.33	0.00	0.00
				7.Total score	5.83	6.00	5.67	5.33	5.00	3.83	2.33	2.33
	219	Placebo	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	0.67	0.50			
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.33	0.17			
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00			
				5.RETARDATION	2.00	2.00	2.00	1.75	1.50			
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.33	0.33			
				7.Total score	6.50	6.50	5.17	4.08	2.50			
	220	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.33	0.33	0.17	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	2.25	1.75	1.50	1.50	1.00
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	0.33	0.33	0.33	0.33
				7.Total score	5.75	5.75	5.75	5.42	3.25	2.83	2.83	2.17
	221	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	0.83	0.50	0.50	0.33	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.50	0.33	0.33	0.17	0.17	0.17	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	2.25	1.75	1.50	1.00	0.75

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day 14	Day 21	Day 28	Day 35	Day 42
8	221	Imipramine	Male	6.SLEEP DISTURBANCE	0.67	1.00	1.00	0.67	0.33	0.33	0.33	0.33
				7.Total score	5.58	5.75	5.58	5.08	2.75	2.50	1.83	1.25
	222	Placebo	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	0.67	0.33	0.33	0.33	0.33	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.17	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.50	1.50	0.75	0.25	0.50	0.50
				6.SLEEP DISTURBANCE	1.00	1.00	0.33	0.00	0.00	0.00	0.67	0.67
				7.Total score	5.75	5.75	2.83	2.00	1.08	0.58	1.50	1.50
	223	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	1.33	1.00	0.67	0.67	0.50	0.50
				2.WEIGHT	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.50	0.67	0.33	0.17	0.17	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	2.00	1.75	1.50	1.25	1.25
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.67	0.67	0.33	0.33	0.33
				7.Total score	6.08	6.08	6.25	4.00	3.25	2.67	2.08	2.08
	224	Placebo	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	0.83	0.67	0.67	0.67	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.50	0.33	0.33	0.33	0.17	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.00	2.00	2.00	1.75	1.75	1.75	1.25	1.00
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.67	0.67	0.67	0.33	0.33
				7.Total score	6.00	5.83	5.17	4.58	4.42	4.25	3.42	3.00
	225	Placebo	Male	1.ANXIETY/SOMATIZATION	1.17	1.33	1.33	1.33	1.33	1.17	0.67	0.50
				2.WEIGHT	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.50	0.33	0.33	0.33
				4.DIURNAL VARIATION	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.75	1.75	1.75	1.75	1.75	1.75	1.50	1.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.33	1.33	1.00	0.67	0.33
				7.Total score	6.08	6.25	7.25	5.92	5.92	5.25	4.17	3.42
	226	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.17	1.17	1.17	1.17	1.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.50	0.50	0.50	0.50
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.00	1.00	1.00
				7.Total score	6.33	6.33	6.33	6.00	6.00	5.67	5.67	5.67
	227	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.33	1.17	1.00	1.00	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.50	0.50	0.33	0.33

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	227	Reboxetine	Male	4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.00	2.00	2.00	1.75	1.75	1.75	1.75	1.75
				6.SLEEP DISTURBANCE	1.00	1.33	1.00	1.00	1.00	0.67	0.67	0.67
				7.Total score	6.00	6.33	5.83	5.58	5.42	4.92	4.75	4.58
	228	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.33	1.33					
				2.WEIGHT	1.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.67					
				4.DIURNAL VARIATION	1.00	1.00	1.00					
				5.RETARDATION	1.75	2.00	2.00					
				6.SLEEP DISTURBANCE	1.00	1.33	1.33					
				7.Total score	6.42	6.17	6.33					
	229	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	0.83	0.83	0.83	0.83	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.33	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.00	2.00	2.00	2.00	1.75	1.75	1.75	1.25
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.00	1.00	1.00
				7.Total score	6.33	6.33	6.33	5.50	5.25	4.92	4.92	4.25
	230	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	1.17	1.17	1.00	1.00	1.00	1.00
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.50	0.33	0.33	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.25	2.25	2.25	2.25	2.00	2.00	1.75	1.50
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.33	1.33	1.00	1.00	1.00
				7.Total score	7.58	6.75	6.58	6.25	5.83	5.33	5.08	4.83
	231	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	1.00	0.83	0.83	0.67	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.17	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.00	2.00	2.00	1.75	1.75	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	0.67	0.67	0.67	0.33
				7.Total score	6.00	6.00	5.83	5.08	4.42	3.75	3.58	3.25
	232	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	0.83	0.83	0.67	0.67	0.50
				2.WEIGHT	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.33	0.17	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00
				5.RETARDATION	2.00	2.00	2.00	1.75	1.75	1.75	1.25	1.25
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	1.00	1.00	0.67	0.67	0.67
				7.Total score	7.00	7.00	6.67	5.08	4.92	4.25	3.58	2.42
	233	Placebo	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	1.17	0.83	0.67	0.67

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	233	Placebo	Female	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.50	0.33	0.33	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.00	2.00	1.75	1.75	1.25
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.00	0.67	0.67	0.67
				7.Total score	6.33	6.33	6.33	6.33	5.67	4.58	4.42	2.75
	234	Placebo	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.17	0.83	0.83	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.50	0.50	0.50	0.50	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.00	2.00	2.00	2.00	2.00	2.00	1.75	1.75
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	0.67	0.67
				7.Total score	6.00	6.00	5.83	5.67	5.33	5.33	4.75	4.58
8/A	235	Placebo	Female	1.ANXIETY/SOMATIZATION	1.67	1.83	1.50	1.33	1.00	0.67	1.00	1.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.67	0.50	0.33	0.33	0.33	0.17
				4.DIURNAL VARIATION	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.00	2.00	1.50	1.50	1.50	1.50	1.50	1.25
				6.SLEEP DISTURBANCE	1.33	1.67	1.67	1.33	1.00	1.33	0.67	1.00
				7.Total score	7.17	8.67	6.33	5.67	4.83	4.83	4.50	4.42
	236	Placebo	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.33	0.67	0.50	0.67	0.33	0.50
				2.WEIGHT	2.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.50	0.33	0.33	0.17	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.75	1.50	1.25	1.00	1.00	0.75
				6.SLEEP DISTURBANCE	1.00	1.33	1.67	1.33	1.00	0.67	1.00	0.67
				7.Total score	7.83	7.17	6.25	3.83	3.08	2.50	2.33	1.92
	237	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	2.00	1.67	1.00	0.67	0.83	0.50	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.50	1.33	0.83	0.50	0.33	0.00	0.17	0.17
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	2.00	1.50	1.50	1.00	1.00	0.75	0.75
				6.SLEEP DISTURBANCE	1.33	1.67	1.33	1.33	1.00	1.33	1.00	0.67
				7.Total score	8.25	9.00	6.33	5.33	3.00	3.17	2.42	1.92
	238	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.33	1.00	1.00	0.83	0.67	0.67	0.83
				2.WEIGHT	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.50	0.17	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.75	1.25	1.25	1.00	1.25	1.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.67	1.00	1.00	0.67	0.67	0.33
				7.Total score	7.58	7.92	6.92	4.42	3.08	2.33	2.58	2.17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8/A	239	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	1.17	1.33	1.00	0.83	0.50	0.50
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	0.83	0.67	0.33	0.33	0.17	0.00	0.00
				4.DIURNAL VARIATION	1.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.50	1.50	1.50	1.25	1.00	1.25
				6.SLEEP DISTURBANCE	1.33	1.67	1.00	0.67	0.67	0.67	0.67	0.67
				7.Total score	7.75	9.08	5.33	3.83	3.50	2.92	2.17	2.42
	240	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	0.83	0.83	0.83	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.83	0.67	0.50	0.33	0.33	0.33
				4.DIURNAL VARIATION	1.00	2.00	2.00	1.00	1.00	1.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.75	1.75	1.50	1.50	1.50	1.25
				6.SLEEP DISTURBANCE	1.00	1.33	1.67	1.33	1.33	0.67	1.00	0.67
				7.Total score	6.58	7.92	7.42	5.58	5.17	4.33	3.67	3.08
	553	Placebo	Female	1.ANXIETY/SOMATIZATION	1.00	1.17	1.00	1.00	1.00	1.00	1.00	1.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.00	0.83	0.83	0.33	0.50	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.50	2.25	1.75	1.75	1.75	1.75	1.25
				6.SLEEP DISTURBANCE	1.33	1.33	1.67	1.33	1.00	1.00	1.33	1.33
				7.Total score	7.25	7.17	6.92	5.92	4.58	4.08	4.58	3.92
	554	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.00	1.00	0.83	0.83	0.67	0.67	0.67	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	0.83	0.83	0.67	0.33	0.17	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.75	1.25	1.50	1.25	0.75	0.75
				6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.00	0.67	0.67	0.67	0.67
				7.Total score	6.92	6.75	5.75	3.75	3.17	2.75	2.25	2.08
	555	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.17	0.83	0.83	0.83	0.83	0.83
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	0.83	0.67	0.50	0.67	0.33	0.33	0.17
				4.DIURNAL VARIATION	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.25	2.00	1.75	1.75	1.50	1.75	1.50	1.00
				6.SLEEP DISTURBANCE	1.33	1.67	1.33	1.00	0.67	0.67	0.67	0.67
				7.Total score	7.92	8.00	5.92	5.08	4.67	4.58	4.33	3.67
	556	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	1.00	0.83	0.83	0.83	0.67
				2.WEIGHT	2.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.33	0.17	0.17	0.17	0.00
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00
				5.RETARDATION	2.50	2.25	1.75	1.50	1.25	0.75	1.00	0.75

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8/A	556	Imipramine	Male	6.SLEEP DISTURBANCE	1.67	1.33	1.00	0.67	1.00	0.67	0.67	0.67
				7.Total score	10.17	8.58	6.58	5.50	5.25	3.42	2.67	2.08
9	241	Placebo	Female	1.ANXIETY/SOMATIZATION	1.17	1.00	1.33	1.67				
				2.WEIGHT	2.00	1.00	1.00	1.00				
				3.COGNITIVE DISTURBANCE	0.83	0.50	0.83	0.83				
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00				
				5.RETARDATION	2.25	2.75	2.75	2.50				
				6.SLEEP DISTURBANCE	2.00	1.00	1.00	2.00				
				7.Total score	8.25	6.25	6.92	8.00				
	242	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	0.83	1.50	1.50			
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.33	0.83	0.83			
				4.DIURNAL VARIATION	1.00	0.00	1.00	0.00	1.00			
				5.RETARDATION	2.25	2.25	1.25	2.00	2.00			
				6.SLEEP DISTURBANCE	2.00	2.00	1.33	1.00	2.00			
				7.Total score	9.42	6.42	4.75	5.33	7.33			
	243	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.17	1.83				
				2.WEIGHT	1.00	1.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.83	1.00				
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00				
				5.RETARDATION	2.25	2.25	2.25	2.50				
				6.SLEEP DISTURBANCE	1.00	1.00	1.67	2.00				
				7.Total score	5.75	5.75	5.92	7.33				
	244	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.67	0.83	0.33	0.33	0.33			
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.17	0.17	0.17			
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00			
				5.RETARDATION	1.75	1.75	1.25	1.25	1.25			
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.00	1.00			
				7.Total score	7.08	6.25	4.42	3.75	3.75			
	245	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	0.83	0.67	0.33	0.17	0.33	0.33
				2.WEIGHT	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.17	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.00	1.25	0.25	0.00	0.25	0.00
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				7.Total score	5.08	6.08	4.50	3.08	1.58	1.17	1.58	1.33
	246	Placebo	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.83	1.83	1.83	1.83		
				2.WEIGHT	2.00	0.00	2.00	2.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.67	0.67	0.67	0.67		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	246	Placebo	Female	4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00		
				5.RETARDATION	2.75	2.75	3.25	3.25	3.25	3.25		
				6.SLEEP DISTURBANCE	2.00	2.00	0.67	0.67	0.67	0.67		
				7.Total score	9.08	7.08	8.42	8.42	6.42	6.42		
	247	Placebo	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	1.00	1.17	1.00		
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.50	0.67	0.67		
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00		
				5.RETARDATION	2.25	2.25	2.00	1.50	1.75	1.75		
				6.SLEEP DISTURBANCE	1.00	1.00	1.33	1.33	1.67	1.67		
				7.Total score	6.25	6.25	6.00	5.33	6.25	6.08		
	248	Placebo	Male	1.ANXIETY/SOMATIZATION	0.83	0.83	1.00	2.17				
				2.WEIGHT	0.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.50	0.67	0.83	1.33				
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00				
				5.RETARDATION	2.50	2.50	2.50	2.25				
				6.SLEEP DISTURBANCE	1.00	1.00	1.33	2.00				
				7.Total score	5.83	6.00	6.67	7.75				
	249	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.83	0.67						
				2.WEIGHT	3.00	3.00						
				3.COGNITIVE DISTURBANCE	0.67	0.83						
				4.DIURNAL VARIATION	0.00	0.00						
				5.RETARDATION	2.50	2.50						
				6.SLEEP DISTURBANCE	1.67	1.00						
				7.Total score	8.67	8.00						
	250	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.67	0.67	0.67	0.67	0.83	0.83		
				2.WEIGHT	0.00	2.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.33	0.33	0.50		
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00		
				5.RETARDATION	2.50	2.50	2.50	2.00	2.25	2.25		
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.00	1.00	1.00		
				7.Total score	6.33	8.33	6.33	5.00	5.42	5.58		
	251	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	0.83	1.33	0.17	0.17		
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.50	0.83	0.17	0.17		
				4.DIURNAL VARIATION	0.00	0.00	1.00	1.00	0.00	0.00		
				5.RETARDATION	3.00	3.00	1.75	2.00	0.50	0.25		
				6.SLEEP DISTURBANCE	0.33	0.33	1.00	1.00	0.33	0.33		
				7.Total score	7.33	7.33	5.08	6.17	1.17	0.92		
	252	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.17	1.17	1.50	1.83			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	252	Reboxetine	Female	2.WEIGHT	0.00	0.00	0.00	1.00	1.00			
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.67	0.83	1.00			
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00			
				5.RETARDATION	2.00	2.25	2.50	2.25	2.25			
				6.SLEEP DISTURBANCE	1.67	1.67	2.00	2.00	2.00			
				7.Total score	5.17	5.58	6.33	7.58	8.08			
	253	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.67					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.83					
				4.DIURNAL VARIATION	0.00	0.00	1.00					
				5.RETARDATION	2.75	2.75	2.00					
				6.SLEEP DISTURBANCE	2.00	2.00	2.00					
				7.Total score	6.25	6.25	7.50					
	254	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	2.00	2.00				
				2.WEIGHT	2.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.83	0.83	1.00	1.00				
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00				
				5.RETARDATION	2.25	2.25	2.50	2.50				
				6.SLEEP DISTURBANCE	1.33	1.33	2.00	2.00				
				7.Total score	10.08	8.08	9.50	9.50				
	255	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	1.50	1.50	1.67		
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	1.00	1.00	1.50		
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00		
				5.RETARDATION	2.00	2.00	2.00	1.75	1.75	1.75		
				6.SLEEP DISTURBANCE	0.67	1.00	1.00	2.00	2.00	2.00		
				7.Total score	5.50	5.83	5.83	7.25	7.25	7.92		
	256	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.50	0.33	0.33	1.00	1.00	1.00
				2.WEIGHT	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	0.17	0.17	0.67	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.75	2.75	0.50	0.50	2.50	1.00	1.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.67	2.00	1.33	1.33
				7.Total score	9.08	8.08	7.25	2.67	2.67	6.17	3.50	3.50
	257	Placebo	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17					
				2.WEIGHT	2.00	2.00	0.00					
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67					
				4.DIURNAL VARIATION	1.00	1.00	1.00					
				5.RETARDATION	2.00	2.00	2.00					
				6.SLEEP DISTURBANCE	1.00	1.00	1.00					
				7.Total score	7.83	7.83	5.83					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	258	Placebo	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.83	1.83				
				2.WEIGHT	1.00	1.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.83	0.83				
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00				
				5.RETARDATION	2.25	2.25	2.25	2.25				
				6.SLEEP DISTURBANCE	1.00	1.00	1.33	1.33				
				7.Total score	7.25	7.25	7.25	7.25				
11	319	Placebo	Male	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	1.00	1.00	1.00	1.17	1.00
				2.WEIGHT	2.00	0.00	0.00	0.00	2.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.00	1.00	1.00	1.00	0.83	0.50
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				5.RETARDATION	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.50
				6.SLEEP DISTURBANCE	1.67	1.67	1.00	1.33	1.67	1.67	1.00	1.67
				7.Total score	9.58	7.58	6.75	7.08	9.42	7.42	6.75	6.67
	320	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.67	1.50	1.67	0.83	1.33	0.83	1.33	0.83
				2.WEIGHT	0.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	1.00	0.50	1.33	0.67	0.50	0.67
				4.DIURNAL VARIATION	2.00	2.00	2.00	0.00	0.00	1.00	1.00	1.00
				5.RETARDATION	1.50	1.50	2.00	1.25	1.75	1.00	1.25	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.33	1.33	1.00	1.00	0.67
				7.Total score	8.00	9.83	8.67	3.92	5.75	4.50	5.08	3.92
	321	Placebo	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.50	1.00	0.67	0.50	0.33	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.50	0.33	0.17	0.17	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	2.00	2.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.75	1.25	1.00	0.50	0.25	0.25
				6.SLEEP DISTURBANCE	1.00	1.33	0.67	0.00	0.67	0.33	0.00	0.00
				7.Total score	5.50	5.83	5.58	4.75	4.67	1.50	0.75	0.58
	322	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.50	0.67	0.83	0.83	1.00	1.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	1.00	0.50	0.50	0.50	0.50	0.50	0.67
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00	2.00	2.00
				5.RETARDATION	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50
				6.SLEEP DISTURBANCE	0.67	1.33	1.67	1.67	1.67	1.67	2.00	1.00
				7.Total score	6.67	7.50	6.17	5.33	5.50	5.50	7.00	6.17
	323	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	0.33	0.17	0.17	0.50	0.50
				2.WEIGHT	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.17	0.17	0.17	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.25	1.25	0.75	1.00	1.00	0.75	0.50	0.75

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	323	Reboxetine	Male	6.SLEEP DISTURBANCE	2.00	2.00	1.00	0.67	0.33	0.00	0.00	0.00
				7.Total score	8.92	8.92	6.08	3.17	2.67	1.08	1.00	1.25
	324	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.50	1.00	1.00	1.33	1.33	1.17
				2.WEIGHT	2.00	1.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.33	0.67	0.67	0.50
				4.DIURNAL VARIATION	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00
				5.RETARDATION	1.25	1.50	1.50	1.50	1.50	1.50	1.50	1.50
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.67	1.33	1.33	1.33	1.33
				7.Total score	7.92	7.17	9.17	6.67	6.17	6.83	6.83	6.50
	325	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.33	1.50	0.83	0.50	0.17	0.33	0.33	0.33
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.17	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.25	1.25	1.00	0.50	0.25	0.25	0.25	0.25
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.33	0.33	0.00	0.33	0.33
				7.Total score	8.08	6.25	4.00	2.33	0.75	0.58	0.92	0.92
	326	Placebo	Male	1.ANXIETY/SOMATIZATION	1.00	1.00	1.33	1.00	1.00	0.50	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.50	0.33	0.67	0.33	0.50	0.50	0.50
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	1.00	2.00	0.00
				5.RETARDATION	1.75	1.75	1.75	2.00	1.75	2.75	2.75	2.75
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				7.Total score	5.42	5.25	5.42	5.67	5.08	6.75	7.75	5.75
	327	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.83	0.83	0.33					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.00					
				4.DIURNAL VARIATION	2.00	2.00	0.00					
				5.RETARDATION	1.50	1.50	1.50					
				6.SLEEP DISTURBANCE	2.00	2.00	0.33					
				7.Total score	7.00	7.00	2.17					
	328	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.33	1.17					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	1.33	1.17	0.83					
				4.DIURNAL VARIATION	2.00	2.00	2.00					
				5.RETARDATION	2.00	1.50	1.25					
				6.SLEEP DISTURBANCE	1.67	1.33	1.00					
				7.Total score	8.83	7.33	6.25					
	329	Placebo	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.17	1.17	0.83	0.67	0.83	1.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.33	0.33	0.00	0.00	0.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	329	Placebo	Female	4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.25	1.25	1.25	1.25	0.50	0.00	0.25
				6.SLEEP DISTURBANCE	1.67	2.00	2.00	2.00	1.33	0.33	0.33	0.33
				7.Total score	6.67	6.75	6.92	6.75	5.75	2.50	1.17	1.58
	330	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.33	1.17	1.33	1.00	1.00	0.67	0.50	0.50
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.83	0.33	0.17	0.17	0.17	0.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00
				5.RETARDATION	1.00	1.00	1.25	0.75	0.25	0.75	0.25	0.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.33	1.67	1.67	1.00	1.33
				7.Total score	8.83	8.67	7.42	5.42	5.08	4.25	2.92	2.83
	331	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.00	0.83	0.83	0.33	0.67	0.83	1.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.33	0.17	0.00	0.17	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	1.00	2.00	2.00
				5.RETARDATION	1.25	1.25	1.00	0.75	0.50	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	2.00	1.33	0.33	0.00	0.00	0.00	0.00	0.00
				7.Total score	5.92	5.08	3.50	2.75	0.83	2.83	4.00	4.17
	332	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.00	1.00	0.67	0.67	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.33	0.17	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	1.75	1.25	0.50	0.25	0.00	0.50	0.25
				6.SLEEP DISTURBANCE	2.00	2.00	1.33	0.33	1.00	0.00	0.00	0.00
				7.Total score	7.67	7.42	4.92	2.00	1.92	0.67	1.33	1.08
	333	Placebo	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.00	0.50	0.67	0.17	0.17
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.33	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.25	1.25	1.00	1.00	0.25	0.25	0.25	0.25
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	1.00	2.00	2.00
				7.Total score	9.08	7.08	6.67	6.33	3.92	2.08	2.58	2.58
	334	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50						
				2.WEIGHT	1.00	0.00						
				3.COGNITIVE DISTURBANCE	0.67	0.50						
				4.DIURNAL VARIATION	2.00	2.00						
				5.RETARDATION	1.50	1.50						
				6.SLEEP DISTURBANCE	2.00	2.00						
				7.Total score	8.67	7.50						
	335	Placebo	Male	1.ANXIETY/SOMATIZATION	1.67	1.33	1.00	0.83	0.83	0.83	0.83	0.67

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	335	Placebo	Male	2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.33	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	0.00	1.00	0.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.50	1.25	1.00	1.00	1.25	1.00
				6.SLEEP DISTURBANCE	0.33	0.33	0.33	1.00	1.33	1.33	1.67	1.33
				7.Total score	6.17	4.83	3.17	4.42	3.50	3.50	4.08	3.33
	336	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50					
				4.DIURNAL VARIATION	0.00	0.00	0.00					
				5.RETARDATION	2.00	2.00	2.00					
				6.SLEEP DISTURBANCE	1.67	1.67	2.00					
				7.Total score	5.67	5.67	6.00					
	337	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.50	1.33	1.00	1.17	1.17	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.50	0.50	0.50
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				5.RETARDATION	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	2.00	1.67	2.00	1.67	1.33	1.33	0.67	1.00
				7.Total score	6.92	6.75	7.08	6.58	5.92	6.25	5.58	5.58
	338	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.33					
				2.WEIGHT	2.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.83	0.67	0.67					
				4.DIURNAL VARIATION	1.00	2.00	2.00					
				5.RETARDATION	1.00	1.50	1.25					
				6.SLEEP DISTURBANCE	1.67	2.00	1.33					
				7.Total score	7.67	7.33	6.58					
12	367	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	0.67	0.50	0.83	0.50	0.00	0.00	0.00
				2.WEIGHT	2.00	2.00	0.00	2.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	0.83	0.50	0.33	0.17	0.17	0.00	0.17
				4.DIURNAL VARIATION	0.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.50	0.75	1.00	0.00	0.25	0.00	0.00
				6.SLEEP DISTURBANCE	1.67	1.67	1.00	1.00	0.67	0.33	0.33	0.67
				7.Total score	8.75	8.67	3.75	6.17	1.33	0.75	0.33	0.83
	368	Placebo	Female	1.ANXIETY/SOMATIZATION	1.00	1.17	1.17	1.00	0.33	0.33	0.50	0.00
				2.WEIGHT	1.00	2.00	0.00	0.00	0.00	0.00	0.00	2.00
				3.COGNITIVE DISTURBANCE	0.50	0.17	0.17	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.75	2.50	1.75	1.25	1.50	1.25
				6.SLEEP DISTURBANCE	1.67	1.33	1.33	0.67	0.67	0.67	0.67	1.00
				7.Total score	7.42	7.92	4.42	4.17	2.75	2.25	2.67	4.25

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
12	369	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.00	0.33	0.67	1.50			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	1.67	1.33	0.50	0.50	1.83			
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	1.00			
				5.RETARDATION	2.00	2.00	0.25	0.75	2.25			
				6.SLEEP DISTURBANCE	1.33	1.33	0.33	0.33	1.00			
				7.Total score	7.17	6.67	1.42	2.25	7.58			
	370	Placebo	Male	1.ANXIETY/SOMATIZATION	1.00	1.33	0.67	1.50	1.50			
				2.WEIGHT	2.00	0.00	0.00	0.00	1.00			
				3.COGNITIVE DISTURBANCE	1.17	0.67	0.33	0.83	1.50			
				4.DIURNAL VARIATION	1.00	1.00	0.00	1.00	1.00			
				5.RETARDATION	1.75	2.00	1.00	2.00	1.75			
				6.SLEEP DISTURBANCE	1.67	1.67	1.00	1.00	1.33			
				7.Total score	8.58	6.67	3.00	6.33	8.08			
	371	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.00	1.67	0.33					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	1.17	0.50	0.50					
				4.DIURNAL VARIATION	1.00	1.00	1.00					
				5.RETARDATION	1.75	1.75	0.75					
				6.SLEEP DISTURBANCE	1.67	1.33	0.33					
				7.Total score	7.58	6.25	2.92					
	372	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.33	1.17	0.83	0.33	0.67	0.17	1.00
				2.WEIGHT	2.00	0.00	2.00	2.00	2.00	0.00	0.00	1.00
				3.COGNITIVE DISTURBANCE	1.00	1.50	1.00	0.50	0.00	0.50	0.00	0.83
				4.DIURNAL VARIATION	2.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.75	1.50	1.00	0.75	0.00	0.00	1.25
				6.SLEEP DISTURBANCE	1.67	2.00	0.67	0.33	0.33	0.00	0.33	0.67
				7.Total score	10.33	7.58	7.33	4.67	3.42	1.17	0.50	4.75
	373	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.33	1.50	0.00	1.00	0.00	0.67	0.00	0.00
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.17	0.67	0.83	0.83	0.50	0.50	0.00
				4.DIURNAL VARIATION	2.00	2.00	1.00	2.00	1.00	2.00	2.00	0.00
				5.RETARDATION	1.75	2.00	1.00	1.25	0.50	0.75	0.25	0.00
				6.SLEEP DISTURBANCE	1.67	1.33	0.67	1.00	0.67	1.33	1.00	1.00
				7.Total score	10.08	8.00	3.33	6.08	3.00	6.25	3.75	1.00
	374	Placebo	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	1.17	0.50	0.50	0.33		
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	1.33	1.17	0.67	0.17	0.33	0.33		
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00		
				5.RETARDATION	2.25	2.25	1.50	1.00	1.75	1.00		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
12	374	Placebo	Female	6.SLEEP DISTURBANCE	0.33	0.00	0.00	0.00	0.00	1.00		
				7.Total score	6.08	5.75	4.33	1.67	2.58	2.67		
	375	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.50	0.83						
				2.WEIGHT	2.00	0.00						
				3.COGNITIVE DISTURBANCE	1.33	1.33						
				4.DIURNAL VARIATION	0.00	1.00						
				5.RETARDATION	1.75	2.00						
				6.SLEEP DISTURBANCE	1.33	1.33						
				7.Total score	6.92	6.50						
13	13	Placebo	Male	1.ANXIETY/SOMATIZATION	0.67	0.67	0.67	0.50	0.33	0.33	0.50	0.50
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.33	0.50	0.33	0.83	0.50	0.50	0.67
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.75	1.75	1.25	1.25	1.25	1.25	1.50	2.00
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.33	1.00	1.00	1.00
				7.Total score	6.75	6.75	4.42	4.08	4.75	4.08	4.50	5.17
	14	Placebo	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	0.50	1.00	0.83	0.50	0.33	0.50
				2.WEIGHT	1.00	1.00	0.00	1.00	1.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.67	0.67	0.83	0.50	0.67	0.67
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	1.00	2.00	1.00
				5.RETARDATION	2.00	2.00	0.50	2.00	1.75	0.50	1.25	1.00
				6.SLEEP DISTURBANCE	0.33	0.33	0.33	0.67	0.33	0.67	0.67	0.33
				7.Total score	7.50	7.50	4.00	7.33	6.75	4.17	4.92	3.50
	15	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.67	0.67	0.67	0.50	0.67	0.50	0.67	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.50	1.50	0.67	0.33	0.50	1.17	0.83	1.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	0.00
				5.RETARDATION	2.25	2.25	1.50	1.00	1.00	2.00	1.75	1.75
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	0.67	1.00	1.33	1.00	1.00
				7.Total score	7.75	7.75	5.83	4.50	5.17	7.00	6.25	4.58
	16	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.83	0.83	1.17	1.17	0.67	0.67	0.67	1.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	0.17	0.67	0.67	0.83
				4.DIURNAL VARIATION	1.00	1.00	2.00	2.00	0.00	2.00	2.00	2.00
				5.RETARDATION	1.25	1.00	2.00	1.25	0.50	0.75	0.75	1.00
				6.SLEEP DISTURBANCE	1.67	2.00	1.67	1.00	0.67	1.00	1.00	2.00
				7.Total score	5.75	5.83	7.83	6.42	2.00	5.08	5.08	7.00
	17	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	0.50	0.83	0.67	0.67	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.50	1.50	1.00	0.50	0.50	0.17	0.17	0.50

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
13	17	Reboxetine	Male	4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.25	1.25	1.00	0.75	0.50	0.75	1.00	0.75
				6.SLEEP DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33
				7.Total score	6.25	6.25	3.83	3.42	3.00	2.92	3.00	3.08
	18	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	0.33	0.33	0.33	0.67	0.33	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.50	0.50	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.25	1.25	0.75	1.25	1.25	1.00
				6.SLEEP DISTURBANCE	0.33	0.33	1.00	0.67	0.67	1.00	0.67	0.67
				7.Total score	5.33	5.33	4.08	3.75	2.08	3.25	2.58	2.33
	409	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	0.83		1.00		0.83
				2.WEIGHT	0.00	0.00	0.00	0.00		0.00		1.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.83	0.50		0.50		0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00		2.00		2.00
				5.RETARDATION	1.25	1.25	1.00	1.00		1.00		0.75
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67		1.33		0.67
				7.Total score	6.92	6.92	6.83	6.00		5.83		5.42
	410	Placebo	Male	1.ANXIETY/SOMATIZATION	1.50	1.17	1.33	1.33	1.33	1.00	1.17	1.17
				2.WEIGHT	0.00	0.00	1.00	1.00	0.00	0.00	1.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.00	1.33	0.50	0.67	0.83	0.17
				4.DIURNAL VARIATION	0.00	0.00	2.00	2.00	2.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.75	1.50	1.75	1.75	1.25	1.50	1.25
				6.SLEEP DISTURBANCE	0.33	1.00	0.67	1.33	1.00	0.00	1.67	1.00
				7.Total score	4.50	5.08	7.50	8.75	6.58	2.92	6.17	3.58
	411	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	0.83	0.67	1.17	1.67	1.17	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.50	0.33	1.33	1.00	0.33
				4.DIURNAL VARIATION	1.00	1.00	2.00	0.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.50	0.75	0.50	2.00	2.00	1.50	1.00
				6.SLEEP DISTURBANCE	1.33	1.33	0.67	0.00	0.00	0.00	0.33	0.00
				7.Total score	5.83	5.83	4.75	1.67	4.50	5.00	4.00	1.83
	423	Placebo	Male	1.ANXIETY/SOMATIZATION	0.83	0.83	0.33	0.17	0.33			0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00			0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.67	0.83	1.17			0.33
				4.DIURNAL VARIATION	2.00	2.00	0.00	0.00	1.00			0.00
				5.RETARDATION	1.25	1.25	1.25	1.50	1.75			0.25
				6.SLEEP DISTURBANCE	1.33	1.33	0.67	1.00	1.00			0.67
				7.Total score	6.42	6.42	2.92	3.50	5.25			1.58
14	19	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.33	1.67	0.17	1.17	1.00		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14	19	Reboxetine	Female	2.WEIGHT	0.00	1.00	2.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	1.50	1.50	1.17	0.33	1.00	1.00	
				4.DIURNAL VARIATION	0.00	1.00	0.00	0.00	2.00	2.00	
				5.RETARDATION	2.75	2.75	2.75	1.75	2.00	2.75	
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.33	2.00	2.00	
				7.Total score	8.08	9.58	9.58	3.58	8.17	8.75	
	20	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.00	0.67	0.17	0.17	0.17	0.00
				2.WEIGHT	3.00	3.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	1.00	0.33	0.33	0.33	0.00	0.17
				4.DIURNAL VARIATION	1.00	1.00	2.00	2.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.75	1.75	1.75	1.00	0.50	0.25	0.00	0.25
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	1.00	0.67	0.00	0.00
				7.Total score	9.75	9.75	7.75	6.00	3.00	2.42	1.17	1.42
	21	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.83	2.00	2.00	0.83	1.50	0.83	1.50	
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	1.17	0.33	0.33	0.50	1.17	1.00	0.67	
				4.DIURNAL VARIATION	2.00	1.00	1.00	1.00	2.00	1.00	1.00	
				5.RETARDATION	2.00	1.75	1.50	1.00	1.75	1.50	1.75	
				6.SLEEP DISTURBANCE	0.67	2.00	1.33	1.00	1.00	1.00	1.00	
				7.Total score	7.67	8.08	6.17	4.33	7.42	5.33	5.92	
15	25	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.00	1.33	1.17	0.50	1.00	1.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	1.00	0.67	0.83	0.83	0.50
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00
				5.RETARDATION	2.50	2.50	2.25	1.50	1.75	1.50	1.50	1.75
				6.SLEEP DISTURBANCE	1.00	1.00	1.67	1.67	1.33	1.33	1.33	1.33
				7.Total score	7.50	7.50	7.58	7.50	6.92	6.17	5.67	5.58
	26	Placebo	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	0.83	0.67	0.83	0.67	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.83	0.67	0.50	0.50	0.67	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	1.00	1.00	0.00
				5.RETARDATION	1.75	1.75	1.25	1.00	1.25	1.50	1.00	1.00
				6.SLEEP DISTURBANCE	1.67	1.67	1.00	1.33	1.00	1.33	0.33	0.67
				7.Total score	6.92	6.92	5.25	4.83	3.42	5.17	3.67	2.33
	27	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	0.83	1.00	0.50	0.33	0.33	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.83	0.17	0.33	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.50	1.50	1.00	0.75	0.50	0.25
				6.SLEEP DISTURBANCE	1.67	1.67	0.67	0.67	0.67	0.33	0.33	0.67
				7.Total score	6.83	6.83	4.67	5.00	3.33	1.75	1.33	1.42

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	28	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	0.67	0.50	0.33	0.33	0.67	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.33	0.33	0.33	0.33	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00
				5.RETARDATION	1.75	1.75	1.50	1.00	1.00	1.00	0.75	0.25
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	0.67	0.33	0.33	0.67	0.00
				7.Total score	6.08	6.08	5.17	3.50	3.00	3.00	3.42	0.92
	29	Placebo	Male	1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.67	1.33			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.83	0.67			
				4.DIURNAL VARIATION	1.00	1.00	2.00	2.00	2.00			
				5.RETARDATION	2.25	2.25	2.25	2.00	2.25			
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.67	1.00			
				7.Total score	6.75	6.75	7.42	7.17	7.25			
	30	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.83	0.83	1.17	1.00	0.50	0.67	0.50	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	0.33	0.67	0.17	0.33
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	0.00	1.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.75	1.75	1.00	1.50	1.00	1.00
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.33	0.33	0.33	0.33	0.33
				7.Total score	6.83	6.83	6.58	5.08	2.17	4.17	2.00	2.33
	403	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	0.50	0.67	0.67	0.50	0.67	0.50
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.50	0.17	0.33	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.00	1.25	1.00	0.50	0.50	0.50
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	0.67	0.67	0.67	0.67	0.67
				7.Total score	8.42	8.42	3.33	2.75	2.67	1.67	1.83	1.67
	404	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.17	1.00	1.00		
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.83	0.83	1.00	1.00	1.00	1.00		
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00		
				5.RETARDATION	1.25	1.25	1.50	1.25	1.50	1.75		
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.00	1.00		
				7.Total score	6.58	6.58	6.00	5.75	5.50	5.75		
	405	Placebo	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.00	1.00	0.67	0.67	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.50	0.17	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.50	1.75	1.00	1.00	0.75	0.25

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	405	Placebo	Female	6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	0.33	0.67	0.33	0.33
				7.Total score	6.33	6.33	5.50	5.25	2.17	2.33	1.58	1.08
	406	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	0.83	0.50	0.33	0.33	0.67
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.33	0.33	0.33	0.50	0.17	0.33
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.50	1.00	0.75	0.50	0.50	0.75
				6.SLEEP DISTURBANCE	0.67	0.67	0.67	1.33	0.67	0.67	0.33	0.67
				7.Total score	7.42	7.42	3.50	3.50	2.25	2.00	1.33	2.42
	407	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	1.17	0.83	0.83	0.83	0.83
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.83	0.83	0.67	0.50	0.33	0.50
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.00	2.00	1.50	1.50	1.00	1.00
				6.SLEEP DISTURBANCE	0.67	0.67	1.00	0.67	0.67	1.00	0.67	0.67
				7.Total score	7.42	7.42	5.00	4.67	3.67	3.83	2.83	3.00
	408	Placebo	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.33	0.67	0.67	0.50	0.67
				2.WEIGHT	0.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.83	0.50	0.67	0.33	0.50
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	0.00	1.00	0.00
				5.RETARDATION	2.75	2.75	2.75	2.75	1.75	1.50	1.25	1.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	0.67	0.67	0.67	0.67	0.67
				7.Total score	7.25	7.25	7.75	7.58	4.58	3.50	3.75	2.83
	418	Placebo	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	1.00	0.83	1.00	0.67	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	0.83	0.67	0.67	0.17	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.75	2.00	1.75	1.50	1.00	0.75
				6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.00	1.00	1.00	0.67	0.67
				7.Total score	7.00	7.00	6.25	5.83	5.25	5.17	2.50	1.75
	419	Placebo	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	0.67	1.17	1.50	1.00	1.17	0.50
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.67	0.50	0.17	0.33	0.50
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	1.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.25	1.50	1.25	1.00	1.25	1.00
				6.SLEEP DISTURBANCE	1.33	1.33	0.67	1.33	1.00	1.00	0.33	0.67
				7.Total score	7.83	7.83	3.92	4.67	4.25	4.17	3.08	2.67

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	1	Imipramine	Female	1	01.REPORTED SADNESS	3	3	1	1	1	1	0
					02.INNER TENSION	2	2	2	1	1	1	1
					03.APPARENT SADNESS	3	2	1	1	0	1	0
					04.SUICIDAL THOUGHTS	2	2	1	0	0	0	0
					05.INERTIA	3	2	1	0	1	1	0
					06.INABILITY TO FEEL	3	2	1	1	0	0	0
					07.PESSIMISTIC THOUGHTS	2	2	1	2	1	1	0
					08.CONCENTRATIONS DIFFICULTIES	3	3	1	1	1	0	1
					09.REDUCED SLEEP	3	2	2	3	2	0	0
					10.REDUCED APPETITE	2	3	1	1	0	0	0
					11.Total score	26	23	12	11	7	5	2
	2	Reboxetine	Male	1	01.REPORTED SADNESS	3	3	1	2	2	1	1
					02.INNER TENSION	2	2	1	1	2	1	1
					03.APPARENT SADNESS	3	3	1	2	2	1	1
					04.SUICIDAL THOUGHTS	3	3	2	2	2	0	1
					05.INERTIA	3	3	2	1	1	0	1
					06.INABILITY TO FEEL	3	2	2	1	1	1	1
					07.PESSIMISTIC THOUGHTS	3	2	2	1	2	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	2	1	1
					09.REDUCED SLEEP	2	2	2	3	2	2	2
					10.REDUCED APPETITE	2	2	1	1	1	1	0
					11.Total score	26	24	16	15	17	9	10
	3	Imipramine	Male	1	01.REPORTED SADNESS	2	1	2	1	1	1	1
					02.INNER TENSION	2	1	1	2	1	0	0
					03.APPARENT SADNESS	2	1	1	1	1	1	1
					04.SUICIDAL THOUGHTS	1	1	0	1	0	0	0
					05.INERTIA	2	1	2	1	1	1	0
					06.INABILITY TO FEEL	1	1	1	1	1	0	0
					07.PESSIMISTIC THOUGHTS	1	1	1	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	1	2	1	0	1	0
					09.REDUCED SLEEP	1	0	1	1	1	1	1
					10.REDUCED APPETITE	1	1	1	1	1	1	0
					11.Total score	15	9	12	10	7	6	4
	4	Placebo	Male	1	01.REPORTED SADNESS	2	2	0	0	0	0	0
					02.INNER TENSION	1	1	1	1	0	0	0
					03.APPARENT SADNESS	2	1	0	0	0	0	0
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	1	0	1	1	0	0	0
					06.INABILITY TO FEEL	2	1	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	0	1	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	0	0
					09.REDUCED SLEEP	2	1	1	1	0	1	1
					10.REDUCED APPETITE	1	1	0	0	0	0	0
					11.Total score	16	9	6	6	3	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	5	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	2	2			
					02.INNER TENSION	2	2	2	2			
					03.APPARENT SADNESS	1	2	2	2			
					04.SUICIDAL THOUGHTS	0	1	1	1			
					05.INERTIA	1	1	1	1			
					06.INABILITY TO FEEL	1	2	2	2			
					07.PESSIMISTIC THOUGHTS	2	2	2	2			
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2			
					09.REDUCED SLEEP	2	2	2	2			
					10.REDUCED APPETITE	1	1	1	1			
					11.Total score	14	17	17	17			
	6	Placebo	Female	1	01.REPORTED SADNESS	2	2	2	1	1	1	1
					02.INNER TENSION	1	2	1	2	1	1	1
					03.APPARENT SADNESS	1	2	1	1	1	1	1
					04.SUICIDAL THOUGHTS	1	1	0	1	1	1	1
					05.INERTIA	1	0	1	0	1	1	1
					06.INABILITY TO FEEL	1	1	1	1	0	1	1
					07.PESSIMISTIC THOUGHTS	1	2	1	1	0	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	2	2	2	2
					09.REDUCED SLEEP	2	3	2	2	1	2	2
					10.REDUCED APPETITE	1	0	0	0	0	1	1
					11.Total score	13	15	10	11	8	12	12
	7	Reboxetine	Female	1	01.REPORTED SADNESS	2	1	1	1	1	0	0
					02.INNER TENSION	2	1	1	1	1	1	0
					03.APPARENT SADNESS	2	1	1	1	0	0	0
					04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
					05.INERTIA	2	1	1	1	0	0	0
					06.INABILITY TO FEEL	2	1	1	0	0	0	0
					07.PESSIMISTIC THOUGHTS	1	2	1	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	0	0	0
					09.REDUCED SLEEP	2	2	1	1	0	0	0
					10.REDUCED APPETITE	2	1	0	0	0	0	0
					11.Total score	18	13	10	6	2	1	0
	8	Placebo	Male	1	01.REPORTED SADNESS	2	1	1	1	1	1	1
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	1	2	1	1	1	0	1
					04.SUICIDAL THOUGHTS	0	1	0	0	0	0	0
					05.INERTIA	2	1	0	0	0	0	0
					06.INABILITY TO FEEL	1	1	1	0	0	0	0
					07.PESSIMISTIC THOUGHTS	1	1	0	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	0
					09.REDUCED SLEEP	2	2	1	1	1	0	1
					10.REDUCED APPETITE	1	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	8	Placebo	Male	1	11.Total score	14	13	6	5	5	3	4
	9	Reboxetine	Female	2	01.APPARENT SADNESS	5	4	3	5	3	3	1
					02.REPORTED SADNESS	4	4	3	4	3	1	2
					03.INNER TENSION	4	3	3	4	3	3	2
					04.REDUCED SLEEP	5	3	4	6	3	3	2
					05.REDUCED APPETITE	3	3	3	1	2	2	0
					06.CONCENTRATIONS DIFFICULTIES	4	3	4	5	3	2	3
					07.LASSITUDE	4	4	3	4	2	2	1
					08.INABILITY TO FEEL	5	4	4	4	2	2	2
					09.PESSIMISTIC THOUGHTS	5	4	4	6	2	2	1
					10.SUICIDAL THOUGHTS	4	2	4	4	2	1	0
					11.Total score	43	34	35	43	25	21	14
	10	Placebo	Male	1	01.REPORTED SADNESS	2	2	1	2	2	1	1
					02.INNER TENSION	2	1	1	1	2	1	1
					03.APPARENT SADNESS	2	1	1	2	1	1	2
					04.SUICIDAL THOUGHTS	1	1	0	1	0	0	0
					05.INERTIA	2	1	1	2	1	2	0
					06.INABILITY TO FEEL	1	1	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	1	0	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	1	1	2	1	1	1
					09.REDUCED SLEEP	2	2	1	1	0	0	0
					10.REDUCED APPETITE	0	0	0	1	0	0	0
					11.Total score	16	11	7	14	9	8	7
	11	Imipramine	Female	1	01.REPORTED SADNESS	1						
					02.INNER TENSION	2						
					03.APPARENT SADNESS	2						
					04.SUICIDAL THOUGHTS	1						
					05.INERTIA	2						
					06.INABILITY TO FEEL	2						
					07.PESSIMISTIC THOUGHTS	2						
					08.CONCENTRATIONS DIFFICULTIES	3						
					09.REDUCED SLEEP	2						
					10.REDUCED APPETITE	3						
					11.Total score	20						
	12	Imipramine	Female	2	01.APPARENT SADNESS	5	3	2	2	1	0	0
					02.REPORTED SADNESS	3	3	2	2	0	0	0
					03.INNER TENSION	4	4	3	2	1	2	1
					04.REDUCED SLEEP	0	0	0	0	1	0	1
					05.REDUCED APPETITE	3	3	0	0	0	0	1
					06.CONCENTRATIONS DIFFICULTIES	5	4	3	3	2	1	2
					07.LASSITUDE	4	4	1	4	1	1	1
					08.INABILITY TO FEEL	4	3	1	1	0	0	0
					09.PESSIMISTIC THOUGHTS	2	4	0	0	1	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	12	Imipramine	Female	2	10.SUICIDAL THOUGHTS	3	3	0	0	0	0	0
					11.Total score	33	31	12	14	7	4	6
	412	Reboxetine	Male	2	01.APPARENT SADNESS	5	4	4	3	2	1	1
					02.REPORTED SADNESS	4	3	3	3	1	1	0
					03.INNER TENSION	4	2	3	3	3	1	1
					04.REDUCED SLEEP	4	1	4	4	4	1	0
					05.REDUCED APPETITE	4	3	1	0	3	0	0
					06.CONCENTRATIONS DIFFICULTIES	4	3	3	2	2	0	1
					07.LASSITUDE	4	3	4	4	4	0	1
					08.INABILITY TO FEEL	4	3	4	3	2	0	0
					09.PESSIMISTIC THOUGHTS	4	4	2	2	1	0	0
					10.SUICIDAL THOUGHTS	4	1	1	2	0	0	0
					11.Total score	41	27	29	26	22	4	4
	413	Placebo	Male	2	01.APPARENT SADNESS	4	2		2		3	2
					02.REPORTED SADNESS	4	2		2		3	2
					03.INNER TENSION	3	2		3		3	2
					04.REDUCED SLEEP	4	1		2		0	0
					05.REDUCED APPETITE	2	1		0		0	0
					06.CONCENTRATIONS DIFFICULTIES	4	2		2		3	3
					07.LASSITUDE	4	1		2		3	3
					08.INABILITY TO FEEL	4	1		2		2	2
					09.PESSIMISTIC THOUGHTS	3	1		2		3	2
					10.SUICIDAL THOUGHTS	3	1		1		2	1
					11.Total score	35	14		18		22	17
	414	Imipramine	Female	2	01.APPARENT SADNESS	4	3	4				
					02.REPORTED SADNESS	3	3	4				
					03.INNER TENSION	4	4	3				
					04.REDUCED SLEEP	5	4	6				
					05.REDUCED APPETITE	3	3	6				
					06.CONCENTRATIONS DIFFICULTIES	4	4	4				
					07.LASSITUDE	4	5	4				
					08.INABILITY TO FEEL	4	3	4				
					09.PESSIMISTIC THOUGHTS	3	3	2				
					10.SUICIDAL THOUGHTS	2	1	1				
					11.Total score	36	33	38				
	415	Imipramine	Male	2	01.APPARENT SADNESS	3	2	2	2	1	0	0
					02.REPORTED SADNESS	3	2	2	1	2	0	0
					03.INNER TENSION	4	4	3	3	1	2	2
					04.REDUCED SLEEP	4	6	2	4	4	4	4
					05.REDUCED APPETITE	2	2	1	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	3	3	3	2	0	1	0
					07.LASSITUDE	4	3	1	1	1	1	1
					08.INABILITY TO FEEL	4	3	2	1	2	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	415	Imipramine	Male	2	09.PESSIMISTIC THOUGHTS	2	2	1	1	1	0	0
					10.SUICIDAL THOUGHTS	2	1	0	0	0	0	0
					11.Total score	31	28	17	15	12	8	7
	416	Reboxetine	Female	2	01.APPARENT SADNESS	3	3	3				
					02.REPORTED SADNESS	3	3	3				
					03.INNER TENSION	5	4	4				
					04.REDUCED SLEEP	4	5	4				
					05.REDUCED APPETITE	2	3	2				
					06.CONCENTRATIONS DIFFICULTIES	3	3	4				
					07.LASSITUDE	3	4	4				
					08.INABILITY TO FEEL	3	4	3				
					09.PESSIMISTIC THOUGHTS	3	3	2				
					10.SUICIDAL THOUGHTS	3	2	1				
					11.Total score	32	34	30				
	421	Imipramine	Male	2	01.APPARENT SADNESS	4	4	3	3	2	1	1
					02.REPORTED SADNESS	4	4	3	2	1	1	1
					03.INNER TENSION	3	3	2	2	1	1	1
					04.REDUCED SLEEP	6	4	2	2	1	1	3
					05.REDUCED APPETITE	2	3	2	2	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	3	3	3	3	1	1	2
					07.LASSITUDE	3	4	3	2	1	2	4
					08.INABILITY TO FEEL	3	3	2	2	0	0	0
					09.PESSIMISTIC THOUGHTS	5	4	2	1	0	0	0
					10.SUICIDAL THOUGHTS	4	4	1	2	0	0	0
					11.Total score	37	36	23	21	7	7	12
	422	Imipramine	Male	2	01.APPARENT SADNESS	3	3	3	2	2	2	1
					02.REPORTED SADNESS	3	3	3	2	2	2	1
					03.INNER TENSION	3	3	2	1	1	1	1
					04.REDUCED SLEEP	3	2	0	2	2	2	0
					05.REDUCED APPETITE	2	2	0	0	2	2	0
					06.CONCENTRATIONS DIFFICULTIES	3	3	2	2	2	2	0
					07.LASSITUDE	3	2	1	2	1	0	0
					08.INABILITY TO FEEL	3	2	0	0	0	0	0
					09.PESSIMISTIC THOUGHTS	2	2	0	0	0	0	0
					10.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					11.Total score	26	23	11	11	12	11	3
2/1	49	Placebo	Female	1	01.REPORTED SADNESS	3	2	1	0	0	0	0
					02.INNER TENSION	2	2	1	0	0	0	0
					03.APPARENT SADNESS	3	2	1	0	0	0	0
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	2	2	1	0	0	0	0
					06.INABILITY TO FEEL	1	1	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	1	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/1	49	Placebo	Female	1	08.CONCENTRATIONS DIFFICULTIES	2	2	1	0	0	0	0
					09.REDUCED SLEEP	2	2	2	2	2	1	1
					10.REDUCED APPETITE	2	2	1	0	0	0	0
					11.Total score	19	17	8	2	2	1	1
	50	Reboxetine	Female	1	01.REPORTED SADNESS	2	1	0	0	0	0	0
					02.INNER TENSION	1	0	0	1	0	0	0
					03.APPARENT SADNESS	2	1	1	0	0	0	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	1	1	0	0	0	0	0
					06.INABILITY TO FEEL	1	0	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	1	1	1	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	0	0	0	0	0	0
					09.REDUCED SLEEP	2	2	2	2	1	1	1
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	11	6	4	3	1	1	1
	51	Imipramine	Female	1	01.REPORTED SADNESS	2	1	1	1	0	0	0
					02.INNER TENSION	2	2	2	1	2	2	2
					03.APPARENT SADNESS	2	1	0	0	0	0	0
					04.SUICIDAL THOUGHTS	2	1	0	0	0	0	0
					05.INERTIA	2	2	1	0	0	0	0
					06.INABILITY TO FEEL	2	1	1	0	0	0	0
					07.PESSIMISTIC THOUGHTS	2	1	0	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	0	0	0	0
					09.REDUCED SLEEP	2	2	2	2	2	2	2
					10.REDUCED APPETITE	2	0	0	0	0	0	0
					11.Total score	20	13	8	4	4	4	4
2/2	43	Imipramine	Female	1	01.REPORTED SADNESS	1	0	0		1	0	
					02.INNER TENSION	1	0	0		1	0	
					03.APPARENT SADNESS	3	0	1		1	1	
					04.SUICIDAL THOUGHTS	1	0	0		0	0	
					05.INERTIA	3	1	1		0	0	
					06.INABILITY TO FEEL	1	0	1		0	0	
					07.PESSIMISTIC THOUGHTS	2	0	0		0	0	
					08.CONCENTRATIONS DIFFICULTIES	2	2	0		0	1	
					09.REDUCED SLEEP	2	0	1		1	0	
					10.REDUCED APPETITE	0	0	0		0	0	
					11.Total score	16	3	4		4	2	
	44	Imipramine	Female	1	01.REPORTED SADNESS	1	1	1	1	0	1	0
					02.INNER TENSION	2	2	1	1	1	1	2
					03.APPARENT SADNESS	2	1	1	0	0	1	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	1	1	0	0	0	0	0
					06.INABILITY TO FEEL	0	2	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/2	44	Imipramine	Female	1	07.PESSIMISTIC THOUGHTS	2	1	1	1	1	2	2
					08.CONCENTRATIONS DIFFICULTIES	2	0	2	2	1	2	2
					09.REDUCED SLEEP	1	2	2	1	1	2	1
					10.REDUCED APPETITE	0	2	0	0	0	0	0
					11.Total score	11	12	8	6	4	9	7
	45	Reboxetine	Female	1	01.REPORTED SADNESS	1	1	1	1	0	1	1
					02.INNER TENSION	1	2	0	1	1	1	1
					03.APPARENT SADNESS	1	1	0	1	1	0	1
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	2	1	1	2	1	1	1
					06.INABILITY TO FEEL	2	2	0	0	0	0	1
					07.PESSIMISTIC THOUGHTS	1	1	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	0	1	0	1	0	0
					09.REDUCED SLEEP	1	1	1	1	0	0	0
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	12	10	6	7	5	4	6
	46	Placebo	Female	1	01.REPORTED SADNESS	2	1		1	0		
					02.INNER TENSION	2	0		1	1		
					03.APPARENT SADNESS	2	1		1	0		
					04.SUICIDAL THOUGHTS	2	0		0	0		
					05.INERTIA	2	2		0	0		
					06.INABILITY TO FEEL	2	2		1	0		
					07.PESSIMISTIC THOUGHTS	2	1		0	0		
					08.CONCENTRATIONS DIFFICULTIES	3	2		1	1		
					09.REDUCED SLEEP	2	0		1	1		
					10.REDUCED APPETITE	0	0		0	0		
					11.Total score	19	9		6	3		
	47	Placebo	Female	1	01.REPORTED SADNESS	2	2	1	1	2	2	2
					02.INNER TENSION	2	1	1	2	2	2	1
					03.APPARENT SADNESS	2	1	1	1	2	2	2
					04.SUICIDAL THOUGHTS	1	1	1	0	1	1	1
					05.INERTIA	2	1	2	1	2	2	2
					06.INABILITY TO FEEL	2	2	3	2	2	1	1
					07.PESSIMISTIC THOUGHTS	1	2	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	2	2	2	2	2	2
					09.REDUCED SLEEP	2	2	1	1	1	1	0
					10.REDUCED APPETITE	1	1	1	0	2	2	1
					11.Total score	16	15	14	11	17	16	13
	48	Reboxetine	Female	1	01.REPORTED SADNESS	3	2	3	1	1	0	1
					02.INNER TENSION	2	2	2	1	2	1	1
					03.APPARENT SADNESS	3	2	3	1	2	1	1
					04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
					05.INERTIA	3	2	3	0	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/2	48	Reboxetine	Female	1	06.INABILITY TO FEEL	2	1	2	1	1	0	1
					07.PESSIMISTIC THOUGHTS	2	1	1	0	1	0	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	0	1	0	0
					09.REDUCED SLEEP	2	2	1	0	2	1	2
					10.REDUCED APPETITE	1	1	0	0	0	0	0
					11.Total score	21	16	18	4	11	4	8
2/3	36/A	Imipramine	Male	1	01.REPORTED SADNESS	2	2	1	1	1	1	1
					02.INNER TENSION	2	2	3	3	3	2	2
					03.APPARENT SADNESS	3	3	1	0	0	0	0
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	2	2	1	0	0	0	0
					06.INABILITY TO FEEL	2	2	1	0	0	0	0
					07.PESSIMISTIC THOUGHTS	1	1	1	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	0	0	0	0	0
					09.REDUCED SLEEP	2	2	1	1	1	1	1
					10.REDUCED APPETITE	1	1	1	0	0	0	0
					11.Total score	18	18	10	5	5	4	4
	37	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	2	1	1	1	1
					02.INNER TENSION	2	3	3	2	2	2	2
					03.APPARENT SADNESS	2	2	2	1	1	1	1
					04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
					05.INERTIA	2	2	2	2	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
					09.REDUCED SLEEP	2	2	2	2	1	1	1
					10.REDUCED APPETITE	2	2	2	1	1	1	1
					11.Total score	19	20	20	13	10	10	10
	38	Placebo	Male	1	01.REPORTED SADNESS	2	1	1	1	1	1	1
					02.INNER TENSION	2	2	2	2	2	1	1
					03.APPARENT SADNESS	2	2	2	1	1	1	1
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	0	0	1
					06.INABILITY TO FEEL	2	1	1	1	1	0	0
					07.PESSIMISTIC THOUGHTS	2	1	1	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	3	3	3	2	2	1	1
					09.REDUCED SLEEP	3	3	3	2	2	1	1
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	19	15	15	12	10	5	6
	39	Imipramine	Female	1	01.REPORTED SADNESS	2	2	1	1	1	0	0
					02.INNER TENSION	2	2	2	1	2	2	1
					03.APPARENT SADNESS	2	2	1	1	0	0	0
					04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/3	39	Imipramine	Female	1	05.INERTIA	2	2	2	1	1	0	0
					06.INABILITY TO FEEL	2	2	2	0	0	0	0
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	0
					08.CONCENTRATIONS DIFFICULTIES	3	3	2	1	1	1	1
					09.REDUCED SLEEP	3	3	1	0	1	0	0
					10.REDUCED APPETITE	2	1	0	0	0	0	0
					11.Total score	20	19	13	6	7	4	2
	40	Reboxetine	Female	1	01.REPORTED SADNESS	1	2	2	1	1	0	0
					02.INNER TENSION	1	2	2	1	1	1	1
					03.APPARENT SADNESS	2	1	1	1	1	0	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	0	0	1	1	1	1	1
					06.INABILITY TO FEEL	1	2	1	1	1	0	1
					07.PESSIMISTIC THOUGHTS	1	1	1	0	2	1	0
					08.CONCENTRATIONS DIFFICULTIES	0	0	0	0	0	0	1
					09.REDUCED SLEEP	1	2	2	1	2	1	0
					10.REDUCED APPETITE	2	1	0	0	0	0	0
					11.Total score	9	11	10	6	9	4	4
	41	Placebo	Male	1	01.REPORTED SADNESS	2	2	2	1	2	3	2
					02.INNER TENSION	2	1	2	1	0	1	2
					03.APPARENT SADNESS	1	2	1	2	1	1	1
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	2	3	2	2	2	3	3
					06.INABILITY TO FEEL	2	2	2	2	2	2	2
					07.PESSIMISTIC THOUGHTS	2	2	1	1	1	2	2
					08.CONCENTRATIONS DIFFICULTIES	1	2	2	2	2	2	2
					09.REDUCED SLEEP	2	2	0	0	0	0	0
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	15	17	12	11	10	14	14
	42	Imipramine	Female	1	01.REPORTED SADNESS	2	1	2	1	0	0	0
					02.INNER TENSION	2	2	2	1	1	2	2
					03.APPARENT SADNESS	2	2	1	1	1	2	2
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	0	1	1	1
					06.INABILITY TO FEEL	1	1	2	1	2	0	0
					07.PESSIMISTIC THOUGHTS	2	1	0	0	0	0	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
					09.REDUCED SLEEP	2	1	2	2	1	1	0
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	15	12	13	8	8	8	8
2/4	31	Placebo	Male	1	01.REPORTED SADNESS	3	3	3	3	3	2	2
					02.INNER TENSION	2	2	2	2	2	2	2
					03.APPARENT SADNESS	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/4	31	Placebo	Male	1	04.SUICIDAL THOUGHTS	3	3	2	2	2	2	2
					05.INERTIA	3	3	3	3	3	2	2
					06.INABILITY TO FEEL	3	3	3	3	3	2	2
					07.PESSIMISTIC THOUGHTS	3	3	3	3	3	2	2
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
					09.REDUCED SLEEP	2	2	2	2	2	2	2
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	22	22	21	21	21	17	17
	32	Reboxetine	Male	1	01.REPORTED SADNESS	3	3	3	2	2	1	0
					02.INNER TENSION	2	2	2	2	2	1	1
					03.APPARENT SADNESS	3	3	3	2	2	2	1
					04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
					05.INERTIA	2	2	2	2	1	1	1
					06.INABILITY TO FEEL	2	2	2	2	2	2	1
					07.PESSIMISTIC THOUGHTS	3	3	3	2	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	3	3	3	3	1	1	1
					09.REDUCED SLEEP	2	2	2	2	1	1	0
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	21	21	21	18	13	11	7
	33	Imipramine	Male	1	01.REPORTED SADNESS	2	2	2	1	1	1	1
					02.INNER TENSION	2	2	2	2	1	1	1
					03.APPARENT SADNESS	3	3	3	2	1	0	0
					04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
					05.INERTIA	1	1	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	1	1	1
					07.PESSIMISTIC THOUGHTS	3	3	3	2	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	3	3	3	2	0	0	0
					09.REDUCED SLEEP	3	3	3	1	0	0	0
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	20	20	20	13	5	4	4
	34	Placebo	Female	1	01.REPORTED SADNESS	3	3	3	2	1	0	0
					02.INNER TENSION	3	3	3	2	1	1	1
					03.APPARENT SADNESS	3	3	3	2	1	1	1
					04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
					05.INERTIA	3	3	3	3	2	1	1
					06.INABILITY TO FEEL	3	3	2	2	1	1	1
					07.PESSIMISTIC THOUGHTS	3	3	3	2	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	3	3	3	2	2	1	1
					09.REDUCED SLEEP	3	3	3	2	1	1	1
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	25	25	24	18	10	7	7
	35	Reboxetine	Female	1	01.REPORTED SADNESS	3	3	2	1	1	1	1
					02.INNER TENSION	2	2	3	2	2	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/4	35	Reboxetine	Female	1	03.APPARENT SADNESS	3	2	2	2	1	1	0
					04.SUICIDAL THOUGHTS	2	2	2	2	1	1	0
					05.INERTIA	3	3	3	2	2	1	1
					06.INABILITY TO FEEL	3	3	3	2	2	1	1
					07.PESSIMISTIC THOUGHTS	2	2	2	2	2	1	1
					08.CONCENTRATIONS DIFFICULTIES	3	3	3	3	2	1	1
					09.REDUCED SLEEP	2	2	2	1	1	1	1
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	23	22	22	17	14	9	6
	36	Imipramine	Female	1	01.REPORTED SADNESS	3	3	2	2	1	1	0
					02.INNER TENSION	3	3	2	2	1	1	1
					03.APPARENT SADNESS	3	3	2	2	1	1	0
					04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
					05.INERTIA	3	3	2	1	1	1	1
					06.INABILITY TO FEEL	3	3	2	1	1	1	1
					07.PESSIMISTIC THOUGHTS	3	3	3	2	1	1	0
					08.CONCENTRATIONS DIFFICULTIES	3	3	3	2	2	1	1
					09.REDUCED SLEEP	3	3	3	2	1	0	0
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	25	25	20	15	9	7	4
2/5	73	Placebo	Male	1	01.REPORTED SADNESS	2	1	1	1	1	1	1
					02.INNER TENSION	1	1	1	1	2	2	2
					03.APPARENT SADNESS	1	1	2	1	2	2	2
					04.SUICIDAL THOUGHTS	0	1	1	0	1	1	2
					05.INERTIA	2	2	1	1	1	1	2
					06.INABILITY TO FEEL	1	1	1	1	2	2	2
					07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	2	2	2
					09.REDUCED SLEEP	1	1	1	1	1	1	1
					10.REDUCED APPETITE	1	0	1	0	1	1	1
					11.Total score	13	11	11	8	14	14	16
	74	Reboxetine	Male	1	01.REPORTED SADNESS	2	1	1	1	1	0	0
					02.INNER TENSION	1	2	1	0	0	0	1
					03.APPARENT SADNESS	2	1	1	0	1	1	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	1	1	1	0	1
					06.INABILITY TO FEEL	1	1	1	0	0	0	0
					07.PESSIMISTIC THOUGHTS	2	2	1	0	0	1	0
					08.CONCENTRATIONS DIFFICULTIES	1	1	0	1	0	0	0
					09.REDUCED SLEEP	1	1	2	1	0	0	0
					10.REDUCED APPETITE	0	0	1	0	0	1	0
					11.Total score	12	11	9	4	3	3	2
	75	Imipramine	Male	1	01.REPORTED SADNESS	2	2	1	0	0	1	0

1320

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/5	75	Imipramine	Male	1	02.INNER TENSION	3	2	2	1	2	1	1
					03.APPARENT SADNESS	2	2	0	0	0	0	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	0	0	1	0	0
					06.INABILITY TO FEEL	2	1	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	2	2	2	1	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	0	1	0
					09.REDUCED SLEEP	2	1	2	2	0	1	1
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	16	13	8	5	3	4	2
	76	Imipramine	Female	1	01.REPORTED SADNESS	3	2	1	2	1	1	1
					02.INNER TENSION	2	2	1	2	2	1	1
					03.APPARENT SADNESS	2	2	0	3	0	0	0
					04.SUICIDAL THOUGHTS	0	1	0	0	0	0	0
					05.INERTIA	2	2	1	2	0	1	0
					06.INABILITY TO FEEL	2	2	0	1	0	0	0
					07.PESSIMISTIC THOUGHTS	2	3	1	2	2	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	1	0	1	1	0	0
					09.REDUCED SLEEP	2	1	1	0	1	0	0
					10.REDUCED APPETITE	2	0	0	1	0	0	0
					11.Total score	18	16	5	14	7	3	2
	77	Placebo	Male	1	01.REPORTED SADNESS	2	1	1	1	1	0	0
					02.INNER TENSION	2	2	1	1	1	1	0
					03.APPARENT SADNESS	1	1	0	0	0	0	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	1	1	1	1	0	0
					06.INABILITY TO FEEL	2	1	0	1	0	0	0
					07.PESSIMISTIC THOUGHTS	2	1	1	1	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	0	0	0	0	0	0
					09.REDUCED SLEEP	1	1	0	0	1	0	0
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	14	8	4	5	4	1	0
	78	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	2	2	1	1	
					02.INNER TENSION	2	2	2	2	1	1	
					03.APPARENT SADNESS	3	2	2	1	1	0	
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	
					05.INERTIA	1	1	2	0	1	1	
					06.INABILITY TO FEEL	2	1	1	0	0	0	
					07.PESSIMISTIC THOUGHTS	2	2	2	2	1	0	
					08.CONCENTRATIONS DIFFICULTIES	1	2	0	1	0	0	
					09.REDUCED SLEEP	1	1	1	0	0	0	
					10.REDUCED APPETITE	0	0	0	0	0	0	
					11.Total score	14	13	12	8	5	3	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/6	55	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	2	0	0	0	0
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	2	2	1	0	0	0	0
					04.SUICIDAL THOUGHTS	2	2	1	0	0	0	0
					05.INERTIA	2	2	2	1	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	0	0	0
					07.PESSIMISTIC THOUGHTS	2	2	2	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
					09.REDUCED SLEEP	3	1	1	0	0	0	0
					10.REDUCED APPETITE	1	1	1	0	0	0	0
					11.Total score	20	18	15	4	3	3	3
	56	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	2	2	1	1	2
					02.INNER TENSION	2	2	2	2	1	1	2
					03.APPARENT SADNESS	2	2	2	2	1	1	2
					04.SUICIDAL THOUGHTS	2	2	2	2	1	1	2
					05.INERTIA	2	2	2	2	2	2	3
					06.INABILITY TO FEEL	2	2	2	2	2	2	2
					07.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	2
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
					09.REDUCED SLEEP	2	1	0	1	0	0	1
					10.REDUCED APPETITE	1	1	1	1	0	0	1
					11.Total score	19	18	17	18	11	11	19
	57	Imipramine	Female	1	01.REPORTED SADNESS	2	2	1	0	0	0	0
					02.INNER TENSION	2	2	1	0	1	1	1
					03.APPARENT SADNESS	2	2	1	0	0	0	0
					04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
					05.INERTIA	2	2	2	1	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	0	0	0
					07.PESSIMISTIC THOUGHTS	1	1	1	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	3	3	2	1	1	1	1
					09.REDUCED SLEEP	2	0	0	0	0	0	0
					10.REDUCED APPETITE	1	1	1	0	1	0	0
					11.Total score	18	16	12	3	4	3	3
	58	Placebo	Female	1	01.REPORTED SADNESS	2	2	2	0	0	0	0
					02.INNER TENSION	1	1	1	0	0	0	0
					03.APPARENT SADNESS	2	2	2	0	0	0	0
					04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
					05.INERTIA	2	2	2	1	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	0	0	0
					07.PESSIMISTIC THOUGHTS	2	1	1	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	2	3	1	1	1	1
					09.REDUCED SLEEP	0	0	0	0	0	0	0
					10.REDUCED APPETITE	2	2	0	0	0	0	0
					11.Total score	15	15	14	3	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/6	59	Placebo	Male	1	01.REPORTED SADNESS	2	2	2	2	2		
					02.INNER TENSION	2	2	2	2	1		
					03.APPARENT SADNESS	2	2	2	2	2		
					04.SUICIDAL THOUGHTS	2	2	2	2	1		
					05.INERTIA	3	3	3	3	3		
					06.INABILITY TO FEEL	3	3	3	2	2		
					07.PESSIMISTIC THOUGHTS	1	2	2	2	2		
					08.CONCENTRATIONS DIFFICULTIES	3	3	2	3	3		
					09.REDUCED SLEEP	2	1	1	0	1		
					10.REDUCED APPETITE	1	1	1	1	1		
					11.Total score	21	21	20	19	18		
	60	Imipramine	Female	1	01.REPORTED SADNESS	2	2	1	0	0	0	0
					02.INNER TENSION	2	2	1	0	0	0	0
					03.APPARENT SADNESS	2	2	1	0	0	0	0
					04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
					05.INERTIA	2	2	1	1	1	1	1
					06.INABILITY TO FEEL	3	2	1	0	0	0	0
					07.PESSIMISTIC THOUGHTS	2	2	1	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	1
					09.REDUCED SLEEP	2	1	1	0	0	0	0
					10.REDUCED APPETITE	1	1	0	0	0	0	0
					11.Total score	19	16	9	2	2	2	2
3/1	61	Imipramine	Male	1	01.REPORTED SADNESS	2	2	2	1	1	1	
					02.INNER TENSION	2	2	1	1	0	0	
					03.APPARENT SADNESS	1	2	1	1	0	0	
					04.SUICIDAL THOUGHTS	1	1	1	0	0	0	
					05.INERTIA	2	2	2	1	0	0	
					06.INABILITY TO FEEL	1	1	1	0	0	0	
					07.PESSIMISTIC THOUGHTS	1	1	1	1	0	0	
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	
					09.REDUCED SLEEP	2	2	1	1	0	0	
					10.REDUCED APPETITE	1	1	1	0	0	0	
					11.Total score	15	16	13	8	2	2	
	62	Imipramine	Female	1	01.REPORTED SADNESS	3	1	1	1	0	0	0
					02.INNER TENSION	2	1	1	1	1	1	1
					03.APPARENT SADNESS	3	1	0	0	1	0	0
					04.SUICIDAL THOUGHTS	2	1	1	0	0	0	0
					05.INERTIA	2	1	1	1	1	1	0
					06.INABILITY TO FEEL	2	1	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	1	1	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	1	0	0	0	0	0
					09.REDUCED SLEEP	3	1	1	0	1	1	1
					10.REDUCED APPETITE	2	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/1	62	Imipramine	Female	1	11.Total score	23	10	7	5	6	4	3
	63	Placebo	Male	1	01.REPORTED SADNESS	3	3	2	2	1	1	1
					02.INNER TENSION	2	2	2	2	1	1	1
					03.APPARENT SADNESS	2	2	1	1	1	1	1
					04.SUICIDAL THOUGHTS	2	2	1	1	1	0	0
					05.INERTIA	3	3	2	2	1	1	1
					06.INABILITY TO FEEL	2	2	2	2	0	0	0
					07.PESSIMISTIC THOUGHTS	2	2	2	2	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
					09.REDUCED SLEEP	2	2	2	2	2	1	1
					10.REDUCED APPETITE	2	2	1	1	1	0	0
					11.Total score	22	22	16	16	10	6	6
	64	Placebo	Female	1	01.REPORTED SADNESS	2	1	2	2	2	2	2
					02.INNER TENSION	2	2	2	2	2	2	2
					03.APPARENT SADNESS	2	2	2	2	2	2	2
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	2	2	3	3	3	3	3
					06.INABILITY TO FEEL	2	2	2	2	2	2	2
					07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
					09.REDUCED SLEEP	2	2	0	0	0	1	1
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	16	15	14	14	14	15	15
	65	Reboxetine	Male	1	01.REPORTED SADNESS	3	2	1	1	1	1	1
					02.INNER TENSION	2	1	1	1	1	1	1
					03.APPARENT SADNESS	2	2	1	1	1	0	0
					04.SUICIDAL THOUGHTS	2	1	1	0	0	0	0
					05.INERTIA	2	2	1	2	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	1	2	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	1	2	1	0	0	0
					09.REDUCED SLEEP	2	1	2	1	1	1	1
					10.REDUCED APPETITE	2	1	1	0	0	0	0
					11.Total score	20	14	13	9	7	5	5
	66	Reboxetine	Male	1	01.REPORTED SADNESS	2	2	1	1	1	1	1
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	2	2	1	0	0	0	0
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	2	2	2	1	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
					09.REDUCED SLEEP	1	1	1	1	0	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/1	66	Reboxetine	Male	1	10.REDUCED APPETITE	2	2	1	1	0	0	0
					11.Total score	18	18	10	8	6	7	7
	139	Imipramine	Male	1	01.REPORTED SADNESS	2	2	2				
					02.INNER TENSION	2	3	3				
					03.APPARENT SADNESS	2	2	3				
					04.SUICIDAL THOUGHTS	2	2	3				
					05.INERTIA	2	2	2				
					06.INABILITY TO FEEL	2	2	2				
					07.PESSIMISTIC THOUGHTS	2	2	3				
					08.CONCENTRATIONS DIFFICULTIES	2	2	2				
					09.REDUCED SLEEP	2	2	2				
					10.REDUCED APPETITE	2	2	2				
					11.Total score	20	21	24				
	140	Placebo	Male	1	01.REPORTED SADNESS	2	2	1	1	0	0	1
					02.INNER TENSION	2	2	1	1	1	1	0
					03.APPARENT SADNESS	2	2	1	0	0	0	0
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	2	2	1	0	0	0	0
					06.INABILITY TO FEEL	2	2	1	0	0	0	0
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	0	0	0	0
					09.REDUCED SLEEP	1	1	1	1	1	1	0
					10.REDUCED APPETITE	2	2	2	1	1	1	1
					11.Total score	18	17	12	5	4	4	3
	141	Placebo	Female	1	01.REPORTED SADNESS	2	2	1	1	1	1	1
					02.INNER TENSION	2	3	1	1	1	0	1
					03.APPARENT SADNESS	2	2	1	0	0	0	0
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	2	2	2	1	1	1	1
					06.INABILITY TO FEEL	1	1	1	0	0	0	0
					07.PESSIMISTIC THOUGHTS	2	2	1	0	1	1	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1
					09.REDUCED SLEEP	1	1	1	1	1	1	1
					10.REDUCED APPETITE	1	1	1	1	1	1	0
					11.Total score	16	16	11	7	8	6	5
	142	Imipramine	Female	1	01.REPORTED SADNESS	2	2	2	2			
					02.INNER TENSION	2	2	2	2			
					03.APPARENT SADNESS	3	3	3	3			
					04.SUICIDAL THOUGHTS	2	2	2	2			
					05.INERTIA	2	2	2	2			
					06.INABILITY TO FEEL	2	2	2	2			
					07.PESSIMISTIC THOUGHTS	2	2	2	2			
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/1	142	Imipramine	Female	1	09.REDUCED SLEEP	2	2	2	2			
					10.REDUCED APPETITE	2	2	2	2			
					11.Total score	21	21	21	21			
	143	Reboxetine	Female	1	01.REPORTED SADNESS	2	1		1	1	1	
					02.INNER TENSION	2	1		1	1	1	
					03.APPARENT SADNESS	2	1		0	0	0	
					04.SUICIDAL THOUGHTS	2	1		0	0	0	
					05.INERTIA	1	1		1	1	1	
					06.INABILITY TO FEEL	1	0		0	0	0	
					07.PESSIMISTIC THOUGHTS	2	1		1	1	1	
					08.CONCENTRATIONS DIFFICULTIES	1	1		1	1	1	
					09.REDUCED SLEEP	1	1		1	1	1	
					10.REDUCED APPETITE	1	1		1	1	1	
					11.Total score	15	9		7	7	7	
	144	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	1		0	0	0
					02.INNER TENSION	1	2	2		2	1	1
					03.APPARENT SADNESS	2	2	1		0	0	0
					04.SUICIDAL THOUGHTS	2	2	0		0	0	0
					05.INERTIA	2	2	1		1	1	1
					06.INABILITY TO FEEL	2	2	1		1	0	0
					07.PESSIMISTIC THOUGHTS	2	2	1		0	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	1	1		1	1	1
					09.REDUCED SLEEP	2	3	1		1	1	0
					10.REDUCED APPETITE	2	2	1		1	1	1
					11.Total score	18	20	10		7	5	4
	451	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	2				
					02.INNER TENSION	2	2	3				
					03.APPARENT SADNESS	2	2	2				
					04.SUICIDAL THOUGHTS	1	0	0				
					05.INERTIA	2	2	2				
					06.INABILITY TO FEEL	2	2	2				
					07.PESSIMISTIC THOUGHTS	2	2	2				
					08.CONCENTRATIONS DIFFICULTIES	2	2	2				
					09.REDUCED SLEEP	2	2	3				
					10.REDUCED APPETITE	1	1	2				
					11.Total score	18	17	20				
	452	Placebo	Male	1	01.REPORTED SADNESS	2	2	1	0	0	1	0
					02.INNER TENSION	2	1	0	0	0	1	1
					03.APPARENT SADNESS	2	1	0	0	0	1	1
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	2	1	0	0	0	0	0
					06.INABILITY TO FEEL	2	1	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	3	2	1	0	0	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/1	452	Placebo	Male	1	08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	0
					09.REDUCED SLEEP	2	1	1	1	1	1	1
					10.REDUCED APPETITE	2	1	0	0	0	0	0
					11.Total score	20	11	4	2	2	6	3
	453	Imipramine	Female	1	01.REPORTED SADNESS	2	2	1	1	1		1
					02.INNER TENSION	2	1	1	0	0		1
					03.APPARENT SADNESS	2	1	1	0	0		0
					04.SUICIDAL THOUGHTS	1	0	0	0	0		0
					05.INERTIA	2	1	1	0	0		0
					06.INABILITY TO FEEL	2	1	1	0	0		0
					07.PESSIMISTIC THOUGHTS	2	1	1	1	0		0
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2		1
					09.REDUCED SLEEP	1	1	1	1	1		1
					10.REDUCED APPETITE	1	1	0	0	0		1
					11.Total score	17	11	9	5	4		5
	454	Reboxetine	Male	1	01.REPORTED SADNESS	2	1	1	0	0	1	0
					02.INNER TENSION	1	1	1	0	0	0	0
					03.APPARENT SADNESS	2	1	1	0	0	0	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	1	1	0	0	0	0
					06.INABILITY TO FEEL	2	0	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	2	1	1	0	0	1	0
					08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	1
					09.REDUCED SLEEP	1	2	1	1	1	1	1
					10.REDUCED APPETITE	1	0	0	0	0	0	0
					11.Total score	15	8	7	2	2	4	2
	455	Placebo	Female	1	01.REPORTED SADNESS	2	2	2	2	1	1	1
					02.INNER TENSION	2	2	2	2	2	1	1
					03.APPARENT SADNESS	2	2	1	1	1	1	1
					04.SUICIDAL THOUGHTS	2	2	1	1	0	0	0
					05.INERTIA	2	2	2	1	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	1	1	1
					07.PESSIMISTIC THOUGHTS	3	3	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
					09.REDUCED SLEEP	1	1	1	1	1	1	1
					10.REDUCED APPETITE	1	1	1	0	1	1	0
					11.Total score	19	19	16	11	10	9	8
	456	Imipramine	Female	1	01.REPORTED SADNESS	2	1	1				
					02.INNER TENSION	2	2	3				
					03.APPARENT SADNESS	2	2	2				
					04.SUICIDAL THOUGHTS	1	0	0				
					05.INERTIA	2	1	1				
					06.INABILITY TO FEEL	2	2	1				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/1	456	Imipramine	Female	1	07.PESSIMISTIC THOUGHTS	2	2	2				
					08.CONCENTRATIONS DIFFICULTIES	2	1	1				
					09.REDUCED SLEEP	2	1	0				
					10.REDUCED APPETITE	1	0	0				
					11.Total score	18	12	11				
3/2	65/A	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	1	2	2	2	2
					02.INNER TENSION	2	2	1	2	1	1	1
					03.APPARENT SADNESS	2	2	1	2	2	1	2
					04.SUICIDAL THOUGHTS	2	2	1	2	2	2	1
					05.INERTIA	1	1	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	2	2	2
					07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
					09.REDUCED SLEEP	1	2	2	1	1	1	2
					10.REDUCED APPETITE	0	1	0	0	0	1	0
					11.Total score	15	17	12	14	14	14	14
3/3	67	Placebo	Male	1	01.REPORTED SADNESS	2	2	2	2	1	1	1
					02.INNER TENSION	2	1	2	1	1	0	1
					03.APPARENT SADNESS	3	2	3	2	1	0	1
					04.SUICIDAL THOUGHTS	2	1	2	0	0	0	0
					05.INERTIA	2	1	2	2	1	1	1
					06.INABILITY TO FEEL	2	2	3	2	1	0	1
					07.PESSIMISTIC THOUGHTS	2	1	2	2	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	1	2	1	1	1	2
					09.REDUCED SLEEP	1	0	2	2	2	1	2
					10.REDUCED APPETITE	0	1	1	0	1	0	0
					11.Total score	18	12	21	14	10	5	10
	68	Reboxetine	Male	1	01.REPORTED SADNESS	2	2	1	0	0	0	0
					02.INNER TENSION	2	1	1	0	0	0	0
					03.APPARENT SADNESS	2	1	1	0	0	0	0
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	2	1	1	1	0	0	0
					06.INABILITY TO FEEL	2	2	1	1	0	0	0
					07.PESSIMISTIC THOUGHTS	2	1	2	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	0	0	0
					09.REDUCED SLEEP	2	1	1	1	0	0	0
					10.REDUCED APPETITE	1	0	0	0	0	0	0
					11.Total score	18	11	10	4	0	0	0
	69	Placebo	Male	1	01.REPORTED SADNESS	2	2	1	1	3	1	1
					02.INNER TENSION	2	2	1	1	3	2	1
					03.APPARENT SADNESS	2	2	1	0	2	1	1
					04.SUICIDAL THOUGHTS	1	2	1	0	2	0	0
					05.INERTIA	2	2	2	1	2	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/3	69	Placebo	Male	1	06.INABILITY TO FEEL	1	2	2	1	3	1	1
					07.PESSIMISTIC THOUGHTS	2	3	2	2	2	1	1
					08.CONCENTRATIONS DIFFICULTIES	3	3	1	1	2	1	1
					09.REDUCED SLEEP	2	1	1	1	2	1	1
					10.REDUCED APPETITE	1	1	1	0	1	0	0
					11.Total score	18	20	13	8	22	9	8
	70	Imipramine	Male	1	01.REPORTED SADNESS	2	2	2	0	1	1	1
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	2	1	1	0	0	0	0
					04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
					05.INERTIA	2	1	1	0	0	0	0
					06.INABILITY TO FEEL	3	1	1	0	1	0	0
					07.PESSIMISTIC THOUGHTS	2	1	1	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	0	0	1	1
					09.REDUCED SLEEP	2	2	2	2	2	1	1
					10.REDUCED APPETITE	3	2	0	0	0	0	0
					11.Total score	21	15	11	4	6	4	4
	71	Imipramine	Female	1	01.REPORTED SADNESS	2	1	1	0	0	0	0
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	1	1	0	0	0	0	0
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	2	1	0	0	0	0	0
					06.INABILITY TO FEEL	1	1	1	1	1	0	0
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	0	0	0	0
					09.REDUCED SLEEP	0	0	0	0	0	0	0
					10.REDUCED APPETITE	1	0	0	0	0	0	0
					11.Total score	13	9	6	3	3	2	2
	72	Reboxetine	Male	1	01.REPORTED SADNESS	2	1	1	1	1	1	1
					02.INNER TENSION	2	2	1	1	2	2	1
					03.APPARENT SADNESS	1	1	1	0	0	0	0
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	1	0	0	0	0	0	0
					06.INABILITY TO FEEL	1	1	1	0	0	0	1
					07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	0	0	0	0	0
					09.REDUCED SLEEP	1	1	0	0	1	0	1
					10.REDUCED APPETITE	0	0	0	0	1	1	1
					11.Total score	12	9	5	3	6	5	7
3/4	79	Imipramine	Female	1	01.REPORTED SADNESS	2	2	2	1	0	0	0
					02.INNER TENSION	2	1	1	1	1	1	1
					03.APPARENT SADNESS	2	1	1	1	0	0	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/4	79	Imipramine	Female	1	05.INERTIA	2	2	1	0	1	0	0
					06.INABILITY TO FEEL	2	1	1	1	1	1	0
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
					09.REDUCED SLEEP	2	2	2	1	1	1	1
					10.REDUCED APPETITE	2	2	2	1	0	0	0
					11.Total score	17	14	13	8	6	4	3
	80	Imipramine	Male	1	01.REPORTED SADNESS	2	2	1	1			
					02.INNER TENSION	2	2	1	1			
					03.APPARENT SADNESS	2	2	1	1			
					04.SUICIDAL THOUGHTS	1	1	0	0			
					05.INERTIA	1	1	1	0			
					06.INABILITY TO FEEL	2	1	1	1			
					07.PESSIMISTIC THOUGHTS	1	1	1	1			
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	0			
					09.REDUCED SLEEP	2	2	2	1			
					10.REDUCED APPETITE	1	0	0	0			
					11.Total score	16	14	9	6			
	81	Reboxetine	Female	1	01.REPORTED SADNESS	3	1	1	1	1	1	1
					02.INNER TENSION	1	1	1	0	1	1	0
					03.APPARENT SADNESS	2	1	0	0	0	0	0
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	2	1	0	0	0	0	0
					06.INABILITY TO FEEL	2	1	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	3	1	0	0	0	0	0
					09.REDUCED SLEEP	3	0	0	0	0	0	0
					10.REDUCED APPETITE	2	1	0	0	0	0	0
					11.Total score	21	8	3	2	3	3	2
	82	Placebo	Male	1	01.REPORTED SADNESS	2	2	1	1	1	1	1
					02.INNER TENSION	1	1	1	1	1	1	1
					03.APPARENT SADNESS	2	1	1	0	1	1	1
					04.SUICIDAL THOUGHTS	2	1	0	0	0	0	0
					05.INERTIA	1	1	1	1	1	1	1
					06.INABILITY TO FEEL	1	1	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	0	0	0	0	0
					09.REDUCED SLEEP	2	2	1	1	0	1	1
					10.REDUCED APPETITE	1	1	1	1	1	0	0
					11.Total score	15	12	7	6	6	6	6
	83	Placebo	Male	1	01.REPORTED SADNESS	2	2					
					02.INNER TENSION	2	3					
					03.APPARENT SADNESS	2	2					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/4	83	Placebo	Male	1	04.SUICIDAL THOUGHTS	1	1					
					05.INERTIA	1	2					
					06.INABILITY TO FEEL	2	2					
					07.PESSIMISTIC THOUGHTS	2	2					
					08.CONCENTRATIONS DIFFICULTIES	1	1					
					09.REDUCED SLEEP	2	2					
					10.REDUCED APPETITE	0	1					
					11.Total score	15	18					
	84	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	1	0	0	0	0
					02.INNER TENSION	2	1	1	1	1	1	1
					03.APPARENT SADNESS	2	1	0	0	0	0	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	1	1	1	0	0	0	0
					06.INABILITY TO FEEL	1	1	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	1	0	0	0	0	0
					09.REDUCED SLEEP	2	1	0	0	0	0	0
					10.REDUCED APPETITE	2	1	0	0	0	0	0
					11.Total score	15	10	4	2	2	2	2
	85	Imipramine	Female	1	01.REPORTED SADNESS	3	3	2	2	2	1	1
					02.INNER TENSION	2	1	1	1	2	1	0
					03.APPARENT SADNESS	2	2	1	1	1	1	0
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	2	1	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	2	1	0
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
					09.REDUCED SLEEP	2	1	0	0	2	2	0
					10.REDUCED APPETITE	2	0	0	0	1	0	0
					11.Total score	19	13	8	8	13	8	3
	86	Imipramine	Male	1	01.REPORTED SADNESS	2	2	1	0	0	0	0
					02.INNER TENSION	2	1	1	1	1	1	1
					03.APPARENT SADNESS	2	2	1	1	1	1	1
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	1	1	0	0	0	0	0
					06.INABILITY TO FEEL	2	2	1	0	0	1	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	1
					09.REDUCED SLEEP	1	0	0	0	0	1	0
					10.REDUCED APPETITE	1	0	0	0	0	0	1
					11.Total score	15	10	6	4	4	6	6
	87	Placebo	Female	1	01.REPORTED SADNESS	2	2	2	2	3	2	2
					02.INNER TENSION	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/4	87	Placebo	Female	1	03.APPARENT SADNESS	2	2	2	1	2	2	1
					04.SUICIDAL THOUGHTS	2	1	1	0	2	1	0
					05.INERTIA	1	1	0	0	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	2	1	1
					07.PESSIMISTIC THOUGHTS	2	2	1	1	2	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	2	1	1
					09.REDUCED SLEEP	2	1	1	0	2	1	0
					10.REDUCED APPETITE	1	0	0	0	2	1	1
					11.Total score	17	14	11	8	20	13	10
	88	Placebo	Male	1	01.REPORTED SADNESS	2	1	1	1	1	1	1
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	1	1	1	0	0	0	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	1	1	0	0	0	0	0
					06.INABILITY TO FEEL	2	1	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	1	0	0	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	0	0	0
					09.REDUCED SLEEP	2	1	1	1	0	0	0
					10.REDUCED APPETITE	1	1	1	0	0	0	0
					11.Total score	14	10	7	5	3	3	3
	89	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	2	2	2	1	1
					02.INNER TENSION	2	1	1	1	1	1	1
					03.APPARENT SADNESS	2	2	2	1	1	1	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	1	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	1	1	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	1
					09.REDUCED SLEEP	2	2	2	2	2	1	1
					10.REDUCED APPETITE	2	2	1	0	0	0	0
					11.Total score	17	15	14	11	11	9	7
	90	Reboxetine	Male	1	01.REPORTED SADNESS	2	2	2	2	1	1	1
					02.INNER TENSION	2	2	1	1	1	0	0
					03.APPARENT SADNESS	2	2	1	1	1	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	1	1	1	1	1	0	0
					06.INABILITY TO FEEL	2	2	2	1	1	1	0
					07.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	0	0
					09.REDUCED SLEEP	2	2	1	0	1	1	1
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	14	14	11	9	8	5	4
	457	Placebo	Female	1	01.REPORTED SADNESS	3	3	3	3			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/4	457	Placebo	Female	1	02.INNER TENSION	2	2	2	2			
					03.APPARENT SADNESS	3	3	2	2			
					04.SUICIDAL THOUGHTS	2	2	2	2			
					05.INERTIA	2	2	2	2			
					06.INABILITY TO FEEL	2	2	2	2			
					07.PESSIMISTIC THOUGHTS	1	2	1	2			
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2			
					09.REDUCED SLEEP	2	2	2	2			
					10.REDUCED APPETITE	2	2	2	2			
					11.Total score	21	22	20	21			
	458	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	2				
					02.INNER TENSION	1	2	2				
					03.APPARENT SADNESS	2	2	2				
					04.SUICIDAL THOUGHTS	1	1	2				
					05.INERTIA	2	2	2				
					06.INABILITY TO FEEL	2	2	2				
					07.PESSIMISTIC THOUGHTS	1	1	2				
					08.CONCENTRATIONS DIFFICULTIES	2	2	2				
					09.REDUCED SLEEP	2	2	2				
					10.REDUCED APPETITE	1	1	2				
					11.Total score	16	17	20				
	459	Placebo	Female	1	01.REPORTED SADNESS	2	1	1	1	1	1	1
					02.INNER TENSION	2	2	2	1	1	1	0
					03.APPARENT SADNESS	1	1	1	1	1	0	0
					04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
					05.INERTIA	1	1	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	1	1	1	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
					09.REDUCED SLEEP	2	1	1	1	0	0	0
					10.REDUCED APPETITE	1	1	1	1	0	0	0
					11.Total score	16	13	11	9	6	5	4
	460	Reboxetine	Male	1	01.REPORTED SADNESS	1	1					
					02.INNER TENSION	1	1					
					03.APPARENT SADNESS	1	1					
					04.SUICIDAL THOUGHTS	0	0					
					05.INERTIA	2	2					
					06.INABILITY TO FEEL	2	2					
					07.PESSIMISTIC THOUGHTS	0	0					
					08.CONCENTRATIONS DIFFICULTIES	2	2					
					09.REDUCED SLEEP	3	3					
					10.REDUCED APPETITE	3	3					
					11.Total score	15	15					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/4	461	Imipramine	Female	1	01.REPORTED SADNESS	2	2					
					02.INNER TENSION	2	2					
					03.APPARENT SADNESS	2	1					
					04.SUICIDAL THOUGHTS	0	0					
					05.INERTIA	1	1					
					06.INABILITY TO FEEL	2	1					
					07.PESSIMISTIC THOUGHTS	1	1					
					08.CONCENTRATIONS DIFFICULTIES	2	2					
					09.REDUCED SLEEP	2	2					
					10.REDUCED APPETITE	1	1					
					11.Total score	15	13					
	462	Imipramine	Female	1	01.REPORTED SADNESS	2	1					
					02.INNER TENSION	2	1					
					03.APPARENT SADNESS	2	1					
					04.SUICIDAL THOUGHTS	0	0					
					05.INERTIA	1	1					
					06.INABILITY TO FEEL	2	1					
					07.PESSIMISTIC THOUGHTS	1	1					
					08.CONCENTRATIONS DIFFICULTIES	2	1					
					09.REDUCED SLEEP	2	2					
					10.REDUCED APPETITE	1	1					
					11.Total score	15	10					
4/1	91	Imipramine	Female	1	01.REPORTED SADNESS	3	2	3	2	2	2	1
					02.INNER TENSION	2	1	2	1	1	1	0
					03.APPARENT SADNESS	2	2	2	1	1	1	1
					04.SUICIDAL THOUGHTS	2	2	2	1	1	1	0
					05.INERTIA	2	2	2	1	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	1	1	0
					07.PESSIMISTIC THOUGHTS	2	1	2	1	1	1	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
					09.REDUCED SLEEP	2	2	1	2	2	2	1
					10.REDUCED APPETITE	2	2	2	1	1	1	0
					11.Total score	21	18	20	12	12	12	5
	92	Reboxetine	Female	1	01.REPORTED SADNESS	3	3	3	3	3	2	2
					02.INNER TENSION	2	2	2	2	2	2	2
					03.APPARENT SADNESS	3	3	3	3	3	3	3
					04.SUICIDAL THOUGHTS	2	2	2	1	2	2	2
					05.INERTIA	2	2	2	2	2	2	2
					06.INABILITY TO FEEL	2	2	2	2	2	2	2
					07.PESSIMISTIC THOUGHTS	2	3	3	3	2	2	2
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
					09.REDUCED SLEEP	3	3	3	3	2	2	2
					10.REDUCED APPETITE	2	2	2	2	2	2	2
					11.Total score	23	24	24	23	22	21	21

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/1	93	Placebo	Male	1	01.REPORTED SADNESS	2	2	2	1	0	0	0
					02.INNER TENSION	1	2	2	1	1	1	0
					03.APPARENT SADNESS	1	2	2	2	0	0	0
					04.SUICIDAL THOUGHTS	1	1	2	1	0	0	0
					05.INERTIA	1	2	2	1	0	0	0
					06.INABILITY TO FEEL	2	2	2	2	1	1	0
					07.PESSIMISTIC THOUGHTS	1	2	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	2	1	0	0	0
					09.REDUCED SLEEP	1	2	2	2	1	1	0
					10.REDUCED APPETITE	0	0	0	1	0	0	0
					11.Total score	11	16	18	13	4	4	1
	94	Placebo	Female	1	01.REPORTED SADNESS	2	2	1	1	0	0	0
					02.INNER TENSION	2	2	1	0	0	0	0
					03.APPARENT SADNESS	2	2	0	0	0	0	0
					04.SUICIDAL THOUGHTS	2	2	0	0	0	0	0
					05.INERTIA	1	1	1	1	1	0	0
					06.INABILITY TO FEEL	2	2	2	1	0	0	0
					07.PESSIMISTIC THOUGHTS	1	1	1	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	0	0
					09.REDUCED SLEEP	2	2	1	0	0	0	0
					10.REDUCED APPETITE	2	2	1	0	0	0	0
					11.Total score	18	18	9	4	2	0	0
	95	Imipramine	Female	1	01.REPORTED SADNESS	2	1	1	1	1	1	0
					02.INNER TENSION	2	1	0	0	0	1	0
					03.APPARENT SADNESS	1	1	1	1	1	1	0
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	2	1	0	0	0	1	0
					06.INABILITY TO FEEL	2	0	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	1	0	0	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	1
					09.REDUCED SLEEP	2	0	0	0	0	0	0
					10.REDUCED APPETITE	0	1	1	1	1	1	0
					11.Total score	15	6	4	4	4	6	1
	96	Reboxetine	Female	1	01.REPORTED SADNESS	3	2	2	1	1	1	1
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	3	2	1	1	1	1	1
					04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
					05.INERTIA	3	2	2	1	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
					09.REDUCED SLEEP	2	2	1	1	1	1	1
					10.REDUCED APPETITE	2	2	2	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/1	96	Reboxetine	Female	1	11.Total score	22	19	15	10	9	9	9
	115	Reboxetine	Female	1	01.REPORTED SADNESS	2	1	1	1	1	1	1
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	2	1	1	1	1	1	1
					04.SUICIDAL THOUGHTS	1	1	1	1	1	1	0
					05.INERTIA	2	1	1	1	1	1	1
					06.INABILITY TO FEEL	1	1	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	0
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
					09.REDUCED SLEEP	2	1	1	1	1	1	1
					10.REDUCED APPETITE	1	1	1	2	1	1	1
					11.Total score	16	12	11	11	10	10	8
	116	Imipramine	Female	1	01.REPORTED SADNESS	2	2					
					02.INNER TENSION	2	2					
					03.APPARENT SADNESS	2	2					
					04.SUICIDAL THOUGHTS	1	1					
					05.INERTIA	2	2					
					06.INABILITY TO FEEL	2	2					
					07.PESSIMISTIC THOUGHTS	2	2					
					08.CONCENTRATIONS DIFFICULTIES	2	2					
					09.REDUCED SLEEP	2	2					
					10.REDUCED APPETITE	1	1					
					11.Total score	18	18					
	117	Imipramine	Female	1	01.REPORTED SADNESS	2	2	1	1	1	1	1
					02.INNER TENSION	2	1	1	0	0	0	0
					03.APPARENT SADNESS	3	2	1	1	1	1	1
					04.SUICIDAL THOUGHTS	2	1	1	1	1	1	1
					05.INERTIA	2	2	1	1	1	1	1
					06.INABILITY TO FEEL	3	2	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	3	2	1	1	1	1	1
					09.REDUCED SLEEP	2	2	1	0	0	0	0
					10.REDUCED APPETITE	2	2	0	0	0	0	0
					11.Total score	23	18	9	7	7	7	7
	118	Reboxetine	Female	1	01.REPORTED SADNESS	1	1	1	1	1	1	1
					02.INNER TENSION	1	1	1	1	1	1	1
					03.APPARENT SADNESS	1	1	1	1	1	1	1
					04.SUICIDAL THOUGHTS	2	1	1	1	0	0	0
					05.INERTIA	2	2	1	1	1	1	1
					06.INABILITY TO FEEL	1	1	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
					09.REDUCED SLEEP	2	2	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/1	118	Reboxetine	Female	1	10.REDUCED APPETITE	1	1	1	1	0	0	0
					11.Total score	15	14	10	10	8	8	8
	119	Placebo	Female	1	01.REPORTED SADNESS	2						
					02.INNER TENSION	1						
					03.APPARENT SADNESS	3						
					04.SUICIDAL THOUGHTS	0						
					05.INERTIA	2						
					06.INABILITY TO FEEL	2						
					07.PESSIMISTIC THOUGHTS	2						
					08.CONCENTRATIONS DIFFICULTIES	2						
					09.REDUCED SLEEP	2						
					10.REDUCED APPETITE	1						
					11.Total score	17						
	120	Placebo	Female	1	01.REPORTED SADNESS	2	2	1	1	1	1	1
					02.INNER TENSION	2	1	1	1	1	1	1
					03.APPARENT SADNESS	1	1	1	1	0	0	0
					04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
					05.INERTIA	2	2	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	1	1	0
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
					09.REDUCED SLEEP	1	1	1	1	1	1	1
					10.REDUCED APPETITE	1	1	1	1	0	0	0
					11.Total score	15	14	11	9	7	7	6
	145	Imipramine	Female	1	01.REPORTED SADNESS	2	1	1	1	1	1	1
					02.INNER TENSION	2	1	1	1	1	1	1
					03.APPARENT SADNESS	2	2	1	1	1	1	0
					04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
					05.INERTIA	1	1	1	1	1	1	1
					06.INABILITY TO FEEL	2	1	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
					09.REDUCED SLEEP	2	1	1	1	1	1	0
					10.REDUCED APPETITE	2	2	1	1	0	0	0
					11.Total score	18	13	10	10	9	8	6
	146	Placebo	Female	1	01.REPORTED SADNESS	2	2	2	1	1	1	1
					02.INNER TENSION	2	2	1	1	1	1	0
					03.APPARENT SADNESS	2	2	2	1	1	1	1
					04.SUICIDAL THOUGHTS	2	1	1	1	1	1	1
					05.INERTIA	2	1	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/1	146	Placebo	Female	1	09.REDUCED SLEEP	2	2	1	1	1	1	0
					10.REDUCED APPETITE	2	1	1	1	1	0	0
					11.Total score	21	17	15	11	10	9	7
	147	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	2	2	1	1	1
					02.INNER TENSION	2	2	2	1	1	1	1
					03.APPARENT SADNESS	2	1	1	1	1	1	1
					04.SUICIDAL THOUGHTS	1	1	1	1	1	1	0
					05.INERTIA	2	2	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	1	2	1
					07.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	1
					09.REDUCED SLEEP	2	2	2	1	1	1	1
					10.REDUCED APPETITE	1	2	2	1	0	0	0
					11.Total score	18	17	16	12	9	10	8
	148	Imipramine	Female	1	01.REPORTED SADNESS	2	2	2	1	1	1	1
					02.INNER TENSION	2	1	1	1	1	1	1
					03.APPARENT SADNESS	2	2	1	1	1	1	1
					04.SUICIDAL THOUGHTS	2	1	1	0	0	0	0
					05.INERTIA	2	1	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	1	1	0
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	1	1	1
					09.REDUCED SLEEP	2	2	2	1	1	1	1
					10.REDUCED APPETITE	2	1	1	0	0	0	0
					11.Total score	21	16	14	9	8	8	7
	149	Reboxetine	Male	1	01.REPORTED SADNESS	2	2	1	1	1	0	0
					02.INNER TENSION	2	2	2	1	1	1	1
					03.APPARENT SADNESS	2	2	1	1	1	1	0
					04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
					05.INERTIA	2	2	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
					09.REDUCED SLEEP	2	1	1	1	1	1	1
					10.REDUCED APPETITE	2	2	2	1	1	0	0
					11.Total score	18	17	12	10	10	7	6
	150	Placebo	Male	1	01.REPORTED SADNESS	2	2	1	1	1	1	1
					02.INNER TENSION	2	2	1	1	1	1	0
					03.APPARENT SADNESS	2	1	1	1	1	1	1
					04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
					05.INERTIA	2	1	1	1	1	1	1
					06.INABILITY TO FEEL	2	1	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/1	150	Placebo	Male	1	08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
					09.REDUCED SLEEP	2	1	1	1	1	1	1
					10.REDUCED APPETITE	1	0	0	0	0	0	0
					11.Total score	18	13	11	10	9	8	7
4/2	93/A	Placebo	Male	1	01.REPORTED SADNESS	3	3	3	1	0	0	0
					02.INNER TENSION	2	2	2	1	1	0	0
					03.APPARENT SADNESS	3	3	3	1	0	0	0
					04.SUICIDAL THOUGHTS	2	2	2	1	0	0	0
					05.INERTIA	2	2	2	2	1	0	0
					06.INABILITY TO FEEL	2	2	2	2	1	0	0
					07.PESSIMISTIC THOUGHTS	1	1	1	1	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	0	0
					09.REDUCED SLEEP	2	2	2	1	0	0	0
					10.REDUCED APPETITE	2	2	2	1	1	1	0
					11.Total score	21	21	21	12	5	1	0
	99/A	Placebo	Male	1	01.REPORTED SADNESS	2	2	1	1	0	0	0
					02.INNER TENSION	2	2	1	1	1	1	0
					03.APPARENT SADNESS	2	2	1	1	1	0	0
					04.SUICIDAL THOUGHTS	2	2	1	1	1	0	0
					05.INERTIA	2	2	1	1	1	0	0
					06.INABILITY TO FEEL	2	2	1	1	1	0	0
					07.PESSIMISTIC THOUGHTS	2	2	1	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	0
					09.REDUCED SLEEP	2	2	1	1	1	0	0
					10.REDUCED APPETITE	2	1	0	0	0	0	0
					11.Total score	19	18	9	9	8	2	0
	104	Reboxetine	Male	1	01.REPORTED SADNESS	3	3	2	2	2	2	2
					02.INNER TENSION	2	2	2	2	2	2	2
					03.APPARENT SADNESS	2	2	2	2	2	2	2
					04.SUICIDAL THOUGHTS	2	2	2	2	2	2	2
					05.INERTIA	2	2	2	2	2	2	2
					06.INABILITY TO FEEL	2	2	2	2	2	2	2
					07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
					09.REDUCED SLEEP	2	2	2	2	2	2	2
					10.REDUCED APPETITE	2	2	2	1	1	1	1
					11.Total score	21	21	20	19	19	19	19
4/3	97	Placebo	Male	1	01.REPORTED SADNESS	2	2	2	2	2	2	2
					02.INNER TENSION	1	1	1	1	2	2	2
					03.APPARENT SADNESS	3	3	3	3	3	3	3
					04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
					05.INERTIA	2	2	2	2	2	2	2
					06.INABILITY TO FEEL	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/3	97	Placebo	Male	1	07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
					09.REDUCED SLEEP	1	1	1	1	1	1	1
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	16	16	16	16	17	17	17
	98	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	2	2	2	3	
					02.INNER TENSION	3	2	2	2	2	3	
					03.APPARENT SADNESS	2	2	2	1	1	3	
					04.SUICIDAL THOUGHTS	1	1	1	1	1	1	
					05.INERTIA	3	2	2	1	1	2	
					06.INABILITY TO FEEL	3	2	2	1	1	2	
					07.PESSIMISTIC THOUGHTS	3	2	2	2	2	2	
					08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	2	2	
					09.REDUCED SLEEP	2	2	2	2	2	2	
					10.REDUCED APPETITE	1	1	1	1	1	1	
					11.Total score	23	18	18	15	15	21	
	99	Placebo	Female	1	01.REPORTED SADNESS	2	2	2				
					02.INNER TENSION	2	2	2				
					03.APPARENT SADNESS	2	2	2				
					04.SUICIDAL THOUGHTS	1	1	1				
					05.INERTIA	2	2	2				
					06.INABILITY TO FEEL	2	2	2				
					07.PESSIMISTIC THOUGHTS	2	2	2				
					08.CONCENTRATIONS DIFFICULTIES	1	1	2				
					09.REDUCED SLEEP	1	1	2				
					10.REDUCED APPETITE	1	1	2				
					11.Total score	16	16	19				
	100	Imipramine	Female	1	01.REPORTED SADNESS	2	2	2	2			
					02.INNER TENSION	2	2	2	2			
					03.APPARENT SADNESS	1	1	2	2			
					04.SUICIDAL THOUGHTS	1	1	2	2			
					05.INERTIA	2	2	2	2			
					06.INABILITY TO FEEL	1	1	2	2			
					07.PESSIMISTIC THOUGHTS	2	1	2	2			
					08.CONCENTRATIONS DIFFICULTIES	2	1	2	2			
					09.REDUCED SLEEP	2	2	2	2			
					10.REDUCED APPETITE	2	2	2	2			
					11.Total score	17	15	20	20			
	101	Imipramine	Male	1	01.REPORTED SADNESS	2	2	2	1	1	0	0
					02.INNER TENSION	2	2	1	1	1	1	0
					03.APPARENT SADNESS	2	2	1	1	1	0	0
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	2	2	2	2	1	1	1

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/3	101	Imipramine	Male	1	06.INABILITY TO FEEL	2	2	2	1	1	1	0
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	0	1
					09.REDUCED SLEEP	1	1	1	0	0	0	0
					10.REDUCED APPETITE	1	1	1	0	0	0	0
					11.Total score	17	17	14	8	7	4	2
4/4	109	Reboxetine	Female	1	01.REPORTED SADNESS	2	1	1	0	0	0	0
					02.INNER TENSION	2	1	1	1	1	1	1
					03.APPARENT SADNESS	3	2	1	0	0	0	0
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	3	3	2	1	0	0	0
					06.INABILITY TO FEEL	1	1	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	2	2	1	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	3	2	1	1	0	0	0
					09.REDUCED SLEEP	2	2	1	1	1	1	0
					10.REDUCED APPETITE	2	2	0	0	0	0	0
					11.Total score	21	17	8	5	3	2	1
	110	Imipramine	Male	1	01.REPORTED SADNESS	2	1	2	1	1	1	1
					02.INNER TENSION	2	2	2	1	1	0	1
					03.APPARENT SADNESS	3	2	2	1	1	1	1
					04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
					05.INERTIA	3	2	2	2	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	1	1	1
					07.PESSIMISTIC THOUGHTS	1	1	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	1	1	1
					09.REDUCED SLEEP	2	2	2	2	0	1	1
					10.REDUCED APPETITE	2	2	2	1	1	0	0
					11.Total score	21	17	19	12	8	7	8
	111	Imipramine	Male	1	01.REPORTED SADNESS	2	2	1	1	1	1	1
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	3	3	2	1	1	0	0
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	2	3	2	1	1	1	0
					06.INABILITY TO FEEL	2	2	1	1	1	1	0
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
					09.REDUCED SLEEP	1	1	1	1	1	0	0
					10.REDUCED APPETITE	2	2	2	1	1	1	1
					11.Total score	18	19	12	9	9	6	4
	112	Placebo	Male	1	01.REPORTED SADNESS	2	2	2	1	1	2	1
					02.INNER TENSION	2	1	2	2	2	2	1
					03.APPARENT SADNESS	2	1	1	1	1	2	1
					04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/4	112	Placebo	Male	1	05.INERTIA	2	2	2	2	1	2	2
					06.INABILITY TO FEEL	1	1	1	1	1	2	2
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	2	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	2	2	2
					09.REDUCED SLEEP	2	1	1	1	1	1	1
					10.REDUCED APPETITE	2	1	1	1	1	2	1
					11.Total score	18	14	14	12	11	17	12
	113	Reboxetine	Male	1	01.REPORTED SADNESS	2	2	2	1	1	1	0
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	2	2	1	1	1	0	0
					04.SUICIDAL THOUGHTS	2	1	1	1	0	0	0
					05.INERTIA	2	2	2	1	1	1	0
					06.INABILITY TO FEEL	2	2	1	1	1	1	0
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
					09.REDUCED SLEEP	2	2	2	1	1	1	1
					10.REDUCED APPETITE	2	2	1	2	2	1	1
					11.Total score	19	18	14	11	10	8	5
	114	Placebo	Female	1	01.REPORTED SADNESS	2	2	1	1	1	1	1
					02.INNER TENSION	2	2	2	2	1	1	1
					03.APPARENT SADNESS	1	1	1	1	1	0	0
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	2	2	1	1	1	1	1
					06.INABILITY TO FEEL	1	2	2	1	1	0	0
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
					09.REDUCED SLEEP	2	3	2	1	1	1	1
					10.REDUCED APPETITE	2	2	1	1	1	0	0
					11.Total score	16	18	12	10	9	6	6
	175	Imipramine	Female	1	01.REPORTED SADNESS	3	3	2	1	1	0	0
					02.INNER TENSION	3	3	2	1	1	1	1
					03.APPARENT SADNESS	3	3	2	1	1	0	0
					04.SUICIDAL THOUGHTS	2	1	1	0	0	0	0
					05.INERTIA	3	3	2	1	1	0	0
					06.INABILITY TO FEEL	2	2	1	1	0	0	0
					07.PESSIMISTIC THOUGHTS	2	2	2	2	2	1	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	0
					09.REDUCED SLEEP	2	2	1	1	1	1	1
					10.REDUCED APPETITE	2	1	1	1	1	0	0
					11.Total score	24	22	16	11	9	4	2
	176	Placebo	Female	1	01.REPORTED SADNESS	3	2	2	2	3		
					02.INNER TENSION	2	2	2	3	2		
					03.APPARENT SADNESS	3	3	2	2	3		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/4	176	Placebo	Female	1	04.SUICIDAL THOUGHTS	1	1	0	0	3		
					05.INERTIA	2	2	2	2	3		
					06.INABILITY TO FEEL	2	2	2	1	2		
					07.PESSIMISTIC THOUGHTS	1	1	1	1	2		
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2		
					09.REDUCED SLEEP	2	2	2	2	3		
					10.REDUCED APPETITE	2	2	2	2	2		
					11.Total score	20	19	17	17	25		
	177	Imipramine	Female	1	01.REPORTED SADNESS	3	3	2				
					02.INNER TENSION	3	2	2				
					03.APPARENT SADNESS	2	3	3				
					04.SUICIDAL THOUGHTS	1	1	1				
					05.INERTIA	1	2	2				
					06.INABILITY TO FEEL	2	2	1				
					07.PESSIMISTIC THOUGHTS	2	2	2				
					08.CONCENTRATIONS DIFFICULTIES	2	2	2				
					09.REDUCED SLEEP	2	2	2				
					10.REDUCED APPETITE	2	2	2				
					11.Total score	20	21	19				
	178	Reboxetine	Female	1	01.REPORTED SADNESS	2	1	1	1	0	0	0
					02.INNER TENSION	2	2	1	1	1	1	0
					03.APPARENT SADNESS	2	1	0	0	0	0	0
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	2	1	1	1	0	0	0
					06.INABILITY TO FEEL	2	2	1	0	0	0	0
					07.PESSIMISTIC THOUGHTS	2	1	1	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	0	0	0	0
					09.REDUCED SLEEP	2	1	1	1	0	0	1
					10.REDUCED APPETITE	2	1	1	1	1	1	1
					11.Total score	19	13	8	6	3	2	2
	179	Placebo	Female	1	01.REPORTED SADNESS	3	3	2	3			
					02.INNER TENSION	3	3	2	3			
					03.APPARENT SADNESS	2	2	2	3			
					04.SUICIDAL THOUGHTS	2	1	1	3			
					05.INERTIA	2	2	1	3			
					06.INABILITY TO FEEL	2	2	2	2			
					07.PESSIMISTIC THOUGHTS	2	2	2	3			
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2			
					09.REDUCED SLEEP	2	1	1	2			
					10.REDUCED APPETITE	2	2	2	2			
					11.Total score	22	20	17	26			
	180	Reboxetine	Male	1	01.REPORTED SADNESS	2	2	1	1	1	0	0
					02.INNER TENSION	2	1	1	1	1	0	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/4	180	Reboxetine	Male	1	03.APPARENT SADNESS	2	1	1	0	0	0	0
					04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
					05.INERTIA	2	2	1	1	0	0	0
					06.INABILITY TO FEEL	2	2	1	1	1	1	0
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	0	0
					09.REDUCED SLEEP	2	2	1	1	1	1	1
					10.REDUCED APPETITE	2	2	1	1	1	0	0
					11.Total score	19	17	11	8	7	3	2
5/1	127	Reboxetine	Male	1	01.REPORTED SADNESS	3	1	2	1	1	1	1
					02.INNER TENSION	2	2	2	1	1	1	1
					03.APPARENT SADNESS	3	2	2	2	1	1	2
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	1	1	2	1	2
					06.INABILITY TO FEEL	2	2	1	1	2	1	2
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	1	2	2
					09.REDUCED SLEEP	2	1	2	1	2	1	1
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	18	13	13	10	11	9	12
	128	Reboxetine	Female	1	01.REPORTED SADNESS	1	1	1	1	1	1	1
					02.INNER TENSION	2	1	1	1	1	1	2
					03.APPARENT SADNESS	1	1	1	1	1	0	0
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	2	1	1	1	1	1	1
					06.INABILITY TO FEEL	2	1	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	1
					09.REDUCED SLEEP	1	0	0	0	1	0	0
					10.REDUCED APPETITE	1	0	0	0	0	0	0
					11.Total score	15	7	6	6	7	5	6
	129	Placebo	Male	1	01.REPORTED SADNESS	1	2	1	1	1	1	2
					02.INNER TENSION	1	2	2	1	1	1	2
					03.APPARENT SADNESS	1	1	0	0	0	1	1
					04.SUICIDAL THOUGHTS	2	2	1	0	0	0	1
					05.INERTIA	2	1	1	1	1	0	1
					06.INABILITY TO FEEL	1	1	1	1	1	0	2
					07.PESSIMISTIC THOUGHTS	1	2	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	0	1	1	1	1
					09.REDUCED SLEEP	2	1	0	0	0	0	1
					10.REDUCED APPETITE	2	1	0	0	0	0	1
					11.Total score	14	14	7	6	6	5	13
	130	Placebo	Male	1	01.REPORTED SADNESS	2	2	2	2	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
5/1	130	Placebo	Male	1	02.INNER TENSION	2	2	1	2	1	0	2
					03.APPARENT SADNESS	2	2	2	2	1	0	1
					04.SUICIDAL THOUGHTS	1	1	1	2	0	0	0
					05.INERTIA	2	2	2	2	1	1	2
					06.INABILITY TO FEEL	1	2	1	2	0	1	1
					07.PESSIMISTIC THOUGHTS	1	2	2	2	1	0	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	2	0	1	1
					09.REDUCED SLEEP	1	0	1	1	2	0	0
					10.REDUCED APPETITE	1	1	0	0	0	0	0
					11.Total score	15	16	13	17	7	4	9
	131	Imipramine	Female	1	01.REPORTED SADNESS	2	2	1	2	1	0	0
					02.INNER TENSION	2	2	1	2	1	1	1
					03.APPARENT SADNESS	3	2	2	2	1	0	0
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	2	2	2	2	1	0	0
					06.INABILITY TO FEEL	2	2	2	3	1	0	0
					07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	0	1	2
					09.REDUCED SLEEP	1	1	1	1	1	1	0
					10.REDUCED APPETITE	1	1	1	0	0	0	0
					11.Total score	17	16	12	14	7	4	4
	132	Imipramine	Male	1	01.REPORTED SADNESS	2	0	0	0	0	0	0
					02.INNER TENSION	1	0	0	0	0	0	0
					03.APPARENT SADNESS	1	0	0	0	0	0	0
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	2	0	0	0	0	0	0
					06.INABILITY TO FEEL	2	0	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	1	0	0	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	0	0	0	0	0	0
					09.REDUCED SLEEP	2	1	0	0	0	0	0
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	13	1	0	0	0	0	0
5/2	121	Imipramine	Female	1	01.REPORTED SADNESS	2	2	2	1	1	1	2
					02.INNER TENSION	2	3	3	1	1	1	2
					03.APPARENT SADNESS	2	2	2	1	1	2	2
					04.SUICIDAL THOUGHTS	2	2	2	0	1	1	2
					05.INERTIA	2	2	2	2	2	2	2
					06.INABILITY TO FEEL	2	2	2	2	2	1	2
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	2
					08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	2	2	2
					09.REDUCED SLEEP	2	2	2	1	1	1	1
					10.REDUCED APPETITE	3	2	3	2	2	2	3
					11.Total score	22	21	22	13	14	14	20

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
5/2	125	Reboxetine	Male	1	01.REPORTED SADNESS	2	2	0	0	0	0	0
					02.INNER TENSION	2	2	0	1	1	1	2
					03.APPARENT SADNESS	2	2	0	0	0	0	0
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	3	2	1	0	0	1	0
					06.INABILITY TO FEEL	2	2	1	0	0	0	0
					07.PESSIMISTIC THOUGHTS	0	1	0	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	1	0	0	0	1	0
					09.REDUCED SLEEP	0	2	1	2	2	1	2
					10.REDUCED APPETITE	2	2	0	1	1	0	0
					11.Total score	16	17	3	4	4	4	4
5/3	133	Placebo	Male	1	01.REPORTED SADNESS	2	2	3				
					02.INNER TENSION	2	2	2				
					03.APPARENT SADNESS	2	2	3				
					04.SUICIDAL THOUGHTS	1	1	2				
					05.INERTIA	1	2	2				
					06.INABILITY TO FEEL	1	2	2				
					07.PESSIMISTIC THOUGHTS	1	1	2				
					08.CONCENTRATIONS DIFFICULTIES	1	1	2				
					09.REDUCED SLEEP	2	2	2				
					10.REDUCED APPETITE	1	1	0				
					11.Total score	14	16	20				
	134	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	0	2	0		0
					02.INNER TENSION	2	2	1	2	0		1
					03.APPARENT SADNESS	1	1	0	2	0		0
					04.SUICIDAL THOUGHTS	1	1	0	1	0		0
					05.INERTIA	2	1	0	0	0		0
					06.INABILITY TO FEEL	2	2	0	1	0		0
					07.PESSIMISTIC THOUGHTS	1	1	0	1	0		0
					08.CONCENTRATIONS DIFFICULTIES	2	2	0	0	0		0
					09.REDUCED SLEEP	2	2	2	2	2		1
					10.REDUCED APPETITE	1	1	0	1	0		0
					11.Total score	16	15	3	12	2		2
	135	Imipramine	Female	1	01.REPORTED SADNESS	2	1	0	0	0	2	2
					02.INNER TENSION	2	1	1	1	1	2	2
					03.APPARENT SADNESS	1	0	0	0	0	1	2
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	1	0	0	1	2	2
					06.INABILITY TO FEEL	2	1	0	0	0	0	1
					07.PESSIMISTIC THOUGHTS	1	0	0	0	0	1	2
					08.CONCENTRATIONS DIFFICULTIES	2	1	0	0	0	1	2
					09.REDUCED SLEEP	2	1	1	1	1	2	2
					10.REDUCED APPETITE	1	0	0	0	0	0	0
					11.Total score	15	6	2	2	3	11	15

9550082

p860X

38

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
5/3	136	Imipramine	Female	1	01.REPORTED SADNESS	2	2	0	0	0	0	0
					02.INNER TENSION	1	1	1	0	1	0	0
					03.APPARENT SADNESS	2	1	0	0	0	0	0
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	2	2	0	0	1	0	0
					06.INABILITY TO FEEL	2	1	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	1	1	0	0	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	0	1	0	0
					09.REDUCED SLEEP	2	2	1	2	2	1	1
					10.REDUCED APPETITE	1	1	0	0	0	0	0
					11.Total score	16	13	3	2	6	1	1
	137	Reboxetine	Female	1	01.REPORTED SADNESS	2	1	0	0	0	0	0
					02.INNER TENSION	2	1	0	0	1	1	1
					03.APPARENT SADNESS	2	2	0	0	0	0	0
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	1	1	1	0	0	0	0
					06.INABILITY TO FEEL	1	1	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	2	1	0	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	1	0	0	0	0	0
					09.REDUCED SLEEP	2	2	2	2	2	1	1
					10.REDUCED APPETITE	2	2	1	0	0	0	0
					11.Total score	17	12	4	2	3	2	2
	138	Placebo	Female	1	01.REPORTED SADNESS	2	2					
					02.INNER TENSION	1	1					
					03.APPARENT SADNESS	2	2					
					04.SUICIDAL THOUGHTS	0	0					
					05.INERTIA	2	2					
					06.INABILITY TO FEEL	1	1					
					07.PESSIMISTIC THOUGHTS	1	1					
					08.CONCENTRATIONS DIFFICULTIES	2	2					
					09.REDUCED SLEEP	2	2					
					10.REDUCED APPETITE	1	1					
					11.Total score	14	14					
	151	Imipramine	Male	1	01.REPORTED SADNESS	2	2					
					02.INNER TENSION	2	1					
					03.APPARENT SADNESS	2	2					
					04.SUICIDAL THOUGHTS	1	0					
					05.INERTIA	1	1					
					06.INABILITY TO FEEL	2	2					
					07.PESSIMISTIC THOUGHTS	1	1					
					08.CONCENTRATIONS DIFFICULTIES	1	1					
					09.REDUCED SLEEP	3	3					
					10.REDUCED APPETITE	2	1					

1347

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/1	151	Imipramine	Male	1	11.Total score	17	14					
	152	Reboxetine	Female	1	01.REPORTED SADNESS	3	2	2	1	1	1	0
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	2	2	2	1	1	1	0
					04.SUICIDAL THOUGHTS	1	1	1	0	1	0	0
					05.INERTIA	1	1	1	1	0	0	0
					06.INABILITY TO FEEL	1	2	1	1	1	0	0
					07.PESSIMISTIC THOUGHTS	1	0	0	0	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	0
					09.REDUCED SLEEP	2	3	3	2	2	2	3
					10.REDUCED APPETITE	2	1	1	1	2	1	1
					11.Total score	17	15	13	9	11	7	5
	153	Reboxetine	Male	1	01.REPORTED SADNESS	1	1	1	0	0	0	1
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	1	2	1	1	1	1	1
					04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
					05.INERTIA	2	2	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	0
					08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	1
					09.REDUCED SLEEP	2	2	1	1	1	1	1
					10.REDUCED APPETITE	1	1	1	1	0	0	1
					11.Total score	15	15	10	9	7	7	8
	154	Imipramine	Female	1	01.REPORTED SADNESS	1						
					02.INNER TENSION	2						
					03.APPARENT SADNESS	1						
					04.SUICIDAL THOUGHTS	1						
					05.INERTIA	1						
					06.INABILITY TO FEEL	1						
					07.PESSIMISTIC THOUGHTS	1						
					08.CONCENTRATIONS DIFFICULTIES	1						
					09.REDUCED SLEEP	3						
					10.REDUCED APPETITE	2						
					11.Total score	14						
	155	Placebo	Male	1	01.REPORTED SADNESS	2	2	3	2	2		
					02.INNER TENSION	2	2	2	2	2		
					03.APPARENT SADNESS	2	2	2	2	2		
					04.SUICIDAL THOUGHTS	1	1	1	1	2		
					05.INERTIA	2	2	2	2	2		
					06.INABILITY TO FEEL	2	2	1	2	2		
					07.PESSIMISTIC THOUGHTS	2	2	2	2	2		
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2		
					09.REDUCED SLEEP	2	2	2	2	2		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/1	155	Placebo	Male	1	10.REDUCED APPETITE	2	2	1	1	2		
					11.Total score	19	19	18	18	20		
	156	Placebo	Female	1	01.REPORTED SADNESS	2	2	1	1	1	0	1
					02.INNER TENSION	1	1	1	2	0	1	0
					03.APPARENT SADNESS	1	1	0	1	0	0	0
					04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					05.INERTIA	2	2	2	0	0	1	1
					06.INABILITY TO FEEL	2	2	1	1	1	0	1
					07.PESSIMISTIC THOUGHTS	1	1	0	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
					09.REDUCED SLEEP	1	0	0	0	0	0	0
					10.REDUCED APPETITE	2	1	0	0	1	0	1
					11.Total score	15	12	6	6	4	3	5
6/2	157	Reboxetine	Male	1	01.REPORTED SADNESS	2	2	2	1	1	1	1
					02.INNER TENSION	2	1	1	1	1	1	1
					03.APPARENT SADNESS	2	2	2	2	2	2	2
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	2	2	2	1	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	2	1	0	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	2	2	2
					09.REDUCED SLEEP	2	2	2	2	1	0	0
					10.REDUCED APPETITE	1	1	0	0	0	0	0
					11.Total score	19	17	13	10	10	9	9
	158	Imipramine	Female	1	01.REPORTED SADNESS	3	3	2	1	1	1	1
					02.INNER TENSION	2	2	2	2	2	1	1
					03.APPARENT SADNESS	2	2	2	2	2	1	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	1	0	0
					07.PESSIMISTIC THOUGHTS	3	3	2	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1
					09.REDUCED SLEEP	2	2	1	1	0	0	0
					10.REDUCED APPETITE	1	1	1	1	0	0	1
					11.Total score	19	19	16	13	10	5	5
	159	Imipramine	Male	1	01.REPORTED SADNESS	2	2	3	3	2	2	3
					02.INNER TENSION	2	2	1	1	1	1	2
					03.APPARENT SADNESS	1	1	2	2	1	1	2
					04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
					05.INERTIA	2	2	2	2	2	2	2
					06.INABILITY TO FEEL	2	2	2	2	1	1	2
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/2	159	Imipramine	Male	1	09.REDUCED SLEEP	1	0	0	0	0	0	0
					10.REDUCED APPETITE	1	1	2	2	0	0	1
					11.Total score	16	15	17	16	10	10	14
	160	Placebo	Male	1	01.REPORTED SADNESS	2	0	0	0	0	0	1
					02.INNER TENSION	2	0	0	0	0	0	1
					03.APPARENT SADNESS	3	0	0	0	0	0	1
					04.SUICIDAL THOUGHTS	2	0	0	0	0	0	1
					05.INERTIA	2	1	1	1	1	1	2
					06.INABILITY TO FEEL	2	1	1	1	1	1	2
					07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	2
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	2
					09.REDUCED SLEEP	3	1	1	1	1	1	1
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	19	5	5	5	5	5	13
	161	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	1	1	1		
					02.INNER TENSION	2	2	2	2	2		
					03.APPARENT SADNESS	2	2	1	1	1		
					04.SUICIDAL THOUGHTS	1	1	1	1	1		
					05.INERTIA	2	2	1	1	1		
					06.INABILITY TO FEEL	2	2	1	1	1		
					07.PESSIMISTIC THOUGHTS	2	2	1	1	1		
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1		
					09.REDUCED SLEEP	1	1	1	1	1		
					10.REDUCED APPETITE	1	1	1	1	1		
					11.Total score	17	17	11	11	11		
	162	Placebo	Male	1	01.REPORTED SADNESS	2	2					
					02.INNER TENSION	2	2					
					03.APPARENT SADNESS	2	2					
					04.SUICIDAL THOUGHTS	1	1					
					05.INERTIA	1	1					
					06.INABILITY TO FEEL	2	2					
					07.PESSIMISTIC THOUGHTS	2	2					
					08.CONCENTRATIONS DIFFICULTIES	3	3					
					09.REDUCED SLEEP	1	1					
					10.REDUCED APPETITE	2	2					
					11.Total score	18	18					
	169	Imipramine	Female	1	01.REPORTED SADNESS	3	0	3	3			
					02.INNER TENSION	2	1	3	3			
					03.APPARENT SADNESS	3	0	3	3			
					04.SUICIDAL THOUGHTS	2	0	2	3			
					05.INERTIA	3	0	3	3			
					06.INABILITY TO FEEL	3	0	3	3			
					07.PESSIMISTIC THOUGHTS	2	0	2	3			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/2	169	Imipramine	Female	1	08.CONCENTRATIONS DIFFICULTIES	2	1	3	3			
					09.REDUCED SLEEP	2	1	2	2			
					10.REDUCED APPETITE	2	0	2	2			
					11.Total score	24	3	26	28			
	170	Placebo	Male	1	01.REPORTED SADNESS	3	1					
					02.INNER TENSION	3	1					
					03.APPARENT SADNESS	3	1					
					04.SUICIDAL THOUGHTS	2	0					
					05.INERTIA	2	1					
					06.INABILITY TO FEEL	3	0					
					07.PESSIMISTIC THOUGHTS	2	0					
					08.CONCENTRATIONS DIFFICULTIES	3	1					
					09.REDUCED SLEEP	2	1					
					10.REDUCED APPETITE	2	0					
					11.Total score	25	6					
	171	Imipramine	Female	1	01.REPORTED SADNESS	1	1	1	0	0	0	0
					02.INNER TENSION	2	2	1	0	0	0	0
					03.APPARENT SADNESS	2	2	1	0	0	0	0
					04.SUICIDAL THOUGHTS	2	2	0	0	0	0	0
					05.INERTIA	2	2	1	0	0	0	0
					06.INABILITY TO FEEL	2	2	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	2	2	1	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	0	0	0	0
					09.REDUCED SLEEP	1	1	1	0	0	0	0
					10.REDUCED APPETITE	1	1	1	0	0	0	0
					11.Total score	17	17	8	0	0	0	0
	172	Reboxetine	Female	1	01.REPORTED SADNESS	3	3	3	3	3	3	3
					02.INNER TENSION	2	2	2	2	2	2	2
					03.APPARENT SADNESS	3	3	3	3	3	3	3
					04.SUICIDAL THOUGHTS	2	2	2	2	2	2	2
					05.INERTIA	3	3	3	3	3	3	3
					06.INABILITY TO FEEL	3	3	3	3	3	3	3
					07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2
					08.CONCENTRATIONS DIFFICULTIES	3	3	3	3	3	3	3
					09.REDUCED SLEEP	2	2	2	2	2	2	2
					10.REDUCED APPETITE	2	2	2	2	2	2	2
					11.Total score	25	25	25	25	25	25	25
	173	Placebo	Male	1	01.REPORTED SADNESS	3	3	3	3	3	2	2
					02.INNER TENSION	2	2	2	2	3	1	1
					03.APPARENT SADNESS	3	2	2	2	3	1	2
					04.SUICIDAL THOUGHTS	2	2	2	2	3	1	1
					05.INERTIA	2	2	2	2	2	2	2
					06.INABILITY TO FEEL	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/2	173	Placebo	Male	1	07.PESSIMISTIC THOUGHTS	2	2	2	2	2	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	3	1	2
					09.REDUCED SLEEP	2	2	2	2	2	1	1
					10.REDUCED APPETITE	0	0	0	1	1	0	0
					11.Total score	20	19	19	20	24	12	14
	174	Reboxetine	Male	1	01.REPORTED SADNESS	3	0	0	0	0	0	2
					02.INNER TENSION	1	0	0	0	0	0	1
					03.APPARENT SADNESS	3	0	0	0	0	0	2
					04.SUICIDAL THOUGHTS	3	0	0	0	0	0	0
					05.INERTIA	3	1	0	0	0	0	2
					06.INABILITY TO FEEL	3	0	0	0	0	0	1
					07.PESSIMISTIC THOUGHTS	2	0	0	0	0	0	1
					08.CONCENTRATIONS DIFFICULTIES	3	1	0	0	0	0	1
					09.REDUCED SLEEP	2	1	0	0	0	0	0
					10.REDUCED APPETITE	2	0	0	0	0	0	0
					11.Total score	25	3	0	0	0	0	10
6/3	163	Reboxetine	Male	1	01.REPORTED SADNESS	2	2					
					02.INNER TENSION	2	2					
					03.APPARENT SADNESS	2	2					
					04.SUICIDAL THOUGHTS	1	1					
					05.INERTIA	1	1					
					06.INABILITY TO FEEL	1	1					
					07.PESSIMISTIC THOUGHTS	1	1					
					08.CONCENTRATIONS DIFFICULTIES	2	2					
					09.REDUCED SLEEP	0	0					
					10.REDUCED APPETITE	0	0					
					11.Total score	12	12					
	164	Imipramine	Male	1	01.REPORTED SADNESS	2	2	2	2	2	2	1
					02.INNER TENSION	2	2	1	2	1	1	1
					03.APPARENT SADNESS	2	2	1	1	1	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	2	2	0
					06.INABILITY TO FEEL	2	2	2	2	2	2	1
					07.PESSIMISTIC THOUGHTS	1	2	2	2	1	1	2
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	2	0	0
					09.REDUCED SLEEP	0	0	0	0	0	0	0
					10.REDUCED APPETITE	1	0	0	0	0	0	0
					11.Total score	13	13	11	12	11	9	6
	165	Imipramine	Female	1	01.REPORTED SADNESS	2	2	2	2	1	2	1
					02.INNER TENSION	2	2	2	2	1	1	1
					03.APPARENT SADNESS	2	2	1	1	1	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	1	2	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/3	165	Imipramine	Female	1	06.INABILITY TO FEEL	2	2	2	2	1	1	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	1	1	2	2	1	2
					09.REDUCED SLEEP	2	1	1	1	0	0	0
					10.REDUCED APPETITE	1	0	0	0	0	0	0
					11.Total score	16	13	12	13	8	9	8
	166	Reboxetine	Female	1	01.REPORTED SADNESS	2	2					
					02.INNER TENSION	2	2					
					03.APPARENT SADNESS	2	2					
					04.SUICIDAL THOUGHTS	0	3					
					05.INERTIA	2	1					
					06.INABILITY TO FEEL	2	2					
					07.PESSIMISTIC THOUGHTS	2	2					
					08.CONCENTRATIONS DIFFICULTIES	1	2					
					09.REDUCED SLEEP	1	2					
					10.REDUCED APPETITE	1	1					
					11.Total score	15	19					
	167	Placebo	Female	1	01.REPORTED SADNESS	2	2	2	1	1	1	0
					02.INNER TENSION	2	2	2	1	1	2	1
					03.APPARENT SADNESS	2	2	1	1	1	0	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	1	1	1	2	1	1	1
					06.INABILITY TO FEEL	1	1	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	1	1	1	1	0	1
					08.CONCENTRATIONS DIFFICULTIES	1	2	1	1	1	1	1
					09.REDUCED SLEEP	0	0	0	0	0	0	0
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	11	11	9	8	7	6	5
	168	Placebo	Female	1	01.REPORTED SADNESS	3	2	2	2	3	3	
					02.INNER TENSION	2	2	2	2	2	2	
					03.APPARENT SADNESS	3	1	1	2	2	3	
					04.SUICIDAL THOUGHTS	0	0	0	0	0	2	
					05.INERTIA	2	1	1	2	2	2	
					06.INABILITY TO FEEL	2	1	1	1	1	1	
					07.PESSIMISTIC THOUGHTS	0	2	2	2	2	2	
					08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	2	3	
					09.REDUCED SLEEP	3	2	0	0	2	2	
					10.REDUCED APPETITE	2	0	0	0	1	1	
					11.Total score	20	13	11	13	17	21	
	505	Imipramine	Female	1	01.REPORTED SADNESS	2	2	2				
					02.INNER TENSION	2	2	2				
					03.APPARENT SADNESS	2	2	2				
					04.SUICIDAL THOUGHTS	0	0	0				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/3	505	Imipramine	Female	1	05.INERTIA	1	2	1				
					06.INABILITY TO FEEL	2	2	1				
					07.PESSIMISTIC THOUGHTS	2	2	1				
					08.CONCENTRATIONS DIFFICULTIES	2	2	1				
					09.REDUCED SLEEP	0	2	3				
					10.REDUCED APPETITE	0	1	1				
					11.Total score	13	17	14				
	506	Placebo	Female	1	01.REPORTED SADNESS	2	2	2	2	1	1	2
					02.INNER TENSION	3	2	2	2	1	2	2
					03.APPARENT SADNESS	2	2	2	1	1	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	1	2	1	1
					06.INABILITY TO FEEL	1	1	1	2	1	1	1
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	3	2	2	2	1
					09.REDUCED SLEEP	2	2	2	2	2	2	2
					10.REDUCED APPETITE	1	0	0	0	0	0	0
					11.Total score	17	15	16	13	11	11	11
	507	Imipramine	Female	1	01.REPORTED SADNESS	2	2	1	1	1	0	1
					02.INNER TENSION	2	2	2	1	0	1	0
					03.APPARENT SADNESS	1	1	2	1	1	1	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	1	1	1	1	1	0	0
					06.INABILITY TO FEEL	2	1	1	1	1	0	0
					07.PESSIMISTIC THOUGHTS	2	1	1	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	2	2	2	2	1	1
					09.REDUCED SLEEP	1	1	0	0	0	1	0
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	12	11	10	8	7	4	2
	508	Reboxetine	Female	1	01.REPORTED SADNESS	2	1	1	1	2	1	0
					02.INNER TENSION	2	1	1	1	1	1	1
					03.APPARENT SADNESS	1	1	1	1	2	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	1	1	1	1	1	1
					06.INABILITY TO FEEL	1	1	1	1	1	1	0
					07.PESSIMISTIC THOUGHTS	2	1	2	1	1	1	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
					09.REDUCED SLEEP	0	1	0	1	0	1	1
					10.REDUCED APPETITE	0	0	0	0	1	0	0
					11.Total score	12	9	9	8	10	8	5
	509	Placebo	Male	1	01.REPORTED SADNESS	2	1	1	1	1	1	1
					02.INNER TENSION	2	1	1	2	1	1	1
					03.APPARENT SADNESS	1	1	2	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.6

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/3	509	Placebo	Male	1	04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	1	0	1	1	1	1	1
					06.INABILITY TO FEEL	2	1	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	2	2	2	1
					09.REDUCED SLEEP	1	2	0	1	0	0	1
					10.REDUCED APPETITE	1	0	1	1	0	1	0
					11.Total score	13	8	9	11	8	9	8
	510	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	2				
					02.INNER TENSION	2	1	2				
					03.APPARENT SADNESS	2	1	2				
					04.SUICIDAL THOUGHTS	0	0	0				
					05.INERTIA	2	1	0				
					06.INABILITY TO FEEL	1	1	1				
					07.PESSIMISTIC THOUGHTS	2	1	1				
					08.CONCENTRATIONS DIFFICULTIES	2	2	2				
					09.REDUCED SLEEP	1	2	2				
					10.REDUCED APPETITE	0	0	0				
					11.Total score	14	11	12				
	511	Imipramine	Female	1	01.REPORTED SADNESS	2	2	1	1	1	2	
					02.INNER TENSION	2	2	1	1	1	1	
					03.APPARENT SADNESS	2	2	0	1	1	2	
					04.SUICIDAL THOUGHTS	0	0	0	0	0	2	
					05.INERTIA	1	1	1	1	1	1	
					06.INABILITY TO FEEL	1	1	1	1	1	2	
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	2	
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	2	2	
					09.REDUCED SLEEP	1	0	1	1	1	1	
					10.REDUCED APPETITE	1	2	1	1	0	0	
					11.Total score	13	13	8	9	9	15	
	512	Placebo	Female	1	01.REPORTED SADNESS	2	2					
					02.INNER TENSION	2	2					
					03.APPARENT SADNESS	2	2					
					04.SUICIDAL THOUGHTS	0	0					
					05.INERTIA	1	1					
					06.INABILITY TO FEEL	1	1					
					07.PESSIMISTIC THOUGHTS	1	1					
					08.CONCENTRATIONS DIFFICULTIES	2	2					
					09.REDUCED SLEEP	2	2					
					10.REDUCED APPETITE	0	0					
					11.Total score	13	13					
	513	Imipramine	Female	1	01.REPORTED SADNESS	2	1	1	1	1	0	1
					02.INNER TENSION	2	2	1	2	2	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/3	513	Imipramine	Female	1	03.APPARENT SADNESS	2	1	1	1	1	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	1	1	1	1	0	0	1
					06.INABILITY TO FEEL	1	1	1	0	0	1	0
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	1	0	2	1	0	0
					09.REDUCED SLEEP	2	2	1	0	1	1	0
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	13	10	7	8	7	5	5
7/02	181	Reboxetine	Male	2	01.APPARENT SADNESS	3	3	3	3	3	2	2
					02.REPORTED SADNESS	3	3	3	3	3	2	2
					03.INNER TENSION	3	3	3	3	3	3	2
					04.REDUCED SLEEP	3	3	3	2	1	1	1
					05.REDUCED APPETITE	1	1	1	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
					07.LASSITUDE	2	2	2	2	2	2	2
					08.INABILITY TO FEEL	3	3	3	3	2	2	2
					09.PESSIMISTIC THOUGHTS	3	3	3	3	3	3	2
					10.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
					11.Total score	24	24	24	22	20	18	16
	182	Placebo	Male	2	01.APPARENT SADNESS	4	4	4	3	3	3	3
					02.REPORTED SADNESS	4	5	4	3	3	3	3
					03.INNER TENSION	4	4	3	3	3	3	3
					04.REDUCED SLEEP	2	2	2	1	1	1	2
					05.REDUCED APPETITE	2	3	2	3	3	3	3
					06.CONCENTRATIONS DIFFICULTIES	3	3	2	2	2	2	2
					07.LASSITUDE	3	3	3	3	2	3	2
					08.INABILITY TO FEEL	3	5	3	3	3	3	3
					09.PESSIMISTIC THOUGHTS	2	3	2	2	2	2	2
					10.SUICIDAL THOUGHTS	1	2	1	1	1	1	1
					11.Total score	28	34	26	24	23	24	24
	183	Imipramine	Male	2	01.APPARENT SADNESS	3	3	3	5			
					02.REPORTED SADNESS	3	4	3	5			
					03.INNER TENSION	3	4	4	4			
					04.REDUCED SLEEP	6	6	6	6			
					05.REDUCED APPETITE	5	4	5	5			
					06.CONCENTRATIONS DIFFICULTIES	2	2	3	4			
					07.LASSITUDE	4	5	4	5			
					08.INABILITY TO FEEL	3	3	3	4			
					09.PESSIMISTIC THOUGHTS	2	3	3	3			
					10.SUICIDAL THOUGHTS	1	1	1	1			
					11.Total score	32	35	35	42			
	184	Imipramine	Female	2	01.APPARENT SADNESS	4	4	3	2	2	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/02	184	Imipramine	Female	2	02.REPORTED SADNESS	4	4	3	2	2	1	1
					03.INNER TENSION	4	4	3	2	2	1	0
					04.REDUCED SLEEP	4	4	4	2	2	1	0
					05.REDUCED APPETITE	2	2	1	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	0	0
					07.LASSITUDE	4	4	2	2	2	0	0
					08.INABILITY TO FEEL	4	4	2	2	2	1	1
					09.PESSIMISTIC THOUGHTS	2	2	2	2	2	1	0
					10.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
					11.Total score	31	31	22	16	16	6	3
	185	Reboxetine	Male	2	01.APPARENT SADNESS	2	3	4	3	3		
					02.REPORTED SADNESS	2	2	3	1	3		
					03.INNER TENSION	2	2	2	2	2		
					04.REDUCED SLEEP	5	5	5	4	5		
					05.REDUCED APPETITE	2	2	2	2	2		
					06.CONCENTRATIONS DIFFICULTIES	1	1	1	2	1		
					07.LASSITUDE	0	1	1	1	1		
					08.INABILITY TO FEEL	1	1	2	1	2		
					09.PESSIMISTIC THOUGHTS	4	4	3	4	2		
					10.SUICIDAL THOUGHTS	1	1	1	1	1		
					11.Total score	20	22	24	21	22		
	186	Placebo	Male	2	01.APPARENT SADNESS	2	1	2	1	1	1	0
					02.REPORTED SADNESS	3	2	2	2	1	1	1
					03.INNER TENSION	4	3	2	2	1	1	1
					04.REDUCED SLEEP	5	5	5	4	4	3	1
					05.REDUCED APPETITE	1	1	1	1	1	1	0
					06.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
					07.LASSITUDE	1	1	1	1	1	1	1
					08.INABILITY TO FEEL	2	2	2	2	2	1	0
					09.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	0
					10.SUICIDAL THOUGHTS	2	2	1	1	1	1	0
					11.Total score	23	20	19	17	14	12	5
	535	Placebo	Male	2	01.APPARENT SADNESS	2	2	2	2	2	2	1
					02.REPORTED SADNESS	1	1	1	1	1	1	1
					03.INNER TENSION	3	3	3	3	3	3	2
					04.REDUCED SLEEP	1	1	1	1	1	1	1
					05.REDUCED APPETITE	1	1	1	1	1	1	0
					06.CONCENTRATIONS DIFFICULTIES	3	3	3	2	2	2	2
					07.LASSITUDE	3	3	3	1	2	2	2
					08.INABILITY TO FEEL	3	3	3	3	2	2	2
					09.PESSIMISTIC THOUGHTS	2	2	2	1	2	2	2
					10.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
					11.Total score	20	20	20	16	17	17	14

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/02	536	Reboxetine	Female	2	01.APPARENT SADNESS	3	3	2	2	1	1	1
					02.REPORTED SADNESS	3	3	2	2	2	1	1
					03.INNER TENSION	2	2	2	2	1	1	1
					04.REDUCED SLEEP	4	4	3	3	1	1	1
					05.REDUCED APPETITE	0	0	0	0	0	1	1
					06.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
					07.LASSITUDE	4	4	3	2	1	1	1
					08.INABILITY TO FEEL	3	3	2	2	1	1	1
					09.PESSIMISTIC THOUGHTS	2	2	2	2	2	1	1
					10.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
					11.Total score	24	24	18	17	11	10	10
7/03	187	Imipramine	Female	2	01.APPARENT SADNESS	4	4	4	4	4	2	2
					02.REPORTED SADNESS	3	3	3	3	3	2	2
					03.INNER TENSION	1	1	1	1	1	0	0
					04.REDUCED SLEEP	4	4	4	4	4	1	1
					05.REDUCED APPETITE	1	1	1	1	1	0	0
					06.CONCENTRATIONS DIFFICULTIES	1	4	4	4	4	2	2
					07.LASSITUDE	2	2	2	2	2	2	2
					08.INABILITY TO FEEL	2	3	3	3	3	3	3
					09.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	1
					10.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					11.Total score	21	23	23	23	23	13	13
	188	Placebo	Male	2	01.APPARENT SADNESS	4	4	4	2	2	1	1
					02.REPORTED SADNESS	4	4	4	2	2	1	1
					03.INNER TENSION	2	2	2	1	1	1	1
					04.REDUCED SLEEP	4	4	4	2	2	1	1
					05.REDUCED APPETITE	2	2	2	1	1	0	0
					06.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	0	0
					07.LASSITUDE	2	2	2	2	2	1	1
					08.INABILITY TO FEEL	2	2	2	1	1	1	1
					09.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
					10.SUICIDAL THOUGHTS	2	2	2	0	0	0	0
					11.Total score	26	26	26	13	13	7	7
	189	Placebo	Male	2	01.APPARENT SADNESS	4	4	4	0	0	0	0
					02.REPORTED SADNESS	4	4	4	1	1	1	1
					03.INNER TENSION	2	2	2	0	0	0	0
					04.REDUCED SLEEP	4	4	4	0	0	0	0
					05.REDUCED APPETITE	2	2	2	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	4	4	4	1	1	1	1
					07.LASSITUDE	1	1	1	1	1	1	1
					08.INABILITY TO FEEL	2	2	2	0	0	0	0
					09.PESSIMISTIC THOUGHTS	1	1	1	0	1	1	1
					10.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
					11.Total score	25	25	25	3	4	4	4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Contre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/03	190	Reboxetine	Male	2	01.APPARENT SADNESS	4	4	4	2	2	2	2
					02.REPORTED SADNESS	3	3	3	1	1	1	1
					03.INNER TENSION	2	2	2	1	1	1	1
					04.REDUCED SLEEP	3	3	3	1	1	1	1
					05.REDUCED APPETITE	1	1	1	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	2	4	4	2	2	2	2
					07.LASSITUDE	2	3	3	1	1	1	1
					08.INABILITY TO FEEL	2	2	2	2	2	2	2
					09.PESSIMISTIC THOUGHTS	1	3	3	1	1	1	1
					10.SUICIDAL THOUGHTS	0	1	1	0	0	0	0
					11.Total score	20	26	26	11	11	11	11
	191	Imipramine	Female	2	01.APPARENT SADNESS	4	3	3	2	2	2	
					02.REPORTED SADNESS	4	2	2	1	1	1	
					03.INNER TENSION	3	1	1	1	1	1	
					04.REDUCED SLEEP	3	1	1	1	1	1	
					05.REDUCED APPETITE	1	1	1	0	0	0	
					06.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	
					07.LASSITUDE	3	2	2	1	1	1	
					08.INABILITY TO FEEL	4	3	3	2	2	2	
					09.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	
					10.SUICIDAL THOUGHTS	1	1	1	1	1	1	
					11.Total score	27	17	17	11	11	11	
	192	Reboxetine	Female	2	01.APPARENT SADNESS	3	3	2	3	3	3	3
					02.REPORTED SADNESS	3	3	1	2	2	2	2
					03.INNER TENSION	1	1	1	1	1	1	1
					04.REDUCED SLEEP	2	2	1	2	2	2	2
					05.REDUCED APPETITE	2	2	0	2	2	2	2
					06.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
					07.LASSITUDE	2	2	2	2	2	2	2
					08.INABILITY TO FEEL	2	2	1	2	2	2	2
					09.PESSIMISTIC THOUGHTS	2	2	1	2	2	2	2
					10.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
					11.Total score	20	20	12	19	19	19	19
	523	Reboxetine	Female	2	01.APPARENT SADNESS	4	4	4	2	2	2	2
					02.REPORTED SADNESS	4	4	4	2	2	2	2
					03.INNER TENSION	2	2	2	1	1	1	1
					04.REDUCED SLEEP	4	4	4	1	1	1	1
					05.REDUCED APPETITE	2	2	2	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
					07.LASSITUDE	4	4	4	1	1	1	1
					08.INABILITY TO FEEL	4	4	4	2	2	2	2
					09.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2
					10.SUICIDAL THOUGHTS	2	2	2	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/03	523	Reboxetine	Female	2	11.Total score	30	30	30	12	12	12	12
	524	Placebo	Female	2	01.APPARENT SADNESS	4	4	4	2	1	1	1
					02.REPORTED SADNESS	4	4	4	2	1	1	1
					03.INNER TENSION	3	3	3	2	0	0	0
					04.REDUCED SLEEP	3	3	3	1	0	0	0
					05.REDUCED APPETITE	1	1	1	1	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
					07.LASSITUDE	2	2	2	1	1	1	1
					08.INABILITY TO FEEL	4	4	4	2	2	2	2
					09.PESSIMISTIC THOUGHTS	3	3	3	2	2	2	2
					10.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
					11.Total score	27	27	27	16	9	9	9
	525	Placebo	Female	2	01.APPARENT SADNESS	4	4	3	2	1	1	1
					02.REPORTED SADNESS	4	4	3	2	2	2	2
					03.INNER TENSION	3	3	2	1	1	1	1
					04.REDUCED SLEEP	3	3	2	1	0	0	0
					05.REDUCED APPETITE	1	1	1	1	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	2	2	1	1	0	0	0
					07.LASSITUDE	3	3	2	2	1	1	1
					08.INABILITY TO FEEL	3	3	3	2	1	1	1
					09.PESSIMISTIC THOUGHTS	3	3	1	1	1	1	1
					10.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					11.Total score	27	27	18	13	7	7	7
	526	Reboxetine	Female	2	01.APPARENT SADNESS	4	4	3	3	3	2	1
					02.REPORTED SADNESS	4	4	3	3	3	2	1
					03.INNER TENSION	2	2	2	2	2	2	0
					04.REDUCED SLEEP	3	3	3	3	3	2	0
					05.REDUCED APPETITE	1	1	1	1	1	0	0
					06.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1
					07.LASSITUDE	3	3	3	3	3	2	0
					08.INABILITY TO FEEL	4	4	3	3	3	2	1
					09.PESSIMISTIC THOUGHTS	3	3	3	3	3	1	1
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	26	26	23	23	23	14	5
	527	Imipramine	Female	2	01.APPARENT SADNESS	4	4	4	2	2	2	2
					02.REPORTED SADNESS	3	3	3	2	2	2	2
					03.INNER TENSION	3	3	3	2	2	2	2
					04.REDUCED SLEEP	2	2	2	1	1	1	1
					05.REDUCED APPETITE	1	1	1	1	1	1	1
					06.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
					07.LASSITUDE	2	2	2	1	1	1	1
					08.INABILITY TO FEEL	3	3	3	2	2	2	2
					09.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1

1360

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/03	527	Imipramine	Female	2	10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	22	22	22	13	13	13	13
	528	Imipramine	Female	2	01.APPARENT SADNESS	3	3	3	3	3	3	
					02.REPORTED SADNESS	4	4	4	4	4	2	
					03.INNER TENSION	3	3	3	3	3	2	
					04.REDUCED SLEEP	2	2	2	2	2	1	
					05.REDUCED APPETITE	1	1	1	1	1	1	
					06.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	
					07.LASSITUDE	2	2	2	2	2	2	
					08.INABILITY TO FEEL	2	2	2	2	2	2	
					09.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	
					11.Total score	21	21	21	21	21	17	
7/04	193	Placebo	Female	2	01.APPARENT SADNESS	5	4	4	3	2	1	1
					02.REPORTED SADNESS	5	5	5	4	2	1	0
					03.INNER TENSION	4	4	3	2	1	2	0
					04.REDUCED SLEEP	5	4	3	2	2	1	0
					05.REDUCED APPETITE	4	4	4	3	2	0	0
					06.CONCENTRATIONS DIFFICULTIES	4	3	2	2	2	1	0
					07.LASSITUDE	4	4	3	2	1	1	1
					08.INABILITY TO FEEL	4	4	4	2	1	1	1
					09.PESSIMISTIC THOUGHTS	4	4	4	3	2	0	0
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	39	36	32	23	15	8	3
	194	Reboxetine	Male	2	01.APPARENT SADNESS	5	5	4	3	2	1	1
					02.REPORTED SADNESS	5	5	4	3	2	1	1
					03.INNER TENSION	3	3	3	2	1	1	1
					04.REDUCED SLEEP	5	5	4	3	2	1	0
					05.REDUCED APPETITE	4	4	3	3	1	1	0
					06.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	1
					07.LASSITUDE	4	4	4	3	2	0	1
					08.INABILITY TO FEEL	4	4	4	3	2	1	0
					09.PESSIMISTIC THOUGHTS	4	4	3	2	1	1	0
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	36	36	31	24	14	8	5
	195	Placebo	Female	2	01.APPARENT SADNESS	6	6	6	4	2	1	1
					02.REPORTED SADNESS	5	5	5	3	1	0	0
					03.INNER TENSION	6	6	6	4	2	1	0
					04.REDUCED SLEEP	4	4	4	3	1	1	1
					05.REDUCED APPETITE	4	4	4	3	1	0	0
					06.CONCENTRATIONS DIFFICULTIES	4	4	4	3	2	1	1
					07.LASSITUDE	4	4	4	3	2	1	0
					08.INABILITY TO FEEL	4	4	4	3	2	2	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/04	195	Placebo	Female	2	09.PESSIMISTIC THOUGHTS	4	4	4	3	1	1	1
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	41	41	41	29	14	8	5
	196	Reboxetine	Female	2	01.APPARENT SADNESS	4	4	4	3	2	1	0
					02.REPORTED SADNESS	4	4	4	3	3	2	1
					03.INNER TENSION	4	4	4	3	3	2	1
					04.REDUCED SLEEP	4	4	4	3	2	2	1
					05.REDUCED APPETITE	4	4	4	4	3	2	1
					06.CONCENTRATIONS DIFFICULTIES	4	4	4	3	2	1	1
					07.LASSITUDE	3	3	3	3	3	2	1
					08.INABILITY TO FEEL	4	4	4	2	2	1	0
					09.PESSIMISTIC THOUGHTS	4	4	4	3	2	2	1
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	35	35	35	27	22	15	7
	197	Imipramine	Male	2	01.APPARENT SADNESS	4	4	4	4	4	4	4
					02.REPORTED SADNESS	4	4	4	4	4	4	4
					03.INNER TENSION	4	4	4	4	4	4	4
					04.REDUCED SLEEP	4	4	4	4	4	4	4
					05.REDUCED APPETITE	4	4	4	4	4	4	4
					06.CONCENTRATIONS DIFFICULTIES	5	5	5	5	5	5	5
					07.LASSITUDE	4	4	4	4	4	4	4
					08.INABILITY TO FEEL	4	4	4	4	4	4	4
					09.PESSIMISTIC THOUGHTS	4	4	4	4	4	4	4
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	37	37	37	37	37	37	37
	198	Imipramine	Female	2	01.APPARENT SADNESS	4	4	4	4	2	4	2
					02.REPORTED SADNESS	4	4	4	4	4	2	2
					03.INNER TENSION	6	6	4	4	2	4	2
					04.REDUCED SLEEP	4	4	2	2	2	2	2
					05.REDUCED APPETITE	4	4	4	2	2	2	2
					06.CONCENTRATIONS DIFFICULTIES	4	4	4	2	2	2	2
					07.LASSITUDE	4	4	4	2	2	2	2
					08.INABILITY TO FEEL	2	2	2	2	2	2	2
					09.PESSIMISTIC THOUGHTS	4	4	4	4	2	2	2
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	36	36	32	26	20	22	18
	199	Imipramine	Male	2	01.APPARENT SADNESS	4	4	4	4	3	3	3
					02.REPORTED SADNESS	4	4	4	4	3	2	2
					03.INNER TENSION	3	4	4	4	2	2	2
					04.REDUCED SLEEP	4	4	4	4	2	2	2
					05.REDUCED APPETITE	4	4	4	4	2	1	1
					06.CONCENTRATIONS DIFFICULTIES	5	5	5	4	4	4	4
					07.LASSITUDE	4	4	4	4	2	2	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/04	199	Imipramine	Male	2	08.INABILITY TO FEEL	4	4	4	3	3	2	1
					09.PESSIMISTIC THOUGHTS	4	4	4	4	2	2	2
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	36	37	37	35	23	20	18
	200	Placebo	Male	2	01.APPARENT SADNESS	4	4	3	3	3	3	2
					02.REPORTED SADNESS	3	3	3	3	2	2	2
					03.INNER TENSION	3	4	4	4	2	2	2
					04.REDUCED SLEEP	4	4	4	4	2	2	1
					05.REDUCED APPETITE	4	4	4	3	2	2	2
					06.CONCENTRATIONS DIFFICULTIES	4	5	4	5	4	4	4
					07.LASSITUDE	4	4	4	4	2	2	2
					08.INABILITY TO FEEL	4	4	4	3	2	2	2
					09.PESSIMISTIC THOUGHTS	4	4	4	4	2	2	2
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	34	36	34	33	21	21	19
	201	Reboxetine	Female	2	01.APPARENT SADNESS	4	4	3	1	2	1	1
					02.REPORTED SADNESS	3	3	3	2	2	1	1
					03.INNER TENSION	3	4	3	2	2	1	1
					04.REDUCED SLEEP	4	4	4	2	2	1	1
					05.REDUCED APPETITE	4	4	4	2	2	1	1
					06.CONCENTRATIONS DIFFICULTIES	4	4	4	3	3	4	4
					07.LASSITUDE	3	4	3	2	2	1	1
					08.INABILITY TO FEEL	4	4	4	1	2	1	1
					09.PESSIMISTIC THOUGHTS	4	4	4	2	2	1	1
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	33	35	32	17	19	12	12
	202	Reboxetine	Male	2	01.APPARENT SADNESS	4	4	3	3	3	2	2
					02.REPORTED SADNESS	4	4	4	4	3	2	2
					03.INNER TENSION	5	5	4	4	3	2	2
					04.REDUCED SLEEP	5	4	4	4	4	3	2
					05.REDUCED APPETITE	2	2	2	2	2	2	2
					06.CONCENTRATIONS DIFFICULTIES	6	6	6	6	5	5	5
					07.LASSITUDE	4	4	4	4	4	4	4
					08.INABILITY TO FEEL	5	5	5	4	4	3	2
					09.PESSIMISTIC THOUGHTS	3	3	3	3	3	2	2
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	38	37	35	34	31	25	23
	203	Placebo	Female	2	01.APPARENT SADNESS	5	5	5	4	3	3	3
					02.REPORTED SADNESS	5	5	5	5	3	3	3
					03.INNER TENSION	5	5	5	5	4	3	2
					04.REDUCED SLEEP	5	5	5	4	4	3	3
					05.REDUCED APPETITE	5	5	5	5	3	3	3
					06.CONCENTRATIONS DIFFICULTIES	5	5	5	5	4	3	4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/04	203	Placebo	Female	2	07.LASSITUDE	4	4	4	4	3	3	3
					08.INABILITY TO FEEL	4	4	4	3	3	3	2
					09.PESSIMISTIC THOUGHTS	4	4	4	4	4	3	3
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	42	42	42	39	31	27	26
	204	Imipramine	Female	2	01.APPARENT SADNESS	5	5	5	4	4	3	3
					02.REPORTED SADNESS	4	4	4	4	3	3	3
					03.INNER TENSION	5	5	4	3	2	2	2
					04.REDUCED SLEEP	5	5	2	1	1	1	1
					05.REDUCED APPETITE	2	2	1	1	1	0	0
					06.CONCENTRATIONS DIFFICULTIES	5	5	5	5	5	5	4
					07.LASSITUDE	5	5	4	3	3	4	3
					08.INABILITY TO FEEL	4	4	3	2	3	2	2
					09.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	37	37	30	24	23	21	19
7/05	205	Placebo	Male	2	01.APPARENT SADNESS	4	4	4	4	4	4	4
					02.REPORTED SADNESS	3	3	3	3	3	3	3
					03.INNER TENSION	4	3	3	3	3	3	3
					04.REDUCED SLEEP	4	4	4	4	4	4	4
					05.REDUCED APPETITE	2	3	3	3	3	3	3
					06.CONCENTRATIONS DIFFICULTIES	3	3	2	2	2	2	2
					07.LASSITUDE	3	3	3	3	3	3	3
					08.INABILITY TO FEEL	3	4	4	4	4	4	4
					09.PESSIMISTIC THOUGHTS	4	4	4	4	4	4	4
					10.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
					11.Total score	31	32	31	31	31	31	31
	206	Imipramine	Female	2	01.APPARENT SADNESS	4	3	3	2	2	2	2
					02.REPORTED SADNESS	3	3	3	2	2	1	1
					03.INNER TENSION	3	3	3	2	2	1	1
					04.REDUCED SLEEP	4	3	2	2	2	2	2
					05.REDUCED APPETITE	3	2	2	1	1	1	1
					06.CONCENTRATIONS DIFFICULTIES	3	3	2	2	2	2	2
					07.LASSITUDE	4	3	2	2	2	2	2
					08.INABILITY TO FEEL	3	3	3	2	2	2	2
					09.PESSIMISTIC THOUGHTS	2	2	2	2	2	1	1
					10.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
					11.Total score	30	26	23	17	17	14	14
	207	Imipramine	Female	2	01.APPARENT SADNESS	3	3	3	2	2	2	2
					02.REPORTED SADNESS	3	3	2	2	2	2	2
					03.INNER TENSION	3	3	3	3	2	2	2
					04.REDUCED SLEEP	3	2	2	2	1	1	1
					05.REDUCED APPETITE	2	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/05	207	Imipramine	Female	2	06.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	1
					07.LASSITUDE	3	2	2	2	2	2	2
					08.INABILITY TO FEEL	2	2	2	2	1	1	1
					09.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	22	19	18	17	13	13	13
	208	Reboxetine	Male	2	01.APPARENT SADNESS	3	3	3	2	2	1	1
					02.REPORTED SADNESS	2	2	2	2	2	1	1
					03.INNER TENSION	3	2	2	1	1	1	1
					04.REDUCED SLEEP	3	2	2	1	1	1	1
					05.REDUCED APPETITE	2	1	1	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	3	2	2	1	1	1	1
					07.LASSITUDE	2	2	2	2	2	1	1
					08.INABILITY TO FEEL	2	2	2	1	1	1	1
					09.PESSIMISTIC THOUGHTS	2	2	1	1	1	0	0
					10.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
					11.Total score	23	18	17	11	11	7	7
	209	Placebo	Male	2	01.APPARENT SADNESS	3	3	3	3	3	3	3
					02.REPORTED SADNESS	3	3	3	3	3	3	3
					03.INNER TENSION	3	3	3	3	3	3	3
					04.REDUCED SLEEP	3	3	3	3	3	3	3
					05.REDUCED APPETITE	2	2	2	2	2	2	2
					06.CONCENTRATIONS DIFFICULTIES	3	3	3	3	3	3	3
					07.LASSITUDE	2	2	2	2	2	2	2
					08.INABILITY TO FEEL	3	3	3	3	3	3	3
					09.PESSIMISTIC THOUGHTS	3	3	3	3	3	3	3
					10.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
					11.Total score	26	26	26	26	26	26	26
	210	Reboxetine	Male	2	01.APPARENT SADNESS	3	2	2	2	1	1	1
					02.REPORTED SADNESS	3	2	1	1	1	1	1
					03.INNER TENSION	3	3	2	1	1	1	1
					04.REDUCED SLEEP	3	2	1	1	1	1	1
					05.REDUCED APPETITE	2	1	1	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	3	3	2	2	2	2	1
					07.LASSITUDE	2	2	2	1	1	1	1
					08.INABILITY TO FEEL	3	2	1	1	1	1	1
					09.PESSIMISTIC THOUGHTS	2	2	1	0	0	0	0
					10.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					11.Total score	25	20	13	9	8	8	7
	541	Reboxetine	Female	2	01.APPARENT SADNESS	4	3	2	1	1	1	1
					02.REPORTED SADNESS	3	3	2	1	1	1	1
					03.INNER TENSION	3	2	2	0	0	0	0
					04.REDUCED SLEEP	4	3	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/05	541	Reboxetine	Female	2	05.REDUCED APPETITE	2	2	0	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	4	3	2	1	1	1	1
					07.LASSITUDE	4	3	2	2	1	1	1
					08.INABILITY TO FEEL	4	3	2	1	1	1	1
					09.PESSIMISTIC THOUGHTS	3	2	1	1	0	0	0
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	31	24	14	7	5	5	5
	542	Imipramine	Male	2	01.APPARENT SADNESS	4	4	4	3	3	3	2
					02.REPORTED SADNESS	4	4	3	3	3	3	2
					03.INNER TENSION	4	4	3	3	2	2	1
					04.REDUCED SLEEP	4	4	3	2	2	2	2
					05.REDUCED APPETITE	1	1	0	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	4	4	4	3	2	2	2
					07.LASSITUDE	4	4	4	3	2	2	2
					08.INABILITY TO FEEL	4	4	3	3	2	2	2
					09.PESSIMISTIC THOUGHTS	4	4	3	2	1	1	1
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	33	33	27	22	17	17	14
	543	Imipramine	Male	2	01.APPARENT SADNESS	4	4	2	2	2	2	1
					02.REPORTED SADNESS	4	3	2	2	2	1	1
					03.INNER TENSION	3	3	3	2	2	2	2
					04.REDUCED SLEEP	5	4	3	2	1	1	1
					05.REDUCED APPETITE	0	0	0	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	3	3	3	2	2	1	1
					07.LASSITUDE	4	3	3	3	2	1	1
					08.INABILITY TO FEEL	3	3	2	2	1	1	1
					09.PESSIMISTIC THOUGHTS	4	3	2	2	1	1	0
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	30	26	20	17	13	10	8
	544	Placebo	Female	2	01.APPARENT SADNESS	4	4	4	4	4	4	4
					02.REPORTED SADNESS	4	4	4	4	4	4	4
					03.INNER TENSION	3	3	3	3	3	3	3
					04.REDUCED SLEEP	4	4	4	4	4	4	4
					05.REDUCED APPETITE	4	3	3	2	3	3	3
					06.CONCENTRATIONS DIFFICULTIES	3	3	3	3	3	3	3
					07.LASSITUDE	4	4	4	4	4	4	4
					08.INABILITY TO FEEL	4	4	4	4	4	4	4
					09.PESSIMISTIC THOUGHTS	2	3	3	3	3	3	3
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	32	32	32	31	32	32	32
	545	Placebo	Male	2	01.APPARENT SADNESS	4	4	4	4	4	4	4
					02.REPORTED SADNESS	4	4	4	4	4	4	4
					03.INNER TENSION	3	3	4	3	3	3	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/05	545	Placebo	Male	2	04.REDUCED SLEEP	5	5	4	5	5	5	5
					05.REDUCED APPETITE	0	0	0	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4
					07.LASSITUDE	5	5	5	5	5	5	4
					08.INABILITY TO FEEL	4	4	4	4	4	4	4
					09.PESSIMISTIC THOUGHTS	3	3	3	3	3	3	3
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	32	32	32	32	32	32	31
	546	Reboxetine	Female	2	01.APPARENT SADNESS	4	4	3	2	1	1	1
					02.REPORTED SADNESS	4	3	3	1	1	1	1
					03.INNER TENSION	3	3	2	2	1	1	0
					04.REDUCED SLEEP	3	3	2	2	1	1	1
					05.REDUCED APPETITE	0	0	0	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	4	3	2	1	1	1	1
					07.LASSITUDE	3	3	2	2	2	2	1
					08.INABILITY TO FEEL	3	3	2	2	2	2	1
					09.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	0
					10.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					11.Total score	26	24	17	13	10	10	6
7/07	529	Placebo	Female	2	01.APPARENT SADNESS	4	4	4	3	4	4	3
					02.REPORTED SADNESS	3	3	3	3	2	2	2
					03.INNER TENSION	3	2	2	2	2	2	2
					04.REDUCED SLEEP	4	4	3	3	3	2	2
					05.REDUCED APPETITE	2	2	2	2	1	1	1
					06.CONCENTRATIONS DIFFICULTIES	3	3	2	2	2	2	2
					07.LASSITUDE	3	3	2	2	1	1	2
					08.INABILITY TO FEEL	2	2	3	2	2	2	2
					09.PESSIMISTIC THOUGHTS	3	3	2	2	2	2	2
					10.SUICIDAL THOUGHTS	2	2	2	1	1	1	1
					11.Total score	29	28	25	22	20	19	19
	530	Imipramine	Female	2	01.APPARENT SADNESS	4	4	3				
					02.REPORTED SADNESS	3	3	3				
					03.INNER TENSION	3	3	3				
					04.REDUCED SLEEP	5	4	3				
					05.REDUCED APPETITE	2	2	1				
					06.CONCENTRATIONS DIFFICULTIES	3	3	2				
					07.LASSITUDE	2	2	2				
					08.INABILITY TO FEEL	2	2	2				
					09.PESSIMISTIC THOUGHTS	3	3	2				
					10.SUICIDAL THOUGHTS	2	2	1				
					11.Total score	29	28	22				
	531	Reboxetine	Female	2	01.APPARENT SADNESS	4	4	4	2	2	2	2
					02.REPORTED SADNESS	4	4	3	3	3	3	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Contre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/07	531	Reboxetine	Female	2	03.INNER TENSION	3	3	2	2	1	1	2
					04.REDUCED SLEEP	4	3	2	2	2	1	1
					05.REDUCED APPETITE	1	2	0	1	1	1	0
					06.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
					07.LASSITUDE	2	2	2	2	2	2	1
					08.INABILITY TO FEEL	3	2	2	3	3	2	2
					09.PESSIMISTIC THOUGHTS	4	3	3	3	3	3	2
					10.SUICIDAL THOUGHTS	2	2	2	0	0	0	0
					11.Total score	29	27	22	20	19	17	14
	532	Imipramine	Female	2	01.APPARENT SADNESS	4	3	4	4	3	3	2
					02.REPORTED SADNESS	3	3	3	3	3	3	2
					03.INNER TENSION	3	3	3	3	3	2	1
					04.REDUCED SLEEP	4	4	2	2	3	4	2
					05.REDUCED APPETITE	4	4	2	2	1	2	1
					06.CONCENTRATIONS DIFFICULTIES	4	4	4	3	3	3	2
					07.LASSITUDE	3	3	3	3	3	3	2
					08.INABILITY TO FEEL	3	3	3	3	3	3	2
					09.PESSIMISTIC THOUGHTS	3	3	3	3	2	2	2
					10.SUICIDAL THOUGHTS	1	1	2	2	0	2	0
					11.Total score	32	31	29	28	24	27	16
	533	Reboxetine	Male	2	01.APPARENT SADNESS	4	4	4	4	3	3	3
					02.REPORTED SADNESS	3	3	4	3	3	3	2
					03.INNER TENSION	3	4	3	3	3	2	2
					04.REDUCED SLEEP	4	4	4	3	3	3	3
					05.REDUCED APPETITE	2	4	4	2	2	1	0
					06.CONCENTRATIONS DIFFICULTIES	4	3	4	3	3	2	2
					07.LASSITUDE	2	3	2	3	2	2	3
					08.INABILITY TO FEEL	3	3	3	3	2	2	2
					09.PESSIMISTIC THOUGHTS	3	3	3	3	3	2	2
					10.SUICIDAL THOUGHTS	4	2	3	3	1	2	1
					11.Total score	32	33	34	30	25	22	20
	534	Placebo	Female	2	01.APPARENT SADNESS	4	4	4	3	3	3	2
					02.REPORTED SADNESS	3	3	3	3	3	2	2
					03.INNER TENSION	3	3	3	3	2	2	1
					04.REDUCED SLEEP	3	3	3	3	3	2	2
					05.REDUCED APPETITE	3	3	2	2	2	0	1
					06.CONCENTRATIONS DIFFICULTIES	3	3	3	3	2	2	2
					07.LASSITUDE	3	2	2	2	3	2	2
					08.INABILITY TO FEEL	3	3	3	3	2	2	2
					09.PESSIMISTIC THOUGHTS	3	3	3	2	2	1	2
					10.SUICIDAL THOUGHTS	2	2	1	1	2	0	0
					11.Total score	30	29	27	25	24	16	16
8	211	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	3				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	211	Reboxetine	Female	1	02.INNER TENSION	2	2	2				
					03.APPARENT SADNESS	2	2	2				
					04.SUICIDAL THOUGHTS	1	1	2				
					05.INERTIA	2	2	3				
					06.INABILITY TO FEEL	2	2	2				
					07.PESSIMISTIC THOUGHTS	2	2	2				
					08.CONCENTRATIONS DIFFICULTIES	1	1	1				
					09.REDUCED SLEEP	1	1	1				
					10.REDUCED APPETITE	1	1	1				
					11.Total score	16	16	19				
	212	Placebo	Female	1	01.REPORTED SADNESS	2	2	2	2	3	3	3
					02.INNER TENSION	2	2	2	2	2	2	2
					03.APPARENT SADNESS	2	2	2	2	2	2	2
					04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
					05.INERTIA	2	2	2	2	2	2	2
					06.INABILITY TO FEEL	2	2	2	2	2	2	2
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
					09.REDUCED SLEEP	1	1	1	1	1	1	1
					10.REDUCED APPETITE	1	1	1	1	1	1	1
					11.Total score	15	15	15	15	16	16	16
	213	Imipramine	Male	1	01.REPORTED SADNESS	2						
					02.INNER TENSION	2						
					03.APPARENT SADNESS	2						
					04.SUICIDAL THOUGHTS	1						
					05.INERTIA	1						
					06.INABILITY TO FEEL	2						
					07.PESSIMISTIC THOUGHTS	2						
					08.CONCENTRATIONS DIFFICULTIES	1						
					09.REDUCED SLEEP	1						
					10.REDUCED APPETITE	1						
					11.Total score	15						
	214	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	2	2	2	2	2
					02.INNER TENSION	1	1	1	1	1	1	1
					03.APPARENT SADNESS	1	1	1	1	1	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	2	2	2
					06.INABILITY TO FEEL	1	1	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
					09.REDUCED SLEEP	2	2	2	2	2	2	2
					10.REDUCED APPETITE	1	1	1	1	1	1	1
					11.Total score	13	13	13	12	12	12	12

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	215	Placebo	Female	1	01.REPORTED SADNESS	2	1	2	1	1	0	0
					02.INNER TENSION	1	1	1	1	0	0	0
					03.APPARENT SADNESS	1	1	2	1	1	0	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	1	1	1	1
					06.INABILITY TO FEEL	1	1	2	1	0	0	0
					07.PESSIMISTIC THOUGHTS	0	0	1	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	0	0	0
					09.REDUCED SLEEP	1	1	1	0	0	0	0
					10.REDUCED APPETITE	2	1	1	0	0	0	0
					11.Total score	11	9	13	6	3	1	1
	216	Imipramine	Male	1	01.REPORTED SADNESS	2	2	2	2	2	2	2
					02.INNER TENSION	1	1	1	1	1	1	1
					03.APPARENT SADNESS	2	2	2	1	1	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	2	2	2
					06.INABILITY TO FEEL	2	2	2	2	2	2	2
					07.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
					09.REDUCED SLEEP	1	1	1	1	0	0	0
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	13	13	13	12	10	10	10
	217	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	1	1	1	1	1
					02.INNER TENSION	1	1	1	1	1	1	1
					03.APPARENT SADNESS	2	2	1	1	1	0	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	1	1	1	1	1
					06.INABILITY TO FEEL	2	1	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	1	1	1	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	0	0	0
					09.REDUCED SLEEP	1	0	0	0	0	0	0
					10.REDUCED APPETITE	1	0	0	0	0	0	0
					11.Total score	13	10	7	6	5	4	4
	218	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	2	2	2	1	1
					02.INNER TENSION	2	2	2	1	1	1	1
					03.APPARENT SADNESS	2	2	2	2	2	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	1	1	1
					06.INABILITY TO FEEL	2	2	2	2	1	1	1
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
					09.REDUCED SLEEP	1	1	1	1	0	0	0
					10.REDUCED APPETITE	1	1	1	1	0	0	0
					11.Total score	16	16	16	13	9	7	7

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	219	Placebo	Female	1	01.REPORTED SADNESS	1	1	1	1			
					02.INNER TENSION	1	1	1	1			
					03.APPARENT SADNESS	1	1	1	1			
					04.SUICIDAL THOUGHTS	0	0	0	0			
					05.INERTIA	2	2	2	1			
					06.INABILITY TO FEEL	2	2	1	1			
					07.PESSIMISTIC THOUGHTS	1	1	1	1			
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1			
					09.REDUCED SLEEP	1	1	0	0			
					10.REDUCED APPETITE	1	1	1	0			
					11.Total score	11	11	9	7			
	220	Imipramine	Female	1	01.REPORTED SADNESS	2	2	2	1	1	1	1
					02.INNER TENSION	2	2	2	1	1	1	1
					03.APPARENT SADNESS	2	2	2	1	1	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	2	2	1
					06.INABILITY TO FEEL	2	2	2	2	2	2	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
					09.REDUCED SLEEP	1	1	1	0	0	0	0
					10.REDUCED APPETITE	1	1	1	1	1	1	0
					11.Total score	14	14	14	10	10	10	7
	221	Imipramine	Male	1	01.REPORTED SADNESS	2	2	2	1	1	1	1
					02.INNER TENSION	2	2	1	1	1	1	0
					03.APPARENT SADNESS	2	2	2	1	1	1	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	1	1	1
					06.INABILITY TO FEEL	2	2	2	2	1	1	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
					09.REDUCED SLEEP	1	1	1	1	0	0	0
					10.REDUCED APPETITE	1	1	0	0	0	0	0
					11.Total score	14	14	12	10	7	7	5
	222	Placebo	Female	1	01.REPORTED SADNESS	1	0	0	0	0	0	0
					02.INNER TENSION	1	1	0	0	0	0	0
					03.APPARENT SADNESS	1	0	0	0	0	0	0
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	1	1	1	1	0	0	0
					06.INABILITY TO FEEL	1	1	1	1	0	0	0
					07.PESSIMISTIC THOUGHTS	1	1	0	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	0	0	0	0
					09.REDUCED SLEEP	1	0	0	0	0	1	1
					10.REDUCED APPETITE	1	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	222	Placebo	Female	1	11.Total score	9	5	3	2	0	1	1
	223	Imipramine	Female	1	01.REPORTED SADNESS	2	2	1	1	1	1	1
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	2	2	1	1	1	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	1	1	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	0	0	0
					09.REDUCED SLEEP	1	1	1	1	0	0	0
					10.REDUCED APPETITE	1	1	1	0	0	0	0
					11.Total score	14	14	11	9	6	5	5
	224	Placebo	Female	1	01.REPORTED SADNESS	2	2	2	2	2	1	1
					02.INNER TENSION	1	1	1	1	1	1	1
					03.APPARENT SADNESS	2	2	1	1	1	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	2	1	1
					06.INABILITY TO FEEL	2	2	2	2	2	2	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	0	0	0	0
					09.REDUCED SLEEP	1	1	1	1	1	1	1
					10.REDUCED APPETITE	1	1	0	0	0	0	0
					11.Total score	13	13	11	10	10	8	7
	225	Placebo	Male	1	01.REPORTED SADNESS	2	2	2	2	2	2	1
					02.INNER TENSION	2	2	2	2	1	1	1
					03.APPARENT SADNESS	1	2	2	2	2	2	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	2	2	1
					06.INABILITY TO FEEL	2	2	2	2	2	2	2
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	0	0	0	0	0	0	0
					09.REDUCED SLEEP	1	2	2	2	1	1	1
					10.REDUCED APPETITE	1	1	1	1	1	0	0
					11.Total score	12	14	14	14	12	11	8
	226	Reboxetine	Male	1	01.REPORTED SADNESS	2	2	2	2	2	2	2
					02.INNER TENSION	2	2	2	2	2	2	2
					03.APPARENT SADNESS	2	2	2	2	2	2	2
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	2	2	2
					06.INABILITY TO FEEL	2	2	2	2	2	2	2
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
					09.REDUCED SLEEP	2	2	2	2	2	2	2

1379

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	226	Reboxetine	Male	1	10.REDUCED APPETITE	1	1	1	1	1	1	1
					11.Total score	15	15	15	15	15	15	15
	227	Reboxetine	Male	1	01.REPORTED SADNESS	2	2	2	2	2	2	2
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	2	2	2	2	2	2	2
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	2	2	2
					06.INABILITY TO FEEL	2	2	2	2	2	2	2
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
					09.REDUCED SLEEP	1	1	1	1	1	1	1
					10.REDUCED APPETITE	1	1	1	1	1	1	1
					11.Total score	14	14	13	13	13	13	13
	228	Imipramine	Male	1	01.REPORTED SADNESS	2	2					
					02.INNER TENSION	2	2					
					03.APPARENT SADNESS	2	2					
					04.SUICIDAL THOUGHTS	0	0					
					05.INERTIA	2	2					
					06.INABILITY TO FEEL	2	2					
					07.PESSIMISTIC THOUGHTS	1	1					
					08.CONCENTRATIONS DIFFICULTIES	1	1					
					09.REDUCED SLEEP	2	2					
					10.REDUCED APPETITE	1	1					
					11.Total score	15	15					
	229	Imipramine	Female	1	01.REPORTED SADNESS	2	2	2	2	2	2	1
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	2	2	2	1	1	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	2	2	1
					06.INABILITY TO FEEL	2	2	2	2	2	2	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
					09.REDUCED SLEEP	2	2	2	2	1	1	1
					10.REDUCED APPETITE	1	1	1	1	1	1	0
					11.Total score	15	15	14	13	12	12	8
	230	Reboxetine	Female	1	01.REPORTED SADNESS	3	3	3	2	2	2	1
					02.INNER TENSION	2	2	2	2	1	1	1
					03.APPARENT SADNESS	2	2	2	2	2	2	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	2	2	2
					06.INABILITY TO FEEL	2	2	2	2	2	2	2
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale Type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	230	Reboxetine	Female	1	09.REDUCED SLEEP	2	2	2	2	1	1	1
					10.REDUCED APPETITE	1	1	1	1	1	1	1
					11.Total score	16	16	16	15	13	13	11
	231	Imipramine	Male	1	01.REPORTED SADNESS	2	2	1	1	1	1	1
					02.INNER TENSION	1	1	1	1	1	1	1
					03.APPARENT SADNESS	2	2	1	1	1	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	1	1	1
					06.INABILITY TO FEEL	2	2	2	2	1	1	1
					07.PESSIMISTIC THOUGHTS	1	1	1	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
					09.REDUCED SLEEP	2	2	1	1	1	1	0
					10.REDUCED APPETITE	1	1	1	1	1	0	0
					11.Total score	14	14	11	10	8	7	6
	232	Reboxetine	Male	1	01.REPORTED SADNESS	2	2	2	2	2	1	1
					02.INNER TENSION	1	1	1	1	1	1	1
					03.APPARENT SADNESS	2	2	2	2	2	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	2	1	1
					06.INABILITY TO FEEL	2	2	2	2	2	1	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	0
					09.REDUCED SLEEP	1	1	1	1	1	1	1
					10.REDUCED APPETITE	1	1	1	1	0	0	0
					11.Total score	13	13	13	13	12	7	6
	233	Placebo	Female	1	01.REPORTED SADNESS	2	2	2	2	1	1	1
					02.INNER TENSION	2	2	2	2	1	1	1
					03.APPARENT SADNESS	2	2	2	2	1	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	2	2	1
					06.INABILITY TO FEEL	2	2	2	2	2	2	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	0
					09.REDUCED SLEEP	2	2	2	2	1	1	1
					10.REDUCED APPETITE	1	1	1	1	1	0	0
					11.Total score	15	15	15	15	11	10	7
	234	Placebo	Female	1	01.REPORTED SADNESS	2	2	2	2	2	2	2
					02.INNER TENSION	2	2	2	1	1	1	1
					03.APPARENT SADNESS	2	2	2	2	2	1	1
					04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
					05.INERTIA	2	2	2	2	2	2	2
					06.INABILITY TO FEEL	2	2	2	2	2	2	2
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale Type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	234	Placebo	Female	1	08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
					09.REDUCED SLEEP	1	1	1	1	1	1	1
					10.REDUCED APPETITE	1	1	1	1	1	1	1
					11.Total score	14	14	14	13	13	12	12
8/A	235	Placebo	Female	1	01.REPORTED SADNESS	3	2	2	2	1	1	1
					02.INNER TENSION	2	2	2	1	1	1	1
					03.APPARENT SADNESS	2	2	2	2	2	1	1
					04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
					05.INERTIA	3	2	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	2	1	1
					09.REDUCED SLEEP	3	2	1	1	1	1	1
					10.REDUCED APPETITE	2	2	2	1	1	1	1
					11.Total score	23	19	16	13	11	9	9
	236	Placebo	Female	1	01.REPORTED SADNESS	3	2	2	1	1	1	1
					02.INNER TENSION	2	1	1	1	1	1	1
					03.APPARENT SADNESS	3	2	1	1	1	0	0
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	2	1	1	1	1	1	1
					06.INABILITY TO FEEL	2	1	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	3	2	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
					09.REDUCED SLEEP	3	3	2	1	1	1	1
					10.REDUCED APPETITE	2	2	2	1	1	1	1
					11.Total score	23	17	12	9	9	8	8
	237	Reboxetine	Female	1	01.REPORTED SADNESS	3	2	1	1	0	0	0
					02.INNER TENSION	2	2	2	1	1	1	0
					03.APPARENT SADNESS	2	2	2	1	1	1	1
					04.SUICIDAL THOUGHTS	1	1	1	1	1	1	0
					05.INERTIA	2	2	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	3	2	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	0
					09.REDUCED SLEEP	3	2	2	1	2	1	1
					10.REDUCED APPETITE	3	2	1	1	1	1	1
					11.Total score	23	19	14	10	10	9	6
	238	Reboxetine	Female	1	01.REPORTED SADNESS	3	2	1	0	0	0	0
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	2	2	2	1	0	0	0
					04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
					05.INERTIA	3	2	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8/A	238	Reboxetine	Female	1	07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	0
					08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	1
					09.REDUCED SLEEP	2	2	1	1	1	1	1
					10.REDUCED APPETITE	2	2	1	1	1	1	1
					11.Total score	21	18	11	9	7	7	6
	239	Imipramine	Female	1	01.REPORTED SADNESS	3	2	2	1	1	1	1
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	2	2	1	1	0	0	1
					04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
					05.INERTIA	2	2	2	2	1	1	0
					06.INABILITY TO FEEL	2	1	1	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	1
					09.REDUCED SLEEP	2	2	1	0	1	0	1
					10.REDUCED APPETITE	3	2	2	2	1	1	0
					11.Total score	21	17	14	11	8	7	7
	240	Imipramine	Female	1	01.REPORTED SADNESS	3	2	2	1	1	1	1
					02.INNER TENSION	2	2	2	1	2	2	1
					03.APPARENT SADNESS	3	3	2	2	2	2	1
					04.SUICIDAL THOUGHTS	1	1	0	1	0	0	0
					05.INERTIA	2	2	2	2	2	2	1
					06.INABILITY TO FEEL	2	2	2	2	2	2	2
					07.PESSIMISTIC THOUGHTS	3	2	2	2	2	2	1
					08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	2	2	2
					09.REDUCED SLEEP	3	3	3	3	2	2	2
					10.REDUCED APPETITE	2	2	1	1	1	1	1
					11.Total score	24	21	18	17	16	16	12
	553	Placebo	Female	1	01.REPORTED SADNESS	2	2	1	1	1	1	1
					02.INNER TENSION	2	2	2	2	1	1	1
					03.APPARENT SADNESS	2	1	1	1	1	1	1
					04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
					05.INERTIA	2	2	2	1	1	1	1
					06.INABILITY TO FEEL	3	2	2	2	2	1	1
					07.PESSIMISTIC THOUGHTS	3	2	2	2	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	2
					09.REDUCED SLEEP	3	3	3	2	2	2	2
					10.REDUCED APPETITE	2	2	2	2	1	1	1
					11.Total score	22	19	18	15	12	11	12
	554	Reboxetine	Male	1	01.REPORTED SADNESS	3	2	2	1	0	0	0
					02.INNER TENSION	2	2	2	1	1	1	0
					03.APPARENT SADNESS	3	2	2	1	0	0	0
					04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
					05.INERTIA	2	2	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8/A	554	Reboxetine	Male	1	06.INABILITY TO FEEL	3	3	2	2	2	1	1
					07.PESSIMISTIC THOUGHTS	3	2	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	3	3	2	1	1	0	0
					09.REDUCED SLEEP	3	3	2	2	1	1	1
					10.REDUCED APPETITE	2	2	1	1	1	1	1
					11.Total score	25	22	17	12	8	6	5
	555	Reboxetine	Female	1	01.REPORTED SADNESS	2	1	1	1	1	1	1
					02.INNER TENSION	2	1	1	1	1	1	1
					03.APPARENT SADNESS	3	2	1	1	1	1	1
					04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
					05.INERTIA	2	2	2	2	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	1	1	1
					07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
					09.REDUCED SLEEP	3	3	2	2	1	2	1
					10.REDUCED APPETITE	2	2	1	1	1	1	1
					11.Total score	21	18	13	12	9	10	9
	556	Imipramine	Male	1	01.REPORTED SADNESS	2	2	1	1	1	0	0
					02.INNER TENSION	2	2	1	0	0	0	0
					03.APPARENT SADNESS	2	2	1	1	1	1	0
					04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
					05.INERTIA	2	2	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	1	1	0
					07.PESSIMISTIC THOUGHTS	3	2	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	1
					09.REDUCED SLEEP	3	3	2	2	2	2	2
					10.REDUCED APPETITE	2	2	2	1	1	1	0
					11.Total score	21	20	14	10	9	8	5
9	241	Placebo	Female	1	01.REPORTED SADNESS	3	3	3				
					02.INNER TENSION	1	2	3				
					03.APPARENT SADNESS	2	2	3				
					04.SUICIDAL THOUGHTS	1	1	1				
					05.INERTIA	2	2	2				
					06.INABILITY TO FEEL	2	2	2				
					07.PESSIMISTIC THOUGHTS	2	2	1				
					08.CONCENTRATIONS DIFFICULTIES	2	2	3				
					09.REDUCED SLEEP	2	2	3				
					10.REDUCED APPETITE	2	2	2				
					11.Total score	19	20	23				
	242	Reboxetine	Female	1	01.REPORTED SADNESS	2	1	2	2			
					02.INNER TENSION	2	1	2	2			
					03.APPARENT SADNESS	2	1	2	2			
					04.SUICIDAL THOUGHTS	1	1	1	2			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	242	Reboxetine	Female	1	05.INERTIA	2	1	1	1			
					06.INABILITY TO FEEL	2	1	2	1			
					07.PESSIMISTIC THOUGHTS	1	1	1	1			
					08.CONCENTRATIONS DIFFICULTIES	2	1	2	1			
					09.REDUCED SLEEP	2	2	2	2			
					10.REDUCED APPETITE	1	0	0	1			
					11.Total score	17	10	15	15			
	243	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	2				
					02.INNER TENSION	2	3	3				
					03.APPARENT SADNESS	2	2	2				
					04.SUICIDAL THOUGHTS	1	1	1				
					05.INERTIA	2	2	2				
					06.INABILITY TO FEEL	1	2	2				
					07.PESSIMISTIC THOUGHTS	2	2	2				
					08.CONCENTRATIONS DIFFICULTIES	1	1	3				
					09.REDUCED SLEEP	1	2	3				
					10.REDUCED APPETITE	1	1	2				
					11.Total score	15	18	22				
	244	Imipramine	Female	1	01.REPORTED SADNESS	2	2	1	1			
					02.INNER TENSION	1	1	1	1			
					03.APPARENT SADNESS	2	1	1	1			
					04.SUICIDAL THOUGHTS	2	0	0	0			
					05.INERTIA	2	2	1	1			
					06.INABILITY TO FEEL	2	2	1	1			
					07.PESSIMISTIC THOUGHTS	0	0	0	0			
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1			
					09.REDUCED SLEEP	2	2	1	1			
					10.REDUCED APPETITE	1	0	0	0			
					11.Total score	16	12	7	7			
	245	Imipramine	Female	1	01.REPORTED SADNESS	2	2	1	0	0	0	0
					02.INNER TENSION	2	2	2	1	1	1	1
					03.APPARENT SADNESS	1	1	0	0	0	0	0
					04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
					05.INERTIA	2	1	1	0	0	1	0
					06.INABILITY TO FEEL	1	1	0	0	0	0	0
					07.PESSIMISTIC THOUGHTS	2	2	0	0	0	0	0
					08.CONCENTRATIONS DIFFICULTIES	1	1	0	0	0	0	0
					09.REDUCED SLEEP	1	1	2	1	2	2	2
					10.REDUCED APPETITE	1	1	0	0	0	0	0
					11.Total score	14	13	6	2	3	4	3
	246	Placebo	Female	1	01.REPORTED SADNESS	3	3	3	3	3		
					02.INNER TENSION	3	3	3	3	3		
					03.APPARENT SADNESS	3	3	3	3	3		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale Type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	246	Placebo	Female	1	04.SUICIDAL THOUGHTS	1	1	1	1	1		
					05.INERTIA	3	3	3	3	3		
					06.INABILITY TO FEEL	3	3	3	3	3		
					07.PESSIMISTIC THOUGHTS	2	2	2	2	3		
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2		
					09.REDUCED SLEEP	2	2	2	2	2		
					10.REDUCED APPETITE	2	2	2	2	2		
					11.Total score	24	24	24	24	25		
	247	Placebo	Female	1	01.REPORTED SADNESS	2	2	2	2	2		
					02.INNER TENSION	2	2	1	2	2		
					03.APPARENT SADNESS	1	1	1	2	2		
					04.SUICIDAL THOUGHTS	1	1	1	1	1		
					05.INERTIA	2	2	1	1	1		
					06.INABILITY TO FEEL	1	1	1	1	2		
					07.PESSIMISTIC THOUGHTS	1	2	1	1	1		
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1		
					09.REDUCED SLEEP	2	2	2	2	2		
					10.REDUCED APPETITE	1	1	1	1	1		
					11.Total score	15	16	12	14	15		
	248	Placebo	Male	1	01.REPORTED SADNESS	2	2	2				
					02.INNER TENSION	1	2	3				
					03.APPARENT SADNESS	2	2	3				
					04.SUICIDAL THOUGHTS	1	1	2				
					05.INERTIA	2	2	3				
					06.INABILITY TO FEEL	2	2	2				
					07.PESSIMISTIC THOUGHTS	1	1	2				
					08.CONCENTRATIONS DIFFICULTIES	2	2	2				
					09.REDUCED SLEEP	2	2	3				
					10.REDUCED APPETITE	1	1	3				
					11.Total score	16	17	25				
	249	Reboxetine	Female	1	01.REPORTED SADNESS	3						
					02.INNER TENSION	1						
					03.APPARENT SADNESS	3						
					04.SUICIDAL THOUGHTS	0						
					05.INERTIA	1						
					06.INABILITY TO FEEL	1						
					07.PESSIMISTIC THOUGHTS	2						
					08.CONCENTRATIONS DIFFICULTIES	2						
					09.REDUCED SLEEP	1						
					10.REDUCED APPETITE	1						
					11.Total score	15						
	250	Imipramine	Female	1	01.REPORTED SADNESS	3	3	3	3	3		
					02.INNER TENSION	1	1	1	1	1		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	250	Imipramine	Female	1	03.APPARENT SADNESS	2	2	2	2	2		
					04.SUICIDAL THOUGHTS	1	1	1	1	1		
					05.INERTIA	2	2	2	2	2		
					06.INABILITY TO FEEL	3	3	3	3	3		
					07.PESSIMISTIC THOUGHTS	1	1	2	2	2		
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2		
					09.REDUCED SLEEP	2	2	2	2	2		
					10.REDUCED APPETITE	2	2	2	2	2		
					11.Total score	19	19	20	20	20		
	251	Imipramine	Female	1	01.REPORTED SADNESS	3	1	2	0	0		
					02.INNER TENSION	2	1	1	0	0		
					03.APPARENT SADNESS	3	1	2	0	0		
					04.SUICIDAL THOUGHTS	2	1	2	0	0		
					05.INERTIA	1	2	2	1	1		
					06.INABILITY TO FEEL	2	1	2	0	0		
					07.PESSIMISTIC THOUGHTS	2	2	2	0	0		
					08.CONCENTRATIONS DIFFICULTIES	2	1	1	0	0		
					09.REDUCED SLEEP	1	2	1	1	1		
					10.REDUCED APPETITE	2	0	1	0	0		
					11.Total score	20	12	16	2	2		
	252	Reboxetine	Female	1	01.REPORTED SADNESS	2	3	3	3			
					02.INNER TENSION	1	2	2	3			
					03.APPARENT SADNESS	1	2	3	3			
					04.SUICIDAL THOUGHTS	1	1	1	1			
					05.INERTIA	2	2	2	2			
					06.INABILITY TO FEEL	2	2	2	2			
					07.PESSIMISTIC THOUGHTS	1	1	1	1			
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1			
					09.REDUCED SLEEP	2	3	3	3			
					10.REDUCED APPETITE	1	1	1	1			
					11.Total score	14	18	19	20			
	253	Reboxetine	Female	1	01.REPORTED SADNESS	3	3					
					02.INNER TENSION	1	3					
					03.APPARENT SADNESS	2	2					
					04.SUICIDAL THOUGHTS	1	3					
					05.INERTIA	2	2					
					06.INABILITY TO FEEL	2	3					
					07.PESSIMISTIC THOUGHTS	1	1					
					08.CONCENTRATIONS DIFFICULTIES	2	2					
					09.REDUCED SLEEP	2	2					
					10.REDUCED APPETITE	1	0					
					11.Total score	17	21					
	254	Imipramine	Female	1	01.REPORTED SADNESS	3	3	3				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	254	Imipramine	Female	1	02.INNER TENSION	2	3	3				
					03.APPARENT SADNESS	2	3	3				
					04.SUICIDAL THOUGHTS	2	2	2				
					05.INERTIA	2	3	3				
					06.INABILITY TO FEEL	1	1	1				
					07.PESSIMISTIC THOUGHTS	1	1	1				
					08.CONCENTRATIONS DIFFICULTIES	1	1	1				
					09.REDUCED SLEEP	2	3	3				
					10.REDUCED APPETITE	1	1	1				
					11.Total score	17	21	21				
	255	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	1	1	2		
					02.INNER TENSION	2	2	3	3	3		
					03.APPARENT SADNESS	1	1	2	2	2		
					04.SUICIDAL THOUGHTS	2	2	2	2	3		
					05.INERTIA	3	3	2	2	3		
					06.INABILITY TO FEEL	2	2	3	3	3		
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1		
					08.CONCENTRATIONS DIFFICULTIES	3	3	3	3	3		
					09.REDUCED SLEEP	1	1	3	3	3		
					10.REDUCED APPETITE	0	0	0	0	0		
					11.Total score	17	17	20	20	23		
	256	Imipramine	Female	1	01.REPORTED SADNESS	3	3	1	1	3	1	1
					02.INNER TENSION	2	2	1	1	2	1	1
					03.APPARENT SADNESS	3	3	0	0	3	1	1
					04.SUICIDAL THOUGHTS	2	2	0	0	2	1	1
					05.INERTIA	3	3	1	1	3	1	1
					06.INABILITY TO FEEL	3	3	1	1	2	1	1
					07.PESSIMISTIC THOUGHTS	2	2	0	0	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	2	1	1
					09.REDUCED SLEEP	2	2	2	2	2	1	1
					10.REDUCED APPETITE	2	2	1	1	1	1	1
					11.Total score	24	24	8	8	21	9	9
	257	Placebo	Male	1	01.REPORTED SADNESS	2	2					
					02.INNER TENSION	2	2					
					03.APPARENT SADNESS	1	1					
					04.SUICIDAL THOUGHTS	2	2					
					05.INERTIA	2	2					
					06.INABILITY TO FEEL	2	2					
					07.PESSIMISTIC THOUGHTS	2	2					
					08.CONCENTRATIONS DIFFICULTIES	1	1					
					09.REDUCED SLEEP	2	2					
					10.REDUCED APPETITE	1	1					
					11.Total score	17	17					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	258	Placebo	Male	1	01.REPORTED SADNESS	3	3	3				
					02.INNER TENSION	2	3	3				
					03.APPARENT SADNESS	2	2	2				
					04.SUICIDAL THOUGHTS	1	1	1				
					05.INERTIA	3	3	3				
					06.INABILITY TO FEEL	1	1	1				
					07.PESSIMISTIC THOUGHTS	2	2	2				
					08.CONCENTRATIONS DIFFICULTIES	2	2	2				
					09.REDUCED SLEEP	2	3	3				
					10.REDUCED APPETITE	1	1	1				
					11.Total score	19	21	21				
11	319	Placebo	Male	1	01.REPORTED SADNESS	2	2	2	2	2	2	1
					02.INNER TENSION	1	1	2	2	2	2	2
					03.APPARENT SADNESS	2	2	2	2	2	2	1
					04.SUICIDAL THOUGHTS	2	1	1	2	2	1	1
					05.INERTIA	1	1	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	2	2	2	1	1
					07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
					09.REDUCED SLEEP	2	2	2	2	2	2	2
					10.REDUCED APPETITE	1	1	1	1	1	1	1
					11.Total score	17	16	17	18	18	16	13
	320	Imipramine	Male	1	01.REPORTED SADNESS	2	3	2	2	1	2	1
					02.INNER TENSION	2	2	2	2	1	2	1
					03.APPARENT SADNESS	2	2	1	2	1	2	1
					04.SUICIDAL THOUGHTS	1	1	1	2	1	1	1
					05.INERTIA	2	2	1	2	1	2	1
					06.INABILITY TO FEEL	1	2	1	2	1	1	0
					07.PESSIMISTIC THOUGHTS	2	2	1	3	1	1	2
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	2	1
					09.REDUCED SLEEP	3	3	2	1	2	2	2
					10.REDUCED APPETITE	0	2	0	0	0	0	0
					11.Total score	17	21	13	18	10	15	10
	321	Placebo	Male	1	01.REPORTED SADNESS	2	2	1	1	0	0	0
					02.INNER TENSION	1	1	1	1	1	1	1
					03.APPARENT SADNESS	1	1	1	1	0	1	0
					04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
					05.INERTIA	1	1	1	1	1	0	0
					06.INABILITY TO FEEL	1	1	1	1	0	0	0
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	0	0
					09.REDUCED SLEEP	2	2	1	1	1	0	0
					10.REDUCED APPETITE	1	1	0	0	0	0	0
					11.Total score	13	13	9	9	5	3	2

1382

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	322	Reboxetine	Female	1	01.REPORTED SADNESS	2	1	1	1	1	2	2
					02.INNER TENSION	2	1	1	1	1	1	1
					03.APPARENT SADNESS	2	1	1	1	1	1	1
					04.SUICIDAL THOUGHTS	2	1	1	1	1	1	1
					05.INERTIA	1	2	1	2	2	2	2
					06.INABILITY TO FEEL	2	2	2	1	1	1	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	1
					09.REDUCED SLEEP	2	2	2	2	2	2	1
					10.REDUCED APPETITE	1	1	0	0	0	0	1
					11.Total score	17	14	12	12	12	13	12
	323	Reboxetine	Male	2	01.APPARENT SADNESS	2	2	1	1	0	0	0
					02.REPORTED SADNESS	3	2	2	2	1	0	1
					03.INNER TENSION	2	2	2	1	2	1	2
					04.REDUCED SLEEP	4	3	3	2	0	0	0
					05.REDUCED APPETITE	2	2	0	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	2	1	1	0	0	0	0
					07.LASSITUDE	2	2	0	2	1	1	1
					08.INABILITY TO FEEL	2	2	2	1	0	0	1
					09.PESSIMISTIC THOUGHTS	3	2	2	2	2	2	0
					10.SUICIDAL THOUGHTS	2	1	1	0	0	0	0
					11.Total score	24	19	14	11	6	4	5
	324	Imipramine	Male	2	01.APPARENT SADNESS	3	3	3	2	3	3	3
					02.REPORTED SADNESS	4	4	4	3	4	3	3
					03.INNER TENSION	3	2	2	2	3	3	3
					04.REDUCED SLEEP	4	4	4	4	4	4	4
					05.REDUCED APPETITE	4	4	3	3	3	3	2
					06.CONCENTRATIONS DIFFICULTIES	4	3	2	3	3	3	3
					07.LASSITUDE	2	3	3	2	2	2	2
					08.INABILITY TO FEEL	3	3	2	2	2	2	2
					09.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2
					10.SUICIDAL THOUGHTS	2	2	2	2	2	2	2
					11.Total score	31	30	27	25	28	27	26
	325	Reboxetine	Male	2	01.APPARENT SADNESS	4	1	1	0	0	0	0
					02.REPORTED SADNESS	4	2	1	0	0	0	0
					03.INNER TENSION	2	2	2	1	1	1	2
					04.REDUCED SLEEP	4	4	2	2	0	0	0
					05.REDUCED APPETITE	3	3	1	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	2	2	1	0	0	0	0
					07.LASSITUDE	3	2	1	1	1	1	1
					08.INABILITY TO FEEL	2	2	2	0	1	1	0
					09.PESSIMISTIC THOUGHTS	2	1	0	0	0	0	0
					10.SUICIDAL THOUGHTS	2	1	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale Type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	325	Reboxetine	Male	2	11.Total score	28	20	12	4	3	3	3
	326	Placebo	Male	2	01.APPARENT SADNESS	5	6	6	5	6	6	6
					02.REPORTED SADNESS	4	5	5	5	6	6	6
					03.INNER TENSION	3	3	4	4	2	2	2
					04.REDUCED SLEEP	5	6	6	5	6	6	6
					05.REDUCED APPETITE	2	3	3	3	4	4	4
					06.CONCENTRATIONS DIFFICULTIES	4	4	4	4	2	2	2
					07.LASSITUDE	3	3	3	3	4	2	4
					08.INABILITY TO FEEL	4	4	4	4	4	4	4
					09.PESSIMISTIC THOUGHTS	3	3	2	2	4	4	4
					10.SUICIDAL THOUGHTS	4	4	4	4	4	4	4
					11.Total score	37	41	41	39	42	40	42
	327	Imipramine	Male	2	01.APPARENT SADNESS	4	2					
					02.REPORTED SADNESS	3	2					
					03.INNER TENSION	3	2					
					04.REDUCED SLEEP	5	2					
					05.REDUCED APPETITE	2	0					
					06.CONCENTRATIONS DIFFICULTIES	3	3					
					07.LASSITUDE	1	2					
					08.INABILITY TO FEEL	2	2					
					09.PESSIMISTIC THOUGHTS	2	1					
					10.SUICIDAL THOUGHTS	2	1					
					11.Total score	27	17					
	328	Imipramine	Female	2	01.APPARENT SADNESS	4	2					
					02.REPORTED SADNESS	4	3					
					03.INNER TENSION	4	3					
					04.REDUCED SLEEP	4	3					
					05.REDUCED APPETITE	2	2					
					06.CONCENTRATIONS DIFFICULTIES	3	3					
					07.LASSITUDE	2	2					
					08.INABILITY TO FEEL	3	2					
					09.PESSIMISTIC THOUGHTS	2	2					
					10.SUICIDAL THOUGHTS	3	2					
					11.Total score	31	24					
	329	Placebo	Female	2	01.APPARENT SADNESS	3	3	3	3	0	0	0
					02.REPORTED SADNESS	4	4	4	3	1	1	0
					03.INNER TENSION	3	4	4	3	3	2	3
					04.REDUCED SLEEP	5	5	5	4	1	2	2
					05.REDUCED APPETITE	0	0	0	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	4	4	4	2	2	2	2
					07.LASSITUDE	4	3	3	2	1	0	1
					08.INABILITY TO FEEL	3	3	3	2	0	0	0
					09.PESSIMISTIC THOUGHTS	3	3	3	2	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale Type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	329	Placebo	Female	2	10.SUICIDAL THOUGHTS	2	2	2	1	0	0	0
					11.Total score	31	31	31	22	8	7	8
	330	Reboxetine	Male	2	01.APPARENT SADNESS	4	4	2	1	2	1	0
					02.REPORTED SADNESS	4	4	4	3	3	2	0
					03.INNER TENSION	4	4	4	3	3	2	2
					04.REDUCED SLEEP	4	4	4	5	5	2	3
					05.REDUCED APPETITE	2	2	2	1	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	3	3	2	2	2	0	0
					07.LASSITUDE	4	4	1	0	1	0	0
					08.INABILITY TO FEEL	4	4	2	0	0	0	0
					09.PESSIMISTIC THOUGHTS	2	2	2	2	1	2	1
					10.SUICIDAL THOUGHTS	2	2	2	1	0	0	0
					11.Total score	33	33	25	18	17	9	6
	331	Imipramine	Male	2	01.APPARENT SADNESS	3	3	2	2	2	2	2
					02.REPORTED SADNESS	4	3	3	2	3	3	3
					03.INNER TENSION	3	4	3	2	3	3	3
					04.REDUCED SLEEP	4	2	0	0	0	0	0
					05.REDUCED APPETITE	1	0	0	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	3	2	2	0	2	2	2
					07.LASSITUDE	2	2	2	2	2	2	1
					08.INABILITY TO FEEL	2	2	1	0	1	2	1
					09.PESSIMISTIC THOUGHTS	3	2	2	0	0	2	0
					10.SUICIDAL THOUGHTS	1	1	0	0	0	1	0
					11.Total score	26	21	15	8	13	17	12
	332	Reboxetine	Male	2	01.APPARENT SADNESS	4	3	1	0	0	0	0
					02.REPORTED SADNESS	4	3	2	0	1	1	0
					03.INNER TENSION	4	3	3	2	2	2	2
					04.REDUCED SLEEP	6	4	2	2	0	0	0
					05.REDUCED APPETITE	0	0	0	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	4	2	1	0	0	0	1
					07.LASSITUDE	3	2	2	1	1	2	2
					08.INABILITY TO FEEL	3	2	1	1	0	0	0
					09.PESSIMISTIC THOUGHTS	3	2	0	0	0	0	0
					10.SUICIDAL THOUGHTS	2	2	0	0	0	0	0
					11.Total score	33	23	12	6	4	5	5
	333	Placebo	Male	2	01.APPARENT SADNESS	4	3	3	1	1	1	1
					02.REPORTED SADNESS	4	3	4	2	1	2	1
					03.INNER TENSION	3	3	3	2	2	2	2
					04.REDUCED SLEEP	5	5	5	5	3	4	4
					05.REDUCED APPETITE	2	2	0	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	3	3	3	1	1	0	1
					07.LASSITUDE	2	2	3	0	0	0	0
					08.INABILITY TO FEEL	2	2	2	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	333	Placebo	Male	2	09.PESSIMISTIC THOUGHTS	3	3	2	2	2	1	1
					10.SUICIDAL THOUGHTS	2	2	2	1	0	0	0
					11.Total score	30	28	27	14	10	10	10
	334	Reboxetine	Female	2	01.APPARENT SADNESS	4						
					02.REPORTED SADNESS	4						
					03.INNER TENSION	4						
					04.REDUCED SLEEP	5						
					05.REDUCED APPETITE	2						
					06.CONCENTRATIONS DIFFICULTIES	2						
					07.LASSITUDE	2						
					08.INABILITY TO FEEL	3						
					09.PESSIMISTIC THOUGHTS	2						
					10.SUICIDAL THOUGHTS	2						
					11.Total score	30						
	335	Placebo	Male	2	01.APPARENT SADNESS	2	2	3	2		2	2
					02.REPORTED SADNESS	4	3	3	2		3	2
					03.INNER TENSION	4	3	3	3		3	2
					04.REDUCED SLEEP	2	2	3	4		4	4
					05.REDUCED APPETITE	2	0	0	0		0	0
					06.CONCENTRATIONS DIFFICULTIES	2	2	2	2		2	2
					07.LASSITUDE	3	3	2	2		2	2
					08.INABILITY TO FEEL	2	3	3	3		3	2
					09.PESSIMISTIC THOUGHTS	2	2	2	2		2	2
					10.SUICIDAL THOUGHTS	2	1	1	2		1	1
					11.Total score	25	21	22	22		22	19
	336	Imipramine	Female	2	01.APPARENT SADNESS	6	6					
					02.REPORTED SADNESS	6	6					
					03.INNER TENSION	4	4					
					04.REDUCED SLEEP	4	4					
					05.REDUCED APPETITE	0	2					
					06.CONCENTRATIONS DIFFICULTIES	4	4					
					07.LASSITUDE	4	4					
					08.INABILITY TO FEEL	5	4					
					09.PESSIMISTIC THOUGHTS	3	3					
					10.SUICIDAL THOUGHTS	2	2					
					11.Total score	38	39					
	337	Reboxetine	Female	2	01.APPARENT SADNESS	2	3	3	3	4	4	3
					02.REPORTED SADNESS	5	5	4	4	5	4	4
					03.INNER TENSION	2	2	2	2	3	3	3
					04.REDUCED SLEEP	4	4	4	4	4	3	4
					05.REDUCED APPETITE	2	2	2	2	2	2	0
					06.CONCENTRATIONS DIFFICULTIES	3	3	2	3	3	3	3
					07.LASSITUDE	3	3	3	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/015
Listing No.: 13.8

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	337	Reboxetine	Female	2	08.INABILITY TO FEEL	4	4	3	3	3	3	3
					09.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2
					10.SUICIDAL THOUGHTS	2	2	2	2	3	3	3
					11.Total score	29	30	27	27	31	29	27
	338	Imipramine	Male	2	01.APPARENT SADNESS	4	4					
					02.REPORTED SADNESS	4	4					
					03.INNER TENSION	3	3					
					04.REDUCED SLEEP	4	4					
					05.REDUCED APPETITE	2	2					
					06.CONCENTRATIONS DIFFICULTIES	2	3					
					07.LASSITUDE	4	4					
					08.INABILITY TO FEEL	4	4					
					09.PESSIMISTIC THOUGHTS	3	3					
					10.SUICIDAL THOUGHTS	3	3					
					11.Total score	33	34					
12	367	Reboxetine	Female	2	01.APPARENT SADNESS	4	2	2	0	0	0	0
					02.REPORTED SADNESS	3	2	1	0	0	0	0
					03.INNER TENSION	3	1	2	2	1	0	0
					04.REDUCED SLEEP	5	3	3	2	2	2	2
					05.REDUCED APPETITE	3	0	1	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	4	1	2	2	1	0	1
					07.LASSITUDE	4	3	3	0	0	0	0
					08.INABILITY TO FEEL	4	3	3	1	0	0	0
					09.PESSIMISTIC THOUGHTS	2	2	1	1	0	0	0
					10.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
					11.Total score	33	18	19	9	4	2	3
	368	Placebo	Female	2	01.APPARENT SADNESS	4	3	3	2	2	2	1
					02.REPORTED SADNESS	4	3	4	2	2	2	2
					03.INNER TENSION	2	3	2	1	2	1	1
					04.REDUCED SLEEP	3	4	2	2	1	2	3
					05.REDUCED APPETITE	2	2	1	0	1	0	1
					06.CONCENTRATIONS DIFFICULTIES	4	4	4	1	2	2	1
					07.LASSITUDE	4	4	4	4	4	4	4
					08.INABILITY TO FEEL	4	4	3	4	3	2	2
					09.PESSIMISTIC THOUGHTS	1	2	2	1	1	1	1
					10.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
					11.Total score	29	30	26	18	19	16	16
	369	Imipramine	Female	2	01.APPARENT SADNESS	2	0	2	4			
					02.REPORTED SADNESS	4	1	2	5			
					03.INNER TENSION	5	1	3	6			
					04.REDUCED SLEEP	4	1	3	2			
					05.REDUCED APPETITE	2	0	0	1			
					06.CONCENTRATIONS DIFFICULTIES	3	1	1	3			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
12	369	Imipramine	Female	2	07.LASSITUDE	4	1	2	5			
					08.INABILITY TO FEEL	5	1	3	5			
					09.PESSIMISTIC THOUGHTS	4	1	2	3			
					10.SUICIDAL THOUGHTS	4	0	1	5			
					11.Total score	37	7	19	39			
	370	Placebo	Male	2	01.APPARENT SADNESS	5	3	4	5			
					02.REPORTED SADNESS	4	3	4	4			
					03.INNER TENSION	2	2	2	3			
					04.REDUCED SLEEP	3	2	3	3			
					05.REDUCED APPETITE	3	2	3	4			
					06.CONCENTRATIONS DIFFICULTIES	3	1	5	3			
					07.LASSITUDE	3	2	4	4			
					08.INABILITY TO FEEL	4	3	4	4			
					09.PESSIMISTIC THOUGHTS	5	2	2	4			
					10.SUICIDAL THOUGHTS	3	1	2	3			
					11.Total score	35	21	33	37			
	371	Imipramine	Female	2	01.APPARENT SADNESS	4	1					
					02.REPORTED SADNESS	4	2					
					03.INNER TENSION	3	2					
					04.REDUCED SLEEP	4	2					
					05.REDUCED APPETITE	0	1					
					06.CONCENTRATIONS DIFFICULTIES	3	2					
					07.LASSITUDE	4	2					
					08.INABILITY TO FEEL	4	1					
					09.PESSIMISTIC THOUGHTS	2	2					
					10.SUICIDAL THOUGHTS	1	1					
					11.Total score	29	16					
	372	Reboxetine	Male	2	01.APPARENT SADNESS	5	4	2	1	0	0	3
					02.REPORTED SADNESS	4	4	1	0	1	0	3
					03.INNER TENSION	5	4	2	2	2	2	2
					04.REDUCED SLEEP	4	2	2	0	0	2	2
					05.REDUCED APPETITE	4	2	0	0	0	0	2
					06.CONCENTRATIONS DIFFICULTIES	4	2	1	1	1	0	2
					07.LASSITUDE	3	3	2	0	0	0	2
					08.INABILITY TO FEEL	4	2	2	0	0	0	2
					09.PESSIMISTIC THOUGHTS	4	5	2	0	0	0	2
					10.SUICIDAL THOUGHTS	4	4	1	0	1	0	2
					11.Total score	41	32	15	4	5	4	22
	373	Reboxetine	Male	2	01.APPARENT SADNESS	4	1	4	1	1	0	0
					02.REPORTED SADNESS	4	1	4	1	1	1	1
					03.INNER TENSION	4	2	3	2	2	0	1
					04.REDUCED SLEEP	3	3	5	4	2	3	2
					05.REDUCED APPETITE	2	0	4	0	0	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
12	373	Reboxetine	Male	2	06.CONCENTRATIONS DIFFICULTIES	0	1	5	3	3	1	0
					07.LASSITUDE	2	0	4	4	3	0	0
					08.INABILITY TO FEEL	2	1	4	3	3	2	0
					09.PESSIMISTIC THOUGHTS	2	2	3	3	3	1	0
					10.SUICIDAL THOUGHTS	4	2	4	2	1	1	0
					11.Total score	27	13	40	23	19	10	4
	374	Placebo	Female	2	01.APPARENT SADNESS	3	3	2	3	2		
					02.REPORTED SADNESS	4	3	1	2	1		
					03.INNER TENSION	2	4	2	3	2		
					04.REDUCED SLEEP	0	0	0	0	4		
					05.REDUCED APPETITE	2	1	0	0	0		
					06.CONCENTRATIONS DIFFICULTIES	2	4	1	2	2		
					07.LASSITUDE	4	2	2	2	2		
					08.INABILITY TO FEEL	4	2	2	3	2		
					09.PESSIMISTIC THOUGHTS	3	2	1	2	1		
					10.SUICIDAL THOUGHTS	2	1	1	1	0		
					11.Total score	26	22	12	18	16		
	375	Imipramine	Male	2	01.APPARENT SADNESS	4						
					02.REPORTED SADNESS	5						
					03.INNER TENSION	4						
					04.REDUCED SLEEP	3						
					05.REDUCED APPETITE	2						
					06.CONCENTRATIONS DIFFICULTIES	3						
					07.LASSITUDE	2						
					08.INABILITY TO FEEL	3						
					09.PESSIMISTIC THOUGHTS	5						
					10.SUICIDAL THOUGHTS	4						
					11.Total score	35						
13	13	Placebo	Male	1	01.REPORTED SADNESS	1	1	0	2	1	2	2
					02.INNER TENSION	2	1	1	2	2	1	2
					03.APPARENT SADNESS	1	1	1	1	1	2	2
					04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
					05.INERTIA	1	2	1	1	1	2	1
					06.INABILITY TO FEEL	1	1	1	1	1	2	2
					07.PESSIMISTIC THOUGHTS	1	1	1	2	1	2	2
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	2	2	2	2
					09.REDUCED SLEEP	1	1	1	1	1	1	1
					10.REDUCED APPETITE	1	1	0	0	0	1	1
					11.Total score	11	11	8	13	11	16	16
	14	Placebo	Male	1	01.REPORTED SADNESS	2	1	2	1	0	1	0
					02.INNER TENSION	2	1	2	1	1	1	1
					03.APPARENT SADNESS	2	0	2	2	0	1	1
					04.SUICIDAL THOUGHTS	1	1	2	1	0	0	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
13	14	Placebo	Male	1	05.INERTIA	1	1	1	2	1	1	1
					06.INABILITY TO FEEL	2	1	2	2	1	1	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	0	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	2	1	1	1
					09.REDUCED SLEEP	1	1	1	0	1	1	1
					10.REDUCED APPETITE	1	1	2	1	1	0	1
					11.Total score	14	9	16	13	6	8	9
	15	Imipramine	Female	1	01.REPORTED SADNESS	2	1	1	1	2	2	2
					02.INNER TENSION	1	1	1	1	1	1	2
					03.APPARENT SADNESS	2	1	1	1	2	2	2
					04.SUICIDAL THOUGHTS	2	1	1	1	2	2	2
					05.INERTIA	2	2	1	1	1	1	2
					06.INABILITY TO FEEL	2	1	1	1	2	1	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	1	1	2	1	2	2
					09.REDUCED SLEEP	1	1	1	2	1	1	1
					10.REDUCED APPETITE	1	1	1	1	1	1	1
					11.Total score	16	11	10	12	14	14	16
	16	Imipramine	Male	2	01.APPARENT SADNESS	2	3	2	1	2	1	2
					02.REPORTED SADNESS	0	2	2	0	1	0	1
					03.INNER TENSION	2	3	2	1	2	2	2
					04.REDUCED SLEEP	3	3	3	2	3	3	4
					05.REDUCED APPETITE	0	0	0	0	1	1	2
					06.CONCENTRATIONS DIFFICULTIES	2	3	2	2	2	2	2
					07.LASSITUDE	2	2	2	1	1	1	2
					08.INABILITY TO FEEL	2	2	2	0	1	0	2
					09.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	2
					10.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
					11.Total score	16	21	17	9	15	12	20
	17	Reboxetine	Male	2	01.APPARENT SADNESS	2	2	2	1	1	1	1
					02.REPORTED SADNESS	2	1	1	2	1	1	0
					03.INNER TENSION	2	2	2	2	2	2	2
					04.REDUCED SLEEP	0	0	0	0	0	0	0
					05.REDUCED APPETITE	0	0	0	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	3	1	0	2	2	2	2
					07.LASSITUDE	2	1	1	1	1	2	1
					08.INABILITY TO FEEL	2	2	2	2	1	1	2
					09.PESSIMISTIC THOUGHTS	3	2	1	1	1	2	1
					10.SUICIDAL THOUGHTS	2	1	1	1	1	1	1
					11.Total score	18	12	10	12	10	12	10
	18	Reboxetine	Male	2	01.APPARENT SADNESS	2	2	2	1	2	1	1
					02.REPORTED SADNESS	1	1	1	1	1	1	1
					03.INNER TENSION	2	2	2	2	2	2	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale Type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
13	18	Reboxetine	Male	2	04.REDUCED SLEEP	1	1	1	0	1	0	2
					05.REDUCED APPETITE	0	0	0	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	2	3	3	3	4	3	2
					07.LASSITUDE	2	1	1	1	1	2	1
					08.INABILITY TO FEEL	1	1	2	2	2	2	1
					09.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	0
					10.SUICIDAL THOUGHTS	1	1	0	0	1	0	0
					11.Total score	13	13	13	11	15	12	9
	409	Reboxetine	Male	2	01.APPARENT SADNESS	2	3	2		2		2
					02.REPORTED SADNESS	1	2	1		2		1
					03.INNER TENSION	3	2	2		2		2
					04.REDUCED SLEEP	2	3	3		2		1
					05.REDUCED APPETITE	0	0	1		2		2
					06.CONCENTRATIONS DIFFICULTIES	2	2	2		2		1
					07.LASSITUDE	1	1	1		1		2
					08.INABILITY TO FEEL	1	2	2		2		1
					09.PESSIMISTIC THOUGHTS	1	2	1		1		1
					10.SUICIDAL THOUGHTS	1	1	1		1		1
					11.Total score	14	18	16		17		14
	410	Placebo	Male	2	01.APPARENT SADNESS	3	3	4	3	2	3	2
					02.REPORTED SADNESS	3	3	3	2	1	3	1
					03.INNER TENSION	3	2	3	3	2	2	2
					04.REDUCED SLEEP	2	2	2	2	0	2	2
					05.REDUCED APPETITE	3	2	3	3	1	2	2
					06.CONCENTRATIONS DIFFICULTIES	3	3	2	2	2	2	2
					07.LASSITUDE	2	2	3	3	2	2	2
					08.INABILITY TO FEEL	2	2	2	2	2	2	1
					09.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
					10.SUICIDAL THOUGHTS	1	1	2	1	1	1	1
					11.Total score	24	22	26	22	14	20	16
	411	Imipramine	Female	2	01.APPARENT SADNESS	2	1	1	3	4	2	1
					02.REPORTED SADNESS	3	1	1	3	3	2	1
					03.INNER TENSION	2	2	1	3	3	2	1
					04.REDUCED SLEEP	3	0	0	0	0	0	0
					05.REDUCED APPETITE	2	1	0	1	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	2	2	1	3	3	2	2
					07.LASSITUDE	2	1	1	2	2	2	1
					08.INABILITY TO FEEL	2	1	0	2	2	1	2
					09.PESSIMISTIC THOUGHTS	2	1	0	1	2	2	1
					10.SUICIDAL THOUGHTS	2	1	1	1	1	1	0
					11.Total score	22	11	6	19	20	14	9
	423	Placebo	Male	2	01.APPARENT SADNESS	2	2	3	2			1
					02.REPORTED SADNESS	1	1	2	2			1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
13	423	Placebo	Male	2	03.INNER TENSION	2	1	2	2			1
					04.REDUCED SLEEP	1	2	2	1			2
					05.REDUCED APPETITE	0	0	0	0			0
					06.CONCENTRATIONS DIFFICULTIES	3	2	2	2			1
					07.LASSITUDE	2	2	2	2			1
					08.INABILITY TO FEEL	2	1	2	2			1
					09.PESSIMISTIC THOUGHTS	2	2	1	2			2
					10.SUICIDAL THOUGHTS	1	1	1	1			1
					11.Total score	16	14	17	16			11
14	19	Reboxetine	Female	2	01.APPARENT SADNESS	6	6	3	4	5		
					02.REPORTED SADNESS	6	6	4	4	4		
					03.INNER TENSION	4	5	3	2	3		
					04.REDUCED SLEEP	5	5	4	4	5		
					05.REDUCED APPETITE	4	5	2	3	4		
					06.CONCENTRATIONS DIFFICULTIES	6	6	3	3	4		
					07.LASSITUDE	5	6	3	4	4		
					08.INABILITY TO FEEL	5	5	4	2	5		
					09.PESSIMISTIC THOUGHTS	3	2	2	2	3		
					10.SUICIDAL THOUGHTS	3	2	2	2	2		
					11.Total score	47	48	30	30	39		
	20	Imipramine	Female	2	01.APPARENT SADNESS	2	3	2	1	1	0	0
					02.REPORTED SADNESS	3	3	1	1	2	0	0
					03.INNER TENSION	4	4	3	2	2	1	1
					04.REDUCED SLEEP	4	4	5	2	2	2	0
					05.REDUCED APPETITE	3	1	0	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	4	3	2	1	0	0	0
					07.LASSITUDE	3	3	4	1	0	0	1
					08.INABILITY TO FEEL	4	3	4	1	1	0	1
					09.PESSIMISTIC THOUGHTS	3	4	2	2	0	0	0
					10.SUICIDAL THOUGHTS	2	2	1	1	0	0	0
					11.Total score	32	30	24	12	8	3	3
	21	Imipramine	Female	2	01.APPARENT SADNESS	4	4	2	4	3	3	
					02.REPORTED SADNESS	4	4	2	4	3	4	
					03.INNER TENSION	3	3	2	3	3	3	
					04.REDUCED SLEEP	5	4	1	3	3	3	
					05.REDUCED APPETITE	4	0	0	2	0	0	
					06.CONCENTRATIONS DIFFICULTIES	4	3	2	3	3	2	
					07.LASSITUDE	4	2	2	2	2	3	
					08.INABILITY TO FEEL	4	4	2	2	2	3	
					09.PESSIMISTIC THOUGHTS	1	2	3	4	2	2	
					10.SUICIDAL THOUGHTS	2	1	1	4	3	2	
					11.Total score	35	27	17	31	24	25	
15	25	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	1	2	2	2	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale Type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	25	Reboxetine	Female	1	02.INNER TENSION	2	2	2	2	1	1	1
					03.APPARENT SADNESS	1	2	1	2	2	1	1
					04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
					05.INERTIA	2	2	1	2	2	2	2
					06.INABILITY TO FEEL	2	2	2	1	1	1	1
					07.PESSIMISTIC THOUGHTS	1	1	1	1	2	1	1
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	1
					09.REDUCED SLEEP	2	2	2	2	1	2	2
					10.REDUCED APPETITE	1	1	1	1	0	0	1
					11.Total score	16	17	14	16	13	12	12
	26	Placebo	Male	1	01.REPORTED SADNESS	2	2	1	1	2	1	1
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	1	1	1	1	2	1	1
					04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
					05.INERTIA	2	1	2	1	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	2	2	0
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	0	1	1	0
					09.REDUCED SLEEP	2	1	2	1	2	1	1
					10.REDUCED APPETITE	1	1	1	1	0	0	0
					11.Total score	15	13	13	9	13	10	7
	27	Imipramine	Female	1	01.REPORTED SADNESS	2	2	1	1	1	0	0
					02.INNER TENSION	2	2	1	1	1	1	1
					03.APPARENT SADNESS	2	1	1	1	0	0	0
					04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
					05.INERTIA	1	2	2	1	0	1	0
					06.INABILITY TO FEEL	2	2	1	0	1	0	0
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	0
					08.CONCENTRATIONS DIFFICULTIES	2	2	1	0	0	0	1
					09.REDUCED SLEEP	2	1	2	1	0	0	1
					10.REDUCED APPETITE	1	0	0	0	0	0	0
					11.Total score	16	14	11	7	4	3	3
	28	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	1	1	1	1	0
					02.INNER TENSION	1	1	1	1	1	0	1
					03.APPARENT SADNESS	2	2	1	1	1	1	0
					04.SUICIDAL THOUGHTS	1	1	1	1	1	1	0
					05.INERTIA	2	1	1	1	1	1	1
					06.INABILITY TO FEEL	1	2	1	0	0	1	0
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	0	0	1	1
					09.REDUCED SLEEP	2	2	2	1	1	1	0
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	13	13	10	7	7	8	4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scal.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	29	Placebo	Male	1	01.REPORTED SADNESS	2	2	2	2			
					02.INNER TENSION	2	2	2	2			
					03.APPARENT SADNESS	1	1	1	2			
					04.SUICIDAL THOUGHTS	1	1	1	1			
					05.INERTIA	2	2	2	2			
					06.INABILITY TO FEEL	1	1	1	2			
					07.PESSIMISTIC THOUGHTS	2	2	2	2			
					08.CONCENTRATIONS DIFFICULTIES	2	2	2	2			
					09.REDUCED SLEEP	2	1	1	1			
					10.REDUCED APPETITE	0	0	0	0			
					11.Total score	15	14	14	16			
	30	Imipramine	Female	1	01.REPORTED SADNESS	2	2	2	1	1	1	0
					02.INNER TENSION	2	2	2	1	1	0	1
					03.APPARENT SADNESS	2	1	1	1	1	0	0
					04.SUICIDAL THOUGHTS	1	1	1	0	1	0	0
					05.INERTIA	1	1	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	1	1	2	1	1
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	0
					09.REDUCED SLEEP	1	1	1	0	1	0	1
					10.REDUCED APPETITE	0	0	0	0	0	0	0
					11.Total score	14	13	12	7	10	5	5
	403	Imipramine	Female	1	01.REPORTED SADNESS	2	1	1	1	0	0	0
					02.INNER TENSION	1	1	2	1	1	1	1
					03.APPARENT SADNESS	2	1	1	1	0	0	0
					04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
					05.INERTIA	2	2	1	1	1	1	1
					06.INABILITY TO FEEL	2	2	2	1	1	0	0
					07.PESSIMISTIC THOUGHTS	1	1	1	1	1	0	0
					08.CONCENTRATIONS DIFFICULTIES	2	1	1	0	0	1	1
					09.REDUCED SLEEP	2	2	2	1	1	1	1
					10.REDUCED APPETITE	1	0	0	0	0	0	0
					11.Total score	16	12	12	7	5	4	4
	404	Reboxetine	Female	1	01.REPORTED SADNESS	2	2	2	2	2		
					02.INNER TENSION	1	2	2	2	2		
					03.APPARENT SADNESS	2	2	2	2	2		
					04.SUICIDAL THOUGHTS	1	1	1	1	1		
					05.INERTIA	2	1	2	2	2		
					06.INABILITY TO FEEL	2	1	1	1	1		
					07.PESSIMISTIC THOUGHTS	2	2	2	1	1		
					08.CONCENTRATIONS DIFFICULTIES	1	1	1	2	2		
					09.REDUCED SLEEP	1	1	2	2	2		
					10.REDUCED APPETITE	1	1	0	0	1		
					11.Total score	15	14	15	15	16		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	405	Placebo	Female	2	01.APPARENT SADNESS	4	3	3	2	1	1	0
					02.REPORTED SADNESS	5	4	4	1	1	1	0
					03.INNER TENSION	3	3	3	2	1	1	1
					04.REDUCED SLEEP	4	4	3	2	1	0	1
					05.REDUCED APPETITE	2	2	2	1	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	3	3	3	2	2	1	1
					07.LASSITUDE	4	4	4	3	2	2	1
					08.INABILITY TO FEEL	4	4	3	2	1	1	0
					09.PESSIMISTIC THOUGHTS	2	2	3	2	1	1	0
					10.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
					11.Total score	32	30	29	18	10	8	4
	406	Imipramine	Male	2	01.APPARENT SADNESS	4	3	3	2	2	2	2
					02.REPORTED SADNESS	4	4	3	2	2	2	2
					03.INNER TENSION	3	3	3	2	2	2	2
					04.REDUCED SLEEP	2	3	2	2	3	2	3
					05.REDUCED APPETITE	3	2	2	1	1	0	0
					06.CONCENTRATIONS DIFFICULTIES	3	3	3	3	2	1	2
					07.LASSITUDE	4	4	3	2	1	1	1
					08.INABILITY TO FEEL	4	4	3	3	2	2	1
					09.PESSIMISTIC THOUGHTS	2	3	2	2	2	2	2
					10.SUICIDAL THOUGHTS	2	2	2	1	1	1	1
					11.Total score	31	31	26	20	18	15	16
	407	Reboxetine	Female	2	01.APPARENT SADNESS	4	3	3	2	2	2	2
					02.REPORTED SADNESS	4	3	3	3	2	2	2
					03.INNER TENSION	3	3	3	3	3	2	2
					04.REDUCED SLEEP	4	3	2	3	3	2	2
					05.REDUCED APPETITE	3	2	2	2	2	1	1
					06.CONCENTRATIONS DIFFICULTIES	3	3	3	3	2	2	3
					07.LASSITUDE	4	4	3	3	3	1	1
					08.INABILITY TO FEEL	4	4	4	4	3	2	1
					09.PESSIMISTIC THOUGHTS	3	3	3	2	2	2	2
					10.SUICIDAL THOUGHTS	3	3	3	2	2	0	0
					11.Total score	35	31	29	27	24	16	16
	408	Placebo	Female	2	01.APPARENT SADNESS	4	4	4	2	2	2	2
					02.REPORTED SADNESS	5	4	4	2	2	2	1
					03.INNER TENSION	4	4	4	2	3	2	1
					04.REDUCED SLEEP	3	3	3	2	3	2	2
					05.REDUCED APPETITE	2	2	2	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	4	3	3	2	2	1	2
					07.LASSITUDE	5	5	5	2	2	1	2
					08.INABILITY TO FEEL	4	4	4	1	1	1	1
					09.PESSIMISTIC THOUGHTS	3	3	3	2	1	2	1
					10.SUICIDAL THOUGHTS	2	2	3	1	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Scale type	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	408	Placebo	Female	2	11.Total score	36	34	35	16	17	14	12
	418	Placebo	Female	2	01.APPARENT SADNESS	4	3	3	2	2	2	1
					02.REPORTED SADNESS	4	4	3	2	2	1	1
					03.INNER TENSION	3	3	2	2	2	2	2
					04.REDUCED SLEEP	3	4	4	3	3	3	2
					05.REDUCED APPETITE	0	1	1	0	0	0	0
					06.CONCENTRATIONS DIFFICULTIES	3	3	2	2	3	2	0
					07.LASSITUDE	4	3	4	4	3	2	0
					08.INABILITY TO FEEL	3	4	4	3	3	1	0
					09.PESSIMISTIC THOUGHTS	3	2	3	3	3	1	1
					10.SUICIDAL THOUGHTS	2	2	1	1	1	1	0
					11.Total score	29	29	27	23	22	15	7
	419	Placebo	Female	2	01.APPARENT SADNESS	4	3	4	4	2	2	2
					02.REPORTED SADNESS	4	3	4	4	2	2	2
					03.INNER TENSION	2	2	3	2	3	3	2
					04.REDUCED SLEEP	4	3	3	3	3	2	2
					05.REDUCED APPETITE	2	0	2	2	2	0	0
					06.CONCENTRATIONS DIFFICULTIES	3	2	3	3	1	3	3
					07.LASSITUDE	3	2	3	3	2	2	2
					08.INABILITY TO FEEL	4	2	2	2	2	2	2
					09.PESSIMISTIC THOUGHTS	2	1	2	3	1	2	2
					10.SUICIDAL THOUGHTS	3	0	2	2	1	0	0
					11.Total score	31	18	28	28	19	18	17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	1	Imipramine	Female	01.FACIAL EXPRESSION	3	3	1	1	1	1	0
				02.BODY GESTURES	3	4	1	1	0	0	0
				03.LOOK	3	2	0	2	0	1	0
				04.OUTWARD APPEARANCE	2	3	1	0	0	0	0
				05.SPEECH	3	3	1	1	0	1	0
				06.VOICE	3	2	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	0	1	1	0
				08.CONTACTS, AFFECTIVE NEED	3	3	2	1	1	1	0
				09.ANGUISH, ANXIETY	3	3	2	2	1	1	1
				10.AGGRESSION, IRRITABILITY	0	1	1	1	0	0	1
				11.SELF-AGGRESSION	0	2	1	0	0	0	0
				12.GLOBAL EVALUATION	3	2	1	0	1	1	0
				11.Total score	28	30	12	9	5	7	2
	2	Reboxetine	Male	01.FACIAL EXPRESSION	3	3	1	1	1	1	1
				02.BODY GESTURES	3	3	1	1	1	0	0
				03.LOOK	3	2	0	0	1	0	0
				04.OUTWARD APPEARANCE	1	2	1	1	1	1	1
				05.SPEECH	2	2	1	1	1	0	2
				06.VOICE	2	2	1	0	1	0	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	0	0	1
				08.CONTACTS, AFFECTIVE NEED	2	3	1	0	1	0	1
				09.ANGUISH, ANXIETY	3	1	1	1	1	0	1
				10.AGGRESSION, IRRITABILITY	1	0	0	0	1	1	1
				11.SELF-AGGRESSION	2	3	0	0	0	0	1
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	26	25	10	7	10	4	8
	3	Imipramine	Male	01.FACIAL EXPRESSION	2	1	1	1	1	1	1
				02.BODY GESTURES	1	0	1	1	1	1	1
				03.LOOK	1	1	1	1	0	1	0
				04.OUTWARD APPEARANCE	0	1	1	1	0	0	0
				05.SPEECH	1	1	1	1	1	0	1
				06.VOICE	1	0	0	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	0	1	1	0	0
				08.CONTACTS, AFFECTIVE NEED	3	1	1	2	1	0	0
				09.ANGUISH, ANXIETY	2	1	1	2	1	1	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	1	1	1	1	1	1
				11.Total score	15	8	8	12	7	5	4
	4	Placebo	Male	01.FACIAL EXPRESSION	1	1	0	0	0	0	0
				02.BODY GESTURES	1	1	0	0	0	0	0
				03.LOOK	0	1	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	0	0	0	0	0
				05.SPEECH	2	0	1	1	0	0	0
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	4	Placebo	Male	08.CONTACTS, AFFECTIVE NEED	2	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	2	1	1	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	3	0	1	1	0	0	0
				12.GLOBAL EVALUATION	1	1	0	0	0	0	0
				11.Total score	13	8	5	5	2	2	2
	5	Reboxetine	Female	01.FACIAL EXPRESSION	2	1	1	1			
				02.BODY GESTURES	1	1	1	1			
				03.LOOK	1	1	1	1			
				04.OUTWARD APPEARANCE	1	0	0	0			
				05.SPEECH	2	2	2	2			
				06.VOICE	1	1	1	1			
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1			
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1			
				09.ANGUISH, ANXIETY	3	2	2	2			
				10.AGGRESSION, IRRITABILITY	1	1	1	1			
				11.SELF-AGGRESSION	0	1	1	1			
				12.GLOBAL EVALUATION	1	2	2	2			
				11.Total score	15	14	14	14			
	6	Placebo	Female	01.FACIAL EXPRESSION	2	1	1	1	1	0	0
				02.BODY GESTURES	2	2	1	1	0	0	0
				03.LOOK	1	2	1	1	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	0	1	1	0	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	0	1	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	0	0	0	0
				09.ANGUISH, ANXIETY	2	2	2	2	2	1	1
				10.AGGRESSION, IRRITABILITY	1	1	2	2	1	0	1
				11.SELF-AGGRESSION	0	0	0	0	1	0	1
				12.GLOBAL EVALUATION	1	0	1	1	1	1	1
				11.Total score	14	11	12	11	7	4	6
	7	Reboxetine	Female	01.FACIAL EXPRESSION	2	1	1	1	1	1	0
				02.BODY GESTURES	1	0	1	0	1	0	0
				03.LOOK	2	1	1	0	0	1	0
				04.OUTWARD APPEARANCE	1	1	0	0	0	0	0
				05.SPEECH	1	1	1	0	0	0	1
				06.VOICE	1	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	1	0	0	0	0	0
				09.ANGUISH, ANXIETY	2	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	0	0	1	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	0	1	0	0	0	0	0
				11.Total score	14	8	6	2	3	3	2

1398

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	8	Placebo	Male	01.FACIAL EXPRESSION	1	1	1	1	0	0	0
				02.BODY GESTURES	1	0	0	0	0	0	0
				03.LOOK	1	0	1	0	0	0	0
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	2	0	1	0	0	0	0
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	0	1	0	1	0	0
				09.ANGUISH, ANXIETY	2	2	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	0	0	0	1	1	1	1
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	0	1	1	1	1	0	0
				11.Total score	9	4	6	4	4	2	2
	9	Reboxetine	Female	01.FACIAL EXPRESSION	1	1	1	1	1	1	0
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	1	1	1	1	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	1	0
				06.VOICE	1	1	1	1	0	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	2	1	0
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	0	1	1	1	1	1	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	1	1	1	1	1	1	1
				11.Total score	10	11	11	11	11	11	5
	10	Placebo	Male	01.FACIAL EXPRESSION	2	1	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	0	1	0	1	1	1	1
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	1	1	1	1	1	1
				11.Total score	12	10	10	11	11	11	11
	11	Imipramine	Female	01.FACIAL EXPRESSION	1						
				02.BODY GESTURES	1						
				03.LOOK	1						
				04.OUTWARD APPEARANCE	1						
				05.SPEECH	1						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	11	Imipramine	Female	06.VOICE	1						
				07.ADAPTABILITY, SUGGESTIBILITY	1						
				08.CONTACTS, AFFECTIVE NEED	1						
				09.ANGUISH, ANXIETY	1						
				10.AGGRESSION, IRRITABILITY	0						
				11.SELF-AGGRESSION	0						
				12.GLOBAL EVALUATION	1						
				11.Total score	10						
	12	Imipramine	Female	01.FACIAL EXPRESSION	1	1	1	1	0	0	0
				02.BODY GESTURES	1	1	1	1	0	0	0
				03.LOOK	1	1	1	1	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	0	0	0
				05.SPEECH	1	1	0	0	1	0	0
				06.VOICE	1	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	0	1	0	0	0
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	0	1	1	1
				11.SELF-AGGRESSION	0	1	0	0	0	1	0
				12.GLOBAL EVALUATION	1	1	0	1	0	0	0
				11.Total score	11	11	6	7	3	3	2
	412	Reboxetine	Male	01.FACIAL EXPRESSION	1	1	1	0	1	1	0
				02.BODY GESTURES	1	1	0	0	1	1	0
				03.LOOK	1	0	0	0	1	1	0
				04.OUTWARD APPEARANCE	1	0	0	1	1	1	0
				05.SPEECH	1	0	1	0	1	0	0
				06.VOICE	1	1	1	0	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	0	1	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	0	1	0	0
				09.ANGUISH, ANXIETY	1	1	1	1	1	0	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	0	0	1
				11.SELF-AGGRESSION	1	0	0	0	1	0	0
				12.GLOBAL EVALUATION	1	1	1	1	1	0	0
				11.Total score	12	8	8	4	11	4	2
	413	Placebo	Male	01.FACIAL EXPRESSION	1	1		1		0	1
				02.BODY GESTURES	1	1		1		0	1
				03.LOOK	1	1		1		1	1
				04.OUTWARD APPEARANCE	1	1		1		1	1
				05.SPEECH	1	1		1		1	1
				06.VOICE	1	1		1		1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1		1		1	1
				08.CONTACTS, AFFECTIVE NEED	1	1		1		1	1
				09.ANGUISH, ANXIETY	1	1		1		1	1
				10.AGGRESSION, IRRITABILITY	1	1		1		0	0
				11.SELF-AGGRESSION	0	0		0		0	0
				12.GLOBAL EVALUATION	1	1		1		1	1

1400

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	413	Placebo	Male	11.Total score	11	11		11		8	10
	414	Imipramine	Female	01.FACIAL EXPRESSION	1	2	2				
				02.BODY GESTURES	1	2	2				
				03.LOOK	1	2	1				
				04.OUTWARD APPEARANCE	1	1	2				
				05.SPEECH	1	2	2				
				06.VOICE	1	1	2				
				07.ADAPTABILITY, SUGGESTIBILITY	1	2	2				
				08.CONTACTS, AFFECTIVE NEED	1	1	2				
				09.ANGUISH, ANXIETY	2	2	2				
				10.AGGRESSION, IRRITABILITY	1	0	0				
				11.SELF-AGGRESSION	0	0	0				
				12.GLOBAL EVALUATION	1	1	2				
				11.Total score	12	16	19				
	415	Imipramine	Male	01.FACIAL EXPRESSION	1	1	1	0	1	0	0
				02.BODY GESTURES	0	0	0	1	0	0	0
				03.LOOK	0	0	1	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	0	1	0	0	0
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	0	1	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	0
				09.ANGUISH, ANXIETY	1	1	1	2	1	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	1	0	0	0
				11.SELF-AGGRESSION	1	0	0	0	0	0	0
				12.GLOBAL EVALUATION	1	1	1	1	0	0	0
				11.Total score	9	8	8	9	5	3	1
	416	Reboxetine	Female	01.FACIAL EXPRESSION	1	1	1				
				02.BODY GESTURES	1	1	1				
				03.LOOK	1	1	1				
				04.OUTWARD APPEARANCE	2	1	1				
				05.SPEECH	1	1	1				
				06.VOICE	1	1	1				
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1				
				08.CONTACTS, AFFECTIVE NEED	1	1	1				
				09.ANGUISH, ANXIETY	1	1	2				
				10.AGGRESSION, IRRITABILITY	1	1	0				
				11.SELF-AGGRESSION	0	0	0				
				12.GLOBAL EVALUATION	1	1	1				
				11.Total score	12	11	11				
	421	Imipramine	Male	01.FACIAL EXPRESSION	2	2	1	1	1	0	0
				02.BODY GESTURES	2	2	1	1	1	0	0
				03.LOOK	1	1	1	0	0	1	0
				04.OUTWARD APPEARANCE	2	1	1	0	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	421	Imipramine	Male	05.SPEECH	1	1	1	1	0	1	1
				06.VOICE	1	1	0	1	0	0	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	2	2	0	1	1	1	0
				09.ANGUISH, ANXIETY	1	1	1	0	1	1	1
				10.AGGRESSION, IRRITABILITY	0	0	1	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	1	1	1	1	1	1	0
				11.Total score	15	13	9	7	7	7	3
	422	Imipramine	Male	01.FACIAL EXPRESSION	2	1	1	0	0	1	0
				02.BODY GESTURES	2	1	1	0	1	0	0
				03.LOOK	1	1	1	1	1	1	0
				04.OUTWARD APPEARANCE	1	1	0	0	1	1	0
				05.SPEECH	2	1	0	0	1	1	0
				06.VOICE	1	1	0	1	0	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	0	0	1	0
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	1	1	1	0	1	1	0
				11.Total score	13	10	6	3	6	8	1
2/1	49	Placebo	Female	01.FACIAL EXPRESSION	2	2	0	0	0	0	0
				02.BODY GESTURES	1	1	0	0	0	0	0
				03.LOOK	1	1	0	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	1	1	0	0	0	0	0
				06.VOICE	1	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	1	0	0	0	0	0
				09.ANGUISH, ANXIETY	2	2	1	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	0	0	0	0	0	0
				12.GLOBAL EVALUATION	1	1	0	0	0	0	0
				11.Total score	14	10	1	0	0	0	0
	50	Reboxetine	Female	01.FACIAL EXPRESSION	0	0	0	0	0	0	0
				02.BODY GESTURES	0	0	0	0	0	0	0
				03.LOOK	0	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	1	0	0	0	0	0	0
				06.VOICE	3	2	1	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	0	0	0	0	0	0	0
				09.ANGUISH, ANXIETY	1	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0

1402

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/1	50	Reboxetine	Female	12.GLOBAL EVALUATION	1	1	0	0	0	0	0
				11.Total score	6	3	1	0	0	0	0
	51	Imipramine	Female	01.FACIAL EXPRESSION	0	0	0	0	0	0	0
				02.BODY GESTURES	0	0	0	0	0	0	0
				03.LOOK	0	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	2	2	1	0	0	0	0
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	0	0	0	0	0
				09.ANGUISH, ANXIETY	3	3	2	1	2	2	2
				10.AGGRESSION, IRRITABILITY	1	1	2	0	0	0	0
				11.SELF-AGGRESSION	3	2	1	0	0	0	0
				12.GLOBAL EVALUATION	1	1	1	0	0	0	0
				11.Total score	12	11	7	1	2	2	2
2/2	43	Imipramine	Female	01.FACIAL EXPRESSION	2	0	1		1	1	
				02.BODY GESTURES	2	0	1		0	0	
				03.LOOK	2	1	2		0	0	
				04.OUTWARD APPEARANCE	0	0	0		0	0	
				05.SPEECH	2	1	1		1	0	
				06.VOICE	1	1	1		0	1	
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	1		0	1	
				08.CONTACTS, AFFECTIVE NEED	2	0	2		0	0	
				09.ANGUISH, ANXIETY	2	1	1		0	0	
				10.AGGRESSION, IRRITABILITY	2	1	1		0	0	
				11.SELF-AGGRESSION	1	0	0		0	0	
				12.GLOBAL EVALUATION	2	0	1		0	0	
				11.Total score	18	5	12		2	3	
	44	Imipramine	Female	01.FACIAL EXPRESSION	1	0	0	1	0	1	0
				02.BODY GESTURES	0	1	0	0	1	1	1
				03.LOOK	0	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	2	2	1	1	0	1	1
				06.VOICE	1	0	0	0	0	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	0	1	1	0	0	0
				09.ANGUISH, ANXIETY	1	3	1	1	0	1	2
				10.AGGRESSION, IRRITABILITY	2	1	2	1	1	1	2
				11.SELF-AGGRESSION	1	1	1	1	1	0	1
				12.GLOBAL EVALUATION	1	0	0	1	0	1	1
				11.Total score	11	8	6	7	3	7	8
	45	Reboxetine	Female	01.FACIAL EXPRESSION	1	1	1	0	1	0	1
				02.BODY GESTURES	1	1	0	1	0	0	1
				03.LOOK	0	0	0	1	0	0	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/2	45	Reboxetine	Female	04.OUTWARD APPEARANCE	0	0	0	1	0	0	1
				05.SPEECH	1	0	1	0	1	1	0
				06.VOICE	1	1	0	0	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	0	1	1	0
				08.CONTACTS, AFFECTIVE NEED	1	1	0	0	0	1	0
				09.ANGUISH, ANXIETY	3	0	1	0	1	1	0
				10.AGGRESSION, IRRITABILITY	2	2	0	1	1	1	1
				11.SELF-AGGRESSION	1	1	0	1	1	1	1
				12.GLOBAL EVALUATION	2	1	0	0	1	0	0
				11.Total score	14	9	3	5	8	7	7
	46	Placebo	Female	01.FACIAL EXPRESSION	1	1		0	0		
				02.BODY GESTURES	1	1		0	0		
				03.LOOK	1	1		0	0		
				04.OUTWARD APPEARANCE	0	0		0	0		
				05.SPEECH	0	0		0	0		
				06.VOICE	1	1		0	0		
				07.ADAPTABILITY, SUGGESTIBILITY	1	1		0	0		
				08.CONTACTS, AFFECTIVE NEED	1	2		0	0		
				09.ANGUISH, ANXIETY	2	0		0	1		
				10.AGGRESSION, IRRITABILITY	2	2		1	1		
				11.SELF-AGGRESSION	2	1		1	1		
				12.GLOBAL EVALUATION	1	1		0	0		
				11.Total score	13	11		2	3		
	47	Placebo	Female	01.FACIAL EXPRESSION	1	2	1	1	2	1	1
				02.BODY GESTURES	2	0	1	1	2	1	1
				03.LOOK	2	2	1	0	2	1	2
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	1
				05.SPEECH	3	2	1	1	2	1	2
				06.VOICE	2	2	1	0	2	1	2
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	0	1	3	1	1
				08.CONTACTS, AFFECTIVE NEED	3	2	2	1	2	2	1
				09.ANGUISH, ANXIETY	3	3	1	1	2	1	2
				10.AGGRESSION, IRRITABILITY	1	2	1	1	2	2	1
				11.SELF-AGGRESSION	2	2	1	1	2	1	1
				12.GLOBAL EVALUATION	1	1	1	0	1	1	1
				11.Total score	23	19	11	8	22	13	16
	48	Reboxetine	Female	01.FACIAL EXPRESSION	3	1	2	1	2	1	1
				02.BODY GESTURES	2	2	2	1	1	1	1
				03.LOOK	3	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	2	1	2	0	0	0	0
				05.SPEECH	2	1	2	1	2	1	2
				06.VOICE	2	1	2	1	1	2	1
				07.ADAPTABILITY, SUGGESTIBILITY	3	2	2	0	0	1	1
				08.CONTACTS, AFFECTIVE NEED	3	3	1	0	1	2	2
				09.ANGUISH, ANXIETY	4	3	2	1	1	1	1
				10.AGGRESSION, IRRITABILITY	2	1	1	1	0	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/2	48	Reboxetine	Female	11.SELF-AGGRESSION	2	2	1	0	1	1	1
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	30	20	20	8	11	13	13
2/3	36/A	Imipramine	Male	01.FACIAL EXPRESSION	3	3	1	0	0	0	0
				02.BODY GESTURES	3	3	1	0	0	0	0
				03.LOOK	3	3	1	0	0	0	0
				04.OUTWARD APPEARANCE	2	2	1	0	0	0	0
				05.SPEECH	2	2	1	0	0	0	0
				06.VOICE	2	2	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	0	0
				09.ANGUISH, ANXIETY	2	2	2	2	2	1	0
				10.AGGRESSION, IRRITABILITY	2	2	3	1	1	0	0
				11.SELF-AGGRESSION	1	1	0	0	0	0	0
				12.GLOBAL EVALUATION	3	3	1	0	0	0	0
				11.Total score	27	27	14	6	5	1	0
	37	Reboxetine	Female	01.FACIAL EXPRESSION	3	3	3	1	1	1	1
				02.BODY GESTURES	3	3	3	2	2	2	2
				03.LOOK	2	2	2	1	1	1	1
				04.OUTWARD APPEARANCE	2	2	2	1	1	1	1
				05.SPEECH	2	2	2	1	1	1	1
				06.VOICE	2	2	2	1	1	1	2
				07.ADAPTABILITY, SUGGESTIBILITY	2	3	3	2	2	1	1
				08.CONTACTS, AFFECTIVE NEED	3	3	3	2	2	2	2
				09.ANGUISH, ANXIETY	3	3	3	2	2	2	2
				10.AGGRESSION, IRRITABILITY	2	2	2	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	3	3	3	2	2	2	2
				11.Total score	28	29	29	17	17	16	17
	38	Placebo	Male	01.FACIAL EXPRESSION	1	2	2	1	1	1	1
				02.BODY GESTURES	3	2	2	2	1	0	1
				03.LOOK	3	2	2	2	2	0	0
				04.OUTWARD APPEARANCE	2	2	2	2	1	1	1
				05.SPEECH	3	3	3	2	1	0	0
				06.VOICE	2	2	2	2	1	1	2
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	3	3	1	1	0
				08.CONTACTS, AFFECTIVE NEED	3	3	3	3	1	1	1
				09.ANGUISH, ANXIETY	3	3	3	3	3	2	2
				10.AGGRESSION, IRRITABILITY	3	3	3	2	3	2	2
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	3	2	2	0	1	1	1
				11.Total score	30	28	28	23	17	11	12
	39	Imipramine	Female	01.FACIAL EXPRESSION	3	3	2	1	1	1	1
				02.BODY GESTURES	3	2	2	1	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/3	39	Imipramine	Female	03.LOOK	2	2	2	1	1	0	0
				04.OUTWARD APPEARANCE	2	2	2	1	0	0	0
				05.SPEECH	2	1	2	1	0	0	0
				06.VOICE	2	2	1	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	3	3	2	1	1	1	0
				09.ANGUISH, ANXIETY	3	3	1	1	2	1	0
				10.AGGRESSION, IRRITABILITY	3	3	2	1	2	1	1
				11.SELF-AGGRESSION	2	1	1	1	1	0	0
				12.GLOBAL EVALUATION	3	3	2	1	1	1	0
				11.Total score	30	27	20	12	12	7	2
	40	Reboxetine	Female	01.FACIAL EXPRESSION	0	1	1	1	1	0	0
				02.BODY GESTURES	1	2	1	1	1	1	1
				03.LOOK	1	0	1	0	0	0	1
				04.OUTWARD APPEARANCE	2	0	0	1	1	1	0
				05.SPEECH	3	1	1	0	0	1	0
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	0	0
				08.CONTACTS, AFFECTIVE NEED	2	0	0	0	0	0	1
				09.ANGUISH, ANXIETY	1	1	1	1	0	1	1
				10.AGGRESSION, IRRITABILITY	2	2	1	0	0	1	0
				11.SELF-AGGRESSION	3	0	0	0	0	0	1
				12.GLOBAL EVALUATION	1	0	0	0	0	0	0
				11.Total score	18	8	7	5	4	5	5
	41	Placebo	Male	01.FACIAL EXPRESSION	2	2	2	2	2	1	2
				02.BODY GESTURES	2	3	2	1	1	1	2
				03.LOOK	0	1	0	0	0	2	2
				04.OUTWARD APPEARANCE	2	2	2	2	3	2	2
				05.SPEECH	2	2	1	1	1	2	1
				06.VOICE	2	2	0	2	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	3	2	2	1	1
				08.CONTACTS, AFFECTIVE NEED	2	1	2	2	1	2	1
				09.ANGUISH, ANXIETY	1	3	2	1	1	1	1
				10.AGGRESSION, IRRITABILITY	0	0	0	0	1	0	0
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	1	1	1	2	0	0
				11.Total score	18	20	16	15	16	14	14
	42	Imipramine	Female	01.FACIAL EXPRESSION	2	2	2	2	1	2	2
				02.BODY GESTURES	1	2	3	3	2	2	2
				03.LOOK	3	2	2	2	1	1	2
				04.OUTWARD APPEARANCE	2	1	1	1	2	0	0
				05.SPEECH	3	2	2	2	3	2	1
				06.VOICE	2	1	1	1	2	2	2
				07.ADAPTABILITY, SUGGESTIBILITY	0	2	2	1	2	2	0
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	2	2
				09.ANGUISH, ANXIETY	2	3	1	0	1	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/3	42	Imipramine	Female	10.AGGRESSION, IRRITABILITY	1	0	2	0	0	0	0
				11.SELF-AGGRESSION	1	1	0	1	1	0	0
				12.GLOBAL EVALUATION	2	2	2	1	2	1	2
				11.Total score	21	20	20	16	19	14	13
2/4	31	Placebo	Male	01.FACIAL EXPRESSION	3	3	2	2	2	2	2
				02.BODY GESTURES	4	4	3	3	3	2	2
				03.LOOK	3	3	3	3	3	2	2
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	3	3	2	2	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	3	3	1	1	1
				08.CONTACTS, AFFECTIVE NEED	0	0	0	0	0	0	0
				09.ANGUISH, ANXIETY	4	3	3	3	3	3	3
				10.AGGRESSION, IRRITABILITY	3	3	3	3	3	2	2
				11.SELF-AGGRESSION	3	3	2	2	2	2	2
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	30	29	25	25	22	19	19
1407	32	Reboxetine	Male	01.FACIAL EXPRESSION	3	3	3	3	2	1	0
				02.BODY GESTURES	3	3	3	3	1	1	1
				03.LOOK	3	3	3	2	1	1	1
				04.OUTWARD APPEARANCE	2	2	1	1	1	1	1
				05.SPEECH	3	3	3	2	1	1	0
				06.VOICE	4	4	4	2	1	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	3	3	1	1	0
				08.CONTACTS, AFFECTIVE NEED	3	3	3	3	1	1	0
				09.ANGUISH, ANXIETY	4	4	4	3	1	1	0
				10.AGGRESSION, IRRITABILITY	4	3	3	2	2	2	1
				11.SELF-AGGRESSION	2	2	1	1	1	1	1
				12.GLOBAL EVALUATION	3	3	2	2	1	1	1
				11.Total score	37	36	33	27	14	13	8
	33	Imipramine	Male	01.FACIAL EXPRESSION	3	3	2	1	1	1	1
				02.BODY GESTURES	3	3	3	2	1	1	0
				03.LOOK	2	2	2	2	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	1	1	0
				05.SPEECH	1	1	1	0	0	0	0
				06.VOICE	1	1	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	0
				09.ANGUISH, ANXIETY	2	2	2	2	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	0	0	0	0
				12.GLOBAL EVALUATION	2	2	2	1	0	0	0
				11.Total score	20	20	18	11	5	4	3
	34	Placebo	Female	01.FACIAL EXPRESSION	4	4	4	3	2	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/4	34	Placebo	Female	02.BODY GESTURES	4	4	3	3	2	1	1
				03.LOOK	4	4	4	3	2	1	1
				04.OUTWARD APPEARANCE	4	4	4	3	1	1	1
				05.SPEECH	4	4	3	3	2	1	0
				06.VOICE	4	4	4	3	2	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	4	3	3	2	2	1	1
				08.CONTACTS, AFFECTIVE NEED	3	3	3	3	1	1	1
				09.ANGUISH, ANXIETY	4	4	4	3	2	1	1
				10.AGGRESSION, IRRITABILITY	4	4	4	3	2	1	1
				11.SELF-AGGRESSION	2	2	2	2	1	1	0
				12.GLOBAL EVALUATION	3	3	3	2	1	1	1
				11.Total score	44	43	41	33	20	12	9
	35	Reboxetine	Female	01.FACIAL EXPRESSION	3	3	3	2	1	1	0
				02.BODY GESTURES	3	3	3	2	2	1	1
				03.LOOK	4	3	2	2	2	1	1
				04.OUTWARD APPEARANCE	3	3	2	2	2	1	0
				05.SPEECH	4	4	3	2	1	1	0
				06.VOICE	2	2	2	2	1	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	3	2	2	1	1
				08.CONTACTS, AFFECTIVE NEED	4	4	3	2	2	1	1
				09.ANGUISH, ANXIETY	4	4	3	2	1	1	1
				10.AGGRESSION, IRRITABILITY	4	4	3	2	2	1	1
				11.SELF-AGGRESSION	3	3	3	2	2	1	0
				12.GLOBAL EVALUATION	3	3	3	2	1	1	1
				11.Total score	40	39	33	24	19	12	7
	36	Imipramine	Female	01.FACIAL EXPRESSION	4	3	3	2	1	1	0
				02.BODY GESTURES	3	3	3	2	1	1	1
				03.LOOK	3	3	3	2	2	1	0
				04.OUTWARD APPEARANCE	4	4	3	2	1	1	1
				05.SPEECH	3	3	3	2	1	0	0
				06.VOICE	4	4	2	2	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	4	3	3	2	1	1	1
				08.CONTACTS, AFFECTIVE NEED	4	4	3	2	1	0	0
				09.ANGUISH, ANXIETY	4	3	3	2	1	0	0
				10.AGGRESSION, IRRITABILITY	2	2	2	2	1	1	1
				11.SELF-AGGRESSION	2	2	2	2	1	1	1
				12.GLOBAL EVALUATION	3	3	2	2	1	0	0
				11.Total score	40	37	32	24	13	8	6
2/5	73	Placebo	Male	01.FACIAL EXPRESSION	1	1	0	1	1	1	2
				02.BODY GESTURES	2	1	1	1	1	1	1
				03.LOOK	2	1	0	1	1	1	1
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	3	2	1	2	2	2	2
				06.VOICE	2	1	1	1	2	2	2
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	2	2	2
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/5	73	Placebo	Male	09.ANGUISH, ANXIETY	2	1	2	1	1	2	2
				10.AGGRESSION, IRRITABILITY	2	2	1	1	1	2	2
				11.SELF-AGGRESSION	2	1	1	1	1	1	2
				12.GLOBAL EVALUATION	2	1	1	1	2	2	2
				11.Total score	22	14	10	12	15	18	20
	74	Reboxetine	Male	01.FACIAL EXPRESSION	1	1	1	1	1	0	0
				02.BODY GESTURES	1	1	1	0	0	0	0
				03.LOOK	2	1	0	0	0	1	0
				04.OUTWARD APPEARANCE	1	1	0	1	1	0	0
				05.SPEECH	3	2	0	0	1	0	0
				06.VOICE	2	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	1	1	0	0	0	0
				09.ANGUISH, ANXIETY	3	1	1	1	0	1	0
				10.AGGRESSION, IRRITABILITY	2	0	1	0	0	0	0
				11.SELF-AGGRESSION	1	0	1	0	0	0	0
				12.GLOBAL EVALUATION	2	2	0	0	1	0	0
				11.Total score	22	11	6	3	4	2	2
	75	Imipramine	Male	01.FACIAL EXPRESSION	2	2	0	0	0	0	0
				02.BODY GESTURES	2	1	0	0	0	0	0
				03.LOOK	2	1	1	0	1	0	0
				04.OUTWARD APPEARANCE	1	2	0	0	0	0	0
				05.SPEECH	3	2	0	1	0	0	0
				06.VOICE	1	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	0	0	1	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	0	0	0	1	0
				09.ANGUISH, ANXIETY	3	2	2	0	0	1	0
				10.AGGRESSION, IRRITABILITY	3	2	2	0	0	0	1
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	3	2	0	0	0	0	0
				11.Total score	23	17	5	1	2	2	2
	76	Imipramine	Female	01.FACIAL EXPRESSION	2	2	0	2	0	0	0
				02.BODY GESTURES	2	1	0	3	0	0	0
				03.LOOK	2	1	0	2	0	1	0
				04.OUTWARD APPEARANCE	2	1	0	2	0	1	0
				05.SPEECH	1	1	0	1	0	0	0
				06.VOICE	0	0	0	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	0	1	0	1	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	2	0	0	0
				09.ANGUISH, ANXIETY	3	2	2	2	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	3	1	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	3	3	1	3	0	0	0
				11.Total score	20	16	7	20	1	3	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/5	77	Placebo	Male	01.FACIAL EXPRESSION	2	0	1	0	0	0	0
				02.BODY GESTURES	2	1	0	1	0	0	0
				03.LOOK	1	2	0	0	0	0	0
				04.OUTWARD APPEARANCE	3	1	1	0	0	0	0
				05.SPEECH	2	0	2	1	0	1	0
				06.VOICE	1	0	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	0	1	0	1	0	0
				09.ANGUISH, ANXIETY	2	2	2	1	1	0	1
				10.AGGRESSION, IRRITABILITY	0	1	1	1	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	3	1	0	0	0	0	0
				11.Total score	19	9	9	5	2	1	1
	78	Reboxetine	Female	01.FACIAL EXPRESSION	1	1	0	1	0	0	
				02.BODY GESTURES	2	1	1	0	0	0	
				03.LOOK	2	2	0	1	1	1	
				04.OUTWARD APPEARANCE	2	1	0	0	1	0	
				05.SPEECH	1	0	0	0	0	0	
				06.VOICE	1	0	0	1	0	0	
				07.ADAPTABILITY, SUGGESTIBILITY	0	1	2	0	1	0	
				08.CONTACTS, AFFECTIVE NEED	2	0	2	1	0	1	
				09.ANGUISH, ANXIETY	2	2	2	2	0	0	
				10.AGGRESSION, IRRITABILITY	2	2	1	2	0	0	
				11.SELF-AGGRESSION	0	0	0	0	0	0	
				12.GLOBAL EVALUATION	2	3	2	2	0	0	
				11.Total score	17	13	10	10	3	2	
2/6	55	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	1	0	0	0	0
				02.BODY GESTURES	2	2	1	0	0	0	0
				03.LOOK	3	2	1	0	0	0	0
				04.OUTWARD APPEARANCE	2	2	1	0	0	0	0
				05.SPEECH	2	2	1	0	0	0	0
				06.VOICE	2	2	1	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	0	0	0	0
				09.ANGUISH, ANXIETY	3	2	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	2	2	1	1	0	0	0
				11.SELF-AGGRESSION	2	1	0	0	0	0	0
				12.GLOBAL EVALUATION	2	2	1	0	0	0	0
				11.Total score	26	23	11	2	1	1	1
	56	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	2	2	1	1	2
				02.BODY GESTURES	2	2	2	2	1	1	2
				03.LOOK	2	2	2	2	1	1	2
				04.OUTWARD APPEARANCE	2	2	2	2	1	1	2
				05.SPEECH	2	1	1	1	1	1	2
				06.VOICE	2	1	1	1	1	1	2
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	1	1	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/6	56	Reboxetine	Female	08.CONTACTS, AFFECTIVE NEED	2	2	2	2	1	1	2
				09.ANGUISH, ANXIETY	2	2	2	2	1	1	2
				10.AGGRESSION, IRRITABILITY	2	2	2	2	1	1	2
				11.SELF-AGGRESSION	1	1	1	1	1	1	2
				12.GLOBAL EVALUATION	3	3	3	2	1	1	2
				11.Total score	24	22	22	21	12	12	24
	57	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	0	0	0	0
				02.BODY GESTURES	2	2	1	0	0	0	0
				03.LOOK	2	2	1	0	0	0	0
				04.OUTWARD APPEARANCE	2	2	1	0	0	0	0
				05.SPEECH	2	2	1	0	0	0	0
				06.VOICE	2	2	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	0	0
				09.ANGUISH, ANXIETY	2	1	1	0	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	0	0	0	0	0	0
				12.GLOBAL EVALUATION	3	2	1	0	0	0	0
				11.Total score	22	19	9	1	1	0	0
	58	Placebo	Female	01.FACIAL EXPRESSION	2	2	2	0	0	0	0
				02.BODY GESTURES	3	2	2	0	0	0	0
				03.LOOK	2	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	3	2	2	0	0	0	0
				06.VOICE	1	1	1	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	1	1	0	0	0	0
				09.ANGUISH, ANXIETY	2	2	1	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	0	0	0	0
				12.GLOBAL EVALUATION	3	2	1	0	0	0	0
				11.Total score	23	18	15	0	0	0	0
	59	Placebo	Male	01.FACIAL EXPRESSION	3	3	2	2	2		
				02.BODY GESTURES	3	3	2	2	2		
				03.LOOK	2	2	2	2	2		
				04.OUTWARD APPEARANCE	3	2	2	2	2		
				05.SPEECH	3	2	2	2	2		
				06.VOICE	1	2	2	2	2		
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	2		
				08.CONTACTS, AFFECTIVE NEED	3	3	2	2	2		
				09.ANGUISH, ANXIETY	2	2	2	2	2		
				10.AGGRESSION, IRRITABILITY	2	2	2	2	2		
				11.SELF-AGGRESSION	2	2	1	1	1		
				12.GLOBAL EVALUATION	3	3	2	2	2		
				11.Total score	29	28	23	23	23		

1411

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/6	60	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	0	0	0	0
				02.BODY GESTURES	2	2	1	0	0	0	0
				03.LOOK	3	2	1	0	0	0	0
				04.OUTWARD APPEARANCE	3	2	1	0	0	0	0
				05.SPEECH	2	2	1	0	0	0	0
				06.VOICE	2	2	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	0	0	0	0
				09.ANGUISH, ANXIETY	2	2	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	2	1	0	0	0	0	0
				11.SELF-AGGRESSION	2	1	0	0	0	0	0
				12.GLOBAL EVALUATION	3	3	1	0	0	0	0
				11.Total score	27	23	8	0	0	0	0
3/1	61	Imipramine	Male	01.FACIAL EXPRESSION	2	2	1	1	0	0	
				02.BODY GESTURES	2	2	1	1	0	0	
				03.LOOK	2	2	1	1	1	1	
				04.OUTWARD APPEARANCE	1	1	1	1	0	0	
				05.SPEECH	1	2	1	1	0	0	
				06.VOICE	1	1	1	1	1	1	
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	0	0	
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	
				09.ANGUISH, ANXIETY	2	2	2	1	1	1	
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	
				11.SELF-AGGRESSION	1	1	1	0	0	0	
				12.GLOBAL EVALUATION	1	1	1	1	1	1	
				11.Total score	16	17	13	10	5	5	
	62	Imipramine	Female	01.FACIAL EXPRESSION	2	1	1	1	0	0	0
				02.BODY GESTURES	2	1	0	0	1	0	0
				03.LOOK	2	1	1	1	0	0	0
				04.OUTWARD APPEARANCE	2	1	0	1	1	1	0
				05.SPEECH	2	1	0	1	1	0	0
				06.VOICE	2	1	1	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	0	0	0	1	0
				08.CONTACTS, AFFECTIVE NEED	2	1	1	1	1	0	0
				09.ANGUISH, ANXIETY	2	1	0	1	1	1	0
				10.AGGRESSION, IRRITABILITY	2	1	0	1	1	0	0
				11.SELF-AGGRESSION	2	1	0	0	0	1	1
				12.GLOBAL EVALUATION	2	1	0	0	0	1	1
				11.Total score	24	12	4	7	6	5	3
	63	Placebo	Male	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	2	2	1	1	0	0	0
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	2	2	1	1	0	1	1
				05.SPEECH	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/1	63	Placebo	Male	06.VOICE	1	1	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	2	2	2	2
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	2	2
				11.SELF-AGGRESSION	1	1	1	1	0	1	1
				12.GLOBAL EVALUATION	2	2	2	2	1	1	1
				11.Total score	19	19	16	16	9	12	12
	64	Placebo	Female	01.FACIAL EXPRESSION	2	2	2	2	2	2	2
				02.BODY GESTURES	2	2	2	2	2	2	2
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	2	2	2	2	2	2	2
				06.VOICE	2	2	2	2	2	2	2
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	16	16	16	16	16	16	16
	65	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	2	1	1	0	1	1	1
				03.LOOK	2	1	1	1	1	0	0
				04.OUTWARD APPEARANCE	2	1	1	1	0	0	0
				05.SPEECH	2	1	1	1	1	0	0
				06.VOICE	2	1	1	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	1	1	1	0	1	1
				09.ANGUISH, ANXIETY	2	3	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	3	1	1	1	0	1	1
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1
				11.Total score	23	16	12	11	9	8	8
	66	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	3	2	2	2	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	2	2	1	1	1	1	1
				05.SPEECH	2	2	1	1	1	1	1
				06.VOICE	2	2	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	2	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	0	0	0
				11.SELF-AGGRESSION	2	2	1	1	0	0	0
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1

1413

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/1	66	Reboxetine	Male	11.Total score	23	22	14	14	10	10	10
	139	Imipramine	Male	01.FACIAL EXPRESSION	2	2	3				
				02.BODY GESTURES	2	2	3				
				03.LOOK	1	1	2				
				04.OUTWARD APPEARANCE	2	2	3				
				05.SPEECH	3	3	3				
				06.VOICE	1	1	2				
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	3				
				08.CONTACTS, AFFECTIVE NEED	2	2	3				
				09.ANGUISH, ANXIETY	1	1	3				
				10.AGGRESSION, IRRITABILITY	1	1	3				
				11.SELF-AGGRESSION	1	1	2				
				12.GLOBAL EVALUATION	1	1	2				
				11.Total score	19	19	32				
	140	Placebo	Male	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	2	2	2	0	0	0	0
				03.LOOK	1	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	1	1	1	1	1	0	0
				06.VOICE	1	1	1	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	0	0	0	0
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	0	0	0	0
				12.GLOBAL EVALUATION	1	1	1	0	0	0	0
				11.Total score	14	14	13	3	3	2	2
	141	Placebo	Female	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	2	2	1	1	1	1	1
				03.LOOK	1	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	2	2	1	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	0	0	0	0
				09.ANGUISH, ANXIETY	2	2	2	2	2	2	1
				10.AGGRESSION, IRRITABILITY	2	2	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	0	0
				12.GLOBAL EVALUATION	1	1	1	1	1	1	1
				11.Total score	17	17	13	10	9	8	7
	142	Imipramine	Female	01.FACIAL EXPRESSION	1	1	1	1			
				02.BODY GESTURES	1	1	1	1			
				03.LOOK	1	1	1	1			
				04.OUTWARD APPEARANCE	1	1	1	1			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/1	142	Imipramine	Female	05.SPEECH	2	2	2	2			
				06.VOICE	2	2	2	2			
				07.ADAPTABILITY, SUGGESTIBILITY	2	3	3	3			
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2			
				09.ANGUISH, ANXIETY	2	2	2	2			
				10.AGGRESSION, IRRITABILITY	2	2	2	2			
				11.SELF-AGGRESSION	1	1	1	2			
				12.GLOBAL EVALUATION	2	2	2	2			
				11.Total score	19	20	20	21			
	143	Reboxetine	Female	01.FACIAL EXPRESSION	2	1		0	0	0	
				02.BODY GESTURES	1	1		1	1	1	
				03.LOOK	1	1		0	0	0	
				04.OUTWARD APPEARANCE	1	1		1	1	1	
				05.SPEECH	1	1		0	0	0	
				06.VOICE	2	0		0	0	0	
				07.ADAPTABILITY, SUGGESTIBILITY	1	1		1	1	1	
				08.CONTACTS, AFFECTIVE NEED	1	1		1	1	1	
				09.ANGUISH, ANXIETY	2	1		1	1	1	
				10.AGGRESSION, IRRITABILITY	2	2		1	1	0	
				11.SELF-AGGRESSION	1	0		0	0	0	
				12.GLOBAL EVALUATION	2	1		1	1	1	
				11.Total score	17	11		7	7	6	
	144	Reboxetine	Female	01.FACIAL EXPRESSION	1	1	1		0	0	0
				02.BODY GESTURES	1	1	1		0	0	0
				03.LOOK	1	1	1		0	0	0
				04.OUTWARD APPEARANCE	0	0	0		0	0	0
				05.SPEECH	1	1	1		1	1	1
				06.VOICE	2	2	1		1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	0		0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1		1	0	0
				09.ANGUISH, ANXIETY	1	1	1		1	1	1
				10.AGGRESSION, IRRITABILITY	0	0	0		0	0	0
				11.SELF-AGGRESSION	0	0	0		0	0	0
				12.GLOBAL EVALUATION	1	1	1		1	1	1
				11.Total score	9	9	8		5	4	4
	451	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	3				
				02.BODY GESTURES	2	2	2				
				03.LOOK	1	1	1				
				04.OUTWARD APPEARANCE	1	1	2				
				05.SPEECH	2	2	2				
				06.VOICE	1	1	2				
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2				
				08.CONTACTS, AFFECTIVE NEED	1	1	2				
				09.ANGUISH, ANXIETY	2	2	2				
				10.AGGRESSION, IRRITABILITY	0	0	2				
				11.SELF-AGGRESSION	1	1	1				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/1	451	Reboxetine	Female	12.GLOBAL EVALUATION	1	1	2				
				11.Total score	16	16	23				
	452	Placebo	Male	01.FACIAL EXPRESSION	2	1	0	0	0	1	1
				02.BODY GESTURES	2	1	0	0	0	1	1
				03.LOOK	1	1	0	0	0	1	1
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	1	1	1	0	0	1	1
				06.VOICE	1	1	1	0	0	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	0	0	1	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	0	0	1	1
				09.ANGUISH, ANXIETY	2	2	1	0	0	2	0
				10.AGGRESSION, IRRITABILITY	1	1	0	1	1	1	0
				11.SELF-AGGRESSION	1	1	1	0	0	0	0
				12.GLOBAL EVALUATION	1	1	1	0	0	1	1
				11.Total score	15	13	8	1	1	11	7
	453	Imipramine	Female	01.FACIAL EXPRESSION	2	1	1	0	0		0
				02.BODY GESTURES	2	1	1	0	0		0
				03.LOOK	2	1	1	0	0		0
				04.OUTWARD APPEARANCE	1	1	1	0	0		1
				05.SPEECH	1	1	1	0	0		0
				06.VOICE	2	1	1	0	1		0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1		1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1		1
				09.ANGUISH, ANXIETY	2	1	1	1	0		1
				10.AGGRESSION, IRRITABILITY	0	1	1	1	0		0
				11.SELF-AGGRESSION	1	1	1	0	0		0
				12.GLOBAL EVALUATION	2	1	1	0	1		1
				11.Total score	17	12	12	4	4		5
	454	Reboxetine	Male	01.FACIAL EXPRESSION	2	1	1	0	0	0	0
				02.BODY GESTURES	1	0	0	0	0	0	0
				03.LOOK	1	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	2	1	1	0	0	0	0
				05.SPEECH	1	0	0	0	0	0	0
				06.VOICE	1	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	1	1	1	0	0	0
				09.ANGUISH, ANXIETY	2	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	0	0	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	1	1	1	1	0	1	1
				11.Total score	15	7	7	3	1	2	2
	455	Placebo	Female	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	1	1	1	0	1	1	1
				03.LOOK	2	2	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/1	455	Placebo	Female	04.OUTWARD APPEARANCE	2	2	1	1	2	2	1
				05.SPEECH	1	1	1	1	0	0	0
				06.VOICE	2	1	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	1	2	2	2
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1
				11.Total score	16	15	11	9	10	10	9
	456	Imipramine	Female	01.FACIAL EXPRESSION	1	1	1				
				02.BODY GESTURES	1	1	1				
				03.LOOK	1	1	1				
				04.OUTWARD APPEARANCE	1	1	1				
				05.SPEECH	1	1	1				
				06.VOICE	1	1	1				
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1				
				08.CONTACTS, AFFECTIVE NEED	1	1	1				
				09.ANGUISH, ANXIETY	1	1	1				
				10.AGGRESSION, IRRITABILITY	1	1	1				
				11.SELF-AGGRESSION	1	1	1				
				12.GLOBAL EVALUATION	1	1	1				
				11.Total score	12	12	12				
3/2	65/A	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	1	2	2	1	2
				02.BODY GESTURES	2	1	1	1	2	1	1
				03.LOOK	1	1	0	1	2	1	2
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	2	1	1	1	1	1	1
				06.VOICE	1	1	0	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	2	2
				09.ANGUISH, ANXIETY	2	2	2	2	1	2	0
				10.AGGRESSION, IRRITABILITY	1	1	1	0	1	1	1
				11.SELF-AGGRESSION	3	1	1	1	2	1	1
				12.GLOBAL EVALUATION	2	2	1	1	2	2	2
				11.Total score	20	15	11	13	17	14	14
3/3	67	Placebo	Male	01.FACIAL EXPRESSION	3	2	3	2	1	0	1
				02.BODY GESTURES	3	1	2	1	1	1	1
				03.LOOK	2	2	2	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	1	1	2	1	0	0	1
				06.VOICE	0	0	2	0	0	0	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	3	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	3	2	2	1	1
				09.ANGUISH, ANXIETY	2	0	3	0	2	0	1
				10.AGGRESSION, IRRITABILITY	0	2	0	0	0	0	0

1417

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/3	67	Placebo	Male	11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	19	15	24	10	10	6	10
	68	Reboxetine	Male	01.FACIAL EXPRESSION	2	1	1	1	0	0	0
				02.BODY GESTURES	3	1	1	0	0	0	0
				03.LOOK	1	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	0	0	0	0	0
				05.SPEECH	3	2	1	0	0	0	0
				06.VOICE	2	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	0	0	0
				09.ANGUISH, ANXIETY	2	1	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	0	1	0	0	0	0
				12.GLOBAL EVALUATION	2	1	1	0	0	0	0
				11.Total score	21	13	8	3	0	0	0
	69	Placebo	Male	01.FACIAL EXPRESSION	2	2	1	1	3	1	1
				02.BODY GESTURES	3	3	1	1	2	1	1
				03.LOOK	1	2	1	0	2	0	0
				04.OUTWARD APPEARANCE	1	1	1	0	2	1	0
				05.SPEECH	2	2	2	1	3	1	1
				06.VOICE	1	1	1	1	1	1	2
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	2	1	1
				08.CONTACTS, AFFECTIVE NEED	3	3	1	0	3	2	2
				09.ANGUISH, ANXIETY	3	3	2	1	3	1	1
				10.AGGRESSION, IRRITABILITY	2	4	1	1	3	1	1
				11.SELF-AGGRESSION	2	2	2	1	2	1	1
				12.GLOBAL EVALUATION	2	3	1	1	3	1	1
				11.Total score	24	28	15	9	29	12	12
	70	Imipramine	Male	01.FACIAL EXPRESSION	3	2	1	1	1	0	0
				02.BODY GESTURES	2	2	1	1	1	1	1
				03.LOOK	1	1	0	0	0	0	0
				04.OUTWARD APPEARANCE	2	1	1	0	0	0	0
				05.SPEECH	2	1	1	0	0	1	1
				06.VOICE	1	1	1	2	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	2	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	2	1	0	1	1	0	0
				09.ANGUISH, ANXIETY	3	2	1	1	1	0	0
				10.AGGRESSION, IRRITABILITY	1	1	0	0	1	0	3
				11.SELF-AGGRESSION	2	2	1	0	0	0	0
				12.GLOBAL EVALUATION	2	2	1	1	1	0	0
				11.Total score	23	17	10	8	7	3	5
	71	Imipramine	Female	01.FACIAL EXPRESSION	1	1	0	0	0	0	0
				02.BODY GESTURES	1	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/3	71	Imipramine	Female	03.LOOK	0	1	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	1	1	1	0	0	0	0
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	0	1	1	0	0	0
				09.ANGUISH, ANXIETY	2	2	2	1	1	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	2	1	1	0	0	0
				12.GLOBAL EVALUATION	1	1	1	1	0	0	0
				11.Total score	11	10	7	5	1	0	0
	72	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	1	0	1	1	1
				02.BODY GESTURES	2	2	1	0	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	1
				05.SPEECH	2	1	1	1	1	1	1
				06.VOICE	1	1	1	0	1	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	2
				08.CONTACTS, AFFECTIVE NEED	2	1	1	0	1	1	2
				09.ANGUISH, ANXIETY	1	1	2	1	1	1	2
				10.AGGRESSION, IRRITABILITY	0	3	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	0	0	1
				12.GLOBAL EVALUATION	2	1	1	1	1	1	2
				11.Total score	17	16	13	7	10	10	15
3/4	79	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	1	0	0	0
				02.BODY GESTURES	1	1	1	1	1	0	0
				03.LOOK	1	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	2	1	1	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	1
				09.ANGUISH, ANXIETY	2	1	1	1	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	1	0	0	0
				12.GLOBAL EVALUATION	2	1	1	1	1	1	1
				11.Total score	17	13	12	7	4	3	3
	80	Imipramine	Male	01.FACIAL EXPRESSION	2	2	1	1			
				02.BODY GESTURES	1	1	1	1			
				03.LOOK	1	1	0	0			
				04.OUTWARD APPEARANCE	0	0	0	0			
				05.SPEECH	1	1	1	1			
				06.VOICE	2	1	1	1			
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	0			
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1			
				09.ANGUISH, ANXIETY	1	1	1	1			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/4	80	Imipramine	Male	10.AGGRESSION, IRRITABILITY	2	1	1	0			
				11.SELF-AGGRESSION	1	1	1	1			
				12.GLOBAL EVALUATION	2	2	1	1			
				11.Total score	16	14	11	8			
	81	Reboxetine	Female	01.FACIAL EXPRESSION	2	1	0	0	0	0	0
				02.BODY GESTURES	2	1	0	0	0	0	0
				03.LOOK	1	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	3	1	0	0	0	0	0
				06.VOICE	2	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	1	0	0	0	0	0
				09.ANGUISH, ANXIETY	3	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	0	1	0	0	1	1	0
				11.SELF-AGGRESSION	1	1	1	0	0	0	0
				12.GLOBAL EVALUATION	1	1	0	0	0	0	0
				11.Total score	19	9	2	1	2	2	1
	82	Placebo	Male	01.FACIAL EXPRESSION	2	2	1	0	0	0	1
				02.BODY GESTURES	1	1	1	0	0	0	0
				03.LOOK	1	1	1	1	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	2	2	1	1	1	1	1
				06.VOICE	2	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	0	0	0	0
				09.ANGUISH, ANXIETY	2	1	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	0	0	0	0
				11.SELF-AGGRESSION	1	1	0	0	0	0	0
				12.GLOBAL EVALUATION	1	1	1	1	1	0	0
				11.Total score	15	13	8	4	3	2	3
	83	Placebo	Male	01.FACIAL EXPRESSION	2	2					
				02.BODY GESTURES	2	2					
				03.LOOK	1	1					
				04.OUTWARD APPEARANCE	0	0					
				05.SPEECH	2	2					
				06.VOICE	2	2					
				07.ADAPTABILITY, SUGGESTIBILITY	1	1					
				08.CONTACTS, AFFECTIVE NEED	2	2					
				09.ANGUISH, ANXIETY	2	3					
				10.AGGRESSION, IRRITABILITY	1	2					
				11.SELF-AGGRESSION	1	2					
				12.GLOBAL EVALUATION	2	2					
				11.Total score	18	21					
	84	Reboxetine	Female	01.FACIAL EXPRESSION	2	1	1	1	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/4	84	Reboxetine	Female	02.BODY GESTURES	1	0	0	0	0	0	0
				03.LOOK	1	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	1	1	1	0	0	0	0
				06.VOICE	2	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	0	0	0	0
				09.ANGUISH, ANXIETY	2	2	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	0	0	0	0
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1
				11.Total score	17	12	8	3	2	2	2
	85	Imipramine	Female	01.FACIAL EXPRESSION	1	1	1	1	1	1	0
				02.BODY GESTURES	1	0	0	0	1	1	0
				03.LOOK	1	0	0	0	1	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	2	1	0	0	0	0	0
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	0	0	0	0	0
				09.ANGUISH, ANXIETY	2	1	1	1	2	1	0
				10.AGGRESSION, IRRITABILITY	1	0	0	0	1	0	0
				11.SELF-AGGRESSION	1	0	0	0	0	0	0
				12.GLOBAL EVALUATION	1	1	1	0	0	0	0
				11.Total score	12	6	4	2	6	3	0
	86	Imipramine	Male	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	0	0	0	0	0
				05.SPEECH	2	1	1	1	1	1	1
				06.VOICE	3	2	1	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	0	0	0	0
				09.ANGUISH, ANXIETY	3	2	1	1	1	2	1
				10.AGGRESSION, IRRITABILITY	2	1	1	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1
				11.Total score	22	17	10	7	7	8	7
	87	Placebo	Female	01.FACIAL EXPRESSION	2	2	1	0	1	1	1
				02.BODY GESTURES	1	1	1	0	1	1	1
				03.LOOK	1	1	1	0	1	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	2	2	1	1	2	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	0	2	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	2	2

1421

9550082

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/4	87	Placebo	Female	09.ANGUISH, ANXIETY	1	1	1	1	2	2	2
				10.AGGRESSION, IRRITABILITY	0	0	0	1	2	1	1
				11.SELF-AGGRESSION	2	1	1	1	3	1	1
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1
				11.Total score	15	14	10	7	17	12	12
	88	Placebo	Male	01.FACIAL EXPRESSION	1	1	1	1	1	1	1
				02.BODY GESTURES	1	1	1	0	0	0	0
				03.LOOK	1	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	2	1	1	1	0	0	0
				06.VOICE	1	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	1	1
				09.ANGUISH, ANXIETY	2	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	2	1	1	1	0	0	0
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1
				11.Total score	17	13	10	9	7	7	7
	89	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	2	2	2	1	0
				02.BODY GESTURES	2	2	1	1	1	1	1
				03.LOOK	2	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	0	0
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	2	1	1	1	1	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	1	1
				09.ANGUISH, ANXIETY	2	2	2	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	0	0	0	0	0	0
				12.GLOBAL EVALUATION	3	2	2	2	2	1	1
				11.Total score	20	16	15	13	13	9	7
	90	Reboxetine	Male	01.FACIAL EXPRESSION	1	1	1	1	0	0	0
				02.BODY GESTURES	1	1	1	1	1	0	0
				03.LOOK	0	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	1	1	1	0	0	0	0
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	1	0
				09.ANGUISH, ANXIETY	1	1	2	1	1	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	0	0	0
				11.SELF-AGGRESSION	1	1	0	0	0	0	0
				12.GLOBAL EVALUATION	1	1	1	1	1	1	0
				11.Total score	9	9	8	6	4	2	0

1422

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/4	457	Placebo	Female	01.FACIAL EXPRESSION	1	1	1	2			
				02.BODY GESTURES	1	1	1	1			
				03.LOOK	1	1	1	1			
				04.OUTWARD APPEARANCE	1	1	1	1			
				05.SPEECH	2	2	2	2			
				06.VOICE	1	1	1	1			
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1			
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1			
				09.ANGUISH, ANXIETY	1	1	1	2			
				10.AGGRESSION, IRRITABILITY	1	1	1	1			
				11.SELF-AGGRESSION	1	1	1	1			
				12.GLOBAL EVALUATION	0	0	0	0			
				11.Total score	12	12	12	14			
	458	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	3				
				02.BODY GESTURES	1	1	2				
				03.LOOK	1	1	1				
				04.OUTWARD APPEARANCE	1	2	2				
				05.SPEECH	2	2	2				
				06.VOICE	1	1	2				
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2				
				08.CONTACTS, AFFECTIVE NEED	2	2	2				
				09.ANGUISH, ANXIETY	1	2	2				
				10.AGGRESSION, IRRITABILITY	1	1	1				
				11.SELF-AGGRESSION	1	1	3				
				12.GLOBAL EVALUATION	1	1	2				
				11.Total score	16	18	24				
	459	Placebo	Female	01.FACIAL EXPRESSION	2	1	1	1	1	1	0
				02.BODY GESTURES	2	1	1	1	1	1	0
				03.LOOK	1	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	2	2	2	1	1	1	0
				06.VOICE	1	1	1	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	0	0
				09.ANGUISH, ANXIETY	2	2	2	2	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	2	1	1	1	1
				11.SELF-AGGRESSION	2	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	1	1	0	0	0	0
				11.Total score	19	14	15	10	9	7	3
	460	Reboxetine	Male	01.FACIAL EXPRESSION	0	0					
				02.BODY GESTURES	1	1					
				03.LOOK	0	0					
				04.OUTWARD APPEARANCE	0	0					
				05.SPEECH	2	2					
				06.VOICE	0	0					
				07.ADAPTABILITY, SUGGESTIBILITY	2	2					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/4	460	Reboxetine	Male	08.CONTACTS, AFFECTIVE NEED	2	2					
				09.ANGUISH, ANXIETY	2	2					
				10.AGGRESSION, IRRITABILITY	1	1					
				11.SELF-AGGRESSION	1	1					
				12.GLOBAL EVALUATION	1	1					
				11.Total score	12	12					
	461	Imipramine	Female	01.FACIAL EXPRESSION	1	1					
				02.BODY GESTURES	2	1					
				03.LOOK	1	1					
				04.OUTWARD APPEARANCE	2	2					
				05.SPEECH	2	2					
				06.VOICE	1	1					
				07.ADAPTABILITY, SUGGESTIBILITY	1	1					
				08.CONTACTS, AFFECTIVE NEED	2	1					
				09.ANGUISH, ANXIETY	1	2					
				10.AGGRESSION, IRRITABILITY	2	2					
				11.SELF-AGGRESSION	1	1					
				12.GLOBAL EVALUATION	2	2					
				11.Total score	18	17					
	462	Imipramine	Female	01.FACIAL EXPRESSION	2	1					
				02.BODY GESTURES	1	1					
				03.LOOK	1	0					
				04.OUTWARD APPEARANCE	1	0					
				05.SPEECH	2	1					
				06.VOICE	1	1					
				07.ADAPTABILITY, SUGGESTIBILITY	1	1					
				08.CONTACTS, AFFECTIVE NEED	1	2					
				09.ANGUISH, ANXIETY	1	1					
				10.AGGRESSION, IRRITABILITY	1	1					
				11.SELF-AGGRESSION	1	1					
				12.GLOBAL EVALUATION	2	2					
				11.Total score	15	12					
4/1	91	Imipramine	Female	01.FACIAL EXPRESSION	2	2	2	2	2	2	1
				02.BODY GESTURES	2	1	2	2	2	2	0
				03.LOOK	1	1	1	1	1	1	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	2	2	2	2	1	1	1
				06.VOICE	2	1	2	2	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	2	2	2	2	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	2	1
				09.ANGUISH, ANXIETY	2	1	2	2	2	2	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	0
				11.SELF-AGGRESSION	3	2	3	3	3	3	1
				12.GLOBAL EVALUATION	1	1	1	1	1	1	1
				11.Total score	21	16	21	21	19	19	8

1424

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/1	92	Reboxetine	Female	01.FACIAL EXPRESSION	3	3	3	3	3	3	3
				02.BODY GESTURES	3	3	3	3	3	3	3
				03.LOOK	4	4	4	3	3	3	3
				04.OUTWARD APPEARANCE	2	3	3	3	2	2	2
				05.SPEECH	3	3	3	3	3	3	3
				06.VOICE	3	4	4	3	3	2	2
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	3	3	3	2	2
				08.CONTACTS, AFFECTIVE NEED	3	3	3	3	3	3	3
				09.ANGUISH, ANXIETY	3	3	3	3	3	3	3
				10.AGGRESSION, IRRITABILITY	2	2	2	3	2	2	2
				11.SELF-AGGRESSION	4	4	4	3	3	3	3
				12.GLOBAL EVALUATION	3	3	3	3	3	3	3
				11.Total score	36	38	38	36	34	32	32
	93	Placebo	Male	01.FACIAL EXPRESSION	1	1	2	1	0	0	0
				02.BODY GESTURES	1	1	2	1	1	1	1
				03.LOOK	2	2	2	1	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	2	2	2	2	0	0	0
				06.VOICE	1	1	3	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	1	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	1	1	2	2	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	2	0	0	0
				10.AGGRESSION, IRRITABILITY	4	0	0	1	0	0	0
				11.SELF-AGGRESSION	0	0	1	1	1	1	0
				12.GLOBAL EVALUATION	1	1	2	2	0	0	0
				11.Total score	14	10	18	15	4	4	3
	94	Placebo	Female	01.FACIAL EXPRESSION	2	1	1	0	0	0	0
				02.BODY GESTURES	2	2	1	1	1	1	0
				03.LOOK	3	2	1	1	1	1	0
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	3	2	2	2	1	1	1
				06.VOICE	2	2	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	1	1	1	2	1	1
				09.ANGUISH, ANXIETY	2	1	1	0	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	0	0	0	0
				11.SELF-AGGRESSION	2	1	1	1	1	1	0
				12.GLOBAL EVALUATION	2	2	2	1	0	0	0
				11.Total score	24	17	14	9	9	8	6
	95	Imipramine	Female	01.FACIAL EXPRESSION	2	1	1	1	1	0	0
				02.BODY GESTURES	2	1	1	1	1	0	0
				03.LOOK	2	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	0	0	0
				05.SPEECH	2	1	1	1	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/1	95	Imipramine	Female	06.VOICE	3	1	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	0	0	0	0	0	0
				09.ANGUISH, ANXIETY	2	1	1	1	0	0	0
				10.AGGRESSION, IRRITABILITY	1	0	0	0	0	0	0
				11.SELF-AGGRESSION	2	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	1	1	1	0	0	0
				11.Total score	22	8	8	8	3	1	1
	96	Reboxetine	Female	01.FACIAL EXPRESSION	2	1	1	1	0	0	0
				02.BODY GESTURES	2	1	1	1	1	1	1
				03.LOOK	2	1	1	1	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	3	2	1	1	0	0	0
				06.VOICE	2	1	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	3	2	1	1	1	1	1
				09.ANGUISH, ANXIETY	3	2	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	2	2	2	1	1	1	1
				11.SELF-AGGRESSION	2	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1
				11.Total score	26	18	13	12	8	8	8
	115	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	2	1	1	1	1
				02.BODY GESTURES	2	2	2	1	1	0	0
				03.LOOK	1	1	1	1	1	0	0
				04.OUTWARD APPEARANCE	2	1	1	1	0	0	0
				05.SPEECH	2	2	2	1	1	1	1
				06.VOICE	2	2	2	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	0
				09.ANGUISH, ANXIETY	2	2	2	1	1	1	1
				10.AGGRESSION, IRRITABILITY	2	2	2	1	1	1	1
				11.SELF-AGGRESSION	2	1	1	0	0	0	0
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	23	20	20	11	10	8	6
	116	Imipramine	Female	01.FACIAL EXPRESSION	2	2					
				02.BODY GESTURES	2	2					
				03.LOOK	1	1					
				04.OUTWARD APPEARANCE	2	2					
				05.SPEECH	2	2					
				06.VOICE	1	1					
				07.ADAPTABILITY, SUGGESTIBILITY	1	1					
				08.CONTACTS, AFFECTIVE NEED	2	2					
				09.ANGUISH, ANXIETY	3	3					
				10.AGGRESSION, IRRITABILITY	2	2					
				11.SELF-AGGRESSION	2	2					
				12.GLOBAL EVALUATION	1	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/1	116	Imipramine	Female	11.Total score	21	21					
	117	Imipramine	Female	01.FACIAL EXPRESSION	3	2	1	0	0	0	0
				02.BODY GESTURES	2	2	1	1	1	0	0
				03.LOOK	2	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	2	1	1	1	1	1	0
				05.SPEECH	3	2	1	1	1	0	0
				06.VOICE	3	2	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	3	2	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	3	2	1	1	1	0	0
				09.ANGUISH, ANXIETY	2	1	1	1	1	1	0
				10.AGGRESSION, IRRITABILITY	2	1	1	1	0	0	0
				11.SELF-AGGRESSION	3	2	1	1	1	1	0
				12.GLOBAL EVALUATION	2	2	1	1	1	1	0
				11.Total score	30	20	12	11	10	7	3
1427	118	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	2	1	0	0	0
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	2	2	1	1	1	1	1
				06.VOICE	1	1	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	0	0	0
				09.ANGUISH, ANXIETY	2	2	2	1	1	1	1
				10.AGGRESSION, IRRITABILITY	2	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	17	15	14	10	7	7	7
	119	Placebo	Female	01.FACIAL EXPRESSION	2						
				02.BODY GESTURES	2						
				03.LOOK	2						
				04.OUTWARD APPEARANCE	0						
				05.SPEECH	2						
				06.VOICE	1						
				07.ADAPTABILITY, SUGGESTIBILITY	2						
				08.CONTACTS, AFFECTIVE NEED	1						
				09.ANGUISH, ANXIETY	2						
				10.AGGRESSION, IRRITABILITY	2						
				11.SELF-AGGRESSION	2						
				12.GLOBAL EVALUATION	1						
				11.Total score	19						
	120	Placebo	Female	01.FACIAL EXPRESSION	2	2	1	0	0	0	0
				02.BODY GESTURES	1	1	0	0	0	0	0
				03.LOOK	1	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/1	120	Placebo	Female	05.SPEECH	2	1	1	1	1	0	0
				06.VOICE	1	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	2	1	2	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1
				11.Total score	18	15	11	8	8	7	7
	145	Imipramine	Female	01.FACIAL EXPRESSION	2	1	1	1	0	0	0
				02.BODY GESTURES	2	1	1	1	1	1	0
				03.LOOK	1	1	1	1	0	0	0
				04.OUTWARD APPEARANCE	2	1	1	1	1	1	1
				05.SPEECH	2	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	3	2	2	1	1	1	1
				10.AGGRESSION, IRRITABILITY	3	2	2	1	1	1	0
				11.SELF-AGGRESSION	2	1	1	1	1	1	1
				12.GLOBAL EVALUATION	3	2	2	1	1	1	1
				11.Total score	25	15	15	12	10	10	8
	146	Placebo	Female	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	2	1	1	1	1	1	0
				03.LOOK	2	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	2	2	1	1	1	1	0
				05.SPEECH	3	2	1	1	1	1	0
				06.VOICE	2	2	2	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	3	2	2	1	1	1	1
				10.AGGRESSION, IRRITABILITY	2	2	2	1	1	1	1
				11.SELF-AGGRESSION	2	1	1	1	1	1	1
				12.GLOBAL EVALUATION	3	2	1	1	1	1	1
				11.Total score	27	20	16	11	11	10	8
	147	Reboxetine	Female	01.FACIAL EXPRESSION	2	1	1	1	1	1	1
				02.BODY GESTURES	2	1	1	1	1	1	1
				03.LOOK	2	1	1	1	1	0	1
				04.OUTWARD APPEARANCE	2	2	1	1	1	1	1
				05.SPEECH	2	1	1	1	1	0	0
				06.VOICE	2	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	2	1
				09.ANGUISH, ANXIETY	2	2	1	1	2	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	2	1	1	1	0	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/1	147	Reboxetine	Female	12.GLOBAL EVALUATION	3	2	2	1	1	1	1
				11.Total score	23	16	13	12	12	11	11
	148	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	2	1	1	1	1	1	1
				03.LOOK	2	1	1	0	0	1	1
				04.OUTWARD APPEARANCE	2	1	1	1	1	1	0
				05.SPEECH	2	1	1	1	1	0	1
				06.VOICE	1	1	1	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	2	2	1	1
				10.AGGRESSION, IRRITABILITY	2	2	1	1	1	0	1
				11.SELF-AGGRESSION	2	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1
				11.Total score	23	17	13	12	12	9	10
	149	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	2	1	1	1	0
				02.BODY GESTURES	2	2	2	1	1	1	0
				03.LOOK	1	1	1	1	0	0	0
				04.OUTWARD APPEARANCE	2	2	1	1	1	0	1
				05.SPEECH	2	2	2	0	1	0	0
				06.VOICE	1	1	1	1	1	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	2	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	2	1	1	1
				10.AGGRESSION, IRRITABILITY	2	2	2	1	1	1	1
				11.SELF-AGGRESSION	2	2	2	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	21	21	19	12	12	9	7
	150	Placebo	Male	01.FACIAL EXPRESSION	2	1	1	1	1	1	1
				02.BODY GESTURES	2	1	1	1	0	1	1
				03.LOOK	1	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	2	1	0	1	1	1	0
				05.SPEECH	1	1	1	1	1	0	1
				06.VOICE	1	1	0	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	2	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	2	1	1	1
				09.ANGUISH, ANXIETY	2	2	1	2	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	2	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	1	1	1	1	1	1
				11.Total score	19	13	10	14	9	9	9
4/2	93/A	Placebo	Male	01.FACIAL EXPRESSION	3	3	2	1	1	0	0
				02.BODY GESTURES	3	3	2	1	1	0	0
				03.LOOK	2	2	2	1	1	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/2	93/A	Placebo	Male	04.OUTWARD APPEARANCE	2	2	2	1	1	0	0
				05.SPEECH	3	3	2	1	1	0	0
				06.VOICE	2	2	2	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	1	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	0	0
				09.ANGUISH, ANXIETY	3	3	2	1	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	0
				11.SELF-AGGRESSION	1	1	1	1	1	0	0
				12.GLOBAL EVALUATION	2	2	2	1	1	0	0
				11.Total score	26	26	22	12	10	1	0
	99/A	Placebo	Male	01.FACIAL EXPRESSION	2	2	1	1	1	0	0
				02.BODY GESTURES	3	3	2	2	1	0	0
				03.LOOK	2	2	1	1	1	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	0	0
				05.SPEECH	2	2	1	1	1	0	0
				06.VOICE	2	2	1	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	0	0
				09.ANGUISH, ANXIETY	2	2	1	1	1	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	1	0	0	0
				12.GLOBAL EVALUATION	2	2	1	1	1	0	0
				11.Total score	21	21	12	12	10	0	0
	104	Reboxetine	Male	01.FACIAL EXPRESSION	3	3	3	2	2	2	2
				02.BODY GESTURES	3	3	3	2	2	2	2
				03.LOOK	2	2	2	2	2	2	2
				04.OUTWARD APPEARANCE	2	2	2	2	2	2	2
				05.SPEECH	2	2	2	2	2	2	2
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	3	2	2	2	2
				08.CONTACTS, AFFECTIVE NEED	2	2	3	2	2	2	2
				09.ANGUISH, ANXIETY	3	3	2	2	2	2	2
				10.AGGRESSION, IRRITABILITY	2	2	2	2	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	26	26	26	22	21	21	21
4/3	97	Placebo	Male	01.FACIAL EXPRESSION	1	0	0	0	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	0	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	2	2	2	2
				08.CONTACTS, AFFECTIVE NEED	1	2	2	2	2	2	2
				09.ANGUISH, ANXIETY	2	2	2	2	2	2	2
				10.AGGRESSION, IRRITABILITY	1	1	1	1	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/3	97	Placebo	Male	11.SELF-AGGRESSION	0	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	11	13	13	14	16	16	16
	98	Reboxetine	Female	01.FACIAL EXPRESSION	1	2	2	1	1	2	
				02.BODY GESTURES	1	2	2	1	1	2	
				03.LOOK	1	1	1	1	1	2	
				04.OUTWARD APPEARANCE	1	1	1	1	1	2	
				05.SPEECH	1	1	1	1	1	2	
				06.VOICE	1	1	1	1	1	2	
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	1	1	2	
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	2	
				09.ANGUISH, ANXIETY	2	2	2	1	1	2	
				10.AGGRESSION, IRRITABILITY	2	1	1	1	1	2	
				11.SELF-AGGRESSION	1	1	1	1	1	2	
				12.GLOBAL EVALUATION	2	2	2	1	1	2	
				11.Total score	17	18	18	12	12	24	
	99	Placebo	Female	01.FACIAL EXPRESSION	2	2	2				
				02.BODY GESTURES	2	2	2				
				03.LOOK	1	2	2				
				04.OUTWARD APPEARANCE	1	2	1				
				05.SPEECH	2	2	2				
				06.VOICE	2	2	2				
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2				
				08.CONTACTS, AFFECTIVE NEED	2	2	2				
				09.ANGUISH, ANXIETY	2	2	2				
				10.AGGRESSION, IRRITABILITY	2	2	2				
				11.SELF-AGGRESSION	1	1	1				
				12.GLOBAL EVALUATION	2	2	2				
				11.Total score	21	23	22				
	100	Imipramine	Female	01.FACIAL EXPRESSION	2	2	2	2			
				02.BODY GESTURES	2	2	2	2			
				03.LOOK	2	2	2	2			
				04.OUTWARD APPEARANCE	2	1	2	2			
				05.SPEECH	2	1	1	1			
				06.VOICE	1	1	1	1			
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1			
				08.CONTACTS, AFFECTIVE NEED	2	1	1	1			
				09.ANGUISH, ANXIETY	2	2	2	2			
				10.AGGRESSION, IRRITABILITY	1	1	2	2			
				11.SELF-AGGRESSION	1	1	1	1			
				12.GLOBAL EVALUATION	2	2	2	2			
				11.Total score	21	17	19	19			
	101	Imipramine	Male	01.FACIAL EXPRESSION	2	2	1	1	1	0	0
				02.BODY GESTURES	2	2	1	1	1	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/3	101	Imipramine	Male	03.LOOK	2	2	1	1	0	0	0
				04.OUTWARD APPEARANCE	2	2	1	1	0	0	0
				05.SPEECH	2	2	1	1	1	0	1
				06.VOICE	2	2	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	1	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	0	1	1
				09.ANGUISH, ANXIETY	2	2	1	1	0	1	0
				10.AGGRESSION, IRRITABILITY	2	2	1	1	0	0	0
				11.SELF-AGGRESSION	1	1	1	0	0	0	0
				12.GLOBAL EVALUATION	2	2	2	2	1	1	0
				11.Total score	23	23	15	12	4	3	2
4/4	109	Reboxetine	Female	01.FACIAL EXPRESSION	2	1	1	0	0	0	0
				02.BODY GESTURES	1	1	1	0	0	0	0
				03.LOOK	1	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	2	2	1	1	0	0	0
				06.VOICE	2	1	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	0	0	0	0
				09.ANGUISH, ANXIETY	2	2	1	1	1	1	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	2	1	0	0	0	0
				11.Total score	18	13	9	4	2	1	0
	110	Imipramine	Male	01.FACIAL EXPRESSION	2	1	2	1	1	1	1
				02.BODY GESTURES	2	2	2	1	1	1	1
				03.LOOK	2	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	2	2	2	1	1	1	1
				05.SPEECH	2	2	2	1	1	1	1
				06.VOICE	3	2	2	1	0	0	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	1	2	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	1	1	0	1
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	0	0	0	0
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	22	18	20	10	9	8	10
	111	Imipramine	Male	01.FACIAL EXPRESSION	3	2	1	1	1	0	0
				02.BODY GESTURES	2	3	2	1	1	1	0
				03.LOOK	2	2	1	1	0	0	0
				04.OUTWARD APPEARANCE	2	2	2	1	1	1	0
				05.SPEECH	3	3	2	2	1	0	0
				06.VOICE	3	3	2	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	2	2	1	1	1
				08.CONTACTS, AFFECTIVE NEED	3	3	2	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/4	111	Imipramine	Male	10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	25	25	18	12	9	6	4
	112	Placebo	Male	01.FACIAL EXPRESSION	1	1	1	1	1	2	1
				02.BODY GESTURES	2	1	1	1	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	2	1	1	1	1	2	2
				06.VOICE	1	1	1	1	1	2	2
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	0	0	0	0
				12.GLOBAL EVALUATION	2	1	1	1	1	2	2
				11.Total score	17	13	12	10	10	14	13
	113	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	2	2	1	1	1	0	0
				03.LOOK	1	1	1	1	1	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	0
				05.SPEECH	2	2	2	1	1	1	0
				06.VOICE	2	2	1	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	2	2	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	0
				09.ANGUISH, ANXIETY	2	2	2	1	1	1	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	4	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	2	2	1	1	0	0
				11.Total score	21	18	15	10	10	6	3
	114	Placebo	Female	01.FACIAL EXPRESSION	2	2	1	1	1	1	0
				02.BODY GESTURES	1	1	1	1	1	1	0
				03.LOOK	2	1	1	1	0	0	0
				04.OUTWARD APPEARANCE	2	1	1	1	1	0	0
				05.SPEECH	1	1	1	1	1	1	0
				06.VOICE	2	1	1	1	1	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	0	0	0
				09.ANGUISH, ANXIETY	2	2	2	1	1	1	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	1	0	0	0	0	0
				12.GLOBAL EVALUATION	2	1	1	1	1	1	0
				11.Total score	19	15	11	10	8	6	2
	175	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	1	1	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/4	175	Imipramine	Female	02.BODY GESTURES	2	2	1	1	0	0	0
				03.LOOK	2	2	0	0	0	0	0
				04.OUTWARD APPEARANCE	2	1	0	0	0	0	0
				05.SPEECH	2	2	1	1	0	0	0
				06.VOICE	2	1	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	1	1	1	0	1	0
				09.ANGUISH, ANXIETY	2	2	1	1	1	1	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	2	1	1	0	0	0
				11.Total score	19	16	8	8	2	2	0
	176	Placebo	Female	01.FACIAL EXPRESSION	2	2	1	1	2		
				02.BODY GESTURES	1	1	1	1	2		
				03.LOOK	1	1	1	1	2		
				04.OUTWARD APPEARANCE	1	1	1	1	2		
				05.SPEECH	2	1	1	1	2		
				06.VOICE	1	1	1	1	2		
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1		
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	2		
				09.ANGUISH, ANXIETY	2	2	2	2	2		
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0		
				11.SELF-AGGRESSION	0	0	0	0	4		
				12.GLOBAL EVALUATION	1	1	1	1	2		
				11.Total score	13	12	11	11	23		
	177	Imipramine	Female	01.FACIAL EXPRESSION	1	2	1				
				02.BODY GESTURES	1	1	1				
				03.LOOK	2	2	1				
				04.OUTWARD APPEARANCE	2	2	1				
				05.SPEECH	2	2	2				
				06.VOICE	2	2	2				
				07.ADAPTABILITY, SUGGESTIBILITY	1	2	1				
				08.CONTACTS, AFFECTIVE NEED	2	2	1				
				09.ANGUISH, ANXIETY	2	2	2				
				10.AGGRESSION, IRRITABILITY	0	1	1				
				11.SELF-AGGRESSION	0	0	0				
				12.GLOBAL EVALUATION	2	2	1				
				11.Total score	17	20	14				
	178	Reboxetine	Female	01.FACIAL EXPRESSION	2	1	1	0	0	0	0
				02.BODY GESTURES	2	1	1	0	1	0	0
				03.LOOK	2	1	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	2	2	0	0	1	0	0
				06.VOICE	2	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/4	178	Reboxetine	Female	09.ANGUISH, ANXIETY	2	1	0	1	1	1	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	1	0	0	0	0	0
				11.Total score	18	11	3	1	3	1	0
	179	Placebo	Female	01.FACIAL EXPRESSION	2	1	1	2			
				02.BODY GESTURES	2	2	1	2			
				03.LOOK	2	2	2	2			
				04.OUTWARD APPEARANCE	2	2	1	2			
				05.SPEECH	2	1	1	2			
				06.VOICE	1	1	1	2			
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	2			
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2			
				09.ANGUISH, ANXIETY	2	2	1	3			
				10.AGGRESSION, IRRITABILITY	0	0	0	0			
				11.SELF-AGGRESSION	1	1	1	3			
				12.GLOBAL EVALUATION	2	2	2	3			
				11.Total score	19	17	14	25			
	180	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	1	0	0	0	0
				02.BODY GESTURES	1	2	1	1	1	0	0
				03.LOOK	2	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	0	0	0
				05.SPEECH	2	2	1	0	0	0	0
				06.VOICE	1	1	1	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	0	0
				09.ANGUISH, ANXIETY	2	2	1	1	1	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	1
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	2	1	0	0	0	0
				11.Total score	16	16	10	5	3	0	1
5/1	127	Reboxetine	Male	01.FACIAL EXPRESSION	4	2	2	2	2	2	2
				02.BODY GESTURES	3	2	1	2	2	1	1
				03.LOOK	3	2	2	1	2	2	2
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	3	2	1	1	2	1	2
				06.VOICE	2	1	1	1	2	1	2
				07.ADAPTABILITY, SUGGESTIBILITY	3	1	1	1	2	1	1
				08.CONTACTS, AFFECTIVE NEED	3	1	1	2	2	2	2
				09.ANGUISH, ANXIETY	1	1	1	1	0	1	1
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	1	0
				11.SELF-AGGRESSION	2	1	1	1	0	2	1
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	27	15	13	13	15	15	15

1435

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
5/1	128	Reboxetine	Female	01.FACIAL EXPRESSION	1	1	0	0	0	0	1
				02.BODY GESTURES	1	0	0	1	0	0	0
				03.LOOK	2	1	2	1	1	1	0
				04.OUTWARD APPEARANCE	2	0	0	1	0	0	0
				05.SPEECH	1	1	0	0	0	0	0
				06.VOICE	1	1	1	0	0	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	1	1	1	0	0	0
				09.ANGUISH, ANXIETY	3	1	1	1	1	1	2
				10.AGGRESSION, IRRITABILITY	1	0	1	1	0	0	1
				11.SELF-AGGRESSION	2	1	2	2	1	1	1
				12.GLOBAL EVALUATION	2	1	0	0	0	0	0
				11.Total score	19	8	8	8	3	4	6
	129	Placebo	Male	01.FACIAL EXPRESSION	2	1	1	1	0	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	2	1	1	0	0	0	1
				04.OUTWARD APPEARANCE	2	2	1	0	0	0	0
				05.SPEECH	2	2	1	2	1	1	1
				06.VOICE	2	1	2	1	1	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	0	0	1	1	0	1
				08.CONTACTS, AFFECTIVE NEED	2	1	1	1	0	0	0
				09.ANGUISH, ANXIETY	3	1	1	1	0	1	2
				10.AGGRESSION, IRRITABILITY	1	0	0	0	0	0	0
				11.SELF-AGGRESSION	3	3	2	1	0	0	2
				12.GLOBAL EVALUATION	2	1	2	1	0	1	1
				11.Total score	24	14	13	10	4	6	10
	130	Placebo	Male	01.FACIAL EXPRESSION	2	2	1	2	1	0	2
				02.BODY GESTURES	1	1	1	2	1	0	1
				03.LOOK	3	2	2	2	0	1	0
				04.OUTWARD APPEARANCE	2	2	1	1	0	0	0
				05.SPEECH	3	2	2	2	1	1	2
				06.VOICE	2	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	1	0	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	1	0	1
				09.ANGUISH, ANXIETY	2	2	2	2	0	0	2
				10.AGGRESSION, IRRITABILITY	0	1	1	1	0	1	0
				11.SELF-AGGRESSION	1	1	1	2	0	0	0
				12.GLOBAL EVALUATION	2	2	2	2	0	0	1
				11.Total score	22	20	18	21	6	4	11
	131	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	2	1	1	0
				02.BODY GESTURES	2	1	1	2	1	1	1
				03.LOOK	1	2	1	1	1	0	0
				04.OUTWARD APPEARANCE	2	1	1	1	1	1	1
				05.SPEECH	2	2	1	2	2	1	0
				06.VOICE	2	2	1	2	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	2	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
5/1	131	Imipramine	Female	08.CONTACTS, AFFECTIVE NEED	3	2	2	2	2	2	1
				09.ANGUISH, ANXIETY	3	2	1	1	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	0	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	0	0	0	0
				12.GLOBAL EVALUATION	1	1	1	1	1	1	0
				11.Total score	23	20	13	15	11	8	4
	132	Imipramine	Male	01.FACIAL EXPRESSION	1	0	0	0	0		0
				02.BODY GESTURES	1	0	0	0	0		0
				03.LOOK	1	0	0	0	0		0
				04.OUTWARD APPEARANCE	0	0	0	0	0		0
				05.SPEECH	2	0	0	0	0		0
				06.VOICE	2	0	0	0	0		0
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	0	0	0		0
				08.CONTACTS, AFFECTIVE NEED	2	0	0	0	0		0
				09.ANGUISH, ANXIETY	1	0	0	0	0		0
				10.AGGRESSION, IRRITABILITY	2	0	0	0	0		0
				11.SELF-AGGRESSION	1	0	0	0	0		0
				12.GLOBAL EVALUATION	1	0	0	0	0		0
				11.Total score	15	0	0	0	0		0
5/2	121	Imipramine	Female	01.FACIAL EXPRESSION	2	2	2	2	1	1	2
				02.BODY GESTURES	1	1	1	2	1	1	2
				03.LOOK	1	1	0	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	0	1	0
				05.SPEECH	3	2	2	2	2	2	2
				06.VOICE	1	2	1	1	2	1	2
				07.ADAPTABILITY, SUGGESTIBILITY	1	2	2	1	1	1	2
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	0	1	3
				09.ANGUISH, ANXIETY	2	3	3	2	2	1	3
				10.AGGRESSION, IRRITABILITY	0	0	0	0	1	2	1
				11.SELF-AGGRESSION	2	1	1	1	1	1	2
				12.GLOBAL EVALUATION	2	2	1	2	2	2	2
				11.Total score	18	19	16	17	14	15	22
	125	Reboxetine	Male	01.FACIAL EXPRESSION	2	1	1	0	0	0	0
				02.BODY GESTURES	3	1	1	0	1	1	0
				03.LOOK	2	1	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	0	1	0	1	0
				05.SPEECH	2	0	1	0	0	0	0
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	0	0	0	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	0	1	1
				09.ANGUISH, ANXIETY	2	3	0	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	2	1	0	1	1	1
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	1	1	0	1	1	0
				11.Total score	18	12	6	3	4	7	4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
5/3	133	Placebo	Male	01.FACIAL EXPRESSION	2	3	3				
				02.BODY GESTURES	2	2	3				
				03.LOOK	1	1	1				
				04.OUTWARD APPEARANCE	1	1	1				
				05.SPEECH	2	3	3				
				06.VOICE	1	1	1				
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1				
				08.CONTACTS, AFFECTIVE NEED	2	2	2				
				09.ANGUISH, ANXIETY	2	2	2				
				10.AGGRESSION, IRRITABILITY	0	0	1				
				11.SELF-AGGRESSION	2	2	2				
				12.GLOBAL EVALUATION	2	2	2				
				11.Total score	18	20	22				
	134	Reboxetine	Female	01.FACIAL EXPRESSION	1	1	0	0	0		0
				02.BODY GESTURES	1	1	0	0	0		0
				03.LOOK	1	1	0	0	0		0
				04.OUTWARD APPEARANCE	0	0	0	0	0		0
				05.SPEECH	2	1	0	0	0		0
				06.VOICE	1	1	0	0	0		0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	1	0		0
				08.CONTACTS, AFFECTIVE NEED	1	1	0	0	0		0
				09.ANGUISH, ANXIETY	2	2	1	3	0		0
				10.AGGRESSION, IRRITABILITY	0	0	0	1	0		0
				11.SELF-AGGRESSION	1	1	0	1	0		0
				12.GLOBAL EVALUATION	1	1	0	1	0		0
				11.Total score	12	11	1	7	0		0
	135	Imipramine	Female	01.FACIAL EXPRESSION	1	0	0	0	0	1	2
				02.BODY GESTURES	1	0	0	0	0	1	2
				03.LOOK	0	0	0	0	0	0	1
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	1	1	0	0	1	2	2
				06.VOICE	1	0	0	0	0	0	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	0	0	1	1
				08.CONTACTS, AFFECTIVE NEED	0	0	0	0	0	0	1
				09.ANGUISH, ANXIETY	1	1	0	0	1	2	1
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	1
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	1	1	0	0	0	1	1
				11.Total score	8	4	0	0	2	8	13
	136	Imipramine	Female	01.FACIAL EXPRESSION	2	1	0	0	0	0	0
				02.BODY GESTURES	1	0	0	0	1	0	0
				03.LOOK	1	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	2	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
5/3	136	Imipramine	Female	06.VOICE	1	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	0	0	1	0	0
				09.ANGUISH, ANXIETY	1	2	1	0	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	1	1	0	0	1	0	0
				11.Total score	12	8	1	0	3	0	0
	137	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	1	0	0	0	0
				02.BODY GESTURES	2	1	1	1	1	1	1
				03.LOOK	1	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	0	0	0	0	0
				05.SPEECH	2	1	1	0	0	0	0
				06.VOICE	2	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	0	0	0	0
				09.ANGUISH, ANXIETY	2	2	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	0	0	0	0	0	0
				12.GLOBAL EVALUATION	1	1	1	0	0	0	0
				11.Total score	19	12	6	2	2	2	2
	138	Placebo	Female	01.FACIAL EXPRESSION	1	1					
				02.BODY GESTURES	2	2					
				03.LOOK	0	0					
				04.OUTWARD APPEARANCE	1	1					
				05.SPEECH	1	1					
				06.VOICE	1	1					
				07.ADAPTABILITY, SUGGESTIBILITY	1	1					
				08.CONTACTS, AFFECTIVE NEED	2	2					
				09.ANGUISH, ANXIETY	2	2					
				10.AGGRESSION, IRRITABILITY	0	0					
				11.SELF-AGGRESSION	0	0					
				12.GLOBAL EVALUATION	1	1					
				11.Total score	12	12					
6/1	151	Imipramine	Male	01.FACIAL EXPRESSION	2	2					
				02.BODY GESTURES	2	2					
				03.LOOK	1	1					
				04.OUTWARD APPEARANCE	2	1					
				05.SPEECH	3	2					
				06.VOICE	1	1					
				07.ADAPTABILITY, SUGGESTIBILITY	1	1					
				08.CONTACTS, AFFECTIVE NEED	2	1					
				09.ANGUISH, ANXIETY	3	2					
				10.AGGRESSION, IRRITABILITY	2	1					
				11.SELF-AGGRESSION	2	2					
				12.GLOBAL EVALUATION	2	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/1	151	Imipramine	Male	11.Total score	23	17					
	152	Reboxetine	Female	01.FACIAL EXPRESSION	2	1	1	1	1	0	0
				02.BODY GESTURES	2	1	1	1	1	1	1
				03.LOOK	1	1	1	1	1	0	0
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	2	1	1	1	1	1	0
				06.VOICE	2	1	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	0	1	0
				09.ANGUISH, ANXIETY	2	2	1	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	2	1	1	1	1	1	0
				12.GLOBAL EVALUATION	2	1	1	1	1	0	0
				11.Total score	19	12	11	10	8	5	3
	153	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	1	0	0	0	0
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	2	2	1	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	1	1
				09.ANGUISH, ANXIETY	2	1	1	0	0	0	0
				10.AGGRESSION, IRRITABILITY	2	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	19	16	12	8	8	8	8
	154	Imipramine	Female	01.FACIAL EXPRESSION	1						
				02.BODY GESTURES	1						
				03.LOOK	1						
				04.OUTWARD APPEARANCE	0						
				05.SPEECH	1						
				06.VOICE	1						
				07.ADAPTABILITY, SUGGESTIBILITY	1						
				08.CONTACTS, AFFECTIVE NEED	0						
				09.ANGUISH, ANXIETY	2						
				10.AGGRESSION, IRRITABILITY	1						
				11.SELF-AGGRESSION	2						
				12.GLOBAL EVALUATION	1						
				11.Total score	12						
	155	Placebo	Male	01.FACIAL EXPRESSION	3	3	2	2	2		
				02.BODY GESTURES	2	2	2	2	2		
				03.LOOK	1	1	1	1	1		
				04.OUTWARD APPEARANCE	1	1	1	1	1		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/1	155	Placebo	Male	05.SPEECH	3	3	2	2	2		
				06.VOICE	2	2	2	1	2		
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	2		
				08.CONTACTS, AFFECTIVE NEED	3	3	2	2	3		
				09.ANGUISH, ANXIETY	3	2	1	1	1		
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1		
				11.SELF-AGGRESSION	1	1	1	1	1		
				12.GLOBAL EVALUATION	2	2	2	2	2		
				11.Total score	24	23	18	17	20		
	156	Placebo	Female	01.FACIAL EXPRESSION	3	3	1	1	1	1	1
				02.BODY GESTURES	2	2	1	1	0	0	1
				03.LOOK	2	2	1	1	1	1	0
				04.OUTWARD APPEARANCE	1	1	1	0	1	0	1
				05.SPEECH	1	1	1	1	1	0	0
				06.VOICE	1	1	0	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	0
				09.ANGUISH, ANXIETY	3	3	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	2	1	2	2	1	1	1
				11.SELF-AGGRESSION	0	1	0	1	1	1	0
				12.GLOBAL EVALUATION	2	1	1	1	1	1	0
				11.Total score	20	19	11	12	11	8	6
6/2	157	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	2	3	2	1	0	1	1
				03.LOOK	2	2	3	2	2	1	1
				04.OUTWARD APPEARANCE	1	2	1	2	2	2	1
				05.SPEECH	2	2	2	1	1	1	1
				06.VOICE	1	2	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	1	1
				09.ANGUISH, ANXIETY	3	2	2	1	2	2	2
				10.AGGRESSION, IRRITABILITY	1	2	2	2	1	2	1
				11.SELF-AGGRESSION	2	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1
				11.Total score	22	23	19	16	15	15	13
	158	Imipramine	Female	01.FACIAL EXPRESSION	2	2	2	1	1		1
				02.BODY GESTURES	2	2	2	2	2		1
				03.LOOK	1	2	1	1	2		1
				04.OUTWARD APPEARANCE	1	1	1	1	1		0
				05.SPEECH	2	2	2	2	1		0
				06.VOICE	2	2	1	1	1		1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	1	1		1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2		1
				09.ANGUISH, ANXIETY	2	2	2	1	2		0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1		1
				11.SELF-AGGRESSION	1	1	1	1	2		0

1441

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/2	158	Imipramine	Female	12.GLOBAL EVALUATION	2	2	2	1	2		0
				11.Total score	20	21	19	15	18		7
	159	Imipramine	Male	01.FACIAL EXPRESSION	1	1	1	1	0	1	0
				02.BODY GESTURES	2	2	1	1	1	1	1
				03.LOOK	1	1	1	1	0	1	0
				04.OUTWARD APPEARANCE	0	0	0	1	0	1	1
				05.SPEECH	2	1	2	1	1	1	0
				06.VOICE	1	1	1	1	1	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	0	1	0
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	2
				09.ANGUISH, ANXIETY	1	2	3	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	2	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	2	0	1	1	1
				12.GLOBAL EVALUATION	1	1	1	1	1	1	1
				11.Total score	14	15	16	11	8	12	8
	160	Placebo	Male	01.FACIAL EXPRESSION	2	1	1	1	1	1	1
				02.BODY GESTURES	2	1	1	1	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	1
				05.SPEECH	1	1	1	1	1	1	0
				06.VOICE	2	2	2	2	2	2	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	2
				08.CONTACTS, AFFECTIVE NEED	3	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	3	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	2	1	1	1	1	1	2
				11.SELF-AGGRESSION	3	1	1	1	1	1	2
				12.GLOBAL EVALUATION	2	1	1	1	1	1	1
				11.Total score	23	12	12	12	12	12	14
	161	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	1	1	1		
				02.BODY GESTURES	3	2	2	2	2		
				03.LOOK	2	2	2	2	2		
				04.OUTWARD APPEARANCE	2	2	1	1	1		
				05.SPEECH	2	2	2	2	2		
				06.VOICE	2	3	2	2	2		
				07.ADAPTABILITY, SUGGESTIBILITY	1	2	1	1	1		
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2		
				09.ANGUISH, ANXIETY	2	2	2	2	2		
				10.AGGRESSION, IRRITABILITY	1	2	2	2	2		
				11.SELF-AGGRESSION	1	2	1	1	1		
				12.GLOBAL EVALUATION	2	2	2	2	2		
				11.Total score	22	25	20	20	20		
	162	Placebo	Male	01.FACIAL EXPRESSION	3	3					
				02.BODY GESTURES	2	2					
				03.LOOK	1	1					

1442

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/2	162	Placebo	Male	04.OUTWARD APPEARANCE	2	1					
				05.SPEECH	2	2					
				06.VOICE	1	1					
				07.ADAPTABILITY, SUGGESTIBILITY	2	2					
				08.CONTACTS, AFFECTIVE NEED	1	1					
				09.ANGUISH, ANXIETY	2	2					
				10.AGGRESSION, IRRITABILITY	1	1					
				11.SELF-AGGRESSION	1	1					
				12.GLOBAL EVALUATION	2	2					
				11.Total score	20	19					
	169	Imipramine	Female	01.FACIAL EXPRESSION	3	0	3	3			
				02.BODY GESTURES	2	0	2	3			
				03.LOOK	3	0	3	3			
				04.OUTWARD APPEARANCE	3	0	3	3			
				05.SPEECH	3	0	3	3			
				06.VOICE	2	0	2	3			
				07.ADAPTABILITY, SUGGESTIBILITY	2	0	3	3			
				08.CONTACTS, AFFECTIVE NEED	3	0	3	3			
				09.ANGUISH, ANXIETY	2	0	3	3			
				10.AGGRESSION, IRRITABILITY	2	0	2	3			
				11.SELF-AGGRESSION	3	0	3	3			
				12.GLOBAL EVALUATION	2	0	3	3			
				11.Total score	30	0	33	36			
	170	Placebo	Male	01.FACIAL EXPRESSION	3	1					
				02.BODY GESTURES	2	1					
				03.LOOK	4	0					
				04.OUTWARD APPEARANCE	3	0					
				05.SPEECH	3	0					
				06.VOICE	3	1					
				07.ADAPTABILITY, SUGGESTIBILITY	3	1					
				08.CONTACTS, AFFECTIVE NEED	3	1					
				09.ANGUISH, ANXIETY	3	1					
				10.AGGRESSION, IRRITABILITY	2	0					
				11.SELF-AGGRESSION	3	1					
				12.GLOBAL EVALUATION	3	1					
				11.Total score	35	8					
	171	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	0	0	0	0
				02.BODY GESTURES	2	2	1	0	0	0	0
				03.LOOK	2	2	1	0	0	0	0
				04.OUTWARD APPEARANCE	2	2	0	0	0	0	0
				05.SPEECH	2	2	1	0	0	0	0
				06.VOICE	2	2	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	0	0	0	0
				09.ANGUISH, ANXIETY	2	2	1	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	0	0	0	0

1443

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/2	171	Imipramine	Female	11.SELF-AGGRESSION	2	2	0	0	0	0	0
				12.GLOBAL EVALUATION	2	2	1	0	0	0	0
				11.Total score	23	23	9	0	0	0	0
	172	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	2	3	3	3	3
				02.BODY GESTURES	2	2	2	2	3	3	3
				03.LOOK	2	2	2	2	2	2	3
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	3
				05.SPEECH	2	2	2	2	2	2	3
				06.VOICE	3	2	2	2	2	2	2
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	3	2	2	2	3
				08.CONTACTS, AFFECTIVE NEED	3	3	3	3	3	3	3
				09.ANGUISH, ANXIETY	3	3	3	3	3	3	3
				10.AGGRESSION, IRRITABILITY	0	1	1	1	2	2	2
				11.SELF-AGGRESSION	3	3	3	3	3	3	3
				12.GLOBAL EVALUATION	2	2	2	2	2	2	3
				11.Total score	25	25	26	26	28	28	34
1444	173	Placebo	Male	01.FACIAL EXPRESSION	2	2	2	2	3	1	1
				02.BODY GESTURES	2	2	2	2	2	1	1
				03.LOOK	2	2	2	2	3	1	1
				04.OUTWARD APPEARANCE	2	2	2	2	2	1	1
				05.SPEECH	2	2	2	2	3	1	1
				06.VOICE	2	2	2	2	2	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	2	2	1
				08.CONTACTS, AFFECTIVE NEED	3	3	3	3	3	2	1
				09.ANGUISH, ANXIETY	3	3	3	3	3	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	2	2	2
				11.SELF-AGGRESSION	3	3	3	3	3	1	2
				12.GLOBAL EVALUATION	2	2	2	2	3	2	2
				11.Total score	26	26	26	26	31	16	14
	174	Reboxetine	Male	01.FACIAL EXPRESSION	2	0	0	0	0	0	1
				02.BODY GESTURES	2	1	0	0	0	0	1
				03.LOOK	4	0	0	0	0	0	1
				04.OUTWARD APPEARANCE	3	0	0	0	0	0	0
				05.SPEECH	2	0	1	0	0	0	1
				06.VOICE	2	1	0	0	0	0	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	0	0	0	0	0	1
				08.CONTACTS, AFFECTIVE NEED	3	1	0	0	0	0	2
				09.ANGUISH, ANXIETY	3	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	3	0	0	0	0	0	1
				11.SELF-AGGRESSION	3	1	0	0	0	0	1
				12.GLOBAL EVALUATION	2	0	0	0	0	0	2
				11.Total score	31	4	1	0	0	0	12
6/3	163	Reboxetine	Male	01.FACIAL EXPRESSION	2	2					
				02.BODY GESTURES	2	2					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/3	163	Reboxetine	Male	03.LOOK	1	1					
				04.OUTWARD APPEARANCE	1	1					
				05.SPEECH	2	2					
				06.VOICE	2	2					
				07.ADAPTABILITY, SUGGESTIBILITY	2	2					
				08.CONTACTS, AFFECTIVE NEED	2	2					
				09.ANGUISH, ANXIETY	3	3					
				10.AGGRESSION, IRRITABILITY	2	2					
				11.SELF-AGGRESSION	2	2					
				12.GLOBAL EVALUATION	2	2					
				11.Total score	23	23					
	164	Imipramine	Male	01.FACIAL EXPRESSION	1	2	2	2	1	1	0
				02.BODY GESTURES	2	2	1	1	1	1	1
				03.LOOK	2	2	2	2	1	1	1
				04.OUTWARD APPEARANCE	1	1	0	1	1	1	0
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	1	1
				09.ANGUISH, ANXIETY	2	2	1	1	2	1	1
				10.AGGRESSION, IRRITABILITY	1	3	1	1	2	1	1
				11.SELF-AGGRESSION	2	2	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1
				11.Total score	19	22	14	15	15	12	8
	165	Imipramine	Female	01.FACIAL EXPRESSION	2	1	1	1	0	0	0
				02.BODY GESTURES	2	1	1	1	1	1	1
				03.LOOK	2	1	1	1	1	0	1
				04.OUTWARD APPEARANCE	1	1	1	0	1	1	1
				05.SPEECH	2	1	1	1	1	1	2
				06.VOICE	1	1	1	1	0	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	0	1	2
				08.CONTACTS, AFFECTIVE NEED	3	1	1	1	1	2	1
				09.ANGUISH, ANXIETY	2	1	1	1	1	2	2
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	0
				11.SELF-AGGRESSION	1	1	1	1	1	1	2
				12.GLOBAL EVALUATION	2	1	1	1	1	2	1
				11.Total score	21	12	12	11	9	13	13
	166	Reboxetine	Female	01.FACIAL EXPRESSION	2	3					
				02.BODY GESTURES	2	3					
				03.LOOK	1	1					
				04.OUTWARD APPEARANCE	2	1					
				05.SPEECH	2	3					
				06.VOICE	1	2					
				07.ADAPTABILITY, SUGGESTIBILITY	1	3					
				08.CONTACTS, AFFECTIVE NEED	2	3					
				09.ANGUISH, ANXIETY	2	3					

1445

9550082

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/3	166	Reboxetine	Female	10.AGGRESSION, IRRITABILITY	1	2					
				11.SELF-AGGRESSION	1	3					
				12.GLOBAL EVALUATION	2	2					
				11.Total score	19	29					
	167	Placebo	Female	01.FACIAL EXPRESSION	1	1	1	1	1	0	0
				02.BODY GESTURES	1	2	1	1	1	1	1
				03.LOOK	0	1	2	1	1	0	0
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	2	2	1	2	1	1	1
				06.VOICE	2	2	1	1	1	0	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	2	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	1	1
				09.ANGUISH, ANXIETY	2	2	2	1	1	2	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	0	0
				11.SELF-AGGRESSION	2	2	2	2	2	2	2
				12.GLOBAL EVALUATION	2	2	2	2	1	1	1
				11.Total score	17	19	16	15	13	9	9
	168	Placebo	Female	01.FACIAL EXPRESSION	2	1	2	2	2	2	
				02.BODY GESTURES	3	2	3	2	2	2	
				03.LOOK	2	1	2	1	2	2	
				04.OUTWARD APPEARANCE	1	1	1	2	2	2	
				05.SPEECH	3	2	2	2	2	3	
				06.VOICE	2	2	2	1	2	2	
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	2	2	2	2	
				08.CONTACTS, AFFECTIVE NEED	2	2	3	2	3	3	
				09.ANGUISH, ANXIETY	3	2	2	2	2	3	
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	2	
				11.SELF-AGGRESSION	2	2	2	2	2	3	
				12.GLOBAL EVALUATION	2	2	2	2	2	2	
				11.Total score	25	19	24	21	24	28	
	505	Imipramine	Female	01.FACIAL EXPRESSION	1	1	2				
				02.BODY GESTURES	1	1	2				
				03.LOOK	2	1	1				
				04.OUTWARD APPEARANCE	1	1	1				
				05.SPEECH	2	2	2				
				06.VOICE	2	2	2				
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2				
				08.CONTACTS, AFFECTIVE NEED	2	2	2				
				09.ANGUISH, ANXIETY	2	2	2				
				10.AGGRESSION, IRRITABILITY	1	2	2				
				11.SELF-AGGRESSION	1	2	2				
				12.GLOBAL EVALUATION	2	2	2				
				11.Total score	19	20	22				
	506	Placebo	Female	01.FACIAL EXPRESSION	2	2	2	1	1	1	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/3	506	Placebo	Female	02.BODY GESTURES	1	2	2	2	2	1	2
				03.LOOK	2	2	2	1	1	0	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	2	2	2	2	1	1	1
				06.VOICE	2	2	2	2	1	1	2
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	2	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	1	1	2
				09.ANGUISH, ANXIETY	2	2	2	2	1	2	2
				10.AGGRESSION, IRRITABILITY	1	2	2	0	1	0	0
				11.SELF-AGGRESSION	2	2	2	2	2	2	2
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	21	23	23	19	16	13	18
	507	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	0	0
				03.LOOK	2	1	1	1	1	0	0
				04.OUTWARD APPEARANCE	1	1	0	0	0	0	0
				05.SPEECH	2	2	2	1	1	0	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	2	1	0
				08.CONTACTS, AFFECTIVE NEED	2	1	2	2	2	1	1
				09.ANGUISH, ANXIETY	2	2	2	1	2	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	0	0	0	0
				11.SELF-AGGRESSION	2	2	2	1	2	1	1
				12.GLOBAL EVALUATION	2	2	2	1	2	1	1
				11.Total score	20	18	16	11	15	6	6
	508	Reboxetine	Female	01.FACIAL EXPRESSION	2	1	2	1	2	1	1
				02.BODY GESTURES	2	1	1	1	1	1	1
				03.LOOK	2	2	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	0	0
				05.SPEECH	2	2	2	1	2	1	1
				06.VOICE	2	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	2	2	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	2	2
				09.ANGUISH, ANXIETY	2	1	2	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	2	0	1	1	0
				11.SELF-AGGRESSION	2	2	2	2	2	2	2
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	22	17	20	15	17	14	13
	509	Placebo	Male	01.FACIAL EXPRESSION	1	1	1	2	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	2	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	0	1	1	1	0
				05.SPEECH	2	2	2	2	2	2	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	2
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/3	509	Placebo	Male	09.ANGUISH, ANXIETY	2	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	0	0	0	1
				11.SELF-AGGRESSION	2	2	2	2	2	2	1
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	19	16	15	16	15	15	14
	510	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	2				
				02.BODY GESTURES	2	1	1				
				03.LOOK	2	1	1				
				04.OUTWARD APPEARANCE	1	1	1				
				05.SPEECH	2	2	1				
				06.VOICE	1	2	1				
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1				
				08.CONTACTS, AFFECTIVE NEED	2	2	1				
				09.ANGUISH, ANXIETY	2	2	2				
				10.AGGRESSION, IRRITABILITY	1	0	1				
				11.SELF-AGGRESSION	2	1	1				
				12.GLOBAL EVALUATION	2	2	2				
				11.Total score	21	18	15				
	511	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	1	1	3	
				02.BODY GESTURES	1	1	1	1	1	1	
				03.LOOK	1	1	1	0	0	1	
				04.OUTWARD APPEARANCE	1	1	0	1	0	1	
				05.SPEECH	2	1	2	1	1	2	
				06.VOICE	1	1	1	1	1	1	
				07.ADAPTABILITY, SUGGESTIBILITY	1	2	1	1	1	1	
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	2	2	
				09.ANGUISH, ANXIETY	2	2	1	1	1	1	
				10.AGGRESSION, IRRITABILITY	1	1	0	0	1	2	
				11.SELF-AGGRESSION	1	2	1	1	2	3	
				12.GLOBAL EVALUATION	2	2	1	1	2	3	
				11.Total score	17	18	11	10	13	21	
	512	Placebo	Female	01.FACIAL EXPRESSION	1	1					
				02.BODY GESTURES	1	1					
				03.LOOK	1	1					
				04.OUTWARD APPEARANCE	1	1					
				05.SPEECH	2	2					
				06.VOICE	2	1					
				07.ADAPTABILITY, SUGGESTIBILITY	2	2					
				08.CONTACTS, AFFECTIVE NEED	2	2					
				09.ANGUISH, ANXIETY	1	2					
				10.AGGRESSION, IRRITABILITY	1	1					
				11.SELF-AGGRESSION	2	2					
				12.GLOBAL EVALUATION	2	2					
				11.Total score	18	18					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/3	513	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	1	1	0	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	1	0	1	0	1
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	2	2	1	1	0	1	0
				06.VOICE	1	1	1	1	1	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	0	2	0	0	1	1
				11.SELF-AGGRESSION	2	2	2	1	1	0	1
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	19	16	15	9	9	8	8
7/02	181	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	2	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	2	2	2	2	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	2	2	2	2	2	2	2
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	2	2	2	2	2	2	2
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	17	17	16	15	14	14	14
	182	Placebo	Male	01.FACIAL EXPRESSION	0	2	0	2	1	1	1
				02.BODY GESTURES	1	0	1	1	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	0	1	0	1	1	1	1
				05.SPEECH	2	1	2	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	2	1	2	2	2	2
				09.ANGUISH, ANXIETY	3	2	2	2	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	2	0	1
				11.SELF-AGGRESSION	1	1	1	2	2	2	2
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	14	15	13	17	16	14	15
	183	Imipramine	Male	01.FACIAL EXPRESSION	3	3	3	2			
				02.BODY GESTURES	2	2	2	2			
				03.LOOK	2	2	2	2			
				04.OUTWARD APPEARANCE	1	1	1	1			
				05.SPEECH	2	2	2	3			
				06.VOICE	1	1	1	1			
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/02	183	Imipramine	Male	08.CONTACTS, AFFECTIVE NEED	2	2	2	1			
				09.ANGUISH, ANXIETY	2	1	2	3			
				10.AGGRESSION, IRRITABILITY	1	1	1	2			
				11.SELF-AGGRESSION	1	1	1	1			
				12.GLOBAL EVALUATION	2	2	2	2			
				11.Total score	20	19	20	21			
	184	Imipramine	Female	01.FACIAL EXPRESSION	3	3	2	1	1	0	0
				02.BODY GESTURES	2	2	2	1	1	1	1
				03.LOOK	1	1	1	1	1	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	3	3	2	1	1	0	0
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	1	1	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	2	2	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	2	1	1
				11.Total score	19	19	16	11	11	6	6
	185	Reboxetine	Male	01.FACIAL EXPRESSION	1	1	1	1	1		
				02.BODY GESTURES	1	1	1	1	1		
				03.LOOK	0	1	1	1	1		
				04.OUTWARD APPEARANCE	1	1	1	1	1		
				05.SPEECH	1	2	1	2	1		
				06.VOICE	1	1	1	1	1		
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1		
				08.CONTACTS, AFFECTIVE NEED	1	1	2	2	1		
				09.ANGUISH, ANXIETY	1	1	1	1	2		
				10.AGGRESSION, IRRITABILITY	1	1	1	1	2		
				11.SELF-AGGRESSION	2	2	2	2	2		
				12.GLOBAL EVALUATION	1	1	2	2	2		
				11.Total score	12	14	15	16	16		
	186	Placebo	Male	01.FACIAL EXPRESSION	1	1	1	1	0	0	0
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	1	1	0	0	0
				04.OUTWARD APPEARANCE	1	1	0	0	0	1	0
				05.SPEECH	2	1	1	1	1	1	1
				06.VOICE	2	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	1	1	2	1	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	2	1	1	1	1	1	0
				12.GLOBAL EVALUATION	2	1	1	1	1	1	0
				11.Total score	16	12	12	11	9	10	4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/02	535	Placebo	Male	01.FACIAL EXPRESSION	1	1	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	2	2	2	2	2	2	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	3	3	3	3	3	3	2
				10.AGGRESSION, IRRITABILITY	2	2	2	2	2	2	1
				11.SELF-AGGRESSION	2	1	1	2	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	1	1	1
				11.Total score	18	17	17	18	16	16	13
	536	Reboxetine	Female	01.FACIAL EXPRESSION	1	1	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	2	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	0	0	0	0	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1
				11.Total score	15	13	11	11	12	12	12
7/03	187	Imipramine	Female	01.FACIAL EXPRESSION	1	1	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	1	1	1	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	1	1
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	2	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	1	1
				09.ANGUISH, ANXIETY	2	2	2	2	2	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	1	1	1	1	1	1
				11.Total score	14	13	13	13	13	9	9
	188	Placebo	Male	01.FACIAL EXPRESSION	1	1	1	0	0	0	0
				02.BODY GESTURES	2	2	2	1	1	0	0
				03.LOOK	1	1	1	1	1	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	1	1
				05.SPEECH	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/03	188	Placebo	Male	06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	2	2	2	1	1	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	14	14	14	9	9	7	7
	189	Placebo	Male	01.FACIAL EXPRESSION	2	2	2	0	0	0	0
				02.BODY GESTURES	2	2	2	0	0	0	0
				03.LOOK	1	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	2	2	2	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	16	16	16	6	6	6	6
	190	Reboxetine	Male	01.FACIAL EXPRESSION	4	4	4	1	4	4	4
				02.BODY GESTURES	3	3	3	1	3	3	3
				03.LOOK	2	2	2	0	2	2	2
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	2	2	2	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	2	2	2	2
				08.CONTACTS, AFFECTIVE NEED	1	1	1	2	2	2	2
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	0	0	0	1	1	1	1
				11.SELF-AGGRESSION	0	0	0	1	1	1	1
				12.GLOBAL EVALUATION	1	1	1	1	1	1	1
				11.Total score	16	16	16	12	19	19	19
	191	Imipramine	Female	01.FACIAL EXPRESSION	2	2	2	2	2	2	
				02.BODY GESTURES	2	2	2	2	2	2	
				03.LOOK	1	1	1	1	1	1	
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	
				05.SPEECH	2	2	2	2	2	2	
				06.VOICE	1	1	1	1	2	2	
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	2	2	
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	2	
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	
				11.SELF-AGGRESSION	1	1	1	1	1	1	
				12.GLOBAL EVALUATION	3	3	3	3	3	3	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/03	191	Imipramine	Female	11.Total score	18	18	18	18	19	19	
	192	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	1	2	2	2	2
				02.BODY GESTURES	2	2	1	2	2	2	2
				03.LOOK	0	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	2	2	1	2	2	2	2
				05.SPEECH	3	3	2	2	2	2	2
				06.VOICE	3	3	3	2	2	2	2
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	2	3	3	3	3
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	2	2	2	2	2	2	2
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	22	22	17	20	20	20	20
	523	Reboxetine	Female	01.FACIAL EXPRESSION	3	3	3	1	1	1	1
				02.BODY GESTURES	2	2	2	1	1	1	1
				03.LOOK	1	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	2	2	2	2	2	2	2
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	2	2	2
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	2	2	2	2
				10.AGGRESSION, IRRITABILITY	0	0	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	0	0	0	1
				12.GLOBAL EVALUATION	2	2	2	0	1	1	1
				11.Total score	18	18	19	11	12	12	13
	524	Placebo	Female	01.FACIAL EXPRESSION	3	3	1	0	0	0	0
				02.BODY GESTURES	2	2	2	1	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	0	0	0	0	0
				05.SPEECH	3	3	3	2	2	2	2
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	2	2	2	2
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	2	2	2	1	1	1	1
				12.GLOBAL EVALUATION	3	2	2	2	2	2	2
				11.Total score	23	22	18	13	13	13	13
	525	Placebo	Female	01.FACIAL EXPRESSION	3	3	1	1	0	0	0
				02.BODY GESTURES	3	3	2	2	0	0	0
				03.LOOK	2	2	1	1	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/03	525	Placebo	Female	05.SPEECH	2	2	1	1	0	0	0
				06.VOICE	3	3	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	1	1
				09.ANGUISH, ANXIETY	3	3	1	1	1	0	0
				10.AGGRESSION, IRRITABILITY	2	2	2	2	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	0	0	0
				12.GLOBAL EVALUATION	2	2	0	0	0	0	0
				11.Total score	25	25	13	13	4	3	3
	526	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	2	2	3	1	0
				02.BODY GESTURES	3	3	2	3	3	2	0
				03.LOOK	2	2	2	2	2	1	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	0	0
				05.SPEECH	2	2	1	2	2	1	1
				06.VOICE	2	2	2	2	2	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	2	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	3	3	2	3	3	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	2	2	0
				11.Total score	22	22	19	22	23	13	6
	527	Imipramine	Female	01.FACIAL EXPRESSION	2	2	2	1	1	1	1
				02.BODY GESTURES	2	2	2	0	0	0	0
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	3	2	2	2	2
				08.CONTACTS, AFFECTIVE NEED	3	3	3	2	2	2	2
				09.ANGUISH, ANXIETY	4	4	4	2	2	2	2
				10.AGGRESSION, IRRITABILITY	2	2	2	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	1	1	1	1	1	1	1
				11.Total score	21	21	21	13	13	13	13
	528	Imipramine	Female	01.FACIAL EXPRESSION	2	2	2	2	2	2	
				02.BODY GESTURES	2	2	2	2	2	2	
				03.LOOK	1	1	1	1	1	1	
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	
				05.SPEECH	1	1	1	1	1	1	
				06.VOICE	1	1	2	2	2	2	
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	2	2	
				08.CONTACTS, AFFECTIVE NEED	3	3	3	3	3	3	
				09.ANGUISH, ANXIETY	3	3	3	3	3	3	
				10.AGGRESSION, IRRITABILITY	2	2	2	2	2	2	
				11.SELF-AGGRESSION	1	1	1	1	1	1	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/03	528	Imipramine	Female	12.GLOBAL EVALUATION	0	0	0	0	0	0	
				11.Total score	18	18	19	19	19	19	
7/04	193	Placebo	Female	01.FACIAL EXPRESSION	3	2	2	1	1	1	0
				02.BODY GESTURES	2	2	2	2	2	1	1
				03.LOOK	2	2	2	2	2	1	0
				04.OUTWARD APPEARANCE	2	2	1	1	1	1	1
				05.SPEECH	2	2	1	1	1	1	1
				06.VOICE	2	1	1	1	1	0	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	3	2	2	1	1	1	0
				09.ANGUISH, ANXIETY	2	2	2	1	1	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	0
				11.SELF-AGGRESSION	2	1	1	1	1	0	0
				12.GLOBAL EVALUATION	2	2	2	1	1	0	0
				11.Total score	25	21	19	14	14	8	5
	194	Reboxetine	Male	01.FACIAL EXPRESSION	3	3	1	2	1	1	1
				02.BODY GESTURES	3	3	2	2	2	0	1
				03.LOOK	2	2	2	1	1	0	0
				04.OUTWARD APPEARANCE	2	1	2	1	1	1	1
				05.SPEECH	3	3	2	2	2	1	1
				06.VOICE	3	2	1	2	1	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	2	1	1	0	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	0
				09.ANGUISH, ANXIETY	2	2	2	2	0	1	0
				10.AGGRESSION, IRRITABILITY	2	2	2	1	1	1	0
				11.SELF-AGGRESSION	2	2	2	1	1	0	0
				12.GLOBAL EVALUATION	2	2	2	2	0	0	0
				11.Total score	29	27	22	18	12	7	6
	195	Placebo	Female	01.FACIAL EXPRESSION	2	2	2	1	0	0	0
				02.BODY GESTURES	3	3	3	1	1	0	0
				03.LOOK	2	2	2	2	1	1	1
				04.OUTWARD APPEARANCE	2	2	2	1	1	1	0
				05.SPEECH	2	2	2	1	1	0	0
				06.VOICE	3	3	3	2	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	1	1	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	0	0	0
				11.SELF-AGGRESSION	1	1	1	1	0	0	0
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	24	24	24	15	9	5	5
	196	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	2	1	1	1	0
				02.BODY GESTURES	2	2	2	1	1	1	0
				03.LOOK	2	2	2	2	1	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/04	196	Reboxetine	Female	04.OUTWARD APPEARANCE	2	2	2	2	1	0	0
				05.SPEECH	2	2	2	1	1	1	1
				06.VOICE	3	3	3	2	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	1	1	0
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	0	0
				09.ANGUISH, ANXIETY	2	2	2	2	1	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	0
				11.SELF-AGGRESSION	1	1	1	1	1	1	0
				12.GLOBAL EVALUATION	2	2	2	1	1	0	0
				11.Total score	23	23	23	17	12	7	2
	197	Imipramine	Male	01.FACIAL EXPRESSION	2	2	2	2	2	2	2
				02.BODY GESTURES	3	3	3	3	3	2	2
				03.LOOK	2	2	2	2	2	2	2
				04.OUTWARD APPEARANCE	2	2	2	2	2	2	2
				05.SPEECH	2	2	2	2	2	2	2
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	2	2	2
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	2	2
				09.ANGUISH, ANXIETY	2	2	2	2	2	2	2
				10.AGGRESSION, IRRITABILITY	2	2	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	23	23	22	22	22	21	21
	198	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	2	2	1	1	1	1	1
				03.LOOK	2	2	1	1	1	1	1
				04.OUTWARD APPEARANCE	2	2	2	2	1	2	1
				05.SPEECH	3	3	2	2	1	2	1
				06.VOICE	3	3	3	3	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	1	1	1	1
				10.AGGRESSION, IRRITABILITY	2	2	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	0
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1
				11.Total score	25	25	18	16	12	14	10
	199	Imipramine	Male	01.FACIAL EXPRESSION	2	2	2	2	1	1	0
				02.BODY GESTURES	3	3	3	2	1	1	1
				03.LOOK	2	2	2	2	1	1	1
				04.OUTWARD APPEARANCE	2	2	2	2	2	1	1
				05.SPEECH	2	2	2	2	1	0	0
				06.VOICE	1	2	2	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	2	1	1	1
				10.AGGRESSION, IRRITABILITY	2	2	2	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/04	199	Imipramine	Male	11.SELF-AGGRESSION	2	1	2	1	0	0	0
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	24	24	25	20	11	9	8
	200	Placebo	Male	01.FACIAL EXPRESSION	2	2	2	2	2	2	2
				02.BODY GESTURES	3	2	2	3	2	2	2
				03.LOOK	3	2	2	2	1	1	1
				04.OUTWARD APPEARANCE	2	2	2	3	2	2	2
				05.SPEECH	2	2	2	2	2	2	2
				06.VOICE	2	3	2	2	3	3	3
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	3	2	2	2	2
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	2	2
				09.ANGUISH, ANXIETY	2	2	2	2	2	2	2
				10.AGGRESSION, IRRITABILITY	2	2	2	2	1	1	1
				11.SELF-AGGRESSION	2	2	2	2	2	2	1
				12.GLOBAL EVALUATION	2	2	2	2	1	1	1
				11.Total score	26	25	25	26	22	22	21
	201	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	2	1	1	1	1
				02.BODY GESTURES	3	3	3	1	1	1	1
				03.LOOK	3	3	3	2	2	1	1
				04.OUTWARD APPEARANCE	2	2	2	1	1	1	1
				05.SPEECH	2	2	3	1	1	1	1
				06.VOICE	2	3	2	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	3	2	2	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	3	2	2	1	1
				09.ANGUISH, ANXIETY	2	2	2	1	1	0	0
				10.AGGRESSION, IRRITABILITY	2	2	2	1	1	1	1
				11.SELF-AGGRESSION	2	2	2	1	1	0	0
				12.GLOBAL EVALUATION	2	2	2	1	1	0	0
				11.Total score	26	27	29	15	15	8	8
	202	Reboxetine	Male	01.FACIAL EXPRESSION	3	3	3	3	3	2	2
				02.BODY GESTURES	3	3	3	3	3	2	2
				03.LOOK	3	3	3	3	3	2	1
				04.OUTWARD APPEARANCE	3	3	3	3	3	3	2
				05.SPEECH	3	3	3	3	3	3	2
				06.VOICE	3	3	3	3	3	2	2
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	3	3	3	2	1
				08.CONTACTS, AFFECTIVE NEED	3	3	3	3	3	2	1
				09.ANGUISH, ANXIETY	3	3	3	3	3	2	1
				10.AGGRESSION, IRRITABILITY	3	3	3	3	3	2	2
				11.SELF-AGGRESSION	2	2	2	2	2	2	1
				12.GLOBAL EVALUATION	3	3	3	3	3	2	1
				11.Total score	35	35	35	35	35	26	18
	203	Placebo	Female	01.FACIAL EXPRESSION	3	3	3	3	3	2	2
				02.BODY GESTURES	3	3	3	3	2	3	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/04	203	Placebo	Female	03.LOOK	3	3	3	3	3	3	2
				04.OUTWARD APPEARANCE	3	3	3	3	2	2	2
				05.SPEECH	3	3	3	3	3	3	2
				06.VOICE	3	0	4	0	3	2	2
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	3	3	2	2	2
				08.CONTACTS, AFFECTIVE NEED	3	3	3	3	2	2	2
				09.ANGUISH, ANXIETY	3	3	3	3	2	2	2
				10.AGGRESSION, IRRITABILITY	3	3	3	2	3	2	2
				11.SELF-AGGRESSION	2	3	3	2	2	2	2
				12.GLOBAL EVALUATION	3	3	3	3	2	2	2
				11.Total score	35	33	37	31	29	27	24
	204	Imipramine	Female	01.FACIAL EXPRESSION	3	3	3	3	3	2	2
				02.BODY GESTURES	3	3	3	3	3	3	2
				03.LOOK	3	3	3	3	3	2	2
				04.OUTWARD APPEARANCE	3	3	3	3	3	2	1
				05.SPEECH	3	3	3	3	3	2	2
				06.VOICE	3	0	0	3	2	0	2
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	3	2	2	3	2
				08.CONTACTS, AFFECTIVE NEED	3	3	3	3	2	2	2
				09.ANGUISH, ANXIETY	3	3	3	3	2	2	2
				10.AGGRESSION, IRRITABILITY	3	3	3	2	2	2	2
				11.SELF-AGGRESSION	3	3	2	1	2	1	1
				12.GLOBAL EVALUATION	3	3	2	2	2	1	2
				11.Total score	36	33	31	31	29	22	22
7/05	205	Placebo	Male	01.FACIAL EXPRESSION	3	3	3	3	3	3	3
				02.BODY GESTURES	3	2	3	3	3	3	3
				03.LOOK	3	3	3	3	3	3	3
				04.OUTWARD APPEARANCE	2	2	2	2	2	2	2
				05.SPEECH	2	2	2	2	2	2	2
				06.VOICE	2	2	2	2	2	2	2
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	2	2	2
				08.CONTACTS, AFFECTIVE NEED	3	3	3	3	3	3	3
				09.ANGUISH, ANXIETY	2	2	2	3	3	2	2
				10.AGGRESSION, IRRITABILITY	2	2	2	2	2	2	2
				11.SELF-AGGRESSION	1	2	2	2	2	2	2
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	27	27	28	29	29	28	28
	206	Imipramine	Female	01.FACIAL EXPRESSION	2	2	2	2	2	1	1
				02.BODY GESTURES	2	2	2	2	2	2	2
				03.LOOK	3	2	1	1	1	1	1
				04.OUTWARD APPEARANCE	2	2	2	2	1	1	1
				05.SPEECH	3	2	2	1	1	1	1
				06.VOICE	2	2	2	2	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	2	2	2
				08.CONTACTS, AFFECTIVE NEED	3	3	2	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/05	206	Imipramine	Female	10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	24	22	20	16	14	13	13
	207	Imipramine	Female	01.FACIAL EXPRESSION	1	1	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	2	2	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	2	2	2	2	1	1	1
				06.VOICE	2	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	2	2
				09.ANGUISH, ANXIETY	2	2	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	2	2	2	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	1	1	1	1
				11.Total score	18	17	15	13	12	12	12
	208	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	2	2	1	1	1	0	0
				05.SPEECH	2	1	1	1	1	1	1
				06.VOICE	2	2	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	0	0
				09.ANGUISH, ANXIETY	1	1	1	1	1	0	0
				10.AGGRESSION, IRRITABILITY	1	0	0	0	0	0	0
				11.SELF-AGGRESSION	2	2	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	1	1	0	0
				11.Total score	19	17	13	11	11	6	6
	209	Placebo	Male	01.FACIAL EXPRESSION	2	2	2	2	2	2	2
				02.BODY GESTURES	2	2	2	2	2	2	2
				03.LOOK	2	2	2	2	2	2	2
				04.OUTWARD APPEARANCE	1	1	1	2	2	2	2
				05.SPEECH	3	3	3	3	3	3	3
				06.VOICE	2	3	3	3	3	3	3
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	3	3	3	3	3
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	3	2	3
				09.ANGUISH, ANXIETY	2	2	2	2	3	3	3
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	22	23	24	25	27	26	27
	210	Reboxetine	Male	01.FACIAL EXPRESSION	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/05	210	Reboxetine	Male	02.BODY GESTURES	2	2	1	1	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	3	2	2	1	1	1	1
				06.VOICE	2	2	1	1	0	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	0	0	0	0
				12.GLOBAL EVALUATION	2	2	1	1	0	0	0
				11.Total score	18	17	13	11	7	8	8
	541	Reboxetine	Female	01.FACIAL EXPRESSION	3	2	1	1	1	1	1
				02.BODY GESTURES	2	2	1	1	1	1	1
				03.LOOK	2	2	2	1	0	0	0
				04.OUTWARD APPEARANCE	2	1	1	1	1	0	0
				05.SPEECH	3	2	2	1	0	0	0
				06.VOICE	3	2	2	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	3	3	2	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	1	0	0	0	0
				10.AGGRESSION, IRRITABILITY	2	2	1	0	0	0	0
				11.SELF-AGGRESSION	2	2	1	0	0	0	0
				12.GLOBAL EVALUATION	2	2	1	1	1	1	0
				11.Total score	28	24	16	8	5	4	3
	542	Imipramine	Male	01.FACIAL EXPRESSION	3	3	3	3	3	2	2
				02.BODY GESTURES	2	2	2	2	2	2	2
				03.LOOK	3	3	2	2	2	2	2
				04.OUTWARD APPEARANCE	2	2	2	2	1	1	1
				05.SPEECH	3	3	2	2	2	2	1
				06.VOICE	2	2	2	2	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	3	2	1	1	1
				08.CONTACTS, AFFECTIVE NEED	3	3	3	2	2	2	1
				09.ANGUISH, ANXIETY	3	3	2	2	1	1	1
				10.AGGRESSION, IRRITABILITY	2	2	2	2	1	1	1
				11.SELF-AGGRESSION	2	2	2	2	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	2	1	1
				11.Total score	30	30	27	25	19	17	15
	543	Imipramine	Male	01.FACIAL EXPRESSION	3	3	1	1	1	1	1
				02.BODY GESTURES	2	2	1	1	1	1	1
				03.LOOK	3	2	2	1	1	1	1
				04.OUTWARD APPEARANCE	2	2	1	1	1	1	1
				05.SPEECH	3	3	3	2	2	1	1
				06.VOICE	3	3	2	2	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	2	2	1
				08.CONTACTS, AFFECTIVE NEED	3	3	3	2	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/05	543	Imipramine	Male	09.ANGUISH, ANXIETY	3	3	2	2	1	1	1
				10.AGGRESSION, IRRITABILITY	2	2	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	1	1	1
				11.Total score	29	28	21	18	14	13	12
	544	Placebo	Female	01.FACIAL EXPRESSION	3	3	3	3	3	3	3
				02.BODY GESTURES	3	3	3	3	3	3	3
				03.LOOK	3	3	3	3	3	3	3
				04.OUTWARD APPEARANCE	2	2	3	2	2	2	2
				05.SPEECH	3	3	3	3	3	3	3
				06.VOICE	3	3	3	3	3	3	3
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	3	3	3	3	4
				08.CONTACTS, AFFECTIVE NEED	3	3	3	3	3	4	4
				09.ANGUISH, ANXIETY	3	3	3	3	3	2	2
				10.AGGRESSION, IRRITABILITY	2	2	2	2	2	2	2
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	3	3	3	3	2	3	3
				11.Total score	32	32	33	32	31	32	33
	545	Placebo	Male	01.FACIAL EXPRESSION	3	3	3	3	3	3	3
				02.BODY GESTURES	3	3	3	3	3	3	3
				03.LOOK	3	3	3	3	3	3	3
				04.OUTWARD APPEARANCE	2	2	2	2	2	2	2
				05.SPEECH	3	3	3	3	3	3	3
				06.VOICE	2	2	2	2	2	2	2
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	3	3	3	3	3
				08.CONTACTS, AFFECTIVE NEED	3	3	3	3	3	3	3
				09.ANGUISH, ANXIETY	3	3	3	3	3	3	3
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	3	3	3	3	3	3	3
				11.Total score	30	30	30	30	30	30	30
	546	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	2	1	1	1	1
				02.BODY GESTURES	2	2	2	2	1	1	1
				03.LOOK	2	2	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	3	2	2	2	1	1	1
				06.VOICE	2	2	2	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	3	2	2	2	2	2	1
				09.ANGUISH, ANXIETY	3	2	2	2	1	1	1
				10.AGGRESSION, IRRITABILITY	2	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	0	0	0
				12.GLOBAL EVALUATION	2	2	2	2	1	0	0
				11.Total score	25	21	20	17	12	11	9

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/07	529	Placebo	Female	01.FACIAL EXPRESSION	3	3	3	2	2	2	2
				02.BODY GESTURES	2	2	2	2	1	1	1
				03.LOOK	2	2	2	1	1	1	1
				04.OUTWARD APPEARANCE	2	2	2	1	1	1	1
				05.SPEECH	2	2	2	1	1	1	1
				06.VOICE	2	1	2	2	2	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	2	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	2	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	1	1	1	2
				10.AGGRESSION, IRRITABILITY	2	2	2	1	1	1	1
				11.SELF-AGGRESSION	2	2	2	1	1	1	1
				12.GLOBAL EVALUATION	2	1	1	1	1	1	1
				11.Total score	25	22	22	17	14	13	14
	530	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1				
				02.BODY GESTURES	2	2	1				
				03.LOOK	2	2	1				
				04.OUTWARD APPEARANCE	1	1	1				
				05.SPEECH	1	1	2				
				06.VOICE	2	2	2				
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1				
				08.CONTACTS, AFFECTIVE NEED	2	2	2				
				09.ANGUISH, ANXIETY	2	2	2				
				10.AGGRESSION, IRRITABILITY	1	2	2				
				11.SELF-AGGRESSION	1	1	2				
				12.GLOBAL EVALUATION	2	1	1				
				11.Total score	20	19	18				
	531	Reboxetine	Female	01.FACIAL EXPRESSION	3	2	2	1	1	1	1
				02.BODY GESTURES	2	2	2	2	1	1	1
				03.LOOK	2	2	2	1	1	1	1
				04.OUTWARD APPEARANCE	2	2	1	1	1	1	0
				05.SPEECH	2	2	2	1	1	1	1
				06.VOICE	2	2	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	2	2	2	1	1
				10.AGGRESSION, IRRITABILITY	2	2	1	1	1	1	1
				11.SELF-AGGRESSION	1	2	1	1	1	1	0
				12.GLOBAL EVALUATION	2	1	1	1	1	1	0
				11.Total score	24	23	18	14	13	12	9
	532	Imipramine	Female	01.FACIAL EXPRESSION	2	2	2	2	2	1	1
				02.BODY GESTURES	2	2	2	2	1	1	1
				03.LOOK	1	1	2	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	0
				05.SPEECH	2	2	1	2	2	1	1
				06.VOICE	1	1	2	2	2	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/07	532	Imipramine	Female	08.CONTACTS, AFFECTIVE NEED	2	1	2	1	2	1	1
				09.ANGUISH, ANXIETY	3	3	2	2	2	2	1
				10.AGGRESSION, IRRITABILITY	2	2	1	1	1	1	0
				11.SELF-AGGRESSION	2	1	1	1	1	2	0
				12.GLOBAL EVALUATION	1	1	2	2	1	1	0
				11.Total score	21	19	20	19	17	14	7
	533	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	2	2	2	1	1
				02.BODY GESTURES	2	1	1	2	1	1	0
				03.LOOK	2	2	2	1	2	1	1
				04.OUTWARD APPEARANCE	1	2	2	1	1	1	0
				05.SPEECH	1	2	2	2	1	1	1
				06.VOICE	2	2	2	2	1	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	1	0	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	0	0
				09.ANGUISH, ANXIETY	2	2	2	2	2	1	1
				10.AGGRESSION, IRRITABILITY	1	2	2	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	2	1	1	0
				12.GLOBAL EVALUATION	1	2	1	1	1	1	1
				11.Total score	19	22	21	20	16	10	7
	534	Placebo	Female	01.FACIAL EXPRESSION	2	2	2	1	2	2	1
				02.BODY GESTURES	2	2	1	1	1	1	0
				03.LOOK	1	1	1	1	1	1	0
				04.OUTWARD APPEARANCE	1	2	1	1	1	0	0
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	2	1	2	1	1	0	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	2	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	2	1	1
				09.ANGUISH, ANXIETY	2	2	2	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	0
				12.GLOBAL EVALUATION	1	2	1	1	1	1	1
				11.Total score	17	19	16	12	14	11	8
8	211	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	3				
				02.BODY GESTURES	2	2	3				
				03.LOOK	2	2	2				
				04.OUTWARD APPEARANCE	2	2	2				
				05.SPEECH	2	2	2				
				06.VOICE	1	1	2				
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	2				
				08.CONTACTS, AFFECTIVE NEED	2	2	3				
				09.ANGUISH, ANXIETY	3	3	3				
				10.AGGRESSION, IRRITABILITY	0	0	0				
				11.SELF-AGGRESSION	0	0	0				
				12.GLOBAL EVALUATION	2	2	2				
				11.Total score	19	19	24				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	212	Placebo	Female	01.FACIAL EXPRESSION	2	2	2	2	2	2	2
				02.BODY GESTURES	2	2	2	2	2	2	2
				03.LOOK	2	2	2	2	2	2	2
				04.OUTWARD APPEARANCE	2	2	2	2	2	2	2
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	2	2
				09.ANGUISH, ANXIETY	3	3	3	2	2	2	2
				10.AGGRESSION, IRRITABILITY	0	0	0	0	1	1	1
				11.SELF-AGGRESSION	0	0	0	0	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	18	18	18	17	19	19	19
	213	Imipramine	Male	01.FACIAL EXPRESSION	2						
				02.BODY GESTURES	2						
				03.LOOK	2						
				04.OUTWARD APPEARANCE	2						
				05.SPEECH	2						
				06.VOICE	1						
				07.ADAPTABILITY, SUGGESTIBILITY	2						
				08.CONTACTS, AFFECTIVE NEED	2						
				09.ANGUISH, ANXIETY	2						
				10.AGGRESSION, IRRITABILITY	1						
				11.SELF-AGGRESSION	1						
				12.GLOBAL EVALUATION	2						
				11.Total score	21						
	214	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	2	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	2	2	2	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	2	2	1	1	1	0
				11.Total score	14	14	14	10	10	10	9
	215	Placebo	Female	01.FACIAL EXPRESSION	2	1	1	0	0	0	0
				02.BODY GESTURES	1	1	0	0	0	0	0
				03.LOOK	1	0	1	0	0	0	0
				04.OUTWARD APPEARANCE	1	0	1	0	0	0	0
				05.SPEECH	1	1	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	215	Placebo	Female	06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	0	0	1	0	0	0	0
				09.ANGUISH, ANXIETY	1	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	0	0	1	0	0	0	0
				12.GLOBAL EVALUATION	1	0	1	0	0	0	0
				11.Total score	8	3	8	0	0	0	0
	216	Imipramine	Male	01.FACIAL EXPRESSION	2	2	2	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	2	2	2	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	2	2	2	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	2	2	2
				09.ANGUISH, ANXIETY	0	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	4	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	15	15	19	11	11	11	11
	217	Reboxetine	Female	01.FACIAL EXPRESSION	1	1	1	0	0	0	0
				02.BODY GESTURES	0	0	0	0	0	0	0
				03.LOOK	1	1	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	0	0
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	0	0	0	0	0	0	0
				09.ANGUISH, ANXIETY	0	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	1
				12.GLOBAL EVALUATION	1	1	0	0	0	0	0
				11.Total score	6	5	3	2	2	1	2
	218	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	2	1	1	0	1
				02.BODY GESTURES	1	1	1	1	1	0	0
				03.LOOK	2	2	2	1	1	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	1	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	218	Reboxetine	Female	11.Total score	13	13	13	11	11	7	8
	219	Placebo	Female	01.FACIAL EXPRESSION	0	0	0	0			
				02.BODY GESTURES	0	0	0	0			
				03.LOOK	0	0	0	0			
				04.OUTWARD APPEARANCE	1	1	1	1			
				05.SPEECH	1	1	1	1			
				06.VOICE	1	1	1	1			
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	0	0			
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1			
				09.ANGUISH, ANXIETY	0	0	0	0			
				10.AGGRESSION, IRRITABILITY	0	0	0	0			
				11.SELF-AGGRESSION	1	1	1	1			
				12.GLOBAL EVALUATION	0	0	0	0			
				11.Total score	5	5	5	5			
	220	Imipramine	Female	01.FACIAL EXPRESSION	2	2	2	1	1	1	1
				02.BODY GESTURES	1	1	0	0	0	0	0
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	0
				09.ANGUISH, ANXIETY	1	1	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	0	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	1	1	1	1	1	1	1
				11.Total score	13	13	10	9	9	9	8
	221	Imipramine	Male	01.FACIAL EXPRESSION	2	2	2	1	1	1	1
				02.BODY GESTURES	2	2	2	1	1	1	0
				03.LOOK	1	1	1	1	1	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	1	1	1
				09.ANGUISH, ANXIETY	1	1	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	1	1	1
				11.Total score	15	15	14	12	9	8	7
	222	Placebo	Female	01.FACIAL EXPRESSION	0	0	0	0	0	0	0
				02.BODY GESTURES	0	0	0	0	0	0	0
				03.LOOK	0	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	222	Placebo	Female	05.SPEECH	1	0	0	0	0	0	0
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	0	0	0	0	0	0	0
				09.ANGUISH, ANXIETY	0	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	0	0	0	0	0	0	0
				12.GLOBAL EVALUATION	0	0	0	0	0	0	0
				11.Total score	2	0	0	0	0	0	0
	223	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	0	0	0
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	1	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	0	0
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	1	1	1	1	1	1	1
				11.Total score	13	13	10	10	9	8	8
	224	Placebo	Female	01.FACIAL EXPRESSION	1	1	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	0	0
				03.LOOK	1	1	1	1	1	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	0	0
				09.ANGUISH, ANXIETY	0	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	1	0	0	0	0	0	0
				11.Total score	9	8	8	7	7	4	4
	225	Placebo	Male	01.FACIAL EXPRESSION	1	1	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	0	1	1	1	1	1	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	1	1	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	0	1	1	1	1	1	0
				09.ANGUISH, ANXIETY	0	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	225	Placebo	Male	12.GLOBAL EVALUATION	1	1	1	1	1	1	0
				11.Total score	7	10	10	10	10	10	6
	226	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	2	2	1	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1
				11.Total score	16	16	12	12	12	12	12
	227	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	0	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	1	1	1	0	0
				11.Total score	13	13	11	11	11	10	10
	228	Imipramine	Male	01.FACIAL EXPRESSION	2	2					
				02.BODY GESTURES	1	1					
				03.LOOK	1	1					
				04.OUTWARD APPEARANCE	1	1					
				05.SPEECH	1	2					
				06.VOICE	1	1					
				07.ADAPTABILITY, SUGGESTIBILITY	1	1					
				08.CONTACTS, AFFECTIVE NEED	1	2					
				09.ANGUISH, ANXIETY	1	1					
				10.AGGRESSION, IRRITABILITY	1	1					
				11.SELF-AGGRESSION	1	1					
				12.GLOBAL EVALUATION	1	2					
				11.Total score	13	16					
	229	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	229	Imipramine	Female	04.OUTWARD APPEARANCE	1	1	1	1	1	1	0
				05.SPEECH	2	2	1	1	1	1	1
				06.VOICE	1	1	1	1	1	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	1	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	1	1	1	1	1
				11.Total score	16	16	11	11	11	11	8
	230	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	2	1	1	1	1
				02.BODY GESTURES	2	2	2	1	1	1	1
				03.LOOK	2	2	2	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	2	2	2	1	1	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	1	1	1
				11.Total score	18	18	18	14	12	12	12
	231	Imipramine	Male	01.FACIAL EXPRESSION	1	1	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	1	1	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	1	1
				09.ANGUISH, ANXIETY	0	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	1	2	1	1	1	1	1
				11.Total score	11	12	9	8	7	7	7
	232	Reboxetine	Male	01.FACIAL EXPRESSION	1	1	1	1	1	0	0
				02.BODY GESTURES	1	1	1	1	1	1	0
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	0	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	232	Reboxetine	Male	11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	1	1	1	1	1	1	1
				11.Total score	9	9	9	9	9	7	6
	233	Placebo	Female	01.FACIAL EXPRESSION	2	1	1	1	1	1	0
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	1	1	1	1	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	0
				09.ANGUISH, ANXIETY	1	1	1	1	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	1	1	1	1	1	1	0
				11.Total score	13	12	12	12	11	10	5
	234	Placebo	Female	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	1	1	1	1	1	1	1
				11.Total score	12	11	10	10	10	9	9
8/A	235	Placebo	Female	01.FACIAL EXPRESSION	2	1	1	0	0	0	0
				02.BODY GESTURES	2	1	1	1	1	1	0
				03.LOOK	1	2	1	0	0	1	1
				04.OUTWARD APPEARANCE	2	2	1	0	0	1	1
				05.SPEECH	1	1	1	1	0	0	0
				06.VOICE	1	2	0	0	0	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	1	1
				09.ANGUISH, ANXIETY	2	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	3	2	1	1	1	1	1
				11.Total score	20	17	11	8	7	10	6
	236	Placebo	Female	01.FACIAL EXPRESSION	1	1	0	0	0	0	0
				02.BODY GESTURES	2	1	0	0	0	0	0

1470

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8/A	236	Placebo	Female	03.LOOK	2	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	0	0	0	0	0
				05.SPEECH	1	1	0	0	0	0	0
				06.VOICE	1	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	2	1	1	1	0	0	0
				09.ANGUISH, ANXIETY	2	1	1	1	0	0	1
				10.AGGRESSION, IRRITABILITY	1	1	0	0	0	0	0
				11.SELF-AGGRESSION	2	1	1	1	0	0	0
				12.GLOBAL EVALUATION	2	2	1	1	0	0	0
				11.Total score	19	14	6	5	1	1	1
	237	Reboxetine	Female	01.FACIAL EXPRESSION	2	1	1	0	0	0	0
				02.BODY GESTURES	2	1	1	0	0	0	0
				03.LOOK	1	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	2	2	0	0	0	0	0
				05.SPEECH	2	1	0	0	1	0	0
				06.VOICE	1	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	0
				09.ANGUISH, ANXIETY	2	2	1	1	1	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	0	0	0	0
				11.SELF-AGGRESSION	2	2	1	1	0	0	0
				12.GLOBAL EVALUATION	3	3	2	1	1	1	0
				11.Total score	21	18	10	5	5	3	1
	238	Reboxetine	Female	01.FACIAL EXPRESSION	2	0	0	0	0	0	0
				02.BODY GESTURES	1	1	0	0	0	0	0
				03.LOOK	1	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	2	1	0	0	0	0	0
				05.SPEECH	1	1	1	0	0	0	0
				06.VOICE	1	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	1	1	0	1	0	0	0
				09.ANGUISH, ANXIETY	1	1	1	1	0	0	0
				10.AGGRESSION, IRRITABILITY	1	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	1	0	0	0	0	0
				12.GLOBAL EVALUATION	2	2	1	1	0	0	0
				11.Total score	16	10	5	4	1	1	0
	239	Imipramine	Female	01.FACIAL EXPRESSION	2	1	1	0	0	0	0
				02.BODY GESTURES	2	1	1	0	0	0	0
				03.LOOK	1	1	1	1	1	1	0
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	1	1	1	0	0	0	0
				06.VOICE	1	1	1	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	1	1	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	1	0	0
				09.ANGUISH, ANXIETY	2	1	1	1	1	0	0

1471

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8/A	239	Imipramine	Female	10.AGGRESSION, IRRITABILITY	1	1	1	1	0	0	0
				11.SELF-AGGRESSION	1	1	1	1	1	0	0
				12.GLOBAL EVALUATION	3	2	2	2	1	0	0
				11.Total score	19	15	15	9	6	1	1
	240	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	3	2	2	2	2	1	1
				03.LOOK	2	2	2	1	1	1	1
				04.OUTWARD APPEARANCE	2	2	1	1	1	1	1
				05.SPEECH	2	2	2	1	1	1	1
				06.VOICE	2	2	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	3	2	2	2	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	1
				09.ANGUISH, ANXIETY	3	2	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	2	2	1	2	1	1	1
				12.GLOBAL EVALUATION	3	3	2	2	2	2	1
				11.Total score	27	24	18	16	14	13	12
	553	Placebo	Female	01.FACIAL EXPRESSION	2	2	1	1	1	1	1
				02.BODY GESTURES	2	1	1	1	1	1	2
				03.LOOK	1	1	1	1	1	2	1
				04.OUTWARD APPEARANCE	2	2	2	2	1	1	1
				05.SPEECH	2	2	2	1	1	1	1
				06.VOICE	2	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	2	2	2	2
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	2	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	2	1	1	1	1	1	1
				12.GLOBAL EVALUATION	3	2	2	2	2	2	2
				11.Total score	22	17	15	15	14	15	15
	554	Reboxetine	Male	01.FACIAL EXPRESSION	2	1	1	1	0	0	0
				02.BODY GESTURES	2	1	1	0	0	0	0
				03.LOOK	2	2	1	1	1	0	0
				04.OUTWARD APPEARANCE	2	2	1	1	0	0	0
				05.SPEECH	2	1	1	0	0	1	0
				06.VOICE	1	1	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	0	0
				09.ANGUISH, ANXIETY	1	1	1	1	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	0	0	0	0
				11.SELF-AGGRESSION	2	1	1	1	1	0	0
				12.GLOBAL EVALUATION	3	3	2	2	1	1	0
				11.Total score	22	18	14	10	5	3	1
	555	Reboxetine	Female	01.FACIAL EXPRESSION	2	1	1	1	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8/A	555	Reboxetine	Female	02.BODY GESTURES	2	2	2	1	0	1	1
				03.LOOK	2	2	1	1	1	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	2	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	1	1
				09.ANGUISH, ANXIETY	2	2	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	0	0	0
				11.SELF-AGGRESSION	2	1	1	1	0	0	0
				12.GLOBAL EVALUATION	3	2	2	2	2	2	1
				11.Total score	22	18	15	13	10	10	8
	556	Imipramine	Male	01.FACIAL EXPRESSION	2	1	1	1	0	0	0
				02.BODY GESTURES	2	2	1	1	1	1	0
				03.LOOK	1	1	1	1	0	0	0
				04.OUTWARD APPEARANCE	2	2	1	1	0	0	0
				05.SPEECH	2	1	1	1	1	0	0
				06.VOICE	2	1	1	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	1	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	0
				09.ANGUISH, ANXIETY	2	2	1	0	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	0	0	0	0
				11.SELF-AGGRESSION	2	1	1	0	0	0	0
				12.GLOBAL EVALUATION	3	3	2	2	1	1	1
				11.Total score	22	18	14	9	5	4	2
9	241	Placebo	Female	01.FACIAL EXPRESSION	1	2	2				
				02.BODY GESTURES	0	3	1				
				03.LOOK	1	1	0				
				04.OUTWARD APPEARANCE	1	2	2				
				05.SPEECH	1	3	2				
				06.VOICE	0	3	0				
				07.ADAPTABILITY, SUGGESTIBILITY	1	3	1				
				08.CONTACTS, AFFECTIVE NEED	1	1	2				
				09.ANGUISH, ANXIETY	2	2	4				
				10.AGGRESSION, IRRITABILITY	1	2	2				
				11.SELF-AGGRESSION	1	1	1				
				12.GLOBAL EVALUATION	1	2	2				
				11.Total score	11	25	19				
	242	Reboxetine	Female	01.FACIAL EXPRESSION	1	1	2	2			
				02.BODY GESTURES	2	1	1	1			
				03.LOOK	1	1	1	1			
				04.OUTWARD APPEARANCE	1	0	1	0			
				05.SPEECH	1	1	2	2			
				06.VOICE	1	0	1	2			
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	2	2			
				08.CONTACTS, AFFECTIVE NEED	1	0	1	1			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	242	Reboxetine	Female	09.ANGUISH, ANXIETY	1	0	2	2			
				10.AGGRESSION, IRRITABILITY	1	1	1	1			
				11.SELF-AGGRESSION	1	0	1	1			
				12.GLOBAL EVALUATION	1	0	1	1			
				11.Total score	13	6	16	16			
	243	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	1				
				02.BODY GESTURES	2	1	1				
				03.LOOK	1	1	1				
				04.OUTWARD APPEARANCE	1	2	3				
				05.SPEECH	3	3	3				
				06.VOICE	0	0	0				
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1				
				08.CONTACTS, AFFECTIVE NEED	0	0	0				
				09.ANGUISH, ANXIETY	1	3	4				
				10.AGGRESSION, IRRITABILITY	0	0	2				
				11.SELF-AGGRESSION	1	1	1				
				12.GLOBAL EVALUATION	1	0	0				
				11.Total score	13	14	17				
	244	Imipramine	Female	01.FACIAL EXPRESSION	1	2	1	1			
				02.BODY GESTURES	2	1	1	1			
				03.LOOK	1	1	1	1			
				04.OUTWARD APPEARANCE	1	0	0	0			
				05.SPEECH	2	1	1	1			
				06.VOICE	0	1	1	1			
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1			
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1			
				09.ANGUISH, ANXIETY	0	0	1	1			
				10.AGGRESSION, IRRITABILITY	0	0	1	1			
				11.SELF-AGGRESSION	0	0	1	1			
				12.GLOBAL EVALUATION	1	0	1	1			
				11.Total score	10	8	11	11			
	245	Imipramine	Female	01.FACIAL EXPRESSION	1	1	1	0	0	0	0
				02.BODY GESTURES	1	1	1	0	0	0	0
				03.LOOK	1	1	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	0	0	0	0	0
				05.SPEECH	0	1	1	0	1	0	0
				06.VOICE	1	1	1	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	1	0	0
				09.ANGUISH, ANXIETY	1	2	2	1	1	1	1
				10.AGGRESSION, IRRITABILITY	3	2	1	1	0	0	0
				11.SELF-AGGRESSION	1	1	0	0	0	0	0
				12.GLOBAL EVALUATION	3	2	1	1	0	0	0
				11.Total score	16	16	9	4	3	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	246	Placebo	Female	01.FACIAL EXPRESSION	2	2	2	2	2		
				02.BODY GESTURES	2	2	2	2	2		
				03.LOOK	1	1	1	2	2		
				04.OUTWARD APPEARANCE	1	1	1	1	1		
				05.SPEECH	2	2	2	3	3		
				06.VOICE	1	1	1	2	2		
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	2	2	2		
				08.CONTACTS, AFFECTIVE NEED	2	2	2	3	3		
				09.ANGUISH, ANXIETY	4	4	4	4	4		
				10.AGGRESSION, IRRITABILITY	2	2	2	1	1		
				11.SELF-AGGRESSION	1	1	1	1	1		
				12.GLOBAL EVALUATION	2	2	2	2	2		
				11.Total score	21	21	22	25	25		
	247	Placebo	Female	01.FACIAL EXPRESSION	1	2	1	1	1		
				02.BODY GESTURES	2	2	1	1	1		
				03.LOOK	1	1	1	1	1		
				04.OUTWARD APPEARANCE	1	1	0	1	1		
				05.SPEECH	1	1	1	1	1		
				06.VOICE	1	1	0	1	1		
				07.ADAPTABILITY, SUGGESTIBILITY	0	1	1	1	1		
				08.CONTACTS, AFFECTIVE NEED	0	0	0	0	0		
				09.ANGUISH, ANXIETY	2	2	1	2	2		
				10.AGGRESSION, IRRITABILITY	1	1	0	1	1		
				11.SELF-AGGRESSION	1	0	1	1	1		
				12.GLOBAL EVALUATION	0	0	0	0	0		
				11.Total score	11	12	7	11	11		
	248	Placebo	Male	01.FACIAL EXPRESSION	2	2	2				
				02.BODY GESTURES	2	2	2				
				03.LOOK	1	1	2				
				04.OUTWARD APPEARANCE	1	1	2				
				05.SPEECH	2	1	3				
				06.VOICE	2	2	2				
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	2				
				08.CONTACTS, AFFECTIVE NEED	1	1	0				
				09.ANGUISH, ANXIETY	1	2	3				
				10.AGGRESSION, IRRITABILITY	0	0	0				
				11.SELF-AGGRESSION	0	0	3				
				12.GLOBAL EVALUATION	1	1	1				
				11.Total score	15	14	22				
	249	Reboxetine	Female	01.FACIAL EXPRESSION	2						
				02.BODY GESTURES	1						
				03.LOOK	1						
				04.OUTWARD APPEARANCE	1						
				05.SPEECH	4						
				06.VOICE	2						
				07.ADAPTABILITY, SUGGESTIBILITY	2						

1475

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	249	Reboxetine	Female	08.CONTACTS, AFFECTIVE NEED	3						
				09.ANGUISH, ANXIETY	2						
				10.AGGRESSION, IRRITABILITY	1						
				11.SELF-AGGRESSION	1						
				12.GLOBAL EVALUATION	3						
				11.Total score	23						
	250	Imipramine	Female	01.FACIAL EXPRESSION	2	2	2	2	2		
				02.BODY GESTURES	2	2	1	1	1		
				03.LOOK	1	2	1	1	1		
				04.OUTWARD APPEARANCE	2	2	1	1	1		
				05.SPEECH	3	3	3	3	3		
				06.VOICE	2	2	1	1	1		
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2	2		
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1		
				09.ANGUISH, ANXIETY	0	0	0	1	1		
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0		
				11.SELF-AGGRESSION	0	0	0	0	0		
				12.GLOBAL EVALUATION	1	1	1	1	1		
				11.Total score	16	17	13	14	14		
	251	Imipramine	Female	01.FACIAL EXPRESSION	3	1	2	0	0		
				02.BODY GESTURES	2	2	1	0	0		
				03.LOOK	1	1	1	0	0		
				04.OUTWARD APPEARANCE	2	1	0	0	0		
				05.SPEECH	3	2	2	0	0		
				06.VOICE	2	1	1	0	0		
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	0	0		
				08.CONTACTS, AFFECTIVE NEED	3	2	1	0	0		
				09.ANGUISH, ANXIETY	2	1	1	1	1		
				10.AGGRESSION, IRRITABILITY	0	0	4	0	0		
				11.SELF-AGGRESSION	1	1	3	0	0		
				12.GLOBAL EVALUATION	2	2	1	0	0		
				11.Total score	23	15	18	1	1		
	252	Reboxetine	Female	01.FACIAL EXPRESSION	1	0	1	1			
				02.BODY GESTURES	1	0	1	1			
				03.LOOK	0	0	1	1			
				04.OUTWARD APPEARANCE	2	1	2	2			
				05.SPEECH	2	2	2	2			
				06.VOICE	0	0	0	0			
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	0			
				08.CONTACTS, AFFECTIVE NEED	0	0	1	1			
				09.ANGUISH, ANXIETY	1	2	2	3			
				10.AGGRESSION, IRRITABILITY	0	1	2	2			
				11.SELF-AGGRESSION	0	0	0	1			
				12.GLOBAL EVALUATION	0	0	1	1			
				11.Total score	8	7	13	15			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	253	Reboxetine	Female	01.FACIAL EXPRESSION	2	2					
				02.BODY GESTURES	2	1					
				03.LOOK	1	1					
				04.OUTWARD APPEARANCE	1	1					
				05.SPEECH	1	2					
				06.VOICE	2	1					
				07.ADAPTABILITY, SUGGESTIBILITY	2	2					
				08.CONTACTS, AFFECTIVE NEED	2	3					
				09.ANGUISH, ANXIETY	0	3					
				10.AGGRESSION, IRRITABILITY	1	1					
				11.SELF-AGGRESSION	1	1					
				12.GLOBAL EVALUATION	1	2					
				11.Total score	16	20					
	254	Imipramine	Female	01.FACIAL EXPRESSION	2	2	2				
				02.BODY GESTURES	2	2	2				
				03.LOOK	1	1	1				
				04.OUTWARD APPEARANCE	0	1	1				
				05.SPEECH	1	2	2				
				06.VOICE	1	1	1				
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1				
				08.CONTACTS, AFFECTIVE NEED	0	1	1				
				09.ANGUISH, ANXIETY	2	3	3				
				10.AGGRESSION, IRRITABILITY	1	2	2				
				11.SELF-AGGRESSION	1	1	1				
				12.GLOBAL EVALUATION	0	1	1				
				11.Total score	12	18	18				
	255	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	2	2	2		
				02.BODY GESTURES	2	2	2	3	3		
				03.LOOK	1	1	2	2	2		
				04.OUTWARD APPEARANCE	1	1	1	2	2		
				05.SPEECH	3	2	2	3	3		
				06.VOICE	1	1	1	2	2		
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	3	3		
				08.CONTACTS, AFFECTIVE NEED	1	1	1	2	2		
				09.ANGUISH, ANXIETY	1	1	2	3	3		
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1		
				11.SELF-AGGRESSION	1	1	2	3	3		
				12.GLOBAL EVALUATION	1	1	2	2	2		
				11.Total score	17	16	20	28	28		
	256	Imipramine	Female	01.FACIAL EXPRESSION	3	3	1	1	2	1	1
				02.BODY GESTURES	3	3	1	1	2	1	1
				03.LOOK	2	2	1	1	1	1	1
				04.OUTWARD APPEARANCE	2	2	1	1	1	1	1
				05.SPEECH	3	3	1	1	2	1	1

1477

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	256	Imipramine	Female	06.VOICE	2	2	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	3	2	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	3	3	1	1	2	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	0
				11.SELF-AGGRESSION	3	2	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	1	1	2	1	1
				11.Total score	28	26	12	12	17	12	11
	257	Placebo	Male	01.FACIAL EXPRESSION	0	0					
				02.BODY GESTURES	1	1					
				03.LOOK	0	0					
				04.OUTWARD APPEARANCE	0	0					
				05.SPEECH	1	1					
				06.VOICE	0	0					
				07.ADAPTABILITY, SUGGESTIBILITY	1	1					
				08.CONTACTS, AFFECTIVE NEED	1	0					
				09.ANGUISH, ANXIETY	1	2					
				10.AGGRESSION, IRRITABILITY	1	1					
				11.SELF-AGGRESSION	0	0					
				12.GLOBAL EVALUATION	1	0					
				11.Total score	7	6					
	258	Placebo	Male	01.FACIAL EXPRESSION	1	1	1				
				02.BODY GESTURES	0	0	0				
				03.LOOK	1	1	1				
				04.OUTWARD APPEARANCE	1	1	1				
				05.SPEECH	1	1	1				
				06.VOICE	0	0	0				
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	0				
				08.CONTACTS, AFFECTIVE NEED	1	1	1				
				09.ANGUISH, ANXIETY	2	3	3				
				10.AGGRESSION, IRRITABILITY	0	0	1				
				11.SELF-AGGRESSION	0	0	0				
				12.GLOBAL EVALUATION	1	1	1				
				11.Total score	8	9	10				
11	319	Placebo	Male	01.FACIAL EXPRESSION	2	2	2	2	2	2	1
				02.BODY GESTURES	1	1	1	1	2	1	1
				03.LOOK	2	2	2	2	2	2	1
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	1	1	1	2	2	2	1
				06.VOICE	1	1	1	1	1	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	2	2	2	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	2	2	1	1
				11.SELF-AGGRESSION	3	1	1	1	1	1	1
				12.GLOBAL EVALUATION	2	2	2	2	2	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	319	Placebo	Male	11.Total score	16	14	14	17	18	15	10
	320	Imipramine	Male	01.FACIAL EXPRESSION	1	3	2	3	1	2	1
				02.BODY GESTURES	1	2	0	1	0	1	0
				03.LOOK	0	1	0	1	0	1	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	1	1	1	2	1	2	2
				06.VOICE	1	1	1	1	0	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	2	1	2	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	0	1	1	0	0
				09.ANGUISH, ANXIETY	3	3	1	2	1	3	2
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	1	1	2	1	1	1
				12.GLOBAL EVALUATION	1	2	1	2	1	1	0
				11.Total score	11	17	8	17	6	12	6
	321	Placebo	Male	01.FACIAL EXPRESSION	1	2	1	0	0	0	0
				02.BODY GESTURES	0	1	0	0	0	0	0
				03.LOOK	0	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	1	1	1	1	0	0	0
				06.VOICE	0	1	1	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	2	1	1	0	0	0
				08.CONTACTS, AFFECTIVE NEED	0	1	0	0	0	0	0
				09.ANGUISH, ANXIETY	2	2	1	0	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	1	0	0	0	0	0
				12.GLOBAL EVALUATION	0	1	1	0	0	0	0
				11.Total score	6	12	6	2	0	0	0
	323	Reboxetine	Male	01.FACIAL EXPRESSION	1	0	0	0	0	0	0
				02.BODY GESTURES	0	0	0	0	0	0	0
				03.LOOK	0	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	0	0	0	0	0	0	0
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	0	0	0	0	0	0
				09.ANGUISH, ANXIETY	0	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	0	0	0	0	0	0
				11.SELF-AGGRESSION	1	0	0	0	0	0	0
				12.GLOBAL EVALUATION	1	0	0	0	0	0	0
				11.Total score	6	0	0	0	0	0	0
	324	Imipramine	Male	01.FACIAL EXPRESSION	1	1	1	1	0	1	1
				02.BODY GESTURES	1	0	0	1	1	0	0
				03.LOOK	0	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	324	Imipramine	Male	05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	0	0	0
				09.ANGUISH, ANXIETY	1	1	0	1	1	2	2
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	2	2	2	1
				12.GLOBAL EVALUATION	1	1	1	1	1	1	1
				11.Total score	10	9	9	11	8	9	8
	325	Reboxetine	Male	01.FACIAL EXPRESSION	1	0		0	0	0	0
				02.BODY GESTURES	0	0		0	0	0	0
				03.LOOK	0	0		0	0	0	0
				04.OUTWARD APPEARANCE	2	1		0	1	0	0
				05.SPEECH	0	0		0	0	0	0
				06.VOICE	1	0		0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	0		0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	0	0		0	0	0	0
				09.ANGUISH, ANXIETY	0	0		0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	0		0	0	0	0
				11.SELF-AGGRESSION	1	0		0	0	0	0
				12.GLOBAL EVALUATION	1	0		0	0	0	0
				11.Total score	7	1		0	1	0	0
	326	Placebo	Male	01.FACIAL EXPRESSION	3	3	3	2	4	4	4
				02.BODY GESTURES	2	2	2	2	3	3	3
				03.LOOK	1	1	1	1	1	2	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	1	1
				05.SPEECH	1	1	2	2	1	1	1
				06.VOICE	2	2	2	1	2	1	2
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	2	2	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	1	0	0	0
				10.AGGRESSION, IRRITABILITY	2	2	2	2	1	1	1
				11.SELF-AGGRESSION	1	1	2	2	2	2	2
				12.GLOBAL EVALUATION	2	2	2	2	2	2	2
				11.Total score	20	19	21	19	19	19	19
	327	Imipramine	Male	01.FACIAL EXPRESSION	1	0					
				02.BODY GESTURES	0	0					
				03.LOOK	1	0					
				04.OUTWARD APPEARANCE	0	0					
				05.SPEECH	0	0					
				06.VOICE	1	1					
				07.ADAPTABILITY, SUGGESTIBILITY	0	0					
				08.CONTACTS, AFFECTIVE NEED	0	0					
				09.ANGUISH, ANXIETY	0	0					
				10.AGGRESSION, IRRITABILITY	0	0					
				11.SELF-AGGRESSION	1	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	327	Imipramine	Male	12.GLOBAL EVALUATION	0	0					
				11.Total score	4	2					
	328	Imipramine	Female	01.FACIAL EXPRESSION	1	0					
				02.BODY GESTURES	1	1					
				03.LOOK	1	0					
				04.OUTWARD APPEARANCE	0	0					
				05.SPEECH	1	0					
				06.VOICE	1	1					
				07.ADAPTABILITY, SUGGESTIBILITY	2	0					
				08.CONTACTS, AFFECTIVE NEED	1	1					
				09.ANGUISH, ANXIETY	2	1					
				10.AGGRESSION, IRRITABILITY	1	1					
				11.SELF-AGGRESSION	2	1					
				12.GLOBAL EVALUATION	1	1					
				11.Total score	14	7					
	329	Placebo	Female	01.FACIAL EXPRESSION	0	0	1	0	0	0	0
				02.BODY GESTURES	1	0	1	0	0	0	0
				03.LOOK	0	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	0	0	1	0	0	0	0
				06.VOICE	1	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	0	0	0	0	0	0	0
				09.ANGUISH, ANXIETY	1	1	1	2	0	0	1
				10.AGGRESSION, IRRITABILITY	1	0	1	1	0	0	0
				11.SELF-AGGRESSION	1	1	1	1	0	0	0
				12.GLOBAL EVALUATION	0	0	0	0	0	0	0
				11.Total score	5	2	7	4	0	0	1
	330	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	1	0	0	0	0
				02.BODY GESTURES	1	1	1	1	0	0	0
				03.LOOK	1	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	2	2	1	0	0	0	0
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	0	0	0	0	0
				09.ANGUISH, ANXIETY	2	2	1	1	1	0	0
				10.AGGRESSION, IRRITABILITY	1	2	2	1	1	0	0
				11.SELF-AGGRESSION	2	2	2	1	1	0	0
				12.GLOBAL EVALUATION	1	1	1	0	0	0	0
				11.Total score	14	15	11	4	3	0	0
	331	Imipramine	Male	01.FACIAL EXPRESSION	0	0	0	0	0	1	1
				02.BODY GESTURES	0	0	0	0	0	0	0
				03.LOOK	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	331	Imipramine	Male	04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	1	1	0	0	1	1	0
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	0	0	1	0	0
				08.CONTACTS, AFFECTIVE NEED	0	0	0	0	0	0	0
				09.ANGUISH, ANXIETY	1	1	1	0	1	1	1
				10.AGGRESSION, IRRITABILITY	0	1	1	0	1	1	1
				11.SELF-AGGRESSION	1	1	1	0	0	0	1
				12.GLOBAL EVALUATION	0	0	0	0	0	0	0
				11.Total score	4	4	3	0	4	4	4
	332	Reboxetine	Male	01.FACIAL EXPRESSION	2	1	0	0	0	0	0
				02.BODY GESTURES	1	1	0	0	0	0	0
				03.LOOK	1	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	1	1	1	0	0	0	0
				06.VOICE	1	1	1	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	0	0	0	0	0
				09.ANGUISH, ANXIETY	2	1	1	0	0	0	0
				10.AGGRESSION, IRRITABILITY	2	2	1	0	0	0	0
				11.SELF-AGGRESSION	2	1	1	0	0	0	0
				12.GLOBAL EVALUATION	2	2	1	0	0	0	0
				11.Total score	16	12	6	0	0	0	0
	333	Placebo	Male	01.FACIAL EXPRESSION	1	1	1	0	0	0	0
				02.BODY GESTURES	1	0	0	0	0	0	0
				03.LOOK	0	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	0	0	0	0	0	0	0
				06.VOICE	1	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	0	0	0	0	0	0	0
				09.ANGUISH, ANXIETY	1	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	0	1	0	0
				11.SELF-AGGRESSION	1	1	1	0	0	0	0
				12.GLOBAL EVALUATION	1	0	0	0	0	0	0
				11.Total score	7	4	3	0	1	0	0
	334	Reboxetine	Female	01.FACIAL EXPRESSION	1						
				02.BODY GESTURES	1						
				03.LOOK	0						
				04.OUTWARD APPEARANCE	0						
				05.SPEECH	1						
				06.VOICE	1						
				07.ADAPTABILITY, SUGGESTIBILITY	0						
				08.CONTACTS, AFFECTIVE NEED	1						
				09.ANGUISH, ANXIETY	2						
				10.AGGRESSION, IRRITABILITY	1						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	334	Reboxetine	Female	11.SELF-AGGRESSION	1						
				12.GLOBAL EVALUATION	1						
				11.Total score	10						
	335	Placebo	Male	01.FACIAL EXPRESSION	0	0	0	0	0	0	0
				02.BODY GESTURES	1	1	1	0	0	0	1
				03.LOOK	1	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	1	0	1	0	0	0	1
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	0	0	0	0	0	0
				09.ANGUISH, ANXIETY	1	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	0	0	0	1
				11.SELF-AGGRESSION	1	2	1	0	0	0	0
				12.GLOBAL EVALUATION	1	0	0	0	0	0	0
				11.Total score	8	4	4	0	0	0	3
	336	Imipramine	Female	01.FACIAL EXPRESSION	3	3					
				02.BODY GESTURES	2	2					
				03.LOOK	1	2					
				04.OUTWARD APPEARANCE	0	0					
				05.SPEECH	2	2					
				06.VOICE	2	2					
				07.ADAPTABILITY, SUGGESTIBILITY	2	2					
				08.CONTACTS, AFFECTIVE NEED	2	3					
				09.ANGUISH, ANXIETY	3	3					
				10.AGGRESSION, IRRITABILITY	2	2					
				11.SELF-AGGRESSION	2	1					
				12.GLOBAL EVALUATION	2	2					
				11.Total score	23	24					
	337	Reboxetine	Female	01.FACIAL EXPRESSION	0	0	1	1	2	1	1
				02.BODY GESTURES	0	0	0	0	1	1	1
				03.LOOK	0	0	0	0	1	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	0	0	0	1	1	1	1
				06.VOICE	0	1	1	0	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	0	0	1	1	1
				08.CONTACTS, AFFECTIVE NEED	0	0	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	0	0	0	1	0	0
				10.AGGRESSION, IRRITABILITY	0	0	1	1	1	1	1
				11.SELF-AGGRESSION	0	1	1	1	1	1	1
				12.GLOBAL EVALUATION	0	0	1	1	1	1	1
				11.Total score	1	2	6	6	12	9	9
	338	Imipramine	Male	01.FACIAL EXPRESSION	2	1					
				02.BODY GESTURES	1	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	338	Imipramine	Male	03.LOOK	1	1					
				04.OUTWARD APPEARANCE	2	1					
				05.SPEECH	1	0					
				06.VOICE	1	1					
				07.ADAPTABILITY, SUGGESTIBILITY	1	1					
				08.CONTACTS, AFFECTIVE NEED	2	1					
				09.ANGUISH, ANXIETY	1	1					
				10.AGGRESSION, IRRITABILITY	1	1					
				11.SELF-AGGRESSION	2	1					
				12.GLOBAL EVALUATION	2	1					
				11.Total score	17	11					
12	367	Reboxetine	Female	01.FACIAL EXPRESSION	1	1	1	0	0	0	0
				02.BODY GESTURES	1	1	1	1	0	0	0
				03.LOOK	0	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	3	1	1	0	0	0	0
				06.VOICE	3	2	2	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	3	1	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	3	2	2	0	0	1	0
				09.ANGUISH, ANXIETY	1	0	1	1	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	0	1	0	0	1
				11.SELF-AGGRESSION	1	1	0	1	0	0	0
				12.GLOBAL EVALUATION	3	1	2	0	0	0	0
				11.Total score	19	10	10	4	0	1	1
	368	Placebo	Female	01.FACIAL EXPRESSION	2	1	2	1	1	1	1
				02.BODY GESTURES	2	1	1	1	1	1	1
				03.LOOK	2	1	1	1	1	1	0
				04.OUTWARD APPEARANCE	0	0	1	1	1	1	1
				05.SPEECH	3	3	2	1	1	1	1
				06.VOICE	3	3	3	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	2	1	1
				09.ANGUISH, ANXIETY	0	1	2	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	0	0	0	0	1	1
				11.SELF-AGGRESSION	1	1	1	0	0	1	0
				12.GLOBAL EVALUATION	1	2	1	1	1	1	1
				11.Total score	19	17	17	9	10	11	9
	369	Imipramine	Female	01.FACIAL EXPRESSION	1	0	1	2			
				02.BODY GESTURES	0	0	0	1			
				03.LOOK	1	0	0	3			
				04.OUTWARD APPEARANCE	0	0	0	0			
				05.SPEECH	1	0	1	1			
				06.VOICE	1	0	0	1			
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	1	1			
				08.CONTACTS, AFFECTIVE NEED	1	0	1	1			
				09.ANGUISH, ANXIETY	2	1	2	3			

1484

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
12	369	Imipramine	Female	10.AGGRESSION, IRRITABILITY	1	1	1	1			
				11.SELF-AGGRESSION	3	0	1	3			
				12.GLOBAL EVALUATION	1	0	1	1			
				11.Total score	13	2	9	18			
	370	Placebo	Male	01.FACIAL EXPRESSION	3	1	3	2			
				02.BODY GESTURES	2	1	2	2			
				03.LOOK	1	1	2	1			
				04.OUTWARD APPEARANCE	1	0	1	1			
				05.SPEECH	3	3	3	3			
				06.VOICE	4	1	3	2			
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	3	2			
				08.CONTACTS, AFFECTIVE NEED	2	2	3	3			
				09.ANGUISH, ANXIETY	1	1	2	2			
				10.AGGRESSION, IRRITABILITY	1	1	1	1			
				11.SELF-AGGRESSION	1	1	2	2			
				12.GLOBAL EVALUATION	2	1	2	2			
				11.Total score	23	15	27	23			
	371	Imipramine	Female	01.FACIAL EXPRESSION	2	0					
				02.BODY GESTURES	2	1					
				03.LOOK	2	1					
				04.OUTWARD APPEARANCE	1	0					
				05.SPEECH	2	1					
				06.VOICE	2	0					
				07.ADAPTABILITY, SUGGESTIBILITY	2	1					
				08.CONTACTS, AFFECTIVE NEED	2	1					
				09.ANGUISH, ANXIETY	3	1					
				10.AGGRESSION, IRRITABILITY	2	0					
				11.SELF-AGGRESSION	2	1					
				12.GLOBAL EVALUATION	1	1					
				11.Total score	23	8					
	372	Reboxetine	Male	01.FACIAL EXPRESSION	3	2	1	1	0	0	2
				02.BODY GESTURES	2	2	1	0	1	1	2
				03.LOOK	3	2	1	1	2	0	2
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	3	2	0	0	0	0	1
				06.VOICE	3	2	0	1	0	0	1
				07.ADAPTABILITY, SUGGESTIBILITY	3	1	1	0	0	0	1
				08.CONTACTS, AFFECTIVE NEED	2	2	1	1	0	1	2
				09.ANGUISH, ANXIETY	3	3	1	1	2	1	2
				10.AGGRESSION, IRRITABILITY	2	1	1	0	2	0	2
				11.SELF-AGGRESSION	3	3	0	0	1	0	1
				12.GLOBAL EVALUATION	2	2	1	0	0	0	0
				11.Total score	30	22	8	5	8	3	16
	373	Reboxetine	Male	01.FACIAL EXPRESSION	1	0	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
12	373	Reboxetine	Male	02.BODY GESTURES	1	0	0	0	0	0	0
				03.LOOK	0	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	2	0	1	0	1	1	0
				06.VOICE	1	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	0	0	0	0	1
				09.ANGUISH, ANXIETY	2	0	1	1	1	1	0
				10.AGGRESSION, IRRITABILITY	2	0	2	1	2	0	0
				11.SELF-AGGRESSION	3	1	0	1	1	0	0
				12.GLOBAL EVALUATION	1	0	0	0	0	0	0
				11.Total score	16	2	5	3	5	2	1
	374	Placebo	Female	01.FACIAL EXPRESSION	2	1	1	2	1		
				02.BODY GESTURES	1	2	1	1	1		
				03.LOOK	2	2	0	1	2		
				04.OUTWARD APPEARANCE	1	0	0	0	0		
				05.SPEECH	2	1	1	0	1		
				06.VOICE	2	1	0	1	1		
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	0	1	2		
				08.CONTACTS, AFFECTIVE NEED	2	2	1	2	2		
				09.ANGUISH, ANXIETY	3	3	1	1	3		
				10.AGGRESSION, IRRITABILITY	2	2	2	2	1		
				11.SELF-AGGRESSION	2	1	0	1	1		
				12.GLOBAL EVALUATION	2	1	0	2	1		
				11.Total score	23	17	7	14	16		
	375	Imipramine	Male	01.FACIAL EXPRESSION	3						
				02.BODY GESTURES	2						
				03.LOOK	1						
				04.OUTWARD APPEARANCE	1						
				05.SPEECH	2						
				06.VOICE	2						
				07.ADAPTABILITY, SUGGESTIBILITY	1						
				08.CONTACTS, AFFECTIVE NEED	2						
				09.ANGUISH, ANXIETY	1						
				10.AGGRESSION, IRRITABILITY	1						
				11.SELF-AGGRESSION	3						
				12.GLOBAL EVALUATION	2						
				11.Total score	21						
13	13	Placebo	Male	01.FACIAL EXPRESSION	1	1	0	1	2	2	3
				02.BODY GESTURES	0	1	1	1	1	2	2
				03.LOOK	0	0	0	1	1	1	3
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	1
				05.SPEECH	1	2	1	1	1	2	3
				06.VOICE	0	1	0	0	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	2
				08.CONTACTS, AFFECTIVE NEED	0	0	0	1	1	1	3

1489

9550082

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
13	13	Placebo	Male	09.ANGUISH, ANXIETY	1	2	1	2	1	2	2
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	2	0	1	1	1	1	1
				12.GLOBAL EVALUATION	0	0	0	0	0	1	2
				11.Total score	7	9	6	10	11	15	24
	14	Placebo	Male	01.FACIAL EXPRESSION	2	1	2	2	0	1	0
				02.BODY GESTURES	1	1	1	2	1	1	1
				03.LOOK	1	1	2	1	0	1	0
				04.OUTWARD APPEARANCE	1	0	1	0	0	0	0
				05.SPEECH	2	2	3	2	1	1	1
				06.VOICE	1	0	1	1	0	1	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	2	2	1	1	0
				08.CONTACTS, AFFECTIVE NEED	2	2	3	1	0	1	1
				09.ANGUISH, ANXIETY	2	1	2	1	0	0	0
				10.AGGRESSION, IRRITABILITY	0	0	1	0	0	1	1
				11.SELF-AGGRESSION	3	1	2	2	0	1	1
				12.GLOBAL EVALUATION	1	0	2	1	0	1	0
				11.Total score	18	10	22	15	3	10	5
	15	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	2	2	2	2
				02.BODY GESTURES	2	1	1	1	1	1	1
				03.LOOK	2	1	1	0	1	1	1
				04.OUTWARD APPEARANCE	0	1	1	0	1	1	1
				05.SPEECH	2	1	1	1	1	2	2
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	0	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	3	1
				09.ANGUISH, ANXIETY	0	0	0	1	1	1	2
				10.AGGRESSION, IRRITABILITY	1	0	0	1	0	1	2
				11.SELF-AGGRESSION	3	2	1	1	3	1	1
				12.GLOBAL EVALUATION	1	1	1	0	0	1	1
				11.Total score	16	12	10	9	13	16	16
	16	Imipramine	Male	01.FACIAL EXPRESSION	1	2	1	1	1	0	2
				02.BODY GESTURES	1	2	1	1	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	0	1	0	0	0	0	0
				05.SPEECH	2	1	1	1	1	1	2
				06.VOICE	1	1	1	0	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	1	2	2	0	0	1	1
				10.AGGRESSION, IRRITABILITY	1	1	2	1	1	1	1
				11.SELF-AGGRESSION	0	2	2	0	2	2	2
				12.GLOBAL EVALUATION	1	1	1	1	0	0	1
				11.Total score	11	16	14	8	10	10	14

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
13	17	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	1	1	2	2	2
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	2	1	1	2	1	1	1
				04.OUTWARD APPEARANCE	0	0	1	0	0	0	0
				05.SPEECH	2	1	1	1	1	2	1
				06.VOICE	1	1	1	0	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	2	0	1	1	0
				08.CONTACTS, AFFECTIVE NEED	2	1	1	1	2	1	1
				09.ANGUISH, ANXIETY	2	1	2	1	1	1	1
				10.AGGRESSION, IRRITABILITY	0	1	1	2	1	0	0
				11.SELF-AGGRESSION	2	2	1	1	1	1	1
				12.GLOBAL EVALUATION	1	1	1	1	1	1	1
				11.Total score	16	13	14	11	13	12	10
	18	Reboxetine	Male	01.FACIAL EXPRESSION	1	1	1	1	1	1	1
				02.BODY GESTURES	1	1	0	0	1	0	0
				03.LOOK	2	1	2	1	1	1	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	2	2	1	1	1	1	1
				06.VOICE	1	1	1	0	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	0	0	1	0	1	0	1
				08.CONTACTS, AFFECTIVE NEED	0	0	1	1	0	1	0
				09.ANGUISH, ANXIETY	1	1	0	0	1	0	1
				10.AGGRESSION, IRRITABILITY	2	2	2	2	2	2	0
				11.SELF-AGGRESSION	0	2	1	0	1	0	1
				12.GLOBAL EVALUATION	0	1	0	0	1	1	0
				11.Total score	10	12	10	6	11	7	5
	409	Reboxetine	Male	01.FACIAL EXPRESSION	2	2	2		2		1
				02.BODY GESTURES	1	1	2		1		1
				03.LOOK	1	1	1		1		2
				04.OUTWARD APPEARANCE	0	0	0		0		0
				05.SPEECH	1	1	2		1		1
				06.VOICE	1	1	1		1		1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1		1		1
				08.CONTACTS, AFFECTIVE NEED	1	1	1		1		1
				09.ANGUISH, ANXIETY	3	2	1		1		1
				10.AGGRESSION, IRRITABILITY	1	1	1		1		1
				11.SELF-AGGRESSION	2	2	2		2		2
				12.GLOBAL EVALUATION	1	1	1		1		1
				11.Total score	15	14	15		13		13
	410	Placebo	Male	01.FACIAL EXPRESSION	2	2	2	2	2	2	1
				02.BODY GESTURES	2	1	2	2	1	1	1
				03.LOOK	1	2	2	2	2	2	2
				04.OUTWARD APPEARANCE	1	0	0	0	0	1	0
				05.SPEECH	2	2	2	1	2	1	1
				06.VOICE	1	1	1	1	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	1	2	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
13	410	Placebo	Male	08.CONTACTS, AFFECTIVE NEED	1	2	2	2	1	1	2
				09.ANGUISH, ANXIETY	1	2	1	2	2	2	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	0
				11.SELF-AGGRESSION	2	2	2	2	1	2	1
				12.GLOBAL EVALUATION	1	1	1	1	1	1	1
				11.Total score	17	17	17	17	15	17	12
	411	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	2	2	2	2
				02.BODY GESTURES	1	1	1	3	3	1	1
				03.LOOK	1	1	1	1	2	1	1
				04.OUTWARD APPEARANCE	0	0	0	1	1	0	0
				05.SPEECH	2	2	2	2	2	2	1
				06.VOICE	2	1	1	2	2	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	1	1
				08.CONTACTS, AFFECTIVE NEED	2	1	1	3	2	1	1
				09.ANGUISH, ANXIETY	2	2	0	2	2	2	2
				10.AGGRESSION, IRRITABILITY	2	1	1	2	2	1	0
				11.SELF-AGGRESSION	1	0	0	2	2	0	1
				12.GLOBAL EVALUATION	2	1	0	2	1	1	1
				11.Total score	18	13	9	23	22	13	12
	423	Placebo	Male	01.FACIAL EXPRESSION	1	1	2	2			1
				02.BODY GESTURES	1	1	1	1			0
				03.LOOK	1	1	1	2			1
				04.OUTWARD APPEARANCE	0	0	0	0			0
				05.SPEECH	1	2	2	2			1
				06.VOICE	0	1	1	1			1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1			1
				08.CONTACTS, AFFECTIVE NEED	1	2	1	2			0
				09.ANGUISH, ANXIETY	1	1	1	1			0
				10.AGGRESSION, IRRITABILITY	1	1	1	2			1
				11.SELF-AGGRESSION	1	1	1	1			0
				12.GLOBAL EVALUATION	1	1	1	0			0
				11.Total score	10	13	13	15			6
14	19	Reboxetine	Female	01.FACIAL EXPRESSION	4	4	1	3	3		
				02.BODY GESTURES	3	3	2	3	3		
				03.LOOK	3	4	2	2	4		
				04.OUTWARD APPEARANCE	3	3	1	1	3		
				05.SPEECH	4	3	2	2	3		
				06.VOICE	3	4	2	2	3		
				07.ADAPTABILITY, SUGGESTIBILITY	3	3	1	2	2		
				08.CONTACTS, AFFECTIVE NEED	3	3	1	2	3		
				09.ANGUISH, ANXIETY	4	3	1	1	1		
				10.AGGRESSION, IRRITABILITY	1	0	0	1	1		
				11.SELF-AGGRESSION	2	1	1	1	1		
				12.GLOBAL EVALUATION	3	3	2	2	3		
				11.Total score	36	34	16	22	30		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14	20	Imipramine	Female	01.FACIAL EXPRESSION	2	2	2	1	1	0	0
				02.BODY GESTURES	1	1	3	1	1	0	0
				03.LOOK	0	1	1	1	0	0	0
				04.OUTWARD APPEARANCE	0	1	0	0	0	0	0
				05.SPEECH	2	2	2	1	1	0	0
				06.VOICE	1	2	1	1	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	1	1	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	1	1	0	1	0	0
				09.ANGUISH, ANXIETY	3	3	2	1	1	0	1
				10.AGGRESSION, IRRITABILITY	1	1	1	0	0	0	1
				11.SELF-AGGRESSION	2	2	0	1	0	0	1
				12.GLOBAL EVALUATION	1	1	1	1	1	0	0
				11.Total score	17	18	15	9	7	0	3
	21	Imipramine	Female	01.FACIAL EXPRESSION	2	3	1	2	2	2	
				02.BODY GESTURES	1	1	1	2	1	2	
				03.LOOK	1	2	0	0	0	1	
				04.OUTWARD APPEARANCE	0	1	1	1	1	1	
				05.SPEECH	2	2	1	2	2	2	
				06.VOICE	1	2	1	1	2	2	
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	2	1	2	
				08.CONTACTS, AFFECTIVE NEED	2	1	1	1	1	1	
				09.ANGUISH, ANXIETY	3	2	2	2	2	2	
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	
				11.SELF-AGGRESSION	1	1	1	2	2	1	
				12.GLOBAL EVALUATION	1	1	1	1	2	1	
				11.Total score	16	18	12	17	17	18	
15	25	Reboxetine	Female	01.FACIAL EXPRESSION	1	2	1	2	1	2	1
				02.BODY GESTURES	1	1	2	1	1	1	1
				03.LOOK	1	1	1	1	1	1	1
				04.OUTWARD APPEARANCE	1	1	1	1	1	0	0
				05.SPEECH	2	2	2	2	1	2	1
				06.VOICE	1	1	1	2	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	2	1	1	1	1	0
				08.CONTACTS, AFFECTIVE NEED	0	2	2	1	1	1	0
				09.ANGUISH, ANXIETY	2	1	2	2	1	1	1
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	0	0
				11.SELF-AGGRESSION	1	2	2	2	2	1	1
				12.GLOBAL EVALUATION	0	0	0	1	0	0	0
				11.Total score	12	16	16	17	12	11	7
	26	Placebo	Male	01.FACIAL EXPRESSION	1	1	1	1	2	1	0
				02.BODY GESTURES	1	1	1	1	1	1	1
				03.LOOK	2	1	0	0	1	0	0
				04.OUTWARD APPEARANCE	1	1	0	0	1	0	0
				05.SPEECH	2	2	1	0	2	0	1

1490

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	26	Placebo	Male	06.VOICE	2	1	1	0	1	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	2	1	0	0	1	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	2	0	2	1	1
				09.ANGUISH, ANXIETY	1	1	1	0	1	0	0
				10.AGGRESSION, IRRITABILITY	2	1	1	1	2	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	0	0	0	0	0	0	0
				11.Total score	16	12	9	4	15	5	5
	27	Imipramine	Female	01.FACIAL EXPRESSION	2	1	0	0	0	0	0
				02.BODY GESTURES	1	1	1	1	0	0	0
				03.LOOK	1	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	2	1	1	1	0	0	0
				06.VOICE	1	1	1	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	1	0	0	0
				08.CONTACTS, AFFECTIVE NEED	3	2	0	0	0	0	0
				09.ANGUISH, ANXIETY	1	2	1	1	0	0	0
				10.AGGRESSION, IRRITABILITY	1	0	1	1	1	0	1
				11.SELF-AGGRESSION	2	2	2	2	1	1	1
				12.GLOBAL EVALUATION	1	0	0	0	0	0	0
				11.Total score	17	11	7	7	2	1	2
	28	Reboxetine	Female	01.FACIAL EXPRESSION	2	2	1	1	0	0	0
				02.BODY GESTURES	1	0	0	0	0	0	0
				03.LOOK	1	1	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	2	2	1	1	1	1	0
				06.VOICE	1	1	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	0	0	0
				08.CONTACTS, AFFECTIVE NEED	0	0	0	0	0	0	0
				09.ANGUISH, ANXIETY	1	1	1	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	0
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	0	0	0	0	0	0	0
				11.Total score	12	10	6	5	3	3	1
	29	Placebo	Male	01.FACIAL EXPRESSION	1	1	2	2			
				02.BODY GESTURES	1	1	1	1			
				03.LOOK	1	1	1	1			
				04.OUTWARD APPEARANCE	0	0	0	0			
				05.SPEECH	1	2	2	2			
				06.VOICE	2	2	1	1			
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	2			
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1			
				09.ANGUISH, ANXIETY	1	1	1	2			
				10.AGGRESSION, IRRITABILITY	3	0	1	0			
				11.SELF-AGGRESSION	2	2	2	2			
				12.GLOBAL EVALUATION	1	0	0	0			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	29	Placebo	Male	11.Total score	17	14	15	14			
	30	Imipramine	Female	01.FACIAL EXPRESSION	2	2	1	1	0	1	0
				02.BODY GESTURES	2	1	1	1	1	0	0
				03.LOOK	1	1	1	0	0	0	1
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	1	1	1	1	1	1	0
				06.VOICE	1	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	1	1	1	0	0
				08.CONTACTS, AFFECTIVE NEED	1	0	0	0	0	0	1
				09.ANGUISH, ANXIETY	1	1	1	1	1	0	0
				10.AGGRESSION, IRRITABILITY	1	1	0	0	1	1	0
				11.SELF-AGGRESSION	2	2	1	2	1	1	1
				12.GLOBAL EVALUATION	0	0	0	0	0	0	1
				11.Total score	13	10	7	7	6	4	4
	403	Imipramine	Female	01.FACIAL EXPRESSION	2	1	1	1	1	0	0
				02.BODY GESTURES	1	1	1	0	0	0	0
				03.LOOK	1	1	1	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	2	1	1	1	0	1	0
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	0	0	0
				09.ANGUISH, ANXIETY	1	1	1	0	0	0	0
				10.AGGRESSION, IRRITABILITY	0	2	0	1	1	0	0
				11.SELF-AGGRESSION	2	1	1	1	1	1	1
				12.GLOBAL EVALUATION	1	1	0	0	0	0	0
				11.Total score	12	10	7	5	3	2	2
	404	Reboxetine	Female	01.FACIAL EXPRESSION	2	1	1	0	1		
				02.BODY GESTURES	1	1	1	1	1		
				03.LOOK	1	0	1	1	0		
				04.OUTWARD APPEARANCE	1	1	0	0	0		
				05.SPEECH	1	2	1	1	1		
				06.VOICE	1	1	1	1	0		
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	0	1		
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1		
				09.ANGUISH, ANXIETY	1	1	1	0	0		
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1		
				11.SELF-AGGRESSION	2	2	2	1	1		
				12.GLOBAL EVALUATION	1	1	1	1	1		
				11.Total score	14	13	11	8	8		
	405	Placebo	Female	01.FACIAL EXPRESSION	2	1	1	0	0	0	0
				02.BODY GESTURES	2	1	0	0	0	0	0
				03.LOOK	1	0	0	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	405	Placebo	Female	05.SPEECH	1	1	1	0	0	0	0
				06.VOICE	0	0	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	1	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	0	0	0	0
				09.ANGUISH, ANXIETY	2	1	1	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	0	0	1	1	1	1	1
				12.GLOBAL EVALUATION	1	0	1	0	0	0	0
				11.Total score	12	6	8	2	2	2	2
	406	Imipramine	Male	01.FACIAL EXPRESSION	1	1	1	0	0	0	1
				02.BODY GESTURES	1	1	1	0	0	0	0
				03.LOOK	1	1	0	0	0	0	0
				04.OUTWARD APPEARANCE	1	0	0	0	0	0	0
				05.SPEECH	1	1	1	1	1	1	1
				06.VOICE	1	1	1	1	1	0	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	1	1
				09.ANGUISH, ANXIETY	0	0	0	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	0	0	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	1	0	1	1	0	0	1
				11.Total score	11	8	7	5	5	4	7
	407	Reboxetine	Female	01.FACIAL EXPRESSION	1	1	2	1	1	0	0
				02.BODY GESTURES	2	2	1	1	0	0	0
				03.LOOK	2	1	2	0	0	0	0
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	2	1	1	1	1	1	1
				06.VOICE	1	1	1	0	0	0	1
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	2	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	1	0	1	1	1
				09.ANGUISH, ANXIETY	1	1	1	0	0	0	0
				10.AGGRESSION, IRRITABILITY	1	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	1
				12.GLOBAL EVALUATION	1	1	1	0	1	1	1
				11.Total score	16	14	15	5	6	5	6
	408	Placebo	Female	01.FACIAL EXPRESSION	2	2	2	1	1	1	0
				02.BODY GESTURES	2	2	2	1	1	0	0
				03.LOOK	1	1	1	1	0	1	0
				04.OUTWARD APPEARANCE	1	1	1	0	0	0	0
				05.SPEECH	3	2	2	1	1	1	1
				06.VOICE	2	2	2	0	1	1	1
				07.ADAPTABILITY, SUGGESTIBILITY	2	2	2	1	0	0	0
				08.CONTACTS, AFFECTIVE NEED	2	2	2	1	1	0	0
				09.ANGUISH, ANXIETY	1	1	1	0	0	1	1
				10.AGGRESSION, IRRITABILITY	0	0	0	0	0	1	1
				11.SELF-AGGRESSION	1	1	1	1	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 14.0

RELATIONAL DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Relational Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	408	Placebo	Female	12.GLOBAL EVALUATION	2	2	2	0	0	0	1
				11.Total score	19	18	18	7	6	7	7
	418	Placebo	Female	01.FACIAL EXPRESSION	2	2	1	0	0	1	0
				02.BODY GESTURES	1	1	1	1	1	0	0
				03.LOOK	1	1	0	0	0	0	0
				04.OUTWARD APPEARANCE	0	0	0	0	0	0	0
				05.SPEECH	2	1	1	1	0	1	1
				06.VOICE	3	2	0	0	0	0	0
				07.ADAPTABILITY, SUGGESTIBILITY	1	1	0	0	0	0	0
				08.CONTACTS, AFFECTIVE NEED	0	1	1	1	1	0	0
				09.ANGUISH, ANXIETY	1	1	1	1	1	0	0
				10.AGGRESSION, IRRITABILITY	0	1	1	1	1	1	1
				11.SELF-AGGRESSION	1	1	2	1	1	1	1
				12.GLOBAL EVALUATION	0	1	0	1	1	0	0
				11.Total score	12	13	8	7	6	4	3
	419	Placebo	Female	01.FACIAL EXPRESSION	1	0	1	1	0	1	
				02.BODY GESTURES	1	1	0	0	1	0	
				03.LOOK	1	0	0	1	0	0	
				04.OUTWARD APPEARANCE	1	0	1	1	0	0	
				05.SPEECH	2	1	2	2	1	1	
				06.VOICE	0	0	0	1	0	1	
				07.ADAPTABILITY, SUGGESTIBILITY	1	0	1	1	1	0	
				08.CONTACTS, AFFECTIVE NEED	1	1	1	1	1	0	
				09.ANGUISH, ANXIETY	1	1	1	1	1	1	
				10.AGGRESSION, IRRITABILITY	2	1	2	2	1	2	
				11.SELF-AGGRESSION	1	1	1	1	1	1	
				12.GLOBAL EVALUATION	1	0	1	0	0	1	
				11.Total score	13	6	11	12	7	8	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	1	Imipramine	Female	Severity of illness	6.00	6.00	4.00	4.00	3.00	3.00	1.00
				Global improvement		6.00	3.00	3.00	2.00	2.00	1.00
				Efficacy index		14.00	10.00	11.00	6.00	6.00	2.00
				Efficacy index (*)		0.50	1.00	0.67	1.50	1.50	2.00
	2	Reboxetine	Male	Severity of illness	6.00	5.00	4.00	4.00	5.00	4.00	4.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		13.00	10.00	10.00	10.00	10.00	6.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.50
	3	Imipramine	Male	Severity of illness	4.00	3.00	4.00	4.00	3.00	3.00	2.00
				Global improvement		4.00	4.00	3.00	3.00	2.00	2.00
				Efficacy index		14.00	14.00	10.00	11.00	3.00	6.00
				Efficacy index (*)		0.50	0.50	1.00	0.67	1.33	1.50
	4	Placebo	Male	Severity of illness	5.00	4.00	2.00	2.00	1.00	1.00	1.00
				Global improvement		2.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index		6.00	6.00	6.00	1.00	1.00	1.00
				Efficacy index (*)		1.50	1.50	1.50	4.00	4.00	4.00
	5	Reboxetine	Female	Severity of illness	5.00	4.00	4.00	4.00			
				Global improvement		3.00	3.00	5.00			
				Efficacy index		10.00	10.00	13.00			
				Efficacy index (*)		1.00	1.00	1.00			
	6	Placebo	Female	Severity of illness	6.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		3.00	3.00	4.00	3.00	3.00	4.00
				Efficacy index		10.00	10.00	14.00	10.00	10.00	16.00
				Efficacy index (*)		1.00	1.00	0.50	1.00	1.00	0.25
	7	Reboxetine	Female	Severity of illness	6.00	4.00	4.00	3.00	2.00	1.00	1.00
				Global improvement		3.00	3.00	2.00	1.00	1.00	1.00
				Efficacy index		10.00	10.00	6.00	2.00	2.00	1.00
				Efficacy index (*)		1.00	1.00	1.50	2.00	2.00	4.00
	8	Placebo	Male	Severity of illness	4.00	4.00	4.00	3.00	2.00	3.00	1.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	1.00
				Efficacy index		9.00	9.00	6.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	2.00	1.50	4.00	4.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	9	Reboxetine	Female	Severity of illness	7.00	6.00	4.00	5.00	4.00	4.00	3.00
				Global improvement		3.00	3.00	4.00	3.00	3.00	2.00
				Efficacy index		10.00	10.00	14.00	10.00	10.00	6.00
				Efficacy index (*)		1.00	1.00	0.50	1.00	1.00	1.50
	10	Placebo	Male	Severity of illness	5.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		13.00	10.00	10.00	10.00	10.00	10.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.00
	11	Imipramine	Female	Severity of illness	4.00						
				Global improvement							
				Efficacy index							
				Efficacy index (*)							
	12	Imipramine	Female	Severity of illness	5.00	4.00	3.00	3.00	2.00	1.00	1.00
				Global improvement		3.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		10.00	2.00	6.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	1.50	4.00	4.00	4.00
	412	Reboxetine	Male	Severity of illness	4.00	4.00	5.00	4.00	4.00	3.00	1.00
				Global improvement		3.00	4.00	3.00	2.00	2.00	1.00
				Efficacy index		9.00	14.00	10.00	6.00	1.00	1.00
				Efficacy index (*)		2.00	0.50	1.00	1.50	4.00	4.00
	413	Placebo	Male	Severity of illness	4.00	4.00		3.00		4.00	3.00
				Global improvement		4.00		3.00		3.00	3.00
				Efficacy index		13.00		10.00		10.00	10.00
				Efficacy index (*)		1.00		1.00		1.00	1.00
	414	Imipramine	Female	Severity of illness	5.00	4.00	5.00				
				Global improvement		4.00	4.00				
				Efficacy index		13.00	9.00				
				Efficacy index (*)		1.00	2.00				
	415	Imipramine	Male	Severity of illness	4.00	4.00	4.00	3.00	3.00	2.00	1.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	1.00
				Efficacy index		14.00	10.00	6.00	2.00	2.00	2.00
				Efficacy index (*)		0.50	1.00	1.50	2.00	2.00	2.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	416	Reboxetine	Female	Severity of illness	5.00	4.00	4.00				
				Global improvement		4.00	3.00				
				Efficacy index		14.00	13.00				
				Efficacy index (*)		0.50	1.00				
	421	Imipramine	Male	Severity of illness	4.00	4.00	4.00	3.00	2.00	3.00	2.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		10.00	11.00	6.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	0.67	1.50	2.00	2.00	2.00
	422	Imipramine	Male	Severity of illness	4.00	4.00	3.00	3.00	3.00	1.00	1.00
				Global improvement		4.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	6.00	6.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.50	1.50	2.00	2.00	2.00
2/1	49	Placebo	Female	Severity of illness	6.00	5.00	2.00	1.00	1.00	1.00	1.00
				Global improvement		3.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		11.00	6.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		0.67	1.50	2.00	2.00	2.00	2.00
	50	Reboxetine	Female	Severity of illness	4.00	3.00	2.00	2.00	2.00	2.00	2.00
				Global improvement		2.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		6.00	3.00	3.00	2.00	2.00	3.00
				Efficacy index (*)		1.50	1.33	1.33	2.00	2.00	1.33
	51	Imipramine	Female	Severity of illness	6.00	5.00	4.00	2.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	1.00	2.00	2.00	2.00
				Efficacy index		10.00	7.00	3.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.00	1.33	2.00	2.00	2.00
2/2	43	Imipramine	Female	Severity of illness	5.00	4.00	4.00		4.00	2.00	
				Global improvement		3.00	2.00		4.00	3.00	
				Efficacy index		10.00	5.00		14.00	10.00	
				Efficacy index (*)		1.00	3.00		0.50	1.00	
	44	Imipramine	Female	Severity of illness	5.00	5.00	3.00	3.00	2.00	4.00	3.00
				Global improvement		5.00	3.00	3.00	2.00	3.00	2.00
				Efficacy index		15.00	6.00	6.00	6.00	6.00	6.00
				Efficacy index (*)		0.33	1.50	1.50	1.50	1.50	1.50

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/2	45	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	4.00	3.00	4.00
				Global improvement		3.00	3.00	3.00	2.00	2.00	3.00
				Efficacy index		10.00	6.00	6.00	6.00	2.00	6.00
				Efficacy index (*)		1.00	1.50	1.50	1.50	2.00	1.50
	46	Placebo	Female	Severity of illness	6.00	4.00	4.00		3.00		
				Global improvement		3.00	3.00		2.00		
				Efficacy index		10.00	6.00		1.00		
				Efficacy index (*)		1.00	1.50		4.00		
	47	Placebo	Female	Severity of illness	4.00	5.00	3.00	3.00	5.00	4.00	4.00
				Global improvement		3.00	2.00	2.00	3.00	3.00	3.00
				Efficacy index		9.00	5.00	5.00	9.00	9.00	9.00
				Efficacy index (*)		2.00	3.00	3.00	2.00	2.00	2.00
	48	Reboxetine	Female	Severity of illness	6.00	5.00	5.00	4.00	4.00	2.00	3.00
				Global improvement		3.00	3.00	2.00	2.00	1.00	2.00
				Efficacy index		10.00	10.00	6.00	6.00	2.00	2.00
				Efficacy index (*)		1.00	1.00	1.50	1.50	2.00	2.00
2/3	36/A	Imipramine	Male	Severity of illness	5.00	5.00	4.00	2.00	2.00	1.00	1.00
				Global improvement		3.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		9.00	1.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		2.00	4.00	2.00	2.00	2.00	2.00
	37	Reboxetine	Female	Severity of illness	5.00	6.00	6.00	4.00	3.00	3.00	3.00
				Global improvement		5.00	4.00	3.00	2.00	2.00	2.00
				Efficacy index		13.00	13.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	1.00	3.00	4.00	4.00	4.00
	38	Placebo	Male	Severity of illness	5.00	3.00	3.00	4.00	3.00	3.00	3.00
				Global improvement		2.00	2.00	3.00	2.00	2.00	2.00
				Efficacy index		5.00	5.00	5.00	5.00	1.00	1.00
				Efficacy index (*)		3.00	3.00	3.00	3.00	4.00	4.00
	39	Imipramine	Female	Severity of illness	5.00	4.00	4.00	3.00	3.00	2.00	2.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		5.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	3.00	4.00	4.00	4.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/3	40	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	3.00	3.00	1.00	1.00
				Global improvement		3.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index		6.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		1.50	2.00	4.00	4.00	4.00	4.00
	41	Placebo	Male	Severity of illness	6.00	5.00	5.00	5.00	5.00	4.00	4.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		14.00	9.00	9.00	10.00	10.00	9.00
				Efficacy index (*)		0.50	2.00	2.00	1.00	1.00	2.00
	42	Imipramine	Female	Severity of illness	5.00	4.00	5.00	3.00	4.00	4.00	4.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		5.00	6.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		3.00	1.50	2.00	2.00	2.00	2.00
2/4	31	Placebo	Male	Severity of illness	5.00	5.00	5.00	5.00	4.00	4.00	4.00
				Global improvement		4.00	4.00	3.00	4.00	3.00	4.00
				Efficacy index		9.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		2.00	2.00	2.00	2.00	2.00	2.00
	32	Reboxetine	Male	Severity of illness	6.00	6.00	6.00	6.00	5.00	4.00	3.00
				Global improvement		4.00	4.00	5.00	3.00	3.00	2.00
				Efficacy index		13.00	13.00	13.00	9.00	9.00	5.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	2.00	3.00
	33	Imipramine	Male	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	1.00
				Global improvement		4.00	4.00	3.00	2.00	2.00	1.00
				Efficacy index		9.00	9.00	5.00	5.00	1.00	1.00
				Efficacy index (*)		2.00	2.00	3.00	3.00	4.00	4.00
	34	Placebo	Female	Severity of illness	6.00	6.00	6.00	5.00	4.00	2.00	2.00
				Global improvement		4.00	4.00	3.00	2.00	2.00	1.00
				Efficacy index		13.00	13.00	9.00	5.00	1.00	1.00
				Efficacy index (*)		1.00	1.00	2.00	3.00	4.00	4.00
	35	Reboxetine	Female	Severity of illness	6.00	6.00	6.00	4.00	3.00	3.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	9.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		2.00	2.00	3.00	3.00	3.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/4	36	Imipramine	Female	Severity of illness	6.00	6.00	5.00	4.00	3.00	2.00	2.00
				Global improvement		4.00	4.00	4.00	3.00	2.00	2.00
				Efficacy index		13.00	13.00	13.00	9.00	5.00	5.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	3.00	3.00
2/5	73	Placebo	Male	Severity of illness	4.00	3.00	3.00	4.00	4.00	5.00	5.00
				Global improvement		3.00	3.00	4.00	3.00	5.00	6.00
				Efficacy index		10.00	9.00	9.00	9.00	13.00	13.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	1.00	1.00
	74	Reboxetine	Male	Severity of illness	5.00	4.00	3.00	2.00	2.00	2.00	1.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index		10.00	6.00	6.00	5.00	1.00	1.00
				Efficacy index (*)		1.00	1.50	1.50	3.00	4.00	4.00
	75	Imipramine	Male	Severity of illness	5.00	5.00	4.00	3.00	1.00	2.00	1.00
				Global improvement		3.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index		9.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	3.00	4.00	4.00	4.00	4.00
	76	Imipramine	Female	Severity of illness	6.00	6.00	4.00	6.00	3.00	2.00	2.00
				Global improvement		3.00	2.00	6.00	2.00	2.00	1.00
				Efficacy index		11.00	2.00	13.00	6.00	2.00	2.00
				Efficacy index (*)		0.67	2.00	1.00	1.50	2.00	2.00
	77	Placebo	Male	Severity of illness	6.00	4.00	4.00	3.00	2.00	2.00	2.00
				Global improvement		2.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		5.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	3.00	4.00	4.00	4.00	4.00
	78	Reboxetine	Female	Severity of illness	5.00	6.00	3.00	3.00	2.00	2.00	
				Global improvement		3.00	3.00	2.00	2.00	1.00	
				Efficacy index		9.00	9.00	5.00	2.00	2.00	
				Efficacy index (*)		2.00	2.00	3.00	2.00	2.00	
2/6	55	Reboxetine	Female	Severity of illness	6.00	6.00	5.00	2.00	2.00	1.00	1.00
				Global improvement		4.00	3.00	2.00	1.00	1.00	1.00
				Efficacy index		13.00	9.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	4.00	4.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2/6	56	Reboxetine	Female	Severity of illness	6.00	6.00	6.00	6.00	4.00	4.00	5.00
				Global improvement		4.00	4.00	4.00	2.00	2.00	3.00
				Efficacy index		13.00	13.00	13.00	5.00	5.00	9.00
				Efficacy index (*)		1.00	1.00	1.00	3.00	3.00	2.00
	57	Imipramine	Female	Severity of illness	5.00	5.00	3.00	1.00	1.00	1.00	1.00
				Global improvement		4.00	3.00	1.00	1.00	1.00	1.00
				Efficacy index		13.00	10.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	2.00	2.00
	58	Placebo	Female	Severity of illness	6.00	6.00	6.00	2.00	1.00	1.00	1.00
				Global improvement		4.00	4.00	2.00	1.00	1.00	1.00
				Efficacy index		13.00	13.00	2.00	2.00	2.00	1.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	2.00	4.00
	59	Placebo	Male	Severity of illness	6.00	6.00	6.00	6.00	6.00		
				Global improvement		4.00	4.00	4.00	4.00		
				Efficacy index		13.00	13.00	13.00	13.00		
				Efficacy index (*)		1.00	1.00	1.00	1.00		
	60	Imipramine	Female	Severity of illness	6.00	6.00	2.00	1.00	1.00	1.00	1.00
				Global improvement		4.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		13.00	6.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.50	2.00	2.00	2.00	2.00
3/1	61	Imipramine	Male	Severity of illness	4.00	4.00	3.00	3.00	2.00	2.00	
				Global improvement		5.00	3.00	2.00	2.00	2.00	
				Efficacy index		14.00	10.00	6.00	6.00	5.00	
				Efficacy index (*)		0.50	1.00	1.50	1.50	3.00	
	62	Imipramine	Female	Severity of illness	6.00	4.00	3.00	3.00	2.00	2.00	2.00
				Global improvement		2.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index		5.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	3.00	4.00	4.00	4.00	4.00
	63	Placebo	Male	Severity of illness	6.00	6.00	4.00	4.00	3.00	2.00	2.00
				Global improvement		4.00	3.00	3.00	2.00	1.00	1.00
				Efficacy index		13.00	9.00	9.00	5.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	2.00	3.00	4.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/1	64	Placebo	Female	Severity of illness	5.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		3.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index		9.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		2.00	1.00	1.00	1.00	1.00	1.00
	65	Reboxetine	Male	Severity of illness	6.00	5.00	4.00	3.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index		9.00	5.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	3.00	3.00	4.00	4.00	4.00
	66	Reboxetine	Male	Severity of illness	4.00	4.00	3.00	3.00	2.00	2.00	2.00
				Global improvement		4.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	3.00	3.00	3.00	3.00	3.00
	139	Imipramine	Male	Severity of illness	4.00	4.00	6.00				
				Global improvement		5.00	6.00				
				Efficacy index		14.00	13.00				
				Efficacy index (*)		0.50	1.00				
	140	Placebo	Male	Severity of illness	4.00	4.00	3.00	2.00	2.00	2.00	2.00
				Global improvement		4.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	3.00	4.00	4.00	4.00	4.00
	141	Placebo	Female	Severity of illness	4.00	4.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	3.00	3.00	3.00	3.00
	142	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00			
				Global improvement		4.00	4.00	4.00			
				Efficacy index		13.00	13.00	13.00			
				Efficacy index (*)		1.00	1.00	1.00			
	143	Reboxetine	Female	Severity of illness	4.00	4.00		3.00	3.00	3.00	
				Global improvement		3.00		2.00	2.00	2.00	
				Efficacy index		9.00		2.00	2.00	3.00	
				Efficacy index (*)		2.00		2.00	2.00	1.33	

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/1	144	Reboxetine	Female	Severity of illness	5.00	5.00	3.00		2.00	2.00	2.00
				Global improvement		5.00	2.00		2.00	1.00	1.00
				Efficacy index		14.00	6.00		2.00	2.00	2.00
				Efficacy index (*)		0.50	1.50		2.00	2.00	2.00
	451	Reboxetine	Female	Severity of illness	5.00	5.00	6.00				
				Global improvement		4.00	6.00				
				Efficacy index		14.00	15.00				
				Efficacy index (*)		0.50	0.33				
	452	Placebo	Male	Severity of illness	4.00	4.00	2.00	1.00	1.00	2.00	1.00
				Global improvement		3.00	1.00	1.00	1.00	2.00	1.00
				Efficacy index		9.00	1.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		2.00	4.00	2.00	2.00	2.00	2.00
	453	Imipramine	Female	Severity of illness	4.00	3.00	3.00	2.00	2.00		2.00
				Global improvement		3.00	3.00	2.00	2.00		2.00
				Efficacy index		10.00	10.00	6.00	6.00		6.00
				Efficacy index (*)		1.00	1.00	1.50	1.50		1.50
	454	Reboxetine	Male	Severity of illness	4.00	3.00	3.00	2.00	2.00	2.00	2.00
				Global improvement		2.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		6.00	6.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.50	1.50	2.00	2.00	2.00	2.00
	455	Placebo	Female	Severity of illness	5.00	5.00	4.00	3.00	4.00	4.00	3.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	2.00
				Efficacy index		13.00	9.00	5.00	9.00	9.00	5.00
				Efficacy index (*)		1.00	2.00	3.00	2.00	2.00	3.00
	456	Imipramine	Female	Severity of illness	4.00	4.00	4.00				
				Global improvement		3.00	3.00				
				Efficacy index		10.00	12.00				
				Efficacy index (*)		1.00	0.50				
3/2	65/A	Reboxetine	Female	Severity of illness	6.00	5.00	4.00	5.00	5.00	5.00	5.00
				Global improvement		3.00	2.00	3.00	3.00	3.00	3.00
				Efficacy index		10.00	6.00	10.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	1.50	1.00	2.00	2.00	2.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/3	67	Placebo	Male	Severity of illness	5.00	5.00	5.00	4.00	3.00	3.00	4.00
				Global improvement		3.00	4.00	3.00	2.00	2.00	2.00
				Efficacy index		9.00	13.00	5.00	6.00	6.00	6.00
				Efficacy index (*)		2.00	1.00	3.00	1.50	1.50	1.50
	68	Reboxetine	Male	Severity of illness	5.00	4.00	3.00	1.00	1.00	1.00	1.00
				Global improvement		2.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		6.00	5.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.50	3.00	2.00	2.00	2.00	2.00
	69	Placebo	Male	Severity of illness	5.00	5.00	4.00	3.00	6.00	4.00	3.00
				Global improvement		5.00	2.00	2.00	6.00	2.00	2.00
				Efficacy index		15.00	6.00	5.00	15.00	6.00	5.00
				Efficacy index (*)		0.33	1.50	3.00	0.33	1.50	3.00
	70	Imipramine	Male	Severity of illness	6.00	5.00	4.00	2.00	4.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		10.00	6.00	2.00	6.00	2.00	2.00
				Efficacy index (*)		1.00	1.50	2.00	1.50	2.00	2.00
	71	Imipramine	Female	Severity of illness	5.00	5.00	4.00	3.00	3.00	2.00	2.00
				Global improvement		2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		6.00	6.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.50	1.50	2.00	2.00	2.00	2.00
	72	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	2.00	3.00	3.00	4.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	3.00
				Efficacy index		5.00	5.00	1.00	5.00	5.00	5.00
				Efficacy index (*)		3.00	3.00	4.00	3.00	3.00	3.00
3/4	79	Imipramine	Female	Severity of illness	5.00	5.00	5.00	3.00	3.00	2.00	2.00
				Global improvement		2.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		6.00	6.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.50	1.50	2.00	2.00	2.00	2.00
	80	Imipramine	Male	Severity of illness	5.00	5.00	4.00	3.00			
				Global improvement		3.00	2.00	2.00			
				Efficacy index		9.00	6.00	4.00			
				Efficacy index (*)		2.00	1.50	1.00			

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/4	81	Reboxetine	Female	Severity of illness	6.00	4.00	2.00	2.00	2.00	2.00	2.00
				Global improvement		2.00	1.00	1.00	1.00	1.00	2.00
				Efficacy index		5.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	4.00	4.00	4.00	4.00	4.00
	82	Placebo	Male	Severity of illness	4.00	4.00	3.00	3.00	3.00	3.00	3.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	5.00	6.00	5.00	5.00	5.00
				Efficacy index (*)		2.00	3.00	1.50	3.00	3.00	3.00
	83	Placebo	Male	Severity of illness	4.00	5.00					
				Global improvement		6.00					
				Efficacy index		16.00					
				Efficacy index (*)		0.25					
	84	Reboxetine	Female	Severity of illness	5.00	4.00	2.00	1.00	1.00	1.00	1.00
				Global improvement		2.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		5.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	4.00	4.00	4.00	4.00	4.00
	85	Imipramine	Female	Severity of illness	5.00	3.00	3.00	3.00	3.00	3.00	2.00
				Global improvement		3.00	2.00	2.00	3.00	2.00	2.00
				Efficacy index		6.00	5.00	6.00	10.00	6.00	2.00
				Efficacy index (*)		1.50	3.00	1.50	1.00	1.50	2.00
	86	Imipramine	Male	Severity of illness	5.00	4.00	3.00	2.00	2.00	2.00	2.00
				Global improvement		2.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		5.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	3.00	4.00	4.00	4.00	4.00
	87	Placebo	Female	Severity of illness	5.00	5.00	5.00	4.00	6.00	5.00	4.00
				Global improvement		3.00	2.00	2.00	6.00	2.00	2.00
				Efficacy index		9.00	5.00	5.00	14.00	6.00	6.00
				Efficacy index (*)		2.00	3.00	3.00	0.50	1.50	1.50
	88	Placebo	Male	Severity of illness	5.00	4.00	4.00	3.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		6.00	6.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		1.50	1.50	3.00	4.00	4.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3/4	89	Reboxetine	Female	Severity of illness	6.00	5.00	5.00	5.00	4.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		5.00	5.00	6.00	6.00	6.00	6.00
				Efficacy index (*)		3.00	3.00	1.50	1.50	1.50	1.50
	90	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	2.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	10.00	6.00	6.00	6.00	2.00
				Efficacy index (*)		0.50	1.00	1.50	1.50	1.50	2.00
	457	Placebo	Female	Severity of illness	5.00	6.00	5.00	6.00			
				Global improvement		5.00	4.00	5.00			
				Efficacy index		13.00	13.00	13.00			
				Efficacy index (*)		1.00	1.00	1.00			
	458	Reboxetine	Female	Severity of illness	5.00	6.00	6.00				
				Global improvement		5.00	6.00				
				Efficacy index		14.00	14.00				
				Efficacy index (*)		0.50	0.50				
	459	Placebo	Female	Severity of illness	5.00	4.00	4.00	4.00	3.00	2.00	2.00
				Global improvement		3.00	3.00	3.00	2.00	2.00	1.00
				Efficacy index		6.00	6.00	6.00	6.00	6.00	2.00
				Efficacy index (*)		1.50	1.50	1.50	1.50	1.50	2.00
	460	Reboxetine	Male	Severity of illness	5.00	5.00					
				Global improvement		4.00					
				Efficacy index		16.00					
				Efficacy index (*)		0.25					
	461	Imipramine	Female	Severity of illness	5.00	5.00					
				Global improvement		3.00					
				Efficacy index		12.00					
				Efficacy index (*)		0.50					
	462	Imipramine	Female	Severity of illness	5.00	4.00					
				Global improvement		3.00					
				Efficacy index		8.00					
				Efficacy index (*)		0.75					

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/1	91	Imipramine	Female	Severity of illness	6.00	6.00	6.00	5.00	5.00	5.00	3.00
				Global improvement		4.00	4.00	4.00	3.00	3.00	2.00
				Efficacy index		15.00	14.00	14.00	10.00	10.00	6.00
				Efficacy index (*)		0.33	0.50	0.50	1.00	1.00	1.50
	92	Reboxetine	Female	Severity of illness	6.00	6.00	6.00	6.00	6.00	6.00	6.00
				Global improvement		5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index		13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.00
	93	Placebo	Male	Severity of illness	4.00	4.00	5.00	5.00	2.00	2.00	1.00
				Global improvement		5.00	6.00	5.00	1.00	1.00	1.00
				Efficacy index		14.00	14.00	14.00	1.00	1.00	1.00
				Efficacy index (*)		0.50	0.50	0.50	4.00	4.00	4.00
	94	Placebo	Female	Severity of illness	5.00	5.00	4.00	4.00	1.00	1.00	1.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	5.00	5.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	3.00	4.00	4.00
	95	Imipramine	Female	Severity of illness	5.00	2.00	2.00	2.00	2.00	1.00	1.00
				Global improvement		2.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		5.00	5.00	5.00	5.00	1.00	1.00
				Efficacy index (*)		3.00	3.00	3.00	3.00	4.00	4.00
	96	Reboxetine	Female	Severity of illness	5.00	4.00	4.00	3.00	2.00	2.00	2.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	9.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	2.00	3.00	4.00	4.00	4.00
	115	Reboxetine	Female	Severity of illness	5.00	4.00	3.00	2.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	3.00	4.00	4.00	4.00	4.00
	116	Imipramine	Female	Severity of illness	5.00	5.00					
				Global improvement		4.00					
				Efficacy index		15.00					
				Efficacy index (*)		0.33					

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=mimimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/1	117	Imipramine	Female	Severity of illness	6.00	4.00	3.00	2.00	2.00	2.00	2.00
				Global improvement		2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		6.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.50	2.00	2.00	2.00	2.00	2.00
	118	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	3.00	2.00	2.00	2.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	4.00	4.00	4.00
	119	Placebo	Female	Severity of illness	3.00						
				Global improvement							
				Efficacy index							
				Efficacy index (*)							
	120	Placebo	Female	Severity of illness	6.00	5.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	3.00	4.00	4.00	4.00	4.00
	145	Imipramine	Female	Severity of illness	5.00	4.00	3.00	3.00	3.00	3.00	2.00
				Global improvement		2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		4.00	4.00	4.00	4.00	4.00	4.00
	146	Placebo	Female	Severity of illness	5.00	5.00	4.00	3.00	3.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	4.00	4.00	4.00	4.00	4.00
	147	Reboxetine	Female	Severity of illness	6.00	6.00	5.00	5.00	4.00	4.00	4.00
				Global improvement		3.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		9.00	9.00	9.00	5.00	5.00	1.00
				Efficacy index (*)		2.00	2.00	2.00	3.00	3.00	4.00
	148	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		9.00	9.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		2.00	2.00	3.00	3.00	3.00	3.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/1	149	Reboxetine	Male	Severity of illness	6.00	6.00	5.00	4.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		15.00	11.00	10.00	5.00	1.00	1.00
				Efficacy index (*)		0.33	0.67	1.00	3.00	4.00	4.00
	150	Placebo	Male	Severity of illness	6.00	5.00	5.00	4.00	4.00	4.00	4.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	9.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	2.00	3.00	4.00	4.00	4.00
4/2	93/A	Placebo	Male	Severity of illness	6.00	6.00	5.00	3.00	2.00	1.00	1.00
				Global improvement		4.00	4.00	2.00	2.00	1.00	1.00
				Efficacy index		13.00	13.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	1.00	3.00	4.00	4.00	4.00
	99/A	Placebo	Male	Severity of illness	5.00	5.00	4.00	4.00	3.00	1.00	1.00
				Global improvement		5.00	2.00	3.00	3.00	1.00	1.00
				Efficacy index		13.00	5.00	5.00	9.00	1.00	1.00
				Efficacy index (*)		1.00	3.00	3.00	2.00	4.00	4.00
	104	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		4.00	3.00	3.00	5.00	5.00	5.00
				Efficacy index		13.00	9.00	9.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	2.00	2.00	1.00	1.00	1.00
4/3	97	Placebo	Male	Severity of illness	4.00	4.00	4.00	4.00	5.00	4.00	4.00
				Global improvement		4.00	4.00	4.00	5.00	6.00	6.00
				Efficacy index		13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.00
	98	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	5.00	
				Global improvement		3.00	3.00	2.00	3.00	6.00	
				Efficacy index		13.00	13.00	9.00	9.00	13.00	
				Efficacy index (*)		1.00	1.00	2.00	2.00	1.00	
	99	Placebo	Female	Severity of illness	5.00	5.00	5.00				
				Global improvement		5.00	6.00				
				Efficacy index		15.00	15.00				
				Efficacy index (*)		0.33	0.33				

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/3	100	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00			
				Global improvement		3.00	6.00	6.00			
				Efficacy index		7.00	15.00	16.00			
				Efficacy index (*)		1.00	0.33	0.25			
	101	Imipramine	Male	Severity of illness	5.00	5.00	4.00	3.00	2.00	2.00	2.00
				Global improvement		4.00	3.00	2.00	2.00	1.00	1.00
				Efficacy index		13.00	9.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	4.00	4.00	4.00
4/4	109	Reboxetine	Female	Severity of illness	5.00	4.00	3.00	2.00	2.00	1.00	1.00
				Global improvement		3.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		10.00	6.00	2.00	2.00	1.00	1.00
				Efficacy index (*)		1.00	1.50	2.00	2.00	4.00	4.00
	110	Imipramine	Male	Severity of illness	6.00	5.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		3.00	4.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	9.00	5.00	6.00	6.00	6.00
				Efficacy index (*)		2.00	2.00	3.00	1.50	1.50	1.50
	111	Imipramine	Male	Severity of illness	5.00	5.00	4.00	4.00	4.00	3.00	3.00
				Global improvement		4.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	5.00	6.00	6.00	6.00	5.00
				Efficacy index (*)		1.00	3.00	1.50	1.50	1.50	3.00
	112	Placebo	Male	Severity of illness	5.00	4.00	4.00	3.00	3.00	4.00	4.00
				Global improvement		3.00	3.00	2.00	2.00	3.00	3.00
				Efficacy index		9.00	9.00	5.00	5.00	9.00	9.00
				Efficacy index (*)		2.00	2.00	3.00	3.00	2.00	2.00
	113	Reboxetine	Male	Severity of illness	5.00	5.00	4.00	4.00	3.00	3.00	2.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	1.00
				Efficacy index		13.00	9.00	9.00	5.00	5.00	1.00
				Efficacy index (*)		1.00	2.00	2.00	3.00	3.00	4.00
	114	Placebo	Female	Severity of illness	4.00	4.00	3.00	3.00	3.00	3.00	2.00
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		14.00	10.00	9.00	9.00	6.00	2.00
				Efficacy index (*)		0.50	1.00	2.00	2.00	1.50	2.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4/4	175	Imipramine	Female	Severity of illness	5.00	5.00	4.00	3.00	3.00	2.00	1.00
				Global improvement		3.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		10.00	6.00	6.00	6.00	2.00	2.00
				Efficacy index (*)		1.00	1.50	1.50	1.50	2.00	2.00
	176	Placebo	Female	Severity of illness	4.00	4.00	4.00	4.00	7.00		
				Global improvement		4.00	3.00	3.00	7.00		
				Efficacy index		13.00	10.00	10.00	14.00		
				Efficacy index (*)		1.00	1.00	1.00	0.50		
	177	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00			
				Global improvement		4.00	3.00	3.00			
				Efficacy index		14.00	10.00	11.00			
				Efficacy index (*)		0.50	1.00	0.67			
	178	Reboxetine	Female	Severity of illness	5.00	4.00	3.00	3.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		9.00	5.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		2.00	3.00	2.00	2.00	2.00	2.00
	179	Placebo	Female	Severity of illness	5.00	5.00	4.00	6.00			
				Global improvement		4.00	3.00	6.00			
				Efficacy index		14.00	6.00	16.00			
				Efficacy index (*)		0.50	1.50	0.25			
	180	Reboxetine	Male	Severity of illness	5.00	5.00	4.00	3.00	3.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		9.00	5.00	5.00	2.00	2.00	1.00
				Efficacy index (*)		2.00	3.00	3.00	2.00	2.00	4.00
5/1	127	Reboxetine	Male	Severity of illness	5.00	4.00	3.00	3.00	3.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	4.00	3.00	3.00
				Efficacy index		9.00	9.00	10.00	14.00	10.00	10.00
				Efficacy index (*)		2.00	2.00	1.00	0.50	1.00	1.00
	128	Reboxetine	Female	Severity of illness	5.00	2.00	2.00	2.00	2.00	1.00	1.00
				Global improvement		1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		2.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index (*)		2.00	2.00	2.00	2.00	4.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
5/1	129	Placebo	Male	Severity of illness	5.00	5.00	4.00	3.00	2.00	3.00	4.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	3.00
				Efficacy index		9.00	5.00	5.00	5.00	5.00	9.00
				Efficacy index (*)		2.00	3.00	3.00	3.00	3.00	2.00
	130	Placebo	Male	Severity of illness	5.00	5.00	5.00	5.00	2.00	2.00	3.00
				Global improvement		3.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		9.00	5.00	9.00	5.00	1.00	5.00
				Efficacy index (*)		2.00	3.00	2.00	3.00	4.00	3.00
	131	Imipramine	Female	Severity of illness	5.00	5.00	4.00	3.00	3.00	2.00	2.00
				Global improvement		3.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		9.00	5.00	5.00	5.00	1.00	1.00
				Efficacy index (*)		2.00	3.00	3.00	3.00	4.00	4.00
	132	Imipramine	Male	Severity of illness	5.00	2.00	1.00	1.00	1.00	1.00	1.00
				Global improvement		2.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		1.00	1.00	1.00	2.00	2.00	2.00
				Efficacy index (*)		4.00	4.00	4.00	2.00	2.00	2.00
5/2	121	Imipramine	Female	Severity of illness	5.00	5.00	5.00	3.00	4.00	4.00	5.00
				Global improvement		3.00	4.00	2.00	5.00	4.00	5.00
				Efficacy index		9.00	9.00	5.00	13.00	9.00	13.00
				Efficacy index (*)		2.00	2.00	3.00	1.00	2.00	1.00
	125	Reboxetine	Male	Severity of illness	5.00	5.00	2.00	2.00	2.00	2.00	2.00
				Global improvement		4.00	1.00	1.00	1.00	2.00	1.00
				Efficacy index		13.00	1.00	2.00	2.00	6.00	2.00
				Efficacy index (*)		1.00	4.00	2.00	2.00	1.50	2.00
5/3	133	Placebo	Male	Severity of illness	5.00	5.00	6.00				
				Global improvement		5.00	6.00				
				Efficacy index		13.00	13.00				
				Efficacy index (*)		1.00	1.00				
	134	Reboxetine	Female	Severity of illness	4.00	4.00	2.00	3.00	1.00		1.00
				Global improvement		4.00	2.00	3.00	1.00		1.00
				Efficacy index		13.00	2.00	10.00	2.00		2.00
				Efficacy index (*)		1.00	2.00	1.00	2.00		2.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
5/3	135	Imipramine	Female	Severity of illness	3.00	2.00	1.00	1.00	2.00	3.00	4.00
				Global improvement		3.00	1.00	1.00	2.00	3.00	4.00
				Efficacy index		5.00	2.00	2.00	2.00	6.00	14.00
				Efficacy index (*)		3.00	2.00	2.00	2.00	1.50	0.50
	136	Imipramine	Female	Severity of illness	5.00	4.00	2.00	1.00	2.00	1.00	1.00
				Global improvement		3.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		10.00	6.00	2.00	2.00	2.00	4.00
				Efficacy index (*)		1.00	1.50	2.00	2.00	2.00	1.00
	137	Reboxetine	Female	Severity of illness	4.00	3.00	2.00	2.00	2.00	1.00	1.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index		5.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		3.00	2.00	2.00	2.00	2.00	2.00
	138	Placebo	Female	Severity of illness	4.00	4.00					
				Global improvement		4.00					
				Efficacy index		13.00					
				Efficacy index (*)		1.00					
6/1	151	Imipramine	Male	Severity of illness	5.00	5.00					
				Global improvement		3.00					
				Efficacy index		12.00					
				Efficacy index (*)		0.50					
	152	Reboxetine	Female	Severity of illness	5.00	4.00	4.00	4.00	4.00	4.00	3.00
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		14.00	10.00	10.00	6.00	5.00	1.00
				Efficacy index (*)		0.50	1.00	1.00	1.50	3.00	4.00
	153	Reboxetine	Male	Severity of illness	5.00	5.00	4.00	4.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		14.00	10.00	10.00	6.00	6.00	6.00
				Efficacy index (*)		0.50	1.00	1.00	1.50	1.50	1.50
	154	Imipramine	Female	Severity of illness	4.00						
				Global improvement							
				Efficacy index							
				Efficacy index (*)							

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/1	155	Placebo	Male	Severity of illness	6.00	6.00	6.00	6.00	6.00		
				Global improvement		4.00	4.00	3.00	4.00		
				Efficacy index		13.00	14.00	10.00	14.00		
				Efficacy index (*)		1.00	0.50	1.00	0.50		
	156	Placebo	Female	Severity of illness	5.00	4.00	3.00	3.00	3.00	2.00	2.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	10.00	5.00	5.00	1.00	5.00
				Efficacy index (*)		0.50	1.00	3.00	3.00	4.00	3.00
6/2	157	Reboxetine	Male	Severity of illness	4.00	3.00	2.00	2.00	2.00	2.00	2.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		15.00	10.00	10.00	5.00	5.00	5.00
				Efficacy index (*)		0.33	1.00	1.00	3.00	3.00	3.00
	158	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	2.00	3.00	1.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	1.00
				Efficacy index		13.00	9.00	6.00	6.00	5.00	1.00
				Efficacy index (*)		1.00	2.00	1.50	1.50	3.00	4.00
	159	Imipramine	Male	Severity of illness	5.00	5.00	4.00	4.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	9.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	2.00	3.00	3.00	3.00
	160	Placebo	Male	Severity of illness	5.00	3.00	3.00	2.00	3.00	3.00	5.00
				Global improvement		2.00	2.00	2.00	2.00	2.00	3.00
				Efficacy index		6.00	6.00	6.00	6.00	6.00	10.00
				Efficacy index (*)		1.50	1.50	1.50	1.50	1.50	1.00
	161	Reboxetine	Female	Severity of illness	6.00	6.00	3.00	3.00	3.00		
				Global improvement		4.00	3.00	3.00	3.00		
				Efficacy index		14.00	6.00	6.00	6.00		
				Efficacy index (*)		0.50	1.50	1.50	1.50		
	162	Placebo	Male	Severity of illness	5.00	5.00					
				Global improvement		4.00					
				Efficacy index		13.00					
				Efficacy index (*)		1.00					

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/2	169	Imipramine	Female	Severity of illness	7.00	1.00	6.00	7.00			
				Global improvement		1.00	5.00	6.00			
				Efficacy index		2.00	13.00	13.00			
				Efficacy index (*)		2.00	1.00	1.00			
	170	Placebo	Male	Severity of illness	6.00	3.00					
				Global improvement		1.00					
				Efficacy index		1.00					
				Efficacy index (*)		4.00					
	171	Imipramine	Female	Severity of illness	5.00	5.00	4.00	1.00	1.00	1.00	1.00
				Global improvement		4.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		13.00	6.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.50	2.00	2.00	2.00	2.00
	172	Reboxetine	Female	Severity of illness	6.00	5.00	5.00	5.00	6.00	6.00	6.00
				Global improvement		4.00	4.00	4.00	5.00	5.00	5.00
				Efficacy index		13.00	14.00	14.00	14.00	14.00	14.00
				Efficacy index (*)		1.00	0.50	0.50	0.50	0.50	0.50
	173	Placebo	Male	Severity of illness	5.00	5.00	5.00	5.00	6.00	4.00	5.00
				Global improvement		4.00	4.00	4.00	6.00	3.00	3.00
				Efficacy index		13.00	13.00	13.00	13.00	5.00	9.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	3.00	2.00
	174	Reboxetine	Male	Severity of illness	6.00	2.00	1.00	1.00	1.00	1.00	4.00
				Global improvement		1.00	1.00	1.00	1.00	1.00	3.00
				Efficacy index		1.00	1.00	1.00	1.00	1.00	9.00
				Efficacy index (*)		4.00	4.00	4.00	4.00	4.00	2.00
6/3	163	Reboxetine	Male	Severity of illness	5.00	5.00					
				Global improvement		4.00					
				Efficacy index		15.00					
				Efficacy index (*)		0.33					
	164	Imipramine	Male	Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	3.00
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		14.00	10.00	9.00	9.00	6.00	6.00
				Efficacy index (*)		0.50	1.00	2.00	2.00	1.50	1.50

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/3	165	Imipramine	Female	Severity of illness	6.00	4.00	5.00	4.00	4.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	3.00	3.00	2.00
				Efficacy index		10.00	10.00	10.00	10.00	9.00	6.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	2.00	1.50
	166	Reboxetine	Female	Severity of illness	6.00	6.00					
				Global improvement		6.00					
				Efficacy index		15.00					
				Efficacy index (*)		0.33					
	167	Placebo	Female	Severity of illness	4.00	4.00	4.00	4.00	2.00	2.00	2.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		15.00	10.00	9.00	5.00	1.00	1.00
				Efficacy index (*)		0.33	1.00	2.00	3.00	4.00	4.00
	168	Placebo	Female	Severity of illness	6.00	5.00	5.00	5.00	5.00	6.00	
				Global improvement		3.00	3.00	3.00	3.00	6.00	
				Efficacy index		10.00	10.00	9.00	10.00	15.00	
				Efficacy index (*)		1.00	1.00	2.00	1.00	0.33	
	505	Imipramine	Female	Severity of illness	5.00	5.00	5.00				
				Global improvement		6.00	4.00				
				Efficacy index		14.00	16.00				
				Efficacy index (*)		0.50	0.25				
	506	Placebo	Female	Severity of illness	5.00	4.00	5.00	4.00	4.00	3.00	4.00
				Global improvement		4.00	5.00	4.00	3.00	3.00	3.00
				Efficacy index		13.00	13.00	14.00	11.00	11.00	11.00
				Efficacy index (*)		1.00	1.00	0.50	0.67	0.67	0.67
	507	Imipramine	Female	Severity of illness	4.00	4.00	4.00	3.00	3.00	2.00	1.00
				Global improvement		3.00	5.00	2.00	2.00	2.00	1.00
				Efficacy index		10.00	15.00	6.00	6.00	2.00	2.00
				Efficacy index (*)		1.00	0.33	1.50	1.50	2.00	2.00
	508	Reboxetine	Female	Severity of illness	5.00	3.00	4.00	3.00	3.00	2.00	2.00
				Global improvement		3.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		9.00	9.00	10.00	10.00	2.00	1.00
				Efficacy index (*)		2.00	2.00	1.00	1.00	2.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
6/3	509	Placebo	Male	Severity of illness	4.00	3.00	3.00	3.00	3.00	3.00	2.00
				Global improvement		2.00	2.00	3.00	2.00	2.00	2.00
				Efficacy index		5.00	5.00	10.00	6.00	6.00	5.00
				Efficacy index (*)		3.00	3.00	1.00	1.50	1.50	3.00
	510	Reboxetine	Female	Severity of illness	4.00	4.00	3.00				
				Global improvement		3.00	3.00				
				Efficacy index		10.00	12.00				
				Efficacy index (*)		1.00	0.50				
	511	Imipramine	Female	Severity of illness	4.00	3.00	3.00	3.00	3.00	5.00	
				Global improvement		3.00	2.00	2.00	2.00	6.00	
				Efficacy index		11.00	6.00	6.00	5.00	16.00	
				Efficacy index (*)		0.67	1.50	1.50	3.00	0.25	
	512	Placebo	Female	Severity of illness	4.00	4.00					
				Global improvement		4.00					
				Efficacy index		16.00					
				Efficacy index (*)		0.25					
	513	Imipramine	Female	Severity of illness	5.00	4.00	3.00	2.00	2.00	2.00	1.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index		11.00	7.00	6.00	2.00	2.00	2.00
				Efficacy index (*)		0.67	1.00	1.50	2.00	2.00	2.00
7/02	181	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	4.00
				Global improvement		5.00	5.00	4.00	4.00	3.00	3.00
				Efficacy index		13.00	13.00	13.00	13.00	9.00	10.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	2.00	1.00
	182	Placebo	Male	Severity of illness	5.00	4.00	3.00	3.00	4.00	3.00	3.00
				Global improvement		4.00	3.00	4.00	3.00	3.00	3.00
				Efficacy index		13.00	9.00	13.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	2.00	1.00	2.00	2.00	2.00
	183	Imipramine	Male	Severity of illness	5.00	4.00	5.00	6.00			
				Global improvement		4.00	5.00	6.00			
				Efficacy index		11.00	15.00	16.00			
				Efficacy index (*)		0.67	0.33	0.25			

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/02	184	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	3.00	2.00	2.00
				Global improvement		4.00	3.00	2.00	1.00	1.00	1.00
				Efficacy index		13.00	9.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	4.00	4.00	4.00
	185	Reboxetine	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00		
				Global improvement		5.00	5.00	5.00	4.00		
				Efficacy index		16.00	16.00	16.00	16.00		
				Efficacy index (*)		0.25	0.25	0.25	0.25		
	186	Placebo	Male	Severity of illness	4.00	3.00	3.00	3.00	3.00	3.00	2.00
				Global improvement		3.00	3.00	3.00	3.00	3.00	2.00
				Efficacy index		10.00	10.00	10.00	10.00	10.00	6.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.50
	535	Placebo	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		5.00	6.00	4.00	4.00	3.00	3.00
				Efficacy index		13.00	13.00	13.00	13.00	9.00	9.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	2.00	2.00
	536	Reboxetine	Female	Severity of illness	5.00	4.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		9.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		2.00	3.00	3.00	3.00	3.00	3.00
7/03	187	Imipramine	Female	Severity of illness	6.00	5.00	4.00	4.00	4.00	2.00	2.00
				Global improvement		4.00	3.00	4.00	3.00	2.00	1.00
				Efficacy index		13.00	9.00	13.00	9.00	5.00	1.00
				Efficacy index (*)		1.00	2.00	1.00	2.00	3.00	4.00
	188	Placebo	Male	Severity of illness	5.00	5.00	5.00	3.00	3.00	3.00	4.00
				Global improvement		4.00	4.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	13.00	1.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	1.00	4.00	3.00	3.00	3.00
	189	Placebo	Male	Severity of illness	5.00	5.00	4.00	2.00	2.00	3.00	3.00
				Global improvement		4.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	3.00	3.00	3.00	3.00	3.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/03	190	Reboxetine	Male	Severity of illness	5.00	5.00	3.00	3.00	2.00	4.00	4.00
				Global improvement		5.00	4.00	2.00	2.00	4.00	4.00
				Efficacy index		14.00	9.00	5.00	5.00	9.00	9.00
				Efficacy index (*)		0.50	2.00	3.00	3.00	2.00	2.00
	191	Imipramine	Female	Severity of illness	5.00	3.00	5.00	3.00	3.00	5.00	
				Global improvement		3.00	4.00	2.00	3.00	4.00	
				Efficacy index		9.00	9.00	5.00	9.00	9.00	
				Efficacy index (*)		2.00	2.00	3.00	2.00	2.00	
	192	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	3.00	5.00	5.00	5.00
				Global improvement		4.00	3.00	2.00	3.00	3.00	3.00
				Efficacy index		13.00	9.00	5.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	2.00	3.00	2.00	2.00	2.00
	523	Reboxetine	Female	Severity of illness	6.00	5.00	5.00	3.00	4.00	4.00	4.00
				Global improvement		4.00	4.00	3.00	2.00	2.00	2.00
				Efficacy index		13.00	13.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	1.00	3.00	3.00	3.00	3.00
	524	Placebo	Female	Severity of illness	5.00	5.00	5.00	3.00	3.00	3.00	3.00
				Global improvement		4.00	4.00	3.00	3.00	3.00	2.00
				Efficacy index		13.00	13.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	1.00	3.00	3.00	3.00	3.00
	525	Placebo	Female	Severity of illness	6.00	6.00	5.00	3.00	3.00	3.00	2.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	9.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	2.00	3.00	3.00	3.00
	526	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	3.00	3.00
				Global improvement		4.00	4.00	4.00	4.00	2.00	2.00
				Efficacy index		13.00	13.00	13.00	13.00	5.00	5.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	3.00	3.00
	527	Imipramine	Female	Severity of illness	6.00	6.00	6.00	6.00	3.00	3.00	3.00
				Global improvement		4.00	4.00	4.00	3.00	3.00	3.00
				Efficacy index		13.00	13.00	13.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	2.00	2.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/03	528	Imipramine	Female	Severity of illness	5.00	3.00	4.00	4.00	4.00	4.00	
				Global improvement		4.00	4.00	4.00	4.00	4.00	
				Efficacy index		13.00	13.00	13.00	13.00	13.00	
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	
7/04	193	Placebo	Female	Severity of illness	5.00	5.00	5.00	4.00	2.00	2.00	2.00
				Global improvement		4.00	4.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	13.00	9.00	1.00	5.00	1.00
				Efficacy index (*)		1.00	1.00	2.00	4.00	3.00	4.00
	194	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	5.00	3.00	2.00	2.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	9.00	5.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	2.00	3.00	4.00	4.00
	195	Placebo	Female	Severity of illness	5.00	5.00	5.00	4.00	2.00	3.00	2.00
				Global improvement		4.00	4.00	3.00	2.00	2.00	2.00
				Efficacy index		14.00	13.00	9.00	1.00	5.00	1.00
				Efficacy index (*)		0.50	1.00	2.00	4.00	3.00	4.00
	196	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	3.00	3.00	3.00	2.00
				Global improvement		4.00	4.00	3.00	3.00	3.00	1.00
				Efficacy index		13.00	13.00	9.00	5.00	5.00	1.00
				Efficacy index (*)		1.00	1.00	2.00	3.00	3.00	4.00
	197	Imipramine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index		14.00	13.00	13.00	14.00	13.00	13.00
				Efficacy index (*)		0.50	1.00	1.00	0.50	1.00	1.00
	198	Imipramine	Female	Severity of illness	5.00	5.00	5.00	3.00	3.00	2.00	2.00
				Global improvement		4.00	4.00	2.00	2.00	2.00	1.00
				Efficacy index		13.00	13.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		1.00	1.00	3.00	3.00	3.00	4.00
	199	Imipramine	Male	Severity of illness	5.00	5.00	5.00	5.00	4.00	4.00	3.00
				Global improvement		4.00	3.00	4.00	2.00	3.00	3.00
				Efficacy index		13.00	10.00	13.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	1.00	1.00	3.00	3.00	3.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/04	200	Placebo	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	4.00
				Global improvement		4.00	4.00	3.00	3.00	3.00	3.00
				Efficacy index		13.00	13.00	9.00	9.00	5.00	5.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	3.00	3.00
	201	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	2.00
				Global improvement		4.00	4.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	13.00	5.00	6.00	5.00	5.00
				Efficacy index (*)		1.00	1.00	3.00	1.50	3.00	3.00
	202	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	3.00
				Global improvement		4.00	4.00	3.00	4.00	2.00	2.00
				Efficacy index		13.00	13.00	9.00	13.00	5.00	5.00
				Efficacy index (*)		1.00	1.00	2.00	1.00	3.00	3.00
	203	Placebo	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	3.00
				Global improvement		4.00	4.00	4.00	3.00	3.00	3.00
				Efficacy index		13.00	13.00	13.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	2.00	2.00
	204	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	4.00
				Global improvement		4.00	4.00	4.00	3.00	4.00	3.00
				Efficacy index		13.00	13.00	14.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	1.00	0.50	2.00	2.00	2.00
7/05	205	Placebo	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index		13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.00
	206	Imipramine	Female	Severity of illness	5.00	5.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		2.00	3.00	3.00	3.00	3.00	3.00
	207	Imipramine	Female	Severity of illness	4.00	4.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	9.00	5.00	6.00	5.00	5.00
				Efficacy index (*)		2.00	2.00	3.00	1.50	3.00	3.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/05	208	Reboxetine	Male	Severity of illness	5.00	4.00	4.00	3.00	3.00	2.00	2.00
				Global improvement		3.00	3.00	2.00	2.00	1.00	1.00
				Efficacy index		9.00	5.00	5.00	5.00	1.00	1.00
				Efficacy index (*)		2.00	3.00	3.00	3.00	4.00	4.00
	209	Placebo	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index		13.00	13.00	13.00	14.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	1.00	0.50	1.00	1.00
	210	Reboxetine	Male	Severity of illness	5.00	4.00	3.00	2.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		9.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	3.00	4.00	4.00	4.00	4.00
	541	Reboxetine	Female	Severity of illness	5.00	3.00	3.00	2.00	2.00	2.00	2.00
				Global improvement		2.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		5.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	3.00	4.00	4.00	4.00	4.00
	542	Imipramine	Male	Severity of illness	5.00	5.00	4.00	4.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		14.00	9.00	9.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	2.00	2.00	3.00	3.00	3.00
	543	Imipramine	Male	Severity of illness	4.00	3.00	3.00	3.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index		9.00	6.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	1.50	3.00	4.00	4.00	4.00
	544	Placebo	Female	Severity of illness	5.00	5.00	5.00	6.00	6.00	6.00	6.00
				Global improvement		4.00	4.00	5.00	5.00	5.00	5.00
				Efficacy index		13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.00
	545	Placebo	Male	Severity of illness	6.00	6.00	6.00	6.00	6.00	6.00	6.00
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index		13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7/05	546	Reboxetine	Female	Severity of illness	5.00	4.00	3.00	3.00	3.00	3.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index		9.00	5.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		2.00	3.00	3.00	3.00	3.00	4.00
7/07	529	Placebo	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	3.00	4.00	3.00	3.00
				Efficacy index		13.00	11.00	8.00	15.00	6.00	10.00
				Efficacy index (*)		1.00	0.67	0.75	0.33	1.50	1.00
	530	Imipramine	Female	Severity of illness	5.00	4.00	5.00				
				Global improvement		4.00	3.00				
				Efficacy index		16.00	12.00				
				Efficacy index (*)		0.25	0.50				
	531	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	4.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	3.00
				Efficacy index		13.00	9.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	3.00	3.00	3.00	3.00
	532	Imipramine	Female	Severity of illness	5.00	5.00	4.00	4.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	1.00
				Efficacy index		9.00	9.00	9.00	9.00	9.00	5.00
				Efficacy index (*)		2.00	2.00	2.00	2.00	2.00	3.00
	533	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	3.00
				Global improvement		4.00	4.00	4.00	3.00	3.00	2.00
				Efficacy index		14.00	14.00	13.00	9.00	9.00	5.00
				Efficacy index (*)		0.50	0.50	1.00	2.00	2.00	3.00
	534	Placebo	Female	Severity of illness	5.00	5.00	4.00	5.00	4.00	3.00	3.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	2.00
				Efficacy index		13.00	9.00	9.00	9.00	9.00	5.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	2.00	3.00
8	211	Reboxetine	Female	Severity of illness	4.00	4.00	5.00				
				Global improvement		4.00	6.00				
				Efficacy index		13.00	13.00				
				Efficacy index (*)		1.00	1.00				

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	212	Placebo	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	4.00	3.00	4.00	4.00	4.00
				Efficacy index		13.00	13.00	9.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	2.00	1.00	1.00	1.00
	213	Imipramine	Male	Severity of illness	4.00						
				Global improvement							
				Efficacy index							
				Efficacy index (*)							
	214	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index		13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.00
	215	Placebo	Female	Severity of illness	3.00	2.00	2.00	2.00	2.00	1.00	1.00
				Global improvement		2.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		5.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	3.00	4.00	4.00	4.00	4.00
	216	Imipramine	Male	Severity of illness	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Global improvement		4.00	4.00	3.00	3.00	3.00	3.00
				Efficacy index		13.00	13.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	2.00	2.00
	217	Reboxetine	Female	Severity of illness	3.00	3.00	3.00	2.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		2.00	3.00	3.00	3.00	3.00	3.00
	218	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	3.00	3.00
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		13.00	9.00	9.00	9.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	3.00	3.00
	219	Placebo	Female	Severity of illness	3.00	3.00	3.00	3.00			
				Global improvement		3.00	3.00	2.00			
				Efficacy index		9.00	9.00	5.00			
				Efficacy index (*)		2.00	2.00	3.00			

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	220	Imipramine	Female	Severity of illness	4.00	4.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		4.00	4.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	13.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	1.00	3.00	3.00	3.00	3.00
	221	Imipramine	Male	Severity of illness	4.00	4.00	4.00	3.00	3.00	3.00	2.00
				Global improvement		4.00	4.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	13.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	1.00	3.00	3.00	3.00	3.00
	222	Placebo	Female	Severity of illness	3.00	3.00	3.00	2.00	1.00	2.00	2.00
				Global improvement		2.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		5.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	3.00	4.00	4.00	4.00	4.00
	223	Imipramine	Female	Severity of illness	4.00	4.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		13.00	9.00	9.00	9.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	3.00	3.00
	224	Placebo	Female	Severity of illness	4.00	4.00	3.00	3.00	3.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		9.00	9.00	9.00	9.00	5.00	5.00
				Efficacy index (*)		2.00	2.00	2.00	2.00	3.00	3.00
	225	Placebo	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00	3.00	3.00
				Global improvement		4.00	4.00	4.00	3.00	3.00	2.00
				Efficacy index		13.00	13.00	13.00	9.00	9.00	5.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	2.00	3.00
	226	Reboxetine	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index		13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.00
	227	Reboxetine	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		13.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	2.00	2.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	228	Imipramine	Male	Severity of illness	4.00	4.00					
				Global improvement		5.00					
				Efficacy index		13.00					
				Efficacy index (*)		1.00					
	229	Imipramine	Female	Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	3.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	2.00
				Efficacy index		13.00	9.00	9.00	9.00	9.00	5.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	2.00	3.00
	230	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	4.00	3.00	3.00	3.00	3.00
				Efficacy index		13.00	13.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	2.00	2.00
	231	Imipramine	Male	Severity of illness	4.00	4.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	3.00	3.00	3.00	3.00
	232	Reboxetine	Male	Severity of illness	4.00	4.00	3.00	3.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		13.00	9.00	9.00	9.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	3.00	3.00
	233	Placebo	Female	Severity of illness	4.00	4.00	4.00	4.00	3.00	3.00	3.00
				Global improvement		4.00	4.00	4.00	3.00	3.00	2.00
				Efficacy index		13.00	13.00	13.00	9.00	9.00	5.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	2.00	3.00
	234	Placebo	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	4.00	3.00	3.00	3.00	3.00
				Efficacy index		13.00	13.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	2.00	2.00
8/A	235	Placebo	Female	Severity of illness	5.00	5.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		9.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		2.00	2.00	2.00	2.00	2.00	2.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8/A	236	Placebo	Female	Severity of illness	5.00	5.00	3.00	3.00	3.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		2.00	3.00	3.00	3.00	3.00	3.00
	237	Reboxetine	Female	Severity of illness	6.00	5.00	4.00	3.00	3.00	2.00	2.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		10.00	9.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	3.00	3.00	3.00	3.00
	238	Reboxetine	Female	Severity of illness	5.00	4.00	3.00	3.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		2.00	3.00	3.00	3.00	3.00	3.00
	239	Imipramine	Female	Severity of illness	5.00	4.00	4.00	3.00	2.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		9.00	5.00	9.00	5.00	6.00	5.00
				Efficacy index (*)		2.00	3.00	2.00	3.00	1.50	3.00
	240	Imipramine	Female	Severity of illness	6.00	5.00	5.00	4.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		13.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	2.00	2.00
	553	Placebo	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	4.00	3.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		13.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	2.00	2.00
	554	Reboxetine	Male	Severity of illness	5.00	5.00	4.00	3.00	2.00	2.00	2.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	1.00
				Efficacy index		9.00	9.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		2.00	2.00	3.00	3.00	3.00	4.00
	555	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	4.00	3.00	4.00	2.00
				Global improvement		3.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		10.00	9.00	9.00	9.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	3.00	3.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8/A	556	Imipramine	Male	Severity of illness	5.00	5.00	4.00	3.00	2.00	2.00	2.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	1.00
				Efficacy index		13.00	9.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	3.00	3.00	4.00
9	241	Placebo	Female	Severity of illness	5.00	5.00	6.00				
				Global improvement		5.00	6.00				
				Efficacy index		14.00	15.00				
				Efficacy index (*)		0.50	0.33				
	242	Reboxetine	Female	Severity of illness	5.00	4.00	5.00	5.00			
				Global improvement		3.00	4.00	4.00			
				Efficacy index		10.00	14.00	15.00			
				Efficacy index (*)		1.00	0.50	0.33			
	243	Reboxetine	Female	Severity of illness	4.00	4.00	5.00				
				Global improvement		5.00	6.00				
				Efficacy index		14.00	15.00				
				Efficacy index (*)		0.50	0.33				
	244	Imipramine	Female	Severity of illness	5.00	4.00	4.00	4.00			
				Global improvement		3.00	3.00	3.00			
				Efficacy index		10.00	10.00	10.00			
				Efficacy index (*)		1.00	1.00	1.00			
	245	Imipramine	Female	Severity of illness	4.00	4.00	3.00	2.00	1.00	1.00	1.00
				Global improvement		3.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		13.00	5.00	2.00	2.00	1.00	2.00
				Efficacy index (*)		1.00	3.00	2.00	2.00	4.00	2.00
	246	Placebo	Female	Severity of illness	6.00	6.00	6.00	6.00	6.00		
				Global improvement		4.00	4.00	4.00	4.00		
				Efficacy index		13.00	13.00	13.00	16.00		
				Efficacy index (*)		1.00	1.00	1.00	0.25		
	247	Placebo	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00		
				Global improvement		4.00	3.00	4.00	4.00		
				Efficacy index		13.00	9.00	14.00	14.00		
				Efficacy index (*)		1.00	2.00	0.50	0.50		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	248	Placebo	Male	Severity of illness	5.00	5.00	6.00				
				Global improvement		5.00	6.00				
				Efficacy index		13.00	15.00				
				Efficacy index (*)		1.00	0.33				
	249	Reboxetine	Female	Severity of illness	4.00						
				Global improvement							
				Efficacy index							
				Efficacy index (*)							
	250	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00		
				Global improvement		4.00	4.00	4.00	4.00		
				Efficacy index		13.00	13.00	14.00	13.00		
				Efficacy index (*)		1.00	1.00	0.50	1.00		
	251	Imipramine	Female	Severity of illness	5.00	4.00	5.00	2.00	1.00		
				Global improvement		2.00	4.00	1.00	1.00		
				Efficacy index		6.00	10.00	2.00	2.00		
				Efficacy index (*)		1.50	1.00	2.00	2.00		
	252	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00			
				Global improvement		5.00	4.00	5.00			
				Efficacy index		14.00	15.00	16.00			
				Efficacy index (*)		0.50	0.33	0.25			
	253	Reboxetine	Female	Severity of illness	5.00	6.00					
				Global improvement		6.00					
				Efficacy index		15.00					
				Efficacy index (*)		0.33					
	254	Imipramine	Female	Severity of illness	5.00	5.00	5.00				
				Global improvement		5.00	5.00				
				Efficacy index		15.00	15.00				
				Efficacy index (*)		0.33	0.33				
	255	Reboxetine	Female	Severity of illness	5.00	5.00	6.00	5.00	5.00		
				Global improvement		4.00	5.00	5.00	6.00		
				Efficacy index		13.00	14.00	14.00	15.00		
				Efficacy index (*)		1.00	0.50	0.50	0.33		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	256	Imipramine	Female	Severity of illness	6.00	6.00	4.00	4.00	5.00	4.00	4.00
				Global improvement		4.00	2.00	2.00	3.00	3.00	3.00
				Efficacy index		14.00	7.00	6.00	11.00	6.00	6.00
				Efficacy index (*)		0.50	1.00	1.50	0.67	1.50	1.50
	257	Placebo	Male	Severity of illness	4.00	4.00					
				Global improvement		4.00					
				Efficacy index		13.00					
				Efficacy index (*)		1.00					
	258	Placebo	Male	Severity of illness	4.00	4.00	4.00				
				Global improvement		4.00	4.00				
				Efficacy index		14.00	14.00				
				Efficacy index (*)		0.50	0.50				
11	319	Placebo	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	4.00
				Global improvement		4.00	4.00	5.00	4.00	4.00	4.00
				Efficacy index		13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.00
	320	Imipramine	Male	Severity of illness	5.00	5.00	3.00	5.00	3.00	4.00	3.00
				Global improvement		5.00	2.00	5.00	2.00	3.00	2.00
				Efficacy index		14.00	6.00	14.00	6.00	10.00	6.00
				Efficacy index (*)		0.50	1.50	0.50	1.50	1.00	1.50
	321	Placebo	Male	Severity of illness	4.00	4.00	4.00	3.00	2.00	1.00	1.00
				Global improvement		4.00	3.00	2.00	1.00	1.00	1.00
				Efficacy index		13.00	10.00	6.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.00	1.50	2.00	2.00	2.00
	322	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		3.00	3.00	3.00	3.00	4.00	4.00
				Efficacy index		10.00	10.00	10.00	10.00	14.00	14.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	0.50	0.50
	323	Reboxetine	Male	Severity of illness	4.00	4.00	3.00	2.00	1.00	1.00	1.00
				Global improvement		3.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		10.00	6.00	2.00	2.00	1.00	1.00
				Efficacy index (*)		1.00	1.50	2.00	2.00	4.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	324	Imipramine	Male	Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	3.00	4.00	4.00	4.00
				Efficacy index		13.00	10.00	10.00	14.00	14.00	14.00
				Efficacy index (*)		1.00	1.00	1.00	0.50	0.50	0.50
	325	Reboxetine	Male	Severity of illness	4.00	3.00	3.00	1.00	1.00	1.00	1.00
				Global improvement		2.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		5.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	3.00	4.00	4.00	4.00	4.00
	326	Placebo	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		5.00	5.00	4.00	4.00	4.00	4.00
				Efficacy index		13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.00
	327	Imipramine	Male	Severity of illness	4.00	3.00					
				Global improvement		2.00					
				Efficacy index		6.00					
				Efficacy index (*)		1.50					
	328	Imipramine	Female	Severity of illness	4.00	4.00					
				Global improvement		3.00					
				Efficacy index		11.00					
				Efficacy index (*)		0.67					
	329	Placebo	Female	Severity of illness	4.00	4.00	4.00	4.00	2.00	2.00	2.00
				Global improvement		4.00	4.00	4.00	1.00	1.00	1.00
				Efficacy index		14.00	13.00	13.00	1.00	1.00	1.00
				Efficacy index (*)		0.50	1.00	1.00	4.00	4.00	4.00
	330	Reboxetine	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00	3.00	2.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		14.00	10.00	9.00	5.00	5.00	1.00
				Efficacy index (*)		0.50	1.00	2.00	3.00	3.00	4.00
	331	Imipramine	Male	Severity of illness	4.00	4.00	3.00	2.00	3.00	3.00	3.00
				Global improvement		3.00	2.00	1.00	2.00	2.00	3.00
				Efficacy index		10.00	6.00	2.00	6.00	6.00	6.00
				Efficacy index (*)		1.00	1.50	2.00	1.50	1.50	1.50

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	332	Reboxetine	Male	Severity of illness	4.00	4.00	3.00	2.00	1.00	2.00	2.00
				Global improvement		3.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		5.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	3.00	4.00	4.00	4.00	4.00
	333	Placebo	Male	Severity of illness	4.00	4.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		4.00	4.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	13.00	5.00	6.00	6.00	5.00
				Efficacy index (*)		0.50	1.00	3.00	1.50	1.50	3.00
	334	Reboxetine	Female	Severity of illness	4.00						
				Global improvement							
				Efficacy index		16.00					
				Efficacy index (*)		0.25					
	335	Placebo	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		9.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		2.00	2.00	2.00	2.00	2.00	2.00
	336	Imipramine	Female	Severity of illness	5.00	5.00					
				Global improvement		4.00					
				Efficacy index		13.00					
				Efficacy index (*)		1.00					
	337	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	4.00	4.00	5.00	4.00	4.00
				Efficacy index		14.00	14.00	14.00	13.00	13.00	13.00
				Efficacy index (*)		0.50	0.50	0.50	1.00	1.00	1.00
	338	Imipramine	Male	Severity of illness	5.00	4.00					
				Global improvement		3.00					
				Efficacy index		9.00					
				Efficacy index (*)		2.00					
12	367	Reboxetine	Female	Severity of illness	5.00	3.00	3.00	1.00	1.00	1.00	2.00
				Global improvement		3.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		10.00	6.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.50	2.00	2.00	2.00	2.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
12	368	Placebo	Female	Severity of illness	4.00	4.00	4.00	3.00	2.00	2.00	2.00
				Global improvement		4.00	4.00	3.00	3.00	3.00	2.00
				Efficacy index		13.00	14.00	10.00	9.00	9.00	5.00
				Efficacy index (*)		1.00	0.50	1.00	2.00	2.00	3.00
	369	Imipramine	Female	Severity of illness	5.00	1.00	2.00	6.00			
				Global improvement		1.00	3.00	7.00			
				Efficacy index		2.00	10.00	13.00			
				Efficacy index (*)		2.00	1.00	1.00			
	370	Placebo	Male	Severity of illness	5.00	4.00	5.00	5.00	5.00		
				Global improvement		3.00	3.00	6.00	6.00		
				Efficacy index		10.00	9.00	14.00	13.00		
				Efficacy index (*)		1.00	2.00	0.50	1.00		
	371	Imipramine	Female	Severity of illness	4.00	2.00					
				Global improvement		2.00					
				Efficacy index		6.00					
				Efficacy index (*)		1.50					
	372	Reboxetine	Male	Severity of illness	5.00	5.00	3.00	2.00	2.00	1.00	3.00
				Global improvement		3.00	2.00	1.00	1.00	1.00	2.00
				Efficacy index		10.00	2.00	2.00	2.00	2.00	6.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	2.00	1.50
	373	Reboxetine	Male	Severity of illness	6.00	2.00	5.00	4.00	4.00	2.00	1.00
				Global improvement		1.00	4.00	2.00	3.00	2.00	1.00
				Efficacy index		2.00	14.00	2.00	10.00	2.00	2.00
				Efficacy index (*)		2.00	0.50	2.00	1.00	2.00	2.00
	374	Placebo	Female	Severity of illness	5.00	4.00	3.00	4.00	4.00		
				Global improvement		3.00	3.00	5.00	3.00		
				Efficacy index		10.00	9.00	13.00	9.00		
				Efficacy index (*)		1.00	2.00	1.00	2.00		
	375	Imipramine	Male	Severity of illness	5.00						
				Global improvement							
				Efficacy index							
				Efficacy index (*)							

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
13	13	Placebo	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		3.00	3.00	5.00	4.00	4.00	6.00
				Efficacy index		10.00	10.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.00
	14	Placebo	Male	Severity of illness	4.00	4.00	4.00	4.00	3.00	4.00	4.00
				Global improvement		3.00	5.00	4.00	2.00	3.00	3.00
				Efficacy index		6.00	14.00	14.00	6.00	10.00	10.00
				Efficacy index (*)		1.50	0.50	0.50	1.50	1.00	1.00
	15	Imipramine	Female	Severity of illness	5.00	4.00	3.00	4.00	4.00	4.00	4.00
				Global improvement		3.00	3.00	3.00	6.00	4.00	5.00
				Efficacy index		10.00	10.00	10.00	14.00	14.00	14.00
				Efficacy index (*)		1.00	1.00	1.00	0.50	0.50	0.50
	16	Imipramine	Male	Severity of illness	4.00	4.00	4.00	3.00	4.00	3.00	4.00
				Global improvement		5.00	5.00	2.00	5.00	3.00	6.00
				Efficacy index		14.00	14.00	6.00	13.00	10.00	14.00
				Efficacy index (*)		0.50	0.50	1.50	1.00	1.00	0.50
	17	Reboxetine	Male	Severity of illness	4.00	4.00	3.00	4.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	4.00	3.00	3.00	3.00
				Efficacy index		14.00	10.00	10.00	10.00	10.00	10.00
				Efficacy index (*)		0.50	1.00	1.00	1.00	1.00	1.00
	18	Reboxetine	Male	Severity of illness	4.00	4.00	4.00	3.00	4.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	5.00	3.00	3.00
				Efficacy index		10.00	10.00	9.00	14.00	10.00	10.00
				Efficacy index (*)		1.00	1.00	2.00	0.50	1.00	1.00
	409	Reboxetine	Male	Severity of illness	4.00	4.00	4.00		4.00		3.00
				Global improvement		4.00	4.00		4.00		3.00
				Efficacy index		14.00	14.00		14.00		10.00
				Efficacy index (*)		0.50	0.50		0.50		1.00
	410	Placebo	Male	Severity of illness	5.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		5.00	4.00	4.00	3.00	4.00	3.00
				Efficacy index		14.00	14.00	14.00	10.00	14.00	10.00
				Efficacy index (*)		0.50	0.50	0.50	1.00	0.50	1.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
13	411	Imipramine	Female	Severity of illness	5.00	4.00	3.00	4.00	4.00	4.00	4.00
				Global improvement		3.00	2.00	5.00	6.00	4.00	3.00
				Efficacy index		10.00	6.00	14.00	14.00	14.00	10.00
				Efficacy index (*)		1.00	1.50	0.50	0.50	0.50	1.00
	423	Placebo	Male	Severity of illness	3.00	3.00	4.00	4.00			3.00
				Global improvement		4.00	4.00	4.00			2.00
				Efficacy index		13.00	13.00	13.00			5.00
				Efficacy index (*)		1.00	1.00	1.00			3.00
14	19	Reboxetine	Female	Severity of illness	6.00	6.00	5.00	5.00	6.00		
				Global improvement		5.00	3.00	4.00	4.00		
				Efficacy index		13.00	10.00	14.00	13.00		
				Efficacy index (*)		1.00	1.00	0.50	1.00		
	20	Imipramine	Female	Severity of illness	5.00	5.00	4.00	3.00	2.00	1.00	1.00
				Global improvement		4.00	3.00	3.00	2.00	1.00	1.00
				Efficacy index		14.00	11.00	7.00	3.00	3.00	2.00
				Efficacy index (*)		0.50	0.67	1.00	1.33	1.33	2.00
	21	Imipramine	Female	Severity of illness	5.00	5.00	4.00	5.00	4.00	4.00	
				Global improvement		3.00	3.00	4.00	3.00	4.00	
				Efficacy index		10.00	10.00	14.00	10.00	14.00	
				Efficacy index (*)		1.00	1.00	0.50	1.00	0.50	
15	25	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	4.00	3.00	5.00	5.00
				Efficacy index		14.00	10.00	10.00	10.00	14.00	14.00
				Efficacy index (*)		0.50	1.00	1.00	1.00	0.50	0.50
	26	Placebo	Male	Severity of illness	4.00	4.00	3.00	3.00	4.00	3.00	2.00
				Global improvement		3.00	2.00	2.00	6.00	2.00	2.00
				Efficacy index		10.00	6.00	6.00	14.00	6.00	6.00
				Efficacy index (*)		1.00	1.50	1.50	0.50	1.50	1.50
	27	Imipramine	Female	Severity of illness	4.00	4.00	4.00	2.00	2.00	2.00	1.00
				Global improvement		3.00	3.00	2.00	1.00	1.00	1.00
				Efficacy index		10.00	10.00	6.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.00	1.50	2.00	2.00	2.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	28	Reboxetine	Female	Severity of illness	4.00	4.00	3.00	3.00	2.00	2.00	1.00
				Global improvement		4.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index		14.00	6.00	6.00	6.00	6.00	2.00
				Efficacy index (*)		0.50	1.50	1.50	1.50	1.50	2.00
	29	Placebo	Male	Severity of illness	4.00	4.00	4.00	4.00			
				Global improvement		4.00	3.00	4.00			
				Efficacy index		13.00	10.00	14.00			
				Efficacy index (*)		1.00	1.00	0.50			
	30	Imipramine	Female	Severity of illness	4.00	4.00	4.00	3.00	3.00	2.00	2.00
				Global improvement		3.00	3.00	2.00	3.00	2.00	2.00
				Efficacy index		10.00	10.00	6.00	6.00	2.00	2.00
				Efficacy index (*)		1.00	1.00	1.50	1.50	2.00	2.00
	403	Imipramine	Female	Severity of illness	4.00	3.00	3.00	2.00	2.00	2.00	2.00
				Global improvement		2.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index		6.00	6.00	5.00	2.00	2.00	2.00
				Efficacy index (*)		1.50	1.50	3.00	2.00	2.00	2.00
	404	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00		
				Global improvement		4.00	4.00	4.00	5.00		
				Efficacy index		13.00	14.00	14.00	14.00		
				Efficacy index (*)		1.00	0.50	0.50	0.50		
	405	Placebo	Female	Severity of illness	4.00	4.00	4.00	2.00	2.00	2.00	1.00
				Global improvement		3.00	3.00	2.00	1.00	1.00	1.00
				Efficacy index		9.00	9.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		2.00	2.00	3.00	3.00	3.00	4.00
	406	Imipramine	Male	Severity of illness	4.00	4.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	10.00	6.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	1.00	1.50	3.00	3.00	3.00
	407	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		10.00	10.00	6.00	6.00	8.00	6.00
				Efficacy index (*)		1.00	1.00	1.50	1.50	0.75	1.50

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	408	Placebo	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	3.00
				Global improvement		4.00	4.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	14.00	6.00	5.00	6.00	6.00
				Efficacy index (*)		1.00	0.50	1.50	3.00	1.50	1.50
	418	Placebo	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	3.00	1.00
				Global improvement		4.00	4.00	3.00	3.00	2.00	1.00
				Efficacy index		14.00	14.00	9.00	9.00	6.00	2.00
				Efficacy index (*)		0.50	0.50	2.00	2.00	1.50	2.00
	419	Placebo	Female	Severity of illness	4.00	3.00	4.00	4.00	3.00	3.00	3.00
				Global improvement		2.00	4.00	4.00	2.00	2.00	2.00
				Efficacy index		6.00	14.00	14.00	6.00	6.00	6.00
				Efficacy index (*)		1.50	0.50	0.50	1.50	1.50	1.50

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Treatment Drug	Start date	End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Stud drug	Symp treat	Hosp	Dis app.	Re app.	Outcome	Still present	(C)
1	1	Imipramine	18/04/91	22/05/91	CONFUSION		Detail	14													
							Detail	21													
						17/04/91(&)	Summary		01/05/91(*)	21											YES
					CONSTIPATION		Detail	21													
						24/04/91(&)	Summary		01/05/91(*)	21											YES
					DYSPEPSIA	17/04/91	Detail	21			3	2	5	1	YES	2	3	3	3		
							Detail	42	16/05/91		3	2	2	1		2	3	3	1	Y	
							Summary		16/05/91	42	3	2	2	1	YES	2	3	3	1	Y	YES
					INSOMNIA		Detail	21													
						24/04/91(&)	Summary		01/05/91(*)	21											YES
					MOUTH DRY		Detail	7													
							Detail	14													
							Detail	21													
						10/04/91(&)	Summary		01/05/91(*)	21											YES
					NAUSEA		Detail	7													
						10/04/91(&)	Summary		17/04/91(*)	7											YES
					PARAESTHESIA		Detail	7													
							Detail	28													
							Detail	35													
						10/04/91(&)	Summary		15/05/91(*)	35											YES
					SWEATING INCREASED		Detail	7													
						10/04/91(&)	Summary		17/04/91(*)	7											YES
					TACHYCARDIA		Detail	21													
							Detail	28													
						24/04/91(&)	Summary		08/05/91(*)	28											YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(&) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
1	1	Imipramine	18/04/91	22/05/91	VISION ABNORMAL	17/04/91	Detail	21			2	2	5	1		2	3	1	3		
							Detail	35			2	2	2	1		2	3	3		Y	
							Summary		22/05/91(*)	35	2	2	2	1		2	3	3		Y	YES
	2	Reboxetine	15/04/91	27/05/91	AGITATION	22/04/91	Detail	7			1	2	3	1		3	3	3	3		
							Summary		22/04/91(*)	7	1	2	3	1		3	3	3	3		YES
					CONSTIPATION	22/04/91	Detail	7			1	2	3	1		3	3	3	3		
							Detail	42				2	3	1		3	3	3	3	Y	
							Summary		27/05/91(*)	42	1	2	3	1		3	3	3	3	Y	YES
					DIZZINESS	22/04/91	Detail	7					3	1		3	3	3	3		
							Detail	14											3		
							Summary		30/04/91(*)	14			3	1		3	3	3	3		YES
						14/05/91	Detail	35			1	2	3	1		2	3	3	3		
							Summary		28/05/91(*)	35	1	2	3	1		2	3	3	3		YES
					FATIGUE	30/04/91	Detail	14					4	1		3	3	3	3		
							Summary		30/04/91(*)	14			4	1		3	3	3	3		YES
					INSOMNIA	30/04/91	Detail	14					4	1	YES	3	3	3	3		
							Summary		30/04/91(*)	14			4	1	YES	3	3	3	3		YES
					LIBIDO DECREASED	30/04/91	Detail	14				2	4	1		3	3	3	3		
							Detail	21													
							Summary		06/05/91(*)	21		2	4	1		3	3	3			YES
					MOUTH DRY	22/04/91	Detail	7				2	3	1		2	3	3	3		
							Detail	35			1	1	3	1		2	3	3	3		
							Detail	42					3	1		3	3	3	3	Y	
							Summary		27/05/91(*)	42	1	1	3	1		2	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
1	2	Reboxetine	15/04/91	27/05/91	NERVOUSNESS	22/04/91	Detail	7			1	2	3	1	3	3	3	3	3		
							Summary		22/04/91(*)	7	1	2	3	1	3	3	3	3	3		YES
					VISION ABNORMAL	30/04/91	Detail	14				2		1	3				3		
							Detail	28											3		
							Summary		13/05/91(*)	28		2		1	3				3		YES
	3	Imipramine	06/05/91	16/06/91	DYSPEPSIA	21/05/91	Detail	28			3	2	2	1	2	3	3	3			
							Detail	35			3	2	3	1	3	3	3	3			
							Detail	42			1	2	3	1	3	3	3	3	Y		
							Summary		17/06/91(*)	42	3	2	2	1	2	3	3	3	Y		YES
					MOUTH DRY	15/05/91	Detail	35			1	1	3	1	3	3	3	3	Y		
							Summary		17/06/91(*)	35	1	1	3	1	3	3	3	3	Y		YES
	4	Placebo	04/06/91	16/07/91	FATIGUE	12/06/91	Detail	14			2	2	4	1	2	3	3	3			
							Summary		16/06/91(*)	14	2	2	4	1	2	3	3	3			YES
					MICTURITION FREQUENCY	05/06/91	Detail	7			1	2	3	1	3	3	3	3			
							Summary		11/06/91(*)	7	1	2	3	1	3	3	3	3			YES
					MYALGIA	05/06/91	Detail	7			1	2	3	1	3	3	3	3			
							Summary		11/06/91(*)	7	1	2	3	1	3	3	3	3			YES
					SOMNOLENCE	12/06/91	Detail	21			1	2	4	1	2	3	3	3			
							Summary		25/06/91(*)	21	1	2	4	1	2	3	3	3			YES
	5	Reboxetine	12/06/91	02/07/91	MOUTH DRY	18/06/91	Detail	7			1	2	3	1	2	3	3	3			
							Summary		19/06/91(*)	7	1	2	3	1	2	3	3	3			YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	[C]
1	5	Reboxetine	12/06/91	02/07/91	SWEATING INCREASED	16/06/91	Detail	7			1	2	3	1		2	3	3	3		
							Detail	14			1	2	3	1		2	3	3	3		
							Summary		25/06/91(*)	14	1	2	3	1		2	3	3	3		YES
					TOOTH DISORDER	12/06/91	Detail	14	19/06/91						YES						
							Summary		19/06/91	14					YES						YES
	6	Placebo	23/05/91	05/07/91	ABDOMINAL PAIN	05/06/91	Detail	21			2	1	3	1		3	3	3	3		
							Summary		13/06/91(*)	21	2	1	3	1		3	3	3	3		YES
					ARTHRALGIA	28/05/91	Detail	7			2	1	4	1	YES	2	3	3	3		
							Summary		30/05/91(*)	7	2	1	4	1	YES	2	3	3	3		YES
					CONSTIPATION	30/05/91	Detail	14			2	2	2	1		3	3	3	3		
							Detail	21			2	2	4	1		2	3	3	3	Y	
							Summary		08/07/91(*)	21	2	2	2	1		2	3	3	3	Y	YES
					FLATULENCE	30/05/91	Detail	21			2	2	4	1		2	3	3	3	Y	
							Summary		08/07/91(*)	21	2	2	4	1		2	3	3	3	Y	YES
					MICTURITION DISORDER	24/05/91	Detail	7			2	1	1	1		3	3	3	3		
							Summary		30/05/91(*)	7	2	1	1	1		3	3	3	3		YES
					MOUTH DRY	24/05/91	Detail	7			1	1	1	1		2	3	3	3		
							Detail	14			1	1	3	1		3	3	3	3		
							Detail	21			2	1	4	1		2	3	3	3	Y	
							Summary		08/07/91(*)	21	2	1	1	1		2	3	3	3	Y	YES
					NAUSEA	25/06/91	Detail	35			2	2	3	1		3	3	3	3		
							Summary		01/07/91(*)	35	2	2	3	1		3	3	3	3		YES
					PARONIRIA	15/06/91	Detail	28			2	2	5	1	YES	3	3	3	3		

Severity: 0=unknowa, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalisation	Disapp.	Reapp.	Outcome	Still present	(C)
1	6	Placebo	23/05/91	05/07/91	PARONIRIA	16/06/91	Summary		28/06/91(*)	28	2	2	5	1	YES	3	3	3	3		YES
					RASH	02/07/91	Detail	42	05/07/91		2	2	3	3		3	2	3	1		
							Summary		05/07/91	42	2	2	3	3		3	2	3	1		YES
					TASTE PERVERSION	16/06/91	Detail	28			2	2	5	1		3	3	3	3		
							Summary		28/06/91(*)	28	2	2	5	1		3	3	3	3		YES
	7	Reboxetine	27/08/91	08/10/91	DIZZINESS		Detail	28													
						28/08/91	Detail	7			2	2	5	1		2	3	3	3		
							Detail	28													
							Summary		25/09/91(*)	28	2	2	5	1		2	3	3			YES
						17/09/91(&)	Summary		25/09/91(*)	28											YES
					HEADACHE	29/08/91	Detail	7			2	2	5	1		3	3	3	3		
							Summary		03/09/91(*)	7	2	2	5	1		3	3	3	3		YES
					MOUTH DRY	28/08/91	Detail	7			1	2	5	1		2	3	3	3		
							Summary		03/09/91(*)	7	1	2	5	1		2	3	3	3		YES
					SWEATING INCREASED		Detail	28													
						17/09/91(&)	Summary		25/09/91(*)	28											YES
					VISION ABNORMAL		Detail	28													
						17/09/91(&)	Summary		25/09/91(*)	28											YES
	8	Placebo	05/09/91	19/10/91	RHINITIS	20/09/91	Detail	21	21/09/91					1	YES						
							Summary		21/09/91	21				1	YES						YES
	9	Reboxetine	27/11/91	06/01/92	HEADACHE	26/11/91	Detail	7			1	2	3	1		3	3	3	3		
							Detail	35			1	2	3	1		3	3	3	3	Y	
							Summary		06/01/92(*)	35	1	2	3	1		3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relship	Study drug	Symp treat	Hosp	Disapp.	Reapp.	Outcome	Still present	(C)
1	9	Reboxetine	27/11/91	06/01/92	MOUTH DRY	27/11/91	Detail	7			2	2	2	1		3	3	3	3	Y	
							Summary		06/01/92(*)	7	2	2	2	1		3	3	3	3	Y	YES
	10	Placebo	24/09/91	04/11/91	HEADACHE	25/09/91	Detail	28			1	2	3	1		2	3	3	3	Y	
							Summary		04/11/91(*)	28	1	2	3	1		2	3	3	3	Y	YES
					INFLUENZA-LIKE SYMPTOMS	21/10/91	Detail	28	21/10/91						YES						
							Summary		21/10/91	28					YES						YES
	11	Imipramine	10/10/91	13/10/91	DIZZINESS	11/10/91	Detail	7			3		1	3		1	2	3	3	Y	
							Summary		14/10/91(*)	7	3		1	3		1	2	3	3	Y	YES
					HYPOTENSION POSTURAL	11/10/91	Detail	7			3		1	3		1	2	3	3	Y	
							Summary		14/10/91(*)	7	3		1	3		1	2	3	3	Y	YES
					SYNCOPE	11/10/91	Detail	7	11/10/91		3		1	1		1	3	3	1		
							Summary		11/10/91	7	3		1	1		1	3	3	1		YES
	12	Imipramine	18/10/91	30/11/91	DIZZINESS	26/10/91	Detail	14			1	2	3	1		2	3	3	3		
							Summary		01/11/91(*)	14	1	2	3	1		2	3	3	3		YES
					HEADACHE	05/11/91	Detail	21			2	2	4	1		2	3	3	3		
							Summary		08/11/91(*)	21	2	2	4	1		2	3	3	3		YES
					INFLUENZA-LIKE SYMPTOMS	13/11/91	Detail	28	15/11/91						YES						
							Summary		15/11/91	28					YES						YES
					MOUTH DRY	26/10/91	Detail	14			1	2	4	1		2	3	3	3		
							Detail	42												Y	
							Summary		03/12/91(*)	42	1	2	4	1		2	3	3		Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
1	12	Imipramine	18/10/91	30/11/91	PARAESTHESIA	18/10/91	Detail	7			2	1	3	1		3	3	3	3		
							Summary		25/10/91(*)	7	2	1	3	1		3	3	3	3		YES
	412	Reboxetine	13/11/91	23/12/91	CONSTIPATION	25/11/91	Detail	21			3	2	4	1		3	3	3	3		
							Summary		04/12/91(*)	21	3	2	4	1		3	3	3	3		YES
					DIZZINESS	05/12/91	Detail	28	09/12/91		1	2	4	1		2	3	3	1		
							Summary		09/12/91	28	1	2	4	1		2	3	3	1		YES
	413	Placebo	09/12/91	20/01/92	FATIGUE	17/12/91	Detail	21			2	2	3	1		2	3	3	3	Y	
							Summary		20/01/92(*)	21	2	2	3	1		2	3	3	3	Y	YES
					HEADACHE	23/12/91	Detail	42			1	3	3	1		2	3	3	3	Y	
							Summary		20/01/92(*)	42	1	3	3	1		2	3	3	3	Y	YES
					MOUTH DRY	30/12/91	Detail	21			1	2	4	1		2	3	3	3	Y	
							Detail	35													
							Summary		13/01/92(*)	35	1	2	4	1		2	3	3			YES
	415	Imipramine	14/01/92	27/02/92	COLD URTICARIA	25/01/92	Detail	14			2	2	5	1		2	3	3	3		
							Summary		28/01/92(*)	14	2	2	5	1		2	3	3	3		YES
					CONSTIPATION	03/02/92	Detail	21			2	2	4	1	YES	2	3	3	3	Y	
							Summary		27/02/92(*)	21	2	2	4	1	YES	2	3	3	3	Y	YES
					MOUTH DRY	15/01/92	Detail	7			2	2	3	1		2	3	3	3	Y	
							Summary		27/02/92(*)	7	2	2	3	1		2	3	3	3	Y	YES
	421	Imipramine	27/02/92	09/04/92	CONSTIPATION	06/03/92	Detail	14			1	2	4	1	YES	3	3	3	3	Y	
							Summary		09/04/92(*)	14	1	2	4	1	YES	3	3	3	3	Y	YES

Saverity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
1	421	Imipramine	27/02/92	09/04/92	DIZZINESS	28/02/92	Detail	7			1	2	3	1	2	3	3	3			
							Detail	14													
							Summary		12/03/92(*)	14	1	2	3	1	2	3	3				YES
					FATIGUE	29/03/92	Detail	42			2	2	3	1	2	3	3	3	Y		
							Summary		09/04/92(*)	42	2	2	3	1	2	3	3	3	Y		YES
					HEADACHE	28/02/92	Detail	7			1	2	3	1	2	3	3	3			
							Summary		05/03/92(*)	7	1	2	3	1	2	3	3	3			YES
					MOUTH DRY	28/02/92	Detail	7			2	2	3	1	3	3	3	3	Y		
							Summary		09/04/92(*)	7	2	2	3	1	3	3	3	3	Y		YES
					MUSCLE CONTRACTIONS INVOL	12/03/92	Detail	21			2	2	3	1	2	3	3	3			
							Detail	28	25/03/92									1			
							Summary		25/03/92	28	2	2	3	1	2	3	3	1			YES
					NAUSEA	14/03/92	Detail	21			1	2	4	1	3	3	3	3			
							Detail	28	25/03/92									1			
							Summary		25/03/92	28	1	2	4	1	3	3	3	1			YES
					VISION ABNORMAL	28/02/92	Detail	7			1	2	3	1	2	3	3	3	Y		
							Summary		09/04/92(*)	7	1	2	3	1	2	3	3	3	Y		YES
	422	Imipramine	05/08/92	17/09/92	MOUTH DRY	05/08/92	Detail	14			1	2	3	1	2	3	3	3	Y		
							Summary		17/09/92(*)	14	1	2	3	1	2	3	3	3	Y		YES
					PALPITATION	06/08/92	Detail	21			1	2	3	1	3	3	3	3	Y		
							Summary		17/09/92(*)	21	1	2	3	1	3	3	3	3	Y		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
2/1	49	Placebo	18/05/91	28/06/91	INSOMNIA	13/05/91	Detail	0			3										
							Detail	0			3										
							Summary		29/06/91(*)	0	3										NO
					MOUTH DRY	18/05/91	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28			1	2	3	1		3	3	3	3		
							Detail	35			1	2	3	1		3	3	3	3		
							Detail	42	23/05/91		1	2	3	1		3	3	3	1		
							Summary		23/05/91	42	1	2	3	1		3	3	3	1		YES
					NAUSEA	18/05/91	Detail	7	21/05/91		2	2	3	1		3	3	3	1		
							Summary		21/05/91	7	2	2	3	1		3	3	3	1		YES
					VOMITING	18/05/91	Detail	7	21/05/91		3	2	3	1		3	3	3	1		
							Summary		21/05/91	7	3	2	3	1		3	3	3	1		YES
	50	Reboxetine	27/12/91	06/02/92	CONSTIPATION	20/01/92	Detail	28			2	2	3	1		2	3	3	3		
							Detail	35			1	2	3	1		2	3	3	3		
							Detail	42			2	2	3	1		2	3	3	3	Y	
							Summary		06/02/92(*)	42	2	2	3	1		2	3	3	3	Y	YES
					DYSPNOEA	22/01/92	Detail	28	22/01/92		2	1	6	1	YES	2	3	3	1		
							Summary		22/01/92	28	2	1	6	1	YES	2	3	3	1		YES
						27/01/92	Detail	35	27/01/92		2	1	6	1	YES	2	3	3	1		
							Summary		27/01/92	35	2	1	6	1	YES	2	3	3	1		YES
						03/02/92	Detail	42	03/02/92		2	1	6	1	YES	2	3	3	1		
							Summary		03/02/92	42	2	1	6	1	YES	2	3	3	1		YES
					FLUSHING	05/01/92	Detail	14			3	2	3	1		2	3	3	3		
							Detail	21	15/01/92		2	2	3	1		2	3	3	1		
							Summary		15/01/92	21	3	2	3	1		2	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
2/1	50	Reboxetine	27/12/91	06/02/92	GAMMA-GT INCREASED	24/12/91	Detail	0			2										
							Detail	21	16/01/92		2	1	6	1		2	3	3	1		
							Summary		16/01/92	21	2	1	6	1		2	3	3	1		ND
					HEADACHE	31/12/91	Detail	7	31/12/91		1	3	6	1	YES	2	3	3	1		
							Summary		31/12/91	7	1	3	6	1	YES	2	3	3	1		YES
					HYPERPYREXIA	29/12/91	Detail	7	30/12/91		1	3	6	1	YES	2	3	3	1		
							Summary		30/12/91	7	1	3	6	1	YES	2	3	3	1		YES
					INSOMNIA		Detail	0			3										
						22/12/91(D)	Summary		06/02/92(*)	0	3										NO
					MOUTH DRY	29/12/91	Detail	7			2	2	3	1		2	3	3	3		
							Detail	14			2	2	3	1		2	3	3	3		
							Detail	21			2	2	3	1		2	3	3	3		
							Detail	28			2	2	3	1		2	3	3	3		
							Detail	35			2	2	3	1		2	3	3	3		
							Detail	42			2	2	3	1		2	3	3	3	Y	
							Summary		06/02/92(*)	42	2	2	3	1		2	3	3	3	Y	YES
					PALPITATION	29/12/91	Detail	7			2	2	3	1		2	3	3	3		
							Detail	14	02/01/92		2	2	3	1		2	3	3	1		
							Summary		02/01/92	14	2	2	3	1		2	3	3	1		YES
					RASH ERYTHEMATOUS	01/02/92	Detail	42			3	2	3	1		2	3	3	3	Y	
							Summary		06/02/92(*)	42	3	2	3	1		2	3	3	3	Y	YES
					SGOT INCREASED	24/12/91	Detail	0			2										
							Detail	21	16/01/92		2	1	6	1		2	3	3	1		
							Summary		16/01/92	21	2	1	6	1		2	3	3	1		NO
	51	Imipramine	02/02/92	15/03/92	CONSTIPATION	10/02/92	Detail	14			3	2	3	1		3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/815
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
2/1	51	Imipramine	02/02/92	15/03/92	CONSTIPATION	10/02/92	Detail	21	23/02/92		3	2	3	1	YES	3	3	3	1		
							Summary		23/02/92	21	3	2	3	1	YES	3	3	3	1		YES
					DIARRHOEA	31/01/92	Detail	8			2											
							Summary		16/03/92(*)	0	2										NO
					HYPOKALAEMIA	24/02/92	Detail	28	28/02/92		1	3	5	1		3	3	3	1		
							Summary		28/02/92	28	1	3	5	1		3	3	3	1		YES
					INSOMNIA		Detail	0			3										
						27/01/92(2)	Summary		16/03/92(*)	0	3										NO
					MOUTH DRY	11/02/92	Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28			1	2	3	1		2	3	3	3		
							Detail	35			1	2	3	1		2	3	3	3		
							Detail	42			1	2	3	1		2	3	3	3	Y	
							Summary		16/03/92(*)	42	1	2	3	1		2	3	3	3	Y	YES
					NAUSEA	09/02/92	Detail	14	13/02/92		2	2	3	1		3	3	3	1		
							Summary		13/02/92	14	2	2	3	1		3	3	3	1		YES
					RHAGADES	18/02/92	Detail	21	09/03/92		2	2	6	1	YES	2	3	3	1		
							Summary		09/03/92	21	2	2	6	1	YES	2	3	3	1		YES
					VERTIGO	05/02/92	Detail	7	07/02/92		2	2	3	1		3	3	3	1		
							Summary		07/02/92	7	2	2	3	1		3	3	3	1		YES
2/2	43	Imipramine	18/04/91	16/05/91	AGITATION	20/04/91	Detail	7	20/04/91		2	1	3	1		2	3	3	1		
							Summary		20/04/91	7	2	1	3	1		2	3	3	1		YES
					HEADACHE	02/05/91	Detail	28	02/05/91		3	1	4		YES	2	3	3	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used

1548

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(c)
2/2	43	Imipramine	18/04/91	16/05/91	HEADACHE	02/05/91	Summary		02/05/91	28	3	1	4		YES	2	3	3	1		YES
					HYPOTENSION POSTURAL	23/04/91	Detail	7	25/04/91		2	2	3	4		2	2	3	1		
							Summary		25/04/91	7	2	2	3	4		2	2	3	1		YES
					INSOMNIA		Detail	0			2										
						18/04/91(D)	Summary		16/05/91(*)	0	2										NO
					NAUSEA	25/04/91	Detail	7	25/04/91		2	1	3			2	3	3	1		
							Summary		25/04/91	7	2	1	3			2	3	3	1		YES
						02/05/91	Detail	28	02/05/91		3	1	3	1	YES	3	3	3	1		
							Summary		02/05/91	28	3	1	3	1	YES	3	3	3	1		YES
					RHINITIS	02/05/91	Detail	35			2	1	3	1		2	3	3	3	Y	
							Summary		16/05/91(*)	35	2	1	3	1		2	3	3	3	Y	YES
	44	Imipramine	19/07/91	29/08/91	AGITATION	19/01/91	Detail	0			2										
							Summary		29/08/91(*)	0	2										NO
					ANAEMIA HYPOCHROMIC	28/08/91	Detail	42			1	3	4	1	YES	2	3	3	3	Y	
							Summary		29/08/91(*)	42	1	3	4	1	YES	2	3	3	3	Y	YES
					CONSTIPATION		Detail	0			2										
						11/07/91(D)	Summary		29/08/91(*)	0	2										NO
					DYSPEPSIA	18/07/91	Detail	7	25/07/91		3	3	3	1	YES	2	3	3	1		
							Summary		25/07/91	7	3	3	3	1	YES	2	3	3	1		NO
					FATIGUE	04/07/91	Detail	0			2										
							Detail	35			3	1	5	1		2	3	3	3		
							Detail	42			2	1	3	1		2	3	3	3	Y	
							Summary		29/08/91(*)	42	3	1	3	1		2	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
2/2	44	Imipramine	19/07/91	29/08/91	HEADACHE	04/07/91	Detail	0			3										
							Summary		29/08/91(*)	0	3										NO
					HYPOTENSION POSTURAL	23/07/91	Detail	7			2	1	3	1	2	3	3	3			
							Detail	14	28/07/91		2	1	3	1	2	3	3	1			
							Summary		28/07/91	14	2	1	3	1	2	3	3	1			YES
					INSOMNIA	19/05/91	Detail	0			2										
							Detail	7			2	1	3	1	2	3	3	3			
							Detail	21	04/08/91		1	2	3	1	2	3	3	1			
							Summary		04/08/91	21	2	1	3	1	2	3	3	1			NO
					MOUTH DRY	22/07/91	Detail	7	25/07/91		3	2	3	1	2	3	3	1			
							Summary		25/07/91	7	3	2	3	1	2	3	3	1			YES
						01/08/91	Detail	14	01/08/91		2	2	3	1	2	3	3	1			
							Summary		01/08/91	14	2	2	3	1	2	3	3	1			YES
						11/08/91	Detail	28			2	2	3	1	2	3	3	3			
							Detail	35	19/08/91		2	2	3	1	2	3	3	1			
							Summary		19/08/91	35	2	2	3	1	2	3	3	1			YES
					PARAESTHESIA	22/07/91	Detail	7	26/07/91		1	1	4	1	2	3	3	1			
							Detail	14	26/07/91		1	2	4	1	2	3	3	1			
							Summary		26/07/91	14	1	1	4	1	2	3	3	1			YES
					SWEATING INCREASED		Detail	0			3										
						11/07/91(@)	Summary		29/08/91(*)	0	3										NO
					TREMOR		Detail	0			1										
						11/07/91(@)	Summary		29/08/91(*)	0	1										NO
	45	Reboxetine	08/09/91	28/10/91	DYSPNOEA	01/10/91	Detail	28	05/10/91		1	2	4	1	2	3	3	1			
							Summary		05/10/91	28	1	2	4	1	2	3	3	1			YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
2/2	45	Reboxetine	08/09/91	20/10/91	GASTRITIS	03/10/91	Detail	28	04/10/91		2	2	3	1	YES	2	3	3	1		
							Summary		04/10/91	28	2	2	3	1	YES	2	3	3	1		YES
					HYPOTENSION POSTURAL	01/10/91	Detail	28			3	2	3	1		2	3	3	3		
							Detail	35	08/10/91		3	2	3	1		2	3	3	1		
							Summary		08/10/91	35	3	2	3	1		2	3	3	1		YES
					MOUTH DRY	13/09/91	Detail	7	13/09/91		3	2	3	1		2	3	3	1		
							Summary		13/09/91	7	3	2	3	1		2	3	3	1		YES
					RHINITIS		Detail	0			1										
							Detail	7			2	1	3	1		3	3	3	3		
							Detail	14	22/09/91		1	1	3	1		2	3	3	1		
						26/08/91(2)	Summary		22/09/91	14	2	1	3	1		2	3	3	1		YES
					SINUSITIS	22/09/91	Detail	21	29/09/91		2	1	6	1		2	3	3	1		
							Summary		29/09/91	21	2	1	6	1		2	3	3	1		YES
	46	Placebo	26/09/91	23/10/91	HYPOTENSION	01/10/91	Detail	7			1	2	3	1		2	3	3	3		
							Detail	21	10/10/91		1	2	3	1		2	3	3	1		
							Summary		10/10/91	21	1	2	3	1		2	3	3	1		YES
					INSOMNIA		Detail	0			2										
						17/09/91(2)	Summary		23/10/91(*)	0	2										NO
					MOUTH DRY	30/09/91	Detail	7			2	2	3	1		2	3	3	3		
							Detail	21	12/10/91		2	2	3	4		2	2	3	1		
							Summary		12/10/91	21	2	2	3	4		2	2	3	1		YES
					NERVOUSNESS	07/10/91	Detail	21	16/10/91		2	2	3	4		2	2	3	1		
							Summary		16/10/91	21	2	2	3	4		2	2	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
2/2	47	Placebo	24/03/92	04/05/92	INSOMNIA	01/03/92	Detail	0			2										
							Detail	28	17/04/92		1	1	6	1		2	3	3	1		
							Summary		17/04/92	28	2	1	6	1		2	3	3	1		NO
	48	Reboxetine	07/04/92	19/05/92	CONSTIPATION	18/04/92	Detail	14			2	2	2	1		2	3	3	3	Y	
							Summary		20/05/92(*)	14	2	2	2	1		2	3	3	3	Y	YES
					INSOMNIA	03/04/92	Detail	0			3										
							Detail	28	25/04/92		3	1	6	1		2	3	3	1		
							Summary		25/04/92	28	3	1	6	1		2	3	3	1		NO
					MOUTH DRY	11/04/92	Detail	7			2	2	2	1		2	3	3	3		
							Detail	35	09/05/92		2	2	2	1		2	3	3	1		
							Summary		09/05/92	35	2	2	2	1		2	3	3	1		YES
2/3	36/A	Imipramine	07/03/91	17/04/91	INSOMNIA	04/04/91	Detail	35			2	1	3	1		2	3	3	3		
							Detail	42			2	1	3	1		2	3	3	3	Y	
							Summary		17/04/91(*)	42	2	1	3	1		2	3	3	3	Y	YES
					MOUTH DRY	22/03/91	Detail	21			1	1	2	1	YES	2	3	3	3		
							Detail	28			1	1	2	1	YES	2	3	3	3		
							Detail	35			1	1	2	1	YES	2	3	3	3		
							Detail	42			1	1	2	1	YES	2	3	3	3	Y	
							Summary		17/04/91(*)	42	1	1	2	1	YES	2	3	3	3	Y	YES
	37	Reboxetine	27/03/91	07/05/91	INSOMNIA	20/03/91	Detail	0			3										
							Detail	28			2	1	4	1	YES	2	3	3	3	Y	
							Summary		07/05/91(*)	28	3	1	4	1	YES	2	3	3	3	Y	NO
	39	Imipramine	18/08/91	20/09/91	INSOMNIA	01/08/91	Detail	0			2										
							Detail	7							YES						
							Detail	14							YES						

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present (¢)
2/3	39	Imipramine	18/08/91	20/09/91	INSOMNIA	01/08/91	Detail	21	26/08/91		2		6	1	YES	2	3	3	1	
							Summary		26/08/91	21	2		6	1	YES	2	3	3	1	NO
	40	Reboxetine	24/10/91	04/12/91	ANOREXIA	01/09/91	Detail	0			3									
							Detail	7	30/10/91		3	1	4	1		3	3	3	1	
							Summary		30/10/91	7	3	1	4	1		3	3	3	1	NO
					INSOMNIA	20/10/91	Detail	0			2									
							Summary		05/12/91(*)	0	2									NO
					NAUSEA	29/10/91	Detail	7	30/10/91		2	1	4	1	YES	3	3	3	1	
							Summary		30/10/91	7	2	1	4	1	YES	3	3	3	1	YES
					VERTIGO	24/10/91	Detail	7			1	1	4	1	YES	2	3	3	3	
							Detail	14	02/11/91		1	2	3	1	YES	2	3	3	1	
							Summary		02/11/91	14	1	1	3	1	YES	2	3	3	1	YES
					VOMITING	01/09/91	Detail	0			2									
							Summary		05/12/91(*)	0	2									NO
	41	Placebo	05/10/91	13/11/91	DIARRHOEA	06/10/91	Detail	7	09/10/91		2	1	4	1		2	3	3	1	
							Summary		09/10/91	7	2	1	4	1		2	3	3	1	YES
					FATIGUE		Detail	0			2									
						25/09/91(@)	Summary		14/11/91(*)	0	2									NO
					HYPOTENSION	24/10/91	Detail	28			1	1	3	1		2	3	3	3	
							Detail	35	05/11/91		2	1	3	1		2	3	3	1	
							Summary		05/11/91	35	2	1	3	1		2	3	3	1	YES
					LIBIDO DECREASED		Detail	0			3									
						25/09/91(@)	Summary		14/11/91(*)	0	3									NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(¢) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
2/3	41	Placebo	03/10/91	13/11/91	PHARYNGITIS	10/10/91	Detail	14	17/10/91		1	1	6	1		2	3	3	1		
							Summary		17/10/91	14	1	1	6	1		2	3	3	1		YES
	42	Imipramine	19/05/92	30/06/92	HEADACHE	04/05/92	Detail	0			2										
							Detail	7	24/05/92		2	1	6	1		2	3	3	1		
							Summary		24/05/92	7	2	1	6	1		2	3	3	1		NO
					INSOMNIA	01/01/87	Detail	0			2										
							Detail	35	22/06/92		2	1	6	1		3	3	3	1		
							Summary		22/06/92	35	2	1	6	1		3	3	3	1		NO
					RASH	17/06/92	Detail	35			3	1	5	1	YES	2	3	3	3	Y	
							Summary		30/06/92(*)	35	3	1	5	1	YES	2	3	3	3	Y	YES
					SWEATING INCREASED	25/05/92	Detail	14			1	1	3	1		2	3	3	3		
							Detail	21	08/06/92		2	1	4	1		2	3	3	1		
							Summary		08/06/92	21	2	1	3	1		2	3	3	1		YES
						10/05/92	Detail	28			2	1	2	1		2	3	3	3		
							Detail	42	26/06/92		2	1	5	1		2	3	3	1		
							Summary		26/06/92	42	2	1	2	1		2	3	3	1		YES
					TREMOR	02/06/92	Detail	21	08/06/92		2	1	4	1		2	3	3	1		
							Summary		08/06/92	21	2	1	4	1		2	3	3	1		YES
					URINARY TRACT INFECTION	04/05/92	Detail	0			3										
							Detail	28	15/06/92		3	1	6	1	YES	2	3	3	1		
							Summary		15/06/92	28	3	1	6	1	YES	2	3	3	1		NO
					VERTIGO	02/06/92	Detail	21	08/06/92		2	1	3	1		2	3	3	1		
							Summary		08/06/92	21	2	1	3	1		2	3	3	1		YES
						10/06/92	Detail	28			2	1	3	1		3	3	3	3		
							Detail	42	26/06/92		2	1	4	1		2	3	3	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20126/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re appear.	Out come	Still present	(C)
2/3	42	Imipramine	19/05/92	30/06/92	VERTIGO	10/06/92	Summary		26/06/92	42	2	1	3	1		2	3	3	1		YES
					VISION ABNORMAL	17/06/92	Detail	35			2	1	4	1		2	3	3	3		
							Detail	42	26/06/92		1	1	6	1		2	3	3	1		
							Summary		26/06/92	42	2	1	4	1		2	3	3	1		YES
2/4	31	Placebo	26/03/91	05/05/91	INSOMNIA		Detail	0			2										
						17/03/91(2)	Summary		06/05/91(*)	0	2										NO
	32	Reboxetine	26/10/91	06/12/91	INSOMNIA		Detail	0			2										
						17/10/91(2)	Summary		06/12/91(*)	0	2										NO
	33	Imipramine	29/05/91	10/07/91	GAMMA-GT INCREASED		Detail	0			2										
						21/05/91(2)	Summary		10/07/91(*)	0	2										NO
					INSOMNIA		Detail	0			2										
							Detail	42	10/07/91		2	1	6	1	YES	2	3	3	1		
						21/05/91(2)	Summary		10/07/91	42	2	1	6	1	YES	2	3	3	1		NO
	35	Reboxetine	15/09/92	26/10/92	URINARY TRACT INFECTION		Detail	42			1	1	6	1		2	3	3	3	Y	
						20/10/92(2)	Summary		27/10/92(*)	42	1	1	6	1		2	3	3	3	Y	YES
	36	Imipramine	12/02/92	24/03/92	INSOMNIA	12/01/92	Detail	0			0										
							Detail	35	17/03/92		0	1	6	1		2	3	3	1		
							Summary		17/03/92	35	0	1	6	1		2	3	3	1		NO
2/5	73	Placebo	07/02/92	20/03/92	INSOMNIA	15/01/92	Detail	0			2									Y	
							Summary		20/03/92(*)	0	2									Y	NO
					MALAISE	25/02/92	Detail	21	25/02/92		2	1	5	1		3	3	3	1		
							Summary		25/02/92	21	2	1	5	1		3	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
2/5	73	Placebo	07/02/92	20/03/92	TREMOR	12/02/92	Detail	7	14/02/92		2	2	5	1		3	3	3	1		
							Summary		14/02/92	7	2	2	5	1		3	3	3	1		YES
	74	Reboxetine	21/06/92	01/08/92	HEADACHE	28/06/92	Detail	14	02/07/92	--	2	3	5	1		2	3	3	1		
							Summary		02/07/92	14	2	3	5	1		2	3	3	1		YES
					SALIVA INCREASED	21/06/92	Detail	7			2	2	3	1		2	3	3	3		
							Detail	21	10/07/92		2	3	3	1		3	3	3	1		
							Summary		10/07/92	21	2	2	3	1		2	3	3	1		YES
					VISION ABNORMAL	21/06/92	Detail	7			1	2	3	1		2	3	3	3		
							Detail	14			2	3	3	1		2	3	3	3		
							Detail	21	05/07/92		2	3	3	1		2	3	3	1		
							Summary		05/07/92	21	2	2	3	1		2	3	3	1		YES
	75	Imipramine	11/09/92	22/10/92	ANXIETY	03/10/92	Detail	28	06/10/92		2	1	6	1	YES	3	3	3	1		
							Summary		06/10/92	28	2	1	6	1	YES	3	3	3	1		YES
					INSOMNIA	03/09/92	Detail	0			2										
							Detail	7			2	1	6	1	YES	3	3	3	3		
							Detail	28	06/10/92		2	1	6	1	YES	3	3	3	1		
							Summary		06/10/92	28	2	1	6	1	YES	3	3	3	1		NO
	76	Imipramine	15/09/92	26/10/92	HEADACHE	24/09/92	Detail	14	28/09/92		2	1	4	1	YES	3	3	3	1		
							Summary		28/09/92	14	2	1	4	1	YES	3	3	3	1		YES
					HYPERTENSION	19/09/92	Detail	7	20/09/92		2	2	3	1		3	3	3	1		
							Summary		20/09/92	7	2	2	3	1		3	3	3	1		YES
					HYPERTRIGLYCERIDAEMIA	28/10/92	Detail	99			1	3	5	1		2	3	3	3	Y	
							Summary		26/11/92(*)	99	1	3	5	1		2	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
2/5	76	Imipramine	15/09/92	26/10/92	HYPOTENSION POSTURAL	09/10/92	Detail	28			3	3	2	1	YES	3	3	3	3		
							Detail	35	18/10/92		2	2	3	1		3	3	3	1		
							Summary		18/10/92	35	3	2	2	1	YES	3	3	3	1		YES
					TACHYCARDIA	19/09/92	Detail	7	20/09/92		1	2	3	1		3	3	3	1		
							Summary		20/09/92	7	1	2	3	1		3	3	3	1		YES
					TREMOR	06/10/92	Detail	28			2	2	3	1		3	3	3	3		
							Detail	35	18/10/92		2	2	3	1		3	3	3	1		
							Summary		18/10/92	35	2	2	3	1		3	3	3	1		YES
	78	Reboxetine	18/10/92	13/11/92	TREMOR	02/11/92	Detail	28			2	3	3	1		2	3	3	3		
							Detail	35	12/11/92		3	3	3	1		2	3	3	1		
							Summary		12/11/92	35	3	3	3	1		2	3	3	1		YES
2/6	55	Reboxetine	12/06/92	23/07/92	INSOMNIA	03/03/92	Detail	0			2										
							Detail	7			2	1	6	1	YES	3	3	3	3		
							Detail	14	26/06/92		1	1	6	1	YES	3	3	3	1		
							Summary		26/06/92	14	2	1	6	1	YES	3	3	3	1		NO
	56	Reboxetine	12/06/92	23/07/92	INSOMNIA	01/03/92	Detail	0			2										
							Detail	7			2	1	6	1	YES	3	3	3	3	Y	
							Summary		24/07/92(*)	7	2	1	6	1	YES	3	3	3	3	Y	NO
	57	Imipramine	05/05/92	15/06/92	CONSTIPATION	15/05/92	Detail	14			2	2	3	1		2	3	3	3	Y	
							Summary		16/06/92(*)	14	2	2	3	1		2	3	3	3	Y	YES
					DIZZINESS	10/06/92	Detail	42			2	2	3	1		3	3	3	3	Y	
							Summary		16/06/92(*)	42	2	2	3	1		3	3	3	3	Y	YES
					INSOMNIA	05/03/92	Detail	0			2										

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
2/6	57	Imipramine	05/05/92	15/06/92	INSOMNIA	05/05/92	Detail	7			2	1	6	1	YES	3	3	3	3		
							Detail	21	25/05/92		1	1	3	1	YES	3	3	3	1		
							Summary		25/05/92	21	2	1	3	1	YES	3	3	3	1		NO
					MOUTH DRY	15/05/92	Detail	14			2	2	3	1		2	3	3	3	Y	
							Summary		16/06/92(*)	14	2	2	3	1		2	3	3	3	Y	YES
	58	Placebo	18/05/92	29/06/92	FATIGUE	05/06/92	Detail	21			1	2	3	1			3	3	3		
							Detail	35	19/06/92		2	2	6	1		3	3	3	1		
							Summary		19/06/92	35	2	2	3	1		3	3	3	1		YES
					INSOMNIA	01/05/92	Detail	0			2										
							Detail	7	18/05/92		0	1	6	1	YES	3	3	3	1		
							Summary		18/05/92	7	2	1	6	1	YES	3	3	3	1		NO
	59	Placebo	27/05/92	23/06/92	INSOMNIA	01/05/92	Detail	0			2										
							Detail	7			2	1	3	1	YES	3	3	3	3	Y	
							Summary		24/06/92(*)	7	2	1	3	1	YES	3	3	3	3	Y	NO
	60	Imipramine	12/05/92	22/06/92	CONSTIPATION	22/05/92	Detail	14			2	2	3	1		3	3	3	3	Y	
							Summary		23/06/92(*)	14	2	2	3	1		3	3	3	3	Y	YES
					DIZZINESS	05/06/92	Detail	28			2	2	3	1		3	3	3	3	Y	
							Summary		23/06/92(*)	28	2	2	3	1		3	3	3	3	Y	YES
					INSOMNIA	07/03/92	Detail	7			2	1	6	1	YES	3	3	3	3	Y	
							Summary		23/06/92(*)	7	2	1	6	1	YES	3	3	3	3	Y	NO
					MOUTH DRY	22/05/92	Detail	14			2	2	3	1		3	3	3	3		
							Detail	28			2	2	2	1		2	3	3	3		
							Detail	35			2	2	2	1		2	3	3	3		
							Detail	42			2	2	2	1		2	3	3	3	Y	
							Summary		23/06/92(*)	42	2	2	2	1		2	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Disapp.	Reapp.	Outcome	Still present	(C)
3/1	61	Imipramine	05/03/91	05/04/91	ASTHENIA	05/03/91	Detail	7			2	2	3	1	2	3	3	3		
							Detail	14			2	2	3	1	2	3	3	3		
							Detail	21			1	2	3	1	2	3	3	3		
							Detail	28			1	2	3	1	1	3	3	3		
							Detail	35	05/04/91		2	2	3	1	2	3	3	1		
							Summary		05/04/91	35	2	2	3	1	1	3	3	1		YES
					SOMNOLENCE	05/03/91	Detail	7			2	2	3	1	2	3	3	3		
							Detail	35	05/04/91		1	2	3	1	2	3	3	1		
							Summary		05/04/91	35	2	2	3	1	2	3	3	1		YES
	141	Placebo	03/10/91	14/11/91	BRONCHITIS	08/11/91	Detail	42	13/11/91		1	3	6	1	3	3	3	1		
							Summary		13/11/91	42	1	3	6	1	3	3	3	1		YES
					HERPES SIMPLEX	08/11/91	Detail	42	13/11/91		1	1	6	1	3	3	3	1		
							Summary		13/11/91	42	1	1	6	1	3	3	3	1		YES
	143	Reboxetine	15/04/92	20/05/92	DYSPNOEA	14/05/92	Detail	35			2	2	3	1	3	3	3	3	Y	
							Summary		20/05/92(*)	35	2	2	3	1	3	3	3	3	Y	YES
					SWEATING INCREASED	24/04/92	Detail	21			1	2	2	1	3	3	3	3		
							Detail	28			1	2	2	1	3	3	3	3		
							Detail	35											Y	
							Summary		20/05/92(*)	35	1	2	2	1	3	3	3		Y	YES
	144	Reboxetine	09/06/92	22/07/92	NERVOUSNESS	10/06/92	Detail	7			2	2	3	1	3	3	3	3		
							Detail	14			2	2	3	1	3	3	3	3		
							Detail	35			1	2	3	1	3	3	3	3	Y	
							Summary		22/07/92(*)	35	2	2	3	1	3	3	3	3	Y	YES
					SWEATING INCREASED	10/06/92	Detail	7			2	2	3	1	3	3	3	3	Y	
							Summary		22/07/92(*)	7	2	2	3	1	3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
3/1	144	Reboxetine	09/06/92	22/07/92	VERTIGO	10/06/92	Detail	7			2	2	3	1		3	3	3	3		
							Detail	35			1	2	3	1	YES	3	3	3	3		
							Detail	42			1	2	3	1	YES	3	3	3	3	Y	
							Summary		22/07/92(*)	42	2	2	3	1	YES	3	3	3	3	Y	YES
	451	Reboxetine	28/01/92	01/02/92	CONSTIPATION	22/01/92	Detail	7			2	1	1	3	YES	2	1	3	3		
							Detail	14			3	2	2	3	YES	2	1	3	3	Y	
							Summary		03/02/92(*)	14	3	1	1	3	YES	2	1	3	3	Y	YES
					HAEMORRHOIDS THROMBOSED	29/01/92	Detail	14			2	1	6	3	YES	2	1	3	3	Y	
							Summary		03/02/92(*)	14	2	1	6	3	YES	2	1	3	3	Y	YES
	452	Placebo	22/01/92	04/03/92	VISION ABNORMAL	31/01/92	Detail	21			2	2	1	1		3	3	3	3		
							Detail	28			2	2	1	1		3	3	3	3		
							Detail	35			1	2	1	1		3	3	3	3		
							Detail	42			1	2	1	1		3	3	3	3	Y	
							Summary		04/03/92(*)	42	2	2	1	1		3	3	3	3	Y	YES
	455	Imipramine	29/01/92	10/03/92	CONSTIPATION	31/01/92	Detail	7			2	1	2	1		2	3	3	3		
							Detail	14			2	1	2	1	YES	2	3	3	3		
							Detail	21			1	1	2	1	YES	3	3	3	3		
							Detail	28			1	1	2	1	YES	3	3	3	3		
							Detail	42			1	1	2	1	YES	3	3	3	3	Y	
							Summary		11/03/92(*)	42	2	1	2	1	YES	2	3	3	3	Y	YES
					VISION ABNORMAL	06/02/92	Detail	14			1	3	2	1		3	3	3	3		
							Detail	21			1	3	2	1		3	3	3	3		
							Detail	28			1	3	2	1		3	3	3	3		
							Detail	42			1	3	2	1		3	3	3	3	Y	
							Summary		11/03/92(*)	42	1	3	2	1		3	3	3	3	Y	YES
	454	Reboxetine	17/02/92	01/04/92	URINARY RETENTION	20/02/92	Detail	7			1	2	3	1		3	3	3	3		
							Detail	21			1	2	1	1		3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
3/1	454	Reboxetine	17/02/92	01/04/92	URINARY RETENTION	20/02/92	Detail	28													
							Detail	35													
							Detail	42	27/03/92		1	2	1	1		3	3	3	1		
							Summary		27/03/92	42	1	2	1	1		3	3	3	1		YES
	456	Imipramine	25/03/92	03/04/92	CHEST PAIN PRECORDIAL	03/04/92	Detail	14	03/04/92		3	2	3	3		3	3	3	1		
							Summary		03/04/92	14	3	2	3	3		3	3	3	1		YES
					CONSTIPATION	27/03/92	Detail	7			2	1	2	1	YES	3	3	3	3	Y	
							Summary		03/04/92(*)	7	2	1	2	1	YES	3	3	3	3	Y	YES
					MOUTH DRY	26/03/92	Detail	7			1	2	2	1		3	3	3	3	Y	
							Summary		03/04/92(*)	7	1	2	2	1		3	3	3	3	Y	YES
					SWEATING INCREASED	27/03/92	Detail	7			1	2	2	1		3	3	3	3	Y	
							Summary		03/04/92(*)	7	1	2	2	1		3	3	3	3	Y	YES
					SYNCOPE	03/04/92	Detail	14	03/04/92		3	2	3	1		2	3	3	1		
							Summary		03/04/92	14	3	2	3	1		2	3	3	1		YES
					TACHYCARDIA	03/04/92	Detail	14	03/04/92		3	2	2	3		2	2	3	1		
							Summary		03/04/92	14	3	2	2	3		2	2	3	1		YES
3/2	65/A	Reboxetine	29/01/91	11/03/91	SWEATING INCREASED	31/01/91	Detail	7			1	2	4	1		3	3	3	3		
							Detail	14			1	2	4	1		3	3	3	3		
							Detail	21	15/02/91		1		4	1		3	3		1		
							Summary		15/02/91	21	1	2	4	1		3	3	3	1		YES
					TREMOR	31/01/91	Detail	7	03/02/91		1	1	3	1		3	3	3	1		
							Summary		03/02/91	7	1	1	3	1		3	3	3	1		YES
3/3	67	Placebo	16/07/91	28/08/91	INSOMNIA		Detail	8			2										

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=requirad, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Disapp.	Reapp.	Outcome	Still present	(C)
3/3	67	Placebo	15/07/91	28/08/91	INSOMNIA		Detail	7	24/07/91		2	1	6	1	YES	3	3	3	1	
						15/07/91(@)	Summary		24/07/91	7	2	1	6	1	YES	3	3	3	1		NO
						01/08/91	Detail	28			3	1	5	1		3	3	3	3		
							Detail	35			3	1	5	1	YES	3	3	3	3		
							Detail	42			3	1	5	1	YES	3	3	3	3	Y	
							Summary		28/08/91(*)	42	3	1	5	1	YES	3	3	3	3	Y	YES
					WEIGHT DECREASE	07/08/91	Detail	28			2	2	3	1		3	3	3	3		
							Detail	35	20/08/91		2	2	5	1		3	3	3	1		
							Summary		20/08/91	35	2	2	3	1		3	3	3	1		YES
	68	Reboxetine	21/01/92	02/03/92	HOT FLUSHES	05/02/92	Detail	21			2	2	2	1		2	3	3	3		
							Detail	28			2	2	2	1		2	3	3	3		
							Detail	35			1	2	2	1		2	3	3	3		
							Detail	42			1	2	2	1		2	3	3	3	Y	
							Summary		02/03/92(*)	42	2	2	2	1		2	3	3	3	Y	YES
					PARAESTHESIA	23/01/92	Detail	7	24/01/92		2	2	3	1		3	3	3	1		
							Summary		24/01/92	7	2	2	3	1		3	3	3	1		YES
					SWEATING INCREASED	23/01/92	Detail	7	24/01/92		2	2	3	1		3	3	3	1		
							Summary		24/01/92	7	2	2	3	1		3	3	3	1		YES
	69	Placebo	04/02/92	16/03/92	AGITATION	29/02/92	Detail	28	01/03/92		3	2	5	1	YES	3	3	3	1		
							Summary		01/03/92	28	3	2	5	1	YES	3	3	3	1		YES
					ANXIETY		Detail	0			0										
						30/01/92(@)	Summary		16/03/92(*)	0	0										NO
						05/02/92	Detail	7			3	1	4	1		3	3	3	3		
							Detail	14	12/02/92		3	1	4	1		3	3	3	1		
							Summary		12/02/92	14	3	1	4	1		3	3	3	1		YES
					HEADACHE		Detail	0			2										
						30/01/92(@)	Summary		16/03/92(*)	0	2										NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

1562

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Outcome	Still present	(C)
3/3	69	Placebo	04/02/92	16/03/92	HEADACHE	05/02/92	Detail	7	08/02/92		2	1	4	1		3	3	3	1		
							Summary		08/02/92	7	2	1	4	1		3	3	3	1		YES
					INSOMNIA	29/01/92	Detail	0			3										
							Detail	7			2	1	6	1	YES	3	3	3	3		
							Detail	14			2	1	6	1	YES	3	3	3	3		
							Detail	21			1	1	6	1	YES	3	3	3	3		
							Detail	28			3	1	6	1	YES	3	3	3	3		
							Detail	35			2	1	6	1	YES	3	3	3	3		
							Detail	42			1	1	6	1	YES	3	3	3	3	Y	
							Summary		16/03/92(*)	42	3	1	6	1	YES	3	3	3	3	Y	NO
					PARAESTHESIA	05/02/92	Detail	7	09/02/92		2	2	3	1		3	3	3	1		
							Summary		09/02/92	7	2	2	3	1		3	3	3	1		YES
					SUICIDE ATTEMPT		Detail	0			3										
						30/01/92(D)	Summary		16/03/92(*)	0	3										NO
						29/02/92	Detail	28			3	1	5	1	YES	3	3	3	3		
							Detail	35	05/03/92		3	1	5	1		3	3	3	1		
							Summary		05/03/92	35	3	1	5	1	YES	3	3	3	1		YES
	70	Imipramine	15/04/92	26/05/92	BACK PAIN		Detail	0			3										
						01/01/88	Detail	7			3	1	6	1	YES	3	3	3	3		
							Detail	14			3	1	6	1	YES	3	3	3	3		
							Detail	21			3	1	6	1	YES	2	3	3	3		
							Detail	28			3	1	6	1	YES	2	3	3	3		
							Detail	35			3	1	6	1	YES	2	3	3	3		
							Detail	42			3	1	6	1	YES	2	3	3	3	Y	
							Summary		26/05/92(*)	42	3	1	6	1	YES	2	3	3	3	Y	NO
						09/04/92(D)	Summary		26/05/92(*)	0	3										NO
					DIZZINESS	18/04/92	Detail	21	25/04/92		2	2	2	1		3	3	3	1		
							Summary		25/04/92	21	2	2	2	1		3	3	3	1		YES
					INSOMNIA	01/02/92	Detail	0			3										

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(c)
3/3	78	Imipramine	15/04/92	26/05/92	INSOMNIA	01/02/92	Detail	7			3	1	6	1	YES	3	3	3	3		
							Detail	14			3	1	6	1	YES	3	3	3	3		
							Detail	21			2	1	6	1	YES	2	3	3	3		
							Detail	28			2	1	6	1	YES	2	3	3	3		
							Detail	35			2	1	6	1	YES	2	3	3	3		
							Detail	42			2	1	6	1	YES	2	3	3	3	Y	
							Summary		26/05/92(*)	42	3	1	6	1	YES	2	3	3	3	Y	NO
					MOUTH DRY	18/04/92	Detail	7			1	2	2	1		3	3	3	3		
							Detail	14			1	2	2	1		3	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3		
							Detail	28			1	2	2	1		2	3	3	3		
							Detail	35			1	2	2	1		2	3	3	3		
							Detail	42			1	2	2	1		2	3	3	3	Y	
							Summary		26/05/92(*)	42	1	2	2	1		2	3	3	3	Y	YES
					SWEATING INCREASED	18/04/92	Detail	7			2	2	2	1		3	3	3	3		
							Detail	14	25/04/92		2	2	2	1		3	3	3	1		
							Summary		25/04/92	14	2	2	2	1		3	3	3	1		YES
					TREMOR	25/04/92	Detail	21	02/05/92		2	2	2	1		2	3	3	1		
							Summary		02/05/92	21	2	2	2	1		2	3	3	1		YES
	71	Imipramine	16/04/92	27/05/92	DIZZINESS	26/04/92	Detail	14			2	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		2	3	3	3		
							Detail	28	18/05/92		1	2	3	1		2	3	3	1		
							Summary		18/05/92	28	2	2	3	1		2	3	3	1		YES
					HEADACHE		Detail	28			1	1	6	1	YES	2	3	3	3		
						01/01/85	Detail	0			3										
							Detail	7			2	1	6	1	YES	3	3	3	3		
							Detail	14			1	1	6	1	YES	3	3	3	3		
							Detail	21			1	1	6	1	YES	2	3	3	3		
							Detail	35			1	1	6	1	YES	2	3	3	3		
							Detail	42			1	1	6	1	YES	2	3	3	3	Y	
							Summary		27/05/92(*)	42	3	1	6	1	YES	2	3	3	3	Y	NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

1564

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
3/3	71	Imipramine	16/04/92	27/05/92	HEADACHE	07/05/92(S)	Summary		13/05/92(*)	28	1	1	6	1	YES	2	3	3	3		YES
					MOUTH DRY	19/04/92	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		2	3	3	3		
							Detail	28			1	2	3	1		2	3	3	3		
							Detail	35			1	2	3	1		2	3	3	3		
							Detail	42			1	2	3	1		2	3	3	3	Y	
							Summary		27/05/92(*)	42	1	2	3	1		2	3	3	3	Y	YES
	72	Reboxetine	25/07/92	04/09/92	INSOMNIA	01/08/92	Detail	0			2										
							Detail	7			2	1	6	1	YES	3	3	3	3		
							Detail	14	01/08/92		2	1	6	1	YES	3	3	3	1		
							Summary		01/08/92	14	2	1	6	1	YES	3	3	3	1		NO
3/4	79	Imipramine	04/05/91	15/06/91	CONSTIPATION	10/06/91	Detail	42			2	2	3	1		2	3	3	3	Y	
							Summary		17/06/91(*)	42	2	2	3	1		2	3	3	3	Y	YES
					INSOMNIA	01/05/91	Detail	0			2										
							Summary		17/06/91(*)	0	2										NO
					SLEEP DISORDER	04/05/91	Detail	7			1	1	3	1		3	3	3	3	Y	
							Summary		17/06/91(*)	7	1	1	3	1		3	3	3	3	Y	YES
					TREMOR	20/05/91	Detail	21			2	2	3	1		2	3	3	3		
							Detail	28			2	2	3	1		2	3	3	3		
							Detail	35			2	2	3	1		2	3	3	3		
							Detail	42			1	2	3	1		2	3	3	3	Y	
							Summary		17/06/91(*)	42	2	2	3	1		2	3	3	3	Y	YES
					VISION ABNORMAL	14/05/91	Detail	14	17/05/91		2	2	3	1		3	3	3	1		
							Summary		17/05/91	14	2	2	3	1		3	3	3	1		YES
						22/05/91	Detail	21			2	2	3	1		2	3	3	3		
							Detail	28			2	2	3	1		2	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(S) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
3/4	79	Imipramine	04/05/91	15/06/91	VISION ABNORMAL	22/05/91	Detail	35	04/06/91		2	2	3	1		3	3	3	1		
							Summary		04/06/91	35	2	2	3	1		2	3	3	1		YES
	80	Imipramine	01/09/91	24/09/91	DIZZINESS	10/09/91	Detail	14			2	2	3	1		3	3	3	3		
							Detail	21			2	2	3	3		3	1	3	3	Y	
							Summary		25/09/91(*)	21	2	2	3	3		3	1	3	3	Y	YES
					VISION ABNORMAL	10/09/91	Detail	14			2	2	3	1		3	3	3	3		
							Detail	21			2	2	3	3		3	1	3	3	Y	
							Summary		25/09/91(*)	21	2	2	3	3		3	1	3	3	Y	YES
	82	Placebo	17/06/91	28/07/91	INSOMNIA	07/06/91	Detail	0			2										
							Detail	21	01/07/91		2	1	4	1		3	3	3	1		
							Summary		01/07/91	21	2	1	4	1		3	3	3	1		NO
	83	Placebo	17/06/91	24/06/91	AGITATION	19/06/91	Detail	7			3	2	3	1		2	3	3	3	Y	
							Summary		24/06/91(*)	7	3	2	3	1		2	3	3	3	Y	YES
					DIARRHOEA	19/06/91	Detail	7			2	2	3	1		2	3	3	3	Y	
							Summary		24/06/91(*)	7	2	2	3	1		2	3	3	3	Y	YES
					INSOMNIA	10/05/91	Detail	0			1										
							Detail	7			2	1	3	1		2	3	3	3	Y	
							Summary		24/06/91(*)	7	2	1	3	1		2	3	3	3	Y	YES
					TREMOR	19/06/91	Detail	7			3	2	3	1		2	3	3	3	Y	
							Summary		24/06/91(*)	7	3	2	3	1		2	3	3	3	Y	YES
	85	Imipramine	29/10/91	08/12/91	INSOMNIA		Detail	0			2										
						24/10/91(@)	Summary		09/12/91(*)	0	2										NO
					MOUTH DRY	01/11/91	Detail	7			1	2	3	1		3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relship	Study drug	Symptomatic treat	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
3/4	85	Imipramine	29/10/91	08/12/91	MOUTH DRY	01/11/91	Detail	14	04/11/91		1	2	5	1		3	3	3	1		
							Summary		04/11/91	14	1	2	5	1		3	3	3	1		YES
					PALPITATION	16/11/91	Detail	21			1	2	5	1		2	3	3	3		
							Detail	28	20/11/91		1	2	5	1		2	3	3	1		
							Summary		20/11/91	28	1	2	5	1		2	3	3	1		YES
					TREMOR	16/11/91	Detail	21			1	2	5	1		1	3	3	3		
							Detail	28			1	2	5	1		2	3	3	3		
							Detail	35			1	2	5	1		2	3	3	3		
							Detail	42			1	2	5	1		2	3	3	3	Y	
							Summary		09/12/91(*)	42	1	2	5	1		1	3	3	3	Y	YES
					VERTIGO	30/10/91	Detail	7	02/11/91		1	2	5	1		3	3	3	1		
							Summary		02/11/91	7	1	2	5	1		3	3	3	1		YES
	87	Placebo	09/12/91	19/01/92	HYPERTONIA	01/01/92	Detail	28			2	2	5	1		2	3	3	3		
							Detail	35			2	2	5	1	YES	2	3	3	3		
							Detail	42	18/01/92						YES				1		
							Summary		18/01/92	42	2	2	5	1	YES	2	3	3	1		YES
					INSOMNIA		Detail	0			2										
						05/12/91(@)	Summary		20/01/92(*)	0	2										NO
	88	Placebo	23/03/92	08/05/92	AGITATION	29/03/92	Detail	7			1	2	5	1		2	3	3	3		
							Detail	14	31/03/92		1	2	5	1		2	3	3	1		
							Summary		31/03/92	14	1	2	5	1		2	3	3	1		YES
	89	Reboxetine	26/03/92	06/05/92	INSOMNIA	10/04/92	Detail	21			5	1	5	1	YES	2	3	3	3		
							Detail	28			3	1	5	1	YES	2	3	3	3		
							Detail	35			1	1	5	1	YES	2	3	3	3		
							Detail	42	01/05/92												
							Summary		01/05/92	42	3	1	3	1	YES	2	3	3			YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
3/4	89	Reboxetine	26/03/92	06/05/92	TACHYCARDIA	18/04/92	Detail	21			2	2	3	1		2	3	3	3		
							Detail	28	17/04/92												
							Summary		17/04/92	28	2	2	3	1		2	3	3			YES
	90	Reboxetine	28/04/92	08/06/92	MICTURITION DISORDER	01/05/92	Detail	7			1	2	3	1		2	3	3	3		
							Detail	42	03/06/92		1	2	3	1		2	3	3	1		
							Summary		03/06/92	42	1	2	3	1		2	3	3	1		YES
					MOUTH DRY	01/04/92	Detail	0			1										
							Summary		09/06/92(*)	0	1										NO
						30/04/92	Detail	7			1	1	3	1		2	3	3	3	Y	
							Summary		09/06/92(*)	7	1	1	3	1		2	3	3	3	Y	YES
	458	Reboxetine	26/05/92	09/06/92	HEADACHE	04/06/92	Detail	14	08/06/92		2	1	4	1	YES	2	3	3	1		
							Summary		08/06/92	14	2	1	4	1	YES	2	3	3	1		YES
					NAUSEA	26/05/92	Detail	7			2	2	3	1	YES	2	3	3	3	Y	
							Summary		09/06/92(*)	7	2	2	3	1	YES	2	3	3	3	Y	YES
	459	Placebo	02/06/92	13/07/92	BACK PAIN	16/06/92	Detail	21	22/06/92		2	1	6	1	YES	2	3	3	1		
							Summary		22/06/92	21	2	1	6	1	YES	2	3	3	1		YES
					CONSTIPATION	19/06/92	Detail	21			2	1	3	1	YES	2	3	3	3	Y	
							Summary		13/07/92(*)	21	2	1	3	1	YES	2	3	3	3	Y	YES
					MOUTH DRY	03/06/92	Detail	7			2	2	3	1	YES	2	3	3	3	Y	
							Summary		13/07/92(*)	7	2	2	3	1	YES	2	3	3	3	Y	YES
					PARAESTHESIA	18/06/92	Detail	21	22/06/92		1	1	6	1	YES	2	3	3	1		
							Summary		22/06/92	21	1	1	6	1	YES	2	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

1568

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
3/4	460	Reboxetine	19/08/92	20/08/92	CONFUSION	19/08/92	Detail	7	22/08/92		3	2	2	3	2	2	2	3	1		
							Summary		22/08/92	7	3	2	2	3	2	2	2	3	1		YES
					MOUTH DRY	19/08/92	Detail	7	22/08/92		2	2	2	3	2	2	2	3	1		
							Summary		22/08/92	7	2	2	2	3	2	2	2	3	1		YES
	461	Imipramine	17/09/92	24/09/92	DIZZINESS	18/09/92	Detail	7			3	2	3	1	2	3	3	3	Y		
							Summary		24/09/92(*)	7	3	2	3	1	2	3	3	3	Y		YES
					MOUTH DRY	18/09/92	Detail	7			3	2	3	1	2	3	3	3	Y		
							Summary		24/09/92(*)	7	3	2	3	1	2	3	3	3	Y		YES
					NAUSEA	18/09/92	Detail	7			2	2	3	1	2	3	3	3	Y		
							Summary		24/09/92(*)	7	2	2	3	1	2	3	3	3	Y		YES
					SWEATING INCREASED	15/09/92	Detail	7			3	2	3	1	2	3	3	3	Y		
							Summary		24/09/92(*)	7	3	2	3	1	2	3	3	3	Y		NO
	462	Imipramine	29/09/92	08/10/92	DEPERSONALIZATION	01/10/92	Detail	7			3	2	3	1	2	3	3	3	Y		
							Summary		08/10/92(*)	7	3	2	3	1	2	3	3	3	Y		YES
					DYSPNOEA	05/10/92	Detail	7	06/10/92		2	2	3	1	2	3	3	1			
							Summary		06/10/92	7	2	2	3	1	2	3	3	1			YES
					HYPERKINESIA	02/10/92	Detail	7			2	2	3	1	2	3	3	3	Y		
							Summary		08/10/92(*)	7	2	2	3	1	2	3	3	3	Y		YES
					INSOMNIA	02/10/92	Detail	7			3	2	3	1	2	3	3	3	Y		
							Summary		08/10/92(*)	7	3	2	3	1	2	3	3	3	Y		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
4/1	91	Imipramine	12/10/91	22/11/91	FATIGUE	10/11/91	Detail	35			2	2	3	1		2	3	3	3		
							Detail	42			2	2	3	1		2	3	3	3	Y	
							Summary		23/11/91(*)	42	2	2	3	1		2	3	3	3	Y	YES
					HOT FLUSHES	23/10/91	Detail	14			2	2	3	1		2	3	3	3		
							Detail	21	30/10/91		2	2	3	1		2	3	3	1		
							Summary		30/10/91	21	2	2	3	1		2	3	3	1		YES
					INSOMNIA		Detail	0			3										
						04/10/91(2)	Summary		23/11/91(*)	0	3										NO
						13/10/91	Detail	7			2	1	3	1		2	3	3	3		
							Detail	14			2	1	3	1		2	3	3	3		
							Detail	21			3	1	3	1		2	3	3	3		
							Detail	28			3	1	3	1		2	3	3	3		
							Detail	35			3	1	3	1		2	3	3	3		
							Detail	42			2	1	3	1		2	3	3	3	Y	
							Summary		23/11/91(*)	42	3	1	3	1		2	3	3	3	Y	YES
					MOUTH DRY	26/10/91	Detail	21			2	2	3	1		2	3	3	3		
							Detail	28			2	2	3	1		2	3	3	3		
							Detail	35			3	2	3	1		2	3	3	3		
							Detail	42			3	2	3	1		2	3	3	3	Y	
							Summary		23/11/91(*)	42	3	2	3	1		2	3	3	3	Y	YES
					NAUSEA	30/10/91	Detail	21			2	3	3	1		2	3	3	3		
							Detail	28	05/11/91		2	3	3	1		2	3	3	1		
							Summary		05/11/91	28	2	3	3	1		2	3	3	1		YES
					PARAESTHESIA	03/11/91	Detail	28			2	3	3	1		2	3	3	3		
							Detail	35	15/11/91		2	3	3	1		2	3	3	1		
							Summary		15/11/91	35	2	3	3	1		2	3	3	1		YES
					SOMNOLENCE	13/10/91	Detail	7	16/10/91		2	2	3	1		2	3	3	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. interr.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit data used

1570

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
4/1	91	Imipramine	12/10/91	22/11/91	SOMNOLENCE	13/10/91	Summary		16/10/91	7	2	2	5	1		2	3	3	1		YES
					SWEATING INCREASED	16/10/91	Detail	7			2	2	3	1		2	3	3	3		
							Detail	14			2	2	3	1		2	3	3	3	Y	
							Summary		23/11/91(*)	14	2	2	3	1		2	3	3	3	Y	YES
	93	Placebo	05/07/91	16/08/91	SOMNOLENCE	06/07/91	Detail	7			2	2	3	1		2	3	3	3		
							Detail	14			2	2	3	1		2	3	3	3		
							Detail	21			2	2	3	1		2	3	3	3		
							Detail	28	25/07/91		2	2	3	1		3	3	3	1		
							Summary		25/07/91	28	2	2	3	1		2	3	3	1		YES
	96	Reboxatine	04/09/91	15/10/91	ANOREXIA		Detail	0			1										
						26/08/91(2)	Summary		16/10/91(*)	0	1										NO
						07/09/91	Detail	7			2	1	6	1		2	3	3	3		
							Detail	14			2	1	6	1	YES	2	3	3	3		
							Detail	21	25/09/91		2	1	6	1		3	3	3	1		
							Summary		25/09/91	21	2	1	6	1	YES	2	3	3	1		YES
					WEIGHT DECREASE	07/09/91	Detail	7			2	1	6	1		2	3	3	3		
							Detail	21	25/09/91		2	1	6	1		3	3	3	1		
							Summary		25/09/91	21	2	1	6	1		2	3	3	1		YES
					WEIGHT INCREASE	05/09/91	Detail	42			2	2	3	1		2	3	3	3	Y	
							Summary		16/10/91(*)	42	2	2	3	1		2	3	3	3	Y	YES
	116	Imipramine	16/05/92	22/05/92	HEADACHE	19/05/92	Detail	7			3	2	3	3		2	1	3	3	Y	
							Summary		23/05/92(*)	7	3	2	3	3		2	1	3	3	Y	YES
					NAUSEA	19/05/92	Detail	7			3	3	3	3		2	1	3	3	Y	
							Summary		23/05/92(*)	7	3	3	3	3		2	1	3	3	Y	YES
					VERTIGO	19/05/92	Detail	7			3	2	3	3		2	1	3	3	Y	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(&) onset date [illegible]

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
4/1	116	Imipramine	16/05/92	22/05/92	VERTIGO	19/05/92	Summary		23/05/92(*)	7	3	2	3	3		2	1	3	3	Y	YES
	117	Imipramine	05/09/91	14/10/91	APPETITE INCREASED	06/09/91	Detail	7			1	2	3	1		2	3	3	3		
							Detail	14			1	2	3	1		2	3	3	3		
							Detail	21			2	2	3	1		2	3	3	3		
							Detail	28			2	2	3	1		2	3	3	3		
							Detail	35			2	2	3	1		2	3	3	3		
							Detail	42			2	2	3	1		2	3	3	3	Y	
							Summary		15/10/91(*)	42	2	2	3	1		2	3	3	3	Y	YES
					MOUTH DRY	05/09/91	Detail	7			2	2	3	1		2	3	3	3		
							Detail	14	10/09/91		2	2	3	1		2	3	3	1		
							Summary		10/09/91	14	2	2	3	1		2	3	3	1		YES
					TINNITUS	06/09/91	Detail	7			1	2	3	1		2	3	3	3		
							Detail	14	12/09/91		1	2	3	1		2	3	3	1		
							Summary		12/09/91	14	1	2	3	1		2	3	3	1		YES
					WEIGHT INCREASE	05/09/91	Detail	42			2	2	3	1		2	3	3	3	Y	
							Summary		15/10/91(*)	42	2	2	3	1		2	3	3	3	Y	YES
	149	Reboxetine	30/09/92	10/11/92	NAUSEA	30/09/92	Detail	7			3	2	3	1		2	3	3	3		
							Detail	21	19/10/92		2	2	3	1		2	3	3	1		
							Summary		19/10/92	21	3	2	3	1		2	3	3	1		YES
4/3	99	Placebo	08/08/91	15/08/91	DIARRHOEA	10/08/91	Detail	7			2	2	3	1		2	3	3	3		
							Detail	14	21/08/91		2	2	3	3		2	2	3	1		
							Summary		21/08/91	14	2	2	3	3		2	2	3	1		YES
					DYSPEPSIA	10/08/91	Detail	7			2	2	3	1	YES	2	3	3	3	Y	
							Detail	14	21/08/91		2	2	3	3	YES	2	2	3	1		
							Summary		21/08/91	14	2	2	3	3	YES	2	2	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
4/3	100	Imipramine	27/11/91	17/12/91	NAUSEA	30/11/91	Detail	7			2	2	3	1	2	3	3	3		
							Detail	14			2	2	3	1	3	3	3	3		
							Detail	21	20/12/91		2	2	3	3	2	2	3	1		
							Summary		20/12/91	21	2	2	3	3	2	2	3	1		YES
					SWEATING INCREASED	06/12/91	Detail	14			2	2	3	1	2	3	3	3		
							Detail	21	20/12/91		2	2	3	3	2	2	3	1		
							Summary		20/12/91	21	2	2	3	3	2	2	3	1		YES
					TREMOR	06/12/91	Detail	14			2	2	3	1	2	3	3	3		
							Detail	21	20/12/91		2	2	3	3	2	2	3	1		
							Summary		20/12/91	21	2	2	3	3	2	2	3	1		YES
					VERTIGO	30/11/91	Detail	7			2	2	3	1	2	3	3	3		
							Detail	14			2	2	3	1	2	3	3	3		
							Detail	21	20/12/91		2	2	3	3	2	2	3	1		
							Summary		20/12/91	21	2	2	3	3	2	2	3	1		YES
4/4	109	Reboxetine	08/06/91	19/07/91	NAUSEA	10/06/91	Detail	7			2	2	3	1	2	3	3	3		
							Detail	28	01/07/91		2	2	3	1	2	3	3	1		
							Summary		01/07/91	28	2	2	3	1	2	3	3	1		YES
	110	Imipramine	15/06/91	26/07/91	HEADACHE	01/06/91	Detail	0			2									
							Detail	14			1	1	6	1	3	3	3	3		
							Detail	21	05/07/91		1	1	6	1		3	3	1		
							Summary		05/07/91	21	2	1	6	1	3	3	3	1		NO
					MOUTH DRY	07/07/91	Detail	28			1	2	3	1	3	3	3	3		
							Detail	35			1	2	3	1	3	3	3	3		
							Detail	42			1	2	3	1		3	3	3	Y	
							Summary		26/07/91[*]	42	1	2	3	1	3	3	3	3	Y	YES
					SWEATING INCREASED	08/07/91	Detail	28			1	2	2	1	3	3	3	3		
							Detail	35			1	2	3	1	3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp tres	Hosp	Dis app.	Re app.	Out come	Still present	(C)
4/4	110	Imipramine	15/06/91	26/07/91	SWEATING INCREASED	08/07/91	Detail	42			1	2	3	1			3	3	3	Y	
							Summary		26/07/91(*)	42	1	2	2	1		3	3	3	3	Y	YES
	111	Imipramine	04/07/91	14/08/91	INSOMNIA	20/06/91	Detail	0			2										
							Summary		14/08/91(*)	0	2										NO
					SWEATING INCREASED	20/07/91	Detail	21			2	2	3	1		2	3	3	3		
							Detail	35	05/08/91		2	2	3	1		2	3	3	1		
							Summary		05/08/91	35	2	2	3	1		2	3	3	1		YES
	112	Placebo	10/07/91	20/08/91	INSOMNIA	01/06/91	Detail	0			2										
							Summary		20/08/91(*)	0	2										NO
	113	Reboxetine	31/08/91	11/10/91	ARTHRALGIA	30/09/91	Detail	35	05/10/91		1	2	6	1	YES	3	3	3	1		
							Summary		05/10/91	35	1	2	6	1	YES	3	3	3	1		YES
	114	Placebo	20/11/91	31/12/91	HOT FLUSHES	20/12/91	Detail	42	29/12/91		1	2	3	1		3	3	3	1		
							Summary		29/12/91	42	1	2	3	1		3	3	3	1		YES
					INSOMNIA	23/11/91	Detail	7			2	1	4	1	YES	3	3	3	3		
							Detail	14	02/12/91		2	3	4	1	YES	3	3	3	1		
							Summary		02/12/91	14	2	1	4	1	YES	3	3	3	1		YES
	175	Imipramine	13/02/92	25/03/92	MOUTH DRY	14/02/92	Detail	7			2	2	3	1	YES	3	3	3	3		
							Detail	14			2	2	3	1	YES	3	3	3	3		
							Detail	21			2	2	3	1	YES	3	3	3	3		
							Detail	28			1	2	3	1	YES	3	3	3	3		
							Detail	35			1	2	3	1	YES	3	3	3	3		
							Detail	42			1	2	3	1	YES	3	3	3	3	Y	
							Summary		25/03/92(*)	42	2	2	3	1	YES	3	3	3	3	Y	YES
					SWEATING INCREASED	15/02/92	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			2	2	3	1		3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

1574

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
4/4	175	Imipramine	13/02/92	25/03/92	SWEATING INCREASED	15/02/92	Detail	21	05/03/92		1	2	3	1		3	3	3	1		
							Summary		05/03/92	21	2	2	3	1		3	3	3	1		YES
	176	Placebo	14/03/92	08/04/92	DEPRESSION AGGRAVATED	09/04/92	Detail	28			3	1	6	3		1	1	3	3	Y	
							Summary		10/04/92(*)	28	3	1	6	3		1	1	3	3	Y	YES
					MOUTH DRY	23/03/92	Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28	10/04/92		1	2	4	1		3	1	3	1		
							Summary		10/04/92	28	1	2	3	1		3	1	3	1		YES
					SUICIDE ATTEMPT	08/04/92	Detail	28	08/04/92		3	2	6	3		1	2	3	2		
							Summary		08/04/92	28	3	2	6	3		1	2	3	2		YES
	177	Imipramine	28/04/92	11/05/92	MOUTH DRY	01/05/92	Detail	7			1	2	3	1		3	1	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			2	2	3	3		3	1	3	3	Y	
							Summary		20/05/92(*)	21	2	2	3	3		3	1	3	3	Y	YES
					SWEATING INCREASED	01/05/92	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	3	3	1		3	3	3	3		
							Detail	21	18/05/92		2	2	3	3		3	2	3	1		
							Summary		18/05/92	21	2	2	3	3		3	2	3	1		YES
	178	Reboxetine	28/04/92	08/06/92	MOUTH DRY	15/05/92	Detail	21			1	2	3	1	YES	3	3	3	3		
							Detail	28			1	2	3	1	YES	3	3	3	3		
							Detail	35			1	2	3	1	YES	3	3	3	3		
							Detail	42			1	2	3	1	YES	3	3	3	3	Y	
							Summary		09/06/92(*)	42	1	2	3	1	YES	3	3	3	3	Y	YES
	179	Placebo	11/09/92	29/09/92	INSOMNIA	07/09/92	Detail	0			3										
							Detail	7			3	2	4	1	YES	3	3	3	3	Y	
							Summary		29/09/92(*)	7	3	2	4	1	YES	3	3	3	3	Y	NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ary	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
4/4	179	Placebo	11/09/92	29/09/92	SUICIDE ATTEMPT	29/09/92	Detail	21	29/09/92		1	1	5	3	YES	1	2	3	1		
							Summary		29/09/92	21	1	1	5	3	YES	1	2	3	1		YES
	180	Reboxetine	07/10/92	17/11/92	HYPOTENSION	03/11/92	Detail	28			2	1	3	1	YES	3	3	3	3		
							Detail	35	18/11/92		2	2	3	1	YES	3	3	3	1		
							Summary		18/11/92	35	2	1	3	1	YES	3	3	3	1		YES
					INSOMNIA	30/09/92	Detail	0			2											
							Detail	7			2	2	4	1	YES	3	3	3	3		
							Detail	28	03/11/92		1	2	4	1	YES	3	3	3	1		
							Summary		03/11/92	28	2	2	4	1	YES	3	3	3	1		NO
5/1	127	Reboxetine	06/06/91	17/07/91	HYPERURICAEMIA	27/06/91	Detail	21			3	2	3	1		3	3	3	3		
							Detail	42	18/07/91		3	2	3	1		3	3	3	1		
							Summary		18/07/91	42	3	2	3	1		3	3	3	1		YES
					INSOMNIA		Detail	0			2											
							Detail	21			1	1	5	1		3	3	3	3		
						02/06/91(2)	Summary		27/06/91(*)	21	2	1	5	1		3	3	3	3		NO
	128	Reboxetine	14/06/91	25/07/91	HYPOTENSION POSTURAL	15/06/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			2	2	3	1		2	3	3	3		
							Detail	28	06/07/91		1	2	3	1		2	3	3	1		
							Summary		06/07/91	28	2	2	3	1		2	3	3	1		YES
					INSOMNIA	01/05/91	Detail	0			2											
							Detail	7	17/06/91		2	1	5	1		3	3	3	1		
							Summary		17/06/91	7	2	1	5	1		3	3	3	1		NO
					TACHYCARDIA	15/06/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
5/1	128	Reboxetine	14/06/91	25/07/91	TACHYCARDIA	15/06/91	Detail	21	30/06/91		2	2	3	1		3	3	3	1		
							Summary		30/06/91	21	2	2	3	1		3	3	3	1		YES
	130	Placebo	05/05/92	15/04/92	SINUSITIS	12/03/92	Detail	14			3	2	5	1	YES	3	3		3		
							Detail	35	07/04/92		3	2	5	1	YES	3	3	3	1		
							Summary		07/04/92	35	3	2	5	1	YES	3	3	3	1		YES
	132	Imipramine	25/06/92	06/08/92	MUSCLE CONTRACTIONS INVOL	19/07/92	Detail	28			2	2	4	1		2	3	3	3		
							Detail	42			2	2	4	1		2	3	3	3	Y	
							Summary		10/08/92(*)	42	2	2	4	1		2	3	3	3	Y	YES
5/2	125	Reboxetine	28/01/91	18/03/91	INSOMNIA	16/02/91	Detail	21			2	2	3	1		2	3	3	3		
							Detail	28			2	2	3	1		2	3	3	3		
							Detail	35			2	2	3	1		2	3	3	3		
							Detail	42			2	2	3	1		2	3	3	3	Y	
							Summary		11/03/91(*)	42	2	2	3	1		2	3	3	3	Y	YES
					NAUSEA	16/02/91	Detail	21			2	2	3	1	YES	2	3	3	3		
							Detail	28			2	2	3	1		2	3	3	3		
							Detail	35			2	2	3	1		2	3	3	3		
							Detail	42			2	2	3	1		2	3	3	3	Y	
							Summary		11/03/91(*)	42	2	2	3	1	YES	2	3	3	3	Y	YES
5/3	134	Reboxetine	05/12/91	16/01/92	SWEATING INCREASED	14/12/91	Detail	14			2	2	2	1		3	3	3	3		
							Detail	42	13/01/92		2	2	2	1		2	3	3	1		
							Summary		13/01/92	42	2	2	2	1		2	3	3	1		YES
	135	Imipramine	18/01/92	20/02/92	ACCOMMODATION ABNORMAL	07/02/92	Detail	35			2	2	2	1		2	3	3	3		
							Detail	42	20/02/92		2	2	2	1		2	3	3	1		
							Summary		20/02/92	42	2	2	2	1		2	3	3	1		YES
					CONSTIPATION	17/01/92	Detail	14			3	2	3	1		3	3	3	3	Y	
							Summary		20/02/92(*)	14	3	2	3	1		3	3	3	3	Y	YES

Severity: 0=unkaown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
5/3	135	Imipramine	10/01/92	20/02/92	MOUTH DRY	24/01/92	Detail	21			2	2	2	1		3	3	3	3	Y	
							Summary		20/02/92(*)	21	2	2	2	1		3	3	3	3	Y	YES
					SWEATING INCREASED	07/02/92	Detail	35			2	2	2	1		2	3	3	3		
							Detail	42	20/02/92		2	2	2	1		2	3	3	1		
							Summary		20/02/92	42	2	2	2	1		2	3	3	1		YES
					TREMOR	24/01/92	Detail	21			2	2	2	1		3	3	3	3		
							Detail	35	13/02/92		2	2	2	1		2	3	3	1		
							Summary		13/02/92	35	2	2	2	1		2	3	3	1		YES
					WEIGHT INCREASE	01/02/92	Detail	28			2	2	2	1		2	3	3	3		
							Detail	42			2	2	3	1		2	3	3	3	Y	
							Summary		20/02/92(M)	42	2	2	2	1		2	3	3	3	Y	YES
	136	Imipramine	02/03/92	12/04/92	CONSTIPATION	06/03/92	Detail	7			2	1	3	1		3	3	3	3	Y	
							Summary		13/04/92(*)	7	2	1	3	1		3	3	3	3	Y	YES
					SWEATING INCREASED	06/03/92	Detail	7			2	1	3	1		3	3	3	3	Y	
							Summary		13/04/92(*)	7	2	1	3	1		3	3	3	3	Y	YES
	137	Reboxetine	15/05/92	25/06/92	CONSTIPATION	22/05/92	Detail	14			2	2	3	1		2	3	3	3	Y	
							Summary		25/06/92(*)	14	2	2	3	1		2	3	3	3	Y	YES
					MOUTH DRY		Detail	0			1										
							Detail	14			2	1	3	1		2	3	3	3	Y	
						10/05/92(@)	Summary		25/06/92(*)	14	2	1	3	1		2	3	3	3	Y	YES
					SWEATING INCREASED		Detail	0			1										
							Detail	14			2	1	3	1		2	3	3	3	Y	
						10/05/92(@)	Summary		25/06/92(M)	14	2	1	3	1		2	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing; first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(c)
6/1	151	Imipramine	21/01/92	28/01/92	ASTHENIA	26/01/92	Detail	7			3	2	3	1		2	3	3	3	Y	
							Summary		28/01/92(*)	7	3	2	3	1		2	3	3	3	Y	YES
					HYPOTENSION POSTURAL	26/01/92	Detail	7			3	2	3	1		2	3	3	3	Y	
							Summary		28/01/92(*)	7	3	2	3	1		2	3	3	3	Y	YES
					INSOMNIA		Detail	0			3										
						12/01/92(2)	Summary		28/01/92(*)	0	3										NO
					MOUTH DRY	24/01/92	Detail	7			3	2	3	1		3	3	3	3	Y	
							Summary		28/01/92(*)	7	3	2	3	1		3	3	3	3	Y	YES
					SWEATING INCREASED	26/01/92	Detail	7			3	2	3	1		2	3	3	3	Y	
							Summary		28/01/92(*)	7	3	2	3	1		2	3	3	3	Y	YES
	152	Reboxetine	24/02/92	07/04/92	CONSTIPATION	25/02/92	Detail	7			2	2	4	1		2	3	3	3		
							Detail	14	08/03/92		2	2	4	1		2	3	3	1		
							Summary		08/03/92	14	2	2	4	1		2	3	3	1		YES
					GASTROENTERITIS	29/03/92	Detail	35	03/04/92		2	3	6	1	YES	2	3	3	1		
							Summary		03/04/92	35	2	3	6	1	YES	2	3	3	1		YES
					INSOMNIA		Detail	0			3										
						16/02/92(2)	Summary		07/04/92(*)	0	3										NO
					MOUTH DRY	25/02/92	Detail	7			2	2	4	1		2	3	3	3		
							Detail	21													
							Detail	28	18/03/92												
							Summary		18/03/92	28	2	2	4	1		2	3	3			YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset data	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Disapp.	Reapp.	Outcome	Still present	(C)
6/1	152	Reboxetine	24/02/92	07/04/92	SINUSITIS	04/03/92	Detail	14	08/03/92		2	3	6	1	YES	2	3	3	1	
							Summary		08/03/92	14	2	3	6	1	YES	2	3	3	1	YES
					TREMOR	25/02/92	Detail	7			1	2	4	1		2	3	3	3	
							Detail	14	09/03/92		1	2	4	1		2	3	3	1	
							Summary		09/03/92	14	1	2	4	1		2	3	3	1	YES
	153	Reboxetine	18/03/91	29/04/91	CONSTIPATION	11/02/91	Detail	0			2									
							Detail	21			2	1	4	1		3	3	3	3	
							Detail	28			2	1	4	1		3	3	3	3	
							Detail	35			2	1	4	1		3			3	
							Detail	42			2	1	4	1		3	3	3	3	Y
							Summary		29/04/91(*)	42	2	1	4	1		3	3	3	3	Y NO
					HEADACHE	11/02/91	Detail	0			2									
							Detail	7			3	1	4	1		2	3	3	3	
							Detail	14			2	1	4	1		3	3	3	3	
							Detail	14			2	1	4	1		3	3	3	3	
							Detail	21			2	1	4	1		3	3	3	3	
							Detail	28			1	1	4	1		3	3	3	3	
							Detail	35			2	1	4	1		3			3	
							Detail	42			2	1	4	1		3	3	3	3	Y
							Summary		29/04/91(*)	42	3	1	4	1		2	3	3	3	Y YES
					INSOMNIA	11/02/91	Detail	0			2									
							Summary		29/04/91(*)	0	2									ND
					MOUTH DRY	11/02/91	Detail	0			2									
							Detail	7			2	1	4	1		2	3	3	3	Y
							Summary		29/04/91(*)	7	2	1	4	1		2	3	3	3	Y ND
	154	Imipramine	30/05/92	06/04/92	INSOMNIA	25/02/92	Detail	0			3									
							Summary		06/04/92(*)	0	3									ND

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
6/1	155	Placebo	05/07/92	04/08/92	HYPERKINESIA	17/07/92	Detail	14			2	2	3	1		2	3	3	3	Y	
							Summary		04/08/92(*)	14	2	2	3	1		2	3	3	3	Y	YES
					INSOMNIA	01/06/92	Detail	0			3										
							Summary		04/08/92(*)	0	3										NO
	156	Placebo	08/09/92	19/10/92	NAUSEA	10/09/92	Detail	7			1	2	3	1		2	3	3	3		
							Detail	14	18/09/92		1	2	3	1		2	3	3	1		
							Summary		18/09/92	14	1	2	3	1		2	3	3	1		YES
6/2	157	Reboxetine	30/04/91	10/06/91	CONSTIPATION	03/05/91	Detail	14			2	2	3	1		2	3	3	3		
							Detail	21	14/05/91		2	2	3	1		2	3	3	1		
							Summary		14/05/91	21	2	2	3	1		2	3	3	1		YES
					DYSURIA	01/05/91	Detail	7			2	2	3	1		2	3	3	3		
							Detail	14	08/05/91		2	2	3	1		2	3	3	1		
							Summary		08/05/91	14	2	2	3	1		2	3	3	1		YES
					INSOMNIA		Detail	0			2										
						21/04/91(Q)	Summary		10/06/91(*)	0	2										NO
						01/05/91	Detail	7	01/05/91		3	1	3	1		2	3	3	1		
							Summary		01/05/91	7	3	1	3	1		2	3	3	1		YES
					TREMOR		Detail	0			1										
							Detail	7	05/05/91		2	1	3	1		2	3	3	1		
						21/04/91(Q)	Summary		05/05/91	7	2	1	3	1		2	3	3	1		YES
	158	Imipramine	24/11/91	05/01/92	MOUTH DRY	10/12/91	Detail	21			2	1	3	1		2	3	3	3		
							Detail	28	18/12/91		2	1	3	1		3	3	3	1		
							Summary		18/12/91	28	2	1	3	1		2	3	3	1		YES
	159	Imipramine	14/07/91	24/08/91	HYPERTENSION		Detail	0			2										
							Detail	7												Y	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(Q) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
6/2	159	Imipramine	14/07/91	24/08/91	HYPERTENSION	07/07/91(@)	Summary		24/08/91(*)	7	2									Y	NO
					INSOMNIA	12/07/91	Detail	0			1										
							Detail	7												Y	
							Summary		24/08/91(*)	7	1									Y	NO
	160	Placebo	24/11/91	04/01/92	INSOMNIA	23/11/91	Detail	7			2	1	3	1	YES	2	3	3	3		
							Detail	21													
							Detail	28													
							Detail	35													
							Detail	42			1	1	3	1	YES	3	3	3	3	Y	
							Summary		04/01/92(*)	42	2	1	3	1	YES	2	3	3	3	Y	NO
	161	Reboxetine	20/02/92	18/03/92	HEADACHE	21/02/92	Detail	7			2	2	3	1		2	3	3	3		
							Detail	14			1	2	3	1		1	3	3	3		
							Detail	21	10/03/92		1	2	3	1		2	3	3	1		
							Summary		10/03/92	21	2	2	3	1		1	3	3	1		YES
					MOUTH DRY	21/02/92	Detail	7			2	2	3	1		2	3	3	3		
							Detail	21			2	2	3	1		2	3	3	3	Y	
							Summary		19/03/92(*)	21	2	2	3	1		2	3	3	3	Y	YES
					URINARY TRACT INFECTION	06/03/92	Detail	21			2	1	6	1	YES	2	3	3	3		
							Detail	28			2	1	6	3	YES	2	1	3	3	Y	
							Summary		19/03/92(*)	28	2	1	6	3	YES	2	1	3	3	Y	YES
	169	Imipramine	26/12/91	15/01/92	DYSPNOEA	30/12/91	Detail	7	02/01/92		1	2	3	1		2	3	3	1		
							Summary		02/01/92	7	1	2	3	1		2	3	3	1		YES
					TACHYCARDIA	28/12/91	Detail	7	31/12/91		1	2	3	1		2	3	3	1		
							Summary		31/12/91	7	1	2	3	1		2	3	3	1		YES
	171	Imipramine	22/07/92	01/09/92	ABDOMINAL PAIN	01/08/92	Detail	14			2	2	3	1	YES	3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(c)
6/2	171	Imipramine	22/07/92	01/09/92	ABDOMINAL PAIN	01/08/92	Detail	21	11/08/92		2	2	3	1		3	3	3	1		
							Summary		11/08/92	21	2	2	3	1	YES	3	3	3	1		YES
					MOUTH DRY	20/08/92	Detail	35			2		3	1		2	3	3	3		
							Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		01/09/92(*)	42	2	2	3	1		2	. 3	3	3	Y	YES
					SPEECH DISORDER	15/08/92	Detail	28			1	2	3	1		3	3	3	3		
							Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		01/09/92(*)	42	1	2	3	1		3	3	3	3	Y	YES
					TREMOR	05/08/92	Detail	21			2	2	3	1		3	3	3	3		
							Detail	28			1	2	3	1		3	3	3	3		
							Detail	35	25/08/92		2	2	3	1		3	3	3	1		
							Summary		25/08/92	35	2	2	3	1		3	3	3	1		YES
	172	Reboxetine	07/07/92	17/08/92	CONSTIPATION	15/07/92	Detail	14			2	2	3	1		3	3	3	3	Y	
							Summary		18/08/92(*)	14	2	2	3	1		3	3	3	3	Y	YES
					FATIGUE	15/07/92	Detail	14			2	2	3	1		3	3	3	3		
							Detail	35			3	2	3	1		3	3	3	3		
							Detail	42			3	2	3	1		2	3	3	3	Y	
							Summary		18/08/92(*)	42	3	2	3	1		2	3	3	3	Y	YES
					MOUTH DRY	13/07/92	Detail	14			2	2	3	1		3	3	3	3		
							Detail	35			3	2	3	1		3	3	3	3	Y	
							Summary		18/08/92(*)	35	3	2	3	1		3	3	3	3	Y	YES
6/3	163	Reboxetine	06/06/91	08/06/91	ANXIETY	06/06/91	Detail	7	08/06/91		3	2	3	3		2	2	3	1		
							Summary		08/06/91	7	3	2	3	3		2	2	3	1		YES
					TACHYCARDIA	01/04/91	Detail	0			2										
							Detail	7	08/06/91		3	1	3	3		2	2	3	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
6/3	163	Reboxetine	06/06/91	08/06/91	TACHYCARDIA	01/04/91	Summary		08/06/91	7	3	1	3	3		2	2	3	1		YES
					VERTIGO	06/06/91	Detail	7	08/06/91		3	2	3	3		2	2	3	1		
							Summary		08/06/91	7	3	2	3	3		2	2	3	1		YES
	164	Imipramine	11/10/91	21/11/91	HEADACHE	14/10/91	Detail	7			2	2	4	1		2	3	3	3		
							Detail	14	22/10/91		2	2	4	1		3	3	3	1		
							Summary		22/10/91	14	2	2	4	1		2	3	3	1		YES
					MOUTH DRY	09/11/91	Detail	35			2	2	2	1		3	3	3	3		
							Detail	42			2	2	2	1		3	3	3	3	Y	
							Summary		22/11/91(*)	42	2	2	2	1		3	3	3	3	Y	YES
					MYALGIA	14/10/91	Detail	7			2	2	4	1		2	3	3	3		
							Detail	14	22/10/91		2	2	4	1		2	3	3	1		
							Summary		22/10/91	14	2	2	4	1		2	3	3	1		YES
					TREMOR	09/11/91	Detail	35			2	2	2	1		3	3	3	3		
							Detail	42			2	2	2	1		3	3	3	3	Y	
							Summary		22/11/91(*)	42	2	2	2	1		3	3	3	3	Y	YES
	165	Imipramine	16/10/91	26/11/91	EOSINOPHILIA	26/11/91	Detail	42			2	2	3	1		2	3	3	3	Y	
							Summary		26/11/91(*)	42	2	2	3	1		2	3	3	3	Y	YES
					GAMMA-GT INCREASED	26/11/91	Detail	42			2	2	3	1		2	3	3	3	Y	
							Summary		26/11/91(*)	42	2	2	3	1		2	3	3	3	Y	YES
					MOUTH DRY		Detail	0			1										
						07/10/91(D)	Summary		26/11/91(*)	0	1										NO
						16/10/91	Detail	7			2	1	3	1		3	3	3	3		
							Detail	14			2	1	3	1			3	3	3		
							Detail	21			1	1	3	1		3	3	3	3		
							Detail	28	18/11/91		1	1	3	1		3	3	3	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Stud drug	Symp treat	Hosp	Dis app.	Re app.	Out come	Still present	(C)
6/3	165	Imipramine	16/10/91	26/11/91	MOUTH DRY	16/10/91	Summary		10/11/91	28	2	1	3	1		3	3	3	1		YES
					PHOSPHATASE ALKALINE INCR	26/11/91	Detail	42			2	2	3	1		2	3	3	3	Y	
							Summary		26/11/91(*)	42	2	2	3	1		2	3	3	3	Y	YES
					TREMOR	23/10/91	Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	1	3	1		3	3	3	3		
							Detail	28	10/11/91		1	1	3	1		3	3	3	1		
							Summary		10/11/91	28	1	1	3	1		3	3	3	1		YES
	166	Reboxetine	25/10/91	29/10/91	HYPOTENSION	01/06/91	Detail	0			1										
							Summary		30/10/91(*)	0	1										NO
					INSOMNIA	29/10/91	Detail	7			2	2	5	3		3	1	3	3	Y	
							Summary		30/10/91(*)	7	2	2	5	3		3	1	3	3	Y	YES
					SUICIDE ATTEMPT	29/10/91	Detail	7			3	2	5	3		3	1	3	3	Y	
							Summary		30/10/91(*)	7	3	2	5	3		3	1	3	3	Y	YES
	167	Placebo	18/11/91	27/12/91	SOMNOLENCE	19/11/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14	27/11/91		1	2	2	1		3	3	3	1		
							Summary		27/11/91	14	2	2	2	1		3	3	3	1		YES
	168	Placebo	03/12/91	06/01/92	CONSTIPATION		Detail	0			1										
							Detail	7			2	1	3	1		3	3	3	3		
							Detail	14	10/12/91		2	1	3	1		3	3	3	1		
						24/11/91(2)	Summary		10/12/91	14	2	1	3	1		3	3	3	1		YES
					INSOMNIA		Detail	0			2										
						24/11/91(2)	Summary		06/01/92(*)	0	2										NO
					MOUTH DRY	24/12/91	Detail	28			2	2	3	1		3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Outcome	Still present	(C)
6/3	168	Placebo	03/12/91	06/01/92	MOUTH DRY	24/12/91	Detail	35			1	2	3	1		3	3	3	3	Y	
							Summary		06/01/92(*)	35	2	2	3	1		3	3	3	3	Y	YES
					SOMNOLENCE	24/12/91	Detail	28			2	2	3	1		3	3	3	3		
							Detail	35			1	2	3	1		3	3	3	3	Y	
							Summary		06/01/92(*)	35	2	2	3	1		3	3	3	3	Y	YES
					SUICIDE ATTEMPT	31/12/91	Detail	35			2	2	3	1		3	3	3	3	Y	
							Summary		06/01/92(*)	35	2	2	3	1		3	3	3	3	Y	YES
					TREMOR		Detail	0			1										
							Detail	7			2	1	3	1		3	3	3	3		
							Detail	14	10/12/91		2	1	2	1		3	3	3	1		
						24/11/91(D)	Summary		10/12/91	14	2	1	2	1		3	3	3	1		YES
	505	Imipramine	03/12/91	17/12/91	INSOMNIA	12/12/91	Detail	14			3	2	3	1		3	3	3	3	Y	
							Summary		17/12/91(*)	14	3	2	3	1		3	3	3	3	Y	YES
					MOUTH DRY	06/12/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			2	2	3	1		3	3	3	3	Y	
							Summary		17/12/91(*)	14	2	2	3	1		3	3	3	3	Y	YES
	506	Placebo	08/01/92	19/02/92	MOUTH DRY	27/01/92	Detail	21			3	2	3	1		3	3	3	3		
							Detail	28			2	2	3	1		3	3	3	3		
							Detail	35	08/02/92		1	2	3	1		3	3	3	1		
							Summary		08/02/92	35	3	2	3	1		3	3	3	1		YES
					SOMNOLENCE	30/01/92	Detail	28			2	2	3	1		3	3	3	3		
							Detail	35			2	2	3	1		3	3	3	3		
							Detail	42			2	2	3	1		3	3	3	3	Y	
							Summary		19/02/92(*)	42	2	2	3	1		3	3	3	3	Y	YES
	507	Imipramine	14/01/92	24/02/92	CONSTIPATION	11/02/92	Detail	35			1	2	3	1		3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
6/3	507	Imipramine	14/01/92	24/02/92	CONSTIPATION	11/02/92	Detail	42	24/02/92		1	2	3	1	3	3	3	3	1		
							Summary		24/02/92	42	1	2	3	1	3	3	3	3	1		YES
					MOUTH DRY	20/01/92	Detail	7			2	2	3	1	3	3	3	3	3		
							Detail	14			2	2	3	1	3	3	3	3	3		
							Detail	21			1	2	3	1	3	3	3	3	3		
							Detail	28			1	2	3	1	3	3	3	3	3		
							Detail	35			1	2	3	1	3	3	3	3	3		
							Detail	42			1	2	2	1	3	3	3	3	3	Y	
							Summary		24/02/92(*)	42	2	2	2	1	3	3	3	3	3	Y	YES
					TREMOR	22/01/92	Detail	14			1	2	3	1	3	3	3	3	3		
							Detail	21	28/01/92		1	2	3	1	3	3	3	3	1		
							Summary		28/01/92	21	1	2	3	1	3	3	3	3	1		YES
	508	Reboxetine	05/02/92	17/03/92	MOUTH DRY	19/02/92	Detail	21			1	2	3	1	3	3	3	3	3		
							Detail	28			1		3	1	3	3	3	3	3		
							Detail	35			1		3	1	3	3	3	3	3		
							Detail	42	11/03/92		1	2	3	1	3	3	3	3	1		
							Summary		11/03/92	42	1	2	3	1	3	3	3	3	1		YES
	509	Placebo	24/02/92	06/04/92	MOUTH DRY	10/03/92	Detail	21			2	2	3	1	3	3	3	3	3		
							Detail	28			1	2	3	1	3	3	3	3	3		
							Detail	35	25/03/92		1	2	3	1	3	3	3	3	1		
							Summary		25/03/92	35	2	2	3	1	3	3	3	3	1		YES
	510	Reboxetine	27/02/92	10/03/92	HYPOTENSION	02/03/92	Detail	7			2	2	2	1	3	3	3	3	3		
							Detail	14			2	2	3	3	3	1	3	3	3	Y	
							Summary		11/03/92(*)	14	2	2	2	3	3	1	3	3	3	Y	YES
					INSOMNIA	06/03/92	Detail	14			3	2	3	3	3	1	3	3	3	Y	
							Summary		11/03/92(*)	14	3	2	3	3	3	1	3	3	3	Y	YES
					VERTIGO	06/03/92	Detail	14			3	2	3	3	3	1	3	3	3	Y	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Treatment Drug	Start date	End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(c)
6/3	518	Reboxetine	27/02/92	18/03/92	VERTIGO	06/03/92	Summary		11/03/92(*)	14	3	2	3	3		3	1	3	3	Y	YES
	511	Imipramine	19/03/92	21/04/92	SOMNOLENCE	18/03/92	Detail	7			3	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21	04/04/92		1		3	1		3	3	3	1		
							Summary		04/04/92	21	3	2	3	1		3	3	3	1		NO
					SUICIDE ATTEMPT	18/04/92	Detail	35			2	2	4	3		3	1	3	3	Y	
							Summary		22/04/92(*)	35	2	2	4	3		3	1	3	3	Y	YES
	512	Placebo	01/04/92	01/04/92	ANXIETY	01/04/92	Detail	7	01/04/92		3	2	4	3		3	2	3	1		
							Summary		01/04/92	7	3	2	4	3		3	2	3	1		YES
	513	Imipramine	13/05/92	23/06/92	MOUTH DRY	14/05/92	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21	01/06/92		1	2	3	1		2	3	3	1		
							Summary		01/06/92	21	2	2	3	1		2	3	3	1		YES
					TREMOR	14/05/92	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			3	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	42			1		3	1		3	3	3	3	Y	
							Summary		23/06/92(*)	42	3	2	3	1		3	3	3	3	Y	YES
7/02	181	Reboxetine	27/01/92	08/03/92	MOUTH DRY	02/03/92	Detail	42	09/03/92		1	3	3	1		2	3	3	1		
							Summary		09/03/92	42	1	3	3	1		2	3	3	1		YES
	182	Placebo	23/11/91	03/01/92	RHINITIS	06/12/91	Detail	21	12/12/91		1	1	6	1		2	3	3	1		
							Summary		12/12/91	21	1	1	6	1		2	3	3	1		YES
	183	Imipramine	02/01/92	18/01/92	ABDOMINAL PAIN	19/01/92	Detail	21			2	2	6	3		2	1	3	3	Y	
							Summary		22/01/92(*)	21	2	2	6	3		2	1	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with sqe., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
7/92	183	Imipramine	02/01/92	18/01/92	AGITATION	09/01/92	Detail	14			2	2	5	1	2	3	3	3	Y	
							Summary		22/01/92(*)	14	2	2	5	1	2	3	3	3	Y	YES
					COLITIS	16/01/92	Detail	21			2	2	5	3	2	1	3	3	Y	
							Summary		22/01/92(*)	21	2	2	5	3	2	1	3	3	Y	YES
					DYSPHAGIA	04/01/92	Detail	7			2	2	5	1	2	3	3	3		
							Detail	21			2	2	5	3	2	1	3	3	Y	
							Summary		22/01/92(*)	21	2	2	5	3	2	1	3	3	Y	YES
					PARAESTHESIA	09/01/92	Detail	14			3	2	5	1	2	3	3	3	Y	
							Summary		22/01/92(*)	14	3	2	5	1	2	3	3	3	Y	YES
					RIGORS	10/01/92	Detail	14			2	2	5	1	2	3	3	3	Y	
							Summary		22/01/92(*)	14	2	2	5	1	2	3	3	3	Y	YES
					SWEATING INCREASED	02/01/92	Detail	7			3	2	3	1	2	3	3	3	Y	
							Detail	14			3	2	3	1	2	3	3	3		
							Summary		15/01/92(*)	14	3	2	3	1	2	3	3	3		YES
					TINNITUS	10/01/92	Detail	14			1	2	5	1	2	3	3	3		
							Detail	21			2	2	1	3	2	1	3	3	Y	
							Summary		22/01/92(*)	21	2	2	1	3	2	1	3	3	Y	YES
					TREMOR	03/01/92	Detail	7			2	3	5	1	2	3	3	3	Y	
							Summary		22/01/92(*)	7	2	3	5	1	2	3	3	3	Y	YES
	185	Reboxetine	10/04/92	05/05/92	EPIDIDYMITIS	12/04/92	Detail	7			2	2	6	1	2	3	3	3		
							Detail	99	13/05/92									1		
							Summary		13/05/92	99	2	2	6	1	2	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit data used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
7/02	185	Reboxetine	10/04/92	05/05/92	GAMMA-GT INCREASED	30/04/92	Detail	21			2	1	4	1		2	3	3	3	Y	
							Summary		07/05/92(*)	21	2	1	4	1		2	3	3	3	Y	YES
					IMPOTENCE	12/04/92	Detail	7			2	2	2	1		2	3	3	3		
							Detail	28			3	2	1	3		2	2	3	3		
							Detail	99	13/05/92										1		
							Summary		13/05/92	99	3	2	1	3		2	2	3	1		YES
					URINARY RETENTION	12/04/92	Detail	7			2	2	1	1	YES	2	3	3	3		
							Detail	14			2	2	1	1	YES	2	3	3	3		
							Detail	28			3	2	2	3	YES	2	2	3	3		
							Detail	99	13/05/92										1		
							Summary		13/05/92	99	3	2	1	3	YES	2	2	3	1		YES
	184	Placebo	16/04/92	27/05/92	MOUTH DRY	17/04/92	Detail	7			1	2	2	1		2	3	3	3	Y	
							Detail	99	30/05/92		1	2	2	3		3	2	3	1		
							Summary		30/05/92	99	1	2	2	3		2	2	3	1		YES
7/03	190	Reboxetine	28/02/92	09/04/92	FATIGUE	28/02/92	Detail	7	03/03/92		1	2	2	1		3	3	3	1		
							Summary		03/03/92	7	1	2	2	1		3	3	3	1		YES
	191	Imipramine	03/03/92	10/04/92	SUICIDE ATTEMPT	10/04/92	Detail	42			3	3	4	3		1	1	3	3	Y	
							Detail	99	15/06/92												
							Summary		15/06/92	99	3	3	4	3		1	1	3			YES
7/04	193	Placebo	25/01/92	06/03/92	MOUTH DRY	27/01/92	Detail	7	30/01/92		1	2	1	1		3	3	3	1		
							Summary		30/01/92	7	1	2	1	1		3	3	3	1		YES
	195	Placebo	25/01/92	06/03/92	MOUTH DRY	30/01/92	Detail	7	31/01/92		1	2	1	1		3	3	3	1		
							Summary		31/01/92	7	1	2	1	1		3	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
[C] adverse event used for statistical analysis
[*] adverse event still present: end date = visit date
[@] onset date missing: first report visit date used
[&] onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
7/04	197	Imipramine	01/02/92	13/03/92	MOUTH DRY	03/02/92	Detail	7	06/02/92		1	2	1	1		3	3	3	1		
							Summary		06/02/92	7	1	2	1	1		3	3	3	1		YES
						23/02/92	Detail	28	27/02/92		1	2	2	1		2	3	3	1		
							Summary		27/02/92	28	1	2	2	1		2	3	3	1		YES
	199	Imipramine	28/03/92	08/05/92	MOUTH DRY	06/04/92	Detail	14	10/04/92		1	2	3	1		2	3	3	1		
							Summary		10/04/92	14	1	2	3	1		2	3	3	1		YES
	201	Reboxetine	28/03/92	08/05/92	HEADACHE	19/04/92	Detail	28	20/04/92		1	1	3	1		2	3	3	1		
							Summary		20/04/92	28	1	1	3	1		2	3	3	1		YES
	204	Imipramine	04/04/92	15/05/92	MOUTH DRY	19/04/92	Detail	21	23/04/92		1	2	3	1		2	3	3	1		
							Summary		23/04/92	21	1	2	3	1		2	3	3	1		YES
7/05	207	Imipramine	28/01/92	09/03/92	MOUTH DRY	23/02/92	Detail	28	24/02/92		1	3	3	1		3	3	3	1		
							Summary		24/02/92	28	1	3	3	1		3	3	3	1		YES
	209	Placebo	05/02/92	17/03/92	NAUSEA	02/03/92	Detail	28	02/03/92		1	3	3	1		3	3	3	1		
							Summary		02/03/92	28	1	3	3	1		3	3	3	1		YES
	542	Imipramine	17/03/92	27/04/92	VOMITING	20/03/92	Detail	7	21/03/92		1	3	3	1		3	3	3	1		
							Summary		21/03/92	7	1	3	3	1		3	3	3	1		YES
	543	Imipramine	18/03/92	28/04/92	MOUTH DRY	26/03/92	Detail	14	27/03/92		1	1	3	1		3	3	3	1		
							Summary		27/03/92	14	1	1	3	1		3	3	3	1		YES
7/07	529	Placebo	18/02/92	30/03/92	NAUSEA	07/03/92	Detail	21			2		2	1		2	3	3	3		
							Detail	28	19/03/92		1	2	5	1		3	3	3	1		
							Summary		19/03/92	28	2	2	2	1		2	3	3	1		YES
					SWEATING INCREASED	26/02/92	Detail	14			2	2	2	1		2	3	3	3		
							Detail	21			2	2	3	1		2	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20126/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
7/07	529	Placebo	18/02/92	30/03/92	SWEATING INCREASED	26/02/92	Detail	28			2	2	1	1	3	3	3	3	Y	
							Summary		31/03/92(*)	28	2	2	1	1	2	3	3	3	Y	YES
					VOMITING	07/03/92	Detail	21	18/03/92		2	2	4	1	2	3	3	1		
							Summary		18/03/92	21	2	2	4	1	2	3	3	1		YES
	530	Imipramine	29/02/92	09/03/92	ABDOMINAL PAIN	21/02/92	Detail	7	26/02/92		1	2	4	1	3	3	3	1		
							Summary		26/02/92	7	1	2	4	1	3	3	3	1		YES
						29/02/92	Detail	14			2	2	3	1	2	3	3	3		
							Detail	21	09/03/92		1	2	5	1	3	3	3	1		
							Summary		09/03/92	21	2	2	3	1	2	3	3	1		YES
					CHEST PAIN	26/02/92	Detail	7	28/02/92		1	2	2	1	3	3	3	1		
							Summary		28/02/92	7	1	2	2	1	3	3	3	1		YES
					CHEST PAIN PRECORDIAL	21/02/92	Detail	7			1	2	2	1	2	3	3	3		
							Detail	21	09/03/92		1		2	1	2	3	3	1		
							Summary		09/03/92	21	1	2	2	1	2	3	3	1		YES
					SWEATING INCREASED	21/02/92	Detail	7			2	2	3	1	2	3	3	3		
							Detail	14	03/03/92		3	2	1	3	2	2	1	1		
							Summary		03/03/92	14	3	2	1	3	2	2	1	1		YES
	532	Imipramine	27/04/92	07/06/92	VERTIGO	18/05/92	Detail	21			2	1	5	1	2	3	3	3		
							Detail	28	21/05/92				5	1		3	3	1		
							Summary		21/05/92	28	2	1	5	1	2	3	3	1		YES
	533	Reboxetine	04/05/92	14/06/92	URINARY RETENTION	09/05/92	Detail	7			1	2	2	1	2	3	3	3		
							Detail	14	14/05/92		1	2	2	1	2	3	3	1		
							Summary		14/05/92	14	1	2	2	1	2	3	3	1		YES
8	213	Imipramine	22/11/91	24/11/91	SUICIDE ATTEMPT	25/11/91	Detail	7	25/11/91				6	1	3	3	3	4	Y	
							Summary		25/11/91	7			6	1	3	3	3	4	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

1699

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28126/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic trea	Hospital	Disapp.	Reapp.	Outcome	Still present (C)	
8	233	Placebo	07/10/92	17/11/92	CONSTIPATION	18/10/92	Detail	14	20/10/92		1	1	5	1		2	3	3	1		
							Summary		20/10/92	14	1	1	5	1		2	3	3	1		YES
8/A	237	Reboxetine	14/10/92	26/11/92	VISION ABNORMAL	18/10/92	Detail	7	18/10/92		1	2	4	1		2	3	3	1		
							Summary		18/10/92	7	1	2	4	1		2	3	3	1		YES
	555	Reboxetine	16/10/92	26/11/92	ASTHENIA	19/10/92	Detail	7	21/10/92		2	1	3	1		2	3	3	1		
							Summary		21/10/92	7	2	1	3	1		2	3	3	1		YES
9	241	Placebo	07/02/91	17/02/91	AGITATION	12/02/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			3	2	3	3		3	3	3	3	Y	
							Summary		18/02/91(*)	14	3	2	3	3		3	3	3	3	Y	YES
					HYPERKINESIA	12/02/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			3	2	3	3		3	3	3	3	Y	
							Summary		18/02/91(*)	14	3	2	3	3		3	3	3	3	Y	YES
	242	Reboxetine	18/02/91	11/03/91	CONSTIPATION	19/02/91	Detail	7			2	1	4	1		3	3	3	3	Y	
							Summary		11/03/91(*)	7	2	1	4	1		3	3	3	3	Y	YES
					FLATULENCE	26/02/91	Detail	14			3	1	4	1	YES	3	3	3	3		
							Detail	21			3	1	4	1	YES	3	3	3	3	Y	
							Summary		11/03/91(*)	21	3	1	4	1	YES	3	3	3	3	Y	YES
					MOUTH DRY	28/02/91	Detail	14			2	1	4	1		3	3	3	3		
							Detail	21			2	1	4	1		3	3	3	3	Y	
							Summary		11/03/91(*)	21	2	1	4	1		3	3	3	3	Y	YES
					VERTIGO	25/02/91	Detail	7	25/02/91		1	1	4	1		3	3	3	1		
							Summary		25/02/91	7	1	1	4	1		3	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(c)
9	243	Reboxetine	28/02/91	06/03/91	AGITATION	26/02/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			3	2	3	1		3	3	3	3	Y	
							Summary		06/03/91(*)	14	3	2	3	1		3	3	3	3	Y	YES
					INSOMNIA	25/02/91	Detail	7			2	2	4	1		3	3	3	3		
							Detail	14			3		4	1		3	3	3	3	Y	
							Summary		06/03/91(*)	14	3	2	4	1		3	3	3	3	Y	YES
					MOUTH DRY	22/02/91	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3	Y	
							Summary		06/03/91(*)	14	1	2	3	1		3	3	3	3	Y	YES
	244	Imipramine	19/02/91	13/03/91	CONJUNCTIVITIS	20/02/91	Detail	7			1	2	5	1		3	3	3	3		
							Detail	14	04/03/91		1	2	5	1		3	3	3	1		
							Summary		04/03/91	14	1	2	5	1		3	3	3	1		YES
					DUODENAL ULCER REACTIVATE	27/02/91	Detail	14			2	1	5	1	YES	3	3	3	3	Y	
							Summary		13/03/91(*)	14	2	1	5	1	YES	3	3	3	3	Y	YES
					EXTRASYSTOLES	11/03/91	Detail	21			2	2	3	1		3	3	3	3	Y	
							Summary		13/03/91(*)	21	2	2	3	1		3	3	3	3	Y	YES
					TREMOR	22/02/91	Detail	7			2	3	4	1		3	3	3	3		
							Detail	21			1	3	4	1		3	3	3	3	Y	
							Summary		13/03/91(*)	21	2	3	4	1		3	3	3	3	Y	YES
	245	Imipramine	22/02/91	04/04/91	DIZZINESS	10/03/91	Detail	21			1	2	4	1		3	3	3	3		
							Detail	28	17/03/91		1	2	4	1		3	3	3	1		
							Summary		17/03/91	28	1	2	4	1		3	3	3	1		YES
					NAUSEA	03/04/91	Detail	42			1	2	4	1		2	3	3	3	Y	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: and date = visit date
(Q) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
9	245	Imipramine	22/02/91	04/04/91	NAUSEA	03/04/91	Summary		05/04/91(*)	42	1	2	4	1		2	3	3	3	Y	YES
	246	Placebo	22/02/91	17/03/91	BRADYCARDIA	14/03/91	Detail	28	18/03/91		3	2	2	3		3	2	3	1		
							Summary		18/03/91	28	3	2	2	3		3	2	3	1		YES
	247	Placebo	25/02/91	26/03/91	NAUSEA	14/03/91	Detail	21			1	2	4	1		3	3	3	3		
							Detail	28	24/03/91		1	2	4	1		3	3	3	1		
							Summary		24/03/91	28	1	2	4	1		3	3	3	1		YES
	248	Placebo	07/03/91	21/03/91	AGITATION	16/03/91	Detail	14			3	2	2	3		3	2		3	Y	
							Summary		22/03/91(*)	14	3	2	2	3		3	2		3	Y	YES
	250	Imipramine	12/03/91	08/04/91	CONSTIPATION	11/03/91	Detail	0													
							Summary		08/04/91(*)	0											NO
					DYSPEPSIA	01/04/91	Detail	21	02/04/91		1	3	5	1		3	3	3	1		
							Summary		02/04/91	21	1	3	5	1		3	3	3	1		YES
					NAUSEA	01/04/91	Detail	21	02/04/91		2	3	5	1		3	3	3	1		
							Summary		02/04/91	21	2	3	5	1		3	3	3	1		YES
	251	Imipramine	20/03/91	12/04/91	MOUTH DRY	23/03/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			2	2	3	1		3	3	3	3		
							Detail	21			2	2	3	1		3	3	3	3		
							Detail	28			2	2	3	1		3	3	3	3	Y	
							Summary		12/04/91(*)	28	2	2	3	1		3	3	3	3	Y	YES
					TREMOR	23/03/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			2	2	3	1		3	3	3	3		
							Detail	21			2	2	3	1		3	3	3	3		
							Detail	28			2	2	3	1		3	3	3	3	Y	
							Summary		12/04/91(*)	28	2	2	3	1		3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
9	252	Reboxetine	02/04/91	28/04/91	AGITATION	10/04/91	Detail	14			3	2	3	1		3	3	3	3		
							Detail	21			3	2	3	2		3	1	3	3	Y	
							Summary		20/04/91(*)	21	3	2	3	2		3	1	3	3	Y	YES
					HEADACHE	08/04/91	Detail	7	10/04/91		2	1	4	1		3	3	3	1		
							Detail	14	10/04/91		2	1	4	1		3	3	3	1		
							Summary		10/04/91	14	2	1	4	1		3	3	3	1		YES
					MOUTH DRY	10/04/91	Detail	14			1	2	4	1		3	3	3	3		
							Detail	21			1	2	3	2		3	1	3	3	Y	
							Summary		28/04/91(*)	21	1	2	3	2		3	1	3	3	Y	YES
					MUSCLE CONTRACTIONS INVOL	16/04/91	Detail	21			2	2	3	2		3	1	3	3	Y	
							Summary		28/04/91(*)	21	2	2	3	2		3	1	3	3	Y	YES
					TREMOR	10/04/91	Detail	14			1	2	4	1		3	3	3	3		
							Detail	21			1	2	3	2		3	1	3	3	Y	
							Summary		28/04/91(*)	21	1	2	3	2		3	1	3	3	Y	YES
	253	Reboxetine	02/04/91	08/04/91	AGITATION	04/04/91	Detail	7			3	2	3	3		3	2	3	3	Y	
							Summary		08/04/91(*)	7	3	2	3	3		3	2	3	3	Y	YES
	254	Imipramine	09/04/91	16/04/91	INSOMNIA	10/04/91	Detail	7			3	1	3	1	YES	3	3	3	3		
							Detail	14			3	1	3	3		3	3	3	3	Y	
							Summary		17/04/91(*)	14	3	1	3	3	YES	3	3	3	3	Y	YES
					MOUTH DRY	10/04/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			2	2	3	3		3	3	3	3	Y	
							Summary		17/04/91(*)	14	2	2	3	3		3	3	3	3	Y	YES
					TREMOR		Detail	0			2										

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic trea	Hosp	Disapp.	Reapp.	Outcome	Still present	(C)
9	254	Imipramine	09/04/91	16/04/91	TREMOR	04/04/91(@)	Summary		17/04/91(*)	8	2										NO
						10/04/91	Detail	7			3	1	3	1		3	3	3	3		
							Detail	14			3	1	3	3		3	3	3	3	Y	
							Summary		17/04/91(*)	14	3	1	3	3		3	3	3	3	Y	YES
	255	Reboxetine	13/05/91	06/06/91	AGITATION	21/05/91	Detail	14			3	2	3	1		3	3	3	3		
							Detail	21			3	2	3	1		3	3	3	3		
							Detail	28			3	2	3	1		3	3	3	3	Y	
							Summary		06/06/91(*)	28	3	2	3	1		3	3	3	3	Y	YES
					CONSTIPATION	23/05/91	Detail	14			2	1	4	1		3	3	3	3		
							Detail	21	04/06/91		2	1	4	1		3	3	3	1		
							Summary		04/06/91	21	2	1	4	1		3	3	3	1		YES
					MOUTH DRY	21/05/91	Detail	28			3	2	3	1		3	3	3	3	Y	
							Summary		06/06/91(*)	28	3	2	3	1		3	3	3	3	Y	YES
						23/05/91	Detail	14			2	2	3	1		3	3	3	3		
							Detail	21			2	2	3	1		3	3	3	3		
							Detail	28			2	2	3	1		3	3	3	3	Y	
							Summary		06/06/91(*)	28	2	2	3	1		3	3	3	3	Y	YES
					MYDRIASIS	24/05/91	Detail	14			1	2	4	1		3	3	3	3		
							Detail	28			1	2	4	1		3	3	3	3	Y	
							Summary		06/06/91(*)	28	1	2	4	1		3	3	3	3	Y	YES
					PYURIA	03/06/91	Detail	28			1	3	6	1		3	3	3	3	Y	
							Summary		06/06/91(*)	28	1	3	6	1		3	3	3	3	Y	YES
	256	Imipramine	27/05/91	08/07/91	CONSTIPATION	26/06/91	Detail	35			2	1	3	2	YES	3	3	3	3		
							Detail	42			2	1	3	2	YES	3	1	3	3	Y	
							Summary		08/07/91(*)	42	2	1	3	2	YES	3	1	3	3	Y	YES
					DYSPEPSIA	01/07/91	Detail	35			2	3	5	2	YES	3	3	3	3		
							Detail	42			2	3	5	2	YES	3	3	3	3	Y	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/815
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(c)
9	256	Imipramine	27/05/91	08/07/91	DYSPEPSIA	01/07/91	Summary		08/07/91(*)	42	2	3	5	2	YES	3	3	3	3	Y	YES
					HYPOTENSION	04/06/91	Detail	14	04/06/91		1	2	3	1		3	3	3	1		
							Summary		04/06/91	14	1	2	3	1		3	3	3	1		YES
					HYPOTENSION POSTURAL	01/07/91	Detail	35			2	3	3	2	YES	3	3	3	3		
							Detail	42			2	3	3	2	YES	3	3	3	3	Y	
							Summary		08/07/91(*)	42	2	3	3	2	YES	3	3	3	3	Y	YES
					INSOMNIA	29/05/91	Detail	7			2	1	4	1	YES	3	3	3	3		
							Detail	28			3	2	3	2	YES	3	1	3	3		
							Detail	42			2	1	4	2	YES	3	1	3	3	Y	
							Summary		08/07/91(*)	42	3	1	3	2	YES	3	1	3	3	Y	YES
					MOUTH DRY	29/05/91	Detail	7			2	2	3	1		2	3	3	3		
							Detail	42			2	2	3	2		3	1	3	3	Y	
							Summary		08/07/91(*)	42	2	2	3	2		2	1	3	3	Y	YES
					SWEATING INCREASED	29/05/91	Detail	7			1	2	3	1		3	3	3	3		
							Detail	42	04/06/91		1	2	3	1		3	3	3	1		
							Summary		04/06/91	42	1	2	3	1		3	3	3	1		YES
					TREMOR	04/06/91	Detail	14			3	2	2	2		3	2	3	3		
							Detail	21			1	2	3	2		3	2	3	3		
							Detail	28			2	2	2	2		3	2	2	3		
							Detail	42			3	2	2	1		3	3	3	3	Y	
							Summary		08/07/91(*)	42	3	2	2	2		3	3	3	3	Y	YES
	258	Placebo	01/07/91	10/07/91	AGITATION	02/07/91	Detail	7			1	2	4	1		3	3	3	3		
							Detail	14			1	2	4	1		3	3	3	3	Y	
							Summary		10/07/91(*)	14	1	2	4	1		3	3	3	3	Y	YES
11	319	Placebo	02/08/91	12/09/91	ANOREXIA		Detail	8			1										

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
11	319	Placebo	02/08/91	12/09/91	ANOREXIA	24/07/91(D)	Summary		12/09/91(*)	0	1										NO
					INSOMNIA		Detail	0			2										
						24/07/91(D)	Summary		12/09/91(*)	0	2										NO
	320	Imipramine	17/08/91	26/09/91	CHEST PAIN		Detail	0			1										
						07/08/91(D)	Summary		26/09/91(*)	0	1										NO
					CONSTIPATION	16/08/91	Detail	7			1	2	2	1		2	3	3	3	Y	
							Summary		26/09/91(*)	7	1	2	2	1		2	3	3	3	Y	YES
					DIZZINESS	25/08/91	Detail	14			2	2	2	1		2	3	3	3		
							Detail	21	30/08/91		2	2	2	1		2	3	3	1		
							Summary		30/08/91	21	2	2	2	1		2	3	3	1		YES
					INSOMNIA		Detail	0			3										
						07/08/91(D)	Summary		26/09/91(*)	0	3										NO
					MOUTH DRY	16/08/91	Detail	7			1	2	2	1		2	3	3	3	Y	
							Summary		26/09/91(*)	7	1	2	2	1		2	3	3	3	Y	YES
					SWEATING INCREASED		Detail	0			1										
						07/08/91(D)	Summary		26/09/91(*)	0	1										NO
	321	Placebo	06/09/91	17/10/91	CONSTIPATION	18/09/91	Detail	21			1	2	2	1		2	3	3	3	Y	
							Summary		17/10/91(*)	21	1	2	2	1		2	3	3	3	Y	YES
					VISION ABNORMAL	15/09/91	Detail	14			1	2	2	1		2	3	3	3	Y	
							Summary		17/10/91(*)	14	1	2	2	1		2	3	3	3	Y	YES
	322	Reboxetine	27/09/91	07/11/91	CONSTIPATION	26/09/91	Detail	7			2	2	2	1		2	3	3	3	Y	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observa bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship drug	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(c)
11	322	Reboxetine	27/09/91	07/11/91	CONSTIPATION	28/09/91	Summary		07/11/91(*)	7	2	2	2	1		2	3	3	5	Y	YES
					INSOMNIA	01/11/91	Detail	42	04/11/91						YES						
							Summary		04/11/91	42					YES						YES
					VISION ABNORMAL	01/10/91	Detail	14	12/10/91		1	2	2	1		2	3	3	1		
							Summary		12/10/91	14	1	2	2	1		2	3	3	1		YES
	325	Reboxetine	15/11/91	26/12/91	MYDRIASIS	15/11/91	Detail	7	19/11/91		1	2	3	1		2	3	3	1		
							Summary		19/11/91	7	1	2	3	1		2	3	3	1		YES
					SWEATING INCREASED	15/11/91	Detail	7	88/12/91		1	1	3	1		2	3	3	1		
							Summary		88/12/91	7	1	1	3	1		2	3	3	1		YES
	324	Imipramine	06/12/91	15/01/92	CONSTIPATION	28/12/91	Detail	21	26/12/91		1	2	2	1		2	3	3	1		
							Summary		26/12/91	21	1	2	2	1		2	3	3	1		YES
					INSOMNIA	03/01/92	Detail	35	08/01/92						YES						
							Summary		08/01/92	35					YES						YES
					TREMOR	14/12/91	Detail	14			1	2	3	1		2	3	3	3		
							Detail	35												Y	
							Detail	42													
							Summary		15/01/92(*)	42	1	2	3	1		2	3	3		Y	YES
	327	Imipramine	30/01/92	05/02/92	DYSURIA	31/01/92	Detail	7	02/02/92		1	2	3	1		2	3	3	1		
							Summary		02/02/92	7	1	2	3	1		2	3	3	1		YES
	328	Imipramine	31/01/92	04/02/92	VERTIGO	02/02/92	Detail	7	04/02/92		2	2	2	1		2	3	3	1		
							Summary		04/02/92	7	2	2	2	1		2	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(9) onset date missing: first report visit date used
(8) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20126/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relship	Stud drug	Symp trea	Hosp	Dis app.	Ra app.	Out come	Still present	(c)
11	329	Placebo	10/04/92	21/05/92	ABDOMINAL PAIN	13/04/92	Detail	7	18/04/92		2	2	3	1		2	3	3	1		
							Summary		18/04/92	7	2	2	3	1		2	3	3	1		YES
	330	Reboxetine	09/04/92	21/05/92	MOUTH DRY	11/04/92	Detail	7	20/04/92		1	2	2	1		2	3	3	1		
							Summary		20/04/92	7	1	2	2	1		2	3	3	1		YES
	331	Imipramine	17/04/92	28/05/92	SOMNOLENCE	17/04/92	Detail	7			1	2	2	1		2	3	3		Y	
							Summary		28/05/92(*)	7	1	2	2	1		2	3	3		Y	YES
	332	Reboxetine	19/05/92	29/06/92	MOUTH DRY	29/05/92	Detail	7	03/06/92		1	2	2	1		2	3	3	1		
							Summary		03/06/92	7	1	2	2	1		2	3	3	1		YES
	333	Placebo	27/05/92	07/07/92	RHINITIS	28/05/92	Detail	7	02/06/92		1	1	4	1		2	3	3	1		
							Summary		02/06/92	7	1	1	4	1		2	3	3	1		YES
					SOMNOLENCE	17/06/92	Detail	28	25/06/92		1	2	2	1		2	3	3	1		
							Summary		25/06/92	28	1	2	2	1		2	3	3	1		YES
	334	Reboxetine	29/05/92	31/05/92	CHEST PAIN	29/05/92	Detail	7			3	1	2	3		2	2	3	3	Y	
							Summary		01/06/92(*)	7	3	1	2	3		2	2	3	3	Y	YES
					DIZZINESS	29/05/92	Detail	7			2	2	2	3		2	2	3	3	Y	
							Summary		01/06/92(*)	7	2	2	2	3		2	2	3	3	Y	YES
					PARAESTHESIA	29/05/92	Detail	7			2		2	3		2	2	3	3	Y	
							Summary		01/06/92(*)	7	2		2	3		2	2	3	3	Y	YES
					SWEATING INCREASED	29/05/92	Detail	7			2	1	2	3		2	2	3	3	Y	
							Summary		01/06/92(*)	7	2	1	2	3		2	2	3	3	Y	YES
	337	Reboxetine	02/07/92	13/08/92	MOUTH DRY	03/07/92	Detail	7	30/07/92		1	2	2	1		2	3	3	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
11	337	Reboxetine	02/07/92	13/08/92	MOUTH DRY	03/07/92	Summary		30/07/92	7	1	2	2	1		2	3	3	1		YES
12	367	Reboxetine	20/12/91	30/01/92	MOUTH DRY	19/12/91	Detail	0			1										
							Detail	7			1	1	4	1		3	3	3	3		
							Detail	14			2	1	1	1		3	3	3	3		
							Detail	21			2		4	1		2	3	3	3		
							Detail	28			2		1	1		2	3	3	3		
							Detail	35			1	1	4	1		2	3	3	3		
							Detail	42			1	1	4	1		2	3	3	3	Y	
							Summary		31/01/92(*)	42	2	1	1	1		2	3	3	3	Y	YES
	368	Placebo	24/12/91	03/02/92	CHEST PAIN PRECORDIAL	05/01/92	Detail	14	06/01/92		1	2	4	1	YES	3	3	3	1		
							Summary		06/01/92	14	1	2	4	1	YES	3	3	3	1		YES
					CHROMATOPSIA	13/01/92	Detail	21	13/01/92		1	2	6	1		3	3	3	1		
							Summary		13/01/92	21	1	2	6	1		3	3	3	1		YES
					MOUTH DRY	02/01/92	Detail	14			1	2	4	1		3	3	3	3		
							Detail	21	14/01/92		1	3	3	1		3	3	3	1		
							Summary		14/01/92	21	1	2	3	1		3	3	3	1		YES
	369	Imipramine	23/04/92	13/05/92	CONSTIPATION	22/04/92	Detail	7	27/04/92		1	1	3	1		2	3	3	1		
							Summary		27/04/92	7	1	1	3	1		2	3	3	1		NO
					DYSPEPSIA	25/04/92	Detail	7	25/04/92		1	2	3	1		3	3	1	1		
							Summary		25/04/92	7	1	2	3	1		3	3	1	1		YES
					MOUTH DRY	25/04/92	Detail	7	27/04/92		1	2	2	1		3	3	3	1		
							Summary		27/04/92	7	1	2	2	1		3	3	3	1		YES
					SWEATING INCREASED	06/05/92	Detail	14	06/05/92		2	2	4	1		2	3	3	1		
							Summary		06/05/92	14	2	2	4	1		2	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

1602

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present (C)
12	370	Placebo	29/04/92	20/05/92	FLUSHING	23/04/92	Detail	0			1									
							Summary		20/05/92(*)	0	1									NO
					HEADACHE	13/05/92	Detail	21	13/05/92		2	1	5	1	2	3	3	1		
							Summary		13/05/92	21	2	1	5	1	2	3	3	1		YES
					MYALGIA	29/04/92	Detail	7	29/04/92		1	2	5	1	3	3	3	1		
							Summary		29/04/92	7	1	2	5	1	3	3	3	1		YES
					OEDEMA LEGS	09/04/92	Detail	0			1									
							Summary		20/05/92(*)	0	1									NO
					PALPITATION	13/05/92	Detail	21	13/05/92		1	2	6	1	2	3	3	1		
							Summary		13/05/92	21	1	2	6	1	2	3	3	1		YES
					TREMOR	29/04/92	Detail	7	29/04/92		1	2	5	1	3	3	3	1		
							Summary		29/04/92	7	1	2	5	1	3	3	3	1		YES
					URINARY RETENTION	29/04/92	Detail	7	29/04/92		1	2	5	1	3	3	3	1		
							Summary		29/04/92	7	1	.2	5	1	3	3	3	1		YES
	371	Imipramine	01/05/92	06/05/92	FURUNCULOSIS	16/04/92	Detail	0			1									
							Summary		08/05/92(*)	0	1									NO
					HEADACHE	17/04/92	Detail	0			2									
							Summary		08/05/92(*)	0	2									NO
					MOUTH DRY	01/05/92	Detail	7			2	2	3	1	3	3	3	3	Y	
							Summary		08/05/92(*)	7	2	2	3	1	3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with sea., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(0) onset date missing: first report visit date used
(8) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
12	371	Imipramine	01/05/92	06/05/92	RHINITIS	22/04/92	Detail	0			2										
							Summary		06/05/92(*)	0	2										NO
	372	Reboxetine	02/06/92	13/07/92	CONSTIPATION	04/06/92	Detail	7			1	2	3	1		3	3	3	3	Y	
							Summary		13/07/92(*)	7	1	2	3	1		3	3	3	3	Y	YES
					HYPERTENSION	02/06/92	Detail	7			2	2	6	1	YES	3	3	3	3	Y	
							Summary		13/07/92(*)	7	2	2	6	1	YES	3	3	3	3	Y	YES
					INSOMNIA	04/06/92	Detail	7			2	2	3	1	YES	3	3	3	3		
							Detail	28			1	1	3	1	YES	3	3	3	3	Y	
							Summary		13/07/92(*)	28	2	1	3	1	YES	3	3	3	3	Y	YES
					MIGRAINE	02/06/92	Detail	0			2										
							Detail	7	03/06/92		3	1	6	1	YES	3	3	3	1		
							Summary		03/06/92	7	3	1	6	1	YES	3	3	3	1		YES
					MOUTH DRY	04/06/92	Detail	7			1	2	3	1		3	3	3	3	Y	
							Summary		13/07/92(*)	7	1	2	3	1		3	3	3	3	Y	YES
					NAUSEA	02/06/92	Detail	7	03/06/92		2	1	6	1	YES	3	3	3	1		
							Summary		03/06/92	7	2	1	6	1	YES	3	3	3	1		YES
					VOMITING	02/06/92	Detail	0			3										
							Detail	7	03/06/92		2	1	6	1		3	3	3	1		
							Summary		03/06/92	7	3	1	6	1		3	3	3	1		YES
	373	Reboxetine	05/06/92	14/07/92	CONSTIPATION	08/06/92	Detail	7	10/06/92		1	2	3	1		3	3	3	1		
							Summary		10/06/92	7	1	2	3	1		3	3	3	1		YES
						08/07/92	Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		14/07/92(*)	42	1	2	3	1		3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with sse., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(E) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/015
Listing No.: 17.6

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
12	373	Reboxetine	05/06/92	14/07/92	DIZZINESS	16/06/92	Detail	14	16/06/92		1	2	4	1	3	3	3	1			
							Summary		16/06/92	14	1	2	4	1	3	3	3	1			YES
					DYSURIA	18/06/92	Detail	7	18/06/92		1	2	4	1	3	3	3	1			
							Summary		18/06/92	7	1	2	4	1	3	3	3	1			YES
					HEADACHE	26/06/92	Detail	28	30/06/92		2	2	6	1	3	3	3	1			
							Summary		30/06/92	28	2	2	6	1	3	3	3	1			YES
					INSOMNIA	07/06/92	Detail	7			2	1	4	1	3	3	3	3			
							Detail	14	12/06/92		2	1	4	1	3	3	3	1			
							Summary		12/06/92	14	2	1	4	1	3	3	3	1			YES
					MICTURITION DISORDER	25/06/92	Detail	21			1	2	4	1	3	3	3	3	Y		
							Summary		16/07/92(*)	21	1	2	4	1	3	3	3	3	Y		YES
					MOUTH DRY	05/06/92	Detail	7			1	2	3	1	3	3	3	3	Y		
							Summary		16/07/92(*)	7	1	2	3	1	3	3	3	3	Y		YES
					PERINEAL PAIN MALE	18/06/92	Detail	7			1	2	4	1	3	3	3	3			
							Detail	42	14/07/92		1	2	4	1	3	3	3	1			
							Summary		14/07/92	42	1	2	4	1	3	3	3	1			YES
					TREMOR	11/06/92	Detail	7			1	2	3	1	3	3	3	3			
							Detail	21	28/06/92		1	2	3	1	3	3	3	1			
							Summary		28/06/92	21	1	2	3	1	3	3	3	1			YES
					VISION ABNORMAL	16/06/92	Detail	14	16/06/92		1	2	3	1	3	3	3	1			
							Summary		16/06/92	14	1	2	3	1	3	3	3	1			YES
						02/07/92	Detail	35			1	2	3	1	3	3	3	3	Y		
							Summary		16/07/92(*)	35	1	2	3	1	3	3	3	3	Y		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(8) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(c)
12	374	Placebo	09/06/92	05/07/92	SWEATING INCREASED	18/06/92	Detail	7	10/06/92		2	2	4	1	3	3	3	1			
							Summary		10/06/92	7	2	2	4	1	3	3	3	1			YES
	375	Imipramine	17/06/92	18/06/92	HEADACHE	15/06/92	Detail	0			2										
							Summary		18/06/92(*)	0	2										NO
					SUICIDE ATTEMPT	18/06/92	Detail	7	18/06/92		2	2	3	3	1	2	3	1			
							Summary		18/06/92	7	2	2	3	3	1	2	3	1			YES
					VISION ABNORMAL	18/06/92	Detail	7	28/06/92		2	2	4	3	1	2	3	1			
							Summary		28/06/92	7	2	2	4	3	1	2	3	1			YES
13	13	Placebo	13/04/91	24/05/91	HEADACHE	17/04/91	Detail	7			2	2	4	1	3	3	3	3			
							Detail	14	25/04/91		2	2	4	1	3	3	3	1			
							Summary		25/04/91	14	2	2	4	1	3	3	3	1			YES
	14	Placebo	02/07/91	13/08/91	CONCENTRATION IMPAIRED		Detail	0			2										
						01/07/91(2)	Summary		13/08/91(*)	0	2										NO
					DIZZINESS	05/07/91	Detail	7			1	2	3	1	2	3	3	3			
							Detail	14			2	3	3	1	2	3	3	3			
							Detail	21			2	3	3	1	2	3	3	3			
							Detail	28	29/07/91		2	3	3	1	2	3	3	1			
							Summary		29/07/91	28	2	2	3	1	2	3	3	1			YES
					FATIGUE	09/07/91	Detail	14			2	3	3	1	2	3	3	3			
							Detail	21	22/07/91		2	3	3	1	3	3	3	1			
							Summary		22/07/91	21	2	3	3	1	2	3	3	1			YES
					SOMNOLENCE		Detail	0			2										
						01/07/91(2)	Summary		13/08/91(*)	0	2										NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(2) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
13	14	Placebo	02/07/91	13/08/91	SWEATING INCREASED	07/07/91	Detail	42			2	3	2	1		3	3	3	3	Y	
							Summary		13/08/91(*)	42	2	3	2	1		3	3	3	3	Y	YES
	15	Imipramine	05/07/91	15/08/91	AGITATION	11/07/91	Detail	28			2	3	3	1		3	3	3	3		
							Detail	42			2	3	2	1		3	3	3	3	Y	
							Summary		15/08/91(*)	42	2	3	2	1		3	3	3	3	Y	YES
					HEADACHE	06/07/91	Detail	7			1	3	3	1	YES	3	3	3	3	Y	
							Summary		15/08/91(*)	7	1	3	3	1	YES	3	3	3	3	Y	YES
					INFECTION FUNGAL	01/07/91	Detail	14							YES					Y	
							Summary		15/08/91(*)	14					YES					Y	NO
					MOUTH DRY	07/07/91	Detail	7			2	1	2	1		3	3	3	3		
							Detail	14			2	1	3	1		3	3	3	3		
							Detail	35			2	1	2	1		3	3	3	3		
							Detail	42			2	3	2	1		3	3	3	3	Y	
							Summary		15/08/91(*)	42	2	1	2	1		3	3	3	3	Y	YES
					NAUSEA	05/07/91	Detail	7			1	2	3	1		2	3	3	3	Y	
							Summary		15/08/91(*)	7	1	2	3	1		2	3	3	3	Y	YES
					RHINITIS	06/07/91	Detail	7			2	2	4	1	YES	2	3	3	3	Y	
							Summary		15/08/91(*)	7	2	2	4	1	YES	2	3	3	3	Y	YES
					SWEATING INCREASED	11/07/91	Detail	35			2	1	2	1		3	3	3	3		
							Detail	42			2	3	3	1		3	3	3	3	Y	
							Summary		15/08/91(*)	42	2	1	2	1		3	3	3	3	Y	YES
					TREMOR	08/07/91	Detail	21			2	1	2	1		3	3	3	3	Y	
							Summary		15/08/91(*)	21	2	1	2	1		3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20126/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
13	16	Imipramine	03/12/91	16/01/92	AGITATION		Detail	7			2	1	4	4	2	1	3	3			
							Detail	21	30/12/91		1	1	5	1	2	3	3	1			
						03/12/91(S)	Summary		30/12/91	21	2	1	3	4	2	3	3	1			YES
					HOT FLUSHES	04/12/91	Detail	7			3	2	3	4	2	1	3	3			
							Detail	21	30/12/91		1	2	3	1	2	3	3	1			
							Summary		30/12/91	21	3	2	3	4	2	3	3	1			YES
						02/01/92	Detail	28			2	1	3	1	2	3	3	3			
							Detail	42			2	1	2	3	2	1	3	3	Y		
							Summary		28/01/92(*)	42	2	1	2	3	2	1	3	3	Y		YES
					NAUSEA	04/12/91	Detail	7			2	2	4	4	2	1	3	3			
							Detail	21	05/12/91		1	2	2	1	2	3	3	1			
							Summary		05/12/91	21	2	2	2	4	2	3	3	1			YES
						14/01/92	Detail	42			3	2	3	3	2	1	3	3	Y		
							Summary		28/01/92(*)	42	3	2	3	3	2	1	3	3	Y		YES
					SWEATING INCREASED	30/12/91	Detail	28			2	3	3	1	2	3	3	3			
							Detail	42			2	1	2	3	2	1	3	3	Y		
							Summary		28/01/92(*)	42	2	1	2	3	2	1	3	3	Y		YES
	17	Reboxetine	21/05/92	01/07/92	AGITATION	09/06/92	Detail	21			2	1	3	1	2	3	3	3			
							Detail	28	17/06/92		2	1	3	1	2	3	3	1			
							Summary		17/06/92	28	2	1	3	1	2	3	3	1			YES
						29/06/92	Detail	42			2	1	3	1	2	3	3	3	Y		
							Summary		02/07/92(*)	42	2	1	3	1	2	3	3	3	Y		YES
					HEADACHE	23/05/92	Detail	7			1	1	3	1	2	3	3	3			
							Detail	21			2	1	3	1	2	3	3	3			
							Detail	28	17/06/92		2	1	3	1	2	3	3	1			
							Summary		17/06/92	28	2	1	3	1	2	3	3	1			YES
					MOUTH DRY	22/05/92	Detail	7			2	1	3	1	2	3	3	3	Y		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Disapp.	Reapp.	Outcome	Still present	(c)
13	17	Reboxetine	21/05/92	01/07/92	MOUTH DRY	22/05/92	Summary		02/07/92(*)	7	2	1	3	1		2	3	3	3	Y	YES
	18	Reboxetine	24/06/92	02/08/92	AGITATION	13/07/92	Detail	28			1	1	3	1		2	3	3	3		
							Detail	42	03/08/92		1	1	3	1		3	3	3	1		
							Summary		03/08/92	42	1	1	3	1		2	3	3	1		YES
					DIZZINESS	27/02/92	Detail	42			1	1	3	1		2	3	3	3	Y	
							Summary		03/08/92(*)	42	1	1	3	1		2	3	3	3	Y	NO
					INFLUENZA-LIKE SYMPTOMS	22/07/92	Detail	35	26/07/92						YES						
							Summary		26/07/92	35					YES						YES
					NAUSEA	10/06/92	Detail	0			2										
							Detail	7			2	1	4	1		2	3	3	3		
							Detail	14	06/07/92		2	1	4	1		2	3	3	1		
							Summary		06/07/92	14	2	1	4	1		2	3	3	1		NO
	409	Reboxetine	18/12/91	20/01/92	MICTURITION DISORDER	02/01/92	Detail	28			1	2	3	1		2	3	3	3	Y	
							Summary		20/01/92(*)	28	1	2	3	1		2	3	3	3	Y	YES
					SWEATING INCREASED	11/12/91	Detail	7			2	3	3	1		2	3	3	3		
							Detail	14	20/12/91		2	2	3	1		2	3	3	1		
							Summary		20/12/91	14	2	2	3	1		2	3	3	1		YES
	410	Placebo	14/02/92	26/03/92	AGITATION	21/02/92	Detail	14			2	1	2	1		2	3	3	3		
							Detail	35	19/03/92		1	1	2	1		2	3	3	1		
							Summary		19/03/92	35	2	1	2	1		2	3	3	1		YES
					NAUSEA		Detail	0			2										
							Detail	7			2	1	2	1		2	3	3	3	Y	
						09/02/92(@)	Summary		26/03/92(*)	7	2	1	2	1		2	3	3	3	Y	NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observa bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/015
Listing No.: 17.6

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
13	410	Placebo	14/02/92	26/03/92	RHINITIS	11/02/92	Detail	0			2										
							Detail	7			2	1	2	1	YES	2	3	3	3		
							Detail	14	27/02/92		2	1	3	1		2	3	3	1		
							Summary		27/02/92	14	2	1	2	1	YES	2	3	3	1		NO
					SOMNOLENCE	13/03/92	Detail	35			2	1	3	1		2	3	3	3	Y	
							Summary		26/03/92(*)	35	2	1	3	1		2	3	3	3	Y	YES
	411	Imipramine	28/03/92	08/05/92	ASTHENIA	13/04/92	Detail	21			2	1	3	1		3	3	3	3	Y	
							Summary		11/05/92(*)	21	2	1	3	1		3	3	3	3	Y	YES
					CONCENTRATION IMPAIRED	22/04/92	Detail	28			2	3	3	1		3	3	3	3		
							Detail	42			2	3	3	1		3	3	3	3	Y	
							Summary		11/05/92(*)	42	2	3	3	1		3	3	3	3	Y	YES
					CONSTIPATION	06/04/92	Detail	14			2	2	3	1	YES	3	3	3	3	Y	
							Summary		11/05/92(*)	14	2	2	3	1	YES	3	3	3	3	Y	YES
					FATIGUE	13/04/92	Detail	21			2	1	3	1		3	3	3	3	Y	
							Summary		11/05/92(*)	21	2	1	3	1		3	3	3	3	Y	YES
					HEADACHE	18/04/92	Detail	28			2	2	4	1	YES	3	3	3	3	Y	
							Summary		11/05/92(*)	28	2	2	4	1	YES	3	3	3	3	Y	YES
					MICTURITION DISORDER	30/03/92	Detail	7			1	2	3	1		3	3	3	3		
							Detail	28			2	2	3	1		3	3	3	3	Y	
							Summary		11/05/92(*)	28	2	2	3	1		3	3	3	3	Y	YES
					MOUTH DRY		Detail	6			1										
							Detail	7			2	1	5	1		3	3	3	3		
							Detail	14			2		5	1		2	3	3	3		
						25/03/92(2)	Summary		13/04/92(*)	14	2	1	5	1		2	3	3	3		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(3) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
13	411	Imipramine	28/03/92	08/05/92	OEDEMA PERIPHERAL		Detail	0			1										
						25/03/92(D)	Summary		11/05/92(*)	0	1										NO
					SLEEP DISORDER		Detail	8			2										
							Detail	7	06/04/92		2	1	4	1		3	3	3	1		
						25/03/92(D)	Summary		06/04/92	7	2	1	4	1		3	3	3	1		NO
					VISION ABNORMAL	27/04/92	Detail	35			2	1	4	1		3	3	3	3	Y	
							Summary		11/05/92(*)	35	2	1	4	1		3	3	3	3	Y	YES
	425	Placebo	14/09/92	27/10/92	DIZZINESS	04/10/92	Detail	21	04/10/92		2	2	3	1		2	3	3	1		
							Summary		04/10/92	21	2	2	3	1		2	3	3	1		YES
14	19	Reboxetine	18/04/92	06/05/92	SWEATING INCREASED	18/04/92	Detail	14	24/04/92		1	2	3	1		3	3	3	1		
							Summary		24/04/92	14	1	2	3	1		3	3	3	1		YES
						25/04/92	Detail	21			1	2	2	1		3	3	3	3	Y	
							Detail	28												Y	
							Summary		07/05/92(*)	28	1	2	2	1		3	3	3		Y	YES
					URINARY TRACT INFECTION	04/04/92	Detail	7	15/04/92		2	3	6	1	YES	3	3	3	1		
							Summary		15/04/92	7	2	3	6	1	YES	3	3	3	1		NO
	20	Imipramine	29/04/92	09/06/92	AUTOLESIONIST BEHAVIOUR	30/04/92	Detail	7	30/04/92		1	2	6	4			3	3	1		
							Summary		30/04/92	7	1	2	6	4			3	3	1		YES
					DIZZINESS	29/04/92	Detail	7			1	2	2	1		3	3	3	3		
							Detail	14	10/05/92		1	2	2	1		3	3	3	1		
							Summary		10/05/92	14	1	2	2	1		3	3	3	1		YES
					MOUTH DRY	29/04/92	Detail	7			2	2	2	1		3	3	3	3	Y	
							Summary		10/06/92(*)	7	2	2	2	1		3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observa bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
14	20	Imipramine	29/04/92	09/06/92	SWEATING INCREASED	29/04/92	Detail	7			1	2	2	1	3	3	3	3			
							Detail	21			2	2	2	1	3	3	3	3			
							Detail	28			1	2	2	1	3	3	3	3			
							Detail	42	10/06/92		1	2	2	1	3	3	3	1			
							Summary		10/06/92	42	2	2	2	1	3	3	3	1			YES
						10/06/92	Detail	42			1	2	2	1	2	3	3	3	Y		
							Summary		10/06/92(*)	42	1	2	2	1	2	3	3	3	Y		YES
					TASTE LOSS	29/04/92	Detail	7			2	2	2	1	3	3	3	3			
							Detail	21	20/05/92		2	2	2	1	3	3	3	1			
							Summary		20/05/92	21	2	2	2	1	3	3	3	1			YES
					TREMOR	30/05/92	Detail	7			1	2	2	1	3	3	3	3			
							Detail	42	10/06/92		1		2	1	3	3	3	1			
							Summary		10/06/92	42	1	2	2	1	3	3	3	1			YES
	21	Imipramine	20/07/92	24/08/92	ABDOMINAL PAIN	21/07/92	Detail	7			1	2	2	1	3	3	3	3			
							Detail	21			1	2	3	1	3	3	3	3			
							Detail	35			1	2	2	1	3	3	3	3	Y		
							Summary		24/08/92(*)	35	1	2	2	1	3	3	3	3	Y		YES
					CONJUNCTIVITIS	28/07/92	Detail	21	10/08/92		1	2	2	1	3	3	3	1			
							Summary		10/08/92	21	1	2	2	1	3	3	3	1			YES
					CONSTIPATION	25/07/92	Detail	14	03/08/92		1	2	2	1	3	3	3	1			
							Summary		03/08/92	14	1	2	2	1	3	3	3	1			YES
					MOUTH DRY	24/07/92	Detail	14	02/08/92		2	2	2	1	3	3	3	1			
							Summary		02/08/92	14	2	2	2	1	3	3	3	1			YES
						03/08/92	Detail	14			1		2	1	3	3	3	3	Y		
							Summary		24/08/92(=)	14	1		2	1	3	3	3	3	Y		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Stud drug	Symp trea	Hosp	Dis app.	Ra app.	Out come	Still present	(C)
14	21	Imipramine	28/07/92	24/08/92	SOMNOLENCE	23/07/92	Detail	14	01/08/92		1	2	2	1		3	3	3	1		
							Summary		01/08/92	14	1	2	2	1		3	3	3	1		YES
15	25	Reboxetine	18/06/91	29/07/91	ABDOMINAL PAIN	03/07/91	Detail	35	22/07/91		2	2	3	1		2	3	3	1		
							Summary		22/07/91	35	2	2	3	1		2	3	3	1		YES
					CONSTIPATION	27/06/91	Detail	14	01/07/91		2	1	4	1		3	3	3	1		
							Summary		01/07/91	14	2	1	4	1		3	3	3	1		YES
						03/07/91	Detail	21	08/07/91		2	3	4	1		2	3	3	1		
							Summary		08/07/91	21	2	3	4	1		2	3	3	1		YES
					EYE ABNORMALITY	19/06/91	Detail	7			1	2	5	1		2	3	3	3		
							Detail	14	30/06/91		1	2	5	1		2	3	3	1		
							Summary		30/06/91	14	1	2	5	1		2	3	3	1		YES
					HEADACHE	19/06/91	Detail	7	22/06/91		2	1	5	1	YES	2	3	3	1		
							Summary		22/06/91	7	2	1	3	1	YES	2	3	3	1		YES
						19/07/91	Detail	35	22/07/91		2	1	4	1	YES	3	3	1	1		
							Summary		22/07/91	35	2	1	4	1	YES	3	3	1	1		YES
					INSOMNIA	19/06/91	Detail	7	23/06/91		2	2	3	1	YES	2	3	3	1		
							Summary		23/06/91	7	2	2	3	1	YES	2	3	3	1		YES
					MOUTH DRY	27/06/91	Detail	14			2	2	2	1		2	3	3	3		
							Detail	21			2	2	2	1		2	3	3	3		
							Detail	28			1	2	2	1		2	3	3	3		
							Detail	35			1	2	2	1		3	3	3	3		
							Detail	42			2	2	2	1		3	3	3	3	Y	
							Summary		30/07/91(*)	42	2	2	2	1		2	3	3	3	Y	YES
					NAUSEA	03/07/91	Detail	21			2	2	3	1		2	3	3	3		
							Detail	28			1	2	3	1		2	3	3	3		
							Detail	35	22/07/91		1	2	3	1		3	3	3	1		
							Summary		22/07/91	35	2	2	3	1		2	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.6

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Treatment Drug	Start date	End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Disapp.	Reapp.	Outcome	Still present	(C)
15	25	Reboxetine	16/06/91	29/07/91	SOMNOLENCE	04/07/91	Detail	21			2	2	3	1	2	3	3	3		
							Detail	28			2	2	3	1	2	3	3	3		
							Detail	35			2	2	3	1	3	3	3	3		
							Detail	42			2	2	3	1	3	3	3	3	Y	
							Summary		30/07/91(*)	42	2	2	3	1	2	3	3	3	Y	YES
					URINARY TRACT INFECTION	04/07/91	Detail	21			1	2	6	1	3	3	3	3		
							Detail	28	15/07/91		1	2	6	1	3	3	3	1		
							Summary		15/07/91	28	1	2	6	1	3	3	3	1		YES
	26	Placebo	20/06/91	01/08/91	ABDOMINAL PAIN	27/06/91	Detail	14			2	2	4	1	2	3	3	3		
							Detail	21	06/07/91		2	2	4	1	2	3	3	1		
							Summary		06/07/91	21	2	2	4	1	2	3	3	1		YES
					DIZZINESS	18/07/91	Detail	28			1	2	5	1	2	3	3	3		
							Detail	35	20/07/91		1	2	4	1	3	3	3	1		
							Summary		20/07/91	35	1	2	5	1	2	3	3	1		YES
					HEADACHE		Detail	0			2									
						14/06/91(@)	Summary		01/08/91(*)	0	2									NO
					MOUTH DRY	25/06/91	Detail	7			1	2	3	1	3	3	3	3		
							Detail	14			1	2	2	1	2	3	3	3		
							Detail	21	09/07/91		1	2	2	1	2	3	3	1		
							Summary		09/07/91	21	1	2	2	1	2	3	3	1		YES
						15/07/91	Detail	28			2	2	2	1	2	3	3	3		
							Detail	35			2	2	2	1	2	3	3	3		
							Detail	42			2	2	2	1	3	3	3	3	Y	
							Summary		01/08/91(*)	42	2	2	2	1	2	3	3	3	Y	YES
					RHINITIS	08/07/91	Detail	21			1	2	6	1	2	3	3	3		
							Detail	28			1	2	6	1	2	3	3	3		
							Detail	35	20/07/91		1	2	6	1	3	3	3	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Treatment Drug	Start date	End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
15	25	Placebo	20/06/91	01/08/91	RHINITIS	08/07/91	Summary		20/07/91	35	1	2	6	1		2	3	3	1		YES
					SOMNOLENCE	21/07/91	Detail	35			1	2	3	1		3	3	3	3		
							Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		01/08/91(*)	42	1	2	3	1		3	3	3	3	Y	YES
					TONGUE ULCERATION	09/07/91	Detail	21			2	2	6	1		2	3	3	3		
							Detail	28	16/07/91		2	2	6	1		2	3	3	1		
							Summary		16/07/91	28	2	2	6	1		2	3	3	1		YES
					VISION ABNORMAL	27/06/91	Detail	14			1	2	2	1		2	3	3	3		
							Detail	21			1	2	2	1		3	3	3	3		
							Detail	28			1	2	2	1		2	3	3	3		
							Detail	35			2	2	2	1		3	3	3	3		
							Detail	42			2	2	2	1		3	3	3	3	Y	
							Summary		01/08/91(*)	42	2	2	2	1		2	3	3	3	Y	YES
	27	Imipramine	02/07/91	13/08/91	APPETITE INCREASED	04/07/91	Detail	7			1	2	5	1		2	3	3	3		
							Detail	14			2	2	5	1		2	3	3	3		
							Detail	21			2	2	5	1		3	3	3	3		
							Detail	28			2	2	5	1		3	3	3	3		
							Detail	35			2	2	5	1		3	3	3	3		
							Detail	42			2	2	5	1		3	3	3	3	Y	
							Summary		13/08/91(*)	42	2	2	5	1		2	3	3	3	Y	YES
					CONFUSION	03/07/91	Detail	7	05/07/91		2	1	4	1		2	3	3	1		
							Summary		05/07/91	7	2	1	4	1		2	3	3	1		YES
					DIZZINESS	05/07/91	Detail	7			2	2	3	1		2	3	3	3		
							Detail	14			2	2	3	1		2	3	3	3		
							Detail	21			2	2	3	1		3	3	3	3		
							Detail	28			1	2	3	1		3	3	3	3		
							Detail	35	04/08/91		1	2	3	1		3	3	3	1		
							Summary		04/08/91	35	2	2	3	1		2	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
15	27	Imipramine	02/07/91	13/08/91	MOUTH DRY	04/07/91	Detail	7			1	2	2	1	2	3	3	3		
							Detail	14			1	2	2	1	2	3	3	3		
							Detail	21			1	2	2	1	3	3	3	3		
							Detail	28			1	2	2	1	3	3	3	3		
							Detail	35			2	2	2	1	3	3	3	3		
							Detail	42			1	2	2	1	3	3	3	3	Y	
							Summary		13/08/91(*)	42	2	2	2	1	2	3	3	3	Y	YES
					NAUSEA	12/07/91	Detail	14			2	2	3	1	2	3	3	3		
							Detail	21			2	2	3	1	3	3	3	3		
							Detail	28	29/07/91		2	2	3	1	3	3	3	1		
							Summary		29/07/91	28	2	2	3	1	2	3	3	1		YES
						10/08/91	Detail	42	12/08/91		1	2	3	1	3	3	3	1		
							Summary		12/08/91	42	1	2	3	1	3	3	3	1		YES
					SWEATING INCREASED	03/07/91	Detail	7	05/07/91		3	1	6	1	2	3	3	1		
							Summary		05/07/91	7	3	1	6	1	2	3	3	1		YES
						16/07/91	Detail	14	15/07/91		2	1	6	1	2	3	3	1		
							Summary		15/07/91	14	2	1	6	1	2	3	3	1		YES
	28	Reboxetine	08/08/91	19/09/91	CONSTIPATION	31/08/91	Detail	28			2	2	2	1	YES	3	3	3	3		
							Detail	35			2	2	2	1		3	3	3	3		
							Detail	42			2	2	2	1	YES	3	3	3	3	Y	
							Detail	42			2	2	2	1	YES	3	1	1	3	Y	
							Summary		20/09/91(*)	42	2	2	2	1	YES	3	1	1	3	Y	YES
					DIZZINESS	07/09/91	Detail	35	10/09/91		2	2	3	1		3	3	3	1		
							Summary		10/09/91	35	2	2	3	1		3	3	3	1		YES
					HEADACHE	08/08/91	Detail	7	10/08/91		1	2	3	1		3	3	3	1		
							Summary		10/08/91	7	1	2	3	1		3	3	3	1		YES
					HOT FLUSHES	16/08/91	Detail	21			2	2	5	1		3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28126/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
15	28	Reboxetine	08/08/91	19/09/91	HOT FLUSHES	16/08/91	Detail	28	30/08/91		1	2	5	1		3	3	3	1		
							Summary		30/08/91	28	2	2	5	1		3	3	3	1		YES
					INSOMNIA	16/08/91	Detail	14			2	1	4	1	YES	3	3	3	3		
							Detail	21			2	1	4	1	YES	3	3	3	3		
							Detail	28			2	1	4	1	YES	3	3	3	3		
							Detail	35			2	1	4	1	YES	3	3	3	3		
							Detail	42	13/09/91		2	1	4	1	YES	3	3	3	1		
							Summary		13/09/91	42	2	1	4	1	YES	3	3	3	1		YES
					NAUSEA	08/08/91	Detail	7	09/08/91		2	2	2	1		3	3	3	1		
							Summary		09/08/91	7	2	2	2	1		3	3	3	1		YES
					NERVOUSNESS	09/08/91	Detail	7			2	1	4	1		3	3	3	3		
							Detail	14			1	1	4	1		3	3	3	3		
							Detail	21	24/08/91		1	1	4	1		3	3	3	1		
							Summary		24/08/91	21	2	1	4	1		3	3	3	1		YES
					SWEATING INCREASED	16/08/91	Detail	28	30/08/91		2	2	5	1		3	3	3	1		
							Summary		30/08/91	28	2	2	5	1		3	3	3	1		YES
					URINARY TRACT INFECTION	25/08/91	Detail	21			2	2	6	1		3	3	3	3		
							Detail	28			2	2	6	1	YES	3	3	3	3		
							Detail	35	07/09/91		2	2	6	1	YES	3	3	3	1		
							Summary		07/09/91	35	2	2	6	1	YES	3	3	3	1		YES
	29	Placebo	29/08/91	19/09/91	DIZZINESS	17/09/91	Detail	21			1	2	5	1		3	3	3	3	Y	
							Summary		19/09/91(*)	21	1	2	5	1		3	3	3	3	Y	YES
					HEADACHE	28/08/91	Detail	8			2										
							Detail	7			2	1	6	1		3	3	3	3		
							Detail	14	06/09/91		2	1	6	1		3	3	3	1		
							Summary		06/09/91	14	2	1	6	1		3	3	3	1		NO
						08/09/91	Detail	14	09/09/91		2	1	6	1		3	3	3	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/315
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(c)
15	29	Placebo	29/08/91	19/09/91	HEADACHE	08/09/91	Summary		09/09/91	14	2	1	6	1	3	3	3	3	1		YES
	36	Imipramine	03/09/91	15/10/91	MOUTH DRY	05/09/91	Detail	7			2	2	2	1	3	3	3	3	3		
							Detail	14			2	2	2	1	3	3	3	3	3		
							Detail	21			2	2	2	1	3	3	3	3	3		
							Detail	28			2	2	2	1	3	3	3	3	3		
							Detail	35			2	2	2	1	3	3	3	3	3		
							Detail	42			2	2	2	1	3	3	3	3	3	Y	
							Summary		15/10/91(*)	42	2	2	2	1	3	3	3	3	3	Y	YES
					SOMNOLENCE	05/09/91	Detail	7			2	2	2	1	3	3	3	3	3		
							Detail	14			2	2	2	1	3	3	3	3	3		
							Detail	21			2	2	2	1	3	3	3	3	3		
							Detail	28			2	2	2	1	3	3	3	3	3		
							Detail	35			2	2	2	1	3	3	3	3	3		
							Detail	42			1	2	2	1	3	3	3	3	3	Y	
							Summary		15/10/91(*)	42	2	2	2	1	3	3	3	3	3	Y	YES
					SWEATING INCREASED	30/09/91	Detail	28	30/09/91		3	2	4	1	3	3	3	3	1		
							Summary		30/09/91	28	3	2	4	1	3	3	3	3	1		YES
						10/10/91	Detail	42	14/10/91		3	2	3	1	3	3	3	3	1		
							Summary		14/10/91	42	3	2	3	1	3	3	3	3	1		YES
					VISION ABNORMAL	07/09/91	Detail	7			1	2	2	1	3	3	3	3	3		
							Detail	14	10/09/91		1	2	2	1	3	3	3	3	1		
							Summary		10/09/91	14	1	2	2	1	3	3	3	3	1		YES
	403	Imipramine	06/10/91	14/11/91	CONSTIPATION	14/10/91	Detail	14			2	1	2	1	3	3	3	3	3		
							Detail	21			2	2	2	1	3	3	3	3	3		
							Detail	28			2	2	2	1	3	3	3	3	3		
							Detail	35	03/11/91		2	2	2	1	3	3	3	3	1		
							Summary		03/11/91	35	2	1	2	1	3	3	3	3	1		YES
					DIZZINESS	19/10/91	Detail	21			2	2	3	1	3	3	3	3	3		
							Detail	28	28/10/91		2	2	3	1	3	3	3	3	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observa bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hosp	Disapp.	Reapp.	Outcome	Still present	(C)
15	403	Imipramine	04/10/91	14/11/91	DIZZINESS	19/10/91	Summary		28/10/91	28	2	2	3	1		3	3	3	1		YES
						02/11/91	Detail	35	02/11/91		2	2	5	1		3	3	3	1		
							Summary		02/11/91	35	2	2	5	1		3	3	3	1		YES
						09/11/91	Detail	42	11/11/91		2	2	3	1		3	3	3	1		
							Summary		11/11/91	42	2	2	3	1		3	3	3	1		YES
					HOT FLUSHES	20/10/91	Detail	21			1	1	5	1		3	3	3	3		
							Detail	28	30/10/91		1	1	5	1		3	3	3	1		
							Summary		30/10/91	28	1	1	5	1		3	3	3	1		YES
					MOUTH DRY	06/10/91	Detail	7			2	2	2	1		3	3	3	3		
							Detail	14			2	2	2	1		3	3	3	3		
							Detail	21			2	2	2	1		3	3	3	3		
							Detail	28			2	2	3	1		3	3	3	3		
							Detail	35			1	2	2	1		3	3	3	3		
							Detail	42			1		2	1		3	3	3	3	Y	
							Summary		14/11/91(*)	42	2	2	2	1		3	3	3	3	Y	YES
					PARAESTHESIA	10/10/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14	12/10/91		2	2	3	1		3	3	3	1		
							Summary		12/10/91	14	2	2	3	1		3	3	3	1		YES
					SOMNOLENCE	06/10/91	Detail	7			1	1	3	1		3	3	3	3		
							Detail	14			1	2	2	1		3	3	3	3		
							Detail	21			2	2	2	1		3	3	3	3		
							Detail	28	26/10/91		2	2	2	1		3	3	3	1		
							Summary		26/10/91	28	2	1	2	1		3	3	3	1		YES
	404	Reboxetine	08/10/91	05/11/91	CONSTIPATION	16/10/91	Detail	14			2	1	4	1		3	3	3	3		
							Detail	21	24/10/91		2	1	4	1		3	3	3	1		
							Summary		24/10/91	21	2	1	4	1		3	3	3	1		YES
						31/10/91	Detail	28			2	1	4	1		3	3	3	3	Y	
							Summary		05/11/91(*)	28	2	1	4	1		3	3	3	3	Y	YES
					NERVOUSNESS	16/10/91	Detail	14	21/10/91		2	2	4	1		3	3	3	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
(D) onset date missing: first report visit date used
(B) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
15	404	Reboxetine	08/10/91	05/11/91	NERVOUSNESS	16/10/91	Summary		21/10/91	14	2	2	4	1		3	3	3	1		YES
					SWEATING INCREASED	17/10/91	Detail	14			2	1	4	1		3	3	3	3		
							Detail	21			2	1	4	1		1	3	3	3		
							Detail	28	03/11/91		2	1	4	1		3	3	3	1		
							Summary		03/11/91	28	2	1	4	1		1	3	3	1		YES
	406	Imipramine	27/11/91	07/01/92	MOUTH DRY	01/12/91	Detail	7			2	2	2	1		3	3	3	3		
							Detail	14			2	2	2	1		3	3	3	3		
							Detail	21	15/12/91		1	2	2	1		3	3	3	1		
							Summary		15/12/91	21	2	2	2	1		3	3	3	1		YES
	407	Reboxetine	03/12/91	14/01/92	HEADACHE	04/12/91	Detail	7			2	1	4	1		3	3	3	3		
							Detail	14	12/12/91		2	1	4	1		3	3	3	1		
							Summary		12/12/91	14	2	1	4	1		3	3	3	1		YES
						13/12/91	Detail	14			2	1	4	1		3	3	3	3		
							Detail	21	22/12/91		2	1	4	1	YES	3	3	3	1		
							Summary		22/12/91	21	2	1	4	1	YES	3	3	3	1		YES
						25/12/91	Detail	28			2	1	4	1		3	3	3	3		
							Detail	35	06/01/92		2	1	4	1		3	3	3	1		
							Summary		06/01/92	35	2	1	4	1		3	3	3	1		YES
						08/01/92	Detail	42			2	1	4	1	YES	3	3	3	3	Y	
							Summary		14/01/92(*)	42	2	1	4	1	YES	3	3	3	3	Y	YES
					NAUSEA	26/12/91	Detail	28			1	2	3	1		3	3	3	3		
							Detail	35			1	2	3	1		3	3	3	3		
							Detail	42	12/01/92		1	2	3	1		1	3	3	1		
							Summary		12/01/92	42	1	2	3	1		1	3	3	1		YES
	408	Placebo	28/01/92	04/03/92	HEADACHE	03/02/92	Detail	14			2	2	4	1	YES	3	3	3	3		
							Detail	21	04/02/92		2	2	4	1	YES	3	3	3	1		
							Summary		04/02/92	21	2	2	4	1	YES	3	3	3	1		YES
						19/02/92	Detail	35	23/02/92		2	1	4	1		3	3	3	1		
							Summary		23/02/92	35	2	1	4	1		3	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(3) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(c)
15	408	Placebo	20/01/92	04/03/92	INSOMNIA	11/02/92	Detail	35							YES					Y	
							Summary		04/03/92(*)	35					YES					Y	YES
					NAUSEA	02/02/92	Detail	21	04/02/92		2	2	4	1		3	3	3	1		
							Summary		04/02/92	21	2	2	4	1		3	3	3	1		YES
						16/02/92	Detail	35			1	2	3	1		3	3	3	3		
							Detail	42	29/02/92		1	2	3	1		3	3	3	1		
							Summary		29/02/92	42	1	2	3	1		3	3	3	1		YES
					RASH	27/02/92	Detail	42	02/03/92		1	2	4	1		3	3	3	1		
							Summary		02/03/92	42	1	2	4	1		3	3	3	1		YES
					VOMITING	02/02/92	Detail	14			2	2	4	1		3	3	3	3		
							Detail	21	04/02/92		2	2	4	1		3	3	3	1		
							Summary		04/02/92	21	2	2	4	1		3	3	3	1		YES
	418	Placebo	30/01/92	12/03/92	CONSTIPATION	28/02/92	Detail	35			1	2	3	1		3	3	3	3		
							Detail	42			2	2	2	1	YES	3	3	3	3	Y	
							Summary		12/03/92(*)	42	2	2	2	1	YES	3	3	3	3	Y	YES
					HEADACHE	21/02/92	Detail	28			1	1	5	1		3	3	3	3		
							Detail	42	10/03/92		1	1	4	1		3	3	3	1		
							Summary		10/03/92	42	1	1	4	1		3	3	3	1		YES
					NAUSEA	10/02/92	Detail	14	12/02/92		1	2	3	1		3	3	3	1		
							Summary		12/02/92	14	1	2	3	1		3	3	3	1		YES
					SOMNOLENCE	31/01/92	Detail	7			1	2	2	1		3	3	3	3		
							Detail	14	08/02/92		1	2	2	1		3	3	3	1		
							Summary		08/02/92	14	1	2	2	1		3	3	3	1		YES
						06/03/92	Detail	42			1	2	2	1		3	3	3	3	Y	
							Summary		12/03/92(*)	42	1	2	2	1		3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
15	419	Placebo	28/04/92	09/06/92	ANXIETY	28/04/92	Detail	7	01/05/92		1	2	3	1		2	3	3	1		
							Summary		01/05/92	7	1	2	3	1		2	3	3	1		YES
					APPETITE INCREASED	29/04/92	Detail	7			2	2	3	1		2	3	3	3		
							Detail	14	08/05/92		2	2	2	1		3	3	3	1		
							Summary		08/05/92	14	2	2	2	1		2	3	3	1		YES
					BACK PAIN	22/05/92	Detail	28			2	1	6	1	YES	2	3	3	3		
							Detail	42			2	1	6	1	YES	2	3	3	3	Y	
							Summary		09/06/92(*)	42	2	1	6	1	YES	2	3	3	3	Y	YES
					HEADACHE	11/05/92	Detail	14			2	2	4	1	YES	2	3	3	3		
							Detail	21	20/05/92		2	2	4	1		2	3	3	1		
							Summary		20/05/92	21	2	2	4	1	YES	2	3	3	1		YES
					NAUSEA	04/05/92	Detail	7	04/05/92		2	2	2	1		2	3	3	1		
							Summary		04/05/92	7	2	2	2	1		2	3	3	1		YES
						10/05/92	Detail	14			1	2	2	1		2	3	3	3		
							Detail	21	21/05/92		1	2	2	1		2	3	3	1		
							Summary		21/05/92	21	1	2	2	1		2	3	3	1		YES
					TREMOR	31/05/92	Detail	35	01/06/92		2	2	4	1		2	3	3	1		
							Summary		01/06/92	35	2	2	4	1		2	3	3	1		YES
					URINARY TRACT INFECTION	05/06/92	Detail	42			2	2	6	1	YES	3	3	3	3	Y	
							Summary		09/06/92(*)	42	2	2	6	1	YES	3	3	3	3	Y	YES
					VOMITING	04/05/92	Detail	7	04/05/92		2	2	2	1		2	3	3	1		
							Summary		04/05/92	7	2	2	2	1		2	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 1 Patient: 1 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/04/91		01/05/91		22/05/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/03/91	14.60		14.50		14.40	
HT	37-47 (%)	01/03/91	42.00		43.00		41.00	
RBC	3.8-5.8 (10¬12/L)	01/03/91	4.78		4.82		4.72	
WBC	4-11 (10¬9/L)	01/03/91	8.40		8.50		10.30	
WBC: N	2-7.5 (10¬9/L)	01/03/91	6.70		5.90		7.80	>
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	1.30		1.90		1.80	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.10		0.20		0.10	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.30		0.40		0.50	
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.00		0.10		0.00	
PLATELETS	150-400 (10¬9/L)	01/03/91	372.00		349.00		341.00	
NA+	137-145 (MMOL/L)	01/03/91	144.00		140.00		139.00	
K+	3.5-5 (MMOL/L)	01/03/91	3.80		3.90		3.90	
CL-	100-111 (MMOL/L)	01/03/91	106.00		105.00		105.00	
Ca++	2.1-2.5 (MMOL/L)	01/03/91	2.35		2.27		2.24	
PO4--	0.7-1.4 (MMOL/L)	01/03/91	0.91		0.91		1.04	
SGOT	5-40 (U/L)	01/03/91	32.00		30.00		15.00	
SGPT	5-55 (U/L)	01/03/91	9.00		14.00		28.00	
GAMMA GT	10-80 (U/L)	01/03/91	27.00		20.00		33.00	
LDH	300-550 (U/L)	01/03/91	520.00		455.00		450.00	
ALK. PHOSPH.	19-95 (U/L)	01/03/91	63.00		68.00		73.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91			5.30		5.40	
UREA	2.5-7.5 (MMOL/L)	01/03/91	3.00		4.40		7.70	>
CREATININE	60-110 (UMOL/L)	01/03/91	76.00		97.00		88.00	
URIC ACID	180-440 (UMOL/L)	01/03/91	259.00		208.00		251.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	12.00		8.00		7.00	
TOT. PROTEINS	62-81 (G/L)	01/03/91	77.00		78.00		77.00	
ALBUMINE	35-50 (G/L)	01/03/91	42.00		45.00		42.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	4.84		4.29		5.17	
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	0.66		0.80		0.66	
TSH	0.2-3.2 (MU/L)	01/03/91	1.30					
T4	11-24 (PMOL/L)	01/03/91	21.70					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 1 Patient: 2 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			11/04/91		06/05/91		27/05/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/03/91	13.30	<	13.70	<	13.80	<
HT	41-53 (%)	01/03/91	39.00	<	40.00	<	40.00	<
RBC	4.5-6.5 (10¬12/L)	01/03/91	4.01	<	4.12	<	4.23	<
WBC	4-11 (10¬9/L)	01/03/91	5.30		5.50		5.60	
WBC: N	2-7.5 (10¬9/L)	01/03/91	3.30		2.80		3.14	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	1.60		2.20		1.85	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.00		0.10		0.17	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.20		0.30		0.45	
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.10		0.10			
PLATELETS	150-400 (10¬9/L)	01/03/91	358.00		278.00		282.00	
NA+	137-145 (MMOL/L)	01/03/91	140.00		140.00		138.00	
K+	3.5-5 (MMOL/L)	01/03/91	3.80		4.60		4.70	
CL-	98-110 (MMOL/L)	01/03/91	104.00		108.00		102.00	
Ca++	2.1-2.55 (MMOL/L)	01/03/91	2.38		2.33		2.35	
PO4--	0.75-1.4 (MMOL/L)	01/03/91	1.06		1.00		1.15	
SGOT	5-40 (U/L)	01/03/91	58.00	>	34.00		19.00	
SGPT	5-55 (U/L)	01/03/91	86.00	>	56.00	>	27.00	
GAMMA GT	10-80 (U/L)	01/03/91	115.00	>	47.00		31.00	
LDH	300-550 (U/L)	01/03/91	705.00	>	687.00	>	693.00	>
ALK. PHOSPH.	19-95 (U/L)	01/03/91	84.00		55.00		55.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	5.10		5.60		6.70	>
UREA	2.5-7.5 (MMOL/L)	01/03/91	3.20		5.00		4.20	
CREATININE	60-110 (UMOL/L)	01/03/91	103.00		109.00		106.00	
URIC ACID	180-440 (UMOL/L)	01/03/91	433.00		437.00		377.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	21.00		8.00		8.00	
TOT. PROTEINS	60-80 (G/L)	01/03/91	81.00	>	78.00		77.00	
ALBUMINE	38-50 (G/L)	01/03/91	44.00		42.00		42.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	7.67	>>	7.52	>>	7.24	>>
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	2.47	>>	1.46		2.34	>>
TSH	0.2-3.2 (MU/L)	01/03/91	0.90					
T4	11-24 (PMOL/L)	01/03/91	13.50					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 1 Patient: 3 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			02/05/91		27/05/91		17/06/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/03/91	14.50		14.90		15.40	
HT	41-53 (%)	01/03/91	42.00		43.00		45.00	
RBC	4.5-6.5 (10¬12/L)	01/03/91	4.63		4.73		4.96	
WBC	4-11 (10¬9/L)	01/03/91	7.80		8.20		7.70	
WBC: N	2-7.5 (10¬9/L)	01/03/91	3.40		3.30		2.70	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	3.30		2.70		2.77	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.50		1.60	>>	1.31	>>
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.50		0.60		0.85	>
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.10		0.00		0.08	
PLATELETS	150-400 (10¬9/L)	01/03/91	283.00		261.00		267.00	
NA+	137-145 (MMOL/L)	01/03/91	140.00		141.00		142.00	
K+	3.5-5 (MMOL/L)	01/03/91	3.80		4.20		3.90	
CL-	98-110 (MMOL/L)	01/03/91	108.00		102.00		105.00	
Ca++	2.1-2.55 (MMOL/L)	01/03/91	2.30		2.32		2.31	
PO4--	0.75-1.4 (MMOL/L)	01/03/91	1.16		1.24		1.31	
SGOT	5-40 (U/L)	01/03/91	17.00		21.00		18.00	
SGPT	5-55 (U/L)	01/03/91	4.00	<	13.00		10.00	
GAMMA GT	10-80 (U/L)	01/03/91	29.00		27.00		31.00	
LDH	300-550 (U/L)	01/03/91	440.00		776.00	>	517.00	
ALK. PHOSPH.	19-95 (U/L)	01/03/91	88.00		110.00	>	82.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	5.30		4.50		4.80	
UREA	2.5-7.5 (MMOL/L)	01/03/91	6.60		6.40		5.70	
CREATININE	60-110 (UMOL/L)	01/03/91	90.00		87.00		94.00	
URIC ACID	180-440 (UMOL/L)	01/03/91	419.00		355.00		368.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	5.00		7.00		10.00	
TOT. PROTEINS	60-80 (G/L)	01/03/91	71.00		76.00		75.00	
ALBUMINE	38-50 (G/L)	01/03/91	39.00		42.00		45.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	4.67		4.52		5.18	
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	2.74	>>	2.57	>>	1.92	>
TSH	0.2-3.2 (MU/L)	01/03/91	1.60					
T4	11-24 (PMOL/L)	01/03/91	14.60					

1625

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 1 Patient: 4 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/06/91		25/06/91		16/07/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	03/06/91	15.10		13.80	<	14.00	
HT	41-53 (%)	03/06/91	44.00		41.00		41.00	
RBC	4.5-6.5 (10¬12/L)	03/06/91	5.13		4.74		4.80	
WBC	4-11 (10¬9/L)	03/06/91	11.00		9.00		7.90	
WBC: N	2-7.5 (10¬9/L)	03/06/91	7.40		6.60		4.19	
WBC: L	1.3-3.6 (10¬9/L)	03/06/91	2.80		1.70		2.92	
WBC: E	0-0.7 (10¬9/L)	03/06/91	0.30		0.30		0.40	
WBC: M	0.2-0.8 (10¬9/L)	03/06/91	0.40		0.20		0.32	
WBC: B	0-0.2 (10¬9/L)	03/06/91	0.10		0.10		0.08	
PLATELETS	150-400 (10¬9/L)	03/06/91	277.00		166.00		199.00	
NA+	137-145 (MMOL/L)	03/06/91	141.00		141.00		140.00	
K+	3.5-5 (MMOL/L)	03/06/91	4.20		4.60		4.50	
CL-	98-110 (MMOL/L)	24/06/91			106.00		105.00	
Ca++	2.1-2.55 (MMOL/L)	24/06/91			2.28		2.30	
PO4--	3.5-5 (MG/DL)	03/06/91	4.20					
	0.75-1.4 (MMOL/L)	24/06/91			1.22		1.16	
SGOT	5-40 (U/L)	03/06/91	21.00		29.00		34.00	
SGPT	5-55 (U/L)	03/06/91	7.00		19.00		21.00	
GAMMA GT	10-80 (U/L)	03/06/91	26.00		22.00		21.00	
LDH	300-550 (U/L)	24/06/91			584.00	>	767.00	>
ALK. PHOSPH.	19-95 (U/L)	03/06/91	70.00		51.00		49.00	
GLUCOSE	3.6-5.8 (MMOL/L)	03/06/91	5.70		4.90		4.80	
UREA	2.5-7.5 (MMOL/L)	24/06/91			5.20		5.90	
CREATININE	60-110 (UMOL/L)	03/06/91	115.00	>	95.00		94.00	
URIC ACID	180-440 (UMOL/L)	24/06/91			444.00	>	389.00	
TOT BILIRUBIN	3-22 (UMOL/L)	03/06/91	8.00		9.00		10.00	
TOT. PROTEINS	60-80 (G/L)	03/06/91	77.00		71.00		77.00	
ALBUMINE	38-50 (G/L)	03/06/91	39.00		41.00		45.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	24/06/91			5.46		5.90	>
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	24/06/91			1.49		0.93	
TSH	0.2-3.2 (MU/L)	03/06/91	1.90					
T4	11-24 (PMOL/L)	03/06/91	17.70					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 1 Patient: 5 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			12/06/91		02/07/91	
			value	(¢)	value	(¢)
Laboratory test	Range value	Range date				
HB	12-16 (G/DL)	01/03/91	16.00		14.40	
HT	37-47 (%)	01/03/91	46.00		43.00	
RBC	3.8-5.8 (10¬12/L)	01/03/91	5.20		4.71	
WBC	4-11 (10¬9/L)	01/03/91	8.80		7.30	
WBC: N	2-7.5 (10¬9/L)	01/03/91	3.87		3.40	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	4.31	>	3.30	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.09		0.10	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.53		0.40	
WBC: B	0-0.2 (10¬9/L)	01/03/91			0.20	
PLATELETS	150-400 (10¬9/L)	01/03/91	403.00	>	372.00	
NA+	137-145 (MMOL/L)	01/03/91	142.00		138.00	
K+	3.5-5 (MMOL/L)	01/03/91	4.30		5.20	>
CL-	100-111 (MMOL/L)	01/03/91	107.00		106.00	
Ca++	2.1-2.5 (MMOL/L)	01/03/91	2.37		2.38	
PO4--	0.7-1.4 (MMOL/L)	01/03/91	1.09		1.10	
SGOT	5-40 (U/L)	01/03/91	19.00		23.00	
SGPT	5-55 (U/L)	01/03/91	12.00		3.00	<
GAMMA GT	10-80 (U/L)	01/03/91	29.00		25.00	
LDH	300-550 (U/L)	01/03/91	493.00		403.00	
ALK. PHOSPH.	19-95 (U/L)	01/03/91	79.00		69.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	5.80		4.40	
UREA	2.5-7.5 (MMOL/L)	01/03/91	1.70	<	2.90	
CREATININE	60-110 (UMOL/L)	01/03/91	67.00		75.00	
URIC ACID	180-440 (UMOL/L)	01/03/91	330.00		308.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	9.00		9.00	
TOT. PROTEINS	62-81 (G/L)	01/03/91	81.00		71.00	
ALBUMINE	35-50 (G/L)	01/03/91	49.00		41.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	6.34	>	6.31	>
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	2.84	>>	1.93	>
TSH	0.2-3.2 (MU/L)	01/03/91	0.90			
T4	11-24 (PMOL/L)	01/03/91	20.70			

1627

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 1 Patient: 6 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			23/05/91		13/06/91		08/07/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/03/91	13.10		14.60		14.60	
HT	37-47 (%)	01/03/91	38.00		42.00		42.00	
RBC	3.8-5.8 (10¬12/L)	01/03/91	4.15		4.63		4.67	
WBC	4-11 (10¬9/L)	01/03/91	7.60		8.90		6.10	
WBC: N	2-7.5 (10¬9/L)	01/03/91	4.40		5.40		3.10	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	2.60		2.90		2.30	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.10		0.10		0.20	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.40		0.40		0.40	
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.10		0.10		0.20	
PLATELETS	150-400 (10¬9/L)	01/03/91	291.00		279.00		272.00	
NA+	137-145 (MMOL/L)	01/03/91	140.00		138.00		137.00	
K+	3.5-5 (MMOL/L)	01/03/91	4.00		2.90	<<	4.80	
CL-	100-111 (MMOL/L)	01/03/91	102.00		95.00	<	100.00	
Ca++	2.1-2.5 (MMOL/L)	01/03/91	2.34		2.34		2.48	
PO4--	0.7-1.4 (MMOL/L)	01/03/91	1.30		1.09		1.24	
SGOT	5-40 (U/L)	01/03/91	10.00		24.00		20.00	
SGPT	5-55 (U/L)	01/03/91	11.00		3.00	<	3.00	<
GAMMA GT	10-80 (U/L)	01/03/91	15.00		18.00		17.00	
LDH	300-550 (U/L)	01/03/91	363.00		528.00		668.00	>
ALK. PHOSPH.	19-95 (U/L)	01/03/91	61.00		60.00		57.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	5.30		6.30	>	5.10	
UREA	2.5-7.5 (MMOL/L)	01/03/91	3.40		2.70		2.80	
CREATININE	60-110 (UMOL/L)	01/03/91	81.00		79.00		83.00	
URIC ACID	180-440 (UMOL/L)	01/03/91	169.00	<	214.00		178.00	<
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	16.00		25.00	>	34.00	>
TOT. PROTEINS	62-81 (G/L)	01/03/91	70.00		81.00		80.00	
ALBUMINE	35-50 (G/L)	01/03/91	41.00		46.00		47.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	4.80		5.58	>	5.37	
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	0.90		0.99		1.17	
TSH	0.2-3.2 (MU/L)	01/03/91	1.00					
T4	11-24 (PMOL/L)	01/03/91	15.90					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 1 Patient: 7 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			27/08/91		17/09/91		08/10/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/03/91	13.80		13.30		12.90	
HT	37-47 (%)	01/03/91	40.00		38.00		38.00	
RBC	3.8-5.8 (10¬12/L)	01/03/91	4.59		4.38		4.20	
WBC	4-11 (10¬9/L)	01/03/91	7.60		5.80		6.00	
WBC: N	2-7.5 (10¬9/L)	01/03/91	4.90		3.80		3.40	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	2.20		1.50		2.00	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.10		0.10		0.20	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.30		0.30		0.20	
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.00		0.10		0.20	
PLATELETS	150-400 (10¬9/L)	01/03/91	315.00		302.00		289.00	
NA+	137-145 (MMOL/L)	01/03/91	143.00		141.00		138.00	
K+	3.5-5 (MMOL/L)	01/03/91	3.80		4.00		5.30	>
CL-	100-111 (MMOL/L)	01/03/91	102.00		105.00		105.00	
Ca++	2.1-2.5 (MMOL/L)	01/03/91	2.37		2.28		2.28	
PO4--	0.7-1.4 (MMOL/L)	01/03/91	1.10		1.09		1.04	
SGOT	5-40 (U/L)	01/03/91	29.00		23.00		27.00	
SGPT	5-55 (U/L)	01/03/91	18.00		6.00		20.00	
GAMMA GT	10-80 (U/L)	01/03/91	21.00		22.00		24.00	
LDH	300-550 (U/L)	01/03/91	432.00		336.00		381.00	
ALK. PHOSPH.	19-95 (U/L)	01/03/91	61.00		51.00		53.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	4.90		3.30	<	4.40	
UREA	2.5-7.5 (MMOL/L)	01/03/91	2.50		2.50		1.50	<
CREATININE	60-110 (UMOL/L)	01/03/91	76.00		70.00		79.00	
URIC ACID	180-440 (UMOL/L)	01/03/91	275.00		224.00		234.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	15.00		13.00		12.00	
TOT. PROTEINS	62-81 (G/L)	01/03/91	82.00	>	77.00		75.00	
ALBUMINE	35-50 (G/L)	01/03/91	45.00		42.00		40.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	3.82		3.13	<	3.52	
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	0.95		0.75		0.89	
TSH	0.2-3.2 (MU/L)	01/03/91	0.60					
T4	11-24 (PMOL/L)	01/03/91	19.90					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 1 Patient: 8 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/09/91		28/09/91		19/10/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/03/91	15.30		14.60		15.20	
HT	41-53 (%)	01/03/91	45.00		43.00		45.00	
RBC	4.5-6.5 (10¬12/L)	01/03/91	4.92		4.71		4.89	
WBC	4-11 (10¬9/L)	01/03/91	8.60		5.70		7.40	
WBC: N	2-7.5 (10¬9/L)	01/03/91	5.10		3.10		4.96	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	2.80		2.00		1.78	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.20		0.10		0.07	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.40		0.20		0.59	
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.20		0.20			
PLATELETS	150-400 (10¬9/L)	01/03/91	292.00		324.00		253.00	
NA+	137-145 (MMOL/L)	01/03/91	141.00		141.00		140.00	
K+	3.5-5 (MMOL/L)	01/03/91	4.20		4.40		4.30	
CL-	98-110 (MMOL/L)	01/03/91	107.00		108.00		104.00	
Ca++	2.1-2.55 (MMOL/L)	01/03/91	2.42		2.31		2.42	
PO4--	0.75-1.4 (MMOL/L)	01/03/91	1.36		1.09		1.20	
SGOT	5-40 (U/L)	01/03/91	38.00		11.00		17.00	
SGPT	5-55 (U/L)	01/03/91	38.00		26.00		21.00	
GAMMA GT	10-80 (U/L)	01/03/91	30.00		26.00		24.00	
LDH	300-550 (U/L)	01/03/91	431.00		365.00		483.00	
ALK. PHOSPH.	19-95 (U/L)	01/03/91	66.00		66.00		67.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	5.00		7.80	>>	6.20	>
UREA	2.5-7.5 (MMOL/L)	01/03/91	6.40		5.50		5.30	
CREATININE	60-110 (UMOL/L)	01/03/91	85.00		55.00	<	62.00	
URIC ACID	180-440 (UMOL/L)	01/03/91	275.00		229.00		242.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	6.00		6.00		9.00	
TOT. PROTEINS	60-80 (G/L)	01/03/91	74.00		71.00		74.00	
ALBUMINE	38-50 (G/L)	01/03/91	44.00		40.00		44.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	4.98		4.14		5.50	
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	1.78	>	0.47		1.23	
TSH	0.2-3.2 (MU/L)	01/03/91	0.70				0.80	
T4	11-24 (PMOL/L)	01/03/91	12.30				11.60	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 1 Patient: 9 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			27/11/91		18/12/91		06/01/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/03/91	11.40	<	11.90	<	11.40	<
HT	37-47 (%)	01/03/91	33.00	<	35.00	<	33.00	<
RBC	3.8-5.8 (10¬12/L)	01/03/91	3.52	<	3.69	<	3.63	<
WBC	4-11 (10¬9/L)	01/03/91	3.00	<	4.20		5.90	
WBC: N	2-7.5 (10¬9/L)	01/03/91	1.38	<<	2.69		4.00	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	1.17	<	0.97	<	1.50	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.03				0.10	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.39		0.42		0.30	
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.03		0.04		0.00	
PLATELETS	150-400 (10¬9/L)	01/03/91	263.00		271.00		217.00	
NA+	137-145 (MMOL/L)	01/03/91	140.00		138.00		138.00	
K+	3.5-5 (MMOL/L)	01/03/91	4.20		4.10		3.90	
CL-	100-111 (MMOL/L)	01/03/91	104.00		102.00		106.00	
Ca++	2.1-2.5 (MMOL/L)	01/03/91	2.20		2.16		2.12	
PO4--	0.7-1.4 (MMOL/L)	01/03/91	1.20		1.17		1.21	
SGOT	5-40 (U/L)	01/03/91	29.00		30.00		35.00	
SGPT	5-55 (U/L)	01/03/91	27.00		23.00		28.00	
GAMMA GT	10-80 (U/L)	01/03/91	32.00		27.00		22.00	
LDH	300-550 (U/L)	01/03/91	423.00		461.00		547.00	
ALK. PHOSPH.	19-95 (U/L)	01/03/91	48.00		46.00		40.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	4.50		4.60			
UREA	2.5-7.5 (MMOL/L)	01/03/91	1.70	<	3.00		3.00	
CREATININE	60-110 (UMOL/L)	01/03/91	83.00		74.00		72.00	
URIC ACID	180-440 (UMOL/L)	01/03/91	265.00		201.00		230.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	8.00		7.00		8.00	
TOT. PROTEINS	62-81 (G/L)	01/03/91	74.00		75.00		72.00	
ALBUMINE	35-50 (G/L)	01/03/91	42.00		42.00		39.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	3.80		4.46		3.48	<
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	0.63		1.53		0.95	
TSH	0.2-3.2 (MU/L)	01/03/91	0.50				1.00	
T4	11-24 (PMOL/L)	01/03/91	17.20				12.30	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 1 Patient: 10 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/09/91		15/10/91		04/11/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/03/91	15.40		15.30		14.70	
HT	41-53 (%)	01/03/91	45.00		45.00		44.00	
RBC	4.5-6.5 (10¬12/L)	01/03/91	4.90		4.82		4.68	
WBC	4-11 (10¬9/L)	01/03/91	8.90		6.10		8.50	
WBC: N	2-7.5 (10¬9/L)	01/03/91	6.40		3.90		6.29	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	1.80		1.60		1.62	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.20		0.20		0.26	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.40		0.30		0.34	
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.00		0.00			
PLATELETS	150-400 (10¬9/L)	01/03/91	246.00		219.00		243.00	
NA+	137-145 (MMOL/L)	01/03/91	143.00		141.00		141.00	
K+	3.5-5 (MMOL/L)	01/03/91	4.20		4.30		4.20	
CL-	98-110 (MMOL/L)	01/03/91	104.00		104.00		104.00	
Ca++	2.1-2.55 (MMOL/L)	01/03/91	2.42		2.46		2.30	
PO4--	0.75-1.4 (MMOL/L)	01/03/91	1.16		0.85		1.06	
SGOT	5-40 (U/L)	01/03/91	34.00		20.00		38.00	
SGPT	5-55 (U/L)	01/03/91	36.00		16.00		23.00	
GAMMA GT	10-80 (U/L)	01/03/91	42.00		33.00		31.00	
LDH	300-550 (U/L)	01/03/91	606.00	>	575.00	>	671.00	>
ALK. PHOSPH.	19-95 (U/L)	01/03/91	51.00		46.00		54.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	5.10		5.50		5.80	
UREA	2.5-7.5 (MMOL/L)	01/03/91	3.60		3.90		3.90	
CREATININE	60-110 (UMOL/L)	01/03/91	98.00		101.00		111.00	>
URIC ACID	180-440 (UMOL/L)	01/03/91	297.00		309.00		308.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	13.00		13.00		17.00	
TOT. PROTEINS	60-80 (G/L)	01/03/91	78.00		75.00		74.00	
ALBUMINE	38-50 (G/L)	01/03/91	46.00		45.00		44.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	5.53	>	4.96		4.69	
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	1.15		0.59		0.69	
TSH	0.2-3.2 (MU/L)	01/03/91	0.70					
T4	11-24 (PMOL/L)	01/03/91	15.20					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 1 Patient: 11 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			10/10/91	
			value	(◊)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/03/91	11.70	<
HT	37-47 (%)	01/03/91	34.00	<
RBC	3.8-5.8 (10¬12/L)	01/03/91	3.71	<
WBC	4-11 (10¬9/L)	01/03/91	5.10	
WBC: N	2-7.5 (10¬9/L)	01/03/91	3.20	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	1.40	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.10	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.30	
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.00	
PLATELETS	150-400 (10¬9/L)	01/03/91	317.00	
NA+	137-145 (MMOL/L)	01/03/91	142.00	
K+	3.5-5 (MMOL/L)	01/03/91	4.10	
CL-	100-111 (MMOL/L)	01/03/91	104.00	
Ca++	2.1-2.5 (MMOL/L)	01/03/91	2.33	
PO4--	0.7-1.4 (MMOL/L)	01/03/91	0.83	
SGOT	5-40 (U/L)	01/03/91	32.00	
SGPT	5-55 (U/L)	01/03/91	17.00	
GAMMA GT	10-80 (U/L)	01/03/91	21.00	
LDH	300-550 (U/L)	01/03/91	496.00	
ALK. PHOSPH.	19-95 (U/L)	01/03/91	54.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	6.80	>
UREA	2.5-7.5 (MMOL/L)	01/03/91	9.20	>
CREATININE	60-110 (UMOL/L)	01/03/91	116.00	>
URIC ACID	180-440 (UMOL/L)	01/03/91	361.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	13.00	
TOT. PROTEINS	62-81 (G/L)	01/03/91	76.00	
ALBUMINE	35-50 (G/L)	01/03/91	45.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	4.69	
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	0.82	
TSH	0.2-3.2 (MU/L)	01/03/91	0.70	
T4	11-24 (PMOL/L)	01/03/91	14.50	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 1 Patient: 12 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/10/91		15/11/91		05/12/91	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/03/91	14.00		14.00		13.30	
HT	37-47 (%)	01/03/91	41.00		41.00		39.00	
RBC	3.8-5.8 (10¬12/L)	01/03/91	4.72		4.77		4.47	
WBC	4-11 (10¬9/L)	01/03/91	7.60		6.40		8.50	
WBC: N	2-7.5 (10¬9/L)	01/03/91	4.30		3.70		5.10	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	2.70		2.20		2.70	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.20		0.10		0.30	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.40		0.40		0.40	
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.10		0.00		0.10	
PLATELETS	150-400 (10¬9/L)	01/03/91	277.00		275.00		244.00	
NA+	137-145 (MMOL/L)	01/03/91	141.00		139.00		141.00	
K+	3.5-5 (MMOL/L)	01/03/91	4.00		4.10		4.30	
CL-	100-111 (MMOL/L)	01/03/91	104.00		104.00		106.00	
Ca++	2.1-2.5 (MMOL/L)	01/03/91	2.47		2.41		2.35	
PO4--	0.7-1.4 (MMOL/L)	01/03/91	1.09		1.17		1.19	
SGOT	5-40 (U/L)	01/03/91	15.00		35.00		35.00	
SGPT	5-55 (U/L)	01/03/91	19.00		26.00		15.00	
GAMMA GT	10-80 (U/L)	01/03/91	18.00		18.00		14.00	
LDH	300-550 (U/L)	01/03/91	547.00		583.00	>	567.00	>
ALK. PHOSPH.	19-95 (U/L)	01/03/91	73.00		82.00		77.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	5.20		6.00	>	4.40	
UREA	2.5-7.5 (MMOL/L)	01/03/91	7.00		6.10		7.10	
CREATININE	60-110 (UMOL/L)	01/03/91	90.00		95.00		87.00	
URIC ACID	180-440 (UMOL/L)	01/03/91	279.00		326.00		234.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	10.00		9.00		7.00	
TOT. PROTEINS	62-81 (G/L)	01/03/91	81.00		77.00		79.00	
ALBUMINE	35-50 (G/L)	01/03/91	47.00		44.00		46.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	6.64	>	5.38		5.43	
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	1.83	>	2.02	>	1.64	
TSH	0.2-3.2 (MU/L)	01/03/91	0.60		0.60		0.70	
T4	11-24 (PMOL/L)	01/03/91	14.90		13.10		13.20	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 1 Patient: 412 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			12/11/91		05/12/91		23/12/91	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/03/91	16.40		15.70		16.40	
HT	41-53 (%)	01/03/91	48.00		46.00		47.00	
RBC	4.5-6.5 (10¬12/L)	01/03/91	5.36		5.15		5.29	
WBC	4-11 (10¬9/L)	01/03/91	14.20	>	18.20	>>	10.70	
WBC: N	2-7.5 (10¬9/L)	01/03/91	10.00	>>	14.10	>>	7.00	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	3.50		3.60		3.00	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.20		0.40		0.20	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.30		0.20		0.30	
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.10		0.00		0.10	
PLATELETS	150-400 (10¬9/L)	01/03/91	236.00		223.00		221.00	
NA+	137-145 (MMOL/L)	01/03/91	140.00		141.00		139.00	
K+	3.5-5 (MMOL/L)	01/03/91	4.20		4.40		4.40	
CL-	98-110 (MMOL/L)	01/03/91	104.00		105.00		105.00	
Ca++	2.1-2.55 (MMOL/L)	01/03/91	2.44		2.53		2.39	
PO4--	0.75-1.4 (MMOL/L)	01/03/91	1.09		0.74	<	0.67	<
SGOT	5-40 (U/L)	01/03/91	58.00	>	42.00	>	53.00	>
SGPT	5-55 (U/L)	01/03/91	101.00	>	49.00		40.00	
GAMMA GT	10-80 (U/L)	01/03/91	46.00		39.00		42.00	
LDH	300-550 (U/L)	01/03/91	678.00	>	928.00	>	783.00	>
ALK. PHOSPH.	19-95 (U/L)	01/03/91	75.00		63.00		69.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	4.60		5.00		4.30	
UREA	2.5-7.5 (MMOL/L)	01/03/91	4.50		7.60	>	4.60	
CREATININE	60-110 (UMOL/L)	01/03/91	102.00		108.00		105.00	
URIC ACID	180-440 (UMOL/L)	01/03/91	307.00		393.00		283.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	9.00		10.00		11.00	
TOT. PROTEINS	60-80 (G/L)	01/03/91	76.00		76.00		74.00	
ALBUMINE	38-50 (G/L)	01/03/91	43.00		41.00		40.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	5.75	>	4.35		4.92	
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	2.36	>>	1.76	>	2.53	>>
TSH	0.2-3.2 (MU/L)	01/03/91	1.40		1.80		1.40	
T4	11-24 (PMOL/L)	01/03/91	10.40	<	13.00		15.10	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 1 Patient: 413 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/12/91		30/12/91		20/01/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/03/91	15.00		14.70		14.50	
HT	41-53 (%)	01/03/91	46.00		43.00		43.00	
RBC	4.5-6.5 (10¬12/L)	01/03/91	4.74		4.48	<	4.49	<
WBC	4-11 (10¬9/L)	01/03/91	4.70		4.40		5.30	
WBC: N	2-7.5 (10¬9/L)	01/03/91	2.30		2.20		2.60	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	1.80		1.60		2.00	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.10		0.10		0.20	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.50		0.40		0.50	
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	01/03/91	154.00		188.00		174.00	
NA+	137-145 (MMOL/L)	01/03/91	141.00		143.00		140.00	
K+	3.5-5 (MMOL/L)	01/03/91	4.10		3.60		3.90	
CL-	98-110 (MMOL/L)	01/03/91	103.00		104.00		103.00	
Ca++	2.1-2.55 (MMOL/L)	01/03/91	2.27		2.20		2.38	
PO4--	0.75-1.4 (MMOL/L)	01/03/91	0.57	<<	0.56	<<	0.77	
SGOT	5-40 (U/L)	01/03/91	50.00	>	47.00	>	30.00	
SGPT	5-55 (U/L)	01/03/91	46.00		44.00		39.00	
GAMMA GT	10-80 (U/L)	01/03/91	26.00		27.00		29.00	
LDH	300-550 (U/L)	01/03/91	739.00	>	651.00	>	479.00	
ALK. PHOSPH.	19-95 (U/L)	01/03/91	78.00		76.00		81.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	4.50		3.80		3.50	<
UREA	2.5-7.5 (MMOL/L)	01/03/91	7.40		8.20	>	7.30	
CREATININE	60-110 (UMOL/L)	01/03/91	95.00		106.00		95.00	
URIC ACID	180-440 (UMOL/L)	01/03/91	345.00		403.00		310.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	14.00		10.00		10.00	
TOT. PROTEINS	60-80 (G/L)	01/03/91	76.00		76.00		79.00	
ALBUMINE	36-50 (G/L)	01/03/91	41.00		41.00		43.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	5.70	>	6.49	>	6.29	>
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	0.54		1.24		1.00	
TSH	0.2-3.2 (MU/L)	01/03/91	1.90		1.50		1.60	
T4	11-24 (PMOL/L)	01/03/91	25.00	>	14.90		17.20	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 1 Patient: 414 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			19/01/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/03/91	15.50	
HT	37-47 (%)	01/03/91	45.00	
RBC	3.8-5.8 (10¬12/L)	01/03/91	5.10	
WBC	4-11 (10¬9/L)	01/03/91	8.20	
WBC: N	2-7.5 (10¬9/L)	01/03/91	5.00	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	2.60	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.10	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.50	
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.10	
PLATELETS	150-400 (10¬9/L)	01/03/91	188.00	
NA+	137-145 (MMOL/L)	01/03/91	139.00	
K+	3.5-5 (MMOL/L)	01/03/91	3.90	
CL-	100-111 (MMOL/L)	01/03/91	103.00	
SGOT	5-40 (U/L)	01/03/91	33.00	
SGPT	5-55 (U/L)	01/03/91	18.00	
GAMMA GT	10-80 (U/L)	01/03/91	22.00	
ALK. PHOSPH.	19-95 (U/L)	01/03/91	90.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	4.40	
UREA	2.5-7.5 (MMOL/L)	01/03/91	5.00	
CREATININE	60-110 (UMOL/L)	01/03/91	82.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	15.00	
TOT. PROTEINS	62-81 (G/L)	01/03/91	79.00	
ALBUMINE	35-50 (G/L)	01/03/91	43.00	
TSH	0.2-3.2 (MU/L)	01/03/91	1.00	
T4	11-24 (PMOL/L)	01/03/91	5.00	<<

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 1 Patient: 415 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			14/01/92		06/02/92		27/02/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/03/91	15.50		15.50		15.80	
HT	41-53 (%)	01/03/91	45.00		45.00		46.00	
RBC	4.5-6.5 (10¬12/L)	01/03/91	4.48	<	4.45	<	4.61	
WBC	4-11 (10¬9/L)	01/03/91	8.20		7.30		7.70	
WBC: N	2-7.5 (10¬9/L)	01/03/91	5.00		4.40		4.40	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	2.70		2.30		2.50	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.10		0.10		0.10	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.30		0.40		0.60	
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.10		0.10		0.10	
PLATELETS	150-400 (10¬9/L)	01/03/91	343.00		331.00		352.00	
NA+	137-145 (MMOL/L)	01/03/91	139.00		141.00		140.00	
K+	3.5-5 (MMOL/L)	01/03/91	4.10		3.30	<	4.20	
CL-	98-110 (MMOL/L)	01/03/91	105.00		98.00		100.00	
Ca++	2.1-2.55 (MMOL/L)	01/03/91	2.34				2.23	
PO4--	0.75-1.4 (MMOL/L)	01/03/91	0.97				0.91	
SGOT	5-40 (U/L)	01/03/91	28.00		36.00		32.00	
SGPT	5-55 (U/L)	01/03/91	36.00		35.00		44.00	
GAMMA GT	10-80 (U/L)	01/03/91	58.00		59.00		54.00	
LDH	300-550 (U/L)	01/03/91	497.00				539.00	
ALK. PHOSPH.	19-95 (U/L)	01/03/91	57.00		64.00		63.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	5.00		6.60	>	4.30	
UREA	2.5-7.5 (MMOL/L)	01/03/91	6.50		3.30		7.00	
CREATININE	60-110 (UMOL/L)	01/03/91	94.00		105.00		96.00	
URIC ACID	180-440 (UMOL/L)	01/03/91	541.00	>			425.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	14.00		9.00		12.00	
TOT. PROTEINS	60-80 (G/L)	01/03/91	79.00		73.00		72.00	
ALBUMINE	38-50 (G/L)	01/03/91	46.00		45.00		45.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	5.07		5.63	>	5.11	
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	0.58		1.34		2.05	>
TSH	0.2-3.2 (MU/L)	01/03/91	0.90		0.70		0.60	
T4	11-24 (PMOL/L)	01/03/91	15.80		17.00		14.90	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 1 Patient: 416 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			20/01/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/03/91	8.40	<<
HT	37-47 (%)	01/03/91	27.00	<<
RBC	3.8-5.8 (10¬12/L)	01/03/91	4.29	
WBC	4-11 (10¬9/L)	01/03/91	8.30	
WBC: N	2-7.5 (10¬9/L)	01/03/91	4.90	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	2.80	
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.70	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.60	
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.20	
PLATELETS	150-400 (10¬9/L)	01/03/91	319.00	
NA+	137-145 (MMOL/L)	01/03/91	138.00	
K+	3.5-5 (MMOL/L)	01/03/91	4.10	
CL-	100-111 (MMOL/L)	01/03/91	105.00	
Ca++	2.1-2.5 (MMOL/L)	01/03/91	2.30	
PO4--	0.7-1.4 (MMOL/L)	01/03/91	1.23	
SGOT	5-40 (U/L)	01/03/91	30.00	
SGPT	5-55 (U/L)	01/03/91	19.00	
GAMMA GT	10-80 (U/L)	01/03/91	17.00	
LDH	300-550 (U/L)	01/03/91	394.00	
ALK. PHOSPH.	19-95 (U/L)	01/03/91	74.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	4.50	
UREA	2.5-7.5 (MMOL/L)	01/03/91	4.70	
CREATININE	60-110 (UMOL/L)	01/03/91	74.00	
URIC ACID	180-440 (UMOL/L)	01/03/91	201.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	8.00	
TOT. PROTEINS	62-81 (G/L)	01/03/91	74.00	
ALBUMINE	35-50 (G/L)	01/03/91	40.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	5.12	
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	0.63	
TSH	0.2-3.2 (MU/L)	01/03/91	100.00	>>
T4	11-24 (PMOL/L)	01/03/91	7.30	<<

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 1 Patient: 421 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			26/02/92		19/03/92		09/04/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	14-18 (G/DL)	01/03/91	14.40		14.60		14.10	
HT	41-53 (%)	01/03/91	42.00		43.00		41.00	
RBC	4.5-6.5 (10¬12/L)	01/03/91	4.42	<	4.50		4.32	<
WBC	4-11 (10¬9/L)	01/03/91	7.30		10.00		8.60	
WBC: N	2-7.5 (10¬9/L)	01/03/91	3.10		5.10		2.49	
WBC: L	1.3-3.6 (10¬9/L)	01/03/91	3.60		4.10	>	5.25	>>
WBC: E	0-0.7 (10¬9/L)	01/03/91	0.10		0.10		0.09	
WBC: M	0.2-0.8 (10¬9/L)	01/03/91	0.50		0.60		0.77	
WBC: B	0-0.2 (10¬9/L)	01/03/91	0.00		0.10		0.00	
PLATELETS	150-400 (10¬9/L)	01/03/91	329.00		320.00		383.00	
NA+	137-145 (MMOL/L)	01/03/91	141.00		141.00		139.00	
K+	3.5-5 (MMOL/L)	01/03/91	4.70		4.30		4.70	
CL-	98-110 (MMOL/L)	01/03/91	102.00		101.00		100.00	
Ca++	2.1-2.55 (MMOL/L)	01/03/91	2.34		2.30		2.38	
PO4--	0.75-1.4 (MMOL/L)	01/03/91	1.33		1.44	>	1.42	>
SGOT	5-40 (U/L)	01/03/91	27.00		26.00		36.00	
SGPT	5-55 (U/L)	01/03/91	33.00		27.00		27.00	
GAMMA GT	10-80 (U/L)	01/03/91	201.00	>>	159.00	>	162.00	>>
LDH	300-550 (U/L)	01/03/91	579.00	>	550.00		591.00	>
ALK. PHOSPH.	19-95 (U/L)	01/03/91	85.00		76.00		79.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	4.80		4.40			
UREA	2.5-7.5 (MMOL/L)	01/03/91					5.00	
CREATININE	60-110 (UMOL/L)	01/03/91	96.00		103.00		98.00	
URIC ACID	180-440 (UMOL/L)	01/03/91	437.00		402.00		436.00	
TOT BILIRUBIN	3-22 (UMOL/L)	01/03/91	20.00		14.00		17.00	
TOT. PROTEINS	60-80 (G/L)	01/03/91	82.00	>	82.00	>	82.00	>
ALBUMINE	38-50 (G/L)	01/03/91	46.00		45.00		46.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	7.02	>	7.74	>>	7.87	>>
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	2.25	>	2.39	>>	1.84	>
TSH	0.2-3.2 (MU/L)	01/03/91	1.90		2.40		2.40	
T4	11-24 (PMOL/L)	01/03/91	17.40		15.60		12.40	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

Laboratory test	Range value	Range date	04/08/92		26/08/92		17/09/92	
			value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	01/03/91	14.80					
HT	41-53 (%)	01/03/91	43.00					
RBC	4.5-6.5 (10-12/L)	01/03/91	4.74					
RBC	4-11 (10-9/L)	01/03/91	7.40					
WBC: N	2-7.5 (10-9/L)	01/03/91	4.00					
WBC: L	1.3-3.6 (10-9/L)	01/03/91	2.22					
WBC: E	0-0.7 (10-9/L)	01/03/91	0.52					
WBC: M	0.2-0.8 (10-9/L)	01/03/91	0.52					
WBC: B	0-0.2 (10-9/L)	01/03/91	0.15					
PLATELETS	150-400 (10-9/L)	01/03/91	244.00					
NA+	137-145 (MMOL/L)	01/03/91	142.00		141.00		141.00	
K+	3.5-5 (MMOL/L)	01/03/91	4.40		5.20	>	4.50	
CL-	98-110 (MMOL/L)	01/03/91	103.00		101.00		100.00	
CA++	2.1-2.55 (MMOL/L)	01/03/91	2.34		2.38		2.40	
PO4--	0.75-1.4 (MMOL/L)	01/03/91	1.07		0.57	<<	1.20	
SGOT	5-40 (U/L)	01/03/91	53.00	>	37.00		43.00	>
SGPT	5-55 (U/L)	01/03/91	40.00		25.00		67.00	>
GAMMA GT	10-80 (U/L)	01/03/91	41.00		30.00		37.00	
LDH	300-550 (U/L)	01/03/91	542.00		607.00	>	547.00	
ALK. PHOSPH.	19-95 (U/L)	01/03/91	69.00		79.00		80.00	
GLUCOSE	3.6-5.8 (MMOL/L)	01/03/91	4.90		5.50		4.40	
UREA	2.5-7.5 (MMOL/L)	01/03/91	8.60	>	5.30		4.20	
CREATININE	60-110 (UMOL/L)	01/03/91	103.00	>	99.00		101.00	
URIC ACID	180-440 (UMOL/L)	01/03/91	507.00	>	284.00		291.00	
TOT. BILIRUBIN	3-22 (UMOL/L)	01/03/91	11.00		11.00		9.00	
TOT. PROTEINS	60-80 (G/L)	01/03/91	72.00		74.00		80.00	
ALBUMINE	38-50 (G/L)	01/03/91	47.00		46.00		50.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	01/03/91	7.12	>	5.97	>	7.38	>>
TRIGLYCERIDES	0.4-1.75 (MMOL/L)	01/03/91	1.01		2.00	>	0.99	
TSH	0.2-3.2 (MU/L)	01/03/91	0.70		0.70		0.90	
T4	11-24 (PMOL/L)	01/03/91	14.00		15.50		17.70	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 2/1 Patient: 49 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			16/05/91		08/06/91		29/06/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-18 (G/100ML)	01/05/91	14.00		12.20		13.10	
HT	35-60 (%)	01/05/91	42.60		35.70		37.20	
RBC	4-6 (10~6/MM3)	01/05/91	4.43		3.77	<	3.98	<
WBC	4.5-10.5 (10~3/MM3)	01/05/91	6.20		4.60		5.10	
WBC: N	40-70 (%)	01/05/91	59.00				45.00	
WBC: L	20-40 (%)	01/05/91	26.00		41.70	>	44.00	>
WBC: E	1-4 (%)	01/05/91	1.00				2.00	
WBC: M	3-7 (%)	01/05/91	13.00	>>	6.20		8.00	>
WBC: B	0-1 (%)	01/05/91	1.00				1.00	
PLATELETS	150-450 (10~3/MM3)	01/05/91	303.00		271.00		299.00	
NA+	135-145 (MMOL/L)	01/05/91	141.00				140.00	
K+	3.5-5 (MMOL/L)	01/05/91	3.90				3.90	
CL-	101-110 (MMOL/L)	01/05/91	103.00				102.00	
Ca++	2.15-2.6 (MMOL/L)	01/05/91	2.46		2.45		2.51	
PO4--	0.81-1.45 (MMOL/L)	01/05/91	1.16		1.39		1.06	
SGOT	6-35 (U/L)	01/05/91	29.00				19.00	
SGPT	6-35 (U/L)	01/05/91	18.00				31.00	
GAMMA GT	8-33 (U/L)	01/05/91	14.00				24.00	
LDH	120-280 (U/L)	01/05/91	220.00		165.00		223.00	
ALK. PHOSPH.	30-90 (U/L)	01/05/91	54.00		50.00		59.00	
GLUCOSE	3.9-6.1 (MMOL/L)	01/05/91	4.80				4.60	
UREA	2.5-6.5 (MMOL/L)	01/05/91	5.40				4.00	
CREATININE	50-110 (UMOL/L)	01/05/91	88.00				81.00	
URIC ACID	180-450 (UMOL/L)	01/05/91	183.00		275.00		315.00	
TOT BILIRUBIN	3-17.1 (UMOL/L)	01/05/91	8.60		7.40		13.80	
DIR BILIRUBIN	0-5.1 (UMOL/L)	01/05/91					3.90	
TOT. PROTEINS	60-80 (G/L)	01/05/91	68.00		62.00		81.00	>
ALBUMINE	35-50 (G/L)	01/05/91	50.80	>	63.60	>	50.40	>
TOT. CHOLEST.	4-6.4 (MMOL/L)	01/05/91	5.97				7.54	>
TRIGLYCERIDES	0.78-1.65 (MMOL/L)	01/05/91	0.92				1.24	
GLOBULINS ALPHA 1	1-4 (G/L)	01/05/91	2.00		3.40		1.50	
GLOBULINS ALPHA 2	5-11 (G/L)	01/05/91	6.70		9.40		6.10	
GLOBULINS BETA	6-13 (G/L)	01/05/91	9.30		12.00		8.80	
GLOBULINS GAMMA	7-15 (G/L)	01/05/91	9.20		11.60		10.20	
TSH	0.2-4.3 (UU/ML)	01/05/91	1.20					
T4	10-26 (PMOL/L)	01/05/91	12.20					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 2/1 Patient: 50 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			24/12/91		16/01/92		06/02/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11-18 (G/100ML)	01/05/91	14.40		13.50		12.70	
HT	35-60 (%)	01/05/91	42.00		39.40		39.40	
RBC	4-6 (10~6/MM3)	01/05/91	4.38		4.19		4.29	
WBC	4.5-10.5 (10~3/MM3)	01/05/91	7.90		6.50		6.90	
WBC: N	40-70 (%)	01/05/91	55.00		66.00		59.00	
WBC: L	20-40 (%)	01/05/91	39.00		19.00	<	35.00	
WBC: E	1-4 (%)	01/05/91	4.00		4.00		8.00	>>
WBC: M	3-7 (%)	01/05/91	2.00	<	9.00	>	4.00	
WBC: B	0-1 (%)	01/05/91	0.00		2.00	>>	0.00	
PLATELETS	150-450 (10~3/MM3)	01/05/91	286.00		264.00		339.00	
NA+	135-145 (MMOL/L)	01/05/91	140.00		139.00		139.00	
K+	3.5-5 (MMOL/L)	01/05/91	4.00		4.00		3.70	
CL-	101-110 (MMOL/L)	01/05/91	104.00		104.00		102.00	
Ca++	2.15-2.6 (MMOL/L)	01/05/91	2.29		2.21		2.30	
PO4--	0.81-1.45 (MMOL/L)	01/05/91	1.01		0.87		0.88	
SGOT	6-35 (U/L)	01/05/91	56.00	>	16.00		16.00	
SGPT	6-35 (U/L)	01/05/91	39.00	>	21.00		12.00	
GAMMA GT	8-33 (U/L)	01/05/91	52.00	>	22.00		15.00	
LDH	120-280 (U/L)	01/05/91	229.00		159.00		151.00	
ALK. PHOSPH.	30-90 (U/L)	01/05/91	31.00		31.00		34.00	
GLUCOSE	3.9-6.1 (MMOL/L)	01/05/91	6.10		4.60		5.20	
UREA	2.5-6.5 (MMOL/L)	01/05/91	4.20		3.40		4.90	
CREATININE	50-110 (UMOL/L)	01/05/91	79.00		76.00		92.00	
URIC ACID	180-450 (UMOL/L)	01/05/91	200.00		270.00		342.00	
TOT BILIRUBIN	3-17.1 (UMOL/L)	01/05/91	10.70		3.80		3.80	
TOT. PROTEINS	60-80 (G/L)	01/05/91	75.00		69.00		72.00	
ALBUMINE	35-50 (G/L)	01/05/91	42.00		45.70		45.30	
TOT. CHOLEST.	4-6.4 (MMOL/L)	01/05/91	6.89	>	5.07		4.94	
TRIGLYCERIDES	0.78-1.65 (MMOL/L)	01/05/91	1.92	>	0.60	<	0.88	
GLOBULINS ALPHA 1	1-4 (G/L)	01/05/91	2.50		1.90		3.40	
GLOBULINS ALPHA 2	5-11 (G/L)	01/05/91	8.40		6.00		6.70	
GLOBULINS BETA	6-13 (G/L)	01/05/91	9.40		6.90		8.30	
GLOBULINS GAMMA	7-15 (G/L)	01/05/91	9.30		8.50		8.30	
TSH	0.2-4.3 (UU/ML)	01/05/91	1.90					
T4	10-26 (PMOL/L)	01/05/91	24.80					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 2/1 Patient: 51 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			28/01/92		24/02/92		16/03/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11-18 (G/100ML)	01/05/91	14.30		13.10		13.40	
HT	35-60 (%)	01/05/91	41.90		38.50		39.40	
RBC	4-6 (10¬6/MM3)	01/05/91	4.58		4.23		4.32	
WBC	4.5-10.5 (10¬3/MM3)	01/05/91	8.40		6.10		6.90	
WBC: N	40-70 (%)	01/05/91	79.00	>	69.00		77.00	>
WBC: L	20-40 (%)	01/05/91	17.00	<	24.00		18.00	<
WBC: E	1-4 (%)	01/05/91	2.00		0.00	<	3.00	
WBC: M	3-7 (%)	01/05/91	2.00	<	7.00		2.00	<
WBC: B	0-1 (%)	01/05/91	0.00		0.00		0.00	
PLATELETS	150-450 (10¬3/MM3)	01/05/91	283.00		227.00		245.00	
NA+	135-145 (MMOL/L)	01/05/91	141.00		142.00		142.00	
K+	3.5-5 (MMOL/L)	01/05/91	3.70		3.30	<	3.80	
CL-	101-110 (MMOL/L)	01/05/91	105.00		104.00		105.00	
Ca++	2.15-2.6 (MMOL/L)	01/05/91	2.17		2.19		2.20	
PO4--	0.81-1.45 (MMOL/L)	01/05/91	1.17		1.12		1.05	
SGOT	6-35 (U/L)	01/05/91	10.00		18.00		10.00	
SGPT	6-35 (U/L)	01/05/91	8.00		12.00		16.00	
GAMMA GT	8-33 (U/L)	01/05/91	13.00		12.00		14.00	
LDH	120-280 (U/L)	01/05/91	162.00		145.00		186.00	
ALK. PHOSPH.	30-90 (U/L)	01/05/91	40.00		37.00		40.00	
GLUCOSE	3.9-6.1 (MMOL/L)	01/05/91	4.60		4.80		4.70	
UREA	2.5-6.5 (MMOL/L)	01/05/91	4.90		4.80		5.90	
CREATININE	50-110 (UMOL/L)	01/05/91	75.00		73.00		75.00	
URIC ACID	180-450 (UMOL/L)	01/05/91	220.00		229.00		206.00	
TOT BILIRUBIN	3-17.1 (UMOL/L)	01/05/91	11.00		11.90		6.30	
TOT. PROTEINS	60-80 (G/L)	01/05/91	68.00		63.00		67.00	
ALBUMINE	35-50 (G/L)	01/05/91	41.40		41.90		44.70	
TOT. CHOLEST.	4-6.4 (MMOL/L)	01/05/91	5.72		3.94	<	5.48	
TRIGLYCERIDES	0.78-1.65 (MMOL/L)	01/05/91	1.16		0.91		0.86	
GLOBULINS ALPHA 1	1-4 (G/L)	01/05/91	2.00		1.80		1.80	
GLOBULINS ALPHA 2	5-11 (G/L)	01/05/91	6.70		5.60		6.10	
GLOBULINS BETA	6-13 (G/L)	01/05/91	7.60		5.60	<	5.80	<
GLOBULINS GAMMA	7-15 (G/L)	01/05/91	10.30		8.10		8.60	
TSH	0.2-4.3 (UU/ML)	01/05/91	3.90					
T4	10-26 (PMOL/L)	01/05/91	18.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 2/2 Patient: 43 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 28	
			11/04/91		13/05/91	
			value	(¢)	value	(¢)
Laboratory test	Range value	Range date				
HB	115-180 (G/L)	11/03/91	123.00		130.00	
HT	0.37-0.47 (L/L)	11/03/91	0.38		0.39	
RBC	4-5 (10¬6/UL)	11/03/91	3.74	<	3.97	<
WBC	4-10 (10¬3/MM3)	11/03/91	5.48		6.10	
WBC: N	1.8-7.5 (10¬3/MM3)	11/03/91	3.51		3.75	
WBC: L	1.5-4 (10¬3/MM3)	11/03/91	1.47	<	1.54	
WBC: E	0.04-0.7 (10¬3/MM3)	11/03/91	0.03	<	0.11	
WBC: M	0.2-1 (10¬3/MM3)	11/03/91	0.38		0.46	
WBC: B	0-0.1 (10¬3/MM3)	11/03/91	0.10		0.03	
PLATELETS	115-400 (10¬3/UL)	11/03/91	165.00		171.00	
NA+	135-145 (MMOL/L)	11/03/91	137.00		137.00	
K+	3.8-4.8 (MMOL/L)	11/03/91	4.50		3.70	<
CL-	98-108 (MMOL/L)	11/03/91	102.00		102.00	
Ca++	2.2-2.6 (MMOL/L)	11/03/91	2.16	<	2.12	<
PO4--	0.8-1.4 (MMOL/L)	11/03/91			1.31	
SGOT	10-45 (U/L)	11/03/91	11.00		16.00	
SGPT	10-45 (U/L)	11/03/91	6.00	<	18.00	
GAMMA GT	5-45 (U/L)	11/03/91	13.00		21.00	
ALK. PHOSPH.	40-110 (U/L)	11/03/91	43.00		58.00	
GLUCOSE	4.5-5 (MMOL/L)	11/03/91	4.70		5.10	>
UREA	3.5-7.5 (MM/L)	11/03/91	4.60		4.30	
CREATININE	45-90 (UMOL/L)	11/03/91	98.20	>	98.50	>
URIC ACID	150-360 (UMOL/L)	11/03/91	176.00		268.00	
TOT BILIRUBIN	4-20 (UMOL/L)	11/03/91	15.00		6.00	
DIR BILIRUBIN	0-20 (UMOL/L)	11/03/91	12.00		5.00	
TOT. PROTEINS	60-75 (G/L)	11/03/91	78.00	>	79.00	>
ALBUMINE	30.6-50.2 (G/L)	11/03/91	43.10		42.40	
TOT. CHOLEST.	4-6 (MMOL/L)	11/03/91	3.88	<	4.30	
TRIGLYCERIDES	0.5-1.5 (MMOL/L)	11/03/91	0.90		2.03	>>
GLOBULINS ALPHA 1	1.8-3.7 (G/L)	11/03/91	1.40	<	1.80	
GLOBULINS ALPHA 2	4.2-9 (G/L)	11/03/91	5.10		9.10	>
GLOBULINS BETA	6-12 (G/L)	11/03/91	6.80		8.40	
GLOBULINS GAMMA	6-13 (G/L)	11/03/91	11.30		14.10	>
TSH	0.1-5 (MU/L)	11/03/91	1.63			
T4	10-23 (PMOL/L)	11/03/91	17.90			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 2/2 Patient: 44 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			12/07/91		09/08/91		28/08/91	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	115-180 (G/L)	10/05/91	121.00		117.00		146.00	
HT	38-48 (%)	10/05/91	34.00	<	35.00	<	39.10	
RBC	4-5 (10~6/UL)	10/05/91	3.80	<	3.90	<	4.16	
WBC	4-10 (10~3/MM3)	10/05/91	6.95		5.30		5.29	
WBC: N	1.8-7.5 (10~3/MM3)	10/05/91	3.98		3.80		2.81	
WBC: L	1.5-4 (10~3/MM3)	10/05/91	2.23		1.90		1.97	
WBC: E	0.04-0.7 (10~3/MM3)	10/05/91	0.06		0.00	<	0.12	
WBC: M	0.2-1 (10~3/MM3)	10/05/91	0.48		0.21		0.25	
WBC: B	0-0.1 (10~3/MM3)	10/05/91	0.02		0.00		0.03	
PLATELETS	115-400 (10~3/UL)	10/05/91	158.00		142.00		220.00	
NA+	135-145 (MMOL/L)	10/05/91	140.00		139.00		137.00	
K+	3.8-4.8 (MMOL/L)	10/05/91	3.50	<	3.30	<	4.00	
CL-	98-108 (MMOL/L)	10/05/91	106.00		102.00		104.00	
Ca++	2.2-2.6 (MMOL/L)	10/05/91	2.11	<	2.16	<	2.14	<
PO4--	0.8-1.4 (MMOL/L)	10/05/91	1.14		1.04		1.00	
SGOT	10-45 (U/L)	10/05/91	19.00		21.00		15.00	
SGPT	10-45 (U/L)	10/05/91	14.00		22.00		10.00	
GAMMA GT	5-45 (U/L)	10/05/91	10.00		14.00		11.00	
LDH	210-450 (UI/L)	10/05/91	322.00		356.00			
ALK. PHOSPH.	40-110 (U/L)	10/05/91	55.00		60.00		60.00	
GLUCOSE	4.5-5 (MMOL/L)	10/05/91	4.10	<	3.60	<	4.30	<
UREA	3.5-7.5 (MMOL/L)	10/05/91	3.60		3.10	<	3.40	<
CREATININE	45-90 (UMOL/L)	10/05/91	80.00		81.00		79.00	
URIC ACID	150-360 (UMOL/L)	10/05/91	138.00	<				
TOT BILIRUBIN	4-20 (UMOL/L)	10/05/91	6.00		5.00		3.90	<
DIR BILIRUBIN	0-20 (UMOL/L)	10/05/91	4.00		1.00		0.70	
TOT. PROTEINS	60-75 (G/L)	10/05/91	71.00		70.00		67.00	
ALBUMINE	30.6-50.2 (G/L)	10/05/91	37.90					
TOT. CHOLEST.	4-6 (MMOL/L)	10/05/91	5.49		5.01			
TRIGLYCERIDES	0.5-1.5 (MMOL/L)	10/05/91	0.85		0.83			
GLOBULINS ALPHA 1	1.8-3.7 (G/L)	10/05/91	2.90					
GLOBULINS ALPHA 2	4.2-9 (G/L)	10/05/91	10.00	>				
GLOBULINS BETA	6-12 (G/L)	10/05/91	10.00					
GLOBULINS GAMMA	6-13 (G/L)	10/05/91	9.90					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 2/2 Patient: 45 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			27/08/91		30/09/91		21/10/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-17 (G/DL)	27/07/91	13.20				12.70	
HT	38-48 (%)	27/07/91	42.00		45.00		40.40	
RBC	3.8-5.8 (10-6/UL)	27/07/91	4.62				4.48	
WBC	4-10 (10-3/UL)	27/07/91	8.43				7.84	
WBC: N	45-74 (%)	27/07/91	64.50				60.10	
WBC: L	16-45 (%)	27/07/91	27.30				31.50	
WBC: E	0-7 (%)	27/07/91	1.00				1.20	
WBC: M	4-10 (%)	27/07/91	3.60	<			4.00	
WBC: B	0-2 (%)	27/07/91	0.80				0.80	
PLATELETS	130-400 (10-3/UL)	27/07/91	241.00				218.00	
NA+	135-145 (MMOL/L)	27/07/91	138.00		138.00		140.00	
K+	3.5-4.8 (MMOL/L)	27/07/91	4.00		4.70		4.20	
CL-	96-108 (MMOL/L)	27/07/91	103.00		98.00		104.00	
Ca++	2.2-2.5 (MMOL/L)	27/07/91	2.25		2.29		2.09	<
PO4--	0.8-1.4 (MMOL/L)	27/07/91	0.87		0.90		0.96	
SGOT	10-45 (UI/L)	27/07/91	18.00		20.00		18.00	
SGPT	10-65 (UI/L)	27/07/91	16.00		13.00		18.00	
GAMMA GT	5-45 (UI/L)	27/07/91	11.00		14.00		10.00	
LDH	210-450 (UI/L)	27/07/91			367.00		328.00	
ALK. PHOSPH.	40-130 (UI/L)	27/07/91	97.00		91.00		80.00	
GLUCOSE	3.5-5.5 (MMOL/L)	27/07/91	5.00		3.20	<	4.70	
BUN	()	27/07/91						
UREA	2.5-7.5 (MMOL/L)	27/07/91	2.60		4.60			
CREATININE	50-130 (UMOL/L)	27/07/91	88.00		85.00		66.00	
URIC ACID	150-360 (UMOL/L)	27/07/91			376.00	>	266.00	
TOT BILIRUBIN	0-17 (UMOL/L)	27/07/91	11.50		6.80		8.40	
DIR BILIRUBIN	0.2-5 (UMOL/L)	27/07/91	1.90		1.30		2.00	
TOT. PROTEINS	60-75 (G/L)	27/07/91	78.00	>	81.00	>	75.00	
ALBUMINE	35-50 (G/L)	27/07/91	47.00		46.00		42.00	
TOT. CHOLEST.	4-6.5 (MMOL/L)	27/07/91			6.23		4.92	
TRIGLYCERIDES	0.6-1.7 (MMOL/L)	27/07/91			2.34	>>	1.03	
GLOBULINS ALPHA 1	2-4 (%)	27/07/91			3.60		2.60	
GLOBULINS ALPHA 2	6-10 (%)	27/07/91			7.40		4.80	<
GLOBULINS BETA	8-12 (%)	27/07/91			13.70	>	10.00	
GLOBULINS GAMMA	11-19 (%)	27/07/91			15.20		11.80	
TSH	0.3-6.2 (MUI/L)	27/07/91	0.70					
T4	58-154 (NMOL/L)	27/07/91	73.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 2/2 Patient: 46 Treatment: Placebo Sex: Female

			Visit number / Laboratory date			
			Screen		Day 28	
			18/09/91		23/10/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11.5-17 (G/DL)	01/09/91	12.90		12.90	
HT	38-48 (%)	01/09/91	39.50		39.80	
RBC	3.8-5.8 (10¬6/UL)	01/09/91	4.10		4.14	
WBC	4-10 (10¬3/UL)	01/09/91	9.80		8.22	
WBC: N	1.9-7.5 (10¬3/UL)	01/09/91	5.96			
	45-74 (%)	20/10/91			59.40	
WBC: L	1.5-4 (10¬3/UL)	01/09/91	3.09			
	16-45 (%)	20/10/91			31.70	
WBC: E	0-0.5 (10¬3/UL)	01/09/91	0.18			
	0-7 (%)	20/10/91			1.90	
WBC: M	0.16-1 (10¬3/UL)	01/09/91	0.32			
	4-10 (%)	20/10/91			3.60	<
WBC: B	0-0.2 (10¬3/UL)	01/09/91	0.03			
	0-2 (%)	20/10/91			0.90	
PLATELETS	130-400 (10¬3/UL)	01/09/91	381.00		331.00	
NA+	135-145 (MMOL/L)	01/09/91	140.00		140.00	
K+	3.8-4.8 (MMOL/L)	01/09/91	3.70	<	3.20	<<
CL-	96-108 (MMOL/L)	01/09/91	102.00		99.00	
Ca++	2.2-2.5 (MMOL/L)	01/09/91	2.17	<	2.19	<
PO4--	0.8-1.4 (MMOL/L)	01/09/91	1.22		1.12	
SGOT	10-45 (UI/L)	01/09/91	14.00		16.00	
SGPT	10-65 (UI/L)	01/09/91	13.00		15.00	
GAMMA GT	5-45 (UI/L)	01/09/91	14.00		15.00	
LDH	210-450 (UI/L)	01/09/91	263.00		301.00	
ALK. PHOSPH.	40-130 (UI/L)	01/09/91	49.00		51.00	
GLUCOSE	3.5-5.5 (MMOL/L)	01/09/91	4.40		4.40	
UREA	2.5-7.5 (MMOL/L)	01/09/91	5.20			
CREATININE	50-130 (UMOL/L)	01/09/91	66.00			
	50-130 (MMOL/L)	20/10/91			62.00	
URIC ACID	150-360 (UMOL/L)	01/09/91	238.00			
	150-360 (MMOL/L)	20/10/91			202.00	
TOT BILIRUBIN	0-17 (UMOL/L)	01/09/91	9.50			
	0-17 (MMOL/L)	20/10/91			6.70	
DIR BILIRUBIN	0.2-5 (UMOL/L)	01/09/91	1.80			
	0.2-5 (MMOL/L)	20/10/91			1.80	
TOT. PROTEINS	60-75 (G/L)	01/09/91	72.00		69.00	
ALBUMINE	35-50 (G/L)	01/09/91	44.00		43.00	
TOT. CHOLEST.	4-6.5 (MMOL/L)	01/09/91	4.44		4.50	
TRIGLYCERIDES	0.5-1.5 (MMOL/L)	01/09/91	0.63		0.53	
GLOBULINS ALPHA 1	1.8-3.7 (G/L)	20/10/91			1.90	
GLOBULINS ALPHA 2	4.2-9 (G/L)	20/10/91			4.60	
GLOBULINS BETA	6-12 (G/L)	20/10/91			7.30	
GLOBULINS GAMMA	6-13 (G/L)	20/10/91			9.10	
TSH	0.3-6.2 (MUI/L)	01/09/91	0.60			
T4	58-154 (NMOL/L)	01/09/91	82.00			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 2/2 Patient: 47 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			13/03/92		14/04/92		05/05/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-17 (G/DL)	01/03/92	11.70		12.30		12.50	
HT	38-48 (%)	01/03/92	34.10	<	39.40		39.30	
RBC	3.8-5.8 (10¬6/UL)	01/03/92	3.95		4.33		4.36	
WBC	4-10 (10¬3/UL)	01/03/92	10.70	>	8.09		7.85	
WBC: N	1.9-7.5 (10¬3/UL)	01/03/92	7.67	>				
	45-74 (%)	10/04/92			60.00		54.30	
WBC: L	1.5-4 (10¬3/UL)	01/03/92	2.19					
	16-45 (%)	10/04/92			31.70		34.80	
WBC: E	0-0.5 (10¬3/UL)	01/03/92	0.05					
	0-7 (%)	10/04/92			1.20		1.90	
WBC: M	0.16-1 (10¬3/UL)	01/03/92	0.56					
	4-10 (%)	10/04/92			4.50		6.20	
WBC: B	0-0.2 (10¬3/UL)	01/03/92	0.04					
	0-2 (%)	10/04/92			0.40		0.50	
PLATELETS	130-400 (10¬3/UL)	01/03/92	253.00		192.00		181.00	
NA+	135-145 (MMOL/L)	01/03/92	138.00		141.00		135.00	
K+	3.5-4.8 (MMOL/L)	01/03/92	4.10		3.90		3.60	
CL-	96-108 (MMOL/L)	01/03/92	101.00		109.00	>	104.00	
Ca++	2.2-2.5 (MMOL/L)	01/03/92	2.29		1.96	<	2.26	
PO4--	0.8-1.4 (MMOL/L)	01/03/92	1.03		1.00		1.01	
SGOT	10-45 (UI/L)	01/03/92	16.00		25.00			
SGPT	10-65 (UI/L)	01/03/92	22.00		32.00			
GAMMA GT	5-45 (UI/L)	01/03/92	19.00		15.00			
ALK. PHOSPH.	40-130 (UI/L)	01/03/92	62.00		46.00			
GLUCOSE	3.5-5.5 (MMOL/L)	01/03/92	5.20		6.40	>	5.50	
UREA	2.5-7.5 (UMOL/L)	01/03/92	3.70					
	2.5-7.5 (MMOL/L)	10/04/92			6.80		4.10	
CREATININE	50-130 (MMOL/L)	01/03/92	62.00		73.00		74.00	
URIC ACID	150-360 (UMOL/L)	01/03/92	200.00					
TOT BILIRUBIN	0-17 (UMOL/L)	01/03/92	6.50					
	0-17 (MMOL/L)	10/04/92			10.40			
DIR BILIRUBIN	0.2-5 (UMOL/L)	01/03/92	0.90					
	0.2-5 (MMOL/L)	10/04/92			2.30			
TOT. PROTEINS	60-75 (G/L)	01/03/92	75.00		78.00	>	71.00	
ALBUMINE	35-50 (G/L)	01/03/92	49.00		52.00	>	48.00	
TOT. CHOLEST.	4-6.5 (MMOL/L)	01/03/92	4.71		5.60			
TRIGLYCERIDES	0.6-1.7 (MMOL/L)	01/03/92	0.66		0.42	<		
GLOBULINS ALPHA 1	1.8-3.7 (G/L)	01/03/92	3.20		2.80			
GLOBULINS ALPHA 2	4.2-9 (G/L)	01/03/92	9.00		7.60			
GLOBULINS BETA	6-12 (G/L)	01/03/92	7.60		13.10	>		
GLOBULINS GAMMA	6-13 (G/L)	01/03/92	10.10		13.80	>		
TSH	0.3-6.2 (MUI/L)	01/03/92	0.60					
T4	10-23 (PMOL/L)	01/03/92	15.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory nôt done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 2/2 Patient: 48 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/04/92		28/04/92		20/05/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	11.5-17 (G/DL)	01/03/92	12.20		12.60			
HT	38-48 (%)	01/03/92	38.70		39.00			
RBC	3.8-5.8 (10~6/UL)	01/03/92	4.09		4.23			
WBC	4-10 (10~3/UL)	01/03/92	7.34		7.16			
WBC: N	45-74 (%)	01/03/92	62.80		58.90			
WBC: L	16-45 (%)	01/03/92	26.80		29.70			
WBC: E	0-7 (%)	01/03/92	2.40		2.50			
WBC: M	4-10 (%)	01/03/92	4.50		5.20			
WBC: B	0-2 (%)	01/03/92	0.60		0.50			
PLATELETS	130-400 (10~3/UL)	01/03/92	289.00		285.00			
NA+	135-145 (MMOL/L)	01/03/92	137.00		136.00			
K+	3.5-4.8 (MMOL/L)	01/03/92	3.80		4.80			
CL-	96-108 (MMOL/L)	01/03/92	105.00		103.00			
Ca++	2.2-2.5 (MMOL/L)	01/03/92	2.22		2.29			
PO4--	0.8-1.4 (MMOL/L)	01/03/92	0.77	<	0.93			
SGOT	10-45 (UI/L)	01/03/92	13.00		17.00		17.00	
SGPT	10-65 (UI/L)	01/03/92	11.00		13.00		13.00	
GAMMA GT	5-45 (UI/L)	01/03/92	19.00		13.00			
ALK. PHOSPH.	40-130 (UI/L)	01/03/92	45.00		66.00		65.00	
GLUCOSE	3.5-5.5 (MMOL/L)	01/03/92			4.80			
UREA	2.5-7.5 (MMOL/L)	01/03/92	4.40		4.30			
CREATININE	50-130 (MMOL/L)	01/03/92			71.00			
URIC ACID	150-360 (MMOL/L)	01/03/92	318.00				413.00	>
TOT BILIRUBIN	0-17 (MMOL/L)	01/03/92	10.70		10.90		10.30	
DIR BILIRUBIN	0.2-5 (MMOL/L)	01/03/92	4.30		2.70		2.70	
TOT. PROTEINS	60-75 (G/L)	01/03/92	70.00		76.00	>		
ALBUMINE	35-50 (G/L)	01/03/92	46.00		53.00	>		
TOT. CHOLEST.	4-6.5 (MMOL/L)	01/03/92	4.55		4.21		4.21	
TRIGLYCERIDES	0.6-1.7 (MMOL/L)	01/03/92			0.52	<	0.52	<
TSH	0.3-6.2 (MUI/L)	01/03/92	3.40					
T4	10-23 (PMOL/L)	01/03/92	13.50					

1650

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 2/3 Patient: 36/A Treatment: Imipramine Sex: Male

			Visit number / Laboratory date			
			Day 21		Day 42	
			22/03/91		08/04/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-14 (GR/DL)	06/02/91	16.50	>		
HT	32-47 (%)	06/02/91	51.30	>		
RBC	4-5.4 (10¬6/UL)	06/02/91	5.59	>		
WBC	5-10 (10¬3/UL)	06/02/91	8.80			
WBC: N	52-68 (%)	06/02/91	73.00	>		
WBC: L	26-38 (%)	06/02/91	23.00	<		
WBC: E	1-3 (%)	06/02/91	1.00			
WBC: M	4-8 (%)	06/02/91	3.00	<		
WBC: B	0-1 (%)	06/02/91	0.00			
PLATELETS	150-450 (10¬3/UL)	06/02/91	299.00			
NA+	135-145 (MEQ/L)	06/02/91	140.00		137.00	
K+	3.5-5.5 (MEQ/L)	06/02/91	5.00		4.80	
CL-	98-107 (MEQ/L)	06/02/91	102.00		98.00	
Ca++	88-102 (MG/L)	06/02/91	101.00		98.00	
PO4--	25-50 (MG/L)	06/02/91	36.00		41.00	
SGOT	5-22 (U/L)	06/02/91	16.00		17.00	
SGPT	5-24 (U/L)	06/02/91	12.00		14.00	
GAMMA GT	5-29 (U/L)	06/02/91	13.00		13.00	
LDH	160-230 (U/L)	06/02/91	215.00		540.00	>>
ALK. PHOSPH.	30-100 (U/L)	06/02/91	43.00		43.00	
GLUCOSE	0.5-1.1 (G/L)	06/02/91	1.44	>>	1.48	>>
UREA	0.2-0.45 (G/L)	06/02/91	0.28		0.28	
CREATININE	6-13 (MG/L)	06/02/91	11.00		9.40	
URIC ACID	30-60 (MG/L)	06/02/91	65.00	>	70.00	>
TOT BILIRUBIN	1.5-10 (MG/L)	06/02/91	5.00		3.00	
DIR BILIRUBIN	0-3 (MG/L)	06/02/91	4.00	>		
TOT. PROTEINS	60-80 (G/L)	06/02/91	69.00		67.00	
ALBUMINE	34-48 (G/L)	06/02/91	39.70		36.30	
TOT. CHOLEST.	1.5-2.4 (G/L)	06/02/91	2.85	>	3.06	>
TRIGLYCERIDES	0.5-1.5 (G/L)	06/02/91	2.20	>>	2.75	>>
GLOBULINS ALPHA 1	1-3 (G/L)	06/02/91	2.40		2.40	
GLOBULINS ALPHA 2	4-7 (G/L)	06/02/91	10.00	>>	11.30	>>
GLOBULINS BETA	6-11 (G/L)	06/02/91	10.30		9.50	
GLOBULINS GAMMA	8-14 (G/L)	06/02/91	6.30	<	7.10	<

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 2/3 Patient: 37 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 42	
			18/03/91		13/05/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
HB	12-16 (G/L)	01/03/91	14.00			
HT	35-45 (%)	01/03/91	44.00			
RBC	4-5 (10¬6/UL)	01/03/91	4.66			
WBC	4-10 (10¬3/UL)	01/03/91	6.40			
WBC: N	50-70 (%)	01/03/91	66.00			
WBC: L	20-40 (%)	01/03/91	27.00			
WBC: E	0-3 (%)	01/03/91	3.00			
WBC: M	2-8 (%)	01/03/91	4.00			
WBC: B	0-2 (%)	01/03/91	0.00			
PLATELETS	150-400 (10¬3/UL)	01/03/91	247.00			
NA+	135-143 (MEQ/L)	01/03/91	137.00		139.00	
K+	3.5-5.5 (MEQ/L)	01/03/91	3.80		3.80	
CL-	97-108 (MEQ/L)	01/03/91	99.00		98.00	
Ca++	86-108 (MEQ/L)	01/03/91	91.00		90.00	
PO4--	28-42 (MG/L)	01/03/91	51.00	>>	42.00	
SGOT	5-25 (UI/L)	01/03/91	28.00	>	23.00	
SGPT	5-25 (UI/L)	01/03/91	14.00		12.00	
GAMMA GT	5-30 (UI/L)	01/03/91	32.00	>	16.00	
LDH	150-320 (UI/L)	01/03/91	216.00		192.00	
ALK. PHOSPH.	50-200 (UI/L)	01/03/91	143.00		122.00	
GLUCOSE	0.7-1.1 (G/L)	01/03/91	0.97		0.92	
UREA	0.15-0.4 (G/L)	01/03/91	0.23		0.25	
CREATININE	6-12 (MG/L)	01/03/91	10.00		11.00	
URIC ACID	20-60 (MG/L)	01/03/91	34.00		50.00	
TOT BILIRUBIN	1.5-10 (MG/L)	01/03/91	9.00		4.00	
TOT. PROTEINS	62-75 (G/L)	01/03/91	68.00		72.00	
ALBUMINE	40-60 (G/L)	01/03/91	42.16		44.64	
TOT. CHOLEST.	2-2.5 (G/L)	01/03/91	3.26	>>	3.16	>
TRIGLYCERIDES	0.45-1.5 (G/L)	01/03/91	1.89	>	3.79	>>
GLOBULINS ALPHA 1	2-5 (%)	01/03/91	2.00		3.00	
GLOBULINS ALPHA 2	4-12 (%)	01/03/91	9.00		10.00	
GLOBULINS BETA	9-15 (%)	01/03/91	13.00		12.00	
GLOBULINS GAMMA	14-20 (%)	01/03/91	14.00		13.00	<

1652

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0
9550082
LABORATORY DATA
Centre: 2/3 Patient: 38 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/08/91		09/09/91		26/09/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	12-17 (G/DL)	25/07/91	15.50		15.40		15.80	
HT	35-54 (%)	25/07/91	44.20		40.00		45.90	
RBC	4-5.5 (10¬6/UL)	25/07/91	4.97		4.51		5.20	
WBC	4-9 (10¬3/UL)	25/07/91	7.50		8.30		7.20	
WBC: N	52-68 (%)	25/07/91	67.00		61.00		66.00	
WBC: L	26-38 (%)	25/07/91	25.00	<	32.00		26.00	
WBC: E	1-3 (%)	25/07/91	2.00		2.00		2.00	
WBC: M	4-8 (%)	25/07/91	6.00		5.00		6.00	
WBC: B	0-1 (%)	25/07/91	0.00		0.00		0.00	
PLATELETS	200-400 (10¬3/UL)	25/07/91	259.00		257.00		307.00	
NA+	137-146 (MEQ/L)	25/07/91	139.00		139.00		140.00	
K+	3.8-5.2 (MEQ/L)	25/07/91	3.70	<	3.70	<	3.70	<
CL-	95-106 (MEQ/L)	25/07/91	101.00		102.00		100.00	
Ca++	90-104 (MG/L)	25/07/91	92.00		94.00		92.00	
PO4--	25-42 (MG/L)	25/07/91	30.00		36.00		37.00	
SGOT	5-25 (UI/L)	25/07/91	8.00		9.00		10.00	
SGPT	5-29 (UI/L)	25/07/91	17.00		15.00		19.00	
GAMMA GT	7-34 (UI/L)	25/07/91	23.00		11.00		26.00	
LDH	140-280 (UI/L)	25/07/91	194.00		201.00		195.00	
ALK. PHOSPH.	30-100 (UI/L)	25/07/91	60.00		59.00		58.00	
GLUCOSE	0.7-1.1 (G/L)	25/07/91	0.91		0.89		0.91	
UREA	0.15-0.5 (G/L)	25/07/91	0.28		0.24		0.21	
CREATININE	5-12 (MG/L)	25/07/91	12.40	>	9.80		11.20	
URIC ACID	34-70 (MG/L)	25/07/91	44.00		62.00		66.00	
TOT BILIRUBIN	1.5-10 (MG/L)	25/07/91	9.60		11.70	>	7.70	
TOT. PROTEINS	65-87 (G/L)	25/07/91			74.00		73.00	
ALBUMINE	57-65 (%)	25/07/91			62.60		59.00	
TOT. CHOLEST.	1.2-2.4 (G/L)	25/07/91	2.48	>	2.39		2.56	>
TRIGLYCERIDES	0.4-1.5 (G/L)	25/07/91	1.23		2.15	>>	2.46	>>
GLOBULINS ALPHA 1	2-4 (%)	25/07/91			3.90		3.30	
GLOBULINS ALPHA 2	6-10 (%)	25/07/91			6.40		6.60	
GLOBULINS BETA	8-12 (%)	25/07/91			9.80		10.40	
GLOBULINS GAMMA	12-19 (%)	25/07/91			17.30		20.60	>

1653

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 2/3 Patient: 39 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			06/08/91		30/08/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12.5-15 (G/DL)	01/08/91	13.50			
HT	36-45 (%)	01/08/91	40.60			
RBC	3.8-5 (10¬6/UL)	01/08/91	4.72			
WBC	6.7-10 (10¬3/UL)	01/08/91	6.70			
WBC: N	52-68 (%)	01/08/91	60.00			
WBC: L	26-38 (%)	01/08/91	35.00			
WBC: E	1-3 (%)	01/08/91	1.00			
WBC: M	4-8 (%)	01/08/91	4.00			
WBC: B	0-1 (%)	01/08/91	0.00			
PLATELETS	200000-450000 (/UL)	01/08/91	344000			
NA+	137-145 (MMOL/L)	01/08/91	140.00		139.00	
K+	3.7-5 (MMOL/L)	01/08/91	3.80		3.80	
CL-	90-110 (MMOL/L)	01/08/91	100.00		99.00	
Ca++	85-104 (MG/L)	01/08/91	103.00		96.40	
PO4--	25-42 (MG/L)	01/08/91	42.20	>	33.60	
SGOT	5-22 (U/L)	01/08/91	10.00		7.00	
SGPT	5-24 (U/L)	01/08/91	12.00		11.00	
GAMMA GT	6-22 (U/L)	01/08/91	13.00		14.00	
LDH	140-280 (UI/L)	01/08/91	237.00		252.00	
ALK. PHOSPH.	30-100 (UI/L)	01/08/91	45.00			
GLUCOSE	0.75-1.1 (G/L)	01/08/91	1.09			
UREA	0.15-0.4 (G/L)	01/08/91	0.41	>	0.25	
CREATININE	6.8-12.4 (MG/L)	01/08/91	8.90		9.60	
URIC ACID	24-57 (MG/L)	01/08/91	36.70		39.00	
TOT BILIRUBIN	3-11 (MG/L)	01/08/91	3.40		3.40	
TOT. PROTEINS	60-80 (G/L)	01/08/91	76.70		72.80	
ALBUMINE	32-50 (G/L)	01/08/91	49.10		46.80	
TOT. CHOLEST.	1.5-2.4 (G/L)	01/08/91	3.27	>>	2.69	>
TRIGLYCERIDES	0.6-1.5 (G/L)	01/08/91	0.88		0.70	
GLOBULINS ALPHA 1	1-4 (G/L)	01/08/91	2.40			
	1.5-4.5 (%)	15/08/91			3.20	
GLOBULINS ALPHA 2	5-11 (G/L)	01/08/91	6.50			
	6-12 (%)	15/08/91			10.30	
GLOBULINS BETA	6-13 (G/L)	01/08/91	9.60			
	11-17 (%)	15/08/91			10.90	<
GLOBULINS GAMMA	7-15 (G/L)	01/08/91	9.10			
	11-19 (%)	15/08/91			9.20	<

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 2/3 Patient: 40 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			24/10/91		15/11/91		05/12/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/10/91	15.00		11.60	<	13.00	
HT	35-52 (%)	01/10/91	43.00		34.70	<	38.10	
RBC	4-6 (10~6/UL)	01/10/91	4.16		3.33	<<	3.62	<
WBC	4-10 (10~3/UL)	01/10/91	4.80		8.20		8.10	
WBC: N	50-76 (%)	01/10/91	53.00		56.00		70.00	
WBC: L	15-45 (%)	01/10/91	42.00		38.00		20.00	
WBC: E	0-5 (%)	01/10/91	1.00		3.00		0.00	
WBC: M	4-9.9 (%)	01/10/91	4.00		3.00	<	8.00	
WBC: B	0-3 (%)	01/10/91	0.00		0.00		0.00	
PLATELETS	150-400 (10~3/UL)	01/10/91	184.00		327.00		285.00	
NA+	137-145 (MMOL/L)	01/10/91	133.00	<	140.00		142.00	
K+	3.3-5 (MMOL/L)	01/10/91	3.70		4.70		5.60	>
CL-	98-106 (MMOL/L)	01/10/91	90.00	<	100.00		101.00	
Ca++	2.2-2.6 (MMOL/L)	01/10/91	2.30		2.20		2.37	
PO4--	0.8-1.3 (MMOL/L)	01/10/91	1.13		1.12		1.39	>
SGOT	0-0.4 (UKAT/L)	01/10/91	1.40	>>	0.30		0.40	
SGPT	0-0.4 (UKAT/L)	01/10/91	0.70	>	0.10		0.70	>
GAMMA GT	0.1-0.4 (UKAT/L)	01/10/91	3.20	>>	0.90	>>	0.90	>>
LDH	2.4-5.5 (UKAT/L)	01/10/91	3.50		3.70		3.60	
ALK. PHOSPH.	0.5-1.7 (UKAT/L)	01/10/91	1.40		0.90		1.20	
GLUCOSE	4-6 (MMOL/L)	01/10/91	4.10		3.90	<	4.90	
UREA	3-6.5 (MMOL/L)	01/10/91	1.60	<	2.80	<	2.10	<
CREATININE	45-90 (UMOL/L)	01/10/91	54.00		47.00		53.00	
URIC ACID	150-360 (UMOL/L)	01/10/91	130.00	<	129.00	<	162.00	
TOT BILIRUBIN	0-17 (UMOL/L)	01/10/91	12.00		4.00		9.00	
DIR BILIRUBIN	0-4 (UMOL/L)	01/10/91	3.00		2.00		3.00	
TOT. PROTEINS	38.7-48.8 (G/L)	01/10/91	56.00	>				
	65-80 (G/L)	14/11/91			51.00	<	53.00	<
ALBUMINE	57-69 (%)	01/10/91	61.00		64.00		55.50	<
TOT. CHOLEST.	3.2-6.3 (MMOL/L)	01/10/91	7.40	>	9.20	>>	10.20	>>
TRIGLYCERIDES	0.4-1.4 (MMOL/L)	01/10/91	1.30		3.50	>>	2.50	>>
GLOBULINS ALPHA 1	1-3 (G/L)	01/10/91	2.60					
	2-4 (%)	14/11/91			3.70		4.30	>
GLOBULINS ALPHA 2	4-10 (G/L)	01/10/91	4.40					
	6-10 (%)	14/11/91			9.20		9.80	
GLOBULINS BETA	5-11 (G/L)	01/10/91	5.30					
	7-12 (%)	14/11/91			10.20		13.10	>
GLOBULINS GAMMA	8-16 (G/L)	01/10/91	9.50					
	10-20 (%)	14/11/91			12.90		17.30	
TSH	0.2-35 (UU/ML)	01/10/91	1.60					
	0.2-3.5 (UU/ML)	14/11/91					16.00	>>
T4	7.3-20.1 (PG/ML)	01/10/91	14.00				12.00	

1655

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 2/3 Patient: 41 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/10/91		29/10/91		19/11/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	01/10/91	14.00		13.30		13.70	
HT	38-52 (%)	01/10/91	42.00		41.00		41.00	
RBC	4.2-5.7 (10¬6/UL)	01/10/91	4.78		4.60		8.30	>
WBC	4-10 (10¬3/UL)	01/10/91	11.90	>	9.20		4.50	
WBC: N	2-7 (10¬3/UL)	01/10/91	8.33	>	5.06		5.31	
WBC: L	1-4 (10¬3/UL)	01/10/91	3.09		3.40		2.41	
WBC: E	40-300 (/UL)	01/10/91	119.00		184.00		166.00	
WBC: M	20-800 (/UL)	01/10/91	357.00		552.00		415.00	
WBC: B	0-100 (/UL)	01/10/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬3/UL)	01/10/91	151.00		206.00		202.00	
NA+	137-146 (MEQ/L)	01/10/91	139.00		140.00		140.00	
K+	3.7-5 (MEQ/L)	01/10/91	3.80		3.90		3.70	
CL-	96-106 (MEQ/L)	01/10/91	100.00		107.00	>	109.00	>
Ca++	92-105 (MG/L)	01/10/91	100.00		98.00		95.00	
PO4--	25-42 (MG/L)	01/10/91	50.00	>>	41.00		42.00	
SGOT	5-27 (UI/L)	01/10/91	30.00	>	14.00		12.00	
SGPT	5-30 (UI/L)	01/10/91	42.00	>	23.00		16.00	
GAMMA GT	5-38 (UI/L)	01/10/91	50.00	>	32.00		19.00	
LDH	160-320 (UI/L)	01/10/91	196.00		169.00		162.00	
ALK. PHOSPH.	30-90 (UI/L)	01/10/91	47.00		37.00		40.00	
GLUCOSE	0.7-1.1 (G/L)	01/10/91	0.98		0.99		1.03	
UREA	0.15-0.45 (G/L)	01/10/91	0.34		0.45		0.32	
CREATININE	6-15 (MG/L)	01/10/91	6.00		8.00		7.00	
URIC ACID	30-79 (MG/L)	01/10/91	70.00		60.00		60.00	
TOT BILIRUBIN	1.5-10 (MG/L)	01/10/91	4.00		3.00		2.80	
TOT. PROTEINS	65-75 (G/L)	01/10/91	65.00		71.00		72.00	
ALBUMINE	35-52 (G/L)	01/10/91	40.10		54.40	>	57.20	>
TOT. CHOLEST.	1.3-2.3 (G/L)	01/10/91	2.57	>	2.77	>	2.16	
TRIGLYCERIDES	0.4-1.5 (G/L)	01/10/91	2.42	>>	2.41	>>	3.36	>>
GLOBULINS ALPHA 1	1-4 (%)	01/10/91	3.50		4.30	>	3.70	
GLOBULINS ALPHA 2	6-10 (%)	01/10/91	8.50		9.00		9.80	
GLOBULINS BETA	8-12 (%)	01/10/91	13.50	>	16.70	>>	14.80	>
GLOBULINS GAMMA	13-19 (%)	01/10/91	12.70	<	14.90		14.50	
TSH	0.2-5 (MUI/L)	01/10/91	0.67				1.02	
T4	6.2-50 (PG/ML)	01/10/91	14.80				12.70	

1656

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 2/3 Patient: 42 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/05/92		06/06/92		30/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	05/03/92	12.50					
	13-16 (G/DL)	05/06/92			11.80	<	12.30	<
HT	35-52 (%)	05/03/92	37.10					
	32-47 (%)	05/06/92			35.00		38.40	
RBC	4-6 (10¬6/UL)	05/03/92	3.90	<				
	4-5.2 (10¬6/UL)	05/06/92			3.71	<	4.02	
WBC	4-10 (10¬3/UL)	05/03/92	3.80	<				
	4,5-9 (10¬3/UL)	05/06/92			8.70		8.10	
WBC: N	50-76 (%)	05/03/92	37.20	<				
	50-70 (%)	05/06/92			74.00	>	67.00	
WBC: L	15-45 (%)	05/03/92	47.60	>				
	25-40 (%)	05/06/92			17.00	<<	29.00	
WBC: E	0-5 (%)	05/03/92	0.50					
	1-4 (%)	05/06/92			3.00		1.00	
WBC: M	4-9.9 (%)	05/03/92	13.70	>>				
	4-10 (%)	05/06/92			5.00		3.00	<
WBC: B	0-3 (%)	05/03/92	1.00					
	0-1 (%)	05/06/92			1.00		0.00	
PLATELETS	150-400 (10¬3/UL)	05/03/92	504.00	>	362.00		470.00	>
NA+	137-145 (MMOL/L)	05/03/92	138.00					
	135-145 (MEQ/L)	05/06/92			140.00		142.00	
K+	3.3-5 (MMOL/L)	05/03/92	3.90					
	3.7-5.2 (MEQ/L)	05/06/92			3.60	<	4.80	
CL-	98-106 (MMOL/L)	05/03/92	104.00					
	97-109 (MEQ/L)	05/06/92			102.00		105.00	
Ca++	2.2-2.6 (MMOL/L)	05/03/92	2.34					
	95-105 (MG/L)	05/06/92			90.00	<	87.00	<
PO4--	0.8-1.3 (MMOL/L)	05/03/92	0.70	<				
	28-45 (MG/L)	05/06/92			21.00	<<	24.00	<
SGOT	0-0.4 (UKAT/L)	05/03/92	0.20					
	5-37 (UI/L)	05/06/92			13.00		11.00	
SGPT	0-0.4 (UKAT/L)	05/03/92	0.10					
	5-40 (UI/L)	05/06/92			6.00		10.00	
GAMMA GT	0.1-0.4 (UKAT/L)	05/03/92	1.30	>>				
	7-32 (UI/L)	05/06/92			63.00	>	89.00	>>
LDH	2.4-5.5 (UKAT/L)	05/03/92	3.50					
	230-460 (UI/L)	05/06/92			557.00	>	421.00	
ALK. PHOSPH.	0.5-1.7 (UKAT/L)	05/03/92	2.20	>				
	39-117 (UI/L)	05/06/92			134.00	>	142.00	>
GLUCOSE	4-6 (MMOL/L)	05/03/92	6.20	>				
	0.8-1.1 (G/L)	05/06/92			1.08		0.93	
UREA	3-6.5 (MMOL/L)	05/03/92	4.20					
	0.15-0.4 (G/L)	05/06/92			0.24		0.17	
CREATININE	45-90 (UMOL/L)	05/03/92	93.00	>				
	5-12 (MG/L)	05/06/92			11.00		10.20	
URIC ACID	150-360 (UMOL/L)	05/03/92	234.00					
	30-70 (MG/L)	05/06/92			56.00		68.00	
TOT BILIRUBIN	0-17 (UMOL/L)	05/03/92	5.00					
	0-10 (MG/L)	05/06/92			1.00		5.00	
DIR BILIRUBIN	0-4 (UMOL/L)	05/03/92	2.00					
TOT. PROTEINS	65-80 (G/L)	05/03/92	72.00		67.00		71.00	
ALBUMINE	57-69 (G/L)	05/03/92	58.20					
	52-65 (%)	05/06/92			49.90	<	53.10	
TOT. CHOLEST.	3.2-6.3 (MMOL/L)	05/03/92	7.10	>				
	1.7-2.3 (G/L)	05/06/92			2.22		2.15	
TRIGLYCERIDES	0.4-1.4 (MMOL/L)	05/03/92	2.40	>>				
	0.5-1.5 (G/L)	05/06/92			1.91	>	2.05	>>
GLOBULINS ALPHA 1	2-4 (%)	05/03/92	4.50	>				
	1-4.6 (%)	05/06/92			3.10		3.80	
GLOBULINS ALPHA 2	6-10 (%)	05/03/92	10.90	>				
	6-17.6 (%)	05/06/92			11.80		16.40	
GLOBULINS BETA	7-12 (%)	05/03/92	13.50	>				

(CONTINUED)

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 2/3 Patient: 42 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/05/92		06/06/92		30/06/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
GLOBULINS BETA	8-15.7 (%)	05/06/92			10.50		15.10	
GLOBULINS GAMMA	10-20 (%)	05/03/92	13.50					
	8-12.2 (%)	05/06/92			8.20		11.60	
TSH	0.2-3.5 (UU/ML)	05/03/92	1.10					
T4	7.3-20.1 (PG/ML)	05/03/92	12.00					

1658

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 2/4 Patient: 31 Treatment: Placebo Sex: Male

			Visit number / Laboratory date			
			Screen		Day 42	
			22/03/91		30/04/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	13-18 (G/DL)	02/03/91	15.80		15.30	
HT	39-52 (%)	02/03/91	44.30		44.10	
RBC	4.2-5.7 (10-6/UL)	02/03/91	4.56		4.50	
WBC	5000-9000 (/UL)	02/03/91	12940.0	>>	9860.00	>
WBC: N	50-70 (%)	02/03/91	69.60		67.40	
WBC: L	25-45 (%)	02/03/91	22.30	<	26.00	
WBC: E	1-3 (%)	02/03/91	0.10	<	1.00	
WBC: M	2-9 (%)	02/03/91	7.40		4.90	
WBC: B	0-1 (%)	02/03/91	0.70		0.60	
NA+	135-145 (MEQ/L)	02/03/91	137.00		140.00	
K+	3.6-4.9 (MEQ/L)	02/03/91	4.60		4.70	
CL-	95-105 (MEQ/L)	02/03/91	96.00		100.00	
Ca++	95-105 (MG/L)	02/03/91	101.00		104.00	
PO4--	25-48 (MG/L)	02/03/91	30.00		28.00	
SGOT	10-41 (UI/L)	02/03/91	31.00		26.00	
SGPT	10-41 (UI/L)	02/03/91	20.00		16.00	
GAMMA GT	7-36 (UI/L)	02/03/91	39.00	>	49.00	>
LDH	220-440 (UI/L)	02/03/91	329.00		462.00	>
ALK. PHOSPH.	35-110 (UI/L)	02/03/91	51.00		39.00	
GLUCOSE	4.45-6.12 (MMOL/L)	02/03/91	5.62		4.32	<
UREA	3.32-8.3 (MMOL/L)	02/03/91	4.29		3.15	<
CREATININE	61.95-115.05 (UMOL/L)	02/03/91	73.81		69.09	
URIC ACID	136.9-416.5 (UMOL/L)	02/03/91	218.80		315.50	
TOT BILIRUBIN	3-17.1 (UMOL/L)	02/03/91	1.29	<	3.04	
DIR BILIRUBIN	0-4.28 (UMOL/L)	02/03/91	0.80			
TOT. PROTEINS	65-80 (G/L)	02/03/91	72.00		67.00	
ALBUMINE	37-52 (G/L)	02/03/91	46.90		42.50	
TOT. CHOLEST.	1.5-2.5 (G/L)	02/03/91	2.52	>	2.81	>
TRIGLYCERIDES	0.5-1.6 (G/L)	02/03/91	0.90		1.50	
GLOBULINS ALPHA 1	2-4 (%)	02/03/91	3.20		3.50	
GLOBULINS ALPHA 2	6-10 (%)	02/03/91	10.30	>	10.00	
GLOBULINS BETA	8-12 (%)	02/03/91	10.00		11.80	
GLOBULINS GAMMA	12-19 (%)	02/03/91	11.20	<	11.40	<
TSH	0.32-3.7 (MU/L)	02/03/91	0.79			
T4	8-20 (PMOL/L)	02/03/91	17.80			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 2/4 Patient: 32 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			17/10/91		15/11/91		06/12/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	01/01/91	14.10		14.00		15.20	
HT	39-52 (%)	01/01/91	43.90		40.90		46.50	
RBC	4.2-5.7 (10-6/UL)	01/01/91	4.58		4.52		4.94	
WBC	5000-9000 (/UL)	01/01/91	6840.00		7590.00		7430.00	
WBC: N	50-70 (%)	01/01/91	70.40	>	77.60	>	71.00	>
WBC: L	25-45 (%)	01/01/91	17.90	<	13.20	<<	17.30	<<
WBC: E	1-3 (%)	01/01/91	4.10	>>	2.30		3.60	>
WBC: M	2-9 (%)	01/01/91	6.80		6.40		6.90	
WBC: B	0-1 (%)	01/01/91	0.80		0.50		0.60	
PLATELETS	200000-400000 (/UL)	01/01/91	223000		228000		202000	
NA+	135-145 (MEQ/L)	01/01/91	143.00		140.00		138.00	
K+	3.6-4.9 (MEQ/L)	01/01/91	4.30		4.80		3.80	
CL-	95-105 (MEQ/L)	01/01/91	102.00		101.00		98.00	
Ca++	95-105 (MG/L)	01/01/91	100.00		98.00		97.00	
PO4--	25-48 (MG/L)	01/01/91	28.00		20.00	<<	33.00	
SGOT	10-41 (UI/L)	01/01/91	16.00		18.00		22.00	
SGPT	10-41 (UI/L)	01/01/91	19.00		21.00		23.00	
GAMMA GT	7-36 (UI/L)	01/01/91	35.00		31.00		38.00	>
LDH	220-440 (UI/L)	01/01/91	325.00		336.00		366.00	
ALK. PHOSPH.	35-110 (UI/L)	01/01/91	40.00		40.00		38.00	
GLUCOSE	0.8-1.1 (G/L)	01/01/91	0.80		0.75	<	0.90	
UREA	0.2-0.5 (G/L)	01/01/91	0.20		0.35		0.33	
CREATININE	7-13 (MG/L)	01/01/91	12.20		11.10		10.60	
URIC ACID	23-70 (MG/L)	01/01/91	71.00	>	64.00		68.00	
TOT BILIRUBIN	0-10 (MG/L)	01/01/91	3.40		3.20		3.80	
TOT. PROTEINS	65-80 (G/L)	01/01/91	77.00		71.00		71.00	
ALBUMINE	37-52 (G/L)	01/01/91	45.90		46.40		42.90	
TOT. CHOLEST.	1.5-2.5 (G/L)	01/01/91	1.57		1.69		1.48	<
TRIGLYCERIDES	0.5-1.6 (G/L)	01/01/91	1.17		0.84		0.76	
GLOBULINS ALPHA 1	1-3 (G/L)	01/01/91	2.00		1.80		2.00	
GLOBULINS ALPHA 2	4-7 (G/L)	01/01/91	8.50	>	5.70		7.30	>
GLOBULINS BETA	5-8 (G/L)	01/01/91	8.40	>	7.30		7.50	
GLOBULINS GAMMA	8-12 (G/L)	01/01/91	12.40	>	9.60		11.00	
TSH	0.32-3.7 (MU/L)	01/01/91	1.10					
T4	8-20 (PMOL/L)	01/01/91	12.70					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 2/4 Patient: 33 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 42	
			27/05/91		10/07/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	13-18 (G/DL)	01/05/91	15.40		16.00	
HT	39-52 (%)	01/05/91	43.90		48.00	
RBC	4.2-5.7 (10-6/UL)	01/05/91	4.53		4.82	
WBC	5000-9000 (/UL)	01/05/91	7290.00		6110.00	
WBC: N	50-70 (%)	01/05/91	60.00		67.30	
WBC: L	25-45 (%)	01/05/91	27.00		22.80	<
WBC: E	1-3 (%)	01/05/91	4.60	>>	3.50	>
WBC: M	2-9 (%)	01/05/91	7.00		5.40	
WBC: B	0-1 (%)	01/05/91	1.00		0.90	
PLATELETS	200000-400000 (/UL)	01/05/91	175000	<	154000	<
NA+	135-145 (MEQ/L)	01/05/91	140.00		142.00	
K+	3.6-4.9 (MEQ/L)	01/05/91	4.20		4.40	
CL-	95-105 (MEQ/L)	01/05/91	100.00		101.00	
Ca++	95-105 (MG/L)	01/05/91	100.00			
	2.38-2.63 (MMOL/L)	10/06/91			2.55	
PO4--	25-48 (MG/L)	01/05/91	41.00			
	0.8-1.54 (MMOL/L)	10/06/91			1.30	
SGOT	10-41 (UI/L)	01/05/91	37.00		60.00	>
SGPT	10-41 (UI/L)	01/05/91	14.00		22.00	
GAMMA GT	7-36 (UI/L)	01/05/91	266.00	>>	396.00	>>
LDH	220-440 (UI/L)	01/05/91	309.00		418.00	
ALK. PHOSPH.	35-110 (UI/L)	01/05/91	54.00		79.00	
GLUCOSE	4.45-6.12 (MMOL/L)	01/05/91	4.30	<	4.85	
UREA	0.2-0.5 (G/L)	01/05/91	0.19	<		
	3.32-8.3 (MMOL/L)	10/06/91			2.29	<
CREATININE	7-13 (MG/L)	01/05/91	7.30			
	61.95-115.05 (UMOL/L)	10/06/91			56.72	<
URIC ACID	23-70 (MG/L)	01/05/91	62.00			
	136.9-416.5 (UMOL/L)	10/06/91			227.90	
TOT BILIRUBIN	0-10 (MG/L)	01/05/91	6.50			
	3-17.1 (MMOL/L)	10/06/91			16.70	
TOT. PROTEINS	65-80 (G/L)	01/05/91	67.00		80.00	
ALBUMINE	37-52 (G/L)	01/05/91	44.30		48.70	
TOT. CHOLEST.	1.5-2.5 (G/L)	01/05/91	1.95			
	3.87-6.45 (MMOL/L)	10/06/91			5.39	
TRIGLYCERIDES	0.5-1.6 (G/L)	01/05/91	1.14			
	0.57-1.82 (MMOL/L)	10/06/91			1.35	
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	1.40		2.20	
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	5.30		8.30	>
GLOBULINS BETA	5-8 (G/L)	01/05/91	5.70		9.30	>
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	10.30		11.70	
TSH	0.32-3.7 (MU/L)	01/05/91	3.27			
T4	8-20 (PMOL/L)	01/05/91	11.30			

1661

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 2/4 Patient: 34 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			11/04/92		12/05/92		25/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	01/03/91	14.00		14.70		15.40	
HT	39-52 (%)	01/03/91	41.10		43.90		45.90	
RBC	4.2-5.7 (10-6/UL)	01/03/91	4.54		4.17	<	4.89	
WBC	5000-9000 (/UL)	01/03/91	8170.00		7060.00		6720.00	
WBC: N	50-70 (%)	01/03/91	62.50		63.50		49.50	<
WBC: L	25-45 (%)	01/03/91	27.50		27.10		38.50	
WBC: E	1-3 (%)	01/03/91	1.70		0.80	<	1.10	
WBC: M	2-9 (%)	01/03/91	7.30		7.80		10.10	>
WBC: B	0-1 (%)	01/03/91	1.00		0.70		0.80	
PLATELETS	200000-400000 (/UL)	01/03/91	207000		303000		244000	
NA+	135-145 (MEQ/L)	01/03/91	141.00		137.00		139.00	
K+	3.6-4.9 (MEQ/L)	01/03/91	4.40		4.70		3.60	
CL-	95-105 (MEQ/L)	01/03/91	100.00		96.00		98.00	
Ca++	95-105 (MG/L)	01/03/91	103.00		97.00		105.00	
PO4--	25-48 (MG/L)	01/03/91	34.00		29.00		36.00	
SGOT	10-41 (UI/L)	01/03/91	20.00		14.00		18.00	
SGPT	10-41 (UI/L)	01/03/91	15.00		13.00		12.00	
GAMMA GT	7-36 (UI/L)	01/03/91	11.00		16.00		12.00	
LDH	220-440 (UI/L)	01/03/91	373.00		270.00		312.00	
ALK. PHOSPH.	35-110 (UI/L)	01/03/91	89.00		78.00		87.00	
GLUCOSE	0.8-1.1 (G/L)	01/03/91	1.09		1.12	>	0.87	
UREA	0.2-0.5 (G/L)	01/03/91			0.44			
CREATININE	7-13 (MG/L)	01/03/91	7.10		6.50	<	7.80	
URIC ACID	23-70 (MG/L)	01/03/91	25.00		22.00	<	26.00	
TOT BILIRUBIN	0-10 (MG/L)	01/03/91	2.40		1.90		3.80	
TOT. PROTEINS	65-80 (G/L)	01/03/91	68.00		67.00		71.00	
ALBUMINE	37-52 (G/L)	01/03/91	44.90		42.30		38.00	
TOT. CHOLEST.	1.5-2.5 (G/L)	01/03/91	1.26	<	1.35	<	1.50	
TRIGLYCERIDES	0.5-1.6 (G/L)	01/03/91	0.74		0.60		0.95	
GLOBULINS ALPHA 1	1-3 (G/L)	01/03/91	2.00		2.20		2.70	
GLOBULINS ALPHA 2	4-7 (G/L)	01/03/91	5.80		6.10		7.70	>
GLOBULINS BETA	5-8 (G/L)	01/03/91	7.10		7.10		9.30	>
GLOBULINS GAMMA	8-12 (G/L)	01/03/91	8.10		8.90		13.30	>

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 2/4 Patient: 35 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			08/09/92		03/10/92		27/10/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	01/03/91	13.20		13.20		12.50	<
HT	39-52 (%)	01/03/91	39.70		37.70	<	36.30	<
RBC	4.2-5.7 (10-6/UL)	01/03/91	3.83	<	3.80	<	3.65	<
WBC	5000-9000 (/UL)	01/03/91	5490.00		6160.00		6480.00	
WBC: N	50-70 (%)	01/03/91	32.70	<<	39.80	<	62.10	
WBC: L	25-45 (%)	01/03/91	60.80	>>	52.90	>	30.50	
WBC: E	1-3 (%)	01/03/91	1.00		1.80		1.80	
WBC: M	2-9 (%)	01/03/91	4.60		4.60		5.10	
WBC: B	0-1 (%)	01/03/91	1.00		0.80		0.60	
PLATELETS	200000-400000 (/UL)	01/03/91	173000	<	166000	<	130000	<<
NA+	135-145 (MEQ/L)	01/03/91	136.00		140.00		142.00	
K+	3.6-4.9 (MEQ/L)	01/03/91	4.80		4.80		4.50	
CL-	95-105 (MEQ/L)	01/03/91	95.00		99.00		102.00	
Ca++	95-105 (MG/L)	01/03/91	102.00		95.00		95.00	
PO4--	25-48 (MG/L)	01/03/91	36.00		37.00		40.00	
SGOT	10-41 (UI/L)	01/03/91	26.00		25.00		27.00	
SGPT	10-41 (UI/L)	01/03/91	19.00		17.00		11.00	
GAMMA GT	7-36 (UI/L)	01/03/91	19.00		12.00		18.00	
LDH	220-440 (UI/L)	01/03/91	261.00		299.00		461.00	>
ALK. PHOSPH.	35-110 (UI/L)	01/03/91	79.00		131.00	>	89.00	
GLUCOSE	0.8-1.1 (G/L)	01/03/91	0.80		0.79	<	1.42	>
UREA	0.2-0.5 (G/L)	01/03/91			0.16	<	0.19	<
CREATININE	7-13 (MG/L)	01/03/91	9.40		9.90		9.60	
URIC ACID	23-70 (MG/L)	01/03/91	61.00		55.00		59.00	
TOT BILIRUBIN	0-10 (MG/L)	01/03/91	4.00		3.60		0.60	
TOT. PROTEINS	65-80 (G/L)	01/03/91	71.00		71.00		70.00	
ALBUMINE	57-65 (%)	01/03/91	68.70	>	66.50	>	65.90	>
TOT. CHOLEST.	1.5-2.5 (G/L)	01/03/91	2.18		1.76		1.99	
TRIGLYCERIDES	0.5-1.6 (G/L)	01/03/91	1.51		1.56		1.25	
GLOBULINS ALPHA 1	2-4 (%)	01/03/91	2.50		3.10		3.80	
GLOBULINS ALPHA 2	6-10 (%)	01/03/91	9.40		8.90		10.90	>
GLOBULINS BETA	8-12 (%)	01/03/91	8.70		7.80	<	8.60	
GLOBULINS GAMMA	12-19 (%)	01/03/91	10.70	<	13.70		10.80	<
TSH	0.25-5 (MU/L)	01/03/91	2.89					
T4	8-22 (PMOL/L)	01/03/91	8.50					

1663

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 2/4 Patient: 36 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/02/92		04/03/92		25/03/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	13-18 (G/DL)	01/01/92	12.40	<	13.90		14.00	
HT	39-52 (%)	01/01/92	41.80		43.40		42.30	
RBC	4.2-5.7 (10-6/UL)	01/01/92	4.03	<	4.54		4.61	
WBC	5000-9000 (/UL)	01/01/92	2190.00	<<	3250.00	<<	3100.00	<<
WBC: N	50-70 (%)	01/01/92	53.80		72.90	>	75.10	>
WBC: L	25-45 (%)	01/01/92	36.60		19.10	<	16.10	<<
WBC: E	1-3 (%)	01/01/92	1.50		1.20		0.50	<
WBC: M	2-9 (%)	01/01/92	7.40		6.00		7.80	
WBC: B	0-1 (%)	01/01/92	0.80		0.80		0.50	
PLATELETS	200000-400000 (/UL)	01/01/92	96000.0	<<	146000	<	160000	<
NA+	135-145 (MEQ/L)	01/01/92	137.00		135.00		133.00	<
K+	3.6-4.9 (MEQ/L)	01/01/92	2.80	<<	3.00	<<	3.30	<
CL-	95-105 (MEQ/L)	01/01/92	93.00	<	94.00	<	91.00	<
Ca++	95-105 (MG/L)	01/01/92	95.00		105.00		100.00	
PO4--	25-48 (MG/L)	01/01/92	22.00	<	23.00	<	36.00	
SGOT	10-41 (UI/L)	01/01/92	138.00	>>	28.00		40.00	
SGPT	10-41 (UI/L)	01/01/92	124.00	>>	13.00		14.00	
GAMMA GT	7-36 (UI/L)	01/01/92	308.00	>>	104.00	>>	128.00	>>
LDH	220-440 (UI/L)	01/01/92	363.00		293.00		417.00	
ALK. PHOSPH.	35-110 (UI/L)	01/01/92	203.00	>	112.00	>	209.00	>
GLUCOSE	0.8-1.1 (G/L)	01/01/92	2.62	>>	0.73	<	0.95	
UREA	0.2-0.5 (G/L)	01/01/92			0.11	<	0.13	<
CREATININE	7-13 (MG/L)	01/01/92	7.90		7.00		6.80	<
URIC ACID	23-70 (MG/L)	01/01/92	30.00		40.00		45.00	
TOT BILIRUBIN	0-10 (MG/L)	01/01/92	10.60	>	4.70		6.90	
TOT. PROTEINS	65-80 (G/L)	01/01/92	70.00		74.00		78.00	
ALBUMINE	37-52 (G/L)	01/01/92	38.90		41.90		44.10	
TOT. CHOLEST.	1.5-2.5 (G/L)	01/01/92	1.71		1.82		1.62	
TRIGLYCERIDES	0.5-1.6 (G/L)	01/01/92	1.86	>	0.78		0.89	
GLOBULINS ALPHA 1	2-4 (%)	01/01/92	4.60	>	4.80	>	5.00	>
GLOBULINS ALPHA 2	6-10 (%)	01/01/92	9.10		11.50	>	12.10	>
GLOBULINS BETA	8-12 (%)	01/01/92	10.10		12.00		11.00	
GLOBULINS GAMMA	12-19 (%)	01/01/92	20.90	>	15.00		15.60	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 2/5 Patient: 73 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/02/92		02/03/92		24/03/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	8-11 (MMOL/L)	01/02/92	8.80		8.40			
	8-13 (G/DL)	20/03/92					15.10	>
HT	38-52 (%)	01/02/92	42.00		39.00			
	40-48 (%)	20/03/92					43.70	
RBC	4.2-5.7 (10¬6/UL)	01/02/92	4.70		4.42			
	4.5-5.5 (10¬6/UL)	20/03/92					4.89	
WBC	4-10 (10¬3/UL)	01/02/92	5.48		6.23			
	5-10 (10¬3/UL)	20/03/92					5.73	
WBC: N	45-74 (%)	01/02/92	65.50		58.80			
	45-70 (%)	20/03/92					65.00	
WBC: L	16-45 (%)	01/02/92	25.40		32.70			
	20-40 (%)	20/03/92					27.50	
WBC: E	0-7 (%)	01/02/92	3.30		2.20			
	1-2 (%)	20/03/92					2.10	>
WBC: M	4-10 (%)	01/02/92	4.70		5.40			
	2-8 (%)	20/03/92					4.60	
WBC: B	0-2 (%)	01/02/92	0.70		0.60			
	0-1 (%)	20/03/92					0.80	
PLATELETS	150-400 (10¬3/UL)	01/02/92	200.00		263.00		191.00	
NA+	135-145 (MEQ/L)	01/02/92	143.00		143.00			
	138-148 (MEQ/L)	20/03/92					141.00	
K+	3.5-5 (MEQ/L)	01/02/92	4.60		4.20			
	3.8-5.3 (MEQ/L)	20/03/92					4.60	
CL-	95-105 (MEQ/L)	01/02/92	107.00	>	105.00		102.00	
Ca++	2.12-2.75 (MMOL/L)	01/02/92	2.29		2.23			
	85-105 (MG/L)	20/03/92					90.00	
PO4--	0.8-1.45 (MMOL/L)	01/02/92	1.17		0.86			
	30-45 (MG/L)	20/03/92					30.00	
SGOT	6-53 (UI/L)	01/02/92	13.00		40.00			
	5-25 (UI/L)	20/03/92					23.00	
SGPT	7-40 (UI/L)	01/02/92	14.00		88.00	>>		
	5-30 (UI/L)	20/03/92					73.00	>>
GAMMA GT	8-38 (UI/L)	01/02/92	20.00		34.00			
	8-33 (UI/L)	20/03/92					37.00	>
LDH	160-280 (UI/L)	01/02/92	132.00	<	159.00	<		
	150-320 (UI/L)	20/03/92					164.00	
ALK. PHOSPH.	30-85 (UI/L)	01/02/92	73.00		109.00	>		
	80-220 (UI/L)	20/03/92					148.00	
GLUCOSE	3.9-5.55 (MMOL/L)	01/02/92	4.66		4.83			
	0.7-1.1 (G/L)	20/03/92					0.98	
UREA	2.65-6.65 (MMOL/L)	01/02/92	6.59		6.02			
	0.18-0.5 (G/L)	20/03/92					0.37	
CREATININE	9-90 (UMOL/L)	01/02/92	88.00		97.00	>		
	5-12 (MG/L)	20/03/92					8.00	
URIC ACID	150-475 (UMOL/L)	01/02/92	277.00		293.00			
	34-70 (MG/L)	20/03/92					48.00	
TOT BILIRUBIN	2-17 (UMOL/L)	01/02/92	9.00		9.00			
TOT. PROTEINS	60-75 (G/L)	01/02/92	60.00		60.00			
	68-83 (G/L)	20/03/92					73.00	
ALBUMINE	500-725 (UMOL/L)	01/02/92	639.00		598.00			
	40-55 (G/L)	20/03/92					48.35	
TOT. CHOLEST.	1.3-2.4 (G/L)	01/02/92	3.60	>>			2.42	>
TRIGLYCERIDES	0.85-1.96 (MMOL/L)	01/02/92	0.93		1.35			
	0.5-1.6 (G/L)	20/03/92					0.79	
GLOBULINS ALPHA 1	2-4 (%)	01/02/92	3.00		3.00			
	2-5 (%)	20/03/92					2.90	
GLOBULINS ALPHA 2	6-10 (%)	01/02/92	6.00		7.00		6.30	
GLOBULINS BETA	8-12 (%)	01/02/92	11.00		11.00			
	8-14 (%)	20/03/92					11.70	
GLOBULINS GAMMA	12-19 (%)	01/02/92	12.00		12.00		11.00	<

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 2/5 Patient: 74 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			14/06/92		11/07/92		01/08/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	8-11 (MMOL/L)	10/06/92	9.10					
	()	10/07/92						
	8-13 (G/DL)	30/07/92					14.30	>
HT	()	10/07/92						
	0.38-0.52 (L/L)	10/06/92	0.46					
	40-48 (%)	30/07/92					43.00	
RBC	()	10/07/92						
	4.2-5.7 (10~6/MM3)	10/06/92	5.16					
	4.5-5.6 (10~6/MM3)	30/07/92					5.03	
WBC	()	10/07/92						
	4-10 (10~3/MM3)	10/06/92	10.56	>				
	5-10 (10~3/MM3)	30/07/92					9.70	
WBC: N	()	10/07/92						
	45-74 (%)	10/06/92	69.70					
	45-70 (%)	30/07/92					73.00	>
WBC: L	()	10/07/92						
	16-45 (%)	10/06/92	21.60					
	20-40 (%)	30/07/92					27.00	
WBC: E	()	10/07/92						
	0-7 (%)	10/06/92	2.00					
	1-2 (%)	30/07/92					1.00	
WBC: M	()	10/07/92						
	4-10 (%)	10/06/92	4.80					
	2-8 (%)	30/07/92					7.00	
WBC: B	()	10/07/92						
	0-2 (%)	10/06/92	1.50					
	0-1 (%)	30/07/92					0.00	
PLATELETS	150-400 (10~3/MM3)	10/06/92	299.00				245.00	
NA+	135-145 (MMOL/L)	10/06/92	144.00					
	138-145 (MMOL/L)	10/07/92			140.00			
	138-148 (MMOL/L)	30/07/92					142.00	
K+	3.5-5 (MMOL/L)	10/06/92	4.20		4.30			
	3.8-5.3 (MMOL/L)	30/07/92					4.20	
CL-	95-105 (MMOL/L)	10/06/92	110.00	>			100.00	
	98-105 (MMOL/L)	10/07/92			106.00	>		
Ca++	2.12-2.75 (MMOL/L)	10/06/92	2.33				2.20	
	2-2.63 (MMOL/L)	10/07/92			2.35			
PO4--	0.8-1.45 (MMOL/L)	10/06/92	1.16					
	0.86-1.44 (MMOL/L)	10/07/92			1.24			
	30-45 (MG/L)	30/07/92					36.00	
SGOT	6-53 (UI/L)	10/06/92	18.00					
	5-25 (UI/L)	10/07/92			11.00		15.00	
SGPT	7-40 (UI/L)	10/06/92	14.00					
	5-29 (UI/L)	10/07/92			17.00			
	5-30 (UI/L)	30/07/92					10.00	
GAMMA GT	8-38 (UI/L)	10/06/92	19.00		4.00	<		
	8-33 (UI/L)	30/07/92					18.00	
LDH	160-280 (UI/L)	10/06/92	181.00					
	140-330 (UI/L)	10/07/92						
	150-320 (UI/L)	30/07/92					194.00	
ALK. PHOSPH.	()	10/07/92						
	30-85 (UI/L)	10/06/92	81.00					
	80-220 (UI/L)	30/07/92					47.00	<
GLUCOSE	3.9-5.55 (MMOL/L)	10/06/92	5.44					
	3.85-5.56 (MMOL/L)	10/07/92			5.06			
	0.7-1.1 (G/L)	30/07/92					0.85	
BUN	()	10/06/92						
UREA	2.65-6.65 (MMOL/L)	10/06/92	7.37	>				
	1.65-6.64 (MMOL/L)	10/07/92			5.64			
	0.18-0.5 (G/L)	30/07/92					0.41	
CREATININE	9-90 (UMOL/L)	10/06/92	111.00	>				
	44-98 (UMOL/L)	10/07/92			101.78	>		

(CONTINUED)

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 2/5 Patient: 74 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			14/06/92		11/07/92		01/08/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
CREATININE	5-12 (MG/L)	30/07/92					11.00	
URIC ACID	150-475 (UMOL/L)	10/06/92	284.00					
	178-416 (UMOL/L)	10/07/92			226.00			
	34-70 (MG/L)	30/07/92					33.00	<
TOT BILIRUBIN	2-17 (UMOL/L)	10/06/92	12.00					
	0-10 (MG/L)	10/07/92			7.06		10.00	
DIR BILIRUBIN	()	10/06/92						
TOT. PROTEINS	60-75 (G/L)	10/06/92	61.00					
	60-80 (G/L)	10/07/92			59.00	<		
	68-83 (G/L)	30/07/92					68.00	
ALBUMINE	()	10/07/92						
	500-725 (UMOL/L)	10/06/92	599.00					
	52-62 (%)	30/07/92					53.70	
TOT. CHOLEST.	3.9-6.3 (MMOL/L)	10/06/92	6.02					
	4.64-6.45 (MMOL/L)	10/07/92			5.16			
	1.3-2.4 (G/L)	30/07/92					2.34	
TRIGLYCERIDES	0.85-1.96 (MMOL/L)	10/06/92	1.55					
	0.85-1.72 (MMOL/L)	10/07/92			1.05			
	0.5-1.6 (G/L)	30/07/92						
GLOBULINS ALPHA 1	()	10/07/92						
	2-4 (%)	10/06/92	3.50					
	2-5 (%)	30/07/92					2.10	
GLOBULINS ALPHA 2	()	10/07/92						
	6-10 (%)	10/06/92	9.50				13.50	>>
GLOBULINS BETA	()	10/07/92						
	8-12 (%)	10/06/92	11.40					
	8-14 (%)	30/07/92					12.50	
GLOBULINS GAMMA	()	10/07/92						
	12-19 (%)	10/06/92	8.80	<			18.20	
TSH	()	10/07/92						
	0.2-5 (MUI/L)	10/06/92						
T4	()	10/07/92						
	11-24 (PMOL/L)	10/06/92						

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 2/5 Patient: 75 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/09/92		01/10/92		22/10/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	8-11 (MMOL/L)	01/09/92	10.20		10.70			
HT	0.38-0.52 (L/L)	01/09/92	0.50		0.52			
RBC	4.2-5.7 (10¬12/L)	01/09/92	5.33		5.63			
WBC	4-10 (10¬9/L)	01/09/92	8.91		9.60			
WBC: N	45-74 (%)	01/09/92	61.30		62.70			
WBC: L	16-45 (%)	01/09/92	30.50		28.10			
WBC: E	0-7 (%)	01/09/92	1.60		1.70			
WBC: M	4-10 (%)	01/09/92	0.50	<	5.80			
WBC: B	0-2 (%)	01/09/92	0.80		1.00			
PLATELETS	150-400 (10¬9/L)	01/09/92	235.00		306.00			
NA+	135-145 (MMOL/L)	01/09/92	140.00		142.00			
	135-148 (MMOL/L)	20/10/92					136.00	
K+	3.5-5 (MMOL/L)	01/09/92	4.20		4.30			
	3.8-4.8 (MMOL/L)	20/10/92					4.70	
CL-	95-105 (MMOL/L)	01/09/92	106.00	>	104.00			
	96-106 (MMOL/L)	20/10/92					97.00	
Ca++	2.12-2.75 (MMOL/L)	01/09/92	2.26		2.35			
	2.02-2.71 (MMOL/L)	20/10/92					2.10	
PO4--	0.8-1.45 (MMOL/L)	01/09/92	0.84		0.84			
	0.8-1.6 (MMOL/L)	20/10/92					1.30	
SGOT	6-53 (UI/L)	01/09/92	17.00		20.00		17.00	
SGPT	7-40 (UI/L)	01/09/92	14.00		16.00			
	7-56 (UI/L)	20/10/92					12.00	
GAMMA GT	8-38 (UI/L)	01/09/92	11.00		16.00			
	7-78 (UI/L)	20/10/92					33.00	
LDH	160-280 (UI/L)	01/09/92			218.00			
	313-618 (U/L)	20/10/92					590.00	
ALK. PHOSPH.	30-85 (UI/L)	01/09/92	51.00		71.00			
	38-126 (UI/L)	20/10/92					72.00	
GLUCOSE	3.9-5.55 (MMOL/L)	01/09/92	4.77		4.50			
	3.89-6.11 (MMOL/L)	20/10/92					4.73	
UREA	2.65-6.65 (MMOL/L)	01/09/92	4.81		5.41			
	1.66-8.33 (MMOL/L)	20/10/92					5.34	
CREATININE	9-90 (UMOL/L)	01/09/92	89.00		93.00	>		
	20-132 (UMOL/L)	20/10/92					88.50	
URIC ACID	150-475 (UMOL/L)	01/09/92	325.00		362.00			
	208-357 (UMOL/L)	20/10/92					309.00	
TOT BILIRUBIN	2-17 (UMOL/L)	01/09/92	15.00		10.00		15.00	
TOT. PROTEINS	60-75 (G/L)	01/09/92	63.00		68.00			
	65-75 (G/L)	20/10/92					75.00	
ALBUMINE	500-725 (UMOL/L)	01/09/92	580.00		618.00			
	34-52 (G/L)	20/10/92					45.08	
TOT. CHOLEST.	3.9-6.3 (MMOL/L)	01/09/92	5.82		8.08	>		
	3.87-6.19 (MMOL/L)	20/10/92					7.04	>
TRIGLYCERIDES	0.85-1.96 (MMOL/L)	01/09/92	2.49	>	3.43	>>		
	0.57-1.82 (MMOL/L)	20/10/92					3.42	>>
GLOBULINS ALPHA 1	2-4 (%)	01/09/92	3.30				3.80	
GLOBULINS ALPHA 2	6-10 (%)	01/09/92	8.00					
	10-14 (%)	20/10/92					11.10	
GLOBULINS BETA	8-12 (%)	01/09/92	11.80					
	6-13 (%)	20/10/92					12.80	
GLOBULINS GAMMA	12-19 (%)	01/09/92	13.10					
	10-19 (%)	20/10/92					12.20	
TSH	0.2-5 (MUI/ML)	01/09/92	1.49					
T4	11-24 (PMOL/L)	01/09/92	17.70					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 2/5 Patient: 76 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			12/09/92		02/10/92		28/10/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	7.4-9.9 (MMOL/L)	01/04/92	9.40		8.60		8.50	
HT	0,32-0,47 (L/L)	01/04/92	0.44		0,43		0,42	
RBC	4-5.5 (10¬12/L)	01/04/92	4.56		4.43		4.26	
WBC	4-10 (10¬9/L)	01/04/92	10.00		6.77		8.61	
WBC: N	45-74 (%)	01/04/92	61.70		54.50		60.70	
WBC: L	16-45 (%)	01/04/92	30.80		36.30		29.10	
WBC: E	0-7 (%)	01/04/92	2.40		3.20		3.90	
WBC: M	4-10 (%)	01/04/92	4.50		4.60		5.10	
WBC: B	0-2 (%)	01/04/92	0.50		0.80		0.70	
PLATELETS	150-400 (10¬9/L)	01/04/92	348.00				341.00	
NA+	135-145 (MMOL/L)	01/04/92	140.00		142.00		140.00	
K+	3.5-5 (MMOL/L)	01/04/92	4.10		4.60		4.50	
CL-	95-105 (MMOL/L)	01/04/92	105.00		104.00		103.00	
Ca++	2.12-2.75 (MMOL/L)	01/04/92	2.34		2.48		2.39	
PO4--	0.8-1.45 (MMOL/L)	01/04/92	1.30		1.39		1.14	
SGOT	6-53 (UI/L)	01/04/92	13.00		15.00		20.00	
SGPT	7-40 (UI/L)	01/04/92	14.00		12.00		41.00	>
GAMMA GT	5-20 (UI/L)	01/04/92	30.00	>	22.00	>		
LDH	160-280 (UI/L)	01/04/92	181.00		161.00			
ALK. PHOSPH.	30-85 (UI/L)	01/04/92	43.00		31.00		35.00	
GLUCOSE	3.9-5.55 (MMOL/L)	01/04/92	5.11		5.00		4.83	
UREA	2.65-6.65 (MMOL/L)	01/04/92	5.62		4.66		3.67	
CREATININE	9-90 (UMOL/L)	01/04/92	72.00		86.00		80.00	
URIC ACID	150-475 (UMOL/L)	01/04/92	139.00	<	198.00		186.00	
TOT BILIRUBIN	2-17 (UMOL/L)	01/04/92	2.93		9.00		5.00	
TOT. PROTEINS	60-75 (G/L)	01/04/92	65.00		67.00			
ALBUMINE	500-725 (UMOL/L)	01/04/92	609.00		623.00			
TOT. CHOLEST.	3.9-6.3 (MMOL/L)	01/04/92					5.69	
TRIGLYCERIDES	0.85-1.96 (MMOL/L)	01/04/92					3.12	>>
TSH	0.2-5 (MUI/L)	01/04/92	1.25					
T4	11-24 (PMOL/L)	01/04/92	14.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 2/5 Patient: 77 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			16/09/92		13/10/92		30/10/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	8-11 (MMOL/L)	01/04/92	10.10		9.30		9.50	
HT	0.38-0.52 (L/L)	01/04/92	0.48		0.46		0.46	
RBC	4.2-5.7 (10¬12/L)	01/04/92	5.14		4.88		4.87	
WBC	4-10 (10¬9/L)	01/04/92	6.78		7.69		8.12	
WBC: N	45-74 (%)	01/04/92	57.00		56.00		72.20	
WBC: L	16-45 (%)	01/04/92	33.50		33.10		18.50	
WBC: E	0-7 (%)	01/04/92	2.00		2.90		0.90	
WBC: M	4-10 (%)	01/04/92	6.70		7.00		7.60	
WBC: B	0-2 (%)	01/04/92	0.40		0.40		0.60	
PLATELETS	150-400 (10¬9/L)	01/04/92	257.00		298.00		327.00	
NA+	135-145 (MMOL/L)	01/04/92	140.00		143.00		142.00	
K+	3.5-5 (MMOL/L)	01/04/92	4.40		4.50		4.50	
CL-	95-105 (MMOL/L)	01/04/92	101.00		106.00	>	108.00	>
Ca++	2.12-2.75 (MMOL/L)	01/04/92	2.44		2.36		2.42	
PO4--	0.8-1.45 (MMOL/L)	01/04/92	1.18		1.07		1.01	
SGOT	6-53 (UI/L)	01/04/92	21.00		28.00		19.00	
SGPT	7-40 (UI/L)	01/04/92	43.00	>	27.00		16.00	
GAMMA GT	8-38 (UI/L)	01/04/92	50.00	>	21.00		16.00	
LDH	160-280 (UI/L)	01/04/92	118.00	<			186.00	
ALK. PHOSPH.	30-85 (UI/L)	01/04/92	105.00	>	90.00	>	89.00	>
GLUCOSE	3.9-5.55 (MMOL/L)	01/04/92	4.16		4.22		5.33	
UREA	2.65-6.65 (MMOL/L)	01/04/92	5.23		5.62		7.16	>
CREATININE	9-90 (UMOL/L)	01/04/92	112.00	>	95.00	>	104.00	>
URIC ACID	150-475 (UMOL/L)	01/04/92	306.00		423.00		467.00	
TOT BILIRUBIN	2-17 (UMOL/L)	01/04/92	9.00		14.00		2.93	
TOT. PROTEINS	60-75 (G/L)	01/04/92	67.00		67.00		69.00	
ALBUMINE	500-725 (UMOL/L)	01/04/92	636.00		624.00		619.00	
TOT. CHOLEST.	3.9-6.3 (MMOL/L)	01/04/92	5.78		5.20		4.49	
TRIGLYCERIDES	0.85-1.96 (MMOL/L)	01/04/92	1.44		0.62	<	0.51	<
GLOBULINS ALPHA 1	2-4 (%)	01/04/92			2.80		4.20	>
GLOBULINS ALPHA 2	6-10 (%)	01/04/92			7.40		7.30	
GLOBULINS BETA	8-12 (%)	01/04/92			11.40		11.50	
GLOBULINS GAMMA	12-19 (%)	01/04/92			12.70		14.00	
TSH	0.2-5 (MUI/L)	01/04/92	4.63					
T4	11-24 (PMOL/L)	01/04/92	13.30					

1670

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

			Screen		Day 21	
			01/10/92		29/10/92	
Laboratory test	Range value	Range date	value	(+)	value	(+)
HB	7.4-9.9 (MMOL/L)	01/04/92	6.70	<	7.30	<
HT	0.32-0.47 (L/L)	01/04/92	0.34		0.34	
RBC	4-5.5 (10-12/L)	01/04/92	3.68	<	3.70	<
HBC	4-10 (10-9/L)	01/04/92	6.57		9.10	
HBC: N	45-74 (%)	01/04/92	65.50			
HBC: L	16-45 (%)	01/04/92	27.10			
HBC: E	0-7 (%)	01/04/92	1.90			
HBC: M	4-10 (%)	01/04/92	4.20			
HBC: B	0-2 (%)	01/04/92	0.60			
PLATELETS	150-400 (10-9/L)	01/04/92	368.00		348.00	
NA+	135-145 (MMOL/L)	01/04/92	139.00		139.00	
K+	3.5-5 (MMOL/L)	01/04/92	4.00		3.70	
CL-	95-105 (MMOL/L)	01/04/92	103.00		104.00	
Ca++	2.12-2.75 (MMOL/L)	01/04/92			2.16	
PO4--	0.8-1.45 (MMOL/L)	01/04/92	1.25			
SGOT	6-53 (UI/L)	01/04/92	13.00			
SGPT	7-40 (UI/L)	01/04/92	10.00			
ALK. PHOSPH.	30-85 (UI/L)	01/04/92	65.00			
GLUCOSE	3.9-5.55 (MMOL/L)	01/04/92	4.72		5.30	
UREA	2.65-6.65 (MMOL/L)	01/04/92	3.60		4.30	
CREATININE	9-90 (UMOL/L)	01/04/92	57.00		58.00	
URIC ACID	150-475 (UMOL/L)	01/04/92	202.00			
TOT BILIRUBIN	2-17 (UMOL/L)	01/04/92	5.00			
TOT. PROTEINS	60-75 (G/L)	01/04/92	67.00			
ALBUMINE	500-725 (UMOL/L)	01/04/92	549.00		73.00	
TOT. CHOLEST.	3.9-6.3 (MMOL/L)	01/04/92	6.34	>		
TRIGLYCERIDES	0.85-1.96 (MMOL/L)	01/04/92	1.03			
GLOBULINS ALPHA 1	2-4 (%)	01/04/92	3.00			
GLOBULINS ALPHA 2	6-10 (%)	01/04/92	7.00			
GLOBULINS BETA	8-12 (%)	01/04/92	13.00	>		
GLOBULINS GAMMA	12-19 (%)	01/04/92	18.00			
TSH	0.2-5 (MUI/L)	01/04/92	1.99			
T4	11-24 (PMOL/L)	01/04/92	14.80			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 2/6 Patient: 55 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 42	
			15/06/92		20/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/L)	05/04/92	12.40		13.90	
HT	36-47 (%)	05/04/92	40.00		41.00	
RBC	4-5.4 (10¬6/UL)	05/04/92	4.01		4.21	
WBC	4000-10000 (/UL)	05/04/92	2100.00	<<	2700.00	<<
WBC: N	50-70 (%)	05/04/92	59.00		54.00	
WBC: L	20-40 (%)	05/04/92	30.00		35.00	
WBC: E	1-5 (%)	05/04/92	1.00		4.00	
WBC: M	3-10 (%)	05/04/92	10.00		7.00	
WBC: B	0-1 (%)	05/04/92	0.00		0.00	
PLATELETS	150-350 (10¬3/UL)	05/04/92	70.00	<<	65.00	<<
NA+	135-145 (MEQ/L)	05/04/92	140.00		145.00	
K+	3.5-5 (MEQ/L)	05/04/92	3.40	<	3.80	
CL-	96-110 (MEQ/L)	05/04/92	108.00		109.00	
SGOT	5-30 (UI/L)	05/04/92	62.00	>>	16.00	
SGPT	5-40 (UI/L)	05/04/92	31.00		7.00	
GAMMA GT	7-29 (UI/L)	05/04/92	392.00	>>	92.00	>>
ALK. PHOSPH.	50-90 (UI/L)	05/04/92	113.00	>	88.00	
GLUCOSE	0.7-1.05 (G/L)	05/04/92	0.84		0.84	
UREA	0.2-0.4 (G/L)	05/04/92	0.28		0.24	
CREATININE	6-12 (MG/L)	05/04/92	8.00		7.00	
URIC ACID	25-60 (MG/L)	05/04/92	43.00		35.00	
TOT. CHOLEST.	1.5-2.3 (G/L)	05/04/92	1.98		1.89	
TRIGLYCERIDES	0.5-1.4 (G/L)	05/04/92	0.42	<	0.60	
TSH	0.4-4 (UU/ML)	05/04/92	1.60			
T4	7-18 (PG/ML)	05/04/92	7.00			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 2/6 Patient: 56 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 42	
			15/06/92		24/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/L)	05/04/92	12.90		14.20	
HT	36-47 (%)	05/04/92	40.00		44.00	
RBC	4-5.4 (10-6/UL)	05/04/92	4.19		4.76	
WBC	4000-10000 (/UL)	05/04/92	4700.00		5300.00	
WBC: N	50-70 (%)	05/04/92	49.00	<	52.00	
WBC: L	20-40 (%)	05/04/92	43.00	>	39.00	
WBC: E	1-5 (%)	05/04/92	3.00		3.00	
WBC: M	3-10 (%)	05/04/92	5.00		6.00	
WBC: B	0-1 (%)	05/04/92	0.00		0.00	
PLATELETS	150-350 (10-3/UL)	05/04/92	180.00		220.00	
NA+	135-145 (MEQ/L)	05/04/92	142.00		142.00	
K+	3.5-5 (MEQ/L)	05/04/92	3.60		3.60	
CL-	96-110 (MEQ/L)	05/04/92	107.00		105.00	
SGOT	5-30 (UI/L)	05/04/92	8.00		9.00	
SGPT	5-40 (UI/L)	05/04/92	7.00		8.00	
GAMMA GT	7-29 (UI/L)	05/04/92	9.00		13.00	
ALK. PHOSPH.	50-90 (UI/L)	05/04/92	70.00		74.00	
GLUCOSE	0.7-1.05 (G/L)	05/04/92	0.80		0.87	
UREA	0.2-0.4 (G/L)	05/04/92	0.30		0.31	
CREATININE	6-12 (MG/L)	05/04/92	9.00		8.00	
URIC ACID	25-60 (MG/L)	05/04/92	48.00		41.00	
TOT. CHOLEST.	1.5-2.3 (G/L)	05/04/92	1.80		2.02	
TRIGLYCERIDES	0.5-1.4 (G/L)	05/04/92	1.38		1.40	
TSH	0.4-4 (UU/ML)	05/04/92	2.60			
T4	7-18 (PG/ML)	05/04/92	9.00			

1673

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 2/6 Patient: 57 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 42	
			30/04/92		15/06/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
HB	12-16 (G/L)	05/04/92	13.00		13.60	
HT	36-47 (%)	05/04/92	39.00		42.00	
RBC	4-5.4 (10~6/UL)	05/04/92	4.44		4.69	
WBC	4000-10000 (/UL)	05/04/92	6500.00		6500.00	
WBC: N	50-70 (%)	05/04/92	68.00		75.00	>
WBC: L	20-40 (%)	05/04/92	26.00		21.00	
WBC: E	1-5 (%)	05/04/92	2.00		2.00	
WBC: M	3-10 (%)	05/04/92	4.00		2.00	<
WBC: B	0-1 (%)	05/04/92	0.00		0.00	
PLATELETS	150-350 (10~3/UL)	05/04/92	290.00		230.00	
NA+	135-145 (MEQ/L)	05/04/92	141.00		140.00	
K+	3.5-5 (MEQ/L)	05/04/92	4.40		3.80	
CL-	96-110 (MEQ/L)	05/04/92	106.00		105.00	
SGOT	5-30 (UI/L)	05/04/92	12.00		16.00	
SGPT	5-40 (UI/L)	05/04/92	14.00		17.00	
GAMMA GT	7-29 (UI/L)	05/04/92	31.00	>	44.00	>
ALK. PHOSPH.	50-90 (UI/L)	05/04/92	85.00		93.00	>
GLUCOSE	0.7-1.05 (G/L)	05/04/92	1.22	>	0.88	
UREA	0.2-0.4 (G/L)	05/04/92	0.35		0.31	
CREATININE	6-12 (MG/L)	05/04/92	9.00		10.00	
URIC ACID	25-60 (MG/L)	05/04/92	46.00		46.00	
TOT. CHOLEST.	1.5-2.3 (G/L)	05/04/92	2.44	>	2.50	>
TRIGLYCERIDES	0.5-1.4 (G/L)	05/04/92	1.59	>	1.59	>
TSH	0.4-4 (UU/ML)	05/04/92			2.00	
T4	7-18 (PG/ML)	05/04/92			7.50	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 2/6 Patient: 58 Treatment: Placebo Sex: Female

			Visit number / Laboratory date			
			Screen		Day 42	
			18/05/92		24/06/92	
			value	(¢)	value	(¢)
Laboratory test	Range value	Range date				
HB	12-16 (G/L)	05/04/92	12.50		11.80	<
HT	36-47 (%)	05/04/92	37.00		36.00	
RBC	4-5.4 (10¬6/UL)	05/04/92	3.90	<	3.80	<
WBC	4000-10000 (/UL)	05/04/92	6500.00		5700.00	
WBC: N	50-70 (%)	05/04/92	65.00		67.00	
WBC: L	20-40 (%)	05/04/92	27.00		24.00	
WBC: E	1-5 (%)	05/04/92	3.00		3.00	
WBC: M	3-10 (%)	05/04/92	5.00		6.00	
WBC: B	0-1 (%)	05/04/92	0.00		0.00	
PLATELETS	150-350 (10¬3/UL)	05/04/92	260.00		265.00	
NA+	135-145 (MEQ/L)	05/04/92	139.00		138.00	
K+	3.5-5 (MEQ/L)	05/04/92	3.70		3.60	
CL-	96-110 (MEQ/L)	05/04/92	109.00		109.00	
SGOT	5-30 (UI/L)	05/04/92	10.00		7.00	
SGPT	5-40 (UI/L)	05/04/92	9.00		8.00	
GAMMA GT	7-29 (UI/L)	05/04/92	17.00		24.00	
ALK. PHOSPH.	50-90 (UI/L)	05/04/92	54.00		49.00	<
GLUCOSE	0.7-1.05 (G/L)	05/04/92	0.95		0.99	
UREA	0.2-0.4 (G/L)	05/04/92	0.32		0.28	
CREATININE	6-12 (MG/L)	05/04/92	10.00		9.00	
URIC ACID	25-60 (MG/L)	05/04/92	42.00		40.00	
TOT. CHOLEST.	1.5-2.3 (G/L)	05/04/92	2.68	>	2.63	>
TRIGLYCERIDES	0.5-1.4 (G/L)	05/04/92	2.00	>>	1.28	
TSH	0.4-4 (UU/ML)	05/04/92			3.90	
T4	7-18 (PG/ML)	05/04/92			6.50	<

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 2/6 Patient: 59 Treatment: Placebo Sex: Male

			Visit number / Laboratory date			
			Screen		Day 28	
			29/05/92		26/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	13-17 (G/L)	05/04/92	15.80		15.50	
HT	40-54 (%)	05/04/92	46.00		47.00	
RBC	4.2-5.7 (10¬6/UL)	05/04/92	5.04		4.98	
WBC	4000-10000 (/UL)	05/04/92	6900.00		6100.00	
WBC: N	50-70 (%)	05/04/92	63.00		62.00	
WBC: L	20-40 (%)	05/04/92	26.00		25.00	
WBC: E	1-5 (%)	05/04/92	4.00		0.00	<
WBC: M	3-10 (%)	05/04/92	7.00		9.00	
WBC: B	0-1 (%)	05/04/92	0.00		0.00	
PLATELETS	150-350 (10¬3/UL)	05/04/92	240.00		305.00	
NA+	135-145 (MEQ/L)	05/04/92	140.00		136.00	
K+	3.5-5 (MEQ/L)	05/04/92	3.70		4.00	
CL-	96-110 (MEQ/L)	05/04/92	104.00		103.00	
SGOT	5-30 (UI/L)	05/04/92	10.00		13.00	
SGPT	5-40 (UI/L)	05/04/92	15.00		29.00	
GAMMA GT	8-33 (UI/L)	05/04/92	17.00		33.00	
ALK. PHOSPH.	50-90 (UI/L)	05/04/92	59.00		58.00	
GLUCOSE	0.7-1.05 (G/L)	05/04/92	0.85		0.92	
UREA	0.2-0.4 (G/L)	05/04/92	0.26		0.34	
CREATININE	6-12 (MG/L)	05/04/92	11.00		11.00	
URIC ACID	25-60 (MG/L)	05/04/92	61.00	>	54.00	
TOT. CHOLEST.	1.5-2.3 (G/L)	05/04/92	2.55	>	2.29	
TRIGLYCERIDES	0.5-1.4 (G/L)	05/04/92	1.21		0.69	
TSH	0.4-4 (UU/ML)	05/04/92			1.90	
T4	7-18 (PG/ML)	05/04/92			6.00	<<

1676

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 2/6 Patient: 60 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 42	
			06/04/92		23/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/L)	05/04/92	15.00		13.20	
HT	36-47 (%)	05/04/92	45.00		39.00	
RBC	4-5.4 (10¬6/UL)	05/04/92	5.07		4.51	
WBC	4000-10000 (/UL)	05/04/92	7500.00		6800.00	
WBC: N	50-70 (%)	05/04/92	34.00	<<	41.00	<
WBC: L	20-40 (%)	05/04/92	55.00	>>	42.00	>
WBC: E	1-5 (%)	05/04/92	4.00		2.00	
WBC: M	3-10 (%)	05/04/92	7.00		15.00	>>
WBC: B	0-1 (%)	05/04/92	0.00		0.00	
PLATELETS	150-350 (10¬3/UL)	05/04/92	230.00		240.00	
NA+	135-145 (MEQ/L)	05/04/92	143.00		139.00	
K+	3.5-5 (MEQ/L)	05/04/92	3.80		4.00	
CL-	96-110 (MEQ/L)	05/04/92	104.00		102.00	
SGOT	5-30 (UI/L)	05/04/92	22.00		17.00	
SGPT	5-40 (UI/L)	05/04/92	28.00		24.00	
GAMMA GT	7-29 (UI/L)	05/04/92	27.00		41.00	>
ALK. PHOSPH.	50-90 (UI/L)	05/04/92	57.00		71.00	
GLUCOSE	0.7-1.05 (G/L)	05/04/92	0.95		0.86	
UREA	0.2-0.4 (G/L)	05/04/92	0.26		0.33	
CREATININE	6-12 (MG/L)	05/04/92	10.00		9.00	
URIC ACID	25-60 (MG/L)	05/04/92	31.00		27.00	
TOT. CHOLEST.	1.5-2.3 (G/L)	05/04/92	1.96		1.93	
TRIGLYCERIDES	0.5-1.4 (G/L)	05/04/92	0.88		1.10	
TSH	0.4-4 (UU/ML)	05/04/92			1.90	
T4	7-18 (PG/ML)	05/04/92			4.50	<<

1677

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/1 Patient: 61 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			04/03/91		03/04/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12.5-17.5 (G/DL)	01/02/91	14.40		14.60	
HT	40-55 (%)	01/02/91	42.80		43.20	
RBC	4.5-5.8 (10-6/UL)	01/02/91	5.06		5.13	
WBC	4500-9000 (/UL)	01/02/91	5300.00		5900.00	
WBC: N	2700-6300 (/UL)	01/02/91	2756.00		3009.00	
WBC: L	900-2700 (/UL)	01/02/91	2279.00		2301.00	
WBC: E	45-360 (/UL)	01/02/91	212.00		354.00	
WBC: M	90-540 (/UL)	01/02/91	53.00	<	236.00	
WBC: B	0-90 (/UL)	01/02/91	0.00		0.00	
PLATELETS	150-400 (10-3/UL)	01/02/91	219.00		241.00	
NA+	138-148 (MEQ/L)	01/02/91	141.40		139.00	
K+	3.8-5.6 (MEQ/L)	01/02/91	4.14		3.99	
CL-	95-108 (MEQ/L)	01/02/91	105.00		103.00	
Ca++	90-110 (MG/L)	01/02/91	96.00		95.00	
PO4--	25-50 (MG/L)	01/02/91	40.00		45.60	
SGOT	5-25 (UI/L)	01/02/91	16.00		20.00	
SGPT	5-29 (UI/L)	01/02/91	14.00		23.00	
GAMMA GT	7-34 (UI/L)	01/02/91	16.00			
LDH	140-330 (UI/L)	01/02/91	198.00		275.00	
ALK. PHOSPH.	30-90 (UI/L)	01/02/91	55.00		89.00	
GLUCOSE	0.7-1.1 (G/L)	01/02/91	1.05		0.84	
UREA	0.2-0.5 (G/L)	01/02/91	0.28		0.34	
CREATININE	7-14 (MG/L)	01/02/91	9.10		12.20	
URIC ACID	30-70 (MG/L)	01/02/91	38.00		32.00	
TOT BILIRUBIN	0-10 (MG/L)	01/02/91	4.50		8.30	
TOT. PROTEINS	65-80 (G/L)	01/02/91	72.00		77.00	
ALBUMINE	55-75 (%)	01/02/91	62.00		57.50	
TOT. CHOLEST.	1.5-2.2 (G/L)	01/02/91	2.04		2.21	>
TRIGLYCERIDES	0.5-1.6 (G/L)	01/02/91	0.63		1.11	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/02/91	1.70		1.70	
GLOBULINS ALPHA 2	6-12 (%)	01/02/91	9.00		10.30	
GLOBULINS BETA	11-16 (%)	01/02/91	13.00		14.30	
GLOBULINS GAMMA	12-17 (%)	01/02/91	14.30		16.20	
TSH	0.2-6.5 (UUI/ML)	01/02/91	0.88			
T4	4.5-12 (UG/DL)	01/02/91	5.50			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max ra
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/1 Patient: 62 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			17/04/91		06/05/91		27/05/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/04/91	13.70		14.50		13.10	
HT	35-50 (%)	01/04/91	40.90		45.40		38.80	
RBC	3.8-5.4 (10¬6/UL)	01/04/91	4.40		4.73		4.18	
WBC	4500-9000 (/UL)	01/04/91	9100.00	>	9260.00	>	9400.00	>
WBC: N	2700-6300 (/MM3)	01/04/91	4823.00		4780.00		4982.00	
WBC: L	900-2700 (/MM3)	01/04/91	3276.00	>	3600.00	>>	3572.00	>>
WBC: E	45-360 (/MM3)	01/04/91	182.00		260.00		188.00	
WBC: M	90-540 (/MM3)	01/04/91	819.00	>>	580.00	>	664.00	>
WBC: B	0-90 (/MM3)	01/04/91	0.00		40.00		0.00	
PLATELETS	150-400 (10¬3/UL)	01/04/91	290.00		349.00		350.00	
NA+	137-145 (MEQ/L)	01/04/91	139.00		143.00		139.00	
K+	3.8-5.6 (MEQ/L)	01/04/91	4.40		5.60		4.50	
CL-	98-108 (MEQ/L)	01/04/91	102.00		101.00		106.00	
Ca++	85-105 (MG/L)	01/04/91	89.00		99.00		86.00	
PO4--	25-42 (MG/L)	01/04/91	31.40		31.00		29.00	
SGOT	6-31 (UI/L)	01/04/91	14.00		12.00		12.00	
SGPT	5-35 (UI/L)	01/04/91	7.00		2.00	<	7.00	
GAMMA GT	9-37 (UI/L)	01/04/91	12.00		14.00		14.00	
LDH	230-460 (UI/L)	01/04/91	220.00	<	450.00		200.00	<
ALK. PHOSPH.	41-133 (UI/L)	01/04/91	70.00		89.00		85.00	
GLUCOSE	0.7-1.1 (G/L)	01/04/91	0.80		0.80		0.75	
UREA	0.2-0.5 (G/L)	01/04/91	0.24		0.34		0.44	
CREATININE	5-13 (MG/L)	01/04/91	9.50		12.00		10.60	
URIC ACID	25-60 (MG/L)	01/04/91	37.00		49.00		35.00	
TOT BILIRUBIN	0-10 (MG/L)	01/04/91	5.00		3.00		6.00	
TOT. PROTEINS	63-78 (G/L)	01/04/91	75.00		83.00	>	70.00	
ALBUMINE	57-65 (%)	01/04/91	57.20		59.90		53.20	<
TOT. CHOLEST.	1.5-2.3 (G/L)	01/04/91	1.89		1.96		1.89	
TRIGLYCERIDES	0.5-1.6 (G/L)	01/04/91	0.90		1.26		1.32	
GLOBULINS ALPHA 1	2-4 (%)	01/04/91	3.50		3.90		4.00	
GLOBULINS ALPHA 2	6-10 (%)	01/04/91	10.80	>	10.70	>	11.60	>
GLOBULINS BETA	8-12 (%)	01/04/91	13.00	>	10.80		12.80	>
GLOBULINS GAMMA	12-19 (%)	01/04/91	15.50		14.70		18.40	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/1 Patient: 63 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/05/91		03/06/91		22/06/91	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/05/91	14.40		14.70		13.80	
HT	40-55 (%)	01/05/91	46.10		45.30		40.50	
RBC	4.5-5.8 (10-6/UL)	01/05/91	5.07		5.32		4.85	
WBC	4500-9000 (/UL)	01/05/91	8500.00		8900.00		8300.00	
WBC: N	2700-6300 (/MM3)	01/05/91	5355.00		5340.00		4980.00	
WBC: L	900-2700 (/MM3)	01/05/91	2380.00		2581.00		2656.00	
WBC: E	45-360 (/MM3)	01/05/91	170.00		356.00		249.00	
WBC: M	90-540 (/MM3)	01/05/91	595.00	>	623.00	>	415.00	
WBC: B	0-90 (/MM3)	01/05/91	0.00		0.00		0.00	
PLATELETS	150-400 (10-3/UL)	01/05/91	270.00		230.00		260.00	
NA+	137-145 (MEQ/L)	01/05/91	142.00		143.00		143.00	
K+	3.8-5.6 (MEQ/L)	01/05/91	4.80		4.30		4.20	
CL-	98-108 (MEQ/L)	01/05/91	107.00		110.00	>	109.00	>
Ca++	85-105 (MG/L)	01/05/91	80.00	<	86.00		82.00	<
PO4--	25-42 (MG/L)	01/05/91	32.00		26.00		29.00	
SGOT	6-37 (UI/L)	01/05/91	17.00		20.00		25.00	
SGPT	6-45 (UI/L)	01/05/91	18.00		20.00		16.00	
GAMMA GT	11-43 (UI/L)	01/05/91	19.00		21.00		17.00	
LDH	230-460 (UI/L)	01/05/91	230.00		350.00		360.00	
ALK. PHOSPH.	41-133 (UI/L)	01/05/91	127.00		131.00		106.00	
GLUCOSE	0.7-1.1 (G/L)	01/05/91	0.96		0.93		1.05	
UREA	0.2-0.5 (G/L)	01/05/91	0.40		0.38		0.42	
CREATININE	5-13 (MG/L)	01/05/91	11.30		10.70		10.30	
URIC ACID	25-65 (MG/L)	01/05/91	45.00		49.00		60.00	
TOT BILIRUBIN	0-10 (MG/L)	01/05/91	3.00		2.00		5.00	
TOT. PROTEINS	63-78 (G/L)	01/05/91	68.00		67.00		77.00	
ALBUMINE	57-65 (%)	01/05/91	54.50	<	57.70		59.30	
TOT. CHOLEST.	1.5-2.3 (G/L)	01/05/91	2.05		2.01		1.96	
TRIGLYCERIDES	0.5-1.6 (G/L)	01/05/91	1.04		1.77	>	1.04	
GLOBULINS ALPHA 1	2-4 (%)	01/05/91	7.40	>>	3.40		3.90	
GLOBULINS ALPHA 2	6-10 (%)	01/05/91	9.20		11.50	>	10.00	
GLOBULINS BETA	8-12 (%)	01/05/91	13.80	>	12.20	>	12.00	
GLOBULINS GAMMA	12-19 (%)	01/05/91	15.10		15.20		14.80	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/1 Patient: 64 Treatment: Placebo Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			08/03/91		03/04/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11.5-15.5 (G/DL)	01/02/91	12.10		11.70	
HT	35-50 (%)	01/02/91	35.50		34.80	<
RBC	3.8-5.4 (10-6/UL)	01/02/91	3.92		3.79	<
WBC	4500-9000 (/UL)	01/02/91	10900.0	>	12800.0	>>
WBC: N	2700-6300 (/UL)	01/02/91	4142.00		6784.00	>
WBC: L	900-2700 (/UL)	01/02/91	4905.00	>>	5632.00	>>
WBC: E	45-360 (/UL)	01/02/91	1417.00	>>	256.00	
WBC: M	90-540 (/UL)	01/02/91	327.00		128.00	
WBC: B	0-90 (/UL)	01/02/91	109.00	>	0.00	
PLATELETS	150-400 (10-3/UL)	01/02/91	275.00		326.00	
NA+	138-148 (MEQ/L)	01/02/91	142.50		143.00	
K+	3.8-5.6 (MEQ/L)	01/02/91	4.40		4.30	
CL-	95-108 (MEQ/L)	01/02/91	107.00		105.00	
Ca++	90-110 (MG/L)	01/02/91	100.00		94.00	
PO4--	25-50 (MG/L)	01/02/91	48.00		34.60	
SGOT	5-25 (UI/L)	01/02/91	14.00		21.00	
SGPT	5-29 (UI/L)	01/02/91	5.00		7.00	
GAMMA GT	6-22 (UI/L)	01/02/91	7.00		6.00	
LDH	140-330 (UI/L)	01/02/91	215.00		165.00	
ALK. PHOSPH.	30-100 (UI/L)	01/02/91	54.00		42.00	
GLUCOSE	0.7-1.1 (G/L)	01/02/91	0.73		0.89	
UREA	0.2-0.5 (G/L)	01/02/91	0.46		0.56	>
CREATININE	7-14 (MG/L)	01/02/91	9.30		9.50	
URIC ACID	30-70 (MG/L)	01/02/91	40.00			
TOT BILIRUBIN	0-10 (MG/L)	01/02/91	7.40		3.30	
TOT. PROTEINS	65-80 (G/L)	01/02/91	74.00		69.00	
ALBUMINE	55-75 (%)	01/02/91	59.70		52.70	<
TOT. CHOLEST.	1.5-2.2 (G/L)	01/02/91	2.81	>	2.33	>
TRIGLYCERIDES	0.5-1.6 (G/L)	01/02/91	0.98		0.67	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/02/91	3.10		3.40	
GLOBULINS ALPHA 2	6-12 (%)	01/02/91	8.60		8.40	
GLOBULINS BETA	11-16 (%)	01/02/91	15.20		16.80	>
GLOBULINS GAMMA	12-17 (%)	01/02/91	13.40		18.70	>
TSH	0.2-6.5 (UUI/ML)	01/02/91	0.81			
T4	4.5-12 (UG/DL)	01/02/91	8.58			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max ran
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/1 Patient: 65 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			11/09/91		07/10/91		28/10/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/08/91	12.90		12.00		12.60	
HT	40-55 (%)	10/08/91	40.20		39.80	<	40.50	
RBC	4.5-5.8 (10-6/UL)	10/08/91	6.57	>	6.50	>	6.26	>
WBC	4500-9000 (/UL)	10/08/91	8800.00		11200.0	>	9400.00	>
WBC: N	2700-6300 (/MM3)	10/08/91	5984.00		6384.00	>	5385.00	
WBC: L	900-2700 (/MM3)	10/08/91	2112.00		2912.00	>	2820.00	>
WBC: E	45-360 (/MM3)	10/08/91	88.00		448.00	>	188.00	
WBC: M	90-540 (/MM3)	10/08/91	528.00		1344.00	>>	940.00	>>
WBC: B	0-90 (/MM3)	10/08/91	0.00		0.00		0.00	
PLATELETS	150-400 (10-3/UL)	10/08/91	320.00		320.00		320.00	
NA+	137-145 (MEQ/L)	10/08/91	141.00		138.00		140.00	
K+	3.8-5.6 (MEQ/L)	10/08/91	5.00		4.90		5.00	
CL-	98-108 (MEQ/L)	10/08/91	109.00	>	107.00		108.00	
Ca++	85-105 (MG/L)	10/08/91	107.00	>	105.00		98.00	
PO4--	25-42 (MG/L)	10/08/91	20.20	<<	26.00		30.00	
SGOT	6-37 (UI/L)	10/08/91	23.00		27.00		26.00	
SGPT	6-45 (UI/L)	10/08/91	19.00		24.00		20.00	
GAMMA GT	11-43 (UI/L)	10/08/91	17.00		18.00		22.00	
LDH	230-460 (UI/L)	10/08/91	320.00		330.00		340.00	
ALK. PHOSPH.	41-133 (UI/L)	10/08/91	144.00	>	153.00	>	141.00	>
GLUCOSE	0.7-1.1 (G/L)	10/08/91	0.89		1.06		0.82	
UREA	0.2-0.5 (G/L)	10/08/91	0.19	<	0.29		0.30	
CREATININE	5-13 (MG/L)	10/08/91	9.90		10.50		10.40	
URIC ACID	25-65 (MG/L)	10/08/91	36.00		35.00		35.00	
TOT BILIRUBIN	0-10 (MG/L)	10/08/91	7.00		5.00		7.00	
TOT. PROTEINS	63-78 (G/L)	10/08/91	74.00		72.00		74.00	
ALBUMINE	57-65 (%)	10/08/91	55.30	<	51.70	<	48.70	<
TOT. CHOLEST.	1.5-2.3 (G/L)	10/08/91	1.59		1.54		1.59	
TRIGLYCERIDES	0.5-1.6 (G/L)	10/08/91	0.69		1.01		0.81	
GLOBULINS ALPHA 1	2-4 (%)	10/08/91	4.20	>	3.90		4.20	>
GLOBULINS ALPHA 2	6-10 (%)	10/08/91	7.80		8.90		10.20	>
GLOBULINS BETA	8-12 (%)	10/08/91	10.20		10.80		11.00	
GLOBULINS GAMMA	12-19 (%)	10/08/91	22.50	>	24.70	>	25.90	>>

1682

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/1 Patient: 66 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/06/91		01/07/91		22/07/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12.5-17.5 (G/DL)	01/02/91	15.00		15.10		15.40	
HT	40-55 (%)	01/02/91	43.70		44.00		46.90	
RBC	4.5-5.8 (10¬6/UL)	01/02/91	4.62		4.75		4.99	
WBC	4500-9000 (/UL)	01/02/91	5200.00		4500.00		5100.00	
WBC: N	2700-6300 (/UL)	01/02/91	2600.00	<	2295.00	<	3060.00	
WBC: L	900-2700 (/UL)	01/02/91	2236.00		1935.00		1187.00	
WBC: E	45-360 (/UL)	01/02/91	208.00		45.00		51.00	
WBC: M	90-540 (/UL)	01/02/91	156.00		135.00		51.00	<
WBC: B	0-90 (/UL)	01/02/91	0.00		90.00		51.00	
PLATELETS	150-400 (10¬3/UL)	01/02/91	224.00		232.00		236.00	
NA+	138-148 (MEQ/L)	01/02/91	142.00		139.00		139.30	
K+	3.8-5.6 (MEQ/L)	01/02/91	4.13		4.38		4.32	
CL-	95-108 (MEQ/L)	01/02/91	104.00		100.00		105.00	
Ca++	90-110 (MG/L)	01/02/91	106.00		99.00		93.00	
PO4--	25-50 (MG/L)	01/02/91	52.50	>	38.20		31.40	
SGOT	5-25 (UI/L)	01/02/91	10.00		5.00		13.00	
SGPT	5-29 (UI/L)	01/02/91	15.00		15.00		13.00	
GAMMA GT	7-34 (UI/L)	01/02/91	27.00		30.00		24.00	
LDH	140-330 (UI/L)	01/02/91	181.00		187.00		195.00	
ALK. PHOSPH.	30-90 (UI/L)	01/02/91	57.00		75.00		72.00	
GLUCOSE	0.7-1.1 (G/L)	01/02/91	1.12	>	1.04		1.09	
UREA	0.2-0.5 (G/L)	01/02/91	0.27		0.38		0.30	
CREATININE	7-14 (MG/L)	01/02/91	9.90		9.90		11.10	
URIC ACID	30-70 (MG/L)	01/02/91	72.00	>	86.00	>	91.00	>
TOT BILIRUBIN	0-10 (MG/L)	01/02/91	6.10		6.10		5.70	
TOT. PROTEINS	65-80 (G/L)	01/02/91	68.00		75.00		72.00	
ALBUMINE	55-75 (%)	01/02/91	47.40	<	61.70		61.10	
TOT. CHOLEST.	1.5-2.2 (G/L)	01/02/91	2.14		2.11		2.07	
TRIGLYCERIDES	0.5-1.6 (G/L)	01/02/91	2.83	>>	2.49	>>	2.10	>>
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/02/91	2.30		1.50		1.50	
GLOBULINS ALPHA 2	6-12 (%)	01/02/91	11.20		9.50		10.50	
GLOBULINS BETA	11-16 (%)	01/02/91	20.30	>	15.90		13.00	
GLOBULINS GAMMA	12-17 (%)	01/02/91	18.80	>	11.40	<	13.90	
TSH	0.2-6.5 (UUI/ML)	01/02/91	1.16					
T4	4.5-12 (UG/DL)	01/02/91	5.47					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/1 Patient: 139 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date	
			Screen	
			03/09/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12.5-17.5 (G/DL)	01/02/91	17.30	
HT	40-55 (%)	01/02/91	50.50	
RBC	4.5-5.8 (10¬6/UL)	01/02/91	5.78	
WBC	4500-9000 (/UL)	01/02/91	6600.00	
WBC: N	2700-6300 (/UL)	01/02/91	3102.00	
WBC: L	900-2700 (/UL)	01/02/91	970.00	
WBC: E	45-360 (/UL)	01/02/91	396.00	>
WBC: M	90-540 (/UL)	01/02/91	132.00	
WBC: B	0-90 (/UL)	01/02/91	0.00	
PLATELETS	150-400 (10¬3/UL)	01/02/91	191.00	
NA+	138-148 (MEQ/L)	01/02/91	139.50	
K+	3.8-5.6 (MEQ/L)	01/02/91	4.01	
CL-	95-108 (MEQ/L)	01/02/91	100.00	
Ca++	90-110 (MG/L)	01/02/91	97.00	
PO4--	25-50 (MG/L)	01/02/91	41.00	
SGOT	5-25 (UI/L)	01/02/91	16.00	
SGPT	5-29 (UI/L)	01/02/91	14.00	
GAMMA GT	7-34 (UI/L)	01/02/91	14.00	
LDH	140-330 (UI/L)	01/02/91	274.00	
ALK. PHOSPH.	30-90 (UI/L)	01/02/91	63.00	
GLUCOSE	0.7-1.1 (G/L)	01/02/91	0.78	
UREA	0.2-0.5 (G/L)	01/02/91	0.48	
CREATININE	7-14 (MG/L)	01/02/91	10.60	
URIC ACID	30-70 (MG/L)	01/02/91	49.00	
TOT BILIRUBIN	0-10 (MG/L)	01/02/91	6.70	
TOT. PROTEINS	65-80 (G/L)	01/02/91	81.00	>
ALBUMINE	55-75 (%)	01/02/91	55.70	
TOT. CHOLEST.	1.5-2.2 (G/L)	01/02/91	2.19	
TRIGLYCERIDES	0.5-1.6 (G/L)	01/02/91	1.09	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/02/91	2.70	
GLOBULINS ALPHA 2	6-12 (%)	01/02/91	8.90	
GLOBULINS BETA	11-16 (%)	01/02/91	11.70	
GLOBULINS GAMMA	12-17 (%)	01/02/91	21.00	>
TSH	0.2-6.5 (UUI/ML)	01/02/91	2.03	
T4	4.5-12 (UG/DL)	01/02/91	8.79	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/1 Patient: 140 Treatment: Placebo Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			10/09/91		03/10/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12.5-17.5 (G/DL)	01/02/91	14.80		15.10	
HT	40-55 (%)	01/02/91	41.70		45.30	
RBC	4.5-5.8 (10¬6/UL)	01/02/91	4.85		5.26	
WBC	4500-9000 (/UL)	01/02/91	4200.00	<	4700.00	
WBC: N	2700-6300 (/UL)	01/02/91	1932.00	<	2491.00	<
WBC: L	900-2700 (/UL)	01/02/91	2058.00		1974.00	
WBC: E	45-360 (/UL)	01/02/91	84.00		141.00	
WBC: M	90-540 (/UL)	01/02/91	84.00	<	47.00	<
WBC: B	0-90 (/UL)	01/02/91	42.00		47.00	
PLATELETS	150-400 (10¬3/UL)	01/02/91	150.00		152.00	
NA+	138-148 (MEQ/L)	01/02/91	143.00		141.50	
K+	3.8-5.6 (MEQ/L)	01/02/91	4.65		4.95	
CL-	95-108 (MEQ/L)	01/02/91	102.00		100.00	
Ca++	90-110 (MG/L)	01/02/91	101.00		92.00	
PO4--	25-50 (MG/L)	01/02/91	40.50		37.60	
SGOT	5-25 (UI/L)	01/02/91	12.00		12.00	
SGPT	5-29 (UI/L)	01/02/91	10.00		12.00	
GAMMA GT	7-34 (UI/L)	01/02/91	12.00		10.00	
LDH	140-330 (UI/L)	01/02/91	177.00		204.00	
ALK. PHOSPH.	30-90 (UI/L)	01/02/91	37.00		51.00	
GLUCOSE	0.7-1.1 (G/L)	01/02/91	0.88		0.90	
UREA	0.2-0.5 (G/L)	01/02/91	0.30		0.40	
CREATININE	7-14 (MG/L)	01/02/91	13.60		11.20	
URIC ACID	30-70 (MG/L)	01/02/91	51.00		59.00	
TOT BILIRUBIN	0-10 (MG/L)	01/02/91	7.20		8.30	
TOT. PROTEINS	65-80 (G/L)	01/02/91	65.00		71.00	
ALBUMINE	55-75 (%)	01/02/91	62.50		61.60	
TOT. CHOLEST.	1.5-2.2 (G/L)	01/02/91	1.58		1.78	
TRIGLYCERIDES	0.5-1.6 (G/L)	01/02/91	0.68		0.88	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/02/91	3.30		1.90	
GLOBULINS ALPHA 2	6-12 (%)	01/02/91	7.60		5.30	<
GLOBULINS BETA	11-16 (%)	01/02/91	8.90	<	10.00	<
GLOBULINS GAMMA	12-17 (%)	01/02/91	17.70	>	21.20	>
TSH	0.2-6.5 (UUI/ML)	01/02/91	0.51			
T4	4.5-12 (UG/DL)	01/02/91	5.85			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/1 Patient: 141 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			26/09/91		23/10/91		14/11/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-15.5 (G/DL)	01/02/91	12.20		12.30		12.70	
HT	35-50 (%)	01/02/91	36.20		36.60		37.90	
RBC	3.8-5.4 (10¬6/UL)	01/02/91	4.09		4.02		4.25	
WBC	4500-9000 (/UL)	01/02/91	5200.00		5900.00		5500.00	
WBC: N	2700-6300 (/UL)	01/02/91	2392.00	<	3658.00		3190.00	
WBC: L	900-2700 (/UL)	01/02/91	2600.00		2124.00		2035.00	
WBC: E	45-360 (/UL)	01/02/91	52.00		0.00	<	165.00	
WBC: M	90-540 (/UL)	01/02/91	156.00		59.00	<	110.00	
WBC: B	0-90 (/UL)	01/02/91	0.00		59.00		0.00	
PLATELETS	150-400 (10¬3/UL)	01/02/91	198.00		197.00		226.00	
NA+	138-148 (MEQ/L)	01/02/91	141.80		144.00		143.50	
K+	3.8-5.6 (MEQ/L)	01/02/91	4.08		4.10		4.30	
CL-	95-108 (MEQ/L)	01/02/91	105.00		104.00		106.00	
Ca++	90-110 (MG/L)	01/02/91	99.00		92.00		97.00	
PO4--	25-50 (MG/L)	01/02/91	45.00		42.80		46.00	
SGOT	5-25 (UI/L)	01/02/91	8.00		10.00		9.00	
SGPT	5-29 (UI/L)	01/02/91	6.00		8.00		8.00	
GAMMA GT	6-22 (UI/L)	01/02/91	10.00		13.00		11.00	
LDH	140-330 (UI/L)	01/02/91	207.00		204.00		194.00	
ALK. PHOSPH.	30-100 (UI/L)	01/02/91	66.00		50.00		42.00	
GLUCOSE	0.7-1.1 (G/L)	01/02/91	1.04		1.01		1.04	
UREA	0.2-0.5 (G/L)	01/02/91	0.47		0.31		0.36	
CREATININE	7-14 (MG/L)	01/02/91	10.50		9.30		10.00	
URIC ACID	30-70 (MG/L)	01/02/91	28.00	<	39.00		37.00	
TOT BILIRUBIN	0-10 (MG/L)	01/02/91	5.30		4.60			
TOT. PROTEINS	65-80 (G/L)	01/02/91	64.00	<	64.00	<	65.00	
ALBUMINE	55-75 (%)	01/02/91	63.90		59.80		67.20	
TOT. CHOLEST.	1.5-2.2 (G/L)	01/02/91	2.57	>	1.99		2.28	>
TRIGLYCERIDES	0.5-1.6 (G/L)	01/02/91	0.62		0.84		0.71	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/02/91	1.00	<<	2.70		2.80	
GLOBULINS ALPHA 2	6-12 (%)	01/02/91	7.70		9.50		7.10	
GLOBULINS BETA	11-16 (%)	01/02/91	14.30		15.80		11.60	
GLOBULINS GAMMA	12-17 (%)	01/02/91	13.10		12.20		11.30	<
TSH	0.2-6.5 (UUI/ML)	01/02/91	0.88					
T4	4.5-12 (UG/DL)	01/02/91	5.52					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/1 Patient: 142 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			14/11/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	11/09/91	13.10	
HT	35-50 (%)	11/09/91	38.20	
RBC	3.8-5.4 (10-6/UL)	11/09/91	4.66	
WBC	4500-9000 (/UL)	11/09/91	6900.00	
WBC: N	45-70 (%)	11/09/91	53.00	
WBC: L	20-40 (%)	11/09/91	34.00	
WBC: E	1-2 (%)	11/09/91	4.00	>>
WBC: M	2-8 (%)	11/09/91	9.00	>
WBC: B	0-1 (%)	11/09/91	0.00	
PLATELETS	150-400 (10-3/UL)	11/09/91	250.00	
NA+	137-145 (MEQ/L)	11/09/91	137.00	
K+	3.8-5.6 (MEQ/L)	11/09/91	4.10	
CL-	98-108 (MEQ/L)	11/09/91	107.00	
Ca++	85-105 (MG/L)	11/09/91	96.00	
PO4--	25-42 (MG/L)	11/09/91	32.00	
SGOT	6-31 (UI/L)	11/09/91	15.00	
SGPT	5-35 (UI/L)	11/09/91	9.00	
GAMMA GT	9-37 (UI/L)	11/09/91	19.00	
LDH	230-460 (UI/L)	11/09/91	220.00	<
ALK. PHOSPH.	41-133 (UI/L)	11/09/91	99.00	
GLUCOSE	0.7-1.1 (G/L)	11/09/91	0.72	
UREA	0.2-0.5 (G/L)	11/09/91	0.18	<
CREATININE	5-13 (MG/L)	11/09/91	8.40	
URIC ACID	25-60 (MG/L)	11/09/91	28.00	
TOT BILIRUBIN	0-10 (MG/L)	11/09/91	7.00	
TOT. PROTEINS	63-78 (G/L)	11/09/91	72.00	
ALBUMINE	57-65 (%)	11/09/91	50.50	<
TOT. CHOLEST.	1.5-2.3 (G/L)	11/09/91	2.26	
TRIGLYCERIDES	0.5-1.6 (G/L)	11/09/91	0.78	
GLOBULINS ALPHA 1	2-4 (%)	11/09/91	5.90	>>
GLOBULINS ALPHA 2	6-10 (%)	11/09/91	10.50	>
GLOBULINS BETA	8-12 (%)	11/09/91	12.30	>
GLOBULINS GAMMA	12-19 (%)	11/09/91	20.80	>

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/1 Patient: 143 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 35	
			14/04/92		20/05/92	
			value	(¢)	value	(¢)
Laboratory test	Range value	Range date				
HB	11.5-15.5 (G/DL)	01/02/91	13.20		13.30	
HT	35-50 (%)	01/02/91	40.50		38.50	
RBC	3.8-5.4 (10-6/UL)	01/02/91	4.40		4.48	
WBC	4500-9000 (/UL)	01/02/91	4900.00		5400.00	
WBC: N	2700-6300 (/UL)	01/02/91	2499.00	<	2322.00	<
WBC: L	900-2700 (/UL)	01/02/91	2156.00		2700.00	
WBC: E	45-360 (/UL)	01/02/91	98.00		54.00	
WBC: M	90-540 (/UL)	01/02/91	147.00		270.00	
WBC: B	0-90 (/UL)	01/02/91	0.00		54.00	
PLATELETS	150-400 (10-3/UL)	01/02/91	211.00		240.00	
NA+	138-148 (MEQ/L)	01/02/91	140.00		138.00	
K+	3.8-5.6 (MEQ/L)	01/02/91	4.30		4.40	
CL-	95-108 (MEQ/L)	01/02/91	106.00		103.00	
Ca++	90-110 (MG/L)	01/02/91	90.00		96.00	
PO4--	25-50 (MG/L)	01/02/91	45.90		39.00	
SGOT	5-25 (UI/L)	01/02/91	11.00		8.00	
SGPT	5-29 (UI/L)	01/02/91	8.00		7.00	
GAMMA GT	6-22 (UI/L)	01/02/91	10.00		10.00	
LDH	140-330 (UI/L)	01/02/91	126.00	<	114.00	<
ALK. PHOSPH.	30-100 (UI/L)	01/02/91	55.00		49.00	
GLUCOSE	0.7-1.1 (G/L)	01/02/91	0.84		0.82	
UREA	0.2-0.5 (G/L)	01/02/91	0.29		0.24	
CREATININE	7-14 (MG/L)	01/02/91	10.00		9.60	
URIC ACID	30-70 (MG/L)	01/02/91	33.00		51.00	
TOT BILIRUBIN	0-10 (MG/L)	01/02/91	2.00		4.00	
TOT. PROTEINS	65-80 (G/L)	01/02/91	64.00	<	63.00	<
ALBUMINE	55-75 (%)	01/02/91	65.80		65.10	
TOT. CHOLEST.	1.5-2.2 (G/L)	01/02/91	2.32	>	2.12	
TRIGLYCERIDES	0.5-1.6 (G/L)	01/02/91	1.30		1.42	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/02/91	2.80		2.80	
GLOBULINS ALPHA 2	6-12 (%)	01/02/91	7.60		7.60	
GLOBULINS BETA	11-16 (%)	01/02/91	10.70	<	10.10	<
GLOBULINS GAMMA	12-17 (%)	01/02/91	13.10		14.40	
TSH	0.2-6.5 (UUI/ML)	01/02/91	0.90			
T4	4.5-12 (UG/DL)	01/02/91	8.30			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/1 Patient: 144 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 42	
			04/06/92		21/07/92	
			value	(¢)	value	(¢)
Laboratory test	Range value	Range date				
HB	11.5-15.5 (G/DL)	01/02/91	12.80		13.50	
HT	35-50 (%)	01/02/91	38.00		40.20	
RBC	3.8-5.4 (10¬6/UL)	01/02/91	4.29		4.48	
WBC	4500-9000 (/UL)	01/02/91	10700.0	>	10700.0	>
WBC: N	2700-6300 (/UL)	01/02/91	6955.00	>	6099.00	
WBC: L	900-2700 (/UL)	01/02/91	3317.00	>	4066.00	>>
WBC: E	45-360 (/UL)	01/02/91	214.00		107.00	
WBC: M	90-540 (/UL)	01/02/91	214.00		428.00	
WBC: B	0-90 (/UL)	01/02/91	0.00		0.00	
PLATELETS	150-400 (10¬3/UL)	01/02/91	156.00		138.00	<
NA+	138-148 (MEQ/L)	01/02/91	138.00		138.00	
K+	3.8-5.6 (MEQ/L)	01/02/91	4.10		3.60	<
CL-	95-108 (MEQ/L)	01/02/91	104.00		103.00	
Ca++	90-110 (MG/L)	01/02/91	88.00	<	95.00	
PO4--	25-50 (MG/L)	01/02/91	28.00		35.00	
SGOT	5-25 (UI/L)	01/02/91	10.00		14.00	
SGPT	5-29 (UI/L)	01/02/91	7.00		8.00	
GAMMA GT	6-22 (UI/L)	01/02/91	14.00		18.00	
LDH	140-330 (UI/L)	01/02/91	157.00		193.00	
ALK. PHOSPH.	30-100 (UI/L)	01/02/91	58.00		56.00	
GLUCOSE	0.7-1.1 (G/L)	01/02/91	0.83		0.60	<
UREA	0.2-0.5 (G/L)	01/02/91	0.16	<	0.22	
CREATININE	7-14 (MG/L)	01/02/91	7.70		9.00	
URIC ACID	30-70 (MG/L)	01/02/91	42.00		52.00	
TOT BILIRUBIN	0-10 (MG/L)	01/02/91	4.00		6.00	
TOT. PROTEINS	65-80 (G/L)	01/02/91	67.00		73.00	
ALBUMINE	55-75 (%)	01/02/91	57.20		63.00	
TOT. CHOLEST.	1.5-2.2 (G/L)	01/02/91	1.65		1.58	
TRIGLYCERIDES	0.5-1.6 (G/L)	01/02/91	0.67		0.65	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/02/91	1.10	<	1.10	<
GLOBULINS ALPHA 2	6-12 (%)	01/02/91	9.80		8.00	
GLOBULINS BETA	11-16 (%)	01/02/91	9.30	<	8.90	<
GLOBULINS GAMMA	12-17 (%)	01/02/91	22.60	>>	19.00	>

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max ra
< out of range (value lower than min range) > out of range (value higher than max
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/1 Patient: 451 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			16/01/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	11.5-15.5 (G/DL)	01/02/91	13.20	
HT	35-50 (%)	01/02/91	39.50	
RBC	3.8-5.4 (10¬6/UL)	01/02/91	4.52	
WBC	4500-9000 (/UL)	01/02/91	4000.00	<
WBC: N	2700-6300 (/UL)	01/02/91	1760.00	<<
WBC: L	900-2700 (/UL)	01/02/91	2160.00	
WBC: E	45-360 (/UL)	01/02/91	0.00	<
WBC: M	90-540 (/UL)	01/02/91	80.00	<
WBC: B	0-90 (/UL)	01/02/91	0.00	
PLATELETS	150-400 (10¬3/UL)	01/02/91	206.00	
NA+	138-148 (MEQ/L)	01/02/91	140.20	
K+	3.8-5.6 (MEQ/L)	01/02/91	4.20	
CL-	95-108 (MEQ/L)	01/02/91	105.00	
Ca++	90-110 (MG/L)	01/02/91	100.00	
PO4--	25-50 (MG/L)	01/02/91	31.00	
SGOT	5-25 (UI/L)	01/02/91	20.00	
SGPT	5-29 (UI/L)	01/02/91	14.00	
GAMMA GT	6-22 (UI/L)	01/02/91	14.00	
LDH	140-330 (UI/L)	01/02/91	234.00	
ALK. PHOSPH.	30-100 (UI/L)	01/02/91	50.00	
GLUCOSE	0.7-1.1 (G/L)	01/02/91	0.82	
UREA	0.2-0.5 (G/L)	01/02/91	0.39	
CREATININE	7-14 (MG/L)	01/02/91	7.10	
URIC ACID	30-70 (MG/L)	01/02/91	38.00	
TOT BILIRUBIN	0-10 (MG/L)	01/02/91	4.50	
TOT. PROTEINS	65-80 (G/L)	01/02/91	76.00	
ALBUMINE	55-75 (%)	01/02/91	58.40	
TOT. CHOLEST.	1.5-2.2 (G/L)	01/02/91	2.30	>
TRIGLYCERIDES	0.5-1.6 (G/L)	01/02/91	1.02	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/02/91	4.50	
GLOBULINS ALPHA 2	6-12 (%)	01/02/91	9.80	
GLOBULINS BETA	11-16 (%)	01/02/91	12.00	
GLOBULINS GAMMA	12-17 (%)	01/02/91	15.30	
TSH	0.2-6.5 (UUI/ML)	01/02/91	1.22	
T4	4.5-12 (UG/DL)	01/02/91	6.80	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 3/1 Patient: 452 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			15/01/92		12/02/92		09/03/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	12.5-17.5 (G/DL)	01/02/91	14.80		14.30		13.80	
HT	40-55 (%)	01/02/91	41.70		44.90		42.20	
RBC	4.5-5.8 (10-6/UL)	01/02/91	4.92		4.97		4.67	
WBC	4500-9000 (/UL)	01/02/91	6500.00		5300.00		4800.00	
WBC: N	2700-6300 (/UL)	01/02/91	2730.00		3021.00		2304.00	<
WBC: L	900-2700 (/UL)	01/02/91	3185.00	>	2014.00		2256.00	
WBC: E	45-360 (/UL)	01/02/91	195.00		159.00		144.00	
WBC: M	90-540 (/UL)	01/02/91	390.00		0.00	<	96.00	
WBC: B	0-90 (/UL)	01/02/91	0.00		106.00	>	0.00	
PLATELETS	150-400 (10-3/UL)	01/02/91	209.00		190.00		178.00	
NA+	138-148 (MEQ/L)	01/02/91	141.70		140.00		140.00	
K+	3.8-5.6 (MEQ/L)	01/02/91	3.90		3.90		3.70	<
CL-	95-108 (MEQ/L)	01/02/91	104.00		102.00		104.00	
Ca++	90-110 (MG/L)	01/02/91	102.00		100.00		97.00	
PO4--	25-50 (MG/L)	01/02/91	34.00		45.00		47.00	
SGOT	5-25 (UI/L)	01/02/91	27.00	>	16.00		16.00	
SGPT	5-29 (UI/L)	01/02/91	26.00		21.00		25.00	
GAMMA GT	7-34 (UI/L)	01/02/91	185.00	>>	72.00	>>	46.00	>
LDH	140-330 (UI/L)	01/02/91	231.00		198.00		189.00	
ALK. PHOSPH.	30-90 (UI/L)	01/02/91	104.00	>	87.00		85.00	
GLUCOSE	0.7-1.1 (G/L)	01/02/91	0.96		0.98		1.67	>>
UREA	0.2-0.5 (G/L)	01/02/91	0.23		0.45		0.34	
CREATININE	7-14 (MG/L)	01/02/91	5.70	<	8.60		8.10	
URIC ACID	30-70 (MG/L)	01/02/91	71.00	>	47.00		41.00	
TOT BILIRUBIN	0-10 (MG/L)	01/02/91	6.50		5.10		4.00	
TOT. PROTEINS	65-80 (G/L)	01/02/91	80.00		78.00		72.00	
ALBUMINE	55-75 (%)	01/02/91	58.60		69.40		63.00	
TOT. CHOLEST.	1.5-2.2 (G/L)	01/02/91	3.28	>>	2.27	>	2.01	
TRIGLYCERIDES	0.5-1.6 (G/L)	01/02/91	3.45	>>	2.14	>>	1.55	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/02/91	9.60	>>	2.20		3.20	
GLOBULINS ALPHA 2	6-12 (%)	01/02/91	9.30		6.80		8.40	
GLOBULINS BETA	11-16 (%)	01/02/91	12.10		11.00		13.70	
GLOBULINS GAMMA	12-17 (%)	01/02/91	10.40	<	10.60	<	11.70	<
TSH	0.2-6.5 (UUI/ML)	01/02/91	3.71					
T4	4.5-12 (UG/DL)	01/02/91	6.40					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/1 Patient: 453 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			28/01/92		19/02/92		11/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-15.5 (G/DL)	01/02/91	12.60		12.70		11.90	
HT	35-50 (%)	01/02/91	36.20		40.20		37.80	
RBC	3.8-5.4 (10¬6/UL)	01/02/91	4.32		4.54		4.27	
WBC	4500-9000 (/UL)	01/02/91	5700.00		5600.00		4800.00	
WBC: N	2700-6300 (/UL)	01/02/91	2508.00	<	2464.00	<	1920.00	<
WBC: L	900-2700 (/UL)	01/02/91	3021.00	>	2800.00	>	2544.00	
WBC: E	45-360 (/UL)	01/02/91	114.00		168.00		144.00	
WBC: M	90-540 (/UL)	01/02/91	57.00	<	168.00		144.00	
WBC: B	0-90 (/UL)	01/02/91	0.00		0.00		48.00	
PLATELETS	150-400 (10¬3/UL)	01/02/91	253.00		275.00		243.00	
NA+	138-148 (MEQ/L)	01/02/91	142.80		141.00		141.00	
K+	3.8-5.6 (MEQ/L)	01/02/91	4.40		4.20		4.20	
CL-	95-108 (MEQ/L)	01/02/91	110.00	>	99.00		105.00	
Ca++	90-110 (MG/L)	01/02/91	91.00		91.00		91.00	
PO4--	25-50 (MG/L)	01/02/91	35.00		37.40		44.00	
SGOT	5-25 (UI/L)	01/02/91	19.00		23.00		24.00	
SGPT	5-29 (UI/L)	01/02/91	19.00		23.00		24.00	
GAMMA GT	6-22 (UI/L)	01/02/91	14.00		25.00	>	17.00	
LDH	140-330 (UI/L)	01/02/91	202.00		197.00		208.00	
ALK. PHOSPH.	30-100 (UI/L)	01/02/91	28.00	<	40.00		46.00	
GLUCOSE	0.7-1.1 (G/L)	01/02/91	1.19	>	1.18	>	1.17	>
UREA	0.2-0.5 (G/L)	01/02/91	0.21		0.28		0.26	
CREATININE	7-14 (MG/L)	01/02/91	5.90	<	6.10	<	6.40	<
URIC ACID	30-70 (MG/L)	01/02/91	24.00	<	39.00		29.00	<
TOT BILIRUBIN	0-10 (MG/L)	01/02/91	4.00		3.20		4.00	
TOT. PROTEINS	65-80 (G/L)	01/02/91	74.00		80.00		73.00	
ALBUMINE	55-75 (%)	01/02/91	67.00		64.70		63.10	
TOT. CHOLEST.	1.5-2.2 (G/L)	01/02/91	1.46	<	2.28	>	2.14	
TRIGLYCERIDES	0.5-1.6 (G/L)	01/02/91	0.88		1.78	>	1.37	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/02/91	1.80		1.80		1.80	
GLOBULINS ALPHA 2	6-12 (%)	01/02/91	6.20		7.40		7.60	
GLOBULINS BETA	11-16 (%)	01/02/91	13.70		15.10		15.10	
GLOBULINS GAMMA	12-17 (%)	01/02/91	11.30	<	11.00	<	12.40	
TSH	0.2-6.5 (UUI/ML)	01/02/91	1.56					
T4	4.5-12 (UG/DL)	01/02/91	7.40					

1692

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/1 Patient: 454 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			13/02/92		09/03/92		01/04/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	12.5-17.5 (G/DL)	01/02/91	14.90		15.00		15.10	
HT	40-55 (%)	01/02/91	45.60		45.20		45.90	
RBC	4.5-5.8 (10-6/UL)	01/02/91	4.44	<	4.57		4.60	
WBC	4500-9000 (/UL)	01/02/91	5600.00		4600.00		5800.00	
WBC: N	2700-6300 (/UL)	01/02/91	2296.00	<	2346.00	<	2494.00	<
WBC: L	900-2700 (/UL)	01/02/91	3192.00	>	2024.00		3016.00	>
WBC: E	45-360 (/UL)	01/02/91	112.00		92.00		116.00	
WBC: M	90-540 (/UL)	01/02/91	0.00	<	92.00		174.00	
WBC: B	0-90 (/UL)	01/02/91	0.00		46.00		0.00	
PLATELETS	150-400 (10-3/UL)	01/02/91	132.00	<	108.00	<	115.00	<
NA+	138-148 (MEQ/L)	01/02/91	138.00		139.00		138.00	
K+	3.8-5.6 (MEQ/L)	01/02/91	4.10		4.00		3.90	
CL-	95-108 (MEQ/L)	01/02/91	104.00		104.00		101.00	
Ca++	90-110 (MG/L)	01/02/91	98.00		102.00		95.00	
PO4--	25-50 (MG/L)	01/02/91	41.00		40.00		38.00	
SGOT	5-25 (UI/L)	01/02/91	16.00		13.00		10.00	
SGPT	5-29 (UI/L)	01/02/91	19.00		14.00		14.00	
GAMMA GT	7-34 (UI/L)	01/02/91	21.00		17.00		19.00	
LDH	140-330 (UI/L)	01/02/91	228.00		267.00		212.00	
ALK. PHOSPH.	30-90 (UI/L)	01/02/91	39.00		38.00		33.00	
GLUCOSE	0.7-1.1 (G/L)	01/02/91	1.18	>	1.22	>	1.28	>
UREA	0.2-0.5 (G/L)	01/02/91	0.59	>	0.50		0.47	
CREATININE	7-14 (MG/L)	01/02/91	10.20		8.40		10.60	
URIC ACID	30-70 (MG/L)	01/02/91	32.00		27.00	<	32.00	
TOT BILIRUBIN	0-10 (MG/L)	01/02/91	8.30		8.00		10.00	
TOT. PROTEINS	65-80 (G/L)	01/02/91	78.00		77.00		75.00	
ALBUMINE	55-75 (%)	01/02/91	65.60		64.10		65.60	
TOT. CHOLEST.	1.5-2.2 (G/L)	01/02/91	1.76		1.80		1.76	
TRIGLYCERIDES	0.5-1.6 (G/L)	01/02/91	1.93	>	1.21		1.39	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/02/91	2.80		2.70		2.90	
GLOBULINS ALPHA 2	6-12 (%)	01/02/91	5.80	<	6.30		6.20	
GLOBULINS BETA	11-16 (%)	01/02/91	11.90		12.60		12.40	
GLOBULINS GAMMA	12-17 (%)	01/02/91	13.90		14.30		12.90	
TSH	0.2-6.5 (UUI/ML)	01/02/91	1.90					
T4	4.5-12 (UG/DL)	01/02/91	5.10					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/1 Patient: 455 Treatment: Placebo Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			03/03/92		01/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11.5-15.5 (G/DL)	01/02/91	13.10		14.00	
HT	35-50 (%)	01/02/91	40.20		43.90	
RBC	3.8-5.4 (10-6/UL)	01/02/91	4.14		4.47	
WBC	4500-9000 (/UL)	01/02/91	8000.00		5000.00	
WBC: N	2700-6300 (/UL)	01/02/91	5360.00		2300.00	<
WBC: L	900-2700 (/UL)	01/02/91	2240.00		2550.00	
WBC: E	45-360 (/UL)	01/02/91	160.00		100.00	
WBC: M	90-540 (/UL)	01/02/91	240.00		50.00	<
WBC: B	0-90 (/UL)	01/02/91	0.00		0.00	
PLATELETS	150-400 (10-3/UL)	01/02/91	247.00		264.00	
NA+	138-148 (MEQ/L)	01/02/91	140.00		139.00	
K+	3.8-5.6 (MEQ/L)	01/02/91	4.30		4.10	
CL-	95-108 (MEQ/L)	01/02/91	104.00		103.00	
Ca++	90-110 (MG/L)	01/02/91	94.00		103.00	
PO4--	25-50 (MG/L)	01/02/91	38.40		32.00	
SGOT	5-25 (UI/L)	01/02/91	19.00		20.00	
SGPT	5-29 (UI/L)	01/02/91	11.00		12.00	
GAMMA GT	6-22 (UI/L)	01/02/91	10.00		9.00	
LDH	140-330 (UI/L)	01/02/91	228.00		207.00	
ALK. PHOSPH.	30-100 (UI/L)	01/02/91	64.00		48.00	
GLUCOSE	0.7-1.1 (G/L)	01/02/91	0.90		1.07	
UREA	0.2-0.5 (G/L)	01/02/91	0.47		0.48	
CREATININE	7-14 (MG/L)	01/02/91	10.10		8.50	
URIC ACID	30-70 (MG/L)	01/02/91	29.00	<	29.00	<
TOT BILIRUBIN	0-10 (MG/L)	01/02/91	5.00		6.00	
TOT. PROTEINS	65-80 (G/L)	01/02/91	71.00		64.00	<
ALBUMINE	55-75 (%)	01/02/91	68.00		69.90	
TOT. CHOLEST.	1.5-2.2 (G/L)	01/02/91	2.20		2.38	>
TRIGLYCERIDES	0.5-1.6 (G/L)	01/02/91	0.51		0.52	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/02/91	2.70		3.10	
GLOBULINS ALPHA 2	6-12 (%)	01/02/91	6.90		5.70	<
GLOBULINS BETA	11-16 (%)	01/02/91	10.40	<	9.30	<
GLOBULINS GAMMA	12-17 (%)	01/02/91	12.00		12.00	
TSH	0.2-6.5 (UUI/ML)	01/02/91	1.60			
T4	4.5-12 (UG/DL)	01/02/91	5.40			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA

Centre: 3/1 Patient: 456 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			18/03/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	11.5-15.5 (G/DL)	01/02/91	12.70	
HT	35-50 (%)	01/02/91	38.80	
RBC	3.8-5.4 (10¬6/UL)	01/02/91	4.04	
WBC	4500-9000 (/UL)	01/02/91	5600.00	
WBC: N	2700-6300 (/UL)	01/02/91	2576.00	<
WBC: L	900-2700 (/UL)	01/02/91	2856.00	>
WBC: E	45-360 (/UL)	01/02/91	56.00	
WBC: M	90-540 (/UL)	01/02/91	112.00	
WBC: B	0-90 (/UL)	01/02/91	0.00	
PLATELETS	150-400 (10¬3/UL)	01/02/91	204.00	
NA+	138-148 (MEQ/L)	01/02/91	137.00	<
K+	3.8-5.6 (MEQ/L)	01/02/91	4.00	
CL-	95-108 (MEQ/L)	01/02/91	99.00	
Ca++	90-110 (MG/L)	01/02/91	95.00	
PO4--	25-50 (MG/L)	01/02/91	32.00	
SGOT	5-25 (UI/L)	01/02/91	10.00	
SGPT	5-29 (UI/L)	01/02/91	14.00	
GAMMA GT	6-22 (UI/L)	01/02/91	10.00	
LDH	140-330 (UI/L)	01/02/91	184.00	
ALK. PHOSPH.	30-100 (UI/L)	01/02/91	35.00	
GLUCOSE	0.7-1.1 (G/L)	01/02/91	0.84	
UREA	0.2-0.5 (G/L)	01/02/91	0.38	
CREATININE	7-14 (MG/L)	01/02/91	7.50	
URIC ACID	30-70 (MG/L)	01/02/91	41.00	
TOT BILIRUBIN	0-10 (MG/L)	01/02/91	5.00	
TOT. PROTEINS	65-80 (G/L)	01/02/91	65.00	
ALBUMINE	55-75 (%)	01/02/91	64.20	
TOT. CHOLEST.	1.5-2.2 (G/L)	01/02/91	2.80	>
TRIGLYCERIDES	0.5-1.6 (G/L)	01/02/91	0.92	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/02/91	2.20	
GLOBULINS ALPHA 2	6-12 (%)	01/02/91	6.80	
GLOBULINS BETA	11-16 (%)	01/02/91	11.10	
GLOBULINS GAMMA	12-17 (%)	01/02/91	15.70	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/2 Patient: 65/A Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/01/91		19/02/91		12/03/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	120-160 (G/L)	01/01/91	129.00		134.00		123.00	
HT	0.37-0.47 (L/L)	01/01/91	0.40		0.41		0.39	
RBC	4.1-5.3 (10¬12/L)	01/01/91	4.24		4.53		4.22	
WBC	4-10 (10¬9/L)	01/01/91	3.40	<	4.00		4.50	
WBC: N	45-74 (%)	01/01/91	53.00		60.00		64.00	
WBC: L	16-45 (%)	01/01/91	40.00		36.00		30.00	
WBC: E	0-7 (%)	01/01/91	2.00		0.00		0.00	
WBC: M	4-10 (%)	01/01/91	5.00		4.00		6.00	
WBC: B	0-2 (%)	01/01/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	01/01/91	261.00		291.00		307.00	
NA+	135-145 (MMOL/L)	01/01/91	142.00		142.00		144.00	
K+	3.5-5 (MMOL/L)	01/01/91	4.20		4.20		4.30	
CL-	95-105 (MMOL/L)	01/01/91	102.00		101.00		101.00	
Ca++	2.1-2.5 (MMOL/L)	01/01/91	2.48		2.38		2.45	
SGOT	5-30 (UI/L)	01/01/91	10.00		12.00		15.00	
SGPT	5-40 (UI/L)	01/01/91	4.00	<	8.00		14.00	
GAMMA GT	6-28 (UI/L)	01/01/91	6.00		5.00	<	6.00	
LDH	140-280 (UI/L)	01/01/91	200.00		175.00		175.00	
ALK. PHOSPH.	30-100 (UI/L)	01/01/91	40.00		41.00		48.00	
GLUCOSE	3.4-5.6 (MMOL/L)	01/01/91	3.70		4.10		4.80	
UREA	2.5-6.7 (MMOL/L)	01/01/91	3.90		4.10		4.30	
CREATININE	70-115 (UMOL/L)	01/01/91	82.00		75.00		77.00	
URIC ACID	235-360 (UMOL/L)	01/01/91	221.00	<	273.00		210.00	<
TOT BILIRUBIN	4-20 (UMOL/L)	01/01/91	8.00		11.00		6.00	
DIR BILIRUBIN	0-10 (UMOL/L)	01/01/91	7.00		5.00		6.00	
TOT. PROTEINS	60-75 (G/L)	01/01/91	65.00		71.00		68.00	
ALBUMINE	37-42 (G/L)	01/01/91	44.40	>	42.70	>	43.40	>
TOT. CHOLEST.	4-6 (MMOL/L)	01/01/91	4.41		5.27		5.52	
TRIGLYCERIDES	0.6-1.7 (MMOL/L)	01/01/91	0.60		0.88		0.70	
GLOBULINS ALPHA 1	1-3 (G/L)	01/01/91	2.30		3.40	>	2.90	
GLOBULINS ALPHA 2	4-7 (G/L)	01/01/91	4.70		6.10		5.40	
GLOBULINS BETA	5-8 (G/L)	01/01/91	5.90		8.60	>	7.80	
GLOBULINS GAMMA	8-12 (G/L)	01/01/91	7.70	<	10.20		8.50	
TSH	0.3-5 (UI/L)	01/01/91	0.95					
T4	8-18 (PMOL/L)	01/01/91	16.40					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/3 Patient: 67 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			16/07/91		07/08/91		28/08/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	13-18 (G/100ML)	23/04/91	15.80		14.80		13.30	
HT	40-50 (%)	23/04/91	45.80		43.10		38.70	<
RBC	4.2-4.9 (10¬6/MM3)	23/04/91	5.40	>	5.16	>	4.69	
WBC	4-10 (10¬3/MM3)	23/04/91	7.90		8.70		9.20	
WBC: N	2-7.5 (10¬3/MM3)	23/04/91	5.60		5.70		5.10	
WBC: L	1.5-4 (10¬3/MM3)	23/04/91	2.00		2.10		3.10	
WBC: E	0.04-0.4 (10¬3/MM3)	23/04/91			0.40		0.00	<
WBC: M	0.2-0.8 (10¬3/MM3)	23/04/91	0.20		0.50		0.90	>
PLATELETS	150-400 (10¬3/MM3)	23/04/91	188.00		174.00		166.00	
NA+	135-145 (MEQ/L)	23/04/91	142.00		142.00		145.00	
K+	3.5-5 (MEQ/L)	23/04/91	4.60		3.90		4.10	
CL-	95-105 (MEQ/L)	23/04/91	106.00	>	108.00	>	109.00	>
Ca++	85-105 (MG/L)	23/04/91	94.00		92.00		92.00	
PO4--	22-45 (MG/L)	23/04/91	40.00		42.00		42.00	
SGOT	8-30 (UI/L)	23/04/91	17.00		16.00		10.00	
SGPT	7-46 (UI/L)	23/04/91	31.00		30.00		15.00	
GAMMA GT	5-36 (UI/L)	23/04/91	34.00		18.00		19.00	
LDH	260-330 (UI/L)	23/04/91			150.00	<	148.00	<
ALK. PHOSPH.	80-220 (UI/L)	23/04/91	123.00		103.00		100.00	
GLUCOSE	0.65-1.1 (G/L)	23/04/91	0.90		0.70		0.83	
UREA	0.15-0.45 (G/L)	23/04/91	0.31		0.29		0.32	
CREATININE	3-15 (MG/L)	23/04/91	10.00		9.00		10.00	
URIC ACID	25-60 (MG/L)	23/04/91	73.00	>	70.00	>	72.00	>
TOT BILIRUBIN	1.5-12 (MG/L)	23/04/91	3.00		4.00		3.00	
DIR BILIRUBIN	0-3 (MG/L)	23/04/91	1.00		1.00		1.00	
TOT. PROTEINS	60-80 (G/L)	23/04/91	66.00		65.00		57.00	<
ALBUMINE	33-50 (G/L)	23/04/91	45.00		45.00		43.00	
TOT. CHOLEST.	1.3-2.1 (G/L)	23/04/91	2.09		2.02		1.77	
TRIGLYCERIDES	0.3-1.5 (G/L)	23/04/91	1.72	>	2.35	>>	1.65	>
GLOBULINS ALPHA 1	1.8-4.8 (G/L)	23/04/91	2.50		2.50		2.30	
GLOBULINS ALPHA 2	3.3-11 (G/L)	23/04/91	7.10		6.90		6.50	
GLOBULINS BETA	5.4-12.8 (G/L)	23/04/91	8.60		8.10		6.90	
GLOBULINS GAMMA	6.6-17.6 (G/L)	23/04/91	5.70	<	5.70	<	4.80	<
TSH	0.15-3 (UU/ML)	23/04/91	0.43					
T4	9-24 (PMOL/L)	23/04/91	13.10					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 3/3 Patient: 68 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			14/01/92		10/02/92		02/03/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/100ML)	23/04/91	13.40		14.30		14.20	
HT	40-50 (%)	23/04/91	39.70	<	43.10		43.70	
RBC	4.2-4.9 (10¬6/MM3)	23/04/91	4.33		4.82		4.88	
WBC	4-10 (10¬3/MM3)	23/04/91	6.30		6.40		7.50	
WBC: N	2-7.5 (10¬3/MM3)	23/04/91	3.60				4.70	
WBC: L	1.5-4 (10¬3/MM3)	23/04/91	1.90				2.30	
WBC: E	0.04-0.4 (10¬3/MM3)	23/04/91	0.20					
WBC: M	0.2-0.8 (10¬3/MM3)	23/04/91	0.60				0.40	
PLATELETS	150-400 (10¬3/MM3)	23/04/91	271.00		283.00		351.00	
NA+	135-145 (MEQ/L)	23/04/91	138.00		142.00		141.00	
K+	3.5-5 (MEQ/L)	23/04/91	3.60		4.10		4.20	
CL-	95-105 (MEQ/L)	23/04/91	103.00		101.00		102.00	
Ca++	85-105 (MG/L)	23/04/91	89.00		93.00		95.00	
PO4--	22-45 (MG/L)	23/04/91	35.00		33.00		31.00	
SGOT	8-30 (UI/L)	23/04/91	11.00		11.00		10.00	
SGPT	7-46 (UI/L)	23/04/91	17.00		16.00		13.00	
GAMMA GT	5-36 (UI/L)	23/04/91	30.00		24.00		31.00	
LDH	260-330 (UI/L)	23/04/91	147.00	<	213.00	<	182.00	<
ALK. PHOSPH.	80-220 (UI/L)	23/04/91	71.00	<	93.00		99.00	
GLUCOSE	0.65-1.1 (G/L)	23/04/91	1.16	>	0.81		0.85	
UREA	0.15-0.45 (G/L)	23/04/91	0.37		0.20		0.25	
CREATININE	3-15 (MG/L)	23/04/91	11.90		11.00		11.00	
URIC ACID	25-60 (MG/L)	23/04/91	66.00	>	56.00		61.00	>
TOT BILIRUBIN	1.5-12 (MG/L)	23/04/91	8.00		4.00		5.00	
DIR BILIRUBIN	0-3 (MG/L)	23/04/91	1.00		0.00		1.00	
TOT. PROTEINS	60-80 (G/L)	23/04/91	63.00		75.00		75.00	
ALBUMINE	33-50 (G/L)	23/04/91	43.00		54.00	>	47.80	
TOT. CHOLEST.	1.3-2.1 (G/L)	23/04/91	2.00		2.90	>>	2.86	>>
TRIGLYCERIDES	0.3-1.5 (G/L)	23/04/91	2.51	>>	2.09	>>	1.54	>
GLOBULINS ALPHA 1	1.8-4.8 (G/L)	23/04/91	2.40		2.50		2.40	
GLOBULINS ALPHA 2	3.3-11 (G/L)	23/04/91	5.80		6.50		5.80	
GLOBULINS BETA	5.4-12.8 (G/L)	23/04/91	7.70		8.50		8.00	
GLOBULINS GAMMA	6.6-17.6 (G/L)	23/04/91	8.80		11.40		11.00	
TSH	0.15-3 (UU/ML)	23/04/91	3.84	>>				
T4	9-24 (PMOL/L)	23/04/91	17.30					

1698

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0
9550082
LABORATORY DATA
Centre: 3/3 Patient: 69 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			31/01/92		24/02/92		16/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/100ML)	23/04/91	14.60		14.50		14.10	
HT	40-50 (%)	23/04/91	45.10		44.70		46.20	
RBC	4.2-4.9 (10¬6/MM3)	23/04/91	5.24	>	5.22	>	5.35	>
WBC	4-10 (10¬3/MM3)	23/04/91	9.90		9.90		8.70	
WBC: N	2-7.5 (10¬3/MM3)	23/04/91	5.30		5.30		4.60	
WBC: L	1.5-4 (10¬3/MM3)	23/04/91	3.20		3.40		2.80	
WBC: E	0.04-0.4 (10¬3/MM3)	23/04/91	0.70	>>	0.50	>	0.70	>>
WBC: M	0.2-0.8 (10¬3/MM3)	23/04/91	0.60		0.60		0.80	
PLATELETS	150-400 (10¬3/MM3)	23/04/91	262.00		218.00		244.00	
NA+	135-145 (MEQ/L)	23/04/91	140.00		141.00		139.00	
K+	3.5-5 (MEQ/L)	23/04/91	4.60		4.50		4.30	
CL-	95-105 (MEQ/L)	23/04/91	103.00		106.00	>	106.00	>
Ca++	85-105 (MG/L)	23/04/91	93.00		95.00		92.00	
PO4--	22-45 (MG/L)	23/04/91	46.00	>	41.00		45.00	
SGOT	8-30 (UI/L)	23/04/91	17.00		23.00		20.00	
SGPT	7-46 (UI/L)	23/04/91	25.00		46.00		37.00	
GAMMA GT	5-36 (UI/L)	23/04/91	52.00	>	23.00		25.00	
LDH	260-330 (UI/L)	23/04/91	186.00	<	160.00	<	140.00	<
ALK. PHOSPH.	80-220 (UI/L)	23/04/91	129.00		127.00		128.00	
GLUCOSE	0.65-1.1 (G/L)	23/04/91	0.86		0.88		0.82	
UREA	0.15-0.45 (G/L)	23/04/91	0.31		0.34		0.30	
CREATININE	3-15 (MG/L)	23/04/91	9.00		7.00		7.00	
URIC ACID	25-60 (MG/L)	23/04/91	46.00		51.00		49.00	
TOT BILIRUBIN	1.5-12 (MG/L)	23/04/91	3.00		5.00		4.00	
DIR BILIRUBIN	0-3 (MG/L)	23/04/91	0.00		1.00		1.00	
TOT. PROTEINS	60-80 (G/L)	23/04/91	70.00		70.00		69.00	
ALBUMINE	33-50 (G/L)	23/04/91	45.00		49.00		47.00	
TOT. CHOLEST.	1.3-2.1 (G/L)	23/04/91	1.69		1.81		1.75	
TRIGLYCERIDES	0.3-1.5 (G/L)	23/04/91	1.26		0.62		1.06	
GLOBULINS ALPHA 1	1.8-4.8 (G/L)	23/04/91	2.10		3.10		3.50	
GLOBULINS ALPHA 2	3.3-11 (G/L)	23/04/91	4.80		5.70		5.20	
GLOBULINS BETA	5.4-12.8 (G/L)	23/04/91	8.10		7.10		6.60	
GLOBULINS GAMMA	6.6-17.6 (G/L)	23/04/91	8.30		10.90		11.30	
TSH	0.15-3 (UU/ML)	23/04/91	0.86					
T4	9-24 (PMOL/L)	23/04/91	19.40					

1699

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015 *
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/3 Patient: 70 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/04/92		05/05/92		26/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/100ML)	23/04/91	15.60		13.30		14.70	
HT	40-50 (%)	23/04/91	45.50		39.60	<	44.00	
RBC	4.2-4.9 (10¬6/MM3)	23/04/91	4.85		4.32		4.74	
WBC	4-10 (10¬3/MM3)	23/04/91	5.20		7.10		4.90	
WBC: N	2-7.5 (10¬3/MM3)	23/04/91	3.10		3.80		2.40	
WBC: L	1.5-4 (10¬3/MM3)	23/04/91	1.60		1.90		2.00	
WBC: E	0.04-0.4 (10¬3/MM3)	23/04/91	0.30		1.40	>>		
WBC: M	0.2-0.8 (10¬3/MM3)	23/04/91	0.30				0.40	
PLATELETS	150-400 (10¬3/MM3)	23/04/91	210.00		248.00		289.00	
NA+	135-145 (MEQ/L)	23/04/91	143.00		138.00		142.00	
K+	3.5-5 (MEQ/L)	23/04/91	4.20		4.20		3.80	
CL-	95-105 (MEQ/L)	23/04/91	104.00		105.00		105.00	
Ca++	85-105 (MG/L)	23/04/91	98.00		89.00		94.00	
PO4--	22-45 (MG/L)	23/04/91	40.00		36.00		29.00	
SGOT	8-30 (UI/L)	23/04/91	20.00		14.00		15.00	
SGPT	7-46 (UI/L)	23/04/91	28.00		17.00		15.00	
GAMMA GT	5-36 (UI/L)	23/04/91	30.00		17.00			
LDH	260-330 (UI/L)	23/04/91	198.00	<	191.00	<		
ALK. PHOSPH.	80-220 (UI/L)	23/04/91	128.00		86.00		104.00	
GLUCOSE	0.65-1.1 (G/L)	23/04/91	0.78		0.79		0.73	
UREA	0.15-0.45 (G/L)	23/04/91	0.35		0.32		0.44	
CREATININE	3-15 (MG/L)	23/04/91	13.00		11.00		10.00	
URIC ACID	25-60 (MG/L)	23/04/91	64.00	>	65.00	>	61.00	>
TOT BILIRUBIN	1.5-12 (MG/L)	23/04/91	10.00		4.00		4.00	
DIR BILIRUBIN	0-3 (MG/L)	23/04/91	1.00		1.00		1.00	
TOT. PROTEINS	60-80 (G/L)	23/04/91	78.00		65.00		74.00	
ALBUMINE	33-50 (G/L)	23/04/91	49.00		46.00		54.00	>
TOT. CHOLEST.	1.3-2.1 (G/L)	23/04/91	2.68	>	2.03		2.40	>
TRIGLYCERIDES	0.3-1.5 (G/L)	23/04/91	2.28	>>	0.97		0.64	
GLOBULINS ALPHA 1	1.8-4.8 (G/L)	23/04/91	2.50				2.80	
GLOBULINS ALPHA 2	3.3-11 (G/L)	23/04/91	6.10				6.10	
GLOBULINS BETA	5.4-12.8 (G/L)	23/04/91	9.60				8.00	
GLOBULINS GAMMA	6.6-17.6 (G/L)	23/04/91	11.00				9.10	
TSH	0.15-3 (UU/ML)	23/04/91	0.46					
T4	9-24 (PMOL/L)	23/04/91	27.90	>>				

1700

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/3 Patient: 71 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			14/04/92		06/05/92		27/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-16.5 (G/100ML)	23/04/91	11.80		13.30		12.80	
HT	38-48 (%)	23/04/91	34.00	<	39.50		38.00	
RBC	4.2-4.9 (10-6/MM3)	23/04/91	3.55	<<	4.11	<	3.97	<
WBC	4-10 (10-3/MM3)	23/04/91	5.40		5.10		5.90	
WBC: N	2-7.5 (10-3/MM3)	23/04/91	3.30		2.40		3.20	
WBC: L	1.5-4 (10-3/MM3)	23/04/91	2.00		2.00		2.40	
WBC: E	0.04-0.4 (10-3/MM3)	23/04/91			0.05			
WBC: M	0.2-0.8 (10-3/MM3)	23/04/91	0.10	<	0.50		0.30	
WBC: B	0.01-0.1 (10-3/MM3)	23/04/91			0.05			
PLATELETS	150-400 (10-3/MM3)	23/04/91	241.00		279.00		312.00	
NA+	135-145 (MEQ/L)	23/04/91	135.00		139.00		139.00	
K+	3.5-5 (MEQ/L)	23/04/91	4.30		3.80		4.20	
CL-	95-105 (MEQ/L)	23/04/91	105.00		104.00		102.00	
Ca++	85-105 (MG/L)	23/04/91	89.00		96.00		99.00	
PO4--	22-45 (MG/L)	23/04/91	32.00		41.00		34.00	
SGOT	8-30 (UI/L)	23/04/91	12.00		11.00		12.00	
SGPT	7-46 (UI/L)	23/04/91	8.00		12.00		9.00	
GAMMA GT	5-36 (UI/L)	23/04/91	10.00		9.00			
LDH	260-330 (UI/L)	23/04/91	160.00	<	201.00	<		
ALK. PHOSPH.	80-220 (UI/L)	23/04/91	65.00	<	71.00	<	84.00	
GLUCOSE	0.65-1.1 (G/L)	23/04/91	0.95		0.88		0.78	
UREA	0.15-0.45 (G/L)	23/04/91	0.16		0.22		0.23	
CREATININE	3-15 (MG/L)	23/04/91	8.00		10.00		11.00	
URIC ACID	25-60 (MG/L)	23/04/91	27.00		35.00		45.00	
TOT BILIRUBIN	1.5-12 (MG/L)	23/04/91	4.00		4.00		3.00	
DIR BILIRUBIN	0-3 (MG/L)	23/04/91	1.00		1.00		0.00	
TOT. PROTEINS	60-80 (G/L)	23/04/91	65.00		75.00		76.00	
ALBUMINE	33-50 (G/L)	23/04/91	45.00		46.30		46.00	
TOT. CHOLEST.	1.3-2.1 (G/L)	23/04/91	1.57		2.48	>	2.13	>
TRIGLYCERIDES	0.3-1.5 (G/L)	23/04/91	0.76		0.87		0.82	
GLOBULINS ALPHA 1	1.8-4.8 (G/L)	23/04/91	2.10		3.80		3.00	
GLOBULINS ALPHA 2	3.3-11 (G/L)	23/04/91	5.60		6.00		6.90	
GLOBULINS BETA	5.4-12.8 (G/L)	23/04/91	7.10		8.00		7.80	
GLOBULINS GAMMA	6.6-17.6 (G/L)	23/04/91	8.70		10.50		11.50	
TSH	0.15-3 (UU/ML)	23/04/91	0.61					
T4	9-24 (PMOL/L)	23/04/91	16.40					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/3 Patient: 72 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			21/07/92		14/08/92		04/09/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/100ML)	23/04/91	14.90		13.80		14.00	
HT	40-50 (%)	23/04/91	42.30		39.20	<	39.50	<
RBC	4.2-4.9 (10¬6/MM3)	23/04/91	4.76		4.43		4.50	
WBC	4-10 (10¬3/MM3)	23/04/91	10.80	>	11.50	>	8.80	
WBC: N	2-7.5 (10¬3/MM3)	23/04/91			7.80	>	4.00	
WBC: L	1.5-4 (10¬3/MM3)	23/04/91			2.30		3.80	
WBC: E	0.04-0.4 (10¬3/MM3)	23/04/91			0.30		0.30	
WBC: M	0.2-0.8 (10¬3/MM3)	23/04/91			1.00	>	0.70	
WBC: B	0.01-0.1 (10¬3/MM3)	23/04/91			0.00	<		
PLATELETS	150-400 (10¬3/MM3)	23/04/91	310.00		291.00		307.00	
NA+	135-145 (MEQ/L)	23/04/91	137.00		139.00		135.00	
K+	3.5-5 (MEQ/L)	23/04/91	4.30		3.70			
CL-	95-105 (MEQ/L)	23/04/91	103.00		103.00		106.00	>
Ca++	85-105 (MG/L)	23/04/91	97.00		97.00		94.00	
PO4--	22-45 (MG/L)	23/04/91	42.00		43.00			
SGOT	8-30 (UI/L)	23/04/91	20.00		14.00		13.00	
SGPT	7-46 (UI/L)	23/04/91	24.00		19.00		17.00	
GAMMA GT	5-36 (UI/L)	23/04/91	60.00	>	28.00			
LDH	260-330 (UI/L)	23/04/91	178.00	<	188.00	<		
ALK. PHOSPH.	80-220 (UI/L)	23/04/91	165.00		143.00		147.00	
GLUCOSE	0.65-1.1 (G/L)	23/04/91	0.99		0.96			
UREA	0.15-0.45 (G/L)	23/04/91	0.37		0.19		0.24	
CREATININE	3-15 (MG/L)	23/04/91	10.00		10.00		10.00	
URIC ACID	25-60 (MG/L)	23/04/91	35.00		41.00		49.00	
TOT BILIRUBIN	1.5-12 (MG/L)	23/04/91	13.00	>	5.00		6.00	
DIR BILIRUBIN	0-3 (MG/L)	23/04/91	2.00		1.00		1.00	
TOT. PROTEINS	60-80 (G/L)	23/04/91	77.00		76.00		78.00	
ALBUMINE	33-50 (G/L)	23/04/91	48.00		44.30		49.10	
TOT. CHOLEST.	1.3-2.1 (G/L)	23/04/91	2.23	>	2.04		1.98	
TRIGLYCERIDES	0.3-1.5 (G/L)	23/04/91	1.00		1.22		0.73	
GLOBULINS ALPHA 1	1.8-4.8 (G/L)	23/04/91	3.60		3.20		2.90	
GLOBULINS ALPHA 2	3.3-11 (G/L)	23/04/91	6.40		5.50		6.00	
GLOBULINS BETA	5.4-12.8 (G/L)	23/04/91	8.30		7.80		9.00	
GLOBULINS GAMMA	6.6-17.6 (G/L)	23/04/91	11.20		7.30		11.00	
TSH	0.15-3 (UU/ML)	23/04/91	0.57					
T4	9-24 (PMOL/L)	23/04/91	19.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/4 Patient: 79 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			01/05/91		24/05/91		19/06/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/04/91	11.90	<	12.20		11.80	<
HT	37-47 (%)	01/04/91	34.70	<	34.20	<	34.40	<
RBC	4.2-5.4 (10-6/UL)	01/04/91	4.04	<	4.10	<	3.93	<
WBC	4.8-10.8 (10-3/UL)	01/04/91	4.68	<	4.46	<	4.72	<
WBC: N	40-74 (%)	01/04/91	43.20		41.00		54.70	
WBC: L	19-48 (%)	01/04/91	45.80		45.60		34.20	
WBC: E	0-7 (%)	01/04/91	2.60		3.20		2.40	
WBC: M	3.4-9 (%)	01/04/91	5.80		6.00		5.90	
WBC: B	0-1.5 (%)	01/04/91	0.80		1.40		0.80	
PLATELETS	130-400 (10-3/MM3)	01/04/91	221.00		230.00		282.00	
NA+	136-145 (MMOL/L)	01/04/91	138.00		137.00		136.00	
K+	3.8-4.8 (MMOL/L)	01/04/91	3.84		4.08		4.08	
CL-	97-106 (MMOL/L)	01/04/91	108.00	>	102.00		102.00	
Ca++	2.3-2.5 (MMOL/L)	01/04/91	2.22	<	2.26	<	2.27	<
PO4--	1-1.3 (MMOL/L)	01/04/91			1.25		1.22	
SGOT	10-30 (UI/L)	01/04/91	12.00		20.00		28.00	
SGPT	10-40 (UI/L)	01/04/91	13.00		18.00		14.00	
GAMMA GT	5-35 (UI/L)	01/04/91			9.00		7.00	
LDH	250-320 (UI/L)	01/04/91	183.00	<	188.00	<	194.00	<
ALK. PHOSPH.	30-90 (UI/L)	01/04/91	32.00		34.00		57.00	
GLUCOSE	4-6 (MMOL/L)	01/04/91	4.80		5.00		4.70	
UREA	3.3-7 (MMOL/L)	01/04/91	6.20		4.10		5.60	
CREATININE	45-108 (UMOL/L)	01/04/91	77.00		69.00		69.00	
URIC ACID	180-350 (UMOL/L)	01/04/91	158.00	<	128.00	<	95.00	<
TOT BILIRUBIN	3-17 (UMOL/L)	01/04/91	22.00	>	27.00	>	15.00	
TOT. PROTEINS	65-79 (G/L)	01/04/91	67.00		73.00		78.00	
ALBUMINE	57-65 (%)	01/04/91	53.50	<	55.10	<		
TOT. CHOLEST.	4.4-7 (MMOL/L)	01/04/91	5.10		5.58		6.26	
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	01/04/91	1.00		1.14		0.81	
GLOBULINS ALPHA 1	2-4 (%)	01/04/91	2.50		2.70			
GLOBULINS ALPHA 2	6-10 (%)	01/04/91	7.90		7.30			
GLOBULINS BETA	8-12 (%)	01/04/91	11.90		10.80			
GLOBULINS GAMMA	10-20 (%)	01/04/91	24.20	>	24.10	>		
TSH	0.3-3.5 (MU/L)	01/04/91	0.83					
T4	13-28 (PMOL/L)	01/04/91	19.90					

1703

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done

>> clinically relevant (value higher than max rang
> out of range (value higher than max rang
() missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/4 Patient: 80 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date	
			Screen	
			31/08/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	14-18 (G/DL)	01/04/91	15.10	
HT	42-52 (%)	01/04/91	44.60	
RBC	4.7-6.1 (10-6/UL)	01/04/91	4.92	
WBC	4.8-10.8 (10-3/UL)	01/04/91	6.55	
WBC: N	40-74 (%)	01/04/91	65.10	
WBC: L	19-48 (%)	01/04/91	24.70	
WBC: E	0-7 (%)	01/04/91	1.80	
WBC: M	3.4-9 (%)	01/04/91	5.90	
WBC: B	0-1.5 (%)	01/04/91	0.90	
NA+	136-145 (MMOL/L)	01/04/91	141.00	
K+	3.8-4.8 (MMOL/L)	01/04/91	3.70	<
CL-	97-106 (MMOL/L)	01/04/91	104.00	
Ca++	2.3-2.6 (MMOL/L)	01/04/91	2.30	
PO4--	1-1.3 (MMOL/L)	01/04/91	1.15	
SGOT	10-30 (UI/L)	01/04/91	13.00	
SGPT	10-40 (UI/L)	01/04/91	12.00	
GAMMA GT	5-35 (UI/L)	01/04/91	17.00	
LDH	250-320 (UI/L)	01/04/91	180.00	<
ALK. PHOSPH.	30-90 (UI/L)	01/04/91	37.00	
GLUCOSE	4-6 (MMOL/L)	01/04/91	5.00	
UREA	3.3-7 (MMOL/L)	01/04/91	8.60	>
CREATININE	45-108 (UMOL/L)	01/04/91	79.00	
TOT BILIRUBIN	3-17 (UMOL/L)	01/04/91	29.00	>
TOT. PROTEINS	65-79 (G/L)	01/04/91	63.00	<
ALBUMINE	57-65 (%)	01/04/91	62.40	
TOT. CHOLEST.	4.4-7 (MMOL/L)	01/04/91	7.45	>
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	01/04/91	1.33	
GLOBULINS ALPHA 1	2-4 (%)	01/04/91	3.60	
GLOBULINS ALPHA 2	6-10 (%)	01/04/91	9.20	
GLOBULINS BETA	8-12 (%)	01/04/91	14.30	>
GLOBULINS GAMMA	10-20 (%)	01/04/91	10.50	
TSH	0.3-3.5 (MU/L)	01/04/91	1.85	
T4	13-28 (PMOL/L)	01/04/91	17.40	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max ran
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/4 Patient: 81 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			15/05/91		04/06/91		28/06/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	12-16 (G/DL)	10/05/91	13.50		13.70		13.00	
HT	37-47 (%)	10/05/91	39.30		40.10		37.20	
RBC	4.2-5.4 (10¬6/UL)	10/05/91	4.30		4.28		4.00	<
WBC	4.8-10.8 (10¬3/UL)	10/05/91	5.23		6.54		6.77	
WBC: N	40-74 (%)	10/05/91	54.50		54.70		75.30	>
WBC: L	19-48 (%)	10/05/91	29.60		26.40		8.10	<<
WBC: E	0-7 (%)	10/05/91	4.90		4.60		3.00	
WBC: M	3.4-9 (%)	10/05/91	6.40		10.30	>	10.50	>
WBC: B	0-1.5 (%)	10/05/91	0.90		1.20		0.50	
PLATELETS	130-400 (10¬3/MM3)	10/05/91	258.00		149.00		126.00	<
NA+	136-145 (MMOL/L)	10/05/91	138.00		140.00		138.00	
K+	3.8-4.8 (MMOL/L)	10/05/91	3.98		3.52	<	3.33	<
CL-	97-106 (MMOL/L)	10/05/91	102.00		105.00		104.00	
Ca++	2.3-2.5 (MMOL/L)	10/05/91	2.17	<	2.20	<	2.23	<
PO4--	25-45 (NG/L)	10/05/91	27.00		28.00			
	1-1.3 (MMOL/L)	25/06/91					1.28	
SGOT	10-30 (UI/L)	10/05/91	14.00		12.00		14.00	
SGPT	10-40 (UI/L)	10/05/91	14.00		14.00		15.00	
GAMMA GT	5-35 (UI/L)	10/05/91	30.00		18.00		29.00	
LDH	250-320 (UI/L)	10/05/91	174.00	<	203.00	<	281.00	
ALK. PHOSPH.	30-90 (UI/L)	10/05/91	57.00		44.00		58.00	
GLUCOSE	4-6 (MMOL/L)	10/05/91	4.90		4.50		4.80	
UREA	3.3-7 (MMOL/L)	25/06/91					5.20	
CREATININE	45-108 (UMOL/L)	10/05/91	55.00		55.00		50.00	
URIC ACID	180-350 (UMOL/L)	10/05/91	121.00	<	140.00	<	130.00	<
TOT BILIRUBIN	3-17 (UMOL/L)	10/05/91	6.00		6.00		7.00	
TOT. PROTEINS	65-79 (G/L)	10/05/91	66.00		71.00		72.00	
ALBUMINE	57-65 (%)	10/05/91	55.60	<			41.60	<
TOT. CHOLEST.	4.4-7 (MMOL/L)	10/05/91	5.32		4.75		4.92	
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	10/05/91	0.67		1.07		1.02	
GLOBULINS ALPHA 1	2-4 (%)	10/05/91	2.90				2.90	
GLOBULINS ALPHA 2	6-10 (%)	10/05/91	7.30				8.60	
GLOBULINS BETA	8-12 (%)	10/05/91	8.30				8.90	
GLOBULINS GAMMA	10-20 (%)	10/05/91	10.60				9.70	<
TSH	0.3-3.5 (MU/L)	10/05/91	0.70					
T4	13-28 (PMOL/L)	10/05/91	14.70					

1705

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/4 Patient: 82 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			14/06/91		08/07/91		29/07/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	01/04/91	16.40		14.00		14.20	
HT	42-52 (%)	01/04/91	45.70		45.20		39.80	<
RBC	4.7-6.1 (10-6/UL)	01/04/91	5.48		5.11		4.73	
WBC	4.8-10.8 (10-3/UL)	01/04/91	6.23		5.07		5.45	
WBC: N	40-74 (%)	01/04/91	48.90		45.30		47.70	
WBC: L	19-48 (%)	01/04/91	35.10		38.00		35.80	
WBC: E	0-7 (%)	01/04/91	4.80		4.30		5.20	
WBC: M	3.4-9 (%)	01/04/91	8.60		9.40	>	8.00	
WBC: B	0-1.5 (%)	01/04/91	0.60		0.70		1.20	
PLATELETS	130-400 (10-3/MM3)	01/04/91	270.00		281.00		277.00	
NA+	136-145 (MMOL/L)	01/04/91	140.00		141.00		139.00	
K+	3.8-4.8 (MMOL/L)	01/04/91	4.12		4.07		4.72	
CL-	97-106 (MMOL/L)	01/04/91	104.00		102.00		102.00	
Ca++	2.3-2.5 (MMOL/L)	01/04/91	2.32		2.34		2.25	<
PO4--	1-1.3 (MMOL/L)	01/07/91			1.15		1.33	>
SGOT	10-30 (UI/L)	01/04/91	15.00		18.00		21.00	
SGPT	10-40 (UI/L)	01/04/91	13.00		27.00		17.00	
GAMMA GT	5-35 (UI/L)	01/04/91	35.00		24.00		21.00	
LDH	250-320 (UI/L)	01/07/91			172.00	<		
ALK. PHOSPH.	30-90 (UI/L)	01/04/91	35.00		43.00		39.00	
GLUCOSE	4-6 (MMOL/L)	01/04/91	6.00		5.30		5.20	
UREA	3.3-7 (MMOL/L)	01/07/91			6.80		5.50	
CREATININE	45-108 (UMOL/L)	01/04/91	93.00		93.00		89.00	
URIC ACID	180-350 (UMOL/L)	01/04/91	287.00		320.00		286.00	
TOT BILIRUBIN	3-17 (UMOL/L)	01/04/91	17.00		15.00		12.00	
TOT. PROTEINS	65-79 (G/L)	01/04/91	71.00		76.00		67.00	
ALBUMINE	57-65 (%)	01/04/91	57.40					
	37-50 (G/L)	01/07/91			44.90		40.30	
TOT. CHOLEST.	4.4-7 (MMOL/L)	01/04/91	5.94		5.27		5.11	
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	01/04/91	1.29		1.38		1.39	
GLOBULINS ALPHA 1	2-4 (%)	01/04/91	2.80		1.50	<	1.60	<
GLOBULINS ALPHA 2	6-10 (%)	01/04/91	9.30		6.00		6.90	
GLOBULINS BETA	8-12 (%)	01/04/91	14.70	>	11.10		9.80	
GLOBULINS GAMMA	10-20 (%)	01/04/91	15.80		12.20		8.80	<
TSH	0.3-3.5 (MU/L)	01/04/91	0.51					
T4	13-28 (PMOL/L)	01/04/91	22.30					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/4 Patient: 83 Treatment: Placebo Sex: Male

			Visit number / Laboratory date	
			Screen	
			13/06/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	14-18 (G/DL)	01/04/91	16.20	
HT	42-52 (%)	01/04/91	46.10	
RBC	4.7-6.1 (10¬6/UL)	01/04/91	5.16	
WBC	4.8-10.8 (10¬3/UL)	01/04/91	6.17	
WBC: N	40-74 (%)	01/04/91	53.00	
WBC: L	19-48 (%)	01/04/91	36.50	
WBC: E	0-7 (%)	01/04/91	2.00	
WBC: M	3.4-9 (%)	01/04/91	5.30	
WBC: B	0-1.5 (%)	01/04/91	0.90	
PLATELETS	130-400 (10¬3/MM3)	01/04/91	172.00	
NA+	136-145 (MMOL/L)	01/04/91	141.00	
K+	3.8-4.8 (MMOL/L)	01/04/91	3.69	<
CL-	97-106 (MMOL/L)	01/04/91	107.00	>
Ca++	2.3-2.5 (MMOL/L)	01/04/91	2.50	
PO4--	1-1.3 (MMOL/L)	01/04/91	1.18	
SGOT	10-30 (UI/L)	01/04/91	18.00	
SGPT	10-40 (UI/L)	01/04/91	21.00	
GAMMA GT	5-35 (UI/L)	01/04/91	20.00	
LDH	250-320 (UI/L)	01/04/91	168.00	<
ALK. PHOSPH.	30-90 (UI/L)	01/04/91	57.00	
GLUCOSE	4-6 (MMOL/L)	01/04/91	5.30	
UREA	3.3-7 (MMOL/L)	01/04/91	6.80	
CREATININE	45-108 (UMOL/L)	01/04/91	110.00	>
URIC ACID	180-350 (UMOL/L)	01/04/91	374.00	>
TOT BILIRUBIN	3-17 (UMOL/L)	01/04/91	6.00	
TOT. PROTEINS	65-79 (G/L)	01/04/91	73.00	
ALBUMINE	57-65 (%)	01/04/91	40.00	<
TOT. CHOLEST.	4,4-7 (MMOL/L)	01/04/91	6.49	
TRIGLYCERIDES	0,55-1.7 (MMOL/L)	01/04/91	2.13	>
GLOBULINS ALPHA 1	2-4 (%)	01/04/91	2.30	
GLOBULINS ALPHA 2	6-10 (%)	01/04/91	7.80	
GLOBULINS BETA	8-12 (%)	01/04/91	10.30	
GLOBULINS GAMMA	10-20 (%)	01/04/91	12.70	
TSH	0.3-3.5 (MU/L)	01/04/91	1.07	
T4	13-28 (PMOL/L)	01/04/91	19.50	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/4 Patient: 84 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			08/10/91		31/10/91		12/11/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/04/91	13.40					
HT	37-47 (%)	01/04/91	38.90					
RBC	4.2-5.4 (10¬6/UL)	01/04/91	4.19	<				
WBC	4.8-10.8 (10¬3/UL)	01/04/91	9.22					
WBC: N	40-74 (%)	01/04/91	54.30					
WBC: L	19-48 (%)	01/04/91	37.70					
WBC: E	0-7 (%)	01/04/91	1.10					
WBC: M	3.4-9 (%)	01/04/91	4.90					
WBC: B	0-1.5 (%)	01/04/91	0.60					
PLATELETS	130-400 (10¬3/MM3)	01/04/91	265.00					
NA+	136-145 (MMOL/L)	01/04/91	142.00		138.00		139.00	
K+	3.8-4.8 (MMOL/L)	01/04/91	3.84		4.09		3.80	
CL-	97-106 (MMOL/L)	01/04/91	105.00		101.00		101.00	
Ca++	2.3-2.5 (MMOL/L)	01/04/91	2.27	<	2.42		2.37	
PO4--	1-1.3 (MMOL/L)	01/04/91	1.27		1.25		0.96	<
SGOT	10-30 (UI/L)	01/04/91	12.00		13.00		18.00	
SGPT	10-40 (UI/L)	01/04/91	17.00		9.00	<	10.00	
GAMMA GT	5-35 (UI/L)	01/04/91	52.00	>	20.00		12.00	
LDH	250-320 (UI/L)	01/04/91	155.00	<	164.00	<	179.00	<
ALK. PHOSPH.	30-90 (UI/L)	01/04/91	40.00		48.00		47.00	
GLUCOSE	4-6 (MMOL/L)	01/04/91	5.60		6.20	>	6.90	>
UREA	3.3-7 (MMOL/L)	01/04/91	3.30		4.80		3.00	<
CREATININE	45-108 (UMOL/L)	01/04/91	81.00		79.00		66.00	
URIC ACID	180-350 (UMOL/L)	01/04/91			328.00		251.00	
TOT BILIRUBIN	3-17 (UMOL/L)	01/04/91	9.00		11.00		7.00	
TOT. PROTEINS	65-79 (G/L)	01/04/91	69.00		78.00		75.00	
ALBUMINE	57-65 (%)	01/04/91	58.70		49.00	<	50.80	<
TOT. CHOLEST.	4.4-7 (MMOL/L)	01/04/91	4.47		4.80			
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	01/04/91	1.14		1.52			
GLOBULINS ALPHA 1	2-4 (%)	01/04/91	3.80		5.00	>	4.30	>
GLOBULINS ALPHA 2	6-10 (%)	01/04/91	9.40		11.30	>	8.50	
GLOBULINS BETA	8-12 (%)	01/04/91	10.50		16.40	>>	11.60	
GLOBULINS GAMMA	10-20 (%)	01/04/91	17.60		18.30		12.40	

1708

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/4 Patient: 85 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			26/10/91		19/11/91		09/12/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	20/10/91	11.50	<	10.80	<	10.80	<
HT	37-47 (%)	20/10/91	35.40	<	32.80	<	31.90	<
RBC	4.2-5.4 (10-6/UL)	20/10/91	3.96	<	3.70	<	3.58	<
WBC	4.8-10.8 (10-3/UL)	20/10/91	3.78	<	3.59	<	5.13	
WBC: N	40-74 (%)	20/10/91	46.90		57.00		66.10	
WBC: L	19-48 (%)	20/10/91	38.60		28.00		18.30	<
WBC: E	0-7 (%)	20/10/91	5.20		4.50		3.50	
WBC: M	3.4-9 (%)	20/10/91	6.40		8.90		7.20	
WBC: B	0-1.5 (%)	20/10/91	0.70		1.70	>	1.00	
PLATELETS	130-400 (10-3/MM3)	20/10/91	287.00		197.00		249.00	
NA+	136-145 (MMOL/L)	20/10/91	143.00		139.00		140.00	
K+	3.8-4.8 (MMOL/L)	20/10/91	3.60	<	3.80		3.62	<
CL-	97-106 (MMOL/L)	20/10/91	106.00		103.00		106.00	
Ca++	2.3-2.5 (MMOL/L)	20/10/91	2.32		2.14	<	2.13	<
PO4--	1-1.3 (MMOL/L)	20/10/91	1.16		1.29		1.16	
SGOT	10-30 (UI/L)	20/10/91	8.00	<	12.00		9.00	<
SGPT	10-40 (UI/L)	20/10/91	7.00	<	10.00		12.00	
GAMMA GT	5-35 (UI/L)	20/10/91	13.00		4.00	<	8.00	
LDH	250-320 (UI/L)	20/10/91	151.00	<	178.00	<	219.00	<
ALK. PHOSPH.	30-90 (UI/L)	20/10/91	40.00		38.00		27.00	<
GLUCOSE	4-6 (MMOL/L)	20/10/91	5.09		4.10		4.70	
UREA	3.3-7 (MMOL/L)	20/10/91	4.20		4.10			
CREATININE	45-108 (UMOL/L)	20/10/91	79.00		78.00		74.00	
URIC ACID	180-350 (UMOL/L)	20/10/91	239.00		288.00		234.00	
TOT BILIRUBIN	3-17 (UMOL/L)	20/10/91	6.00		6.00		8.00	
TOT. PROTEINS	65-79 (G/L)	20/10/91	72.00		65.00		69.00	
ALBUMINE	37-50 (G/L)	20/10/91	38.70		35.40	<		
TOT. CHOLEST.	4.4-7 (MMOL/L)	20/10/91	4.68		4.97		5.90	
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	20/10/91	0.71		0.59		0.54	<
GLOBULINS ALPHA 1	2-4 (%)	20/10/91	3.10		2.40			
GLOBULINS ALPHA 2	6-10 (%)	20/10/91	7.60		4.70	<		
GLOBULINS BETA	8-12 (%)	20/10/91	10.40		8.60			
GLOBULINS GAMMA	10-20 (%)	20/10/91	12.20		10.50			
TSH	0.3-3.5 (MU/L)	20/10/91	2.96					
T4	13-28 (PMOL/L)	20/10/91	19.10					

1709

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA

Centre: 3/4 Patient: 86 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 42	
			02/12/91		15/01/92	
			value	(◊)	value	(◊)
Laboratory test	Range value	Range date				
HB	14-18 (G/DL)	01/04/91	14.90		14.00	
HT	42-52 (%)	01/04/91	44.20		40.70	<
RBC	4.7-6.1 (10-6/UL)	01/04/91	5.10		4.65	<
WBC	4.8-10.8 (10-3/UL)	01/04/91	9.92		6.99	
WBC: N	40-74 (%)	01/04/91	59.30		66.40	
WBC: L	19-48 (%)	01/04/91	27.00		24.70	
WBC: E	0-7 (%)	01/04/91	4.60		0.00	
WBC: M	3.4-9 (%)	01/04/91	6.10		5.70	
WBC: B	0-1.5 (%)	01/04/91	0.60		0.50	
PLATELETS	130-400 (10-3/MM3)	01/04/91	165.00		185.00	
NA+	136-145 (MMOL/L)	01/04/91	140.00		139.00	
K+	3.8-4.8 (MMOL/L)	01/04/91	3.27	<	4.33	
CL-	97-106 (MMOL/L)	01/04/91	104.00		102.00	
Ca++	2.3-2.5 (MMOL/L)	01/04/91	2.36		2.30	
PO4--	1-1.3 (MMOL/L)	01/04/91	0.77	<<	0.86	<
SGOT	10-30 (UI/L)	01/04/91	21.00		20.00	
SGPT	10-40 (UI/L)	01/04/91	27.00		36.00	
GAMMA GT	5-35 (UI/L)	01/04/91	5.00		25.00	
LDH	250-320 (UI/L)	01/04/91	220.00	<	200.00	<
ALK. PHOSPH.	30-90 (UI/L)	01/04/91	42.00		59.00	
GLUCOSE	4-6 (MMOL/L)	01/04/91	5.60		4.60	
UREA	3.3-7 (MMOL/L)	01/04/91	4.10			
CREATININE	45-108 (UMOL/L)	01/04/91	80.00		80.00	
URIC ACID	180-350 (UMOL/L)	01/04/91	337.00		304.00	
TOT BILIRUBIN	3-17 (UMOL/L)	01/04/91	16.00		13.00	
TOT. PROTEINS	65-79 (G/L)	01/04/91	82.00	>	79.80	>
ALBUMINE	57-65 (%)	01/04/91	44.10	<	45.90	<
TOT. CHOLEST.	4.4-7 (MMOL/L)	01/04/91	5.57		5.13	
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	01/04/91	1.70		0.73	
GLOBULINS ALPHA 1	2-4 (%)	01/04/91	2.20		3.00	
GLOBULINS ALPHA 2	6-10 (%)	01/04/91	5.50	<	6.40	
GLOBULINS BETA	8-12 (%)	01/04/91	10.60		9.20	
GLOBULINS GAMMA	10-20 (%)	01/04/91	19.60		15.30	
TSH	0.3-3.5 (MU/L)	01/04/91	1.63			
T4	13-28 (PMOL/L)	01/04/91	20.80			

1710

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 3/4 Patient: 87 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			07/12/91		27/12/91		20/01/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/12/91	14.30		12.70		13.10	
HT	37-47 (%)	01/12/91	42.90		38.70		40.50	
RBC	4.2-5.4 (10¬6/UL)	01/12/91	4.78		4.18	<	4.40	
WBC	4.8-10.8 (10¬3/UL)	01/12/91	7.55		6.16		6.60	
WBC: N	40-74 (%)	01/12/91	62.70		61.30		67.10	
WBC: L	19-48 (%)	01/12/91	24.90		25.30		17.80	<
WBC: E	0-7 (%)	01/12/91	1.80		3.90		4.20	
WBC: M	3.4-9 (%)	01/12/91	7.50		6.60		8.10	
WBC: B	0-1.5 (%)	01/12/91	0.80		0.50		0.50	
PLATELETS	130-400 (10¬3/MM3)	01/12/91	380.00		360.00		365.00	
NA+	136-145 (MMOL/L)	01/12/91	141.00		138.00		139.00	
K+	3.8-4.8 (MMOL/L)	01/12/91	3.65	<	3.67	<	3.63	<
CL-	97-106 (MMOL/L)	01/12/91	104.00		105.00		109.00	>
Ca++	2.3-2.5 (MMOL/L)	01/12/91	2.47		2.33		2.49	
PO4--	1-1.3 (MMOL/L)	01/12/91	1.37	>	1.23			
SGOT	10-30 (UI/L)	01/12/91	14.00		10.00		9.00	<
SGPT	10-40 (UI/L)	01/12/91	20.00		5.00	<	8.00	<
GAMMA GT	5-35 (UI/L)	01/12/91	19.00		8.00		14.00	
LDH	250-320 (UI/L)	01/12/91	237.00	<	181.00	<	260.00	
ALK. PHOSPH.	30-90 (UI/L)	01/12/91	64.00		40.00		61.00	
GLUCOSE	4-6 (MMOL/L)	01/12/91	4.20		4.30		4.30	
UREA	3.3-7 (MMOL/L)	01/12/91	3.90				2.30	<
CREATININE	45-108 (UMOL/L)	01/12/91	66.00		64.00		69.00	
URIC ACID	180-350 (UMOL/L)	01/12/91	296.00		236.00		211.00	
TOT BILIRUBIN	3-17 (UMOL/L)	01/12/91	19.00	>	13.00		11.00	
TOT. PROTEINS	65-79 (G/L)	01/12/91	79.00		69.00		81.00	>
ALBUMINE	37-50 (G/L)	01/12/91	39.00		37.60		39.80	
TOT. CHOLEST.	4.4-7 (MMOL/L)	01/12/91	7.75	>	5.98		7.32	>
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	01/12/91	1.07		0.90		1.02	
GLOBULINS ALPHA 1	2-4 (%)	01/12/91	3.90		3.40		4.60	>
GLOBULINS ALPHA 2	6-10 (%)	01/12/91	7.10		6.30		8.50	
GLOBULINS BETA	8-12 (%)	01/12/91	11.80		9.10		11.00	
GLOBULINS GAMMA	10-20 (%)	01/12/91	17.00		12.50		17.00	
TSH	0.3-3.5 (MU/L)	01/12/91	1.01					
T4	13-28 (PMOL/L)	01/12/91	19.30					

1711

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/4 Patient: 88 Treatment: Placebo Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			18/03/92		22/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	14-18 (G/DL)	01/04/91	14.40		14.20	
HT	42-52 (%)	01/04/91	40.70	<	41.60	<
RBC	4.7-6.1 (10¬6/UL)	01/04/91	4.92		4.98	
WBC	4.8-10.8 (10¬3/UL)	01/04/91	4.90		3.69	<
WBC: N	40-74 (%)	01/04/91	50.00		54.10	
WBC: L	19-48 (%)	01/04/91	38.00		37.40	
WBC: E	0-7 (%)	01/04/91	2.90		0.70	
WBC: M	3.4-9 (%)	01/04/91	5.60		5.00	
WBC: B	0-1.5 (%)	01/04/91	0.60		0.60	
PLATELETS	130-400 (10¬3/MM3)	01/04/91	269.00		277.00	
NA+	136-145 (MMOL/L)	01/04/91	138.00		141.00	
K+	3.8-4.8 (MMOL/L)	01/04/91	3.82		3.99	
CL-	97-106 (MMOL/L)	01/04/91	106.00		107.00	>
Ca++	2.3-2.5 (MMOL/L)	01/04/91	2.40		2.37	
PO4--	1-1.3 (MMOL/L)	01/04/91	1.26		1.02	
SGOT	10-30 (UI/L)	01/04/91	16.00		17.00	
SGPT	10-40 (UI/L)	01/04/91	25.00		25.00	
GAMMA GT	5-35 (UI/L)	01/04/91	31.00		35.00	
LDH	250-320 (UI/L)	01/04/91	147.00	<	263.00	
ALK. PHOSPH.	30-90 (UI/L)	01/04/91	54.00		55.00	
GLUCOSE	4-6 (MMOL/L)	01/04/91	5.80		6.90	>
UREA	3.3-7 (MMOL/L)	01/04/91	7.70	>	6.80	
CREATININE	45-108 (UMOL/L)	01/04/91	89.00		88.00	
URIC ACID	180-350 (UMOL/L)	01/04/91	192.00		170.00	<
TOT BILIRUBIN	3-17 (UMOL/L)	01/04/91	12.00		10.00	
TOT. PROTEINS	65-79 (G/L)	01/04/91	80.10	>	83.00	>
ALBUMINE	57-65 (%)	01/04/91	47.00	<	47.20	<
TOT. CHOLEST.	4.4-7 (MMOL/L)	01/04/91	7.27	>	7.69	>
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	01/04/91	1.34		0.89	
GLOBULINS ALPHA 1	2-4 (%)	01/04/91	2.00		2.40	
GLOBULINS ALPHA 2	6-10 (%)	01/04/91	5.90	<	7.40	
GLOBULINS BETA	8-12 (%)	01/04/91	11.50		12.10	>
GLOBULINS GAMMA	10-20 (%)	01/04/91	13.70		13.90	
TSH	0.3-3.5 (MU/L)	01/04/91	0.66			
T4	13-28 (PMOL/L)	01/04/91	16.80			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/4 Patient: 89 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			23/03/92		15/04/92		12/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/04/91	14.00		14.00		13.50	
HT	37-47 (%)	01/04/91	41.90		43.10		41.30	
RBC	4.2-5.4 (10¬6/UL)	01/04/91	4.73		4.72		4.55	
WBC	4.8-10.8 (10¬3/UL)	01/04/91	5.00		6.40		3.75	<
WBC: N	40-74 (%)	01/04/91	47.00		36.00	<	39.50	<
WBC: L	19-48 (%)	01/04/91	32.20		53.00	>	42.80	
WBC: E	0-7 (%)	01/04/91	4.20		6.00		4.70	
WBC: M	3.4-9 (%)	01/04/91	11.90	>>	5.00		8.50	
WBC: B	0-1.5 (%)	01/04/91	0.90		0.00		0.60	
PLATELETS	130-400 (10¬3/MM3)	01/04/91	219.00				123.00	<
NA+	136-145 (MMOL/L)	01/04/91	140.00		139.00		142.00	
K+	3.8-4.8 (MMOL/L)	01/04/91	3.60	<	3.90		4.27	
CL-	97-106 (MMOL/L)	01/04/91	109.00	>	104.00		109.00	>
Ca++	2.3-2.5 (MMOL/L)	01/04/91	2.30		2.55	>	2.38	
PO4--	1-1.3 (MMOL/L)	01/04/91	0.99	<	1.43	>		
SGOT	10-30 (UI/L)	01/04/91	9.00	<	13.00		11.00	
SGPT	10-40 (UI/L)	01/04/91	7.00	<	7.00	<	8.00	<
GAMMA GT	5-35 (UI/L)	01/04/91	11.00		10.00	<	15.00	
LDH	250-320 (UI/L)	01/04/91	190.00	<	215.00	<		
ALK. PHOSPH.	30-90 (UI/L)	01/04/91	37.00		21.00	<	24.00	<
GLUCOSE	4-6 (MMOL/L)	01/04/91	5.00		5.05		4.80	
UREA	3.3-7 (MMOL/L)	01/04/91	2.60	<	3.48		3.00	<
CREATININE	45-108 (UMOL/L)	01/04/91	59.00		61.00		53.00	
URIC ACID	180-350 (UMOL/L)	01/04/91			124.00	<	131.00	<
TOT BILIRUBIN	3-17 (UMOL/L)	01/04/91	12.00		7.00		8.00	
TOT. PROTEINS	65-79 (G/L)	01/04/91	78.00				73.00	
ALBUMINE	57-65 (%)	01/04/91	58.30		46.40	<	42.20	<
TOT. CHOLEST.	4.4-7 (MMOL/L)	01/04/91	5.60		5.57		5.59	
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	01/04/91	1.28		0.68		0.80	
GLOBULINS ALPHA 1	2-4 (%)	01/04/91	3.00				2.10	
GLOBULINS ALPHA 2	6-10 (%)	01/04/91	8.00				5.30	<
GLOBULINS BETA	8-12 (%)	01/04/91	11.50				8.60	
GLOBULINS GAMMA	10-20 (%)	01/04/91	19.20				14.30	
TSH	0.3-3.5 (MU/L)	01/04/91	1.27					
T4	13-28 (PMOL/L)	01/04/91	13.70					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/4 Patient: 90 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			28/04/92		19/05/92		23/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	20/04/92	15.80		16.40		16.10	
HT	42-52 (%)	20/04/92	46.80		48.70		47.80	
RBC	4.7-6.1 (10-6/UL)	20/04/92	5.25		5.41		5.22	
WBC	4.8-10.8 (10-3/UL)	20/04/92	5.82		5.68		6.56	
WBC: N	40-74 (%)	20/04/92	56.90		59.90		59.20	
WBC: L	19-48 (%)	20/04/92	31.00		30.10		27.80	
WBC: E	0-7 (%)	20/04/92	3.80		1.90		2.70	
WBC: M	3.4-9 (%)	20/04/92	6.20		6.00		7.20	
WBC: B	0-1.5 (%)	20/04/92	0.60		0.40		0.90	
PLATELETS	130-400 (10-3/MM3)	20/04/92	285.00		288.00		292.00	
NA+	136-145 (MMOL/L)	20/04/92	140.00		142.00		140.00	
K+	3.8-4.8 (MMOL/L)	20/04/92	4.33		4.49		3.82	
CL-	97-106 (MMOL/L)	20/04/92	107.00	>	109.00	>	107.00	>
Ca++	2.3-2.5 (MMOL/L)	20/04/92	2.45		2.52	>	2.41	
PO4--	1-1.3 (MMOL/L)	20/04/92	1.02		0.80	<<	0.79	<<
SGOT	10-30 (UI/L)	20/04/92	29.00		13.00		13.00	
SGPT	10-40 (UI/L)	20/04/92	23.00		20.00		12.00	
GAMMA GT	5-35 (UI/L)	20/04/92	10.00		19.00		20.00	
LDH	250-320 (UI/L)	20/04/92	286.00				296.00	
ALK. PHOSPH.	30-90 (UI/L)	20/04/92	53.00		46.00		48.00	
GLUCOSE	4-6 (MMOL/L)	20/04/92	5.40		5.60		5.20	
UREA	3.3-7 (MMOL/L)	20/04/92	5.40		5.30			
CREATININE	45-108 (UMOL/L)	20/04/92	73.00		75.00		83.00	
URIC ACID	180-350 (UMOL/L)	20/04/92	287.00		257.00		328.00	
TOT BILIRUBIN	3-17 (UMOL/L)	20/04/92	10.00		9.00		9.00	
TOT. PROTEINS	65-79 (G/L)	20/04/92	74.00		78.00		76.00	
ALBUMINE	37-50 (G/L)	20/04/92	38.40		43.00		41.00	
TOT. CHOLEST.	4.4-7 (MMOL/L)	20/04/92	7.24	>	6.72			
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	20/04/92	0.95		1.23		1.02	
GLOBULINS ALPHA 1	2-4 (%)	20/04/92	2.70		2.50		2.40	
GLOBULINS ALPHA 2	6-10 (%)	20/04/92	7.30		6.60		6.30	
GLOBULINS BETA	8-12 (%)	20/04/92	10.80		10.50		10.10	
GLOBULINS GAMMA	10-20 (%)	20/04/92	14.80		15.50		16.10	
TSH	0.3-3.5 (MU/L)	20/04/92	1.46					
T4	13-28 (PMOL/L)	20/04/92	18.90					

1714

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/4 Patient: 457 Treatment: Placebo Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			18/05/92		10/06/92	
			value	(¢)	value	(¢)
Laboratory test	Range value	Range date				
HB	12-16 (G/DL)	10/05/92	13.10		13.20	
HT	37-47 (%)	10/05/92	39.80		40.70	
RBC	4.2-5.4 (10-6/UL)	10/05/92	4.52		4.86	
WBC	4,8-10.8 (10-3/UL)	10/05/92	4.09	<	5.07	
WBC: N	40-74 (%)	10/05/92	51.00		40.10	
WBC: L	19-48 (%)	10/05/92	37.00		46.50	
WBC: E	0-7 (%)	10/05/92	3.70		0.21	
WBC: M	3.4-9 (%)	10/05/92	5.70		6.20	
WBC: B	0-1.5 (%)	10/05/92	0.80		0.90	
PLATELETS	130-400 (10-3/MM3)	10/05/92	243.00		214.00	
NA+	136-145 (MMOL/L)	10/05/92	143.00		140.00	
K+	3.8-4.8 (MMOL/L)	10/05/92	3.88		4.14	
CL-	97-106 (MMOL/L)	10/05/92	110.00	>	102.00	
Ca++	2.3-2.5 (MMOL/L)	10/05/92	2.37		2.31	
PO4--	25-45 (MG/L)	10/05/92	29.00		30.00	
SGOT	10-30 (UI/L)	10/05/92	16.00		10.00	
SGPT	10-40 (UI/L)	10/05/92	13.00		22.00	
GAMMA GT	5-35 (UI/L)	10/05/92	19.00		17.00	
LDH	250-320 (UI/L)	10/05/92	184.00	<	167.00	<
ALK. PHOSPH.	30-90 (UI/L)	10/05/92	48.00		62.00	
GLUCOSE	4-6 (MMOL/L)	10/05/92	5.00		4.60	
UREA	3.3-7 (MMOL/L)	10/05/92	5.60		5.30	
CREATININE	45-108 (UMOL/L)	10/05/92	73.00		68.00	
URIC ACID	180-350 (UMOL/L)	10/05/92	321.00		320.00	
TOT BILIRUBIN	3-17 (UMOL/L)	10/05/92	12.00		7.00	
TOT. PROTEINS	65-79 (G/L)	10/05/92	67.00		65.00	
ALBUMINE	37-50 (G/L)	10/05/92	38.70		35.30	<
TOT. CHOLEST.	4.4-7 (MMOL/L)	10/05/92	6.48		5.01	
TRIGLYCERIDES	0.5-1.5 (G/L)	10/05/92	1.64	>	2.04	>>
GLOBULINS ALPHA 1	1-3 (G/L)	10/05/92	1.70		2.20	
GLOBULINS ALPHA 2	4-7 (G/L)	10/05/92	6.10		5.90	
GLOBULINS BETA	5-8 (G/L)	10/05/92	9.70	>	10.30	>
GLOBULINS GAMMA	8-12 (G/L)	10/05/92	10.60		11.10	
TSH	0.3-3.5 (MU/L)	10/05/92	0.74			
T4	13-28 (PMOL/L)	10/05/92	13.60			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/4 Patient: 458 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			18/05/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	10/05/92	14.60	
HT	37-47 (%)	10/05/92	43.20	
WBC	4.8-10.8 (10-3/UL)	10/05/92	6.30	
WBC: N	4800-10800 (/MM3)	10/05/92	2961.00	<<
WBC: L	2000-7500 (/MM3)	10/05/92	2961.00	
WBC: E	40-700 (/MM3)	10/05/92	63.00	
WBC: M	200-1000 (/MM3)	10/05/92	315.00	
WBC: B	10-200 (/MM3)	10/05/92	0.00	<
PLATELETS	130-400 (10-3/MM3)	10/05/92	245.00	
NA+	136-145 (MMOL/L)	10/05/92	139.00	
K+	3.8-4.8 (MMOL/L)	10/05/92	3.80	
CL-	97-106 (MMOL/L)	10/05/92	110.00	>
Ca++	2.3-2.5 (MMOL/L)	10/05/92	2.38	
PO4--	25-45 (MG/L)	10/05/92	29.00	
SGOT	10-30 (UI/L)	10/05/92	11.00	
SGPT	10-40 (UI/L)	10/05/92	14.00	
GAMMA GT	5-35 (UI/L)	10/05/92	20.00	
LDH	250-320 (UI/L)	10/05/92	180.00	<
ALK. PHOSPH.	30-90 (UI/L)	10/05/92	111.00	>
GLUCOSE	0.6-1.1 (G/L)	10/05/92	1.04	
UREA	3.3-7 (MMOL/L)	10/05/92	0.35	<
CREATININE	45-108 (UMOL/L)	10/05/92	65.00	
URIC ACID	180-350 (UMOL/L)	10/05/92	291.50	
TOT BILIRUBIN	3-17 (UMOL/L)	10/05/92	10.00	
TOT. PROTEINS	65-79 (G/L)	10/05/92	69.00	
ALBUMINE	37-50 (G/L)	10/05/92	35.00	<
TOT. CHOLEST.	1.2-2.2 (G/L)	10/05/92	2.27	>
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	10/05/92	0.92	
GLOBULINS ALPHA 1	2-4 (%)	10/05/92	2.30	
GLOBULINS ALPHA 2	6-10 (%)	10/05/92	14.60	>>
GLOBULINS BETA	8-12 (%)	10/05/92	12.80	>
GLOBULINS GAMMA	10-20 (%)	10/05/92	18.50	
TSH	0.3-3.5 (MU/L)	10/05/92	3.04	
T4	13-28 (PMOL/L)	10/05/92	13.40	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/4 Patient: 459 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			29/05/92		23/06/92		15/07/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	20/05/92	15.10		13.60		14.70	
HT	37-47 (%)	20/05/92	45.40		42.00		42.70	
RBC	4.2-5.4 (10-6/UL)	20/05/92	4.98		5.05		4.91	
WBC	4.8-10.8 (10-3/UL)	20/05/92	6.49		6.15		6.50	
WBC: N	40-74 (%)	20/05/92	54.80		50.40		56.80	
WBC: L	19-48 (%)	20/05/92	31.10		36.90		30.20	
WBC: E	0-7 (%)	20/05/92	1.50		3.10		2.00	
WBC: M	3.4-9 (%)	20/05/92	9.50	>	6.50		10.00	>
WBC: B	0-1.5 (%)	20/05/92	1.00		0.40		1.00	
PLATELETS	130-400 (10-3/MM3)	20/05/92	242.00		230.00		241.00	
NA+	136-145 (MMOL/L)	20/05/92	141.00		141.00		140.00	
K+	3.8-4.8 (MMOL/L)	20/05/92	4.90	>	4.49		4.80	
CL-	97-106 (MMOL/L)	20/05/92	105.00		104.00		104.00	
Ca++	90-105 (MG/L)	20/05/92	96.00				95.00	
	2.3-2.5 (MMOL/L)	20/06/92			2.39			
PO4--	25-45 (MG/L)	20/05/92	42.00				41.00	
SGOT	10-30 (UI/L)	20/05/92	15.00		13.00		15.00	
SGPT	10-40 (UI/L)	20/05/92	14.00		20.00		14.00	
GAMMA GT	5-35 (UI/L)	20/05/92	36.00	>	32.00		45.00	>
LDH	250-320 (UI/L)	20/05/92	250.00		222.00	<	270.00	
ALK. PHOSPH.	30-90 (UI/L)	20/05/92	30.00		67.00		32.00	
GLUCOSE	0.6-1.1 (G/L)	20/05/92	0.94				0.98	
	4-6 (MMOL/L)	20/06/92			5.50			
UREA	3.3-7 (MMOL/L)	20/05/92	5.82		5.90			
CREATININE	45-108 (UMOL/L)	20/05/92	64.00		88.00		65.00	
URIC ACID	25-65 (MG/L)	20/05/92	36.00				38.00	
	180-350 (UMOL/L)	20/06/92			301.00			
TOT BILIRUBIN	3-17 (UMOL/L)	20/05/92	5.70		8.00		5.00	
TOT. PROTEINS	65-79 (G/L)	20/05/92	67.00		71.00		68.00	
ALBUMINE	37-50 (G/L)	20/05/92	42.54					
	57-65 (%)	10/07/92					43.20	<
TOT. CHOLEST.	1.2-2.2 (G/L)	20/05/92	2.44	>			2.20	
	4.4-7 (MMOL/L)	20/06/92			5.22			
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	20/05/92	0.64		1.30		0.50	<
GLOBULINS ALPHA 1	1-3 (G/L)	20/05/92	2.25					
	2-4 (%)	10/07/92					3.40	
GLOBULINS ALPHA 2	4-7 (G/L)	20/05/92	5.20					
	6-10 (%)	10/07/92					7.80	
GLOBULINS BETA	5-8 (G/L)	20/05/92	7.19					
	8-12 (%)	10/07/92					10.70	
GLOBULINS GAMMA	8-12 (G/L)	20/05/92	9.82					
	10-20 (%)	10/07/92					14.70	
TSH	0.3-3.5 (MU/L)	20/05/92	2.50					
T4	13-28 (PMOL/L)	20/05/92	14.20					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 3/4 Patient: 460 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date	
			Screen	
			17/08/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	14-18 (G/DL)	10/08/92	15.90	
HT	42-52 (%)	10/08/92	47.40	
RBC	4.7-6.1 (10-6/UL)	10/08/92	5.34	
WBC	4.8-10.8 (10-3/UL)	10/08/92	6.08	
WBC: N	40-74 (%)	10/08/92	55.00	
WBC: L	19-48 (%)	10/08/92	33.60	
WBC: E	0-7 (%)	10/08/92	2.30	
WBC: M	3.4-9 (%)	10/08/92	6.60	
WBC: B	0-1.5 (%)	10/08/92	0.70	
PLATELETS	130-400 (10-3/MM3)	10/08/92	161.00	
NA+	136-145 (MMOL/L)	10/08/92	140.00	
K+	3.8-4.8 (MMOL/L)	10/08/92	3.70	<
CL-	97-106 (MMOL/L)	10/08/92	102.00	
Ca++	2.3-2.5 (MMOL/L)	10/08/92	2.39	
PO4--	1-1.3 (MMOL/L)	10/08/92	1.24	
SGOT	10-30 (UI/L)	10/08/92	11.00	
SGPT	10-40 (UI/L)	10/08/92	15.00	
GAMMA GT	5-35 (UI/L)	10/08/92	2.00	<
LDH	250-320 (UI/L)	10/08/92	239.00	<
ALK. PHOSPH.	30-90 (UI/L)	10/08/92	53.00	
GLUCOSE	4-6 (MMOL/L)	10/08/92	4.50	
UREA	3.3-7 (MMOL/L)	10/08/92	5.70	
CREATININE	45-108 (UMOL/L)	10/08/92	105.00	
URIC ACID	180-350 (UMOL/L)	10/08/92	354.00	>
TOT BILIRUBIN	3-17 (UMOL/L)	10/08/92	11.00	
TOT. PROTEINS	65-79 (G/L)	10/08/92	69.00	
ALBUMINE	37-50 (G/L)	10/08/92	39.90	
TOT. CHOLEST.	4.4-7 (MMOL/L)	10/08/92	5.23	
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	10/08/92	1.60	
GLOBULINS ALPHA 1	2-4 (%)	10/08/92	2.70	
GLOBULINS ALPHA 2	6-10 (%)	10/08/92	6.80	
GLOBULINS BETA	8-12 (%)	10/08/92	8.90	
GLOBULINS GAMMA	10-20 (%)	10/08/92	10.90	
TSH	0.3-3.5 (MU/L)	10/08/92	0.97	
T4	13-28 (PMOL/L)	10/08/92	15.20	

1718

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/4 Patient: 461 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			15/09/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	10/09/92	15.20	
HT	37-47 (%)	10/09/92	44.00	
RBC	4.2-5.4 (10¬6/UL)	10/09/92	4.97	
WBC	4.8-10.8 (10¬3/UL)	10/09/92	6.00	
WBC: N	2-7.5 (10¬3/MM3)	10/09/92	4.02	
WBC: L	1.5-4 (10¬3/MM3)	10/09/92	1.68	
WBC: E	0.04-0.7 (10¬3/MM3)	10/09/92	0.70	
WBC: M	0.2-1 (10¬3/MM3)	10/09/92	0.30	
WBC: B	0.01-0.2 (10¬3/MM3)	10/09/92	0.20	
PLATELETS	130-400 (10¬3/MM3)	10/09/92	248.00	
NA+	136-145 (MMOL/L)	10/09/92	139.00	
K+	3.8-4.8 (MMOL/L)	10/09/92	4.30	
CL-	97-106 (MMOL/L)	10/09/92	102.00	
Ca++	2.3-2.5 (MMOL/L)	10/09/92	2.41	
PO4--	1-1.3 (MMOL/L)	10/09/92	1.21	
SGOT	10-30 (UI/L)	10/09/92	10.00	
SGPT	10-40 (UI/L)	10/09/92	5.00	<
GAMMA GT	5-35 (UI/L)	10/09/92	12.00	
LDH	250-320 (UI/L)	10/09/92	239.00	<
ALK. PHOSPH.	30-90 (UI/L)	10/09/92	65.00	
GLUCOSE	4-6 (MMOL/L)	10/09/92	4.40	
UREA	3.3-7 (MMOL/L)	10/09/92	3.80	
CREATININE	45-108 (UMOL/L)	10/09/92	72.00	
URIC ACID	180-350 (UMOL/L)	10/09/92	259.00	
TOT BILIRUBIN	3-17 (UMOL/L)	10/09/92	5.00	
TOT. PROTEINS	65-79 (G/L)	10/09/92	72.00	
ALBUMINE	57-65 (%)	10/09/92	45.79	<
TOT. CHOLEST.	4.4-7 (MMOL/L)	10/09/92	5.96	
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	10/09/92	2.62	>>
GLOBULINS ALPHA 1	2-4 (%)	10/09/92	2.38	
GLOBULINS ALPHA 2	6-10 (%)	10/09/92	5.90	<
GLOBULINS BETA	8-12 (%)	10/09/92	7.78	<
GLOBULINS GAMMA	10-20 (%)	10/09/92	10.15	
TSH	0.3-3.5 (MU/L)	10/09/92	2.62	
T4	13-28 (PMOL/L)	10/09/92	14.90	

1719

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 3/4 Patient: 462 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			29/09/92	
			value	(◊)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	20/09/92	14.30	
HT	37-47 (%)	20/09/92	40.60	
RBC	4.2-5.4 (10-6/UL)	20/09/92	4.70	
WBC	4.8-10.8 (10-3/UL)	20/09/92	8.70	
WBC: N	2-7.5 (10-3/MM3)	20/09/92	6.18	
WBC: L	1.5-4 (10-3/MM3)	20/09/92	2.18	
WBC: E	0.04-0.7 (10-3/MM3)	20/09/92	0.70	
WBC: M	0.2-1 (10-3/MM3)	20/09/92	0.35	
WBC: B	0.01-0.2 (10-3/MM3)	20/09/92	0.20	
PLATELETS	130-400 (10-3/MM3)	20/09/92	298.00	
NA+	136-145 (MMOL/L)	20/09/92	140.00	
K+	3.8-4.8 (MMOL/L)	20/09/92	3.90	
CL-	97-106 (MMOL/L)	20/09/92	106.00	
Ca++	2.3-2.5 (MMOL/L)	20/09/92	2.32	
PO4--	1-1.3 (MMOL/L)	20/09/92	1.03	
SGOT	10-30 (UI/L)	20/09/92	11.00	
SGPT	10-40 (UI/L)	20/09/92	8.00	<
GAMMA GT	5-35 (UI/L)	20/09/92	28.00	
LDH	250-320 (UI/L)	20/09/92	226.00	<
ALK. PHOSPH.	30-90 (UI/L)	20/09/92	42.00	
GLUCOSE	4-6 (MMOL/L)	20/09/92	4.80	
UREA	3.3-7 (MMOL/L)	20/09/92	2.30	<
CREATININE	45-108 (UMOL/L)	20/09/92	76.00	
URIC ACID	180-350 (UMOL/L)	20/09/92	243.00	
TOT BILIRUBIN	3-17 (UMOL/L)	20/09/92	7.00	
TOT. PROTEINS	65-79 (G/L)	20/09/92	70.00	
ALBUMINE	57-65 (%)	20/09/92	45.22	<
TOT. CHOLEST.	4.4-7 (MMOL/L)	20/09/92	5.36	
TRIGLYCERIDES	0.55-1.7 (MMOL/L)	20/09/92	0.74	
GLOBULINS ALPHA 1	2-4 (%)	20/09/92	2.24	
GLOBULINS ALPHA 2	6-10 (%)	20/09/92	5.53	<
GLOBULINS BETA	8-12 (%)	20/09/92	6.93	<
GLOBULINS GAMMA	10-20 (%)	20/09/92	10.08	

1720

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0
9550082
LABORATORY DATA
Centre: 4/1 Patient: 91 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			17/10/91	
			value	(¢)
Laboratory test	Range value	Range date		
NA+	135-145 (MEQ/L)	01/10/91	139.00	
K+	3.6-5.3 (MEQ/L)	01/10/91	3.80	
CL-	95-105 (MEQ/L)	01/10/91	108.00	>
Ca++	90-105 (MG/L)	01/10/91	92.00	
PO4--	28-45 (MG/L)	01/10/91	38.00	
SGOT	6-25 (U/L)	01/10/91	8.00	
SGPT	7-28 (U/L)	01/10/91	14.00	
GAMMA GT	6-26 (U/L)	01/10/91	21.00	
LDH	120-280 (U/L)	01/10/91	237.00	
ALK. PHOSPH.	30-90 (UI/L)	01/10/91	94.00	>
GLUCOSE	0.75-1.05 (G/L)	01/10/91	0.99	
UREA	0.19-0.42 (G/L)	01/10/91	0.25	
CREATININE	0.006-0.011 (G/L)	01/10/91	0.01	
URIC ACID	0.03-0.06 (G/L)	01/10/91	0.04	
TOT BILIRUBIN	2-10 (MG/L)	01/10/91	4.00	
TOT. PROTEINS	60-78 (G/L)	01/10/91	69.00	
ALBUMINE	57-61 (%)	01/10/91	56.70	<
TOT. CHOLEST.	1.3-2 (G/L)	01/10/91	2.18	>
TRIGLYCERIDES	0.45-1.2 (G/L)	01/10/91	2.04	>>
GLOBULINS ALPHA 1	3-5.5 (%)	01/10/91	5.30	
GLOBULINS ALPHA 2	7-9.5 (%)	01/10/91	11.10	>
GLOBULINS BETA	10-14 (%)	01/10/91	14.10	>
GLOBULINS GAMMA	14-17 (%)	01/10/91	12.80	<
TSH	0.15-3.5 (UU/ML)	01/10/91	0.92	
T4	4-12 (NG/DL)	01/10/91	11.20	

1721

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/1 Patient: 92 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/08/91		28/08/91		18/09/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	02/08/91	11.80	<	12.50		13.20	
HT	35-47 (%)	02/08/91	35.70		36.90		38.90	
RBC	4-5.2 (10¬6/UL)	02/08/91	4.26		4.34		4.59	
WBC	4000-9000 (/UL)	02/08/91	4900.00		6100.00		7100.00	
WBC: N	1500-7000 (/MM3)	02/08/91	2793.00					
	50-70 (%)	27/08/91			61.00		51.00	
WBC: L	800-4500 (/MM3)	02/08/91	1519.00					
	20-45 (%)	27/08/91			30.00		36.00	
WBC: E	0-400 (/MM3)	02/08/91	147.00					
	1-4 (%)	27/08/91			1.00		2.00	
WBC: M	200-800 (/MM3)	02/08/91	392.00					
	3-8 (%)	27/08/91			6.00		10.00	>
WBC: B	0-100 (/MM3)	02/08/91	49.00					
	0-1 (%)	27/08/91			2.00	>>	1.00	
PLATELETS	150000-400000 (/UL)	02/08/91	295000		308000		490000	>
NA+	135-145 (MEQ/L)	02/08/91	142.00		142.00		141.00	
K+	3.6-5.3 (MEQ/L)	02/08/91	3.70		3.50	<	2.30	<<
CL-	95-105 (MEQ/L)	02/08/91	103.00		101.00		99.00	
Ca++	90-105 (MG/L)	02/08/91	91.00		92.00		95.00	
PO4--	28-45 (MG/L)	02/08/91	32.00		34.00		34.00	
SGOT	6-25 (U/L)	02/08/91	12.00		12.00		29.00	>
SGPT	7-28 (U/L)	02/08/91	9.00		10.00		59.00	>>
GAMMA GT	6-26 (U/L)	02/08/91	8.00		9.00		13.00	
LDH	120-280 (U/L)	02/08/91	187.00		189.00		223.00	
ALK. PHOSPH.	30-90 (UI/L)	02/08/91	29.00	<	32.00		41.00	
GLUCOSE	0.75-1.05 (G/L)	02/08/91	0.83		0.69	<	0.86	
UREA	0.19-0.42 (G/L)	02/08/91	0.17	<	0.28		0.34	
CREATININE	0.006-0.011 (G/L)	02/08/91	0.01		0.01		0.01	
URIC ACID	0.03-0.06 (G/L)	02/08/91	0.06		0.08	>>	0.09	>>
TOT BILIRUBIN	2-10 (MG/L)	02/08/91	17.00	>	23.00	>>	9.00	
TOT. PROTEINS	60-78 (G/L)	02/08/91	67.10		68.80		69.50	
ALBUMINE	57-61 (%)	02/08/91	65.00	>	62.00	>	65.00	>
TOT. CHOLEST.	1.3-2 (G/L)	02/08/91	1.90		1.96		1.92	
TRIGLYCERIDES	0.45-1.2 (G/L)	02/08/91	0.68		0.83		0.81	
GLOBULINS ALPHA 1	3-5.5 (%)	02/08/91	3.50		4.00		3.50	
GLOBULINS ALPHA 2	7-9.5 (%)	02/08/91	8.00		8.50		8.50	
GLOBULINS BETA	10-14 (%)	02/08/91	12.00		12.50		12.50	
GLOBULINS GAMMA	14-17 (%)	02/08/91	11.50	<	13.00	<	10.50	<
TSH	0.15-3.5 (UU/ML)	02/08/91	0.84					
T4	45-120 (NG/ML)	02/08/91	64.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/1 Patient: 93 Treatment: Placebo Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			29/06/91		24/07/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
HB	13-18 (G/DL)	01/06/91	15.40		15.10	
HT	42-52 (%)	01/06/91	44.40		44.30	
RBC	4.5-5.8 (10-6/UL)	01/06/91	4.69		4.69	
WBC	4000-9000 (/UL)	01/06/91	4200.00		4400.00	
WBC: N	45-74 (%)	01/06/91	42.00	<	30.00	<<
WBC: L	16-45 (%)	01/06/91	46.00	>	58.00	>
WBC: E	0-7 (%)	01/06/91	2.00		2.00	
WBC: M	4-10 (%)	01/06/91	9.00		10.00	
WBC: B	0-2 (%)	01/06/91	1.00		0.00	
PLATELETS	150000-400000 (/UL)	01/06/91	302000		289000	
NA+	135-145 (MEQ/L)	01/06/91	141.00		139.00	
K+	3.6-5.3 (MEQ/L)	01/06/91	4.20		4.40	
CL-	95-105 (MEQ/L)	01/06/91	100.00		97.00	
Ca++	90-105 (MG/L)	01/06/91	91.00		91.00	
PO4--	28-45 (MG/L)	01/06/91	36.00		40.00	
SGOT	7-30 (U/L)	01/06/91	10.00		14.00	
SGPT	9-33 (U/L)	01/06/91	16.00		10.00	
GAMMA GT	8-35 (U/L)	01/06/91	15.00		12.00	
LDH	120-280 (U/L)	01/06/91	192.00		185.00	
ALK. PHOSPH.	30-90 (UI/L)	01/06/91	52.00		54.00	
GLUCOSE	0.75-1.05 (G/L)	01/06/91	0.75		0.92	
UREA	0.19-0.42 (G/L)	01/06/91	0.38		0.37	
CREATININE	0.007-0.014 (G/L)	01/06/91	0.01		0.01	
URIC ACID	0.03-0.06 (G/L)	01/06/91	0.06	>	0.05	
TOT BILIRUBIN	2-10 (MG/L)	01/06/91	9.00		6.00	
TOT. PROTEINS	60-78 (G/L)	01/06/91	73.40		68.10	
ALBUMINE	57-61 (%)	01/06/91	63.00	>	61.50	>
TOT. CHOLEST.	1.3-1.7 (G/L)	01/06/91	1.71	>	1.65	
TRIGLYCERIDES	0.45-1.2 (G/L)	01/06/91	0.38	<	0.74	
GLOBULINS ALPHA 1	3-5.5 (%)	01/06/91	3.00		3.00	
GLOBULINS ALPHA 2	7-9.5 (%)	01/06/91	8.00		8.00	
GLOBULINS BETA	10-14 (%)	01/06/91	11.00		11.00	
GLOBULINS GAMMA	14-17 (%)	01/06/91	15.00		16.50	
TSH	0.15-3.5 (UU/ML)	01/06/91	1.08			
T4	45-120 (NG/ML)	01/06/91	57.60			

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/1 Patient: 94 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			29/06/91		24/07/91		27/08/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	13-18 (G/DL)	01/06/91	14.10		14.60		14.70	
HT	42-52 (%)	01/06/91	41.80	<	44.10		44.00	
RBC	4.5-5.8 (10¬6/UL)	01/06/91	4.47	<	4.72		4.62	
WBC	4000-9000 (/UL)	01/06/91	9000.00		8800.00		10000.0	>
WBC: N	45-74 (%)	01/06/91	33.00	<	39.00	<	41.00	<
WBC: L	16-45 (%)	01/06/91	36.00		43.00		38.00	
WBC: E	0-7 (%)	01/06/91	22.00	>>	11.00	>>	15.00	>>
WBC: M	4-10 (%)	01/06/91	8.00		7.00		6.00	
WBC: B	0-2 (%)	01/06/91	1.00		0.00		0.00	
PLATELETS	150000-400000 (/UL)	01/06/91	293000		310000		321000	
NA+	135-145 (MEQ/L)	01/06/91	142.00		140.00		143.00	
K+	3.6-5.3 (MEQ/L)	01/06/91	3.90		4.60		4.70	
CL-	95-105 (MEQ/L)	01/06/91	104.00		99.00		103.00	
Ca++	90-105 (MG/L)	01/06/91	93.00		98.00		99.00	
PO4--	28-45 (MG/L)	01/06/91	29.00		31.00		28.00	
SGOT	7-30 (U/L)	01/06/91	14.00		11.00		11.00	
SGPT	9-33 (U/L)	01/06/91	15.00		18.00		9.00	
GAMMA GT	8-35 (U/L)	01/06/91	10.00		13.00		13.00	
LDH	120-280 (U/L)	01/06/91	229.00		180.00		203.00	
ALK. PHOSPH.	30-90 (UI/L)	01/06/91	69.00		65.00		75.00	
GLUCOSE	0.75-1.05 (G/L)	01/06/91	0.88		0.94		0.93	
UREA	0.19-0.42 (G/L)	01/06/91	0.37		0.49	>	0.45	>
CREATININE	0.007-0.014 (G/L)	01/06/91	0.01		0.01		0.01	
URIC ACID	0.03-0.06 (G/L)	01/06/91	0.04		0.04		0.04	
TOT BILIRUBIN	2-10 (MG/L)	01/06/91	5.00		6.00		6.00	
TOT. PROTEINS	60-78 (G/L)	01/06/91	75.30		74.30		76.10	
ALBUMINE	57-61 (%)	01/06/91	57.00		59.00		56.00	<
TOT. CHOLEST.	1.3-1.7 (G/L)	01/06/91	2.20	>	2.33	>>	2.43	>>
TRIGLYCERIDES	0.45-1.2 (G/L)	01/06/91	1.14		1.22	>	1.15	
GLOBULINS ALPHA 1	3-5.5 (%)	01/06/91	3.00		3.00		3.00	
GLOBULINS ALPHA 2	7-9.5 (%)	01/06/91	8.50		8.00		9.00	
GLOBULINS BETA	10-14 (%)	01/06/91	12.00		11.50		12.50	
GLOBULINS GAMMA	14-17 (%)	01/06/91	19.50	>	18.50	>	19.50	>
TSH	0.15-3.5 (UU/ML)	01/06/91	0.32					
T4	45-120 (NG/ML)	01/06/91	73.20					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

			09/06/91		28/06/91		17/	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-15.8 (G/DL)	01/05/91	10.70	<	10.30	<	10.50	<
HT	37-46 (%)	01/05/91	33.30	<	32.80	<	33.50	<
RBC	4.1-5.2 (10~6/UL)	01/05/91	5.23	>	5.14		5.27	>
WBC	4500-10500 (/UL)	01/05/91	6200.00		4600.00		5600.00	
WBC: N	45-74 (%)	01/05/91	50.20		46.50		46.90	
WBC: L	16-45 (%)	01/05/91	38.50		44.00		42.60	
WBC: E	0-7 (%)	01/05/91	5.00		2.90		2.90	
WBC: M	4-10 (%)	01/05/91	0.70	<	6.20		7.10	
WBC: B	0-2 (%)	01/05/91	5.50	>>	0.40		0.40	
PLATELETS	150000-380000 (/UL)	01/05/91			340000		319000	
NA+	137-145 (MEQ/L)	01/05/91			141.00		142.00	
K+	3.8-4.8 (MEQ/L)	01/05/91			3.94		3.84	
CL-	95-107 (MEQ/L)	01/05/91			99.00		103.00	
Ca++	88-105 (MG/L)	01/05/91			93.60		93.60	
PO4--	29-44 (MG/L)	01/05/91			34.00		33.20	
SGOT	5-40 (UI/L)	01/05/91	12.00		17.00		16.00	
SGPT	5-40 (UI/L)	01/05/91	15.00		29.00		24.00	
GAMMA GT	8-40 (UI/L)	01/05/91			13.00		13.00	
LDH	100-300 (UI/L)	01/05/91			145.00		278.00	
ALK. PHOSPH.	30-90 (UI/L)	01/05/91			43.00		41.00	
GLUCOSE	0.75-1.06 (G/L)	01/05/91	0.90		0.87		0.91	
UREA	0.17-0.44 (G/L)	01/05/91			0.23		0.25	
CREATININE	5.65-11.3 (MG/L)	01/05/91	8.10		7.80		8.30	
URIC ACID	25-70 (MG/L)	01/05/91	34.70		29.60		30.10	
TOT BILIRUBIN	2-13 (MG/L)	01/05/91			6.50		6.60	
TOT. PROTEINS	66-81 (G/L)	01/05/91			76.00		70.00	
ALBUMINE	33-53 (G/L)	01/05/91			39.00		40.00	
TOT. CHOLEST.	1.32-2.35 (G/L)	01/05/91	2.45	>	2.68	>	2.27	
TRIGLYCERIDES	0.3-1.65 (G/L)	01/05/91	0.42		0.38		0.41	
GLOBULINS ALPHA 1	2-4 (%)	01/05/91			2.60		2.70	
GLOBULINS ALPHA 2	6-10 (%)	01/05/91			7.70		9.20	
GLOBULINS BETA	8-12 (%)	01/05/91			9.80		17.30	>>
GLOBULINS GAMMA	12-19 (%)	01/05/91			17.70		19.90	>
TSH	0.2-6.2 (MU/L)	01/05/91	1.49					
T4	7-22 (UG/DL)	01/05/91	13.30					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/1 Patient: 96 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			30/08/91		25/09/91		25/10/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	12-16 (G/DL)	07/07/91	13.10		14.30		13.90	
HT	35-47 (%)	07/07/91	38.30		42.70		40.70	
RBC	4-5.2 (10¬6/UL)	07/07/91	4.27		4.70		4.75	
WBC	4000-9000 (/UL)	07/07/91	5800.00		6000.00		7400.00	
WBC: N	50-70 (%)	07/07/91	53.00		50.00		48.00	<
WBC: L	20-45 (%)	07/07/91	38.00		41.00		43.00	
WBC: E	1-4 (%)	07/07/91	2.00		2.00		2.00	
WBC: M	3-8 (%)	07/07/91	6.00		7.00		7.00	
WBC: B	0-1 (%)	07/07/91	1.00		0.00		0.00	
PLATELETS	150000-400000 (/UL)	07/07/91	254000		327000		328000	
NA+	135-145 (MEQ/L)	07/07/91	142.00		142.00		140.00	
K+	3.6-5.3 (MEQ/L)	07/07/91	4.10		4.10		4.30	
CL-	95-105 (MEQ/L)	07/07/91	101.00		102.00		99.00	
Ca++	90-105 (MG/L)	07/07/91	88.00	<	97.00		92.00	
PO4--	28-45 (MG/L)	07/07/91	33.00		36.00		31.00	
SGOT	6-25 (U/L)	07/07/91	22.00		16.00		27.00	>
SGPT	7-28 (U/L)	07/07/91	19.00		12.00		8.00	
GAMMA GT	6-26 (U/L)	07/07/91	12.00		11.00		13.00	
LDH	120-280 (U/L)	07/07/91	226.00		223.00		302.00	>
ALK. PHOSPH.	30-90 (UI/L)	07/07/91	89.00		105.00	>	114.00	>
GLUCOSE	0.75-1.05 (G/L)	07/07/91	0.99		0.88		0.87	
UREA	0.19-0.42 (G/L)	07/07/91	0.43	>	0.31		0.48	>
CREATININE	0.006-0.011 (G/L)	07/07/91	0.01		0.01		0.01	>
URIC ACID	0.03-0.06 (G/L)	07/07/91	0.07	>	0.05		0.05	
TOT BILIRUBIN	2-10 (MG/L)	07/07/91	3.00		5.00		7.00	
TOT. PROTEINS	60-78 (G/L)	07/07/91	69.80		76.60		77.10	
ALBUMINE	57-61 (%)	07/07/91	57.00		55.50	<	56.00	<
TOT. CHOLEST.	1.3-2 (G/L)	07/07/91	2.38	>	2.27	>	2.39	>
TRIGLYCERIDES	0.45-1.2 (G/L)	07/07/91	1.19		0.66		0.85	
GLOBULINS ALPHA 1	3-5.5 (%)	07/07/91	2.50	<	3.00		3.00	
GLOBULINS ALPHA 2	7-9.5 (%)	07/07/91	9.00		10.00	>	10.00	>
GLOBULINS BETA	10-14 (%)	07/07/91	15.00	>	14.50	>	14.50	>
GLOBULINS GAMMA	14-17 (%)	07/07/91	16.50		17.00		16.50	
TSH	0.15-3.5 (UU/ML)	07/07/91	3.54	>				
T4	45-120 (NG/ML)	07/07/91	61.20					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max ra
< out of range (value lower than min range) > out of range (value higher than max ran
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/1 Patient: 115 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			30/04/92		02/06/92		19/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	07/07/91	14.70		15.10		15.20	
HT	35-47 (%)	07/07/91	43.90		44.10		44.50	
RBC	4-5.2 (10¬6/UL)	07/07/91	4.75		4.78		4.90	
WBC	4000-9000 (/UL)	07/07/91	5600.00		5700.00		7000.00	
WBC: N	50-70 (%)	07/07/91	45.00	<	36.00	<	41.00	<
WBC: L	20-45 (%)	07/07/91	45.00		53.00	>	48.00	>
WBC: E	1-4 (%)	07/07/91	3.00		3.00		4.00	
WBC: M	3-8 (%)	07/07/91	6.00		7.00		6.00	
WBC: B	0-1 (%)	07/07/91	1.00		1.00		1.00	
PLATELETS	150000-400000 (/UL)	07/07/91	344000		311000		384000	
NA+	135-145 (MEQ/L)	07/07/91	140.00		138.00		135.00	
K+	3.6-5.3 (MEQ/L)	07/07/91	4.30		4.40		3.80	
CL-	95-105 (MEQ/L)	07/07/91	102.00		99.00		94.00	<
Ca++	90-105 (MG/L)	07/07/91	98.00		93.00		97.00	
PO4--	28-45 (MG/L)	07/07/91	29.00		28.00		32.00	
SGOT	6-25 (U/L)	07/07/91	23.00		18.00		14.00	
SGPT	7-28 (U/L)	07/07/91	15.00		12.00		9.00	
GAMMA GT	6-26 (U/L)	07/07/91	21.00		20.00		15.00	
LDH	120-280 (U/L)	07/07/91	188.00		203.00		197.00	
ALK. PHOSPH.	30-90 (UI/L)	07/07/91	93.00	>	81.00		84.00	
GLUCOSE	0.75-1.05 (G/L)	07/07/91	1.08	>	0.89		0.86	
UREA	0.19-0.42 (G/L)	07/07/91	0.37		0.29		0.43	>
CREATININE	0.006-0.011 (G/L)	07/07/91	0.01		0.01		0.01	
URIC ACID	0.03-0.06 (G/L)	07/07/91	0.04		0.06		0.05	
TOT BILIRUBIN	2-10 (MG/L)	07/07/91	4.00		7.00		8.00	
TOT. PROTEINS	60-78 (G/L)	07/07/91	77.60		72.90		73.10	
ALBUMINE	57-61 (%)	07/07/91	62.00	>	61.00		58.00	
TOT. CHOLEST.	1.3-2 (G/L)	07/07/91	2.69	>>	2.24	>	2.33	>
TRIGLYCERIDES	0.45-1.2 (G/L)	07/07/91	1.09		0.96		1.28	>
GLOBULINS ALPHA 1	3-5.5 (%)	07/07/91	3.50		3.00		3.50	
GLOBULINS ALPHA 2	7-9.5 (%)	07/07/91	7.50		8.50		9.00	
GLOBULINS BETA	10-14 (%)	07/07/91	13.00		13.00		14.50	>
GLOBULINS GAMMA	14-17 (%)	07/07/91	14.00		14.50		15.00	
TSH	0.15-3.5 (UU/ML)	07/07/91	0.26					
T4	45-120 (NG/ML)	07/07/91	66.90					

1727

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 4/1 Patient: 116 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			09/05/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	07/07/91	13.50	
HT	35-47 (%)	07/07/91	40.40	
RBC	4-5.2 (10¬6/UL)	07/07/91	4.41	
WBC	4000-9000 (/UL)	07/07/91	8300.00	
WBC: N	50-70 (%)	07/07/91	59.00	
WBC: L	20-45 (%)	07/07/91	31.00	
WBC: E	1-4 (%)	07/07/91	3.00	
WBC: M	3-8 (%)	07/07/91	6.00	
WBC: B	0-1 (%)	07/07/91	1.00	
PLATELETS	150000-400000 (/UL)	07/07/91	200000	
NA+	135-145 (MEQ/L)	07/07/91	141.00	
K+	3.6-5.3 (MEQ/L)	07/07/91	4.10	
CL-	95-105 (MEQ/L)	07/07/91	99.00	
Ca++	90-105 (MG/L)	07/07/91	93.00	
PO4--	28-45 (MG/L)	07/07/91	33.00	
SGOT	6-25 (U/L)	07/07/91	17.00	
SGPT	7-28 (U/L)	07/07/91	14.00	
GAMMA GT	6-26 (U/L)	07/07/91	10.00	
LDH	120-280 (U/L)	07/07/91	175.00	
ALK. PHOSPH.	30-90 (UI/L)	07/07/91	37.00	
GLUCOSE	0.75-1.05 (G/L)	07/07/91	0.86	
UREA	0.19-0.42 (G/L)	07/07/91	0.34	
CREATININE	0.006-0.011 (G/L)	07/07/91	0.01	
URIC ACID	0.03-0.06 (G/L)	07/07/91	0.03	
TOT BILIRUBIN	2-10 (MG/L)	07/07/91	5.00	
TOT. PROTEINS	60-78 (G/L)	07/07/91	66.50	
ALBUMINE	57-61 (%)	07/07/91	58.50	
TOT. CHOLEST.	1.3-2 (G/L)	07/07/91	2.14	>
TRIGLYCERIDES	0.45-1.2 (G/L)	07/07/91	0.78	
GLOBULINS ALPHA 1	3-5.5 (%)	07/07/91	3.50	
GLOBULINS ALPHA 2	7-9.5 (%)	07/07/91	8.00	
GLOBULINS BETA	10-14 (%)	07/07/91	12.00	
GLOBULINS GAMMA	14-17 (%)	07/07/91	18.00	>
TSH	0.15-3.5 (UU/ML)	07/07/91	1.86	
T4	45-120 (NG/ML)	07/07/91	81.50	

1728

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/1 Patient: 117 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			29/08/91		24/09/91		15/10/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	07/07/91	13.20		13.90		13.90	
HT	35-47 (%)	07/07/91	39.00		40.80		39.90	
RBC	4-5.2 (10-6/UL)	07/07/91	4.49		4.64		4.61	
WBC	4000-9000 (/UL)	07/07/91	4000.00		4000.00		3400.00	<
WBC: N	50-70 (%)	07/07/91	44.00	<	45.00	<	39.00	<
WBC: L	20-45 (%)	07/07/91	41.00		40.00		44.00	
WBC: E	1-4 (%)	07/07/91	5.00	>	6.00	>>	6.00	>>
WBC: M	3-8 (%)	07/07/91	9.00	>	9.00	>	10.00	>
WBC: B	0-1 (%)	07/07/91	1.00		0.00		1.00	
PLATELETS	150000-400000 (/UL)	07/07/91	257000		281000		239000	
NA+	135-145 (MEQ/L)	07/07/91	142.00		141.00		138.00	
K+	3.6-5.3 (MEQ/L)	07/07/91	4.00		4.50		4.50	
CL-	95-105 (MEQ/L)	07/07/91	101.00		101.00		95.00	
Ca++	90-105 (MG/L)	07/07/91	97.00		99.00		96.00	
PO4--	28-45 (MG/L)	07/07/91	29.00		39.00		29.00	
SGOT	6-25 (U/L)	07/07/91	12.00		19.00		21.00	
SGPT	7-28 (U/L)	07/07/91	15.00		37.00	>	24.00	
GAMMA GT	6-26 (U/L)	07/07/91	23.00		38.00	>	36.00	>
LDH	120-280 (U/L)	07/07/91	227.00		228.00		215.00	
ALK. PHOSPH.	30-90 (UI/L)	07/07/91	78.00		113.00	>	119.00	>
GLUCOSE	0.75-1.05 (G/L)	07/07/91	0.93		0.81		0.77	
UREA	0.19-0.42 (G/L)	07/07/91	0.30		0.35		0.31	
CREATININE	0.006-0.011 (G/L)	07/07/91	0.01		0.01		0.01	
URIC ACID	0.03-0.06 (G/L)	07/07/91	0.03	<	0.03	<	0.03	<
TOT BILIRUBIN	2-10 (MG/L)	07/07/91	4.00		3.00		4.00	
TOT. PROTEINS	60-78 (G/L)	07/07/91	60.40		65.90		66.50	
ALBUMINE	57-61 (%)	07/07/91	58.50		58.00		58.00	
TOT. CHOLEST.	1.3-2 (G/L)	07/07/91	2.06	>	2.49	>	2.26	>
TRIGLYCERIDES	0.45-1.2 (G/L)	07/07/91	1.33	>	0.99		1.03	
GLOBULINS ALPHA 1	3-5.5 (%)	07/07/91	5.00		5.00		4.50	
GLOBULINS ALPHA 2	7-9.5 (%)	07/07/91	11.00	>	11.50	>	11.00	>
GLOBULINS BETA	10-14 (%)	07/07/91	14.50	>	15.00	>	14.50	>
GLOBULINS GAMMA	14-17 (%)	07/07/91	11.00	<	10.50	<	12.00	<
TSH	0.15-3.5 (UU/ML)	07/07/91	0.04	<<				
T4	45-120 (NG/ML)	07/07/91	118.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/1 Patient: 118 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Day 21		Day 42	
			13/06/92		04/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/DL)	07/07/91	13.90		14.20	
HT	35-47 (%)	07/07/91	40.20		40.80	
RBC	4-5.2 (10-6/UL)	07/07/91	4.31		4.35	
WBC	4000-9000 (/UL)	07/07/91	7100.00		9400.00	>
WBC: N	50-70 (%)	07/07/91	59.00		65.00	
WBC: L	20-45 (%)	07/07/91	29.00		24.00	
WBC: E	1-4 (%)	07/07/91	2.00		2.00	
WBC: M	3-8 (%)	07/07/91	9.00	>	8.00	
WBC: B	0-1 (%)	07/07/91	1.00		1.00	
PLATELETS	150000-400000 (/UL)	07/07/91	229000		275000	
NA+	135-145 (MEQ/L)	07/07/91	139.00		140.00	
K+	3.6-5.3 (MEQ/L)	07/07/91	4.30		4.60	
CL-	95-105 (MEQ/L)	07/07/91	100.00		102.00	
Ca++	90-105 (MG/L)	07/07/91	95.00		87.00	<
PO4--	28-45 (MG/L)	07/07/91	45.00		28.00	
SGOT	6-25 (U/L)	07/07/91	27.00	>	30.00	>
SGPT	7-28 (U/L)	07/07/91	20.00		28.00	
GAMMA GT	6-26 (U/L)	07/07/91	41.00	>	31.00	>
LDH	120-280 (U/L)	07/07/91	334.00	>	266.00	
ALK. PHOSPH.	30-90 (UI/L)	07/07/91	90.00		77.00	
GLUCOSE	0.75-1.05 (G/L)	07/07/91	0.99		1.01	
UREA	0.19-0.42 (G/L)	07/07/91	0.37		0.33	
CREATININE	0.006-0.011 (G/L)	07/07/91	0.01		0.01	
URIC ACID	0.03-0.06 (G/L)	07/07/91	0.03		0.03	
TOT BILIRUBIN	2-10 (MG/L)	07/07/91	3.00		3.00	
TOT. PROTEINS	60-78 (G/L)	07/07/91	70.60		65.50	
ALBUMINE	57-61 (%)	07/07/91	55.00	<	60.00	
TOT. CHOLEST.	1.3-2 (G/L)	07/07/91	2.09	>	1.99	
TRIGLYCERIDES	0.45-1.2 (G/L)	07/07/91	1.03		0.90	
GLOBULINS ALPHA 1	3-5.5 (%)	07/07/91	4.00		4.00	
GLOBULINS ALPHA 2	7-9.5 (%)	07/07/91	11.50	>	8.50	
GLOBULINS BETA	10-14 (%)	07/07/91	13.00		12.00	
GLOBULINS GAMMA	14-17 (%)	07/07/91	16.50		15.50	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/1 Patient: 119 Treatment: Placebo Sex: Female

			Visit number / Laboratory date	
			Screen	
			16/03/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	07/07/91	13.10	
HT	35-47 (%)	07/07/91	38.00	
RBC	4-5.2 (10¬6/UL)	07/07/91	4.15	
WBC	4000-9000 (/UL)	07/07/91	4100.00	
WBC: N	50-70 (%)	07/07/91	60.00	
WBC: L	20-45 (%)	07/07/91	31.00	
WBC: E	1-4 (%)	07/07/91	1.00	
WBC: M	3-8 (%)	07/07/91	7.00	
WBC: B	0-1 (%)	07/07/91	1.00	
PLATELETS	150000-400000 (/UL)	07/07/91	248000	
NA+	135-145 (MEQ/L)	07/07/91	139.00	
K+	3.6-5.3 (MEQ/L)	07/07/91	4.20	
CL-	95-105 (MEQ/L)	07/07/91	99.00	
Ca++	90-105 (MG/L)	07/07/91	98.00	
PO4--	28-45 (MG/L)	07/07/91	34.00	
SGOT	6-25 (U/L)	07/07/91	11.00	
SGPT	7-28 (U/L)	07/07/91	16.00	
GAMMA GT	6-26 (U/L)	07/07/91	9.00	
LDH	120-280 (U/L)	07/07/91	201.00	
ALK. PHOSPH.	30-90 (UI/L)	07/07/91	36.00	
GLUCOSE	0.75-1.05 (G/L)	07/07/91	1.02	
UREA	0.19-0.42 (G/L)	07/07/91	0.26	
CREATININE	0.006-0.011 (G/L)	07/07/91	0.01	
URIC ACID	0.03-0.06 (G/L)	07/07/91	0.03	
TOT BILIRUBIN	2-10 (MG/L)	07/07/91	6.00	
TOT. PROTEINS	60-78 (G/L)	07/07/91	73.90	
ALBUMINE	57-61 (%)	07/07/91	61.50	>
TOT. CHOLEST.	1.3-2 (G/L)	07/07/91	2.77	>>
TRIGLYCERIDES	0.45-1.2 (G/L)	07/07/91	0.62	
GLOBULINS ALPHA 1	3-5.5 (%)	07/07/91	3.50	
GLOBULINS ALPHA 2	7-9.5 (%)	07/07/91	8.00	
GLOBULINS BETA	10-14 (%)	07/07/91	14.50	>
GLOBULINS GAMMA	14-17 (%)	07/07/91	12.50	<
TSH	0.15-3.5 (UU/ML)	07/07/91	0.66	
T4	45-120 (NG/ML)	07/07/91	73.10	

1731

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/1 Patient: 120 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/06/92		21/08/92		22/09/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	120-160 (G/L)	04/05/92	127.00		131.00		124.00	
HT	37-52 (%)	04/05/92	37.20		39.40		38.00	
RBC	4000000-5400000 (/MM3)	04/05/92	4200000		4490000		4350000	
WBC	4000-10000 (/UL)	04/05/92	5000.00		5100.00		5800.00	
WBC: N	50-70 (%)	04/05/92	55.20		66.00		64.20	
WBC: L	20-30 (%)	04/05/92	35.90	>	27.90		27.10	
WBC: E	1-2 (%)	04/05/92	2.80	>>	2.00		2.30	>
WBC: M	5-8 (%)	04/05/92	5.80		3.70	<	6.10	
WBC: B	0-1 (%)	04/05/92	0.10		0.10		0.00	
PLATELETS	150000-400000 (/UL)	04/05/92	189000		203000		163000	
NA+	135-145 (MEQ/L)	04/05/92	142.00		144.00		140.00	
K+	3.5-5.5 (MEQ/L)	04/05/92	4.30		3.80		4.20	
CL-	95-105 (MEQ/L)	04/05/92	102.00		106.00	>	103.00	
Ca++	84-102 (MG/L)	04/05/92	91.00		93.00		90.00	
PO4--	25-45 (MG/L)	04/05/92	37.00		38.00		36.00	
SGOT	7-45 (UI/L)	04/05/92	26.00		33.00		27.00	
SGPT	5-56 (UI/L)	04/05/92	65.00	>	44.00		40.00	
GAMMA GT	8-78 (UI/L)	04/05/92	74.00		43.00		35.00	
LDH	313-618 (UI/L)	04/05/92	319.00		338.00		313.00	
ALK. PHOSPH.	37-123 (UI/L)	04/05/92	58.00		76.00		66.00	
GLUCOSE	0.75-1.1 (G/L)	04/05/92	0.87		0.84		0.85	
UREA	0.1-0.45 (G/L)	04/05/92	0.28		0.25		0.28	
CREATININE	4-15 (MG/L)	04/05/92	10.00		11.00		9.00	
URIC ACID	30-70 (MG/L)	04/05/92	49.00		65.00		58.00	
TOT BILIRUBIN	2-10 (MG/L)	04/05/92	4.00		6.00		5.00	
TOT. PROTEINS	60-82 (G/L)	04/05/92	68.00		72.00		73.00	
ALBUMINE	35-45 (G/L)	04/05/92	44.88		44.64		43.07	
TOT. CHOLEST.	1.5-2 (G/L)	04/05/92	2.04	>	2.48	>	1.99	
TRIGLYCERIDES	0.4-1.6 (G/L)	04/05/92	1.20		1.26		0.80	
GLOBULINS ALPHA 1	2-4 (G/L)	04/05/92	1.36	<<	2.16		2.19	
GLOBULINS ALPHA 2	5-7 (G/L)	04/05/92	4.76	<	5.76		5.84	
GLOBULINS BETA	7-11 (G/L)	04/05/92	7.48		9.36		10.22	
GLOBULINS GAMMA	8-14 (G/L)	04/05/92	9.52		10.08		11.68	
TSH	0.32-5 (UU/ML)	04/05/92	0.00	<<	0.90		1.12	
T4	7-18 (PG/ML)	04/05/92	16.20		10.20		11.50	

1732

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/1 Patient: 145 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			30/09/92		30/10/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/DL)	25/09/92	9.30	<<		
HT	37-47 (%)	25/09/92	29.50	<<		
RBC	4.2-5.4 (10¬6/UL)	25/09/92	4.21			
WBC	4.8-10.8 (10¬3/UL)	25/09/92	5.71			
WBC: N	40-74 (%)	25/09/92	65.00			
WBC: L	19-48 (%)	25/09/92	26.00			
WBC: E	0-7 (%)	25/09/92	4.00			
WBC: M	3.4-9 (%)	25/09/92	4.00			
WBC: B	0-1.5 (%)	25/09/92	1.00			
PLATELETS	130-400 (10¬3/UL)	25/09/92	317.00			
NA+	137-145 (MEQ/L)	25/09/92	138.00		136.00	<
K+	3.6-5 (MEQ/L)	25/09/92	4.50		4.00	
CL-	101-111 (MEQ/L)	25/09/92	104.00		100.00	<
Ca++	84-102 (MG/L)	25/09/92	97.00		96.00	
PO4--	25-45 (MG/L)	25/09/92	32.00		35.00	
SGOT	5-35 (U/L)	25/09/92	15.00		14.00	
SGPT	7-56 (U/L)	25/09/92	26.00		20.00	
GAMMA GT	8-78 (U/L)	25/09/92	19.00		18.00	
LDH	313-618 (U/L)	25/09/92	439.00		391.00	
ALK. PHOSPH.	38-126 (U/L)	25/09/92	50.00		61.00	
GLUCOSE	0.65-1.05 (G/L)	25/09/92	0.94		0.87	
UREA	0.15-0.45 (G/L)	25/09/92	0.29		0.24	
CREATININE	5-12 (NG/L)	25/09/92	10.00		11.00	
URIC ACID	25-62 (NG/L)	25/09/92	33.00		34.00	
TOT BILIRUBIN	2-13 (NG/L)	25/09/92	4.50		4.90	
DIR BILIRUBIN	0-3 (NG/L)	25/09/92	0.00		0.00	
TOT. PROTEINS	63-82 (G/L)	25/09/92	67.00		71.00	
ALBUMINE	57-65 (%)	25/09/92	53.40	<	62.90	
TOT. CHOLEST.	1.1-2 (G/L)	25/09/92	2.54	>	2.31	>
TRIGLYCERIDES	0.35-1.35 (G/L)	25/09/92	0.86		0.88	
GLOBULINS ALPHA 1	2-4 (%)	25/09/92	4.00		3.10	
GLOBULINS ALPHA 2	6-10 (%)	25/09/92	10.20	>	7.80	
GLOBULINS BETA	8-12 (%)	25/09/92	16.50	>>	11.80	
GLOBULINS GAMMA	12-19 (%)	25/09/92	15.90		14.40	
TSH	0.16-3.5 (MUI/L)	25/09/92	1.31			
T4	9-25 (PMOL/L)	25/09/92	15.10			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang-
< out of range (value lower than min range) > out of range (value higher than max rang-
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/1 Patient: 146 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/08/92		05/10/92		27/10/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-17 (G/DL)	01/07/92	13.80		13.90		13.40	
HT	37-52 (%)	01/07/92	41.30		41.80		40.20	
RBC	4000000-5500000 (/UL)	01/07/92	4800000		4880000		4670000	
WBC	4000-9000 (/UL)	01/07/92	3100.00	<	3600.00	<	3100.00	<
WBC: N	50-70 (%)	01/07/92	51.00		59.00		50.00	
WBC: L	20-30 (%)	01/07/92	37.00	>	33.00	>	40.00	>>
WBC: E	1-2 (%)	01/07/92	0.00	<	0.00	<	1.00	
WBC: M	5-8 (%)	01/07/92	9.00	>	8.00		9.00	>
WBC: B	0-1 (%)	01/07/92	0.00		0.00		0.00	
PLATELETS	150000-400000 (/UL)	01/07/92	209000		219000		223000	
NA+	135-143 (MEQ/L)	01/07/92	141.00		142.00		143.00	
K+	3.7-4.8 (MEQ/L)	01/07/92	4.30		4.40		4.30	
CL-	95-108 (MEQ/L)	01/07/92	103.00		108.00		107.00	
Ca++	88-102 (MG/L)	01/07/92	96.00		97.00		98.00	
PO4--	25-50 (MG/L)	01/07/92	35.00		37.00		34.00	
SGOT	5-22 (UI/L)	01/07/92	23.00	>	24.00	>	27.00	>
SGPT	5-24 (UI/L)	01/07/92	13.00		12.00		12.00	
GAMMA GT	5-25 (UI/L)	01/07/92	9.00		9.00		9.00	
LDH	140-330 (UI/L)	01/07/92	228.00		222.00		260.00	
ALK. PHOSPH.	50-210 (UI/L)	01/07/92	192.00		229.00	>	197.00	
GLUCOSE	0.75-1.1 (G/L)	01/07/92	1.01		1.01		1.00	
UREA	0.2-0.4 (G/L)	01/07/92	0.29		0.27		0.22	
CREATININE	4-13 (MG/L)	01/07/92	8.00		8.00		8.00	
URIC ACID	0.03-0.055 (G/L)	01/07/92	0.04		0.04		0.04	
TOT BILIRUBIN	3-10 (MG/L)	01/07/92	5.00		5.00		5.00	
TOT. PROTEINS	60-80 (G/L)	01/07/92	72.00		71.00		83.00	>
ALBUMINE	32-50 (G/L)	01/07/92	42.30		43.70		48.10	
TOT. CHOLEST.	1.3-2.2 (G/L)	01/07/92	2.99	>>	2.97	>>	2.76	>
TRIGLYCERIDES	0.5-1.5 (G/L)	01/07/92	1.60	>	1.71	>	1.59	>
GLOBULINS ALPHA 1	1-4 (G/L)	01/07/92	2.10		1.60		2.20	
GLOBULINS ALPHA 2	5-11 (G/L)	01/07/92	6.60		6.00		7.80	
GLOBULINS BETA	6-15 (G/L)	01/07/92	9.40		8.90		9.10	
GLOBULINS GAMMA	7-15 (G/L)	01/07/92	11.70		10.90		15.80	>
TSH	0.3-5 (UUI/ML)	01/07/92	1.52					
T4	4.9-12.5 (UG/DL)	01/07/92	8.48					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA

Centre: 4/1 Patient: 147 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			16/07/92		21/09/92		13/10/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-17 (G/DL)	01/07/92	14.00		13.80		13.90	
HT	37-52 (%)	01/07/92	43.90		42.00		43.20	
RBC	4000000-5500000 (/UL)	01/07/92	4870000		4780000		4940000	
WBC	4000-9000 (/UL)	01/07/92	6400.00		6710.00		6600.00	
WBC: N	50-70 (%)	01/07/92	55.40		66.00		63.70	
WBC: L	20-30 (%)	01/07/92	33.60	>	26.00		26.80	
WBC: E	1-2 (%)	01/07/92	1.90		2.60	>	2.70	>>
WBC: M	5-8 (%)	01/07/92	8.10	>	4.50	<	6.10	
WBC: B	0-1 (%)	01/07/92	1.00		0.90		0.70	
PLATELETS	150000-400000 (/UL)	01/07/92			197000		204000	
NA+	135-145 (MEQ/L)	01/07/92	143.00		143.00		144.00	
K+	3.5-5 (MEQ/L)	01/07/92	3.90		4.10		4.20	
CL-	95-105 (MEQ/L)	01/07/92	103.00		100.00		99.00	
Ca++	88-102 (MG/L)	01/07/92	95.00		99.00		92.00	
PO4--	25-40 (MG/L)	01/07/92	40.00		44.00	>	40.00	
SGOT	10-37 (UI/L)	01/07/92	16.00		15.00		14.00	
SGPT	10-40 (UI/L)	01/07/92	26.00		24.00		21.00	
GAMMA GT	11-43 (UI/L)	01/07/92	39.00		35.00		27.00	
LDH	200-480 (U/L)	01/07/92	238.00		285.00		280.00	
ALK. PHOSPH.	100-290 (UI/L)	01/07/92	110.00		102.00		108.00	
GLUCOSE	0.75-1.15 (G/L)	01/07/92	1.38	>	1.19	>	1.18	>
UREA	0.2-0.4 (G/L)	01/07/92	0.27		0.31		0.28	
CREATININE	6-15 (MG/L)	01/07/92	11.00		10.00		10.00	
URIC ACID	25-70 (MG/L)	01/07/92	69.00		74.00	>	78.00	>
TOT BILIRUBIN	2-10 (MG/L)	01/07/92	2.00		3.00		3.00	
TOT. PROTEINS	60-78 (G/L)	01/07/92	60.00		63.00		68.00	
ALBUMINE	35-53 (G/L)	01/07/92	36.90		38.30		40.30	
TOT. CHOLEST.	1.3-2 (G/L)	01/07/92	2.84	>>	2.58	>	2.60	>
TRIGLYCERIDES	0.4-1.55 (G/L)	01/07/92	3.06	>>	2.73	>>	4.00	>>
GLOBULINS ALPHA 1	1.2-3.9 (G/L)	01/07/92	2.04		2.14		2.38	
GLOBULINS ALPHA 2	3.6-8.6 (G/L)	01/07/92	6.36		6.43		7.28	
GLOBULINS BETA	5-11 (G/L)	01/07/92	8.27		9.01		10.60	
GLOBULINS GAMMA	7-15 (G/L)	01/07/92	6.42	<	7.12		7.48	
TSH	0.15-3.9 (MUI/L)	01/07/92	2.16				3.12	
T4	4-12 (UG/100ML)	01/07/92	10.10				10.00	

1735

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/1 Patient: 148 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			11/09/92		20/10/92		10/11/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-17 (G/DL)	01/09/92	13.30		14.20		13.70	
HT	37-52 (%)	01/09/92	42.10		44.60		42.90	
RBC	4000000-5500000 (/UL)	01/09/92	4700000		4990000		4720000	
WBC	4000-9000 (/UL)	01/09/92	6650.00		6880.00		7470.00	
WBC: N	50-70 (%)	01/09/92	50.70		58.30		51.70	
WBC: L	20-30 (%)	01/09/92	36.30	>	30.70	>	36.90	>
WBC: E	1-2 (%)	01/09/92	4.00	>>	3.40	>>	3.20	>>
WBC: M	5-8 (%)	01/09/92	7.80		6.60		7.00	
WBC: B	0-1 (%)	01/09/92	1.20	>	1.00		1.20	>
PLATELETS	150000-400000 (/UL)	01/09/92	219000		239000		225000	
NA+	135-145 (MEQ/L)	01/09/92	138.00		139.00		137.00	
K+	3.5-5 (MEQ/L)	01/09/92	4.50		4.80		4.40	
CL-	95-105 (MEQ/L)	01/09/92	99.00		93.00	<	98.00	
Ca++	88-102 (MG/L)	01/09/92	93.00		96.00		94.00	
PO4--	25-40 (MG/L)	01/09/92	33.00		53.00	>>	38.00	
SGOT	10-37 (UI/L)	01/09/92	19.00		64.00	>	16.00	
SGPT	10-40 (UI/L)	01/09/92	33.00		113.00	>>	26.00	
GAMMA GT	11-43 (UI/L)	01/09/92	17.00		25.00		27.00	
LDH	200-480 (U/L)	01/09/92	332.00		325.00		302.00	
ALK. PHOSPH.	100-290 (UI/L)	01/09/92	108.00		148.00		138.00	
GLUCOSE	0.75-1.15 (G/L)	01/09/92	1.04		0.93		0.95	
UREA	0.2-0.4 (G/L)	01/09/92	0.31		0.48	>	0.33	
CREATININE	6-15 (MG/L)	01/09/92	10.00		11.00		10.00	
URIC ACID	25-70 (MG/L)	01/09/92	47.00		53.00		50.00	
TOT BILIRUBIN	2-10 (MG/L)	01/09/92	5.00		3.00		3.00	
TOT. PROTEINS	60-78 (G/L)	01/09/92	68.00		77.00		73.00	
ALBUMINE	35-53 (G/L)	01/09/92	35.50		44.70		43.40	
TOT. CHOLEST.	1.3-2 (G/L)	01/09/92	1.95		2.61	>>	2.18	>
TRIGLYCERIDES	0.4-1.55 (G/L)	01/09/92	1.68	>	2.13	>>	1.94	>
GLOBULINS ALPHA 1	1.2-3.9 (G/L)	01/09/92	2.45		1.77		1.31	
GLOBULINS ALPHA 2	3.6-8.6 (G/L)	01/09/92	8.09		7.70		6.57	
GLOBULINS BETA	5-11 (G/L)	01/09/92	8.57		9.39		8.18	
GLOBULINS GAMMA	7-15 (G/L)	01/09/92	13.40		13.40		13.60	
TSH	0.15-3.9 (MUI/L)	01/09/92	1.72					
T4	4-12 (UG/100ML)	01/09/92	6.20					

1736

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/1 Patient: 149 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/09/92		21/10/92		18/11/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-17 (G/DL)	20/09/92	15.40		15.60		15.50	
HT	37-52 (%)	20/09/92	46.50		46.30		45.90	
RBC	4000000-5500000 (/UL)	20/09/92	5100000		5100000		5000000	
WBC	4000-9000 (/UL)	20/09/92	7800.00		8000.00		6400.00	
WBC: N	50-70 (%)	20/09/92	62.00		57.00		55.00	
WBC: L	20-30 (%)	20/09/92	22.00		23.00		29.00	
WBC: E	1-2 (%)	20/09/92	4.00	>>	4.00	>>	4.00	>>
WBC: M	5-8 (%)	20/09/92	11.00	>>	14.00	>>	11.00	>>
WBC: B	0-1 (%)	20/09/92	1.00		2.00	>>	1.00	
PLATELETS	150000-400000 (/UL)	20/09/92	302000		296000		273000	
NA+	135-143 (MEQ/L)	20/09/92	139.00		141.00		142.00	
K+	3.7-4.8 (MEQ/L)	20/09/92	4.10		3.90		4.40	
CL-	95-108 (MEQ/L)	20/09/92	101.00		100.00		101.00	
Ca++	88-102 (MG/L)	20/09/92	96.00		99.00		100.00	
PO4--	25-50 (MG/L)	20/09/92	28.00		31.00		34.00	
SGOT	5-22 (UI/L)	20/09/92	12.00		15.00		25.00	>
SGPT	5-24 (UI/L)	20/09/92	16.00		14.00		18.00	
GAMMA GT	5-25 (UI/L)	20/09/92	31.00	>	19.00		28.00	>
LDH	140-330 (UI/L)	20/09/92	168.00		179.00		192.00	
ALK. PHOSPH.	50-210 (UI/L)	20/09/92	60.00		51.00		56.00	
GLUCOSE	0.75-1.1 (G/L)	20/09/92	1.09		1.01		1.01	
UREA	0.2-0.4 (G/L)	20/09/92	0.28		0.31		0.26	
CREATININE	0.007-0.014 (G/L)	20/09/92	0.01		0.01		0.01	
URIC ACID	0.03-0.055 (G/L)	20/09/92	0.04		0.05		0.04	
TOT BILIRUBIN	3-10 (MG/L)	20/09/92	7.00		9.00		4.00	
TOT. PROTEINS	60-80 (G/L)	20/09/92	69.10		68.50		72.70	
ALBUMINE	32-50 (G/L)	20/09/92	58.00	>	59.50	>	59.00	>
TOT. CHOLEST.	1.3-2.2 (G/L)	20/09/92	2.22	>	2.22	>	2.51	>
TRIGLYCERIDES	0.5-1.5 (G/L)	20/09/92	0.60		0.73		0.44	<
GLOBULINS ALPHA 1	1-4 (G/L)	20/09/92	4.00		5.00	>	4.50	>
GLOBULINS ALPHA 2	5-11 (G/L)	20/09/92	8.50		8.00		7.50	
GLOBULINS BETA	6-15 (G/L)	20/09/92	13.50		13.00		13.50	
GLOBULINS GAMMA	7-15 (G/L)	20/09/92	16.00	>	14.50		15.50	>
TSH	0.3-5 (UUI/ML)	20/09/92	1.06					
T4	4.9-12.5 (UG/DL)	20/09/92	12.50					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 4/1 Patient: 150 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			23/09/92		15/10/92		10/11/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	20/09/92	15.00		15.40		15.60	
HT	35-47 (%)	20/09/92	44.70		46.40		46.50	
RBC	4-5.2 (10-6/MM3)	20/09/92	5.17		5.33	>	5.36	>
WBC	4000-9000 (/MM3)	20/09/92	6600.00		7100.00		7100.00	
WBC: N	1500-7000 (/MM3)	20/09/92	3630.00		3763.00			
	50-70 (%)	05/11/92					54.00	
WBC: L	800-4500 (/MM3)	20/09/92	1980.00		2272.00			
	20-45 (%)	05/11/92					31.00	
WBC: E	0-400 (/MM3)	20/09/92	396.00		426.00	>		
	1-4 (%)	05/11/92					7.00	>>
WBC: M	200-800 (/MM3)	20/09/92	528.00		639.00			
	3-8 (%)	05/11/92					8.00	
WBC: B	0-100 (/MM3)	20/09/92	66.00		0.00			
	0-1 (%)	05/11/92					0.00	
PLATELETS	150000-400000 (/MM3)	20/09/92	191000		200000			
NA+	135-145 (MEQ/L)	20/09/92	142.00		141.00		137.00	
K+	3.6-5.3 (MEQ/L)	20/09/92	4.40		4.60		4.40	
CL-	95-105 (MEQ/L)	20/09/92	102.00		101.00		98.00	
Ca++	90-105 (MG/L)	20/09/92	97.00		94.00		94.00	
PO4--	28-45 (MG/L)	20/09/92	34.00		33.00		32.00	
SGOT	6-25 (U/L)	20/09/92	21.00		16.00		12.00	
SGPT	7-28 (U/L)	20/09/92	29.00	>	18.00		14.00	
GAMMA GT	6-26 (U/L)	20/09/92	26.00		35.00	>	31.00	>
LDH	120-280 (U/L)	20/09/92	236.00		210.00		219.00	
ALK. PHOSPH.	30-90 (UI/L)	20/09/92	64.00		66.00		64.00	
GLUCOSE	0.75-1.05 (G/L)	20/09/92	1.13	>	1.02		1.18	>
UREA	0.19-0.42 (G/L)	20/09/92	0.42		0.42		0.40	
CREATININE	0.006-0.011 (G/L)	20/09/92	0.01	>	0.01		0.01	
URIC ACID	0.03-0.06 (G/L)	20/09/92	0.05		0.05		0.05	
TOT BILIRUBIN	2-10 (MG/L)	20/09/92	5.00		3.00		4.00	
TOT. PROTEINS	60-78 (G/L)	20/09/92	69.30		67.80		66.10	
ALBUMINE	57-61 (%)	20/09/92	60.00		60.50		61.00	
TOT. CHOLEST.	1.4-2 (G/L)	20/09/92	2.15	>	2.45	>	2.42	>
TRIGLYCERIDES	0.5-2 (G/L)	20/09/92	2.78	>>	4.75	>>	4.19	>>
GLOBULINS ALPHA 1	3-5.5 (%)	20/09/92	3.50		3.00		3.00	
GLOBULINS ALPHA 2	7-9.5 (%)	20/09/92	8.50		9.00		8.50	
GLOBULINS BETA	10-14 (%)	20/09/92	15.00	>	14.50	>	14.50	>
GLOBULINS GAMMA	14-17 (%)	20/09/92	13.00	<	13.00	<	13.00	<
TSH	0.15-3.5 (UU/ML)	20/09/92	1.40					
T4	7.8-19.4 (PG/ML)	20/09/92	9.80					

1738

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/2 Patient: 93/A Treatment: Placebo Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			23/02/91		18/03/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	125-160 (G/L)	01/02/91	149.00		143.00	
HT	0.37-0.54 (L/L)	01/02/91	0.45		0.44	
RBC	4-5.5 (10¬12/L)	01/02/91	5.13		4.89	
WBC	4-10 (10¬9/L)	01/02/91	8.30		7.00	
WBC: N	1500-7500 (/MM3)	01/02/91	4814.00		3920.00	
WBC: L	1000-4000 (/MM3)	01/02/91	2988.00		2660.00	
WBC: E	50-300 (/MM3)	01/02/91	166.00		140.00	
WBC: M	100-800 (/MM3)	01/02/91	332.00		280.00	
WBC: B	0-100 (/MM3)	01/02/91	0.00		0.00	
PLATELETS	150-400 (10¬9/L)	01/02/91	256.00		263.00	
NA+	137-147 (MMOL/L)	01/02/91	141.00		135.00	<
K+	3.5-5 (MMOL/L)	01/02/91	4.50		4.40	
CL-	98-107 (MMOL/L)	01/02/91	99.00		102.00	
Ca++	2.2-2.5 (MMOL/L)	01/02/91	2.40		2.41	
PO4--	0.8-1.6 (MMOL/L)	01/02/91	0.97		1.16	
SGOT	9-30 (UI/L)	01/02/91	15.00		20.00	
SGPT	8-42 (UI/L)	01/02/91	16.00		14.00	
GAMMA GT	8-33 (UI/L)	01/02/91	27.00		57.00	>
LDH	140-330 (UI/L)	01/02/91	130.00	<	182.00	
ALK. PHOSPH.	80-220 (UI/L)	01/02/91	110.00		96.00	
GLUCOSE	4.1-6.1 (MMOL/L)	01/02/91	5.05		4.94	
UREA	3-7.5 (MMOL/L)	01/02/91	5.66		5.66	
CREATININE	71-106 (UMOL/L)	01/02/91	106.08	>	106.08	>
URIC ACID	180-420 (UMOL/L)	01/02/91	417.00		506.00	>
TOT BILIRUBIN	5-17 (UMOL/L)	01/02/91	9.41		10.77	
TOT. PROTEINS	60-80 (G/L)	01/02/91	71.00		68.00	
ALBUMINE	50-65 (%)	01/02/91	51.80		49.50	<
TOT. CHOLEST.	3.6-7 (MMOL/L)	01/02/91	6.48		7.85	>
TRIGLYCERIDES	0.46-1.6 (MMOL/L)	01/02/91	2.83	>>	1.92	>
GLOBULINS ALPHA 1	2-6 (%)	01/02/91	2.80		2.40	
GLOBULINS ALPHA 2	6-10 (%)	01/02/91	12.30	>	10.50	>
GLOBULINS BETA	9-14 (%)	01/02/91	14.90	>	14.90	>
GLOBULINS GAMMA	14-22 (%)	01/02/91	18.30		22.70	>
TSH	0.25-5 (MU/L)	01/02/91	0.30			
T4	7.1-18.5 (NG/L)	01/02/91	15.00			

1739

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/2 Patient: 99/A Treatment: Placebo Sex: Male

			Visit number / Laboratory date			
			Day 21		Day 42	
			10/04/91		04/05/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
HB	12-16 (G/DL)	01/02/91	13.50		15.30	
HT	35-45 (%)	01/02/91	40.00		47.00	>
RBC	4-5 (10-6/UL)	01/02/91	4.63		5.17	>
WBC	4000-10000 (/UL)	01/02/91	5800.00		8500.00	
WBC: N	50-70 (%)	01/02/91	52.00		59.00	
WBC: L	20-40 (%)	01/02/91	42.00	>	37.00	
WBC: E	0-3 (%)	01/02/91	2.00		1.00	
WBC: M	2-8 (%)	01/02/91	4.00		3.00	
WBC: B	0-2 (%)	01/02/91	0.00		0.00	
PLATELETS	150000-400000 (/UL)	01/02/91	205000		230000	
NA+	138-146 (MEQ/L)	01/02/91	142.00		140.00	
K+	3.8-5 (MEQ/L)	01/02/91	3.80		4.00	
CL-	95-105 (MEQ/L)	01/02/91	101.00		99.00	
Ca++	88-102 (MG/L)	01/02/91	93.50			
PO4--	25-50 (MG/L)	01/02/91	26.00			
SGOT	5-27 (UI/L)	01/02/91	11.00			
SGPT	5-32 (UI/L)	01/02/91	8.00			
GAMMA GT	5-35 (UI/L)	01/02/91	7.00			
LDH	120-320 (UI/L)	01/02/91	196.00			
ALK. PHOSPH.	30-90 (UI/L)	01/02/91	28.00	<		
GLUCOSE	0.8-1.05 (G/L)	01/02/91	1.42	>>		
UREA	0.15-0.45 (G/L)	01/02/91	0.16			
CREATININE	6-13 (MG/L)	01/02/91	11.70			
URIC ACID	30-70 (MG/L)	01/02/91	56.00			
TOT. PROTEINS	65-78 (G/L)	01/02/91	69.00		77.00	
ALBUMINE	57-65 (%)	01/02/91	56.00	<	44.60	<
TOT. CHOLEST.	1.5-2.5 (G/L)	01/02/91	1.47	<		
TRIGLYCERIDES	0.4-1.6 (G/L)	01/02/91	1.95	>		
GLOBULINS ALPHA 1	2-4 (%)	01/02/91	3.20		4.10	>
GLOBULINS ALPHA 2	6-10 (%)	01/02/91	9.50		13.00	>
GLOBULINS BETA	8-12 (%)	01/02/91	13.20	>	16.20	>>
GLOBULINS GAMMA	12-19 (%)	01/02/91	18.10		22.10	>
TSH	0.25-5 (MU/L)	01/02/91	1.60			
T4	7.1-18.5 (NG/L)	01/02/91	13.50			

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 4/2 Patient: 104 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date	
			Day 21	
			04/06/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/02/91	14.20	
HT	35-45 (%)	01/02/91	45.00	
RBC	4-5 (10-6/UL)	01/02/91	4.89	
WBC	4000-10000 (/UL)	01/02/91	6100.00	
WBC: N	50-70 (%)	01/02/91	51.00	
WBC: L	20-40 (%)	01/02/91	44.00	>
WBC: E	0-3 (%)	01/02/91	0.00	
WBC: M	2-8 (%)	01/02/91	5.00	
WBC: B	0-2 (%)	01/02/91	0.00	
PLATELETS	150000-400000 (/UL)	01/02/91	240000	
NA+	138-146 (MEQ/L)	01/02/91	139.00	
K+	3.8-5 (MEQ/L)	01/02/91	4.20	
CL-	95-105 (MEQ/L)	01/02/91	98.00	
Ca++	88-102 (MG/L)	01/02/91	93.70	
PO4--	25-50 (MG/L)	01/02/91	39.00	
SGOT	5-27 (UI/L)	01/02/91	13.00	
SGPT	5-32 (UI/L)	01/02/91	6.00	
GAMMA GT	5-35 (UI/L)	01/02/91	10.00	
LDH	120-320 (UI/L)	01/02/91	287.00	
ALK. PHOSPH.	30-90 (UI/L)	01/02/91	51.00	
GLUCOSE	0.8-1.05 (G/L)	01/02/91	1.04	
UREA	0.15-0.45 (G/L)	01/02/91	0.30	
CREATININE	6-13 (MG/L)	01/02/91	11.00	
URIC ACID	30-70 (MG/L)	01/02/91	63.00	
TOT BILIRUBIN	1.5-10 (MG/L)	01/02/91	3.90	
TOT. PROTEINS	65-78 (G/L)	01/02/91	78.00	
ALBUMINE	57-65 (%)	01/02/91	50.90	<
TOT. CHOLEST.	1.5-2.5 (G/L)	01/02/91	2.42	
TRIGLYCERIDES	0.4-1.6 (G/L)	01/02/91	1.23	
GLOBULINS ALPHA 1	2-4 (%)	01/02/91	2.30	
GLOBULINS ALPHA 2	6-10 (%)	01/02/91	10.80	>
GLOBULINS BETA	8-12 (%)	01/02/91	12.10	>
GLOBULINS GAMMA	12-19 (%)	01/02/91	23.90	>
TSH	0.25-5 (MU/L)	01/02/91	0.72	
T4	7.1-18.5 (NG/L)	01/02/91	11.70	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 4/3 Patient: 97 Treatment: Placebo Sex: Male

			Visit number / Laboratory date			
			Screen		Day 42	
			11/04/91		28/05/91	
			value	(¢)	value	(¢)
Laboratory test	Range value	Range date				
HB	12-18 (G/DL)	01/03/91	15.20		16.00	
HT	35-54 (%)	01/03/91	44.44		45.40	
RBC	4-5.9 (10¬6/UL)	01/03/91	5.00		4.93	
WBC	4500-9999 (/UL)	01/03/91	13500.0	>>	10200.0	>
WBC: N	45-70 (%)	01/03/91	67.00		56.00	
WBC: L	20-40 (%)	01/03/91	26.00		33.00	
WBC: E	1-4 (%)	01/03/91	3.00		1.00	
WBC: M	3-10 (%)	01/03/91	4.00		10.00	
WBC: B	0-1 (%)	01/03/91	0.00		0.00	
PLATELETS	200-400 (10¬3/UL)	01/03/91	280.00		299.00	
NA+	138-145 (MMOL/L)	01/03/91	139.00		138.00	
K+	3.9-4.8 (MMOL/L)	01/03/91	4.50		4.00	
CL-	98-107 (MMOL/L)	01/03/91	103.00		98.00	
Ca++	88-104 (MG/L)	01/03/91	100.10		101.40	
PO4--	25-45 (MG/L)	01/03/91	36.60		38.60	
SGOT	2-38 (UI/L)	01/03/91	11.00		12.00	
SGPT	5-41 (UI/L)	01/03/91	23.00		15.00	
GAMMA GT	6-28 (UI/L)	01/03/91	14.00		11.00	
LDH	140-330 (UI/L)	01/03/91	200.00		262.00	
ALK. PHOSPH.	30-90 (UI/L)	01/03/91	51.00		41.00	
GLUCOSE	0.7-1.1 (G/L)	01/03/91	1.10		1.05	
UREA	0.2-0.45 (G/L)	01/03/91	0.29		0.29	
CREATININE	6-12 (MG/L)	01/03/91	9.60		12.00	
URIC ACID	25-65 (MG/L)	01/03/91	53.80		59.00	
TOT BILIRUBIN	1.5-10 (MG/L)	01/03/91	6.10		5.60	
TOT. PROTEINS	60-80 (G/L)	01/03/91	66.00		64.00	
ALBUMINE	55-65 (%)	01/03/91	68.80	>	63.90	
TOT. CHOLEST.	1.4-2 (G/L)	01/03/91	2.79	>>	2.60	>
TRIGLYCERIDES	0.4-1.6 (G/L)	01/03/91	1.63	>	1.13	
GLOBULINS ALPHA 1	1-4 (%)	01/03/91	3.20		3.00	
GLOBULINS ALPHA 2	5-10 (%)	01/03/91	9.80		13.40	>>
GLOBULINS BETA	8-13 (%)	01/03/91	9.70		11.20	
GLOBULINS GAMMA	12-20 (%)	01/03/91	8.50	<	8.50	<
TSH	0.2-2.9 (UUI/ML)	01/03/91	1.26			
T4	10-28 (PMOL/L)	01/03/91	15.30			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 4/3 Patient: 98 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 35	
			17/06/91		13/07/91		02/08/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	12-16 (G/DL)	01/06/91	14.80		14.80		15.40	
HT	37-47 (%)	01/06/91	46.40		46.40		44.70	
RBC	4.1-5.3 (10-6/UL)	01/06/91	5.01		5.01		5.33	>
WBC	4000-10000 (/UL)	01/06/91	5300.00		5300.00		5900.00	
WBC: N	60-70 (%)	01/06/91	53.00	<	53.00	<	63.00	
WBC: L	25-50 (%)	01/06/91	43.00		43.00		34.00	
WBC: E	0-3 (%)	01/06/91	1.00		1.00		0.00	
WBC: M	0-10 (%)	01/06/91	3.00		3.00		3.00	
WBC: B	0-3 (%)	01/06/91	0.00		0.00		0.00	
PLATELETS	200000-500000 (/UL)	01/06/91	242000				278000	
NA+	130-145 (MEQ/L)	01/06/91	140.00		142.00		143.00	
K+	3.6-4.8 (MEQ/L)	01/06/91	4.80		4.60		4.80	
CL-	95-110 (MEQ/L)	01/06/91	100.00		103.00		101.00	
Ca++	85-105 (MG/L)	01/06/91	91.00		96.00		95.00	
PO4--	25-50 (MG/L)	01/06/91	46.00		35.00		40.00	
SGOT	5-30 (UI/L)	01/06/91	36.00	>	17.00		19.00	
SGPT	7-32 (UI/L)	01/06/91	33.00	>	18.00		15.00	
GAMMA GT	7-32 (UI/L)	01/06/91			18.00		12.00	
LDH	190-380 (UI/L)	01/06/91	284.00		249.00		261.00	
ALK. PHOSPH.	30-125 (UI/L)	01/06/91			60.00		56.00	
GLUCOSE	0.75-1.1 (G/L)	01/06/91	0.86		0.94		0.90	
UREA	0.1-0.5 (G/L)	01/06/91	0.39		0.22		0.25	
CREATININE	5-12 (MG/L)	01/06/91	11.00		11.00		12.00	
URIC ACID	25-60 (MG/L)	01/06/91	35.00		38.00		42.00	
TOT BILIRUBIN	2-12 (MG/L)	01/06/91	3.00		3.00		3.00	
DIR BILIRUBIN	0-3 (MG/L)	01/06/91	2.00		2.00		2.00	
TOT. PROTEINS	65-80 (G/L)	01/06/91	76.00		67.00		60.00	<
ALBUMINE	37-42 (G/L)	01/06/91	44.00	>	39.40		34.00	<
TOT. CHOLEST.	1.5-2.4 (G/L)	01/06/91	2.27		2.00		1.98	
TRIGLYCERIDES	0.5-1.5 (G/L)	01/06/91	0.69		0.65		0.64	
GLOBULINS ALPHA 1	1-3 (G/L)	01/06/91	2.30		2.00		2.10	
GLOBULINS ALPHA 2	1-3 (G/L)	01/06/91	7.40	>>	6.40	>>	5.90	>>
GLOBULINS BETA	5-8 (G/L)	01/06/91	10.90	>>	9.20	>	8.80	>
GLOBULINS GAMMA	8-12 (G/L)	01/06/91	11.40		10.00		9.20	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 4/3 Patient: 99 Treatment: Placebo Sex: Female

			Visit number / Laboratory date	
			Screen	
			07/08/91	
Laboratory test	Range value	Range date	value	(◊)
HB	12-17 (G/DL)	01/08/91	12.70	
HT	35-54 (%)	01/08/91	35.90	
RBC	4000000-5500000 (/UL)	01/08/91	4050000	
WBC	4000-9000 (/UL)	01/08/91	7300.00	
WBC: N	60-70 (%)	01/08/91	58.00	<
WBC: L	25-50 (%)	01/08/91	33.00	
WBC: E	0-3 (%)	01/08/91	3.00	
WBC: M	0-10 (%)	01/08/91	6.00	
WBC: B	0-3 (%)	01/08/91	0.00	
PLATELETS	200000-400000 (/UL)	01/08/91	355000	
NA+	137-146 (MMOL/L)	01/08/91	140.00	
K+	3.8-5.2 (MMOL/L)	01/08/91	3.90	
CL-	95-106 (MMOL/L)	01/08/91	102.00	
Ca++	85-101 (MG/L)	01/08/91	99.00	
PO4--	25-42 (MG/L)	01/08/91	37.00	
SGOT	0-25 (UI/L)	01/08/91	10.00	
SGPT	0-29 (UI/L)	01/08/91	7.00	
GAMMA GT	7-34 (UI/L)	01/08/91	11.00	
LDH	140-280 (UI/L)	01/08/91	181.00	
ALK. PHOSPH.	30-100 (UI/L)	01/08/91	80.00	
GLUCOSE	0.7-1.1 (G/L)	01/08/91	0.92	
UREA	0.15-0.5 (G/L)	01/08/91	0.35	
CREATININE	5-12 (MG/L)	01/08/91	7.00	
URIC ACID	24-57 (MG/L)	01/08/91	22.00	<
TOT BILIRUBIN	1.5-10 (MG/L)	01/08/91	4.60	
TOT. PROTEINS	65-87 (G/L)	01/08/91	65.00	
ALBUMINE	57-65 (%)	01/08/91	64.40	
TOT. CHOLEST.	1.2-2 (G/L)	01/08/91	2.19	>
TRIGLYCERIDES	0.4-1.5 (G/L)	01/08/91	0.81	
GLOBULINS ALPHA 1	2-4 (%)	01/08/91	3.00	
GLOBULINS ALPHA 2	6-10 (%)	01/08/91	7.70	
GLOBULINS BETA	8-12 (%)	01/08/91	11.40	
GLOBULINS GAMMA	12-19 (%)	01/08/91	13.50	
TSH	0.3-5 (UUI/ML)	01/08/91	3.10	
T4	6.8-17.6 (PG/ML)	01/08/91	12.77	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 4/3 Patient: 100 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			22/11/91		08/01/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/100ML)	20/11/91	14.00		13.50	
HT	37-47 (%)	20/11/91	41.70		40.90	
RBC	4.1-5.3 (10¬6/MM3)	20/11/91	4.59		4.51	
WBC	4000-10000 (/MM3)	20/11/91	6300.00		5900.00	
WBC: N	45-74 (%)	20/11/91	44.00	<	47.00	
WBC: L	16-45 (%)	20/11/91	46.00	>	42.00	
WBC: E	0-7 (%)	20/11/91	5.00		6.00	
WBC: M	4-10 (%)	20/11/91	5.00		5.00	
WBC: B	0-2 (%)	20/11/91	0.00		0.00	
PLATELETS	200-500 (10¬3/MM3)	20/11/91	280.00		263.00	
NA+	135-145 (MEQ/L)	20/11/91	138.00		139.00	
K+	3.7-5.2 (MEQ/L)	20/11/91	3.40	<	3.80	
CL-	100-107 (MEQ/L)	20/11/91	101.00		101.00	
Ca++	90-105 (MG/L)	20/11/91	92.00		94.00	
PO4--	25-45 (MG/L)	20/11/91	33.00		38.00	
SGOT	2-25 (UI/L)	20/11/91	17.00		14.00	
SGPT	5-35 (UI/L)	20/11/91	10.00		9.00	
GAMMA GT	7-35 (UI/L)	20/11/91	8.00		9.00	
LDH	190-380 (UI/L)	20/11/91	341.00		332.00	
ALK. PHOSPH.	30-100 (UI/L)	20/11/91	65.00		50.00	
GLUCOSE	0.7-1.1 (G/L)	20/11/91	0.84		0.99	
UREA	0.2-0.45 (G/L)	20/11/91	0.27		0.25	
CREATININE	5-12 (MG/L)	20/11/91	8.90		6.30	
URIC ACID	30-70 (MG/L)	20/11/91	39.00		43.00	
TOT BILIRUBIN	1.5-10 (MG/L)	20/11/91	7.30		3.10	
TOT. PROTEINS	60-80 (G/L)	20/11/91	70.00		72.00	
ALBUMINE	37-42 (G/L)	20/11/91	38.90		37.80	
TOT. CHOLEST.	1.5-2.5 (G/L)	20/11/91	2.49		2.93	>
TRIGLYCERIDES	0.4-1.5 (G/L)	20/11/91			0.57	
GLOBULINS ALPHA 1	1-3 (G/L)	20/11/91	2.50		1.50	
GLOBULINS ALPHA 2	4-7 (G/L)	20/11/91	7.20	>	6.40	
GLOBULINS BETA	5-8 (G/L)	20/11/91	8.50	>	10.50	>>
GLOBULINS GAMMA	8-12 (G/L)	20/11/91	12.70	>	15.60	>
TSH	0.2-4 (UUI/ML)	20/11/91	0.94			
T4	7-17 (PG/ML)	20/11/91	12.50			

1745

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang-
< out of range (value lower than min range) > out of range (value higher than max rang-
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/3 Patient: 101 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 42	
			16/03/92		27/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/DL)	15/03/91	15.30		14.40	
HT	37-47 (%)	15/03/91	44.60		41.40	
RBC	4.1-5.3 (10-6/UL)	15/03/91	4.73		4.51	
WBC	4000-10000 (/UL)	15/03/91	5300.00		4700.00	
WBC: N	60-70 (%)	15/03/91	51.00	<	54.00	<
WBC: L	25-50 (%)	15/03/91	41.00		38.00	
WBC: E	0-3 (%)	15/03/91	1.00		0.00	
WBC: M	0-10 (%)	15/03/91	6.00		7.00	
WBC: B	0-3 (%)	15/03/91	1.00		1.00	
PLATELETS	200-500 (10-3/MM3)	15/03/91	232.00		221.00	
NA+	130-145 (MEQ/L)	15/03/91	141.00		138.00	
K+	3.6-4.8 (MEQ/L)	15/03/91	4.00		3.90	
CL-	95-110 (MEQ/L)	15/03/91	101.00		100.00	
Ca++	85-105 (MG/L)	15/03/91	92.00		90.00	
PO4--	25-50 (MG/L)	15/03/91	31.00		33.00	
SGOT	5-30 (UI/L)	15/03/91	29.00		62.00	>>
SGPT	7-32 (UI/L)	15/03/91	37.00	>	73.00	>>
GAMMA GT	7-35 (UI/ML)	15/03/91	59.00	>	63.00	>
LDH	190-380 (UI/L)	15/03/91	297.00		346.00	
ALK. PHOSPH.	30-100 (UI/L)	15/03/91	76.00		97.00	
GLUCOSE	0.75-1.1 (G/L)	15/03/91	1.11	>	1.05	
UREA	0.1-0.5 (G/L)	15/03/91	0.37		0.36	
CREATININE	5-12 (MG/L)	15/03/91	10.00		8.60	
URIC ACID	25-60 (MG/L)	15/03/91	60.00		57.00	
TOT BILIRUBIN	2-12 (MG/L)	15/03/91	14.20	>	12.80	>
TOT. PROTEINS	65-80 (G/L)	15/03/91	68.00		68.00	
ALBUMINE	37-42 (G/L)	15/03/91	39.90		42.70	>
TOT. CHOLEST.	1.5-2.4 (G/L)	15/03/91	1.81		1.84	
TRIGLYCERIDES	0.5-1.5 (G/L)	15/03/91	0.79		0.65	
GLOBULINS ALPHA 1	1-3 (G/L)	15/03/91	2.20		2.30	
GLOBULINS ALPHA 2	4-7 (G/L)	15/03/91	4.80		4.10	
GLOBULINS BETA	5-8 (G/L)	15/03/91	9.70	>	8.50	>
GLOBULINS GAMMA	8-12 (G/L)	15/03/91	11.20		10.10	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/4 Patient: 109 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/06/91		27/06/91		20/08/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-17 (G/DL)	01/05/91	13.50		13.30		14.00	
HT	36-52 (%)	01/05/91	40.70		40.10		41.30	
RBC	4.5-5.5 (10¬12/L)	01/05/91	4.17	<	4.15	<	4.19	<
WBC	4-10 (10¬9/L)	01/05/91	6.10		6.00		8.00	
WBC: N	2-7.5 (10¬9/L)	01/05/91	2.98		3.36		4.96	
WBC: L	1.5-4 (10¬9/L)	01/05/91	2.56		2.16		2.48	
WBC: E	0.04-0.5 (10¬9/L)	01/05/91	0.24		0.18		0.16	
WBC: M	0.2-1 (10¬9/L)	01/05/91	0.30		0.36		0.32	
WBC: B	0.04-0.5 (10¬9/L)	01/05/91	0.00	<	0.00	<	0.08	
PLATELETS	200-400 (10¬9/L)	01/05/91	225.00		204.00		185.00	<
NA+	136-144 (MMOL/L)	01/05/91	141.00		141.00		142.00	
K+	3.6-5 (MMOL/L)	01/05/91	4.60		4.40		4.00	
CL-	95-105 (MMOL/L)	01/05/91	106.00	>	108.00	>	109.00	>
Ca++	2.15-2.6 (MMOL/L)	01/05/91	2.51		2.43		2.37	
PO4--	0.8-1.4 (MMOL/L)	01/05/91			1.42	>	1.11	
SGOT	5-25 (U/L)	01/05/91	11.00		12.00		10.00	
SGPT	5-35 (U/L)	01/05/91	11.00		11.00		12.00	
GAMMA GT	5-25 (U/L)	01/05/91	9.00		8.00		10.00	
LDH	120-320 (U/L)	01/05/91	241.00		224.00		192.00	
ALK. PHOSPH.	35-85 (U/L)	01/05/91	44.00		40.00		42.00	
GLUCOSE	3.9-5.8 (MMOL/L)	01/05/91	5.80		4.80		4.70	
UREA	2.8-7.4 (MMOL/L)	01/05/91	4.60		5.20		4.10	
CREATININE	55-100 (UMOL/L)	01/05/91	81.00		69.00		75.00	
URIC ACID	180-360 (UMOL/L)	01/05/91	242.00		255.00		256.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	6.00		3.00		3.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/05/91			1.00			
TOT. PROTEINS	63-80 (G/L)	01/05/91	70.00		67.00		68.00	
ALBUMINE	38-50 (G/L)	01/05/91	44.70		43.60		44.50	
TOT. CHOLEST.	4-7 (MMOL/L)	01/05/91	4.61		4.84		5.06	
TRIGLYCERIDES	0.5-1.6 (MMOL/L)	01/05/91	0.58		0.53		0.66	
GLOBULINS ALPHA 1	1-4 (G/L)	01/05/91	2.90		2.00		2.00	
GLOBULINS ALPHA 2	4-9 (G/L)	01/05/91	6.00		5.60		5.40	
GLOBULINS BETA	6-12 (G/L)	01/05/91	7.30		7.20		7.10	
GLOBULINS GAMMA	7-15 (G/L)	01/05/91	9.00		8.60		8.90	
TSH	0.3-5 (UU/ML)	01/05/91	3.86					
T4	9.2-22.7 (PMOL/ML)	01/05/91	16.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/4 Patient: 110 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			11/06/91		04/07/91		26/07/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	11.5-17 (G/DL)	01/05/91	13.30		14.00		14.90	
HT	36-52 (%)	01/05/91	39.60		41.60		43.60	
RBC	4-5.8 (10¬12/L)	01/05/91	4.51		4.71		4.99	
WBC	4-10 (10¬9/L)	01/05/91	5.20		4.40		4.70	
WBC: N	2-7.5 (10¬9/L)	01/05/91	2.54		2.28		2.06	
WBC: L	1.5-4 (10¬9/L)	01/05/91	2.08		1.67		2.11	
WBC: E	0.04-0.5 (10¬9/L)	01/05/91	0.15		0.13		0.14	
WBC: M	0.2-1 (10¬9/L)	01/05/91	0.36		0.26		0.32	
WBC: B	0.01-0.1 (10¬9/L)	01/05/91	0.05		0.04		0.04	
PLATELETS	200-400 (10¬9/L)	01/05/91	244.00		295.00		332.00	
NA+	136-144 (MMOL/L)	01/05/91	142.00		140.00		142.00	
K+	3.6-5 (MMOL/L)	01/05/91	4.40		3.90		4.20	
CL-	95-105 (MMOL/L)	01/05/91	100.00		99.00		99.00	
Ca++	2.15-2.6 (MMOL/L)	01/05/91	2.54		2.46		2.52	
PO4--	0.8-1.4 (MMOL/L)	01/05/91			1.05		1.32	
SGOT	5-25 (U/L)	01/05/91	17.00		14.00		32.00	>
SGPT	5-35 (U/L)	01/05/91	26.00		28.00		62.00	>
GAMMA GT	5-25 (U/L)	01/05/91	85.00	>>	87.00	>>	195.00	>>
LDH	120-320 (U/L)	01/05/91	186.00		172.00		231.00	
ALK. PHOSPH.	50-200 (U/L)	01/05/91	87.00		73.00		74.00	
GLUCOSE	3.9-5.8 (MMOL/L)	01/05/91	5.30		5.20		4.90	
UREA	3.2-7.7 (MMOL/L)	01/05/91	4.40		3.10	<	5.10	
CREATININE	63-112 (UMOL/L)	01/05/91	68.00		64.00		68.00	
URIC ACID	240-420 (UMOL/L)	01/05/91	330.00		472.00	>	551.00	>>
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	5.00		4.00		4.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/05/91	2.00				1.00	
TOT. PROTEINS	63-80 (G/L)	01/05/91	63.00		63.00		66.00	
ALBUMINE	38-50 (G/L)	01/05/91	37.40	<	38.80		41.20	
TOT. CHOLEST.	3.5-5.2 (MMOL/L)	01/05/91	7.04	>>			9.01	>>
TRIGLYCERIDES	0.5-1.6 (MMOL/L)	01/05/91	2.77	>>			2.31	>>
GLOBULINS ALPHA 1	1-4 (G/L)	01/05/91	2.70		2.40		2.50	
GLOBULINS ALPHA 2	4-9 (G/L)	01/05/91	6.60		5.40		5.20	
GLOBULINS BETA	6-12 (G/L)	01/05/91	8.90		9.10		4.80	<
GLOBULINS GAMMA	7-15 (G/L)	01/05/91	7.40		7.40		7.50	
TSH	0.3-5 (UU/ML)	01/05/91	1.29					
T4	9.2-22.7 (PMOL/ML)	01/05/91	10.90					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 4/4 Patient: 111 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			24/06/91		24/07/91		14/08/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-17 (G/DL)	01/05/91	16.10		15.00		15.10	
HT	36-52 (%)	01/05/91	48.70		45.00		44.90	
RBC	4-5.8 (10¬12/L)	01/05/91	5.65		5.19		5.16	
WBC	4-10 (10¬9/L)	01/05/91	9.60		8.80		8.20	
WBC: N	2-7.5 (10¬9/L)	01/05/91	7.00		5.89		5.33	
WBC: L	1.5-4 (10¬9/L)	01/05/91	1.92		2.20		2.21	
WBC: E	0.04-0.5 (10¬9/L)	01/05/91	0.19		0.25		0.24	
WBC: M	0.2-1 (10¬9/L)	01/05/91	0.38		0.35		0.32	
WBC: B	0.01-0.1 (10¬9/L)	01/05/91	0.09		0.08		0.08	
PLATELETS	200-400 (10¬9/L)	01/05/91	311.00		307.00		291.00	
NA+	136-144 (MMOL/L)	01/05/91	141.00		141.00		144.00	
K+	3.6-5 (MMOL/L)	01/05/91	4.00		4.40		4.40	
CL-	95-105 (MMOL/L)	01/05/91	102.00		101.00		105.00	
Ca++	2.15-2.6 (MMOL/L)	01/05/91	2.53		2.49		2.51	
PO4--	0.8-1.4 (MMOL/L)	01/05/91	1.25		1.18		1.09	
SGOT	5-25 (U/L)	01/05/91	12.00		7.00		10.00	
SGPT	5-35 (U/L)	01/05/91	12.00		7.00		8.00	
GAMMA GT	5-25 (U/L)	01/05/91	16.00		12.00		11.00	
LDH	120-320 (U/L)	01/05/91	197.00		144.00		151.00	
ALK. PHOSPH.	50-200 (U/L)	01/05/91	63.00		51.00		49.00	<
GLUCOSE	3.9-5.8 (MMOL/L)	01/05/91	4.30		5.30		4.80	
UREA	3.2-7.7 (MMOL/L)	01/05/91	4.80		6.80		7.80	>
CREATININE	63-112 (UMOL/L)	01/05/91	77.00		83.00		84.00	
URIC ACID	240-420 (UMOL/L)	01/05/91	302.00		285.00		290.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	14.00		10.00		8.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/05/91			2.00			
TOT. PROTEINS	63-80 (G/L)	01/05/91	78.00		67.00		69.00	
ALBUMINE	38-50 (G/L)	01/05/91	52.40	>	44.20		44.00	
TOT. CHOLEST.	3.5-5.2 (MMOL/L)	01/05/91	8.65	>>	7.78	>>	8.15	>>
TRIGLYCERIDES	0.5-1.6 (MMOL/L)	01/05/91	1.46		1.25		0.53	
GLOBULINS ALPHA 1	1-4 (G/L)	01/05/91	1.70		1.60		1.70	
GLOBULINS ALPHA 2	4-9 (G/L)	01/05/91	6.40		5.20		6.10	
GLOBULINS BETA	6-12 (G/L)	01/05/91	8.70		4.40	<	9.70	
GLOBULINS GAMMA	7-15 (G/L)	01/05/91	8.70		7.60		7.70	
TSH	0.3-5 (UU/ML)	01/05/91	1.11					
T4	9.2-22.7 (PMOL/ML)	01/05/91	13.20					

1749

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 4/4 Patient: 112 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/07/91		31/07/91		20/08/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-17 (G/DL)	01/05/91	14.40		15.60		15.20	
HT	36-52 (%)	01/05/91	42.60		46.90		45.40	
RBC	4-5.8 (10¬12/L)	01/05/91	4.73		5.20		5.13	
WBC	4-10 (10¬9/L)	01/05/91	6.20		6.40		5.70	
WBC: N	2-7.5 (10¬9/L)	01/05/91	2.66		3.71		3.07	
WBC: L	1.5-4 (10¬9/L)	01/05/91	2.85		2.17		2.10	
WBC: E	0.04-0.5 (10¬9/L)	01/05/91	0.24		0.19		0.17	
WBC: M	0.2-1 (10¬9/L)	01/05/91	0.37		0.32		0.28	
WBC: B	0.01-0.1 (10¬9/L)	01/05/91	0.06		0.00	<	0.05	
PLATELETS	200-400 (10¬9/L)	01/05/91	395.00		386.00		358.00	
NA+	136-144 (MMOL/L)	01/05/91	142.00		142.00		143.00	
K+	3.6-5 (MMOL/L)	01/05/91	4.00		3.60		3.70	
CL-	95-105 (MMOL/L)	01/05/91	103.00		107.00	>	104.00	
Ca++	2.15-2.6 (MMOL/L)	01/05/91	2.47		2.51		2.56	
PO4--	0.8-1.4 (MMOL/L)	01/05/91	1.83	>>	1.05		1.28	
SGOT	5-25 (U/L)	01/05/91	14.00		10.00		12.00	
SGPT	5-35 (U/L)	01/05/91	24.00		20.00		17.00	
GAMMA GT	5-25 (U/L)	01/05/91	16.00		14.00		11.00	
LDH	120-320 (U/L)	01/05/91			153.00		161.00	
ALK. PHOSPH.	50-200 (U/L)	01/05/91	49.00	<	58.00		59.00	
GLUCOSE	3.9-5.8 (MMOL/L)	01/05/91	5.10		5.00		4.60	
UREA	3.2-7.7 (MMOL/L)	01/05/91	3.70		4.50		3.40	
CREATININE	63-112 (UMOL/L)	01/05/91	67.00		85.00		89.00	
URIC ACID	240-420 (UMOL/L)	01/05/91	300.00		358.00		350.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	9.00		12.00		6.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/05/91	1.00					
TOT. PROTEINS	63-80 (G/L)	01/05/91	73.00		77.00		83.00	>
ALBUMINE	38-50 (G/L)	01/05/91	46.90		48.90		51.10	>
TOT. CHOLEST.	3.5-5.2 (MMOL/L)	01/05/91	5.76	>	5.71	>	6.17	>
TRIGLYCERIDES	0.5-1.6 (MMOL/L)	01/05/91	0.96		1.03		1.22	
GLOBULINS ALPHA 1	1-4 (G/L)	01/05/91	2.00		1.90		2.20	
GLOBULINS ALPHA 2	4-9 (G/L)	01/05/91	5.00		5.20		5.70	
GLOBULINS BETA	6-12 (G/L)	01/05/91	4.70	<	8.90		9.10	
GLOBULINS GAMMA	7-15 (G/L)	01/05/91	10.30		12.20		10.90	
TSH	0.3-5 (UU/ML)	01/05/91	1.20					
T4	9.2-22.7 (PMOL/ML)	01/05/91	18.50					

1750

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/4 Patient: 113 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			26/08/91		23/09/91		11/10/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-17 (G/DL)	01/05/91	14.00		13.50		13.80	
HT	36-52 (%)	01/05/91	40.80		39.20		39.40	
RBC	4-5.8 (10~12/L)	01/05/91	4.71		4.53		4.56	
WBC	4-10 (10~9/L)	01/05/91	8.20		6.60		7.50	
WBC: N	2-7.5 (10~9/L)	01/05/91	4.67		3.89		4.42	
WBC: L	1.5-4 (10~9/L)	01/05/91	2.54		1.84		2.17	
WBC: E	0.04-0.5 (10~9/L)	01/05/91	0.41		0.33		0.45	
WBC: M	0.2-1 (10~9/L)	01/05/91	0.49		0.46		0.37	
WBC: B	0.01-0.1 (10~9/L)	01/05/91	0.08		0.06		0.07	
PLATELETS	200-400 (10~9/L)	01/05/91	253.00		265.00		242.00	
NA+	136-144 (MMOL/L)	01/05/91	142.00		140.00		142.00	
K+	3.6-5 (MMOL/L)	01/05/91	4.10		3.50	<	4.00	
CL-	95-105 (MMOL/L)	01/05/91	105.00		102.00		102.00	
Ca++	2.15-2.6 (MMOL/L)	01/05/91	2.46		2.52		2.47	
PO4--	0.8-1.4 (MMOL/L)	01/05/91	1.37		1.36		1.41	>
SGOT	5-25 (U/L)	01/05/91	10.00		12.00		9.00	
SGPT	5-35 (U/L)	01/05/91	19.00		18.00		17.00	
GAMMA GT	5-25 (U/L)	01/05/91	11.00		12.00		11.00	
LDH	120-320 (U/L)	01/05/91	135.00		157.00		134.00	
ALK. PHOSPH.	50-200 (U/L)	01/05/91	44.00	<	46.00	<	45.00	<
GLUCOSE	3.9-5.8 (MMOL/L)	01/05/91	5.60		5.40		5.50	
UREA	3.2-7.7 (MMOL/L)	01/05/91	4.30		4.40		4.10	
CREATININE	63-112 (UMOL/L)	01/05/91	84.00		81.00		87.00	
URIC ACID	240-420 (UMOL/L)	01/05/91	312.00		509.00	>	447.00	>
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	11.00		16.00			
TOT. PROTEINS	63-80 (G/L)	01/05/91	66.00		64.00		66.00	
ALBUMINE	38-50 (G/L)	01/05/91	43.50		44.50		46.50	
TOT. CHOLEST.	3.5-5.2 (MMOL/L)	01/05/91	3.12	<	3.37	<	3.60	
TRIGLYCERIDES	0.5-1.6 (MMOL/L)	01/05/91	0.69		0.51		0.45	<
GLOBULINS ALPHA 1	1-4 (G/L)	01/05/91	2.20		1.80		1.70	
GLOBULINS ALPHA 2	4-9 (G/L)	01/05/91	5.10		3.90	<	3.80	<
GLOBULINS BETA	6-12 (G/L)	01/05/91	6.70		6.10		5.70	<
GLOBULINS GAMMA	7-15 (G/L)	01/05/91	8.50		7.80		8.40	
TSH	0.3-5 (UU/ML)	01/05/91	1.45					
T4	9.2-22.7 (PMOL/ML)	01/05/91	18.60					

1751

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/4 Patient: 114 Treatment: Placebo Sex: Female

			Visit number / Laboratory date							
			Screen		Day 0		Day 21		Day 42	
			07/11/91		07/11/91		10/12/91		31/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)	value	(¢)
HB	11.5-17 (G/DL)	01/05/91	13.50		13.10		13.00		13.30	
HT	36-52 (%)	01/05/91	39.10		39.00		37.50		38.20	
RBC	4.5-5.5 (10¬12/L)	01/05/91	4.41	<	4.40	<	4.26	<	4.35	<
WBC	4-10 (10¬9/L)	01/05/91	3.10	<	4.58		3.80	<	2.90	<
WBC: N	2-7.5 (10¬9/L)	01/05/91	1.05	<<	1.79	<	1.52	<	1.10	<<
WBC: L	1.5-4 (10¬9/L)	01/05/91	1.64		2.34		1.78		1.30	<
WBC: E	0.04-0.5 (10¬9/L)	01/05/91	0.18		0.14		0.22		0.23	
WBC: M	0.2-1 (10¬9/L)	01/05/91	0.18	<	0.27		0.22		0.23	
WBC: B	0.04-0.5 (10¬9/L)	01/05/91	0.03	<	0.05		0.03	<	0.02	<
PLATELETS	200-400 (10¬9/L)	01/05/91	241.00				232.00		247.00	
NA+	136-144 (MMOL/L)	01/05/91	141.00				141.00		140.00	
K+	3.6-5 (MMOL/L)	01/05/91	3.80				3.50	<	3.40	<
CL-	95-105 (MMOL/L)	01/05/91	102.00				102.00		102.00	
Ca++	2.15-2.6 (MMOL/L)	01/05/91	2.39				2.38		2.34	
PO4--	0.8-1.4 (MMOL/L)	01/05/91	0.90				0.91		0.84	
SGOT	5-25 (U/L)	01/05/91	12.00				11.00		11.00	
SGPT	5-35 (U/L)	01/05/91	11.00				14.00		13.00	
GAMMA GT	5-25 (U/L)	01/05/91	16.00				14.00		13.00	
LDH	120-320 (U/L)	01/05/91	202.00				190.00		200.00	
ALK. PHOSPH.	35-85 (U/L)	01/05/91	62.00				59.00		60.00	
GLUCOSE	3.9-5.8 (MMOL/L)	01/05/91	6.50	>			5.80		5.40	
UREA	2.8-7.4 (MMOL/L)	01/05/91	3.50				4.20		3.50	
CREATININE	55-100 (UMOL/L)	01/05/91	65.00				68.00		62.00	
URIC ACID	180-360 (UMOL/L)	01/05/91	176.00	<			189.00		189.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	9.00				8.00		7.00	
TOT. PROTEINS	63-80 (G/L)	01/05/91	75.00				72.00		73.00	
ALBUMINE	38-50 (G/L)	01/05/91	45.60				37.90	<		
TOT. CHOLEST.	4-7 (MMOL/L)	01/05/91	7.21	>			5.70		5.55	
TRIGLYCERIDES	0.5-1.6 (MMOL/L)	01/05/91	0.87				1.02		0.73	
GLOBULINS ALPHA 1	1-4 (G/L)	01/05/91	2.10				2.60		2.30	
GLOBULINS ALPHA 2	4-9 (G/L)	01/05/91	5.30				5.00		5.00	
GLOBULINS BETA	6-12 (G/L)	01/05/91	8.30				8.40		8.30	
GLOBULINS GAMMA	7-15 (G/L)	01/05/91	13.80				14.70		13.80	
TSH	0.3-5 (UU/ML)	01/05/91	0.95							
T4	9.2-22.7 (PMOL/ML)	01/05/91	12.60							

1752

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/4 Patient: 175 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/02/92		04/03/92		25/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-17 (G/DL)	01/05/91	11.90		12.30		11.80	
HT	36-52 (%)	01/05/91	34.70	<	36.80		36.10	
RBC	4.5-5.5 (10¬12/L)	01/05/91	3.97	<	4.19	<	4.07	<
WBC	4-10 (10¬9/L)	01/05/91	7.90		8.00		6.10	
WBC: N	2-7.5 (10¬9/L)	01/05/91	4.66		5.28		3.60	
WBC: L	1.5-4 (10¬9/L)	01/05/91	2.60		2.08		1.83	
WBC: E	0.04-0.5 (10¬9/L)	01/05/91	0.15		0.24		0.24	
WBC: M	0.2-1 (10¬9/L)	01/05/91	0.39		0.32		0.31	
WBC: B	0.04-0.5 (10¬9/L)	01/05/91	0.07		0.08		0.12	
PLATELETS	200-400 (10¬9/L)	01/05/91	280.00		286.00		243.00	
NA+	136-144 (MMOL/L)	01/05/91	142.00		140.00		140.00	
K+	3.6-5 (MMOL/L)	01/05/91	3.80		4.00		3.90	
CL-	95-105 (MMOL/L)	01/05/91	101.00		99.00		98.00	
Ca++	2.15-2.6 (MMOL/L)	01/05/91	2.47		2.42		2.42	
PO4--	0.8-1.4 (MMOL/L)	01/05/91	1.39		1.35		1.21	
SGOT	5-25 (U/L)	01/05/91	7.00		11.00		14.00	
SGPT	5-35 (U/L)	01/05/91	9.00		15.00		19.00	
GAMMA GT	5-25 (U/L)	01/05/91	19.00		15.00		13.00	
LDH	120-320 (U/L)	01/05/91	218.00				214.00	
ALK. PHOSPH.	35-85 (U/L)	01/05/91	61.00		62.00		72.00	
GLUCOSE	3.9-5.8 (MMOL/L)	01/05/91	5.00		4.50		4.30	
UREA	2.8-7.4 (MMOL/L)	01/05/91	3.60		7.40		4.80	
CREATININE	55-100 (UMOL/L)	01/05/91	76.00		82.00		73.00	
URIC ACID	180-360 (UMOL/L)	01/05/91	249.00		375.00	>	336.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	13.00		7.00		8.00	
TOT. PROTEINS	63-80 (G/L)	01/05/91	63.00		68.00		69.00	
ALBUMINE	38-50 (G/L)	01/05/91	41.50		45.20		46.60	
TOT. CHOLEST.	4-7 (MMOL/L)	01/05/91	6.90		8.39	>	7.54	>
TRIGLYCERIDES	0.5-1.6 (MMOL/L)	01/05/91	1.36		1.94	>	1.39	
GLOBULINS ALPHA 1	1-4 (G/L)	01/05/91	2.10		2.20		2.20	
GLOBULINS ALPHA 2	4-9 (G/L)	01/05/91	5.00		4.70		5.00	
GLOBULINS BETA	6-12 (G/L)	01/05/91	7.30		8.20		7.90	
GLOBULINS GAMMA	7-15 (G/L)	01/05/91	7.00		7.70		7.40	
TSH	0.3-5 (UU/ML)	01/05/91	1.35					
T4	9.2-22.7 (PMOL/ML)	01/05/91	14.20					

1753

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/4 Patient: 176 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 28	
			13/03/92		06/04/92		09/04/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	11.5-17 (G/DL)	01/03/92	13.30		14.50		10.70	<
HT	36-52 (%)	01/03/92	39.80		44.00		33.00	<
RBC	4.5-5.5 (10¬12/L)	01/03/92	4.41	<	4.80		3.57	<<
WBC	4-10 (10¬9/L)	01/03/92	4.70		8.40		7.60	
WBC: N	2-7.5 (10¬9/L)	01/03/92	2.40		6.55			
	45-74 (%)	08/04/92					77.20	>
WBC: L	1.5-4 (10¬9/L)	01/03/92	1.74		1.26	<		
	16-45 (%)	08/04/92					15.20	<
WBC: E	0.04-0.5 (10¬9/L)	01/03/92	0.19		0.08			
	0-7 (%)	08/04/92					0.70	
WBC: M	0.2-1 (10¬9/L)	01/03/92	0.33		0.42			
	4-10 (%)	08/04/92					6.60	
WBC: B	0.04-0.5 (10¬9/L)	01/03/92	0.05		0.08			
	0-2 (%)	08/04/92					0.40	
PLATELETS	200-400 (10¬9/L)	01/03/92	251.00		288.00		205.00	
NA+	136-144 (MMOL/L)	01/03/92	141.00		146.00	>	140.00	
K+	3.6-5 (MMOL/L)	01/03/92	3.90		3.30	<	3.60	
CL-	95-105 (MMOL/L)	01/03/92	102.00		107.00	>	107.00	>
Ca++	2.15-2.6 (MMOL/L)	01/03/92	2.32		2.46		2.12	<
PO4--	0.8-1.4 (MMOL/L)	01/03/92	1.38		1.23			
SGOT	5-25 (U/L)	01/03/92	8.00		7.00		28.00	>
SGPT	5-35 (U/L)	01/03/92	11.00		9.00		15.00	
GAMMA GT	5-25 (U/L)	01/03/92	12.00		13.00			
LDH	120-320 (U/L)	01/03/92	181.00		196.00			
ALK. PHOSPH.	35-85 (U/L)	01/03/92	34.00	<	37.00			
GLUCOSE	3.9-5.8 (MMOL/L)	01/03/92	4.70		5.10			
UREA	2.8-7.4 (MMOL/L)	01/03/92	4.30		2.70	<	2.50	<
CREATININE	55-100 (UMOL/L)	01/03/92	84.00		81.00		59.00	
URIC ACID	180-360 (UMOL/L)	01/03/92	199.00		222.00		171.00	<
TOT BILIRUBIN	3-20 (UMOL/L)	01/03/92	3.00		8.00			
TOT. PROTEINS	63-80 (G/L)	01/03/92	63.00		73.00		60.00	<
ALBUMINE	38-50 (G/L)	01/03/92	40.40		47.20			
TOT. CHOLEST.	4-7 (MMOL/L)	01/03/92	5.70		6.88			
TRIGLYCERIDES	0.5-1.6 (MMOL/L)	01/03/92	0.75		0.47	<		
GLOBULINS ALPHA 1	1-4 (G/L)	01/03/92	2.10		2.30			
GLOBULINS ALPHA 2	4-9 (G/L)	01/03/92	4.20		5.50			
GLOBULINS BETA	6-12 (G/L)	01/03/92	6.20		6.90			
GLOBULINS GAMMA	7-15 (G/L)	01/03/92	10.10		11.10			
TSH	0.3-5 (UU/ML)	01/03/92	1.37					
T4	9.2-22.7 (PMOL/ML)	01/03/92	16.50					

1754

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang-
< out of range (value lower than min range) > out of range (value higher than max rang-
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/4 Patient: 177 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			22/04/92		27/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11.5-17 (G/DL)	01/05/91	12.80		13.00	
HT	36-52 (%)	01/05/91	38.60		39.60	
RBC	4.5-5.5 (10¬12/L)	01/05/91	4.15	<	4.32	<
WBC	4-10 (10¬9/L)	01/05/91	5.50		5.20	
WBC: N	2-7.5 (10¬9/L)	01/05/91	3.08		3.02	
WBC: L	1.5-4 (10¬9/L)	01/05/91	2.09		1.72	
WBC: E	0.04-0.5 (10¬9/L)	01/05/91	0.06		0.00	<
WBC: M	0.2-1 (10¬9/L)	01/05/91	0.22		0.47	
WBC: B	0.04-0.5 (10¬9/L)	01/05/91	0.06		0.00	<
PLATELETS	200-400 (10¬9/L)	01/05/91	302.00		418.00	>
NA+	136-144 (MMOL/L)	01/05/91	144.00		143.00	
K+	3.6-5 (MMOL/L)	01/05/91	3.80		4.20	
CL-	95-105 (MMOL/L)	01/05/91	103.00		100.00	
Ca++	2.15-2.6 (MMOL/L)	01/05/91	2.45		2.53	
PO4--	0.8-1.4 (MMOL/L)	01/05/91	1.29			
SGOT	5-25 (U/L)	01/05/91	11.00			
SGPT	5-35 (U/L)	01/05/91	25.00			
GAMMA GT	5-25 (U/L)	01/05/91	22.00			
LDH	120-320 (U/L)	01/05/91	193.00			
ALK. PHOSPH.	35-85 (U/L)	01/05/91	65.00			
GLUCOSE	3.9-5.8 (MMOL/L)	01/05/91	5.80		5.60	
UREA	2.8-7.4 (MMOL/L)	01/05/91	4.10		2.50	<
CREATININE	55-100 (UMOL/L)	01/05/91	63.00		64.00	
URIC ACID	180-360 (UMOL/L)	01/05/91	289.00			
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	4.00			
TOT. PROTEINS	63-80 (G/L)	01/05/91	75.00			
ALBUMINE	38-50 (G/L)	01/05/91	45.00			
TOT. CHOLEST.	4-7 (MMOL/L)	01/05/91	7.18	>		
TRIGLYCERIDES	0.5-1.6 (MMOL/L)	01/05/91	0.70			
GLOBULINS ALPHA 1	1-4 (G/L)	01/05/91	2.20			
GLOBULINS ALPHA 2	4-9 (G/L)	01/05/91	5.60			
GLOBULINS BETA	6-12 (G/L)	01/05/91	9.10			
GLOBULINS GAMMA	7-15 (G/L)	01/05/91	13.10			
TSH	0.3-5 (UU/ML)	01/05/91	1.30			
T4	9.2-22.7 (PMOL/ML)	01/05/91	17.60			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 4/4 Patient: 178 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			21/04/92		18/05/92		09/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-17 (G/DL)	01/05/91	11.20	<	13.70			
HT	36-52 (%)	01/05/91	33.10	<	41.70			
RBC	4.5-5.5 (10¬12/L)	01/05/91	3.15	<<	4.00	<		
WBC	4-10 (10¬9/L)	01/05/91	3.80	<	4.70			
WBC: N	2-7.5 (10¬9/L)	01/05/91	2.13		3.15			
WBC: L	1.5-4 (10¬9/L)	01/05/91	1.25	<	1.18	<		
WBC: E	0.04-0.5 (10¬9/L)	01/05/91	0.19		0.14			
WBC: M	0.2-1 (10¬9/L)	01/05/91	0.19	<	0.24			
WBC: B	0.04-0.5 (10¬9/L)	01/05/91	0.04		0.00	<		
PLATELETS	200-400 (10¬9/L)	01/05/91	143.00	<	168.00	<		
NA+	136-144 (MMOL/L)	01/05/91	140.00		141.00		141.00	
K+	3.6-5 (MMOL/L)	01/05/91	3.50	<	4.20		4.50	
CL-	95-105 (MMOL/L)	01/05/91	106.00	>	103.00		102.00	
Ca++	2.15-2.6 (MMOL/L)	01/05/91	2.41		2.48		2.42	
PO4--	0.8-1.4 (MMOL/L)	01/05/91	1.44	>			1.40	
SGOT	5-25 (U/L)	01/05/91	11.00		9.00		9.00	
SGPT	5-35 (U/L)	01/05/91	12.00		17.00		15.00	
GAMMA GT	5-25 (U/L)	01/05/91	57.00	>>	27.00	>	16.00	
LDH	120-320 (U/L)	01/05/91	166.00		179.00		178.00	
ALK. PHOSPH.	35-85 (U/L)	01/05/91	47.00		62.00		58.00	
GLUCOSE	3.9-5.8 (MMOL/L)	01/05/91	4.70		4.00		4.70	
UREA	2.8-7.4 (MMOL/L)	01/05/91	3.20		3.20		2.70	<
CREATININE	55-100 (UMOL/L)	01/05/91	59.00		65.00		60.00	
URIC ACID	180-360 (UMOL/L)	01/05/91	277.00		288.00		273.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	3.00		6.00		9.00	
TOT. PROTEINS	63-80 (G/L)	01/05/91	59.00	<	68.00		65.00	
ALBUMINE	38-50 (G/L)	01/05/91	39.40		47.40		45.40	
TOT. CHOLEST.	4-7 (MMOL/L)	01/05/91	5.12		5.47		5.24	
TRIGLYCERIDES	0.5-1.6 (MMOL/L)	01/05/91	1.76	>	1.01		1.05	
GLOBULINS ALPHA 1	1-4 (G/L)	01/05/91	2.60		2.40		2.10	
GLOBULINS ALPHA 2	4-9 (G/L)	01/05/91	5.00		5.00		4.90	
GLOBULINS BETA	6-12 (G/L)	01/05/91	6.70		6.70		6.10	
GLOBULINS GAMMA	7-15 (G/L)	01/05/91	5.30	<	6.60	<	6.60	<
TSH	0.3-5 (UU/ML)	01/05/91	1.38					
T4	9.2-22.7 (PMOL/ML)	01/05/91	16.10					

1756

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0
9550082
LABORATORY DATA
Centre: 4/4 Patient: 179 Treatment: Placebo Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			08/09/92		30/09/92	
			value	(¢)	value	(¢)
Laboratory test	Range value	Range date				
HB	11.5-17 (G/DL)	01/05/91	13.50		13.89	
HT	36-52 (%)	01/05/91	39.70		41.00	
RBC	4.5-5.5 (10¬12/L)	01/05/91	4.51		4.65	
WBC	4-10 (10¬9/L)	01/05/91	6.70		7.70	
WBC: N	2-7.5 (10¬9/L)	01/05/91	4.22		4.93	
WBC: L	1.5-4 (10¬9/L)	01/05/91	1.94		2.31	
WBC: E	0.04-0.5 (10¬9/L)	01/05/91	0.20		0.08	
WBC: M	0.2-1 (10¬9/L)	01/05/91	0.27		0.31	
WBC: B	0.04-0.5 (10¬9/L)	01/05/91	0.07		0.08	
PLATELETS	200-400 (10¬9/L)	01/05/91	231.00		264.00	
NA+	136-144 (MMOL/L)	01/05/91	142.00			
K+	3.6-5 (MMOL/L)	01/05/91	4.40			
CL-	95-105 (MMOL/L)	01/05/91	102.00			
Ca++	2.15-2.6 (MMOL/L)	01/05/91	2.17		2.24	
PO4--	0.8-1.4 (MMOL/L)	01/05/91	1.20		1.15	
SGOT	5-25 (U/L)	01/05/91	4.00	<	9.00	
SGPT	5-35 (U/L)	01/05/91	9.00		12.00	
GAMMA GT	5-25 (U/L)	01/05/91	16.00		13.00	
LDH	120-320 (U/L)	01/05/91	167.00		189.00	
ALK. PHOSPH.	35-85 (U/L)	01/05/91	67.00		72.00	
GLUCOSE	3.9-5.8 (MMOL/L)	01/05/91	5.70		5.00	
UREA	2.8-7.4 (MMOL/L)	01/05/91	8.30	>	6.00	
CREATININE	55-100 (UMOL/L)	01/05/91	76.00		73.00	
URIC ACID	180-360 (UMOL/L)	01/05/91	122.00	<	193.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	5.00			
TOT. PROTEINS	63-80 (G/L)	01/05/91	63.00		66.00	
ALBUMINE	38-50 (G/L)	01/05/91	38.70		40.70	
TOT. CHOLEST.	4-7 (MMOL/L)	01/05/91	6.09		5.67	
TRIGLYCERIDES	0.5-1.6 (MMOL/L)	01/05/91	0.78		0.78	
GLOBULINS ALPHA 1	1-4 (G/L)	01/05/91	2.10		2.60	
GLOBULINS ALPHA 2	4-9 (G/L)	01/05/91	4.50		4.90	
GLOBULINS BETA	6-12 (G/L)	01/05/91	8.10		8.00	
GLOBULINS GAMMA	7-15 (G/L)	01/05/91	9.60		9.90	
TSH	0.3-5 (UU/ML)	01/05/91	1.29			
T4	9.2-22.7 (PMOL/ML)	01/05/91	11.60			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 4/4 Patient: 180 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			30/09/92		27/10/92		17/11/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-17 (G/DL)	01/05/91			14.70		14.50	
HT	36-52 (%)	01/05/91	44.40		41.40		43.20	
RBC	4-5.8 (10¬12/L)	01/05/91	4.62		4.41		4.61	
WBC	4-10 (10¬9/L)	01/05/91	6.30		6.70		10.30	>
WBC: N	2-7.5 (10¬9/L)	01/05/91	3.53		4.09		8.03	>
WBC: L	1.5-4 (10¬9/L)	01/05/91	1.95		2.01		1.85	
WBC: E	0.04-0.5 (10¬9/L)	01/05/91	0.32		0.27		0.21	
WBC: M	0.2-1 (10¬9/L)	01/05/91	0.44		0.34		0.10	<
WBC: B	0.01-0.1 (10¬9/L)	01/05/91	0.06		0.00	<	0.10	
PLATELETS	200-400 (10¬9/L)	01/05/91	208.00		197.00	<	209.00	
NA+	136-144 (MMOL/L)	01/05/91	138.00		139.00		141.00	
K+	3.6-5 (MMOL/L)	01/05/91	4.00		4.00		4.00	
CL-	95-105 (MMOL/L)	01/05/91	103.00		102.00		104.00	
Ca++	2.15-2.6 (MMOL/L)	01/05/91	2.37		2.32		2.35	
PO4--	0.8-1.4 (MMOL/L)	01/05/91			1.24		0.95	
SGOT	5-25 (U/L)	01/05/91	39.00	>	10.00		9.00	
SGPT	5-35 (U/L)	01/05/91	47.00	>	18.00		12.00	
GAMMA GT	5-25 (U/L)	01/05/91	67.00	>>	27.00	>	18.00	
LDH	120-320 (U/L)	01/05/91			154.00		191.00	
ALK. PHOSPH.	50-200 (U/L)	01/05/91	37.00	<	41.00	<	41.00	<
GLUCOSE	3.9-5.8 (MMOL/L)	01/05/91	4.80		5.20		6.00	>
BUN	()	01/05/91						
UREA	3.2-7.7 (MMOL/L)	01/05/91	4.20		3.80		4.00	
CREATININE	63-112 (UMOL/L)	01/05/91	81.00		76.00		76.00	
URIC ACID	240-420 (UMOL/L)	01/05/91	391.00		344.00		449.00	>
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	14.00		7.00		4.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/05/91			2.00		2.00	
TOT. PROTEINS	63-80 (G/L)	01/05/91	60.00	<	61.00	<	65.00	
ALBUMINE	38-50 (G/L)	01/05/91			40.90		42.60	
TOT. CHOLEST.	3.5-5.2 (MMOL/L)	01/05/91	4.69		4.62		5.04	
TRIGLYCERIDES	0.5-1.6 (MMOL/L)	01/05/91	1.58		1.00		1.40	
GLOBULINS ALPHA 1	1-4 (G/L)	01/05/91			1.30		2.00	
GLOBULINS ALPHA 2	4-9 (G/L)	01/05/91			4.10		4.60	
GLOBULINS BETA	6-12 (G/L)	01/05/91			8.90		8.60	
GLOBULINS GAMMA	7-15 (G/L)	01/05/91			5.70	<	7.10	
TSH	0.3-5 (UU/ML)	01/05/91						
T4	9.2-22.7 (PMOL/ML)	01/05/91						

1758

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 5/1 Patient: 127 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/06/91		27/06/91		18/07/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-17 (G/DL)	01/06/91	14.80		14.70		15.70	
HT	37-52 (%)	01/06/91	42.90		42.50		44.80	
RBC	4100000-5700000 (/UL)	01/06/91	4600000		4700000		4900000	
WBC	4000-10000 (/UL)	01/06/91	5370.00		6980.00		7620.00	
WBC: N	45-70 (%)	01/06/91	46.00		41.00	<	57.00	
WBC: L	20-40 (%)	01/06/91	51.00	>	40.00		39.00	
WBC: E	1-3 (%)	01/06/91	3.00		6.00	>>	4.00	>>
WBC: M	3-7 (%)	01/06/91	0.00	<	3.00		0.00	<
WBC: B	0-1 (%)	01/06/91	0.00		0.00		0.00	
PLATELETS	150000-400000 (/UL)	01/06/91	247000		253000		295000	
NA+	135-145 (MMOL/L)	01/06/91	141.00		139.00		140.00	
K+	3.5-5 (MMOL/L)	01/06/91	3.40	<	3.80		3.60	
CL-	95-110 (MMOL/L)	01/06/91	100.00		100.00		105.00	
Ca++	2.12-2.6 (MMOL/L)	01/06/91	2.41		2.43		2.44	
PO4--	0.81-1.62 (MMOL/L)	01/06/91	0.98		1.26		1.22	
SGOT	5-41 (UI/L)	01/06/91	37.00		18.00		21.00	
SGPT	5-41 (UI/L)	01/06/91	22.00		28.00		41.00	
GAMMA GT	11-50 (UI/L)	01/06/91	22.00		20.00		24.00	
LDH	220-440 (UI/L)	01/06/91	507.00	>			476.00	>
ALK. PHOSPH.	100-290 (UI/L)	01/06/91	152.00		149.00		176.00	
GLUCOSE	3.9-5.8 (MMOL/L)	01/06/91	5.44		5.08		5.16	
UREA	1.7-8.3 (MMOL/L)	01/06/91	6.90		7.40		6.00	
CREATININE	62-110 (UMOL/L)	01/06/91	92.00		81.00		77.00	
URIC ACID	200-415 (UMOL/L)	01/06/91	343.00		602.00	>>	370.00	
TOT BILIRUBIN	3-17 (UMOL/L)	01/06/91	5.00		6.00		4.00	
TOT. PROTEINS	66-83 (G/L)	01/06/91	69.00		73.00		77.00	
ALBUMINE	57-70 (%)	01/06/91	56.50	<			42.27	<
TOT. CHOLEST.	4-7 (MMOL/L)	01/06/91	5.05		5.13		5.84	
TRIGLYCERIDES	0.6-1.9 (MMOL/L)	01/06/91	1.22		1.52		1.30	
GLOBULINS ALPHA 1	2-4 (%)	01/06/91	2.30				2.30	
GLOBULINS ALPHA 2	10-14 (%)	01/06/91	9.80	<			9.20	<
GLOBULINS BETA	6-13 (%)	01/06/91	11.80				14.80	>
GLOBULINS GAMMA	10-19 (%)	01/06/91	19.60	>			18.80	
TSH	0.3-5 (UI/ML)	01/06/91	2.09					
T4	7-18 (PG/ML)	01/06/91	12.20					

1759

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 5/1 Patient: 128 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/06/91		05/07/91		26/07/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-17 (G/DL)	01/06/91	13.09		12.87		13.90	
HT	37-52 (%)	01/06/91	38.00		38.40		41.20	
RBC	4100000-5700000 (/UL)	01/06/91	4200000		4200000		4600000	
WBC	4000-10000 (/UL)	01/06/91	6860.00		5200.00		7320.00	
WBC: N	45-70 (%)	01/06/91	63.00		50.00		67.00	
WBC: L	20-40 (%)	01/06/91	33.00		40.00		29.00	
WBC: E	1-3 (%)	01/06/91	2.00		6.00	>>	3.00	
WBC: M	3-7 (%)	01/06/91	2.00	<	4.00		1.00	<
WBC: B	0-1 (%)	01/06/91	0.00		0.00		0.00	
PLATELETS	150000-400000 (/UL)	01/06/91	214000		234000		271000	
NA+	135-145 (MMOL/L)	01/06/91	139.00		137.00		138.00	
K+	3.5-5 (MMOL/L)	01/06/91	3.90		3.60		3.70	
CL-	95-110 (MMOL/L)	01/06/91	101.00		98.00		104.00	
Ca++	2.12-2.6 (MMOL/L)	01/06/91	2.18		2.16		2.31	
PO4--	0.81-1.62 (MMOL/L)	01/06/91	1.07		1.30		1.11	
SGOT	5-36 (UI/L)	01/06/91	14.00		16.00		17.00	
SGPT	5-37 (UI/L)	01/06/91	12.00		12.00		14.00	
GAMMA GT	7-32 (UI/L)	01/06/91	15.00		14.00		25.00	
LDH	220-440 (UI/L)	01/06/91	421.00		457.00	>	512.00	>
ALK. PHOSPH.	100-290 (UI/L)	01/06/91	131.00		130.00		144.00	
GLUCOSE	3.9-5.8 (MMOL/L)	01/06/91	4.33		4.43		4.95	
UREA	1.7-8.3 (MMOL/L)	01/06/91	4.10		4.00		4.00	
CREATININE	53-95 (UMOL/L)	01/06/91	66.00		65.00		66.00	
URIC ACID	140-340 (UMOL/L)	01/06/91	247.00		273.00		262.00	
TOT BILIRUBIN	3-17 (UMOL/L)	01/06/91	8.00		8.00		12.00	
TOT. PROTEINS	66-83 (G/L)	01/06/91	66.00		68.00		78.00	
ALBUMINE	57-70 (%)	01/06/91			58.70		59.50	
TOT. CHOLEST.	4-7 (MMOL/L)	01/06/91	5.13		5.35		5.78	
TRIGLYCERIDES	0.6-1.9 (MMOL/L)	01/06/91	0.89		0.74		0.78	
GLOBULINS ALPHA 1	2-4 (%)	01/06/91			2.50		1.80	<
GLOBULINS ALPHA 2	10-14 (%)	01/06/91			10.00		11.30	
GLOBULINS BETA	6-13 (%)	01/06/91			12.10		10.90	
GLOBULINS GAMMA	10-19 (%)	01/06/91			16.70		16.50	
TSH	0.3-5 (UI/ML)	01/06/91	0.74					
T4	7-18 (PG/ML)	01/06/91	8.50					

1760

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 5/1 Patient: 129 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			23/12/91		13/01/92		03/02/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-17 (G/DL)	20/12/91	15.00		16.60		16.00	
HT	37-52 (%)	20/12/91	43.00		48.00		47.00	
RBC	4.1-5.7 (10-6/MM3)	20/12/91	4.90		5.50		5.40	
WBC	4000-10000 (/UL)	20/12/91	4630.00		8600.00		8700.00	
WBC: N	45-70 (%)	20/12/91	58.00		41.00	<	56.00	
WBC: L	20-40 (%)	20/12/91	42.00	>	50.00	>	44.00	>
WBC: E	1-3 (%)	20/12/91	0.00	<	6.00	>>	0.00	<
WBC: M	3-7 (%)	20/12/91	0.00	<	3.00		0.00	<
WBC: B	0-1 (%)	20/12/91	0.00		0.00		0.00	
PLATELETS	150000-400000 (/UL)	20/12/91	158000		283000		367000	
NA+	135-145 (MMOL/L)	20/12/91	137.00		140.00		140.00	
K+	3.5-5 (MMOL/L)	20/12/91	3.60		4.30		4.00	
CL-	95-110 (MMOL/L)	20/12/91	102.00		104.00		101.00	
Ca++	2.12-2.6 (MMOL/L)	20/12/91	2.44		2.57		2.55	
PO4--	0.81-1.62 (MMOL/L)	20/12/91	1.10		1.36		1.25	
SGOT	5-41 (UI/L)	20/12/91	28.00		22.00		21.00	
SGPT	5-41 (UI/L)	20/12/91	20.00		19.00		26.00	
GAMMA GT	11-50 (UI/L)	20/12/91	19.00		14.00		18.00	
LDH	220-440 (UI/L)	20/12/91	397.00		349.00		274.00	
ALK. PHOSPH.	100-290 (UI/L)	20/12/91	129.00		184.00		178.00	
GLUCOSE	0.7-1.05 (G/L)	20/12/91	0.93		0.81		0.77	
UREA	1.7-8.3 (MMOL/L)	20/12/91	3.50		3.80		3.30	
CREATININE	62-110 (UMOL/L)	20/12/91	92.00		89.00		75.00	
URIC ACID	200-415 (UMOL/L)	20/12/91	374.00		490.00	>	328.00	
TOT BILIRUBIN	3-17 (UMOL/L)	20/12/91	5.00		4.00		5.00	
DIR BILIRUBIN	0-7 (UMOL/L)	20/12/91	2.00		2.00		2.00	
TOT. PROTEINS	66-83 (G/L)	20/12/91	65.00	<	67.00		76.00	
ALBUMINE	37-42 (G/L)	20/12/91	37.00		41.67		47.00	>
TOT. CHOLEST.	1.55-2.7 (G/L)	20/12/91	1.33	<				
	4-7 (MMOL/L)	12/01/92			4.18		3.48	<
TRIGLYCERIDES	0.52-1.65 (G/L)	20/12/91	0.94					
	0.6-1.9 (MMOL/L)	12/01/92			0.72		0.70	
GLOBULINS ALPHA 1	1-3 (G/L)	20/12/91	2.67		1.94		1.75	
GLOBULINS ALPHA 2	4-7 (G/L)	20/12/91	8.26	>	10.40	>>	8.00	>
GLOBULINS BETA	5-8 (G/L)	20/12/91	8.91	>	8.31	>	8.97	>
GLOBULINS GAMMA	8-12 (G/L)	20/12/91	7.22	<	8.11		9.65	
TSH	0.3-5 (UI/ML)	20/12/91	3.52					
T4	7-18 (PG/ML)	20/12/91	8.58					

1761

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 5/1 Patient: 130 Treatment: Placebo Sex: Male

			Visit number / Laboratory data					
			Screen		Day 21		Day 42	
			25/02/92		25/03/92		15/04/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	12-17 (G/DL)	20/12/91	15.53		14.00		14.49	
HT	37-52 (%)	20/12/91	45.00		39.00		42.00	
RBC	4.1-5.7 (10-6/MM3)	20/12/91	5.10		4.50		4.80	
WBC	4000-10000 (/UL)	20/12/91	8110.00		6500.00		6400.00	
WBC: N	45-70 (%)	20/12/91	59.00		49.00		52.00	
WBC: L	20-40 (%)	20/12/91	30.00		39.00		44.00	>
WBC: E	1-3 (%)	20/12/91	6.00	>>	6.00	>>	1.00	
WBC: M	3-7 (%)	20/12/91	4.00		5.00		2.00	<
WBC: B	0-1 (%)	20/12/91	1.00		1.00		1.00	
PLATELETS	150000-400000 (/UL)	20/12/91	359000		250000		273000	
NA+	135-145 (MMOL/L)	20/12/91	140.00		139.00		141.00	
K+	3.5-5 (MMOL/L)	20/12/91	3.90		3.90		4.20	
CL-	95-110 (MMOL/L)	20/12/91	105.00		102.00		103.00	
Ca++	2.12-2.6 (MMOL/L)	20/12/91	2.39		2.37		2.55	
PO4--	0.81-1.62 (MMOL/L)	20/12/91	1.27		1.33		0.90	
SGOT	5-41 (UI/L)	20/12/91	43.00	>	14.00		17.00	
SGPT	5-41 (UI/L)	20/12/91	35.00		13.00		11.00	
GAMMA GT	11-50 (UI/L)	20/12/91	40.00		15.00		13.00	
LDH	220-440 (UI/L)	20/03/92			187.00	<	228.00	
ALK. PHOSPH.	100-290 (UI/L)	20/12/91	171.00		134.00		140.00	
GLUCOSE	0.7-1.05 (G/L)	20/12/91	0.76		0.83		0.88	
UREA	0.1-0.5 (G/L)	20/12/91	0.28					
	1.7-8.3 (MMOL/L)	20/03/92			3.80		4.10	
CREATININE	62-110 (UMOL/L)	20/12/91	76.00		71.00		74.00	
URIC ACID	200-415 (UMOL/L)	20/12/91	296.00		323.00		380.00	
TOT BILIRUBIN	3-17 (UMOL/L)	20/12/91	7.00		9.00		7.00	
DIR BILIRUBIN	0-7 (UMOL/L)	20/12/91	0.90		4.00		1.00	
TOT. PROTEINS	66-83 (G/L)	20/12/91	66.00		64.00	<	73.00	
ALBUMINE	37-42 (G/L)	20/12/91	40.00		41.00		46.00	>
TOT. CHOLEST.	1.55-2.7 (G/L)	20/12/91	1.80				1.55	
	4-7 (MMOL/L)	20/03/92			4.00			
TRIGLYCERIDES	0.52-1.65 (G/L)	20/12/91	0.71				0.39	<
	0.6-1.9 (MMOL/L)	20/03/92			0.46	<		
GLOBULINS ALPHA 1	1-3 (G/L)	20/12/91	2.50		1.15		1.46	
GLOBULINS ALPHA 2	4-7 (G/L)	20/12/91	5.60		4.99		6.35	
GLOBULINS BETA	5-8 (G/L)	20/12/91	7.70		7.10		8.03	>
GLOBULINS GAMMA	8-12 (G/L)	20/12/91	9.60		9.40		10.73	
TSH	0.3-5 (UI/ML)	20/12/91	0.30					
T4	7-18 (PG/ML)	20/12/91	15.60					

1762

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 5/1 Patient: 131 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			20/03/92		10/04/92		30/04/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	12-17 (G/DL)	15/03/92	12.00		14.31		13.88	
HT	37-52 (%)	15/03/92	35.55	<	41.00		41.00	
RBC	4.1-5.7 (10-6/MM3)	15/03/92	4.06	<	4.70		4.70	
WBC	4000-10000 (/UL)	15/03/92	4360.00		6070.00		6400.00	
WBC: N	45-70 (%)	15/03/92	59.00		67.00		60.00	
WBC: L	20-40 (%)	15/03/92	41.00	>	32.00		38.00	
WBC: E	1-3 (%)	15/03/92	0.00	<	0.00	<	0.00	<
WBC: M	3-7 (%)	15/03/92	0.00	<	1.00	<	2.00	<
WBC: B	0-1 (%)	15/03/92	0.00		0.00		0.00	
PLATELETS	150000-400000 (/UL)	15/03/92	193000		266000		307000	
NA+	135-145 (MMOL/L)	15/03/92	141.00		138.00		140.00	
K+	3.5-5 (MMOL/L)	15/03/92	3.90		4.00		3.60	
CL-	95-110 (MMOL/L)	15/03/92	107.00		101.00		102.00	
Ca++	2.12-2.6 (MMOL/L)	15/03/92	2.22		2.47		2.56	
PO4--	0.81-1.62 (MMOL/L)	15/03/92	1.17		0.77	<	0.85	
SGOT	5-36 (UI/L)	15/03/92	34.00		14.00		18.00	
SGPT	5-37 (UI/L)	15/03/92	40.00	>	15.00		20.00	
GAMMA GT	7-32 (UI/L)	15/03/92	34.00	>	5.00	<	28.00	
LDH	220-440 (UI/L)	15/03/92	270.00		226.00		288.00	
ALK. PHOSPH.	100-290 (UI/L)	15/03/92	144.00		170.00		154.00	
GLUCOSE	0.7-1.05 (G/L)	15/03/92	0.87		0.95		1.06	>
UREA	1.7-8.3 (MMOL/L)	15/03/92	5.90		3.60		3.80	
CREATININE	53-95 (UMOL/L)	15/03/92	67.00		76.00		77.00	
URIC ACID	140-340 (UMOL/L)	15/03/92	259.00		261.00			
TOT BILIRUBIN	3-17 (UMOL/L)	15/03/92	3.00		5.00		4.00	
DIR BILIRUBIN	0-7 (UMOL/L)	15/03/92	0.20		2.00			
TOT. PROTEINS	66-83 (G/L)	15/03/92	62.00	<	70.00		70.00	
ALBUMINE	37-42 (G/L)	15/03/92	35.00	<	43.60	>	41.09	
TOT. CHOLEST.	1.55-2.7 (G/L)	15/03/92	2.42		2.43		2.22	
TRIGLYCERIDES	0.52-1.65 (G/L)	15/03/92	3.33	>>	1.11		1.13	
GLOBULINS ALPHA 1	1-3 (G/L)	15/03/92	1.43		1.68		2.03	
GLOBULINS ALPHA 2	4-7 (G/L)	15/03/92	8.99	>	7.63	>	8.68	>
GLOBULINS BETA	5-8 (G/L)	15/03/92	8.80	>	8.40	>	9.38	>
GLOBULINS GAMMA	8-12 (G/L)	15/03/92	7.75	<	8.68		8.82	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 5/1 Patient: 132 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			23/06/92		16/07/92		10/08/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-17 (G/DL)	20/06/92	16.00		15.01		14.25	
HT	37-52 (%)	20/06/92	46.40		45.04		42.23	
RBC	4.1-5.7 (10-6/MM3)	20/06/92	5.07		5.00		4.75	
WBC	4000-10000 (/UL)	20/06/92	7040.00		7650.00		8420.00	
WBC: N	45-70 (%)	20/06/92	49.00		34.00	<	54.00	
WBC: L	20-40 (%)	20/06/92	51.00	>	60.00	>>	44.00	>
WBC: E	1-3 (%)	20/06/92	0.00	<	4.00	>>	2.00	
WBC: M	3-7 (%)	20/06/92	0.00	<	0.00	<	0.00	<
WBC: B	0-1 (%)	20/06/92	0.00		2.00	>>	0.00	
PLATELETS	150000-400000 (/UL)	20/06/92	258000		270000		312000	
NA+	135-145 (MMOL/L)	20/06/92	141.00		135.00		137.00	
K+	3.5-5 (MMOL/L)	20/06/92	4.00		3.80		3.90	
CL-	95-110 (MMOL/L)	20/06/92	106.00		103.00		103.00	
Ca++	2.12-2.6 (MMOL/L)	20/06/92	2.48		2.65	>	2.39	
PO4--	0.81-1.62 (MMOL/L)	20/06/92	1.31		1.53		1.30	
SGOT	5-41 (UI/L)	20/06/92	18.00				22.00	
SGPT	5-41 (UI/L)	20/06/92	38.00				51.00	>
GAMMA GT	11-50 (UI/L)	20/06/92	45.00		50.00		36.00	
LDH	220-440 (UI/L)	20/06/92	263.00		276.00		328.00	
ALK. PHOSPH.	100-290 (UI/L)	20/06/92	138.00		123.00		137.00	
GLUCOSE	3.9-5.8 (MMOL/L)	20/06/92	5.66		5.60		4.99	
UREA	1.7-8.3 (MMOL/L)	20/06/92	4.00		4.40		3.40	
CREATININE	62-110 (UMOL/L)	20/06/92	80.00		91.00		86.00	
URIC ACID	200-415 (UMOL/L)	20/06/92	350.00		419.00	>	353.00	
TOT BILIRUBIN	3-17 (UMOL/L)	20/06/92	10.00		6.00		5.00	
DIR BILIRUBIN	0-7 (UMOL/L)	20/06/92	1.30					
TOT. PROTEINS	66-83 (G/L)	20/06/92	59.00	<	74.00		70.00	
ALBUMINE	37-42 (G/L)	20/06/92	52.90	>	46.40	>	44.17	>
TOT. CHOLEST.	4-7 (MMOL/L)	20/06/92	7.05	>	7.66	>	5.32	
TRIGLYCERIDES	0.6-1.9 (MMOL/L)	20/06/92	1.76		1.35		1.28	
GLOBULINS ALPHA 1	1-3 (G/L)	20/06/92	1.53		1.55		1.96	
GLOBULINS ALPHA 2	4-7 (G/L)	20/06/92	6.25		6.51		7.42	>
GLOBULINS BETA	5-8 (G/L)	20/06/92	6.84		8.88	>	7.84	
GLOBULINS GAMMA	8-12 (G/L)	20/06/92	9.50		10.58		8.61	
TSH	0.3-5 (UI/ML)	20/06/92	0.88					
T4	7-18 (PG/ML)	20/06/92	11.29					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0
9550082
LABORATORY DATA
Centre: 5/2 Patient: 121 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			13/12/91		10/01/92		28/01/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	24/01/91	13.40		15.00		13.20	
HT	37-48 (%)	24/01/91	40.10		44.00		39.30	
RBC	3.9-5.3 (10-6/UL)	24/01/91	4.30		4.80		4.25	
WBC	4-10 (10-3/UL)	24/01/91	6.10		5.60		6.50	
WBC: N	40-75 (%)	24/01/91	59.00		63.00		56.00	
WBC: L	20-45 (%)	24/01/91	40.00		32.00		40.00	
WBC: E	1-5 (%)	24/01/91	1.00		3.00		1.00	
WBC: M	2-10 (%)	24/01/91	0.00	<	2.00		3.00	
WBC: B	0-4 (%)	24/01/91	0.00		0.00		0.00	
PLATELETS	250-450 (10-3/UL)	24/01/91	228.00	<	190.00	<	245.00	<
NA+	138-145 (MMOL/L)	24/01/91	142.00		140.00		143.00	
K+	3.5-5 (MMOL/L)	24/01/91	4.20		4.50		3.90	
CL-	98-106 (MMOL/L)	24/01/91	101.00		102.00		106.00	
Ca++	2.2-2.55 (MMOL/L)	24/01/91	2.32		2.48		2.08	<
PO4--	0.9-1.5 (MMOL/L)	24/01/91	1.43		1.30		1.42	
SGOT	5-40 (UI/L)	24/01/91	6.00		8.00		8.00	
SGPT	5-40 (UI/L)	24/01/91	4.00	<	4.00	<	5.00	
GAMMA GT	5-40 (UI/L)	24/01/91	10.00		11.00		8.00	
LDH	120-300 (UI/ML)	24/01/91	244.00		280.00		238.00	
ALK. PHOSPH.	50-90 (UI/L)	24/01/91	28.00	<	28.00	<	24.00	<
GLUCOSE	4-6 (MMOL/L)	24/01/91	4.20		4.35		4.00	
CREATININE	50-110 (UMOL/L)	24/01/91	77.00		98.00		59.00	
URIC ACID	150-360 (UMOL/L)	24/01/91	4.50	<	9.50	<	4.50	<
TOT BILIRUBIN	1.7-17 (UMOL/L)	24/01/91	17.00		17.00		17.00	
TOT. PROTEINS	64-80 (G/L)	24/01/91	68.00		76.00		61.00	<
ALBUMINE	27-44 (G/L)	24/01/91	56.00	>	52.20	>		
TOT. CHOLEST.	3.5-7 (MMOL/L)	24/01/91	5.45		6.90		4.80	
TRIGLYCERIDES	0.4-1.9 (MMOL/L)	24/01/91	1.46		1.45		1.10	
GLOBULINS ALPHA 1	1-4 (G/L)	24/01/91	4.65	>	2.70		2.10	
GLOBULINS ALPHA 2	5-10 (G/L)	24/01/91	11.50	>	13.30	>>	8.30	
GLOBULINS BETA	6-12 (G/L)	24/01/91	13.40	>	14.10	>	8.30	
GLOBULINS GAMMA	6-16 (G/L)	24/01/91	14.50		17.70	>	9.50	
TSH	0.2-4 (UI/ML)	24/01/91	1.60					
T4	5-13 (MG/100ML)	24/01/91	8.50					

1765

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 5/2 Patient: 125 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/01/91		11/02/91		11/03/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	24/01/91	14.70		15.90		15.40	
HT	40-54 (%)	24/01/91	44.90		47.70		44.80	
RBC	4.3-5.7 (10-6/UL)	24/01/91	4.84		5.15		5.03	
WBC	4-10 (10-3/UL)	24/01/91	9.90		6.30		6.40	
WBC: N	40-75 (%)	24/01/91	56.00		48.00		40.00	
WBC: L	20-45 (%)	24/01/91	39.00		47.00	>	54.00	>
WBC: E	1-5 (%)	24/01/91	2.00		1.00		2.00	
WBC: M	2-10 (%)	24/01/91	3.00		4.00		4.00	
WBC: B	0-4 (%)	24/01/91	0.00		0.00		0.00	
PLATELETS	250-450 (10-3/UL)	24/01/91	321.00		290.00		400.00	
NA+	138-145 (MMOL/L)	24/01/91	143.00		143.00		142.00	
K+	3.5-5 (MMOL/L)	24/01/91	3.70		4.10		4.50	
CL-	98-106 (MMOL/L)	24/01/91	104.00		104.00		107.00	>
Ca++	2.2-2.55 (MMOL/L)	24/01/91	2.35		2.35		2.40	
PO4--	0.8-1.44 (MMOL/L)	24/01/91	1.25		1.15		1.16	
SGOT	5-40 (UI/L)	24/01/91	16.00		19.00		19.00	
SGPT	5-40 (UI/L)	24/01/91	44.00	>	45.00	>	28.00	
GAMMA GT	5-40 (UI/L)	24/01/91	54.00	>	44.00	>	35.00	
LDH	120-300 (UI/ML)	24/01/91	201.00		214.00		260.00	
ALK. PHOSPH.	50-90 (UI/L)	24/01/91	42.00	<	41.00	<	49.00	<
GLUCOSE	4-6 (MMOL/L)	24/01/91	4.20		5.00		5.30	
UREA	2.5-7.5 (MMOL/L)	24/01/91	7.10		4.80		5.30	
CREATININE	50-110 (UMOL/L)	24/01/91	88.00		32.00	<	95.00	
URIC ACID	150-420 (UMOL/L)	24/01/91	339.00		320.00		299.00	
TOT BILIRUBIN	1.7-17 (UMOL/L)	24/01/91	17.00		17.00		17.00	
TOT. PROTEINS	64-80 (G/L)	24/01/91	71.00		71.00		76.00	
ALBUMINE	27-44 (G/L)	24/01/91	48.00	>	35.70		39.50	
TOT. CHOLEST.	3.5-7 (MMOL/L)	24/01/91	4.20		5.10			
TRIGLYCERIDES	0.4-1.9 (MMOL/L)	24/01/91	1.50		2.00	>		
GLOBULINS ALPHA 1	1-4 (G/L)	24/01/91	1.40		1.70		1.70	
GLOBULINS ALPHA 2	5-10 (G/L)	24/01/91	6.90		7.00		8.80	
GLOBULINS BETA	6-12 (G/L)	24/01/91	8.70		10.00		10.40	
GLOBULINS GAMMA	6-16 (G/L)	24/01/91	15.80		15.70		17.20	>
TSH	0.2-4 (UI/ML)	24/01/91	1.20					
T4	5-13 (MG/100ML)	24/01/91	5.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 5/3 Patient: 133 Treatment: Placebo Sex: Male

			Visit number / Laboratory date			
			Screen		Day 14	
			26/11/91		13/12/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
HB	12-18 (G/DL)	01/10/91	15.90		15.40	
HT	35-55 (%)	01/10/91	48.60		46.40	
RBC	3.5-6 (10-6/UL)	01/10/91	5.26		4.97	
WBC	3.5-11 (10-3/UL)	01/10/91	6.92		8.45	
WBC: N	50-70 (%)	01/10/91	56.10		56.00	
WBC: L	25-45 (%)	01/10/91	28.80		30.80	
WBC: E	1-5 (%)	01/10/91	4.00		3.60	
WBC: M	2-10 (%)	01/10/91	10.10	>	8.50	
WBC: B	0.25-0.75 (%)	01/10/91	0.50		0.80	>
PLATELETS	125-425 (10-3/UL)	01/10/91	281.00		267.00	
NA+	138-145 (MMOL/L)	01/10/91	141.00		141.00	
K+	3.8-5 (MMOL/L)	01/10/91	4.50		5.00	
CL-	98-107 (MMOL/L)	01/10/91	102.00		102.00	
Ca++	2.3-2.55 (MMOL/L)	01/10/91	2.39		2.61	>
PO4--	0.9-1.75 (MMOL/L)	01/10/91	1.29		1.34	
SGOT	5-25 (UI/L)	01/10/91	15.00		13.00	
SGPT	5-32 (UI/L)	01/10/91	16.00		14.00	
GAMMA GT	5-37 (UI/L)	01/10/91	18.00		18.00	
LDH	120-300 (UI/L)	01/10/91	195.00		181.00	
ALK. PHOSPH.	30-100 (UI/L)	01/10/91	91.00		89.00	
GLUCOSE	4.2-6.2 (MMOL/L)	01/10/91	5.20		5.00	
UREA	3.5-7.5 (MMOL/L)	01/10/91	6.10		6.30	
CREATININE	80-115 (UMOL/L)	01/10/91	114.00		113.00	
URIC ACID	150-420 (UMOL/L)	01/10/91	384.00		551.00	>>
TOT BILIRUBIN	7-17 (UMOL/L)	01/10/91	21.00	>	15.00	
TOT. PROTEINS	65-77 (G/L)	01/10/91	71.00		73.00	
ALBUMINE	35-50 (G/L)	01/10/91	38.90		39.50	
TOT. CHOLEST.	3.7-5.8 (MMOL/L)	01/10/91	6.80	>	6.10	>
TRIGLYCERIDES	0.69-1.61 (MMOL/L)	01/10/91	1.11		1.37	
GLOBULINS ALPHA 1	2.5-5.7 (G/L)	01/10/91	1.90	<	2.30	<
GLOBULINS ALPHA 2	4.1-10.1 (G/L)	01/10/91	6.90		6.80	
GLOBULINS BETA	5.6-12.6 (G/L)	01/10/91	11.80		13.30	>
GLOBULINS GAMMA	7.8-19.3 (G/L)	01/10/91	11.50		11.10	
TSH	0.2-4 (MUI/L)	01/10/91	1.01			
T4	13-29 (PMOL/L)	01/10/91	12.80	<		

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 5/3 Patient: 134 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/12/91		27/12/91		16/01/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-18 (G/DL)	01/10/91	13.00		13.80		13.30	
HT	35-55 (%)	01/10/91	39.50		40.90		39.60	
RBC	3.5-6 (10-6/UL)	01/10/91	4.13		4.34		4.14	
WBC	3.5-11 (10-3/UL)	01/10/91	3.91		4.58		4.31	
WBC: N	50-70 (%)	01/10/91	49.90	<	57.40		48.50	<
WBC: L	25-45 (%)	01/10/91	38.00		27.40		37.30	
WBC: E	1-5 (%)	01/10/91	4.20		4.50		5.90	>
WBC: M	8-10 (%)	01/10/91	6.70	<	9.60		6.70	<
WBC: B	0.25-0.75 (%)	01/10/91	0.50		0.50		0.90	>
PLATELETS	125-425 (10-3/UL)	01/10/91	250.00		334.00		341.00	
NA+	138-145 (MMOL/L)	01/10/91	136.00	<	138.00		138.00	
K+	3.8-5 (MMOL/L)	01/10/91	4.20		4.00		4.60	
CL-	98-107 (MMOL/L)	01/10/91	98.00		98.00		101.00	
Ca++	2.3-2.55 (MMOL/L)	01/10/91	2.42		2.36		2.34	
PO4--	0.9-1.75 (MMOL/L)	01/10/91	1.62		1.33		1.10	
SGOT	5-25 (UI/L)	01/10/91	16.00		17.00		19.00	
SGPT	5-32 (UI/L)	01/10/91	21.00		23.00		22.00	
GAMMA GT	5-37 (UI/L)	01/10/91	60.00	>	61.00	>	50.00	>
LDH	120-300 (UI/L)	01/10/91	174.00		212.00		194.00	
ALK. PHOSPH.	30-100 (UI/L)	01/10/91	24.00	<	25.00	<	32.00	
GLUCOSE	4.2-6.2 (MMOL/L)	01/10/91	4.80		5.40		5.00	
UREA	3.5-7.5 (MMOL/L)	01/10/91	4.50		5.00		4.20	
CREATININE	80-115 (UMOL/L)	01/10/91	88.00		71.00	<	77.00	<
URIC ACID	150-420 (UMOL/L)	01/10/91	244.00		246.00		171.00	
TOT BILIRUBIN	7-17 (UMOL/L)	01/10/91	13.00		13.00		11.00	
TOT. PROTEINS	65-77 (G/L)	01/10/91	68.00		71.00		80.00	>
ALBUMINE	35-50 (G/L)	01/10/91	42.70		40.50		43.20	
TOT. CHOLEST.	3.7-5.8 (MMOL/L)	01/10/91	4.70		5.50		5.40	
TRIGLYCERIDES	0.69-1.61 (MMOL/L)	01/10/91	0.81		0.55	<	1.12	
GLOBULINS ALPHA 1	2.5-5.7 (G/L)	01/10/91			2.30	<	3.00	
GLOBULINS ALPHA 2	4.1-10.1 (G/L)	01/10/91			5.80		8.20	
GLOBULINS BETA	5.6-12.6 (G/L)	01/10/91			10.10		11.40	
GLOBULINS GAMMA	7.8-19.3 (G/L)	01/10/91			12.30		14.20	
TSH	0.2-4 (MUI/L)	01/10/91	0.38					
T4	13-29 (PMOL/L)	01/10/91	17.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 5/3 Patient: 135 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/01/92		30/01/92		20/02/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/10/91	13.40		12.80		13.00	
HT	35-55 (%)	01/10/91	39.50		38.50		40.50	
RBC	3.5-6 (10¬6/UL)	01/10/91	4.36		4.21		4.53	
WBC	3.5-11 (10¬3/UL)	01/10/91	5.90		6.58		6.02	
WBC: N	50-70 (%)	01/10/91	52.70		61.60		61.80	
WBC: L	25-45 (%)	01/10/91	34.70		29.20		28.40	
WBC: E	1-5 (%)	01/10/91	3.00		2.20		1.30	
WBC: M	8-10 (%)	01/10/91	7.80	<	6.70	<	6.60	<
WBC: B	0.25-0.75 (%)	01/10/91	0.70		0.00	<	1.40	>>
PLATELETS	125-425 (10¬3/UL)	01/10/91	316.00		304.00		372.00	
NA+	138-145 (MMOL/L)	01/10/91	139.00		138.00		138.00	
K+	3.8-5 (MMOL/L)	01/10/91	4.70		4.50		4.40	
CL-	98-107 (MMOL/L)	01/10/91	103.00		100.00		105.00	
Ca++	2.3-2.55 (MMOL/L)	01/10/91	2.48		2.27	<	2.31	
PO4--	0.9-1.75 (MMOL/L)	01/10/91			1.15		1.13	
SGOT	5-25 (UI/L)	01/10/91	16.00		14.00		17.00	
SGPT	5-32 (UI/L)	01/10/91	20.00		18.00		24.00	
GAMMA GT	5-37 (UI/L)	01/10/91	22.00		21.00		25.00	
LDH	120-300 (UI/L)	01/10/91			190.00		249.00	
ALK. PHOSPH.	30-100 (UI/L)	01/10/91					56.00	
GLUCOSE	4.2-6.2 (MMOL/L)	01/10/91	5.10		4.60		3.80	<
UREA	3.5-7.5 (MMOL/L)	01/10/91	6.50		4.00		5.00	
CREATININE	80-115 (UMOL/L)	01/10/91	90.00		88.00		112.00	
URIC ACID	150-420 (UMOL/L)	01/10/91			235.00		225.00	
TOT BILIRUBIN	7-17 (UMOL/L)	01/10/91	8.00		10.00		10.00	
TOT. PROTEINS	65-77 (G/L)	01/10/91	73.00		67.00		74.00	
ALBUMINE	35-50 (G/L)	01/10/91	40.40		33.70	<	41.40	
TOT. CHOLEST.	3.7-5.8 (MMOL/L)	01/10/91	6.70	>	5.30		6.20	>
TRIGLYCERIDES	0.69-1.61 (MMOL/L)	01/10/91	0.91		0.78			
GLOBULINS ALPHA 1	2.5-5.7 (G/L)	01/10/91	2.30	<	1.90	<	2.60	
GLOBULINS ALPHA 2	4.1-10.1 (G/L)	01/10/91	8.20		8.50		7.70	
GLOBULINS BETA	5.6-12.6 (G/L)	01/10/91	11.70		13.10	>	12.10	
GLOBULINS GAMMA	7.8-19.3 (G/L)	01/10/91	10.40		9.80		10.20	
TSH	0.2-4 (MUI/L)	01/10/91	2.26					
T4	13-29 (PMOL/L)	01/10/91	13.10					

1769

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 5/3 Patient: 136 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			02/03/92		24/03/92		13/04/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/10/91	14.40		14.80		15.20	
HT	35-55 (%)	01/10/91	44.00		44.00		44.40	
RBC	3.5-6 (10¬6/UL)	01/10/91	4.88		4.85		5.00	
WBC	3.5-11 (10¬3/UL)	01/10/91	6.20		7.19		8.80	
WBC: N	50-70 (%)	01/10/91	36.70	<	49.10	<	46.90	<
WBC: L	25-45 (%)	01/10/91	53.10	>	41.50		43.20	
WBC: E	1-5 (%)	01/10/91	4.40		2.60		3.20	
WBC: M	8-10 (%)	01/10/91	4.70	<	5.90	<	5.40	<
WBC: B	0.25-0.75 (%)	01/10/91	0.90	>	0.20	<	0.20	<
PLATELETS	125-425 (10¬3/UL)	01/10/91	314.00		259.00		289.00	
NA+	138-145 (MMOL/L)	01/10/91	138.00		136.00	<	137.00	<
K+	3.8-5 (MMOL/L)	01/10/91	4.10		4.20		4.50	
CL-	98-107 (MMOL/L)	01/10/91	102.00		96.00	<	102.00	
Ca++	2.3-2.55 (MMOL/L)	01/10/91	2.32		2.41		2.49	
PO4--	0.9-1.75 (MMOL/L)	01/10/91	1.13		1.33		1.25	
SGOT	5-25 (UI/L)	01/10/91	22.00		36.00	>	30.00	>
SGPT	5-32 (UI/L)	01/10/91	46.00	>	80.00	>>	59.00	>
GAMMA GT	5-37 (UI/L)	01/10/91	246.00	>>	194.00	>>	260.00	>>
LDH	120-300 (UI/L)	01/10/91	255.00		291.00		292.00	
ALK. PHOSPH.	30-100 (UI/L)	01/10/91	84.00		84.00		93.00	
GLUCOSE	4.2-6.2 (MMOL/L)	01/10/91	5.60		5.10		6.10	
UREA	3.5-7.5 (MMOL/L)	01/10/91	6.30		6.40		5.50	
CREATININE	80-115 (UMOL/L)	01/10/91	98.00		86.00		109.00	
URIC ACID	150-420 (UMOL/L)	01/10/91	339.00		384.00		314.00	
TOT BILIRUBIN	7-17 (UMOL/L)	01/10/91	12.00		12.00		13.00	
TOT. PROTEINS	65-77 (G/L)	01/10/91	74.00		76.00		82.00	>
ALBUMINE	35-50 (G/L)	01/10/91	41.80		41.70		45.60	
TOT. CHOLEST.	3.7-5.8 (MMOL/L)	01/10/91	6.60	>	7.10	>	6.70	>
TRIGLYCERIDES	0.69-1.61 (MMOL/L)	01/10/91	3.56	>>	1.66	>		
GLOBULINS ALPHA 1	2.5-5.7 (G/L)	01/10/91	2.30	<	2.70		2.10	<
GLOBULINS ALPHA 2	4.1-10.1 (G/L)	01/10/91	7.10		7.40		8.30	
GLOBULINS BETA	5.6-12.6 (G/L)	01/10/91	11.40		11.80		12.30	
GLOBULINS GAMMA	7.8-19.3 (G/L)	01/10/91	11.40		12.40		13.70	
TSH	0.2-4 (MUI/L)	01/10/91	0.48					
T4	13-29 (PMOL/L)	01/10/91	14.40					

1770

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 5/3 Patient: 137 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			12/05/92		05/06/92		25/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/05/92	14.60		14.30		12.30	
HT	35-55 (%)	01/05/92	43.80		43.90		36.90	
RBC	3.5-6 (10¬6/UL)	01/05/92	4.89		4.86		4.02	
WBC	3.5-11 (10¬3/UL)	01/05/92	7.65		10.58		5.81	
WBC: N	2-8.6 (10¬3/UL)	01/05/92	3.73		7.40		3.29	
WBC: L	0.8-4 (10¬3/UL)	01/05/92	3.12		2.24		2.02	
WBC: E	0.04-0.5 (10¬3/UL)	01/05/92	0.14		0.09		0.09	
WBC: M	0.1-1 (10¬3/UL)	01/05/92	0.63		0.77		0.34	
WBC: B	0.01-0.1 (10¬3/UL)	01/05/92	0.00	<	0.00	<	0.02	
PLATELETS	125-425 (10¬3/UL)	01/05/92	229.00		204.00		228.00	
NA+	138-145 (MMOL/L)	01/05/92	135.00	<	139.00		138.00	
K+	3.8-5 (MMOL/L)	01/05/92	3.80		4.20		4.20	
CL-	98-107 (MMOL/L)	01/05/92	98.00		105.00		102.00	
Ca++	2.3-2.55 (MMOL/L)	01/05/92	2.44		2.47		2.20	<
PO4--	0.9-1.75 (MMOL/L)	01/05/92	0.97		1.23		1.11	
SGOT	5-25 (UI/L)	01/05/92	15.00		14.00		14.00	
SGPT	5-32 (UI/L)	01/05/92	9.00		11.00		11.00	
GAMMA GT	5-37 (UI/L)	01/05/92	12.00		11.00		11.00	
LDH	120-300 (UI/L)	01/05/92	188.00		196.00		191.00	
ALK. PHOSPH.	30-100 (UI/L)	01/05/92	29.00	<	32.00		30.00	
GLUCOSE	4.2-6.2 (MMOL/L)	01/05/92	4.40		4.90		5.10	
UREA	3.5-7.5 (MMOL/L)	01/05/92	2.00	<	4.40		4.60	
CREATININE	80-115 (UMOL/L)	01/05/92	66.00	<	65.00	<	75.00	<
URIC ACID	150-420 (UMOL/L)	01/05/92	319.00		135.00	<	213.00	
TOT BILIRUBIN	7-17 (UMOL/L)	01/05/92	15.00		11.00		8.00	
TOT. PROTEINS	65-77 (G/L)	01/05/92	79.00	>	84.00	>	75.00	
ALBUMINE	54-65 (%)	01/05/92	46.90	<	42.00	<	44.10	<
TOT. CHOLEST.	3.7-5.8 (MMOL/L)	01/05/92	6.00	>	4.50		3.60	<
TRIGLYCERIDES	0.69-1.61 (MMOL/L)	01/05/92	1.66	>	1.42		0.69	
GLOBULINS ALPHA 1	2-5 (%)	01/05/92	2.70		2.80		2.60	
GLOBULINS ALPHA 2	6-10 (%)	01/05/92	9.20		8.20		5.90	<
GLOBULINS BETA	10-16 (%)	01/05/92	13.10		12.60		10.50	
GLOBULINS GAMMA	11-21 (%)	01/05/92	15.60		18.40		11.90	
TSH	0.2-4 (MUI/L)	01/05/92	0.93					
T4	13-29 (PMOL/L)	01/05/92	21.70					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 5/3 Patient: 138 Treatment: Placebo Sex: Female

			Visit number / Laboratory date			
			Screen		Follow up	
			14/05/92		04/06/92	
			value	(◊)	value	(◊)
Laboratory test	Range value	Range date				
HB	12-18 (G/DL)	01/05/92	13.40			
	12-16 (G/DL)	01/06/92			13.70	
HT	35-55 (%)	01/05/92	41.40			
	36-53 (%)	01/06/92			41.40	
RBC	3.5-6 (10¬6/UL)	01/05/92	4.45			
	4-5 (10¬6/MM3)	01/06/92			4.49	
WBC	3.5-11 (10¬3/UL)	01/05/92	6.06			
	4-10 (10¬3/MM3)	01/06/92			7.70	
WBC: N	60-70 (%)	01/05/92	67.80		63.00	
WBC: L	20-30 (%)	01/05/92	22.60		29.00	
WBC: E	1-3 (%)	01/05/92	6.30	>>	4.00	>>
WBC: M	5-10 (%)	01/05/92	3.10	<	4.00	<
WBC: B	0-1 (%)	01/05/92	0.10		0.00	
PLATELETS	125-425 (10¬3/UL)	01/05/92	98.00	<		
	()	01/06/92				
NA+	()	01/06/92				
	138-145 (MMOL/L)	01/05/92	140.00			
K+	()	01/06/92				
	3.8-5 (MMOL/L)	01/05/92	3.90			
CL-	()	01/06/92				
	98-107 (MMOL/L)	01/05/92	95.00	<		
Ca++	()	01/06/92				
	2.3-2.55 (MMOL/L)	01/05/92	2.26	<		
PO4--	()	01/06/92				
	0.9-1.75 (MMOL/L)	01/05/92	1.28			
SGOT	5-25 (UI/L)	01/05/92	720.00	>>		
	10-35 (UI/L)	01/06/92			18.00	
SGPT	5-32 (UI/L)	01/05/92	575.00	>>		
	10-44 (UI/L)	01/06/92			49.00	>
GAMMA GT	5-37 (UI/L)	01/05/92	127.00	>>		
	7-32 (UI/L)	01/06/92			60.00	>
LDH	120-300 (UI/L)	01/05/92	924.00	>>		
	150-450 (UI/L)	01/06/92			154.00	
ALK. PHOSPH.	30-100 (UI/L)	01/05/92	36.00			
	39-117 (UI/L)	01/06/92			41.00	
GLUCOSE	()	01/06/92				
	4.2-6.2 (MMOL/L)	01/05/92	4.90			
BUN	()	01/05/92				
UREA	()	01/06/92				
	3.5-7.5 (MMOL/L)	01/05/92	3.50			
CREATININE	()	01/06/92				
	80-115 (UMOL/L)	01/05/92	69.00	<		
URIC ACID	()	01/06/92				
	150-420 (UMOL/L)	01/05/92	253.00			
TOT BILIRUBIN	7-17 (UMOL/L)	01/05/92	9.00			
	2-12 (MG/L)	01/06/92			5.00	
DIR BILIRUBIN	()	01/05/92				
TOT. PROTEINS	()	01/06/92				
	65-77 (G/L)	01/05/92	67.00			
ALBUMINE	35-50 (G/L)	01/05/92	36.30			
	37-48 (G/L)	01/06/92				
TOT. CHOLEST.	()	01/06/92				
	3.7-5.8 (MMOL/L)	01/05/92	5.40			
TRIGLYCERIDES	()	01/06/92				
	0.69-1.61 (MMOL/L)	01/05/92	0.94			
GLOBULINS ALPHA 1	2.5-5.7 (G/L)	01/05/92	2.60			
	2-3 (G/L)	01/06/92				
GLOBULINS ALPHA 2	4.1-10.1 (G/L)	01/05/92	7.80			
	4-7 (G/L)	01/06/92				
GLOBULINS BETA	5.6-12.6 (G/L)	01/05/92	10.40			
	7-12 (G/L)	01/06/92				

1772

(CONTINUED)

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA

Centre: 5/3 Patient: 138 Treatment: Placebo Sex: Female

			Visit number / Laboratory date			
			Screen		Follow up	
			14/05/92		04/06/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
GLOBULINS GAMMA	7.8-19.3 (G/L)	01/05/92	9.80			
	7-15 (G/L)	01/06/92				
TSH	0.2-4 (MUI/L)	01/05/92	5.82			
	0.3-5 (UU/L)	01/06/92				
T4	13-29 (PMOL/L)	01/05/92	17.30			
	50-115 (UG/L)	01/06/92				

1773

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 6/1 Patient: 151 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 7	
			15/01/92		30/01/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	14-17 (G/DL)	01/01/91	15.20		15.60	
HT	40-54 (%)	01/01/91	46.20		46.80	
RBC	4.5-5.7 (10-6/UL)	01/01/91	4.72		4.95	
WBC	5-10 (10-3/UL)	01/01/91	7.90		8.50	
WBC: N	52-68 (%)	01/01/91	56.00		56.00	
WBC: L	26-38 (%)	01/01/91	40.00	>	34.00	
WBC: E	0-5 (%)	01/01/91	1.00		4.00	
WBC: M	0-8 (%)	01/01/91	3.00		5.00	
WBC: B	0-2 (%)	01/01/91	0.00		1.00	
PLATELETS	150-450 (10-3/UL)	01/01/91	242.00		238.00	
NA+	135-145 (MEQ/L)	01/01/91	144.00		140.00	
K+	3.5-5 (MEQ/L)	01/01/91	4.00		5.20	>
CL-	92-105 (MEQ/L)	01/01/91	100.00		103.00	
Ca++	90-100 (MG/L)	01/01/91	96.00		89.00	<
PO4--	25-50 (MG/L)	01/01/91	47.00		40.00	
SGOT	5-37 (UI/L)	01/01/91	35.00		44.00	>
SGPT	5-40 (UI/L)	01/01/91	22.00		30.00	
GAMMA GT	11-43 (UI/L)	01/01/91	92.00	>>	86.00	>>
LDH	200-480 (UI/L)	01/01/91	395.00		242.00	
ALK. PHOSPH.	100-290 (UI/L)	01/01/91	148.00		66.00	<
GLUCOSE	0.8-1.1 (G/L)	01/01/91	0.88		0.78	<
UREA	3.32-8.3 (MMOL/L)	01/01/91	2.15	<	2.65	<
CREATININE	79.6-132.7 (UMOL/L)	01/01/91	57.50	<	61.90	<
URIC ACID	180-416 (UMOL/L)	01/01/91	245.00		285.00	
TOT BILIRUBIN	3-17.1 (UMOL/L)	01/01/91	10.20		3.00	
TOT. PROTEINS	65-75 (G/L)	01/01/91	69.00		66.00	
ALBUMINE	35-47 (G/L)	01/01/91	40.00		36.50	
TOT. CHOLEST.	5.16-7.22 (MMOL/L)	01/01/91	4.41	<	4.18	<
TRIGLYCERIDES	0.5-1.71 (MMOL/L)	01/01/91	1.61		0.86	
GLOBULINS ALPHA 1	1-3 (G/L)	01/01/91	3.10	>	2.00	
GLOBULINS ALPHA 2	4-9 (G/L)	01/01/91	7.80		8.50	
GLOBULINS BETA	7-13 (G/L)	01/01/91	9.20		8.90	
GLOBULINS GAMMA	9-14 (G/L)	01/01/91	8.70	<	9.90	
TSH	0.2-3 (UUI/ML)	01/01/91	3.81	>>		
T4	8-20 (PG/ML)	01/01/91	9.10			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0
9550082
LABORATORY DATA
Centre: 6/1 Patient: 152 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			19/02/92		16/03/92		11/04/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-17 (G/DL)	01/01/91	12.40	<	13.30	<	13.30	<
HT	40-54 (%)	01/01/91	36.60	<	41.20		39.60	<
RBC	4.5-5.7 (10-6/UL)	01/01/91	4.15	<	4.58		4.45	<
WBC	5-10 (10-3/UL)	01/01/91	6.80		7.80		5.70	
WBC: N	52-68 (%)	01/01/91	58.00		68.00		62.00	
WBC: L	26-38 (%)	01/01/91	34.00		25.00	<	34.00	
WBC: E	0-5 (%)	01/01/91	5.00		3.00		2.00	
WBC: M	0-8 (%)	01/01/91	3.00		4.00		2.00	
WBC: B	0-2 (%)	01/01/91	0.00		0.00		0.00	
PLATELETS	150-450 (10-3/UL)	01/01/91	215.00		216.00		215.00	
NA+	135-145 (MEQ/L)	01/01/91	142.00		144.00		145.00	
K+	3.5-5 (MEQ/L)	01/01/91	3.90		4.00		4.40	
CL-	92-105 (MEQ/L)	01/01/91	101.00		100.00		101.00	
Ca++	90-100 (MG/L)	01/01/91	96.00		98.00		101.00	>
PO4--	25-50 (MG/L)	01/01/91	36.00		36.00		38.00	
SGOT	5-37 (UI/L)	01/01/91	23.00		16.00		23.00	
SGPT	5-40 (UI/L)	01/01/91	22.00		16.00		24.00	
GAMMA GT	11-43 (UI/L)	01/01/91	20.00		16.00		18.00	
LDH	200-480 (UI/L)	01/01/91	263.00		228.00		211.00	
ALK. PHOSPH.	100-290 (UI/L)	01/01/91	158.00		169.00		189.00	
GLUCOSE	0.8-1.1 (G/L)	01/01/91	0.86		0.89		0.90	
UREA	3.32-8.3 (MMOL/L)	01/01/91	6.64		5.47		5.14	
CREATININE	79.6-132.7 (UMOL/L)	01/01/91	79.60		90.20		90.20	
URIC ACID	180-416 (UMOL/L)	01/01/91	321.00		297.00		339.00	
TOT BILIRUBIN	3-17 (UMOL/L)	01/01/91	7.00		4.00		3.00	
TOT. PROTEINS	65-75 (G/L)	01/01/91	67.00		67.00		67.00	
ALBUMINE	35-47 (G/L)	01/01/91	40.10		37.70		34.30	<
TOT. CHOLEST.	5.16-7.22 (MMOL/L)	01/01/91	5.34		5.72		4.61	<
TRIGLYCERIDES	0.5-1.71 (MMOL/L)	01/01/91	0.79		1.32		0.95	
GLOBULINS ALPHA 1	1-3 (G/L)	01/01/91	1.80		1.90		2.70	
GLOBULINS ALPHA 2	4-9 (G/L)	01/01/91	7.30		8.50		8.90	
GLOBULINS BETA	7-13 (G/L)	01/01/91	7.50		8.70		9.30	
GLOBULINS GAMMA	9-14 (G/L)	01/01/91	10.00		10.00		11.60	
TSH	0.2-3 (UUI/ML)	01/01/91	0.43					
T4	8-20 (PG/ML)	01/01/91	11.90					

1775

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/1 Patient: 153 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/03/91		08/04/91		03/05/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-17 (G/DL)	01/01/91	15.40		15.70		15.30	
HT	40-54 (%)	01/01/91	47.00		48.60		46.40	
RBC	4.5-5.7 (10¬6/UL)	01/01/91	5.20		5.36		5.10	
WBC	5-10 (10¬3/UL)	01/01/91	6.20		9.60		6.50	
WBC: N	52-68 (%)	01/01/91	50.00	<	62.00		63.00	
WBC: L	26-38 (%)	01/01/91	43.00	>	31.00		33.00	
WBC: E	0-5 (%)	01/01/91	5.00		5.00		2.00	
WBC: M	0-8 (%)	01/01/91	2.00		2.00		2.00	
WBC: B	0-2 (%)	01/01/91	0.00		0.00		0.00	
PLATELETS	150-450 (10¬3/UL)	01/01/91	210.00		208.00		200.00	
NA+	135-145 (MEQ/L)	01/01/91	140.00		140.00		139.00	
K+	3.5-5 (MEQ/L)	01/01/91	3.80		4.20		3.40	<
CL-	92-105 (MEQ/L)	01/01/91	96.00		101.00		101.00	
Ca++	90-100 (MG/L)	01/01/91	96.00		90.00		99.00	
PO4--	25-50 (MG/L)	01/01/91	30.00		38.00		42.00	
SGOT	5-37 (UI/L)	01/01/91	20.00		31.00		19.00	
SGPT	5-40 (UI/L)	01/01/91	22.00		32.00		19.00	
GAMMA GT	11-43 (UI/L)	01/01/91	20.00		29.00		26.00	
LDH	200-480 (UI/L)	01/01/91	265.00		245.00		239.00	
ALK. PHOSPH.	100-290 (UI/L)	01/01/91	135.00		130.00		131.00	
GLUCOSE	0.8-1.1 (G/L)	01/01/91	0.95		1.07		0.77	<
UREA	3.32-8.3 (MMOL/L)	01/01/91	3.65		6.80		5.31	
CREATININE	79.6-132.7 (UMOL/L)	01/01/91	78.60	<	81.40		83.20	
URIC ACID	180-416 (UMOL/L)	01/01/91	297.00		297.00		339.00	
TOT BILIRUBIN	3-17.1 (UMOL/L)	01/01/91	13.20		15.40		10.00	
TOT. PROTEINS	65-75 (G/L)	01/01/91	64.00	<	69.00		68.00	
ALBUMINE	35-47 (G/L)	01/01/91	40.50		42.10		39.00	
TOT. CHOLEST.	5.16-7.22 (MMOL/L)	01/01/91	3.89	<	4.18	<	3.94	<
TRIGLYCERIDES	0.5-1.71 (MMOL/L)	01/01/91	1.22		1.34		0.87	
GLOBULINS ALPHA 1	1-3 (G/L)	01/01/91	1.40		2.20		2.20	
GLOBULINS ALPHA 2	4-9 (G/L)	01/01/91	4.20		4.90		5.10	
GLOBULINS BETA	7-13 (G/L)	01/01/91	6.40	<	7.70		8.30	
GLOBULINS GAMMA	9-14 (G/L)	01/01/91	11.40		12.00		13.20	
TSH	0.2-3 (UUI/ML)	01/01/91	1.65					
T4	8-20 (PG/ML)	01/01/91	14.20					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 6/1 Patient: 154 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			25/03/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	14-17 (G/DL)	01/01/91	12.80	<
HT	40-54 (%)	01/01/91	36.90	<
RBC	4.5-5.7 (10¬6/UL)	01/01/91	4.48	<
WBC	5-10 (10¬3/UL)	01/01/91	7.30	
WBC: N	52-68 (%)	01/01/91	45.00	<
WBC: L	26-38 (%)	01/01/91	49.00	>
WBC: E	0-5 (%)	01/01/91	4.00	
WBC: M	0-8 (%)	01/01/91	2.00	
WBC: B	0-2 (%)	01/01/91	0.00	
PLATELETS	150-450 (10¬3/UL)	01/01/91	246.00	
NA+	135-145 (MEQ/L)	01/01/91	141.00	
K+	3.5-5 (MEQ/L)	01/01/91	4.30	
CL-	92-105 (MEQ/L)	01/01/91	102.00	
Ca++	90-100 (MG/L)	01/01/91	100.00	
PO4--	25-50 (MG/L)	01/01/91	35.00	
SGOT	5-37 (UI/L)	01/01/91	19.00	
SGPT	5-40 (UI/L)	01/01/91	14.00	
GAMMA GT	11-43 (UI/L)	01/01/91	14.00	
LDH	200-480 (UI/L)	01/01/91	267.00	
ALK. PHOSPH.	100-290 (UI/L)	01/01/91	106.00	
GLUCOSE	0.8-1.1 (G/L)	01/01/91	0.94	
UREA	3.32-8.3 (MMOL/L)	01/01/91	4.64	
CREATININE	79.6-132.7 (UMOL/L)	01/01/91	80.50	
URIC ACID	180-416 (UMOL/L)	01/01/91	196.00	
TOT BILIRUBIN	3-17 (UMOL/L)	01/01/91	4.00	
TOT. PROTEINS	65-75 (G/L)	01/01/91	68.00	
ALBUMINE	35-47 (G/L)	01/01/91	39.50	
TOT. CHOLEST.	5.16-7.22 (MMOL/L)	01/01/91	4.64	<
TRIGLYCERIDES	0.5-1.71 (MMOL/L)	01/01/91	0.39	<
GLOBULINS ALPHA 1	1-3 (G/L)	01/01/91	2.40	
GLOBULINS ALPHA 2	4-9 (G/L)	01/01/91	7.70	
GLOBULINS BETA	7-13 (G/L)	01/01/91	7.80	
GLOBULINS GAMMA	9-14 (G/L)	01/01/91	10.40	
TSH	0.2-3 (UUI/ML)	01/01/91	4.20	>>
T4	8-20 (PG/ML)	01/01/91	11.30	

1777

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA

Centre: 6/1 Patient: 155 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 28	
			02/07/92		30/07/92		06/08/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-17 (G/DL)	01/07/92	16.40		14.70			
	14-18 (G/DL)	01/08/92					13.90	<
HT	40-54 (%)	01/07/92	49.60		45.10			
	42-52 (%)	01/08/92					41.00	<
RBC	4.5-5.7 (10¬6/UL)	01/07/92	5.08		4.58			
	4.7-5.1 (10¬6/UL)	01/08/92					4.27	<
WBC	5-10 (10¬3/UL)	01/07/92	8.20		5.80			
	4.8-10.8 (10¬3/UL)	01/08/92					7.90	
WBC: N	52-68 (%)	01/07/92	55.00		55.00			
	42-75 (%)	01/08/92					58.00	
WBC: L	26-38 (%)	01/07/92	42.00	>	38.00			
	20-50 (%)	01/08/92					33.10	
WBC: E	0-5 (%)	01/07/92	2.00		2.00			
	0-10 (%)	01/08/92					0.40	
WBC: M	0-8 (%)	01/07/92	1.00		5.00			
	0-9.3 (%)	01/08/92					2.90	
WBC: B	0-2 (%)	01/07/92	0.00		0.00			
	0-0.2 (%)	01/08/92					0.40	>>
PLATELETS	150-450 (10¬3/UL)	01/07/92	237.00		214.00			
	130-400 (10¬3/UL)	01/08/92					217.00	
NA+	135-145 (MEQ/L)	01/07/92	140.00		144.00			
	135-145 (MMOL/L)	01/08/92					143.00	
K+	3.5-5 (MEQ/L)	01/07/92	4.30		4.10			
	3.6-5 (MMOL/L)	01/08/92					4.00	
CL-	92-105 (MEQ/L)	01/07/92	98.00		101.00			
	97-107 (MMOL/L)	01/08/92					103.00	
Ca++	2.2-2.62 (MMOL/L)	01/07/92	2.57		2.62			
	2.2-2.6 (MMOL/L)	01/08/92					2.50	
PO4--	0.8-1.61 (MMOL/L)	01/07/92	1.16		1.00			
	0.8-1.3 (MMOL/L)	01/08/92					1.16	
SGOT	5-37 (UI/L)	01/07/92	20.00		23.00			
	5-25 (UI/L)	01/08/92					11.00	
SGPT	5-40 (UI/L)	01/07/92	15.00		17.00			
	5-27 (UI/L)	01/08/92					10.00	
GAMMA GT	11-43 (UI/L)	01/07/92	27.00		17.00			
	5-35 (UI/L)	01/08/92					7.00	
LDH	200-480 (UI/L)	01/07/92	269.00		276.00		225.00	
ALK. PHOSPH.	100-290 (UI/L)	01/07/92	122.00		102.00			
	60-220 (UI/L)	01/08/92					43.00	<
GLUCOSE	4.44-6.1 (MMOL/L)	01/07/92	5.99		5.05			
	3.6-5.8 (MMOL/L)	01/08/92					4.30	
UREA	3.32-8.3 (MMOL/L)	01/07/92	6.97		4.81			
	2-8 (MMOL/L)	01/08/92					6.80	
CREATININE	79.6-132.7 (UMOL/L)	01/07/92	95.50		106.20			
	45-110 (UMOL/L)	01/08/92					97.00	
URIC ACID	180-416 (UMOL/L)	01/07/92	392.00		559.00	>>		
	200-400 (UMOL/L)	01/08/92					636.00	>>
TOT BILIRUBIN	3-17.1 (UMOL/L)	01/07/92	10.20		8.50			
	2-17 (UMOL/L)	01/08/92					7.00	
TOT. PROTEINS	65-75 (G/L)	01/07/92	76.00	>	71.00			
	60-75 (G/L)	01/08/92					65.00	
ALBUMINE	35-47 (G/L)	01/07/92	42.20		42.60			
	35-55 (G/L)	01/08/92					40.20	
TOT. CHOLEST.	5.16-7.22 (MMOL/L)	01/07/92	6.94		6.47		6.30	
TRIGLYCERIDES	0.5-1.71 (MMOL/L)	01/07/92	0.86		1.04			
GLOBULINS ALPHA 1	1-3 (G/L)	01/07/92	2.50		2.10			
	3-5 (%)	01/08/92					4.40	
GLOBULINS ALPHA 2	4-9 (G/L)	01/07/92	8.40		7.20			
	6-10 (%)	01/08/92					6.60	
GLOBULINS BETA	7-13 (G/L)	01/07/92	10.10		8.20			
	10-15 (%)	01/08/92					12.20	

1778

(CONTINUED)

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/1 Patient: 155 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 28	
			02/07/92		30/07/92		06/08/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
GLOBULINS GAMMA	9-14 (G/L)	01/07/92	12.60		10.70			
	12-20 (%)	01/08/92					16.00	
TSH	0.2-3 (UUI/ML)	01/07/92	0.92					
T4	8-20 (PG/ML)	01/07/92	10.50					

1779

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 6/1 Patient: 156 Treatment: Placebo Sex: Female

			Visit number / Laboratory date	
			Screen	
			03/09/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	14-17 (G/DL)	01/01/91	12.70	<
HT	40-54 (%)	01/01/91	37.90	<
RBC	4.5-5.7 (10¬6/UL)	01/01/91	4.26	<
WBC	5-10 (10¬3/UL)	01/01/91	10.10	>
WBC: N	52-68 (%)	01/01/91	53.00	
WBC: L	26-38 (%)	01/01/91	42.00	>
WBC: E	0-5 (%)	01/01/91	4.00	
WBC: M	0-8 (%)	01/01/91	1.00	
WBC: B	0-2 (%)	01/01/91	0.00	
PLATELETS	150-450 (10¬3/UL)	01/01/91	301.00	
NA+	135-145 (MEQ/L)	01/01/91	140.00	
K+	3.5-5 (MEQ/L)	01/01/91	4.10	
CL-	92-105 (MEQ/L)	01/01/91	102.00	
Ca++	90-100 (MG/L)	01/01/91	95.00	
PO4--	25-50 (MG/L)	01/01/91	27.00	
SGOT	5-37 (UI/L)	01/01/91	22.00	
SGPT	5-40 (UI/L)	01/01/91	36.00	
GAMMA GT	11-43 (UI/L)	01/01/91	46.00	>
LDH	200-480 (UI/L)	01/01/91	278.00	
ALK. PHOSPH.	100-290 (UI/L)	01/01/91	63.00	<
GLUCOSE	0.8-1.1 (G/L)	01/01/91	1.05	
UREA	3.32-8.3 (MMOL/L)	01/01/91	7.80	
CREATININE	79.6-132.7 (UMOL/L)	01/01/91	67.20	<
URIC ACID	180-416 (UMOL/L)	01/01/91	208.00	
TOT BILIRUBIN	3-17 (UMOL/L)	01/01/91	5.10	
TOT. PROTEINS	65-75 (G/L)	01/01/91	63.00	<
ALBUMINE	35-47 (G/L)	01/01/91	35.40	
TOT. CHOLEST.	5.16-7.22 (MMOL/L)	01/01/91	5.05	<
TRIGLYCERIDES	0.5-1.71 (MMOL/L)	01/01/91	1.02	
GLOBULINS ALPHA 1	1-3 (G/L)	01/01/91	2.00	
GLOBULINS ALPHA 2	4-9 (G/L)	01/01/91	9.30	>
GLOBULINS BETA	7-13 (G/L)	01/01/91	8.70	
GLOBULINS GAMMA	9-14 (G/L)	01/01/91	7.40	<
TSH	0.2-3 (UUI/ML)	01/01/91	2.03	
T4	8-20 (PG/ML)	01/01/91	8.50	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/2 Patient: 157 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			23/04/91		21/05/91		10/06/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-15 (G/DL)	01/04/91	16.50	>	15.40	>	16.20	>
HT	35-55 (%)	01/04/91	46.40		43.70		45.20	
RBC	4.5-5.5 (10~6/UL)	01/04/91	5.20		4.92		5.10	
WBC	4-10 (10~3/UL)	01/04/91	5.60		6.30		6.10	
WBC: N	50-75 (%)	01/04/91	57.00		57.00		57.00	
WBC: L	25-40 (%)	01/04/91	41.00	>	38.00		39.00	
WBC: E	1-3 (%)	01/04/91	0.00	<	3.00		0.00	<
WBC: M	2-10 (%)	01/04/91	2.00		2.00		2.00	
WBC: B	0-1 (%)	01/04/91	0.00		0.00		2.00	>>
PLATELETS	150-400 (10~3/UL)	01/04/91	252.00		286.00		266.00	
NA+	135-145 (MEQ/L)	01/04/91	142.00		140.00		142.00	
K+	3.5-5.5 (MEQ/L)	01/04/91	5.20		3.60		4.20	
CL-	95-105 (MEQ/L)	01/04/91	102.00		100.00		102.00	
Ca++	90-105 (MG/L)	01/04/91	99.00		92.00		93.00	
PO4--	25-40 (MG/L)	01/04/91	34.00		33.00		29.00	
SGOT	5-22 (UI/L)	01/04/91	22.00		21.00		15.00	
SGPT	5-24 (UI/L)	01/04/91	14.00		15.00		12.00	
GAMMA GT	5-28 (UI/L)	01/04/91	11.00		11.00		12.00	
LDH	140-280 (UI/L)	01/04/91	165.00		165.00		177.00	
ALK. PHOSPH.	50-170 (UI/L)	01/04/91	56.00		52.00		74.00	
GLUCOSE	0.7-1.1 (G/L)	01/04/91	1.09		1.04		1.02	
UREA	0.2-0.5 (G/L)	01/04/91	0.32		0.33		0.27	
CREATININE	7-13 (MG/L)	01/04/91	10.10		9.20		9.00	
URIC ACID	30-60 (MG/L)	01/04/91	41.00		25.00	<	37.00	
TOT BILIRUBIN	3-10 (MG/L)	01/04/91	8.00		6.00		11.00	>
TOT. PROTEINS	60-80 (G/L)	01/04/91	73.00		70.00		72.70	
ALBUMINE	52-67 (%)	01/04/91	74.30	>	57.80		68.00	>
TOT. CHOLEST.	1.2-2.4 (G/L)	01/04/91	2.43	>	2.10		1.98	
TRIGLYCERIDES	0.45-1.5 (G/L)	01/04/91	0.43	<	0.40	<	0.38	<
GLOBULINS ALPHA 1	2.4-4.6 (%)	01/04/91	1.00	<<	3.70		2.70	
GLOBULINS ALPHA 2	6.6-14 (%)	01/04/91	5.30	<	8.50		7.50	
GLOBULINS BETA	9-15 (%)	01/04/91	8.60	<	13.40		8.00	<
GLOBULINS GAMMA	9-21 (%)	01/04/91	10.80		16.60		9.30	
TSH	0.5-4 (UU/ML)	01/04/91	1.26					
T4	5-20 (NG/L)	01/04/91	12.80					

1781

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 6/2 Patient: 158 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Day 21		Day 42	
			17/12/91		10/01/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-14 (G/%)	01/11/91	12.90		13.40	
HT	37-47 (%)	01/11/91	39.70		41.60	
RBC	4.2-5.4 (10-6/UL)	01/11/91	4.34		4.42	
WBC	4000-9000 (/UL)	01/11/91	9100.00	>	6500.00	
WBC: N	50-70 (%)	01/11/91	66.00		60.00	
WBC: L	25-45 (%)	01/11/91	27.00		31.00	
WBC: E	1-3 (%)	01/11/91	3.00		3.00	
WBC: M	2-10 (%)	01/11/91	4.00		5.00	
WBC: B	0-1 (%)	01/11/91	0.00		1.00	
PLATELETS	150-400 (10-3/UL)	01/11/91	290.00		292.00	
NA+	136-145 (MMOL/L)	01/11/91	138.00		139.00	
K+	3.8-4.8 (MMOL/L)	01/11/91	3.80		4.27	
CL-	96-108 (MMOL/L)	01/11/91	100.00		100.00	
Ca++	95-105 (MG/L)	01/11/91	95.00		98.00	
PO4--	30-40 (MG/L)	01/11/91	40.00		44.80	>
SGOT	5-25 (UI/L)	01/11/91	10.00		12.00	
SGPT	5-25 (UI/L)	01/11/91	7.00		8.00	
GAMMA GT	5-25 (UI/L)	01/11/91	13.00		17.00	
LDH	140-280 (UI/L)	01/11/91	187.00		206.00	
ALK. PHOSPH.	50-240 (UI/L)	01/11/91	72.00		82.00	
GLUCOSE	0.7-1.1 (G/L)	01/11/91	0.84		0.87	
UREA	0.15-0.45 (G/L)	01/11/91	0.27		0.35	
CREATININE	6-12 (MG/L)	01/11/91	8.30		9.00	
URIC ACID	40-60 (MG/L)	01/11/91	31.00	<	35.00	<
TOT BILIRUBIN	1.5-10 (MG/L)	01/11/91	5.00		6.00	
TOT. PROTEINS	60-75 (G/L)	01/11/91	66.00		71.00	
ALBUMINE	53-63 (G/L)	01/11/91	64.60	>	61.80	
TOT. CHOLEST.	1.2-2.6 (G/L)	01/11/91	1.98		2.26	
TRIGLYCERIDES	0.6-1.4 (G/L)	01/11/91	0.78		0.73	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/11/91	2.20		1.60	
GLOBULINS ALPHA 2	6-12 (%)	01/11/91	10.60		10.50	
GLOBULINS BETA	11-17 (%)	01/11/91	11.60		13.10	
GLOBULINS GAMMA	11-19 (%)	01/11/91	10.90	<	13.00	

1782

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 6/2 Patient: 159 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			11/07/91		07/08/91		29/08/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	7.4-11 (G/DL)	01/06/91	16.30	>	17.80	>	16.50	>
HT	32-52 (%)	01/06/91	47.90		49.40		47.20	
RBC	4-5.7 (10¬6/UL)	01/06/91	5.74	>	5.97	>	5.65	
WBC	4-10 (10¬3/UL)	01/06/91	9.50		8.90		10.60	>
WBC: N	2500-6500 (/MM3)	01/06/91	5320.00		5162.00		5300.00	
WBC: L	1500-3500 (/MM3)	01/06/91	3135.00		3026.00		3604.00	>
WBC: E	50-250 (/MM3)	01/06/91	95.00		0.00	<	742.00	>>
WBC: M	200-600 (/MM3)	01/06/91	950.00	>>	712.00	>	954.00	>>
WBC: B	0-100 (/MM3)	01/06/91	0.00		0.00		0.00	
PLATELETS	150000-300000 (/UL)	01/06/91	272000		278000		231000	
NA+	137-150 (MEQ/L)	01/06/91	141.00		141.00		141.00	
K+	3.7-5.2 (MEQ/L)	01/06/91	4.30		3.90		3.80	
CL-	95-104 (MEQ/L)	01/06/91	106.00	>	106.00	>	107.00	>
Ca++	90-100 (MG/L)	01/06/91	99.00		100.00		100.00	
PO4--	25-42 (MG/L)	01/06/91	42.00		33.00		37.00	
SGOT	8-20 (UI/L)	01/06/91	14.00		16.00		13.00	
SGPT	8-30 (UI/L)	01/06/91	25.00		26.00		17.00	
GAMMA GT	8-30 (UI/L)	01/06/91	22.00		16.00		25.00	
LDH	160-320 (U/L)	01/06/91	146.00	<	199.00		184.00	
ALK. PHOSPH.	30-90 (U/L)	01/06/91	44.00		52.00		45.00	
GLUCOSE	0.7¬1.1 (G/L)	01/06/91	0.87		1.10		1.01	
UREA	0.2-0.5 (G/L)	01/06/91	0.29		0.21		0.23	
CREATININE	7-13 (MG/L)	01/06/91	9.00		10.00		9.00	
URIC ACID	30-70 (MG/L)	01/06/91	65.00		62.00		64.00	
TOT BILIRUBIN	1.5-10 (MG/L)	01/06/91	8.00		8.00		9.00	
TOT. PROTEINS	65-80 (G/L)	01/06/91	70.00		74.00		73.00	
ALBUMINE	37-45 (G/L)	01/06/91	44.70		47.50	>	47.90	>
TOT. CHOLEST.	1.6-2.6 (G/L)	01/06/91	1.89		1.96		1.93	
TRIGLYCERIDES	0.5-1.7 (G/L)	01/06/91	0.84		0.93		0.89	
GLOBULINS ALPHA 1	1-3 (G/L)	01/06/91	2.10		2.40		2.80	
GLOBULINS ALPHA 2	4-7 (G/L)	01/06/91	5.60		6.20		5.70	
GLOBULINS BETA	5-8 (G/L)	01/06/91	8.50	>	8.90	>	7.70	
GLOBULINS GAMMA	8-14 (G/L)	01/06/91	9.10		9.00		8.90	
TSH	0.2-3 (UU/ML)	01/06/91	0.72					
T4	7-19 (NG/L)	01/06/91	14.80					

1783

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/2 Patient: 160 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/11/91		14/12/91		28/01/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	7.4-11 (G/DL)	01/11/91	15.30	>	14.00	>	15.70	>
HT	32-52 (%)	01/11/91	43.10		41.20		45.50	
RBC	4-5.7 (10-6/UL)	01/11/91	4.68		4.51		4.75	
WBC	4-10 (10-3/UL)	01/11/91	5.90		5.10		7.70	
WBC: N	50-70 (%)	01/11/91	53.00		52.00		63.00	
WBC: L	25-45 (%)	01/11/91	37.00		42.00		34.00	
WBC: E	1-3 (%)	01/11/91	2.00		1.00		0.00	<
WBC: M	2-9 (%)	01/11/91	8.00		5.00		3.00	
WBC: B	0-1 (%)	01/11/91	0.00		0.00		0.00	
PLATELETS	150000-300000 (/UL)	01/11/91	279000		323000	>		
NA+	137-150 (MEQ/L)	01/11/91	139.00		142.00		139.00	
K+	3.7-5.2 (MEQ/L)	01/11/91	4.50		4.60		4.40	
CL-	95-104 (MEQ/L)	01/11/91	105.00	>	105.00	>	103.00	
Ca++	90-100 (MG/L)	01/11/91	93.00		94.00		90.00	
PO4--	25-42 (MG/L)	01/11/91	35.00		37.00		30.00	
SGOT	8-20 (UI/L)	01/11/91	44.00	>>	34.00	>	32.00	>
SGPT	8-30 (UI/L)	01/11/91	78.00	>>	71.00	>>	47.00	>
GAMMA GT	8-30 (UI/L)	01/11/91	45.00	>	42.00	>	39.00	>
LDH	160-320 (U/L)	01/11/91	126.00	<	198.00		213.00	
ALK. PHOSPH.	30-90 (U/L)	01/11/91	28.00	<	59.00		53.00	
GLUCOSE	0.7-1.1 (G/L)	01/11/91	0.94		1.06		1.07	
UREA	0.2-0.5 (G/L)	01/11/91	0.33		0.27		0.31	
CREATININE	7-13 (MG/L)	01/11/91	11.00		13.00		11.00	
URIC ACID	30-70 (MG/L)	01/11/91	76.00	>	69.00		60.00	
TOT BILIRUBIN	1.5-10 (MG/L)	01/11/91	13.00	>	3.00		6.00	
TOT. PROTEINS	65-80 (G/L)	01/11/91	66.00		75.00		69.00	
ALBUMINE	37-45 (G/L)	01/11/91	40.60		47.90	>	40.30	
TOT. CHOLEST.	1.6-2.6 (G/L)	01/11/91	2.23		2.25		2.06	
TRIGLYCERIDES	0.5-1.7 (G/L)	01/11/91	1.48		1.77	>	0.98	
GLOBULINS ALPHA 1	1-3 (G/L)	01/11/91	1.60		2.00		2.20	
GLOBULINS ALPHA 2	4-7 (G/L)	01/11/91	4.40		4.70		5.40	
GLOBULINS BETA	5-8 (G/L)	01/11/91	8.90	>	8.40	>	8.30	>
GLOBULINS GAMMA	8-14 (G/L)	01/11/91	10.40		12.10		12.80	
TSH	0.2-3 (UU/ML)	01/11/91	0.90					
T4	7-19 (NG/L)	01/11/91	17.30					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/2 Patient: 161 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			18/02/92		11/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-17 (G/DL)	01/01/92	15.20		14.80	
HT	42-52 (%)	01/01/92	47.10		45.50	
RBC	4.2-5.2 (10¬6/UL)	01/01/92	5.62	>	5.34	>
WBC	4-10 (10¬3/UL)	01/01/92	9.20		19.10	>>
WBC: N	50-75 (%)	01/01/92	38.00	<	63.00	
WBC: L	25-40 (%)	01/01/92	59.00	>>	32.00	
WBC: E	1-3 (%)	01/01/92	1.00		2.00	
WBC: M	2-10 (%)	01/01/92	2.00		8.00	
WBC: B	0-1 (%)	01/01/92	0.00		0.00	
PLATELETS	150-400 (10¬3/UL)	01/01/92	255.00		285.00	
NA+	135-145 (MEQ/L)	01/01/92	138.00		137.00	
K+	3.5-5.5 (MEQ/L)	01/01/92	4.40		4.40	
CL-	95-105 (MEQ/L)	01/01/92	100.00		98.00	
Ca++	85-105 (MG/L)	01/01/92	88.00		88.00	
PO4--	20-50 (MG/L)	01/01/92	34.00		31.00	
SGOT	7-30 (U/L)	01/01/92	11.00		12.00	
SGPT	10-50 (U/L)	01/01/92	10.00		23.00	
GAMMA GT	5-25 (UI/L)	01/01/92	14.00		18.00	
LDH	150-240 (U/L)	01/01/92	114.00	<	129.00	<
ALK. PHOSPH.	60-170 (U/L)	01/01/92	67.00		50.00	<
GLUCOSE	0.7-1.1 (G/L)	01/01/92	0.85		0.90	
UREA	0.2-0.45 (G/L)	01/01/92	0.20		0.19	<
CREATININE	7-15 (MG/L)	01/01/92	7.70		8.10	
URIC ACID	30-60 (MG/L)	01/01/92	38.00		31.00	
TOT BILIRUBIN	1.5-10 (MG/L)	01/01/92	5.90		5.40	
TOT. PROTEINS	65-75 (G/L)	01/01/92	64.00	<	64.00	<
ALBUMINE	35-50 (G/L)	01/01/92	37.10		52.70	>
TOT. CHOLEST.	1.2-2 (G/L)	01/01/92	2.71	>>	2.44	>
TRIGLYCERIDES	0.4-1.5 (G/L)	01/01/92	0.95		0.75	
GLOBULINS ALPHA 1	3-4 (%)	01/01/92	2.80	<	4.20	>
GLOBULINS ALPHA 2	9-11 (%)	01/01/92	12.40	>	13.10	>
GLOBULINS BETA	12-14 (%)	01/01/92	15.00	>	9.80	<
GLOBULINS GAMMA	12-15 (%)	01/01/92	11.90	<	9.40	<
TSH	0.1-4 (MUI/L)	01/01/92	1.50			
T4	9.1-21.8 (NG/L)	01/01/92	13.60			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/2 Patient: 162 Treatment: Placebo Sex: Male

			Visit number / Laboratory data	
			Screen	
			08/07/91	
			value	(◊)
Laboratory test	Range value	Range date		
HB	7.4-11 (G/DL)	01/06/91	14.90	>
HT	32-52 (%)	01/06/91	44.20	
RBC	4-5.7 (10¬6/UL)	01/06/91	4.94	
WBC	4-10 (10¬3/UL)	01/06/91	9.90	
WBC: N	50-70 (%)	01/06/91	67.00	
WBC: L	25-45 (%)	01/06/91	24.00	<
WBC: E	1-3 (%)	01/06/91	1.00	
WBC: M	2-9 (%)	01/06/91	8.00	
WBC: B	0-1 (%)	01/06/91	0.00	
PLATELETS	150000-300000 (/UL)	01/06/91	304000	>
NA+	137-150 (MEQ/L)	01/06/91	140.00	
K+	3.7-5.2 (MEQ/L)	01/06/91	4.30	
CL-	95-104 (MEQ/L)	01/06/91	103.00	
Ca++	90-100 (MG/L)	01/06/91	98.00	
PO4--	25-42 (MG/L)	01/06/91	30.00	
SGOT	8-20 (UI/L)	01/06/91	13.00	
SGPT	8-30 (UI/L)	01/06/91	12.00	
GAMMA GT	8-30 (UI/L)	01/06/91	19.00	
LDH	160-320 (U/L)	01/06/91	159.00	<
ALK. PHOSPH.	30-90 (U/L)	01/06/91	32.00	
GLUCOSE	0.7-1.1 (G/L)	01/06/91	0.95	
UREA	0.2-0.5 (G/L)	01/06/91	0.35	
CREATININE	7-13 (MG/L)	01/06/91	10.00	
URIC ACID	30-70 (MG/L)	01/06/91	37.00	
TOT BILIRUBIN	1.5-10 (MG/L)	01/06/91	5.00	
TOT. PROTEINS	65-80 (G/L)	01/06/91	68.00	
ALBUMINE	37-45 (G/L)	01/06/91	42.70	
TOT. CHOLEST.	1.6-2.6 (G/L)	01/06/91	1.84	
TRIGLYCERIDES	0.5-1.7 (G/L)	01/06/91	0.89	
GLOBULINS ALPHA 1	1-3 (G/L)	01/06/91	2.20	
GLOBULINS ALPHA 2	4-7 (G/L)	01/06/91	5.60	
GLOBULINS BETA	5-8 (G/L)	01/06/91	8.70	>
GLOBULINS GAMMA	8-14 (G/L)	01/06/91	8.80	
TSH	0.2-3 (UU/ML)	01/06/91	0.30	
T4	7-19 (NG/L)	01/06/91	15.10	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 6/2 Patient: 169 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			09/12/91		15/01/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	7.4-11 (G/DL)	01/12/91	12.20	>	13.50	>
HT	32-52 (%)	01/12/91	35.60		41.20	
RBC	4-5.7 (10-6/UL)	01/12/91	3.78	<	4.39	
WBC	4-10 (10-3/UL)	01/12/91	9.70		11.00	>
WBC: N	50-70 (%)	01/12/91	68.00		68.00	
WBC: L	25-45 (%)	01/12/91	30.00		28.00	
WBC: E	1-3 (%)	01/12/91	1.00		2.00	
WBC: M	2-9 (%)	01/12/91	1.00	<	2.00	
WBC: B	0-1 (%)	01/12/91	0.00		0.00	
PLATELETS	150000-350000 (/UL)	01/12/91	190000		183000	
NA+	137-150 (MEQ/L)	01/12/91	135.00	<	142.00	
K+	3.7-5.2 (MEQ/L)	01/12/91	4.40		4.70	
CL-	100-104 (MEQ/L)	01/12/91	98.00	<	101.00	
Ca++	90-105 (MG/L)	01/12/91	99.00		102.00	
PO4--	30-40 (MG/L)	01/12/91	40.00		30.00	
SGOT	5-18 (UI/L)	01/12/91	19.00	>	15.00	
SGPT	5-15 (UI/L)	01/12/91	6.00		8.00	
GAMMA GT	4-28 (UI/L)	01/12/91	14.00		10.00	
LDH	120-240 (UI/L)	01/12/91	221.00		239.00	
ALK. PHOSPH.	60-170 (UI/L)	01/12/91	99.00		103.00	
GLUCOSE	0.7-1.1 (G/L)	01/12/91	0.91		0.98	
UREA	0.2-0.45 (G/L)	01/12/91	0.38		0.46	>
CREATININE	5-13 (MG/L)	01/12/91	11.50		11.90	
URIC ACID	40-65 (MG/L)	01/12/91	36.00	<	37.00	<
TOT BILIRUBIN	2-10 (MG/L)	01/12/91	8.00		3.00	
TOT. PROTEINS	60-75 (G/L)	01/12/91	63.00		73.00	
ALBUMINE	34-48 (G/L)	01/12/91	41.00		43.20	
TOT. CHOLEST.	1.8-2.6 (G/L)	01/12/91	2.13		2.45	
TRIGLYCERIDES	0.6-1.5 (G/L)	01/12/91	0.47	<	0.88	
GLOBULINS ALPHA 1	1-4 (%)	01/12/91	2.40		3.90	
GLOBULINS ALPHA 2	6-9 (%)	01/12/91	7.10		9.00	
GLOBULINS BETA	10-14 (%)	01/12/91	11.40		12.50	
GLOBULINS GAMMA	13-19 (%)	01/12/91	14.00		15.30	

1787

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0
9550082
LABORATORY DATA
Centre: 6/2 Patient: 170 Treatment: Placebo Sex: Male

			Visit number / Laboratory date	
			Screen	
			29/10/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	11-15 (G/DL)	01/10/91	14.20	
HT	42-48 (%)	01/10/91	39.00	<
RBC	4.5-5.5 (10-6/UL)	01/10/91	4.59	
WBC	5-10 (10-3/UL)	01/10/91	5.60	
WBC: N	45-70 (%)	01/10/91	60.00	
WBC: L	20-40 (%)	01/10/91	32.00	
WBC: E	1-2 (%)	01/10/91	3.00	>>
WBC: M	2-8 (%)	01/10/91	3.00	
WBC: B	0-1 (%)	01/10/91	2.00	>>
NA+	135-145 (MMOL/L)	01/10/91	139.00	
K+	3.5-5 (MMOL/L)	01/10/91	4.50	
CL-	95-110 (MMOL/L)	01/10/91	103.00	
Ca++	81-104 (MG/L)	01/10/91	89.00	
PO4--	25-50 (MG/L)	01/10/91	36.00	
SGOT	4-45 (UI/L)	01/10/91	11.00	
SGPT	4-45 (UI/L)	01/10/91	10.00	
GAMMA GT	3-38 (UI/L)	01/10/91	19.00	
LDH	160-320 (UI/L)	01/10/91	262.00	
ALK. PHOSPH.	50-70 (UI/L)	01/10/91	75.00	>
GLUCOSE	0.6-1.1 (G/L)	01/10/91	0.83	
UREA	0.18-0.43 (G/L)	01/10/91	0.22	
CREATININE	0-12 (MG/L)	01/10/91	10.50	
URIC ACID	34-70 (MG/L)	01/10/91	46.00	
TOT BILIRUBIN	1-10 (MG/L)	01/10/91	3.70	
TOT. PROTEINS	62-80 (G/L)	01/10/91	69.00	
ALBUMINE	39-53 (G/L)	01/10/91	42.60	
TOT. CHOLEST.	1.4-2.5 (G/L)	01/10/91	2.55	>
TRIGLYCERIDES	0.5-1.5 (G/L)	01/10/91	1.13	
GLOBULINS ALPHA 1	2-4.5 (%)	01/10/91	1.70	<
GLOBULINS ALPHA 2	10-14 (%)	01/10/91	9.90	<
GLOBULINS BETA	6-13 (%)	01/10/91	12.40	
GLOBULINS GAMMA	10-19 (%)	01/10/91	14.20	
TSH	0.6-4.8 (UU/ML)	01/10/91	1.84	
T4	4.6-12 (UG/DL)	01/10/91	7.70	

1788

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/2 Patient: 171 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			20/07/92		11/08/92		16/09/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/92	12.60		12.50		12.20	
HT	37-47 (%)	01/06/92	38.60		38.10		37.40	
RBC	4-5.4 (10¬6/UL)	01/06/92	4.11		4.07		3.99	<
WBC	5-10 (10¬3/UL)	01/06/92	6.00		6.10		4.60	<
WBC: N	45-70 (%)	01/06/92	60.90		67.36		56.21	
WBC: L	20-40 (%)	01/06/92	31.28		25.19		35.17	
WBC: E	1-2 (%)	01/06/92	1.32		1.01		1.29	
WBC: M	2-8 (%)	01/06/92	5.98		5.93		6.55	
WBC: B	0-1 (%)	01/06/92	0.52		0.50		0.78	
PLATELETS	150-450 (10¬3/UL)	01/06/92	245.00		247.00		252.00	
NA+	132-145 (MEQ/L)	01/06/92	144.00		141.00		143.00	
K+	3.8-5.2 (MEQ/L)	01/06/92	4.00		4.00		4.10	
CL-	90-110 (MEQ/L)	01/06/92	102.00		107.00		106.00	
Ca++	88-102 (MG/L)	01/06/92	99.00		95.00		94.00	
PO4--	25-47 (MG/L)	01/06/92	42.00		37.00		38.00	
SGOT	5-25 (UI/L)	01/06/92	17.00		20.00		20.00	
SGPT	5-22 (UI/L)	01/06/92	13.00		21.00		30.00	>
GAMMA GT	5-25 (UI/L)	01/06/92	5.00		12.00		14.00	
LDH	140-280 (UI/L)	01/06/92	181.00		202.00		229.00	
ALK. PHOSPH.	30-90 (UI/L)	01/06/92	50.00		61.00		62.00	
GLUCOSE	0.6-1.1 (G/L)	01/06/92	1.00		0.95		0.95	
UREA	0.15-0.45 (G/L)	01/06/92	0.34		0.36		0.30	
CREATININE	5-14 (MG/L)	01/06/92	6.30		8.00		9.40	
URIC ACID	20-60 (MG/L)	01/06/92	50.00		47.00		43.00	
TOT BILIRUBIN	2-12 (MG/L)	01/06/92	6.00		6.00		5.00	
TOT. PROTEINS	60-75 (G/L)	01/06/92	68.00		67.00		66.00	
ALBUMINE	52-65 (%)	01/06/92	57.70		65.50	>	61.70	
TOT. CHOLEST.	1.5-2.6 (G/L)	01/06/92	2.09		1.86		2.09	
TRIGLYCERIDES	0.4-1.5 (G/L)	01/06/92	0.52		0.43		0.43	
GLOBULINS ALPHA 1	1.2-5 (%)	01/06/92	6.00	>	2.30		4.50	
GLOBULINS ALPHA 2	6-12 (%)	01/06/92	11.70		9.80		11.20	
GLOBULINS BETA	11-17 (%)	01/06/92	15.10		11.30		9.40	<
GLOBULINS GAMMA	11-20 (%)	01/06/92	9.50	<	11.10		13.20	
TSH	0.32-5 (UU/ML)	01/06/92	0.80					
T4	4.5-12 (UG/DL)	01/06/92	6.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang-
< out of range (value lower than min range) > out of range (value higher than max rang-
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/2 Patient: 172 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			07/07/92		27/07/92		22/08/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-14 (G/DL)	01/07/92	10.70	<	12.50		11.90	<
HT	37-47 (%)	01/07/92	32.90	<	35.30	<		
	34-47 (%)	01/08/92					34.70	
RBC	4.2-5.4 (10~6/UL)	01/07/92	3.56	<<	3.90	<	3.85	<
WBC	4-9 (10~3/UL)	01/07/92	4.60		4.85		3.60	<
WBC: N	45-70 (%)	01/07/92	73.00	>	63.00		59.00	
WBC: L	20-40 (%)	01/07/92	21.00		27.00		33.00	
WBC: E	1-2 (%)	01/07/92	1.00		2.00		2.00	
WBC: M	2-8 (%)	01/07/92	5.00		7.00		5.00	
WBC: B	0-1 (%)	01/07/92	0.00		1.00		1.00	
PLATELETS	150-500 (10~3/UL)	01/07/92	269.00		231.00			
	150-450 (10~3/UL)	01/08/92					259.00	
NA+	136-145 (MMOL/L)	01/07/92	136.00		140.00			
	135-145 (MMOL/L)	01/08/92					144.00	
K+	3.8-4.8 (MMOL/L)	01/07/92	4.40		3.90			
	3.5-5 (MMOL/L)	01/08/92					4.80	
CL-	96-108 (MMOL/L)	01/07/92	101.00		104.00			
	95-107 (MMOL/L)	01/08/92					106.00	
Ca++	95-105 (MG/L)	01/07/92	99.00		99.00		95.00	
PO4--	30-40 (MG/L)	01/07/92	42.00	>	35.00			
	25-51 (MG/L)	01/08/92					29.00	
SGOT	5-25 (UI/L)	01/07/92	10.00		10.00			
	5-21 (UI)	01/08/92					12.00	
SGPT	5-25 (UI/L)	01/07/92	9.00		9.00			
	5-22 (UI)	01/08/92					11.00	
GAMMA GT	5-25 (UI/L)	01/07/92	20.00		21.00		11.00	
LDH	140-280 (UI/L)	01/07/92	250.00		221.00			
	150-320 (UI/L)	01/08/92					187.00	
ALK. PHOSPH.	50-240 (UI/L)	01/07/92	76.00		85.00			
	73-207 (MU/ML)	01/08/92					59.00	<
GLUCOSE	0.7-1.1 (G/L)	01/07/92	0.88		0.86			
	0.7-1.15 (G/L)	01/08/92					0.72	
UREA	0.15-0.45 (G/L)	01/07/92	0.44		0.38		0.35	
CREATININE	6-12 (MG/L)	01/07/92	12.00		11.00			
	5-13 (MG/L)	01/08/92					10.00	
URIC ACID	40-60 (MG/L)	01/07/92	43.00		28.00	<		
	30-70 (MG/L)	01/08/92					36.00	
TOT BILIRUBIN	3-10 (MG/L)	01/07/92	4.00		4.00			
	1.5-10 (MG/L)	01/08/92					3.40	
DIR BILIRUBIN	0-2.5 (MG/L)	01/08/92					0.60	
TOT. PROTEINS	62-76 (G/L)	01/07/92	74.00		71.00			
	65-75 (G/L)	01/08/92					66.00	
ALBUMINE	53-63 (%)	01/07/92	50.20	<	63.20	>		
	58-67 (%)	01/08/92					68.10	>
TOT. CHOLEST.	1.2-2.6 (G/L)	01/07/92	2.64	>	2.59		2.13	
TRIGLYCERIDES	0.6-1.4 (G/L)	01/07/92	0.61		0.54	<		
	0.1-1.9 (G/L)	01/08/92					0.58	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/07/92	3.80		2.10			
	2-4 (%)	01/08/92					2.50	
GLOBULINS ALPHA 2	6-12 (%)	01/07/92	15.10	>	9.00			
	6-10 (%)	01/08/92					5.80	<
GLOBULINS BETA	5-17 (%)	01/07/92	15.90		13.30			
	8-13.5 (%)	01/08/92					11.10	
GLOBULINS GAMMA	8-19 (%)	01/07/92	14.90		12.40			
	12-19 (%)	01/08/92					12.50	
TSH	0.4-5 (UU/ML)	01/07/92	2.30		2.00			
T4	4.5-12 (UG/DL)	01/07/92	6.50		5.70			

1790

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/2 Patient: 173 Treatment: Placebo Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			26/06/92		25/07/92	
			value	(◊)	value	(◊)
Laboratory test	Range value	Range date				
HB	13-17 (G/DL)	01/06/92	15.80		15.40	
HT	40-54 (%)	01/06/92	46.20		45.20	
RBC	4.5-5.8 (10¬6/UL)	01/06/92	4.90		4.74	
WBC	4-10 (10¬3/UL)	01/06/92	4.90		5.20	
WBC: N	45-70 (%)	01/06/92	52.00		53.00	
WBC: L	20-40 (%)	01/06/92	43.00	>	42.00	>
WBC: E	1-2 (%)	01/06/92	2.00		0.00	<
WBC: M	2-8 (%)	01/06/92	2.00		5.00	
WBC: B	0-1 (%)	01/06/92	1.00		0.00	
PLATELETS	150-400 (10¬3/UL)	01/06/92	238.00		178.00	
NA+	135-145 (MEQ/L)	01/06/92	138.00		140.00	
K+	3.8-4.6 (MEQ/L)	01/06/92	4.00		4.00	
CL-	95-110 (MEQ/L)	01/06/92	103.00		104.00	
Ca++	88-102 (MG/L)	01/06/92	93.00		93.00	
PO4--	25-40 (MG/L)	01/06/92	44.00	>	26.00	
SGOT	7-25 (UI/L)	01/06/92	15.00		11.00	
SGPT	7-30 (UI/L)	01/06/92	25.00		17.00	
GAMMA GT	8-38 (UI/L)	01/06/92	22.00		24.00	
LDH	140-330 (UI/L)	01/06/92	261.00		134.00	<
ALK. PHOSPH.	30-100 (UI/L)	01/06/92	53.00		48.00	
GLUCOSE	0.7-1.1 (G/L)	01/06/92	1.08		0.91	
UREA	0.15-0.45 (G/L)	01/06/92	0.34		0.28	
CREATININE	5-13 (MG/L)	01/06/92	14.10	>	14.70	>
URIC ACID	25-70 (MG/L)	01/06/92	43.00		50.00	
TOT BILIRUBIN	1.5-10 (MG/L)	01/06/92	5.40		5.50	
TOT. PROTEINS	60-80 (G/L)	01/06/92	72.00		69.00	
ALBUMINE	57-67 (%)	01/06/92	58.90		66.80	
TOT. CHOLEST.	1.2-2.4 (G/L)	01/06/92	2.56	>	2.23	
TRIGLYCERIDES	0.5-1.5 (G/L)	01/06/92	0.81		0.63	
GLOBULINS ALPHA 1	2-4 (%)	01/06/92	3.60		2.90	
GLOBULINS ALPHA 2	6-10 (%)	01/06/92	8.30		7.20	
GLOBULINS BETA	8-12 (%)	01/06/92	15.00	>	11.80	
GLOBULINS GAMMA	12-20 (%)	01/06/92	14.20		11.30	<
TSH	0.24-4 (MUI/L)	01/06/92	1.25			
T4	0.78-1.95 (NG/DL)	01/06/92	1.10			

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA

Centre: 6/2 Patient: 174 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/05/92		01/06/92		27/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/04/92	15.90		15.20		16.00	
HT	33-52 (%)	01/04/92	45.80		45.40		47.40	
RBC	4-5.7 (10-6/UL)	01/04/92	5.11		4.95		5.23	
WBC	4-10 (10-3/UL)	01/04/92	6.00		5.90		7.30	
WBC: N	45-70 (%)	01/04/92	61.00		55.00		64.00	
WBC: L	20-40 (%)	01/04/92	34.00		38.00		30.00	
WBC: E	1-2 (%)	01/04/92	0.00	<	0.00	<	0.00	<
WBC: M	2-8 (%)	01/04/92	5.00		7.00		6.00	
WBC: B	0-1 (%)	01/04/92	0.00		0.00		0.00	
PLATELETS	150-400 (10-3/UL)	01/04/92	266.00		266.00		275.00	
NA+	135-145 (MEQ/L)	01/04/92	144.00		142.00		144.00	
K+	3.7-5.2 (MEQ/L)	01/04/92	3.80		4.00		4.00	
CL-	95-105 (MEQ/L)	01/04/92	107.00	>	106.00	>	108.00	>
Ca++	85-105 (MG/L)	01/04/92	87.00		86.00		86.00	
PO4--	25-45 (MG/L)	01/04/92	22.00	<	34.00		30.00	
SGOT	6-30 (UI/L)	01/04/92	11.00		8.00		8.00	
SGPT	5-45 (UI/L)	01/04/92	18.00		15.00		17.00	
GAMMA GT	5-38 (UI/L)	01/04/92	21.00		19.00		18.00	
LDH	140-280 (UI/L)	01/04/92	172.00		193.00		151.00	
ALK. PHOSPH.	30-100 (UI/L)	01/04/92	67.00		77.00		81.00	
GLUCOSE	0.65-1.1 (G/L)	01/04/92	1.15	>	0.92		1.16	>
UREA	0.2-0.5 (G/L)	01/04/92	0.45		0.32		0.48	
CREATININE	6-12 (MG/L)	01/04/92	11.00		9.00		10.00	
URIC ACID	20-60 (MG/L)	01/04/92	38.00		46.00		40.00	
TOT BILIRUBIN	1.5-10 (MG/L)	01/04/92	7.00		8.00		5.00	
TOT. PROTEINS	60-80 (G/L)	01/04/92	70.00		66.00		64.00	
ALBUMINE	32-50 (G/L)	01/04/92	42.20		38.30		37.20	
TOT. CHOLEST.	1.2-2.2 (G/L)	01/04/92	2.05		1.74		1.74	
TRIGLYCERIDES	0.5-1.5 (G/L)	01/04/92	0.98		0.71		0.68	
GLOBULINS ALPHA 1	1.5-4.5 (%)	01/04/92	1.90		1.80		2.60	
GLOBULINS ALPHA 2	6-12 (%)	01/04/92	8.10		7.60		8.50	
GLOBULINS BETA	11-17 (%)	01/04/92	12.10		13.60		13.30	
GLOBULINS GAMMA	11-19 (%)	01/04/92	17.50		18.90		17.40	
TSH	0.45-5 (UU/ML)	01/04/92	0.90					
T4	5-12 (UG/DL)	01/04/92	4.70	<				

1792

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 6/3 Patient: 163 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date	
			Screen	
			05/06/91	
			value	(◊)
Laboratory test	Range value	Range date		
HB	13-17 (G/DL)	01/05/91	13.50	
HT	40-54 (%)	01/05/91	42.00	
RBC	4500000-5500000 (/MM3)	01/05/91	4640000	
WBC	5000-10000 (/MM3)	01/05/91	6400.00	
WBC: N	50-70 (%)	01/05/91	55.80	
WBC: L	25-40 (%)	01/05/91	30.50	
WBC: E	1-4 (%)	01/05/91	7.20	>>
WBC: M	4-8 (%)	01/05/91	6.00	
WBC: B	0-2 (%)	01/05/91	0.50	
PLATELETS	150000-400000 (/MM3)	01/05/91	288000	
NA+	135-145 (MEQ/L)	01/05/91	140.00	
K+	3.5-4.5 (MEQ/L)	01/05/91	4.20	
CL-	95-105 (MEQ/L)	01/05/91	100.00	
Ca++	88-104 (MG/L)	01/05/91	93.00	
PO4--	25-45 (MG/L)	01/05/91	25.00	
SGOT	5-35 (UI/L)	01/05/91	12.00	
SGPT	5-35 (UI/L)	01/05/91	13.00	
GAMMA GT	5-40 (UI/L)	01/05/91	10.00	
LDH	140-330 (UI/L)	01/05/91	278.00	
ALK. PHOSPH.	50-130 (UI/L)	01/05/91	79.00	
GLUCOSE	0.8-1.1 (G/L)	01/05/91	1.00	
UREA	0.15-0.5 (G/L)	01/05/91	0.20	
CREATININE	6-12 (MG/L)	01/05/91	14.80	>
URIC ACID	20-60 (MG/L)	01/05/91	49.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	3.00	
TOT. PROTEINS	60-80 (G/L)	01/05/91	71.00	
ALBUMINE	37-42 (G/L)	01/05/91	45.90	>
TOT. CHOLEST.	1.8-2.5 (G/L)	01/05/91	2.29	
TRIGLYCERIDES	0.25-1.6 (G/L)	01/05/91	0.86	
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	2.06	
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	3.98	<
GLOBULINS BETA	5-8 (G/L)	01/05/91	6.96	
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	12.10	>
TSH	0.15-3.2 (UUI/ML)	01/05/91	0.68	
T4	7-18 (PG/ML)	01/05/91	12.00	

1793

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/3 Patient: 164 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			07/10/91		31/10/91		22/11/91	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	13-17 (G/DL)	01/05/91	15.50		16.00		15.40	
HT	40-54 (%)	01/05/91	48.00		49.00		46.00	
RBC	4500000-5500000 (/MM3)	01/05/91	5500000		5610000	>	5240000	
WBC	5000-10000 (/MM3)	01/05/91	4300.00	<	4300.00	<	3700.00	<
WBC: N	50-70 (%)	01/05/91	44.40	<	48.90	<	48.50	<
WBC: L	25-40 (%)	01/05/91	46.20	>	43.00	>	41.30	>
WBC: E	1-4 (%)	01/05/91	1.80		1.90		2.50	
WBC: M	4-8 (%)	01/05/91	6.80		5.30		6.00	
WBC: B	0-2 (%)	01/05/91	0.80		0.90		1.70	
PLATELETS	150000-400000 (/MM3)	01/05/91	252000		295000		261000	
NA+	135-145 (MEQ/L)	01/05/91	140.00		138.00		138.00	
K+	3.5-4.5 (MEQ/L)	01/05/91	3.90		4.60	>	4.30	
CL-	95-105 (MEQ/L)	01/05/91	100.00		95.00		102.00	
Ca++	88-104 (MG/L)	01/05/91	89.00		89.00		88.00	
PO4--	25-45 (MG/L)	01/05/91	28.00		26.00		27.00	
SGOT	5-35 (UI/L)	01/05/91	31.00		32.00		19.00	
SGPT	5-35 (UI/L)	01/05/91	15.00		16.00		37.00	>
GAMMA GT	5-40 (UI/L)	01/05/91	15.00		20.00		23.00	
LDH	140-330 (UI/L)	01/05/91	304.00		191.00		217.00	
ALK. PHOSPH.	50-130 (UI/L)	01/05/91	81.00		99.00		112.00	
GLUCOSE	0.8-1.1 (G/L)	01/05/91	0.90		0.91		0.78	<
UREA	0.15-0.5 (G/L)	01/05/91	0.30		0.30		0.36	
CREATININE	6-12 (MG/L)	01/05/91	14.00	>	16.10	>	15.40	>
URIC ACID	20-60 (MG/L)	01/05/91	58.00		58.00		61.00	>
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	5.00		5.00		5.00	
TOT. PROTEINS	60-80 (G/L)	01/05/91	72.00		74.00		69.00	
ALBUMINE	37-42 (G/L)	01/05/91	51.20	>	53.10	>	49.40	>
TOT. CHOLEST.	1.8-2.5 (G/L)	01/05/91	1.76	<	2.00		2.16	
TRIGLYCERIDES	0.25-1.6 (G/L)	01/05/91	0.50		0.49		0.55	
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	1.08		1.41		0.96	<
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	4.10		3.85	<	3.66	<
GLOBULINS BETA	5-8 (G/L)	01/05/91	5.40		5.25		5.52	
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	10.20		10.40		9.45	
TSH	0.15-3.2 (UUI/ML)	01/05/91	0.49					
T4	7-18 (PG/ML)	01/05/91	15.10					

1794

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 6/3 Patient: 165 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/10/91		05/11/91		26/11/91	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	11.5-15 (G/DL)	01/05/91	13.50				12.70	
HT	37-47 (%)	01/05/91	40.00				38.00	
RBC	4000000-5000000 (/MM3)	01/05/91	4750000				4490000	
WBC	5000-10000 (/MM3)	01/05/91	7100.00				8700.00	
WBC: N	50-70 (%)	01/05/91	53.80				62.20	
WBC: L	25-40 (%)	01/05/91	38.60				23.60	<
WBC: E	1-4 (%)	01/05/91	0.60	<			6.70	>>
WBC: M	4-8 (%)	01/05/91	6.20				6.60	
WBC: B	0-2 (%)	01/05/91	0.80				0.90	
PLATELETS	150000-400000 (/MM3)	01/05/91	278000				351000	
NA+	135-145 (MEQ/L)	01/05/91	139.00		139.00		140.00	
K+	3.5-4.5 (MEQ/L)	01/05/91	3.40	<	3.90		3.80	
CL-	95-105 (MEQ/L)	01/05/91	99.00		97.00		102.00	
Ca++	88-104 (MG/L)	01/05/91	98.00		95.00		96.00	
PO4--	25-45 (MG/L)	01/05/91	27.00		39.00		28.00	
SGOT	5-35 (UI/L)	01/05/91	15.00		22.00		17.00	
SGPT	5-35 (UI/L)	01/05/91	9.00		14.00		43.00	>
GAMMA GT	5-40 (UI/L)	01/05/91	13.00		22.00		184.00	>>
LDH	140-330 (UI/L)	01/05/91	250.00		207.00		279.00	
ALK. PHOSPH.	50-130 (UI/L)	01/05/91	63.00		72.00		276.00	>>
GLUCOSE	0.8-1.1 (G/L)	01/05/91	0.90		0.89		0.91	
BUN	()	01/05/91						
UREA	0.15-0.5 (G/L)	01/05/91	0.29		0.36		0.26	
CREATININE	6-12 (MG/L)	01/05/91	9.50		10.40		9.80	
URIC ACID	20-60 (MG/L)	01/05/91	52.00		48.00		42.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	5.00		4.00		3.00	
DIR BILIRUBIN	()	01/05/91						
TOT. PROTEINS	60-80 (G/L)	01/05/91	80.00		75.00		79.00	
ALBUMINE	37-42 (G/L)	01/05/91	54.60	>	50.60	>	52.00	>
TOT. CHOLEST.	1.8-2.5 (G/L)	01/05/91	3.13	>	3.00	>	2.98	>
TRIGLYCERIDES	0.25-1.6 (G/L)	01/05/91	1.01		2.36	>>	1.21	
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	2.48		2.03		2.29	
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	5.28		5.40		6.79	
GLOBULINS BETA	5-8 (G/L)	01/05/91	8.24	>	7.65		8.45	>
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	9.36		9.38		9.48	
TSH	0.15-3.2 (UUI/ML)	01/05/91	0.57					
T4	7-18 (PG/ML)	01/05/91	15.90					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/3 Patient: 166 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			25/10/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	11.5-15 (G/DL)	01/05/91	15.00	
HT	37-47 (%)	01/05/91	44.00	
RBC	4000000-5000000 (/MM3)	01/05/91	4530000	
WBC	5000-10000 (/MM3)	01/05/91	12700.0	>
WBC: N	50-70 (%)	01/05/91	66.10	
WBC: L	25-40 (%)	01/05/91	24.90	<
WBC: E	1-4 (%)	01/05/91	2.90	
WBC: M	4-8 (%)	01/05/91	5.20	
WBC: B	0-2 (%)	01/05/91	0.90	
PLATELETS	150000-400000 (/MM3)	01/05/91	210000	
NA+	135-145 (MEQ/L)	01/05/91	138.00	
K+	3.5-4.5 (MEQ/L)	01/05/91	3.40	<
CL-	95-105 (MEQ/L)	01/05/91	100.00	
Ca++	88-104 (MG/L)	01/05/91	91.00	
PO4--	25-45 (MG/L)	01/05/91	27.00	
SGOT	5-35 (UI/L)	01/05/91	26.00	
SGPT	5-35 (UI/L)	01/05/91	28.00	
GAMMA GT	5-40 (UI/L)	01/05/91	26.00	
LDH	140-330 (UI/L)	01/05/91	236.00	
ALK. PHOSPH.	50-130 (UI/L)	01/05/91	96.00	
GLUCOSE	0.8-1.1 (G/L)	01/05/91	0.99	
UREA	0.15-0.5 (G/L)	01/05/91	0.38	
CREATININE	6-12 (MG/L)	01/05/91	10.30	
URIC ACID	20-60 (MG/L)	01/05/91	43.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	9.00	
TOT. PROTEINS	60-80 (G/L)	01/05/91	69.00	
ALBUMINE	37-42 (G/L)	01/05/91	46.40	>
TOT. CHOLEST.	1.8-2.5 (G/L)	01/05/91	2.06	
TRIGLYCERIDES	0.25-1.6 (G/L)	01/05/91	1.43	
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	2.00	
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	5.31	
GLOBULINS BETA	5-8 (G/L)	01/05/91	6.49	
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	8.76	
TSH	0.15-3.2 (UUI/ML)	01/05/91	0.67	
T4	7-18 (PG/ML)	01/05/91	13.20	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/3 Patient: 167 Treatment: Placebo Sex: Female

			Visit number / Laboratory data					
			Screen		Day 21		Day 42	
			14/11/91		09/12/91		27/12/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-15 (G/DL)	01/05/91	13.30		13.90		13.00	
HT	37-47 (%)	01/05/91	39.00		40.50		38.00	
RBC	4000000-5000000 (/MM3)	01/05/91	4230000		4430000		4140000	
WBC	5000-10000 (/MM3)	01/05/91	6700.00		5800.00		6100.00	
WBC: N	50-70 (%)	01/05/91	48.00	<	37.00	<	45.30	<
WBC: L	25-40 (%)	01/05/91	43.10	>	53.90	>>	45.10	>
WBC: E	1-4 (%)	01/05/91	2.30		2.00		2.40	
WBC: M	4-8 (%)	01/05/91	6.00		6.40		6.50	
WBC: B	0-2 (%)	01/05/91	0.60		0.70		0.70	
PLATELETS	150000-400000 (/MM3)	01/05/91	204000		220000		206000	
NA+	135-145 (MEQ/L)	01/05/91	139.00		137.00		136.00	
K+	3.5-4.5 (MEQ/L)	01/05/91	4.00		3.40	<	3.90	
CL-	95-105 (MEQ/L)	01/05/91	98.00		97.00		97.00	
Ca++	88-104 (MG/L)	01/05/91	89.00		93.00		90.00	
PO4--	25-45 (MG/L)	01/05/91	38.00		38.00		34.00	
SGOT	5-35 (UI/L)	01/05/91	26.00		9.00		11.00	
SGPT	5-35 (UI/L)	01/05/91	18.00		15.00		14.00	
GAMMA GT	5-40 (UI/L)	01/05/91	10.00		9.00		13.00	
LDH	140-330 (UI/L)	01/05/91	164.00		174.00		150.00	
ALK. PHOSPH.	50-130 (UI/L)	01/05/91	60.00		70.00		56.00	
GLUCOSE	0.8-1.1 (G/L)	01/05/91	0.84		0.92		0.92	
UREA	0.15-0.5 (G/L)	01/05/91	0.33		0.26		0.22	
CREATININE	6-12 (MG/L)	01/05/91	9.00		10.30		9.80	
URIC ACID	20-60 (MG/L)	01/05/91	45.00		55.00		50.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	3.00		4.00		3.00	
TOT. PROTEINS	60-80 (G/L)	01/05/91	63.00		72.00		67.00	
ALBUMINE	37-42 (G/L)	01/05/91	44.20	>	50.00	>	46.30	>
TOT. CHOLEST.	1.8-2.5 (G/L)	01/05/91	1.96		1.60	<	1.78	<
TRIGLYCERIDES	0.25-1.6 (G/L)	01/05/91	0.57		0.67		1.14	
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	1.58		1.80		1.81	
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	4.03		4.82		4.69	
GLOBULINS BETA	5-8 (G/L)	01/05/91	5.67		6.48		5.90	
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	7.56	<	8.86		8.31	
TSH	0.15-3.2 (UUI/ML)	01/05/91	0.89					
T4	7-18 (PG/ML)	01/05/91	14.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/3 Patient: 168 Treatment: Placebo Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			26/11/91		23/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11.5-15 (G/DL)	01/05/91	12.90		13.60	
HT	37-47 (%)	01/05/91	38.00		40.00	
RBC	4000000-5000000 (/MM3)	01/05/91	4050000		4170000	
WBC	5000-10000 (/MM3)	01/05/91	6000.00		5800.00	
WBC: N	50-70 (%)	01/05/91	52.20		49.40	<
WBC: L	25-40 (%)	01/05/91	39.00		41.00	>
WBC: E	1-4 (%)	01/05/91	1.90		3.50	
WBC: M	4-8 (%)	01/05/91	6.30		5.60	
WBC: B	0-2 (%)	01/05/91	0.60		0.50	
PLATELETS	150000-400000 (/MM3)	01/05/91	217000		207000	
NA+	135-145 (MEQ/L)	01/05/91	139.00		140.00	
K+	3.5-4.5 (MEQ/L)	01/05/91	4.20		3.90	
CL-	95-105 (MEQ/L)	01/05/91	100.00		101.00	
Ca++	88-104 (MG/L)	01/05/91	89.00		84.00	<
PO4--	25-45 (MG/L)	01/05/91	42.00		30.00	
SGOT	5-35 (UI/L)	01/05/91	11.00		10.00	
SGPT	5-35 (UI/L)	01/05/91	10.00		10.00	
GAMMA GT	5-40 (UI/L)	01/05/91	19.00		25.00	
LDH	140-330 (UI/L)	01/05/91	214.00		150.00	
ALK. PHOSPH.	50-130 (UI/L)	01/05/91	47.00	<	38.00	<
GLUCOSE	0.8-1.1 (G/L)	01/05/91	0.94		0.82	
UREA	0.15-0.5 (G/L)	01/05/91	0.39		0.23	
CREATININE	6-12 (MG/L)	01/05/91	9.60		7.60	
URIC ACID	20-60 (MG/L)	01/05/91	40.00		47.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	2.00	<	3.00	
TOT. PROTEINS	60-80 (G/L)	01/05/91	73.00		67.00	
ALBUMINE	37-42 (G/L)	01/05/91	48.80	>	44.20	>
TOT. CHOLEST.	1.8-2.5 (G/L)	01/05/91	1.88		1.96	
TRIGLYCERIDES	0.25-1.6 (G/L)	01/05/91	1.82	>	4.52	>>
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	2.99		2.14	
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	4.02		4.29	
GLOBULINS BETA	5-8 (G/L)	01/05/91	7.30		7.04	
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	9.86		9.31	
TSH	0.15-3.2 (UUI/ML)	01/05/91	1.64			
T4	7-18 (PG/ML)	01/05/91	11.70			

1798

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/3 Patient: 505 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 14	
			29/11/91		20/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11.5-15 (G/DL)	01/05/91	13.80		14.40	
HT	37-47 (%)	01/05/91	40.00		43.00	
RBC	4000000-5000000 (/MM3)	01/05/91	4290000		4520000	
WBC	5000-10000 (/MM3)	01/05/91	6400.00		8100.00	
WBC: N	50-70 (%)	01/05/91	72.00	>	77.50	>
WBC: L	25-40 (%)	01/05/91	22.00	<	14.40	<<
WBC: E	1-4 (%)	01/05/91	1.00		0.50	<
WBC: M	4-8 (%)	01/05/91	4.00		7.10	
WBC: B	0-2 (%)	01/05/91	1.00		0.50	
PLATELETS	150000-400000 (/MM3)	01/05/91	245000		213000	
NA+	135-145 (MEQ/L)	01/05/91	139.00		138.00	
K+	3.5-4.5 (MEQ/L)	01/05/91	3.90		3.90	
CL-	95-105 (MEQ/L)	01/05/91	101.00		101.00	
Ca++	88-104 (MG/L)	01/05/91	92.00		89.00	
PO4--	25-45 (MG/L)	01/05/91	28.00		21.00	<<
SGOT	5-35 (UI/L)	01/05/91	16.00		16.00	
SGPT	5-35 (UI/L)	01/05/91	18.00		17.00	
GAMMA GT	5-40 (UI/L)	01/05/91	10.00		8.00	
LDH	140-330 (UI/L)	01/05/91	236.00		214.00	
ALK. PHOSPH.	50-130 (UI/L)	01/05/91	62.00		80.00	
GLUCOSE	0.8-1.1 (G/L)	01/05/91	0.77	<	0.84	
UREA	0.15-0.5 (G/L)	01/05/91	0.30		0.19	
CREATININE	6-12 (MG/L)	01/05/91	11.30		9.00	
URIC ACID	20-60 (MG/L)	01/05/91	44.00		28.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	3.00		2.00	<
TOT. PROTEINS	60-80 (G/L)	01/05/91	73.00		69.00	
ALBUMINE	37-42 (G/L)	01/05/91	50.70	>	46.90	>
TOT. CHOLEST.	1.8-2.5 (G/L)	01/05/91	2.33		2.03	
TRIGLYCERIDES	0.25-1.6 (G/L)	01/05/91	1.33		1.76	>
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	2.19		2.42	
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	4.23		4.90	
GLOBULINS BETA	5-8 (G/L)	01/05/91	6.79		6.35	
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	9.05		8.49	
TSH	0.15-3.2 (UUI/ML)	01/05/91	1.13			
T4	7-18 (PG/ML)	01/05/91	12.80			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/3 Patient: 506 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/01/92		29/01/92		19/02/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-15 (G/DL)	01/05/91	13.50		12.50		12.40	
HT	37-47 (%)	01/05/91	42.00		37.00		39.00	
RBC	4000000-5000000 (/MM3)	01/05/91	4970000		4500000		4610000	
WBC	5000-10000 (/MM3)	01/05/91	7100.00		6320.00		6060.00	
WBC: N	50-70 (%)	01/05/91	59.10		53.00		59.00	
WBC: L	25-40 (%)	01/05/91	34.40		41.10	>	36.20	
WBC: E	1-4 (%)	01/05/91	0.40	<	0.20	<	0.30	<
WBC: M	4-8 (%)	01/05/91	6.00		5.50		4.30	
WBC: B	0-2 (%)	01/05/91	0.10		0.20		0.20	
PLATELETS	150000-400000 (/MM3)	01/05/91	273000		219000		231000	
NA+	135-145 (MEQ/L)	01/05/91	138.00		141.00		141.00	
K+	3.5-4.5 (MEQ/L)	01/05/91	3.80		4.00		3.80	
CL-	95-105 (MEQ/L)	01/05/91	100.00		104.00		104.00	
Ca++	88-104 (MG/L)	01/05/91	90.00		88.00		88.00	
PO4--	25-45 (MG/L)	01/05/91	23.00	<	26.00		20.00	<<
SGOT	5-35 (UI/L)	01/05/91	17.00		8.00		6.00	
SGPT	5-35 (UI/L)	01/05/91	28.00		14.00		10.00	
GAMMA GT	5-40 (UI/L)	01/05/91	10.00		9.00		8.00	
LDH	140-330 (UI/L)	01/05/91	174.00		144.00		135.00	<
ALK. PHOSPH.	50-130 (UI/L)	01/05/91	42.00	<	48.00	<	42.00	<
GLUCOSE	0.8-1.1 (G/L)	01/05/91	0.90		0.96		0.85	
UREA	0.15-0.5 (G/L)	01/05/91	0.35		0.37		0.35	
CREATININE	6-12 (MG/L)	01/05/91	11.10		9.60		10.20	
URIC ACID	20-60 (MG/L)	01/05/91	63.00	>	48.00		53.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	3.00		2.00	<	3.00	
TOT. PROTEINS	60-80 (G/L)	01/05/91	71.00		66.00		63.00	
ALBUMINE	37-42 (G/L)	01/05/91	46.90	>	43.50	>	42.70	>
TOT. CHOLEST.	1.8-2.5 (G/L)	01/05/91	2.28		2.10		1.89	
TRIGLYCERIDES	0.25-1.6 (G/L)	01/05/91	1.31		0.93		1.24	
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	2.49		2.18		1.83	
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	5.75		5.54		5.04	
GLOBULINS BETA	5-8 (G/L)	01/05/91	8.17	>	7.79		7.06	
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	7.74	<	7.00	<	6.36	<
TSH	0.15-3.2 (UUI/ML)	01/05/91	1.73					
T4	7-18 (PG/ML)	01/05/91	13.50					

1800

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 6/3 Patient: 507 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			09/01/92		04/02/92		24/02/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-15 (G/DL)	01/05/91	13.00		13.60		12.70	
HT	37-47 (%)	01/05/91	39.00		40.00		37.00	
RBC	4000000-5000000 (/MM3)	01/05/91	4450000		4620000		4330000	
WBC	5000-10000 (/MM3)	01/05/91	7300.00		7140.00		5350.00	
WBC: N	50-70 (%)	01/05/91	72.30	>	78.70	>	71.70	>
WBC: L	25-40 (%)	01/05/91	19.40	<	14.30	<<	21.90	<
WBC: E	1-4 (%)	01/05/91	1.30		1.30		2.20	
WBC: M	4-8 (%)	01/05/91	6.60		5.30		3.60	<
WBC: B	0-2 (%)	01/05/91	0.40		0.40		0.60	
PLATELETS	150000-400000 (/MM3)	01/05/91	295000		317000		293000	
NA+	135-145 (MEQ/L)	01/05/91	143.00		138.00		141.00	
K+	3.5-4.5 (MEQ/L)	01/05/91	4.00		3.90		4.40	
CL-	95-105 (MEQ/L)	01/05/91	101.00		99.00		102.00	
Ca++	88-104 (MG/L)	01/05/91	90.00		86.00	<	87.00	<
PO4--	25-45 (MG/L)	01/05/91	32.00		36.00		32.00	
SGOT	5-35 (UI/L)	01/05/91	14.00		22.00		21.00	
SGPT	5-35 (UI/L)	01/05/91	35.00		65.00	>	34.00	
GAMMA GT	5-40 (UI/L)	01/05/91	25.00		32.00		36.00	
LDH	140-330 (UI/L)	01/05/91	180.00		208.00		217.00	
ALK. PHOSPH.	50-130 (UI/L)	01/05/91	64.00		74.00		86.00	
GLUCOSE	0.8-1.1 (G/L)	01/05/91	0.92		0.84		0.98	
UREA	0,15-0.5 (G/L)	01/05/91	0.39		0.33		0.34	
CREATININE	6-12 (MG/L)	01/05/91	7.80		9.80		8.30	
URIC ACID	20-60 (MG/L)	01/05/91	32.00		34.00		28.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	3.00		5.00		2.00	<
TOT. PROTEINS	60-80 (G/L)	01/05/91	71.00		73.00		70.00	
ALBUMINE	37-42 (G/L)	01/05/91	49.40	>	51.70	>	46.80	>
TOT. CHOLEST.	1.8-2.5 (G/L)	01/05/91	2.05		1.99		1.76	<
TRIGLYCERIDES	0.25-1.6 (G/L)	01/05/91	0.72		0.74		0.43	
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	1.70		1.31		1.68	
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	3.76	<	3.29	<	4.27	
GLOBULINS BETA	5-8 (G/L)	01/05/91	6.32		6.50		6.37	
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	9.80		10.20		10.90	
TSH	0.15-3.2 (UUI/ML)	01/05/91	0.46					
T4	7-18 (PG/ML)	01/05/91	14.90					

1801

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/3 Patient: 508 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			30/01/92		25/02/92		17/03/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	11.5-15 (G/DL)	01/05/91	13.10		14.30		13.20	
HT	37-47 (%)	01/05/91	41.00		43.00		40.00	
RBC	4000000-5000000 (/MM3)	01/05/91	4210000		4480000		4210000	
WBC	5000-10000 (/MM3)	01/05/91	4270.00	<	5460.00		4910.00	<
WBC: N	50-70 (%)	01/05/91	63.20		60.90		65.20	
WBC: L	25-40 (%)	01/05/91	30.80		31.30		27.50	
WBC: E	1-4 (%)	01/05/91	1.50		2.40		1.80	
WBC: M	4-8 (%)	01/05/91	3.80	<	4.70		4.70	
WBC: B	0-2 (%)	01/05/91	0.70		0.70		0.80	
PLATELETS	150000-400000 (/MM3)	01/05/91	339000		332000		322000	
NA+	135-145 (MEQ/L)	01/05/91	140.00		139.00		140.00	
K+	3.5-4.5 (MEQ/L)	01/05/91	4.30		4.40		4.40	
CL-	95-105 (MEQ/L)	01/05/91	103.00		99.00		102.00	
Ca++	88-104 (MG/L)	01/05/91	88.00		92.00		90.00	
PO4--	25-45 (MG/L)	01/05/91	27.00		32.00		29.00	
SGOT	5-35 (UI/L)	01/05/91	8.00		8.00		8.00	
SGPT	5-35 (UI/L)	01/05/91	13.00		13.00		15.00	
GAMMA GT	5-40 (UI/L)	01/05/91			12.00		11.00	
LDH	140-330 (UI/L)	01/05/91	244.00		206.00		175.00	
ALK. PHOSPH.	50-130 (UI/L)	01/05/91	78.00		90.00		77.00	
GLUCOSE	0.8-1.1 (G/L)	01/05/91	1.05		1.04		0.93	
UREA	0.15-0.5 (G/L)	01/05/91	0.32		0.37		0.26	
CREATININE	6-12 (MG/L)	01/05/91	11.50		11.70		10.40	
URIC ACID	20-60 (MG/L)	01/05/91	45.00		43.00		44.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	3.00		3.00		3.00	
TOT. PROTEINS	60-80 (G/L)	01/05/91	70.00		78.00		70.00	
ALBUMINE	37-42 (G/L)	01/05/91	46.30	>	50.90	>	45.40	>
TOT. CHOLEST.	1.8-2.5 (G/L)	01/05/91	2.34		2.61	>	2.14	
TRIGLYCERIDES	0.25-1.6 (G/L)	01/05/91	0.75		1.00		0.75	
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	1.82		2.03		1.82	
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	4.90		5.62		4.83	
GLOBULINS BETA	5-8 (G/L)	01/05/91	7.84		8.97	>	8.40	>
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	9.10		10.50		9.52	
TSH	0.15-3.2 (UUI/ML)	01/05/91	1.01					
T4	7-18 (PG/ML)	01/05/91	16.30					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 6/3 Patient: 509 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			24/02/92		16/03/92		06/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-17 (G/DL)	01/05/91	17.80	>	17.10	>	17.40	>
HT	40-54 (%)	01/05/91	50.00		51.00		50.00	
RBC	4500000-5500000 (/MM3)	01/05/91	5870000	>	5880000	>	5820000	>
WBC	5000-10000 (/MM3)	01/05/91	6270.00		10300.0	>	6510.00	
WBC: N	50-70 (%)	01/05/91	69.10		76.50	>	64.00	
WBC: L	25-40 (%)	01/05/91	20.40	<	13.50	<<	25.50	
WBC: E	1-4 (%)	01/05/91	3.30		3.40		2.70	
WBC: M	4-8 (%)	01/05/91	5.80		5.80		6.80	
WBC: B	0-2 (%)	01/05/91	1.40		0.80		1.00	
PLATELETS	150000-400000 (/MM3)	01/05/91	230000		224000		272000	
NA+	135-145 (MEQ/L)	01/05/91	139.00		141.00		142.00	
K+	3.5-4.5 (MEQ/L)	01/05/91	3.70		3.50		3.80	
CL-	95-105 (MEQ/L)	01/05/91	95.00		101.00		100.00	
Ca++	88-104 (MG/L)	01/05/91	89.00		90.00		90.00	
PO4--	25-45 (MG/L)	01/05/91	29.00		27.00		38.00	
SGOT	5-35 (UI/L)	01/05/91	12.00		11.00		12.00	
SGPT	5-35 (UI/L)	01/05/91	10.00		9.00		10.00	
GAMMA GT	5-40 (UI/L)	01/05/91	13.00		14.00		12.00	
LDH	140-330 (UI/L)	01/05/91	140.00		197.00		174.00	
ALK. PHOSPH.	50-130 (UI/L)	01/05/91	49.00	<	57.00		52.00	
GLUCOSE	0.8-1.1 (G/L)	01/05/91	0.82		0.83		0.85	
UREA	0.15-0.5 (G/L)	01/05/91	0.18		0.25		0.32	
CREATININE	6-12 (MG/L)	01/05/91	11.80		10.90		10.30	
URIC ACID	20-60 (MG/L)	01/05/91	55.00		48.00		56.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	6.00		6.00		8.00	
TOT. PROTEINS	60-80 (G/L)	01/05/91	75.00		78.00		78.00	
ALBUMINE	37-42 (G/L)	01/05/91	48.40	>	49.80	>	50.00	>
TOT. CHOLEST.	1.8-2.5 (G/L)	01/05/91	1.38	<	1.31	<	1.47	<
TRIGLYCERIDES	0.25-1.6 (G/L)	01/05/91	0.68		0.68		0.58	
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	1.88		1.79		1.79	
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	4.20		4.21		3.90	<
GLOBULINS BETA	5-8 (G/L)	01/05/91	6.90		7.49		7.18	
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	13.70	>	14.70	>	15.10	>
TSH	0.15-3.2 (UUI/ML)	01/05/91	1.05					
T4	7-18 (PG/ML)	01/05/91	16.90					

1803

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 6/3 Patient: 510 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			26/02/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	11.5-15 (G/DL)	01/05/91	12.40	
HT	37-47 (%)	01/05/91	36.00	<
RBC	4000000-5000000 (/MM3)	01/05/91	4490000	
WBC	5000-10000 (/MM3)	01/05/91	5930.00	
WBC: N	50-70 (%)	01/05/91	55.60	
WBC: L	25-40 (%)	01/05/91	34.00	
WBC: E	1-4 (%)	01/05/91	3.70	
WBC: M	4-8 (%)	01/05/91	5.80	
WBC: B	0-2 (%)	01/05/91	0.90	
PLATELETS	150000-400000 (/MM3)	01/05/91	322000	
NA+	135-145 (MEQ/L)	01/05/91	138.00	
K+	3.5-4.5 (MEQ/L)	01/05/91	4.20	
CL-	95-105 (MEQ/L)	01/05/91	100.00	
Ca++	88-104 (MG/L)	01/05/91	88.00	
PO4--	25-45 (MG/L)	01/05/91	33.00	
SGOT	5-35 (UI/L)	01/05/91	10.00	
SGPT	5-35 (UI/L)	01/05/91	13.00	
GAMMA GT	5-40 (UI/L)	01/05/91	5.00	
LDH	140-330 (UI/L)	01/05/91	203.00	
ALK. PHOSPH.	50-130 (UI/L)	01/05/91	61.00	
GLUCOSE	0.8-1.1 (G/L)	01/05/91	0.63	<
UREA	0.15-0.5 (G/L)	01/05/91	0.29	
CREATININE	6-12 (MG/L)	01/05/91	9.00	
URIC ACID	20-60 (MG/L)	01/05/91	40.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	2.00	<
TOT. PROTEINS	60-80 (G/L)	01/05/91	76.00	
ALBUMINE	37-42 (G/L)	01/05/91	48.30	>
TOT. CHOLEST.	1.8-2.5 (G/L)	01/05/91	1.98	
TRIGLYCERIDES	0.25-1.6 (G/L)	01/05/91	0.90	
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	2.05	
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	6.31	
GLOBULINS BETA	5-8 (G/L)	01/05/91	7.45	
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	11.90	
TSH	0.15-3.2 (UUI/ML)	01/05/91	1.24	
T4	7-18 (PG/ML)	01/05/91	14.00	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 6/3 Patient: 511 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			19/03/92		07/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11.5-15 (G/DL)	01/05/91	13.50		14.20	
HT	37-47 (%)	01/05/91	40.00		42.00	
RBC	4000000-5000000 (/MM3)	01/05/91	4610000		4690000	
WBC	5000-10000 (/MM3)	01/05/91	5310.00		4610.00	<
WBC: N	50-70 (%)	01/05/91	55.70		50.20	
WBC: L	25-40 (%)	01/05/91	36.50		40.20	>
WBC: E	1-4 (%)	01/05/91	1.40		2.70	
WBC: M	4-8 (%)	01/05/91	5.70		5.70	
WBC: B	0-2 (%)	01/05/91	0.70		1.20	
PLATELETS	150000-400000 (/MM3)	01/05/91	251000		263000	
NA+	135-145 (MEQ/L)	01/05/91	140.00		139.00	
K+	3.5-4.5 (MEQ/L)	01/05/91	3.50		3.90	
CL-	95-105 (MEQ/L)	01/05/91	100.00		97.00	
Ca++	88-104 (MG/L)	01/05/91	93.00		92.00	
PO4--	25-45 (MG/L)	01/05/91	31.00		33.00	
SGOT	5-35 (UI/L)	01/05/91	11.00		11.00	
SGPT	5-35 (UI/L)	01/05/91	12.00		16.00	
GAMMA GT	5-40 (UI/L)	01/05/91	7.00		9.00	
LDH	140-330 (UI/L)	01/05/91	170.00		177.00	
ALK. PHOSPH.	50-130 (UI/L)	01/05/91	92.00		86.00	
GLUCOSE	0.8-1.1 (G/L)	01/05/91	0.82		0.81	
UREA	0.15-0.5 (G/L)	01/05/91	0.28		0.17	
CREATININE	6-12 (MG/L)	01/05/91	9.80		9.10	
URIC ACID	20-60 (MG/L)	01/05/91	51.00		53.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	5.00		3.00	
TOT. PROTEINS	60-80 (G/L)	01/05/91	71.00		70.00	
ALBUMINE	37-42 (G/L)	01/05/91	47.80	>	47.60	>
TOT. CHOLEST.	1.8-2.5 (G/L)	01/05/91	1.90		2.00	
TRIGLYCERIDES	0.25-1.6 (G/L)	01/05/91	0.47		0.61	
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	1.99		1.89	
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	4.83		4.90	
GLOBULINS BETA	5-8 (G/L)	01/05/91	7.24		7.00	
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	9.16		8.61	
TSH	0.15-3.2 (UUI/ML)	01/05/91	1.79			
T4	7-18 (PG/ML)	01/05/91	13.40			

1805

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/3 Patient: 512 Treatment: Placebo Sex: Female

			Visit number / Laboratory date	
			Screen	
			27/03/92	
			value	(◊)
Laboratory test	Range value	Range date		
HB	11.5-15 (G/DL)	01/05/91	13.50	
HT	37-47 (%)	01/05/91	40.00	
RBC	4000000-5000000 (/MM3)	01/05/91	4940000	
WBC	5000-10000 (/MM3)	01/05/91	4460.00	<
WBC: N	50-70 (%)	01/05/91	23.20	<<
WBC: L	25-40 (%)	01/05/91	71.00	>>
WBC: E	1-4 (%)	01/05/91	2.60	
WBC: M	4-8 (%)	01/05/91	2.50	<
WBC: B	0-2 (%)	01/05/91	0.70	
PLATELETS	150000-400000 (/MM3)	01/05/91	291000	
NA+	135-145 (MEQ/L)	01/05/91	137.00	
K+	3.5-4.5 (MEQ/L)	01/05/91	4.10	
CL-	95-105 (MEQ/L)	01/05/91	101.00	
Ca++	88-104 (MG/L)	01/05/91	93.00	
PO4--	25-45 (MG/L)	01/05/91	35.00	
SGOT	5-35 (UI/L)	01/05/91	8.00	
SGPT	5-35 (UI/L)	01/05/91	12.00	
GAMMA GT	5-40 (UI/L)	01/05/91	8.00	
LDH	140-330 (UI/L)	01/05/91	145.00	
ALK. PHOSPH.	50-130 (UI/L)	01/05/91	56.00	
GLUCOSE	0.8-1.1 (G/L)	01/05/91	0.93	
UREA	0.15-0.5 (G/L)	01/05/91	0.29	
CREATININE	6-12 (MG/L)	01/05/91	10.50	
URIC ACID	20-60 (MG/L)	01/05/91	36.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	2.00	<
TOT. PROTEINS	60-80 (G/L)	01/05/91	75.00	
ALBUMINE	37-42 (G/L)	01/05/91	47.60	>
TOT. CHOLEST.	1.8-2.5 (G/L)	01/05/91	2.14	
TRIGLYCERIDES	0.25-1.6 (G/L)	01/05/91	1.62	>
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	3.45	>
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	5.40	
GLOBULINS BETA	5-8 (G/L)	01/05/91	7.35	
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	11.30	
TSH	0.15-3.2 (UUI/ML)	01/05/91	1.01	
T4	7-18 (PG/ML)	01/05/91	14.10	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 6/3 Patient: 513 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/05/92		02/06/92		23/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-15 (G/DL)	01/05/91	13.40		13.50		14.50	
HT	37-47 (%)	01/05/91	38.00		40.00		42.00	
RBC	4000000-5000000 (/MM3)	01/05/91	4200000		4310000		4510000	
WBC	5000-10000 (/MM3)	01/05/91	4470.00	<	6090.00		5890.00	
WBC: N	50-70 (%)	01/05/91	76.10	>	67.90		67.80	
WBC: L	25-40 (%)	01/05/91	18.70	<	28.10		25.10	
WBC: E	1-4 (%)	01/05/91	1.70		2.00		2.40	
WBC: M	4-8 (%)	01/05/91	2.80	<	1.20	<	3.80	<
WBC: B	0-2 (%)	01/05/91	0.70		0.80		0.90	
PLATELETS	150000-400000 (/MM3)	01/05/91	333000		340000		353000	
NA+	135-145 (MEQ/L)	01/05/91	138.00		138.00		138.00	
K+	3.5-4.5 (MEQ/L)	01/05/91	3.50		3.50		3.50	
CL-	95-105 (MEQ/L)	01/05/91	101.00		100.00		97.00	
Ca++	88-104 (MG/L)	01/05/91	89.00		87.00	<	90.00	
PO4--	25-45 (MG/L)	01/05/91	27.00		27.00		31.00	
SGOT	5-35 (UI/L)	01/05/91	15.00		13.00		12.00	
SGPT	5-35 (UI/L)	01/05/91	11.00		7.00		20.00	
GAMMA GT	5-40 (UI/L)	01/05/91	12.00		12.00		14.00	
LDH	140-330 (UI/L)	01/05/91	185.00		174.00		179.00	
ALK. PHOSPH.	50-130 (UI/L)	01/05/91	44.00	<	41.00	<	55.00	
GLUCOSE	0.8-1.1 (G/L)	01/05/91	0.77	<	0.88		0.78	<
UREA	0.15-0.5 (G/L)	01/05/91	0.28		0.32		0.30	
CREATININE	6-12 (MG/L)	01/05/91	8.70		10.30		10.30	
URIC ACID	20-60 (MG/L)	01/05/91	29.00		29.00		26.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/05/91	4.00		4.00		4.00	
TOT. PROTEINS	60-80 (G/L)	01/05/91	71.00		71.00		76.00	
ALBUMINE	37-42 (G/L)	01/05/91	47.90	>	38.40		50.50	>
TOT. CHOLEST.	1.8-2.5 (G/L)	01/05/91	1.95		1.97		2.34	
TRIGLYCERIDES	0.25-1.6 (G/L)	01/05/91	0.90		1.50		0.93	
GLOBULINS ALPHA 1	1-3 (G/L)	01/05/91	2.27		1.85		1.98	
GLOBULINS ALPHA 2	4-7 (G/L)	01/05/91	5.40		5.96		5.32	
GLOBULINS BETA	5-8 (G/L)	01/05/91	7.03		9.37	>	7.90	
GLOBULINS GAMMA	8-12 (G/L)	01/05/91	8.45		15.40	>	10.30	
TSH	0.15-3.2 (UUI/ML)	01/05/91	0.81					
T4	7-18 (PG/ML)	01/05/91	15.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/02 Patient: 181 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/01/92		17/02/92		09/03/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	130-180 (G/L)	20/10/91	126.00	<	131.00		134.00	
HT	0.4-0.54 (L/L)	20/10/91	0.33	<<	0.37	<	0.39	<
RBC	4.2-6 (10¬12/L)	20/10/91	4.11	<	4.08	<	4.15	<
WBC	4.3-10 (10¬9/L)	20/10/91	10.60	>	5.40		6.00	
WBC: N	25-74 (%)	20/10/91	73.00		53.00		50.00	
WBC: L	20-44 (%)	20/10/91	27.00		40.00		39.00	
WBC: E	1-5 (%)	20/10/91	0.00	<	2.00		4.00	
WBC: M	2-7 (%)	20/10/91	0.00	<	5.00		7.00	
WBC: B	0-1 (%)	20/10/91	0.00		0.00		0.00	
PLATELETS	150-440 (10¬9/L)	20/10/91	334.00		219.00		243.00	
NA+	135-144 (MMOL/L)	20/10/91	138.00		139.00		136.00	
K+	3.6-5.1 (MMOL/L)	20/10/91	3.90		4.30		4.10	
CL-	97-108 (MMOL/L)	20/10/91	101.00		105.00		105.00	
Ca++	2.2-2.6 (MMOL/L)	20/10/91	2.40		2.50		2.40	
PO4--	0.84-1.45 (MMOL/L)	20/10/91	1.15		1.20		1.10	
SGOT	5-19 (U/L)	20/10/91	8.00		7.00		10.00	
SGPT	5-23 (U/L)	20/10/91	6.00		21.00		18.00	
GAMMA GT	6-28 (U/L)	20/10/91	27.00		17.00		14.00	
LDH	120-240 (U/L)	20/10/91	134.00		149.00		131.00	
ALK. PHOSPH.	40-190 (U/L)	20/10/91	218.00	>	71.00		62.00	
GLUCOSE	70-180 (MG/DL)	20/10/91	67.00	<	100.00		79.00	
BUN	10-50 (MG/DL)	20/10/91	16.00		35.00		44.00	
CREATININE	0.7-1.4 (MG/DL)	20/10/91	0.90		0.90		0.80	
URIC ACID	2-6.8 (MG/DL)	20/10/91	5.30		5.20		4.80	
TOT BILIRUBIN	0.2-1 (MG/DL)	20/10/91	0.50		0.60		0.70	
TOT. PROTEINS	61-82 (G/L)	20/10/91	68.00		72.00		70.00	
ALBUMINE	35-55 (G/L)	20/10/91	59.40	>	57.50	>	60.50	>
TOT. CHOLEST.	130-250 (MG/DL)	20/10/91	282.00	>	177.00		189.00	
TRIGLYCERIDES	45-200 (MG/DL)	20/10/91	157.00		83.00		64.00	
GLOBULINS ALPHA 1	1.6-5.8 (%)	20/10/91	3.90		3.00		3.10	
GLOBULINS ALPHA 2	5.9-11.1 (%)	20/10/91	12.20	>	8.60		6.60	
GLOBULINS BETA	7.9-13.9 (%)	20/10/91	10.20		12.00		12.50	
GLOBULINS GAMMA	10-18.2 (%)	20/10/91	14.30		18.90	>	17.30	
TSH	0.1-3.5 (UU/ML)	20/10/91	0.28					
T4	0.8-2 (NG/DL)	20/10/91	0.79	<				

1808

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/02 Patient: 182 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/11/91		13/12/91		03/01/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	130-180 (G/L)	20/10/91	139.00		141.00		142.00	
HT	0.4-0.54 (L/L)	20/10/91	0.41		0.40	<	0.38	<
RBC	4.2-6 (10¬12/L)	20/10/91	4.33		4.44		4.46	
WBC	4.3-10 (10¬9/L)	20/10/91	9.20		9.50		8.40	
WBC: N	25-74 (%)	20/10/91	70.00		64.00		50.00	
WBC: L	20-44 (%)	20/10/91	28.00		32.00		44.00	
WBC: E	1-5 (%)	20/10/91	2.00		2.00		2.00	
WBC: M	2-7 (%)	20/10/91	0.00	<	2.00		4.00	
WBC: B	0-1 (%)	20/10/91	0.00		0.00		0.00	
PLATELETS	150-440 (10¬9/L)	20/10/91	401.00		397.00		372.00	
NA+	135-144 (MMOL/L)	20/10/91	145.00	>	138.00		136.00	
K+	3.6-5.1 (MMOL/L)	20/10/91	4.40		4.40		4.30	
CL-	97-108 (MMOL/L)	20/10/91	105.00		103.00		104.00	
Ca++	2.2-2.6 (MMOL/L)	20/10/91	2.60		2.40		2.40	
PO4--	0.84-1.45 (MMOL/L)	20/10/91	1.10		1.16		1.24	
SGOT	5-19 (U/L)	20/10/91	9.00		8.00		8.00	
SGPT	5-23 (U/L)	20/10/91	16.00		8.00		7.00	
GAMMA GT	6-28 (U/L)	20/10/91	12.00		12.00		12.00	
LDH	120-240 (U/L)	20/10/91	159.00		162.00		133.00	
ALK. PHOSPH.	40-190 (U/L)	20/10/91	120.00		118.00		99.00	
GLUCOSE	70-180 (MG/DL)	20/10/91	70.00		68.00	<	75.00	
BUN	10-50 (MG/DL)	20/10/91	38.00		25.00		32.00	
CREATININE	0.7-1.4 (MG/DL)	20/10/91	0.90		0.80		0.80	
URIC ACID	2-6.8 (MG/DL)	20/10/91	5.30		5.10		5.30	
TOT BILIRUBIN	0.2-1 (MG/DL)	20/10/91	0.80		0.70		0.50	
DIR BILIRUBIN	0-0.3 (MG/DL)	20/10/91	0.00		0.00		0.00	
TOT. PROTEINS	61-82 (G/L)	20/10/91	69.00		67.00		67.00	
ALBUMINE	35-55 (G/L)	20/10/91	57.50	>	65.70	>	63.40	>
TOT. CHOLEST.	130-250 (MG/DL)	20/10/91	271.00	>	236.00		307.00	>
TRIGLYCERIDES	45-200 (MG/DL)	20/10/91	124.00		79.00		201.00	>
GLOBULINS ALPHA 1	1.6-5.8 (%)	20/10/91	4.00		2.90		3.00	
GLOBULINS ALPHA 2	5.9-11.1 (%)	20/10/91	12.00	>	9.90		10.70	
GLOBULINS BETA	7.9-13.9 (%)	20/10/91	11.70		10.90		9.70	
GLOBULINS GAMMA	10-18.2 (%)	20/10/91	14.80		10.60		13.10	
TSH	0.1-3.5 (UU/ML)	20/10/91	0.79					
T4	0.8-2 (NG/DL)	20/10/91	0.67	<<				

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
.** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 7/02 Patient: 183 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			30/12/91		22/01/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	130-180 (G/L)	20/10/91	147.00		147.00	
HT	0.4-0.54 (L/L)	20/10/91	0.42		0.40	<
RBC	4.2-6 (10¬12/L)	20/10/91	4.82		4.93	
WBC	4.3-10 (10¬9/L)	20/10/91	7.50		8.40	
WBC: N	25-74 (%)	20/10/91	60.00		64.00	
WBC: L	20-44 (%)	20/10/91	40.00		34.00	
WBC: E	1-5 (%)	20/10/91	0.00	<	0.00	<
WBC: M	2-7 (%)	20/10/91	0.00	<	2.00	
WBC: B	0-1 (%)	20/10/91	0.00		0.00	
PLATELETS	150-440 (10¬9/L)	20/10/91	301.00		269.00	
NA+	135-144 (MMOL/L)	20/10/91	140.00		135.00	
K+	3.6-5.1 (MMOL/L)	20/10/91	3.90		4.60	
CL-	97-108 (MMOL/L)	20/10/91	101.00		103.00	
Ca++	2.2-2.6 (MMOL/L)	20/10/91	2.50		2.50	
PO4--	0.84-1.45 (MMOL/L)	20/10/91	0.90		1.03	
SGOT	5-19 (U/L)	20/10/91	10.00		8.00	
SGPT	5-23 (U/L)	20/10/91	18.00		14.00	
GAMMA GT	6-28 (U/L)	20/10/91	29.00	>	20.00	
LDH	120-240 (U/L)	20/10/91	143.00		121.00	
ALK. PHOSPH.	40-190 (U/L)	20/10/91	138.00		133.00	
GLUCOSE	70-180 (MG/DL)	20/10/91	84.00		91.00	
BUN	10-50 (MG/DL)	20/10/91	27.00		7.00	<
CREATININE	0.7-1.4 (MG/DL)	20/10/91	1.00		0.70	
URIC ACID	2-6.8 (MG/DL)	20/10/91	4.40		4.10	
TOT BILIRUBIN	0.2-1 (MG/DL)	20/10/91	1.00		1.00	
DIR BILIRUBIN	0-0.3 (MG/DL)	20/10/91	0.00		0.00	
TOT. PROTEINS	61-82 (G/L)	20/10/91	68.00		68.00	
ALBUMINE	35-55 (G/L)	20/10/91	71.30	>	66.20	>
TOT. CHOLEST.	130-250 (MG/DL)	20/10/91	231.00		240.00	
TRIGLYCERIDES	45-200 (MG/DL)	20/10/91	137.00		151.00	
GLOBULINS ALPHA 1	1.6-5.8 (%)	20/10/91	2.60		2.60	
GLOBULINS ALPHA 2	5.9-11.1 (%)	20/10/91	8.30		8.60	
GLOBULINS BETA	7.9-13.9 (%)	20/10/91	8.50		11.20	
GLOBULINS GAMMA	10-18.2 (%)	20/10/91	9.30	<	11.50	
TSH	0.1-3.5 (UU/ML)	20/10/91	0.03	<<		
T4	0.8-2 (NG/DL)	20/10/91	1.63			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/02 Patient: 184 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			23/01/92		17/02/92		09/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	120-160 (G/L)	20/10/91	138.00		126.00		135.00	
HT	0.37-0.47 (L/L)	20/10/91	0.38		0.36	<	0.39	
RBC	4-5.5 (10¬12/L)	20/10/91	4.23		3.92	<	4.14	
WBC	4.3-10 (10¬9/L)	20/10/91	9.70		5.30		5.80	
WBC: N	25-74 (%)	20/10/91	56.00		48.00		45.00	
WBC: L	20-44 (%)	20/10/91	40.00		44.00		52.00	>
WBC: E	1-5 (%)	20/10/91	2.00		2.00		2.00	
WBC: M	2-7 (%)	20/10/91	2.00		6.00		1.00	<
WBC: B	0-1 (%)	20/10/91	0.00		0.00		0.00	
PLATELETS	150-440 (10¬9/L)	20/10/91	532.00	>	204.00		234.00	
NA+	135-144 (MMOL/L)	20/10/91	136.00		140.00		137.00	
K+	3.6-5.1 (MMOL/L)	20/10/91	4.80		4.20		3.90	
CL-	97-108 (MMOL/L)	20/10/91	99.00		105.00		104.00	
Ca++	2.2-2.6 (MMOL/L)	20/10/91	2.40		2.50		2.40	
PO4--	0.84-1.45 (MMOL/L)	20/10/91	1.21		1.24		1.05	
SGOT	5-15 (U/L)	20/10/91	9.00		5.00		12.00	
SGPT	5-19 (U/L)	20/10/91	10.00		17.00		26.00	>
GAMMA GT	4-18 (U/L)	20/10/91	21.00	>	14.00		18.00	
LDH	120-240 (U/L)	20/10/91	150.00		119.00	<	154.00	
ALK. PHOSPH.	40-190 (U/L)	20/10/91	103.00		59.00		81.00	
GLUCOSE	70-180 (MG/DL)	20/10/91	69.00	<	100.00		90.00	
BUN	10-50 (MG/DL)	20/10/91	34.00		34.00		42.00	
CREATININE	0.5-1.2 (MG/DL)	20/10/91	0.60		0.90		0.80	
URIC ACID	2-6.3 (MG/DL)	20/10/91	4.10		5.30		4.80	
TOT BILIRUBIN	0.2-1 (MG/DL)	20/10/91	0.30		0.60		0.70	
TOT. PROTEINS	61-82 (G/L)	20/10/91	73.00		70.00		70.00	
ALBUMINE	35-55 (G/L)	20/10/91	53.20		58.00	>	60.60	>
TOT. CHOLEST.	130-250 (MG/DL)	20/10/91	166.00		170.00		159.00	
TRIGLYCERIDES	45-200 (MG/DL)	20/10/91	130.00		78.00		61.00	
GLOBULINS ALPHA 1	1.6-5.8 (%)	20/10/91	4.40		2.30		3.30	
GLOBULINS ALPHA 2	5.9-11.1 (%)	20/10/91	12.20	>	7.30		6.30	
GLOBULINS BETA	7.9-13.9 (%)	20/10/91	11.40		12.50		13.30	
GLOBULINS GAMMA	10-18.2 (%)	20/10/91	17.80		19.90	>	16.60	
TSH	0.1-3.5 (UU/ML)	20/10/91	0.73					
T4	0.8-2 (NG/DL)	20/10/91	1.18					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang-
< out of range (value lower than min range) > out of range (value higher than max rang-
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/02 Patient: 185 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			09/04/92		30/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	130-180 (G/L)	20/10/91	147.00		138.00	
HT	0.4-0.54 (L/L)	20/10/91	0.43		0.41	
RBC	4.2-6 (10¬12/L)	20/10/91	5.19		4.87	
WBC	4.3-10 (10¬9/L)	20/10/91	10.40	>	7.70	
WBC: N	25-74 (%)	20/10/91	80.00	>	64.00	
WBC: L	20-44 (%)	20/10/91	16.00	<	30.00	
WBC: E	1-5 (%)	20/10/91	0.00	<	2.00	
WBC: M	2-7 (%)	20/10/91	4.00		4.00	
WBC: B	0-1 (%)	20/10/91	0.00		0.00	
PLATELETS	150-440 (10¬9/L)	20/10/91	315.00		282.00	
NA+	135-144 (MMOL/L)	20/10/91	134.00	<	140.00	
K+	3.6-5.1 (MMOL/L)	20/10/91	4.20		4.50	
CL-	97-108 (MMOL/L)	20/10/91	103.00		101.00	
Ca++	2.2-2.6 (MMOL/L)	20/10/91	2.50		2.50	
PO4--	0.84-1.45 (MMOL/L)	20/10/91	1.12		1.28	
SGOT	5-19 (U/L)	20/10/91	13.00		8.00	
SGPT	5-23 (U/L)	20/10/91	17.00		18.00	
GAMMA GT	6-28 (U/L)	20/10/91	57.00	>>	112.00	>>
LDH	120-240 (U/L)	20/10/91	139.00		112.00	<
ALK. PHOSPH.	40-190 (U/L)	20/10/91	217.00	>	174.00	
GLUCOSE	70-180 (MG/DL)	20/10/91	145.00		258.00	>>
BUN	10-50 (MG/DL)	20/10/91	27.00		33.00	
CREATININE	0.7-1.4 (MG/DL)	20/10/91	1.00		0.80	
URIC ACID	2-6.8 (MG/DL)	20/10/91	5.10		5.50	
TOT BILIRUBIN	0.2-1 (MG/DL)	20/10/91	0.80		0.70	
TOT. PROTEINS	61-82 (G/L)	20/10/91	77.00		72.00	
ALBUMINE	35-55 (G/L)	20/10/91	61.20	>	61.10	>
TOT. CHOLEST.	130-250 (MG/DL)	20/10/91	223.00		230.00	
TRIGLYCERIDES	45-200 (MG/DL)	20/10/91	257.00	>	180.00	
GLOBULINS ALPHA 1	1.6-5.8 (%)	20/10/91	1.30	<	2.20	
GLOBULINS ALPHA 2	5.9-11.1 (%)	20/10/91	6.90		7.60	
GLOBULINS BETA	7.9-13.9 (%)	20/10/91	12.80		10.90	
GLOBULINS GAMMA	10-18.2 (%)	20/10/91	17.80		18.20	
TSH	0.1-3.5 (UU/ML)	20/10/91	0.71			
T4	0.8-2 (NG/DL)	20/10/91	1.00			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/02 Patient: 186 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			15/04/92		06/05/92		27/05/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	130-180 (G/L)	20/10/91	151.00		131.00		141.00	
HT	0.4-0.54 (L/L)	20/10/91	0.44		0.40	<	0.43	
RBC	4.2-6 (10¬12/L)	20/10/91	4.95		4.47		4.93	
WBC	4.3-10 (10¬9/L)	20/10/91	9.50		7.90		7.60	
WBC: N	25-74 (%)	20/10/91	64.00		52.00		54.00	
WBC: L	20-44 (%)	20/10/91	26.00		42.00		44.00	
WBC: E	1-5 (%)	20/10/91	0.00	<	4.00		0.00	<
WBC: M	2-7 (%)	20/10/91	10.00	>>	2.00		2.00	
WBC: B	0-1 (%)	20/10/91	0.00		0.00		0.00	
PLATELETS	150-440 (10¬9/L)	20/10/91	337.00		292.00		540.00	>
NA+	135-144 (MMOL/L)	20/10/91	142.00		134.00	<	139.00	
K+	3.6-5.1 (MMOL/L)	20/10/91	4.20		3.80		4.30	
CL-	97-108 (MMOL/L)	20/10/91	101.00		104.00		102.00	
Ca++	2.2-2.6 (MMOL/L)	20/10/91	2.60		2.30		2.50	
PO4--	0.84-1.45 (MMOL/L)	20/10/91	0.82	<	1.09		1.16	
SGOT	5-19 (U/L)	20/10/91	11.00		12.00		10.00	
SGPT	5-23 (U/L)	20/10/91	17.00		7.00		16.00	
GAMMA GT	6-28 (U/L)	20/10/91	13.00		8.00		16.00	
LDH	120-240 (U/L)	20/10/91	147.00		90.00	<	138.00	
ALK. PHOSPH.	40-190 (U/L)	20/10/91	100.00		89.00		119.00	
GLUCOSE	70-180 (MG/DL)	20/10/91	59.00	<	70.00		80.00	
BUN	10-50 (MG/DL)	20/10/91	26.00		26.00		18.00	
CREATININE	0.7-1.4 (MG/DL)	20/10/91	0.80		0.70		0.80	
URIC ACID	2-6.8 (MG/DL)	20/10/91	6.60		4.50		5.20	
TOT BILIRUBIN	0.2-1 (MG/DL)	20/10/91	0.60		0.50		0.70	
TOT. PROTEINS	61-82 (G/L)	20/10/91	79.00		67.00		70.00	
ALBUMINE	35-55 (G/L)	20/10/91	69.10	>	66.00	>	61.70	>
TOT. CHOLEST.	130-250 (MG/DL)	20/10/91	191.00		181.00		167.00	
TRIGLYCERIDES	45-200 (MG/DL)	20/10/91	157.00		84.00		51.00	
GLOBULINS ALPHA 1	1.6-5.8 (%)	20/10/91	2.20		2.60		3.70	
GLOBULINS ALPHA 2	5.9-11.1 (%)	20/10/91	7.20		8.10		10.50	
GLOBULINS BETA	7.9-13.9 (%)	20/10/91	9.70		9.90		9.90	
GLOBULINS GAMMA	10-18.2 (%)	20/10/91	11.80		13.40		14.20	
TSH	0.1-3.5 (UU/ML)	20/10/91	0.65					
T4	0.8-2 (NG/DL)	20/10/91	1.36					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/02 Patient: 535 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			15/04/92		09/05/92		27/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	130-180 (G/L)	20/10/91	153.00		135.00		147.00	
HT	0.4-0.54 (L/L)	20/10/91	0.44		0.39	<	0.43	
RBC	4.2-6 (10¬12/L)	20/10/91	4.95		4.12	<	4.94	
WBC	4.3-10 (10¬9/L)	20/10/91	6.80		6.10		7.70	
WBC: N	25-74 (%)	20/10/91	57.00		47.00		33.00	
WBC: L	20-44 (%)	20/10/91	34.00		44.00		64.00	>>
WBC: E	1-5 (%)	20/10/91	1.00		2.00		2.00	
WBC: M	2-7 (%)	20/10/91	8.00	>	7.00		0.00	<
WBC: B	0-1 (%)	20/10/91	1.00		0.00		1.00	
PLATELETS	150-440 (10¬9/L)	20/10/91	256.00		253.00		345.00	
NA+	135-144 (MMOL/L)	20/10/91	139.00		137.00		137.00	
K+	3.6-5.1 (MMOL/L)	20/10/91	4.30		4.00		4.40	
CL-	97-108 (MMOL/L)	20/10/91	108.00		103.00		101.00	
Ca++	2.2-2.6 (MMOL/L)	20/10/91	2.40		2.40		2.50	
PO4--	0.84-1.45 (MMOL/L)	20/10/91	1.21		1.12		1.22	
SGOT	5-19 (U/L)	20/10/91	11.00		12.00		17.00	
SGPT	5-23 (U/L)	20/10/91	13.00		18.00		9.00	
GAMMA GT	6-28 (U/L)	20/10/91	22.00		14.00		10.00	
LDH	120-240 (U/L)	20/10/91	147.00		117.00	<	190.00	
ALK. PHOSPH.	40-190 (U/L)	20/10/91	107.00		51.00		57.00	
GLUCOSE	70-180 (MG/DL)	20/10/91	76.00		94.00		79.00	
BUN	10-50 (MG/DL)	20/10/91	38.00		46.00		30.00	
CREATININE	0.7-1.4 (MG/DL)	20/10/91	1.10		1.00		0.90	
URIC ACID	2-6.8 (MG/DL)	20/10/91	6.80		5.20		5.90	
TOT BILIRUBIN	0.2-1 (MG/DL)	20/10/91	0.80		1.00		0.70	
TOT. PROTEINS	61-82 (G/L)	20/10/91	73.00		73.00			
ALBUMINE	35-55 (G/L)	20/10/91	70.90	>	64.20	>	80.00	>>
TOT. CHOLEST.	130-250 (MG/DL)	20/10/91	224.00		193.00		165.00	
TRIGLYCERIDES	45-200 (MG/DL)	20/10/91	136.00		99.00		90.00	
GLOBULINS ALPHA 1	1.6-5.8 (%)	20/10/91	1.60		1.80		3.20	
GLOBULINS ALPHA 2	5.9-11.1 (%)	20/10/91	7.80		5.90		7.80	
GLOBULINS BETA	7.9-13.9 (%)	20/10/91	9.40		10.10		9.80	
GLOBULINS GAMMA	10-18.2 (%)	20/10/91	10.30		18.00		17.20	
TSH	0.1-3.5 (UU/ML)	20/10/91	1.97					
T4	0.8-2 (NG/DL)	20/10/91	1.01					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/02 Patient: 536 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			08/05/92		29/05/92		22/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	120-160 (G/L)	20/10/91	131.00		126.00		128.00	
HT	0.37-0.47 (L/L)	20/10/91	0.39		0.36	<	0.38	
RBC	4-5.5 (10¬12/L)	20/10/91	4.59		3.93	<	4.07	
WBC	4.3-10 (10¬9/L)	20/10/91	4.80		6.50		6.20	
WBC: N	25-74 (%)	20/10/91	56.00		56.00		54.00	
WBC: L	20-44 (%)	20/10/91	36.00		44.00		37.00	
WBC: E	1-5 (%)	20/10/91	2.00				7.00	>>
WBC: M	2-7 (%)	20/10/91	6.00				1.00	<
WBC: B	0-1 (%)	20/10/91	0.00				1.00	
PLATELETS	150-440 (10¬9/L)	20/10/91	402.00		204.00		203.00	
NA+	135-144 (MMOL/L)	20/10/91	134.00	<	135.00		140.00	
K+	3.6-5.1 (MMOL/L)	20/10/91	3.80		4.30		4.50	
CL-	97-108 (MMOL/L)	20/10/91	102.00		101.00		105.00	
Ca++	2.2-2.6 (MMOL/L)	20/10/91	2.30		2.40		2.60	
PO4--	0.84-1.45 (MMOL/L)	20/10/91	1.23		1.11		1.37	
SGOT	5-15 (U/L)	20/10/91	12.00		7.00		8.00	
SGPT	5-19 (U/L)	20/10/91	4.00	<	6.00		7.00	
GAMMA GT	4-18 (U/L)	20/10/91	18.00		8.00		9.00	
LDH	120-240 (U/L)	20/10/91	213.00		130.00		128.00	
ALK. PHOSPH.	40-190 (U/L)	20/10/91	111.00		88.00		75.00	
GLUCOSE	70-180 (MG/DL)	20/10/91	60.00	<	79.00		72.00	
BUN	10-50 (MG/DL)	20/10/91	26.00		27.00		27.00	
CREATININE	0.5-1.2 (MG/DL)	20/10/91	0.70		0.60		0.70	
URIC ACID	2-6.3 (MG/DL)	20/10/91			3.50		3.70	
TOT BILIRUBIN	0.2-1 (MG/DL)	20/10/91	0.60		0.60		1.00	
TOT. PROTEINS	61-82 (G/L)	20/10/91	63.00		65.00		65.00	
ALBUMINE	35-55 (G/L)	20/10/91	65.00	>	63.40	>	65.50	>
TOT. CHOLEST.	130-250 (MG/DL)	20/10/91	262.00	>	194.00		196.00	
TRIGLYCERIDES	45-200 (MG/DL)	20/10/91	75.00		101.00		117.00	
GLOBULINS ALPHA 1	1.6-5.8 (%)	20/10/91	2.80		2.30		2.30	
GLOBULINS ALPHA 2	5.9-11.1 (%)	20/10/91	9.80		8.70		9.20	
GLOBULINS BETA	7.9-13.9 (%)	20/10/91	11.10		9.90		8.60	
GLOBULINS GAMMA	10-18.2 (%)	20/10/91	11.30		15.80		14.40	
TSH	0.1-3.5 (UU/ML)	20/10/91	1.59					
T4	0.8-2 (NG/DL)	20/10/91	1.22					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/03 Patient: 187 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			11/02/92		10/03/92		31/03/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/02/92	13.70		14.10		14.10	
HT	37-54 (%)	01/02/92	43.30		46.70		44.00	
RBC	3.8-5.2 (10¬6/UL)	01/02/92	4.76		4.99		4.81	
WBC	4-10.8 (10¬3/UL)	01/02/92	6.87		7.18		6.96	
WBC: N	45-70 (%)	01/02/92	39.00	<	58.00		53.50	
WBC: L	25-45 (%)	01/02/92	52.10	>	34.20		35.20	
WBC: E	1-5 (%)	01/02/92	1.40		1.00		1.80	
WBC: M	1-9 (%)	01/02/92	4.80		3.80		4.30	
WBC: B	0-2 (%)	01/02/92	0.60		0.60		2.20	>
PLATELETS	150-450 (10¬3/UL)	01/02/92	242.00		266.00		301.00	
NA+	132-151 (MMOL/L)	01/02/92	140.00		144.00		146.00	
K+	3.6-5.2 (MMOL/L)	01/02/92	4.89		5.30	>	6.76	>>
CL-	97-108 (MMOL/L)	01/02/92	98.00		100.00		97.00	
Ca++	2.2-2.65 (MMOL/L)	01/02/92	2.37		2.63		2.43	
PO4--	2.5-5 (MG/DL)	01/02/92	4.30		7.80	>>	5.30	>
SGOT	5-15 (U/L)	01/02/92	8.00		12.00		13.00	
SGPT	5-19 (U/L)	01/02/92	9.00		15.00		12.00	
GAMMA GT	5-18 (U/L)	01/02/92	14.00		18.00		19.00	>
LDH	150-240 (U/L)	01/02/92	219.00		225.00		355.00	>
ALK. PHOSPH.	65-175 (U/L)	01/02/92	122.00		138.00		129.00	
GLUCOSE	50-100 (MG/DL)	01/02/92	91.00		94.00		106.00	>
BUN	10-50 (MG/DL)	01/02/92	27.30		21.70		27.90	
CREATININE	0.5-0.9 (MG/DL)	01/02/92	0.98	>	1.36	>>	1.07	>
URIC ACID	2.5-6 (MG/DL)	01/02/92	5.30		5.90		6.20	>
TOT BILIRUBIN	0.2-1 (MG/DL)	01/02/92	0.40		0.43		0.28	
TOT. PROTEINS	6-8.5 (G/DL)	01/02/92	7.00		7.70		8.00	
ALBUMINE	55-68 (%)	01/02/92	61.70		65.50		61.70	
TOT. CHOLEST.	120-220 (MG/DL)	01/02/92	338.00	>>	345.00	>>	370.00	>>
TRIGLYCERIDES	45-200 (MG/DL)	01/02/92	182.00		232.00	>	237.00	>
GLOBULINS ALPHA 1	1-5 (%)	01/02/92	3.20		2.20		2.50	
GLOBULINS ALPHA 2	5-10 (%)	01/02/92	8.90		7.70		11.30	>
GLOBULINS BETA	7-12 (%)	01/02/92	9.40		8.60		8.30	
GLOBULINS GAMMA	11-20 (%)	01/02/92	16.80		16.00		16.20	
TSH	0.3-3 (MU/L)	01/02/92	4.90	>>				
T4	4.5-12 (NG/DL)	01/02/92	6.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 7/03 Patient: 188 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/02/92		17/03/92		07/04/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	10/02/92	15.50		16.30		15.90	
HT	40-54 (%)	10/02/92	49.60		55.80	>	51.70	
RBC	4.4-5.9 (10-6/UL)	10/02/92	5.24		5.41		5.10	
WBC	4-10.8 (10-3/UL)	10/02/92	9.80		12.51	>	13.17	>
WBC: N	45-70 (%)	10/02/92	63.40		78.00	>	75.10	>
WBC: L	25-45 (%)	10/02/92	20.20	<	12.60	<<	14.60	<<
WBC: E	1-5 (%)	10/02/92	5.20	>	1.70		2.10	
WBC: M	1-9 (%)	10/02/92	7.80		5.50		5.60	
WBC: B	0-2 (%)	10/02/92	1.10		0.70		0.80	
PLATELETS	150-450 (10-3/UL)	10/02/92	209.00		198.00		186.00	
NA+	132-151 (MMOL/L)	10/02/92	138.00		142.00		142.00	
K+	3.6-5.2 (MMOL/L)	10/02/92	8.46	>>			6.13	>>
CL-	97-108 (MMOL/L)	10/02/92	93.00	<	104.00		102.00	
Ca++	2.2-2.65 (MMOL/L)	10/02/92	2.54		2.60		2.52	
PO4--	2.5-5 (MG/DL)	10/02/92	3.20		9.60	>>	7.12	>>
SGOT	5-19 (U/L)	10/02/92	8.00		5.00		9.00	
SGPT	5-23 (U/L)	10/02/92	10.00		12.00		11.00	
GAMMA GT	5-28 (U/L)	10/02/92	18.00		16.00		15.00	
LDH	150-240 (U/L)	10/02/92	191.00		340.00	>	185.00	
ALK. PHOSPH.	65-175 (U/L)	10/02/92	121.00		105.00		122.00	
GLUCOSE	50-100 (MG/DL)	10/02/92	84.00		103.00	>	93.00	
BUN	10-50 (MG/DL)	10/02/92	17.60		25.80		23.20	
CREATININE	0.6-1.1 (MG/DL)	10/02/92	0.74		1.28	>	1.15	>
URIC ACID	3.5-7 (MG/DL)	10/02/92	4.00		3.70		3.90	
TOT BILIRUBIN	0.2-1 (MG/DL)	10/02/92	0.46		0.32		0.34	
TOT. PROTEINS	6-8.5 (G/DL)	10/02/92	7.30		8.00		7.30	
ALBUMINE	55-68 (%)	10/02/92	75.10	>	69.70	>	68.20	>
TOT. CHOLEST.	120-220 (MG/DL)	10/02/92	192.00		217.00		192.00	
TRIGLYCERIDES	45-200 (MG/DL)	10/02/92	299.00	>>	222.00	>	270.00	>>
GLOBULINS ALPHA 1	1-5 (%)	10/02/92	2.40		3.30		3.40	
GLOBULINS ALPHA 2	5-10 (%)	10/02/92	7.80		10.10	>	9.90	
GLOBULINS BETA	7-12 (%)	10/02/92	6.50	<	7.60		8.50	
GLOBULINS GAMMA	11-20 (%)	10/02/92	8.20	<	9.30	<	10.00	<
TSH	0.3-3 (MU/L)	10/02/92	1.30					
T4	4.5-12 (NG/DL)	10/02/92	7.20					

1817

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/03 Patient: 189 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/02/92		17/03/92		07/04/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	05/02/92	16.30		15.10		15.00	
HT	40-54 (%)	05/02/92	52.50		48.10		47.30	
RBC	4,4-5.9 (10¬6/UL)	05/02/92	5.83		5.35		5.02	
WBC	4-10.8 (10¬3/UL)	05/02/92	8.72		8.34		13.85	>
WBC: N	45-70 (%)	05/02/92	59.20		55.50		72.80	>
WBC: L	25-45 (%)	05/02/92	26.10		33.40		20.80	<
WBC: E	1-5 (%)	05/02/92	3.20		1.50		0.40	<
WBC: M	1-9 (%)	05/02/92	6.50		5.10		3.90	
WBC: B	0-2 (%)	05/02/92	1.20		1.10		0.50	
PLATELETS	150-450 (10¬3/UL)	05/02/92	313.00		322.00		313.00	
NA+	132-151 (MMOL/L)	05/02/92	140.00		138.00		141.00	
K+	3.6-5.2 (MMOL/L)	05/02/92			7.38	>>	6.72	>>
CL-	97-108 (MMOL/L)	05/02/92	94.00	<	96.00	<	100.00	
Ca++	2.2-2.65 (MMOL/L)	05/02/92	2.53		2.49		2.52	
PO4--	2.5-5 (MG/DL)	05/02/92	2.94		4.80		5.34	>
SGOT	5-19 (U/L)	05/02/92	11.00		10.00		9.00	
SGPT	5-23 (U/L)	05/02/92	18.00		17.00		17.00	
GAMMA GT	5-28 (U/L)	05/02/92	19.00		20.00		22.00	
LDH	150-240 (U/L)	05/02/92	264.00	>	243.00	>	242.00	>
ALK. PHOSPH.	65-175 (U/L)	05/02/92	68.00		55.00	<	59.00	<
GLUCOSE	50-100 (MG/DL)	05/02/92	97.00		100.00		108.00	>
BUN	10-50 (MG/DL)	05/02/92	34.90		35.30		40.10	
CREATININE	0.6-1.1 (MG/DL)	05/02/92	0.85		0.96		1.12	>
URIC ACID	3.5-7 (MG/DL)	05/02/92	6.10		5.10		5.70	
TOT BILIRUBIN	0.2-1 (MG/DL)	05/02/92	0.67		0.38		0.37	
TOT. PROTEINS	6-8.5 (G/DL)	05/02/92	7.20		7.20		6.90	
ALBUMINE	55-68 (%)	05/02/92	66.70		67.00		66.60	
TOT. CHOLEST.	120-220 (MG/DL)	05/02/92	305.00	>>	285.00	>	266.00	>
TRIGLYCERIDES	45-200 (MG/DL)	05/02/92	200.00		188.00		163.00	
GLOBULINS ALPHA 1	1-5 (%)	05/02/92	2.60		2.40		2.60	
GLOBULINS ALPHA 2	5-10 (%)	05/02/92	9.00		7.90		8.60	
GLOBULINS BETA	7-12 (%)	05/02/92	10.10		10.50		11.10	
GLOBULINS GAMMA	11-20 (%)	05/02/92	11.60		12.20		11.10	
TSH	0.3-3 (MU/L)	05/02/92	1.50					
T4	4.5-12 (NG/DL)	05/02/92	6.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/03 Patient: 190 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			21/02/92		20/03/92		10/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	15/02/92	14.70		15.00		15.00	
HT	40-54 (%)	15/02/92	50.80		51.70		49.70	
RBC	4.4-5.9 (10¬6/UL)	15/02/92	5.16		5.34		5.12	
WBC	4-10.8 (10¬3/UL)	15/02/92	8.96		7.49		8.18	
WBC: N	45-70 (%)	15/02/92	69.50		60.50		73.20	>
WBC: L	25-45 (%)	15/02/92	20.50	<	25.80		17.40	<<
WBC: E	1-5 (%)	15/02/92	1.10		2.70		2.40	
WBC: M	1-9 (%)	15/02/92	5.90		7.20		4.90	
WBC: B	0-2 (%)	15/02/92	0.80		1.50		0.90	
PLATELETS	150-450 (10¬3/UL)	15/02/92	360.00		370.00		337.00	
NA+	132-151 (MMOL/L)	15/02/92	142.00		140.00		144.00	
K+	3.6-5.2 (MMOL/L)	15/02/92	4.29				7.95	>>
CL-	97-108 (MMOL/L)	15/02/92	96.00	<	98.00		100.00	
Ca++	2.2-2.65 (MMOL/L)	15/02/92	2.43		2.57		2.20	
PO4--	2.5-5 (MG/DL)	15/02/92	3.76		6.10	>>	17.00	>>
SGOT	5-19 (U/L)	15/02/92	11.00		8.00		14.00	
SGPT	5-23 (U/L)	15/02/92	9.00		7.00		10.00	
GAMMA GT	5-28 (U/L)	15/02/92	11.00		12.00		12.00	
LDH	150-240 (U/L)	15/02/92	290.00	>	227.00		408.00	>
ALK. PHOSPH.	65-175 (U/L)	15/02/92	201.00	>	207.00	>	199.00	>
GLUCOSE	50-100 (MG/DL)	15/02/92	108.00	>	97.00		101.00	>
BUN	10-50 (MG/DL)	15/02/92	15.50		15.30		18.30	
CREATININE	0.6-1.1 (MG/DL)	15/02/92	0.84		1.12	>	1.37	>
URIC ACID	3.5-7 (MG/DL)	15/02/92	6.20		5.30		5.70	
TOT BILIRUBIN	0.2-1 (MG/DL)	15/02/92	0.41		0.33		0.49	
TOT. PROTEINS	6-8.5 (G/DL)	15/02/92	7.40		7.40		7.80	
ALBUMINE	55-68 (%)	15/02/92	66.00		66.20		68.50	>
TOT. CHOLEST.	120-220 (MG/DL)	15/02/92	274.00	>	281.00	>	284.00	>
TRIGLYCERIDES	45-200 (MG/DL)	15/02/92	167.00		136.00		112.00	
GLOBULINS ALPHA 1	1-5 (%)	15/02/92	2.80		2.50		2.60	
GLOBULINS ALPHA 2	5-10 (%)	15/02/92	8.90		10.10	>	11.00	>
GLOBULINS BETA	7-12 (%)	15/02/92	10.20		8.50		7.30	
GLOBULINS GAMMA	11-20 (%)	15/02/92	12.10		12.70		10.60	<
TSH	0.3-3 (MU/L)	15/02/92	2.20					
T4	4.5-12 (NG/DL)	15/02/92	7.20					

1819

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 7/03 Patient: 191 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			25/02/92		24/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/DL)	20/02/92	13.80		14.20	
HT	37-54 (%)	20/02/92	45.70		44.80	
RBC	3.8-5.2 (10-6/UL)	20/02/92	4.85		4.85	
WBC	4-10.8 (10-3/UL)	20/02/92	6.44		8.21	
WBC: N	45-70 (%)	20/02/92	66.70		73.20	>
WBC: L	25-45 (%)	20/02/92	23.40	<	18.20	<
WBC: E	1-5 (%)	20/02/92	0.80	<	0.80	<
WBC: M	1-9 (%)	20/02/92	5.10		4.90	
WBC: B	0-2 (%)	20/02/92	0.90		0.70	
PLATELETS	150-450 (10-3/UL)	20/02/92	274.00		323.00	
NA+	132-151 (MMOL/L)	20/02/92	144.00		140.00	
K+	3.6-5.2 (MMOL/L)	20/02/92	5.28	>	5.04	
CL-	97-108 (MMOL/L)	20/02/92	102.00		97.00	
Ca++	2.2-2.65 (MMOL/L)	20/02/92	2.38		2.35	
PO4--	2.5-5 (MG/DL)	20/02/92	3.91			
SGOT	5-15 (U/L)	20/02/92	6.00		9.00	
SGPT	5-19 (U/L)	20/02/92	7.00		10.00	
GAMMA GT	5-18 (U/L)	20/02/92	12.00		15.00	
LDH	150-240 (U/L)	20/02/92	291.00	>	260.00	>
ALK. PHOSPH.	65-175 (U/L)	20/02/92	84.00		79.00	
GLUCOSE	50-100 (MG/DL)	20/02/92	107.00	>	110.00	>
BUN	10-50 (MG/DL)	20/02/92	24.30		24.60	
CREATININE	0.5-0.9 (MG/DL)	20/02/92	0.68		0.63	
URIC ACID	2.5-6 (MG/DL)	20/02/92	4.20		4.40	
TOT BILIRUBIN	0.2-1 (MG/DL)	20/02/92	0.40		0.28	
TOT. PROTEINS	6-8.5 (G/DL)	20/02/92	6.90		7.00	
ALBUMINE	55-68 (%)	20/02/92	63.80		64.40	
TOT. CHOLEST.	120-220 (MG/DL)	20/02/92	201.00		216.00	
TRIGLYCERIDES	45-200 (MG/DL)	20/02/92	98.00		123.00	
GLOBULINS ALPHA 1	1-5 (%)	20/02/92	2.80		3.00	
GLOBULINS ALPHA 2	5-10 (%)	20/02/92	7.70		8.50	
GLOBULINS BETA	7-12 (%)	20/02/92	9.00		9.00	
GLOBULINS GAMMA	11-20 (%)	20/02/92	16.70		15.10	
TSH	0.3-3 (MU/L)	20/02/92	1.00			
T4	4.5-12 (NG/DL)	20/02/92	7.80			

1820

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/03 Patient: 192 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/03/92		31/03/92		21/04/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/03/92	14.50		14.50		14.40	
HT	37-54 (%)	01/03/92	48.60		47.60		48.00	
RBC	3.8-5.2 (10~6/UL)	01/03/92	5.00		4.91		4.73	
WBC	4-10.8 (10~3/UL)	01/03/92	7.82		5.84		5.73	
WBC: N	45-70 (%)	01/03/92	64.90		49.60		48.70	
WBC: L	25-45 (%)	01/03/92	26.10		37.20		41.20	
WBC: E	1-5 (%)	01/03/92	0.70	<	1.60		1.30	
WBC: M	1-9 (%)	01/03/92	5.40		5.80		5.40	
WBC: B	0-2 (%)	01/03/92	0.60		2.00		0.60	
PLATELETS	150-450 (10~3/UL)	01/03/92	265.00		257.00		280.00	
NA+	132-151 (MMOL/L)	01/03/92	146.00		143.00		145.00	
K+	3.6-5.2 (MMOL/L)	01/03/92	5.93	>	6.80	>>	5.36	>
CL-	97-108 (MMOL/L)	01/03/92	100.00		98.00		104.00	
Ca++	2.2-2.65 (MMOL/L)	01/03/92	2.61		2.55		2.53	
PO4--	2.5-5 (MG/DL)	01/03/92	6.96	>>	6.20	>>	5.80	>>
SGOT	5-15 (U/L)	01/03/92	11.00		13.00		10.00	
SGPT	5-19 (U/L)	01/03/92	10.00		9.00		11.00	
GAMMA GT	5-18 (U/L)	01/03/92	10.00		8.00		10.00	
LDH	150-240 (U/L)	01/03/92	285.00	>	326.00	>	341.00	>
ALK. PHOSPH.	65-175 (U/L)	01/03/92	149.00		140.00		139.00	
GLUCOSE	50-100 (MG/DL)	01/03/92	71.00		88.00		112.00	>
BUN	10-50 (MG/DL)	01/03/92	38.20		38.70		34.40	
CREATININE	0.5-0.9 (MG/DL)	01/03/92	1.14	>	1.04	>	1.07	>
URIC ACID	2.5-6 (MG/DL)	01/03/92	5.40		5.50		5.20	
TOT BILIRUBIN	0.2-1 (MG/DL)	01/03/92	0.67		0.54		0.51	
TOT. PROTEINS	6-8.5 (G/DL)	01/03/92	7.60		7.80		7.90	
ALBUMINE	55-68 (%)	01/03/92	64.40		67.00		65.70	
TOT. CHOLEST.	120-220 (MG/DL)	01/03/92	298.00	>>	281.00	>	297.00	>>
TRIGLYCERIDES	45-200 (MG/DL)	01/03/92	89.00		73.00		89.00	
GLOBULINS ALPHA 1	1-5 (%)	01/03/92	1.60		2.00		2.10	
GLOBULINS ALPHA 2	5-10 (%)	01/03/92	8.10		9.10		6.90	
GLOBULINS BETA	7-12 (%)	01/03/92	12.00		10.50		9.90	
GLOBULINS GAMMA	11-20 (%)	01/03/92	13.90		11.40		11.10	
TSH	0.3-3 (MU/L)	01/03/92	1.40					
T4	4.5-12 (NG/DL)	01/03/92	8.30					

1821

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 7/03 Patient: 523 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/05/92		26/05/92		16/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/04/92	13.50		14.90		14.30	
HT	35-47 (%)	01/04/92	40.00		48.00	>	43.00	
RBC	3.8-5.2 (10-6/MM3)	01/04/92	4.30		4.70		4.50	
WBC	4-10 (10-3/MM3)	01/04/92	4.70		5.10		5.20	
WBC: N	45-70 (%)	01/04/92	54.00		59.00		60.00	
WBC: L	25-40 (%)	01/04/92	33.00		31.00		32.00	
WBC: E	1-4 (%)	01/04/92	2.00		3.00		2.00	
WBC: M	1-8 (%)	01/04/92	7.00		3.00		4.00	
WBC: B	0-2 (%)	01/04/92	1.00		2.00		1.00	
PLATELETS	200-300 (10-3/MM3)	01/04/92	235.00		287.00		281.00	
NA+	135-144 (MMOL/L)	01/04/92	147.00	>	143.00		143.00	
K+	3.6-5.6 (MMOL/L)	01/04/92	4.30		4.40		4.30	
CL-	97-108 (MMOL/L)	01/04/92	109.00	>	106.00		104.00	
Ca++	2.1-2.6 (MMOL/L)	01/04/92	2.49		2.44		2.25	
PO4--	0.81-1.45 (MMOL/L)	01/04/92	1.32		1.14		1.13	
SGOT	5-15 (U/L)	01/04/92	8.00		6.00		7.00	
SGPT	5-17 (U/L)	01/04/92	8.00		5.00		8.00	
GAMMA GT	5-18 (U/L)	01/04/92	7.00		5.00		7.00	
LDH	150-240 (U/L)	01/04/92	149.00	<	142.00	<	151.00	
ALK. PHOSPH.	60-200 (U/L)	01/04/92	107.00		117.00		91.00	
GLUCOSE	60-110 (MG/DL)	01/04/92	91.00		88.00		102.00	
BUN	10-50 (MG/DL)	01/04/92	37.00		41.00		36.00	
CREATININE	0.5-1.2 (MG/DL)	01/04/92	0.87		0.88		0.85	
URIC ACID	2.5-6 (MG/DL)	01/04/92	2.60		1.90	<	2.20	<
TOT BILIRUBIN	0.2-1 (MG/DL)	01/04/92	0.28		0.22		0.38	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/04/92	0.11					
TOT. PROTEINS	6-8 (G/DL)	01/04/92	7.00		7.20		6.70	
ALBUMINE	58.8-69.6 (%)	01/04/92	67.20		66.70		69.60	
TOT. CHOLEST.	120-220 (MG/DL)	01/04/92	210.00		194.00		182.00	
TRIGLYCERIDES	50-172 (MG/DL)	01/04/92	41.00	<	82.00		74.00	
GLOBULINS ALPHA 1	1.8-3.8 (%)	01/04/92	2.80		3.60		3.50	
GLOBULINS ALPHA 2	3.7-13.1 (%)	01/04/92	7.60		8.00		7.20	
GLOBULINS BETA	8.9-13.6 (%)	01/04/92	10.80		11.00		10.50	
GLOBULINS GAMMA	8.4-18.3 (%)	01/04/92	11.70		10.70		9.30	
TSH	0.2-5 (UU/ML)	01/04/92	1.30					
T4	4-13 (UG/DL)	01/04/92	6.40					

1822

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/03 Patient: 524 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/05/92		26/05/92		16/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/04/92	13.40		13.60		13.70	
HT	35-47 (%)	01/04/92	38.00		39.00		38.00	
RBC	3.8-5.2 (10¬6/MM3)	01/04/92	4.40		4.50		4.50	
WBC	4-10 (10¬3/MM3)	01/04/92	5.30		5.00		3.80	<
WBC: N	45-70 (%)	01/04/92	52.00		55.00		45.00	
WBC: L	25-40 (%)	01/04/92	33.00		28.00		37.00	
WBC: E	1-4 (%)	01/04/92	3.00		4.00		4.00	
WBC: M	1-8 (%)	01/04/92	9.00	>	10.00	>	12.00	>>
WBC: B	0-2 (%)	01/04/92	1.00		1.00		1.00	
PLATELETS	200-300 (10¬3/MM3)	01/04/92	101.00	<<	104.00	<<	107.00	<<
NA+	135-144 (MMOL/L)	01/04/92	149.00	>	135.00		137.00	
K+	3.6-5.6 (MMOL/L)	01/04/92	4.10		3.60		3.80	
CL-	97-108 (MMOL/L)	01/04/92	110.00	>	99.00		101.00	
Ca++	2.1-2.6 (MMOL/L)	01/04/92	2.43		2.42		2.39	
PO4--	0.81-1.45 (MMOL/L)	01/04/92	1.04		0.96		1.11	
SGOT	5-15 (U/L)	01/04/92	8.00		6.00		7.00	
SGPT	5-17 (U/L)	01/04/92	6.00		6.00		8.00	
GAMMA GT	5-18 (U/L)	01/04/92	9.00		7.00		9.00	
LDH	150-240 (U/L)	01/04/92	146.00	<	130.00	<	114.00	<
ALK. PHOSPH.	60-200 (U/L)	01/04/92	57.00	<	60.00		69.00	
GLUCOSE	60-110 (MG/DL)	01/04/92	54.00	<	63.00		54.00	<
BUN	10-50 (MG/DL)	01/04/92	36.00		17.00		53.00	>
CREATININE	0.5-1.2 (MG/DL)	01/04/92	0.94		0.79		0.84	
URIC ACID	2.5-6 (MG/DL)	01/04/92	4.90		3.60		3.90	
TOT BILIRUBIN	0.2-1 (MG/DL)	01/04/92	0.35		0.38		0.32	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/04/92	0.21					
TOT. PROTEINS	6-8 (G/DL)	01/04/92	7.60		7.00		6.80	
ALBUMINE	58.8-69.6 (%)	01/04/92	63.10		66.80		69.20	
TOT. CHOLEST.	120-220 (MG/DL)	01/04/92	179.00		176.00		174.00	
TRIGLYCERIDES	50-172 (MG/DL)	01/04/92	102.00		149.00		113.00	
GLOBULINS ALPHA 1	1.8-3.8 (%)	01/04/92	3.60		3.70		3.50	
GLOBULINS ALPHA 2	3.7-13.1 (%)	01/04/92	11.70		8.40		7.70	
GLOBULINS BETA	8.9-13.6 (%)	01/04/92	13.00		10.40		9.50	
GLOBULINS GAMMA	8.4-18.3 (%)	01/04/92	8.60		10.70		10.10	
TSH	0.2-5 (UU/ML)	01/04/92	1.30					
T4	4-13 (UG/DL)	01/04/92	10.40					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/03 Patient: 525 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/05/92		26/05/92		16/06/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/04/92	14.30		13.70		14.00	
HT	35-47 (%)	01/04/92	44.00		41.00		40.00	
RBC	3.8-5.2 (10-6/MM3)	01/04/92	4.60		4.30		4.50	
WBC	4-10 (10-3/MM3)	01/04/92	4.10		6.00		4.30	
WBC: N	45-70 (%)	01/04/92	56.00		53.00		49.00	
WBC: L	25-40 (%)	01/04/92	33.00		37.00		40.00	
WBC: E	1-4 (%)	01/04/92	4.00		2.00		3.00	
WBC: M	1-8 (%)	01/04/92	5.00		6.00		6.00	
WBC: B	0-2 (%)	01/04/92	1.00		1.00		1.00	
PLATELETS	200-300 (10-3/MM3)	01/04/92	282.00		284.00		197.00	<
NA+	135-144 (MMOL/L)	01/04/92	149.00	>	137.00		136.00	
K+	3.6-5.6 (MMOL/L)	01/04/92	4.40		4.80		4.30	
CL-	97-108 (MMOL/L)	01/04/92	113.00	>	105.00		101.00	
Ca++	2.1-2.6 (MMOL/L)	01/04/92	2.47		2.26		2.27	
PO4--	0.81-1.45 (MMOL/L)	01/04/92	1.59	>	0.94		0.98	
SGOT	5-15 (U/L)	01/04/92	14.00		6.00		6.00	
SGPT	5-17 (U/L)	01/04/92	22.00	>	6.00		8.00	
GAMMA GT	5-18 (U/L)	01/04/92	35.00	>	7.00		9.00	
LDH	150-240 (U/L)	01/04/92	218.00		185.00		209.00	
ALK. PHOSPH.	60-200 (U/L)	01/04/92	135.00		85.00		86.00	
GLUCOSE	60-110 (MG/DL)	01/04/92	64.00		68.00		65.00	
BUN	10-50 (MG/DL)	01/04/92	25.00		32.00		39.00	
CREATININE	0.5-1.2 (MG/DL)	01/04/92	1.09		0.86		0.80	
URIC ACID	2.5-6 (MG/DL)	01/04/92	5.10		3.70		4.00	
TOT BILIRUBIN	0.2-1 (MG/DL)	01/04/92	0.33		0.28		0.39	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/04/92	0.12					
TOT. PROTEINS	6-8 (G/DL)	01/04/92	6.90		6.60		6.60	
ALBUMINE	58.8-69.6 (%)	01/04/92	62.70				63.00	
TOT. CHOLEST.	120-220 (MG/DL)	01/04/92			200.00		207.00	
TRIGLYCERIDES	50-172 (MG/DL)	01/04/92			50.00		74.00	
GLOBULINS ALPHA 1	1.8-3.8 (%)	01/04/92	3.70				3.50	
GLOBULINS ALPHA 2	3.7-13.1 (%)	01/04/92	11.80				8.60	
GLOBULINS BETA	8.9-13.6 (%)	01/04/92	12.50				11.90	
GLOBULINS GAMMA	8.4-18.3 (%)	01/04/92	9.20				13.00	
TSH	0.2-5 (UU/ML)	01/04/92	1.60					
T4	4-13 (UG/DL)	01/04/92	7.40					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/03 Patient: 526 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/05/92		26/05/92		16/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/04/92	14.50		14.30		13.50	
HT	35-47 (%)	01/04/92	44.00		43.00		38.00	
RBC	3.8-5.2 (10¬6/MM3)	01/04/92	4.60		4.60		4.40	
WBC	4-10 (10¬3/MM3)	01/04/92	4.90		6.40		4.90	
WBC: N	45-70 (%)	01/04/92	50.00		53.00		52.00	
WBC: L	25-40 (%)	01/04/92	40.00		34.00		37.00	
WBC: E	1-4 (%)	01/04/92	2.00		3.00		3.00	
WBC: M	1-8 (%)	01/04/92	5.00		4.00		5.00	
WBC: B	0-2 (%)	01/04/92	1.00		1.00		1.00	
PLATELETS	200-300 (10¬3/MM3)	01/04/92	261.00		233.00		217.00	
NA+	135-144 (MMOL/L)	01/04/92	149.00	>	137.00		140.00	
K+	3.6-5.6 (MMOL/L)	01/04/92	4.56		4.00		3.90	
CL-	97-108 (MMOL/L)	01/04/92	109.00	>	103.00		106.00	
Ca++	2.1-2.6 (MMOL/L)	01/04/92	2.39		2.46		2.40	
PO4--	0.81-1.45 (MMOL/L)	01/04/92	1.34		1.51	>	1.19	
SGOT	5-15 (U/L)	01/04/92	6.00		10.00		12.00	
SGPT	5-17 (U/L)	01/04/92	9.00		16.00		18.00	>
GAMMA GT	5-18 (U/L)	01/04/92	9.00		25.00	>	31.00	>
LDH	150-240 (U/L)	01/04/92	231.00		198.00		197.00	
ALK. PHOSPH.	60-200 (U/L)	01/04/92	97.00		122.00		110.00	
GLUCOSE	60-110 (MG/DL)	01/04/92	62.00		90.00		89.00	
BUN	10-50 (MG/DL)	01/04/92	39.00		36.00		42.00	
CREATININE	0.5-1.2 (MG/DL)	01/04/92	0.91		1.21	>	1.19	
URIC ACID	2.5-6 (MG/DL)	01/04/92	4.90		5.20		5.70	
TOT BILIRUBIN	0.2-1 (MG/DL)	01/04/92	0.34		0.44		0.47	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/04/92	0.13					
TOT. PROTEINS	6-8 (G/DL)	01/04/92	7.00		7.10		6.60	
ALBUMINE	58.8-69.6 (%)	01/04/92	63.60				66.00	
TOT. CHOLEST.	120-220 (MG/DL)	01/04/92			316.00	>>	311.00	>>
TRIGLYCERIDES	50-172 (MG/DL)	01/04/92			317.00	>>	358.00	>>
GLOBULINS ALPHA 1	1.8-3.8 (%)	01/04/92	3.10				3.00	
GLOBULINS ALPHA 2	3.7-13.1 (%)	01/04/92	9.00				9.20	
GLOBULINS BETA	8.9-13.6 (%)	01/04/92	12.70				13.10	
GLOBULINS GAMMA	8.4-18.3 (%)	01/04/92	11.60				8.70	
TSH	0.2-5 (UU/ML)	01/04/92	0.80					
T4	4-13 (UG/DL)	01/04/92	9.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 7/03 Patient: 527 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			12/05/92		09/06/92		30/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/04/92	13.70		13.60		13.90	
HT	35-47 (%)	01/04/92	40.00		38.00		39.00	
RBC	3.8-5.2 (10¬6/MM3)	01/04/92	4.60		4.10		4.20	
WBC	4-10 (10¬3/MM3)	01/04/92	4.40		9.10		9.10	
WBC: N	45-70 (%)	01/04/92	62.00		67.00		70.00	
WBC: L	25-40 (%)	01/04/92	27.00		22.00	<	20.00	<
WBC: E	1-4 (%)	01/04/92	1.00		2.00		2.00	
WBC: M	1-8 (%)	01/04/92	7.00		7.00		6.00	
WBC: B	0-2 (%)	01/04/92	1.00		1.00		1.00	
PLATELETS	200-300 (10¬3/MM3)	01/04/92	264.00		307.00	>	307.00	>
NA+	135-144 (MMOL/L)	01/04/92	141.00		126.00	<	135.00	
K+	3.6-5.6 (MMOL/L)	01/04/92	4.60		4.00		4.10	
CL-	97-108 (MMOL/L)	01/04/92	104.00		95.00	<	100.00	
Ca++	2.1-2.6 (MMOL/L)	01/04/92	2.33		2.30		2.40	
PO4--	0.81-1.45 (MMOL/L)	01/04/92	1.05		1.11		1.19	
SGOT	5-15 (U/L)	01/04/92	7.00		6.00		8.00	
SGPT	5-17 (U/L)	01/04/92	5.00		5.00		5.00	
GAMMA GT	5-18 (U/L)	01/04/92	5.00		7.00		8.00	
LDH	150-240 (U/L)	01/04/92	159.00		162.00		168.00	
ALK. PHOSPH.	60-200 (U/L)	01/04/92	41.00	<	70.00		71.00	
GLUCOSE	60-110 (MG/DL)	01/04/92	70.00		71.00		68.00	
BUN	10-50 (MG/DL)	01/04/92	42.00		36.00		23.00	
CREATININE	0.5-1.2 (MG/DL)	01/04/92	0.96		1.01		0.97	
URIC ACID	2.5-6 (MG/DL)	01/04/92	2.00	<	4.10		4.50	
TOT BILIRUBIN	0.2-1 (MG/DL)	01/04/92	0.27		0.40		0.48	
TOT. PROTEINS	6-8 (G/DL)	01/04/92	7.30		6.60		6.40	
ALBUMINE	58.8-69.6 (%)	01/04/92	64.60		66.50		66.00	
TOT. CHOLEST.	120-220 (MG/DL)	01/04/92	193.00		182.00		189.00	
TRIGLYCERIDES	50-172 (MG/DL)	01/04/92	41.00	<	140.00		127.00	
GLOBULINS ALPHA 1	1.8-3.8 (%)	01/04/92	2.90		5.40	>>	2.60	
GLOBULINS ALPHA 2	3.7-13.1 (%)	01/04/92	7.30		9.50		9.10	
GLOBULINS BETA	8.9-13.6 (%)	01/04/92	12.00		10.50		10.10	
GLOBULINS GAMMA	8.4-18.3 (%)	01/04/92	13.30		10.30		12.30	
TSH	0.2-5 (UU/ML)	01/04/92	0.70					
T4	4-13 (UG/DL)	01/04/92	8.10					

1826

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 7/03 Patient: 528 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			12/05/92		09/06/92	
			value	(◊)	value	(◊)
Laboratory test	Range value	Range date				
HB	12-16 (G/DL)	01/04/92	13.60		13.80	
HT	35-47 (%)	01/04/92	39.00		42.00	
RBC	3.8-5.2 (10¬6/MM3)	01/04/92	4.10		4.60	
WBC	4-10 (10¬3/MM3)	01/04/92	9.80		5.00	
WBC: N	45-70 (%)	01/04/92	66.00		63.00	
WBC: L	25-40 (%)	01/04/92	23.00	<	26.00	
WBC: E	1-4 (%)	01/04/92	3.00		2.00	
WBC: M	1-8 (%)	01/04/92	6.00		7.00	
WBC: B	0-2 (%)	01/04/92	1.00		1.00	
PLATELETS	200-300 (10¬3/MM3)	01/04/92	278.00		259.00	
NA+	135-144 (MMOL/L)	01/04/92	140.00		125.00	<
K+	3.6-5.6 (MMOL/L)	01/04/92	4.40		3.80	
CL-	97-108 (MMOL/L)	01/04/92	100.00		93.00	<
Ca++	2.1-2.6 (MMOL/L)	01/04/92	2.32		2.66	>
PO4--	0.81-1.45 (MMOL/L)	01/04/92	1.34		1.18	
SGOT	5-15 (U/L)	01/04/92	8.00		9.00	
SGPT	5-17 (U/L)	01/04/92	5.00		8.00	
GAMMA GT	5-18 (U/L)	01/04/92	7.00		7.00	
LDH	150-240 (U/L)	01/04/92	180.00		148.00	<
ALK. PHOSPH.	60-200 (U/L)	01/04/92	81.00		45.00	<
GLUCOSE	60-110 (MG/DL)	01/04/92	81.00		75.00	
BUN	10-50 (MG/DL)	01/04/92	34.00		35.00	
CREATININE	0.5-1.2 (MG/DL)	01/04/92	1.03		0.95	
URIC ACID	2.5-6 (MG/DL)	01/04/92	3.90		2.40	<
TOT BILIRUBIN	0.2-1 (MG/DL)	01/04/92	0.27		0.42	
TOT. PROTEINS	6-8 (G/DL)	01/04/92	7.00		7.00	
ALBUMINE	58.8-69.6 (%)	01/04/92	64.20		63.60	
TOT. CHOLEST.	120-220 (MG/DL)	01/04/92	198.00		206.00	
TRIGLYCERIDES	50-172 (MG/DL)	01/04/92	125.00		40.00	<
GLOBULINS ALPHA 1	1.8-3.8 (%)	01/04/92	3.60		2.10	
GLOBULINS ALPHA 2	3.7-13.1 (%)	01/04/92	10.40		8.60	
GLOBULINS BETA	8.9-13.6 (%)	01/04/92	11.50		10.80	
GLOBULINS GAMMA	8.4-18.3 (%)	01/04/92	10.40		14.90	
TSH	0.2-5 (UU/ML)	01/04/92	0.70			
T4	4-13 (UG/DL)	01/04/92	6.00			

1827

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/04 Patient: 193 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/01/92		15/02/92		07/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	12/12/91	13.30		14.10		12.90	
HT	37-54 (%)	12/12/91	43.00		50.50		42.60	
RBC	3.8-5.2 (10¬6/UL)	12/12/91	4.60		4.96		4.35	
WBC	4-10.8 (10¬3/UL)	12/12/91	6.30		5.77		6.50	
WBC: N	45-70 (%)	12/12/91	59.60		65.60		57.40	
WBC: L	25-45 (%)	12/12/91	32.50		28.50		31.90	
WBC: E	1-5 (%)	12/12/91	0.50	<	0.30	<	0.90	<
WBC: M	1-9 (%)	12/12/91	4.00		2.40		6.40	
WBC: B	0-2 (%)	12/12/91	1.00		1.20		1.20	
PLATELETS	150-450 (10¬3/UL)	12/12/91	248.00		227.00		266.00	
NA+	132-151 (MMOL/L)	12/12/91	143.00		139.00		146.00	
K+	3.6-5.2 (MMOL/L)	12/12/91	4.60		5.09		5.33	>
CL-	97-108 (MMOL/L)	12/12/91	102.00		104.00		102.00	
Ca++	2.2-2.65 (MMOL/L)	12/12/91	2.44		2.50		2.54	
PO4--	2.5-5 (MG/DL)	12/12/91	4.10		3.20		4.40	
SGOT	5-15 (U/L)	12/12/91	9.00		13.00		9.00	
SGPT	5-19 (U/L)	12/12/91	5.00		5.00		6.00	
GAMMA GT	5-18 (U/L)	12/12/91	14.00		17.00		13.00	
LDH	150-240 (U/L)	12/12/91	174.00		358.00	>	223.00	
ALK. PHOSPH.	65-175 (U/L)	12/12/91	135.00		143.00		120.00	
GLUCOSE	50-100 (MG/DL)	12/12/91	86.00		41.00	<	37.00	<
BUN	10-50 (MG/DL)	12/12/91	39.00		34.90		43.80	
CREATININE	0.5-1 (MG/DL)	12/12/91	0.82		0.81		0.81	
URIC ACID	2.5-6 (MG/DL)	12/12/91	4.50		4.30		4.20	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/12/91	0.30		0.56		0.42	
TOT. PROTEINS	6-8.5 (G/DL)	12/12/91	7.50		8.40		7.00	
ALBUMINE	55-68 (%)	12/12/91	66.50		67.20		62.90	
TOT. CHOLEST.	120-220 (MG/DL)	12/12/91	253.00	>	259.00	>	238.00	>
TRIGLYCERIDES	45-200 (MG/DL)	12/12/91	82.00		85.00		107.00	
GLOBULINS ALPHA 1	1-5 (%)	12/12/91	2.70		2.50		3.00	
GLOBULINS ALPHA 2	5-10 (%)	12/12/91	7.70		7.10		9.40	
GLOBULINS BETA	7-12 (%)	12/12/91	9.90		11.10		10.00	
GLOBULINS GAMMA	11-20 (%)	12/12/91	13.20		12.10		14.70	
TSH	0.3-3 (MU/L)	12/12/91	0.80					
T4	4.5-12 (NG/DL)	12/12/91	7.20					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/04 Patient: 194 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/01/92		15/02/92		07/03/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	13-18 (G/DL)	12/12/91	15.70		15.30		15.70	
HT	40-54 (%)	12/12/91	48.00		52.00		50.80	
RBC	4.4-5.9 (10¬6/UL)	12/12/91	5.20		5.51		5.16	
WBC	4-10.8 (10¬3/UL)	12/12/91	4.30		5.84		5.50	
WBC: N	45-70 (%)	12/12/91	48.60		40.00	<	60.10	
WBC: L	25-45 (%)	12/12/91	38.80		56.00	>	29.70	
WBC: E	1-5 (%)	12/12/91	2.00		3.00		3.00	
WBC: M	1-9 (%)	12/12/91	7.00		1.00		3.90	
WBC: B	0-2 (%)	12/12/91	0.50		0.00		0.50	
PLATELETS	150-450 (10¬3/UL)	12/12/91	135.00	<	149.00	<	156.00	
NA+	132-151 (MMOL/L)	12/12/91	136.00		144.00		142.00	
K+	3.6-5.2 (MMOL/L)	12/12/91	4.20		4.79		4.26	
CL-	97-108 (MMOL/L)	12/12/91	92.00	<	100.00		103.00	
Ca++	2.2-2.65 (MMOL/L)	12/12/91	2.40		2.60		2.47	
PO4--	2.5-5 (MG/DL)	12/12/91	2.96		3.60		4.00	
SGOT	5-19 (U/L)	12/12/91	28.00	>	12.00		15.00	
SGPT	5-23 (U/L)	12/12/91	68.00	>>	22.00		36.00	>
GAMMA GT	5-28 (U/L)	12/12/91	11.00		24.00		9.00	
LDH	150-240 (U/L)	12/12/91	230.00		171.00		189.00	
ALK. PHOSPH.	65-175 (U/L)	12/12/91	162.00		165.00		123.00	
GLUCOSE	50-100 (MG/DL)	12/12/91	102.00	>	96.00		56.00	
BUN	10-50 (MG/DL)	12/12/91	35.00		37.20		34.30	
CREATININE	0.6-1.1 (MG/DL)	12/12/91	0.83		1.07		0.84	
URIC ACID	3.5-7 (MG/DL)	12/12/91	5.00		7.00		4.30	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/12/91	1.43	>	0.47		1.18	>
DIR BILIRUBIN	0-0.3 (MG/DL)	12/12/91	0.25				0.20	
TOT. PROTEINS	6-8.5 (G/DL)	12/12/91	7.80		8.30		7.90	
ALBUMINE	55-68 (%)	12/12/91	62.10		69.40	>	71.00	>
TOT. CHOLEST.	120-220 (MG/DL)	12/12/91	175.00		222.00	>	180.00	
TRIGLYCERIDES	45-200 (MG/DL)	12/12/91	74.00		425.00	>>	140.00	
GLOBULINS ALPHA 1	1-5 (%)	12/12/91	2.90		2.60		1.60	
GLOBULINS ALPHA 2	5-10 (%)	12/12/91	7.10		5.90		5.30	
GLOBULINS BETA	7-12 (%)	12/12/91	10.50		9.10		6.30	<
GLOBULINS GAMMA	11-20 (%)	12/12/91	17.40		13.00		15.80	
TSH	0.3-3 (MU/L)	12/12/91	1.20					
T4	4.5-12 (NG/DL)	12/12/91	7.20					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA

Centre: 7/04 Patient: 195 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/01/92		15/02/92		07/03/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/12/91	14.60		14.70		14.10	
HT	37-54 (%)	12/12/91	45.00		44.80		45.20	
RBC	3.8-5.2 (10-6/UL)	12/12/91	5.00		4.52		4.66	
WBC	4-10.8 (10-3/UL)	12/12/91	9.40		8.46		9.50	
WBC: N	45-70 (%)	12/12/91	49.10		56.90		39.20	<
WBC: L	25-45 (%)	12/12/91	40.50		37.50		52.40	>
WBC: E	1-5 (%)	12/12/91	1.80		0.70	<	0.90	<
WBC: M	1-9 (%)	12/12/91	5.70		1.90		3.10	
WBC: B	0-2 (%)	12/12/91	0.80		1.10		0.80	
PLATELETS	150-450 (10-3/UL)	12/12/91	290.00		306.00		264.00	
NA+	132-151 (MMOL/L)	12/12/91	136.00		141.00		142.00	
K+	3.6-5.2 (MMOL/L)	12/12/91	4.20		5.33	>	4.65	
CL-	97-108 (MMOL/L)	12/12/91	90.00	<	100.00		101.00	
Ca++	2.2-2.65 (MMOL/L)	12/12/91	2.42		2.56		2.39	
PO4--	2.5-5 (MG/DL)	12/12/91	4.70		7.20	>>	6.80	>>
SGOT	5-15 (U/L)	12/12/91	8.00		9.00		8.00	
SGPT	5-19 (U/L)	12/12/91	6.00		8.00		9.00	
GAMMA GT	5-18 (U/L)	12/12/91	11.00		19.00	>	11.00	
LDH	150-240 (U/L)	12/12/91	233.00		307.00	>	207.00	
ALK. PHOSPH.	65-175 (U/L)	12/12/91	90.00		152.00		88.00	
GLUCOSE	50-100 (MG/DL)	12/12/91	98.00		89.00		61.00	
BUN	10-50 (MG/DL)	12/12/91	43.00		25.90		44.30	
CREATININE	0.5-1 (MG/DL)	12/12/91	0.90		0.92		0.86	
URIC ACID	2.5-6 (MG/DL)	12/12/91	4.80		5.50		4.50	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/12/91	0.49		0.77		0.33	
TOT. PROTEINS	6-8.5 (G/DL)	12/12/91	7.60		8.00		7.30	
ALBUMINE	55-68 (%)	12/12/91	61.60		70.50	>	63.80	
TOT. CHOLEST.	120-220 (MG/DL)	12/12/91	356.00	>>	232.00	>	327.00	>>
TRIGLYCERIDES	45-200 (MG/DL)	12/12/91	166.00		214.00	>	173.00	
GLOBULINS ALPHA 1	1-5 (%)	12/12/91	2.20		2.80		2.20	
GLOBULINS ALPHA 2	5-10 (%)	12/12/91	9.40		7.70		9.40	
GLOBULINS BETA	7-12 (%)	12/12/91	10.70		9.00		9.40	
GLOBULINS GAMMA	11-20 (%)	12/12/91	16.10		10.00	<	15.20	
TSH	0.3-3 (MU/L)	12/12/91	0.80					
T4	4.5-12 (NG/DL)	12/12/91	7.80					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 7/04 Patient: 196 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			01/02/92		22/02/92		14/03/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/12/91	12.60		12.30		12.90	
HT	37-54 (%)	12/12/91	38.80		39.50		37.80	
RBC	3.8-5.2 (10-6/UL)	12/12/91	4.40		4.32		4.60	
WBC	4-10.8 (10-3/UL)	12/12/91	3.90	<	4.21		5.35	
WBC: N	45-70 (%)	12/12/91	42.00	<	59.40		60.00	
WBC: L	25-45 (%)	12/12/91	48.00	>	25.70		36.00	
WBC: E	1-5 (%)	12/12/91	0.00	<	3.30		2.00	
WBC: M	1-9 (%)	12/12/91	10.00	>	7.90		2.00	
WBC: B	0-2 (%)	12/12/91	0.00		1.00		0.00	
PLATELETS	150-450 (10-3/UL)	12/12/91	262.00		234.00		231.00	
NA+	132-151 (MMOL/L)	12/12/91	141.00		143.00		140.00	
K+	3.6-5.2 (MMOL/L)	12/12/91	3.95		5.58	>	4.00	
CL-	97-108 (MMOL/L)	12/12/91	100.00		97.00		100.00	
Ca++	2.2-2.65 (MMOL/L)	12/12/91	2.49		2.42		2.39	
PO4--	2.5-5 (MG/DL)	12/12/91	3.33		3.84		3.40	
SGOT	5-15 (U/L)	12/12/91	9.00		12.00		9.00	
SGPT	5-19 (U/L)	12/12/91	14.00		12.00		14.00	
GAMMA GT	5-18 (U/L)	12/12/91	15.00		11.00		44.00	>>
LDH	150-240 (U/L)	12/12/91	184.00		353.00	>	223.00	
ALK. PHOSPH.	65-175 (U/L)	12/12/91	124.00		128.00		212.00	>
GLUCOSE	50-100 (MG/DL)	12/12/91	91.00		98.00		51.00	
BUN	10-50 (MG/DL)	12/12/91	32.80		41.80		37.10	
CREATININE	0.5-1 (MG/DL)	12/12/91	0.82		0.71		0.67	
URIC ACID	2.5-6 (MG/DL)	12/12/91	5.10		4.80		3.00	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/12/91	0.43		0.35		0.52	
TOT. PROTEINS	6-8.5 (G/DL)	12/12/91	7.10		7.40		7.20	
ALBUMINE	55-68 (%)	12/12/91	68.40	>	68.10	>	65.70	
TOT. CHOLEST.	120-220 (MG/DL)	12/12/91	195.00		194.00		216.00	
TRIGLYCERIDES	45-200 (MG/DL)	12/12/91	59.00		61.00		170.00	
GLOBULINS ALPHA 1	1-5 (%)	12/12/91	2.30		2.10		2.50	
GLOBULINS ALPHA 2	5-10 (%)	12/12/91	6.30		8.20		5.30	
GLOBULINS BETA	7-12 (%)	12/12/91	9.50		8.00		11.40	
GLOBULINS GAMMA	11-20 (%)	12/12/91	13.50		13.60		15.10	
TSH	0.3-3 (MU/L)	12/12/91	2.10					
T4	4,5-12 (NG/DL)	12/12/91	7.40					

1831

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/04 Patient: 197 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			01/02/92		22/02/92		14/03/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	13-18 (G/DL)	12/12/91	16.60		15.90		16.00	
HT	40-54 (%)	12/12/91	50.00		49.60		48.50	
RBC	4.4-5.9 (10~6/UL)	12/12/91	5.74		5.09		5.69	
WBC	4-10.8 (10~3/UL)	12/12/91	6.08		5.66		6.21	
WBC: N	45-70 (%)	12/12/91	67.80		79.80	>	62.60	
WBC: L	25-45 (%)	12/12/91	23.50	<	15.00	<<	30.60	
WBC: E	1-5 (%)	12/12/91	2.60		0.80	<	0.90	<
WBC: M	1-9 (%)	12/12/91	3.80		2.50		3.90	
WBC: B	0-2 (%)	12/12/91	0.80		0.50		0.60	
PLATELETS	150-450 (10~3/UL)	12/12/91	242.00		186.00		319.00	
NA+	132-151 (MMOL/L)	12/12/91	144.00		142.00		141.00	
K+	3.6-5.2 (MMOL/L)	12/12/91	3.79		4.20		5.21	>
CL-	97-108 (MMOL/L)	12/12/91	106.00		98.00		98.00	
Ca++	2.2-2.65 (MMOL/L)	12/12/91	2.43		2.43		2.57	
PO4--	2.5-5 (MG/DL)	12/12/91	2.96		3.68		2.60	
SGOT	5-19 (U/L)	12/12/91	9.00		8.00		10.00	
SGPT	5-23 (U/L)	12/12/91	11.00		7.00		15.00	
GAMMA GT	5-28 (U/L)	12/12/91	11.00		13.00		15.00	
LDH	150-240 (U/L)	12/12/91	146.00	<	235.00		252.00	>
ALK. PHOSPH.	65-175 (U/L)	12/12/91	115.00		99.00		111.00	
GLUCOSE	50-100 (MG/DL)	12/12/91	121.00	>	79.00		68.00	
BUN	10-50 (MG/DL)	12/12/91	24.00		29.50		31.00	
CREATININE	0.6-1.1 (MG/DL)	12/12/91	1.18	>	1.06		0.75	
URIC ACID	3.5-7 (MG/DL)	12/12/91	5.70		5.00		5.80	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/12/91	0.96		0.57		1.17	>
TOT. PROTEINS	6-8.5 (G/DL)	12/12/91	7.40		6.40		7.90	
ALBUMINE	55-68 (%)	12/12/91	73.90	>	65.70		68.80	>
TOT. CHOLEST.	120-220 (MG/DL)	12/12/91	183.00		166.00		186.00	
TRIGLYCERIDES	45-200 (MG/DL)	12/12/91	198.00		56.00		100.00	
GLOBULINS ALPHA 1	1-5 (%)	12/12/91	1.10		2.60		2.20	
GLOBULINS ALPHA 2	5-10 (%)	12/12/91	3.90	<	7.70		5.50	
GLOBULINS BETA	7-12 (%)	12/12/91	8.00		8.40		9.90	
GLOBULINS GAMMA	11-20 (%)	12/12/91	13.10		15.60		13.60	
TSH	0.3-3 (MU/L)	12/12/91	0.10	<<				
T4	4.5-12 (NG/DL)	12/12/91	9.60					

1832

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/04 Patient: 198 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			01/02/92		22/02/92		14/03/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/12/91	14.00		14.70		14.10	
HT	37-54 (%)	12/12/91	44.70		50.50		49.00	
RBC	3.8-5.2 (10~6/UL)	12/12/91	4.93		4.91		4.80	
WBC	4-10.8 (10~3/UL)	12/12/91	6.22		6.35		6.10	
WBC: N	45-70 (%)	12/12/91	51.80		57.10		56.90	
WBC: L	25-45 (%)	12/12/91	37.00		35.80		35.80	
WBC: E	1-5 (%)	12/12/91	1.30		1.70		1.70	
WBC: M	1-9 (%)	12/12/91	4.80		2.00		2.00	
WBC: B	0-2 (%)	12/12/91	0.50		1.50		1.60	
PLATELETS	150-450 (10~3/UL)	12/12/91	271.00		178.00		170.00	
NA+	132-151 (MMOL/L)	12/12/91	140.00		141.00		142.00	
K+	3.6-5.2 (MMOL/L)	12/12/91	3.67				5.30	>
CL-	97-108 (MMOL/L)	12/12/91	98.00		100.00		102.00	
Ca++	2.2-2.65 (MMOL/L)	12/12/91	2.43		2.52		2.60	
PO4--	2.5-5 (MG/DL)	12/12/91	3.50		3.93		3.70	
SGOT	5-15 (U/L)	12/12/91	7.00		9.00		11.00	
SGPT	5-19 (U/L)	12/12/91	3.00	<	12.00		10.00	
GAMMA GT	5-18 (U/L)	12/12/91	9.00		9.00		10.00	
LDH	150-240 (U/L)	12/12/91	158.00		244.00	>	239.00	
ALK. PHOSPH.	65-175 (U/L)	12/12/91	81.00		106.00		105.00	
GLUCOSE	50-100 (MG/DL)	12/12/91	101.00	>	89.00		91.00	
BUN	10-50 (MG/DL)	12/12/91	25.00		27.50		44.50	
CREATININE	0.5-1 (MG/DL)	12/12/91	0.81		0.92		0.81	
URIC ACID	2.5-6 (MG/DL)	12/12/91	3.00		2.70		5.00	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/12/91	0.28		0.61		0.48	
TOT. PROTEINS	6-8.5 (G/DL)	12/12/91	7.60		7.90		7.80	
ALBUMINE	55-68 (%)	12/12/91	69.80	>	64.90		64.90	
TOT. CHOLEST.	120-220 (MG/DL)	12/12/91	259.00	>	277.00	>	231.00	>
TRIGLYCERIDES	45-200 (MG/DL)	12/12/91	163.00		110.00		180.00	
GLOBULINS ALPHA 1	1-5 (%)	12/12/91	2.70		2.40		2.30	
GLOBULINS ALPHA 2	5-10 (%)	12/12/91	6.50		9.50		9.40	
GLOBULINS BETA	7-12 (%)	12/12/91	8.90		6.10	<	6.20	<
GLOBULINS GAMMA	11-20 (%)	12/12/91	12.10		17.10		16.90	
TSH	0.3-3 (MU/L)	12/12/91	1.80					
T4	4.5-12 (NG/DL)	12/12/91	8.80					

1833

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 7/04 Patient: 199 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			28/03/92		18/04/92		09/05/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	12.8-17 (G/DL)	20/03/92	13.90		14.20		14.30	
HT	39-53 (%)	20/03/92	41.00		42.00		44.00	
RBC	4.2-5.7 (10¬6/UL)	20/03/92	4.60		4.50		4.70	
WBC	4.5-10 (10¬3/UL)	20/03/92	9.00		8.60		8.60	
WBC: N	45-70 (%)	20/03/92	66.00		64.00		65.00	
WBC: L	25-45 (%)	20/03/92	24.00	<	27.00		25.00	
WBC: E	1-5 (%)	20/03/92	5.00		4.00		4.00	
WBC: M	1-9 (%)	20/03/92	4.00		3.00		6.00	
WBC: B	0-2 (%)	20/03/92	1.00		2.00		0.00	
PLATELETS	130-300 (10¬3/UL)	20/03/92	232.00		214.00		276.00	
NA+	133-149 (MMOL/L)	20/03/92	143.00		140.00		141.00	
K+	3.7-5 (MMOL/L)	20/03/92	4.10		3.90		4.30	
CL-	96-106 (MMOL/L)	20/03/92	103.00		99.00		100.00	
Ca++	2.2-2.7 (MMOL/L)	20/03/92	2.50		2.50		2.30	
PO4--	2.4-5.1 (MG/DL)	20/03/92	4.10		5.10		4.30	
SGOT	5-20 (U/L)	20/03/92	14.00		11.00		11.00	
SGPT	5-23 (U/L)	20/03/92	16.00		13.00		14.00	
GAMMA GT	5-27 (U/L)	20/03/92	11.00		14.00		20.00	
LDH	150-230 (U/L)	20/03/92	200.00		180.00		187.00	
ALK. PHOSPH.	60-180 (U/L)	20/03/92	151.00		160.00		97.00	
GLUCOSE	45-105 (MG/DL)	20/03/92	88.00		86.00		81.00	
BUN	8-55 (MG/DL)	20/03/92	33.00		31.00		11.00	
CREATININE	0.5-1.2 (MG/DL)	20/03/92	0.60		0.70		0.60	
URIC ACID	4-6.9 (MG/DL)	20/03/92	5.50		5.10		7.00	>
TOT BILIRUBIN	0.2-1 (MG/DL)	20/03/92	0.60		0.30		0.80	
DIR BILIRUBIN	0-0.35 (MG/DL)	20/03/92	0.20		0.10		0.30	
TOT. PROTEINS	5.8-8.7 (G/DL)	20/03/92	7.30		7.20		6.10	
ALBUMINE	52-70 (%)	20/03/92	67.00		65.00		68.00	
TOT. CHOLEST.	120-220 (MG/DL)	20/03/92	255.00	>	270.00	>	201.00	
TRIGLYCERIDES	45-200 (MG/DL)	20/03/92	230.00	>	234.00	>	209.00	>
GLOBULINS ALPHA 1	1-5 (%)	20/03/92	1.10		2.00		4.40	
GLOBULINS ALPHA 2	5-11 (%)	20/03/92	8.00		7.50		10.80	
GLOBULINS BETA	6-12 (%)	20/03/92	11.00		12.00		6.60	
GLOBULINS GAMMA	10-20 (%)	20/03/92	12.90		13.50		10.20	
TSH	0.2-3.1 (MU/L)	20/03/92	2.10					
T4	4.3-12.5 (NG/DL)	20/03/92	8.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/04 Patient: 200 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			28/03/92		18/04/92		09/05/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12.8-17 (G/DL)	20/03/92	14.10		14.40		14.30	
HT	39-53 (%)	20/03/92	45.00		45.00		46.00	
RBC	4.2-5.7 (10-6/UL)	20/03/92	4.60		4.50		4.70	
WBC	4.5-10 (10-3/UL)	20/03/92	8.70		7.90		7.90	
WBC: N	45-70 (%)	20/03/92	66.00		64.00		64.00	
WBC: L	25-45 (%)	20/03/92	22.00	<	23.00	<	23.00	<
WBC: E	1-5 (%)	20/03/92	3.00		3.00		4.00	
WBC: M	1-9 (%)	20/03/92	8.00		9.00		9.00	
WBC: B	0-2 (%)	20/03/92	1.00		1.00		0.00	
PLATELETS	130-300 (10-3/UL)	20/03/92	273.00		258.00		266.00	
NA+	133-149 (MMOL/L)	20/03/92	141.00		144.00		142.00	
K+	3.7-5 (MMOL/L)	20/03/92	4.40		4.30		4.30	
CL-	96-106 (MMOL/L)	20/03/92	101.00		100.00		98.00	
Ca++	2.2-2.7 (MMOL/L)	20/03/92	2.60		2.50		2.40	
PO4--	2.4-5.1 (MG/DL)	20/03/92	4.80		4.70		3.10	
SGOT	5-20 (U/L)	20/03/92	21.00	>	19.00		9.00	
SGPT	5-23 (U/L)	20/03/92	20.00		18.00		11.00	
GAMMA GT	5-27 (U/L)	20/03/92	14.00		15.00		12.00	
LDH	150-230 (U/L)	20/03/92	156.00		149.00	<	171.00	
ALK. PHOSPH.	60-180 (U/L)	20/03/92	110.00		112.00		91.00	
GLUCOSE	45-105 (MG/DL)	20/03/92	78.00		81.00		86.00	
BUN	8-55 (MG/DL)	20/03/92	11.00		22.00		14.00	
CREATININE	0.5-1.2 (MG/DL)	20/03/92	0.70		0.60		0.70	
URIC ACID	4-6.9 (MG/DL)	20/03/92	7.10	>	7.60	>	7.10	>
TOT BILIRUBIN	0.2-1 (MG/DL)	20/03/92	0.60		0.50		0.80	
DIR BILIRUBIN	0-0.35 (MG/DL)	20/03/92	0.20		0.20		0.20	
TOT. PROTEINS	5.8-8.7 (G/DL)	20/03/92	6.80		6.90		7.00	
ALBUMINE	52-70 (%)	20/03/92	66.00		65.00		68.00	
TOT. CHOLEST.	120-220 (MG/DL)	20/03/92	231.00	>	211.00		231.00	>
TRIGLYCERIDES	45-200 (MG/DL)	20/03/92	188.00		201.00	>	176.00	
GLOBULINS ALPHA 1	1-5 (%)	20/03/92	4.00		2.00		3.00	
GLOBULINS ALPHA 2	5-11 (%)	20/03/92	6.00		7.00		5.00	
GLOBULINS BETA	6-12 (%)	20/03/92	10.00		11.00		9.00	
GLOBULINS GAMMA	10-20 (%)	20/03/92	14.00		15.00		15.00	
TSH	0.2-3.1 (MU/L)	20/03/92	0.25					
T4	4.3-12.5 (NG/DL)	20/03/92	4.90					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/04 Patient: 201 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			28/03/92		18/04/92		09/05/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-15.5 (G/DL)	20/03/92	12.60		12.90		12.80	
HT	36-55 (%)	20/03/92	41.00		42.00		42.00	
RBC	3.7-5.2 (10¬6/UL)	20/03/92	4.10		4.00		4.20	
WBC	4.5-10 (10¬3/UL)	20/03/92	7.00		6.80		6.80	
WBC: N	45-70 (%)	20/03/92	62.00		59.00		60.00	
WBC: L	25-45 (%)	20/03/92	24.00	<	26.00		26.00	
WBC: E	1-5 (%)	20/03/92	4.00		4.00		5.00	
WBC: M	1-9 (%)	20/03/92	8.00		9.00		8.00	
WBC: B	0-2 (%)	20/03/92	2.00		2.00		1.00	
PLATELETS	130-300 (10¬3/UL)	20/03/92	248.00		273.00		253.00	
NA+	133-149 (MMOL/L)	20/03/92	143.00		143.00		141.00	
K+	3.7-5 (MMOL/L)	20/03/92	4.80		4.60		4.10	
CL-	96-106 (MMOL/L)	20/03/92	100.00		97.00		100.00	
Ca++	2.2-2.7 (MMOL/L)	20/03/92	2.30		2.60		2.40	
PO4--	2.4-5.1 (MG/DL)	20/03/92	4.10		4.30		3.00	
SGOT	5-16 (U/L)	20/03/92	11.00		8.00		11.00	
SGPT	5-20 (U/L)	20/03/92	8.00		14.00		14.00	
GAMMA GT	5-20 (U/L)	20/03/92	12.00		9.00		12.00	
LDH	150-230 (U/L)	20/03/92	204.00		209.00		210.00	
ALK. PHOSPH.	60-180 (U/L)	20/03/92	117.00		61.00		110.00	
GLUCOSE	45-105 (MG/DL)	20/03/92	100.00		91.00		91.00	
BUN	8-55 (MG/DL)	20/03/92	33.00		11.00		33.00	
CREATININE	0.4-1 (MG/DL)	20/03/92	0.80		0.70		0.70	
URIC ACID	3-6 (MG/DL)	20/03/92	6.30	>	5.90		6.80	>
TOT BILIRUBIN	0.2-1 (MG/DL)	20/03/92	0.50		0.60		0.60	
DIR BILIRUBIN	0-0.35 (MG/DL)	20/03/92	0.20		0.20		0.30	
TOT. PROTEINS	5.8-8.7 (G/DL)	20/03/92	7.10		7.30		7.20	
ALBUMINE	52-70 (%)	20/03/92	68.00		66.00		67.00	
TOT. CHOLEST.	120-220 (MG/DL)	20/03/92	271.00	>	244.00	>	213.00	
TRIGLYCERIDES	45-200 (MG/DL)	20/03/92	198.00		231.00	>	230.00	>
GLOBULINS ALPHA 1	1-5 (%)	20/03/92	3.00		5.00		4.00	
GLOBULINS ALPHA 2	5-11 (%)	20/03/92	10.00		10.00		9.00	
GLOBULINS BETA	6-12 (%)	20/03/92	9.00		10.00		8.00	
GLOBULINS GAMMA	10-20 (%)	20/03/92	10.00		9.00	<	12.00	
TSH	0.2-3.1 (MU/L)	20/03/92	1.10					
T4	4.3-12.5 (NG/DL)	20/03/92	8.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 7/04 Patient: 202 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			01/04/92		25/04/92		16/05/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12.8-17 (G/DL)	20/03/92	15.10		14.90		14.90	
HT	39-53 (%)	20/03/92	49.00		48.00		47.00	
RBC	4.2-5.7 (10¬6/UL)	20/03/92	4.80		5.20		4.70	
WBC	4.5-10 (10¬3/UL)	20/03/92	6.80		7.10		7.10	
WBC: N	45-70 (%)	20/03/92	67.00		66.00		65.00	
WBC: L	25-45 (%)	20/03/92	26.00		25.00		27.00	
WBC: E	1-5 (%)	20/03/92	3.00		4.00		3.00	
WBC: M	1-9 (%)	20/03/92	3.00		3.00		3.00	
WBC: B	0-2 (%)	20/03/92	1.00		2.00		2.00	
PLATELETS	130-300 (10¬3/UL)	20/03/92	211.00		235.00		210.00	
NA+	133-149 (MMOL/L)	20/03/92	141.00		140.00		140.00	
K+	3.7-5 (MMOL/L)	20/03/92	4.20		4.40		4.20	
CL-	96-106 (MMOL/L)	20/03/92	98.00		99.00		97.00	
Ca++	2.2-2.7 (MMOL/L)	20/03/92	2.60		2.50		2.50	
PO4--	2.4-5.1 (MG/DL)	20/03/92	3.00		2.90		3.00	
SGOT	5-20 (U/L)	20/03/92	19.00		12.00		17.00	
SGPT	5-23 (U/L)	20/03/92	18.00		15.00		14.00	
GAMMA GT	5-27 (U/L)	20/03/92	16.00		10.00		15.00	
LDH	150-230 (U/L)	20/03/92	104.00	<	181.00		98.00	<
ALK. PHOSPH.	60-180 (U/L)	20/03/92	88.00		76.00		93.00	
GLUCOSE	45-105 (MG/DL)	20/03/92	77.00		81.00		109.00	>
BUN	8-55 (MG/DL)	20/03/92	18.00		17.00		17.00	
CREATININE	0.5-1.2 (MG/DL)	20/03/92	0.60		0.60		0.50	
URIC ACID	4-6.9 (MG/DL)	20/03/92	6.60		6.30		6.40	
TOT BILIRUBIN	0.2-1 (MG/DL)	20/03/92	0.40		0.40		0.40	
DIR BILIRUBIN	0-0.35 (MG/DL)	20/03/92	0.20		0.20		0.20	
TOT. PROTEINS	5.8-8.7 (G/DL)	20/03/92	7.10		8.00		7.30	
ALBUMINE	52-70 (%)	20/03/92	66.00		63.00		65.00	
TOT. CHOLEST.	120-220 (MG/DL)	20/03/92	214.00		198.00		213.00	
TRIGLYCERIDES	45-200 (MG/DL)	20/03/92	205.00	>	190.00		181.00	
GLOBULINS ALPHA 1	1-5 (%)	20/03/92	4.00		5.00		5.00	
GLOBULINS ALPHA 2	5-11 (%)	20/03/92	10.00		10.00		9.00	
GLOBULINS BETA	6-12 (%)	20/03/92	8.00		8.00		8.00	
GLOBULINS GAMMA	10-20 (%)	20/03/92	12.00		14.00		13.00	
TSH	0.2-3.1 (MU/L)	20/03/92	2.40					
T4	4.3-12.5 (NG/DL)	20/03/92	5.60					

1837

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/04 Patient: 203 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			01/04/92		25/04/92		16/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-15.5 (G/DL)	20/03/92	13.10		13.30		13.10	
HT	36-55 (%)	20/03/92	43.00		44.00		43.00	
RBC	3.7-5.2 (10¬6/UL)	20/03/92	4.20		4.30		4.10	
WBC	4.5-10 (10¬3/UL)	20/03/92	7.30		6.90		8.10	
WBC: N	45-70 (%)	20/03/92	62.00		63.00		64.00	
WBC: L	25-45 (%)	20/03/92	27.00		26.00		27.00	
WBC: E	1-5 (%)	20/03/92	4.00		4.00		4.00	
WBC: M	1-9 (%)	20/03/92	5.00		4.00		3.00	
WBC: B	0-2 (%)	20/03/92	2.00		3.00	>>	2.00	
PLATELETS	130-300 (10¬3/UL)	20/03/92	201.00		255.00		241.00	
NA+	133-149 (MMOL/L)	20/03/92	141.00		142.00		143.00	
K+	3.7-5 (MMOL/L)	20/03/92	4.20		4.30		4.20	
CL-	96-106 (MMOL/L)	20/03/92	95.00	<	100.00		103.00	
Ca++	2.2-2.7 (MMOL/L)	20/03/92	2.60		2.50		2.78	>
PO4--	2.4-5.1 (MG/DL)	20/03/92	2.70		4.90		4.30	
SGOT	5-16 (U/L)	20/03/92	9.00		14.00		11.00	
SGPT	5-20 (U/L)	20/03/92	8.00		12.00		7.00	
GAMMA GT	5-20 (U/L)	20/03/92	12.00		17.00		15.00	
LDH	150-230 (U/L)	20/03/92	88.00	<	200.00		94.00	<
ALK. PHOSPH.	60-180 (U/L)	20/03/92	77.00		120.00		133.00	
GLUCOSE	45-105 (MG/DL)	20/03/92	100.00		76.00		71.00	
BUN	8-55 (MG/DL)	20/03/92	22.00		34.00		23.00	
CREATININE	0.4-1 (MG/DL)	20/03/92	0.50		0.50		0.40	
URIC ACID	3-6 (MG/DL)	20/03/92	6.10	>	6.80	>	7.10	>
TOT BILIRUBIN	0.2-1 (MG/DL)	20/03/92	0.40		0.30		0.40	
DIR BILIRUBIN	0-0.35 (MG/DL)	20/03/92	0.10		0.10		0.10	
TOT. PROTEINS	5.8-8.7 (G/DL)	20/03/92	6.90		7.00		6.90	
ALBUMINE	52-70 (%)	20/03/92	67.00		62.00		64.00	
TOT. CHOLEST.	120-220 (MG/DL)	20/03/92	188.00		179.00		180.00	
TRIGLYCERIDES	45-200 (MG/DL)	20/03/92	204.00	>	211.00	>	203.00	>
GLOBULINS ALPHA 1	1-5 (%)	20/03/92	4.00		5.00		4.00	
GLOBULINS ALPHA 2	5-11 (%)	20/03/92	9.00		10.00		11.00	
GLOBULINS BETA	6-12 (%)	20/03/92	7.00		9.00		10.00	
GLOBULINS GAMMA	10-20 (%)	20/03/92	13.00		14.00		11.00	
TSH	0.2-3.1 (MU/L)	20/03/92	2.60					
T4	4.3-12.5 (NG/DL)	20/03/92	6.10					

1838

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/04 Patient: 204 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			01/04/92		25/04/92		16/05/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-15.5 (G/DL)	20/03/92	12.10		12.40		12.30	
HT	36-55 (%)	20/03/92	41.00		42.00		42.00	
RBC	3.7-5.2 (10-6/UL)	20/03/92	3.90		4.00		4.10	
WBC	4.5-10 (10-3/UL)	20/03/92	6.10		7.00		7.10	
WBC: N	45-70 (%)	20/03/92	65.00		66.00		64.00	
WBC: L	25-45 (%)	20/03/92	24.00	<	23.00	<	23.00	<
WBC: E	1-5 (%)	20/03/92	3.00		4.00		5.00	
WBC: M	1-9 (%)	20/03/92	6.00		5.00		5.00	
WBC: B	0-2 (%)	20/03/92	2.00		2.00		3.00	>>
PLATELETS	130-300 (10-3/UL)	20/03/92	210.00		279.00		266.00	
NA+	133-149 (MMOL/L)	20/03/92	140.00		143.00		141.00	
K+	3.7-5 (MMOL/L)	20/03/92	4.00		4.20		4.30	
CL-	96-106 (MMOL/L)	20/03/92	100.00		98.00		88.00	<
Ca++	2.2-2.7 (MMOL/L)	20/03/92	2.50		2.40		2.50	
PO4--	2.4-5.1 (MG/DL)	20/03/92	3.20		3.30		3.70	
SGOT	5-16 (U/L)	20/03/92	11.00		12.00		11.00	
SGPT	5-20 (U/L)	20/03/92	16.00		8.00		14.00	
GAMMA GT	5-20 (U/L)	20/03/92	14.00		11.00		9.00	
LDH	150-230 (U/L)	20/03/92	190.00		188.00		122.00	<
ALK. PHOSPH.	60-180 (U/L)	20/03/92	75.00		97.00		96.00	
GLUCOSE	45-105 (MG/DL)	20/03/92	90.00		81.00		83.00	
BUN	8-55 (MG/DL)	20/03/92	21.00		21.00		21.00	
CREATININE	0.4-1 (MG/DL)	20/03/92	0.40		0.40		0.50	
URIC ACID	3-6 (MG/DL)	20/03/92	6.10	>	7.10	>	6.80	>
TOT BILIRUBIN	0.2-1 (MG/DL)	20/03/92	0.40		0.40		0.30	
DIR BILIRUBIN	0-0.35 (MG/DL)	20/03/92	0.20		0.10		0.10	
TOT. PROTEINS	5.8-8.7 (G/DL)	20/03/92	7.10		7.20		6.90	
ALBUMINE	52-70 (%)	20/03/92	70.00		67.00		66.00	
TOT. CHOLEST.	120-220 (MG/DL)	20/03/92	190.00		214.00		201.00	
TRIGLYCERIDES	45-200 (MG/DL)	20/03/92	181.00		171.00		187.00	
GLOBULINS ALPHA 1	1-5 (%)	20/03/92	4.00		5.00		5.00	
GLOBULINS ALPHA 2	5-11 (%)	20/03/92	6.00		7.00		8.00	
GLOBULINS BETA	6-12 (%)	20/03/92	8.00		9.00		9.00	
GLOBULINS GAMMA	10-20 (%)	20/03/92	12.00		12.00		12.00	
TSH	0.2-3.1 (MU/L)	20/03/92	0.90					
T4	4.3-12.5 (NG/DL)	20/03/92	4.50					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/05 Patient: 205 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			30/12/91		17/02/92		09/03/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	23/12/91	16.30		16.40		16.00	
HT	40-54 (%)	23/12/91	48.00		46.00		46.00	
RBC	4-5.9 (10¬6/MM3)	23/12/91	5.20		5.60		7.20	>
WBC	4-9 (10¬3/MM3)	23/12/91	7.20		6.40		6.10	
WBC: N	50-70 (%)	23/12/91	61.00		58.00		60.00	
WBC: L	25-40 (%)	23/12/91	29.00		31.00		30.00	
WBC: E	2-4 (%)	23/12/91	3.00		3.00		3.00	
WBC: M	2-6 (%)	23/12/91	6.00		7.00	>	6.00	
WBC: B	0-1 (%)	23/12/91	1.00		1.00		1.00	
PLATELETS	150-400 (10¬3/MM3)	23/12/91	287.00		271.00		246.00	
NA+	135-145 (MMOL/L)	23/12/91	142.00		138.00		141.00	
K+	3-5 (MMOL/L)	23/12/91	4.70		4.50		4.70	
CL-	96-107 (MMOL/L)	23/12/91	102.00		100.00		101.00	
Ca++	2.2-2.65 (MMOL/L)	23/12/91	2.48		2.41		2.56	
PO4--	2.5-5 (MG/DL)	23/12/91	3.60		4.10		4.90	
SGOT	5-18 (U/L)	23/12/91	12.00		8.00		10.00	
SGPT	5-22 (U/L)	23/12/91	14.00		12.00		6.00	
GAMMA GT	5-28 (U/L)	23/12/91	19.00		19.00		14.00	
LDH	120-240 (U/L)	23/12/91	189.00		210.00		196.00	
ALK. PHOSPH.	60-170 (U/L)	23/12/91	141.00		117.00		121.00	
GLUCOSE	70-120 (MG/DL)	23/12/91	87.00		81.00		87.00	
BUN	10-50 (MG/DL)	23/12/91	29.00		31.00		32.00	
CREATININE	0.6-1.1 (MG/DL)	23/12/91	1.00		1.00		1.00	
URIC ACID	3.6-7 (MG/DL)	23/12/91	4.10		3.80		3.40	<
TOT BILIRUBIN	0.2-1 (MG/DL)	23/12/91	0.60		0.50		0.60	
DIR BILIRUBIN	0-0.3 (MG/DL)	23/12/91	0.10		0.10		0.10	
TOT. PROTEINS	6-8.5 (G/DL)	23/12/91	7.40		7.80		7.60	
ALBUMINE	55-68 (%)	23/12/91	62.00		63.00		60.00	
TOT. CHOLEST.	120-220 (MG/DL)	23/12/91	189.00		176.00		184.00	
TRIGLYCERIDES	45-200 (MG/DL)	23/12/91	151.00		142.00		158.00	
GLOBULINS ALPHA 1	1-5 (%)	23/12/91	3.00		4.00		6.00	>
GLOBULINS ALPHA 2	5-10 (%)	23/12/91	7.00		9.00		9.00	
GLOBULINS BETA	7-12 (%)	23/12/91	10.00		8.00		10.00	
GLOBULINS GAMMA	11-20 (%)	23/12/91	18.00		16.00		15.00	
TSH	0.3-3 (MU/L)	23/12/91	2.10					
T4	4.5-11.5 (UG/DL)	23/12/91	7.30					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0
9550082
LABORATORY DATA
Centre: 7/05 Patient: 206 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			14/01/92		18/02/92		10/03/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	23/12/91	14.10		14.40		14.60	
HT	36-50 (%)	23/12/91	39.00		38.00		39.00	
RBC	3.8-5.2 (10~6/MM3)	23/12/91	4.10		4.30		4.50	
WBC	4-9 (10~3/MM3)	23/12/91	5.20		5.90		6.20	
WBC: N	50-70 (%)	23/12/91	65.00		64.00		63.00	
WBC: L	25-40 (%)	23/12/91	28.00		30.00		29.00	
WBC: E	2-4 (%)	23/12/91	2.00		2.00		3.00	
WBC: M	2-6 (%)	23/12/91	4.00		4.00		4.00	
WBC: B	0-1 (%)	23/12/91	1.00		0.00		1.00	
PLATELETS	150-400 (10~3/MM3)	23/12/91	212.00		183.00		214.00	
NA+	135-145 (MMOL/L)	23/12/91	142.00		139.00		141.00	
K+	3.6-5 (MMOL/L)	23/12/91	3.90		4.20		4.40	
CL-	96-107 (MMOL/L)	23/12/91	97.00		101.00		102.00	
Ca++	2.2-2.65 (MMOL/L)	23/12/91	2.29		2.37		2.65	
PO4--	2.5-5 (MG/DL)	23/12/91	2.90		3.30		3.60	
SGOT	5-16 (U/L)	23/12/91	8.00		10.00		14.00	
SGPT	5-18 (U/L)	23/12/91	10.00		8.00		12.00	
GAMMA GT	5-20 (U/L)	23/12/91	10.00		14.00		19.00	
LDH	120-240 (U/L)	23/12/91	153.00		169.00		187.00	
ALK. PHOSPH.	60-170 (U/L)	23/12/91	161.00		124.00		102.00	
GLUCOSE	70-120 (MG/DL)	23/12/91	78.00		81.00		76.00	
BUN	10-50 (MG/DL)	23/12/91	32.00		33.00		36.00	
CREATININE	0.5-0.9 (MG/DL)	23/12/91	0.70		0.70		0.70	
URIC ACID	2.4-6 (MG/DL)	23/12/91	2.90		3.20		3.90	
TOT BILIRUBIN	0.2-1 (MG/DL)	23/12/91	0.40		0.50		0.60	
DIR BILIRUBIN	0-0.3 (MG/DL)	23/12/91	0.10		0.10		0.10	
TOT. PROTEINS	6-8.5 (G/DL)	23/12/91	6.90		7.10		7.30	
ALBUMINE	55-68 (%)	23/12/91	62.00		64.00		62.00	
TOT. CHOLEST.	120-220 (MG/DL)	23/12/91	157.00		162.00		189.00	
TRIGLYCERIDES	45-200 (MG/DL)	23/12/91	161.00		127.00		174.00	
GLOBULINS ALPHA 1	1-5 (%)	23/12/91	4.00		4.00		3.00	
GLOBULINS ALPHA 2	5-10 (%)	23/12/91	10.00		6.00		9.00	
GLOBULINS BETA	7-12 (%)	23/12/91	10.00		10.00		9.00	
GLOBULINS GAMMA	11-20 (%)	23/12/91	14.00		16.00		17.00	
TSH	0.3-3 (MU/L)	23/12/91	1.70					
T4	4.5-11.5 (UG/DL)	23/12/91	6.20					

1841

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 7/05 Patient: 207 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			21/01/92		18/02/92		10/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	23/12/91	14.70		14.30		13.80	
HT	36-50 (%)	23/12/91	41.00		40.00		39.00	
RBC	3.8-5.2 (10¬6/MM3)	23/12/91	4.60		4.30		4.50	
WBC	4-9 (10¬3/MM3)	23/12/91	7.10		6.30		5.80	
WBC: N	50-70 (%)	23/12/91	62.00		63.00		61.00	
WBC: L	25-40 (%)	23/12/91	30.00		31.00		33.00	
WBC: E	2-4 (%)	23/12/91	2.00		1.00	<	2.00	
WBC: M	2-6 (%)	23/12/91	5.00		4.00		3.00	
WBC: B	0-1 (%)	23/12/91	1.00		1.00		1.00	
PLATELETS	150-400 (10¬3/MM3)	23/12/91	312.00		283.00		250.00	
NA+	135-145 (MMOL/L)	23/12/91	139.00		137.00		139.00	
K+	3.6-5 (MMOL/L)	23/12/91	3.90		3.80		4.00	
CL-	96-107 (MMOL/L)	23/12/91	101.00		97.00		99.00	
Ca++	2.2-2.65 (MMOL/L)	23/12/91	2.52		2.61		2.46	
PO4--	2.5-5 (MG/DL)	23/12/91	4.10		4.40		3.20	
SGOT	5-16 (U/L)	23/12/91	12.00		10.00		8.00	
SGPT	5-18 (U/L)	23/12/91	10.00		10.00		10.00	
GAMMA GT	5-20 (U/L)	23/12/91	19.00		19.00		13.00	
LDH	120-240 (U/L)	23/12/91	187.00		203.00		184.00	
ALK. PHOSPH.	60-170 (U/L)	23/12/91	96.00		83.00		97.00	
GLUCOSE	70-120 (MG/DL)	23/12/91	81.00		77.00		81.00	
BUN	10-50 (MG/DL)	23/12/91	36.00		33.00		31.00	
CREATININE	0.5-0.9 (MG/DL)	23/12/91	0.70		0.70		0.70	
URIC ACID	2.4-6 (MG/DL)	23/12/91	3.20		2.90		4.60	
TOT BILIRUBIN	0.2-1 (MG/DL)	23/12/91	0.40		0.70		0.60	
DIR BILIRUBIN	0-0.3 (MG/DL)	23/12/91	0.10		0.20		0.10	
TOT. PROTEINS	6-8.5 (G/DL)	23/12/91	6.90		7.00		6.90	
ALBUMINE	55-68 (%)	23/12/91	62.00		63.00		65.00	
TOT. CHOLEST.	120-220 (MG/DL)	23/12/91	147.00		129.00		136.00	
TRIGLYCERIDES	45-200 (MG/DL)	23/12/91	158.00		151.00		147.00	
GLOBULINS ALPHA 1	1-5 (%)	23/12/91	2.00		3.00		3.00	
GLOBULINS ALPHA 2	5-10 (%)	23/12/91	8.00		7.00		6.00	
GLOBULINS BETA	7-12 (%)	23/12/91	9.00		9.00		9.00	
GLOBULINS GAMMA	11-20 (%)	23/12/91	19.00		18.00		17.00	
TSH	0.3-3 (MU/L)	23/12/91	2.70					
T4	4.5-11.5 (UG/DL)	23/12/91	8.60					

1842

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/05 Patient: 208 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			24/01/92		20/02/92		12/03/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	14-18 (G/DL)	23/12/91	17.30		16.90		17.10	
HT	40-54 (%)	23/12/91	49.00		48.00		47.00	
RBC	4-5.9 (10~6/MM3)	23/12/91	4.70		5.00		5.20	
WBC	4-9 (10~3/MM3)	23/12/91	5.50		6.70		6.40	
WBC: N	50-70 (%)	23/12/91	63.00		62.00		63.00	
WBC: L	25-40 (%)	23/12/91	29.00		33.00		30.00	
WBC: E	2-4 (%)	23/12/91	2.00		1.00	<	2.00	
WBC: M	2-6 (%)	23/12/91	5.00		4.00		4.00	
WBC: B	0-1 (%)	23/12/91	1.00		0.00		1.00	
PLATELETS	150-400 (10~3/MM3)	23/12/91	281.00		252.00		238.00	
NA+	135-145 (MMOL/L)	23/12/91	142.00		140.00		142.00	
K+	3-5 (MMOL/L)	23/12/91	4.70		4.50		4.10	
CL-	96-107 (MMOL/L)	23/12/91	102.00		101.00		99.00	
Ca++	2.2-2.65 (MMOL/L)	23/12/91	2.55		2.43		2.40	
PO4--	2.5-5 (MG/DL)	23/12/91	3.10		3.70		4.20	
SGOT	5-18 (U/L)	23/12/91	12.00		12.00		10.00	
SGPT	5-22 (U/L)	23/12/91	12.00		10.00		10.00	
GAMMA GT	5-28 (U/L)	23/12/91	19.00		15.00		14.00	
LDH	120-240 (U/L)	23/12/91	221.00		200.00		182.00	
ALK. PHOSPH.	60-170 (U/L)	23/12/91	158.00		149.00		116.00	
GLUCOSE	70-120 (MG/DL)	23/12/91	72.00		82.00		74.00	
BUN	10-50 (MG/DL)	23/12/91	37.00		35.00		34.00	
CREATININE	0.6-1.1 (MG/DL)	23/12/91	0.90		1.00		1.00	
URIC ACID	3.6-7 (MG/DL)	23/12/91	4.70		4.30		4.00	
TOT BILIRUBIN	0.2-1 (MG/DL)	23/12/91	0.60		0.70		0.60	
DIR BILIRUBIN	0-0.3 (MG/DL)	23/12/91	0.20		0.20		0.10	
TOT. PROTEINS	6-8.5 (G/DL)	23/12/91	8.10		8.00		8.20	
ALBUMINE	55-68 (%)	23/12/91	64.00		63.00		62.00	
TOT. CHOLEST.	120-220 (MG/DL)	23/12/91	202.00		189.00		177.00	
TRIGLYCERIDES	45-200 (MG/DL)	23/12/91	186.00		156.00		162.00	
GLOBULINS ALPHA 1	1-5 (%)	23/12/91	3.00		4.00		4.00	
GLOBULINS ALPHA 2	5-10 (%)	23/12/91	9.00		7.00		8.00	
GLOBULINS BETA	7-12 (%)	23/12/91	8.00		10.00		11.00	
GLOBULINS GAMMA	11-20 (%)	23/12/91	16.00		16.00		15.00	
TSH	0.3-3 (MU/L)	23/12/91	1.20					
T4	4.5-11.5 (UG/DL)	23/12/91	5.30					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/05 Patient: 209 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			29/01/92		26/02/92		18/03/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	23/12/91	16.90		17.20		17.60	
HT	40-54 (%)	23/12/91	47.00		49.00		51.00	
RBC	4-5.9 (10¬6/MM3)	23/12/91	4.90		5.40		5.60	
WBC	4-9 (10¬3/MM3)	23/12/91	6.30		6.70		4.90	
WBC: N	50-70 (%)	23/12/91	62.00		61.00		62.00	
WBC: L	25-40 (%)	23/12/91	33.00		34.00		33.00	
WBC: E	2-4 (%)	23/12/91	2.00		1.00	<	2.00	
WBC: M	2-6 (%)	23/12/91	3.00		4.00		3.00	
WBC: B	0-1 (%)	23/12/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬3/MM3)	23/12/91	194.00		214.00		164.00	
NA+	135-145 (MMOL/L)	23/12/91	142.00		139.00		141.00	
K+	3-5 (MMOL/L)	23/12/91	4.30		4.50		4.10	
CL-	96-107 (MMOL/L)	23/12/91	104.00		103.00		102.00	
Ca++	2.2-2.65 (MMOL/L)	23/12/91	2.59		2.41		2.46	
PO4--	2.5-5 (MG/DL)	23/12/91	4.30		4.00		3.70	
SGOT	5-18 (U/L)	23/12/91	12.00		12.00		12.00	
SGPT	5-22 (U/L)	23/12/91	16.00		15.00		13.00	
GAMMA GT	5-28 (U/L)	23/12/91	22.00		21.00		19.00	
LDH	120-240 (U/L)	23/12/91	181.00		209.00		164.00	
ALK. PHOSPH.	60-170 (U/L)	23/12/91	126.00		112.00		153.00	
GLUCOSE	70-120 (MG/DL)	23/12/91	83.00		78.00		94.00	
BUN	10-50 (MG/DL)	23/12/91	35.00		37.00		34.00	
CREATININE	0.6-1.1 (MG/DL)	23/12/91	1.00		1.10		1.00	
URIC ACID	3.6-7 (MG/DL)	23/12/91	5.10		5.90		6.20	
TOT BILIRUBIN	0.2-1 (MG/DL)	23/12/91	0.70		0.60		0.70	
DIR BILIRUBIN	0-0.3 (MG/DL)	23/12/91	0.20		0.10		0.20	
TOT. PROTEINS	6-8.5 (G/DL)	23/12/91	8.20		8.30		8.10	
ALBUMINE	55-68 (%)	23/12/91	66.00		64.00		62.00	
TOT. CHOLEST.	120-220 (MG/DL)	23/12/91	219.00		197.00		212.00	
TRIGLYCERIDES	45-200 (MG/DL)	23/12/91	180.00		163.00		183.00	
GLOBULINS ALPHA 1	1-5 (%)	23/12/91	5.00		3.00		3.00	
GLOBULINS ALPHA 2	5-10 (%)	23/12/91	7.00		5.00		8.00	
GLOBULINS BETA	7-12 (%)	23/12/91	8.00		11.00		9.00	
GLOBULINS GAMMA	11-20 (%)	23/12/91	14.00		17.00		18.00	
TSH	0.3-3 (MU/L)	23/12/91	2.10					
T4	4.5-11.5 (UG/DL)	23/12/91	8.30					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/05 Patient: 210 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/02/92		28/02/92		20/03/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	23/12/91	16.40		16.90		16.40	
HT	40-54 (%)	23/12/91	45.00		47.00		45.00	
RBC	4-5.9 (10¬6/MM3)	23/12/91	4.50		5.00		5.20	
WBC	4-9 (10¬3/MM3)	23/12/91	4.80		5.80		7.50	
WBC: N	50-70 (%)	23/12/91	58.00		60.00		59.00	
WBC: L	25-40 (%)	23/12/91	33.00		33.00		32.00	
WBC: E	2-4 (%)	23/12/91	2.00		8.00	>>	2.00	
WBC: M	2-6 (%)	23/12/91	6.00		4.00		6.00	
WBC: B	0-1 (%)	23/12/91	1.00		1.00		1.00	
PLATELETS	150-400 (10¬3/MM3)	23/12/91	259.00		288.00		243.00	
NA+	135-145 (MMOL/L)	23/12/91	142.00		143.00		141.00	
K+	3-5 (MMOL/L)	23/12/91	4.10		4.70		4.10	
CL-	96-107 (MMOL/L)	23/12/91	98.00		97.00		99.00	
Ca++	2.2-2.65 (MMOL/L)	23/12/91	2.41		2.50		2.27	
PO4--	2.5-5 (MG/DL)	23/12/91	3.70		4.10		4.70	
SGOT	5-18 (U/L)	23/12/91	12.00		16.00		12.00	
SGPT	5-22 (U/L)	23/12/91	10.00		12.00		16.00	
GAMMA GT	5-28 (U/L)	23/12/91	16.00		22.00		21.00	
LDH	120-240 (U/L)	23/12/91	180.00		191.00		216.00	
ALK. PHOSPH.	60-170 (U/L)	23/12/91	125.00		149.00		132.00	
GLUCOSE	70-120 (MG/DL)	23/12/91	98.00		84.00		76.00	
BUN	10-50 (MG/DL)	23/12/91	31.00		32.00		36.00	
CREATININE	0.6-1.1 (MG/DL)	23/12/91	1.00		1.00		1.10	
URIC ACID	3.6-7 (MG/DL)	23/12/91	3.70		5.90		5.20	
TOT BILIRUBIN	0.2-1 (MG/DL)	23/12/91	0.70		0.60		0.60	
DIR BILIRUBIN	0-0.3 (MG/DL)	23/12/91	0.20		0.10		0.10	
TOT. PROTEINS	6-8.5 (G/DL)	23/12/91	8.10		8.30		8.20	
ALBUMINE	55-68 (%)	23/12/91	62.00		60.00		62.00	
TOT. CHOLEST.	120-220 (MG/DL)	23/12/91	199.00		214.00		184.00	
TRIGLYCERIDES	45-200 (MG/DL)	23/12/91	156.00		143.00		130.00	
GLOBULINS ALPHA 1	1-5 (%)	23/12/91	3.00		3.00		2.00	
GLOBULINS ALPHA 2	5-10 (%)	23/12/91	7.00		7.00		9.00	
GLOBULINS BETA	7-12 (%)	23/12/91	11.00		11.00		10.00	
GLOBULINS GAMMA	11-20 (%)	23/12/91	17.00		19.00		17.00	
TSH	0.3-3 (MU/L)	23/12/91	2.10					
T4	4.5-11.5 (UG/DL)	23/12/91	5.90					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/05 Patient: 541 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			02/03/92		07/04/92		28/04/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	23/12/91	12.70		12.30		12.40	
HT	36-50 (%)	23/12/91	41.00		42.00		42.00	
RBC	3.8-5.2 (10~6/MM3)	23/12/91	4.60		4.30		4.50	
WBC	4-9 (10~3/MM3)	23/12/91	5.50		6.20		6.50	
WBC: N	50-70 (%)	23/12/91	62.00		60.00		62.00	
WBC: L	25-40 (%)	23/12/91	31.00		33.00		33.00	
WBC: E	2-4 (%)	23/12/91	2.00		2.00		1.00	<
WBC: M	2-6 (%)	23/12/91	4.00		4.00		4.00	
WBC: B	0-1 (%)	23/12/91	1.00		1.00		0.00	
PLATELETS	150-400 (10~3/MM3)	23/12/91	217.00		243.00		255.00	
NA+	135-145 (MMOL/L)	23/12/91	142.00		140.00		141.00	
K+	3.6-5 (MMOL/L)	23/12/91	4.30		4.10		4.00	
CL-	96-107 (MMOL/L)	23/12/91	103.00		100.00		101.00	
Ca++	2.2-2.65 (MMOL/L)	23/12/91	2.49		2.29		2.24	
PO4--	2.5-5 (MG/DL)	23/12/91	3.60		3.10		2.90	
SGOT	5-16 (U/L)	23/12/91	8.00		10.00		10.00	
SGPT	5-18 (U/L)	23/12/91	10.00		12.00		10.00	
GAMMA GT	5-20 (U/L)	23/12/91	10.00		15.00		14.00	
LDH	120-240 (U/L)	23/12/91	184.00		173.00		199.00	
ALK. PHOSPH.	60-170 (U/L)	23/12/91	97.00		101.00		141.00	
GLUCOSE	70-120 (MG/DL)	23/12/91	84.00		78.00		79.00	
BUN	10-50 (MG/DL)	23/12/91	32.00		33.00		29.00	
CREATININE	0.5-0.9 (MG/DL)	23/12/91	0.80		0.70		0.70	
URIC ACID	2.4-6 (MG/DL)	23/12/91	4.00		3.80		3.00	
TOT BILIRUBIN	0.2-1 (MG/DL)	23/12/91	0.70		0.60		0.60	
DIR BILIRUBIN	0-0.3 (MG/DL)	23/12/91	0.20		0.10		0.10	
TOT. PROTEINS	6-8.5 (G/DL)	23/12/91	7.60		7.30		7.50	
ALBUMINE	55-68 (%)	23/12/91	61.00		64.00		62.00	
TOT. CHOLEST.	120-220 (MG/DL)	23/12/91	180.00		203.00		187.00	
TRIGLYCERIDES	45-200 (MG/DL)	23/12/91	159.00		165.00		153.00	
GLOBULINS ALPHA 1	1-5 (%)	23/12/91	4.00		2.00		5.00	
GLOBULINS ALPHA 2	5-10 (%)	23/12/91	8.00		9.00		9.00	
GLOBULINS BETA	7-12 (%)	23/12/91	9.00		10.00		10.00	
GLOBULINS GAMMA	11-20 (%)	23/12/91	18.00		15.00		14.00	
TSH	0.3-3 (MU/L)	23/12/91	1.70					
T4	4.5-11.5 (UG/DL)	23/12/91	8.90					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 7/05 Patient: 542 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			02/03/92		07/04/92		28/04/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	23/12/91	16.30		16.90		17.30	
HT	40-54 (%)	23/12/91	49.00		51.00		50.00	
RBC	4-5.9 (10-6/MM3)	23/12/91	5.20		4.90		5.40	
WBC	4-9 (10-3/MM3)	23/12/91	7.30		7.00		6.80	
WBC: N	50-70 (%)	23/12/91	62.00		64.00		62.00	
WBC: L	25-40 (%)	23/12/91	29.00		30.00		30.00	
WBC: E	2-4 (%)	23/12/91	3.00		2.00		3.00	
WBC: M	2-6 (%)	23/12/91	5.00		4.00		4.00	
WBC: B	0-1 (%)	23/12/91	1.00		1.00		1.00	
PLATELETS	150-400 (10-3/MM3)	23/12/91	361.00		347.00		368.00	
NA+	135-145 (MMOL/L)	23/12/91	144.00		142.00		144.00	
K+	3-5 (MMOL/L)	23/12/91	4.80		4.60		4.80	
CL-	96-107 (MMOL/L)	23/12/91	103.00		105.00		104.00	
Ca++	2.2-2.65 (MMOL/L)	23/12/91	2.23		2.41		2.47	
PO4--	2.5-5 (MG/DL)	23/12/91	4.00		3.80		4.10	
SGOT	5-18 (U/L)	23/12/91	14.00		16.00		14.00	
SGPT	5-22 (U/L)	23/12/91	19.00		12.00		15.00	
GAMMA GT	5-28 (U/L)	23/12/91	22.00		24.00		21.00	
LDH	120-240 (U/L)	23/12/91	214.00		226.00		197.00	
ALK. PHOSPH.	60-170 (U/L)	23/12/91	146.00		129.00		136.00	
GLUCOSE	70-120 (MG/DL)	23/12/91	89.00		76.00		76.00	
BUN	10-50 (MG/DL)	23/12/91	38.00		41.00		39.00	
CREATININE	0.6-1.1 (MG/DL)	23/12/91	1.00		1.00		1.00	
URIC ACID	3.6-7 (MG/DL)	23/12/91	4.90		5.60		4.40	
TOT BILIRUBIN	0.2-1 (MG/DL)	23/12/91	0.80		0.70		0.80	
DIR BILIRUBIN	0-0.3 (MG/DL)	23/12/91	0.20		0.20		0.10	
TOT. PROTEINS	6-8.5 (G/DL)	23/12/91	8.30		8.20		8.00	
ALBUMINE	55-68 (%)	23/12/91	63.00		64.00		60.00	
TOT. CHOLEST.	120-220 (MG/DL)	23/12/91	216.00		184.00		197.00	
TRIGLYCERIDES	45-200 (MG/DL)	23/12/91	159.00		126.00		146.00	
GLOBULINS ALPHA 1	1-5 (%)	23/12/91	4.00		3.00		4.00	
GLOBULINS ALPHA 2	5-10 (%)	23/12/91	7.00		9.00		6.00	
GLOBULINS BETA	7-12 (%)	23/12/91	9.00		10.00		11.00	
GLOBULINS GAMMA	11-20 (%)	23/12/91	17.00		14.00		19.00	
TSH	0.3-3 (MU/L)	23/12/91	1.90					
T4	4.5-11.5 (UG/DL)	23/12/91	8.30					

1847

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/05 Patient: 543 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/03/92		08/04/92		29/04/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	23/12/91	17.20		17.40		17.00	
HT	40-54 (%)	23/12/91	52.00		51.00		49.00	
RBC	4-5.9 (10~6/MM3)	23/12/91	5.50		5.80		5.20	
WBC	4-9 (10~3/MM3)	23/12/91	7.60		8.10		6.20	
WBC: N	50-70 (%)	23/12/91	63.00		62.00		60.00	
WBC: L	25-40 (%)	23/12/91	33.00		33.00		34.00	
WBC: E	2-4 (%)	23/12/91	2.00		3.00		2.00	
WBC: M	2-6 (%)	23/12/91	2.00		2.00		3.00	
WBC: B	0-1 (%)	23/12/91	0.00		0.00		1.00	
PLATELETS	150-400 (10~3/MM3)	23/12/91	226.00		280.00		307.00	
NA+	135-145 (MMOL/L)	23/12/91	138.00		141.00		137.00	
K+	3-5 (MMOL/L)	23/12/91	4.00		4.20		3.90	
CL-	96-107 (MMOL/L)	23/12/91	101.00		97.00		98.00	
Ca++	2.2-2.65 (MMOL/L)	23/12/91	2.49		2.36		2.55	
PO4--	2.5-5 (MG/DL)	23/12/91	2.80		3.10		4.70	
SGOT	5-18 (U/L)	23/12/91	10.00		9.00		11.00	
SGPT	5-22 (U/L)	23/12/91	9.00		10.00		18.00	
GAMMA GT	5-28 (U/L)	23/12/91	13.00		15.00		22.00	
LDH	120-240 (U/L)	23/12/91	197.00		184.00		167.00	
ALK. PHOSPH.	60-170 (U/L)	23/12/91	87.00		101.00		142.00	
GLUCOSE	70-120 (MG/DL)	23/12/91	95.00		92.00		103.00	
BUN	10-50 (MG/DL)	23/12/91	39.00		42.00		41.00	
CREATININE	0.6-1.1 (MG/DL)	23/12/91	1.10		1.10		1.10	
URIC ACID	3.6-7 (MG/DL)	23/12/91	6.10		5.80		4.70	
TOT BILIRUBIN	0.2-1 (MG/DL)	23/12/91	0.80		0.70		0.70	
DIR BILIRUBIN	0-0.3 (MG/DL)	23/12/91	0.20		0.10		0.20	
TOT. PROTEINS	6-8.5 (G/DL)	23/12/91	8.30		8.20		8.40	
ALBUMINE	55-68 (%)	23/12/91	64.00		63.00		67.00	
TOT. CHOLEST.	120-220 (MG/DL)	23/12/91	174.00		162.00		173.00	
TRIGLYCERIDES	45-200 (MG/DL)	23/12/91	89.00		100.00		97.00	
GLOBULINS ALPHA 1	1-5 (%)	23/12/91	2.00		2.00		2.00	
GLOBULINS ALPHA 2	5-10 (%)	23/12/91	8.00		8.00		6.00	
GLOBULINS BETA	7-12 (%)	23/12/91	9.00		7.00		10.00	
GLOBULINS GAMMA	11-20 (%)	23/12/91	17.00		20.00		15.00	
TSH	0.3-3 (MU/L)	23/12/91	1.60					
T4	4.5-11.5 (UG/DL)	23/12/91	9.30					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0
9550082
LABORATORY DATA
Centre: 7/05 Patient: 544 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/03/92		14/04/92		05/05/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	23/12/91	13.60		13.30		13.00	
HT	36-50 (%)	23/12/91	39.00		41.00		42.00	
RBC	3.8-5.2 (10¬6/MM3)	23/12/91	4.10		4.30		4.40	
WBC	4-9 (10¬3/MM3)	23/12/91	5.00		6.90		6.20	
WBC: N	50-70 (%)	23/12/91	58.00		59.00		61.00	
WBC: L	25-40 (%)	23/12/91	36.00		33.00		31.00	
WBC: E	2-4 (%)	23/12/91	2.00		2.00		3.00	
WBC: M	2-6 (%)	23/12/91	3.00		5.00		4.00	
WBC: B	0-1 (%)	23/12/91	1.00		1.00		1.00	
PLATELETS	150-400 (10¬3/MM3)	23/12/91	187.00		207.00		298.00	
NA+	135-145 (MMOL/L)	23/12/91	136.00		139.00		140.00	
K+	3.6-5 (MMOL/L)	23/12/91	4.60		4.20		3.90	
CL-	96-107 (MMOL/L)	23/12/91	99.00		101.00		104.00	
Ca++	2.2-2.65 (MMOL/L)	23/12/91	2.50		2.41		2.49	
PO4--	2.5-5 (MG/DL)	23/12/91	3.70		3.40		4.00	
SGOT	5-16 (U/L)	23/12/91	9.00		6.00		11.00	
SGPT	5-18 (U/L)	23/12/91	6.00		6.00		8.00	
GAMMA GT	5-20 (U/L)	23/12/91	8.00		9.00		16.00	
LDH	120-240 (U/L)	23/12/91	184.00		170.00		204.00	
ALK. PHOSPH.	60-170 (U/L)	23/12/91	123.00		142.00		144.00	
GLUCOSE	70-120 (MG/DL)	23/12/91	104.00		99.00		75.00	
BUN	10-50 (MG/DL)	23/12/91	37.00		35.00		32.00	
CREATININE	0.5-0.9 (MG/DL)	23/12/91	0.70		0.60		0.60	
URIC ACID	2.4-6 (MG/DL)	23/12/91	3.10		2.90		3.80	
TOT BILIRUBIN	0.2-1 (MG/DL)	23/12/91	0.60		0.60		0.50	
DIR BILIRUBIN	0-0.3 (MG/DL)	23/12/91	0.10		0.10		0.10	
TOT. PROTEINS	6-8.5 (G/DL)	23/12/91	7.40		7.00		6.70	
ALBUMINE	55-68 (%)	23/12/91	63.00		62.00		60.00	
TOT. CHOLEST.	120-220 (MG/DL)	23/12/91	166.00		146.00		154.00	
TRIGLYCERIDES	45-200 (MG/DL)	23/12/91	187.00		160.00		149.00	
GLOBULINS ALPHA 1	1-5 (%)	23/12/91	2.00		3.00		4.00	
GLOBULINS ALPHA 2	5-10 (%)	23/12/91	9.00		8.00		7.00	
GLOBULINS BETA	7-12 (%)	23/12/91	10.00		9.00		11.00	
GLOBULINS GAMMA	11-20 (%)	23/12/91	16.00		18.00		18.00	
TSH	0.3-3 (MU/L)	23/12/91	2.10					
T4	4.5-11.5 (UG/DL)	23/12/91	8.90					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/05 Patient: 545 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			09/03/92		15/04/92		06/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	23/12/91	15.90		16.20		16.90	
HT	40-54 (%)	23/12/91	52.00		50.00		52.00	
RBC	4-5.9 (10-6/MM3)	23/12/91	5.30		5.00		5.30	
WBC	4-9 (10-3/MM3)	23/12/91	7.80		7.20		8.10	
WBC: N	50-70 (%)	23/12/91	62.00		63.00		64.00	
WBC: L	25-40 (%)	23/12/91	31.00		33.00		29.00	
WBC: E	2-4 (%)	23/12/91	2.00		2.00		2.00	
WBC: M	2-6 (%)	23/12/91	4.00		2.00		5.00	
WBC: B	0-1 (%)	23/12/91	1.00		0.00		0.00	
PLATELETS	150-400 (10-3/MM3)	23/12/91	279.00		243.00		179.00	
NA+	135-145 (MMOL/L)	23/12/91	144.00		142.00		145.00	
K+	3-5 (MMOL/L)	23/12/91	3.90		4.10		4.70	
CL-	96-107 (MMOL/L)	23/12/91	99.00		102.00		100.00	
Ca++	2.2-2.65 (MMOL/L)	23/12/91	2.49		2.55		2.61	
PO4--	2.5-5 (MG/DL)	23/12/91	4.60		4.20		4.70	
SGOT	5-18 (U/L)	23/12/91	14.00		14.00		16.00	
SGPT	5-22 (U/L)	23/12/91	19.00		12.00		19.00	
GAMMA GT	5-28 (U/L)	23/12/91	26.00		19.00		26.00	
LDH	120-240 (U/L)	23/12/91	219.00		236.00		219.00	
ALK. PHOSPH.	60-170 (U/L)	23/12/91	143.00		119.00		154.00	
GLUCOSE	70-120 (MG/DL)	23/12/91	86.00		80.00		72.00	
BUN	10-50 (MG/DL)	23/12/91	35.00		41.00		43.00	
CREATININE	0.6-1.1 (MG/DL)	23/12/91	1.00		1.10		1.10	
URIC ACID	3.6-7 (MG/DL)	23/12/91	6.10		5.80		6.30	
TOT BILIRUBIN	0.2-1 (MG/DL)	23/12/91	0.60		0.60		0.60	
DIR BILIRUBIN	0-0.3 (MG/DL)	23/12/91	0.10		0.20		0.20	
TOT. PROTEINS	6-8.5 (G/DL)	23/12/91	8.00		8.30		8.00	
ALBUMINE	55-68 (%)	23/12/91	63.00		64.00		67.00	
TOT. CHOLEST.	120-220 (MG/DL)	23/12/91	198.00		182.00		200.00	
TRIGLYCERIDES	45-200 (MG/DL)	23/12/91	200.00		194.00		177.00	
GLOBULINS ALPHA 1	1-5 (%)	23/12/91	4.00		3.00		3.00	
GLOBULINS ALPHA 2	5-10 (%)	23/12/91	6.00		6.00		8.00	
GLOBULINS BETA	7-12 (%)	23/12/91	10.00		9.00		8.00	
GLOBULINS GAMMA	11-20 (%)	23/12/91	17.00		18.00		14.00	
TSH	0.3-3 (MU/L)	23/12/91	0.98					
T4	4.5-11.5 (UG/DL)	23/12/91	10.10					

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done
>> clinically relevant (value higher than max range)
> out of range (value higher than max range)
() missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/05 Patient: 546 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/03/92		15/04/92		06/05/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	23/12/91	13.10		13.60		13.30	
HT	36-50 (%)	23/12/91	41.00		43.00		41.00	
RBC	3.8-5.2 (10~6/MM3)	23/12/91	4.50		4.60		4.20	
WBC	4-9 (10~3/MM3)	23/12/91	6.30		5.70		6.00	
WBC: N	50-70 (%)	23/12/91	62.00		63.00		61.00	
WBC: L	25-40 (%)	23/12/91	31.00		33.00		30.00	
WBC: E	2-4 (%)	23/12/91	3.00		2.00		3.00	
WBC: M	2-6 (%)	23/12/91	4.00		2.00		5.00	
WBC: B	0-1 (%)	23/12/91	0.00		0.00		1.00	
PLATELETS	150-400 (10~3/MM3)	23/12/91	189.00		200.00		241.00	
NA+	135-145 (MMOL/L)	23/12/91	141.00		139.00		136.00	
K+	3.6-5 (MMOL/L)	23/12/91	4.60		4.40		4.00	
CL-	96-107 (MMOL/L)	23/12/91	103.00		101.00		99.00	
Ca++	2.2-2.65 (MMOL/L)	23/12/91	2.39		2.22		2.28	
PO4--	2.5-5 (MG/DL)	23/12/91	3.10		3.60		3.10	
SGOT	5-16 (U/L)	23/12/91	8.00		6.00		8.00	
SGPT	5-18 (U/L)	23/12/91	9.00		6.00		10.00	
GAMMA GT	5-20 (U/L)	23/12/91	6.00		9.00		17.00	
LDH	120-240 (U/L)	23/12/91	231.00		209.00		184.00	
ALK. PHOSPH.	60-170 (U/L)	23/12/91	154.00		141.00		109.00	
GLUCOSE	70-120 (MG/DL)	23/12/91	88.00		93.00		81.00	
BUN	10-50 (MG/DL)	23/12/91	34.00		33.00		38.00	
CREATININE	0.5-0.9 (MG/DL)	23/12/91	0.70		0.70		0.80	
URIC ACID	2.4-6 (MG/DL)	23/12/91	3.90		3.40		3.80	
TOT BILIRUBIN	0.2-1 (MG/DL)	23/12/91	0.60		0.70		0.60	
DIR BILIRUBIN	0-0.3 (MG/DL)	23/12/91	0.10		0.20		0.10	
TOT. PROTEINS	6-8.5 (G/DL)	23/12/91	6.90		7.00		7.40	
ALBUMINE	55-68 (%)	23/12/91	64.00		63.00		61.00	
TOT. CHOLEST.	120-220 (MG/DL)	23/12/91	194.00		174.00		162.00	
TRIGLYCERIDES	45-200 (MG/DL)	23/12/91	165.00		144.00		113.00	
GLOBULINS ALPHA 1	1-5 (%)	23/12/91	4.00		4.00		3.00	
GLOBULINS ALPHA 2	5-10 (%)	23/12/91	8.00		9.00		8.00	
GLOBULINS BETA	7-12 (%)	23/12/91	9.00		10.00		11.00	
GLOBULINS GAMMA	11-20 (%)	23/12/91	15.00		14.00		17.00	
TSH	0.3-3 (MU/L)	23/12/91	1.60					
T4	4.5-11.5 (UG/DL)	23/12/91	8.30					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/07 Patient: 529 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			17/02/92		10/03/92		31/03/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	28/11/91	12.10		12.80		13.10	
HT	37-54 (%)	28/11/91	41.20		39.90		31.20	<<
RBC	3.8-5.2 (10¬6/UL)	28/11/91	4.13		4.15		4.21	
WBC	4-10.8 (10¬3/UL)	28/11/91	5.39		4.91		4.88	
WBC: N	45-70 (%)	28/11/91	46.40		74.00	>	49.00	
WBC: L	25-45 (%)	28/11/91	40.50		21.00	<	41.70	
WBC: E	1-5 (%)	28/11/91	5.40	>	1.00		2.50	
WBC: M	1-9 (%)	28/11/91	3.90		3.00		2.90	
WBC: B	0-2 (%)	28/11/91	0.70		1.00		3.50	>>
PLATELETS	150-450 (10¬3/UL)	28/11/91	177.00		165.00		185.00	
NA+	132-151 (MMOL/L)	28/11/91	140.00		141.00		143.00	
K+	3.6-5.2 (MMOL/L)	28/11/91	6.53	>>	4.47		6.56	>>
CL-	97-108 (MMOL/L)	28/11/91	100.00		98.00		98.00	
Ca++	2.2-2.65 (MMOL/L)	28/11/91	2.38		2.33		2.29	
PO4--	2.5-5 (MG/DL)	28/11/91	4.30		4.30		4.20	
SGOT	5-15 (U/L)	28/11/91	8.00		7.00		9.00	
SGPT	5-19 (U/L)	28/11/91	7.00		8.00		7.00	
GAMMA GT	5-18 (U/L)	28/11/91	8.00		9.00		9.00	
LDH	120-240 (U/L)	28/11/91	198.00		184.00		206.00	
ALK. PHOSPH.	65-175 (U/L)	28/11/91	73.00		82.00		86.00	
GLUCOSE	50-100 (MG/DL)	28/11/91	86.00		86.00		104.00	>
CREATININE	0.5-0.9 (MG/DL)	28/11/91	0.66		0.70		0.74	
URIC ACID	2.5-6 (MG/DL)	28/11/91	3.50		3.70		3.70	
TOT BILIRUBIN	0.2-1 (MG/DL)	28/11/91	0.46		0.58		0.55	
TOT. PROTEINS	6-8.5 (G/DL)	28/11/91	6.50		6.90		7.20	
ALBUMINE	55-60 (%)	28/11/91	71.40	>	68.90	>	69.70	>
TOT. CHOLEST.	120-220 (MG/DL)	28/11/91	284.00	>	283.00	>	265.00	>
TRIGLYCERIDES	45-200 (MG/DL)	28/11/91	197.00		95.00		160.00	
GLOBULINS ALPHA 1	1-5 (%)	28/11/91	2.20		2.30		2.50	
GLOBULINS ALPHA 2	5-10 (%)	28/11/91	7.10		7.80		8.30	
GLOBULINS BETA	7-12 (%)	28/11/91	7.10		7.90		7.20	
GLOBULINS GAMMA	11-20 (%)	28/11/91	12.20		13.10		12.30	
TSH	0.3-3 (MU/L)	28/11/91	2.60					
T4	4.5-12 (NG/DL)	28/11/91	6.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 7/07 Patient: 530 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			17/02/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	28/11/91	13.90	
HT	37-54 (%)	28/11/91	43.00	
RBC	3.8-5.2 (10¬6/UL)	28/11/91	5.20	
WBC	4-10.8 (10¬3/UL)	28/11/91	5.98	
WBC: N	45-70 (%)	28/11/91	46.00	
WBC: L	25-45 (%)	28/11/91	43.00	
WBC: E	1-5 (%)	28/11/91	3.20	
WBC: M	1-9 (%)	28/11/91	4.60	
WBC: B	0-2 (%)	28/11/91	0.60	
PLATELETS	150-450 (10¬3/UL)	28/11/91	270.00	
NA+	132-151 (MMOL/L)	28/11/91	146.00	
K+	3.6-5.2 (MMOL/L)	28/11/91	4.62	
CL-	97-108 (MMOL/L)	28/11/91	98.00	
Ca++	2.2-2.65 (MMOL/L)	28/11/91	2.59	
PO4--	2.5-5 (MG/DL)	28/11/91	3.70	
SGOT	5-15 (U/L)	28/11/91	10.00	
SGPT	5-19 (U/L)	28/11/91	13.00	
GAMMA GT	5-18 (U/L)	28/11/91	11.00	
LDH	120-240 (U/L)	28/11/91	211.00	
ALK. PHOSPH.	65-175 (U/L)	28/11/91	110.00	
GLUCOSE	50-100 (MG/DL)	28/11/91	86.00	
CREATININE	0.5-0.9 (MG/DL)	28/11/91	0.69	
URIC ACID	2.5-6 (MG/DL)	28/11/91	3.90	
TOT BILIRUBIN	0.2-1 (MG/DL)	28/11/91	1.03	>
DIR BILIRUBIN	0-0.3 (MG/DL)	28/11/91	0.12	
TOT. PROTEINS	6-8.5 (G/DL)	28/11/91	8.20	
ALBUMINE	55-60 (%)	28/11/91	64.00	>
TOT. CHOLEST.	120-220 (MG/DL)	28/11/91	225.00	>
TRIGLYCERIDES	45-200 (MG/DL)	28/11/91	83.00	
GLOBULINS ALPHA 1	1-5 (%)	28/11/91	2.40	
GLOBULINS ALPHA 2	5-10 (%)	28/11/91	6.00	
GLOBULINS BETA	7-12 (%)	28/11/91	11.30	
GLOBULINS GAMMA	11-20 (%)	28/11/91	16.30	
TSH	0.3-3 (MU/L)	28/11/91	0.70	
T4	4.5-12 (NG/DL)	28/11/91	9.60	

1853

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 7/07 Patient: 531 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/02/92		17/03/92		06/04/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	28/11/91	12.60		13.40			
HT	37-54 (%)	28/11/91	41.20		43.70			
RBC	3.8-5.2 (10¬6/UL)	28/11/91	4.75		4.88			
WBC	4-10.8 (10¬3/UL)	28/11/91	5.90		4.74			
WBC: N	45-70 (%)	28/11/91	49.20		56.50			
WBC: L	25-45 (%)	28/11/91	40.60		32.50			
WBC: E	1-5 (%)	28/11/91	2.30		1.80			
WBC: M	1-9 (%)	28/11/91	3.80		4.50			
WBC: B	0-2 (%)	28/11/91	0.80		0.70			
PLATELETS	150-450 (10¬3/UL)	28/11/91	198.00		209.00			
NA+	132-151 (MMOL/L)	28/11/91	138.00		140.00		144.00	
K+	3.6-5.2 (MMOL/L)	28/11/91	5.40	>	4.90		5.02	
CL-	97-108 (MMOL/L)	28/11/91	84.00	<<	90.00	<	88.00	<
Ca++	2.2-2.65 (MMOL/L)	28/11/91	2.42		2.51		2.57	
PO4--	2.5-5 (MG/DL)	28/11/91	3.20		3.20		2.80	
SGOT	5-15 (U/L)	28/11/91	10.00		10.00		11.00	
SGPT	5-19 (U/L)	28/11/91	4.00	<	15.00		11.00	
GAMMA GT	5-18 (U/L)	28/11/91	14.00		17.00		15.00	
LDH	120-240 (U/L)	28/11/91	189.00		242.00	>	254.00	>
ALK. PHOSPH.	65-175 (U/L)	28/11/91	106.00		129.00		109.00	
GLUCOSE	50-100 (MG/DL)	28/11/91	127.00	>	151.00	>>	146.00	>>
CREATININE	0.5-0.9 (MG/DL)	28/11/91	0.43	<	0.60		0.47	<
URIC ACID	2.5-6 (MG/DL)	28/11/91	5.10		5.90		5.80	
TOT BILIRUBIN	0.2-1 (MG/DL)	28/11/91	0.50		0.26		0.46	
TOT. PROTEINS	6-8.5 (G/DL)	28/11/91	7.50		8.20		7.90	
ALBUMINE	55-60 (%)	28/11/91	63.80	>	64.10	>	60.60	>
TOT. CHOLEST.	120-220 (MG/DL)	28/11/91	261.00	>	304.00	>>	282.00	>
TRIGLYCERIDES	45-200 (MG/DL)	28/11/91	225.00	>	380.00	>>	186.00	
GLOBULINS ALPHA 1	1-5 (%)	28/11/91	3.00		2.80		3.30	
GLOBULINS ALPHA 2	5-10 (%)	28/11/91	9.20		9.00		11.50	>
GLOBULINS BETA	7-12 (%)	28/11/91	8.70		8.90		9.50	
GLOBULINS GAMMA	11-20 (%)	28/11/91	15.30		15.20		15.10	
TSH	0.3-3 (MU/L)	28/11/91	2.10					
T4	4.5-12 (NG/DL)	28/11/91	8.40					

1854

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 7/07 Patient: 532 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			23/04/92		18/05/92		09/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	28/11/91	13.50		14.60		14.30	
HT	37-54 (%)	28/11/91	42.70		47.70		45.90	
RBC	3.8-5.2 (10¬6/UL)	28/11/91	3.93		4.05		4.11	
WBC	4-10.8 (10¬3/UL)	28/11/91	4.54		8.03		6.51	
WBC: N	45-70 (%)	28/11/91	57.90		84.50	>	61.40	
WBC: L	25-45 (%)	28/11/91	32.50		10.50	<<	28.90	
WBC: E	1-5 (%)	28/11/91	1.70		0.50	<	1.10	
WBC: M	1-9 (%)	28/11/91	4.50		2.40		5.90	
WBC: B	0-2 (%)	28/11/91	1.10		1.10		1.00	
PLATELETS	150-450 (10¬3/UL)	28/11/91	185.00		276.00		228.00	
NA+	132-151 (MMOL/L)	28/11/91	143.00		140.00		143.00	
K+	3.6-5.2 (MMOL/L)	28/11/91	4.21		4.14		3.06	<<
CL-	97-108 (MMOL/L)	28/11/91	97.00		94.00	<	98.00	
Ca++	2.2-2.65 (MMOL/L)	28/11/91	2.45		2.00	<	2.27	
PO4--	2.5-5 (MG/DL)	28/11/91	5.34	>	10.20	>>	5.60	>
SGOT	5-15 (U/L)	28/11/91	71.00	>>	62.00	>>	50.00	>>
SGPT	5-19 (U/L)	28/11/91	50.00	>>	42.00	>>	44.00	>>
GAMMA GT	5-18 (U/L)	28/11/91	733.00	>>	752.00	>>	617.00	>>
LDH	120-240 (U/L)	28/11/91	270.00	>	301.00	>	210.00	
ALK. PHOSPH.	65-175 (U/L)	28/11/91	219.00	>	250.00	>	201.00	>
GLUCOSE	50-100 (MG/DL)	28/11/91	73.00		88.00		121.00	>
CREATININE	0.5-0.9 (MG/DL)	28/11/91	0.86		1.04	>	0.79	
URIC ACID	2.5-6 (MG/DL)	28/11/91	8.60	>>	8.30	>>	8.40	>>
TOT BILIRUBIN	0.2-1 (MG/DL)	28/11/91	0.69		0.72		0.85	
TOT. PROTEINS	6-8.5 (G/DL)	28/11/91	8.80	>	8.90	>	7.50	
ALBUMINE	55-60 (%)	28/11/91	62.80	>	62.40	>	59.00	
TOT. CHOLEST.	120-220 (MG/DL)	28/11/91	415.00	>>	381.00	>>	362.00	>>
TRIGLYCERIDES	45-200 (MG/DL)	28/11/91	562.00	>>	405.00	>>	221.00	>
GLOBULINS ALPHA 1	1-5 (%)	28/11/91	2.50		1.90		2.30	
GLOBULINS ALPHA 2	5-10 (%)	28/11/91	9.90		7.20		10.30	>
GLOBULINS BETA	7-12 (%)	28/11/91	11.00		11.40		12.40	>
GLOBULINS GAMMA	11-20 (%)	28/11/91	13.00		17.10		16.10	
TSH	0.3-3 (MU/L)	28/11/91	2.90					
T4	4.5-12 (NG/DL)	28/11/91	5.50					

1855

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 7/07 Patient: 533 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date			
			Day 21		Day 42	
			25/05/92		15/06/92	
Laboratory test	Range value	Range date	value	(ϕ)	value	(ϕ)
HB	13-18 (G/DL)	28/11/91			13.50	
HT	40-54 (%)	28/11/91			46.30	
RBC	4.4-5.9 (10¬6/UL)	28/11/91			4.82	
WBC	4-10.8 (10¬3/UL)	28/11/91			11.75	>
WBC: N	45-70 (%)	28/11/91			65.90	
WBC: L	25-45 (%)	28/11/91			27.90	
WBC: E	1-5 (%)	28/11/91			1.20	
WBC: M	1-9 (%)	28/11/91			2.30	
WBC: B	0-2 (%)	28/11/91			0.80	
PLATELETS	150-450 (10¬3/UL)	28/11/91			257.00	
NA+	132-151 (MMOL/L)	28/11/91	144.00		145.00	
K+	3.6-5.2 (MMOL/L)	28/11/91	3.75		6.66	>>
CL-	97-108 (MMOL/L)	28/11/91	98.00		97.00	
Ca++	2.2-2.65 (MMOL/L)	28/11/91	2.49		2.02	<
PO4--	2.5-5 (MG/DL)	28/11/91	5.90	>>	19.30	>>
SGOT	5-19 (U/L)	28/11/91	9.00		12.00	
SGPT	5-23 (U/L)	28/11/91	10.00		14.00	
GAMMA GT	5-28 (U/L)	28/11/91	22.00		28.00	
LDH	120-240 (U/L)	28/11/91	287.00	>	378.00	>
ALK. PHOSPH.	65-175 (U/L)	28/11/91	125.00		144.00	
GLUCOSE	50-100 (MG/DL)	28/11/91	104.00	>	104.00	>
BUN	10-50 (MG/DL)	28/11/91				
UREA	()	28/11/91				
CREATININE	0.6-1.1 (MG/DL)	28/11/91	0.82		1.27	>
URIC ACID	3.5-7 (MG/DL)	28/11/91	5.60		5.20	
TOT BILIRUBIN	0.2-1 (MG/DL)	28/11/91	0.61		0.41	
DIR BILIRUBIN	0-0.3 (MG/DL)	28/11/91				
TOT. PROTEINS	6-8.5 (G/DL)	28/11/91	7.90		8.10	
ALBUMINE	55-60 (%)	28/11/91	60.10	>	63.40	>
TOT. CHOLEST.	120-220 (MG/DL)	28/11/91	344.00	>>	364.00	>>
TRIGLYCERIDES	45-200 (MG/DL)	28/11/91	360.00	>>	551.00	>>
GLOBULINS ALPHA 1	1-5 (%)	28/11/91	3.60		4.80	
GLOBULINS ALPHA 2	5-10 (%)	28/11/91	12.80	>	11.40	>
GLOBULINS BETA	7-12 (%)	28/11/91	9.40		6.00	<
GLOBULINS GAMMA	11-20 (%)	28/11/91	14.10		14.40	
TSH	0.3-3 (MU/L)	28/11/91				
T4	4.5-12 (NG/DL)	28/11/91				

1856

(ϕ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 7/07 Patient: 534 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			12/05/92		05/06/92		24/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	28/11/91	14.10		14.20		13.60	
HT	37-54 (%)	28/11/91	47.90		49.80		48.70	
RBC	3.8-5.2 (10-6/UL)	28/11/91	4.92		5.23	>	5.11	
WBC	4-10.8 (10-3/UL)	28/11/91	5.20		5.07		5.30	
WBC: N	45-70 (%)	28/11/91	64.20		70.10	>	65.70	
WBC: L	25-45 (%)	28/11/91	30.90		23.80	<	28.40	
WBC: E	1-5 (%)	28/11/91	0.30	<	0.40	<	0.40	<
WBC: M	1-9 (%)	28/11/91	2.20		3.10		3.00	
WBC: B	0-2 (%)	28/11/91	0.90		1.00		1.10	
PLATELETS	150-450 (10-3/UL)	28/11/91	181.00		216.00		187.00	
NA+	132-151 (MMOL/L)	28/11/91	143.00		140.00		145.00	
K+	3.6-5.2 (MMOL/L)	28/11/91	7.67	>>	4.95		4.44	
CL-	97-108 (MMOL/L)	28/11/91	94.00	<	98.00		98.00	
Ca++	2.2-2.65 (MMOL/L)	28/11/91	2.16	<	2.26		2.41	
PO4--	2.5-5 (MG/DL)	28/11/91	21.70	>>	3.90		6.20	>>
SGOT	5-15 (U/L)	28/11/91	8.00		11.00		10.00	
SGPT	5-19 (U/L)	28/11/91	9.00		10.00		9.00	
GAMMA GT	5-18 (U/L)	28/11/91	20.00	>	18.00		21.00	>
LDH	120-240 (U/L)	28/11/91	207.00		229.00		221.00	
ALK. PHOSPH.	65-175 (U/L)	28/11/91	89.00		74.00		79.00	
GLUCOSE	50-100 (MG/DL)	28/11/91	101.00	>			92.00	
CREATININE	0.5-0.9 (MG/DL)	28/11/91	1.11	>	0.75		0.76	
URIC ACID	2.5-6 (MG/DL)	28/11/91	3.70		3.90		3.50	
TOT BILIRUBIN	0.2-1 (MG/DL)	28/11/91	0.56		0.39		0.27	
TOT. PROTEINS	6-8.5 (G/DL)	28/11/91	7.80		7.20		7.30	
ALBUMINE	55-60 (%)	28/11/91	70.00	>	68.00	>	68.00	>
TOT. CHOLEST.	120-220 (MG/DL)	28/11/91	246.00	>	226.00	>	208.00	
TRIGLYCERIDES	45-200 (MG/DL)	28/11/91	487.00	>>	44.00	<	415.00	>>
GLOBULINS ALPHA 1	1-5 (%)	28/11/91	1.90		2.30		1.60	
GLOBULINS ALPHA 2	5-10 (%)	28/11/91	7.00		8.00		7.10	
GLOBULINS BETA	7-12 (%)	28/11/91	8.70		8.60		8.70	
GLOBULINS GAMMA	11-20 (%)	28/11/91	12.40		13.10		14.60	
TSH	0.3-3 (MU/L)	28/11/91	2.80					
T4	4.5-12 (NG/DL)	28/11/91	7.80					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8 Patient: 211 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			07/05/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	14/02/91	14.30	
HT	37-47 (%)	14/02/91	40.60	
RBC	4.2-5 (10-6/UL)	14/02/91	4.97	
WBC	4-9 (10-3/UL)	14/02/91	8.42	
WBC: N	40-74 (%)	14/02/91	58.50	
WBC: L	19-48 (%)	14/02/91	34.40	
WBC: E	0-7 (%)	14/02/91	1.20	
WBC: M	3.4-9 (%)	14/02/91	5.40	
WBC: B	0-1.5 (%)	14/02/91	0.50	
PLATELETS	130-400 (10-3/UL)	14/02/91	253.00	
NA+	138-150 (MEQ/L)	14/02/91	139.00	
K+	3.5-5 (MEQ/L)	14/02/91	4.50	
CL-	98-110 (MEQ/L)	14/02/91	101.00	
Ca++	8.5-10.5 (MG/DL)	14/02/91	9.50	
PO4--	2.5-4.5 (MG/DL)	14/02/91	3.90	
SGOT	5-40 (U/L)	14/02/91	15.00	
SGPT	5-40 (U/L)	14/02/91	14.00	
GAMMA GT	6-28 (U/L)	14/02/91	14.00	
LDH	240-450 (U/L)	14/02/91	159.00	<
ALK. PHOSPH.	80-300 (U/L)	14/02/91	94.00	
GLUCOSE	65-110 (MG/DL)	14/02/91	78.00	
BUN	10-20 (MG/DL)	14/02/91	16.00	
CREATININE	0.6-1.2 (MG/DL)	14/02/91	1.10	
URIC ACID	2.5-7.5 (MG/DL)	14/02/91	4.80	
TOT BILIRUBIN	0.1-1 (MG/DL)	14/02/91	0.30	
DIR BILIRUBIN	0.1-0.3 (MG/DL)	14/02/91	0.10	
TOT. PROTEINS	6-8 (G/DL)	14/02/91	7.10	
ALBUMINE	2.6-5.2 (G/DL)	14/02/91	4.50	
TOT. CHOLEST.	120-220 (MG/DL)	14/02/91	214.00	
TRIGLYCERIDES	60-170 (MG/DL)	14/02/91	94.00	
GLOBULINS ALPHA 1	1.5-5 (%)	14/02/91	1.34	<
GLOBULINS ALPHA 2	7.4-11 (%)	14/02/91	9.62	
GLOBULINS BETA	9-14.1 (%)	14/02/91	14.99	>
GLOBULINS GAMMA	13-20.1 (%)	14/02/91	16.67	
TSH	0.1-5 (UU/ML)	14/02/91	6.40	>>
T4	4.5-12.5 (UG/100ML)	14/02/91	11.60	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8 Patient: 212 Treatment: Placebo Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			10/09/91		05/10/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/DL)	14/02/91	13.70			
HT	37-47 (%)	14/02/91	41.00			
RBC	4.2-5 (10¬6/UL)	14/02/91	4.52			
WBC	4-9 (10¬3/UL)	14/02/91	5.60			
WBC: N	40-74 (%)	14/02/91	64.50			
WBC: L	19-48 (%)	14/02/91	25.70			
WBC: E	0-7 (%)	14/02/91	1.70			
WBC: M	3.4-9 (%)	14/02/91	7.00			
WBC: B	0-1.5 (%)	14/02/91	1.10			
PLATELETS	130-400 (10¬3/UL)	14/02/91	215.00			
NA+	138-150 (MEQ/L)	14/02/91	146.00			
K+	3.5-5 (MEQ/L)	14/02/91	4.80			
CL-	98-110 (MEQ/L)	14/02/91	102.00			
Ca++	8.5-10.5 (MG/DL)	14/02/91	8.80			
PO4--	2.5-4.5 (MG/DL)	14/02/91	3.80			
SGOT	5-40 (U/L)	14/02/91	16.00			
SGPT	5-40 (U/L)	14/02/91	14.00			
GAMMA GT	6-28 (U/L)	14/02/91	14.00			
LDH	240-450 (U/L)	14/02/91	227.00	<		
ALK. PHOSPH.	80-300 (U/L)	14/02/91	145.00			
GLUCOSE	65-110 (MG/DL)	14/02/91	74.00			
BUN	10-20 (MG/DL)	14/02/91	16.00			
CREATININE	0.6-1.2 (MG/DL)	14/02/91	1.00			
URIC ACID	2.5-7.5 (MG/DL)	14/02/91	3.30			
TOT BILIRUBIN	0.1-1 (MG/DL)	14/02/91	0.55			
DIR BILIRUBIN	0.1-0.3 (MG/DL)	14/02/91	0.19			
TOT. PROTEINS	6-8 (G/DL)	14/02/91	6.00			
ALBUMINE	2.6-5.2 (G/DL)	14/02/91	4.40			
TOT. CHOLEST.	120-220 (MG/DL)	14/02/91	252.00	>		
TRIGLYCERIDES	60-170 (MG/DL)	14/02/91	123.00			
GLOBULINS ALPHA 1	1.5-5 (%)	14/02/91	2.41			
GLOBULINS ALPHA 2	7.4-11 (%)	14/02/91	11.13	>		
GLOBULINS BETA	9-14.1 (%)	14/02/91	13.58			
GLOBULINS GAMMA	13-20.1 (%)	14/02/91	12.07	<		
TSH	0.1-5 (UU/ML)	14/02/91			6.00	>>
T4	4.5-12.5 (UG/100ML)	14/02/91			11.20	

1859

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang-
< out of range (value lower than min range) > out of range (value higher than max rang-
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8 Patient: 213 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date	
			Screen	
			18/11/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	14-18 (G/DL)	14/02/91	13.90	<
HT	42-52 (%)	14/02/91	41.10	<
RBC	4.6-5.6 (10-6/UL)	14/02/91	4.54	<
WBC	4-9 (10-3/UL)	14/02/91	8.14	
WBC: N	40-74 (%)	14/02/91	60.30	
WBC: L	19-48 (%)	14/02/91	29.20	
WBC: E	0-7 (%)	14/02/91	1.60	
WBC: M	3.4-9 (%)	14/02/91	8.20	
WBC: B	0-1.5 (%)	14/02/91	0.80	
PLATELETS	130-400 (10-3/UL)	14/02/91	286.00	
NA+	138-150 (MEQ/L)	14/02/91	143.00	
K+	3.5-5 (MEQ/L)	14/02/91	4.30	
CL-	98-110 (MEQ/L)	14/02/91	101.00	
Ca++	8.5-10.5 (MG/DL)	14/02/91	9.40	
PO4--	2.5-4.5 (MG/DL)	14/02/91	4.00	
SGOT	5-40 (U/L)	14/02/91	18.00	
SGPT	5-40 (U/L)	14/02/91	13.00	
GAMMA GT	6-28 (U/L)	14/02/91	12.00	
LDH	240-450 (U/L)	14/02/91	172.00	<
ALK. PHOSPH.	80-300 (U/L)	14/02/91	196.00	
GLUCOSE	65-110 (MG/DL)	14/02/91	84.00	
BUN	10-20 (MG/DL)	14/02/91	26.00	>
CREATININE	0.6-1.2 (MG/DL)	14/02/91	1.20	
URIC ACID	2.5-7.5 (MG/DL)	14/02/91	5.60	
TOT BILIRUBIN	0.1-1 (MG/DL)	14/02/91	2.20	>>
DIR BILIRUBIN	0.1-0.3 (MG/DL)	14/02/91	0.46	>
TOT. PROTEINS	6-8 (G/DL)	14/02/91	7.60	
ALBUMINE	2.6-5.2 (G/DL)	14/02/91	4.80	
TOT. CHOLEST.	120-220 (MG/DL)	14/02/91	249.00	>
TRIGLYCERIDES	60-170 (MG/DL)	14/02/91	102.00	
GLOBULINS ALPHA 1	1.5-5 (%)	14/02/91	2.53	
GLOBULINS ALPHA 2	7.4-11 (%)	14/02/91	7.88	
GLOBULINS BETA	9-14.1 (%)	14/02/91	14.90	>
GLOBULINS GAMMA	13-20.1 (%)	14/02/91	18.90	
TSH	0.1-5 (UU/ML)	14/02/91	0.20	
T4	4.5-12.5 (UG/100ML)	14/02/91	7.60	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 8 Patient: 214 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			19/11/91		13/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/DL)	14/02/91	13.90		14.30	
HT	37-47 (%)	14/02/91	40.00		40.30	
RBC	4.2-5 (10-6/UL)	14/02/91	4.49		4.61	
WBC	4-9 (10-3/UL)	14/02/91	7.62		8.05	
WBC: N	40-74 (%)	14/02/91	70.60		63.90	
WBC: L	19-48 (%)	14/02/91	22.20		25.60	
WBC: E	0-7 (%)	14/02/91	1.80		3.30	
WBC: M	3.4-9 (%)	14/02/91	4.20		6.30	
WBC: B	0-1.5 (%)	14/02/91	1.20		0.90	
PLATELETS	130-400 (10-3/UL)	14/02/91	253.00		288.00	
NA+	138-150 (MEQ/L)	14/02/91	144.00		144.00	
K+	3.5-5 (MEQ/L)	14/02/91	4.40		4.40	
CL-	98-110 (MEQ/L)	14/02/91	101.00		101.00	
Ca++	8.5-10.5 (MG/DL)	14/02/91	9.90		10.10	
PO4--	2.5-4.5 (MG/DL)	14/02/91	2.90		4.00	
SGOT	5-40 (U/L)	14/02/91	12.00		18.00	
SGPT	5-40 (U/L)	14/02/91	13.00		20.00	
GAMMA GT	6-28 (U/L)	14/02/91	10.00		13.00	
LDH	240-450 (U/L)	14/02/91	141.00	<	175.00	<
ALK. PHOSPH.	80-300 (U/L)	14/02/91	247.00		259.00	
GLUCOSE	65-110 (MG/DL)	14/02/91	84.00		87.00	
BUN	10-20 (MG/DL)	14/02/91	17.00		13.00	
CREATININE	0.6-1.2 (MG/DL)	14/02/91	1.00		0.90	
URIC ACID	2.5-7.5 (MG/DL)	14/02/91	4.20		4.30	
TOT BILIRUBIN	0.1-1 (MG/DL)	14/02/91	0.57		0.38	
DIR BILIRUBIN	0.1-0.3 (MG/DL)	14/02/91	0.21		0.24	
TOT. PROTEINS	6-8 (G/DL)	14/02/91	7.30		7.70	
ALBUMINE	2.6-5.2 (G/DL)	14/02/91	4.60		4.70	
TOT. CHOLEST.	120-220 (MG/DL)	14/02/91	168.00		209.00	
TRIGLYCERIDES	60-170 (MG/DL)	14/02/91	136.00		266.00	>>
GLOBULINS ALPHA 1	1.5-5 (%)	14/02/91	2.11		2.80	
GLOBULINS ALPHA 2	7.4-11 (%)	14/02/91	9.49		7.82	
GLOBULINS BETA	9-14.1 (%)	14/02/91	13.64		15.95	>
GLOBULINS GAMMA	13-20.1 (%)	14/02/91	17.58		17.76	
TSH	0.1-5 (UU/ML)	14/02/91	2.10			
T4	4.5-12.5 (UG/100ML)	14/02/91	11.40			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA

Centre: 8 Patient: 215 Treatment: Placebo Sex: Female

			Visit number / Laboratory date	
			Day 42	
			31/03/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	14/02/91	15.40	
HT	37-47 (%)	14/02/91	46.50	
RBC	4.2-5 (10~6/UL)	14/02/91	4.96	
WBC	4-9 (10~3/UL)	14/02/91	4.79	
WBC: N	40-74 (%)	14/02/91	56.10	
WBC: L	19-48 (%)	14/02/91	37.50	
WBC: E	0-7 (%)	14/02/91	0.20	
WBC: M	3.4-9 (%)	14/02/91	5.50	
WBC: B	0-1.5 (%)	14/02/91	0.70	
PLATELETS	130-400 (10~3/UL)	14/02/91	274.00	
NA+	138-150 (MEQ/L)	14/02/91	142.00	
K+	3.5-5 (MEQ/L)	14/02/91	4.10	
CL-	98-110 (MEQ/L)	14/02/91	99.00	
Ca++	8.5-10.5 (MG/DL)	14/02/91	9.70	
PO4--	2.5-4.5 (MG/DL)	14/02/91	4.30	
SGOT	5-40 (U/L)	14/02/91	10.00	
SGPT	5-40 (U/L)	14/02/91	9.00	
GAMMA GT	6-28 (U/L)	14/02/91	14.00	
LDH	240-450 (U/L)	14/02/91	144.00	<
ALK. PHOSPH.	80-300 (U/L)	14/02/91	173.00	
GLUCOSE	65-110 (MG/DL)	14/02/91	75.00	
BUN	10-20 (MG/DL)	14/02/91	18.00	
CREATININE	0.6-1.2 (MG/DL)	14/02/91	0.90	
URIC ACID	2.5-7.5 (MG/DL)	14/02/91	3.00	
TOT BILIRUBIN	0.1-1 (MG/DL)	14/02/91	0.79	
DIR BILIRUBIN	0.1-0.3 (MG/DL)	14/02/91	0.21	
TOT. PROTEINS	6-8 (G/DL)	14/02/91	7.80	
ALBUMINE	2.6-5.2 (G/DL)	14/02/91	4.90	
TOT. CHOLEST.	120-220 (MG/DL)	14/02/91	220.00	
TRIGLYCERIDES	60-170 (MG/DL)	14/02/91	71.00	

1862

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 8 Patient: 216 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			27/03/92		14/04/92		05/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	14/02/91	16.50		16.40			
HT	42-52 (%)	14/02/91	49.70		50.90			
RBC	4.6-5.6 (10¬6/UL)	14/02/91	5.36		5.49			
WBC	4-9 (10¬3/UL)	14/02/91	7.20		10.55	>		
WBC: N	40-74 (%)	14/02/91	55.90		61.50			
WBC: L	19-48 (%)	14/02/91	34.70		29.50			
WBC: E	0-7 (%)	14/02/91	3.10		2.10			
WBC: M	3.4-9 (%)	14/02/91	5.00		5.90			
WBC: B	0-1.5 (%)	14/02/91	1.30		1.00			
PLATELETS	130-400 (10¬3/UL)	14/02/91	234.00		295.00			
NA+	138-150 (MEQ/L)	14/02/91	141.00		145.00		140.00	
K+	3.5-5 (MEQ/L)	14/02/91	4.50		4.20		4.50	
CL-	98-110 (MEQ/L)	14/02/91	100.00		97.00	<	102.00	
Ca++	8.5-10.5 (MG/DL)	14/02/91	9.80		10.20		9.40	
PO4--	2.5-4.5 (MG/DL)	14/02/91	3.30		3.70		3.30	
SGOT	5-40 (U/L)	14/02/91	19.00		14.00		26.00	
SGPT	5-40 (U/L)	14/02/91	35.00		34.00		28.00	
GAMMA GT	6-28 (U/L)	14/02/91	31.00	>	34.00	>		
LDH	240-450 (U/L)	14/02/91	119.00	<	125.00	<		
ALK. PHOSPH.	80-300 (U/L)	14/02/91	190.00		224.00		195.00	
GLUCOSE	65-110 (MG/DL)	14/02/91	96.00		95.00		84.00	
BUN	10-20 (MG/DL)	14/02/91	13.00		13.00		18.00	
CREATININE	0.6-1.2 (MG/DL)	14/02/91	1.00		1.00		1.10	
URIC ACID	2.5-7.5 (MG/DL)	14/02/91	5.00		5.80		5.00	
TOT BILIRUBIN	0.1-1 (MG/DL)	14/02/91	0.34		0.74		0.65	
DIR BILIRUBIN	0.1-0.3 (MG/DL)	14/02/91	0.19		0.16		0.08	<
TOT. PROTEINS	6-8 (G/DL)	14/02/91	7.20		7.80		7.90	
ALBUMINE	2.6-5.2 (G/DL)	14/02/91	4.60		4.90		6.10	>
TOT. CHOLEST.	120-220 (MG/DL)	14/02/91	311.00	>>	330.00	>>		
TRIGLYCERIDES	60-170 (MG/DL)	14/02/91	390.00	>>	455.00	>>		
GLOBULINS ALPHA 1	1.5-5 (%)	14/02/91			2.95		4.00	
GLOBULINS ALPHA 2	7.4-11 (%)	14/02/91			3.79	<<	10.00	
GLOBULINS BETA	9-14.1 (%)	14/02/91			16.07	>	12.00	
GLOBULINS GAMMA	13-20.1 (%)	14/02/91			16.09		13.00	
TSH	0.1-5 (UU/ML)	14/02/91	1.20					
T4	4.5-12.5 (UG/100ML)	14/02/91	9.40					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8 Patient: 217 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			23/03/92		20/04/92	
			value	(¢)	value	(¢)
Laboratory test	Range value	Range date				
HB	12-16 (G/DL)	14/02/91	15.70		15.40	
HT	37-47 (%)	14/02/91	47.60	>	45.80	
RBC	4.2-5 (10¬6/UL)	14/02/91	4.77		4.69	
WBC	4-9 (10¬3/UL)	14/02/91	6.95		6.23	
WBC: N	40-74 (%)	14/02/91	50.20		57.30	
WBC: L	19-48 (%)	14/02/91	40.50		33.40	
WBC: E	0-7 (%)	14/02/91	3.20		1.90	
WBC: M	3.4-9 (%)	14/02/91	5.20		6.80	
WBC: B	0-1.5 (%)	14/02/91	0.90		0.60	
PLATELETS	130-400 (10¬3/UL)	14/02/91	171.00		161.00	
NA+	138-150 (MEQ/L)	14/02/91	142.00		144.00	
K+	3.5-5 (MEQ/L)	14/02/91	4.10		4.30	
CL-	98-110 (MEQ/L)	14/02/91	100.00		103.00	
Ca++	8.5-10.5 (MG/DL)	14/02/91	10.00		9.80	
PO4--	2.5-4.5 (MG/DL)	14/02/91	3.10		3.30	
SGOT	5-40 (U/L)	14/02/91	22.00		20.00	
SGPT	5-40 (U/L)	14/02/91	21.00		21.00	
GAMMA GT	6-28 (U/L)	14/02/91	47.00	>	40.00	>
LDH	240-450 (U/L)	14/02/91	153.00	<	150.00	<
ALK. PHOSPH.	80-300 (U/L)	14/02/91	186.00		174.00	
GLUCOSE	65-110 (MG/DL)	14/02/91	73.00		80.00	
BUN	10-20 (MG/DL)	14/02/91	13.00		14.00	
CREATININE	0.6-1.2 (MG/DL)	14/02/91	0.90		0.80	
URIC ACID	2.5-7.5 (MG/DL)	14/02/91	2.80		3.20	
TOT BILIRUBIN	0.1-1 (MG/DL)	14/02/91	1.09	>	1.00	
DIR BILIRUBIN	0.1-0.3 (MG/DL)	14/02/91	0.34	>	0.28	
TSH	0.1-5 (UU/ML)	14/02/91	1.20			
T4	4.5-12.5 (UG/100ML)	14/02/91	11.30			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8 Patient: 218 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory data	
			Day 42	
			21/05/92	
			value	(¢)
Laboratory test	Range value	Range date		
NA+	135-148 (MEQ/L)	20/05/92	143.00	
K+	3.5-5 (MEQ/L)	20/05/92	4.10	
CL-	98-108 (MEQ/L)	20/05/92	104.00	
Ca++	8.5-10.5 (MG/DL)	20/05/92	9.00	
PO4--	2.5-4.5 (MG/DL)	20/05/92	3.90	
SGOT	1-40 (U/L)	20/05/92	21.00	
SGPT	1-40 (U/L)	20/05/92	16.00	
GAMMA GT	1-18 (U/L)	20/05/92	8.00	
LDH	360-460 (U/L)	20/05/92	118.00	<
ALK. PHOSPH.	70-210 (U/L)	20/05/92	114.00	
GLUCOSE	50-100 (MG/DL)	20/05/92	89.00	
BUN	7-25 (MG/DL)	20/05/92	18.00	
CREATININE	0.7-1.3 (MG/DL)	20/05/92	0.90	
URIC ACID	3-7 (MG/DL)	20/05/92	5.00	
TOT BILIRUBIN	0.3-1.1 (MG/DL)	20/05/92	0.65	
DIR BILIRUBIN	0.05-0.2 (MG/DL)	20/05/92	0.13	
TOT. PROTEINS	6.5-8.4 (G/DL)	20/05/92	7.20	
ALBUMINE	55-65 (%)	20/05/92	55.00	
TOT. CHOLEST.	160-240 (MG/DL)	20/05/92	210.00	
TRIGLYCERIDES	50-160 (MG/DL)	20/05/92	140.00	
GLOBULINS ALPHA 1	2-5 (%)	20/05/92	3.00	
GLOBULINS ALPHA 2	7-12 (%)	20/05/92	11.00	
GLOBULINS BETA	8-14 (%)	20/05/92	12.00	
GLOBULINS GAMMA	12-20 (%)	20/05/92	19.00	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 8 Patient: 219 Treatment: Placebo Sex: Female

			Visit number / Laboratory date	
			Screen	
			08/04/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	02/04/92	11.60	<
HT	37-47 (%)	02/04/92	35.60	<
RBC	4.2-5 (10~6/UL)	02/04/92	4.46	
WBC	4-9 (10~3/UL)	02/04/92	6.72	
WBC: N	40-74 (%)	02/04/92	54.20	
WBC: L	19-48 (%)	02/04/92	38.20	
WBC: E	0-7 (%)	02/04/92	1.00	
WBC: M	3.4-9 (%)	02/04/92	6.10	
WBC: B	0-1.5 (%)	02/04/92	0.50	
PLATELETS	130-400 (10~3/UL)	02/04/92	263.00	
NA+	138-150 (MEQ/L)	02/04/92	141.00	
K+	3.5-5 (MEQ/L)	02/04/92	4.40	
CL-	98-110 (MEQ/L)	02/04/92	106.00	
Ca++	8.5-10.5 (MG/DL)	02/04/92	9.40	
PO4--	2.5-4.5 (MG/DL)	02/04/92	5.20	>>
SGOT	5-40 (U/L)	02/04/92	19.00	
SGPT	5-40 (U/L)	02/04/92	12.00	
GAMMA GT	6-28 (U/L)	02/04/92	5.00	<
LDH	240-450 (U/L)	02/04/92	91.00	<
ALK. PHOSPH.	80-300 (U/L)	02/04/92	206.00	
GLUCOSE	65-110 (MG/DL)	02/04/92	98.00	
BUN	10-20 (MG/DL)	02/04/92	12.00	
CREATININE	0.6-1.2 (MG/DL)	02/04/92	0.80	
URIC ACID	2.5-7.5 (MG/DL)	02/04/92	4.10	
TOT BILIRUBIN	0.1-1 (MG/DL)	02/04/92	0.29	
DIR BILIRUBIN	0.1-0.3 (MG/DL)	02/04/92	0.15	
TOT. PROTEINS	6-8 (G/DL)	02/04/92	8.90	>
ALBUMINE	50-67 (%)	02/04/92	40.19	<
TOT. CHOLEST.	120-220 (MG/DL)	02/04/92	126.00	
TRIGLYCERIDES	60-170 (MG/DL)	02/04/92	128.00	
GLOBULINS ALPHA 1	1.5-5 (%)	02/04/92	2.83	
GLOBULINS ALPHA 2	7.4-11 (%)	02/04/92	10.11	
GLOBULINS BETA	9-14.1 (%)	02/04/92	13.07	
GLOBULINS GAMMA	13-20.1 (%)	02/04/92	33.80	>>
TSH	0.1-5 (UU/ML)	02/04/92	1.00	
T4	4.5-12.5 (UG/100ML)	02/04/92	5.70	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8 Patient: 220 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Day 21	
			18/05/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	14/02/91	12.20	
HT	37-47 (%)	14/02/91	37.70	
RBC	4.2-5 (10¬6/UL)	14/02/91	3.97	<
WBC	4-9 (10¬3/UL)	14/02/91	3.60	<
WBC: N	40-74 (%)	14/02/91	40.40	
WBC: L	19-48 (%)	14/02/91	49.50	>
WBC: E	0-7 (%)	14/02/91	1.00	
WBC: M	3.4-9 (%)	14/02/91	8.40	
WBC: B	0-1.5 (%)	14/02/91	0.60	
PLATELETS	130-400 (10¬3/UL)	14/02/91	212.00	
NA+	138-150 (MEQ/L)	14/02/91	136.00	<
K+	3.5-5 (MEQ/L)	14/02/91	4.00	
CL-	98-110 (MEQ/L)	14/02/91	101.00	
Ca++	8.5-10.5 (MG/DL)	14/02/91	9.70	
PO4--	2.5-4.5 (MG/DL)	14/02/91	3.60	
SGOT	5-40 (U/L)	14/02/91	16.00	
SGPT	5-40 (U/L)	14/02/91	12.00	
GAMMA GT	6-28 (U/L)	14/02/91	7.00	
LDH	240-450 (U/L)	14/02/91	118.00	<
ALK. PHOSPH.	80-300 (U/L)	14/02/91	148.00	
GLUCOSE	65-110 (MG/DL)	14/02/91	69.00	
BUN	10-20 (MG/DL)	14/02/91	11.00	
CREATININE	0.6-1.2 (MG/DL)	14/02/91	0.80	
URIC ACID	2.5-7.5 (MG/DL)	14/02/91	2.50	
TOT BILIRUBIN	0.1-1 (MG/DL)	14/02/91	0.61	
DIR BILIRUBIN	0.1-0.3 (MG/DL)	14/02/91	0.19	
TOT. PROTEINS	6-8 (G/DL)	14/02/91	6.90	
ALBUMINE	2.6-5.2 (G/DL)	14/02/91	4.20	
TOT. CHOLEST.	120-220 (MG/DL)	14/02/91	159.00	
TRIGLYCERIDES	60-170 (MG/DL)	14/02/91	56.00	<
GLOBULINS ALPHA 1	1.5-5 (%)	14/02/91	2.00	
GLOBULINS ALPHA 2	7.4-11 (%)	14/02/91	8.30	
GLOBULINS BETA	9-14.1 (%)	14/02/91	8.80	<
GLOBULINS GAMMA	13-20.1 (%)	14/02/91	13.80	

1867

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 8 Patient: 221 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			24/04/92		19/05/92		09/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	20/04/92						
	11-16 (G/DL)	08/06/92					16.00	
HT	42-52 (%)	20/04/92						
	36-48 (%)	08/06/92					48.00	
RBC	4.6-5.6 (10-6/UL)	20/04/92						
	3.9-5.4 (10-6/UL)	08/06/92					5.30	
WBC	4-9 (10-3/UL)	20/04/92						
	4-8 (10-3/UL)	08/06/92					9.50	>
WBC: N	40-74 (%)	20/04/92						
	50-80 (%)	08/06/92					58.00	
WBC: L	19-48 (%)	20/04/92						
	10-40 (%)	08/06/92					33.00	
WBC: E	0-7 (%)	20/04/92						
	0-4 (%)	08/06/92					3.00	
WBC: M	3.4-9 (%)	20/04/92						
	2-8 (%)	08/06/92					6.00	
WBC: B	0-1.5 (%)	20/04/92						
	0-2 (%)	08/06/92					0.00	
PLATELETS	130-400 (10-3/UL)	20/04/92						
	150-400 (10-3/UL)	08/06/92						
NA+	138-150 (MEQ/L)	20/04/92			140.00			
	135-148 (MEQ/L)	08/06/92					142.00	
K+	3.5-5 (MEQ/L)	20/04/92	5.00		4.40		4.40	
CL-	98-110 (MEQ/L)	20/04/92	96.00	<	104.00			
	98-108 (MEQ/L)	08/06/92						
Ca++	8.5-10.5 (MG/DL)	20/04/92	9.50		10.00		8.80	
PO4--	2.5-4.5 (MG/DL)	20/04/92	3.30		4.20		3.80	
SGOT	5-40 (U/L)	20/04/92	14.00		22.00			
	1-40 (U/L)	08/06/92					34.00	
SGPT	5-40 (U/L)	20/04/92	24.00		49.00	>		
	1-40 (U/L)	08/06/92					66.00	>
GAMMA GT	6-28 (U/L)	20/04/92	29.00	>	38.00	>		
	1-18 (U/L)	08/06/92						
LDH	240-450 (U/L)	20/04/92	150.00	<	152.00	<		
	360-460 (U/L)	08/06/92						
ALK. PHOSPH.	80-300 (U/L)	20/04/92	219.00		222.00			
	70-210 (U/L)	08/06/92					242.00	>
GLUCOSE	65-110 (MG/DL)	20/04/92	82.00		83.00			
	50-100 (MG/DL)	08/06/92					90.00	
BUN	10-20 (MG/DL)	20/04/92	14.00		19.00			
	7-25 (MG/DL)	08/06/92					14.00	
UREA	()	20/04/92						
	15-58 (MG/DL)	08/06/92						
CREATININE	0.6-1.2 (MG/DL)	20/04/92	0.90		1.10			
	0.7-1.3 (MG/DL)	08/06/92					0.90	
URIC ACID	2.5-7.5 (MG/DL)	20/04/92	5.30		6.60			
	3-7 (MG/DL)	08/06/92					6.10	
TOT BILIRUBIN	0.1-1 (MG/DL)	20/04/92	0.82		0.65			
	0.3-1.1 (MG/DL)	08/06/92					0.60	
DIR BILIRUBIN	0.1-0.3 (MG/DL)	20/04/92	0.23		0.19			
	0.05-0.2 (MG/DL)	08/06/92					0.10	
TOT. PROTEINS	6-8 (G/DL)	20/04/92	7.20		7.70			
	6.5-8.4 (G/DL)	08/06/92					7.30	
ALBUMINE	2.6-5.2 (G/DL)	20/04/92	4.50		4.60			
	55-65 (%)	08/06/92					55.00	
TOT. CHOLEST.	120-220 (MG/DL)	20/04/92	151.00		171.00			
	160-240 (MG/DL)	08/06/92						
TRIGLYCERIDES	60-170 (MG/DL)	20/04/92	160.00		111.00			
	50-160 (MG/DL)	08/06/92						
GLOBULINS ALPHA 1	1.5-5 (%)	20/04/92	3.56		2.43			
	2-5 (%)	08/06/92					4.00	
GLOBULINS ALPHA 2	7.4-11 (%)	20/04/92	9.58		8.03			

(CONTINUED)

1868

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 8 Patient: 221 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			24/04/92		19/05/92		09/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
GLOBULINS ALPHA 2	7-12 (%)	08/06/92					12.00	
GLOBULINS BETA	9-14.1 (%)	20/04/92	13.93		14.55	>		
	8-14 (%)	08/06/92					10.00	
GLOBULINS GAMMA	13-20.1 (%)	20/04/92	19.50		18.15			
	12-20 (%)	08/06/92					19.00	
TSH	0.1-5 (UU/ML)	20/04/92	0.10					
	0.5-5 (UU/ML)	08/06/92						
T4	4.5-12.5 (UG/100ML)	20/04/92	11.50					
	4.5-11 (UG/DL)	08/06/92						

1869

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8 Patient: 222 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			20/04/92		19/05/92		28/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/04/92	14.00		13.50			
	11-16 (G/DL)	27/06/92					13.00	
HT	37-47 (%)	01/04/92	41.50		39.10			
	36-48 (%)	27/06/92					40.00	
RBC	4.2-5 (10-6/UL)	01/04/92	4.47		4.19	<		
	3.9-5.4 (10-6/UL)	27/06/92					4.14	
WBC	4-9 (10-3/UL)	01/04/92	8.04		8.32			
	4-8 (10-3/UL)	27/06/92					7.50	
WBC: N	40-74 (%)	01/04/92	48.00					
	50-80 (%)	27/06/92					65.00	
WBC: L	19-48 (%)	01/04/92	45.00					
	10-40 (%)	27/06/92					31.00	
WBC: E	0-7 (%)	01/04/92	1.30					
	0-4 (%)	27/06/92					2.00	
WBC: M	3.4-9 (%)	01/04/92	5.00					
	2-8 (%)	27/06/92					2.00	
WBC: B	0-1.5 (%)	01/04/92	0.70					
	0-2 (%)	27/06/92					0.00	
PLATELETS	130-400 (10-3/UL)	01/04/92	257.00		211.00			
	150-400 (10-3/UL)	27/06/92					223.00	
NA+	138-150 (MEQ/L)	01/04/92	139.00		145.00			
	135-148 (MEQ/L)	27/06/92					140.00	
K+	3.5-5 (MEQ/L)	01/04/92	4.70		4.30		4.50	
CL-	98-110 (MEQ/L)	01/04/92	102.00		107.00			
Ca++	8.5-10.5 (MG/DL)	01/04/92	9.60		9.10		9.10	
PO4--	2.5-4.5 (MG/DL)	01/04/92	3.60		3.20		3.20	
SGOT	5-40 (U/L)	01/04/92	17.00		15.00			
	1-40 (U/L)	27/06/92					31.00	
SGPT	5-40 (U/L)	01/04/92	12.00		14.00			
	1-40 (U/L)	27/06/92					19.00	
GAMMA GT	6-28 (U/L)	01/04/92	14.00		15.00			
	1-18 (U/L)	27/06/92					15.00	
LDH	240-450 (U/L)	01/04/92	193.00	<	191.00	<		
	360-460 (U/L)	27/06/92					300.00	<
ALK. PHOSPH.	80-300 (U/L)	01/04/92	229.00		236.00			
	70-210 (U/L)	27/06/92					196.00	
GLUCOSE	65-110 (MG/DL)	01/04/92	86.00		80.00			
	50-100 (MG/DL)	27/06/92					117.00	>
BUN	10-20 (MG/DL)	01/04/92	18.00		19.00			
	7-25 (MG/DL)	27/06/92					21.00	
CREATININE	0.6-1.2 (MG/DL)	01/04/92	1.10		1.10			
	0.7-1.3 (MG/DL)	27/06/92					1.10	
URIC ACID	2.5-7.5 (MG/DL)	01/04/92	4.80		5.10			
	3-7 (MG/DL)	27/06/92					4.60	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/04/92	0.42		0.30			
	0.3-1.1 (MG/DL)	27/06/92					0.54	
DIR BILIRUBIN	0.1-0.3 (MG/DL)	01/04/92	0.23		0.14			
	0.05-0.2 (MG/DL)	27/06/92					0.10	
TOT. PROTEINS	6-8 (G/DL)	01/04/92	7.10		6.90			
	6.5-8.4 (G/DL)	27/06/92					7.30	
ALBUMINE	2.6-5.2 (G/DL)	01/04/92	4.40		4.30			
	55-65 (%)	27/06/92					60.00	
TOT. CHOLEST.	120-220 (MG/DL)	01/04/92	247.00	>	254.00	>		
	160-240 (MG/DL)	27/06/92					225.00	
TRIGLYCERIDES	60-170 (MG/DL)	01/04/92	152.00		275.00	>>		
	50-160 (MG/DL)	27/06/92					175.00	>
GLOBULINS ALPHA 1	1.5-5 (%)	01/04/92	3.14		2.88			
	2-5 (%)	27/06/92					5.00	
GLOBULINS ALPHA 2	7.4-11 (%)	01/04/92	12.11	>	10.96			
	7-12 (%)	27/06/92					9.00	
GLOBULINS BETA	9-14.1 (%)	01/04/92	13.61		13.98			
	8-14 (%)	27/06/92					12.00	

1870

(CONTINUED)

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 8 Patient: 222 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			20/04/92		19/05/92		28/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
GLOBULINS GAMMA	13-20.1 (%)	01/04/92	17.27		15.60			
	12-20 (%)	27/06/92					14.00	
TSH	0.1-5 (UU/ML)	01/04/92	3.50					
T4	4.5-12.5 (UG/100ML)	01/04/92	5.90					

1871

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA

Centre: 8 Patient: 223 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Day 21	
			01/06/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	21/05/92	14.60	
HT	37-47 (%)	21/05/92	46.00	
RBC	4.2-5 (10¬6/UL)	21/05/92	4.89	
WBC	4-9 (10¬3/UL)	21/05/92	7.57	
WBC: N	40-74 (%)	21/05/92	51.40	
WBC: L	19-48 (%)	21/05/92	40.00	
WBC: E	0-7 (%)	21/05/92	2.30	
WBC: M	3.4-9 (%)	21/05/92	5.00	
WBC: B	0-1.5 (%)	21/05/92	1.30	
PLATELETS	130-400 (10¬3/UL)	21/05/92	315.00	
NA+	138-150 (ME/L)	21/05/92	146.00	
K+	3.5-5 (ME/L)	21/05/92	4.80	
CL-	98-110 (ME/L)	21/05/92	101.00	
Ca++	8.5-10.5 (MG/DL)	21/05/92	10.10	
PO4--	2.5-4.5 (MG/DL)	21/05/92	3.50	
SGOT	5-40 (U/L)	21/05/92	22.00	
SGPT	5-40 (U/L)	21/05/92	15.00	
GAMMA GT	6-28 (U/L)	21/05/92	20.00	
LDH	240-450 (U/L)	21/05/92	140.00	<
ALK. PHOSPH.	80-300 (U/L)	21/05/92	189.00	
GLUCOSE	65-110 (MG/DL)	21/05/92	89.00	
BUN	10-20 (MG/DL)	21/05/92	12.00	
CREATININE	0.6-1.2 (MG/DL)	21/05/92	1.00	
URIC ACID	2.5-7.5 (MG/DL)	21/05/92	5.40	
TOT BILIRUBIN	0.1-1 (MG/DL)	21/05/92	0.84	
DIR BILIRUBIN	0.1-0.3 (MG/DL)	21/05/92	0.28	
TOT. PROTEINS	6-8 (G/DL)	21/05/92	7.30	
ALBUMINE	2.6-5.2 (G/DL)	21/05/92	4.40	
TOT. CHOLEST.	160-240 (MG/DL)	21/05/92	204.00	
TRIGLYCERIDES	60-170 (MG/DL)	21/05/92	164.00	
GLOBULINS ALPHA 1	1.5-5 (%)	21/05/92	3.10	
GLOBULINS ALPHA 2	7.4-11 (%)	21/05/92	9.80	
GLOBULINS BETA	9-14.1 (%)	21/05/92	12.90	
GLOBULINS GAMMA	13-20.1 (%)	21/05/92	12.60	<

1872

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 8 Patient: 224 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			27/08/92		28/09/92		19/10/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	11-16 (G/DL)	21/05/92	11.00		12.00		11.80	
HT	36-48 (%)	21/05/92	34.00	<	37.00		35.00	<
RBC	3.9-5.4 (10¬6/UL)	21/05/92	4.08		4.40		4.10	
WBC	4-8 (10¬3/UL)	21/05/92	8.70	>	7.40		8.80	>
WBC: N	50-80 (%)	21/05/92	59.00		52.00		55.00	
WBC: L	10-40 (%)	21/05/92	36.00		40.00		37.00	
WBC: E	0-4 (%)	21/05/92	2.00		5.00	>	6.00	>>
WBC: M	2-8 (%)	21/05/92	3.00		3.00		2.00	
WBC: B	0-2 (%)	21/05/92	0.00		0.00		0.00	
PLATELETS	150-400 (10¬3/UL)	21/05/92	220.00		220.00		210.00	
NA+	135-148 (MEQ/L)	21/05/92	140.00		142.00		146.00	
K+	3.5-5 (MEQ/L)	21/05/92	3.80		3.70		4.30	
CL-	98-108 (MEQ/L)	21/05/92	102.00		101.00		104.00	
Ca++	8.5-10.5 (MG/DL)	21/05/92	9.40		9.30		9.10	
PO4--	2.5-4.5 (MG/DL)	21/05/92	3.20		2.90		3.10	
SGOT	1-40 (U/L)	21/05/92	30.00		27.00		20.00	
SGPT	1-40 (U/L)	21/05/92	19.00		16.00		14.00	
GAMMA GT	1-18 (U/L)	21/05/92	7.00		7.00		6.00	
LDH	360-460 (U/L)	21/05/92	252.00	<	232.00	<	281.00	<
ALK. PHOSPH.	70-210 (U/L)	21/05/92	125.00		163.00		111.00	
GLUCOSE	50-100 (MG/DL)	21/05/92	79.00		81.00		68.00	
BUN	7-25 (MG/DL)	21/05/92	14.00		16.00		18.00	
CREATININE	0.7-1.3 (MG/DL)	21/05/92	0.30	<	0.80		0.80	
URIC ACID	3-7 (MG/DL)	21/05/92	3.20		3.50		2.90	<
TOT BILIRUBIN	0.3-1.1 (MG/DL)	21/05/92	0.65		0.85		0.82	
DIR BILIRUBIN	0.05-0.2 (MG/DL)	21/05/92	0.10		0.14		0.14	
TOT. PROTEINS	6.5-8.4 (G/DL)	21/05/92	7.60		7.70		7.40	
ALBUMINE	55-65 (%)	21/05/92	55.00		55.00		54.00	<
TOT. CHOLEST.	160-240 (MG/DL)	21/05/92	166.00		158.00	<	151.00	<
TRIGLYCERIDES	50-160 (MG/DL)	21/05/92	54.00		65.00		70.00	
GLOBULINS ALPHA 1	2-5 (%)	21/05/92	3.00		3.00		4.00	
GLOBULINS ALPHA 2	7-12 (%)	21/05/92	10.00		9.00		10.00	
GLOBULINS BETA	8-14 (%)	21/05/92	11.00		11.00		11.00	
GLOBULINS GAMMA	12-20 (%)	21/05/92	20.00		22.00	>	21.00	>
TSH	0.5-5 (UU/ML)	21/05/92	2.30					
T4	4.5-11 (UG/100ML)	21/05/92	5.20					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 8 Patient: 225 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/09/92		02/10/92		23/10/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	21/05/92	15.20		16.00		14.50	
HT	36-48 (%)	21/05/92	44.00		47.00		42.00	
RBC	3.9-5.4 (10¬6/UL)	21/05/92	4.95		5.30		4.70	
WBC	4-8 (10¬3/UL)	21/05/92	8.00		7.20		7.40	
WBC: N	50-80 (%)	21/05/92	58.00		61.00		52.00	
WBC: L	10-40 (%)	21/05/92	39.00		34.00		44.00	>
WBC: E	0-4 (%)	21/05/92	1.00		1.00		1.00	
WBC: M	2-8 (%)	21/05/92	2.00		4.00		3.00	
WBC: B	0-2 (%)	21/05/92	0.00		0.00		0.00	
PLATELETS	150-400 (10¬3/UL)	21/05/92	220.00		205.00		185.00	
NA+	135-148 (MEQ/L)	21/05/92	140.00		138.00		140.00	
K+	3.5-5 (MEQ/L)	21/05/92	5.00		4.70		4.70	
CL-	98-108 (MEQ/L)	21/05/92	107.00		99.00		100.00	
Ca++	8.5-10.5 (MG/DL)	21/05/92	8.50		9.00		9.30	
PO4--	2.5-4.5 (MG/DL)	21/05/92	3.60		3.10		3.50	
SGOT	1-40 (U/L)	21/05/92	34.00		30.00		37.00	
SGPT	1-40 (U/L)	21/05/92	37.00		28.00		42.00	>
GAMMA GT	1-18 (U/L)	21/05/92	13.00		12.00		11.00	
LDH	360-460 (U/L)	21/05/92	339.00	<	271.00	<	329.00	<
ALK. PHOSPH.	70-210 (U/L)	21/05/92	237.00	>	225.00	>	202.00	
GLUCOSE	50-100 (MG/DL)	21/05/92	82.00		68.00		78.00	
BUN	7-25 (MG/DL)	21/05/92	18.00		16.00		16.00	
CREATININE	0.7-1.3 (MG/DL)	21/05/92	0.80		0.80		0.80	
URIC ACID	3-7 (MG/DL)	21/05/92	4.00		5.00		4.30	
TOT BILIRUBIN	0.3-1.1 (MG/DL)	21/05/92	1.51	>	1.89	>	1.49	>
DIR BILIRUBIN	0.05-0.2 (MG/DL)	21/05/92	0.87	>>	1.11	>>	0.69	>>
TOT. PROTEINS	6.5-8.4 (G/DL)	21/05/92	8.40					
ALBUMINE	55-65 (%)	21/05/92	59.00					
TOT. CHOLEST.	160-240 (MG/DL)	21/05/92	184.00					
TRIGLYCERIDES	50-160 (MG/DL)	21/05/92	75.00					
GLOBULINS ALPHA 1	2-5 (%)	21/05/92	5.00					
GLOBULINS ALPHA 2	7-12 (%)	21/05/92	9.00					
GLOBULINS BETA	8-14 (%)	21/05/92	12.00					
GLOBULINS GAMMA	12-20 (%)	21/05/92	15.00					
TSH	0.5-5 (UU/ML)	21/05/92	1.30					
T4	4.5-11 (UG/100ML)	21/05/92	9.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 8 Patient: 226 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			15/09/92		14/10/92		04/11/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	14/09/92	15.40		15.10		14.90	
HT	42-52 (%)	14/09/92	45.30		43.20		44.30	
RBC	4.6-5.6 (10¬6/UL)	14/09/92	4.83		4.72		4.90	
WBC	4-9 (10¬3/UL)	14/09/92	5.53		6.10		7.53	
WBC: N	40-74 (%)	14/09/92	62.00		59.60		55.40	
WBC: L	19-48 (%)	14/09/92	30.00		30.10		35.20	
WBC: E	0-7 (%)	14/09/92	3.20		0.90		3.00	
WBC: M	3.4-9 (%)	14/09/92	3.60		8.80		6.10	
WBC: B	0-1.5 (%)	14/09/92	1.20		0.40		0.30	
PLATELETS	130-400 (10¬3/UL)	14/09/92	210.00		227.00		273.00	
NA+	138-150 (MEQ/L)	14/09/92	145.00		142.00		146.00	
K+	3.5-5 (MEQ/L)	14/09/92	4.80		3.80		3.50	
CL-	98-110 (MEQ/L)	14/09/92	100.00		101.00			
Ca++	8.5-10.5 (MG/DL)	14/09/92	9.70		9.40		9.70	
PO4--	2.5-4.5 (MG/DL)	14/09/92	3.80		3.50			
SGOT	5-40 (U/L)	14/09/92	32.00		24.00		16.00	
SGPT	5-40 (U/L)	14/09/92	39.00		30.00		17.00	
GAMMA GT	6-28 (U/L)	14/09/92	10.00		11.00		10.00	
LDH	240-450 (U/L)	14/09/92			233.00	<		
ALK. PHOSPH.	80-300 (U/L)	14/09/92	102.00		123.00		197.00	
GLUCOSE	65-110 (MG/DL)	14/09/92	77.00		79.00		90.00	
BUN	10-20 (MG/DL)	14/09/92	20.00		14.00		12.00	
CREATININE	0.6-1.2 (MG/DL)	14/09/92	1.10		1.10		1.00	
URIC ACID	2.5-7.5 (MG/DL)	14/09/92	3.90		4.50		5.40	
TOT BILIRUBIN	0.1-1 (MG/DL)	14/09/92	1.33	>	1.14	>	0.43	
DIR BILIRUBIN	0.1-0.3 (MG/DL)	14/09/92	0.48	>	0.34	>	0.23	
TOT. PROTEINS	6-8 (G/DL)	03/11/92					7.80	
ALBUMINE	50-67 (%)	03/11/92					64.50	
TOT. CHOLEST.	120-220 (MG/DL)	03/11/92					159.00	
TRIGLYCERIDES	60-170 (MG/DL)	03/11/92					91.00	
GLOBULINS ALPHA 1	1.5-5 (%)	03/11/92					2.40	
GLOBULINS ALPHA 2	7.4-11 (%)	03/11/92					6.20	<
GLOBULINS BETA	9-14.1 (%)	03/11/92					10.50	
GLOBULINS GAMMA	13-20.1 (%)	03/11/92					16.40	
TSH	0.1-5 (UU/ML)	14/09/92	0.90					
T4	4.5-12.5 (UG/100ML)	14/09/92	8.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8 Patient: 227 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/09/92		16/10/92		06/11/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	21/05/92	15.40		14.60		14.10	
HT	42-52 (%)	21/05/92	46.70		46.00		43.50	
RBC	4.6-5.6 (10¬6/UL)	21/05/92	5.26		4.89		4.56	<
WBC	4-9 (10¬3/UL)	21/05/92	9.24	>	7.57		9.59	>
WBC: N	40-74 (%)	21/05/92	45.00		51.40		45.10	
WBC: L	19-48 (%)	21/05/92	45.30		40.00		44.00	
WBC: E	0-7 (%)	21/05/92	1.50		2.30		3.60	
WBC: M	3.4-9 (%)	21/05/92	7.20		5.00		6.30	
WBC: B	0-1.5 (%)	21/05/92	1.00		1.30		1.00	
PLATELETS	130-400 (10¬3/UL)	21/05/92	291.00		315.00		238.00	
NA+	138-150 (ME/L)	21/05/92	137.00	<	146.00		140.00	
K+	3.5-5 (ME/L)	21/05/92	4.00		4.80		4.90	
CL-	98-110 (ME/L)	21/05/92	94.00	<	101.00		106.00	
Ca++	8.5-10.5 (MG/DL)	21/05/92	9.90		10.10		9.60	
PO4--	2.5-4.5 (MG/DL)	21/05/92	3.10		3.10			
SGOT	5-40 (U/L)	21/05/92	9.00		22.00		32.00	
SGPT	5-40 (U/L)	21/05/92	12.00		15.00		28.00	
GAMMA GT	6-28 (U/L)	21/05/92	13.00		20.00		9.00	
LDH	240-450 (U/L)	21/05/92	117.00	<			241.00	
ALK. PHOSPH.	80-300 (U/L)	21/05/92	186.00		300.00		133.00	
GLUCOSE	65-110 (MG/DL)	21/05/92	87.00		89.00		89.00	
BUN	10-20 (MG/DL)	21/05/92	15.00		12.00		11.00	
CREATININE	0.6-1.2 (MG/DL)	21/05/92	1.10		1.00		0.90	
URIC ACID	2.5-7.5 (MG/DL)	21/05/92	6.00		5.40		3.90	
TOT BILIRUBIN	0.1-1 (MG/DL)	21/05/92	0.46		0.84		0.46	
DIR BILIRUBIN	0.1-0.3 (MG/DL)	21/05/92	0.17		0.28		0.20	
TOT. PROTEINS	6-8 (G/DL)	21/05/92	7.20		7.30		7.20	
ALBUMINE	2.6-5.2 (G/DL)	21/05/92	4.40		4.40		4.70	
TOT. CHOLEST.	160-240 (MG/DL)	21/05/92	215.00		244.00	>	211.00	
TRIGLYCERIDES	60-170 (MG/DL)	21/05/92	203.00	>	164.00		111.00	
GLOBULINS ALPHA 1	1.5-5 (%)	21/05/92	2.55		3.10		2.90	
GLOBULINS ALPHA 2	7.4-11 (%)	21/05/92	9.38		9.80		11.40	>
GLOBULINS BETA	9-14.1 (%)	21/05/92	15.34	>	12.90		11.50	
GLOBULINS GAMMA	13-20.1 (%)	21/05/92	16.29		12.90	<	9.30	<
TSH	0.1-5 (UU/ML)	21/05/92	1.30					
T4	4.5-12.5 (UG/100ML)	21/05/92	5.20					

1876

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8 Patient: 228 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date	
			Screen	
			19/09/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	14-18 (G/DL)	14/02/91	15.70	
HT	42-52 (%)	14/02/91	45.10	
RBC	4.6-5.6 (10¬6/UL)	14/02/91	5.03	
WBC	4-9 (10¬3/UL)	14/02/91	7.29	
WBC: N	40-74 (%)	14/02/91	64.10	
WBC: L	19-48 (%)	14/02/91	21.60	
WBC: E	0-7 (%)	14/02/91	4.40	
WBC: M	3.4-9 (%)	14/02/91	8.40	
WBC: B	0-1.5 (%)	14/02/91	1.50	
PLATELETS	130-400 (10¬3/UL)	14/02/91	280.00	
NA+	138-150 (MEQ/L)	14/02/91	140.00	
K+	3.5-5 (MEQ/L)	14/02/91	4.10	
CL-	98-110 (MEQ/L)	14/02/91	103.00	
Ca++	8.5-10.5 (MG/DL)	14/02/91	10.00	
PO4--	2.5-4.5 (MG/DL)	14/02/91	3.20	
SGOT	5-40 (U/L)	14/02/91	23.00	
SGPT	5-40 (U/L)	14/02/91	20.00	
GAMMA GT	6-28 (U/L)	14/02/91	13.00	
LDH	240-450 (U/L)	14/02/91	259.00	
ALK. PHOSPH.	80-300 (U/L)	14/02/91	171.00	
GLUCOSE	65-110 (MG/DL)	14/02/91	82.00	
BUN	10-20 (MG/DL)	14/02/91	17.00	
CREATININE	0.6-1.2 (MG/DL)	14/02/91	1.30	>
URIC ACID	2.5-7.5 (MG/DL)	14/02/91	5.30	
TOT BILIRUBIN	0.1-1 (MG/DL)	14/02/91	1.32	>
DIR BILIRUBIN	0.1-0.3 (MG/DL)	14/02/91	0.37	>
TOT. PROTEINS	6-8 (G/DL)	14/02/91	8.10	>
ALBUMINE	2.6-5.2 (G/DL)	14/02/91	4.90	
TOT. CHOLEST.	120-220 (MG/DL)	14/02/91	221.00	>
TRIGLYCERIDES	60-170 (MG/DL)	14/02/91	73.00	
GLOBULINS ALPHA 1	1.5-5 (%)	14/02/91	1.70	
GLOBULINS ALPHA 2	7.4-11 (%)	14/02/91	7.00	<
GLOBULINS BETA	9-14.1 (%)	14/02/91	10.10	
GLOBULINS GAMMA	13-20.1 (%)	14/02/91	19.50	
TSH	0.1-5 (UU/ML)	14/02/91	0.60	
T4	8-20 (PG/ML)	14/02/91	15.70	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max ra
< out of range (value lower than min range) > out of range (value higher than max ra
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8 Patient: 229 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			24/09/92		21/10/92		11/11/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	23/09/92	13.90		15.60		13.50	
HT	37-47 (%)	23/09/92	41.90		46.60		43.00	
RBC	4.2-5 (10¬6/UL)	23/09/92	4.54		5.33	>	4.82	
WBC	4-9 (10¬3/UL)	23/09/92	7.35		6.71		6.90	
WBC: N	40-74 (%)	23/09/92	53.20				63.00	
WBC: L	19-48 (%)	23/09/92	37.40				28.60	
WBC: E	0-7 (%)	23/09/92	3.50				2.60	
WBC: M	3.4-9 (%)	23/09/92	5.40				5.20	
WBC: B	0-1.5 (%)	23/09/92	0.50				0.70	
PLATELETS	130-400 (10¬3/UL)	23/09/92	279.00		179.00		287.00	
NA+	138-150 (MEQ/L)	23/09/92	140.00		143.00		138.00	
K+	3.5-5 (MEQ/L)	23/09/92	3.70		3.90		4.50	
CL-	98-110 (MEQ/L)	23/09/92	100.00		98.00		101.00	
Ca++	8.5-10.5 (MG/DL)	23/09/92	9.30		9.70		10.60	>
PO4--	2.5-4.5 (MG/DL)	23/09/92	3.90		2.70		5.20	>>
SGOT	5-40 (U/L)	23/09/92	21.00		17.00		23.00	
SGPT	5-40 (U/L)	23/09/92	33.00		16.00		10.00	
GAMMA GT	6-28 (U/L)	23/09/92	12.00		11.00		9.00	
LDH	240-450 (U/L)	23/09/92	271.00		196.00	<	177.00	<
ALK. PHOSPH.	80-300 (U/L)	23/09/92	179.00				199.00	
GLUCOSE	65-110 (MG/DL)	23/09/92	111.00	>			112.00	>
BUN	10-20 (MG/DL)	23/09/92	10.00		20.00		15.00	
CREATININE	0.6-1.2 (MG/DL)	23/09/92	0.80		0.90		1.10	
URIC ACID	2.5-7.5 (MG/DL)	23/09/92	5.00		4.70			
TOT BILIRUBIN	0.1-1 (MG/DL)	23/09/92	0.41		0.48		0.50	
DIR BILIRUBIN	0.1-0.3 (MG/DL)	23/09/92	0.16		0.17		0.00	<
TOT. PROTEINS	6-8 (G/DL)	23/09/92	7.30		7.70			
ALBUMINE	2.6-5.2 (G/DL)	23/09/92	4.20		4.80			
	50-67 (%)	10/11/92					58.50	
TOT. CHOLEST.	120-220 (MG/DL)	23/09/92	221.00	>	208.00		207.00	
TRIGLYCERIDES	60-170 (MG/DL)	23/09/92	212.00	>	94.00		102.00	
GLOBULINS ALPHA 1	1.5-5 (%)	23/09/92	2.30		3.26		2.80	
GLOBULINS ALPHA 2	7.4-11 (%)	23/09/92	8.90		10.75		8.80	
GLOBULINS BETA	9-14.1 (%)	23/09/92	12.60		11.77		12.30	
GLOBULINS GAMMA	13-20.1 (%)	23/09/92	18.00		18.89		17.60	
TSH	0.1-5 (UU/ML)	23/09/92	0.90					
T4	4.5-12.5 (UG/100ML)	23/09/92	7.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max r
< out of range (value lower than min range) > out of range (value higher than max r
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8 Patient: 230 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			24/09/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	21/05/92	14.00	
HT	37-47 (%)	21/05/92	42.80	
RBC	4.2-5 (10¬6/UL)	21/05/92	4.74	
WBC	4-9 (10¬3/UL)	21/05/92	8.90	
WBC: N	40-74 (%)	21/05/92	67.70	
WBC: L	19-48 (%)	21/05/92	24.30	
WBC: E	0-7 (%)	21/05/92	1.50	
WBC: M	3.4-9 (%)	21/05/92	5.80	
WBC: B	0-1.5 (%)	21/05/92	0.70	
PLATELETS	130-400 (10¬3/UL)	21/05/92	369.00	
NA+	138-150 (ME/L)	21/05/92	146.00	
K+	3.5-5 (ME/L)	21/05/92	4.30	
CL-	98-110 (ME/L)	21/05/92	101.00	
Ca++	8.5-10.5 (MG/DL)	21/05/92	9.90	
PO4--	2.5-4.5 (MG/DL)	21/05/92	4.30	
SGOT	5-40 (U/L)	21/05/92	18.00	
SGPT	5-40 (U/L)	21/05/92	14.00	
GAMMA GT	6-28 (U/L)	21/05/92	13.00	
LDH	240-450 (U/L)	21/05/92	270.00	
ALK. PHOSPH.	80-300 (U/L)	21/05/92	292.00	
GLUCOSE	65-110 (MG/DL)	21/05/92	72.00	
BUN	10-20 (MG/DL)	21/05/92	10.00	
CREATININE	0.6-1.2 (MG/DL)	21/05/92	0.80	
URIC ACID	2.5-7.5 (MG/DL)	21/05/92	4.70	
TOT BILIRUBIN	0.1-1 (MG/DL)	21/05/92	0.67	
DIR BILIRUBIN	0.1-0.3 (MG/DL)	21/05/92	0.20	
TOT. PROTEINS	6-8 (G/DL)	21/05/92	7.60	
ALBUMINE	2.6-5.2 (G/DL)	21/05/92	4.80	
TOT. CHOLEST.	160-240 (MG/DL)	21/05/92	219.00	
TRIGLYCERIDES	60-170 (MG/DL)	21/05/92	137.00	
TSH	0.1-5 (UU/ML)	21/05/92	1.30	
T4	4.5-12.5 (UG/100ML)	21/05/92	9.90	

1879

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang-
< out of range (value lower than min range) > out of range (value higher than max rang-
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8 Patient: 231 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/09/92		21/10/92		11/11/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	14-18 (G/DL)	14/02/91	15.00		14.40		14.40	
HT	42-52 (%)	14/02/91	44.20		42.60		43.30	
RBC	4.6-5.6 (10¬6/UL)	14/02/91	4.95		4.58	<	4.60	
WBC	4-9 (10¬3/UL)	14/02/91	7.75		5.41		12.25	>>
WBC: N	40-74 (%)	14/02/91	59.60		57.50		59.80	
WBC: L	19-48 (%)	14/02/91	33.30		33.10		31.40	
WBC: E	0-7 (%)	14/02/91	1.70		1.60		1.40	
WBC: M	3.4-9 (%)	14/02/91	4.90		6.80		6.40	
WBC: B	0-1.5 (%)	14/02/91	0.50		0.90		1.00	
PLATELETS	130-400 (10¬3/UL)	14/02/91	303.00		183.00		226.00	
NA+	138-150 (MEQ/L)	14/02/91	140.00		145.00		143.00	
K+	3.5-5 (MEQ/L)	14/02/91	4.50		3.90		4.20	
CL-	98-110 (MEQ/L)	14/02/91	99.00		101.00		103.00	
Ca++	8.5-10.5 (MG/DL)	14/02/91	9.80				8.60	
PO4--	2.5-4.5 (MG/DL)	14/02/91	3.40				3.10	
SGOT	5-40 (U/L)	14/02/91	29.00		24.00		19.00	
SGPT	5-40 (U/L)	14/02/91	40.00		34.00		18.00	
GAMMA GT	6-28 (U/L)	14/02/91	23.00		9.00		10.00	
LDH	240-450 (U/L)	14/02/91	318.00				242.00	
ALK. PHOSPH.	80-300 (U/L)	14/02/91	220.00		136.00		193.00	
GLUCOSE	65-110 (MG/DL)	14/02/91	93.00		67.00		71.00	
BUN	10-20 (MG/DL)	14/02/91	13.00		19.00		19.00	
CREATININE	0.6-1.2 (MG/DL)	14/02/91	1.00		1.10		1.00	
URIC ACID	2.5-7.5 (MG/DL)	14/02/91	4.50		3.40		5.70	
TOT BILIRUBIN	0.1-1 (MG/DL)	14/02/91	1.02	>	0.88		0.52	
DIR BILIRUBIN	0.1-0.3 (MG/DL)	14/02/91	0.34	>	0.28		0.19	
TOT. PROTEINS	6-8 (G/DL)	14/02/91	8.00		7.40		6.80	
ALBUMINE	2.6-5.2 (G/DL)	14/02/91	5.00		4.50		4.80	
TOT. CHOLEST.	120-220 (MG/DL)	14/02/91	201.00		207.00		181.00	
TRIGLYCERIDES	60-170 (MG/DL)	14/02/91	146.00		101.00		163.00	
GLOBULINS ALPHA 1	1.5-5 (%)	14/02/91	2.00				2.90	
GLOBULINS ALPHA 2	7.4-11 (%)	14/02/91	8.40				8.50	
GLOBULINS BETA	9-14.1 (%)	14/02/91	11.30				12.40	
GLOBULINS GAMMA	13-20.1 (%)	14/02/91	13.00				8.90	<<
TSH	0.1-5 (UU/ML)	14/02/91	0.80					
T4	8-20 (PG/ML)	14/02/91	18.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8 Patient: 232 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/09/92		23/10/92		13/11/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	21/05/92	16.70	>	15.60		15.20	
HT	36-48 (%)	21/05/92	48.00		43.00		44.00	
RBC	3.9-5.4 (10-6/UL)	21/05/92	5.10		4.75		4.66	
WBC	4-8 (10-3/UL)	21/05/92	6.70		6.00		6.20	
WBC: N	50-80 (%)	21/05/92	65.00		64.00		62.00	
WBC: L	10-40 (%)	21/05/92	29.00		32.00		32.00	
WBC: E	0-4 (%)	21/05/92	2.00		1.00		2.00	
WBC: M	2-8 (%)	21/05/92	4.00		3.00		4.00	
WBC: B	0-2 (%)	21/05/92	0.00		0.00		0.00	
PLATELETS	150-400 (10-3/UL)	21/05/92	177.00		180.00		170.00	
NA+	135-148 (MEQ/L)	21/05/92	143.00		140.00		146.00	
K+	3.5-5 (MEQ/L)	21/05/92	4.50		5.30	>	5.20	>
CL-	98-108 (MEQ/L)	21/05/92	104.00		103.00		106.00	
Ca++	8.5-10.5 (MG/DL)	21/05/92	9.20		9.50		9.50	
PO4--	2.5-4.5 (MG/DL)	21/05/92	3.50		3.20		3.40	
SGOT	1-40 (U/L)	21/05/92	32.00		25.00		18.00	
SGPT	1-40 (U/L)	21/05/92	27.00		19.00		17.00	
GAMMA GT	1-18 (U/L)	21/05/92	15.00		8.00		8.00	
LDH	360-460 (U/L)	21/05/92	300.00	<	252.00	<	310.00	<
ALK. PHOSPH.	70-210 (U/L)	21/05/92	161.00		184.00		154.00	
GLUCOSE	50-100 (MG/DL)	21/05/92	85.00		85.00		80.00	
BUN	7-25 (MG/DL)	21/05/92	16.00		22.00		46.00	>>
CREATININE	0.7-1.3 (MG/DL)	21/05/92	1.10		1.10		1.10	
URIC ACID	3-7 (MG/DL)	21/05/92	6.80		6.20		5.70	
TOT BILIRUBIN	0.3-1.1 (MG/DL)	21/05/92	1.27	>	0.69		0.73	
DIR BILIRUBIN	0.05-0.2 (MG/DL)	21/05/92	0.68	>>	0.11		0.13	
TOT. PROTEINS	6.5-8.4 (MG/DL)	21/05/92	7.90		8.00		7.60	
ALBUMINE	55-65 (%)	21/05/92	58.00		55.00		56.00	
TOT. CHOLEST.	160-240 (MG/DL)	21/05/92	278.00	>	230.00		234.00	
TRIGLYCERIDES	50-160 (MG/DL)	21/05/92	209.00	>>	145.00		201.00	>
GLOBULINS ALPHA 1	2-5 (%)	21/05/92	4.00		4.00		4.00	
GLOBULINS ALPHA 2	7-12 (%)	21/05/92	8.00		10.00		11.00	
GLOBULINS BETA	8-14 (%)	21/05/92	13.00		10.00		10.00	
GLOBULINS GAMMA	12-20 (%)	21/05/92	17.00		21.00	>	19.00	
TSH	0.5-5 (UU/ML)	21/05/92	1.70					
T4	4.5-11 (UG/100ML)	21/05/92	11.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8 Patient: 233 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			28/09/92		28/10/92		18/11/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	21/05/92	11.70		12.00		11.90	
HT	36-48 (%)	21/05/92	35.00	<	36.00		35.00	<
RBC	3.9-5.4 (10¬6/UL)	21/05/92	4.02		4.02		4.02	
WBC	4-8 (10¬3/UL)	21/05/92	5.30		5.50		8.50	>
WBC: N	50-80 (%)	21/05/92	65.00		63.00		69.00	
WBC: L	10-40 (%)	21/05/92	32.00		31.00		27.00	
WBC: E	0-4 (%)	21/05/92	2.00		1.00		1.00	
WBC: M	2-8 (%)	21/05/92	1.00	<	5.00		3.00	
WBC: B	0-2 (%)	21/05/92	0.00		0.00		0.00	
PLATELETS	150-400 (10¬3/UL)	21/05/92	227.00		226.00		350.00	
NA+	135-148 (MEQ/L)	21/05/92	142.00		143.00		144.00	
K+	3.5-5 (MEQ/L)	21/05/92	4.80		5.50	>	3.70	
CL-	98-108 (MEQ/L)	21/05/92	103.00		96.00	<	102.00	
Ca++	8.5-10.5 (MG/DL)	21/05/92	9.10		9.20		9.50	
PO4--	2.5-4.5 (MG/DL)	21/05/92	3.20		2.90		3.40	
SGOT	1-40 (U/L)	21/05/92	22.00		20.00		32.00	
SGPT	1-40 (U/L)	21/05/92	13.00		13.00		21.00	
GAMMA GT	1-18 (U/L)	21/05/92	6.00		6.00		7.00	
LDH	360-460 (U/L)	21/05/92	300.00	<	261.00	<	252.00	<
ALK. PHOSPH.	70-210 (U/L)	21/05/92	193.00		153.00		144.00	
GLUCOSE	50-100 (MG/DL)	21/05/92	84.00		90.00		90.00	
BUN	7-25 (MG/DL)	21/05/92	11.00		10.00		9.00	
CREATININE	0.7-1.3 (MG/DL)	21/05/92	0.80		0.60	<	0.70	
URIC ACID	3-7 (MG/DL)	21/05/92	4.30		4.00		2.80	<
TOT BILIRUBIN	0.3-1.1 (MG/DL)	21/05/92	0.65		0.65		0.54	
DIR BILIRUBIN	0.05-0.2 (MG/DL)	21/05/92	0.11		0.11		0.10	
TOT. PROTEINS	6.5-8.4 (MG/DL)	21/05/92	7.30		7.70		7.90	
ALBUMINE	55-65 (%)	21/05/92	51.00	<	45.00	<	48.00	<
TOT. CHOLEST.	160-240 (MG/DL)	21/05/92	170.00		216.00		196.00	
TRIGLYCERIDES	50-160 (MG/DL)	21/05/92	74.00		93.00		131.00	
GLOBULINS ALPHA 1	2-5 (%)	21/05/92	3.00		4.00		5.00	
GLOBULINS ALPHA 2	7-12 (%)	21/05/92	9.00		11.00		10.00	
GLOBULINS BETA	8-14 (%)	21/05/92	11.00		10.00		10.00	
GLOBULINS GAMMA	12-20 (%)	21/05/92	26.00	>	30.00	>>	27.00	>>
TSH	0.5-5 (UU/ML)	21/05/92	0.80					
T4	4.5-11 (UG/100ML)	21/05/92	10.20					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 8 Patient: 234 Treatment: Placebo Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			30/09/92		28/10/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11-16 (G/DL)	21/05/92	13.50		13.70	
HT	36-48 (%)	21/05/92	40.00		40.00	
RBC	3.9-5.4 (10-6/UL)	21/05/92	4.36		4.42	
WBC	4-8 (10-3/UL)	21/05/92	7.80		6.90	
WBC: N	50-80 (%)	21/05/92	68.00		63.00	
WBC: L	10-40 (%)	21/05/92	27.00		32.00	
WBC: E	0-4 (%)	21/05/92	2.00		2.00	
WBC: M	2-8 (%)	21/05/92	2.00		3.00	
WBC: B	0-2 (%)	21/05/92	1.00		0.00	
PLATELETS	150-400 (10-3/UL)	21/05/92	260.00		260.00	
NA+	135-148 (MEQ/L)	21/05/92	142.00		140.00	
K+	3.5-5 (MEQ/L)	21/05/92	4.70		5.30	>
CL-	98-108 (MEQ/L)	21/05/92	107.00		101.00	
Ca++	8.5-10.5 (MG/DL)	21/05/92	8.90		9.10	
PO4--	2.5-4.5 (MG/DL)	21/05/92	2.90		4.30	
SGOT	1-40 (U/L)	21/05/92	28.00		38.00	
SGPT	1-40 (U/L)	21/05/92	17.00		17.00	
GAMMA GT	1-18 (U/L)	21/05/92	21.00	>	22.00	>
LDH	360-460 (U/L)	21/05/92	261.00	<	281.00	<
ALK. PHOSPH.	70-210 (U/L)	21/05/92	189.00		171.00	
GLUCOSE	50-100 (MG/DL)	21/05/92	73.00		69.00	
BUN	7-25 (MG/DL)	21/05/92	16.00		16.00	
UREA	()	21/05/92				
CREATININE	0.7-1.3 (MG/DL)	21/05/92	1.00		1.10	
URIC ACID	3-7 (MG/DL)	21/05/92	4.70		4.70	
TOT BILIRUBIN	0.3-1.1 (MG/DL)	21/05/92	0.54		0.58	
DIR BILIRUBIN	0.05-0.2 (MG/DL)	21/05/92	0.10		0.10	
TOT. PROTEINS	6.5-8.4 (MG/DL)	21/05/92	8.10		8.00	
ALBUMINE	55-65 (%)	21/05/92	58.00		59.00	
TOT. CHOLEST.	160-240 (MG/DL)	21/05/92	235.00		260.00	>
TRIGLYCERIDES	50-160 (MG/DL)	21/05/92	155.00		222.00	>>
GLOBULINS ALPHA 1	2-5 (%)	21/05/92	4.00		4.00	
GLOBULINS ALPHA 2	7-12 (%)	21/05/92	10.00		9.00	
GLOBULINS BETA	8-14 (%)	21/05/92	11.00		10.00	
GLOBULINS GAMMA	12-20 (%)	21/05/92	17.00		18.00	
TSH	0.5-5 (UU/ML)	21/05/92	1.10			
T4	4.5-11 (UG/100ML)	21/05/92	7.30			

1883

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8/A Patient: 235 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/09/92		03/11/92		24/11/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-18 (G/DL)	01/09/92	15.50		14.00		15.00	
RBC	3500000-5600000 (/UL)	01/09/92	4570000		4600000		4590000	
WBC	4000-10000 (/UL)	01/09/92	7100.00		6800.00		7600.00	
WBC: N	50-70 (%)	01/09/92	54.00		70.00		63.00	
WBC: L	20-30 (%)	01/09/92	44.00	>>	30.00		37.00	>
WBC: E	0-1 (%)	01/09/92	0.00		0.00		0.00	
WBC: M	0-1 (%)	01/09/92	2.00	>>	0.00		0.00	
WBC: B	0-1 (%)	01/09/92	0.00		0.00		0.00	
NA+	135-150 (MEQ/L)	01/09/92	145.00		140.00		140.00	
K+	3.6-5.5 (MEQ/L)	01/09/92	5.10		4.00		4.40	
CL-	98-115 (MEQ/L)	01/09/92	111.00					
PO4--	2-6.8 (MEQ/L)	01/09/92	3.20		3.60		4.90	
SGOT	5-24 (U/L)	01/09/92	20.00		18.00		18.00	
SGPT	5-22 (U/L)	01/09/92	22.00		24.00	>	21.00	
ALK. PHOSPH.	72-244 (MU/ML)	01/09/92	237.00		220.00		218.00	
GLUCOSE	0.76-1.1 (MG/DL)	01/09/92	0.92		0.98		0.97	
BUN	0.22-0.6 (MG/DL)	01/09/92	0.43		0.45		0.47	
CREATININE	0.5-0.9 (MG/DL)	01/09/92	0.80		0.86		0.82	
URIC ACID	2-6 (MG/DL)	01/09/92	5.00		5.20		4.80	
TOT BILIRUBIN	0.25-1 (MG/DL)	01/09/92	0.57		0.70		0.68	
DIR BILIRUBIN	0.1-0.25 (MG/DL)	01/09/92	0.16		0.20		0.17	
TOT. PROTEINS	6.5-8 (MG/DL)	01/09/92			7.00		7.20	
ALBUMINE	50-64 (%)	01/09/92	56.90		56.10		57.70	
TOT. CHOLEST.	130-250 (MG/DL)	01/09/92	241.00		248.00		237.00	
TRIGLYCERIDES	70-172 (MG/DL)	01/09/92	142.00		130.00		118.00	
GLOBULINS ALPHA 1	2-4 (%)	01/09/92	3.00		3.90		4.70	>
GLOBULINS ALPHA 2	6-10 (%)	01/09/92	7.40		10.90	>	8.80	
GLOBULINS BETA	8-12 (%)	01/09/92	9.20		12.60	>	10.20	
GLOBULINS GAMMA	14-22 (%)	01/09/92	23.50	>	16.50		18.60	
TSH	0.35-7 (MU/ML)	01/09/92	2.20					
T4	5-10.6 (UG%)	01/09/92	9.10					

1884

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 8/A Patient: 236 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/09/92		03/11/92		24/11/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/09/92	12.10		12.00		12.00	
RBC	3500000-5600000 (/UL)	01/09/92	5990000	>	5400000		5900000	>
WBC	4000-10000 (/UL)	01/09/92	9300.00		8800.00		8700.00	
WBC: N	50-70 (%)	01/09/92	68.00		65.00		74.00	>
WBC: L	20-30 (%)	01/09/92	30.00		35.00	>	26.00	
WBC: E	0-1 (%)	01/09/92	0.00		0.00		0.00	
WBC: M	0-1 (%)	01/09/92	2.00	>>	0.00		0.00	
WBC: B	0-1 (%)	01/09/92	0.00		0.00		0.00	
NA+	135-150 (MEQ/L)	01/09/92	142.00		140.00		144.00	
K+	3.6-5.5 (MEQ/L)	01/09/92	4.40		3.80		3.90	
CL-	98-115 (MEQ/L)	01/09/92	110.00					
PO4--	2-6.8 (MEQ/L)	01/09/92			3.00		3.60	
SGOT	5-24 (U/L)	01/09/92	12.00		17.00		13.20	
SGPT	5-22 (U/L)	01/09/92	17.00		18.00		15.70	
ALK. PHOSPH.	72-244 (MU/ML)	01/09/92	124.00		117.00		177.00	
GLUCOSE	0.76-1.1 (MG/DL)	01/09/92	0.76		0.88		0.82	
BUN	0.22-0.6 (MG/DL)	01/09/92	0.25		0.27		0.31	
CREATININE	0.5-0.9 (MG/DL)	01/09/92	0.80		0.84		0.78	
URIC ACID	2-6 (MG/DL)	01/09/92	5.00		4.40		4.00	
TOT BILIRUBIN	0.25-1 (MG/DL)	01/09/92	0.71		0.70		0.74	
DIR BILIRUBIN	0.1-0.25 (MG/DL)	01/09/92	0.16		0.15		0.17	
TOT. PROTEINS	6.5-8 (MG/DL)	01/09/92	7.40		7.30		7.20	
ALBUMINE	50-64 (%)	01/09/92	60.97		56.30		62.09	
TOT. CHOLEST.	130-250 (MG/DL)	01/09/92	201.00		210.00		198.00	
TRIGLYCERIDES	70-172 (MG/DL)	01/09/92	112.00		110.00		96.00	
GLOBULINS ALPHA 1	2-4 (%)	01/09/92	3.90		3.70		3.70	
GLOBULINS ALPHA 2	6-10 (%)	01/09/92	8.09		9.90		6.40	
GLOBULINS BETA	8-12 (%)	01/09/92	14.09	>	11.60		10.80	
GLOBULINS GAMMA	14-22 (%)	01/09/92	12.95	<	18.50		17.20	
TSH	0.35-7 (MU/ML)	01/09/92	2.10					
T4	5-10.6 (UG%)	01/09/92	7.90					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8/A Patient: 237 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/09/92		03/11/92		24/11/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/09/92	14.40		14.00		14.80	
RBC	3500000-5600000 (/UL)	01/09/92	5000000		4800000		4880000	
WBC	4000-10000 (/UL)	01/09/92	5100.00		4600.00		5600.00	
WBC: N	50-70 (%)	01/09/92	56.00		74.00	>	57.00	
WBC: L	20-30 (%)	01/09/92	42.00	>>	26.00		40.00	>>
WBC: E	0-1 (%)	01/09/92	0.00		0.00		0.00	
WBC: M	0-1 (%)	01/09/92	2.00	>>	0.00		3.00	>>
WBC: B	0-1 (%)	01/09/92	0.00		0.00		0.00	
NA+	135-150 (MEQ/L)	01/09/92	142.00		143.00		144.00	
K+	3.6-5.5 (MEQ/L)	01/09/92	4.20		4.00		4.30	
PO4--	2-6.8 (MEQ/L)	01/09/92	3.40		3.90		4.00	
SGOT	5-24 (U/L)	01/09/92	20.00		28.20	>	22.00	
SGPT	5-22 (U/L)	01/09/92	29.00	>	32.50	>	29.00	>
ALK. PHOSPH.	72-244 (MU/ML)	01/09/92	179.00		188.00		213.00	
GLUCOSE	0.76-1.1 (MG/DL)	01/09/92	0.86		0.90		0.90	
BUN	0.22-0.6 (MG/DL)	01/09/92	0.24		0.32		0.30	
CREATININE	0.5-0.9 (MG/DL)	01/09/92	0.70		0.76		0.69	
URIC ACID	2-6 (MG/DL)	01/09/92	4.00		4.80		4.40	
TOT BILIRUBIN	0.25-1 (MG/DL)	01/09/92	0.50		0.55		0.57	
DIR BILIRUBIN	0.1-0.25 (MG/DL)	01/09/92	0.15		0.20		0.12	
TOT. PROTEINS	6.5-8 (MG/DL)	01/09/92	7.60		7.00		7.70	
ALBUMINE	50-64 (%)	01/09/92	60.47		54.70		62.30	
TOT. CHOLEST.	130-250 (MG/DL)	01/09/92	314.00	>	298.00	>	288.00	>
TRIGLYCERIDES	70-172 (MG/DL)	01/09/92	158.00		144.00		155.00	
GLOBULINS ALPHA 1	2-4 (%)	01/09/92	4.16	>	4.00		2.70	
GLOBULINS ALPHA 2	6-10 (%)	01/09/92	8.57		9.60		8.00	
GLOBULINS BETA	8-12 (%)	01/09/92	14.79	>	16.20	>>	11.60	
GLOBULINS GAMMA	14-22 (%)	01/09/92	12.01	<	15.50		15.40	
TSH	0.35-7 (MU/ML)	01/09/92	1.48					
T4	5-10.6 (UG%)	01/09/92	9.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 8/A Patient: 238 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/09/92		03/11/92		24/11/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/09/92	13.00		12.00		13.10	
RBC	3500000-5600000 (/UL)	01/09/92	3980000		3700000		4000000	
WBC	4000-10000 (/UL)	01/09/92	6000.00		6600.00		6700.00	
WBC: N	50-70 (%)	01/09/92	60.00		67.00		75.00	>
WBC: L	20-30 (%)	01/09/92	38.00	>	33.00	>	25.00	
WBC: E	0-1 (%)	01/09/92	0.00		0.00		0.00	
WBC: M	0-1 (%)	01/09/92	2.00	>>	0.00		0.00	
WBC: B	0-1 (%)	01/09/92	0.00		0.00		0.00	
NA+	135-150 (MEQ/L)	01/09/92	144.00		144.00		140.00	
K+	3.6-5.5 (MEQ/L)	01/09/92	4.50		4.20		4.40	
CL-	98-115 (MEQ/L)	01/09/92	114.00					
PO4--	2-6.8 (MEQ/L)	01/09/92	3.70		3.90		3.90	
SGOT	5-24 (U/L)	01/09/92	19.00		18.00		13.00	
SGPT	5-22 (U/L)	01/09/92	21.00		21.00		15.00	
ALK. PHOSPH.	72-244 (MU/ML)	01/09/92	194.00		177.00		188.00	
GLUCOSE	0.76-1.1 (MG/DL)	01/09/92	0.94		0.95		0.95	
BUN	0.22-0.6 (MG/DL)	01/09/92	0.39		0.40		0.41	
CREATININE	0.5-0.9 (MG/DL)	01/09/92	0.90		0.92	>	0.82	
URIC ACID	2-6 (MG/DL)	01/09/92	6.00		6.30	>	5.50	
TOT BILIRUBIN	0.25-1 (MG/DL)	01/09/92	0.75		0.76		0.79	
DIR BILIRUBIN	0.1-0.25 (MG/DL)	01/09/92	0.18		0.16		0.20	
TOT. PROTEINS	6.5-8 (MG/DL)	01/09/92	6.30	<	6.50		7.00	
ALBUMINE	50-64 (%)	01/09/92	59.37		59.70		59.70	
TOT. CHOLEST.	130-250 (MG/DL)	01/09/92	168.00		176.00		176.00	
TRIGLYCERIDES	70-172 (MG/DL)	01/09/92	223.00	>	226.00	>>	165.00	
GLOBULINS ALPHA 1	2-4 (%)	01/09/92	4.11	>	2.40		2.40	
GLOBULINS ALPHA 2	6-10 (%)	01/09/92	8.72		7.50		7.50	
GLOBULINS BETA	8-12 (%)	01/09/92	17.00	>>	8.40		10.40	
GLOBULINS GAMMA	14-22 (%)	01/09/92	10.80	<	22.00		20.00	
TSH	0.35-7 (MU/ML)	01/09/92	0.78					
T4	5-10.6 (UGX)	01/09/92	8.50					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 8/A Patient: 239 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/09/92		05/11/92		26/11/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/09/92	13.50		13.00		13.20	
RBC	3500000-5600000 (/UL)	01/09/92	4450000		4400000		4550000	
WBC	4000-10000 (/UL)	01/09/92	6500.00		6900.00		7300.00	
WBC: N	50-70 (%)	01/09/92	66.00		76.00	>	75.00	>
WBC: L	20-30 (%)	01/09/92	34.00	>	24.00		25.00	
WBC: E	0-1 (%)	01/09/92	0.00		0.00		0.00	
WBC: M	0-1 (%)	01/09/92	0.00		0.00		0.00	
WBC: B	0-1 (%)	01/09/92	0.00		0.00		0.00	
NA+	135-150 (MEQ/L)	01/09/92	138.00		144.00		143.00	
K+	3.6-5.5 (MEQ/L)	01/09/92	4.60		4.10		4.50	
PO4--	2-6.8 (MEQ/L)	01/09/92	3.90		6.00		6.00	
SGOT	5-24 (U/L)	01/09/92	12.00		11.00		12.00	
SGPT	5-22 (U/L)	01/09/92	16.00		16.00		15.00	
ALK. PHOSPH.	72-244 (MU/ML)	01/09/92	117.00		203.00		188.00	
GLUCOSE	0.76-1.1 (MG/DL)	01/09/92	0.98		0.94		0.90	
BUN	0.22-0.6 (MG/DL)	01/09/92	0.41		0.38		0.35	
CREATININE	0.5-0.9 (MG/DL)	01/09/92	0.76		0.73		0.70	
URIC ACID	2-6 (MG/DL)	01/09/92	4.00		4.00		3.50	
TOT BILIRUBIN	0.25-1 (MG/DL)	01/09/92	0.70		0.62		0.70	
DIR BILIRUBIN	0.1-0.25 (MG/DL)	01/09/92	0.12		0.13		0.14	
TOT. PROTEINS	6.5-8 (MG/DL)	01/09/92	6.90		7.10		6.80	
ALBUMINE	50-64 (%)	01/09/92	56.30		58.10		56.20	
TOT. CHOLEST.	130-250 (MG/DL)	01/09/92	213.00		198.00		196.00	
TRIGLYCERIDES	70-172 (MG/DL)	01/09/92	117.00		103.00		90.00	
GLOBULINS ALPHA 1	2-4 (%)	01/09/92	3.70		4.70	>	4.50	>
GLOBULINS ALPHA 2	6-10 (%)	01/09/92	10.90	>	7.30		11.60	>
GLOBULINS BETA	8-12 (%)	01/09/92	11.60		12.40	>	13.50	>
GLOBULINS GAMMA	14-22 (%)	01/09/92	17.50		17.50		14.20	
TSH	0.35-7 (MU/ML)	01/09/92	1.90					
T4	5-10.6 (UG%)	01/09/92	7.40					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D*

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8/A Patient: 240 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/09/92		05/11/92		26/11/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/09/92	13.00		13.00		13.70	
RBC	3500000-5600000 (/UL)	01/09/92	4220000		4330000		4440000	
WBC	4000-10000 (/UL)	01/09/92	5700.00		4800.00		5400.00	
WBC: N	50-70 (%)	01/09/92	61.00		63.00		64.00	
WBC: L	20-30 (%)	01/09/92	36.00	>	35.00	>	36.00	>
WBC: E	0-1 (%)	01/09/92	0.00		0.00		0.00	
WBC: M	0-1 (%)	01/09/92	0.00		2.00	>>	0.00	
WBC: B	0-1 (%)	01/09/92	0.00		0.00		0.00	
NA+	135-150 (MEQ/L)	01/09/92	143.00		138.00		139.00	
K+	3.6-5.5 (MEQ/L)	01/09/92	3.60		4.30		4.30	
PO4--	2-6.8 (MEQ/L)	01/09/92	4.50		5.30		5.00	
SGOT	5-24 (U/L)	01/09/92	16.00		14.00		12.00	
SGPT	5-22 (U/L)	01/09/92	19.00		17.00		11.00	
ALK. PHOSPH.	72-244 (MU/ML)	01/09/92	123.00		177.00		155.00	
GLUCOSE	0.76-1.1 (MG/DL)	01/09/92	0.78		0.84		0.87	
BUN	0.22-0.6 (MG/DL)	01/09/92	0.26		0.28		0.32	
CREATININE	0.5-0.9 (MG/DL)	01/09/92	0.71		0.76		0.68	
URIC ACID	2-6 (MG/DL)	01/09/92	4.50		5.00		4.70	
TOT BILIRUBIN	0.25-1 (MG/DL)	01/09/92	0.58		0.63		0.65	
DIR BILIRUBIN	0.1-0.25 (MG/DL)	01/09/92	0.10		0.14		0.15	
TOT. PROTEINS	6.5-8 (MG/DL)	01/09/92	6.60		7.10		6.90	
ALBUMINE	50-64 (%)	01/09/92	63.30		54.10		53.10	
TOT. CHOLEST.	130-250 (MG/DL)	01/09/92	178.00		194.00		190.00	
TRIGLYCERIDES	70-172 (MG/DL)	01/09/92	110.00		116.00		94.00	
GLOBULINS ALPHA 1	2-4 (%)	01/09/92	3.70		3.90		3.70	
GLOBULINS ALPHA 2	6-10 (%)	01/09/92	8.80		10.30	>	9.90	
GLOBULINS BETA	8-12 (%)	01/09/92	9.40		10.90		12.30	>
GLOBULINS GAMMA	14-22 (%)	01/09/92	14.80		20.80		21.00	
TSH	0.35-7 (MU/ML)	01/09/92	0.95					
T4	5-10.6 (UG%)	01/09/92	8.50					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8/A Patient: 553 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			23/09/92		05/11/92		26/11/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/09/92	12.80		13.00		13.60	
RBC	3500000-5600000 (/UL)	01/09/92	4300000		4410000		4620000	
WBC	4000-10000 (/UL)	01/09/92	4200.00		4600.00		5400.00	
WBC: N	50-70 (%)	01/09/92	67.00		76.00	>	76.00	>
WBC: L	20-30 (%)	01/09/92	33.00	>	24.00		24.00	
WBC: E	0-1 (%)	01/09/92	0.00		0.00		0.00	
WBC: M	0-1 (%)	01/09/92	0.00		0.00		0.00	
WBC: B	0-1 (%)	01/09/92	0.00		0.00		0.00	
NA+	135-150 (MEQ/L)	01/09/92	144.00		140.00		142.00	
K+	3.6-5.5 (MEQ/L)	01/09/92	4.10		4.30		4.40	
PO4--	2-6.8 (MEQ/L)	01/09/92	4.20		3.80		4.70	
SGOT	5-24 (U/L)	01/09/92	15.70		14.00		13.30	
SGPT	5-22 (U/L)	01/09/92	18.20		16.00		17.10	
ALK. PHOSPH.	72-244 (MU/ML)	01/09/92	177.30		172.30		177.00	
GLUCOSE	0.76-1.1 (MG/DL)	01/09/92	1.16	>	1.17	>	1.19	>
BUN	0.22-0.6 (MG/DL)	01/09/92	0.34		0.38		0.38	
CREATININE	0.5-0.9 (MG/DL)	01/09/92	0.63		0.72		0.74	
URIC ACID	2-6 (MG/DL)	01/09/92	4.20		6.00		5.50	
TOT BILIRUBIN	0.25-1 (MG/DL)	01/09/92	0.62		0.80		0.76	
DIR BILIRUBIN	0.1-0.25 (MG/DL)	01/09/92	0.18		0.18		0.20	
TOT. PROTEINS	6.5-8 (MG/DL)	01/09/92	7.00		7.20		7.00	
ALBUMINE	50-64 (%)	01/09/92	58.20		62.30		61.30	
TOT. CHOLEST.	130-250 (MG/DL)	01/09/92	206.00		210.00		206.00	
TRIGLYCERIDES	70-172 (MG/DL)	01/09/92	142.00		148.00		116.00	
GLOBULINS ALPHA 1	2-4 (%)	01/09/92	3.00		2.70		3.40	
GLOBULINS ALPHA 2	6-10 (%)	01/09/92	10.40	>	8.00		9.50	
GLOBULINS BETA	8-12 (%)	01/09/92	10.60		10.60		11.20	
GLOBULINS GAMMA	14-22 (%)	01/09/92	17.80		16.40		14.60	
TSH	0.35-7 (MU/ML)	01/09/92	2.20					
T4	5-10.6 (UG%)	01/09/92	8.80					

1890

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 8/A Patient: 554 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/09/92		05/11/92		26/11/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-18 (G/DL)	01/09/92	14.00		14.00		13.80	
RBC	4500000-6500000 (/UL)	01/09/92	4600000		4770000		4800000	
WBC	4000-10000 (/UL)	01/09/92	6400.00		6200.00		5400.00	
WBC: N	50-70 (%)	01/09/92	61.00		74.00	>	70.00	
WBC: L	20-30 (%)	01/09/92	35.00	>	26.00		28.00	
WBC: E	0-1 (%)	01/09/92	3.00	>>	0.00		0.00	
WBC: M	0-1 (%)	01/09/92	1.00		0.00		2.00	>>
WBC: B	0-1 (%)	01/09/92	0.00		0.00		0.00	
NA+	135-150 (MEQ/L)	01/09/92	141.00		138.00		140.00	
K+	3.6-5.5 (MEQ/L)	01/09/92	3.90		4.30		4.00	
PO4--	2-6.8 (MEQ/L)	01/09/92	4.10		4.10		4.50	
SGOT	5-29 (U/L)	01/09/92	16.00		14.00		12.00	
SGPT	5-27 (U/L)	01/09/92	9.00		16.00		15.00	
ALK. PHOSPH.	72-244 (MU/ML)	01/09/92	144.00		188.00		203.00	
GLUCOSE	0.76-1.1 (MG/DL)	01/09/92	1.48	>>	1.51	>>	1.41	>
BUN	0.22-0.6 (MG/DL)	01/09/92	0.43		0.40		0.38	
CREATININE	0.9-1.4 (MG/DL)	01/09/92	0.74	<	0.75	<	0.73	<
URIC ACID	3-7 (MG/DL)	01/09/92	4.00		4.20		4.40	
TOT BILIRUBIN	0.25-1 (MG/DL)	01/09/92	0.78		0.82		0.76	
DIR BILIRUBIN	0.1-0.25 (MG/DL)	01/09/92	0.18		0.12		0.14	
TOT. PROTEINS	6.5-8 (MG/DL)	01/09/92	7.80		7.20		7.10	
ALBUMINE	50-64 (%)	01/09/92	66.10	>	53.60		53.20	
TOT. CHOLEST.	130-250 (MG/DL)	01/09/92	233.00		244.00		240.00	
TRIGLYCERIDES	70-172 (MG/DL)	01/09/92	165.00		170.00		165.00	
GLOBULINS ALPHA 1	2-4 (%)	01/09/92	2.90		2.80		4.00	
GLOBULINS ALPHA 2	6-10 (%)	01/09/92	7.60		8.30		9.70	
GLOBULINS BETA	8-12 (%)	01/09/92	10.40		12.90	>	11.20	
GLOBULINS GAMMA	14-22 (%)	01/09/92	13.00	<	19.70		21.90	
TSH	0.35-7 (MU/ML)	01/09/92	1.70					
T4	5-10.6 (UG%)	01/09/92	7.80					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 8/A Patient: 555 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/09/92		05/11/92		26/11/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/09/92	13.00		13.00		14.00	
RBC	3500000-5600000 (/UL)	01/09/92	4550000		4420000		4900000	
WBC	4000-10000 (/UL)	01/09/92	6900.00		6400.00		6500.00	
WBC: N	50-70 (%)	01/09/92	70.00		66.00		70.00	
WBC: L	20-30 (%)	01/09/92	30.00		34.00	>	30.00	
WBC: E	0-1 (%)	01/09/92	0.00		0.00		0.00	
WBC: M	0-1 (%)	01/09/92	0.00		0.00		0.00	
WBC: B	0-1 (%)	01/09/92	0.00		0.00		0.00	
NA+	135-150 (MEQ/L)	01/09/92	140.00		140.00		141.00	
K+	3.6-5.5 (MEQ/L)	01/09/92	4.30		4.20		4.40	
PO4--	2-6.8 (MEQ/L)	01/09/92	3.90		5.03		5.00	
SGOT	5-24 (U/L)	01/09/92	11.00		13.00		12.00	
SGPT	5-22 (U/L)	01/09/92	13.00		15.00		14.00	
ALK. PHOSPH.	72-244 (MU/ML)	01/09/92	199.00		177.00		169.00	
GLUCOSE	0.76-1.1 (MG/DL)	01/09/92	1.04		0.95		1.44	>>
BUN	0.22-0.6 (MG/DL)	01/09/92	0.34		0.38		0.38	
CREATININE	0.5-0.9 (MG/DL)	01/09/92	0.72		0.68		0.75	
URIC ACID	2-6 (MG/DL)	01/09/92	3.50		4.00		4.00	
TOT BILIRUBIN	0.25-1 (MG/DL)	01/09/92	0.70		0.63		0.76	
DIR BILIRUBIN	0.1-0.25 (MG/DL)	01/09/92	0.12		0.13		0.17	
TOT. PROTEINS	6.5-8 (MG/DL)	01/09/92	7.10		7.00		7.00	
ALBUMINE	50-64 (%)	01/09/92	56.80		60.20		60.20	
TOT. CHOLEST.	130-250 (MG/DL)	01/09/92	204.00		195.00		68.00	<
TRIGLYCERIDES	70-172 (MG/DL)	01/09/92	113.00		31.00	<	190.00	>
GLOBULINS ALPHA 1	2-4 (%)	01/09/92	3.10		3.80		3.90	
GLOBULINS ALPHA 2	6-10 (%)	01/09/92	7.40		9.80		9.70	
GLOBULINS BETA	8-12 (%)	01/09/92	9.20		11.20		11.00	
GLOBULINS GAMMA	14-22 (%)	01/09/92	23.50	>	15.00		15.20	
TSH	0.35-7 (MU/ML)	01/09/92	9.20	>>				
T4	5-10.6 (UG%)	01/09/92	1.70	<<				

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 8/A Patient: 556 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/09/92		05/11/92		26/11/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/09/92			13.60		13.50	
HT	()	01/09/92						
RBC	4500000-6500000 (/UL)	01/09/92			4600000		4600000	
WBC	4000-10000 (/UL)	01/09/92			6800.00		6600.00	
WBC: N	50-70 (%)	01/09/92			60.00		64.00	
WBC: L	20-30 (%)	01/09/92			40.00	>>	30.50	>
WBC: E	0-1 (%)	01/09/92			0.00		0.00	
WBC: M	0-1 (%)	01/09/92			0.00		5.60	>>
WBC: B	0-1 (%)	01/09/92			0.00		0.00	
PLATELETS	()	01/09/92						
NA+	135-150 (MEQ/L)	01/09/92	136.00		144.00		140.00	
K+	3.6-5.5 (MEQ/L)	01/09/92	4.20		4.00		3.90	
CL-	98-115 (MEQ/L)	01/09/92						
Ca++	()	01/09/92						
PO4--	2-6.8 (MEQ/L)	01/09/92	2.90		3.30		3.00	
SGOT	5-29 (U/L)	01/09/92	12.00		11.00		12.00	
SGPT	5-27 (U/L)	01/09/92	19.00		18.00		14.00	
GAMMA GT	()	01/09/92						
LDH	()	01/09/92						
ALK. PHOSPH.	72-244 (MU/ML)	01/09/92	176.00		155.00		166.00	
GLUCOSE	0.76-1.1 (MG/DL)	01/09/92	0.97		0.99		0.91	
BUN	0.22-0.6 (MG/DL)	01/09/92	0.22		0.28		0.28	
UREA	()	01/09/92						
CREATININE	0.9-1.4 (MG/DL)	01/09/92	0.70	<	0.73	<	0.71	<
URIC ACID	3-7 (MG/DL)	01/09/92	4.00		4.40		4.00	
TOT BILIRUBIN	0.25-1 (MG/DL)	01/09/92	0.65		0.66		0.68	
DIR BILIRUBIN	0.1-0.25 (MG/DL)	01/09/92	0.14		0.17		0.16	
TOT. PROTEINS	6.5-8 (MG/DL)	01/09/92	6.90		7.10		7.20	
ALBUMINE	50-64 (%)	01/09/92	58.60		61.20		60.30	
TOT. CHOLEST.	130-250 (MG/DL)	01/09/92	176.00		188.00		180.00	
TRIGLYCERIDES	70-172 (MG/DL)	01/09/92	133.00		127.00		112.00	
GLOBULINS ALPHA 1	2-4 (%)	01/09/92	3.80		4.90	>	4.70	>
GLOBULINS ALPHA 2	6-10 (%)	01/09/92	9.40		7.70		7.10	
GLOBULINS BETA	8-12 (%)	01/09/92	10.70		10.00		11.30	
GLOBULINS GAMMA	14-22 (%)	01/09/92	17.50		16.40		16.60	
TSH	0.35-7 (MU/ML)	01/09/92	1.40					
T4	5-10.6 (UG%)	01/09/92	5.20				17.70	

1893

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 9 Patient: 241 Treatment: Placebo Sex: Female

			Visit number / Laboratory date	
			Screen	
			04/02/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/02/91	13.60	
HT	37-47 (%)	01/02/91	39.90	
RBC	4.2-5.4 (10-6/UL)	01/02/91	4.27	
WBC	4.8-10.8 (10-3/UL)	01/02/91	8.60	
WBC: L	20.5-51.1 (%)	01/02/91	23.90	
WBC: M	1.7-9.3 (%)	01/02/91	4.90	
PLATELETS	130-400 (10-3/UL)	01/02/91	425.00	>
NA+	135-148 (MMOL/L)	01/02/91	143.70	
K+	3.5-5 (MMOL/L)	01/02/91	4.59	
CL-	96-108 (MMOL/L)	01/02/91	106.00	
Ca++	2.1-2.6 (MMOL/L)	01/02/91	2.58	
SGOT	5-41 (U/L)	01/02/91	13.00	
SGPT	6-55 (U/L)	01/02/91	17.00	
GAMMA GT	11-50 (U/L)	01/02/91	47.00	
LDH	200-460 (U/L)	01/02/91	303.00	
ALK. PHOSPH.	90-279 (U/L)	01/02/91	160.00	
GLUCOSE	60-105 (MG/DL)	01/02/91	88.00	
BUN	10-50 (MG/DL)	01/02/91	29.00	
CREATININE	0.5-1.15 (MG/DL)	01/02/91	0.95	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/02/91	0.84	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	01/02/91	0.03	
TOT. PROTEINS	6-8 (G/100ML)	01/02/91	7.70	
ALBUMINE	3.5-5.5 (G/100ML)	01/02/91	4.67	
TOT. CHOLEST.	125-200 (MG/DL)	01/02/91	250.00	>
TRIGLYCERIDES	35-170 (MG/DL)	01/02/91	80.00	
GLOBULINS ALPHA 1	0.2-0.4 (G/100ML)	01/02/91	0.22	
GLOBULINS ALPHA 2	0.5-0.9 (G/100ML)	01/02/91	0.63	
GLOBULINS BETA	0.6-1.1 (G/100ML)	01/02/91	0.91	
GLOBULINS GAMMA	0.7-1.7 (G/100ML)	01/02/91	1.27	
TSH	0.2-4 (UU/ML)	01/02/91	0.99	
T4	50-115 (NG/ML)	01/02/91	110.00	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 9 Patient: 242 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			12/02/91		11/03/91	
			value	(◊)	value	(◊)
Laboratory test	Range value	Range date				
HB	12-16 (G/DL)	01/02/91	13.70		13.30	
HT	37-47 (%)	01/02/91	40.20		39.00	
RBC	4.2-5.4 (10-6/UL)	01/02/91	4.30		4.25	
WBC	4.8-10.8 (10-3/UL)	01/02/91	7.20		9.50	
WBC: L	20.5-51.1 (%)	01/02/91	24.90		21.20	
WBC: M	1.7-9.3 (%)	01/02/91	2.00		4.10	
PLATELETS	130-400 (10-3/UL)	01/02/91	348.00		365.00	
NA+	135-148 (MMOL/L)	01/02/91	141.00		143.20	
K+	3.5-5 (MMOL/L)	01/02/91	4.79		4.73	
CL-	96-108 (MMOL/L)	01/02/91	105.00		107.00	
Ca++	2.1-2.6 (MMOL/L)	01/02/91			2.27	
PO4--	0.8-1.55 (MMOL/L)	01/02/91			1.26	
SGOT	5-41 (U/L)	01/02/91	13.00		14.00	
SGPT	6-55 (U/L)	01/02/91	22.00		18.00	
GAMMA GT	11-50 (U/L)	01/02/91	22.00		13.00	
LDH	200-460 (U/L)	01/02/91			279.00	
ALK. PHOSPH.	90-279 (U/L)	01/02/91	181.00		139.00	
GLUCOSE	60-105 (MG/DL)	01/02/91	107.00	>	88.00	
BUN	10-50 (MG/DL)	01/02/91	31.00		30.00	
CREATININE	0.5-1.15 (MG/DL)	01/02/91			0.76	
URIC ACID	2.5-7 (MG/DL)	01/02/91			3.90	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/02/91	0.82		0.28	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	01/02/91	0.06		0.02	
TOT. PROTEINS	6-8 (G/100ML)	01/02/91	6.80		7.00	
ALBUMINE	3.5-5.5 (G/100ML)	01/02/91	4.30		4.56	
TOT. CHOLEST.	125-200 (MG/DL)	01/02/91	272.00	>>	252.00	>
TRIGLYCERIDES	35-170 (MG/DL)	01/02/91	133.00		97.00	
GLOBULINS ALPHA 1	0.2-0.4 (G/100ML)	01/02/91	0.22		0.22	
GLOBULINS ALPHA 2	0.5-0.9 (G/100ML)	01/02/91	0.52		0.47	<
GLOBULINS BETA	0.6-1.1 (G/100ML)	01/02/91	0.80		0.74	
GLOBULINS GAMMA	0.7-1.7 (G/100ML)	01/02/91	0.95		1.01	
TSH	0.2-4 (UU/ML)	01/02/91	1.53			
T4	50-115 (NG/ML)	01/02/91	53.00			

1895

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA

Centre: 9 Patient: 243 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 14	
			15/02/91		06/03/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/DL)	23/11/90			13.40	
HT	37-47 (%)	23/11/90			37.70	
RBC	4.2-5.4 (10-6/UL)	23/11/90			4.33	
WBC	4.8-10.8 (10-3/UL)	23/11/90			6.20	
WBC: N	()	23/11/90				
WBC: L	20.5-51.1 (%)	23/11/90			41.00	
WBC: E	()	23/11/90				
WBC: M	1.7-9.3 (%)	23/11/90			4.40	
WBC: B	()	23/11/90				
PLATELETS	130-400 (10-3/UL)	23/11/90			189.00	
NA+	135-148 (MMOL/L)	23/11/90	144.80		139.80	
K+	3.5-5 (MMOL/L)	23/11/90	4.67		4.28	
CL-	96-108 (MMOL/L)	23/11/90	105.00		107.00	
Ca++	2.1-2.6 (MMOL/L)	23/11/90			1.17	<<
PO4--	0.8-1.55 (MMOL/L)	23/11/90			1.19	
SGOT	5-41 (U/L)	23/11/90	21.00		20.00	
SGPT	6-55 (U/L)	23/11/90	20.00		25.00	
GAMMA GT	11-50 (U/L)	23/11/90	12.00		13.00	
LDH	200-460 (U/L)	23/11/90	308.00		327.00	
ALK. PHOSPH.	90-279 (U/L)	23/11/90	188.00		218.00	
GLUCOSE	60-105 (MG/DL)	23/11/90	105.00		108.00	>
BUN	10-50 (MG/DL)	23/11/90	37.00		37.00	
UREA	()	23/11/90				
CREATININE	0.5-1.15 (MG/DL)	23/11/90	0.70		0.71	
URIC ACID	2.5-7 (MG/DL)	23/11/90			4.50	
TOT BILIRUBIN	0.1-1 (MG/DL)	23/11/90	0.47		0.86	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	23/11/90	0.05		0.03	
TOT. PROTEINS	6-8 (G/DL)	23/11/90	6.90		6.90	
ALBUMINE	55-69 (%)	23/11/90	64.60		67.20	
TOT. CHOLEST.	125-200 (MG/DL)	23/11/90	209.00	>	178.00	
TRIGLYCERIDES	35-170 (MG/DL)	23/11/90	111.00		72.00	
GLOBULINS ALPHA 1	2-4 (%)	23/11/90	2.80		2.70	
GLOBULINS ALPHA 2	6.5-11 (%)	23/11/90	8.00		7.00	
GLOBULINS BETA	7.5-12.5 (%)	23/11/90	12.10		11.40	
GLOBULINS GAMMA	12-24 (%)	23/11/90	12.50		11.70	<
TSH	0.2-4 (UU/ML)	23/11/90	3.04			
T4	50-115 (NG/ML)	23/11/90	105.00			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 9 Patient: 244 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			14/02/91		12/03/91	
			value	(¢)	value	(¢)
Laboratory test	Range value	Range date				
HB	12-16 (G/DL)	01/02/91	14.70		14.30	
HT	37-47 (%)	01/02/91	43.00		42.60	
RBC	4.2-5.4 (10¬6/UL)	01/02/91	5.16		5.16	
WBC	4.8-10.8 (10¬3/UL)	01/02/91	9.50		6.70	
WBC: L	20.5-51.1 (%)	01/02/91	32.80		34.90	
WBC: M	1.7-9.3 (%)	01/02/91	4.00		3.90	
PLATELETS	130-400 (10¬3/UL)	01/02/91	370.00		323.00	
NA+	135-148 (MMOL/L)	01/02/91	137.50		141.60	
K+	3.5-5 (MMOL/L)	01/02/91	4.28		4.57	
CL-	96-108 (MMOL/L)	01/02/91	102.00		110.00	>
Ca++	2.1-2.6 (MMOL/L)	01/02/91	2.34		2.29	
PO4--	0.8-1.55 (MMOL/L)	01/02/91			1.02	
SGOT	5-41 (U/L)	01/02/91	17.00		13.00	
SGPT	6-55 (U/L)	01/02/91	24.00		17.00	
GAMMA GT	11-50 (U/L)	01/02/91	29.00		21.00	
LDH	200-460 (U/L)	01/02/91	299.00		263.00	
ALK. PHOSPH.	90-279 (U/L)	01/02/91	253.00		210.00	
GLUCOSE	60-105 (MG/DL)	01/02/91	90.00		103.00	
BUN	10-50 (MG/DL)	01/02/91	34.00		38.00	
CREATININE	0.5-1.15 (MG/DL)	01/02/91	0.86		0.74	
URIC ACID	178-387 (UMOL/L)	01/02/91			184.00	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/02/91	0.59		0.24	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	01/02/91	0.07		0.02	
TOT. PROTEINS	6-8 (G/100ML)	01/02/91	7.20		6.60	
ALBUMINE	3.5-5.5 (G/100ML)	01/02/91	4.61		4.26	
TOT. CHOLEST.	125-200 (MG/DL)	01/02/91	241.00	>	225.00	>
TRIGLYCERIDES	35-170 (MG/DL)	01/02/91	155.00		184.00	>
GLOBULINS ALPHA 1	0.2-0.4 (G/100ML)	01/02/91	0.20		0.18	<
GLOBULINS ALPHA 2	0.5-0.9 (G/100ML)	01/02/91	0.60		0.53	
GLOBULINS BETA	0.6-1.1 (G/100ML)	01/02/91	0.86		0.77	
GLOBULINS GAMMA	0.7-1.7 (G/100ML)	01/02/91	0.93		0.87	
TSH	0.2-4 (UU/ML)	01/02/91	4.31	>		
T4	50-115 (NG/ML)	01/02/91	63.00			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 9 Patient: 245 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/02/91		15/03/91		05/04/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	23/11/90	12.00		12.00		12.30	
HT	37-47 (%)	23/11/90	35.30	<	35.00	<	36.00	<
RBC	4.2-5.4 (10¬6/UL)	23/11/90	4.04	<	3.99	<	4.13	<
WBC	4.8-10.8 (10¬3/UL)	23/11/90	5.70		5.20		5.60	
WBC: L	20.5-51.1 (%)	23/11/90	28.70		28.00		20.00	<
WBC: M	1.7-9.3 (%)	23/11/90	7.60		4.20		1.50	<
PLATELETS	130-400 (10¬3/UL)	23/11/90	323.00		298.00		302.00	
NA+	135-148 (MMOL/L)	23/11/90	139.60		140.00		140.20	
K+	3.5-5 (MMOL/L)	23/11/90	3.88		3.91		3.77	
CL-	96-108 (MMOL/L)	23/11/90	105.00		109.00	>	107.00	
Ca++	2.1-2.6 (MMOL/L)	23/11/90			2.30		2.45	
PO4--	0.8-1.55 (MMOL/L)	23/11/90			0.96		1.09	
SGOT	5-41 (U/L)	23/11/90	12.00		20.00		20.00	
SGPT	6-55 (U/L)	23/11/90	14.00		24.00		27.00	
GAMMA GT	11-50 (U/L)	23/11/90	13.00		15.00		15.00	
LDH	200-460 (U/L)	23/11/90			220.00		258.00	
ALK. PHOSPH.	90-279 (U/L)	23/11/90	126.00		135.00		146.00	
GLUCOSE	60-105 (MG/DL)	23/11/90	93.00		81.00		106.00	>
BUN	10-50 (MG/DL)	23/11/90	24.00		32.00		29.00	
CREATININE	0.5-1.15 (MG/DL)	23/11/90	0.51		0.53		0.59	
URIC ACID	2.5-7 (MG/DL)	23/11/90			3.00		2.70	
TOT BILIRUBIN	0.1-1 (MG/DL)	23/11/90	0.37		0.22		0.21	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	23/11/90	0.05		0.02		0.04	
TOT. PROTEINS	6-8 (G/DL)	23/11/90	7.40		7.40		8.10	>
ALBUMINE	55-69 (%)	23/11/90	61.90		61.90		59.90	
TOT. CHOLEST.	125-200 (MG/DL)	23/11/90	185.00		218.00	>	231.00	>
TRIGLYCERIDES	35-170 (MG/DL)	23/11/90	71.00		152.00		79.00	
GLOBULINS ALPHA 1	2-4 (%)	23/11/90	3.00		3.60		3.50	
GLOBULINS ALPHA 2	6.5-11 (%)	23/11/90	7.10		6.70		6.80	
GLOBULINS BETA	7.5-12.5 (%)	23/11/90	11.50		12.00		11.70	
GLOBULINS GAMMA	12-24 (%)	23/11/90	16.50		15.80		18.10	
TSH	0.2-4 (UU/ML)	23/11/90	0.99					
T4	50-115 (NG/ML)	23/11/90	114.00					

1898

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 9 Patient: 246 Treatment: Placebo Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			13/02/91		15/03/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
HB	12-16 (G/DL)	01/02/91	14.60		14.40	
HT	37-47 (%)	01/02/91	43.20		41.20	
RBC	4.2-5.4 (10¬6/UL)	01/02/91	4.85		4.78	
WBC	4.8-10.8 (10¬3/UL)	01/02/91	8.50		5.00	
WBC: L	20.5-51.1 (%)	01/02/91	18.30	<	26.00	
WBC: M	1.7-9.3 (%)	01/02/91	0.20	<	0.20	<
PLATELETS	130-400 (10¬3/UL)	01/02/91	207.00		157.00	
NA+	135-148 (MMOL/L)	01/02/91	140.80		137.10	
K+	3.5-5 (MMOL/L)	01/02/91	4.37		3.72	
CL-	96-108 (MMOL/L)	01/02/91	108.00		107.00	
Ca++	2.1-2.6 (MMOL/L)	01/02/91	2.43			
SGOT	5-41 (U/L)	01/02/91	11.00		13.00	
SGPT	6-55 (U/L)	01/02/91	19.00		19.00	
GAMMA GT	11-50 (U/L)	01/02/91	21.00		15.00	
LDH	200-460 (U/L)	01/02/91	358.00		281.00	
ALK. PHOSPH.	90-279 (U/L)	01/02/91	156.00		158.00	
GLUCOSE	60-105 (MG/DL)	01/02/91	85.00		88.00	
BUN	10-50 (MG/DL)	01/02/91	33.00		23.00	
CREATININE	0.5-1.15 (MG/DL)	01/02/91	1.26	>	0.94	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/02/91	0.48		0.42	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	01/02/91	0.04		0.04	
TOT. PROTEINS	6-8 (G/100ML)	01/02/91	7.20		6.40	
ALBUMINE	3.5-5.5 (G/100ML)	01/02/91	4.64		4.29	
TOT. CHOLEST.	125-200 (MG/DL)	01/02/91	204.00	>	195.00	
TRIGLYCERIDES	35-170 (MG/DL)	01/02/91	96.00		53.00	
GLOBULINS ALPHA 1	0.2-0.4 (G/100ML)	01/02/91	0.23		0.17	<
GLOBULINS ALPHA 2	0.5-0.9 (G/100ML)	01/02/91	0.63		0.40	<
GLOBULINS BETA	0.6-1.1 (G/100ML)	01/02/91	0.73		0.56	<
GLOBULINS GAMMA	0.7-1.7 (G/100ML)	01/02/91	0.96		0.97	
TSH	0.2-4 (UU/ML)	01/02/91	1.50			
T4	50-115 (NG/ML)	01/02/91	77.00			

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 9 Patient: 247 Treatment: Placebo Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			20/02/91		18/03/91	
			value	(◊)	value	(◊)
Laboratory test	Range value	Range date				
HB	12-16 (G/DL)	23/11/90	13.60		12.30	
HT	37-47 (%)	23/11/90	39.20		35.80	<
RBC	4.2-5.4 (10¬6/UL)	23/11/90	4.42		4.01	<
WBC	4.8-10.8 (10¬3/UL)	23/11/90	6.20		4.50	<
WBC: L	20.5-51.1 (%)	23/11/90	30.10		34.70	
WBC: M	1.7-9.3 (%)	23/11/90	7.00		6.60	
PLATELETS	130-400 (10¬3/UL)	23/11/90	309.00		283.00	
NA+	135-148 (MMOL/L)	23/11/90	144.00		141.50	
K+	3.5-5 (MMOL/L)	23/11/90	4.00		4.37	
CL-	96-108 (MMOL/L)	23/11/90	85.00	<<	111.00	>
Ca++	2.1-2.6 (MMOL/L)	23/11/90	2.27		2.37	
PO4--	0.8-1.55 (MMOL/L)	23/11/90			1.18	
SGOT	5-41 (U/L)	23/11/90	23.00		21.00	
SGPT	6-55 (U/L)	23/11/90	22.00		29.00	
GAMMA GT	11-50 (U/L)	23/11/90	24.00		19.00	
LDH	200-460 (U/L)	23/11/90	296.00		206.00	
ALK. PHOSPH.	90-279 (U/L)	23/11/90	191.00		137.00	
GLUCOSE	60-105 (MG/DL)	23/11/90	91.00		72.00	
BUN	10-50 (MG/DL)	23/11/90	14.00		9.00	<
CREATININE	0.5-1.15 (MG/DL)	23/11/90	0.76		0.58	
URIC ACID	2.5-7 (MG/DL)	23/11/90			4.60	
TOT BILIRUBIN	0.1-1 (MG/DL)	23/11/90	0.68		0.42	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	23/11/90	0.13		0.04	
TOT. PROTEINS	6-8 (G/DL)	23/11/90	6.90		6.50	
ALBUMINE	55-69 (%)	23/11/90	59.70		62.80	
TOT. CHOLEST.	125-200 (MG/DL)	23/11/90	146.00		183.00	
TRIGLYCERIDES	35-170 (MG/DL)	23/11/90	129.00		84.00	
GLOBULINS ALPHA 1	2-4 (%)	23/11/90	3.60		3.30	
GLOBULINS ALPHA 2	6.5-11 (%)	23/11/90	7.50		7.60	
GLOBULINS BETA	7.5-12.5 (%)	23/11/90	9.60		10.40	
GLOBULINS GAMMA	12-24 (%)	23/11/90	19.60		15.90	
TSH	0.2-4 (UU/ML)	23/11/90	1.71			
T4	50-115 (NG/ML)	23/11/90	81.00			

1900

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 9 Patient: 248 Treatment: Placebo Sex: Male

			Visit number / Laboratory date			
			Screen		Day 14	
			04/03/91		22/03/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	14-18 (G/DL)	23/11/90	15.70		14.80	
HT	42-52 (%)	23/11/90	45.90		42.70	
RBC	4.3-6.1 (10¬6/UL)	23/11/90	5.37		4.99	
WBC	4.8-10.8 (10¬3/UL)	23/11/90	9.80		6.60	
WBC: L	20.5-51.1 (%)	23/11/90	10.70	<<	38.60	
WBC: M	1.7-9.3 (%)	23/11/90	5.80		7.60	
PLATELETS	130-400 (10¬3/UL)	23/11/90	300.00		284.00	
NA+	135-148 (MMOL/L)	23/11/90	139.30		138.80	
K+	3.5-5 (MMOL/L)	23/11/90	4.61		4.10	
CL-	96-108 (MMOL/L)	23/11/90	104.00		103.00	
Ca++	2.1-2.6 (MMOL/L)	23/11/90			2.59	
PO4--	0.8-1.55 (MMOL/L)	23/11/90			1.25	
SGOT	5-41 (U/L)	23/11/90	13.00		21.00	
SGPT	6-55 (U/L)	23/11/90	20.00		32.00	
GAMMA GT	11-50 (U/L)	23/11/90	20.00		28.00	
LDH	200-460 (U/L)	23/11/90			271.00	
ALK. PHOSPH.	90-279 (U/L)	23/11/90			212.00	
GLUCOSE	60-105 (MG/DL)	23/11/90	74.00		94.00	
BUN	10-50 (MG/DL)	23/11/90	24.00		17.00	
CREATININE	0.5-1.15 (MG/DL)	23/11/90	0.84		0.68	
URIC ACID	2.5-7 (MG/DL)	23/11/90	4.90			
TOT BILIRUBIN	0.1-1 (MG/DL)	23/11/90	0.64		0.60	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	23/11/90	0.05		0.10	
TOT. PROTEINS	6-8 (G/DL)	23/11/90	6.40		7.00	
ALBUMINE	55-69 (%)	23/11/90	66.50		68.20	
TOT. CHOLEST.	125-200 (MG/DL)	23/11/90	246.00	>	251.00	>
TRIGLYCERIDES	35-170 (MG/DL)	23/11/90	133.00		89.00	
GLOBULINS ALPHA 1	2-4 (%)	23/11/90	2.90		3.10	
GLOBULINS ALPHA 2	6.5-11 (%)	23/11/90	8.70		8.00	
GLOBULINS BETA	7.5-12.5 (%)	23/11/90	10.80		9.70	
GLOBULINS GAMMA	12-24 (%)	23/11/90	11.10	<	11.00	<

1901

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA

Centre: 9 Patient: 249 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			04/03/91	
			value	(◊)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	23/11/90	13.70	
HT	37-47 (%)	23/11/90	39.10	
RBC	4.2-5.4 (10¬6/UL)	23/11/90	4.39	
WBC	4.8-10.8 (10¬3/UL)	23/11/90	8.20	
WBC: L	20.5-51.1 (%)	23/11/90	25.80	
WBC: M	1.7-9.3 (%)	23/11/90	4.10	
PLATELETS	130-400 (10¬3/UL)	23/11/90	423.00	>
NA+	135-148 (MMOL/L)	23/11/90	136.40	
K+	3.5-5 (MMOL/L)	23/11/90	4.23	
CL-	96-108 (MMOL/L)	23/11/90	103.00	
Ca++	2.1-2.6 (MMOL/L)	23/11/90	2.57	
SGOT	5-41 (U/L)	23/11/90	23.00	
SGPT	6-55 (U/L)	23/11/90	36.00	
GAMMA GT	11-50 (U/L)	23/11/90	51.00	>
LDH	200-460 (U/L)	23/11/90	342.00	
ALK. PHOSPH.	90-279 (U/L)	23/11/90	208.00	
GLUCOSE	60-105 (MG/DL)	23/11/90	89.00	
BUN	10-50 (MG/DL)	23/11/90	89.00	>>
CREATININE	0.5-1.15 (MG/DL)	23/11/90	0.65	
TOT BILIRUBIN	0.1-1 (MG/DL)	23/11/90	0.58	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	23/11/90	0.04	
TOT. PROTEINS	6-8 (G/DL)	23/11/90	7.90	
ALBUMINE	55-69 (%)	23/11/90	65.60	
TOT. CHOLEST.	125-200 (MG/DL)	23/11/90	282.00	>>
TRIGLYCERIDES	35-170 (MG/DL)	23/11/90	111.00	
GLOBULINS ALPHA 1	2-4 (%)	23/11/90	2.70	
GLOBULINS ALPHA 2	6.5-11 (%)	23/11/90	8.60	
GLOBULINS BETA	7.5-12.5 (%)	23/11/90	11.40	
GLOBULINS GAMMA	12-24 (%)	23/11/90	11.70	<
TSH	0.2-4 (UU/ML)	23/11/90	1.43	
T4	50-115 (NG/ML)	23/11/90	100.00	

1902

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max ran
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 9 Patient: 250 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 28	
			07/03/91		02/04/91		08/04/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	12-16 (G/DL)	01/03/91	12.10		11.10	<	11.80	<
HT	37-47 (%)	01/03/91	36.20	<	33.40	<	36.40	<
RBC	4.2-5.4 (10~6/UL)	01/03/91	4.78		4.36		4.73	
WBC	4.8-10.8 (10~3/UL)	01/03/91	4.70	<	6.50		3.70	<
WBC: L	20.5-51.1 (%)	01/03/91	27.70		26.30		38.20	
WBC: M	1.7-9.3 (%)	01/03/91	6.10		4.60		7.60	
PLATELETS	130-400 (10~3/UL)	01/03/91	250.00		243.00		254.00	
NA+	135-148 (MMOL/L)	01/03/91	141.00		140.90		139.30	
K+	3.5-5 (MMOL/L)	01/03/91	4.63		4.11		4.63	
CL-	96-108 (MMOL/L)	01/03/91			109.00	>	105.00	
Ca++	2.1-2.6 (MMOL/L)	01/03/91	2.26		2.23		2.29	
PO4--	0.8-1.55 (MMOL/L)	01/03/91	0.87		1.02		1.18	
SGOT	5-41 (U/L)	01/03/91	11.00		11.00		12.00	
SGPT	6-55 (U/L)	01/03/91	14.00		12.00		13.00	
GAMMA GT	11-50 (U/L)	01/03/91	8.00	<	9.00	<	11.00	
LDH	200-460 (U/L)	01/03/91	273.00		325.00		298.00	
ALK. PHOSPH.	90-279 (U/L)	01/03/91	99.00		103.00		119.00	
GLUCOSE	60-105 (MG/DL)	01/03/91	68.00		79.00		72.00	
BUN	10-50 (MG/DL)	01/03/91	23.00		23.00		24.00	
CREATININE	0.5-1.15 (MG/DL)	01/03/91	0.72		0.74		0.81	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/03/91	0.35		0.30		0.64	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	01/03/91	0.03		0.08		0.09	
TOT. PROTEINS	6-8 (G/100ML)	01/03/91	7.00		7.20		7.60	
ALBUMINE	3.5-5.5 (G/100ML)	01/03/91	4.25		4.38		4.63	
TOT. CHOLEST.	125-200 (MG/DL)	01/03/91	174.00		197.00		224.00	>
TRIGLYCERIDES	35-170 (MG/DL)	01/03/91	49.00		75.00		85.00	
GLOBULINS ALPHA 1	0.2-0.4 (G/100ML)	01/03/91	0.19	<	0.17	<	0.21	
GLOBULINS ALPHA 2	0.5-0.9 (G/100ML)	01/03/91	0.43	<	0.41	<	0.43	<
GLOBULINS BETA	0.6-1.1 (G/100ML)	01/03/91	0.77		0.74		0.80	
GLOBULINS GAMMA	0.7-1.7 (G/100ML)	01/03/91	1.37		1.50		1.54	
TSH	0.2-4 (UU/ML)	01/03/91	1.26					
T4	50-115 (NG/ML)	01/03/91	79.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0
9550082
LABORATORY DATA
Centre: 9 Patient: 251 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			18/03/91		10/04/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/DL)	23/11/90	13.50		12.80	
HT	37-47 (%)	23/11/90	40.60		37.90	
RBC	4.2-5.4 (10¬6/UL)	23/11/90	4.64		4.35	
WBC	4.8-10.8 (10¬3/UL)	23/11/90	7.10		7.50	
WBC: L	20.5-51.1 (%)	23/11/90	30.00		31.30	
WBC: M	1.7-9.3 (%)	23/11/90	10.00	>	3.80	
PLATELETS	130-400 (10¬3/UL)	23/11/90	391.00		353.00	
NA+	135-148 (MMOL/L)	23/11/90	139.50		140.30	
K+	3.5-5 (MMOL/L)	23/11/90	4.75		4.45	
CL-	96-108 (MMOL/L)	23/11/90	105.00		106.00	
Ca++	2.1-2.6 (MMOL/L)	23/11/90			2.40	
PO4--	0.8-1.55 (MMOL/L)	23/11/90			1.34	
SGOT	5-41 (U/L)	23/11/90	11.00		14.00	
SGPT	6-55 (U/L)	23/11/90	15.00		15.00	
GAMMA GT	11-50 (U/L)	23/11/90	9.00	<	9.00	<
LDH	200-460 (U/L)	23/11/90	231.00		221.00	
ALK. PHOSPH.	90-279 (U/L)	23/11/90	107.00		137.00	
GLUCOSE	60-105 (MG/DL)	23/11/90	88.00		78.00	
BUN	10-50 (MG/DL)	23/11/90	23.00		25.00	
CREATININE	0.5-1.15 (MG/DL)	23/11/90	0.88		0.87	
URIC ACID	2.5-7 (MG/DL)	23/11/90			3.60	
TOT BILIRUBIN	0.1-1 (MG/DL)	23/11/90	0.26		0.34	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	23/11/90	0.03		0.04	
TOT. PROTEINS	6-8 (G/DL)	23/11/90	6.70		6.70	
ALBUMINE	55-69 (%)	23/11/90	65.60		65.60	
TOT. CHOLEST.	125-200 (MG/DL)	23/11/90	202.00	>	189.00	
TRIGLYCERIDES	35-170 (MG/DL)	23/11/90	85.00		48.00	
GLOBULINS ALPHA 1	2-4 (%)	23/11/90	2.60		3.60	
GLOBULINS ALPHA 2	6.5-11 (%)	23/11/90	7.80		7.20	
GLOBULINS BETA	7.5-12.5 (%)	23/11/90	10.70		10.10	
GLOBULINS GAMMA	12-24 (%)	23/11/90	13.30		13.50	
TSH	0.2-4 (UU/ML)	23/11/90	1.90			
T4	50-115 (NG/ML)	23/11/90	77.00			

1904

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 9 Patient: 252 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			28/03/91		20/04/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/DL)	23/11/90	13.40		14.20	
HT	37-47 (%)	23/11/90	39.10		42.40	
RBC	4.2-5.4 (10¬6/UL)	23/11/90	4.51		4.87	
WBC	4.8-10.8 (10¬3/UL)	23/11/90	9.10		9.10	
WBC: L	20.5-51.1 (%)	23/11/90	48.00		34.00	
WBC: M	1.7-9.3 (%)	23/11/90	4.00		2.00	
PLATELETS	130-400 (10¬3/UL)	23/11/90	273.00		371.00	
NA+	135-148 (MMOL/L)	23/11/90	143.80		141.70	
K+	3.5-5 (MMOL/L)	23/11/90	3.40	<	3.48	<
CL-	96-108 (MMOL/L)	23/11/90	95.00	<	103.00	
Ca++	2.1-2.6 (MMOL/L)	23/11/90	2.25		2.35	
PO4--	0.8-1.55 (MMOL/L)	23/11/90			1.48	
SGOT	5-41 (U/L)	23/11/90	15.00		14.00	
SGPT	6-55 (U/L)	23/11/90	13.00		14.00	
GAMMA GT	11-50 (U/L)	23/11/90	29.00		35.00	
LDH	200-460 (U/L)	23/11/90	307.00		305.00	
ALK. PHOSPH.	90-279 (U/L)	23/11/90	236.00		195.00	
GLUCOSE	60-105 (MG/DL)	23/11/90	94.00		111.00	>
BUN	10-50 (MG/DL)	23/11/90	29.00		37.00	
CREATININE	0.5-1.15 (MG/DL)	23/11/90	0.80		0.91	
URIC ACID	2.5-7 (MG/DL)	23/11/90			8.70	>
TOT BILIRUBIN	0.1-1 (MG/DL)	23/11/90	0.40		0.34	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	23/11/90	0.09		0.05	
TOT. PROTEINS	6-8 (G/DL)	23/11/90	7.30		7.80	
ALBUMINE	55-69 (%)	23/11/90	53.30	<	55.30	
TOT. CHOLEST.	125-200 (MG/DL)	23/11/90	208.00	>	210.00	>
TRIGLYCERIDES	35-170 (MG/DL)	23/11/90	139.00		111.00	
GLOBULINS ALPHA 1	2-4 (%)	23/11/90	2.90		2.60	
GLOBULINS ALPHA 2	6.5-11 (%)	23/11/90	9.80		9.10	
GLOBULINS BETA	7.5-12.5 (%)	23/11/90	14.10	>	14.10	>
GLOBULINS GAMMA	12-24 (%)	23/11/90	19.90		18.90	
TSH	0.2-4 (UU/ML)	23/11/90	3.60			
T4	50-115 (NG/ML)	23/11/90	83.00			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 9 Patient: 253 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			29/03/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/03/91	13.80	
HT	37-47 (%)	01/03/91	39.90	
RBC	4.2-5.4 (10¬6/UL)	01/03/91	4.42	
WBC	4.8-10.8 (10¬3/UL)	01/03/91	6.10	
WBC: L	20.5-51.1 (%)	01/03/91	30.80	
WBC: M	1.7-9.3 (%)	01/03/91	6.20	
PLATELETS	130-400 (10¬3/UL)	01/03/91	267.00	
NA+	135-148 (MMOL/L)	01/03/91	142.00	
K+	3.5-5 (MMOL/L)	01/03/91	3.84	
CL-	96-108 (MMOL/L)	01/03/91	107.00	
Ca++	2.1-2.6 (MMOL/L)	01/03/91	2.30	
PO4--	0.8-1.55 (MMOL/L)	01/03/91	0.75	<
SGOT	5-41 (U/L)	01/03/91	11.00	
SGPT	6-55 (U/L)	01/03/91	14.00	
GAMMA GT	11-50 (U/L)	01/03/91	12.00	
LDH	200-460 (U/L)	01/03/91	247.00	
ALK. PHOSPH.	90-279 (U/L)	01/03/91	107.00	
GLUCOSE	60-105 (MG/DL)	01/03/91	90.00	
BUN	10-50 (MG/DL)	01/03/91	30.00	
CREATININE	0.5-1.15 (MG/DL)	01/03/91	0.75	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/03/91	0.88	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	01/03/91	0.06	
TOT. PROTEINS	6-8 (G/100ML)	01/03/91	6.40	
ALBUMINE	3.5-5.5 (G/100ML)	01/03/91	4.39	
TOT. CHOLEST.	125-200 (MG/DL)	01/03/91	164.00	
TRIGLYCERIDES	35-170 (MG/DL)	01/03/91	104.00	
GLOBULINS ALPHA 1	0.2-0.4 (G/100ML)	01/03/91	0.17	<
GLOBULINS ALPHA 2	0.5-0.9 (G/100ML)	01/03/91	0.45	<
GLOBULINS BETA	0.6-1.1 (G/100ML)	01/03/91	0.61	
GLOBULINS GAMMA	0.7-1.7 (G/100ML)	01/03/91	0.78	
TSH	0.2-4 (UU/ML)	01/03/91	1.85	
T4	50-115 (NG/ML)	01/03/91	84.00	

1906

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 9 Patient: 254 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 14	
			05/04/91		08/05/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/DL)	23/11/90	13.70		14.00	
HT	37-47 (%)	23/11/90	40.20		41.60	
RBC	4.2-5.4 (10¬6/UL)	23/11/90	4.37		4.56	
WBC	4.8-10.8 (10¬3/UL)	23/11/90	9.70		12.70	>
WBC: L	20.5-51.1 (%)	23/11/90	31.90		25.70	
WBC: M	1.7-9.3 (%)	23/11/90	1.80		2.70	
PLATELETS	130-400 (10¬3/UL)	23/11/90	236.00		250.00	
NA+	135-148 (MMOL/L)	23/11/90	139.50		140.40	
K+	3.5-5 (MMOL/L)	23/11/90	4.46		4.78	
CL-	96-108 (MMOL/L)	23/11/90	105.00		103.00	
Ca++	2.1-2.6 (MMOL/L)	23/11/90	2.41		2.46	
PO4--	0.8-1.55 (MMOL/L)	23/11/90			1.57	>
SGOT	5-41 (U/L)	23/11/90	15.00		15.00	
SGPT	6-55 (U/L)	23/11/90	12.00		11.00	
GAMMA GT	11-50 (U/L)	23/11/90	37.00		39.00	
LDH	200-460 (U/L)	23/11/90	256.00		335.00	
ALK. PHOSPH.	90-279 (U/L)	23/11/90	93.00		99.00	
GLUCOSE	60-105 (MG/DL)	23/11/90	96.00		83.00	
BUN	10-50 (MG/DL)	23/11/90	29.00		26.00	
CREATININE	0.5-1.15 (MG/DL)	23/11/90	0.81		0.87	
URIC ACID	2.5-7 (MG/DL)	23/11/90			5.40	
TOT BILIRUBIN	0.1-1 (MG/DL)	23/11/90	0.40		0.45	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	23/11/90	0.14		0.04	
TOT. PROTEINS	6-8 (G/DL)	23/11/90	6.90		7.40	
ALBUMINE	55-69 (%)	23/11/90	62.80		61.10	
TOT. CHOLEST.	125-200 (MG/DL)	23/11/90	274.00	>>	272.00	>>
TRIGLYCERIDES	35-170 (MG/DL)	23/11/90	367.00	>>	282.00	>>
GLOBULINS ALPHA 1	2-4 (%)	23/11/90	3.60		3.10	
GLOBULINS ALPHA 2	6.5-11 (%)	23/11/90	9.60		10.50	
GLOBULINS BETA	7.5-12.5 (%)	23/11/90	12.10		12.80	>
GLOBULINS GAMMA	12-24 (%)	23/11/90	11.90	<	12.50	
TSH	0.2-4 (UU/ML)	23/11/90	2.84			
T4	50-115 (NG/ML)	23/11/90	70.00			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 9 Patient: 255 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			08/05/91		03/06/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/05/91	11.40	<	11.80	<
HT	37-47 (%)	01/05/91	35.40	<	35.70	<
RBC	4.2-5.4 (10¬6/UL)	01/05/91	4.79		4.92	
WBC	4.8-10.8 (10¬3/UL)	01/05/91	8.30		8.80	
WBC: L	20.5-51.1 (%)	01/05/91	32.40		30.80	
WBC: M	1.7-9.3 (%)	01/05/91	4.00		4.70	
PLATELETS	130-400 (10¬3/UL)	01/05/91	396.00		406.00	>
NA+	135-148 (MMOL/L)	01/05/91	138.90		136.80	
K+	3.5-5 (MMOL/L)	01/05/91	3.85		3.94	
CL-	96-108 (MMOL/L)	01/05/91	109.00	>	102.00	
Ca++	2.1-2.6 (MMOL/L)	01/05/91	2.30		2.30	
PO4--	0.8-1.55 (MMOL/L)	01/05/91			1.28	
SGOT	5-41 (U/L)	01/05/91	14.00		13.00	
SGPT	6-55 (U/L)	01/05/91	14.00		14.00	
GAMMA GT	11-50 (U/L)	01/05/91	22.00		14.00	
LDH	200-460 (U/L)	01/05/91	266.00		242.00	
ALK. PHOSPH.	90-279 (U/L)	01/05/91	249.00		241.00	
GLUCOSE	60-105 (MG/DL)	01/05/91	76.00		80.00	
BUN	10-50 (MG/DL)	01/05/91	27.00		31.00	
CREATININE	0.5-1.15 (MG/DL)	01/05/91	0.84		0.78	
URIC ACID	2.5-7 (MG/DL)	01/05/91			2.90	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/05/91	0.40		0.17	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	01/05/91	0.09		0.04	
TOT. PROTEINS	6-8 (G/100ML)	01/05/91	8.00		7.60	
ALBUMINE	3.5-5.5 (G/100ML)	01/05/91	4.86		4.40	
TOT. CHOLEST.	125-200 (MG/DL)	01/05/91	135.00		111.00	<
TRIGLYCERIDES	35-170 (MG/DL)	01/05/91	54.00		36.00	
GLOBULINS ALPHA 1	0.2-0.4 (G/100ML)	01/05/91	0.18	<	0.25	
GLOBULINS ALPHA 2	0.5-0.9 (G/100ML)	01/05/91	0.53		0.50	
GLOBULINS BETA	0.6-1.1 (G/100ML)	01/05/91	0.87		0.79	
GLOBULINS GAMMA	0.7-1.7 (G/100ML)	01/05/91	1.56		1.65	
TSH	0.2-4 (UU/ML)	01/05/91	1.43			
T4	50-115 (NG/ML)	01/05/91	106.00			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 9 Patient: 256 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 42	
			23/05/91		02/07/91	
			value	(◊)	value	(◊)
Laboratory test	Range value	Range date				
HB	12-16 (G/DL)	23/11/90	13.90		13.40	
HT	37-47 (%)	23/11/90	41.00		38.50	
RBC	4.2-5.4 (10¬6/UL)	23/11/90	4.43		4.08	<
WBC	4.8-10.8 (10¬3/UL)	23/11/90	6.50		5.30	
WBC: L	20.5-51.1 (%)	23/11/90	24.30		24.80	
WBC: M	1.7-9.3 (%)	23/11/90	6.00		7.50	
PLATELETS	130-400 (10¬3/UL)	23/11/90	331.00		316.00	
NA+	135-148 (MMOL/L)	23/11/90	139.60		137.50	
K+	3.5-5 (MMOL/L)	23/11/90	3.87		3.93	
CL-	96-108 (MMOL/L)	23/11/90	101.00		101.00	
Ca++	2.1-2.6 (MMOL/L)	23/11/90			2.30	
SGOT	5-41 (U/L)	23/11/90	17.00		14.00	
SGPT	6-55 (U/L)	23/11/90	15.00		15.00	
GAMMA GT	11-50 (U/L)	23/11/90	20.00		25.00	
LDH	200-460 (U/L)	23/11/90			303.00	
ALK. PHOSPH.	90-279 (U/L)	23/11/90	135.00		166.00	
GLUCOSE	60-105 (MG/DL)	23/11/90	91.00		99.00	
BUN	10-50 (MG/DL)	23/11/90	27.00		35.00	
CREATININE	0.5-1.15 (MG/DL)	23/11/90	0.84		0.84	
URIC ACID	2.5-7 (MG/DL)	23/11/90			2.90	
TOT BILIRUBIN	0.1-1 (MG/DL)	23/11/90	0.65		0.49	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	23/11/90	0.05		0.04	
TOT. PROTEINS	6-8 (G/DL)	23/11/90	7.30		7.10	
ALBUMINE	55-69 (%)	23/11/90	64.90		69.40	>
TOT. CHOLEST.	125-200 (MG/DL)	23/11/90	216.00	>	251.00	>
TRIGLYCERIDES	35-170 (MG/DL)	23/11/90			100.00	
GLOBULINS ALPHA 1	2-4 (%)	23/11/90	2.70		1.70	<
GLOBULINS ALPHA 2	6.5-11 (%)	23/11/90	5.90	<	4.00	<<
GLOBULINS BETA	7.5-12.5 (%)	23/11/90	9.20		7.90	
GLOBULINS GAMMA	12-24 (%)	23/11/90	17.30		17.00	
TSH	0.2-4 (UU/ML)	23/11/90	2.21			
T4	50-115 (NG/ML)	23/11/90	94.00			

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 9 Patient: 257 Treatment: Placebo Sex: Male

			Visit number / Laboratory date	
			Screen	
			21/06/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	14-18 (G/DL)	23/11/90	16.40	
HT	42-52 (%)	23/11/90	47.60	
RBC	4.3-6.1 (10¬6/UL)	23/11/90	5.09	
WBC	4.8-10.8 (10¬3/UL)	23/11/90	8.40	
WBC: L	20.5-51.1 (%)	23/11/90	37.10	
WBC: M	1.7-9.3 (%)	23/11/90	4.80	
PLATELETS	130-400 (10¬3/UL)	23/11/90	208.00	
NA+	135-148 (MMOL/L)	23/11/90	138.40	
K+	3.5-5 (MMOL/L)	23/11/90	3.92	
CL-	96-108 (MMOL/L)	23/11/90	108.00	
SGOT	5-41 (U/L)	23/11/90	17.00	
SGPT	6-55 (U/L)	23/11/90	21.00	
GAMMA GT	11-50 (U/L)	23/11/90	13.00	
LDH	200-460 (U/L)	23/11/90	275.00	
ALK. PHOSPH.	90-279 (U/L)	23/11/90	142.00	
GLUCOSE	60-105 (MG/DL)	23/11/90	75.00	
BUN	10-50 (MG/DL)	23/11/90	33.00	
CREATININE	0.5-1.15 (MG/DL)	23/11/90	0.91	
URIC ACID	2.5-7 (MG/DL)	23/11/90	6.40	
TOT BILIRUBIN	0.1-1 (MG/DL)	23/11/90	0.83	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	23/11/90	0.14	
TOT. PROTEINS	6-8 (G/DL)	23/11/90	7.00	
ALBUMINE	55-69 (%)	23/11/90	64.90	
TOT. CHOLEST.	125-200 (MG/DL)	23/11/90	157.00	
TRIGLYCERIDES	35-170 (MG/DL)	23/11/90	127.00	
GLOBULINS ALPHA 1	2-4 (%)	23/11/90	1.50	<
GLOBULINS ALPHA 2	6.5-11 (%)	23/11/90	5.40	<
GLOBULINS BETA	7.5-12.5 (%)	23/11/90	8.80	
GLOBULINS GAMMA	12-24 (%)	23/11/90	19.40	

1910

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 9 Patient: 258 Treatment: Placebo Sex: Male

			Visit number / Laboratory date	
			Screen	
			26/06/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	14-18 (G/DL)	23/11/90	14.70	
HT	42-52 (%)	23/11/90	43.60	
RBC	4.3-6.1 (10¬6/UL)	23/11/90	4.90	
WBC	4.8-10.8 (10¬3/UL)	23/11/90	5.80	
WBC: L	20.5-51.1 (%)	23/11/90	39.10	
WBC: M	1.7-9.3 (%)	23/11/90	3.70	
PLATELETS	130-400 (10¬3/UL)	23/11/90	215.00	
NA+	135-148 (MMOL/L)	23/11/90	139.10	
K+	3.5-5 (MMOL/L)	23/11/90	3.71	
CL-	96-108 (MMOL/L)	23/11/90	102.00	
Ca++	2.1-2.6 (MMOL/L)	23/11/90	2.34	
PO4--	0.8-1.55 (MMOL/L)	23/11/90	1.29	
SGOT	5-41 (U/L)	23/11/90	16.00	
SGPT	6-55 (U/L)	23/11/90	13.00	
GAMMA GT	11-50 (U/L)	23/11/90	16.00	
GLUCOSE	60-105 (MG/DL)	23/11/90	90.00	
BUN	10-50 (MG/DL)	23/11/90	29.00	
CREATININE	0.5-1.15 (MG/DL)	23/11/90	0.98	
URIC ACID	2.5-7 (MG/DL)	23/11/90	4.80	
TOT BILIRUBIN	0.1-1 (MG/DL)	23/11/90	0.65	
DIR BILIRUBIN	0.01-0.25 (MG/DL)	23/11/90	0.10	
TOT. PROTEINS	6-8 (G/100ML)	23/11/90	7.10	
ALBUMINE	3.5-5.5 (G/100ML)	23/11/90	4.62	
TOT. CHOLEST.	125-200 (MG/DL)	23/11/90	206.00	>
TRIGLYCERIDES	35-170 (MG/DL)	23/11/90	198.00	>
GLOBULINS ALPHA 1	2-4 (%)	23/11/90	1.30	<<
GLOBULINS ALPHA 2	6.5-11 (%)	23/11/90	4.80	<
GLOBULINS BETA	7.5-12.5 (%)	23/11/90	9.70	
GLOBULINS GAMMA	12-24 (%)	23/11/90	19.10	
TSH	0.2-4 (UU/ML)	23/11/90	1.50	
T4	50-115 (MG/ML)	23/11/90	75.00	

1911

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 11 Patient: 319 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/07/91		22/08/91		12/09/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	23/07/91	15.10		15.40		14.70	
HT	40-45 (%)	23/07/91	43.10		43.60			
RBC	4.5-6.5 (10¬12/L)	23/07/91	4.69		4.80		4.52	
WBC	4-11 (10¬9/L)	23/07/91	10.20		9.50		8.10	
WBC: N	40-75 (%)	23/07/91			69.80		65.00	
WBC: L	20-45 (%)	23/07/91	23.10		27.40		28.00	
WBC: E	1-6 (%)	23/07/91			2.00		1.00	
WBC: M	2-10 (%)	23/07/91	2.90		2.80		5.00	
WBC: B	0-1 (%)	23/07/91			0.00		1.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	255.00		259.00		265.00	
NA+	135-145 (MMOL/L)	23/07/91	141.00		139.00		139.00	
K+	3.5-5 (MMOL/L)	23/07/91	3.90		4.20		4.30	
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.50		2.42		2.31	
PO4--	0.8-1.4 (MMOL/L)	23/07/91	1.04		1.38		1.59	>
SGOT	3-40 (U/L)	23/07/91	20.00		20.00		15.00	
SGPT	9-40 (U/L)	23/07/91	16.00		128.00	>>	17.00	
GAMMA GT	10-60 (U/L)	23/07/91	16.00		18.00		15.00	
LDH	80-210 (U/L)	23/07/91	148.00		128.00		136.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	136.00		136.00		117.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	4.70		5.40		4.50	
BUN	2.5-6.5 (MMOL/L)	23/07/91	4.90		5.40		5.00	
CREATININE	50-110 (UMOL/L)	23/07/91	98.00		100.00		94.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	249.00		203.00		349.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	10.00		13.00		5.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	3.00		5.00		2.00	
TOT. PROTEINS	56-85 (G/L)	23/07/91	75.00		76.00		74.00	
ALBUMINE	38-50 (G/L)	23/07/91	49.00		49.00		46.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	7.20	>	7.50	>	7.60	>
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91			1.40		1.90	
TSH	0.4-4 (MU/L)	23/07/91	0.60					
T4	8.5-19 (PMOL/L)	23/07/91	16.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 11 Patient: 320 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			08/08/91		05/09/91		26/09/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	23/07/91	15.80		16.00		16.10	
HT	40-45 (%)	23/07/91	45.80	>			46.90	>
RBC	4.5-6.5 (10¬12/L)	23/07/91	6.03		6.39			
WBC	4-11 (10¬9/L)	23/07/91	6.40		6.30		7.30	
WBC: N	40-75 (%)	23/07/91	62.00		56.00		55.00	
WBC: L	20-45 (%)	23/07/91	31.00		41.00		40.00	
WBC: E	1-6 (%)	23/07/91	2.00		1.00		2.00	
WBC: M	2-10 (%)	23/07/91	5.00		2.00		3.00	
WBC: B	0-1 (%)	23/07/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	325.00		263.00		300.00	
NA+	135-145 (MMOL/L)	23/07/91	144.00		140.00		140.00	
K+	3.5-5 (MMOL/L)	23/07/91	4.70		4.20		5.00	
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.48		2.35		2.62	>
PO4--	0.8-1.4 (MMOL/L)	23/07/91	1.09		0.88		0.90	
SGOT	3-40 (U/L)	23/07/91	21.00		33.00		36.00	
SGPT	9-40 (U/L)	23/07/91	24.00		19.00		22.00	
GAMMA GT	10-60 (U/L)	23/07/91	14.00		16.00		18.00	
LDH	80-210 (U/L)	23/07/91	117.00				147.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	173.00		188.00		158.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	5.20		4.40		5.10	
BUN	2.5-6.5 (MMOL/L)	23/07/91	4.80		5.20		5.90	
CREATININE	50-110 (UMOL/L)	23/07/91	96.00		103.00		96.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	193.00		262.00		359.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	26.00	>	19.00	>	20.00	>
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	9.00	>	6.00	>	6.00	>
TOT. PROTEINS	56-85 (G/L)	23/07/91	82.00				80.00	
ALBUMINE	38-50 (G/L)	23/07/91	50.00		46.00		48.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	5.80		6.40		7.70	>
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	0.90		1.90		1.30	
TSH	0.4-4 (MU/L)	23/07/91	0.40					
T4	8.5-19 (PMOL/L)	23/07/91	15.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 11 Patient: 321 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/08/91		26/09/91		17/10/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	13-18 (G/DL)	23/07/91	15.80		15.30		15.80	
HT	40-45 (%)	23/07/91			42.80		46.10	>
RBC	4.5-6.5 (10-12/L)	23/07/91	4.92		4.65		5.05	
WBC	4-11 (10-9/L)	23/07/91	9.00		8.70		10.40	
WBC: N	40-75 (%)	23/07/91			57.00		71.00	
WBC: L	20-45 (%)	23/07/91	34.90		38.00		28.00	
WBC: E	1-6 (%)	23/07/91			1.00		1.00	
WBC: M	2-10 (%)	23/07/91	6.20		4.00		0.00	<
WBC: B	0-1 (%)	23/07/91			0.00		0.00	
PLATELETS	150-400 (10-9/L)	23/07/91	294.00		280.00		325.00	
NA+	135-145 (MMOL/L)	23/07/91	143.00		143.00			
K+	3.5-5 (MMOL/L)	23/07/91	4.60		4.40			
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.42		2.38			
PO4--	0.8-1.4 (MMOL/L)	23/07/91	0.96		0.74	<		
SGOT	3-40 (U/L)	23/07/91	17.00		17.00			
SGPT	9-40 (U/L)	23/07/91	15.00		67.00	>		
GAMMA GT	10-60 (U/L)	23/07/91	21.00		19.00			
LDH	80-210 (U/L)	23/07/91	136.00		151.00			
ALK. PHOSPH.	100-275 (U/L)	23/07/91	237.00		199.00			
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	5.40		6.10			
BUN	2.5-6.5 (MMOL/L)	23/07/91	6.30		8.00	>		
CREATININE	50-110 (UMOL/L)	23/07/91	87.00		90.00			
URIC ACID	155-405 (UMOL/L)	23/07/91	199.00		202.00			
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	7.00		8.00			
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	4.00		2.00			
TOT. PROTEINS	56-85 (G/L)	23/07/91	78.00		69.00			
ALBUMINE	38-50 (G/L)	23/07/91	49.00		44.00			
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	8.60	>	8.70	>		
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	2.40	>	1.80			
TSH	0.4-4 (MU/L)	23/07/91	1.40					
T4	8.5-19 (PMOL/L)	23/07/91	11.20					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 11 Patient: 322 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			19/09/91		17/10/91		07/11/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	23/07/91	14.70		14.50		13.80	
HT	37-47 (%)	23/07/91			43.70			
RBC	4.5-6.5 (10¬12/L)	23/07/91	4.47	<	4.67		4.41	<
WBC	4-11 (10¬9/L)	23/07/91	5.90		6.10		6.50	
WBC: N	40-75 (%)	23/07/91	56.00		63.00		78.00	>
WBC: L	20-45 (%)	23/07/91	35.00		35.00		20.00	
WBC: E	1-6 (%)	23/07/91	6.00		1.00		0.00	<
WBC: M	2-10 (%)	23/07/91	3.00		1.00	<	1.00	<
WBC: B	0-1 (%)	23/07/91	0.00		0.00		1.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	334.00				325.00	
NA+	135-145 (MMOL/L)	23/07/91	139.00		140.00		145.00	
K+	3.5-5 (MMOL/L)	23/07/91	5.00		4.70		5.10	>
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.46		2.35		2.47	
PO4--	0.8-1.4 (MMOL/L)	23/07/91	1.04		1.19		1.21	
SGOT	3-40 (U/L)	23/07/91	20.00		14.00		18.00	
SGPT	9-40 (U/L)	23/07/91	9.00		10.00		17.00	
GAMMA GT	10-60 (U/L)	23/07/91	33.00		20.00		23.00	
LDH	80-210 (U/L)	23/07/91	165.00		134.00		145.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	149.00		149.00		177.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	5.50		4.80			
BUN	2.5-6.5 (MMOL/L)	23/07/91	7.20	>	7.40	>	6.40	
CREATININE	50-110 (UMOL/L)	23/07/91	90.00		102.00		87.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	150.00	<	203.00		213.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	10.00		6.00		7.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	4.00		4.00		2.00	
TOT. PROTEINS	56-85 (G/L)	23/07/91	76.00		65.00		66.00	
ALBUMINE	38-50 (G/L)	23/07/91	49.00		46.00		49.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	6.50		6.50		6.20	
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	2.20	>	1.20		1.20	
TSH	0.4-4 (MU/L)	23/07/91	3.20					
T4	8.5-19 (PMOL/L)	23/07/91	9.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 11 Patient: 323 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/11/91		05/12/91		27/12/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	23/07/91	14.90		17.30		16.60	
HT	40-45 (%)	23/07/91			50.70	>		
RBC	4.5-6.5 (10¬12/L)	23/07/91	4.50		5.26		5.06	
WBC	4-11 (10¬9/L)	23/07/91	5.60		6.70		6.80	
WBC: N	40-75 (%)	23/07/91	87.00	>	70.00		66.00	
WBC: L	20-45 (%)	23/07/91	13.00	<<	26.00		32.00	
WBC: E	1-6 (%)	23/07/91	0.00	<	1.00		1.00	
WBC: M	2-10 (%)	23/07/91	0.00	<	3.00		1.00	<
WBC: B	0-1 (%)	23/07/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	207.00		266.00		296.00	
NA+	135-145 (MMOL/L)	23/07/91	142.00		142.00		142.00	
K+	3.5-5 (MMOL/L)	23/07/91	4.70		5.20	>	4.40	
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.37		2.34		2.43	
PO4--	0.8-1.4 (MMOL/L)	23/07/91	1.07		1.16		1.03	
SGOT	3-40 (U/L)	23/07/91	18.00		21.00		28.00	
SGPT	9-40 (U/L)	23/07/91	15.00		25.00			
GAMMA GT	10-60 (U/L)	23/07/91	51.00		58.00		44.00	
LDH	80-210 (U/L)	23/07/91	131.00		166.00			
ALK. PHOSPH.	100-275 (U/L)	23/07/91	114.00		155.00		149.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	6.00		3.90		4.70	
BUN	2.5-6.5 (MMOL/L)	23/07/91	3.50		3.60		3.30	
CREATININE	50-110 (UMOL/L)	23/07/91	87.00		86.00		85.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	336.00		368.00		342.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	12.00		17.00		12.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	3.00		2.00		3.00	
TOT. PROTEINS	56-85 (G/L)	23/07/91	72.00		87.00	>	79.00	
ALBUMINE	38-50 (G/L)	23/07/91	50.00		59.00	>	55.00	>
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	5.60		6.90	>	6.60	
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	2.80	>>	6.80	>>	3.30	>>
TSH	0.4-4 (MU/L)	23/07/91	1.50					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 11 Patient: 324 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			20/11/91		27/12/91		16/01/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	23/07/91	15.30		15.60		14.60	
HT	40-45 (%)	23/07/91	45.40	>			41.90	
RBC	4.5-6.5 (10¬12/L)	23/07/91	5.12		5.22		4.82	
WBC	4-11 (10¬9/L)	23/07/91	4.50		4.30		3.30	<
WBC: N	40-75 (%)	23/07/91	62.00		73.00		45.00	
WBC: L	20-45 (%)	23/07/91	32.00		20.00		48.00	>
WBC: E	1-6 (%)	23/07/91	1.00		0.00	<	0.00	<
WBC: M	2-10 (%)	23/07/91	4.00		1.00	<	7.00	
WBC: B	0-1 (%)	23/07/91	1.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	352.00		313.00		332.00	
NA+	135-145 (MMOL/L)	23/07/91	141.00		143.00		140.00	
K+	3.5-5 (MMOL/L)	23/07/91	5.10	>	4.40		4.60	
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.39		2.13		2.22	
PO4--	0.8-1.4 (MMOL/L)	23/07/91					1.02	
SGOT	3-40 (U/L)	23/07/91	28.00				24.00	
SGPT	9-40 (U/L)	23/07/91	21.00		22.00		33.00	
GAMMA GT	10-60 (U/L)	23/07/91	23.00		25.00		26.00	
LDH	80-210 (U/L)	23/07/91	139.00				148.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	125.00		108.00		108.00	
GLUCOSE	3,5-8 (MMOL/L)	23/07/91	5.10		4.80		4.60	
BUN	2.5-6.5 (MMOL/L)	23/07/91	5.30		5.30		4.20	
CREATININE	50-110 (UMOL/L)	23/07/91	109.00		111.00	>	110.00	
URIC ACID	155-405 (UMOL/L)	23/07/91					342.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	13.00		11.00		11.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91					3.00	
TOT. PROTEINS	56-85 (G/L)	23/07/91	73.00		51.00	<	70.00	
ALBUMINE	38-50 (G/L)	23/07/91	53.00	>	51.00	>	52.00	>
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91			6.00		6.10	
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	1.30				0.90	
TSH	0,4-4 (MU/L)	23/07/91	1.60					
T4	8.5-19 (PMOL/L)	23/07/91	16.00					

1917

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA

Centre: 11 Patient: 325 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/12/91		02/01/92		23/01/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	23/07/91	14.00		14.40		14.40	
RBC	4.5-6.5 (10¬12/L)	23/07/91	4.99		5.04		4.94	
WBC	4-11 (10¬9/L)	23/07/91	3.90	<	5.40		4.30	
WBC: N	40-75 (%)	23/07/91	73.00		88.00	>	79.00	>
WBC: L	20-45 (%)	23/07/91	23.60		12.00	<<	19.00	<
WBC: E	1-6 (%)	23/07/91	0.00	<	0.00	<	0.00	<
WBC: M	2-10 (%)	23/07/91	3.40		0.00	<	1.00	<
WBC: B	0-1 (%)	23/07/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	265.00		283.00		254.00	
NA+	135-145 (MMOL/L)	23/07/91	146.00	>	146.00	>	142.00	
K+	3.5-5 (MMOL/L)	23/07/91			4.90		5.20	>
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.35		2.28		2.36	
PO4--	0.8-1.4 (MMOL/L)	23/07/91	1.29		1.22			
SGOT	3-40 (U/L)	23/07/91	26.00		38.00		25.00	
SGPT	9-40 (U/L)	23/07/91	22.00		22.00		37.00	
GAMMA GT	10-60 (U/L)	23/07/91	25.00		33.00		35.00	
LDH	80-210 (U/L)	23/07/91	158.00		174.00		152.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	150.00		196.00		198.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	4.70		4.90		4.30	
BUN	2.5-6.5 (MMOL/L)	23/07/91	8.00	>	7.90	>	8.60	>
CREATININE	50-110 (UMOL/L)	23/07/91	111.00	>	104.00		109.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	262.00		330.00		346.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	8.00		10.00		7.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91			3.00		2.00	
TOT. PROTEINS	56-85 (G/L)	23/07/91	69.00		66.00		70.00	
ALBUMINE	38-50 (G/L)	23/07/91	49.00		48.00		49.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	7.60	>	6.50		7.10	>
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	1.50		1.40		3.00	>>
TSH	0.4-4 (MU/L)	23/07/91	0.60					

1918

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 11 Patient: 326 Treatment: Placebo Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			14/01/92		06/02/92	
			value	(◊)	value	(◊)
Laboratory test	Range value	Range date				
HB	13-18 (G/DL)	23/07/91	15.70		16.10	
RBC	4.5-6.5 (10~12/L)	23/07/91	5.02		5.05	
WBC	4-11 (10~9/L)	23/07/91	8.80		9.80	
WBC: N	40-75 (%)	23/07/91	57.00		75.00	
WBC: L	20-45 (%)	23/07/91	38.00		20.00	
WBC: E	1-6 (%)	23/07/91	2.00		2.00	
WBC: M	2-10 (%)	23/07/91	3.00		3.00	
WBC: B	0-1 (%)	23/07/91	0.00		0.00	
PLATELETS	150-400 (10~9/L)	23/07/91	323.00		320.00	
NA+	135-145 (MMOL/L)	23/07/91	146.00	>	146.00	>
K+	3.5-5 (MMOL/L)	23/07/91	4.40		5.10	>
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.26		2.37	
PO4--	0.8-1.4 (MMOL/L)	23/07/91			0.72	<
SGOT	3-40 (U/L)	23/07/91	17.00		21.00	
SGPT	9-40 (U/L)	23/07/91	19.00		15.00	
GAMMA GT	10-60 (U/L)	23/07/91	17.00		18.00	
LDH	80-210 (U/L)	23/07/91	170.00		157.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	192.00		202.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	5.60		5.60	
BUN	2.5-6.5 (MMOL/L)	23/07/91	3.60		4.10	
CREATININE	50-110 (UMOL/L)	23/07/91	108.00		116.00	>
URIC ACID	155-405 (UMOL/L)	23/07/91	248.00		238.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	15.00		18.00	>
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	3.00		3.00	
TOT. PROTEINS	56-85 (G/L)	23/07/91	69.00		69.00	
ALBUMINE	38-50 (G/L)	23/07/91	46.00		48.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	5.30		6.20	
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	2.60	>>	2.60	>>
TSH	0.4-4 (MU/L)	23/07/91	3.00			
T4	8.5-19 (PMOL/L)	23/07/91	12.50			

1919

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 11 Patient: 327 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date	
			Screen	
			23/01/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	13-18 (G/DL)	23/07/91	15.50	
RBC	4.5-6.5 (10¬12/L)	23/07/91	4.83	
WBC	4-11 (10¬9/L)	23/07/91	7.80	
WBC: N	40-75 (%)	23/07/91	58.00	
WBC: L	20-45 (%)	23/07/91	37.00	
WBC: E	1-6 (%)	23/07/91	0.00	<
WBC: M	2-10 (%)	23/07/91	5.00	
WBC: B	0-1 (%)	23/07/91	0.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	222.00	
NA+	135-145 (MMOL/L)	23/07/91	139.00	
K+	3.5-5 (MMOL/L)	23/07/91	4.50	
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.31	
PO4--	0.8-1.4 (MMOL/L)	23/07/91	1.26	
SGOT	3-40 (U/L)	23/07/91	16.00	
SGPT	9-40 (U/L)	23/07/91	17.00	
GAMMA GT	10-60 (U/L)	23/07/91	21.00	
LDH	80-210 (U/L)	23/07/91	112.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	168.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	4.60	
BUN	2.5-6.5 (MMOL/L)	23/07/91	4.60	
CREATININE	50-110 (UMOL/L)	23/07/91	94.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	228.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	15.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	4.00	
TOT. PROTEINS	56-85 (G/L)	23/07/91	74.00	
ALBUMINE	38-50 (G/L)	23/07/91	54.00	>
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	5.10	
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	1.30	
TSH	0.4-4 (MU/L)	23/07/91	2.20	
T4	8.5-19 (PMOL/L)	23/07/91	18.20	

1920

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 11 Patient: 328 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			28/01/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	13-18 (G/DL)	23/07/91	13.00	
RBC	4.5-6.5 (10¬12/L)	23/07/91	4.29	<
WBC	4-11 (10¬9/L)	23/07/91	5.10	
WBC: N	40-75 (%)	23/07/91	69.00	
WBC: L	20-45 (%)	23/07/91	29.00	
WBC: E	1-6 (%)	23/07/91	1.00	
WBC: M	2-10 (%)	23/07/91	1.00	<
WBC: B	0-1 (%)	23/07/91	0.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	312.00	
NA+	135-145 (MMOL/L)	23/07/91	141.00	
K+	3.5-5 (MMOL/L)	23/07/91	4.40	
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.18	
PO4--	0.8-1.4 (MMOL/L)	23/07/91	1.34	
SGOT	3-40 (U/L)	23/07/91	19.00	
SGPT	9-40 (U/L)	23/07/91	13.00	
GAMMA GT	10-60 (U/L)	23/07/91	7.00	<
LDH	80-210 (U/L)	23/07/91	143.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	113.00	
BUN	2.5-6.5 (MMOL/L)	23/07/91	6.10	
CREATININE	50-110 (UMOL/L)	23/07/91	78.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	178.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	8.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	3.00	
ALBUMINE	38-50 (G/L)	23/07/91	48.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	3.80	
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	0.70	<
TSH	0.4-4 (MU/L)	23/07/91	15.00	>>
T4	8.5-19 (PMOL/L)	23/07/91	7.70	<

1021

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 11 Patient: 329 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			01/04/92		30/04/92		21/05/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	13-18 (G/DL)	23/07/91	13.60		13.70		13.00	
RBC	4.5-6.5 (10~12/L)	23/07/91	4.56		4.63		4.55	
WBC	4-11 (10~9/L)	23/07/91	5.30		5.50		6.80	
WBC: N	40-75 (%)	23/07/91	76.00	>	63.00			
WBC: L	20-45 (%)	23/07/91	22.00		34.00		34.90	
WBC: E	1-6 (%)	23/07/91	1.00		1.00			
WBC: M	2-10 (%)	23/07/91	1.00	<	2.00		8.90	
WBC: B	0-1 (%)	23/07/91	0.00		0.00			
PLATELETS	150-400 (10~9/L)	23/07/91	255.00		246.00		318.00	
NA+	135-145 (MMOL/L)	23/07/91	144.00		139.00		134.00	<
K+	3.5-5 (MMOL/L)	23/07/91	4.20		4.40		4.40	
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.22		2.19		2.41	
PO4--	0.8-1.4 (MMOL/L)	23/07/91	1.09		1.18		1.32	
SGOT	3-40 (U/L)	23/07/91	17.00		15.00		14.00	
SGPT	9-40 (U/L)	23/07/91			22.00			
GAMMA GT	10-60 (U/L)	23/07/91	37.00		24.00		29.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	131.00		129.00		120.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	6.40		5.00		4.60	
BUN	2.5-6.5 (MMOL/L)	23/07/91	6.50		5.70		4.80	
CREATININE	50-110 (UMOL/L)	23/07/91	86.00		80.00		77.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	303.00		276.00		275.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	4.00		6.00		9.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	2.00		4.00		3.00	
TOT. PROTEINS	56-85 (G/L)	23/07/91	79.00				73.00	
ALBUMINE	38-50 (G/L)	23/07/91	45.00		46.00		45.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	6.70		5.80		6.40	
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	3.40	>>	2.80	>>	4.20	>>
TSH	0.4-4 (MU/L)	23/07/91	1.50					
T4	8.5-19 (PMOL/L)	23/07/91	17.40					

1922

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 11 Patient: 330 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/04/92		30/04/92		21/05/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	23/07/91	15.70		16.90		15.70	
RBC	4.5-6.5 (10¬12/L)	23/07/91	5.26		5.36		4.95	
WBC	4-11 (10¬9/L)	23/07/91	9.30		4.70		5.40	
WBC: N	40-75 (%)	23/07/91	85.00	>	84.00	>	90.00	>
WBC: L	20-45 (%)	23/07/91	15.00	<	14.00	<	9.00	<<
WBC: E	1-6 (%)	23/07/91	0.00	<	2.00		0.00	<
WBC: M	2-10 (%)	23/07/91	0.00	<	0.00	<	1.00	<
WBC: B	0-1 (%)	23/07/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	267.00		282.00		319.00	
NA+	135-145 (MMOL/L)	23/07/91	144.00				142.00	
K+	3.5-5 (MMOL/L)	23/07/91	4.90				4.50	
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.34				2.28	
PO4--	0.8-1.4 (MMOL/L)	23/07/91	1.73	>>			1.06	
SGOT	3-40 (U/L)	23/07/91	20.00				85.00	>>
SGPT	9-40 (U/L)	23/07/91					77.00	>
GAMMA GT	10-60 (U/L)	23/07/91	11.00				11.00	
LDH	80-210 (U/L)	23/07/91					196.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	156.00				155.00	
GLUCOSE	3.5-6 (MMOL/L)	23/07/91	4.20				3.80	
BUN	2.5-6.5 (MMOL/L)	23/07/91	5.20				5.00	
CREATININE	50-110 (UMOL/L)	23/07/91	108.00				93.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	397.00				325.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	14.00				12.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	4.40				3.00	
TOT. PROTEINS	56-85 (G/L)	23/07/91	69.00				68.00	
ALBUMINE	38-50 (G/L)	23/07/91	44.00				43.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	4.90				4.90	
TRIGLYCERIDES	0,8-1.9 (MMOL/L)	23/07/91	1.00				1.50	
TSH	0,4-4 (MU/L)	23/07/91	2.20				1.90	
T4	8.5-19 (PMOL/L)	23/07/91	14.00					

1923

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 11 Patient: 331 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			08/04/92		07/05/92		28/05/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	23/07/91	14.20		15.50		14.70	
RBC	4.5-6.5 (10¬12/L)	23/07/91	4.84				5.09	
WBC	4-11 (10¬9/L)	23/07/91	4.90		4.00		4.70	
WBC: N	40-75 (%)	23/07/91	66.00				71.00	
WBC: L	20-45 (%)	23/07/91	29.00				27.00	
WBC: E	1-6 (%)	23/07/91	0.00	<			1.00	
WBC: M	2-10 (%)	23/07/91	5.00				1.00	<
WBC: B	0-1 (%)	23/07/91	0.00				0.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	268.00		254.00		296.00	
NA+	135-145 (MMOL/L)	23/07/91	141.00		140.00		138.00	
K+	3.5-5 (MMOL/L)	23/07/91	4.30		4.10		4.30	
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.27		2.46		2.51	
PO4--	0.8-1.4 (MMOL/L)	23/07/91					0.92	
SGOT	3-40 (U/L)	23/07/91	41.00	>	38.00		23.00	
SGPT	9-40 (U/L)	23/07/91			74.00	>	28.00	
GAMMA GT	10-60 (U/L)	23/07/91	141.00	>>	160.00	>>	85.00	>
LDH	80-210 (U/L)	23/07/91	139.00		135.00		120.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	196.00		215.00		197.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	6.10		5.80		5.10	
BUN	2.5-6.5 (MMOL/L)	23/07/91	5.00		7.60	>	5.60	
CREATININE	50-110 (UMOL/L)	23/07/91	97.00		111.00	>	95.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	272.00		356.00		260.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	6.00		9.00		8.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91			5.00		3.00	
TOT. PROTEINS	56-85 (G/L)	23/07/91	81.00		84.00		80.00	
ALBUMINE	38-50 (G/L)	23/07/91	46.00		49.00		47.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	6.10		7.40	>	6.70	
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	1.90		1.70		1.90	
TSH	0.4-4 (MU/L)	23/07/91	0.50					
T4	8.5-19 (PMOL/L)	23/07/91	12.50					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 11 Patient: 332 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			13/05/92		08/06/92		29/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	23/07/91	16.70		16.00		15.50	
RBC	4.5-6.5 (10¬12/L)	23/07/91	5.16		5.04		4.96	
WBC	4-11 (10¬9/L)	23/07/91	7.30		6.40		7.50	
WBC: N	40-75 (%)	23/07/91	95.00	>			76.20	>
WBC: L	20-45 (%)	23/07/91	3.00	<<			17.80	<
WBC: E	1-6 (%)	23/07/91	0.00	<			0.00	<
WBC: M	2-10 (%)	23/07/91	2.00				6.00	
WBC: B	0-1 (%)	23/07/91	0.00				0.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	289.00		274.00		277.00	
NA+	135-145 (MMOL/L)	23/07/91	145.00		148.00	>	143.00	
K+	3.5-5 (MMOL/L)	23/07/91	3.30	<	3.80		3.40	<
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.42		2.22		2.41	
PO4--	0.8-1.4 (MMOL/L)	23/07/91	0.94		0.84		0.87	
SGOT	3-40 (U/L)	23/07/91	16.00		25.00		22.00	
SGPT	9-40 (U/L)	23/07/91	17.00		17.00		24.00	
GAMMA GT	10-60 (U/L)	23/07/91	29.00		28.00		27.00	
LDH	80-210 (U/L)	23/07/91	180.00		190.00		217.00	>
ALK. PHOSPH.	100-275 (U/L)	23/07/91	131.00		145.00		156.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	5.10		5.70		6.10	
BUN	2.5-6.5 (MMOL/L)	23/07/91	6.10		6.20			
CREATININE	50-110 (UMOL/L)	23/07/91	154.00	>	159.00	>	147.00	>
URIC ACID	155-405 (UMOL/L)	23/07/91	430.00	>	427.00	>		
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	7.00		9.00		8.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	2.00		3.00		3.00	
TOT. PROTEINS	56-85 (G/L)	23/07/91	76.00		71.00		78.00	
ALBUMINE	38-50 (G/L)	23/07/91	42.00		41.00		43.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	5.80		5.50		6.40	
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	1.20		1.60		1.30	
TSH	0.4-4 (MU/L)	23/07/91	0.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 11 Patient: 333 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/05/92		16/06/92		07/07/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	23/07/91	15.40		14.60		15.40	
RBC	4.5-6.5 (10¬12/L)	23/07/91	5.18		4.82		5.08	
WBC	4-11 (10¬9/L)	23/07/91	5.90		6.30		7.60	
WBC: N	40-75 (%)	23/07/91	76.00	>	71.90		67.00	
WBC: L	20-45 (%)	23/07/91	22.00		25.80		28.00	
WBC: E	1-6 (%)	23/07/91	1.00		0.00	<	0.00	<
WBC: M	2-10 (%)	23/07/91	0.00	<	2.30		4.00	
WBC: B	0-1 (%)	23/07/91	1.00		0.00		1.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	341.00		216.00		352.00	
NA+	135-145 (MMOL/L)	23/07/91	142.00		141.00		145.00	
K+	3.5-5 (MMOL/L)	23/07/91	4.20		3.90		4.80	
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.38		2.26		2.30	
PO4--	0.8-1.4 (MMOL/L)	23/07/91	0.86		0.76	<	1.10	
SGOT	3-40 (U/L)	23/07/91			35.00		34.00	
SGPT	9-40 (U/L)	23/07/91	24.00		28.00		24.00	
GAMMA GT	10-60 (U/L)	23/07/91	63.00	>	57.00		74.00	>
LDH	80-210 (U/L)	23/07/91			214.00	>	153.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	186.00		186.00		206.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	4.80		6.00		4.70	
BUN	2.5-6.5 (MMOL/L)	23/07/91	4.00		5.60		5.70	
CREATININE	50-110 (UMOL/L)	23/07/91	100.00		98.00		103.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	436.00	>	446.00	>	453.00	>
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	15.00		12.00		8.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	3.00		1.00		2.00	
TOT. PROTEINS	56-85 (G/L)	23/07/91	75.00		70.00		71.00	
ALBUMINE	38-50 (G/L)	23/07/91	46.00		44.00		41.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	5.80		6.00		6.40	
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	1.50		2.30	>	2.40	>
TSH	0.4-4 (MU/L)	23/07/91	0.30	<<				

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 11 Patient: 334 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			21/05/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	13-18 (G/DL)	23/07/91	13.40	
RBC	4.5-6.5 (10¬12/L)	23/07/91	4.86	
WBC	4-11 (10¬9/L)	23/07/91	4.60	
WBC: N	40-75 (%)	23/07/91	77.00	>
WBC: L	20-45 (%)	23/07/91	20.00	
WBC: E	1-6 (%)	23/07/91	1.00	
WBC: M	2-10 (%)	23/07/91	2.00	
WBC: B	0-1 (%)	23/07/91	0.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	367.00	
NA+	135-145 (MMOL/L)	23/07/91	140.00	
K+	3.5-5 (MMOL/L)	23/07/91	5.40	>
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.28	
PO4--	0.8-1.4 (MMOL/L)	23/07/91	1.10	
SGOT	3-40 (U/L)	23/07/91	10.00	
SGPT	9-40 (U/L)	23/07/91	16.00	
GAMMA GT	10-60 (U/L)	23/07/91	10.00	
LDH	80-210 (U/L)	23/07/91	86.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	130.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	5.70	
BUN	2.5-6.5 (MMOL/L)	23/07/91	4.30	
CREATININE	50-110 (UMOL/L)	23/07/91	72.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	226.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	11.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	3.00	
TOT. PROTEINS	56-85 (G/L)	23/07/91	69.00	
ALBUMINE	38-50 (G/L)	23/07/91	44.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	5.10	
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	0.50	<
TSH	0.4-4 (MU/L)	23/07/91	1.10	

1927

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 11 Patient: 335 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			21/05/92		23/06/92		14/07/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	23/07/91	16.70		15.80		16.00	
RBC	4.5-6.5 (10¬12/L)	23/07/91	5.44		5.37		5.34	
WBC	4-11 (10¬9/L)	23/07/91	5.30		5.60		7.50	
WBC: N	40-75 (%)	23/07/91	57.00		56.30		59.80	
WBC: L	20-45 (%)	23/07/91	43.00		37.00		36.10	
WBC: E	1-6 (%)	23/07/91	0.00	<	0.00	<	0.00	<
WBC: M	2-10 (%)	23/07/91	0.00	<	6.70		4.10	
WBC: B	0-1 (%)	23/07/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	369.00		295.00		334.00	
NA+	135-145 (MMOL/L)	23/07/91	140.00		141.00		136.00	
K+	3.5-5 (MMOL/L)	23/07/91	4.40		4.30		4.30	
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.49		2.45		2.40	
PO4--	0.8-1.4 (MMOL/L)	23/07/91	1.14		1.19		1.18	
SGOT	3-40 (U/L)	23/07/91			14.00		17.00	
SGPT	9-40 (U/L)	23/07/91	16.00		14.00		26.00	
GAMMA GT	10-60 (U/L)	23/07/91	25.00		17.00		22.00	
LDH	80-210 (U/L)	23/07/91			91.00		115.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	172.00		151.00		175.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	4.60		5.30		4.70	
BUN	2.5-6.5 (MMOL/L)	23/07/91	6.40		7.30	>	6.20	
CREATININE	50-110 (UMOL/L)	23/07/91	108.00		107.00		105.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	378.00		421.00	>	392.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	8.00		10.00		9.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	2.00		3.00		3.00	
TOT. PROTEINS	56-85 (G/L)	23/07/91	82.00		74.00		77.00	
ALBUMINE	38-50 (G/L)	23/07/91	47.00		47.00		45.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	7.20	>	6.00		6.60	
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	6.50	>>	3.60	>>	6.90	>>
TSH	0.4-4 (MU/L)	23/07/91	0.90					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0
9550082
LABORATORY DATA
Centre: 11 Patient: 336 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			15/06/92	
			value	(◊)
Laboratory test	Range value	Range date		
HB	13-18 (G/DL)	23/07/91	13.10	
RBC	4.5-6.5 (10¬12/L)	23/07/91	4.48	<
WBC	4-11 (10¬9/L)	23/07/91	10.80	
WBC: N	40-75 (%)	23/07/91	81.00	>
WBC: L	20-45 (%)	23/07/91	11.00	<<
WBC: E	1-6 (%)	23/07/91	1.00	
WBC: M	2-10 (%)	23/07/91	1.00	<
WBC: B	0-1 (%)	23/07/91	0.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	432.00	>
NA+	135-145 (MMOL/L)	23/07/91	137.00	
K+	3.5-5 (MMOL/L)	23/07/91	3.70	
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.45	
PO4--	0.8-1.4 (MMOL/L)	23/07/91	0.89	
SGOT	3-40 (U/L)	23/07/91	13.00	
SGPT	9-40 (U/L)	23/07/91	25.00	
GAMMA GT	10-60 (U/L)	23/07/91	32.00	
LDH	80-210 (U/L)	23/07/91	147.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	164.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	3.40	<
BUN	2.5-6.5 (MMOL/L)	23/07/91	6.10	
CREATININE	50-110 (UMOL/L)	23/07/91	71.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	413.00	>
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	5.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	2.00	
ALBUMINE	38-50 (G/L)	23/07/91	42.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	6.40	
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	3.90	>>
TSH	0.4-4 (MU/L)	23/07/91	2.60	

1929

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 11 Patient: 337 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			14/06/92		23/07/92		13/08/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	23/07/91	12.50	<	12.90	<	13.50	
RBC	4.5-6.5 (10-12/L)	23/07/91	3.97	<	4.04	<	4.17	<
WBC	4-11 (10-9/L)	23/07/91	6.10		6.70		7.30	
WBC: N	40-75 (%)	23/07/91	82.00	>			66.00	
WBC: L	20-45 (%)	23/07/91	14.00	<			22.00	
WBC: E	1-6 (%)	23/07/91	1.00				3.00	
WBC: M	2-10 (%)	23/07/91	3.00				7.00	
WBC: B	0-1 (%)	23/07/91	0.00				2.00	>>
PLATELETS	150-400 (10-9/L)	23/07/91	179.00		173.00		189.00	
NA+	135-145 (MMOL/L)	23/07/91	142.00		140.00		143.00	
K+	3.5-5 (MMOL/L)	23/07/91	4.20		4.80		4.50	
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.27		2.30		2.21	
PO4--	0.8-1.4 (MMOL/L)	23/07/91	0.98		1.32			
SGOT	3-40 (U/L)	23/07/91	20.00		15.00		23.00	
SGPT	9-40 (U/L)	23/07/91	27.00		22.00		15.00	
GAMMA GT	10-60 (U/L)	23/07/91	16.00		15.00		15.00	
LDH	80-210 (U/L)	23/07/91	127.00		121.00		113.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	108.00		117.00		127.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	3.30	<	4.50		4.60	
BUN	2.5-6.5 (MMOL/L)	23/07/91	6.20		5.00		4.60	
CREATININE	50-110 (UMOL/L)	23/07/91	82.00		85.00		79.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	183.00		196.00		162.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	9.00		7.00		7.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	3.00		2.00			
TOT. PROTEINS	56-85 (G/L)	23/07/91	69.00		72.00		72.00	
ALBUMINE	38-50 (G/L)	23/07/91	43.00		45.00		44.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	5.00		4.60		4.70	
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	0.40	<	0.40	<	0.40	<
TSH	0.4-4 (MU/L)	23/07/91	0.40				0.80	
T4	8.5-19 (PMOL/L)	23/07/91	14.00				14.90	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 11 Patient: 338 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date	
			Screen	
			14/07/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	13-18 (G/DL)	23/07/91	14.10	
RBC	4.5-6.5 (10¬12/L)	23/07/91	4.43	<
WBC	4-11 (10¬9/L)	23/07/91	6.60	
WBC: N	40-75 (%)	23/07/91	65.00	
WBC: L	20-45 (%)	23/07/91	34.00	
WBC: E	1-6 (%)	23/07/91	0.00	<
WBC: M	2-10 (%)	23/07/91	1.00	<
WBC: B	0-1 (%)	23/07/91	0.00	
PLATELETS	150-400 (10¬9/L)	23/07/91	155.00	
NA+	135-145 (MMOL/L)	23/07/91	138.00	
K+	3.5-5 (MMOL/L)	23/07/91	4.00	
Ca++	2.1-2.6 (MMOL/L)	23/07/91	2.21	
PO4--	0.8-1.4 (MMOL/L)	23/07/91	0.79	<
SGOT	3-40 (U/L)	23/07/91	18.00	
SGPT	9-40 (U/L)	23/07/91	14.00	
GAMMA GT	10-60 (U/L)	23/07/91	17.00	
LDH	80-210 (U/L)	23/07/91	128.00	
ALK. PHOSPH.	100-275 (U/L)	23/07/91	151.00	
GLUCOSE	3.5-8 (MMOL/L)	23/07/91	6.20	
BUN	2.5-6.5 (MMOL/L)	23/07/91	2.60	
CREATININE	50-110 (UMOL/L)	23/07/91	87.00	
URIC ACID	155-405 (UMOL/L)	23/07/91	297.00	
TOT BILIRUBIN	2-17 (UMOL/L)	23/07/91	12.00	
DIR BILIRUBIN	0-5 (UMOL/L)	23/07/91	3.00	
TOT. PROTEINS	56-85 (G/L)	23/07/91	66.00	
ALBUMINE	38-50 (G/L)	23/07/91	43.00	
TOT. CHOLEST.	3.5-6.7 (MMOL/L)	23/07/91	4.10	
TRIGLYCERIDES	0.8-1.9 (MMOL/L)	23/07/91	0.70	<
TSH	0.4-4 (MU/L)	23/07/91	1.50	

1931

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0
9550082
LABORATORY DATA
Centre: 12 Patient: 367 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/12/91		10/01/92		31/01/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	120-150 (G/L)	15/12/91	158.00	>	139.00		143.00	
HT	0.37-0.43 (L/L)	15/12/91	0.45	>	0.42		0.42	
RBC	4-4.5 (10¬12/L)	15/12/91	4.97	>	4.60	>	4.64	>
WBC	4.5-10.5 (10¬9/L)	15/12/91	9.20		5.10		6.10	
WBC: N	65-72 (%)	15/12/91	46.00	<	71.00		68.00	
WBC: L	20-35 (%)	15/12/91	32.00		24.00		23.00	
WBC: E	1-3 (%)	15/12/91	0.00	<	1.00		3.00	
WBC: M	3-7 (%)	15/12/91	2.00	<	4.00		5.00	
WBC: B	0-1 (%)	15/12/91	0.00		0.00		1.00	
PLATELETS	150-400 (10¬9/L)	15/12/91	317.00		315.00		365.00	
NA+	135-145 (MMOL/L)	15/12/91	142.00		139.00		139.00	
K+	3.5-5 (MMOL/L)	15/12/91	4.00		3.80		4.10	
CL-	98-108 (MMOL/L)	15/12/91	100.00		102.00		104.00	
Ca++	2.1-2.55 (MMOL/L)	15/12/91	2.55		2.45		2.30	
PO4--	0.9-1.45 (MMOL/L)	15/12/91	1.27		1.25		1.12	
SGOT	10-42 (IU/L)	15/12/91	24.00		21.00		46.00	>
SGPT	10-60 (IU/L)	15/12/91	20.00		19.00		63.00	>
GAMMA GT	7-64 (IU/L)	15/12/91	22.00		20.00		74.00	>
LDH	91-180 (IU/L)	15/12/91	180.00		157.00		177.00	
ALK. PHOSPH.	42-121 (IU/L)	15/12/91	68.00		66.00		102.00	
GLUCOSE	3.9-5.8 (MMOL/L)	15/12/91	5.70		4.40		5.40	
BUN	2.5-6.4 (MMOL/L)	15/12/91	5.50		6.90	>	6.60	>
CREATININE	53-115 (UMOL/L)	15/12/91	70.00		65.00		70.00	
URIC ACID	155-428 (UMOL/L)	15/12/91	274.00		305.00		338.00	
TOT BILIRUBIN	3.4-17.1 (UMOL/L)	15/12/91	16.20		10.80		11.80	
DIR BILIRUBIN	0-3.4 (UMOL/L)	15/12/91	0.00		0.00		0.80	
TOT. PROTEINS	60-83 (G/L)	15/12/91	73.00		65.00		68.00	
ALBUMINE	32-55 (G/L)	15/12/91	41.90		39.20		37.00	
TOT. CHOLEST.	4.15-8 (MMOL/L)	15/12/91	5.69		5.80		6.57	
TRIGLYCERIDES	0.4-1.92 (MMOL/L)	15/12/91	1.10		1.42		2.00	>
GLOBULINS ALPHA 1	0.03-0.06 ()	15/12/91	0.04		0.05		0.04	
GLOBULINS ALPHA 2	0.07-0.12 ()	15/12/91	0.09		0.09		0.08	
GLOBULINS BETA	0.09-0.15 ()	15/12/91	0.13		0.13		0.13	
GLOBULINS GAMMA	0.12-0.2 ()	15/12/91	0.12		0.11	<	0.13	
TSH	0.5-4 (MU/L)	15/12/91	3.70					
T4	64-167 (NMOL/L)	15/12/91	116.00					

1932

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 12 Patient: 368 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			19/12/91		14/01/92		04/02/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	120-150 (G/L)	15/12/91	134.00		144.00		137.00	
HT	0.37-0.43 (L/L)	15/12/91	0.40		0.42		0.41	
RBC	4-4.5 (10¬12/L)	15/12/91	4.44		4.74	>	4.55	>
WBC	4.5-10.5 (10¬9/L)	15/12/91	9.00		7.90		6.70	
WBC: N	65-72 (%)	15/12/91	78.00	>	72.00		77.00	>
WBC: L	20-35 (%)	15/12/91	18.00	<	25.00		20.00	
WBC: E	1-3 (%)	15/12/91	1.00		1.00		1.00	
WBC: M	3-7 (%)	15/12/91	3.00		2.00	<	2.00	<
PLATELETS	150-400 (10¬9/L)	15/12/91	295.00		356.00		304.00	
NA+	135-145 (MMOL/L)	15/12/91	136.00		137.00		139.00	
K+	3.5-5 (MMOL/L)	15/12/91	4.60		4.60		4.30	
CL-	98-108 (MMOL/L)	15/12/91	101.00		102.00		104.00	
Ca++	2.1-2.55 (MMOL/L)	15/12/91	2.57	>	2.53		2.49	
PO4--	0.9-1.45 (MMOL/L)	15/12/91	1.16		1.27		1.13	
SGOT	10-42 (IU/L)	15/12/91	17.00		18.00		17.00	
SGPT	10-60 (IU/L)	15/12/91	25.00		21.00		17.00	
GAMMA GT	7-64 (IU/L)	15/12/91	23.00		21.00		17.00	
LDH	91-180 (IU/L)	15/12/91	133.00		137.00		112.00	
ALK. PHOSPH.	42-121 (IU/L)	15/12/91	92.00		86.00		89.00	
GLUCOSE	3.9-5.8 (MMOL/L)	15/12/91	5.60		5.40		5.40	
BUN	2.5-6.4 (MMOL/L)	15/12/91	2.90		4.10		4.60	
CREATININE	53-115 (UMOL/L)	15/12/91	66.00		74.00		67.00	
URIC ACID	155-428 (UMOL/L)	15/12/91	372.00		304.00		335.00	
TOT BILIRUBIN	3.4-17.1 (UMOL/L)	15/12/91	8.40		9.70		8.30	
DIR BILIRUBIN	0-3.4 (UMOL/L)	15/12/91	0.00		0.60		0.60	
TOT. PROTEINS	60-83 (G/L)	15/12/91	84.00	>	76.00		74.00	
ALBUMINE	32-55 (G/L)	15/12/91	36.80		40.60		38.20	
TOT. CHOLEST.	4.15-8 (MMOL/L)	15/12/91	5.84		5.14		5.37	
TRIGLYCERIDES	0.4-1.92 (MMOL/L)	15/12/91	1.78		2.60	>>	2.12	>
GLOBULINS ALPHA 1	0.03-0.06 ()	15/12/91	0.03		0.03		0.03	
GLOBULINS ALPHA 2	0.07-0.12 ()	15/12/91	0.12		0.08		0.08	
GLOBULINS BETA	0.09-0.15 ()	15/12/91	0.17	>	0.15		0.15	
GLOBULINS GAMMA	0.12-0.2 ()	15/12/91	0.15		0.16		0.16	
TSH	0.5-4 (MU/L)	15/12/91	2.20					
T4	64-167 (NMOL/L)	15/12/91	83.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 12 Patient: 369 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			22/04/92		13/05/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
HB	120-150 (G/L)	15/12/91	130.00		130.00	
HT	0.37-0.43 (L/L)	15/12/91	0.40		0.39	
RBC	4-4.5 (10¬12/L)	15/12/91	4.32		4.29	
WBC	4.5-10.5 (10¬9/L)	15/12/91	7.00		6.40	
WBC: N	65-72 (%)	15/12/91	83.00	>	81.00	>
WBC: L	20-35 (%)	15/12/91	12.00	<<	18.00	<
WBC: E	1-3 (%)	15/12/91	2.00		0.00	<
WBC: M	3-7 (%)	15/12/91	3.00		1.00	<
WBC: B	0-1 (%)	15/12/91	0.00		0.00	
PLATELETS	150-400 (10¬9/L)	15/12/91	352.00		352.00	
NA+	135-145 (MMOL/L)	15/12/91	139.00		136.00	
K+	3.5-5 (MMOL/L)	15/12/91	4.10		5.20	>
CL-	98-108 (MMOL/L)	15/12/91	101.00		105.00	
Ca++	2.1-2.55 (MMOL/L)	15/12/91	2.38		2.42	
PO4--	0.9-1.45 (MMOL/L)	15/12/91	1.15		1.41	
SGOT	10-42 (IU/L)	15/12/91	26.00		33.00	
SGPT	10-60 (IU/L)	15/12/91	28.00		38.00	
GAMMA GT	7-64 (IU/L)	15/12/91	11.00		7.00	
LDH	91-180 (IU/L)	15/12/91	143.00		285.00	>
ALK. PHOSPH.	42-121 (IU/L)	15/12/91	73.00		76.00	
GLUCOSE	3.9-5.8 (MMOL/L)	15/12/91	5.10		5.20	
BUN	2.5-6.4 (MMOL/L)	15/12/91	4.00		6.10	
CREATININE	53-115 (UMOL/L)	15/12/91	68.00		72.00	
URIC ACID	155-428 (UMOL/L)	15/12/91	226.00		257.00	
TOT BILIRUBIN	3.4-17.1 (UMOL/L)	15/12/91	8.00		24.20	>
DIR BILIRUBIN	0-3.4 (UMOL/L)	15/12/91	1.20		5.50	>
TOT. PROTEINS	60-83 (G/L)	15/12/91	70.00		69.00	
ALBUMINE	32-55 (G/L)	15/12/91	40.40		40.30	
TOT. CHOLEST.	4.15-8 (MMOL/L)	15/12/91	6.86		5.93	
TRIGLYCERIDES	0.4-1.92 (MMOL/L)	15/12/91	1.35		1.53	
GLOBULINS ALPHA 1	0.03-0.06 ()	15/12/91	0.06		0.03	
GLOBULINS ALPHA 2	0.07-0.12 ()	15/12/91	0.08		0.12	
GLOBULINS BETA	0.09-0.15 ()	15/12/91	0.15		0.15	
GLOBULINS GAMMA	0.12-0.2 ()	15/12/91	0.11	<	0.11	<
TSH	0.5-4 (MU/L)	15/12/91	0.50			
T4	64-167 (NMOL/L)	15/12/91	89.00			

1934

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0
9550082
LABORATORY DATA
Centre: 12 Patient: 370 Treatment: Placebo Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			27/04/92		19/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	140-160 (G/L)	15/12/91	152.00		150.00	
HT	0.42-0.5 (L/L)	15/12/91	0.44		0.44	
RBC	4.5-5 (10¬12/L)	15/12/91	4.97		5.03	>
WBC	4.5-10 (10¬9/L)	15/12/91	9.00		7.80	
WBC: N	65-72 (%)	15/12/91	64.00	<	59.00	<
WBC: L	20-35 (%)	15/12/91	31.00		37.00	>
WBC: E	1-3 (%)	15/12/91	1.00		1.00	
WBC: M	3-7 (%)	15/12/91	2.00	<	3.00	
WBC: B	0-1 (%)	15/12/91	2.00	>>	0.00	
PLATELETS	150-400 (10¬9/L)	15/12/91	293.00		301.00	
NA+	135-145 (MMOL/L)	15/12/91	146.00	>	140.00	
K+	3.5-5 (MMOL/L)	15/12/91	4.20		4.50	
CL-	98-108 (MMOL/L)	15/12/91	108.00		102.00	
Ca++	2.1-2.55 (MMOL/L)	15/12/91	2.51		2.55	
PO4--	0.9-1.45 (MMOL/L)	15/12/91	1.09		1.06	
SGOT	10-42 (IU/L)	15/12/91	23.00		22.00	
SGPT	10-60 (IU/L)	15/12/91	22.00		37.00	
GAMMA GT	7-64 (IU/L)	15/12/91	33.00		30.00	
LDH	91-180 (IU/L)	15/12/91	114.00		114.00	
ALK. PHOSPH.	42-121 (IU/L)	15/12/91	98.00		83.00	
GLUCOSE	3.9-5.8 (MMOL/L)	15/12/91	6.50	>	6.10	>
BUN	2.5-6.4 (MMOL/L)	15/12/91	10.10	>>	5.80	
CREATININE	53-115 (UMOL/L)	15/12/91	108.00		125.00	>
URIC ACID	155-428 (UMOL/L)	15/12/91	399.00		457.00	>
TOT BILIRUBIN	3.4-17.1 (UMOL/L)	15/12/91	14.00		14.00	
DIR BILIRUBIN	0-3.4 (UMOL/L)	15/12/91	1.10		0.00	
TOT. PROTEINS	60-83 (G/L)	15/12/91	71.00		66.00	
ALBUMINE	32-55 (G/L)	15/12/91	41.10		42.30	
TOT. CHOLEST.	4.15-8 (MMOL/L)	15/12/91	6.11		6.35	
TRIGLYCERIDES	0.4-1.92 (MMOL/L)	15/12/91	2.23	>	2.15	>
GLOBULINS ALPHA 1	0.03-0.06 ()	15/12/91	0.02	<<	0.03	
GLOBULINS ALPHA 2	0.07-0.12 ()	15/12/91	0.07		0.07	
GLOBULINS BETA	0.09-0.15 ()	15/12/91	0.13		0.13	
GLOBULINS GAMMA	0.12-0.2 ()	15/12/91	0.13		0.13	
TSH	0.5-4 (MU/L)	15/12/91	0.40	<<		
T4	64-167 (NMOL/L)	15/12/91	84.00			

1935

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 12 Patient: 371 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 7	
			21/04/92		08/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	120-150 (G/L)	15/12/91	143.00		124.00	
HT	0.37-0.43 (L/L)	15/12/91	0.42		0.37	
RBC	4-4.5 (10¬12/L)	15/12/91	4.51	>	4.07	
WBC	4.5-10.5 (10¬9/L)	15/12/91	9.60		7.30	
WBC: N	65-72 (%)	15/12/91	56.00	<	56.00	<
WBC: L	20-35 (%)	15/12/91	39.00	>	39.00	>
WBC: E	1-3 (%)	15/12/91	3.00		2.00	
WBC: M	3-7 (%)	15/12/91	2.00	<	3.00	
WBC: B	0-1 (%)	15/12/91	0.00		0.00	
PLATELETS	150-400 (10¬9/L)	15/12/91	238.00		213.00	
NA+	135-145 (MMOL/L)	15/12/91	140.00		138.00	
K+	3.5-5 (MMOL/L)	15/12/91	4.20		4.10	
CL-	98-108 (MMOL/L)	15/12/91	100.00		105.00	
Ca++	2.1-2.55 (MMOL/L)	15/12/91	2.47		2.43	
PO4--	0.9-1.45 (MMOL/L)	15/12/91	1.24		1.34	
SGOT	10-42 (IU/L)	15/12/91	19.00		17.00	
SGPT	10-60 (IU/L)	15/12/91	13.00		12.00	
GAMMA GT	7-64 (IU/L)	15/12/91	17.00		17.00	
LDH	91-180 (IU/L)	15/12/91	142.00		131.00	
ALK. PHOSPH.	42-121 (IU/L)	15/12/91	83.00		74.00	
GLUCOSE	3.9-5.8 (MMOL/L)	15/12/91	4.60		4.60	
BUN	2.5-6.4 (MMOL/L)	15/12/91	4.40		4.70	
CREATININE	53-115 (UMOL/L)	15/12/91	77.00		81.00	
URIC ACID	155-428 (UMOL/L)	15/12/91	219.00		228.00	
TOT BILIRUBIN	3.4-17.1 (UMOL/L)	15/12/91	8.70		8.30	
DIR BILIRUBIN	0-3.4 (UMOL/L)	15/12/91	0.00		0.20	
TOT. PROTEINS	60-83 (G/L)	15/12/91	77.00		66.50	
ALBUMINE	32-55 (G/L)	15/12/91	39.20		36.30	
TOT. CHOLEST.	4.15-8 (MMOL/L)	15/12/91	6.27		6.25	
TRIGLYCERIDES	0.4-1.92 (MMOL/L)	15/12/91	1.81		2.05	>
GLOBULINS ALPHA 1	0.03-0.06 ()	15/12/91	0.03			
GLOBULINS ALPHA 2	0.07-0.12 ()	15/12/91	0.09			
GLOBULINS BETA	0.09-0.15 ()	15/12/91	0.15			
GLOBULINS GAMMA	0.12-0.2 ()	15/12/91	0.17			
TSH	0.5-4 (MU/L)	15/12/91	0.90			
T4	64-167 (NMOL/L)	15/12/91	81.00			

1936

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max ran
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 12 Patient: 372 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			01/06/92		01/07/92		17/07/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	140-160 (G/L)	15/12/91	158.00		149.00		152.00	
HT	0.42-0.5 (L/L)	15/12/91	0.47		0.45		0.46	
RBC	4.5-5 (10¬12/L)	15/12/91	5.13	>	4.88		5.00	
WBC	4.5-10 (10¬9/L)	15/12/91	4.90		4.90		4.70	
WBC: N	65-72 (%)	15/12/91	51.00	<	47.00	<	52.00	<
WBC: L	20-35 (%)	15/12/91	47.00	>>	51.00	>>	45.00	>
WBC: E	1-3 (%)	15/12/91	0.00	<	0.00	<	0.00	<
WBC: M	3-7 (%)	15/12/91	2.00	<	2.00	<	3.00	
WBC: B	0-1 (%)	15/12/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	15/12/91	190.00		208.00		209.00	
NA+	135-145 (MMOL/L)	15/12/91	137.00		138.00		138.00	
K+	3.5-5 (MMOL/L)	15/12/91	4.50		4.00		4.40	
CL-	98-108 (MMOL/L)	15/12/91	101.00		102.00		102.00	
Ca++	2.1-2.55 (MMOL/L)	15/12/91	2.36		2.26		2.29	
PO4--	0.9-1.45 (MMOL/L)	15/12/91	1.08		1.25		0.92	
SGOT	10-42 (IU/L)	15/12/91	19.00		17.00		18.00	
SGPT	10-60 (IU/L)	15/12/91	13.00		12.00		12.00	
GAMMA GT	7-64 (IU/L)	15/12/91	16.00		12.00		12.00	
LDH	91-180 (IU/L)	15/12/91	142.00		127.00		126.00	
ALK. PHOSPH.	42-121 (IU/L)	15/12/91	78.00		75.00		74.00	
GLUCOSE	3.9-5.8 (MMOL/L)	15/12/91	5.30		5.00		4.70	
BUN	2.5-6.4 (MMOL/L)	15/12/91	4.90		4.10		5.20	
CREATININE	53-115 (UMOL/L)	15/12/91	113.00		114.00		108.00	
URIC ACID	155-428 (UMOL/L)	15/12/91	404.00		430.00	>	441.00	>
TOT BILIRUBIN	3.4-17.1 (UMOL/L)	15/12/91	10.60		15.80		17.10	
DIR BILIRUBIN	0-3.4 (UMOL/L)	15/12/91	0.70		0.80		0.00	
TOT. PROTEINS	60-83 (G/L)	15/12/91	69.00		68.00		70.00	
ALBUMINE	32-55 (G/L)	15/12/91	38.00		36.40		37.90	
TOT. CHOLEST.	4.15-8 (MMOL/L)	15/12/91	5.02		5.03		5.49	
TRIGLYCERIDES	0.4-1.92 (MMOL/L)	15/12/91	1.57		1.07		1.05	
GLOBULINS ALPHA 1	0.03-0.06 ()	15/12/91	0.03		0.03		0.02	<<
GLOBULINS ALPHA 2	0.07-0.12 ()	15/12/91	0.09		0.10		0.09	
GLOBULINS BETA	0.09-0.15 ()	15/12/91	0.15		0.12		0.13	
GLOBULINS GAMMA	0.12-0.2 ()	15/12/91	0.15		0.20		0.17	
TSH	0.5-4 (MU/L)	15/12/91	0.40	<<				
T4	64-167 (NMOL/L)	15/12/91	92.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 12 Patient: 373 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/06/92		25/06/92		14/07/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	140-160 (G/L)	15/12/91	157.00		143.00		156.00	
HT	0.42-0.5 (L/L)	15/12/91	0.46		0.48		0.46	
RBC	4.5-5 (10¬12/L)	15/12/91	5.06	>	5.28	>	5.04	>
WBC	4.5-10 (10¬9/L)	15/12/91	7.70		8.30		12.10	>
WBC: N	65-72 (%)	15/12/91	91.00	>	66.00		80.00	>
WBC: L	20-35 (%)	15/12/91	7.00	<<	30.00		17.00	<
WBC: E	1-3 (%)	15/12/91	1.00		1.00		1.00	
WBC: M	3-7 (%)	15/12/91	1.00	<	3.00		2.00	<
WBC: B	0-1 (%)	15/12/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	15/12/91	338.00		346.00		336.00	
NA+	135-145 (MMOL/L)	15/12/91	139.00		138.00		136.00	
K+	3.5-5 (MMOL/L)	15/12/91	4.10		5.20	>	4.60	
CL-	98-108 (MMOL/L)	15/12/91	105.00		102.00		102.00	
Ca++	2.1-2.55 (MMOL/L)	15/12/91	2.43		2.72	>	2.35	
PO4--	0.9-1.45 (MMOL/L)	15/12/91	1.13		1.40		1.08	
SGOT	10-42 (IU/L)	15/12/91	24.00		28.00		28.00	
SGPT	10-60 (IU/L)	15/12/91	20.00		26.00		21.00	
GAMMA GT	7-64 (IU/L)	15/12/91	18.00		22.00		13.00	
LDH	91-180 (IU/L)	15/12/91	119.00		149.00		151.00	
ALK. PHOSPH.	42-121 (IU/L)	15/12/91	78.00		123.00	>	88.00	
GLUCOSE	3.9-5.8 (MMOL/L)	15/12/91	4.60		5.70		5.00	
BUN	2.5-6.4 (MMOL/L)	15/12/91	6.80	>	6.60	>	6.00	
CREATININE	53-115 (UMOL/L)	15/12/91	98.00		97.00		85.00	
URIC ACID	155-428 (UMOL/L)	15/12/91	258.00		258.00		209.00	
TOT BILIRUBIN	3.4-17.1 (UMOL/L)	15/12/91	9.00		11.60		10.90	
DIR BILIRUBIN	0-3.4 (UMOL/L)	15/12/91	0.00		1.40		0.20	
TOT. PROTEINS	60-83 (G/L)	15/12/91	66.00		77.00		73.00	
ALBUMINE	32-55 (G/L)	15/12/91	40.00		45.80		42.00	
TOT. CHOLEST.	4.15-8 (MMOL/L)	15/12/91	4.82		6.77		4.39	
TRIGLYCERIDES	0.4-1.92 (MMOL/L)	15/12/91	1.74		1.78		1.53	
GLOBULINS ALPHA 1	0.03-0.06 ()	15/12/91	0.03		0.03		0.03	
GLOBULINS ALPHA 2	0.07-0.12 ()	15/12/91	0.08		0.12		0.08	
GLOBULINS BETA	0.09-0.15 ()	15/12/91	0.10		0.11		0.10	
GLOBULINS GAMMA	0.12-0.2 ()	15/12/91	0.21	>	0.15		0.14	
TSH	0.5-4 (MU/L)	15/12/91	0.60					
T4	64-167 (NMOL/L)	15/12/91	91.00					

1938

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 12 Patient: 374 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 28	
			09/06/92		30/06/92		06/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	120-150 (G/L)	15/12/91	130.00		133.00		138.00	
HT	0.37-0.43 (L/L)	15/12/91	0.39		0.40		0.42	
RBC	4-4.5 (10¬12/L)	15/12/91	4.40		4.56	>	4.73	>
WBC	4.5-10.5 (10¬9/L)	15/12/91	6.90		8.50		7.70	
WBC: N	65-72 (%)	15/12/91	62.00	<	66.00		69.00	
WBC: L	20-35 (%)	15/12/91	29.00		25.00		25.00	
WBC: E	1-3 (%)	15/12/91	4.00	>>	1.00		4.00	>>
WBC: M	3-7 (%)	15/12/91	4.00		8.00	>	2.00	<
WBC: B	0-1 (%)	15/12/91	1.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	15/12/91	409.00	>	302.00		321.00	
NA+	135-145 (MMOL/L)	15/12/91	141.00		139.00		140.00	
K+	3.5-5 (MMOL/L)	15/12/91	4.30		4.20		4.90	
CL-	98-108 (MMOL/L)	15/12/91	105.00		106.00		102.00	
Ca++	2.1-2.55 (MMOL/L)	15/12/91	2.51		2.39		2.43	
PO4--	0.9-1.45 (MMOL/L)	15/12/91	1.28		1.02		1.17	
SGOT	10-42 (IU/L)	15/12/91	20.00		20.00		19.00	
SGPT	10-60 (IU/L)	15/12/91	22.00		22.00		24.00	
GAMMA GT	7-64 (IU/L)	15/12/91	22.00		16.00		20.00	
LDH	91-180 (IU/L)	15/12/91	123.00		139.00		126.00	
ALK. PHOSPH.	42-121 (IU/L)	15/12/91	74.00		70.00		77.00	
GLUCOSE	3.9-5.8 (MMOL/L)	15/12/91	5.20		5.30		5.00	
BUN	2.5-6.4 (MMOL/L)	15/12/91	3.30		4.10		4.80	
CREATININE	53-115 (UMOL/L)	15/12/91	85.00		77.00		97.00	
URIC ACID	155-428 (UMOL/L)	15/12/91	285.00		345.00		361.00	
TOT BILIRUBIN	3.4-17.1 (UMOL/L)	15/12/91	10.30		14.50		10.60	
DIR BILIRUBIN	0-3.4 (UMOL/L)	15/12/91	0.70		0.00		0.00	
TOT. PROTEINS	60-83 (G/L)	15/12/91	71.00		70.00		72.00	
ALBUMINE	32-55 (G/L)	15/12/91	44.00		41.80		43.30	
TOT. CHOLEST.	4.15-8 (MMOL/L)	15/12/91	5.67		5.07		5.14	
TRIGLYCERIDES	0.4-1.92 (MMOL/L)	15/12/91	1.61		1.23		1.20	
GLOBULINS ALPHA 1	0.03-0.06 ()	15/12/91	0.03		0.04		0.04	
GLOBULINS ALPHA 2	0.07-0.12 ()	15/12/91	0.09		0.08		0.09	
GLOBULINS BETA	0.09-0.15 ()	15/12/91	0.15		0.12		0.15	
GLOBULINS GAMMA	0.12-0.2 ()	15/12/91	0.11	<	0.11	<	0.14	
TSH	0.5-4 (MU/L)	15/12/91	1.00					
T4	64-167 (NMOL/L)	15/12/91	159.00					

1939

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 12 Patient: 375 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date	
			Screen	
			12/06/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	140-160 (G/L)	15/12/91	157.00	
HT	0.42-0.5 (L/L)	15/12/91	0.47	
RBC	4.5-5 (10¬12/L)	15/12/91	4.92	
WBC	4.5-10 (10¬9/L)	15/12/91	9.00	
WBC: N	65-72 (%)	15/12/91	75.00	>
WBC: L	20-35 (%)	15/12/91	15.00	<
WBC: E	1-3 (%)	15/12/91	3.00	
WBC: M	3-7 (%)	15/12/91	7.00	
WBC: B	0-1 (%)	15/12/91	0.00	
PLATELETS	150-400 (10¬9/L)	15/12/91	223.00	
NA+	135-145 (MMOL/L)	15/12/91	140.00	
K+	3.5-5 (MMOL/L)	15/12/91	4.40	
CL-	98-108 (MMOL/L)	15/12/91	105.00	
Ca++	2.1-2.55 (MMOL/L)	15/12/91	2.39	
PO4¬¬	0.9-1.45 (MMOL/L)	15/12/91	1.32	
SGOT	10-42 (IU/L)	15/12/91	17.00	
SGPT	10-60 (IU/L)	15/12/91	17.00	
GAMMA GT	7-64 (IU/L)	15/12/91	28.00	
LDH	91-180 (IU/L)	15/12/91	127.00	
ALK. PHOSPH.	42-121 (IU/L)	15/12/91	68.00	
GLUCOSE	3.9-5.8 (MMOL/L)	15/12/91	4.10	
BUN	2.5-6.4 (MMOL/L)	15/12/91	6.00	
CREATININE	53-115 (UMOL/L)	15/12/91	83.00	
URIC ACID	155-428 (UMOL/L)	15/12/91	316.00	
TOT BILIRUBIN	3.4-17.1 (UMOL/L)	15/12/91	11.30	
DIR BILIRUBIN	0-3.4 (UMOL/L)	15/12/91	1.20	
TOT. PROTEINS	60-83 (G/L)	15/12/91	62.00	
ALBUMINE	32-55 (G/L)	15/12/91	37.40	
TOT. CHOLEST.	4.15-8 (MMOL/L)	15/12/91	6.03	
TRIGLYCERIDES	0.4-1.92 (MMOL/L)	15/12/91	1.60	
GLOBULINS ALPHA 1	0.03-0.06 ()	15/12/91	0.03	
GLOBULINS ALPHA 2	0.07-0.12 ()	15/12/91	0.09	
GLOBULINS BETA	0.09-0.15 ()	15/12/91	0.12	
GLOBULINS GAMMA	0.12-0.2 ()	15/12/91	0.11	<
TSH	0.5-4 (MU/L)	15/12/91	0.40	<<
T4	64-167 (NMOL/L)	15/12/91	94.00	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 13 Patient: 13 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/04/91		02/05/91		24/05/91	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	01/04/91	15.40		16.00		16.40	
HT	42-54 (%)	01/04/91	45.30		47.00		48.20	
RBC	4-6 (10¬12/L)	01/04/91	5.35		5.53		5.69	
WBC	4-11 (10¬9/L)	01/04/91	8.49		8.77		8.37	
WBC: N	2.27-7.68 (10¬9/L)	01/04/91	4.53		4.40		4.62	
WBC: L	0.83-3.14 (10¬9/L)	01/04/91	2.89		3.09		2.38	
WBC: E	0-0.49 (10¬9/L)	01/04/91	0.49		0.58	>	0.51	>
WBC: M	0.12-0.8 (10¬9/L)	01/04/91	0.50		0.63		0.83	>
WBC: B	0-0.16 (10¬9/L)	01/04/91	0.08		0.07		0.03	
PLATELETS	150-350 (10¬9/L)	01/04/91	282.00		285.00		311.00	
NA+	135-145 (MMOL/L)	01/04/91	136.00		140.00		141.00	
K+	3.5-5 (MMOL/L)	01/04/91	3.80		4.30		4.50	
CL-	95-105 (MMOL/L)	01/04/91	98.00					
Ca++	2.1-2.6 (MMOL/L)	01/04/91	2.41		2.34		2.44	
PO4--	0.6-1.4 (MMOL/L)	01/04/91	0.94		1.16		1.00	
SGOT	11-55 (U/L)	01/04/91	29.00		30.00		24.00	
GAMMA GT	5-80 (U/L)	01/04/91	12.00		7.00			
LDH	120-240 (U/L)	01/04/91					131.00	
ALK. PHOSPH.	35-110 (U/L)	01/04/91	60.00		71.00		81.00	
GLUCOSE	3.3-6.4 (MMOL/L)	01/04/91	4.90		5.30			
UREA	2.5-7.7 (MMOL/L)	01/04/91	5.60		5.30		4.00	
CREATININE	0.03-0.11 (MMOL/L)	01/04/91	0.07		0.10		0.09	
TOT BILIRUBIN	3-18 (UMOL/L)	01/04/91	9.00		7.00		13.00	
DIR BILIRUBIN	0-7 (UMOL/L)	01/04/91	4.00					
TOT. PROTEINS	61-84 (G/L)	01/04/91	67.00		71.00		73.00	
ALBUMINE	35-50 (G/L)	01/04/91	42.00		47.00		48.00	
TOT. CHOLEST.	3-5.5 (MMOL/L)	01/04/91	5.40		5.50		5.50	
TRIGLYCERIDES	0.5-2 (MMOL/L)	01/04/91	1.20		1.30		1.40	
GLOBULINS ALPHA 1	2-6 (G/L)	01/04/91	3.00		3.00		3.00	
GLOBULINS ALPHA 2	4-9 (G/L)	01/04/91	5.00		5.00		6.00	
GLOBULINS BETA	6-11 (G/L)	01/04/91	7.00		8.00		6.00	
GLOBULINS GAMMA	8-18 (G/L)	01/04/91	7.00	<	9.00		7.00	<
TSH	0.15-3.5 (MU/L)	01/04/91	1.30					
T4	9.4-25 (NMOL/L)	01/04/91	17.50					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 13 Patient: 14 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			09/07/91		24/07/91		15/08/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	03/04/91	15.10		15.70		14.90	
HT	40-54 (%)	03/04/91					43.40	
RBC	4.5-6.5 (10¬12/L)	03/04/91	5.76		5.97		5.62	
WBC	4-11 (10¬9/L)	03/04/91	6.70		6.70		5.90	
WBC: N	2-8 (10¬9/L)	03/04/91	4.20		4.00		3.10	
WBC: L	1-4 (10¬9/L)	03/04/91	1.50		1.70		1.90	
WBC: E	0-0.6 (10¬9/L)	03/04/91	0.60		0.60		0.60	
WBC: M	0-1 (10¬9/L)	03/04/91	0.30		0.30		0.20	
WBC: B	0-0.2 (10¬9/L)	03/04/91	0.10		0.10		0.10	
PLATELETS	150-450 (10¬9/L)	03/04/91	319.00		306.00		318.00	
NA+	136-146 (MMOL/L)	03/04/91	139.00		139.00		142.00	
K+	3.5-5 (MMOL/L)	03/04/91	5.00		4.70		4.00	
CL-	95-110 (MMOL/L)	03/04/91	101.00		103.00		104.00	
Ca++	2.15-2.65 (MMOL/L)	03/04/91	2.33		2.32		2.22	
PO4--	0.8-1.4 (MMOL/L)	03/04/91	1.30		1.20		1.30	
SGOT	0-40 (U/L)	03/04/91	36.00		38.00		46.00	>
SGPT	0-40 (U/L)	03/04/91					15.00	
GAMMA GT	0-45 (U/L)	03/04/91	19.00		17.00			
LDH	250-520 (U/L)	03/04/91	295.00		275.00		259.00	
ALK. PHOSPH.	30-120 (U/L)	03/04/91	54.00		62.00		50.00	
GLUCOSE	4-5.5 (MMOL/L)	03/04/91	4.50		5.10		4.30	
UREA	2.3-7.6 (MMOL/L)	03/04/91	5.90		4.30		4.00	
CREATININE	0.05-0.11 (MMOL/L)	03/04/91	0.10		0.10		0.10	
URIC ACID	0.18-0.48 (MMOL/L)	03/04/91	0.22		0.18		0.18	
TOT BILIRUBIN	0-20 (UMOL/L)	03/04/91	13.00		13.00		8.00	
TOT. PROTEINS	60-80 (G/L)	03/04/91	84.00	>	82.00	>	78.00	
ALBUMINE	35-50 (G/L)	03/04/91	49.00		47.00		45.00	
TOT. CHOLEST.	3-5.5 (MMOL/L)	03/04/91	5.40		5.30		5.00	
TRIGLYCERIDES	0.5-2 (MMOL/L)	03/04/91	1.40		1.30		2.30	>
TSH	0.5-4 (MIU/L)	03/04/91	3.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 13 Patient: 15 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			01/07/91		25/07/91		15/08/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	01/06/91	12.00	<	12.50	<	13.20	
HT	42-54 (%)	01/06/91	37.30	<	38.50	<	40.10	<
RBC	4-6 (10¬12/L)	01/06/91	4.12		4.39		4.58	
WBC	4-11 (10¬9/L)	01/06/91	10.96		8.41		9.30	
WBC: N	2.27-7.68 (10¬9/L)	01/06/91	4.44		4.46		4.75	
WBC: L	0.83-3.14 (10¬9/L)	01/06/91	3.96	>	3.19	>	3.87	>
WBC: E	0-0.49 (10¬9/L)	01/06/91	0.32		0.38		0.36	
WBC: M	0.12-0.8 (10¬9/L)	01/06/91	1.10	>>	0.37		0.26	
WBC: B	0-0.16 (10¬9/L)	01/06/91	0.00				0.06	
PLATELETS	150-350 (10¬9/L)	01/06/91			263.00		262.00	
NA+	135-145 (MMOL/L)	01/06/91	135.00		141.00		141.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.11		4.00		4.00	
Ca++	2.1-2.6 (MMOL/L)	01/06/91	2.31				2.29	
PO4--	0.6-1.4 (MMOL/L)	01/06/91	0.98				1.22	
SGOT	11-55 (U/L)	01/06/91	57.00	>	29.00		24.00	
GAMMA GT	5-60 (U/L)	01/06/91			188.00	>>		
ALK. PHOSPH.	35-110 (U/L)	01/06/91	198.00	>	118.00	>	122.00	>
GLUCOSE	3.3-6.4 (MMOL/L)	01/06/91	4.50		5.20		5.00	
UREA	2.5-7.7 (MMOL/L)	01/06/91	4.20		3.60		4.10	
CREATININE	0.03-0.11 (MMOL/L)	01/06/91	0.06		0.06		0.04	
URIC ACID	0.12-0.42 (MMOL/L)	01/06/91					0.27	
TOT BILIRUBIN	3-18 (UMOL/L)	01/06/91	14.00		6.00		1.00	<
TOT. PROTEINS	61-84 (G/L)	01/06/91	75.00		70.00		67.00	
ALBUMINE	35-50 (G/L)	01/06/91	39.00		41.00		42.00	
TOT. CHOLEST.	3-5.5 (MMOL/L)	01/06/91			5.60	>	6.00	>
TRIGLYCERIDES	0.5-2 (MMOL/L)	01/06/91			2.40	>	3.80	>>
GLOBULINS ALPHA 1	2-6 (G/L)	01/06/91	4.00		2.00			
GLOBULINS ALPHA 2	4-9 (G/L)	01/06/91	11.00	>	6.00			
GLOBULINS BETA	6-11 (G/L)	01/06/91	9.00		7.00			
GLOBULINS GAMMA	8-18 (G/L)	01/06/91	14.00		9.00			
TSH	0.15-3.5 (MU/L)	01/06/91	1.00					
T4	9.4-25 (NMOL/L)	01/06/91	29.50	>>				

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 13 Patient: 16 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 42	
			03/12/91		06/01/92		20/01/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	03/04/91	15.80		16.40		16.50	
HT	40-54 (%)	03/04/91	45.30		46.30		47.00	
RBC	4.5-6.5 (10¬12/L)	03/04/91	4.96		5.10		5.16	
WBC	4-11 (10¬9/L)	03/04/91	6.20		6.40		8.40	
WBC: N	2-8 (10¬9/L)	03/04/91	4.20		4.50		6.10	
WBC: L	1-4 (10¬9/L)	03/04/91	1.50		1.20		1.70	
WBC: E	0-0.6 (10¬9/L)	03/04/91	0.10		0.10		0.20	
WBC: M	0-1 (10¬9/L)	03/04/91	0.30		0.50		0.30	
WBC: B	0-0.2 (10¬9/L)	03/04/91	0.10		0.10		0.10	
PLATELETS	150-450 (10¬9/L)	03/04/91	220.00		207.00		239.00	
NA+	136-146 (MMOL/L)	03/04/91	146.00		141.00		145.00	
K+	3.5-5 (MMOL/L)	03/04/91	3.80		4.20		3.80	
CL-	95-110 (MMOL/L)	03/04/91	101.00		97.00		100.00	
Ca++	2.15-2.65 (MMOL/L)	03/04/91	2.32		2.31		2.39	
PO4--	0.8-1.4 (MMOL/L)	03/04/91	1.00		1.00		1.00	
SGOT	0-40 (U/L)	03/04/91	33.00		33.00		42.00	>
SGPT	0-40 (U/L)	03/04/91	26.00		31.00		34.00	
LDH	250-520 (U/L)	03/04/91			313.00			
ALK. PHOSPH.	30-120 (U/L)	03/04/91	86.00		86.00		87.00	
GLUCOSE	4-5.5 (MMOL/L)	03/04/91	4.90		5.10		4.90	
UREA	2.3-7.6 (MMOL/L)	03/04/91	8.20	>	8.30	>	8.30	>
CREATININE	0.05-0.11 (MMOL/L)	03/04/91	0.10		0.10		0.09	
URIC ACID	0.18-0.48 (MMOL/L)	03/04/91	0.43		0.42		0.41	
TOT BILIRUBIN	0-20 (UMOL/L)	03/04/91	12.00		14.00		15.00	
TOT. PROTEINS	60-80 (G/L)	03/04/91	76.00		76.00		83.00	>
ALBUMINE	35-50 (G/L)	03/04/91	46.00		46.00		54.00	>
TOT. CHOLEST.	3-5.5 (MMOL/L)	03/04/91	4.50		4.60		5.50	
TRIGLYCERIDES	0.5-2 (MMOL/L)	03/04/91	1.30		1.00		1.40	
TSH	0.5-4 (MIU/L)	03/04/91	1.80					
T4	10-19 (PMOL/L)	03/04/91	18.20					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 13 Patient: 17 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			23/05/92		11/06/92		02/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	03/04/91	13.60		14.50		13.90	
HT	40-54 (%)	03/04/91	39.30	<	40.40		39.30	<
RBC	4.5-6.5 (10¬12/L)	03/04/91	4.25	<	4.49	<	4.34	<
WBC	4-11 (10¬9/L)	03/04/91	4.70		5.40		5.30	
WBC: N	2-8 (10¬9/L)	03/04/91	2.40		3.00		2.80	
WBC: L	1-4 (10¬9/L)	03/04/91	1.70		1.80		1.90	
WBC: E	0-0.6 (10¬9/L)	03/04/91	0.20		0.20		0.20	
WBC: M	0-1 (10¬9/L)	03/04/91	0.40		0.40		0.50	
WBC: B	0-0.2 (10¬9/L)	03/04/91	0.00		0.00		0.00	
PLATELETS	150-450 (10¬9/L)	03/04/91	181.00		209.00		197.00	
NA+	136-146 (MMOL/L)	03/04/91	140.00		138.00		140.00	
K+	3.5-5 (MMOL/L)	03/04/91	4.20		4.60		4.40	
CL-	95-110 (MMOL/L)	03/04/91	100.00		101.00		101.00	
Ca++	2.15-2.65 (MMOL/L)	03/04/91	2.22		2.39		2.37	
PO4--	0.8-1.4 (MMOL/L)	03/04/91	1.00		1.10		1.10	
SGOT	0-40 (U/L)	03/04/91	17.00		35.00		19.00	
GAMMA GT	0-45 (U/L)	03/04/91	17.00		15.00		16.00	
LDH	250-520 (U/L)	03/04/91	220.00	<				
ALK. PHOSPH.	30-120 (U/L)	03/04/91	57.00		59.00		61.00	
GLUCOSE	4-5.5 (MMOL/L)	03/04/91	4.80		4.30		4.80	
UREA	2.3-7.6 (MMOL/L)	03/04/91	5.80		6.20		5.90	
CREATININE	0.05-0.11 (MMOL/L)	03/04/91	0.08		0.09		0.09	
URIC ACID	0.18-0.48 (MMOL/L)	03/04/91	0.32		0.33		0.32	
TOT BILIRUBIN	0-20 (UMOL/L)	03/04/91	10.00		19.00		13.00	
TOT. PROTEINS	60-80 (G/L)	03/04/91	69.00		74.00		74.00	
ALBUMINE	35-50 (G/L)	03/04/91	40.00		46.00		47.00	
TOT. CHOLEST.	3-5.5 (MMOL/L)	03/04/91	5.30		5.10		4.70	
TRIGLYCERIDES	0.5-2 (MMOL/L)	03/04/91	0.40	<	0.80		0.70	
TSH	0,5-4 (MIU/L)	03/04/91	1.30					
T4	10-19 (PMOL/L)	03/04/91	17.80					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 13 Patient: 18 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			26/06/92		13/07/92		03/08/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	03/04/91	15.00		14.80		15.20	
HT	40-54 (%)	03/04/91	43.30		44.60		44.60	
RBC	4.5-6.5 (10¬12/L)	03/04/91	4.97		5.03		5.07	
WBC	4-11 (10¬9/L)	03/04/91	5.50		6.00		7.70	
WBC: N	2-8 (10¬9/L)	03/04/91	3.20		3.40		4.60	
WBC: L	1-4 (10¬9/L)	03/04/91	1.90		2.20		2.40	
WBC: E	0-0.6 (10¬9/L)	03/04/91	0.20		0.20		0.30	
WBC: M	0-1 (10¬9/L)	03/04/91	0.20		0.20		0.30	
WBC: B	0-0.2 (10¬9/L)	03/04/91	0.10		0.10		0.10	
PLATELETS	150-450 (10¬9/L)	03/04/91	173.00		175.00		177.00	
NA+	136-146 (MMOL/L)	03/04/91	142.00		141.00		141.00	
K+	3.5-5 (MMOL/L)	03/04/91	4.40		4.40		4.30	
CL-	95-110 (MMOL/L)	03/04/91	104.00		104.00		100.00	
Ca++	2.15-2.65 (MMOL/L)	03/04/91	2.31		2.32		2.35	
PO4--	0.8-1.4 (MMOL/L)	03/04/91	0.90		1.10		1.10	
SGPT	0-40 (U/L)	03/04/91	25.00		22.00		36.00	
GAMMA GT	0-45 (U/L)	03/04/91	28.00		25.00		25.00	
LDH	250-520 (U/L)	03/04/91					401.00	
ALK. PHOSPH.	30-120 (U/L)	03/04/91	55.00		55.00		58.00	
GLUCOSE	4-5.5 (MMOL/L)	03/04/91	5.50		5.90	>	5.10	
UREA	2.3-7.6 (MMOL/L)	03/04/91	7.30		7.10		4.10	
CREATININE	0.05-0.11 (MMOL/L)	03/04/91	0.08		0.09		0.09	
URIC ACID	0.18-0.48 (MMOL/L)	03/04/91			0.33		0.36	
TOT BILIRUBIN	0-20 (UMOL/L)	03/04/91	10.00		7.00		10.00	
TOT. PROTEINS	60-80 (G/L)	03/04/91	75.00		72.00		72.00	
ALBUMINE	35-50 (G/L)	03/04/91	44.00		44.00		44.00	
TOT. CHOLEST.	3-5.5 (MMOL/L)	03/04/91	6.90	>	6.10	>	6.30	>
TRIGLYCERIDES	0.5-2 (MMOL/L)	03/04/91	1.10		1.50		1.90	
TSH	0.5-4 (MIU/L)	03/04/91	1.10					
T4	10-19 (PMOL/L)	03/04/91	16.40					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 13 Patient: 409 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/12/91		03/01/92		22/01/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	03/04/91	14.30		14.20		13.10	
HT	40-54 (%)	03/04/91	42.80		42.20		40.20	
RBC	4.5-6.5 (10¬12/L)	03/04/91	4.46	<	4.45	<	4.26	<
HBC	4-11 (10¬9/L)	03/04/91	4.40		4.70		4.30	
HBC: N	2-8 (10¬9/L)	03/04/91	2.70		2.60		2.50	
HBC: L	1-4 (10¬9/L)	03/04/91	1.40		1.60		1.40	
HBC: E	0-0.6 (10¬9/L)	03/04/91	0.00		0.10		0.10	
HBC: M	0-1 (10¬9/L)	03/04/91	0.20		0.30		0.20	
HBC: B	0-0.2 (10¬9/L)	03/04/91	0.00		0.00		0.00	
PLATELETS	150-450 (10¬9/L)	03/04/91	243.00		215.00		208.00	
NA+	136-146 (MMOL/L)	03/04/91	138.00		140.00		142.00	
K+	3.5-5 (MMOL/L)	03/04/91	4.30		3.50		3.50	
CL-	95-110 (MMOL/L)	03/04/91	100.00		101.00		103.00	
Ca++	2.15-2.65 (MMOL/L)	03/04/91	2.16		2.17		2.15	
PO4--	0.8-1.4 (MMOL/L)	03/04/91	1.10		0.80		0.90	
SGOT	0-40 (U/L)	03/04/91	25.00		23.00		27.00	
SGPT	0-40 (U/L)	03/04/91	18.00		17.00		16.00	
LDH	250-520 (U/L)	03/04/91					477.00	
ALK. PHOSPH.	30-120 (U/L)	03/04/91	60.00		60.00		55.00	
GLUCOSE	4-5.5 (MMOL/L)	03/04/91	3.80	<	4.40		4.20	
UREA	2.3-7.6 (MMOL/L)	03/04/91	3.40		3.80		6.20	
CREATININE	0.05-0.11 (MMOL/L)	03/04/91	0.08		0.09		0.08	
URIC ACID	0.18-0.48 (MMOL/L)	03/04/91	0.30		0.33		0.37	
TOT BILIRUBIN	0-20 (UMOL/L)	03/04/91	9.00		15.00		13.00	
TOT. PROTEINS	60-80 (G/L)	03/04/91	72.00		67.00		70.00	
ALBUMINE	35-50 (G/L)	03/04/91	41.00		40.00		41.00	
TOT. CHOLEST.	3-5.5 (MMOL/L)	03/04/91			6.40	>	5.50	
TRIGLYCERIDES	0.5-2 (MMOL/L)	03/04/91			1.00		1.20	
TSH	0.5-4 (MIU/L)	03/04/91	2.10					
T4	10-19 (PMOL/L)	03/04/91	17.40					

1947

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 13 Patient: 410 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			11/02/92		06/03/92		27/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	03/04/91	14.40		14.50		13.60	
HT	40-54 (%)	03/04/91	42.20		43.60		40.30	
RBC	4.5-6.5 (10¬12/L)	03/04/91	4.71		4.90		4.56	
WBC	4-11 (10¬9/L)	03/04/91	8.50		7.30		6.40	
WBC: N	2-8 (10¬9/L)	03/04/91	5.60		5.20		3.90	
WBC: L	1-4 (10¬9/L)	03/04/91	2.90		1.70		1.90	
WBC: E	0-0.6 (10¬9/L)	03/04/91	0.00		0.10		0.10	
WBC: M	0-1 (10¬9/L)	03/04/91	0.00		0.30		0.40	
WBC: B	0-0.2 (10¬9/L)	03/04/91	0.00		0.10		0.00	
PLATELETS	150-450 (10¬9/L)	03/04/91	316.00		295.00		260.00	
NA+	136-146 (MMOL/L)	03/04/91	140.00		142.00			
K+	3.5-5 (MMOL/L)	03/04/91	3.80		3.70			
CL-	95-110 (MMOL/L)	03/04/91	108.00		104.00			
Ca++	2.15-2.65 (MMOL/L)	03/04/91	2.18		2.15		2.18	
PO4--	0.8-1.4 (MMOL/L)	03/04/91	0.90		1.00		1.10	
SGOT	0-40 (U/L)	03/04/91	28.00		31.00		30.00	
GAMMA GT	0-45 (U/L)	03/04/91	19.00		18.00		17.00	
LDH	250-520 (U/L)	03/04/91	309.00		273.00		243.00	<
ALK. PHOSPH.	30-120 (U/L)	03/04/91	77.00		70.00		62.00	
GLUCOSE	4-5.5 (MMOL/L)	03/04/91	4.40		3.90	<	3.90	<
UREA	2.3-7.6 (MMOL/L)	03/04/91	4.80		6.10		.	
CREATININE	0.05-0.11 (MMOL/L)	03/04/91	0.09		0.10			
URIC ACID	0.18-0.48 (MMOL/L)	03/04/91	0.25		0.28		0.26	
TOT BILIRUBIN	0-20 (UMOL/L)	03/04/91	13.00		16.00		12.00	
TOT. PROTEINS	60-80 (G/L)	03/04/91	66.00		71.00		66.00	
ALBUMINE	35-50 (G/L)	03/04/91	38.00		40.00		40.00	
TOT. CHOLEST.	3-5.5 (MMOL/L)	03/04/91	4.20		4.30		4.50	
TRIGLYCERIDES	0.5-2 (MMOL/L)	03/04/91	0.90		0.80		0.90	
TSH	0.5-4 (MIU/L)	03/04/91	0.90					
T4	10-19 (PMOL/L)	03/04/91	18.30					

1948

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 13 Patient: 411 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			20/03/92		16/04/92		05/05/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	01/03/92	12.30	<	13.40		12.30	<
HT	42-54 (%)	01/03/92	38.00	<	41.60	<	38.30	<
RBC	4-6 (10¬12/L)	01/03/92	4.15		4.58		4.19	
WBC	4-11 (10¬9/L)	01/03/92	9.56		5.98		5.71	
WBC: N	2.27-7.68 (10¬9/L)	01/03/92	3.82		3.56		2.91	
WBC: L	0.83-3.14 (10¬9/L)	01/03/92	4.87	>>	1.86		2.18	
WBC: E	0-0.49 (10¬9/L)	01/03/92	0.57	>	0.24		0.40	
WBC: M	0.12-0.8 (10¬9/L)	01/03/92	0.19		0.28		0.16	
WBC: B	0-0.16 (10¬9/L)	01/03/92	0.00		0.04		0.06	
PLATELETS	150-350 (10¬9/L)	01/03/92	241.00		405.00	>	293.00	
NA+	135-145 (MMOL/L)	01/03/92	142.00		139.00		141.00	
K+	3.5-5 (MMOL/L)	01/03/92	4.40		3.80		4.10	
CL-	95-105 (MMOL/L)	01/03/92			102.00			
Ca++	2.1-2.6 (MMOL/L)	01/03/92	2.30		2.36		2.37	
PO4--	0.6-1.4 (MMOL/L)	01/03/92	1.20		1.20		1.29	
SGOT	11-55 (U/L)	01/03/92			35.00			
SGPT	30-65 (U/L)	01/03/92					23.00	<
LDH	120-240 (U/L)	01/03/92			133.00			
ALK. PHOSPH.	35-110 (U/L)	01/03/92	35.00		43.00		41.00	
GLUCOSE	3.3-6.4 (MMOL/L)	01/03/92	4.90		5.30		5.50	
UREA	2.5-7.7 (MMOL/L)	01/03/92	4.90		4.10		2.90	
CREATININE	0.03-0.11 (MMOL/L)	01/03/92	0.09		0.08		0.08	
URIC ACID	0.12-0.42 (MMOL/L)	01/03/92					0.18	
TOT BILIRUBIN	3-18 (UMOL/L)	01/03/92	8.00				4.00	
TOT. PROTEINS	61-84 (G/L)	01/03/92	63.00		74.00		65.00	
ALBUMINE	35-50 (G/L)	01/03/92	38.00		44.00		40.00	
TOT. CHOLEST.	3-5.5 (MMOL/L)	01/03/92					4.80	
TRIGLYCERIDES	0.5-2 (MMOL/L)	01/03/92					1.10	
GLOBULINS ALPHA 1	2-6 (G/L)	01/03/92					3.00	
GLOBULINS ALPHA 2	4-9 (G/L)	01/03/92					5.00	
GLOBULINS BETA	6-11 (G/L)	01/03/92					7.00	
GLOBULINS GAMMA	8-18 (G/L)	01/03/92					11.00	
TSH	0.15-3.5 (MU/L)	01/03/92	1.60					
T4	9.4-25 (NMOL/L)	01/03/92	13.20					

1949

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA

Centre: 13 Patient: 423 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			14/09/92		05/10/92		29/10/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	03/04/91	13.80		14.20		12.80	<
HT	40-54 (%)	03/04/91	40.10		40.70		37.70	<
RBC	4.5-6.5 (10¬12/L)	03/04/91	4.06	<	4.17	<	3.93	<
WBC	4-11 (10¬9/L)	03/04/91	8.20		6.60		5.80	
WBC: N	2-8 (10¬9/L)	03/04/91	5.20		4.00		3.50	
WBC: L	1-4 (10¬9/L)	03/04/91	2.10		1.90		1.60	
WBC: E	0-0.6 (10¬9/L)	03/04/91	0.30		0.20		0.20	
WBC: M	0-1 (10¬9/L)	03/04/91	0.60		0.40		0.50	
WBC: B	0-0.2 (10¬9/L)	03/04/91	0.00		0.10		0.10	
PLATELETS	150-450 (10¬9/L)	03/04/91	236.00		298.00		242.00	
NA+	136-146 (MMOL/L)	03/04/91	134.00	<	137.00			
K+	3.5-5 (MMOL/L)	03/04/91	4.50		4.20			
CL-	95-110 (MMOL/L)	03/04/91	97.00		99.00			
Ca++	2.15-2.65 (MMOL/L)	03/04/91	2.14	<	2.22		2.18	
PO4--	0.8-1.4 (MMOL/L)	03/04/91	1.10		1.20		1.00	
SGPT	0-40 (U/L)	03/04/91	49.00	>	46.00	>		
GAMMA GT	0-45 (U/L)	03/04/91	15.00		17.00			
LDH	250-520 (U/L)	03/04/91	450.00				434.00	
ALK. PHOSPH.	30-120 (U/L)	03/04/91	73.00		77.00			
GLUCOSE	4-5.5 (MMOL/L)	03/04/91	4.40		4.70		4.50	
UREA	2.3-7.6 (MMOL/L)	03/04/91	2.60		2.20	<		
CREATININE	0.05-0.11 (MMOL/L)	03/04/91	0.08		0.08			
URIC ACID	0.18-0.48 (MMOL/L)	03/04/91	0.35		0.31		0.29	
TOT BILIRUBIN	0-20 (UMOL/L)	03/04/91	11.00		12.00			
TOT. PROTEINS	60-80 (G/L)	03/04/91	74.00		76.00		63.00	
ALBUMINE	35-50 (G/L)	03/04/91	43.00		42.00		38.00	
TOT. CHOLEST.	3-5.5 (MMOL/L)	03/04/91	4.30		4.70		4.50	
TRIGLYCERIDES	0.5-2 (MMOL/L)	03/04/91	2.40	>	2.70	>>	1.40	
TSH	0.5-4 (MIU/L)	03/04/91	0.50					
T4	10-19 (PMOL/L)	03/04/91	15.80					

1950

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 14 Patient: 19 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 28	
			03/04/92		01/05/92		07/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	115-160 (G/L)	10/03/92	156.00		154.00		149.00	
HT	0.37-0.47 (L/L)	10/03/92	0.46		0.44		0.44	
RBC	3.8-5.8 (10¬6/UL)	10/03/92	5.47		5.31		5.08	
WBC	4-11 (10¬3/UL)	10/03/92	6.90		9.40		11.80	>
WBC: N	2.5-7.5 (10¬3/UL)	10/03/92	5.22		6.70		9.78	>>
WBC: L	1.5-4 (10¬3/UL)	10/03/92	0.92	<<	1.68		1.09	<
WBC: E	0.04-0.44 (10¬3/UL)	10/03/92	0.06		0.16		0.04	
WBC: M	0.2-0.8 (10¬3/UL)	10/03/92	0.65		0.83	>	0.80	
WBC: B	0.01-0.1 (10¬3/UL)	10/03/92	0.08		0.04		0.05	
PLATELETS	150-400 (10¬3/UL)	10/03/92	311.00		402.00	>	414.00	>
NA+	135-145 (MMOL/L)	10/03/92	142.00		142.00		139.00	
K+	3.5-5 (MMOL/L)	10/03/92	4.30		3.70		4.40	
CL-	92-107 (MMOL/L)	10/03/92	106.00		103.00		104.00	
Ca++	2.13-2.62 (MMOL/L)	10/03/92	2.44		2.40		2.59	
PO4--	0.73-1.37 (MMOL/L)	10/03/92	1.17		1.06		1.04	
SGOT	5-43 (IU/L)	10/03/92	14.00		21.00		6.00	
SGPT	5-55 (IU/L)	10/03/92	15.00		13.00		19.00	
GAMMA GT	5-50 (IU/L)	10/03/92	13.00		17.00		25.00	
LDH	210-420 (IU/L)	10/03/92	300.00				433.00	>
ALK. PHOSPH.	50-90 (IU/L)	10/03/92	127.00	>	121.00	>	120.00	>
GLUCOSE	3.6-5.3 (MMOL/L)	10/03/92	7.40	>>	4.20		6.80	>
UREA	2.5-8.3 (MMOL/L)	10/03/92	5.60		4.20		4.90	
CREATININE	0.05-0.11 (MMOL/L)	10/03/92	0.08		0.08		0.08	
URIC ACID	0.18-0.42 (MMOL/L)	10/03/92	0.27		0.28		0.31	
TOT BILIRUBIN	3-19 (UMOL/L)	10/03/92	9.00		5.00		6.00	
TOT. PROTEINS	61-83 (G/L)	10/03/92	72.00		78.00		76.00	
ALBUMINE	35-50 (G/L)	10/03/92	40.00		40.00		41.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	10/03/92	6.00	>	5.60	>	6.00	>
TRIGLYCERIDES	0.17-2 (MMOL/L)	10/03/92	1.73		1.77		1.50	
TSH	0.1-4 (MU/L)	10/03/92	0.93					
T4	9-27 (PMOL/L)	10/03/92	13.00					

1951

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.8

LABORATORY DATA 9550082

Centre: 14 Patient: 20 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			27/04/92		20/05/92		19/06/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	115-160 (G/L)	10/03/92	152.00		141.00		137.00	
HT	0.37-0.47 (L/L)	10/03/92	0.46		0.44		0.42	
RBC	3.8-5.8 (10-6/UL)	10/03/92	5.07		4.73		4.61	
WBC	4-11 (10-3/UL)	10/03/92	6.10		4.20		3.40	<
WBC: N	2.5-7.5 (10-3/UL)	10/03/92	4.45		2.89		2.24	<
WBC: L	1.5-4 (10-3/UL)	10/03/92	1.32	<	1.02	<<	0.81	<<
WBC: E	0.04-0.44 (10-3/UL)	10/03/92	0.11		0.16		0.06	
WBC: M	0.2-0.8 (10-3/UL)	10/03/92	0.23		0.14	<	0.20	
WBC: B	0.01-0.1 (10-3/UL)	10/03/92			0.01		0.03	
PLATELETS	150-400 (10-3/UL)	10/03/92	300.00		293.00		243.00	
NA+	135-145 (MMOL/L)	10/03/92	138.00		137.00		142.00	
K+	3.5-5 (MMOL/L)	10/03/92	3.90		4.00		4.70	
CL-	92-107 (MMOL/L)	10/03/92	107.00		103.00		105.00	
Ca++	2.13-2.62 (MMOL/L)	10/03/92	2.39		2.25		2.25	
PO4--	0.73-1.37 (MMOL/L)	10/03/92	1.17		1.28		1.25	
SGOT	5-43 (IU/L)	10/03/92	22.00		16.00		32.00	
SGPT	5-55 (IU/L)	10/03/92	18.00		20.00		53.00	
GAMMA GT	5-50 (IU/L)	10/03/92	21.00		31.00		38.00	
LDH	210-420 (IU/L)	10/03/92	396.00		335.00		423.00	>
ALK. PHOSPH.	50-90 (IU/L)	10/03/92	83.00		78.00		74.00	
GLUCOSE	3.6-5.3 (MMOL/L)	10/03/92	6.50	>	5.30		5.90	>
UREA	2.5-8.3 (MMOL/L)	10/03/92	4.00		5.40		6.20	
CREATININE	0.05-0.11 (MMOL/L)	10/03/92	0.10		0.08		0.08	
URIC ACID	0.18-0.42 (MMOL/L)	10/03/92	0.22		0.22		0.24	
TOT BILIRUBIN	3-19 (UMOL/L)	10/03/92	7.00		7.00		8.00	
TOT. PROTEINS	61-83 (G/L)	10/03/92	76.00		71.00		76.00	
ALBUMINE	35-50 (G/L)	10/03/92	40.00		36.00		37.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	10/03/92	4.80		5.20		5.50	
TRIGLYCERIDES	0.17-2 (MMOL/L)	10/03/92	1.39		1.51		1.02	
TSH	0.1-4 (MU/L)	10/03/92	1.70					
T4	9-27 (PMOL/L)	10/03/92	13.00					

1952

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 14 Patient: 21 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 35	
			16/07/92		10/08/92		24/08/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	115-160 (G/L)	10/03/92	145.00		128.00		132.00	
HT	0.37-0.47 (L/L)	10/03/92	0.45		0.41		0.41	
RBC	3.8-5.8 (10¬6/UL)	10/03/92	5.12		4.43		4.68	
WBC	4-11 (10¬3/UL)	10/03/92	5.30		4.50		6.20	
WBC: N	2.5-7.5 (10¬3/UL)	10/03/92	3.69		2.87		4.41	
WBC: L	1.5-4 (10¬3/UL)	10/03/92	1.38	<	1.34	<	1.59	
WBC: E	0.04-0.44 (10¬3/UL)	10/03/92	0.04		0.05		0.09	
WBC: M	0.2-0.8 (10¬3/UL)	10/03/92	0.13	<	0.22		0.13	<
WBC: B	0.01-0.1 (10¬3/UL)	10/03/92	0.04		0.05		0.04	
PLATELETS	150-400 (10¬3/UL)	10/03/92	268.00		292.00		345.00	
NA+	135-145 (MMOL/L)	10/03/92	140.00		138.00		139.00	
K+	3.5-5 (MMOL/L)	10/03/92	4.00		4.20		4.10	
CL-	92-107 (MMOL/L)	10/03/92			104.00		102.00	
Ca++	2.13-2.62 (MMOL/L)	10/03/92	2.39		2.23		2.23	
PO4--	0.73-1.37 (MMOL/L)	10/03/92	1.05		1.10		1.19	
SGOT	5-43 (IU/L)	10/03/92	24.00		17.00		18.00	
SGPT	5-55 (IU/L)	10/03/92	26.00		18.00		17.00	
GAMMA GT	5-50 (IU/L)	10/03/92	23.00		15.00		18.00	
LDH	210-420 (IU/L)	10/03/92	344.00		359.00		332.00	
ALK. PHOSPH.	50-90 (IU/L)	10/03/92	98.00	>	78.00		74.00	
GLUCOSE	3.6-5.3 (MMOL/L)	10/03/92	5.60	>	4.90		5.10	
UREA	2.5-8.3 (MMOL/L)	10/03/92	5.50		4.90		4.30	
CREATININE	0.05-0.11 (MMOL/L)	10/03/92	0.07		0.07		0.05	
URIC ACID	0.18-0.42 (MMOL/L)	10/03/92	0.20		0.17	<	0.22	
TOT BILIRUBIN	3-19 (UMOL/L)	10/03/92	10.00		7.00		6.00	
TOT. PROTEINS	61-83 (G/L)	10/03/92	82.00		75.00		77.00	
ALBUMINE	35-50 (G/L)	10/03/92	46.00		36.00		37.00	
TOT. CHOLEST.	3.5-5.5 (MMOL/L)	10/03/92	6.70	>	6.00	>	6.90	>
TRIGLYCERIDES	0.17-2 (MMOL/L)	10/03/92	0.89		0.97		0.89	
TSH	0.1-4 (MU/L)	10/03/92	0.61					
T4	9-27 (PMOL/L)	10/03/92	19.00					

1953

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 15 Patient: 25 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			17/06/91		09/07/91		30/07/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	11.5-16.5 (G/DL)	18/05/91	16.20		15.90		16.60	>
HT	0.35-0.47 (L/L)	18/05/91	0.46		0.47		0.48	>
RBC	3.9-5.6 (10¬12/L)	18/05/91	5.07		5.05		5.15	
WBC	3.5-12 (10¬9/L)	18/05/91	9.80		8.50		9.40	
WBC: N	2.5-8 (10¬9/L)	18/05/91	5.80		5.10		6.40	
WBC: L	1.2-4 (10¬9/L)	18/05/91	3.40		2.80		2.80	
WBC: E	0-0.5 (10¬9/L)	18/05/91	0.00		0.00		0.00	
WBC: M	0.1-1.1 (10¬9/L)	18/05/91	0.60		0.50		0.20	
WBC: B	0-0.1 (10¬9/L)	18/05/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	18/05/91	396.00		365.00		421.00	>
NA+	135-145 (MMOL/L)	18/05/91	139.00		136.00		140.00	
K+	3.5-4.5 (MMOL/L)	18/05/91	5.00	>	4.60	>	4.90	>
CL-	95-105 (MMOL/L)	18/05/91	102.00		99.00		99.00	
Ca++	2.25-2.75 (MMOL/L)	18/05/91	2.50		2.39		2.39	
PO4--	0.6-1.3 (MMOL/L)	18/05/91	1.50	>>	1.00		1.05	
SGOT	0-35 (U/L)	18/05/91	18.00		24.00		18.00	
GAMMA GT	5-23 (U/L)	18/05/91	45.00	>	40.00	>	45.00	>
LDH	70-170 (U/L)	18/05/91	174.00	>	164.00		162.00	
ALK. PHOSPH.	18-70 (U/L)	18/05/91	90.00	>	86.00	>	100.00	>
GLUCOSE	3.3-6.7 (MMOL/L)	18/05/91	5.70		6.80	>	6.40	
UREA	2.5-7.5 (MMOL/L)	18/05/91	3.10		2.80		3.60	
CREATININE	0.04-0.12 (MMOL/L)	18/05/91	0.06		0.07		0.07	
URIC ACID	0.1-0.39 (MMOL/L)	18/05/91	0.44	>	0.46	>	0.41	>
TOT BILIRUBIN	0-17 (UMOL/L)	18/05/91	8.00		8.00		7.00	
DIR BILIRUBIN	0-5 (UMOL/L)	18/05/91	2.00		2.00		2.00	
TOT. PROTEINS	68-83 (G/L)	18/05/91	76.00		70.00		74.00	
ALBUMINE	36-49 (G/L)	18/05/91	50.00	>	46.00		48.00	
TOT. CHOLEST.	3-8.5 (MMOL/L)	18/05/91	7.80		6.40		6.40	
TRIGLYCERIDES	0.1-1.7 (MMOL/L)	18/05/91	5.10	>>	3.60	>>	4.20	>>
TSH	0.5-6.5 (MIU/L)	18/05/91	1.39					
T4	86-148 (NMOL/L)	18/05/91	120.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 15 Patient: 26 Treatment: Placebo Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			17/06/91		10/07/91		01/08/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13.5-17.5 (G/DL)	18/05/91	15.70		14.50		15.90	
HT	0.4-0.54 (L/L)	18/05/91	0.45		0.43		0.47	
RBC	4.5-6.5 (10¬12/L)	18/05/91	5.26		4.91		5.33	
WBC	3.5-10 (10¬9/L)	18/05/91	8.20		7.40		7.10	
WBC: N	1.5-6.5 (10¬9/L)	18/05/91	5.20		5.70		4.70	
WBC: L	1.2-4 (10¬9/L)	18/05/91	2.70		1.20		1.40	
WBC: E	0-0.5 (10¬9/L)	18/05/91	0.00		0.00		0.10	
WBC: M	0.1-1.1 (10¬9/L)	18/05/91	0.40		0.50		0.60	
WBC: B	0-0.1 (10¬9/L)	18/05/91	0.00		0.00		0.30	>>
PLATELETS	150-400 (10¬9/L)	18/05/91	300.00		295.00		273.00	
NA+	135-145 (MMOL/L)	18/05/91	140.00		134.00	<	142.00	
K+	3.5-4.5 (MMOL/L)	18/05/91	4.40		4.40		4.30	
CL-	95-105 (MMOL/L)	18/05/91	103.00		98.00		104.00	
Ca++	2.25-2.75 (MMOL/L)	18/05/91	2.39		2.18	<	2.30	
PO4--	0.6-1.3 (MMOL/L)	18/05/91	1.44	>	1.02		1.13	
SGOT	0-35 (U/L)	18/05/91	34.00		36.00	>	30.00	
GAMMA GT	5-23 (U/L)	18/05/91	58.00	>>	48.00	>>	44.00	>
LDH	70-170 (U/L)	18/05/91	179.00	>	212.00	>	164.00	
ALK. PHOSPH.	18-70 (U/L)	18/05/91	74.00	>	96.00	>	86.00	>
GLUCOSE	3.3-6.7 (MMOL/L)	18/05/91	5.30		5.40		5.80	
UREA	2.5-7.5 (MMOL/L)	18/05/91	6.50		5.20		7.90	>
CREATININE	0.04-0.12 (MMOL/L)	18/05/91	0.08		0.08		0.09	
URIC ACID	0.1-0.39 (MMOL/L)	18/05/91	0.37		0.38		0.40	>
TOT BILIRUBIN	0-17 (UMOL/L)	18/05/91	15.00		17.00		13.00	
DIR BILIRUBIN	0-5 (UMOL/L)	18/05/91	3.00		3.00		3.00	
TOT. PROTEINS	68-83 (G/L)	18/05/91	76.00		71.00		76.00	
ALBUMINE	36-49 (G/L)	18/05/91	49.00		43.00		47.00	
TOT. CHOLEST.	3-8.5 (MMOL/L)	18/05/91	5.50		3.60		5.00	
TRIGLYCERIDES	0.1-1.7 (MMOL/L)	18/05/91	5.30	>>	1.40		2.30	>>
TSH	0.5-6.5 (MIU/L)	18/05/91	2.68					
T4	86-148 (NMOL/L)	18/05/91	108.00					

1955

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 15 Patient: 27 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			27/06/91		23/07/91		13/08/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	18/05/91	11.80		10.70	<	12.00	
HT	0.35-0.47 (L/L)	18/05/91	0.35		0.34	<	0.36	
RBC	3.9-5.6 (10¬12/L)	18/05/91	3.81	<	3.78	<	3.92	
WBC	3.5-12 (10¬9/L)	18/05/91	6.70		7.30		7.20	
WBC: N	2.5-8 (10¬9/L)	18/05/91	3.80		4.60		4.40	
WBC: L	1.2-4 (10¬9/L)	18/05/91	2.50		2.30		2.40	
WBC: E	0-0.5 (10¬9/L)	18/05/91	0.00		0.00		0.00	
WBC: M	0.1-1.1 (10¬9/L)	18/05/91	0.40		0.40		0.40	
WBC: B	0-0.1 (10¬9/L)	18/05/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	18/05/91	329.00		338.00		330.00	
NA+	135-145 (MMOL/L)	18/05/91	137.00		138.00		136.00	
K+	3.5-4.5 (MMOL/L)	18/05/91	4.00		4.20		4.30	
CL-	95-105 (MMOL/L)	18/05/91	101.00		100.00		96.00	
Ca++	2.25-2.75 (MMOL/L)	18/05/91	2.32		2.21	<	2.23	<
PO4--	0.6-1.3 (MMOL/L)	18/05/91	1.08		0.96		1.07	
SGOT	0-35 (U/L)	18/05/91	20.00		17.00		18.00	
GAMMA GT	5-23 (U/L)	18/05/91	18.00		18.00		17.00	
LDH	70-170 (U/L)	18/05/91					188.00	>
ALK. PHOSPH.	18-70 (U/L)	18/05/91	33.00		26.00		32.00	
GLUCOSE	3.3-6.7 (MMOL/L)	18/05/91	5.00		4.50		5.10	
UREA	2.5-7.5 (MMOL/L)	18/05/91	7.00		8.90	>	9.50	>
CREATININE	0.04-0.12 (MMOL/L)	18/05/91	0.05		0.06		0.06	
URIC ACID	0.1-0.39 (MMOL/L)	18/05/91	0.19		0.19		0.20	
TOT BILIRUBIN	0-17 (UMOL/L)	18/05/91	7.00		4.00		6.00	
DIR BILIRUBIN	0-5 (UMOL/L)	18/05/91	1.00		2.00		1.00	
TOT. PROTEINS	68-83 (G/L)	18/05/91	62.00	<	59.00	<	63.00	<
ALBUMINE	36-49 (G/L)	18/05/91	41.00		38.00		39.00	
TOT. CHOLEST.	3-8.5 (MMOL/L)	18/05/91	4.80		4.90		5.40	
TRIGLYCERIDES	0.1-1.7 (MMOL/L)	18/05/91	1.30		1.20		1.20	
TSH	0.5-6.5 (MIU/L)	18/05/91	1.25					
T4	86-148 (NMOL/L)	18/05/91	102.00					

1956

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 15 Patient: 28 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/08/91		29/08/91		20/09/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	18/05/91	13.00		13.20		13.30	
HT	0.35-0.47 (L/L)	18/05/91	0.39		0.39		0.39	
RBC	3.9-5.6 (10¬12/L)	18/05/91	4.49		4.47		4.56	
WBC	3.5-12 (10¬9/L)	18/05/91	10.00		6.30		7.20	
WBC: N	2.5-8 (10¬9/L)	18/05/91	6.20		3.70		4.60	
WBC: L	1.2-4 (10¬9/L)	18/05/91	3.40		2.10		2.20	
WBC: E	0-0.5 (10¬9/L)	18/05/91	0.00		0.00		0.00	
WBC: M	0.1-1.1 (10¬9/L)	18/05/91	0.40		0.50		0.40	
WBC: B	0-0.1 (10¬9/L)	18/05/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	18/05/91	353.00		297.00		311.00	
NA+	135-145 (MMOL/L)	18/05/91	138.00		136.00		138.00	
K+	3.5-4.5 (MMOL/L)	18/05/91	4.00		4.10		3.80	
CL-	95-105 (MMOL/L)	18/05/91	104.00		103.00		104.00	
Ca++	2.25-2.75 (MMOL/L)	18/05/91	2.28		2.40		2.32	
PO4--	0.6-1.3 (MMOL/L)	18/05/91	1.11		1.02		0.85	
SGOT	0-35 (U/L)	18/05/91	20.00		17.00		19.00	
GAMMA GT	5-23 (U/L)	18/05/91	20.00		17.00		17.00	
LDH	70-170 (U/L)	18/05/91	154.00		149.00		154.00	
ALK. PHOSPH.	18-70 (U/L)	18/05/91	61.00		52.00		61.00	
GLUCOSE	3.3-6.7 (MMOL/L)	18/05/91	4.30		3.40		3.40	
UREA	2.5-7.5 (MMOL/L)	18/05/91	4.10		5.60		3.60	
CREATININE	0.04-0.12 (MMOL/L)	18/05/91	0.07		0.08		0.08	
URIC ACID	0.1-0.39 (MMOL/L)	18/05/91	0.31		0.29		0.29	
TOT BILIRUBIN	0-17 (UMOL/L)	18/05/91	8.00		9.00		11.00	
DIR BILIRUBIN	0-5 (UMOL/L)	18/05/91	2.00		2.00		3.00	
TOT. PROTEINS	68-83 (G/L)	18/05/91	71.00		70.00		69.00	
ALBUMINE	36-49 (G/L)	18/05/91	47.00		47.00		46.00	
TOT. CHOLEST.	3-8.5 (MMOL/L)	18/05/91	5.10		5.10		4.90	
TRIGLYCERIDES	0.1-1.7 (MMOL/L)	18/05/91	0.80		0.70		0.90	
TSH	0.5-6.5 (MIU/L)	18/05/91	1.51					
T4	86-148 (NMOL/L)	18/05/91	103.00					

1957

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 15 Patient: 29 Treatment: Placebo Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			29/08/91		19/09/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	13.5-17.5 (G/DL)	18/05/91	16.10		15.40	
HT	0.4-0.54 (L/L)	18/05/91	0.48		0.46	
RBC	4.5-6.5 (10¬12/L)	18/05/91	5.17		5.01	
WBC	3.5-10 (10¬9/L)	18/05/91	8.30		10.00	
WBC: N	1.5-6.5 (10¬9/L)	18/05/91	5.70		7.00	>
WBC: L	1.2-4 (10¬9/L)	18/05/91	2.20		2.50	
WBC: E	0-0.5 (10¬9/L)	18/05/91	0.00		0.00	
WBC: M	0.1-1.1 (10¬9/L)	18/05/91	0.30		0.50	
WBC: B	0-0.1 (10¬9/L)	18/05/91	0.00		0.00	
PLATELETS	150-400 (10¬9/L)	18/05/91	333.00		289.00	
NA+	135-145 (MMOL/L)	18/05/91	140.00		140.00	
K+	3.5-4.5 (MMOL/L)	18/05/91	4.40		3.90	
CL-	95-105 (MMOL/L)	18/05/91	103.00		103.00	
Ca++	2.25-2.75 (MMOL/L)	18/05/91	2.50		2.45	
PO4--	0.6-1.3 (MMOL/L)	18/05/91	1.07		0.97	
SGOT	0-35 (U/L)	18/05/91	17.00		16.00	
GAMMA GT	5-23 (U/L)	18/05/91	28.00	>	30.00	>
LDH	70-170 (U/L)	18/05/91	160.00		163.00	
ALK. PHOSPH.	18-70 (U/L)	18/05/91	73.00	>	70.00	
GLUCOSE	3.3-6.7 (MMOL/L)	18/05/91	5.00		6.50	
UREA	2.5-7.5 (MMOL/L)	18/05/91	4.80		6.40	
CREATININE	0.04-0.12 (MMOL/L)	18/05/91	0.10		0.09	
URIC ACID	0.1-0.39 (MMOL/L)	18/05/91	0.30		0.28	
TOT BILIRUBIN	0-17 (UMOL/L)	18/05/91	27.00	>	25.00	>
DIR BILIRUBIN	0-5 (UMOL/L)	18/05/91	4.00		4.00	
TOT. PROTEINS	68-83 (G/L)	18/05/91	75.00		71.00	
ALBUMINE	36-49 (G/L)	18/05/91	50.00	>	48.00	
TOT. CHOLEST.	3-8.5 (MMOL/L)	18/05/91	5.70		5.70	
TRIGLYCERIDES	0.1-1.7 (MMOL/L)	18/05/91	1.20		1.40	
TSH	0.5-6.5 (MIU/L)	18/05/91	0.42	<<		
T4	86-148 (NMOL/L)	18/05/91	102.00			

1958

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 15 Patient: 30 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/09/91		24/09/91		15/10/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	18/05/91	14.20		13.80		15.40	
HT	0.35-0.47 (L/L)	18/05/91	0.41		0.40		0.44	
RBC	3.9-5.6 (10¬12/L)	18/05/91	4.42		4.35		4.85	
WBC	3.5-12 (10¬9/L)	18/05/91	5.50		4.80		4.80	
WBC: N	2.5-8 (10¬9/L)	18/05/91	3.40		3.10		2.90	
WBC: L	1.2-4 (10¬9/L)	18/05/91	1.90		1.50		1.50	
WBC: E	0-0.5 (10¬9/L)	18/05/91	0.00		0.00		0.00	
WBC: M	0.1-1.1 (10¬9/L)	18/05/91	0.20		0.20		0.40	
WBC: B	0-0.1 (10¬9/L)	18/05/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	18/05/91	332.00		294.00		310.00	
NA+	135-145 (MMOL/L)	18/05/91	136.00		136.00		136.00	
K+	3.5-4.5 (MMOL/L)	18/05/91	3.80		4.50		3.60	
CL-	95-105 (MMOL/L)	18/05/91	100.00		103.00		99.00	
Ca++	2.25-2.75 (MMOL/L)	18/05/91	2.44		2.31		2.38	
PO4--	0.6-1.3 (MMOL/L)	18/05/91	1.01		0.86		1.03	
SGOT	0-35 (U/L)	18/05/91	15.00		16.00		101.00	>>
GAMMA GT	5-23 (U/L)	18/05/91	26.00	>	23.00		54.00	>>
LDH	70-170 (U/L)	18/05/91	160.00		169.00		231.00	>
ALK. PHOSPH.	18-70 (U/L)	18/05/91	54.00		50.00		69.00	
GLUCOSE	3.3-6.7 (MMOL/L)	18/05/91	5.40		5.30		6.10	
UREA	2.5-7.5 (MMOL/L)	18/05/91	4.80		3.80		3.70	
CREATININE	0.04-0.12 (MMOL/L)	18/05/91	0.07		0.07		0.08	
URIC ACID	0.1-0.39 (MMOL/L)	18/05/91	0.30		0.24		0.35	
TOT BILIRUBIN	0-17 (UMOL/L)	18/05/91	11.00		8.00		14.00	
DIR BILIRUBIN	0-5 (UMOL/L)	18/05/91	3.00		2.00		5.00	
TOT. PROTEINS	68-83 (G/L)	18/05/91	79.00		73.00		81.00	
ALBUMINE	36-49 (G/L)	18/05/91	50.00	>	45.00		49.00	
TOT. CHOLEST.	3-8.5 (MMOL/L)	18/05/91	5.10		4.50		5.60	
TRIGLYCERIDES	0.1-1.7 (MMOL/L)	18/05/91	1.50		0.80		1.10	
TSH	0.5-6.5 (MIU/L)	18/05/91	1.78					
T4	86-148 (NMOL/L)	18/05/91	92.00					

1959

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 15 Patient: 403 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/10/91		28/10/91		14/11/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-16.5 (G/DL)	18/05/91	13.60		13.40		13.80	
HT	0.35-0.47 (L/L)	18/05/91	0.39		0.39		0.40	
RBC	3.9-5.6 (10¬12/L)	18/05/91	4.47		4.43		4.57	
WBC	3.5-12 (10¬9/L)	18/05/91	7.70		7.00		8.60	
WBC: N	2.5-8 (10¬9/L)	18/05/91	5.80		5.70		7.10	
WBC: L	1.2-4 (10¬9/L)	18/05/91	1.60		1.20		1.30	
WBC: E	0-0.5 (10¬9/L)	18/05/91	0.00		0.00		0.00	
WBC: M	0.1-1.1 (10¬9/L)	18/05/91	0.30		0.20		0.20	
WBC: B	0-0.1 (10¬9/L)	18/05/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	18/05/91	294.00		274.00		278.00	
NA+	135-145 (MMOL/L)	18/05/91	134.00	<	135.00		136.00	
K+	3.5-4.5 (MMOL/L)	18/05/91	4.80	>	4.10		3.90	
CL-	95-105 (MMOL/L)	18/05/91	101.00		97.00		98.00	
Ca++	2.25-2.75 (MMOL/L)	18/05/91	2.27		2.19	<	2.33	
PO4--	0.6-1.3 (MMOL/L)	18/05/91	1.48	>	1.39	>	1.14	
SGOT	0-35 (U/L)	18/05/91	11.00		21.00		14.00	
GAMMA GT	5-23 (U/L)	18/05/91	20.00		21.00		20.00	
LDH	70-170 (U/L)	18/05/91	116.00		126.00		108.00	
ALK. PHOSPH.	18-70 (U/L)	18/05/91	49.00		51.00		51.00	
GLUCOSE	3.3-6.7 (MMOL/L)	18/05/91	6.40		5.10		5.10	
UREA	2.5-7.5 (MMOL/L)	18/05/91	4.80		3.70		3.80	
CREATININE	0.04-0.12 (MMOL/L)	18/05/91	0.09		0.08		0.07	
URIC ACID	0.1-0.39 (MMOL/L)	18/05/91	0.27		0.17		0.21	
TOT BILIRUBIN	0-17 (UMOL/L)	18/05/91	9.00		8.00		10.00	
DIR BILIRUBIN	0-5 (UMOL/L)	18/05/91	3.00		3.00		3.00	
TOT. PROTEINS	68-83 (G/L)	18/05/91	71.00		70.00		69.00	
ALBUMINE	36-49 (G/L)	18/05/91	48.00		47.00		46.00	
TOT. CHOLEST.	3-8.5 (MMOL/L)	18/05/91	4.30		3.90		4.20	
TRIGLYCERIDES	0.1-1.7 (MMOL/L)	18/05/91	1.30		1.70		1.00	
TSH	0.5-6.5 (MIU/L)	18/05/91	0.52					
T4	86-148 (NMOL/L)	18/05/91	111.00					

1960

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 15 Patient: 404 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			10/09/91		29/10/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11.5-16.5 (G/DL)	18/05/91	13.70		14.40	
HT	0.35-0.47 (L/L)	18/05/91	0.41		0.41	
RBC	3.9-5.6 (10¬12/L)	18/05/91	4.35		4.46	
WBC	3.5-12 (10¬9/L)	18/05/91	11.70		10.20	
WBC: N	2.5-8 (10¬9/L)	18/05/91	8.70	>	6.20	
WBC: L	1.2-4 (10¬9/L)	18/05/91	2.60		3.40	
WBC: E	0-0.5 (10¬9/L)	18/05/91	0.00		0.00	
WBC: M	0.1-1.1 (10¬9/L)	18/05/91	0.50		0.60	
WBC: B	0-0.1 (10¬9/L)	18/05/91	0.00		0.00	
PLATELETS	150-400 (10¬9/L)	18/05/91	336.00		324.00	
NA+	135-145 (MMOL/L)	18/05/91	138.00		133.00	<
K+	3.5-4.5 (MMOL/L)	18/05/91	3.90		3.80	
CL-	95-105 (MMOL/L)	18/05/91	100.00		97.00	
Ca++	2.25-2.75 (MMOL/L)	18/05/91	2.42		2.25	
PO4--	0.6-1.3 (MMOL/L)	18/05/91	0.76		1.17	
SGOT	0-35 (U/L)	18/05/91	20.00		29.00	
GAMMA GT	5-23 (U/L)	18/05/91	29.00	>	67.00	>>
LDH	70-170 (U/L)	18/05/91	162.00		155.00	
ALK. PHOSPH.	18-70 (U/L)	18/05/91	56.00		62.00	
GLUCOSE	3.3-6.7 (MMOL/L)	18/05/91	4.40		5.30	
UREA	2.5-7.5 (MMOL/L)	18/05/91	3.00		4.50	
CREATININE	0.04-0.12 (MMOL/L)	18/05/91	0.08		0.10	
URIC ACID	0.1-0.39 (MMOL/L)	18/05/91	0.38		0.40	>
TOT BILIRUBIN	0-17 (UMOL/L)	18/05/91	11.00		9.00	
DIR BILIRUBIN	0-5 (UMOL/L)	18/05/91	4.00		2.00	
TOT. PROTEINS	68-83 (G/L)	18/05/91	79.00		76.00	
ALBUMINE	36-49 (G/L)	18/05/91	49.00		49.00	
TOT. CHOLEST.	3-8.5 (MMOL/L)	18/05/91	6.70		8.00	
TRIGLYCERIDES	0.1-1.7 (MMOL/L)	18/05/91	1.10		2.10	>
TSH	0.5-6.5 (MIU/L)	18/05/91	3.02			
T4	86-148 (NMOL/L)	18/05/91	112.00			

1961

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082

Centre: 15 Patient: 405 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			11/11/91		02/12/91		23/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-16.5 (G/DL)	18/05/91	13.20		13.70		13.00	
HT	0.35-0.47 (L/L)	18/05/91	0.38		0.40		0.38	
RBC	3.9-5.6 (10¬12/L)	18/05/91	4.20		4.36		4.20	
WBC	3.5-12 (10¬9/L)	18/05/91	4.20		5.20		4.00	
WBC: N	2.5-8 (10¬9/L)	18/05/91	1.80	<	2.80		2.10	<
WBC: L	1.2-4 (10¬9/L)	18/05/91	1.80		1.90		1.80	
WBC: E	0-0.5 (10¬9/L)	18/05/91	0.20		0.00		0.00	
WBC: M	0.1-1.1 (10¬9/L)	18/05/91	0.40		0.50		0.10	
WBC: B	0-0.1 (10¬9/L)	18/05/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	18/05/91	246.00		235.00		233.00	
NA+	135-145 (MMOL/L)	18/05/91	142.00		141.00		142.00	
K+	3.5-4.5 (MMOL/L)	18/05/91	3.80		4.10		4.20	
CL-	95-105 (MMOL/L)	18/05/91	104.00		101.00		104.00	
Ca++	2.25-2.75 (MMOL/L)	18/05/91	2.37		2.24	<	2.21	<
PO4--	0.6-1.3 (MMOL/L)	18/05/91	1.27		1.38	>	1.30	
SGOT	0-35 (U/L)	18/05/91	18.00		17.00		15.00	
GAMMA GT	5-23 (U/L)	18/05/91	18.00		18.00		18.00	
LDH	70-170 (U/L)	18/05/91	139.00		132.00		129.00	
ALK. PHOSPH.	18-70 (U/L)	18/05/91	52.00		53.00		52.00	
GLUCOSE	3.3-6.7 (MMOL/L)	18/05/91	4.50		4.90		4.20	
UREA	2.5-7.5 (MMOL/L)	18/05/91	4.50		4.30		4.60	
CREATININE	0.04-0.12 (MMOL/L)	18/05/91	0.05		0.05		0.05	
URIC ACID	0.1-0.39 (MMOL/L)	18/05/91	0.21		0.19		0.24	
TOT BILIRUBIN	0-17 (UMOL/L)	18/05/91	15.00		14.00		15.00	
DIR BILIRUBIN	0-5 (UMOL/L)	18/05/91	3.00		3.00		3.00	
TOT. PROTEINS	68-83 (G/L)	18/05/91	68.00		66.00	<	67.00	<
ALBUMINE	36-49 (G/L)	18/05/91	48.00		46.00		45.00	
TOT. CHOLEST.	3-8.5 (MMOL/L)	18/05/91	6.30		6.10		6.10	
TRIGLYCERIDES	0.1-1.7 (MMOL/L)	18/05/91	0.80		1.10		0.90	
TSH	0.5-6.5 (MIU/L)	18/05/91	2.58					
T4	86-148 (NMOL/L)	18/05/91	100.00					

1962

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max ran
< out of range (value lower than min range) > out of range (value higher than max ran
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 15 Patient: 406 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			27/11/91		17/12/91		07/01/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	13.5-17.5 (G/DL)	18/05/91	15.10		15.60		15.40	
HT	0.4-0.54 (L/L)	18/05/91	0.44		0.46		0.46	
RBC	4.5-6.5 (10¬12/L)	18/05/91	5.32		5.41		5.35	
WBC	3.5-10 (10¬9/L)	18/05/91	9.40		7.60		7.90	
WBC: N	1.5-6.5 (10¬9/L)	18/05/91	7.20	>	5.20		5.50	
WBC: L	1.2-4 (10¬9/L)	18/05/91	1.60		1.50		1.80	
WBC: E	0-0.5 (10¬9/L)	18/05/91	0.00		0.30		0.00	
WBC: M	0.1-1.1 (10¬9/L)	18/05/91	0.60		0.60		0.60	
WBC: B	0-0.1 (10¬9/L)	18/05/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	18/05/91	318.00		330.00		382.00	
NA+	135-145 (MMOL/L)	18/05/91	139.00		138.00		142.00	
K+	3.5-4.5 (MMOL/L)	18/05/91	4.10		4.30		4.10	
CL-	95-105 (MMOL/L)	18/05/91	100.00		100.00		102.00	
Ca++	2.25-2.75 (MMOL/L)	18/05/91	2.38		2.33		2.33	
PO4--	0.6-1.3 (MMOL/L)	18/05/91	1.11		1.19		0.89	
SGOT	0-35 (U/L)	18/05/91	13.00		16.00		19.00	
GAMMA GT	5-23 (U/L)	18/05/91	23.00		29.00	>	32.00	>
LDH	70-170 (U/L)	18/05/91	121.00		139.00		134.00	
ALK. PHOSPH.	18-70 (U/L)	18/05/91	74.00	>	78.00	>	97.00	>
GLUCOSE	3.3-6.7 (MMOL/L)	18/05/91	5.20		5.50		5.10	
UREA	2.5-7.5 (MMOL/L)	18/05/91	6.60		5.90		4.00	
CREATININE	0.04-0.12 (MMOL/L)	18/05/91	0.11		0.10		0.10	
URIC ACID	0.1-0.39 (MMOL/L)	18/05/91	0.33		0.29		0.37	
TOT BILIRUBIN	0-17 (UMOL/L)	18/05/91	11.00		7.00		9.00	
DIR BILIRUBIN	0-5 (UMOL/L)	18/05/91	3.00		3.00		3.00	
TOT. PROTEINS	68-83 (G/L)	18/05/91	75.00		75.00		74.00	
ALBUMINE	36-49 (G/L)	18/05/91	49.00		49.00		47.00	
TOT. CHOLEST.	3-8.5 (MMOL/L)	18/05/91	6.20		6.80		6.80	
TRIGLYCERIDES	0.1-1.7 (MMOL/L)	18/05/91	2.60	>>	4.00	>>	2.00	>
TSH	0.5-6.5 (MIU/L)	18/05/91	0.28	<<				
T4	86-148 (NMOL/L)	18/05/91	99.00					

1963

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0
9550082
LABORATORY DATA
Centre: 15 Patient: 407 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			02/12/91		24/12/91		14/01/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	18/05/91	15.20		15.00		14.70	
HT	0.35-0.47 (L/L)	18/05/91	0.45		0.44		0.42	
RBC	3.9-5.6 (10¬12/L)	18/05/91	5.05		4.90		4.82	
WBC	3.5-12 (10¬9/L)	18/05/91	10.00		13.70	>	11.80	
WBC: N	2.5-8 (10¬9/L)	18/05/91	6.40		9,40	>	8.00	
WBC: L	1.2-4 (10¬9/L)	18/05/91	2.80		3.50		3.10	
WBC: E	0-0.5 (10¬9/L)	18/05/91	0.00		0.00		0.00	
WBC: M	0.1-1.1 (10¬9/L)	18/05/91	0.70		0.80		0.80	
WBC: B	0-0.1 (10¬9/L)	18/05/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	18/05/91	334.00		344.00		294.00	
NA+	135-145 (MMOL/L)	18/05/91	140.00		135.00		139.00	
K+	3.5-4.5 (MMOL/L)	18/05/91	4.20		4.60	>	4.40	
CL-	95-105 (MMOL/L)	18/05/91	104.00		106.00	>	101.00	
Ca++	2.25-2.75 (MMOL/L)	18/05/91	2.22	<	2.18	<	2.17	<
PO4--	0.6-1.3 (MMOL/L)	18/05/91	1.12		1.10		1.27	
SGOT	0-35 (U/L)	18/05/91	14.00		17.00		13.00	
GAMMA GT	5-23 (U/L)	18/05/91	19.00		20.00		19.00	
LDH	70-170 (U/L)	18/05/91	182.00	>	291.00	>	191.00	>
ALK. PHOSPH.	18-70 (U/L)	18/05/91	62.00		62.00		63.00	
GLUCOSE	3.3-6.7 (MMOL/L)	18/05/91	4.20		3.20	<	4.00	
UREA	2.5-7.5 (MMOL/L)	18/05/91	3.50		5.00		4.20	
CREATININE	0.04-0.12 (MMOL/L)	18/05/91	0.07		0.06		0.06	
URIC ACID	0.1-0.39 (MMOL/L)	18/05/91	0.21		0.16		0.14	
TOT BILIRUBIN	0-17 (UMOL/L)	18/05/91	11.00		8.00		8.00	
DIR BILIRUBIN	0-5 (UMOL/L)	18/05/91	2.00				2.00	
TOT. PROTEINS	68-83 (G/L)	18/05/91	69.00		64.00	<	69.00	
ALBUMINE	36-49 (G/L)	18/05/91	46.00		42.00		46.00	
TOT. CHOLEST.	3-8.5 (MMOL/L)	18/05/91	4.20		4.00		4.00	
TRIGLYCERIDES	0.1-1.7 (MMOL/L)	18/05/91	1.30		1.10		1.70	
TSH	0.5-6.5 (MIU/L)	18/05/91	1.11					
T4	86-148 (NMOL/L)	18/05/91	100.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 15 Patient: 408 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			09/01/92		10/02/92		04/03/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	18/05/91	13.20		13.00		14.00	
HT	0.35-0.47 (L/L)	18/05/91	0.39		0.39		0.41	
RBC	3.9-5.6 (10¬12/L)	18/05/91	4.24		4.13		4.43	
WBC	3.5-12 (10¬9/L)	18/05/91	6.40		5.20		5.90	
WBC: N	2.5-8 (10¬9/L)	18/05/91	4.50		3.30		3.50	
WBC: L	1.2-4 (10¬9/L)	18/05/91	1.40		1.40		1.80	
WBC: E	0-0.5 (10¬9/L)	18/05/91	0.00		0.00		0.00	
WBC: M	0.1-1.1 (10¬9/L)	18/05/91	0.50		0.50		0.60	
WBC: B	0-0.1 (10¬9/L)	18/05/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	18/05/91	403.00	>	362.00		391.00	
NA+	135-145 (MMOL/L)	18/05/91	138.00		142.00		138.00	
K+	3.5-4.5 (MMOL/L)	18/05/91	4.50		4.20		4.20	
CL-	95-105 (MMOL/L)	18/05/91	99.00		106.00	>	103.00	
Ca++	2.25-2.75 (MMOL/L)	18/05/91	2.31		2.15	<	2.27	
PO4--	0.6-1.3 (MMOL/L)	18/05/91	1.21		1.10		1.18	
SGOT	0-35 (U/L)	18/05/91	25.00		15.00		16.00	
GAMMA GT	5-23 (U/L)	18/05/91	48.00	>>	27.00	>	22.00	
LDH	70-170 (U/L)	18/05/91	165.00		153.00		147.00	
ALK. PHOSPH.	18-70 (U/L)	18/05/91	88.00	>	77.00	>	77.00	>
GLUCOSE	3.3-6.7 (MMOL/L)	18/05/91	4.90		4.10		5.10	
UREA	2.5-7.5 (MMOL/L)	18/05/91	5.50		6.40		5.40	
CREATININE	0.04-0.12 (MMOL/L)	18/05/91	0.08		0.07		0.06	
URIC ACID	0.1-0.39 (MMOL/L)	18/05/91	0.15		0.07	<	0.11	
TOT BILIRUBIN	0-17 (UMOL/L)	18/05/91	4.00		5.00		7.00	
DIR BILIRUBIN	0-5 (UMOL/L)	18/05/91	1.00		2.00		2.00	
TOT. PROTEINS	68-83 (G/L)	18/05/91	63.00	<	67.00	<	69.00	
ALBUMINE	36-49 (G/L)	18/05/91	42.00		45.00		46.00	
TOT. CHOLEST.	3-8.5 (MMOL/L)	18/05/91	7.00		6.90		7.20	
TRIGLYCERIDES	0.1-1.7 (MMOL/L)	18/05/91	0.80		1.50		1.00	
TSH	0.5-6.5 (MIU/L)	18/05/91	0.82					
T4	86-148 (NMOL/L)	18/05/91	91.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

9550082

LABORATORY DATA
Centre: 15 Patient: 418 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			30/01/92		20/02/92		12/03/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	18/05/91	14.10		13.20		13.00	
HT	0.35-0.47 (L/L)	18/05/91	0.41		0.39		0.39	
RBC	3.9-5.6 (10¬12/L)	18/05/91	4.79		4.55		4.48	
WBC	3.5-12 (10¬9/L)	18/05/91	5.10		6.80		5.50	
WBC: N	2.5-8 (10¬9/L)	18/05/91	3.10		4.70		3.50	
WBC: L	1.2-4 (10¬9/L)	18/05/91	1.50		1.70		1.60	
WBC: E	0-0.5 (10¬9/L)	18/05/91	0.10		0.00		0.00	
WBC: M	0.1-1.1 (10¬9/L)	18/05/91	0.40		0.40		0.50	
WBC: B	0-0.1 (10¬9/L)	18/05/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	18/05/91	365.00		379.00		375.00	
NA+	135-145 (MMOL/L)	18/05/91	140.00		140.00		134.00	<
K+	3.5-4.5 (MMOL/L)	18/05/91	4.20		3.60		3.80	
CL-	95-105 (MMOL/L)	18/05/91	102.00		100.00		101.00	
Ca++	2.25-2.75 (MMOL/L)	18/05/91	2.36		2.29		2.34	
PO4--	0.6-1.3 (MMOL/L)	18/05/91	1.34	>	1.38	>	1.37	>
SGOT	0-35 (U/L)	18/05/91	16.00		21.00		21.00	
GAMMA GT	5-23 (U/L)	18/05/91	30.00	>	31.00	>	28.00	>
LDH	70-170 (U/L)	18/05/91	182.00	>	185.00	>	178.00	>
ALK. PHOSPH.	18-70 (U/L)	18/05/91	809.00	>>	770.00	>>	775.00	>>
GLUCOSE	3.3-6.7 (MMOL/L)	18/05/91	5.00		6.40		4.90	
UREA	2.5-7.5 (MMOL/L)	18/05/91	5.70		6.00		4.90	
CREATININE	0.04-0.12 (MMOL/L)	18/05/91	0.07		0.08		0.08	
URIC ACID	0.1-0.39 (MMOL/L)	18/05/91	0.23		0.20		0.21	
TOT BILIRUBIN	0-17 (UMOL/L)	18/05/91	10.00		10.00		9.00	
DIR BILIRUBIN	0-5 (UMOL/L)	18/05/91	2.00		2.00		3.00	
TOT. PROTEINS	68-83 (G/L)	18/05/91	68.00		65.00	<	67.00	<
ALBUMINE	36-49 (G/L)	18/05/91	46.00		46.00		45.00	
TOT. CHOLEST.	3-8.5 (MMOL/L)	18/05/91	7.00		6.70		6.60	
TRIGLYCERIDES	0.1-1.7 (MMOL/L)	18/05/91	1.40		1.00		1.70	
TSH	0.5-6.5 (MIU/L)	18/05/91	3.19					
T4	86-148 (NMOL/L)	18/05/91	89.00					

1966

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 18.0

LABORATORY DATA 9550082
Centre: 15 Patient: 419 Treatment: Placebo Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			27/04/92		19/05/92		09/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-16.5 (G/DL)	18/05/91	14.10		14.00		14.50	
HT	0.35-0.47 (L/L)	18/05/91	0.41		0.41		0.43	
RBC	3.9-5.6 (10¬12/L)	18/05/91	4.66		4.62		4.79	
WBC	3.5-12 (10¬9/L)	18/05/91	6.30		7.70		7.60	
WBC: N	2.5-8 (10¬9/L)	18/05/91	3.90		5.90		5.10	
WBC: L	1.2-4 (10¬9/L)	18/05/91	2.10		1.30		2.10	
WBC: E	0-0.5 (10¬9/L)	18/05/91	0.00		0.30		0.20	
WBC: M	0.1-1.1 (10¬9/L)	18/05/91	0.30		0.20		0.20	
WBC: B	0-0.1 (10¬9/L)	18/05/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬9/L)	18/05/91	208.00		225.00		207.00	
NA+	135-145 (MMOL/L)	18/05/91	138.00		139.00		138.00	
K+	3.5-4.5 (MMOL/L)	18/05/91	4.00		3.70		3.70	
CL-	95-105 (MMOL/L)	18/05/91	101.00		99.00		103.00	
Ca++	2.25-2.75 (MMOL/L)	18/05/91	2.27		2.18	<	2.34	
PO4--	0.6-1.3 (MMOL/L)	18/05/91	1.28		1.28		1.25	
SGOT	0-35 (U/L)	18/05/91	14.00		8.00		14.00	
GAMMA GT	5-23 (U/L)	18/05/91	18.00		18.00		18.00	
LDH	70-170 (U/L)	18/05/91	130.00		111.00		117.00	
ALK. PHOSPH.	18-70 (U/L)	18/05/91	45.00		42.00		38.00	
GLUCOSE	3.3-6.7 (MMOL/L)	18/05/91	4.50		5.00		4.90	
UREA	2.5-7.5 (MMOL/L)	18/05/91	5.60		4.90		5.30	
CREATININE	0.04-0.12 (MMOL/L)	18/05/91	0.08		0.07		0.06	
URIC ACID	0.1-0.39 (MMOL/L)	18/05/91	0.25		0.23		0.23	
TOT BILIRUBIN	0-17 (UMOL/L)	18/05/91	8.00		7.00		8.00	
DIR BILIRUBIN	0-5 (UMOL/L)	18/05/91	2.00		1.00		2.00	
TOT. PROTEINS	68-83 (G/L)	18/05/91	71.00		68.00		73.00	
ALBUMINE	36-49 (G/L)	18/05/91	50.00	>	48.00		51.00	>
TOT. CHOLEST.	3-8.5 (MMOL/L)	18/05/91	5.70		5.80		6.30	
TRIGLYCERIDES	0.1-1.7 (MMOL/L)	18/05/91	0.80		2.40	>>	0.90	
TSH	0.5-6.5 (MIU/L)	18/05/91	0.56					
T4	86-148 (NMOL/L)	18/05/91	108.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang-
< out of range (value lower than min range) > out of range (value higher than max rang-
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test						
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
1	1	Imipramine	Female	Evaluated	10/04/91	22/05/91	43	Screen	10/04/91	1	Not done	Absent	Absent	Absent	Absent
								Day 21	01/05/91	22	Not done	Absent	Absent	Not done	Not done
								Day 42	22/05/91	43	Not done	Present	Absent	Absent	Absent
	2	Reboxetine	Male	Without screen	15/04/91	27/05/91	43	Screen	11/04/91	0	Not done	Absent	Absent	Not done	Not done
								Day 21	06/05/91	22	Not done	Absent	Absent	Not done	Not done
								Day 42	27/05/91	43	Not done	Absent	Absent	Present	Present
	3	Imipramine	Male	Without screen	06/05/91	16/06/91	42	Screen	02/05/91	0	Not done	Absent	Absent	Not done	Not done
								Day 21	27/05/91	22	Not done	Absent	Absent	Present	Present
								Day 42	17/06/91	43	Not done	Not done	Absent	Present	Not done
	4	Placebo	Male	Evaluated	04/06/91	16/07/91	43	Screen	04/06/91	1	Not done	Present	Absent	Present	Present
								Day 21	25/06/91	22	Not done	Not done	Absent	Present	Present
								Day 42	16/07/91	43	Not done	Not done	Absent	Present	Present
	5	Reboxetine	Female	Evaluated	12/06/91	02/07/91	21	Screen	12/06/91	1	Not done	Not done	Absent	Present	Present
								Day 21	02/07/91	21	Not done	Not done	Absent	Present	Present
	6	Placebo	Female	Evaluated	23/05/91	05/07/91	44	Screen	23/05/91	1	Not done	Present	Absent	Present	Present
								Day 21	13/06/91	22	Not done	Not done	Absent	Present	Present
								Day 42	08/07/91	47	Not done	Not done	Absent	Present	Present
	7	Reboxetine	Female	Evaluated	27/08/91	08/10/91	43	Screen	27/08/91	1	Not done	Not done	Absent	Present	Present
								Day 21	17/09/91	22	Not done	Absent	Absent	Present	Present
								Day 42	08/10/91	43	Not done	Absent	Absent	Present	Present
	8	Placebo	Male	Evaluated	05/09/91	19/10/91	45	Screen	05/09/91	1	Not done	Not done	Absent	Present	Present
								Day 21	28/09/91	24	Not done	Absent	Absent	Present	Present
								Day 42	19/10/91	45	Not done	Absent	Absent	Present	Present
	9	Reboxetine	Female	Without screen	27/11/91	06/01/92	41	Screen	27/11/91	1	Not done	Not done	Present	Not done	Not done
								Day 21	18/12/91	22	Not done	Absent	Absent	Present	Present
								Day 42	06/01/92	41	Not done	Absent	Absent	Present	Present
	10	Placebo	Male	Evaluated	24/09/91	04/11/91	42	Screen	04/09/91	0	Not done	Absent	Absent	Present	Present
								Day 21	15/10/91	22	Not done	Present	Absent	Present	Present
								Day 42	04/11/91	42	Not done	Absent	Absent	Present	Present

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period: Start date	Treatment period: End date	Treatment period: Days	Urinalysis test: Assessment	Urinalysis test: Date	Urinalysis test: (*)	Urinalysis test: Specific gravity	Urinalysis test: Albumin	Urinalysis test: Sugar	Urinalysis test: RBC	Urinalysis test: WBC
1	11	Imipramine	Female	Only screening	10/10/91	13/10/91	4	Screen	10/10/91	1	Normal	Absent	Absent	Absent	Absent
	12	Imipramine	Female	Evaluated	18/10/91	30/11/91	44	Screen	18/10/91	1	Not done	Not done	Present	Present	Present
								Day 21	15/11/91	29	Not done	Present	Absent	Present	Present
								Day 42	05/12/91	49	Not done	Absent	Absent	Present	Present
	412	Reboxetine	Male	Evaluated	13/11/91	23/12/91	41	Screen	12/11/91	0	Not done	Absent	Absent	Present	Present
								Day 21	05/12/91	23	Not done	Absent	Absent	Present	Present
								Day 42	23/12/91	41	Not done	Absent	Absent	Present	Present
	413	Placebo	Male	Evaluated	09/12/91	20/01/92	43	Screen	03/12/91	0	Not done	Absent	Absent	Present	Present
								Day 21	30/12/91	22	Not done	Absent	Absent	Present	Present
								Day 42	20/01/92	43	Not done	Absent	Absent	Present	Present
	414	Imipramine	Female	Only screening	22/01/92	29/01/92	8	Screen	19/01/92	0	Not done	Absent	Absent	Present	Present
	415	Imipramine	Male	Evaluated	14/01/92	27/02/92	45	Screen	14/01/92	1	Not done	Absent	Absent	Present	Present
								Day 21	06/02/92	24	Not done	Present	Absent	Present	Present
								Day 42	27/02/92	45	Not done	Absent	Present	Present	Present
	416	Reboxetine	Female	Only screening	17/01/92	28/01/92	12	Screen	20/01/92	4	Not done	Absent	Absent	Present	Present
	421	Imipramine	Male	Evaluated	27/02/92	09/04/92	43	Screen	26/02/92	0	Not done	Absent	Absent	Present	Present
								Day 21	19/03/92	22	Not done	Absent	Absent	Present	Present
								Day 42	09/04/92	43	Not done	Absent	Absent	Absent	Absent
	422	Imipramine	Male	Evaluated	05/08/92	17/09/92	44	Screen	04/08/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	26/08/92	22	Not done	Absent	Absent	Present	Present
								Day 42	17/09/92	44	Not done	Absent	Absent	Not done	Not done
2/1	49	Placebo	Female	Evaluated	18/05/91	28/06/91	42	Screen	16/05/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	08/06/91	22	Normal	Absent	Absent	Absent	Absent
								Day 42	29/06/91	43	Normal	Absent	Absent	Absent	Absent
	50	Reboxetine	Female	Evaluated	27/12/91	06/02/92	42	Screen	24/12/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	16/01/92	21	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
2/1	50	Reboxetine	Female	Evaluated	27/12/91	06/02/92	42	Day 42	06/02/92	42	Normal	Present	Absent	Absent	Absent
	51	Imipramine	Female	Evaluated	02/02/92	15/03/92	43	Screen	28/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	24/02/92	23	Normal	Present	Absent	Absent	Absent
								Day 42	16/03/92	44	Normal	Absent	Absent	Absent	Absent
2/2	43	Imipramine	Female	Only screening	18/04/91	16/05/91	29	Screen	11/04/91	0	Not done	Present	Absent	Absent	Present
								Day 28	13/05/91	26	Not done	Not done	Not done	Not done	Not done
	44	Imipramine	Female	Evaluated	19/07/91	29/08/91	42	Screen	12/07/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	09/08/91	22	Normal	Absent	Absent	Absent	Absent
								Day 42	28/08/91	41	Normal	Absent	Absent	Absent	Absent
	45	Reboxetine	Female	Evaluated	08/09/91	20/10/91	43	Screen	27/08/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	30/09/91	23	Normal	Absent	Absent	Absent	Absent
								Day 42	21/10/91	44	Normal	Absent	Absent	Absent	Absent
	46	Placebo	Female	Evaluated	26/09/91	23/10/91	28	Screen	18/09/91	0	Not done	Absent	Absent	Absent	Absent
								Day 28	23/10/91	28	Normal	Absent	Absent	Absent	Absent
	47	Placebo	Female	Without Urinal	24/03/92	04/05/92	42	Screen	13/03/92	0	Normal	Not done	Not done	Not done	Not done
								Day 21	14/04/92	22	Normal	Not done	Not done	Not done	Not done
								Day 42	05/05/92	43	Not done	Not done	Not done	Not done	Not done
	48	Reboxetine	Female	Without Urinal	07/04/92	19/05/92	43	Screen	03/04/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	28/04/92	22	Not done	Not done	Not done	Not done	Not done
								Day 42	20/05/92	44	Not done	Not done	Not done	Not done	Not done
2/3	36/A	Imipramine	Male	Without screen	07/03/91	17/04/91	42	Day 21	22/03/91	16	Not done	Absent	Absent	Present	Present
								Day 42	08/04/91	33	Not done	Absent	Absent	Present	Present
	37	Reboxetine	Female	Evaluated	27/03/91	07/05/91	42	Screen	18/03/91	0	Normal	Present	Absent	Absent	Absent
								Day 21	16/04/91	21	Not done	Not done	Not done	Not done	Not done
								Day 42	13/05/91	48	Not done	Present	Absent	Absent	Absent
	38	Placebo	Male	Evaluated	14/08/91	25/09/91	43	Screen	10/08/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	09/09/91	27	Not done	Absent	Absent	Absent	Absent
								Day 42	26/09/91	44	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period: Start date	Treatment period: End date	Treatment period: Days	Urinalysis test: Assessment	Urinalysis test: Date	Urinalysis test: (*)	Urinalysis test: Specific gravity	Urinalysis test: Albumin	Urinalysis test: Sugar	Urinalysis test: RBC	Urinalysis test: WBC
2/3	39	Imipramine	Female	Evaluated	10/08/91	20/09/91	42	Screen	06/08/91	0	Not done	Absent	Absent	Present	Present
								Day 21	30/08/91	21	Not done	Absent	Absent	Absent	Absent
								Day 42	20/09/91	42	Not done	Not done	Not done	Not done	Not done
	40	Reboxetine	Female	Evaluated	24/10/91	04/12/91	42	Screen	24/10/91	1	Not done	Present	Absent	Absent	Absent
								Day 21	15/11/91	23	Normal	Absent	Absent	Absent	Absent
								Day 42	05/12/91	43	Normal	Present	Absent	Absent	Absent
	41	Placebo	Male	Evaluated	03/10/91	13/11/91	42	Screen	10/10/91	8	Normal	Absent	Absent	Present	Present
								Day 21	29/10/91	27	Not done	Absent	Absent	Present	Present
								Day 42	19/11/91	48	Normal	Absent	Absent	Present	Present
	42	Imipramine	Female	Evaluated	19/05/92	30/06/92	43	Screen	03/05/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	06/06/92	19	Not done	Present	Absent	Absent	Absent
								Day 42	30/06/92	43	Not done	Present	Absent	Present	Present
2/4	31	Placebo	Male	Evaluated	26/03/91	05/05/91	41	Screen	22/03/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	15/04/91	21	Not done	Not done	Not done	Not done	Not done
								Day 42	30/04/91	36	Normal	Absent	Absent	Absent	Absent
	32	Reboxetine	Male	Evaluated	26/10/91	06/12/91	42	Screen	17/10/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	15/11/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	06/12/91	42	Normal	Absent	Absent	Absent	Absent
	33	Imipramine	Male	Evaluated	29/05/91	10/07/91	43	Screen	27/05/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	19/06/91	22	Not done	Not done	Not done	Not done	Not done
								Day 42	10/07/91	43	Normal	Absent	Absent	Absent	Absent
	34	Placebo	Female	Without screen	17/04/92	28/05/92	42	Screen	11/04/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	12/05/92	26	Normal	Absent	Present	Absent	Absent
								Day 42	25/05/92	39	Not done	Not done	Not done	Not done	Not done
	35	Reboxetine	Female	Evaluated	15/09/92	26/10/92	42	Screen	08/09/92	0	Normal	Absent	Absent	Present	Present
								Day 21	03/10/92	19	Normal	Absent	Absent	Present	Present
								Day 42	27/10/92	43	Normal	Absent	Absent	Present	Present
	36	Imipramine	Female	Only screening	12/02/92	24/03/92	42	Screen	05/02/92	0	Normal	Absent	Present	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
2/4	36	Imipramine	Female	Only screening	12/02/92	24/03/92	42	Day 21	04/03/92	22	Normal	Absent	Absent	Not done	Not done
								Day 42	25/03/92	43	Normal	Absent	Absent	Not done	Not done
2/5	73	Placebo	Male	Without screen	07/02/92	20/03/92	43	Screen	03/02/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	02/03/92	25	Not done	Absent	Absent	Present	Present
								Day 42	24/03/92	47	Not done	Absent	Absent	Present	Present
	74	Reboxetine	Male	Only screening	21/06/92	01/08/92	42	Screen	14/06/92	0	Not done	Absent	Absent	Not done	Absent
								Day 21	11/07/92	21	Missing	Absent	Absent	Absent	Not done
								Day 42	01/08/92	42	Not done	Absent	Absent	Absent	Not done
	75	Imipramine	Male	Without Urinal	11/09/92	22/10/92	42	Screen	04/09/92	0	Not done	Absent	Absent	Absent	Not done
								Day 21	01/10/92	21	Not done	Absent	Absent	Absent	Not done
								Day 42	22/10/92	42	Not done	Absent	Absent	Absent	Not done
	76	Imipramine	Female	Without screen	15/09/92	26/10/92	42	Screen	12/09/92	0	Not done	Absent	Absent	Absent	Not done
								Day 21	02/10/92	18	Not done	Not done	Not done	Not done	Not done
								Day 42	28/10/92	44	Not done	Absent	Absent	Present	Present
	77	Placebo	Male	Without Urinal	22/09/92	02/11/92	42	Screen	16/09/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	13/10/92	22	Not done	Not done	Not done	Not done	Not done
								Day 42	30/10/92	39	Not done	Not done	Not done	Not done	Not done
	78	Reboxetine	Female	Without Urinal	10/10/92	13/11/92	35	Screen	01/10/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	29/10/92	20	Not done	Not done	Not done	Not done	Not done
2/6	55	Reboxetine	Female	Without Urinal	12/06/92	23/07/92	42	Screen	15/06/92	4	Not done	Not done	Not done	Not done	Not done
								Day 21	03/07/92	22	Not done	Not done	Not done	Not done	Not done
								Day 42	20/07/92	39	Not done	Not done	Not done	Not done	Not done
	56	Reboxetine	Female	Without Urinal	12/06/92	23/07/92	42	Screen	15/06/92	4	Not done	Not done	Not done	Not done	Not done
								Day 21	03/07/92	22	Not done	Not done	Not done	Not done	Not done
								Day 42	24/07/92	43	Not done	Not done	Not done	Not done	Not done
	57	Imipramine	Female	Without Urinal	05/05/92	15/06/92	42	Screen	30/04/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	26/05/92	22	Not done	Not done	Not done	Not done	Not done
								Day 42	15/06/92	42	Not done	Not done	Not done	Not done	Not done

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
2/6	58	Placebo	Female	Without Urinal	18/05/92	29/06/92	43	Screen	18/05/92	1	Not done	Not done	Not done	Not done	Not done
								Day 21	09/06/92	23	Not done	Not done	Not done	Not done	Not done
								Day 42	24/06/92	38	Not done	Not done	Not done	Not done	Not done
	59	Placebo	Male	Without Urinal	27/05/92	23/06/92	28	Screen	29/05/92	3	Not done	Not done	Not done	Not done	Not done
								Day 21	17/06/92	22	Not done	Not done	Not done	Not done	Not done
								Day 28	26/06/92	31	Not done	Not done	Not done	Not done	Not done
	60	Imipramine	Female	Without Urinal	12/05/92	22/06/92	42	Screen	06/04/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	02/06/92	22	Not done	Not done	Not done	Not done	Not done
								Day 42	23/06/92	43	Not done	Not done	Not done	Not done	Not done
3/1	61	Imipramine	Male	Evaluated	05/03/91	08/04/91	35	Screen	04/03/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	03/04/91	30	Not done	Absent	Absent	Absent	Absent
	62	Imipramine	Female	Evaluated	16/04/91	26/05/91	41	Screen	17/04/91	2	Normal	Absent	Absent	Absent	Absent
								Day 21	06/05/91	21	Not done	Absent	Absent	Present	Present
								Day 42	27/05/91	42	Normal	Absent	Absent	Present	Present
	63	Placebo	Male	Evaluated	13/05/91	23/06/91	42	Screen	10/05/91	0	Normal	Absent	Absent	Present	Present
								Day 21	03/06/91	22	Normal	Absent	Absent	Present	Present
								Day 42	22/06/91	41	Not done	Absent	Absent	Absent	Absent
	64	Placebo	Female	Without Urinal	14/03/91	24/04/91	42	Screen	08/03/91	0	Not done	Absent	Absent	Not done	Not done
								Day 21	03/04/91	21	Not done	Absent	Absent	Not done	Not done
	65	Reboxetine	Male	Evaluated	16/09/91	27/10/91	42	Screen	11/09/91	0	Not done	Absent	Absent	Present	Present
								Day 21	07/10/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	28/10/91	43	Not done	Absent	Absent	Absent	Absent
	66	Reboxetine	Male	Without Urinal	10/06/91	21/07/91	42	Screen	06/06/91	0	Not done	Absent	Absent	Not done	Not done
								Day 21	01/07/91	22	Not done	Absent	Absent	Not done	Not done
								Day 42	22/07/91	43	Not done	Absent	Absent	Not done	Not done
	139	Imipramine	Male	Only screening	03/09/91	12/09/91	10	Screen	03/09/91	1	Not done	Absent	Absent	Absent	Absent
	140	Placebo	Male	Only screening	12/09/91	23/10/91	42	Screen	10/09/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	03/10/91	22	Not done	Absent	Absent	Not done	Not done

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
3/1	141	Placebo	Female	Evaluated	03/10/91	14/11/91	43	Screen	26/09/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	23/10/91	21	Not done	Absent	Absent	Not done	Not done
								Day 42	14/11/91	43	Not done	Absent	Absent	Absent	Absent
	142	Imipramine	Female	Only screening	18/11/91	08/12/91	21	Screen	14/11/91	0	Normal	Absent	Absent	Present	Present
	143	Reboxetine	Female	Without screen	15/04/92	20/05/92	36	Screen	14/04/92	0	Not done	Absent	Absent	Not done	Not done
								Day 21	06/05/92	22	Not done	Not done	Not done	Not done	Not done
								Day 35	20/05/92	36	Not done	Absent	Absent	Absent	Absent
	144	Reboxetine	Female	Evaluated	09/06/92	22/07/92	44	Screen	04/06/92	0	Not done	Absent	Absent	Absent	Absent
								Day 42	21/07/92	43	Not done	Absent	Absent	Absent	Absent
	451	Reboxetine	Female	Only screening	20/01/92	01/02/92	13	Screen	16/01/92	0	Not done	Absent	Absent	Absent	Absent
	452	Placebo	Male	Only screening	22/01/92	04/03/92	43	Screen	15/01/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	12/02/92	22	Not done	Absent	Absent	Not done	Not done
								Day 42	09/03/92	48	Not done	Not done	Not done	Not done	Not done
	453	Imipramine	Female	Evaluated	29/01/92	10/03/92	42	Screen	28/01/92	0	Not done	Absent	Absent	Present	Present
								Day 21	19/02/92	22	Not done	Absent	Absent	Not done	Not done
								Day 42	11/03/92	43	Not done	Absent	Absent	Absent	Absent
	454	Reboxetine	Male	Without screen	17/02/92	01/04/92	45	Screen	13/02/92	0	Not done	Absent	Absent	Not done	Not done
								Day 21	09/03/92	22	Not done	Absent	Absent	Absent	Absent
								Day 42	01/04/92	45	Not done	Absent	Absent	Absent	Absent
	455	Placebo	Female	Without screen	11/03/92	22/04/92	43	Screen	03/03/92	0	Not done	Absent	Absent	Not done	Not done
								Day 21	01/04/92	22	Not done	Absent	Absent	Absent	Absent
								Day 42	22/04/92	43	Not done	Not done	Not done	Not done	Not done
	456	Imipramine	Female	Only screening	25/03/92	03/04/92	10	Screen	18/03/92	0	Not done	Absent	Absent	Absent	Absent
3/2	65/A	Reboxetine	Female	Without Urinal	29/01/91	11/03/91	42	Screen	25/01/91	0	Not done	Absent	Absent	Absent	Not done
								Day 21	19/02/91	22	Not done	Absent	Absent	Absent	Not done
								Day 42	12/03/91	43	Not done	Absent	Absent	Absent	Not done

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period: Start date	Treatment period: End date	Treatment period: Days	Urinalysis test: Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
3/3	67	Placebo	Male	Evaluated	18/07/91	28/08/91	42	Screen	16/07/91	0	Normal	Absent	Absent	Present	Present
								Day 21	07/08/91	21	Normal	Present	Present	Present	Present
								Day 42	28/08/91	42	Normal	Absent	Absent	Absent	Absent
	68	Reboxetine	Male	Only screening	21/01/92	02/03/92	42	Screen	14/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	10/02/92	21	Normal	Absent	Absent	Not done	Not done
								Day 42	02/03/92	42	Not done	Absent	Absent	Not done	Not done
	69	Placebo	Male	Evaluated	04/02/92	16/03/92	42	Screen	31/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	24/02/92	21	Not done	Absent	Absent	Absent	Present
								Day 42	16/03/92	42	Normal	Absent	Absent	Absent	Present
	70	Imipramine	Male	Only screening	15/04/92	26/05/92	42	Screen	10/04/92	0	Normal	Absent	Absent	Present	Present
								Day 21	05/05/92	21	Not done	Absent	Absent	Not done	Not done
								Day 42	26/05/92	42	Not done	Absent	Absent	Not done	Not done
	71	Imipramine	Female	Only screening	16/04/92	27/05/92	42	Screen	14/04/92	0	Normal	Absent	Absent	Present	Present
								Day 21	06/05/92	21	Not done	Absent	Absent	Not done	Not done
								Day 42	27/05/92	42	Normal	Absent	Absent	Not done	Not done
	72	Reboxetine	Male	Only screening	25/07/92	04/09/92	42	Screen	21/07/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	14/08/92	21	Not done	Absent	Absent	Not done	Not done
								Day 42	04/09/92	42	Not done	Absent	Absent	Not done	Not done
3/4	79	Imipramine	Female	Without Urinal	04/05/91	15/06/91	43	Screen	01/05/91	0	Not done	Not done	Not done	Not done	Not done
								Day 21	24/05/91	21	Not done	Not done	Not done	Not done	Not done
								Day 42	19/06/91	47	Not done	Not done	Not done	Not done	Not done
	80	Imipramine	Male	Without Urinal	01/09/91	24/09/91	24	Screen	31/08/91	0	Not done	Not done	Not done	Not done	Not done
	81	Reboxetine	Female	Without screen	17/05/91	27/06/91	42	Screen	15/05/91	0	Not done	Absent	Absent	Present	Not done
								Day 21	04/06/91	19	Not done	Absent	Absent	Absent	Absent
								Day 42	28/06/91	43	Normal	Absent	Absent	Absent	Not done
	82	Placebo	Male	Without Urinal	17/06/91	28/07/91	42	Screen	14/06/91	0	Not done	Absent	Absent	Absent	Not done
								Day 21	08/07/91	22	Not done	Absent	Absent	Absent	Not done
								Day 42	29/07/91	43	Not done	Absent	Absent	Absent	Not done

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
3/4	83	Placebo	Male	Only screening	17/06/91	24/06/91	8	Screen	13/06/91	0	Not done	Absent	Absent	Absent	Absent
	84	Reboxetine	Female	Only screening	09/10/91	23/11/91	46	Screen	08/10/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	31/10/91	23	Not done	Not done	Not done	Not done	Not done
								Day 42	12/11/91	35	Not done	Not done	Not done	Not done	Not done
	85	Imipramine	Female	Without Urinal	29/10/91	08/12/91	41	Screen	26/10/91	0	Not done	Absent	Absent	Absent	Not done
								Day 21	19/11/91	22	Not done	Absent	Absent	Present	Not done
								Day 42	09/12/91	42	Not done	Absent	Absent	Present	Not done
	86	Imipramine	Male	Evaluated	03/12/91	15/01/92	44	Screen	02/12/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	24/12/91	22	Not done	Not done	Not done	Not done	Not done
								Day 42	15/01/92	44	Not done	Absent	Absent	Absent	Absent
	87	Placebo	Female	Only screening	09/12/91	19/01/92	42	Screen	07/12/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	27/12/91	19	Not done	Absent	Absent	Absent	Not done
								Day 42	20/01/92	43	Not done	Absent	Absent	Absent	Not done
	88	Placebo	Male	Evaluated	23/03/92	08/05/92	47	Screen	18/03/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	22/04/92	31	Normal	Absent	Absent	Absent	Absent
								Day 42	09/05/92	48	Not done	Not done	Not done	Not done	Not done
	89	Reboxetine	Female	Evaluated	26/03/92	06/05/92	42	Screen	23/03/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	15/04/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	12/05/92	48	Normal	Absent	Absent	Absent	Absent
	90	Reboxetine	Male	Only screening	28/04/92	08/06/92	42	Screen	28/04/92	1	Not done	Absent	Absent	Absent	Absent
								Day 21	19/05/92	22	Not done	Absent	Absent	Not done	Not done
								Day 42	23/06/92	57	Not done	Absent	Absent	Absent	Not done
	457	Placebo	Female	Without screen	22/05/92	11/06/92	21	Screen	18/05/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	10/06/92	20	Not done	Absent	Absent	Absent	Absent
	458	Reboxetine	Female	Only screening	26/05/92	09/06/92	15	Screen	18/05/92	0	Not done	Absent	Absent	Absent	Absent
	459	Placebo	Female	Evaluated	02/06/92	13/07/92	42	Screen	29/05/92	0	Not done	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
3/4	459	Placebo	Female	Evaluated	02/06/92	13/07/92	42	Day 21	23/06/92	22	Not done	Absent	Absent	Absent	Absent
								Day 42	15/07/92	44	Not done	Absent	Absent	Absent	Absent
	460	Reboxetine	Male	Only screening	19/08/92	20/08/92	2	Screen	17/08/92	0	Not done	Absent	Absent	Absent	Absent
	461	Imipramine	Female	Without Urinal	17/09/92	24/09/92	8	Screen	15/09/92	0	Normal	Not done	Not done	Not done	Not done
	462	Imipramine	Female	Without Urinal	29/09/92	08/10/92	10	Screen	29/09/92	1	Normal	Not done	Not done	Not done	Not done
4/1	91	Imipramine	Female	Only screening	12/10/91	22/11/91	42	Screen	17/10/91	6	Normal	Absent	Absent	Absent	Absent
								Day 21	02/11/91	22	Not done	Not done	Not done	Not done	Not done
								Day 42	23/11/91	43	Not done	Not done	Not done	Not done	Not done
	92	Reboxetine	Female	Evaluated	07/08/91	17/09/91	42	Screen	03/08/91	0	Normal	Absent	Absent	Present	Present
								Day 21	28/08/91	22	Normal	Absent	Absent	Present	Present
								Day 42	18/09/91	43	Normal	Absent	Absent	Present	Present
	93	Placebo	Male	Evaluated	03/07/91	16/08/91	45	Screen	29/06/91	0	Normal	Absent	Absent	Present	Present
								Day 21	24/07/91	22	Normal	Absent	Absent	Absent	Absent
								Day 42	14/08/91	43	Not done	Not done	Not done	Not done	Not done
	94	Placebo	Female	Evaluated	05/07/91	13/08/91	40	Screen	29/06/91	0	Normal	Absent	Absent	Present	Present
								Day 21	24/07/91	20	Normal	Absent	Absent	Not done	Not done
								Day 42	27/08/91	54	Normal	Absent	Absent	Present	Present
	95	Imipramine	Female	Without screen	03/06/91	16/07/91	44	Screen	09/06/91	7	Not done	Not done	Not done	Not done	Not done
								Day 21	28/06/91	26	Not done	Absent	Absent	Absent	Present
								Day 42	17/07/91	45	Not done	Absent	Absent	Absent	Present
	96	Reboxetine	Female	Evaluated	04/09/91	16/10/91	43	Screen	30/08/91	0	Normal	Absent	Absent	Absent	Present
								Day 21	25/09/91	22	Normal	Absent	Absent	Absent	Absent
								Day 42	25/10/91	52	Normal	Absent	Absent	Absent	Absent
	115	Reboxetine	Female	Evaluated	06/05/92	16/06/92	42	Screen	30/04/92	0	Normal	Absent	Absent	Present	Present
								Day 21	02/06/92	28	Normal	Absent	Absent	Absent	Present
								Day 42	19/06/92	45	Normal	Absent	Absent	Present	Present

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test						
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
4/1	116	Imipramine	Female	Only screening	16/05/92	22/05/92	7	Screen	09/05/92	0	Normal	Absent	Absent	Absent	Absent
	117	Imipramine	Female	Evaluated	03/09/91	14/10/91	42	Screen	29/08/91	0	Normal	Absent	Absent	Absent	Present
								Day 21	24/09/91	22	Normal	Absent	Absent	Present	Present
								Day 42	15/10/91	43	Normal	Absent	Absent	Absent	Absent
	118	Reboxetine	Female	Without screen	23/05/92	03/07/92	42	Screen	15/05/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	13/06/92	22	Normal	Absent	Absent	Present	Present
								Day 42	04/07/92	43	Normal	Absent	Absent	Present	Present
	119	Placebo	Female	Only screening				Screen	16/03/92		Normal	Absent	Absent	Absent	Absent
	120	Placebo	Female	Evaluated	31/07/92	11/09/92	43	Screen	04/06/92	0	Not done	Absent	Absent	Present	Present
								Day 21	21/08/92	22	Normal	Absent	Absent	Present	Present
								Day 42	22/09/92	54	Normal	Absent	Absent	Present	Present
	145	Imipramine	Female	Evaluated	30/09/92	10/11/92	42	Screen	30/09/92	1	Not done	Absent	Absent	Absent	Present
								Day 21	30/10/92	31	Normal	Absent	Absent	Absent	Present
								Day 42	10/11/92	42	Not done	Not done	Not done	Not done	Not done
	146	Placebo	Female	Evaluated	16/09/92	27/10/92	42	Screen	03/08/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	05/10/92	20	Normal	Absent	Absent	Absent	Absent
								Day 42	27/10/92	42	Normal	Absent	Absent	Absent	Absent
	147	Reboxetine	Female	Evaluated	01/09/92	12/10/92	42	Screen	16/07/92	0	Normal	Absent	Absent	Present	Present
								Day 21	21/09/92	21	Not done	Absent	Absent	Absent	Present
								Day 42	13/10/92	43	Not done	Absent	Absent	Absent	Present
	148	Imipramine	Female	Evaluated	26/09/92	06/11/92	42	Screen	11/09/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	20/10/92	25	Not done	Absent	Absent	Present	Present
								Day 42	10/11/92	46	Not done	Absent	Absent	Absent	Present
	149	Reboxetine	Male	Evaluated	30/09/92	10/11/92	42	Screen	22/09/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	21/10/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	18/11/92	50	Normal	Absent	Absent	Absent	Absent
	150	Placebo	Male	Evaluated	30/09/92	10/11/92	42	Screen	23/09/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	15/10/92	16	Normal	Absent	Absent	Present	Present

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
4/1	150	Placebo	Male	Evaluated	30/09/92	10/11/92	42	Day 42	10/11/92	42	Normal	Absent	Absent	Present	Present
4/2	93/A	Placebo	Male	Without Urinal	22/02/91	04/04/91	42	Screen	23/02/91	2	Not done	Not done	Not done	Not done	Not done
								Day 21	18/03/91	25	Not done	Not done	Not done	Not done	Not done
	99/A	Placebo	Male	Without Urinal	27/03/91	07/05/91	42	Day 21	10/04/91	15	Not done	Not done	Not done	Not done	Not done
								Day 42	04/05/91	39	Not done	Not done	Not done	Not done	Not done
	104	Reboxetine	Male	Without Urinal	22/05/91	02/07/91	42	Day 21	04/06/91	14	Not done	Not done	Not done	Not done	Not done
4/3	97	Placebo	Male	Evaluated	17/04/91	28/05/91	42	Screen	11/04/91	0	Normal	Present	Absent	Present	Present
								Day 21	07/05/91	21	Not done	Not done	Not done	Not done	Not done
								Day 42	28/05/91	42	Normal	Present	Absent	Present	Present
	98	Reboxetine	Female	Evaluated	20/06/91	21/07/91	32	Screen	17/06/91	0	Not done	Absent	Absent	Present	Present
								Day 21	13/07/91	24	Not done	Absent	Absent	Present	Present
								Day 35	02/08/91	44	Not done	Absent	Absent	Present	Present
	99	Placebo	Female	Only screening	08/08/91	15/08/91	8	Screen	07/08/91	0	Normal	Absent	Absent	Present	Present
	100	Imipramine	Female	Evaluated	27/11/91	17/12/91	21	Screen	22/11/91	0	Normal	Absent	Absent	Present	Present
								Day 21	08/01/92	43	Normal	Absent	Absent	Present	Present
	101	Imipramine	Male	Evaluated	17/03/92	27/04/92	42	Screen	16/03/92	0	Normal	Absent	Present	Present	Present
								Day 21	06/04/92	21	Not done	Not done	Not done	Not done	Not done
								Day 42	27/04/92	42	Normal	Present	Present	Present	Present
4/4	109	Reboxetine	Female	Only screening	08/06/91	19/07/91	42	Screen	03/06/91	0	Not done	Not done	Not done	Present	Present
								Day 21	27/06/91	20	Not done	Not done	Not done	Not done	Not done
								Day 42	20/08/91	74	Not done	Not done	Not done	Not done	Not done
	110	Imipramine	Male	Evaluated	15/06/91	26/07/91	42	Screen	11/06/91	0	Normal	Not done	Absent	Absent	Present
								Day 21	04/07/91	20	Normal	Present	Absent	Present	Present
								Day 42	26/07/91	42	Normal	Absent	Absent	Present	Present
	111	Imipramine	Male	Evaluated	04/07/91	14/08/91	42	Screen	24/06/91	0	Normal	Present	Absent	Present	Present
								Day 21	24/07/91	21	Normal	Absent	Absent	Present	Present

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
4/4	111	Imipramine	Male	Evaluated	04/07/91	14/08/91	42	Day 42	14/08/91	42	Not done	Not done	Not done	Not done	Not done
	112	Placebo	Male	Evaluated	10/07/91	20/08/91	42	Screen	10/07/91	1	Normal	Present	Absent	Present	Present
								Day 21	31/07/91	22	Normal	Present	Absent	Present	Present
								Day 42	20/08/91	42	Normal	Absent	Present	Present	Not done
	113	Reboxetine	Male	Evaluated	31/08/91	11/10/91	42	Screen	26/08/91	0	Normal	Absent	Absent	Absent	Present
								Day 21	23/09/91	24	Normal	Absent	Absent	Present	Present
								Day 42	11/10/91	42	Normal	Absent	Absent	Present	Present
	114	Placebo	Female	Without Urinal	20/11/91	31/12/91	42	Screen	07/11/91	0	Normal	Present	Absent	Present	Not done
								Day 0	07/11/91	0	Normal	Present	Absent	Present	Not done
								Day 21	10/12/91	21	Normal	Not done	Absent	Not done	Not done
								Day 42	31/12/91	42	Normal	Not done	Absent	Not done	Not done
	175	Imipramine	Female	Without screen	13/02/92	25/03/92	42	Screen	05/02/92	0	Normal	Present	Absent	Absent	Not done
								Day 21	04/03/92	21	Normal	Present	Absent	Absent	Not done
								Day 42	25/03/92	42	Normal	Present	Absent	Absent	Absent
	176	Placebo	Female	Without Urinal	14/03/92	08/04/92	26	Screen	13/03/92	0	Normal	Not done	Absent	Not done	Not done
								Day 21	06/04/92	24	Normal	Absent	Absent	Present	Not done
								Day 28	09/04/92	27	Not done	Not done	Not done	Not done	Not done
	177	Imipramine	Female	Evaluated	28/04/92	11/05/92	14	Screen	22/04/92	0	Normal	Present	Absent	Absent	Absent
								Day 21	27/05/92	30	Normal	Present	Absent	Absent	Absent
	178	Reboxetine	Female	Evaluated	28/04/92	08/06/92	42	Screen	21/04/92	0	Normal	Present	Absent	Absent	Absent
								Day 21	18/05/92	21	Normal	Present	Absent	Absent	Absent
								Day 42	09/06/92	43	Normal	Present	Absent	Present	Present
	179	Placebo	Female	Only screening	11/09/92	29/09/92	19	Screen	08/09/92	0	Normal	Present	Absent	Present	Present
								Day 21	30/09/92	20	Normal	Present	Present	Not done	Not done
	180	Reboxetine	Male	Without screen	07/10/92	17/11/92	42	Screen	30/09/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	27/10/92	21	Normal	Present	Absent	Absent	Absent
								Day 42	17/11/92	42	Normal	Present	Absent	Absent	Absent
5/1	127	Reboxetine	Male	Without Urinal	06/06/91	17/07/91	42	Screen	03/06/91	0	Not done	Not done	Not done	Not done	Not done

(*) days of treatment

1980

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
5/1	127	Reboxetine	Male	Without Urinal	06/06/91	17/07/91	42	Day 21	27/06/91	22	Not done	Absent	Absent	Not done	Not done
								Day 42	18/07/91	43	Not done	Absent	Absent	Not done	Not done
	128	Reboxetine	Female	Without Urinal	14/06/91	25/07/91	42	Screen	10/06/91	0	Not done	Not done	Not done	Not done	Not done
								Day 21	05/07/91	22	Not done	Absent	Absent	Not done	Not done
								Day 42	26/07/91	43	Not done	Absent	Absent	Not done	Not done
	129	Placebo	Male	Evaluated	24/12/91	03/02/92	42	Screen	23/12/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	13/01/92	21	Not done	Absent	Absent	Absent	Absent
								Day 42	03/02/92	42	Not done	Absent	Absent	Absent	Absent
	130	Placebo	Male	Evaluated	05/03/92	15/04/92	42	Screen	25/02/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	25/03/92	21	Not done	Absent	Absent	Absent	Absent
								Day 42	15/04/92	42	Not done	Absent	Absent	Absent	Absent
	131	Imipramine	Female	Evaluated	21/03/92	30/04/92	41	Screen	20/03/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	10/04/92	21	Not done	Absent	Absent	Absent	Absent
								Day 42	30/04/92	41	Not done	Absent	Absent	Absent	Absent
	132	Imipramine	Male	Evaluated	25/06/92	06/08/92	43	Screen	23/06/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	16/07/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	10/08/92	47	Not done	Not done	Not done	Not done	Not done
5/2	121	Imipramine	Female	Without screen	20/12/91	27/01/92	39	Screen	13/12/91	0	Not done	Not done	Not done	Not done	Not done
								Day 21	10/01/92	22	Not done	Not done	Not done	Not done	Not done
								Day 42	28/01/92	40	Not done	Absent	Absent	Absent	Absent
	125	Reboxetine	Male	Evaluated	28/01/91	10/03/91	42	Screen	25/01/91	0	Not done	Absent	Absent	Present	Present
								Day 21	11/02/91	15	Not done	Absent	Absent	Absent	Absent
								Day 42	11/03/91	43	Not done	Absent	Present	Absent	Absent
5/3	133	Placebo	Male	Without Urinal	29/11/91	12/12/91	14	Screen	26/11/91	0	Not done	Not done	Not done	Not done	Not done
								Day 14	13/12/91	15	Not done	Not done	Not done	Not done	Not done
	134	Reboxetine	Female	Evaluated	06/12/91	16/01/92	42	Screen	04/12/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	27/12/91	22	Normal	Absent	Absent	Absent	Absent
								Day 42	16/01/92	42	Not done	Not done	Not done	Not done	Not done

(*) days of treatment

1981

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
5/3	135	Imipramine	Female	Without Urinal	10/01/92	20/02/92	42	Screen	06/01/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	30/01/92	21	Not done	Not done	Not done	Not done	Not done
								Day 42	20/02/92	42	Not done	Not done	Not done	Not done	Not done
	136	Imipramine	Female	Without Urinal	02/03/92	12/04/92	42	Screen	02/03/92	1	Not done	Not done	Not done	Not done	Not done
								Day 21	24/03/92	23	Not done	Not done	Not done	Not done	Not done
								Day 42	13/04/92	43	Not done	Not done	Not done	Not done	Not done
	137	Reboxetine	Female	Without Urinal	15/05/92	25/06/92	42	Screen	12/05/92	0	Normal	Not done	Not done	Not done	Not done
								Day 21	05/06/92	22	Normal	Not done	Not done	Not done	Not done
								Day 42	25/06/92	42	Normal	Not done	Not done	Not done	Not done
	138	Placebo	Female	Without Urinal	15/05/92	16/05/92	2	Screen	14/05/92	0	Normal	Not done	Not done	Not done	Not done
6/1	151	Imipramine	Male	Evaluated	21/01/92	28/01/92	8	Screen	15/01/92	0	Normal	Absent	Absent	Present	Present
								Day 7	30/01/92	10	Normal	Absent	Absent	Present	Present
	152	Reboxetine	Female	Evaluated	24/02/92	07/04/92	44	Screen	19/02/92	0	Normal	Absent	Absent	Present	Present
								Day 21	16/03/92	22	Normal	Absent	Absent	Present	Present
								Day 42	11/04/92	48	Normal	Absent	Absent	Present	Present
	153	Reboxetine	Male	Evaluated	18/03/91	29/04/91	43	Screen	04/03/91	0	Normal	Absent	Absent	Present	Present
								Day 21	08/04/91	22	Normal	Absent	Absent	Present	Present
								Day 42	03/05/91	47	Normal	Absent	Absent	Present	Present
	154	Imipramine	Female	Only screening	30/03/92	06/04/92	8	Screen	25/03/92	0	Normal	Absent	Absent	Present	Present
	155	Placebo	Male	Evaluated	08/07/92	04/08/92	28	Screen	02/07/92	0	Normal	Absent	Absent	Present	Present
								Day 21	30/07/92	23	Normal	Absent	Absent	Present	Present
								Day 28	06/08/92	30	Not done	Not done	Not done	Not done	Not done
	156	Placebo	Female	Only screening	08/09/92	19/10/92	42	Screen	03/09/92	0	Normal	Absent	Absent	Present	Present
								Day 21	29/09/92	22	Not done	Not done	Not done	Not done	Not done
								Day 42	20/10/92	43	Not done	Not done	Not done	Not done	Not done
6/2	157	Reboxetine	Male	Evaluated	30/04/91	10/06/91	42	Screen	23/04/91	0	Not done	Absent	Absent	Present	Present
								Day 21	21/05/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	10/06/91	42	Normal	Absent	Absent	Present	Present

(*) days of treatment

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
6/2	158	Imipramine	Female	Without Urinal	24/11/91	05/01/92	43	Day 21	17/12/91	24	Not done	Not done	Not done	Not done	Not done
								Day 42	10/01/92	48	Not done	Not done	Not done	Not done	Not done
	159	Imipramine	Male	Evaluated	14/07/91	24/08/91	42	Screen	11/07/91	0	Normal	Present	Absent	Present	Present
								Day 21	07/08/91	25	Not done	Absent	Absent	Present	Present
								Day 42	29/08/91	47	Normal	Absent	Absent	Present	Present
	160	Placebo	Male	Evaluated	24/11/91	04/01/92	42	Screen	22/11/91	0	Not done	Present	Absent	Present	Present
								Day 21	14/12/91	21	Not done	Present	Absent	Not done	Not done
								Day 42	28/01/92	66	Not done	Present	Absent	Present	Present
	161	Reboxetine	Female	Evaluated	20/02/92	18/03/92	28	Screen	18/02/92	0	Normal	Absent	Absent	Present	Present
								Day 21	11/03/92	21	Not done	Absent	Absent	Present	Present
	162	Placebo	Male	Only screening	10/07/91	13/07/91	4	Screen	08/07/91	0	Normal	Present	Absent	Present	Present
	169	Imipramine	Female	Evaluated	26/12/91	15/01/92	21	Screen	09/12/91	0	Not done	Present	Absent	Present	Present
								Day 21	15/01/92	21	Not done	Absent	Absent	Present	Present
	170	Placebo	Male	Only screening	01/11/91	15/11/91	15	Screen	29/10/91	0	Not done	Absent	Absent	Absent	Absent
	171	Imipramine	Female	Evaluated	22/07/92	01/09/92	42	Screen	20/07/92	0	Not done	Absent	Absent	Present	Present
								Day 21	11/08/92	21	Not done	Absent	Absent	Present	Present
								Day 42	16/09/92	57	Not done	Absent	Absent	Present	Present
	172	Reboxetine	Female	Evaluated	07/07/92	17/08/92	42	Screen	07/07/92	1	Normal	Absent	Absent	Absent	Absent
								Day 21	27/07/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	22/08/92	47	Normal	Absent	Absent	Present	Present
	173	Placebo	Male	Evaluated	05/07/92	15/08/92	42	Screen	26/06/92	0	Not done	Absent	Absent	Present	Present
								Day 21	25/07/92	21	Not done	Absent	Absent	Present	Present
	174	Reboxetine	Male	Evaluated	11/05/92	21/06/92	42	Screen	06/05/92	0	Normal	Absent	Absent	Present	Present
								Day 21	01/06/92	22	Normal	Absent	Absent	Absent	Present
								Day 42	27/06/92	48	Normal	Absent	Absent	Present	Present

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
6/3	163	Reboxetine	Male	Only screening	06/06/91	08/06/91	3	Screen	05/06/91	0	Normal	Absent	Absent	Present	Present
	164	Imipramine	Male	Evaluated	11/10/91	21/11/91	42	Screen	07/10/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	31/10/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	22/11/91	43	Normal	Absent	Absent	Absent	Absent
	165	Imipramine	Female	Evaluated	16/10/91	26/11/91	42	Screen	10/10/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	05/11/91	21	Normal	Absent	Absent	Absent	Present
								Day 42	26/11/91	42	Normal	Absent	Absent	Absent	Absent
	166	Reboxetine	Female	Only screening	25/10/91	29/10/91	5	Screen	25/10/91	1	Normal	Present	Absent	Absent	Absent
	167	Placebo	Female	Evaluated	18/11/91	27/12/91	40	Screen	14/11/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	09/12/91	22	Not done	Absent	Absent	Present	Present
								Day 42	27/12/91	40	Normal	Absent	Absent	Present	Present
	168	Placebo	Female	Evaluated	03/12/91	06/01/92	35	Screen	26/11/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	23/12/91	21	Normal	Absent	Absent	Absent	Absent
	505	Imipramine	Female	Evaluated	03/12/91	17/12/91	15	Screen	29/11/91	0	Normal	Absent	Absent	Absent	Absent
								Day 14	20/12/91	18	Normal	Absent	Absent	Absent	Absent
	506	Placebo	Female	Evaluated	08/01/92	19/02/92	43	Screen	06/01/92	0	Normal	Absent	Absent	Present	Present
								Day 21	29/01/92	22	Normal	Absent	Absent	Present	Present
								Day 42	19/02/92	43	Normal	Absent	Absent	Present	Present
	507	Imipramine	Female	Evaluated	14/01/92	24/02/92	42	Screen	09/01/92	0	Normal	Absent	Absent	Present	Present
								Day 21	04/02/92	22	Normal	Absent	Absent	Present	Present
								Day 42	24/02/92	42	Normal	Present	Absent	Present	Present
	508	Reboxetine	Female	Evaluated	05/02/92	17/03/92	42	Screen	30/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	25/02/92	21	Not done	Absent	Absent	Absent	Absent
								Day 42	17/03/92	42	Normal	Absent	Absent	Present	Present
	509	Placebo	Male	Without screen	24/02/92	06/04/92	43	Screen	24/02/92	1	Normal	Absent	Absent	Not done	Not done
								Day 21	16/03/92	22	Normal	Absent	Absent	Present	Present

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
6/3	509	Placebo	Male	Without screen	24/02/92	06/04/92	43	Day 42	06/04/92	43	Normal	Absent	Absent	Present	Present
	510	Reboxetine	Female	Only screening	27/02/92	10/03/92	13	Screen	26/02/92	0	Normal	Absent	Absent	Present	Present
	511	Imipramine	Female	Evaluated	19/03/92	21/04/92	34	Screen	19/03/92	1	Normal	Absent	Absent	Present	Present
								Day 21	07/04/92	20	Normal	Absent	Absent	Present	Present
	512	Placebo	Female	Only screening	01/04/92	01/04/92	1	Screen	27/03/92	0	Normal	Present	Absent	Present	Present
	513	Imipramine	Female	Evaluated	13/05/92	23/06/92	42	Screen	05/05/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	02/06/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	23/06/92	42	Normal	Absent	Absent	Absent	Absent
7/02	181	Reboxetine	Male	Evaluated	27/01/92	08/03/92	42	Screen	22/01/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	17/02/92	22	Not done	Absent	Absent	Absent	Absent
								Day 42	09/03/92	43	Not done	Absent	Absent	Absent	Absent
	182	Placebo	Male	Evaluated	23/11/91	03/01/92	42	Screen	22/11/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	13/12/91	21	Not done	Absent	Absent	Present	Present
								Day 42	03/01/92	42	Abnormal	Absent	Absent	Present	Present
	183	Imipramine	Male	Evaluated	02/01/92	18/01/92	17	Screen	30/12/91	0	Not done	Absent	Absent	Present	Present
								Day 21	22/01/92	21	Not done	Absent	Absent	Present	Present
	184	Imipramine	Female	Evaluated	27/01/92	08/03/92	42	Screen	23/01/92	0	Abnormal	Absent	Absent	Absent	Absent
								Day 21	17/02/92	22	Not done	Absent	Absent	Absent	Absent
								Day 42	09/03/92	43	Not done	Absent	Absent	Present	Present
	185	Reboxetine	Male	Evaluated	10/04/92	05/05/92	26	Screen	09/04/92	0	Normal	Absent	Present	Present	Present
								Day 21	30/04/92	21	Normal	Absent	Present	Present	Present
	186	Placebo	Male	Evaluated	16/04/92	27/05/92	42	Screen	15/04/92	0	Normal	Absent	Absent	Present	Present
								Day 21	06/05/92	21	Not done	Absent	Absent	Present	Present
								Day 42	27/05/92	42	Not done	Absent	Absent	Present	Present
	535	Placebo	Male	Evaluated	15/04/92	26/05/92	42	Screen	15/04/92	1	Not done	Absent	Absent	Absent	Absent
								Day 21	09/05/92	25	Not done	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
7/02	535	Placebo	Male	Evaluated	15/04/92	26/05/92	42	Day 42	27/05/92	43	Not done	Absent	Absent	Absent	Absent
	536	Reboxetine	Female	Evaluated	08/05/92	18/06/92	42	Screen	08/05/92	1	Not done	Absent	Absent	Absent	Absent
								Day 21	29/05/92	22	Not done	Absent	Absent	Absent	Absent
								Day 42	22/06/92	46	Not done	Absent	Absent	Absent	Absent
7/03	187	Imipramine	Female	Only screening	18/02/92	30/03/92	42	Screen	11/02/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	10/03/92	22	Not done	Not done	Not done	Not done	Not done
								Day 42	31/03/92	43	Not done	Not done	Not done	Not done	Not done
	188	Placebo	Male	Only screening	25/02/92	06/04/92	42	Screen	18/02/92	0	Not done	Absent	Absent	Present	Absent
								Day 21	17/03/92	22	Not done	Not done	Not done	Not done	Not done
								Day 42	07/04/92	43	Not done	Not done	Not done	Not done	Not done
	189	Placebo	Male	Evaluated	25/02/92	06/04/92	42	Screen	18/02/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	17/03/92	22	Not done	Absent	Absent	Absent	Absent
								Day 42	07/04/92	43	Not done	Absent	Absent	Absent	Absent
	190	Reboxetine	Male	Evaluated	28/02/92	09/04/92	42	Screen	21/02/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	20/03/92	22	Not done	Absent	Absent	Absent	Absent
								Day 42	10/04/92	43	Not done	Absent	Absent	Absent	Absent
	191	Imipramine	Female	Only screening	03/03/92	10/04/92	39	Screen	25/02/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	24/03/92	22	Not done	Not done	Not done	Not done	Not done
	192	Reboxetine	Female	Evaluated	10/03/92	20/04/92	42	Screen	03/03/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	31/03/92	22	Not done	Absent	Absent	Absent	Absent
								Day 42	21/04/92	43	Not done	Absent	Absent	Absent	Absent
	523	Reboxetine	Female	Evaluated	06/05/92	16/06/92	42	Screen	05/05/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	26/05/92	21	Not done	Absent	Absent	Absent	Absent
								Day 42	16/06/92	42	Not done	Absent	Absent	Absent	Absent
	524	Placebo	Female	Evaluated	06/05/92	16/06/92	42	Screen	05/05/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	26/05/92	21	Not done	Absent	Absent	Absent	Absent
								Day 42	16/06/92	42	Not done	Absent	Absent	Absent	Absent
	525	Placebo	Female	Evaluated	06/05/92	16/06/92	42	Screen	05/05/92	0	Not done	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
7/03	525	Placebo	Female	Evaluated	06/05/92	16/06/92	42	Day 21	26/05/92	21	Not done	Absent	Absent	Absent	Absent
								Day 42	16/06/92	42	Not done	Absent	Absent	Absent	Absent
	526	Reboxetine	Female	Evaluated	06/05/92	16/06/92	42	Screen	05/05/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	26/05/92	21	Not done	Absent	Absent	Absent	Absent
								Day 42	16/06/92	42	Not done	Absent	Absent	Absent	Absent
	527	Imipramine	Female	Evaluated	19/05/92	29/06/92	42	Screen	12/05/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	09/06/92	22	Not done	Not done	Not done	Not done	Not done
								Day 42	30/06/92	43	Not done	Absent	Absent	Absent	Absent
	528	Imipramine	Female	Evaluated	19/05/92	22/06/92	35	Screen	12/05/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	09/06/92	22	Not done	Absent	Absent	Absent	Absent
7/04	193	Placebo	Female	Without Urinal	25/01/92	06/03/92	42	Screen	25/01/92	1	Normal	Not done	Not done	Not done	Not done
								Day 21	15/02/92	22	Normal	Not done	Not done	Not done	Not done
								Day 42	07/03/92	43	Normal	Not done	Not done	Not done	Not done
	194	Reboxetine	Male	Without screen	25/01/92	06/03/92	42	Screen	25/01/92	1	Normal	Not done	Not done	Not done	Not done
								Day 21	15/02/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	07/03/92	43	Normal	Absent	Absent	Absent	Absent
	195	Placebo	Female	Evaluated	25/01/92	06/03/92	42	Screen	25/01/92	1	Normal	Absent	Absent	Absent	Absent
								Day 21	15/02/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	07/03/92	43	Normal	Absent	Absent	Absent	Absent
	196	Reboxetine	Female	Evaluated	01/02/92	13/03/92	42	Screen	01/02/92	1	Normal	Absent	Absent	Absent	Absent
								Day 21	22/02/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	14/03/92	43	Normal	Absent	Absent	Absent	Absent
	197	Imipramine	Male	Evaluated	01/02/92	13/03/92	42	Screen	01/02/92	1	Normal	Absent	Absent	Absent	Absent
								Day 21	22/02/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	14/03/92	43	Normal	Absent	Absent	Absent	Absent
	198	Imipramine	Female	Evaluated	01/02/92	13/03/92	42	Screen	01/02/92	1	Normal	Absent	Absent	Absent	Absent
								Day 21	22/02/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	14/03/92	43	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
7/04	199	Imipramine	Male	Evaluated	28/03/92	08/05/92	42	Screen	28/03/92	1	Normal	Absent	Absent	Absent	Absent
								Day 21	18/04/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	09/05/92	43	Normal	Absent	Absent	Absent	Absent
	200	Placebo	Male	Evaluated	28/03/92	08/05/92	42	Screen	28/03/92	1	Normal	Absent	Absent	Absent	Absent
								Day 21	18/04/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	09/05/92	43	Normal	Absent	Absent	Absent	Absent
	201	Reboxetine	Female	Evaluated	28/03/92	08/05/92	42	Screen	28/03/92	1	Not done	Absent	Absent	Absent	Absent
								Day 21	18/04/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	09/05/92	43	Normal	Absent	Absent	Absent	Absent
	202	Reboxetine	Male	Evaluated	04/04/92	15/05/92	42	Screen	01/04/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	25/04/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	16/05/92	43	Normal	Absent	Absent	Absent	Absent
	203	Placebo	Female	Evaluated	04/04/92	15/05/92	42	Screen	01/04/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	25/04/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	16/05/92	43	Normal	Absent	Absent	Absent	Absent
	204	Imipramine	Female	Evaluated	04/04/92	15/05/92	42	Screen	01/04/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	25/04/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	16/05/92	43	Normal	Absent	Absent	Absent	Absent
7/05	205	Placebo	Male	Evaluated	27/01/92	08/03/92	42	Screen	30/12/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	17/02/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	09/03/92	43	Normal	Absent	Absent	Absent	Absent
	206	Imipramine	Female	Evaluated	28/01/92	09/03/92	42	Screen	14/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	18/02/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	10/03/92	43	Normal	Absent	Absent	Absent	Absent
	207	Imipramine	Female	Evaluated	28/01/92	09/03/92	42	Screen	21/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	18/02/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	10/03/92	43	Normal	Absent	Absent	Absent	Absent
	208	Reboxetine	Male	Evaluated	30/01/92	11/03/92	42	Screen	24/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	20/02/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	12/03/92	43	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
7/05	209	Placebo	Male	Evaluated	05/02/92	17/03/92	42	Screen	29/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	26/02/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	18/03/92	43	Normal	Absent	Absent	Absent	Absent
	210	Reboxetine	Male	Evaluated	07/02/92	19/03/92	42	Screen	03/02/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	28/02/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	20/03/92	43	Normal	Absent	Absent	Absent	Absent
	541	Reboxetine	Female	Evaluated	17/03/92	27/04/92	42	Screen	02/03/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	07/04/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	28/04/92	43	Normal	Absent	Absent	Absent	Absent
	542	Imipramine	Male	Evaluated	17/03/92	27/04/92	42	Screen	02/03/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	07/04/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	28/04/92	43	Normal	Absent	Absent	Absent	Absent
	543	Imipramine	Male	Evaluated	18/03/92	28/04/92	42	Screen	03/03/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	08/04/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	29/04/92	43	Normal	Absent	Absent	Absent	Absent
	544	Placebo	Female	Evaluated	24/03/92	04/05/92	42	Screen	04/03/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	14/04/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	05/05/92	43	Normal	Absent	Absent	Absent	Absent
	545	Placebo	Male	Evaluated	25/03/92	05/05/92	42	Screen	09/03/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	15/04/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	06/05/92	43	Normal	Absent	Absent	Absent	Absent
	546	Reboxetine	Female	Evaluated	25/03/92	05/05/92	42	Screen	10/03/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	15/04/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	06/05/92	43	Normal	Absent	Absent	Absent	Absent
7/07	529	Placebo	Female	Evaluated	18/02/92	30/03/92	42	Screen	17/02/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	10/03/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	31/03/92	43	Normal	Absent	Absent	Absent	Absent
	530	Imipramine	Female	Only screening	20/02/92	09/03/92	19	Screen	17/02/92	0	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period: Start date	Treatment period: End date	Treatment period: Days	Urinalysis test: Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
7/07	531	Reboxetine	Female	Evaluated	24/02/92	05/04/92	42	Screen	18/02/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	17/03/92	23	Not done	Absent	Absent	Absent	Absent
								Day 42	06/04/92	43	Not done	Absent	Absent	Absent	Absent
	532	Imipramine	Female	Evaluated	27/04/92	07/06/92	42	Screen	23/04/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	18/05/92	22	Normal	Present	Absent	Absent	Absent
								Day 42	09/06/92	44	Normal	Absent	Absent	Absent	Absent
	533	Reboxetine	Male	Without screen	04/05/92	14/06/92	42	Screen	27/04/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	25/05/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	15/06/92	43	Normal	Absent	Absent	Absent	Absent
	534	Placebo	Female	Evaluated	15/05/92	25/06/92	42	Screen	12/05/92	0	Normal	Absent	Absent	Present	Absent
								Day 21	05/06/92	22	Normal	Absent	Absent	Present	Absent
								Day 42	24/06/92	41	Normal	Absent	Absent	Absent	Absent
8	211	Reboxetine	Female	Only screening	13/05/91	26/05/91	14	Screen	07/05/91	0	Normal	Absent	Absent	Absent	Absent
	212	Placebo	Female	Only screening	14/09/91	25/10/91	42	Screen	10/09/91	0	Normal	Absent	Absent	Absent	Absent
	213	Imipramine	Male	Only screening	22/11/91	24/11/91	3	Screen	18/11/91	0	Normal	Absent	Absent	Absent	Absent
	214	Reboxetine	Female	Evaluated	23/11/91	03/01/92	42	Screen	19/11/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	13/12/91	21	Normal	Absent	Absent	Absent	Absent
	215	Placebo	Female	Without screen	18/02/92	30/03/92	42	Day 42	31/03/92	43	Normal	Absent	Absent	Absent	Absent
	216	Imipramine	Male	Evaluated	27/03/92	07/05/92	42	Screen	27/03/92	1	Normal	Absent	Absent	Absent	Absent
								Day 21	14/04/92	19	Normal	Absent	Absent	Absent	Absent
								Day 42	05/05/92	40	Normal	Absent	Absent	Absent	Absent
	217	Reboxetine	Female	Evaluated	30/03/92	10/05/92	42	Screen	23/03/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	20/04/92	22	Normal	Absent	Absent	Absent	Absent
	218	Reboxetine	Female	Without screen	09/04/92	20/05/92	42	Day 42	21/05/92	43	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period: Start date	Treatment period: End date	Treatment period: Days	Urinalysis test: Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
8	219	Placebo	Female	Only screening	11/04/92	01/05/92	21	Screen	08/04/92	0	Normal	Absent	Absent	Absent	Absent
	220	Imipramine	Female	Without screen	27/04/92	07/06/92	42	Day 21	18/05/92	22	Normal	Absent	Absent	Absent	Absent
	221	Imipramine	Male	Evaluated	28/04/92	08/06/92	42	Screen	24/04/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	19/05/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	09/06/92	43	Normal	Absent	Absent	Absent	Absent
	222	Placebo	Female	Evaluated	28/04/92	08/06/92	42	Screen	20/04/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	19/05/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	28/06/92	62	Normal	Absent	Absent	Absent	Absent
	223	Imipramine	Female	Without screen	11/05/92	21/06/92	42	Day 21	01/06/92	22	Normal	Absent	Absent	Absent	Absent
	224	Placebo	Female	Evaluated	07/09/92	18/10/92	42	Screen	27/08/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	28/09/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	19/10/92	43	Normal	Absent	Absent	Absent	Absent
	225	Placebo	Male	Evaluated	11/09/92	22/10/92	42	Screen	05/09/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	02/10/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	23/10/92	43	Normal	Absent	Absent	Absent	Absent
	226	Reboxetine	Male	Evaluated	23/09/92	03/11/92	42	Screen	15/09/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	14/10/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	04/11/92	43	Normal	Absent	Absent	Absent	Absent
	227	Reboxetine	Male	Evaluated	25/09/92	05/11/92	42	Screen	18/09/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	16/10/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	06/11/92	43	Normal	Absent	Absent	Absent	Absent
	228	Imipramine	Male	Only screening	26/09/92	02/10/92	7	Screen	19/09/92	0	Normal	Absent	Absent	Absent	Absent
	229	Imipramine	Female	Evaluated	30/09/92	10/11/92	42	Screen	24/09/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	21/10/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	11/11/92	43	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albunin	Sugar	RBC	WBC
8	230	Reboxetine	Female	Only screening	28/09/92	08/11/92	42	Screen	24/09/92	0	Normal	Absent	Absent	Absent	Absent
	231	Imipramine	Male	Evaluated	30/09/92	10/11/92	42	Screen	25/09/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	21/10/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	11/11/92	43	Normal	Absent	Absent	Absent	Absent
	232	Reboxetine	Male	Evaluated	02/10/92	12/11/92	42	Screen	25/09/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	23/10/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	13/11/92	43	Normal	Absent	Absent	Absent	Absent
	233	Placebo	Female	Evaluated	07/10/92	17/11/92	42	Screen	28/09/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	28/10/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	18/11/92	43	Normal	Absent	Absent	Absent	Absent
	234	Placebo	Female	Evaluated	07/10/92	17/11/92	42	Screen	30/09/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	28/10/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	18/11/92	43	Normal	Absent	Absent	Absent	Absent
8/A	235	Placebo	Female	Evaluated	14/10/92	24/11/92	42	Screen	18/09/92	0	Normal	Absent	Absent	Present	Present
								Day 21	03/11/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	24/11/92	42	Normal	Absent	Absent	Absent	Present
	236	Placebo	Female	Evaluated	14/10/92	24/11/92	42	Screen	18/09/92	0	Normal	Absent	Absent	Present	Present
								Day 21	03/11/92	21	Normal	Absent	Absent	Present	Present
								Day 42	24/11/92	42	Normal	Absent	Absent	Absent	Present
	237	Reboxetine	Female	Evaluated	14/10/92	24/11/92	42	Screen	18/09/92	0	Normal	Absent	Absent	Present	Present
								Day 21	03/11/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	24/11/92	42	Normal	Absent	Absent	Absent	Present
	238	Reboxetine	Female	Evaluated	14/10/92	24/11/92	42	Screen	18/09/92	0	Normal	Absent	Absent	Present	Present
								Day 21	03/11/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	24/11/92	42	Normal	Absent	Absent	Absent	Present
	239	Imipramine	Female	Evaluated	16/10/92	26/11/92	42	Screen	22/09/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	05/11/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	26/11/92	42	Normal	Absent	Absent	Absent	Present

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
8/A	240	Imipramine	Female	Evaluated	16/10/92	26/11/92	42	Screen	22/09/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	05/11/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	26/11/92	42	Normal	Absent	Absent	Absent	Present
	553	Placebo	Female	Evaluated	16/10/92	26/11/92	42	Screen	23/09/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	05/11/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	26/11/92	42	Normal	Absent	Absent	Absent	Present
	554	Reboxetine	Male	Evaluated	16/10/92	26/11/92	42	Screen	22/09/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	05/11/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	26/11/92	42	Normal	Absent	Absent	Absent	Absent
	555	Reboxetine	Female	Evaluated	16/10/92	26/11/92	42	Screen	22/09/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	05/11/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	26/11/92	42	Normal	Absent	Absent	Absent	Present
	556	Imipramine	Male	Evaluated	16/10/92	26/11/92	42	Screen	22/09/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	05/11/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	26/11/92	42	Normal	Absent	Absent	Present	Present
9	241	Placebo	Female	Only screening	07/02/91	17/02/91	11	Screen	04/02/91	0	Normal	Absent	Absent	Absent	Present
	242	Reboxetine	Female	Evaluated	18/02/91	11/03/91	22	Screen	12/02/91	0	Normal	Absent	Absent	Absent	Present
								Day 21	11/03/91	22	Normal	Absent	Absent	Absent	Present
	243	Reboxetine	Female	Evaluated	20/02/91	06/03/91	15	Screen	15/02/91	0	Normal	Absent	Absent	Present	Present
								Day 14	06/03/91	15	Normal	Present	Absent	Present	Present
	244	Imipramine	Female	Evaluated	19/02/91	13/03/91	23	Screen	14/02/91	0	Normal	Absent	Absent	Absent	Present
								Day 21	12/03/91	22	Normal	Absent	Absent	Present	Present
	245	Imipramine	Female	Evaluated	22/02/91	04/04/91	42	Screen	18/02/91	0	Normal	Absent	Absent	Absent	Present
								Day 21	15/03/91	22	Normal	Absent	Absent	Absent	Absent
								Day 42	05/04/91	43	Normal	Present	Absent	Absent	Present
	246	Placebo	Female	Evaluated	22/02/91	17/03/91	24	Screen	13/02/91	0	Normal	Absent	Absent	Present	Present

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
9	246	Placebo	Female	Evaluated	22/02/91	17/03/91	24	Day 21	15/03/91	22	Normal	Absent	Absent	Absent	Present
	247	Placebo	Female	Evaluated	25/02/91	26/03/91	30	Screen	20/02/91	0	Normal	Present	Absent	Absent	Present
								Day 21	18/03/91	22	Normal	Absent	Absent	Absent	Absent
	248	Placebo	Male	Evaluated	07/03/91	21/03/91	15	Screen	04/03/91	0	Normal	Absent	Absent	Absent	Absent
								Day 14	22/03/91	16	Normal	Absent	Absent	Absent	Absent
	249	Reboxetine	Female	Only screening	08/03/91	11/03/91	4	Screen	04/03/91	0	Normal	Absent	Absent	Absent	Present
	250	Imipramine	Female	Evaluated	12/03/91	08/04/91	28	Screen	07/03/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	02/04/91	22	Normal	Absent	Absent	Absent	Absent
								Day 28	08/04/91	28	Normal	Absent	Absent	Absent	Absent
	251	Imipramine	Female	Evaluated	20/03/91	12/04/91	24	Screen	18/03/91	0	Normal	Absent	Absent	Absent	Present
								Day 21	10/04/91	22	Normal	Absent	Absent	Absent	Present
	252	Reboxetine	Female	Evaluated	02/04/91	20/04/91	19	Screen	28/03/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	20/04/91	19	Normal	Absent	Absent	Absent	Present
	253	Reboxetine	Female	Only screening	02/04/91	08/04/91	7	Screen	29/03/91	0	Normal	Absent	Absent	Present	Absent
	254	Imipramine	Female	Evaluated	09/04/91	16/04/91	8	Screen	05/04/91	0	Normal	Absent	Absent	Absent	Absent
								Day 14	08/05/91	30	Normal	Absent	Absent	Absent	Present
	255	Reboxetine	Female	Without screen	13/05/91	06/06/91	25	Screen	08/05/91	0	Not done	Not done	Not done	Not done	Not done
								Day 21	03/06/91	22	Normal	Absent	Absent	Absent	Present
	256	Imipramine	Female	Only screening	27/05/91	08/07/91	43	Screen	23/05/91	0	Normal	Absent	Absent	Present	Present
								Day 42	02/07/91	37	Not done	Not done	Not done	Not done	Not done
	257	Placebo	Male	Only screening	25/06/91	01/07/91	7	Screen	21/06/91	0	Normal	Absent	Absent	Absent	Absent
	258	Placebo	Male	Only screening	01/07/91	10/07/91	10	Screen	26/06/91	0	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
11	319	Placebo	Male	Without Urinal	02/08/91	12/09/91	42	Screen	25/07/91	0	Normal	Absent	Absent	Absent	Not done
								Day 21	22/08/91	21	Not done	Absent	Absent	Absent	Not done
								Day 42	12/09/91	42	Not done	Absent	Absent	Absent	Not done
	320	Imipramine	Male	Without Urinal	17/08/91	26/09/91	41	Screen	08/08/91	0	Not done	Absent	Absent	Absent	Not done
								Day 21	05/09/91	20	Not done	Absent	Absent	Absent	Not done
								Day 42	26/09/91	41	Not done	Absent	Absent	Absent	Not done
	321	Placebo	Male	Without Urinal	06/09/91	17/10/91	42	Screen	22/08/91	0	Not done	Present	Absent	Absent	Not done
								Day 21	26/09/91	21	Not done	Absent	Absent	Absent	Not done
								Day 42	17/10/91	42	Not done	Absent	Absent	Absent	Not done
	322	Reboxetine	Female	Without Urinal	27/09/91	07/11/91	42	Screen	19/09/91	0	Not done	Absent	Absent	Absent	Not done
								Day 21	17/10/91	21	Not done	Absent	Absent	Absent	Not done
								Day 42	07/11/91	42	Not done	Absent	Absent	Absent	Not done
	323	Reboxetine	Male	Without Urinal	15/11/91	26/12/91	42	Screen	05/11/91	0	Not done	Absent	Absent	Absent	Not done
								Day 21	05/12/91	21	Not done	Absent	Absent	Absent	Not done
								Day 42	27/12/91	43	Not done	Absent	Absent	Absent	Not done
	324	Imipramine	Male	Without Urinal	06/12/91	16/01/92	42	Screen	20/11/91	0	Not done	Absent	Absent	Absent	Not done
								Day 21	27/12/91	22	Not done	Absent	Absent	Absent	Not done
								Day 42	16/01/92	42	Not done	Absent	Absent	Absent	Not done
	325	Reboxetine	Male	Without Urinal	13/12/91	23/01/92	42	Screen	06/12/91	0	Not done	Absent	Absent	Absent	Not done
								Day 21	02/01/92	21	Not done	Absent	Absent	Absent	Not done
								Day 42	23/01/92	42	Not done	Absent	Absent	Absent	Not done
	326	Placebo	Male	Without Urinal	16/01/92	27/02/92	43	Screen	14/01/92	0	Not done	Absent	Absent	Absent	Not done
								Day 21	06/02/92	22	Not done	Absent	Absent	Absent	Not done
								Day 42	27/02/92	43	Not done	Absent	Absent	Absent	Not done
	327	Imipramine	Male	Without Urinal	30/01/92	05/02/92	7	Screen	23/01/92	0	Not done	Absent	Absent	Absent	Not done
	328	Imipramine	Female	Without Urinal	31/01/92	04/02/92	5	Screen	28/01/92	0	Not done	Absent	Absent	Absent	Not done
	329	Placebo	Female	Without Urinal	10/04/92	21/05/92	42	Screen	01/04/92	0	Not done	Absent	Absent	Absent	Not done
								Day 21	30/04/92	21	Not done	Absent	Absent	Absent	Not done

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
11	329	Placebo	Female	Without Urinal	10/04/92	21/05/92	42	Day 42	21/05/92	42	Not done	Absent	Absent	Absent	Not done
	330	Reboxetine	Male	Without Urinal	09/04/92	21/05/92	43	Screen	06/04/92	0	Not done	Absent	Absent	Absent	Not done
								Day 21	30/04/92	22	Not done	Absent	Absent	Absent	Not done
								Day 42	21/05/92	43	Not done	Absent	Absent	Absent	Not done
	331	Imipramine	Male	Without Urinal	17/04/92	28/05/92	42	Screen	08/04/92	0	Not done	Absent	Absent	Absent	Not done
								Day 21	07/05/92	21	Not done	Absent	Absent	Absent	Not done
								Day 42	28/05/92	42	Not done	Absent	Absent	Absent	Not done
	332	Reboxetine	Male	Without Urinal	19/05/92	29/06/92	42	Screen	13/05/92	0	Not done	Absent	Absent	Absent	Not done
								Day 21	08/06/92	21	Not done	Absent	Absent	Absent	Not done
								Day 42	29/06/92	42	Not done	Absent	Absent	Absent	Not done
	333	Placebo	Male	Without Urinal	27/05/92	07/07/92	42	Screen	18/05/92	0	Not done	Absent	Absent	Absent	Not done
								Day 21	16/06/92	21	Not done	Absent	Absent	Absent	Not done
								Day 42	07/07/92	42	Not done	Absent	Absent	Absent	Not done
	334	Reboxetine	Female	Without Urinal	29/05/92	31/05/92	3	Screen	21/05/92	0	Not done	Absent	Absent	Absent	Not done
	335	Placebo	Male	Without Urinal	03/06/92	14/07/92	42	Screen	21/05/92	0	Not done	Absent	Absent	Absent	Not done
								Day 21	23/06/92	21	Not done	Absent	Absent	Absent	Not done
								Day 42	14/07/92	42	Not done	Absent	Absent	Absent	Not done
	336	Imipramine	Female	Without Urinal	18/06/92	25/06/92	8	Screen	15/06/92	0	Not done	Absent	Absent	Absent	Not done
	337	Reboxetine	Female	Without Urinal	02/07/92	13/08/92	43	Screen	14/06/92	0	Not done	Absent	Absent	Absent	Not done
								Day 21	23/07/92	22	Not done	Absent	Absent	Absent	Not done
								Day 42	13/08/92	43	Not done	Absent	Absent	Absent	Not done
	338	Imipramine	Male	Without Urinal	23/07/92	30/07/92	8	Screen	14/07/92	0	Not done	Absent	Absent	Absent	Not done
12	367	Reboxetine	Female	Evaluated	20/12/91	30/01/92	42	Screen	18/12/91	0	Normal	Absent	Absent	Absent	Present
								Day 21	10/01/92	22	Normal	Absent	Absent	Absent	Present
								Day 42	31/01/92	43	Normal	Absent	Absent	Absent	Present
	368	Placebo	Female	Evaluated	24/12/91	03/02/92	42	Screen	19/12/91	0	Normal	Absent	Absent	Absent	Present

(*) days of treatment

1996

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
12	368	Placebo	Female	Evaluated	24/12/91	03/02/92	42	Day 21	14/01/92	22	Normal	Absent	Absent	Absent	Present
								Day 42	04/02/92	43	Normal	Absent	Absent	Absent	Present
	369	Imipramine	Female	Evaluated	23/04/92	13/05/92	21	Screen	22/04/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	13/05/92	21	Normal	Absent	Absent	Absent	Present
	370	Placebo	Male	Evaluated	29/04/92	20/05/92	22	Screen	27/04/92	0	Normal	Absent	Absent	Present	Present
								Day 21	19/05/92	21	Normal	Absent	Absent	Absent	Present
	371	Imipramine	Female	Evaluated	01/05/92	06/05/92	6	Screen	21/04/92	0	Normal	Absent	Absent	Absent	Present
								Day 7	08/05/92	8	Normal	Absent	Absent	Absent	Present
	372	Reboxetine	Male	Evaluated	02/06/92	13/07/92	42	Screen	01/06/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	01/07/92	30	Normal	Present	Absent	Absent	Present
								Day 42	17/07/92	46	Normal	Present	Absent	Absent	Present
	373	Reboxetine	Male	Evaluated	05/06/92	14/07/92	40	Screen	05/06/92	1	Normal	Absent	Absent	Absent	Present
								Day 21	25/06/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	14/07/92	40	Normal	Absent	Absent	Absent	Absent
	374	Placebo	Female	Evaluated	09/06/92	05/07/92	27	Screen	09/06/92	1	Normal	Absent	Absent	Present	Present
								Day 21	30/06/92	22	Normal	Absent	Absent	Present	Present
								Day 28	06/07/92	28	Normal	Absent	Absent	Absent	Absent
	375	Imipramine	Male	Only screening	17/06/92	18/06/92	2	Screen	12/06/92	0	Normal	Absent	Absent	Absent	Absent
13	13	Placebo	Male	Without Urinal	13/04/91	24/05/91	42	Screen	04/04/91	0	Normal	Not done	Not done	Not done	Not done
								Day 21	02/05/91	20	Normal	Not done	Not done	Not done	Not done
								Day 42	24/05/91	42	Normal	Not done	Not done	Not done	Not done
	14	Placebo	Male	Evaluated	02/07/91	13/08/91	43	Screen	09/07/91	8	Normal	Absent	Absent	Absent	Absent
								Day 21	24/07/91	23	Normal	Not done	Not done	Not done	Not done
								Day 42	15/08/91	45	Normal	Absent	Absent	Absent	Absent
	15	Imipramine	Female	Without screen	05/07/91	15/08/91	42	Screen	01/07/91	0	Normal	Not done	Not done	Not done	Not done
								Day 21	25/07/91	21	Normal	Not done	Not done	Not done	Not done
								Day 42	15/08/91	42	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period: Start date	Treatment period: End date	Treatment period: Days	Urinalysis test: Assessment	Urinalysis test: Date	Urinalysis test: (*)	Urinalysis test: Specific gravity	Urinalysis test: Albumin	Urinalysis test: Sugar	Urinalysis test: RBC	Urinalysis test: WBC
13	16	Imipramine	Male	Evaluated	03/12/91	16/01/92	45	Screen	03/12/91	1	Normal	Absent	Absent	Absent	Absent
								Day 28	06/01/92	35	Not done	Absent	Absent	Absent	Absent
								Day 42	20/01/92	49	Normal	Absent	Absent	Absent	Absent
	17	Reboxetine	Male	Without screen	21/05/92	01/07/92	42	Screen	23/05/92	3	Not done	Not done	Not done	Not done	Not done
								Day 21	11/06/92	22	Normal	Present	Absent	Present	Present
								Day 42	02/07/92	43	Normal	Absent	Absent	Absent	Absent
	18	Reboxetine	Male	Evaluated	24/06/92	02/08/92	40	Screen	26/06/92	3	Normal	Absent	Absent	Present	Present
								Day 21	13/07/92	20	Normal	Present	Absent	Absent	Absent
								Day 42	03/08/92	41	Normal	Absent	Absent	Absent	Present
	409	Reboxetine	Male	Evaluated	10/12/91	20/01/92	42	Screen	10/12/91	1	Normal	Absent	Absent	Absent	Absent
								Day 21	03/01/92	25	Normal	Absent	Absent	Absent	Absent
								Day 42	22/01/92	44	Normal	Present	Absent	Absent	Absent
	410	Placebo	Male	Without Urinal	14/02/92	26/03/92	42	Screen	11/02/92	0	Normal	Absent	Absent	Not done	Not done
								Day 21	06/03/92	22	Normal	Absent	Absent	Not done	Not done
								Day 42	27/03/92	43	Normal	Absent	Absent	Not done	Not done
	411	Imipramine	Female	Without Urinal	28/03/92	08/05/92	42	Screen	20/03/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	16/04/92	20	Not done	Not done	Not done	Not done	Not done
								Day 42	05/05/92	39	Not done	Not done	Not done	Not done	Not done
	423	Placebo	Male	Evaluated	14/09/92	27/10/92	44	Screen	14/09/92	1	Normal	Absent	Absent	Absent	Absent
								Day 21	05/10/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	29/10/92	46	Normal	Not done	Not done	Not done	Not done
14	19	Reboxetine	Female	Evaluated	10/04/92	06/05/92	27	Screen	03/04/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	01/05/92	22	Normal	Absent	Absent	Absent	Absent
								Day 28	07/05/92	28	Normal	Present	Absent	Present	Present
	20	Imipramine	Female	Evaluated	29/04/92	09/06/92	42	Screen	27/04/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	20/05/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	19/06/92	52	Normal	Absent	Absent	Absent	Absent
	21	Imipramine	Female	Evaluated	20/07/92	24/08/92	36	Screen	16/07/92	0	Normal	Present	Absent	Present	Present

(*) days of treatment

1998

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
14	21	Imipramine	Female	Evaluated	20/07/92	24/08/92	36	Day 21	10/08/92	22	Normal	Absent	Absent	Absent	Absent
								Day 35	24/08/92	36	Normal	Present	Absent	Present	Present
15	25	Reboxetine	Female	Evaluated	18/06/91	29/07/91	42	Screen	17/06/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	09/07/91	22	Normal	Absent	Absent	Present	Absent
								Day 42	30/07/91	43	Normal	Absent	Absent	Absent	Absent
	26	Placebo	Male	Evaluated	20/06/91	01/08/91	43	Screen	17/06/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	10/07/91	21	Normal	Absent	Absent	Present	Present
								Day 42	01/08/91	43	Normal	Absent	Absent	Absent	Absent
	27	Imipramine	Female	Evaluated	02/07/91	13/08/91	43	Screen	27/06/91	0	Normal	Absent	Absent	Present	Absent
								Day 21	23/07/91	22	Normal	Absent	Absent	Absent	Absent
								Day 42	13/08/91	43	Normal	Absent	Absent	Present	Absent
	28	Reboxetine	Female	Evaluated	08/08/91	19/09/91	43	Screen	06/08/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	29/08/91	22	Normal	Absent	Absent	Present	Absent
								Day 42	20/09/91	44	Normal	Absent	Absent	Present	Absent
	29	Placebo	Male	Without screen	29/08/91	19/09/91	22	Screen	29/08/91	1	Normal	Absent	Absent	Present	Not done
								Day 21	19/09/91	22	Normal	Absent	Absent	Present	Absent
	30	Imipramine	Female	Evaluated	03/09/91	15/10/91	43	Screen	03/09/91	1	Not done	Absent	Absent	Absent	Absent
								Day 21	24/09/91	22	Normal	Absent	Absent	Absent	Present
								Day 42	15/10/91	43	Normal	Absent	Absent	Absent	Absent
	403	Imipramine	Female	Evaluated	04/10/91	14/11/91	42	Screen	04/10/91	1	Normal	Absent	Absent	Present	Present
								Day 21	28/10/91	25	Not done	Absent	Absent	Absent	Absent
								Day 42	14/11/91	42	Normal	Absent	Absent	Absent	Present
	404	Reboxetine	Female	Evaluated	08/10/91	05/11/91	29	Screen	10/09/91	0	Normal	Absent	Absent	Present	Absent
								Day 21	29/10/91	22	Normal	Absent	Absent	Absent	Absent
	405	Placebo	Female	Evaluated	11/11/91	23/12/91	43	Screen	11/11/91	1	Normal	Absent	Absent	Absent	Absent
								Day 21	02/12/91	22	Normal	Absent	Absent	Absent	Absent
								Day 42	23/12/91	43	Normal	Absent	Absent	Absent	Absent
	406	Imipramine	Male	Evaluated	27/11/91	07/01/92	42	Screen	27/11/91	1	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albunin	Sugar	RBC	WBC
15	406	Imipramine	Male	Evaluated	27/11/91	07/01/92	42	Day 21	17/12/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	07/01/92	42	Normal	Absent	Absent	Absent	Absent
	407	Reboxetine	Female	Without screen	03/12/91	14/01/92	43	Screen	02/12/91	0	Normal	Absent	Absent	Not done	Not done
								Day 21	24/12/91	22	Normal	Absent	Absent	Absent	Present
								Day 42	14/01/92	43	Normal	Absent	Absent	Absent	Absent
	408	Placebo	Female	Evaluated	20/01/92	04/03/92	45	Screen	09/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	10/02/92	22	Normal	Absent	Absent	Not done	Not done
								Day 42	04/03/92	45	Normal	Absent	Absent	Absent	Absent
	418	Placebo	Female	Evaluated	30/01/92	12/03/92	43	Screen	30/01/92	1	Normal	Absent	Absent	Absent	Absent
								Day 21	20/02/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	12/03/92	43	Normal	Absent	Absent	Absent	Absent
	419	Placebo	Female	Evaluated	28/04/92	09/06/92	43	Screen	27/04/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	19/05/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	09/06/92	43	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
1	1	Imipramine	Female	Screen	10/04/91	36.70	15		115	80	94	110	82	94
				Day 0	10/04/91	36.70		54.00	115	80	94	110	82	
				Day 7	17/04/91	37.10		52.00	122	86	86	116	82	
				Day 14	24/04/91	37.00		52.00	122	82		115	82	
				Day 21	01/05/91	36.70		53.50	110	70	85	104	68	88
				Day 28	08/05/91	36.60		53.50	105	65	96	101	70	101
				Day 35	15/05/91	36.50		54.00	108	75	96	101	75	101
				Day 42	22/05/91	36.90		55.00	110	70	78	110	70	82
	2	Reboxetine	Male	Screen	11/04/91	36.80	16		145	90	81	140	88	89
				Day 0	15/04/91	36.70		76.00	122	84		118	84	
				Day 7	22/04/91	36.60		75.00	118	88	82	114	88	
				Day 14	30/04/91	36.70		76.00	116	86	90	105	88	
				Day 21	06/05/91	36.20		76.00	130	86	82	105	90	
				Day 28	13/05/91	36.40		76.00	126	95	71	118	88	78
				Day 35	20/05/91	36.50		76.00	130	90	78	110	75	92
				Day 42	27/05/91	36.40		76.00	122	84	84	108	88	84
	3	Imipramine	Male	Screen	02/05/91	36.30			112	92				
				Day 0	06/05/91	36.30		77.50	122	82	79	120	80	
				Day 7	13/05/91			75.50	118	82	68	108	80	68
				Day 14	20/05/91	36.20		75.00	112	80	76	100	80	
				Day 21	27/05/91	36.80		75.00	140	90	70	125	85	76
				Day 28	03/06/91	36.40		75.00	120	80	80	118	80	80
				Day 35	11/06/91	36.40		74.50	124	86	84	120	86	
				Day 42	17/06/91	36.10		75.00	128	92	60	116	86	90
	4	Placebo	Male	Screen	04/06/91	36.60			130	80	88			
				Day 0	04/06/91	36.60		93.00	130	80	88			
				Day 7	11/06/91	36.40		93.30	130	82	80	120	88	84
				Day 14	18/06/91	36.50		93.00	130	88	90	126	88	92
				Day 21	25/06/91	36.50		93.00	125	80	80	125	80	80
				Day 28	02/07/91	36.80		94.00	125	80	80	125	80	80
				Day 35	09/07/91	36.80		94.00	130	80		125	80	
				Day 42	16/07/91	36.50		94.00	125	80		120	80	
	5	Reboxetine	Female	Screen	12/06/91	37.00			118	84	62	118	86	60
				Day 0	12/06/91	37.80		67.00	118	84	62	118	86	60
				Day 7	19/06/91	36.50		67.00	150	90	90	130	90	96
				Day 14	25/06/91	36.50		67.00	140	90	90	140	90	90
				Day 21	02/07/91	36.50		65.00	130	90		130	90	
	6	Placebo	Female	Screen	23/05/91	36.50			108	70	66	105	70	68
				Day 0	23/05/91	36.50		54.00	108	70	66	105	70	68

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
1	6	Placebo	Female	Day 7	30/05/91	36.20		54.00	122		72	110		90
				Day 14	06/06/91	37.00		54.00	110	68	78	95	70	90
				Day 21	13/06/91	36.70		53.60	110	74	72	110	74	72
				Day 28	20/06/91	36.30		54.00	108	70	72	100	70	82
				Day 35	01/07/91	36.00		55.00	110	70	80	100	65	84
				Day 42	08/07/91	37.00		54.00	120	60	84	130	70	92
	7	Reboxetine	Female	Screen	27/08/91	36.40			110	70	102	102	64	118
				Day 0	27/08/91	36.70		46.00	110	70	110	102	64	118
				Day 7	03/09/91	36.40		48.00	104	60	105	70	40	140
				Day 14	10/09/91	36.50		48.00	98	60	96	70	50	110
				Day 21	17/09/91	36.40		48.00	104	66	84	88	58	120
				Day 28	25/09/91	36.40		43.00	104	60	90	98	60	100
				Day 35	02/10/91	36.50		50.00	110	60	84	100	60	84
				Day 42	08/10/91	36.40		49.00	110	70		110	70	84
	8	Placebo	Male	Screen	05/09/91	36.40			122	84	72	122	84	72
				Day 0	05/09/91	36.40		64.00	122	84		122	84	
				Day 14	19/09/91	36.50		64.00	120	80	84	118	80	84
				Day 21	28/09/91	36.70		64.00	124	82	76	124	80	78
				Day 28	05/10/91	36.90		64.00	110	84	78	110	84	79
				Day 35	11/10/91	36.90		64.00	105	70	72	100	70	76
				Day 42	19/10/91	36.90		68.00	110	75	70	108	74	70
	9	Reboxetine	Female	Day 0	27/11/91	36.90		64.00	95	70	74	90	70	80
				Day 7	04/12/91	37.20		63.50	105	72	74	96	77	82
				Day 14	11/12/91	36.90		65.00	98	60	62	94	60	65
				Day 21	18/12/91	36.80		65.00	102	80	70	100	80	66
				Day 28	23/12/91	37.20		66.00	112	70		106	70	
				Day 35	30/12/91	37.20		67.00	110	70				
				Day 42	06/01/92	36.10		68.00	108	68		102	65	
	10	Placebo	Male	Screen	24/09/91	36.80			116	70	72	116	70	74
				Day 0	24/09/91	36.80		77.00	116	70	72	116	70	74
				Day 7	01/10/91	36.40		77.00	110	85	78	110	85	78
				Day 14	08/10/91	36.70		77.00	118	70	74	118	70	76
				Day 21	15/10/91	36.70		77.00	120	70	80	120	70	85
				Day 28	22/10/91	37.10		77.00	118	80	72	116	80	72
				Day 35	29/10/91	36.40		77.00	108	68	70	108	70	72
				Day 42	04/11/91	36.50		78.00	102	64	84	102	64	86
	11	Imipramine	Female	Screen	10/10/91	36.90			140	109	84	140	100	84
				Day 0	10/10/91	36.90		58.00	140	100	84	140	100	84

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
1	12	Imipramine	Female	Screen	18/10/91	37.10			116	78	78	108	76	84
				Day 0	18/10/91	37.10		62.00	116	78	78	108	76	84
				Day 7	25/10/91	37.10		63.00	118	80	76	105	80	88
				Day 14	01/11/91			63.00	116	80	82	100	75	100
				Day 21	08/11/91	36.50		63.00	105	80	86	95	80	97
				Day 28	15/11/91	37.10		61.00	120	80	96	105	80	110
				Day 35	22/11/91	37.10		66.00	112	74	73	102	75	
				Day 42	03/12/91	37.30		66.00	110	80	74	105	80	76
	412	Reboxetine	Male	Screen	12/11/91	37.20			115	80	76	115	75	80
				Day 0	12/11/91	37.20		76.00	115	80	76	115	75	80
				Day 7	20/11/91	36.80		75.00	105	80	74	105	80	72
				Day 14	27/11/91	36.90		75.00	112	84	96	106	84	100
				Day 21	04/12/91				112	68		105	65	
				Day 28	11/12/91	36.70		74.00	105	84	84	105	88	89
				Day 35	18/12/91	36.80		74.00	118	90		115	80	72
				Day 42	23/12/91	36.60		73.00	105	80		105	80	
	413	Placebo	Male	Screen	03/12/91	37.00			120	75	84	116	75	84
				Day 0	09/12/91	37.30		72.00	122	70	80	114	70	80
				Day 21	30/12/91	36.70		71.00	122	68	74	120	70	76
				Day 35	13/01/92	36.90		72.00	105	70	82	98	70	84
				Day 42	20/01/92	37.00		72.50	112	72		112	70	
	414	Imipramine	Female	Screen	21/01/92	37.00			120	90	104			
				Day 0	21/01/92	37.00		67.70	120	90	104			
				Day 7	28/01/92			65.00	110	75	80	105	75	
				Day 14	30/01/92	36.40		63.90	110	70	76			
	415	Imipramine	Male	Screen	14/01/92	37.10			142	84	96	130	82	105
				Day 0	14/01/92	37.10		67.00	142	84	96	130	85	105
				Day 7	21/01/92	37.10		66.00	145	88	92	136	90	101
				Day 14	28/01/92	37.10		65.00	128	80	76	116	80	78
				Day 21	06/02/92	36.80		65.00	140	90	68	110	84	71
				Day 28	13/02/92	36.80		66.00	135	95	84	118	95	120
				Day 35	20/02/92	37.10		66.00	130	95	75	122	100	78
				Day 42	27/02/92	37.10		65.00	144	90	96	128	82	106
	416	Reboxetine	Female	Screen	14/01/92	36.80			112	72	86	106	78	92
				Day 0	17/01/92	36.80		66.00	112	72	72	106	92	78
				Day 7	24/01/92	36.20		61.00	108	76	79	105	75	
				Day 14	30/01/92	36.30		61.00	125	80	82	120	76	84

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
1	421	Imipramine	Male	Screen	26/02/92	36.50			150	100	72	142	90	78
				Day 0	26/02/92	36.80		77.00	150	100	72	142	90	78
				Day 7	05/03/92	36.70		76.00	112	86	96	108	80	100
				Day 14	12/03/92	37.10		77.00	116	78	102	110	80	106
				Day 21	19/03/92	36.40			112	76	87	110	78	92
				Day 28	26/03/92	37.10		79.00	115	86	84	111	84	84
				Day 35	02/04/92	37.10		79.00	142	88	96	124	84	103
				Day 42	09/04/92	36.60		78.00	118	90	76	105	84	80
	422	Imipramine	Male	Screen	04/08/92	36.60			140	90	90	132	88	94
				Day 0	04/08/92	36.60		61.00	140	90	90	132	88	94
				Day 7	12/08/92	36.70		62.00	135	88	88	118	88	92
				Day 14	19/08/92	37.20		62.00	130	86	72	120	84	96
				Day 21	26/08/92			64.00	135	105	96	122	95	104
				Day 28	02/09/92	36.90		63.50	128	90	96	122	90	96
				Day 42	17/09/92	37.10		61.00	135	90	78	130	90	80
2/1	49	Placebo	Female	Screen	14/05/91	36.80	24		100	60	72	95	60	100
				Day 0	18/05/91	37.00		60.00	105	65	76	100	60	104
				Day 7	25/05/91	36.80		59.00	110	70	96	120	80	104
				Day 14	01/06/91	36.50		59.50	110	60	80	120	70	96
				Day 21	08/06/91	36.60		60.50	95	50	66	105	60	81
				Day 28	14/06/91	35.90		60.50	100	70	78	110	75	88
				Day 35	22/06/91	37.10		61.50	105	70	72	110	80	80
				Day 42	29/06/91	36.80		62.00	100	70	70	110	70	76
	50	Reboxetine	Female	Screen	23/12/91	37.10	18		135	95	84	140	100	95
				Day 0	26/12/91	37.10		50.00	150	95	88	140	100	94
				Day 7	02/01/92	36.90		50.00	125	95	68	130	95	76
				Day 14	09/01/92	36.90		50.00	140	100	80	130	95	88
				Day 21	16/01/92	37.20		50.50	110	90	68	125	80	76
				Day 28	23/01/92	37.30		51.00	120	85	72	125	95	76
				Day 35	30/01/92	36.90		51.00	130	95	96	125	100	92
				Day 42	06/02/92	37.30		51.00	125	80	92	125	80	88
	51	Imipramine	Female	Screen	28/01/92	36.40	18		110	70	72	95	70	76
				Day 0	01/02/92	36.20		68.00	130	80	64	125	80	92
				Day 7	08/02/92	37.00		66.00	120	70	66	90	75	70
				Day 14	15/02/92	37.00		66.00	135	90	68	130	90	86
				Day 21	24/02/92	37.00		66.00	110	70	88	130	70	100
				Day 28	03/03/92	37.00		67.00	120	90	76	120	80	79
				Day 35	09/03/92	36.80		66.00	120	65	88	125	80	80
				Day 42	16/03/92	36.90		67.00	115	70	68	105	70	68

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
2/2	43	Imipramine	Female	Screen	11/04/91	37.00	16		105	75	68	115	75	84
				Day 0	18/04/91	37.00		61.00	105	75	68	115	75	
				Day 7	25/04/91	37.70		61.00	100	75		95	80	88
				Day 14	02/05/91	37.00		61.00	105	70	60	100	80	84
				Day 28	13/05/91			62.00	115	70	88	122	95	104
				Day 35	16/05/91	37.00		62.00	130	88	76	115	90	94
	44	Imipramine	Female	Screen	12/07/91	37.00	22		130	85	80	120	85	80
				Day 0	19/07/91			62.00	130	80	76	125	90	104
				Day 7	25/07/91	37.80		61.00	135	100	88	80	60	134
				Day 14	01/08/91			62.70	115	70	92	105	80	112
				Day 21	08/08/91	37.50		62.90	125	80	88	115	90	112
				Day 28	14/08/91	37.50		62.80	135	85	96	120	95	124
				Day 35	23/08/91			63.00	120	85	104	110	90	132
				Day 42	29/08/91	37.40		62.00	140	100	100	115	85	104
	45	Reboxetine	Female	Screen	27/08/91	37.30	15		110	85	64	120	90	100
				Day 0	07/09/91	37.30		60.20	110	70	68	105	75	84
				Day 7	15/09/91	37.40		61.60	110	80	52	100	70	76
				Day 14	22/09/91	37.40		60.50	110	80	54	80	60	80
				Day 21	30/09/91	37.10		60.50	110	95	64	85		96
				Day 28	06/10/91	37.40		62.00	140	100		110	85	
				Day 35	13/10/91			62.00	110	80	60	100	70	80
				Day 42	21/10/91	37.40		64.50	110	80	64	90	70	100
	46	Placebo	Female	Screen	18/09/91				120	80	64	105	85	72
				Day 0	26/09/91			63.00	125	80	64	105	85	72
				Day 7	03/10/91			63.00	120	80	64	125	95	80
				Day 21	17/10/91	36.80			110	80	64	105	85	72
				Day 28	23/10/91			63.00	120	85	84	130	90	84
	47	Placebo	Female	Screen	13/03/92	37.00	16		105	65	84	100	65	94
				Day 0	24/03/92	37.00		53.00	130	90		125	85	70
				Day 7	31/03/92	37.00		54.00	110	80		110	80	
				Day 14	07/04/92	37.00		53.00	125	85	66	115	80	67
				Day 21	14/04/92	37.00		53.00	120	80	70	120	65	67
				Day 28	21/04/92	37.00		53.00	130	90	70	130	95	73
				Day 35	28/04/92	37.00		53.00	130	90	90	125	80	85
				Day 42	05/05/92	37.00		54.00	130	85	70	120	85	75
	48	Reboxetine	Female	Screen	03/04/92	37.00	17		140	90	105	130	90	102
				Day 0	07/04/92	37.00		64.00	140	90	90	140	90	88

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
2/2	48	Reboxetine	Female	Day 7	14/04/92	37.00		64.00	125	90		130	100	80
				Day 14	21/04/92	37.00		64.00	120	70	85	130	95	80
				Day 21	28/04/92	37.00		64.00	130	90	80	130	100	
				Day 28	06/05/92	37.00		65.00	135	90	80	135	110	80
				Day 35	12/05/92	37.00		65.00	135	110	80	130	110	80
				Day 42	20/05/92	37.00		65.00	130	90	82	135	95	84
2/3	36/A	Imipramine	Male	Screen	06/03/91	37.10	15		130	80	88	130	80	88
				Day 0	06/03/91	37.20		99.00	130	70	80	130	70	80
				Day 7	13/03/91	37.40		99.00	135	80	80	120	80	86
				Day 14	20/03/91	37.40		99.00	130	80	80	120	80	80
				Day 21	28/03/91	37.00		99.00	130	80	80	130	80	80
				Day 28	03/04/91			98.00	130	70	80			
				Day 35	10/04/91	37.50		99.00	140	80		140	80	
				Day 42	17/04/91	37.00		99.00	130	70	80			
	37	Reboxetine	Female	Screen	18/03/91	35.50	15		120	88	78	120	80	82
				Day 0	26/03/91	37.50		43.00	130	80	72	120	80	72
				Day 7	02/04/91	37.50		43.00	130	80	72	120	80	72
				Day 14	09/04/91	37.50		43.00	130	80	100	130	80	100
				Day 21	16/04/91	37.10		43.00	130	80	90	130	90	90
				Day 28	23/04/91	37.40		43.00	125	80	90	120	80	90
				Day 35	30/04/91	37.20		43.00	120	80	80	110	80	84
				Day 42	07/05/91	37.40		44.00	120	80	90	115	80	90
	38	Placebo	Male	Screen	10/08/91	37.50	16		135	80	80	130	80	86
				Day 0	14/08/91	37.50		94.00	135	80	80	130	80	80
				Day 7	20/08/91	37.40		94.00	135	80	80	135	80	80
				Day 14	28/08/91			96.00	130	80	76	130	80	80
				Day 21	05/09/91			94.00	130	80	76	130	80	80
				Day 28	12/09/91			94.00	140	80	76	135	80	80
				Day 35	19/09/91	37.00		95.00	140	80	80	140	80	80
				Day 42	26/09/91	37.20		94.00	140	80	80	135	80	72
	39	Imipramine	Female	Screen	05/08/91		15		130	85	85	130	85	80
				Day 0	09/08/91			58.00	130	80	100	125	80	100
				Day 7	16/08/91			60.00	125	80	90	130	80	100
				Day 14	23/08/91	37.40		60.00	120	70	80	120	70	90
				Day 21	30/08/91	37.20		60.00	125	85	95	105	75	98
				Day 28	06/09/91			58.00	130	80	90	130	80	90
				Day 35	13/09/91	37.30		58.00	125	85	80	130	85	80
				Day 42	20/09/91			60.00	140	80	88	130	80	90
	40	Reboxetine	Female	Screen	24/10/91	37.00	16		110	60	90	100	60	90

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
2/3	40	Reboxetine	Female	Day 0	24/10/91	37.00		38.00	110	70	90	100	60	90
				Day 7	31/10/91	37.00		40.00	100	50	104	90	50	106
				Day 14	07/11/91	37.20		41.00	110	60	90	110	60	90
				Day 21	14/11/91	37.00		41.00	120	60	84	110	60	90
				Day 28	21/11/91	36.80		41.00	130	70	84	120	70	84
				Day 35	28/11/91	36.80		41.50	110	60	78	110	60	84
				Day 42	05/12/91	37.20		42.00	130	70	68	120	70	72
	41	Placebo	Male	Screen	26/09/91	37.00	20		140	70	120	140	70	120
				Day 0	03/10/91	37.00		63.00	140	70	100	130	70	120
				Day 7	10/10/91	37.00		63.00	125	60	90	110	60	90
				Day 14	17/10/91	37.00		63.00	120	70	84	110	70	84
				Day 21	24/10/91	37.00		66.00	110	60	100	100	60	120
				Day 28	31/10/91	36.50		65.00	105	60	90	100	60	104
				Day 35	06/11/91	37.10		65.00	110	70	84	110	70	90
				Day 42	14/11/91	37.20		65.50	120	60	72	130	60	84
	42	Imipramine	Female	Screen	06/05/92	37.00	15		130	70	92	120	80	92
				Day 0	18/05/92	37.00		78.00	130	90	90	120	80	90
				Day 7	25/05/92	37.30		78.00	130	80	84	120	80	90
				Day 14	01/06/92	37.00		78.00	140	70	90	120	60	96
				Day 21	09/06/92	37.00		78.00	130	80	96	120	70	96
				Day 28	16/06/92	37.00		78.00	110	80	72	120	80	72
				Day 35	23/06/92	37.50		77.00	130	70	76	120	70	80
				Day 42	30/06/92	37.00		78.00	130	70	78	120	70	84
2/4	31	Placebo	Male	Screen	18/03/91	36.50	20		130	70	80	130	70	80
				Day 0	25/03/91	36.50		75.00	130	70	78	130	70	
				Day 7	01/04/91	36.40		75.00	125	70	80	130	70	
				Day 14	08/04/91	37.00		75.00	125	70	80	130	70	
				Day 21	15/04/91	37.00		75.00	125	70	80	130	70	80
				Day 28	22/04/91	36.40		75.00	130	70	72	130	70	
				Day 35	29/04/91	36.30		75.00	125	60	75	125	60	
				Day 42	06/05/91	36.40		75.00	125	60	75	125	60	75
	32	Reboxetine	Male	Screen	18/10/91	36.70	30		130	70	60	130	70	64
				Day 0	25/10/91	36.80		80.00	120	70	62	120	70	65
				Day 7	01/11/91	36.70		80.00	130	70	62	130	70	65
				Day 14	08/11/91	36.80		80.00	130	70	60	130	70	64
				Day 21	15/11/91	36.80		80.00	110	70	75	110	70	80
				Day 28	22/11/91	36.70		80.00	130	70	82	130	70	85
				Day 35	29/11/91	36.80		80.00	125	70	84	125	70	88
				Day 42	06/12/91	36.80		80.00	130	70	86	130	70	90

2001

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
2/4	33	Imipramine	Male	Screen	22/05/91	36.40	20		130	75	76	130	75	76
				Day 0	29/05/91	36.40		80.00	130	70	76	130	75	
				Day 7	05/06/91	36.60		80.00	125	60	76	130	70	
				Day 14	12/06/91	36.50		80.00	130	70		130	70	
				Day 21	19/06/91	36.50		80.00	130	70	76	130	70	76
				Day 28	26/06/91	36.40		80.00	135	79	78	135	79	
				Day 35	03/07/91	36.50		80.00	135	75	78	135	75	
				Day 42	10/07/91	36.50		80.00	135	75	78	135	75	78
	34	Placebo	Female	Screen	10/04/92	36.50	17		130	70	78	130	70	81
				Day 0	17/04/92	36.50		42.00	130	70	80	130	70	82
				Day 7	24/04/92	36.50		42.00	130	70	78	130	70	80
				Day 14	01/05/92	36.40		42.00	125	70	78	125	70	80
				Day 21	08/05/92	36.50		42.00	130	70	76	130	70	78
				Day 28	15/05/92	36.60		42.00	125	70	76	125	70	77
				Day 35	22/05/92	36.40		42.00	130	70	80	130	70	80
				Day 42	29/05/92	36.60		42.00	120	70	75	120	70	77
	35	Reboxetine	Female	Screen	08/09/92	36.60	30		130	60	76	130	60	78
				Day 0	15/09/92	36.50		65.00	130	60	74	130	60	76
				Day 7	22/09/92	36.40		65.00	125	60	76	125	60	78
				Day 14	29/09/92	36.70		65.00	130	60	78	130	60	80
				Day 21	06/10/92	36.60		65.00	135	70	75	135	70	80
				Day 28	13/10/92	36.50		65.00	120	60	74	120	60	76
				Day 35	20/10/92	36.70		65.00	125	65	76	130	70	78
				Day 42	27/10/92	36.50		65.00	135	70	75	135	70	80
	36	Imipramine	Female	Screen	05/02/92	36.60	24		130	70	60	130	70	62
				Day 0	12/02/92	36.50		45.00	130	70	72	130	70	75
				Day 7	19/02/92	36.60		45.00	125	60	62	130	60	66
				Day 14	26/02/92	36.60		45.00	130	60	65	130	60	67
				Day 21	04/03/92	36.50		45.00	130	60	64	130	60	66
				Day 28	11/03/92	36.60		45.00	130	60	68	130	60	70
				Day 35	18/03/92	36.70		45.00	130	60	64	130	60	67
				Day 42	25/03/92	36.50		45.00	130	60	62	130	60	65
2/5	73	Placebo	Male	Screen	03/02/92	37.00			120	70	80	120	70	80
				Day 0	06/02/92	37.00		73.00	120	80	80	120	80	80
				Day 7	14/02/92	37.00		72.00	110	50	72	115	70	72
				Day 14	21/02/92	37.00		71.00	120	60	72	120	70	72
				Day 21	28/02/92	37.00		72.00	120	80	80	110	80	78
				Day 28	06/03/92	37.00		72.00	120	70	78	125	70	84
				Day 35	13/03/92	37.00		71.00	110	60	72	120	70	76
				Day 42	20/03/92	37.00		72.00	120	70	76	120	70	78

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
2/5	74	Reboxetine	Male	Screen	16/06/92	37.00			130	70	78	130	70	78
				Day 0	20/06/92	36.50		65.00	125	70	80	125	70	80
				Day 7	27/06/92	37.00		65.00	130	70	76	130	70	76
				Day 14	04/07/92	36.00		65.00	135	70	78	135	70	78
				Day 21	11/07/92	37.00		64.00	110	70		110	70	120
				Day 28	18/07/92	36.50		64.00	105	70	100	105	70	100
				Day 35	25/07/92	37.00		64.00	110	75	98	105	70	110
				Day 42	01/08/92	37.00		64.00	115	70	78	110	70	78
	75	Imipramine	Male	Screen	03/09/92	36.50			110	70	82	110	70	82
				Day 0	10/09/92	37.00		71.00	130	80	78	130	80	78
				Day 7	17/09/92	37.00		71.00	120	70	80	120	70	80
				Day 14	24/09/92	37.00		72.00	130	70	76	130	70	76
				Day 21	01/10/92	37.00		72.00	130	70	78	130	70	78
				Day 28	08/10/92	37.00		72.00	130	70	80	130	70	80
				Day 35	15/10/92	37.00		71.00	120	70	88	120	70	88
				Day 42	22/10/92	37.00		71.00	130	70	80	125	70	80
	76	Imipramine	Female	Screen	12/09/92	37.00			100	70	70	110	70	70
				Day 0	15/09/92	37.00		45.00	100	70	72	100	70	72
				Day 7	21/09/92	36.50		46.00	95	70	76	95	70	76
				Day 14	28/09/92	37.00		46.00	95	70	74	95	70	74
				Day 21	05/10/92	36.00		48.00	95	50	70	95	50	70
				Day 28	12/10/92	37.00		48.00	92	70	76	70	50	90
				Day 35	19/10/92	36.80		48.50	90	50	76	90	50	76
				Day 42	26/10/92	37.00		49.00	90	60	80	90	60	80
	77	Placebo	Male	Screen	15/09/92	37.00			140	70	76	140	70	76
				Day 0	21/09/92	37.00		77.00	135	70	76	130	70	76
				Day 7	28/09/92	37.00		77.00	130	70	76	130	70	76
				Day 14	05/10/92	37.00		77.00	130	70	76	130	70	76
				Day 21	12/10/92	37.00		76.50	120	70	78	120	70	78
				Day 28	19/10/92	37.00		77.00	115	70	80	120	70	80
				Day 35	26/10/92	36.90		77.00	120	70	78	120	70	78
				Day 42	02/11/92	37.00		78.00	125	70	80	130	70	80
	78	Reboxetine	Female	Screen	01/10/92	37.00			105	70	76	105	70	76
				Day 0	09/10/92	37.00		57.00	105	70	72	110	70	72
				Day 7	16/10/92	36.80		57.00	110	70	70	110	70	70
				Day 14	23/10/92	37.00		57.00	120	70	74	120	70	74
				Day 21	30/10/92	36.80		58.00	125	60	70	125	60	70
				Day 28	06/11/92	37.00		58.00	115	70	76	120	70	76
				Day 35	13/11/92	37.00		58.00	130	70	80	130	70	80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
2/6	55	Reboxetine	Female	Screen	12/06/92	37.00	17		140	80	76	130	80	74
				Day 0	12/06/92	37.00		55.00	140	80	76	130	80	76
				Day 7	19/06/92	37.00		55.00	140	80	78	130	80	76
				Day 14	26/06/92	37.00		55.00	130	80	74	130	80	74
				Day 21	03/07/92	37.00		55.00	130	80	74	120	80	74
				Day 28	10/07/92	37.00		55.00	120	80	70	110	80	70
				Day 35	17/07/92	37.00		55.00	120	80	74	120	80	74
				Day 42	24/07/92	37.00		55.00	120	80	74	120	80	74
	56	Reboxetine	Female	Screen	12/06/92	37.00	18		150	90	76	140	90	74
				Day 0	12/06/92	37.20		64.00	150	90	74	140	90	74
				Day 7	19/06/92	37.20		64.00	150	90	76	140	90	76
				Day 14	26/06/92	37.00		64.00	130	80	76	110	80	76
				Day 21	03/07/92	37.00		64.00	130	80	76	120	80	76
				Day 28	10/07/92	37.00		64.00	130	80	74	120	80	74
				Day 35	17/07/92	37.00		64.00	140	80	74	130	80	74
				Day 42	24/07/92	37.00		64.00	140	80	76	130	80	76
	57	Imipramine	Female	Screen	05/05/92	37.00	18		140	80	74	130	80	72
				Day 0	05/05/92	37.00		60.00	140	80	72	130	80	72
				Day 7	12/05/92	37.00		60.00	140	90	72	120	80	72
				Day 14	19/05/92	37.00		60.00	130	80	74	130	80	74
				Day 21	26/05/92	37.00		60.00	130	80	76	120	70	76
				Day 28	02/06/92	37.00		60.00	130	80	76	120	80	76
				Day 35	09/06/92	37.00		62.00	130	70	80	90	60	80
				Day 42	16/06/92	37.00		63.00	100	70	80	90	70	80
	58	Placebo	Female	Screen	18/05/92	37.00	20		130	80	74	120	80	74
				Day 0	18/05/92	37.00		55.00	130	80	76	120	80	76
				Day 7	25/05/92	37.00		55.00	140	90	80	120	90	80
				Day 14	01/06/92	37.00		56.00	130	80	76	120	80	76
				Day 21	09/06/92	37.00		56.00	130	90	74	120	90	74
				Day 28	16/06/92	37.00		55.00	130	90	74	120	90	74
				Day 35	23/06/92	37.00		55.00	120	80	74	110	80	76
				Day 42	30/06/92	37.00		55.00	120	80	74	120	80	74
	59	Placebo	Male	Screen	27/05/92	37.00	18		130	80	76	120	80	72
				Day 0	27/05/92	37.00		70.00	130	80	74	120	80	74
				Day 7	03/06/92	37.00		70.00	140	90	76	130	90	76
				Day 14	10/06/92	37.00		70.00	130	80	76	130	80	76
				Day 21	17/06/92	37.00		70.00	120	70	76	120	80	76
				Day 28	24/06/92	37.00		70.00	130	80	76	120	70	76

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
2/6	60	Imipramine	Female	Screen	12/05/92	37.00	18		130	80	74	120	80	72
				Day 0	12/05/92	37.20		47.00	130	80	76	120	80	76
				Day 7	19/05/92	37.20		47.00	120	80	74	120	80	74
				Day 14	26/05/92	37.20		49.00	110	70	76	90	60	76
				Day 21	02/06/92	37.20		49.00	100	70	76	90	60	76
				Day 28	09/06/92	37.00		49.00	100	70	76	90	60	76
				Day 35	16/06/92	37.00		50.00	90	70	78	80	60	78
				Day 42	23/06/92	37.00		50.00	90	70	76	80	60	76
3/1	61	Imipramine	Male	Screen	25/02/91	37.00			110	70	76	115	70	80
				Day 0	04/03/91	37.00		79.00	110	70	80	110	70	84
				Day 7	11/03/91	37.00		79.00	115	70	76	110	70	80
				Day 14	18/03/91	37.00		78.00	105	70	84	110	70	88
				Day 21	25/03/91	37.00		78.00	115	60	80	120	60	86
				Day 28	03/04/91	37.00		77.00	130	80	78	130	80	80
				Day 35	08/04/91			77.00	120	60	80	125	60	86
	62	Imipramine	Female	Screen	12/04/91	37.00			110	60	69	110	65	70
				Day 0	16/04/91	37.00		60.00	110	65	74	110	70	80
				Day 7	22/04/91	37.00		60.00	110	60		110	70	
				Day 14	29/04/91	37.00		60.00	120	70		120	65	
				Day 21	06/05/91	37.00		60.00	110	60	80	110	65	82
				Day 28	13/05/91	37.00		60.00	110	60	80	110	60	82
				Day 35	20/05/91	37.00		60.00	110	60	80	110	60	82
				Day 42	27/05/91	37.00		60.00	110	60		120	70	
	63	Placebo	Male	Screen	13/05/91	37.00			120	60	80	120	65	84
				Day 0	13/05/91	37.00		70.00	120	60	84	120	65	82
				Day 7	20/05/91	37.00		70.00	120	60	80	120	60	82
				Day 14	27/05/91	37.00		70.00	120	60	80	120	70	82
				Day 21	03/06/91	37.00		70.00	120	70	80	120	75	84
				Day 28	10/06/91	37.00		70.00	120	70		125	80	
				Day 35	17/06/91	37.00		70.00	120	60	82	110	70	84
				Day 42	24/06/91	37.00		70.00	120	60	80	115	70	80
	64	Placebo	Female	Screen	08/03/91				100	60	88	105	60	90
				Day 0	13/03/91			63.00	110	60	86	115	60	88
				Day 7	20/03/91			63.00	130	80	80	140	80	80
				Day 14	28/03/91			63.00	130	70	80	130	70	86
				Day 21	03/04/91			63.00	130	90	80	130	90	84
				Day 28	10/04/91			63.00	130	80	78	130	80	80
				Day 35	17/04/91			63.00	125	80	80	130	80	84
				Day 42	24/04/91			63.00	120	80		130	80	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
3/1	65	Reboxetine	Male	Screen	11/09/91	37.00			120	65	82	115	70	80
				Day 0	16/09/91	37.00		70.00	110	60	72	110	65	72
				Day 7	23/09/91	37.00		70.50	120	60	76	120	70	78
				Day 14	30/09/91	37.00		70.50	120	65	80	120	70	82
				Day 21	07/10/91	37.00		70.50	125	60		120	70	
				Day 28	14/10/91	37.00		71.00	110	65		105	70	
				Day 35	21/10/91	37.00		71.00	110	65	76	110	70	80
				Day 42	28/10/91	37.00		71.00	110	60	76	110	65	78
	66	Reboxetine	Male	Screen	05/06/91				140	70	76	130	60	82
				Day 0	10/06/91			90.00	140	70	76	130	60	80
				Day 7	17/06/91			90.00	130	70	80	130	70	84
				Day 14	24/06/91			90.00	140	70	92	130	70	100
				Day 21	01/07/91			89.00	130	70	88	130	70	92
				Day 28	08/07/91			88.50	140	90	88	140	90	90
				Day 35	15/07/91			89.00	130	90	78	130	90	84
				Day 42	22/07/91			89.00	160	90	100	140	80	98
	139	Imipramine	Male	Screen	28/08/91				130	80	96	120	80	100
				Day 0	02/09/91			61.00	130	80		125	80	
				Day 7	09/09/91			61.00	130	80	92	130	80	100
				Day 14	13/09/91			61.00	110	60	100	110	60	104
	140	Placebo	Male	Screen	04/09/91				110	70	72	105	60	70
				Day 0	11/09/91			67.00	110	70		110	70	
				Day 7	18/09/91			67.00	130	80	64	120	80	68
				Day 14	25/09/91			67.00	130	80	68	120	80	76
				Day 21	03/10/91			67.00	120	60	72	120	60	80
				Day 28	09/10/91			67.00	120	80	68	120	80	72
				Day 35	15/10/91			67.50	125	80	70	125	80	76
				Day 42	23/10/91			67.00	120	80	72	120	80	76
	141	Placebo	Female	Screen	25/09/91				110	60	80	105	60	86
				Day 0	02/10/91			56.50	100	60	84	95	60	88
				Day 7	09/10/91			57.00	110	60	86	100	60	88
				Day 14	16/10/91			56.00	100	60	80	100	60	88
				Day 21	23/10/91			56.00	110	60		110	60	
				Day 28	30/10/91			56.00	110	60	86	105	60	90
				Day 35	06/11/91			55.00	115	70	80	110	70	88
				Day 42	14/11/91			55.00	115	60	80	110	60	84
	142	Imipramine	Female	Screen	14/11/91	37.00			120	60	76	110	70	80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
3/1	142	Imipramine	Female	Day 0	18/11/91	37.00		50.00	120	60	80	110	65	82
				Day 7	25/11/91	37.00		50.00	120	60	80	120	65	82
				Day 14	02/12/91	37.00		50.00	110	60	87	120	70	88
				Day 21	09/12/91	37.00		50.00	120	60	80	115	65	82
	143	Reboxetine	Female	Screen	08/04/92				130	70	76	120	60	80
				Day 0	15/04/92			48.00	125	70	72	120	70	78
				Day 7	22/04/92			48.00	105	60	64	100	60	68
				Day 21	06/05/92			48.00	110	60	68	110	60	72
				Day 28	13/05/92			48.00	120	60	68	120	60	76
				Day 35	20/05/92			48.00	110	60	72	115	60	80
	144	Reboxetine	Female	Screen	01/06/92				110	60	86	110	60	88
				Day 0	09/06/92			42.00	110	60	90	105	60	88
				Day 7	15/06/92			43.00	95	60	100	95	60	98
				Day 14	22/06/92			43.00	100	60	90	100	60	92
				Day 28	06/07/92			44.00	100	60	88	95	60	92
				Day 35	13/07/92			44.00	100	70	86	100	70	92
				Day 42	22/07/92			44.00	105	60	78	100	60	88
	451	Reboxetine	Female	Screen	15/01/92				150	80	86	140	80	88
				Day 0	20/01/92			76.00	130	70	78	120	60	82
				Day 7	27/01/92			76.00	130	80	90	120	80	96
				Day 14	03/02/92			75.00	130	80	90	130	80	88
	452	Placebo	Male	Screen	15/01/92				120	80	86	120	80	88
				Day 0	22/01/92			70.00	120	80	86	120	70	88
				Day 7	29/01/92			71.00	135	70	84	130	70	88
				Day 14	05/02/92			70.00	130	80	80	130	80	84
				Day 21	12/02/92			69.00	130	80	80	125	80	84
				Day 28	19/02/92			69.00	130	80	80	130	80	84
				Day 35	26/02/92			69.00	115	60	80	110	60	86
				Day 42	04/03/92			69.00	120	60	76	120	60	80
	453	Imipramine	Female	Screen	22/01/92				140	70	80	140	70	84
				Day 0	29/01/92			72.00	145	70	80	140	70	84
				Day 7	05/02/92			72.00	150	80	88	145	80	92
				Day 14	12/02/92			74.00	140	80	68	140	80	72
				Day 21	19/02/92			74.00	135	80	66	140	80	70
				Day 28	26/02/92			73.00	140	80	70	140	80	78
				Day 42	11/03/92			73.00	145	80	72	140	70	78
	454	Reboxetine	Male	Screen	12/02/92				145	80	104	150	80	116

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
3/1	454	Reboxetine	Male	Day 0	17/02/92			77.00	140	80	86	145	80	92
				Day 7	24/02/92			76.00	135	80	76	140	80	80
				Day 14	29/02/92			76.00	140	80		140	80	
				Day 21	09/03/92			75.00	140	70	76	135	70	80
				Day 28	18/03/92			75.00	140	70	72	130	70	80
				Day 35	25/03/92			75.00	120	80	81	120	80	84
				Day 42	01/04/92			75.00	130	80	76	120	80	80
	455	Placebo	Female	Screen	26/02/92				100	60	76	100	60	78
				Day 0	11/03/92			58.00	105	60		100	60	
				Day 7	18/03/92			58.00	110	60		100	60	
				Day 14	25/03/92			58.00	120	60	66	110	60	70
				Day 21	01/04/92			58.00	110	60	68	110	60	70
				Day 28	08/04/92			58.00	120	60	68	115	60	74
				Day 35	15/04/92			58.00	100	70	66	95	70	74
				Day 42	22/04/92			58.00	105	70	66	100	70	76
	456	Imipramine	Female	Screen	18/03/92				130	80	88	125	80	92
				Day 0	25/03/92			47.00	115	70	64	110	70	66
				Day 7	01/04/92			49.00	110	60	68	110	60	76
				Day 14	03/04/92			49.00	130	60	88	110	60	96
3/2	65/A	Reboxetine	Female	Screen	25/01/91	37.00	14		100	80	80	105	80	84
				Day 0	29/01/91	36.50		56.50	100	80	80	110	65	84
				Day 7	05/02/91	37.00		55.00	120	60	88	110	55	92
				Day 14	12/02/91	36.60		56.30	110	60	92	80	50	108
				Day 21	19/02/91	36.70		57.00	100	55	80	110	60	80
				Day 28	26/02/91	36.90		57.00	105	70	92	105	70	96
				Day 35	05/03/91	36.80		58.00	110	60	92	115	60	104
				Day 42	12/03/91	36.80		58.50	100	60	80	90	50	84
3/3	67	Placebo	Male	Screen	16/07/91	37.20	16		120	80	72	130	80	80
				Day 0	17/07/91	36.70		61.00	120	80	78	140	80	85
				Day 7	24/07/91	37.10		60.00	120	80	80	140	90	80
				Day 14	31/07/91	37.40		61.00	120	80	72	130	90	76
				Day 21	07/08/91	37.00		62.00	120	80	72	120	80	80
				Day 28	14/08/91	37.10		60.00	140	90	72	140	90	80
				Day 35	21/08/91	36.90		60.00	140	80	72	140	90	80
				Day 42	28/08/91	36.50		61.00	140	80	72	140	80	80
	68	Reboxetine	Male	Screen	14/01/92	36.50	15		130	80	62	160	100	75
				Day 0	20/01/92	37.30		80.00	150	100	84	140	90	92
				Day 7	27/01/92	37.00		80.00	140	85	80	130	80	84
				Day 14	03/02/92	36.70		80.00	145	90	78	135	85	84

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
3/3	68	Reboxetine	Male	Day 21	10/02/92	36.80		80.00	130	70	62	130	80	68
				Day 28	17/02/92	37.20		80.00	140	70	68	130	80	72
				Day 35	24/02/92	36.70		80.00	130	80	62	150	90	68
				Day 42	02/03/92	37.30		80.00	140	70	62	130	80	72
	69	Placebo	Male	Screen	31/01/92	36.50	15		115	70	76	105	70	84
				Day 0	03/02/92	36.80		60.00	110	70	72	105	70	80
				Day 7	10/02/92	37.30		60.00	130	80	92	120	70	96
				Day 14	17/02/92	37.20		59.00	150	90	88	140	90	92
				Day 21	24/02/92	36.80		60.00	120	70	72	110	70	89
				Day 28	02/03/92	37.40		60.00	125	80		110	70	
				Day 35	09/03/92	37.00		60.00	140	90	84	135	85	92
				Day 42	16/03/92	36.80		60.00	135	75	80	120	70	92
	70	Imipramine	Male	Screen	10/04/92	37.20	16		160	90	80	155	100	88
				Day 0	13/04/92	36.00		77.00	140	90	88	165	100	100
				Day 7	21/04/92	37.00		76.00	110	70	88	120	70	80
				Day 14	28/04/92	36.80		76.00	120	70	88	135	80	78
				Day 21	05/05/92	36.80		75.00	120	70	80	100	70	88
				Day 28	12/05/92	36.60		75.00	130	90	80	120	80	88
				Day 35	19/05/92	36.80		74.00	130	80	75	110	70	88
				Day 42	26/05/92	37.10		74.00	120	80	60	110	70	80
	71	Imipramine	Female	Screen	14/04/92	37.00	16		100	70	88	90	60	92
				Day 0	15/04/92	36.90		57.00	135	90	76	125	100	88
				Day 7	22/04/92	37.00		57.00	110	60	78	120	70	80
				Day 14	29/04/92	36.80		57.00	110	60	80	120	70	82
				Day 21	06/05/92	37.20		57.00	120	80	74	120	80	72
				Day 28	13/05/92	36.70		57.00	145	90	76	130	80	72
				Day 35	20/05/92	37.00		57.00	160	100	80	150	90	72
				Day 42	27/05/92	37.30		57.00	155	100	72	145	80	68
	72	Reboxetine	Male	Screen	21/07/92	37.00	25		140	60	70	130	70	85
				Day 0	24/07/92	36.50		66.00	145	70	72	130	70	80
				Day 7	31/07/92	37.00		67.00	150	80	72	135	70	80
				Day 14	07/08/92	37.60		67.50	170	80	100	150	80	120
				Day 21	14/08/92	37.50		68.00	120	80	88	120	70	92
				Day 28	21/08/92	36.70		69.00	130	80	84	120	70	88
				Day 35	28/08/92	37.00		69.00	120	80	76	105	70	88
				Day 42	04/09/92	36.70		66.00	140	100	76	125	90	80
3/4	79	Imipramine	Female	Screen	01/05/91	36.90	15		115	70				
				Day 0	04/05/91	37.00		50.00	115	65	64	110	65	65
				Day 7	11/05/91	37.10		49.00	115	75	72	110	75	84

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
3/4	79	Imipramine	Female	Day 14	17/05/91	36.90		50.00	120	80	76	110	85	92
				Day 21	24/05/91	37.00		50.00	120	75	62	115	75	66
				Day 28	31/05/91	37.10		50.00	120	65	62	110	60	64
				Day 35	07/06/91	36.90		50.00	115	65	64	110	60	66
				Day 42	17/06/91	37.00		51.00	110	60	60	105	60	64
	80	Imipramine	Male	Screen	31/08/91	37.00	15		125	75	62	120	70	62
				Day 0	31/08/91	37.00		68.00	125	75	62	120	70	62
				Day 7	09/09/91	36.90		68.00	125	70	60	120	65	60
				Day 14	17/09/91	37.00		68.50	130	70	60	120	65	60
				Day 21	25/09/91	37.00		68.00	130	75	60	120	70	64
	81	Reboxetine	Female	Screen	14/05/91	36.80	20		120	85	82	130	90	92
				Day 0	17/05/91	36.70		55.00	130	90	84	130	90	92
				Day 7	24/05/91			55.00	135	90	96	130	90	90
				Day 14	31/05/91	36.70		55.00	140	90	80	120	80	90
				Day 21	07/06/91			55.00	120	80	80	130	90	90
				Day 28	14/06/91	36.90		55.00	125	80	80	130	90	84
				Day 35	21/06/91	36.90		56.00	130	90	80	130	90	84
				Day 42	28/06/91			57.00	140	90	90	140	90	100
	82	Placebo	Male	Screen	17/06/91		19		130	80	70	140	90	80
				Day 0	17/06/91			70.00	130	80	70	140	90	80
				Day 7	24/06/91			71.00	130	80	72	140	90	80
				Day 14	01/07/91			69.00	140	90	64	145	90	68
				Day 21	08/07/91			68.00	130	80	78	120	70	80
				Day 28	15/07/91			69.00	130	80		140	80	
				Day 35	22/07/91			69.00	135	80		140	90	
				Day 42	29/07/91			69.00	140	90	60	140	90	70
	83	Placebo	Male	Screen	17/06/91				120	80	90	120	80	90
				Day 0	17/06/91			75.00	120	80	90	120	80	80
				Day 7	24/06/91			75.00	120	70	80	140	80	84
	84	Reboxetine	Female	Screen	07/10/91	37.00	14		120	70	68	115	65	68
				Day 0	07/10/91	37.00		60.00	135	80	68	115	65	68
				Day 7	16/10/91	36.90		60.00	130	80	66	120	70	66
				Day 14	23/10/91	37.00		60.00	130	75	64	115	65	64
				Day 21	31/10/91	36.90		60.50	120	70	70	115	60	68
				Day 28	07/11/91	37.00		60.50	120	65	60	115	60	64
				Day 35	15/11/91	37.00		61.00	120	70	62	120	65	66
				Day 42	23/11/91	37.00		61.00	125	70	66	120	70	68

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
3/4	85	Imipramine	Female	Screen	25/10/91		17		115	60		100	70	
				Day 0	28/10/91			54.00	120	60		110	70	
				Day 7	04/11/91			55.00	140	80	76	145	70	80
				Day 14	12/11/91			55.00	120	80	76	110	70	84
				Day 21	18/11/91			56.00	120	80	74	110	70	80
				Day 28	25/11/91			57.00	125	80	96	115	80	98
				Day 35	02/12/91			56.50	130	80	82	120	70	88
				Day 42	09/12/91			57.00	110	70	90	100	60	90
	86	Imipramine	Male	Screen	03/12/91	37.00	15		140	85	64	135	80	62
				Day 0	03/12/91	37.00		63.00	140	85	64	135	80	62
				Day 7	11/12/91	37.00		63.00	130	80	60	125	75	60
				Day 14	18/12/91	37.00		63.00	130	75	60	130	70	60
				Day 21	24/12/91	37.00		63.50	125	70	62	120	70	60
				Day 28	30/12/91	37.00		63.50	125	70	64	120	70	62
				Day 35	07/01/92	37.00		63.50	125	70	66	120	65	64
				Day 42	15/01/92	37.00		63.50	160	90	74	160	100	84
2017	87	Placebo	Female	Screen	06/12/91		17		120	80	80	115	80	84
				Day 0	09/12/91			61.00	110	80	80	110	70	80
				Day 7	16/12/91			61.00	110	80	80	100	70	78
				Day 14	22/12/91			61.00	120	80	84	110	70	80
				Day 21	29/12/91			63.00	120	80	88	100	60	90
				Day 28	06/01/92			61.00	150	90	70	160	90	80
				Day 35	13/01/92			60.00	140	80	84	160	80	100
				Day 42	20/01/92			59.50	140	80	80	130	80	84
	88	Placebo	Male	Screen	23/03/92	37.00	14		110	60	60	120	70	62
				Day 0	23/03/92	37.00		76.00	110	60	60	120	70	62
				Day 7	30/03/92	37.00		76.00	130	80	58	125	75	60
				Day 14	06/04/92	37.00		76.00	125	75	60	120	75	60
				Day 21	13/04/92	37.00		76.00	120	70	62	120	75	60
				Day 28	22/04/92	37.00		76.00	120	75	63	125	75	61
				Day 35	30/04/92	37.00		75.50	120	70	64	125	80	62
				Day 42	09/05/92	37.00		76.00	120	75	62	125	75	60
	89	Reboxetine	Female	Screen	26/03/92	37.00	14		115	75	60	115	70	58
				Day 0	26/03/92	37.00		51.00	115	75	60	115	70	58
				Day 7	02/04/92	37.10		50.50	120	75	60	115	70	62
				Day 14	07/04/92	37.00		51.00	120	70	60	115	70	60
				Day 21	14/04/92	37.00		50.50	115	70	64	115	75	65
				Day 28	21/04/92	36.90		50.60	115	70	63	120	70	64
				Day 35	28/04/92	37.00		50.80	120	65	62	120	70	64
				Day 42	06/05/92	37.00		51.00	115	65	60	120	70	64

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
3/4	90	Reboxetine	Male	Screen	27/04/92		15		120	85	80	150	90	90
				Day 0	27/04/92			72.00	120	85	80	150	90	90
				Day 7	05/05/92			73.00	140	95	80	130	90	88
				Day 14	12/05/92			73.00	135	90	80	130	90	84
				Day 21	19/05/92			73.00	130	70		120	80	
				Day 28	26/05/92			73.00	130	80	80	140	90	84
				Day 35	02/06/92			73.00	140	80	70	150	90	80
				Day 42	09/06/92			73.00	130	80	70	135	80	74
	457	Placebo	Female	Screen	18/05/92	37.00	17				75			90
				Day 0	21/05/92	37.00		63.00	120	80	75	130	85	90
				Day 7	29/05/92	36.80		62.00	120	70	80	115	65	90
				Day 14	04/06/92	37.00		62.00	125	70	80	105	65	90
				Day 21	11/06/92	36.90		61.00	120	70	80	100	60	90
	458	Reboxetine	Female	Screen	18/05/92	37.00	18		120	85	70	110	80	85
				Day 0	26/05/92	37.10		79.00	135	85	72	105	65	90
				Day 7	02/06/92	36.00		78.00	120	80	70	100	60	95
				Day 14	09/06/92	36.90		78.00	125	85	70	110	65	90
	459	Placebo	Female	Screen	29/05/92	37.10	20		130	70	80	110	60	90
				Day 0	01/06/92	37.10		41.00	130	70	84	110	60	84
				Day 7	09/06/92	37.00		41.00	135	75	80	110	60	90
				Day 14	16/06/92	37.00		41.00	130	70	80	105	60	90
				Day 21	22/06/92	36.90		40.50	135	65	75	110	55	90
				Day 28	29/06/92	37.00		41.00	130	60	70	110	50	85
				Day 35	06/07/92	37.20		41.00	135	65	65	110	50	75
				Day 42	13/07/92	36.90		41.50	120	60	65	105	55	80
	460	Reboxetine	Male	Screen	14/08/92		15		125	89	80	130	85	85
				Day 0	19/08/92			62.00	125	80		130	85	
				Day 7	26/08/92			62.00	130	80		135	80	
	461	Imipramine	Female	Screen	15/09/92	37.00	14		130	70	80	125	70	80
				Day 0	17/09/92	37.00		79.00	130	70		125	70	
				Day 7	24/09/92	37.00		79.00	140	75		135	75	
	462	Imipramine	Female	Screen	29/09/92	37.10	13		130	70	75	125	70	76
				Day 0	29/09/92	37.10		68.00	130	70	75	125	70	72
				Day 7	08/10/92	37.10		68.00	125	70		125	60	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
4/1	91	Imipramine	Female	Screen	05/10/91	37.20	17		120	70	70	130	80	65
				Day 0	12/10/91	37.00		67.00	120	70	65	130	80	65
				Day 7	19/10/91	36.80		66.00	120	70		120	70	
				Day 14	26/10/91	37.00		65.00	120	70	70	105	60	76
				Day 21	02/11/91	37.00		64.00						
				Day 28	09/11/91	37.00		64.00	135	80	70	115	80	75
				Day 35	16/11/91	37.00		64.00	125	70	70	115	70	75
	92	Reboxetine	Female	Screen	07/08/91	36.80	14		120	75	70	120	70	74
				Day 0	07/08/91	36.80		41.00	120	75	70	120	70	74
				Day 7	14/08/91	36.90		41.00	100	65	102	110	70	94
				Day 14	21/08/91	36.80		41.00	110	70	92	115	75	86
				Day 21	28/08/91	37.60		40.00	105	70	72	100	65	64
				Day 28	04/09/91	37.30		38.00	105	75	70	100	75	68
				Day 35	11/09/91	37.50		38.00	110	85	68	105	85	66
				Day 42	18/09/91	37.40		39.00	120	85	86	115	80	82
	93	Placebo	Male	Screen	28/06/91	37.00	20		130	100	64	130	100	66
				Day 0	03/07/91	37.00		68.00	130	80	64	120	90	70
				Day 7	09/07/91	37.00		69.00	130	80	72	130	80	70
				Day 14	17/07/91	37.00		69.00	130	80		130	80	68
				Day 21	24/07/91	37.00		70.00	125	90	72	130	80	76
				Day 28	31/07/91	37.00		70.00	120	70	60	120	70	66
				Day 35	09/08/91	37.00		71.00	120	80	75	120	90	80
				Day 42	16/08/91	37.00		70.00	120	70	50	120	70	50
	94	Placebo	Female	Screen	27/06/91	37.00	16		120	90	72	130	80	76
				Day 0	05/07/91	37.00		60.00	120	90		130	80	
				Day 7	12/07/91	37.00		58.00	130	90		130	80	
				Day 14	16/07/91	37.00		58.00	120	80		110	80	
				Day 21	23/07/91	37.00		58.00	150	80				
				Day 28	30/07/91	37.00		58.00	130	80		130	90	
				Day 35	07/08/91	38.00		58.00	125	80		130	80	
				Day 42	14/08/91	37.00		58.00	120	80		120	80	
	95	Imipramine	Female	Screen	03/06/91	37.50	20		110	70	75	110	80	84
				Day 0	03/06/91	37.00		77.00	120	80	72	120	90	76
				Day 7	10/06/91	37.20		77.00	110	80	68	120	80	70
				Day 14	17/06/91	37.00		77.00	130	80	68	130	80	72
				Day 28	02/07/91	37.00		77.00	130	70	75	130	80	70
				Day 35	09/07/91	37.00		77.00	130	80	70	120	70	76
				Day 42	17/07/91	37.00		78.00	120	70	70	120	70	76

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
4/1	96	Reboxetine	Female	Screen	27/08/91	37.40			125	85	70	125	80	72
				Day 0	04/09/91	37.40		79.00	125	85	70	125	80	72
				Day 7	11/09/91	37.50		77.00	125	85	70	120	80	74
				Day 14	18/09/91	37.60		76.00	120	80	70	115	75	76
				Day 21	25/09/91	37.50		75.00	140	90	96	140	85	100
				Day 28	02/10/91	37.60		75.00	135	85	88	130	80	90
				Day 35	09/10/91	37.50		75.00	130	80	86	130	80	90
				Day 42	16/10/91	36.70		75.00	125	85	72	130	90	70
	115	Reboxetine	Female	Screen	28/04/92	36.80	16		125	80	76	120	80	78
				Day 0	05/05/92	37.20		76.00	120	80	72	115	75	74
				Day 7	12/05/92	37.20		75.50	120	80	80	120	75	82
				Day 14	19/05/92	37.40		74.50	120	80	82	115	75	84
				Day 21	26/05/92	37.20		73.50	120	80	82	125	80	82
				Day 28	02/06/92	37.40		72.50	125	80	80	125	75	82
				Day 35	09/06/92	37.30		72.00	130	90	76	125	85	80
				Day 42	16/06/92	37.20		72.00	125	85	78	120	80	80
	116	Imipramine	Female	Screen	07/05/92	36.80	19		130	80	82	125	75	80
				Day 0	15/05/92	36.80		56.00	125	75	80	125	70	82
				Day 7	23/05/92	36.80		56.00	125	75	82	125	70	82
	117	Imipramine	Female	Screen	27/08/91	36.90	16		110	65	65	110	60	65
				Day 0	03/09/91	37.20		65.00	140	85		135	80	
				Day 7	10/09/91	37.50		65.00	135	85	86	130	80	80
				Day 14	17/09/91	37.40		66.00	130	80	84	125	80	78
				Day 21	24/09/91	37.50		70.00	130	85	78	125	85	72
				Day 28	01/10/91	37.40		70.00	130	85	72	125	80	70
				Day 35	08/10/91	37.50		70.00	135	85	76	120	75	70
				Day 42	15/10/91	37.50		70.00	135	85	76	120	75	70
	118	Reboxetine	Female	Screen	15/05/92	36.90	17		120	80	84	120	80	84
				Day 0	22/05/92	37.30		84.00	125	75	94	120	75	96
				Day 7	29/05/92	37.40		84.00	130	75	86	125	70	86
				Day 14	05/06/92	37.20		84.00	125	75	86	120	75	86
				Day 21	12/06/92	37.20		85.00	125	75	88	120	75	88
				Day 28	19/06/92	37.10		85.00	115	70	82	115	65	82
				Day 35	26/06/92	37.20		85.00	125	75	80	120	75	84
				Day 42	03/07/92	37.10		85.00	115	70	80	115	70	84
	119	Placebo	Female	Screen	16/03/92	36.50			110	80		120	90	
				Day 0	16/03/92	36.50		54.00	110	80		120	90	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
4/1	120	Placebo	Female	Screen	25/07/92	36.80	16		125	75	60	120	75	62
				Day 0	31/07/92	36.70		56.00	125	75	56	125	70	58
				Day 7	07/08/92	36.70		55.50	130	80	60	125	75	56
				Day 14	17/08/92	36.70		56.00	115	70	56	115	65	56
				Day 21	21/08/92	36.70		56.00	115	70	58	115	70	58
				Day 28	28/08/92	36.80		56.00	120	75	56	115	70	58
				Day 35	04/09/92	36.70		56.50	115	75	60	115	70	58
				Day 42	11/09/92	36.70		56.00	125	65	60	125	60	62
	145	Imipramine	Female	Screen	23/09/92	36.70	15		125	85	75	125	85	72
				Day 0	29/09/92	36.70		62.00	125	80	80	125	75	80
				Day 7	06/10/92	36.70		61.50	120	75	76	115	75	80
				Day 14	14/10/92	36.70		62.00	120	75	76	120	70	76
				Day 21	20/10/92	36.70		61.00	125	80	90	125	75	90
				Day 28	27/10/92	36.80		61.00	125	75	86	125	70	86
				Day 35	03/11/92	36.70		61.00	115	70	76	115	70	78
				Day 42	10/11/92	36.70		61.50	120	80	92	120	80	92
	146	Placebo	Female	Screen	30/08/92	36.70	12		150	100	90	145	95	88
				Day 0	15/09/92	36.70		59.00	145	80	92	145	75	92
				Day 7	23/09/92	36.70		59.00	145	80	86	145	80	82
				Day 14	29/09/92	36.80		59.50	140	75	88	140	80	86
				Day 21	06/10/92	36.70		57.00	150	100	62	150	95	65
				Day 28	14/10/92	36.90		57.00	150	90	66	145	90	66
				Day 35	20/10/92	37.60		58.00	145	90	68	145	85	66
				Day 42	27/10/92	36.90		58.50	135	80	60	135	75	60
	147	Reboxetine	Female	Screen	18/08/92	36.70	13		150	80	68	145	80	70
				Day 0	31/08/92	36.80		96.00	150	90	75	145	90	75
				Day 7	07/09/92	36.80		97.00	150	85	78	150	85	76
				Day 14	14/09/92	36.70		97.00	145	85	75	145	80	77
				Day 21	21/09/92	37.10		96.00	150	90	75	150	85	75
				Day 28	28/09/92	37.60		96.00	145	85	76	145	85	78
				Day 35	05/10/92	36.70		97.00	150	85	76	150	80	78
				Day 42	12/10/92	36.70		97.00	130	75	80	130	80	80
	148	Imipramine	Female	Screen	21/09/92	36.80	16		125	85	65	125	80	70
				Day 0	25/09/92	36.80		77.50	125	85	65	125	80	65
				Day 7	02/10/92	36.70		77.00	120	80	65	120	75	67
				Day 14	09/10/92	37.00		77.00	125	85	70	125	85	70
				Day 21	16/10/92	36.90		77.00	130	80	85	125	75	85
				Day 28	23/10/92	36.70		77.00	125	75	80	125	70	82
				Day 35	30/10/92	36.90		77.00	125	80	72	120	75	72

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
4/1	148	Imipramine	Female	Day 42	06/11/92	37.10		77.50	140	85	80	140	85	80
	149	Reboxetine	Male	Screen	22/09/92	36.70	14		135	80	68	135	80	70
				Day 0	29/09/92	37.10		74.00	140	80	70	140	80	74
				Day 7	06/10/92	36.90		73.50	140	80	72	135	75	74
				Day 14	13/10/92	36.70		74.00	135	80	70	135	75	70
				Day 21	20/10/92	36.70		73.50	140	85	62	135	85	61
				Day 28	27/10/92	36.90		74.50	140	80	76	140	80	78
				Day 35	03/11/92	36.70		74.00	135	75	80	135	75	80
				Day 42	10/11/92	37.10		74.00	145	90	70	140	85	72
	150	Placebo	Male	Screen	18/09/92	37.00	17		120	80	60	115	75	62
				Day 0	29/09/92	37.00		82.00	120	80	64	115	80	66
				Day 7	06/10/92	36.90		82.00	130	85	66	125	85	66
				Day 14	13/10/92	36.80		82.00	130	85	66	125	85	66
				Day 21	20/10/92	36.80		82.00	130	90	100	130	90	100
				Day 28	27/10/92	36.70		82.00	130	90	92	130	90	92
				Day 35	03/11/92	36.80		82.00	135	90	88	135	90	86
				Day 42	10/11/92	36.20		84.00	125	80	60	125	80	60
4/2	93/A	Placebo	Male	Screen	21/02/91	37.00	22		150	90	90	150	90	90
				Day 0	21/02/91	37.00		100.00	150	90	80	150	90	80
				Day 7	01/03/91	37.00		98.00	130	80	70	120	80	75
				Day 14	08/03/91	37.00		97.00	130	70	80	100	70	95
				Day 21	15/03/91	37.00		97.00	160	80	80	140	80	98
				Day 28	22/03/91	37.00		97.00	150	80	86	140	80	95
				Day 35	29/03/91	37.00		97.00	140	80	80	140	80	85
				Day 42	05/04/91	37.00		97.50	140	80	80	140	80	85
	99/A	Placebo	Male	Screen	26/03/91	37.00	20		120	70	82	120	70	80
				Day 0	26/03/91	37.00		83.00	120	70	82	120	70	92
				Day 7	02/04/91	37.00		83.00	120	70	88	120	70	95
				Day 14	09/04/91	37.00		83.00	120	60	82	120	60	98
				Day 21	16/04/91	37.00		83.00	120	70	75	120	70	82
				Day 28	23/04/91	37.00		85.00	130	80	80	130	70	86
				Day 35	30/04/91	37.00		83.50	120	70	82	120	70	88
	104	Reboxetine	Male	Screen	20/05/91	37.00	20		140	80	80	130	80	82
				Day 0	20/05/91	37.00		82.00	140	80	80	130	80	82
				Day 7	29/05/91	37.00		81.00	130	80	82	120	80	98
				Day 14	04/06/91	37.00		80.00	140	80	90	130	80	98
				Day 21	11/06/91	37.00		80.00	130	60	80	120	60	88
				Day 28	18/06/91	37.00		80.00	130	80	90	120	80	96
				Day 35	25/06/91	37.00		80.00	120	60	90	110	60	98

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
4/3	97	Placebo	Male	Screen	11/04/91	37.00	14		130	80	80	130	80	75
				Day 0	16/04/91	37.00		62.00	130	90	60	130	90	60
				Day 7	23/04/91	37.00		62.00	130	80	90	130	80	80
				Day 14	30/04/91	37.00		62.00	130	80	90	130	80	80
				Day 21	07/05/91	37.00		62.00	130	80	80	130	80	80
				Day 28	14/05/91	37.00		62.00	130	80	80	130	80	80
				Day 35	21/05/91	37.00		62.00	130	80	80	130	80	
				Day 42	28/05/91	37.00		62.00	130	80	80	130	80	
	98	Reboxetine	Female	Screen	19/06/91				140	80	80	140	80	90
				Day 0	19/06/91	37.00		53.00	130	80	90	120	80	80
				Day 7	26/06/91	37.00		53.00	130	80	90	130	80	80
				Day 14	03/07/91	37.20		52.50	140	90	80	135	90	80
				Day 21	10/07/91	37.10		53.00	140	90	80	130	90	80
				Day 28	17/07/91	37.00		53.00	140	90	80	130	90	80
				Day 35	24/07/91	37.20		53.00	140	90	90	140	90	100
	99	Placebo	Female	Screen	07/08/91	37.00			150	80	90	150	80	80
				Day 0	07/08/91	37.00		60.00	150	80	90	150	80	80
				Day 7	14/08/91	37.00		60.00	150	80	80	150	80	80
				Day 14	21/08/91	37.30		60.00	150	80	80	150	80	80
	100	Imipramine	Female	Screen	27/11/91	37.00	20		110	70	80	110	70	80
				Day 0	27/11/91	37.00		44.00	110	70	80	110	70	90
				Day 7	03/12/91	37.00		44.00	110	70	80	110	70	90
				Day 14	11/12/91	37.20		44.00	120	80	80	120	80	90
				Day 21	18/12/91	37.20		44.00	120	80	80	120	80	75
	101	Imipramine	Male	Screen	13/03/92	37.00			120	90	90	120	90	90
				Day 0	16/03/92	37.00		74.00	120	90	90	120	90	90
				Day 7	23/03/92	37.00		74.00	120	70	80	120	70	80
				Day 14	30/03/92	37.00		74.00	130	90	90	120	90	90
				Day 21	06/04/92	37.00		74.00	130	90	80	120	90	80
				Day 28	13/04/92	37.00		74.00	130	80		120	80	
				Day 35	21/04/92	37.00		74.00	130	90	80	120	90	80
				Day 42	27/04/92	37.00		74.00	130	90	80	130	90	80
4/4	109	Reboxetine	Female	Screen	03/06/91	37.30	22		120	70	84	120	60	80
				Day 0	08/06/91	37.20		59.00	115	75		110	70	
				Day 7	15/06/91	37.00		60.00	110	60	76	105	60	80
				Day 14	22/06/91	37.10		60.50	110	50	88	100	50	96
				Day 21	28/06/91	36.80		60.50	120	80	90	110	70	92

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
4/4	109	Reboxetine	Female	Day 28	06/07/91	36.90		61.00	120	80	92	130	90	92
				Day 35	12/07/91	36.80		61.00	120	80	84	110	70	92
				Day 42	08/08/91			61.00	110	70	80	105	75	88
	110	Imipramine	Male	Screen	11/06/91	36.80	20		150	90	80	150	100	84
				Day 0	15/06/91	37.00		66.50	130	90	84	120	80	88
				Day 7	22/06/91	35.60		67.00	120	70	88	110	70	84
				Day 14	29/06/91	36.70		68.00	120	80	88	110	60	96
				Day 21	06/07/91			71.00	120	70	76	115	70	92
				Day 28	13/07/91	37.10		71.00	120	70	84	115	60	92
				Day 35	20/07/91	36.90		71.50	110	70	80	110	80	88
				Day 42	26/07/91	36.20		73.00	145	90	96	150	90	94
	111	Imipramine	Male	Screen	27/06/91	36.80	27		120	80	78	120	70	86
				Day 0	03/07/91	37.00		66.00	120	50	84	120	70	80
				Day 7	10/07/91	37.30		66.00	120	70	92	120	70	96
				Day 14	17/07/91	37.00		67.00	115	60	72	120	70	80
				Day 21	24/07/91				115	76	88	120	80	80
				Day 28	31/07/91	37.50		66.00	120	60	88	90	50	68
				Day 35	07/08/91	36.70		66.00	115	60	68	130	70	68
				Day 42	14/08/91				110	60	90	100	60	88
	112	Placebo	Male	Screen	05/07/91	37.10	20		120	70	64	115	70	72
				Day 0	09/07/91	36.80		65.00	150	100	66	140	100	76
				Day 7	17/07/91	36.90		65.00	130	80	66	120	70	70
				Day 14	24/07/91	36.90		66.00	110	70	72	140	90	76
				Day 21	31/07/91	37.00		66.00	130	70	72	120	70	78
				Day 28	07/08/91			66.00	125	70	70	110	70	76
				Day 35	14/08/91			65.00	125	70	66	110	70	72
				Day 42	20/08/91	37.00		66.00	110	60	72	110	70	76
	113	Reboxetine	Male	Screen	26/08/91	36.90	18		125	70	64	130	80	76
				Day 0	30/08/91	36.90		96.00	125	70	64	130	80	76
				Day 7	07/09/91	37.00		95.00	120	60	76	120	70	80
				Day 14	14/09/91	37.10		96.00	150	90	78	170	100	96
				Day 21	23/09/91	37.00		94.00	120	70	68	120	80	72
				Day 28	27/09/91	37.10		94.00	130	90	84	120	90	84
				Day 35	05/10/91	37.00		94.00	140	90	80	120	90	84
				Day 42	11/10/91	36.50		94.00	120	60	84	110	80	80
	114	Placebo	Female	Screen	13/11/91	36.90	19		170	100	64	165	80	76
				Day 0	20/11/91	36.70		61.00	160	80	66	150	90	72
				Day 7	27/11/91			61.00	150	80	68	155	80	76
				Day 14	04/12/91			61.00	150	70	72	150	80	84

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
4/4	114	Placebo	Female	Day 21	11/12/91	36.70		61.00	160	80	60	135	80	64
				Day 28	18/12/91	37.00		61.50	150	90	62	150	85	66
				Day 35	24/12/91			61.00	160	85	70	150	80	76
				Day 42	31/12/91	36.70		61.00	190	100	72	180	90	60
	175	Imipramine	Female	Screen	05/02/92		19		120	80	80	115	70	82
				Day 0	13/02/92	37.00		59.00	130	80	84	120	80	80
				Day 7	20/02/92	36.90		61.00	110	80	88	110	80	94
				Day 14	27/02/92	37.00		61.00	120	90	76	120	80	96
				Day 21	05/03/92			60.00	120	90	72	110	80	90
				Day 28	12/03/92			60.00	110	75	72	105	75	90
				Day 35	19/03/92			61.00	130	80	82	110	75	92
				Day 42	25/03/92			62.00	100	70	76	100	70	70
	176	Placebo	Female	Screen	11/03/92	36.80	19		130	80	66	110	80	90
				Day 0	13/03/92	37.00		50.00	120	80	70	110	80	84
				Day 7	21/03/92			50.00	135	80	72	120	90	80
				Day 14	28/03/92			50.50	120	75	68	120	80	70
				Day 21	06/04/92	37.00		49.50	140	90	84	120	90	94
				Day 28	10/04/92				130	80				
	177	Imipramine	Female	Screen	22/04/92		23		150	100	70	140	90	78
				Day 0	28/04/92	36.80		59.00	160	80	70	140	85	80
				Day 7	04/05/92			59.00	160	90	82	130	80	90
				Day 14	11/05/92			58.00	170	90	80	150	80	92
				Day 21	20/05/92			59.00	165	80	82	150	70	98
	178	Reboxetine	Female	Screen	21/04/92	36.70	19		140	90	76	150	100	84
				Day 0	28/04/92	36.80		71.00	135	100	70	150	100	96
				Day 7	04/05/92	36.40		71.00	140	80	78	150	90	90
				Day 14	11/05/92			71.00	130	80	82	135	90	96
				Day 21	18/05/92	36.50		70.00	140	80	84	120	80	98
				Day 28	27/05/92			70.00	130	85	78	130	80	84
				Day 35	01/06/92	36.70		69.00	110	70	100	90	60	104
				Day 42	09/06/92	36.80		68.00	140	100	100	140	90	104
	179	Placebo	Female	Screen	07/09/92	36.80	23		110	70	80	110	80	80
				Day 0	10/09/92	36.80		64.50	110	60	72	110	70	74
				Day 7	17/09/92	36.50		64.00	120	80	72	130	70	76
				Day 14	24/09/92	36.70		64.00	110	60	72	100	60	68
				Day 21	29/09/92	36.80		63.00	100	50	78	110	70	88
	180	Reboxetine	Male	Screen	30/09/92	36.60	20		110	80	70	105	80	72

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
4/4	180	Reboxetine	Male	Day 0	06/10/92	36.40		69.00	100	70	60	110	80	90
				Day 7	13/10/92	36.80		69.00	100	70	60	100	80	84
				Day 14	20/10/92			69.00	120	70	72	110	70	80
				Day 21	27/10/92	36.70		67.50	105	50	64	100	50	72
				Day 28	03/11/92	36.80		67.50	90	60	64	95	60	72
				Day 35	10/11/92			67.50	110	70	70	110	80	76
				Day 42	17/11/92			68.00	120	80	76	130	90	88
5/1	127	Reboxetine	Male	Screen	03/06/91	37.00	20		120	80	80	120	75	80
				Day 0	05/06/91	37.20		84.00	120	75	90	120	80	80
				Day 7	13/06/91	37.00		82.00	120	80	80	120	90	80
				Day 14	20/06/91	36.80		83.00	130	80	92	125	80	96
				Day 21	27/06/91	37.00		84.00	120	70	84	120	65	90
				Day 28	04/07/91	36.80		84.00	140	80		130	75	
				Day 35	11/07/91	37.20		84.00	120	75	90	115	75	90
				Day 42	18/07/91	37.20		85.00	120	80	90	110	80	100
	128	Reboxetine	Female	Screen	10/06/91	37.00	22		125	80	80	120	75	90
				Day 0	13/06/91	37.20		54.00	110	75	80	115	80	90
				Day 7	21/06/91	37.20		54.00	120	70	100	100	65	120
				Day 14	28/06/91	37.10		55.00	100	70	80	95	65	80
				Day 21	05/07/91	36.80		54.60	120	80	84	110	75	90
				Day 28	12/07/91	37.00		55.00	115	75	84	100	75	90
				Day 35	19/07/91	37.00		54.50	115	80	90	110	85	100
				Day 42	26/07/91	37.30		53.50	115	70	90	110	70	90
	129	Placebo	Male	Screen	23/12/91	37.00	14		120	70	72	100	60	72
				Day 0	23/12/91	37.00		55.00	120	70	72	100	60	72
				Day 7	30/12/91	37.00		55.00	120	70	80	120	70	
				Day 14	06/01/92	37.00		54.00	120	70	84	120	70	80
				Day 21	13/01/92	37.00		56.00	120	70	70	120	70	70
				Day 28	20/01/92	37.00		56.00	130	80	80	130	70	80
				Day 35	27/01/92	37.00		56.00	120	70	72	120	70	68
				Day 42	03/02/92	37.00		55.00	120	70	72	120	70	72
	130	Placebo	Male	Screen	04/03/92	37.00	18		100	60	70	100	60	78
				Day 0	04/03/92	37.00		58.00	100	60	78	100	60	78
				Day 7	11/03/92	37.00		58.00	120	70	72	110	70	70
				Day 14	18/03/92	37.00		58.00	130	80	70	120	60	70
				Day 21	25/03/92	37.00		58.00	120	70	78	110	70	78
				Day 28	01/04/92	37.00		59.00	110	70	76	110	70	72
				Day 35	08/04/92	37.00		59.00	110	60	80	100	60	80
				Day 42	15/04/92	37.00		59.00	120	70	80	120	60	80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
5/1	131	Imipramine	Female	Screen	20/03/92	37.00	14		110	60	66	100	60	64
				Day 0	20/03/92	37.00		81.00	110	60	70	100	60	66
				Day 7	27/03/92	37.00		81.00	120	70		100	70	
				Day 14	03/04/92	37.00		76.00	140	90	80	110	70	80
				Day 21	10/04/92	37.00		80.00	120	70	80	110	70	80
				Day 28	17/04/92	37.00		79.00	115	70	72	110	70	72
				Day 35	24/04/92	37.00		77.00	120	70	112	120	80	
				Day 42	30/04/92	37.00		77.00	130	70		130	80	
	132	Imipramine	Male	Screen	23/06/92	37.00	16		140	80	80	140	80	80
				Day 0	25/06/92	36.80		83.00	160	100	80	150	90	84
				Day 7	02/07/92	36.70		83.00	140	90	78	140	90	84
				Day 14	09/07/92	37.00		84.00	140	80	80	80	80	84
				Day 21	16/07/92	37.00		83.00	140	80	64	140	80	72
				Day 28	23/07/92	37.00		83.00	150	90	80	140	80	88
				Day 42	10/08/92	37.00		83.00	120	80	78	120	70	82
5/2	121	Imipramine	Female	Screen	13/12/91	36.80	20		110	65	72	105	60	78
				Day 0	20/12/91	36.80		45.00	110	60	76	105	60	78
				Day 7	27/12/91	36.80		44.00	110	80	72	140	90	80
				Day 14	03/01/92	36.80		42.50	120	80	56	110	60	84
				Day 21	10/01/92	36.70		42.00	110	70	66	105	60	78
				Day 28	19/01/92	36.80		42.00	120	60	88	130	65	92
				Day 35	24/01/92	36.90		42.00	140	65	84	130	70	92
				Day 42	27/01/92	37.20		40.00	130	60	88	130	70	96
	125	Reboxetine	Male	Screen	22/01/91	36.50	14		135	80	60	135	90	70
				Day 0	28/01/91	37.00		72.00	135	70	68	120	70	73
				Day 7	04/02/91	37.40		72.00	130	60	76	120	70	108
				Day 14	11/02/91	37.20		72.00	110	70	92	110	70	120
				Day 21	18/02/91	37.00		72.00	140	80		120	70	
				Day 28	25/02/91	37.00		75.00	140	90	84	150	90	90
				Day 35	04/03/91	36.50		74.00	120	80	72	115	75	80
				Day 42	11/03/91	36.80		74.50	150	100	80	110	70	88
5/3	133	Placebo	Male	Screen	25/11/91				120	70	76	140	80	80
				Day 0	29/11/91			69.00	120	70	76	140	80	80
				Day 7	06/12/91			69.00	130	60	68	125	55	68
				Day 14	13/12/91			70.00	135	80	88	130	80	86
	134	Reboxetine	Female	Screen	02/12/91	37.00			110	60	68	110	55	72
				Day 0	06/12/91	36.90		47.00	115	65	74	110	65	79
				Day 7	13/12/91			48.00	110	70	84	110	60	88
				Day 14	20/12/91			50.00	110	60	76	110	60	80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
5/3	134	Reboxetine	Female	Day 21	27/12/91			47.00	110	55	72	105	55	76
				Day 42	16/01/92			49.00	110	60	84	100	50	78
	135	Imipramine	Female	Screen	06/01/92	37.50	22		150	80	82	150	80	86
				Day 0	10/01/92	37.50		76.00	150	80	82	150	80	88
				Day 7	16/01/92	37.50		74.00	150	80	80	150	80	80
				Day 14	23/01/92			74.00	125	65	68	125	60	66
				Day 28	06/02/92			77.00	140	90	84	130	80	80
				Day 35	13/02/92			78.00	150	90	88	140	80	82
				Day 42	20/02/92			79.00	150	90	86	130	80	80
	136	Imipramine	Female	Screen	21/02/92	37.30			115	60		125	60	
				Day 0	02/03/92			74.00	115	60	66	110	60	72
				Day 7	09/03/92			73.00	110	60	72	115	60	72
				Day 14	16/03/92			74.00	110	70	80	110	70	80
				Day 28	30/03/92			75.00	110	60	82	100	50	78
				Day 35	06/04/92			75.00	110	60	82	100	50	78
				Day 42	13/04/92			75.00	115	60	88	100	50	82
	137	Reboxetine	Female	Screen	11/05/92				110	60	76	110	60	78
				Day 0	14/05/92			44.00	110	60	76	110	60	79
				Day 7	21/05/92			43.00	110	70	60	100	65	60
				Day 14	29/05/92			43.00	120	60	64	110	50	64
				Day 21	05/06/92			44.00	120	70	64	110	75	75
				Day 28	11/06/92			43.00	105	70		100	70	
				Day 35	18/06/92			44.00	110	70	80	100	70	84
				Day 42	25/06/92			44.50	110	60	64	95	50	64
	138	Placebo	Female	Screen	14/05/92				110	60	68	110	60	72
				Day 0	15/05/92			61.00	110	60	68	110	60	72
6/1	151	Imipramine	Male	Screen	13/01/92	37.00	13		140	90	80	140	90	84
				Day 0	21/01/92	37.00		55.00	140	80	88	140	80	92
				Day 7	28/01/92	37.00		55.00	120	90	100	85	65	64
	152	Reboxetine	Female	Screen	17/02/92	37.00	16		140	90	76	120	80	80
				Day 0	24/02/92	37.00		67.40	130	80	74	130	80	74
				Day 7	02/03/92	37.00		67.30	160	100	72	165	100	88
				Day 14	09/03/92	37.00		67.00	150	100	78	140	95	82
				Day 21	16/03/92	37.00		66.00	150	95	80	140	90	80
				Day 28	22/03/92	37.00		65.00	150	90	76	140	90	80
				Day 35	31/03/92	37.50		66.00	150	95	76	150	90	84
				Day 42	07/04/92	37.00		67.00	145	85	66	140	90	66

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
6/1	153	Reboxetine	Male	Screen	04/03/91	37.20	12		120	90	72	125	100	75
				Day 0	18/03/91	37.00		75.00	120	90	72	125	100	75
				Day 7	25/03/91	37.00		75.00	135	90	80	135	100	80
				Day 14	02/04/91			75.00	140	90	80	140	90	80
				Day 21	08/04/91			76.00	135	90	70	140	100	70
				Day 28	15/04/91			76.00	130	90	70	135	95	75
				Day 35	22/04/91			76.00	140	90	70	140	90	70
				Day 42	29/04/91			76.00	135	85	60	140	90	65
	154	Imipramine	Female	Screen	25/03/92	37.00	17		130	80	80	125	80	80
				Day 0	30/03/92	37.00		57.00	130	80	80	130	80	80
	155	Placebo	Male	Screen	01/07/92	37.00	14		130	80	100	130	85	100
				Day 0	07/07/92	37.00		76.00	155	90	100	130	90	100
				Day 7	15/07/92	37.00		75.00	150	90	85	140	90	90
				Day 14	21/07/92	37.00		76.00	140	80	92	130	80	96
				Day 21	28/07/92	37.00		76.00	140	80	92	140	80	94
				Day 28	04/08/92	37.00		76.00	145	80	96	135	80	96
	156	Placebo	Female	Screen	01/09/92	37.40	20		140	80	70	130	70	72
				Day 0	08/09/92	37.40		72.00	130	70	74	130	70	72
				Day 7	15/09/92	37.20		72.00	135	70	74	130	75	72
				Day 14	22/09/92	37.40		71.00	130	70	72	125	70	76
				Day 21	29/09/92	37.30		71.00	120	70	70	120	70	76
				Day 28	06/10/92	37.20		71.00	130	70	72	120	70	74
				Day 35	13/10/92	37.20		70.00	130	70	72	120	75	74
				Day 42	20/10/92	37.40		70.00	110	70	66	110	70	62
6/2	157	Reboxetine	Male	Screen	22/04/91	37.00	15		140	75	80	140	80	80
				Day 0	29/04/91	37.00		62.00	125	70	84	120	70	86
				Day 7	06/05/91	37.20		61.00	125	70	78	125	75	80
				Day 14	13/05/91	37.20		60.00	130	75	80	130	75	80
				Day 21	21/05/91	37.30		60.00	125	70	76	125	70	80
				Day 28	27/05/91	37.30		60.00	130	80		130	80	
				Day 35	03/06/91	37.00		61.00	130	70	72	135	75	76
				Day 42	10/06/91	37.00		63.00	140	80	76	150	80	80
	158	Imipramine	Female	Screen	20/11/91	37.30	16		110	70	80	120	65	76
				Day 0	23/11/91	37.00		52.00	120	70	80	130	70	80
				Day 7	30/11/91	37.00		52.00	110	70	74	100	70	76
				Day 14	07/12/91	37.20		53.00	120	70	76	110	70	80
				Day 21	14/12/91	37.00		53.00	120	70	92	110	70	92

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
6/2	158	Imipramine	Female	Day 28	21/12/91	37.00		52.00	120	70	80	125	70	80
				Day 42	06/01/92	37.00		52.00	120	60	80	110	60	84
	159	Imipramine	Male	Screen	08/07/91	37.10	20		150	90	92	140	84	88
				Day 0	13/07/91	37.10		89.00	150	90	96	140	90	88
				Day 7	20/07/91	38.00		86.40	150	90	100	150	90	100
				Day 14	27/07/91	36.90		85.20	150	90	84	150	90	80
				Day 21	03/08/91	36.90		85.00	160	100	96	140	80	104
				Day 28	10/08/91	37.00		85.00	140	110	100	160	120	100
				Day 35	17/08/91	37.00		85.00	140	100	92	130	90	96
				Day 42	24/08/91	36.70		84.80	130	100	92	130	90	92
	160	Placebo	Male	Screen	22/11/91	37.50	12		120	80	75	120	80	82
				Day 0	23/11/91	37.50		89.00	120	80	73	120	80	82
				Day 7	30/11/91	37.40		91.00	105	60	70	105	60	72
				Day 14	07/12/91	37.00		90.00	110	60	70	110	60	78
				Day 21	14/12/91	39.20		88.40	130	80	70	125	70	70
				Day 28	21/12/91	36.90		88.00	120	70	70	120	70	70
				Day 35	28/12/91	36.90		87.00	130	80	68	120	80	72
				Day 42	04/01/92	37.00		87.00	110	80	60	115	85	64
	161	Reboxetine	Female	Screen	10/02/92	37.00			120	70	80	125	70	80
				Day 0	19/02/92	37.20		56.00	130	70	84	130	70	80
				Day 7	26/02/92	37.00		57.00	130	75	80	125	75	82
				Day 14	04/03/92	37.00		57.00	130	70	80	130	70	80
				Day 21	11/03/92	37.00		56.00	120	70	80	120	70	80
				Day 28	19/03/92	37.00		58.00	120	70	82	120	70	82
	162	Placebo	Male	Screen	08/07/91	37.00	22		130	80	92	130	80	88
				Day 0	10/07/91	37.00		70.00	135	90	88	130	80	88
				Day 7	13/07/91	37.00		70.00	130	80	86	130	80	86
	169	Imipramine	Female	Screen	09/12/91	37.00	20		120	80	88	120	80	90
				Day 0	26/12/91	37.00		52.00	120	80	88	120	80	88
				Day 7	02/01/92	37.00		52.00	120	80	85	120	80	85
				Day 14	09/01/92	37.00		52.00	120	80	90	120	80	90
				Day 21	15/01/92				120	86	90	120	86	90
	170	Placebo	Male	Screen	17/10/91	37.00	24		140	90	88	140	80	90
				Day 0	01/11/91	37.00		88.00	140	90	85	140	80	88
				Day 7	08/11/91	37.00		88.00	140	90	83	130	80	90

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
6/2	171	Imipramine	Female	Screen	27/06/92	37.00	26		100	60	80	100	60	85
				Day 0	21/07/92	37.00		52.00	100	60	80	100	60	85
				Day 7	28/07/92	37.00		52.00	100	60	80	100	60	87
				Day 14	04/08/92	37.00		52.00	100	60	75	100	50	80
				Day 21	11/08/92	37.00		52.00	130	60	90	110	60	90
				Day 28	18/08/92	37.00		53.00	110	60	90	130	60	90
				Day 35	25/08/92	37.00		53.00	110	60	90	130	60	88
				Day 42	01/09/92	37.00		53.00	140	80	90	140	80	90
	172	Reboxetine	Female	Screen	07/07/92	37.00	25		145	80	70	100	50	83
				Day 0	07/07/92	37.00		52.00	145	80	70	100	50	80
				Day 7	13/07/92	37.00		52.00	140	80	71	105	50	82
				Day 14	20/07/92	37.00		51.50	140	80	77	90	50	90
				Day 21	27/07/92	37.00		51.00	140	90	75	100	50	90
				Day 28	03/08/92	37.00		51.00	140	90	75	100	50	88
				Day 35	11/08/92	37.00		51.00	130	70	70	80	60	80
				Day 42	18/08/92	37.00		51.00	130	70	76	80	60	80
	173	Placebo	Male	Screen	26/06/92	37.00	19		100	70	62	100	70	70
				Day 0	04/07/92	37.00		75.00	100	70	60	100	70	60
				Day 7	11/07/92	37.00		75.00	100	70	63	100	70	65
				Day 14	18/07/92	37.00		75.00	110	70	64	110	70	67
				Day 21	25/07/92	37.00		75.00	120	70	60	120	70	67
				Day 28	01/08/92	37.00		75.00	120	70	62	105	70	70
				Day 35	08/08/92	37.00		75.50	120	70	63	100	70	71
				Day 42	17/08/92	37.00		75.50	100	80	60	110	80	60
	174	Reboxetine	Male	Screen	04/05/92	37.00	20		140	90	70	140	90	75
				Day 0	11/05/92	37.00		77.00	140	90	75	140	90	80
				Day 7	18/05/92	37.00		77.00	140	80	80	140	80	80
				Day 14	25/05/92	37.00		77.00	140	90	85	140	90	84
				Day 21	01/06/92	37.00		77.00	150	90	80	130	90	88
				Day 28	09/06/92	37.00		77.00	150	90	85	140	80	88
				Day 35	15/06/92	37.00		77.00	150	90	86	140	80	90
				Day 42	22/06/92	37.00		77.00	150	80	80	140	80	85
6/3	163	Reboxetine	Male	Screen	29/05/91				120	80	80	120	80	80
				Day 0	05/06/91			63.00	130	70	60	110	70	
				Day 7	12/06/91			63.00	130	70	70	110	70	
	164	Imipramine	Male	Screen	04/10/91				130	70	70	130	60	70
				Day 0	11/10/91			74.00	130	70	60	130	70	60
				Day 7	18/10/91			74.00	130	80	60	120	70	60
				Day 14	25/10/91			74.00	130	80	70	120	80	70

2031

9550082

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
6/3	164	Imipramine	Male	Day 21	31/10/91			74.00	130	80	65	120	70	65
				Day 28	08/11/91			74.00	120	80	60	120	80	60
				Day 35	15/11/91			74.00	130	80	60	120	70	70
				Day 42	22/11/91			74.00	130	80	55	115	80	55
	165	Imipramine	Female	Screen	08/10/91				120	70	80	130	70	90
				Day 0	15/10/91			49.00	150	90	60	130	90	70
				Day 7	22/10/91			49.00	150	90	60	140	90	70
				Day 14	29/10/91			49.00	140	90	70	130	80	70
				Day 21	05/11/91			49.00	160	100	100	130	90	100
				Day 28	12/11/91			49.00	140	90	80	130	90	80
				Day 35	19/11/91			49.00	130	80	70	120	80	70
				Day 42	26/11/91			49.00	160	100	110	120	80	110
	166	Reboxetine	Female	Screen	16/10/91				110	70	60	110	70	60
				Day 0	25/10/91			60.00	110	70	60	120	80	60
				Day 7	30/10/91			60.00	110	70	80	120	80	80
	167	Placebo	Female	Screen	13/11/91				120	70	60	130	80	60
				Day 0	18/11/91			55.00	120	70	60	130	80	60
				Day 7	25/11/91			55.00	120	70	60	130	70	60
				Day 14	02/12/91			55.00	120	70	60	120	70	60
				Day 21	09/12/91			55.00	110	60	60	110	60	60
				Day 28	16/12/91			55.00	110	60	60	110	60	60
				Day 35	23/12/91			55.00	110	60	60	110	60	60
				Day 42	27/12/91			55.00	110	60	60	105	70	60
	168	Placebo	Female	Screen	25/11/91				130	80	90	115	70	90
				Day 0	02/12/91			80.00	130	80	90	115	70	90
				Day 7	09/12/91			80.00	130	80	80	120	70	80
				Day 14	16/12/91			80.00	120	80	80	120	80	80
				Day 21	23/12/91			80.00	140	90	80	130	80	80
				Day 28	30/12/91			80.00	140	90	80	130	80	80
				Day 35	06/01/92			80.00	140	90	90	130	80	80
	505	Imipramine	Female	Screen	26/11/91				120	80	60	120	80	60
				Day 0	03/12/91			56.00	120	80	60	120	80	60
				Day 7	10/12/91			56.00	120	80	60	120	80	60
				Day 14	17/12/91			56.00	130	80	70	120	80	70
	506	Placebo	Female	Screen	02/01/92				130	80	70	120	80	70
				Day 0	08/01/92			89.00	130	70	80	120	70	80
				Day 7	15/01/92			89.00	130	70	80	120	70	80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
6/3	506	Placebo	Female	Day 14	22/01/92			89.00	130	70	80	120	70	80
				Day 21	29/01/92			89.00	130	80	70	130	90	70
				Day 28	05/02/92			91.00	130	80		130	80	
				Day 35	12/02/92			90.00	130	80		130	80	
				Day 42	19/02/92			90.00	130	80	65	130	80	65
	507	Imipramine	Female	Screen	06/01/92				120	80	75	120	80	75
				Day 0	13/01/92			58.00	120	80	70	120	80	70
				Day 7	21/01/92			58.00	120	80	70	120	80	70
				Day 14	27/01/92			58.00	120	80	80	105	80	80
				Day 21	04/02/92			58.00	120	80	80	100	70	80
				Day 28	10/02/92			59.00	110	80	80	105	80	80
				Day 35	17/02/92			59.00	115	80	80	105	80	80
				Day 42	24/02/92			59.00	115	80	80	105	80	80
	508	Reboxetine	Female	Screen	28/01/92	37.00			120	70	80	100	60	80
				Day 0	04/02/92			60.00	120	70	80	100	60	80
				Day 7	11/02/92			60.00	120	70	80	110	60	80
				Day 14	18/02/92			60.00	120	70	80	110	60	80
				Day 21	25/02/92			60.00	130	70	100	120	80	100
				Day 28	04/03/92			60.00	130	70	80	120	80	80
				Day 35	10/03/92			60.00	120	70	100	110	70	100
				Day 42	17/03/92			60.00	120	70	100	100	70	
	509	Placebo	Male	Screen	17/02/92	37.00			110	80	58			
				Day 0	24/02/92			52.00	120	80	80	110	70	80
				Day 7	02/03/92			52.00	120	80	80	110	70	80
				Day 14	09/03/92			52.00	120	70	70	110	70	70
				Day 21	16/03/92			52.00	120	80	70	110	80	70
				Day 28	23/03/92			53.00	120	80	70	110	70	70
				Day 35	30/03/92			53.00	110	70	70	110	70	70
				Day 42	06/04/92			53.00	110	70	64	110	70	
	510	Reboxetine	Female	Screen	14/02/92	37.00			120	70	70	120	70	70
				Day 0	26/02/92			55.00	120	70	70	120	70	70
				Day 7	04/03/92			55.00	110	80	70	100	70	70
				Day 14	11/03/92			55.00	110	80	80	100	80	80
	511	Imipramine	Female	Screen	18/03/92				130	80	82	130	80	80
				Day 0	18/03/92			68.00	130	80	80	130	80	80
				Day 7	25/03/92			68.00	120	70	80	110	70	80
				Day 14	31/03/92			68.00	120	70	70	120	70	70
				Day 21	07/04/92			68.00	150	90	110	150	90	110
				Day 28	13/04/92			68.00	120	70	80	120	70	80

2033

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
6/3	511	Imipramine	Female	Day 35	22/04/92			68.00	120	70	80	120	70	80
	512	Placebo	Female	Screen	24/03/92	36.50			130	80	70	130	80	70
				Day 0	31/03/92			45.00	130	80	70	130	80	70
				Day 7	07/04/92			45.00	130	80	80	130	80	80
	513	Imipramine	Female	Screen	04/05/92	37.00			130	90	90	130	90	90
				Day 0	12/05/92			55.00	130	90	90	130	90	90
				Day 7	19/05/92			55.00	130	80	80	130	80	80
				Day 14	27/05/92			55.00	140	70	70	120	70	70
				Day 21	02/06/92			55.00	130	80	108	130	80	108
				Day 28	09/06/92			55.00	130	80	100	130	80	100
				Day 35	16/06/92			55.00	120	70	80	110	70	80
				Day 42	23/06/92			55.00	130	80	100	130	80	100
7/02	181	Reboxetine	Male	Screen	17/01/92	36.60	18		130	80	60	140	80	64
				Day 0	27/01/92	36.60		85.00	120	80	60	130	80	68
				Day 7	03/02/92	36.60		85.00	120	80	64	130	75	72
				Day 14	10/02/92	36.70		85.00	120	80	60	130	80	72
				Day 21	17/02/92	36.60		85.00	120	80	60	130	80	72
				Day 28	24/02/92	36.70		85.00	125	80	64	130	80	72
				Day 35	02/03/92	36.60		85.00	120	80	64	130	80	76
				Day 42	09/03/92	36.70		86.00	125	85	60	130	80	68
	182	Placebo	Male	Screen	22/11/91	36.90	18		145	100	76	150	100	84
				Day 0	22/11/91	36.90		64.00	145	100	76	150	100	84
				Day 7	29/11/91	36.80		62.00	150	100	84	160	110	88
				Day 14	06/12/91	36.90		63.00	140	90	80	155	115	88
				Day 21	13/12/91	36.50		66.50	180	110	76	185	120	80
				Day 28	20/12/91	36.60		66.00	160	105	75	165	115	78
				Day 35	27/12/91	36.40		66.50	160	100	80	170	105	84
				Day 42	03/01/92	36.90		66.00	155	100	78	165	105	84
	183	Imipramine	Male	Screen	30/12/91	36.60	18		140	95	60	140	105	66
				Day 0	31/12/91	36.60		93.00	140	95	60	140	105	66
				Day 7	08/01/92	36.90		93.00	130	90	80	140	95	84
				Day 14	15/01/92	36.80		92.00	140	95	66	160	100	74
				Day 21	22/01/92	36.90		92.00	145	100	72	165	105	80
	184	Imipramine	Female	Screen	17/01/92	36.70	16		120	80	72	125	80	76
				Day 0	27/01/92	36.80		60.00	115	80	68	125	80	76
				Day 7	03/02/92	36.80		60.00	120	80	68	130	80	76
				Day 14	10/02/92	36.90		60.00	120	80	72	130	85	80

2034

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
7/02	184	Imipramine	Female	Day 21	17/02/92	36.80		60.00	110	70	64	125	80	80
				Day 28	24/02/92	36.80		61.00	110	75	68	120	80	76
				Day 35	02/03/92	36.80		61.00	115	80	68	130	80	76
				Day 42	09/03/92	36.80		60.00	115	80	68	125	80	80
	185	Reboxetine	Male	Screen	09/04/92	36.20	17		155	110	80	160	105	96
				Day 0	09/04/92	36.20		73.10	155	110	80	160	105	96
				Day 7	16/04/92	36.20		72.80	140	100	80	150	105	92
				Day 14	23/04/92	36.00		73.50	130	80	75	150	95	87
				Day 21	30/04/92	37.10		73.00	135	85	86	150	100	92
				Day 28	07/05/92	36.90		73.00	150	110	85	155	110	92
	186	Placebo	Male	Screen	15/04/92	36.70	15		150	95	66	160	110	80
				Day 0	15/04/92	36.70		67.00	150	95	58	160	110	64
				Day 7	22/04/92	36.80		66.40	120	90	72	160	105	80
				Day 14	29/04/92	36.60		66.80	120	95	70	160	110	82
				Day 21	06/05/92	36.50		66.60	120	90	60	150	100	78
				Day 28	13/05/92	36.60		66.80	110	70	80	130	95	84
				Day 35	20/05/92	36.80		67.00	120	75	78	145	100	84
				Day 42	27/05/92	36.00		66.50	130	80	80	150	100	86
	535	Placebo	Male	Screen	15/04/92	37.50	20		105	65	56	110	70	60
				Day 0	15/04/92	37.50		85.00	105	65	56	110	70	60
				Day 7	22/04/92	36.90		85.00	105	65	60	110	70	68
				Day 14	29/04/92	36.80		86.00	110	70	56	110	65	60
				Day 21	06/05/92	36.80		86.00	130	80	60	140	80	68
				Day 28	13/05/92	36.70		86.50	120	80	56	125	80	64
				Day 35	20/05/92	36.90		86.00	120	80	60	130	80	68
				Day 42	27/05/92	36.80		86.00	110	80	56	130	80	68
	536	Reboxetine	Female	Screen	08/05/92	36.80	20		135	85	64	135	85	72
				Day 0	08/05/92	36.80		80.00	135	85	64	135	85	72
				Day 7	15/05/92	36.80		80.00	120	80	60	140	85	68
				Day 14	22/05/92	36.80		81.00	120	80	68	135	80	76
				Day 21	29/05/92	36.80		81.00	120	80	68	130	80	72
				Day 28	05/06/92	36.70		82.00	120	80	64	130	80	72
				Day 35	12/06/92	36.80		82.00	120	80	64	135	75	80
				Day 42	19/06/92	37.80		83.00	120	80	64	130	80	68
7/03	187	Imipramine	Female	Screen	11/02/92	36.30	16		140	80	76	150	80	80
				Day 0	18/02/92	36.30		77.00	140	80	80	150	80	76
				Day 7	25/02/92	36.20		75.00	140	80	74	140	90	72
				Day 14	03/03/92	36.10		76.00	110	75	70	110	80	70
				Day 21	10/03/92	36.30		76.00	120	70	70	120	70	72

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
7/03	187	Imipramine	Female	Day 28	17/03/92	36.40		77.00	140	80	70	145	80	74
				Day 35	24/03/92	36.40		75.00	135	85	78	140	90	80
				Day 42	31/03/92	36.30		77.00	150	90	78	150	95	80
	188	Placebo	Male	Screen	18/02/92	36.70	14		110	80	70	115	70	70
				Day 0	25/02/92	37.00		70.00	110	70	74	110	70	76
				Day 7	03/03/92	36.60		71.00	125	80	78	135	80	80
				Day 14	10/03/92	36.60		69.50	125	80	72	130	80	76
				Day 21	17/03/92	36.70		69.50	130	80	76	130	80	78
				Day 28	24/03/92	36.60		70.00	125	80	76	130	80	78
				Day 35	31/03/92	36.50		70.00	135	70	76	140	70	78
				Day 42	07/04/92	36.30		69.00	115	70	76	120	70	78
	189	Placebo	Male	Screen	18/02/92	36.00	15		125	80	70	130	80	72
				Day 0	25/02/92	36.10		86.00	105	65	72	110	70	74
				Day 7	03/03/92	36.30		86.00	105	65	74	110	70	76
				Day 14	10/03/92	36.80		86.00	120	80	74	120	86	76
				Day 21	17/03/92	36.50		88.00	120	80	72	130	80	78
				Day 28	24/03/92	36.40		89.00	135	80	78	140	80	80
				Day 35	31/03/92	36.50		89.00	120	80	78	120	80	80
				Day 42	07/04/92	36.50		88.00	120	80	78	125	80	80
	190	Reboxetine	Male	Screen	21/02/92	36.40	15		110	80	71	110	80	70
				Day 0	28/02/92	36.70		80.00	130	80	71	130	80	72
				Day 7	06/03/92	36.40		80.00	120	80	71	130	80	71
				Day 14	13/03/92	36.50		80.00	120	80	78	120	80	80
				Day 21	20/03/92	36.60		80.00	120	80	71	120	80	73
				Day 28	27/03/92	36.60		80.00	120	80	70	120	80	72
				Day 35	03/04/92	36.40		79.00	120	80	70	120	80	72
				Day 42	10/04/92	36.50		78.00	120	80	72	120	80	74
	191	Imipramine	Female	Screen	25/02/92	37.00	16		130	90	84	125	85	88
				Day 0	03/03/92	36.40		84.00	135	85	74	140	90	78
				Day 7	10/03/92	36.70		84.00	135	85	80	140	90	86
				Day 14	17/03/92	36.50		85.00	140	80	76	140	85	78
				Day 21	24/03/92	36.90		83.00	135	80	78	140	80	80
				Day 28	31/03/92	36.70		82.00	130	80	72	140	70	71
				Day 35	07/04/92	36.60		82.00	130	85	72	130	90	74
	192	Reboxetine	Female	Screen	03/03/92	36.90	16		140	80	80	135	75	84
				Day 0	10/03/92	36.60		82.00	120	80	71	120	80	73
				Day 7	17/03/92	36.30		82.00	120	80	70	125	80	72
				Day 14	24/03/92	36.30		80.00	120	80	72	120	80	74
				Day 21	31/03/92	36.40		81.00	135	80	72	140	80	74

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
7/03	192	Reboxetine	Female	Day 28	07/04/92	36.40		80.00	130	80	74	130	80	74
				Day 35	14/04/92	36.50		80.00	140	100	80	140	100	82
				Day 42	21/04/92	36.50		80.00	130	80	80	130	80	82
	523	Reboxetine	Female	Screen	28/04/92	36.90	16		105	70	78	100	70	78
				Day 0	05/05/92	36.40		52.00	100	70	76	100	70	74
				Day 7	12/05/92	36.40		52.00	110	70	75	110	70	73
				Day 14	19/05/92	36.50		52.00	110	70	75	110	70	78
				Day 21	26/05/92	36.80		52.00	110	70	60	115	70	64
				Day 28	02/06/92	36.50		53.00	110	70	64	120	70	68
				Day 35	09/06/92	36.50		55.00	110	80	64	120	80	68
				Day 42	16/06/92	36.40		55.00	105	70	64	110	70	68
	524	Placebo	Female	Screen	28/04/92	36.70	15		110	80	66	115	75	70
				Day 0	05/05/92	36.80		52.00	110	80	66	115	75	70
				Day 7	12/05/92	36.60		52.00	110	80	68	115	75	76
				Day 14	19/05/92	36.50		52.00	110	70	68	105	70	70
				Day 21	26/05/92	36.40		50.00	105	70	72	110	70	75
				Day 28	02/06/92	36.80		50.00	105	70	72	110	70	73
				Day 35	09/06/92	36.40		50.00	105	70	70	110	70	74
				Day 42	16/06/92	36.60		50.00	105	65	72	110	70	74
	525	Placebo	Female	Screen	28/04/92	36.80	15		110	70	78	110	70	80
				Day 0	05/05/92	36.60		91.00	110	70	78	110	70	80
				Day 7	12/05/92	36.60		91.00	110	70	76	110	70	78
				Day 14	19/05/92	36.60		91.00	110	70	76	110	70	78
				Day 21	26/05/92	36.50		91.00	120	80	76	125	80	78
				Day 28	02/06/92	36.80			120	80	72	120	85	76
				Day 35	09/06/92	36.70		91.00	120	70	76	115	80	78
				Day 42	16/06/92	36.40		90.00	110	70	76	115	80	78
	526	Reboxetine	Female	Screen	28/04/92	36.20	16		130	90	76	130	90	78
				Day 0	05/05/92	36.70		97.00	130	90	76	130	90	78
				Day 7	12/05/92	36.60		96.00	130	80	76	130	80	78
				Day 14	19/05/92	36.60		96.00	130	80	76	130	80	78
				Day 21	26/05/92	36.60		95.00	110	80	74	120	80	78
				Day 28	02/06/92	36.60		97.00	130	80	75	130	80	77
				Day 35	09/06/92	36.40		95.00	130	100	73	140	100	76
				Day 42	16/06/92	36.40		95.00	130	100	75	135	100	78
	527	Imipramine	Female	Screen	12/05/92	36.50	16		120	80	75	120	80	77
				Day 0	19/05/92	36.50		60.00	120	80	75	120	80	77
				Day 7	26/05/92	36.50		59.00	115	80	75	120	80	78
				Day 14	02/06/92	36.50		59.00	110	70	75	120	70	78

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
7/03	527	Imipramine	Female	Day 21	09/06/92	36.70		58.00	110	70	72	120	80	74
				Day 28	16/06/92	36.50		60.00	100	60	76	110	70	78
				Day 35	23/06/92	36.50		60.00	110	70	74	120	80	77
				Day 42	30/06/92	36.50		60.00	110	70	73	120	80	76
	528	Imipramine	Female	Screen	12/05/92	36.50	16		180	86	76	120	80	78
				Day 0	19/05/92	36.50		64.00	120	80	76	120	80	78
				Day 7	26/05/92	36.50		64.00	100	70	74	110	70	76
				Day 14	02/06/92	36.50		55.80	110	70	68	115	70	70
				Day 21	09/06/92	36.50		55.00	110	70	68	115	70	70
				Day 28	16/06/92	36.40		55.00	110	70	68	115	70	70
				Day 35	23/06/92	36.80		55.00	110	70	72	110	75	76
7/04	193	Placebo	Female	Screen	25/01/92	36.70	21		120	88	64	115	85	72
				Day 0	25/01/92	36.70		61.00	120	82	64	115	85	72
				Day 7	01/02/92	36.60		61.00	130	80	64	130	85	72
				Day 14	08/02/92	36.80		60.00	130	70	82	135	70	80
				Day 21	15/02/92	36.80		61.00	130	80	72	125	80	80
				Day 28	22/02/92	36.50		60.50	140	70	64	135	80	72
				Day 35	29/02/92	36.30		60.70	130	80	80	120	75	78
				Day 42	07/03/92	36.50		61.00	130	70	64	140	80	72
	194	Reboxetine	Male	Screen	25/01/92	36.60	19		120	80	72	120	90	75
				Day 0	25/01/92	36.60		78.00	120	80	72	120	90	75
				Day 7	01/02/92	36.80		78.00	140	70	64	135	75	72
				Day 14	08/02/92	36.90		78.00	130	80	72	130	80	80
				Day 21	15/02/92	36.80		77.50	130	70	68	125	75	80
				Day 28	22/02/92	36.50		77.00	120	70	72	115	80	80
				Day 35	29/02/92	36.80		77.50	130	70	64	125	80	72
				Day 42	07/03/92	36.60		78.00	130	80	64	125	80	72
	195	Placebo	Female	Screen	25/01/92	36.80	20		130	70	64	125	75	72
				Day 0	25/01/92	36.80		67.00	130	70	64	125	75	72
				Day 7	01/02/92	36.50		67.00	140	70	68	135	75	72
				Day 14	08/02/92	36.60		67.00	140	70	80	135	70	82
				Day 21	15/02/92	36.60		67.30	140	80	74	130	85	80
				Day 28	22/02/92	36.50		67.80	140	70	68	135	80	80
				Day 35	29/02/92	36.70		68.00	130	90	87	125	95	92
				Day 42	07/03/92	36.70		68.00	140	70	68	130	70	84
	196	Reboxetine	Female	Screen	01/02/92	36.50	18		120	70	68	115	75	74
				Day 0	01/02/92	36.50		67.00	120	70	68	115	75	74
				Day 7	08/02/92	36.30		67.00	140	70	68	130	80	72
				Day 14	15/02/92	36.60		66.50	130	80	64	125	85	72

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
7/04	196	Reboxetine	Female	Day 21	22/02/92	36.50		66.70	130	80	72	125	85	80
				Day 28	29/02/92	36.70		67.00	140	70	72	135	75	80
				Day 35	07/03/92	36.60		67.10	130	70	86	140	75	80
				Day 42	14/03/92	36.50		67.50	130	80	81	120	70	90
	197	Imipramine	Male	Screen	01/02/92	36.50	22		130	80	64	120	85	68
				Day 0	01/02/92	36.50		79.00	130	80	64	120	85	68
				Day 7	08/02/92	36.80		79.00	130	80	67	125	85	72
				Day 14	15/02/92	36.50		78.60	140	80	72	140	85	80
				Day 21	22/02/92	36.70		78.80	140	80	72	135	85	80
				Day 28	29/02/92	36.50		79.20	120	70	72	115	80	80
				Day 35	07/03/92	36.60		79.00	140	70	82	135	80	72
				Day 42	14/03/92	36.50		79.40	130	80	81	130	85	87
	198	Imipramine	Female	Screen	01/02/92	36.80	18		130	90	74	125	95	80
				Day 0	01/02/92	36.80		61.00	130	90	74	125	95	80
				Day 7	08/02/92	36.50		61.00	140	70	72	135	72	80
				Day 14	15/02/92	36.50		60.30	145	90	72	140	90	84
				Day 21	22/02/92	36.80		60.50	130	80	64	125	85	72
				Day 28	29/02/92	36.90		60.60	130	70	64	120	80	72
				Day 35	07/03/92	36.60		60.90	130	70	80	120	80	84
				Day 42	14/03/92	36.60		70.10	120	70	72	115	75	84
	199	Imipramine	Male	Screen	28/03/92	36.80	20		130	70	64	125	75	72
				Day 0	28/03/92	36.80		78.00	130	70	64	135	75	72
				Day 7	04/04/92	36.60		78.00	140	70	64	135	70	64
				Day 14	11/04/92	36.60		77.60	140	80	72	140	85	80
				Day 21	18/04/92	36.80		78.00	130	80	68	130	75	72
				Day 28	25/04/92	36.60		78.30	140	80	72	130	84	80
				Day 35	02/05/92	36.60		79.00	130	80	72	130	85	72
				Day 42	09/05/92	36.50		79.20	130	80	84	125	84	90
	200	Placebo	Male	Screen	28/03/92	36.40	21		130	80	64	125	85	72
				Day 0	28/03/92	36.40		89.00	130	80	64	125	85	72
				Day 7	04/04/92	36.70		88.90	140	70	64	135	75	82
				Day 14	11/04/92	36.60		89.10	140	80	72	180	85	80
				Day 21	18/04/92	36.80		89.00	150	80	72	140	70	64
				Day 28	25/04/92	36.60		89.00	130	70	68	130	75	72
				Day 35	02/05/92	36.60		88.90	140	70	72	135	75	80
				Day 42	09/05/92	36.70		89.00	120	70	68	118	72	72
	201	Reboxetine	Female	Screen	28/03/92	36.00	24		130	80	72	125	84	80
				Day 0	28/03/92	36.80		79.00	130	80	74	130	75	80
				Day 7	04/04/92	36.40		79.00	130	80	72	125	85	80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
7/04	201	Reboxetine	Female	Day 14	11/04/92	36.20		79.10	130	70	64	130	75	70
				Day 21	18/04/92	37.00		79.20	130	70	76	125	80	80
				Day 28	25/04/92	36.40		79.40	140	70	76	135	75	80
				Day 35	02/05/92	36.70		79.50	140	80	72	135	80	74
				Day 42	09/05/92	36.70		79.80	140	80	80	130	78	84
	202	Reboxetine	Male	Screen	01/04/92	36.30	19		130	80	72	125	80	80
				Day 0	04/04/92	36.60		96.00	130	70	72	125	75	80
				Day 7	11/04/92	36.50		96.00	130	70	80	120	80	84
				Day 14	18/04/92	36.60		93.00	130	80	72	125	85	80
				Day 21	25/04/92	36.10		95.80	130	70	74	125	75	82
				Day 28	02/05/92	36.70		96.00	130	75	64	125	80	72
				Day 35	09/05/92	36.60		96.00	140	80	64	130	84	72
				Day 42	16/05/92	36.70		96.00	140	95	78	140	92	80
	203	Placebo	Female	Screen	01/04/92	36.80	19		120	70	68	115	80	84
				Day 0	04/04/92	36.80		67.00	140	70	64	135	75	72
				Day 7	11/04/92	36.00		66.50	130	80	72	135	85	84
				Day 14	18/04/92	36.70		66.00	130	70	64	125	75	72
				Day 21	25/04/92	36.60		66.20	130	80	72	125	85	80
				Day 28	02/05/92	36.10		66.10	130	80	72	130	85	75
				Day 35	09/05/92	36.40		66.30	120	70	64	120	75	72
				Day 42	16/05/92	36.70		66.50	130	80	72	125	85	74
	204	Imipramine	Female	Screen	01/04/92	36.30	18		130	80	72	130	85	80
				Day 0	04/04/92	36.50		87.00	130	80	72	125	85	80
				Day 7	11/04/92	36.70		86.80	130	70	72	135	75	80
				Day 14	18/04/92	36.60		86.50	130	80	72	125	80	80
				Day 21	25/04/92	36.70		86.60	130	80	72	130	80	74
				Day 28	02/05/92	36.60		86.70	130	80	72	125	80	74
				Day 35	09/05/92	36.50		86.70	120	70	72	130	80	80
				Day 42	16/05/92	36.90		86.70	130	70	78	130	75	80
7/05	205	Placebo	Male	Screen	30/12/91	36.40	15		130	70	64	130	75	72
				Day 0	27/01/92	36.20		74.00	135	70	68	130	75	72
				Day 7	03/02/92	36.00		73.70	130	70	74	140	75	75
				Day 14	10/02/92	36.20		73.40	135	75	68	140	75	70
				Day 21	17/02/92	36.40		73.20	130	70	76	140	75	72
				Day 28	24/02/92	36.10		73.20	140	80	76	145	75	72
				Day 35	02/03/92	36.50		73.60	135	80	68	140	85	67
				Day 42	09/03/92	36.20		73.40	130	80	60	130	85	68
	206	Imipramine	Female	Screen	14/01/92	36.10	14		145	90	78	140	90	82
				Day 0	28/01/92	36.20		70.00	140	85	82	140	90	80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
7/05	206	Imipramine	Female	Day 7	04/02/92	36.30		70.10	145	82	86	140	90	84
				Day 14	11/02/92	36.00		70.20	140	80	78	145	85	82
				Day 21	18/02/92	36.20		70.40	140	85	68	135	80	62
				Day 28	25/02/92	36.30		70.50	140	80	64	145	80	67
				Day 35	03/03/92	36.40		70.20	140	75	74	140	85	70
				Day 42	10/03/92	36.50		70.40	135	70	62	140	80	64
	207	Imipramine	Female	Screen	21/01/92	36.40	17		110	70	62	115	75	60
				Day 0	28/01/92	36.20		72.00	115	70	68	110	75	65
				Day 7	04/02/92	36.40		72.30	110	70	64	110	70	64
				Day 14	11/02/92	36.30		72.30	110	70	68	115	70	72
				Day 21	18/02/92	36.40		72.10	110	65	62	110	70	67
				Day 28	25/02/92	36.20		72.30	115	70	67	110	70	70
				Day 35	03/03/92	36.20		70.30	110	70	62	110	75	65
				Day 42	10/03/92	36.50		70.90	115	70	64	110	70	68
	208	Reboxetine	Male	Screen	24/01/92	36.60	14		120	80	70	115	85	74
				Day 0	30/01/92	36.30		75.00	110	70	72	115	75	78
				Day 7	06/02/92	36.10		75.30	110	70	68	110	75	70
				Day 14	13/02/92	36.30		75.10	115	75	74	110	75	77
				Day 21	20/02/92	36.30		75.20	115	80	72	115	75	74
				Day 28	27/02/92	36.30		75.40	110	75	70	115	75	75
				Day 35	05/03/92	36.40		75.20	110	70	68	115	75	75
				Day 42	12/03/92	36.30		75.60	115	70	68	115	75	76
	209	Placebo	Male	Screen	29/01/92	36.10	18		130	80	60	135	80	81
				Day 0	05/02/92	36.20		86.00	125	75	64	135	80	67
				Day 7	12/02/92	36.40		86.10	130	80	62	135	80	64
				Day 14	19/02/92	36.40		86.00	125	84	67	130	79	69
				Day 21	26/02/92	36.10		86.20	135	80	65	130	75	62
				Day 28	04/03/92	36.20		86.00	130	80	64	135	75	62
				Day 35	11/03/92	36.40		86.00	140	80	68	135	75	69
				Day 42	18/03/92	36.10		86.30	130	80	61	125	75	67
	210	Reboxetine	Male	Screen	03/02/92	36.00	13		150	90	88	150	95	86
				Day 0	07/02/92	36.20		76.00	160	90	90	150	95	88
				Day 7	14/02/92	36.40		75.90	155	85	88	160	90	85
				Day 14	21/02/92	36.50		76.10	150	80	84	150	85	87
				Day 21	28/02/92	36.50		76.40	155	85	82	150	90	85
				Day 28	06/03/92	36.70		76.60	140	85	76	150	85	79
				Day 35	13/03/92	36.30		76.20	150	85	86	155	90	89
				Day 42	20/03/92	36.30		76.30	150	90	82	145	85	84
	541	Reboxetine	Female	Screen	02/03/92	36.10	14		125	85	60	140	90	74

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
7/05	541	Reboxetine	Female	Day 0	17/03/92	36.40		74.30	130	80	64	135	85	78
				Day 7	24/03/92	36.20		74.10	140	80	62	140	85	72
				Day 14	31/03/92	36.10		74.50	130	75	68	140	85	76
				Day 21	07/04/92	36.50		74.30	135	80	60	140	90	73
				Day 28	14/04/92	36.50		74.60	140	90	71	140	85	79
				Day 35	21/04/92	36.00		74.50	140	80	63	135	85	74
				Day 42	28/04/92	36.00		74.40	130	75	60	130	80	68
	542	Imipramine	Male	Screen	02/03/92	36.80	17		110	80	87	110	75	91
				Day 0	17/03/92	36.70		83.70	110	70	82	110	75	84
				Day 7	24/03/92	36.70		83.20	115	75	84	110	80	89
				Day 14	31/03/92	36.70		83.50	105	75	79	110	80	84
				Day 21	07/04/92	36.10		83.70	115	75	83	120	80	87
				Day 28	14/04/92	36.80		83.70	110	75	78	110	70	89
				Day 35	21/04/92	36.70		83.20	110	70	80	125	75	87
				Day 42	28/04/92	36.60		83.90	120	70	80	115	80	89
2042	543	Imipramine	Male	Screen	03/03/92	36.10	14		125	85	64	120	85	68
				Day 0	18/03/92	36.10		98.40	115	75	62	120	80	65
				Day 7	25/03/92	36.20		98.30	120	75	64	110	80	67
				Day 14	01/04/92	36.30		98.70	110	70	60	115	80	62
				Day 21	08/04/92	36.40		98.30	110	75	60	115	80	66
				Day 28	15/04/92	36.20		99.00	125	70	66	110	80	73
				Day 35	22/04/92	36.40		99.00	105	80	68	105	75	74
				Day 42	29/04/92	36.40		98.70	110	85	60	105	90	67
	544	Placebo	Female	Screen	04/03/92	36.40	17		120	65	82	125	80	76
				Day 0	24/03/92	36.10		77.10	120	75	78	125	80	79
				Day 7	31/03/92	36.30		76.90	115	80	74	125	85	81
				Day 14	07/04/92	36.40		76.00	120	80	76	115	85	82
				Day 21	14/04/92	36.50		76.10	120	75	70	110	80	74
				Day 28	21/04/92	36.40		75.90	120	75	70	120	80	73
				Day 35	28/04/92	36.40		75.60	115	80	64	110	80	71
				Day 42	05/05/92	36.20		75.80	125	75	70	120	75	78
	545	Placebo	Male	Screen	05/03/92	36.90	18		130	60	66	130	80	64
				Day 0	25/03/92	36.50		74.90	130	70	62	135	70	68
				Day 7	01/04/92	36.70		74.70	130	70	70	140	80	76
				Day 14	08/04/92	36.50		74.70	125	70	64	130	75	66
				Day 21	15/04/92	36.40		74.30	120	75	61	125	70	66
				Day 28	22/04/92	36.50		74.80	130	80	64	130	85	70
				Day 35	29/04/92	36.40		74.60	130	80	60	125	85	69
				Day 42	06/05/92	36.20		74.70	125	80	61	130	80	64

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
7/05	546	Reboxetine	Female	Screen	10/03/92	36.00	14		110	70	72	115	75	78
				Day 0	25/03/92	36.10		73.20	110	70	80	110	75	84
				Day 7	01/04/92	36.30		73.50	120	75	76	125	80	79
				Day 14	08/04/92	36.00		73.20	115	70	78	110	75	85
				Day 21	15/04/92	36.00		73.30	110	75	76	115	75	81
				Day 28	22/04/92	36.40		73.50	115	80	76	120	75	70
				Day 35	29/04/92	36.00		73.20	110	75	72	105	80	79
				Day 42	06/05/92	36.20		73.20	110	70	76	110	75	84
7/07	529	Placebo	Female	Screen	17/02/92	36.60	12		125	80	60	130	85	72
				Day 0	18/02/92	36.80		75.00	110	80	66	120	70	72
				Day 7	25/02/92	36.70		75.00	135	75	66	135	80	72
				Day 14	03/03/92	36.80		75.00	130	75	66	135	80	72
				Day 21	10/03/92	36.80		75.00	120	80	66	130	70	78
				Day 28	17/03/92	36.90		75.00	110	70	66	105	75	72
				Day 35	24/03/92	36.80		75.00	100	65	66	95	70	72
				Day 42	31/03/92	36.90		75.00	100	60	70	95	65	76
	530	Imipramine	Female	Screen	17/02/92	36.70	13		145	90	90	140	90	108
				Day 0	20/02/92	36.80		73.00	140	90	82	145	80	90
				Day 7	27/02/92	36.80		74.00	130	85	78	140	80	84
				Day 14	05/03/92	36.90		74.00	140	80	78	145	85	84
	531	Reboxetine	Female	Screen	18/02/92	36.70	11		160	100	78	165	105	72
				Day 0	24/02/92	36.80		85.00	150	95	66	160	90	72
				Day 7	02/03/92	36.80		85.00	140	90	66	150	85	72
				Day 14	09/03/92	36.70		85.00	160	90	68	150	85	72
				Day 21	16/03/92	36.80		85.00	160	90	72	150	85	76
				Day 28	23/03/92	36.80		85.00	140	85	66	150	90	72
				Day 35	30/03/92	36.70		85.00	140	80	66	145	85	72
				Day 42	06/04/92	36.80		85.00	186	110	90	144	86	93
	532	Imipramine	Female	Screen	23/04/92	36.80	12		140	90	95	145	95	117
				Day 0	27/04/92	36.70		58.00	137	77	112	137	96	128
				Day 7	04/05/92	36.80		58.00	130	72	98	135	76	110
				Day 14	11/05/92	36.80		58.00	128	85	107	121	78	112
				Day 21	18/05/92	36.80		58.00	156	100	83	158	100	102
				Day 28	25/05/92	36.80		58.00	115	74	91	117	85	107
				Day 35	01/06/92	36.80		58.00	110	68	88	109	72	98
				Day 42	09/06/92	36.70		58.00	96	66	97	118	78	111
	533	Reboxetine	Male	Screen	27/04/92	36.70	14		138	85	76	142	95	98
				Day 0	04/05/92	36.80		85.00	125	76	88	138	93	111
				Day 7	11/05/92	36.80		85.00	117	78	83	132	92	102

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
7/07	533	Reboxetine	Male	Day 14	18/05/92	36.80		85.00	116	73	87	126	99	112
				Day 21	25/05/92	36.90		85.00	131	77	86	126	90	117
				Day 28	01/06/92	36.80		85.00	122	74	93	122	92	113
				Day 35	08/06/92	36.80		85.00	130	89	87	138	106	116
				Day 42	15/06/92	36.80		85.00	123	81	90	139	102	125
	534	Placebo	Female	Screen	12/05/92	36.60	12		129	78	57	125	86	93
				Day 0	15/05/92	36.80		66.00	121	78	56	120	78	48
				Day 7	22/05/92	36.70		66.00	117	72	78	113	62	72
				Day 14	29/05/92	36.70		66.00	116	76	72	113	74	83
				Day 21	05/06/92	36.70		66.00	124	73	69	117	77	83
				Day 28	12/06/92	36.80		66.00	117	78	59	124	86	77
				Day 35	19/06/92	36.70		69.00	114	74	61	118	75	71
				Day 42	26/06/92	36.60		69.00	116	74	60	120	76	72
8	211	Reboxetine	Female	Screen	07/05/91	36.60	15		120	85	76	120	85	76
				Day 0	13/05/91	36.50		65.00	125	80	74	120	80	74
				Day 7	20/05/91	36.60		65.00	120	80	70	120	80	72
				Day 14	27/05/91	36.70		65.00	130	80	72	125	80	74
	212	Placebo	Female	Screen	10/09/91	36.70	15		130	80	72	125	80	74
				Day 0	14/09/91	36.60		76.50	130	80	74	125	80	76
				Day 7	21/09/91	36.50		76.50	130	80	74	130	80	74
				Day 14	28/09/91	36.50		76.50	130	85	74	130	80	74
				Day 21	05/10/91	36.70		76.50	130	80	74	130	80	74
				Day 28	12/10/91	36.70		76.50	130	85	74	130	85	74
				Day 35	19/10/91	36.60		76.50	135	85	76	130	85	76
				Day 42	26/10/91	36.50		76.50	135	85	74	130	85	74
	213	Imipramine	Male	Screen	18/11/91	36.60	16		125	80	64	125	80	64
				Day 0	22/11/91	36.60		79.00	125	80	64	125	80	64
	214	Reboxetine	Female	Screen	19/11/91	36.80	16		135	90	72	135	90	72
				Day 0	23/11/91	36.50		72.00	120	85	72	120	85	72
				Day 7	30/11/91	36.50		72.00	120	85	72	120	85	72
				Day 14	07/12/91	36.60		72.00	125	85	70	120	85	70
				Day 21	14/12/91	36.60		72.00	120	85	74	120	85	74
				Day 28	21/12/91	36.70		72.00	125	85	74	125	85	74
				Day 35	28/12/91	36.50		72.00	125	85	74	125	85	74
	215	Placebo	Female	Screen	14/02/92	36.40	15		120	80	64	120	80	64
				Day 0	18/02/92	36.40		44.00	115	80	70	115	80	70
				Day 7	25/02/92	36.60		48.50	115	80	70	115	80	70

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
8	215	Placebo	Female	Day 14	03/03/92	36.80		48.20	110	75	70	110	75	70
				Day 21	10/03/92	36.40		49.00	125	80	70	125	80	70
				Day 28	17/03/92	36.60		48.00	120	80	72	120	80	72
				Day 35	24/03/92	36.50		48.00	120	80	70	120	80	70
				Day 42	31/03/92	36.60		48.00	120	80	72	120	75	72
	216	Imipramine	Male	Screen	23/03/92	36.40	16		130	80	80	130	80	80
				Day 0	27/03/92	36.40		92.00	130	85	80	130	85	80
				Day 7	03/04/92	36.40		92.00	125	85	80	125	85	80
				Day 14	10/04/92	36.50		92.50	120	85	78	120	85	78
				Day 21	17/04/92	36.50		92.50	125	85	76	125	85	76
				Day 28	24/04/92	36.50		92.50	130	85	76	130	85	76
				Day 35	01/05/92	36.50		92.50	130	90	84	130	80	84
				Day 42	08/05/92	36.50		92.50	135	80	78	135	80	78
	217	Reboxetine	Female	Screen	23/03/92	36.60	16		120	80	82	120	80	82
				Day 0	30/03/92	36.50		62.80	120	80	80	120	80	80
				Day 7	06/04/92	36.60		62.50	120	80	82	115	80	82
				Day 14	13/04/92	36.50		62.50	125	80	84	120	80	84
				Day 21	20/04/92	36.60		62.80	120	80	80	120	80	80
				Day 28	27/04/92	36.60		63.00	125	80	82	125	80	82
				Day 35	04/05/92	36.50		63.00	125	80	82	125	80	82
				Day 42	11/05/92	36.70		63.00	125	75	84	125	75	84
	218	Reboxetine	Female	Screen	01/04/92	36.60	16		155	90	72	155	90	72
				Day 0	09/04/92	36.60		66.00	155	90	72	150	85	74
				Day 7	16/04/92	36.60		66.00	150	90	74	150	90	74
				Day 14	23/04/92	36.50		66.00	145	90	76	145	90	76
				Day 21	30/04/92	36.60		66.30	140	90	76	140	90	76
				Day 28	07/05/92	36.50		66.30	140	90	76	140	90	76
				Day 35	14/05/92	36.60		66.30	140	90	74	140	90	74
				Day 42	21/05/92	36.60		66.40	140	90	78	140	90	78
	219	Placebo	Female	Screen	03/04/92	36.50	16		110	80	70	110	80	70
				Day 0	11/04/92	36.50		52.00	110	80	72	110	80	72
				Day 7	18/04/92	36.60		52.00	110	80	70	110	80	70
				Day 14	24/04/92	36.60		52.00	115	80	70	115	80	70
				Day 21	02/05/92	36.50		52.00	115	75	70	115	75	70
	220	Imipramine	Female	Screen	21/04/92	36.50	16		115	80	84	115	80	84
				Day 0	27/04/92	36.60		56.50	120	80	82	120	80	82
				Day 7	04/05/92	36.50			120	80	82	120	80	82
				Day 14	11/05/92	36.60		56.60	125	85	84	125	85	84
				Day 21	18/05/92	36.60		56.80	115	80	82	115	80	82

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
8	220	Imipramine	Female	Day 28	25/05/92	36.60		56.80	125	80	82	120	75	84
				Day 35	01/06/92	36.60		56.70	130	80	80	125	75	84
				Day 42	08/06/92	36.50		56.70	130	80	78	130	75	78
	221	Imipramine	Male	Screen	24/04/92	36.60	16		130	80	78	130	80	78
				Day 0	28/04/92	36.60		77.00	130	80	78	130	80	78
				Day 7	05/05/92	36.50		77.00	130	85	80	130	85	80
				Day 14	12/05/92	36.60		77.00	135	85	82	135	85	82
				Day 21	19/05/92	36.50		77.00	135	85	78	130	85	80
				Day 28	26/05/92	36.50		77.00	130	80	78	130	80	78
				Day 35	02/06/92	36.60		77.00	130	80	80	130	80	80
	222	Placebo	Female	Screen	20/04/92	36.40	16		120	70	64	120	70	64
				Day 0	28/04/92	36.50		66.00	120	75	62	120	75	62
				Day 7	05/05/92	36.60		66.00	125	80	64	125	80	64
				Day 14	12/05/92	36.50		66.00	130	80	64	130	80	64
				Day 21	19/05/92	36.50		66.20	125	80	62	125	80	62
				Day 28	26/05/92	36.50		66.20	130	80	60	125	80	62
				Day 35	02/06/92	36.60		66.30	130	80	62	130	80	62
				Day 42	09/06/92	36.60		66.30	120	80	66	120	80	66
	223	Imipramine	Female	Screen	04/05/92	36.40	16		110	80	82	110	80	82
				Day 0	11/05/92	36.40		54.00	125	75	80	125	75	80
				Day 7	18/05/92	36.60		54.00	125	80	78	125	80	78
				Day 14	25/05/92	36.60		54.00	120	80	78	120	80	78
				Day 21	01/06/92	36.50		54.00	115	80	70	115	80	70
				Day 28	08/06/92	36.60		54.20	125	80	80	125	80	80
				Day 35	15/06/92	36.50		54.20	120	75	82	120	75	82
				Day 42	22/06/92	36.40		54.20	125	85	72	120	80	75
	224	Placebo	Female	Screen	27/08/92	36.70	16		115	80	80	115	80	80
				Day 0	07/09/92	36.60		56.00	115	80	82	115	80	82
				Day 7	14/09/92	36.50		56.00	110	80	82	110	80	82
				Day 14	21/09/92	36.50		56.00	115	85	80	115	85	80
				Day 21	28/09/92	36.60		56.00	115	80	80	115	80	80
				Day 28	05/10/92	36.60		56.50	115	85	82	115	85	82
				Day 35	12/10/92	36.50		56.50	115	80	82	115	80	82
				Day 42	19/10/92	36.60		56.50	115	75	80	115	75	80
	225	Placebo	Male	Screen	05/09/92	36.60	16		120	80	78	120	80	78
				Day 0	11/09/92	36.50		68.00	120	80	80	120	80	80
				Day 7	18/09/92	36.60		68.00	120	85	82	120	85	82
				Day 14	25/09/92	36.50		68.00	115	85	80	115	85	80
				Day 21	02/10/92	36.50		68.00	115	85	80	115	85	80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
8	225	Placebo	Male	Day 28	09/10/92	36.60		68.00	115	80	82	110	80	82
				Day 35	16/10/92	36.50		68.00	115	85	82	115	80	82
				Day 42	23/10/92	36.50		68.00	110	85	82	110	80	84
	226	Reboxetine	Male	Screen	21/09/92	36.50	16		140	90	78	140	90	78
				Day 0	23/09/92	36.60		62.00	140	90	78	140	90	78
				Day 7	30/09/92	36.50		62.00	140	90	80	140	85	80
				Day 14	07/10/92	36.60		62.00	140	85	82	140	85	82
				Day 21	14/10/92	36.60		62.00	135	80	80	135	80	80
				Day 28	21/10/92	36.50		62.00	135	85	82	130	85	84
				Day 35	28/10/92	36.50		62.00	135	80	82	135	80	82
				Day 42	04/11/92	36.40		62.00	135	85	72	135	80	74
	227	Reboxetine	Male	Screen	18/09/92	36.50	16		160	90	86	160	90	86
				Day 0	25/09/92	36.60		70.00	160	90	84	160	90	84
				Day 7	02/10/92	36.50		70.00	160	90	86	160	90	86
				Day 14	09/10/92	36.50		70.00	155	90	84	155	90	84
				Day 21	16/10/92	36.50		70.00	160	90	84	160	85	84
				Day 28	23/10/92	36.70		70.00	150	90	82	150	90	82
				Day 35	30/10/92	36.60		70.00	150	90	82	150	85	84
				Day 42	06/11/92	36.60		70.00	155	90	82	150	90	82
	228	Imipramine	Male	Screen	18/09/92	36.50	16		125	85	82	125	85	82
				Day 0	26/09/92	36.60		74.00	120	80	82	120	80	82
				Day 7	03/10/92	36.60		74.00	115	80	82	115	80	82
	229	Imipramine	Female	Screen	24/09/92	36.50	16		135	85	82	135	85	82
				Day 0	30/09/92	36.70		66.00	140	85	82	135	85	82
				Day 7	07/10/92	36.30		66.00	135	80	78	135	80	78
				Day 14	14/10/92	36.50		66.00	135	85	80	130	85	82
				Day 21	21/10/92	36.60		66.50	125	80	82	125	75	82
				Day 28	28/10/92	36.70		66.50	130	80	78	130	80	78
				Day 35	04/11/92	36.60		66.50	125	80	80	125	80	80
				Day 42	11/11/92	36.50		66.50	130	85	82	130	85	82
	230	Reboxetine	Female	Screen	24/09/92	36.60	16		125	80	74	120	80	76
				Day 0	28/09/92	36.50		56.00	115	80	74	115	80	74
				Day 7	05/10/92	36.50		56.00	120	85	70	120	85	70
				Day 14	12/10/92	36.70		56.00	115	80	72	115	80	72
				Day 21	19/10/92	36.70		56.00	120	75	70	120	75	70
				Day 28	26/10/92	36.50		56.00	125	80	72	125	80	72
				Day 35	02/11/92	36.60		56.00	125	85	72	120	85	74
				Day 42	09/11/92	36.70		56.00	125	85	72	125	85	72

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
8	231	Imipramine	Male	Screen	25/09/92	36.60	16		145	85	76	145	85	76
				Day 0	30/09/92	36.50		88.00	140	85	72	140	80	74
				Day 7	07/10/92	36.40		88.00	140	85	72	140	85	72
				Day 14	14/10/92	36.50		88.00	135	85	68	135	85	68
				Day 21	21/10/92	36.60		88.00	140	80	70	135	80	70
				Day 28	28/10/92	36.50		88.00	135	85	72	135	85	72
				Day 35	04/11/92	36.50		88.00	135	85	70	135	80	72
				Day 42	11/11/92	36.70		88.00	140	85	72	135	85	72
	232	Reboxetine	Male	Screen	25/09/92	36.50	16		130	85	88	125	85	88
				Day 0	02/10/92	36.60		76.00	125	85	86	125	85	86
				Day 7	09/10/92	36.60		76.00	130	85	86	130	85	86
				Day 14	16/10/92	36.60		76.00	130	85	88	130	85	88
				Day 21	23/10/92	36.70		76.00	120	80	82	120	80	82
				Day 28	30/10/92	36.50		76.00	125	85	86	125	85	86
				Day 35	06/11/92	36.50		76.00	130	90	86	130	85	86
				Day 42	13/11/92	36.70		76.00	125	85	82	125	85	82
	233	Placebo	Female	Screen	28/09/92	36.40	16		125	80	84	125	80	84
				Day 0	07/10/92	36.50		70.00	125	85	82	125	85	82
				Day 7	14/10/92	36.50		70.00	120	85	84	120	85	84
				Day 14	21/10/92	36.70		70.00	125	85	82	125	85	82
				Day 21	28/10/92	36.70		69.00	130	90	86	130	85	86
				Day 28	04/11/92	36.60		69.00	130	85	84	130	85	84
				Day 35	11/11/92	36.60		69.50	130	85	84	125	85	86
				Day 42	18/11/92	36.80		70.00	120	80	78	120	80	80
	234	Placebo	Female	Screen	30/09/92	36.40	16		150	82	70	150	85	70
				Day 0	07/10/92	36.50		62.00	155	85	78	155	85	78
				Day 7	14/10/92	36.60		62.00	155	85	76	155	85	76
				Day 14	21/10/92	36.50		62.00	150	85	74	150	85	74
				Day 21	28/10/92	36.70		62.00	145	85	72	145	80	74
				Day 28	04/11/92	36.50		62.00	140	80	72	140	80	72
				Day 35	11/11/92	36.60		62.00	140	85	74	140	80	74
				Day 42	18/11/92	36.70		62.00	140	80	72	135	80	72
8/A	235	Placebo	Female	Screen	18/09/92	36.00	20		145	65	70	140	85	72
				Day 0	14/10/92	36.20		75.00	145	85	72	140	85	70
				Day 7	20/10/92	36.00		75.00	140	80	70	135	80	72
				Day 14	27/10/92	36.20		75.00	140	75	70	135	75	71
				Day 21	04/11/92	36.40		75.00	135	75	70	130	75	69
				Day 28	10/11/92	36.30		74.00	135	80	68	135	80	69
				Day 35	17/11/92	36.30		74.00	135	80	70	135	80	72

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
8/A	235	Placebo	Female	Day 42	24/11/92	36.30		74.00	130	75	70	130	70	70
	236	Placebo	Female	Screen	18/09/92	36.40	19		120	75	72	125	80	71
				Day 0	14/10/92	36.80		85.00	135	80	74	140	80	73
				Day 7	20/10/92	36.60		84.50	130	80	77	140	80	77
				Day 14	27/10/92	36.00		84.00	125	80	76	130	80	75
				Day 21	04/11/92	36.00		83.50	130	70	70	130	75	68
				Day 28	10/11/92	36.50		85.00	130	80	70	135	85	72
				Day 35	17/11/92	36.40		84.50	130	75	70	130	80	72
				Day 42	24/11/92	36.20		83.00	130	70	70	125	70	72
	237	Reboxetine	Female	Screen	18/09/92	36.00	21		130	80	82	130	80	84
				Day 0	14/10/92	36.10		62.00	130	80	84	130	80	84
				Day 7	20/10/92	36.40		62.00	125	80	82	130	80	82
				Day 14	27/10/92	36.40		62.00	125	80	82	130	80	80
				Day 21	03/11/92	36.00		62.00	130	75	68	130	80	68
				Day 28	10/11/92	36.50		62.00	130	80	77	130	85	79
				Day 35	18/11/92	36.10		61.50	130	70	72	135	70	72
				Day 42	24/11/92	36.20		62.00	130	75	68	125	70	68
	238	Reboxetine	Female	Screen	18/09/92	36.30	22		145	85	80	140	85	80
				Day 0	14/10/92	36.20		60.00	145	85	80	140	85	80
				Day 7	20/10/92	36.00		59.00	135	85	82	135	80	80
				Day 14	27/10/92	36.30		59.00	135	80	80	130	75	82
				Day 21	04/11/92	36.40		60.00	140	75	70	140	75	72
				Day 28	10/11/92	36.40		59.00	135	80	68	135	80	68
				Day 35	17/11/92	36.10		59.50	130	80	67	130	75	69
				Day 42	24/11/92	36.10		59.00	130	75	65	130	70	67
	239	Imipramine	Female	Screen	22/09/92	36.30	20		145	90	68	140	85	68
				Day 0	16/10/92	36.20		61.50	145	85	70	145	80	70
				Day 7	22/10/92	36.30		62.00	140	75	70	140	85	72
				Day 14	29/10/92	36.30		62.00	140	80	70	145	80	70
				Day 21	05/11/92	36.20		62.00	140	80	68	140	75	68
				Day 28	12/11/92	36.00		61.50	130	85	68	135	85	70
				Day 35	19/11/92	36.60		61.50	130	70	70	130	75	70
				Day 42	26/11/92	36.40		62.00	135	80	78	135	75	76
	240	Imipramine	Female	Screen	22/09/92	36.00	18		120	80	84	120	78	84
				Day 0	16/10/92	36.20		68.00	135	80	78	135	75	78
				Day 7	22/10/92	36.40		68.00	125	80	76	125	80	76
				Day 14	29/10/92	36.30		68.50	130	85	74	130	80	74
				Day 21	05/11/92	36.00		68.00	130	75	78	130	80	78
				Day 28	12/11/92	36.30		68.50	130	80	72	130	80	72

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
8/A	240	Imipramine	Female	Day 35	19/11/92	36.00		68.00	125	70	70	120	70	70
				Day 42	26/11/92	36.20		68.00	125	70	70	125	75	70
	553	Placebo	Female	Screen	22/09/92	36.00	18		115	70	80	115	70	80
				Day 0	16/10/92	36.60		68.00	145	75	78	140	80	78
				Day 7	22/10/92	36.60		68.00	145	90	80	140	80	80
				Day 14	29/10/92	36.20		68.00	140	70	80	140	70	80
				Day 21	05/11/92	36.40		68.00	130	70	80	130	70	80
				Day 28	12/11/92	36.30		68.00	140	75	72	140	70	72
				Day 35	19/11/92	36.30		68.00	140	75	72	140	75	72
				Day 42	26/11/92	36.30		68.00	130	70	68	130	70	68
	554	Reboxetine	Male	Screen	22/09/92	36.00	16		145	80	62	140	80	62
				Day 0	16/10/92	36.30		64.00	150	85	64	150	80	64
				Day 7	22/10/92	36.40		64.00	145	80	62	140	80	62
				Day 14	29/10/92	36.60		64.00	145	75	64	140	75	64
				Day 21	05/11/92	36.30		64.00	145	80	64	140	80	64
				Day 28	12/11/92	36.40		64.00	150	80	62	145	80	62
				Day 35	19/11/92	36.20		64.00	145	75	62	140	75	60
				Day 42	26/11/92	36.10		64.00	150	80	60	145	80	60
	555	Reboxetine	Female	Screen	22/09/92	36.60	19		145	85	71	140	85	72
				Day 0	16/10/92	36.10		57.00	140	80	72	140	80	70
				Day 7	22/10/92	36.70		57.50	145	85	74	145	80	74
				Day 14	29/10/92	36.60		56.50	135	80	72	130	80	72
				Day 21	05/11/92	36.30		58.00	140	80	68	140	75	68
				Day 28	12/11/92	36.30		56.00	140	75	70	140	70	70
				Day 35	19/11/92	36.40		56.00	135	70	68	130	70	68
				Day 42	26/11/92	36.20		56.50	130	70	68	130	75	68
	556	Imipramine	Male	Screen	22/09/92	36.40	19		120	60	82	120	60	82
				Day 0	16/10/92	36.30		64.00	125	60	80	120	60	80
				Day 7	22/10/92	36.20		64.00	120	80	80	120	70	80
				Day 14	29/10/92	36.20		64.00	120	60	80	120	60	80
				Day 21	05/11/92	36.30		64.00	125	65	84	125	60	82
				Day 28	12/11/92	36.20		64.00	120	70	82	120	70	80
				Day 35	19/11/92	36.40		64.00	130	80	82	130	80	82
				Day 42	26/11/92	36.20		64.00	130	70	90	130	70	90
9	241	Placebo	Female	Screen	04/02/91	36.00	18		120	80	80	120	80	83
				Day 0	07/02/91	36.20		58.00	115	70	83	110	70	87
				Day 7	14/02/91	36.90		53.80	115	75	82	115	75	85
				Day 14	18/02/91				140	90				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
9	242	Reboxetine	Female	Screen	12/02/91	36.00	20		115	80	90	115	80	90
				Day 0	18/02/91	36.20		50.00	140	80	84	135	80	88
				Day 7	25/02/91	36.30		50.00	130	80	82	130	80	84
				Day 14	04/03/91	36.40		50.00	120	80	80	120	80	80
				Day 21	11/03/91	36.30		50.00	110	80	80	110	80	80
	243	Reboxetine	Female	Screen	15/02/91	36.20	13		120	80	70	120	80	70
				Day 0	20/02/91	36.10		67.50	120	80	74	120	80	74
				Day 7	26/02/91	36.10		67.30	130	90	70	130	90	70
				Day 14	06/03/91	36.40		67.20	150	100	75	150	100	75
	244	Imipramine	Female	Screen	14/02/91	36.00	15		130	80	80	130	80	80
				Day 0	19/02/91	36.40		72.00	130	80	80	130	80	80
				Day 7	26/02/91	36.80		72.00	130	80	80	130	80	80
				Day 14	05/03/91	36.30		71.50	130	80	80	130	80	80
				Day 21	12/03/91	36.30		72.00	130	80	82	130	80	80
				Day 28	13/03/91	36.40		72.00	120	70	85	120	70	85
	245	Imipramine	Female	Screen	18/02/91	36.30	12		110	70	68	110	70	70
				Day 0	22/02/91	36.20		60.00	120	70	68	120	70	68
				Day 7	01/03/91	36.10		60.20	110	70	70	110	70	70
				Day 14	08/03/91	36.20		60.50	110	80	66	110	80	66
				Day 21	15/03/91	36.30		61.00	110	70	72	110	70	72
				Day 28	22/03/91	36.20		61.00	110	70	66	110	70	66
				Day 35	29/03/91	36.30		61.20	115	70	68	115	70	68
				Day 42	05/04/91	36.10		61.50	110	70	70	110	70	70
	246	Placebo	Female	Screen	13/02/91	36.00	18		130	80	80	125	75	85
				Day 0	22/02/91	36.40		63.00	120	80	90	120	80	90
				Day 7	01/03/91	36.20		60.00	160	85	70	160	85	70
				Day 14	08/03/91	36.40		58.00	130	80	70	130	80	70
				Day 21	15/03/91	36.20		58.00	110	60	60	100	60	60
				Day 28	18/03/91	36.90		57.70	130	100	80	130	95	80
	247	Placebo	Female	Screen	20/02/91	36.20	14		105	70	70	105	70	70
				Day 0	25/02/91	36.20			105	70	68	105	70	68
				Day 7	04/03/91	36.30			115	70	74	115	70	70
				Day 14	11/03/91	36.10			110	65	70	110	65	72
				Day 21	18/03/91	36.10			90	60	90	90	60	90
				Day 28	26/03/91	36.20			95	75	78	95	75	78

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
9	248	Placebo	Male	Screen	04/03/91	36.30	13		120	75	74	120	75	74
				Day 0	08/03/91	36.20		81.20	110	70	76	110	70	78
				Day 7	15/03/91	36.20		80.90	100	70	74	100	70	74
				Day 14	22/03/91	36.30		81.10	120	70	78	120	70	78
	249	Reboxetine	Female	Screen	04/03/91	36.00	18		120	70	72	120	70	70
				Day 0	04/03/91	36.00		72.00	110	60	72	110	60	72
	250	Imipramine	Female	Screen	07/03/91	36.00	15		140	100	74	135	98	76
				Day 0	12/03/91	36.40		54.50	130	90	83	130	90	83
				Day 7	19/03/91	35.80		54.00	130	80	80	130	80	80
				Day 14	26/03/91	36.20		54.00	130	80	82	130	80	82
				Day 21	02/04/91	35.90		54.50	130	90	83	130	90	83
				Day 28	08/04/91	36.20		54.50	135	90	80	135	90	80
	251	Imipramine	Female	Screen	18/03/91	36.40	12		120	80	68	120	80	68
				Day 0	20/03/91	36.20		61.00	125	80	76	125	80	76
				Day 7	27/03/91	37.20		61.10	120	80	72	120	80	72
				Day 14	03/04/91	36.30		61.00	120	80	76	120	80	76
				Day 21	10/04/91	36.10		61.00	125	80	80	125	80	80
	252	Reboxetine	Female	Screen	28/03/91	36.40	14		130	90	82	130	90	82
				Day 0	02/04/91	36.30		116.00	140	80	70	140	80	70
				Day 7	09/04/91	36.30		116.00	130	90	78	130	90	78
				Day 14	16/04/91	36.10		115.00	140	70	74	140	70	74
				Day 21	20/04/91	36.10		115.00	150	90	72	150	90	72
	253	Reboxetine	Female	Screen	29/03/91	36.00	15		115	70	80	115	70	80
				Day 0	02/04/91	36.40		67.50	110	80		110	75	
				Day 7	08/04/91	36.20		67.50	115	80	80	110	80	80
	254	Imipramine	Female	Screen	05/04/91	36.10	13		125	80	78	125	80	78
				Day 0	09/04/91	36.10		71.00	130	80	72	130	80	72
				Day 7	16/04/91	36.30		71.00	140	80	70	140	80	70
				Day 14	17/04/91	36.20		71.00	140	80	72	140	80	72
	255	Reboxetine	Female	Screen	08/05/91	36.00	18		130	70	80	130	70	80
				Day 0	13/05/91	36.20		76.00	110	75	80	105	75	80
				Day 7	20/05/91	36.40		76.00	110	70	83	110	70	85
				Day 14	27/05/91	36.40		76.00	115	65	80	110	65	84
				Day 21	03/06/91	36.40		76.00	110	70	80	115	75	88
				Day 28	06/06/91	36.20		76.30	110	70	80	110	70	84

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
9	256	Imipramine	Female	Screen	23/05/91	36.00	15		130	90	80	130	90	83
				Day 0	27/05/91	36.50		56.20	120	80		120	80	
				Day 7	03/06/91	36.90		57.00	100	70	75	110	70	75
				Day 14	10/06/91	36.40		57.00	120	90	80	120	90	85
				Day 21	17/06/91	36.40		57.00	130	90	80	130	90	80
				Day 28	24/06/91	36.40		57.00	120	80	80	120	80	80
				Day 35	01/07/91	36.20		57.00	100	60	83	100	60	85
	257	Placebo	Male	Screen	21/06/91	36.20	12		105	60	80	100	60	80
				Day 0	25/06/91	36.10		64.00	125	80	74	125	80	74
				Day 7	01/07/91	36.10		64.00	100	75	74	100	75	74
	258	Placebo	Male	Screen	26/06/91	36.30	13		100	70	80	100	70	80
				Day 0	01/07/91	36.10		48.50	100	70	70	100	70	70
				Day 7	08/07/91	36.30		48.30	105	70	70	105	70	70
				Day 14	10/07/91	36.40		48.20	100	70	78	100	70	78
11	319	Placebo	Male	Screen	25/07/91	37.00	16		125	85	80	120	85	76
				Day 0	01/08/91	37.00		74.00	120	70	76	120	75	72
				Day 7	08/08/91	37.00		75.00	130	75	72	125	75	72
				Day 14	15/08/91	37.00		75.00	140	80	72	130	80	72
				Day 21	22/08/91	37.00		73.50	130	85	72	125	80	72
				Day 28	29/08/91	37.00		75.00	130	80	72	130	80	72
				Day 35	05/09/91	37.00		75.00	130	80	72	125	80	72
				Day 42	12/09/91	37.00		75.00	130	80	72	125	80	72
	320	Imipramine	Male	Screen	08/08/91	37.00	14		175	80	72	125	80	72
				Day 0	15/08/91	37.00		72.00	110	80	76	110	75	76
				Day 7	22/08/91	37.00		72.00	120	80	76	115	80	76
				Day 14	29/08/91	37.00		72.00	130	90	72	120	80	72
				Day 21	05/09/91	37.00		72.00	120	80	72	110	80	72
				Day 28	12/09/91	37.00		73.00	120	80	76	120	85	76
				Day 35	19/09/91	37.00		74.00	140	100	72	120	90	72
				Day 42	26/09/91	37.00		74.00	120	80	72	120	80	72
	321	Placebo	Male	Screen	27/08/91	37.00	12		130	85	76	130	85	76
				Day 0	05/09/91	37.00		65.00	130	85	76	130	85	76
				Day 7	12/09/91	37.00		65.00	130	100	76	130	95	76
				Day 14	19/09/91	37.00		65.00	130	85	76	130	85	76
				Day 21	26/09/91	37.00		67.00	140	100	72	140	95	72
				Day 28	03/10/91	37.00		67.00	130	90	72	130	90	72
				Day 35	10/10/91	37.00		67.00	130	90	72	130	90	72

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
11	321	Placebo	Male	Day 42	17/10/91	37.00		67.00	140	100	72	130	90	72
	322	Reboxetine	Female	Screen	19/09/91	37.00	14		130	80	76	134	80	76
				Day 0	26/09/91	37.00		73.00	130	85	76	130	80	76
				Day 7	03/10/91	37.00		73.00	120	80	72	120	75	72
				Day 14	10/10/91	37.00		73.00	130	90	72	130	90	72
				Day 21	19/10/91	37.00		73.00	130	85	72	120	80	72
				Day 28	24/10/91	37.00		72.50	130	80	72	110	75	72
				Day 35	31/10/91	37.00		72.00	120	80	72	120	80	72
				Day 42	07/11/91	37.00		73.00	120	80	72	120	80	72
	323	Reboxetine	Male	Screen	05/11/91	37.00	14		130	80	72	130	80	72
				Day 0	14/11/91	37.00		65.00	130	80	72	130	80	72
				Day 7	21/11/91	37.00		63.00	120	80	72	120	80	72
				Day 14	28/11/91	37.00		64.00	130	80	72	125	80	72
				Day 21	05/12/91	37.00		64.00	130	75	72	130	70	72
				Day 28	12/12/91	37.00		64.50	110	90	76	130	85	72
				Day 35	19/12/91	37.00		65.00	130	80	72	130	80	72
				Day 42	27/12/91	37.00		65.00	130	80	72	130	80	72
	324	Imipramine	Male	Screen	29/11/91	37.00	14		130	85	72	130	80	72
				Day 0	05/12/91	37.00		76.00	130	90	76	130	85	72
				Day 7	12/12/91	37.00		75.00	125	90	76	120	85	76
				Day 14	19/12/91	37.00		75.00	120	90	76	120	85	72
				Day 21	27/12/91	37.00		75.00	120	85	76	120	85	72
				Day 28	02/01/92	37.00		75.00	130	90	72	130	90	72
				Day 35	09/01/92	37.00		75.00	130	90	76	130	85	72
				Day 42	16/01/92	37.00		75.00	120	90	76	120	90	76
	325	Reboxetine	Male	Screen	06/12/91	37.00	14		110	75	72	110	72	72
				Day 0	12/12/91	37.00		83.00	110	75	72	110	70	72
				Day 7	19/12/91	37.00		83.00	113	75	72	115	75	72
				Day 14	27/12/91	37.00		83.00	115	75	72	115	75	72
				Day 21	02/01/92	37.00		83.00	120	80	72	120	72	72
				Day 28	09/01/92	37.00		83.00	120	80	72	120	80	72
				Day 35	16/01/92	37.00		83.00	120	80	72	120	80	72
				Day 42	23/01/92	37.00		83.00	120	85	72	115	80	72
	326	Placebo	Male	Screen	14/01/92	37.00	12		130	105	72	130	100	72
				Day 0	16/01/92	37.00		75.00	130	105	72	130	100	72
				Day 7	23/01/92	37.00		75.00	140	100	72	130	100	72
				Day 14	30/01/92	37.00		76.00	140	100	72	110	100	72
				Day 21	06/02/92	37.00		76.00	150	100	72	145	100	72
				Day 28	13/02/92	37.00		76.00	130	100	72	130	100	72

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
11	326	Placebo	Male	Day 35	20/02/92	37.00		76.00	130	100	72	125	100	72
				Day 42	27/02/92	37.00		76.00	130	100	72	130	100	72
	327	Imipramine	Male	Screen	23/01/92	37.00	12		120	70	72	120	70	72
				Day 0	29/01/92	37.00		64.50	120	70	72	115	70	72
				Day 7	05/02/92	37.00		64.00	120	80	72	120	80	72
	328	Imipramine	Female	Screen	28/01/92	37.00	14		110	80	76	110	80	76
				Day 0	30/01/92	37.00		60.00	110	75	76	110	75	76
				Day 7	05/02/92	37.00		60.00	110	80	72	110	70	72
	329	Placebo	Female	Screen	01/04/92	37.00	12		140	95	72	140	95	72
				Day 0	09/04/92	37.00		86.00	140	95	76	140	95	72
				Day 7	16/04/92	37.00		87.00	140	95	76	140	95	76
				Day 14	23/04/92	37.00		88.00	145	95	76	140	95	72
				Day 21	30/04/92	37.00		88.00	160	110	72	160	110	72
				Day 28	07/05/92	37.00		87.00	140	105	72	140	105	72
				Day 35	14/05/92	37.00		89.00	140	90	72	140	90	72
				Day 42	21/05/92	37.00		89.00	135	90	72	140	90	72
	330	Reboxetine	Male	Screen	06/04/92	37.00	14		120	80	76	120	80	76
				Day 0	09/04/92	37.00		69.00	120	90	76	120	80	76
				Day 7	16/04/92	37.00		69.00	125	80	76	120	80	72
				Day 14	23/04/92	37.00		69.00	120	80	72	120	80	72
				Day 21	30/04/92	37.00		69.00	120	85	78	120	80	72
				Day 28	07/05/92	37.00		69.00	125	80	72	120	80	72
				Day 35	14/05/92	37.00		69.00	120	85	72	120	85	72
				Day 42	21/05/92	37.00		69.00	120	85	76	120	85	72
	331	Imipramine	Male	Screen	08/04/92	37.00	14		120	85	72	120	85	72
				Day 0	16/04/92	37.00		74.00	120	85	72	120	85	72
				Day 7	23/04/92	37.00		74.00	130	90	72	130	90	72
				Day 14	30/04/92	37.00		74.50	130	90	72	130	90	72
				Day 21	07/05/92	37.00		75.00	130	90	72	130	90	72
				Day 28	14/05/92	37.00		75.00	130	90	76	125	90	72
				Day 35	21/05/92	37.00		75.00	130	90	72	130	90	72
				Day 42	28/05/92	37.00		75.00	130	90	72	130	90	72
	332	Reboxetine	Male	Screen	13/05/92	37.00	12		130	85	72	130	85	72
				Day 0	18/05/92	37.00		79.00	130	85	72	130	85	72
				Day 7	26/05/92	37.00		79.00	130	80	76	130	80	72
				Day 14	01/06/92	37.00		79.00	130	80	72	130	80	72
				Day 21	08/06/92	37.00		79.00	130	80	76	130	80	76

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
11	332	Reboxetine	Male	Day 28	15/06/92	37.00		79.00	125	85	72	125	85	72
				Day 35	22/06/92	37.00		79.00	120	80	72	120	80	72
				Day 42	29/06/92	37.00		79.00	120	80	72	120	80	72
	333	Placebo	Male	Screen	18/05/92	37.00	17		130	85	76	130	85	72
				Day 0	26/05/92	37.00		133.00	130	85	72	130	85	72
				Day 7	02/06/92	37.00		133.00	130	80	72	130	80	72
				Day 14	09/06/92	37.00		133.00	130	85	72	130	85	72
				Day 21	16/06/92	37.00		133.00	130	80	72	130	80	72
				Day 28	23/06/92	37.00		133.00	130	80	72	130	80	72
				Day 35	30/06/92	37.00		133.00	130	80	72	130	80	72
				Day 42	07/07/92	37.00		133.00	130	80	72	130	80	72
	334	Reboxetine	Female	Screen	24/05/92	37.00	12		110	75	68	110	75	68
				Day 0	28/05/92	37.00		43.00	110	75	76	110	70	72
				Day 7	01/06/92	37.00			95	65	80	90	60	80
	335	Placebo	Male	Screen	21/05/92	37.00	12		110	70	72	110	70	72
				Day 0	02/06/92	37.00		103.00	110	75	72	110	75	72
				Day 7	09/06/92	37.00		103.00	110	70	72	110	70	72
				Day 14	16/06/92	37.00		103.00	110	75	72	110	75	72
				Day 21	23/06/92	37.00		103.00	110	80	72	110	80	72
				Day 28	30/06/92	37.00		103.00	110	80	72	110	80	72
				Day 35	07/07/92	37.00		103.00	115	85	72	115	85	72
				Day 42	14/07/92	37.00		103.00	115	80	72	115	80	72
	336	Imipramine	Female	Screen	15/06/92	37.00	14		130	95	76	130	95	76
				Day 0	18/06/92	37.00		99.50	130	95	76	130	90	76
				Day 7	25/06/92	37.00		99.00	130	80	76	130	80	76
	337	Reboxetine	Female	Screen	16/06/92	37.00	12		110	70	72	110	70	72
				Day 0	02/07/92	37.00		64.00	110	70	72	110	70	72
				Day 7	09/07/92	37.00		64.00	120	75	72	120	75	72
				Day 14	16/07/92	37.00		64.00	120	75	72	120	75	72
				Day 21	23/07/92	37.00		64.00	105	65	72	100	65	72
				Day 28	30/07/92	37.00		64.00	110	65	76	110	65	76
				Day 35	06/08/92	37.00		64.00	115	65	76	110	65	76
				Day 42	13/08/92	37.00		64.00	115	60	76	115	60	76
	338	Imipramine	Male	Screen	14/07/92	37.00	14		120	70	76	120	70	76
				Day 0	23/07/92	37.00		75.00	120	70	76	120	70	76
				Day 7	30/07/92	37.00		75.00	110	70	76	110	70	76

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
12	367	Reboxetine	Female	Screen	17/12/91	37.00	20		144	80	78	136	80	92
				Day 0	20/12/91	37.50		50.10	138	84	76	134	84	74
				Day 7	27/12/91	36.70		52.90	104	70	78	90	58	80
				Day 14	03/01/92	36.80		51.00	124	86	78	100	78	90
				Day 21	10/01/92	36.00		52.70	104	70	78	110	80	78
				Day 28	16/01/92	36.30		52.70	100	50	92	90	60	88
				Day 35	23/01/92	35.40		53.40	112	70	84	90	60	90
				Day 42	31/01/92	36.50		56.20	106	72	72	98	52	86
	368	Placebo	Female	Screen	19/12/91	36.90	16		124	78	76	110	70	90
				Day 0	24/12/91	36.40		96.20	104	60	74	100	62	90
				Day 7	31/12/91	36.80		96.00	112	74	70	110	80	86
				Day 14	07/01/92	36.80		96.00	102	64	70	100	68	84
				Day 21	14/01/92	36.70		96.30	108	72	64	110	78	72
				Day 28	21/01/92	34.70		98.00	110	64	72	110	60	80
				Day 35	28/01/92	36.40		98.00	102	70	72	98	66	74
				Day 42	04/02/92	36.70		96.50	92	60	72	98	62	70
	369	Imipramine	Female	Screen	17/04/92	36.30	24		116	89	97	113	90	90
				Day 0	22/04/92	36.50		70.40	112	86	97	114	84	95
				Day 7	29/04/92	36.30		71.30	112	72	84	98	70	88
				Day 14	06/05/92	36.30		70.80	126	90	80	102	80	84
				Day 21	13/05/92	36.40		71.30	118	76	66	102	76	71
	370	Placebo	Male	Screen	23/04/92	36.30	24		160	94	84	140	92	92
				Day 0	28/04/92	36.50		89.20	136	74	76	130	72	80
				Day 7	05/05/92	36.40		89.90	126	80	70	110	72	88
				Day 14	12/05/92	36.30		89.40	158	86	69	146	80	78
				Day 21	19/05/92	37.00		88.50	172	86	76	114	70	82
				Day 28	20/05/92	37.00		88.50	148	86	74	112	80	82
	371	Imipramine	Female	Screen	27/04/92	36.40	20		110	60	70	100	70	66
				Day 0	01/05/92	36.70		71.70	100	70	56	110	74	58
				Day 7	08/05/92	37.00		72.60	114	76	72	104	72	84
	372	Reboxetine	Male	Screen	28/05/92	36.30	24		160	110	66	120	50	68
				Day 0	02/06/92	36.00		141.00	160	108	68	120	80	67
				Day 7	08/06/92	36.00		138.00	142	102	66	110	80	80
				Day 14	15/06/92	36.50		136.00	160	120	76	114	80	80
				Day 21	22/06/92	37.00		135.00	150	100	72	120	84	67
				Day 28	30/06/92	37.00		133.00	140	100	76	120	90	72
				Day 35	06/07/92	36.00		132.00	170	112	66	110	80	80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
12	372	Reboxetine	Male	Day 42	13/07/92	37.30		130.00	170	114	64	110	80	72
	373	Reboxetine	Male	Screen	03/06/92	36.40	16		118	74	76	112	70	80
				Day 0	05/06/92	36.20		71.70	114	72	70	110	70	72
				Day 7	11/06/92	36.20		72.00	110	72	72	97	64	90
				Day 14	18/06/92	36.40		71.00	100	60	70	98	66	86
				Day 21	25/06/92	36.20		75.50	120	74	74	104	62	92
				Day 28	02/07/92	36.80		74.90	110	60	76	102	68	84
				Day 35	09/07/92	36.50		74.30	104	70	62	108	68	70
				Day 42	16/07/92	36.50		72.40	102	70	78	104	72	80
	374	Placebo	Female	Screen	03/06/92	36.00	24		106	68	72	98	56	80
				Day 0	09/06/92	37.00		71.20	102	68	70	96	70	76
				Day 7	15/06/92	36.20		72.10	116	72	70	114	78	74
				Day 14	22/06/92	36.30		72.60	120	72	73	102	68	76
				Day 21	30/06/92	36.20		76.30	100	68	70	110	72	68
				Day 28	06/07/92	34.40		72.00	120	78	59	110	68	66
	375	Imipramine	Male	Screen	11/06/92	35.70	16		98	52	64	90	52	76
				Day 0	15/06/92	37.00		70.30	100	70	62	90	50	74
13	13	Placebo	Male	Screen	11/04/91	37.00	20		130	70	80	125	70	82
				Day 0	12/04/91	37.00		80.00	130	80	78	125	80	84
				Day 7	19/04/91	36.80		80.00	100	80	76	95	75	80
				Day 14	26/04/91	36.80		81.00	95	80	76	100	80	80
				Day 21	03/05/91	36.70		79.20	105	75	68	95	75	70
				Day 28	10/05/91	36.20		80.00	95	68	66	98	60	70
				Day 35	17/05/91	36.70		78.00	95	65	68	90	65	76
				Day 42	24/05/91	36.60		78.40	95	65	68	105	70	76
	14	Placebo	Male	Screen	02/07/91	37.00	18		100	75	76	105	80	82
				Day 0	02/07/91	36.80		78.00	100	65	76	95	65	78
				Day 7	09/07/91	36.80		78.00	110	75	80	100	80	80
				Day 14	16/07/91	37.00		76.00	95	70	70	90	75	74
				Day 21	23/07/91	37.00		75.50	95	75	72	105	80	76
				Day 28	30/07/91	36.80		74.50	110	85	72	110	90	72
				Day 35	06/08/91	36.60		76.00	95	70	66	105	75	68
				Day 42	13/08/91	36.80		76.50	120	75	78	120	80	80
	15	Imipramine	Female	Screen	04/07/91	36.80	18		100	70	78	100	70	86
				Day 0	04/07/91	37.10		80.00	110	75	78	100	70	80
				Day 7	11/07/91	37.00		79.90	105	85	80	100	70	84
				Day 14	18/07/91	36.70		80.80	120	90	72	120	80	76

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
13	15	Imipramine	Female	Day 21	25/07/91	36.50		80.80	110	90	80	110	90	80
				Day 28	01/08/91	36.50		80.80	110	90	80	110	80	84
				Day 35	08/08/91	36.60		81.10	120	80	72	120	80	72
				Day 42	15/08/91	36.80		80.10	120	80	80	120	75	84
	16	Imipramine	Male	Screen	02/12/91	37.00	16		120	80	64	130	75	70
				Day 0	02/12/91	37.00		95.00	120	80	74	120	80	80
				Day 7	16/12/91	36.60		95.00	120	85	78	120	80	80
				Day 14	20/12/91	36.80		95.40	120	90	76	105	90	82
				Day 21	30/12/91	37.00		95.00	115	80	90	110	80	100
				Day 28	06/01/92	36.60		94.00	100	80	92	100	80	100
				Day 35	10/01/92	36.60		94.00	115	80	80	105	85	86
				Day 42	20/01/92	36.80		94.00	120	85	86	110	85	94
	17	Reboxetine	Male	Screen	20/05/92	36.50	16		115	80	68	110	70	72
				Day 0	20/05/92	36.80		65.00	115	80	80	110	70	72
				Day 7	27/05/92	36.80		65.40	110	75	80	105	75	96
				Day 14	03/06/92	36.60		64.00	125	75	76	105	80	88
				Day 21	11/06/92	36.60		65.00	110	80	72	100	80	84
				Day 28	17/06/92	36.60		65.00	115	75	76	100	80	88
				Day 35	24/06/92	36.60		64.00	105	80	76	130	85	84
				Day 42	02/07/92	36.60		64.00	95	70	80	85	65	92
	18	Reboxetine	Male	Screen	23/06/92	36.80			110	80	80	105	80	88
				Day 0	23/06/92	36.80		82.00	110	80	80	105	80	88
				Day 7	30/06/92	36.60		82.50	120	85	88	105	70	100
				Day 14	06/07/92	36.60		82.00	130	75	90	135	80	105
				Day 21	13/07/92	36.60		81.70	115	80	92	100	80	98
				Day 28	20/07/92	36.60		81.30	120	75	84	105	80	96
				Day 35	27/07/92	36.60		81.60	115	85	86	100	85	96
				Day 42	03/08/92	36.60		81.50	115	80	80	105	75	86
	409	Reboxetine	Male	Screen	09/12/91	37.00	16		135	95	78	140	100	82
				Day 0	09/12/91	37.00		68.00	130	95	80	140	100	84
				Day 7	16/12/91	36.80		68.00	130	90	74	135	85	74
				Day 14	23/12/91	36.60		68.00	130	95	84	145	100	78
				Day 28	06/01/92	36.80		67.00	135	90	86	120	90	90
				Day 42	20/01/92	36.60		65.00	135	80	100	120	80	100
	410	Placebo	Male	Screen	10/02/92	36.80			115	75	80	120	80	92
				Day 0	14/02/92	36.90		64.00	110	80	76	130	90	86
				Day 7	20/02/92	37.00		62.00	120	80	78	120	85	78
				Day 14	27/02/92	36.80		61.00	125	80	72	120	85	72
				Day 21	05/03/92	36.80		61.00	115	80	72	130	95	76

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
13	410	Placebo	Male	Day 28	12/03/92	36.80		61.00	125	90	80	120	90	76
				Day 35	19/03/92	36.80		61.00	120	80	72	110	90	84
				Day 42	26/03/92	36.80		61.00	115	90	76	105	85	84
	411	Imipramine	Female	Screen	26/03/92	36.80	20		100	60	80	90	60	88
				Day 0	26/03/92	36.80		46.70	100	60	80	90	60	88
				Day 7	06/04/92	36.80		48.00	105	60	84	85	60	86
				Day 14	13/04/92	36.60		47.20	110	60	68	100	55	74
				Day 21	22/04/92	36.80		49.20	100	60	76	90	60	82
				Day 28	27/04/92	36.50		47.50	100	70	78	95	65	82
				Day 35	04/05/92	36.60		47.50	100	70	82	90	60	82
				Day 42	11/05/92	36.40		47.80	110	60	92	85	60	104
	423	Placebo	Male	Screen	14/09/92	36.80	14		120	90	80	130	100	86
				Day 0	14/09/92	36.40		87.20	125	90	90	135	110	94
				Day 7	21/09/92	36.80		87.20	120	95	84	130	105	88
				Day 14	29/09/92	36.60		85.50	115	90	80	110	85	84
				Day 21	05/10/92	36.40		87.20	110	80	68	100	70	76
				Day 42	28/10/92	36.60		88.00	140	95	80	135	100	84
14	19	Reboxetine	Female	Screen	03/04/92	37.00	12		130	100	92	140	100	90
				Day 0	10/04/92	36.50		89.00	150	90	80	130	80	80
				Day 7	17/04/92	36.00		85.70	140	90	82	120	90	80
				Day 14	24/04/92	36.50		87.70	110	70	100	100	60	
				Day 21	01/05/92	36.50		86.00	110	70	90	100	70	92
				Day 28	07/05/92	37.00		85.70	140	120	80	90	80	82
	20	Imipramine	Female	Screen	27/04/92	37.00	16		140	90	86	120	70	80
				Day 0	29/04/92	36.00		85.00	145	80		120	70	
				Day 7	06/05/92	36.00		86.50	120	80	100	105	70	100
				Day 14	13/05/92	36.50		85.60	140	70	100	100	70	102
				Day 21	20/05/92	36.50		87.70	150	80	70	135	80	70
				Day 28	27/05/92	36.00		88.00	120	80	80	150	90	80
				Day 35	02/06/92	36.60		91.50	160	90	88	130	80	90
				Day 42	10/06/92	37.00		91.00	150	90	88	130	80	86
	21	Imipramine	Female	Screen	15/07/92	39.00	12		160	90	100	140	90	110
				Day 0	20/07/92	36.40		83.00	160	90	100	140	90	112
				Day 7	27/07/92	36.00		82.70	150	95	100	125	90	96
				Day 14	03/08/92	36.60		83.00	100	75	92	110	80	94
				Day 21	12/08/92	36.50		83.70	120	80	90	120	80	90
				Day 28	17/08/92	36.50		84.00	110	70	92	100	70	94
				Day 35	24/08/92	36.10		86.00	120	80	92	120	80	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
15	25	Reboxetine	Female	Screen	17/06/91	36.60	15		138	80	90	136	80	86
				Day 0	18/06/91	36.60		65.00	138	80	90	136	80	86
				Day 7	25/06/91	36.60		65.00	140	80	92	142	80	96
				Day 14	02/07/91	36.60		65.50	136	78	94	146	80	96
				Day 21	09/07/91	36.40		65.00	140	80	90	136	80	90
				Day 28	16/07/91	36.60		64.50	142	84	86	140	80	90
				Day 35	23/07/91	36.80		65.00	140	82	88	136	86	86
				Day 42	30/07/91	36.80		65.00	140	86	90	136	86	94
	26	Placebo	Male	Screen	17/06/91	36.40	12		134	90	80	132	94	80
				Day 0	20/06/91	36.40		80.00	134	90	80	132	94	80
				Day 7	27/06/91	36.60		80.00	134	92	78	132	90	84
				Day 14	04/07/91	36.40		79.00	134	90	84	132	92	80
				Day 21	11/07/91	36.60		79.00	134	82	84	128	80	86
				Day 28	18/07/91			78.00	134	86	90	130	86	92
				Day 35	25/07/91	36.80		77.50	140	88	92	136	88	90
				Day 42	01/08/91	36.60		76.00	134	90	86	128	90	88
	27	Imipramine	Female	Screen	27/06/91	36.40	13		104	74	78	102	74	76
				Day 0	02/07/91	36.40		40.00	104	74	78	102	74	76
				Day 7	09/07/91	36.60		41.00	104	70	72	100	70	76
				Day 14	17/07/91	36.40		41.00	98	70	76	100	72	76
				Day 21	23/07/91	36.80		41.50	100	70	70	96	72	68
				Day 28	30/07/91	36.40		41.50	104	74	70	106	74	74
				Day 35	06/08/91	36.60		42.00	120	80	76	120	80	74
				Day 42	13/08/91	36.40		43.00	110	78	72	108	78	72
	28	Reboxetine	Female	Screen	06/08/91	36.60	12		108	70	68	110	74	70
				Day 0	08/08/91	36.60		82.00	108	70	68	110	74	70
				Day 7	15/08/91	36.60		81.00	110	70	90	110	74	86
				Day 14	22/08/91	36.40		80.00	124	80	82	120	80	82
				Day 21	29/08/91	36.60		79.50	116	78	104	110	80	106
				Day 28	05/09/91	36.40		79.00	114	70	82	118	74	84
				Day 35	12/09/91	36.40		79.00	118	76	96	114	80	100
				Day 42	20/09/91	36.60		79.00	120	70	86	120	74	86
	29	Placebo	Male	Screen	29/08/91	36.40	14		122	82	90	120	80	88
				Day 0	29/08/91	36.40		87.00	122	82	90	120	80	88
				Day 7	05/09/91	36.80		88.50	130	90	84	132	94	84
				Day 14	13/09/91	36.60		89.00	124	88	76	126	90	76
				Day 21	19/09/91	36.40		90.00	128	86	78	126	86	82

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
15	30	Imipramine	Female	Screen	03/09/91	36.40	12		108	80	76	106	80	80
				Day 0	03/09/91	36.40		85.00	108	80	76	106	80	80
				Day 7	10/09/91	36.60		84.00	110	80	82	110	82	86
				Day 14	17/09/91	36.40		84.00	114	80	84	110	80	88
				Day 21	24/09/91	36.80		84.00	118	80	86	116	84	90
				Day 28	01/10/91	36.40		84.00	110	80	88	106	80	90
				Day 35	08/10/91	36.60		84.50	114	84	80	116	84	84
				Day 42	15/10/91	36.40		83.50	112	80	94	114	82	90
	403	Imipramine	Female	Screen	04/10/91	36.40	14		140	90	76	138	86	78
				Day 0	04/10/91	36.40		61.00	140	90	76	138	86	78
				Day 7	11/10/91	36.60		61.50	130	90	86	130	88	90
				Day 14	18/10/91	36.40		61.00	104	80	84	100	80	88
				Day 21	25/10/91	36.60		60.00	114	80	84	104	80	88
				Day 28	31/10/91	36.40		60.00	110	80	86	104	76	90
				Day 35	08/11/91	36.60		60.00	116	80	82	114	80	78
				Day 42	14/11/91	36.40		60.00	116	80	96	100	80	100
	404	Reboxetine	Female	Screen	08/10/91	36.80	13		120	76	78	118	76	76
				Day 0	08/10/91	36.80		67.00	120	76	78	118	76	76
				Day 7	15/10/91	36.80		67.00	104	70	86	102	70	90
				Day 14	22/10/91	36.60		67.50	100	70	90	104	72	88
				Day 21	29/10/91	36.80		68.00	108	72	80	104	70	82
				Day 28	05/11/91	36.80		68.00	100	76	80	104	78	80
	405	Placebo	Female	Screen	11/11/91	36.40	12		120	80	68	116	80	72
				Day 0	11/11/91	36.40		56.50	120	80	68	116	80	72
				Day 7	18/11/91	36.80		56.50	104	76	74	102	76	76
				Day 14	25/11/91	36.80		56.50	100	70	70	102	70	72
				Day 21	02/12/91	36.60		55.50	96	70	78	96	70	80
				Day 28	10/12/91	36.60		56.50	100	70	70	96	70	70
				Day 35	16/12/91	36.60		56.50	94	70	76	94	72	76
				Day 42	23/12/91	36.80		56.50	100	74	72	102	74	70
	406	Imipramine	Male	Screen	27/11/91	36.80	16		114	82	86	114	84	86
				Day 0	27/11/91	36.80		77.00	114	82	86	114	86	86
				Day 7	03/12/91	36.80		78.00	126	90	98	120	90	110
				Day 14	10/12/91	36.80		78.00	134	92	90	124	90	88
				Day 21	17/12/91	36.80		78.00	136	90	96	132	92	94
				Day 28	24/12/91	36.60		78.00	124	90	86	120	90	88
				Day 35	31/12/91	36.60		79.00	126	90	88	124	90	88
				Day 42	07/01/92	36.80		80.00	120	90	86	114	86	86
	407	Reboxetine	Female	Screen	02/12/91	36.60	14		126	82	70	130	80	72

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
15	407	Reboxetine	Female	Day 0	03/12/91	36.60		52.50	126	82	70	130	80	72
				Day 7	10/12/91	36.60		52.00	106	76	78	104	76	82
				Day 14	17/12/91	36.80		52.50	104	74	86	102	74	88
				Day 21	24/12/91	36.80		52.50	104	74	86	104	70	90
				Day 28	31/12/91	36.80		53.00	116	74	80	110	76	80
				Day 35	07/01/92	36.80		52.00	112	80	78	114	78	82
				Day 42	14/01/92	36.80		53.50	116	80	80	112	80	84
	408	Placebo	Female	Screen	20/01/92	36.90	18		110	70	72	105	66	72
				Day 0	20/01/92	36.90		80.00	110	70	72	105	66	72
				Day 7	28/01/92	36.80		78.50	114	80	90	110	80	92
				Day 14	03/02/92	36.60		76.50	110	78	96	106	80	96
				Day 21	10/02/92	36.80		78.00	120	80	86	114	80	86
				Day 28	17/02/92	36.80		79.00	120	80	98	106	74	96
				Day 35	25/02/92	37.00		77.50	110	84	72	110	84	70
				Day 42	04/03/92	36.80		76.00	118	80	78	114	80	80
	418	Placebo	Female	Screen	30/01/92	36.60	14		120	70	76	120	68	76
				Day 0	30/01/92	36.60		58.50	120	70	76	120	68	76
				Day 7	06/02/92	36.80		58.50	124	80	84	120	80	86
				Day 14	13/02/92	36.60		58.00	122	76	80	124	78	80
				Day 21	20/02/92	36.60		59.00	130	70	80	126	70	88
				Day 28	27/02/92	36.80		58.00	122	76	80	112	76	80
				Day 35	05/03/92	36.60		57.50	120	76	74	122	76	76
				Day 42	12/03/92	36.70		58.00	120	78	74	122	78	74
	419	Placebo	Female	Screen	27/04/92	36.80	16		100	70	76	102	70	80
				Day 0	28/04/92	36.40		56.50	100	70	76	102	70	80
				Day 7	05/05/92	36.60		56.50	104	70	74	100	72	76
				Day 14	12/05/92	36.70		56.50	108	70	76	108	72	76
				Day 21	19/05/92	36.90		56.00	106	72	76	102	74	74
				Day 28	26/05/92	36.90		57.50	110	72	76	106	74	78
				Day 35	02/06/92	36.80		58.00	108	70	82	106	74	78
				Day 42	09/06/92	36.80		58.50	110	74	70	106	74	72

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
1	1	Imipramine	Female	10/04/91	22/05/91	Screen	0	Screening	10/04/91	Normal	
						Day 21	21	1-21 days	01/05/91	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 42	42	22-42 days	22/05/91	Abnormal	SINUS TACHYCARDIA (> 100)
	2	Reboxetine	Male	15/04/91	27/05/91	Screen	-4	Screening	11/04/91	Normal	
						Day 21	21	1-21 days	06/05/91	Normal	
						Day 42	42	22-42 days	27/05/91	Normal	
	3	Imipramine	Male	06/05/91	16/06/91	Screen	-4	Screening	02/05/91	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 21	21	1-21 days	27/05/91	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 42	42	22-42 days	17/06/91	Normal	
	4	Placebo	Male	04/06/91	16/07/91	Screen	0	Screening	04/06/91	Normal	
						Day 21	21	1-21 days	25/06/91	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 42	42	22-42 days	16/07/91	Abnormal	SINUS BRADYCARDIA (< 60)
	5	Reboxetine	Female	12/06/91	02/07/91	Screen	0	Screening	12/06/91	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 21	20	1-21 days	02/07/91	Normal	
	6	Placebo	Female	23/05/91	05/07/91	Screen	1	Screening	24/05/91	Normal	
						Day 21	21	1-21 days	13/06/91	Normal	
						Day 42	46	22-42 days	08/07/91	Normal	
	7	Reboxetine	Female	27/08/91	08/10/91	Screen	1	Screening	28/08/91	Normal	
	8	Placebo	Male	05/09/91	19/10/91	Screen	0	Screening	05/09/91	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 42	46	22-42 days	21/10/91	Normal	
	9	Reboxetine	Female	27/11/91	06/01/92	Screen	0	Screening	27/11/91	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 42	40	22-42 days	06/01/92	Normal	
	10	Placebo	Male	24/09/91	04/11/91	Screen	1	Screening	25/09/91	Normal	
						Day 21	21	1-21 days	15/10/91	Normal	
						Day 42	41	22-42 days	04/11/91	Normal	
	11	Imipramine	Female	10/10/91	13/10/91	Screen	0	Screening	10/10/91	Normal	
	12	Imipramine	Female	18/10/91	30/11/91	Screen	3	Screening	21/10/91	Normal	
						Day 42	46	22-42 days	03/12/91	Abnormal	SINUS BRADYCARDIA (< 60)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
1	412	Reboxetine	Male	13/11/91	23/12/91	Screen	-1	Screening	12/11/91	Normal	
						Day 21	22	1-21 days	05/12/91	Normal	
						Day 42	40	22-42 days	23/12/91	Normal	
	413	Placebo	Male	09/12/91	20/01/92	Screen	-6	Screening	03/12/91	Normal	
						Day 21	21	1-21 days	30/12/91	Normal	
						Day 42	42	22-42 days	20/01/92	Normal	
	414	Imipramine	Female	22/01/92	29/01/92	Screen	-4	Screening	18/01/92	Normal	
	415	Imipramine	Male	14/01/92	27/02/92	Screen	0	Screening	14/01/92	Normal	
						Day 21	23	1-21 days	06/02/92	Normal	
						Day 42	44	22-42 days	27/02/92	Normal	
	416	Reboxetine	Female	17/01/92	28/01/92			Screening			
	421	Imipramine	Male	27/02/92	09/04/92	Screen	0	Screening	27/02/92	Normal	
						Day 21	21	1-21 days	19/03/92	Normal	
						Day 42	42	22-42 days	09/04/92	Normal	
	422	Imipramine	Male	05/08/92	17/09/92	Day 21	21	1-21 days	26/08/92	Normal	
						Day 42	44	22-42 days	18/09/92	Normal	
2/1	49	Placebo	Female	18/05/91	28/06/91	Screen	-1	Screening	17/05/91	Normal	
						Day 21	23	1-21 days	10/06/91	Normal	
						Day 42	42	22-42 days	29/06/91	Normal	
	50	Reboxetine	Female	27/12/91	06/02/92	Screen	-3	Screening	24/12/91	Normal	
						Day 21	20	1-21 days	16/01/92	Abnormal	ATRIAL ECTOPIC BEATS - OCCASIONAL
						Day 42	41	22-42 days	06/02/92	Normal	
	51	Imipramine	Female	02/02/92	15/03/92	Screen	-5	Screening	28/01/92	Normal	
						Day 21	23	1-21 days	25/02/92	Abnormal	RIGHT BUNDLE BRANCH BLOCK
						Day 42	43	22-42 days	16/03/92	Abnormal	RIGHT BUNDLE BRANCH BLOCK
2/2	43	Imipramine	Female	18/04/91	16/05/91	Screen	-7	Screening	11/04/91	Normal	
						Day 28	28	22-42 days	16/05/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
2/2	44	Imipramine	Female	19/07/91	29/08/91	Screen	-7	Screening	12/07/91	Normal	
						Day 21	20	1-21 days	08/08/91	Normal	
						Day 42	40	22-42 days	28/08/91	Normal	
	45	Reboxetine	Female	08/09/91	20/10/91	Screen	-12	Screening	27/08/91	Abnormal	SINUS BRADYCARDIA (< 60) ATRIAL ECTOPIC BEATS - OCCASIONAL
						Day 21	22	1-21 days	30/09/91	Normal	
						Day 42	43	22-42 days	21/10/91	Abnormal	SINUS BRADYCARDIA (< 60)
	46	Placebo	Female	26/09/91	23/10/91	Screen	-8	Screening	18/09/91	Normal	
						Day 28	27	22-42 days	23/10/91	Normal	
	47	Placebo	Female	24/03/92	04/05/92	Screen	-11	Screening	13/03/92	Normal	
						Day 21	21	1-21 days	14/04/92	Normal	
						Day 42	44	22-42 days	07/05/92	Normal	
	48	Reboxetine	Female	07/04/92	19/05/92	Screen	-4	Screening	03/04/92	Normal	
						Day 21	21	1-21 days	28/04/92	Normal	
						Day 42	43	22-42 days	20/05/92	Normal	
2/3	36/A	Imipramine	Male	07/03/91	17/04/91	Screen	1	Screening	08/03/91	Normal	
						Day 21	21	1-21 days	28/03/91	Normal	
						Day 42	41	22-42 days	17/04/91	Normal	
	37	Reboxetine	Female	27/03/91	07/05/91	Screen	-9	Screening	18/03/91	Normal	
						Day 21	20	1-21 days	16/04/91	Normal	
						Day 42	47	22-42 days	13/05/91	Normal	
	38	Placebo	Male	14/08/91	25/09/91	Screen	-2	Screening	12/08/91	Normal	
						Day 21	22	1-21 days	05/09/91	Normal	
						Day 42	55	22-42 days	08/10/91	Normal	
	39	Imipramine	Female	10/08/91	20/09/91	Screen	-4	Screening	06/08/91	Normal	
						Day 21	20	1-21 days	30/08/91	Normal	
						Day 42	38	22-42 days	17/09/91	Normal	
	40	Reboxetine	Female	24/10/91	04/12/91	Screen	0	Screening	24/10/91	Normal	
						Day 21	21	1-21 days	14/11/91	Normal	
						Day 42	42	22-42 days	05/12/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
2/3	41	Placebo	Male	03/10/91	13/11/91	Screen	-7	Screening	26/09/91	Normal	
						Day 21	21	1-21 days	24/10/91	Normal	
						Day 42	42	22-42 days	14/11/91	Normal	
	42	Imipramine	Female	19/05/92	30/06/92	Screen	-12	Screening	07/05/92	Normal	
						Day 21	21	1-21 days	09/06/92	Normal	
						Day 42	49	22-42 days	07/07/92	Normal	
2/4	31	Placebo	Male	26/03/91	05/05/91	Screen	-6	Screening	20/03/91	Normal	
						Day 21	20	1-21 days	15/04/91	Normal	
						Day 42	34	22-42 days	29/04/91	Normal	
	32	Reboxetine	Male	26/10/91	06/12/91	Screen	-10	Screening	16/10/91	Abnormal	ATRIAL FIBRILLATION / FLUTTER
						Day 21	20	1-21 days	15/11/91	Abnormal	ATRIAL FIBRILLATION / FLUTTER
						Day 42	41	22-42 days	06/12/91	Abnormal	ATRIAL FIBRILLATION / FLUTTER
	33	Imipramine	Male	29/05/91	10/07/91	Screen	-2	Screening	27/05/91	Normal	
						Day 21	21	1-21 days	19/06/91	Normal	
						Day 42	77	22-42 days	14/08/91	Normal	
	34	Placebo	Female	17/04/92	28/05/92	Screen	-7	Screening	10/04/92	Normal	
						Day 21	24	1-21 days	11/05/92	Normal	
						Day 42	42	22-42 days	29/05/92	Normal	
	35	Reboxetine	Female	15/09/92	26/10/92	Screen	-7	Screening	08/09/92	Normal	
						Day 21	21	1-21 days	06/10/92	Normal	
						Day 42	42	22-42 days	27/10/92	Normal	
	36	Imipramine	Female	12/02/92	24/03/92	Screen	-7	Screening	05/02/92	Normal	
						Day 21	21	1-21 days	04/03/92	Normal	
						Day 42	42	22-42 days	25/03/92	Normal	
2/5	73	Placebo	Male	07/02/92	20/03/92	Screen	-4	Screening	03/02/92	Normal	
						Day 21	21	1-21 days	28/02/92	Normal	
						Day 42	42	22-42 days	20/03/92	Normal	
	74	Reboxetine	Male	21/06/92	01/08/92	Screen	-4	Screening	17/06/92	Normal	
						Day 21	21	1-21 days	12/07/92	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 42	41	22-42 days	01/08/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
2/5	75	Imipramine	Male	11/09/92	22/10/92	Screen	-7	Screening	04/09/92	Normal	
						Day 21	20	1-21 days	01/10/92	Normal	
						Day 42	41	22-42 days	22/10/92	Normal	
	76	Imipramine	Female	15/09/92	26/10/92	Screen	-3	Screening	12/09/92	Normal	
						Day 21	22	1-21 days	07/10/92	Normal	
						Day 42	40	22-42 days	25/10/92	Normal	
	77	Placebo	Male	22/09/92	02/11/92	Screen	-6	Screening	16/09/92	Normal	
						Day 21	20	1-21 days	12/10/92	Normal	
						Day 42	41	22-42 days	02/11/92	Normal	
	78	Reboxetine	Female	10/10/92	13/11/92	Screen	-9	Screening	01/10/92	Normal	
						Day 21	19	1-21 days	29/10/92	Normal	
2/6	55	Reboxetine	Female	12/06/92	23/07/92	Screen	4	Screening	16/06/92	Normal	
						Day 42	39	22-42 days	21/07/92	Normal	
	56	Reboxetine	Female	12/06/92	23/07/92	Screen	4	Screening	16/06/92	Normal	
						Day 42	42	22-42 days	24/07/92	Abnormal	ATRIAL ECTOPIC BEATS - OCCASIONAL
	57	Imipramine	Female	05/05/92	15/06/92	Screen	-5	Screening	30/04/92	Normal	
						Day 42	42	22-42 days	16/06/92	Normal	
	58	Placebo	Female	18/05/92	29/06/92	Screen	0	Screening	18/05/92	Normal	
						Day 42	36	22-42 days	23/06/92	Normal	
	59	Placebo	Male	27/05/92	23/06/92	Screen	7	Screening	03/06/92	Normal	
	60	Imipramine	Female	12/05/92	22/06/92	Screen	-39	Screening	03/04/92	Normal	
						Day 42	42	22-42 days	23/06/92	Normal	
3/1	61	Imipramine	Male	05/03/91	08/04/91	Screen	1	Screening	06/03/91	Normal	
						Day 21	20	1-21 days	25/03/91	Abnormal	RIGHT BUNDLE BRANCH BLOCK
	62	Imipramine	Female	16/04/91	26/05/91	Screen	-4	Screening	12/04/91	Normal	
						Day 21	21	1-21 days	07/05/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
3/1	62	Imipramine	Female	16/04/91	26/05/91	Day 42	41	22-42 days	27/05/91	Normal	
	63	Placebo	Male	13/05/91	23/06/91	Screen	-3	Screening	10/05/91	Normal	
						Day 21	21	1-21 days	03/06/91	Normal	
						Day 42	42	22-42 days	24/06/91	Normal	
	64	Placebo	Female	14/03/91	24/04/91	Screen	0	Screening	14/03/91	Normal	
						Day 21	27	1-21 days	10/04/91	Normal	
	65	Reboxetine	Male	16/09/91	27/10/91	Screen	-5	Screening	11/09/91	Normal	
						Day 21	21	1-21 days	07/10/91	Normal	
						Day 42	42	22-42 days	28/10/91	Normal	
	66	Reboxetine	Male	10/06/91	21/07/91	Day 21	21	1-21 days	01/07/91	Normal	
						Day 42	39	22-42 days	19/07/91	Normal	
	139	Imipramine	Male	03/09/91	12/09/91	Screen	-6	Screening	28/08/91	Normal	
	140	Placebo	Male	12/09/91	23/10/91	Screen	-2	Screening	10/09/91	Normal	
						Day 21	21	1-21 days	03/10/91	Normal	
						Day 42	74	22-42 days	25/11/91	Normal	
	141	Placebo	Female	03/10/91	14/11/91	Screen	-7	Screening	26/09/91	Normal	
						Day 21	27	1-21 days	30/10/91	Normal	
						Day 42	42	22-42 days	14/11/91	Normal	
	142	Imipramine	Female	18/11/91	08/12/91	Screen	-4	Screening	14/11/91	Normal	
	143	Reboxetine	Female	15/04/92	20/05/92	Screen	1	Screening	16/04/92	Normal	
	144	Reboxetine	Female	09/06/92	22/07/92	Screen	-5	Screening	04/06/92	Normal	
	451	Reboxetine	Female	20/01/92	01/02/92	Screen	-5	Screening	15/01/92	Normal	
	452	Placebo	Male	22/01/92	04/03/92	Screen	-7	Screening	15/01/92	Normal	
						Day 21	21	1-21 days	12/02/92	Normal	
						Day 42	50	22-42 days	12/03/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	E.C.G. Assessment	Date	Value	Abnormality
3/1	453	Imipramine	Female	29/01/92	10/03/92	Screen	-1	Screening	28/01/92	Normal	
						Day 42	42	22-42 days	11/03/92	Normal	
	454	Reboxetine	Male	17/02/92	01/04/92	Screen	-5	Screening	12/02/92	Normal	
						Day 21	21	1-21 days	09/03/92	Normal	
	455	Placebo	Female	11/03/92	22/04/92	Screen	-7	Screening	04/03/92	Normal	
						Day 21	31	1-21 days	11/04/92	Normal	
	456	Imipramine	Female	25/03/92	03/04/92	Screen	-7	Screening	18/03/92	Normal	
						Day 14	9	1-21 days	03/04/92	Normal	
3/2	65/A	Reboxetine	Female	29/01/91	11/03/91	Screen	-4	Screening	25/01/91	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 21	21	1-21 days	19/02/91	Normal	
						Day 42	42	22-42 days	12/03/91	Abnormal	SINUS TACHYCARDIA (> 100)
3/3	67	Placebo	Male	18/07/91	28/08/91	Screen	-2	Screening	16/07/91	Normal	
						Day 21	20	1-21 days	07/08/91	Normal	
						Day 42	41	22-42 days	28/08/91	Normal	
	68	Reboxetine	Male	21/01/92	02/03/92	Screen	-7	Screening	14/01/92	Normal	
						Day 21	20	1-21 days	10/02/92	Normal	
						Day 42	41	22-42 days	02/03/92	Normal	
	69	Placebo	Male	04/02/92	16/03/92	Screen	-4	Screening	31/01/92	Normal	
						Day 21	20	1-21 days	24/02/92	Normal	
						Day 42	41	22-42 days	16/03/92	Normal	
	70	Imipramine	Male	15/04/92	26/05/92	Screen	-5	Screening	10/04/92	Normal	
						Day 21	20	1-21 days	05/05/92	Normal	
						Day 42	41	22-42 days	26/05/92	Normal	
	71	Imipramine	Female	16/04/92	27/05/92	Screen	-2	Screening	14/04/92	Normal	
						Day 21	20	1-21 days	06/05/92	Normal	
						Day 42	41	22-42 days	27/05/92	Normal	
	72	Reboxetine	Male	25/07/92	04/09/92	Screen	-2	Screening	23/07/92	Normal	
						Day 21	19	1-21 days	13/08/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
3/3	72	Reboxetine	Male	25/07/92	04/09/92	Day 42	41	22-42 days	04/09/92	Normal	
3/4	79	Imipramine	Female	04/05/91	15/06/91	Screen	-3	Screening	01/05/91	Normal	
						Day 21	20	1-21 days	24/05/91	Normal	
						Day 42	44	22-42 days	17/06/91	Normal	
	80	Imipramine	Male	01/09/91	24/09/91	Screen	-1	Screening	31/08/91	Normal	
	81	Reboxetine	Female	17/05/91	27/06/91	Screen	-1	Screening	16/05/91	Normal	
						Day 21	28	1-21 days	14/06/91	Normal	
						Day 42	42	22-42 days	28/06/91	Normal	
	82	Placebo	Male	17/06/91	28/07/91	Screen	-3	Screening	14/06/91	Normal	
						Day 21	21	1-21 days	08/07/91	Normal	
						Day 42	42	22-42 days	29/07/91	Normal	
	83	Placebo	Male	17/06/91	24/06/91	Screen	-6	Screening	11/06/91	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH BLOCK
	84	Reboxetine	Female	09/10/91	23/11/91	Screen	-1	Screening	08/10/91	Normal	
						Day 21	22	1-21 days	31/10/91	Normal	
						Day 42	34	22-42 days	12/11/91	Normal	
	85	Imipramine	Female	29/10/91	08/12/91	Screen	-3	Screening	26/10/91	Normal	
						Day 21	21	1-21 days	19/11/91	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL
						Day 42	41	22-42 days	09/12/91	Normal	
	86	Imipramine	Male	03/12/91	15/01/92	Screen	0	Screening	03/12/91	Normal	
						Day 42	43	22-42 days	15/01/92	Normal	
	87	Placebo	Female	09/12/91	19/01/92	Screen	-1	Screening	08/12/91	Normal	
						Day 21	18	1-21 days	27/12/91	Normal	
						Day 42	42	22-42 days	20/01/92	Abnormal	ATRIAL ECTOPIC BEATS - OCCASIONAL
	88	Placebo	Male	23/03/92	08/05/92	Screen	-5	Screening	18/03/92	Normal	
						Day 42	47	22-42 days	09/05/92	Normal	
	89	Reboxetine	Female	26/03/92	06/05/92	Screen	-3	Screening	23/03/92	Normal	
						Day 21	12	1-21 days	07/04/92	Normal	
						Day 42	47	22-42 days	12/05/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	E.C.G. Assessment	E.C.G. Date	E.C.G. Value	E.C.G. Abnormality
3/4	90	Reboxetine	Male	28/04/92	08/06/92	Screen	0	Screening	28/04/92	Normal	
						Day 21	22	1-21 days	20/05/92	Normal	
						Day 42	57	22-42 days	24/06/92	Normal	
	457	Placebo	Female	22/05/92	11/06/92	Screen	-3	Screening	19/05/92	Normal	
						Day 21	25	1-21 days	16/06/92	Normal	
	458	Reboxetine	Female	26/05/92	09/06/92	Screen	-8	Screening	18/05/92	Normal	
	459	Placebo	Female	02/06/92	13/07/92	Screen	-4	Screening	29/05/92	Normal	
	460	Reboxetine	Male	19/08/92	28/08/92	Screen	-5	Screening	14/08/92	Normal	
	461	Imipramine	Female	17/09/92	24/09/92	Screen	-2	Screening	15/09/92	Normal	
	462	Imipramine	Female	29/09/92	08/10/92	Screen	0	Screening	29/09/92	Normal	
4/1	91	Imipramine	Female	12/10/91	22/11/91	Screen	-5	Screening	07/10/91	Normal	
	92	Reboxetine	Female	07/08/91	17/09/91	Screen	0	Screening	07/08/91	Normal	
						Day 21	21	1-21 days	28/08/91	Normal	
						Day 42	42	22-42 days	18/09/91	Normal	
	93	Placebo	Male	03/07/91	16/08/91	Screen	-4	Screening	29/06/91	Normal	
						Day 21	28	1-21 days	23/07/91	Normal	
						Day 42	42	22-42 days	14/08/91	Abnormal	SINUS BRADYCARDIA (< 60)
	94	Placebo	Female	05/07/91	13/08/91	Screen	-6	Screening	29/06/91	Normal	
						Day 21	19	1-21 days	24/07/91	Normal	
						Day 42	58	22-42 days	27/08/91	Normal	
	95	Imipramine	Female	03/06/91	16/07/91	Screen	4	Screening	07/06/91	Normal	
						Day 21	26	1-21 days	29/06/91	Normal	
						Day 42	38	22-42 days	11/07/91	Normal	
	96	Reboxetine	Female	04/09/91	16/10/91	Screen	-5	Screening	30/08/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
4/1	96	Reboxetine	Female	04/09/91	16/10/91	Day 21	28	1-21 days	02/10/91	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 42	49	22-42 days	23/10/91	Normal	
	115	Reboxetine	Female	06/05/92	16/06/92	Screen	8	Screening	14/05/92	Normal	
						Day 21	21	1-21 days	27/05/92	Normal	
						Day 42	42	22-42 days	17/06/92	Normal	
	116	Imipramine	Female	16/05/92	22/05/92	Screen	-9	Screening	07/05/92	Normal	
	117	Imipramine	Female	03/09/91	14/10/91	Screen	0	Screening	03/09/91	Normal	
						Day 21	21	1-21 days	24/09/91	Normal	
						Day 42	42	22-42 days	15/10/91	Abnormal	SINUS TACHYCARDIA (> 100)
	118	Reboxetine	Female	23/05/92	03/07/92	Screen	-8	Screening	15/05/92	Normal	
						Day 21	20	1-21 days	12/06/92	Normal	
						Day 42	41	22-42 days	03/07/92	Normal	
	119	Placebo	Female			Screen		Screening	25/11/91	Normal	
	120	Placebo	Female	31/07/92	11/09/92	Screen	-49	Screening	12/06/92	Normal	
						Day 21	25	1-21 days	25/08/92	Normal	
						Day 42	53	22-42 days	22/09/92	Normal	
	145	Imipramine	Female	30/09/92	10/11/92	Screen	-6	Screening	24/09/92	Normal	
						Day 21	35	1-21 days	04/11/92	Normal	
						Day 42	44	22-42 days	13/11/92	Normal	
	146	Placebo	Female	16/09/92	27/10/92	Screen	-47	Screening	31/07/92	Normal	
						Day 21	20	1-21 days	06/10/92	Normal	
						Day 42	41	22-42 days	27/10/92	Normal	
	147	Reboxetine	Female	01/09/92	12/10/92	Screen	-46	Screening	17/07/92	Normal	
						Day 21	20	1-21 days	21/09/92	Normal	
						Day 42	41	22-42 days	12/10/92	Normal	
	148	Imipramine	Female	26/09/92	06/11/92	Screen	-15	Screening	11/09/92	Normal	
						Day 21	23	1-21 days	19/10/92	Normal	
						Day 42	44	22-42 days	09/11/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
4/1	149	Reboxetine	Male	30/09/92	10/11/92	Screen	-7	Screening	23/09/92	Normal	
						Day 21	21	1-21 days	21/10/92	Normal	
						Day 42	41	22-42 days	10/11/92	Normal	
	150	Placebo	Male	30/09/92	10/11/92	Screen	-6	Screening	24/09/92	Normal	
						Day 21	20	1-21 days	20/10/92	Normal	
						Day 42	40	22-42 days	09/11/92	Normal	
4/2	93/A	Placebo	Male	22/02/91	04/04/91	Screen	1	Screening	23/02/91	Normal	
						Day 21	21	1-21 days	15/03/91	Normal	
						Day 42	42	22-42 days	05/04/91	Normal	
	99/A	Placebo	Male	27/03/91	07/05/91	Screen	-1	Screening	26/03/91	Normal	
						Day 21	20	1-21 days	16/04/91	Normal	
						Day 42	33	22-42 days	29/04/91	Normal	
	104	Reboxetine	Male	22/05/91	02/07/91	Screen	-2	Screening	20/05/91	Normal	
						Day 21	20	1-21 days	11/06/91	Normal	
						Day 42	41	22-42 days	02/07/91	Normal	
4/3	97	Placebo	Male	17/04/91	28/05/91	Screen	-6	Screening	11/04/91	Normal	
						Day 42	41	22-42 days	28/05/91	Normal	
	98	Reboxetine	Female	20/06/91	21/07/91	Screen	-2	Screening	18/06/91	Normal	
						Day 21	26	1-21 days	16/07/91	Normal	
	99	Placebo	Female	08/08/91	15/08/91	Screen	-1	Screening	07/08/91	Abnormal	OTHER
	100	Imipramine	Female	27/11/91	17/12/91	Screen	-6	Screening	21/11/91	Abnormal	ATRIAL ECTOPIC BEATS - OCCASIONAL
	101	Imipramine	Male	17/03/92	27/04/92	Screen	-1	Screening	16/03/92	Normal	
						Day 21	20	1-21 days	06/04/92	Normal	
						Day 42	41	22-42 days	27/04/92	Normal	
4/4	109	Reboxetine	Female	08/06/91	19/07/91	Screen	-5	Screening	03/06/91	Normal	
						Day 21	19	1-21 days	27/06/91	Normal	
						Day 42	73	22-42 days	20/08/91	Normal	
	110	Imipramine	Male	15/06/91	26/07/91	Screen	-4	Screening	11/06/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	Assessment	E.C.G. Date	E.C.G. Value	E.C.G. Abnormality
4/4	110	Imipramine	Male	15/06/91	26/07/91	Day 21	19	1-21 days	04/07/91	Normal	
						Day 42	41	22-42 days	26/07/91	Normal	
	111	Imipramine	Male	04/07/91	14/08/91	Screen	-7	Screening	27/06/91	Normal	
						Day 21	20	1-21 days	24/07/91	Normal	
						Day 42	41	22-42 days	14/08/91	Normal	
	112	Placebo	Male	10/07/91	20/08/91	Screen	0	Screening	10/07/91	Normal	
						Day 21	21	1-21 days	31/07/91	Normal	
						Day 42	41	22-42 days	20/08/91	Normal	
	113	Reboxetine	Male	31/08/91	11/10/91	Screen	-5	Screening	26/08/91	Normal	
						Day 21	23	1-21 days	23/09/91	Normal	
						Day 42	41	22-42 days	11/10/91	Normal	
	114	Placebo	Female	20/11/91	31/12/91	Screen	-13	Screening	07/11/91	Normal	
						Day 21	21	1-21 days	11/12/91	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 42	41	22-42 days	31/12/91	Abnormal	SINUS BRADYCARDIA (< 60)
	175	Imipramine	Female	13/02/92	25/03/92	Screen	-8	Screening	05/02/92	Normal	
						Day 21	21	1-21 days	05/03/92	Normal	
						Day 42	41	22-42 days	25/03/92	Normal	
	176	Placebo	Female	14/03/92	08/04/92	Screen	-1	Screening	13/03/92	Normal	
						Day 21	23	1-21 days	06/04/92	Normal	
	177	Imipramine	Female	28/04/92	11/05/92	Screen	-6	Screening	22/04/92	Normal	
						Day 21	29	1-21 days	27/05/92	Normal	
	178	Reboxetine	Female	28/04/92	08/06/92	Screen	-7	Screening	21/04/92	Normal	
						Day 21	20	1-21 days	18/05/92	Normal	
						Day 42	42	22-42 days	09/06/92	Normal	
	179	Placebo	Female	11/09/92	29/09/92	Screen	-2	Screening	09/09/92	Normal	
						Day 21	19	1-21 days	30/09/92	Normal	
	180	Reboxetine	Male	07/10/92	17/11/92	Screen	-7	Screening	30/09/92	Normal	
						Day 21	20	1-21 days	27/10/92	Normal	
						Day 42	41	22-42 days	17/11/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	E.C.G. Assessment	E.C.G. Date	E.C.G. Value	E.C.G. Abnormality
5/1	127	Reboxetine	Male	06/06/91	17/07/91	Screen	-6	Screening	31/05/91	Normal	
						Day 21	21	1-21 days	27/06/91	Normal	
						Day 42	42	22-42 days	18/07/91	Normal	
	128	Reboxetine	Female	14/06/91	25/07/91	Screen	-1	Screening	13/06/91	Normal	
						Day 21	21	1-21 days	05/07/91	Normal	
						Day 42	42	22-42 days	26/07/91	Normal	
	129	Placebo	Male	24/12/91	03/02/92	Screen	-4	Screening	20/12/91	Normal	
						Day 21	20	1-21 days	13/01/92	Normal	
						Day 42	41	22-42 days	03/02/92	Normal	
2076	130	Placebo	Male	05/03/92	15/04/92	Screen	-3	Screening	02/03/92	Normal	
						Day 21	20	1-21 days	25/03/92	Normal	
						Day 42	41	22-42 days	15/04/92	Normal	
	131	Imipramine	Female	21/03/92	30/04/92	Screen	-1	Screening	20/03/92	Normal	
						Day 21	20	1-21 days	10/04/92	Normal	
						Day 42	40	22-42 days	30/04/92	Abnormal	SINUS TACHYCARDIA (> 100)
	132	Imipramine	Male	25/06/92	06/08/92	Screen	-1	Screening	24/06/92	Normal	
						Day 21	21	1-21 days	16/07/92	Normal	
						Day 42	46	22-42 days	10/08/92	Normal	
5/2	121	Imipramine	Female	20/12/91	27/01/92	Screen	0	Screening	20/12/91	Abnormal	SINUS TACHYCARDIA (> 100) ATRIAL ECTOPIC BEATS - OCCASIONAL VENTRICULAR ECTOPIC BEATS - OCCASIONAL
						Day 21	21	1-21 days	10/01/92	Abnormal	SINUS TACHYCARDIA (> 100) ATRIAL ECTOPIC BEATS - OCCASIONAL VENTRICULAR ECTOPIC BEATS - OCCASIONAL
						Day 42	39	22-42 days	28/01/92	Normal	
	125	Reboxetine	Male	28/01/91	10/03/91	Screen	-4	Screening	24/01/91	Normal	
						Day 21	14	1-21 days	11/02/91	Normal	
						Day 42	42	22-42 days	11/03/91	Normal	
5/3	133	Placebo	Male	29/11/91	12/12/91	Screen	-4	Screening	25/11/91	Normal	
	134	Reboxetine	Female	06/12/91	16/01/92	Screen	-3	Screening	03/12/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	E.C.G. Assessment	E.C.G. Date	E.C.G. Value	E.C.G. Abnormality
5/3	134	Reboxetine	Female	06/12/91	16/01/92	Day 21	21	1-21 days	27/12/91	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH BLOCK
						Day 42	41	22-42 days	16/01/92	Normal	
	135	Imipramine	Female	10/01/92	20/02/92	Screen	-4	Screening	06/01/92	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 42	41	22-42 days	20/02/92	Normal	
	136	Imipramine	Female	02/03/92	12/04/92	Screen	0	Screening	02/03/92	Normal	
						Day 42	42	22-42 days	13/04/92	Normal	
	137	Reboxetine	Female	15/05/92	25/06/92	Screen	-4	Screening	11/05/92	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 21	21	1-21 days	05/06/92	Normal	
						Day 42	41	22-42 days	25/06/92	Normal	
	138	Placebo	Female	15/05/92	16/05/92	Screen	-1	Screening	14/05/92	Normal	
6/1	151	Imipramine	Male	21/01/92	28/01/92	Screen	-5	Screening	16/01/92	Normal	
						Day 7	13	1-21 days	03/02/92	Normal	
	152	Reboxetine	Female	24/02/92	07/04/92	Screen	-6	Screening	18/02/92	Normal	
						Day 21	24	1-21 days	19/03/92	Normal	
						Day 42	46	22-42 days	10/04/92	Normal	
	153	Reboxetine	Male	18/03/91	29/04/91	Screen	-4	Screening	14/03/91	Normal	
						Day 21	21	1-21 days	08/04/91	Normal	
						Day 42	45	22-42 days	02/05/91	Normal	
	154	Imipramine	Female	30/03/92	06/04/92	Screen	-2	Screening	28/03/92	Normal	
	155	Placebo	Male	08/07/92	04/08/92	Screen	-2	Screening	06/07/92	Normal	
						Day 21	20	1-21 days	28/07/92	Normal	
						Day 28	27	22-42 days	04/08/92	Normal	
	156	Placebo	Female	08/09/92	19/10/92	Screen	0	Screening	08/09/92	Normal	
						Day 42	44	22-42 days	22/10/92	Normal	
6/2	157	Reboxetine	Male	30/04/91	10/06/91	Screen	-8	Screening	22/04/91	Normal	
						Day 21	21	1-21 days	21/05/91	Normal	
						Day 42	41	22-42 days	10/06/91	Normal	

2077

9550082

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	E.C.G. Assessment	Date	Value	Abnormality
6/2	158	Imipramine	Female	24/11/91	05/01/92	Screen	-3	Screening	21/11/91	Normal	
						Day 21	20	1-21 days	14/12/91	Normal	
						Day 42	60	22-42 days	23/01/92	Normal	
	159	Imipramine	Male	14/07/91	24/08/91	Screen	-3	Screening	11/07/91	Normal	
						Day 21	24	1-21 days	07/08/91	Normal	
						Day 42	46	22-42 days	29/08/91	Normal	
	160	Placebo	Male	24/11/91	04/01/92	Screen	-2	Screening	22/11/91	Abnormal	RIGHT BUNDLE BRANCH BLOCK
						Day 21	20	1-21 days	14/12/91	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH BLOCK
						Day 42	41	22-42 days	04/01/92	Abnormal	RIGHT BUNDLE BRANCH BLOCK
	161	Reboxetine	Female	20/02/92	18/03/92	Screen	-2	Screening	18/02/92	Normal	
						Day 21	20	1-21 days	11/03/92	Normal	
	162	Placebo	Male	10/07/91	13/07/91	Screen	-2	Screening	08/07/91	Normal	
	169	Imipramine	Female	26/12/91	15/01/92	Screen	-17	Screening	09/12/91	Normal	
						Day 21	20	1-21 days	15/01/92	Normal	
	170	Placebo	Male	01/11/91	15/11/91	Screen	-6	Screening	26/10/91	Normal	
	171	Imipramine	Female	22/07/92	01/09/92	Screen	-105	Screening	08/04/92	Normal	
						Day 21	20	1-21 days	11/08/92	Normal	
						Day 42	56	22-42 days	16/09/92	Normal	
	172	Reboxetine	Female	07/07/92	17/08/92	Screen	0	Screening	07/07/92	Normal	
						Day 21	20	1-21 days	27/07/92	Normal	
						Day 42	57	22-42 days	02/09/92	Normal	
	173	Placebo	Male	05/07/92	15/08/92	Screen	-4	Screening	01/07/92	Normal	
						Day 21	20	1-21 days	25/07/92	Normal	
	174	Reboxetine	Male	11/05/92	21/06/92	Screen	-6	Screening	05/05/92	Normal	
						Day 21	21	1-21 days	01/06/92	Normal	
						Day 42	47	22-42 days	27/06/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	E.C.G. Assessment	E.C.G. Date	E.C.G. Value	E.C.G. Abnormality
6/3	163	Reboxetine	Male	06/06/91	08/06/91	Screen	-6	Screening	31/05/91	Normal	
	164	Imipramine	Male	11/10/91	21/11/91	Screen	-4	Screening	07/10/91	Normal	
						Day 21	20	1-21 days	31/10/91	Normal	
						Day 42	42	22-42 days	22/11/91	Normal	
	165	Imipramine	Female	16/10/91	26/11/91	Screen	-6	Screening	10/10/91	Normal	
						Day 21	20	1-21 days	05/11/91	Normal	
						Day 42	41	22-42 days	26/11/91	Abnormal	SINUS TACHYCARDIA (> 100)
	166	Reboxetine	Female	25/10/91	29/10/91	Screen	-8	Screening	17/10/91	Normal	
	167	Placebo	Female	18/11/91	27/12/91	Screen	-4	Screening	14/11/91	Normal	
						Day 21	21	1-21 days	09/12/91	Normal	
						Day 42	39	22-42 days	27/12/91	Normal	
	168	Placebo	Female	03/12/91	06/01/92	Screen	-16	Screening	17/11/91	Normal	
						Day 21	19	1-21 days	22/12/91	Normal	
	505	Imipramine	Female	03/12/91	17/12/91	Screen	-4	Screening	29/11/91	Normal	
						Day 14	15	1-21 days	18/12/91	Normal	
	506	Placebo	Female	08/01/92	19/02/92	Screen	-2	Screening	06/01/92	Normal	
						Day 21	21	1-21 days	29/01/92	Normal	
						Day 42	42	22-42 days	19/02/92	Normal	
	507	Imipramine	Female	14/01/92	24/02/92	Screen	-7	Screening	07/01/92	Normal	
						Day 21	21	1-21 days	04/02/92	Normal	
						Day 42	41	22-42 days	24/02/92	Normal	
	508	Reboxetine	Female	05/02/92	17/03/92	Screen	-7	Screening	29/01/92	Normal	
						Day 21	20	1-21 days	25/02/92	Normal	
						Day 42	41	22-42 days	17/03/92	Normal	
	509	Placebo	Male	24/02/92	06/04/92	Screen	0	Screening	24/02/92	Normal	
						Day 21	21	1-21 days	16/03/92	Normal	
						Day 42	42	22-42 days	06/04/92	Normal	
	510	Reboxetine	Female	27/02/92	10/03/92	Screen	-13	Screening	14/02/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	E.C.G. Assessment	E.C.G. Date	E.C.G. Value	E.C.G. Abnormality
6/3	511	Imipramine	Female	19/03/92	21/04/92	Screen	0	Screening	19/03/92	Normal	
						Day 21	19	1-21 days	07/04/92	Abnormal	SINUS TACHYCARDIA (> 100)
	512	Placebo	Female	01/04/92	01/04/92	Screen	-5	Screening	27/03/92	Normal	
	513	Imipramine	Female	13/05/92	23/06/92	Screen	-8	Screening	05/05/92	Normal	
						Day 21	20	1-21 days	02/06/92	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 42	41	22-42 days	23/06/92	Abnormal	SINUS TACHYCARDIA (> 100)
7/02	181	Reboxetine	Male	27/01/92	08/03/92	Screen	-10	Screening	17/01/92	Normal	
						Day 21	21	1-21 days	17/02/92	Normal	
						Day 42	42	22-42 days	09/03/92	Normal	
	182	Placebo	Male	23/11/91	03/01/92	Screen	-1	Screening	22/11/91	Normal	
						Day 21	20	1-21 days	13/12/91	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL MYOCARDIAL ISCHEMIA
						Day 42	41	22-42 days	03/01/92	Normal	
	183	Imipramine	Male	02/01/92	18/01/92	Screen	-3	Screening	30/12/91	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 21	20	1-21 days	22/01/92	Normal	
	184	Imipramine	Female	27/01/92	08/03/92	Screen	-4	Screening	23/01/92	Normal	
						Day 21	21	1-21 days	17/02/92	Normal	
						Day 42	42	22-42 days	09/03/92	Normal	
	185	Reboxetine	Male	10/04/92	05/05/92	Screen	-1	Screening	09/04/92	Normal	
						Day 21	20	1-21 days	30/04/92	Normal	
	186	Placebo	Male	16/04/92	27/05/92	Screen	-1	Screening	15/04/92	Normal	
						Day 21	20	1-21 days	06/05/92	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 42	41	22-42 days	27/05/92	Normal	
	535	Placebo	Male	15/04/92	26/05/92	Screen	0	Screening	15/04/92	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 21	21	1-21 days	06/05/92	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 42	42	22-42 days	27/05/92	Abnormal	SINUS BRADYCARDIA (< 60)
	536	Reboxetine	Female	08/05/92	18/06/92	Screen	0	Screening	08/05/92	Normal	
						Day 21	21	1-21 days	29/05/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	Assessment	E.C.G. Date	E.C.G. Value	E.C.G. Abnormality
7/02	536	Reboxetine	Female	08/05/92	18/06/92	Day 42	42	22-42 days	19/06/92	Normal	
7/03	187	Imipramine	Female	18/02/92	30/03/92	Screen	-7	Screening	11/02/92	Normal	
						Day 21	21	1-21 days	10/03/92	Normal	
						Day 42	42	22-42 days	31/03/92	Normal	
	188	Placebo	Male	25/02/92	06/04/92	Screen	-7	Screening	18/02/92	Normal	
						Day 21	21	1-21 days	17/03/92	Normal	
						Day 42	42	22-42 days	07/04/92	Normal	
	189	Placebo	Male	25/02/92	06/04/92	Screen	-7	Screening	18/02/92	Normal	
						Day 21	21	1-21 days	17/03/92	Normal	
						Day 42	42	22-42 days	07/04/92	Normal	
	190	Reboxetine	Male	28/02/92	09/04/92	Screen	-7	Screening	21/02/92	Normal	
						Day 21	21	1-21 days	20/03/92	Normal	
						Day 42	42	22-42 days	10/04/92	Normal	
	191	Imipramine	Female	03/03/92	10/04/92	Screen	-7	Screening	25/02/92	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 21	21	1-21 days	24/03/92	Abnormal	SINUS TACHYCARDIA (> 100)
	192	Reboxetine	Female	10/03/92	20/04/92	Screen	-7	Screening	03/03/92	Normal	
						Day 21	21	1-21 days	31/03/92	Normal	
						Day 42	42	22-42 days	21/04/92	Normal	
	523	Reboxetine	Female	06/05/92	16/06/92	Screen	-8	Screening	28/04/92	Normal	
						Day 21	20	1-21 days	26/05/92	Normal	
						Day 42	41	22-42 days	16/06/92	Normal	
	524	Placebo	Female	06/05/92	16/06/92	Screen	-8	Screening	28/04/92	Normal	
						Day 21	20	1-21 days	26/05/92	Normal	
						Day 42	41	22-42 days	16/06/92	Normal	
	525	Placebo	Female	06/05/92	16/06/92	Screen	-8	Screening	28/04/92	Normal	
						Day 21	20	1-21 days	26/05/92	Normal	
						Day 42	41	22-42 days	16/06/92	Normal	
	526	Reboxetine	Female	06/05/92	16/06/92	Screen	-28	Screening	08/04/92	Normal	
						Day 21	20	1-21 days	26/05/92	Normal	
						Day 42	41	22-42 days	16/06/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	E.C.G. Assessment	E.C.G. Date	E.C.G. Value	E.C.G. Abnormality
7/03	527	Imipramine	Female	19/05/92	29/06/92	Screen	-7	Screening	12/05/92	Normal	
						Day 21	21	1-21 days	09/06/92	Normal	
						Day 42	42	22-42 days	30/06/92	Normal	
	528	Imipramine	Female	19/05/92	22/06/92	Screen	-7	Screening	12/05/92	Normal	
						Day 21	21	1-21 days	09/06/92	Normal	
7/04	193	Placebo	Female	25/01/92	06/03/92	Screen	0	Screening	25/01/92	Normal	
						Day 21	21	1-21 days	15/02/92	Normal	
						Day 42	42	22-42 days	07/03/92	Normal	
	194	Reboxetine	Male	25/01/92	06/03/92	Screen	0	Screening	25/01/92	Normal	
						Day 21	21	1-21 days	15/02/92	Normal	
						Day 42	42	22-42 days	07/03/92	Normal	
	195	Placebo	Female	25/01/92	06/03/92	Screen	0	Screening	25/01/92	Normal	
						Day 21	21	1-21 days	15/02/92	Normal	
						Day 42	42	22-42 days	07/03/92	Normal	
	196	Reboxetine	Female	01/02/92	13/03/92	Screen	0	Screening	01/02/92	Normal	
						Day 21	21	1-21 days	22/02/92	Normal	
						Day 42	42	22-42 days	14/03/92	Normal	
	197	Imipramine	Male	01/02/92	13/03/92	Screen	0	Screening	01/02/92	Normal	
						Day 21	21	1-21 days	22/02/92	Normal	
						Day 42	42	22-42 days	14/03/92	Normal	
	198	Imipramine	Female	01/02/92	13/03/92	Screen	0	Screening	01/02/92	Normal	
						Day 21	21	1-21 days	22/02/92	Normal	
						Day 42	42	22-42 days	14/03/92	Normal	
	199	Imipramine	Male	28/03/92	08/05/92	Screen	0	Screening	28/03/92	Abnormal	RIGHT BUNDLE BRANCH BLOCK
						Day 21	21	1-21 days	18/04/92	Abnormal	RIGHT BUNDLE BRANCH BLOCK
						Day 42	42	22-42 days	09/05/92	Abnormal	RIGHT BUNDLE BRANCH BLOCK
	200	Placebo	Male	28/03/92	08/05/92	Screen	0	Screening	28/03/92	Normal	
						Day 21	21	1-21 days	18/04/92	Normal	
						Day 42	42	22-42 days	09/05/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
7/04	201	Reboxetine	Female	28/03/92	08/05/92	Screen	0	Screening	28/03/92	Normal	
						Day 21	21	1-21 days	18/04/92	Normal	
						Day 42	42	22-42 days	09/05/92	Normal	
	202	Reboxetine	Male	04/04/92	15/05/92	Screen	-3	Screening	01/04/92	Normal	
						Day 21	21	1-21 days	25/04/92	Normal	
						Day 42	42	22-42 days	16/05/92	Normal	
	203	Placebo	Female	04/04/92	15/05/92	Screen	-3	Screening	01/04/92	Normal	
						Day 21	21	1-21 days	25/04/92	Normal	
						Day 42	42	22-42 days	16/05/92	Normal	
	204	Imipramine	Female	04/04/92	15/05/92	Screen	-3	Screening	01/04/92	Normal	
						Day 21	21	1-21 days	25/04/92	Normal	
						Day 42	42	22-42 days	16/05/92	Normal	
7/05	205	Placebo	Male	27/01/92	08/03/92	Screen	-28	Screening	30/12/91	Normal	
						Day 21	21	1-21 days	17/02/92	Normal	
						Day 42	42	22-42 days	09/03/92	Normal	
	206	Imipramine	Female	28/01/92	09/03/92	Screen	-14	Screening	14/01/92	Normal	
						Day 21	21	1-21 days	18/02/92	Normal	
						Day 42	42	22-42 days	10/03/92	Normal	
	207	Imipramine	Female	28/01/92	09/03/92	Screen	-7	Screening	21/01/92	Normal	
						Day 42	42	22-42 days	10/03/92	Normal	
	208	Reboxetine	Male	30/01/92	11/03/92	Screen	-6	Screening	24/01/92	Normal	
						Day 21	21	1-21 days	20/02/92	Normal	
						Day 42	42	22-42 days	12/03/92	Normal	
	209	Placebo	Male	05/02/92	17/03/92	Screen	-7	Screening	29/01/92	Normal	
						Day 21	21	1-21 days	26/02/92	Normal	
						Day 42	42	22-42 days	18/03/92	Normal	
	210	Reboxetine	Male	07/02/92	19/03/92	Screen	-4	Screening	03/02/92	Normal	
						Day 21	21	1-21 days	28/02/92	Normal	
						Day 42	42	22-42 days	20/03/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	E.C.G. Assessment	Date	Value	Abnormality
7/05	541	Reboxetine	Female	17/03/92	27/04/92	Screen	-15	Screening	02/03/92	Normal	
						Day 21	21	1-21 days	07/04/92	Normal	
						Day 42	42	22-42 days	28/04/92	Normal	
	542	Imipramine	Male	17/03/92	27/04/92	Screen	-15	Screening	02/03/92	Normal	
						Day 21	21	1-21 days	07/04/92	Normal	
						Day 42	42	22-42 days	28/04/92	Normal	
	543	Imipramine	Male	18/03/92	28/04/92	Screen	-15	Screening	03/03/92	Normal	
						Day 21	21	1-21 days	08/04/92	Normal	
						Day 42	42	22-42 days	29/04/92	Normal	
	544	Placebo	Female	24/03/92	04/05/92	Screen	-20	Screening	04/03/92	Normal	
						Day 21	21	1-21 days	14/04/92	Normal	
						Day 42	42	22-42 days	05/05/92	Normal	
	545	Placebo	Male	25/03/92	05/05/92	Screen	-16	Screening	09/03/92	Normal	
						Day 21	21	1-21 days	15/04/92	Normal	
						Day 42	42	22-42 days	06/05/92	Normal	
	546	Reboxetine	Female	25/03/92	05/05/92	Screen	-15	Screening	10/03/92	Normal	
						Day 21	21	1-21 days	15/04/92	Normal	
						Day 42	42	22-42 days	06/05/92	Normal	
7/07	529	Placebo	Female	18/02/92	30/03/92	Screen	-1	Screening	17/02/92	Normal	
						Day 21	21	1-21 days	10/03/92	Normal	
						Day 42	42	22-42 days	31/03/92	Normal	
	530	Imipramine	Female	20/02/92	09/03/92	Screen	-3	Screening	17/02/92	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 14	21	1-21 days	12/03/92	Abnormal	SINUS TACHYCARDIA (> 100)
	531	Reboxetine	Female	24/02/92	05/04/92	Screen	-6	Screening	18/02/92	Normal	
						Day 21	21	1-21 days	16/03/92	Normal	
						Day 42	42	22-42 days	06/04/92	Normal	
	532	Imipramine	Female	27/04/92	07/06/92	Screen	-4	Screening	23/04/92	Normal	
						Day 21	21	1-21 days	18/05/92	Normal	
						Day 42	43	22-42 days	09/06/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	E.C.G. Assessment	Date	Value	Abnormality
7/07	533	Reboxetine	Male	04/05/92	14/06/92	Screen	-7	Screening	27/04/92	Normal	
						Day 21	21	1-21 days	25/05/92	Normal	
						Day 42	42	22-42 days	15/06/92	Normal	
	534	Placebo	Female	15/05/92	25/06/92	Screen	-3	Screening	12/05/92	Normal	
						Day 21	21	1-21 days	05/06/92	Normal	
						Day 42	42	22-42 days	26/06/92	Normal	
8	211	Reboxetine	Female	13/05/91	26/05/91	Screen	0	Screening	13/05/91	Normal	
	212	Placebo	Female	14/09/91	25/10/91			Screening			
	213	Imipramine	Male	22/11/91	24/11/91			Screening			
	214	Reboxetine	Female	23/11/91	03/01/92	Screen	-13	Screening	10/11/91	Normal	
	215	Placebo	Female	18/02/92	30/03/92			Screening			
	216	Imipramine	Male	27/03/92	07/05/92	Day 21	21	1-21 days	17/04/92	Normal	
	217	Reboxetine	Female	30/03/92	10/05/92			Screening			
	218	Reboxetine	Female	09/04/92	20/05/92	Screen	-8	Screening	01/04/92	Normal	
	219	Placebo	Female	11/04/92	01/05/92	Screen	-8	Screening	03/04/92	Normal	
	220	Imipramine	Female	27/04/92	07/06/92			Screening			
	221	Imipramine	Male	28/04/92	08/06/92			Screening			
	222	Placebo	Female	28/04/92	08/06/92			Screening			
	223	Imipramine	Female	11/05/92	21/06/92			Screening			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	E.C.G. Assessment	E.C.G. Date	E.C.G. Value	E.C.G. Abnormality
8	224	Placebo	Female	07/09/92	18/10/92	Screen	-11	Screening	27/08/92	Normal	
						Day 42	28	22-42 days	05/10/92	Normal	
	225	Placebo	Male	11/09/92	22/10/92	Screen	-6	Screening	05/09/92	Normal	
						Day 21	21	1-21 days	02/10/92	Normal	
	226	Reboxetine	Male	23/09/92	03/11/92	Screen	-2	Screening	21/09/92	Normal	
	227	Reboxetine	Male	25/09/92	05/11/92			Screening			
	228	Imipramine	Male	26/09/92	02/10/92			Screening			
	229	Imipramine	Female	30/09/92	10/11/92			Screening			
	230	Reboxetine	Female	28/09/92	08/11/92			Screening			
	231	Imipramine	Male	30/09/92	10/11/92	Screen	-5	Screening	25/09/92	Normal	
						Day 21	21	1-21 days	21/10/92	Normal	
						Day 42	42	22-42 days	11/11/92	Normal	
	232	Reboxetine	Male	02/10/92	12/11/92	Screen	-3	Screening	29/09/92	Normal	
						Day 42	38	22-42 days	09/11/92	Normal	
	233	Placebo	Female	07/10/92	17/11/92	Screen	-9	Screening	28/09/92	Normal	
						Day 42	33	22-42 days	09/11/92	Normal	
	234	Placebo	Female	07/10/92	17/11/92	Screen	-7	Screening	30/09/92	Normal	
						Day 42	34	22-42 days	10/11/92	Normal	
8/A	235	Placebo	Female	14/10/92	24/11/92	Screen	-26	Screening	18/09/92	Normal	
						Day 21	21	1-21 days	04/11/92	Normal	
						Day 42	41	22-42 days	24/11/92	Normal	
	236	Placebo	Female	14/10/92	24/11/92	Screen	-26	Screening	18/09/92	Normal	
						Day 21	21	1-21 days	04/11/92	Normal	
						Day 42	41	22-42 days	24/11/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
8/A	237	Reboxetine	Female	14/10/92	24/11/92	Screen	-26	Screening	18/09/92	Abnormal	RIPOLARIZATION DISTURBANCES
						Day 21	20	1-21 days	03/11/92	Abnormal	RIPOLARIZATION DISTURBANCES
						Day 42	41	22-42 days	24/11/92	Abnormal	RIPOLARIZATION DISTURBANCES
	238	Reboxetine	Female	14/10/92	24/11/92	Screen	-26	Screening	18/09/92	Normal	
						Day 21	21	1-21 days	04/11/92	Normal	
						Day 42	41	22-42 days	24/11/92	Normal	
	239	Imipramine	Female	16/10/92	26/11/92	Screen	-24	Screening	22/09/92	Abnormal	MYOCARDIAL ISCHEMIA
						Day 21	20	1-21 days	05/11/92	Abnormal	MYOCARDIAL ISCHEMIA
						Day 42	43	22-42 days	28/11/92	Abnormal	MYOCARDIAL ISCHEMIA
	240	Imipramine	Female	16/10/92	26/11/92	Screen	-24	Screening	22/09/92	Abnormal	LEFT AXIAL DEVIATION
						Day 21	20	1-21 days	05/11/92	Abnormal	LEFT AXIAL DEVIATION
						Day 42	41	22-42 days	26/11/92	Abnormal	LEFT AXIAL DEVIATION
	553	Placebo	Female	16/10/92	26/11/92	Screen	-23	Screening	23/09/92	Normal	
						Day 21	20	1-21 days	05/11/92	Normal	
						Day 42	41	22-42 days	26/11/92	Normal	
	554	Reboxetine	Male	16/10/92	26/11/92	Screen	-24	Screening	22/09/92	Normal	
						Day 21	20	1-21 days	05/11/92	Normal	
						Day 42	41	22-42 days	26/11/92	Normal	
	555	Reboxetine	Female	16/10/92	26/11/92	Screen	-24	Screening	22/09/92	Normal	
						Day 21	20	1-21 days	05/11/92	Normal	
						Day 42	41	22-42 days	26/11/92	Normal	
	556	Imipramine	Male	16/10/92	26/11/92	Screen	-24	Screening	22/09/92	Normal	
						Day 21	20	1-21 days	05/11/92	Normal	
						Day 42	41	22-42 days	26/11/92	Normal	
9	241	Placebo	Female	07/02/91	17/02/91	Screen	-14	Screening	24/01/91	Normal	
	242	Reboxetine	Female	18/02/91	11/03/91	Screen	-11	Screening	07/02/91	Abnormal	CONDUCTION DISORDER
						Day 21	22	1-21 days	12/03/91	Abnormal	CONDUCTION DISORDER
	243	Reboxetine	Female	20/02/91	06/03/91	Screen	-5	Screening	15/02/91	Abnormal	RIPOLARIZATION DISTURBANCES

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	E.C.G. Assessment	Date	Value	Abnormality
9	243	Reboxetine	Female	20/02/91	06/03/91	Day 14	14	1-21 days	06/03/91	Normal	
	244	Imipramine	Female	19/02/91	13/03/91	Screen	-5	Screening	14/02/91	Normal	
						Day 21	20	1-21 days	11/03/91	Abnormal	ATRIAL ECTOPIC BEATS - OCCASIONAL
						Day 28	27	22-42 days	18/03/91	Normal	
	245	Imipramine	Female	22/02/91	04/04/91	Screen	-4	Screening	18/02/91	Abnormal	OTHER
						Day 21	21	1-21 days	15/03/91	Abnormal	LEFT VENTRICULAR HYPERTROPHY OTHER
	246	Placebo	Female	22/02/91	17/03/91	Screen	-9	Screening	13/02/91	Abnormal	RIPOLARIZATION DISTURBANCES
						Day 21	21	1-21 days	15/03/91	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 28	25	22-42 days	19/03/91	Normal	
	247	Placebo	Female	25/02/91	26/03/91	Screen	-5	Screening	20/02/91	Abnormal	RIPOLARIZATION DISTURBANCES
						Day 21	21	1-21 days	18/03/91	Abnormal	RIPOLARIZATION DISTURBANCES
	248	Placebo	Male	07/03/91	21/03/91	Screen	-3	Screening	04/03/91	Normal	
						Day 14	15	1-21 days	22/03/91	Normal	
	249	Reboxetine	Female	08/03/91	11/03/91	Screen	-4	Screening	04/03/91	Abnormal	A-V BLOCK 1ST DEGREE
	250	Imipramine	Female	12/03/91	08/04/91	Screen	-5	Screening	07/03/91	Normal	
						Day 21	21	1-21 days	02/04/91	Abnormal	OTHER
						Day 28	28	22-42 days	09/04/91	Normal	
	251	Imipramine	Female	20/03/91	12/04/91	Screen	-2	Screening	18/03/91	Normal	
						Day 21	21	1-21 days	10/04/91	Normal	
	252	Reboxetine	Female	02/04/91	20/04/91	Screen	-5	Screening	28/03/91	Normal	
						Day 21	18	1-21 days	20/04/91	Normal	
	253	Reboxetine	Female	02/04/91	08/04/91	Screen	-18	Screening	15/03/91	Normal	
	254	Imipramine	Female	09/04/91	16/04/91	Screen	-4	Screening	05/04/91	Normal	
						Day 14	8	1-21 days	17/04/91	Abnormal	LEFT AXIAL DEVIATION
	255	Reboxetine	Female	13/05/91	06/06/91	Screen	-5	Screening	08/05/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
9	255	Reboxetine	Female	13/05/91	06/06/91	Day 21	28	1-21 days	10/06/91	Abnormal	SINUS TACHYCARDIA (> 100)
	256	Imipramine	Female	27/05/91	08/07/91	Screen	-5	Screening	22/05/91	Normal	
						Day 42	35	22-42 days	01/07/91	Normal	
	257	Placebo	Male	25/06/91	01/07/91	Screen	-4	Screening	21/06/91	Normal	
	258	Placebo	Male	01/07/91	10/07/91	Screen	-5	Screening	26/06/91	Normal	
11	319	Placebo	Male	02/08/91	12/09/91	Screen	-8	Screening	25/07/91	Normal	
						Day 21	20	1-21 days	22/08/91	Normal	
						Day 42	41	22-42 days	12/09/91	Normal	
	320	Imipramine	Male	17/08/91	26/09/91	Screen	-9	Screening	08/08/91	Normal	
						Day 21	20	1-21 days	06/09/91	Normal	
						Day 42	44	22-42 days	30/09/91	Normal	
	321	Placebo	Male	06/09/91	17/10/91	Screen	-14	Screening	23/08/91	Abnormal	LEFT AXIAL DEVIATION
						Day 21	20	1-21 days	26/09/91	Abnormal	LEFT AXIAL DEVIATION
						Day 42	41	22-42 days	17/10/91	Abnormal	LEFT AXIAL DEVIATION
	322	Reboxetine	Female	27/09/91	07/11/91	Screen	-8	Screening	19/09/91	Abnormal	SINUS BRADYCARDIA (< 60) PREVIOUS MYOCARDIAL INFARCTION
						Day 21	20	1-21 days	17/10/91	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
						Day 42	41	22-42 days	07/11/91	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
	323	Reboxetine	Male	15/11/91	26/12/91	Screen	-9	Screening	06/11/91	Abnormal	LEFT VENTRICULAR HYPERTROPHY
						Day 21	20	1-21 days	05/12/91	Abnormal	LEFT VENTRICULAR HYPERTROPHY
						Day 42	63	22-42 days	17/01/92	Abnormal	SINUS TACHYCARDIA (> 100) LEFT VENTRICULAR HYPERTROPHY
	324	Imipramine	Male	06/12/91	16/01/92	Screen	-4	Screening	02/12/91	Normal	
						Day 21	21	1-21 days	27/12/91	Normal	
						Day 42	41	22-42 days	16/01/92	Normal	
	325	Reboxetine	Male	13/12/91	23/01/92	Screen	-4	Screening	09/12/91	Abnormal	NON SPECIFIC ST-T WAVE CHANGES
						Day 21	20	1-21 days	02/01/92	Abnormal	NON SPECIFIC ST-T WAVE CHANGES
						Day 42	41	22-42 days	23/01/92	Abnormal	NON SPECIFIC ST-T WAVE CHANGES

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
11	326	Placebo	Male	16/01/92	27/02/92	Screen	-1	Screening	15/01/92	Normal	
						Day 21	22	1-21 days	07/02/92	Normal	
	327	Imipramine	Male	30/01/92	05/02/92	Screen	-6	Screening	24/01/92	Normal	
	328	Imipramine	Female	31/01/92	04/02/92	Screen	-2	Screening	29/01/92	Abnormal	SINUS BRADYCARDIA (< 60)
	329	Placebo	Female	10/04/92	21/05/92	Screen	-9	Screening	01/04/92	Abnormal	MYOCARDIAL ISCHEMIA
						Day 21	20	1-21 days	30/04/92	Normal	
						Day 42	40	22-42 days	20/05/92	Normal	
	330	Reboxetine	Male	09/04/92	21/05/92	Screen	-2	Screening	07/04/92	Normal	
						Day 21	21	1-21 days	30/04/92	Normal	
	331	Imipramine	Male	17/04/92	28/05/92	Screen	-9	Screening	08/04/92	Abnormal	MYOCARDIAL ISCHEMIA LEFT BUNDLE BRANCH BLOCK LEFT ANTERIOR HEMIBLOCK
						Day 21	20	1-21 days	07/05/92	Abnormal	LEFT BUNDLE BRANCH BLOCK LEFT ANTERIOR HEMIBLOCK
						Day 42	46	22-42 days	02/06/92	Abnormal	MYOCARDIAL ISCHEMIA LEFT BUNDLE BRANCH BLOCK LEFT ANTERIOR HEMIBLOCK
	332	Reboxetine	Male	19/05/92	29/06/92	Screen	-6	Screening	13/05/92	Abnormal	SINUS BRADYCARDIA (< 60) LEFT VENTRICULAR HYPERTROPHY
						Day 21	21	1-21 days	09/06/92	Abnormal	LEFT VENTRICULAR HYPERTROPHY
						Day 42	51	22-42 days	09/07/92	Abnormal	LEFT VENTRICULAR HYPERTROPHY
	333	Placebo	Male	27/05/92	07/07/92	Screen	-8	Screening	19/05/92	Normal	
						Day 21	20	1-21 days	16/06/92	Normal	
						Day 42	42	22-42 days	08/07/92	Normal	
	334	Reboxetine	Female	29/05/92	31/05/92	Screen	-8	Screening	21/05/92	Normal	
	335	Placebo	Male	03/06/92	14/07/92	Screen	-15	Screening	19/05/92	Normal	
						Day 21	27	1-21 days	30/06/92	Normal	
						Day 42	41	22-42 days	14/07/92	Normal	
	336	Imipramine	Female	18/06/92	25/06/92	Screen	-2	Screening	16/06/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
11	337	Reboxetine	Female	02/07/92	13/08/92	Screen	-9	Screening	23/06/92	Normal	
						Day 21	21	1-21 days	23/07/92	Normal	
						Day 42	43	22-42 days	14/08/92	Normal	
	338	Imipramine	Male	23/07/92	30/07/92	Screen	-8	Screening	15/07/92	Normal	
12	367	Reboxetine	Female	20/12/91	30/01/92	Screen	-3	Screening	17/12/91	Abnormal	NON SPECIFIC ST-T WAVE CHANGES
						Day 21	21	1-21 days	10/01/92	Normal	
						Day 42	42	22-42 days	31/01/92	Normal	
	368	Placebo	Female	24/12/91	03/02/92	Screen	-5	Screening	19/12/91	Normal	
						Day 21	21	1-21 days	14/01/92	Normal	
						Day 42	42	22-42 days	04/02/92	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL
	369	Imipramine	Female	23/04/92	13/05/92	Screen	-1	Screening	22/04/92	Normal	
						Day 21	20	1-21 days	13/05/92	Normal	
	370	Placebo	Male	29/04/92	20/05/92	Screen	-2	Screening	27/04/92	Abnormal	LEFT VENTRICULAR HYPERTROPHY CONDUCTION DISORDER
						Day 21	20	1-21 days	19/05/92	Abnormal	LEFT ANTERIOR HEMIBLOCK NON SPECIFIC ST-T WAVE CHANGES
	371	Imipramine	Female	01/05/92	06/05/92	Screen	-10	Screening	21/04/92	Abnormal	MYOCARDIAL ISCHEMIA
						Day 7	7	1-21 days	08/05/92	Abnormal	MYOCARDIAL ISCHEMIA
	372	Reboxetine	Male	02/06/92	13/07/92	Screen	-1	Screening	01/06/92	Normal	
						Day 21	20	1-21 days	22/06/92	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 42	41	22-42 days	13/07/92	Normal	
	373	Reboxetine	Male	05/06/92	14/07/92	Screen	0	Screening	05/06/92	Normal	
						Day 21	20	1-21 days	25/06/92	Normal	
						Day 42	39	22-42 days	14/07/92	Normal	
	374	Placebo	Female	09/06/92	05/07/92	Screen	0	Screening	09/06/92	Normal	
						Day 21	21	1-21 days	30/06/92	Normal	
						Day 28	27	22-42 days	06/07/92	Normal	
	375	Imipramine	Male	17/06/92	18/06/92	Screen	-2	Screening	15/06/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
13	13	Placebo	Male	13/04/91	24/05/91	Screen	-2	Screening	11/04/91	Normal	
						Day 21	20	1-21 days	03/05/91	Normal	
						Day 42	41	22-42 days	24/05/91	Normal	
	14	Placebo	Male	02/07/91	13/08/91	Screen	7	Screening	09/07/91	Normal	
						Day 21	22	1-21 days	24/07/91	Normal	
						Day 42	44	22-42 days	15/08/91	Normal	
	15	Imipramine	Female	05/07/91	15/08/91	Screen	-1	Screening	04/07/91	Normal	
						Day 21	20	1-21 days	25/07/91	Normal	
						Day 42	40	22-42 days	14/08/91	Normal	
	16	Imipramine	Male	03/12/91	16/01/92	Screen	0	Screening	03/12/91	Normal	
						Day 28	34	22-42 days	06/01/92	Normal	
						Day 42	48	22-42 days	20/01/92	Normal	
	17	Reboxetine	Male	21/05/92	01/07/92	Screen	2	Screening	23/05/92	Normal	
						Day 21	21	1-21 days	11/06/92	Normal	
						Day 42	42	22-42 days	02/07/92	Normal	
	18	Reboxetine	Male	24/06/92	02/08/92	Screen	2	Screening	26/06/92	Normal	
						Day 21	19	1-21 days	13/07/92	Normal	
						Day 42	40	22-42 days	03/08/92	Normal	
	409	Reboxetine	Male	10/12/91	20/01/92	Screen	0	Screening	10/12/91	Normal	
						Day 21	24	1-21 days	03/01/92	Normal	
						Day 42	43	22-42 days	22/01/92	Normal	
	410	Placebo	Male	14/02/92	26/03/92	Screen	-3	Screening	11/02/92	Normal	
						Day 21	20	1-21 days	05/03/92	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 42	42	22-42 days	27/03/92	Normal	
	411	Imipramine	Female	28/03/92	08/05/92	Screen	-2	Screening	26/03/92	Normal	
						Day 21	24	1-21 days	21/04/92	Normal	
						Day 42	38	22-42 days	05/05/92	Normal	
	423	Placebo	Male	14/09/92	27/10/92	Screen	1	Screening	15/09/92	Normal	
						Day 21	21	1-21 days	05/10/92	Normal	
						Day 42	45	22-42 days	29/10/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	Assessment	E.C.G. Date	E.C.G. Value	E.C.G. Abnormality
14	19	Reboxetine	Female	10/04/92	06/05/92	Screen	-7	Screening	03/04/92	Abnormal	NON SPECIFIC ST-T WAVE CHANGES
						Day 28	27	22-42 days	07/05/92	Abnormal	NON SPECIFIC ST-T WAVE CHANGES
	20	Imipramine	Female	29/04/92	09/06/92	Screen	-2	Screening	27/04/92	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH BLOCK NON SPECIFIC ST-T WAVE CHANGES
						Day 21	21	1-21 days	20/05/92	Abnormal	RIGHT BUNDLE BRANCH BLOCK
						Day 42	71	22-42 days	09/07/92	Abnormal	RIGHT BUNDLE BRANCH BLOCK
	21	Imipramine	Female	20/07/92	24/08/92	Screen	-4	Screening	16/07/92	Normal	
						Day 21	21	1-21 days	10/08/92	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
						Day 35	35	22-42 days	24/08/92	Normal	
15	25	Reboxetine	Female	18/06/91	29/07/91	Screen	-1	Screening	17/06/91	Normal	
						Day 21	21	1-21 days	09/07/91	Normal	
						Day 42	42	22-42 days	30/07/91	Normal	
	26	Placebo	Male	20/06/91	01/08/91	Screen	-3	Screening	17/06/91	Normal	
						Day 21	20	1-21 days	10/07/91	Normal	
						Day 42	42	22-42 days	01/08/91	Normal	
	27	Imipramine	Female	02/07/91	13/08/91	Screen	-5	Screening	27/06/91	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 21	21	1-21 days	23/07/91	Normal	
						Day 42	42	22-42 days	13/08/91	Abnormal	SINUS BRADYCARDIA (< 60)
	28	Reboxetine	Female	08/08/91	19/09/91	Screen	-2	Screening	06/08/91	Normal	
						Day 21	21	1-21 days	29/08/91	Normal	
						Day 42	43	22-42 days	20/09/91	Normal	
	29	Placebo	Male	29/08/91	19/09/91	Screen	0	Screening	29/08/91	Normal	
						Day 21	21	1-21 days	19/09/91	Normal	
	30	Imipramine	Female	03/09/91	15/10/91	Screen	0	Screening	03/09/91	Normal	
						Day 21	21	1-21 days	24/09/91	Normal	
						Day 42	42	22-42 days	15/10/91	Normal	
	403	Imipramine	Female	04/10/91	14/11/91	Screen	0	Screening	04/10/91	Normal	
						Day 21	24	1-21 days	28/10/91	Normal	
						Day 42	41	22-42 days	14/11/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/015
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
15	404	Reboxetine	Female	08/10/91	05/11/91	Screen	-28	Screening	10/09/91	Normal	
						Day 21	21	1-21 days	29/10/91	Normal	
	405	Placebo	Female	11/11/91	23/12/91	Screen	0	Screening	11/11/91	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 21	21	1-21 days	02/12/91	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 42	42	22-42 days	23/12/91	Abnormal	SINUS BRADYCARDIA (< 60)
	406	Imipramine	Male	27/11/91	07/01/92	Screen	0	Screening	27/11/91	Normal	
						Day 21	20	1-21 days	17/12/91	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 42	41	22-42 days	07/01/92	Abnormal	SINUS TACHYCARDIA (> 100)
	407	Reboxetine	Female	03/12/91	14/01/92	Screen	-1	Screening	02/12/91	Normal	
						Day 21	21	1-21 days	24/12/91	Normal	
						Day 42	42	22-42 days	14/01/92	Normal	
	408	Placebo	Female	20/01/92	04/03/92	Screen	-5	Screening	15/01/92	Normal	
						Day 21	22	1-21 days	11/02/92	Normal	
						Day 42	44	22-42 days	04/03/92	Normal	
	418	Placebo	Female	30/01/92	12/03/92	Screen	0	Screening	30/01/92	Normal	
						Day 21	21	1-21 days	20/02/92	Normal	
						Day 42	42	22-42 days	12/03/92	Normal	
	419	Placebo	Female	28/04/92	09/06/92	Screen	-1	Screening	27/04/92	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 0	0	Screening	28/04/92	Normal	
						Day 21	21	1-21 days	19/05/92	Normal	
						Day 42	42	22-42 days	09/06/92	Normal	

12.2.3 CRFs

Individual patient CRFs are filed in the Study Master File.